10091617	0	(S1 (NP (NP (NP (JJ Doc_10091617_0_10_Chemical-induced) (NN Doc_10091617_19_39_Disease)) (PP (IN in) (NP (NNP Doc_10091617_43_62_Disease)))) (: :) (NP (NP (DT a) (JJ longitudinal) (NN study)) (PP (IN on) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug) (NN withdrawal)))))) (. .)))
10091617	1	(S1 (S (NP (DT The) (NNP United) (NNP Kingdom) (NNP Doc_10091617_151_170_Disease) (NNP Research) (NNP Group) (PRN (-LRB- -LRB-) (NP (NNP UKPDRG)) (-RRB- -RRB-)) (NN trial)) (VP (VBD found) (NP (NP (DT an) (VBN increased) (NN mortality)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (NNP Doc_10091617_247_266_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10091617_268_270_Disease)) (-RRB- -RRB-)) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 10) (NNS mg)) (ADJP (JJ Doc_10091617_300_310_Chemical) (PP (IN per) (NP (NN day)))))))))) (CC and) (NP (NNP Doc_10091617_323_329_Chemical))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBG taking) (NP (NP (NNP Doc_10091617_357_363_Chemical)) (ADVP (RB alone)))))))) (. .)))
10091617	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_10091617_408_418_Chemical)) (CC and) (NP (NNP Doc_10091617_423_429_Chemical))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ selective) (NN Doc_10091617_460_492_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN abolished) (PP (IN by) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_10091617_530_540_Chemical)))))))))))))))) (. .)))
10091617	3	(S1 (S (NP (NP (DT This) (JJ unwanted) (NN effect)) (PP (IN on) (NP (JJ postural) (NN blood) (NN pressure)))) (VP (AUX was) (RB not) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ underlying) (JJ autonomic) (NN failure))))) (. .)))
10091617	4	(S1 (S (NP (NP (DT The) (NNS aims)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX were) (S (VP (VP (TO to) (VP (VB confirm) (NP (NP (PRP$ our) (JJ previous) (NNS findings)) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN cohort)) (PP (IN of) (NP (NNS patients)))))))) (CC and) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP (DT the) (JJ cardiovascular) (NNS consequences)) (PP (IN of) (S (VP (VBG stopping) (NP (NNP Doc_10091617_816_826_Chemical)) (PP (IN in) (NP (DT the) (NN expectation) (SBAR (IN that) (S (NP (DT this)) (VP (MD might) (VP (VB shed) (NP (NN light)) (PP (IN on) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (NN drug)) (VP (VBZ causes) (NP (NN Doc_10091617_916_939_Disease)))))))))))))))))))))))) (. .)))
10091617	5	(S1 (S (NP (NP (DT The) (JJ cardiovascular) (NNS responses)) (PP (TO to) (NP (NP (NN standing)) (CC and) (NP (NN head-up) (NN tilt))))) (VP (AUX were) (VP (VBN studied) (ADVP (RB repeatedly)) (UCP (PP (IN in) (NP (NP (JJ Doc_10091617_1035_1037_Disease) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_10091617_1057_1067_Chemical))))) (CC and) (SBAR (IN as) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN withdrawn)))))))) (. .)))
10091617	6	(S1 (S (NP (JJ Head-up) (NN tilt)) (VP (VBD caused) (NP (NP (NN Doc_10091617_1128_1160_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN marked) (PP (IN in) (NP (NP (QP (CD six) (IN of) (CD 20)) (JJ Doc_10091617_1191_1193_Disease) (NNS patients)) (PP (IN on) (NP (NNP Doc_10091617_1206_1216_Chemical))) (, ,) (SBAR (WHNP (CD one) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (VBD lost) (NP (NN consciousness)) (PP (IN with) (NP (JJ unrecordable) (NN blood) (NNS pressures)))))))))))))) (. .)))
10091617	7	(S1 (S (NP (NP (DT A) (JJR lesser) (NN degree)) (PP (IN of) (NP (NNP Doc_10091617_1303_1326_Disease)))) (VP (VBD occurred) (PP (IN with) (NP (NN standing)))) (. .)))
10091617	8	(S1 (S (NP (NN Doc_10091617_1351_1374_Disease)) (VP (AUX was) (VP (VP (VBN ameliorated) (NP (CD 4) (NNS days)) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_10091617_1418_1428_Chemical)))))) (CC and) (VP (ADVP (RB totally)) (VBN abolished) (PP (NP (CD 7) (NNS days)) (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (. .)))
10091617	9	(S1 (S (NP (NN Stopping) (NN Doc_10091617_1502_1512_Chemical)) (ADVP (RB also)) (ADVP (RB significantly)) (VP (VBP Doc_10091617_1532_1589_Disease) (NP (ADJP (JJ consistent) (PP (IN with) (NP (DT a) (ADJP (RB previously) (VBN undescribed)) (NN supine) (NN pressor)))) (NN action))) (. .)))
10091617	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ confirms) (NP (NP (PRP$ our) (JJ previous) (NN finding)) (SBAR (WHNP (IN that)) (S (NP (NP (NNP Doc_10091617_1712_1722_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_10091617_1743_1749_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ selective) (NN Doc_10091617_1779_1802_Disease))))))))) (. .)))
10091617	11	(S1 (S (NP (NP (DT The) (NNS possibilities)) (SBAR (WHNP (IN that)) (S (NP (DT these) (JJ cardiovascular) (NNS findings)) (VP (MD might) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (PP (IN of) (NP (NP (JJ non-selective) (NN inhibition)) (PP (IN of) (NP (JJ monoamine) (NN oxidase))))) (CC or) (PP (IN of) (NP (NP (NNP Doc_10091617_1932_1943_Chemical)) (CC and) (NP (NNP Doc_10091617_1948_1962_Chemical))))))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
1009330	0	(S1 (NP (NP (JJ Further) (NNS studies)) (PP (IN on) (NP (NP (NNS effects)) (PP (IN of) (NP (NN irrigation) (NNS solutions))) (PP (IN on) (NP (NN rat) (NNS bladders))))) (. .)))
1009330	1	(S1 (S (NP (NP (JJ Further) (NNS studies)) (PP (IN on) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ certain) (NN irrigating) (NNS fluids))))) (PP (IN on) (NP (DT the) (NN rat) (NN bladder))) (PP (IN for) (NP (CD 18) (NNS hours)))) (VP (AUX are) (VP (VBN reported))) (. .)))
1009330	2	(S1 (S (NP (DT The) (NNS results)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (DT the) (NN degradation) (NN product) (NN Doc_1009330_226_242_Chemical)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ significant) (NN factor)) (PP (IN in) (NP (JJ Doc_1009330_274_299_Chemical) (JJ associated) (NN erosive) (NNP Doc_1009330_319_327_Disease))))))))) (. .)))
1009330	3	(S1 (S (NP (NP (DT A) (JJ high) (NN percentage)) (PP (IN of) (NP (JJ Doc_1009330_350_359_Chemical-Doc_1009330_360_368_Chemical) (CC and) (JJ Doc_1009330_373_388_Chemical) (NNS irrigations)))) (VP (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJ erosive) (NN Doc_1009330_430_438_Disease))))) (CC and) (VP (VBD suggested) (NP (NP (DT a) (JJ possible) (NN complication)) (PP (IN with) (NP (JJ human) (NN usage)))))) (. .)))
1009330	4	(S1 (S (S (NP (NN Doc_1009330_495_506_Chemical) (NNS irrigations)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (JJ erosive) (NN Doc_1009330_565_573_Disease))))))))) (CC but) (S (NP (JJ further) (NNS studies)) (VP (MD would) (VP (AUX have) (S (VP (TO to) (VP (AUX be) (VP (VBN performed) (SBAR (IN before) (S (NP (PRP it)) (VP (MD could) (VP (AUX be) (VP (VBN recommended) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (JJ urological) (NNS procedures))))))))))))))))) (. .)))
10193204	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP Doc_10193204_11_22_Chemical)) (CC and) (NP (NNP Doc_10193204_27_40_Chemical)))) (PP (IN on) (NP (NP (JJ experimental) (NNP Doc_10193204_57_67_Disease)) (PP (IN in) (NP (NP (NNS mice)) (CC and) (NP (JJ human) (NN Doc_10193204_86_106_Disease)))))) (. .)))
10193204	1	(S1 (S (NP (NP (NP (NNP Doc_10193204_108_119_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_121_124_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_10193204_130_143_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_145_148_Chemical)) (-RRB- -RRB-)))) (VP (AUX are) (NP (NP (CD two) (ADJP (RB naturally) (VBG occurring)) (NNS analogues)) (PP (IN with) (NP (DT a) (JJ Doc_10193204_195_216_Chemical) (NN structure))))) (. .)))
10193204	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10193204_291_294_Chemical) (CC and) (NNP Doc_10193204_299_302_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (JJ experimental) (NNP Doc_10193204_323_333_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NN collagen)) (CC plus) (NP (NP (NNP Doc_10193204_359_370_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_372_374_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNS mice))))) (, ,) (CC and) (NP (NP (NNP Doc_10193204_389_409_Disease) (CC and) (NNP Doc_10193204_414_431_Disease)) (PP (IN in) (NP (NN vitro)))))))))))) (. .)))
10193204	3	(S1 (S (PP (IN In) (NP (NP (DT the)) (PP (IN in) (NP (NN vivo) (NN study))))) (, ,) (NP (NP (DT the) (NN administration)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (, ,) (NP (CD i.p.)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_10193204_503_506_Chemical) (CC and) (NNP Doc_10193204_511_514_Chemical)) (PP (IN in) (NP (NNS mice)))))) (VP (VBD showed) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NNP Doc_10193204_548_558_Disease)))) (PP (IN by) (NP (NP (CD 55) (NN %)) (CC and) (NP (CD 35) (NN %)))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN while) (S (NP (NP (NNP Doc_10193204_595_615_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_617_620_Chemical)) (, ,) (NP (CD 50) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)) (, ,) (NP (DT a) (JJ positive) (NN control)) (, ,)) (VP (VBD showed) (NP (QP (RB only) (CD 30)) (NN %) (NN inhibition)))))) (. .)))
10193204	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NN vitro) (NN human) (NN Doc_10193204_706_727_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNS agonists)) (VP (VBN used) (PP (IN in) (NP (NNS tests))))))))) (, ,) (NP (NP (NNP Doc_10193204_767_770_Chemical)) (CC and) (NP (NNP Doc_10193204_775_778_Chemical))) (VP (VBD showed) (NP (DT the) (NNS inhibitions) (NN dose)) (ADVP (RB dependently))) (. .)))
10193204	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT neither) (NNP Doc_10193204_841_844_Chemical) (CC nor) (NNP Doc_10193204_849_852_Chemical)) (VP (VBD showed) (NP (DT any) (JJ anticoagulation) (NNS activities)) (PP (IN in) (NP (NP (DT the) (NN measurement)) (PP (IN of) (S (NP (NP (DT the) (VBN activated) (JJ partial) (NN thromboplastin) (NN time)) (PRN (-LRB- -LRB-) (NP (NNP APTT)) (-RRB- -RRB-)) (, ,) (NP (NP (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NNP PT)) (-RRB- -RRB-)) (CC and) (NP (NN thrombin) (NN time))) (PRN (-LRB- -LRB-) (NP (NNP TT)) (-RRB- -RRB-))) (VP (VBG using) (NP (JJ human-citrated) (NN plasma)))))))) (. .)))
10193204	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN antithrombosis)) (PP (IN of) (NP (NP (NNP Doc_10193204_1082_1085_Chemical)) (CC and) (NP (NNP Doc_10193204_1090_1093_Chemical)))) (PP (IN in) (NP (NNS mice)))) (VP (MD may) (VP (AUX be) (ADJP (RB mainly) (JJ related) (PP (TO to) (NP (DT the) (JJ antiplatelet) (NN aggregation) (NNS activities))))))))) (. .)))
10342929	0	(S1 (FRAG (NP (NP (NN Doc_10342929_0_10_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_10342929_18_32_Chemical))))) (: :) (S (UCP (ADJP (JJ common)) (CC and) (VP (ADVP (RB inadequately)) (VBN diagnosed)))) (. .)))
10342929	1	(S1 (S (NP (NP (DT The) (VBN estimated) (NN incidence)) (PP (IN of) (NP (NNP Doc_10342929_96_106_Disease))) (PP (IN during) (NP (JJ Doc_10342929_114_159_Chemical) (NN treatment)))) (VP (AUX is) (PP (IN between) (NP (CD 1) (CC and) (CD 7))) (PP (IN per) (NP (CD thousand) (NNS patients)))) (. .)))
10342929	2	(S1 (S (NP (DT This) (ADJP (RB potentially) (JJ serious)) (JJ adverse) (NN effect)) (VP (AUX is) (ADVP (RB often)) (VP (VBN preceded) (PP (IN by) (NP (NP (JJ minor) (NNS manifestations)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB serve) (PP (IN as) (NP (DT a) (NN warning))))))))))) (. .)))
10365197	0	(S1 (NP (NP (JJ Doc_10365197_0_7_Chemical-induced) (NNP Doc_10365197_16_29_Disease)) (: :) (NP (NP (NP (JJ prevalence) (NNS rates)) (CC and) (NP (JJ Doc_10365197_52_63_Disease) (NNS symptoms))) (PP (IN in) (NP (DT an) (NN outpatient) (JJ Doc_10365197_90_97_Chemical-dependent) (NN sample)))) (. .)))
10365197	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ attempts) (S (VP (TO to) (VP (VP (VB examine)) (CC and) (VP (VB compare) (SBAR (S (NP (NP (NN prevalence) (NNS rates)) (CC and) (NP (NP (NN symptom) (NNS patterns)) (PP (IN of) (NP (NP (NNP DSM) (JJ substance-induced) (CC and) (JJ other) (NNP Doc_10365197_232_246_Disease.) (CD 243) (JJ Doc_10365197_252_259_Chemical-dependent) (NNS outpatients)) (PP (IN with) (NP (NP (NP (NNP Doc_10365197_287_294_Chemical-induced) (NNP Doc_10365197_303_316_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10365197_318_322_Disease)) (-RRB- -RRB-))) (, ,) (NP (JJ other) (NNP Doc_10365197_331_345_Disease)) (, ,) (CC or) (NP (DT no) (NNP Doc_10365197_353_366_Disease)))))))) (VP (AUX were) (VP (VBN compared) (PP (IN on) (NP (NP (NNS measures)) (PP (IN of) (NP (NNP Doc_10365197_396_407_Disease) (NNS symptoms)))))))))))))) (. .)))
10365197	2	(S1 (S (NP (NP (DT The) (NN prevalence) (NN rate)) (PP (IN for) (NP (NNP Doc_10365197_442_446_Disease)))) (VP (AUX was) (NP (CD 12) (NN %)) (PP (IN at) (NP (NN baseline)))) (. .)))
10365197	3	(S1 (S (NP (NP (NN Introduction)) (PP (IN of) (NP (NP (DT the) (JJ DSM-IV) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10365197_508_512_Disease)))))) (VP (AUX did) (RB not) (VP (ADVP (RB substantially)) (VB affect) (NP (NP (NNS rates)) (PP (IN of) (NP (DT the) (JJ other) (NN Doc_10365197_561_581_Disease)))))) (. .)))
10365197	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_10365197_597_601_Disease)))) (VP (AUX had) (NP (NP (NN symptom) (NN severity) (NNS levels)) (PP (IN between) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNS patients)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (DT a) (NN Doc_10365197_675_688_Disease)))))))))) (. .)))
10365197	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VP (VBP suggest) (NP (NP (DT some) (NN validity)) (PP (IN for) (NP (NP (DT the) (JJ new) (JJ DSM-IV) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10365197_759_763_Disease))))))) (, ,) (CONJP (CC but) (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ requires) (NP (NP (JJ further) (NN specification)) (CC and) (NP (NN replication)))))))) (. .)))
10406016	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_10406016_10_18_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ collagenase-induced) (NN Doc_10406016_52_76_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
10406016	1	(S1 (S (NP (JJ Inflammatory) (NNS cells)) (VP (AUX are) (VP (VBN postulated) (S (VP (TO to) (VP (VB mediate) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (JJ Doc_10406016_143_155_Disease) (JJ following) (NN Doc_10406016_166_181_Disease))))))))) (. .)))
10406016	2	(S1 (S (NP (NN Doc_10406016_183_207_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (RBR more)) (NP (NNP Doc_10406016_232_244_Disease))) (PP (IN than) (NP (NNP Doc_10406016_250_265_Disease))))))) (. .)))
10406016	3	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (NP (DT the) (JJ sulfated) (NN polysaccharide) (NN Doc_10406016_305_313_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (JJ inflammatory) (NNP Doc_10406016_362_374_Disease))))) (, ,) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_10406016_394_418_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (JJ bacterial) (NN collagenase))) (PP (IN into) (NP (DT the) (JJ caudate) (NN nucleus))))))))))))))) (. .)))
10406016	4	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (CD seven) (NN day) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_10406016_548_556_Chemical))) (PRN (-LRB- -LRB-) (ADJP (NP (CD 30) (NNS micrograms)) (JJ h-1)) (-RRB- -RRB-))) (CC or) (NP (NN vehicle)))))) (. .)))
10406016	5	(S1 (S (NP (DT The) (NNP Doc_10406016_593_601_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NN vivo))) (PP (IN by) (NP (JJ magnetic) (NN resonance) (NN imaging))))) (. .)))
10406016	6	(S1 (S (NP (NP (NN Motor) (NN behavior)) (, ,) (NP (NN passive) (NN avoidance)) (, ,) (CC and) (NP (JJ skilled) (NN forelimb) (NN function))) (VP (AUX were) (VP (VBN tested) (ADVP (RB repeatedly)) (PP (IN for) (NP (CD six) (NNS weeks))))) (. .)))
10406016	7	(S1 (S (NP (JJ Doc_10406016_757_765_Chemical-treated) (NNS rats)) (VP (VP (VBD exhibited) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_10406016_801_824_Disease)) (CC and) (NP (NNP Doc_10406016_829_841_Disease)))))) (, ,) (VP (AUX had) (NP (JJR larger) (NN Doc_10406016_854_863_Disease))) (, ,) (CC and) (VP (VBD tended) (S (VP (TO to) (VP (AUX have) (ADJP (RBR less) (JJ Doc_10406016_889_901_Disease)) (PP (IN in) (NP (NP (DT the) (NN vicinity)) (PP (IN of) (NP (DT the) (NNP Doc_10406016_925_933_Disease))))) (PP (IN after) (NP (CD three) (NNS days)))))))) (. .)))
10406016	8	(S1 (S (NP (PRP They)) (VP (VBD showed) (NP (NP (NP (ADJP (RB significantly) (JJR more)) (JJ rapid) (NN improvement)) (PP (IN of) (NP (NN motor) (NN function))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN week)) (VP (VBG following) (NP (NNP Doc_10406016_1047_1057_Disease)))))) (CC and) (NP (JJR better) (NN memory) (NN retention))) (PP (IN in) (NP (DT the) (JJ passive) (NN avoidance) (NN test)))) (. .)))
10406016	9	(S1 (S (NP (NP (NP (JJ Acute) (NN Doc_10406016_1123_1141_Disease)) (CC and) (NP (JJ eventual) (NN Doc_10406016_1155_1168_Disease))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (ADJP (JJ adjacent) (PP (TO to) (NP (DT the) (NNP Doc_10406016_1201_1209_Disease))))))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
10406016	10	(S1 (S (NP (NP (NN Investigation)) (PP (IN of) (NP (NP (JJR more) (JJ specific) (NN anti-inflammatory) (NNS agents)) (CC and) (NP (VBG hemodiluting) (NNS agents))))) (VP (AUX are) (VP (VBN warranted) (PP (IN in) (NP (NNP Doc_10406016_1346_1370_Disease))))) (. .)))
10457883	0	(S1 (NP (NP (NN Recurarization)) (PP (IN in) (NP (DT the) (NN recovery) (NN room))) (. .)))
10457883	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NN recurarization))) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))) (VP (AUX is) (VP (VBN reported))) (. .)))
10457883	2	(S1 (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (NNP Doc_10457883_112_122_Chemical))) (PP (IN in) (NP (DT the) (JJ intravenous) (NN line)))) (VP (VBD led) (PP (TO to) (NP (NN recurarization))) (PP (IN after) (S (VP (VBG flushing) (NP (NP (DT the) (NN line)) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))))))) (. .)))
10457883	3	(S1 (S (NP (NP (DT A) (NN Doc_10457883_217_235_Disease)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_10457883_248_260_Disease)) (CC and) (NP (NNP Doc_10457883_265_276_Disease))))) (VP (VBD occurred)) (. .)))
10457883	4	(S1 (S (NP (NP (NP (NP (NNS Circumstances)) (VP (VBG leading) (PP (TO to) (NP (DT this) (NN event))))) (CC and) (NP (NP (DT the) (NNS mechanisms)) (VP (VBG enabling) (NP (NP (DT a) (NN Doc_10457883_353_375_Disease)) (SBAR (S (VP (TO to) (VP (VB occur))))))))) (, ,) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ small) (NN dose)) (PP (IN of) (NP (NN relaxant))))))) (, ,)) (VP (AUX are) (VP (VBN discussed))) (. .)))
10520387	0	(S1 (NP (NP (DT The) (JJ haemodynamic) (NNS effects)) (PP (IN of) (NP (NNP Doc_10520387_28_36_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NNP Doc_10520387_57_66_Chemical)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP ASA) (NNS groups) (QP (CD 3) (CC and) (CD 4))) (-RRB- -RRB-)))))))) (. .)))
10520387	1	(S1 (S (NP (NP (DT The) (VBN marked) (ADJP (JJ vasodilator) (CC and) (JJ negative)) (JJ inotropic) (NNS effects)) (PP (IN of) (NP (NNP Doc_10520387_166_174_Chemical)))) (VP (AUX are) (NP (NP (NNS disadvantages)) (PP (IN in) (NP (JJ frail) (JJ elderly) (NNS patients))))) (. .)))
10520387	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (S (VP (VBG adding) (NP (NP (JJ different) (NNS doses)) (PP (IN of) (NP (NNP Doc_10520387_289_298_Chemical)))) (PP (TO to) (NP (NNP Doc_10520387_302_310_Chemical))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB obtund) (NP (DT the) (JJ Doc_10520387_334_345_Disease) (NN response))))))))))) (. .)))
10520387	3	(S1 (S (NP (NP (DT The) (JJ haemodynamic) (NNS effects)) (PP (IN of) (S (VP (VBG adding) (NP (NP (CD 15) (, ,) (CD 20) (CC or) (CD 25) (NNS mg)) (PP (IN of) (NP (NNP Doc_10520387_410_419_Chemical)))) (PP (TO to) (NP (NP (QP (CD 200) (CD mg))) (PP (IN of) (NP (NNP Doc_10520387_433_441_Chemical))))))))) (VP (AUX were) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (PP (IN in) (NP (NP (CD 40) (NNP ASA) (CD 3/4) (NNS patients)) (PP (IN over) (NP (NP (CD 60) (NNS years)) (VP (VBG presenting) (PP (IN for) (NP (JJ genito-urinary) (NN surgery))))))))))))) (. .)))
10520387	4	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NNP Doc_10520387_559_568_Chemical))) (PP (TO to) (NP (NNP Doc_10520387_572_580_Chemical)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN method)) (PP (IN of) (S (VP (VBG obtunding) (NP (NP (DT the) (JJ Doc_10520387_632_643_Disease) (NN response)) (PP (TO to) (NP (NNP Doc_10520387_656_664_Chemical)))) (PP (IN at) (NP (NP (DT all) (NNS doses)) (VP (VBN used) (PP (IN in) (NP (DT this) (NN study)))))))))))))) (. .)))
10520387	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ marked) (NN Doc_10520387_714_725_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_10520387_753_762_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_10520387_783_791_Chemical))))))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NNS patients))))) (, ,) (S (ADVP (RB occasionally)) (VP (VBG reaching) (NP (JJ high) (NNS levels)) (PP (IN in) (NP (JJ individual) (NNS patients)))))) (. .)))
10520387	6	(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT this) (NNP Doc_10520387_912_923_Disease) (VBG inducing) (NN Doc_10520387_933_952_Disease))))) (, ,) (NP (PRP we)) (VP (MD would) (RB not) (VP (VB recommend) (NP (NP (DT the) (NN use)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS Doc_10520387_1019_1028_Chemical/Doc_10520387_1029_1037_Chemical/mixtures)) (VP (VBN studied))))))))))) (. .)))
10526274	0	(S1 (S (NP (NP (NNP Doc_10526274_0_11_Chemical) (CC plus) (NNP Doc_10526274_17_28_Chemical)) (PP (IN in) (NP (NNP Doc_10526274_32_60_Disease) (NNS patients)))) (VP (VBP age) (NP (NP (CD 70) (NNS years) (QP (CC or) (JJR older))) (CC or) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB cannot)) (VP (VBP receive) (NP (NNP Doc_10526274_123_132_Chemical)))))))) (. .)))
10526274	1	(S1 (NP (NNP Oncopaz) (NNP Cooperative) (NNP Group) (. .)))
10526274	2	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (NNP Doc_10526274_200_228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_230_235_Disease)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ high)) (PP (IN among) (NP (JJ elderly) (NNS patients)))))) (, ,) (NP (JJ few) (NNS data)) (VP (AUX are) (ADJP (JJ available)) (PP (VBG regarding) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_10526274_319_327_Disease)) (PP (IN of) (NP (NN chemotherapy))) (PP (IN in) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
10526274	3	(S1 (S (NP (JJ Recent) (NNS reports)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ single) (NN agent) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_10526274_426_437_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_439_442_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_10526274_447_458_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_460_463_Chemical)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB obtain) (NP (NP (DT a) (NN response) (NN rate)) (PP (IN of) (NP (CD 20-30) (NN %)))) (PP (IN in) (NP (JJ elderly) (NNS patients))) (, ,) (PP (IN with) (NP (NP (NP (JJ acceptable) (NN Doc_10526274_539_547_Disease) (CC and) (NN improvement)) (PP (IN in) (NP (NNS symptoms)))) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))))))))) (. .)))
10526274	4	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_10526274_635_643_Disease)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_10526274_666_669_Chemical)) (CC and) (NP (NNP Doc_10526274_674_677_Chemical)))))) (PP (IN in) (NP (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_10526274_712_717_Disease)))) (CC or) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT some) (NN contraindication)) (PP (TO to) (S (VP (VBG receiving) (NP (NNP Doc_10526274_767_776_Chemical))))))))))) (VP (AUX were) (VP (VBN assessed))) (. .)))
10526274	5	(S1 (S (S (NP (NP (JJ Forty-nine) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_10526274_835_840_Disease)))) (VP (AUX were) (VP (VBN included) (, ,) (SBAR (WHNP (CD 38) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (NP (NN age)) (PP (IN >/=) (NP (CD 70) (NNS years))))))))) (CC and) (S (NP (CD 11)) (VP (AUX were) (UCP (NP (NP (NN age) (CD <)) (NP (CD 70) (NNS years))) (CC but) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT some) (NN contraindication)) (PP (TO to) (S (VP (VBG receiving) (NP (NNP Doc_10526274_963_972_Chemical)))))))))))) (. .)))
10526274	6	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (CC and) (NP (NN Doc_10526274_1019_1027_Disease)))))) (. .)))
10526274	7	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN comprised) (PP (IN of) (NP (NP (NP (NNP Doc_10526274_1056_1059_Chemical)) (, ,) (NP (NP (CD 25) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (CC plus) (NP (NNP Doc_10526274_1078_1081_Chemical))) (, ,) (NP (NP (CD 1000) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NP (DT both)) (PP (IN on) (NP (NNPS Days) (CD 1) (, ,) (CD 8)))) (, ,)) (CC and) (NP (NP (CD 15)) (NP (DT every) (CD 28) (NNS days))))))) (. .)))
10526274	8	(S1 (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (CD three) (NNS courses)))) (SBAR (IN unless) (S (NP (JJ progressive) (NN disease)) (VP (AUX was) (VP (VBN detected)))))) (. .)))
10526274	9	(S1 (S (NP (QP (CD One) (CD hundred)) (JJ sixty-five) (NNS courses)) (VP (AUX were) (VP (VBN administered) (, ,) (PP (IN with) (NP (NP (DT a) (NN median)) (PP (IN of) (S (VP (VBG 3.) (NP (NP (CD 6) (NNS courses)) (PP (IN per) (NP (NN patient))))))))))) (. .)))
10526274	10	(S1 (S (NP (DT The) (JJ overall) (NN response) (NN rate)) (VP (AUX was) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (NN confidence) (NN interval)) (, ,) (NP (CD 15-41) (NN %))) (-RRB- -RRB-)))) (. .)))
10526274	11	(S1 (S (NP (NP (NP (NP (CD Two) (NNS patients)) (VP (VBN attained) (NP (DT a) (JJ complete) (NN response)))) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 11) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-)))) (VP (VBD achieved) (NP (DT a) (JJ partial) (NN response))) (. .)))
10526274	12	(S1 (S (NP (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN performance) (NN status)) (VP (VBD improved) (PP (IN in) (NP (NP (CD 35) (NN %)) (PP (IN of) (NP (NP (DT those) (NNS patients)) (PP (IN with) (NP (NP (DT an) (JJ initial) (NN value)) (VP (VBD >) (NP (CD 0))))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN relief)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD 1)) (NN symptom)) (PP (IN without) (NP (NP (VBG worsening)) (PP (IN of) (NP (JJ other) (NNS symptoms)))))))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 27) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 55) (NN %)) (-RRB- -RRB-))))))))) (. .)))
10526274	13	(S1 (S (S (NP (NP (DT The) (JJ median) (NN time)) (PP (TO to) (NP (NN progression)))) (VP (AUX was) (NP (CD 16) (NNS weeks)))) (CC and) (S (NP (DT the) (JJ 1-year) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 33) (NN %)))) (. .)))
10526274	14	(S1 (S (NP (NN Doc_10526274_1795_1803_Disease)) (VP (AUX was) (ADJP (JJ mild))) (. .)))
10526274	15	(S1 (S (S (NP (NP (CD Six) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP World) (NNP Health) (NNP Organization) (NNP Grade) (NN 3-4) (NNP Doc_10526274_1873_1884_Disease)))) (, ,) (S (NP (NP (CD 2) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Grade) (NN 3-4) (NNP Doc_10526274_1916_1932_Disease)))) (, ,) (CC and) (S (NP (NP (CD 2) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Grade) (CD 3)) (NP (NNP Doc_10526274_1966_1979_Disease)))) (. .)))
10526274	16	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_10526274_2008_2019_Disease))) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (VP (VBD died) (PP (IN of) (NP (NNP Doc_10526274_2033_2039_Disease)))) (. .)))
10526274	17	(S1 (S (NP (NP (DT The) (JJ median) (NN age)) (PP (IN of) (NP (NP (DT those) (NNS patients)) (VP (VBG developing) (NP (NNP Grade) (NN 3-4) (NNP Doc_10526274_2095_2106_Disease)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (VBG remaining) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 75) (NNS years)) (CC vs.) (NP (CD 72) (NNS years))) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.047)))) (-RRB- -RRB-)))))))) (. .)))
10526274	18	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_10526274_2236_2239_Chemical)) (CC and) (NP (NNP Doc_10526274_2244_2247_Chemical))))) (VP (AUX is) (ADJP (ADJP (RB moderately) (JJ active)) (CC and) (ADJP (RB well) (JJ tolerated))) (PP (IN except) (PP (IN in) (NP (NP (NNS patients)) (SBAR (S (NP (NN age)) (VP (VBZ >/=) (NP (CD 75) (NNS years))))))))) (. .)))
10526274	19	(S1 (S (NP (DT This) (NN age) (NN group)) (VP (AUX had) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_10526274_2365_2381_Disease))))) (. .)))
10526274	20	(S1 (S (ADVP (RB Therefore)) (NP (NP (DT the) (JJ prophylactic) (NN use)) (PP (IN of) (NP (JJ granulocyte-colony) (JJ stimulating) (NN factor)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN with) (NP (DT this) (NN treatment)))))) (. .)))
10526274	21	(S1 (S (NP (NP (JJ New) (JJ chemotherapy) (NNS combinations)) (PP (IN with) (NP (NP (JJR higher) (NN activity)) (CC and) (NP (JJR lower) (NN Doc_10526274_2558_2566_Disease))))) (VP (AUX are) (VP (VBN needed) (PP (IN for) (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NN Doc_10526274_2613_2618_Disease))))))) (. .)))
10579464	0	(S1 (NP (NP (NP (DT A) (JJ selective) (NNP Doc_10579464_12_20_Chemical) (NNP D4) (NN receptor) (NN antagonist)) (, ,) (NP (NNP Doc_10579464_45_52_Chemical))) (: :) (NP (DT a) (JJ preclinical) (NN neuropharmacological) (NN profile)) (. .)))
10579464	1	(S1 (S (NP (NP (NNP Doc_10579464_98_105_Chemical)) (, ,) (NP (NNP Doc_10579464_107_212_Chemical)) (, ,)) (VP (AUX has) (NP (NP (DT a) (JJ high) (NN affinity)) (PP (IN for) (NP (JJ human) (VBN cloned) (JJ Doc_10579464_251_259_Chemical) (CD D4.2) (, ,) (CD D4.4) (CC and) (CD D4.7) (NNS receptors)))) (, ,) (PP (IN with) (NP (NP (JJ Ki) (NNS values)) (PP (IN of) (NP (NP (CD 0.5)) (, ,) (NP (CD 0.9)) (CC and) (NP (CD 2.7) (NN nM)) (, ,) (ADVP (RB respectively))))))) (. .)))
10579464	2	(S1 (S (NP (NNP Doc_10579464_344_351_Chemical)) (VP (AUX is) (ADVP (RB over)) (ADVP (RB 20,000fold)) (ADJP (RBR more) (JJ potent)) (PP (IN at) (NP (DT the) (NNP Doc_10579464_390_398_Chemical) (CD D4.2) (NN receptor))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ human) (VBN cloned) (NNP Doc_10579464_444_452_Chemical) (NNP D2L) (NN receptor))))) (. .)))
10579464	3	(S1 (S (NP (NNP Doc_10579464_467_474_Chemical)) (VP (AUX has) (NP (JJ negligible) (NN affinity)) (PP (IN for) (NP (NP (DT the) (JJ human) (VBN cloned) (NNP Doc_10579464_520_528_Chemical) (NNP D3) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP Ki=39) (CD nM)) (-RRB- -RRB-)))) (, ,) (S (VP (VP (VB rat) (NP (NP (NNP Doc_10579464_557_566_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_10579464_568_572_Chemical) (-RRB- -RRB-)) (JJ 2A) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Ki=180) (CD nM)) (-RRB- -RRB-)))) (CC and) (VP (VB rat) (NP (NP (JJ alpha1) (NN adrenoceptor)) (PRN (-LRB- -LRB-) (NP (CD Ki=237) (NNS nM)) (-RRB- -RRB-))))))) (. .)))
10579464	4	(S1 (S (NP (NNP Doc_10579464_639_646_Chemical) (CC and) (NNP Doc_10579464_651_660_Chemical)) (VP (VBD antagonized) (NP (NP (NN locomotor) (NN Doc_10579464_683_696_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_10579464_708_723_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10579464_725_728_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS mice)))))) (. .)))
10579464	5	(S1 (S (NP (NP (NNP Doc_10579464_739_746_Chemical)) (CC and) (NP (NNP Doc_10579464_751_760_Chemical))) (VP (VBD antagonized) (NP (JJ Doc_10579464_773_776_Chemical-induced) (JJ stereotyped) (NN behavior)) (PP (IN in) (NP (NNS mice))) (, ,) (SBAR (IN although) (S (NP (PRP$ their) (NNS effects)) (VP (AUX did) (RB not) (VP (VB exceed) (NP (ADJP (CD 50) (NN %)) (NN inhibition)))))) (, ,) (PP (ADVP (RB even)) (IN at) (NP (NP (DT the) (JJS highest) (NN dose)) (VP (VBN given))))) (. .)))
10579464	6	(S1 (S (NP (NP (NNP Doc_10579464_901_908_Chemical)) (CC and) (NP (NNP Doc_10579464_913_922_Chemical))) (VP (ADVP (RB significantly)) (VBN induced) (NP (NNP Doc_10579464_945_954_Disease)) (PP (IN in) (NP (NNS rats))) (, ,) (SBAR (IN although) (S (NP (PRP$ their) (NNS effects)) (VP (AUX did) (RB not) (VP (VB exceed) (NP (ADJP (CD 50) (NN %)) (NN induction)) (ADVP (RB even)) (PP (IN at) (NP (NP (DT the) (JJS highest) (NN dose)) (VP (VBN given))))))))) (. .)))
10579464	7	(S1 (S (NP (NP (NNP Doc_10579464_1048_1055_Chemical)) (CC and) (NP (NNP Doc_10579464_1060_1069_Chemical))) (VP (ADVP (RB significantly)) (VBD reversed) (NP (NP (DT the) (NN disruption)) (PP (IN of) (NP (NP (JJ prepulse) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NNP PPI)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_10579464_1157_1168_Chemical)))))))) (. .)))
10579464	8	(S1 (S (NP (NP (NNP Doc_10579464_1170_1177_Chemical) (CC and) (NNP Doc_10579464_1182_1191_Chemical)) (VP (ADVP (RB significantly)) (VBN shortened) (NP (NP (DT the) (NNP Doc_10579464_1220_1233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10579464_1235_1238_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (NP (NP (JJ prolonged) (NN swimming) (NN latency)) (PP (IN in) (NP (NNS rats)))) (PP (IN in) (NP (DT a) (NN water) (NN maze) (NN task)))) (. .)))
10579464	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_10579464_1333_1340_Chemical)) (VP (MD may) (VP (AUX have) (NP (JJ unique) (JJ antipsychotic) (NNS activities)) (PP (IN without) (NP (NP (DT the) (NN liability)) (PP (IN of) (NP (NP (NN motor) (NN side) (NNS effects)) (ADJP (JJ typical) (PP (IN of) (NP (JJ classical) (NNS antipsychotics))))))))))))) (. .)))
10669626	0	(S1 (S (NP (JJ Doc_10669626_0_8_Chemical-induced) (NN Doc_10669626_17_37_Disease)) (VP (AUX is) (VP (VBN accelerated) (PP (IN by) (NP (NP (NN growth)) (CC and) (NP (NN Doc_10669626_67_76_Chemical)))))) (. .)))
10669626	1	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN growth)) (CC and) (NP (JJ Doc_10669626_126_135_Chemical) (NN treatment))) (VP (VB enhance) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NNP Doc_10669626_168_188_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (VBN given) (NP (NP (JJ sufficient) (NNS doses)) (PP (IN of) (NP (NNP Doc_10669626_223_231_Chemical)))) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN gamma-carboxylation)) (PP (IN of) (NP (NP (NNP matrix) (NNP Gla) (NN protein)) (, ,) (NP (NP (DT a) (JJ Doc_10669626_288_301_Disease) (NN inhibitor)) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (VP (VBN expressed) (PP (IN by) (NP (NP (JJ smooth) (NN muscle) (NNS cells)) (CC and) (NP (NP (NNS macrophages)) (PP (IN in) (NP (DT the) (NN artery) (NN wall)))))))))))))))))))))))) (. .)))
10669626	2	(S1 (S (NP (NP (DT The) (JJ first) (NN series)) (PP (IN of) (NP (NNS experiments)))) (VP (VBD examined) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NN age)) (CC and) (NP (NN growth) (NN status)))) (PP (IN on) (NP (NP (NNP Doc_10669626_476_496_Disease)) (PP (IN in) (NP (JJ Doc_10669626_500_508_Chemical-treated) (NNS rats))))))) (. .)))
10669626	3	(S1 (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (PP (IN with) (NP (NNP Doc_10669626_550_558_Chemical)))))) (VP (VBD caused) (NP (NP (NP (JJ massive) (JJ focal) (JJ Doc_10669626_580_607_Disease) (NNS media)) (PP (IN in) (NP (JJ 20-day-old) (NNS rats)))) (CC and) (NP (NP (ADJP (RBR less) (JJ extensive)) (JJ focal) (NN Doc_10669626_658_671_Disease)) (PP (IN in) (NP (JJ 42-day-old) (NNS rats)))))) (. .)))
10669626	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT no) (NN Doc_10669626_708_728_Disease)) (VP (MD could) (VP (AUX be) (VP (VBN detected) (PP (IN in) (NP (JJ 10-month-old) (NN adult) (NNS rats))) (PP (ADVP (RB even)) (IN after) (NP (NP (CD 4) (NNS weeks)) (PP (IN of) (NP (JJ Doc_10669626_796_804_Chemical) (NN treatment)))))))) (. .)))
10669626	5	(S1 (S (S (VP (TO To) (VP (ADVP (RB directly)) (VB examine) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NN growth))) (PP (TO to) (NP (NNP Doc_10669626_864_872_Chemical-induced) (NNP Doc_10669626_881_901_Disease))) (PP (IN in) (NP (NP (NNS animals)) (PP (IN of) (NP (DT the) (JJ same) (NN age))))))))) (, ,) (NP (JJ 20-day-old) (NNS rats)) (VP (AUX were) (VP (VBN fed) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (CC either) (NP (DT an) (NN ad) (NN libitum)))) (NP (NP (NN diet)) (CC or) (NP (NP (DT a) (JJ 6-g/d) (JJ restricted) (NN diet)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ maintains) (NP (NN weight))) (CC but) (VP (VBZ prevents) (NP (NN growth)))))))))) (. .)))
10669626	6	(S1 (S (NP (NP (JJ Concurrent) (NN treatment)) (PP (IN of) (NP (DT both) (JJ dietary) (NNS groups))) (PP (IN with) (NP (NNP Doc_10669626_1112_1120_Chemical)))) (VP (VP (VBD produced) (NP (JJ massive) (JJ focal) (NN Doc_10669626_1144_1171_Disease) (NNS media)) (PP (IN in) (NP (DT the) (NN ad) (JJ libitum-fed) (NNS rats)))) (CC but) (VP (NP (DT no) (JJ detectable) (NN Doc_10669626_1223_1243_Disease)) (PP (IN in) (NP (DT the) (JJ restricted-diet) (, ,) (JJ growth-inhibited) (NN group))))) (. .)))
10669626	7	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN explanation)) (PP (IN for) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_10669626_1345_1365_Disease)) (CC and) (NP (NN growth) (NN status) (NN cannot))))))) (VP (AUX be) (VP (VBN determined) (PP (IN from) (NP (DT the) (JJ present) (NN study))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (JJR higher) (NN serum) (NN Doc_10669626_1475_1484_Chemical)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_10669626_1507_1527_Disease))))))) (, ,) (PP (IN with) (NP (NP (ADJP (NP (CD 30) (NN %)) (JJR higher)) (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_10669626_1561_1570_Chemical))) (PP (IN in) (NP (NP (JJ young) (, ,) (ADJP (NN ad) (JJ libitum-fed)) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NP (DT either)) (PP (IN of) (NP (NP (NP (DT the) (NNS groups)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (JJ resistant) (PP (TO to) (NP (JJ Doc_10669626_1658_1666_Chemical-induced) (NNP Doc_10669626_1675_1695_Disease)))))))) (, ,) (NP (NNS ie)) (, ,) (NP (DT the) (JJ 10-month-old) (NNS rats)) (CC and) (NP (DT the) (JJ restricted-diet) (, ,) (JJ growth-inhibited) (JJ young) (NNS rats)))))))))))) (. .)))
10669626	8	(S1 (S (NP (DT This) (NN observation)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (VBN increased) (NN susceptibility)) (PP (TO to) (NP (NNP Doc_10669626_1836_1844_Chemical-induced) (NNP Doc_10669626_1853_1873_Disease)))) (VP (MD could) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (JJR higher) (NN serum) (JJ Doc_10669626_1907_1916_Chemical) (NNS levels))))))))) (. .)))
10669626	9	(S1 (S (NP (NP (DT The) (JJ second) (NN set)) (PP (IN of) (NP (NNS experiments)))) (VP (VBD examined) (NP (NP (DT the) (JJ possible) (NN synergy)) (PP (IN between) (NP (NP (NP (NNP Doc_10669626_1993_2002_Chemical)) (CC and) (NP (NNP Doc_10669626_2007_2015_Chemical))) (PP (IN in) (NP (NNP Doc_10669626_2019_2039_Disease))))))) (. .)))
10669626	10	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NNP Doc_10669626_2055_2064_Chemical)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_10669626_2084_2111_Disease) (NNS media)) (PP (IN in) (NP (QP (RB as) (JJ little) (IN as) (CD 3) (TO to) (CD 4)) (NNS days)))))))) (. .)))
10669626	11	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (DT the) (NNP Doc_10669626_2165_2174_Chemical) (NN antagonist) (NN Doc_10669626_2186_2194_Chemical)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_10669626_2219_2246_Disease) (NNS media))))) (, ,) (UCP (CC but) (PP (IN at) (NP (NP (NN treatment) (NNS times)) (PP (IN of) (NP (CD 2) (NNS weeks))))) (CC or) (ADVP (ADVP (RB longer)) (CC yet) (ADVP (RB not) (IN at) (NP (CD 1) (NN week))))))) (. .)))
10669626	12	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD investigated) (NP (NP (DT the) (NN synergy)) (PP (IN between) (NP (DT these) (CD 2) (NNS treatments))))) (CC and) (VP (VBD found) (SBAR (IN that) (S (NP (JJ concurrent) (NNP Doc_10669626_2420_2428_Chemical) (NN administration)) (ADVP (RB dramatically)) (VP (VBD increased) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NNP Doc_10669626_2481_2494_Disease)))) (PP (IN in) (NP (NP (DT the) (NNS media)) (PP (IN of) (NP (JJ Doc_10669626_2511_2520_Chemical-treated) (NNS rats))))) (PP (IN at) (NP (QP (CD 3) (CC and) (CD 4)) (NNS days)))))))) (. .)))
10669626	13	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ close) (NN parallel)) (PP (IN between) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_10669626_2600_2609_Chemical) (NN dose))) (PP (IN on) (NP (NNP Doc_10669626_2618_2638_Disease)))) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_10669626_2657_2666_Chemical) (NN dose))) (PP (IN on) (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (NNP serum) (NNP Doc_10669626_2698_2705_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_10669626_2727_2736_Chemical)) (VP (MD may) (VP (VB induce) (NP (NNP Doc_10669626_2748_2768_Disease)) (PP (IN through) (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (JJ serum) (NNP Doc_10669626_2797_2804_Chemical))))))))))))))))))))) (. .)))
10669626	14	(S1 (S (SBAR (IN Because) (S (NP (JJ Doc_10669626_2814_2822_Chemical) (NN treatment)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN elevation)) (PP (IN in) (NP (JJ serum) (NNP Doc_10669626_2873_2880_Chemical))) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_10669626_2893_2902_Chemical)))))))))) (, ,) (NP (NP (DT the) (NN synergy)) (PP (IN between) (NP (NNP Doc_10669626_2924_2932_Chemical) (CC and) (NNP Doc_10669626_2937_2946_Chemical)))) (VP (AUX is) (ADVP (RB probably)) (VP (ADVP (RBS best)) (VBN explained) (PP (IN by) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_10669626_2997_3005_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (PP (IN as) (NP (DT a) (NNP Doc_10669626_3055_3068_Disease) (NN inhibitor)))))))))) (. .)))
10669626	15	(S1 (S (S (NP (NP (JJ High) (NNS levels)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (VP (AUX are) (VP (VBN found) (PP (IN at) (NP (NP (NNS sites)) (PP (IN of) (NP (NNP Doc_10669626_3136_3156_Disease))))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_10669626_3178_3187_Chemical)) (CC plus) (NP (NNP Doc_10669626_3193_3201_Chemical)))))))))) (, ,) (CC and) (S (NP (NN chemical) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN protein) (SBAR (IN that) (S (VP (VBN accumulated))))) (VP (AUX was) (ADVP (RB indeed)) (RB not) (ADJP (JJ Doc_10669626_3281_3299_Chemical))))))) (. .)))
10669626	16	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (IN although) (S (NP (NP (DT the) (JJ Doc_10669626_3347_3369_Chemical) (NNS residues)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (VP (AUX are) (ADVP (RB apparently)) (VP (VBN required) (PP (IN for) (NP (PRP$ its) (NN function))) (PP (IN as) (NP (DT a) (JJ Doc_10669626_3447_3460_Disease) (NN inhibitor))))))) (, ,) (NP (PRP they)) (VP (AUX are) (RB not) (VP (VBN required) (PP (IN for) (NP (NP (PRP$ its) (NN accumulation)) (PP (IN at) (NP (JJ Doc_10669626_3518_3531_Disease) (NNS sites)))))))))) (. .)))
10683478	0	(S1 (S (NP (NN Test) (NNS conditions)) (VP (VBP influence) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (DT a) (NN drug) (NN challenge)) (PP (IN in) (NP (NNS rodents))))))) (. .)))
10683478	1	(S1 (S (NP (DT These) (NNS studies)) (VP (AUX were) (VP (VBN conducted) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN differential) (NN response)) (PP (TO to) (NP (NP (DT a) (NN drug) (NN challenge)) (PP (IN under) (NP (NP (JJ varied) (JJ experimental) (NN test) (NNS conditions)) (VP (ADVP (RB routinely)) (VBN employed) (S (VP (TO to) (VP (VB study) (NP (NP (JJ drug-induced) (JJ behavioral) (CC and) (JJ neurophysiological) (NNS responses)) (PP (IN in) (NP (NNS rodents)))))))))))))))))) (. .)))
10683478	2	(S1 (S (NP (NP (NNP Doc_10683478_296_307_Chemical)) (, ,) (NP (DT a) (JJ nonselective) (NN Doc_10683478_324_340_Chemical)) (, ,)) (VP (AUX was) (VP (VBN selected) (PP (JJ due) (TO to) (NP (NP (PRP$ its) (JJ biphasic) (JJ behavioral) (NNS effects)) (, ,) (NP (PRP$ its) (NN ability) (S (VP (VP (TO to) (VP (VB induce) (NP (NNP Doc_10683478_417_428_Disease)))) (, ,) (CC and) (VP (TO to) (VP (VB produce) (NP (NP (JJ distinct) (NNS changes)) (PP (TO to) (NP (NP (JJ Doc_10683478_465_473_Chemical) (NN turnover)) (PP (IN in) (NP (DT the) (JJ rodent) (NN brain))))))))))))))) (. .)))
10683478	3	(S1 (S (PP (IN From) (NP (JJ such) (NNS experiments))) (NP (EX there)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (NP (NN characterization)) (CC and) (NP (NN detection))) (PP (IN of) (NP (JJ Doc_10683478_583_594_Chemical-induced) (NN activity))) (PP (IN in) (NP (NNS rodents)))) (ADVP (RB critically)) (VP (VBZ depends) (PP (IN upon) (NP (NP (DT the) (NN test) (NNS conditions)) (VP (VBN employed))))))))) (. .)))
10683478	4	(S1 (S (PP (IN In) (NP (NNS rats))) (, ,) (NP (NP (NN detection)) (PP (IN of) (NP (NNP Doc_10683478_699_710_Chemical-induced) (NNP Doc_10683478_719_732_Disease)))) (VP (AUX was) (VP (VBN facilitated) (PP (IN by) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NN acclimatization))) (PP (TO to) (NP (DT the) (NN test) (NNS conditions))))))) (. .)))
10683478	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN test) (NNS conditions)) (VP (MD can) (VP (VB impact) (PP (IN upon) (NP (NP (JJ other) (JJ physiological) (NNS responses)) (PP (TO to) (NP (NNP Doc_10683478_879_890_Chemical))) (PP (JJ such) (IN as) (NP (JJ drug-induced) (NNP Doc_10683478_912_923_Disease))))))) (. .)))
10683478	6	(S1 (S (PP (IN In) (NP (NNS mice))) (, ,) (NP (NNP Doc_10683478_934_945_Chemical)) (VP (VBD produced) (NP (ADJP (RB qualitatively) (JJ different)) (NNS responses)) (PP (IN under) (NP (JJ novel) (NNS conditions))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (NP (DT those) (NNS behaviors)) (VP (VBN elicited) (PP (IN in) (NP (DT the) (NN home) (NN test) (NN cage)))))))))) (. .)))
10683478	7	(S1 (S (NP (JJ Drug-induced) (JJ gross) (NN activity) (NNS counts)) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ novel) (JJ exploratory) (NN box) (RB only))) (, ,) (SBAR (IN while) (S (NP (NP (NNS measures)) (PP (IN of) (NP (JJ stereotypic) (NN behavior)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN in) (NP (DT both))))))))) (. .)))
10683478	8	(S1 (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (JJ Doc_10683478_1236_1247_Chemical-induced) (NN locomotion)) (VP (AUX was) (ADJP (RBR more) (JJ prominent)) (PP (IN in) (NP (DT the) (JJ novel) (JJ exploratory) (NN box)))) (. .)))
10683478	9	(S1 (S (NP (NP (JJ Doc_10683478_1316_1324_Chemical) (NN turnover) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_10683478_1342_1347_Chemical)) (: :) (NP (NP (NNP Doc_10683478_1348_1350_Chemical)) (CC and) (NP (NNP Doc_10683478_1355_1358_Chemical))) (: :) (NP (NNP Doc_10683478_1359_1361_Chemical))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJR lower)) (PP (IN in) (NP (NP (DT those) (NNS animals)) (VP (VBN exposed) (PP (TO to) (NP (DT the) (JJ exploratory) (NN box)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN home) (NN cage) (NNS counterparts))))))))))) (. .)))
10683478	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ Doc_10683478_1490_1501_Chemical-induced) (NNS reductions)) (PP (IN in) (NP (JJ striatal) (JJ Doc_10683478_1533_1541_Chemical) (NN turnover)))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (DT both) (NN novel) (CC and) (NN home) (NN cage) (NNS environments))))) (. .)))
10683478	11	(S1 (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (AUX are) (VP (VBN discussed) (PP (IN with) (NP (JJ particular) (NN emphasis))) (PP (IN upon) (S (VP (VBG conducting) (NP (JJ psychopharmacological) (NN challenge) (NNS tests)) (PP (IN in) (NP (NNS rodents)))))))) (. .)))
10704919	0	(S1 (S (NP (NP (NN Doc_10704919_0_9_Disease)) (PP (IN of) (NP (NP (JJ human) (NNS erythrocytes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10704919_43_52_Chemical))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (NN disruption)) (PP (IN of) (NP (NN membrane) (NN structure))))))) (. .)))
10704919	1	(S1 (S (NP (NP (NP (NNP Doc_10704919_101_110_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10704919_112_115_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ antiestrogenic) (NN drug)) (VP (ADVP (RBS most) (RB widely)) (VBN prescribed) (PP (IN in) (NP (NP (DT the) (NN chemotherapy)) (PP (IN of) (NP (NNP Doc_10704919_188_201_Disease))))))) (, ,)) (VP (VBZ induces) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ normal) (JJ discoid) (NN shape)) (PP (IN of) (NP (NP (NNS erythrocytes)) (CC and) (NP (NNP Doc_10704919_263_279_Disease)))))))) (. .)))
10704919	2	(S1 (S (NP (DT This) (NN work)) (VP (VBZ evaluates) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10704919_316_319_Chemical))) (PP (IN on) (NP (VBN isolated) (JJ human) (NNS erythrocytes)))) (, ,) (S (VP (VBG attempting) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (VBG underlying) (NNS mechanisms)) (PP (IN on) (NP (NP (JJ Doc_10704919_404_407_Chemical-induced) (NN Doc_10704919_416_432_Disease)) (CC and) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNS biomembranes))) (PP (IN in) (NP (PRP$ its) (JJ cytostatic) (NN action) (NNS mechanisms))))))))))))) (. .)))
10704919	3	(S1 (S (NP (NN Doc_10704919_506_509_Chemical)) (VP (VBZ induces) (NP (NP (NN Doc_10704919_518_527_Disease)) (PP (IN of) (NP (NNS erythrocytes)))) (PP (IN as) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (NN concentration)))))) (. .)))
10704919	4	(S1 (S (S (NP (NP (DT The) (NN extension)) (PP (IN of) (NP (NNP Doc_10704919_593_602_Disease)))) (VP (AUX is) (ADJP (JJ variable) (PP (IN with) (NP (JJ erythrocyte) (NNS samples)))))) (, ,) (CC but) (S (NP (CD 12.5) (NN microM) (NN Doc_10704919_657_660_Chemical)) (VP (VBZ induces) (NP (NP (JJ total) (NN Doc_10704919_675_684_Disease)) (PP (IN of) (NP (DT all) (VBN tested) (NNS suspensions)))))) (. .)))
10704919	5	(S1 (S (PP (IN Despite) (S (VP (VBG inducing) (NP (JJ extensive) (NN erythrocyte) (NN lysis))))) (, ,) (NP (NNP Doc_10704919_758_761_Chemical)) (VP (AUX does) (RB not) (VP (VB shift) (NP (NP (DT the) (JJ osmotic) (NN fragility) (NNS curves)) (PP (IN of) (NP (NNS erythrocytes)))))) (. .)))
10704919	6	(S1 (S (NP (NP (DT The) (JJ Doc_10704919_827_836_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_10704919_847_850_Chemical)))) (VP (AUX is) (VP (VBN prevented) (PP (IN by) (NP (NP (NP (JJ low) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_10704919_889_905_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10704919_907_914_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_10704919_920_944_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_10704919_946_955_Chemical) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (VP (VBN inactivated) (NP (JJ functional) (NNP Doc_10704919_981_989_Chemical))) (-RRB- -RRB-))) (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP Doc_10704919_1007_1010_Chemical-induced) (NNP Doc_10704919_1019_1028_Disease)) (VP (AUX is) (RB not) (VP (VBN related) (S (VP (TO to) (VP (VB oxidative) (NP (JJ membrane) (NN damage)))))))))))))) (. .)))
10704919	7	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RB further)) (VP (VP (VBN evidenced) (PP (IN by) (NP (NP (NN absence)) (PP (IN of) (NP (NP (JJ Doc_10704919_1115_1121_Chemical) (NN consumption)) (CC and) (NP (NN hemoglobin) (NN oxidation))))))) (CC both) (VP (VBN determined) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (NNP Doc_10704919_1192_1195_Chemical-induced) (NNP Doc_10704919_1204_1213_Disease)))))))) (. .)))
10704919	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN observed) (SBAR (IN that) (S (NP (NNP Doc_10704919_1249_1252_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN peroxidation)) (PP (IN of) (NP (NP (JJ human) (NNS erythrocytes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10704919_1312_1316_Chemical))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG ruling) (PP (IN out) (NP (JJ Doc_10704919_1334_1337_Chemical-induced) (NN cell) (NN oxidative) (NN stress)))))))))) (. .)))
10704919	9	(S1 (S (NP (NP (NN Doc_10704919_1369_1378_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_10704919_1389_1392_Chemical))))) (VP (AUX was) (RB not) (VP (VBN preceded) (PP (IN by) (NP (NP (DT the) (NN leakage)) (PP (IN of) (NP (NP (NNP Doc_10704919_1428_1429_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)))) (PP (IN from) (NP (DT the) (NNS cells))))) (, ,) (S (ADVP (RB also)) (VP (VBG excluding) (NP (NP (DT a) (JJ colloid-osmotic) (NN type) (NN mechanism)) (PP (IN of) (NP (NNP Doc_10704919_1500_1509_Disease)))))) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (JJ osmotic) (NN fragility) (NNS curves)))))))) (. .)))
10704919	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_10704919_1574_1577_Chemical)) (VP (VBZ induces) (NP (NP (NN release)) (PP (IN of) (NP (NP (JJ peripheral) (NNS proteins)) (PP (IN of) (NP (NP (NN membrane-cytoskeleton) (CC and) (NN cytosol) (NNS proteins)) (VP (ADVP (RB essentially)) (VBN bound) (S (VP (TO to) (VP (VB band) (NP (CD 3)))))))))))) (. .)))
10704919	11	(S1 (S (CC Either) (NP (NP (NNP Doc_10704919_1699_1706_Chemical)) (CC or) (NP (NNP Doc_10704919_1710_1719_Chemical))) (VP (VP (VBZ increases) (NP (NN membrane) (NN packing))) (CC and) (VP (VBZ prevents) (NP (JJ Doc_10704919_1760_1763_Chemical) (NN partition)) (PP (IN into) (NP (NN model) (NNS membranes))))) (. .)))
10704919	12	(S1 (S (NP (DT These) (NNS effects)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT the) (NN protection)) (PP (IN from) (NP (NNP Doc_10704919_1843_1852_Disease))) (PP (IN by) (NP (NNP Doc_10704919_1856_1867_Chemical)))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (VBN decreased) (JJ Doc_10704919_1894_1897_Chemical) (NN incorporation)) (PP (IN in) (NP (JJ condensed) (NNS membranes)))))))) (CC and) (S (NP (NP (DT the) (JJ structural) (NN damage)) (PP (IN of) (NP (DT the) (JJ erythrocyte) (NN membrane)))) (VP (AUX is) (ADVP (RB consequently)) (VP (VBN avoided))))))) (. .)))
10704919	13	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_10704919_2025_2028_Chemical-induced) (NNP Doc_10704919_2037_2046_Disease)) (VP (VBZ results) (PP (IN from) (NP (NP (DT a) (JJ structural) (NN perturbation)) (PP (IN of) (NP (JJ red) (NN cell) (NN membrane))))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN framework)) (PP (IN of) (NP (DT the) (JJ erythrocyte) (NN membrane)))))) (CC and) (NP (NP (PRP$ its) (NN cytoskeleton)) (VP (VBN caused) (PP (IN by) (NP (NP (PRP$ its) (JJ high) (NN partition)) (PP (IN in) (NP (DT the) (NN membrane))))))))))) (. .)))
10704919	14	(S1 (S (NP (DT These) (NNS defects)) (VP (VBP explain) (NP (NP (NP (DT the) (JJ abnormal) (NN erythrocyte) (NN shape)) (CC and) (NP (VBN decreased) (JJ mechanical) (NN stability))) (VP (VBN promoted) (PP (IN by) (NP (NNP Doc_10704919_2339_2342_Chemical))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_10704919_2357_2373_Disease)))))) (. .)))
10704919	15	(S1 (S (ADVP (RB Additionally)) (, ,) (SBAR (IN since) (S (NP (NN membrane) (NN leakage)) (VP (AUX is) (NP (NP (DT a) (JJ final) (NN stage)) (PP (IN of) (NP (NN cytotoxicity))))))) (, ,) (NP (NP (DT the) (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ structural) (NNS characteristics)) (PP (IN of) (NP (NNS biomembranes))) (PP (IN by) (NP (NNP Doc_10704919_2514_2517_Chemical)))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ multiple) (NNS mechanisms)) (PP (IN of) (NP (PRP$ its) (NN anticancer) (NN action))))))) (. .)))
10706004	0	(S1 (S (NP (NP (NNS Changes)) (PP (IN of) (NP (NP (NNP Doc_10706004_11_17_Chemical) (CC and) (NNP Doc_10706004_22_25_Chemical) (NNS affinities)) (PP (IN of) (NP (DT the) (JJ cardiac) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_53_55_Chemical)) (, ,) (NP (NNP Doc_10706004_56_57_Chemical)) (-RRB- -RRB-)) (NN -ATPase))))) (PP (IN during) (CC and) (IN after) (NP (NNP Doc_10706004_83_95_Chemical)))) (VP (VBP deficient) (NP (NN Doc_10706004_106_118_Disease))) (. .)))
10706004	1	(S1 (S (PP (IN In) (NP (DT the) (JJ cardiovascular) (NN system))) (, ,) (NP (NNP Doc_10706004_150_152_Chemical)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS functions))))))))) (. .)))
10706004	2	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_10706004_224_226_Chemical) (NN synthesis) (VBZ induces)))) (VP (VBD sustained) (NP (NN Doc_10706004_255_267_Disease))) (. .)))
10706004	3	(S1 (S (PP (IN In) (NP (NP (JJ several) (NNS models)) (PP (IN of) (NP (NNP Doc_10706004_290_302_Disease))))) (, ,) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ intracellular) (JJ Doc_10706004_331_337_Chemical) (NN level)))) (VP (AUX was) (VP (VBN documented) (PP (IN in) (NP (JJ cardiac) (NN tissue))))) (. .)))
10706004	4	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN of) (NP (NP (NNS disturbances)) (PP (IN in) (NP (NP (JJ transmembraneous) (NN transport)) (PP (IN of) (NP (NNP Doc_10706004_457_459_Chemical+))))))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (JJ cardiac) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_498_500_Chemical)) (, ,) (NP (NNP Doc_10706004_501_502_Chemical)) (-RRB- -RRB-)) (NN -ATPase))) (PP (TO to) (NP (NP (NNP Doc_10706004_514_516_Chemical-deficient) (NNP Doc_10706004_527_539_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (JJ Doc_10706004_559_561_Chemical-synthase) (NN inhibition)) (PP (IN with) (NP (NP (CD 40) (NN mg/kg/day)) (NP (NP (NNP Doc_10706004_600_634_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_636_642_Chemical)) (-RRB- -RRB-))))))) (PP (IN for) (NP (QP (CD 4) (CD four)) (NNS weeks)))))))) (. .)))
10706004	5	(S1 (S (PP (IN After) (NP (NP (JJ 4-week) (NN administration)) (PP (IN of) (NP (NNP Doc_10706004_693_699_Chemical))))) (, ,) (NP (NP (DT the) (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (VP (VBN increased) (PP (IN by) (NP (CD 36) (NN %)))) (. .)))
10706004	6	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN after) (S (VP (VBG terminating) (NP (DT the) (NN treatment))))) (, ,) (NP (DT the) (NNS SBP)) (VP (VBD recovered) (S (VP (TO to) (VP (VB control) (NP (NN value)))))) (. .)))
10706004	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG activating) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_853_855_Chemical)) (, ,) (NP (NNP Doc_10706004_856_857_Chemical)) (-RRB- -RRB-)) (NN -ATPase)) (PP (IN with) (NP (PRP$ its) (JJ substrate) (NN Doc_10706004_885_888_Chemical)))))) (, ,) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (UCP (NNP Km) (CC and) (NNP Vmax)) (NNS values)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_10706004_940_942_Chemical-deficient) (NNS rats))))) (. .)))
10706004	8	(S1 (S (PP (IN During) (NP (NP (NN activation)) (PP (IN with) (NP (NNP Doc_10706004_982_984_Chemical+))))) (, ,) (NP (DT the) (NNP Vmax)) (VP (VBD remained) (ADJP (JJ unchanged)) (, ,) (ADVP (RB however)) (SBAR (S (NP (NP (DT the) (NNP Doc_10706004_1028_1029_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1030_1032_Chemical)) (-RRB- -RRB-))) (VP (VBD increased) (PP (IN by) (NP (CD 50) (NN %))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ profound) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN affinity)) (PP (IN of) (NP (NP (DT the) (JJ Doc_10706004_1106_1108_Chemical+-binding) (NN site)) (PP (IN in) (NP (JJ Doc_10706004_1126_1128_Chemical-deficient) (NNS rats)))))))))))))) (. .)))
10706004	9	(S1 (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN from) (NP (NNP Doc_10706004_1165_1177_Disease))))) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1196_1198_Chemical)) (, ,) (NP (NNP Doc_10706004_1199_1200_Chemical)) (-RRB- -RRB-)) (NN -ATPase)))) (VP (VBD increased) (, ,) (PP (JJ due) (TO to) (NP (NP (JJR higher) (NN affinity)) (PP (IN of) (NP (DT the) (JJ Doc_10706004_1250_1253_Chemical-binding) (NN site))))) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN from) (NP (NP (DT the) (VBN lowered) (JJ Km) (NN value)) (PP (IN for) (NP (NNP Doc_10706004_1310_1313_Chemical))))))))) (. .)))
10706004	10	(S1 (S (NP (NP (DT The) (NNP Doc_10706004_1319_1320_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1321_1323_Chemical)) (-RRB- -RRB-)) (NN value)) (PP (IN for) (NP (NNP Doc_10706004_1335_1337_Chemical+)))) (VP (VBD returned) (S (VP (TO to) (VP (VB control) (NP (NN value)))))) (. .)))
10706004	11	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_10706004_1380_1382_Chemical-synthase)))) (VP (VBN induced) (NP (NP (DT a) (JJ reversible) (NN Doc_10706004_1413_1425_Disease)) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_10706004_1441_1450_Disease) (NNP Doc_10706004_1451_1453_Chemical+-extrusion))))) (PP (IN from) (NP (JJ cardiac) (NNS cells))) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (JJ deteriorated) (JJ Doc_10706004_1517_1519_Chemical+-binding) (NNS properties)) (PP (IN of) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1548_1550_Chemical)) (, ,) (NP (NNP Doc_10706004_1551_1552_Chemical)) (-RRB- -RRB-)) (NN -ATPase)))))))) (. .)))
10706004	12	(S1 (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (TO to) (NP (NN control) (NNS values))))) (, ,) (NP (NP (DT the) (NN extrusion)) (PP (IN of) (NP (NNP Doc_10706004_1631_1633_Chemical+))) (PP (IN from) (NP (JJ cardiac) (NNS cells)))) (VP (AUX was) (VP (VBN normalized) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (NP (NN restoration)) (PP (IN of) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1705_1707_Chemical)) (, ,) (NP (NNP Doc_10706004_1708_1709_Chemical)) (-RRB- -RRB-)) (JJ -ATPase) (NN activity)))))))))) (. .)))
10721819	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (JJ long-term) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10721819_39_52_Chemical))))) (PP (IN on) (NP (NP (NNP Doc_10721819_56_69_Chemical-induced) (NNP Doc_10721819_78_89_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
10721819	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (PP (IN that) (NP (NP (JJ Doc_10721819_132_145_Chemical-induced) (NNP Doc_10721819_154_165_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD persisted) (SBAR (S (S (PP (IN after) (NP (NN adrenalectomy))) (, ,) (VP (AUX is) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (VP (VBN mediated) (PP (IN by) (NP (JJ central) (NNP Doc_10721819_231_239_Chemical) (NNP D2) (NN receptor) (NN activation)))))) (CC and) (S (NP (-LRB- -LRB-) (NNP ii) (-RRB- -RRB-)) (VP (VBN reduced) (PP (IN by) (NP (JJ 5-day) (JJ Doc_10721819_289_302_Chemical) (NN pretreatment))))))) (, ,) (S (VP (VBG supporting) (ADVP (RB therefore)) (SBAR (S (NP (NP (DT the) (NN hypothesis)) (PP (IN that) (NP (DT this) (NN effect)))) (VP (AUX is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ sympathetic) (NN outflow)) (PP (TO to) (NP (DT the) (NN heart)))))))))))))))))))) (. .)))
10721819	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (NP (JJ prolonged) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10721819_492_505_Chemical)))) (VP (MD could) (VP (VB abolish) (NP (NP (JJ Doc_10721819_520_533_Chemical-induced) (NN Doc_10721819_542_553_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))))))))))) (. .)))
10721819	3	(S1 (S (NP (NP (JJ Doc_10721819_573_586_Chemical) (NN pretreatment)) (PP (IN for) (NP (CD 15) (NNS days)))) (VP (VBD caused) (NP (NN Doc_10721819_619_638_Disease)) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NN baseline) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))))) (. .)))
10721819	4	(S1 (S (PP (IN In) (NP (NN control) (NNS rats))) (, ,) (NP (NP (JJ intravenous) (NNP Doc_10721819_726_739_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 150) (NN microg/kg)) (-RRB- -RRB-))) (VP (VBN induced) (S (ADJP (JJ significant) (NP (NP (NNP Doc_10721819_776_787_Disease)) (CC and) (NP (NNP Doc_10721819_792_803_Disease)))))) (. .)))
10721819	5	(S1 (S (NP (JJ Doc_10721819_805_818_Chemical-induced) (NNP Doc_10721819_827_838_Disease)) (VP (AUX was) (ADJP (JJ unaffected) (PP (IN by) (NP (JJ Doc_10721819_857_870_Chemical) (NN pretreatment)))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_10721819_891_902_Disease)) (VP (AUX was) (VP (VBN reversed) (PP (TO to) (NP (JJ significant) (NNP Doc_10721819_931_942_Disease))) (, ,) (NP (NP (DT an) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADVP (RB partly)) (VP (VBN reduced) (PP (IN by) (S (VP (VBG i.v.) (NP (NP (NNP Doc_10721819_986_997_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)))))))))))))))) (. .)))
10721819	6	(S1 (S (NP (CC Neither) (NP (JJ cardiac) (NN vagal)) (CC nor) (NP (JJ sympathetic) (NN tone))) (VP (AUX was) (VP (VBN altered) (PP (IN by) (NP (JJ Doc_10721819_1069_1082_Chemical) (NN pretreatment))))) (. .)))
10721819	7	(S1 (S (PP (IN In) (NP (NP (JJ isolated) (JJ perfused) (NN heart) (NNS preparations)) (PP (IN from) (NP (JJ Doc_10721819_1142_1155_Chemical-pretreated) (NNS rats))))) (, ,) (NP (NP (DT the) (JJ Doc_10721819_1177_1190_Chemical-induced) (JJ maximal) (NN increase)) (PP (IN in) (NP (JJ left) (JJ ventricular) (NN systolic) (NN pressure)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (JJ saline-pretreated) (NNS rats)) (PRN (-LRB- -LRB-) (S (NP (NP (DT the) (CD EC50)) (PP (IN of) (NP (NP (DT the) (JJ Doc_10721819_1335_1348_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ left) (JJ ventricular) (NN systolic) (NN pressure)))))) (VP (AUX was) (VP (VBN enhanced) (S (ADJP (RB approximately) (JJ 22-fold)))))) (-RRB- -RRB-))))))) (. .)))
10721819	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ 15-day) (JJ Doc_10721819_1472_1485_Chemical) (NN pretreatment)) (VP (CONJP (RB not) (RB only)) (VP (VBD abolished) (CC but) (VBD reversed) (NP (JJ Doc_10721819_1531_1544_Chemical-induced) (NN Doc_10721819_1553_1564_Disease)) (PP (TO to) (NP (NP (NNP Doc_10721819_1568_1579_Disease)) (, ,) (NP (NP (DT an) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADVP (RB mainly)) (VP (VBN related) (PP (TO to) (NP (JJ further) (JJ cardiac) (NN beta-adrenoceptor) (NN desensitization))))))))))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (NN impairment)) (PP (IN of) (NP (NP (JJ autonomic) (NN regulation)) (PP (IN of) (NP (DT the) (NN heart))))))))))) (. .)))
10721819	9	(S1 (S (NP (PRP They)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (JJ normal) (JJ conscious) (NNS rats))) (, ,) (NP (NP (DT the) (JJ central) (NN Doc_10721819_1788_1799_Disease)) (PP (IN of) (NP (NNP Doc_10721819_1803_1816_Chemical)))) (VP (VBZ appears) (S (VP (VP (TO to) (VP (VB predominate))) (CC and) (VP (TO to) (VP (NN mask) (NP (NP (DT the) (NN Doc_10721819_1856_1867_Disease)) (PP (IN of) (NP (DT this) (NN agonist))) (PP (IN at) (NP (JJ peripheral) (NNP Doc_10721819_1898_1906_Chemical) (NNP D2) (NNS receptors)))))))))))) (. .)))
10737864	0	(S1 (NP (NP (DT A) (JJ developmental) (NN analysis)) (PP (IN of) (NP (NP (NP (NNP Doc_10737864_28_37_Chemical) (POS 's)) (NNS effects)) (PP (IN on) (NP (NP (JJ cardiac) (NN rate) (CC and) (NN ultrasound) (NN production)) (PP (IN in) (NP (NN infant) (NNS rats))))))) (. .)))
10737864	1	(S1 (S (PP (IN Under) (NP (JJ controlled) (NNS conditions))) (, ,) (NP (NN infant) (NNS rats)) (VP (VBP emit) (NP (JJ ultrasonic) (NNS vocalizations)) (PP (PP (IN during) (NP (JJ extreme) (JJ cold) (NN exposure))) (CC and) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT the) (NN alpha) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN adrenoceptor) (NN agonist)) (, ,) (NP (NNP Doc_10737864_269_278_Chemical)))))))) (. .)))
10737864	2	(S1 (S (NP (JJ Previous) (NNS investigations)) (VP (AUX have) (VP (VBN determined) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_10737864_341_350_Chemical))))) (, ,) (NP (NN ultrasound) (NN production)) (VP (VP (VBZ increases) (PRT (RP through)) (NP (DT the) (JJ 2nd-week) (NN postpartum))) (CC and) (VP (VBZ decreases) (ADVP (RB thereafter)))))))) (. .)))
10737864	3	(S1 (S (S (VP (VP (VBN Given) (NP (DT that) (JJ sympathetic) (JJ neural) (NN dominance) (NNS exhibits)) (NP (DT a) (JJ similar) (NN developmental) (NN pattern))) (, ,) (CC and) (VP (VBN given) (SBAR (IN that) (S (NP (NNP Doc_10737864_539_548_Chemical)) (VP (VBZ induces) (NP (NP (JJ sympathetic) (NN withdrawal)) (CC and) (NP (NNP Doc_10737864_584_595_Disease))))))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_10737864_618_627_Chemical) (POS 's)) (JJ developmental) (NNS effects)) (PP (IN on) (NP (NP (JJ cardiac) (NN rate)) (CC and) (NP (NN ultrasound) (NN production))))) (VP (MD would) (VP (VB mirror) (NP (DT each) (JJ other))))))) (. .)))
10737864	4	(S1 (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (DT the) (JJ present) (NN experiment))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10737864_772_781_Chemical) (NN administration))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN on) (NP (JJ cardiac) (NN rate) (CC and) (NN ultrasound) (NN production)))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (NN 2-)) (, ,) (NP (NN 8-)) (, ,) (NP (NN 15-)) (, ,) (CC and) (NP (JJ 20-day-old) (NNS rats)))))) (. .)))
10737864	5	(S1 (S (NP (NP (JJ Age-related) (NNS changes)) (PP (IN in) (NP (NN ultrasound) (NN production)))) (VP (VBD corresponded) (PP (IN with) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ cardiovascular) (NNS variables)) (, ,) (PP (VBG including) (NP (NP (NN baseline) (JJ cardiac) (NN rate)) (CC and) (NP (JJ Doc_10737864_1038_1047_Chemical-induced) (NN Doc_10737864_1056_1067_Disease))))))))) (. .)))
10737864	6	(S1 (S (NP (DT This) (NN experiment)) (VP (AUX is) (VP (VBN discussed) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NN ultrasound) (NN production)) (VP (AUX is) (NP (NP (DT the) (JJ acoustic) (NN by-product)) (PP (IN of) (NP (NP (DT a) (JJ physiological) (NN maneuver)) (SBAR (WHNP (WDT that)) (S (VP (VBZ compensates) (PP (IN for) (NP (NP (NP (NNP Doc_10737864_1231_1240_Chemical) (POS 's)) (JJ detrimental) (NNS effects)) (PP (IN on) (NP (JJ cardiovascular) (NN function)))))))))))))))))))) (. .)))
10739826	0	(S1 (FRAG (NP (NN Recurrent) (NN use)) (PP (IN of) (NP (NP (JJR newer) (NN Doc_10739826_23_42_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10739826_59_81_Disease)))))) (. .)))
10739826	1	(S1 (NP (NP (DT The) (JJ epidemiological) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD assessed) (SBAR (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_10739826_137_159_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10739826_161_164_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (JJR newer) (NNP Doc_10739826_188_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10739826_209_211_Chemical)) (-RRB- -RRB-)))))) (VP (AUX did) (RB not) (VP (VB distinguish) (PP (IN between) (NP (NP (NP (NNS patterns)) (PP (IN of) (NP (JJ Doc_10739826_253_255_Chemical) (NN use)))) (, ,) (ADVP (RB namely)) (NP (JJ first-time) (NNS users)) (, ,) (NP (NNS repeaters)) (CC and) (NP (NNS switchers))))))))))) (. .)))
10739826	2	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (DT a) (JJ Transnational) (NN case-control) (NN study)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10739826_388_391_Disease))) (PP (IN for) (NP (NP (DT the) (JJ latter) (NNS patterns)) (PP (IN of) (NP (NN use))))))))) (, ,) (SBAR (IN while) (S (VP (VBG accounting) (PP (IN for) (NP (NP (NN duration)) (PP (IN of) (NP (NN use)))))))))) (. .)))
10739826	3	(S1 (S (PP (IN Over) (NP (DT the) (NN period) (CD 1993-1996))) (, ,) (NP (NP (CD 551) (NNS cases)) (PP (IN of) (NP (NNP Doc_10739826_502_505_Disease)))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (NP (NNP Germany)) (CC and) (NP (DT the) (NNP UK)))) (PP (IN along) (PP (IN with) (NP (CD 2066) (NNS controls)))))) (. .)))
10739826	4	(S1 (S (NP (NP (NNS Totals)) (PP (IN of) (NP (NP (CD 128) (NNS cases)) (CC and) (NP (CD 650) (NNS controls))))) (VP (AUX were) (VP (VBN analysed) (PP (IN for) (NP (NP (NN repeat) (NN use)) (CC and) (NP (NP (NP (CD 135) (NNS cases)) (CC and) (NP (CD 622) (NNS controls))) (PP (IN for) (NP (VBG switching) (NNS patterns)))))))) (. .)))
10739826	5	(S1 (S (NP (NP (DT The) (JJ adjusted) (NN rate) (NN ratio)) (PP (IN of) (NP (NNP Doc_10739826_718_721_Disease))) (PP (IN for) (NP (NP (NN repeat) (NNS users)) (PP (IN of) (NP (JJ third) (NN generation))))) (NP (NNP Doc_10739826_759_761_Chemical))) (VP (AUX was) (NP (NP (CD 0.6)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI:0.3-1.2)) (-RRB- -RRB-)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NN repeat) (NNS users)) (PP (IN of) (NP (JJ second) (NN generation) (NNS pills))) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX was) (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI:0.7-2.4)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NNS switchers)) (PP (IN from) (NP (NP (ADJP (JJ second) (TO to) (JJ third)) (NN generation) (NNS pills)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NNS switchers)) (PP (PP (IN from) (NP (JJ third))) (PP (TO to) (NP (JJ second) (NN generation) (NNS pills))))))))))))))))))) (. .)))
10739826	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (ADJP (JJ second) (CC and) (JJ third)) (NN generation) (NNS agents)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ equivalent) (NNS risks)) (PP (IN of) (NP (NNP Doc_10739826_1081_1084_Disease))))) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ same) (NN agent)) (VP (AUX is) (VP (VBN used) (ADVP (RB repeatedly)) (PP (IN after) (NP (NN interruption) (NNS periods))))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (NNS users)) (VP (AUX are) (VP (VBN switched) (PP (IN between) (NP (NP (DT the) (CD two) (NNS generations)) (PP (IN of) (NP (NNS pills))))))))))))))) (. .)))
10739826	7	(S1 (S (NP (DT These) (NNS analyses)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJR higher) (NN risk)) (VP (VBN observed) (PP (IN for) (NP (NP (DT the) (JJR newer) (NN Doc_10739826_1283_1285_Chemical)) (PP (IN in) (NP (JJ other) (NNS studies))))))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ inadequate) (NNS comparisons)) (PP (IN of) (NP (NN pill) (NNS users))) (PP (IN with) (NP (NP (JJ different) (NNS patterns)) (PP (IN of) (NP (NN pill) (NN use))))))))))))) (. .)))
10743446	0	(S1 (S (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (NP (ADJP (RB systemically) (VBN administered)) (NNP Doc_10743446_50_58_Chemical)) (CC and) (NP (NNP Doc_10743446_63_72_Chemical)))) (PP (IN on) (NP (ADJP (JJ dynamic) (CC and) (JJ static)) (NNP Doc_10743446_95_107_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intradermal) (NN Doc_10743446_131_140_Chemical)) (PP (IN in) (NP (NNS humans)))))) (. .)))
10743446	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (NNP Doc_10743446_210_218_Chemical) (CC and) (NNP Doc_10743446_223_232_Chemical))))) (PP (IN on) (NP (NP (JJ brush-evoked) (-LRB- -LRB-) (JJ dynamic) (-RRB- -RRB-) (NNP Doc_10743446_259_263_Disease)) (CC and) (NP (JJ punctate-evoked) (-LRB- -LRB-) (JJ static) (-RRB- -RRB-) (NNP Doc_10743446_293_305_Disease) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10743446_317_326_Chemical)))))))))) (. .)))
10743446	2	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ crossover) (NN study))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (CD 12) (NNS volunteers)) (PP (IN in) (NP (CD three) (NNS experiments)))) (. .)))
10743446	3	(S1 (S (NP (JJ Doc_10743446_443_452_Chemical) (CD 100) (NNS micrograms)) (VP (AUX was) (VP (VBN injected) (ADVP (RB intradermally)) (PP (IN on) (NP (NP (DT the) (JJ volar) (NN forearm)) (VP (VBN followed) (PP (IN by) (NP (NP (DT an) (JJ i.v.) (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_10743446_548_556_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ bolus) (CD 0.1) (ADJP (RB mg) (JJ kg-1) (PP (IN over) (NP (NP (CD 10) (NN min)) (VP (VBN followed) (PP (IN by) (NP (NP (NN infusion)) (PP (IN of) (NP (CD 7) (NNS micrograms))))))))) (JJ kg-1) (NN min-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_10743446_638_647_Chemical) (CD 5) (NN mg) (NN kg-1)) (CC or) (NP (NP (NN saline)) (PP (IN for) (NP (CD 50) (NN min)))))))))))))) (. .)))
10743446	4	(S1 (S (NP (NN Infusion)) (VP (VBD started) (NP (CD 15) (NN min)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_10743446_723_732_Chemical)))))) (. .)))
10743446	5	(S1 (S (S (NP (DT The) (JJ following)) (VP (AUX were) (VP (VBN measured)))) (: :) (S (NP (NP (JJ spontaneous) (NN Doc_10743446_775_779_Disease)) (, ,) (NP (NNP Doc_10743446_781_785_Disease))) (VP (VBN evoked) (PP (IN by) (NP (NP (NP (NN punctate) (CC and) (NN brush) (NNS stimuli)) (PRN (-LRB- -LRB-) (NP (NNP VAS)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNS areas)) (PP (IN of) (NP (ADJP (JJ brush-evoked) (CC and) (JJ punctate-evoked)) (NNP Doc_10743446_876_888_Disease)))))))) (. .)))
10743446	6	(S1 (S (S (NP (NN Doc_10743446_890_898_Chemical)) (VP (VBD reduced) (NP (NP (PDT both) (DT the) (NN area)) (PP (IN of) (NP (ADJP (JJ brush-evoked) (CC and) (JJ punctate-evoked)) (NN Doc_10743446_957_969_Disease)))) (ADVP (RB significantly)))) (CC and) (S (NP (PRP it)) (VP (VBD tended) (S (VP (TO to) (VP (VB reduce) (NP (JJ brush-evoked) (NN Doc_10743446_1021_1025_Disease))))))) (. .)))
10743446	7	(S1 (S (NP (NN Doc_10743446_1027_1036_Chemical)) (VP (VBD reduced) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (JJ punctate-evoked) (NN Doc_10743446_1073_1085_Disease)))) (ADVP (RB significantly))) (. .)))
10743446	8	(S1 (S (NP (PRP It)) (VP (VP (VBD tended) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN VAS) (NNS scores)) (PP (IN of) (NP (JJ spontaneous) (NN Doc_10743446_1147_1151_Disease)))))))) (CC but) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ evoked) (NNP Doc_10743446_1180_1184_Disease)))))) (. .)))
10743446	9	(S1 (S (NP (NP (DT The) (NN differential) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10743446_1214_1222_Chemical)) (CC and) (NP (NNP Doc_10743446_1227_1236_Chemical)))) (PP (IN on) (NP (NP (JJ static)) (CC and) (NP (JJ dynamic) (NNP Doc_10743446_1259_1271_Disease))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (CD two) (NNS types)) (PP (IN of) (NP (NNP Doc_10743446_1302_1314_Disease)))) (VP (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (JJ separate) (NNS mechanisms))))) (CC and) (VP (AUX have) (NP (DT a) (JJ distinct) (NN pharmacology))))))) (. .)))
10791295	0	(S1 (NP (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_10791295_15_26_Chemical-induced) (NNP Doc_10791295_35_54_Disease)))) (: :) (NP (NP (NN comparison)) (PP (IN of) (NP (NN adult) (ADJP (JJ male) (CC and) (JJ female)) (NN Wistar) (NNS rats)))) (. .)))
10791295	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NNP Doc_10791295_124_135_Chemical-induced) (PRN (-LRB- -LRB-) (NP (NP (CD 1.0) (JJ mg/kg) (NNP s.c.)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)) (NNP Doc_10791295_172_191_Disease)) (PP (IN of) (NP (NP (JJ adult) (ADJP (JJ male) (CC and) (JJ female)) (JJ Wistar) (NNS rats)) (VP (VBN obtained) (PP (IN from) (NP (DT the) (JJ same) (NN breeder))))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD two) (JJ consecutive) (NNS sets))))) (. .)))
10791295	2	(S1 (S (PP (IN In) (NP (JJ male) (NNS animals))) (, ,) (NP (VBN repeated) (JJ Doc_10791295_323_334_Chemical) (NN treatment)) (VP (VBN induced) (NP (NP (DT a) (JJ gradual) (NN development)) (PP (IN of) (NP (NNP Doc_10791295_378_397_Disease)))) (SBAR (IN as) (S (VP (VP (VBN evidenced) (PP (IN by) (NP (NP (DT the) (VBN increased) (NN intensity)) (PP (IN of) (NP (NNP Doc_10791295_441_455_Disease)))))) (CC and) (VP (VBN shortened) (NP (NN latency)) (PP (IN before) (NP (NP (DT the) (JJ first) (NN attack)) (PP (IN toward) (NP (DT the) (NN opponent)))))))))) (. .)))
10791295	3	(S1 (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (NP (RB only) (DT a) (JJ weak) (NN tendency)) (PP (IN toward) (NP (NNP Doc_10791295_567_581_Disease)))) (VP (AUX was) (VP (VBN found))) (. .)))
10791295	4	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VP (VBZ demonstrates) (NP (NN gender) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ Doc_10791295_684_695_Chemical-induced) (NN Doc_10791295_704_723_Disease)))))) (CC and) (VP (VBZ indicates) (SBAR (IN that) (S (NP (DT the) (JJ female) (NNS rats)) (VP (AUX do) (RB not) (VP (VB fill) (NP (NP (DT the) (JJ validation) (NNS criteria)) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (DT this) (NN method)))))))))))) (. .)))
10807237	0	(S1 (NP (NP (NP (NN Doc_10807237_0_22_Disease)) (CC and) (NP (NN Doc_10807237_27_40_Disease))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (JJ prognostic) (NNS indicators)))) (. .)))
10807237	1	(S1 (S (NP (NP (DT The) (NN outcome)) (PP (IN of) (NP (NNP Doc_10807237_103_126_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10807237_143_156_Disease))))) (VP (AUX is) (ADVP (RB reportedly)) (ADJP (JJ poor))) (. .)))
10807237	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT no) (NN study)) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX has) (VP (VBN reported) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (JJ statistical) (NN model)) (SBAR (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NNS variables)) (SBAR (WHNP (WDT that)) (S (VP (VBP influence) (NP (NN outcome))))))))))))))) (. .)))
10807237	3	(S1 (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (NNS admissions)))) (PP (IN during) (NP (DT a) (JJ 6-year) (NN period))) (VP (VBD revealed) (NP (NP (CD 14) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_387_394_Chemical-related) (NNP Doc_10807237_403_412_Disease))))) (. .)))
10807237	4	(S1 (S (NP (DT This) (NN group)) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT a) (NN control) (NN group)) (PP (IN of) (NP (NP (CD 135) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_480_498_Disease)))))) (CC and) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_10807237_517_530_Disease)))))))) (. .)))
10807237	5	(S1 (S (PP (NP (NN Age)) (IN at) (NP (NN presentation))) (, ,) (NP (NP (NN time)) (PP (IN of) (NP (NN ictus))) (PP (IN after) (NP (NP (NN intoxication)) (, ,) (NP (NP (NNP Hunt) (CC and) (NNP Hess) (NN grade)) (PP (IN of) (NP (NNP Doc_10807237_610_633_Disease)))) (, ,) (NP (NP (NN size)) (PP (IN of) (NP (DT the) (NNP Doc_10807237_647_655_Disease)))) (, ,) (NP (NP (NN location)) (PP (IN of) (NP (DT the) (NNP Doc_10807237_673_681_Disease)))) (, ,) (CC and) (NP (DT the) (NNP Glasgow) (NN Outcome) (NN Scale) (NN score))))) (VP (VP (AUX were) (VP (VBN assessed))) (CC and) (VP (VBN compared))) (. .)))
10807237	6	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN in) (NP (DT the) (NN study) (NN group)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR younger)) (PP (IN than) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.002))) (-RRB- -RRB-))) (. .)))
10807237	7	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NN study) (NN group))))) (, ,) (NP (DT all) (NNP Doc_10807237_903_912_Disease)) (VP (AUX were) (VP (VBN located) (PP (IN in) (NP (DT the) (NNP anterior) (NN circulation))))) (. .)))
10807237	8	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (DT these) (NNP Doc_10807237_977_986_Disease)))) (VP (AUX were) (ADJP (ADJP (JJR smaller)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (NN control) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 8) (CD +/-)) (QP (CD 6.08) (CD mm) (CC versus) (CD 11)) (JJ +/-) (CD 5.4) (NNS mm)) (: ;) (NP (NNP P) (SYM =) (CD 0.05))) (-RRB- -RRB-))) (. .)))
10807237	9	(S1 (S (NP (NP (DT The) (NNS differences)) (PP (IN in) (NP (NP (NN mortality)) (CC and) (NP (NN morbidity)))) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (VP (AUX were) (RB not) (ADJP (JJ significant))) (. .)))
10807237	10	(S1 (S (NP (NP (NP (NP (NN Hunt)) (CC and) (NP (NNP Hess) (NN grade))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.005))) (-RRB- -RRB-))) (CC and) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.007))) (-RRB- -RRB-)))) (VP (AUX were) (NP (NP (JJ significant) (NNS predictors)) (PP (IN of) (NP (NP (NN outcome)) (PP (IN for) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_1281_1288_Chemical-related) (NNP Doc_10807237_1297_1306_Disease))))))))) (. .)))
10807237	11	(S1 (S (NP (JJ Doc_10807237_1320_1327_Chemical) (NN use)) (VP (VBD predisposed) (NP (NNP Doc_10807237_1344_1362_Disease)) (PP (PP (IN at) (NP (DT a) (ADJP (RB significantly) (JJR earlier)) (NN age))) (CC and) (PP (IN in) (NP (ADJP (RB much) (JJR smaller)) (NN Doc_10807237_1414_1423_Disease))))) (. .)))
10807237	12	(S1 (S (ADVP (JJ Contrary) (PP (TO to) (NP (DT the) (VBN published) (NN literature)))) (, ,) (NP (DT this) (NN group)) (VP (AUX did) (ADVP (RB reasonably)) (ADVP (RB well)) (PP (IN with) (NP (JJ aggressive) (NN management)))) (. .)))
10835440	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10835440_22_32_Chemical))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN outcome)))) (PP (IN after) (NP (NNP Doc_10835440_69_81_Disease))) (. .)))
10835440	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN PURPOSE))) (: :) (S (NP (NP (DT The) (JJ Intravenous) (NNP Doc_10835440_123_133_Chemical) (NNP West) (NNP European) (NNP Doc_10835440_148_154_Disease) (NNP Trial)) (PRN (-LRB- -LRB-) (NP (NNP INWEST)) (-RRB- -RRB-))) (VP (VBD found) (NP (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP (NP (NNP Doc_10835440_198_208_Chemical-induced) (NNP Doc_10835440_217_244_Disease)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (CC and) (NP (NP (DT an) (JJ unfavorable) (NN outcome)) (PP (IN in) (NP (NNP Doc_10835440_280_292_Disease))))))))) (. .)))
10835440	2	(S1 (S (NP (PRP We)) (VP (VBD sought) (S (VP (VP (TO to) (VP (VB confirm) (NP (NP (DT this) (NN correlation)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ prognostic) (NNS variables))))))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (NN outcome)) (PP (IN in) (NP (NP (NNS subgroups)) (PP (IN with) (NP (NP (VBG increasing) (NNS levels)) (PP (IN of) (NP (NNP Doc_10835440_451_463_Disease))))))))))))) (. .)))
10835440	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10835440_512_527_Disease))))) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 24) (NNS hours))) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB consecutively)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD n=100)) (-RRB- -RRB-)) (, ,) (NP (QP (CD 1) (CD mg/h)) (PRN (-LRB- -LRB-) (NP (NN low-dose)) (-RRB- -RRB-)) (NNP Doc_10835440_621_631_Chemical)) (PRN (-LRB- -LRB-) (NP (CD n=101)) (-RRB- -RRB-)) (, ,) (CC or) (NP (NP (QP (CD 2) (CD mg/h)) (PRN (-LRB- -LRB-) (NP (NN high-dose)) (-RRB- -RRB-)) (NNP Doc_10835440_663_673_Chemical)) (PRN (-LRB- -LRB-) (NP (CD n=94)) (-RRB- -RRB-))))))))) (. .)))
10835440	4	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (NP (JJ average) (NNP BP) (NN change)) (PP (IN during) (NP (DT the) (JJ first) (CD 2) (NNS days)))) (CC and) (NP (NP (DT the) (NN outcome)) (PP (IN at) (NP (NN day) (CD 21))))))) (VP (AUX was) (VP (VBN analyzed))) (. .)))
10835440	5	(S1 (S (NP (QP (CD Two) (CD hundred)) (JJ sixty-five) (NNS patients)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (NP (DT this) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD n=92)) (, ,) (NP (CD 93)) (, ,) (CC and) (NP (CD 80))) (PP (IN for) (NP (NP (NN placebo)) (, ,) (NP (JJ low) (NN dose)) (, ,) (CC and) (NP (JJ high) (NN dose)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-)))))) (. .)))
10835440	6	(S1 (S (NP (JJ Doc_10835440_931_941_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NNP Doc_10835440_992_1016_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ diastolic) (NNP BP)) (PRN (-LRB- -LRB-) (NP (NNP DBP)) (-RRB- -RRB-))))) (PP (IN from) (NP (NN baseline))) (PP (VBN compared) (PP (IN with) (NP (NN placebo)))) (PP (IN during) (NP (DT the) (JJ first) (JJ few) (NNS days)))) (. .)))
10835440	7	(S1 (S (PP (IN In) (NP (NN multivariate) (NN analysis))) (, ,) (NP (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_10835440_1169_1182_Disease) (CC and) (VBG worsening)) (PP (IN of) (NP (DT the) (JJ neurological) (NN score)))))) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NP (DT the) (JJ high-dose) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD beta=0.49)) (, ,) (NP (NNP P=0.) (CD 048))) (-RRB- -RRB-)))))) (. .)))
10835440	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (NN Doc_10835440_1296_1309_Disease)) (PP (IN of) (NP (NP (QP (CD >) (CC or) (CD =20)) (NN %)) (PP (IN in) (NP (DT the) (JJ high-dose) (NN group)))))))) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (VBN increased))) (VP (VBN adjusted) (PP (CC OR) (PP (IN for) (NP (NP (NP (DT the) (NN compound) (NN outcome)) (NP (JJ variable) (NNP Doc_10835440_1422_1427_Disease))) (CC or) (NP (NP (NN dependency)) (-LRB- -LRB-) (NP (NNP Barthel) (NNP Index) (CD <60)) (-RRB- -RRB-)))) (PRN (-LRB- -LRB-) (NP (NP (CD n/N=25/26)) (, ,) (CC OR) (NP (QP (CD 10.) (CD 16))) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.02) (TO to) (CD 101.74)))) (-RRB- -RRB-)) (CC and) (NP (NP (NNP Doc_10835440_1512_1517_Disease)) (ADVP (RB alone)))) (PRN (-LRB- -LRB-) (S (NP (NP (CD n/N=9/26)) (, ,) (CC OR) (NP (CD 4.336)) (, ,) (NP (CD 95) (NN %))) (VP (VBG CI) (NP (QP (CD 1.131) (CD 16.619))))) (-RRB- -RRB-)) (PP (VBN compared) (PP (IN with) (NP (NP (DT all) (NN placebo) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD n/N=62/92) (CC and) (CD 14/92)) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
10835440	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (S (VP (VBG SBP) (NP (NP (NN change)) (CC and) (NP (NN outcome)))))))) (. .)))
10835440	10	(S1 (S (NP (NP (NN DBP)) (, ,) (CONJP (CC but) (RB not)) (NP (NN SBP)) (, ,) (NP (NN reduction))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ neurological) (VBG worsening)) (PP (IN after) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_10835440_1829_1839_Chemical))) (PP (IN after) (NP (NNP Doc_10835440_1846_1858_Disease))))))))) (. .)))
10835440	11	(S1 (S (PP (IN For) (NP (JJ low-dose) (NNP Doc_10835440_1873_1883_Chemical))) (, ,) (NP (DT the) (NNS results)) (VP (AUX were) (RB not) (ADJP (JJ conclusive))) (. .)))
10835440	12	(S1 (S (NP (DT These) (NNS results)) (VP (AUX do) (RB not) (VP (VB confirm) (CC or) (VB exclude) (NP (NP (DT a) (JJ neuroprotective) (NN property)) (PP (IN of) (NP (NNP Doc_10835440_1988_1998_Chemical)))))) (. .)))
1085609	0	(S1 (NP (NP (JJ Neonatal) (JJ Doc_1085609_9_19_Chemical) (JJ responsive) (NN Doc_1085609_31_42_Disease)) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_1085609_50_59_Chemical) (NN therapy)))) (. .)))
1085609	1	(S1 (S (NP (NP (DT A) (JJ 17-day-old) (NN infant)) (PP (IN on) (S (NP (NNP Doc_1085609_92_101_Chemical) (NN therapy) (CD 13)) (VP (VBG mg/kg) (ADVP (RB daily)) (PP (IN from) (NP (NN birth))) (PP (IN because) (IN of) (NP (JJ maternal) (NNP Doc_1085609_156_168_Disease))))))) (VP (AUX was) (VP (VBN admitted) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NNP Doc_1085609_198_209_Disease))))))) (. .)))
1085609	2	(S1 (S (NP (NP (DT No) (JJ underlying) (NN infective)) (CC or) (NP (JJ biochemical) (NN cause))) (VP (MD could) (VP (AUX be) (VP (VBN found)))) (. .)))
1085609	3	(S1 (S (NP (DT The) (NNP Doc_1085609_276_280_Disease)) (VP (VBD ceased) (PP (IN within) (NP (NP (CD 4) (NNS hours)) (PP (IN of) (S (VP (VBG administering) (NP (JJ intramuscular) (NNP Doc_1085609_334_344_Chemical))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (NN aetiology)) (PP (IN of) (NP (JJ Doc_1085609_373_383_Chemical) (NN deficiency))) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_1085609_408_417_Chemical) (NN medication)))))))) (. .)))
10901305	0	(S1 (NP (NP (JJ Doc_10901305_0_8_Chemical) (NN sedation)) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_50_59_Disease))) (PP (IN in) (NP (DT the) (NN emergency) (NN department))))) (. .)))
10901305	1	(S1 (S (NP (EX There)) (ADVP (RB recently)) (VP (AUX has) (VP (AUX been) (NP (NP (DT a) (NN resurgence)) (PP (IN in) (NP (NP (DT the) (NN utilization)) (PP (IN of) (NP (NP (NNP Doc_10901305_160_168_Chemical)) (, ,) (NP (NP (DT a) (JJ unique) (NN anesthetic)) (, ,) (PP (IN for) (NP (NP (JJ emergency-department) (NNS procedures)) (VP (VBG requiring) (NP (NN sedation))))))))))))) (. .)))
10901305	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NNP Doc_10901305_322_330_Chemical))) (PP (IN for) (NP (NN sedation))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_375_384_Disease)) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))))))))))) (. .)))
10901305	3	(S1 (S (NP (NP (QP (CD One) (CD hundred) (CC and) (CD fourteen)) (NNS children)) (PRN (-LRB- -LRB-) (NP (NP (JJ average) (NN age)) (, ,) (NP (CD 5.3) (NNS years))) (: ;) (NP (NP (NN range)) (, ,) (NP (NP (NP (CD twelve) (NNS months)) (PP (TO to) (NP (CD ten) (NNS years)))) (CC and) (NP (CD ten) (NNS months)))) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (VBN closed) (NN reduction)) (PP (IN of) (NP (NP (DT an) (VBN isolated) (NNP Doc_10901305_578_586_Disease)) (CC or) (NP (NNP Doc_10901305_590_601_Disease))))) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN at) (NP (DT a) (JJ level-I) (JJ Doc_10901305_643_649_Disease) (NN center))))))))) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN evaluated))) (. .)))
10901305	4	(S1 (S (NP (NNP Doc_10901305_687_709_Chemical)) (VP (AUX was) (VP (VP (VBN administered) (ADVP (RB intravenously)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD two) (NNS milligrams)) (PP (IN per) (NP (NP (NN kilogram)) (PP (IN of) (NP (NN body) (NN weight))))))))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN ninety-nine)) (PP (IN of) (NP (DT the) (NNS patients)))))) (CC and) (ADVP (RB intramuscularly)) (-LRB- -LRB-) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD four) (NNS milligrams)) (PP (IN per) (NP (NP (NN kilogram)) (PP (IN of) (NP (NN body) (NN weight))))))))) (-RRB- -RRB-) (PP (IN in) (NP (DT the) (JJ other) (NNS fifteen))))) (. .)))
10901305	5	(S1 (S (S (NP (NP (DT A) (JJ board-certified) (NN emergency) (NN physician)) (ADJP (JJ skilled) (PP (IN in) (NP (JJ airway) (NN management))))) (VP (VBD supervised) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN anesthetic)))))) (, ,) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN by) (NP (DT a) (JJ registered) (NN nurse)))))) (. .)))
10901305	6	(S1 (S (NP (NP (DT Any) (NN Doc_10901305_1102_1106_Disease)) (PP (IN during) (NP (DT the) (NN reduction)))) (VP (AUX was) (VP (VBN rated) (PP (IN by) (S (NP (DT the) (JJ orthopaedic) (NN surgeon)) (VP (VBG treating) (NP (DT the) (NN patient)) (PP (VBG according) (PP (TO to) (NP (NP (NP (DT the) (NNS Children) (POS 's)) (NNP Hospital)) (PP (IN of) (NP (NP (NNP Eastern) (NNP Ontario) (NNP Doc_10901305_1242_1246_Disease) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNP CHEOPS)) (-RRB- -RRB-)))))))))))) (. .)))
10901305	7	(S1 (S (S (NP (NP (DT The) (JJ average) (NN time)) (PP (IN from) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_10901305_1324_1332_Chemical))))) (PP (TO to) (NP (NP (NN manipulation)) (PP (IN of) (NP (DT the) (NNP Doc_10901305_1356_1364_Disease) (CC or) (NNP Doc_10901305_1368_1379_Disease)))))) (VP (AUX was) (NP (NP (CD one) (NN minute)) (CC and) (NP (NP (JJ thirty-six) (NNS seconds)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NP (CD twenty) (NNS seconds)) (PP (TO to) (NP (CD five) (NNS minutes)))) (-RRB- -RRB-)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ average) (NN time)) (PP (IN from) (NP (JJ intramuscular) (NN administration))) (PP (TO to) (NP (NN manipulation)))) (VP (AUX was) (NP (NP (CD four) (NNS minutes)) (CC and) (NP (NP (JJ forty-two) (NNS seconds)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NP (CD sixty) (NNS seconds)) (PP (TO to) (NP (JJ fifteen) (NNS minutes)))) (-RRB- -RRB-)))))) (. .)))
10901305	8	(S1 (S (NP (DT The) (JJ average) (NN score)) (PP (VBG according) (PP (TO to) (NP (DT the) (NNP Children) (POS 's)))) (NP (NAC (NNP Hospital) (PP (IN of) (NP (NNP Eastern) (NNP Ontario)))) (NNP Doc_10901305_1686_1690_Disease) (NNP Scale)) (VP (AUX was) (NP (NP (CD 6.4) (NNS points)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (QP (CD 5) (TO to) (CD 10)) (NNS points)) (-RRB- -RRB-))) (, ,) (S (VP (VP (VBG reflecting) (ADJP (JJ minimal))) (CC or) (VP (NP (DT no) (NN Doc_10901305_1762_1766_Disease)) (PP (IN during) (NP (JJ Doc_10901305_1774_1782_Disease) (NN reduction))))))) (. .)))
10901305	9	(S1 (S (NP (JJ Adequate) (NN Doc_10901305_1803_1811_Disease) (NN reduction)) (VP (AUX was) (VP (VBN obtained) (PP (IN in) (NP (NP (CD 111)) (PP (IN of) (NP (DT the) (NNS children))))))) (. .)))
10901305	10	(S1 (S (NP (NP (JJ Ninety-nine) (NN percent)) (PRN (-LRB- -LRB-) (NP (NN sixty-eight)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (JJ sixty-nine) (NNS parents)) (ADJP (JJ present) (PP (IN during) (NP (DT the) (NN reduction))))))) (VP (VP (AUX were) (VP (VBN pleased) (PP (IN with) (NP (DT the) (NN sedation))))) (CC and) (VP (MD would) (VP (VB allow) (S (NP (PRP it)) (VP (TO to) (VP (AUX be) (VP (VBN used) (ADVP (RB again)) (PP (IN in) (NP (DT a) (JJ similar) (NN situation)))))))))) (. .)))
10901305	11	(S1 (S (NP (NP (NN Patency)) (PP (IN of) (NP (DT the) (ADJP (JJ airway) (CC and) (JJ independent)) (NN respiration)))) (VP (AUX were) (VP (VBN maintained) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS patients))))))) (. .)))
10901305	12	(S1 (S (NP (NP (NN Blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))) (VP (VBD remained) (ADJP (JJ stable))) (. .)))
10901305	13	(S1 (S (NP (JJ Minor) (NN side) (NNS effects)) (VP (VBD included) (NP (NP (NP (NNP Doc_10901305_2204_2210_Disease)) (PRN (-LRB- -LRB-) (NP (JJ thirteen) (NNS patients)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_10901305_2232_2238_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD eight)) (PP (IN of) (NP (NP (DT the) (JJ thirteen) (NNS patients)) (PP (IN with) (NP (NNP Doc_10901305_2276_2282_Disease)))))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10901305_2285_2295_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ evident)) (PP (IN as) (NP (NNP Doc_10901305_2308_2324_Disease))) (PP (IN in) (NP (CD ten) (NNS patients)))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NNP Doc_10901305_2347_2365_Disease)) (PRN (-LRB- -LRB-) (NP (CD one) (NN patient)) (-RRB- -RRB-))))) (. .)))
10901305	14	(S1 (S (S (NP (DT No) (JJ long-term) (NNS sequelae)) (VP (AUX were) (VP (VBN noted)))) (, ,) (CC and) (S (NP (DT no) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_10901305_2435_2449_Disease)) (CC or) (NP (NNS nightmares))))) (. .)))
10901305	15	(S1 (S (VP (VB Doc_10901305_2478_2486_Chemical) (ADVP (RB reliably)) (, ,) (ADVP (RB safely)) (, ,) (CC and) (ADVP (RB quickly)) (VP (VBN provided) (NP (JJ adequate) (NN sedation)) (S (VP (TO to) (VP (ADVP (RB effectively)) (VB facilitate) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_2598_2607_Disease))) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN at) (NP (PRP$ our) (NN institution))))))))))) (. .)))
10901305	16	(S1 (S (NP (NN Doc_10901305_2656_2664_Chemical)) (VP (MD should) (ADVP (RB only)) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (DT an) (NN environment)) (PP (JJ such) (IN as) (NP (NP (DT the) (NN emergency) (NN department)) (, ,) (SBAR (WHADVP (WRB where)) (S (S (NP (JJ proper) (JJ one-on-one) (NN monitoring)) (VP (AUX is) (VP (VBN used)))) (CC and) (S (NP (NP (JJ board-certified) (NNS physicians)) (ADJP (JJ skilled) (PP (IN in) (NP (JJ airway) (NN management))))) (VP (AUX are) (VP (ADVP (RB directly)) (VBN involved) (PP (IN in) (NP (NP (DT the) (NN care)) (PP (IN of) (NP (DT the) (NN patient))))))))))))))))) (. .)))
11007689	0	(S1 (NP (NNP Doc_11007689_0_12_Chemical) (CC and) (NNP Doc_11007689_17_27_Chemical-associated) (NNP Doc_11007689_39_65_Disease) (. .)))
11007689	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NNP Doc_11007689_86_112_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11007689_114_117_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11007689_146_158_Chemical))))))) (VP (AUX has) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
11007689	2	(S1 (S (NP (NNS Treatments)) (VP (AUX have) (VP (VBN included) (NP (NP (NP (NN discontinuation)) (CC or) (NP (NN reduction))) (PP (IN of) (NP (JJ Doc_11007689_242_254_Chemical) (NN dose)))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (JJ concurrent) (NN plasma) (NN exchange)) (, ,) (NP (NN plasma) (NN infusion)) (, ,) (NP (NN anticoagulation)) (, ,) (CC and) (NP (JJ intravenous) (JJ immunoglobulin) (NNP G) (NN infusion))))))) (. .)))
11007689	3	(S1 (S (ADVP (RB However)) (, ,) (PP (IN for) (NP (NP (NNS recipients)) (PP (IN of) (NP (NN organ) (NN transplantation))))) (, ,) (VP (VBG removing) (NP (DT the) (VBG inciting) (NN agent))) (VP (AUX is) (RB not) (PP (IN without) (NP (NP (DT the) (JJ attendant) (NN risk)) (PP (IN of) (S (VP (VBG precipitating) (NP (NP (JJ acute) (NN rejection)) (CC and) (NP (NN graft) (NN loss))))))))) (. .)))
11007689	4	(S1 (S (NP (DT The) (JJ last) (NN decade)) (VP (AUX has) (VP (VBN seen) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NNP Doc_11007689_584_594_Chemical)))) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN immunosuppressive) (NN agent)) (PP (IN with) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NN action))) (ADJP (RB virtually) (JJ identical) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11007689_689_701_Chemical)))))))))))) (. .)))
11007689	5	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (NP (NN switching)) (PP (TO to) (NP (NNP Doc_11007689_729_739_Chemical)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (NP (DT a) (JJ viable) (JJ therapeutic) (NN option)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NNP Doc_11007689_810_822_Chemical-induced) (NNP Doc_11007689_831_834_Disease))))))))))) (. .)))
11007689	6	(S1 (S (PP (IN With) (NP (NP (DT the) (ADJP (RBR more) (JJ widespread)) (NN application)) (PP (IN of) (NP (NNP Doc_11007689_876_886_Chemical))) (PP (IN in) (NP (NN organ) (NN transplantation))))) (, ,) (NP (NNP Doc_11007689_913_923_Chemical-associated) (NNP Doc_11007689_935_938_Disease)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN recognized)))) (. .)))
11007689	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN literature)) (VP (VBG regarding) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_11007689_1030_1033_Disease))))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN exposed) (ADVP (RB sequentially)) (PP (TO to) (NP (NP (NNP Doc_11007689_1070_1082_Chemical)) (CC and) (NP (NNP Doc_11007689_1087_1097_Chemical)))))))))) (VP (AUX is) (VP (VBN limited))) (. .)))
11007689	8	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (VBG living) (NN donor) (JJ renal) (NN transplant) (NN recipient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ Doc_11007689_1186_1198_Chemical-induced) (NN Doc_11007689_1207_1210_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD responded) (PP (TO to) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_11007689_1247_1259_Chemical))))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NNS plasmapheresis)) (CC and) (NP (JJ fresh) (JJ frozen) (NN plasma) (NN replacement) (NN therapy))))))))))))))))) (. .)))
11007689	9	(S1 (S (NP (NP (NN Introduction)) (PP (IN of) (NP (NNP Doc_11007689_1356_1366_Chemical))) (PP (IN as) (NP (DT an) (JJ alternative) (NN immunosuppressive) (NN agent)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_11007689_1439_1442_Disease)))) (CC and) (NP (NP (DT the) (JJ subsequent) (NN loss)) (PP (IN of) (NP (DT the) (JJ renal) (NN allograft))))))) (. .)))
11007689	10	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN switched) (PP (IN from) (NP (NNP Doc_11007689_1522_1534_Chemical))) (PP (TO to) (NP (NP (NNP Doc_11007689_1538_1548_Chemical)) (CC or) (NP (NN vice))))))))) (ADVP (RB versa)) (VP (MD should) (VP (AUX be) (VP (ADVP (RB closely)) (VBN monitored) (PP (IN for) (NP (NP (DT the) (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_11007689_1631_1634_Disease)))))))) (. .)))
11027905	0	(S1 (NP (NP (NP (JJ Analgesic) (NN effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_11027905_32_40_Chemical))) (PP (IN in) (NP (NNP Doc_11027905_44_50_Disease) (NNS patients))) (PP (IN on) (NP (JJ Doc_11027905_63_71_Chemical) (NN therapy)))) (: :) (NP (DT a) (VBN randomized) (, ,) (VBN controlled) (, ,) (JJ double-blind) (, ,) (JJ crossover) (, ,) (JJ double-dose) (NN study)) (. .)))
11027905	1	(S1 (S (S (NP (NN Doc_11027905_151_155_Disease)) (ADJP (RB not) (JJ responsive) (PP (TO to) (NP (NNP Doc_11027905_174_182_Chemical))))) (VP (AUX is) (ADVP (RB often)) (ADJP (JJ problematic))) (. .)))
11027905	2	(S1 (S (NP (NN Animal) (CC and) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NNP Doc_11027905_253_273_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027905_275_279_Chemical)) (-RRB- -RRB-)) (NNS antagonists)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_302_310_Chemical))) (, ,)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG improving) (NP (JJ opioid) (NN analgesia)) (PP (IN in) (NP (NP (JJ difficult) (JJ Doc_11027905_372_376_Disease) (NNS syndromes)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_396_412_Disease))))))))))))))) (. .)))
11027905	3	(S1 (S (NP (NP (DT A) (JJ slow) (NN bolus)) (PP (IN of) (NP (NP (JJ subhypnotic) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_11027905_451_459_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.25) (NN mg/kg)) (CC or) (NP (CD 0.50) (NN mg/kg))) (-RRB- -RRB-))))))) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (CD 10) (JJ Doc_11027905_503_509_Disease) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN Doc_11027905_525_529_Disease)) (S (VP (AUX was) (VP (VBN unrelieved) (PP (IN by) (NP (NNP Doc_11027905_548_556_Chemical))) (PP (IN in) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ crossover) (, ,) (JJ double-dose) (NN study))))))))))) (. .)))
11027905	4	(S1 (S (NP (NP (JJ Doc_11027905_618_622_Disease) (NN intensity)) (PP (IN on) (NP (NP (NP (NP (DT a) (QP (CD 0) (TO to) (CD 10)) (JJ numerical) (NN scale)) (: ;) (NP (NP (NP (NNP Doc_11027905_663_669_Disease) (CC and) (NNP Doc_11027905_674_682_Disease)) (, ,) (NP (NN drowsiness)) (, ,) (NP (NNP Doc_11027905_696_705_Disease)) (, ,) (CC and) (NP (NNP Doc_11027905_711_720_Disease)) (, ,)) (VP (VBG using) (NP (NP (DT a) (NN scale)) (PP (IN from) (NP (QP (CD 0) (TO to) (CD 3)))) (PRN (-LRB- -LRB-) (ADVP (RB not)) (PP (IN at) (NP (DT all))) (, ,) (NP (NP (JJ slight)) (, ,) (NP (DT a) (NN lot)) (, ,) (NP (JJ awful))) (-RRB- -RRB-))))) (: ;) (NP (NNP Mini-Mental) (NNP State) (NNP Examination))) (-LRB- -LRB-) (NP (NNP MMSE)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 0-30)) (-RRB- -RRB-)) (: ;) (CC and) (NP (JJ arterial) (NN pressure))))) (VP (AUX were) (VP (VBN recorded) (PP (IN before) (NP (NP (NN administration)) (PP (PP (IN of) (NP (NP (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP T0)) (-RRB- -RRB-)))) (CC and) (PP (IN after) (NP (NP (NP (CD 30) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T30) (-RRB- -RRB-))) (, ,) (NP (NP (CD 60) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T60) (-RRB- -RRB-))) (, ,) (NP (NP (CD 120) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T120) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD 180) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T180) (-RRB- -RRB-))))))))) (. .)))
11027905	5	(S1 (S (NP (NP (NN Doc_11027905_991_999_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NN saline) (NN solution)) (, ,)) (VP (ADVP (RB significantly)) (VBN reduced) (NP (DT the) (JJ Doc_11027905_1052_1056_Disease) (NN intensity)) (PP (IN in) (NP (RB almost) (PDT all) (DT the) (NNS patients))) (PP (IN at) (NP (DT both) (NNS doses)))) (. .)))
11027905	6	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (ADJP (RBR more) (JJ relevant)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJR higher) (NNS doses))))))) (. .)))
11027905	7	(S1 (S (S (NP (NN Doc_11027905_1178_1192_Disease)) (VP (VBD occurred) (PP (IN in) (NP (CD 4) (NNS patients))))) (, ,) (CC and) (S (NP (NP (DT an) (JJ unpleasant) (NN sensation)) (PRN (-LRB- -LRB-) (NP (`` ``) (JJ empty) (NN head) ('' '')) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (VP (VBN reported) (PP (IN by) (NP (CD 2) (NNS patients)))))) (. .)))
11027905	8	(S1 (S (NP (DT These) (NNS episodes)) (VP (VBD reversed) (SBAR (IN after) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_11027905_1345_1353_Chemical) (CD 1)))) (VP (VBD mg) (ADVP (RB intravenously)))))) (. .)))
11027905	9	(S1 (S (NP (NP (JJ Significant) (NNS increases)) (PP (IN in) (NP (NN drowsiness)))) (VP (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11027905_1449_1457_Chemical))) (PP (IN in) (NP (DT both) (NNS groups)))))))) (CC and) (VP (AUX were) (ADJP (RBR more) (JJ marked)) (PP (IN with) (NP (NNP Doc_11027905_1499_1507_Chemical) (CD 0.50) (NN mg/kg))))) (. .)))
11027905	10	(S1 (S (NP (NP (DT A) (JJ significant) (NN difference)) (PP (IN in) (NP (NN MMSE)))) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NNP T30))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (CD 0.50) (NN mg/kg)) (PP (IN of) (NP (NNP Doc_11027905_1612_1620_Chemical))))))))))) (. .)))
11027905	11	(S1 (S (NP (NN Doc_11027905_1622_1630_Chemical)) (VP (MD can) (VP (VB improve) (NP (NP (JJ Doc_11027905_1643_1651_Chemical) (NN analgesia)) (PP (IN in) (NP (NP (JJ difficult) (JJ Doc_11027905_1675_1679_Disease) (NNS syndromes)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_1699_1715_Disease)))))))) (. .)))
11027905	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ central) (JJ adverse) (NNS effects)))) (VP (MD should) (VP (AUX be) (VP (VBN taken) (PP (IN into) (NP (NN account))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBG using) (NP (JJR higher) (NNS doses)))))))) (. .)))
11027905	13	(S1 (S (NP (DT This) (NN observation)) (VP (MD should) (VP (AUX be) (VP (VBN tested) (PP (IN in) (NP (NP (NNS studies)) (PP (IN of) (NP (VBN prolonged) (NNP Doc_11027905_1892_1900_Chemical) (NN administration)))))))) (. .)))
11135224	0	(S1 (S (NP (NP (NNP Doc_11135224_0_10_Chemical)) (, ,) (NP (NNP Doc_11135224_12_21_Chemical)) (, ,) (CC and) (NP (JJ Doc_11135224_27_38_Chemical) (NN combination))) (VP (VBZ chemotherapy) (PP (IN within) (NP (NP (DT a) (JJ multidisciplinary) (JJ therapeutic) (NN approach)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_11135224_126_154_Disease)))))) (. .)))
11135224	1	(S1 (S (NP (JJ Doc_11135224_168_177_Chemical-based) (JJ chemotherapy) (NNS combinations)) (VP (VBP improve) (NP (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))) (CC and) (NP (NP (NN survival)) (PP (IN in) (NP (NP (JJ advanced) (NNP Doc_11135224_259_287_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11135224_289_294_Disease)) (-RRB- -RRB-))))))) (. .)))
11135224	2	(S1 (S (NP (NP (DT The) (NN emergence)) (PP (IN of) (NP (JJ new) (JJ active) (NNS drugs)))) (VP (MD might) (VP (VB translate) (PP (IN into) (NP (NP (ADJP (RBR more) (JJ effective)) (NNS regimens)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (DT this) (NN disease))))))))) (. .)))
11135224	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN feasibility)) (, ,) (NP (NN response) (NN rate)))))) (, ,) (CC and) (S (NP (NP (NNP Doc_11135224_501_509_Disease)) (PP (IN of) (NP (DT a) (NNP Doc_11135224_515_525_Chemical) (, ,) (NNP Doc_11135224_527_536_Chemical) (, ,) (CC and) (NNP Doc_11135224_542_553_Chemical) (NN combination)))) (VP (TO to) (VP (VB treat) (NP (JJ metastatic) (NN Doc_11135224_586_591_Disease))))))) (. .)))
11135224	4	(S1 (S (NP (NP (NP (JJ Thirty-five) (JJ consecutive) (JJ chemotherapy-naive) (NNS patients)) (PP (IN with) (NP (NNP Stage) (NNP IV) (NNP Doc_11135224_659_664_Disease)))) (CC and) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN performance) (NN status)) (PP (IN of) (NP (JJ 0-2))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11135224_768_778_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 135) (NNS mg/m)) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 3) (NNS hours))))) (-RRB- -RRB-) (PP (IN on) (NP (NNP Day) (CD 1))) (, ,)) (NNP Doc_11135224_834_843_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NNS mg/m) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 6) (NNS hours)))) (-RRB- -RRB-))) (PP (IN on) (NP (NNP Day) (CD 1)))) (, ,) (CC and) (NNP Doc_11135224_903_914_Chemical) (-LRB- -LRB-) (S (NP (CD 800) (NNS mg/m)) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 30) (NNS minutes))))) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NNS Days) (CD 1) (CC and) (CD 8)) (, ,) (NP (DT every) (CD 4) (NNS weeks)))))) (. .)))
11135224	5	(S1 (S (SBAR (IN Although) (S (NP (VBG responding) (NNS patients)) (VP (AUX were) (VP (VBN scheduled) (S (VP (TO to) (VP (VB receive) (NP (NP (NN consolidation)) (SBAR (S (NP (NP (NNS radiotherapy)) (CC and) (NP (CD 24) (NNS patients))) (VP (VBD received) (NP (JJ preplanned) (JJ second-line) (NN chemotherapy)) (PP (IN after) (NP (NN disease) (NN progression)))))))))))))) (, ,) (NP (NP (DT the) (NN response) (CC and) (NN Doc_11135224_1182_1190_Disease) (NNS rates)) (VP (VBN reported))) (VP (VBP refer) (ADVP (RB only)) (PP (TO to) (NP (NP (DT the) (JJ chemotherapy) (NN regimen)) (VP (VBN given))))) (. .)))
11135224	6	(S1 (S (S (NP (PDT All) (DT the) (NNS patients)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NN Doc_11135224_1296_1304_Disease)))))) (: ;) (S (NP (CD 34)) (VP (AUX were) (ADJP (JJ examinable) (PP (IN for) (NP (NN response)))))) (. .)))
11135224	7	(S1 (S (NP (DT An) (JJ objective) (NN response)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 73.5) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 95) (NN %)) (NN confidence)) (JJ interval) (NN -LSB-CI) (NN -RSB-)) (, ,) (NP (CD 55.6-87.1) (NN %))) (-RRB- -RRB-)))))) (, ,) (PP (VBG including) (NP (NP (CD 4) (JJ complete) (NNS responses)) (PRN (-LRB- -LRB-) (NP (CD 11.7) (NN %)) (-RRB- -RRB-)))))) (. .)))
11135224	8	(S1 (S (PP (VBG According) (PP (TO to) (NP (NN intention-to-treat)))) (, ,) (NP (DT the) (JJ overall) (NN response) (NN rate)) (VP (AUX was) (NP (NP (CD 71.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (RB CI)) (, ,) (NP (QP (CD 53.) (CD 7-85.4)) (NN %))) (-RRB- -RRB-)))) (. .)))
11135224	9	(S1 (S (PP (IN After) (NP (NP (CD 154) (NNS courses)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (DT the) (JJ median) (NN dose) (NN intensity)) (VP (AUX was) (NP (NP (NP (QP (CD 131) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-) (PP (IN for) (NP (NP (NNP Doc_11135224_1651_1661_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 97.3) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (QP (CD 117) (CD mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP Doc_11135224_1687_1696_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 97.3) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (QP (CD 1378) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP Doc_11135224_1727_1738_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 86.2) (NN %)) (-RRB- -RRB-))))))) (. .)))
11135224	10	(S1 (S (NP (NNP World) (NNP Health) (NNP Organization) (NNP Grade) (NN 3-4) (NNP Doc_11135224_1784_1795_Disease) (CC and) (NNP Doc_11135224_1800_1816_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 39.9) (NN %)) (CC and) (NP (NP (CD 11.4) (NN %)) (PP (IN of) (NP (NNS patients)))))) (, ,) (ADVP (RB respectively))) (. .)))
11135224	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (CD one) (JJ treatment-related) (NN Doc_11135224_1904_1909_Disease))) (. .)))
11135224	12	(S1 (S (NP (NNP Nonhematologic) (NNP Doc_11135224_1926_1936_Disease)) (VP (AUX were) (ADJP (JJ mild))) (. .)))
11135224	13	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 22) (NNS months))))) (, ,) (S (NP (DT the) (JJ median) (NN progression) (JJ free) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 7) (NNS months)))) (, ,) (CC and) (S (NP (DT the) (JJ median) (NN survival) (NN time)) (VP (AUX was) (NP (CD 16) (NNS months)))) (. .)))
11135224	14	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11135224_2119_2129_Chemical)) (, ,) (NP (NNP Doc_11135224_2131_2140_Chemical)) (, ,) (CC and) (NP (NNP Doc_11135224_2146_2157_Chemical))))) (VP (VP (AUX is) (ADVP (RB well)) (VP (VBN tolerated))) (CC and) (VP (VBZ shows) (NP (NP (JJ high) (NN activity)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_11135224_2214_2219_Disease)))))) (. .)))
11135224	15	(S1 (S (NP (DT This) (NN treatment)) (VP (NNS merits) (ADVP (RB further)) (NP (NP (NN comparison)) (PP (IN with) (NP (JJ other) (JJ Doc_11135224_2273_2282_Chemical-based) (NNS regimens))))) (. .)))
11147747	0	(S1 (NP (NNP Doc_11147747_0_28_Chemical) (CC and) (NNP Doc_11147747_33_53_Disease) (. .)))
11147747	1	(S1 (S (NP (JJ Many) (JJ new) (JJ Doc_11147747_64_92_Chemical)) (VP (AUX have) (VP (AUX been) (VP (VBN introduced) (PP (IN over) (NP (DT the) (JJ past) (NN decade)))))) (. .)))
11147747	2	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_11147747_145_165_Disease)) (VP (AUX is) (VP (VBN listed) (PP (IN as) (NP (NP (CD one) (NN side) (NN effect)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (PP (IN in) (NP (PRP$ their) (NN package) (NNS inserts))))))))))) (NP (EX there)) (VP (AUX is) (NP (NP (QP (RB only) (CD one)) (NN report)) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
11147747	3	(S1 (S (NP (DT This)) (VP (VBZ concerns) (NP (NP (CD 2) (JJ male) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (NNP Doc_11147747_325_337_Disease)) (PP (IN while) (S (VP (VBG taking) (NP (NN Doc_11147747_351_362_Chemical)))))))))) (. .)))
11147747	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN paper))) (NP (DT the) (NNS authors)) (VP (VBP describe) (NP (NP (CD 2) (JJ female) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_11147747_438_450_Disease) (JJ secondary)) (PP (TO to) (NP (NP (DT the) (JJ selective) (NNP Doc_11147747_478_487_Chemical) (NN reuptake) (NNS inhibitors) (NNP Doc_11147747_508_518_Chemical) (CC and) (NNP Doc_11147747_523_533_Chemical)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ third)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT this) (NN side) (NN effect)) (PP (IN on) (NP (NNP Doc_11147747_588_599_Chemical)))))))))))))) (. .)))
11147747	5	(S1 (S (PP (IN In) (NP (NP (CD 2)) (PP (IN of) (NP (DT the) (CD 3) (NNS cases))))) (NP (DT the) (NNS patients)) (VP (AUX were) (ADVP (RB also)) (VP (VBG taking) (NP (NP (NP (NNP Doc_11147747_651_668_Chemical)) (CC and) (NP (NNS beta-blockers))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (DT the) (NNP Doc_11147747_732_744_Disease))))))))))) (. .)))
11147747	6	(S1 (S (NP (NN Animal) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_11147747_774_786_Disease) (JJ secondary)) (PP (TO to) (NP (NNP Doc_11147747_800_828_Chemical)))) (VP (MD could) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ 5HT4) (NNS receptors)) (VP (VBN found) (PP (IN on) (NP (DT the) (NN bladder)))))))))))) (. .)))
11147747	7	(S1 (S (NP (JJ Further) (NN research)) (VP (AUX is) (VP (VBN needed) (S (VP (TO to) (VP (VB delineate) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (DT this) (JJ troubling) (NN side) (NN effect)))) (SBAR (CC and) (WHADVP (WRB how)) (S (ADVP (RB best)) (VP (TO to) (VP (VB treat) (NP (PRP it))))))))))) (. .)))
11166519	0	(S1 (NP (NP (JJ Acute) (JJ Doc_11166519_6_13_Chemical-induced) (NN Doc_11166519_22_30_Disease)) (: :) (NP (NP (NN differential) (NN sensitivity)) (PP (IN of) (NP (CD six) (JJ inbred) (NN mouse) (NNS strains)))) (. .)))
11166519	1	(S1 (S (NP (NP (JJ Mature) (ADJP (JJ male) (CC and) (JJ female)) (NNS mice)) (PP (IN from) (NP (CD six) (JJ inbred) (NNS stains)))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NN susceptibility))) (PP (TO to) (NP (NP (JJ behavioral) (NN Doc_11166519_182_190_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NNP Doc_11166519_224_231_Chemical)))))))))) (. .)))
11166519	2	(S1 (S (S (NP (NN Doc_11166519_233_240_Chemical)) (VP (AUX was) (VP (VBN injected) (ADVP (RB ip)) (PP (IN over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 50-100) (NNS mg/kg)) (-RRB- -RRB-))))))))) (CC and) (S (NP (NN behavior)) (VP (AUX was) (VP (VBN monitored) (PP (IN for) (NP (CD 20) (NNS minutes)))))) (. .)))
11166519	3	(S1 (S (NP (JJ Doc_11166519_337_344_Disease) (NN end) (NNS points)) (VP (VBD included) (NP (NN latency)) (PP (TO to) (NP (NP (NN forelimb) (CC or) (NN hindlimb) (NN clonus)) (, ,) (NP (NP (NN latency)) (PP (TO to) (NP (JJ clonic) (NN running) (NN Doc_11166519_431_438_Disease)))) (CC and) (NP (NP (NN latency)) (PP (TO to) (NP (NP (VBG jumping)) (VP (VBG bouncing) (NP (NNP Doc_11166519_471_478_Disease))))))))) (. .)))
11166519	4	(S1 (S (NP (NP (DT A) (NN range)) (PP (IN of) (NP (NN strain) (NN specific) (NNS sensitivities)))) (VP (AUX was) (VP (VBN documented) (PP (IN with) (S (NP (NNP A/J) (CC and) (NNP SJL) (NNS mice)) (VP (AUXG being) (ADJP (ADJP (RBS most) (JJ sensitive)) (CC and) (ADJP (JJ C57BL/6J) (RBS most) (JJ resistant)))))))) (. .)))
11166519	5	(S1 (S (NP (NP (NNS DBA/2J)) (, ,) (NP (NNS BALB/cByJ)) (CC and) (NP (JJ NZW/LacJ) (NNS strains))) (VP (VBD exhibited) (NP (JJ intermediate) (NN sensitivity))) (. .)))
11166519	6	(S1 (S (NP (NNP EEG) (NNS recordings)) (VP (AUX were) (VP (VBN made) (PP (IN in) (NP (NP (NNP SJL) (, ,) (NNP A/J) (CC and) (NNP C57BL/6J) (NNS mice)) (VP (VBG revealing) (NP (NP (DT a) (JJ close) (NN correspondence)) (PP (IN between) (NP (NP (JJ electrical) (NN activity)) (CC and) (NP (NN behavior)))))))))) (. .)))
11166519	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP Doc_11166519_837_844_Chemical))) (VP (VBN determined) (PP (IN in) (NP (NP (NN hippocampus)) (CC and) (NP (NN cortex)))))) (VP (AUX were) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (ADJP (JJ sensitive) (CC and) (JJ resistant)) (NNS strains)))) (. .)))
11166519	8	(S1 (S (NP (NP (JJ Additional) (NNS studies)) (PP (IN of) (NP (DT these) (JJ murine) (NNS strains)))) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG investigating) (NP (JJ genetic) (NNS influences)) (PP (IN on) (NP (NNP Doc_11166519_1039_1046_Chemical-induced) (NNP Doc_11166519_1055_1063_Disease))))))))) (. .)))
11198499	0	(S1 (S (NP (NN Doc_11198499_0_11_Disease)) (VP (VBG following) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11198499_40_50_Chemical)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (DT an) (NNP Doc_11198499_80_91_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (PP (IN for) (NP (JJ chronic) (NNP Doc_11198499_132_144_Disease))))))))) (. .)))
11198499	1	(S1 (S (NP (ADJP (RB Centrally) (JJ acting)) (JJ alpha-2) (NN adrenergic) (NNS agonists)) (VP (AUX are) (NP (NP (CD one)) (PP (IN of) (NP (NP (JJ several) (JJ pharmacologic) (NNS agents)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11198499_256_266_Disease)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_11198499_278_317_Disease))))))))))))) (. .)))
11198499	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NNP Doc_11198499_351_361_Disease))))))) (, ,) (NP (JJ certain) (JJ adverse) (NN cardiorespiratory) (NNS effects)) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
11198499	3	(S1 (S (NP (NP (NNS Adults)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (S (NP (NNP Doc_11198499_457_468_Chemical)) (VP (VBG converting) (NP (JJ enzyme) (NNS inhibitors))))))) (VP (MD may) (VP (AUX have) (NP (DT a) (JJ limited) (NN ability) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NNP Doc_11198499_539_550_Disease))))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ sympathetic) (NN response)) (VP (AUX is) (ADVP (RB simultaneously)) (VP (VBN blocked))))))) (. .)))
11198499	4	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (DT a) (JJ 10-year-old) (NN boy)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NP (NNP Doc_11198499_671_681_Chemical)) (, ,) (NP (DT an) (NNP Doc_11198499_686_697_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (, ,))) (S (VP (TO to) (VP (VB control) (NP (NP (NNP Doc_11198499_738_750_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_11198499_765_776_Disease)) (PP (VBG following) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NNP Doc_11198499_803_813_Chemical)) (, ,) (NP (DT an) (JJ alpha-2) (NN agonist))))))))))))) (, ,) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11198499_856_866_Disease)))))))) (. .)))
11198499	5	(S1 (S (NP (NP (DT The) (JJ possible) (NN interaction)) (PP (IN of) (NP (NP (NNP Doc_11198499_896_906_Chemical)) (CC and) (NP (JJ other) (JJ antihypertensive) (NNS agents))))) (VP (MD should) (VP (AUX be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NN therapy)) (S (VP (TO to) (VP (VB treat) (NP (DT either) (NNP Doc_11198499_1005_1017_Disease) (CC or) (NNP Doc_11198499_1021_1031_Disease)) (PP (IN in) (NP (JJ such) (NNS patients)))))))))))) (. .)))
11206082	0	(S1 (S (NP (NP (CD Two) (NN mouse) (NNS lines)) (VP (VBN selected) (PP (IN for) (NP (NP (NN differential) (NNS sensitivities)) (PP (TO to) (NP (NNP Doc_11206082_59_73_Chemical-induced) (NNP Doc_11206082_82_90_Disease))))))) (VP (AUX are) (ADVP (RB also)) (ADJP (RB differentially) (JJ sensitive) (PP (TO to) (NP (NP (JJ various) (JJ pharmacological) (NNS effects)) (PP (IN of) (NP (JJ other) (NNP Doc_11206082_169_173_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NN receptor) (NNS ligands))))))) (. .)))
11206082	1	(S1 (S (NP (CD Two) (NN mouse) (NNS lines)) (VP (AUX were) (ADVP (RB selectively)) (VP (VBN bred) (PP (VBG according) (PP (TO to) (NP (NP (NP (PRP$ their) (NN sensitivity)) (PRN (-LRB- -LRB-) (NP (NNP BS) (NN line)) (-RRB- -RRB-))) (CC or) (NP (NP (NN resistance)) (PRN (-LRB- -LRB-) (NP (CD BR) (NN line)) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (NP (NNP Doc_11206082_301_309_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11206082_348_383_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11206082_385_393_Chemical)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT an) (JJ inverse) (NN agonist)) (PP (IN of) (NP (DT the) (NNP Doc_11206082_422_426_Chemical)))))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-)) (S (VP (NN receptor) (NP (JJ Doc_11206082_439_453_Chemical) (NN site)))))) (. .)))
11206082	2	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT both) (NNS lines) (POS ')) (NNS sensitivities)) (PP (TO to) (NP (NP (JJ various) (JJ physiological) (NNS effects)) (PP (IN of) (NP (NP (JJ other) (NNS ligands)) (PP (IN of) (NP (DT the) (NNP Doc_11206082_571_575_Chemical) (-LRB- -LRB-) (NNP A) (-RRB- -RRB-) (NN receptor))))))))))) (. .)))
11206082	3	(S1 (S (NP (PRP We)) (VP (VP (VBD measured) (NP (JJ Doc_11206082_601_609_Chemical-induced) (NN anxiolysis)) (PP (IN with) (NP (NP (DT the) (JJ elevated) (JJ plus-maze) (NN test)) (, ,) (NP (JJ Doc_11206082_663_671_Chemical-induced) (NN sedation)))) (PP (IN by) (S (VP (VBG recording) (NP (DT the) (JJ vigilance) (NNS states)))))) (, ,) (CC and) (VP (NP (NNP Doc_11206082_728_738_Chemical-) (CC and) (NNP Doc_11206082_744_761_Chemical-induced) (NNP Doc_11206082_770_778_Disease)) (PP (IN after) (S (VP (VBG i.p.) (NP (NNS injections))))))) (. .)))
11206082	4	(S1 (S (NP (NP (NNS Results)) (VP (VBN presented) (ADVP (RB here)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN differential) (NNS sensitivities)) (PP (IN of) (NP (NN BS) (CC and) (NN BR) (NNS lines))) (PP (TO to) (NP (NNP Doc_11206082_888_896_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN extended) (PP (TO to) (NP (NP (NNP Doc_11206082_916_924_Chemical)) (, ,) (NP (NNP Doc_11206082_926_936_Chemical)) (, ,) (CC and) (NP (NNP Doc_11206082_942_959_Chemical)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ genetic) (NN selection)) (PP (IN of) (NP (NP (DT a) (JJ general) (NN sensitivity)) (CC and) (NP (NP (NN resistance)) (PP (TO to) (NP (NP (JJ several) (NNS ligands)) (PP (IN of) (NP (DT the) (JJ Doc_11206082_1058_1062_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NN receptor))))))))))))))))) (. .)))
11250767	0	(S1 (S (NP (JJ Doc_11250767_0_16_Chemical-induced) (NNS perinuclear-staining)) (VP (VBP antineutrophil) (NP (NP (JJ cytoplasmic) (JJ autoantibody-positive) (NN Doc_11250767_95_105_Disease)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_11250767_126_138_Disease))))))) (. .)))
11250767	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ Doc_11250767_173_189_Chemical-induced) (JJ Doc_11250767_198_208_Disease) (NN manifesting)) (PP (IN with) (NP (NNP Doc_11250767_226_238_Disease))))))))) (. .)))
11250767	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (NNP Doc_11250767_298_313_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11250767_327_343_Chemical)))))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (DT a) (NN syndrome)) (PP (IN of) (NP (NP (NNP Doc_11250767_366_378_Disease)) (, ,) (NP (NNP Doc_11250767_380_385_Disease)) (, ,) (CC and) (NP (NNP Doc_11250767_391_409_Disease))))) (VP (VBD developed)))))) (. .)))
11250767	3	(S1 (S (S (NP (NP (JJ Serologic) (NN testing)) (CC and) (NP (JJ immunologic) (NNS studies))) (VP (AUX were) (VP (AUX done)))) (, ,) (CC and) (S (NP (DT a) (JJ pericardial) (NN biopsy)) (VP (AUX was) (VP (VBN performed)))) (. .)))
11250767	4	(S1 (S (NP (NP (DT A) (JJ 25-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_11250767_548_563_Disease)))) (VP (AUX had) (NP (NP (DT a) (NN Doc_11250767_570_585_Disease) (CC and) (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_11250767_602_614_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (NN biopsy))))))))))) (. .)))
11250767	5	(S1 (S (NP (JJ Serologic) (NN evaluation)) (VP (VBD revealed) (NP (NP (DT the) (NN presence)) (PP (IN of) (S (VP (VBG perinuclear-staining) (NP (NP (JJ antineutrophil) (JJ cytoplasmic) (NNS autoantibodies)) (PRN (-LRB- -LRB-) (NP (NN pANCA)) (-RRB- -RRB-))) (PP (IN against) (NP (NP (JJ myeloperoxidase)) (PRN (-LRB- -LRB-) (NP (NNP MPO)) (-RRB- -RRB-))))))))) (. .)))
11250767	6	(S1 (S (S (NP (JJ Doc_11250767_795_811_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN withdrawn)))) (, ,) (CC and) (S (NP (PRP she)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ 1-month) (NN course)) (PP (IN of) (NP (NNP Doc_11250767_880_890_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD alleviated) (NP (PRP$ her) (NNS symptoms)))))))))) (. .)))
11250767	7	(S1 (S (NP (DT A) (NN literature) (NN review)) (VP (VBD revealed) (NP (NP (DT no) (JJ prior) (NNS reports)) (PP (IN of) (NP (NP (NNP Doc_11250767_972_984_Disease)) (PP (IN in) (NP (NP (JJ anti-MPO) (JJ pANCA-positive) (NN Doc_11250767_1012_1022_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_11250767_1039_1057_Chemical) (NN therapy)))))))))) (. .)))
11250767	8	(S1 (S (NP (NN Doc_11250767_1079_1091_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ initial) (NN manifestation)) (PP (IN of) (NP (NP (JJ drug-induced) (NN Doc_11250767_1141_1151_Disease)) (ADJP (JJ attributable) (PP (TO to) (NP (JJ Doc_11250767_1168_1186_Chemical) (NN therapy))))))))) (. .)))
11256525	0	(S1 (S (VP (VBN Repeated) (NP (JJ transient) (NNP Doc_11256525_19_25_Disease)) (PP (VBG following) (NP (NNP Doc_11256525_36_44_Chemical) (NN administration))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (DT a) (JJ solitary) (NN kidney)))))) (. .)))
11256525	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 70-year-old) (JJ Doc_11256525_133_145_Disease) (NN man)) (PP (IN with) (NP (NP (DT a) (JJ solitary) (NN kidney) (CC and) (NN Doc_11256525_177_204_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (CD two) (NNS episodes)) (PP (IN of) (NP (JJ transient) (NNP Doc_11256525_245_251_Disease)))) (PP (IN after) (NP (NNP Doc_11256525_258_266_Chemical) (NN administration)))))))))))) (. .)))
11256525	2	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN hospitalized) (PP (IN for) (NP (NP (DT a) (NN Doc_11256525_309_330_Disease)) (PP (IN with) (NP (NNP Doc_11256525_336_351_Disease))) (, ,) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NNS diuretics)))))))) (. .)))
11256525	3	(S1 (S (PP (JJ Due) (TO to) (NP (JJ severe))) (NP (NNP Doc_11256525_401_421_Disease) (NNP Doc_11256525_422_430_Chemical)) (VP (AUX was) (VP (VBN prescribed))) (. .)))
11256525	4	(S1 (S (ADVP (RB Surprisingly)) (, ,) (NP (NP (DT the) (JJ first) (NN dose)) (PP (IN of) (NP (NP (CD 50) (NN mg)) (PP (IN of) (NP (NNP Doc_11256525_488_496_Chemical)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ sudden) (NN Doc_11256525_518_524_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD lasted) (NP (CD eight) (NNS hours)) (PP (IN despite) (NP (NP (JJ high-dose) (NN Doc_11256525_569_579_Chemical)) (CC and) (NP (JJ Doc_11256525_584_589_Chemical) (NN infusion)))))))))) (. .)))
11256525	5	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (PP (IN by) (NP (NN mistake))) (, ,) (NP (NNP Doc_11256525_628_636_Chemical)) (VP (VP (AUX was) (VP (VBN prescribed) (ADVP (RB again)))) (CC and) (VP (PP (IN after) (NP (NP (DT the) (JJ second) (NN dose)) (PP (IN of) (NP (NP (CD 50) (NNS mg)) (, ,) (NP (DT the) (NN patient)))))) (VBD developed) (NP (NP (DT a) (JJ second) (NN episode)) (PP (IN of) (NP (JJ transient) (NNP Doc_11256525_746_752_Disease))) (VP (VBG lasting) (NP (CD 10) (NNS hours)))))) (. .)))
11256525	6	(S1 (S (PP (IN During) (NP (DT these) (CD two) (NNS episodes))) (, ,) (S (NP (PRP$ his) (NN blood) (NN pressure)) (VP (VBN diminished))) (CC but) (S (NP (DT no) (JJ severe) (NN Doc_11256525_842_853_Disease)) (VP (AUX was) (VP (VBN noted)))) (. .)))
11256525	7	(S1 (S (ADVP (RB Ultimately)) (, ,) (NP (DT an) (NN arteriography)) (VP (VBD showed) (NP (DT a) (ADJP (CD 70-80) (NN %)) (NN Doc_11256525_910_931_Disease))) (. .)))
11256525	8	(S1 (S (PP (IN In) (NP (DT this) (NN patient))) (, ,) (NP (NNP Doc_11256525_950_971_Disease)) (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_11256525_986_999_Disease)) (CC and) (NP (NP (JJ diuretic) (NN therapy)) (VP (ADVP (RB certainly)) (VBN resulted) (PP (IN in) (NP (NP (DT a) (JJ strong) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ renin-Doc_11256525_1076_1087_Chemical) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP RAS)) (-RRB- -RRB-))))))))))) (. .)))
11256525	9	(S1 (S (PP (IN Under) (NP (JJ such) (NNS conditions))) (, ,) (NP (NP (JJ Doc_11256525_1125_1139_Chemical) (NN receptor) (NN blockade)) (PP (IN by) (NP (NNP Doc_11256525_1161_1169_Chemical)))) (ADVP (RB probably)) (VP (VBN induced) (NP (DT a) (JJ critical) (NN fall)) (PP (IN in) (NP (JJ glomerular) (NN filtration) (NN pressure)))) (. .)))
11256525	10	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ highlights) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (DT the) (NNP Doc_11256525_1284_1298_Chemical) (NN receptor) (NN antagonist) (NN Doc_11256525_1319_1327_Chemical)) (VP (VP (MD can) (VP (VB cause) (NP (JJ serious) (JJ unexpected) (NNS complications)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11256525_1388_1408_Disease))))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (JJ extreme) (NN caution))) (PP (IN in) (NP (DT this) (NN setting))))))))))) (. .)))
11263551	0	(S1 (NP (NP (NP (JJ Calcineurin-inhibitor) (VBN induced) (JJ Doc_11263551_30_34_Disease) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11263551_45_49_Disease)) (-RRB- -RRB-))) (: :) (NP (NP (DT a) (JJ severe) (VBG disabling) (NN complication)) (PP (IN after) (NP (NN organ) (NN transplantation)))) (. .)))
11263551	1	(S1 (S (NP (NP (NN Bone) (NN Doc_11263551_118_122_Disease)) (PP (IN after) (NP (NN transplantation)))) (VP (AUX is) (NP (NP (DT a) (JJ frequent) (NN complication)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (JJ several) (NNS diseases)))))))))) (. .)))
11263551	2	(S1 (S (NP (NN Treatment) (NNS strategies)) (VP (VBP depend) (PP (IN on) (NP (NP (DT the) (JJ correct) (NN diagnosis)) (PP (IN of) (NP (DT the) (NNP Doc_11263551_272_276_Disease)))))) (. .)))
11263551	3	(S1 (S (NP (NP (NP (CD Nine) (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_11263551_304_308_Disease))) (PP (IN in) (NP (PRP$ their) (NNS feet)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN registered) (PP (IN after) (NP (NN transplantation))))))) (, ,)) (VP (AUX were) (VP (VBN investigated))) (. .)))
11263551	4	(S1 (S (NP (NN Bone) (NNS scans)) (VP (VBD showed) (NP (NP (DT an) (VBN increased) (NNP tracer) (NN uptake)) (PP (IN of) (NP (DT the) (NN foot) (NNS bones))))) (. .)))
11263551	5	(S1 (S (NP (JJ Magnetic) (NN resonance) (NN imaging)) (VP (VBD demonstrated) (NP (NNP Doc_11263551_491_509_Disease)) (PP (IN in) (NP (DT the) (JJ painful) (NNS bones)))) (. .)))
11263551	6	(S1 (S (NP (NN Doc_11263551_532_536_Disease)) (VP (AUX was) (RB not) (VP (VBN explained) (PP (IN by) (NP (NP (JJ other) (NNS diseases)) (VP (VBG causing) (NP (NN foot) (NN Doc_11263551_586_590_Disease)) (, ,) (PP (IN like) (NP (NNP Doc_11263551_597_625_Disease) (, ,) (NNP Doc_11263551_627_641_Disease) (, ,) (NNP Doc_11263551_643_661_Disease) (, ,) (NNP Doc_11263551_663_667_Disease) (, ,) (NNP Doc_11263551_669_681_Disease) (, ,) (NNP Doc_11263551_683_701_Disease) (, ,) (NNP Doc_11263551_703_728_Disease) (, ,) (NP (JJ orthopaedic) (NNP Doc_11263551_742_758_Disease)) (, ,) (NP (NNP Doc_11263551_760_776_Disease)) (, ,) (CC and) (NP (NNP Doc_11263551_782_801_Disease))))))))) (. .)))
11263551	7	(S1 (S (NP (NP (NP (DT The) (NN reduction)) (PP (IN of) (NP (JJ Doc_11263551_820_832_Chemical-) (CC or) (JJ Doc_11263551_837_847_Chemical) (NN trough) (NNS levels)))) (CC and) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ Doc_11263551_888_895_Chemical) (NN channel) (NNS blockers))))) (VP (VBD led) (PP (TO to) (NP (NP (NN relief)) (PP (IN of) (NP (NNP Doc_11263551_930_934_Disease)))))) (. .)))
11263551	8	(S1 (S (NP (NP (DT The) (JJ Calcineurin-inhibitor) (VBN Induced) (NN Doc_11263551_970_974_Disease) (NN Syndrome)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11263551_985_989_Disease)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ severe)) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_11263551_1027_1039_Chemical) (CC or) (NNP Doc_11263551_1043_1053_Chemical))))) (CC and) (VP (AUX is) (ADVP (RB accurately)) (VP (VBN diagnosed) (PP (IN by) (NP (NP (PRP$ its) (JJ typical) (NN presentation)) (, ,) (NP (JJ magnetic) (NN resonance) (NN imaging)) (CC and) (NP (NN bone) (NNS scans))))))) (. .)))
11263551	9	(S1 (S (NP (NP (JJ Incorrect) (NN diagnosis)) (PP (IN of) (NP (DT the) (NN syndrome)))) (VP (MD will) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN of) (NP (NN life) (NN quality))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_11263551_1270_1274_Disease)))))))))) (. .)))
11279304	0	(S1 (S (NP (NN Brain) (JJ natriuretic) (NN peptide)) (VP (AUX is) (NP (NP (DT a) (NN predictor)) (PP (IN of) (NP (NNP Doc_11279304_44_57_Chemical-induced) (NNP Doc_11279304_66_80_Disease))))) (. .)))
11279304	1	(S1 (S (S (NP (NN Doc_11279304_82_96_Chemical)) (VP (AUX are) (NP (JJ effective) (JJ antineoplastic) (NNS drugs)))) (, ,) (CC but) (S (NP (PRP they)) (ADVP (RB frequently)) (VP (VBP cause) (NP (JJ dose-related) (NNP Doc_11279304_172_186_Disease)))) (. .)))
11279304	2	(S1 (S (NP (NP (DT The) (NNP Doc_11279304_192_206_Disease)) (PP (IN of) (NP (JJ conventional) (JJ Doc_11279304_223_236_Chemical) (NN therapy)))) (VP (VBZ highlights) (NP (NP (DT a) (NN need)) (PP (TO to) (NP (NP (NN search)) (PP (IN for) (NP (NP (NNS methods)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (ADJP (RB highly) (JJ sensitive)) (CC and) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG predicting) (NP (NNP Doc_11279304_337_356_Disease)))))))))))))))) (. .)))
11279304	3	(S1 (S (NP (PRP We)) (VP (VBD measured) (NP (NP (DT the) (NN plasma) (NN level)) (PP (IN of) (NP (NP (NN brain) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP BNP)) (-RRB- -RRB-))))) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NNP BNP)) (VP (MD might) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ simple) (JJ diagnostic) (NN indicator)) (PP (IN of) (NP (NP (NNP Doc_11279304_495_508_Chemical-induced) (NNP Doc_11279304_517_531_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11279304_549_563_Disease))) (VP (VBN treated) (PP (IN with) (NP (DT a) (JJ Doc_11279304_579_591_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11279304_593_596_Chemical)) (-RRB- -RRB-)) (JJ -containing) (NN regimen)))))))))))))))))) (. .)))
11279304	4	(S1 (S (NP (NP (JJ Thirteen) (NNS patients)) (PP (IN with) (NP (NNP Doc_11279304_641_655_Disease)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (DT a) (JJ Doc_11279304_676_679_Chemical-containing) (NN regimen))))) (. .)))
11279304	5	(S1 (S (NP (JJ Cardiac) (NNS functions)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN radionuclide) (NN angiography)) (PP (IN before) (NP (NNS chemotherapies))))))) (. .)))
11279304	6	(S1 (S (NP (NP (DT The) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NP (JJ atrial) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP ANP)) (-RRB- -RRB-))) (CC and) (NP (NNS BNP))))) (VP (AUX were) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN radionuclide) (NN angiography))))))) (. .)))
11279304	7	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD developed) (NP (NN Doc_11279304_928_952_Disease)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN chemotherapy)))))) (. .)))
11279304	8	(S1 (S (NP (CD Five) (NNS patients)) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (JJ subclinical) (NN Doc_11279304_1042_1055_Disease)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN chemotherapy)))))))))) (. .)))
11279304	9	(S1 (S (NP (NP (DT The) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNS BNP)) (PP (IN in) (NP (PDT all) (DT the) (NNS patients))) (PP (IN with) (NP (ADJP (JJ clinical) (CC and) (JJ subclinical)) (NNP Doc_11279304_1169_1182_Disease)))))) (VP (VBN increased) (PP (IN above) (NP (NP (DT the) (JJ normal) (NN limit)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN pg/ml)) (-RRB- -RRB-)))) (PP (IN before) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (ADJP (JJ clinical) (CC or) (JJ subclinical)) (NNP Doc_11279304_1275_1288_Disease))))) (PP (IN by) (NP (JJ radionuclide) (NN angiography)))) (. .)))
11279304	10	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP BNP)) (VP (AUX did) (RB not) (VP (VB increase) (PP (IN in) (NP (DT the) (NNS patients))) (PP (PP (IN without) (NP (NP (NNP Doc_11279304_1382_1395_Disease)) (VP (VBN given) (NP (NNP Doc_11279304_1402_1405_Chemical))))) (, ,) (RB even) (PP (IN at) (NP (NP (QP (JJR more) (IN than) (CD 700) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))))) (. .)))
11279304	11	(S1 (S (NP (NP (DT The) (NN plasma) (NN level)) (PP (IN of) (NP (NN ANP)))) (VP (AUX did) (RB not) (ADVP (RB always)) (VP (VB increase) (PP (IN in) (NP (PDT all) (DT the) (NNS patients))) (PP (IN with) (NP (ADJP (JJ clinical) (CC and) (JJ subclinical)) (NN Doc_11279304_1536_1549_Disease))))) (. .)))
11279304	12	(S1 (S (NP (DT These) (JJ preliminary) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS BNP)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN as) (NP (NP (DT an) (JJ early) (CC and) (JJ sensitive) (NN indicator)) (PP (IN of) (NP (JJ Doc_11279304_1647_1660_Chemical-induced) (NN Doc_11279304_1669_1683_Disease))))))))))) (. .)))
1130930	0	(S1 (NP (NP (NN Doc_1130930_0_14_Disease)) (PP (IN of) (NP (JJ combined) (JJ Doc_1130930_27_38_Chemical-Doc_1130930_39_49_Chemical) (NN regimen))) (. .)))
1130930	1	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (NNP Doc_1130930_82_104_Disease)) (, ,) (S (VP (VBN characterized) (ADVP (RB clinically)) (PP (IN by) (NP (JJ acute) (NNP Doc_1130930_140_162_Disease))))) (, ,) (SBAR (IN while) (S (NP (PRP they)) (VP (AUX were) (VP (VBG receiving) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_1130930_207_225_Chemical)) (CC and) (NP (JJ Doc_1130930_230_248_Chemical) (NN therapy)))))))))) (. .)))
1130930	2	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN given) (NP (DT this) (NN drug) (NN regimen))))))) (VP (MD should) (VP (AUX be) (VP (VBN observed) (ADVP (RB very) (RB carefully)) (PP (IN for) (NP (NP (JJ early) (NNS signs)) (PP (IN of) (NP (NNP Doc_1130930_352_366_Disease)))))))) (. .)))
1130930	3	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (DT this) (JJ antibiotic) (NN combination)))) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (PP (ADVP (RB especially)) (IN in) (NP (JJ elderly) (NNS patients)))))) (. .)))
1130930	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_1130930_474_493_Disease)))) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN given) (NP (DT this) (NN regimen))))) (. .)))
11334364	0	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NP (NN protection)) (PP (IN of) (NP (NN dna) (NN damage)))) (VP (VBN associated) (NP (ADJP (JJ apoptotic) (CC and) (JJ Doc_11334364_58_66_Disease)) (NN cell) (NNS deaths)) (PP (IN during) (NP (NP (NNP Doc_11334364_86_99_Chemical-induced) (NNP Doc_11334364_108_122_Disease)) (, ,) (NP (NNP Doc_11334364_124_134_Chemical-induced) (NNP Doc_11334364_143_156_Disease)) (CC and) (NP (NNP Doc_11334364_161_172_Chemical-induced) (NNP Doc_11334364_181_195_Disease)))) (PP (IN by) (NP (DT a) (JJ novel) (NN Doc_11334364_207_248_Chemical)))) (. .)))
11334364	1	(S1 (S (NP (NP (NNP Doc_11334364_250_268_Chemical)) (, ,) (NP (NP (RB primarily) (DT a) (NN mixture)) (PP (IN of) (NP (NNP Doc_11334364_293_310_Chemical)))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VBP modulate) (NP (NP (DT a) (NN wide-range)) (PP (IN of) (NP (NP (JJ biological) (, ,) (ADJP (JJ pharmacological) (CC and) (JJ toxicological)) (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADVP (RB mainly)) (ADJP (JJ cytoprotective)))))))))))))) (. .)))
11334364	2	(S1 (S (S (NP (DT This) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NNP Doc_11334364_477_518_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_520_524_Chemical)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_11334364_537_550_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_552_555_Chemical)) (-RRB- -RRB-))))))) (NP (JJ -induced) (NNP Doc_11334364_565_579_Disease)))) (, ,) (S (NP (NP (NNP Doc_11334364_581_591_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_593_596_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_11334364_606_619_Disease)))) (, ,) (CC and) (S (NP (NP (NNP Doc_11334364_625_636_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_638_641_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_11334364_651_665_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11334364	3	(S1 (S (NP (JJ Experimental) (NN design)) (VP (VBD consisted) (PP (IN of) (NP (CD four) (NNS groups))) (: :) (NP (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (NN vehicle) (RB alone)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_11334364_746_750_Chemical)) (ADVP (RB alone))) (, ,) (NP (NP (NN drug)) (ADVP (RB alone))) (CC and) (NP (NNP Doc_11334364_773_777_Chemical+drug))))) (. .)))
11334364	4	(S1 (S (PP (IN For) (NP (DT the) (NN cytoprotection) (NN study))) (, ,) (NP (NNS animals)) (VP (AUX were) (ADVP (RB orally)) (VP (VBN gavaged) (NP (QP (CD 100) (CD mg/Kg)) (NN Doc_11334364_852_856_Chemical)) (PP (IN for) (NP (NP (CD 7-10) (NNS days)) (VP (VBN followed) (PP (IN by) (S (VP (VBG i.p.) (NP (NP (NNS injections)) (PP (IN of) (NP (NP (NN organ) (JJ specific) (CD three) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_930_933_Chemical)) (: :) (NP (NP (NP (CD 500) (NNS mg/Kg)) (PP (IN for) (NP (CD 24))) (NP (NP (NNP h)) (: ;) (NP (NNP Doc_11334364_955_958_Chemical)) (: :) (NP (NP (CD 50) (NN mg/Kg/day)) (PP (IN for) (NP (CD four) (NNS days)))) (: ;) (NP (NNP Doc_11334364_988_991_Chemical)) (: :) (NP (NP (CD 20) (NN mg/Kg)) (PP (IN for) (NP (CD 48)))))) (NP (NNP h))) (-RRB- -RRB-))))))))))))) (. .)))
11334364	5	(S1 (S (NP (NP (NNS Parameters)) (PP (IN of) (NP (NN study)))) (VP (VBD included) (NP (NP (NP (NN analysis)) (PP (IN of) (NP (JJ serum) (NN chemistry) (PRN (-LRB- -LRB-) (NP (NNP ALT) (, ,) (NNP BUN) (CC and) (NNP CPK)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (JJ orderly) (NN fragmentation)) (PP (IN of) (NP (NP (JJ genomic) (NN DNA)) (PRN (-LRB- -LRB-) (ADJP (DT both) (JJ endonuclease-dependent) (CC and) (JJ independent)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NN addition))) (PP (TO to) (NP (NP (JJ microscopic) (NN evaluation)) (PP (IN of) (NP (NN damage) (NN and/or) (NN protection))))) (PP (IN in) (NP (NP (JJ corresponding) (NNS PAS)) (VP (VBN stained) (NP (NNS tissues)))))) (. .)))
11334364	6	(S1 (S (NP (NNS Results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_11334364_1303_1307_Chemical)) (VP (VP (VBD preexposure) (ADVP (RB prior) (PP (TO to) (NP (NP (NNP Doc_11334364_1329_1332_Chemical) (, ,) (NNP Doc_11334364_1334_1337_Chemical) (CC and) (NNP Doc_11334364_1342_1345_Chemical)) (, ,) (VP (VBN provided) (PP (IN near) (NP (JJ complete) (NN protection))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ serum) (NN chemistry) (NNS changes)) (PRN (-LRB- -LRB-) (NP (NNP ALT) (, ,) (NNP BUN) (CC and) (NNP CPK)) (-RRB- -RRB-))))))) (, ,))))) (CC and) (VP (ADVP (RB significantly)) (VBN reduced) (NP (NN DNA) (NN fragmentation))))))) (. .)))
11334364	7	(S1 (S (NP (NP (JJ Histopathological) (NN examination)) (PP (IN of) (NP (NN kidney) (, ,) (NN heart) (CC and) (NN lung) (NNS sections)))) (VP (VBD revealed) (ADJP (JJ moderate)) (PP (TO to) (NP (NP (JJ massive) (NN Doc_11334364_1576_1589_Disease)) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ morphological) (NNS aberrations)) (PP (IN by) (NP (NP (PDT all) (DT the) (CD three) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ Doc_11334364_1675_1679_Chemical) (NN preexposure)))))))))))) (PP (IN than) (PP (IN in) (NP (PRP$ its) (NN presence)))))) (. .)))
11334364	8	(S1 (S (NP (JJ Doc_11334364_1714_1718_Chemical+drug) (JJ exposed) (NNS tissues)) (VP (VBD exhibited) (NP (NP (JJ minor) (JJ residual) (NN damage)) (CC or) (NP (JJ near) (JJ total) (NN recovery)))) (. .)))
11334364	9	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NN histopathological) (NNS alterations)) (VP (VBD mirrored) (NP (NP (DT both) (JJ serum) (NN chemistry) (NNS changes)) (CC and) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NN DNA) (NN fragmentation)))))) (. .)))
11334364	10	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (PDT all) (DT the) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (, ,) (NP (NP (NNP Doc_11334364_1955_1958_Chemical)) (, ,) (NP (NNP Doc_11334364_1960_1963_Chemical)) (CC and) (NP (NNP Doc_11334364_1968_1971_Chemical))))) (VP (VBN induced) (NP (JJ apoptotic) (NN death)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_11334364_2011_2019_Disease))))) (PP (IN in) (NP (NP (DT the) (JJ respective) (NNS organs)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADVP (RB very) (RB effectively)) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_11334364_2083_2087_Chemical)))))))))) (. .)))
11334364	11	(S1 (S (SBAR (IN Since) (S (NP (NP (NNP Doc_11334364_2095_2098_Chemical)) (, ,) (NP (NNP Doc_11334364_2100_2103_Chemical)) (CC and) (NP (NNP Doc_11334364_2108_2111_Chemical))) (VP (VP (VBP undergo) (NP (NN biotransformation))) (CC and) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB produce) (NP (JJ damaging) (NNS radicals)) (PP (IN in) (NP (NN vivo))))))))))) (, ,) (NP (NP (DT the) (NN protection)) (PP (IN by) (NP (NNP Doc_11334364_2208_2212_Chemical)))) (VP (MD may) (VP (AUX be) (VP (VBN linked) (PP (TO to) (NP (NP (DT both) (NN inhibition)) (PP (IN of) (NP (NP (NN metabolism) (NN and/or) (NN detoxification)) (PP (IN of) (NP (JJ cytotoxic) (NNS radicals)))))))))) (. .)))
11334364	12	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (PRP$ its) (POS ') (JJ presumed) (NN contribution)) (PP (TO to) (NP (NN DNA) (NN repair)))) (VP (MD may) (VP (AUX be) (NP (NP (DT another) (JJ important) (NN attribute)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD played) (NP (DT a) (NN role)) (PP (IN in) (NP (DT the) (NN chemoprevention) (NN process))))))))) (. .)))
11334364	13	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (DT this)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN on) (NP (NP (JJ Doc_11334364_2500_2503_Chemical-induced) (JJ apoptotic) (NN death)) (PP (IN in) (NP (DT the) (NN lung) (NN tissue))))))))) (. .)))
11334364	14	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS events)) (ADVP (RB undoubtedly)) (VP (VB establish) (NP (NP (NP (NNP Doc_11334364_2599_2603_Chemical) (POS 's)) (JJ abundant) (NN bioavailability)) (, ,) (CC and) (NP (DT the) (NN power))) (S (VP (TO to) (VP (VB defend) (NP (JJ multiple) (NN target) (NNS organs)) (PP (IN from) (NP (NP (JJ toxic) (NNS assaults)) (VP (VBN induced) (PP (IN by) (NP (ADJP (ADJP (RB structurally) (JJ diverse)) (CC and) (ADJP (RB functionally) (JJ different))) (NNS entities))) (PP (IN in) (NP (NN vivo)))))))))) (. .)))
11379838	0	(S1 (NP (NP (NP (JJ Doc_11379838_0_14_Chemical-induced) (NN Doc_11379838_23_28_Disease)) (PP (IN in) (NP (NNP Doc_11379838_32_39_Disease) (NNS patients)))) (: :) (NP (NP (NN identification)) (PP (IN of) (NP (NN risk) (NNS factors)))) (. .)))
11379838	1	(S1 (S (NP (NP (NNS Concerns)) (PP (IN about) (NP (NP (JJ possible) (NNS risks)) (PP (IN of) (S (VP (VBG switching) (PP (TO to) (NP (NNP Doc_11379838_140_145_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11379838_162_177_Chemical))))))) (VP (VBP continue) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (NP (DT an) (JJ optimal) (NN treatment) (NN paradigm)) (PP (IN for) (NP (NN Doc_11379838_260_278_Disease))))))))))) (. .)))
11379838	2	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (NP (CD 44) (NNS patients)) (VP (VBG meeting) (NP (JJ DSM-IV) (NNS criteria)) (PP (IN for) (NP (NNP Doc_11379838_344_360_Disease)))))) (PP (TO to) (NP (JJ naturalistic) (NN treatment)))) (VP (AUX was) (VP (VBN assessed) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD 6)) (NNS weeks)) (VP (VBG using) (NP (NP (DT the) (NNP Montgomery-Asberg) (NNP Depression) (NNP Rating) (NNP Scale)) (CC and) (NP (DT the) (JJ Bech-Rafaelson) (NN Mania) (NNP Rating) (NNP Scale)))))))) (. .)))
11379838	3	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT a) (NNP Doc_11379838_543_548_Disease) (CC or) (NNP Doc_11379838_552_561_Disease) (NN switch)))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (PP (IN on) (NP (NP (JJ several) (NNS variables)) (VP (VBG including) (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NP (NP (NN diagnosis)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_658_674_Disease) (FW vs.) (NNP Doc_11379838_679_689_Disease)) (-RRB- -RRB-)) (, ,) (NP (NP (NN number)) (PP (IN of) (NP (JJ previous) (NNP Doc_11379838_711_716_Disease) (NNS episodes)))) (, ,) (NP (NN type))) (PP (IN of) (NP (NNP Doc_11379838_735_749_Chemical) (NN therapy))) (VP (VBN used) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ electroconvulsive) (NN therapy)) (PP (IN vs.) (NP (NNP Doc_11379838_794_808_Chemical) (NNS drugs)))) (CC and) (, ,) (ADVP (RBR more) (RB particularly)) (, ,) (NP (JJ selective) (JJ Doc_11379838_849_878_Chemical) (JJ -LSB-Doc_11379838_880_885_Chemical) (NN -RSB-))) (-RRB- -RRB-)))) (, ,) (NP (NP (NN use) (CC and) (NN type)) (PP (IN of) (NP (NP (NN mood) (NNS stabilizers)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_923_930_Chemical) (FW vs.) (FW anticonvulsants)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (NN temperament)) (PP (IN of) (NP (NP (DT the) (NN patient)) (, ,) (VP (VBN assessed) (PP (IN during) (NP (NP (DT a) (JJ normothymic) (NN period)) (VP (VBG using) (NP (NP (DT the) (NN hyperthymia) (NN component)) (PP (IN of) (NP (DT the) (JJ Semi-structured) (NNP Affective) (NN Temperament) (NN Interview))))))))))))))))))))))) (. .)))
11379838	4	(S1 (S (NP (NP (NNS Switches)) (PP (TO to) (NP (NNP Doc_11379838_1131_1140_Disease) (CC or) (NNP Doc_11379838_1144_1149_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (CD 27) (NN %)) (PP (IN of) (NP (DT all) (NNS patients)))) (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 12)) (-RRB- -RRB-) (-LRB- -LRB-) (CC and) (NP (NP (QP (IN in) (CD 24)) (NN %)) (PP (IN of) (NP (NP (DT the) (NN subgroup)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11379838_1244_1249_Chemical) (CD -LSB-8/33) (NN -RSB-))))))))) (-RRB- -RRB-)) (: ;) (NP (NP (CD 16) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 7)) (-RRB- -RRB-)) (NP (JJ experienced) (JJ Doc_11379838_1283_1288_Disease) (NNS episodes))) (, ,) (CC and) (NP (NP (CD 11) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 5)) (-RRB- -RRB-)) (NP (JJ experienced) (JJ Doc_11379838_1327_1336_Disease) (NNS episodes)))))) (. .)))
11379838	5	(S1 (S (NP (NP (NN Sex)) (, ,) (NP (NN age)) (, ,) (NP (NN diagnosis)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_1368_1377_Disease) (FW vs.) (NNP Doc_11379838_1382_1392_Disease)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ additional) (NN treatment))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN switching)))))) (. .)))
11379838	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN mood) (NNS switches)))) (VP (VBD seemed) (S (RB not) (VP (TO to) (VP (VB differ) (PP (IN between) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT an) (NN anticonvulsant)))) (CC and) (NP (NP (DT those)) (VP (VBG receiving) (NP (DT no) (NN mood) (NN stabilizer)))))))))) (. .)))
11379838	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN mood) (NNS switches)) (VP (AUX were) (ADJP (RBR less) (JJ frequent) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_11379838_1663_1670_Chemical)))))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (, ,) (NP (CD 4/26)) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (NP (NNS patients)) (VP (RB not) (VBN treated) (PP (IN with) (NP (NNP Doc_11379838_1717_1724_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 44) (NN %)) (, ,) (NP (CD 8/18))) (: ;) (NP (NN p)) (X (SYM =)) (CD .04)) (-RRB- -RRB-))))))) (. .)))
11379838	8	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ previous) (NNP Doc_11379838_1770_1775_Disease) (NNS episodes)))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN probability)) (PP (IN of) (NP (NN switching)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT a) (JJ high) (NN score)) (PP (IN on) (NP (NP (DT the) (NN hyperthymia) (NN component)) (PP (IN of) (NP (DT the) (JJ Semistructured) (JJ Affective) (NN Temperament) (NN Interview)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG switching) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD .008)) (-RRB- -RRB-))))))))))))) (. .)))
11379838	9	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NN mood) (NN switching))) (VP (VBN associated) (PP (IN with) (NP (JJ acute) (JJ Doc_11379838_2060_2074_Chemical) (NN therapy))))) (VP (MD may) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (NP (JJ Doc_11379838_2101_2108_Chemical) (NN treatment)))))) (. .)))
11379838	10	(S1 (S (NP (JJ Particular) (NN attention)) (VP (MD should) (VP (AUX be) (VP (VBN paid) (PP (TO to) (NP (NNS patients))) (PP (IN with) (NP (NP (DT a) (JJ hyperthymic) (NN temperament)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (NP (NN mood) (NNS switches)))))))))))) (. .)))
11391224	0	(S1 (NP (NP (NP (JJ Peritubular) (JJ capillary) (NN basement) (NN membrane) (NN reduplication)) (PP (IN in) (NP (NP (NNS allografts)) (CC and) (NP (JJ native) (NN Doc_11391224_79_93_Disease))))) (: :) (NP (NP (DT a) (JJ clinicopathologic) (NN study)) (PP (IN of) (NP (CD 278) (JJ consecutive) (JJ renal) (NNS specimens)))) (. .)))
11391224	1	(S1 (S (NP (DT An) (NN association)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (IN between) (NP (NP (NP (NNP Doc_11391224_207_232_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11391224_234_236_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (NN reduplication)) (PP (IN of) (NP (NP (JJ peritubular) (JJ capillary) (NN basement) (NNS membranes)) (PRN (-LRB- -LRB-) (NP (NNP PTCR)) (-RRB- -RRB-)))))))))) (. .)))
11391224	2	(S1 (S (SBAR (IN Although) (S (NP (PDT such) (DT an) (NN association)) (VP (AUX is) (PP (IN of) (NP (ADJP (ADJP (JJ practical)) (CC and) (ADJP (JJ theoretical))) (NN importance)))))) (, ,) (NP (QP (RB only) (CD one)) (JJ prospective) (NN study)) (VP (AUX has) (VP (VBN tried) (S (VP (TO to) (VP (VB confirm) (NP (PRP it))))))) (. .)))
11391224	3	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (CD 278) (JJ consecutive) (JJ renal) (NNS specimens)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (CD 135) (NNS transplants)) (CC and) (NP (CD 143) (JJ native) (NNS kidneys)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (JJ ultrastructural) (NN evidence)) (PP (IN of) (NP (NNP PTCR)))))) (. .)))
11391224	4	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ renal) (NNS allografts)) (PP (IN with) (NP (NNP Doc_11391224_607_609_Disease))))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (NNS grafts)) (PP (IN with) (NP (NP (JJ acute) (NN rejection)) (, ,) (NP (JJ recurrent) (NN Doc_11391224_667_685_Disease)) (, ,) (NP (NNP Doc_11391224_687_716_Disease)) (CC and) (NP (NP (JJ stable) (NNS grafts)) (PRN (-LRB- -LRB-) (`` ``) (NP (NN protocol) (NNS biopsies)) ('' '') (-RRB- -RRB-))))))) (. .)))
11391224	5	(S1 (S (NP (JJ Native) (NN kidney) (NNS specimens)) (VP (VBD included) (NP (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NNP Doc_11391224_807_823_Disease)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_11391224_844_870_Disease)) (, ,) (NP (NNP Doc_11391224_872_894_Disease)) (, ,) (NP (JJ acute) (NNP Doc_11391224_902_924_Disease)) (, ,) (CC and) (NP (NNP Doc_11391224_930_952_Disease))))))) (. .)))
11391224	6	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NNP PTCR)) (PP (PP (IN in) (NP (NP (CD 14)) (PP (IN of) (NP (NP (CD 15) (NNS cases)) (PP (IN of) (NP (NNP Doc_11391224_998_1000_Disease))))))) (, ,) (PP (IN in) (NP (NP (CD 7) (NN transplant) (NN biopsy) (NNS specimens)) (PP (IN without) (NP (NNP Doc_11391224_1043_1045_Disease))))) (, ,) (CC and) (PP (IN in) (NP (NP (CD 13)) (PP (IN of) (NP (CD 143) (JJ native) (NN kidney) (NN biopsy) (NNS specimens))))))) (. .)))
11391224	7	(S1 (S (NP (DT These) (CD 13)) (VP (VBD included) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_11391224_1123_1145_Disease)) (, ,) (NP (NNP Doc_11391224_1147_1173_Disease)) (, ,) (NP (NNP Doc_11391224_1175_1190_Disease)) (, ,) (NP (NNP Doc_11391224_1192_1218_Disease)) (, ,) (NP (JJ crescentic) (NNP Doc_11391224_1231_1249_Disease)) (, ,) (CC and) (NP (JJ Doc_11391224_1255_1262_Chemical-related) (NNP Doc_11391224_1271_1290_Disease)))))) (. .)))
11391224	8	(S1 (S (NP (NP (JJ Mild) (NNS PTCR)) (PP (IN in) (NP (NP (NNS allografts)) (PP (IN without) (NP (NNP Doc_11391224_1324_1326_Disease)))))) (VP (AUX did) (RB not) (VP (VB predict) (NP (NP (NN Doc_11391224_1343_1356_Disease)) (CC or) (NP (JJ significant) (NN Doc_11391224_1372_1383_Disease))) (PP (IN after) (NP (NP (JJ follow-up) (NNS periods)) (PP (IN of) (NP (QP (IN between) (CD 3) (NNS months) (CC and) (CD 1) (NN year)))))))) (. .)))
11391224	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (PP (IN in) (NP (NNS transplants))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN association)) (PP (IN between) (NP (NP (JJ well-developed) (NNP PTCR)) (CC and) (NP (NNP Doc_11391224_1548_1550_Disease))))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (NP (JJ mild) (NN PTCR)) (CC and) (NP (PRP$ its) (JJ predictive) (NN value)))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_11391224_1631_1633_Disease)))))) (VP (AUX is) (ADJP (JJ unclear))))))))) (. .)))
11391224	10	(S1 (S (NP (NNP PTCR)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN in) (NP (JJ certain) (JJ native) (NN Doc_11391224_1681_1696_Disease))) (, ,) (SBAR (IN though) (S (NP (DT the) (NN association)) (VP (AUX is) (RB not) (ADJP (RB as) (JJ strong) (PP (IN as) (NP (NP (DT that)) (PP (IN for) (NP (NNP Doc_11391224_1750_1752_Disease)))))))))) (. .)))
11391224	11	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NP (DT that) (VBN repeated) (NN Doc_11391224_1779_1797_Disease)) (, ,) (PP (VBG including) (NP (NNP Doc_11391224_1809_1827_Disease))) (, ,)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (PP (IN of) (NP (DT this) (NN lesion))) (CC both) (PP (IN in) (NP (NP (NNS allografts)) (CC and) (NP (JJ native) (NNS kidneys))))))))))) (. .)))
11419773	0	(S1 (NP (NP (JJ Doc_11419773_0_8_Chemical-induced) (NN Doc_11419773_17_35_Disease)) (: :) (NP (NP (DT an) (JJ unrecognised) (NN danger)) (PP (IN of) (NP (NN healthfood) (NNS products)))) (. .)))
11419773	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 25-year-old) (NN woman)) (PP (IN with) (NP (JJ pre-existing) (NNP Doc_11419773_134_155_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ intractable) (NN Doc_11419773_182_206_Disease)) (PP (IN after) (NP (NP (NN consuming) (NP (DT a) (`` ``) (JJ natural) (NN energy) ('' '')) (NNP guarana) (NN health) (NN drink)) (VP (VBG containing) (NP (NP (DT a) (JJ high) (NN concentration)) (PP (IN of) (NP (NNP Doc_11419773_298_306_Chemical)))))))))))) (. .)))
11419773	2	(S1 (S (NP (DT This) (NN case)) (VP (VBZ highlights) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ adequate) (NN labelling)) (CC and) (NP (NP (NN regulation)) (PP (IN of) (NP (JJ such) (NNS products)))))))) (. .)))
11426838	0	(S1 (S (NP (NP (NP (ADJP (RB Conformationally) (VBN restricted)) (NNS analogs)) (PP (IN of) (NP (NNP Doc_11426838_39_45_Chemical)))) (CC and) (NP (DT an) (JJ antisense) (JJ Doc_11426838_63_83_Chemical) (VBG targeting) (NN sigma1) (NNS receptors))) (VP (VBP produce) (NP (NP (JJ anti-Doc_11426838_124_131_Chemical) (NNS effects)) (PP (IN in) (NP (NNS mice))))) (. .)))
11426838	1	(S1 (S (NP (NP (NN Doc_11426838_149_156_Chemical) (POS 's)) (NN ability) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NNP sigma) (NNS receptors))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT these) (NNS proteins)) (VP (VB mediate) (NP (NP (DT some)) (PP (IN of) (NP (PRP$ its) (JJ behavioral) (NNS effects)))))))) (. .)))
11426838	2	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (ADJP (CD three) (NN novel)) (NNP sigma) (NN receptor) (NNS ligands)) (PP (IN with) (NP (JJ antagonist) (NN activity)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNP Swiss) (NNP Webster) (NNS mice)) (: :) (NP (NP (NP (NNP Doc_11426838_378_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_386_450_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_11426838_453_459_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_461_511_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_11426838_518_523_Chemical) (PRN (-LRB- -LRB-) (NP (NP (JJ 1R,2S-) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -cis-N--LSB-2-) (-LRB- -LRB-) (NN 3,4-dichlorophenyl) (-RRB- -RRB-) (NNP ethyl)) (NP (JJ -RSB-) (JJ -2-) (PRN (-LRB- -LRB-) (NP (NN 1-pyrrolidinyl)) (-RRB- -RRB-)) (NN cyclohexylamine))) (-RRB- -RRB-)))))))) (. .)))
11426838	3	(S1 (S (NP (NN Competition) (JJ binding) (NNS assays)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT all) (CD three) (NNS compounds)) (VP (AUX have) (NP (NP (JJ high) (NNS affinities)) (PP (IN for) (NP (JJ sigma1) (NNS receptors)))))))) (. .)))
11426838	4	(S1 (S (NP (DT The) (CD three) (NNS compounds)) (VP (VBP vary) (PP (IN in) (NP (NP (PRP$ their) (NNS affinities)) (PP (IN for) (NP (NP (JJ sigma2) (NNS receptors)) (CC and) (NP (NP (NN exhibit) (JJ negligible) (NNS affinities)) (PP (IN for) (NP (NP (NNP Doc_11426838_819_827_Chemical)) (, ,) (NP (NN opioid)) (, ,) (NP (NP (NNP Doc_11426838_837_841_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP A)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_11426838_849_853_Chemical) (NNS receptors)))))))))) (. .)))
11426838	5	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS studies))) (, ,) (NP (NP (NN pre-treatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (NNP Doc_11426838_915_921_Chemical)) (, ,) (NP (NNP Doc_11426838_923_929_Chemical)) (, ,) (CC or) (NP (NNP Doc_11426838_934_939_Chemical))))))) (VP (ADVP (RB significantly)) (VBD attenuated) (NP (NP (JJ Doc_11426838_965_972_Chemical-induced) (NN Doc_11426838_981_992_Disease)) (CC and) (NP (NN lethality)))) (. .)))
11426838	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN post-treatment)) (PP (IN with) (NP (NNP Doc_11426838_1038_1043_Chemical)))) (VP (VBD prevented) (NP (JJ Doc_11426838_1054_1061_Chemical-induced) (NN lethality)) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN proportion)) (PP (IN of) (NP (NNS animals)))))) (. .)))
11426838	7	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN protection)) (VP (VBN provided) (PP (IN by) (NP (DT the) (JJ putative) (NNS antagonists)))))))) (, ,) (NP (NP (NP (DT the) (JJ well-characterized) (NNP sigma) (NN receptor) (NN agonist) (NNP Doc_11426838_1234_1253_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_1255_1258_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT the) (JJ novel) (NNP sigma) (NN receptor) (NN agonist) (NNP Doc_11426838_1297_1303_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_1305_1369_Chemical)) (-RRB- -RRB-))) (NP (DT each)))) (VP (VBD worsened) (NP (NP (DT the) (JJ behavioral) (NN Doc_11426838_1400_1408_Disease)) (PP (IN of) (NP (NNP Doc_11426838_1412_1419_Chemical))))) (. .)))
11426838	8	(S1 (S (PP (IN At) (NP (NP (NNS doses)) (SBAR (WHADVP (WRB where)) (S (ADVP (RB alone)) (, ,) (NP (PRP they)) (VP (VBD produced) (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NN locomotion)))))))) (, ,) (NP (NNP Doc_11426838_1495_1501_Chemical) (, ,) (NNP Doc_11426838_1503_1509_Chemical) (CC and) (NNP Doc_11426838_1514_1519_Chemical)) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NP (DT the) (JJ locomotor) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_11426838_1582_1589_Chemical))))) (. .)))
11426838	9	(S1 (S (S (VP (TO To) (VP (ADVP (RB further)) (VB validate) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT the) (JJ anti-Doc_11426838_1640_1647_Chemical) (NNS effects)) (PP (IN of) (NP (DT the) (JJ novel) (NNS ligands)))) (VP (VBD involved) (NP (NP (NN antagonism)) (PP (IN of) (NP (NNP sigma) (NNS receptors))))))))))) (, ,) (NP (NP (DT an) (JJ antisense) (NN Doc_11426838_1730_1750_Chemical)) (PP (IN against) (NP (JJ sigma1) (NNS receptors)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN shown) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB attenuate) (NP (NP (DT the) (ADJP (JJ Doc_11426838_1822_1832_Disease) (CC and) (JJ locomotor)) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_11426838_1870_1877_Chemical))))))))) (. .)))
11426838	10	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT the) (NN data)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ functional) (NN antagonism)) (PP (IN of) (NP (NNP sigma) (NNS receptors)))) (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG attenuating) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ Doc_11426838_1991_1998_Chemical-induced) (NNS behaviors)))))))))))) (. .)))
11431197	0	(S1 (NP (NP (JJ Doc_11431197_0_10_Chemical-induced) (JJ acute) (NN Doc_11431197_25_47_Disease)) (PP (IN in) (NP (DT a) (JJ cadaveric) (JJ renal) (NN allograft))) (. .)))
11431197	1	(S1 (S (NP (NN Doc_11431197_80_90_Chemical)) (ADVP (RB frequently)) (VP (AUX is) (VP (VBN used) (PP (IN for) (S (VP (VBG preventing) (NP (JJ peptic) (NN ulceration)) (PP (IN after) (NP (JJ renal) (NN transplantation)))))))) (. .)))
11431197	2	(S1 (S (NP (DT This) (NN drug)) (ADVP (RB occasionally)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ acute) (NN Doc_11431197_226_248_Disease)) (PP (IN in) (NP (JJ native) (NNS kidneys)))))))) (. .)))
11431197	3	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (JJ similar) (NNS reports)) (PP (IN with) (NP (JJ renal) (NN transplantation))))) (. .)))
11431197	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_11431197_345_355_Chemical-induced) (JJ acute) (NN Doc_11431197_370_392_Disease)))) (PP (IN in) (NP (NP (DT a) (NN recipient)) (PP (IN of) (NP (NP (DT a) (JJ cadaveric) (JJ renal) (NN allograft)) (VP (VBG presenting) (PP (IN with) (NP (JJ acute) (NN allograft) (NN dysfunction))) (PP (IN within) (NP (NP (CD 48) (NNS hours)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NN drug))))))))))))) (. .)))
11431197	5	(S1 (S (NP (DT The) (JJ biopsy) (NNS specimen)) (VP (VBD showed) (NP (NP (JJ pathognomonic) (NNS features)) (, ,) (PP (VBG including) (NP (NP (JJ eosinophilic) (NN infiltration)) (PP (IN of) (NP (DT the) (JJ interstitial) (NN compartment))))))) (. .)))
11431197	6	(S1 (S (NP (JJ Allograft) (NN function)) (VP (VP (VBD improved) (ADVP (RB rapidly))) (CC and) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (S (VP (VBG stopping) (NP (DT the) (NN drug))))))) (. .)))
1147734	0	(S1 (S (NP (NN Doc_1147734_0_13_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_1147734_24_40_Chemical)))) (. .)))
1147734	1	(S1 (S (NP (DT This) (NN report)) (VP (VBZ presents) (NP (NP (DT the) (JJ clinical) (, ,) (NN laboratory) (, ,) (CC and) (NN light)) (CC and) (NP (NNP electron) (JJ microscopic) (NNS observations))) (PP (IN on) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_1147734_155_192_Disease))) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_1147734_225_241_Chemical))))))))) (. .)))
1147734	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT an) (NN addition)) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD must) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (JJ chronic) (NN Doc_1147734_337_350_Disease)))))))))))))))) (. .)))
11532387	0	(S1 (NP (NP (NN Doc_11532387_0_35_Disease)) (PP (IN during) (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (NNP Doc_11532387_61_72_Chemical))))) (. .)))
11532387	1	(S1 (S (NP (NP (NN Doc_11532387_74_89_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11532387_91_93_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ rare) (JJ extrapyramidal) (NN side) (NN effect)) (VP (VBN caused) (PP (IN by) (NP (JJ prolonged) (JJ neuroleptic) (NN medication)))))) (. .)))
11532387	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_11532387_202_224_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (JJ first)) (PP (IN of) (NP (PRP$ its) (NN kind) (S (VP (TO to) (VP (AUX be) (VP (VBN reported))))))))))))) (. .)))
11532387	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (NN Doc_11532387_295_297_Disease)) (PP (IN during) (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (NNP Doc_11532387_323_334_Chemical)))))) (. .)))
11532387	4	(S1 (S (NP (DT The) (NN symptom)) (VP (AUX was) (VP (VBN treated) (ADVP (RB successfully)) (PP (IN with) (NP (JJ Doc_11532387_378_393_Chemical) (JJ anticholinergic) (NN therapy))))) (. .)))
11532387	5	(S1 (S (NP (NP (DT The) (JJ underlying) (NN mechanism)) (PP (IN of) (NP (NNP Doc_11532387_447_469_Disease))) (PP (IN in) (NP (DT the) (JJ present) (NN case)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ pharmacological) (NN profile)) (PP (IN of) (NP (NP (NNP Doc_11532387_546_557_Chemical)) (, ,) (NP (DT a) (JJ Doc_11532387_561_570_Chemical-Doc_11532387_571_579_Chemical) (NN antagonist))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ pathophysiologic) (NN influence)) (PP (IN of) (NP (DT the) (JJ Doc_11532387_641_650_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11532387_680_682_Disease))))))))))) (. .)))
11569530	0	(S1 (NP (NP (JJ Pharmacokinetic/pharmacodynamic) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11569530_61_66_Chemical) (, ,) (NNP Doc_11569530_68_77_Chemical) (, ,) (NNP Doc_11569530_79_90_Chemical) (CC and) (NNP Doc_11569530_95_105_Chemical))) (PP (IN on) (NP (NP (JJ monophasic) (NN action) (JJ potential) (NN duration)) (PP (IN in) (NP (NNP dog.) (CD 1))))))) (. .)))
11569530	1	(S1 (S (NP (NP (NNP Doc_11569530_157_176_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11569530_178_181_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ fatal)) (NN Doc_11569530_206_229_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (JJ QT) (NN interval)) (CC and) (NP (NP (JJ monophasic) (NN action) (JJ potential) (NN duration)) (PRN (-LRB- -LRB-) (NP (NNP MAPD)) (-RRB- -RRB-)))))))))) (. .)))
11569530	2	(S1 (S (NP (NN Doc_11569530_320_323_Disease)) (VP (AUX is) (NP (NP (DT a) (NN side-effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (NN withdrawal)) (PP (IN of) (NP (JJ several) (NNS drugs))) (PP (IN from) (NP (NP (DT the) (NN market)) (PRN (-LRB- -LRB-) (NP (NNP e.g.) (NNP Doc_11569530_407_418_Chemical) (CC and) (NNP Doc_11569530_423_433_Chemical)) (-RRB- -RRB-)))) (. .) (CD 2))))))))) (. .)))
11569530	3	(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN of) (NP (NP (NNS compounds)) (SBAR (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_11569530_475_478_Disease))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG monitoring) (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NP (NNP MAPD)) (PP (IN in) (NP (NN dog)))))))))) (. .)))
11569530	4	(S1 (NP (NP (NP (CD Four) (NNS compounds)) (VP (VBN known) (S (VP (TO to) (VP (VP (VB increase) (NP (CD QT) (NN interval))) (CC and) (VP (VB cause) (SBAR (S (NP (NNP Doc_11569530_592_595_Disease)) (VP (AUX were) (VP (VBN investigated))))))))))) (: :) (NP (NNP Doc_11569530_615_626_Chemical) (, ,) (NNP Doc_11569530_628_638_Chemical) (, ,) (NNP Doc_11569530_640_649_Chemical) (CC and) (NNP Doc_11569530_654_659_Chemical)) (. .)))
11569530	5	(S1 (S (PP (IN On) (NP (DT the) (NN basis) (SBAR (IN that) (S (NP (NP (RB only) (JJ free) (NN drug)) (PP (IN in) (NP (DT the) (JJ systemic) (NN circulation)))) (VP (MD will) (VP (VB elicit) (NP (DT a) (JJ pharmacological) (NN response) (NN target)))))))) (, ,) (NP (NP (JJ free) (NNS concentrations)) (PP (IN in) (NP (NN plasma)))) (VP (AUX were) (VP (VBN selected) (S (VP (TO to) (VP (VB mimic) (NP (NP (DT the) (JJ free) (NN drug) (NNS exposures)) (PP (IN in) (NP (NN man))))))))) (. .)))
11569530	6	(S1 (S (NP (NN Infusion) (NNS regimens)) (VP (AUX were) (VP (VBN designed) (SBAR (IN that) (S (NP (NP (NP (ADJP (RB rapidly) (VBN achieved) (CC and) (VBN maintained)) (JJ target-free) (NNS concentrations)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (PP (IN in) (NP (NN plasma)))))) (CC and) (NP (NP (NNS data)) (PP (IN on) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ free) (NN concentration)) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NNP MAPD)))))))))) (VP (AUX were) (VP (VBN obtained) (PP (IN for) (NP (DT these) (JJ compounds.) (CD 3))))))))) (. .)))
11569530	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ free) (CD ED50)) (PP (IN in) (NP (NP (NN plasma)) (PP (IN for) (NP (NP (NP (NNP Doc_11569530_1142_1153_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.9) (NN nM)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_11569530_1164_1174_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 76) (NN nM)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_11569530_1184_1193_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN nM)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_11569530_1206_1211_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.9) (NN nM)) (-RRB- -RRB-)))))))) (ADVP (RB closely)) (VP (VB correlate) (PP (IN with) (NP (DT the) (JJ free) (NN concentration))) (PP (IN in) (NP (NP (NN man)) (VP (VBG causing) (NP (JJ QT) (NNS effects))))))))) (. .)))
11569530	8	(S1 (S (PP (IN For) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN shown) (NP (NNP Doc_11569530_1324_1327_Disease)) (PP (IN in) (NP (DT the) (NN clinic))))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_11569530_1343_1354_Chemical)) (, ,) (NP (NNP Doc_11569530_1356_1366_Chemical)) (, ,) (NP (NNP Doc_11569530_1368_1377_Chemical)) (-RRB- -RRB-)) (NP (EX there)) (VP (AUX is) (NP (NP (JJ little) (NN differentiation)) (PP (IN between) (NP (NP (DT the) (NN dog) (CD ED50)) (CC and) (NP (NP (DT the) (JJ efficacious) (JJ free) (NN plasma) (NNS concentrations)) (PP (IN in) (NP (NP (NN man)) (PRN (-LRB- -LRB-) (NP (NNP <) (JJ 10-fold)) (-RRB- -RRB-)) (VP (VBG reflecting) (NP (PRP$ their) (JJ limited) (NN safety) (NNS margins)))))))))) (. .)))
11569530	9	(S1 (S (NP (DT These) (NNS data)) (VP (VB underline) (NP (NP (DT the) (NN need) (S (VP (TO to) (VP (VB maximize) (NP (DT the) (JJ therapeutic) (NN ratio)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NNP Doc_11569530_1619_1622_Disease)) (PP (IN in) (NP (JJ potential) (NN development) (NNS candidates))))))))))) (CC and) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG using) (NP (NP (JJ free) (NN drug) (NNS concentrations)) (PP (IN in) (NP (JJ pharmacokinetic/pharmacodynamic) (NNS studies)))))))))) (. .)))
11581460	0	(S1 (S (S (NP (NN Bladder)) (VP (VBP Doc_11581460_8_26_Disease) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (JJ continuous) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_11581460_77_85_Chemical))))))))) (: :) (S (NP (CD 2) (NN case)) (VP (VBZ reports))) (. .)))
11581460	1	(S1 (S (NP (NNP Sedation)) (VP (AUX has) (VP (AUX been) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (DT the) (NN neonate) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN stress) (CC and) (NN Doc_11581460_177_181_Disease)) (PP (IN from) (NP (NP (DT the) (NX (NX (JJ noxious) (NNS stimuli)) (CC and) (NX (JJ invasive) (NNS procedures)))) (PP (IN in) (NP (NP (DT the) (JJ neonatal) (JJ intensive) (NN care) (NN unit)) (, ,) (CONJP (RB as) (RB well) (IN as)) (S (VP (TO to) (VP (VB facilitate) (NP (NP (NN synchrony)) (PP (IN between) (NP (NP (NN ventilator)) (CC and) (NP (JJ spontaneous) (NNS breaths))))))))))))))))))))) (. .)))
11581460	2	(S1 (S (NP (NP (NN Doc_11581460_347_355_Chemical)) (, ,) (NP (DT an) (JJ opioid) (JJ analgesic)) (, ,)) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ neonatal) (JJ intensive) (NN care) (NN unit)) (VP (VBG setting) (PP (IN for) (NP (DT these) (JJ very) (NNS purposes)))))))) (. .)))
11581460	3	(S1 (S (NP (NP (JJ Various) (JJ reported) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_11581460_499_507_Chemical) (NN administration)))) (VP (VBP include) (NP (NP (NNP Doc_11581460_531_550_Disease)) (, ,) (NP (NNP Doc_11581460_552_563_Disease)) (, ,) (NP (NNP Doc_11581460_565_587_Disease)) (, ,) (CC and) (NP (NNP Doc_11581460_593_604_Disease)))) (. .)))
11581460	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_11581460_623_648_Disease))) (VP (VBG leading) (PP (TO to) (NP (JJ renal) (JJ pelvocalyceal) (NN dilatation) (NN mimicking) (NNP Doc_11581460_701_715_Disease))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_11581460_754_762_Chemical))))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
11587867	0	(S1 (NP (NP (NP (JJ Fatal) (NN Doc_11587867_6_25_Disease)) (ADJP (JJ due) (S (VP (TO to) (VP (VB accidental) (NP (JJ intrathecal) (JJ Doc_11587867_56_66_Chemical) (NN administration))))))) (: :) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
11587867	1	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (CD two) (JJ fatal) (NNS cases)) (PP (IN of) (NP (NP (JJ accidental) (JJ intrathecal) (JJ Doc_11587867_161_172_Chemical) (NN instillation)) (PP (IN in) (NP (NP (NP (DT a) (JJ 5-year) (JJ old) (NN girl)) (PP (IN with) (NP (JJ recurrent) (NN Doc_11587867_222_250_Disease)))) (CC and) (NP (NP (DT a) (JJ 57-year) (JJ old) (NN man)) (PP (IN with) (NP (NNP Doc_11587867_278_300_Disease))))))))))) (. .)))
11587867	2	(S1 (S (NP (DT The) (NN girl)) (VP (VBD died) (NP (CD seven) (NNS days)) (, ,) (PP (NP (DT the) (NN man) (CD four) (NNS weeks)) (IN after) (NP (NP (JJ intrathecal) (NN injection)) (PP (IN of) (NP (NNP Doc_11587867_378_389_Chemical)))))) (. .)))
11587867	3	(S1 (S (ADVP (RB Clinically)) (, ,) (NP (DT the) (NN onset)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NP (NNP Doc_11587867_447_490_Disease)) (CC and) (NP (VBG ascending) (NNP Doc_11587867_505_514_Disease)))))))) (. .)))
11587867	4	(S1 (S (NP (NP (JJ Histological) (CC and) (JJ immunohistochemical) (NNS investigations)) (PRN (-LRB- -LRB-) (NP (NP (NNP HE-LFB)) (, ,) (NP (CD CD-68))) (, ,) (NP (NNP Neurofilament)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (NNP Doc_11587867_608_640_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_11587867_652_679_Disease)) (PP (IN in) (NP (NP (NNS areas)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_11587867_700_711_Chemical)))))) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ secondary) (NNS changes)) (PP (IN with) (NP (JJ numerous) (JJ prominent) (NNS macrophages))))))))) (. .)))
11587867	5	(S1 (S (NP (NP (DT The) (JJ clinical) (UCP (NN course) (CC and) (JJ histopathological)) (NNS results)) (PP (IN of) (NP (DT the) (CD two) (NNS cases)))) (VP (AUX are) (VP (VBN presented))) (. .)))
11587867	6	(S1 (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (DT all) (JJ reported) (NNS cases))) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX is) (VP (VBN given))) (. .)))
11587867	7	(S1 (S (NP (NP (DT A) (ADJP (RB better) (VBN controlled)) (NN regimen)) (PP (IN for) (S (VP (VBG administering) (NP (JJ Doc_11587867_970_981_Chemical) (CC and) (JJ intrathecal) (NN chemotherapy)))))) (VP (AUX is) (VP (VBN recommended))) (. .)))
11642480	0	(S1 (NP (NP (NN Doc_11642480_0_19_Disease)) (PP (IN in) (NP (DT a) (JJ Doc_11642480_25_34_Disease) (JJ adolescent))) (PP (IN on) (NP (NNP Doc_11642480_49_59_Chemical))) (. .)))
11642480	1	(S1 (S (NP (JJ Current) (NNS estimates)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN between) (NP (NP (CD 0.4) (NN %)) (CC and) (NP (NP (CD 8.3) (NN %)) (PP (IN of) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents))))))) (VP (AUX are) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_11642480_158_174_Disease)))))))) (. .)))
11642480	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ favorable) (NN response)) (PP (TO to) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11642480_225_235_Chemical)))) (PP (IN by) (NP (NP (DT a) (JJ 15-year-old) (NN boy)) (PP (IN with) (NP (NNP Doc_11642480_262_278_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD exhibited) (NP (NNP Doc_11642480_293_312_Disease)) (PP (IN during) (NP (NP (PRP$ his) (JJ first) (CD 2) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))))))) (. .)))
11642480	3	(S1 (S (NP (DT This)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_11642480_388_398_Chemical)))) (SBAR (IN as) (S (NP (PRP it)) (VP (VBD remitted) (PP (IN with) (NP (NP (NN redistribution)) (PP (IN of) (NP (NNS doses))))))))))) (. .)))
11672959	0	(S1 (S (NP (DT The) (JJ 3-week) (JJ Doc_11672959_11_25_Chemical) (NN syndrome)) (VP (VBZ strikes) (ADVP (RB again))) (. .)))
11672959	1	(S1 (S (NP (DT A) (JJ 34-year-old) (NN lady)) (VP (VBD developed) (NP (NP (DT a) (NN constellation)) (PP (IN of) (NP (NNP Doc_11672959_98_108_Disease) (, ,) (NNP Doc_11672959_110_115_Disease) (, ,) (NNP Doc_11672959_117_132_Disease) (CC and) (NNP Doc_11672959_137_146_Disease)))) (, ,) (S (VP (VBG beginning) (PP (IN on) (NP (NP (DT the) (JJ 17th) (NN day)) (PP (IN of) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (JJ oral) (NN Doc_11672959_194_208_Chemical)) (PP (IN for) (NP (JJ sero-negative) (NN Doc_11672959_227_247_Disease)))))))))))) (. .)))
11672959	2	(S1 (S (S (NP (JJ Cervical) (CC and) (JJ inguinal) (NN lymph) (NN node) (NNS biopsies)) (VP (VBD showed) (NP (NP (DT the) (NNS features)) (PP (IN of) (NP (JJ severe) (NN necrotising) (NN Doc_11672959_333_346_Disease))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (NNS erythrophagocytosis)) (CC and) (NP (JJ prominent) (JJ eosinophilic) (NNS infiltrates))))) (, ,)) (PP (IN without) (NP (JJ viral) (NN inclusion) (NNS bodies))) (, ,) (ADJP (JJ suggestive) (PP (IN of) (NP (DT an) (JJ Doc_11672959_473_494_Disease.A) (NN week)))) (ADVP (RB later)))) (, ,) (NP (NP (JJ fulminant) (NNP Doc_11672959_519_541_Disease)) (, ,) (VP (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ anti-nuclear) (NNS autoantibodies)) (PRN (-LRB- -LRB-) (CC but) (ADVP (RB not)) (PP (IN with) (NP (NP (JJ other) (NNS markers)) (PP (IN of) (NP (NNP Doc_11672959_634_646_Disease))))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_11672959_668_687_Disease) (CC and) (NNP Doc_11672959_692_698_Disease))))) (, ,)) (VP (VBD supervened)) (. .)))
11672959	3	(S1 (S (NP (PRP She)) (ADVP (RB subsequently)) (VP (VBD died) (SBAR (NP (DT some) (CD 5) (NNS weeks)) (IN after) (S (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (PRP$ her) (NN drug) (NN therapy.Post-mortem) (NN examination)))) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_11672959_833_864_Disease)) (, ,) (NP (NP (JJ acute) (NN hypersensitivity) (NN Doc_11672959_889_900_Disease)) (, ,) (NP (JJ focal) (JJ acute) (JJ tubulo-interstitial) (NN Doc_11672959_934_943_Disease)) (CC and) (NP (JJ extensive) (NN Doc_11672959_958_978_Disease))) (, ,)))) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_11672959_1000_1010_Disease))))))))) (. .)))
11672959	4	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN thought) (SBAR (IN that) (S (NP (NP (DT the) (JJ clinico-pathological) (NNS features)) (CC and) (NP (NP (NN chronology)) (PP (IN of) (NP (DT this) (NN case))))) (VP (VBD bore) (NP (NP (DT the) (NNS hallmarks)) (PP (IN of) (NP (DT the) (JJ so-called) (`` ``) (JJ 3-week) (JJ Doc_11672959_1137_1151_Chemical) (NN syndrome) ('' '')))) (, ,) (NP (NP (DT a) (JJ rare) (PRN (, ,) (CC but) (ADVP (RB often)) (ADJP (JJ fatal)) (, ,)) (JJ immunoallergic) (NN reaction)) (PP (TO to) (NP (NNP Doc_11672959_1215_1229_Chemical))))))))) (. .)))
11679859	0	(S1 (FRAG (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_11679859_30_46_Chemical))) (PP (IN by) (NP (NP (JJ 15-minute) (NN infusion)) (CC versus) (NP (JJ 2-minute) (NN bolus))))) (VP (AUX does) (RB not) (VP (VB affect) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11679859_124_133_Disease))))))) (: :) (NP (DT a) (JJ prospective) (, ,) (VBN randomized) (, ,) (VBN controlled) (NN trial)) (. .)))
11679859	1	(S1 (NP (NN STUDY) (NN OBJECTIVE) (: :) (S (NP (PRP We)) (VP (VBD sought) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NNP Doc_11679859_230_239_Disease))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_11679859_276_292_Chemical)))))) (PP (IN as) (NP (NP (DT a) (JJ 2-minute) (NN bolus)) (CC or) (NP (JJ 15-minute) (NN infusion))))))))) (. .)))
11679859	2	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (NN study)) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN of) (NP (DT a) (JJ central-city) (NN teaching) (NN hospital)))))) (. .)))
11679859	3	(S1 (S (NP (NP (NNS Patients)) (VP (VBN aged) (NP (NP (CD 18) (NNS years)) (CC or) (NP (NP (JJR older)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11679859_514_530_Chemical)))))) (PP (IN for) (NP (NP (NNP Doc_11679859_535_543_Disease)) (, ,) (NP (NNP Doc_11679859_545_551_Disease)) (, ,) (CC or) (NP (NNP Doc_11679859_556_564_Disease)))))) (VP (AUX were) (ADJP (JJ eligible) (PP (IN for) (NP (NN inclusion))))) (. .)))
11679859	4	(S1 (S (NP (NN Study) (NNS participants)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NNP Doc_11679859_649_665_Chemical))) (VP (VBN administered) (ADVP (RB intravenously)) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (NP (NP (JJ 2-minute) (NN push)) (PRN (-LRB- -LRB-) (NP (JJ bolus) (NN group)) (-RRB- -RRB-))) (CC or) (NP (CD 10) (NN mg))) (VP (VBN diluted) (PP (IN in) (NP (NP (CD 50) (NNS mL)) (PP (IN of) (NP (NP (JJ normal) (NN saline) (NN solution)) (VP (VBN administered) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN during) (NP (NP (DT a) (JJ 15-minute) (NN period)) (PRN (-LRB- -LRB-) (NP (NN infusion) (NN group)) (-RRB- -RRB-))))))))))))))))))))))))) (. .)))
11679859	5	(S1 (S (NP (DT The) (JJ main) (NN outcome)) (VP (AUX was) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN study) (NNS participants))) (VP (VBG experiencing) (NP (NNP Doc_11679859_942_951_Disease)) (PP (IN within) (NP (NP (CD 60) (NNS minutes)) (PP (IN of) (NP (NN administration)))))))) (. .)))
11679859	6	(S1 (S (NP (NNP Akathisia)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (RB either) (DT a) (JJ spontaneous) (NN report)) (PP (IN of) (NP (NP (NN restlessness)) (CC or) (NP (NNP Doc_11679859_1061_1070_Disease))))) (CC or) (NP (NP (NP (DT a) (NN change)) (PP (IN of) (NP (QP (CD 2) (CC or) (JJR more)))) (PP (IN in) (NP (DT the) (JJ patient-reported) (NNP Doc_11679859_1120_1129_Disease) (NN rating) (NN scale)))) (CC and) (NP (NP (DT a) (NN change)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 1)))) (PP (IN in) (NP (DT the) (JJ investigator-observed) (NNP Doc_11679859_1199_1208_Disease) (NN rating) (NN scale))))))))) (. .)))
11679859	7	(S1 (S (NP (NP (DT The) (NN intensity)) (PP (IN of) (NP (NP (NNP Doc_11679859_1240_1248_Disease)) (CC and) (NP (NNP Doc_11679859_1253_1259_Disease))))) (VP (AUX was) (VP (VBN measured) (PP (IN with) (NP (DT a) (JJ 100-mm) (JJ visual) (NN analog) (NN scale))))) (. .)))
11679859	8	(S1 (S (NP (QP (CD One) (CD hundred)) (NNS patients)) (VP (AUX were) (VP (VBD enrolled))) (. .)))
11679859	9	(S1 (S (NP (CD One) (NN study) (NN participant)) (VP (AUX was) (VP (VBN excluded) (PP (IN after) (NP (NN protocol) (NN violation))))) (. .)))
11679859	10	(S1 (S (NP (NP (NP (JJ Seventy-three) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 73/99)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN study) (NNS participants)))) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (NP (NN Doc_11679859_1487_1495_Disease)) (CC and) (NP (NP (CD 70) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 70/99)) (-RRB- -RRB-))))) (PP (IN for) (NP (NNP Doc_11679859_1516_1522_Disease))))) (. .)))
11679859	11	(S1 (S (PP (IN In) (NP (DT the) (JJ bolus) (NN group))) (, ,) (NP (NP (CD 26.0) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 13/50)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_11679859_1562_1571_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 32.7) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 16/49)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN infusion) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD Delta=-6.7) (NN %)) (: ;) (NP (NP (CD 95) (NN %) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-) (QP (CD -24.6) (NN %) (TO to) (CD 11.2) (NN %)))) (-RRB- -RRB-))))) (. .)))
11679859	12	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN between) (NP (DT the) (NN bolus) (CC and) (NN infusion) (NNS groups))) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNS participants)) (SBAR (WHNP (WP who)) (S (VP (VBD saw) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (PRP$ their) (NNP Doc_11679859_1803_1811_Disease) (NN intensity)))) (PP (IN within) (NP (CD 30) (NNS minutes))))))))))) (VP (AUX was) (NP (NP (CD 11.8) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (NP (QP (CD CI) (CD -9.6) (NN %) (TO to) (CD 33.3) (NN %)))) (-RRB- -RRB-)))) (. .)))
11679859	13	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NNS patients))))) (PP (IN with) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (PRP$ their) (NN Doc_11679859_1950_1956_Disease)))))) (VP (AUX was) (NP (NP (CD 12.6) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD -4.6) (NN %) (TO to) (CD 29.8) (NN %))) (-RRB- -RRB-)))) (. .)))
11679859	14	(S1 (S (NP (NP (NP (DT A) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11679859_2040_2049_Disease))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11679859_2055_2071_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (JJ 15-minute) (JJ intravenous) (NN infusion)))))))))) (CC versus) (NP (DT a) (JJ 2-minute) (JJ intravenous) (NN push))) (VP (AUX was) (RB not) (VP (VBN detected))) (. .)))
11679859	15	(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NNP Doc_11679859_2201_2217_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11679859_2238_2246_Disease)) (CC and) (NP (NNP Doc_11679859_2251_2257_Disease))))))) (ADVP (RB likewise)) (VP (AUX did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN administration))))))))) (, ,) (SBAR (IN although) (S (NP (DT no) (JJ formal) (JJ statistical) (NNS comparisons)) (VP (AUX were) (VP (VBN made))))))) (. .)))
11706060	0	(S1 (S (NP (VBN Combined) (JJ antiretroviral) (NN therapy)) (VP (VP (VBZ causes) (NP (NN Doc_11706060_39_53_Disease))) (CC and) (VP (VBZ elevates) (NP (NP (NN plasma) (NN Doc_11706060_74_81_Chemical)) (PP (IN in) (NP (NNP transgenic) (NNP Doc_11706060_96_100_Disease) (NNS mice)))))) (. .)))
11706060	1	(S1 (S (NP (NP (ADJP (RB Highly) (JJ active)) (NN antiretroviral) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HAART)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN implicated) (PP (PP (IN in) (NP (NP (NNP Doc_11706060_169_183_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11706060_185_187_Disease)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNP Doc_11706060_212_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11706060_221_223_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNP Doc_11706060_228_232_Disease))) (PP (IN through) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_11706060_255_280_Disease))))))) (. .)))
11706060	2	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (JJ mitochondrial) (NNS events)) (PP (IN from) (NP (NNP HAART)))) (PP (IN in) (NP (NN vivo)))))) (, ,) (NP (NP (NP (JJ 8-week-old) (JJ hemizygous) (NNP transgenic) (NNP Doc_11706060_369_373_Disease) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (JJ NL4-3Delta) (NN gag/pol)) (: ;) (NP (NNP TG))) (-RRB- -RRB-))) (CC and) (NP (JJ wild-type) (NN FVB/n) (NNS littermates))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (JJ HAART) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11706060_479_489_Chemical)) (, ,) (NP (NNP Doc_11706060_491_501_Chemical)) (, ,) (CC and) (NP (NNP Doc_11706060_507_516_Chemical))))) (CC or) (NP (NN vehicle) (NN control)))) (PP (IN for) (NP (NP (CD 10) (NNS days)) (CC or) (NP (CD 35) (NNS days)))))) (. .)))
11706060	3	(S1 (S (PP (IN At) (NP (NP (NN termination)) (PP (IN of) (NP (DT the) (NNS experiments))))) (, ,) (NP (NNS mice)) (VP (VBD underwent) (NP (NP (NN echocardiography)) (, ,) (NP (NP (NN quantitation)) (PP (IN of) (NP (NP (NN abundance)) (PP (IN of) (NP (NP (JJ molecular) (NNS markers)) (PP (IN of) (NP (NNP Doc_11706060_678_680_Disease))) (PRN (-LRB- -LRB-) (S (NP (JJ ventricular) (NNS mRNA)) (VP (VBG encoding) (NP (JJ atrial) (JJ natriuretic) (NN factor)) (NP (JJ -LSB-ANF) (JJ -RSB-) (CC and) (JJ sarcoplasmic) (NNP Doc_11706060_757_764_Chemical) (NNP ATPase) (JJ -LSB-SERCA2) (NN -RSB-)))) (-RRB- -RRB-))))))) (, ,) (CC and) (NP (NP (NN determination)) (PP (IN of) (NP (NN plasma) (NN Doc_11706060_811_813_Chemical)))))) (. .)))
11706060	4	(S1 (S (S (NP (JJ Myocardial) (JJ histologic) (NNS features)) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB semiquantitatively))))) (CC and) (S (NP (NNS results)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NN transmission) (NNP electron) (NN microscopy)))))) (. .)))
11706060	5	(S1 (S (PP (IN After) (NP (NP (CD 35) (NNS days)) (PP (IN in) (NP (DT the) (JJ TG) (NN +) (NN HAART) (NN cohort))))) (, ,) (NP (JJ left) (JJ ventricular) (NN mass)) (VP (VBD increased) (NP (CD 160) (NN %)) (PP (IN by) (NP (NN echocardiography)))) (. .)))
11706060	6	(S1 (S (ADVP (RB Molecularly)) (, ,) (S (NP (NN ANF) (NNS mRNA)) (VP (VBD increased) (NP (CD 250) (NN %)))) (CC and) (S (NP (JJ SERCA2) (NN mRNA)) (VP (VBD decreased) (NP (CD 57) (NN %)))) (. .)))
11706060	7	(S1 (S (ADVP (RB Biochemically)) (, ,) (NP (NNP Doc_11706060_1124_1126_Chemical)) (VP (AUX was) (NP (NP (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 8.5) (NN +/-) (CD 2.0) (NN mM)) (-RRB- -RRB-)))) (. .)))
11706060	8	(S1 (S (ADVP (RB Pathologically)) (, ,) (NP (JJ granular) (NN cytoplasmic) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ cardiac) (NNS myocytes))) (, ,) (S (VP (VBG indicating) (NP (JJ enlarged) (, ,) (JJ damaged) (NNS mitochondria)))))) (. .)))
11706060	9	(S1 (S (NP (NNS Findings)) (VP (AUX were) (VP (VBN confirmed) (ADVP (RB ultrastructurally)))) (. .)))
11706060	10	(S1 (S (NP (DT No) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ other) (NNS cohorts))))) (. .)))
11706060	11	(S1 (S (PP (IN After) (NP (CD 10) (NNS days))) (, ,) (NP (JJ only) (NN ANF)) (VP (AUX was) (UCP (ADJP (JJ elevated)) (, ,) (CC and) (PP (ADVP (RB only)) (IN in) (NP (DT the) (NNP TG) (NNP +) (NN HAART) (NN cohort))))) (. .)))
11706060	12	(S1 (S (NP (NNS Results)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ cumulative) (NN HAART)) (VP (VBD caused) (NP (NP (JJ mitochondrial) (NN Doc_11706060_1490_1492_Disease)) (PP (IN with) (NP (JJ elevated) (NN Doc_11706060_1507_1509_Chemical))) (PP (IN in) (NP (NNP Doc_11706060_1513_1517_Disease) (NNP transgenic) (NNS mice)))))))) (. .)))
11745184	0	(S1 (NP (NP (NP (DT A) (NN Phase) (NNP II) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_11745184_20_29_Chemical) (CC plus) (NNP Doc_11745184_35_42_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11745184_44_54_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (JJ metastatic) (NN Doc_11745184_71_87_Disease)))) (: :) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NNP Study)) (PRN (-LRB- -LRB-) (NP (NNP E8188)) (-RRB- -RRB-))) (. .)))
11745184	1	(S1 (S (NP (NN Doc_11745184_154_163_Chemical)) (VP (AUX has) (NP (NP (JJ minimal) (NN antitumor) (NN activity)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN as) (NP (NP (JJ second-) (CC or) (JJ third-line) (NN treatment)) (PP (IN of) (NP (JJ metastatic) (NNP Doc_11745184_254_270_Disease)))))))))) (. .)))
11745184	2	(S1 (S (NP (JJR Older) (NNS reports)) (VP (VBP suggest) (NP (NP (DT an) (JJ objective) (NN response) (NN rate)) (PP (IN of) (NP (CD 8) (NN %)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD 60-120) (NN mg/m2)) (PP (IN of) (NP (NNP Doc_11745184_348_357_Chemical)))) (VP (AUX is) (VP (VBN administered) (NP (DT every) (JJ 3-4) (NNS weeks))))))) (. .)))
11745184	3	(S1 (S (SBAR (IN Although) (S (NP (DT a) (JJ dose-response) (NN effect)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_11745184_446_455_Chemical)))))))) (, ,) (NP (NP (DT the) (JJ dose-limiting) (NNP Doc_11745184_475_485_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_11745184_502_511_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP e.g.)) (, ,) (NP (NNP Doc_11745184_519_533_Disease)) (, ,) (NP (NNP Doc_11745184_535_546_Disease)) (, ,) (CC and) (NP (NNP Doc_11745184_552_565_Disease))) (-RRB- -RRB-)))))) (VP (AUX have) (VP (VBN limited) (NP (PRP$ its) (NN use)) (PP (IN as) (NP (NP (DT a) (NN treatment)) (PP (IN for) (NP (NNP Doc_11745184_607_623_Disease))))))) (. .)))
11745184	4	(S1 (S (NP (NP (NNP Doc_11745184_625_632_Chemical)) (CC or) (NP (NNP Doc_11745184_636_646_Chemical))) (ADVP (RB initially)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB protect) (NP (JJ military) (NNS personnel)) (PP (IN in) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (JJ nuclear) (NN war)))))))))) (. .)))
11745184	5	(S1 (S (NP (NN Doc_11745184_730_740_Chemical)) (ADVP (RB subsequently)) (VP (AUX was) (VP (VBN shown) (S (VP (TO to) (VP (VB protect) (NP (JJ normal) (NNS tissues)) (PP (IN from) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_11745184_816_833_Chemical)) (CC and) (NP (NNP Doc_11745184_838_847_Chemical)))))) (PP (IN without) (S (VP (VBG decreasing) (NP (NP (DT the) (JJ antitumor) (NN effect)) (PP (IN of) (NP (DT the) (NN chemotherapy)))))))))))) (. .)))
11745184	6	(S1 (S (NP (NP (JJ Early) (NNS trials)) (PP (IN of) (NP (NP (NNP Doc_11745184_925_934_Chemical)) (CC and) (NP (NNP Doc_11745184_939_949_Chemical))))) (ADVP (RB also)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_11745184_1000_1009_Chemical-induced) (NNP Doc_11745184_1018_1032_Disease)) (, ,) (NP (NNP Doc_11745184_1034_1045_Disease)) (, ,) (CC and) (NP (NNP Doc_11745184_1051_1061_Disease))))) (VP (AUX were) (VP (VBN reduced)))))) (. .)))
11745184	7	(S1 (S (NP (NP (DT A) (NN Phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NNP Doc_11745184_1124_1133_Chemical) (CC plus) (NNP Doc_11745184_1139_1149_Chemical)))))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ progressive) (JJ metastatic) (NNP Doc_11745184_1204_1220_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NP (NN one)) (, ,) (CC but) (NP (QP (RB not) (JJR more) (IN than) (CD one))) (, ,) (NP (NP (JJ chemotherapy) (NN regimen)) (PP (IN for) (NP (JJ metastatic) (NN disease))))))))))))))) (. .)))
11745184	8	(S1 (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (NNP Doc_11745184_1329_1339_Chemical)) (, ,) (NP (CD 910) (NN mg/m2))) (ADVP (RB intravenously)) (PP (IN over) (NP (CD 15) (NNS minutes)))) (. .)))
11745184	9	(S1 (S (PP (IN After) (NP (NP (NN completion)) (PP (IN of) (NP (DT the) (JJ Doc_11745184_1406_1416_Chemical) (NN infusion))))) (, ,) (NP (NNP Doc_11745184_1427_1436_Chemical) (CD 120) (NN mg/m2)) (VP (AUX was) (VP (VBN administered) (PP (IN over) (NP (CD 30) (NNS minutes))))) (. .)))
11745184	10	(S1 (S (NP (NP (JJ Intravenous) (NN hydration)) (CC and) (NP (NNP Doc_11745184_1507_1515_Chemical))) (VP (AUX was) (VP (VBN administered) (PP (IN before) (CC and) (IN after) (NP (NNP Doc_11745184_1550_1559_Chemical))))) (. .)))
11745184	11	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN administered) (NP (DT every) (CD 3) (NNS weeks)) (PP (IN until) (NP (NN disease) (NN progression))))) (. .)))
11745184	12	(S1 (S (NP (JJ Forty-four) (NNS patients)) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT the) (NN study)) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (CD 7)) (PRN (-LRB- -LRB-) (NP (CD 16) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (NP (NN ineligible))))))))) (. .)))
11745184	13	(S1 (S (NP (NP (DT A) (NN median)) (PP (IN of) (NP (NP (CD 2) (NNS cycles)) (PP (IN of) (NP (NN therapy)))))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT the) (CD 37) (NN eligible) (NNS patients))))) (. .)))
11745184	14	(S1 (S (NP (CD Six) (JJ partial) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 16) (NN %))))))) (. .)))
11745184	15	(S1 (S (NP (NP (JJS Most) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 57) (NN %)) (-RRB- -RRB-))) (VP (VBD stopped) (NP (NN treatment)) (PP (IN because) (IN of) (NP (NN disease) (NN progression)))) (. .)))
11745184	16	(S1 (S (NP (NN Doc_11745184_1940_1959_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (CD 52) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
11745184	17	(S1 (S (NP (CD Seven) (JJ different) (JJ life-threatening) (NN Doc_11745184_2026_2036_Disease)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NNS patients))) (SBAR (IN while) (S (VP (VBG receiving) (NP (NN treatment))))))) (. .)))
11745184	18	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11745184_2122_2131_Chemical)) (CC and) (NP (NNP Doc_11745184_2136_2146_Chemical)))) (PP (IN in) (NP (DT this) (NN study)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 16) (NN %)))))) (. .)))
11745184	19	(S1 (S (NP (CC Neither) (NP (DT a) (JJ Doc_11745184_2216_2221_Disease-protective) (NN effect)) (CC nor) (NP (NP (VBN reduced) (NN Doc_11745184_2252_2260_Disease)) (PP (TO to) (NP (JJ normal) (NNS tissues))))) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_11745184_2313_2323_Chemical))) (PP (TO to) (NP (NNP Doc_11745184_2327_2336_Chemical))))) (PP (IN in) (NP (DT this) (NN trial))))) (. .)))
11752354	0	(S1 (NP (NP (NP (NN Doc_11752354_0_19_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_36_57_Disease))))) (. .)))
11752354	1	(S1 (S (NP (NP (DT An) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11752354_105_124_Chemical)))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_141_162_Disease))))))) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (IN in) (NP (NP (DT some)) (, ,) (CC but) (RB not) (NP (DT all)) (, ,) (NP (NNS studies))))))) (. .)))
11752354	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (DT this) (NN association)) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (NNP Doc_11752354_268_279_Chemical))) (VP (VBD included) (S (PP (IN in) (NP (NP (NP (NN third-generation)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_11752354_316_327_Chemical) (CC or) (NNP Doc_11752354_331_340_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NN second-generation)))) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_11752354_371_385_Chemical)) (-RRB- -RRB-)) (NP (NNP Doc_11752354_387_406_Chemical)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11752354_420_428_Chemical)) (, ,) (CC and) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (JJ prothrombotic) (NNS mutations) (NNS METHODS))))))) (: :) (PP (IN In) (NP (DT a) (JJ nationwide) (, ,) (JJ population-based) (, ,) (JJ case-control) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD identified)) (CC and) (VP (VBD enrolled) (NP (CD 248) (NNS women)) (NP (CD 18)) (PP (IN through) (NP (NP (CD 49) (NNS years)) (PP (IN of) (NP (NN age))) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (NP (NP (DT a) (JJ first) (NNP Doc_11752354_633_654_Disease) (ADJP (QP (IN between) (CD 1990) (CC and) (CD 1995) (CC and) (CD 925) (NN control))) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not) (VP (AUX had) (NP (DT a) (NNP Doc_11752354_717_738_Disease))))))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN matched) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NP (NN calendar) (NN year)) (PP (IN of) (NP (DT the) (NN index) (NN event)))) (, ,) (CC and) (NP (NP (NN area)) (PP (IN of) (NP (NN residence))))))))))))))))))))) (. .)))
11752354	3	(S1 (S (NP (NNS Subjects)) (VP (VBD supplied) (NP (NN information)) (PP (IN on) (NP (NP (JJ Doc_11752354_859_877_Chemical) (NN use)) (CC and) (NP (JJ major) (JJ cardiovascular) (NN risk) (NNS factors))))) (. .)))
11752354	4	(S1 (S (S (NP (NP (DT An) (NN analysis)) (PP (IN for) (NP (NP (NN factor) (NNP V) (NNP Leiden)) (CC and) (NP (DT the) (NNP G20210A) (NN mutation)))) (PP (IN in) (NP (DT the) (JJ prothrombin) (NN gene)))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (CD 217) (NNS patients)) (CC and) (NP (CD 763) (NNS controls) (NNS RESULTS))))))) (: :) (S (NP (NP (DT The) (NNS odds) (NN ratio)) (PP (IN for) (NP (NNP Doc_11752354_1077_1098_Disease))) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (DT any) (NN type)) (PP (IN of) (NP (JJ combined) (NNP Doc_11752354_1141_1159_Chemical)))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NNS nonusers))))))))))) (, ,)) (VP (AUX was) (NP (NP (CD 2.0)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 2.8))) (-RRB- -RRB-))))) (. .)))
11752354	5	(S1 (S (NP (DT The) (VBN adjusted) (NNS odds) (NN ratio)) (VP (AUX was) (NP (NP (CD 2.5)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 4.1))) (-RRB- -RRB-))) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (JJ second-generation) (NN Doc_11752354_1358_1377_Chemical)) (CC and) (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 0.7) (TO to) (CD 2.5))) (-RRB- -RRB-)))) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (JJ third-generation) (NNP Doc_11752354_1469_1488_Chemical))))))))))))) (. .)))
11752354	6	(S1 (S (S (PP (IN Among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NNP Doc_11752354_1511_1530_Chemical))))))) (, ,) (NP (DT the) (NNS odds) (NN ratio)) (VP (AUX was) (NP (NP (NP (CD 2.1)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 3.0))) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT those)) (PP (IN without) (NP (DT a) (JJ prothrombotic) (NN mutation)))))) (CC and) (NP (NP (CD 1.9)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (CD 0.6) (TO to) (CD 5.5)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT those)) (PP (IN with) (NP (DT a) (NN mutation) (NNS CONCLUSIONS))))))))) (: :) (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_1747_1768_Disease)))) (VP (AUX was) (VP (VBN increased) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (JJ second-generation) (NNP Doc_11752354_1822_1841_Chemical)))))))))) (. .)))
11752354	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ third-generation) (NNP Doc_11752354_1899_1918_Chemical)))))))) (VP (VP (AUX were) (ADJP (JJ inconclusive))) (CC but) (VP (VBD suggested) (SBAR (IN that) (S (NP (DT the) (NN risk)) (VP (AUX was) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT the) (NN risk)) (VP (VBN associated) (PP (IN with) (NP (JJ second-generation) (NN Doc_11752354_2023_2042_Chemical)))))))))))) (. .)))
11752354	8	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_2056_2077_Disease)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NNP Doc_11752354_2111_2130_Chemical)) (SBAR (IN whether) (CC or) (RB not) (S (NP (PRP they)) (VP (AUX had) (NP (DT a) (JJ prothrombotic) (NN mutation))))))))))) (. .)))
11773892	0	(S1 (NP (NP (NP (NN Doc_11773892_0_23_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_25_29_Disease)) (-RRB- -RRB-)) (PP (IN after) (S (NP (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP OLTX)) (-RRB- -RRB-))) (VP (VBG using) (NP (JJ calcineurin-based) (NN immunotherapy)))))) (: :) (NP (NP (NN risk)) (PP (IN of) (NP (NP (NN development)) (CC and) (NP (NN treatment))))) (. .)))
11773892	1	(S1 (S (NP (NP (DT The) (JJ calcineurin) (NNS inhibitors)) (ADJP (JJ Doc_11773892_190_202_Chemical) (CC and) (JJ Doc_11773892_207_217_Chemical))) (VP (AUX are) (DT both) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_11773892_239_250_Disease))))))) (. .)))
11773892	2	(S1 (S (NP (NP (PRP$ Their) (NN use)) (PP (IN in) (NP (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP OLTX)) (-RRB- -RRB-))))) (VP (AUX has) (ADVP (RB dramatically)) (VP (VBN improved) (NP (NN success) (NNS rates)))) (. .)))
11773892	3	(S1 (S (ADVP (RB Recently)) (, ,) (ADVP (RB however)) (, ,) (NP (PRP we)) (VP (AUX have) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG presenting) (PP (IN after) (NP (NP (NN OLTX)) (PP (IN with) (NP (NP (NNP Doc_11773892_436_459_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_461_465_Disease)) (-RRB- -RRB-))))))))))))))) (. .)))
11773892	4	(S1 (S (NP (DT This) (NN retrospective) (NN study)) (VP (VBZ examines) (NP (NP (DT the) (NN incidence) (CC and) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11773892_533_537_Disease)) (CC and) (NP (NP (NNP Doc_11773892_542_563_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_565_568_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NN OLTX) (NNS patients))))) (. .)))
11773892	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT an) (NN OLTX)) (ADVP (RB only)) (PP (IN from) (NP (NNP June) (CD 1985))) (PP (IN through) (NP (NP (NNP December)) (PP (IN of) (NP (CD 1994)))))) (SBAR (WHNP (WP who)) (S (VP (VBD survived) (ADVP (NP (CD 6) (NNS months)) (RB postoperatively)))))) (VP (AUX were) (VP (VBN studied) (PRN (-LRB- -LRB-) (NP (CD n=834)) (-RRB- -RRB-)))) (. .)))
11773892	6	(S1 (S (NP (PRP$ Our) (ADJP (RB prospectively) (VBN collected)) (NN database)) (VP (AUX was) (NP (NP (DT the) (NN source)) (PP (IN of) (NP (NN information))))) (. .)))
11773892	7	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (CD three) (NNS groups)) (: :) (NP (NP (NNS Controls)) (, ,) (NP (NP (DT no) (NNP Doc_11773892_851_854_Disease) (CC or) (NNP Doc_11773892_858_862_Disease)) (, ,) (NP (CD n=748)) (: ;) (NP (NP (NNP Doc_11773892_871_874_Disease)) (, ,) (NP (NP (JJ sustained) (JJ serum) (NNP Doc_11773892_892_902_Chemical) (CD >2.5) (NN mg/dl)) (, ,) (NP (CD n=41)))) (: ;) (CC and) (NP (NP (NNP Doc_11773892_925_929_Disease)) (, ,) (NP (CD n=45))))))))) (. .)))
11773892	8	(S1 (S (NP (NNS Groups)) (VP (AUX were) (VP (VBN compared) (PP (IN for) (NP (NP (JJ preoperative) (NN laboratory) (NNS variables)) (, ,) (NP (NN diagnosis)) (, ,) (NP (JJ postoperative) (NNS variables)) (, ,) (NP (NN survival)) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (JJ Doc_11773892_1051_1055_Disease) (NN therapy)))) (, ,) (CC and) (NP (NP (NN survival)) (PP (IN from) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_11773892_1092_1096_Disease)))))))))) (. .)))
11773892	9	(S1 (S (PP (IN At) (NP (NP (CD 13) (NNS years)) (PP (IN after) (NP (NN OLTX))))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ severe) (NNP Doc_11773892_1155_1172_Disease)))) (VP (AUX was) (NP (NP (CD 18.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11773892_1184_1187_Disease) (CD 8.6) (NN %)) (CC and) (NP (NNP Doc_11773892_1197_1201_Disease) (CD 9.5) (NN %))) (-RRB- -RRB-)))) (. .)))
11773892	10	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN control) (NNS patients)))) (, ,) (NP (NNP Doc_11773892_1241_1244_Disease) (CC and) (NNP Doc_11773892_1249_1253_Disease) (NNS patients)) (VP (AUX had) (NP (NP (JJR higher) (JJ preoperative) (NN serum) (NN Doc_11773892_1293_1303_Chemical) (NNS levels)) (, ,) (NP (NP (DT a) (JJR greater) (NN percentage)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_11773892_1350_1370_Disease)) (, ,) (NP (NP (JJR higher) (NN percentage) (NN requirement)) (PP (IN for) (NP (NP (NN dialysis)) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 3) (NNS months)) (ADVP (RB postoperatively))))))) (, ,)))))) (CC and) (NP (DT a) (JJR higher) (JJ 1-year) (NN serum) (NN Doc_11773892_1480_1490_Chemical)))) (. .)))
11773892	11	(S1 (S (S (NP (NP (JJ Multivariate) (JJ stepwise) (JJ logistic) (NN regression) (NN analysis)) (VP (VBG using) (NP (NP (NN preoperative)) (CC and) (NP (JJ postoperative) (NNS variables))))) (VP (VBD identified) (SBAR (IN that) (S (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (JJ serum) (NNP Doc_11773892_1627_1637_Chemical)))) (VP (VBN compared) (PP (IN with) (NP (NN average))) (PP (IN at) (NP (NP (CD 1) (NN year)) (, ,) (NP (CD 3) (NNS months))))))))) (, ,) (CC and) (S (NP (CD 4) (NNS weeks)) (ADVP (RB postoperatively)) (VP (AUX were) (NP (JJ independent) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11773892_1762_1765_Disease) (CC or) (NNP Doc_11773892_1769_1773_Disease))) (PP (IN with) (NP (NP (NNS odds) (NNS ratios)) (PP (IN of) (NP (NP (CD 2.6)) (, ,) (NP (CD 2.2)) (, ,) (CC and) (NP (CD 1.6)) (, ,) (ADVP (RB respectively)))))))))) (. .)))
11773892	12	(S1 (S (S (NP (NP (JJ Overall) (NN survival)) (PP (IN from) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NNS OLTX)))))) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ different)) (PP (IN among) (NP (NNS groups))))) (, ,) (CC but) (S (PP (IN by) (NP (NN year) (CD 13))) (, ,) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NN Doc_11773892_1965_1969_Disease)))))))) (VP (AUX was) (NP (QP (RB only) (CD 28.2)) (NN %)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 54.6) (NN %)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))))) (. .)))
11773892	13	(S1 (S (NP (NP (NNS Patients)) (VP (VBG developing) (NP (NNP Doc_11773892_2047_2051_Disease)))) (VP (AUX had) (NP (DT a) (JJ 6-year) (NN survival)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNP Doc_11773892_2089_2093_Disease)) (PP (IN of) (NP (CD 27) (NN %))))))) (PP (IN for) (NP (NP (DT the) (NNS patients)) (VP (VBG receiving) (NP (NP (NN hemodialysis)) (CC versus) (NP (CD 71.4) (NN %))) (PP (IN for) (NP (NP (DT the) (NNS patients)) (VP (VBG developing) (NP (NP (NNP Doc_11773892_2182_2186_Disease)) (SBAR (WHNP (WP who)) (S (ADVP (RB subsequently)) (VP (VBD received) (NP (NN kidney) (NNS transplants))))))))))))) (. .)))
11773892	14	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (NP (QP (JJR more) (IN than) (CD 10)) (NNS years)) (JJ post-OLTX)))))) (VP (AUX have) (NP (NP (NNP Doc_11773892_2297_2300_Disease)) (CC and) (NP (NNP Doc_11773892_2305_2309_Disease))) (PP (IN at) (NP (DT a) (JJ high) (NN rate)))) (. .)))
11773892	15	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_11773892_2345_2349_Disease)))) (VP (VBZ decreases) (NP (NN survival)) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT those) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN dialysis))) (ADVP (RB only)))))) (. .)))
11773892	16	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP develop) (NP (NNP Doc_11773892_2450_2454_Disease)))))) (VP (VP (AUX have) (NP (NP (DT a) (JJR higher) (NN preoperative)) (CC and) (NP (JJ 1-year) (NN serum) (NN Doc_11773892_2499_2509_Chemical)))) (CC and) (VP (AUX are) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_11773892_2538_2558_Disease)))))))) (. .)))
11773892	17	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (JJ serum) (NNP Doc_11773892_2590_2600_Chemical))) (PP (IN at) (NP (JJ various) (NNS times)))) (ADVP (RB postoperatively)) (VP (AUX is) (ADJP (RBR more) (JJ predictive) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_11773892_2675_2678_Disease)) (CC or) (NP (NNP Doc_11773892_2682_2686_Disease)))))))) (. .)))
11773892	18	(S1 (S (NP (NP (JJ New) (NNS strategies)) (PP (IN for) (NP (JJ long-term) (NN immunosuppression)))) (VP (MD may) (VP (AUX be) (VP (VBN needed) (S (VP (TO to) (VP (VB decrease) (NP (DT this) (NN complication)))))))) (. .)))
11807648	0	(S1 (S (VP (VB Doc_11807648_0_18_Disease) (S (VP (VBG following) (NP (NP (JJ cortical) (NN application)) (PP (IN of) (NP (NP (JJ fibrin) (NNS sealants)) (VP (VBG containing) (NP (NNP Doc_11807648_80_95_Chemical))))) (PP (IN in) (NP (NNS rats))))))) (. .)))
11807648	1	(S1 (S (NP (NP (NP (JJ Fibrin) (NNS sealants)) (PRN (-LRB- -LRB-) (NP (NNP FS)) (-RRB- -RRB-))) (VP (VBN derived) (PP (IN from) (NP (JJ human) (NN plasma))))) (VP (AUX are) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NN neurosurgery))))) (. .)))
11807648	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB increase) (NP (JJ clot) (NN stability)))))) (, ,) (NP (NNS FS)) (ADVP (RB typically)) (VP (VBP contain) (NP (NP (NN aprotinin)) (, ,) (NP (DT a) (JJ natural) (NN fibrinolysis) (NN inhibitor)))) (. .)))
11807648	3	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (JJ synthetic) (NN fibrinolysis) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_11807648_356_371_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11807648_373_378_Chemical)) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN considered) (PP (IN as) (NP (NP (NNS substitutes)) (PP (IN for) (NP (NN aprotinin)))))))) (. .)))
11807648	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_11807648_440_445_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_11807648_470_488_Disease)))))))) (. .)))
11807648	5	(S1 (S (NP (PRP We)) (VP (VBD wanted) (S (VP (TO to) (VP (VB study) (SBAR (IN whether) (S (NP (NNP Doc_11807648_517_522_Chemical)) (VP (VBZ retains) (NP (PRP$ its) (JJ Doc_11807648_535_545_Disease) (NN action)) (SBAR (IN if) (S (VP (VBN incorporated) (PP (IN into) (NP (DT a) (NN FS))))))))))))) (. .)))
11807648	6	(S1 (S (NP (NP (NP (NP (NNS FS)) (VP (VBG containing) (NP (NN aprotinin)))) (CC or) (NP (NP (JJ different) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_11807648_643_648_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.5-47.5) (NNS mg/ml)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN applied) (PP (TO to) (NP (NP (DT the) (JJ pial) (NN surface)) (PP (IN of) (NP (NP (DT the) (NN cortex)) (PP (IN of) (NP (JJ anaesthetized) (NNS rats))))))))) (. .)))
11807648	7	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (DT the) (NNS animals)))) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NN electroencephalography)) (FRAG (CC and) (PP (IN by) (S (VP (VBG monitoring) (NP (NP (DT the) (JJ clinical) (NNS behaviour)) (PP (IN during) (CC and) (IN after) (NP (NP (NN recovery)) (PP (IN from) (NP (NN anaesthesia)))))))))))))) (. .)))
11807648	8	(S1 (S (NP (NP (NNS FS)) (VP (VBG containing) (NP (NNP Doc_11807648_916_921_Chemical)))) (VP (VBD caused) (NP (NP (JJ paroxysmal) (NN brain) (NN activity)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (JJ distinct) (JJ Doc_11807648_990_1000_Disease) (NNS behaviours))))))))) (. .)))
11807648	9	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (DT these) (NNP Doc_11807648_1033_1041_Disease)))) (VP (VBD increased) (PP (IN with) (NP (NP (JJ increasing) (NN concentration)) (PP (IN of) (NP (NNP Doc_11807648_1085_1090_Chemical)))))) (. .)))
11807648	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NNP FS)) (VP (VBG containing) (NP (NP (CD 47.5) (NN mg/ml)) (SBAR (S (NP (NNP Doc_11807648_1123_1128_Chemical)) (VP (VBD evoked) (NP (NNP Doc_11807648_1136_1156_Disease)) (PP (IN in) (NP (DT all) (VBN tested) (NNS rats))) (PRN (-LRB- -LRB-) (JJ n=6) (-RRB- -RRB-)) (PP (IN while) (NP (NP (DT the) (JJS lowest) (NN concentration)) (PP (IN of) (NP (NNP Doc_11807648_1216_1221_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/ml)) (-RRB- -RRB-)))))))) (ADVP (RB only)) (VP (VBD evoked) (NP (NP (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ jerk-correlated) (NNP Doc_11807648_1280_1290_Disease) (NNS potentials)))) (PP (IN in) (NP (NP (CD 1)) (PP (IN of) (NP (CD 6) (NNS rats)))))) (. .)))
11807648	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS FS)) (VP (VBG containing) (NP (NN aprotinin)))) (VP (AUX did) (RB not) (VP (VB evoke) (NP (DT any) (JJ paroxysmal) (NN activity)))) (. .)))
11807648	12	(S1 (S (NP (NN Doc_11807648_1410_1425_Chemical)) (VP (VBZ retains) (NP (NP (PRP$ its) (JJ Doc_11807648_1438_1448_Disease) (NN action)) (PP (IN within) (NP (NNS FS))))) (. .)))
11807648	13	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNS FS)) (VP (VBG containing) (NP (NNP Doc_11807648_1494_1499_Chemical)) (PP (IN for) (NP (NN surgery))) (ADVP (IN within) (CC or) (JJ close)) (PP (TO to) (NP (DT the) (NNS CNS))))))) (VP (MD may) (VP (VB pose) (NP (NP (DT a) (JJ substantial) (NN risk)) (PP (TO to) (NP (DT the) (NN patient)))))) (. .)))
11875660	0	(S1 (NP (NP (NP (JJ Sequential) (NNS observations)) (PP (IN of) (NP (NP (NNP Doc_11875660_27_38_Disease)) (CC and) (NP (JJ subsequent) (JJ morphological) (NNS changes)))) (PP (IN by) (NP (NN mouse) (CD exo) (NN utero) (NN development) (NN system)))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN transformation))))) (PP (PP (IN from) (NP (NNP Doc_11875660_164_175_Disease))) (PP (TO to) (NP (NNP Doc_11875660_179_190_Disease))))) (. .)))
11875660	1	(S1 (S (S (NP (NN Doc_11875660_192_203_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (VB develop) (PP (IN from) (NP (NNP Doc_11875660_239_250_Disease)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (S (NP (EX there)) (VP (AUX is) (NP (NP (JJ little) (JJ direct) (JJ experimental) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (DT this))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN transformation)))) (VP (VBZ remains) (ADJP (JJ unclear))))) (. .)))
11875660	2	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (DT this) (NN theory)) (S (VP (VBG using) (NP (NP (DT the) (JJ exo) (NN utero) (NN development) (NN system)) (SBAR (WHNP (WDT that)) (S (VP (VBZ allows) (NP (NP (JJ direct) (CC and) (JJ sequential) (NNS observations)) (PP (IN of) (NP (NN mid-)))) (PP (TO to) (NP (NN late-gestation) (NN mouse) (NNS embryos)))))))))) (. .)))
11875660	3	(S1 (S (NP (PRP We)) (VP (VP (VBD observed) (S (NP (DT the) (NNP Doc_11875660_543_554_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11875660_566_579_Chemical))) (PP (IN at) (NP (NP (JJ embryonic) (NN day) (CD 13.5)) (PRN (-LRB- -LRB-) (NP (CD E13.5)) (-RRB- -RRB-))))))) (, ,) (VP (VBD let) (S (NP (DT the) (NNS embryos)) (VP (VB develop) (NP (CD exo) (NN utero)) (PP (IN until) (NP (CD E18.5)))))) (, ,) (CC and) (VP (VBD re-observed) (NP (DT the) (JJ same) (NNS embryos)) (PP (IN at) (NP (CD E18.5))))) (. .)))
11875660	4	(S1 (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ several) (NNS cases)) (PP (IN of) (NP (NN transformation))) (PP (IN from) (NP (NNP Doc_11875660_751_762_Disease)))) (PP (TO to) (NP (NNP Doc_11875660_766_777_Disease)))) (. .)))
11875660	5	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (JJ many) (NNS cases))) (, ,) (NP (DT the) (NNP Doc_11875660_807_819_Disease) (NN brain) (NN tissue)) (VP (AUX was) (VP (VBN preserved) (PP (IN with) (NP (ADJP (JJR more) (CC or) (JJR less)) (NN reduction))) (PP (IN during) (NP (DT this) (NN period))))) (. .)))
11875660	6	(S1 (S (S (VP (TO To) (VP (VB analyze) (NP (DT the) (NN transformation) (NNS patterns))))) (, ,) (NP (PRP we)) (VP (VBD classified) (NP (DT the) (NNP Doc_11875660_953_964_Disease)) (PP (IN by) (NP (NP (NN size) (CC and) (NN shape)) (PP (IN of) (NP (DT the) (NNP Doc_11875660_990_1002_Disease) (NN tissue))))) (PP (IN into) (NP (NP (JJ several) (NNS types)) (PP (IN at) (NP (NP (CD E13.5)) (CC and) (NP (CD E18.5))))))) (. .)))
11875660	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (S (NP (NP (DT the) (NN transformation)) (PP (IN of) (NP (NNP Doc_11875660_1089_1101_Disease) (NN tissue)))) (VP (AUX was) (RB not) (ADJP (RB simply) (JJ size-dependent)))) (, ,) (CC and) (S (NP (NP (DT all) (NNS cases)) (PP (IN of) (NP (NNP Doc_11875660_1157_1168_Disease))) (PP (IN at) (NP (CD E18.5)))) (VP (VBD resulted) (PP (IN from) (NP (NP (NNS embryos)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN amount)) (PP (IN of) (NP (NP (JJ Doc_11875660_1223_1235_Disease) (NN tissue)) (PP (IN at) (NP (CD E13.5))))))))))))))) (. .)))
11875660	8	(S1 (S (NP (JJ Microscopic) (NN observation)) (VP (VBD showed) (NP (NP (NP (DT the) (NN configuration)) (PP (IN of) (NP (NNP Doc_11875660_1305_1316_Disease))) (PP (IN at) (NP (CD E13.5)))) (, ,) (NP (NP (JJ frequent) (NN Doc_11875660_1336_1348_Disease) (CC and) (NN detachment)) (PP (IN of) (NP (NP (DT the) (JJ neural) (NN plate)) (PP (IN from) (NP (NP (NN surface) (NN ectoderm)) (PP (IN in) (NP (NP (DT the) (JJ Doc_11875660_1413_1425_Disease) (NN head)) (PP (IN at) (NP (CD E15.5)))))))))) (, ,) (CC and) (NP (NP (JJ multiple) (NNS modes)) (PP (IN of) (NP (NN reduction))))) (PP (IN in) (NP (DT the) (NNP Doc_11875660_1480_1492_Disease) (NN tissue))) (PP (IN at) (NP (CD E18.5)))) (. .)))
11875660	9	(S1 (S (PP (IN From) (NP (NP (NNS observations)) (PP (IN of) (NP (DT the) (NN vasculature))))) (, ,) (NP (NP (VBN altered) (NN distribution) (NNS patterns)) (PP (IN of) (NP (NNS vessels)))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ Doc_11875660_1612_1624_Disease) (NN head))))) (. .)))
11875660	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN overgrowth)) (PP (IN of) (NP (DT the) (JJ Doc_11875660_1677_1689_Disease) (JJ neural) (NN tissue)))) (VP (VBZ causes) (NP (NP (DT the) (JJ altered) (NN distribution) (NNS patterns)) (PP (IN of) (NP (NP (NNS vessels)) (, ,) (NP (NP (JJ subsequent) (JJ peripheral) (NNP Doc_11875660_1779_1798_Disease) (FW and/or) (NNP Doc_11875660_1806_1818_Disease)) (PP (IN in) (NP (NP (JJ various) (NNS parts)) (PP (IN of) (NP (DT the) (NNP Doc_11875660_1843_1855_Disease) (NN head)))))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (JJ multiple) (NNS modes)) (PP (IN of) (NP (NN tissue) (NN reduction))))) (PP (IN during) (NP (NN transformation))) (PP (PP (IN from) (NP (NNP Doc_11875660_1939_1950_Disease))) (PP (TO to) (NP (NNP Doc_11875660_1954_1965_Disease)))))))))))) (. .)))
11897407	0	(S1 (NP (NP (NN Doc_11897407_0_15_Chemical)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NP (NNP Doc_11897407_33_46_Chemical-induced) (NNP Doc_11897407_55_76_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
11897407	1	(S1 (S (NP (JJ Doc_11897407_86_93_Disease-avid) (NNS radiopharmaceuticals)) (VP (AUX are) (ADJP (JJ necessary) (PP (IN for) (NP (NP (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ timely))) (NN diagnosis)) (PP (IN of) (NP (JJ acute) (NNP Doc_11897407_174_195_Disease))))))) (. .)))
11897407	2	(S1 (S (NP (NP (DT The) (NN animal) (NN model)) (VP (VBN used) (S (VP (TO to) (VP (VB produce) (NP (NNP Doc_11897407_230_240_Disease))))))) (VP (VBZ implies) (SBAR (S (NP (NP (NN artery) (NN ligation)) (CC but) (NP (NN chemical) (NN induction))) (VP (MD can) (VP (AUX be) (ADVP (RB easily)) (VP (VBN obtained) (PP (IN with) (NP (NNP Doc_11897407_316_329_Chemical))))))))) (. .)))
11897407	3	(S1 (S (NP (NP (DT A) (JJ new) (JJ Doc_11897407_337_344_Disease-avid) (NN radiopharmaceutical)) (VP (VBN based) (PP (IN on) (NP (NNP Doc_11897407_379_392_Chemical))))) (VP (AUX was) (VP (VBN prepared) (SBAR (IN in) (S (NP (NP (DT the) (NN hospital) (NN radiopharmacy)) (PP (IN of) (NP (DT the) (NNP INCMNSZ.) (NNP Doc_11897407_452_467_Chemical)))) (VP (VP (AUX was) (ADJP (ADJP (JJ easy) (SBAR (S (VP (TO to) (VP (VB prepare)))))) (, ,) (ADJP (JJ stable) (PP (IN for) (NP (CD 96))))) (NP (NNP h))) (CC and) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (NP (PRP$ its) (NN biodistribution)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ Doc_11897407_560_573_Chemical-induced) (JJ acute) (NN Doc_11897407_588_609_Disease)))))))))))))))) (. .)))
11897407	4	(S1 (S (NP (NN Histological) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT the) (NNS rats)) (VP (VBD developed) (NP (DT an) (NNP Doc_11897407_672_679_Disease) (CD 18) (NNP h)) (PP (IN after) (NP (NNP Doc_11897407_691_704_Chemical) (NN administration))))))) (. .)))
11897407	5	(S1 (S (NP (DT The) (NN rat) (NN biodistribution) (NNS studies)) (VP (VBD showed) (NP (NP (DT a) (JJ rapid) (NN blood) (NN clearance)) (PP (IN via) (NP (DT the) (NNS kidneys))))) (. .)))
11897407	6	(S1 (S (NP (NP (CD Thirty) (NNS minutes)) (PP (IN after) (NP (NNP Doc_11897407_822_837_Chemical) (NN administration)))) (NP (DT the) (JJ standardised) (NN heart) (NN uptake) (NN value) (NNP S) (PRN (-LRB- -LRB-) (NP (NNP h)) (-RRB- -RRB-)) (NNP UV)) (VP (AUX was) (NP (NP (CD 4.7)) (PP (IN in) (NP (JJ infarcted) (NN rat) (NN heart))) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (ADJP (NP (CD six) (NNS times)) (JJR more)) (PP (IN than) (PP (IN in) (NP (JJ normal) (NNS rats)))))))))) (. .)))
11897407	7	(S1 (S (NP (NP (NNS ROIs)) (VP (VBN drawn) (PP (IN over) (NP (DT the) (NN gamma) (NN camera) (NNS images))))) (VP (VBD showed) (NP (NP (DT a) (NN ratio)) (PP (IN of) (NP (CD 4.4))))) (. .)))
11897407	8	(S1 (S (NP (DT The) (JJ high) (NN image) (NN quality)) (VP (VBZ suggests) (SBAR (IN that) (S (S (NP (JJ high) (NN contrast) (NNS images)) (VP (MD can) (VP (AUX be) (VP (VBN obtained) (PP (IN in) (NP (NNS humans))))))) (CC and) (S (NP (DT the) (CD 96) (NNP h) (NN stability)) (VP (VBZ makes) (S (NP (PRP it)) (NP (NP (DT an) (JJ ideal) (NN agent)) (SBAR (S (VP (TO to) (VP (VB detect) (, ,) (PP (IN in) (NP (NNS patients))) (, ,) (NP (JJ early) (NN Doc_11897407_1196_1214_Disease))))))))))))) (. .)))
11928786	0	(S1 (NP (NNP Doc_11928786_0_9_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11928786_11_16_Chemical)) (-RRB- -RRB-)) (NNP Doc_11928786_18_26_Disease) (. .)))
11928786	1	(S1 (S (NP (NN Doc_11928786_28_37_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ monocyclic) (NN Doc_11928786_54_68_Chemical)) (VP (ADVP (RB structurally)) (VBN related) (PP (TO to) (NP (NNP Doc_11928786_93_104_Chemical)))))) (. .)))
11928786	2	(S1 (S (NP (NP (NNP Doc_11928786_106_111_Chemical)) (, ,) (NP (NP (DT a) (JJ sustained-release) (NN formulation)) (PP (IN of) (NP (NNP Doc_11928786_148_171_Chemical)))) (, ,)) (VP (AUX was) (ADVP (RB recently)) (VP (VBN released) (PP (IN in) (NP (NNP Ireland))) (, ,) (PP (IN as) (NP (DT a) (NN smoking) (NN cessation) (NN aid))))) (. .)))
11928786	3	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ initial) (CD 6) (NNS months)) (SBAR (WHNP (IN since)) (S (NP (PRP it)) (VP (AUX 's) (NP (NN introduction))))))) (, ,) (NP (CD 12) (JJ Doc_11928786_287_295_Disease) (NNS cases)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (TO to) (NP (NP (DT The) (NNP National) (NNS Poisons) (NNP Information) (NNP Centre.) (CD 8) (NNS patients)) (VP (VBN developed) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_11928786_398_406_Disease)))))))))) (. .)))
11928786	4	(S1 (S (NP (JJ Common) (NNS features)) (VP (VBD included) (NP (NP (NNP Doc_11928786_433_444_Disease)) (, ,) (NP (NNP drowsiness)) (, ,) (NP (NNP Doc_11928786_458_472_Disease)) (CC and) (NP (NNP Doc_11928786_477_488_Disease)))) (. .)))
11928786	5	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ severe) (NN Doc_11928786_520_539_Disease)) (, ,) (PP (VBG including) (NP (NP (CD one) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN resuscitated) (PP (VBG following) (NP (DT a) (NN Doc_11928786_596_610_Disease)))))))))) (. .)))
11928786	6	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recovered) (PP (IN without) (NP (NN sequelae)))) (. .)))
11928786	7	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 31) (NN year)) (JJ old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (NN admission)) (PP (TO to) (NP (DT the) (JJ Intensive) (NN Care) (NN Unit))) (PP (IN for) (NP (NP (NN ventilation)) (CC and) (NP (JJ full) (JJ supportive) (NN therapy)))) (, ,) (PP (VBG following) (NP (NP (NN ingestion)) (PP (IN of) (NP (JJ 13.5g) (NNP Doc_11928786_818_827_Chemical)))))))))))) (. .)))
11928786	8	(S1 (S (S (NP (NNP Recurrent) (NNP Doc_11928786_839_847_Disease)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11928786_866_874_Chemical)))))) (CC and) (S (NP (JJ broad) (JJ complex) (NN Doc_11928786_893_904_Disease)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11928786_935_944_Chemical)))))) (. .)))
11928786	9	(S1 (S (NP (NN Doc_11928786_946_951_Chemical)) (VP (VBD caused) (NP (JJ significant) (NN Doc_11928786_971_1011_Disease)) (PP (IN in) (NP (NNP Doc_11928786_1015_1023_Disease)))) (. .)))
11928786	10	(S1 (S (NP (DT The) (JJ potential) (JJ toxic) (NNS effects)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (PRP it)) (PP (IN as) (NP (DT a) (NN smoking) (NN cessation) (NN aid))))))))) (. .)))
11961407	0	(S1 (NP (NP (NP (CD GLEPP1) (NN receptor)) (NP (NP (NNP Doc_11961407_16_24_Chemical) (NNP phosphatase)) (PRN (-LRB- -LRB-) (NP (NNP Ptpro)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN rat) (NNP Doc_11961407_52_55_Chemical) (NNP Doc_11961407_56_65_Disease))) (. .)))
11961407	1	(S1 (NP (NP (DT A) (NN marker)) (PP (IN of) (NP (JJ acute) (NN podocyte) (NN injury))) (. .)))
11961407	2	(S1 (S (NP (NP (NNP Glomerular) (JJ epithelial) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP GLEPP1)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ podocyte) (NN receptor) (NN membrane) (NN protein) (JJ Doc_11961407_183_191_Chemical) (NN phosphatase)) (VP (VBN located) (PP (IN on) (NP (NP (DT the) (JJ apical) (NN cell) (NN membrane)) (PP (IN of) (NP (JJ visceral) (JJ glomerular) (JJ epithelial) (NN cell) (CC and) (NN foot) (NNS processes)))))))) (. .)))
11961407	3	(S1 (S (NP (DT This) (NN receptor)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN structure) (CC and) (NN function)) (PP (IN of) (NP (JJ podocyte) (NN foot) (NN process)))))))) (. .)))
11961407	4	(S1 (S (S (VP (TO To) (VP (ADVP (RB better)) (VB understand) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NNS GLEPP1)))) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_11961407_451_468_Disease)))))))) (, ,) (NP (NP (DT the) (NX (NX (NN amount)) (CC and) (NX (NN distribution)))) (PP (IN of) (NP (NP (JJ GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))))) (VP (AUX were) (VP (VBN examined) (PP (IN by) (NP (NP (NN immunohistochemistry)) (, ,) (NP (NNP Western) (NNP blot)) (CC and) (NP (JJ RNase) (NN protection) (NN assay)))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ podocyte) (NN injury))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
11961407	5	(S1 (S (NP (NNP Doc_11961407_646_671_Chemical) (NNP Doc_11961407_672_681_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (JJ single) (JJ intraperitoneal) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11961407_733_758_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11961407_760_763_Chemical)) (, ,) (NP (CD 20) (JJ mg/100g) (NNS BW))) (-RRB- -RRB-)))))))) (. .)))
11961407	6	(S1 (S (NP (NNS Tissues)) (VP (AUX were) (VP (VBN analyzed) (ADVP (IN at) (NP (NP (CD 0) (, ,) (CD 5) (, ,) (CD 7) (, ,) (CD 11) (, ,) (CD 21) (, ,) (CD 45) (, ,) (CD 80) (CC and) (CD 126) (NNS days) (IN after)) (NNP Doc_11961407_849_852_Chemical) (NN injection)) (ADVP (RB so) (RB as) (S (VP (TO to) (VP (VB include) (NP (DT both) (NP (NP (DT the) (JJ acute) (NN phase)) (PP (IN of) (NP (NNP Doc_11961407_904_915_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (NN foot) (NN process) (NN effacement)) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 5-11)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT the) (JJ chronic) (NN phase)) (PP (IN of) (NP (NNP Doc_11961407_993_1004_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11961407_1021_1039_Disease))) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 45-126)) (-RRB- -RRB-)))))))))))) (. .)))
11961407	7	(S1 (S (PP (IN At) (NP (NN day) (CD 5))) (, ,) (NP (NP (CD GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))) (VP (AUX were) (VP (VBN reduced) (PP (IN from) (NP (NP (DT the) (JJ normal) (NN range)) (PRN (-LRB- -LRB-) (NP (QP (CD 265.2) (CD +/-) (CD 79.6) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN moles/glomerulus) (CC and) (CD 100) (NN %))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 15) (NN %)) (PP (IN of) (NP (NP (JJ normal)) (PRN (-LRB- -LRB-) (NP (NP (CD 41.8) (JJ +/-) (CD 4.8) (NAC (NAC (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (NN moles/glomerulus)) (, ,) (NP (NNP p) (NNP <) (CD 0.005))) (-RRB- -RRB-)))))))) (. .)))
11961407	8	(S1 (S (NP (DT This)) (VP (VBD occurred) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ urinary) (NN protein) (NN content)) (PP (IN from) (NP (NP (NP (QP (CD 1.8) (JJ +/-) (CD 1) (TO to) (CD 99.0)) (NNS +/-)) (NP (CD 61) (NN mg/day))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
11961407	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN podocalyxin)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly)) (PP (IN at) (NP (DT this) (NN time))))) (. .)))
11961407	10	(S1 (S (PP (IN By) (NP (NN day) (CD 11))) (, ,) (NP (NP (NN GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))) (VP (AUX had) (VP (VBN begun) (S (VP (TO to) (VP (VB return) (PP (IN towards) (NP (NN baseline)))))))) (. .)))
11961407	11	(S1 (S (PP (IN By) (NP (NN day) (CD 45-126))) (, ,) (PP (IN at) (NP (NP (DT a) (NN time)) (SBAR (WHADVP (WRB when)) (S (NP (JJ glomerular) (NN scarring)) (VP (AUX was) (ADJP (JJ present))))))) (, ,) (NP (NNP GLEPP1)) (VP (AUX was) (ADJP (JJ absent)) (PP (IN from) (NP (JJ glomerulosclerotic) (NNS areas))) (SBAR (IN although) (S (NP (NP (DT the) (JJ total) (NN glomerular) (NN content)) (PP (IN of) (NP (NNS GLEPP1)))) (VP (AUX was) (RB not) (ADJP (JJ different) (PP (IN from) (NP (JJ normal)))))))) (. .)))
11961407	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ GLEPP1) (NN expression)) (, ,) (PP (IN unlike) (NP (NN podocalyxin))) (, ,) (VP (VBZ reflects) (NP (NP (JJ podocyte) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11961407_1790_1793_Chemical))))))))) (. .)))
11961407	13	(S1 (S (NP (JJ GLEPP1) (NN expression)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN marker)) (PP (IN of) (NP (JJ podocyte) (NN injury)))))) (. .)))
12041669	0	(S1 (NP (NP (NN Doc_12041669_0_22_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12041669_43_58_Chemical-induced) (NNP Doc_12041669_67_82_Disease))))) (. .)))
12041669	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ Doc_12041669_107_129_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_12041669_142_157_Disease)))) (PP (JJ due) (TO to) (NP (JJ Doc_12041669_165_180_Chemical) (NN therapy))))))) (VP (AUX is) (VP (VBN described))) (. .)))
12041669	2	(S1 (S (S (NP (NP (NN Bone) (NN marrow) (NN recovery)) (CC and) (NP (JJ peripheral) (NN blood) (NN recovery))) (VP (AUX were) (ADJP (JJ complete)) (NP (QP (CD 1) (NN month) (CC and) (CD 3)) (NNS months)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN after) (NP (NN treatment))))) (, ,) (CC and) (S (NP (NP (NN blood) (NN transfusion)) (CC or) (NP (JJ other) (NNS therapies))) (VP (AUX were) (RB not) (ADJP (JJ necessary)) (PP (IN in) (NP (NP (DT a) (JJ follow-up) (NN period)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 2)) (NNS years))))))) (. .)))
12041669	3	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_12041669_432_454_Chemical)))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ optimal) (NN treatment)) (PP (IN of) (NP (JJ Doc_12041669_487_502_Chemical-induced) (NN Doc_12041669_511_526_Disease)))))) (. .)))
12063090	0	(S1 (S (NP (NN Doc_12063090_0_9_Chemical)) (VP (VP (VBZ potentiates) (NP (JJ Doc_12063090_22_30_Chemical) (NN antinociception))) (CC but) (RB not) (VP (NNP Doc_12063090_55_67_Disease) (PP (IN after) (NP (JJ chronic) (NN treatment))))) (. .)))
12063090	1	(S1 (S (NP (DT This) (NN work)) (VP (VBZ evaluates) (NP (NP (DT the) (UCP (JJ antinociceptive) (CC and) (NNP Doc_12063090_137_149_Disease)) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (CD 3.2) (NN mg/kg) (NNP s.c.) (NNP Doc_12063090_195_203_Chemical))))) (PP (IN with) (NP (NP (CD 177.8) (JJ mg/kg) (NNP s.c.) (NNP Doc_12063090_226_235_Chemical)) (PP (IN in) (NP (ADJP (ADVP (RB acutely) (CC and) (RB chronically)) (VBN treated)) (PRN (-LRB- -LRB-) (ADVP (RB once)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 12) (NNS days)))) (-RRB- -RRB-)) (NNS rats))))))) (. .)))
12063090	2	(S1 (S (PP (IN On) (NP (DT the) (JJ 13th) (NN day))) (, ,) (S (NP (NN antinociceptive) (NNS effects)) (VP (AUX were) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NP (JJ inflammatory) (NN nociception)) (, ,) (NP (JJ Doc_12063090_400_404_Disease-induced) (JJ functional) (NN impairment) (NN model)))))))))) (, ,) (CC and) (S (NP (DT the) (JJ Doc_12063090_450_458_Chemical) (NN meal) (NN test)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (DT the) (JJ intestinal) (NN transit)))))))) (. .)))
12063090	3	(S1 (S (NP (NP (JJ Simultaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_12063090_545_553_Chemical))) (PP (IN with) (NP (NNP Doc_12063090_559_568_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (RB markedly) (JJ antinociceptive)) (NN potentiation)) (CC and) (NP (NP (NP (NP (DT an) (VBG increasing)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN action))))) (PP (IN after) (NP (NP (DT a) (JJ single)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 298+/-7) (CC vs.) (CD 139+/-36) (NNS units)) (NN area)) (PRN (-LRB- -LRB-) (NP (NN ua)) (-RRB- -RRB-))) (: ;) (NP (NNP P<0.001))) (-RRB- -RRB-))))) (CC and) (NP (VBN repeated) (NN administration))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 280+/-17) (CC vs.) (CD 131+/-22) (NN ua))) (: ;) (NP (NNP P<0.001))) (-RRB- -RRB-)))))) (. .)))
12063090	4	(S1 (S (NP (NP (JJ Antinociceptive) (NN effect)) (PP (IN of) (NP (NNP Doc_12063090_819_827_Chemical)))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (RB chronically) (VBN treated) (NNS rats))) (PRN (-LRB- -LRB-) (NP (QP (CD 39+/-10) (CC vs.) (CD 18+/-5)) (NN au)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (DT the) (JJ combination-induced) (NN antinociception)) (VP (AUX was) (VP (VBN remained) (ADJP (JJ similar)) (PP (IN as) (NP (NP (DT an) (JJ acute) (NN treatment)) (PRN (-LRB- -LRB-) (NP (QP (CD 298+/-7) (CC vs.) (CD 280+/-17)) (NNS au)) (-RRB- -RRB-)))))))))) (. .)))
12063090	5	(S1 (S (NP (NP (JJ Acute) (JJ antinociceptive) (NNS effects)) (PP (IN of) (NP (DT the) (NN combination)))) (VP (AUX were) (ADVP (RB partially)) (VP (VBN prevented) (PP (IN by) (NP (NP (CD 3.2) (NNS mg/kg)) (NP (NP (NNP Doc_12063090_1095_1103_Chemical) (NNP s.c.)) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ partial) (NN involvement)) (PP (IN of) (NP (DT the) (JJ opioidergic) (NN system))) (PP (IN in) (NP (NP (DT the) (NN synergism)) (VP (VBN observed))))))))) (. .)))
12063090	6	(S1 (S (PP (IN In) (NP (JJ independent) (NNS groups))) (, ,) (NP (NNP Doc_12063090_1230_1238_Chemical)) (VP (VBD inhibited) (NP (DT the) (JJ intestinal) (NN transit)) (PP (IN in) (NP (NP (JJ 48+/-4) (NN %)) (CC and) (NP (JJ 38+/-4) (NN %)))) (PP (IN after) (NP (ADJP (JJ acute) (CC and) (JJ chronic)) (NN treatment))) (, ,) (ADVP (RB respectively)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN tolerance)) (VP (AUX did) (RB not) (VP (VB develop) (PP (TO to) (NP (DT the) (JJ Doc_12063090_1393_1405_Disease) (NNS effects)))))))))) (. .)))
12063090	7	(S1 (S (NP (DT The) (NN combination)) (VP (VBD inhibited) (NP (NP (JJ intestinal) (NN transit)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_12063090_1488_1496_Chemical)))))))) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN treatment)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP Doc_12063090_1550_1559_Chemical)) (VP (AUX did) (RB not) (VP (VB potentiate) (NP (JJ Doc_12063090_1579_1587_Chemical-induced) (NN Doc_12063090_1596_1608_Disease))))))))) (. .)))
12063090	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP show) (NP (NP (DT a) (JJ significant) (NN interaction)) (PP (IN between) (NP (NP (NP (NNP Doc_12063090_1664_1672_Chemical)) (CC and) (NP (NNP Doc_12063090_1677_1686_Chemical))) (PP (IN in) (NP (RB chronically) (VBN treated) (NNS rats)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT this) (NN combination)) (VP (MD could) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12063090_1786_1798_Disease))))))))))))) (. .)))
12084448	0	(S1 (S (NP (NNP Doc_12084448_0_10_Chemical) (NNP Doc_12084448_11_25_Disease)) (VP (VBG presenting) (PP (IN with) (NP (NNP Doc_12084448_42_51_Disease)))) (. .)))
12084448	1	(S1 (S (NP (NP (JJ CNS) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ antineoplastic) (NN agent) (NNP Doc_12084448_99_109_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12084448_111_114_Chemical)) (-RRB- -RRB-))))) (VP (VP (AUX are) (ADJP (JJ frequent))) (CC and) (VP (VBP include) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ neurological) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB limit) (NP (NN drug) (NN use))))))))))) (. .)))
12084448	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 51-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (S (ADJP (JJ severe))) (, ,) (S (VP (VBG disabling) (NP (NP (JJ negative) (NN Doc_12084448_280_289_Disease)) (PP (IN of) (NP (NP (DT the) (JJ upper)) (CC and) (NP (JJR lower) (NNS extremities))))) (PP (IN after) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_12084448_347_357_Chemical))) (PP (IN for) (NP (NNP Doc_12084448_362_374_Disease)))))))))))))) (. .)))
12084448	3	(S1 (S (NP (PRP He)) (VP (AUX was) (ADVP (RB awake)) (, ,) (PP (VBN revealed) (NP (NP (DT no) (NNS changes)) (PP (PP (IN of) (NP (JJ mental) (NN status))) (CC and) (PP (IN at) (NP (NN rest)))) (SBAR (S (NP (EX there)) (VP (AUX were) (NP (DT no) (JJ further) (NN motor) (NNS symptoms)))))))) (. .)))
12084448	4	(S1 (S (NP (NP (JJ Cranial) (JJ magnetic) (NN resonance) (NN imaging)) (CC and) (NP (JJ extensive) (NN laboratory) (NNS studies))) (VP (VBD failed) (S (VP (TO to) (VP (VB reveal) (NP (NP (NNP Doc_12084448_562_593_Disease)) (CC and) (NP (NNP Doc_12084448_598_621_Disease))))))) (. .)))
12084448	5	(S1 (S (NP (DT An) (NN electroencephalogram)) (VP (VBD showed) (NP (NP (JJ continuous) (, ,) (JJ generalized) (JJ irregular) (NN slowing)) (PP (IN with) (NP (NP (JJ admixed) (JJ periodic) (NN triphasic) (NNS waves)) (VP (VBG indicating) (NP (JJ symptomatic) (NNP Doc_12084448_757_771_Disease))))))) (. .)))
12084448	6	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_12084448_795_805_Chemical)))) (VP (VP (AUX was) (VP (VBN discontinued))) (CC and) (VP (PP (IN within) (NP (CD 12) (NNP h) (DT the) (NNP Doc_12084448_843_852_Disease))) (VBD resolved) (ADVP (RB completely)))) (. .)))
12084448	7	(S1 (S (PP (IN In) (NP (NP (DT the) (NN patient)) (VP (VBN described)))) (, ,) (NP (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_12084448_916_925_Disease))) (PP (IN during) (NP (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_12084448_945_955_Chemical)))) (, ,) (NP (JJ normal) (NN laboratory) (NNS findings)) (CC and) (NP (NN imaging) (NNS studies))))) (CC and) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (VBG following) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ negative) (NN Doc_12084448_1099_1108_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12084448_1139_1142_Chemical)))))))))) (. .)))
12090760	0	(S1 (NP (NP (NN Antagonism)) (PP (IN between) (NP (NP (NN interleukin) (CD 3)) (CC and) (NP (NN erythropoietin)))) (PP (PP (IN in) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_12090760_65_79_Chemical-induced) (NNP Doc_12090760_88_94_Disease))))) (CC and) (PP (IN in) (NP (NN bone) (NN marrow) (NN endothelial) (NNS cells)))) (. .)))
12090760	1	(S1 (S (NP (NP (JJ Doc_12090760_133_147_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12090760_149_152_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12090760_162_168_Disease)) (PP (IN in) (NP (NNS mice)))) (VP (MD can) (VP (AUX be) (VP (VBN reversed) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN IGF-IL-3))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN fusion) (NN protein)) (PP (IN of) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (NNP II)) (PRN (-LRB- -LRB-) (NP (NNP IGF) (NNP II)) (-RRB- -RRB-))))) (CC and) (NP (NN interleukin) (CD 3))) (-RRB- -RRB-))))) (. .)))
12090760	2	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (NN interleukin) (CD 3)) (PRN (-LRB- -LRB-) (JJ IL-3) (-RRB- -RRB-))) (CC and) (NP (NP (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NNP EPO)) (-RRB- -RRB-)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB act) (ADVP (RB synergistically)) (PP (IN on) (NP (NP (JJ hematopoietic) (NN cell) (NN proliferation)) (PP (IN in) (NP (NN vitro)))))))))))) (, ,) (NP (NP (NN injection)) (PP (IN of) (NP (NNP IGF-IL-3) (CC and) (NNP EPO))) (PP (IN in) (NP (JJ Doc_12090760_472_475_Chemical-treated) (NNS mice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ red) (NNS cells)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN plasma) (NNP EPO) (NNS levels)))))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP IGF-IL-3) (CC or) (NNP EPO)) (ADVP (RB alone)))))))))) (. .)))
12090760	3	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT the) (JJ antagonistic) (NN effect)) (PP (IN of) (NP (NP (NNP IL-3)) (CC and) (NP (NNP EPO)))) (PP (IN on) (NP (JJ erythroid) (NNS cells)))) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (JJ endothelial) (NNS cells)))))))))) (. .)))
12090760	4	(S1 (S (NP (JJ Bovine) (NN liver) (NN erythroid) (NNS cells)) (VP (AUX were) (VP (VBN cultured) (PP (IN on) (NP (NP (NNS monolayers)) (PP (IN of) (NP (NP (JJ human) (NN bone) (NN marrow) (NN endothelial) (NNS cells)) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NP (NNP EPO)) (CC and) (NP (NNP IGF-IL-3))))))))))) (. .)))
12090760	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN of) (NP (NP (JJ Doc_12090760_924_933_Chemical) (NN incorporation)) (PP (IN into) (NP (DT both) (JJ erythroid) (CC and) (JJ endothelial) (NNS cells))) (PP (IN in) (NP (NP (NNS cultures)) (VP (VBN pre-treated) (PP (IN with) (NP (NP (NNP IGF-IL-3)) (CC and) (NP (NNP EPO))))))))))) (. .)))
12090760	6	(S1 (S (NP (NP (JJ Endothelial) (NN cell) (NN culture) (NNS supernatants)) (VP (VBN separated) (PP (IN by) (NP (NN ultrafiltration) (CC and) (NN ultracentrifugation))) (PP (IN from) (NP (NNS cells))))) (VP (VP (VBD treated) (PP (IN with) (NP (NNP EPO)))) (CC and) (VP (ADVP (JJ IL-3) (RB significantly)) (VBD reduced) (NP (JJ Doc_12090760_1187_1196_Chemical) (NN incorporation)) (PP (IN into) (NP (JJ erythroid) (NNS cells))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (JJ identical) (NNS fractions)) (VP (VBN obtained) (PP (IN from) (NP (NP (DT the) (NNS media)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBN cultured) (PP (IN with) (NP (NP (NNP EPO)) (ADVP (RB alone)))))))))))))))) (. .)))
12090760	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ endothelial) (NNS cells)) (VP (VBN treated) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NNP EPO)) (CC and) (NP (NNP IL-3)))))) (VP (AUX have) (NP (NP (DT a) (JJ negative) (NN effect)) (PP (IN on) (NP (JJ erythroid) (NN cell) (NN production)))))))) (. .)))
12198388	0	(S1 (S (NP (NP (DT The) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (JJ hippocampal) (JJ Doc_12198388_37_50_Chemical) (NN release)) (CC and) (NP (JJ cholinergic) (JJ convulsant) (NN sensitivity))) (PP (IN in) (NP (NN withdrawal) (NN Doc_12198388_112_119_Disease-prone)))) (CC and) (NP (NN withdrawal) (NN Doc_12198388_141_148_Disease-resistant))))) (VP (VBD selected) (NP (NN mouse) (NNS lines))) (. .)))
12198388	1	(S1 (S (S (NP (DT The) (JJ septo-hippocampal) (NN cholinergic) (NN pathway)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NN epileptogenesis))))))) (, ,) (CC and) (S (NP (JJ genetic) (NNS factors)) (VP (VBP influence) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (JJ cholinergic) (NNS agents)))))) (, ,) (CC but) (S (NP (JJ limited) (NNS data)) (VP (AUX are) (ADJP (JJ available)) (PP (IN on) (NP (NP (JJ cholinergic) (NN involvement)) (PP (IN in) (NP (JJ Doc_12198388_402_409_Chemical) (NN withdrawal) (NN severity))))))) (. .)))
12198388	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ cholinergic) (NN activity)) (CC and) (NP (NP (NN responsiveness)) (CC and) (NP (JJ Doc_12198388_506_513_Chemical) (NN withdrawal)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (DT a) (JJ genetic) (NN animal) (NN model)) (PP (IN of) (NP (JJ Doc_12198388_571_578_Chemical) (NN withdrawal) (NN severity))))))) (. .)))
12198388	3	(S1 (S (NP (JJ Cholinergic) (NN convulsant) (NN sensitivity)) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NNP Doc_12198388_660_667_Chemical-na) (NN ve) (NN Withdrawal) (NNP Doc_12198388_686_693_Disease-Prone) (PRN (-LRB- -LRB-) (NP (NNP WSP)) (-RRB- -RRB-)) (JJ and-Resistant) (PRN (-LRB- -LRB-) (NP (NNP WSR)) (-RRB- -RRB-)) (NNS mice))))) (. .)))
12198388	4	(S1 (S (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN administered) (NP (NP (NNP Doc_12198388_758_766_Chemical)) (, ,) (NP (NNP Doc_12198388_768_777_Chemical)) (, ,) (CC or) (NP (NNP Doc_12198388_782_793_Chemical))) (PP (IN via) (NP (VBN timed) (NN tail) (NN vein) (NN infusion)))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS latencies)) (PP (TO to) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNP Doc_12198388_854_860_Disease)) (CC and) (NP (NNS clonus))))))) (VP (AUX were) (VP (VBN recorded) (CC and) (VBN converted) (PP (TO to) (NP (NN threshold) (NN dose)))))) (. .)))
12198388	5	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD used) (NP (NN microdialysis)) (S (VP (TO to) (VP (VB measure) (NP (NP (NN basal)) (CC and) (NP (NP (NNP Doc_12198388_967_976_Chemical-stimulated) (NNP Doc_12198388_988_1001_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12198388_1003_1006_Chemical)) (-RRB- -RRB-)) (NN release)) (PP (IN in) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NN hippocampus))))))))))) (. .)))
12198388	6	(S1 (S (NP (NN Doc_12198388_1054_1063_Chemical)) (VP (AUX was) (VP (VP (VBN applied) (PP (IN by) (NP (JJ reverse) (NN dialysis))) (ADVP (RB twice))) (, ,) (VP (VBN separated) (PP (IN by) (NP (CD 75) (NN min)))))) (. .)))
12198388	7	(S1 (S (NP (NNP Hippocampal) (NNP Doc_12198388_1136_1139_Chemical)) (ADVP (RB also)) (VP (AUX was) (VP (VBN measured) (PP (IN during) (NP (NN testing))) (PP (IN for) (NP (JJ handling-induced) (NN Doc_12198388_1194_1205_Disease))))) (. .)))
12198388	8	(S1 (S (NP (NP (NN Sensitivity)) (PP (TO to) (NP (NP (JJ several) (NNP Doc_12198388_1239_1249_Disease) (NNS endpoints)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_12198388_1271_1279_Chemical)) (, ,) (NP (NNP Doc_12198388_1281_1290_Chemical)) (, ,) (CC and) (NP (NNP Doc_12198388_1296_1307_Chemical)))))))) (VP (AUX were) (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (NNP WSR) (CC versus) (NNP WSP) (NNS mice)))) (. .)))
12198388	9	(S1 (S (PP (IN In) (NP (NN microdialysis) (NNS experiments))) (, ,) (NP (DT the) (NNS lines)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN in) (NP (NP (NP (JJ basal) (NN release)) (PP (IN of) (NP (NNP Doc_12198388_1434_1437_Chemical)))) (, ,) (CC and) (NP (ADJP (CD 50) (NN mM)) (JJ Doc_12198388_1449_1452_Chemical) (VBN increased) (JJ Doc_12198388_1463_1466_Chemical) (NN output)))) (PP (IN in) (NP (NP (DT both) (NNS lines)) (PP (IN of) (NP (NNS mice))))))) (. .)))
12198388	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN release)) (PP (IN of) (NP (NNP Doc_12198388_1533_1536_Chemical))))) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (JJ first) (NN application)) (PP (IN of) (NP (NNP Doc_12198388_1574_1577_Chemical))))))) (VP (AUX was) (ADJP (RB 2-fold) (JJR higher)) (PP (IN in) (NP (NNP WSP) (CC versus) (NNP WSR) (NNS mice)))) (. .)))
12198388	11	(S1 (FRAG (SBAR (WHADVP (WRB When)) (S (NP (JJ hippocampal) (NNP Doc_12198388_1637_1640_Chemical)) (VP (AUX was) (VP (VBN measured) (PP (IN during) (S (VP (VBG testing) (SBAR (S (PP (IN for) (NP (JJ handling-induced) (NNP Doc_12198388_1690_1701_Disease))) (, ,) (NP (JJ extracellular) (NNP Doc_12198388_1717_1720_Chemical)) (VP (VP (AUX was) (ADJP (RB significantly) (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 192) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP WSP) (NNS mice)))) (, ,) (CC but) (VP (AUX was) (ADJP (RB nonsignificantly) (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 59) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP WSR) (NNS mice)))))))))))))) (. .)))
12198388	12	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ cholinergic) (NN activity)) (CC and) (NP (JJ postsynaptic) (NN sensitivity)))) (PP (TO to) (NP (JJ cholinergic) (NNP Doc_12198388_1941_1952_Disease)))) (VP (MD may) (VP (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12198388_1976_1983_Chemical) (NN withdrawal) (NN severity))))) (CC and) (VP (VB implicate) (NP (JJ cholinergic) (NNS mechanisms)) (PP (IN in) (NP (JJ Doc_12198388_2044_2051_Chemical) (NN withdrawal))))))))) (. .)))
12198388	13	(S1 (S (ADVP (RB Specifically)) (, ,) (NP (NNP WSP) (NNS mice)) (VP (MD may) (VP (AUX have) (NP (JJR lower) (NN sensitivity)) (S (VP (TO to) (VP (VB cholinergic) (NP (NNP Doc_12198388_2129_2140_Disease)) (PP (VBN compared) (PP (IN with) (NP (NNP WSR)))) (PP (IN because) (IN of) (NP (NP (JJ postsynaptic) (NN receptor) (NN desensitization)) (VP (VBN brought) (PRT (RP on)) (PP (IN by) (NP (NP (JJR higher) (NN activity)) (PP (IN of) (NP (JJ cholinergic) (NNS neurons))))))))))))) (. .)))
12202650	0	(S1 (S (NP (JJ Doc_12202650_0_9_Chemical-induced) (NN Doc_12202650_18_29_Disease)) (VP (VBZ alters) (NP (NP (DT the) (NN excitability)) (PP (IN of) (NP (DT the) (JJ human) (JJ jaw-stretch) (JJ reflex))))) (. .)))
12202650	1	(S1 (S (S (NP (NP (DT The) (NN pathophysiology)) (PP (IN of) (NP (JJ painful) (NNP Doc_12202650_118_145_Disease)))) (VP (AUX is) (RB not) (ADVP (RB fully)) (VP (VBN understood)))) (, ,) (CC but) (S (NP (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_12202650_198_209_Disease)) (VP (VBZ modulates) (NP (NN motor) (NN function)) (PP (IN in) (NP (JJ characteristic) (NNS ways)))))))) (. .)))
12202650	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD tested) (NP (DT the) (NN hypothesis)) (SBAR (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NNP Doc_12202650_311_329_Disease) (NN afferent) (NNS fibers)))) (VP (MD would) (VP (AUX be) (VP (VBN linked) (PP (TO to) (NP (NP (DT an) (VBN increased) (NN excitability)) (PP (IN of) (NP (DT the) (JJ human) (JJ jaw-stretch) (JJ reflex)))))))))) (CC and) (SBAR (IN whether) (S (NP (DT this) (NN process)) (VP (MD would) (VP (AUX be) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NP (NN length)) (CC and) (NP (NN velocity))) (PP (IN of) (NP (DT the) (NN stretch)))))))))))) (. .)))
12202650	3	(S1 (S (NP (NP (NNP Doc_12202650_506_515_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (JJ micro) (NNP g)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (PP (IN into) (NP (DT the) (NN masseter) (NN muscle))) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_12202650_577_581_Disease)) (PP (IN in) (NP (CD 11) (JJ healthy) (NNS volunteers)))))))) (. .)))
12202650	4	(S1 (S (NP (JJ Short-latency) (JJ reflex) (NNS responses)) (VP (AUX were) (VP (VBN evoked) (PP (IN in) (NP (DT the) (NN masseter) (CC and) (NN temporalis) (NNS muscles))) (PP (IN by) (NP (NP (DT a) (JJ stretch) (NN device)) (PP (IN with) (NP (NP (JJ different) (NNS velocities)) (CC and) (NP (NNS displacements)))) (ADVP (RB before)) (, ,) (PP (PP (IN during)) (, ,) (CC and) (PP (IN after) (NP (DT the) (NNP Doc_12202650_784_788_Disease)))))))) (. .)))
12202650	5	(S1 (S (NP (DT The) (JJ normalized) (JJ reflex) (NN amplitude)) (VP (VP (VBD increased) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN velocity))))) (PP (IN at) (NP (DT a) (VBN given) (NN displacement)))) (, ,) (CC but) (VP (VBD remained) (ADJP (JJ constant)) (PP (IN with) (NP (JJ different) (NNS displacements))) (PP (IN at) (NP (DT a) (VBN given) (NN velocity))))) (. .)))
12202650	6	(S1 (S (NP (DT The) (JJ normalized) (JJ reflex) (NN amplitude)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)) (PP (IN during) (NP (NNP Doc_12202650_1022_1026_Disease))) (, ,) (FRAG (CC but) (ADVP (RB only)) (PP (IN at) (NP (NP (JJR faster) (NNS stretches)) (PP (IN in) (NP (DT the) (NNP Doc_12202650_1064_1078_Disease))))))) (. .)))
12202650	7	(S1 (S (NP (NP (VBN Increased) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN fusimotor) (NN system))) (PP (IN during) (NP (JJ acute) (NN Doc_12202650_1139_1150_Disease)))) (VP (MD could) (VP (AUX be) (NP (NP (CD one) (JJ likely) (NN mechanism)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (DT the) (NNS findings))))))))) (. .)))
12369736	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)))) (VP (VBD microinjected) (PP (IN into) (NP (DT the) (NN accumbal) (NN shell) (CC or) (NN core))) (PP (IN on) (NP (NP (DT the) (JJ Doc_12369736_88_95_Chemical-induced) (NN Doc_12369736_104_127_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
12369736	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)) (VP (VBN microinjected) (PP (IN into) (NP (NP (DT the) (NNS subregions)) (PP (IN of) (NP (NP (DT the) (NN nucleus) (NNS accumbens)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN shell)) (CC and) (NP (DT the) (NN core))) (-RRB- -RRB-))))))))) (PP (IN on) (NP (NP (DT the) (NNP Doc_12369736_308_331_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12369736_343_350_Chemical))) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12369736	2	(S1 (S (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN implanted) (ADVP (RB bilaterally)) (PP (IN with) (NP (NNS cannulae))) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell) (CC or) (NN core)))))) (, ,) (CC and) (S (ADVP (RB then)) (VP (AUX were) (ADVP (RB locally)) (VP (VBN injected) (PP (IN with) (NP (NP (NP (NNP Doc_12369736_488_496_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (JJ 5-HT1B) (NNS receptors)))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12369736_536_544_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agonist)) (PP (IN of) (NP (JJ 5-HT1B) (NNS receptors)))) (-RRB- -RRB-)))))))) (. .)))
12369736	3	(S1 (S (S (VP (VBN Given) (ADVP (RB alone)) (PP (TO to) (NP (DT any) (JJ accumbal) (NN subregion))))) (, ,) (NP (NP (NP (NNP Doc_12369736_618_626_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12369736_651_659_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-)))) (VP (AUX did) (RB not) (VP (VB change) (NP (JJ basal) (JJ locomotor) (NN activity)))) (. .)))
12369736	4	(S1 (S (NP (NP (JJ Systemic) (NNP Doc_12369736_731_738_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (JJ locomotor) (NN activity)) (PP (IN of) (NP (NNS rats))))) (. .)))
12369736	5	(S1 (S (NP (NP (NP (NNP Doc_12369736_806_814_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN administered) (JJ intra-accumbens) (NN shell)) (PP (ADVP (RB prior)) (TO to) (NP (NNP Doc_12369736_881_888_Chemical)))) (, ,)) (ADVP (RB dose-dependently)) (VP (VBD attenuated) (NP (DT the) (JJ psychostimulant-induced) (NNP Doc_12369736_946_969_Disease))) (. .)))
12369736	6	(S1 (S (NP (JJ Such) (NN attenuation)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (VP (AUX been) (VP (VBN injected) (PP (IN with) (NP (NNP Doc_12369736_1042_1050_Chemical))) (PP (IN into) (NP (DT the) (JJ accumbens) (NN core)))))))))))) (. .)))
12369736	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN injected) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell))) (PRN (-LRB- -LRB-) (CC but) (NP (RB not) (DT the) (NN core)) (-RRB- -RRB-)) (PP (IN before) (NP (NNP Doc_12369736_1141_1148_Chemical)))))) (, ,) (NP (NNP Doc_12369736_1150_1158_Chemical) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (VP (VP (VBD enhanced) (NP (NP (DT the) (JJ locomotor) (NN response)) (PP (TO to) (NP (NNP Doc_12369736_1215_1222_Chemical))))) (: ;) (NP (NP (DT the) (JJ maximum) (NN effect)) (VP (AUXG being) (VP (VBN observed) (PP (IN after) (NP (NP (CD 10) (NN microg/side)) (PP (IN of) (NP (DT the) (NN agonist))))))))) (. .)))
12369736	8	(S1 (S (NP (DT The) (JJ later) (NN enhancement)) (VP (AUX was) (VP (VBN attenuated) (PP (IN after) (NP (NP (JJ intra-accumbens) (NN shell) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_12369736_1375_1383_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN microg/side)) (-RRB- -RRB-)))))))) (. .)))
12369736	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NNP Doc_12369736_1428_1435_Chemical)) (VP (VBN induced) (SBAR (S (NP (NNP Doc_12369736_1444_1459_Disease)) (VP (AUX is) (VP (VBN modified) (PP (IN by) (NP (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)) (VP (VBN microinjected) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell)))))))))))) (, ,) (CC but) (S (ADJP (RB not) (JJ core)) (, ,) (NP (DT this) (NN modification)) (VP (VBG consisting) (PP (IN in) (NP (NP (JJ inhibitory) (CC and) (JJ facilitatory) (NNS effects)) (PP (IN of) (NP (NP (NP (DT the) (JJ 5-HT1B) (NN receptor) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12369736_1656_1664_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NN agonist)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12369736_1679_1687_Chemical)) (-RRB- -RRB-))))))) (, ,) (ADVP (RB respectively))))))) (. .)))
12369736	10	(S1 (S (PP (IN In) (NP (JJ other) (NNS words))) (, ,) (NP (DT the) (JJ present) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ accumbal) (NN shell) (NN 5-HT1B) (NNS receptors)) (VP (VBP play) (NP (DT a) (JJ permissive) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ behavioural) (NN response)) (PP (TO to) (NP (DT the) (NN psychostimulant))))))))) (. .)))
12443032	0	(S1 (S (S (NP (NN Doc_12443032_0_7_Chemical)) (VP (VBD related) (NP (NN Doc_12443032_16_26_Disease)))) (: :) (SQ (AUX are) (NP (PRP we)) (VP (VBG seeing) (NP (NP (DT the) (NN tip)) (PP (IN of) (NP (DT an) (NN iceberg))))) (. ?))))
12443032	1	(S1 (S (NP (NP (DT The) (JJ recreational) (NN use)) (PP (IN of) (NP (NNP Doc_12443032_89_96_Chemical)))) (VP (AUX is) (PP (IN on) (NP (DT the) (NN increase)))) (. .)))
12443032	2	(S1 (S (NP (DT The) (NN emergency) (NN nurse)) (VP (MD ought) (S (VP (TO to) (VP (AUX be) (ADJP (JJ familiar) (PP (IN with) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ cardiovascular) (NNS consequences)) (PP (IN of) (NP (JJ Doc_12443032_206_213_Chemical) (NN use)))))))))))) (. .)))
12443032	3	(S1 (S (PP (IN In) (NP (NN particular))) (, ,) (NP (NP (DT the) (NN tendency)) (PP (IN of) (NP (NNP Doc_12443032_250_257_Chemical)))) (VP (TO to) (VP (VB produce) (SBAR (S (NP (NNP Doc_12443032_269_279_Disease)) (VP (MD ought) (S (VP (TO to) (VP (AUX be) (PP (IN in) (NP (NP (DT the) (NN mind)) (PP (IN of) (NP (DT the) (NN emergency) (NN nurse))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN faced) (PP (IN with) (NP (NP (DT a) (JJ young) (NN victim)) (PP (IN of) (NP (NNP Doc_12443032_361_371_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX is) (ADVP (RB otherwise)) (PP (IN at) (NP (JJ low) (NN risk))))))))))))))))))) (. .)))
12443032	4	(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_12443032_419_429_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_12443032_441_448_Chemical) (NN use))))) (VP (AUX is) (VP (VBN discussed)))) (CC and) (S (NP (NN treatment) (NNS dilemmas)) (VP (AUX are) (VP (VBN discussed)))) (. .)))
12443032	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (JJ moral) (NNS issues)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NN testing)) (PP (IN of) (NP (JJ potential) (JJ Doc_12443032_563_570_Chemical) (NNS users))))))) (VP (MD will) (VP (AUX be) (VP (VBN addressed)))) (. .)))
12464714	0	(S1 (S (NP (NP (NN Crossover) (NN comparison)) (PP (IN of) (NP (NP (NN efficacy) (CC and) (NN preference)) (PP (IN for) (NP (NNP Doc_12464714_52_63_Chemical) (CD 10)))))) (VP (VBD mg) (PP (IN versus) (NP (NNP Doc_12464714_77_87_Chemical/Doc_12464714_88_96_Chemical))) (PP (IN in) (NP (NNP Doc_12464714_100_108_Disease)))) (. .)))
12464714	1	(S1 (S (NP (NNP Doc_12464714_110_121_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (NNP Doc_12464714_137_141_Chemical) (PRN (-LRB- -LRB-) (NP (NN 1B/1D)) (-RRB- -RRB-)) (NN receptor)) (ADJP (JJ agonist) (PP (IN with) (NP (NP (JJ rapid) (JJ oral) (NN absorption) (CC and) (JJ early) (NN onset)) (PP (IN of) (NP (NN action))) (PP (IN in) (NP (NP (DT the) (JJ acute) (NN treatment)) (PP (IN of) (NP (NNP Doc_12464714_245_253_Disease)))))))))) (. .)))
12464714	2	(S1 (S (NP (DT This) (JJ randomized) (JJ double-) (JJ blind) (NN crossover) (NN outpatient) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN preference)) (PP (IN for) (NP (NP (NP (QP (CD 1) (JJ Doc_12464714_342_353_Chemical) (CD 10) (CD mg) (NN tablet) (TO to) (CD 2)) (NNP Doc_12464714_372_382_Chemical) (CD 1) (NN mg/Doc_12464714_388_396_Chemical)) (NP (QP (CD 100) (CD mg)) (NNS tablets))) (PP (IN in) (NP (NP (CD 439) (NNS patients)) (VP (VBG treating) (NP (NP (DT a) (JJ single) (NN Doc_12464714_446_454_Disease) (NN attack)) (PP (IN with) (NP (DT each) (NN therapy))))))))))) (. .)))
12464714	3	(S1 (S (PP (IN Of) (NP (NP (NNS patients)) (VP (VBG expressing) (NP (NP (DT a) (NN preference)) (PRN (-LRB- -LRB-) (NP (CD 89.1) (NN %)) (-RRB- -RRB-)))))) (, ,) (ADVP (RBR more) (IN than) (RB twice) (RB as)) (NP (JJ many)) (VP (VBN preferred) (NP (NNP Doc_12464714_560_571_Chemical)) (PP (TO to) (NP (NP (NNP Doc_12464714_575_585_Chemical/Doc_12464714_586_594_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 69.9)) (CC vs.) (NP (CD 30.1) (NN %))) (, ,) (NP (CD p) (NN <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))))) (. .)))
12464714	4	(S1 (S (NP (NP (JJR Faster) (NN relief)) (PP (IN of) (NP (NNP Doc_12464714_646_654_Disease)))) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NN reason)) (PP (IN for) (NP (NN preference))) (, ,) (VP (VBN cited) (PP (IN by) (NP (NP (NP (CD 67.3) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG preferring) (NP (NNP Doc_12464714_739_750_Chemical)))))) (CC and) (NP (NP (CD 54.2) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD preferred) (NP (NN Doc_12464714_787_797_Chemical/Doc_12464714_798_806_Chemical))))))))))))) (. .)))
12464714	5	(S1 (S (NP (NP (DT The) (JJ co-primary) (NN endpoint)) (PP (IN of) (S (VP (AUXG being) (ADJP (NNP Doc_12464714_841_845_Disease) (JJ free))))) (PP (IN at) (NP (CD 2) (NNP h)))) (VP (AUX was) (ADVP (RB also)) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NNP Doc_12464714_879_890_Chemical)))))) (. .)))
12464714	6	(S1 (S (NP (NP (JJ Forty-nine) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (ADJP (NNP Doc_12464714_928_932_Disease) (JJ free)) (NP (CD 2) (NNP h)) (PP (IN after) (NP (NNP Doc_12464714_948_959_Chemical))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 24.3) (NN %)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_12464714_994_1004_Chemical/Doc_12464714_1005_1013_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12464714_1032_1043_Chemical)) (VP (AUXG being) (ADJP (JJ superior)) (PP (IN within) (NP (NP (CD 1) (NNP h)) (PP (IN of) (NP (NN treatment)))))))))))))) (. .)))
12464714	7	(S1 (S (NP (NP (JJ Doc_12464714_1084_1092_Disease) (NN relief)) (PP (IN at) (NP (CD 2) (NNP h)))) (VP (AUX was) (NP (NP (NP (CD 75.9) (NN %)) (PP (IN for) (NP (NNP Doc_12464714_1121_1132_Chemical)))) (CC and) (NP (NP (CD 47.3) (NN %)) (PP (IN for) (NP (NP (NNP Doc_12464714_1147_1157_Chemical/Doc_12464714_1158_1166_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-)))))) (, ,) (PP (IN with) (S (NP (NNP Doc_12464714_1190_1201_Chemical)) (VP (AUXG being) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_12464714_1220_1230_Chemical/Doc_12464714_1231_1239_Chemical)))) (PP (IN within) (NP (NP (CD 30) (NN min)) (PP (IN of) (NP (NN dosing))))))))) (. .)))
12464714	8	(S1 (S (NP (NP (QP (RB Almost) (CD 36)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNP Doc_12464714_1295_1306_Chemical)))))) (VP (VP (AUX were) (ADJP (NNP Doc_12464714_1312_1316_Disease) (JJ free)) (PP (IN at) (NP (CD 2) (NNP h)))) (CC and) (VP (AUX had) (NP (NP (DT no) (NN recurrence) (CC or) (NN need)) (PP (IN for) (NP (NP (JJ additional) (NN medication)) (PP (IN within) (NP (CD 24)))))) (NP (NNP h))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NNP Doc_12464714_1429_1439_Chemical/Doc_12464714_1440_1448_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-)))))))))) (. .)))
12464714	9	(S1 (S (NP (NNP Doc_12464714_1467_1478_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_12464714_1500_1510_Chemical/Doc_12464714_1511_1519_Chemical)))) (PP (PP (IN in) (NP (NP (DT the) (NNS proportions)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (DT no) (NNP Doc_12464714_1559_1565_Disease) (, ,) (NNP Doc_12464714_1567_1575_Disease) (, ,) (NNP Doc_12464714_1577_1588_Disease) (CC or) (NNP Doc_12464714_1592_1603_Disease))))))) (CC and) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ normal) (NN function)) (, 2) (NP (NP (NP (NNP h)) (PP (IN after) (NP (NN drug) (NN intake)))) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-))))))))) (. .)))
12464714	10	(S1 (S (NP (JJR More) (NNS patients)) (VP (AUX were) (PRN (-LRB- -LRB-) (ADVP (RB completely)) (, ,) (ADVP (RB very) (CC or) (RB somewhat)) (-RRB- -RRB-)) (VP (VBN satisfied) (NP (CD 2) (NNP h)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12464714_1767_1778_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 69.8) (NN %)) (-RRB- -RRB-)))) (PP (IN than) (PP (IN at) (NP (NP (CD 2) (NNP h)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12464714_1820_1830_Chemical/Doc_12464714_1831_1839_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 38.6) (NN %)) (, ,) (NP (JJ p) (NNS <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
12464714	11	(S1 (S (NP (NN Recurrence) (NNS rates)) (VP (AUX were) (NP (NP (NP (CD 31.4) (NN %)) (PP (IN with) (NP (NNP Doc_12464714_1898_1909_Chemical)))) (CC and) (NP (NP (CD 15.3) (NN %)) (PP (IN with) (NP (NNP Doc_12464714_1925_1935_Chemical/Doc_12464714_1936_1944_Chemical)))))) (. .)))
12464714	12	(S1 (S (NP (DT Both) (JJ active) (NNS treatments)) (VP (AUX were) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
12464714	13	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS events)) (-LRB- -LRB-) (NP (NN incidence)) (VP (VBZ >) (CC or) (SYM =) (NP (NP (CD 5) (NN %)) (PP (IN in) (NP (CD one) (NN group)))) (-RRB- -RRB-) (SBAR (S (PP (IN after) (NP (NNP Doc_12464714_2062_2073_Chemical) (CC and) (NNP Doc_12464714_2078_2088_Chemical/Doc_12464714_2089_2097_Chemical))) (, ,) (ADVP (RB respectively)) (, ,) (VP (AUX were) (NP (NP (NNP Doc_12464714_2118_2127_Disease) (PRN (-LRB- -LRB-) (NP (CD 6.7) (CC and) (CD 5.3) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_12464714_2144_2150_Disease) (PRN (-LRB- -LRB-) (NP (CD 4.2) (CC and) (CD 8.5) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12464714_2170_2180_Disease) (PRN (-LRB- -LRB-) (NP (QP (CD 5.5) (CC and) (CD 2.3)) (NN %)) (-RRB- -RRB-)))))))) (. .)))
12483326	0	(S1 (NP (NP (JJ Severe) (NN Doc_12483326_7_34_Disease)) (PP (IN after) (NP (NP (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_67_78_Chemical))))) (PP (IN for) (NP (NN recurrent) (NN Doc_12483326_93_106_Disease))) (. .)))
12483326	1	(S1 (S (NP (NN Doc_12483326_120_132_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_12483326_138_153_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ occurs) (PP (IN in) (NP (DT the) (NN cerebrum))) (PP (IN during) (NP (NN adulthood)))))))) (. .)))
12483326	2	(S1 (S (PP (IN With) (NP (NP (JJ current) (NN treatment) (NNS regimens)) (PP (VBG including) (NP (NP (JJ combined) (NN surgery)) (, ,) (NP (NN radiation)) (CC and) (NP (NN chemotherapy)))))) (, ,) (NP (NP (DT the) (JJ average) (NN life) (NN expectancy)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX is) (VP (VBN limited) (PP (TO to) (NP (QP (RB approximately) (CD 1)) (NN year))))) (. .)))
12483326	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12483326_393_405_Disease)))) (ADVP (RB sometimes)) (VP (AUX have) (S (NP (NP (NN intracarotid) (NN injection)) (PP (IN of) (NP (NNS carcinostatics)))) (VP (VBN added) (PP (TO to) (NP (DT the) (NN treatment) (NN regimen)))))) (. .)))
12483326	4	(S1 (S (ADVP (RB Generally)) (, ,) (NP (NNP Doc_12483326_505_516_Chemical)) (VP (AUX is) (VP (VBN said) (S (VP (TO to) (VP (AUX have) (NP (NN milder) (NN side) (NNS effects)) (PP (IN than) (NP (NP (NNP Doc_12483326_558_567_Chemical)) (, ,) (SBAR (WHNP (WP$ whose) (NN Doc_12483326_575_602_Disease)) (S (VP (AUX are) (VP (ADVP (RB well)) (VBN known)))))))))))) (. .)))
12483326	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBD experienced) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ severe) (NN Doc_12483326_660_687_Disease)))) (PP (IN after) (NP (NP (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_720_731_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB infrequently)) (VP (VBN reported)))))))) (. .)))
12483326	6	(S1 (S (NP (DT A) (JJ 58-year-old) (NN man)) (VP (VBD received) (NP (NP (DT an) (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_827_838_Chemical))) (PP (IN for) (NP (NP (JJ recurrent) (NN Doc_12483326_853_866_Disease)) (PP (IN in) (NP (PRP$ his) (JJ left) (JJ temporal) (NN lobe))))))) (. .)))
12483326	7	(S1 (S (NP (PRP He)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_12483326_911_961_Disease) (CD 30))) (NP (NNP h)) (PP (IN after) (NP (DT the) (NN injection)))) (. .)))
12483326	8	(S1 (S (NP (NP (NP (JJ Various) (JJ ocular) (NNS symptoms)) (CC and) (NP (NNS findings))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_12483326_1035_1046_Chemical) (NNP Doc_12483326_1047_1055_Disease))))) (VP (AUX were) (VP (VBN seen))) (. .)))
12483326	9	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNS corticosteroids)))) (CC and) (NP (NP (NNP Doc_12483326_1146_1154_Chemical)) (PP (IN for) (NP (CD 6) (NN days)))))) (PP (IN after) (NP (DT the) (NN injection))))) (. .)))
12483326	10	(S1 (S (SBAR (IN Although) (S (S (NP (NP (DT the) (JJ intraocular) (NN pressure) (NN elevation)) (VP (VBN caused) (PP (IN by) (NP (JJ secondary) (JJ acute) (NN angle-closure) (NN Doc_12483326_1271_1279_Disease))))) (VP (VBD decreased))) (CC and) (S (NP (NNP Doc_12483326_1294_1305_Disease)) (VP (VBD diminished))))) (, ,) (NP (NP (JJ inexorable) (NNP Doc_12483326_1329_1340_Disease)) (CC and) (NP (JJ exudative) (NNP Doc_12483326_1355_1373_Disease))) (VP (VBD continued) (PP (IN for) (NP (CD 3) (NNS weeks)))) (. .)))
12483326	11	(S1 (S (ADVP (RB Finally)) (, ,) (ADVP (NP (CD 6) (NNS weeks)) (RB later)) (, ,) (S (NP (NP (NN diffuse) (NN Doc_12483326_1429_1450_Disease)) (PP (IN with) (NP (NNP Doc_12483326_1456_1469_Disease)))) (VP (VBD occurred))) (CC and) (S (NP (NP (DT the) (NN vision)) (PP (IN in) (NP (PRP$ his) (JJ left) (NN eye)))) (VP (AUX was) (VP (VBN lost)))) (. .)))
12483326	12	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG performing) (NP (NP (NN intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_1574_1585_Chemical))))))) (, ,) (NP (PRP we)) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (PRP$ its) (ADJP (RB potentially) (JJ blinding)) (NN Doc_12483326_1632_1647_Disease)))))) (. .)))
12483326	13	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (JJ further) (NNS studies)) (CC and) (NP (NNS investigations))) (VP (AUX are) (VP (VBN undertaken) (PP (IN in) (NP (DT the) (NN effort) (S (VP (TO to) (VP (VB minimize) (NP (JJ such) (JJ severe) (NN side) (NNS effects))))))))))))) (. .)))
12523465	0	(S1 (S (NP (NN Doc_12523465_0_21_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12523465_38_48_Chemical)))) (. .)))
12523465	1	(S1 (S (NP (NN Doc_12523465_50_60_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ broad-spectrum) (JJ antiepileptic) (NN drug)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NN Doc_12523465_131_139_Disease)))))))))) (. .)))
12523465	2	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_12523465_150_171_Disease)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN of) (NP (DT this) (NN agent)))))))))) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (CD three) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD experienced) (NP (JJ complex) (NN Doc_12523465_282_303_Disease))) (CC and) (VP (VBD altered) (NP (JJ mental) (NN status)) (SBAR (IN after) (S (S (NP (JJ Doc_12523465_336_346_Chemical) (NN treatment)) (VP (AUX was) (VP (VBN begun)))) (CC or) (S (NP (PRP$ its) (NN dosage)) (VP (VBD increased))))))))))) (. .)))
12523465	3	(S1 (S (S (NP (DT All) (CD three)) (VP (AUX had) (VP (AUX been) (VP (VBN diagnosed) (ADVP (RB earlier)) (PP (IN with) (NP (NNP Doc_12523465_434_442_Disease))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN electroencephalogram) (PRN (-LRB- -LRB-) (NP (NNP EEG)) (-RRB- -RRB-)) (NNS findings)) (VP (AUX were) (ADJP (JJ abnormal)))) (. .)))
12523465	4	(S1 (S (PP (IN During) (NP (NN monitoring))) (, ,) (NP (NNP Doc_12523465_524_545_Disease)) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NNP EEG) (NNS readings))) (, ,) (SBAR (SINV (CC nor) (AUX did) (NP (NN video) (NN recording)) (VP (VB capture) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (VBN described) (NNS events))))))))) (. .)))
12523465	5	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (VP (VBN experienced) (NP (NNP Doc_12523465_681_702_Disease)) (PP (IN before) (NP (DT this) (NN event))))) (. .)))
12523465	6	(S1 (S (NP (NP (DT The) (JJ only) (JJ recent) (NN change)) (PP (IN in) (NP (PRP$ their) (NN treatment)))) (VP (AUX was) (NP (NP (DT the) (NN introduction)) (CC or) (NP (NP (VBN increased) (NN dosage)) (PP (IN of) (NP (NNP Doc_12523465_808_818_Chemical)))))) (. .)))
12523465	7	(S1 (S (PP (IN With) (NP (CC either) (NP (NN discontinuation)) (CC or) (NP (NP (VBN decreased) (NN dosage)) (PP (IN of) (NP (DT the) (NN drug)))))) (NP (DT the) (NNS symptoms)) (VP (VP (VBD disappeared)) (CC and) (VP (AUX did) (RB not) (VP (VB recur)))) (. .)))
12523465	8	(S1 (S (NP (NP (JJ Further) (NNS observations)) (CC and) (NP (NNS reports))) (VP (MD will) (VP (VB help) (S (VP (VB clarify) (NP (DT this) (JJ adverse) (NN effect)))))) (. .)))
12523465	9	(S1 (S (PP (IN Until) (NP (RB then))) (, ,) (NP (NNS clinicians)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT this) (JJ possible) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_12523465_1082_1092_Chemical))))))))))) (. .)))
12536034	0	(S1 (NP (JJ Anti-Doc_12536034_5_14_Disease) (JJ drugs-induced) (FW de) (FW novo) (FW Doc_12536034_37_53_Disease) (. .)))
12536034	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (CD three) (NNS patients)) (PP (IN with) (NP (FW de) (FW novo) (NNP Doc_12536034_103_119_Disease)))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_12536034_144_157_Chemical)) (CC and) (NP (NNP Doc_12536034_162_172_Chemical))))))) (. .)))
12536034	2	(S1 (S (PP (IN Despite) (NP (DT the) (JJ underlying) (NNS diseases))) (, ,) (NP (NP (DT the) (NN prognosis)) (PP (IN for) (NP (JJ drug-induced) (JJ de) (NN novo) (NN Doc_12536034_246_261_Disease)))) (VP (AUX is) (ADJP (JJ good)) (SBAR (IN because) (S (NP (PRP it)) (VP (NNS subsides) (ADVP (RB rapidly)) (PP (IN after) (S (VP (VBG discontinuing) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (VBG offending) (NNS drugs))))))))))) (. .)))
12536034	3	(S1 (S (NP (DT The) (JJ Doc_12536034_354_377_Chemical-transmitted) (JJ thalamocortical) (NN circuitry)) (VP (VBZ accounts) (PP (IN for) (NP (NP (DT a) (JJ major) (NN part)) (PP (IN of) (NP (NP (DT the) (JJ underlying) (NN neurophysiology)) (PP (IN of) (NP (DT the) (NNP Doc_12536034_483_499_Disease)))))))) (. .)))
12536034	4	(S1 (S (SBAR (IN Because) (S (NP (JJ drug-induced) (JJ de) (NN novo) (NN Doc_12536034_530_545_Disease)) (VP (AUX is) (ADJP (JJ rare))))) (, ,) (NP (JJ pro-absence) (NNS drugs)) (VP (MD can) (ADVP (RB only)) (VP (AUX be) (VP (VBN considered) (NP (DT a) (VBG promoting) (NN factor))))) (. .)))
12536034	5	(S1 (S (NP (NP (NP (DT The) (JJ underlying) (NN epileptogenecity)) (PP (IN of) (NP (DT the) (NNS patients)))) (CC or) (NP (NP (DT the) (JJ synergistic) (NNS effects)) (PP (IN of) (NP (DT the) (JJ accompanying) (NNS drugs))))) (VP (AUX is) (VP (VBN required) (S (VP (TO to) (VP (VB trigger) (NP (DT the) (JJ de) (NN novo) (NN Doc_12536034_752_767_Disease))))))) (. .)))
12536034	6	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ drug-induced) (NN aggravation)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB whenever)) (S (NP (NP (DT an) (JJ unexpected) (NN increase)) (PP (IN in) (NP (NNP Doc_12536034_869_876_Disease) (NN frequency) (NN and/or) (JJ new) (NN Doc_12536034_898_905_Disease) (NNS types)))) (VP (VBP appear) (PP (VBG following) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN drug) (NN treatment))))))))))) (. .)))
12536034	7	(S1 (S (PP (IN By) (S (VP (VBG understanding) (NP (NP (DT the) (JJ underlying) (NN mechanism)) (PP (IN of) (NP (NNP Doc_12536034_1002_1018_Disease))))))) (, ,) (NP (PRP we)) (VP (MD can) (VP (VP (VB avoid) (NP (NP (DT the) (JJ inappropriate) (NN use)) (PP (IN of) (NP (NNS anticonvulsants))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_12536034_1091_1099_Disease))))))) (CC and) (VP (VB prevent) (NP (JJ drug-induced) (NN Doc_12536034_1125_1141_Disease))))) (. .)))
12574103	0	(S1 (NP (NP (JJ Prenatal) (JJ Doc_12574103_9_22_Chemical) (NNS programs)) (NP (NP (NP (NNP Doc_12574103_32_44_Disease)) (CC and) (NP (NNP Doc_12574103_49_61_Disease))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
12574103	1	(S1 (S (NP (NN Dexamethasone)) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN administered) (PP (TO to) (NP (NP (DT the) (VBG developing) (NN fetus)) (SBAR (S (VP (TO to) (VP (VB accelerate) (NP (JJ pulmonary) (NN development)))))))))) (. .)))
12574103	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (JJ prenatal) (NNP Doc_12574103_238_251_Chemical)) (VP (VBN programmed) (NP (NP (DT a) (JJ progressive) (NN Doc_12574103_277_303_Disease)) (CC and) (NP (NP (NNP Doc_12574103_308_320_Disease)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12574103	3	(S1 (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN given) (NP (DT either) (NN vehicle) (CC or) (NP (NP (CD 2) (JJ daily) (JJ intraperitoneal) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_12574103_411_424_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.2) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ gestational) (NNS days) (CD 11) (CC and) (CD 12) (, ,) (CD 13) (CC and) (CD 14) (, ,) (CD 15) (CC and) (CD 16) (, ,) (CD 17) (CC and) (CD 18)))) (, ,) (CC or) (NP (CD 19) (CC and) (CD 20))))) (. .)))
12574103	4	(S1 (S (NP (NP (NN Offspring)) (PP (IN of) (NP (NNS rats)))) (VP (VBN administered) (NP (NNP Doc_12574103_558_571_Chemical)) (PP (IN on) (NP (NP (NNS days)) (SBAR (S (NP (QP (CD 15) (CC and) (CD 16)) (NN gestation)) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 20) (NN %)) (NN Doc_12574103_610_640_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (NN control)) (PP (IN at) (NP (NP (QP (CD 6) (TO to) (CD 9)) (NNS months)) (PP (IN of) (NP (NN age))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 22) (CD 527+/-509))) (CC versus) (NP (QP (CD 28) (CD 050+/-561)))) (, ,) (NP (NNP P<0.05))) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT the) (NN percent) (NN reduction)) (PP (IN in) (NP (NP (NNS glomeruli)) (VP (VBN measured) (PP (IN at) (NP (NP (CD 3) (NNS weeks)) (PP (IN of) (NP (NN age)))))))))))))))))))))))))) (. .)))
12574103	5	(S1 (S (NP (NP (NNS Six-)) (PP (TO to) (NP (NP (JJ 9-month) (JJ old) (NNS rats)) (VP (VBG receiving) (NP (JJ prenatal) (NNP Doc_12574103_862_875_Chemical)) (PP (IN on) (NP (NP (NNS days) (CD 17) (CC and) (CD 18)) (PP (IN of) (NP (NN gestation))))))))) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 17) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (NNS glomeruli)) (PRN (-LRB- -LRB-) (NP (CD 23) (CD 380+/-587)) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)))))) (. .)))
12574103	6	(S1 (S (S (NP (NP (NP (JJ Male) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (JJ prenatal) (NNP Doc_12574103_1025_1038_Chemical)) (PP (IN on) (NP (NNS days) (CD 15) (CC and) (CD 16) (, ,) (CD 17) (CC and) (CD 18))))))) (, ,) (CC and) (NP (NP (CD 13) (CC and) (CD 14)) (PP (IN of) (NP (NN gestation))))) (VP (AUX had) (NP (NNP Doc_12574103_1100_1124_Disease)) (PP (IN at) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (NN age))))))) (: ;) (S (NP (DT the) (JJ latter) (NN group)) (VP (AUX did) (RB not) (VP (AUX have) (NP (DT a) (NNP Doc_12574103_1177_1207_Disease))))) (. .)))
12574103	7	(S1 (S (NP (NP (NN Adult) (NNS rats)) (VP (VBN given) (NP (NNP Doc_12574103_1226_1239_Chemical)) (PP (IN on) (NP (NP (NNS days) (CD 15) (CC and) (CD 16)) (PP (IN of) (NP (NN gestation))))))) (VP (AUX had) (ADJP (ADJP (RBR more) (JJ glomeruli)) (PP (IN with) (NP (NNP Doc_12574103_1295_1313_Disease))) (PP (IN than) (NP (NN control) (NNS rats))))) (. .)))
12574103	8	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (JJ prenatal) (NN Doc_12574103_1364_1377_Chemical)) (PP (IN in) (NP (NNS rats)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (NNP Doc_12574103_1399_1429_Disease)) (, ,) (NP (NNP Doc_12574103_1431_1449_Disease)) (, ,) (CC and) (NP (NNP Doc_12574103_1455_1467_Disease)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN at) (NP (NP (JJ specific) (NNS points)) (PP (IN during) (NP (NN gestation)))))))))))) (. .)))
12574103	9	(S1 (S (NP (NN Doc_12574103_1523_1535_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (NP (NP (DT a) (NN reduction)) (PP (PP (IN in) (NP (NNS glomeruli))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT a) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (DT a) (NN Doc_12574103_1636_1666_Disease)))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT a) (NN Doc_12574103_1686_1716_Disease)) (VP (AUX is) (RB not) (NP (NP (DT the) (JJ sole) (NN cause)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12574103_1762_1774_Disease)))))))))))))))))) (. .)))
12584269	0	(S1 (NP (NP (NP (NN Kidney) (NN function)) (CC and) (NP (NN morphology))) (PP (IN after) (NP (NP (JJ short-term) (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_12584269_73_87_Chemical)) (, ,) (NP (NNP Doc_12584269_89_99_Chemical)) (CC and) (NP (NNP Doc_12584269_104_113_Chemical)))) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
12584269	1	(S1 (S (NP (NP (NNP Doc_12584269_138_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_149_152_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (VB supplement) (NP (NN calcineurin) (NNS inhibitors)) (PP (IN in) (NP (JJ clinical) (NN organ) (NN transplantation))))) (. .)))
12584269	2	(S1 (S (S (NP (DT These)) (VP (AUX are) (ADJP (JJ Doc_12584269_237_248_Disease)))) (, ,) (CC but) (S (NP (NNP Doc_12584269_254_257_Chemical)) (VP (VBZ seems) (S (VP (TO to) (VP (VB act) (ADVP (RB differently)) (S (VP (VBG displaying) (NP (ADJP (RB only) (JJ minor)) (JJ Doc_12584269_305_316_Disease) (NNS effects))))))) (, ,) (SBAR (IN although) (S (NP (DT this) (NN question)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ open))))))) (. .)))
12584269	3	(S1 (S (PP (IN In) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NN treatment) (NNS protocols))) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_12584269_405_408_Chemical)) (VP (AUX was) (VP (VBN combined) (PP (IN with) (NP (DT a) (JJ calcineurin) (NN inhibitor))))))))) (NP (NP (NNS indications)) (PP (IN of) (NP (DT a) (JJ synergistic) (NN Doc_12584269_480_491_Disease) (NN effect)))) (VP (AUX were) (VP (VBN described))) (. .)))
12584269	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (ADVP (RB further)) (NP (NP (DT the) (JJ renal) (NN function)) (, ,) (PP (VBG including) (NP (NP (JJ morphological) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS kidneys)) (PP (IN of) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_12584269_676_690_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_692_695_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12584269_698_708_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_710_715_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_12584269_720_723_Chemical)))) (PP (PP (IN as) (NP (NNS monotherapies))) (CC or) (PP (IN in) (NP (JJ different) (NNS combinations)))))))))))))))) (. .)))
12584269	5	(S1 (S (PP (IN For) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 2) (NNS weeks))))) (, ,) (NP (NP (NNP Doc_12584269_805_808_Chemical) (CD 15) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB orally))) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_12584269_838_843_Chemical) (CD 3.0) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB orally))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12584269_876_879_Chemical) (CD 0.4) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB intraperitoneally))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN administered) (PP (IN once) (NP (DT a) (NN day))) (SBAR (IN as) (S (NP (DT these) (NNS doses)) (VP (AUX have) (ADVP (RB earlier)) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT a) (JJ significant) (JJ immunosuppressive) (NN effect)) (PP (IN in) (NP (NNP Sprague-Dawley) (NNS rats)))))))))))))) (. .)))
12584269	6	(S1 (S (PP (IN In) (NP (DT the))) (: ') (NP (JJ conscious) (JJ catheterized) (NN rat) ('' ') (NN model)) (, ,) (NP (NP (DT the) (JJ glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN GFR)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN as) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNP Cr)) (PRN (-LRB- -LRB-) (NP (NNP EDTA)) (-RRB- -RRB-)))))))) (. .)))
12584269	7	(S1 (S (NP (NP (DT The) (JJ morphological) (NN analysis)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (VBD included) (NP (NP (DT a) (JJ semi-quantitative) (NN scoring) (NN system)) (VP (VBG analysing) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (JJ striped) (NNP Doc_12584269_1302_1310_Disease)) (, ,) (NP (JJ subcapsular) (NNP Doc_12584269_1324_1332_Disease)) (CC and) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ basophilic) (NNS tubules))))))) (, ,) (CC plus) (NP (NP (DT an) (JJ additional) (JJ stereological) (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN grade)) (PP (IN of) (NP (NNP Doc_12584269_1435_1443_Disease))))))) (PP (IN in) (NP (NP (DT the) (NN cortex)) (VP (VBN stained) (PP (IN with) (NP (NNP Sirius) (NNP Red))))))))) (. .)))
12584269	8	(S1 (S (NP (NP (NNP Doc_12584269_1492_1495_Chemical)) (, ,) (NP (NNP Doc_12584269_1497_1502_Chemical)) (CC and) (NP (NNP Doc_12584269_1507_1510_Chemical))) (VP (ADVP (DT all) (RB significantly)) (VBD decreased) (NP (DT the) (NN GFR))) (. .)))
12584269	9	(S1 (S (NP (DT A) (JJ further) (NN deterioration)) (VP (AUX was) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12584269_1586_1589_Chemical)) (VP (AUX was) (VP (VBN combined) (PP (IN with) (NP (DT either) (NNP Doc_12584269_1615_1620_Chemical) (CC or) (NNP Doc_12584269_1624_1627_Chemical))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN GFR)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12584269_1690_1695_Chemical)) (CC plus) (NP (NNP Doc_12584269_1701_1704_Chemical))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN treatment))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ single) (NNS substances))))))))))))) (. .)))
12584269	10	(S1 (S (NP (DT The) (JJ morphological) (NNS changes)) (VP (VBD presented) (NP (DT a) (JJ similar) (NN pattern))) (. .)))
12584269	11	(S1 (S (S (NP (DT The) (JJ semi-quantitative) (NN scoring)) (VP (AUX was) (ADJP (RB significantly) (JJS worst)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12584269_1904_1907_Chemical) (CC plus) (NNP Doc_12584269_1913_1916_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP P<0.001)) (VP (VBN compared) (PP (IN with) (NP (NNS controls))))) (-RRB- -RRB-))))))))) (CC and) (S (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN grade)) (PP (IN of) (NP (NNP Doc_12584269_1989_1997_Disease)))))) (ADVP (RB also)) (VP (VP (VBD showed) (NP (DT the) (JJS highest) (NN proportion)) (PP (IN in) (NP (DT the) (JJ same) (NN group)))) (CC and) (VP (AUX was) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P<0.02)) (-RRB- -RRB-)))))))) (. .)))
12584269	12	(S1 (S (NP (DT The) (NNP Doc_12584269_2111_2116_Chemical) (CC plus) (NNP Doc_12584269_2122_2125_Chemical) (NN combination)) (VP (VBD showed) (NP (NP (RB only) (DT a) (ADJP (RB marginally) (JJR higher)) (NN degree)) (PP (IN of) (NP (NNP Doc_12584269_2180_2188_Disease)))) (ADVP (RB as)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.05)) (-RRB- -RRB-)))))) (. .)))
12584269	13	(S1 (S (NP (DT This) (NN rat) (NN study)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ synergistic) (JJ Doc_12584269_2279_2290_Disease) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_12584269_2301_2304_Chemical)) (CC plus) (NP (NNP Doc_12584269_2310_2313_Chemical))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_12584269_2323_2328_Chemical) (CC plus) (NNP Doc_12584269_2334_2337_Chemical)) (VP (AUX was) (ADVP (RB better)) (VP (VBN tolerated)))))) (. .)))
12589964	0	(S1 (NP (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (JJ cardiac) (NN troponin) (NN I) (CC and) (NN T) (NNS levels)) (PP (IN as) (NP (NP (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_60_77_Disease))))) (PP (IN in) (NP (JJ Doc_12589964_81_92_Chemical-induced) (NNP Doc_12589964_101_115_Disease) (NNS rats)))))) (, ,) (CC and) (NP (NP (PRP$ their) (NN relationship)) (PP (IN with) (NP (JJ echocardiographic) (CC and) (JJ histological) (NNS findings)))) (. .)))
12589964	1	(S1 (S (NP (NP (NP (NP (JJ Cardiac) (NNS troponins)) (NP (PRP I))) (PRN (-LRB- -LRB-) (NNS cTnI) (-RRB- -RRB-))) (CC and) (NP (NP (NNS T)) (PRN (-LRB- -LRB-) (NP (NN cTnT)) (-RRB- -RRB-)))) (VP (AUX have) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (UCP (ADJP (RB highly) (JJ sensitive)) (CC and) (NP (NP (JJ specific) (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_310_332_Disease))))))))))) (. .)))
12589964	2	(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (JJ diagnostic) (NN value)) (PP (IN of) (NP (NN cTnI) (CC and) (NN cTnT)))) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_12589964_409_426_Disease))))) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NNP Doc_12589964_445_456_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12589964_458_461_Chemical)) (-RRB- -RRB-)))))) (NP (JJ -induced) (NNP Doc_12589964_471_485_Disease)))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ serial) (NNS cTnI)) (CC and) (NP (NN cTnT)))) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12589964_573_590_Disease))) (VP (VBN monitored) (PP (IN by) (NP (NP (JJ echocardiography) (CC and) (JJ histological) (NNS examinations)) (PP (IN in) (NP (DT this) (NN model))))))))))) (. .)))
12589964	3	(S1 (S (NP (JJ Thirty-five) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN given) (NP (NP (CD 1.5) (NN mg/kg)) (ADJP (JJ Doc_12589964_720_723_Chemical) (, ,) (JJ i.v.) (, ,) (JJ weekly))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 8)) (NNS weeks))) (PP (IN for) (NP (NP (DT a) (JJ total) (JJ cumulative) (NN dose)) (PP (IN of) (NP (CD 12) (JJ mg/kg) (NNS BW))))))) (. .)))
12589964	4	(S1 (S (NP (CD Ten) (NNS rats)) (VP (VBD received) (NP (NN saline)) (PP (IN as) (NP (DT a) (NN control) (NN group)))) (. .)))
12589964	5	(S1 (S (NP (NNP cTnI)) (VP (AUX was) (VP (VBN measured) (PP (PP (IN with) (NP (NP (NP (NN Access)) (PRN (-LRB- -LRB-) (NP (NN R)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NN ng/ml)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (NN research) (NN immunoassay)) (PRN (-LRB- -LRB-) (NP (NN pg/ml)) (-RRB- -RRB-))))) (, ,) (CC and) (PP (VBN compared) (PP (IN with) (NP (JJ cTnT) (, ,) (JJ CK-MB) (NN mass) (CC and) (NN CK))))))) (. .)))
12589964	6	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (JJ transthoracic) (NN echocardiography))))) (, ,) (NP (NP (NNP anterior)) (CC and) (NP (NP (NP (NN posterior) (NN wall) (NN thickness)) (, ,) (NP (JJ LV) (NNS diameters)) (CC and) (NP (JJ LV) (JJ fractional) (NN shortening))) (PRN (-LRB- -LRB-) (NP (NNP FS)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT all) (NNS rats))) (SBAR (IN before) (S (UCP (ADJP (JJ Doc_12589964_1125_1128_Chemical) (CC or) (JJ saline)) (, ,) (CC and) (PP (IN at) (NP (NP (NNS weeks) (CD 6) (CC and) (CD 9)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN in) (NP (DT all) (VBG surviving) (NNS rats)))))))))))) (. .)))
12589964	7	(S1 (S (NP (NN Histology)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (NNP Doc_12589964_1227_1230_Chemical-rats))) (PP (IN at) (NP (NP (QP (CD 6) (CC and) (CD 9)) (NNS weeks)) (PP (PP (IN after) (NP (DT the) (JJ last) (JJ Doc_12589964_1268_1271_Chemical) (NN dose))) (CC and) (PP (IN in) (NP (DT all) (NNS controls)))))))) (. .)))
12589964	8	(S1 (S (NP (NP (CD Eighteen)) (PP (IN of) (NP (DT the) (JJ Doc_12589964_1323_1326_Chemical) (NNS rats)))) (VP (VBD died) (ADVP (RB prematurely)) (PP (IN of) (NP (JJ general) (NN Doc_12589964_1360_1368_Disease))) (PP (IN during) (NP (DT the) (JJ 9-week) (NN period)))) (. .)))
12589964	9	(S1 (S (NP (ADJP (ADJP (JJ End-diastolic)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)) (CC and) (ADJP (JJ end-systolic)) (PRN (-LRB- -LRB-) (JJ ES) (-RRB- -RRB-))) (NN LV) (NNS diameters/BW)) (VP (ADVP (RB significantly)) (VBD increased) (, ,) (SBAR (IN whereas) (S (NP (NNP LV) (NNP FS)) (VP (AUX was) (VP (VBN decreased) (PP (IN after) (NP (NP (NP (CD 9) (NNS weeks)) (PP (IN in) (NP (DT the) (NNP Doc_12589964_1526_1529_Chemical) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))))))))) (. .)))
12589964	10	(S1 (S (NP (DT These) (NNS parameters)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NNS controls)))) (. .)))
12589964	11	(S1 (S (NP (NP (JJ Histological) (NN evaluation)) (PP (IN of) (NP (NP (NNS hearts)) (PP (IN from) (NP (NP (DT all) (NNS rats)) (VP (VBN given) (NP (NNP Doc_12589964_1650_1653_Chemical)))))))) (VP (VBD revealed) (NP (NP (JJ significant) (JJ slight) (NNS degrees)) (PP (IN of) (NP (NP (NN perivascular)) (CC and) (NP (JJ interstitial) (NN Doc_12589964_1723_1731_Disease)))))) (. .)))
12589964	12	(S1 (S (PP (IN In) (NP (NP (CD 7)) (PP (IN of) (NP (DT the) (CD 18) (NNS rats))))) (, ,) (NP (NP (NN degeneration)) (CC and) (NP (NN myocyte) (NN vacuolisation))) (VP (AUX were) (VP (VBN found))) (. .)))
12589964	13	(S1 (S (NP (NP (RB Only) (CD five)) (PP (IN of) (NP (DT the) (NNS controls)))) (VP (VBD exhibited) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ very) (JJ slight) (NN perivascular) (NN Doc_12589964_1878_1886_Disease))))) (. .)))
12589964	14	(S1 (S (NP (NP (DT A) (JJ significant) (NN rise)) (PP (IN in) (NP (NN cTnT)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (JJ Doc_12589964_1928_1931_Chemical) (NNS rats))) (PP (IN after) (NP (NP (JJ cumulative) (NNS doses)) (PP (IN of) (NP (CD 7.5) (CC and) (CD 12))) (VP (VBN mg/kg) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NN baseline)) (PRN (-LRB- -LRB-) (NP (CD p<0.05)) (-RRB- -RRB-))))))))))) (. .)))
12589964	15	(S1 (S (NP (NN cTnT)) (VP (VBD found) (PP (IN in) (NP (NNS rats))) (SBAR (IN after) (S (NP (CD 12) (NNS mg/kg)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN than) (NP (NP (DT that)) (VP (VBN found) (PP (IN after) (NP (QP (CD 7.5) (CD mg/kg)) (NN Doc_12589964_2111_2114_Chemical))))))))))) (. .)))
12589964	16	(S1 (S (NP (NP (NP (JJ Maximal) (NNS cTnI)) (PRN (-LRB- -LRB-) (NP (NN pg/ml)) (-RRB- -RRB-))) (CC and) (NP (JJ cTnT) (NNS levels))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (JJ Doc_12589964_2185_2188_Chemical) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD p=0.006)) (, ,) (NP (CD 0.007)) (-RRB- -RRB-))))))) (. .)))
12589964	17	(S1 (S (NP (NP (NP (NNP cTnI)) (PRN (-LRB- -LRB-) (NP (NNP ng/ml)) (-RRB- -RRB-))) (, ,) (NP (NN CK-MB) (NN mass)) (CC and) (NP (NNP CK))) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NP (JJ Doc_12589964_2289_2292_Chemical) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NNS controls))))))) (. .)))
12589964	18	(S1 (S (NP (DT All) (NNS markers)) (VP (VBD remained) (ADJP (JJ stable)) (PP (IN in) (NP (NNS controls)))) (. .)))
12589964	19	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NNS data)))) (VP (VBD revealed) (NP (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP (NP (JJ maximal) (NN cTnT)) (CC and) (NP (NP (NNP ED) (CC and) (NNP ES) (NNP LV) (NNS diameters/BW)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD r=0.81)) (CC and) (NP (CD 0.65))) (: ;) (NP (CD p<0.0001))) (-RRB- -RRB-))))))) (. .)))
12589964	20	(S1 (S (NP (DT A) (JJ significant) (NN relationship)) (VP (AUX was) (VP (VBN observed) (PP (PP (IN between) (NP (NP (JJ maximal) (NN cTnT)) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ myocardial) (JJ morphological) (NNS changes)))))) (, ,) (CC and) (PP (IN between) (NP (NP (JJ LV) (NNS diameters/BW)) (CC and) (NP (JJ histological) (NNS findings))))))) (. .)))
12589964	21	(S1 (S (PP (IN Among) (NP (NP (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_2693_2708_Disease))))) (PP (IN after) (NP (NP (NNP Doc_12589964_2715_2718_Chemical)) (PP (IN in) (NP (NNS rats))))) (, ,) (NP (NN cTnT)) (VP (VBD showed) (NP (NP (DT the) (JJS greatest) (NN ability)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (NP (NN Doc_12589964_2771_2788_Disease)) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ echocardiographic) (NN detection)) (CC and) (NP (JJ histological) (NNS changes)))))))))))) (. .)))
12589964	22	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN discrepancy)) (PP (IN between) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN cTnI) (CC and) (NN cTnT)))))) (PP (IN after) (NP (NNP Doc_12589964_2930_2933_Chemical))) (, ,) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NP (NN heterogeneity)) (PP (IN in) (NP (NP (NNS cross-reactivities)) (PP (IN of) (NP (NP (NNS mAbs)) (PP (TO to) (NP (JJ various) (NNS cTnI) (CC and) (NN cTnT) (NNS forms))))))))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ likely) (SBAR (SBAR (IN that) (S (NP (NP (NN cTnT)) (PP (IN in) (NP (NNS rats))) (PP (IN after) (NP (NNP Doc_12589964_3064_3067_Chemical)))) (VP (VBZ indicates) (S (NP (NP (NN cell) (NN damage)) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NN injury))))))) (VP (VBN induced)))))) (CC and) (SBAR (IN that) (S (NP (NN cTnT)) (VP (MD should) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN marker)) (PP (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_12589964_3221_3235_Disease))))) (CC and) (PP (ADVP (RB possibly)) (IN for) (NP (JJ cardioprotective) (NNS experiments)))))))))))) (. .)))
12596116	0	(S1 (NP (NP (NP (JJ Doc_12596116_0_10_Chemical-induced) (NN Doc_12596116_19_28_Disease)) (CC and) (NP (NNP Doc_12596116_33_55_Disease))) (PP (IN in) (NP (JJ premature) (NNS neonates))) (. .)))
12596116	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP report) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NP (JJ premature) (NNS neonates)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ enterocutaneous) (JJ Doc_12596116_152_159_Disease) (NN complicating) (NN Doc_12596116_173_198_Disease))))))))) (. .)))
12596116	2	(S1 (S (NP (NN Doc_12596116_200_222_Disease)) (VP (VBD developed) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT a) (NN somatostatin) (NN analogue)) (, ,) (NP (NNP Doc_12596116_282_292_Chemical)) (, ,))))) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN resolution)) (PP (IN of) (NP (DT the) (NNP Doc_12596116_323_330_Disease)))))))) (. .)))
12596116	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VP (VB discuss) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT this) (NN complication))))))) (CC and) (VP (VB recommend) (NP (NP (NN caution)) (PP (IN of) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (JJ high-risk) (JJ premature) (NNS neonates)))))))) (. .)))
12615818	0	(S1 (NP (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_12_34_Disease))) (PP (IN in) (NP (NP (NNS women)) (VP (VBN prescribed) (NP (NNP Doc_12615818_55_74_Chemical)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_12615818_95_112_Chemical))))))))) (: :) (NP (NP (DT a) (JJ nested) (NN cohort) (NN analysis)) (CC and) (NP (JJ case-control) (NN study))) (. .)))
12615818	1	(S1 (S (NP (NP (NN Doc_12615818_175_194_Chemical)) (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_12615818_209_226_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_228_231_Chemical/Doc_12615818_232_234_Chemical)) (-RRB- -RRB-)))))) (VP (VP (AUX is) (VP (VBN licensed) (PP (IN in) (NP (DT the) (NNP UK))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_12615818_290_294_Disease)) (CC and) (NP (NNP Doc_12615818_299_308_Disease)))))))))) (CC and) (VP (AUX is) (ADVP (RB also)) (NP (NP (DT a) (NN treatment) (NN option)) (PP (IN for) (NP (NP (NNP Doc_12615818_344_369_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_371_375_Disease)) (-RRB- -RRB-))))))) (. .)))
12615818	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_12615818_434_456_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_458_461_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12615818_479_482_Chemical/Doc_12615818_483_485_Chemical))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ conventional) (JJ combined) (NNP Doc_12615818_522_541_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP COCs)) (-RRB- -RRB-))))))))) (. .)))
12615818	3	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT those) (NNS studies)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN affected) (PP (IN by) (NP (JJ residual) (NN confounding)))))))))) (. .)))
12615818	4	(S1 (S (S (VP (VBG Using) (NP (DT the) (JJ General) (NN Practice) (NN Research) (NN Database)))) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (JJ cohort) (NN analysis) (CC and) (NN case-control) (NN study)) (VP (VBN nested) (PP (IN within) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NP (NNS women)) (VP (VBN aged) (PP (IN between) (NP (CD 15) (CC and) (CD 39) (NNS years))) (PP (IN with) (NP (NNP Doc_12615818_816_820_Disease) (, ,) (NNP Doc_12615818_822_831_Disease) (CC or) (NNP Doc_12615818_835_839_Disease))) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_864_867_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12615818_884_887_Chemical/Doc_12615818_888_890_Chemical)))))))))))))))) (. .)))
12615818	5	(S1 (S (NP (NP (DT The) (JJ age-adjusted) (NN incidence) (NN rate) (NN ratio)) (PP (IN for) (NP (NNP Doc_12615818_943_946_Chemical/Doc_12615818_947_949_Chemical))) (PP (IN versus) (NP (JJ conventional) (NNS COCs)))) (VP (AUX was) (NP (NP (CD 2.20) (ADJP (CD -LSB-95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-)) (NP (CD 1.35-3.58) (NN -RSB-)))) (. .)))
12615818	6	(S1 (S (PP (VBG Using) (PP (IN as) (NP (NP (DT the) (NN reference) (NN group) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (VP (VBG using) (NP (JJ oral) (NN contraception))))))))) (, ,) (VP (AUX had) (NP (NP (DT no) (JJ recent) (NN pregnancy)) (CC or) (NP (JJ menopausal) (NNS symptoms))) (, ,) (S (NP (DT the) (JJ case-control) (NN analysis)) (VP (VBD gave) (NP (NP (NP (DT an) (JJ adjusted) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (CC OR) (-LRB- -LRB-) (CD adj) (-RRB- -RRB-) (-RRB- -RRB-)) (PP (IN of) (NP (CD 7.44)))) (-LRB- -LRB-) (NP (CD 95) (NN %) (NNP CI) (CD 3.67-15.08)) (-RRB- -RRB-)) (PP (IN for) (NP (JJ Doc_12615818_1244_1247_Chemical/Doc_12615818_1248_1250_Chemical) (NN use))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT an)) (CC OR) (PRN (-LRB- -LRB-) (NP (NN adj)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 2.58)))))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (NN 1.60-4.18)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (JJ conventional) (NNS COCs)))))))) (. .)))
12615818	7	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_1392_1395_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12615818_1423_1426_Chemical/Doc_12615818_1427_1429_Chemical))))))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_12615818_1444_1448_Disease)) (, ,) (NP (NNP Doc_12615818_1450_1459_Disease)) (CC or) (NP (NNP Doc_12615818_1463_1467_Disease)))))) (SBAR (IN although) (S (NP (NP (JJ residual) (NN confounding)) (PP (IN by) (NP (NN indication) (NN cannot)))) (VP (AUX be) (VP (VBN excluded))))))) (. .)))
12617329	0	(S1 (NP (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_12617329_29_39_Chemical))) (PP (IN on) (NP (NP (NNP Doc_12617329_43_53_Chemical) (NNP Doc_12617329_54_68_Disease)) (PP (IN in) (NP (NNS rats)))))) (: :) (NP (DT a) (JJ preliminary) (NN study)) (. .)))
12617329	1	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN work))) (NP (PRP we)) (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_12617329_168_178_Chemical))))))) (PP (IN on) (NP (NP (NNP Doc_12617329_182_201_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12617329_213_223_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12617329_225_227_Chemical)) (-RRB- -RRB-)) (NNP Doc_12617329_229_243_Disease)))))))) (. .)))
12617329	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 2) (CD mL/kg))) (PP (IN of) (NP (JJ distilled) (NN water)))) (CC and) (NP (NP (NP (CD 5) (NN %)) (NP (CD w/v) (NN cellulose))) (, ,) (NP (CD 10) (NNS days)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12617329_340_350_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN mL/kg)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 10) (NN %)) (JJ w/v) (JJ aqueous) (NN suspension)) (PP (IN of) (NP (NNP Doc_12617329_395_405_Chemical) (NNP powder))))) (, ,) (PP (ADVP (RB orally)) (IN for) (NP (CD 10) (NNS days)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_12617329_438_448_Chemical)))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NNP Doc_12617329_468_470_Chemical))) (PRN (-LRB- -LRB-) (S (VP (VB 80mg/kg/day) (ADVP (RB intramuscularly)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ last) (CD six) (NNS days)) (PP (IN of) (NP (DT the) (NN treatment) (NN period))))))) (-RRB- -RRB-)))) (. .)))
12617329	3	(S1 (S (NP (NN Doc_12617329_552_566_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (PP (IN by) (S (VP (VBG measuring) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_12617329_615_625_Chemical) (CC and) (NNP Doc_12617329_630_634_Chemical)) (PP (IN in) (NP (DT the) (NN plasma)))) (CC and) (NP (NP (JJ reduced) (NNP Doc_12617329_661_672_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12617329_674_677_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN kidney) (NN cortex))))))) (, ,) (CC and) (PP (IN by) (NP (NP (JJ light) (JJ microscopic) (NN examination)) (PP (IN of) (NP (NN kidney) (NNS sections)))))))) (. .)))
12617329	4	(S1 (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_12617329_812_822_Chemical) (CC and) (NNP Doc_12617329_827_829_Chemical)))) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NNP Doc_12617329_854_864_Chemical) (CC and) (NNP Doc_12617329_869_873_Chemical)) (PP (IN by) (NP (NP (QP (IN about) (CD 183) (CC and) (CD 239)) (NN %)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (TO to) (NP (QP (CD 432) (CC and) (CD 346)) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN in) (S (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NN cellulose)) (CC and) (NP (NNP Doc_12617329_986_988_Chemical)))))))) (-RRB- -RRB-))) (, ,) (CC and) (VP (VBD decreased) (NP (NP (DT that)) (PP (IN of) (NP (JJ cortical) (NNP Doc_12617329_1022_1025_Chemical)))) (PP (IN by) (NP (CD 21) (NN %))) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (TO to) (NP (CD 27) (NN %))) (PP (IN in) (NP (DT the) (NN cellulose) (CC plus) (JJ Doc_12617329_1072_1074_Chemical) (NN group)))) (-RRB- -RRB-)) (SBAR (S (NP (DT The) (JJ Doc_12617329_1086_1088_Chemical-induced) (JJ proximal) (NN Doc_12617329_1106_1122_Disease)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (RB slightly) (RBR less) (JJ severe)) (PP (IN in) (NP (NP (NP (NNS rats)) (VP (VBN given) (NP (NNP Doc_12617329_1173_1175_Chemical)) (ADVP (RB together)) (PP (IN with) (NP (NNP Doc_12617329_1190_1200_Chemical))) (PP (IN than) (PP (IN in) (NP (DT those) (VBN given) (NNP Doc_12617329_1221_1223_Chemical)))))) (CC and) (NP (NN cellulose))))))))))))))) (. .)))
12617329	5	(S1 (S (NP (PRP It)) (VP (MD could) (VP (AUX be) (VP (VBN inferred) (SBAR (IN that) (S (NP (JJ Doc_12617329_1265_1275_Chemical) (NN treatment)) (VP (AUX has) (VP (VBN induced) (NP (NP (DT a) (JJ modest) (NN amelioration)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ histological) (CC and) (JJ biochemical) (NNS indices)) (PP (IN of) (NP (NNP Doc_12617329_1375_1377_Chemical) (NNP Doc_12617329_1378_1392_Disease))))))))))))))) (. .)))
12617329	6	(S1 (S (NP (JJ Further) (NN work)) (VP (AUX is) (VP (VBN warranted) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NNS treatments))) (PP (PP (IN on) (NP (NP (JJ renal) (JJ functional) (NNS aspects)) (PP (IN in) (NP (NP (NNS models)) (PP (IN of) (NP (NNP Doc_12617329_1493_1514_Disease))))))) (, ,) (CC and) (PP (IN on) (NP (NP (DT the) (NN mechanism)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (VP (VBN involved))))))))) (. .)))
12627929	0	(S1 (NP (NP (VBN Increased) (NN frequency)) (PP (IN of) (NP (NNP Doc_12627929_23_45_Disease))) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_12627929_70_79_Chemical) (CC and) (NNP Doc_12627929_84_95_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ metastatic) (JJ androgen-independent) (NN Doc_12627929_145_160_Disease))))))))) (. .)))
12627929	1	(S1 (NP (NN STUDY) (NN OBJECTIVE) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NNP Doc_12627929_208_230_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12627929_232_235_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (JJ androgen-independent) (NN Doc_12627929_284_299_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12627929_322_331_Chemical)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_12627929_361_372_Chemical))))))))))))))))) (. .)))
12627929	2	(S1 (NP (NP (NN Retrospective) (NN analysis)) (PP (IN of) (NP (DT a) (VBN randomized) (NN phase) (NNP II) (NN trial))) (. .)))
12627929	3	(S1 (NP (NP (NNP National) (NNPS Institutes)) (PP (IN of) (NP (NNP Health) (JJ clinical) (NN research) (NN center))) (. .)))
12627929	4	(S1 (NP (NP (CD Seventy) (NNS men)) (, ,) (VP (VBN aged) (NP (CD 50-80) (NNS years))) (, ,) (PP (IN with) (NP (JJ advanced) (JJ androgen-independent) (NN Doc_12627929_578_593_Disease))) (. .)))
12627929	5	(S1 (S (NP (DT Each) (NN patient)) (VP (VBD received) (NP (DT either) (JJ intravenous) (JJ Doc_12627929_650_659_Chemical) (CD 30) (NN mg/m2/week)) (PP (IN for) (NP (CD 3) (JJ consecutive) (NNS weeks))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NP (CD 1) (NN week)) (ADJP (RB off))) (, ,) (CC or) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (JJ continuous) (JJ oral) (NNP Doc_12627929_761_772_Chemical) (CD 200) (NNS mg)))))) (NP (NP (DT every) (NN evening)) (PP (CC plus) (NP (DT the) (JJ same) (JJ Doc_12627929_808_817_Chemical) (NN regimen))))))) (. .)))
12627929	6	(S1 (S (NP (DT This) (JJ 4-week) (NN cycle)) (VP (AUX was) (VP (VBN repeated) (SBAR (IN until) (S (NP (EX there)) (VP (AUX was) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (JJ excessive) (NN Doc_12627929_896_904_Disease)) (CC or) (NP (NN disease) (NN progression)))))))))) (. .)))
12627929	7	(S1 (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (NP (NP (NN None)) (PP (IN of) (NP (NP (CD 23) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_12627929_993_1002_Chemical)) (ADVP (RB alone)) (VP (VBD developed) (NP (NNP Doc_12627929_1019_1022_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 9)) (PP (IN of) (NP (NP (NP (CD 47) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 19) (NN %)) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NNP Doc_12627929_1068_1077_Chemical)) (CC plus) (NP (NNP Doc_12627929_1083_1094_Chemical))))))))) (VP (VBD developed) (NP (NP (NNP Doc_12627929_1105_1108_Disease)) (PRN (-LRB- -LRB-) (NP (CD p=0.025)) (-RRB- -RRB-))))))))))))))) (. .)))
12627929	8	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NNP Doc_12627929_1148_1159_Chemical))) (PP (TO to) (NP (NNP Doc_12627929_1163_1172_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12627929_1193_1208_Disease)))))) (ADVP (RB significantly)) (VP (VBZ increases) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_12627929_1250_1253_Disease))))) (. .)))
12627929	9	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ potential) (NN complication)))) (SBAR (WHADVP (WRB when)) (S (VP (VBG adding) (NP (NN Doc_12627929_1325_1336_Chemical)) (PP (TO to) (NP (JJ chemotherapeutic) (NNS regimens)))))))) (. .)))
12639165	0	(S1 (NP (JJ Doc_12639165_0_11_Chemical-induced) (NN Doc_12639165_20_41_Disease) (. .)))
12639165	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB report) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_12639165_75_86_Chemical-induced) (NNP Doc_12639165_95_116_Disease))))) (, ,) (VP (VB investigate) (NP (PRP$ its) (NN mechanism))) (, ,) (CC and) (VP (VB compare) (NP (NP (DT the) (JJ observed) (JJ main) (NNS characteristics)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (VBN published) (NNS cases)))))))))) (. .)))
12639165	2	(S1 (NP (NP (NN CASE) (NNS SUMMARIES)) (: :) (NP (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ prolonged) (NNP Doc_12639165_275_296_Disease)) (PP (IN after) (S (VP (VBG receiving) (NP (NNP Doc_12639165_313_324_Chemical)) (PP (VBG following) (NP (JJ percutaneous) (JJ coronary) (NN angioplasty)))))) (, ,) (PP (IN with) (NP (JJ complete) (NN remission))) (PP (IN during) (NP (DT the) (JJ follow-up) (NN period))))) (. .)))
12639165	3	(S1 (S (NP (NP (JJ T-cell) (NN stimulation)) (PP (IN by) (NP (NP (JJ therapeutic) (NN concentration)) (PP (IN of) (NP (NNP Doc_12639165_474_485_Chemical)))))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN in) (NP (NN vitro))) (PP (IN in) (NP (DT the) (NNS patients))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (JJ healthy) (NNS controls)))))) (. .)))
12639165	4	(S1 (S (S (NP (NN Doc_12639165_570_591_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (DT the) (JJ antiplatelet) (NN agent) (NN Doc_12639165_641_652_Chemical)))))) (: ;) (S (NP (JJ several) (NNS cases)) (VP (AUX have) (VP (AUX been) (VP (VP (VBN reported)) (CC but) (VP (ADJP (JJ few)) (PP (IN in) (NP (DT the) (JJ English) (NN literature)))))))) (. .)))
12639165	5	(S1 (S (NP (PRP$ Our) (NNS patients)) (VP (VP (VBD developed) (NP (NP (NNP Doc_12639165_745_753_Disease) (JJ following) (NN treatment)) (PP (IN with) (NP (NNP Doc_12639165_779_790_Chemical))))) (CC and) (VP (VBD showed) (NP (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NNS characteristics)) (PP (IN of) (NP (NP (NNP Doc_12639165_849_870_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))))))))))))) (. .)))
12639165	6	(S1 (S (S (NP (NN Doc_12639165_922_931_Disease)) (VP (VP (MD may) (VP (VB develop) (NP (NP (NNS weeks)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (CC and) (VP (MD may) (VP (VB run) (NP (DT a) (JJ prolonged) (NN course)))))) (, ,) (CC but) (S (NP (JJ complete) (NN remission)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT all) (JJ reported) (NNS cases)))))) (. .)))
12639165	7	(S1 (S (NP (DT An) (JJ objective) (NN causality) (NN assessment)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (JJ adverse) (NN drug) (NN event)) (VP (AUX was) (ADVP (RB probably)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12639165_1181_1192_Chemical)))))))))) (. .)))
12639165	8	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (DT this) (JJ Doc_12639165_1217_1228_Chemical-induced) (NN Doc_12639165_1237_1248_Disease)))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
12639165	9	(S1 (S (NP (JJ Immune) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN drug) (POS 's)) (NNP Doc_12639165_1310_1324_Disease))) (, ,) (SBAR (IN as) (S (VP (VBN suggested) (PP (IN by) (NP (NP (DT the) (JJ T-cell) (NN stimulation) (NN study)) (VP (VBN reported) (ADVP (RB here))))))))))) (. .)))
12639165	10	(S1 (S (NP (NN Doc_12639165_1399_1420_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (JJ adverse) (NN effect)) (PP (IN of) (NP (NNP Doc_12639165_1449_1460_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (NP (JJ immune) (NN mediated)))))))) (. .)))
12639165	11	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT the) (NN drug)))) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (PP (IN with) (NP (NN liver) (NN function) (NNS tests))) (ADVP (IN along) (PP (IN with) (NP (JJ complete) (NN blood) (NN cell) (NNS counts))))))) (. .)))
12639165	12	(S1 (S (NP (DT This) (NN complication)) (VP (MD will) (VP (AUX be) (VP (VBN observed) (ADVP (RB even) (RBR less) (RB often)) (PP (IN in) (NP (DT the) (NN future))) (SBAR (IN as) (S (NP (NNP Doc_12639165_1671_1682_Chemical)) (VP (AUX is) (VP (AUXG being) (VP (VBN replaced) (PP (IN by) (NP (DT the) (JJR newer) (NN antiplatelet) (NN agent) (NN Doc_12639165_1733_1744_Chemical))))))))))) (. .)))
12653683	0	(S1 (S (NP (NP (NNP Epithelial) (NNP Doc_12653683_11_17_Chemical) (NNP channel)) (PRN (-LRB- -LRB-) (NP (NNP ENaC)) (-RRB- -RRB-))) (VP (VBD subunit) (NP (NP (NN mRNA)) (CC and) (NP (NN protein) (NN expression))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_12653683_82_107_Chemical-induced) (NNP Doc_12653683_116_134_Disease)))))) (. .)))
12653683	1	(S1 (S (PP (IN In) (NP (JJ experimental) (NNP Doc_12653683_152_170_Disease))) (, ,) (NP (JJ urinary) (JJ Doc_12653683_180_186_Chemical) (NN excretion)) (VP (AUX is) (VP (VBN decreased) (PP (IN during) (NP (NP (DT the) (JJ early) (NN phase)) (PP (IN of) (NP (DT the) (NN disease))))))) (. .)))
12653683	2	(S1 (S (NP (DT The) (JJ molecular) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (VP (VBG leading) (PP (TO to) (NP (NN salt) (NN retention))))) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB completely)) (VP (VBN elucidated)))) (. .)))
12653683	3	(S1 (S (NP (NP (DT The) (JJ rate-limiting) (NN constituent)) (PP (IN of) (S (VP (VBG collecting) (NP (JJ duct) (JJ Doc_12653683_387_393_Chemical) (NN transport)))))) (VP (AUX is) (NP (NP (DT the) (JJ epithelial) (NN Doc_12653683_422_428_Chemical) (NN channel)) (PRN (-LRB- -LRB-) (NP (NNP ENaC)) (-RRB- -RRB-)))) (. .)))
12653683	4	(S1 (S (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN abundance)) (PP (IN of) (NP (NNP ENaC) (NN subunit) (NNS mRNAs)))))) (CC and) (S (NP (NP (NNS proteins)) (PP (IN in) (NP (NP (NNP Doc_12653683_509_534_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12653683_536_539_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (NP (NNP Doc_12653683_549_567_Disease)))) (. .)))
12653683	5	(S1 (S (NP (NP (DT The) (NN time) (NNS courses)) (PP (IN of) (NP (NP (NN urinary) (JJ Doc_12653683_597_603_Chemical) (NN excretion)) (, ,) (NP (NN plasma) (JJ Doc_12653683_622_633_Chemical) (NN concentration)) (CC and) (NP (NNP Doc_12653683_652_663_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (DT either) (NN Doc_12653683_742_745_Chemical) (CC or) (NN vehicle)))))))))) (. .)))
12653683	6	(S1 (S (NP (NP (DT The) (JJ relative) (NNS amounts)) (PP (IN of) (NP (NN alphaENaC) (, ,) (NN betaENaC) (CC and) (NN gammaENaC) (NNS mRNAs)))) (VP (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NP (NNS kidneys)) (PP (IN from) (NP (NP (DT these) (NNS rats)) (PP (IN by) (NP (JJ real-time) (JJ quantitative) (NNP TaqMan) (NNP PCR))))))))) (, ,) (CC and) (VP (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NNS proteins)))) (PP (IN by) (NP (NNP Western) (NNP blot))))) (. .)))
12653683	7	(S1 (S (NP (NP (NP (DT The) (NNS kinetics)) (PP (IN of) (NP (JJ urinary) (JJ Doc_12653683_972_978_Chemical) (NN excretion)))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_12653683_1011_1022_Disease))))) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT those)) (VP (VBN reported) (ADVP (RB previously))))))) (. .)))
12653683	8	(S1 (S (NP (JJ Doc_12653683_1071_1077_Chemical) (NN retention)) (VP (VBD occurred) (PP (IN on) (NP (NNS days))) (NP (CD 2) (, ,) (CD 3) (CC and) (CD 6)) (PP (IN after) (NP (JJ Doc_12653683_1122_1125_Chemical) (NN injection)))) (. .)))
12653683	9	(S1 (S (NP (NP (DT A) (JJ significant) (NN up-regulation)) (PP (IN of) (NP (NN alphaENaC) (CC and) (NN betaENaC) (NNS mRNA)))) (VP (VBP abundance) (PP (IN on) (NP (NP (NNS days)) (SBAR (S (NP (CD 1) (CC and) (CD 2)) (VP (VBN preceded) (NP (JJ Doc_12653683_1231_1237_Chemical) (NN retention)) (PP (IN on) (NP (NNS days) (CD 2) (CC and) (CD 3))))))))) (. .)))
12653683	10	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (NN alphaENaC) (, ,) (NN betaENaC) (CC and) (NN gammaENaC) (NN mRNA) (NN expression)) (PP (IN on) (NP (NN day) (CD 3)))))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ high) (NNP Doc_12653683_1388_1399_Chemical) (NNS concentrations)))))) (, ,) (CC and) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (NN return)) (PP (IN of) (NP (NP (JJ Doc_12653683_1448_1454_Chemical) (NN excretion)) (SBAR (S (VP (TO to) (VP (VB control) (NP (NNS values))))))))))))) (. .)))
12653683	11	(S1 (S (NP (NP (DT The) (NNS amounts)) (PP (IN of) (NP (NP (NN alphaENaC)) (, ,) (NP (NN betaENaC)) (CC and) (NP (NN gammaENaC) (NNS proteins))))) (VP (AUX were) (RB not) (VP (VBN increased) (PP (IN during) (NP (JJ Doc_12653683_1568_1571_Chemical-induced) (JJ Doc_12653683_1580_1586_Chemical) (NN retention))))) (. .)))
12653683	12	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (JJ ENaC) (NN mRNA) (NN expression)) (, ,) (ADJP (RB especially) (JJ alphaENaC)) (, ,)) (VP (VP (AUX is) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (ADJP (RB very) (JJ early)) (NN phase)) (PP (IN of) (NP (NP (DT the) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ Doc_12653683_1723_1726_Chemical-induced) (NNP Doc_12653683_1735_1753_Disease))) (PP (IN in) (NP (NNS rats))))))))) (, ,) (CC but) (VP (VBZ appears) (S (VP (TO to) (VP (VB escape) (PP (IN from) (NP (DT the) (NN regulation))) (PP (IN by) (NP (NNP Doc_12653683_1808_1819_Chemical))) (PP (IN after) (NP (NN day) (CD 3)))))))) (. .)))
12684739	0	(S1 (S (NP (NP (JJ Sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_21_37_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_39_49_Chemical)) (-RRB- -RRB-))) (VP (VBZ inhibits) (NP (NP (JJ Doc_12684739_60_67_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NN nucleus) (NNS accumbens) (NNP Doc_12684739_107_115_Chemical))))) (. .)))
12684739	1	(S1 (S (NP (NP (NNP Doc_12684739_128_144_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_146_149_Chemical)) (-RRB- -RRB-))) (ADVP (RB irreversibly)) (VP (VBZ inhibits) (NP (NN Doc_12684739_173_177_Chemical-transaminase))) (. .)))
12684739	2	(S1 (S (NP (DT This) (JJ non-receptor) (JJ mediated) (NN inhibition)) (VP (VBZ requires) (NP (NP (JJ de) (NN novo) (NN synthesis)) (PP (IN for) (NP (NP (NN restoration)) (PP (IN of) (NP (JJ functional) (JJ Doc_12684739_287_291_Chemical) (NN catabolism))))))) (. .)))
12684739	3	(S1 (S (PP (VBN Given) (NP (NP (PRP$ its) (JJ preclinical) (NN success)) (PP (IN for) (S (VP (VBG treating) (NP (NP (NNP Doc_12684739_359_374_Disease)) (CC and) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_12684739_401_421_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_423_426_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (JJ cumulative) (NN lifetime) (NN exposure))))))))))) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_522_525_Chemical))) (PP (IN on) (NP (NP (JJ Doc_12684739_529_536_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NP (NN nucleus) (NNS accumbens)) (PRN (-LRB- -LRB-) (NP (NNP NAcc)) (-RRB- -RRB-))) (NP (NP (NNP Doc_12684739_583_591_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_593_595_Chemical)) (-RRB- -RRB-))))))))) (. .)))
12684739	4	(S1 (S (S (VP (VBG Using) (PP (IN in) (NP (NN vivo) (NNS microdialysis))))) (, ,) (NP (PRP we)) (VP (VBD compared) (NP (NP (JJ acute) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD 450) (NNS mg/kg)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (DT an) (JJ identical) (JJ sub-chronic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NP (CD 150) (NNS mg/kg)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD 3) (NNS days)))) (-RRB- -RRB-)))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NN 1-)) (CC or) (NP (JJ 3-day) (NN washout))))))) (. .)))
12684739	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ low) (NN dose)) (PP (IN of) (NP (NP (CD 150) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))) (S (VP (VBG using) (NP (DT a) (JJ similar) (NN washout) (NN period))))) (. .)))
12684739	6	(S1 (S (NP (JJ Sub-chronic) (JJ Doc_12684739_896_899_Chemical) (NN exposure)) (VP (VBD inhibited) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_12684739_933_940_Chemical)))) (PP (IN for) (NP (CD 3) (NNS days))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD exceeded) (PP (IN in) (NP (NP (NN magnitude)) (CC and) (NP (NN duration)))) (NP (DT the) (JJ identical) (JJ acute) (NN dose)))))) (. .)))
12684739	7	(S1 (S (NP (JJ Sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_1054_1057_Chemical)) (VP (VP (VBZ potentiates)) (CC and) (VP (VBZ extends) (NP (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (JJ Doc_12684739_1100_1107_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_12684739_1129_1137_Chemical)) (, ,) (VP (ADVP (RB effectively)) (VBG reducing) (NP (JJ cumulative) (NNS exposures)))))))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNS VFDS))))))) (. .)))
12695819	0	(S1 (NP (NP (NNP MR) (NN imaging)) (PP (IN with) (NP (NP (JJ quantitative) (NN diffusion) (NN mapping)) (PP (IN of) (NP (NNP Doc_12695819_50_60_Chemical-induced) (NNP Doc_12695819_69_82_Disease))) (PP (IN in) (NP (NN organ) (NN transplant) (NNS patients))))) (. .)))
12695819	1	(S1 (S (NP (PRP$ Our) (NN objective)) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (NN brain) (NNP MR) (NN imaging) (NNS findings)) (CC and) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (JJ diffusion-weighted) (PRN (-LRB- -LRB-) (NP (NNP DW)) (-RRB- -RRB-)) (NN imaging))) (PP (IN in) (NP (NP (NN organ) (NN transplant) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ neurologic) (NNS symptoms)) (PP (IN during) (NP (JJ Doc_12695819_293_303_Chemical) (NN therapy)))))))))))))) (. .)))
12695819	2	(S1 (S (NP (NP (NN Brain) (NNP MR) (NNS studies)) (, ,) (PP (VBG including) (NP (CD DW) (NN imaging))) (, ,)) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN performed) (PP (IN in) (NP (NP (CD 14) (NN organ) (NN transplant) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_12695819_424_434_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_12695819_449_473_Disease))))))))))) (. .)))
12695819	3	(S1 (S (PP (IN In) (NP (NP (DT each) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NNS abnormalities)) (PP (IN on) (NP (DT the) (JJ initial) (NNP MR) (NN study)))))))) (, ,) (NP (DT a) (JJ follow-up) (NNP MR) (NN study)) (VP (AUX was) (VP (VBN performed) (ADVP (NP (CD 1) (NN month)) (RB later)))) (. .)))
12695819	4	(S1 (S (NP (NP (JJ Apparent) (NN diffusion) (NN coefficient)) (PRN (-LRB- -LRB-) (NP (NNP ADC)) (-RRB- -RRB-))) (VP (VBZ values) (PP (IN on) (NP (NP (DT the) (JJ initial) (NNP MR) (NN study)) (SBAR (S (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NP (NN reversibility)) (PP (IN of) (NP (DT the) (NNS lesions)))))))))))) (. .)))
12695819	5	(S1 (S (PP (IN Of) (NP (DT the) (CD 14) (NNS patients))) (, ,) (S (NP (NP (CD 5)) (PRN (-LRB- -LRB-) (NP (CD 35.7) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_12695819_741_767_Disease)))) (, ,) (S (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (CD 7.1) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_12695819_782_802_Disease)))) (, ,) (CC and) (S (NP (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 57.1) (NN %)) (-RRB- -RRB-)) (VP (AUX had) (NP (JJ normal) (NNS findings)) (PP (IN on) (NP (JJ initial) (NNP MR) (NNS images))))) (. .)))
12695819	6	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 5) (NNS patients)) (PP (IN with) (NP (NNP Doc_12695819_886_912_Disease))))) (, ,) (NP (NP (CD 4) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 80.0) (NN %)) (-RRB- -RRB-))) (VP (VP (VBD showed) (ADVP (RBR higher) (PP (IN than) (NP (JJ normal) (NN ADC) (NNS values)))) (PP (IN on) (NP (JJ initial) (NNP MR) (NNS images)))) (, ,) (CC and) (VP (ADVP (RB all)) (VBD showed) (NP (JJ complete) (NN resolution)) (PP (IN on) (NP (JJ follow-up) (NNS images))))) (. .)))
12695819	7	(S1 (S (NP (NP (DT The) (VBG remaining) (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 20.0) (NN %)) (-RRB- -RRB-))) (VP (VP (VBD showed) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (JJ normal) (NN ADC) (NN value))))) (CC and) (VP (VBD showed) (NP (JJ incomplete) (NN resolution)) (PP (IN with) (NP (NNP Doc_12695819_1153_1178_Disease))))) (. .)))
12695819	8	(S1 (S (NP (JJ Diffusion-weighted) (NN imaging)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG predicting) (NP (NP (DT the) (NNS outcomes)) (PP (IN of) (NP (NP (DT the) (NNS lesions)) (PP (IN of) (NP (NNP Doc_12695819_1266_1276_Chemical-induced) (NNP Doc_12695819_1285_1298_Disease)))))))))))) (. .)))
12707296	0	(S1 (FRAG (NP (JJ Doc_12707296_0_10_Chemical) (NN transport)) (PP (IN in) (NP (NP (NNS humans)) (PP (IN with) (NP (JJ Doc_12707296_36_44_Chemical-induced) (NNP Doc_12707296_53_65_Disease))))) (. .)))
12707296	1	(S1 (S (NP (DT A) (JJ deficient) (JJ Doc_12707296_79_89_Chemical-Doc_12707296_90_102_Chemical) (NN system)) (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (NNP Doc_12707296_127_135_Chemical-induced) (NNP Doc_12707296_144_156_Disease))))) (. .)))
12707296	2	(S1 (S (NP (PRP We)) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NNS abnormalities)) (PP (IN in) (NP (NNP Doc_12707296_198_208_Chemical)))) (ADVP (RB uptake)) (VP (VBP contribute) (PP (TO to) (NP (DT this) (NN deficiency))))))) (. .)))
12707296	3	(S1 (S (NP (CD Eight) (JJ healthy) (NNS men)) (VP (AUX were) (VP (VBN recruited))) (. .)))
12707296	4	(S1 (S (NP (NP (NN Doc_12707296_281_303_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (NP (QP (RB orally) (DT every) (CD 6)) (NNS hours)) (PP (IN for) (NP (NP (CD 24) (NNS hours)) (PP (IN after) (NP (NP (DT a) (JJ 5-day) (NN fixed-salt) (NN diet)) (PRN (-LRB- -LRB-) (NP (CD 150) (NNS mmol/d)) (-RRB- -RRB-)))))))) (. .)))
12707296	5	(S1 (S (NP (NN Crossover) (NNS studies)) (VP (AUX were) (VP (VBN performed) (ADVP (NP (CD 2) (NNS weeks)) (RB apart)))) (. .)))
12707296	6	(S1 (S (NP (NP (CD Thirty) (NNS milliliters)) (PP (IN of) (NP (NN blood)))) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (NP (NN isolation)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells))))) (PP (IN after) (NP (DT each) (NN treatment) (NN period))))) (. .)))
12707296	7	(S1 (S (NP (JJ Doc_12707296_570_580_Chemical) (NN uptake)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (NNP Doc_12707296_637_647_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (TO to) (CD 300)) (NNS micromol/L)) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG incorporating) (NP (QP (CD 100) (CD nmol/L)) (NNP Doc_12707296_696_711_Chemical)) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 5) (NNS minutes))))) (PP (IN at) (NP (NP (CD 37) (NNS degrees)) (SBAR (S (NP (NNP C.) (NNP Forearm) (NNP Doc_12707296_763_778_Chemical) (NN extraction)) (VP (AUX was) (VP (VBN calculated) (PP (IN after) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_12707296_823_838_Chemical))))) (PP (IN into) (NP (DT the) (JJ brachial) (NN artery))) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (CD 100) (NN nCi/min)) (PP (IN for) (NP (CD 80) (NNS minutes))))))))))))))))) (. .)))
12707296	8	(S1 (S (NP (JJ Deep) (NN forearm) (NN venous) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (JJ Doc_12707296_969_979_Chemical) (NN extraction))))))) (. .)))
12707296	9	(S1 (S (NP (NN Plasma) (NN Doc_12707296_999_1007_Chemical) (NNS concentrations)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN raised) (PP (IN during) (NP (NP (DT the) (JJ active) (NN phase)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 323+/-43) (TO to) (CD 1082+/-245)) (NN mmol/L)) (, ,) (NP (NNP P<0.05))) (-RRB- -RRB-)))))) (. .)))
12707296	10	(S1 (S (NP (JJ Systolic) (NN blood) (NN pressure)) (VP (AUX was) (ADJP (JJ elevated) (PP (IN by) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 7) (NN mm) (NNP Hg))))))) (. .)))
12707296	11	(S1 (S (S (NP (NP (NP (DT Neither) (JJ Doc_12707296_1185_1195_Chemical) (NN transport)) (PP (IN into) (NP (NP (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (ADJP (NNP vs) (JJ active))) (, ,) (NP (NP (CD 26.3+/-3.6) (NNP vs) (CD 29.0+/-2.1) (JJ pmol/10) (CD 000) (NNS cells)) (PP (IN per) (NP (CD 5) (NNS minutes))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN at) (NP (NP (DT an) (JJ Doc_12707296_1327_1337_Chemical) (NN concentration)) (PP (IN of) (NP (CD 300) (NNS micromol/L)))))) (-RRB- -RRB-))))) (CC nor) (NP (NP (JJ Doc_12707296_1375_1385_Chemical) (NN extraction)) (PP (IN in) (NP (DT the) (NN forearm))) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (NP (CD 80) (NNS minutes)) (, ,) (NP (NP (NN placebo)) (ADJP (NNP vs) (JJ active)))) (, ,) (NP (CD 1) (CD 868) (CD 904+/-434) (CD 962) (NNP vs)))) (NP (NP (QP (CD 2) (CD 013)) (JJ 910+/-770) (CD 619) (NNS disintegrations)) (PP (IN per) (NP (NN minute)))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN affected) (PP (IN by) (NP (JJ Doc_12707296_1534_1542_Chemical) (NN treatment)))))) (: ;) (S (ADVP (RB ie)) (, ,) (NP (DT that) (NNP Doc_12707296_1563_1573_Chemical) (NN uptake)) (VP (AUX is) (RB not) (VP (VBN affected) (PP (IN by) (NP (JJ short-term) (JJ Doc_12707296_1611_1619_Chemical) (NN treatment)))))) (. .)))
12707296	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_12707296_1648_1656_Chemical-induced) (NNP Doc_12707296_1665_1692_Disease)) (VP (AUX are) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (DT the) (JJ Doc_12707296_1738_1748_Chemical) (NN transport) (NN system)))))))))) (. .)))
12716030	0	(S1 (S (NP (NP (NN Amount)) (PP (IN of) (NP (NP (NNP Doc_12716030_10_18_Disease)) (CC and) (NP (NNP Doc_12716030_23_31_Disease))))) (VP (VBP size) (PP (IN in) (NP (DT the) (JJ collagenase-induced) (NNP Doc_12716030_64_88_Disease) (NN rat) (NN model)))) (. .)))
12716030	1	(S1 (S (NP (NP (DT The) (VBN aggravated) (NN risk)) (PP (IN on) (NP (NP (NP (NNP Doc_12716030_123_147_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12716030_149_152_Disease)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN used) (PP (IN for) (NP (JJ Doc_12716030_174_180_Disease) (NNS patients))))))))) (VP (MD should) (VP (AUX be) (VP (VBN estimated) (ADVP (RB carefully))))) (. .)))
12716030	2	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VP (VBD established) (NP (JJ sensitive) (NN quantification) (NNS methods))) (CC and) (VP (VBD provided) (NP (NP (DT a) (NN rat) (NNP Doc_12716030_298_301_Disease) (NN model)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ Doc_12716030_325_328_Disease) (NN deterioration)))))))) (. .)))
12716030	3	(S1 (S (PP (IN In) (NP (NP (NNP Doc_12716030_347_350_Disease)) (VP (ADVP (RB intrastriatally)) (VBN induced) (PP (IN by) (NP (NP (NN 0.014-unit)) (, ,) (NP (NN 0.070-unit)) (, ,) (CC and) (NP (JJ 0.350-unit) (NN collagenase))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NNP Doc_12716030_444_452_Disease)))) (VP (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (NP (DT a) (NN hemoglobin) (NN assay)) (VP (VBN developed) (PP (IN in) (NP (DT the) (JJ present) (NN study))))))))) (CC and) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (DT the) (ADJP (RB morphologically) (VBN determined)) (NN Doc_12716030_575_583_Disease) (NN volume)))))) (. .)))
12716030	4	(S1 (S (S (NP (NP (DT The) (NN blood) (NNS amounts)) (CC and) (NP (JJ Doc_12716030_614_622_Disease) (NNS volumes))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN correlated)))) (, ,) (CC and) (S (NP (NP (DT the) (NNP Doc_12716030_670_678_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ 0.014-unit) (NN collagenase))))) (VP (AUX was) (ADJP (JJ adequate) (S (VP (TO to) (VP (VB detect) (NP (JJ Doc_12716030_736_739_Disease) (NN deterioration)))))))) (. .)))
12716030	5	(S1 (S (PP (IN In) (NP (NP (JJ Doc_12716030_758_761_Disease) (NN induction)) (VP (VBG using) (NP (JJ 0.014-unit) (NN collagenase))))) (, ,) (NP (NNP Doc_12716030_802_809_Chemical)) (VP (VBD enhanced) (NP (NP (DT the) (NNP Doc_12716030_823_831_Disease) (NN volume) (NN 3.4-fold)) (PP (IN over) (NP (NP (DT that)) (VP (VBN seen) (PP (IN in) (NP (NP (NN control) (NN Doc_12716030_874_877_Disease) (NNS animals)) (CC and) (NP (DT the) (NNP Doc_12716030_894_902_Disease) (NN 7.6-fold))))))))) (. .)))
12716030	6	(S1 (S (NP (NNS Data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (DT this) (JJ sensitive) (NN hemoglobin) (NN assay)) (VP (AUX is) (ADJP (JJ useful) (PP (IN for) (NP (JJ Doc_12716030_977_980_Disease) (NN detection))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (NN model)) (PP (IN with) (NP (NP (DT a) (JJ small) (NN Doc_12716030_1022_1025_Disease)) (VP (VBN induced) (PP (IN with) (NP (DT a) (JJ low-dose) (NN collagenase))))))) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (NN evaluation)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NN Doc_12716030_1117_1120_Disease))))))))))))))))) (. .)))
12757899	0	(S1 (S (NP (NN Doc_12757899_0_9_Chemical)) (VP (VBZ reduces) (NP (JJ Doc_12757899_18_25_Disease-induced) (NN Doc_12757899_34_52_Disease)) (PP (PP (IN in) (NP (JJ ovariectomized) (NN female))) (CC but) (PP (RB not) (IN in) (NP (JJ male) (NNS rats))))) (. .)))
12757899	1	(S1 (S (NP (NNS Estrogens)) (VP (VBP protect) (NP (NP (JJ ovariectomized) (NNS rats)) (PP (IN from) (NP (NP (NNP Doc_12757899_143_161_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_12757899_173_184_Chemical-induced) (NNP Doc_12757899_193_211_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12757899_213_215_Disease)) (-RRB- -RRB-))))))))) (. .)))
12757899	2	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_12757899_245_261_Chemical)))) (PP (IN in) (NP (NP (JJ adult) (ADJP (JJ male) (CC and) (JJ ovariectomized)) (JJ female) (NNS rats)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_12757899_320_327_Chemical-Doc_12757899_328_339_Chemical-induced) (NNP Doc_12757899_348_350_Disease))))))) (. .)))
12757899	3	(S1 (S (NP (NNS Rats)) (VP (VBD received) (NP (NP (JJ subcutaneous) (NNS injections)) (PP (IN of) (NP (NP (NP (NNP Doc_12757899_393_409_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN microg/rat)) (-RRB- -RRB-))) (CC or) (NP (NN oil))))) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD four) (JJ consecutive) (NNS days)))) (. .)))
12757899	4	(S1 (S (NP (NN Doc_12757899_470_472_Disease)) (VP (AUX was) (VP (VP (VBN induced) (NP (CD 20) (NNP h) (NN following)) (NP (DT the) (JJ second) (NN injection))) (CC and) (VP (VBN terminated) (NP (CD 3) (NNP h)) (ADVP (RB later))))) (. .)))
12757899	5	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (JJ Doc_12757899_561_567_Chemical-stained) (NN CA3)) (CC and) (NP (JJ CA1) (JJ hippocampal) (NNS neurons))))) (VP (AUX was) (VP (VBN evaluated) (NP (CD 2) (NNS days)) (SBAR (IN after) (S (NP (NNP Doc_12757899_635_637_Disease.) (NNP Doc_12757899_639_655_Chemical)) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ first) (NNS clonus)) (PP (IN in) (NP (VBN ovariectomized) (NNS rats)))))))) (CC but) (VP (VBD accelerated) (NP (PRP it)) (PP (IN in) (NP (JJ males.) (NNP Doc_12757899_748_764_Chemical)))) (VP (VBD reduced) (NP (NP (DT the) (JJ argyrophilic) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NN CA1) (CC and) (NN CA3-C) (NNS sectors)) (PP (IN of) (NP (VBN ovariectomized) (NNS rats)))))))))))) (. .)))
12757899	6	(S1 (S (PP (IN In) (NP (NNS males))) (, ,) (NP (NNP Doc_12757899_861_870_Chemical)) (VP (VBD increased) (NP (DT the) (JJ total) (NN damage) (NN score))) (. .)))
12757899	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_12757899_948_957_Chemical))) (PP (IN on) (NP (NP (JJ Doc_12757899_961_968_Disease) (NN threshold)) (CC and) (NP (NN damage))))) (VP (MD may) (VP (AUX be) (VP (VBN altered) (PP (IN by) (NP (NP (JJ sex-related) (NNS differences)) (PP (IN in) (NP (DT the) (JJ hormonal) (NN environment))))))))))) (. .)))
12789195	0	(S1 (S (NP (NN Doc_12789195_0_16_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (NNP Doc_12789195_49_58_Chemical)))))) (. .)))
12789195	1	(S1 (S (NP (NN Doc_12789195_60_70_Disease)) (VP (AUX is) (NP (NP (DT an) (NN Doc_12789195_77_95_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ chronic) (JJ excessive) (NN growth) (NN hormone) (NN secretion)) (PP (IN from) (NP (DT the) (NNP anterior) (NN pituitary) (NN gland)))))))) (. .)))
12789195	2	(S1 (S (NP (JJ Significant) (NN disfiguring) (NNS changes)) (VP (VBP occur) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN bone)) (, ,) (NP (NN cartilage)) (, ,) (CC and) (NP (JJ soft) (NN tissue) (NN Doc_12789195_270_281_Disease)) (, ,) (PP (VBG including) (NP (NP (NP (DT the) (NN thickening)) (PP (IN of) (NP (DT the) (NN skin)))) (, ,) (NP (NP (NN coarsening)) (PP (IN of) (NP (JJ facial) (NNS features)))) (, ,) (CC and) (NP (NN Doc_12789195_356_377_Disease))))))))) (. .)))
12789195	3	(S1 (S (NP (NN Doc_12789195_379_395_Disease)) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (AUX is) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ similar) (JJ acromegaloid) (NNS features))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ elevated) (NN growth) (NN hormone) (CC or) (JJ insulin-like) (NN growth) (NN factor) (NNS levels))))))) (. .)))
12789195	4	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_12789195_571_587_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN from) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (NNP Doc_12789195_628_637_Chemical))) (PP (IN at) (NP (DT an) (ADJP (RB unusually) (JJ high)) (NN dose)))))))))) (. .)))
12789195	5	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (NNP Doc_12789195_698_714_Disease)))) (PP (IN as) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (JJ Doc_12789195_735_744_Chemical) (NN use)))))) (. .)))
12820454	0	(S1 (S (NP (JJ Combined) (NNS androgen)) (VP (VBD blockade-induced) (NP (NNP Doc_12820454_35_41_Disease)) (PP (IN in) (NP (NNP Doc_12820454_45_60_Disease) (NNS patients))) (PP (IN without) (NP (NN bone) (NN involvement)))) (. .)))
12820454	1	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN onset) (CC and) (NN extent)) (PP (IN of) (NP (NP (JJ combined) (NN androgen) (NN blockade)) (PRN (-LRB- -LRB-) (NP (NN CAB)) (-RRB- -RRB-)))))))) (VP (VBD -induced) (NP (NNP Doc_12820454_186_192_Disease)) (PP (IN in) (NP (NNP Doc_12820454_196_211_Disease) (NNS patients))) (PP (IN without) (NP (NN bone) (NN involvement)))) (. .)))
12820454	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (JJ Forty-two) (NNS patients)) (PP (IN with) (NP (NP (NP (NP (JJ biopsy-proven) (NNP Doc_12820454_307_331_Disease) (CD -LSB-26)) (PP (IN with) (NP (NN stage) (NN C)))) (PRN (-LRB- -LRB-) (NP (NNP T3N0M0)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 16)) (PP (IN with) (NP (NN stage) (NNP D1) (PRN (-LRB- -LRB-) (NP (NNP T3N1M0)) (-RRB- -RRB-)) (NN -RSB-))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
12820454	3	(S1 (S (NP (DT All) (NNS patients)) (VP (VP (VBD received) (NP (NP (NP (NP (NN CAB) (NN -LSB-Doc_12820454_445_463_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12820454_465_471_Chemical)) (-RRB- -RRB-))) (NP (CD 3.75) (NNS mg)) (, ,) (ADVP (RB intramuscularly))) (, ,) (NP (NP (DT every) (CD 28) (NNS days)) (CC plus) (NP (NP (CD 250) (NNS mg)) (ADJP (NNP Doc_12820454_525_534_Chemical) (, ,) (JJ tid)))) (, ,)) (PP (IN per) (NP (NNP Os) (NN -RSB-)))) (CC and) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NP (NP (NNP Doc_12820454_572_578_Disease)) (PP (IN by) (NP (NP (JJ physical) (NN examination)) (CC and) (NP (NN laboratory) (NNS tests)))) (PP (IN at) (NP (NN baseline)))) (CC and) (NP (NP (CD 4) (JJ subsequent) (NNS intervals)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 1) (, ,) (CD 2) (, ,) (CD 3) (CC and) (CD 6) (NNS months)) (JJ post-CAB)) (-RRB- -RRB-)))))))) (. .)))
12820454	4	(S1 (S (NP (NNP Hb) (, ,) (NNP PSA) (CC and) (NNP Doc_12820454_708_720_Chemical) (NNS measurements)) (VP (AUX were) (VP (VBN recorded))) (. .)))
12820454	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NN stage) (JJ D2-3) (NN disease)) (, ,) (NP (JJ abnormal) (NN hemoglobin) (NN level)) (CC or) (NP (JJ renal) (CC and) (NN liver) (NN function) (NNS tests)))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT the) (JJ upper) (NNS limits)))))))) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))))) (. .)))
12820454	6	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (NP (CD six) (NNS months))) (. .)))
12820454	7	(S1 (S (NP (DT The) (JJ mean) (NN hemoglobin) (PRN (-LRB- -LRB-) (NP (NNP Hb)) (-RRB- -RRB-)) (NNS levels)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN declined) (PP (IN in) (NP (DT all) (NNS patients))) (PP (IN from) (NP (NP (NN baseline)) (PP (IN of) (NP (NP (QP (CD 14.2) (CD g/dl) (TO to) (CD 14.0)) (NNS g/dl)) (, ,) (NP (NP (CD 13.5) (NN g/dl)) (, ,) (NP (CD 13.2) (NN g/dl)) (CC and) (NP (NP (CD 12.7) (NN g/dl)) (PP (IN at) (NP (CD 1) (, ,) (CD 2) (, ,) (CD 3) (CC and) (CD 6) (NNS months) (NN post-CAB))))) (, ,) (ADVP (RB respectively)))))))) (. .)))
12820454	8	(S1 (S (NP (NP (ADJP (ADJP (JJ Severe)) (CC and) (ADJP (RB clinically) (JJ evident))) (NN Doc_12820454_1193_1199_Disease)) (PP (IN of) (NP (NP (NNP Hb) (NNP <) (CD 11) (NNS g/dl)) (PP (IN with) (NP (JJ clinical) (NNS symptoms)))))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (CD 6) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 14.3) (NN %)) (-RRB- -RRB-)))))) (. .)))
12820454	9	(S1 (S (NP (DT This) (JJ CAB-induced) (NN Doc_12820454_1292_1298_Disease)) (VP (AUX was) (ADJP (ADJP (JJ normochromic)) (CC and) (ADJP (JJ normocytic)))) (. .)))
12820454	10	(S1 (S (PP (IN At) (ADJP (NP (CD six) (NNS months)) (JJ post-CAB))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_12820454_1377_1383_Disease)))) (VP (AUX had) (NP (NP (DT a) (JJ Hb) (JJ mean) (NN value)) (PP (IN of) (NP (NP (CD 10.2) (JJ +/-) (CD 0.1) (NNS g/dl)) (PRN (-LRB- -LRB-) (NP (NNP X) (JJ +/-) (FW SE)) (-RRB- -RRB-))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ other) (NNS patients)) (VP (AUX had) (NP (NP (JJ mild) (NAC (NNP Doc_12820454_1473_1479_Disease) (PP (IN with) (NP (NNP Hb)))) (NN mean) (NN value)) (PP (IN of) (NP (NP (NP (CD 13.2) (NN +/-)) (NP (CD 0.17))) (PRN (-LRB- -LRB-) (FRAG (X (SYM X)) (NP (JJ +/-) (FW SE))) (-RRB- -RRB-))))))))) (. .)))
12820454	11	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (JJ severe) (NNP Doc_12820454_1554_1560_Disease))) (PP (IN at) (NP (QP (CD 6) (NNS months)) (NN post-CAB)))) (VP (AUX was) (ADJP (JJ predictable) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNP Hb) (NN baseline) (NN value)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 2.5)) (NN g/dl)))))))) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NP (NN CAB)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.01)) (-RRB- -RRB-))))))) (. .)))
12820454	12	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (JJ severe) (JJ CAB-induced) (NNP Doc_12820454_1730_1736_Disease)) (PP (IN in) (NP (NNP Doc_12820454_1740_1755_Disease) (NNS patients)))))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (S (VP (VBG T) (NP (NP (NN baseline) (NNS values)) (PRN (-LRB- -LRB-) (NP (NNP T) (QP (CD <) (CD 3) (NN ng/ml) (CC versus) (CD T) (NN >) (CC or) (SYM =) (CD 3) (CD ng/ml))) (-RRB- -RRB-))) (, ,) (PP (IN with) (NP (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD <) (CD 76) (NNS yrs)) (PP (IN versus) (NP (NNP >)))) (CC or) (NP (NP (SYM =)) (NP (CD 76) (NNS yrs)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ clinical) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN stage) (NN C) (CC versus) (NN stage) (NNPS D1)) (-RRB- -RRB-)))))))))) (. .)))
12820454	13	(S1 (S (NP (ADJP (JJ Severe) (CC and) (ADJP (RB clinically) (JJ evident))) (NNP Doc_12820454_1963_1969_Disease)) (VP (AUX was) (ADVP (RB easily)) (VP (VBN corrected) (PP (IN by) (NP (NP (JJ subcutaneous) (NNS injections)) (PRN (-LRB- -LRB-) (NP (NP (CD 3) (NN times/week)) (PP (IN for) (NP (CD 1) (NN month)))) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ recombinant) (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NN rHuEPO-beta)) (-RRB- -RRB-)))))))) (. .)))
12820454	14	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ rHuEPO-beta) (JJ correctable) (JJ CAB-induced) (NN Doc_12820454_2160_2166_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (NP (CD 14.3) (NN %)) (PP (IN of) (NP (JJ Doc_12820454_2186_2201_Disease) (NNS patients))))) (PP (IN after) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (NN therapy))))))))) (. .)))
12905102	0	(S1 (NP (NP (NP (NN Doc_12905102_0_8_Disease)) (PP (IN during) (NP (JJ Doc_12905102_16_25_Chemical) (NN treatment)))) (: :) (NP (NP (NN incidence)) (CC and) (NP (JJ associated) (NN risk) (NNS factors))) (. .)))
12905102	1	(S1 (S (NP (NP (NN Incidence) (CC and) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_12905102_119_127_Disease) (IN during) (NNP Doc_12905102_135_144_Chemical) (NN treatment)))) (VP (VBP require) (NP (JJ further) (NN clarification))) (. .)))
12905102	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (JJ computerized) (NN pharmacy) (NNS records)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT all) (JJ adult) (NNP Doc_12905102_255_266_Disease) (NNS inpatients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_12905102_291_300_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1995-96)) (-RRB- -RRB-))) (, ,) (VP (VP (VBN reviewed) (NP (PRP$ their) (JJ medical) (NNS records)) (PP (TO to) (NP (NP (NN score) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_12905102_378_386_Disease)))))) (, ,) (CC and) (VP (VBN tested) (NP (NNS associations)) (PP (IN with) (NP (JJ potential) (NN risk) (NNS factors))))))))))))) (. .)))
12905102	3	(S1 (S (S (NP (NP (NNS Subjects)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 139)) (-RRB- -RRB-))) (VP (AUX were) (NP (CD 72) (NNS women)))) (CC and) (S (NP (NP (CD 67) (NNS men)) (, ,) (VP (VP (VBN aged) (NP (CD 40.8) (JJ +/-) (CD 12.1) (NNS years))) (, ,) (VP (VBN hospitalized) (PP (IN for) (NP (CD 24.9) (JJ +/-) (CD 23.3) (NNS days)))) (, ,) (CC and) (VP (VBN given) (NP (NNP Doc_12905102_568_577_Chemical)))) (, ,)) (ADVP (RB gradually)) (VP (VBD increased) (PP (TO to) (NP (NP (DT an) (JJ average) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 282) (JJ +/-) (CD 203) (NNS mg)) (PRN (-LRB- -LRB-) (NP (CD 3.45) (JJ +/-) (CD 2.45) (NNS mg/kg)) (-RRB- -RRB-)))))) (PP (IN for) (NP (NP (CD 18.9) (NN +/-)) (NP (CD 16.4) (NNS days)))))) (. .)))
12905102	4	(S1 (S (S (NP (NN Doc_12905102_688_696_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN in) (NP (CD 14))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10.1) (NN %)) (NN incidence)) (, ,) (CC or) (NP (NP (CD 1.48) (NN cases/person-years)) (PP (IN of) (NP (NN exposure))))) (-RRB- -RRB-))))) (: ;) (S (NP (NP (CD 71.4) (NN %)) (PP (IN of) (NP (NNS cases)))) (VP (AUX were) (ADJP (JJ moderate) (CC or) (JJ severe)))) (. .)))
12905102	5	(S1 (S (S (NP (JJ Associated) (NNS factors)) (VP (AUX were) (ADJP (JJ co-treatment) (PP (IN with) (NP (NP (JJ other) (ADJP (RB centrally) (JJ antimuscarinic)) (NNS agents)) (, ,) (NP (JJ poor) (JJ clinical) (NN outcome)) (, ,) (NP (JJR older) (NN age)) (, ,) (CC and) (NP (JJR longer) (NN hospitalization))))) (PRN (-LRB- -LRB-) (PP (IN by) (NP (NP (CD 17.5) (NNS days)) (, ,) (NP (VBG increasing) (NN cost)))) (-RRB- -RRB-)))) (: ;) (S (NP (NP (NP (NN sex)) (, ,) (NP (NN diagnosis)) (CC or) (NP (JJ medical) (NN co-morbidity))) (, ,) (CC and) (NP (JJ daily) (JJ Doc_12905102_1043_1052_Chemical) (NN dose)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD fell) (PP (IN with) (NP (NN age)))))) (, ,)) (VP (AUX were) (ADJP (JJ unrelated)))) (. .)))
12905102	6	(S1 (S (NP (NN Doc_12905102_1109_1117_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (JJ Doc_12905102_1139_1148_Chemical-treated) (NNS inpatients))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (JJR older) (NNS patients)) (VP (VBN exposed) (PP (TO to) (NP (JJ other) (JJ central) (NNS anticholinergics)))))))) (. .)))
12905102	7	(S1 (S (NP (NN Doc_12905102_1243_1251_Disease)) (VP (VP (AUX was) (ADVP (RB inconsistently)) (VP (VBN recognized) (ADVP (RB clinically)) (PP (IN in) (NP (JJ milder) (NNS cases))))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN length-of-stay)) (CC and) (NP (JJR higher) (NNS costs)) (, ,) (CC and) (NP (JJ inferior) (JJ clinical) (NN outcome))))))) (. .)))
12907309	0	(S1 (S (NP (NP (JJ Neuroprotective) (NN action)) (PP (IN of) (NP (NP (NNP Doc_12907309_26_30_Chemical)) (, ,) (NP (DT a) (JJ selective) (NN mGluR5) (NN antagonist)) (, ,))) (PP (IN in) (NP (JJ Doc_12907309_66_81_Chemical-induced) (JJ dopaminergic) (NN Doc_12907309_103_116_Disease)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_12907309_150_158_Chemical) (NN outflow)))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_12907309_185_197_Disease)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
12907309	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ metabotropic) (NNP Doc_12907309_269_278_Chemical) (NN receptor) (CD 5)) (PRN (-LRB- -LRB-) (NP (NN mGluR5)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (JJ toxic) (NN action)) (PP (IN of) (NP (NNP Doc_12907309_322_337_Chemical))) (PP (IN on) (NP (NP (JJ dopaminergic) (NNS neurones)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12907309	2	(S1 (S (NP (NP (NNP Doc_12907309_372_387_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)) (, ,) (VP (VBN administered) (NP (CD five) (NNS times))) (, ,)) (VP (VBD reduced) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_12907309_450_458_Chemical)) (CC and) (NP (PRP$ its) (NNS metabolites)))) (PP (IN in) (NP (JJ striatal) (NN tissue)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (NP (CD 72) (NNP h)) (PP (IN after) (NP (DT the) (JJ last) (NN injection))))))) (. .)))
12907309	3	(S1 (S (NP (NP (DT A) (JJ selective) (NN antagonist)) (PP (IN of) (NP (NP (CD mGluR5)) (, ,) (NP (NP (NNP Doc_12907309_577_611_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_12907309_613_617_Chemical)) (: ;) (NP (QP (CD 5) (CD mg/kg) (NN ip)))) (-RRB- -RRB-))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (NP (CD five) (NNS times)) (PP (ADVP (RB immediately)) (IN before) (NP (DT each) (JJ Doc_12907309_685_700_Chemical) (NN injection))))))))) (VP (VBD reversed) (NP (DT the) (JJ above-mentioned) (JJ Doc_12907309_740_755_Chemical) (NNS effects))) (. .)))
12907309	4	(S1 (S (NP (DT A) (JJ single) (NNP Doc_12907309_774_778_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (NN injection)) (VP (VBD reduced) (NP (NP (NP (DT the) (JJ basal) (NN extracellular) (JJ Doc_12907309_834_842_Chemical) (NN level)) (PP (IN in) (NP (DT the) (NN striatum)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_12907309_877_885_Chemical) (NN release)) (VP (VBN stimulated) (PP (CC either) (PP (IN by) (NP (NP (NNP Doc_12907309_915_930_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (ADJP (RB intrastriatally) (VBN administered)) (NNP Doc_12907309_980_991_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN microM)) (-RRB- -RRB-))))))))) (. .)))
12907309	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (PRP it)) (ADVP (RB transiently)) (VP (VP (VBD diminished) (NP (DT the) (JJ Doc_12907309_1046_1061_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12907309_1084_1096_Disease))) (CC and) (VP (VBD reduced) (NP (JJ basal) (NN body) (NN temperature)))) (. .)))
12907309	6	(S1 (S (S (NP (NP (NN Doc_12907309_1133_1137_Chemical)) (VP (VBN administered) (PP (IN into) (NP (DT the) (NN striatum))) (PP (IN at) (NP (NP (JJ high) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN microM)) (-RRB- -RRB-)))))) (VP (VBD increased) (NP (JJ extracellular) (JJ Doc_12907309_1229_1237_Chemical) (NNS levels)))) (, ,) (IN while) (S (NP (NP (JJR lower) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 50-100) (NN microM)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ devoid) (PP (IN of) (NP (DT any) (NN effect)))))) (. .)))
12907309	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NN mGluR5))) (PP (IN by) (NP (NNP Doc_12907309_1381_1385_Chemical)))) (VP (MD may) (VP (VB protect) (NP (JJ dopaminergic) (NNS neurones)) (PP (IN against) (NP (JJ Doc_12907309_1428_1443_Chemical-induced) (NN Doc_12907309_1452_1460_Disease)))))))) (. .)))
12907309	8	(S1 (S (NP (NP (NN Neuroprotection)) (VP (VBN rendered) (PP (IN by) (NP (NNP Doc_12907309_1490_1494_Chemical))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (PP (IN with) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (DT the) (JJ Doc_12907309_1539_1554_Chemical-induced) (JJ Doc_12907309_1563_1571_Chemical) (NN efflux)) (PP (IN in) (NP (NP (DT the) (NN striatum)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (JJ extrastriatal) (NNS mGluR5)))))))))))) (, ,) (CC and) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NNP Doc_12907309_1663_1675_Disease))))))))) (. .)))
12921865	0	(S1 (NP (NP (JJ Protective) (NN efficacy)) (PP (IN of) (NP (JJ neuroactive) (NNP Doc_12921865_35_43_Chemical))) (PP (IN against) (NP (NP (JJ Doc_12921865_52_59_Chemical) (NN kindled-Doc_12921865_68_76_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
12921865	1	(S1 (S (NP (NNP Neuroactive) (NNP Doc_12921865_98_106_Chemical)) (VP (VBP demonstrate) (NP (NP (JJ pharmacological) (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (NP (NN relevance)) (PP (IN for) (NP (NP (DT a) (NN host)) (PP (IN of) (NP (NN Doc_12921865_177_215_Disease)))))))))) (. .)))
12921865	2	(S1 (S (NP (PRP They)) (VP (VP (VBP offer) (NP (NP (NN protection)) (PP (IN against) (NP (NNP Doc_12921865_247_255_Disease)))) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNS models)))))) (CC and) (VP (VBP seem) (S (VP (TO to) (VP (VB inhibit) (NP (NP (JJ certain) (NNS stages)) (PP (IN of) (NP (NP (NNP Doc_12921865_315_330_Disease)) (PP (IN in) (NP (JJ preclinical) (NNS assessments))))))))))) (. .)))
12921865	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NP (CD two) (NNS endogenous)) (CC and) (NP (CD one) (JJ synthetic) (JJ neuroactive) (NN Doc_12921865_447_454_Chemical))) (SBAR (WHNP (WDT that)) (S (ADVP (RB positively)) (VP (VBP modulate) (NP (NP (DT the) (NNP Doc_12921865_484_507_Chemical) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_12921865_509_513_Chemical)) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))) (-RRB- -RRB-)) (NN receptor)) (PP (IN against) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN sensitivity))) (PP (TO to) (NP (NP (DT the) (JJ convulsant) (NNS effects)) (PP (IN of) (NP (NNP Doc_12921865_592_599_Chemical))) (VP (VBN engendered) (PP (IN by) (NP (NP (VBN repeated) (NNP Doc_12921865_623_630_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_647_654_Disease) (NN kindling)) (-RRB- -RRB-))))))))))))))))))) (. .)))
12921865	4	(S1 (S (NP (NP (NP (NNP Doc_12921865_666_682_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_684_720_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12921865_723_735_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_737_772_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_12921865_778_788_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ synthetic) (NN derivative)) (PP (IN of) (NP (NNP Doc_12921865_816_832_Chemical) (NNP Doc_12921865_833_882_Chemical)))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB suppress) (NP (NP (NP (NP (DT the) (NN expression)) (PRN (-LRB- -LRB-) (NP (JJ anticonvulsant) (NN effect)) (-RRB- -RRB-))) (CC and) (NP (NP (NN development)) (PRN (-LRB- -LRB-) (NP (JJ antiepileptogenic) (NN effect)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ Doc_12921865_1011_1018_Chemical-kindled) (NNP Doc_12921865_1027_1035_Disease)))) (PP (IN in) (NP (NN male))) (, ,) (NP (NNP Swiss-Webster) (NNS mice))))))))) (. .)))
12921865	5	(S1 (S (NP (VBN Kindled) (NN Doc_12921865_1073_1081_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NP (CD 60) (NNS mg/kg)) (ADJP (JJ Doc_12921865_1131_1138_Chemical) (PP (IN for) (NP (CD 5) (NN days)))))))))) (. .)))
12921865	6	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (DT these) (JJ positive) (NNP Doc_12921865_1173_1177_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NNS modulators)))) (VP (VBD suppressed) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (VBN kindled) (NNP Doc_12921865_1229_1237_Disease)))) (, ,) (SBAR (IN whereas) (RB only) (S (NP (NP (NNP Doc_12921865_1252_1268_Chemical)) (CC and) (NP (NNP Doc_12921865_1273_1283_Chemical))) (VP (VBD inhibited) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN kindling)))))))) (. .)))
12921865	7	(S1 (S (NP (NP (NP (NNP Doc_12921865_1323_1339_Chemical)) (CC and) (NP (NNP Doc_12921865_1344_1356_Chemical))) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_12921865_1366_1376_Chemical)) (, ,)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (JJ cumulative) (NN lethality)) (VP (VBN associated) (PP (IN with) (NP (NN kindling)))))) (. .)))
12921865	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT some)) (VP (VBP neuroactive) (S (NP (NNP Doc_12921865_1487_1495_Chemical)) (VP (VP (VB attenuate) (NP (NP (NN convulsant) (CC and) (NN sensitizing) (NNS properties)) (PP (IN of) (NP (NNP Doc_12921865_1547_1554_Chemical))))) (CC and) (VP (VB add) (PP (TO to) (NP (NP (DT a) (VBG growing) (NN literature)) (PP (IN on) (NP (NP (PRP$ their) (JJ potential) (NN use)) (PP (IN in) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse)))))))))))))))))))) (. .)))
137340	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ humoral) (NNS modulators)) (PP (IN of) (NP (NP (NNP Doc_137340_32_40_Chemical-induced) (NNP Doc_137340_49_79_Disease)) (PP (IN of) (NP (NNS mice))))))) (. .)))
137340	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ humoral) (NNS modulators))) (PP (IN on) (NP (NP (DT the) (JJ Doc_137340_129_137_Chemical-induced) (NN Doc_137340_146_176_Disease)) (PP (IN of) (NP (NNS mice)))))) (VP (AUX was) (VP (VBN studied))) (. .)))
137340	2	(S1 (S (NP (NP (DT The) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NP (CD 10) (NN mg/kg)) (PP (IN of) (NP (NNP Doc_137340_245_253_Chemical-HC1)))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN Doc_137340_276_306_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
137340	3	(S1 (S (NP (DT The) (JJ Doc_137340_320_328_Chemical-induced) (NN Doc_137340_337_350_Disease)) (VP (AUX was) (VP (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_137340_370_381_Chemical)))) (CC and) (VP (VBN attenuated) (PP (IN by) (NP (NNP Doc_137340_400_413_Chemical)))))) (. .)))
137340	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT both) (NP (NNP Doc_137340_433_448_Chemical)) (CC and) (NP (NNP Doc_137340_453_464_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX do) (RB not) (VP (VB penetrate) (NP (DT the) (JJ blood-brain) (NN barrier)))))) (, ,)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNP Doc_137340_535_548_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_137340_561_569_Chemical)))))))) (. .)))
137340	5	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (NP (NNP Doc_137340_597_617_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (CD mg/kg) (NN i.p.)) (, ,) (NP (CD one) (NN hour))) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (JJ Doc_137340_661_669_Chemical) (NN hydroxylase)))) (, ,)))))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_742_750_Chemical))))) (. .)))
137340	6	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_137340_789_810_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 3) (SYM X) (CD 320) (CD mg/kg)) (NN i.p.)) (, ,) (NP (CD 24) (NNS hr))) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ Doc_137340_842_851_Chemical) (NN depletor)) (, ,)))) (VP (VBD caused) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (DT the) (NNP Doc_137340_898_911_Disease))))) (. .)))
137340	7	(S1 (S (NP (DT The) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_972_980_Chemical)))) (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNP Doc_137340_1012_1026_Chemical))) (PP (IN from) (NP (NP (JJ adrenergic) (NNS neurons)) (PP (IN in) (NP (DT the) (NN brain)))))))))))) (. .)))
137340	8	(S1 (S (CC And) (NP (DT the) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_137340_1121_1129_Chemical)) (VP (VBZ acts) (PP (IN by) (S (VP (VBG retarding) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNP Doc_137340_1163_1176_Chemical)))) (PP (IN at) (NP (DT some) (JJ central) (JJ cholinergic) (NNS synapses))))))))))))) (. .)))
137340	9	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB also)) (VP (VBN suggested) (PP (IN from) (NP (VBN collected) (NN evidence))) (SBAR (IN that) (S (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_1300_1308_Chemical))) (PP (IN in) (NP (NNS mice)))) (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS mechanisms)) (ADJP (JJ different) (PP (IN from) (NP (NP (DT those)) (SBAR (WHNP (WDT which)) (S (VP (VB mediate) (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_1414_1422_Chemical))) (PP (IN in) (NP (NNS rats)))))))))))))))))) (. .)))
1378968	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (ADJP (JJ uninephrectomy) (CC and) (JJ high)) (NN protein))) (VP (VBG feeding) (PP (IN on) (NP (NP (JJ Doc_1378968_54_61_Chemical-induced) (NN Doc_1378968_70_91_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1378968	1	(S1 (S (NP (NP (NNS Rats)) (PP (IN with) (NP (JJ Doc_1378968_111_118_Chemical-induced) (NNP Doc_1378968_127_138_Disease)))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (NP (JJ high) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP HP)) (-RRB- -RRB-)) (NP (NN feeding))) (, ,) (NP (NP (NN uninephrectomy)) (PRN (-LRB- -LRB-) (NP (NN NX)) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (DT these)))))) (, ,) (PP (IN in) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ glomerular) (NN hyperfiltration)) (CC and) (NP (NP (JJ further) (NN progression)) (PP (IN of) (NP (NNP Doc_1378968_309_322_Disease)))))))))))) (. .)))
1378968	2	(S1 (S (NP (JJ Newborn) (JJ female) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VP (VBN fed) (NP (NP (DT a) (JJ Doc_1378968_362_369_Chemical-containing) (NN diet)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mmol/kg)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 8) (NNS weeks)))) (CC and) (VP (ADVP (RB then)) (VBN randomized) (PP (TO to) (NP (NP (JJ normal) (NN diet)) (, ,) (NP (NP (NNP HP) (NN diet)) (PRN (-LRB- -LRB-) (NP (NP (CD 40)) (CC vs.) (NP (CD 19) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NNS NX)) (CC or) (NP (NN HP+NX)))) (PP (IN for) (NP (DT another) (CD 8) (NNS weeks)))))) (. .)))
1378968	3	(S1 (S (NP (JJ Corresponding) (JJ non-Doc_1378968_520_527_Chemical) (JJ pretreated) (NNS groups)) (VP (AUX were) (VP (VBN generated))) (. .)))
1378968	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG comparing) (NP (NP (DT all) (NNP Doc_1378968_581_588_Chemical)) (VP (VBN treated) (PP (IN versus) (NP (JJ non-Doc_1378968_608_615_Chemical-treated) (NNS groups)))))))) (, ,) (NP (NNP Doc_1378968_632_639_Chemical)) (VP (VBD caused) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (SYM GFR)) (-RRB- -RRB-)))) (PP (IN without) (NP (NP (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (PRN (-LRB- -LRB-) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (DT a) (NN marker)) (VP (VBN secreted) (PP (IN into) (NP (DT the) (JJ proximal) (NNS tubules))))))))) (-RRB- -RRB-))))))) (CC or) (NP (JJ Doc_1378968_820_827_Chemical) (NN clearance)))) (. .)))
1378968	5	(S1 (S (ADVP (RB Consequently)) (, ,) (NP (JJ Doc_1378968_853_860_Chemical) (NN pretreatment)) (VP (VBD caused) (NP (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (NN filtration) (NN fraction)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ fractional) (JJ Doc_1378968_941_943_Chemical) (NN excretion)))))) (. .)))
1378968	6	(S1 (S (NP (NN Doc_1378968_955_962_Chemical)) (ADVP (RB also)) (VP (VBD caused) (NP (NP (NNP Doc_1378968_975_986_Disease)) (CC and) (NP (JJ systolic) (NNP Doc_1378968_1000_1012_Disease))) (PP (IN in) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_1378968_1027_1045_Disease)))))) (. .)))
1378968	7	(S1 (S (NP (NNP HP)) (VP (VP (VBD failed) (S (VP (TO to) (VP (VB accentuante) (NP (NP (NN progression)) (PP (IN of) (NP (NNP Doc_1378968_1087_1100_Disease)))))))) (CC and) (VP (PP (IN in) (NP (NN fact))) (VBD tended) (S (VP (TO to) (VP (VP (VB increase) (NP (SYM GFR))) (CC and) (VP (VB decrease) (NP (NP (NN plasma) (JJ Doc_1378968_1156_1166_Chemical) (NNS levels)) (PP (IN in) (NP (JJ Doc_1378968_1177_1184_Chemical) (JJ pretreated) (NNS rats)))))))))) (. .)))
1378968	8	(S1 (S (NP (NNS NX)) (VP (VBD caused) (NP (NP (DT an) (JJ additive) (NN deterioration)) (PP (IN in) (NP (NN GFR))) (SBAR (WHNP (WDT which)) (S (, ,) (ADVP (RB however)) (, ,) (VP (AUX was) (VP (VBN ameliorated) (PP (IN by) (NP (NNP HP))))))))) (. .)))
1378968	9	(S1 (S (NP (NNS NX+HP)) (VP (VBD caused) (NP (NP (DT a) (JJ further) (NN rise)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (PP (IN in) (NP (JJ Doc_1378968_1333_1335_Chemical-pretreated) (NNS rats))))))) (. .)))
1378968	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_1378968_1379_1381_Chemical-induced) (NNP Doc_1378968_1390_1401_Disease)) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (NP (DT the) (NN GFR)) (VP (AUX is) (ADVP (RB only) (RB modestly)) (VP (VBN reduced))))) (, ,)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_1378968_1466_1477_Disease)) (CC and) (NP (JJ arterial) (JJ systolic) (NN Doc_1378968_1500_1512_Disease))))))))) (. .)))
1378968	11	(S1 (S (PP (IN In) (NP (NP (DT this) (NN model)) (PP (IN of) (NP (NNP Doc_1378968_1531_1552_Disease))))) (NP (NP (DT the) (NN decline)) (PP (IN in) (NP (NNS GFR)))) (VP (AUX is) (RB not) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ corresponding) (NN fall)) (PP (IN in) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ functional) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ nonfiltrating) (JJ atubular) (NNS glomeruli)))))))))))))))) (. .)))
1378968	12	(S1 (S (NP (NP (DT The) (JJ fractional) (NN reabsorption)) (PP (IN of) (NP (JJ tubular) (NN fluid))) (PP (IN by) (NP (DT the) (JJ proximal) (NNS tubules)))) (VP (AUX is) (VP (VBN reduced) (, ,) (S (VP (VBG leaving) (NP (NP (DT the) (JJ distal) (NN delivery) (NNS unchanged.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))
1420741	0	(S1 (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_1420741_13_28_Disease))) (PP (IN with) (NP (NNP Doc_1420741_34_46_Chemical)))) (: :) (NP (NP (DT an) (JJ antibiotic)) (PP (IN with) (NP (NP (JJ immunosuppressive) (NNS properties)) (ADJP (JJ similar) (PP (TO to) (NP (NNP Doc_1420741_107_118_Chemical))))))) (. .)))
1420741	1	(S1 (S (NP (JJ Fusidic) (NN acid)) (VP (AUX is) (NP (NP (DT an) (JJ antibiotic)) (PP (IN with) (NP (NP (JJ T-cell) (JJ specific) (JJ immunosuppressive) (NNS effects)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_1420741_217_228_Chemical)))))))))) (. .)))
1420741	2	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ new) (NNS treatments))) (PP (IN for) (NP (NNP Doc_1420741_292_307_Disease))))))) (, ,) (NP (DT a) (NN pilot) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NNS pharmacodynamics) (CC and) (NN tolerability)) (PP (IN of) (NP (JJ Doc_1420741_391_403_Chemical) (NN treatment))) (PP (IN in) (NP (JJ chronic) (JJ active) (, ,) (JJ therapy-resistant) (NNS patients))))))))) (. .)))
1420741	3	(S1 (S (NP (CD Eight) (JJ Doc_1420741_467_482_Disease) (NNS patients)) (VP (AUX were) (VP (VBN included))) (. .)))
1420741	4	(S1 (S (S (NP (NN Doc_1420741_507_519_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 500) (JJ mg) (NN t.d.s.)))))))) (CC and) (S (NP (DT the) (NN treatment)) (VP (AUX was) (VP (VBN planned) (S (VP (TO to) (VP (VB last) (NP (CD 8) (NNS weeks)))))))) (. .)))
1420741	5	(S1 (S (NP (DT The) (NN disease) (NN activity)) (VP (AUX was) (ADVP (RB primarily)) (VP (VBN measured) (PP (IN by) (NP (DT a) (VBN modified) (JJ individual) (NN grading) (NN score))))) (. .)))
1420741	6	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (NP (CD 8) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-))))) (VP (VBD improved) (PP (IN during) (NP (NP (JJ Doc_1420741_743_755_Chemical) (NN treatment)) (: :) (NP (NP (NP (CD 3)) (PP (IN at) (NP (CD two) (NNS weeks)))) (CC and) (NP (NP (CD 2)) (PP (IN after) (NP (CD four) (NNS weeks)))))))) (. .)))
1420741	7	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ serious) (JJ clinical) (NN side) (NNS effects)))) (, ,) (CC but) (S (NP (NN dose) (NN reduction)) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (CD two) (NNS patients))) (PP (IN because) (IN of) (NP (NN Doc_1420741_910_916_Disease)))))) (. .)))
1420741	8	(S1 (S (ADVP (RB Biochemically)) (, ,) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ alkaline) (NNS phosphatases)))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 5)) (PP (IN of) (NP (NP (CD 8) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (DT the) (JJS greatest) (NNS increases)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ elevated) (NNS levels)) (ADVP (RB prior) (PP (TO to) (NP (NN treatment)))))))))))) (. .)))
1420741	9	(S1 (S (NP (DT All)) (VP (VBD reversed) (PP (TO to) (NP (JJ pre-treatment) (NNS levels))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN treatment)))))) (. .)))
1420741	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN pilot) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1420741_1205_1217_Chemical)) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN benefit))) (PP (IN in) (NP (NP (JJ selected) (JJ chronic) (JJ active) (NN Doc_1420741_1263_1278_Disease) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ conventional) (NN treatment)) (VP (AUX is) (ADJP (JJ ineffective)))))))))))) (. .)))
1420741	11	(S1 (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBZ seems) (S (VP (TO to) (VP (VB exist) (NP (NP (DT a) (JJ scientific) (NN rationale)) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1420741_1402_1414_Chemical))) (PP (IN at) (NP (NP (DT the) (JJ cytokine) (NN level)) (PP (IN in) (NP (NNP Doc_1420741_1440_1466_Disease)))))))))))))) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT this) (NN treatment)))) (VP (MD should) (VP (AUX be) (VP (ADVP (RB further)) (VBN investigated))))))) (. .)))
1428568	0	(S1 (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ Doc_1428568_11_21_Disease) (NN status))) (VP (VBN associated) (PP (IN with) (NP (JJ topical) (NNS beta-blockers)))) (. .)))
1428568	1	(S1 (S (NP (NP (NNP Doc_1428568_68_78_Disease)) (CC and) (NP (NNP Doc_1428568_83_101_Disease))) (VP (AUX have) (VP (AUX been) (ADJP (JJ related) (PP (TO to) (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (JJ topical) (NNS beta-blockers)))))))) (. .)))
1428568	2	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (DT a) (JJ preliminary) (NN study)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT any) (NN difference)) (PP (IN between) (NP (NP (NP (NP (DT a) (JJ non) (JJ selective) (NN beta-blocker)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1428568_270_277_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ selective) (NN beta-blocker)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1428568_309_318_Chemical)) (-RRB- -RRB-)))) (VP (VBG regarding) (NP (NNP CNS) (NN side) (NNS effects)))))))))) (. .)))
1428568	3	(S1 (S (NP (NP (CD Eight) (JJ Doc_1428568_354_366_Disease) (NNS patients)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1428568_401_408_Chemical) (ADJP (CD 0.5) (NN %)) (NNS /12h)) (, ,) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_1428568_434_444_Disease)) (VP (VBN diagnosed) (PP (IN through) (NP (JJ DMS-III-R) (NNS criteria))))))) (, ,))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
1428568	4	(S1 (S (PP (IN During) (NP (NP (DT the) (JJ six-month)) (VP (VB follow) (PRT (RP up))))) (, ,) (NP (NNP Doc_1428568_543_553_Disease)) (VP (AUX was) (VP (VBN quantified) (PP (IN through) (NP (DT the) (NNP Beck) (CC and) (NNP Zung-Conde) (NNS scales))) (NP (DT every) (CD two) (NNS months)))) (. .)))
1428568	5	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ double) (JJ blind) (NN cross-over) (NN study)) (PP (IN with) (NP (NN control) (NN group))))) (, ,) (NP (NP (DT the) (NNS patients)) (PP (IN under) (NP (JJ Doc_1428568_700_707_Chemical) (NN treatment)))) (VP (VBD presented) (NP (NP (JJR higher) (NNP Doc_1428568_735_745_Disease) (NNS values)) (VP (VBN measured) (PP (IN through) (NP (NP (DT the) (NNP Beck)) (CC and) (NP (NP (DT the) (JJ Zung-Conde) (NNS scales)) (PRN (-LRB- -LRB-) (NP (CD p) (NN <) (CD 0.001) (NNP vs) (NN control)) (-RRB- -RRB-)))))))) (. .)))
1428568	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1428568_856_865_Chemical)) (VP (MD could) (VP (AUX be) (NP (NP (JJR less)) (PP (IN of) (NP (DT a) (NN Doc_1428568_885_895_Disease-inducer))) (PP (IN than) (NP (NP (NNP Doc_1428568_909_916_Chemical)) (PP (IN in) (NP (JJ predisposed) (NNS patients))))))))))) (. .)))
1436384	0	(S1 (NP (NP (NN Protection)) (PP (IN against) (NP (NNP Doc_1436384_19_30_Chemical-induced) (NNP Doc_1436384_39_52_Disease))) (PP (IN toward) (NP (NP (JJ striatal) (JJ Doc_1436384_69_77_Chemical) (NNS neurons)) (PP (IN in) (NP (NP (NNS rodents)) (PP (IN by) (NP (NP (NNP Doc_1436384_100_108_Chemical)) (, ,) (NP (DT an) (JJ excitatory) (NNP Doc_1436384_124_134_Chemical) (NN antagonist)))))))) (. .)))
1436384	1	(S1 (S (NP (NP (NNP Doc_1436384_147_155_Chemical)) (, ,) (NP (NNP Doc_1436384_157_235_Chemical)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (NP (DT the) (NNP Doc_1436384_286_306_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_1436384_308_312_Chemical)) (-RRB- -RRB-)) (NN subtype)) (PP (IN of) (NP (JJ Doc_1436384_325_334_Chemical) (NN receptor)))))))))) (. .)))
1436384	2	(S1 (S (ADVP (RB Here)) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_403_411_Chemical))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN by) (NP (NNP Doc_1436384_431_442_Chemical))) (PP (IN in) (NP (JJ Doc_1436384_446_455_Chemical-treated) (NNS rats)))))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
1436384	3	(S1 (S (NP (NP (DT A) (JJ single) (ADJP (CD 18.4) (NN mg/kg)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-)) (NN dose)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_1436384_523_534_Chemical) (NN hemisulfate))) (, ,) (VP (VBN given) (PP (TO to) (NP (NNS rats))) (PP (VBN pretreated) (PP (IN with) (NP (NNP Doc_1436384_578_587_Chemical))))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ persistent) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_625_633_Chemical))))) (PP (IN in) (NP (DT the) (NN striatum))) (ADVP (NP (CD 1) (NN week)) (RB later))) (. .)))
1436384	4	(S1 (S (NP (NP (DT This) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_692_700_Chemical))) (PP (IN in) (NP (DT the) (NN striatum)))) (VP (AUX was) (VP (VBN antagonized) (PP (PP (IN by) (NP (NP (NNP Doc_1436384_736_747_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_1436384_749_755_Chemical)) (, ,) (NP (NP (DT a) (JJ non-competitive) (NN antagonist)) (PP (IN of) (NP (JJ Doc_1436384_789_793_Chemical) (NNS receptors))))) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (NNP Doc_1436384_811_819_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ competitive) (NN antagonist)) (PP (IN of) (NP (JJ Doc_1436384_849_853_Chemical) (NNS receptors)))) (-RRB- -RRB-))))))) (. .)))
1436384	5	(S1 (S (NP (NP (DT The) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_1436384_891_899_Chemical)))) (VP (AUX was) (ADJP (JJ dose-dependent)) (, ,) (S (VP (AUXG being) (ADJP (JJ maximum)) (PP (IN at) (NP (NP (JJ 10-40) (NNS mgkg)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-))))))) (. .)))
1436384	6	(S1 (S (NP (NP (DT A) (ADJP (CD 10) (NN mg/kg)) (NN dose)) (PP (IN of) (NP (NNP Doc_1436384_975_983_Chemical)))) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_1031_1039_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (, ,) (SBAR (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (QP (RB as) (JJ long) (IN as) (CD 8)) (NN hr)) (PP (ADVP (RB prior)) (TO to) (NP (NNP Doc_1436384_1093_1104_Chemical)))))) (CC but) (SBAR (WHADVP (RB not) (WRB when)) (S (VP (VBN given) (NP (CD 24) (NN hr)) (PP (RB prior) (PP (TO to) (NP (NNP Doc_1436384_1139_1150_Chemical))))))))))))))) (. .)))
1436384	7	(S1 (S (S (NP (NP (NN Depletion)) (PP (IN of) (NP (NNP Doc_1436384_1165_1173_Chemical))) (PP (IN in) (NP (DT the) (NN striatum)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN antagonized) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_1436384_1216_1224_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_1436384_1258_1269_Chemical)))))))))))) (: ;) (S (NP (NNP Doc_1436384_1271_1279_Chemical)) (VP (VBD protected) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PRT (RP up)) (PP (TO to) (NP (QP (CD 4) (CD hr)))) (SBAR (IN after) (FRAG (CC but) (RB not) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (QP (CD 8) (CC or) (CD 24)) (NN hr)) (PP (IN after) (NP (NNP Doc_1436384_1354_1365_Chemical))))))))))))) (. .)))
1436384	8	(S1 (S (NP (NP (DT The) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_1394_1402_Chemical))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN in) (NP (NNS mice)))))) (, ,) (PP (VBN given) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_1436384_1457_1472_Chemical))))) (, ,) (VP (AUX was) (ADVP (RB also)) (VP (VBN antagonized) (ADVP (RB dose-dependently) (CC and) (RB completely)) (PP (IN by) (NP (NNP Doc_1436384_1530_1538_Chemical))))) (. .)))
1436384	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP strengthen) (NP (DT the) (NN evidence) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ Doc_1436384_1582_1592_Disease) (NN effect)) (PP (IN of) (NP (NP (UCP (NNP Doc_1436384_1603_1614_Chemical) (CC and) (JJ related)) (NNS compounds)) (PP (IN toward) (NP (JJ nigrostriatal) (NNP Doc_1436384_1658_1666_Chemical) (NNS neurons)))))) (VP (VBZ involves) (NP (JJ Doc_1436384_1684_1688_Chemical) (NNS receptors))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_1436384_1708_1716_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ Doc_1436384_1723_1727_Chemical) (NN receptor) (NN antagonist)) (PP (IN with) (NP (NP (NN long-lasting)) (PP (IN in) (NP (NP (NN vivo) (NNS effects)) (PP (IN in) (NP (NNS rats)))))))))))))) (. .)))
14513889	0	(S1 (NP (JJ Doc_14513889_0_12_Chemical-induced) (NN Doc_14513889_21_40_Disease) (. .)))
14513889	1	(S1 (S (NP (DT A) (JJ 77-y-old) (NN patient)) (VP (VBD developed) (NP (NNP Doc_14513889_71_94_Disease) (, ,) (NNP Doc_14513889_96_110_Disease) (, ,) (NNP Doc_14513889_112_122_Disease) (CC and) (NNP Doc_14513889_127_133_Disease) (CD 1) (NNP h)) (PP (IN after) (NP (NP (NN ingestion)) (PP (IN of) (NP (QP (CD 200) (CD mg)) (NN Doc_14513889_164_176_Chemical))) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (PP (IN in) (NP (PRP$ his) (NN life)))))))) (. .)))
14513889	2	(S1 (S (S (NP (DT All) (NNS complaints)) (VP (VBN faded) (PRT (RP away)) (PP (IN within) (NP (CD 24) (NNP h.) (JJ Few) (NNS days))) (ADVP (RB later)))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBN used) (NP (DT another) (ADJP (CD 200) (NN mg)) (JJ Doc_14513889_296_308_Chemical) (NN tablet))) (, ,) (CC and) (VP (PP (IN within) (NP (DT an) (NN hour))) (VBD experienced) (NP (NP (DT a) (JJ similar) (JJ clinical) (NN picture)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (ADVP (RB again)) (ADVP (RB spontaneously)) (PP (IN within) (NP (NNS hours))))))))) (. .)))
14513889	3	(S1 (S (NP (NP (NN Laboratory) (NNS evaluations)) (, ,) (PP (VBG including) (S (NP (NN head) (NNS CT)) (VP (VB scan)))) (, ,)) (VP (AUX were) (ADJP (JJ normal))) (. .)))
14513889	4	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ close) (NN vigilance)) (PP (IN in) (NP (NNP Doc_14513889_540_562_Disease)))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (DT the) (JJ elderly)))) (. .)))
14568327	0	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (NP (NNP Doc_14568327_15_23_Chemical-induced) (NNP Doc_14568327_32_43_Disease)) (PP (IN in) (NP (JJ Doc_14568327_47_59_Disease) (NNS monkeys)))))) (VP (MD may) (VP (VB depend) (PP (IN upon) (NP (NP (NN rate)) (PP (IN of) (NP (NP (NN symptom) (NN onset) (NN and/or) (NN duration)) (PP (IN of) (NP (NNS symptoms))))))))) (. .)))
14568327	1	(S1 (S (NP (NP (JJ Doc_14568327_135_143_Chemical-induced) (NNP Doc_14568327_152_163_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14568327_165_169_Disease)) (-RRB- -RRB-))) (VP (VBP present) (NP (NP (DT a) (JJ major) (NN problem)) (PP (IN for) (NP (NP (DT the) (JJ long-term) (NN management)) (PP (IN of) (NP (NNP Doc_14568327_227_246_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_14568327_248_250_Disease)) (-RRB- -RRB-)) (NNS patients))))))) (. .)))
14568327	2	(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN interdependence)) (PP (IN of) (NP (NN risk) (NNS factors))) (PP (IN in) (NP (JJ clinical) (NNS populations))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (ADVP (RB independently)) (VP (VB examine) (NP (NP (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_14568327_417_421_Disease))))))))))))))) (. .)))
14568327	3	(S1 (S (S (VP (VBG Using) (NP (NN macaque) (NNS monkeys)) (PP (IN with) (NP (NP (JJ different) (NNS types)) (PP (IN of) (NP (NNP Doc_14568327_469_473_Chemical-induced) (NNP Doc_14568327_482_494_Disease))))))) (, ,) (NP (DT the) (JJ current) (NN study)) (VP (VBN evaluated) (NP (NP (DT the) (NN degree)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NN rate)) (PP (IN of) (NP (NP (NN symptom) (NN progression)) (, ,) (NP (NN symptom) (NN severity)) (, ,) (CC and) (NP (NP (NN response)) (PP (TO to) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (JJ Doc_14568327_623_631_Chemical) (NN therapy))))))))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_14568327_678_682_Disease)))))))))))) (. .)))
14568327	4	(S1 (S (NP (NP (NNS Monkeys)) (PP (IN with) (NP (NP (JJ acute) (PRN (-LRB- -LRB-) (JJ short-term) (-RRB- -RRB-)) (JJ Doc_14568327_716_720_Chemical) (NN exposure)) (, ,) (NP (JJ rapid) (NN symptom) (NN onset)) (CC and) (NP (JJ short) (NN symptom) (NN duration))))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_14568327_801_809_Chemical) (NN therapy)))))) (VP (VBD developed) (NP (NNP Doc_14568327_828_838_Disease)) (PP (IN between) (NP (NP (CD 11) (CC and) (CD 24) (NNS days)) (PP (IN of) (NP (JJ daily) (JJ Doc_14568327_871_879_Chemical) (NN administration)))))) (. .)))
14568327	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS monkeys)) (PP (IN with) (NP (NP (JJ long-term) (JJ Doc_14568327_932_936_Chemical) (NN exposure)) (, ,) (NP (JJ slow) (NN symptom) (NN progression) (NN and/or) (JJ long) (NN symptom) (NN duration))))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_14568327_1024_1032_Chemical) (NN therapy)))))) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ resistant)) (PP (TO to) (S (VP (VBG developing) (NP (NP (NNP Doc_14568327_1075_1079_Disease)) (PRN (-LRB- -LRB-) (NP (NNP e.g.)) (, ,) (NP (NP (NNP Doc_14568327_1087_1097_Disease)) (VP (VBD developed) (ADVP (DT no) (RBR sooner)) (PP (IN than) (NP (NP (CD 146) (NNS days)) (PP (IN of) (NP (JJ chronic) (NNP Doc_14568327_1143_1151_Chemical) (NN administration))))))) (-RRB- -RRB-)))))))) (. .)))
14568327	6	(S1 (S (NP (DT All) (NNS animals)) (VP (VP (AUX were) (ADJP (RB similarly) (JJ symptomatic)) (PP (IN at) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (JJ Doc_14568327_1224_1232_Chemical) (NN treatment)))))) (CC and) (VP (AUX had) (NP (NP (JJ similar) (JJ therapeutic) (NNS responses)) (PP (TO to) (NP (DT the) (NN drug)))))) (. .)))
14568327	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ distinct) (NNS differences)) (PP (IN in) (NP (DT the) (NN propensity) (S (VP (TO to) (VP (VP (VB develop) (NP (NN Doc_14568327_1363_1367_Disease)) (PP (IN in) (NP (NP (NNS monkeys)) (PP (IN with) (NP (NP (JJ different) (NNS rates)) (PP (IN of) (NP (NN symptom) (NN progression) (CC or) (NN symptom) (NNS durations))))))) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_14568327_1453_1461_Chemical))))) (CC and) (VP (VB demonstrate) (NP (NP (DT the) (NN value)) (PP (IN of) (NP (DT these) (NNS models)))) (PP (IN for) (S (ADVP (RB further)) (VP (VBG studying) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_14568327_1548_1552_Disease))))))))))))))) (. .)))
14596845	0	(S1 (S (NP (DT A) (NN diet) (VBG promoting) (NN Doc_14596845_17_33_Disease)) (VP (VBZ causes) (NP (NN Doc_14596845_41_71_Disease)) (PP (TO to) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_14596845_89_100_Chemical)))))) (. .)))
14596845	1	(S1 (S (NP (NP (JJ Previous) (NN research)) (PP (IN in) (NP (DT this) (NN laboratory)))) (VP (AUX has) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT a) (NN diet)) (PP (IN of) (NP (JJ intermittent) (JJ excessive) (NN sugar) (NN consumption)))) (VP (VBZ produces) (NP (NP (DT a) (NN state)) (PP (IN with) (NP (NP (JJ neurochemical) (CC and) (JJ behavioral) (NNS similarities)) (PP (TO to) (NP (NN Doc_14596845_272_287_Disease))))))))))) (. .)))
14596845	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (JJ female) (NNS rats)) (PP (IN on) (NP (NP (JJ various) (NNS regimens)) (PP (IN of) (NP (NN sugar) (NN access)))))) (VP (MD would) (VP (VB show) (NP (NN Doc_14596845_383_413_Disease)) (PP (TO to) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_14596845_431_442_Chemical)))))))))) (. .)))
14596845	3	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ 30-min) (JJ baseline) (NN measure)) (PP (IN of) (NP (NP (NN locomotor) (NN activity)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 0)) (-RRB- -RRB-)))))) (, ,) (NP (NNS animals)) (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (JJ cyclic) (NN diet)) (PP (IN of) (NP (JJ 12-h) (NN deprivation))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ 12-h) (NN access)) (PP (TO to) (NP (NP (NP (CD 10) (NN %)) (NP (NNP Doc_14596845_599_606_Chemical) (NN solution) (CC and) (NN chow) (NNS pellets))) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNP h) (NN access)) (VP (VBG starting) (NP (CD 4) (NNP h)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (DT the) (JJ dark) (NN period))))))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 21) (NNS days)))))))))) (. .)))
14596845	4	(S1 (S (NP (NN Locomotor) (NN activity)) (VP (AUX was) (VP (VBN measured) (ADVP (RB again)) (PP (IN for) (NP (CD 30) (NN min))) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (NNS days) (CD 1) (CC and) (CD 21)) (PP (IN of) (NP (NN sugar) (NN access))))))))) (. .)))
14596845	5	(S1 (S (PP (VBG Beginning) (PP (IN on) (NP (NN day) (CD 22)))) (, ,) (NP (DT all) (NNS rats)) (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NN ad) (NN libitum) (NN chow))))) (. .)))
14596845	6	(S1 (S (ADVP (NP (CD Nine) (NNS days)) (RB later)) (NP (NN locomotor) (NN activity)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT a) (JJ single) (JJ low) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_14596845_954_965_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)))))))))) (. .)))
14596845	7	(S1 (S (NP (NP (DT The) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ cyclic) (NN Doc_14596845_1019_1026_Chemical) (CC and) (NN chow))))))) (VP (AUX were) (ADJP (JJ Doc_14596845_1041_1052_Disease) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_14596845_1068_1079_Chemical)))))) (PP (VBN compared) (PP (IN with) (NP (NP (CD four) (NN control) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN ad) (NN libitum)) (NP (CD 10) (NN %))) (ADJP (JJ Doc_14596845_1130_1137_Chemical) (CC and) (JJ chow))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_14596845_1159_1170_Chemical) (NN injection)) (, ,) (NP (NP (JJ cyclic) (NN chow)) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_14596845_1206_1217_Chemical) (NN injection)) (, ,) (NP (NP (NN ad) (NN libitum) (NN chow)) (PP (IN with) (NP (NNP Doc_14596845_1250_1261_Chemical)))) (, ,) (CC or) (NP (JJ cyclic) (ADJP (CD 10) (NN %)) (NN Doc_14596845_1277_1284_Chemical)))))) (CC and) (NP (NP (NN chow)) (PP (IN with) (NP (DT a) (JJ saline) (NN injection)))))))) (-RRB- -RRB-)))))) (. .)))
14596845	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (NN diet)) (VP (VBN comprised) (PP (IN of) (S (VP (VBG alternating) (NP (NP (NN deprivation) (CC and) (NN access)) (PP (TO to) (NP (NP (DT a) (NN sugar) (NN solution)) (CC and) (NP (NN chow)))))))))) (VP (VBZ produces) (NP (NP (NN bingeing)) (PP (IN on) (NP (NN sugar))) (SBAR (WHNP (WDT that)) (S (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ long) (JJ lasting) (NN state)) (PP (IN of) (NP (NP (JJ increased) (NN sensitivity)) (PP (TO to) (NP (NNP Doc_14596845_1521_1532_Chemical))))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (PP (TO to) (NP (NP (DT a) (JJ lasting) (NN alteration)) (PP (IN in) (NP (DT the) (JJ Doc_14596845_1578_1586_Chemical) (NN system)))))))))))))) (. .)))
14657095	0	(S1 (S (NP (JJ Reversible) (NNP Doc_14657095_11_33_Disease)) (VP (VBD related) (PP (TO to) (NP (JJ Doc_14657095_45_59_Chemical) (NN therapy)))) (. .)))
14657095	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NN Doc_14657095_105_127_Disease)) (CC and) (NP (JJ clinical) (JJ congestive) (NN Doc_14657095_152_165_Disease))) (PP (IN after) (NP (NP (CD 2) (NNS months)) (PP (IN of) (NP (NN therapy))))) (PP (IN with) (NP (NP (NNP Doc_14657095_197_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14657095_213_216_Chemical)) (-RRB- -RRB-)))))))) (PP (IN for) (NP (VBN disseminated) (NN Doc_14657095_235_253_Disease)))) (. .)))
14657095	2	(S1 (S (NP (NP (PRP$ His) (JJ echocardiographic) (NNS abnormalities)) (CC and) (NP (NNP Doc_14657095_295_308_Disease))) (VP (VBD resolved) (SBAR (IN after) (S (NP (NNP Doc_14657095_324_336_Chemical)) (VP (AUX was) (VP (VBN substituted) (PP (IN for) (NP (NN Doc_14657095_357_360_Chemical)))))))) (. .)))
14657095	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB recognize) (NP (NP (DT the) (ADJP (ADJP (JJ rare)) (CC and) (ADJP (RB potentially) (JJ reversible))) (NN Doc_14657095_427_435_Disease)) (PP (IN of) (NP (NNP Doc_14657095_439_442_Chemical)))))))) (. .)))
14659530	0	(S1 (NP (NP (JJ Doc_14659530_0_2_Chemical-induced) (NN Doc_14659530_11_19_Disease) (NN attack)) (: :) (NP (NP (NP (JJ strong) (NN increase)) (PP (IN in) (NP (NN plasma) (NNP Doc_14659530_54_85_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_87_91_Chemical)) (-RRB- -RRB-)) (NN concentration)))) (CC and) (NP (NP (JJ negative) (NN correlation)) (PP (IN with) (NP (JJ platelet) (JJ Doc_14659530_146_155_Chemical) (NN release))))) (. .)))
14659530	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB investigate) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NN plasma) (NNP Doc_14659530_235_266_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_268_272_Chemical)) (-RRB- -RRB-)) (NN concentration))))) (CC and) (VP (VB platelet) (NP (NP (NNP Doc_14659530_301_310_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_312_331_Chemical)) (, ,) (NP (NNP Doc_14659530_333_337_Chemical)) (-RRB- -RRB-)) (NN content)) (PP (IN during) (NP (NP (DT the) (JJ immediate) (NN Doc_14659530_368_376_Disease)) (CC and) (NP (NP (DT the) (VBN delayed) (JJ genuine) (NN Doc_14659530_401_409_Disease) (NN attack)) (VP (VBN provoked) (PP (IN by) (NP (NNP Doc_14659530_429_442_Chemical))))))))))))) (. .)))
14659530	2	(S1 (S (NP (NP (JJ Fifteen) (NN female) (NN Doc_14659530_459_485_Disease)) (CC and) (NP (CD eight) (NNS controls))) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
14659530	3	(S1 (S (NP (NP (NNP Sublingual) (NNP Doc_14659530_543_556_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered))) (. .)))
14659530	4	(S1 (S (NP (NN Blood)) (VP (AUX was) (VP (VBN collected) (PP (IN from) (NP (DT the) (JJ antecubital) (NN vein))) (NP (NP (CD four) (NNS times)) (: :) (NP (NP (NP (CD 60) (NN min)) (PP (IN before) (CC and) (IN after) (NP (DT the) (NNP Doc_14659530_670_683_Chemical) (NN application)))) (, ,) (CC and) (NP (NP (QP (CD 60) (CC and) (CD 120)) (NN min)) (PP (IN after) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (DT the) (JJ Doc_14659530_743_751_Disease) (NN attack)) (PRN (-LRB- -LRB-) (NP (NP (QP (JJ mean) (CD 344) (CC and) (CD 404) (NN min))) (: ;) (NP (CD 12) (NNS subjects))) (-RRB- -RRB-))))))))))) (. .)))
14659530	5	(S1 (S (PP (IN In) (NP (NP (DT those) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT no) (JJ Doc_14659530_825_833_Disease) (NN attack))))) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS subjects)) (-RRB- -RRB-)))) (NP (DT a) (JJ similar) (NN time) (NN schedule)) (VP (AUX was) (VP (VBN used))) (. .)))
14659530	6	(S1 (S (NP (NN Plasma) (JJ Doc_14659530_896_900_Chemical) (NN concentration)) (VP (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01)) (-RRB- -RRB-)) (PP (IN during) (NP (DT the) (NNP Doc_14659530_959_967_Disease) (NN attack)))) (CC and) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (NP (NP (DT the) (NN cessation)) (PP (IN of) (NP (DT the) (NNP Doc_14659530_1027_1035_Disease))))))) (. .)))
14659530	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT both) (NN change)) (CC and) (NP (NN peak)) (, ,)) (VP (VBD showed) (NP (NP (JJ significant) (JJ positive) (NNS correlations)) (PP (IN with) (NP (NP (NNP Doc_14659530_1118_1126_Disease) (NNP Doc_14659530_1127_1135_Disease) (NN intensity)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (-RRB- -RRB-)))))) (. .)))
14659530	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NN plasma) (NN Doc_14659530_1173_1177_Chemical) (NNS concentrations)) (VP (VBD failed) (S (VP (TO to) (VP (VB change) (PP (PP (IN during) (NP (JJ immediate) (NN Doc_14659530_1227_1235_Disease))) (CC and) (PP (IN in) (NP (NP (DT the) (NNS subjects)) (PP (IN with) (NP (DT no) (JJ Doc_14659530_1264_1272_Disease) (NN attack)))))))))) (. .)))
14659530	9	(S1 (S (S (NP (JJ Basal) (JJ Doc_14659530_1287_1291_Chemical) (NN concentration)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)))) (CC and) (S (NP (NN platelet) (JJ Doc_14659530_1344_1348_Chemical) (NN content)) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (ADJP (JJR lower)) (PP (IN in) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT a) (JJ Doc_14659530_1406_1414_Disease) (NN attack)))))))))))) (. .)))
14659530	10	(S1 (S (S (NP (NNP Platelet) (NNP Doc_14659530_1432_1441_Chemical) (NN content)) (VP (VBD decreased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01)) (-RRB- -RRB-)) (PP (IN after) (NP (NP (NNP Doc_14659530_1489_1502_Chemical)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (DT no) (NNP Doc_14659530_1523_1531_Disease) (NN attack))))))))) (CC but) (S (NP (DT no) (JJ consistent) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_14659530_1594_1602_Disease) (NN attack)))))))) (. .)))
14659530	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NN plasma) (JJ Doc_14659530_1647_1651_Chemical) (NN concentration)) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN timing) (CC and) (NN severity)) (PP (IN of) (NP (DT a) (JJ Doc_14659530_1711_1719_Disease) (NN Doc_14659530_1720_1728_Disease))))))))) (VP (VBZ suggests) (NP (NP (DT a) (JJ direct) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_14659530_1768_1772_Chemical)) (CC and) (NP (NNP Doc_14659530_1777_1785_Disease)))))) (. .)))
14659530	12	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ Doc_14659530_1800_1809_Chemical) (NN release)) (PP (IN from) (NP (NNS platelets)))) (VP (AUX does) (RB not) (VP (VB provoke) (NP (NNP Doc_14659530_1850_1858_Disease)) (, ,) (SBAR (S (NP (PRP it)) (VP (MD may) (ADVP (RB even)) (VP (VB counteract) (NP (NP (DT the) (NN Doc_14659530_1887_1895_Disease)) (CC and) (NP (DT the) (JJ concomitant) (JJ Doc_14659530_1916_1920_Chemical) (NN release))) (PP (IN in) (NP (DT this) (NN model))))))))) (. .)))
1468485	0	(S1 (NP (NP (JJ Hyperbaric) (JJ Doc_1468485_11_17_Chemical) (NN therapy)) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (JJ intractable) (JJ Doc_1468485_53_69_Chemical-induced) (NN Doc_1468485_78_98_Disease))))) (. .)))
1468485	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ intractable) (NNP Doc_1468485_132_152_Disease)))) (PP (JJ due) (TO to) (NP (NP (JJ Doc_1468485_160_176_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_1468485_189_213_Disease)))))) (. .)))
1468485	2	(S1 (S (NP (NP (JJ Conservative) (NN treatment)) (, ,) (PP (VBG including) (NP (NP (NP (NN bladder) (NN irrigation)) (PP (IN with) (NP (JJ physiological) (NN saline)))) (CC and) (NP (NP (NN instillation)) (PP (IN of) (NP (NNP Doc_1468485_314_336_Chemical)))))) (, ,)) (VP (VBD failed) (S (VP (TO to) (ADVP (RB totally)) (VP (VB control) (NP (NNP Doc_1468485_364_374_Disease)))))) (. .)))
1468485	3	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD used) (NP (JJ hyperbaric) (NNP Doc_1468485_400_406_Chemical)) (PP (IN at) (NP (NP (DT an) (JJ absolute) (NN pressure)) (PP (IN of) (NP (NP (CD 2) (NN atm)) (, ,) (NP (NP (CD 5) (NNS days)) (NP (DT a) (NN week))))) (PP (IN for) (NP (CD 8) (JJ consecutive) (NNS weeks)))))) (. .)))
1468485	4	(S1 (S (S (NP (DT The) (NNP Doc_1468485_484_492_Disease)) (VP (VBD ceased) (ADVP (RB completely)) (PP (IN by) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN treatment))))))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD remained) (ADJP (JJ free) (PP (IN of) (NP (NNP Doc_1468485_568_577_Disease)))) (ADVP (RB thereafter)))) (. .)))
1468485	5	(S1 (S (NP (DT No) (NN side) (NN effect)) (VP (AUX was) (VP (VBN noted) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN therapy))))))) (. .)))
1468485	6	(S1 (S (PP (IN In) (NP (NN future))) (, ,) (NP (NP (DT this) (NN form)) (PP (IN of) (NP (NN therapy)))) (VP (MD can) (VP (VB offer) (NP (DT a) (JJ safe) (NN alternative)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_1468485_726_742_Chemical-induced) (NNP Doc_1468485_751_771_Disease))))))) (. .)))
14698717	0	(S1 (S (VP (VB Doc_14698717_0_15_Disease) (PP (JJ due) (TO to) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_14698717_38_47_Chemical))) (PP (IN in) (NP (DT a) (JJ nonepileptic) (NN patient)))) (. .)))
14698717	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_14698717_94_103_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ antiepileptic) (NN drug) (NN treatment))))) (VP (AUX is) (ADVP (RB usually)) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (DT the) (JJ Doc_14698717_197_206_Disease) (NN brain) (NN substratum)) (CC and) (NP (DT the) (JJ antiepileptic) (NNS drugs)))))))) (. .)))
14698717	2	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ nonepileptic) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_14698717_302_311_Disease)) (PP (VBG following) (NP (NP (JJ Doc_14698717_322_331_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_14698717_346_366_Disease))))))))))) (VP (AUX is) (VP (VBN described))) (. .)))
14698717	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_14698717_409_427_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (VBG following) (NP (NP (JJ Doc_14698717_449_458_Chemical) (NN treatment)) (PP (IN in) (NP (DT some) (JJ Doc_14698717_477_486_Disease) (NNS patients))))))))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ direct) (NN result)) (PP (IN of) (NP (NN medication))) (, ,) (ADJP (JJ unrelated) (PP (TO to) (NP (NN Doc_14698717_549_557_Disease)))))))))) (. .)))
14765563	0	(S1 (NP (NP (NNS Risks)) (PP (IN of) (NP (NP (DT the) (NN consumption)) (PP (IN of) (NP (NP (NNS beverages)) (VP (VBG containing) (NP (NNP Doc_14765563_49_56_Chemical))))))) (. .)))
14765563	1	(S1 (S (SBAR (IN Although) (S (NP (DT the) (NNP United) (NNP States) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (VP (VBD banned) (NP (NP (PRP$ its) (NN use)) (PP (IN for) (NP (NNP Doc_14765563_133_153_Disease)))) (PP (JJ due) (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))))))))) (, ,) (NP (NNP Doc_14765563_190_197_Chemical)) (VP (AUX is) (ADJP (RB widely) (JJ available) (PP (IN in) (NP (NP (NNS beverages)) (PP (VBG including) (NP (NP (NN tonic) (NN water)) (CC and) (NP (JJ bitter) (NNP lemon)))))))) (. .)))
14765563	2	(S1 (S (NP (JJ Numerous) (JJ anecdotal) (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS products)) (VP (VBG containing) (NP (NNP Doc_14765563_331_338_Chemical)))) (VP (MD may) (VP (VB produce) (NP (NN Doc_14765563_351_377_Disease)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_14765563_389_398_Disease)) (, ,) (NP (JJ altered) (JJ mental) (NN status)) (, ,) (NP (NNP Doc_14765563_423_431_Disease)) (, ,) (CC and) (NP (NNP Doc_14765563_437_441_Disease)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJR older) (NNS women)))))))) (. .)))
14765563	3	(S1 (S (NP (NNS Psychologists)) (VP (AUX need) (S (VP (TO to) (VP (VB inquire) (PP (IN about) (NP (NP (NN consumption)) (PP (IN of) (NP (JJ Doc_14765563_523_530_Chemical-containing) (NNS beverages))))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT an) (NN evaluation) (NN process))))))))) (. .)))
14976857	0	(S1 (S (NP (JJ Transient) (NNP Doc_14976857_10_45_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14976857_57_68_Chemical) (NNP Doc_14976857_69_77_Disease))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (PP (IN with) (NP (NNP Doc_14976857_100_117_Disease)))))) (. .)))
14976857	1	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 37-year-old) (JJ white) (NN woman)) (PP (IN with) (NP (NP (NNP Doc_14976857_189_206_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT a) (JJ rare) (NN syndrome)) (VP (VBN called) (S (NP (NP (NNP Doc_14976857_245_266_Disease)) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ massive) (JJ right-to-left) (JJ interatrial) (NN shunting)) (PP (IN with) (NP (NP (JJ transient) (JJ profound) (NN Doc_14976857_352_359_Disease)) (CC and) (NP (NNP Doc_14976857_364_372_Disease)))))))))))))))))))) (. .)))
14976857	2	(S1 (S (NP (NP (DT This) (NN shunt)) (PP (IN of) (NP (NN blood))) (PP (IN via) (NP (DT a) (NNP Doc_14976857_400_420_Disease)))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ normal) (NN pulmonary) (NN artery) (NN pressure)))))) (, ,) (CC and) (VP (AUX was) (ADVP (RB probably)) (VP (VBD precipitated) (PP (IN by) (NP (DT a) (NNP Doc_14976857_520_531_Chemical) (NNP Doc_14976857_532_540_Disease)))))) (. .)))
14976857	3	(S1 (S (NP (DT This) (NN drug)) (VP (VBD caused) (NP (NP (NP (NNP Doc_14976857_559_584_Disease)) (, ,) (ADJP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ negative) (NN inotropic) (NN effect)))) (, ,)) (CC and) (NP (NNP Doc_14976857_628_639_Disease))) (, ,) (PP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ peripheral) (NN vasodilatory) (NN effect))))) (. .)))
14976857	4	(S1 (S (NP (DT These) (NNS effects)) (VP (VBD gave) (NP (NN rise)) (PP (TO to) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ right) (NN atrial) (NN pressure)))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (NN left) (CD one)))))) (PP (IN with) (NP (NP (NP (DT a) (JJ consequent) (VBG stretching)) (PP (IN of) (NP (DT the) (JJ foramen) (NN ovale)))) (CC and) (NP (NP (DT the) (NN creation)) (PP (IN of) (NP (JJ massive) (JJ right-to-left) (NN shunting))))))) (. .)))
14976857	5	(S1 (S (PP (IN In) (NP (PRP$ our) (NN case))) (NP (DT this) (JJ interatrial) (NN shunt)) (VP (AUX was) (ADVP (RB very) (RB accurately)) (VP (VBN detected) (PP (IN at) (NP (NN bubble) (NN contrast) (NN echocardiography))))) (. .)))
15009014	0	(S1 (S (NP (NP (JJ Noxious) (NN chemical) (NN stimulation)) (PP (IN of) (NP (NN rat) (JJ facial) (NNS mucosa)))) (VP (VBZ increases) (NP (JJ intracranial) (NN blood) (NN flow)) (PP (IN through) (NP (NP (DT a) (JJ trigemino-parasympathetic) (JJ reflex--an) (JJ experimental) (NN model)) (PP (IN for) (NP (NP (NNP Doc_15009014_154_175_Disease)) (PP (IN in) (NP (NNP Doc_15009014_179_195_Disease)))))))) (. .)))
15009014	1	(S1 (S (NP (NN Doc_15009014_197_213_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ typical) (JJ autonomic) (NNS dysfunctions)) (PP (VBG including) (NP (JJ facial) (CC and) (NNP Doc_15009014_286_320_Disease))))))) (. .)))
15009014	2	(S1 (S (NP (CC Both) (NP (DT the) (NN trigeminal)) (CC and) (NP (DT the) (JJ cranial) (NN parasympathetic) (NNS systems))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (S (VP (VBG mediating) (NP (DT these) (NNS dysfunctions)))))))) (. .)))
15009014	3	(S1 (S (NP (DT An) (JJ experimental) (NN model)) (VP (AUX was) (VP (VBN developed) (PP (IN in) (NP (DT the) (NN rat) (S (VP (TO to) (VP (VB measure) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NN lacrimation)))) (CC and) (NP (JJ intracranial) (NN blood) (NN flow))) (PP (VBG following) (NP (NP (JJ noxious) (NN chemical) (NN stimulation)) (PP (IN of) (NP (JJ facial) (NNS mucosa)))))))))))) (. .)))
15009014	4	(S1 (S (NP (NN Blood) (NN flow)) (VP (AUX was) (VP (VBN monitored) (PP (IN in) (NP (NP (NNS arteries)) (PP (IN of) (NP (NP (DT the) (VBN exposed) (NN cranial) (NN dura) (NN mater)) (CC and) (NP (NP (DT the) (JJ parietal) (NN cortex)) (VP (VBG using) (NP (NN laser) (NN Doppler) (NN flowmetry)))))))))) (. .)))
15009014	5	(S1 (S (NP (NP (NN Doc_15009014_723_732_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.01-1) (NN mm)) (-RRB- -RRB-))) (VP (VP (VBD applied) (PP (TO to) (NP (ADJP (JJ oral) (CC or) (JJ nasal)) (ADJP (RB mucosa) (VBN induced)) (NN Doc_15009014_785_827_Disease)))) (CC and) (VP (VBD provoked) (NP (NN lacrimation)))) (. .)))
15009014	6	(S1 (S (NP (DT These) (NNS responses)) (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (NP (JJ systemic) (NN pre-administration)) (PP (IN of) (NP (NP (NNP Doc_15009014_917_939_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
15009014	7	(S1 (S (NP (DT The) (JJ evoked) (NN Doc_15009014_963_992_Disease)) (VP (AUX were) (ADVP (RB also)) (VP (VBN abolished) (PP (IN by) (NP (NP (JJ topical) (NN pre-administration)) (PP (IN of) (NP (NP (NP (NNP Doc_15009014_1046_1054_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mm)) (-RRB- -RRB-))) (CC and) (NP (NP (NN -LSB-Lys1)) (, ,) (NP (NP (NNP Pro2,5) (, ,) (NNP Arg3,4) (, ,) (NNP Tyr6) (JJ -RSB-) (NN -VIP)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mm)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ vasoactive) (JJ intestinal) (NN polypeptide) (PRN (-LRB- -LRB-) (NNP VIP) (-RRB- -RRB-)) (NN antagonist)) (, ,)))))) (PP (IN onto) (NP (DT the) (VBN exposed) (NN dura) (NN mater))))) (. .)))
15009014	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ noxious) (NN stimulation)) (PP (IN of) (NP (JJ facial) (NNS mucosa)))) (VP (VBZ increases) (NP (NP (JJ intracranial) (NN blood) (NN flow)) (CC and) (NP (NN lacrimation))) (PP (IN via) (NP (DT a) (JJ trigemino-parasympathetic) (JJ reflex))))))) (. .)))
15009014	9	(S1 (S (NP (DT The) (NN blood) (NN flow) (NNS responses)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (NNP Doc_15009014_1399_1412_Chemical)) (CC and) (NP (NNP VIP)))) (PP (IN within) (NP (DT the) (NNS meninges)))))))))) (. .)))
15009014	10	(S1 (S (NP (JJ Similar) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_15009014_1500_1516_Disease)))))))) (. .)))
15036754	0	(S1 (NP (NP (NP (JJ Doc_15036754_0_15_Chemical-induced) (NN Doc_15036754_24_35_Disease)) (CC and) (NP (NN prevention))) (PP (IN of) (NP (NNP Doc_15036754_54_79_Disease))) (. .)))
15036754	1	(S1 (S (NP (NP (JJ Such) (NNP Doc_15036754_86_102_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_104_106_Chemical)) (-RRB- -RRB-)) (NNS compounds)) (PP (IN as) (NP (NP (NP (NNP Doc_15036754_121_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_149_152_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_15036754_155_160_Chemical)) (CC and) (NP (NNP Doc_15036754_165_170_Chemical))))) (VP (AUX are) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NP (NP (NNS acetylcholinesterases)) (PRN (-LRB- -LRB-) (NP (NNP AChEs)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS butyrylcholinesterases)) (PRN (-LRB- -LRB-) (NP (NNP BChEs)) (-RRB- -RRB-))))))) (. .)))
15036754	2	(S1 (S (NP (NP (DT The) (JJ acute) (NN Doc_15036754_272_280_Disease)) (PP (IN of) (NP (NNP Doc_15036754_284_287_Chemical)))) (VP (AUX is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (PRP$ their) (JJ irreversible) (ADJP (JJ binding) (PP (IN with) (NP (NP (NNS AChEs)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ elevates) (NP (NNP Doc_15036754_395_408_Chemical)))))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_410_413_Chemical)) (-RRB- -RRB-)) (NNS levels))))) (. .)))
15036754	3	(S1 (S (NP (NP (DT The) (JJ protective) (NN action)) (PP (IN of) (NP (NP (RB subcutaneously)) (PRN (-LRB- -LRB-) (NP (NNP SC)) (-RRB- -RRB-)))) (VP (VBN administered) (NP (NP (NNS antidotes)) (CC or) (NP (PRP$ their) (NNS combinations))) (PP (IN in) (NP (NNP Doc_15036754_516_519_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-)) (NN intoxication))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (JJ 9-10-weeks-old) (JJ Han-Wistar) (NN male) (NNS rats))))) (. .)))
15036754	4	(S1 (S (NP (DT The) (NNS rats)) (VP (VP (VBD received) (NP (NP (NP (NP (NP (NNP AChE) (NN reactivator) (NNP Doc_15036754_635_657_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_15036754_659_663_Chemical) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (QP (CD 30.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-)) (, ,) (NP (JJ anticonvulsant) (NNP Doc_15036754_697_705_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ -Doc_15036754_727_736_Chemical) (NN receptor) (NN agonist)) (NP (NP (NNP Doc_15036754_754_780_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_15036754_782_785_Chemical) (-RRB- -RRB-)))) (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_15036754_803_807_Chemical-receptor) (NN antagonist) (NNP Doc_15036754_828_847_Chemical)) (PRN (-LRB- -LRB-) (NP (CD +-MK801) (NN hydrogen) (NN maleate)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-))) (CC or) (NP (PRP$ their) (NNS combinations))) (PP (IN with) (NP (JJ cholinolytic) (NN drug))) (NP (NNP Doc_15036754_935_951_Chemical)) (-LRB- -LRB-) (NP (QP (CD 50.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-) (ADVP (RB immediately))) (CC or) (VP (NP (CD 30) (NN min)) (PP (IN after) (NP (NP (DT the) (JJ single) (NN SC) (NN injection)) (PP (IN of) (NP (NNP Doc_15036754_1023_1026_Chemical))))))) (. .)))
15036754	5	(S1 (S (NP (DT The) (NN control) (NNS rats)) (VP (VBD received) (NP (NP (NNP Doc_15036754_1054_1070_Chemical)) (, ,) (CONJP (CC but) (RB also)) (NP (NP (NN saline)) (CC and) (NP (NN olive) (NN oil))) (CONJP (RB instead) (IN of)) (NP (JJ other) (NNS antidotes)) (CC and) (NP (NP (NNP Doc_15036754_1133_1136_Chemical)) (, ,) (ADVP (RB respectively))))) (. .)))
15036754	6	(S1 (S (NP (DT All) (NNS rats)) (VP (AUX were) (VP (VBN terminated) (NP (DT either) (CD 24) (NNP h) (CC or) (NNP 3) (NNS weeks)) (PP (IN after) (NP (DT the) (JJ Doc_15036754_1210_1213_Chemical) (NN injection))))) (. .)))
15036754	7	(S1 (S (NP (NP (DT The) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15036754_1247_1250_Chemical-Doc_15036754_1251_1259_Chemical))))) (VP (VBD showed) (NP (JJ severe) (JJ typical) (JJ Doc_15036754_1282_1284_Chemical-induced) (NN Doc_15036754_1293_1301_Disease) (NNS signs))) (. .)))
15036754	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_15036754_1314_1317_Chemical) (, ,) (NNP Doc_15036754_1319_1327_Chemical) (CC or) (NNP Doc_15036754_1331_1335_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB immediately)) (PP (IN after) (NP (NNP Doc_15036754_1364_1367_Chemical-Doc_15036754_1368_1376_Chemical))))))) (, ,) (NP (DT these) (NNS treatments)) (VP (VP (VBN prevented)) (, ,) (VP (VBN delayed)) (CC or) (VP (VBN shortened) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ serious) (NNS signs)) (PP (IN of) (NP (NNP Doc_15036754_1462_1471_Disease)))))))) (. .)))
15036754	9	(S1 (S (NP (NN Doc_15036754_1473_1481_Chemical-Doc_15036754_1482_1487_Chemical)) (VP (AUX did) (RB not) (VP (VB offer) (NP (NP (DT any) (JJ additional) (NN protection)) (PP (IN against) (NP (NNP Doc_15036754_1536_1539_Chemical) (NNP Doc_15036754_1540_1548_Disease)))))) (. .)))
15036754	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNP Doc_15036754_1565_1568_Chemical) (, ,) (NNP Doc_15036754_1570_1578_Chemical) (CC and) (NNP Doc_15036754_1583_1587_Chemical)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_15036754_1608_1616_Chemical)))))) (VP (VP (VBD prevented) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ serious) (NNS signs)) (PP (IN of) (NP (NNP Doc_15036754_1662_1671_Disease))))))) (CC and) (VP (ADVP (RB thus)) (VBD reduced) (NP (NP (DT the) (NN Doc_15036754_1693_1701_Disease)) (PP (IN of) (NP (NNP Doc_15036754_1705_1708_Chemical))) (PP (IN in) (NP (NN rat)))))) (. .)))
150790	0	(S1 (S (NP (DT A) (JJ Doc_150790_2_12_Chemical-dependent) (NN Doc_150790_23_42_Disease)) (VP (VBN unmasked) (PP (IN by) (NP (NNP Doc_150790_55_64_Chemical)))) (. .)))
150790	1	(S1 (S (NP (DT A) (JJ 3-year-old) (NN girl)) (VP (AUX had) (NP (NN Doc_150790_88_112_Disease)) (, ,) (PP (IN with) (NP (NP (NNP Doc_150790_119_131_Disease)) (, ,) (NP (NNP Doc_150790_133_145_Disease)) (, ,) (CC and) (NP (NNP Doc_150790_151_172_Disease)))) (PP (IN after) (NP (NP (DT the) (JJ therapeutic) (NN administration)) (PP (IN of) (NP (NNP Doc_150790_213_222_Chemical)))))) (. .)))
150790	2	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ pharmacologic) (NNS doses)) (PP (IN of) (NP (NNP Doc_150790_269_293_Chemical)))))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (NN disappearance)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
150790	3	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (JJ Doc_150790_350_359_Chemical) (NN therapy))))) (NP (NP (DT a) (JJ similar) (NN pattern)) (PP (IN of) (NP (NN behavior)))) (VP (AUX was) (VP (VBN noted) (SBAR (IN that) (S (VP (AUX was) (VP (VBN controlled) (PP (IN by) (NP (NN Doc_150790_431_441_Chemical))))))))) (. .)))
150790	4	(S1 (S (S (NP (DT A) (NN placebo)) (VP (AUX had) (NP (DT no) (NN effect)))) (, ,) (CC but) (S (NP (NNP Doc_150790_472_483_Chemical)) (VP (AUX was) (ADJP (RB as) (JJ effective) (PP (IN as) (NP (NN Doc_150790_504_514_Chemical)))))) (. .)))
150790	5	(S1 (S (NP (NP (JJ Periodic) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_150790_539_549_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NN return)) (PP (IN of) (NP (DT the) (NNP Doc_150790_584_596_Disease))))))) (. .)))
150790	6	(S1 (S (NP (NP (DT The) (NN level)) (PP (IN of) (NP (NNP Doc_150790_611_620_Chemical))) (PP (IN in) (NP (DT the) (NN blood)))) (VP (AUX was) (ADVP (RB normal)) (PP (IN during) (NP (NP (DT the) (NNS periods)) (PP (IN of) (NP (NN relapse)))))) (. .)))
150790	7	(S1 (S (NP (JJ Metabolic) (NNS studies)) (VP (VBD suggested) (NP (DT a) (NN block)) (PP (IN in) (NP (NP (DT the) (JJ Doc_150790_719_729_Chemical) (NN pathway)) (PP (IN of) (NP (JJ Doc_150790_741_751_Chemical) (NN metabolism)))))) (. .)))
150790	8	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN followed) (PP (IN for) (NP (CD six) (NNS years)))))) (CC and) (VP (AUX has) (VP (VBN required) (NP (NP (JJ pharmacologic) (NNS doses)) (PP (IN of) (NP (NNP Doc_150790_848_858_Chemical)))) (S (VP (TO to) (VP (VB control) (NP (PRP$ her) (NN behavior)))))))) (. .)))
15120741	0	(S1 (NP (NP (NN Recurrent) (NN excitation)) (PP (IN in) (NP (NP (DT the) (JJ dentate) (NN gyrus)) (PP (IN of) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_15120741_63_85_Disease))))))) (. .)))
15120741	1	(S1 (S (S (NP (ADJP (JJ Similar) (PP (TO to) (NP (NNS rats)))) (, ,) (JJ systemic) (NNP Doc_15120741_113_124_Chemical) (NN injection)) (VP (VBZ causes) (NP (NP (NP (NNP Doc_15120741_142_160_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15120741_162_164_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ eventual) (NN development)) (PP (IN of) (NP (NP (NP (JJ spontaneous) (NN Doc_15120741_210_218_Disease)) (CC and) (NP (JJ mossy) (NN fiber))) (VP (VBG sprouting) (PP (IN in) (NP (UCP (NNP C57BL/6) (CC and) (JJ CD1)) (NNS mice)))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ physiological) (NNS correlates)) (PP (IN of) (NP (DT these) (NNS events)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN identified) (PP (IN in) (NP (NNS mice))))))) (. .)))
15120741	2	(S1 (S (NP (NP (NN Population) (NNS responses)) (PP (IN in) (NP (NP (JJ granule) (NNS cells)) (PP (IN of) (NP (DT the) (JJ dentate) (NNS gyrus)))))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (JJ transverse) (NNS slices)) (PP (IN of) (NP (NP (DT the) (JJ ventral) (NNS hippocampus)) (PP (IN from) (NP (ADJP (JJ Doc_15120741_479_490_Chemical-treated) (CC and) (JJ untreated)) (NNS mice))))))))) (. .)))
15120741	3	(S1 (S (PP (IN In) (NP (NP (NNP Doc_15120741_522_524_Chemical) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -free) (NN bathing) (NN medium)) (VP (VBG containing) (NP (NP (NNP Doc_15120741_560_571_Chemical)) (, ,) (NP (NP (NNS conditions)) (VP (VBN designed) (S (VP (TO to) (VP (VB increase) (NP (NN excitability)) (PP (IN in) (NP (DT the) (NNS slices)))))))))))) (, ,) (NP (NP (JJ electrical) (NN stimulation)) (PP (IN of) (NP (DT the) (NN hilus)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ single) (NN population) (NN spike)) (PP (IN in) (NP (NP (JJ granule) (NNS cells)) (PP (IN from) (NP (NP (NN control) (NNS mice)) (CC and) (NP (JJ Doc_15120741_746_757_Chemical-treated) (NNS mice)))) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB experience) (NP (NNP Doc_15120741_795_797_Disease))))))))))) (. .)))
15120741	4	(S1 (S (PP (IN In) (NP (JJ Doc_15120741_802_804_Disease) (NNS survivors))) (, ,) (NP (JJ similar) (NN stimulation)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN population)) (VP (ADVP (RB spike)) (VBN followed) (, ,) (PP (IN at) (NP (DT a) (JJ variable) (NN latency))) (, ,) (PP (IN by) (NP (NP (JJ negative) (JJ DC) (NNS shifts)) (CC and) (NP (NP (JJ repetitive) (NNS afterdischarges)) (PP (IN of) (NP (NP (CD 3-60) (NNP s) (NN duration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (JJ ionotropic) (JJ Doc_15120741_1006_1015_Chemical) (NN receptor) (NNS antagonists)))))))))))))))) (. .)))
15120741	5	(S1 (S (NP (NP (JJ Focal) (JJ Doc_15120741_1044_1053_Chemical) (NN photostimulation)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer))) (PP (IN at) (NP (NP (NNS sites)) (PP (JJ distant) (IN from) (NP (DT the) (NN recording) (NN pipette)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN population) (NNS responses)) (PP (IN of) (NP (NP (CD 1-30) (NNP s) (NN duration)) (PP (IN in) (NP (NP (NNS slices)) (PP (IN from) (NP (NP (NNP Doc_15120741_1208_1210_Disease) (NNS survivors)) (CONJP (CC but) (RB not)) (NP (JJ other) (NNS groups))))))))))) (. .)))
15120741	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (JJ Doc_15120741_1282_1284_Disease-induced) (JJ mossy) (NN fiber) (VBG sprouting)) (CC and) (NP (JJ synaptic) (NN reorganization))) (VP (AUX are) (NP (NP (JJ relevant) (NNS characteristics)) (PP (IN of) (NP (NP (JJ Doc_15120741_1375_1382_Disease) (NN development)) (PP (IN in) (NP (DT these) (JJ murine) (NNS strains)))))) (, ,) (S (VP (VBG resembling) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (JJ human) (NNP Doc_15120741_1451_1473_Disease))))))))))) (. .)))
15130900	0	(S1 (NP (NP (NP (NN Doc_15130900_0_22_Disease)) (PP (IN in) (NP (NNP Doc_15130900_26_50_Disease)))) (: :) (NP (NP (NNS risks)) (CC and) (NP (NP (NN relation)) (PP (TO to) (NP (NNP Doc_15130900_74_90_Chemical))))) (. .)))
15130900	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB assess)) (CC and) (VP (VB characterise) (NP (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_142_156_Disease)))) (, ,) (CC and) (NP (NP (PRP$ its) (NN relation)) (PP (TO to) (NP (NNP Doc_15130900_178_194_Chemical)))) (, ,)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15130900_213_237_Disease))))))))) (. .)))
15130900	2	(S1 (S (PP (IN In) (NP (NP (DT the) (NN population)) (VP (VBN based)))) (, ,) (NP (NP (JJ nationwide) (NNP Swedish) (NNP Inpatient) (NNP Register)) (NP (NP (DT a) (NN cohort)) (PP (IN of) (NP (CD 1065) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_15130900_342_366_Disease)) (, ,) (NP (CD 1969-95)) (, ,))))) (VP (AUX was) (VP (VBN identified))) (. .)))
15130900	3	(S1 (S (PP (IN Through) (NP (NP (NN linkage)) (PP (IN with) (NP (DT the) (NNP Swedish) (NNP Doc_15130900_426_432_Disease) (NNP Register))))) (, ,) (NP (NP (DT all) (NNS subjects)) (PP (IN in) (NP (NP (DT this) (NN cohort)) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_15130900_486_500_Disease))))))) (VP (AUX were) (VP (VBN identified))) (. .)))
15130900	4	(S1 (S (PP (VBN Nested) (PP (IN within) (NP (DT the) (NN cohort)))) (, ,) (NP (DT a) (VBN matched) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_15130900_623_639_Chemical)) (CC and) (NP (NNP Doc_15130900_644_658_Disease))))) (S (VP (VBG using) (NP (NP (NNS odds) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NNS ORs)) (-RRB- -RRB-))) (PP (IN as) (NP (JJ relative) (NN risk)))))))))) (. .)))
15130900	5	(S1 (S (PP (IN In) (NP (DT the) (NN cohort))) (NP (NP (NP (DT the) (JJ cumulative) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_738_752_Disease))) (PP (IN after) (NP (NNP Doc_15130900_759_783_Disease)))) (, ,) (CC and) (NP (NP (DT the) (JJ relative) (NN prevalence)) (PP (IN of) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15130900_829_843_Disease))))) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_872_896_Disease)))))))) (, ,)) (VP (AUX were) (ADVP (RB also)) (VP (VBN estimated))) (. .)))
15130900	6	(S1 (S (NP (NP (DT The) (JJ median) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_15130900_959_975_Chemical)))) (PP (IN among) (NP (NP (NP (NNS cases)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 11)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 25)) (-RRB- -RRB-))))) (VP (AUX were) (NP (NP (CD 113) (NNP g)) (CC and) (NP (CD 25) (NNP g))) (, ,) (ADVP (RB respectively))) (. .)))
15130900	7	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_1066_1080_Disease)))) (VP (VBN doubled) (PP (IN for) (NP (DT every) (CD 10) (NNP g) (NN increment))) (PP (IN in) (NP (NNP Doc_15130900_1117_1133_Chemical) (-LRB- -LRB-) (CC OR) (NP (NP (NP (NP (SYM =) (CD 2.0)) (, ,) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval))) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (QP (CD 0.8) (TO to) (CD 4.9))) (-RRB- -RRB-)))) (. .)))
15130900	8	(S1 (S (NP (NP (NN Treatment) (NN duration)) (NP (QP (RBR longer) (IN than) (CD 1)) (NN year))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ eightfold) (VBN increased) (NN risk)) (PRN (-LRB- -LRB-) (NP (QP (CC OR) (SYM =) (CD 7.7) (, ,) (CD 95)) (NN %) (QP (CD CI) (CD 0.9) (TO to) (CD 69))) (-RRB- -RRB-)))))) (. .)))
15130900	9	(S1 (S (S (NP (NP (DT The) (JJ absolute) (NN risk)) (PP (IN for) (NP (NNP Doc_15130900_1325_1339_Disease))) (PP (IN in) (NP (DT the) (NN cohort)))) (VP (VBD reached) (NP (CD 10) (NN %)) (NP (CD 16) (NNS years)) (PP (IN after) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_1394_1418_Disease))))))) (, ,) (CC and) (S (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15130900_1437_1451_Disease)))) (VP (AUX was) (PRN (-LRB- -LRB-) (ADVP (RB non-significantly)) (-RRB- -RRB-)) (ADVP (RB twice) (IN as) (JJ common)) (SBAR (IN as) (S (VP (VBN expected) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_1532_1556_Disease)))))))))))) (. .)))
15130900	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (JJ dose-response) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_15130900_1628_1644_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_15130900_1661_1675_Disease) (, ,) (JJ high) (JJ cumulative) (NNS risks)) (PP (IN in) (NP (DT the) (JJ entire) (NN cohort))))))))) (, ,) (S (CC and) (ADVP (RB also)) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN risk) (NNS factors)))) (VP (VBG operating) (PP (ADVP (RB even)) (IN before) (NP (NNP Doc_15130900_1784_1808_Disease)))))) (. .)))
15145918	0	(S1 (NP (NP (NN Differential) (NN modulation)) (PP (IN by) (NP (NP (NNP Doc_15145918_27_35_Chemical)) (PP (IN of) (NP (NP (JJ alpha2-adrenergic) (CC and) (JJ I1-Doc_15145918_64_75_Chemical) (JJ receptor-mediated) (NN Doc_15145918_94_105_Disease)) (PP (IN in) (NP (JJ female) (NNS rats))))))) (. .)))
15145918	1	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB recently)) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_15145918_150_158_Chemical)) (ADVP (RB negatively)) (VP (VP (VBZ modulates) (NP (NP (DT the) (JJ Doc_15145918_184_195_Disease) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_15145918_206_215_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ mixed) (NN alpha2-/I1-receptor) (NN agonist)) (-RRB- -RRB-))))) (PP (IN in) (NP (JJ female) (NNS rats)))) (CC and) (VP (VBZ implicates) (NP (DT the) (JJ cardiovascular) (JJ autonomic) (NN control)) (PP (IN in) (NP (DT this) (NN interaction))))))))) (. .)))
15145918	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (DT this) (NN effect)) (PP (IN of) (NP (NNP Doc_15145918_394_402_Chemical)))) (VP (VBZ involves) (NP (NP (NN interaction)) (PP (IN with) (NP (JJ alpha2-) (NN and/or) (NNS I1-receptors)))))))) (. .)))
15145918	3	(S1 (S (NP (NP (NNS Changes)) (VP (VBN evoked) (PP (IN by) (NP (NP (DT a) (JJ single) (JJ intraperitoneal) (NN injection)) (PP (IN of) (NP (NP (NP (NNP Doc_15145918_514_525_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN microg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NP (NNP Doc_15145918_545_561_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (JJ selective) (NNP I1-)) (CC and) (NP (JJ alpha2-receptor) (NNS agonists))) (, ,) (ADVP (RB respectively)) (, ,)))))) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (JJ hemodynamic) (NN variability)) (, ,) (CC and) (NP (JJ locomotor) (NN activity)))))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ radiotelemetered) (ADJP (JJ sham-operated) (CC and) (JJ ovariectomized)) (PRN (-LRB- -LRB-) (NP (NNP Ovx)) (-RRB- -RRB-)) (NNP Sprague-Dawley) (NN female) (NNS rats)) (PP (IN with) (CC or) (PP (IN without) (NP (NN 12-wk) (NNP Doc_15145918_822_830_Chemical) (NN replacement)))))))) (. .)))
15145918	4	(S1 (S (S (NP (NP (CD Three) (NN time) (NN domain) (NNS indexes)) (PP (IN of) (NP (JJ hemodynamic) (NN variability)))) (VP (AUX were) (VP (VBN employed)))) (: :) (S (NP (NP (NP (DT the) (JJ standard) (NN deviation)) (PP (IN of) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN as) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (NP (NN blood) (NN pressure) (NN variability)) (CC and) (NP (NP (DT the) (JJ standard) (NN deviation)) (PP (IN of) (NP (JJ beat-to-beat) (NNS intervals))) (PRN (-LRB- -LRB-) (NP (NNP SDRR)) (-RRB- -RRB-)))))))))) (CC and) (NP (DT the) (NN root))) (VP (VBP mean) (NP (NP (NN square)) (PP (IN of) (NP (NP (JJ successive) (NNS differences)) (PP (IN in) (NP (JJ R-wave-to-R-wave) (NNS intervals))) (PP (IN as) (NP (NP (NNS measures)) (PP (IN of) (NP (NN heart) (NN rate) (NN variability)))))))))) (. .)))
15145918	5	(S1 (S (PP (IN In) (NP (JJ sham-operated) (NNS rats))) (, ,) (NP (NP (NNP Doc_15145918_1207_1218_Chemical)) (CC or) (NP (NNP Doc_15145918_1222_1238_Chemical))) (VP (VBD elicited) (NP (NP (JJ similar) (NN Doc_15145918_1256_1267_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBD lasted) (NP (QP (IN at) (JJS least) (CD 5)) (NNP h))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (JJ standard) (NN deviation)) (PP (IN of) (NP (JJ mean) (JJ arterial) (NN pressure)))))))))))))) (. .)))
15145918	6	(S1 (S (NP (NNP SDRR)) (VP (AUX was) (VP (VBN reduced) (PP (ADVP (RB only)) (IN by) (NP (NNP Doc_15145918_1402_1418_Chemical))))) (. .)))
15145918	7	(S1 (S (NP (NNP Ovx)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NP (DT the) (JJ Doc_15145918_1451_1462_Disease) (NN response)) (PP (TO to) (NP (NNP Doc_15145918_1475_1491_Chemical)))) (, ,) (PP (IN in) (NP (NN contrast))) (PP (TO to) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NNP Doc_15145918_1521_1532_Chemical) (NNP Doc_15145918_1533_1544_Disease)))))) (. .)))
15145918	8	(S1 (S (NP (NP (DT The) (VBN enhanced) (NNP Doc_15145918_1559_1575_Chemical) (NNP Doc_15145918_1576_1587_Disease)) (PP (IN in) (NP (NNP Ovx) (NNS rats)))) (VP (AUX was) (VP (VBN paralleled) (PP (IN with) (NP (NP (JJ further) (NN reduction)) (PP (IN in) (NP (NP (NNP SDRR)) (CC and) (NP (NNP Doc_15145918_1650_1678_Disease)))))))) (. .)))
15145918	9	(S1 (S (NP (NP (JJ Estrogen) (NN replacement)) (PRN (-LRB- -LRB-) (NP (NP (JJ Doc_15145918_1702_1718_Chemical) (JJ subcutaneous) (NN pellet)) (, ,) (NP (NP (CD 14.2) (NN microg/day)) (, ,) (NP (CD 12) (NNS wk)))) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Ovx) (NNS rats)))) (VP (VBD restored) (NP (NP (DT the) (JJ hemodynamic) (CC and) (JJ locomotor) (NNS effects)) (PP (IN of) (NP (NNP Doc_15145918_1826_1842_Chemical))) (PP (TO to) (NP (JJ sham-operated) (NNS levels))))) (. .)))
15145918	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_15145918_1896_1904_Chemical)) (VP (VP (VBZ downregulates) (NP (ADJP (ADJP (JJ alpha2-)) (CC but) (ADJP (RB not) (JJ I1-receptor-mediated))) (NN Doc_15145918_1956_1967_Disease))) (CC and) (VP (VB highlight) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT the) (JJ cardiac) (JJ autonomic) (NN control))) (PP (IN in) (NP (JJ Doc_15145918_2026_2042_Chemical-Doc_15145918_2043_2051_Chemical) (NN interaction))))))))) (. .)))
15188772	0	(S1 (S (NP (NP (JJ Severe) (JJ reversible) (NN Doc_15188772_18_69_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NN accidental))))) (VP (VBP iatrogenic) (NP (NNP Doc_15188772_99_110_Chemical) (NNP Doc_15188772_111_119_Disease))) (. .)))
15188772	1	(S1 (S (NP (NP (JJ Doc_15188772_121_134_Chemical-induced) (NN Doc_15188772_143_157_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN chronic) (NN excess)) (PP (IN of) (NP (JJ endogenous) (NNP Doc_15188772_194_208_Chemical))))))) (VP (AUX has) (VP (AUX been) (VP (VBN recognized) (PP (IN for) (NP (NNS decades))) (PP (IN as) (NP (DT a) (JJ clinical) (NN phenomenon)))))) (. .)))
15188772	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS reports)) (PP (IN of) (NP (NNP Doc_15188772_291_313_Disease))) (PP (JJ due) (TO to) (NP (JJ acute) (JJ iatrogenic) (NN Doc_15188772_338_346_Disease)))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
15188772	3	(S1 (S (NP (NP (DT A) (JJ 35-year-old) (NN woman)) (SBAR (WHNP (WP$ whose) (NN cervix) (NN uteri)) (S (VP (AUX was) (VP (ADVP (RB inadvertently)) (VBN injected) (PP (IN with) (NP (NP (CD 8) (NN mg)) (PP (IN of) (NP (NNP Doc_15188772_436_447_Chemical)))))))))) (VP (VP (VBD developed) (NP (NP (NN Doc_15188772_458_477_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ hemodynamic) (NN compromise)) (, ,) (NP (ADJP (JJ profound) (, ,) (IN albeit) (JJ transient) (, ,)) (NNP Doc_15188772_563_614_Disease)))))))))) (, ,) (CC and) (ADVP (RB only) (RB modestly)) (VP (VBD elevated) (NP (NP (JJ biochemical) (NNS markers)) (PP (IN of) (NP (NNP Doc_15188772_666_685_Disease)))))) (. .)))
15188772	4	(S1 (S (NP (PRP$ Our) (NN case)) (VP (VBZ illustrates) (NP (NP (DT the) (JJ serious) (NNS consequences)) (PP (IN of) (NP (NP (JJ medical) (NNS errors)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN avoided) (PP (IN through) (NP (NP (VBN improved) (NN medication) (VBG labeling)) (CC and) (NP (NN staff) (NN supervision))))))))))))) (. .)))
15233872	0	(S1 (NP (NP (JJ Cardioprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_15233872_27_48_Chemical))) (PP (IN on) (NP (NP (NNP Doc_15233872_52_65_Chemical-induced) (NNP Doc_15233872_74_95_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
15233872	1	(S1 (S (NP (NP (NP (NNP Doc_15233872_105_126_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15233872_128_131_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NNP Doc_15233872_137_181_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15233872_183_202_Chemical)) (-RRB- -RRB-))) (, ,)) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (ADJP (JJ herbal) (CC and) (JJ homeopathic)) (NN medicine))))) (. .)))
15233872	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (AUX done) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_15233872_316_319_Chemical))) (PP (IN on) (NP (NP (ADJP (RB experimentally) (VBN induced)) (NN Doc_15233872_346_367_Disease)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
15233872	3	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNP Doc_15233872_393_396_Chemical)))) (, ,) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (QP (CD 0.5) (CD mL/100)) (NNP g) (NN bodyweight))) (PP (IN per) (NP (NN day))))) (, ,) (ADVP (RB orally) (PP (IN for) (NP (CD 30) (NNS days)))) (, ,) (VP (VBD prevented) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN lipid) (NN peroxidation) (CC and) (NN activity)) (PP (IN of) (NP (NP (JJR marker) (NNS enzymes)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ Doc_15233872_552_565_Chemical-induced) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 85) (NN mg) (NN kg) (-LRB- -LRB-) (NN -1) (-RRB- -RRB-) (NNP s.) (NNP c.)) (PP (IN for) (NP (NP (CD 2) (NNS days)) (PP (IN at) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (CD 24) (NNP h)))))))) (-RRB- -RRB-))))))))))) (. .)))
15233872	4	(S1 (S (NP (NN Doc_15233872_635_638_Chemical)) (VP (VP (VBD prevented) (NP (NP (DT the) (JJ Doc_15233872_653_666_Chemical-induced) (NN decrease)) (PP (IN in) (NP (JJ antioxidant) (NNS enzymes))) (PP (IN in) (NP (DT the) (NN heart))))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_15233872_746_749_Chemical-stimulated) (JJ Doc_15233872_761_767_Chemical) (NN uptake)) (CC and) (NP (JJ respiratory) (NN coupling) (NN ratio))))))) (. .)))
15233872	5	(S1 (S (NP (NN Doc_15233872_807_810_Chemical)) (VP (VBN protected) (PP (IN against) (NP (NP (JJ pathological) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15233872_861_874_Chemical))) (PP (IN in) (NP (NN rat) (NN heart))))))) (. .)))
15233872	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_15233872_929_932_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN damage)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15233872_983_996_Chemical))) (PP (IN in) (NP (NN rat) (NN heart)))))))))))))) (. .)))
1527456	0	(S1 (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_1527456_13_21_Disease))) (PP (IN by) (NP (NP (JJ intratympanic) (NN instillation)) (PP (IN of) (NP (NP (NNP Doc_1527456_55_65_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_67_76_Chemical)) (-RRB- -RRB-))))))) (NP (NP (CD 2)) (PP (IN per) (NP (NN cent))) (PP (IN through) (NP (NN ventilation) (NNS tubes)))) (. .)))
1527456	1	(S1 (S (NP (NP (NN Doc_1527456_116_146_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_148_151_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (RBS most) (JJ obscure) (JJ otological) (NNS pathologies))))) (. .)))
1527456	2	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ presents) (NP (NP (DT the) (NNS results)) (PP (IN of) (S (VP (VBG treating) (NP (NNP Doc_1527456_248_251_Disease)) (PP (IN by) (NP (NP (JJ intratympanic) (NN instillation)) (PP (IN of) (NP (NP (NNP Doc_1527456_285_295_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_297_306_Chemical)) (-RRB- -RRB-)) (, 2) (PP (IN per) (NP (NN cent))))))) (PP (IN through) (NP (DT a) (NN grommet))) (, ,) (PP (IN for) (NP (CD five) (JJ weekly) (NNS courses)))))))) (. .)))
1527456	3	(S1 (S (S (NP (NP (JJ Fifty-two) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ intractable) (NNP Doc_1527456_409_417_Disease))))) (VP (VBD entered) (NP (DT this) (JJ therapeutic) (NN trial)))) (, ,) (CC but) (S (NP (QP (RB only) (CD nine))) (VP (VBD finished) (NP (DT all) (CD five) (NNS courses)))) (. .)))
1527456	4	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (S (NP (DT the) (NNP Doc_1527456_511_519_Disease)) (VP (AUX was) (ADVP (RB almost) (RB completely)) (VP (VBN abolished)))) (, ,) (CC but) (S (PP (IN in) (NP (PDT all) (DT the) (CD nine) (NNS patients))) (NP (DT the) (JJ decompensated) (NN Doc_1527456_600_608_Disease)) (VP (VBD changed) (PP (TO to) (NP (DT a) (VBN compensated) (NN one))))) (. .)))
1527456	5	(S1 (S (NP (PRP We)) (VP (VBP suggest) (NP (NP (DT this) (NN mode)) (PP (IN of) (NP (NN treatment))) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADVP (RB previously)) (VP (VBN treated) (PP (IN by) (NP (NP (NNS drugs)) (, ,) (NP (NN acupuncture)) (CC and) (NP (NN biofeedback))))))))))) (, ,) (PP (IN with) (NP (JJ disappointing) (NNS results)))) (. .)))
1527456	6	(S1 (S (NP (NNS Patients)) (VP (MD should) (VP (AUX be) (VP (VBN warned) (PP (IN about) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1527456_834_841_Disease)) (CC and) (NP (NNP Doc_1527456_846_854_Disease)))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (NNS subsides)) (UCP (PP (ADVP (RB gradually)) (IN with) (NP (DT every) (JJ new) (NN instillation))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT the) (NNP Doc_1527456_923_931_Disease)) (VP (VP (MD may) (RB not) (VP (VB disappear))) (CC but) (VP (MD will) (VP (AUX be) (VP (VBN alleviated) (, ,) (S (VP (VBG enabling) (S (NP (PRP them)) (VP (TO to) (VP (VP (VB cope) (ADVP (RBR more) (RB easily)) (PP (IN with) (NP (DT the) (NN disease)))) (CC and) (VP (VB lead) (NP (DT a) (ADJP (RBR more) (JJ normal)) (NN life)))))))))))))))))))))) (. .)))
15275829	0	(S1 (S (NP (DT The) (ADJP (JJ alpha3) (CC and) (JJ beta4)) (JJ nicotinic) (JJ Doc_15275829_31_44_Chemical) (NN receptor) (NNS subunits)) (VP (AUX are) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NNP Doc_15275829_81_89_Chemical-induced) (NNP Doc_15275829_98_106_Disease) (CC and) (NNP Doc_15275829_111_125_Disease)) (PP (IN in) (NP (NNS mice))))))) (. .)))
15275829	1	(S1 (S (NP (NP (JJ Binding)) (PP (IN of) (NP (NNP Doc_15275829_146_154_Chemical))) (PP (TO to) (NP (NP (JJ nicotinic) (JJ Doc_15275829_168_181_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS nAChRs)) (-RRB- -RRB-))))) (VP (VBZ elicits) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ dose-dependent) (NNS behaviors))) (SBAR (WHNP (WDT that)) (S (VP (VBP go) (PP (IN from) (NP (NP (JJ altered) (NN exploration)) (, ,) (NP (NN sedation)) (, ,) (CC and) (NP (NNP Doc_15275829_294_301_Disease)) (, ,))) (PP (TO to) (NP (NNP Doc_15275829_306_314_Disease) (CC and) (NNP Doc_15275829_319_324_Disease)))))))) (. .)))
15275829	2	(S1 (S (NP (NNS nAChRs)) (VP (AUX are) (NP (JJ pentameric) (NN ion) (NNS channels)) (ADVP (RB usually)) (VP (VBN composed) (PP (IN of) (NP (NP (NN alpha)) (CC and) (NP (JJ beta) (NNS subunits)))))) (. .)))
15275829	3	(S1 (S (NP (DT A) (NN gene) (NN cluster)) (VP (VBZ comprises) (NP (NP (DT the) (NN alpha3) (, ,) (NN alpha5) (CC and) (NN beta4) (NNS subunits)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP coassemble) (S (VP (TO to) (VP (VB form) (NP (JJ functional) (NNS receptors)))))))))) (. .)))
15275829	4	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ beta4) (NNS subunits))) (PP (IN in) (NP (NP (JJ Doc_15275829_563_571_Chemical-induced) (NNP Doc_15275829_580_588_Disease) (CC and) (NNP Doc_15275829_593_607_Disease)) (PP (IN in) (NP (NP (NP (JJ beta4) (JJ homozygous) (NN null)) (PRN (-LRB- -LRB-) (NP (CD beta4) (NN -/-)) (-RRB- -RRB-)) (CC and) (NP (JJ alpha3) (NN heterozygous))) (-LRB- -LRB-) (NP (NN +/-)) (-RRB- -RRB-) (FW mice.) (FW beta4)))))) (SBAR (S (NP (JJ -/-) (NNS mice)) (VP (AUX were) (ADJP (RBR less) (JJ sensitive) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_15275829_734_742_Chemical)))))) (PP (DT both) (PP (IN at) (NP (NP (JJ low) (NNS doses)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (VBN decreased) (NN exploration)) (PP (IN in) (NP (DT an) (JJ open) (NN field)))))) (, ,))) (CC and) (PP (IN at) (NP (NP (JJ high) (NNS doses)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ Doc_15275829_860_868_Chemical-induced) (NNP Doc_15275829_877_885_Disease))))))))))))) (. .)))
15275829	5	(S1 (S (S (S (VP (VBG Using) (PRT (RP in)) (NP (JJ situ) (NN hybridization) (NNS probes)) (PP (IN for) (NP (DT the) (JJ alpha3) (CC and) (JJ alpha5) (NNS subunits))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN alpha5) (NN mRNA) (NNS levels)) (VP (AUX are) (ADJP (JJ unchanged)) (, ,) (SBAR (IN whereas) (S (NP (JJ alpha3) (NN mRNA) (NNS levels)) (VP (AUX are) (ADVP (RB selectively)) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (JJ mitral) (NN cell) (NN layer)) (PP (IN of) (NP (DT the) (JJ olfactory) (NN bulb)))))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ inferior)) (CC and) (NP (NP (DT the) (JJ superior) (NN colliculus)) (PP (IN of) (NP (CD beta4) (JJ -/-) (JJ brains.) (NN alpha3) (NN +/-) (NNS mice))))) (VP (AUX were) (ADJP (RB partially) (JJ resistant) (PP (TO to) (NP (JJ Doc_15275829_1218_1226_Chemical-induced) (NNP Doc_15275829_1235_1243_Disease)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (JJ wild-type) (NNS littermates)))))))) (. .)))
15275829	6	(S1 (S (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NP (DT the) (NNS alpha5)) (CC and) (NP (DT the) (JJ beta4) (NNS subunits))))) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN in) (NP (JJ alpha3) (JJ +/-) (NNS brains)))) (. .)))
15275829	7	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS beta4)) (CC and) (NP (DT the) (JJ alpha3) (NNS subunits))) (VP (AUX are) (NP (NP (NNS mediators)) (PP (IN of) (NP (NNP Doc_15275829_1459_1467_Chemical-induced) (NNP Doc_15275829_1476_1484_Disease) (CC and) (NNP Doc_15275829_1489_1503_Disease)))))))) (. .)))
15278670	0	(S1 (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_15278670_15_26_Chemical))) (PP (IN on) (NP (NNP Doc_15278670_30_39_Chemical-induced) (NNP Doc_15278670_48_59_Disease))) (. .)))
15278670	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_15278670_78_89_Chemical))) (PP (IN on) (NP (NNP Doc_15278670_93_102_Chemical-induced) (NNP Doc_15278670_111_122_Disease)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS cats))))) (. .)))
15278670	2	(S1 (S (NP (NP (DT The) (NNP Doc_15278670_148_158_Disease) (NN threshold)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NN SD)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 41.4) (NN +/-)) (ADJP (CD 6.5) (NN mg.) (NP (NP (NNP l)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNP Doc_15278670_215_224_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 6) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .min)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG increasing) (ADVP (RB significantly)) (PP (TO to) (NP (NP (CD 66.6) (NN +/-)) (NP (NP (QP (CD 10.9) (CD mg.)) (NN l)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))))))) (ADVP (WRB when)) (S (NP (NP (DT the) (JJ end-tidal) (NN concentration)) (PP (IN of) (NP (NNP Doc_15278670_345_356_Chemical)))) (VP (AUX was) (NP (CD 0.8) (NN %)))) (. .)))
15278670	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN threshold)) (PRN (-LRB- -LRB-) (NP (NP (CD 61.6) (NN +/-)) (ADJP (CD 8.7) (CD mg.) (NN l) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))) (-RRB- -RRB-)) (PP (IN during) (NP (ADJP (CD 1.6) (NN %)) (NNP Doc_15278670_427_438_Chemical)))) (VP (AUX was) (RB not) (ADJP (JJ significant)) (PP (IN from) (NP (DT that))) (PP (IN during) (NP (ADJP (CD 0.8) (NN %)) (NN Doc_15278670_481_492_Chemical))) (, ,) (S (VP (VBG indicating) (NP (DT a) (VBG celling) (NN effect))))) (. .)))
15278670	4	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (DT the) (NNP Doc_15278670_566_576_Disease) (NN threshold))) (PP (IN between) (NP (NP (NNP Doc_15278670_595_606_Chemical)) (CC and) (NP (NNP Doc_15278670_611_620_Chemical)))))) (. .)))
15278670	5	(S1 (S (NP (NP (DT The) (NN rise)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (VBD became) (ADJP (RBR less) (JJ marked)) (SBAR (WHADVP (WRB when)) (S (S (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_15278670_698_709_Chemical)) (CC or) (NP (NNP Doc_15278670_713_722_Chemical))))) (VP (AUX were) (VP (VBN administered)))) (CC and) (S (NP (NP (DT the) (NN blood) (NN pressure)) (PP (IN at) (NP (NNP Doc_15278670_767_778_Disease)))) (VP (VBD decreased) (PP (RB significantly) (PP (IN in) (NP (ADJP (CD 1.6) (NN %)) (NNP Doc_15278670_811_822_Chemical))) (, ,) (CC and) (PP (IN in) (NP (NP (NP (CD 0.8) (NN %)) (CC and) (NP (CD 1.6) (NN %))) (NNP Doc_15278670_845_854_Chemical))))))))) (. .)))
15278670	6	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15278670_908_917_Chemical) (NNS concentrations)) (VP (VBN measured) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ systolic) (NN blood) (NN pressure)) (VP (VBD became) (NP (CD 70) (NN mmHg)))))))))) (. .)))
15278670	7	(S1 (S (NP (NP (NNP Doc_15278670_991_997_Chemical)) (, ,) (NP (NP (DT a) (JJ selective) (NN blocker)) (PP (IN of) (NP (JJ Doc_15278670_1022_1029_Chemical-dependent) (NNP Doc_15278670_1040_1049_Chemical) (NNS channels)))) (, ,)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intracerebroventricularly)) (PP (IN in) (NP (NP (NNS rats)) (ADJP (JJ anesthetized) (PP (IN with) (NP (CD 0.8) (NN %)))))) (NP (NNP Doc_15278670_1134_1145_Chemical)) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT the) (JJ anticonvulsive) (NNS effects))))))))) (. .)))
15278670	8	(S1 (S (S (NP (NP (NN Doc_15278670_1206_1212_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN ng)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT a) (NN tendency) (S (VP (TO to) (VP (VB decrease) (NP (DT the) (NNP Doc_15278670_1252_1262_Disease) (NN threshold)))))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 21.6) (JJ +/-) (CD 2.2) (TO to) (CD 19.9)) (NN +/-)) (ADJP (ADJP (QP (CD 2.5) (CD mg.)) (NN l)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))) (-RRB- -RRB-)) (CC but) (S (NP (DT this)) (VP (AUX was) (RB not) (ADJP (RB statistically) (JJ significant)))) (. .)))
15278670	9	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_15278670_1379_1390_Chemical)) (VP (VP (VBZ reduces) (NP (NP (DT the) (JJ Doc_15278670_1403_1413_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_15278670_1424_1433_Chemical) (NNP Doc_15278670_1434_1442_Disease))))) (CC but) (VP (VBZ carries) (NP (NP (DT some) (NN risk)) (ADJP (JJ due) (PP (TO to) (NP (JJ circulatory) (NN Doc_15278670_1484_1494_Disease))))))))))) (. .)))
15325671	0	(S1 (S (NP (NN Doc_15325671_0_16_Disease)) (VP (VBD observed) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (JJ high-dose) (JJ Doc_15325671_56_72_Chemical-based) (NN chemotherapy)) (PP (IN for) (NP (JJ metastatic) (NNP Doc_15325671_107_120_Disease)))))) (. .)))
15325671	1	(S1 (S (NP (NN Doc_15325671_136_152_Chemical)) (VP (AUX is) (NP (NP (DT an) (VBG alkylating) (NN agent)) (VP (VBN given) (ADVP (RB frequently)) (PP (IN as) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (JJ many) (NN conditioning) (NNS regimens)))))))) (. .)))
15325671	2	(S1 (S (PP (IN In) (NP (JJ high) (NNS doses))) (, ,) (NP (PRP$ its) (JJ nonhematological) (NN dose-limiting) (NN Doc_15325671_289_297_Disease)) (VP (AUX is) (ADJP (JJ Doc_15325671_301_315_Disease))) (. .)))
15325671	3	(S1 (NP (NN STUDY) (NN DESIGN) (: :) (S (NP (PRP We)) (VP (VBD combined) (NP (NP (NP (NNP Doc_15325671_343_353_Chemical)) (, ,) (NP (NNP Doc_15325671_355_364_Chemical)) (CC and) (NP (JJ high-dose) (NNP Doc_15325671_379_395_Chemical))) (, ,) (NP (NNP Doc_15325671_397_405_Chemical)) (, ,) (CC and) (NP (NNP Doc_15325671_411_422_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ triple) (JJ sequential) (NN high-dose) (NN regimen)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ metastatic) (NNP Doc_15325671_493_506_Disease))))))))) (. .)))
15325671	4	(S1 (S (NP (NN Analysis)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (NP (CD 61) (NNS women)) (PP (IN with) (NP (NP (JJ chemotherapy-responsive) (JJ metastatic) (NN Doc_15325671_583_596_Disease)) (VP (VBG receiving) (NP (JJ 96-h) (JJ infusional) (NN Doc_15325671_623_639_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ triple) (JJ sequential) (NN high-dose) (NN regimen)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (NN association)) (PP (IN between) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NP (JJ peritransplant) (NNP Doc_15325671_746_770_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15325671_772_775_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT the) (JJ following) (NN pretreatment) (NNS characteristics)))))))))))))))))) (: :) (NP (NP (NP (NN presence)) (PP (IN of) (NP (NN electrocardiogram) (-LRB- -LRB-) (CD EKG) (-RRB- -RRB-) (NNS abnormalities)))) (, ,) (NP (NN age)) (, ,) (NP (NNP Doc_15325671_881_893_Disease)) (, ,) (NP (JJ prior) (JJ cardiac) (NN history)) (, ,) (NP (NN smoking)) (, ,) (NP (NNP Doc_15325671_927_944_Disease)) (, ,) (NP (NP (JJ prior) (NN use)) (PP (IN of) (NP (NNP Doc_15325671_959_973_Chemical)))) (, ,) (CC and) (NP (JJ left-sided) (NN chest) (NN irradiation))))))) (. .)))
15325671	5	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (NP (CD 61) (NNS women)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (ADJP (RB clinically) (JJ reversible)) (NN grade)) (NP (CD 3) (NN Doc_15325671_1080_1083_Disease)) (PP (VBG following) (NP (NP (JJ infusional) (NN Doc_15325671_1105_1121_Chemical)) (PP (IN with) (NP (NP (DT a) (JJ median) (NN percent) (NN decline)) (PP (IN in) (NP (NP (NN ejection) (NN fraction)) (PP (IN of) (NP (CD 31) (NN %)))))))))) (. .)))
15325671	6	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (NP (JJ transient) (JJ Doc_15325671_1204_1220_Chemical-related) (NN Doc_15325671_1229_1245_Disease)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ comparable) (PP (TO to) (NP (JJ previous) (JJ recorded) (NN literature))))) (. .)))
15325671	7	(S1 (S (NP (JJR Older) (NN age)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN correlated) (PP (PP (IN with) (NP (DT the) (NNP Doc_15325671_1347_1350_Disease) (NN development))) (: ;) (PP (IN with) (NP (NP (JJ median) (NNS ages)) (PP (IN for) (NP (DT the) (JJ entire) (NN group))))) (CC and) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG developing) (NP (NP (NNP Doc_15325671_1430_1433_Disease)) (PP (IN of) (NP (NP (CD 45)) (CC and) (NP (CD 59)))) (, ,) (ADVP (RB respectively))))))))) (. .)))
15325671	8	(S1 (S (NP (DT No) (NN association)) (VP (AUX was) (VP (VBN found) (PP (IN with) (NP (JJ other) (NN pretreatment) (NNS characteristics))))) (. .)))
15325671	9	(S1 (S (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT these) (NNS findings))))) (, ,) (NP (NNS oncologists)) (VP (MD should) (ADVP (RB carefully)) (VP (VB monitor) (NP (NP (NN fluid) (NN balance)) (PP (IN in) (NP (JJR older) (NNS patients)))))) (. .)))
15325671	10	(S1 (S (NP (NP (JJ Routine) (NNS EKG)) (VP (VBG monitoring) (PP (IN during) (NP (JJ infusional) (NNP Doc_15325671_1683_1699_Chemical))))) (VP (AUX did) (RB not) (VP (VB predict) (NP (JJ Doc_15325671_1716_1719_Disease) (NN development)))) (. .)))
15338796	0	(S1 (S (NP (NP (JJ Doc_15338796_0_6_Disease) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_15338796_23_33_Chemical)))) (, ,) (VP (VBN quantified) (PP (IN by) (NP (DT a) (NN laser) (NN pointer) (NN technique)))) (. .)))
15338796	1	(S1 (S (S (VP (TO To) (VP (VB study) (NP (NP (NNP Doc_15338796_96_102_Disease) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_15338796_119_129_Chemical)))) (NP (DT an) (ADJP (ADJP (RB easily) (JJ applicable)) (, ,) (ADJP (JJ quick)) (CC and) (ADJP (JJ low-priced))) (NN method))))) (VP (AUX is) (VP (VBN needed))) (. .)))
15338796	2	(S1 (S (NP (NP (DT A) (JJ new) (NN method)) (VP (VBG using) (NP (DT a) (ADJP (RB commercially) (JJ available)) (, ,) (JJ pen-shaped) (NN laser) (NN pointer)))) (VP (AUX was) (VP (VBN developed))) (. .)))
15338796	3	(S1 (S (NP (NP (NN Aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (NN sensitivity)) (, ,) (NP (NN reproducibility)) (, ,) (NP (NN reference) (NNS values)) (CC and) (NP (NP (DT the) (NN agreement)) (PP (IN with) (NP (DT a) (NN questionnaire))))))))) (. .)))
15338796	4	(S1 (S (NP (NN Doc_15338796_406_412_Disease)) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (DT a) (NN laser) (NN pointer) (NN technique)))))) (. .)))
15338796	5	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NN sensitivity))))) (NP (PRP we)) (VP (VBD assessed) (NP (NN Doc_15338796_496_502_Disease)) (PP (IN in) (NP (NP (CD 44) (NNS patients)) (PP (IN with) (NP (NNP Doc_15338796_523_547_Disease))))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_15338796_592_602_Chemical)))))))) (. .)))
15338796	6	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (VP (VBN asked) (S (VP (TO to) (VP (VB aim) (PP (IN at) (NP (NP (DT the) (NNP centre)) (PP (IN of) (NP (NP (DT a) (NN target)) (, ,) (VP (VBN subdivided) (PP (IN in) (NP (JJ concentric) (NNS circles))))))))))) (, ,) (PP (IN from) (NP (CD 5) (NNP m) (NN distance))))) (. .)))
15338796	7	(S1 (S (NP (NP (DT The) (NN circle)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN participant)) (VP (VBD succeeded) (PP (TO to) (NP (NN aim))))))) (VP (AUX was) (VP (VBN recorded) (PP (IN in) (NP (JJ millimetres) (NNS radius))))) (. .)))
15338796	8	(S1 (S (PP (IN In) (NP (NP (DT another) (NN series)) (PP (IN of) (NP (NNS measurements))))) (, ,) (NP (NP (NN reproducibility) (CC and) (NN reference) (NNS values)) (PP (IN of) (NP (DT the) (NNP Doc_15338796_879_885_Disease)))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (CD 65) (JJ healthy) (NNS subjects)) (PP (IN in) (NP (CD three) (NNS sessions))))) (, ,) (PP (IN at) (NP (NP (CD 9) (NN a.m.)) (, ,) (NP (CD 4) (NN p.m.)) (CC and) (NP (NP (CD 9) (NN a.m.)) (, ,) (ADVP (RB respectively))))) (, ,) (ADVP (NP (CD 1) (NN week)) (RB later)))) (. .)))
15338796	9	(S1 (S (S (NP (NNP Postural) (NNP Doc_15338796_1008_1014_Disease)) (VP (AUX was) (VP (VBN measured) (PP (IN with) (NP (NP (DT the) (NN arm) (ADJP (RB horizontally) (VBN outstretched)) (NN rest)) (ADJP (JJ Doc_15338796_1072_1078_Disease) (PP (IN with) (NP (NP (DT the) (NN arm)) (VP (VBN supported) (PP (IN by) (NP (DT an) (NN armrest)))))))))))) (CC and) (S (ADVP (RB finally)) (NP (NNP Doc_15338796_1128_1134_Disease)) (VP (AUX was) (VP (VBN measured) (PP (IN after) (S (VP (VBG holding) (NP (NP (DT a) (JJ 2-kg) (NN weight)) (PP (IN until) (NP (NN exhaustion)))))))))) (. .)))
15338796	10	(S1 (S (NP (JJ Inter-observer) (NN variability)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (CD 10) (JJ healthy) (NNS subjects))))))) (. .)))
15338796	11	(S1 (S (NP (NN Doc_15338796_1270_1276_Disease)) (VP (AUX was) (VP (VBN measured) (ADVP (RB simultaneously)) (PP (IN by) (NP (CD two) (JJ independent) (NNS observers))))) (. .)))
15338796	12	(S1 (S (NP (NN Doc_15338796_1344_1354_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (JJ Doc_15338796_1379_1385_Disease) (NN severity)) (PP (IN in) (NP (NNS patients))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN way)))) (. .)))
15338796	13	(S1 (S (PP (IN Within) (NP (JJ healthy) (NNS adults))) (NP (DT no) (NN age-dependency)) (VP (MD could) (VP (AUX be) (VP (VBN found) (PRN (-LRB- -LRB-) (FRAG (NP (NNP b)) (X (SYM =) (ADJP (CD 0.262) (NN mm/year))) (: ;) (NP (NN P)) (X (SYM =)) (NP (CD 0.72))) (-RRB- -RRB-))))) (. .)))
15338796	14	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN agreement)) (PP (IN between) (NP (NP (DT the) (NN questionnaire)) (CC and) (NP (NP (JJ Doc_15338796_1571_1577_Disease) (NN severity)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.093)) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.53)))) (-RRB- -RRB-))))))) (. .)))
15338796	15	(S1 (S (NP (NNP Postural) (NNP Doc_15338796_1619_1625_Disease)) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (DT the) (JJ first) (CC and) (JJ third) (NN session)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.07)))) (-RRB- -RRB-)))))) (. .)))
15338796	16	(S1 (S (S (NP (NP (NN Support)) (PP (IN of) (NP (DT the) (NN arm)))) (VP (VBD decreased) (NP (JJ Doc_15338796_1736_1742_Disease) (NN severity)))) (, ,) (NP (NN exhaustion)) (VP (VBD increased) (NP (JJ Doc_15338796_1774_1780_Disease) (NN severity)) (ADVP (RB significantly))) (. .)))
15338796	17	(S1 (S (NP (DT A) (JJ good) (NN agreement)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (CD two) (JJ independent) (NNS observers)) (PRN (-LRB- -LRB-) (NP (JJ interclass) (NN correlation) (NN coefficient) (NN 0.72)) (-RRB- -RRB-)))))) (. .)))
15338796	18	(S1 (S (S (VP (VBG Quantifying) (NP (NN Doc_15338796_1933_1939_Disease)) (PP (IN by) (S (VP (VBG using) (NP (DT an) (JJ inexpensive) (NN laser) (NN pointer))))))) (VP (AUX is) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NNS children)) (PRN (-LRB- -LRB-) (NP (CD <12) (NNS years)) (-RRB- -RRB-)))))) (NP (DT a) (ADJP (JJ sensitive) (CC and) (JJ reproducible)) (NN method))) (. .)))
15458908	0	(S1 (NP (NP (NP (NP (NN Safety)) (CC and) (NP (JJ adverse) (NNS effects))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_15458908_43_53_Chemical))))) (: :) (NP (NP (JJ multiple) (NNS outcomes)) (PP (IN of) (NP (JJ Doc_15458908_76_86_Chemical) (NN evaluation)))) (. .)))
15458908	1	(S1 (FRAG (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_15458908_135_145_Chemical))) (PP (IN on) (NP (NP (JJ major) (JJ adverse) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN with) (NP (NP (JJ postmenopausal) (JJ Doc_15458908_201_209_Chemical) (NN therapy)) (CC or) (NP (NNP Doc_15458908_221_230_Chemical))))))))))))) (. .)))
15458908	2	(S1 (S (NP (NP (DT The) (JJ Multiple) (NNS Outcomes)) (PP (IN of) (NP (NP (JJ Doc_15458908_266_276_Chemical) (NN Evaluation)) (, ,) (NP (DT a) (NN multicenter)) (, ,) (NP (NN randomized)) (, ,) (NP (JJ double-blind) (NN trial)) (, ,)))) (VP (VBD enrolled) (NP (NP (CD 7,705) (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NNP Doc_15458908_377_389_Disease))))) (. .)))
15458908	3	(S1 (S (NP (NNS Women)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NNP Doc_15458908_423_433_Chemical) (CD 60) (NN mg/d)) (CC or) (NP (NP (CD 120) (NN mg/d)) (CC or) (NP (NN placebo))))))) (. .)))
15458908	4	(S1 (S (NP (NNS Outcomes)) (VP (VBD included) (NP (NP (NNP Doc_15458908_484_506_Disease)) (, ,) (NP (NNP Doc_15458908_508_517_Disease)) (, ,) (NP (NNP Doc_15458908_519_538_Disease)) (, ,) (CC and) (NP (NNP Doc_15458908_544_577_Disease)))) (. .)))
15458908	5	(S1 (S (PP (IN During) (NP (NP (DT a) (JJ mean) (NN follow-up)) (PP (IN of) (NP (CD 3.3) (NNS years))))) (, ,) (NP (NNP Doc_15458908_626_636_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_679_701_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ relative) (NN risk) (JJ -LSB-RR) (NN -RSB-) (CD 2.1)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (NP (JJ interval) (JJ -LSB-CI) (JJ -RSB-) (NNS 1.2-3.8)))) (-RRB- -RRB-)))))))) (. .)))
15458908	6	(S1 (S (S (NP (DT The) (JJ excess) (NN event) (NN rate)) (VP (AUX was) (NP (NP (QP (CD 1.8) (IN per) (CD 1,000)) (NNS woman-years)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD -0.5-4.1))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT the) (NN number)) (VP (VBD needed) (S (VP (TO to) (VP (VB treat) (S (VP (TO to) (VP (VB cause) (SBAR (S (NP (CD 1) (NN event)) (VP (AUX was) (NP (CD 170)))))))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 100-582))) (-RRB- -RRB-)) (PP (IN over) (NP (CD 3.3) (NNS years)))))))) (. .)))
15458908	7	(S1 (S (NP (NP (NN Risk)) (PP (IN in) (NP (DT the) (NNP Doc_15458908_938_948_Chemical) (NN group)))) (VP (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN placebo) (NN group)) (PP (IN for) (NP (DT the) (JJ first) (CD 2) (NNS years)))))))) (, ,) (CC but) (VP (VBD decreased) (PP (TO to) (NP (RB about) (DT the) (JJ same) (NN rate))) (PP (IN as) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (ADVP (RB thereafter)))) (. .)))
15458908	8	(S1 (S (NP (NNP Doc_15458908_1088_1098_Chemical)) (VP (AUX did) (RB not) (VP (VB increase) (NP (NP (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_1125_1134_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 0.9)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.8-1.1)))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_15458908_1161_1180_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.0)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.7-1.3))) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_15458908_1207_1230_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 1.3)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.4-5.1)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NNP Doc_15458908_1260_1278_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 0.9)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.3-2.7)))) (-RRB- -RRB-)))))))) (. .)))
15458908	9	(S1 (S (S (NP (NN Doc_15458908_1317_1327_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NNP Doc_15458908_1370_1392_Disease)))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (VBN increased) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_1430_1439_Disease)) (, ,) (NP (NNP Doc_15458908_1441_1460_Disease)) (, ,) (NP (NNP Doc_15458908_1462_1485_Disease)) (, ,) (CC or) (NP (NNP Doc_15458908_1490_1508_Disease))))))) (. .)))
15458908	10	(S1 (NP (NP (NP (NN LEVEL)) (PP (IN OF) (NP (NN EVIDENCE)))) (: :) (NP (PRP I))))
1549199	0	(S1 (NP (NP (NN Optimization)) (PP (IN of) (NP (JJ Doc_1549199_16_24_Chemical) (NN therapy))) (. .)))
1549199	1	(S1 (S (SBAR (IN While) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (JJ single) (JJ correct) (NN starting) (NN dose)) (PP (IN for) (NP (JJ Doc_1549199_85_93_Chemical) (NN therapy))))))) (, ,) (NP (JJ many) (NNS individuals)) (VP (MD can) (VP (AUX be) (VP (VBN started) (PP (IN on) (NP (CC either) (DT the) (NN 25/100) (CC or) (NN controlled-release) (NN formula))) (, ,) (PP (VBG following) (NP (NP (DT the) (JJ general) (NN rule)) (SBAR (S (RB not) (VP (TO to) (VP (VB attempt) (S (VP (TO to) (VP (VB titrate) (ADJP (JJ Doc_1549199_240_249_Chemical-Doc_1549199_250_258_Chemical) (PP (TO to) (NP (NP (DT the) (NN point)) (PP (IN of) (NP (`` ``) (NP (NN normality)) (, ,) ('' '') (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NNP Doc_1549199_306_314_Disease)))))))))))))))))))))))) (. .)))
1549199	2	(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (ADVP (RB also)) (VP (VB determine) (NP (NP (DT the) (JJ proper) (NN use)) (PP (IN of) (NP (DT any) (JJ adjunctive) (NNS medications))))))) (: ;) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (AUX has) (VP (VBN become) (NP (NP (DT the) (JJ standard) (NN approach)) (PP (TO to) (NP (NN treatment))))))) (. .)))
1549199	3	(S1 (S (PP (VBG Following) (NP (NP (DT the) (JJ initial) (NN period)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (VBG emerging) (NNS difficulties)) (VP (VBP require) (NP (NP (DT a) (NN reassessment)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS approaches)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN dosage) (NN adjustment) (CC or) (NN introduction)) (PP (IN of) (NP (DT a) (JJ Doc_1549199_627_635_Chemical) (NN agonist))))))))) (. .)))
1549199	4	(S1 (S (NP (NP (JJ Other) (JJ possible) (JJ adverse) (NN effects--such)) (PP (IN as) (NP (NP (NNP Doc_1549199_685_711_Disease)) (, ,) (NP (NNP Doc_1549199_713_736_Disease)) (, ,) (NP (NNP Doc_1549199_738_746_Chemical-induced) (NNP Doc_1549199_755_764_Disease) (, ,) (NNP Doc_1549199_766_784_Disease) (CC or) (NNP Doc_1549199_788_799_Disease)) (, ,) (CC or) (NP (NN drug) (NN interactions--also))))) (VP (VBP require) (NP (ADJP (RB carefully) (VBN monitored)) (JJ individual) (NN treatment))) (. .)))
1549199	5	(S1 (S (NP (JJ Nonpharmacologic) (NNS concerns)) (VP (MD can) (VP (VB help) (S (NP (DT the) (NNP Doc_1549199_917_936_Disease) (NN patient)) (VP (VP (VB achieve)) (CC and) (VP (VB maintain) (NP (NP (JJ optimal) (NN functioning)) (, ,) (PP (VBG including) (NP (NP (JJ daily) (NN exercise)) (, ,) (NP (JJ physical) (NN therapy)) (, ,) (CC and) (NP (NP (NN involvement)) (PP (IN with) (NP (NN support) (NNS groups)))))))))))) (. .)))
15515654	0	(S1 (FRAG (NP (NP (JJ Long) (NN term) (NN audiological) (NN evaluation)) (PP (IN of) (NP (NNP Doc_15515654_37_53_Disease) (NNS patients)))) (. .)))
15515654	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB identify) (NP (DT the) (NN incidence)))) (CC and) (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_15515654_167_179_Disease))) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NP (JJ young) (NNS adults)) (PP (IN with) (NP (NNP Doc_15515654_214_230_Disease) (NN major)))))))))))) (. .)))
15515654	2	(S1 (S (NP (NP (QP (CD One) (CD hundred) (CC and) (CD four)) (PRN (-LRB- -LRB-) (NP (CD 104)) (-RRB- -RRB-)) (NNS patients)) (VP (VBN aged) (NP (NP (CD 6-35) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ 17,2) (NNS years)) (-RRB- -RRB-))))) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
15515654	3	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (PP (IN on) (NP (NP (DT a) (JJ regular) (NN transfusion-chelation) (NN program)) (VP (VBG maintaining) (NP (NP (DT a) (JJ mean) (NN hemoglobin) (NN level)) (PP (IN of) (NP (CD 9.5) (NN gr/dl)))))))) (. .)))
15515654	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (S (VP (VBG receiving) (NP (NP (NNP Doc_15515654_479_494_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15515654_496_499_Chemical)) (-RRB- -RRB-)) (NN chelation) (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ mean) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 50-60) (NN mg/kg)) (, ,) (NP (NP (CD 5-6) (NNS days)) (NP (DT a) (NN week)))))))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD six) (NNS years)) (PP (IN of) (NP (NP (DT the) (NN study)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADVP (RB then)) (VP (VBN reduced) (PP (TO to) (NP (QP (CD 40-50) (CD mg/kg)))) (PP (IN for) (NP (DT the) (JJ following) (CD eight) (NNS years)))))))))))))) (. .)))
15515654	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN followed) (PP (IN for) (NP (CD 8-14) (NNS years))))) (. .)))
15515654	6	(S1 (S (ADVP (RB Overall)) (, ,) (NP (NP (QP (CD 21) (IN out) (IN of) (CD 104)) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 20.2) (NN %)) (-RRB- -RRB-))) (VP (VP (VBN presented) (PP (IN with) (NP (NP (JJ high) (NN frequency) (NNP Doc_15515654_804_830_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15515654_832_836_Disease)) (-RRB- -RRB-))))) (, ,) (CC either) (VP (ADJP (JJ unilateral) (CC or) (JJ bilateral)))) (. .)))
15515654	7	(S1 (S (NP (NP (DT No) (JJ Doc_15515654_874_882_Disease) (NN factor)) (, ,) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_15515654_902_905_Chemical)))) (, ,)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS patients))))))) (. .)))
15515654	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_15515654_957_961_Disease))) (VP (VBN presented) (PP (IN with) (NP (NP (ADJP (RB relatively) (JJR lower)) (NN serum) (NN ferritin) (NNS levels)) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (JJ normal) (NN hearing))))))))) (, ,) (ADVP (RB however)) (, ,) (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NN difference)) (VP (AUX was) (VP (VBN observed))) (. .)))
15515654	9	(S1 (S (NP (NP (NNS Subjects)) (PP (IN with) (NP (NNP Doc_15515654_1125_1129_Disease)))) (VP (AUX were) (VP (VBN submitted) (PP (TO to) (NP (NP (JJ Doc_15515654_1148_1151_Chemical) (NN reduction)) (CC or) (NP (JJ temporary) (NN withdrawal)))))) (. .)))
15515654	10	(S1 (S (PP (VBG Following) (NP (NN intervention))) (, ,) (S (NP (NP (CD 7) (NN out)) (PP (IN of) (NP (CD 21) (JJ affected) (NNS patients)))) (VP (VBD recovered))) (, ,) (S (NP (CD 10)) (VP (VBD remained) (ADJP (JJ stable)))) (CC and) (S (NP (CD 4)) (VP (VBD demonstrated) (NP (NN aggravation)))) (. .)))
15515654	11	(S1 (S (NP (DT The) (NNS findings)) (VP (AUX are) (ADJP (JJ indicative) (PP (IN of) (NP (NP (NP (NNP Doc_15515654_1346_1349_Chemical) (POS 's)) (VBG contributing) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15515654_1392_1410_Disease))))))))) (. .)))
15515654	12	(S1 (S (NP (JJ Regular) (JJ audiologic) (NN evaluation)) (VP (AUX is) (ADJP (JJ imperative)) (PP (IN in) (NP (DT all) (JJ Doc_15515654_1463_1474_Disease) (NNS patients))) (SBAR (IN so) (IN that) (S (S (NP (JJ early) (NNS changes)) (VP (MD may) (VP (AUX be) (VP (VBN recognized))))) (CC and) (S (NP (NN treatment)) (VP (MD may) (VP (AUX be) (VP (ADVP (RB judiciously)) (VBN adjusted) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VP (VB prevent)) (CC or) (VP (VB reverse) (NP (NNP Doc_15515654_1597_1615_Disease)))))))))))))) (. .)))
15572383	0	(S1 (S (NP (NP (JJ Individual) (NNS differences)) (PP (IN in) (NP (NP (JJ renal) (NN ACE) (NN activity)) (PP (IN in) (NP (JJ healthy) (NNS rats)))))) (VP (VBP predict) (NP (NN susceptibility)) (PP (TO to) (NP (JJ Doc_15572383_87_97_Chemical-induced) (NN Doc_15572383_106_118_Disease)))) (. .)))
15572383	1	(S1 (S (PP (IN In) (NP (NN man))) (, ,) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_15572383_155_166_Chemical-converting) (NN enzyme) (PRN (-LRB- -LRB-) (NP (NNP ACE)) (-RRB- -RRB-)) (NNS levels)) (, ,) (VP (VBN related) (PP (TO to) (NP (NNP ACE) (PRN (-LRB- -LRB-) (NP (NNP I/D)) (-RRB- -RRB-)) (NN genotype)))) (, ,)))) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (JJ renal) (NN prognosis))))) (. .)))
15572383	2	(S1 (S (NP (DT This)) (VP (VBZ raises) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (IN that)) (S (NP (NP (JJ individual) (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ renal) (NN susceptibility)) (PP (TO to) (NP (VBN inflicted) (NN damage))))))))))) (. .)))
15572383	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ predictive) (NN effect)) (PP (IN of) (NP (JJ renal) (NN ACE) (NN activity))) (PP (IN for) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_15572383_488_500_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_15572383_534_544_Chemical)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
15572383	4	(S1 (S (NP (NP (JJ Renal) (NN ACE) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (JJ Doc_15572383_583_594_Chemical) (NN cleavage)) (PP (IN by) (NP (JJ cortical) (NNS homogenates)))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (JJ renal) (NN biopsy)) (PP (IN in) (NP (CD 27) (NN adult) (NN male) (JJ Wistar) (NNS rats))))))) (. .)))
15572383	5	(S1 (S (S (PP (IN After) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NN recovery))))) (, ,) (NP (NNP Doc_15572383_716_727_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15572383_743_753_Chemical) (CD -LSB-1.5))) (PP (IN mg/kg) (NP (JJ intravenously) (PRN (-LRB- -LRB-) (CD i.v.) (-RRB- -RRB-) (NP (NNP n) (SYM =) (CD 18)) (: ;)) (NNS controls)))))) (, ,) (NP (NN saline) (NN i.v.) (NNP n)) (VP (SYM =) (NP (CD 9) (NN -RSB-))) (. .)))
15572383	6	(S1 (S (NP (NN Doc_15572383_824_835_Disease)) (VP (AUX was) (VP (VBN measured) (NP (DT every) (CD 2) (NNS weeks)))) (. .)))
15572383	7	(S1 (S (PP (IN After) (NP (CD 12) (NNS weeks))) (, ,) (S (NP (NNS rats)) (VP (AUX were) (VP (VBN sacrificed)))) (CC and) (S (NP (PRP$ their) (NNS kidneys)) (VP (VBN harvested))) (. .)))
15572383	8	(S1 (S (SBAR (IN As) (S (VP (VBN anticipated)))) (, ,) (NP (NNP Doc_15572383_955_965_Chemical)) (VP (VBD elicited) (S (NP (NNP Doc_15572383_975_984_Disease)) (VP (VB range) (NP (NP (NNP Doc_15572383_991_1002_Disease)) (, ,) (NP (NNP Doc_15572383_1004_1029_Disease)) (CC and) (NP (JJ mild) (NN Doc_15572383_1039_1063_Disease)))))) (. .)))
15572383	9	(S1 (S (NP (JJ Baseline) (JJ renal) (NN ACE)) (ADVP (RB positively)) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (JJ relative) (NN rise)) (PP (IN in) (NP (NNP Doc_15572383_1132_1143_Disease))) (PP (IN after) (NP (NP (NNP Doc_15572383_1150_1160_Chemical)) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.62) (, ,) (CD P<0.01)) (-RRB- -RRB-)) (, ,) (NP (JJ renal) (JJ interstitial) (JJ alpha-smooth) (NN muscle) (NN actin)) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.49)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)) (, ,) (NP (JJ interstitial) (NN macrophage) (NN influx)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.56)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (JJ interstitial) (NN collagen) (NNP III)) (PRN (-LRB- -LRB-) (NP (QP (SYM r) (SYM =) (CD 0.53))) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-))) (, ,) (NP (JJ glomerular) (NX (NX (NX (JJ alpha-smooth) (NN muscle) (NN actin)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.74)) (, ,) (NP (NNP P<0.01)) (-RRB- -RRB-))) (CC and) (NX (NX (JJ glomerular) (NN desmin)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.48)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-))))))))))) (. .)))
15572383	10	(S1 (S (NP (JJ Baseline) (JJ renal) (NN ACE)) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NNP Doc_15572383_1483_1507_Disease)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.22)) (, ,) (NP (NNP NS)) (-RRB- -RRB-)))))) (. .)))
15572383	11	(S1 (S (PP (IN In) (NP (NNS controls))) (, ,) (NP (NP (DT no) (JJ predictive) (NNS values)) (PP (IN for) (NP (JJ renal) (NNS parameters)))) (VP (AUX were) (VP (VBN observed))) (. .)))
15572383	12	(S1 (S (NP (NP (JJ Individual) (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (VBP predict) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_15572383_1675_1685_Chemical-induced) (NNP Doc_15572383_1694_1706_Disease))) (PP (IN in) (NP (DT this) (JJ outbred) (NN rat) (NN strain))))) (. .)))
15572383	13	(S1 (S (NP (DT This)) (VP (VBZ supports) (NP (DT the) (NN assumption) (SBAR (IN that) (S (NP (NP (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (VB predispose) (PP (TO to) (NP (NP (DT a) (ADJP (RBR less) (JJ favourable)) (NN course)) (PP (IN of) (NP (NN Doc_15572383_1845_1857_Disease)))))))))) (. .)))
15602202	0	(S1 (S (NP (JJ Recurrent) (JJ acute) (NN Doc_15602202_16_38_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15602202_50_62_Chemical)))) (. .)))
15602202	1	(S1 (S (NP (DT A) (JJ 14-year-old) (NN girl)) (VP (AUX is) (VP (VBN reported) (PP (IN with) (NP (ADJP (JJ recurrent) (, ,) (JJ Doc_15602202_111_123_Chemical-induced) (, ,) (JJ acute)) (NNP Doc_15602202_139_161_Disease))))) (. .)))
15602202	2	(S1 (S (S (NP (DT The) (JJ second) (NN episode)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ severe)) (PP (IN than) (NP (DT the) (JJ first)))))) (: ;) (S (CC and) (SBAR (IN although) (S (NP (DT both)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ intensive) (JJ corticosteroid) (NN therapy))))))) (, ,) (NP (JJ renal) (NN function)) (VP (VBD remained) (ADJP (JJ impaired)))) (. .)))
15602202	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJS most) (NNS cases)) (PP (IN of) (NP (JJ antibiotic) (VBN induced) (JJ acute) (NNP Doc_15602202_366_388_Disease)))) (VP (AUX are) (ADJP (ADJP (JJ benign)) (CC and) (ADJP (JJ self-limited)))))) (, ,) (NP (DT some) (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NN risk))) (PP (IN for) (NP (JJ permanent) (NN Doc_15602202_458_470_Disease)))) (. .)))
15632880	0	(S1 (NP (NP (NNP Doc_15632880_0_14_Chemical-induced) (NNP Doc_15632880_23_42_Disease) (CC and) (NNP Doc_15632880_47_59_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15632880_77_90_Disease))))) (. .)))
15632880	1	(S1 (S (NP (NP (DT A) (JJ previous) (JJ randomized) (JJ controlled) (NN trial)) (VP (VBG evaluating) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_15632880_165_179_Chemical))) (PP (IN in) (NP (NNP Doc_15632880_183_196_Disease) (NNS patients)))))) (VP (VBD reported) (NP (NP (DT a) (JJ low) (NN risk)) (PP (IN of) (NP (NP (NP (NNP Doc_15632880_229_241_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15632880_251_270_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))))))) (. .)))
15632880	2	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS treatments)) (PP (IN for) (NP (NNP Doc_15632880_300_313_Disease)))) (VP (AUX have) (VP (VBN changed) (SBAR (IN since) (S (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (NNP Doc_15632880_349_363_Chemical)))) (VP (AUX were) (VP (VBN reported))))))))) (, ,) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (DT these) (NNS complications)))) (VP (MD may) (VP (VB differ) (PP (IN in) (NP (JJ current) (JJ clinical) (NN practice))))) (. .)))
15632880	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD sought) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ prevalence) (CC and) (JJ clinical) (NNS associations)) (PP (IN of) (NP (NP (NNP Doc_15632880_535_547_Disease)) (CC and) (NP (NNP Doc_15632880_552_571_Disease))))) (PP (IN in) (NP (NP (JJ Doc_15632880_575_588_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15632880_611_625_Chemical)))))))))) (. .)))
15632880	4	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT a) (NN case) (NN control) (NN study)) (PP (IN of) (NP (NP (JJ Doc_15632880_673_686_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15632880_709_723_Chemical))) (PP (IN in) (NP (PRP$ our) (JJ clinical) (NN practice)))))))) (. .)))
15632880	5	(S1 (S (S (NP (NNS Cases)) (VP (AUX were) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (NNP Doc_15632880_784_796_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Doc_15632880_798_799_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-))) (NP (CD >5.0) (NN mEq/L))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_15632880_818_837_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15632880_839_841_Chemical) (QP (CD >or=2.5) (CD mg/dL))) (-RRB- -RRB-)))))))))) (, ,) (CC and) (S (NP (PRP they)) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (CD 2) (ADJP (RB randomly) (VBN selected)) (NNS controls)) (PP (IN per) (NP (NN case)))))))) (. .)))
15632880	6	(S1 (S (NP (NP (NP (JJ Clinical) (NNS characteristics)) (, ,) (NP (NNS medications)) (, ,) (CC and) (NP (NN serum) (NNS chemistries))) (PP (IN at) (NP (NP (NN baseline)) (CC and) (NP (JJ follow-up) (NN time) (NNS periods))))) (VP (AUX were) (VP (VBN compared))) (. .)))
15632880	7	(S1 (S (NP (NP (NN Sixty-seven)) (PP (IN of) (NP (NP (CD 926) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 7.2) (NN %)) (-RRB- -RRB-))))) (VP (VBD required) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_15632880_1110_1124_Chemical))) (PP (JJ due) (TO to) (NP (NP (NP (NNP Doc_15632880_1132_1144_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 33)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_15632880_1157_1170_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 34)) (-RRB- -RRB-))))))) (. .)))
15632880	8	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_15632880_1204_1216_Disease)))))) (VP (VP (AUX were) (ADJP (ADJP (JJR older)) (CC and) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (ADJP (JJ Doc_15632880_1252_1260_Disease)))))))) (, ,) (VP (AUX had) (NP (NP (JJR higher) (NN baseline) (NN serum) (JJ Doc_15632880_1288_1297_Chemical) (NNS levels)) (CC and) (NP (JJR lower) (NN baseline) (JJ Doc_15632880_1324_1333_Chemical) (NN supplement) (NNS doses)))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (NNS beta-blockers)))))))) (PP (IN than) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 134)) (-RRB- -RRB-))))))) (. .)))
15632880	9	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_15632880_1454_1473_Disease)))))) (VP (VP (AUX had) (NP (NP (JJR lower) (JJ baseline) (NN body) (NN weight)) (CC and) (NP (JJR higher) (JJ baseline) (NN serum) (NN Doc_15632880_1531_1541_Chemical)))) (, ,) (VP (VBN required) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN loop) (NNS diuretics))))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_15632880_1624_1632_Chemical) (NNS diuretics)))))))) (PP (IN than) (NP (NNS controls)))))) (. .)))
15632880	10	(S1 (S (NP (JJ Doc_15632880_1671_1685_Chemical-induced) (NNP Doc_15632880_1694_1706_Disease) (CC and) (NNP Doc_15632880_1711_1730_Disease)) (VP (AUX are) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (PRP$ our) (JJ clinical) (NN experience))) (SBAR (IN than) (S (VP (VBN reported) (ADVP (RB previously)))))) (. .)))
15632880	11	(S1 (S (NP (DT This) (NN difference)) (VP (AUX is) (VP (VBN explained) (PP (IN by) (NP (NP (JJ patient) (NNS comorbidities)) (CC and) (NP (NP (ADJP (RBR more) (JJ frequent)) (NN use)) (PP (IN of) (NP (NNS beta-blockers)))))))) (. .)))
15649445	0	(S1 (S (NP (JJ Acute) (UCP (NNP Doc_15649445_6_15_Chemical) (CC and) (JJ subchronic)) (JJ Doc_15649445_31_42_Chemical) (NNS treatments)) (VP (VP (VBP change) (NP (JJ synaptosomal) (NN brain) (JJ Doc_15649445_80_89_Chemical) (NN uptake))) (CC and) (VP (VBP elicit) (NP (NP (NN Doc_15649445_108_128_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
15649445	1	(S1 (S (NP (ADJP (JJ Doc_15649445_138_147_Chemical-) (CC and) (JJ Doc_15649445_153_164_Chemical-induced)) (NNP Doc_15649445_173_193_Disease)) (VP (AUX are) (NP (NP (JJ putative) (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_15649445_224_242_Disease) (-LRB- -LRB-) (NNP Doc_15649445_244_246_Disease) (-RRB- -RRB-))) (SBAR (WHNP (WP$ whose) (NN pathophysiology)) (S (VP (AUX has) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (JJ free) (JJ radical) (NN generation)) (CC and) (NP (JJ oxidative) (NN stress))))))))))) (. .)))
15649445	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (DT the) (NNS authors)) (VP (VBN induced) (NP (NNP Doc_15649445_378_398_Disease)) (PP (IN by) (NP (NP (JJ acute) (JJ Doc_15649445_408_417_Chemical) (CC and) (JJ subchronic) (JJ Doc_15649445_433_444_Chemical) (NN administration)) (PP (TO to) (NP (NNS rats)))))) (. .)))
15649445	3	(S1 (S (NP (NP (JJ Doc_15649445_469_478_Chemical) (NN injection)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (QP (CD 1) (CD mg/kg)))) (NP (NNP s.c.))) (-RRB- -RRB-))) (NP (NP (DT every) (JJ other) (NN day)) (PP (IN for) (NP (CD 3) (NNS days)))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN vacuous) (VBG chewing)) (, ,) (NP (NN tongue) (NN protrusion)) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (JJ facial) (NN twitching))))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN control))))) (. .)))
15649445	4	(S1 (S (NP (NP (JJ Doc_15649445_670_681_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (CD 12) (NNS mg/kg))) (PP (IN once) (NP (DT a) (NN week))) (NP (NNP s.c.))) (-RRB- -RRB-)) (PP (IN for) (NP (CD 4) (NNS weeks)))) (VP (VBD caused) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN vacuous) (VBG chewing)) (, ,) (NP (NN tongue) (NN protrusion)) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (NP (JJ facial) (NNS twitching)) (VP (VBN observed) (PP (IN in) (NP (CD four) (JJ weekly) (NNS evaluations))))))))))) (. .)))
15649445	5	(S1 (S (PP (IN After) (NP (NP (DT the) (NNS treatments)) (CC and) (NP (JJ behavioral) (NN observation)))) (, ,) (NP (NP (JJ Doc_15649445_925_934_Chemical) (NN uptake)) (PP (IN by) (NP (NP (NNS segments)) (PP (IN of) (NP (DT the) (NN brain)))))) (VP (AUX was) (VP (VBN analyzed))) (. .)))
15649445	6	(S1 (S (NP (DT A) (VBN decreased) (JJ Doc_15649445_993_1002_Chemical) (NN uptake)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ subcortical) (NNS parts)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15649445_1072_1081_Chemical)) (CC and) (NP (NNP Doc_15649445_1086_1097_Chemical))))))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN control)))))) (. .)))
15649445	7	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_15649445_1151_1160_Chemical) (NN uptake)))) (VP (VBZ correlates) (ADVP (RB negatively)) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_15649445_1227_1247_Disease)))))))) (. .)))
15649445	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ early) (NNS changes)) (PP (IN in) (NP (JJ Doc_15649445_1294_1303_Chemical) (NN transport)))) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
15737522	0	(S1 (NP (NP (JJ Doc_15737522_0_11_Chemical-associated) (NN Doc_15737522_23_46_Disease)) (PP (IN in) (NP (JJ paediatric) (JJ surgical) (NNS patients))) (. .)))
15737522	1	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB well)) (VP (VBN known) (SBAR (IN that) (S (NP (NNP Doc_15737522_102_113_Chemical)) (VP (VBZ leads) (PP (TO to) (NP (NNP Doc_15737522_123_138_Disease))) (PP (IN in) (NP (DT some) (NNS patients)))))))) (. .)))
15737522	2	(S1 (S (NP (JJ Clinical) (CC and) (JJ experimental) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS situations)) (VP (VBG causing) (NP (NNP Doc_15737522_228_251_Disease))) (, ,) (PP (JJ such) (IN as) (NP (NN fasting))) (, ,)) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15737522_309_324_Disease))))))))))) (. .)))
15737522	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NX (NX (NN incidence)) (CC and) (NX (JJ clinical) (NN importance)))) (PP (IN of) (NP (NNP Doc_15737522_409_424_Disease))) (PP (IN in) (NP (NP (JJ paediatric) (JJ surgical) (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_15737522_467_478_Chemical) (NN treatment))) (, ,) (SBAR (WHNP (WP who)) (S (ADVP (RB often)) (VP (AUX had) (S (VP (TO to) (ADVP (RB fast)) (PP (IN in) (NP (DT the) (JJ post-operative) (NN period)))))))))))) (. .)))
15737522	4	(S1 (S (NP (NP (JJ Fifty) (NNS children)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN given) (NP (NNP Doc_15737522_572_583_Chemical))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (JJ serial) (JJ abdominal) (NNS sonograms))))) (. .)))
15737522	5	(S1 (S (PP (IN Of) (NP (DT those))) (, ,) (NP (NP (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (JJ biliary) (NN pathology))) (. .)))
15737522	6	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (DT the) (NNS patients))) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_15737522_721_736_Disease)))) (VP (VBD revealed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (NN treatment) (CC and) (NN starvation) (NNS variables)))))))))) (. .)))
15737522	7	(S1 (S (PP (IN After) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN treatment))))) (, ,) (NP (NNP Doc_15737522_884_899_Disease)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (IN within) (NP (DT a) (JJ short) (NN period)))) (. .)))
15737522	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_15737522_963_978_Disease)))) (VP (AUX is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN fasting))))) (. .)))
15804801	0	(S1 (NP (NP (NN Doc_15804801_0_17_Disease)) (PP (IN after) (NP (NP (NN implantation)) (PP (IN of) (NP (DT a) (JJ Doc_15804801_42_52_Chemical-eluting) (NN stent))))) (. .)))
15804801	1	(S1 (S (S (NP (NP (NN Formation)) (PP (IN of) (NP (NNP Doc_15804801_81_98_Disease)))) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (S (VP (VBG stenting) (PP (IN with) (NP (JJ bare) (NN metal) (NNS stents))))))))) (, ,) (CC but) (S (PP (VBN based) (PP (IN on) (NP (JJ experimental) (NNS studies)))) (NP (JJ drug-eluting) (NNS stents)) (VP (MD may) (VP (VB induce) (NP (JJ toxic) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN vessel) (NN wall)) (PP (PP (IN with) (NP (NP (JJ incomplete) (NN stent) (NN apposition)) (, ,) (NP (JJ Doc_15804801_290_298_Disease) (NN formation)))) (CC and) (PP (IN with) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (JJ stent) (NNP Doc_15804801_341_351_Disease) (CC or) (NNP Doc_15804801_355_369_Disease))))))))))) (. .)))
15804801	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 43-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT a) (NN Doc_15804801_416_433_Disease)) (PP (IN in) (NP (DT the) (JJ right) (JJ coronary) (NN artery))) (PP (NP (CD 6) (NNS months)) (IN after) (S (VP (VBG receiving) (NP (DT a) (JJ Doc_15804801_490_500_Chemical-eluting) (NN stent)))))))))) (. .)))
15804801	3	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX was) (ADJP (JJ asymptomatic)))) (CC and) (S (NP (DT the) (NNP Doc_15804801_553_561_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (DT a) (JJ routine) (NN control)))))) (. .)))
15804801	4	(S1 (S (NP (NN Angiography) (CC and) (NN intracoronary) (NN ultrasound)) (VP (VBD demonstrated) (NP (NP (NN lack)) (PP (IN of) (NP (NN contact))) (PP (IN between) (NP (NN stent) (CC and) (NN vessel) (NN wall)))) (PP (IN in) (NP (DT a) (JJ 15-mm) (JJ long) (NN segment))) (PP (IN with) (NP (NP (JJ maximal) (JJ Doc_15804801_734_742_Disease) (NN diameter)) (PP (IN of) (NP (CD 6.0) (NNS mm)))))) (. .)))
15804801	5	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (DT a) (NN graft) (NN stent))))) (. .)))
15859940	0	(S1 (NP (NP (NNS Causes)) (PP (IN of) (NP (NP (JJ acute) (NN Doc_15859940_16_42_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN kidney) (NN transplantation))))))) (. .)))
15859940	1	(S1 (S (NP (NN Doc_15859940_101_127_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN problem)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG following) (NP (JJ renal) (NN transplantation))))))) (. .)))
15859940	2	(S1 (S (PP (IN In) (NP (JJ postrenal) (NN transplantation))) (, ,) (NP (NNP Doc_15859940_227_253_Disease)) (VP (AUX is) (ADVP (RB often)) (NP (NP (DT a) (NN reflection)) (PP (IN of) (NP (NNP Doc_15859940_279_304_Disease))))) (. .)))
15859940	3	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (DT the) (NNS causes)) (PP (IN of) (NP (NNP Doc_15859940_342_368_Disease))) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (JJ renal) (NN transplantation) (NNS recipients))))))) (CC and) (VP (VB discuss) (NP (DT the) (NN literature))))))) (. .)))
15859940	4	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS causes)) (PP (IN of) (NP (NNP Doc_15859940_502_528_Disease)))) (PP (IN during) (NP (DT a) (JJ 1-year) (NN period))) (, ,) (PP (IN from) (NP (NNP June) (CD 2003))) (PP (TO to) (NP (NNP June) (CD 2004))) (, ,) (PP (IN at) (NP (NP (DT the) (NNP King) (NNP Fahad) (NNP National) (NNP Guard) (NNP Hospital)) (PP (IN in) (NP (NP (NNP Riyadh)) (, ,) (NP (NNP Saudi) (NNP Arabia)))))) (, ,) (PP (IN by) (S (VP (VBG reviewing) (NP (NP (DT the) (NNS slides)) (PP (IN of) (NP (NP (NP (DT all) (NN transplant) (NNS biopsies)) (PRN (-LRB- -LRB-) (NP (CD n=25)) (-RRB- -RRB-))) (VP (VBN performed) (PP (IN during) (NP (DT this) (NN interval)))))))))))) (. .)))
15859940	5	(S1 (S (NP (NP (NN Pre-)) (CC and) (NP (NN posttransplant) (NN crossmatching))) (VP (AUX was) (VP (AUX done) (SBAR (WHADVP (WRB when)) (FRAG (ADJP (JJ possible)))))) (. .)))
15859940	6	(S1 (S (NP (NP (CD Five) (NNS cases)) (PP (IN of) (NP (NNP Doc_15859940_824_850_Disease)))) (VP (AUX were) (VP (VBN found))) (. .)))
15859940	7	(S1 (S (NP (NP (CD Three)) (PP (IN of) (NP (DT these) (NNS cases)))) (VP (AUX were) (PP (IN from) (NP (NP (DT the) (CD 25) (NNS transplantations)) (VP (VBN performed) (PP (IN at) (NP (NNP King) (NNP Fahad) (NNP National) (NNP Guard) (NNP Hospital)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ other) (CD 2) (NNS transplantations)) (VP (VP (AUX had) (VP (AUX been) (VP (VBN performed) (ADVP (RB abroad))))) (CC and) (VP (AUX were) (VP (VBN referred) (PP (TO to) (NP (PRP us))) (PP (IN for) (NP (NN follow-up))))))))) (. .)))
15859940	8	(S1 (S (S (NP (CD Three) (NNS cases)) (VP (AUX were) (VP (VBN related) (PP (TO to) (NP (NNP Doc_15859940_1095_1107_Chemical)))))) (, ,) (CC and) (S (NP (CD 1) (NN case)) (VP (AUX was) (ADJP (JJ secondary) (PP (TO to) (NP (PDT both) (NP (NNP Doc_15859940_1142_1154_Chemical)) (CC and) (NP (NNP Doc_15859940_1159_1169_Chemical))))))) (. .)))
15859940	9	(S1 (S (NP (DT The) (JJ fifth) (NN case)) (VP (AUX had) (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_15859940_1202_1228_Disease))) (ADJP (JJ related) (PP (TO to) (NP (NP (DT an) (NN Doc_15859940_1243_1268_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_15859940_1287_1315_Disease)))))))))) (. .)))
15859940	10	(S1 (S (PP (IN In) (NP (DT the) (NN literature))) (, ,) (NP (NP (DT the) (JJ most-frequent) (NN cause)) (PP (IN of) (NP (NNP Doc_15859940_1376_1401_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG following) (NP (JJ renal) (NN transplantation)))))) (VP (AUX is) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT the) (NNP Doc_15859940_1467_1492_Disease))))) (. .)))
15859940	11	(S1 (S (NP (JJ Other) (NNS causes)) (VP (VBP include) (NP (NP (JJ drug-related) (PRN (-LRB- -LRB-) (NP (NNP Doc_15859940_1529_1541_Chemical)) (, ,) (NP (NNP Doc_15859940_1543_1553_Chemical)) (-RRB- -RRB-)) (NNP Doc_15859940_1555_1563_Disease)) (, ,) (NP (JJ procoagulant) (NN status)) (, ,) (CC and) (NP (JJ antibody-mediated) (NN rejection)))) (. .)))
15859940	12	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (DT the) (JJ most-frequent) (NN cause)) (PP (IN of) (NP (NNP Doc_15859940_1660_1686_Disease)))) (VP (AUX was) (ADJP (NN drug) (VBN related)) (, ,) (PP (JJ secondary) (ADVP (RB mainly)) (TO to) (NP (NNP Doc_15859940_1725_1737_Chemical))))))) (. .)))
15859940	13	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_15859940_1778_1804_Disease)))) (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (NN percentage)) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (NN literature)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))))))))) (. .)))
15863244	0	(S1 (NP (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ developmental) (NNP Doc_15863244_28_36_Disease)) (PP (IN of) (NP (ADJP (JJ selective) (CC and) (JJ non-selective)) (JJ cyclooxygenase-2) (NNS inhibitors))) (PP (IN in) (NP (NNP CRL)))))) (: :) (NP (PRN (-LRB- -LRB-) (NP (NNP WI)) (-RRB- -RRB-)) (NNP WUBR) (NNP Wistar) (ADJP (JJ rats--Doc_15863244_125_128_Chemical) (CC and) (JJ Doc_15863244_133_142_Chemical)) (NN study)) (. .)))
15863244	1	(S1 (S (NP (JJ Cyclooxygenase) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)) (NNS inhibitors)) (VP (AUX are) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (RB often) (VBN ingested)) (NNS drugs)))) (PP (IN during) (NP (NN pregnancy)))) (. .)))
15863244	2	(S1 (S (PP (IN Unlike) (NP (JJ general) (JJ Doc_15863244_268_276_Disease) (NNS data))) (, ,) (NP (PRP$ their) (JJ prenatal) (JJ toxic) (NNS effects)) (VP (AUX were) (RB not) (VP (ADVP (RB extensively)) (VBN studied) (ADVP (RB before)))) (. .)))
15863244	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN experiment)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ developmental) (NN Doc_15863244_409_417_Disease)) (PP (IN of) (NP (NP (NP (DT the) (JJ non-selective)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15863244_440_449_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ selective) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15863244_466_469_Chemical)) (: ;) (NP (NNP Doc_15863244_471_545_Chemical))) (-RRB- -RRB-)) (JJ COX-2) (NNS inhibitors))))))))) (. .)))
15863244	4	(S1 (S (NP (NNS Drugs)) (VP (AUX were) (ADVP (RB separately)) (, ,) (SBAR (RB orally) (RB once) (S (ADVP (RB daily)) (VP (VBN dosed) (PP (TO to) (NP (NP (JJ pregnant) (NNS rats)) (PP (PP (IN from) (NP (NN day) (CD 8))) (PP (TO to) (NP (NP (CD 21)) (PRN (-LRB- -LRB-) (NP (JJ GD1=plug) (NN day)) (-RRB- -RRB-))))))))))) (. .)))
15863244	5	(S1 (S (NP (NNS Doses)) (VP (AUX were) (VP (VBN set) (PP (IN at) (NP (CD 0.3) (, ,) (CD 3.0) (CC and) (CD 30.0mg/kg))) (PP (IN for) (NP (NP (NNP Doc_15863244_716_725_Chemical)) (CC and) (NP (NP (CD 0.2)) (, ,) (NP (CD 2.0)) (CC and) (NP (NP (CD 20.0mg/kg)) (PP (IN for) (NP (NNP Doc_15863244_757_760_Chemical))))))))) (. .)))
15863244	6	(S1 (S (NP (NNS Fetuses)) (VP (VP (AUX were) (VP (VBN delivered) (PP (IN on) (NP (NNP GD) (CD 21))))) (CC and) (VP (ADVP (RB routinely)) (VBN examined))) (. .)))
15863244	7	(S1 (S (NP (JJ Comprehensive) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ developmental))) (NNS measurements)) (VP (AUX were) (VP (AUX done))) (. .)))
15863244	8	(S1 (S (NP (NP (DT The) (VBN pooled) (JJ statistical) (NN analysis)) (PP (IN for) (NP (NNP Doc_15863244_919_968_Disease)))) (VP (AUX was) (VP (VBN performed) (PP (IN for) (NP (NP (NN rat) (NNS fetuses)) (VP (VBN exposed) (PP (TO to) (NP (NP (NNP Doc_15863244_1010_1019_Chemical)) (, ,) (NP (NP (JJ selective) (CC and) (JJ non-selective) (JJ COX-2) (NN inhibitor)) (VP (VBN based) (PP (IN on) (NP (NP (NN present)) (CC and) (NP (JJ historic) (NNS data))))))))))))) (. .)))
15863244	9	(S1 (S (NP (NP (NNP Maternal) (NNP Doc_15863244_1119_1127_Disease)) (, ,) (NP (NNP Doc_15863244_1129_1160_Disease)) (, ,) (CC and) (NP (NNP Doc_15863244_1166_1210_Disease))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NNP Doc_15863244_1263_1272_Chemical)))))))))) (. .)))
15863244	10	(S1 (S (NP (NP (NN Decrease)) (PP (IN of) (NP (JJ fetal) (NN length)))) (VP (AUX was) (NP (NP (DT the) (JJ only) (NNS signs)) (PP (IN of) (NP (NP (DT the) (JJ Doc_15863244_1325_1328_Chemical) (NN developmental) (NN Doc_15863244_1343_1351_Disease)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS pups)) (VP (VBN exposed) (PP (TO to) (NP (DT the) (JJS highest) (NN compound) (NN dose))))))))))) (. .)))
15863244	11	(S1 (S (NP (NP (NN Lack)) (PP (IN of) (NP (NN teratogenicity)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNP Doc_15863244_1443_1452_Chemical)) (CC and) (NP (JJ Doc_15863244_1457_1460_Chemical-exposed) (NNS groups)))))) (. .)))
15863244	12	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (JJ non-selective) (NNP COX) (NNS inhibitors)))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP VSD)) (CC and) (NP (NNP MD))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (JJ historic) (NN control)))))) (FRAG (CC but) (RB not) (PP (IN with) (NP (JJ selective) (JJ COX-2) (NNS inhibitors))))) (. .)))
15863244	13	(S1 (S (NP (DT Both) (JJ selective) (CC and) (JJ non-selective) (NN COX-2) (NNS inhibitors)) (VP (AUX were) (ADJP (JJ toxic)) (PP (IN for) (NP (NNS rats) (NNS fetuses))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (DT the) (JJS highest) (NN dose))))))) (. .)))
15863244	14	(S1 (S (PP (IN Unlike) (NP (NNP Doc_15863244_1771_1774_Chemical))) (, ,) (NP (NNP Doc_15863244_1776_1785_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (RB highly) (JJ toxic) (PP (TO to) (NP (DT the) (NNS dams))))) (. .)))
15863244	15	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (JJ selective) (JJ COX-2) (NNS inhibitors)))) (VP (AUX does) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_15863244_1899_1937_Disease))) (PP (IN in) (NP (NN rat)))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (NP (JJ non-selective) (NNS drugs)) (CC and) (NP (JJ historic) (NN control))))))))) (. .)))
15899738	0	(S1 (S (NP (NNP Lone) (NNP Doc_15899738_5_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_15899738_41_49_Chemical) (NN monohydrate) (NN supplementation)))) (. .)))
15899738	1	(S1 (S (NP (NP (NN Doc_15899738_79_98_Disease)) (PP (IN in) (NP (JJ young) (NNS patients))) (PP (IN without) (NP (JJ structural) (NN Doc_15899738_136_149_Disease)))) (VP (AUX is) (ADJP (JJ rare))) (. .)))
15899738	2	(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_15899738_179_189_Disease)) (VP (AUX is) (ADJP (JJ present)) (PP (IN in) (NP (DT this) (NN population)))))) (, ,) (NP (JJ reversible) (NNS causes)) (VP (MD must) (VP (AUX be) (VP (VP (VBN identified)) (CC and) (VP (VBN resolved))))) (. .)))
15899738	3	(S1 (S (NP (NP (NN Doc_15899738_272_289_Disease)) (, ,) (NP (JJ illicit) (NN drug) (CC or) (NN stimulant) (NN use)) (, ,) (CC and) (NP (NNP Doc_15899738_326_352_Disease))) (VP (AUX are) (PP (IN among) (NP (DT these) (NNS causes)))) (. .)))
15899738	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 30-year-old) (JJ Caucasian) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD came) (PP (TO to) (NP (DT the) (NN emergency) (NN department))) (PP (IN in) (NP (NNP Doc_15899738_467_486_Disease))) (PP (IN with) (NP (JJ rapid) (JJ ventricular) (NN response)))))))))) (. .)))
15899738	5	(S1 (S (NP (PRP$ His) (JJ medical) (NN history)) (VP (AUX was) (ADJP (JJ unremarkable)) (, ,) (PP (IN except) (PP (IN for) (NP (NP (JJ minor) (NN Doc_15899738_575_584_Disease)) (PP (IN of) (NP (DT the) (NNS fingers) (CC and) (NN foot))))))) (. .)))
15899738	6	(S1 (S (S (NP (NP (NP (JJ Thyroid-stimulating) (NN hormone)) (, ,) (NP (NNP Doc_15899738_639_648_Chemical)) (, ,)) (CC and) (NP (JJ Doc_15899738_654_663_Chemical) (NNS levels))) (VP (AUX were) (PP (IN within) (NP (JJ normal) (NNS limits))))) (, ,) (S (NP (NN urine) (NN drug) (NN screen)) (VP (AUX was) (ADJP (JJ negative)))) (, ,) (CC and) (S (NP (JJ Doc_15899738_734_741_Chemical) (NN use)) (VP (AUX was) (VP (VBN denied)))) (. .)))
15899738	7	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN questioned) (PP (IN about) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ herbal) (NNS products)) (CC and) (NP (NNS supplements)))))))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_15899738_856_864_Chemical) (NN monohydrate)))) (VP (AUX was) (VP (VBN revealed))) (. .)))
15899738	8	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital)))) (, ,) (VP (VBN anticoagulated) (PP (IN with) (NP (JJ unfractionated) (NNP Doc_15899738_968_975_Chemical)))) (, ,) (CC and) (VP (VBN given) (NP (JJ intravenous) (NNP Doc_15899738_999_1008_Chemical)) (PP (IN for) (NP (NP (NN rate) (NN control)) (CC and) (NP (JJ intravenous) (NN Doc_15899738_1042_1052_Chemical)))) (PP (IN for) (NP (NP (NN rate)) (CC and) (NP (NN rhythm) (NN control))))))) (. .)))
15899738	9	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN discharged) (ADVP (NP (QP (JJR less) (IN than) (CD 24)) (NNS hours)) (RB later))))) (, ,) (NP (PRP he)) (VP (AUX was) (VP (VBG receiving) (NP (NP (NNP Doc_15899738_1141_1151_Chemical)) (CC and) (NP (NNP Doc_15899738_1156_1163_Chemical))) (, ,) (PP (IN with) (NP (NP (JJ follow-up) (NNS plans)) (PP (IN for) (NP (NP (NN echocardiography)) (CC and) (NP (JJ nuclear) (NN imaging)))) (S (VP (TO to) (VP (VB assess) (NP (NN perfusion))))))))) (. .)))
15899738	10	(S1 (S (NP (NNP Exogenous) (NNP Doc_15899738_1258_1266_Chemical)) (VP (AUX is) (VP (VBN used) (PP (IN by) (NP (NNS athletes))) (S (VP (TO to) (ADVP (RB theoretically)) (VP (VB improve) (NP (NN exercise) (NN performance))))))) (. .)))
15899738	11	(S1 (S (NP (NNS Vegetarians)) (VP (MD may) (ADVP (RB also)) (VP (VB take) (NP (NNP Doc_15899738_1360_1368_Chemical)) (S (VP (TO to) (VP (VB replace) (SBAR (WHNP (WP what)) (S (NP (PRP they)) (VP (AUX are) (RB not) (NP (NP (NN consuming)) (PP (IN from) (NP (NP (NN meat)) (, ,) (NP (NN fish)) (, ,) (CC and) (NP (JJ other) (NN animal) (NNS products))))))))))))) (. .)))
15899738	12	(S1 (S (NP (JJ Previous) (JJ anecdotal) (NNS reports)) (VP (AUX have) (VP (VBN linked) (NP (NNP Doc_15899738_1491_1499_Chemical)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15899738_1522_1532_Disease))))))) (. .)))
15899738	13	(S1 (S (NP (NNS Clinicians)) (VP (MD must) (VP (AUX be) (ADJP (JJ diligent)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG interviewing) (NP (NNS patients)) (PP (IN about) (NP (PRP$ their) (NN drug) (NN therapy) (NNS histories)))) (CC and) (VP (VBP include) (NP (NP (NNS questions)) (PP (IN about) (NP (NP (PRP$ their) (NN use)) (PP (IN of) (NP (NP (JJ herbal) (NNS products)) (CC and) (NP (JJ dietary) (NNS supplements))))))))))))) (. .)))
15899738	14	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP it)) (VP (AUX is) (UCP (ADJP (JJ important) (S (VP (TO to) (VP (VB report) (NP (NP (JJ adverse) (NNS effects)) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB frequently) (VBN consumed)) (NNS supplements)) (CC and) (NP (JJ herbal) (NNS products)))))) (PP (TO to) (NP (DT the) (NNP Food) (CC and) (NNP Drug) (NNP Administration))))))) (CC and) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
1592014	0	(S1 (S (NP (NN Doc_1592014_0_8_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ Doc_1592014_24_31_Chemical) (NN metabolite) (NN Doc_1592014_43_58_Chemical)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1592014	1	(S1 (S (S (NP (NP (DT The) (NN half-life)) (PRN (-LRB- -LRB-) (NP (NN t1/2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_1592014_92_99_Chemical)))) (VP (AUX is) (ADJP (RB relatively) (JJ short)))) (, ,) (CC but) (S (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (NP (PRP$ its) (NN use))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_1592014_170_178_Disease)) (CC and) (NP (NNP Doc_1592014_183_190_Disease)))) (, ,)) (VP (MD can) (VP (VB occur) (NP (NP (NNS hours)) (PP (IN after) (NP (NN exposure))))))) (. .)))
1592014	2	(S1 (S (NP (DT This)) (VP (VBD led) (NP (PRP us)) (S (VP (TO to) (VP (VB hypothesize) (SBAR (IN that) (S (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NNP Doc_1592014_272_279_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT some)) (PP (IN of) (NP (DT those) (JJ delayed) (NNS sequelae)))))))))))))) (. .)))
1592014	3	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN metabolite)) (PP (IN of) (NP (NP (NNP Doc_1592014_389_396_Chemical)) (, ,) (NP (NP (NNP Doc_1592014_398_413_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1592014_415_417_Chemical)) (-RRB- -RRB-))) (, ,))))) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_1592014_429_437_Disease))))))) (. .)))
1592014	4	(S1 (S (NP (NP (NP (CD Two) (JJ separate) (NN equimolar) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.2)) (CC and) (NP (CD 0.4) (NN mumol))) (-RRB- -RRB-))) (PP (IN of) (NP (DT either) (NNP Doc_1592014_498_505_Chemical) (CC or) (NNP Doc_1592014_509_511_Chemical)))) (VP (AUX were) (VP (VBN injected) (ADVP (RB ventricularly)) (PP (IN in) (NP (JJ unanesthetized) (JJ juvenile) (NNS rats))))) (. .)))
1592014	5	(S1 (S (NP (VBN Treated) (NNS rats)) (VP (AUX were) (ADVP (RB then)) (VP (VBN evaluated) (PP (PP (IN for) (NP (NP (NN incidence)) (, ,) (NP (NN latency)) (, ,) (CC and) (NP (JJ Doc_1592014_634_641_Disease) (NN pattern)))) (CC or) (PP (IN for) (NP (NP (NN locomotor) (NN activity)) (PP (IN in) (NP (NP (NNS animals)) (PP (IN without) (NP (NNP Doc_1592014_695_703_Disease)))))))))) (. .)))
1592014	6	(S1 (S (NP (JJ Doc_1592014_705_707_Chemical-Induced) (NN Doc_1592014_716_724_Disease)) (VP (VP (VBD occurred) (ADVP (RBR more) (RB frequently))) (CC and) (VP (AUX had) (ADJP (ADVP (RB significantly) (RBR longer)) (JJ latencies) (PP (IN than) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ equimolar) (NNS amounts)) (PP (IN of) (NP (NNP Doc_1592014_832_839_Chemical))))))))))) (. .)))
1592014	7	(S1 (S (SBAR (IN Whereas) (S (NP (NNP Doc_1592014_849_856_Chemical-induced) (NNP Doc_1592014_865_873_Disease)) (VP (VP (AUX were) (ADVP (RB best)) (VP (VBN characterized) (PP (IN as) (NP (NP (NN brief)) (, ,) (NP (NN generalized)) (, ,) (CC and) (NP (NN tonic)))))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_1592014_947_952_Disease))))))) (, ,) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1592014_971_973_Chemical))))) (VP (VP (AUX were) (ADJP (JJ prolonged) (, ,) (RB often) (JJ multiple) (CC and) (JJ mixed)) (PP (IN in) (NP (NN type)))) (, ,) (CC and) (ADVP (RB rarely)) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_1592014_1047_1052_Disease))))) (. .)))
1592014	8	(S1 (S (NP (NP (JJ Electrical) (NNS recordings)) (PP (IN from) (NP (DT the) (NN hippocampus)))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ rhythmic) (NN progression)) (PP (IN in) (NP (NNP EEG) (NN frequency)))) (CC and) (NP (NP (NN voltage)) (PP (IN with) (NP (JJ clinical) (JJ Doc_1592014_1170_1177_Disease) (NN expression)))))) (. .)))
1592014	9	(S1 (S (NP (NP (JJ Doc_1592014_1190_1192_Chemical-Injected) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_1592014_1225_1233_Disease))))))) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR more)) (NN locomotor) (NN activity)) (PP (IN than) (NP (NP (JJ Doc_1592014_1281_1288_Chemical-injected) (NNS animals)) (PP (IN without) (NP (NNP Doc_1592014_1314_1322_Disease))))))) (. .)))
1592014	10	(S1 (S (NP (DT The) (NN finding) (SBAR (IN that) (S (NP (NP (NNP Doc_1592014_1341_1348_Chemical-)) (CC and) (NP (NNP Doc_1592014_1354_1356_Chemical-induced) (NNP Doc_1592014_1365_1373_Disease))) (VP (VBP differ) (PP (IN in) (NP (JJ several) (NNS respects))))))) (VP (VP (VBZ suggests) (NP (NP (QP (JJR more) (IN than) (CD one)) (NN mechanism)) (PP (IN for) (NP (JJ Doc_1592014_1438_1445_Chemical-induced) (NN Doc_1592014_1454_1462_Disease))))) (CC and) (VP (VBZ emphasizes) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NP (DT a) (JJ Doc_1592014_1498_1505_Chemical) (NN metabolite)) (, ,) (NP (NNP Doc_1592014_1518_1520_Chemical))))))) (. .)))
15957009	0	(S1 (S (NP (DT The) (JJ selective) (JJ 5-HT6) (NN receptor) (NN antagonist) (NN Doc_15957009_40_49_Chemical)) (VP (VBZ restores) (NP (NN memory) (NN performance)) (PP (IN in) (NP (NP (JJ cholinergic) (CC and) (JJ serotonergic) (NNS models)) (PP (IN of) (NP (NP (NNP Doc_15957009_120_137_Disease)) (PP (IN in) (NP (DT the) (NN rat)))))))) (. .)))
15957009	1	(S1 (S (NP (NP (NNS Antagonists)) (PP (IN at) (NP (NNP Doc_15957009_165_174_Chemical) (NN type) (CD 6)))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15957009_183_187_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NP (NNS receptors)) (VP (VBP show) (NP (NP (NN activity)) (PP (IN in) (NP (NP (NNS models)) (PP (IN of) (NP (NP (NN learning)) (CC and) (NP (NN memory)))))))) (. .)))
15957009	2	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ underlying) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-))) (VP (AUX are) (RB not) (VP (ADVP (RB well)) (VBN understood))))) (, ,) (NP (DT these) (NNS effects)) (VP (MD may) (VP (VB involve) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_15957009_353_366_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_368_371_Chemical)) (-RRB- -RRB-)) (NNS levels)))))) (. .)))
15957009	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBD sought) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT the) (JJ cognitive-enhancing) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NNP Doc_15957009_461_465_Chemical) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN antagonist)) (NP (NP (NNP Doc_15957009_480_489_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_491_545_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (DT a) (NN rat) (NN object) (NN recognition) (NN task)) (VP (VBG employing) (NP (NP (NP (DT a) (JJ cholinergic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_605_616_Chemical) (NN pretreatment)) (-RRB- -RRB-))) (CC and) (NP (DT a) (JJ serotonergic-) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_652_662_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_664_667_Chemical)) (-RRB- -RRB-)) (NN depletion)) (-RRB- -RRB-)) (NN deficient) (NN model)))))))))) (, ,) (CC and) (VP (VBN compared) (NP (PRP$ its) (NN pattern)) (PP (IN of) (NP (NP (NN action)) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN acetylcholinesterase) (NN inhibitor) (NNP Doc_15957009_780_791_Chemical))))))))) (. .)))
15957009	4	(S1 (S (NP (NP (JJ Initial) (NN testing)) (PP (IN in) (NP (NP (DT a) (JJ time-dependent) (VBG forgetting) (NN task)) (VP (VBG employing) (NP (NP (DT a) (JJ 24-h) (NN delay)) (PP (IN between) (NP (NN training) (CC and) (NN testing)))))))) (VP (VBD showed) (NP (NP (DT that) (JJ Doc_15957009_909_920_Chemical) (JJ improved) (NN object) (NN recognition)) (PRN (-LRB- -LRB-) (NP (QP (IN at) (CD 10) (CC and) (CD 30)) (NNS mg/kg)) (, ,) (NP (CD p.o.)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_15957009_985_994_Chemical)) (VP (AUX was) (ADJP (JJ inactive)))))) (. .)))
15957009	5	(S1 (S (NP (DT Both)) (, ,) (NP (NP (NP (NNP Doc_15957009_1015_1024_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CC and) (CD 10)) (NN mg/kg)) (, ,) (RB intraperitoneally) (PRN (-LRB- -LRB-) (NP (CD i.p.)) (-RRB- -RRB-)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15957009_1072_1083_Chemical)) (PRN (-LRB- -LRB-) (FRAG (NP (CD 10) (NN mg/kg)) (, ,) (NP (NN p.o.)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))) (VP (VBD reversed) (NP (NNP Doc_15957009_1124_1139_Disease)) (S (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15957009_1151_1162_Chemical) (CC and) (NNP Doc_15957009_1167_1170_Chemical) (NN depletion)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NNS mg/kg)) (, ,) (NP (NNS i.p.)) (, ,) (CC and) (NP (CD 3) (NN mg/kg)) (, ,) (NP (NNS p.o.))) (, ,) (RB respectively) (-RRB- -RRB-))))))) (. .)))
15957009	6	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_15957009_1256_1265_Chemical)) (VP (AUX did) (RB not) (VP (VB improve) (NP (DT a) (JJ time-related) (NN retention) (NN deficit)))))) (, ,) (NP (PRP it)) (VP (VBD reversed) (NP (NP (DT a) (NN cholinergic)) (CC and) (NP (DT a) (JJ serotonergic) (NN Doc_15957009_1361_1375_Disease))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT both) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (NP (DT the) (NN facilitation)) (PP (IN of) (NP (NN object) (NN memory))) (PP (IN by) (NP (NNP Doc_15957009_1465_1474_Chemical)))) (CC and) (, ,) (ADVP (RB possibly)) (, ,) (NP (JJ other) (JJ Doc_15957009_1496_1500_Chemical) (PRN (-LRB- -LRB-) (CD 6) (-RRB- -RRB-)) (NN receptor) (NNS antagonists)))))))))))) (. .)))
16005948	0	(S1 (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (DT the) (JJ anticocaine) (JJ monoclonal) (NN antibody)) (ADJP (JJ Doc_16005948_50_57_Chemical) (PP (IN as) (NP (NP (DT an) (NN immunotherapy)) (PP (IN for) (NP (NNP Doc_16005948_82_98_Disease)))))))) (. .)))
16005948	1	(S1 (S (S (NP (NP (DT The) (JJ illicit) (NN use)) (PP (IN of) (NP (NNP Doc_16005948_119_126_Chemical)))) (VP (VBZ continues) (PP (IN in) (NP (NN epidemic) (NNS proportions))))) (CC and) (S (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_16005948_179_195_Disease)))) (VP (VBZ remains) (ADJP (JJ elusive)))) (. .)))
16005948	2	(S1 (S (NP (JJ Current) (JJ protein-based) (NN technology)) (VP (VBZ offers) (NP (NP (DT a) (JJ new) (JJ therapeutic) (NN venue)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS antibodies)) (VP (NN bind) (NP (DT the) (NN drug)) (PP (IN in) (NP (DT the) (NN blood) (NN stream))) (, ,) (S (VP (VBG inactivating) (NP (PRP$ its) (JJ toxic) (NNS effects))))))))) (. .)))
16005948	3	(S1 (S (NP (NP (DT The) (JJ therapeutic) (NN potential)) (PP (IN of) (NP (DT the) (JJ anticocaine) (NN antibody) (NN Doc_16005948_418_425_Chemical)))) (VP (AUX was) (VP (VBN examined) (S (VP (VBG using) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_16005948_456_472_Disease)))))))) (. .)))
16005948	4	(S1 (S (NP (NP (JJ Swiss) (NN albino) (NNS mice)) (VP (VBN prepared) (PP (IN with) (NP (JJ intrajugular) (NNS catheters))))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (JJ photocell) (NNS cages))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (CD 93) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (CD LD50)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_16005948_603_610_Chemical) (CC and) (NNP Doc_16005948_615_622_Chemical) (NNS infusions)) (VP (VBG ranging) (PP (PP (IN from) (NP (CD 30))) (PP (TO to) (NP (CD 190) (CD mg/kg))))))))))))) (. .)))
16005948	5	(S1 (S (NP (NN Doc_16005948_663_670_Chemical)) (VP (AUX was) (VP (VP (VBN delivered) (ADVP (NP (CD 30) (NN min)) (RB before)) (, ,) (ADVP (RB concomitantly))) (CC or) (VP (NP (CD 3) (NN min)) (PP (IN after) (NP (JJ Doc_16005948_729_736_Chemical) (NN treatment)))))) (. .)))
16005948	6	(S1 (S (NP (NP (JJ Significant) (NN blockade)) (PP (IN of) (NP (NNP Doc_16005948_772_779_Chemical) (NNP Doc_16005948_780_788_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_16005948_826_833_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 190) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NN premorbid) (NNS behaviors)) (VP (AUX were) (VP (VBN reduced) (PRT (RP up)) (PP (TO to) (NP (CD 40) (NN %)))))))) (, ,) (NP (NP (NNP Doc_16005948_897_905_Disease)) (PP (IN up) (PP (TO to) (NP (CD 77) (NN %))))) (CC and) (NP (NNP Doc_16005948_920_925_Disease)))))) (PP (IN by) (NP (CD 72) (NN %))))) (. .)))
16005948	7	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NNP Doc_16005948_947_954_Chemical)) (VP (VBD prevented) (NP (NNP Doc_16005948_965_970_Disease) (ADJP (RB even) (JJ post-Doc_16005948_981_988_Chemical)) (NN injection))) (. .)))
16005948	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP support) (NP (NP (DT the) (JJ important) (NN potential)) (PP (IN of) (NP (NNP Doc_16005948_1047_1054_Chemical)))) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN tool)) (PP (IN against) (NP (NNP Doc_16005948_1085_1101_Disease)))))) (. .)))
1601297	0	(S1 (S (NP (NP (JJ Electrocardiographic) (NN evidence)) (PP (IN of) (NP (NNP Doc_1601297_33_50_Disease))) (PP (IN in) (NP (ADJP (RB psychiatrically) (VBN hospitalized)) (NN Doc_1601297_83_90_Chemical)))) (VP (VBZ abusers)) (. .)))
1601297	1	(S1 (S (NP (NP (NP (DT The) (NNS electrocardiograms)) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 99) (JJ Doc_1601297_135_142_Chemical-abusing) (NNS patients)))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS ECGs)) (PP (IN of) (NP (CD 50) (JJ Doc_1601297_194_207_Disease) (NNS controls))))))) (. .)))
1601297	2	(S1 (S (NP (NP (CD Eleven)) (PP (IN of) (NP (NP (DT the) (JJ Doc_1601297_232_239_Chemical) (NNS abusers)) (CC and) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS controls))))))) (VP (AUX had) (NP (NP (JJ ECG) (NN evidence)) (PP (IN of) (NP (NP (JJ significant) (NN Doc_1601297_305_322_Disease)) (VP (VBN defined) (PP (IN as) (NP (NP (NNP Doc_1601297_334_355_Disease)) (, ,) (NP (NNP Doc_1601297_357_365_Disease)) (, ,) (CC and) (NP (NNP Doc_1601297_371_390_Disease))))))))) (. .)))
16160878	0	(S1 (S (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_16160878_22_34_Chemical)))) (ADVP (RB centrally)) (VP (VBN administered) (PP (IN in) (NP (NNS mice)))) (. .)))
16160878	1	(S1 (S (NP (JJ Doc_16160878_67_79_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16160878_81_85_Chemical)) (-RRB- -RRB-)) (NNS receptors)) (VP (AUX are) (ADVP (RB widely)) (VP (VBN distributed) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system))))) (. .)))
16160878	2	(S1 (S (NP (NP (JJ Intracerebroventricular) (PRN (-LRB- -LRB-) (VBG i.c.v.) (-RRB- -RRB-)) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_197_201_Chemical)))) (VP (VP (VBZ causes) (NP (NP (NNP Doc_16160878_209_221_Disease)) (CC and) (NP (NNP Doc_16160878_226_237_Disease)))) (CC and) (VP (VBZ stimulates) (NP (NP (NN prolactin)) (CC and) (NP (NN thyrotropin) (NN secretion))))) (. .)))
16160878	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (ADJP (RB centrally) (VBN administered)) (NN Doc_16160878_348_352_Chemical)))) (VP (AUX have) (VP (VBN received) (NP (JJ little) (NN attention)))) (. .)))
16160878	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ i.c.v.) (NNS injections)) (PP (IN of) (NP (NNP Doc_16160878_453_457_Chemical))))) (PP (IN on) (NP (NP (ADJP (JJ behavioral) (, ,) (JJ metabolic) (, ,) (CC and) (JJ endocrine)) (NNS responses)) (PP (IN in) (NP (NNS mice))))))) (. .)))
16160878	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (JJ graded) (NNS doses)) (PP (IN of) (NP (NNP Doc_16160878_551_555_Chemical) (PRN (-LRB- -LRB-) (NP (CD 1-10,000) (NN ng/mouse)) (-RRB- -RRB-))))))) (VP (VP (VP (VBD provoked) (: :) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NP (DT a) (JJ dose-dependent) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN head) (NNS dips)) (PP (IN in) (NP (DT the) (JJ hole-board) (NN test)))))))) (PRN (: ;) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NP (DT a) (JJ dose-dependent) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS entries)) (PP (IN in) (NP (NP (DT the) (JJ white) (NN chamber)) (PP (IN in) (NP (DT the) (JJ black-and-white) (NN compartment) (NN test))))))))))) (, ,) (CC and) (PP (IN in) (NP (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS entries)) (PP (IN in) (NP (NP (DT the) (JJ central) (NN platform)) (CC and) (NP (NP (JJ open) (NNS arms)) (PP (IN in) (NP (DT the) (JJ plus-maze) (NN test))))))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN immobility)) (PP (IN in) (NP (DT the) (JJ forced-swimming) (NN test) (CC and) (NN tail) (NN suspension) (NN test))))))))))) (. .)))
16160878	6	(S1 (S (NP (NP (JJ Intracerebroventricular) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_1031_1035_Chemical)))) (ADVP (RB also)) (VP (VBD caused) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (: :) (NN food) (NN intake))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 100) (CC and) (CD 1,000)) (NN ng/mouse)))))) (, ,) (NP (NP (NN water) (NN intake)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 100-10,000) (NN ng/mouse)))))) (, ,) (CC and) (NP (NP (JJ horizontal) (NN locomotion) (NN activity)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 10,000) (NN ng/mouse)))))))) (. .)))
16160878	7	(S1 (S (SBAR (WHNP (WDT Whatever)) (S (VP (AUX was) (NP (DT the) (NN dose))))) (, ,) (NP (NP (DT the) (JJ central) (NN administration)) (PP (IN of) (NP (NNP Doc_16160878_1276_1280_Chemical)))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN body) (NN temperature)) (, ,) (NP (NN nociception)) (, ,) (NP (NNP Doc_16160878_1329_1340_Chemical-induced) (NNP Doc_16160878_1349_1364_Disease) (CC and) (VBG climbing) (NN behavior)) (, ,) (CC and) (NP (JJ stress-induced) (NN plasma) (JJ Doc_16160878_1414_1428_Chemical) (NN level)))))) (. .)))
16160878	8	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (DT the) (JJ central) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_1513_1517_Chemical))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 1-10,000) (NN ng/mouse)))))) (VP (VBZ induces) (NP (NP (NN anxiogenic-)) (CC and) (NP (JJ depressant-like) (NNS effects))) (PP (IN in) (NP (NN mouse))))))) (. .)))
16160878	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_16160878_1630_1634_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT some) (NNS aspects)) (PP (IN of) (NP (NN Doc_16160878_1670_1691_Disease))))))))))) (. .)))
1616457	0	(S1 (S (NP (NP (NN Learning)) (PP (IN of) (NP (NNS rats))) (PP (IN under) (NP (NNP Doc_1616457_23_30_Disease)))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_1616457_41_54_Chemical)))) (. .)))
1616457	1	(S1 (S (NP (NP (JJ Dissociated) (NN learning)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN in) (NP (NP (DT the) (JJ normal) (NN state)) (CC and) (NP (NP (DT the) (NN state)) (PP (IN of) (NP (NNP Doc_1616457_122_129_Disease)))))) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_1616457_142_155_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg)) (, ,) (NP (NN ip)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
1616457	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VB approach) (NP (NP (DT a) (NN shelf)) (SBAR (WHADVP (WRB where)) (S (NP (PRP they)) (VP (VBD received) (NP (NN food) (NN reinforcement))))))))))) (. .)))
1616457	3	(S1 (S (PP (IN In) (NP (NNP Group) (CD 1))) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN trained) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_1616457_322_335_Chemical))))) (S (VP (TO to) (VP (VB run) (PP (TO to) (NP (DT the) (JJ same) (NN shelf))) (PP (IN as) (PP (IN in) (NP (DT the) (JJ normal) (NN state))))))))) (. .)))
1616457	4	(S1 (S (PP (IN In) (NP (NNP Group))) (, 2) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VB approach) (NP (JJ different) (NNS shelves)) (PP (IN in) (NP (JJ different) (NN drug) (NNS states)))))))) (. .)))
1616457	5	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_1616457_492_511_Disease)) (VP (VBD occurred) (PP (IN in) (NP (DT both) (NNS groups)))))))) (. .)))
1616457	6	(S1 (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NP (DT the) (NNS parameters)) (PP (IN of) (NP (NP (NN training)) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_1616457_602_615_Chemical))))))))) (PP (IN between) (NP (NNS Groups) (CD 1) (CC and) (CD 2)))) (VP (AUX were) (VP (VBN revealed))) (. .)))
1616457	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ brain-dissociated) (NN state)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1616457_718_731_Chemical))))) (VP (AUX is) (VP (VBN formed) (PP (IN with) (NP (NP (DT the) (NN participation)) (PP (IN of) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NN information) (NN perception)))))))))))) (. .)))
16167916	0	(S1 (NP (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ short-term) (JJ Doc_16167916_26_36_Chemical) (NN therapy))) (PP (IN on) (NP (NN fibrinolysis) (NNS markers)))) (: :) (NP (NP (NNP TAFI)) (, ,) (NP (NNP tPA)) (, ,) (CC and) (NP (NNP PAI-1))) (. .)))
16167916	1	(S1 (S (NP (NP (NNS Markers)) (PP (IN of) (NP (NP (NNS fibrinolysis)) (, ,) (NP (JJ thrombin-activatable) (NN fibrinolysis) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP TAFI)) (-RRB- -RRB-)) (, ,) (NP (JJ tissue-type) (JJ plasminogen) (NN activator)) (PRN (-LRB- -LRB-) (NP (NNP tPA)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ plasminogen) (JJ activator) (JJ inhibitor-1) (PRN (-LRB- -LRB-) (JJ PAI-1) (-RRB- -RRB-)) (NNS levels))))) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (JJ short-term) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_16167916_332_342_Chemical) (NN administration)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))))))) (. .)))
16167916	2	(S1 (S (NP (NP (JJ Thirty-nine) (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NP (NNP Doc_16167916_430_440_Disease)) (CC or) (NP (NNP Doc_16167916_444_456_Disease))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (JJ prospective) (, ,) (JJ controlled) (JJ clinical) (NN study))))) (. .)))
16167916	3	(S1 (S (NP (CD Twenty-five) (NNS women)) (VP (AUX were) (VP (VBN given) (NP (NP (NP (NNP Doc_16167916_548_572_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mg/day)) (-RRB- -RRB-))) (CC plus) (NP (NP (NNP Doc_16167916_590_597_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/day)) (-RRB- -RRB-)))))) (. .)))
16167916	4	(S1 (S (NP (NP (JJ Age-matched) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 14)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN given) (NP (JJ only) (NNP Doc_16167916_658_665_Chemical)))) (. .)))
16167916	5	(S1 (S (NP (NP (NN Plasma) (NNS TAFI)) (, ,) (NP (NNP tPA)) (, ,) (CC and) (NP (JJ PAI-1) (NN antigen) (NNS levels))) (VP (AUX were) (VP (VBN measured) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NN treatment)))))) (PP (IN by) (NP (ADJP (RB commercially) (JJ available)) (NNP ELISA) (NNS kits))))) (. .)))
16167916	6	(S1 (S (NP (NP (NNS Variations)) (PP (IN of) (NP (NNS individuals)))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (NP (NP (NNP Wilcoxon) (POS 's)) (NN test))))) (. .)))
16167916	7	(S1 (S (NP (NP (NN Relationship)) (PP (IN between) (NP (NP (DT those) (NNS markers)) (CC and) (NP (JJ demographic) (NNS characteristics))))) (VP (AUX were) (VP (VBN investigated))) (. .)))
16167916	8	(S1 (S (NP (NP (CD Three) (NNS months)) (PP (IN of) (NP (JJ Doc_16167916_977_987_Chemical) (NN treatment)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN TAFI) (NN antigen) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 16) (NN %)) (NN change)) (, ,) (NP (NNP P) (NNP <) (CD 0.01))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NNP tPA) (NN antigen) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 25) (NN %)) (NN change)) (, ,) (NP (NNP P) (NNP <) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
16167916	9	(S1 (S (NP (DT A) (JJ significant) (NN correlation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (JJ baseline) (JJ TAFI) (NN antigen) (NNS concentrations)) (CC and) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_16167916_1289_1299_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <) (CD 0.05)) (: ;) (NP (SYM r)) (X (SYM =)) (CD 0.33)) (-RRB- -RRB-))))))))) (. .)))
16167916	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_16167916_1372_1394_Disease))) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_16167916_1402_1412_Chemical) (NN treatment))))) (VP (MD may) (VP (AUX be) (UCP (VP (VBN related) (PP (TO to) (NP (VBN increased) (NNP tPA) (NNS levels)))) (, ,) (CC but) (RB not) (NP (JJ TAFI) (NNS levels)))))))) (. .)))
16181582	0	(S1 (NP (JJ Doc_16181582_0_9_Chemical-induced) (NN Doc_16181582_18_32_Disease) (. .)))
16181582	1	(S1 (S (NP (JJ Doc_16181582_34_43_Chemical-induced) (NN Doc_16181582_52_66_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN syndrome)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VBP manifest) (PP (IN in) (NP (ADJP (RB otherwise) (JJ normal)) (NN Doc_16181582_124_133_Disease) (NNS individuals))))))))) (. .)))
16181582	2	(S1 (S (NP (PRP It)) (VP (MD may) (ADVP (RB even)) (VP (VB present) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN tolerated) (NP (DT this) (NN medicine)) (ADVP (RB well)) (PP (IN in) (NP (DT the) (NN past))))))))))) (. .)))
16181582	3	(S1 (S (NP (PRP It)) (VP (AUX is) (UCP (ADVP (RB usually)) (CC but) (VP (RB not) (ADVP (RB necessarily)) (VBN associated) (PP (IN with) (NP (NN Doc_16181582_280_294_Disease)))))) (. .)))
16181582	4	(S1 (S (NP (DT The) (NNP EEG)) (VP (VBZ shows) (NP (NP (JJ characteristic) (JJ triphasic) (NNS waves)) (PP (IN in) (NP (JJS most) (NNS patients))) (PP (IN with) (NP (DT this) (NN complication))))) (. .)))
16181582	5	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_16181582_392_401_Chemical-induced) (NNP Doc_16181582_410_424_Disease)))) (VP (AUX is) (VP (VBN presented))) (. .)))
16181582	6	(S1 (S (NP (NP (DT The) (NNS problems)) (PP (IN in) (S (VP (VBG diagnosing) (NP (DT this) (NN condition)))))) (VP (AUX are) (ADVP (RB subsequently)) (VP (VBN discussed))) (. .)))
16274958	0	(S1 (NP (NNP Recurrent) (NNP Doc_16274958_10_19_Disease) (CC and) (NNP Doc_16274958_24_33_Chemical) (. .)))
16274958	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN woman)) (VP (VBG complaining) (PP (IN of) (NP (NNP Doc_16274958_80_89_Disease))) (SBAR (IN while) (S (NP (PRP she)) (VP (AUX was) (VP (VBN treated) (PP (IN by) (NP (NNP Doc_16274958_115_124_Chemical)))))))))))) (. .)))
16274958	2	(S1 (S (NP (PRP$ Her) (NNS symptoms)) (VP (VP (ADVP (RB totally)) (VBN regressed) (PP (IN after) (NP (NN drug) (NN withdrawal)))) (CC and) (VP (VBD reappeared) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16274958_199_208_Chemical)) (VP (AUX was) (VP (VBN reintroduced))))))) (. .)))
16274958	3	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_16274958_271_280_Chemical-induced) (NN Doc_16274958_289_298_Disease))))) (. .)))
16274958	4	(S1 (S (NP (DT This) (NN effect)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ pharmacological) (NN effect)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN on) (NP (JJ mucous) (NNS membranes)))))))) (. .)))
16298782	0	(S1 (NP (NP (NN Doc_16298782_0_29_Chemical)) (: :) (NP (NP (DT a) (JJ potential) (NN protector)) (PP (IN against) (NP (NNP Doc_16298782_61_71_Chemical) (NNP Doc_16298782_72_83_Disease)))) (. .)))
16298782	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_16298782_89_101_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16298782_103_105_Chemical)) (-RRB- -RRB-)) (NN inhibitor) (NNP Doc_16298782_117_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16298782_148_154_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NP (DT an) (NN otoprotectant)) (PP (IN against) (NP (NNP Doc_16298782_192_219_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_16298782_230_240_Chemical))))))))) (, ,) (CC but) (S (NP (JJ further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB confirm) (SBAR (S (NP (NN this.Doc_16298782_289_303_Chemical) (NNS antibiotics)) (VP (AUX are) (ADVP (RB still)) (VP (ADVP (RB widely)) (VBN used) (PP (IN by) (NP (NP (NN virtue)) (PP (IN of) (NP (NP (PRP$ their) (NN efficacy)) (CC and) (NP (JJ low) (NN cost)))))))))))))))) (. .)))
16298782	2	(S1 (S (NP (PRP$ Their) (NN Doc_16298782_386_397_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ serious) (NN health) (NN problem)) (SBAR (S (CC and) (, ,) (SBAR (IN as) (S (NP (PRP$ their) (JJ Doc_16298782_440_448_Disease) (NN mechanism)) (VP (VBZ involves) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NNP Doc_16298782_486_488_Chemical))))))) (, ,) (NP (PRP we)) (VP (AUX need) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_16298782_519_521_Chemical) (NNS inhibitors))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (JJ Doc_16298782_555_569_Chemical-induced) (NNP Doc_16298782_578_604_Disease)))))))))))))) (. .)))
16298782	3	(S1 (S (PP (IN In) (NP (DT this) (JJ experimental) (NN study))) (NP (PRP we)) (VP (VBD used) (NP (NP (CD 30) (JJ Sprague-Dawley) (NNS rats)) (, ,) (SBAR (WHNP (CD 27) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX had) (ADVP (RB Doc_16298782_681_691_Chemical)) (VP (VBN instilled) (PP (IN into) (NP (DT the) (JJ middle) (NN ear))))))))) (. .)))
16298782	4	(S1 (S (NP (DT The) (JJ otoprotectant) (NN Doc_16298782_741_747_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB topically)) (PP (TO to) (NP (CD 12/27) (NNS animals))))) (. .)))
16298782	5	(S1 (S (NP (PRP$ Its) (NN effect)) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN attenuation)) (PP (IN of) (NP (NNP Doc_16298782_846_858_Disease))))) (, ,) (VP (VBN measured) (PP (IN by) (NP (NNS shifts))) (PP (IN in) (NP (DT the) (JJ auditory) (NN brainstem) (NN response) (NN threshold)))))))) (. .)))
16298782	6	(S1 (S (NP (NN Doc_16298782_925_931_Chemical)) (VP (VP (VBD reduced) (NP (JJ Doc_16298782_940_950_Chemical-induced) (NN Doc_16298782_959_971_Disease)) (PP (IN in) (NP (DT the) (JJ high-frequency) (NN range)))) (, ,) (CC but) (VP (VBD gave) (NP (DT no) (NN protection)) (PP (IN in) (NP (NP (DT the) (NN middle)) (CC or) (NP (JJ low) (NNS frequencies)))))) (. .)))
16330293	0	(S1 (NP (NP (NP (NN Safety) (NN profile)) (PP (IN of) (NP (DT a) (JJ Doc_16330293_20_28_Chemical) (NN lozenge))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ Doc_16330293_59_67_Chemical) (NN gum)) (PP (IN in) (NP (NN adult) (NNS smokers))) (PP (IN with) (NP (JJ underlying) (JJ medical) (NNS conditions))))))))) (: :) (NP (DT a) (JJ 12-week) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN study)) (. .)))
16330293	1	(S1 (S (NP (JJ Doc_16330293_178_186_Chemical) (NN polacrilex) (NNS lozenges)) (VP (VBP deliver) (ADJP (NP (CD 25) (NN %) (TO to) (CD 27) (NN %)) (RBR more) (JJ Doc_16330293_231_239_Chemical)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ equivalent) (NNS doses)) (PP (IN of) (NP (JJ Doc_16330293_274_282_Chemical) (NN polacrilex) (NN gum))))))) (. .)))
16330293	2	(S1 (S (NP (NP (DT The) (VBN increased) (JJ Doc_16330293_313_321_Chemical) (NN exposure)) (PP (IN from) (NP (DT the) (NN lozenge)))) (VP (AUX has) (VP (VBN raised) (NP (NP (NNS questions)) (PP (IN about) (NP (NP (DT the) (JJ relative) (NN safety)) (PP (IN of) (NP (DT the) (NN lozenge) (CC and) (NN gum)))))))) (. .)))
16330293	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN safety) (NNS profiles)) (PP (IN of) (NP (NP (DT the) (JJ 4-mg) (NNP Doc_16330293_505_513_Chemical) (NN lozenge)) (CC and) (NP (JJ 4-mg) (JJ Doc_16330293_531_539_Chemical) (NN gum)))) (PP (IN in) (NP (NNS smokers)))) (PP (IN with) (NP (VBN selected) (JJ label-restricted) (NNS diseases))))))) (. .)))
16330293	4	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ multicenter) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN study)) (PP (IN in) (NP (NP (NN adult) (NNS smokers)) (PP (IN with) (NP (NP (NNP Doc_16330293_680_693_Disease)) (, ,) (NP (NP (NNP Doc_16330293_695_707_Disease)) (VP (RB not) (VBN controlled) (PP (IN by) (NP (NN medication))))) (, ,) (NP (NNP and/or) (NNP Doc_16330293_745_762_Disease)))))))) (. .)))
16330293	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN randomized) (PP (IN in) (NP (NP (DT a) (CD 1:1) (NN ratio)) (SBAR (S (VP (TO to) (VP (VB receive) (NP (NP (DT the) (JJ 4-mg) (JJ Doc_16330293_824_832_Chemical) (NN lozenge)) (CC or) (NP (JJ 4-mg) (JJ Doc_16330293_849_857_Chemical) (NN gum))))))))))) (. .)))
16330293	6	(S1 (S (NP (NN Safety) (NNS assessments)) (VP (AUX were) (VP (VBN made) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN at) (NP (NP (CD 2)) (, ,) (NP (CD 4)) (, ,) (NP (CD 6)) (, ,) (CC and) (NP (NP (CD 12) (NNS weeks)) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN product) (NN use))))))))))) (. .)))
16330293	7	(S1 (S (NP (CD Nine) (CD hundred) (CD one) (NNS patients)) (VP (AUX were) (VP (VBN randomized) (PP (TO to) (NP (NP (NN treatment)) (, ,) (NP (NP (NP (CD 447)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (DT the) (NN lozenge)))))) (CC and) (NP (NP (CD 454)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT the) (NN gum)) (PRN (-LRB- -LRB-) (NP (NN safety) (NN population)) (-RRB- -RRB-)))))))))))) (. .)))
16330293	8	(S1 (S (NP (DT The) (NN majority)) (VP (AUX were) (NP (NP (NNS women)) (PRN (-LRB- -LRB-) (NP (CD 52.7) (NN %)) (-RRB- -RRB-)))) (. .)))
16330293	9	(S1 (S (S (NP (NP (NNS Patients) (POS ')) (JJ mean) (NN age)) (VP (AUX was) (NP (CD 53.9) (NNS years)))) (, ,) (S (NP (PRP$ their) (JJ mean) (NN weight)) (VP (AUX was) (NP (CD 193.9) (NNS pounds)))) (, ,) (CC and) (S (NP (PRP they)) (VP (VBD smoked) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 25.2) (NNS cigarettes))) (PP (IN per) (NP (NN day)))) (PP (IN at) (NP (NN baseline))))) (. .)))
16330293	10	(S1 (S (NP (NP (CD Five) (CD hundred) (JJ fifty-three) (NNS patients)) (, ,) (NP (NP (NP (CD 264)) (VP (VBG taking) (NP (DT the) (NN lozenge)))) (CC and) (NP (NP (CD 289)) (VP (VBG taking) (NP (DT the) (NN gum))))) (, ,)) (VP (VBD used) (NP (NP (DT the) (NN study) (NN product)) (PP (IN for) (NP (QP (CD >) (CC or) (CD =4)) (NNS days))) (PP (IN per) (NP (NN week)))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (JJ evaluable) (NN population)) (-RRB- -RRB-))))) (. .)))
16330293	11	(S1 (S (NP (NP (DT The) (JJ Doc_16330293_1460_1468_Chemical) (NN lozenge)) (CC and) (NP (NNP Doc_16330293_1481_1489_Chemical) (NN gum))) (VP (AUX were) (ADJP (RB equally) (RB well) (JJ tolerated)) (, ,) (PP (IN despite) (NP (NP (VBN increased) (JJ Doc_16330293_1541_1549_Chemical) (NN exposure)) (PP (IN from) (NP (DT the) (NN lozenge)))))) (. .)))
16330293	12	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups)))))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS weeks)) (PP (IN of) (NP (NP (NN product) (NN use)) (PRN (-LRB- -LRB-) (NP (NP (NN evaluation) (NN population)) (: :) (NP (CD 55.3) (NN %) (NN lozenge))) (, ,) (NP (CD 54.7) (NN %) (NN gum)) (-RRB- -RRB-)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (DT the) (JJ entire) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (NN safety) (NN population)) (: :) (NP (NP (CD 63.8) (NN %)) (CC and) (NP (CD 58.6) (NN %)))) (, ,) (RB respectively) (-RRB- -RRB-))))) (. .)))
16330293	13	(S1 (S (NP (NP (NN Stratification)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN by) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (NP (NP (NN extent)) (PP (IN of) (NP (JJ concurrent) (NN smoking)))) (, ,) (NP (NP (NN extent)) (PP (IN of) (NP (NN product) (NN use)))) (, ,) (CC and) (NP (NP (NN severity)) (PP (IN of) (NP (JJ adverse) (NNS events))))))))) (VP (VBD revealed) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (DT the) (NN lozenge) (CC and) (NN gum))))) (. .)))
16330293	14	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS events)) (VP (AUX were) (NP (NP (NP (NNP Doc_16330293_2051_2057_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 17.2) (NN %) (CC and) (CD 16.1) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (QP (CD -3.7) (TO to) (CD 6.0)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16330293_2098_2105_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 10.7) (NN %) (CC and) (CD 6.6) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (QP (CD 0.5) (TO to) (CD 7.8)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_16330293_2148_2156_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 8.7) (NN %) (CC and) (CD 9.9) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP Cl)) (, ,) (NP (QP (CD -5.0) (TO to) (CD 2.6)))) (-RRB- -RRB-))))) (. .)))
16330293	15	(S1 (S (NP (JJ Serious) (JJ adverse) (NNS events)) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (QP (CD 11) (CC and) (CD 13)) (NNS patients))) (PP (IN in) (NP (DT the) (JJ respective) (NNS groups))))) (. .)))
16330293	16	(S1 (S (NP (NP (QP (JJR Fewer) (IN than) (CD 6)) (NN %)) (PP (IN of) (NP (NNS patients))) (PP (IN in) (NP (DT either) (NN group)))) (VP (AUX were) (VP (VBN considered) (PP (IN by) (NP (NP (DT the) (NN investigator)) (SBAR (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (VBG worsening)) (PP (IN of) (NP (PRP$ their) (JJ overall) (NN disease) (NN condition)))) (PP (IN during) (NP (DT the) (NN study))))))))))) (. .)))
16330293	17	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD >60) (NN %)) (-RRB- -RRB-))))) (VP (VBD experienced) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (PRP$ their) (NN disease) (NN status)) (PP (IN from) (NP (NN baseline))))))) (. .)))
16330293	18	(S1 (S (NP (DT The) (NP (JJ 4-mg) (JJ Doc_16330293_2545_2553_Chemical) (NN lozenge)) (CC and) (NP (JJ 4-mg) (JJ Doc_16330293_2571_2579_Chemical) (NN gum))) (VP (AUX had) (NP (JJ comparable) (NN safety) (NNS profiles)) (PP (IN in) (NP (DT these) (NNS patients))) (PP (IN with) (NP (JJ label-restricted) (JJ medical) (NNS conditions)))) (. .)))
16330766	0	(S1 (NP (NP (JJ Pharmacological) (NN modulation)) (PP (IN of) (NP (JJ Doc_16330766_30_34_Disease-related) (NN brain) (NN activity))) (PP (IN during) (NP (NP (JJ normal) (CC and) (JJ central) (NN sensitization) (NNS states)) (PP (IN in) (NP (NNS humans))))) (. .)))
16330766	1	(S1 (S (NP (NP (JJ Abnormal) (NN processing)) (PP (IN of) (NP (NP (JJ somatosensory) (NNS inputs)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (JJ central) (NN sensitization)) (-RRB- -RRB-))))))) (VP (AUX is) (NP (NP (DT the) (NN mechanism)) (PP (VBG accounting) (PP (IN for) (NP (NP (DT the) (JJ enhanced) (JJ Doc_16330766_259_263_Disease) (NN sensitivity)) (PP (IN in) (NP (NP (DT the) (NN skin)) (VP (VBG surrounding) (NP (NP (NNP Doc_16330766_300_313_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16330766_315_337_Disease)) (-RRB- -RRB-))))))))))) (. .)))
16330766	2	(S1 (S (NP (NN Doc_16330766_340_362_Disease)) (VP (VBZ shares) (NP (JJ clinical) (NNS characteristics)) (PP (IN with) (NP (NP (NNP Doc_16330766_400_423_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16330766_441_457_Disease)))))))) (. .)))
16330766	3	(S1 (S (NP (NP (JJ Abnormal) (NN brain) (NNS responses)) (PP (TO to) (NP (JJ somatosensory) (NNS stimuli)))) (VP (AUX have) (VP (AUX been) (VP (VP (VBN found) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16330766_542_554_Disease)))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (JJ normal) (NNS subjects))) (PP (IN during) (NP (JJ experimental) (JJ central) (NN sensitization)))))) (. .)))
16330766	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_16330766_679_689_Chemical)) (, ,) (NP (NP (DT a) (NN drug) (NN effective)) (PP (IN in) (NP (NNP Doc_16330766_711_727_Disease) (NNS patients)))) (, ,))) (PP (IN on) (NP (NP (NN brain) (NN processing)) (PP (IN of) (NP (JJ nociceptive) (NN information))) (PP (IN in) (NP (JJ normal) (CC and) (JJ central) (NN sensitization) (NNS states)))))))))) (. .)))
16330766	5	(S1 (S (S (VP (VBG Using) (NP (NP (JJ functional) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NN fMRI)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ Doc_16330766_917_927_Chemical-induced) (NN modulation)) (PP (IN of) (NP (NP (NN brain) (NN activity)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ nociceptive) (JJ mechanical) (NN stimulation)) (PP (IN of) (NP (NP (JJ normal) (NN skin)) (CC and) (NP (JJ Doc_16330766_1034_1043_Chemical-induced) (NN Doc_16330766_1052_1074_Disease)))))))))))) (. .)))
16330766	6	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_16330766_1088_1098_Chemical)))) (VP (AUX was) (NP (CD 1,800) (NN mg)) (PP (IN per) (NP (NN os))) (, ,) (PP (IN in) (NP (DT a) (JJ single) (NN administration)))) (. .)))
16330766	7	(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (DT that) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (NNP Doc_16330766_1166_1176_Chemical)) (VP (VBD reduced) (NP (DT the) (NNS activations)) (PP (IN in) (NP (DT the) (JJ bilateral) (NN operculoinsular) (NN cortex))) (, ,) (ADVP (RB independently)) (PP (IN of) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ central) (NN sensitization)))))))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (NNP ii)) (-RRB- -RRB-)) (NNP Doc_16330766_1303_1313_Chemical)) (VP (VBD reduced) (NP (DT the) (NN activation)) (PP (IN in) (NP (DT the) (NN brainstem))) (, ,) (ADVP (RB only)) (PP (IN during) (NP (JJ central) (NN sensitization))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (NNP iii)) (-RRB- -RRB-)) (NNP Doc_16330766_1396_1406_Chemical)) (VP (VBD suppressed) (NP (JJ stimulus-induced) (NNS deactivations)) (, ,) (ADVP (RB only)) (PP (IN during) (NP (JJ central) (NN sensitization))))) (: ;) (S (NP (DT this) (NN effect)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ robust)) (PP (IN than) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (NN brain) (NN activation)))))))) (. .)))
16330766	8	(S1 (S (NP (DT The) (JJ observed) (JJ drug-induced) (NNS effects)) (VP (AUX were) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NN baseline) (NN fMRI) (NN signal))))))) (. .)))
16330766	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_16330766_1666_1676_Chemical)) (VP (AUX has) (NP (NP (DT a) (JJ measurable) (NN antinociceptive) (NN effect)) (CC and) (NP (NP (DT a) (JJR stronger) (JJ antihyperalgesic) (NN effect)) (ADJP (RBS most) (JJ evident)))) (PP (IN in) (NP (NP (DT the) (NN brain) (NNS areas)) (VP (VBG undergoing) (NP (NN deactivation)))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG supporting) (NP (NP (DT the) (NN concept)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_16330766_1846_1856_Chemical)) (VP (AUX is) (ADJP (RBR more) (JJ effective) (PP (IN in) (S (VP (VBG modulating) (NP (JJ nociceptive) (NN transmission)) (SBAR (WHADVP (WRB when)) (S (NP (JJ central) (NN sensitization)) (VP (AUX is) (ADJP (JJ present)))))))))))))))) (. .)))
16337777	0	(S1 (NP (NP (NN Investigation)) (PP (IN of) (NP (NP (JJ mitochondrial) (NN involvement)) (PP (IN in) (NP (NP (DT the) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_16337777_72_80_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16337777_92_103_Chemical)))))))) (. .)))
16337777	1	(S1 (S (NP (NNP Doc_16337777_105_132_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS aspects)) (PP (IN of) (NP (NN epileptogenesis))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN energy) (NN generation)) (, ,) (NP (NP (NN control)) (PP (IN of) (NP (NN cell) (NN Doc_16337777_238_243_Disease)))) (, ,) (NP (NN neurotransmitter) (NN synthesis)) (, ,) (CC and) (NP (ADJP (JJ free) (JJ radical)) (PRN (-LRB- -LRB-) (NP (NNP FR)) (-RRB- -RRB-)) (NN production))))))))) (. .)))
16337777	2	(S1 (S (NP (NP (VBN Increased) (NN production)) (PP (IN of) (NP (NNS FRs)))) (VP (MD may) (VP (VB cause) (NP (NP (NN mtDNA) (NN damage)) (VP (VBG leading) (PP (TO to) (NP (NP (VBN decreased) (NNS activities)) (PP (IN of) (NP (NP (JJ oxidative) (NN phosphorylation) (NNS complexes)) (VP (VBG containing) (NP (JJ mtDNA-encoded) (NNS subunits))))))))))) (. .)))
16337777	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (VBN increased) (NN generation)) (PP (IN of) (NP (NN FR))) (PP (IN during) (NP (NNP Doc_16337777_537_555_Disease)))) (VP (MD would) (VP (AUX be) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB provoke) (NP (NP (NNS abnormalities)) (PP (PP (IN in) (NP (NN mtDNA))) (CC and) (PP (IN in) (NP (NP (DT the) (NN expression) (CC and) (NN activity)) (PP (IN of) (NP (JJ cytochrome) (NNP c) (NN oxidase))) (PRN (-LRB- -LRB-) (NP (NNP CCO)) (-RRB- -RRB-)) (, ,) (ADJP (JJ complex) (NP (NP (NNP IV)) (PP (IN of) (NP (DT the) (JJ respiratory) (NN chain))))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ chronic) (NN phase)) (PP (IN of) (NP (NP (DT the) (JJ Doc_16337777_741_752_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_16337777_762_784_Disease)))))))))))))))))))) (. .)))
16337777	4	(S1 (S (NP (NN DNA) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ low) (NNS amounts)) (PP (PP (IN of) (NP (DT a) (CD 4.8) (NN kb) (NN mtDNA) (NN deletion))) (CC but) (PP (IN with) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NN frequency)) (CC or) (NP (NN quantity)))) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (JJ experimental) (NNS groups))))))))) (. .)))
16337777	5	(S1 (S (NP (PRP We)) (VP (AUX did) (RB not) (VP (VB find) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (NP (DT the) (NN expression) (CC and) (NN distribution)) (PP (IN of) (NP (NP (NP (DT an) (JJ mtDNA-encoded) (NN subunit)) (PP (IN of) (NP (NP (NNP CCO)) (PRN (-LRB- -LRB-) (NP (NNP CCO-I)) (-RRB- -RRB-))))) (CC or) (NP (NP (DT a) (JJ relative) (NN decrease)) (PP (IN in) (NP (NP (NNS CCO-I)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ nuclear-encoded) (NNS subunits)) (PRN (-LRB- -LRB-) (ADJP (JJ CCO-IV) (CC and) (JJ SDH-fp)) (-RRB- -RRB-))))))))))))))))) (. .)))
16337777	6	(S1 (S (NP (NP (DT No) (NN abnormality)) (PP (IN in) (NP (NN CCO) (NN activity)))) (VP (AUX was) (VP (VBN observed) (PP (IN through) (NP (NN histochemistry))))) (. .)))
16337777	7	(S1 (S (SBAR (IN Although) (S (NP (NP (NNS evidences)) (PP (IN of) (NP (NNP Doc_16337777_1231_1258_Disease)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (ADJP (RB previously) (VBN published)) (NNS studies))))))) (, ,) (NP (PRP$ our) (NNS results)) (VP (AUX do) (RB not) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS FRs)) (, ,) (VP (VBN generated) (PP (IN during) (NP (DT the) (JJ acute) (NN phase)))) (, ,)) (VP (VBD determined) (NP (NP (JJ important) (NNS abnormalities)) (PP (PP (IN in) (NP (NN mtDNA))) (, ,) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP (NN CCO-I))))) (, ,) (CC and) (PP (IN in) (NP (NN CCO) (NN activity)))))))))) (. .)))
1639466	0	(S1 (S (NP (NP (JJ Adverse) (NN effect)) (PP (IN of) (NP (DT the) (JJ Doc_1639466_22_29_Chemical) (NN channel) (NN blocker)))) (VP (NNP Doc_1639466_46_58_Chemical) (PP (IN on) (NP (NNP Doc_1639466_62_77_Disease))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_1639466_91_116_Disease)))))) (. .)))
1639466	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ 6-week) (NN treatment)) (PP (IN with) (NP (NP (NP (DT the) (JJ Doc_1639466_160_167_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_1639466_184_196_Chemical))) (CC or) (NP (NP (DT the) (NNP Doc_1639466_204_215_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (NP (NNP Doc_1639466_244_253_Chemical))))))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NNP Doc_1639466_273_284_Disease)) (, ,) (NP (JJ renal) (NNS hemodynamics)) (, ,) (CC and) (NP (NP (NN morphology)) (PP (IN of) (NP (DT the) (JJ nonclipped) (NN kidney))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))) (PP (IN with) (NP (NP (NN two-kidney)) (, ,) (NP (NP (CD one) (NN clip)) (NP (NNP Doc_1639466_392_417_Disease))))))) (. .)))
1639466	2	(S1 (S (SBAR (NP (CD Six) (NNS weeks)) (IN after) (S (VP (VBG clipping) (PP (IN of) (NP (CD one) (JJ renal) (NN artery)))))) (, ,) (NP (NP (NNP Doc_1639466_465_477_Disease) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 178) (NNS +/-)) (NP (CD 4) (NN mm) (NNP Hg))) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (CD three) (NNS groups)) (: :) (NP (NP (JJ untreated) (JJ Doc_1639466_551_563_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))))) (, ,) (ADJP (ADJP (JJ Doc_1639466_582_591_Chemical-treated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)) (, ,) (CC or) (ADJP (JJ Doc_1639466_612_624_Chemical-treated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))))) (. .)))
1639466	3	(S1 (S (NP (JJ Sham-operated) (NNS rats)) (VP (VBD served) (PP (IN as) (NP (NP (JJ normotensive) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 128) (NN +/-) (CD 3) (NN mm) (NNP Hg)) (, ,) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-))))) (. .)))
1639466	4	(S1 (S (PP (IN After) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (JJ renal) (NNS hemodynamics)) (PRN (-LRB- -LRB-) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (CC and) (NP (JJ renal) (NN plasma) (NN flow))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT the) (JJ anesthetized) (NNS rats))))) (. .)))
1639466	5	(S1 (S (NP (JJ Renal) (NN tissue)) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ glomerular) (NN size)) (CC and) (NP (NN sclerosis)))))))) (. .)))
1639466	6	(S1 (S (S (ADJP (ADJP (JJ Doc_1639466_936_945_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_1639466_954_966_Chemical)))) (VP (VBN reduced) (NP (NN blood) (NN pressure)) (ADVP (RB significantly))) (. .)))
1639466	7	(S1 (S (PP (IN After) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (JJ glomerular) (NN filtration) (NN rate)) (VP (AUX was) (RB not) (ADJP (JJ different)) (PP (IN among) (NP (DT the) (VBN studied) (NNS groups)))) (. .)))
1639466	8	(S1 (S (S (NP (JJ Renal) (NN plasma) (NN flow)) (VP (VBD increased))) (, ,) (CC but) (S (NP (NP (NN albumin) (NN excretion)) (CC and) (NP (NNP Doc_1639466_1157_1175_Disease))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN after) (NP (JJ Doc_1639466_1197_1206_Chemical) (NN treatment)))))) (. .)))
1639466	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (DT the) (JJ Doc_1639466_1238_1250_Chemical-treated) (NN group))) (NP (NNP Doc_1639466_1265_1276_Disease)) (VP (VBD increased) (PP (IN from) (NP (CD 12.8) (NN +/-)) (, 2) (ADVP (RB progressively))) (PP (TO to) (NP (QP (CD 163) (CD +/-)) (CD 55))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 19.2) (NN +/-)) (NP (QP (CD 9) (CD mg/24)) (NNS hr))) (PP (IN in) (NP (DT the) (NNP Doc_1639466_1372_1384_Disease) (NNS controls))))))) (. .)))
1639466	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_1639466_1408_1426_Disease) (NN index)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_1639466_1468_1480_Chemical-treated) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ Doc_1639466_1513_1525_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 0.38) (JJ +/-) (CD 0.1) (CC versus) (CD 0.13) (NN +/-) (CD 0.04)) (-RRB- -RRB-))))))) (. .)))
1639466	11	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (S (NP (NN glomerular) (NN size)) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (DT the) (JJ Doc_1639466_1619_1631_Chemical-treated) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 14.9) (JJ +/-) (ADJP (QP (CD 0.17) (CD 10))) (PRN (-LRB- -LRB-) (JJ -3) (-RRB- -RRB-)) (NN mm2)) (-RRB- -RRB-))))) (CC but) (ADJP (JJR lower) (PP (IN in) (NP (NP (DT the) (JJ Doc_1639466_1690_1699_Chemical-treated) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 11.5) (JJ +/-) (ADJP (QP (CD 0.15) (CD 10))) (PRN (-LRB- -LRB-) (JJ -3) (-RRB- -RRB-)) (NN mm2)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNP Doc_1639466_1759_1771_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 12.1) (NN +/-)) (NP (CD 0.17) (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NN mm2)) (-RRB- -RRB-)))))) (. .)) (PRN (-LRB- -LRB-) (S (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
16403073	0	(S1 (S (NP (NN Doc_16403073_0_12_Chemical)) (VP (VBN induced) (NP (NNP Doc_16403073_21_40_Disease)) (PP (IN without) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ QT) (JJ interval-prolonging) (NN drug)))))) (. .)))
16403073	1	(S1 (S (NP (NN Doc_16403073_97_109_Chemical)) (VP (AUX is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ proarrhythmic)) (PP (IN without) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ QT) (JJ interval-prolonging) (NNS drugs)))))))))) (. .)))
16403073	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (NNP Doc_16403073_223_246_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT a) (ADVP (RB markedly)) (NN Doc_16403073_272_293_Disease)) (CC and) (NP (NP (NNP Doc_16403073_298_317_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16403073_319_322_Disease)) (-RRB- -RRB-)))) (PP (IN after) (S (VP (VBG taking) (NP (NNP Doc_16403073_337_349_Chemical)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_16403073_367_383_Disease))))))))))))) (. .)))
16403073	3	(S1 (S (NP (PRP$ Her) (JJ QT) (NN interval)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN upon) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_16403073_439_451_Chemical)))))) (. .)))
16403073	4	(S1 (S (NP (JJ Genetic) (NN study)) (VP (AUX did) (RB not) (VP (VB find) (NP (NP (DT any) (NN mutation)) (PP (IN in) (NP (NP (PRP$ her) (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP encode) (NP (JJ cardiac) (JJ IKr) (NN channel) (NNS proteins)))))))))) (. .)))
16403073	5	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (PP (IN by) (NP (NP (NN virtue)) (PP (IN of) (NP (NP (PRP$ its) (JJ direct) (VBG blocking) (NN action)) (PP (IN on) (NP (NN IKr))))))) (, ,) (NP (NNP Doc_16403073_614_626_Chemical)) (ADVP (RB alone)) (VP (MD may) (VP (VP (VB prolong) (NP (CD QT) (NN interval))) (CC and) (VP (VB induce) (NP (NN Doc_16403073_668_671_Disease)))))))) (. .)))
16403073	6	(S1 (S (NP (DT This)) (VP (VBZ calls) (PP (IN for) (NP (NN attention))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16403073_703_715_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN risk) (NNS factors))) (PP (IN for) (NP (VBN acquired) (NN Doc_16403073_775_791_Disease)))))))))) (. .)))
16428221	0	(S1 (NP (NP (NP (JJ Doc_16428221_0_19_Disease) (JJ following) (JJ oral) (JJ Doc_16428221_35_50_Chemical) (NN intake)) (PP (IN in) (NP (DT an) (NN adult)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
16428221	1	(S1 (S (NP (NN Doc_16428221_86_101_Chemical)) (VP (AUX is) (ADVP (ADVP (RB structurally)) (CC and) (ADVP (RB functionally))) (ADJP (JJ similar) (PP (TO to) (NP (NNP Doc_16428221_146_157_Chemical))))) (. .)))
16428221	2	(S1 (S (S (NP (NP (NN Doc_16428221_159_178_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16428221_195_212_Disease))))) (VP (AUX is) (ADVP (RB well)) (VP (VBN documented)))) (, ,) (CC and) (S (PP (IN in) (NP (JJ rare) (NNS cases))) (NP (NNP Doc_16428221_251_267_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (JJ Doc_16428221_292_307_Chemical) (NN intake)) (PP (IN in) (NP (NNS children))))))))) (. .)))
16428221	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 63-year-old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16428221_392_407_Chemical)) (UCP (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_16428221_415_428_Disease)))) (CC and) (VP (VBN suffered) (PP (IN from) (NP (JJ multiple) (NN Doc_16428221_456_473_Disease))))))))))))))) (. .)))
16428221	4	(S1 (S (NP (PRP We)) (VP (VBP consider) (NP (JJ drug-induced) (NN Doc_16428221_500_519_Disease)) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ likely)) (NN cause)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_16428221_558_575_Disease))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT any) (JJ pathological) (NNS findings))))))) (PP (IN during) (NP (DT the) (JJ diagnostic) (NN work-up)))) (. .)))
16428221	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ Doc_16428221_668_683_Chemical) (JJ mediated) (NN Doc_16428221_693_703_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ neurological) (NNS symptoms)) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ Doc_16428221_781_796_Chemical) (NN therapy)))))))))))))) (. .)))
16428221	6	(S1 (S (NP (NP (DT This) (JJ potential) (NN side-effect)) (, ,) (SBAR (IN though) (FRAG (ADJP (RB very) (JJ rare)))) (, ,)) (VP (VBZ represents) (NP (NP (CD one) (JJR more) (NN reason)) (SBAR (S (VP (TO to) (VP (AUX be) (ADJP (RB very) (JJ restrictive)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_16428221_916_931_Chemical))))))))))) (. .)))
16574712	0	(S1 (S (NP (JJ Doc_16574712_0_4_Chemical) (NN polydrug) (NNS users)) (VP (VBP show) (NP (NP (JJ process-specific) (JJ central) (NN executive) (NNS impairments)) (VP (VBN coupled) (PP (IN with) (NP (NN Doc_16574712_85_134_Disease)))))) (. .)))
16574712	1	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (NP (JJ working) (NNP Doc_16574712_160_175_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_16574712_207_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574712_213_246_Chemical)) (, ,) (NP (NNP Doc_16574712_248_255_Chemical)) (-RRB- -RRB-))))))))) (. .)))
16574712	2	(S1 (S (NP (NP (DT The) (JJ current) (NN study)) (VP (VBN aimed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ Doc_16574712_306_310_Chemical) (NN use))) (PP (PP (IN on) (NP (NP (CD three) (JJ separate) (JJ central) (NN executive) (NNS processes)) (PRN (-LRB- -LRB-) (NP (NP (NN set) (VBG shifting)) (, ,) (NP (NN inhibition)) (CC and) (NP (NN memory))) (VBG updating) (-RRB- -RRB-)))) (CC and) (RB also) (PP (IN on) (`` ``) (ADJP (JJ prefrontal)) ('' ''))))))))) (VP (VBD mediated) (NP (ADJP (JJ social) (CC and) (JJ emotional)) (NN judgement) (NNS processes))) (. .)))
16574712	3	(S1 (S (NP (NNP Fifteen)) (VP (VBD polydrug) (SBAR (S (NP (NP (NNP Doc_16574712_501_508_Chemical) (NNS users)) (CC and) (NP (ADJP (CD 15) (NN polydrug)) (JJ non-Doc_16574712_535_542_Chemical) (NN user) (NNS controls))) (VP (VBD completed) (NP (NP (DT a) (JJ general) (NN drug) (NN use) (NN questionnaire)) (, ,) (NP (NP (DT the) (NNP Brixton) (NNP Spatial) (NN Anticipation) (NN task)) (PRN (-LRB- -LRB-) (NP (VB set) (VBG shifting)) (-RRB- -RRB-))) (, ,) (RB Backward) (NP (NP (NNP Digit) (NNP Span) (NN procedure)) (PRN (-LRB- -LRB-) (NP (NN memory)) (VBG updating) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Inhibition)) (PP (IN of) (NP (NP (NN Return)) (PRN (-LRB- -LRB-) (NP (NN inhibition)) (-RRB- -RRB-))))) (, ,) (NP (DT an) (JJ emotional) (NN intelligence) (NN scale)) (, ,) (NP (DT the) (NNP Tromso) (NNP Social) (NNP Intelligence) (NNP Scale)) (CC and) (NP (NP (DT the) (NNP Dysexecutive) (NN Questionnaire)) (PRN (-LRB- -LRB-) (NP (NNP DEX)) (-RRB- -RRB-)))))))) (. .)))
16574712	4	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ Doc_16574712_865_869_Chemical-free) (NN polydrug) (NNS controls)))) (, ,) (NP (NNP Doc_16574712_894_898_Chemical) (NN polydrug) (NNS users)) (VP (VBD showed) (NP (NNS impairments)) (PP (IN in) (NP (NP (VBN set) (VBG shifting) (CC and) (NN memory)) (UCP (VP (VBG updating)) (, ,) (CC and) (PP (ADVP (RB also)) (IN in) (NP (ADJP (JJ social) (CC and) (JJ emotional)) (NN judgement) (NNS processes))))))) (. .)))
16574712	5	(S1 (S (NP (DT The) (JJ latter) (CD two) (NNS deficits)) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (JJ other) (NN drug) (NN use))))))) (. .)))
16574712	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP lend) (NP (JJ further) (NN support)) (PP (TO to) (NP (DT the) (NN proposal) (SBAR (IN that) (S (NP (NP (JJ cognitive) (NNS processes)) (VP (VBN mediated) (PP (IN by) (NP (DT the) (JJ prefrontal) (NN cortex))))) (VP (MD may) (VP (AUX be) (VP (VBN impaired) (PP (IN by) (NP (JJ recreational) (JJ Doc_16574712_1246_1253_Chemical) (NN use))))))))))) (. .)))
1664218	0	(S1 (NP (NP (NN Phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (DT the) (NNP Doc_1664218_22_31_Chemical) (NN analogue) (NNP Doc_1664218_41_47_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1664218_49_59_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_1664218_64_90_Disease))) (. .)))
1664218	1	(S1 (S (NP (NP (NNP Doc_1664218_92_98_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_1664218_100_110_Chemical)) (: ;) (NP (NNP Doc_1664218_112_202_Chemical))) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ topoisomerase) (NNP II) (NN poison)) (PP (IN with) (NP (JJ high) (JJ experimental) (NN antitumour) (NN activity))))) (. .)))
1664218	2	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN administered) (PP (IN by) (NP (NP (CD 15) (JJ min) (NN infusion)) (PP (TO to) (NP (NP (CD 16) (JJ evaluable) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_1664218_346_372_Disease) (-LRB- -LRB-) (NNP Doc_1664218_374_379_Disease) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 7)) (PP (IN with) (NP (DT no) (JJ prior) (NN treatment)))) (, ,) (NP (NP (CD 9) (NNS patients)) (PP (IN in) (NP (JJ relapse) (JJ following) (NN surgery/radiotherapy))))) (-RRB- -RRB-)))))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 648) (NNS mg/m2)) (VP (VBN divided) (PP (IN over) (NP (CD 3) (NNS days))))) (, ,) (VP (VBN repeated) (NP (DT every) (CD 3) (NNS weeks))) (-RRB- -RRB-)) (VP (VBN determined) (PP (IN by) (NP (NN phase) (NN I) (NN trial)))))))) (. .)))
1664218	3	(S1 (S (NP (NNS Patients)) (VP (AUX had) (NP (NP (NP (DT a) (JJ median) (NN performance) (NN status)) (PP (IN of) (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (WP WHO)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (JJ median) (NN age)) (PP (IN of) (NP (CD 61) (NNS years)))))) (. .)))
1664218	4	(S1 (S (NP (DT The) (NN histology)) (VP (VBN comprised) (NP (NP (NP (NNP Doc_1664218_663_681_Disease)) (PRN (-LRB- -LRB-) (NP (CD 11)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1664218_688_702_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ mixed) (NN histology)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1664218_729_756_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ large) (NN cell) (NNP Doc_1664218_776_802_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
1664218	5	(S1 (S (NP (NP (JJ Doc_1664218_808_819_Disease) (NN grade)) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (CD 3)))))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 15) (NNS patients)) (, ,) (NP (NP (NP (NNP Doc_1664218_878_888_Disease)) (PP (IN with) (NP (NP (NN recovery)) (PP (IN in) (NP (NNP 3)))))) (, ,) (CC and) (NP (NP (JJ grand) (JJ mal) (NNP Doc_1664218_923_931_Disease)) (PP (IN in) (NP (CD 1) (NN patient))))))))) (. .)))
1664218	6	(S1 (S (S (NP (NN Grade)) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 2) (NNP Doc_1664218_976_982_Disease) (CC and) (NNP Doc_1664218_987_995_Disease)))) (VP (VP (VBD occurred) (PP (IN in) (NP (ADJP (CD 66) (NN %)) (NNS courses)))) (CC and) (VP (NP (NNP Doc_1664218_1024_1033_Disease)) (PP (IN in) (NP (NP (DT the) (NN infusion) (NN arm)) (PP (IN in) (NP (CD 37) (NN %)))))))) (. .) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (NNP Doc_1664218_1077_1100_Disease)))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN response)) (VP (VBG lasting) (NP (CD 5) (NNS months))))) (. .)))
1664218	7	(S1 (S (NP (NP (JJ Further) (NN testing)) (PP (IN in) (NP (NP (DT this)) (CC and) (NP (JJ other) (NN Doc_1664218_1181_1187_Disease) (NNS types)))) (VP (VBG using) (NP (JJ multiple) (JJ daily) (NNS schedules)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
16680561	0	(S1 (NP (NP (NP (NNS Pharmacokinetics)) (PP (IN of) (NP (NNP Doc_16680561_20_35_Chemical)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NNP Doc_16680561_59_73_Chemical)))))) (. .)))
16680561	1	(S1 (S (PP (IN In) (NP (NN vitro))) (NP (NN work)) (VP (AUX has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_16680561_122_132_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (JJ cytochrome) (JJ P450) (NN isoenzyme) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-)) (NNS 2D6))))))))) (. .)))
16680561	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_16680561_251_261_Chemical))) (PP (IN on) (NP (NN CYP2D6) (NN activity)))) (, ,) (S (VP (VBG using) (NP (NNP Doc_16680561_288_299_Chemical)) (PP (IN as) (NP (DT a) (NN probe) (NN substrate))))) (, ,) (PP (IN in) (NP (JJ healthy) (NNS subjects))))))) (. .)))
16680561	3	(S1 (NP (NP (NNP Seventeen) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN genotyped) (PP (IN as) (S (NP (CD CYP2D6) (JJ extensive) (NNS metabolizers)) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT this) (JJ randomized) (, ,) (JJ open-label) (, ,) (JJ crossover) (NN study) (S (VP (TO to) (VP (VB receive) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_16680561_518_529_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NNS mg)) (-RRB- -RRB-))))) (PP (IN on) (NP (CD two) (JJ separate) (NNS occasions))))))) (, ,) (UCP (ADVP (RB once) (RB alone)) (CC and) (PP (RB once) (IN after) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_16680561_609_619_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 90) (NNS mg)) (PP (IN for) (NP (CD 7) (NNS days)))) (-RRB- -RRB-))))))))))))))))) (. .)))
16680561	4	(S1 (S (NP (NN Blood) (NNS samples)) (VP (AUX were) (VP (VP (VBN obtained) (NP (NN predose))) (CC and) (VP (ADVP (RB up)) (PP (TO to) (NP (CD 72) (NNP h) (NN postdose)))))) (. .)))
16680561	5	(S1 (S (NP (CD Fourteen) (NNS subjects)) (VP (VBD completed) (NP (DT both) (NN treatment) (NNS arms))) (. .)))
16680561	6	(S1 (S (ADVP (JJ Relative) (PP (TO to) (NP (NP (NNP Doc_16680561_771_782_Chemical)) (ADVP (RB alone))))) (, ,) (VP (VBP mean) (SBAR (S (NP (NP (NP (NNP AUC)) (CC and) (NP (NNP C))) (PRN (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_16680561_813_824_Chemical)))) (VP (VBD increased) (ADJP (JJ 3.6-) (CC and) (JJ 1.8-fold)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NNP Doc_16680561_878_888_Chemical)))))))))) (. .)))
16680561	7	(S1 (S (NP (NP (DT The) (NNP t)) (PRN (-LRB- -LRB-) (NP (NNP 1/2)) (, ,) (NP (NNP z)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_16680561_907_918_Chemical)))) (VP (AUX was) (ADVP (RB longer)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16680561_935_946_Chemical)) (VP (AUX was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NNP Doc_16680561_971_981_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 21.0) (CC versus) (CD 43.3)) (NNS hs)) (-RRB- -RRB-))))))))) (. .)))
16680561	8	(S1 (S (NP (NP (DT The) (NNP t)) (PRN (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (NNS regimens)))) (. .)))
16680561	9	(S1 (S (NP (JJR Fewer) (NNS subjects)) (VP (VBD reported) (NP (NP (JJ adverse) (NNS events)) (VP (VBG following) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16680561_1115_1126_Chemical))) (ADVP (ADVP (RB alone)) (SBAR (IN than) (S (SBAR (WHADVP (WRB when)) (S (VP (VBG receiving) (NP (NNP Doc_16680561_1153_1164_Chemical)) (PP (IN with) (NP (NP (NNP Doc_16680561_1170_1180_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 33) (CC versus) (CD 86)) (NN %)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (RBS most) (JJ frequent)) (WHPP (IN of) (WHNP (WDT which) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_16680561_1226_1232_Disease)) (CC and) (NP (NNP Doc_16680561_1237_1245_Disease))) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT either) (NNP Doc_16680561_1299_1310_Chemical) (CC or) (NNP Doc_16680561_1314_1324_Chemical))))))))))))))) (. .)))
16680561	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NNP Doc_16680561_1367_1377_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6)))))))) (. .)))
16680561	11	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN during) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_16680561_1469_1479_Chemical))))) (, ,) (NP (NN dose) (NN adjustment)) (VP (MD may) (VP (AUX be) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP demonstrate) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index))) (CC and) (VP (AUX are) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6)))))))))))))))) (. .)))
16740173	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (JJ acute) (JJ unintentional) (NN Doc_16740173_33_42_Chemical) (NN intoxication)) (. .)))
16740173	1	(S1 (S (NP (NP (NNS Intoxications)) (PP (IN with) (NP (NP (NNP Doc_16740173_90_99_Chemical)) (, ,) (NP (DT a) (JJ muscarinic) (JJ cholinergic) (NN receptor) (NN agonist))))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
16740173	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (JJ interesting) (NN case)) (VP (VBG investigating) (NP (DT a) (-LRB- -LRB-) (JJ near) (-RRB- -RRB-) (JJ fatal) (NN Doc_16740173_212_221_Disease))))) (. .)))
16740173	3	(S1 (S (NP (NP (DT The) (NN son)) (PP (IN of) (NP (DT an) (JJ 84-year-old) (NN male)))) (VP (VBD discovered) (NP (NP (DT a) (NN newspaper) (NN report)) (VP (VBG stating) (NP (JJ clinical) (NN success)) (PP (IN with) (NP (NP (NN plant) (NNS extracts)) (PP (IN in) (NP (NNP Doc_16740173_341_360_Disease)))))))) (. .)))
16740173	4	(S1 (S (S (NP (NP (DT The) (NN mode)) (PP (IN of) (NP (NN action)))) (VP (AUX was) (VP (VBN said) (S (VP (TO to) (VP (AUX be) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ synthetic) (NN compound) (POS ')) (NX (NNP Doc_16740173_442_456_Chemical) (POS '))))))))))))) (: ;) (S (NP (DT that)) (VP (AUX is) (, ,) (NP (NNP Doc_16740173_468_477_Chemical)))) (. .)))
16740173	5	(S1 (S (S (NP (PRP He)) (VP (VBD bought) (NP (NP (CD 25) (NNP g)) (PP (IN of) (NP (NNP Doc_16740173_497_506_Chemical)))) (PP (IN as) (NP (NP (JJ pure) (NN substance)) (PP (IN in) (NP (DT a) (NN pharmacy))))))) (, ,) (CC and) (S (NP (DT the) (NN father)) (VP (AUX was) (VP (VBN administered) (NP (QP (CD 400) (TO to) (CD 500)) (NNS mg))))) (. .)))
16740173	6	(S1 (S (NP (NP (JJ Doc_16740173_587_596_Chemical) (NNS concentrations)) (PP (IN in) (NP (NP (NP (NP (NN serum)) (CC and) (NP (NN urine))) (PP (IN on) (NP (NN day) (CD 1)))) (CC and) (NP (NP (CD 2)) (PP (IN of) (NP (NN hospital) (NN admission))))))) (VP (AUX were) (VP (VBN analysed) (PP (IN by) (NP (JJ HPLC-mass) (NN spectrometry))))) (. .)))
16740173	7	(S1 (S (PP (NP (NNS Minutes)) (IN after) (NP (JJ oral) (NN administration))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD developed) (NP (NP (NNP Doc_16740173_775_781_Disease)) (, ,) (NP (NP (NN sweating)) (CC and) (NP (NN Doc_16740173_796_807_Disease))) (, ,))) (CC and) (VP (ADVP (RB finally)) (VBD collapsed))) (. .)))
16740173	8	(S1 (S (NP (NP (NN Doc_16740173_832_843_Disease)) (, ,) (NP (JJ cholinergic) (NNS symptoms)) (CC and) (NP (NNP Doc_16740173_870_878_Disease))) (VP (VBD occurred)) (. .)))
16740173	9	(S1 (S (NP (NP (NP (JJ Initial) (JJ cardiopulmonary) (NN resuscitation)) (CC and) (NP (JJ immediate) (NN treatment))) (PP (IN with) (NP (NP (NP (NNP Doc_16740173_956_966_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16740173_968_979_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16740173_982_990_Chemical)) (CC and) (NP (NNP Doc_16740173_995_1005_Chemical))))) (VP (AUX was) (ADJP (JJ successful))) (. .)))
16740173	10	(S1 (S (PP (IN On) (NP (NN hospital) (NN admission))) (, ,) (NP (NP (NN blood) (NN pressure)) (PP (IN of) (NP (DT the) (VBN intubated) (, ,) (JJ bradyarrhythmic) (NN patient)))) (VP (AUX was) (NP (CD 100/65) (NN mmHg))) (. .)))
16740173	11	(S1 (S (S (NP (JJ Further) (NNS signs)) (VP (AUX were) (NP (NP (NNP Doc_16740173_1138_1151_Disease)) (, ,) (NP (NNP Doc_16740173_1153_1168_Disease)) (, ,) (NP (NNP Doc_16740173_1170_1183_Disease)) (, ,) (CC and) (NP (JJ severe) (NN Doc_16740173_1196_1202_Disease))))) (: ;) (S (NP (DT the) (JJ electrocardiographic) (NN finding)) (VP (AUX was) (ADJP (JJ Doc_16740173_1241_1271_Disease)))) (. .)))
16740173	12	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_16740173_1287_1295_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN up) (TO to) (CD 50)) (NN mg)) (PP (IN per) (NP (CD 24) (NNS hours)))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16740173_1324_1334_Chemical)) (CC and) (NP (NNP Doc_16740173_1339_1347_Chemical))))) (VP (AUX were) (ADJP (JJ necessary))) (. .)))
16740173	13	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN extubated) (ADVP (NP (CD 1) (NN week)) (RB later)))) (. .)))
16740173	14	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (VBN increased) (NN Doc_16740173_1423_1431_Disease)) (CC and) (NP (NNP Doc_16740173_1436_1448_Disease))) (VP (VBD necessitated) (NP (NN reintubation))) (. .)))
16740173	15	(S1 (S (NP (NN Doc_16740173_1476_1501_Disease)) (VP (AUX was) (ADVP (RB further)) (VP (VBN worsened) (PP (IN by) (NP (NP (NN Doc_16740173_1526_1553_Disease)) (CC and) (NP (JJ severe) (NN bronchoconstriction)))))) (. .)))
16740173	16	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (NP (DT the) (NN patient)) (VP (VP (AUX was) (ADVP (RB again)) (VP (VBN extubated))) (CC and) (VP (ADVP (NP (CD 3) (NNS days)) (RB later)) (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT a) (JJ peripheral) (NN ward)))))) (. .)))
16740173	17	(S1 (S (PP (IN On) (NP (DT the) (JJ next) (NN day))) (NP (PRP he)) (VP (VBD died) (, ,) (ADVP (RB probably)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_16740173_1738_1751_Disease)))))) (. .)))
16740173	18	(S1 (S (NP (NP (NN Serum) (NNS samples)) (PP (IN from) (NP (DT the) (JJ first) (CC and) (JJ second) (NNS days)))) (VP (VBD contained) (NP (QP (CD 3.6) (CC and) (CD 1.9) (CD mg/l))) (NP (NNP Doc_16740173_1825_1834_Chemical)) (, ,) (ADVP (RB respectively))) (. .)))
16740173	19	(S1 (S (NP (DT The) (JJ corresponding) (NN urine) (NNS concentrations)) (VP (VBD amounted) (PP (TO to) (NP (QP (CD 374) (CC and) (CD 554)) (NNS mg/l)))) (. .)))
16740173	20	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBD started) (PP (IN with) (NP (DT a) (NNS media) (NN report))) (PP (IN in) (NP (NP (DT a) (JJ popular) (NN newspaper)) (, ,) (VP (VBN initiated) (PP (IN by) (NP (NP (VBN published) (, ,) (JJ peer-reviewed) (NN research)) (PP (IN on) (NP (NNS herbals)))))) (, ,)))) (CC and) (VP (VBD involved) (NP (JJ human) (NN failure)) (PP (IN in) (NP (NP (DT a) (NN case) (NN history)) (, ,) (NP (JJ medical) (NN examination)) (CC and) (NP (JJ clinical) (NN treatment)))))) (. .)))
16740173	21	(S1 (S (PP (IN For) (NP (DT the) (JJ first) (NN time))) (, ,) (NP (NP (DT an) (JJ analytical) (NN method)) (PP (IN for) (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NNP Doc_16740173_2208_2217_Chemical))) (PP (IN in) (NP (NP (NN plasma)) (CC and) (NP (NN urine))))))) (VP (AUX has) (VP (AUX been) (VP (VBN developed)))) (. .)))
16740173	22	(S1 (S (NP (DT The) (JJ analysed) (JJ Doc_16740173_2271_2280_Chemical) (NN concentration)) (VP (VBD exceeded) (NP (NP (DT the) (JJ supposed) (NN serum) (NN level)) (VP (VBG resulting) (PP (IN from) (NP (DT a) (JJ therapeutic) (NN dose))))) (PP (IN by) (NP (NP (DT a) (NN factor)) (PP (IN of) (NP (QP (CD 130) (TO to) (CD 260))))))) (. .)))
16740173	23	(S1 (S (PP (ADVP (RB Especially)) (IN in) (NP (JJ old) (NNS patients))) (, ,) (NP (NNS intensivists)) (VP (MD should) (VP (VB consider) (NP (NNS intoxications)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NNS cholinergics))) (-RRB- -RRB-)) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NNP Doc_16740173_2495_2523_Disease))))))) (. .)))
16755009	0	(S1 (NP (NP (JJ Pharmacological) (NN evidence)) (PP (IN for) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (JJ Daucus) (NNS carota))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_16755009_81_103_Disease))))))) (. .)))
16755009	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN aimed) (PP (IN at) (S (VP (VBG investigating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Daucus) (NN carota) (NNS seeds))) (PP (IN on) (NP (NP (JJ cognitive) (NNS functions)) (, ,) (NP (JJ total) (JJ serum) (JJ Doc_16755009_221_232_Chemical) (NNS levels)) (CC and) (NP (NP (NN brain) (NN cholinesterase) (NN activity)) (PP (IN in) (NP (NNS mice)))))))))))) (. .)))
16755009	2	(S1 (S (NP (NP (DT The) (JJ ethanolic) (NNP Doc_16755009_297_327_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16755009_329_332_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN in) (NP (NP (CD three) (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 100) (, ,) (CD 200) (, ,) (CD 400) (NNS mg/kg)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (CD seven) (JJ successive) (NNS days)) (PP (TO to) (NP (NP (JJ different) (NNS groups)) (PP (IN of) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))))))) (. .)))
16755009	3	(S1 (S (NP (NP (JJ Elevated) (NN plus) (NN maze)) (CC and) (NP (JJ passive) (NN avoidance) (NN apparatus))) (VP (VBD served) (PP (IN as) (NP (NP (DT the) (JJ exteroceptive) (JJ behavioral) (NNS models)) (PP (IN for) (NP (NN testing) (NN memory)))))) (. .)))
16755009	4	(S1 (S (NP (NP (NNP Doc_16755009_582_590_Chemical-)) (, ,) (NP (NNP Doc_16755009_593_604_Chemical-)) (CC and) (NP (JJ ageing-induced) (NNP Doc_16755009_625_632_Disease))) (VP (VBD served) (PP (IN as) (NP (DT the) (JJ interoceptive) (JJ behavioral) (NNS models)))) (. .)))
16755009	5	(S1 (S (NP (NP (NN Doc_16755009_680_683_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200)) (, ,) (NP (QP (CD 400) (CD mg/kg))) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (JJ significant) (NN improvement)) (PP (IN in) (NP (NP (NN memory) (NNS scores)) (PP (IN of) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))))) (. .)))
16755009	6	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN memory) (NN improvement)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_16755009_822_825_Chemical))))))) (VP (AUX was) (NP (NP (NP (CD 23) (NN %)) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 200) (NN mg/kg)))))) (CC and) (NP (NP (CD 35) (NN %)) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD 400) (NNS mg/kg)) (PP (IN in) (NP (NP (JJ young) (NNS mice)) (VP (VBG using) (NP (JJ elevated) (JJ plus) (NN maze)))))))))))) (. .)))
16755009	7	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ significant) (NNS improvements)) (PP (IN in) (NP (NN memory) (NNS scores)))) (VP (AUX were) (VP (VBN observed) (S (VP (VBG using) (NP (NP (NN passive) (NN avoidance) (NN apparatus)) (CC and) (NP (VBN aged) (NNS mice))))))) (. .)))
16755009	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_16755009_1061_1064_Chemical)) (VP (VBD reversed) (NP (NP (DT the) (NN Doc_16755009_1078_1085_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_16755009_1097_1108_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.4) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16755009_1131_1139_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)))))))) (. .)))
16755009	9	(S1 (S (NP (NP (NN Doc_16755009_1157_1178_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200)) (, ,) (NP (QP (CD 400) (CD mg/kg))) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (VP (VBD reduced) (ADVP (RB significantly)) (NP (NP (DT the) (NN brain) (NN acetylcholinesterase) (NN activity) (CC and) (JJ Doc_16755009_1268_1279_Chemical) (NNS levels)) (PP (IN in) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))) (. .)))
16755009	10	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN brain) (NN cholinesterase) (NN activity)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_16755009_1379_1382_Chemical))) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (QP (CD 400) (CD mg/kg)))))))))))) (VP (AUX was) (NP (NP (NP (CD 22) (NN %)) (PP (IN in) (NP (NN young)))) (CC and) (NP (NP (CD 19) (NN %)) (PP (IN in) (NP (VBN aged) (NNS mice)))))) (. .)))
16755009	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ remarkable) (NN reduction)) (PP (IN in) (NP (JJ total) (JJ Doc_16755009_1489_1500_Chemical) (NN level)))) (ADVP (RB as) (RB well)) (, ,) (PP (TO to) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NP (CD 23) (NN %)) (PP (IN in) (NP (NN young)))) (CC and) (NP (NP (CD 21) (NN %)) (PP (IN in) (NP (NP (VBN aged) (NNS animals)) (PP (IN with) (NP (NP (DT this) (NN dose)) (PP (IN of) (NP (NNP Doc_16755009_1588_1591_Chemical))))))))))))) (. .)))
16755009	12	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_16755009_1604_1607_Chemical)) (VP (MD may) (VP (VB prove) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN remedy)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_16755009_1662_1684_Disease)))))) (PP (IN on) (NP (NP (NN account)) (PP (IN of) (NP (NP (PRP$ its) (JJ multifarious) (JJ beneficial) (NNS effects)) (PP (JJ such) (IN as) (, ,) (NP (NP (NN memory) (VBG improving) (NN property)) (, ,) (NP (JJ Doc_16755009_1771_1782_Chemical) (VBG lowering) (NN property)) (CC and) (NP (JJ anticholinesterase) (NN activity))))))))))))) (. .)))
16787750	0	(S1 (S (NP (NN Doc_16787750_0_13_Chemical)) (VP (VBN induced) (NP (JJ Doc_16787750_22_36_Disease--19) (JJ new) (NNS cases)) (PP (IN in) (NP (NNP Germany))) (PP (PP (IN from) (NP (CD 1994))) (PP (TO to) (NP (NP (JJ 2003--a) (NN side) (NN effect)) (VP (VBN associated) (S (VP (TO to) (VP (VB Doc_16787750_109_112_Chemical-therapy) (ADVP (RB not) (RB only)) (PP (IN in) (NP (JJ young) (NNS children))))))))))) (. .)))
16787750	1	(S1 (S (NP (NP (NNP Doc_16787750_149_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16787750_164_167_Chemical)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (DT a) (JJ broad-spectrum) (JJ antiepileptic) (NN drug))) (CC and) (VP (AUX is) (ADVP (RB usually)) (VP (VBN well-tolerated)))) (. .)))
16787750	2	(S1 (S (NP (JJ Rare) (JJ serious) (NNS complications)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT some) (NNS patients))) (, ,) (PP (VBG including) (NP (NP (JJ haemorrhagic) (NNP Doc_16787750_317_329_Disease)) (, ,) (NP (NNP Doc_16787750_331_354_Disease)) (, ,) (NP (NNP Doc_16787750_356_359_Chemical-induced) (NNP Doc_16787750_368_382_Disease)) (CC and) (NP (NNP Doc_16787750_387_390_Chemical-induced) (NNP Doc_16787750_399_413_Disease)))))) (. .)))
16787750	3	(S1 (S (NP (NP (DT The) (JJ typical) (NNS signs)) (PP (IN of) (NP (NNP Doc_16787750_436_439_Chemical-induced) (NNP Doc_16787750_448_462_Disease)))) (VP (AUX are) (NP (NP (NNP Doc_16787750_467_489_Disease)) (, ,) (NP (ADJP (RB sometimes) (JJ marked)) (NNP EEG) (NN background) (NN slowing)) (, ,) (NP (VBN increased) (NNP Doc_16787750_542_549_Disease) (NN frequency))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NNP Doc_16787750_577_591_Disease))))) (. .)))
16787750	4	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB still)) (NP (NP (DT no) (NN proof)) (PP (IN of) (NP (NP (JJ causative) (NN effect)) (PP (IN of) (NP (NNP Doc_16787750_640_643_Chemical))))) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16787750_661_675_Disease))))) (, ,) (CC but) (ADVP (RB only)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (DT an) (JJ assumed) (JJ causal) (NN relation)))))))) (. .)))
16787750	5	(S1 (S (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 19) (NNS patients)) (PP (IN with) (NP (NNP Doc_16787750_764_767_Chemical-associated) (NNP Doc_16787750_779_793_Disease))) (PP (IN in) (NP (NNP Germany)))) (PP (IN from) (NP (DT the) (NNS years) (CD 1994) (TO to) (CD 2003))))) (, ,) (NP (NP (NN none)) (WHPP (IN of) (WHNP (WP whom)))) (VP (AUX had) (VP (AUX been) (VP (VBN published) (ADVP (RB previously))))) (. .)))
16858720	0	(S1 (NP (NP (NP (NN Doc_16858720_0_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16858720_32_40_Chemical))))) (: -) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ drug-drug) (NNS interactions)))) (. .)))
16858720	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN frequency) (, ,) (NN severity) (CC and) (NN preventability)) (PP (IN of) (NP (NNP Doc_16858720_151_159_Chemical-induced) (NNP Doc_16858720_168_189_Disease) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_16858720_197_205_Chemical) (CC and) (NNP Doc_16858720_210_218_Chemical-drug)))) (NNS interactions)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG living) (PP (IN in) (NP (NP (DT the) (NN county)) (PP (IN of) (NP (NNP Osterg) (NN tland))))))))))) (, ,) (NP (NNP Sweden)) (. .)))
16858720	2	(S1 (S (NP (NP (DT All) (NNS patients)) (PP (IN with) (NP (DT a) (VBN diagnosed) (NN Doc_16858720_335_355_Disease))) (PP (IN at) (NP (CD three) (NNS hospitals))) (PP (IN during) (NP (DT the) (NN period) (CD 2000-2002)))) (VP (AUX were) (VP (VBN identified))) (. .)))
16858720	3	(S1 (S (NP (JJ Medical) (NNS records)) (VP (AUX were) (VP (VBN studied) (ADVP (RB retrospectively)) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (NP (NNP Doc_16858720_485_493_Chemical)) (CC and) (NP (JJ Doc_16858720_498_506_Chemical-drug) (NNS interactions))) (VP (MD could) (VP (AUX have) (VP (VBN caused) (NP (DT the) (NNP Doc_16858720_547_567_Disease)))))))))))) (. .)))
16858720	4	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (RB possibly) (JJ avoidable) (NNS cases))) (PP (JJ due) (TO to) (NP (NN drug) (NNS interactions)))) (VP (AUX was) (VP (VBN estimated))) (. .)))
16858720	5	(S1 (S (PP (IN Among) (NP (NP (CD 593) (NNS patients)) (PP (IN with) (NP (NNP Doc_16858720_685_705_Disease))))) (, ,) (NP (NP (CD 59)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN assessed) (SBAR (IN as) (S (VP (VBN related) (PP (TO to) (NP (JJ Doc_16858720_744_752_Chemical) (NN treatment)))))))) (. .)))
16858720	6	(S1 (S (NP (DT This)) (VP (VBP imply) (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (CD 1.7/100,000) (NN treatment) (NNS years))))) (. .)))
16858720	7	(S1 (S (PP (IN Of) (NP (DT the) (CD 59) (NNS cases))) (, ,) (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 44) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT a) (JJ fatal) (NN outcome)) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (NP (CD 136)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-) (PP (IN among) (NP (DT the) (JJ non-Doc_16858720_903_911_Chemical) (NNS patients))))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
16858720	8	(S1 (S (NP (DT A) (JJ Doc_16858720_935_943_Chemical-drug) (NN interaction)) (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (DT the) (NNP Doc_16858720_991_1002_Disease))) (PP (PP (IN in) (NP (NP (NP (CD 24)) (PRN (-LRB- -LRB-) (NP (CD 41) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (JJ Doc_16858720_1022_1030_Chemical) (NNS patients))))) (CC and) (PP (IN in) (NP (NP (CD 7)) (PP (IN of) (NP (DT these)))))) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-)) (SBAR (S (NP (DT the) (NNP Doc_16858720_1068_1076_Disease) (NN complication)) (VP (AUX was) (VP (VBN considered) (S (VP (AUXG being) (ADJP (JJ possible) (S (VP (TO to) (VP (VB avoid)))))))))))))) (. .)))
16858720	9	(S1 (S (NP (JJ Doc_16858720_1143_1151_Chemical-induced) (NNP Doc_16858720_1160_1181_Disease)) (VP (AUX are) (NP (NP (DT a) (JJ major) (JJ clinical) (NN problem)) (PP (IN with) (NP (DT a) (JJ high) (NN fatality) (NN rate))))) (. .)))
16858720	10	(S1 (S (NP (NP (RB Almost) (NN half)) (PP (IN of) (NP (DT the) (NNS cases)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (DT a) (JJ Doc_16858720_1280_1288_Chemical-drug) (NN interaction))))) (. .)))
16858720	11	(S1 (S (NP (NP (DT A) (JJ significant) (NN proportion)) (PP (IN of) (NP (JJ Doc_16858720_1335_1343_Chemical-related) (NNP Doc_16858720_1352_1373_Disease)))) (VP (MD might) (VP (AUX have) (VP (AUX been) (VP (VBN prevented) (SBAR (IN if) (S (NP (JJR greater) (NN caution)) (VP (AUX had) (VP (AUX been) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN Doc_16858720_1480_1488_Chemical)))))))))))))))))))) (. .)))
16867021	0	(S1 (NP (NP (NP (JJ Antipsychotic-like) (NN profile)) (PP (IN of) (NP (NNP Doc_16867021_30_42_Chemical)))) (, ,) (NP (NP (DT a) (JJ selective) (JJ H3-receptor) (NN antagonist)) (PP (IN in) (NP (NNS mice)))) (. .)))
16867021	1	(S1 (S (NP (JJ Experimental) (CC and) (JJ clinical) (NN evidence)) (VP (VBZ points) (PP (TO to) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (JJ central) (JJ histaminergic) (NN system))) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_16867021_195_208_Disease)))))))) (. .)))
16867021	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_16867021_264_273_Chemical) (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -receptor) (NNS ligands))) (PP (IN on) (NP (NP (NP (JJ neuroleptic-induced) (NN Doc_16867021_319_328_Disease)) (, ,) (NP (JJ Doc_16867021_330_341_Chemical-induced) (VBG climbing) (NN behavior)) (CC and) (NP (JJ Doc_16867021_372_383_Chemical-induced) (NN locomotor) (NNS activities))) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
16867021	3	(S1 (S (NP (NN Doc_16867021_422_431_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_16867021_447_458_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-)))) (, ,) (SBAR (IN while) (S (NP (NP (NP (NNP Doc_16867021_481_492_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CD mg/kg)) (NNP s.c.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16867021_514_525_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NNP s.c.)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN used) (PP (IN for) (S (VP (VP (VBG studying) (NP (VBG climbing) (NN behavior) (CC and) (NN locomotor) (NNS activities))) (, ,) (VP (VBG respectively.) (NP (NP (NP (NP (NNP Doc_16867021_622_647_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_16867021_649_653_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg) (NN i.c.v.)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_16867021_677_689_Chemical)) (-LRB- -LRB-) (NP (NNP Doc_16867021_691_694_Chemical)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))) (, ,) (ADVP (FW per) (FW se)) (VP (AUX did) (RB not) (VP (VB cause) (NP (NNP Doc_16867021_734_743_Disease))))))))))))) (. .)))
16867021	4	(S1 (S (NP (NAC (NNP Administration) (PP (IN of) (NP (NNP Doc_16867021_763_766_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 3.75) (, ,) (CD 7.5) (CC and) (CD 15) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-)) (CD 1)) (NNP h)) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_16867021_810_821_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_16867021_867_876_Disease) (NNS times)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
16867021	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_16867021_922_926_Chemical)))) (ADVP (RB significantly)) (VP (VBD reversed) (NP (NP (PDT such) (DT an) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_16867021_968_971_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-)))))) (. .)))
16867021	6	(S1 (S (S (NP (NN Doc_16867021_989_993_Chemical)) (ADVP (FW per) (FW se)) (VP (VBD showed) (NP (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (NN locomotor) (NN time)) (, ,) (NP (NP (NN distance)) (VP (VBN traveled))) (CC and) (NP (JJ average) (NN speed)))))) (CC but) (S (NP (NP (NNP Doc_16867021_1089_1092_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (ADVP (FW per) (FW se)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (DT these) (NNS parameters)))))) (. .)))
16867021	7	(S1 (S (PP (IN On) (NP (NNP Doc_16867021_1154_1165_Chemical-induced) (NNP Doc_16867021_1174_1187_Disease))) (, ,) (NP (NP (NNP Doc_16867021_1189_1192_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.75) (CC and) (CD 7.5) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NP (NN locomotor) (NN time)) (, ,) (NP (NP (NN distance)) (VP (VBN traveled))) (CC and) (NP (NP (JJ average) (NN speed)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
16867021	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NNP Doc_16867021_1309_1313_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg) (NN i.c.v.)) (-RRB- -RRB-))))) (VP (MD could) (ADVP (RB partially)) (VP (VB reverse) (NP (NP (JJ such) (NNS effects)) (PP (IN of) (NP (NNP Doc_16867021_1372_1375_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 3.75) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))))) (. .)))
16867021	9	(S1 (S (NP (NP (VBG Climbing) (NN behavior)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16867021_1424_1435_Chemical))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16867021_1472_1475_Chemical)))))))) (. .)))
16867021	10	(S1 (S (NP (PDT Such) (DT an) (NN effect)) (VP (AUX was) (, ,) (ADVP (RB however)) (, ,) (ADJP (JJ reversed)) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (NNP Doc_16867021_1530_1534_Chemical)))))) (. .)))
16867021	11	(S1 (S (NP (NN Doc_16867021_1536_1539_Chemical)) (VP (VBD exhibited) (NP (DT an) (JJ antipsychotic-like) (NN profile)) (PP (IN by) (S (VP (VP (VBG potentiating) (NP (JJ Doc_16867021_1596_1607_Chemical-induced) (NNP Doc_16867021_1616_1625_Disease))) (, ,) (VP (VBG reducing) (NP (JJ Doc_16867021_1636_1647_Chemical-induced) (NNP Doc_16867021_1656_1669_Disease))) (CC and) (VP (VBG reducing) (NP (NP (JJ Doc_16867021_1683_1694_Chemical-induced)) (VP (VBG climbing) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
16867021	12	(S1 (S (NP (NP (JJ Such) (NNS effects)) (PP (IN of) (NP (NNP Doc_16867021_1737_1740_Chemical)))) (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_16867021_1758_1762_Chemical))) (S (VP (VBG indicating) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNP Doc_16867021_1793_1802_Chemical) (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNS -receptors)))))))) (. .)))
16867021	13	(S1 (S (NP (NNS Findings)) (VP (VBP suggest) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -receptor) (NNS antagonists)))) (PP (IN in) (S (VP (VBG improving) (NP (NP (DT the) (JJ refractory) (NNS cases)) (PP (IN of) (NP (NN Doc_16867021_1915_1928_Disease)))))))) (. .)))
16904497	0	(S1 (NP (NP (NP (NN Doc_16904497_0_21_Disease)) (PP (IN after) (NP (JJ epidural) (JJ Doc_16904497_37_44_Chemical) (NN injection)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
16904497	1	(S1 (S (NP (NP (JJ Conventional) (NN treatment) (NNS methods)) (PP (IN of) (NP (JJ lumbusacral) (NNP Doc_16904497_128_141_Disease)))) (VP (AUX are) (NP (NP (JJ physical) (NN therapy)) (, ,) (NP (JJ epidural) (JJ Doc_16904497_173_180_Chemical) (NNS injections)) (, ,) (NP (JJ oral) (NNS medications)) (, ,) (CC and) (NP (JJ spinal) (JJ manipulative) (NN therapy)))) (. .)))
16904497	2	(S1 (S (NP (NN Doc_16904497_244_265_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (JJ epidural) (NNS anesthesia))))) (. .)))
16904497	3	(S1 (S (NP (DT The) (JJ following) (NN case)) (VP (AUX is) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (NNP Doc_16904497_347_368_Disease))) (VP (ADVP (RB possibly)) (VBN caused) (PP (IN by) (NP (NP (JJ epidural) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_16904497_410_423_Chemical)) (CC and) (NP (NNP Doc_16904497_428_439_Chemical))))))))) (. .)))
16904497	4	(S1 (NP (NP (JJ CLINICAL) (NNS FEATURES)) (: :) (NP (NP (DT A) (JJ 50-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_16904497_485_512_Disease))) (SBAR (S (VP (AUX was) (VP (VBN scheduled) (PP (IN for) (NP (JJ epidural) (JJ Doc_16904497_540_547_Chemical) (NN injection)))))))) (. .)))
16904497	5	(S1 (NP (NP (NP (NN INTERVENTION)) (CC AND) (NP (NN OUTCOME))) (: :) (S (NP (DT An) (JJ 18-gauge) (NNP Touhy) (NN needle)) (VP (AUX was) (VP (VBN inserted) (SBAR (IN until) (S (NP (NP (NN loss)) (PP (IN of) (NP (NN resistance)))) (VP (VBD occurred) (PP (IN at) (NP (DT the) (JJ L4-5) (NN level))))))))) (. .)))
16904497	6	(S1 (S (NP (NP (NN Spread)) (PP (IN of) (NP (NP (DT the) (NN contrast) (NN medium)) (PP (IN within) (NP (DT the) (JJ epidural) (NN space)))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ radiographic) (NN imaging))))) (. .)))
16904497	7	(S1 (S (PP (IN After) (S (VP (VBG verifying) (NP (DT the) (NN epidural) (NN space))))) (, ,) (NP (NP (NNP Doc_16904497_808_819_Chemical)) (CC and) (NP (NNP Doc_16904497_824_847_Chemical))) (VP (AUX were) (VP (VBN injected))) (. .)))
16904497	8	(S1 (S (PP (IN After) (NP (DT the) (NN injection))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ radicular) (NNS symptoms))))) (. .)))
16904497	9	(S1 (S (ADVP (NP (CD Three) (NNS hours)) (RB later)) (, ,) (NP (PRP she)) (VP (VBD complained) (PP (IN of) (NP (NN perineal))) (NP (NP (NNP Doc_16904497_975_983_Disease)) (CC and) (NP (NNP Doc_16904497_988_1012_Disease)))) (. .)))
16904497	10	(S1 (S (NP (DT The) (JJ neurologic) (NN evaluation)) (VP (VBD revealed) (NP (NP (NP (NN Doc_16904497_1049_1066_Disease)) (PP (IN in) (NP (DT the) (NNP saddle) (NN area)))) (CC and) (NP (NP (JJ medial) (NN aspect)) (PP (IN of) (NP (PRP$ her) (JJ right) (NN leg)))))) (. .)))
16904497	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN perception)) (PP (IN of) (NP (NN pinprick) (NN test))))))) (. .)))
16904497	12	(S1 (S (NP (NN Deep-tendon) (NNS reflexes)) (VP (AUX were) (VP (VBN decreased) (ADVP (RB especially)) (PP (IN in) (NP (DT the) (JJ right) (NN leg))))) (. .)))
16904497	13	(S1 (S (NP (PRP She)) (VP (AUX was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB urinate)))))) (. .)))
16904497	14	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (NNS symptoms)) (VP (VBD improved) (ADVP (RB slightly)) (PP (IN over) (NP (DT the) (JJ next) (JJ few) (NNS hours)))) (. .)))
16904497	15	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (NP (NP (DT a) (JJ gradual) (NN return)) (PP (IN of) (NP (NN motor) (NN function)))) (CC and) (NP (NP (NN ability)) (PP (IN of) (S (VP (VBG feeling) (NP (NNP Foley) (NN catheter)))))))) (. .)))
16904497	16	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (DT the) (NNS symptoms)))) (VP (AUX were) (ADVP (RB completely)) (VP (VBN resolved) (PP (IN over) (NP (DT the) (JJ next) (CD 8) (NNS hours))))) (. .)))
16904497	17	(S1 (S (NP (NP (NNS Complications)) (VP (VBN associated) (PP (IN with) (NP (JJ epidural) (JJ Doc_16904497_1538_1545_Chemical) (NNS injections))))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
16904497	18	(S1 (S (NP (NP (NP (JJ Clinical) (NN examination)) (CC and) (NP (JJ continued) (NN vigilance))) (PP (IN for) (NP (NNP Doc_16904497_1616_1640_Disease))) (PP (IN after) (NP (JJ epidural) (JJ Doc_16904497_1656_1663_Chemical) (NNS injections)))) (VP (AUX is) (ADJP (JJ important))) (. .)))
16938416	0	(S1 (S (NP (NNP High-dose) (NNP Doc_16938416_10_22_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_16938416_42_57_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))) (. .)))
16938416	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (JJ long-term) (NNS effects)) (PP (IN of) (NP (JJ androgen) (NN treatment))) (PP (IN on) (NP (NP (NNP Doc_16938416_151_166_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))))) (. .)))
16938416	2	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ population-based) (NN study)) (PP (IN in) (NP (NP (CD 513) (RB naturally) (JJ postmenopausal) (NNS women)) (VP (VBN aged) (NP (JJ 54-67) (NNS years))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (JJ self-reported) (ADJP (RB intramuscularly) (VBN administered)) (NN high-dose) (JJ Doc_16938416_373_381_Chemical-Doc_16938416_382_394_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16938416_404_438_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ aortic) (NN Doc_16938416_451_466_Disease)))))) (. .)))
16938416	3	(S1 (S (NP (NNP Aortic) (NNP Doc_16938416_475_490_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN by) (NP (NP (JJ radiographic) (NN detection)) (PP (IN of) (NP (NP (JJ calcified) (NNS deposits)) (PP (IN in) (NP (NP (DT the) (JJ abdominal) (NN aorta)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB reflect) (NP (NN intima) (NN Doc_16938416_617_632_Disease)))))))))))))))))) (. .)))
16938416	4	(S1 (S (NP (NN Hormone) (NN therapy) (NNS users)) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (RB never) (NNS users))))) (. .)))
16938416	5	(S1 (S (NP (NP (JJ Intramuscular) (NN hormone) (NN therapy) (NN use)) (PP (IN for) (NP (QP (CD 1) (NN year) (CC or) (JJR longer))))) (VP (AUX was) (VP (VBN reported) (PP (IN by) (NP (CD 25) (NNS women))))) (. .)))
16938416	6	(S1 (S (PP (IN In) (NP (NP (RB almost) (NN half)) (PP (IN of) (NP (DT these) (NNS women))))) (NP (NP (JJ severe) (NNP Doc_16938416_815_830_Disease)) (PP (IN of) (NP (DT the) (NN aorta)))) (VP (AUX was) (ADJP (JJ present)) (PRN (-LRB- -LRB-) (NP (CD n=11)) (-RRB- -RRB-)) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (NNS women))) (PP (IN without) (NP (NN hormone) (NN use))) (NP (NP (JJ severe) (NN Doc_16938416_906_921_Disease)) (PP (IN of) (NP (DT the) (NN aorta)))) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (NP (NP (NP (NP (QP (JJR less) (IN than) (CD 20)) (NN %)) (-LRB- -LRB-) (CC OR) (CD 3.1)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 1.1-8.5)) (, ,)) (VP (VBN adjusted) (PP (IN for) (NP (NN age))))))) (PRN (, ,) (NP (NP (NNS years)) (PP (IN since) (NP (NN menopause) (, ,) (NN smoking) (, ,) (CC and) (NN body) (NN mass) (NN index)))) (-RRB- -RRB-)))))) (. .)))
16938416	7	(S1 (S (NP (DT The) (NN association)) (VP (VBD remained) (PP (IN after) (NP (JJ additional) (NN adjustment))) (PP (IN for) (NP (NP (NNP Doc_16938416_1119_1127_Disease) (, ,) (NNP Doc_16938416_1129_1140_Chemical) (NN level)) (, ,) (NP (JJ systolic) (NN blood) (NN pressure)) (, ,) (CC or) (NP (JJ Doc_16938416_1176_1183_Chemical) (NN use))))) (. .)))
16938416	8	(S1 (S (NP (DT No) (NN association)) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NN hormone) (NN use))) (NP (QP (JJR less) (IN than) (CD 1)) (NN year)))) (. .)))
16938416	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ high-dose) (JJ Doc_16938416_1295_1307_Chemical) (NN therapy)) (VP (MD may) (VP (ADVP (RB adversely)) (VB affect) (NP (NNP Doc_16938416_1337_1352_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women)))))))) (CC and) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ androgen) (NN replacement)) (PP (IN in) (NP (DT these) (NNS women)))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ harmless)))))))) (. .)))
17020434	0	(S1 (NP (NP (JJ Optimising) (JJ Doc_17020434_11_17_Disease) (NN prevention)) (PP (IN in) (NP (JJ non-valvular) (NNP Doc_17020434_45_64_Disease))) (. .)))
17020434	1	(S1 (S (NP (NN Doc_17020434_66_85_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ substantial) (NN morbidity)) (CC and) (NP (NN mortality)))))) (. .)))
17020434	2	(S1 (S (NP (NP (VBN Pooled) (NNS data)) (PP (IN from) (NP (NP (NNS trials)) (VP (VBG comparing) (NP (JJ antithrombotic) (NN treatment)) (PP (IN with) (NP (NN placebo))))))) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (S (NP (NNP Doc_17020434_230_238_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_17020434_259_265_Disease)))) (PP (IN by) (NP (CD 62) (NN %))))) (, ,) (CC and) (S (NP (NP (DT that) (NNP Doc_17020434_283_290_Chemical)) (ADVP (RB alone))) (VP (VBZ reduces) (NP (DT the) (NN risk)) (PP (IN by) (NP (CD 22) (NN %))))))))) (. .)))
17020434	3	(S1 (S (ADVP (RB Overall)) (, ,) (PP (IN in) (NP (JJ high-risk) (NNS patients))) (, ,) (NP (NNP Doc_17020434_354_362_Chemical)) (VP (AUX is) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_17020434_378_385_Chemical)))) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_17020434_400_407_Disease))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk) (NN reduction)) (PP (IN of) (NP (CD 36) (NN %)))))) (. .)))
17020434	4	(S1 (S (NP (NP (NNP Doc_17020434_448_460_Chemical)) (, ,) (NP (DT an) (JJ oral) (JJ direct) (NN thrombin) (NN inhibitor)) (, ,)) (VP (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB as) (JJ efficient) (PP (IN as) (NP (NP (JJ Doc_17020434_529_538_Chemical) (NN antagonist) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_17020434_577_591_Disease))))))))))))) (, ,) (CC but) (VP (AUX has) (VP (AUX been) (ADVP (RB recently)) (VP (VBN withdrawn) (PP (IN because) (IN of) (NP (JJ Doc_17020434_636_659_Disease) (NNS tests))))))) (. .)))
17020434	5	(S1 (S (NP (DT The) (JJ ACTIVE-W) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_17020434_681_700_Disease) (NNP Doc_17020434_701_712_Chemical) (NNP Trial)) (PP (IN with) (NP (NNP Doc_17020434_724_734_Chemical))) (PP (IN for) (NP (NP (NNP Prevention)) (PP (IN of) (NP (JJ Vascular) (NNS Events)))))) (-RRB- -RRB-)) (NN study)) (VP (AUX has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_17020434_798_806_Chemical)) (VP (AUX is) (ADJP (JJ superior) (PP (TO to) (NP (NP (JJ platelet) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17020434_840_851_Chemical) (CC plus) (NNP Doc_17020434_857_864_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN prevention) (NN af) (NN Doc_17020434_887_901_Disease)))))))) (. .)))
17020434	6	(S1 (S (NP (NP (NNP Doc_17020434_903_914_Chemical)) (, ,) (NP (DT a) (NN Factor) (NNP Xa) (NN inhibitor)) (, ,)) (VP (AUX is) (VP (AUXG being) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17020434_975_994_Disease)))))))) (. .)))
17020434	7	(S1 (S (NP (NP (JJ Doc_17020434_996_1007_Chemical-converting) (NN enzyme) (NNS inhibitors)) (CC and) (NP (JJ Doc_17020434_1041_1055_Chemical) (NN receptor-blocking) (NNS drugs))) (VP (VBP hold) (NP (NN promise)) (PP (IN in) (NP (NNP Doc_17020434_1096_1115_Disease))) (PP (IN through) (NP (NNP Doc_17020434_1124_1143_Disease)))) (. .)))
17020434	8	(S1 (S (NP (JJ Preliminary) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_17020434_1178_1185_Chemical)) (VP (MD could) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN recurrence))) (PP (IN after) (NP (JJ electrical) (NN cardioversion)))))))))) (. .)))
17020434	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (JJ percutaneous) (NNS methods)) (PP (IN for) (NP (NP (DT the) (NN exclusion)) (PP (IN of) (NP (JJ left) (JJ atrial) (NN appendage)))))) (VP (AUX are) (PP (IN under) (NP (NN investigation))) (PP (IN in) (NP (JJ high-risk) (NNS patients)))) (. .)))
17042910	0	(S1 (S (NP (NP (JJ Anti-oxidant) (NNS effects)) (PP (IN of) (NP (NNP Doc_17042910_24_36_Chemical))) (PP (IN in) (NP (NNP Doc_17042910_40_53_Chemical-induced)))) (VP (VBP Doc_17042910_62_74_Disease) (PP (IN in) (NP (DT the) (NN rat.) (CD 1)))) (. .)))
17042910	1	(S1 (S (NP (NP (NNP Doc_17042910_90_103_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_105_108_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_17042910_118_130_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ endothelial) (NN dysfunction)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17042910_191_203_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_205_207_Chemical)) (-RRB- -RRB-)) (NN deficiency)) (CC and) (NP (VBN increased) (NNP Doc_17042910_234_244_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_246_249_Chemical)) (-RRB- -RRB-)) (NN production)))))))))))) (. .)))
17042910	2	(S1 (S (NP (NP (NNP Doc_17042910_263_275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_277_280_Chemical)) (-RRB- -RRB-))) (VP (VBZ possesses) (NP (NP (JJ pleiotropic) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB improve) (NP (NN endothelial) (NN function)) (PP (IN through) (NP (NP (NP (JJ increased) (NN availability)) (PP (IN of) (NP (NNP Doc_17042910_405_407_Chemical)))) (CC and) (NP (NP (JJ reduced) (NN Doc_17042910_420_423_Chemical) (NN production)) (PP (IN in) (NP (NP (JJ various) (NNS forms)) (PP (IN of) (NP (NNP Doc_17042910_455_467_Disease)))))))))))))))))) (. .)))
17042910	3	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN day)))) (, ,) (ADVP (RB p.o.)) (, ,) (NP (NNP Doc_17042910_539_542_Chemical)) (VP (MD could) (VP (VB prevent) (NP (NP (JJ endothelial) (JJ Doc_17042910_569_571_Chemical) (NN synthase) (PRN (-LRB- -LRB-) (NN eNOS) (-RRB- -RRB-)) (NN downregulation)) (CC and) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NNP Doc_17042910_623_626_Chemical))) (PP (IN in) (NP (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG reducing) (NP (NN blood) (FW pressure.) (CD 2))))))))) (. .)))
17042910	4	(S1 (S (NP (NP (JJ Male) (NN SD) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 30)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17042910_732_735_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN mg/kg)) (PP (IN per) (NP (NN day))) (PP (IN in) (NP (NN drinking) (NN water)))) (-RRB- -RRB-)) (CC or) (VP (VB tap) (NP (NN water)) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
17042910	5	(S1 (S (NP (NP (NP (NN Doc_17042910_799_812_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10) (NNS microg/kg)) (PP (IN per) (NP (NN day)))) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))) (CC or) (NP (NN saline))) (VP (AUX was) (VP (VP (VBN started) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN in) (NP (ADJP (JJ Doc_17042910_880_883_Chemical-treated) (CC and) (JJ non-treated)) (NNS rats)))))) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD 11-13) (NNS days)))))) (. .)))
17042910	6	(S1 (S (NP (NP (JJ Systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN on) (NP (NP (JJ alternate) (NNS days)) (VP (VBG using) (NP (DT the) (JJ tail-cuff) (NN method))))))) (. .)))
17042910	7	(S1 (S (NP (JJ Endothelial) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ Doc_17042910_1069_1082_Chemical-induced) (NN vasorelaxation)) (CC and) (NP (JJ Doc_17042910_1110_1123_Chemical-induced) (NN vasoconstriction)))) (PP (IN in) (NP (JJ aortic) (NNS segments))))) (. .)))
17042910	8	(S1 (S (NP (JJ Vascular) (NN eNOS) (NN mRNA)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ semi-quantitative) (JJ reverse) (NN transcription-polymerase) (NN chain)) (QP (RB reaction.) (CD 3)))))) (. .)))
17042910	9	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17042910_1295_1298_Chemical)) (ADVP (RB alone))))))) (, ,) (NP (NNP SBP)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (NP (CD 109) (NN +/-)) (NP (QP (CD 2) (TO to) (CD 133)) (JJ +/-) (CD 2) (NNS mmHg))) (PP (IN on) (NP (NP (NN Days) (CD 4)) (CC and) (NP (NP (NNP Day) (CD 14) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (CD <) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
17042910	10	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_17042910_1412_1415_Chemical) (NNP +) (NNP Doc_17042910_1418_1421_Chemical) (NN group))) (, ,) (NP (NNP SBP)) (VP (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (NP (CD 113) (NN +/-)) (NP (QP (CD 2) (TO to) (CD 119)) (JJ +/-) (CD 2) (NNS mmHg))) (PP (IN on) (NP (NP (NP (NNS Days)) (NP (QP (CD 4) (TO to) (CD 14))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))))))) (, ,) (CC but) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NN SBP)))) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17042910_1586_1589_Chemical) (RB alone)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-))))))))) (. .)))
17042910	11	(S1 (S (NP (NP (JJ Endothelial-dependent) (NN relaxation)) (CC and) (NP (NN eNOS) (NN mRNA) (NN expression))) (VP (AUX were) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (NNP Doc_17042910_1686_1689_Chemical) (NNP +) (NNP Doc_17042910_1692_1695_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ Doc_17042910_1714_1717_Chemical) (JJ only) (NN group)) (PRN (-LRB- -LRB-) (VP (VP (VBN P) (NP (NNP <) (CD 0.05))) (CC and) (VP (VBN P) (NP (NNP <) (CD 0.0001)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
17042910	12	(S1 (S (NP (JJ Aortic) (NN Doc_17042910_1777_1787_Chemical) (NN production)) (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (NNP Doc_17042910_1816_1819_Chemical) (NNP +) (NNP Doc_17042910_1822_1825_Chemical) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_17042910_1869_1872_Chemical)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-)) (. .) (CD 4)))))))) (. .)))
17042910	13	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_17042910_1911_1914_Chemical)))) (VP (VBD improved) (NP (NP (JJ endothelial) (NN function)) (, ,) (NP (JJ reduced) (JJ Doc_17042910_1954_1964_Chemical) (NN production)) (CC and) (NP (NP (VBN reduced) (NN SBP)) (PP (IN in) (NP (JJ Doc_17042910_1995_1998_Chemical-treated) (NN SD) (NNS rats)))))) (. .)))
17111419	0	(S1 (S (NP (JJ Severe) (NNP Doc_17111419_7_14_Chemical) (NNP Doc_17111419_15_23_Disease) (NN complicating) (NN volunteer) (NNS apheresis)) (VP (VBP platelet) (NP (NN donation))) (. .)))
17111419	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ severe) (JJ Doc_17111419_103_110_Chemical) (NN Doc_17111419_111_119_Disease)))) (PP (IN during) (NP (NN volunteer) (NN donor) (NN apheresis) (NN platelet) (NN collection)))) (. .)))
17111419	2	(S1 (S (NP (DT The) (NN donor)) (VP (AUX was) (NP (NP (DT a) (JJ 40-year-old) (NN female)) (, ,) (NP (JJ first-time) (NN apheresis) (NN platelet) (NN donor)))) (. .)))
17111419	3	(S1 (S (NP (JJ Past) (JJ medical) (NN history)) (VP (AUX was) (ADJP (JJ remarkable) (PP (IN for) (NP (NP (NNP Doc_17111419_287_299_Disease)) (, ,) (NP (NNP Doc_17111419_301_315_Disease)) (, ,) (CC and) (NP (NNP Doc_17111419_321_331_Disease)))))) (. .)))
17111419	4	(S1 (S (NP (JJ Reported) (NNS medications)) (VP (VBD included) (NP (NP (NNP Doc_17111419_363_373_Chemical)) (, ,) (NP (NNP Doc_17111419_375_386_Chemical)) (, ,) (CC and) (NP (NNP Doc_17111419_392_402_Chemical)))) (. .)))
17111419	5	(S1 (S (NP (NP (CD Thirty) (NNS minutes)) (PP (IN from) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT the) (NN procedure)))))) (, ,) (NP (DT the) (NN donor)) (VP (VBD noted) (NP (NN tingling)) (PP (IN around) (NP (DT the) (NN mouth))) (, ,) (NP (NP (NNS hands)) (, ,) (CC and) (NP (NNS feet)))) (. .)))
17111419	6	(S1 (S (NP (PRP She)) (ADVP (RB then)) (ADVP (RB very) (RB rapidly)) (VP (VBD developed) (NP (NP (JJ acute) (NN onset)) (PP (IN of) (NP (JJ severe) (JJ facial) (CC and) (NN extremity) (NN Doc_17111419_587_593_Disease))))) (. .)))
17111419	7	(S1 (S (S (NP (NP (JJ Empirical) (NN treatment)) (PP (IN with) (NP (JJ intravenous) (NNP Doc_17111419_632_649_Chemical)))) (VP (AUX was) (VP (VBN initiated)))) (, ,) (CC and) (S (NP (NNP Doc_17111419_669_688_Disease)) (VP (ADVP (RB slowly)) (VBN subsided) (PP (IN over) (NP (QP (RB approximately) (CD 10) (TO to) (CD 15)) (NNS minutes))))) (. .)))
17111419	8	(S1 (S (NP (DT The) (NNS events)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ severe) (NN reaction)) (PP (TO to) (NP (JJ Doc_17111419_794_801_Chemical) (NN chelation))) (PP (IN by) (NP (NP (JJ Doc_17111419_815_829_Chemical) (NN anticoagulant)) (VP (VBG resulting) (PP (IN in) (NP (JJ symptomatic) (JJ systemic) (NN Doc_17111419_878_890_Disease)))))))))) (. .)))
17111419	9	(S1 (S (PP (IN Upon) (NP (JJ additional) (NN retrospective) (NN analysis))) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN noted) (SBAR (IN that) (S (NP (NNP Doc_17111419_950_960_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17111419_966_979_Chemical)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB cause) (NP (JJ significant) (NN Doc_17111419_1007_1019_Disease)))))))))))) (. .)))
17111419	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ careful) (NN screening)) (PP (IN for) (NP (NP (NNS medications)) (CC and) (NP (VBG underlying) (NNS conditions)))) (VP (VBG predisposing) (PP (TO to) (NP (NNP Doc_17111419_1114_1126_Disease))))) (VP (AUX is) (VP (VBN recommended) (S (VP (TO to) (VP (VB help) (S (VP (VB prevent) (NP (NP (JJ severe) (NNS reactions)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_17111419_1182_1189_Chemical) (NNP Doc_17111419_1190_1198_Disease))))))))))))))) (. .)))
17111419	11	(S1 (S (NP (NP (NN Laboratory) (NN measurement)) (PP (IN of) (NP (NP (JJ pre-procedure) (NN serum) (NN Doc_17111419_1246_1253_Chemical) (NNS levels)) (PP (IN in) (NP (JJ selected) (NNS donors)))))) (VP (MD may) (VP (VB identify) (NP (NP (NNS cases)) (VP (VBG requiring) (NP (JJ heightened) (NN vigilance)))))) (. .)))
17111419	12	(S1 (S (NP (DT The) (NN case)) (ADVP (RB also)) (VP (VBZ illustrates) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG maintaining) (NP (NN preparedness)) (PP (IN for) (S (VP (VBG managing) (NP (ADJP (JJ rare) (CC but) (JJ serious)) (NNS reactions)) (PP (IN in) (NP (NN volunteer) (NN apheresis) (NN blood) (NNS donors))))))))))) (. .)))
17147461	0	(S1 (NP (JJ Doc_17147461_0_9_Chemical-associated) (NNP Doc_17147461_21_32_Disease) (CC and) (NNP Doc_17147461_37_54_Disease) (. .)))
17147461	1	(S1 (S (NP (NN Doc_17147461_56_65_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ novel) (NN immunosuppressant)) (PP (IN with) (NP (NP (JJ potent) (JJ antiproliferative) (NNS actions)) (PP (IN through) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (JJ raptor-containing) (JJ mammalian) (NN target)) (PP (IN of) (NP (JJ Doc_17147461_206_215_Chemical) (NN protein) (NN kinase))))))))))))) (. .)))
17147461	2	(S1 (S (NP (NN Doc_17147461_232_241_Chemical)) (VP (VBZ represents) (NP (NP (DT a) (JJ major) (JJ therapeutic) (NN advance)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (JJ acute) (JJ renal) (NN allograft) (NN rejection)) (CC and) (NP (JJ chronic) (NN allograft) (NN Doc_17147461_356_367_Disease)))))))) (. .)))
17147461	3	(S1 (S (NP (NP (PRP$ Its) (NN role)) (PP (IN in) (NP (NP (DT the) (NN therapy)) (PP (IN of) (NP (NNP Doc_17147461_396_414_Disease) (, ,) (NNP Doc_17147461_416_428_Disease) (, ,) (NNP Doc_17147461_430_451_Disease) (CC and) (NNP Doc_17147461_456_468_Disease)))))) (VP (AUX is) (PP (IN under) (NP (NN investigation)))) (. .)))
17147461	4	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_17147461_501_510_Chemical)) (VP (AUX does) (RB not) (VP (VB share) (NP (NP (DT the) (JJ vasomotor) (JJ renal) (JJ adverse) (NNS effects)) (VP (VBN exhibited) (PP (IN by) (NP (NN calcineurin) (NNS inhibitors))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (VP (AUX been) (VP (VBN designated) (NP (DT a) (: ') (JJ non-Doc_17147461_629_640_Disease) (NN drug) (POS '))))) (. .)))
17147461	5	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ clinical) (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN under) (NP (DT some) (NNS circumstances))) (, ,) (NP (NNP Doc_17147461_714_723_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17147461_743_754_Disease)) (CC and) (NP (NNP Doc_17147461_759_782_Disease))))))))) (. .)))
17147461	6	(S1 (S (NP (DT A) (JJ common) (NN risk) (NN factor)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (NN presence)) (PP (IN of) (NP (JJ pre-existing) (NN Doc_17147461_844_864_Disease)))))))) (. .)))
17147461	7	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_17147461_884_893_Chemical-associated) (NNP Doc_17147461_905_916_Disease)))) (VP (VP (AUX are) (ADJP (JJ multifactorial))) (CC and) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ glomerular) (JJ capillary) (NN pressure)) (VP (VBG following) (NP (JJ calcineurin) (NN inhibitor) (NN withdrawal))))))))))) (. .)))
17147461	8	(S1 (S (S (NP (PRP It)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_17147461_1075_1084_Chemical)) (ADVP (RB directly)) (VP (VBZ causes) (NP (JJ increased) (JJ glomerular) (NN permeability/injury))))))))) (, ,) (CC but) (S (NP (NP (NN evidence)) (PP (IN for) (NP (DT this) (NN mechanism)))) (VP (AUX is) (ADVP (RB currently)) (ADJP (JJ inconclusive)))) (. .)))
17147461	9	(S1 (S (NP (NP (DT The) (NNP Doc_17147461_1206_1229_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17147461_1246_1255_Chemical))))) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (PP (IN in) (NP (JJ delayed) (NN graft) (NN function)))) (-RRB- -RRB-)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (JJ compensatory) (JJ renal) (NN cell) (NN proliferation)) (CC and) (NP (JJ survival/repair) (NNS processes))))))))) (. .)))
17147461	10	(S1 (S (SBAR (IN Although) (S (NP (DT these) (JJ adverse) (NNS effects)) (VP (VBP occur) (PP (IN in) (NP (DT some) (NNS patients)))))) (, ,) (NP (PRP$ their) (NN occurrence)) (VP (MD could) (VP (AUX be) (VP (VBN minimised) (PP (IN by) (NP (NP (NP (NN knowledge)) (PP (IN of) (NP (NP (NP (DT the) (JJ molecular) (NNS effects)) (PP (IN of) (NP (NNP Doc_17147461_1522_1531_Chemical))) (PP (IN on) (NP (DT the) (NN kidney)))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17147461_1558_1567_Chemical))) (PP (IN in) (NP (JJ appropriate) (NN patient) (NNS populations)))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NNP Doc_17147461_1624_1635_Disease)))) (CC and) (NP (JJ renal) (NN function))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ Doc_17147461_1663_1674_Chemical-converting) (JJ enzyme) (NNS inhibitors)) (CC or) (NP (NP (JJ Doc_17147461_1707_1721_Chemical) (NN receptor) (NNS blockers)) (SBAR (IN if) (S (NP (NNP Doc_17147461_1743_1754_Disease)) (VP (VBZ occurs)))))))) (CC and) (NP (NN withdrawal)))) (SBAR (IN if) (S (VP (VBN needed))))))) (. .)))
17147461	11	(S1 (S (NP (NP (JJ Further) (JJ long-term) (NN analysis)) (PP (IN of) (NP (NP (JJ renal) (JJ allograft) (NNS studies)) (VP (VBG using) (NP (NNP Doc_17147461_1848_1857_Chemical)) (PP (IN as) (NP (NP (JJ de) (NN novo) (NN immunosuppression)) (PP (IN along) (PP (IN with) (NP (JJ clinical) (CC and) (NN laboratory) (NNS studies)))))))))) (VP (MD will) (VP (VB refine) (NP (DT these) (NNS issues)) (PP (IN in) (NP (DT the) (NN future))))) (. .)))
17175308	0	(S1 (S (VP (VB Doc_17175308_0_11_Disease) (PP (IN after) (NP (NN conversion))) (PP (TO to) (NP (NNP Doc_17175308_32_41_Chemical))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients)))) (. .)))
17175308	1	(S1 (S (NP (NP (NNP Doc_17175308_74_83_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17175308_85_88_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (DT a) (JJ new) (, ,) (JJ potent) (NN immunosuppressive) (NN agent))) (. .)))
17175308	2	(S1 (S (ADVP (RBR More) (RB recently)) (, ,) (NP (NNP Doc_17175308_147_158_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (JJ Doc_17175308_197_206_Chemical) (NN therapy))))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN mechanism)) (VP (AUX has) (VP (VBN remained) (ADJP (JJ unclear))))))))) (. .)))
17175308	3	(S1 (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBD examined) (NP (NP (DT the) (NNS records)) (PP (IN of) (NP (NP (CD 25) (JJ renal) (NN transplant) (NNS patients)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed)) (CC or) (VP (VBD displayed) (NP (JJ increased) (NN Doc_17175308_371_382_Disease)) (PP (IN after) (NP (JJ Doc_17175308_389_392_Chemical) (NN conversion))))))))))) (. .)))
17175308	4	(S1 (S (NP (NP (DT The) (JJ patient) (NN cohort)) (PRN (-LRB- -LRB-) (NP (CD 14) (NNS men)) (, ,) (NP (CD 11) (NNS women)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17175308_460_463_Chemical))) (PP (IN as) (NP (NN conversion) (NN therapy))) (, ,) (PP (JJ due) (PP (TO to) (NP (NP (NP (NP (NP (NP (NNP Doc_17175308_494_523_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17175308_525_528_Disease)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 15)) (-RRB- -RRB-)) (NP (NP (NNP Doc_17175308_539_548_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)))) (PRN (: ;) (NP (NP (NNP Doc_17175308_558_574_Disease)) (, ,) (NP (NNP Four) (NNP Doc_17175308_581_593_Disease)) (, ,) (NP (NNP One) (NNP Doc_17175308_599_616_Disease))) (, ,) (NP (NNP One) (NNP Doc_17175308_622_641_Disease)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP BK) (NN virus) (NNP Doc_17175308_655_666_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)))))))) (. .)))
17175308	5	(S1 (S (NP (NN Doc_17175308_676_679_Chemical)) (VP (AUX was) (VP (VBN started) (PP (IN at) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (NP (NP (CD 78) (NN +/-)) (NP (CD 42) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (TO to) (CD 163))) (-RRB- -RRB-)) (NNS months))) (PP (IN after) (NP (NN transplantation))))))))) (. .)))
17175308	6	(S1 (S (NP (NP (JJ Mean) (NN follow-up)) (PP (IN on) (NP (JJ Doc_17175308_775_778_Chemical) (NN therapy)))) (VP (AUX was) (NP (CD 20) (JJ +/-) (CD 12) (PRN (-LRB- -LRB-) (NP (QP (CD 6) (TO to) (CD 43))) (-RRB- -RRB-)) (NNS months))) (. .)))
17175308	7	(S1 (S (NP (NN Doc_17175308_819_830_Disease)) (VP (VBD increased) (PP (IN from) (NP (NP (CD 0.445)) (PRN (-LRB- -LRB-) (NP (QP (CD 0) (TO to) (CD 1.5))) (-RRB- -RRB-))) (ADVP (RB g/d))) (PP (IN before) (NP (NP (NN conversion)) (PP (TO to) (NP (QP (CD 3.2) (CD g/dL)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.2) (TO to) (CD 12))) (-RRB- -RRB-)) (PP (IN after) (NP (NN conversion))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.001)) (-RRB- -RRB-))) (. .)))
17175308	8	(S1 (S (PP (IN Before) (NP (NN conversion) (CD 8))) (PRN (-LRB- -LRB-) (NP (CD 32) (NN %)) (-RRB- -RRB-)) (NP (NNS patients)) (VP (AUX had) (NP (DT no) (NN Doc_17175308_981_992_Disease)) (, ,) (SBAR (IN whereas) (S (ADVP (RB afterwards)) (NP (DT all) (NNS patients)) (VP (AUX had) (NP (NN Doc_17175308_1030_1041_Disease)))))) (. .)))
17175308	9	(S1 (S (PP (IN In) (NP (NP (CD 28) (NN %)) (PP (IN of) (NP (NNS patients))))) (NP (NNP Doc_17175308_1062_1073_Disease)) (VP (VBD remained) (ADJP (JJ unchanged)) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBD increased) (PP (IN in) (NP (NP (CD 68) (NN %)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
17175308	10	(S1 (S (PP (IN In) (NP (CD 40) (NN %))) (NP (PRP it)) (VP (VBN increased) (PP (IN by) (NP (QP (JJR more) (IN than) (CD 100)) (NN %)))) (. .)))
17175308	11	(S1 (S (NP (NP (JJ Twenty-eight) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (VBD showed) (NP (NP (VBN increased) (NN Doc_17175308_1224_1235_Disease)) (PP (TO to) (NP (DT the) (NNP Doc_17175308_1243_1252_Disease) (NN range))))) (. .)))
17175308	12	(S1 (NP (NP (NP (NNS Biopsies)) (VP (VBN performed) (PP (IN in) (NP (NP (CD five) (NNS patients)) (VP (VBN revealed) (NP (JJ new) (JJ pathological) (NNS changes))))))) (: :) (NP (NP (NNP One) (NNP Doc_17175308_1335_1371_Disease)) (CC and) (NP (NNP Doc_17175308_1376_1398_Disease))) (. .)))
17175308	13	(S1 (S (NP (DT These) (NNS patients)) (VP (VBD showed) (NP (ADJP (RB persistently) (JJ good)) (NN graft) (NN function))) (. .)))
17175308	14	(S1 (S (S (NP (NNP Serum) (NNP Doc_17175308_1462_1472_Chemical) (NNS values)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly))))) (: :) (S (NP (NP (CD 1.98) (JJ +/-) (CD 0.8) (NNS mg/dL)) (PP (IN before) (NP (JJ Doc_17175308_1536_1539_Chemical) (NN therapy) (CC and) (CD 2.53) (NN +/-) (CD 1.9)))) (VP (VBD mg/dL) (PP (IN at) (NP (NP (JJ last) (NN follow-up)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .14)) (-RRB- -RRB-)))))) (. .)))
17175308	15	(S1 (S (S (NP (CD Five) (NNS grafts)) (VP (AUX were) (VP (VBN lost)))) (CC and) (S (NP (DT the) (NNS patients)) (VP (VBN returned) (PP (TO to) (NP (NN dialysis))))) (. .)))
17175308	16	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD displayed) (NP (NP (NNP Doc_17175308_1685_1688_Disease)) (CC and) (NP (NNP Doc_17175308_1693_1709_Disease)))) (. .)))
17175308	17	(S1 (S (NP (NP (JJ Mean) (NN urinary) (NN protein)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD returned) (PP (TO to) (NP (NN dialysis))))))))) (VP (AUX was) (NP (NP (NP (CD 1.26)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.5) (TO to) (CD 3.5))) (-RRB- -RRB-)) (VP (VBG g/d) (ADVP (RB before)))) (CC and) (NP (NP (CD 4.7)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (TO to) (CD 12))) (-RRB- -RRB-)) (VP (VBN g/d) (PP (IN after) (NP (NP (NN conversion)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .01)) (-RRB- -RRB-)))))))) (. .)))
17175308	18	(S1 (S (NP (NP (JJ Mean) (NN serum) (JJ Doc_17175308_1863_1873_Chemical) (NN level)) (PP (IN before) (NP (NN conversion)))) (VP (AUX was) (NP (NP (CD 2.21) (NN mg/dL)) (CC and) (ADVP (RB thereafter)) (, ,) (NP (NP (CD 4.93) (NN mg/dL)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .02)) (-RRB- -RRB-))))) (. .)))
17175308	19	(S1 (S (NP (NNP Heavy) (NNP Doc_17175308_1957_1968_Disease)) (VP (AUX was) (ADJP (JJ common)) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17175308_1997_2000_Chemical))) (PP (IN as) (NP (NP (NN rescue) (NN therapy)) (PP (IN for) (NP (JJ renal) (NN transplantation)))))))) (. .)))
17175308	20	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN conversion)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (RB not) (VP (VBN developed) (NP (NNP advanced) (NNP Doc_17175308_2134_2137_Disease) (CC and) (NNP Doc_17175308_2142_2153_Disease))))))))))) (. .)))
17175308	21	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (IN de) (NN novo) (NN glomerular) (NN pathology))) (PP (IN under) (NP (JJ Doc_17175308_2209_2212_Chemical) (NN treatment)))) (VP (VBZ requires) (NP (NP (JJ further) (NN investigation)) (PP (IN by) (NP (JJ renal) (NN biopsy))))) (. .)))
1720453	0	(S1 (NP (NP (NP (JJ Long-term) (NN follow-up)) (PP (IN of) (NP (NNP Doc_1720453_23_33_Chemical) (NNP Doc_1720453_34_48_Disease))) (PP (IN in) (NP (NP (NNS children)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_1720453_73_101_Disease))))))) (: :) (NP (NP (DT an) (JJ International) (NN Society)) (PP (IN of) (NP (NNP Pediatric) (NNP Oncology) (NN report)))) (. .)))
1720453	1	(S1 (S (NP (NP (DT The) (JJ renal) (NN function)) (PP (IN of) (NP (NP (CD 74) (NNS children)) (PP (IN with) (NP (NNP Doc_1720453_197_225_Disease))))) (PP (IN in) (NP (NP (JJ complete) (NN remission)) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN received) (NP (NP (DT the) (JJ same) (JJ Doc_1720453_279_289_Chemical) (JJ chemotherapy) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NP (NNP International) (NNP Society)) (PP (IN of) (NP (NNP Pediatric) (NNP Oncology) (NNP Doc_1720453_357_384_Disease) (NNP Study)))) (NP (CD 84) (JJ -LSB-SIOP) (NNP MMT) (CD 84) (NN -RSB-)) (-RRB- -RRB-)))))))))) (VP (AUX were) (VP (VBN studied) (NP (CD 1) (NN year)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN treatment))))))) (. .)))
1720453	2	(S1 (S (NP (JJ Total) (JJ cumulative) (NNS doses)) (VP (AUX were) (NP (NP (QP (CD 36) (CC or) (CD 60)) (NN g/m2)) (PP (IN of) (NP (NP (NNP Doc_1720453_509_519_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD six) (CC or) (CD 10)) (NNS cycles)) (PP (IN of) (NP (JJ Doc_1720453_541_582_Chemical) (JJ -LSB-Doc_1720453_584_587_Chemical) (NNS -RSB-)))) (-RRB- -RRB-)))))) (. .)))
1720453	3	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (PRP them)))) (VP (AUX had) (VP (VBN received) (NP (NNP Doc_1720453_617_626_Chemical) (CD chemotherapy)))) (. .)))
1720453	4	(S1 (S (S (NP (NNS Ages)) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 4) (NNS months) (TO to) (CD 17)) (NNS years))))) (: ;) (S (NP (CD 58) (NNS patients)) (VP (AUX were) (NP (NNS males) (CC and) (CD 42) (NNS females)))) (. .)))
1720453	5	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ primary) (NN Doc_1720453_743_748_Disease) (NN site)) (VP (AUX was) (NP (DT the) (NP (NN head)) (CC and) (NP (NN neck)))) (. .)))
1720453	6	(S1 (S (NP (JJ Renal) (NN function)) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN plasma) (CC and) (NN urinary) (NNS electrolytes)) (, ,) (NP (NP (NNP Doc_1720453_855_865_Disease)) (, ,) (NP (NP (NAC (NNP Doc_1720453_867_878_Disease) (, ,) (NNP Doc_1720453_880_893_Disease) (, ,)) (NN urinary) (NN pH)) (, ,) (NP (NN osmolarity)) (, ,) (NP (JJ Doc_1720453_919_929_Chemical) (NN clearance)) (, ,) (NP (JJ Doc_1720453_941_950_Chemical) (JJ tubular) (NN reabsorption)) (, ,) (NP (NN beta) (CD 2) (NN microglobulinuria)) (, ,) (CC and) (NP (NN lysozymuria)))))))))) (. .)))
1720453	7	(S1 (S (NP (NP (JJ Fifty-eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 78) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (JJ normal) (JJ renal) (NNS tests)) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 16) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_1720453_1097_1116_Disease)))))) (. .)))
1720453	8	(S1 (S (S (NP (NP (CD Two) (NNS subsets)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (VP (VBN identified) (PP (IN from) (NP (DT this) (JJ latter) (NN group)))))) (: :) (S (NP (DT the) (JJ first)) (VP (VBN included) (NP (NP (NP (CD four) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NN population)))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ major) (NNP Doc_1720453_1264_1272_Disease)) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_1720453_1286_1304_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1720453_1306_1310_Disease)) (-RRB- -RRB-)))))))))))) (: ;) (CC and) (S (NP (DT the) (JJ second) (NN group)) (VP (VBD included) (NP (CD five) (NNS patients)) (PP (IN with) (NP (NP (NP (JJ elevated) (NN beta)) (ADJP (CD 2) (NN microglobulinuria))) (CC and) (NP (JJ low) (JJ Doc_1720453_1404_1413_Chemical) (NN reabsorption)))))) (. .)))
1720453	9	(S1 (S (NP (DT The) (JJ remaining) (CD seven) (NNS patients)) (VP (AUX had) (VP (VBN isolated) (NP (NN beta) (CD 2) (NN microglobulinuria)))) (. .)))
1720453	10	(S1 (S (NP (JJ Severe) (NNP Doc_1720453_1503_1511_Disease)) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (NP (DT the) (JJR higher) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NP (CD 60) (NNS g/m2)) (PP (IN of) (NP (NP (NNP Doc_1720453_1573_1583_Chemical)) (, ,) (NP (NP (DT a) (JJR younger) (NN age)) (PRN (-LRB- -LRB-) (ADJP (NP (QP (JJR less) (IN than) (CD 2) (CD 1/2)) (NNS years)) (JJ old)) (-RRB- -RRB-))) (, ,)))))) (CC and) (NP (NP (DT a) (NN predominance)) (PP (IN of) (NP (JJ vesicoprostatic) (JJ Doc_1720453_1666_1671_Disease) (NN involvement)))))))) (. .)))
1720453	11	(S1 (S (NP (NP (DT This) (JJ low) (NN percentage)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NNS TDFS)))) (VP (MD must) (VP (AUX be) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_1720453_1768_1778_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1720453_1799_1817_Disease)) (PP (IN in) (NP (NNS children)))))))))))))) (. .)))
17241784	0	(S1 (S (NP (NP (NNP Progressive) (NNP Doc_17241784_12_20_Disease)) (PP (IN with) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NNS MHC-I)))))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_17241784_65_71_Chemical) (NN therapy)))) (. .)))
17241784	1	(S1 (S (NP (NN Doc_17241784_81_88_Chemical)) (VP (MD can) (VP (VB cause) (NP (NP (DT a) (JJ necrotizing) (NN Doc_17241784_113_121_Disease) (CC and) (NN Doc_17241784_126_138_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ reversible) (PP (IN on) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug)))))))))))) (. .)))
17241784	2	(S1 (S (SBAR (WHNP (WP What)) (S (VP (AUX is) (ADJP (ADVP (RBR less) (RB well)) (VBN known))))) (VP (AUX is) (NP (NP (DT a) (NN phenomenon)) (SBAR (WHADVP (WRB whereby)) (S (NP (NNP Doc_17241784_233_240_Chemical)) (VP (VP (MD may) (VP (VB induce) (NP (NP (DT a) (NN Doc_17241784_254_262_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ persists))))))) (CC or) (VP (MD may) (VP (VB progress) (PP (IN after) (S (VP (VBG stopping) (NP (DT the) (NN drug)))))))))))) (. .)))
17241784	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN muscle) (NN pathology)) (PP (IN in) (NP (CD 8) (JJ such) (NNS cases))))) (. .)))
17241784	4	(S1 (S (S (NP (DT All)) (VP (AUX had) (NP (JJ myofibre) (NN Doc_17241784_391_399_Disease)))) (CC but) (S (NP (QP (RB only) (CD 3))) (VP (AUX had) (NP (DT an) (JJ inflammatory) (VB infiltrate)))) (. .)))
17241784	5	(S1 (S (PP (IN In) (NP (DT all) (NNS cases))) (NP (EX there)) (VP (AUX was) (NP (NP (NN diffuse) (CC or) (NN multifocal) (NN up-regulation)) (PP (IN of) (NP (JJ MHC-I) (NN expression)))) (PP (ADVP (RB even)) (IN in) (NP (JJ non-Doc_17241784_534_542_Disease) (NNS fibres)))) (. .)))
17241784	6	(S1 (S (NP (JJ Progressive) (NN improvement)) (VP (VBD occurred) (PP (IN in) (NP (CD 7) (NNS cases))) (PP (PP (IN after) (NP (NP (NN commencement)) (PP (IN of) (NP (NP (NNP Doc_17241784_617_629_Chemical)) (CC and) (NP (NNP Doc_17241784_634_646_Chemical)))))) (, ,) (CC and) (PP (IN in) (NP (CD one) (NN case)))) (ADVP (RB spontaneously))) (. .)))
17241784	7	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_17241784_711_718_Chemical)) (VP (MD may) (VP (VB initiate) (NP (NP (DT an) (JJ immune-mediated) (NN Doc_17241784_751_759_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ persists) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN drug)))))) (CC and) (VP (VBZ responds) (PP (TO to) (NP (JJ immunosuppressive) (NN therapy))))))))))))) (. .)))
17241784	8	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (NN Doc_17241784_868_876_Disease)))) (VP (VP (AUX is) (ADJP (JJ uncertain))) (CC but) (VP (MD may) (VP (VB involve) (NP (NP (DT the) (NN induction)) (PP (IN by) (NP (NP (NNP Doc_17241784_923_930_Chemical)) (PP (IN of) (NP (NP (DT an) (JJ endoplasmic) (NN reticulum) (NN stress) (NN response)) (PP (IN with) (NP (NP (VBN associated) (NN up-regulation)) (PP (IN of) (NP (NP (JJ MHC-I) (NN expression)) (CC and) (NP (NN antigen) (NN presentation)))) (PP (IN by) (NP (NN muscle) (NNS fibres))))))))))))) (. .)))
17242861	0	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NN chromosome) (NN substitution) (NNS strains)))) (VP (TO to) (VP (VB identify) (NP (NP (NN Doc_17242861_51_58_Disease) (NN susceptibility) (NNS loci)) (PP (IN in) (NP (NNS mice)))))) (. .)))
17242861	1	(S1 (S (NP (JJ Doc_17242861_88_95_Disease) (NN susceptibility)) (VP (VBZ varies) (PP (IN among) (NP (JJ inbred) (NN mouse) (NNS strains)))) (. .)))
17242861	2	(S1 (S (NP (NP (NP (NN Chromosome) (NN substitution) (NNS strains)) (PRN (-LRB- -LRB-) (NP (NNP CSS)) (-RRB- -RRB-))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (JJ single) (NN chromosome)) (PP (IN from) (NP (NP (CD one) (JJ inbred) (NN strain)) (PRN (-LRB- -LRB-) (NP (NN donor)) (-RRB- -RRB-))))) (VP (AUX has) (VP (AUX been) (VP (VBN transferred) (PP (IN onto) (NP (NP (DT a) (JJ second) (NN strain)) (PRN (-LRB- -LRB-) (NP (NN host)) (-RRB- -RRB-)))) (PP (IN by) (NP (VBN repeated) (NN backcrossing)))))))) (, ,)) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ quantitative) (NN trait) (NNS loci)) (PRN (-LRB- -LRB-) (NP (NNP QTLs)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBP contribute) (PP (TO to) (NP (NNP Doc_17242861_394_401_Disease) (NN susceptibility))))))))))))) (. .)))
17242861	3	(S1 (S (S (NP (NP (NNS QTLs)) (PP (IN for) (NP (NN susceptibility))) (PP (TO to) (NP (NP (NNP Doc_17242861_445_456_Chemical-induced) (NNP Doc_17242861_465_473_Disease)) (, ,) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_17242861_486_508_Disease)))) (, ,)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported))))) (, ,) (CC and) (S (NP (NNS CSS)) (VP (AUX have) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB localize) (NP (JJ Doc_17242861_584_591_Disease) (JJ susceptibility) (NNS genes))))))))) (. .)))
17242861	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NNS QTLs)) (VP (VBN identified) (S (VP (VBG using) (NP (DT a) (NNP B6) (PRN (-LRB- -LRB-) (NP (NN host)) (-RRB- -RRB-)) (NNP x) (NNP A/J) (PRN (-LRB- -LRB-) (NP (NN donor)) (-RRB- -RRB-)) (NN CSS) (NN panel)) (S (VP (TO to) (VP (VB localize) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17242861_730_741_Chemical-induced) (NNP Doc_17242861_750_758_Disease))))))))))))))) (. .)))
17242861	5	(S1 (S (NP (NP (CD Three) (CD hundred) (JJ fifty-five) (NN adult) (NN male) (NN CSS) (NNS mice)) (, ,) (NP (CD 58) (NNS B6)) (, ,) (CC and) (NP (CD 39) (NNS A/J))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17242861_858_869_Chemical-induced) (NNP Doc_17242861_878_886_Disease))))))) (. .)))
17242861	6	(S1 (S (S (NP (JJS Highest) (NN stage)) (VP (VBN reached))) (CC and) (S (NP (NP (NN latency)) (PP (TO to) (NP (DT each) (NN stage)))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (DT all) (NNS mice)))))) (. .)))
17242861	7	(S1 (S (NP (NN B6) (NNS mice)) (VP (AUX were) (ADJP (ADJP (JJ resistant) (PP (TO to) (NP (NNP Doc_17242861_990_998_Disease)))) (CC and) (ADJP (JJR slower) (SBAR (S (VP (TO to) (VP (VB reach) (NP (NNS stages)) (PP (VBN compared) (PP (TO to) (NP (JJ A/J) (NNS mice))))))))))) (. .)))
17242861	8	(S1 (S (NP (NP (DT The) (NN CSS)) (PP (IN for) (NP (NNS Chromosomes) (CD 10) (CC and) (CD 18)))) (VP (VBD progressed) (PP (TO to) (NP (DT the) (RBS most) (JJ severe) (NNS stages))) (, ,) (S (VP (VBG diverging) (ADVP (RB dramatically)) (PP (IN from) (NP (DT the) (NNP B6) (NN phenotype)))))) (. .)))
17242861	9	(S1 (S (NP (NP (NNS Latencies)) (PP (TO to) (NP (NNS stages)))) (VP (AUX were) (ADVP (RB also)) (ADJP (RB significantly) (JJR shorter)) (PP (IN for) (NP (QP (CD CSS10) (CC and) (CD CSS18)) (NNS mice)))) (. .)))
17242861	10	(S1 (S (NP (JJ CSS) (NN mapping)) (VP (VBZ suggests) (NP (NP (JJ Doc_17242861_1265_1272_Disease) (NN susceptibility) (NN loci)) (PP (IN on) (NP (NN mouse) (NNS Chromosomes) (CD 10) (CC and) (CD 18))))) (. .)))
17242861	11	(S1 (S (NP (DT This) (NN approach)) (VP (VBZ provides) (NP (NP (DT a) (NN framework)) (PP (IN for) (S (VP (VBG identifying) (ADJP (RB potentially) (JJ novel)) (ADVP (RB homologous)) (NP (NN candidate) (NNS genes)) (PP (IN for) (NP (JJ human) (NN Doc_17242861_1431_1453_Disease)))))))) (. .)))
17244258	0	(S1 (FRAG (PP (IN In) (NP (NP (NN vitro) (NN characterization)) (PP (IN of) (NP (NP (ADJP (JJ parasympathetic) (CC and) (JJ sympathetic)) (NNS responses)) (PP (IN in) (NP (NP (NNP Doc_17244258_74_90_Chemical-induced) (NNP Doc_17244258_99_107_Disease)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
17244258	1	(S1 (S (PP (IN In) (NP (NP (NNP Doc_17244258_123_139_Chemical-induced) (NNP Doc_17244258_148_156_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (, ,) (S (NP (NN detrusor) (NN function)) (VP (AUX is) (ADJP (JJ impaired)))) (CC and) (S (NP (NP (DT the) (NN expression) (CC and) (NNS effects)) (PP (IN of) (NP (JJ muscarinic) (NNS receptors)))) (VP (VBD altered))) (. .)))
17244258	2	(S1 (S (SBAR (IN Whether) (S (CC or) (RB not) (NP (DT the) (JJ neuronal) (NN transmission)) (VP (MD may) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_17244258_323_331_Disease)))))))) (VP (AUX was) (ADVP (RB presently)) (VP (VBN investigated))) (. .)))
17244258	3	(S1 (S (NP (NP (NNS Responses)) (PP (IN of) (NP (NP (JJ urinary) (NN strip) (NNS preparations)) (PP (IN from) (NP (NP (NN control)) (CC and) (NP (JJ Doc_17244258_417_433_Chemical-pretreated) (NNS rats)))))) (PP (PP (TO to) (NP (JJ electrical) (NN field) (NN stimulation))) (CC and) (PP (TO to) (NP (NNS agonists))))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (DT the) (NN absence) (CC and) (NN presence)) (PP (IN of) (NP (ADJP (JJ muscarinic) (, ,) (JJ adrenergic) (CC and) (JJ purinergic)) (NN receptor) (NNS antagonists))))))) (. .)))
17244258	4	(S1 (S (S (ADVP (RB Generally)) (, ,) (NP (NNP Doc_17244258_614_622_Chemical)) (VP (VBD reduced) (NP (NNS contractions)))) (, ,) (CC but) (S (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NNS controls))))) (, ,) (NP (PRP it)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (NNS responses)) (PP (TO to) (NP (NP (JJ low) (JJ electrical) (NN field) (NN stimulation) (NN intensity)) (PRN (-LRB- -LRB-) (NP (CD 1-5) (NN Hz)) (-RRB- -RRB-))))) (PP (IN in) (NP (JJ inflamed) (NNS preparations))))) (. .)))
17244258	5	(S1 (S (PP (IN In) (NP (DT both) (NNS types))) (, ,) (NP (NP (NN purinoceptor) (NN desensitization)) (PP (IN with) (NP (NP (NNP Doc_17244258_830_876_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17244258_878_894_Chemical)) (-RRB- -RRB-))))) (VP (VBD caused) (NP (NP (JJ further) (NNS reductions)) (PP (IN at) (NP (NP (JJ low) (NNS frequencies)) (PRN (-LRB- -LRB-) (NP (CD <10) (NNS Hz)) (-RRB- -RRB-)))))) (. .)))
17244258	6	(S1 (S (NP (DT The) (JJ muscarinic) (NN receptor) (NNS antagonists)) (NP (NP (NP (NNP Doc_17244258_987_995_Chemical)) (, ,) (NP (NNP Doc_17244258_997_1033_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_17244258_1035_1041_Chemical) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (VP (POS ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ /M) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ /M) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (NN -selective) ('' '))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_17244258_1073_1086_Chemical)) (PRN (-LRB- -LRB-) ('' ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN -selective) ('' ')) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_17244258_1110_1121_Chemical)) (PRN (-LRB- -LRB-) ('' ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN -selective) ('' ')) (-RRB- -RRB-)))) (VP (VBD antagonized) (SBAR (S (NP (NP (DT the) (NN tonic) (NN component)) (PP (IN of) (NP (DT the) (JJ electrical) (NN field)))) (VP (VBD stimulation-evoked) (NP (JJ contractile) (NN response)) (ADVP (ADVP (RBR more) (RB potently)) (SBAR (IN than) (S (NP (DT the) (JJ phasic) (NN component.) (NNP Doc_17244258_1278_1284_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (NN tonic) (NNS contractions)) (PP (IN in) (NP (NNS controls)))) (ADVP (ADVP (RBR more) (RB potently)) (PP (IN than) (NP (NNP Doc_17244258_1349_1362_Chemical) (CC and) (NNP Doc_17244258_1367_1378_Chemical)))))))))))) (. .)))
17244258	7	(S1 (S (PP (IN In) (NP (JJ inflamed) (NNS preparations))) (, ,) (S (NP (NP (DT the) (JJ muscarinic) (NN receptor) (NN antagonism)) (PP (IN on) (NP (NP (DT the) (JJ phasic) (NN component)) (PP (IN of) (NP (DT the) (JJ electrical) (NN field) (JJ stimulation-evoked) (NN contraction)))))) (VP (AUX was) (VP (VBN decreased)))) (CC and) (S (NP (NP (DT the) (ADJP (JJ Doc_17244258_1542_1553_Chemical) (CC and) (JJ Doc_17244258_1558_1564_Chemical)) (NN antagonism)) (PP (IN on) (NP (DT the) (NN tonic) (NN component)))) (VP (AUX was) (ADJP (ADVP (RB much) (RBR less)) (JJ efficient) (PP (IN than) (PP (IN in) (NP (NNS controls))))))) (. .)))
17244258	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NNS controls))))) (, ,) (NP (NNP Doc_17244258_1666_1679_Chemical)) (VP (VBD increased) (: --) (CONJP (RB instead) (IN of)) (VP (VBN decreased)) (: --) (NP (NP (DT the) (NN tonic) (NNS responses)) (PP (IN at) (NP (JJ high) (NNS frequencies))))) (. .)))
17244258	9	(S1 (S (SBAR (IN While) (S (NP (NP (NNS contractions)) (PP (TO to) (NP (NNP Doc_17244258_1780_1789_Chemical) (CC and) (NNP Doc_17244258_1794_1797_Chemical)))) (VP (AUX were) (NP (NP (DT the) (JJ same)) (SBAR (SBAR (IN in) (S (VP (VBN inflamed)))) (CC and) (SBAR (IN in) (S (NP (NN control)) (VP (VBZ strips) (SBAR (WHADVP (WRB when)) (S (VP (VBN related) (PP (TO to) (NP (DT a) (NN reference) (JJ Doc_17244258_1874_1883_Chemical) (NN response)))))))))))))) (, ,) (NP (JJ Doc_17244258_1894_1906_Chemical-induced) (NNS relaxations)) (VP (AUX were) (ADJP (JJR smaller)) (PP (IN in) (NP (JJ inflamed) (NNS strips)))) (. .)))
17244258	10	(S1 (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (NP (JJ Doc_17244258_1969_1977_Disease) (JJ substantial) (NNS changes)) (PP (IN of) (NP (DT the) (JJ efferent) (JJ functional) (NNS responses))))) (VP (VBP occur)) (. .)))
17244258	11	(S1 (S (SBAR (IN While) (S (NP (JJ postjunctional) (JJ beta-adrenoceptor-mediated) (NNS relaxations)) (VP (AUX are) (VP (VBN reduced))))) (, ,) (NP (NP (NNS effects)) (PP (IN by) (NP (JJ prejunctional) (NN inhibitory) (NN muscarinic) (NNS receptors)))) (VP (MD may) (VP (AUX be) (VP (VBN increased)))) (. .)))
17261653	0	(S1 (NP (NP (JJ Direct) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ hyperpolarization-activated) (JJ Doc_17261653_57_74_Chemical-gated) (NN pacemaker) (NNS channels))) (PP (IN by) (NP (NNP Doc_17261653_103_112_Chemical))) (. .)))
17261653	1	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ sympathetic) (NN tone)))) (VP (VBZ represents) (NP (NP (DT an) (JJ important) (NN strategy)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_17261653_215_237_Disease))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_17261653_249_259_Disease)) (, ,) (NP (NNP Doc_17261653_261_283_Disease)) (, ,) (CC and) (NP (NN chronic) (NN Doc_17261653_297_310_Disease)))))))) (. .)))
17261653	2	(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ presynaptic) (NNS alpha2-adrenoceptors)))) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (RB widely) (VBN accepted)) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (DT the) (JJ antisympathetic) (NN drug) (NN Doc_17261653_435_444_Chemical)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ other) (NN target) (NNS proteins)) (VP (AUX have) (VP (AUX been) (VP (VBN postulated) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (DT the)) (PP (IN in) (NP (NP (JJ vivo) (NNS actions)) (PP (IN of) (NP (NNP Doc_17261653_538_547_Chemical)))))))))))))) (. .)))
17261653	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (S (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NNP Doc_17261653_586_595_Chemical)) (VP (VBZ elicits) (S (NP (JJ pharmacological) (NNS effects)) (ADJP (JJ independent) (PP (IN of) (NP (NNS alpha2-adrenoceptors))))))))))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN generated) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (DT a) (JJ targeted) (NN deletion)) (PP (IN of) (NP (NP (DT all) (CD 3) (JJ alpha2-adrenoceptor) (NNS subtypes)) (PRN (-LRB- -LRB-) (JJ alpha2ABC-/-) (-RRB- -RRB-)))))))))) (. .)))
17261653	4	(S1 (S (S (NP (JJ Alpha2ABC-/-) (NNS mice)) (VP (AUX were) (ADJP (RB completely) (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ analgesic) (CC and) (JJ hypnotic) (NNS effects)) (PP (IN of) (NP (NNP Doc_17261653_855_864_Chemical)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_17261653_875_884_Chemical)) (VP (ADVP (RB significantly)) (VBD lowered) (NP (NN heart) (NN rate)) (PP (IN in) (NP (JJ alpha2ABC-/-) (NNS mice))) (PP (IN by) (NP (QP (IN up) (TO to) (CD 150) (CD bpm)))))) (. .)))
17261653	5	(S1 (S (NP (NP (JJ Doc_17261653_957_966_Chemical-induced) (NNP Doc_17261653_975_986_Disease)) (PP (IN in) (NP (JJ conscious) (JJ alpha2ABC-/-) (NNS mice)))) (VP (AUX was) (NP (NP (NP (NP (CD 32.3) (NN %)) (-LRB- -LRB-) (NP (CD 10) (NNS microg/kg)) (-RRB- -RRB-)) (CC and) (NP (NP (CD 26.6) (NN %)) (-LRB- -LRB-) (NP (CD 100) (NNS microg/kg)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN in) (NP (JJ wild-type) (NNS mice))))))) (. .)))
17261653	6	(S1 (S (NP (NP (DT A) (JJ similar) (JJ bradycardic) (NN effect)) (PP (IN of) (NP (NNP Doc_17261653_1134_1143_Chemical)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (VBN isolated) (ADJP (RB spontaneously) (VBG beating)) (JJ right) (NN atria)) (PP (IN from) (NP (NP (NN alpha2ABC-knockout)) (CC and) (NP (JJ wild-type) (NNS mice)))))))) (. .)))
17261653	7	(S1 (S (NP (NNP Doc_17261653_1247_1256_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (JJ native) (NN pacemaker) (NN current)) (PRN (-LRB- -LRB-) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NNP f) (-RRB- -RRB-))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (VBN isolated) (JJ sinoatrial) (NN node) (NN pacemaker) (NNS cells)) (CC and) (NP (NP (NP (NP (NP (DT the) (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP f)) (-RRB- -RRB-))) (JJ -generating) (JJ hyperpolarization-activated) (JJ Doc_17261653_1399_1416_Chemical-gated)) (PRN (-LRB- -LRB-) (NP (NNP HCN)) (-RRB- -RRB-))) (NP (QP (CD 2) (CC and) (CD HCN4)) (NNS channels)) (PP (IN in) (NP (JJ transfected) (CD HEK293) (NNS cells)))))))) (. .)))
17261653	8	(S1 (S (PP (IN As) (NP (NP (DT a) (NN consequence)) (PP (IN of) (S (VP (VBG blocking) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP f)) (-RRB- -RRB-)))))))) (, ,) (NP (NNP Doc_17261653_1513_1522_Chemical)) (VP (VBD reduced) (NP (NP (NP (DT the) (NN slope)) (PP (IN of) (NP (DT the) (JJ diastolic) (NN depolarization)))) (CC and) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN pacemaker) (NNS potentials))))) (PP (IN in) (NP (NP (JJ sinoatrial) (NN node) (NNS cells)) (PP (IN from) (NP (ADJP (JJ wild-type) (CC and) (JJ alpha2ABC-knockout)) (NNS mice)))))) (. .)))
17261653	9	(S1 (S (S (NP (NP (JJ Direct) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (NN HCN) (NN pacemaker) (NNS channels)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ bradycardic) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_17261653_1791_1800_Chemical) (JJ gene-targeted) (NNS mice)) (PP (IN in) (NP (NN vivo))))))))) (, ,) (CC and) (S (ADVP (RB thus)) (, ,) (NP (JJ Doc_17261653_1839_1848_Chemical-like) (NNS drugs)) (VP (VBP represent) (NP (NP (JJ novel) (NNS structures)) (PP (IN for) (NP (JJ future) (NN HCN) (NN channel) (NNS inhibitors)))))) (. .)))
1728522	0	(S1 (NP (NP (NN Doc_1728522_0_23_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_1728522_31_77_Chemical)))) (. .)))
1728522	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_1728522_116_143_Chemical-induced) (NNP Doc_1728522_152_161_Disease))) (PP (IN with) (NP (JJ histologic) (JJ multiple) (NN Doc_1728522_187_197_Disease))))))) (. .)))
1728522	2	(S1 (S (NP (NP (DT This) (NN type)) (PP (IN of) (NP (NN lesion)))) (VP (VBZ broadens) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (NNP Doc_1728522_244_256_Disease))) (ADJP (JJ due) (PP (TO to) (NP (DT this) (NN drug) (NN combination)))) (, ,) (VP (ADVP (RB mainly)) (VBN represented) (PP (IN by) (NP (DT a) (JJ benign) (NN Doc_1728522_318_338_Disease)))))) (. .)))
1728522	3	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NP (NNP Doc_1728522_359_369_Disease)) (CC and) (NP (NNP Doc_1728522_374_386_Disease))))) (VP (VBP favor) (NP (DT an) (JJ immunoallergic) (NN mechanism))) (. .)))
1728522	4	(S1 (FRAG (SBAR (IN As) (S (NP (NP (JJ Doc_1728522_425_435_Chemical) (NNS derivatives)) (CC and) (NP (NP (NNP Doc_1728522_452_463_Chemical)) (ADVP (RB alone)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ such) (NNS types)) (PP (IN of) (NP (NNS lesions))))))))))) (, ,) (NP (DT the) (JJ Doc_1728522_517_528_Chemical) (NN component)) (, ,) (SBAR (IN with) (S (CC or) (PP (IN without) (NP (NP (DT a) (JJ potentiating) (NN effect)) (PP (IN of) (NP (NNP Doc_1728522_581_596_Chemical))))) (, ,) (VP (MD might) (VP (AUX have) (NP (DT a) (JJ major) (NN role)))))) (. .)))
1732369	0	(S1 (NP (NP (JJ Doc_1732369_0_10_Chemical) (NN stress) (NN echocardiography)) (: :) (NP (NP (DT a) (JJ sensitive) (NN indicator)) (PP (IN of) (NP (JJ diminished) (JJ myocardial) (NN function))) (PP (IN in) (NP (NP (JJ asymptomatic) (JJ Doc_1732369_108_119_Chemical-treated) (JJ long-term) (NNS survivors)) (PP (IN of) (NP (NN childhood) (NN Doc_1732369_161_167_Disease)))))) (. .)))
1732369	1	(S1 (S (NP (NNP Doc_1732369_169_180_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN anticancer) (JJ chemotherapeutic) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (ADJP (ADJP (JJ acute)) (CC and) (ADJP (JJ chronic))) (NN Doc_1732369_264_278_Disease)))))))) (. .)))
1732369	2	(S1 (S (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (JJ echocardiographic) (NN screening) (NN test)) (PP (IN for) (NP (NNP Doc_1732369_345_359_Disease)))) (PP (JJ due) (TO to) (NP (NNP Doc_1732369_367_378_Chemical)))))) (, ,) (NP (DT a) (NN cohort) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (JJ Doc_1732369_415_425_Chemical) (NN infusion)) (S (VP (TO to) (VP (VB differentiate) (NP (NP (JJ asymptomatic) (JJ long-term) (NNS survivors)) (PP (IN of) (NP (NP (NN childhood) (NN Doc_1732369_498_504_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1732369_518_529_Chemical))) (PP (IN from) (NP (JJ healthy) (NN control) (NNS subjects)))))))))))))) (. .)))
1732369	3	(S1 (S (NP (NP (JJ Echocardiographic) (NNS data)) (PP (IN from) (NP (NP (DT the) (JJ experimental) (NN group)) (PP (IN of) (NP (NP (CD 21) (NNS patients)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age)) (NP (CD 16) (JJ +/-) (CD 5) (NNS years)) (-RRB- -RRB-)))) (VP (VBN treated) (PP (IN from) (NP (NP (QP (CD 1.6) (TO to) (CD 14.3)) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN median) (CD 5.3)) (-RRB- -RRB-)))) (PP (IN before) (NP (DT this) (NN study))) (PP (IN with) (NP (NP (QP (CD 27) (TO to) (CD 532)) (NNS mg/m2)) (PP (IN of) (NP (NNP Doc_1732369_739_750_Chemical)))))))) (PRN (-LRB- -LRB-) (NP (VB mean) (CD 196)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (JJ echocardiographic) (NNS data)) (PP (IN from) (NP (CD 12) (JJ normal) (JJ age-matched) (NN control) (NNS subjects))))))) (. .)))
1732369	4	(S1 (S (NP (NP (JJ Graded) (JJ Doc_1732369_856_866_Chemical) (NNS infusions)) (PP (IN of) (NP (CD 0.5) (, ,) (CD 2.5) (, ,) (CD 5) (CC and) (CD 10) (NN micrograms/kg))) (PP (IN per) (NP (NN min)))) (VP (AUX were) (VP (VBN administered))) (. .)))
1732369	5	(S1 (S (NP (JJ Echocardiographic) (NNP Doppler) (NNS studies)) (VP (AUX were) (VP (VBN performed) (PP (PP (IN before) (NP (NN infusion))) (CC and) (PP (IN after) (NP (NP (CD 15) (NN min)) (PP (IN of) (NP (NN infusion)))))) (PP (IN at) (NP (DT each) (NN rate))))) (. .)))
1732369	6	(S1 (S (NP (NP (JJ Doc_1732369_1048_1058_Chemical) (NN infusion)) (PP (IN at) (NP (CD 10) (NNS micrograms/kg))) (PP (IN per) (NP (NN min)))) (VP (AUX was) (VP (VBN discontinued) (PP (IN after) (NP (NP (CD six) (NNS studies)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN incidence) (NN rate)) (PP (IN of) (NP (JJ adverse) (NNS symptoms)))))))))) (. .)))
1732369	7	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ important)) (NNS findings)) (VP (AUX were) (SBAR (IN that) (S (S (PP (VBN compared) (PP (IN with) (NP (NP (NNS values)) (PP (IN in) (NP (NN control) (NNS subjects)))))) (, ,) (NP (NP (JJ end-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension) (CC and) (NN percent)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (NN posterior) (NN wall)) (VP (VBG thickening) (PP (IN in) (NP (JJ Doc_1732369_1382_1393_Chemical-treated) (NNS patients))))))) (VP (AUX were) (VP (VBN decreased) (PP (IN at) (NP (JJ baseline) (NN study)))))) (CC and) (S (NP (DT these) (NNS findings)) (VP (AUX were) (ADVP (RBR more) (RB clearly)) (VP (VBN delineated) (PP (IN with) (NP (JJ Doc_1732369_1497_1507_Chemical) (NN stimulation))))))))) (. .)))
1732369	8	(S1 (S (NP (NP (JJ End-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension)) (PP (IN at) (NP (NN baseline))) (PP (IN for) (NP (DT the) (JJ Doc_1732369_1596_1607_Chemical-treated) (NN group)))) (VP (AUX was) (NP (NP (CD 11) (NN +/-) (QP (CD 1.9) (CD mm) (CC versus) (CD 13.1) (JJR +/-) (CD 1.5) (CD mm))) (PP (IN for) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
1732369	9	(S1 (NP (NP (NP (JJ End-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension)) (PP (IN at) (NP (DT the) (NN 5-micrograms/kg)))) (S (NP (NP (FW per) (FW min) (JJ Doc_1732369_1790_1800_Chemical) (NN infusion)) (PP (IN for) (NP (DT the) (JJ Doc_1732369_1818_1829_Chemical-treated) (NN group)))) (VP (AUX was) (NP (NP (NP (CD 14.1) (NN +/-)) (NP (QP (CD 2.4) (CD mm) (CC versus) (CD 19.3)) (JJ +/-) (CD 2.6) (NNS mm))) (PP (IN for) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
17343925	0	(S1 (NP (NP (NN Influence)) (PP (IN of) (NP (NNP Doc_17343925_13_20_Chemical))) (PP (IN on) (S (VP (VBG developing) (NP (NN cochlea))))) (. .)))
17343925	1	(S1 (SQ (AUX Does) (NP (NP (NNP Doc_17343925_49_56_Chemical)) (PP (IN during) (NP (NN pregnancy)))) (VP (VB affect) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (NP (JJ transient) (JJ evoked) (NN otoacoustic) (NNS emissions)) (PP (IN in) (NP (NNS newborns))))))) (. ?)))
17343925	2	(S1 (S (NP (JJ Maternal) (NN tobacco) (NN Doc_17343925_179_186_Chemical)) (VP (AUX has) (NP (NP (JJ negative) (NNS effects)) (PP (IN on) (NP (JJ fetal) (NN growth))))) (. .)))
17343925	3	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_17343925_242_249_Chemical))) (PP (IN during) (NP (NN pregnancy))) (PP (IN on) (NP (DT the) (VBG developing) (NN cochlea)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN estimated) (, ,) (SBAR (IN although) (S (NP (NNP Doc_17343925_326_333_Chemical)) (VP (AUX has) (VP (AUX been) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17343925_370_382_Disease)) (PP (IN in) (NP (NNS adults))))))))))))) (. .)))
17343925	4	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ maternal) (NNP Doc_17343925_463_470_Chemical))) (PP (IN on) (NP (NP (NP (JJ transient) (JJ evoked) (NN otoacoustic) (NNS emissions)) (PRN (-LRB- -LRB-) (NP (NNP TEOAEs)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ healthy) (NNS neonates)))))))))) (. .)))
17343925	5	(S1 (S (NP (DT This) (NN study)) (VP (VP (AUX was) (VP (VBN undertaken) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ neonatal) (NN screening)) (PP (IN for) (NP (NNP Doc_17343925_612_630_Disease))))))))) (CC and) (VP (VBD involved) (NP (NP (DT both) (NNS ears)) (PP (IN of) (NP (CD 200) (NNS newborns)))))) (. .)))
17343925	6	(S1 (S (NP (NP (NNS Newborns)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD reported) (NP (NNP Doc_17343925_703_710_Chemical)) (PP (IN during) (NP (NN pregnancy)))))) (PRN (-LRB- -LRB-) (NP (CD n=200) (NNS ears)) (-RRB- -RRB-))) (VP (AUX were) (PP (VBN compared) (PP (TO to) (NP (NP (DT a) (NN control) (NN group)) (PP (IN of) (NP (NP (NNS newborns)) (PRN (-LRB- -LRB-) (NP (CD n=200) (NNS ears)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (AUX were) (NP (NNS non-smokers))))))))) (. .)))
17343925	7	(S1 (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NN tobacco)))) (VP (AUX was) (VP (VBN characterized) (PP (IN as) (NP (ADJP (ADJP (JJ low)) (PRN (-LRB- -LRB-) (NP (NP (JJ <5) (NNS cigarettes)) (PP (IN per) (NP (NN day)))) (, ,) (NP (CD n=88) (NNS ears)) (-RRB- -RRB-)) (, ,) (ADJP (JJ moderate)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS 5<) (CC or) (NNS =cigarettes)) (PP (IN per) (NP (CD day<10)))) (, ,) (NP (CD n=76))) (-RRB- -RRB-)) (CC or) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD >) (CC or) (CD =10)) (NNS cigarettes)) (PP (IN per) (NP (NN day)))) (, ,) (NP (CD n=36))) (-RRB- -RRB-))))))) (. .)))
17343925	8	(S1 (S (PP (IN In) (NP (JJ exposed) (NNS neonates))) (, ,) (NP (NNS TEOAEs)) (VP (VBP mean) (SBAR (S (NP (NP (NP (NN response)) (PRN (-LRB- -LRB-) (PP (IN across) (NP (NN frequency))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ mean) (NN amplitude)) (PP (IN at) (NP (NNS 4000Hz))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (PP (IN in) (NP (JJ non-exposed) (NNS neonates))))))))) (. .)))
17343925	9	(S1 (S (NP (NP (NNS Comparisons)) (PP (IN between) (NP (NP (VBN exposed) (NNS newborns) (POS ')) (NNS subgroups)))) (VP (VBD revealed) (NP (DT no) (JJ significant) (NNS differences))) (. .)))
17343925	10	(S1 (S (ADVP (RB However)) (, ,) (PP (IN by) (S (VP (VBG comparing) (NP (DT each) (NN subgroup) (S (VP (TO to) (VP (VB control) (NP (NN group))))))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (ADJP (RB statistically) (JJ significant)) (NN Doc_17343925_1331_1361_Disease)) (PP (IN at) (NP (NP (NNS 4000Hz)) (PP (IN for) (NP (DT all) (CD three) (NNS groups)))))) (. .)))
17343925	11	(S1 (S (NP (NP (JJ Mean) (JJ TEOAEs) (NNS responses)) (PP (IN of) (NP (ADJP (RB highly) (VBN exposed)) (NNS newborns)))) (VP (AUX were) (ADVP (RB also)) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (PRP$ our) (NN control) (NN group)))))) (. .)))
17343925	12	(S1 (S (PP (IN In) (NP (NN utero))) (, ,) (NP (NP (NN exposure)) (PP (TO to) (NP (NN tobacco) (NN Doc_17343925_1551_1558_Chemical)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ small) (NN impact)) (PP (IN on) (NP (JJ outer) (NN hair) (NNS cells)))))))) (. .)))
17343925	13	(S1 (S (NP (DT These) (NNS effects)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (ADJP (RB equally) (JJ true) (PP (IN for) (NP (DT all) (VBN exposed) (NNS newborns)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN exposure)))))))))) (. .)))
17343925	14	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB establish) (NP (NP (DT a) (JJ potential) (JJ negative) (NN effect)) (PP (IN of) (NP (JJ maternal) (NNP Doc_17343925_1800_1807_Chemical))) (PP (IN on) (NP (NP (DT the) (NN neonate) (POS 's)) (NN hearing) (NN acuity)))))))))) (. .)))
17344566	0	(S1 (NP (NP (NP (JJ Doc_17344566_0_11_Chemical-induced) (JJ bilateral) (NN leg) (NN Doc_17344566_34_54_Disease)) (CC and) (NP (NNP Doc_17344566_59_70_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17344566_87_101_Disease)))) (. .)))
17344566	1	(S1 (S (NP (NP (DT A) (JJ 54-year-old) (JJ Doc_17344566_117_128_Disease) (NN male)) (VP (VBG taking) (NP (NP (NNP Doc_17344566_141_150_Chemical)) (CC and) (NP (NNP Doc_17344566_155_166_Chemical))))) (VP (VBD presented) (PP (IN with) (NP (JJ bilateral) (NN leg) (NNP Doc_17344566_196_216_Disease) (CC and) (NNP Doc_17344566_221_232_Disease)))) (. .)))
17344566	2	(S1 (S (S (NP (JJ Urgent) (NNS fasciotomies)) (VP (AUX were) (VP (VBN performed)))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD made) (NP (NP (DT an) (JJ uneventful) (NN recovery)) (PP (IN with) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_17344566_336_347_Chemical)))))))) (. .)))
17344566	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (DT this) (NN complication)) (VP (MD will) (VP (AUX be) (VP (VBN seen) (ADVP (RBR more) (RB often)) (PP (IN with) (NP (NP (NP (DT the) (VBN increased) (NNP worldwide) (NN use)) (PP (IN of) (NP (DT this) (NN drug)))) (CC and) (NP (NP (PRP$ its) (NN approval)) (PP (IN for) (NP (DT all) (JJ Doc_17344566_480_493_Disease) (NNS patients)))))))))))) (. .)))
17400887	0	(S1 (NP (NP (NP (NP (NNP Doc_17400887_0_17_Disease)) (CC and) (NP (NNP Doc_17400887_22_46_Disease))) (PP (IN after) (NP (NP (JJ neonatal) (JJ Doc_17400887_62_73_Chemical) (NN treatment)) (PP (IN in) (NP (NNS rats)))))) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NNP Doc_17400887_110_116_Disease)))) (. .)))
17400887	1	(S1 (S (NP (NN Doc_17400887_118_124_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17400887_130_157_Disease)) (VP (VBG presenting) (PP (IN before) (NP (NP (CD 3) (NNS years)) (PP (IN of) (NP (NN age))))) (PP (IN with) (NP (NP (NNP Doc_17400887_196_239_Disease)) (CC and) (NP (NNP Doc_17400887_244_264_Disease))))))) (. .)))
17400887	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (JJ genetic) (NNS influences))))) (, ,) (NP (JJ recent) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ prenatal) (NN drug) (CC or) (NN chemical) (NNS exposures)) (VP (AUX are) (NP (NN risk) (NNS factors)) (PP (IN for) (NP (NN Doc_17400887_386_392_Disease))))))) (. .)))
17400887	3	(S1 (S (NP (NP (NNP Doc_17400887_394_405_Chemical)) (, ,) (NP (NP (DT a) (JJ beta2-adrenoceptor) (NN agonist)) (VP (VBN used) (S (VP (TO to) (VP (VB arrest) (NP (NNP Doc_17400887_451_464_Disease))))))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN concordance)) (PP (IN for) (NP (NP (NNP Doc_17400887_517_523_Disease)) (PP (IN in) (NP (JJ dizygotic) (NNP twins)))))))))) (. .)))
17400887	4	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_17400887_570_581_Chemical))) (PP (IN on) (NP (NP (JJ microglial) (NN activation)) (PP (IN in) (NP (NP (JJ different) (NN brain) (NNS regions)) (CC and) (NP (NP (JJ behavioral) (NNS outcomes)) (PP (IN in) (NP (VBG developing) (NNS rats)))))))))) (. .)))
17400887	5	(S1 (S (NP (JJ Newborn) (NNS rats)) (VP (AUX were) (VP (VP (VBN given) (NP (NP (NNP Doc_17400887_702_713_Chemical) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (NN daily)) (PP (IN on) (NP (JJ postnatal) (NNS days))) (PRN (-LRB- -LRB-) (NP (NNP PN)) (-RRB- -RRB-))) (NP (NP (QP (CD 2) (TO to) (CD 5))) (CC or) (NP (QP (CD PN) (CD 11)))) (PP (TO to) (NP (CD 14)))) (CC and) (VP (VBN examined) (NP (CD 24) (NNP h)) (PP (PP (IN after) (NP (DT the) (JJ last) (NN dose))) (CC and) (PP (IN at) (NP (NNP PN) (CD 30))))))) (. .)))
17400887	6	(S1 (S (NP (JJ Immunohistochemical) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_17400887_886_897_Chemical))) (PP (IN on) (NP (NP (NNP PN)) (QP (CD 2) (TO to) (CD 5))))) (VP (VBD produced) (NP (NP (DT a) (JJ robust) (NN increase)) (PP (IN in) (NP (NP (JJ microglial) (NN activation)) (PP (IN on) (NP (NNP PN) (CD 30))))) (PP (IN in) (NP (DT the) (JJ cerebral) (NN cortex))) (, ,) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (NN cerebellar)) (CC and) (NP (JJ cerebrocortical) (JJ white) (NN matter)))))))))) (. .)))
17400887	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN given) (NP (NNP Doc_17400887_1103_1114_Chemical)) (PP (IN on) (S (VP (VBG PN) (NP (CD 11)) (PP (TO to) (NP (CD 14)))))))))) (. .)))
17400887	8	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS tests))) (, ,) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17400887_1173_1184_Chemical))) (PP (IN on) (NP (QP (CD PN) (CD 2) (TO to) (CD 5)))))) (VP (VBD showed) (NP (NP (JJ consistent) (NNS patterns)) (PP (IN of) (NP (NN hyper-reactivity)))) (PP (TO to) (NP (NP (NN novelty)) (CC and) (NP (JJ aversive) (NNS stimuli)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN assessed) (PP (PP (IN in) (NP (DT a) (JJ novel) (JJ open) (NN field))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT the) (JJ acoustic) (JJ startle) (NN response) (NN test)))))))) (. .)))
17400887	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (S (NP (NP (DT that) (JJ beta2-adrenoceptor) (NN overstimulation)) (PP (IN during) (NP (DT an) (JJ early) (JJ critical) (NN period)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ microglial) (NN activation)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ innate) (NN neuroinflammatory) (NNS pathways)) (CC and) (NP (NP (NNP Doc_17400887_1545_1569_Disease)) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN described) (PP (IN in) (NP (NNP Doc_17400887_1601_1607_Disease))))))))))))))))) (. .)))
17400887	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ provides) (NP (NP (DT a) (JJ useful) (NN animal) (NN model)) (PP (IN for) (S (VP (VBG understanding) (NP (NP (DT the) (JJ neuropathological) (NNS processes)) (VP (VBG underlying) (NP (NN Doc_17400887_1712_1737_Disease))))))))) (. .)))
17437408	0	(S1 (S (NP (NP (NN Upregulation)) (PP (IN of) (NP (NP (NN brain) (NN expression)) (PP (IN of) (NP (NNP P-glycoprotein))))) (PP (IN in) (NP (NP (JJ MRP2-deficient) (NNS TR)) (SBAR (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats))))))) (VP (VBZ resembles) (NP (NP (JJ Doc_17437408_90_97_Disease-induced) (NN up-regulation)) (PP (IN of) (NP (DT this) (NN drug) (NN efflux) (NN transporter))) (PP (IN in) (NP (JJ normal) (NNS rats))))) (. .)))
17437408	1	(S1 (S (NP (NP (NP (DT The) (JJ multidrug) (NN resistance) (NN protein)) (NP (CD 2))) (PRN (-LRB- -LRB-) (NP (NNP MRP2)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN drug) (NN efflux) (NN transporter)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX is) (VP (VBN expressed) (ADVP (RB predominantly)) (PP (IN at) (NP (NP (DT the) (JJ apical) (NN domain)) (PP (IN of) (NP (NNS hepatocytes))))))) (CC but) (VP (VBZ seems) (S (ADVP (RB also)) (VP (TO to) (VP (AUX be) (VP (VBN expressed) (PP (IN at) (NP (NP (DT the) (JJ apical) (NN membrane)) (PP (IN of) (NP (NP (NN brain) (NN capillary) (NN endothelial) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
17437408	2	(S1 (S (NP (NNP MRP2)) (VP (AUX is) (ADJP (JJ absent)) (PP (IN in) (NP (DT the) (NN transport-deficient))) (PRN (-LRB- -LRB-) (NNP TR) (-LRB- -LRB-) (S (NP (LST (: -) (-RRB- -RRB-) (-RRB- -RRB-)) (NNP Wistar) (NN rat)) (ADJP (JJ mutant))) (, ,)) (SBAR (RB so) (IN that) (S (NP (DT this) (NN rat) (NN strain)) (VP (AUX was) (ADJP (RB very) (JJ helpful) (PP (IN in) (S (VP (VBG defining) (NP (NNS substrates)) (PP (IN of) (NP (NNP MRP2))) (PP (IN by) (S (VP (VBG comparing) (NP (NP (NN tissue) (NNS concentrations)) (CC or) (NP (NP (JJ functional) (NNS activities)) (PP (IN of) (NP (NNS compounds))))) (PP (IN in) (NP (NP (JJ MRP2-deficient) (NNS rats)) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ transport-competent) (NNP Wistar) (NNS rats)))))))))))))))))) (. .)))
17437408	3	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (DT this) (NN strategy)) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NN MRP2))) (PP (IN in) (NP (NP (NN brain) (NN access)) (PP (IN of) (NP (NP (JJ antiepileptic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS AEDs)) (-RRB- -RRB-))))))))))))) (, ,) (NP (PRP we)) (ADVP (RB recently)) (VP (VBD reported) (SBAR (IN that) (S (NP (NNP Doc_17437408_861_870_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NNS MRP2)) (PP (IN in) (NP (DT the) (NNP BBB)))))))))) (. .)))
17437408	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD one) (NN drawback)) (PP (IN of) (NP (JJ such) (NNS studies))) (PP (IN in) (NP (ADJP (RB genetically) (JJ deficient)) (NNS rats)))) (VP (AUX is) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (JJ compensatory) (NNS changes)) (PP (IN with) (NP (NP (NN upregulation)) (PP (IN of) (NP (JJ other) (NNS transporters)))))) (VP (MD can) (VP (VB occur))))))) (. .)))
17437408	5	(S1 (S (NP (DT This)) (VP (VBD prompted) (NP (PRP us)) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN brain) (NN expression)) (PP (IN of) (NP (NP (NP (NNP P-glycoprotein)) (PRN (-LRB- -LRB-) (NP (NNP Pgp)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ major) (NN drug) (NN efflux) (NN transporter)) (PP (IN in) (NP (JJ many) (NNS tissues))) (, ,) (PP (VBG including) (NP (NP (DT the) (NNP BBB)) (, ,) (PP (IN in) (NP (NNP TR) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (JJ nonmutant) (PRN (-LRB- -LRB-) (JJ wild-type) (-RRB- -RRB-)) (NNP Wistar) (NNS rats)))))))))))))))) (. .)))
17437408	6	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NNP MRP2)) (CC and) (NP (NNP Pgp)))) (PP (IN in) (NP (NP (NN brain) (CC and) (NN liver) (NNS sections)) (PP (IN of) (NP (NNP TR) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (CC and) (NP (JJ normal) (NNP Wistar) (NNS rats))))))) (VP (AUX was) (VP (VBN determined) (PP (IN with) (NP (NN immunohistochemistry))) (, ,) (PP (IN by) (S (VP (VBG using) (NP (NP (DT a) (JJ novel) (, ,) (ADJP (RB highly) (JJ selective)) (JJ monoclonal) (NN MRP2) (NN antibody)) (CC and) (NP (NP (DT the) (JJ monoclonal) (NNP Pgp) (NN antibody)) (NP (NP (CD C219)) (, ,) (ADVP (RB respectively)))))))))) (. .)))
17437408	7	(S1 (S (NP (NP (JJ Immunofluorescence) (NN staining)) (PP (IN with) (NP (DT the) (JJ MRP2) (NN antibody)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB label) (NP (NP (DT a) (JJ high) (NN number)) (PP (IN of) (NP (NNS microvessels)))) (PP (IN throughout) (NP (NP (DT the) (NN brain)) (PP (IN in) (NP (JJ normal) (NNP Wistar) (NNS rats)))))))) (, ,) (SBAR (IN whereas) (S (NP (JJ such) (VBG labeling)) (VP (AUX was) (ADJP (JJ absent) (PP (IN in) (S (VP (VBG TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats)))))))))))) (. .)))
17437408	8	(S1 (S (NP (NNP TR)) (-LRB- -LRB-) (LST (: -) (-RRB- -RRB-)) (NP (NNS rats)) (VP (VBD exhibited) (NP (NP (DT a) (JJ significant) (NN up-regulation)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (NN brain) (NN capillary) (JJ endothelial) (NNS cells)))) (PP (VBN compared) (PP (IN with) (NP (JJ wild-type) (NNS controls))))) (. .)))
17437408	9	(S1 (S (NP (NP (DT No) (JJ such) (JJ obvious) (NN upregulation)) (PP (IN of) (NP (NNP Pgp)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NN liver) (NNS sections))))) (. .)))
17437408	10	(S1 (S (NP (NP (DT A) (JJ comparable) (NN overexpression)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (DT the) (NNP BBB)))) (VP (AUX was) (VP (VBN obtained) (PP (IN after) (NP (NP (JJ Doc_17437408_1987_1998_Chemical-induced) (NN Doc_17437408_2007_2015_Disease)) (PP (IN in) (NP (JJ wild-type) (JJ Wistar) (NNS rats))))))) (. .)))
17437408	11	(S1 (S (S (NP (NP (NNS Experiments)) (PP (IN with) (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (DT the) (NNP Pgp)))))) (VP (VBP substrate) (NP (NP (NNP Doc_17437408_2104_2117_Chemical)) (CC and) (NP (DT the) (JJ selective) (NNP Pgp) (FW inhibitor) (NNP Doc_17437408_2150_2160_Chemical))) (PP (IN in) (NP (NNP TR))))) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (VP (VBD substantiated) (SBAR (IN that) (S (NP (NNP Pgp)) (VP (VP (AUX is) (ADJP (JJ functional))) (CC and) (VP (VBZ compensates) (PP (IN for) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (NNS MRP2)) (PP (IN in) (NP (DT the) (NNP BBB)))))))))))) (. .)))
17437408	12	(S1 (S (NP (NP (DT The) (NNS data)) (PP (IN on) (S (VP (VBG TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats))))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Pgp)) (VP (VBZ plays) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN compensation)) (PP (IN of) (NP (CD MRP2) (NN deficiency))) (PP (IN in) (NP (DT the) (NNP BBB)))))))))) (. .)))
17437408	13	(S1 (S (SBAR (IN Because) (S (NP (PDT such) (DT a) (JJ compensatory) (NN mechanism)) (ADVP (RBS most) (RB likely)) (VP (VBZ occurs) (S (VP (TO to) (VP (VB reduce) (NP (NNP Doc_17437408_2457_2476_Disease)) (PP (IN from) (NP (JJ cytotoxic) (NNS compounds))))))))) (, ,) (NP (DT the) (JJ present) (NNS data)) (VP (VB substantiate) (NP (NP (DT the) (NN concept)) (SBAR (WHNP (WDT that)) (S (ADVP (RB MRP2)) (VP (VBZ performs) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN in) (NP (DT the) (NNP BBB))))))))) (. .)))
17437408	14	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats)))) (VP (AUX are) (NP (NP (DT an) (JJ interesting) (NN tool)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (NNS consequences)) (PP (IN of) (NP (NP (NN overexpression)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (NP (DT the) (NNP BBB)) (PP (IN on) (NP (NP (NN access)) (PP (IN of) (NP (NNS drugs))))) (PP (IN in) (NP (DT the) (NN brain)))))))) (, ,) (PP (IN without) (NP (NP (DT the) (NN need)) (PP (IN of) (S (VP (VBG inducing) (NP (NP (NNP Doc_17437408_2784_2792_Disease)) (CC or) (NP (JJ other) (JJ Pgp-enhancing) (NNS events))) (PP (IN for) (NP (DT this) (NN purpose))))))))))))))))) (. .)))
17439425	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (JJ Doc_17439425_8_16_Chemical) (NN oxidase))) (PP (IN in) (NP (NP (NNP Doc_17439425_28_41_Chemical-induced) (NNP Doc_17439425_50_62_Disease)) (PP (IN in) (NP (NNP rats.) (CD 1))))) (. .)))
17439425	1	(S1 (S (NP (NP (NP (JJ Glucocorticoid-induced) (NNP Doc_17439425_98_110_Disease)) (PRN (-LRB- -LRB-) (NP (NNP GC-Doc_17439425_115_117_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN rat)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17439425_149_161_Chemical-redox) (FW imbalance.) (CD 2))))) (. .)))
17439425	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NP (NNP Doc_17439425_205_213_Chemical) (NNP oxidase)) (PRN (-LRB- -LRB-) (NP (NNP XO)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ reactive) (NN oxygen) (NNS species))))))))) (, ,))) (PP (IN in) (NP (NP (NNP Doc_17439425_297_310_Chemical-induced) (NNP Doc_17439425_319_331_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17439425_333_336_Chemical-Doc_17439425_337_339_Disease)) (-RRB- -RRB-)) (. .) (CD 3))))) (. .)))
17439425	3	(S1 (S (NP (CD Thirty) (JJ male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN divided) (ADVP (RB randomly)) (PP (IN into) (NP (NP (CD four) (NN treatment) (NNS groups)) (: :) (NP (NP (NP (NNP saline)) (, ,) (NP (NNP Doc_17439425_435_448_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17439425_450_453_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_17439425_456_467_Chemical)) (CC plus) (NP (NN saline))) (, ,) (CC and) (NP (NNP Doc_17439425_485_496_Chemical)) (CC plus) (NP (NNP Doc_17439425_502_505_Chemical.) (CD 4))))))) (. .)))
17439425	4	(S1 (S (NP (NP (NP (JJ Systolic) (NN blood) (NNS pressures)) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-))) (CC and) (NP (NNS bodyweights))) (VP (AUX were) (VP (VBN recorded) (NP (DT each) (JJ alternate) (NN day)))) (. .)))
17439425	5	(S1 (S (S (NP (JJ Thymus) (NN weight)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ glucocorticoid) (NN activity)))))))) (, ,) (CC and) (S (NP (NN serum)) (ADJP (JJ Doc_17439425_664_669_Chemical) (S (VP (TO to) (VP (VB assess) (NP (NN XO) (NN inhibition.) (CD 5))))))) (. .)))
17439425	6	(S1 (NP (NP (NP (NP (NNP Doc_17439425_698_701_Chemical) (NNP Doc_17439425_702_715_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 110) (CD +/-)) (JJ 2-126) (JJ +/-) (CD 3) (NN mmHg)) (: ;) (NP (NNP P) (NNP <) (CD 0.001))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17439425_758_802_Disease))) (PRN (-LRB- -LRB-) (NP (NNP P) ('' '') (NNP <) (CD 0.01)) (-RRB- -RRB-)) (. .)))
17439425	7	(S1 (S (NP (NNP Doc_17439425_816_827_Chemical)) (VP (VBD decreased) (NP (NN serum)) (NP (NNP Doc_17439425_844_849_Chemical)) (PP (PP (IN from) (NP (NP (NP (QP (CD 76) (JJ +/-) (CD 5) (TO to) (CD 30) (NN +/-))) (NP (NP (QP (CD 3) (CD micromol/L))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))) (PP (IN in) (NP (NN saline))))) (CC and) (PP (IN from) (NP (NP (NP (CD 84) (NN +/-)) (NP (QP (CD 13) (TO to) (CD 28)) (JJ +/-) (CD 2) (NNS micromol/L))) (PP (IN in) (NP (JJ Doc_17439425_954_957_Chemical-treated) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)) (JJ groups.) (CD 6))))))) (. .)))
17439425	8	(S1 (S (NP (NN Doc_17439425_988_999_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NN Doc_17439425_1016_1019_Chemical-Doc_17439425_1020_1022_Disease)))) (. .)))
17439425	9	(S1 (S (NP (DT This)) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (PRP$ our) (JJ previous) (NNS findings)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_17439425_1071_1082_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (NP (JJ adrenocorticotrophic) (NN hormone)) (VP (VBN induced) (NP (NNP Doc_17439425_1138_1150_Disease)))))))))))) (, ,) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN XO) (NN activity)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ major) (NN determinant)) (PP (IN of) (NP (NN GC-Doc_17439425_1211_1213_Disease)))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
17466854	0	(S1 (NP (NP (JJ Side) (NNS effects)) (PP (IN of) (NP (NP (NN postoperative) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_17466854_48_66_Chemical)) (CC and) (NP (NNP Doc_17466854_71_81_Chemical)))))) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))) (. .)))
17466854	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (JJ emetic) (NN side) (NNS effects))) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_17466854_218_236_Chemical) (CC and) (NNP Doc_17466854_241_251_Chemical)))))) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (JJ routine) (JJ Doc_17466854_311_319_Disease) (NN surgery)))))))) (. .)))
17466854	2	(S1 (S (NP (NNP St.) (NNP Luke)) (VP (AUX 's) (NP (NNP Hospital) (, ,) (NNP Gwardamangia) (, ,) (NNP Malta))) (. .)))
17466854	3	(S1 (S (NP (DT A) (JJ double-blind) (JJ double-armed) (JJ prospective) (NN study)) (VP (VBN comprised) (NP (NP (CD 40) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ uneventful) (NN sutureless) (NN phacoemulsification)) (PP (IN under) (NP (NP (NP (NN sub-Tenon) (POS 's)) (JJ local) (NN infiltration)) (PP (IN of) (NP (NP (CD 3) (NN mL)) (PP (IN of) (NP (JJ plain) (NNP Doc_17466854_561_571_Chemical)))))))))))) (. .)))
17466854	4	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN procedure))))) (, ,) (S (NP (NP (NNP Group) (NNP A)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (NP (NP (QP (CD 20) (CD mg/0.5)) (NNS mL)) (PP (IN of) (NP (NNP Doc_17466854_639_657_Chemical)))) (CC and) (NP (NP (QP (CD 10) (CD mg/0.5)) (NNS mL)) (PP (IN of) (NP (NNP Doc_17466854_678_688_Chemical))))) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))))))) (CC and) (S (NP (NP (NNP Group) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT the) (JJ same) (NN combination)) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (NNP anterior) (NN sub-Tenon) (POS 's)) (NN space))))))) (. .)))
17466854	5	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (DT all) (NNS patients)) (VP (AUX were) (VP (VBN assessed) (PP (IN for) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_17466854_887_903_Disease)) (, ,) (CC and) (NP (NNP Doc_17466854_909_917_Disease)))))))) (. .)))
17466854	6	(S1 (S (NP (DT A) (JJ chi-square) (NN test)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ statistical) (NN significance)) (PP (IN of) (NP (NNS results))))))))) (. .)))
17466854	7	(S1 (S (S (NP (NP (CD Sixty) (NN percent)) (PP (IN in) (NP (NNP Group) (NNP A)))) (VP (VBD developed) (NP (NP (NN Doc_17466854_1041_1070_Disease)) (, ,) (NP (NN Doc_17466854_1072_1080_Disease)) (, ,) (CC or) (NP (DT both))))) (: ;) (S (NP (NP (CD 1) (NN patient)) (PP (IN in) (NP (NNP Group) (NNP B)))) (VP (VBD developed) (NP (NNS symptoms)))) (. .)))
17466854	8	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_17466854_1167_1185_Chemical)) (CC and) (NP (NNP Doc_17466854_1190_1200_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NNP Doc_17466854_1294_1310_Disease)) (, ,) (CC and) (NP (NNP Doc_17466854_1316_1324_Disease)))))))))) (. .)))
17466854	9	(S1 (S (NP (DT All) (JJ adverse) (NNS effects)) (VP (AUX were) (ADJP (JJ self-limiting))) (. .)))
17491223	0	(S1 (NP (NP (NN Assessment)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ non-invasive) (NN index)) (PP (IN of) (NP (JJ cardiac) (NN performance))))) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NNP Doc_17491223_79_89_Chemical-induced) (NNP Doc_17491223_98_117_Disease))))) (. .)))
17491223	1	(S1 (S (NP (NN Electrocardiography)) (VP (AUX has) (NP (NP (DT a) (ADJP (RB very) (JJ low)) (NN sensitivity)) (PP (IN in) (S (VP (VBG detecting) (NP (JJ Doc_17491223_191_201_Chemical-induced) (NNP Doc_17491223_210_229_Disease))))))) (. .)))
17491223	2	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (VBN added) (JJ diagnostic) (NN value)) (PP (IN of) (NP (DT a) (JJ new) (JJ cardiac) (NN performance) (NN index) (PRN (-LRB- -LRB-) (JJ dP/dtejc) (-RRB- -RRB-)) (NN measurement))))))) (, ,) (VP (VBN based) (PP (IN on) (NP (JJ brachial) (NN artery) (NN flow) (NNS changes))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ standard) (JJ 12-lead) (NNS ECG))) (, ,) (PP (IN for) (S (VP (VBG detecting) (NP (JJ Doc_17491223_429_439_Chemical-induced) (NNP Doc_17491223_448_467_Disease))))) (, ,) (S (VP (VBG using) (NP (NNP Doc_17491223_475_490_Chemical) (NN single-photon) (NN emission) (JJ computed) (NN tomography)) (PP (IN as) (NP (NP (DT the) (JJ gold) (NN standard)) (PP (IN of) (NP (NN comparison))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN presence)) (CC or) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_17491223_606_614_Disease)))))))))))))))) (. .)))
17491223	3	(S1 (S (NP (DT The) (NN study) (NN group)) (VP (VBN comprised) (NP (NP (CD 40) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_17491223_674_683_Chemical-SPECT/Doc_17491223_690_700_Chemical) (NN stress) (NN test))))) (. .)))
17491223	4	(S1 (S (NP (NP (JJ Simultaneous) (NNS measurements)) (PP (IN of) (NP (NP (NNS ECG)) (CC and) (NP (JJ brachial) (NN artery) (NNS dP/dtejc))))) (VP (AUX were) (VP (VBN performed) (PP (IN at) (NP (DT each) (JJ Doc_17491223_799_809_Chemical) (NN level))))) (. .)))
17491223	5	(S1 (S (NP (NP (QP (IN In) (CD 19))) (PP (IN of) (NP (DT the) (CD 40) (NNS patients)))) (VP (VBP perfusion) (SBAR (S (NP (NP (NNS defects)) (ADJP (JJ compatible) (PP (IN with) (NP (NNP Doc_17491223_876_884_Disease))))) (VP (AUX were) (VP (VBN detected) (PP (IN on) (NP (NN SPECT)))))))) (. .)))
17491223	6	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN dP/dtejc))) (PP (IN during) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_17491223_953_963_Chemical))))) (PP (IN in) (NP (DT this) (NN group)))) (VP (AUX was) (ADJP (RB severely) (JJ impaired)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (JJ non-ischemic) (NN group))))))) (. .)))
17491223	7	(S1 (S (NP (JJ dP/dtejc) (NN outcome)) (VP (AUX was) (VP (VP (VBN combined) (PP (IN with) (NP (DT the) (JJ ECG) (NNS results))) (, ,) (S (VP (VBG giving) (NP (DT an) (JJ ECG-enhanced) (NN value))))) (, ,) (CC and) (VP (VBN compared) (S (VP (TO to) (VP (VB ECG) (ADVP (RB alone)))))))) (. .)))
17491223	8	(S1 (S (S (NP (DT The) (NN sensitivity)) (VP (VBD improved) (ADVP (RB dramatically) (PP (IN from) (NP (CD 16) (NN %)))) (PP (TO to) (NP (CD 79) (NN %))))) (, ,) (S (NP (JJ positive) (JJ predictive) (NN value)) (VP (VBD increased) (PP (IN from) (NP (NP (QP (CD 60) (NN %) (TO to) (CD 68)) (NN %)) (CC and) (NP (JJ negative) (JJ predictive) (NN value)))) (PP (IN from) (NP (CD 54) (NN %))) (PP (TO to) (NP (CD 78) (NN %))))) (, ,) (CC and) (S (NP (NN specificity)) (VP (VBD decreased) (PP (IN from) (NP (CD 90) (NN %))) (PP (TO to) (NP (CD 67) (NN %))))) (. .)))
17491223	9	(S1 (S (SBAR (IN If) (S (NP (NP (NN ECG)) (ADVP (RB alone))) (VP (AUX is) (VP (VBN used) (PP (IN for) (NP (NN specificity))))))) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN with) (NP (NNS dP/dtejc)))) (VP (VP (VBD improved) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN test))))) (CC and) (VP (MD could) (VP (AUX be) (NP (NP (DT a) (JJ cost-savings) (NN alternative)) (PP (TO to) (NP (JJ cardiac) (NN imaging) (CC or) (NN perfusion) (NNS studies)))) (S (VP (TO to) (VP (VB detect) (NP (NNP Doc_17491223_1562_1581_Disease))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (ADJP (JJ unable) (PP (TO to) (NP (NN exercise))))))))) (. .)))
1749407	0	(S1 (NP (NP (JJ Doc_1749407_0_7_Chemical-induced) (NNP Doc_1749407_16_37_Disease)) (: :) (NP (NP (JJ clinical) (NNS observations)) (CC and) (NP (JJ pathogenetic) (NNS considerations))) (. .)))
1749407	1	(S1 (S (NP (NP (ADJP (ADJP (JJ Clinical)) (CC and) (ADJP (JJ experimental))) (NNS data)) (VP (VBN published) (PP (TO to) (NP (NN date))))) (VP (VBP suggest) (NP (NP (JJ several) (JJ possible) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_1749407_188_195_Chemical)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NNP Doc_1749407_210_237_Disease))))))))) (. .)))
1749407	2	(S1 (S (PP (IN In) (NP (NP (NNS individuals)) (PP (IN with) (NP (NN preexisting))))) (, ,) (NP (NP (JJ high-grade) (JJ coronary) (NN arterial) (NN narrowing)) (, ,) (NP (NNP Doc_1749407_312_339_Disease))) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ myocardial) (JJ Doc_1749407_382_388_Chemical) (NN demand)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_1749407_412_419_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ rate-pressure) (NN product)))))))))))) (. .)))
1749407	3	(S1 (S (PP (IN In) (NP (NP (JJ other) (NNS individuals)) (PP (IN with) (NP (DT no) (JJ underlying) (NN Doc_1749407_503_530_Disease))))) (, ,) (NP (NNP Doc_1749407_532_550_Disease)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_1749407_565_570_Disease)) (, ,) (NP (NNP Doc_1749407_572_580_Disease)) (, ,) (CC or) (NP (DT both))))))) (. .)))
1749407	4	(S1 (S (PP (IN With) (NP (NP (NN regard)) (PP (TO to) (NP (NNP Doc_1749407_606_611_Disease))))) (, ,) (S (NP (DT the) (JJ clinical) (NNS findings)) (VP (AUX are) (ADVP (RB largely)) (NP (NN circumstantial)))) (, ,) (CC and) (S (NP (NP (DT the) (NN locus)) (PP (IN of) (NP (JJ Doc_1749407_680_687_Chemical-induced) (NN vasoconstriction)))) (VP (VBZ remains) (ADJP (JJ speculative)))) (. .)))
1749407	5	(S1 (S (SBAR (IN Although) (S (NP (JJ certain) (JJ clinical) (CC and) (JJ experimental) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_1749407_814_819_Disease)) (VP (VBZ involves) (NP (DT the) (JJ epicardial) (, ,) (JJ medium-size) (NNS vessels))))))))) (, ,) (NP (JJ other) (NNS data)) (VP (VBP suggest) (NP (JJ intramural) (NN vasoconstriction))) (. .)))
1749407	6	(S1 (S (NP (JJ Diffuse) (NN intramural) (NN vasoconstriction)) (VP (AUX is) (RB not) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ segmental) (, ,) (JJ discrete) (NNP Doc_1749407_1004_1014_Disease))))))) (. .)))
1749407	7	(S1 (S (SBAR (IN Whereas) (S (ADJP (JJ certain)) (SBAR (IN in) (S (NP (NN vivo) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (AUX are) (ADJP (JJ alpha-mediated)))))))))) (, ,) (NP (JJ other) (ADJP (IN in) (NN vitro)) (NNS data)) (VP (VBP suggest) (NP (DT the) (NN opposite))) (. .)))
1749407	8	(S1 (S (NP (NP (DT The) (NN finding)) (PP (IN of) (NP (JJ Doc_1749407_1149_1156_Chemical-induced) (NN vasoconstriction))) (PP (IN in) (NP (NP (NNS segments)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (JJ noninnervated) (-RRB- -RRB-)) (JJ human) (NN umbilical) (NN artery)))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (JJ intact) (NN innervation)))) (VP (AUX is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB explain) (NP (NP (DT the) (JJ discrepant) (NNS data)) (VP (VBG involving) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ alpha-mediated) (NNS effects)))))))))))))) (. .)))
1749407	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (DT a) (JJ primary) (, ,) (JJ Doc_1749407_1438_1448_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_1749407_1459_1466_Chemical)))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN excluded)))) (. .)))
17532790	0	(S1 (NP (NP (JJ Proteomic) (NN analysis)) (PP (IN of) (NP (NP (JJ striatal) (NNS proteins)) (PP (IN in) (NP (NP (DT the) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_17532790_60_66_Chemical-induced) (NNP Doc_17532790_75_85_Disease))))))) (. .)))
17532790	1	(S1 (S (NP (NP (JJ Doc_17532790_87_93_Chemical-induced) (NNP Doc_17532790_102_112_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17532790_114_117_Disease)) (-RRB- -RRB-))) (VP (AUX is) (PP (IN among) (NP (NP (DT the) (NN motor) (NNS complications)) (SBAR (WHNP (WDT that)) (S (VP (VBP arise) (PP (IN in) (NP (NNP Doc_17532790_166_185_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_17532790_187_189_Disease)) (-RRB- -RRB-)) (NNS patients))) (PP (IN after) (NP (NP (DT a) (JJ prolonged) (NN treatment)) (PP (IN with) (NP (NNP Doc_17532790_233_239_Chemical))))))))))) (. .)))
17532790	2	(S1 (S (PP (TO To) (NP (DT this) (NN day))) (, ,) (NP (JJ transcriptome) (NN analysis)) (VP (AUX has) (VP (AUX been) (VP (VBN performed) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (JJ Doc_17532790_314_317_Disease) (NN -LSB-Neurobiol)))))))) (. .)))
17532790	3	(S1 (S (NP (NP (NP (NN Dis.)) (, ,) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 2004)) (-RRB- -RRB-))) (, ,) (NP (CD 219) (NN -RSB-)) (CC but) (NP (NN information))) (VP (VBG regarding) (NP (DT the) (NN proteome)))) (VP (AUX is) (ADVP (RB still)) (VP (VBG lacking))) (. .)))
17532790	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS changes)) (VP (VBG occurring) (PP (IN at) (NP (DT the) (NN protein) (NN level))) (PP (IN in) (NP (NP (JJ striatal) (NNS samples)) (VP (VBN obtained) (PP (IN from) (NP (NP (NP (DT the) (ADJP (RB unilaterally) (JJ Doc_17532790_541_558_Chemical-lesion)) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_17532790_579_581_Disease))) (VP (VBN treated) (PP (IN with) (NP (NN saline))))) (, ,) (NP (NNP Doc_17532790_603_609_Chemical)) (CC or) (NP (NNP Doc_17532790_613_626_Chemical)))) (S (VP (VBG using) (NP (NP (JJ two-dimensional) (NN difference) (NN gel) (NNS electrophoresis)) (CC and) (NP (NP (JJ mass) (NN spectrometry)) (PRN (-LRB- -LRB-) (NP (NNP MS)) (-RRB- -RRB-)))))))))))) (. .)))
17532790	5	(S1 (S (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17532790_726_732_Chemical))))) (VP (AUX were) (VP (VBN allocated) (PP (TO to) (NP (NP (CD two) (NNS groups)) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NN Doc_17532790_798_801_Disease)))))))))) (. .)))
17532790	6	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 2000) (NNS spots)) (PP (VBN compared) (PP (IN for) (NP (JJ statistical) (NN difference)))))) (, ,) (NP (CD 67) (NNS spots)) (VP (VP (AUX were) (VP (ADVP (RB significantly)) (VBN changed) (PP (IN in) (NP (NN abundance))))) (CC and) (VP (VBN identified) (S (VP (VBG using) (NP (NP (JJ matrix-assisted) (NN laser) (NN desorption/ionization) (NN time-of-flight) (NNS MS)) (, ,) (NP (JJ atmospheric) (NN pressure) (JJ matrix-assisted) (NN laser) (NN desorption/ionization)) (CC and) (NP (NP (JJ HPLC) (VBN coupled) (NN tandem) (NNS MS)) (PRN (-LRB- -LRB-) (NP (NNP LC/MS/MS)) (-RRB- -RRB-)))))))) (. .)))
17532790	7	(S1 (S (PP (IN Out) (PP (IN of) (NP (DT these) (CD 67) (NNS proteins)))) (, ,) (NP (NNP Doc_17532790_1124_1127_Disease)) (ADVP (RB significantly)) (VP (VBD changed) (NP (NP (DT the) (NN expression) (NN level)) (PP (IN of) (NP (NP (CD five) (NNS proteins)) (: :) (NP (NP (NN alphabeta-crystalin)) (, ,) (NP (NN gamma-enolase)) (, ,) (NP (NN guanidoacetate) (NN methyltransferase)) (, ,) (NP (NN vinculin)) (, ,) (CC and) (NP (JJ proteasome) (JJ alpha-2) (NN subunit))))))) (. .)))
17532790	8	(S1 (S (NP (NP (JJ Complementary) (NNS techniques)) (PP (JJ such) (IN as) (NP (NP (JJ western) (NN immunoblotting)) (CC and) (NP (NN immunohistochemistry))))) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN validity)) (PP (IN of) (NP (NP (DT the) (NNS data)) (VP (VBN obtained) (S (VP (VBG using) (NP (DT the) (JJ proteomic) (NN approach))))))))))))) (. .)))
17532790	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT this) (NN study)) (VP (VBZ provides) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN protein) (NNS changes)) (VP (VBG occurring) (PP (IN in) (NP (NNP Doc_17532790_1562_1565_Disease)))))))) (. .)))
17562951	0	(S1 (NP (NP (NP (NNP Cardiac) (NNP Angiography)) (PP (IN in) (NP (NNP Renally) (JJ Impaired) (NNPS Patients) (PRN (-LRB- -LRB-) (NP (NN CARE)) (-RRB- -RRB-)) (NN study)))) (: :) (NP (NP (DT a) (JJ randomized) (NN double-blind) (NN trial)) (PP (IN of) (NP (JJ contrast-induced) (NNP Doc_17562951_115_126_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_144_166_Disease)))))) (. .)))
17562951	1	(S1 (S (NP (DT No) (JJ direct) (NNS comparisons)) (VP (VBP exist) (PP (IN of) (NP (NP (DT the) (JJ renal) (NN tolerability)) (PP (IN of) (NP (DT the) (JJ low-osmolality) (NNP Doc_17562951_256_271_Chemical) (NNP Doc_17562951_272_281_Chemical))))) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ iso-osmolality) (NNP Doc_17562951_314_329_Chemical) (NNP Doc_17562951_330_339_Chemical)) (PP (IN in) (NP (JJ high-risk) (NNS patients)))))))) (. .)))
17562951	2	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (DT The) (JJ present) (NN study)) (VP (AUX is) (NP (NP (DT a) (NN multicenter) (, ,) (VBN randomized) (, ,) (JJ double-blind) (NN comparison)) (PP (IN of) (NP (NP (NNP Doc_17562951_459_468_Chemical) (CC and) (NNP Doc_17562951_473_482_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_500_522_Disease))) (PRN (-LRB- -LRB-) (NP (NP (JJ estimated) (JJ glomerular) (NN filtration) (NN rate)) (, ,) (NP (QP (CD 20) (TO to) (CD 59)) (NN mL/min))) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (JJ cardiac) (NN angiography)) (CC or) (NP (JJ percutaneous) (JJ coronary) (NNS interventions))))))))))))) (. .)))
17562951	3	(S1 (S (NP (NP (NNP Serum) (NNP Doc_17562951_659_669_Chemical) (PRN (-LRB- -LRB-) (NP (NNP SCr)) (-RRB- -RRB-)) (NNS levels)) (CC and) (NP (VBN estimated) (JJ glomerular) (NN filtration) (NN rate))) (VP (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NN baseline))))) (CC and) (VP (NP (QP (CD 2) (TO to) (CD 5)) (NNS days)) (PP (IN after) (S (VP (VBG receiving) (NP (NNS medications))))))) (. .)))
17562951	4	(S1 (S (NP (DT The) (JJ primary) (NN outcome)) (VP (AUX was) (NP (NP (DT a) (JJ postdose) (NN SCr) (NN increase)) (VP (VBG >) (NP (QP (CC or) (SYM =) (CD 0.5) (CD mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 44.2) (NNS micromol/L)) (-RRB- -RRB-))) (PP (IN over) (NP (NN baseline)))))) (. .)))
17562951	5	(S1 (S (NP (JJ Secondary) (NNS outcomes)) (VP (AUX were) (NP (NP (NP (DT a) (JJ postdose) (NNP SCr) (NN increase)) (VP (VBG >) (CC or) (SYM =) (NP (CD 25) (NN %)))) (, ,) (NP (NP (DT a) (JJ postdose) (JJ estimated) (JJ glomerular) (NN filtration) (NN rate) (NN decrease)) (PP (IN of) (NP (NP (NNS >)) (CC or) (NP (NP (SYM =)) (NP (CD 25) (NN %)))))) (, ,) (CC and) (NP (NP (DT the) (JJ mean) (JJ peak) (NN change)) (PP (IN in) (NP (NNP SCr)))))) (. .)))
17562951	6	(S1 (S (PP (IN In) (NP (CD 414) (NNS patients))) (, ,) (NP (NP (NN contrast) (NN volume)) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (NNP Doc_17562951_1104_1121_Disease)))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNP Doc_17562951_1130_1146_Chemical)) (, ,) (NP (JJ mean) (NN baseline) (NN SCr)) (, ,)))) (CC and) (NP (VBN estimated) (JJ glomerular) (NN filtration) (NN rate))) (VP (AUX were) (ADJP (JJ comparable)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups)))) (. .)))
17562951	7	(S1 (S (NP (NNP SCr) (NNS increases)) (VP (VBG >) (CC or) (SYM =) (S (NP (CD 0.5) (NN mg/dL)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (CD 4.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 9)) (PP (IN of) (NP (CD 204) (NNS patients)))) (-RRB- -RRB-))) (PP (IN after) (NP (NNP Doc_17562951_1315_1324_Chemical)))) (CC and) (NP (NP (CD 6.7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 14)) (PP (IN of) (NP (CD 210) (NNS patients)))) (-RRB- -RRB-))))) (PP (IN after) (NP (NP (NNP Doc_17562951_1361_1370_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P=0.39)) (-RRB- -RRB-)))) (, ,) (PP (IN whereas) (NP (NP (NNS rates)) (PP (IN of) (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =) (S (NP (CD 25) (NN %)) (VP (AUX were) (NP (NP (NP (CD 9.8) (NN %)) (CC and) (NP (CD 12.4) (NN %)) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP P=0.44)) (-RRB- -RRB-)))))))))))) (. .)))
17562951	8	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_1484_1492_Disease))))) (, ,) (S (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =)) (NP (CD 0.5) (NN mg/dL)) (VP (AUX were) (NP (NP (NP (NP (CD 5.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 78) (NNS patients)))) (-RRB- -RRB-))) (PP (IN with) (NP (NNP Doc_17562951_1559_1568_Chemical)))) (CC and) (NP (NP (NP (CD 13.0) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 12)) (PP (IN of) (NP (CD 92) (NNS patients)))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NNP Doc_17562951_1604_1613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P=0.11)) (-RRB- -RRB-)))))))) (, ,) (IN whereas) (S (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =)) (NP (CD 25) (NN %)) (VP (AUX were) (NP (NP (CD 10.3) (NN %)) (CC and) (NP (CD 15.2) (NN %))) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (NNP P=0.37)) (-RRB- -RRB-)))) (. .)))
17562951	9	(S1 (S (NP (JJ Mean) (NN post-SCr) (NNS increases)) (VP (AUX were) (ADJP (RB significantly) (JJR less)) (PP (IN with) (NP (NP (NNP Doc_17562951_1755_1764_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT all) (NNS patients)) (: :) (NP (NP (NP (CD 0.07)) (PP (IN versus) (NP (CD 0.12) (CD mg/dL) (, ,) (CD 6.2) (CC versus) (CD 10.6) (NN micromol/L)))) (, ,) (NP (NNP P=0.03))) (: ;) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_1854_1862_Disease))))) (: :) (NP (NP (CD 0.07)) (CC versus) (NP (CD 0.16) (CD mg/dL) (, ,) (CD 6.2) (CC versus) (CD 14.1) (NN micromol/L)))) (, ,) (NP (NNP P=0.01)) (-RRB- -RRB-))))) (. .)))
17562951	10	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (JJ contrast-induced) (NNP Doc_17562951_1967_1978_Disease))) (, ,) (VP (VBN defined) (PP (IN by) (NP (JJ multiple) (NN end) (NNS points)))) (, ,)) (VP (AUX is) (RB not) (ADJP (RB statistically) (JJ different)) (PP (IN after) (NP (NP (DT the) (JJ intraarterial) (NN administration)) (PP (IN of) (NP (NNP Doc_17562951_2085_2094_Chemical) (CC or) (NNP Doc_17562951_2098_2107_Chemical))) (PP (TO to) (NP (JJ high-risk) (NNS patients))))) (, ,) (PP (IN with) (CC or) (PP (IN without) (NP (NNP Doc_17562951_2147_2164_Disease))))) (. .)))
17562951	11	(S1 (S (NP (NP (DT Any) (JJ true) (NN difference)) (PP (IN between) (NP (DT the) (NNS agents)))) (VP (VP (AUX is) (ADJP (JJ small))) (CC and) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (ADJP (RB clinically) (JJ significant))))))) (. .)))
17600377	0	(S1 (S (NP (NP (DT A) (JJ novel) (NN compound)) (, ,) (NP (NNP Doc_17600377_18_38_Chemical)) (, ,)) (VP (VP (VBZ attenuates) (NP (NNP Doc_17600377_51_69_Disease))) (CC and) (VP (VBZ shows) (NP (NP (JJ neuroprotective) (NNS effects)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo) (NN Doc_17600377_125_133_Disease) (NNS models))))))) (. .)))
17600377	1	(S1 (S (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (ADJP (JJ novel) (CC and) (JJ effective)) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB enhance) (NP (NP (JJ cognitive) (NN function)) (CC and) (NP (NN neuroprotection))))))))))) (, ,) (NP (PRP we)) (ADVP (RB newly)) (VP (VBD synthesized) (NP (NNP Doc_17600377_260_280_Chemical)) (PP (IN by) (NP (NP (DT the) (NN esterification)) (PP (IN of) (NP (NP (NNP Doc_17600377_306_312_Chemical)) (CC and) (NP (NNP Doc_17600377_317_332_Chemical))))))) (. .)))
17600377	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NNP Doc_17600377_380_400_Chemical)) (VP (MD could) (VP (VB improve) (NP (NN Doc_17600377_415_432_Disease)) (PP (PP (IN in) (NP (JJ Doc_17600377_436_447_Chemical-injected) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Doc_17600377_469_495_Chemical-infused) (NNS rats))))))))) (. .)))
17600377	3	(S1 (S (NP (NN Doc_17600377_510_530_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (VP (TO to) (VP (VB attenuate) (NP (NNP Doc_17600377_554_572_Disease)) (PP (IN in) (NP (DT both) (NN rat) (NNS models))) (S (VP (VBG using) (NP (JJ passive) (NN avoidance) (NN test)))))) (CC and) (VP (TO to) (VP (VB reduce) (NP (NP (JJ apoptotic) (NN cell) (NN death)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN of) (NP (DT the) (JJ Doc_17600377_691_717_Chemical-infused) (NNS rats))))))))))))) (. .)))
17600377	4	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (DT the) (JJ neuroprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_17600377_780_800_Chemical))) (PP (IN in) (NP (NN vitro)))) (S (VP (VBG using) (NP (JJ SH-SY5Y) (NNS cells))))) (. .)))
17600377	5	(S1 (S (NP (NNS Cells)) (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_17600377_858_878_Chemical))) (, ,) (SBAR (IN before) (S (VP (VBN exposed) (PP (TO to) (NP (NP (NNP Doc_17600377_898_924_Chemical)) (, ,) (NP (NNP Doc_17600377_926_935_Chemical)) (CC or) (NP (NNP Doc_17600377_939_943_Chemical))))))))) (. .)))
17600377	6	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NNP Doc_17600377_959_979_Chemical)) (VP (VP (ADVP (RB significantly)) (VBD decreased) (NP (JJ apoptotic) (NN cell) (NN death))) (CC and) (VP (VBD reduced) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (, ,) (NP (NN cytochrome) (NN c) (NN release)) (, ,) (CC and) (NP (NN caspase) (CD 3) (NN activation)))))))) (. .)))
17600377	7	(S1 (S (S (VP (VBG Taking) (NP (DT these)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NP (NN vivo) (NNS results)) (ADVP (RB together))))))) (, ,) (NP (PRP$ our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_17600377_1186_1206_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ effective)) (NN candidate)) (PP (IN against) (NP (NNP Doc_17600377_1252_1271_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ wide) (NN spread) (NN Doc_17600377_1309_1323_Disease)) (CC and) (NP (JJ progressive) (NN Doc_17600377_1340_1369_Disease))))))))))))) (. .)))
17608141	0	(S1 (NP (NP (NN Attenuation)) (PP (IN of) (NP (NP (JJ Doc_17608141_15_30_Chemical-induced) (JJ nigrostriatal) (JJ dopaminergic) (NN Doc_17608141_66_79_Disease)) (PP (IN in) (NP (NNS mice))))) (PP (IN by) (NP (JJ Doc_17608141_91_109_Chemical) (NN pretreatment))) (. .)))
17608141	1	(S1 (S (NP (JJ Immunological) (NN activation)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (JJ Doc_17608141_185_200_Chemical-induced) (NN Doc_17608141_209_237_Disease))))))))) (. .)))
17608141	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (NNP Doc_17608141_279_297_Chemical)) (, ,) (NP (NP (DT a) (JJ pro-inflammatory) (CC and) (JJ inflammatory) (NN factor)) (, ,) (NP (NN treatment)))))) (PP (IN in) (S (VP (VBG modulating) (NP (DT the) (JJ Doc_17608141_371_386_Chemical-induced) (JJ nigrostriatal) (NNP Doc_17608141_409_417_Chemical) (NNP Doc_17608141_418_431_Disease)))))) (. .)))
17608141	3	(S1 (S (NP (JJ Doc_17608141_433_451_Chemical) (NN pretreatment)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ basal) (NN body) (NN temperature)) (CC or) (NP (JJ Doc_17608141_510_525_Chemical-elicited) (NNP Doc_17608141_535_547_Disease))) (ADVP (NP (CD three) (NNS days)) (RB later)))) (. .)))
17608141	4	(S1 (S (NP (JJ Such) (JJ systemic) (JJ Doc_17608141_580_598_Chemical) (NN treatment)) (VP (VBD mitigated) (NP (NP (JJ Doc_17608141_619_634_Chemical-induced) (JJ striatal) (NN Doc_17608141_652_660_Chemical)) (CC and) (NP (JJ Doc_17608141_665_695_Chemical) (NNS depletions))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
17608141	5	(S1 (S (SBAR (IN As) (S (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_17608141_772_790_Chemical)))) (VP (AUX was) (VP (VBN administered) (NP (NP (CD two) (NNS weeks)) (, ,) (NP (CD one) (NN day))) (PP (IN before) (CC or) (IN after) (NP (DT the) (JJ Doc_17608141_847_862_Chemical) (NN dosing) (NN regimen))))))) (, ,) (NP (JJ Doc_17608141_879_894_Chemical-induced) (JJ striatal) (UCP (NNP Doc_17608141_912_920_Chemical) (CC and) (NNP Doc_17608141_925_955_Chemical)) (NNS depletions)) (VP (VBD remained) (ADJP (JJ unaltered))) (. .)))
17608141	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ systemic) (JJ Doc_17608141_1006_1024_Chemical) (NN pretreatment)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD attenuated) (NP (JJ local) (NNP Doc_17608141_1065_1080_Chemical) (JJ infusion-produced) (NNP Doc_17608141_1099_1107_Chemical) (CC and) (NNP Doc_17608141_1112_1142_Chemical) (NNS depletions)) (PP (IN in) (NP (DT the) (NN striatum))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_17608141_1212_1230_Chemical)))) (VP (AUX is) (ADJP (ADVP (RBR less) (RB likely)) (JJ due) (PP (TO to) (NP (NP (JJ interrupted) (JJ peripheral) (NN distribution)) (CC or) (NP (NP (NN metabolism)) (PP (IN of) (NP (NNP Doc_17608141_1306_1321_Chemical))))))))))))) (. .)))
17608141	7	(S1 (S (NP (PRP We)) (VP (VBD concluded) (NP (NP (DT a) (JJ critical) (NN time) (NN window)) (PP (IN for) (NP (NP (JJ systemic) (JJ Doc_17608141_1372_1390_Chemical) (NN pretreatment)) (PP (IN in) (S (VP (VBG exerting) (NP (JJ effective) (NN protection)) (PP (IN against) (NP (JJ Doc_17608141_1445_1460_Chemical-induced) (NN nigrostriatal) (NNP Doc_17608141_1483_1491_Chemical) (NNP Doc_17608141_1492_1505_Disease)))))))))) (. .)))
17612891	0	(S1 (S (NP (JJ Acute) (NN Doc_17612891_6_17_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17612891_34_43_Chemical)))) (. .)))
17612891	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_17612891_72_83_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (NNP Doc_17612891_120_129_Chemical))))))) (VP (AUX is) (VP (VBN described) (, ,) (S (VP (VBG highlighting) (NP (NP (DT the) (NN onset)) (, ,) (NP (NN course)) (CC and) (NP (JJ possible) (VBG contributing) (NNS factors))))))) (. .)))
17612891	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB raise) (NP (NP (NN awareness)) (PP (IN about) (NP (NP (DT this) (ADJP (RB potentially) (JJ fatal)) (NN complication)) (PP (IN of) (NP (JJ Doc_17612891_298_307_Chemical) (NN use)))))))))))) (. .)))
17612891	3	(S1 (S (NP (NP (DT A) (JJ 20-year-old) (NN male)) (PP (IN with) (NP (NNP Doc_17612891_346_359_Disease)))) (VP (VBD developed) (NP (NP (DT a) (JJ sudden) (NN onset)) (PP (IN of) (NP (NNP Doc_17612891_388_399_Disease)))) (PP (IN after) (NP (NP (NN commencement)) (PP (IN of) (NP (NNP Doc_17612891_422_431_Chemical)))))) (. .)))
17612891	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (PP (IN with) (NP (JJ intensive) (JJ medical) (NN support)))) (. .)))
17612891	5	(S1 (S (NP (DT The) (NNS symptoms)) (VP (VBD occurred) (PP (IN around) (NP (CD 2) (NNS weeks))) (PP (IN after) (S (VP (VBG starting) (NP (NNP Doc_17612891_539_548_Chemical)) (PP (IN in) (NP (DT an) (JJ inpatient) (NN setting))))))) (. .)))
17612891	6	(S1 (S (NP (JJ Possible) (JJ contributing) (NNS factors)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (JJ concomitant) (JJ Doc_17612891_630_644_Chemical) (NN use)) (CC and) (NP (JJ unaccustomed) (JJ physical) (NN activity)))))) (. .)))
17612891	7	(S1 (S (NP (NN Doc_17612891_698_709_Disease)) (VP (AUX is) (NP (NP (DT an) (ADJP (RB increasingly) (VBN recognized)) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17612891_780_789_Chemical)))))))) (. .)))
17612891	8	(S1 (S (NP (PRP It)) (VP (MD can) (VP (AUX be) (ADJP (JJ fatal)) (SBAR (IN if) (S (RB not) (VP (VP (VBN recognized)) (CC and) (VP (VBN treated) (ADVP (RB early)))))))) (. .)))
17612891	9	(S1 (S (PP (VBG Considering) (SBAR (IN that) (S (NP (NNP Doc_17612891_861_870_Chemical)) (VP (VBZ remains) (NP (NP (DT the) (JJ gold) (NN standard)) (PP (IN in) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ resistant) (NNP Doc_17612891_923_932_Disease)))))))))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB raise) (NP (NP (NN awareness)) (PP (IN among) (NP (NP (JJ medical) (CC and) (JJ paramedical) (NN staff)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN care)) (PP (IN of) (NP (DT these) (NNS patients))))))))))))))) (. .)))
17612891	10	(S1 (S (NP (EX There)) (VP (AUX are) (ADVP (RB also)) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NP (NNS recommendations)) (CC and) (NP (NNS regulations))) (VP (VBG regarding) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17612891_1138_1147_Chemical))))))))) (. .)))
17615423	0	(S1 (S (NP (JJ Severe) (NNP Doc_17615423_7_21_Disease) (CC and) (NNP Doc_17615423_26_45_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NNP Doc_17615423_78_89_Chemical)) (, ,) (NP (NNP Doc_17615423_91_101_Chemical)) (, ,) (CC and) (NP (NNP Doc_17615423_107_117_Chemical))))))) (. .)))
17615423	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ severe) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17615423_179_190_Chemical)) (, ,) (NP (NNP Doc_17615423_192_202_Chemical)) (, ,) (CC and) (NP (NNP Doc_17615423_208_218_Chemical)))))) (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_17615423_232_246_Disease)) (CC and) (NP (NNP Doc_17615423_251_270_Disease))))))))) (. .)))
17615423	2	(S1 (S (NP (NP (DT A) (JJ 72-year-old) (JJ white) (NN man)) (PP (IN with) (NP (NP (JJ underlying) (NNP Doc_17615423_324_352_Disease)) (, ,) (NP (NNP Doc_17615423_354_373_Disease)) (, ,) (NP (NNP Doc_17615423_375_398_Disease)) (, ,) (CC and) (NP (NNP Doc_17615423_404_418_Disease))))) (VP (VBD presented) (SBAR (IN with) (S (VP (VBN generalized) (NP (NP (NNP Doc_17615423_446_450_Disease)) (, ,) (NP (NNP Doc_17615423_452_459_Disease)) (, ,) (CC and) (NP (JJ dark) (NN orange) (NN urine))) (PP (IN for) (NP (CD 3) (NNS days))))))) (. .)))
17615423	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBG taking) (NP (QP (CD 80) (CD mg)) (NN Doc_17615423_524_535_Chemical)) (PP (IN at) (NP (NP (NP (NP (NP (NN bedtime)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (CD 27) (NNS days)) (RB earlier))) (-RRB- -RRB-)) (: ;) (NP (NNP Doc_17615423_576_586_Chemical)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 400) (NNS mg)) (PP (JJ daily) (IN for) (NP (CD 7) (NNS days)))))))) (, ,) (RB then) (NP (CD 200) (NNS mg)) (JJ daily)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (CD 19) (NNS days)) (RB earlier))) (-RRB- -RRB-)) (: ;)) (CC and) (NP (NP (CD 400) (JJ mg) (NNP Doc_17615423_683_693_Chemical) (NN daily)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (QP (IN at) (JJS least) (CD 2)) (NNS years)) (RB previously))) (-RRB- -RRB-))))))) (. .)))
17615423	4	(S1 (S (NP (NN Laboratory) (NN evaluation)) (VP (VBD revealed) (NP (NP (CD 66,680) (NNP U/L) (NNP Doc_17615423_783_791_Chemical) (NN kinase)) (, ,) (NP (NP (CD 93) (NN mg/dL)) (NP (NNP Doc_17615423_809_828_Chemical))) (, ,) (NP (NP (CD 4.6) (NN mg/dL)) (NP (NNP Doc_17615423_840_850_Chemical))) (, ,) (NP (CD 1579) (NNP U/L) (NNP Doc_17615423_861_870_Chemical) (NN aminotransferase)) (, ,) (CC and) (NP (CD 738) (NNP U/L) (NNP Doc_17615423_901_908_Chemical) (NN aminotransferase)))) (. .)))
17615423	5	(S1 (S (S (NP (NP (NP (NNP Doc_17615423_927_938_Chemical)) (, ,) (NP (NNP Doc_17615423_940_950_Chemical)) (, ,)) (CC and) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_17615423_970_998_Disease) (NNS medications))) (VP (AUX were) (ADVP (DT all) (RB temporarily)) (VP (VBN discontinued)))) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VP (VBN given) (NP (JJ forced) (NN alkaline) (NNS diuresis))) (CC and) (VP (VBN started) (PP (IN on) (NP (NN dialysis))))))) (. .)))
17615423	6	(S1 (S (ADVP (NP (CD Nine) (NNS days)) (RB later)) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_17615423_1151_1159_Chemical) (NN kinase)) (VP (AUX had) (VP (VBN dropped) (PP (TO to) (NP (CD 1695))) (SBAR (S (NP (NP (NNP U/L)) (CC and) (NP (NNP Doc_17615423_1195_1205_Chemical))) (VP (AUX was) (NP (CD 3.3) (NN mg/dL))))))) (. .)))
17615423	7	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (VP (VBN discharged))) (CC and) (VP (VBD continued) (NP (NN outpatient) (NN dialysis)) (PP (IN for) (NP (CD 1) (NN month))) (PP (IN until) (NP (NP (PRP$ his) (JJ renal) (NN function)) (VP (VBD recovered)))))) (. .)))
17615423	8	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_17615423_1354_1368_Disease)))) (VP (AUX is) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ concomitant) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (JJ Doc_17615423_1432_1443_Chemical) (NN metabolism))))))))))) (. .)))
17615423	9	(S1 (S (NP (NN Doc_17615423_1456_1467_Chemical)) (VP (AUX is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))) (. .)))
17615423	10	(S1 (S (NP (NP (NNP Doc_17615423_1494_1504_Chemical)) (CC and) (NP (NNP Doc_17615423_1509_1519_Chemical))) (VP (AUX are) (VP (VBN recognized) (PP (IN CYP3A4) (NP (NNS inhibitors))))) (. .)))
17615423	11	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS differences)) (PP (IN in) (NP (NNP Doc_17615423_1598_1605_Chemical)))) (VP (AUX are) (NP (NP (DT an) (JJ important) (NN consideration)) (PP (IN for) (S (VP (VBG assessing) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ potential) (NN drug) (NNS interactions))))))))) (. .)))
17615423	12	(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VP (VBG requiring) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NNP Doc_17615423_1736_1743_Chemical))))) (CC and) (VP (VBG CYP3A4) (NP (NNS inhibitors)))))) (, ,) (NP (NNP Doc_17615423_1767_1778_Chemical) (, ,) (NNP Doc_17615423_1780_1791_Chemical) (, ,) (CC and) (NNP Doc_17615423_1797_1809_Chemical)) (VP (VBP carry) (NP (NP (DT the) (JJS lowest) (NN risk)) (PP (IN of) (NP (NN drug) (NNS interactions)))))) (: ;) (S (NP (NNP Doc_17615423_1854_1866_Chemical)) (VP (VBZ carries) (NP (JJ moderate) (NN risk)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_17615423_1898_1909_Chemical) (CC and) (NNP Doc_17615423_1914_1924_Chemical)) (VP (VP (AUX have) (NP (DT the) (JJS highest) (NN risk))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (JJ concomitant) (JJ CYP3A4) (NNS inhibitors))))))))))))) (. .)))
17639754	0	(S1 (NP (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_20_28_Chemical)) (CC and) (NP (NNP Doc_17639754_33_45_Chemical))))) (: :) (NP (NN case) (NN series)) (. .)))
17639754	1	(S1 (S (NP (NN Doc_17639754_60_68_Chemical)) (VP (VP (AUX is) (NP (DT the) (ADJP (RBS most) (RB widely) (VBN used)) (JJ oral) (NN anticoagulant))) (CC and) (VP (AUX is) (VP (VBN indicated) (PP (IN for) (NP (JJ many) (JJ clinical) (NNS conditions)))))) (. .)))
17639754	2	(S1 (S (NP (NP (NNP Doc_17639754_159_171_Chemical)) (, ,) (NP (DT a) (NN Doc_17639754_175_190_Chemical)) (, ,)) (VP (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (RB commonly) (VBN prescribed)) (NNS antibiotics)) (PP (IN in) (NP (JJ clinical) (NN practice))))))) (CC and) (VP (AUX is) (ADJP (JJ effective) (PP (IN against) (NP (ADJP (ADJP (JJ Gram-positive)) (, ,) (ADJP (JJ Gram-negative)) (, ,) (CC and) (ADJP (JJ atypical))) (NNS bacteria)))))) (. .)))
17639754	3	(S1 (S (SBAR (IN While) (S (NP (JJ small) (JJ prospective) (NNS studies)) (VP (AUX have) (RB not) (VP (VBN revealed) (NP (NP (DT any) (JJ significant) (NN drug-drug) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_438_446_Chemical)) (CC and) (NP (NNP Doc_17639754_451_463_Chemical))))))))) (, ,) (NP (JJ several) (NN case) (NNS reports)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NNP Doc_17639754_506_518_Chemical)) (VP (MD may) (ADVP (RB significantly)) (VP (VB potentiate) (NP (NP (DT the) (JJ anticoagulation) (NN effect)) (PP (IN of) (NP (NNP Doc_17639754_578_586_Chemical)))))))))) (. .)))
17639754	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 3) (NNS cases)) (PP (IN of) (NP (NP (JJ serious) (JJ Doc_17639754_617_625_Disease) (NNS complications)) (SBAR (WHNP (WDT that)) (S (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_696_704_Chemical)) (CC and) (NP (NNP Doc_17639754_709_721_Chemical))))))))))))))))) (. .)))
17639754	5	(S1 (S (NP (NNS Physicians)) (VP (MD should) (VP (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ potential) (NN interaction))))) (CC and) (VP (VB use) (NP (NN caution)) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NNP Doc_17639754_813_825_Chemical)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN Doc_17639754_845_853_Chemical))))))))))) (. .)))
17854040	0	(S1 (S (S (NP (NNS Mutations)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_17854040_26_36_Chemical-resistance))) (PP (IN in) (NP (JJ therapy-Doc_17854040_59_61_Chemical) (JJ ve) (NNP Doc_17854040_66_98_Disease) (NNS patients))) (PP (IN with) (CC and) (IN without) (NP (NNP Doc_17854040_125_141_Disease))))) (: :) (S (NP (NNS implications)) (PP (IN for) (NP (NP (JJ antiretroviral) (NN therapy)) (PP (IN in) (NP (NNP Doc_17854040_186_209_Disease) (NNP South) (NNP African) (NNS patients)))))) (. .)))
17854040	1	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT an) (JJ exploratory) (NN study)) (SBAR (S (VP (TO to) (VP (VB investigate) (NP (NP (JJ Doc_17854040_279_289_Chemical-resistant) (JJ Doc_17854040_300_311_Disease) (NN virus) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-)) (NNS strains)) (PP (IN in) (NP (NP (VBN selected) (JJ Doc_17854040_344_354_Chemical-Doc_17854040_355_357_Chemical) (NN ve) (NN HBV) (NNS carriers)) (PP (IN with) (CC and) (IN without) (NP (NP (NNP Doc_17854040_392_439_Disease)) (PP (IN in) (NP (NNP South) (NNP African) (NNS patients)))))))))))))) (. .)))
17854040	2	(S1 (UCP (S (NP (NP (JJ Thirty-five) (JJ Doc_17854040_479_489_Chemical-Doc_17854040_490_492_Chemical) (JJ ve) (NNP Doc_17854040_497_509_Disease) (NNS patients)) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_17854040_535_551_Disease)))) (VP (AUX were) (VP (VBN studied)))) (: :) (NP (NP (CD 15) (JJ chronic) (NN Doc_17854040_577_594_Disease) (NNS patients)) (CC and) (NP (CD 20) (JJ Doc_17854040_611_630_Disease) (NNS patients))) (. .)))
17854040	3	(S1 (S (NP (DT The) (JJ latter) (NN group)) (VP (AUX was) (ADVP (RB further)) (VP (VBN sub-divided) (PP (IN into) (NP (NP (NP (CD 13) (JJ occult) (NNS HBV)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17854040_702_707_Chemical-negative)) (-RRB- -RRB-))) (CC and) (NP (ADJP (CD 7) (NN overt)) (NN HBV) (PRN (-LRB- -LRB-) (ADJP (NNP Doc_17854040_735_740_Chemical-) (JJ positive)) (-RRB- -RRB-)) (NNS patients)))))) (. .)))
17854040	4	(S1 (S (ADVP (JJ Doc_17854040_762_767_Chemical)) (, ,) (NP (NP (NNS anti-HBs)) (, ,) (NP (NNS anti-HBc)) (, ,) (CC and) (NP (JJ anti-HIV) (NNS 1/2))) (VP (AUX were) (VP (VBN determined) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ routine) (NN diagnosis)) (VP (VBG using) (NP (NP (JJ Axsym) (NNS assays)) (PRN (-LRB- -LRB-) (NP (NP (NNP Abbott) (NNP Laboratories)) (, ,) (NP (NNP North) (NNP Chicago))) (, ,) (NP (NNP IL)) (-RRB- -RRB-)))))))))) (. .)))
17854040	5	(S1 (S (NP (NN Serum) (NNS samples)) (VP (AUX were) (RB PCR) (VP (VBN amplified) (PP (IN with) (NP (NP (JJ HBV) (JJ reverse) (NN transcriptase) (PRN (-LRB- -LRB-) (NP (NNP RT)) (-RRB- -RRB-)) (NNS primers)) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (JJ direct) (NN sequencing)) (PP (IN across) (NP (NP (DT the) (JJ Doc_17854040_1031_1039_Chemical-Doc_17854040_1040_1050_Chemical-Doc_17854040_1051_1060_Chemical-Doc_17854040_1061_1070_Chemical) (PRN (-LRB- -LRB-) (NP (NNP YMDD)) (-RRB- -RRB-)) (NN motif)) (PP (IN of) (NP (DT the) (JJ major) (JJ catalytic) (NN region))) (PP (IN in) (NP (NP (DT the) (NNP C) (NN domain)) (PP (IN of) (NP (DT the) (NNP HBV) (NNP RT) (NN enzyme)))))))))))))) (. .)))
17854040	6	(S1 (S (NP (CD HBV) (JJ viral) (NN load)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (NP (NNP Amplicor) (NNP HBV) (NNP Monitor) (NN test) (NNS v2.0)) (PRN (-LRB- -LRB-) (NP (NP (NNP Roche) (NNPS Diagnostics)) (, ,) (NP (NNP Penzberg) (, ,) (NNP Germany))) (-RRB- -RRB-)))))) (. .)))
17854040	7	(S1 (S (NP (JJ HBV) (JJ Doc_17854040_1261_1271_Chemical-resistant) (NNS strains)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (NP (CD 3)) (PP (IN of) (NP (CD 15) (JJ mono-infected) (JJ chronic) (NN Doc_17854040_1337_1348_Disease) (NNS patients)))) (CC and) (NP (NP (CD 10)) (PP (IN of) (NP (CD 20) (NNP Doc_17854040_1371_1390_Disease) (NNS patients)))))))) (. .)))
17854040	8	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (DT this)) (VP (VBZ constitutes) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (JJ HBV) (JJ Doc_17854040_1472_1482_Chemical-resistant) (NNS strains))) (PP (IN in) (NP (JJ therapy-Doc_17854040_1512_1514_Chemical) (JJ ve) (NNP Doc_17854040_1519_1538_Disease) (NNS patients))))) (. .)))
17854040	9	(S1 (S (NP (NP (DT The) (CD HBV) (JJ viral) (NNS loads)) (PP (IN for) (NP (ADJP (JJ mono-infected) (CC and) (JJ co-infected)) (NNS patients)))) (VP (VBD ranged) (PP (IN from) (NP (NP (CD 3.32) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (TO to) (NP (NP (CD 3.82) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 7)) (-RRB- -RRB-))) (CC and) (NP (NP (QP (CD <200) (TO to) (CD 4.40)) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))) (ADVP (RB copies/ml))) (, ,) (ADVP (RB respectively))) (. .)))
17854040	10	(S1 (S (NP (PRP It)) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN seen) (SBAR (S (IN whether) (NP (JJ such) (JJ pre-existing) (JJ antiviral) (NNS mutations)) (VP (MD could) (VP (VB result) (PP (IN in) (NP (NP (JJ widespread) (NN emergence)) (PP (IN of) (NP (JJ HBV) (NN resistant) (NNS strains))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_17854040_1838_1848_Chemical-containing) (ADJP (RB highly) (JJ active)) (NN antiretroviral) (PRN (-LRB- -LRB-) (NP (NNP ARV)) (-RRB- -RRB-)) (NN treatment) (PRN (-LRB- -LRB-) (NP (NNP HAART)) (-RRB- -RRB-)) (NNS regimens)) (VP (VBP become) (ADJP (RB widely) (VBN applied) (PP (IN in) (NP (NNP South) (NNP Africa)))) (, ,) (SBAR (IN as) (S (NP (DT this)) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (JJ potential) (NNS implications)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_17854040_2031_2050_Disease) (NNS patients)))))))))))))))))))))))) (. .)))
1786266	0	(S1 (S (NP (NP (NN Doc_1786266_0_15_Disease)) (, ,) (NP (JJ Doc_1786266_17_31_Chemical) (NN use)) (, ,) (CC and) (NP (JJ cerebral) (NN perfusion))) (VP (VB SPECT) (VP (VB scan) (NP (NNS findings)))) (. .)))
1786266	1	(S1 (S (NP (DT The) (NNP Doc_1786266_85_100_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ extrapyramidal) (NN side) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (JJ neuroleptic) (NN therapy)))))) (. .)))
1786266	2	(S1 (S (NP (NP (PRP$ Its) (NN occurrence)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1786266_226_236_Chemical)))))))) (VP (AUX is) (VP (VBN described) (, ,) (S (VP (VBG representing) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (DT this) (NN syndrome))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_1786266_325_340_Chemical)))))))))) (. .)))
1786266	3	(S1 (S (NP (VBN Repeated) (JJ cerebral) (NN perfusion) (NN SPECT) (NNS scans)) (VP (VBD revealed) (NP (NN Doc_1786266_391_424_Disease)) (SBAR (IN while) (S (NP (DT the) (NNP Doc_1786266_435_452_Disease)) (VP (VP (AUX was) (ADJP (JJ present))) (, ,) (CC and) (VP (NP (NP (DT a) (NN return)) (PP (TO to) (NP (JJ normal) (NN perfusion)))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_1786266_508_523_Disease)) (VP (VBD resolved))))))))) (. .)))
17879945	0	(S1 (S (NP (NNP Estrogen)) (VP (VBZ prevents) (NP (NP (JJ Doc_17879945_18_35_Chemical) (NN accumulation)) (PP (IN in) (NP (NP (NNS macrophages)) (VP (VBN induced) (PP (IN by) (NP (DT the) (NNP HIV) (NN protease) (NN inhibitor) (NN Doc_17879945_102_111_Chemical)))))))) (. .)))
17879945	1	(S1 (S (NP (NP (NNS Individuals)) (PP (IN with) (NP (NNP HIV)))) (VP (MD can) (ADVP (RB now)) (VP (VBP live) (NP (NP (JJ long) (NNS lives)) (PP (IN with) (NP (NP (NN drug) (NN therapy)) (SBAR (WHNP (WDT that)) (S (ADVP (RB often)) (VP (VBZ includes) (NP (NP (JJ protease) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NNP Doc_17879945_224_233_Chemical)))))))))))) (. .)))
17879945	2	(S1 (S (NP (JJ Many) (NNS patients)) (, ,) (ADVP (RB however)) (, ,) (VP (VBP develop) (NP (NP (JJ negative) (JJ long-term) (NN side) (NNS effects)) (PP (JJ such) (IN as) (NP (NN Doc_17879945_307_332_Disease))))) (. .)))
17879945	3	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (JJ Doc_17879945_371_380_Chemical) (NN treatment)) (VP (VBZ increases) (NP (NP (JJ Doc_17879945_401_423_Disease) (NN formation)) (PP (IN in) (NP (JJ male) (NNS mice)))) (PP (TO to) (NP (DT a) (JJR greater) (NN extent))) (PP (IN than) (PP (IN in) (NP (JJ female) (NNS mice))))))))) (. .)))
17879945	4	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ peripheral) (NN blood) (NNS monocytes)) (VP (VBN isolated) (PP (IN from) (NP (JJ Doc_17879945_542_551_Chemical-treated) (NNS females))))) (VP (AUX had) (NP (ADJP (RBR less) (JJ Doc_17879945_577_594_Chemical)) (NN accumulation))) (. .)))
17879945	5	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN investigated) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ female) (NNS hormones)) (VP (VBP influence) (NP (NP (JJ Doc_17879945_712_723_Chemical) (NN metabolism)) (PP (IN in) (NP (NNS macrophages)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NNP HIV) (NN protease) (NN inhibitor) (NNP Doc_17879945_792_801_Chemical))))))))))) (. .)))
17879945	6	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN utilized) (NP (NP (DT the) (JJ human) (JJ monocyte) (NN cell) (NN line)) (, ,) (NP (NN THP-1))) (PP (IN as) (NP (NP (DT a) (NN model)) (SBAR (S (VP (TO to) (VP (VB address) (NP (DT this) (NN question)))))))))) (. .)))
17879945	7	(S1 (S (ADVP (RB Briefly)) (, ,) (NP (NNS cells)) (VP (AUX were) (VP (VBN differentiated) (SBAR (IN for) (S (NP (CD 72) (NAC (NNP h) (PP (IN with) (NP (CD 100) (CD nM)))) (NNP PMA)) (VP (TO to) (VP (VB obtain) (NP (DT a) (JJ macrophage-like) (NN phenotype)) (PP (IN in) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NP (NP (QP (CD 1) (CD nM)) (NNP Doc_17879945_1026_1042_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17879945_1044_1046_Chemical)) (-RRB- -RRB-))) (, ,) (NP (CD 100) (JJ nM) (NNP Doc_17879945_1056_1068_Chemical)) (CC or) (NP (NP (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.01) (NN %)) (NP (NNP Doc_17879945_1087_1094_Chemical))) (-RRB- -RRB-))))))))))))) (. .)))
17879945	8	(S1 (S (S (NP (NNS Cells)) (VP (AUX were) (ADVP (RB then)) (VP (VBN treated) (PP (IN with) (NP (NP (CD 30) (NNS ng/ml)) (UCP (JJ Doc_17879945_1135_1144_Chemical) (CC or) (NN vehicle)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ aggregated) (NNS LDL))))) (SBAR (IN for) (S (NP (CD 24) (NNP h.) (NN Cell) (NNS extracts)) (VP (AUX were) (VP (VBN harvested)))))))) (, ,) (CC and) (S (NP (NN lipid) (CC or) (JJ total) (NNP RNA)) (VP (AUX was) (VP (VBN isolated)))) (. .)))
17879945	9	(S1 (S (NP (NN Doc_17879945_1267_1269_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NNP Doc_17879945_1300_1318_Chemical))) (PP (IN in) (NP (NP (NNS macrophages)) (VP (VBG following) (NP (JJ Doc_17879945_1344_1353_Chemical) (NN treatment))))))) (. .)))
17879945	10	(S1 (S (NP (NN Doc_17879945_1365_1374_Chemical)) (VP (VBD increased) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN scavenger) (NN receptor)))) (, ,) (NP (CD CD36) (NN mRNA)) (, ,) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN uptake)) (PP (IN of) (NP (NNP LDL))))))) (. .)))
17879945	11	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (JJ Doc_17879945_1487_1496_Chemical) (NN treatment)) (ADVP (RB selectively)) (VP (VBD increased) (NP (NP (DT the) (JJ relative) (NNS levels)) (PP (IN of) (NP (NP (FW PPARgamma) (FW mRNA)) (, ,) (NP (NP (DT a) (JJ transcription) (NN factor)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (CD CD36) (NN mRNA) (NN expression))))))))))) (. .)))
17879945	12	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_17879945_1662_1664_Chemical)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (DT these) (NNS increases)) (PP (IN at) (NP (DT the) (JJ mRNA) (NN level))))))) (. .)))
17879945	13	(S1 (S (NP (NNP Doc_17879945_1728_1730_Chemical)) (VP (AUX did) (, ,) (ADVP (RB however)) (, ,) (VP (ADVP (RB significantly)) (VB suppress) (NP (CD CD36) (NN protein) (NNS levels)) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (JJ fluorescent) (NN immunocytochemistry)))))))) (. .)))
17879945	14	(S1 (S (NP (DT This) (NN data)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_17879945_1860_1862_Chemical)) (VP (VBZ modifies) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (CD CD36)))) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN protein) (NN expression))) (PP (IN in) (NP (NP (JJ monocyte-derived) (NNS macrophages)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ reduced) (JJ Doc_17879945_1983_2000_Chemical) (NN accumulation)) (VP (VBG following) (NP (JJ Doc_17879945_2024_2033_Chemical) (NN treatment)))))))))))))) (. .)))
17919553	0	(S1 (S (NP (JJ Acute) (NNP Doc_17919553_6_15_Disease)) (VP (VBP attack) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_17919553_41_54_Chemical)))))) (. .)))
17919553	1	(S1 (S (NP (JJ Antibiotic-associated) (NN Doc_17919553_92_106_Disease)) (VP (AUX is) (ADJP (JJ rare))) (. .)))
17919553	2	(S1 (S (S (PP (IN With) (NP (NP (JJ widespread) (NN use)) (PP (IN of) (NP (JJ antimicrobial) (NNS agents))))) (, ,) (ADVP (RB however)) (, ,) (NP (NNP Doc_17919553_170_184_Disease)) (VP (VBZ occurs) (ADVP (RB frequently)))) (, ,) (CC and) (S (PP (IN among) (NP (NNP Doc_17919553_214_236_Disease))) (, ,) (NP (JJ idiosyncratic) (NNS reactions)) (VP (AUX are) (NP (DT the) (RBS most) (JJ serious)))) (. .)))
17919553	3	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 25-year-old) (NN male) (NN patient)) (, ,) (PP (IN with) (NP (NP (DT a) (NN height)) (PP (IN of) (NP (NP (CD 175) (NNS cm)) (CC and) (NP (NP (NN weight)) (PP (IN of) (NP (NP (CD 72) (NNS kg)) (VP (VBN presented) (PP (TO to) (NP (NP (NNP Marmara) (NNP University) (NNP Hospital) (NNP Emergency) (NNP Department)) (, ,) (NP (NNP Istanbul)) (, ,) (NP (NNP Turkey)))))))))))) (, ,) (PP (IN with) (NP (NP (NP (CD 5) (NNS days) (POS ')) (NN history)) (PP (IN of) (NP (NP (NNP Doc_17919553_475_483_Disease)) (, ,) (NP (NN malaise)) (, ,) (NP (NNP Doc_17919553_494_500_Disease)) (, ,) (CC and) (NP (NNP Doc_17919553_506_514_Disease))))))) (. .)))
17919553	4	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBN prescribed) (NP (NNP Doc_17919553_539_552_Chemical) (CD 400)) (PP (IN mg/d) (S (VP (VBG PO) (S (VP (TO to) (VP (VB treat) (NP (DT an) (NN Doc_17919553_577_610_Disease)) (ADVP (NP (CD 7) (NNS days)) (RB prior))))))))))) (. .)))
17919553	5	(S1 (S (NP (NN Admission) (NN laboratory) (NNS tests)) (VP (AUX were) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (JJ Doc_17919553_669_676_Chemical) (NN aminotransferase)) (, ,) (NP (NP (NP (NP (CD 67) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (NP (NN reference) (NN range)) (, ,) (NP (CD 10-37) (NNP U/L))) (-RRB- -RRB-)) (: ;)) (JJ Doc_17919553_732_741_Chemical) (NN aminotransferase)) (, ,) (NP (NP (CD 98) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (JJ 10-40) (NNP U/L)) (-RRB- -RRB-))))) (: ;) (NP (NP (JJ alkaline) (NN phosphatase)) (, ,) (NP (NP (CD 513) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (JJ 0-270) (NNP U/L)) (-RRB- -RRB-)))) (: ;) (NP (NP (NP (NN gamma-glutamyltransferase)) (, ,) (NP (NP (NP (CD 32) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (CD 7-49) (NNP U/L)) (-RRB- -RRB-))) (: ;) (NP (NP (NN amylase)) (, ,) (NP (NP (CD 46) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (CD 0-220) (NNP U/L)) (-RRB- -RRB-)) (: ;) (NP (JJ total) (NNP Doc_17919553_904_913_Chemical)) (, ,) (NP (NP (CD 20.1) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 0.2-1.0) (NNS mg/dL)) (-RRB- -RRB-)) (: ;) (NP (JJ direct) (NNP Doc_17919553_950_959_Chemical))) (, ,) (NP (NP (CD 14.8) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 0-0.3) (NNS mg/dL)) (-RRB- -RRB-))))) (: ;) (CC and) (NP (NN albumin)))) (, ,) (NP (NP (QP (CD 4.7) (CD mg/dL))) (PRN (-LRB- -LRB-) (NP (CD 3.5-5.4) (NNS mg/dL)) (-RRB- -RRB-))))))) (. .)))
17919553	6	(S1 (S (NP (NP (DT No) (NN toxin)) (, ,) (NP (NN Doc_17919553_1037_1044_Chemical)) (, ,) (CC or) (NP (JJ other) (NNS drugs))) (VP (AUX were) (VP (VBN reported))) (. .)))
17919553	7	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (VP (VBN suffered) (NP (NP (DT a) (JJ previous) (NN episode)) (PP (IN of) (NP (`` ``) (NP (JJ acute) (NN Doc_17919553_1130_1139_Disease)) (PP (IN of) (NP (JJ unknown) (NN origin))) (, ,) ('' '') (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (JJ Doc_17919553_1180_1193_Chemical) (NN usage))))))))))) (. .)))
17919553	8	(S1 (S (NP (DT Both) (NNS incidents)) (VP (VBD occurred) (PP (IN within) (NP (DT a) (NN year)))) (. .)))
17919553	9	(S1 (S (NP (NN Doc_17919553_1252_1265_Chemical)) (VP (AUX is) (NP (NP (DT the) (JJ first)) (PP (IN of) (NP (DT the) (JJ ketolide) (NNS antibacterials))) (SBAR (S (VP (TO to) (VP (VB receive) (NP (NP (NNP US) (NNP Food) (CC and) (NNP Drug) (NNP Administration) (NN approval)) (PP (IN for) (NP (JJ clinical) (NN use)))))))))) (. .)))
17919553	10	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (JJ infrequent)) (CC and) (ADJP (RB usually) (JJ reversible))) (JJ severe) (NN Doc_17919553_1449_1468_Disease)))))) (. .)))
17919553	11	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT a) (NN score)) (PP (IN of) (NP (CD 8))) (PP (IN on) (NP (DT the) (NNP Naranjo) (NNP Doc_17919553_1507_1528_Disease) (NN probability) (NN scale)))))) (, ,) (S (NP (NNP Doc_17919553_1548_1561_Chemical)) (VP (AUX was) (NP (NP (DT the) (JJ probable) (NN cause)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_17919553_1594_1603_Disease)) (PP (IN in) (NP (DT this) (NN patient)))))))) (, ,) (CC and) (S (NP (JJ pathological) (NNS findings)) (VP (VBD suggested) (NP (JJ drug-induced) (NNP Doc_17919553_1670_1685_Disease)))) (. .)))
17919553	12	(S1 (S (NP (NP (NN Recurrence)) (PP (IN of) (NP (NN Doc_17919553_1701_1710_Disease) (NN attack)))) (VP (MD might) (VP (AUX have) (VP (AUX been) (VP (VBN avoided) (SBAR (IN if) (S (NP (DT the) (JJ initial) (NN incident)) (VP (AUX had) (VP (AUX been) (VP (VBN communicated) (PP (TO to) (NP (NP (DT the) (VBG attending) (NN physician)) (SBAR (WHNP (WP who)) (S (VP (VBN prescribed) (PP (JJ Doc_17919553_1830_1843_Chemical) (NP (DT the) (JJ second) (NN time))))))))))))))))) (. .)))
17919553	13	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (NN Doc_17919553_1904_1913_Disease)) (VP (ADVP (RB probably)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_17919553_1961_1974_Chemical)))))))))) (. .)))
17931375	0	(S1 (NP (NP (DT A) (NN study)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_17931375_54_61_Chemical) (NN injection))) (PP (IN on) (NP (NP (NNP Doc_17931375_75_83_Disease)) (CC and) (NP (NNP Doc_17931375_88_92_Disease)))))))) (. .)))
17931375	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN injection) (NN duration))) (PP (IN on) (NP (NP (NNP Doc_17931375_175_183_Disease)) (CC and) (NP (NNP Doc_17931375_188_192_Disease))))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NNP Doc_17931375_255_262_Chemical)))))))))))) (. .)))
17931375	2	(S1 (S (SBAR (IN Although) (S (NP (JJ different) (NNS methods) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_17931375_314_322_Disease) (CC and) (NNP Doc_17931375_327_331_Disease)) (VP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NNP Doc_17931375_372_379_Chemical)))))))))) (VP (AUX have) (VP (AUX been) (ADVP (RB widely)) (VP (VBN studied) (CC and) (VBN described)))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN injection) (NN duration))) (PP (IN on) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (NNP Doc_17931375_474_482_Disease)) (CC and) (NP (NNP Doc_17931375_487_491_Disease))))))) (VP (AUX is) (ADVP (RB little)) (VP (VBN documented))) (. .)))
17931375	3	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (PP (IN as) (NP (NP (NN within-subject)) (, ,) (NP (JJ quasi-experimental) (NN research)))))) (. .)))
17931375	4	(S1 (S (NP (NP (DT The) (NN sample)) (PP (IN for) (NP (DT the) (NN study)))) (VP (VBD consisted) (PP (IN of) (NP (CD 50) (NNS patients))) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (JJ subcutaneous) (NN Doc_17931375_673_680_Chemical)) (VP (AUX was) (VP (VBN administered)))))) (. .)))
17931375	5	(S1 (S (NP (NN Doc_17931375_699_706_Chemical)) (VP (AUX was) (VP (VBN injected) (PP (IN over) (NP (NP (NP (CD 10) (NNS seconds)) (PP (IN on) (NP (DT the) (JJ right) (JJ abdominal) (NN site)))) (CC and) (NP (NP (CD 30) (NNS seconds)) (PP (IN on) (NP (DT the) (JJ left) (JJ abdominal) (NN site)))))))) (. .)))
17931375	6	(S1 (S (NP (NNS Injections) (NNS areas)) (VP (AUX were) (VP (VBN assessed) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_17931375_858_866_Disease))))) (PP (IN at) (NP (NP (CD 48) (CC and) (CD 72) (NNS hours)) (PP (IN after) (NP (DT each) (NN injection))))))) (. .)))
17931375	7	(S1 (S (NP (NP (NNS Dimensions)) (PP (IN of) (NP (DT the) (NNP Doc_17931375_926_934_Disease))) (PP (IN on) (NP (DT the) (JJ Doc_17931375_942_949_Chemical) (JJ applied) (NNS areas)))) (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (JJ transparent) (JJ millimetric) (NN measuring) (NN paper)))))) (. .)))
17931375	8	(S1 (S (S (NP (NP (DT The) (JJ visual) (NN analog) (NN scale)) (PRN (-LRB- -LRB-) (INTJ (UH VAS)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (JJ Doc_17931375_1075_1079_Disease) (NN intensity)))))))) (CC and) (S (NP (DT a) (NN stop-watch)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB time) (NP (DT the) (JJ Doc_17931375_1128_1132_Disease) (NN period)))))))) (. .)))
17931375	9	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analysed) (S (VP (VBG using) (NP (NP (NN chi-square) (NN test)) (, ,) (NP (NNP Mann-Whitney) (NNP U)) (, ,) (NP (NNP Wilcoxon) (JJ signed) (NNS ranks) (NNS tests)) (CC and) (NP (NN correlation))))))) (. .)))
17931375	10	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ Doc_17931375_1271_1279_Disease) (NN occurrence)))) (VP (AUX was) (NP (CD 64) (NN %)) (PP (IN with) (NP (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (CD 10) (NNS seconds) (NN duration)))) (CC and) (NP (NP (CD 42) (NN %)) (PP (IN in) (NP (DT the) (JJ 30-second) (NN injection))))))) (. .)))
17931375	11	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN determined) (SBAR (IN that) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (NNP Doc_17931375_1416_1424_Disease)))) (VP (AUX was) (ADJP (JJR smaller)) (PP (IN in) (NP (DT the) (JJ 30-second) (NN injection)))))))) (. .)))
17931375	12	(S1 (S (NP (NP (JJ Doc_17931375_1465_1469_Disease) (NN intensity)) (CC and) (NP (JJ Doc_17931375_1484_1488_Disease) (NN period))) (VP (AUX were) (ADJP (ADJP (RB statistically) (RB significantly) (JJR lower)) (PP (IN for) (NP (DT the) (JJ 30-second) (NN injection))) (PP (IN than) (PP (IN for) (NP (DT the) (JJ 10-second) (NN injection)))))) (. .)))
17931375	13	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN determined) (SBAR (IN that) (S (NP (NN injection) (NN duration)) (VP (AUX had) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_17931375_1669_1677_Disease)) (CC and) (NP (NNP Doc_17931375_1682_1686_Disease))))) (PP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_17931375_1732_1739_Chemical)))))))))) (. .)))
17931375	14	(S1 (S (NP (DT This) (NN study)) (VP (MD should) (VP (AUX be) (VP (VBN repeated) (PP (IN on) (NP (DT a) (JJR larger) (NN sample)))))) (. .)))
17931375	15	(S1 (NP (NP (NP (NN RELEVANCE)) (PP (TO TO) (NP (JJ CLINICAL) (NN PRACTICE)))) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBG administering) (NP (JJ subcutaneous) (JJ Doc_17931375_1855_1862_Chemical) (NNS injections))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB extend) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (DT the) (NN injection))))))))) (. .)))
18004067	0	(S1 (S (NP (NP (NN Doc_18004067_0_19_Disease)) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (JJ regular) (JJ Doc_18004067_49_56_Chemical) (NN consumption)))))) (VP (VBD ingesting) (NP (NNP Doc_18004067_79_90_Chemical)) (PP (IN at) (NP (JJ therapeutic) (NN dosage)))) (. .)))
18004067	1	(S1 (S (NP (NP (DT The) (JJ possible) (NN role)) (PP (IN of) (NP (NNP Doc_18004067_147_154_Chemical))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18004067_177_191_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_18004067_229_240_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18004067_242_255_Chemical)) (-RRB- -RRB-)))))))))) (VP (AUX is) (ADVP (RB currently)) (VP (VBN debated))) (. .)))
18004067	2	(S1 (S (S (NP (NN CASE)) (VP (VBP REPORT))) (: :) (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 2) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NP (JJ regular) (NNS consumers)) (PP (IN of) (NP (NNP Doc_18004067_345_352_Chemical))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_18004067_371_384_Disease)) (PP (IN within) (NP (CD 3-5) (NNS days))) (PP (IN after) (NP (NP (NN hospitalization)) (CC and) (NP (NN stopping) (JJ Doc_18004067_436_443_Chemical) (NN consumption))))))))) (PP (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (CD 4) (NNP g) (NNP Doc_18004067_485_496_Chemical/day))))))))) (. .)))
18004067	3	(S1 (S (NP (NP (DT A) (JJ Doc_18004067_504_515_Chemical) (NN serum) (NN level)) (VP (VBN obtained) (PP (IN in) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS patients))))))) (VP (AUX was) (RB not) (PP (IN in) (NP (DT the) (JJ toxic) (NN range)))) (. .)))
18004067	4	(S1 (S (NP (NP (JJ Possible) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18004067_635_649_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NNP Doc_18004067_696_707_Chemical))))))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
18004067	5	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN risk) (NNS factors))))) (, ,) (NP (NP (JJ e.g.) (JJ regular) (NN consumption)) (PP (IN of) (NP (NP (NNP Doc_18004067_794_801_Chemical)) (, ,) (NP (NNP Doc_18004067_803_816_Disease))))) (VP (AUX is) (ADJP (JJ possible)) (SBAR (WHADVP (WRB when)) (S (NP (JJ therapeutic) (NNS doses)) (VP (AUX are) (VP (VBN ingested)))))) (. .)))
18004067	6	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (SBAR (IN that) (S (NP (DT the) (JJ Doc_18004067_886_897_Chemical) (NN dose)) (VP (MD should) (RB not) (VP (VB exceed) (NP (CD 2) (NN g/day)) (PP (IN in) (NP (JJ such) (NNS patients))))))) (CC and) (SBAR (IN that) (S (NP (PRP$ their) (NN liver) (NN function)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (ADVP (RB closely)) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NN Doc_18004067_1029_1040_Chemical)))))))))))))) (. .)))
18020536	0	(S1 (NP (NP (NP (NNS Associations)) (PP (IN between) (NP (NP (NP (NN use)) (PP (IN of) (NP (UCP (NNP Doc_18020536_28_43_Chemical) (CC or) (JJ related)) (NNS drugs)))) (CC and) (NP (NN health) (, ,) (JJ physical) (NNS abilities) (CC and) (NN cognitive) (NN function))))) (: :) (NP (NP (DT a) (JJ non-randomised) (JJ clinical) (NN study)) (PP (IN in) (NP (DT the) (JJ elderly)))) (. .)))
18020536	1	(S1 (S (S (VP (TO To) (VP (VB describe) (NP (NP (NNS associations)) (PP (IN between) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NP (UCP (NNP Doc_18020536_219_234_Chemical) (CC or) (JJ related)) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18020536_253_257_Chemical/RDs)) (-RRB- -RRB-))) (CC and) (NP (NN health)))))))))) (, ,) (NP (NP (JJ functional) (NNS abilities)) (CC and) (NP (NN cognitive))) (VP (VBP function) (PP (IN in) (NP (DT the) (JJ elderly)))) (. .)))
18020536	2	(S1 (S (NP (NP (DT A) (JJ non-randomised) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN aged) (NP (QP (CD >) (CC or) (CD =65)) (NNS years)))))) (VP (VBD admitted) (PP (TO to) (NP (JJ acute) (NN hospital) (NNS wards))) (SBAR (IN during) (S (NP (NP (QP (CD 1) (CD month.)) (CD 164) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age) (JJ +/-) (JJ standard) (NN deviation)) (NP (QP (RB -LSB-SD) (CD -RSB-) (CD 81.6)) (JJ +/-) (CD 6.8) (NNS years))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN admitted)))))) (. .)))
18020536	3	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (S (NP (NP (RB nearly) (NN half)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 78)) (-RRB- -RRB-))) (VP (AUX had) (VP (VBN used) (NP (NNP Doc_18020536_583_587_Chemical/RDs)) (PP (IN before) (NP (NN admission)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN remainder)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 86)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ non-users)))) (. .)))
18020536	4	(S1 (S (NP (JJ Cognitive) (NN ability)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (DT the) (NNP Mini-Mental) (NNP State) (NNP Examination)) (PRN (-LRB- -LRB-) (NP (NNP MMSE)) (-RRB- -RRB-)))))) (. .)))
18020536	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG scoring) (NP (QP (CD >) (CC or) (CD =20)) (NN MMSE) (NN sum) (NNS points)))) (VP (VP (AUX were) (VP (VBN interviewed))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 79)) (-RRB- -RRB-)) (CC and) (VP (VBD questioned) (NP (NP (VBG regarding) (NNS symptoms)) (CC and) (NP (JJ functional) (NNS abilities))) (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission)))))))) (. .)))
18020536	6	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_907_911_Chemical/RDs))) (PP (IN before) (NP (NN admission)))) (, ,) (NP (JJ current) (NNS medications)) (CC and) (NP (NN discharge) (NNS diagnoses))))) (VP (AUX were) (VP (VBN collected) (PP (IN from) (NP (JJ medical) (NNS records))))) (. .)))
18020536	7	(S1 (S (S (NP (NP (NN Health) (, ,) (JJ physical) (NNS abilities)) (CC and) (NP (JJ cognitive) (NN function))) (VP (AUX were) (VP (VBN compared) (PP (IN between) (NP (NP (JJ BZD/RD) (NNS users)) (CC and) (NP (NNS non-users))))))) (, ,) (CC and) (S (NP (NNS adjustments)) (VP (AUX were) (VP (VBN made) (PP (IN for) (NP (JJ confounding) (NNS variables)))))) (. .)))
18020536	8	(S1 (S (NP (NP (DT The) (JJ residual) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_18020536_1205_1213_Chemical)) (, ,) (NP (NNP Doc_18020536_1215_1224_Chemical)) (CC and) (NP (NNP Doc_18020536_1229_1238_Chemical))))) (VP (AUX were) (VP (VBN analysed))) (. .)))
18020536	9	(S1 (S (NP (NP (DT The) (JJ mean) (JJ +/-) (NN SD) (NN duration)) (PP (IN of) (NP (JJ BZD/RD) (NN use)))) (VP (AUX was) (NP (NP (CD 7) (JJ +/-) (CD 7) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 1-31)) (-RRB- -RRB-)))) (. .)))
18020536	10	(S1 (S (S (NP (QP (CD Two) (CC or) (CD three)) (NNS Doc_18020536_1347_1351_Chemical/RDs)) (VP (AUX were) (ADVP (RB concomitantly)) (VP (VBN taken) (PP (IN by) (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (NNS users)))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-)) (. .)))
18020536	11	(S1 (S (NP (NP (JJ Long-term) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ female) (NN sex)) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN number)) (PP (IN of) (NP (NNS drugs))))) (PP (IN with) (NP (NP (NNS effects)) (PP (IN on) (NP (DT the) (NNS CNS))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (VBN diagnosed) (NNP Doc_18020536_1568_1576_Disease))))))))))))))))) (. .)))
18020536	12	(S1 (S (PP (IN After) (NP (NP (NN adjustment)) (PP (IN for) (NP (NP (DT these) (NNS variables)) (PP (IN as) (NP (NNS confounders))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_1638_1642_Chemical/RDs)))) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ cognitive) (NN function))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (DT the) (NN MMSE)))))))) (. .)))
18020536	13	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_1731_1735_Chemical/RDs)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_18020536_1760_1769_Disease)) (, ,) (NP (NNP Doc_18020536_1771_1789_Disease)))) (PP (IN after) (S (VP (VBG awaking) (PP (IN at) (NP (NP (NN night)) (CC and) (NP (NNP Doc_18020536_1817_1826_Disease)))) (PP (IN in) (NP (DT the) (NNS mornings))) (PP (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission)))))) (CC and) (PP (IN with) (NP (NP (JJR stronger) (NN Doc_18020536_1896_1915_Disease)) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (DT the) (NN hospital) (NN stay)))))))))))))) (. .)))
18020536	14	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_18020536_1971_1975_Chemical/RDs)))) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (VBN reduced) (NN ability) (S (VP (TO to) (VP (VB walk))))) (CC and) (NP (JJR shorter) (JJ night-time) (NN sleep)))) (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission))))))))))) (. .)))
18020536	15	(S1 (S (NP (NP (DT A) (JJR higher) (JJ residual) (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_18020536_2141_2150_Chemical)))) (VP (VBD correlated) (PP (IN with) (NP (DT a) (JJR lower) (NN MMSE) (NN sum) (NN score))) (PP (IN after) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ confounding) (NNS variables)))))) (. .)))
18020536	16	(S1 (S (NP (NP (NP (JJ Long-term) (NN use)) (CC and) (NP (JJ concomitant) (NN use))) (PP (IN of) (NP (QP (JJR more) (IN than) (CD one)) (NN BZD/RD)))) (VP (AUX were) (ADJP (JJ common)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBN hospitalised) (PP (IN because) (IN of) (NP (JJ acute) (NNS illnesses))))))) (. .)))
18020536	17	(S1 (S (NP (JJ Long-term) (NN use)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (JJ daytime) (CC and) (JJ night-time)) (NNS symptoms)) (UCP (ADJP (JJ indicative) (PP (IN of) (NP (JJR poorer) (NN health)))) (CC and) (VP (ADVP (RB potentially)) (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .)))
18023325	0	(S1 (S (NP (JJ Acute)) (VP (VBP Doc_18023325_6_22_Disease) (PP (IN after) (NP (JJ acute) (JJ Doc_18023325_35_45_Chemical) (NN intoxication)))) (. .)))
18023325	1	(S1 (S (S (NP (NP (JJ Acute) (NN Doc_18023325_66_87_Disease)) (VP (VBN caused) (PP (IN by) (NP (DT a) (JJ Doc_18023325_100_110_Chemical) (NN Doc_18023325_111_119_Disease))))) (VP (AUX is) (ADJP (RB very) (JJ rare)))) (CC and) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN report)) (PP (IN of) (NP (NP (PRP it)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_18023325_173_189_Disease))))))))) (. .)))
18023325	2	(S1 (S (NP (DT A) (JJ 49-year-old) (NN woman)) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (PRP$ our) (NN department))) (PP (IN because) (IN of) (NP (NNP Doc_18023325_256_269_Disease))) (, ,) (S (VP (VBG lancinating) (NP (NP (NNP Doc_18023325_283_287_Disease)) (, ,) (NP (NNP Doc_18023325_289_301_Disease)) (, ,) (CC and) (NP (NP (NNP Doc_18023325_307_318_Disease)) (PP (IN of) (NP (DT the) (JJ distal) (NNS limbs))))))))) (. .)))
18023325	3	(S1 (S (ADVP (NP (CD One) (NN month)) (RB previously)) (, ,) (NP (PRP she)) (VP (AUX had) (VP (VBN taken) (NP (NP (NP (DT a) (JJ single) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_18023325_398_408_Chemical)))) (-LRB- -LRB-) (NP (NP (CD 130) (NNS tablets)) (PP (IN of) (NP (JJ Doc_18023325_425_432_Chemical) (NN STOP) (NN TAB)))) (, ,) (NP (JJ Shin-Poong) (NN Pharm))))) (. .)))
18023325	4	(S1 (NP (NP (NNP Co.)) (, ,) (NP (NP (NP (NNP Ansan)) (PRN (, ,) (NP (NNP Korea)) (-RRB- -RRB-))) (PP (IN in) (NP (DT a) (NN suicide) (NN attempt)))) (. .)))
18023325	5	(S1 (S (NP (PRP She)) (VP (AUX was) (RB not) (NP (DT an) (JJ alcoholic))) (. .)))
18023325	6	(S1 (S (PP (IN For) (NP (NP (DT the) (JJ first) (JJ few) (NNS days)) (PP (IN after) (NP (NN ingestion))))) (, ,) (NP (PRP she)) (VP (VP (AUX was) (PP (IN in) (NP (DT a) (VBN confused) (NN state)))) (CC and) (VP (AUX had) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (NP (NP (NNP Doc_18023325_621_627_Disease)) (CC and) (NP (NNP Doc_18023325_632_641_Disease))))))))) (. .)))
18023325	7	(S1 (S (NP (PRP She)) (VP (VP (VBD noticed) (NP (NN Doc_18023325_655_665_Disease))) (CC and) (VP (ADVP (RB distally)) (VBD accentuated) (NP (NP (NN motor)) (CC and) (NP (JJ sensory) (NN dysfunction))) (SBAR (IN after) (S (NP (PRP she)) (VP (AUX had) (VP (VBN recovered) (PP (IN from) (NP (DT this) (NN state))))))))) (. .)))
18023325	8	(S1 (S (NP (DT A) (NN nerve) (NN conduction) (NN study)) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (JJ severe) (NN sensorimotor) (NN axonal) (NN Doc_18023325_834_848_Disease))))) (. .)))
18023325	9	(S1 (S (NP (NP (JJ Laryngeal) (NN electromyography)) (PRN (-LRB- -LRB-) (NP (JJ thyroarytenoid) (NN muscle)) (-RRB- -RRB-))) (VP (VBD showed) (NP (JJ ample) (NN denervation) (NNS potentials))) (. .)))
18023325	10	(S1 (S (NP (NNP Laryngoscopy)) (VP (VBD revealed) (NP (NN asymmetric) (NN vocal) (VB fold) (NNS movements)) (PP (IN during) (NP (NN phonation)))) (. .)))
18023325	11	(S1 (S (NP (NP (PRP$ Her) (JJ vocal) (NN change)) (CC and) (NP (NN weakness))) (VP (VBD began) (S (VP (TO to) (VP (VB improve) (ADVP (RB spontaneously))))) (PP (NP (QP (RB about) (CD 3)) (NNS weeks)) (IN after) (NP (NN transfer)))) (. .)))
18023325	12	(S1 (S (NP (DT This)) (VP (VP (AUX was) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_18023325_1126_1131_Disease)) (PP (IN of) (NP (DT the) (JJ recurrent) (JJ laryngeal) (NN nerve))))))) (CC and) (VP (VBN superimposed) (NP (NP (JJ severe) (JJ acute) (NN sensorimotor) (NN axonal) (NN Doc_18023325_1215_1229_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ high-dose) (JJ Doc_18023325_1250_1260_Chemical) (NN intoxication))))))) (. .)))
18081909	0	(S1 (S (NP (NP (NN Doc_18081909_0_14_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18081909_26_39_Chemical))))) (VP (VBD added) (PP (TO to) (NP (NNP Doc_18081909_49_58_Chemical)))) (. .)))
18081909	1	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (DT a) (JJ Doc_18081909_108_121_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18081909_123_126_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_18081909_136_150_Disease)))))) (. .)))
18081909	2	(S1 (S (NP (NP (DT A) (JJ 28-year-old) (NN man)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_18081909_195_214_Disease))) (PP (IN with) (NP (JJ generalized) (NNP Doc_18081909_232_240_Disease))))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_18081909_258_261_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3000) (NN mg)) (-RRB- -RRB-)))) (PP (VBN added) (PP (TO to) (NP (NP (NP (NNP Doc_18081909_281_290_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18081909_292_295_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 2000) (NN mg)) (-RRB- -RRB-))))))) (. .)))
18081909	3	(S1 (S (NP (NP (NN Frequency)) (PP (IN of) (NP (JJ generalized) (NNP Doc_18081909_333_354_Disease)))) (VP (VBN increased) (PP (IN from) (NP (CD one))) (PP (IN per) (NP (CD 6) (NNS months))) (PP (TO to) (NP (NP (CD two)) (PP (IN per) (NP (NN month)))))) (. .)))
18081909	4	(S1 (S (NP (JJ Neuropsychological) (NN testing)) (VP (VBD showed) (NP (NN Doc_18081909_439_498_Disease))) (. .)))
18081909	5	(S1 (S (NP (NP (DT The) (JJ interictal) (NN electroencephalogram)) (PRN (-LRB- -LRB-) (NP (NNP EEG)) (-RRB- -RRB-))) (VP (VBD showed) (NP (DT a) (JJ generalized) (NN slowing)) (PP (TO to) (NP (NP (CD 5)) (PP (IN per) (NP (NP (JJ second) (JJ theta) (NNS rhythms)) (PP (IN with) (NP (JJ bilateral) (JJ generalized) (NN high-amplitude) (NNS discharges)))))))) (. .)))
18081909	6	(S1 (S (S (NP (NP (JJ Following) (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_18081909_693_696_Chemical)) (, ,) (NP (NNP EEG)) (CC and) (NP (JJ neuropsychological) (NNS findings))))) (VP (VBD improved))) (CC and) (S (NP (JJ Doc_18081909_747_754_Disease) (NN frequency)) (VP (VBD decreased))) (. .)))
18083142	0	(S1 (S (NP (NP (NN Doc_18083142_0_14_Chemical)) (VP (VBG signaling) (PP (IN through) (NP (JJ beta-adrenergic) (NNS receptors))))) (VP (AUX is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (NNP Doc_18083142_89_96_Chemical-induced) (NNP Doc_18083142_105_112_Disease))))))) (. .)))
18083142	1	(S1 (S (NP (NN Doc_18083142_126_133_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB widely) (VBN abused)) (NN psychostimulant)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (DT both) (ADJP (ADJP (JJ rewarding)) (CC and) (ADJP (JJ aversive))) (NNS properties))))))) (. .)))
18083142	2	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (NNP Doc_18083142_250_257_Chemical) (POS 's)) (JJ rewarding) (NNS effects)))) (VP (AUX have) (VP (AUX been) (VP (VBN studied) (ADVP (RB extensively))))))) (, ,) (NP (JJR less) (NN attention)) (VP (AUX has) (VP (AUX been) (VP (VBN paid) (PP (TO to) (NP (NP (DT the) (JJ unpleasant) (JJ behavioral) (NNS states)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18083142_385_392_Chemical)))) (, ,) (PP (JJ such) (IN as) (NP (NN Doc_18083142_402_409_Disease)))))))) (. .)))
18083142	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBN evaluated) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (NP (JJ Doc_18083142_467_475_Chemical) (JJ beta-hydroxylase) (NN knockout) (PRN (-LRB- -LRB-) (NNP Dbh) (NN -/-) (-RRB- -RRB-)) (NNS mice)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP lack) (NP (NP (NNP Doc_18083142_529_543_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18083142_545_547_Chemical)) (-RRB- -RRB-)))))) (, ,)))) (PP (IN in) (NP (DT the) (JJ elevated) (JJ plus) (NN maze) (PRN (-LRB- -LRB-) (NNP EPM) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (NN noradrenergic)) (VP (VBG signaling) (PP (TO to) (NP (NNP Doc_18083142_640_647_Chemical-induced) (NNP Doc_18083142_656_663_Disease))))))))))))) (. .)))
18083142	4	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NNP Doc_18083142_688_695_Chemical)) (ADVP (RB dose-dependently)) (VP (VBD increased) (NP (JJ Doc_18083142_723_730_Disease-like) (NN behavior)) (PP (IN in) (NP (JJ control) (PRN (-LRB- -LRB-) (NP (NNP Dbh) (CD +/-)) (-RRB- -RRB-)) (NNS mice))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ open) (NN arm) (NN exploration)))))))))))) (. .)))
18083142	5	(S1 (S (NP (DT The) (NNP Dbh) (NN -/-) (NNS mice)) (VP (VP (AUX had) (NP (NP (JJ normal) (NN baseline) (NN performance)) (PP (IN in) (NP (DT the) (NN EPM))))) (CC but) (VP (AUX were) (ADJP (RB completely) (JJ resistant) (PP (TO to) (NP (NP (DT the) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_18083142_942_949_Chemical)))))))) (. .)))
18083142	6	(S1 (S (NP (JJ Doc_18083142_951_958_Chemical-induced) (NN Doc_18083142_967_974_Disease)) (VP (AUX was) (ADVP (RB also)) (VP (VBN attenuated) (PP (IN in) (NP (NNP Dbh) (JJ +/-) (NNS mice))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_18083142_1039_1049_Chemical)) (, ,) (NP (DT a) (JJ Doc_18083142_1053_1061_Chemical) (NN beta-hydroxylase) (PRN (-LRB- -LRB-) (NP (NNP DBH)) (-RRB- -RRB-)) (NN inhibitor)))))))) (. .)))
18083142	7	(S1 (S (PP (IN In) (NP (NP (NNS experiments)) (VP (VBG using) (NP (JJ specific) (JJ adrenergic) (NNS antagonists))))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (DT the) (JJ beta-adrenergic) (NN receptor) (NN antagonist) (NNP Doc_18083142_1222_1233_Chemical)))) (VP (VBD blocked) (NP (JJ Doc_18083142_1242_1249_Chemical-induced) (JJ Doc_18083142_1258_1265_Disease-like) (NN behavior)) (PP (IN in) (NP (NP (NNP Dbh) (NNS +/-)) (CC and) (NP (JJ wild-type) (NNP C57BL6/J) (NNS mice)))) (, ,) (SBAR (IN while) (S (NP (NP (NP (DT the) (NN alpha) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN antagonist)) (NP (NNP Doc_18083142_1350_1358_Chemical))) (CC and) (NP (NP (DT the) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))) (VP (VBP antagonist) (SBAR (S (NP (NNP Doc_18083142_1387_1396_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)))))))))))) (. .)))
18083142	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN noradrenergic)) (VP (VBG signaling) (PP (IN via) (NP (JJ beta-adrenergic) (NNS receptors))))) (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (JJ Doc_18083142_1523_1530_Chemical-induced) (NN Doc_18083142_1539_1546_Disease)) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
18162529	0	(S1 (S (NP (NP (JJ Hypothalamic) (NN prolactin) (NN receptor) (NN messenger) (JJ Doc_18162529_42_58_Chemical) (NNS levels)) (, ,) (NP (NN prolactin) (VBG signaling)) (, ,) (CC and) (NP (NP (JJ Doc_18162529_92_110_Disease) (NN inhibition)) (PP (IN of) (NP (JJ pulsatile) (JJ luteinizing) (NN hormone) (NN secretion))))) (VP (AUX are) (ADJP (JJ dependent) (PP (IN on) (NP (NNP Doc_18162529_182_191_Chemical))))) (. .)))
18162529	1	(S1 (S (NP (NN Doc_18162529_193_211_Disease)) (VP (MD can) (VP (VB reduce) (NP (NP (NN fertility)) (CC and) (NP (NN libido))))) (. .)))
18162529	2	(S1 (S (SBAR (IN Although) (S (NP (JJ central) (NN prolactin) (NNS actions)) (VP (AUX are) (VP (VBN thought) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (DT this)))))))))) (, ,) (NP (DT the) (NNS mechanisms)) (VP (AUX are) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
18162529	3	(S1 (S (NP (PRP We)) (ADVP (RB first)) (VP (VBD tested) (SBAR (IN whether) (S (NP (JJ chronic) (NNP Doc_18162529_385_403_Disease)) (VP (VBD inhibited) (NP (NP (NP (CD two) (JJ neuroendocrine) (NNS parameters)) (ADJP (JJ necessary) (PP (IN for) (NP (JJ female) (NN fertility))))) (: :) (NP (NP (JJ pulsatile) (NN LH) (NN secretion)) (CC and) (NP (DT the) (JJ Doc_18162529_507_515_Chemical-induced) (NN LH) (NN surge)))))))) (. .)))
18162529	4	(S1 (S (NP (NP (JJ Chronic) (NN Doc_18162529_542_560_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT the) (JJ Doc_18162529_576_584_Chemical) (NN antagonist) (NN Doc_18162529_596_605_Chemical))))) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD 40) (NN %)) (NN reduction)) (VP (VBG LH) (NP (NN pulse) (NN frequency)) (PP (PP (IN in) (NP (VBN ovariectomized) (NNS rats))) (, ,) (CONJP (CC but) (RB only)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ chronic) (JJ low) (NNS levels)) (PP (IN of) (NP (NNP Doc_18162529_722_731_Chemical))))))))))) (. .)))
18162529	5	(S1 (S (NP (NN Doc_18162529_733_742_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (DT a) (JJ Doc_18162529_777_784_Chemical-induced) (NN LH) (NN surge)))) (CC or) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNP GnRH) (NNS neurons)) (VP (VBN activated) (PP (IN during) (NP (DT the) (NN surge)))))))))) (. .)))
18162529	6	(S1 (S (NP (NN Doc_18162529_864_873_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB influence) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ long) (NN form)) (PP (IN of) (NP (NP (NP (JJ prolactin) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP PRL-R)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS components)) (PP (IN of) (NP (NP (NN prolactin) (POS 's)) (VBG signaling) (NN pathway)))))))))))))) (. .)))
18162529	7	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NNP Doc_18162529_1032_1040_Chemical)) (VP (VBZ increases) (NP (NP (JJ PRL-R) (NN expression)) (CC and) (NP (NN sensitivity))) (PP (TO to) (NP (NN prolactin)))))))))) (, ,) (NP (PRP we)) (ADVP (RB next)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNP Doc_18162529_1124_1133_Chemical)) (ADVP (RB greatly)) (VP (VBZ augments) (NP (JJ prolactin-induced) (NN STAT5) (NN activation)))))) (. .)))
18162529	8	(S1 (S (ADVP (RB Lastly)) (, ,) (NP (PRP we)) (VP (VBD measured) (NP (NP (NN PRL-R) (CC and) (NN suppressor)) (PP (IN of) (NP (NN cytokine)))) (S (VP (VBG signaling) (NP (PRN (-LRB- -LRB-) (NP (NP (NN SOCS-1) (CC and) (NN -3)) (CC and) (NP (NP (NNP CIS)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP reflect) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN prolactin) (VBG signaling))))))))) (-RRB- -RRB-)) (NNS mRNAs)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_18162529_1343_1352_Chemical) (CC and) (NNP Doc_18162529_1357_1366_Chemical)))))))) (. .)))
18162529	9	(S1 (S (S (NP (NN Doc_18162529_1368_1377_Chemical)) (VP (VP (VBN induced) (ADJP (RB only) (JJ SOCS-1)) (PP (PP (IN in) (NP (NP (DT the) (JJ medial) (JJ preoptic) (NN area)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NNP GnRH) (NNS neurons)) (VP (AUX are) (VP (VBN regulated))))) (, ,))) (CC but) (PP (IN in) (NP (DT the) (JJ arcuate) (NN nucleus))))) (CC and) (VP (VBN choroid) (S (ADJP (JJ plexus) (, ,) (JJ PRL-R) (, ,) (JJ SOCS-3)))))) (, ,) (CC and) (S (NP (NN CIS) (NN mRNA) (NNS levels)) (VP (AUX were) (ADVP (RB also)) (VP (VBN induced)))) (. .)))
18162529	10	(S1 (S (NP (NN Doc_18162529_1562_1571_Chemical)) (VP (VBD enhanced) (NP (NP (DT these) (NNS effects)) (PP (IN on) (NP (NP (NN SOCS-3)) (CC and) (NP (NN CIS)))))) (. .)))
18162529	11	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NNP Doc_18162529_1629_1638_Chemical)) (ADVP (RB also)) (VP (VBN induced) (NP (NN PRL-R) (, ,) (NN SOCS-3) (, ,) (CC and) (NN CIS) (NN mRNA) (NNS levels)) (ADVP (RB independently))) (. .)))
18162529	12	(S1 (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP GnRH) (NN pulse) (NN frequency)) (VP (AUX is) (VP (VBD inhibited) (PP (IN by) (NP (NN chronic) (NN Doc_18162529_1768_1786_Disease))) (PP (IN in) (NP (DT a) (JJ Doc_18162529_1792_1799_Chemical-dependent) (NN manner)))))))) (. .)))
18162529	13	(S1 (S (NP (PRP They)) (ADVP (RB also)) (VP (VBP provide) (NP (NN evidence)) (PP (IN for) (NP (NP (NN Doc_18162529_1849_1858_Chemical-dependent)) (CC and) (NP (NP (NN brain) (JJ region-specific) (NN regulation)) (PP (IN of) (NP (NP (JJ PRL-R) (NN expression)) (CC and) (NP (VBG signaling) (NNS responses)))) (PP (IN by) (NP (NN prolactin))))))) (. .)))
18182964	0	(S1 (NP (NP (NP (NN Doc_18182964_0_9_Chemical)) (PP (IN for) (NP (NNP Doc_18182964_14_54_Disease)))) (: :) (NP (NNP II)) (. .)))
18182964	1	(S1 (NP (NP (NP (JJ ECG) (NNS changes)) (CC and) (NP (JJ adverse) (NNS events) (NN analysis))) (. .)))
18182964	2	(S1 (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN safety) (CC and) (NN tolerability)) (PP (IN of) (NP (NNP Doc_18182964_154_163_Chemical))))))) (VP (VBD used) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NNP Doc_18182964_183_198_Chemical)))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NNP Doc_18182964_216_256_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18182964_258_262_Disease)) (-RRB- -RRB-))))))) (. .)))
18182964	3	(S1 (S (PP (IN In) (NP (DT a) (JJ 16-week) (JJ multicenter) (, ,) (JJ double-blind) (NN trial))) (, ,) (NP (NP (CD 122) (NNS children)) (PP (IN with) (NP (NNP Doc_18182964_337_341_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (NNP Doc_18182964_368_377_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 31)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_18182964_388_403_Chemical) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 29)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_18182964_414_423_Chemical) (CC and) (NNP Doc_18182964_428_443_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 32)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 30)) (-RRB- -RRB-))))))) (. .)))
18182964	4	(S1 (S (NP (NNS Doses)) (VP (AUX were) (ADVP (RB flexibly)) (VP (VBN titrated) (PRT (RP up)) (PP (TO to) (NP (NP (NP (NP (CD 0.6) (NN mg/day)) (PP (IN for) (NP (NNP Doc_18182964_525_534_Chemical)))) (CC and) (NP (NP (CD 60) (NN mg/day)) (PP (IN for) (NP (NNP Doc_18182964_553_568_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (DT both)) (PP (IN with) (NP (VBN divided) (NN dosing)))) (-RRB- -RRB-)))))) (. .)))
18182964	5	(S1 (S (NP (NNS Groups)) (VP (AUX were) (VP (VBN compared) (PP (VBG regarding) (NP (NP (JJ adverse) (NNS events)) (CC and) (NP (NP (NNS changes)) (PP (IN from) (NP (NN baseline))) (PP (TO to) (NP (NN week) (CD 16))) (PP (IN in) (NP (NP (NNS electrocardiograms)) (CC and) (NP (JJ vital) (NNS signs))))))))) (. .)))
18182964	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (JJR more) (NNS incidents)) (PP (IN of) (NP (NNP Doc_18182964_757_768_Disease)))) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18182964_794_803_Chemical))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT those) (ADJP (RB not) (VBN treated))) (PP (IN with) (NP (NP (NNP Doc_18182964_841_850_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 17.5) (NN %)) (CC versus) (NP (CD 3.4) (NN %))) (: ;) (QP (CD p) (CD =.02))) (-RRB- -RRB-))))) (, ,) (CC but) (NP (NP (DT no) (JJ other) (JJ significant) (NN group) (NNS differences)) (VP (VBG regarding) (NP (NP (NN electrocardiogram)) (CC and) (NP (JJ other) (JJ cardiovascular) (NNS outcomes)))))))))))) (. .)))
18182964	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS suggestions)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NNP Doc_18182964_1036_1045_Chemical)) (CC and) (NP (NNP Doc_18182964_1050_1065_Chemical)))) (VP (VBG regarding) (NP (JJ cardiovascular) (NNS outcomes))))))) (. .)))
18182964	8	(S1 (S (NP (ADJP (JJ Moderate) (CC or) (JJ severe)) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN on) (NP (NNP Doc_18182964_1167_1176_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (CD 79.4) (NN %)) (CC versus) (NP (NP (CD 49.2) (NN %)) (: ;) (NP (NNP p) (CD =.0006)))) (-RRB- -RRB-)) (CC but) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (JJR higher) (NNS rates)) (PP (IN of) (NP (JJ early) (NN study) (NN withdrawal))))))) (. .)))
18182964	9	(S1 (S (S (NP (NN Doc_18182964_1272_1282_Disease)) (VP (AUX was) (ADJP (JJ common)) (PP (IN on) (NP (NNP Doc_18182964_1297_1306_Chemical))))) (, ,) (CC but) (S (ADVP (RB generally)) (VP (VBN resolved) (PP (IN by) (NP (QP (CD 6) (TO to) (CD 8)) (NNS weeks))))) (. .)))
18182964	10	(S1 (S (NP (NP (NN Doc_18182964_1361_1370_Chemical)) (, ,) (VP (VBN used) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NNP Doc_18182964_1391_1406_Chemical))))) (, ,)) (VP (VBZ appears) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (RB well) (VBN tolerated) (PP (IN in) (NP (NN childhood) (NN Doc_18182964_1453_1457_Disease)))))) (. .)))
18182964	11	(S1 (S (NP (NP (NNS Physicians)) (VP (VBG prescribing) (NP (NNP Doc_18182964_1482_1491_Chemical)))) (VP (MD should) (VP (VP (VB monitor) (PP (IN for) (NP (NNP Doc_18182964_1511_1522_Disease)))) (CC and) (VP (VB advise) (NP (NNS patients)) (PP (IN about) (NP (NP (DT the) (JJ high) (NN likelihood)) (PP (IN of) (NP (JJ initial) (NN Doc_18182964_1580_1590_Disease)))))))) (. .)))
18186898	0	(S1 (NP (NP (NP (NP (NN Doc_18186898_0_22_Disease)) (CC and) (NP (NN Doc_18186898_27_35_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation)))) (: :) (NP (JJ drug-related) (NNP Doc_18186898_78_101_Disease)) (. ?)))
18186898	1	(S1 (S (NP (NP (NNS Advances)) (PP (IN in) (NP (NP (DT the) (NN field)) (PP (IN of) (NP (NN transplantation)))))) (VP (VP (VBP provide) (NP (NP (DT a) (JJR better) (NN quality)) (PP (IN of) (NP (NN life))))) (CC and) (VP (VBP allow) (NP (NP (RBR more) (JJ favorable) (NNS conditions)) (PP (IN for) (NP (NP (NN growth) (CC and) (NN development)) (PP (IN in) (NP (NNS children)))))))) (. .)))
18186898	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS combinations)) (PP (IN of) (NP (JJ different) (JJ therapeutic) (NNS regimens)))) (VP (VBP require) (NP (NP (NN consideration)) (PP (IN of) (NP (JJ potential) (JJ adverse) (NNS reactions))))) (. .)))
18186898	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 15-yr-old) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PP (IN because) (IN of) (NP (NN Doc_18186898_444_460_Disease)))))))) (. .)))
18186898	4	(S1 (S (NP (NP (NNP Doc_18186898_462_472_Chemical)) (, ,) (NP (NNP Doc_18186898_474_477_Chemical)) (, ,) (CC and) (NP (NNP Doc_18186898_483_491_Chemical))) (VP (AUX were) (VP (VBN given) (PP (IN as) (NP (NN immunosuppressant))))) (. .)))
18186898	5	(S1 (S (NP (NN Doc_18186898_525_535_Chemical)) (VP (AUX was) (VP (VBN added) (PP (IN because) (IN of) (NP (IN de) (NNP nova) (NNP Doc_18186898_565_586_Disease))) (PP (IN during) (NP (PRP$ her) (NN follow-up))))) (. .)))
18186898	6	(S1 (S (PP (NP (CD Three) (NNS yr)) (IN after) (NP (NN transplantation))) (NP (PRP she)) (VP (VBD developed) (NP (NNP Doc_18186898_654_676_Disease)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_18186898_689_707_Disease)) (, ,) (NP (NNP Doc_18186898_709_725_Disease)) (, ,) (NP (NNP Doc_18186898_727_737_Disease)) (, ,) (CC and) (NP (NNP Doc_18186898_743_756_Disease))))) (. .)))
18186898	7	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_18186898_767_777_Chemical)) (VP (VP (AUX was) (VP (VBN suspected) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (JJ late) (JJ post-transplant) (JJ renal) (NN Doc_18186898_838_846_Disease))))))))) (CC and) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NNP Doc_18186898_867_876_Chemical)))))))) (, ,) (NP (NP (NNP Doc_18186898_878_886_Disease)) (, ,) (CC and) (NP (NN electrolyte) (NN imbalance))) (VP (VBD got) (ADJP (JJR worse))) (. .)))
18186898	8	(S1 (S (NP (NNP Proximal) (NNP Doc_18186898_934_949_Disease)) (VP (AUX has) (VP (VBN developed) (PP (IN during) (NP (PRP$ her) (NN follow-up))))) (. .)))
18186898	9	(S1 (S (NP (NP (NN Doc_18186898_986_1002_Disease)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_18186898_1015_1023_Disease)) (, ,)) (VP (AUX is) (ADVP (RB well)) (VP (VP (VBN recognized) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18186898_1061_1084_Disease)))))) (CC and) (VP (VBN caused) (PP (IN by) (NP (NP (NN depletion)) (PP (IN of) (NP (NN mtDNA)))))))) (. .)))
18186898	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (PRP$ our) (NN patient) (POS 's)) (NNP Doc_18186898_1149_1168_Disease) (CC and) (NNP Doc_18186898_1173_1181_Disease)) (VP (MD may) (VP (AUX have) (VP (VBN resulted) (PP (IN from) (NP (NP (NNP Doc_18186898_1205_1230_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VP (VBN triggered) (PP (IN by) (NP (NNP Doc_18186898_1253_1263_Chemical)))) (CC and) (VP (VBN augmented) (PP (IN by) (NP (NN Doc_18186898_1281_1291_Chemical)))))))))))))))) (. .)))
18208574	0	(S1 (S (NP (NP (JJR Higher) (JJ optical) (NN density)) (PP (IN of) (NP (DT an) (NN antigen) (NN assay)))) (VP (VBZ predicts) (NP (NN Doc_18208574_52_62_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18208574_80_87_Chemical-induced) (NNP Doc_18208574_96_112_Disease)))))) (. .)))
18208574	1	(S1 (S (S (VP (TO To) (VP (VB correlate) (NP (NP (JJ optical) (NN density)) (CC and) (NP (NP (NN percent) (NN inhibition)) (PP (IN of) (NP (NP (DT a) (JJ two-step) (JJ Doc_18208574_192_199_Chemical-induced) (NNP Doc_18208574_208_224_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_18208574_226_229_Disease)) (-RRB- -RRB-)) (NN antigen) (NN assay)) (PP (IN with) (NP (NNP Doc_18208574_250_260_Disease)))))))))) (: ;) (S (NP (DT the) (NN assay)) (VP (VBZ utilizes) (NP (NP (NN reaction) (NN inhibition) (NNS characteristics)) (PP (IN of) (NP (DT a) (JJ high) (JJ Doc_18208574_327_334_Chemical) (NN concentration)))))) (. .)))
18208574	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NNPS Patients)) (PP (IN with) (NP (NP (NP (QP (JJR more) (IN than) (CD 50)) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (JJ platelet) (NN count)) (CC or) (NP (NP (NNP Doc_18208574_430_446_Disease)) (PRN (-LRB- -LRB-) (NP (CD <150) (NNP x) (CD 10) (-LRB- -LRB-) (CD 9) (-RRB- -RRB-) (NNS /L)) (-RRB- -RRB-))))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_18208574_482_489_Chemical)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ positive) (JJ two-step) (NN antigen) (NN assay) (JJ -LSB-optical) (NN density)) (PRN (-LRB- -LRB-) (NP (NNP OD)) (-RRB- -RRB-)) (NP (QP (CD >0.4) (CC and) (CD >50)) (NN inhibition))) (PP (IN with) (NP (NP (JJ high) (NN concentration)) (PP (IN of) (NP (JJ Doc_18208574_606_613_Chemical) (NNS -RSB-))))))))))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
18208574	3	(S1 (S (S (NP (NP (CD Forty)) (PP (IN of) (NP (CD 94) (NNP Doc_18208574_664_667_Disease) (NNS patients)))) (VP (AUX had) (NP (NN Doc_18208574_681_691_Disease)) (PP (IN at) (NP (NN diagnosis))))) (: ;) (S (NP (CD 54/94)) (VP (AUX had) (NP (NN isolated-Doc_18208574_725_728_Disease)) (PP (IN without) (NP (NNP Doc_18208574_737_747_Disease))))) (. .)))
18208574	4	(S1 (S (S (NP (NP (CD Eight)) (PP (IN of) (NP (DT the) (JJ isolated-Doc_18208574_771_774_Disease) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_18208574_794_804_Disease)) (PP (IN within) (NP (NP (DT the) (JJ next) (CD 30)) (NP (NNP d)))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 48) (NNS patients)))) (VP (AUX had) (NP (NN Doc_18208574_860_870_Disease)) (PP (IN at) (NP (NN day) (CD 30))))) (. .)))
18208574	5	(S1 (S (PP (IN At) (NP (NN diagnosis))) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NN OD))) (PP (IN between) (NP (NP (NP (JJ Doc_18208574_945_948_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_18208574_963_973_Disease)))) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NN isolated-Doc_18208574_998_1001_Disease)))))))) (. .)))
18208574	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP OD)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18208574_1061_1071_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 48)) (, ,) (NP (QP (CD 1.34) (CD +/-)) (CD 0.89)) (-RRB- -RRB-)))) (, ,) (PP (VBG including) (NP (NP (JJ isolated-Doc_18208574_1116_1119_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB later)) (VP (VBD developed) (NP (NNP Doc_18208574_1149_1159_Disease)) (PP (IN within) (NP (NP (CD 30)) (NP (NNP d)))) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 8)) (, ,) (NP (CD 1.84) (JJ +/-) (NN 0.64))) (-RRB- -RRB-)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ isolated-Doc_18208574_1219_1222_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VB develop) (NP (NP (NNP Doc_18208574_1252_1262_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.96) (NN +/-) (CD 0.75)) (: ;) (NP (NNP P) (SYM =) (CD 0.011) (CC and) (CD P)) (X (SYM =)) (CD 0.008)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
18208574	7	(S1 (S (NP (DT The) (NN Receiver)) (NP (JJ Operative) (JJ Characteristic) (NN Curve)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP OD) (CD >1.27)) (PP (IN in) (NP (DT the) (JJ isolated-Doc_18208574_1386_1389_Disease) (NN group)))) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN chance)) (PP (IN of) (S (VP (VBG developing) (NP (NN Doc_18208574_1444_1454_Disease)) (PP (IN by) (NP (NN day) (CD 30))))))))))) (. .)))
18208574	8	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NNS groups)))) (VP (VBD showed) (NP (NP (JJ significant) (NN difference)) (PP (IN in) (NP (NN percent) (NN inhibition))))) (. .)))
18208574	9	(S1 (S (NP (JJ Multivariate) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (JJ 2.8-fold) (JJ increased) (NN risk)) (PP (IN of) (NP (NNP Doc_18208574_1598_1608_Disease))) (PP (IN in) (NP (NNS females))))) (. .)))
18208574	10	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NN Doc_18208574_1632_1642_Disease) (NN risk)) (VP (VBN increased) (PP (IN with) (NP (NP (NN age)) (CC and) (NP (NN OD) (NNS values))))) (. .)))
18208574	11	(S1 (S (S (NP (JJR Higher) (NN OD)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ significant) (NN risk)) (PP (IN of) (NP (NP (JJ subsequent) (NN Doc_18208574_1754_1764_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN isolated-Doc_18208574_1791_1794_Disease)))))))))))) (: ;) (S (NP (NN percent) (NN inhibition)) (, ,) (ADVP (RB however)) (, ,) (VP (AUX was) (RB not) (ADJP (JJ predictive)))) (. .)))
18217897	0	(S1 (S (NP (NNP Doc_18217897_0_11_Chemical)) (VP (AUX has) (NP (NP (NP (JJ limited) (JJ single-agent) (NN activity)) (PP (IN in) (NP (JJ relapsed) (CC or) (JJ refractory) (NN indolent) (NN Doc_18217897_81_102_Disease)))) (: :) (NP (NP (DT a) (NN phase) (NNP II) (NN trial)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18217897_128_134_Disease)) (CC and) (NP (NNP Doc_18217897_139_147_Disease) (NNP Group) (NNP B))))))) (. .)))
18217897	1	(S1 (S (NP (NN Doc_18217897_157_168_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ immunomodulatory) (NN agent)) (PP (IN with) (NP (NP (VBN demonstrated) (NN activity)) (PP (IN in) (NP (NP (NNP Doc_18217897_228_244_Disease)) (, ,) (NP (NNP Doc_18217897_246_266_Disease)) (CC and) (NP (NNP Doc_18217897_271_297_Disease)))))))) (. .)))
18217897	2	(S1 (S (NP (PRP$ Its) (NN activity)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (NP (JJ due) (NN modulation)) (PP (IN of) (NP (DT the) (NNP Doc_18217897_352_358_Disease) (NN milieu))))))) (, ,) (PP (VBG including) (NP (NP (NN downregulation)) (PP (IN of) (NP (NP (NNS angiogenesis)) (CC and) (NP (JJ inflammatory) (NNS cytokines)))))))) (. .)))
18217897	3	(S1 (S (PP (IN Between) (NP (NNP July) (CD 2001) (CC and) (NP (NNP April) (CD 2004)))) (, ,) (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (JJ relapsed/refractory) (NN indolent) (NN Doc_18217897_516_525_Disease)))) (VP (VBD received) (NP (NP (NNP Doc_18217897_535_546_Chemical) (CD 200) (NNS mg)) (ADJP (JJ daily) (PP (IN with) (NP (NN escalation))))) (PP (IN by) (NP (NP (CD 100) (NNS mg)) (ADVP (RB daily) (NP (DT every) (JJ 1-2) (NNS weeks)) (PP (IN as) (ADJP (JJ tolerated)))))) (, ,) (ADVP (RB up) (PP (TO to) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (NP (CD 800) (NNS mg)) (ADVP (RB daily)))))))) (. .)))
18217897	4	(S1 (S (NP (NNS Patients)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 2) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NN 1-4)) (-RRB- -RRB-)) (JJ prior) (NNS regimens)))))) (. .)))
18217897	5	(S1 (S (PP (IN Of) (NP (CD 24) (JJ evaluable) (NNS patients))) (, ,) (NP (NP (NP (CD two)) (VP (VBN achieved) (NP (DT a) (JJ complete) (NN remission)))) (CC and) (NP (CD one))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN remission)) (PP (IN for) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 12.5) (NN %))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN confidence) (NN interval)) (: :) (NP (CD 2.6-32.4) (NN %))) (-RRB- -RRB-)))))) (. .)))
18217897	6	(S1 (S (NP (CD Eleven) (NNS patients)) (VP (VBD progressed) (PP (IN during) (NP (NN therapy)))) (. .)))
18217897	7	(S1 (S (NP (NN Grade) (NN 3-4) (JJ adverse) (NNS effects)) (VP (VBD included) (NP (NNP Doc_18217897_971_987_Disease) (, ,) (NNP Doc_18217897_989_996_Disease) (, ,) (NNP Doc_18217897_998_1008_Disease/Doc_18217897_1009_1023_Disease) (, ,) (NNP Doc_18217897_1025_1035_Disease) (CC and) (NNP Doc_18217897_1040_1047_Disease))) (. .)))
18217897	8	(S1 (SINV (PP (IN Of) (NP (NN concern))) (VP (AUX was)) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (CD four) (JJ Doc_18217897_1087_1101_Disease) (NNS events)))) (. .)))
18217897	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD failed) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (NP (DT an) (JJ important) (NN response) (NN rate)) (PP (TO to) (NP (NP (JJ single) (NN agent) (NNP Doc_18217897_1187_1198_Chemical)) (PP (IN in) (NP (JJ indolent) (NNP Doc_18217897_1211_1220_Disease)))))) (CC and) (NP (NP (NN contrast)) (PP (IN with) (NP (NP (DT the) (JJR higher) (NN activity) (NN level)) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ second) (NN generation) (NN immunomodulatory) (NN agent)) (, ,) (NP (NNP Doc_18217897_1325_1337_Chemical))))))))))))) (. .)))
18221780	0	(S1 (NP (NP (NP (NN Sex) (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_18221780_19_23_Chemical) (NN antagonist) (NN enhancement)) (PP (IN of) (NP (JJ Doc_18221780_50_58_Chemical) (NNS antihyperalgesia))) (PP (IN in) (NP (NP (DT a) (JJ Doc_18221780_81_90_Chemical) (NN model)) (PP (IN of) (NP (JJ persistent) (NNP Doc_18221780_111_115_Disease)))))))) (: :) (NP (NP (NNS comparisons)) (PP (TO to) (NP (NP (CD two) (NNS models)) (PP (IN of) (NP (NNP Doc_18221780_146_156_Disease)))))) (. .)))
18221780	1	(S1 (S (PP (IN In) (NP (NNP Doc_18221780_161_171_Disease) (NNS models))) (, ,) (NP (NNP Doc_18221780_180_200_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18221780_202_206_Chemical)) (-RRB- -RRB-)) (NNS antagonists)) (VP (VB enhance) (NP (NP (DT the) (JJ antinociceptive) (NNS effects)) (PP (IN of) (NP (NNP Doc_18221780_259_267_Chemical)))) (PP (TO to) (NP (DT a) (JJR greater) (NN extent))) (PP (IN in) (NP (NP (NNS males)) (PP (IN than) (NP (NNS females)))))) (. .)))
18221780	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB extend) (NP (DT these) (NNS findings)) (PP (TO to) (NP (NP (DT a) (JJ persistent) (NN Doc_18221780_390_394_Disease) (NN model)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX be) (VP (VBN distinguished) (PP (IN from) (NP (NNP Doc_18221780_435_445_Disease) (NNS models))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NP (DT the) (JJ nociceptive) (NNS fibers)) (VP (VBN activated))) (, ,) (NP (JJ neurochemical) (NNS substrates)) (, ,) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (JJ nociceptive) (NN stimulus))))))))))))))))))) (. .)))
18221780	3	(S1 (S (PP (TO To) (NP (DT this) (NN end))) (, ,) (NP (JJ persistent) (NN Doc_18221780_595_607_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_18221780_641_650_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN tail)) (PP (IN of) (NP (ADJP (RB gonadally) (JJ intact)) (JJ F344) (NNS rats))))) (, ,) (S (VP (VBG following) (SBAR (WHNP (WDT which)) (S (S (NP (DT the) (NN tail)) (VP (AUX was) (VP (VBN immersed) (PP (IN in) (NP (DT a) (ADJP (RB mildly) (JJ noxious)) (JJ thermal) (NN stimulus)))))) (, ,) (CC and) (S (NP (JJ tail-withdrawal) (NNS latencies)) (VP (VBN measured))))))))) (. .)))
18221780	4	(S1 (S (PP (IN For) (NP (NN comparison))) (, ,) (NP (NNS tests)) (VP (AUX were) (VP (VBN conducted) (PP (IN in) (NP (NP (CD two) (JJ Doc_18221780_854_864_Disease) (NNS models)) (, ,) (NP (DT the) (NN hotplate)) (CC and) (NP (JJ warm) (NN water) (NN tail-withdrawal) (NNS procedures)))))) (. .)))
18221780	5	(S1 (S (PP (IN In) (NP (NNS males))) (, ,) (NP (DT the) (JJ non-competitive) (JJ Doc_18221780_959_963_Chemical) (NN antagonist) (NNP Doc_18221780_975_991_Chemical)) (VP (VBD enhanced) (NP (NP (DT the) (JJ antihyperalgesic) (NN effect)) (PP (IN of) (NP (NN low)))) (PP (TO to) (NP (NP (JJ moderate) (NNS doses)) (PP (IN of) (NP (NNP Doc_18221780_1057_1065_Chemical))))) (PP (IN in) (NP (DT a) (JJ dose-and) (JJ time-dependent) (NN manner)))) (. .)))
18221780	6	(S1 (S (PP (IN Across) (NP (NP (DT the) (NNS doses) (CC and) (NN pretreatment) (NNS times)) (VP (VBN examined)))) (, ,) (NP (NN enhancement)) (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NNS females))))) (. .)))
18221780	7	(S1 (S (NP (NP (NN Enhancement)) (PP (IN of) (NP (JJ Doc_18221780_1209_1217_Chemical) (NN antinociception))) (PP (IN by) (NP (NNP Doc_18221780_1237_1253_Chemical)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (DT both) (NNS males) (CC and) (NNS females)) (PP (IN in) (NP (DT the) (NNP Doc_18221780_1296_1306_Disease) (NNS models))))) (, ,) (PP (IN with) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (S (NP (DT this) (NN effect)) (VP (AUXG being) (ADJP (JJR greater)) (PP (IN in) (NP (NNS males)))))))))) (. .)))
18221780	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ sexually-dimorphic) (NN interaction)) (PP (IN between) (NP (NP (JJ Doc_18221780_1441_1445_Chemical) (NNS antagonists) (CC and) (NNP Doc_18221780_1462_1470_Chemical)) (PP (IN in) (NP (NP (DT a) (JJ persistent) (NN Doc_18221780_1487_1491_Disease) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN distinguished) (PP (IN from) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_18221780_1547_1557_Disease) (NNS models))))))))))))))))) (. .)))
18261172	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_18261172_15_26_Disease))) (PP (IN after) (NP (NN switch))) (PP (TO to) (NP (NP (JJ Doc_18261172_43_52_Chemical-based) (NN immunosuppression)) (PP (IN in) (NP (JJ long-term) (JJ cardiac) (NN transplant) (NNS patients))))) (. .)))
18261172	1	(S1 (S (NP (JJ Calcineurin-inhibitor) (NN therapy)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_18261172_161_178_Disease)) (PP (IN in) (NP (NN heart) (NN transplantation) (NNS patients))))))) (. .)))
18261172	2	(S1 (S (S (NP (NP (DT The) (JJ novel) (JJ immunosuppressive) (PRN (-LRB- -LRB-) (NP (AUX IS)) (-RRB- -RRB-)) (NN drug) (NNP Doc_18261172_252_260_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18261172_262_265_Chemical)) (-RRB- -RRB-))) (VP (VBZ lacks) (NP (NNP Doc_18261172_273_284_Disease) (NNS effects)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NNP Doc_18261172_303_314_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18261172_331_334_Chemical))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (VBG following) (NP (JJ renal) (NN transplantation))))))) (. .)))
18261172	3	(S1 (S (PP (IN In) (NP (JJ cardiac) (NN transplantation))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18261172_431_442_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18261172_459_462_Chemical))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
18261172	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (JJ long-term) (JJ cardiac) (NN transplant) (NNS patients)) (VP (AUX were) (VP (VBN switched) (PP (IN from) (NP (NNP Doc_18261172_547_559_Chemical))) (PP (TO to) (NP (JJ Doc_18261172_563_566_Chemical-based) (NNS IS))))) (. .)))
18261172	5	(S1 (S (NP (NN Concomitant)) (VP (AUX IS) (VP (VBN consisted) (PP (IN of) (NP (JJ Doc_18261172_605_626_Chemical) (JJ +/-) (NN Doc_18261172_631_639_Chemical))))) (. .)))
18261172	6	(S1 (S (NP (NNP Proteinuria)) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN from) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 0.13) (JJ g/day) (PRN (-LRB- -LRB-) (NP (NN range) (CD 0-5.7)) (-RRB- -RRB-)) (NN preswitch))))) (PP (TO to) (NP (NP (CD 0.23) (NN g/day)) (PRN (-LRB- -LRB-) (NP (CD 0-9.88)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (CD 24) (NNS months) (JJ postswitch)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0024)) (-RRB- -RRB-))))) (. .)))
18261172	7	(S1 (S (S (PP (IN Before) (NP (DT the) (NN switch))) (, ,) (NP (NP (CD 11.5) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (NP (JJ high-grade) (NN Doc_18261172_842_853_Disease)) (PRN (-LRB- -LRB-) (NP (CD >1.0) (NN g/day)) (-RRB- -RRB-))))) (: ;) (S (NP (DT this)) (VP (VBN increased) (PP (TO to) (NP (ADJP (CD 22.9) (NN %)) (NN postswitch))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.006)))) (-RRB- -RRB-)))) (. .)))
18261172	8	(S1 (S (NP (NP (NN Doc_18261172_916_929_Chemical)) (CC and) (NP (NNP Doc_18261172_934_963_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18261172_965_968_Chemical)) (-RRB- -RRB-)) (NN therapy))) (VP (VBD reduced) (NP (JJ Doc_18261172_986_997_Disease) (NN development))) (. .)))
18261172	9	(S1 (S (NP (NP (NNPS Patients)) (PP (IN without) (NP (NNP Doc_18261172_1028_1039_Disease)))) (VP (AUX had) (VP (VBN increased) (NP (NP (JJ renal) (NN function)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ median) (CD 42.5)) (CC vs.) (NP (CD 64.1))) (, ,) (NP (NNP p) (SYM =) (CD 0.25))) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ high-grade) (NNP Doc_18261172_1145_1156_Disease)))))) (VP (VBD showed) (NP (NP (VBN decreased) (JJ renal) (NN function)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN follow-up))))) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (CD 39.6) (CC vs.) (CD 29.2)) (, ,) (NP (NNP p) (SYM =) (CD 0.125))) (-RRB- -RRB-)))))))) (. .)))
18261172	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_18261172_1254_1265_Disease)) (VP (MD may) (VP (VB develop) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NNS patients))) (PP (IN after) (NP (NN switch))) (PP (TO to) (NP (NP (NNP Doc_18261172_1325_1328_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX have) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (DT these) (NNS patients)))))))))))))) (. .)))
18261172	11	(S1 (S (NP (NNP Doc_18261172_1400_1403_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NP (JJ Doc_18261172_1424_1428_Chemical/Doc_18261172_1429_1432_Chemical) (NN therapy)) (CC and) (NP (NP (NNS patients)) (VP (VBN monitored) (PP (IN for) (NP (NP (NNP Doc_18261172_1468_1479_Disease)) (CC and) (NP (VBN increased) (NNP Doc_18261172_1494_1511_Disease))))))))))) (. .)))
18308784	0	(S1 (S (NP (NN Doc_18308784_0_15_Chemical)) (VP (VBZ restores) (NP (NP (DT the) (NNP Doc_18308784_29_51_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ chronic) (JJ Doc_18308784_71_79_Chemical) (NN administration)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
18308784	1	(S1 (S (NP (NN Doc_18308784_104_107_Chemical)) (, ,) (PP (IN as) (NP (NP (DT a) (NN Doc_18308784_114_125_Chemical)) (VP (VBN extracted) (PP (IN from) (NP (JJ Panax) (NN ginseng)))))) (, ,) (VP (MD could) (VP (VB ameliorate) (NP (JJ spatial) (NNP Doc_18308784_181_200_Disease)))) (. .)))
18308784	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_18308784_242_245_Chemical)) (VP (MD might) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN prevention) (CC and) (NN treatment)) (PP (IN of) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN Doc_18308784_329_337_Chemical)))))))))))))) (. .)))
18308784	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_18308784_394_397_Chemical))) (PP (IN on) (NP (NNP Doc_18308784_401_420_Disease)))) (PP (IN by) (NP (NP (JJ chronic) (JJ Doc_18308784_432_440_Chemical) (NN administration)) (CC and) (NP (NP (DT the) (NN mechanism)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN effect))))))))))) (. .)))
18308784	4	(S1 (S (S (NP (JJ Male) (NNS rats)) (VP (AUX were) (ADVP (RB subcutaneously)) (VP (VBN injected) (PP (IN with) (NP (NP (NNP Doc_18308784_547_555_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)))) (ADVP (RB twice) (NP (DT a) (NN day))) (PP (IN at) (NP (NP (ADJP (CD 12) (NN hour)) (NNS intervals)) (PP (IN for) (NP (CD 10) (NNS days)))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_18308784_617_620_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB intraperitoneally)) (VP (VBN injected) (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NP (DT the) (JJ second) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_18308784_701_709_Chemical)) (ADVP (RB once) (NP (DT a) (NN day)) (PP (IN for) (NP (CD 10) (NNS days))))))))))) (. .)))
18308784	5	(S1 (S (NP (JJ Spatial) (NN learning) (NN capacity)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (DT the) (NNP Morris) (NN water) (NN maze))))) (. .)))
18308784	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNS rats)) (VP (VP (VBD treated) (PP (IN with) (NP (JJ Doc_18308784_841_849_Chemical/Doc_18308784_850_853_Chemical) (VBN decreased) (NN escape) (NN latency)))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN time)) (VP (VBN spent) (PP (IN in) (NP (NN platform) (UCP (NNP quadrant) (CC and) (VBG entering)) (NN frequency)))))))))) (. .)))
18308784	7	(S1 (S (PP (IN By) (NP (NP (NN implantation)) (PP (IN of) (NP (NP (NNS electrodes)) (CC and) (NP (NN electrophysiological) (NN recording)))) (PP (IN in) (NP (NN vivo))))) (, ,) (NP (DT the) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_18308784_1051_1054_Chemical)) (VP (VBD restored) (NP (NP (DT the) (JJ long-term) (NN potentiation)) (PRN (-LRB- -LRB-) (NP (NNP LTP)) (-RRB- -RRB-)) (VP (VBN impaired) (PP (IN by) (NP (NNP Doc_18308784_1109_1117_Chemical))) (PP (IN in) (NP (DT both) (ADJP (ADJP (RB freely) (JJ moving)) (CC and) (ADJP (JJ anaesthetised))) (NNS rats))))))))) (. .)))
18308784	8	(S1 (S (S (NP (NP (DT The) (JJ electrophysiological) (NN recording)) (PP (IN in) (NP (NN vitro)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_18308784_1220_1223_Chemical)) (VP (VP (VBD restored) (NP (NP (DT the) (NNS LTP)) (PP (IN in) (NP (NNS slices)))) (PP (IN from) (NP (NP (DT the) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18308784_1278_1286_Chemical))))))) (, ,) (CC but) (RB not) (VP (VBD changed) (NP (NN LTP)) (PP (IN in) (NP (NP (DT the) (NNS slices)) (PP (IN from) (NP (JJ normal) (ADJP (JJ saline-) (CC or) (JJ Doc_18308784_1345_1353_Chemical/Doc_18308784_1354_1357_Chemical-treated)) (NNS rats))))))))))) (: ;) (S (NP (DT this) (NN restoration)) (VP (MD could) (VP (AUX be) (VP (VBD inhibited) (PP (IN by) (NP (NNP Doc_18308784_1411_1431_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18308784_1433_1437_Chemical)) (-RRB- -RRB-)) (NN receptor) (NN antagonist) (NNP Doc_18308784_1459_1464_Chemical))))))) (. .)))
18308784	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_18308784_1483_1486_Chemical)) (VP (MD may) (ADVP (RB significantly)) (VP (VP (VB improve) (NP (NP (DT the) (JJ spatial) (NN learning) (NN capacity)) (VP (VBN impaired) (PP (IN by) (NP (JJ chonic) (JJ Doc_18308784_1562_1570_Chemical) (NN administration)))))) (CC and) (VP (VB restore) (NP (DT the) (JJ Doc_18308784_1602_1610_Chemical-inhibited) (NN LTP)))))))) (. .)))
18308784	10	(S1 (S (NP (DT This) (NN effect)) (VP (AUX is) (ADJP (NP (JJ Doc_18308784_1641_1645_Chemical) (NN receptor)) (JJ dependent))) (. .)))
18329269	0	(S1 (NP (NP (NN Synthesis)) (PP (IN of) (NP (NNP Doc_18329269_13_46_Chemical))) (PP (IN as) (NP (NNP Doc_18329269_50_59_Chemical) (NNP A2A) (NN receptor) (NNS antagonists))) (. .)))
18329269	1	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NNP Doc_18329269_98_130_Chemical) (NNP Doc_18329269_131_140_Chemical) (NNP A) (PRN (-LRB- -LRB-) (NP (NN 2A)) (-RRB- -RRB-)) (NNS antagonists)))) (VP (AUX is) (VP (VBN described))) (. .)))
18329269	2	(S1 (S (NP (NNP SAR) (NNS studies)) (VP (VBD led) (S (VP (TO to) (VP (VB compound) (NP (NP (CD 14)) (PP (IN with) (NP (NP (NP (JJ excellent) (NN potency)) (PRN (-LRB- -LRB-) (NP (NP (NNP K)) (SBAR (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (VP (SYM =) (NP (CD 0.4) (CD nM)))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN selectivity)) (PRN (-LRB- -LRB-) (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN /A) (-LRB- -LRB-) (NN 2A) (-RRB- -RRB-) (NNP >) (CD 100)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN efficacy)) (PRN (-LRB- -LRB-) (VP (VBN MED) (NP (QP (CD 10) (CD mg/kg)) (NNS p.o.))) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NP (DT the) (NN rat)) (JJ Doc_18329269_320_331_Chemical-induced) (NNP Doc_18329269_340_349_Disease) (NN model)) (PP (IN for) (NP (NNP Doc_18329269_360_379_Disease))))))))) (. .)))
1833784	0	(S1 (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_41_49_Chemical) (NNS receptors))) (PP (IN in) (S (VP (VBG mediating) (NP (JJ Doc_1833784_73_81_Chemical-induced) (NNP Doc_1833784_90_103_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
1833784	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (VBN repeated) (NN exposure)) (PP (IN of) (NP (NNS rats))) (PP (PP (TO to) (NP (DT the) (NN drug))) (CC or) (PP (TO to) (NP (DT the) (JJ experimental) (NN environment))))) (VP (AUX is) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB observe) (NP (JJ Doc_1833784_247_255_Chemical-induced) (NN locomotor) (NN stimulation))))))))))) (. .)))
1833784	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN habituation))) (PP (TO to) (NP (DT the) (JJ experimental) (NN environment))) (PP (IN on) (NP (NP (DT the) (NN stimulant) (NN effect)) (PP (IN of) (NP (NNP Doc_1833784_391_399_Chemical))))) (PP (IN in) (NP (NNS rats)))) (VP (AUX was) (VP (VBN examined))) (. .)))
1833784	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ Doc_1833784_447_455_Chemical) (NNS receptors))) (PP (IN in) (S (VP (VBG mediating) (NP (JJ Doc_1833784_479_487_Chemical-induced) (NN locomotor) (NN stimulation)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG examining) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ selective) (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_583_591_Chemical) (NN receptor) (NNS antagonists))) (PP (IN on) (NP (NP (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1833784_636_644_Chemical)))))))))))) (. .)))
1833784	4	(S1 (S (NP (NN Locomotor) (NN activity)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN tested) (PP (IN in) (NP (JJ photocell) (NNS cages)))))))) (. .)))
1833784	5	(S1 (S (NP (NP (NN Doc_1833784_733_741_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.0) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN Doc_1833784_775_805_Disease)) (PP (IN in) (NP (NNS rats))) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX were) (VP (VBN habituated) (PP (TO to) (NP (DT the) (NN test) (NN environment))))) (, ,) (CC but) (VP (AUX had) (NP (RB only) (DT a) (JJ weak) (CC and) (JJ delayed) (NN stimulant) (NN action)) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ unfamiliar) (PP (IN with) (NP (DT the) (NN test) (NN environment))))))))))))))) (. .)))
1833784	6	(S1 (S (NP (NP (DT The) (NN stimulant) (NN action)) (PP (IN of) (NP (NNP Doc_1833784_989_997_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (DT the) (JJ central) (JJ nicotinic) (NN antagonist) (NNP Doc_1833784_1046_1058_Chemical))) (CC but) (PP (RB not) (IN by) (NP (NP (DT the) (JJ peripheral) (JJ nicotinic) (NN blocker) (NNP Doc_1833784_1103_1116_Chemical)) (, ,) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (NN response)) (VP (AUX is) (ADVP (RB probably)) (VP (VBN mediated) (PP (IN by) (NP (JJ central) (JJ nicotinic) (NNS receptors))))))))))))) (. .)))
1833784	7	(S1 (S (NP (JJ Doc_1833784_1200_1208_Chemical-induced) (NN Doc_1833784_1217_1230_Disease)) (VP (AUX was) (VP (VBN blocked) (PP (IN by) (NP (NP (DT the) (JJ selective) (NNP D1) (NN antagonist) (NNP Doc_1833784_1274_1283_Chemical)) (, ,) (NP (DT the) (JJ selective) (NNP D2) (NN antagonist) (NNP Doc_1833784_1313_1323_Chemical)) (CC and) (NP (DT the) (NNP D1/D2) (NN antagonist) (NNP Doc_1833784_1349_1361_Chemical)))))) (. .)))
1833784	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (DT the) (NNP D2) (NN agonist) (NN Doc_1833784_1396_1400_Chemical)))) (VP (VBD enhanced) (NP (JJ Doc_1833784_1410_1418_Chemical-induced) (NNP Doc_1833784_1427_1440_Disease)) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NNP D1) (NNP agonist) (NNP Doc_1833784_1465_1474_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)))))) (. .)))
1833784	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ acute) (JJ Doc_1833784_1522_1530_Chemical) (NN injection)) (VP (VBZ induces) (NP (NP (DT a) (JJ pronounced) (NN Doc_1833784_1562_1575_Disease)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN habituated) (PP (TO to) (NP (DT the) (NN test) (NN environment))))))))))) (. .)))
1833784	10	(S1 (S (S (NP (DT The) (NN effect)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ central) (JJ Doc_1833784_1665_1673_Chemical) (NNS receptors)) (, ,) (VP (ADVP (RB possibly)) (VBN located) (PP (IN on) (NP (JJ dopaminergic) (NNS neurons)))))))))))) (, ,) (CC and) (S (ADVP (RB also)) (VP (VBZ requires) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT both) (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_1778_1786_Chemical) (NNS receptors)))))) (. .)))
18343374	0	(S1 (S (NP (NNP Central) (NNP Doc_18343374_8_30_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_18343374_47_57_Chemical-induced) (NN ovulation)))) (. .)))
18343374	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ central) (NN Doc_18343374_116_138_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_18343374_155_173_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18343374_175_177_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
18343374	2	(S1 (FRAG (NP (NN Case) (NN study)) (. .)))
18343374	3	(S1 (NP (NP (NN Ophthalmology) (NN clinic)) (PP (IN of) (NP (DT an) (JJ academic) (NN hospital))) (. .)))
18343374	4	(S1 (NP (NP (NP (NN PATIENT)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (DT A) (JJ 36-year-old) (NN woman)) (VP (VBN referred) (PP (IN from) (NP (NP (DT the) (JJ Doc_18343374_305_316_Disease) (NN clinic)) (PP (IN for) (NP (NNP Doc_18343374_328_342_Disease))))))) (. .)))
18343374	5	(S1 (NP (NP (NP (NN INTERVENTION)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (JJ Ophthalmic) (NN examination)) (PP (IN after) (NP (JJ Doc_18343374_390_392_Chemical) (NN therapy)))) (. .)))
18343374	6	(S1 (NP (NP (NP (JJ MAIN) (NN OUTCOME) (NN MEASURE)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (NNP Central) (NNP Doc_18343374_435_457_Disease)) (PP (IN after) (NP (NP (NN ovulation) (NN induction)) (PP (IN with) (NP (NNP Doc_18343374_489_491_Chemical)))))) (. .)))
18343374	7	(S1 (NP (NP (NP (NN RESULT)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (DT A) (JJ 36-year-old) (JJ Chinese) (NN woman)) (VP (VBN developed) (NP (JJ central) (NNP Doc_18343374_550_572_Disease)) (PP (IN after) (NP (NP (CD eight) (NNS courses)) (PP (IN of) (NP (NNP Doc_18343374_596_598_Chemical))))))) (. .)))
18343374	8	(S1 (S (NP (NP (DT A) (NN search)) (PP (IN of) (NP (NP (DT the) (NN literature)) (PP (IN on) (NP (NP (DT the) (JJ Doc_18343374_634_648_Disease) (NNS complications)) (PP (IN of) (NP (NNP Doc_18343374_666_668_Chemical)))))))) (VP (AUX does) (RB not) (VP (VB include) (NP (DT this) (JJ severe) (JJ ophthalmic) (NN complication)) (, ,) (SBAR (IN although) (S (NP (NP (JJ mild) (NN Doc_18343374_737_755_Disease)) (PP (IN after) (NP (JJ Doc_18343374_762_764_Chemical) (NN intake)))) (VP (AUX is) (RB not) (ADJP (JJ uncommon))))))) (. .)))
18343374	9	(S1 (NP (NP (NP (NN CONCLUSION)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (JJ central) (NNP Doc_18343374_847_869_Disease)))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_18343374_891_893_Chemical))))))) (. .)))
18343374	10	(S1 (S (S (NP (JJ Extra) (NN caution)) (VP (AUX is) (VP (VBN warranted) (PP (IN in) (S (VP (VBG treating) (NP (NNP Doc_18343374_934_945_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_18343374_960_962_Chemical))))))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (AUX be) (ADVP (RB well)) (VP (VBN informed) (PP (IN of) (NP (DT this) (NN side) (NN effect))) (PP (IN before) (NP (NP (NN commencement)) (PP (IN of) (NP (NN therapy))))))))) (. .)))
1835291	0	(S1 (NP (NP (JJ Acute) (JJ bronchodilating) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1835291_33_52_Chemical) (CC and) (NNP Doc_1835291_57_69_Chemical)) (PP (IN in) (NP (NNP Doc_1835291_73_110_Disease))))) (. .)))
1835291	1	(S1 (S (NP (NP (DT The) (JJ bronchodilator) (NNS effects)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (JJ Doc_1835291_159_178_Chemical) (NN aerosol)) (PRN (-LRB- -LRB-) (NP (CD 36) (NNS micrograms)) (-RRB- -RRB-))))) (CC and) (NP (JJ short-acting) (JJ Doc_1835291_220_232_Chemical) (NNS tablets))))) (PRN (-LRB- -LRB-) (S (NP (NN dose)) (VP (VBN titrated) (S (VP (TO to) (VP (VB produce) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (CD 10-20) (NNS micrograms/mL))))))))) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN crossover) (NN study)) (PP (IN in) (NP (NP (CD 21) (NNS patients)) (PP (IN with) (NP (NP (NN stable)) (, ,) (NP (NNP Doc_1835291_400_437_Disease)))))))))) (. .)))
1835291	2	(S1 (S (VP (VB Mean) (S (S (NP (NN peak)) (VP (VBN forced) (NP (NN expiratory) (NN volume)) (PP (IN in) (NP (NP (CD 1) (JJ second) (PRN (-LRB- -LRB-) (NP (NNP FEV1)) (-RRB- -RRB-)) (NNS increases)) (PP (IN over) (NP (NN baseline))))))) (CC and) (S (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG attaining) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (ADJP (CD 15) (NN %)) (NN increase)) (PP (IN in) (NP (DT the) (NN FEV1))) (PRN (-LRB- -LRB-) (NP (NNS responders)) (-RRB- -RRB-))))))) (VP (AUX were) (NP (NP (NP (CD 31) (NN %)) (CC and) (NP (CD 90) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN for) (NP (NP (NNP Doc_1835291_643_654_Chemical)) (CC and) (NP (NP (NP (CD 17) (NN %)) (CC and) (NP (CD 50) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN for) (NP (NNP Doc_1835291_690_702_Chemical))))))))))) (. .)))
1835291	3	(S1 (S (NP (DT The) (JJ average) (NN FEV1) (NNS increases)) (PP (IN during) (NP (DT the) (JJ 6-hour) (NN observation) (NN period))) (VP (AUX were) (NP (NP (NP (CD 18) (NN %)) (PP (IN for) (NP (NNP Doc_1835291_781_792_Chemical)))) (CC and) (NP (NP (CD 8) (NN %)) (PP (IN for) (NP (NNP Doc_1835291_804_816_Chemical)))))) (. .)))
1835291	4	(S1 (S (NP (NP (DT The) (JJ mean) (NN duration)) (PP (IN of) (NP (NN action)))) (VP (AUX was) (NP (NP (NP (CD 3.8) (NNS hours)) (PP (IN with) (NP (NNP Doc_1835291_865_876_Chemical)))) (CC and) (NP (NP (CD 2.4) (NNS hours)) (PP (IN with) (NP (NNP Doc_1835291_896_908_Chemical)))))) (. .)))
1835291	5	(S1 (S (SBAR (IN While) (S (NP (NN side) (NNS effects)) (VP (AUX were) (ADJP (JJ rare))))) (, ,) (NP (NP (DT those)) (VP (VBN experienced) (PP (IN after) (NP (JJ Doc_1835291_964_976_Chemical) (NN use))))) (VP (AUX did) (VP (VB involve) (NP (DT the) (NNP Doc_1835291_997_1040_Disease)))) (. .)))
1835291	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_1835291_1066_1077_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN bronchodilator)) (PP (IN than) (NP (NP (JJ oral) (NN Doc_1835291_1120_1132_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1835291_1150_1177_Disease)))))))))))) (. .)))
18410508	0	(S1 (S (NP (NP (JJ Doc_18410508_0_15_Chemical-induced) (NN Doc_18410508_24_37_Disease)) (CC and) (NP (JJ microglial) (NN activation))) (VP (AUX are) (RB not) (VP (VBN mediated) (PP (IN by) (NP (JJ fractalkine) (NN receptor) (VBG signaling))))) (. .)))
18410508	1	(S1 (S (S (NP (NP (NNP Doc_18410508_116_131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18410508_133_137_Chemical)) (-RRB- -RRB-))) (VP (VBZ damages) (NP (NNP Doc_18410508_147_155_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18410508_157_159_Chemical)) (-RRB- -RRB-)) (NN nerve) (NNS endings)) (PP (IN by) (NP (NP (DT a) (NN process)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN linked) (PP (TO to) (NP (JJ microglial) (NN activation)))))))))))) (CC but) (S (NP (NP (DT the) (VBG signaling) (NNS pathways)) (SBAR (WHNP (WDT that)) (S (VP (VB mediate) (NP (DT this) (NN response)))))) (VP (AUX have) (RB not) (ADVP (RB yet)) (VP (AUX been) (VP (VBN delineated))))) (. .)))
18410508	2	(S1 (S (NP (NNS Cardona) (CC et) (NNS al.)) (VP (VBP -LSB-Nat)) (. .)))
18410508	3	(S1 (S (NP (NP (NP (NNP Neurosci.) (CD 9)) (PRN (-LRB- -LRB-) (NP (CD 2006)) (-RRB- -RRB-))) (, ,) (NP (CD 917) (NN -RSB-))) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (DT the) (JJ microglial-specific) (NN fractalkine) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP CX3CR1)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT an) (JJ important) (NN mediator)) (PP (IN of) (NP (NP (NNP Doc_18410508_466_470_Chemical-induced) (NNP Doc_18410508_479_496_Disease)) (PP (IN of) (NP (JJ Doc_18410508_500_502_Chemical) (NNS neurons)))))))) (. .)))
18410508	4	(S1 (S (SBAR (IN Because) (S (NP (NP (DT the) (NN Doc_18410508_524_534_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18410508_545_549_Chemical) (CC and) (NNP Doc_18410508_554_558_Chemical))))) (VP (AUX is) (ADJP (RB highly) (JJ selective) (PP (IN for) (NP (DT the) (JJ Doc_18410508_587_589_Chemical) (JJ neuronal) (NN system)))) (PP (IN in) (NP (NP (NN mouse) (NNS models)) (PP (IN of) (NP (NNP Doc_18410508_625_638_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (DT the) (NN CX3CR1)) (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NP (JJ Doc_18410508_688_692_Chemical-induced) (NN Doc_18410508_701_714_Disease)) (CC and) (NP (JJ microglial) (NN activation))))))))) (. .)))
18410508	5	(S1 (S (NP (NP (NNS Mice)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (JJ CX3CR1) (NN gene)) (VP (AUX has) (VP (AUX been) (VP (VBN deleted) (CC and) (VBN replaced) (PP (IN with) (NP (NP (DT a) (NN cDNA)) (VP (VBG encoding) (NP (NP (JJ enhanced) (JJ green) (NN fluorescent) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN eGFP)) (-RRB- -RRB-)))))))))))) (VP (AUX were) (VP (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18410508_883_887_Chemical)))) (CC and) (VP (VBN examined) (PP (IN for) (NP (JJ striatal) (NNP Doc_18410508_914_927_Disease)))))) (. .)))
18410508	6	(S1 (S (NP (NNP Doc_18410508_929_933_Chemical)) (VP (VP (VBD depleted) (NP (NNP Doc_18410508_943_945_Chemical))) (, ,) (VP (VBD caused) (NP (JJ microglial) (NN activation))) (, ,) (CC and) (VP (VBD increased) (NP (NP (NN body) (NN temperature)) (PP (PP (IN in) (NP (NP (JJ CX3CR1) (NN knockout) (NNS mice)) (PP (TO to) (NP (DT the) (JJ same) (NN extent))))) (CC and) (PP (IN over) (NP (NP (DT the) (JJ same) (NN time) (NN course)) (VP (VBN seen) (PP (IN in) (NP (JJ wild-type) (NNS controls)))))))))) (. .)))
18410508	7	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_18410508_1124_1128_Chemical))) (PP (IN in) (NP (NN CX3CR1) (NN knockout) (NNS mice)))) (VP (VP (AUX were) (RB not) (ADJP (JJ gender-dependent))) (CC and) (VP (AUX did) (RB not) (VP (VB extend) (PP (IN beyond) (NP (DT the) (NN striatum)))))) (. .)))
18410508	8	(S1 (S (NP (NP (JJ Striatal) (NNS microglia)) (VP (VBG expressing) (NP (NNS eGFP)))) (ADVP (RB constitutively)) (VP (VBP show) (NP (NP (JJ morphological) (NNS changes)) (PP (IN after) (NP (NNP Doc_18410508_1302_1306_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ characteristic) (PP (IN of) (NP (NN activation))))))))) (. .)))
18410508	9	(S1 (S (NP (DT This) (NN response)) (VP (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (DT the) (NN striatum))))) (CC and) (VP (VBN contrasted) (ADVP (RB sharply)) (PP (IN with) (NP (NP (JJ unresponsive) (NNS eGFP-microglia)) (PP (IN in) (NP (VBG surrounding) (NN brain) (NNS areas))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (RB not) (VP (VBN damaged) (PP (IN by) (NP (NNP Doc_18410508_1498_1502_Chemical))))))))))) (. .)))
18410508	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (PP (IN from) (NP (NP (DT these) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBZ CX3CR1) (S (VP (VBG signaling) (SBAR (S (VP (AUX does) (RB not) (VP (VBP modulate) (NP (NNP Doc_18410508_1575_1579_Chemical) (NNP Doc_18410508_1580_1593_Disease) (CC or) (JJ microglial) (NN activation)))))))))))))) (. .)))
18410508	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP (JJ striatal-resident) (NNS microglia)) (VP (VP (VB respond) (PP (TO to) (NP (NNP Doc_18410508_1688_1692_Chemical))) (PP (IN with) (NP (DT an) (NN activation) (NN cascade)))) (CC and) (RB then) (VP (VB return) (PP (TO to) (NP (DT a) (VBG surveying) (NN state))) (PP (IN without) (S (VP (VBG undergoing) (NP (NP (NN apoptosis)) (CC or) (NP (NN migration))))))))))) (. .)))
18417364	0	(S1 (S (NP (NP (JJ Doc_18417364_0_8_Chemical-induced) (JJ Doc_18417364_17_26_Disease) (NNS correlates)) (PP (IN with) (NP (NN midpontine)))) (VP (VBP activation)) (. .)))
18417364	1	(S1 (S (NP (NP (DT The) (NN pathomechanism)) (PP (IN of) (NP (NP (JJ Doc_18417364_88_96_Chemical-induced) (NNP Doc_18417364_105_114_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18417364_116_119_Disease)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
18417364	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB delineate) (NP (NP (NN brain) (NNS structures)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_18417364_210_213_Disease) (NN generation)))))))))))) (. .)))
18417364	3	(S1 (S (S (NP (CD Eight) (JJ healthy) (NNS volunteers)) (VP (VBD inhaled) (NP (NNP Doc_18417364_259_267_Chemical)) (PP (IN in) (NP (NN darkness))) (PP (IN during) (NP (DT a) (JJ functional) (JJ magnetic) (NN resonance) (NN imaging) (-LRB- -LRB-) (NN fMRI) (-RRB- -RRB-) (NN experiment))))) (: ;) (S (NP (NN eye) (NNS movements)) (VP (AUX were) (VP (VBN registered) (S (VP (VBG using) (NP (NN video-oculography))))))) (. .)))
18417364	4	(S1 (S (NP (NN Doc_18417364_401_404_Disease)) (VP (VBD correlated) (PP (IN with) (NP (NN blood) (JJ Doc_18417364_427_433_Chemical) (JJ level-dependent) (PRN (-LRB- -LRB-) (JJ BOLD) (-RRB- -RRB-)) (NN activity) (NNS levels))) (PP (IN in) (NP (NP (DT a) (JJ midpontine) (NN site)) (PP (IN in) (NP (DT the) (JJ posterior) (NN basis) (NNS pontis)))))) (. .)))
18417364	5	(S1 (S (NP (JJ Doc_18417364_525_528_Disease-induced) (NN midpontine) (NN activation)) (VP (MD may) (VP (VB correspond) (PP (TO to) (NP (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ dorsomedial) (NN pontine) (NN nuclei)))) (CC and) (NP (NP (DT the) (NN nucleus)) (ADJP (FW reticularis) (FW tegmenti) (FW pontis))))) (, ,) (NP (NP (NNS structures)) (VP (VBN known) (S (VP (TO to) (VP (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (JJ multidirectional) (NNS saccades)))))) (CC and) (VP (VB smooth) (NP (NN pursuit) (NN eye) (NNS movements)))))))))) (. .)))
18439803	0	(S1 (NP (NP (JJ Acute) (NNS effects)) (PP (IN of) (NP (NNP Doc_18439803_17_42_Chemical))) (PP (IN on) (NP (NP (JJ hippocampal) (JJ Doc_18439803_58_68_Chemical) (NNS neurotransmitters)) (PP (IN in) (NP (NP (NNP Doc_18439803_90_101_Chemical-induced) (NNP Doc_18439803_110_117_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
18439803	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ anticonvulsant) (NN activity)) (PP (IN as) (ADVP (RB well) (PP (IN as) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (JJ hippocampal) (JJ Doc_18439803_245_255_Chemical) (NNS neurotransmitters)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_275_284_Chemical) (, ,) (NNP Doc_18439803_286_295_Chemical) (, ,) (NNP Doc_18439803_297_304_Chemical) (CC and) (NNP Doc_18439803_309_313_Chemical)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_18439803_318_343_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_345_348_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (PRP$ its) (NN parent) (NN compound)) (, ,) (NP (NP (NNP Doc_18439803_388_401_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_403_406_Chemical)) (-RRB- -RRB-)))))))))))))))))) (. .)))
18439803	2	(S1 (S (NP (NNP Doc_18439803_409_412_Chemical)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NNP Doc_18439803_434_437_Chemical)))) (, ,) (S (VP (VBG exhibiting) (NP (NP (DT the) (JJ median) (JJ effective) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (NNP ED)) (PRN (-LRB- -LRB-) (NP (CD 50)) (-RRB- -RRB-))) (-RRB- -RRB-)) (PP (IN of) (NP (CD 49) (NN mg/kg)))) (PP (IN in) (S (VP (VBG protecting) (NP (NNS rats)) (PP (IN against) (NP (JJ Doc_18439803_524_535_Chemical-induced) (NNP Doc_18439803_544_551_Disease))) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ corresponding) (NN value)) (PP (IN for) (NP (NNP Doc_18439803_588_591_Chemical)))) (VP (AUX was) (NP (CD 322) (NN mg/kg))))))))))) (. .)))
18439803	3	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NN microdialysis)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT an) (JJ intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_18439803_684_695_Chemical)))) (VP (VBN induced) (NP (NP (DT a) (JJ pronounced) (NN increment)) (PP (IN of) (NP (JJ hippocampal) (NNP Doc_18439803_742_751_Chemical) (CC and) (NNP Doc_18439803_756_765_Chemical)))) (SBAR (IN whereas) (S (NP (DT no) (JJ significant) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NNP Doc_18439803_825_832_Chemical)) (CC and) (NP (NNP Doc_18439803_837_841_Chemical)))))))))))))) (. .)))
18439803	4	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_18439803_868_871_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC and) (CD 100)) (NNS mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_18439803_894_897_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 300) (CC and) (CD 600)) (NN mg/kg)) (-RRB- -RRB-)))))) (ADVP (RB completely)) (VP (VBD abolished) (NP (NP (JJ Doc_18439803_939_950_Chemical-evoked) (NNS increases)) (PP (IN in) (NP (JJ extracellular) (NNP Doc_18439803_985_994_Chemical) (CC and) (NNP Doc_18439803_999_1008_Chemical))))) (. .)))
18439803	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN reduction)) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed) (PP (IN on) (NP (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NNP Doc_18439803_1095_1099_Chemical)) (CC and) (NP (NNP Doc_18439803_1104_1111_Chemical))))) (CC but) (NP (NP (JJR less)) (PP (IN than) (NP (NP (DT a) (JJ drastic) (NN reduction)) (PP (IN of) (NP (NNP Doc_18439803_1149_1158_Chemical) (CC and) (NNP Doc_18439803_1163_1172_Chemical) (NN level)))))))))) (. .)))
18439803	6	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT the) (NN finding) (SBAR (IN that) (S (NP (NNP Doc_18439803_1206_1209_Chemical) (CC and) (NNP Doc_18439803_1214_1217_Chemical)) (VP (MD could) (VP (VB protect) (NP (DT the) (NNS animals)) (PP (IN against) (NP (NNP Doc_18439803_1252_1263_Chemical-induced) (NNP Doc_18439803_1272_1279_Disease)))))))))) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (JJ inhibitory) (JJ Doc_18439803_1329_1339_Chemical) (NNS neurotransmitters)))) (VP (AUX was) (UCP (ADJP (RB comparatively) (JJ minor)) (CC and) (VP (VBN offset) (PP (IN by) (NP (NP (DT a) (JJ pronounced) (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_18439803_1422_1431_Chemical)) (CC and) (NP (NNP Doc_18439803_1436_1445_Chemical))))))))))))) (. .)))
18439803	7	(S1 (S (ADVP (RB Therefore)) (, ,) (PP (IN like) (NP (NNP Doc_18439803_1463_1466_Chemical))) (, ,) (NP (DT the) (NN finding) (SBAR (IN that) (S (NP (NNP Doc_18439803_1485_1488_Chemical)) (VP (MD could) (ADVP (RB drastically)) (VP (VB reduce) (NP (NP (JJ Doc_18439803_1514_1525_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_18439803_1547_1556_Chemical)) (CC and) (NP (NNP Doc_18439803_1561_1570_Chemical)))))))))) (VP (MD should) (VP (VB account) (, ,) (ADVP (ADVP (IN at) (JJS least)) (RB partly)) (, ,) (PP (IN for) (NP (NP (PRP$ its) (JJ anticonvulsant) (NN activity)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_18439803_1648_1659_Chemical-induced) (NNP Doc_18439803_1668_1675_Disease))) (PP (IN in) (NP (JJ experimental) (NNS animals)))))))) (. .)))
18439803	8	(S1 (S (NP (NP (DT Some) (JJ other) (NN mechanism)) (PP (IN than) (NP (NP (DT those)) (VP (AUXG being) (VP (VBN reported) (NP (NN herein))))))) (VP (MD should) (VP (AUX be) (VP (ADVP (RB further)) (VBN investigated)))) (. .)))
18442015	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_18442015_21_30_Chemical))) (PP (IN on) (NP (NP (NNP Doc_18442015_34_53_Disease) (NNP Doc_18442015_54_60_Disease)) (PP (IN in) (NP (JJ severe) (JJ Doc_18442015_71_86_Disease) (NNS rats))))) (. .)))
18442015	1	(S1 (S (NP (NP (NP (NP (NNS Studies)) (VP (VBG concerning) (PP (IN with) (NP (NP (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_18442015_133_151_Disease))))))) (CC and) (NP (JJ mucosal) (NN ulceration))) (VP (VBN produced) (PP (IN in) (NP (NNP Doc_18442015_187_202_Disease) (NNS rats))))) (VP (AUX are) (VP (VBG lacking))) (. .)))
18442015	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (NN mast) (NN cell) (NNP Doc_18442015_308_317_Chemical) (NN release)) (, ,) (NP (NN lipid) (NN peroxide) (PRN (-LRB- -LRB-) (NNP LPO) (-RRB- -RRB-)) (NN generation)) (CC and) (NP (JJ mucosal) (JJ microvascular) (NN permeability)))) (PP (IN in) (S (VP (VBG modulating) (NP (NNP Doc_18442015_412_430_Disease) (CC and) (NNP Doc_18442015_435_440_Disease)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_18442015_454_469_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NNP Doc_18442015_501_511_Chemical) (CC and) (NNP Doc_18442015_516_527_Chemical)))))))))))))))) (. .)))
18442015	3	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_18442015_568_577_Chemical))) (PP (IN on) (NP (DT this) (NNP Doc_18442015_586_591_Disease) (NN model)))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
18442015	4	(S1 (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN challenged) (ADVP (RB intragastrically) (RB once) (RB daily)) (PP (IN for) (NP (NP (CD 9) (NNS days)) (PP (IN with) (NP (NP (CD 1.0) (NN ml/kg)) (PP (IN of) (NP (NP (NN corn) (NN oil)) (VP (VBG containing) (NP (NP (NNP Doc_18442015_723_733_Chemical)) (CC and) (NP (NNP Doc_18442015_738_749_Chemical))) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_18442015_760_775_Disease)))))))))))))) (. .)))
18442015	5	(S1 (S (NP (NN Control) (NNS rats)) (VP (VBD received) (NP (NN corn) (NN oil)) (ADVP (RB only))) (. .)))
18442015	6	(S1 (S (PP (IN After) (NP (NN gastric) (NN surgery))) (, ,) (NP (NN rat) (NNS stomachs)) (VP (AUX were) (VP (VBN irrigated) (PP (IN for) (NP (NP (CD 3) (NNP h)) (PP (IN with) (NP (NP (DT either) (JJ simulated) (JJ gastric) (NN juice)) (CC or) (NP (JJ normal) (NN saline)))))))) (. .)))
18442015	7	(S1 (S (NP (NP (JJ Gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ mucosal) (NN LPO) (NN generation)) (, ,) (NP (JJ Doc_18442015_980_989_Chemical) (NN concentration)) (, ,) (NP (JJ microvascular) (NN permeability)) (, ,) (NP (JJ Doc_18442015_1033_1040_Chemical) (NN hemoglobin) (NN content)) (CC and) (NP (JJ Doc_18442015_1064_1069_Disease) (NNS areas))) (VP (AUX were) (VP (VBN determined))) (. .)))
18442015	8	(S1 (S (NP (NP (JJ Elevated) (JJ Doc_18442015_1102_1117_Disease) (NNS parameters)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN serum) (NN Doc_18442015_1144_1151_Chemical)) (, ,) (NP (JJ total) (NN Doc_18442015_1159_1170_Chemical)) (CC and) (NP (NN low-density) (NN lipoprotein) (NN concentration))))) (VP (AUX were) (VP (VBN obtained) (PP (IN in) (NP (NNP Doc_18442015_1230_1245_Disease) (NNS rats))))) (. .)))
18442015	9	(S1 (S (NP (NP (JJ Severe) (JJ gastric) (NN Doc_18442015_1267_1273_Disease)) (VP (VBN accompanied) (PP (IN with) (NP (NP (JJ increased) (JJ ulcerogenic) (NNS factors)) (, ,) (PP (VBG including) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ Doc_18442015_1361_1370_Chemical) (NN release)) (, ,) (NP (JJ LPO) (NN generation)) (CC and) (NP (JJ Doc_18442015_1399_1406_Chemical) (NN hemoglobin) (NN content)))))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (DT these) (NNS rats))))) (. .)))
18442015	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN of) (NP (NNP Doc_18442015_1496_1505_Chemical))) (PP (PP (TO to) (NP (NNP Doc_18442015_1509_1527_Disease))) (CC and) (PP (TO to) (NP (NNP Doc_18442015_1535_1540_Disease))))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT those) (JJ Doc_18442015_1560_1575_Disease) (NNS rats))))) (. .)))
18442015	11	(S1 (S (NP (NP (DT This) (NNP Doc_18442015_1587_1598_Disease) (NNP Doc_18442015_1599_1604_Disease)) (CC and) (NP (JJ various) (JJ ulcerogenic) (NNS parameters))) (VP (AUX were) (ADVP (RB dose-dependently)) (VP (VBN ameliorated) (PP (IN by) (NP (JJ daily) (JJ intragastric) (NN Doc_18442015_1696_1705_Chemical))))) (. .)))
18442015	12	(S1 (S (NP (NN Doc_18442015_1707_1722_Disease)) (VP (MD could) (VP (VB produce) (NP (NP (NNP Doc_18442015_1737_1756_Disease) (NNP Doc_18442015_1757_1762_Disease)) (PP (IN via) (NP (NP (NN aggravation)) (PP (IN of) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ LPO) (NN generation)) (, ,) (NP (JJ Doc_18442015_1827_1836_Chemical) (NN release)) (CC and) (NP (JJ microvascular) (NN permeability)))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (VBN ameliorated) (PP (IN by) (NP (NNP Doc_18442015_1905_1914_Chemical))) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
18464113	0	(S1 (S (NP (NP (NN Doc_18464113_0_10_Chemical)) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_18464113_33_44_Disease) (NN virus)))))) (VP (VBP reactivation) (PP (IN in) (NP (NP (NNP Doc_18464113_67_94_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18464113_96_101_Chemical)) (-RRB- -RRB-)))) (S (NP (JJ seropositive) (NNP Doc_18464113_116_122_Disease) (NNS patients)) (VP (VBG undergoing) (NP (JJ cytotoxic) (NN chemotherapy))))) (. .)))
18464113	1	(S1 (S (NP (NP (JJ Doc_18464113_167_178_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HBV)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (NNS causes)) (PP (IN of) (NP (JJ chronic) (NNP Doc_18464113_229_242_Disease) (NNP worldwide))))))) (. .)))
18464113	2	(S1 (S (S (NP (NP (JJ Doc_18464113_254_260_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (NP (NP (JJ chronic) (NNS carriers)) (PP (IN of) (NP (NNS HBV)))))))) (VP (AUX have) (NP (DT a) (JJR higher) (NN Doc_18464113_316_336_Disease) (NN rate)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NP (JJ cytotoxic) (NN chemotherapy)) (PRN (-LRB- -LRB-) (NP (NNP CT)) (-RRB- -RRB-)))))))) (CC and) (S (NP (DT this)) (VP (AUX has) (ADVP (RB mainly)) (VP (AUX been) (VP (VBN attributed) (PP (TO to) (NP (CD HBV) (NN reactivation))))))) (. .)))
18464113	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (JJ Doc_18464113_458_464_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (ADJP (JJ solid) (CC and) (JJ Doc_18464113_493_519_Disease)) (PP (IN with) (NP (JJ chronic) (NNP Doc_18464113_533_546_Disease))))))) (VP (VBD received) (NP (DT the) (JJ antiviral) (NN agent) (NN Doc_18464113_576_586_Chemical)) (UCP (ADVP (RB prior)) (CC and) (PP (IN during) (NP (NP (NNS CT)) (PP (VBN compared) (PP (IN with) (NP (JJ historical) (NN control) (NN group)))) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VB receive) (NP (NNP Doc_18464113_666_676_Chemical)))))))))) (. .)))
18464113	4	(S1 (S (NP (DT The) (NNS objectives)) (VP (AUX were) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_18464113_724_734_Chemical)))) (PP (IN in) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (CD HBV) (NN reactivation))))) (, ,) (CC and) (VP (VBG diminishing) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN during) (NP (NN CT))))))))))) (. .)))
18464113	5	(S1 (S (NP (CD Two) (NNS groups)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
18464113	6	(S1 (S (NP (DT The) (JJ prophylactic) (JJ Doc_18464113_890_899_Chemical) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 37) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ prophylactic) (JJ Doc_18464113_957_967_Chemical) (NN treatment)))))))) (. .)))
18464113	7	(S1 (S (NP (DT The) (JJ historical) (NNS controls)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 50) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN CT)) (PP (IN without) (NP (JJ prophylactic) (NN Doc_18464113_1078_1088_Chemical))))))))) (. .)))
18464113	8	(S1 (S (NP (PRP They)) (VP (AUX were) (VP (VBN followed) (PRT (RP up)) (PP (IN during) (NP (QP (CC and) (IN for) (CD 8)) (NNS weeks))) (PP (IN after) (NP (NN CT))))) (. .)))
18464113	9	(S1 (S (NP (DT The) (NNS outcomes)) (VP (AUX were) (VP (VBN compared) (PP (IN for) (NP (DT both) (NNS groups))))) (. .)))
18464113	10	(S1 (S (PP (IN Of) (NP (NP (PRP$ our) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 50)) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 21) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN established) (NP (NN Doc_18464113_1254_1263_Disease)))) (. .)))
18464113	11	(S1 (S (NP (NP (NP (CD Twelve)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN as) (NP (JJ severe) (NN Doc_18464113_1311_1320_Disease))))) (. .)))
18464113	12	(S1 (S (PP (IN In) (NP (DT the) (JJ prophylactic) (JJ Doc_18464113_1342_1352_Chemical) (NN group))) (NP (JJ severe) (NNP Doc_18464113_1366_1375_Disease)) (VP (AUX were) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NP (NP (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 2.7) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD 37) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.006))) (-RRB- -RRB-)))))))) (. .)))
18464113	13	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (DT the) (JJ mean) (NN ALT) (NNS values)))) (VP (VBD revealed) (NP (NP (NP (ADJP (RB significantly) (JJR higher)) (JJ mean) (JJ Doc_18464113_1512_1519_Chemical) (NN aminotransferase) (PRN (-LRB- -LRB-) (NP (NNP ALT)) (-RRB- -RRB-)) (NNS values)) (PP (IN in) (NP (NP (DT the) (NN control) (NN group)) (PP (IN than) (NP (DT the) (JJ prophylactic) (JJ Doc_18464113_1593_1603_Chemical) (NN group)))))) (: ;) (NP (NP (CD 154:64)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.32)) (-RRB- -RRB-))))) (. .)))
18464113	14	(S1 (S (NP (PRP$ Our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ prophylactic) (NNP Doc_18464113_1667_1677_Chemical)) (ADVP (RB significantly)) (VP (VBZ decreases) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ HBV) (NN reactivation)) (CC and) (NP (JJ overall) (NN morbidity)))) (PP (IN in) (NP (NP (JJ Doc_18464113_1761_1767_Disease) (NNS patients)) (PP (IN during) (CC and) (IN after) (NP (JJ immunosuppressive) (NN therapy)))))))))) (. .)))
18464113	15	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB determine) (NP (DT the) (ADJP (RBS most) (JJ appropriate)) (NNP Doc_18464113_1882_1892_Chemical) (CC or) (NNP Doc_18464113_1896_1906_Chemical) (NN analogue)) (PP (IN for) (NP (JJ antiviral) (NNS prophylaxis))) (PP (IN during) (NP (NP (NN CT)) (CC and) (NP (NP (DT the) (JJ optimal) (NN duration)) (PP (IN of) (NP (NN administration))) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NNS CT))))))))))))) (. .)))
18503483	0	(S1 (NP (NP (NN Recovery)) (PP (IN of) (NP (NNP Doc_18503483_12_22_Chemical-associated) (NNP Doc_18503483_34_51_Disease))) (PP (IN after) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_18503483_72_82_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ pediatric) (JJ renal) (NN transplant) (NN recipient--case) (NN report)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature)))))))) (. .)))
18503483	1	(S1 (S (NP (NN Doc_18503483_168_171_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ potent) (NN immunosuppressive) (NN agent)) (PP (IN for) (NP (NP (JJ solid) (NN organ) (NN transplantation)) (PP (IN in) (NP (NNS pediatrics)))))))))))) (. .)))
18503483	2	(S1 (S (NP (NN Doc_18503483_273_286_Disease)) (VP (AUX is) (NP (DT a) (ADJP (RB potentially) (JJ serious)) (NN toxic) (NN effect))) (. .)))
18503483	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_18503483_349_363_Disease)) (, ,) (NP (NNP Doc_18503483_365_374_Disease)) (, ,) (NP (NNP Doc_18503483_376_384_Disease)) (, ,) (CC or) (NP (NNP Doc_18503483_389_410_Disease)))))) (. .)))
18503483	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT an) (JJ eight-and-a-half-yr-old) (JJ male) (JJ renal) (NN transplant) (NN recipient)) (PP (IN with) (NP (JJ right) (NNS BN))))) (. .)))
18503483	5	(S1 (S (NP (NNP MRI)) (VP (VBD demonstrated) (NP (JJ hyperintense) (JJ T2) (NNS signals)) (PP (IN in) (NP (NP (DT the) (JJ cervical) (UCP (NN cord) (CC and) (JJ right)) (JJ brachial) (NN plexus) (NNS roots)) (ADJP (JJ indicative) (PP (IN of) (NP (DT both) (NNP Doc_18503483_617_625_Disease) (CC and) (JJ right) (NNP Doc_18503483_636_653_Disease))))))) (. .)))
18503483	6	(S1 (S (NP (NNS Symptoms)) (VP (VBD persisted) (PP (IN for) (NP (CD three) (NNS months))) (PP (IN despite) (NP (NP (JJ Doc_18503483_699_702_Chemical) (NN dose) (NN reduction)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN IVIG)))) (CC and) (NP (NP (CD four) (NNS doses)) (PP (IN of) (NP (JJ Doc_18503483_760_778_Chemical) (NN pulse) (NN therapy))))))) (. .)))
18503483	7	(S1 (S (NP (NP (NN Improvement)) (CC and) (NP (ADJP (RB eventually) (JJ full)) (NN recovery))) (ADVP (RB only)) (VP (VBD occurred) (SBAR (IN after) (S (NP (NNP Doc_18503483_855_858_Chemical)) (VP (AUX was) (VP (VP (ADVP (RB completely)) (VBN discontinued)) (CC and) (VP (ADVP (RB successfully)) (VBN replaced) (PP (IN by) (NP (NNP Doc_18503483_916_926_Chemical))))))))) (. .)))
18544179	0	(S1 (S (NP (NNP Omitting) (NNP Doc_18544179_9_17_Chemical)) (VP (VBZ reduces) (NP (NP (NNP Doc_18544179_26_32_Disease)) (CC and) (NP (NNP Doc_18544179_37_45_Disease))) (, ,) (PP (IN without) (S (VP (VBG increasing) (NP (NNP Doc_18544179_66_70_Disease))))) (, ,) (PP (IN after) (NP (NP (NNP Doc_18544179_78_89_Chemical)) (PP (IN for) (NP (NN day) (NN surgery)))))) (. .)))
18544179	1	(S1 (FRAG (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN OBJECTIVE))) (: :) (S (PP (IN Despite) (NP (NP (NNS advantages)) (PP (IN of) (NP (NP (NN induction)) (CC and) (NP (NP (NN maintenance)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP Doc_18544179_201_212_Chemical)))))))) (, ,) (NP (NNP Doc_18544179_214_247_Disease)) (VP (VBZ occurs) (ADVP (RB frequently)))) (. .)))
18544179	2	(S1 (S (NP (NN Doc_18544179_267_275_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN supplement)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (DT this)))))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (MD may) (ADVP (RB also)) (VP (VB improve) (NP (NN analgesia))))))) (. .)))
18544179	3	(S1 (S (NP (DT This) (JJ double-blind) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_18544179_447_480_Disease)) (CC and) (NP (NNP Doc_18544179_485_489_Disease))))) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 24) (NAC (NNP h) (PP (IN after) (NP (NNP Doc_18544179_514_525_Chemical)))) (NN anaesthesia)) (PP (IN in) (NP (CD 216) (NN adult) (NN day) (NN surgery) (NNS patients)))))) (. .)))
18544179	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (ADVP (RB either)) (VB receive) (CC or) (RB not) (VB receive) (NP (QP (CD 1) (CD 1)) (NN Doc_18544179_643_651_Chemical))))) (, ,) (SBAR (IN while) (S (NP (DT a) (JJ third) (NN group)) (VP (VBD received) (NP (NNP Doc_18544179_682_695_Chemical)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_18544179_711_719_Chemical)))))))))) (. .)))
18544179	5	(S1 (S (NP (NP (NN Omission)) (PP (IN of) (NP (NNP Doc_18544179_742_750_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB reduce) (NP (NP (DT the) (JJ overall) (NN incidence)) (PP (IN of) (NP (NNP Doc_18544179_791_824_Disease)))))) (, ,) (CC but) (VP (AUX did) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18544179_858_866_Disease) (NN and/or))) (PP (JJ moderate) (TO to) (NP (JJ severe) (NNP Doc_18544179_893_899_Disease)))) (ADVP (RB prior) (PP (TO to) (NP (NN discharge)))) (PP (PP (IN from) (NP (NP (CD 20) (NN %)) (CC and) (NP (NP (CD 17) (NN %)) (PP (IN with) (NP (NP (NNP Doc_18544179_941_949_Chemical)) (CC and) (NP (NNP Doc_18544179_954_962_Chemical-Doc_18544179_963_976_Chemical))))) (, ,) (ADVP (RB respectively)) (, ,))) (PP (TO to) (NP (CD 5) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.013)) (-RRB- -RRB-))))) (. .)))
18544179	6	(S1 (S (NP (JJ Antiemetic) (NNS requirements)) (VP (AUX were) (VP (VBN reduced) (PP (IN from) (NP (NP (CD 24) (NN %)) (CC and) (NP (CD 31) (NN %)))) (PP (TO to) (NP (NP (CD 7) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.0012)) (-RRB- -RRB-)))))) (. .)))
18544179	7	(S1 (S (NP (NN Doc_18544179_1085_1098_Chemical)) (VP (AUX had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC or) (NN severity)) (PP (IN of) (NP (NNP Doc_18544179_1157_1190_Disease)))))) (. .)))
18544179	8	(S1 (S (S (VP (VBG Combining) (NP (DT the) (CD two) (NNP Doc_18544179_1210_1218_Chemical) (NNS groups)))) (VP (VBD revealed) (NP (JJ further) (JJ significant) (NNS benefits)) (PP (IN from) (NP (NP (DT the) (NN avoidance)) (PP (IN of) (NP (NNS opioids))))) (, ,) (S (VP (VBG reducing) (NP (NNP Doc_18544179_1304_1337_Disease) (CC and) (NNP Doc_18544179_1342_1348_Disease)) (ADVP (RB prior) (PP (TO to) (NP (NP (NN discharge)) (PP (IN from) (NP (NP (NP (QP (CD 35) (NN %) (CC and) (CD 33) (NN %) (TO to) (CD 22) (NN %) (CC and) (CD 19)) (NN %)) (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.049) (CC and) (CD P)) (PRN (FRAG (X (SYM =)) (NP (CD 0.035))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))))))) (, ,) (SBAR (IN while) (S (NP (NAC (NNP Doc_18544179_1447_1453_Disease) (PP (IN in) (NP (DT the) (JJ first) (CD 24)))) (NNP h)) (VP (AUX was) (VP (VBN decreased) (PP (PP (IN from) (NP (CD 42) (NN %))) (PP (TO to) (NP (CD 27) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.034)) (-RRB- -RRB-))))))) (. .)))
18544179	9	(S1 (S (NP (NP (JJ Doc_18544179_1515_1519_Disease) (NN severity)) (CC and) (NP (JJ analgesic) (NNS requirements))) (VP (AUX were) (ADJP (JJ unaffected) (PP (IN by) (NP (NP (DT the) (NN omission)) (PP (IN of) (NP (NNP Doc_18544179_1591_1599_Chemical))))))) (. .)))
18544179	10	(S1 (S (NP (NNP Doc_18544179_1601_1609_Chemical)) (VP (VP (AUX did) (VP (VB reduce) (NP (JJ minor) (NN intraoperative) (NN movement)))) (CC but) (VP (AUX had) (NP (DT no) (JJ Doc_18544179_1662_1673_Chemical-sparing) (NN effect))) (CC and) (VP (VBD increased) (NP (NP (NNP Doc_18544179_1703_1725_Disease)) (, ,) (NP (NNP Doc_18544179_1727_1738_Disease)) (CC and) (NP (NNP Doc_18544179_1743_1754_Disease))))) (. .)))
18544179	11	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_18544179_1771_1779_Chemical)) (VP (VP (VBD exacerbated) (NP (NN Doc_18544179_1792_1825_Disease)) (PP (IN without) (NP (NP (DT an) (NN improvement)) (PP (IN in) (NP (NNP Doc_18544179_1852_1870_Disease)))))) (CC and) (VP (ADVP (RB also)) (AUX had) (NP (JJ adverse) (JJ cardiorespiratory) (NNS effects)))))) (, ,) (NP (PRP it)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (ADJP (ADJP (JJ unnecessary)) (CC and) (ADJP (ADVP (RB possibly)) (JJ detrimental))) (NN supplement)) (PP (TO to) (NP (NNP Doc_18544179_1990_2001_Chemical)))) (PP (IN in) (NP (NN day) (NN surgery))))))) (. .)))
18560792	0	(S1 (NP (NP (NN Doc_18560792_0_22_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18560792_40_59_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_73_82_Chemical)))))))) (. .)))
18560792	1	(S1 (S (NP (NN Course)) (VP (VBG following) (NP (NN treatment) (NNS modifications))) (. .)))
18560792	2	(S1 (S (NP (NN Doc_18560792_126_154_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (NNP Doc_18560792_191_210_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18560792_212_214_Disease)) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_229_238_Chemical))))))))))) (. .)))
18560792	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (DT these) (NNS abnormalities)))) (VP (VBP vary) (PP (IN from) (NP (NN study))) (PP (TO to) (NP (NP (NN study)) (CC and) (NP (PRP$ their) (NN course)))) (SBAR (IN after) (S (NP (NN drug) (NN withdrawal)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB systematically)) (VP (VBN assessed))))))) (. .)))
18560792	4	(S1 (FRAG (S (VP (TO To) (VP (VB estimate) (NP (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_18560792_455_481_Disease)))) (CC and) (NP (NP (PRP$ its) (JJ possible) (NN reversibility)) (PP (IN after) (NP (NN drug) (NN withdrawal))))) (PP (IN in) (NP (DT a) (JJ case-control) (NN study)))))) (. .)))
18560792	5	(S1 (S (NP (NP (DT All) (JJ Doc_18560792_573_575_Disease) (NNS patients)) (PP (IN in) (NP (NP (DT the) (NNP Amiens) (NN area)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_617_626_Chemical))))))) (VP (AUX were) (VP (VBN invited) (S (VP (TO to) (VP (VB attend) (NP (NP (DT a) (JJ cardiologic) (NN assessment)) (PP (VBG including) (NP (JJ transthoracic) (NN echocardiography))))))))) (. .)))
18560792	6	(S1 (S (NP (CD Thirty) (NNP Doc_18560792_724_726_Disease) (NNS patients)) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
18560792	7	(S1 (S (NP (DT A) (JJ second) (NN echocardiography)) (VP (AUX was) (VP (VBN performed) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN interval)) (: :) (NP (CD 13) (NNS months))) (-RRB- -RRB-)) (PP (IN after) (NP (NP (JJ Doc_18560792_838_847_Chemical) (NN withdrawal)) (PRN (-LRB- -LRB-) (NP (CD n=10) (NNS patients)) (-RRB- -RRB-)))))) (. .)))
18560792	8	(S1 (S (NP (NP (NP (NNS Controls)) (SBAR (S (VP (AUX were) (ADJP (JJ age-)))))) (CC and) (NP (JJ sex-matched) (NN non-Doc_18560792_915_917_Disease) (NNS patients))) (VP (VBD referred) (PP (TO to) (NP (DT the) (NN cardiology) (NN department)))) (. .)))
18560792	9	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (NNS controls)))) (, ,) (NP (NP (NP (NNP Doc_18560792_997_1017_Disease)) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 3.1)) (: ;) (NP (NP (CD 95) (NN %)) (ADVP (RB IC))) (: :) (NP (CD 1.1-8.8))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18560792_1049_1069_Disease)) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 10.7)) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS IC))) (: :) (NP (CD 2.1-53))) (-RRB- -RRB-)))) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NP (JJ Doc_18560792_1119_1121_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN tricuspid)) (: :) (NP (NNP NS))) (-RRB- -RRB-))))) (. .)))
18560792	10	(S1 (S (NP (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ affected) (NNS valves))) (PRN (-LRB- -LRB-) (NP (CD n=2.4+/-0.7)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NN regurgitation) (NNS grades))) (PRN (-LRB- -LRB-) (NP (CD n=2.8+/-1.09)) (-RRB- -RRB-)))) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PRN (-LRB- -LRB-) (NP (CD p=0.008) (CC and) (CD p=0.006)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP Doc_18560792_1298_1307_Chemical) (NN group)))) (. .)))
18560792	11	(S1 (S (NP (NP (NN Severity)) (PP (IN of) (NP (NN regurgitation)))) (VP (AUX was) (RB not) (VP (VBN correlated) (PP (IN with) (NP (JJ Doc_18560792_1365_1374_Chemical) (JJ cumulative) (NN dose))))) (. .)))
18560792	12	(S1 (S (NP (NP (DT A) (JJ restrictive) (NN pattern)) (PP (IN of) (NP (NP (NNP Doc_18560792_1417_1439_Disease)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_18560792_1467_1476_Chemical)))))) (, ,)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (JJ 12/30) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-)) (NNS patients)) (PP (VBG including) (NP (NP (CD two)) (PP (IN with) (NP (NNP Doc_18560792_1534_1547_Disease))))))))) (. .)))
18560792	13	(S1 (S (S (NP (NN Doc_18560792_1549_1558_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PP (IN with) (NP (NNP Doc_18560792_1596_1618_Disease))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJR lower) (NN regurgitation) (NN grade)) (PRN (-LRB- -LRB-) (NP (CD p=0.01)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (JJ second) (JJ transthoracic) (NN echocardiography)))))))) (CC and) (S (NP (NP (DT the) (CD two) (NNS patients)) (PP (IN with) (NP (NNP Doc_18560792_1741_1754_Disease)))) (VP (VBD returned) (PP (TO to) (NP (RB nearly) (JJ normal) (JJ clinical) (NN examination))))) (. .)))
18560792	14	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ supports) (NP (NP (DT the) (JJ high) (NN frequency)) (PP (IN of) (NP (JJ restrictive) (NNP Doc_18560792_1857_1876_Disease))) (PP (IN in) (NP (NP (JJ Doc_18560792_1880_1882_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_1905_1914_Chemical)))))))) (CC and) (VP (VBZ reveals) (SBAR (IN that) (S (NP (DT a) (JJ significant) (NN improvement)) (VP (AUX is) (ADJP (JJ usual)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN treatment)) (VP (AUX is) (VP (VBN converted) (PP (TO to) (NP (JJ non-ergot) (JJ Doc_18560792_2012_2020_Chemical) (NNS agonists)))))))))))) (. .)))
18619688	0	(S1 (S (NP (JJ Doc_18619688_0_10_Chemical-induced) (JJ autophagic) (NN cardiomyocyte) (NN Doc_18619688_44_49_Disease)) (VP (VBZ plays) (NP (DT a) (JJ pathogenic) (NN role)) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_18619688_92_105_Disease)))))) (. .)))
18619688	1	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (NNP Doc_18619688_145_158_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_170_180_Chemical))))))) (VP (AUX are) (ADJP (ADJP (RB very) (JJ complicated)) (CC and) (ADJP (RB still) (JJ unclear)))) (. .)))
18619688	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (SBAR (IN whether) (S (NP (NN autophagy)) (VP (AUX was) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_18619688_315_328_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_340_350_Chemical)))))))))) (, ,) (CC so) (SBAR (IN that) (S (NP (PRP we)) (VP (MD can) (VP (VB develop) (NP (NP (DT a) (JJ novel) (NN treatment) (NN strategy)) (PP (IN for) (NP (NNP Doc_18619688_406_419_Disease))))))))))))) (. .)))
18619688	3	(S1 (S (NP (NP (NP (NNP Doc_18619688_430_445_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18619688_447_450_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN on) (NP (NN autophagy))))) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NP (DT a) (JJ Doc_18619688_501_514_Disease) (NN model)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_540_550_Chemical)))))))))) (. .)))
18619688	4	(S1 (S (NP (JJ Neonatal) (NNS cardiomyocytes)) (VP (AUX were) (VP (VP (VBN isolated) (PP (IN from) (NP (JJ Sprague-Dawley) (NN rat) (NNS hearts)))) (CC and) (VP (ADVP (RB randomly)) (VBN divided) (PP (IN into) (NP (NP (NNS controls)) (, ,) (NP (NP (DT an) (JJ Doc_18619688_660_670_Chemical-treated) (NN group)) (, ,) (CC and) (NP (DT a) (JJ Doc_18619688_692_695_Chemical) (JJ plus) (JJ Doc_18619688_701_711_Chemical-treated) (NN group)))))))) (. .)))
18619688	5	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD examined) (NP (NP (DT the) (NN morphology)) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NP (QP (RB beclin) (CD 1)) (NN gene)) (, ,) (NP (NP (JJ mitochondrial) (NN permeability) (NN transition)) (PRN (-LRB- -LRB-) (NP (NNP MPT)) (-RRB- -RRB-))) (, ,)))) (CC and) (NP (NP (JJ Na+-Doc_18619688_842_843_Chemical+) (NN ATPase) (NN activity)) (PP (IN in) (NP (NN vivo)))))) (. .)))
18619688	6	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD assessed) (NP (NP (NN cell) (NN viability)) (, ,) (NP (JJ mitochondrial) (JJ membrane) (JJ potential) (NNS changes)) (CC and) (NP (NP (VBN counted) (JJ autophagic) (NNS vacuoles)) (PP (IN in) (NP (JJ cultured) (NNS cardiomyocytes)))))) (. .)))
18619688	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN autophagy) (JJ associated) (NN gene)))) (, ,) (S (S (NP (NN beclin) (CD 1)) (VP (VBG using) (NP (NN RT-PCR)))) (CC and) (S (NP (NNP Western)) (VP (VBG blotting) (PP (IN in) (NP (DT an) (NN animal) (NN model))))))) (. .)))
18619688	8	(S1 (S (NP (NN Doc_18619688_1146_1149_Chemical)) (ADVP (RB significantly)) (VP (VBD improved) (NP (NP (JJ cardiac) (NN function)) (CC and) (NP (JJ reduced) (JJ mitochondrial) (NN injury)))) (. .)))
18619688	9	(S1 (S (ADVP (RB Furthermore)) (, ,) (S (NP (NNP Doc_18619688_1237_1247_Chemical)) (VP (VBN induced) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ autophagic) (NNS vacuoles)))))) (, ,) (CC and) (S (NP (NNP Doc_18619688_1298_1301_Chemical)) (ADVP (RB strongly)) (VP (VP (VBD downregulated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN beclin) (CD 1))) (PP (IN in) (NP (JJ Doc_18619688_1355_1365_Chemical-induced) (VBG failing) (NN heart))))) (CC and) (VP (VBD inhibited) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ autophagic) (NNS vacuoles))))))) (. .)))
18619688	10	(S1 (S (NP (JJ Autophagic) (NN cardiomyocyte) (NNP Doc_18619688_1477_1482_Disease)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_18619688_1530_1543_Disease))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_1563_1573_Chemical))))))))) (. .)))
18619688	11	(S1 (S (NP (JJ Mitochondrial) (NN injury)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_18619688_1634_1647_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18619688_1658_1668_Chemical))) (PP (IN via) (NP (DT the) (JJ autophagy) (NN pathway))))))))) (. .)))
18631865	0	(S1 (NP (NP (NN mToR) (JJ inhibitors-induced) (NN Doc_18631865_24_35_Disease)) (: :) (NP (NP (NNS mechanisms)) (, ,) (NP (NN significance)) (, ,) (CC and) (NP (NN management))) (. .)))
18631865	1	(S1 (S (NP (JJ Massive) (NN urinary) (NN protein) (NN excretion)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN after) (NP (NP (NN conversion)) (PP (IN from) (NP (JJ calcineurin) (NNS inhibitors))) (PP (TO to) (NP (NP (JJ mammalian) (NN target)) (PP (IN of) (NP (NP (NNP Doc_18631865_199_208_Chemical) (-LRB- -LRB-) (NN mToR) (-RRB- -RRB-) (NNS inhibitors)) (, ,) (ADVP (RB especially)) (NP (NNP Doc_18631865_239_248_Chemical)) (, ,))))))) (PP (IN in) (NP (NP (JJ renal) (NN transplant) (NNS recipients)) (PP (IN with) (NP (NNP Doc_18631865_286_315_Disease)))))))) (. .)))
18631865	2	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_18631865_325_336_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ predictive) (NN factor)) (PP (IN of) (NP (JJ poor) (NN transplantation) (NN outcome))))))) (, ,) (NP (JJ many) (NNS studies)) (VP (VBD focused) (PP (IN on) (NP (DT this) (JJ adverse) (NN event))) (PP (IN during) (NP (DT the) (JJ past) (NNS years)))) (. .)))
18631865	3	(S1 (S (SBAR (IN Whether) (S (NP (NNP Doc_18631865_473_484_Disease)) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_18631865_496_505_Chemical)))))) (CC or) (RB only) (S (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (JJ calcineurin) (NNS inhibitors) (NN withdrawal)))) (VP (VBD remained) (NP (NNP unsolved)) (PP (IN until) (NP (JJ high) (NN range)))))) (NP (NNP Doc_18631865_600_611_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN during) (NP (JJ Doc_18631865_637_646_Chemical) (NN therapy))) (PP (PP (IN in) (NP (JJ islet) (NN transplantation))) (CC and) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ Doc_18631865_709_718_Chemical) (JJ de) (NN novo))))))))))) (. .)))
18631865	4	(S1 (S (S (NP (NP (JJ Podocyte) (NN injury)) (CC and) (NP (JJ focal) (JJ segmental) (NN Doc_18631865_764_782_Disease))) (VP (AUX have) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (NN mToR) (NN inhibition)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS pathways)) (VP (VBG underlying) (NP (DT these) (NNS lesions)))) (VP (VBP remain) (ADJP (JJ hypothetic)))) (. .)))
18631865	5	(S1 (S (NP (PRP We)) (VP (VB discuss) (S (VP (VBG herein) (NP (NP (DT the) (JJ possible) (NNS mechanisms)) (CC and) (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (JJ mToR) (JJ blockade-induced) (NN Doc_18631865_987_998_Disease)))))))) (. .)))
1867351	0	(S1 (NP (NP (JJ Neuropsychiatric) (JJ side) (NNS effects)) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1867351_47_57_Chemical))))) (. .)))
1867351	1	(S1 (S (NP (DT This) (NN study)) (VP (VBZ describes) (NP (JJ neuropsychiatric) (NN side) (NNS effects)) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_1867351_143_153_Chemical)))))) (. .)))
1867351	2	(S1 (S (NP (NNS Reactions)) (VP (VBD consisted) (ADVP (RB mainly)) (PP (IN of) (NP (NP (ADJP (NNP Doc_1867351_185_193_Disease) (, ,) (JJ acute)) (NNP Doc_1867351_201_210_Disease)) (, ,) (NP (NNP Doc_1867351_212_228_Disease)) (, ,) (CC and) (NP (JJ major) (NNP Doc_1867351_240_273_Disease))))) (. .)))
1867351	3	(S1 (S (NP (NN Side) (NNS effects)) (VP (VP (VBD occurred) (PP (IN after) (NP (DT both) (ADJP (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ prophylactic))) (NN intake)))) (CC and) (VP (AUX were) (VP (VBN graded) (PP (IN from) (ADJP (JJ moderate) (TO to) (JJ severe)))))) (. .)))
1867351	4	(S1 (S (PP (IN In) (NP (NP (DT a) (NN risk) (NN analysis)) (PP (IN of) (NP (NP (JJ neuropsychiatric) (NN side) (NNS effects)) (PP (IN in) (NP (NNP Germany))))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN estimated) (SBAR (IN that) (S (NP (NP (CD one)) (PP (IN of) (NP (CD 8,000) (JJ Doc_1867351_483_493_Chemical) (NNS users)))) (VP (VBZ suffers) (PP (IN from) (NP (JJ such) (NNS reactions)))))))) (. .)))
1867351	5	(S1 (S (NP (DT The) (NN incidence) (NN calculation)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (CD one)) (PP (IN of) (NP (CD 215) (JJ therapeutic) (NNS users)))) (VP (AUX had) (NP (NNS reactions)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (CD 13,000)))))) (PP (IN in) (NP (DT the) (NN prophylaxis) (NN group))) (, ,) (S (VP (VBG making) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ neuropsychiatric) (NNS reactions)))) (PP (IN after) (NP (NP (JJ Doc_1867351_719_729_Chemical) (NN treatment)) (ADJP (ADJP (NP (CD 60) (NNS times)) (JJR higher)) (PP (IN than) (PP (IN after) (NP (NN prophylaxis))))))))))))) (. .)))
1867351	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ certain) (NNS limitations)) (PP (IN for) (NP (NP (NNP Doc_1867351_815_822_Disease) (NN prophylaxis) (CC and) (NN treatment)) (PP (IN with) (NP (NNP Doc_1867351_854_864_Chemical)))))) (VP (AUX are) (VP (VBN recommended))) (. .)))
18703024	0	(S1 (S (NP (JJ Prenatal) (NN protein) (NN deprivation)) (VP (VBZ alters) (NP (NP (JJ Doc_18703024_36_44_Chemical-mediated) (NNS behaviors)) (CC and) (NP (NP (NN dopaminergic)) (CC and) (NP (JJ glutamatergic) (NN receptor) (VBG binding))))) (. .)))
18703024	1	(S1 (S (NP (JJ Epidemiological) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ prenatal) (JJ nutritional) (NN deprivation)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN Doc_18703024_215_228_Disease))))))))) (. .)))
18703024	2	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (AUX was) (S (VP (TO to) (VP (VB use) (NP (DT an) (NN animal) (NN model)) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ prenatal) (NN protein) (NN deprivation))) (PP (IN on) (NP (NP (NP (NNS behaviors)) (CC and) (NP (NN receptor))) (ADJP (JJ binding) (PP (IN with) (NP (NP (NN relevance)) (PP (TO to) (NP (NNP Doc_18703024_390_403_Disease)))))))))))))))) (. .)))
18703024	3	(S1 (S (NP (PRP We)) (VP (VBP report) (SBAR (IN that) (S (NP (JJ prenatally) (NN protein)) (VP (VBD deprived) (SBAR (S (NP (PRN (-LRB- -LRB-) (NP (NNP PD)) (-RRB- -RRB-)) (JJ female) (NNS rats)) (VP (VBD showed) (NP (NP (NP (DT an) (VBN increased) (JJ stereotypic) (NN response)) (PP (TO to) (NP (NNP Doc_18703024_509_520_Chemical)))) (CC and) (NP (NP (DT an) (VBN increased) (JJ locomotor) (NN response)) (PP (TO to) (NP (NP (NNP Doc_18703024_560_571_Chemical)) (PP (IN in) (NP (NN adulthood)))))))))))))) (. .)))
18703024	4	(S1 (S (NP (DT These) (NNS differences)) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN during) (NP (NN puberty))))) (. .)))
18703024	5	(S1 (S (NP (NP (DT No) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_18703024_652_663_Chemical-induced) (NN Doc_18703024_672_681_Disease)) (CC or) (NP (JJ Doc_18703024_685_691_Chemical-induced) (NN locomotion))))) (VP (AUX were) (VP (VBN seen) (PP (VBG following) (NP (NN PD))))) (. .)))
18703024	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ PD) (NN female) (NNS rats)) (VP (VBD showed) (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_783_784_Chemical-Doc_18703024_785_791_Chemical) (VBG binding)) (PP (IN in) (NP (DT the) (NN striatum) (CC and) (NN hippocampus))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (DT the) (NN cortex))))) (. .)))
18703024	7	(S1 (S (NP (JJ PD) (NN female) (NNS rats)) (ADVP (RB also)) (VP (VP (VBD showed) (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_896_897_Chemical-Doc_18703024_898_909_Chemical) (VBG binding))) (CC and) (VP (VBD decreased) (NP (NP (JJ Doc_18703024_932_940_Chemical) (NN transporter) (VBG binding)) (PP (IN in) (NP (NN striatum)))))) (. .)))
18703024	8	(S1 (S (NP (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (NN behavior)) (CC or) (NP (NN receptor) (VBG binding))))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (JJ PD) (NNS males)) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_1101_1102_Chemical-Doc_18703024_1103_1109_Chemical) (VBG binding)) (PP (IN in) (NP (NN cortex))))))))))) (. .)))
18703024	9	(S1 (S (NP (DT This) (NN animal) (NN model)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ prenatal) (NNP Doc_18703024_1205_1227_Disease)) (VP (VP (VBZ enhances) (NP (NP (NN risk)) (PP (IN for) (NP (NNP Doc_18703024_1246_1259_Disease))) (PP (IN in) (NP (NNS humans))))) (CC and) (VP (MD may) (ADVP (RB also)) (VP (AUX have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (JJ developmental) (NNS processes)) (VP (VBG leading) (PP (TO to) (NP (NP (NN differential) (NN sensitivity)) (PP (TO to) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse))))))))))))))))))))))) (. .)))
18726058	0	(S1 (S (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (JJ topical) (NNP Doc_18726058_27_37_Chemical))) (PP (IN on) (NP (JJ auditory) (NN nerve)))) (VP (VBP function)) (. .)))
18726058	1	(S1 (S (NP (NN Doc_18726058_78_102_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ direct-acting) (NN vasodilator)) (VP (VBN used) (S (VP (TO to) (VP (VB manage) (NP (NN Doc_18726058_149_158_Disease)) (PP (IN during) (NP (JJ various) (JJ neurosurgical) (NNS operations))))))))) (. .)))
18726058	2	(S1 (S (NP (JJ Transient) (NNP Doc_18726058_210_235_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (NP (DT a) (JJ few) (NNS cases)) (PP (IN with) (NP (JJ topical) (NNP Doc_18726058_283_293_Chemical)))))))) (. .)))
18726058	3	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ supports) (NP (JJ previous) (NNS reports))) (CC and) (VP (VBZ provides) (NP (NP (JJ neurophysiological) (NN evidence)) (PP (IN of) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (DT the) (JJ auditory) (NN nerve)))))))) (. .)))
18726058	4	(S1 (S (NP (PRP We)) (VP (VP (VBD conducted) (NP (NP (DT a) (NN retrospective) (NN review)) (PP (IN of) (NP (CD 70) (JJ consecutive) (JJ microvascular) (NN decompression) (NNS operations))))) (CC and) (VP (VBD studied) (NP (NP (DT those) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ topical) (NNP Doc_18726058_567_577_Chemical)) (PP (IN for) (NP (NN Doc_18726058_582_591_Disease))))))))) (. .)))
18726058	5	(S1 (S (NP (JJ Topical) (NNP Doc_18726058_601_611_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ direct) (JJ therapeutic) (NN action)) (SBAR (S (VP (TO to) (VP (VB manage) (NP (NN Doc_18726058_662_671_Disease)) (PP (IN in) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 11) (NNS patients))))))))))))) (. .)))
18726058	6	(S1 (S (NP (NP (DT The) (NN timing)) (PP (IN of) (NP (NP (JJ Doc_18726058_713_723_Chemical) (NN application)) (CC and) (NP (JJ ongoing) (JJ operative) (NNS events))))) (VP (AUX was) (VP (VBN reviewed) (ADVP (JJ relative) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ neurophysiological) (NNS recordings)))))))) (. .)))
18726058	7	(S1 (S (NP (NP (NNP Brainstem) (JJ auditory) (VBN evoked) (NNS potentials)) (PRN (-LRB- -LRB-) (NP (NNP BAEPs)) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB routinely)) (VP (VBN used) (S (VP (TO to) (VP (VB monitor) (NP (JJ cochlear) (NN nerve) (NN function)) (PP (IN during) (NP (DT these) (NNS operations)))))))) (. .)))
18726058	8	(S1 (S (NP (DT A) (JJ temporal) (NN relationship)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (JJ topical) (JJ Doc_18726058_1017_1027_Chemical) (CC and) (JJ BAEP) (NNS changes)) (VP (VBG leading) (S (VP (TO to) (VP (VB complete) (NP (JJ waveform) (NN loss)))))))))) (. .)))
18726058	9	(S1 (S (NP (NP (NP (DT The) (JJ average) (JJ temporal) (NN delay)) (PP (IN between) (NP (NNP Doc_18726058_1115_1125_Chemical)))) (CC and) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT an) (JJ adverse) (NN BAEP) (NN change))))) (VP (AUX was) (NP (CD 5) (NN min))) (. .)))
18726058	10	(S1 (S (PP (IN In) (NP (NP (CD 10)) (PP (IN of) (NP (CD 11) (NNS patients))))) (, ,) (NP (NN BAEP) (NNS waves)) (ADVP (RB II/III-V) (RB completely)) (VP (VBD disappeared) (PP (IN within) (NP (QP (CD 2) (TO to) (CD 25)) (NN min))) (PP (IN after) (NP (NNP Doc_18726058_1267_1277_Chemical)))) (. .)))
18726058	11	(S1 (S (NP (NP (CD Eight)) (PP (IN of) (NP (DT these) (CD 10) (NNS patients)))) (VP (AUX had) (NP (NP (JJ complete) (NN loss)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (IN within) (NP (CD 10) (NN min))))) (. .)))
18726058	12	(S1 (S (NP (CD One) (NN patient)) (VP (VBD showed) (NP (NP (NP (DT no) (NN recovery)) (PP (IN of) (NP (JJ later) (NNS waves)))) (CC and) (NP (DT a) (JJ delayed) (JJ profound) (NN Doc_18726058_1426_1452_Disease)))) (. .)))
18726058	13	(S1 (S (NP (NP (DT The) (JJ average) (NN recovery) (NN time)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (TO to) (NP (JJ pre-Doc_18726058_1505_1515_Chemical) (NN baseline) (NNS values)))) (VP (AUX was) (NP (CD 39) (NN min))) (. .)))
18726058	14	(S1 (S (NP (NP (JJ Topical) (NN Doc_18726058_1565_1575_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_18726058_1597_1606_Disease)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT a) (JJ transient) (NN disturbance))) (PP (IN in) (NP (NP (JJ neurophysiological) (NN function)) (PP (IN of) (NP (DT the) (VBG ascending) (NN auditory) (NN brainstem) (NN pathway))))))))) (. .)))
18726058	15	(S1 (S (NP (NP (DT The) (JJ complete) (NN disappearance)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (IN with) (NP (DT a) (JJ consistent) (JJ temporal) (NN delay)))) (VP (VBZ suggests) (NP (DT a) (JJ possible) (NN Doc_18726058_1838_1881_Disease))) (. .)))
18726058	16	(S1 (S (NP (NP (NNS Recommendations)) (SBAR (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ potential) (NN Doc_18726058_1918_1940_Disease)) (PP (IN from) (NP (NNP Doc_18726058_1946_1956_Chemical))))))))) (VP (AUX are) (VP (VBN provided))) (. .)))
18752389	0	(S1 (S (NP (JJ Doc_18752389_0_21_Chemical-induced) (NNP Doc_18752389_30_45_Disease)) (VP (VBD necessitating) (NP (NN liver) (NN transplantation))) (. .)))
18752389	1	(S1 (S (NP (JJ Abstract) (NNP Serum) (NN aminotransferase) (NNS elevations)) (VP (AUX are) (NP (NP (DT a) (ADJP (RB commonly) (VBN known)) (JJ adverse) (NN effect)) (PP (IN of) (NP (NN 3-hydroxy-3-methylglutaryl)))) (ADVP (RB coenzyme) (NP (DT A) (JJ reductase) (NN inhibitor) (PRN (-LRB- -LRB-) (NP (NNP Doc_18752389_224_230_Chemical)) (-RRB- -RRB-)) (NN therapy)))) (. .)))
18752389	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_18752389_250_261_Disease) (NNS events)) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB widely)) (VP (VBN published) (PP (IN with) (NP (NP (NNP Doc_18752389_305_314_Chemical)) (CC or) (NP (DT the) (NN combination) (NN agent) (NNP Doc_18752389_340_361_Chemical))))))) (. .)))
18752389	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 70-year-old) (JJ Hispanic) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_18752389_418_443_Disease) (JJ necessitating) (NN liver) (NN transplantation)) (PP (NP (CD 10) (NNS weeks)) (IN after) (NP (NP (NN conversion)) (PP (IN from) (NP (NNP Doc_18752389_511_522_Chemical) (CD 40) (NN mg/day))) (PP (TO to) (NP (NNP Doc_18752389_536_569_Chemical/day)))))))))) (. .)))
18752389	4	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (NN lipid) (NN panel)) (VP (AUX had) (VP (AUX been) (VP (VBN maintained) (PP (IN with) (NP (NNP Doc_18752389_626_637_Chemical))) (PP (IN for) (NP (NP (CD 18) (NNS months)) (PP (IN before) (NP (NP (DT the) (NN conversion)) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_18752389_694_708_Disease)))))))))))) (. .)))
18752389	5	(S1 (S (NP (NP (NP (DT A) (JJ routine) (NN laboratory) (NN work-up)) (NP (CD 10) (NNS weeks))) (PP (IN after) (NP (NN conversion)))) (VP (VBD revealed) (NP (JJ elevated) (NN serum) (NN aminotransferase) (NNS levels))) (. .)))
18752389	6	(S1 (S (S (NP (NP (NP (NNP Doc_18752389_814_834_Chemical)) (CC and) (NP (NNP Doc_18752389_839_851_Chemical))) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (NP (PRP she)) (VP (AUX was) (VP (VBG taking) (PP (IN for) (NP (NNP Doc_18752389_878_888_Disease))))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (NP (JJ other) (JJ potential) (NNS causes)) (PP (IN of) (NP (NNP Doc_18752389_939_953_Disease)))) (VP (AUX were) (VP (VBN excluded)))) (. .)))
18752389	7	(S1 (S (S (NP (DT A) (NN repeat) (NN work-up)) (VP (VBD revealed) (NP (JJ further) (NNS elevations)) (PP (IN in) (NP (JJ aminotransferase) (NNS levels))))) (, ,) (CC and) (S (NP (NN liver) (NN biopsy)) (VP (VBD revealed) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ moderate-to-severe) (NN Doc_18752389_1099_1112_Disease)))))) (. .)))
18752389	8	(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NN liver) (NN transplantation)) (PP (IN with) (NP (DT an) (JJ uneventful) (NN postoperative) (NN course)))) (. .)))
18752389	9	(S1 (S (S (NP (PRP$ Her) (NN aminotransferase) (NNS levels)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN by) (NP (NN postoperative) (NN day) (CD 23))))) (, ,) (CC and) (S (NP (PRP$ her) (JJ 2-year) (NN follow-up)) (VP (VBD showed) (NP (DT no) (JJ adverse) (NNS events)))) (. .)))
18752389	10	(S1 (S (NP (NN Doc_18752389_1314_1323_Chemical)) (VP (VP (VBZ undergoes) (NP (NP (JJ extensive) (NN glucuronidation)) (PP (IN by) (NP (NP (JJ Doc_18752389_1363_1382_Chemical) (NNS glucoronosyltransferases)) (PRN (-LRB- -LRB-) (NP (NNP UGT)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN intestine) (CC and) (NN liver)))) (CC and) (VP (MD may) (VP (AUX have) (VP (VBD inhibited) (NP (NP (DT the) (NN glucuronidation)) (PP (IN of) (NP (NNP Doc_18752389_1487_1511_Chemical))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (JJ Doc_18752389_1536_1547_Chemical) (NN exposure)) (CC and) (NP (JJ subsequent) (NN Doc_18752389_1572_1586_Disease)))))))))) (. .)))
18752389	11	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (JJ Doc_18752389_1639_1660_Chemical-induced) (NNP Doc_18752389_1669_1682_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NN liver) (NN transplantation)))))))) (. .)))
18752389	12	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT the) (JJ Doc_18752389_1762_1782_Chemical-induced) (NN Doc_18752389_1791_1805_Disease)))) (VP (AUX is) (NP (NP (DT the) (VBN increased) (JJ Doc_18752389_1823_1834_Chemical) (NN exposure)) (PP (IN by) (NP (NP (JJ Doc_18752389_1847_1856_Chemical) (NN inhibition)) (PP (IN of) (NP (JJ UGT) (NNS enzymes)))))))))) (. .)))
18752389	13	(S1 (S (NP (NNS Clinicians)) (VP (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (JJ potential) (NN Doc_18752389_1924_1938_Disease)) (PP (IN with) (NP (NNP Doc_18752389_1944_1965_Chemical)))))) (PP (ADVP (RB especially)) (IN in) (NP (JJ elderly) (NNS patients))))) (CC and) (VP (MD should) (ADVP (RB carefully)) (VP (VB monitor) (NP (NN serum) (NN aminotransferase) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (S (VP (VBG starting) (NP (NN therapy)))) (CC and) (S (VP (VBG titrating) (NP (DT the) (NN dosage))))))))) (. .)))
18754075	0	(S1 (NP (NP (NP (JJ Massive) (NN Doc_18754075_8_19_Disease)) (CC and) (NP (NNP Doc_18754075_24_43_Disease))) (PP (IN after) (NP (JJ oral) (NNP Doc_18754075_55_69_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18754075_71_82_Chemical)) (-RRB- -RRB-)) (NN administration))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_18754075_117_151_Disease))))) (. .)))
18754075	1	(S1 (S (NP (NP (DT A) (JJ 61-year-old) (JJ Japanese) (NN man)) (PP (IN with) (NP (NNP Doc_18754075_185_203_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_18754075_211_245_Disease)))) (VP (AUX was) (ADVP (RB initially)) (VP (VBG responding) (ADVP (RB well)) (PP (TO to) (NP (JJ Doc_18754075_279_286_Chemical) (NN therapy))))) (. .)))
18754075	2	(S1 (S (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (JJ daily) (JJ urinary) (NN protein)))) (VP (VBD decreased) (PP (IN from) (NP (QP (CD 15.6) (TO to) (CD 2.8)) (NNP g.))) (PP (IN Within) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (DT the) (JJ oral) (NNP Doc_18754075_389_403_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18754075_405_423_Chemical)) (-RRB- -RRB-)) (NN administration))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ daily) (JJ urinary) (NN protein)))) (VP (VBD increased) (ADVP (RB rapidly)) (ADVP (RB up)) (PP (TO to) (NP (NP (CD 12.8) (NNP g)) (PP (IN with) (NP (NNP Doc_18754075_513_532_Disease)))))) (. .)))
18754075	3	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (DT the) (JJ oral) (NN Doc_18754075_563_574_Chemical))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD underwent) (NP (NP (NP (CD six) (NNS cycles)) (PP (IN of) (NP (NN hemodialysis)))) (CC and) (NP (NP (CD four) (NNS cycles)) (PP (IN of) (NP (NNP LDL) (NNS apheresis)))))) (. .)))
18754075	4	(S1 (S (NP (NP (JJ Urinary) (NN volume)) (CC and) (NP (NN serum) (NN Doc_18754075_684_694_Chemical) (NNS levels))) (VP (VBD recovered) (PP (TO to) (NP (DT the) (JJ normal) (NN range))) (, ,) (PP (IN with) (NP (NP (JJ urinary) (NN protein)) (VP (VBG disappearing) (ADVP (RB completely)) (PP (IN within) (NP (CD 40) (NNS days))))))) (. .)))
18754075	5	(S1 (S (NP (DT This) (NN report)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (ADJP (ADJP (ADVP (RB not) (RB only)) (JJ intravenous)) (, ,) (CONJP (CC but) (RB also)) (ADJP (JJ oral))) (NNP Doc_18754075_860_875_Chemical)) (VP (MD can) (VP (VB aggravate) (NP (NP (NNP Doc_18754075_890_901_Disease)) (CC and) (NP (NNP Doc_18754075_906_925_Disease)))))))) (. .)))
18768591	0	(S1 (S (NP (NP (NN Serum-)) (CC and) (NP (NN glucocorticoid-inducible))) (VP (VBP kinase) (NP (CD 1)) (PP (IN in) (NP (NNP Doc_18768591_48_59_Chemical-induced) (NNP Doc_18768591_68_86_Disease)))) (. .)))
18768591	1	(S1 (S (NP (JJ Doc_18768591_88_99_Chemical-induced) (NNP Doc_18768591_108_119_Disease)) (VP (VBZ leads) (PP (TO to) (NP (NP (JJ epithelial) (JJ Doc_18768591_140_146_Chemical) (NN channel) (PRN (-LRB- -LRB-) (NNP ENaC) (-RRB- -RRB-)) (NN -dependent) (NN Doc_18768591_172_188_Disease)) (CC and) (NP (JJ renal) (NN Doc_18768591_199_207_Disease))))) (. .)))
18768591	2	(S1 (S (NP (NP (DT The) (JJ Doc_18768591_213_224_Chemical-sensitive) (NN serum-)) (CC and) (NP (JJ glucocorticoid-inducible) (NN kinase) (NN SGK1))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NNP ENaC))))))) (CC and) (VP (TO to) (VP (VB mediate) (NP (JJ renal) (NNP Doc_18768591_361_369_Disease)) (PP (VBG following) (NP (NP (NN mineralocorticoid)) (CC and) (NP (NN salt) (NN excess))))))))))) (. .)))
18768591	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP SGK1)))) (PP (IN in) (NP (DT the) (NNP Doc_18768591_484_500_Disease) (CC and) (NNP Doc_18768591_505_513_Disease))) (PP (IN during) (NP (NN Doc_18768591_521_539_Disease)))))))) (. .)))
18768591	4	(S1 (S (PP (TO To) (NP (DT this) (NN end))) (, ,) (NP (NP (NNP Doc_18768591_554_565_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mug/g)) (NN body) (NN wt)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB intravenously)) (PP (IN into) (NP (NP (JJ gene-targeted) (NNS mice)) (VP (VBG lacking) (NP (NP (NN SGK1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD sgk1)) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ their) (JJ wild-type) (NNS littermates)) (PRN (-LRB- -LRB-) (NN sgk1) (-LRB- -LRB-) (NP (CD +/+)) (-RRB- -RRB-)))) (-RRB- -RRB-)))))))) (. .)))
18768591	5	(S1 (S (NP (JJ Doc_18768591_706_717_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ heavy) (NN Doc_18768591_746_757_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD >100) (CD mg)) (NN protein/mg) (NN crea)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (CD 15/44)) (PP (IN of) (NP (NP (NNS sgk1)) (PRN (-LRB- -LRB-) (NP (NN +/+)) (-RRB- -RRB-))))) (CC and) (NP (NP (CD 15/44)) (PP (IN of) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ severe) (NNP Doc_18768591_852_870_Disease)) (PP (IN with) (NP (NP (NNP Doc_18768591_876_883_Disease)) (, ,) (NP (NNP Doc_18768591_885_894_Disease)) (, ,) (CC and) (NP (NNP Doc_18768591_900_915_Disease)))) (PP (IN in) (NP (DT both) (NNS genotypes)))))))))))) (. .)))
18768591	6	(S1 (S (NP (NN Plasma) (NN Doc_18768591_942_953_Chemical) (NNS levels)) (VP (VP (VBD increased) (PP (IN in) (NP (NP (JJ Doc_18768591_974_983_Disease) (NNS mice)) (PP (IN of) (NP (DT both) (NNS genotypes)))))) (CC and) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (VBN increased) (JJ SGK1) (NN protein) (NN expression)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ +/+) (-RRB- -RRB-)) (NNS mice)))))))) (. .)))
18768591	7	(S1 (S (NP (JJ Urinary) (JJ Doc_18768591_1088_1094_Chemical) (NN excretion)) (VP (VP (VBD reached) (NP (ADJP (RB signficantly) (JJR lower)) (NNS values)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ +/+) (-RRB- -RRB-)) (NNS mice))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN +/-)) (NP (QP (CD 5) (CD mumol/mg)) (NN crea)) (-RRB- -RRB-) (PP (IN than) (NP (NP (IN in) (JJ sgk1) (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-) (NNS mice)) (-LRB- -LRB-) (NP (CD 35) (NN +/-)) (QP (CD 5) (CD mumol/mg) (NN crea)))) (-RRB- -RRB-))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN body) (NN Doc_18768591_1282_1293_Disease)) (PP (IN in) (NP (NP (NNS sgk1)) (PRN (-LRB- -LRB-) (NP (CD +/+)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD +6.6) (JJ +/-) (NP (CD 0.7) (CC vs.) (CD +4.1) (NN +/-) (CD 0.8)) (NNP g)) (-RRB- -RRB-)))))))) (. .)))
18768591	8	(S1 (S (PP (IN During) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_18768591_1392_1410_Disease))))) (, ,) (NP (JJ serum) (NNP Doc_18768591_1418_1422_Chemical) (NNS concentrations)) (VP (VBD increased) (ADVP (RB significantly) (RBR faster)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice))) (PP (IN than) (PP (IN in) (NP (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-)) (NNS mice)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_18768591_1521_1527_Disease))))) (CC and) (NP (NP (DT a) (VBN reduced) (JJ median) (NN survival)) (PP (IN in) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (CD 29) (CC vs.) (CD 40) (NNS days)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-)) (NNS mice)))) (-RRB- -RRB-))))))))) (. .)))
18768591	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (JJ gene-targeted) (NNS mice)) (VP (VBG lacking) (NP (NNS SGK1)))) (VP (VP (VBD showed) (VP (VBN blunted) (NP (NNP Doc_18768591_1674_1690_Disease)))) (, ,) (CC yet) (VP (AUX were) (RB not) (VP (VBN protected) (PP (IN against) (NP (JJ renal) (NNP Doc_18768591_1729_1737_Disease))) (PP (IN during) (NP (JJ experimental) (NN Doc_18768591_1758_1776_Disease)))))) (. .)))
18791946	0	(S1 (S (S (NP (NP (JJ Severe) (NN Doc_18791946_7_23_Disease)) (CC and) (NP (NNP Doc_18791946_28_46_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18791946_63_76_Chemical))))) (: :) (S (NP (DT a) (NN case)) (VP (VBP report) (PP (IN with) (NP (JJ fatal) (NN outcome))))) (. .)))
18791946	1	(S1 (S (NP (NP (JJ Haematological) (JJ adverse) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (JJ fatal) (NN outcome))))) (VP (AUX are) (ADJP (JJ rare)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_18791946_206_219_Chemical)))))) (. .)))
18791946	2	(S1 (S (NP (DT A) (JJ 30-year) (JJ old) (JJ Caucasian) (NN man)) (VP (VBD reported) (PP (IN with) (NP (NP (NNP Doc_18791946_263_277_Disease)) (CC and) (NP (NNP Doc_18791946_282_290_Disease)))) (PP (IN after) (NP (NP (JJ 3-day) (NN administration)) (PP (IN of) (NP (JJ oral) (NNP Doc_18791946_326_339_Chemical))))) (PP (IN for) (NP (NP (DT a) (NN suspect)) (PP (IN of) (NP (NNP Doc_18791946_357_380_Disease)))))) (. .)))
18791946	3	(S1 (S (NP (JJ Clinical) (NNS evaluations)) (VP (VBD suggested) (NP (NP (DT an) (JJ initial) (NN diagnosis)) (PP (IN of) (NP (JJ severe) (NNP Doc_18791946_444_460_Disease) (CC and) (NNP Doc_18791946_465_475_Disease))))) (. .)))
18791946	4	(S1 (S (NP (DT The) (NN patient)) (ADVP (RB progressively)) (VP (VBD developed) (NP (NP (NNP Doc_18791946_513_522_Disease)) (CC and) (NP (NNP Doc_18791946_527_534_Disease))) (PP (IN on) (NP (NP (NN thorax)) (CC and) (NP (JJR lower) (NNS limbs))))) (. .)))
18791946	5	(S1 (S (PP (IN Despite) (NP (ADJP (ADJP (JJ pharmacological)) (CC and) (ADJP (JJ supportive))) (NNS interventions))) (, ,) (S (NP (NN laboratory) (NNS parameters)) (VP (VBD worsened))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD died) (PP (NP (CD 17) (NNS hours)) (IN after) (NP (NN admission))))) (. .)))
18791946	6	(S1 (S (NP (DT An) (JJ accurate) (NN autopsy)) (VP (VBD revealed) (NP (NP (JJS most) (NNS organs)) (PP (IN with) (NP (JJ diffuse) (JJ petechial) (NN Doc_18791946_758_770_Disease))))) (. .)))
18791946	7	(S1 (S (NP (NP (DT No) (NNS signs)) (PP (IN of) (NP (NNP Doc_18791946_784_806_Disease)))) (VP (AUX were) (VP (VBN found))) (. .)))
18791946	8	(S1 (S (NP (NP (DT No) (NN Doc_18791946_822_829_Disease) (CC or) (NNS signs)) (PP (IN of) (NP (NNP Doc_18791946_842_859_Disease)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ arterial) (NNS vessels))))) (. .)))
18791946	9	(S1 (S (NP (NN Blood) (CC and) (NN urine) (NNS cultures)) (VP (AUX did) (RB not) (VP (VB show) (NP (DT any) (JJ bacterial) (NN growth)))) (. .)))
18791946	10	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP Doc_18791946_983_996_Chemical)) (VP (MD may) (VP (VB precipitate) (ADJP (JJ life-threatening)) (NP (NP (NNP Doc_18791946_1030_1046_Disease)) (CC and) (NP (NNP Doc_18791946_1051_1069_Disease))) (, ,) (PP (RB even) (PP (IN in) (NP (NP (DT the) (JJ early) (NNS phases)) (PP (IN of) (NP (NN treatment))))) (CC and) (PP (IN without) (NP (JJ apparent) (JJ previous) (NNS exposures))))))))) (. .)))
18809400	0	(S1 (S (NP (NN Doc_18809400_0_17_Chemical)) (VP (VBZ prevents) (NP (NP (NNP Doc_18809400_27_47_Disease)) (CC and) (NP (NNP Doc_18809400_52_65_Disease))) (PP (IN in) (NP (JJ experimental) (JJ chemotherapy) (NN Doc_18809400_95_105_Disease)))) (. .)))
18809400	1	(S1 (S (NP (DT The) (NN study)) (VP (VBZ investigates) (SBAR (SBAR (IN if) (S (NP (NNP Doc_18809400_133_150_Chemical)) (VP (AUX is) (ADJP (JJ neuroprotective)) (PP (IN against) (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_199_212_Disease)))))) (, ,) (SBAR (IN if) (S (NP (NNP Doc_18809400_217_237_Disease)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NNP Doc_18809400_263_294_Disease)))))) (, ,) (CC and) (SBAR (IN if) (S (NP (NP (JJ neuroprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_18809400_330_347_Chemical)))) (VP (VBP depend) (PP (IN on) (NP (NN mitochondria) (NN protection)))))))) (. .)))
18809400	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (DT an)) (PP (IN in) (NP (NP (NN vitro) (NN model)) (PP (IN of) (NP (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_433_454_Disease)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB closely)) (VBP mimic) (NP (NP (DT the)) (PP (IN in) (NP (NN vivo) (NN condition)))) (PP (IN by) (S (VP (VBG exposing) (NP (NP (JJ primary) (NNS cultures)) (PP (IN of) (NP (NP (JJ dorsal) (NN root) (NN ganglion)) (PRN (-LRB- -LRB-) (NP (NNP DRG)) (-RRB- -RRB-))))) (NP (JJ sensory) (NNS neurons)) (PP (TO to) (NP (NP (NNP Doc_18809400_574_584_Chemical)) (CC and) (NP (NNP Doc_18809400_589_598_Chemical)))) (, ,) (NP (CD two) (ADJP (ADJP (RB widely) (VBN used)) (CC and) (ADJP (RB highly) (JJ effective))) (JJ chemotherapeutic) (NNS drugs))))))))))))) (. .)))
18809400	3	(S1 (S (NP (DT This) (NN approach)) (VP (VBD allowed) (S (VP (VBG investigating) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_18809400_713_730_Chemical)))) (PP (IN in) (S (VP (VBG preventing) (NP (NP (NN Doc_18809400_745_758_Disease) (CC and) (NN apoptosis)) (CC and) (NP (NP (NP (DT the) (NN function)) (CC and) (NP (JJ ultrastructural) (NN morphology))) (PP (IN of) (NP (NN mitochondria))))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (JJ toxic) (NNS agents) (CC and) (NNP Doc_18809400_872_889_Chemical))))))))))) (. .)))
18809400	4	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT both) (NNP Doc_18809400_925_934_Chemical) (CC and) (NNP Doc_18809400_939_949_Chemical)) (VP (VBP cause) (NP (JJ early) (NN Doc_18809400_962_986_Disease)) (PP (IN with) (NP (NP (NP (NN loss)) (PP (IN of) (NP (JJ membrane) (NN potential)))) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NP (JJ autophagic) (NNS vacuoles)) (PP (IN in) (NP (NNS neurons)))))))))))) (. .)))
18809400	5	(S1 (S (S (NP (NNP Doc_18809400_1068_1085_Chemical)) (VP (VBZ exerts) (NP (NP (JJ neuroprotective) (NNS effects)) (PP (IN against) (NP (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_1146_1159_Disease)) (PP (IN in) (NP (JJ sensory) (NNS neurons)))))))) (: :) (S (NP (PRP it)) (VP (VP (VBZ rescues) (NP (DT the) (NNP Doc_18809400_1195_1217_Disease))) (CC and) (VP (VBZ induces) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN frataxin)) (, ,) (NP (NP (DT an) (JJ essential) (JJ mitochondrial) (NN protein)) (PP (IN with) (NP (NN anti-oxidant) (CC and) (NN chaperone) (NNS properties)))))))))) (. .)))
18809400	6	(S1 (S (PP (IN In) (NP (NN conclusion))) (NP (NNP Doc_18809400_1351_1373_Disease)) (VP (AUX is) (NP (DT an) (JJ early) (JJ common) (NN event)) (PP (DT both) (IN in) (NP (NNP Doc_18809400_1407_1417_Chemical) (CC and) (NNP Doc_18809400_1422_1431_Chemical) (VBN induced) (NN Doc_18809400_1440_1453_Disease)))) (. .)))
18809400	7	(S1 (S (NP (NN Doc_18809400_1455_1472_Chemical)) (VP (VBZ protects) (NP (JJ sensory) (NNS neurons)) (PP (IN through) (NP (NP (PRP$ its) (NN anti-oxidant)) (CC and) (NP (JJ mitochondrial) (JJ regulatory) (NNS functions)))) (, ,) (S (ADVP (RB possibly)) (VP (VBG inducing) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN frataxin))))))) (. .)))
18809400	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_18809400_1637_1654_Chemical)) (VP (MD might) (VP (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NN Doc_18809400_1691_1716_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN chemotherapy))))))))))) (CC and) (VP (VB encourage) (NP (JJ further) (JJ confirmatory) (JJ clinical) (NNS trials)))))))) (. .)))
18821488	0	(S1 (NP (NP (NN Doc_18821488_0_8_Disease)) (PP (IN in) (NP (NP (JJ rhesus) (NNS monkeys)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18821488_59_75_Chemical) (NNP Doc_18821488_76_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18821488_154_162_Chemical)) (-RRB- -RRB-)))))))) (. .)))
18821488	1	(S1 (S (NP (NP (JJ Many) (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (NN methemoglobin)) (PRN (-LRB- -LRB-) (NP (NN MHb)) (-RRB- -RRB-))))))) (ADVP (RB effectively)) (VP (VBP counter) (NP (JJ cyanide) (PRN (-LRB- -LRB-) (NP (NNP CN)) (-RRB- -RRB-)) (NNP Doc_18821488_258_266_Disease))) (. .)))
18821488	2	(S1 (S (SBAR (IN Although) (S (NP (NN MHb) (NNS formers)) (VP (AUX are) (ADVP (RB generally)) (VP (VBN applied) (PP (IN as) (NP (NP (NNS treatments)) (PP (IN for) (NP (NNP CN) (NNP Doc_18821488_332_341_Disease))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (DT a) (JJ stable) (, ,) (JJ long-acting) (NN MHb) (NN former)) (VP (MD could) (VP (VB serve) (PP (IN as) (NP (DT a) (JJ CN) (NN pretreatment)))))))))) (. .)))
18821488	3	(S1 (S (S (VP (VBG Using) (NP (DT this) (NN rationale)))) (, ,) (NP (NP (DT the) (NNP Doc_18821488_462_478_Chemical) (NNP Doc_18821488_479_487_Chemical)) (, ,) (NP (NP (DT a) (JJ potent) (JJ long-lasting) (NN MHb) (NN former)) (PP (IN in) (NP (NP (NNS rodents)) (CC and) (NP (JJ beagle) (NNS dogs))))) (, ,)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (DT the) (JJ rhesus) (NN monkey)) (PP (IN for) (NP (JJ advanced) (NN development))))) (PP (IN as) (NP (DT a) (JJ potential) (NN CN) (NN pretreatment))))) (. .)))
18821488	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NNP Doc_18821488_664_672_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (CD 2) (JJ female) (CC and) (CD 4) (JJ male) (JJ rhesus) (NNS monkeys)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 3.5) (NN and/or) (QP (CD 7.0) (CD mg/kg))) (: ;) (NP (NP (DT a) (JJ single) (NN male)) (SBAR (S (ADVP (RB also)) (VP (VBD received) (NP (NNP Doc_18821488_809_817_Chemical)) (ADVP (RB orally)) (PRN (-LRB- -LRB-) (NP (NNP PO)) (-RRB- -RRB-)) (PP (IN at) (NP (CD 7.0) (CD mg/kg))))))))))))))) (. .)))
18821488	5	(S1 (S (NP (NN Health) (NN status) (CC and) (NN MHb) (NNS levels)) (VP (AUX were) (VP (VBN monitored) (PP (VBG following) (NP (NN exposure))))) (. .)))
18821488	6	(S1 (S (NP (NP (DT The) (VBN selected) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_18821488_939_947_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD produced) (NP (JJ significant) (NN Doc_18821488_976_993_Disease)) (PP (IN in) (NP (JJ beagle) (NNS dogs))) (PP (IN in) (NP (NP (JJR earlier) (NNS studies)) (VP (VBN conducted) (ADVP (RB elsewhere)))))))) (, ,)))) (VP (VBD produced) (NP (ADJP (RB very) (JJ little)) (NN MHb)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (QP (CD <) (CD 2.0)) (NN %)))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ rhesus) (NN monkey)))) (. .)))
18821488	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (S (NP (JJ transient) (NNP Doc_18821488_1133_1147_Disease)) (VP (AUX was) (VP (VBN noted) (NP (QP (RB approximately) (CD 60)) (NNS minutes)) (NP (NP (NN postinjection)) (PP (IN of) (NP (NP (NNP Doc_18821488_1200_1208_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.5) (CC or) (CD 7.0)) (NNS mg/kg)) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (CD 2) (NNS lethalities)) (VP (VBD occurred) (PRN (-LRB- -LRB-) (NP (NP (NP (CD one)) (NP (NNP IV))) (CC and) (NP (CD one) (NN PO))) (-RRB- -RRB-)) (S (VP (VBG following) (NP (DT the) (ADJP (CD 7.0) (NN mg/kg)) (NN dose)))))) (. .)))
18821488	8	(S1 (S (NP (NN Doc_18821488_1306_1319_Disease)) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed) (PP (VBG following) (NP (DT the) (CD 7.0) (NN mg/kg) (NN dose))))) (. .)))
18821488	9	(S1 (S (NP (NP (JJ Histopathology) (NNS analyses)) (PP (IN in) (NP (DT the) (CD 2) (NNS animals))) (SBAR (WHNP (WDT that)) (S (VP (VBD died))))) (VP (VBD revealed) (NP (NN Doc_18821488_1428_1453_Disease)) (, ,) (PP (IN with) (NP (NP (JJR greater) (NN severity)) (PP (IN in) (NP (DT the) (JJ orally-treated) (NN animal)))))) (. .)))
18821488	10	(S1 (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (NP (JJ direct) (JJ and/or) (JJ indirect) (JJ drug-induced) (NN Doc_18821488_1579_1587_Disease))) (. .)))
18821488	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_18821488_1610_1618_Chemical)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN pursued) (PP (IN as) (NP (NP (DT a) (NN pretreatment)) (PP (IN for) (NP (NNP CN) (NNP Doc_18821488_1666_1675_Disease))))) (SBAR (IN unless) (S (NP (NP (DT the) (JJ anti-CN) (NNS characteristics)) (PP (IN of) (NP (DT this) (NN compound)))) (VP (MD can) (VP (AUX be) (ADVP (RB successfully)) (VP (VBN dissociated) (PP (IN from) (NP (NP (DT those)) (VP (VBG producing) (NP (JJ undesirable) (NN Doc_18821488_1793_1801_Disease))))))))))))))))) (. .)))
18951540	0	(S1 (NP (NP (JJ Repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PP (IN for) (NP (NP (NNP Doc_18951540_49_57_Chemical-induced) (NNP Doc_18951540_66_77_Disease)) (PP (IN in) (NP (NNP Doc_18951540_81_100_Disease))))) (. .)))
18951540	1	(S1 (S (PP (IN In) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ single-blinded) (, ,) (JJR crossover) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (`` ``) (JJ real) ('' '') (JJ repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNS rTMS)) (-RRB- -RRB-)))))) (CC versus) (`` ``) (INTJ (UH sham)) ('' '') (SBAR (S (VP (VBZ rTMS) (PRN (-LRB- -LRB-) (NP (NN placebo)) (-RRB- -RRB-)) (PP (IN on) (NP (NP (JJ peak) (NN dose) (NNP Doc_18951540_287_298_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18951540_316_335_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18951540_337_339_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
18951540	2	(S1 (S (S (NP (NP (CD Ten) (NNS patients)) (PP (IN with) (NP (UCP (NNP Doc_18951540_360_362_Disease) (CC and) (JJ prominent) (SBAR (S (NP (NNP Doc_18951540_377_388_Disease)) (VP (AUX had) (NP (NP (NNS rTMS)) (PRN (-LRB- -LRB-) (NP (CD 1,800) (NNS pulses)) (: ;) (NP (CD 1) (NNP Hz) (NN rate)) (-RRB- -RRB-)) (VP (VBN delivered) (PP (IN over) (NP (DT the) (NN motor) (NN cortex))))) (PP (IN for) (NP (CD 4) (JJ consecutive) (NNS days))) (ADVP (RB twice))))) (, ,) (PP (IN once) (NP (JJ real) (NNS stimuli))) (CC and) (ADVP (RB once))) (NN sham) (NN stimulation)))) (VP (AUX were) (VP (VBN used)))) (: ;) (S (NP (NNS evaluations)) (VP (AUX were) (VP (AUX done) (PP (IN at) (NP (NP (DT the) (NN baseline)) (CC and) (NP (NP (CD 1) (NN day)) (PP (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NN treatment) (NN series))))))))))))) (. .)))
18951540	3	(S1 (S (NP (NP (JJ Direct) (NN comparison)) (PP (IN between) (NP (NP (NN sham)) (CC and) (NP (JJ real) (JJ rTMS) (NNS effects))))) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (JJ clinician-assessed) (JJ Doc_18951540_744_754_Disease) (NN severity))))) (. .)))
18951540	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN comparison)) (PP (IN with) (NP (DT the) (NN baseline)))) (VP (VBD showed) (NP (NP (JJ small) (CC but) (JJ significant) (NN reduction)) (PP (IN in) (NP (NNP Doc_18951540_845_855_Disease) (NN severity)))) (PP (VBG following) (NP (NP (JJ real) (NNS rTMS)) (CONJP (CC but) (RB not)) (NP (NN placebo))))) (. .)))
18951540	5	(S1 (S (NP (DT The) (JJ major) (NN effect)) (VP (AUX was) (PP (IN on) (NP (NNP Doc_18951540_926_934_Disease) (CD subscore)))) (. .)))
18951540	6	(S1 (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (NN patient) (NNS diaries))) (, ,) (SBAR (IN although) (S (NP (DT both) (NNS treatments)) (VP (VBD caused) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ subjective) (JJ Doc_18951540_1032_1042_Disease) (NNS scores)))) (PP (IN during) (NP (NP (DT the) (NNS days)) (PP (IN of) (NP (NN intervention)))))))) (, ,) (NP (DT the) (NN effect)) (VP (AUX was) (VP (VBN sustained) (PP (IN for) (NP (CD 3) (NNS days))) (PP (IN after) (NP (NP (DT the) (NN intervention)) (PP (IN for) (NP (DT the) (JJ real) (NNS rTMS) (RB only))))))) (. .)))
18951540	7	(S1 (S (NP (NP (JJ Following) (NNS rTMS)) (, ,) (NP (DT no) (JJ side) (NNS effects)) (CC and) (NP (NP (DT no) (JJ adverse) (NNS effects)) (PP (IN on) (NP (NP (NN motor) (NN function)) (CC and) (NP (JJ Doc_18951540_1243_1245_Disease) (NNS symptoms)))))) (VP (AUX were) (VP (VBN noted))) (. .)))
18951540	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (JJ residual) (JJ beneficial) (JJ clinical) (NNS aftereffects)) (PP (IN of) (NP (NP (JJ consecutive) (JJ daily) (NNS applications)) (PP (IN of) (NP (NN low-frequency) (NNS rTMS))))) (PP (IN on) (NP (NP (NNP Doc_18951540_1405_1416_Disease)) (PP (IN in) (NP (NNP Doc_18951540_1420_1422_Disease))))))))) (. .)))
18951540	9	(S1 (S (NP (DT The) (NNS effects)) (VP (MD may) (VP (AUX be) (ADVP (RB further)) (VP (VBN exploited) (PP (IN for) (NP (JJ potential) (JJ therapeutic) (NNS uses)))))) (. .)))
18996674	0	(S1 (NP (NP (NNP Intracavernous) (NNP Doc_18996674_15_26_Chemical)) (: :) (NP (NP (DT a) (ADJP (RB minimally) (JJ invasive)) (NN treatment)) (PP (IN for) (NP (NNP Doc_18996674_63_71_Disease))) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))) (. .)))
18996674	1	(S1 (S (NP (NN Doc_18996674_101_109_Disease)) (VP (AUX is) (NP (NP (DT the) (VBN prolonged) (NN erection)) (PP (IN of) (NP (DT the) (NNS penis))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ sexual) (NN arousal))))))) (. .)))
18996674	2	(S1 (S (NP (NP (DT A) (JJ 45-year-old) (NN man)) (, ,) (NP (DT an) (VBN admitted) (JJ frequent) (JJ Doc_18996674_223_230_Chemical) (NN user)) (, ,)) (VP (VBD presented) (PP (TO to) (NP (NP (DT the) (NNP Emergency) (NNP Department)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (CD two) (JJ separate) (NNS occasions)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_18996674_324_332_Disease))) (PP (IN after) (NP (JJ Doc_18996674_339_346_Chemical) (NN use)))))))) (. .)))
18996674	3	(S1 (S (NP (NP (DT The) (NN management) (NNS options)) (PP (IN in) (NP (DT the) (NNP ED)))) (PRN (, ,) (SBAR (IN as) (S (VP (VBN exemplified) (PP (IN by) (NP (CD four) (JJ individual) (NN case) (NNS reports))) (, ,) (PP (IN in) (NP (NP (JJ particular) (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (ADJP (RB minimally) (JJ invasive)) (NN method)) (PP (IN of) (NP (JJ intracorporal) (JJ Doc_18996674_504_515_Chemical) (NN instillation)))))))))) (, ,)) (VP (AUX are) (VP (VBN discussed))) (. .)))
19037603	0	(S1 (S (NP (NP (JJ Prophylactic) (NN use)) (PP (IN of) (NP (NNP Doc_19037603_20_30_Chemical))) (PP (IN with) (NP (NN chronic)))) (VP (VBP immunosuppressive) (NP (NN therapy)) (PP (IN for) (NP (NNP Doc_19037603_74_97_Disease)))) (. .)))
19037603	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB report) (NP (NP (PRP$ our) (NN experience)) (VP (VBG concerning) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ prophylactic) (NN administration)) (PP (IN of) (NP (NNP Doc_19037603_223_233_Chemical)))))) (PP (IN in) (NP (NP (NNP Doc_19037603_237_270_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19037603_272_278_Chemical)) (-RRB- -RRB-)) (JJ positive) (NNS patients)) (PP (IN with) (NP (NNP Doc_19037603_303_324_Disease))))))))))) (. .)))
19037603	2	(S1 (S (PP (PP (IN From) (NP (NNP June) (CD 2004))) (PP (TO to) (NP (NNP October) (CD 2006)))) (, ,) (NP (NP (CD 11) (JJ Doc_19037603_361_367_Chemical) (JJ positive) (NNS patients)) (PP (IN with) (NP (NNP Doc_19037603_391_413_Disease))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (PP (IN on) (NP (DT both) (JJ immunosuppressive) (CC and) (JJ prophylactic) (JJ Doc_19037603_467_477_Chemical) (NNS therapies)))))) (, ,)) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN assessed))) (. .)))
19037603	3	(S1 (S (NP (NP (NN Liver) (NN function) (NNS tests)) (, ,) (NP (JJ Doc_19037603_542_553_Disease) (NN virus) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-)) (JJ serologic) (NNS markers)) (, ,) (CC and) (NP (NP (NN HBV) (NN DNA) (NNS levels)) (PP (IN of) (NP (DT the) (NNS patients))) (PP (IN during) (NP (NN follow-up))))) (VP (AUX were) (VP (VBN obtained) (PP (IN from) (NP (NN hospital) (NN file) (NNS records))))) (. .)))
19037603	4	(S1 (S (NP (NP (NP (NP (NP (CD Eleven) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD six) (NN male)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ median) (NN age))) (NP (CD 47) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 27-73)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ median) (NN disease) (NN duration)) (NP (NP (CD 50) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 9-178)) (-RRB- -RRB-))))) (CC and) (NP (JJ median) (JJ follow-up) (NN period))) (PP (IN of) (NP (NNS patients))) (NP (CD 13.8) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 5-27)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
19037603	5	(S1 (S (NP (JJ Doc_19037603_888_898_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN started) (ADVP (NP (CD 3-7) (NNS days)) (RB prior)) (S (VP (TO to) (VP (VB immunosuppressive) (NP (NN therapy)) (PP (IN in) (NP (DT all) (NNS patients)))))))) (. .)))
19037603	6	(S1 (S (NP (NN Baseline) (, ,) (NN liver) (NN function) (NNS tests)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ fourth) (NN patient)) (: :) (NP (NP (CD ALT:122) (NN IU/l)) (, ,) (NP (CD AST:111) (NN IU/l)) (, ,) (NP (NN tenth) (NN patient))) (: :) (NP (NP (CD ALT:294) (NN IU/l)) (, ,) (NP (CD AST:274) (NNS IU/l))) (, ,) (PP (IN with) (NP (NP (JJ minimal) (NNS changes)) (PP (IN in) (NP (DT the) (NN liver) (NN biopsy))) (PP (IN in) (NP (DT both)))))) (-RRB- -RRB-))))) (. .)))
19037603	7	(S1 (S (S (PP (ADVP (RB Shortly)) (IN after) (NP (NN treatment))) (NP (PRP$ their) (NNS tests)) (VP (VBD normalized))) (CC and) (S (PP (IN during) (NP (JJ follow-up) (NN period))) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (NP (JJ Doc_19037603_1279_1302_Disease) (NNS tests)))) (. .)))
19037603	8	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (NP (NNP HBV) (NN DNA) (NNS levels)) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ normal)))) (PP (IN at) (NP (NN baseline)))) (. .)))
19037603	9	(S1 (S (S (NP (NP (CD Two)) (PP (IN of) (NP (DT these)))) (VP (VBD normalized))) (CC and) (S (NP (DT the) (NNS others)) (VP (VBD increased) (ADVP (RB later)))) (. .)))
19037603	10	(S1 (S (PP (IN In) (NP (CD three) (JJ additional) (NNS patients))) (, ,) (NP (NN HBV) (NN DNA) (NNS levels)) (VP (AUX were) (VP (VBN increased) (PP (IN during) (NP (NN follow-up))))) (. .)))
19037603	11	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (NP (NP (JJ significant) (JJ clinical) (VBZ sings)) (PP (IN of) (NP (CD HBV) (NN activation))))) (. .)))
19037603	12	(S1 (S (NP (NN Doc_19037603_1584_1594_Chemical)) (VP (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated))) (CC and) (VP (AUX was) (VP (VBN continued) (PP (IN in) (NP (DT all) (NNS patients)))))) (. .)))
19037603	13	(S1 (S (NP (NP (JJ Prophylactic) (NN administration)) (PP (IN of) (NP (NNP Doc_19037603_1680_1690_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (JJ immunosuppressive) (NN therapy)))))))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJ safe)) (, ,) (ADJP (RB well) (VBN tolerated)) (CC and) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG preventing) (NP (CD HBV) (NN reactivation))))))))))) (. .)))
19058010	0	(S1 (S (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_19058010_10_19_Chemical)))) (CC and) (NP (NP (JJ Doc_19058010_24_33_Chemical) (NN combination)) (PP (IN in) (NP (NNP Doc_19058010_49_62_Chemical))))) (VP (VBN induced) (NP (NNP Doc_19058010_71_92_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
19058010	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (VBN combined) (NNS effects)) (PP (IN of) (NP (NNP Doc_19058010_169_178_Chemical) (CC and) (NNP Doc_19058010_183_192_Chemical))) (PP (IN on) (NP (NP (NN heart) (NN weight)) (, ,) (NP (NN body) (NN weight)) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (JJ endogenous) (NNS antioxidants)) (CC and) (NP (NP (NN membrane) (VBN bound) (NNS ATPases)) (PP (IN in) (NP (NP (NNP Doc_19058010_319_332_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19058010_334_337_Chemical)) (-RRB- -RRB-)))) (VP (VBN -induced) (NP (NNP Doc_19058010_347_368_Disease)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
19058010	2	(S1 (NP (NP (JJ Adult) (JJ male) (NN albino) (NNS rats)) (, ,) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19058010_415_418_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 2) (NNS days))) (PP (IN at) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (NP (CD 24)) (SBAR (S (NP (NNP h)) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN elevation)) (PP (IN of) (NP (NP (NN heart) (NN weight)) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (CC and) (NP (NNP Doc_19058010_573_575_Chemical+2) (NNP ATPase) (NN level))))) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (NP (NN body) (NN weight)) (, ,) (NP (JJ endogenous) (NNS antioxidants)) (, ,) (NP (NNP Doc_19058010_682_684_Chemical+/) (NNP Doc_19058010_687_688_Chemical+) (NNP ATPase)) (CC and) (NP (NNP Doc_19058010_701_703_Chemical+2) (NN ATPase) (NNS levels)))))))))))))))) (. .)))
19058010	3	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NP (NNP Doc_19058010_739_748_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg/day)) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_19058010_775_784_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg/day)) (, ,) (NP (CD p.o.))) (-RRB- -RRB-)))))) (ADVP (RB together) (PP (IN for) (NP (CD 30) (JJ consecutive) (NNS days)))) (VP (CC and) (VP (VBD challenged) (PP (IN with) (NP (NP (NP (NNP Doc_19058010_860_863_Chemical)) (PP (IN on) (NP (NP (DT the) (NN day) (NN 29th)) (CC and) (NP (JJ 30th) (PRN (, ,) (S (VP (VBD showed) (NP (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (NN heart) (NN weight)))) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (NNP Doc_19058010_988_990_Chemical+2) (NNP ATPase)) (CC and) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (DT the) (NN body) (NN weight))))))) (, ,)) (JJ endogenous) (NNS antioxidants))))) (, ,) (NP (NNP Doc_19058010_1072_1074_Chemical+/Doc_19058010_1076_1077_Chemical+) (NNP ATPase)) (CC and) (NP (NNP Doc_19058010_1090_1092_Chemical+2) (NNP ATPase)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (SBAR (IN with) (S (NP (NNP Doc_19058010_1121_1124_Chemical)) (VP (VBD treated) (SBAR (S (NP (NP (NN group)) (CC and) (NP (NNP Doc_19058010_1143_1152_Chemical) (CC or) (NNP Doc_19058010_1156_1165_Chemical))) (ADVP (RB alone)) (VP (VBN treated) (NP (NNS groups))))))))))))) (. .)))
19058010	4	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (NP (NP (DT the) (JJ synergistic) (JJ protective) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_19058010_1249_1258_Chemical)) (CC and) (NP (NNP Doc_19058010_1263_1272_Chemical))))) (PP (IN during) (NP (NP (JJ Doc_19058010_1280_1283_Chemical) (VBN induced) (NN Doc_19058010_1292_1313_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1919871	0	(S1 (NP (NP (JJ Irreversible) (NN damage)) (PP (TO to) (NP (DT the) (JJ medullary) (NN interstitium))) (PP (IN in) (NP (NP (JJ experimental) (JJ analgesic) (NN Doc_1919871_76_87_Disease)) (PP (IN in) (NP (CD F344) (NNS rats))))) (. .)))
1919871	1	(S1 (S (NP (NP (NP (NNP Doc_1919871_102_126_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1919871_128_131_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT a) (VBN decreased) (NN urinary) (VBG concentrating) (NN ability))) (VP (VBD developed) (PP (IN during) (NP (NP (JJ continuous) (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_1919871_232_239_Chemical)) (CC and) (NP (NNP Doc_1919871_244_255_Chemical)))))) (PP (IN in) (NP (JJ female) (NNP Fischer) (CD 344) (NNS rats)))) (. .)))
1919871	2	(S1 (S (NP (NP (JJ Renal) (NN structure)) (CC and) (NP (VBG concentrating) (NN ability))) (VP (AUX were) (VP (VBN examined) (PP (IN after) (NP (NP (DT a) (NN recovery) (NN period)) (PP (IN of) (NP (QP (IN up) (TO to) (CD 18)) (NNS weeks))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT no) (NNS analgesics)) (VP (AUX were) (VP (VBN given))))) (, ,) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (DT the) (JJ analgesic-induced) (NNS changes)) (VP (AUX were) (ADJP (JJ reversible)))))))))) (. .)))
1919871	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN repair)) (PP (TO to) (NP (NP (DT the) (VBN damaged) (NN medullary) (NN interstitial) (NNP matrix) (, ,) (CC or) (NN proliferation)) (PP (IN of) (NP (NP (VBG remaining) (JJ undamaged) (NN type)) (PP (NP (CD 1) (JJ medullary) (NN interstitial) (NNS cells)) (IN after) (NP (NP (DT the) (NN recovery) (NN period)) (VP (VBG following) (NP (JJ analgesic) (NN treatment))))))))))))) (. .)))
1919871	4	(S1 (S (NP (NP (DT The) (NN recovery)) (PP (IN of) (NP (NN urinary) (VBG concentrating) (NN ability)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (NP (DT the) (NN length)) (PP (IN of) (NP (JJ analgesic) (NN treatment)))) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (VBG resulting) (JJ inner) (JJ medullary) (JJ structural) (NN damage)))))))) (. .)))
1919871	5	(S1 (S (S (PP (IN During) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (JJ analgesic) (NN treatment))))) (, ,) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN urinary) (VBG concentrating) (NN ability)))) (VP (AUX were) (ADJP (JJ reversible)))) (, ,) (CC but) (S (PP (IN after) (NP (JJ prolonged) (JJ analgesic) (NN treatment))) (, ,) (NP (NN maximum) (NN urinary) (VBG concentrating) (NN ability)) (VP (VBD failed) (S (VP (TO to) (VP (VB recover)))))) (. .)))
1919871	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (VBN prolonged) (JJ analgesic) (NN treatment)) (PP (IN in) (NP (NNP Fischer) (CD 344) (NNS rats)))) (VP (VP (VBZ causes) (NP (ADJP (JJ progressive) (CC and) (JJ irreversible)) (NN damage)) (PP (TO to) (NP (DT the) (JJ interstitial) (NNP matrix)))) (CC and) (VP (NN type) (NP (NP (CD 1) (JJ interstitial) (NNS cells)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_1919871_1248_1251_Disease)))))))))) (. .)))
1919871	7	(S1 (S (NP (DT The) (VBN associated) (NN urinary) (VBG concentrating) (NN defect)) (VP (AUX is) (ADJP (JJ reversible)) (ADVP (RB only)) (PP (IN during) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NP (JJ structural) (NN damage)) (PP (TO to) (NP (DT the) (JJ inner) (NN medulla)))))))) (. .)))
19211690	0	(S1 (NP (NP (NP (JJ Doc_19211690_0_12_Chemical-dependent) (NN Doc_19211690_23_35_Disease)) (CC and) (NP (NN upregulation))) (PP (IN of) (NP (JJ intrarenal) (NNS angiotensinogen))) (PP (IN in) (NP (NNP Dahl) (JJ Doc_19211690_91_95_Chemical-sensitive) (NNS rats))) (. .)))
19211690	1	(S1 (S (NP (NP (NN Blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ Doc_19211690_140_144_Chemical)) (JJ sensitive)) (PP (IN in) (NP (NNS men))) (PP (IN than) (PP (IN in) (NP (JJ premenopausal) (NNS women))))) (. .)))
19211690	2	(S1 (S (PP (IN In) (NP (NP (NNP Dahl) (JJ Doc_19211690_199_203_Chemical-sensitive) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNS DS)) (-RRB- -RRB-)))) (, ,) (NP (JJ high-Doc_19211690_230_234_Chemical) (-LRB- -LRB-) (NN HS) (-RRB- -RRB-) (NN diet)) (VP (VBZ increases) (NP (NNP BP)) (ADVP (RBR more)) (PP (IN in) (NP (NP (NNS males)) (PP (IN than) (NP (NNS females)))))) (. .)))
19211690	3	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (JJ systemic) (NN renin-Doc_19211690_320_331_Chemical) (NN system)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (CD HS))))) (PP (IN in) (NP (JJ male) (NNS DS))))))))))) (, ,) (S (NP (JJ intrarenal) (JJ angiotensinogen) (NN expression)) (VP (AUX is) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NP (JJ intrarenal) (NNS levels)) (PP (IN of) (NP (NNP ANG) (NNP II)))) (VP (AUX are) (RB not) (VP (VBN suppressed)))) (. .)))
19211690	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (DT the) (NN hypothesis)) (VP (AUX was) (VP (VBN tested) (SBAR (IN that) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (JJ sexual) (NN dimorphism)) (PP (IN in) (NP (NP (JJ HS-induced) (NN upregulation)) (PP (IN of) (NP (NP (JJ intrarenal) (NNS angiotensinogen)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_19211690_638_650_Chemical)))))))) (SBAR (WHNP (WDT that)) (S (ADVP (RB also)) (VP (VBZ causes) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NNP BP)) (CC and) (NP (NNP Doc_19211690_688_700_Disease)))))))))))))) (. .)))
19211690	5	(S1 (S (PP (IN On) (NP (DT a) (JJ low-Doc_19211690_711_715_Chemical) (PRN (-LRB- -LRB-) (NP (NNP LS)) (-RRB- -RRB-)) (NN diet))) (, ,) (NP (JJ male) (NNS DS)) (VP (AUX had) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (JJ intrarenal) (JJ angiotensinogen) (NNS mRNA))) (PP (IN than) (NP (NNS females))))) (. .)))
19211690	6	(S1 (S (NP (NP (JJ HS) (NN diet)) (PP (IN for) (NP (CD 4) (NN wk)))) (VP (VBD increased) (NP (NP (JJ renal) (JJ cortical) (NN angiotensinogen) (NN mRNA)) (CC and) (NP (NN protein))) (PP (ADVP (RB only)) (IN in) (NP (NP (JJ male) (NNS DS)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NN castration)))))))))) (. .)))
19211690	7	(S1 (S (NP (NP (NN Ovariectomy)) (PP (IN of) (NP (JJ female) (NNS DS)))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ intrarenal) (JJ angiotensinogen) (NN expression)) (PP (IN on) (NP (DT either) (NN diet))))))) (. .)))
19211690	8	(S1 (S (NP (NNP Radiotelemetric) (NNP BP)) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (NP (NNS males)) (CC and) (NP (JJ castrated) (NNS rats)))) (PP (IN on) (NP (CD LS) (NN diet)))) (. .)))
19211690	9	(S1 (S (NP (NP (JJ HS) (NN diet)) (PP (IN for) (NP (CD 4) (NN wk)))) (VP (VBD caused) (NP (NP (DT a) (JJ progressive) (NN increase)) (PP (IN in) (NP (NP (NP (NNP BP)) (, ,) (NP (NP (NN protein)) (CC and) (NP (NN albumin) (NN excretion))) (, ,)) (CC and) (NP (NNP Doc_19211690_1190_1210_Disease)))) (PP (IN in) (NP (JJ male) (NNS DS) (NNS rats))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN attenuated) (PP (IN by) (NP (NN castration))))))))) (. .)))
19211690	10	(S1 (S (NP (NP (JJ Doc_19211690_1265_1277_Chemical) (NN replacement)) (PP (IN in) (NP (JJ castrated) (NNS DS) (NNS rats)))) (VP (VBD increased) (NP (NP (NNP BP)) (, ,) (NP (NNP Doc_19211690_1325_1337_Disease)) (, ,) (CC and) (NP (NP (NN upregulation)) (PP (IN of) (NP (NP (JJ renal) (NNS angiotensinogen)) (VP (VBN associated) (PP (IN with) (NP (CD HS) (NN diet))))))))) (. .)))
19211690	11	(S1 (S (NP (NNP Doc_19211690_1406_1418_Chemical)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19211690_1453_1465_Disease) (CC and) (NNP Doc_19211690_1470_1482_Disease))) (PP (IN in) (NP (JJ male) (NNS DS) (NNS rats))) (PP (IN on) (NP (CD HS) (NN diet))))) (ADVP (RB possibly)) (PP (IN through) (NP (NP (NN upregulation)) (PP (IN of) (NP (DT the) (JJ intrarenal) (JJ renin-Doc_19211690_1564_1575_Chemical) (NN system)))))) (. .)))
19269743	0	(S1 (NP (NP (NP (JJ Explicit) (JJ episodic) (NN memory)) (PP (IN for) (NP (NP (JJ sensory-discriminative) (NNS components)) (PP (IN of) (NP (NNP Doc_19269743_66_75_Chemical-induced) (NNP Doc_19269743_84_88_Disease)))))) (: :) (NP (ADJP (JJ immediate) (CC and) (JJ delayed)) (NNS ratings)) (. .)))
19269743	1	(S1 (S (NP (JJ Doc_19269743_121_125_Disease) (NN memory)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (VP (VB affect) (NP (JJ future) (JJ Doc_19269743_161_165_Disease) (NN sensitivity))) (CC and) (ADVP (RB thus)) (VP (VB contribute) (PP (TO to) (NP (JJ clinical) (JJ Doc_19269743_210_214_Disease) (NNS conditions))))))))) (. .)))
19269743	2	(S1 (S (NP (NP (JJ Systematic) (NNS investigations)) (PP (IN of) (NP (DT the) (JJ human) (NN capacity) (S (VP (TO to) (VP (VB remember) (NP (NP (JJ sensory) (NNS features)) (PP (IN of) (NP (JJ experimental) (NN Doc_19269743_320_324_Disease)))))))))) (VP (AUX are) (ADJP (JJ sparse))) (. .)))
19269743	3	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB address) (NP (NP (JJ long-term) (JJ Doc_19269743_367_371_Disease) (NN memory)) (, ,) (SBAR (S (NP (CD nine) (JJ healthy) (NN male) (NNS volunteers)) (VP (VBD received) (NP (NP (JJ intradermal) (NNS injections)) (PP (IN of) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_19269743_459_468_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.05) (, ,) (CD 1) (CC and) (CD 20) (NN microg)) (, ,) (VP (VBN separated) (PP (IN by) (NP (CD 15) (JJ min) (NNS breaks))))) (-RRB- -RRB-))))))))))))))) (, ,) (NP (DT each)) (VP (VBN given) (NP (CD three) (NNS times)) (PP (IN in) (NP (NP (DT a) (JJ balanced) (NN design)) (PP (IN across) (NP (NP (CD three) (NNS sessions)) (PP (IN at) (NP (CD one) (NN week) (NNS intervals)))))))) (. .)))
19269743	4	(S1 (S (NP (JJ Doc_19269743_611_615_Disease) (NN rating)) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (NP (DT a) (JJ computerized) (JJ visual) (NN analogue) (NN scale)) (PRN (-LRB- -LRB-) (NP (CD 0-100)) (-RRB- -RRB-)) (VP (VBN digitized) (PP (IN at) (NP (NP (NN 1/s)) (, ,) (CC either) (ADVP (RB immediately)) (NP (NN online)) (CC or) (NP (NP (NP (CD one) (NN hour)) (CC or) (NP (CD one) (NN day))) (PP (IN after) (NP (NN injection)))))))))))) (. .)))
19269743	5	(S1 (S (NP (NNS Subjects)) (ADVP (RB also)) (VP (VBD recalled) (NP (PRP$ their) (NNP Doc_19269743_801_806_Disease) (CD one) (NN week)) (ADVP (RB later))) (. .)))
19269743	6	(S1 (S (NP (JJ Doc_19269743_823_832_Chemical) (NN injection)) (ADVP (RB reliably)) (VP (VBN induced) (NP (NP (DT a) (JJ dose-dependent) (NN flare)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))) (PP (IN without) (NP (DT any) (NN difference))) (PP (IN within) (NP (QP (CC or) (IN across)) (NNS sessions)))) (. .)))
19269743	7	(S1 (S (NP (DT The) (JJ strong) (NN burning) (NN Doc_19269743_962_966_Disease)) (VP (VBD decayed) (ADVP (RB exponentially)) (PP (IN within) (NP (DT a) (JJ few) (NNS minutes)))) (. .)))
19269743	8	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (ADJP (JJ able) (PP (TO to) (NP (NP (ADJP (RB reliably) (JJ discriminate)) (NN Doc_19269743_1055_1059_Disease) (NN magnitude)) (CC and) (NP (NN duration))))) (PP (IN across) (NP (NP (JJ Doc_19269743_1090_1099_Chemical) (NNS doses)) (PRN (-LRB- -LRB-) (NP (DT both) (CD p<0.001)) (-RRB- -RRB-)))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP (JJ first-time) (NNS ratings)) (VP (AUX were) (VP (VBN requested) (ADVP (RB immediately)))))))) (, ,) (PP (PP (IN after) (NP (CD one) (NN hour))) (CC or) (PP (IN after) (NP (CD one) (NN day))))) (. .)))
19269743	9	(S1 (S (NP (NP (JJ Doc_19269743_1224_1228_Disease) (NN recall)) (PP (IN after) (NP (CD one) (NN week)))) (VP (AUX was) (ADJP (ADJP (RB similarly) (JJ precise)) (PRN (-LRB- -LRB-) (NP (NP (NN magnitude)) (: :) (NP (NP (CD p<0.01)) (, ,) (NP (NN duration))) (: :) (NP (CD p<0.05))) (-RRB- -RRB-)))) (. .)))
19269743	10	(S1 (S (NP (NP (NN Correlation)) (PP (IN with) (NP (NN rating) (NN recall))) (PP (IN after) (NP (CD one) (NN week)))) (VP (AUX was) (ADVP (RB best)) (SBAR (WHADVP (WRB when)) (S (NP (JJ first-time) (NNS ratings)) (VP (AUX were) (VP (VBN requested) (ADVP (ADVP (RB as) (RB late)) (PP (IN as) (NP (NP (CD one) (NN day)) (PP (IN after) (NP (NP (NN injection)) (PRN (-LRB- -LRB-) (NP (NP (NN R)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (CD =0.79))) (-RRB- -RRB-)) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT both) (NN rating) (NNS retrievals)) (VP (VBD utilized) (NP (JJ similar) (NN memory) (NNS traces)))))))))))))))) (. .)))
19269743	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (JJ reliable) (NN memory)) (PP (IN for) (NP (NP (NP (NN magnitude)) (CC and) (NP (NN duration))) (PP (IN of) (NP (ADJP (RB experimentally) (VBN induced)) (NN Doc_19269743_1618_1622_Disease))))))) (. .)))
19269743	12	(S1 (S (NP (DT The) (NNS data)) (ADVP (RB further)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN consolidation)) (PP (IN of) (NP (DT this) (NN memory)))) (VP (VP (AUX is) (NP (DT an) (JJ important) (JJ interim) (NN stage))) (, ,) (CC and) (VP (MD may) (VP (VB take) (PRT (RP up)) (PP (TO to) (NP (CD one) (NN day))))))))) (. .)))
19299179	0	(S1 (FRAG (ADJP (JJ Severe) (CC and) (JJ long)) (S (VP (VBG lasting) (NP (NNP Doc_19299179_24_35_Disease)) (PP (IN after) (NP (NP (JJ high-dose) (JJ Doc_19299179_52_66_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19299179_81_103_Disease))))) (PP (IN in) (NP (NP (JJ Doc_19299179_107_119_Disease) (JJ patients--a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases))))))) (. .)))
19299179	1	(S1 (S (NP (NP (NP (NNP Doc_19299179_153_175_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19299179_177_180_Disease)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ common) (NN Doc_19299179_192_215_Disease)) (PP (IN in) (NP (JJ Doc_19299179_219_231_Disease) (NNS individuals)))) (, ,)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_19299179_285_299_Chemical))))))) (. .)))
19299179	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NN treatment)) (VP (AUX is) (ADVP (RB often)) (VP (VBN limited) (PP (IN by) (NP (JJ adverse) (NNS effects))))) (. .)))
19299179	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NP (ADJP (RB severely) (VBN immunocompromised)) (JJ Doc_19299179_413_425_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ severe) (NNP Doc_19299179_456_480_Disease)) (, ,) (CC and) (PP (IN in) (NP (NP (CD one) (JJ patient) (NNS lesions)) (VP (VBG mimicking) (NP (NNP Doc_19299179_519_532_Disease) (NN formation)) (PP (IN on) (NP (JJ radiologic) (NNS exams)))))) (, ,) (PP (IN during) (NP (NP (JJ Doc_19299179_571_585_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19299179_600_603_Disease)))))))))))) (. .)))
19299179	4	(S1 (S (SBAR (IN Whereas) (S (NP (NN patient) (CD 1)) (VP (VBD showed) (NP (NP (NNS lesions)) (PP (IN of) (NP (QP (IN up) (TO to) (CD 1) (CD cm)))) (ADJP (RB readily) (JJ detectable))) (PP (IN on) (NP (JJ magnetic) (NN resonance) (NN imaging))) (PP (IN under) (NP (JJ prolonged) (JJ Doc_19299179_717_731_Chemical) (NN treatment)))))) (, ,) (NP (NP (NN therapy)) (PP (IN of) (NP (NN patient) (CD 2)))) (VP (AUX was) (VP (VBN switched) (ADVP (RB early)))) (. .)))
19300402	0	(S1 (S (NP (NP (NP (JJ Doc_19300402_0_10_Chemical) (NNS receptors) (NNS antagonists)) (CC and) (NP (JJ Doc_19300402_37_49_Chemical) (NN synthase) (NNS inhibitors))) (PP (IN in) (NP (NP (NNP Doc_19300402_73_84_Chemical)) (CC and) (NP (NNP Doc_19300402_89_103_Chemical))))) (VP (VBN induced) (S (NP (NNP Doc_19300402_112_124_Disease)) (PP (IN in) (NP (ADJP (JJ chemotherapy) (CC and) (JJ Doc_19300402_145_164_Disease)) (NN rat) (NN model))))) (. .)))
19300402	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NP (DT an) (JJ irreversible) (NN inhibitor)) (PP (IN of) (NP (NP (JJ constitutive) (JJ Doc_19300402_244_246_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP L-NOArg)) (: ;) (NP (QP (CD 1.0) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (DT a) (ADJP (RB relatively) (JJ selective)) (NN inhibitor)) (PP (IN of) (NP (NP (JJ inducible) (JJ Doc_19300402_327_329_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP L-NIL)) (: ;) (NP (QP (CD 1.0) (CD mg/kg)) (NN ip)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (ADJP (RB relatively) (JJ specific)) (NN inhibitor)) (PP (IN of) (NP (JJ neuronal) (JJ Doc_19300402_409_411_Chemical) (NN synthase))))) (PRN (-LRB- -LRB-) (NP (NN 7-NI)) (: ;) (NP (QP (CD 0.1) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (, ,) (PP (IN on) (NP (NP (JJ antihyperalgesic) (NN action)) (PP (IN of) (NP (NP (NP (JJ selective) (NNS antagonists)) (PP (IN of) (NP (UCP (JJ B2) (CC and) (NNP B1)) (NNS receptors)))) (: :) (NP (NP (NNP D-Arg--LSB-Hyp3) (, ,) (NNP Thi5) (, ,) (NNP D-Tic7)) (, ,) (NP (NP (NNP Oic8) (NN -RSB-) (NNP Doc_19300402_549_559_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19300402_561_568_Chemical)) (: ;) (NP (QP (CD 70) (CD nmol/kg)) (NN ip)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_19300402_588_605_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 70) (CD nmol/kg)) (NN ip)) (-RRB- -RRB-)))))))))) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (NP (NN model)) (PP (IN of) (NP (NNP Doc_19300402_648_724_Disease)))))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
19300402	2	(S1 (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (JJ Doc_19300402_767_771_Disease) (NNS thresholds)))) (VP (AUX were) (VP (VBN determined) (S (VP (VBG using) (NP (NP (JJ mechanical) (NN stimuli--the) (NN modification)) (PP (IN of) (NP (NP (DT the) (JJ classic) (NN paw) (NN withdrawal) (NN test)) (VP (VBN described) (PP (IN by) (NP (NNP Randall-Selitto))))))))))) (. .)))
19300402	3	(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN paper)))) (VP (VP (VBP confirm) (NP (NP (DT that) (NN inhibition)) (PP (IN of) (NP (JJ Doc_19300402_969_979_Chemical) (NNS receptors))))) (CC and) (VP (VBP inducible) (NP (JJ Doc_19300402_1004_1006_Chemical) (NN synthase))))) (CC but) (S (NP (RB not) (JJ neuronal) (JJ Doc_19300402_1033_1035_Chemical) (NN synthase) (NN activity)) (VP (VBZ reduces) (NP (NNP Doc_19300402_1062_1083_Disease)))) (. .)))
19300402	4	(S1 (S (NP (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP L-NOArg) (CC and) (NNP L-NIL)))) (CC but) (RB not) (NP (NN 7-NI)) (, ,)) (VP (ADVP (RB significantly)) (VBZ increases) (NP (NP (JJ antihyperalgesic) (NN activity)) (CC both) (NP (NNP Doc_19300402_1190_1197_Chemical) (CC and) (NNP Doc_19300402_1202_1219_Chemical)))) (. .)))
19300402	5	(S1 (S (NP (PRP It)) (VP (AUX was) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT both) (NNS products)) (PP (IN of) (NP (NP (NP (JJ inducible) (JJ Doc_19300402_1271_1273_Chemical) (NN synthase)) (CC and) (NP (JJ neuronal) (JJ Doc_19300402_1296_1298_Chemical) (NN synthase) (NN activation))) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_19300402_1330_1340_Chemical))))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_19300402_1357_1369_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_19300402_1382_1393_Chemical)))))))))))) (. .)))
19300402	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NNP L-NOArg)) (CC and) (NP (NNS 7-NI) (CONJP (CC but) (RB not)) (NNP L-NIL))) (VP (VB intensify) (NP (NP (JJ antihyperalgesic) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_19300402_1475_1482_Chemical)) (CC or) (NP (NNP Doc_19300402_1486_1502_Chemical)))) (PP (IN in) (NP (NNP Doc_19300402_1506_1522_Disease))))) (. .)))
19300402	7	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (ADJP (JJ B1) (CC and) (JJ B2)) (NNS receptors)) (VP (AUX are) (VP (VBN engaged) (PP (IN in) (NP (NP (NN transmission)) (PP (IN of) (NP (JJ nociceptive) (NNS stimuli))) (PP (IN in) (NP (DT both) (NNP Doc_19300402_1654_1683_Disease)))))))))) (. .)))
19300402	8	(S1 (S (PP (IN In) (NP (NNP Doc_19300402_1688_1702_Chemical-induced) (NNP Doc_19300402_1711_1723_Disease))) (, ,) (NP (JJ inducible) (JJ Doc_19300402_1735_1737_Chemical) (NN synthase)) (VP (VBZ participates) (PP (IN in) (NP (NP (JJ pronociceptive) (NN activity)) (PP (IN of) (NP (NNP Doc_19300402_1790_1800_Chemical))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NNP Doc_19300402_1813_1824_Chemical-induced) (NNP Doc_19300402_1833_1845_Disease) (NNP Doc_19300402_1846_1856_Chemical))) (VP (VBD seemed) (S (VP (TO to) (VP (VBP activate) (NP (JJ neuronal) (JJ Doc_19300402_1885_1887_Chemical) (NN synthase) (NN pathway))))))))) (. .)))
19300402	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ small) (NNS doses)) (PP (IN of) (NP (NP (JJ Doc_19300402_1962_1972_Chemical) (NN receptor) (NNS antagonists)) (CC and) (NP (JJ Doc_19300402_1998_2000_Chemical) (NN synthase) (NNS inhibitors))))))) (VP (MD can) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (NP (NP (NN alleviation)) (PP (IN of) (NP (NNP Doc_19300402_2056_2072_Disease)))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NN hospital) (NN care))))) (. .)))
19308880	0	(S1 (NP (NP (NN Doc_19308880_0_9_Disease)) (, ,) (NP (NP (DT a) (ADJP (RB rather) (JJ serious)) (JJ adverse) (NN drug) (NN reaction)) (PP (IN with) (NP (NNP Doc_19308880_55_68_Chemical)))) (: :) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (DT the) (JJ French) (NN Pharmacovigilance) (NN database)))) (. .)))
19308880	1	(S1 (S (NP (NN Doc_19308880_135_144_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ adverse) (NN drug) (NN reaction)) (VP (ADVP (RB frequently)) (VBN observed) (PP (IN with) (NP (NNP Doc_19308880_198_211_Chemical)))))) (. .)))
19308880	2	(S1 (S (S (NP (DT Some) (NN case) (NNS reports)) (VP (AUX are) (VP (VBN published) (PP (IN in) (NP (DT the) (NN literature)))))) (CC but) (S (NP (NP (DT no) (JJ systematic) (NN study)) (PP (IN from) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX has) (VP (AUX been) (VP (VBN published))))) (. .)))
19308880	3	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (DT this) (NN study)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB describe) (NP (NP (DT the) (JJ main) (NNS characteristics)) (PP (IN of) (NP (DT this) (JJ adverse) (NN drug) (NN reaction)))))))) (. .)))
19308880	4	(S1 (S (S (VP (VBG Using) (NP (DT the) (JJ French) (NN Pharmacovigilance) (NN database)))) (, ,) (NP (PRP we)) (VP (VBD selected) (NP (NP (DT the) (NNS cases)) (PP (IN of) (NP (NNP Doc_19308880_513_522_Disease))) (VP (VBN reported) (PP (IN since) (NP (CD 1985))) (PP (IN with) (NP (NNP Doc_19308880_548_561_Chemical)))))) (. .)))
19308880	5	(S1 (S (S (NP (NP (CD 272) (NNS cases)) (PP (IN of) (NP (NNP Doc_19308880_585_594_Disease)))) (VP (AUX were) (VP (VBN reported) (PP (IN with) (NP (NNP Doc_19308880_614_627_Chemical)))))) (: :) (FRAG (NP (NP (CD 153) (NNS women)) (CC and) (NP (CD 119) (NNS men)))) (. .)))
19308880	6	(S1 (S (NP (NN Doc_19308880_652_661_Disease)) (ADVP (RB mostly)) (VP (VBD occurred) (PP (IN during) (NP (DT the) (CD two) (JJ first) (NNS weeks))) (PP (VBG following) (NP (NP (JJ Doc_19308880_715_728_Chemical) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD 39.7) (NN %)) (-RRB- -RRB-))))) (. .)))
19308880	7	(S1 (S (NP (PRP It)) (VP (AUX was) (ADJP (`` ``) (JJ serious) ('' '') (PP (IN for) (NP (NP (NP (QP (RB almost) (CD 2/3))) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 62.5) (NN %)) (-RRB- -RRB-))))) (CC and) (NP (NP (PRP$ its) (NN outcome) (JJ favourable)) (PP (IN in) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 82) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
19308880	8	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (DT this) (NN ADR)))) (VP (AUX was) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN aged) (PP (IN between) (NP (CD 61) (CC and) (CD 80) (NNS years))))))) (. .)))
19308880	9	(S1 (S (NP (DT This) (NN work)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NNP Doc_19308880_978_987_Disease)) (PP (IN with) (NP (NNP Doc_19308880_993_1006_Chemical)))) (VP (AUX is) (NP (DT a) (JJ serious) (, ,) (ADJP (RB rather) (JJ frequent) (CC but) (JJ reversible)) (JJ adverse) (NN drug) (NN reaction)))))) (. .)))
19308880	10	(S1 (S (NP (PRP It)) (VP (VBZ occurs) (PP (ADVP (RB especially)) (PP (IN in) (NP (JJR older) (NNS patients))) (CC and) (PP (IN during) (NP (NP (DT the) (JJ first) (CD two) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))) (. .)))
19346865	0	(S1 (NP (NP (NP (JJ Reversible) (NNP Doc_19346865_11_37_Disease)) (PP (IN in) (NP (NNP Doc_19346865_41_54_Chemical-induced) (NNP Doc_19346865_63_77_Disease)))) (: :) (NP (NP (JJ magnetic) (NN resonance) (NNS findings)) (PP (IN on) (NP (ADJP (JJ diffusion-weighted) (CC and) (JJ fluid)) (JJ attenuated) (NN inversion) (NN recovery) (NN imaging)))) (. .)))
19346865	1	(S1 (S (NP (DT This)) (VP (AUX is) (S (VP (TO to) (VP (VB present) (NP (JJ reversible) (NN Doc_19346865_219_246_Disease)) (PP (IN in) (NP (NNP Doc_19346865_250_263_Chemical-induced) (NNP Doc_19346865_272_286_Disease))) (, ,) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NP (NP (DT the) (JJ diffusion-weighted) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP DWI)) (-RRB- -RRB-))) (CC and) (NP (JJ fluid) (JJ attenuated) (NN inversion) (NN recovery) (PRN (-LRB- -LRB-) (NP (NN FLAIR)) (-RRB- -RRB-)) (NN imaging))))))))))) (. .)))
19346865	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (PP (PP (IN From) (NP (NNP November) (CD 2005))) (PP (TO to) (NP (NNP September) (CD 2007)))) (, ,) (NP (NP (CD 8) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NNS men)) (CC and) (NP (CD 3) (NNS women))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (NP (JJ Doc_19346865_511_524_Chemical-induced) (NN Doc_19346865_533_547_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN age) (NN range)) (: ;) (NP (CD 43-78) (NNS years))) (-RRB- -RRB-))))))))) (. .)))
19346865	3	(S1 (S (NP (PRP They)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NP (NNP Doc_19346865_595_608_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ total) (NN dosage)) (, ,) (NP (CD 45-120) (NNP g))) (: ;) (NP (NP (NP (NN duration)) (, ,) (NP (CD 30) (NNS days))) (TO to) (NP (CD 2) (NNS months)))) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB treat) (NP (NP (DT the) (NN Doc_19346865_678_687_Disease)) (PP (IN in) (NP (JJ various) (NNS organs)))))))))) (. .)))
19346865	4	(S1 (S (NP (NP (JJ Initial) (NN brain) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN obtained) (PP (IN after) (NP (DT the) (NN hospitalization))) (, ,) (PP (VBG including) (NP (NP (NNP DWI)) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)))) (, ,) (NP (NP (JJ apparent) (NN diffusion) (NN coefficient) (PRN (-LRB- -LRB-) (NNP ADC) (-RRB- -RRB-)) (NN map)) (PRN (-LRB- -LRB-) (NP (CD 4/8)) (-RRB- -RRB-)) (, ,) (NP (NN FLAIR)) (PRN (-LRB- -LRB-) (NP (CD 7/8)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ T2-weighted) (NN image)) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)))))) (. .)))
19346865	5	(S1 (S (NP (JJ Follow-up) (NNS MRIs)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (QP (CD 5) (NNS patients) (IN from) (JJ third) (TO to) (JJ 14th)) (NNS days))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_19346865_999_1012_Chemical) (NN administration))))))) (. .)))
19346865	6	(S1 (S (NP (NP (NNS Findings)) (PP (IN of) (NP (ADJP (JJ initial) (CC and) (JJ follow-up)) (NNS MRIs)))) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN evaluated) (PP (IN by) (NP (CD 2) (NNS neuroradiologists))) (PP (IN by) (NP (NN consensus))) (, ,) (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ abnormal) (NN signal) (NNS intensities)) (, ,) (NP (PRP$ their) (NNS locations)) (, ,) (CC and) (NP (NN signal) (NNS changes))))) (PP (IN on) (NP (JJ follow-up) (NNS images)))))))) (. .)))
19346865	7	(S1 (S (NP (JJ Initial) (NN MRIs)) (VP (VBD showed) (NP (NP (NP (JJ abnormal) (JJ high) (NN signal) (NNS intensities)) (PP (IN on) (NP (NP (NNP DWI)) (CC and) (NP (NP (NP (NN FLAIR)) (PRN (-LRB- -LRB-) (CC or) (NP (JJ T2-weighted) (NN image)) (-RRB- -RRB-))) (PP (IN at) (NP (DT the) (JJ dentate) (NN nucleus))) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)) (, ,))))) (JJ inferior) (NN colliculus) (PRN (-LRB- -LRB-) (NP (CD 6/8)) (-RRB- -RRB-)) (, ,) (NP (JJ corpus) (NN callosum)) (PRN (-LRB- -LRB-) (NP (CD 2/8)) (-RRB- -RRB-)) (, ,) (NP (NNP pons)) (PRN (-LRB- -LRB-) (CD 2/8) (-RRB- -RRB-)) (, ,) (NP (NP (NN medulla)) (PRN (-LRB- -LRB-) (NP (CD 1/8)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ bilateral) (JJ cerebral) (JJ white) (NN matter)) (PRN (-LRB- -LRB-) (NP (CD 1/8)) (-RRB- -RRB-))))) (. .)))
19346865	8	(S1 (S (S (NP (NP (JJ High-signal) (NN intensity) (NNS lesions)) (PP (IN on) (NP (NNP DWI)))) (VP (VBD tended) (S (VP (TO to) (VP (VB show) (NP (NP (JJ low) (NN signal) (NN intensity)) (PP (IN on) (NP (NP (JJ ADC) (NN map)) (PRN (-LRB- -LRB-) (NP (CD 3/4)) (-RRB- -RRB-)))))))))) (, ,) (CC but) (S (PP (IN in) (NP (CD one) (NN patient))) (, ,) (NP (JJ high) (NN signal) (NN intensity)) (VP (AUX was) (VP (VBN shown) (PP (IN at) (NP (JJ bilateral) (FW dentate) (FW nuclei))) (PP (IN on) (NP (CONJP (RB not) (RB only)) (NP (NN DWI)) (CONJP (CC but) (RB also)) (NP (JJ ADC) (NN map))))))) (. .)))
19346865	9	(S1 (S (S (NP (NP (PDT All) (DT the) (NNS lesions)) (PP (IN in) (NP (NP (NN dentate)) (, ,) (NP (JJ inferior) (NN colliculus)) (, ,) (NP (NNP pons)) (, ,) (CC and) (NP (NNS medullas))))) (VP (AUX had) (VP (AUX been) (VP (VBN resolved) (ADVP (RB completely)) (PP (IN on) (NP (JJ follow-up) (NNS MRIs))) (PP (IN in) (NP (CD 5) (NNS patients))))))) (, ,) (CC but) (S (PP (IN in) (NP (NP (CD 1) (NN patient)) (PP (IN of) (NP (PRP them))))) (, ,) (NP (JJ corpus) (NNP Doc_19346865_1869_1884_Disease)) (VP (VBD persisted))) (. .)))
19346865	10	(S1 (S (NP (JJ Reversible) (NN Doc_19346865_1920_1947_Disease)) (VP (MD could) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT the) (NN characteristic)) (PP (IN for) (NP (NP (NNP Doc_19346865_1994_2007_Chemical-induced) (NNP Doc_19346865_2016_2030_Disease)) (, ,) (ADVP (JJ next) (PP (TO to) (NP (DT the) (NN dentate) (NN nucleus) (NN involvement))))))))))) (. .)))
19356053	0	(S1 (FRAG (ADJP (RB Clinically) (JJ significant)) (S (NP (NNP Doc_19356053_23_34_Disease)) (VP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_19356053_67_76_Chemical))) (PP (TO to) (NP (JJ renal) (NN transplant) (NNS recipients)))))) (. .)))
19356053	1	(S1 (S (NP (NN Doc_19356053_121_130_Chemical)) (VP (VP (AUX is) (NP (NP (DT the) (JJS latest) (JJ immunosuppressive) (NN agent)) (VP (VBN used) (S (VP (TO to) (VP (VB prevent) (NP (NN rejection)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX have) (NP (ADJP (ADJP (RBR less) (JJ Doc_19356053_214_228_Disease)) (PP (IN than) (NP (JJ calcineurin) (NN inhibitor)))) (PRN (-LRB- -LRB-) (NP (NNP CNI)) (-RRB- -RRB-)) (JJ -based) (NNS regimens))))) (. .)))
19356053	2	(S1 (S (PP (TO To) (NP (NN date))) (NP (EX there)) (VP (AUX has) (VP (AUX been) (NP (NP (JJ little) (NN documentation)) (PP (IN of) (NP (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_19356053_348_359_Disease)) (VP (VBN linked) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_19356053_383_392_Chemical))))))))))) (. .)))
19356053	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN encountered) (NP (NP (JJ several) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ substantial) (NN Doc_19356053_457_468_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_19356053_485_494_Chemical) (NN use))))))))))) (. .)))
19356053	4	(S1 (S (PP (IN In) (NP (DT each) (NN patient))) (, ,) (NP (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (JJ Doc_19356053_576_585_Chemical) (NN therapy)))) (CC and) (NP (NNP Doc_19356053_598_609_Disease))))) (VP (VBN implicated) (NP (NNP Doc_19356053_621_630_Chemical)) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ likely)) (NN etiology)) (PP (IN of) (NP (DT the) (NNP Doc_19356053_666_677_Disease)))))) (. .)))
19356053	5	(S1 (S (NP (PRP We)) (VP (VBD analyzed) (S (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NN information)) (ADJP (JJ available) (PP (IN for) (NP (NP (DT all) (CD 119) (NNS patients)) (VP (VBN transplanted) (PP (IN at) (NP (NP (DT the) (NNP Washington) (NNP Hospital) (NNP Center)) (PP (IN between) (NP (NP (CD 1999-2003)) (SBAR (WHPP (IN for) (WHNP (WP whom))) (S (NP (NNP Doc_19356053_845_854_Chemical)) (VP (AUX was) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (PRP$ their) (JJ immunosuppressant) (NN regimen))))))))))))))))) (. .)))
19356053	6	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NNP Doc_19356053_943_954_Disease)))) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NN morning) (NN urine) (NNS samples))) (PP (IN by) (NP (NP (JJ turbidometric) (NN measurement) (CC or) (JJ random) (NN urine) (NN protein)) (: :) (NP (JJ Doc_19356053_1046_1056_Chemical) (NNS ratios)) (, ,) (NP (NP (DT an) (NN estimate)) (PP (IN of) (NP (NP (NNS grams)) (PP (IN of) (NP (NNP Doc_19356053_1089_1100_Disease/day)))))))))) (. .)))
19356053	7	(S1 (S (NP (NN Laboratory) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (IN between) (NP (NP (RB prior)) (, ,) (NP (IN during)) (CC and) (NP (JJ following) (JJ Doc_19356053_1175_1184_Chemical) (NN use)))))) (. .)))
19356053	8	(S1 (S (NP (NP (JJ Twenty-eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (VBN increased) (NN Doc_19356053_1247_1258_Disease)) (PP (IN from) (NP (NN baseline))) (PP (IN during) (NP (PRP$ their) (NN post-transplantation) (NN course)))) (. .)))
19356053	9	(S1 (S (PP (IN In) (NP (CD 21) (NNS patients))) (NP (NP (DT an) (JJ alternative) (NN cause)) (PP (IN of) (NP (NNP Doc_19356053_1354_1365_Disease) (AUX was) (ADJP (DT either) (JJ obvious) (CC or) (JJ insufficient)) (NNS data)))) (VP (AUX was) (ADJP (JJ available) (S (VP (TO to) (VP (AUX be) (ADJP (JJ conclusive))))))) (. .)))
19356053	10	(S1 (S (PP (IN In) (NP (NP (CD 7)) (PP (IN of) (NP (DT the) (CD 28) (NNS patients))))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ striking) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_19356053_1530_1539_Chemical)))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19356053_1563_1572_Disease-range) (NNP Doc_19356053_1579_1590_Disease)))))))) (. .)))
19356053	11	(S1 (S (NP (NN Doc_19356053_1592_1603_Disease)) (VP (VBD correlated) (ADVP (RBS most) (RB strongly)) (PP (IN with) (NP (JJ Doc_19356053_1634_1643_Chemical) (NN therapy))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (JJ other) (ADJP (JJ demographic) (CC and) (JJ clinical)) (NNS variables))))))) (. .)))
19356053	12	(S1 (S (PP (IN In) (NP (JJS most) (NNS patients))) (, ,) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_19356053_1748_1757_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN decrease)) (, ,) (CONJP (CC but) (RB not)) (NP (NN resolution)) (, ,)) (PP (IN of) (NP (NNP Doc_19356053_1805_1816_Disease)))))) (. .)))
19356053	13	(S1 (S (NP (NN Doc_19356053_1831_1840_Chemical)) (VP (VBZ induces) (CC or) (VBZ aggravates) (NP (JJ pre-existing) (NN Doc_19356053_1876_1887_Disease)) (PP (IN in) (NP (NP (DT an) (JJ unpredictable) (NN subset)) (PP (IN of) (NP (JJ renal) (NN allograft) (NNS recipients)))))) (. .)))
19356053	14	(S1 (S (S (NP (NN Doc_19356053_1946_1957_Disease)) (VP (MD may) (VP (VB improve)))) (, ,) (CC but) (S (VP (AUX does) (RB not) (VP (VB resolve) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_19356053_1998_2007_Chemical)) (VP (AUX is) (VP (VBN withdrawn)))))))) (. .)))
19356307	0	(S1 (S (NP (NP (NNS Components)) (PP (IN of) (NP (NNP lemon) (JJ essential) (NN oil)))) (VP (VBP attenuate) (NP (NP (NNP Doc_19356307_44_52_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19356307_64_75_Chemical)))))) (. .)))
19356307	1	(S1 (S (NP (NP (DT The) (JJ anti-Doc_19356307_86_94_Disease) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_19356307_106_116_Chemical)) (CC and) (NP (NNP Doc_19356307_121_139_Chemical))))) (VP (AUX were) (VP (VBN observed) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ passive) (NN avoidance) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP PA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ open) (NN field) (NN habituation) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP OFH)) (-RRB- -RRB-)))))))) (. .)))
19356307	2	(S1 (S (S (NP (DT These) (NNP lemon) (JJ essential) (NNS oils)) (VP (VBD showed) (NP (JJ strong) (NN ability) (S (VP (TO to) (VP (VB improve) (NP (NNP Doc_19356307_295_310_Disease)) (PP (IN by) (NP (NNP Doc_19356307_314_325_Chemical))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_19356307_336_354_Chemical)) (VP (VP (VBD relieved) (NP (DT the) (NNP Doc_19356307_368_397_Disease)) (PP (IN in) (NP (NNP PA))) (ADVP (RB only))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB improve) (NP (JJ non-associative) (NN memory)) (ADVP (RB significantly)) (PP (IN in) (NP (NN OFH))))))) (. .)))
19356307	3	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (JJ neurotransmitter) (NN concentration)) (PP (IN in) (NP (DT some) (NN brain) (NNS regions))) (PP (IN on) (NP (DT the) (NN test) (NN day)))))) (VP (VBD showed) (SBAR (IN that) (S (S (NP (NP (JJ Doc_19356307_568_576_Chemical) (NN concentration)) (PP (IN of) (NP (DT the) (JJ vehicle/Doc_19356307_606_617_Chemical) (NN group)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ vehicle/vehicle) (NN group)))))))) (, ,) (CC but) (S (NP (DT this) (NN phenomenon)) (VP (AUX was) (ADJP (JJ reversed)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_19356307_726_736_Chemical)) (CC or) (NP (NNP Doc_19356307_740_758_Chemical))) (VP (AUX were) (VP (VBN administered) (PP (IN before) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_19356307_801_812_Chemical)))))))))))))) (. .)))
19356307	4	(S1 (S (ADVP (RB Simultaneously)) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (DT these) (CD two) (NNP lemon) (JJ essential) (NN oil) (NNS components)) (VP (MD could) (VP (VB inhibit) (NP (NP (NN acetylcholinesterase) (NN activity)) (PP (IN in) (NP (NN vitro)))) (S (VP (VBG using) (NP (DT the) (NNP Ellman) (NN method))))))))) (. .)))
19387625	0	(S1 (NP (NP (JJ Attentional) (NN modulation)) (PP (IN of) (NP (VBN perceived) (NNP Doc_19387625_36_40_Disease) (NN intensity))) (PP (IN in) (NP (JJ Doc_19387625_54_63_Chemical-induced) (JJ secondary) (NN Doc_19387625_82_94_Disease))) (. .)))
19387625	1	(S1 (S (NP (VBN Perceived) (NN Doc_19387625_106_110_Disease) (NN intensity)) (VP (AUX is) (VP (VBN modulated) (PP (IN by) (NP (NN attention))))) (. .)))
19387625	2	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (RB not) (VP (VBN known) (SBAR (IN that) (WHADVP (WRB how)) (S (NP (NNP Doc_19387625_182_186_Disease) (NN intensity) (NNS ratings)) (VP (AUX are) (VP (VBN affected) (PP (IN by) (NP (NN attention))) (PP (IN in) (NP (JJ Doc_19387625_234_243_Chemical-induced) (JJ secondary) (NN Doc_19387625_262_274_Disease))))))))) (. .)))
19387625	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (VBN perceived) (JJ Doc_19387625_304_308_Disease) (NN intensity)) (PP (IN in) (NP (JJ secondary) (NNP Doc_19387625_332_344_Disease)))) (VP (AUX is) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (NP (NN attention)) (VP (AUX is) (VP (VBN distracted) (PRT (RP away)) (PP (IN from) (NP (NP (DT the) (JJ painful) (NN pinprick) (NN stimulus)) (PP (IN with) (NP (DT a) (JJ visual) (NN task)))))))))))))) (. .)))
19387625	4	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (JJ attentional) (NN modulation))) (PP (IN in) (NP (JJ secondary) (NNP Doc_19387625_531_543_Disease)))) (VP (AUX is) (ADJP (RB very) (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (JJ Doc_19387625_571_580_Chemical-untreated) (, ,) (JJ control) (NN condition))))))))))) (. .)))
19387625	5	(S1 (S (NP (NP (PRP$ Our) (NNS findings)) (, ,) (VP (VBG showing) (NP (NP (DT no) (NN interaction)) (PP (IN between) (NP (NP (JJ Doc_19387625_656_665_Chemical) (NN treatment)) (CC and) (NP (JJ attentional) (NN modulation))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_19387625_716_725_Chemical-induced) (JJ secondary) (NN Doc_19387625_744_756_Disease)) (CC and) (NP (NN attention))) (VP (MD might) (VP (VB affect) (NP (JJ mechanical) (NN Doc_19387625_795_799_Disease)) (PP (IN through) (NP (JJ independent) (NNS mechanisms)))))))) (. .)))
19445921	0	(S1 (NP (NP (JJ Cardioprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_19445921_27_45_Chemical))) (PP (IN on) (NP (NP (NNP Doc_19445921_49_62_Chemical-induced) (NNP Doc_19445921_71_92_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
19445921	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ cardioprotective) (NN potential)) (PP (IN of) (NP (NNP Doc_19445921_179_197_Chemical))) (PP (IN on) (NP (NP (NNP Doc_19445921_201_214_Chemical-induced) (NNP Doc_19445921_223_244_Disease)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
19445921	2	(S1 (S (NP (NP (JJ Hemodynamic) (NNS parameters)) (CC and) (NP (NN lead) (NNP II) (NN electrocardiograph))) (VP (AUX were) (VP (VP (VBN monitored)) (CC and) (VP (VBN recorded) (ADVP (RB continuously))))) (. .)))
19445921	3	(S1 (S (NP (NP (NP (JJ Cardiac) (NN marker) (NNS enzymes)) (CC and) (NP (JJ antioxidative) (NNS parameters))) (PP (IN in) (NP (NP (NN serum)) (CC and) (NP (NN heart) (NNS tissues))))) (VP (AUX were) (VP (VBN measured))) (. .)))
19445921	4	(S1 (S (NP (NP (NP (NN Assay)) (PP (IN for) (NP (JJ mitochondrial) (NN respiratory) (NN function)))) (CC and) (NP (NP (JJ histopathological) (NN examination)) (PP (IN of) (NP (NN heart) (NNS tissues))))) (VP (AUX were) (VP (VBN performed))) (. .)))
19445921	5	(S1 (S (NP (JJ Doc_19445921_556_569_Chemical-treated) (NNS rats)) (VP (VBD showed) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ Doc_19445921_629_636_Chemical) (NN dehydrogenase)) (, ,) (NP (JJ Doc_19445921_652_661_Chemical) (NN transaminase)) (, ,) (NP (JJ Doc_19445921_676_684_Chemical) (NN kinase)) (CC and) (NP (JJ Doc_19445921_696_711_Chemical) (CC and) (JJ significant) (NNS decreases)))) (PP (IN in) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (JJ Doc_19445921_759_769_Chemical) (NN dismutase)) (, ,) (NP (NN catalase)) (CC and) (NP (NP (JJ Doc_19445921_794_805_Chemical) (NN peroxidase)) (PP (IN in) (NP (NN serum) (CC and) (NN heart)))))))))))) (. .)))
19445921	6	(S1 (S (NP (DT These) (NNS rats)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (NNS declines)) (PP (IN in) (NP (NP (JJ left) (JJ ventricular) (JJ systolic) (NN pressure)) (, ,) (NP (NP (NN maximum) (CC and) (NN minimum) (NN rate)) (PP (IN of) (NP (VBN developed) (JJ left) (NN ventricular) (NN pressure)))) (, ,) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (CC and) (NP (NN ST-segment))))))))) (. .)))
19445921	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNP mitochondrial) (NNP Doc_19445921_1073_1096_Disease)) (VP (VBN characterized) (PP (IN by) (NP (VBN decreased) (JJ respiratory) (NN control) (NN ratio))))) (CC and) (NP (NNP Doc_19445921_1154_1157_Chemical/O))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_19445921_1176_1189_Chemical-treated) (NNS rats))))) (. .)))
19445921	8	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_19445921_1222_1240_Chemical))) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 8) (NN days)))))) (VP (VP (ADVP (RB significantly)) (VBD attenuated) (NP (NNP Doc_19445921_1289_1302_Chemical-induced) (NNP Doc_19445921_1311_1330_Disease) (CC and) (NNP Doc_19445921_1335_1352_Disease))) (CC and) (VP (VBD improved) (NP (JJ mitochondrial) (NN respiratory) (NN function)))) (. .)))
19445921	9	(S1 (S (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Doc_19445921_1425_1443_Chemical))) (PP (IN against) (NP (NNP Doc_19445921_1452_1465_Chemical-induced) (NNP Doc_19445921_1474_1491_Disease)))) (VP (AUX was) (ADVP (RB further)) (VP (VBN confirmed) (PP (IN by) (NP (JJ histopathological) (NN examination))))) (. .)))
19445921	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_19445921_1586_1604_Chemical) (VBG possessing) (NN antioxidant) (NN activity)) (VP (AUX has) (NP (NP (DT a) (JJ significant) (JJ protective) (NN effect)) (PP (IN against) (NP (NNP Doc_19445921_1681_1694_Chemical-induced) (NNP Doc_19445921_1703_1724_Disease)))))))) (. .)))
19473225	0	(S1 (S (NP (JJ Long-term) (JJ Doc_19473225_10_19_Chemical) (NN supplementation)) (VP (VBD failed) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_19473225_62_86_Disease)) (PP (IN of) (NP (NNP Doc_19473225_90_100_Chemical))))))))) (. .)))
19473225	1	(S1 (S (NP (JJ Toxic) (NN Doc_19473225_108_129_Disease)) (VP (AUX is) (ADVP (RB still)) (NP (NP (DT a) (JJ significant) (VBG limiting) (NN factor)) (PP (IN for) (NP (NP (NN chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_19473225_191_201_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19473225_203_206_Chemical)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN although) (S (NP (NP (NNP Doc_19473225_218_227_Chemical)) (CC and) (NP (PRP$ its) (ADJP (RB closely) (VBN related)) (NNP Doc_19473225_252_262_Chemical) (NNP Doc_19473225_263_272_Chemical))) (VP (AUX were) (VP (VBN claimed) (S (VP (TO to) (VP (VB ameliorate) (NP (NNP Doc_19473225_300_303_Chemical) (NNP Doc_19473225_304_317_Disease)))))))))) (. .)))
19473225	2	(S1 (S (NP (DT This) (NN pilot) (NN trial)) (VP (VBD aimed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ Doc_19473225_366_375_Chemical) (NN supplementation))) (PP (IN for) (S (VP (VBG preventing) (NP (JJ Doc_19473225_407_410_Chemical-induced) (NNP Doc_19473225_419_440_Disease)) (PP (IN in) (NP (DT a) (JJ randomized) (, ,) (JJ placebo-controlled) (, ,) (JJ double-blinded) (ADJP (JJ clinical) (CC and) (JJ electro-diagnostic)) (NN study))))))))))) (. .)))
19473225	3	(S1 (S (S (NP (JJ Forty-three) (NNP Doc_19473225_544_558_Disease) (NNS patients)) (VP (AUX were) (ADJP (JJ available) (PP (IN for) (NP (NN analysis)))) (PP (VBG following) (NP (NP (CD six) (NNS cycles)) (PP (IN of) (NP (DT the) (JJ same) (JJ Doc_19473225_629_632_Chemical-containing) (NN regimen))))))) (: :) (S (NP (CD 23)) (VP (AUX had) (VP (AUX been) (VP (VBN supplemented) (PP (IN by) (NP (NNP Doc_19473225_681_690_Chemical))) (ADVP (RB all)) (PP (IN along) (NP (DT the) (NN treatment) (NN period))) (, ,) (PP (IN at) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD three) (NNS times)) (NP (NP (CD 500) (NNS mg)) (PRN (-LRB- -LRB-) (NP (NN group) (NNP G)) (-RRB- -RRB-))))))))))) (, ,) (CC and) (S (NP (CD 20)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN group) (NNS P)) (-RRB- -RRB-)))))) (. .)))
19473225	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (NP (JJ neurological) (NNS examinations)) (, ,) (NP (NNS questionnaires)) (CC and) (NP (NN sensory-motor) (NN nerve) (NN conduction) (NNS studies)))))) (. .)))
19473225	5	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNS signs) (CC or) (NNS symptoms))))) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (SBAR (IN although) (S (NP (NNP Doc_19473225_1032_1045_Disease) (NNS symptoms)) (VP (VBD presented) (PP (ADVP (RB mostly)) (IN with) (NP (NP (JJR lower) (NNS scores)) (PP (IN of) (NP (NN severity))))) (PP (IN in) (NP (NN group) (NNP G.))) (ADVP (RB However))))))) (, ,) (NP (DT this) (NN difference)) (VP (VBD reached) (NP (JJ statistical) (NN significance)) (PP (ADVP (RB only)) (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (VBN reported) (JJ Doc_19473225_1201_1205_Disease) (NN sensation)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.011)) (-RRB- -RRB-))))))) (. .)))
19473225	6	(S1 (S (ADVP (RB Also)) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (JJ abnormal) (JJ electro-diagnostic) (NNS findings)))) (VP (VBD showed) (NP (NP (NN similarity)) (PP (IN between) (NP (NP (DT the) (CD two) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP G)) (: :) (NP (NP (NP (CD 7/23)) (VP (SYM =) (NP (CD 30.4) (NN %)))) (: ;) (NP (CD P)) (: :) (NP (QP (CD 6/20) (SYM =) (CD 30)) (NN %))) (-RRB- -RRB-)))))) (. .)))
19473225	7	(S1 (S (NP (DT This) (NN pilot) (NN study)) (VP (VBZ leads) (PP (TO to) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP (NP (JJ Doc_19473225_1409_1418_Chemical) (NN supplementation)) (PP (IN at) (NP (DT the) (VBN chosen) (NN regimen)))) (VP (VBZ fails) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_19473225_1482_1506_Disease)) (PP (IN of) (NP (NN Doc_19473225_1510_1513_Chemical)))))))))))))) (. .)))
19581773	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_19581773_15_32_Disease))) (PP (IN during) (NP (NP (NNP Doc_19581773_40_60_Chemical) (CC and) (NNP Doc_19581773_65_74_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19581773_89_108_Disease))))) (. .)))
19581773	1	(S1 (S (NP (DT A) (JJ 63-year-old) (NN male)) (VP (VBD experienced) (NP (JJ sudden) (NNP Doc_19581773_148_156_Disease)) (PP (IN after) (NP (NP (CD 9) (NNS weeks)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_19581773_192_227_Chemical)) (CC and) (NP (NNP Doc_19581773_232_241_Chemical)))) (PP (IN for) (NP (NP (NNP Doc_19581773_246_265_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19581773_267_270_Disease)) (-RRB- -RRB-))))))))) (. .)))
19581773	2	(S1 (S (NP (JJ Ophthalmologic) (NNS examinations)) (VP (VBD showed) (NP (NP (NNP Doc_19581773_308_337_Disease)) (CC and) (NP (NNP Doc_19581773_342_371_Disease))) (PP (IN without) (NP (DT any) (JJ other) (JJ neurological) (NNS signs)))) (. .)))
19581773	3	(S1 (S (NP (NP (DT A) (NN brain) (NN imaging) (NN study)) (CC and) (NP (JJ repetitive) (NN nerve) (NN stimulation) (NN test))) (VP (VBD indicated) (NP (DT no) (NN abnormality))) (. .)))
19581773	4	(S1 (S (S (NP (NP (DT The) (JJ Doc_19581773_500_513_Chemical) (NN receptor) (NN antibody) (NN titer)) (CC and) (NP (NP (NN response)) (PP (TO to) (NP (JJ acetylcholinesterase) (NNS inhibitors))))) (VP (AUX were) (ADJP (JJ negative)))) (, ,) (CC and) (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ thyroid) (NN function) (NNS tests)))) (VP (AUX were) (ADJP (JJ normal)))) (. .)))
19581773	5	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ ophthalmological) (NNS symptoms)) (VP (VBD improved) (ADVP (RB rapidly) (NP (CD 3) (NNS weeks))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_19581773_746_768_Chemical)) (CC and) (NP (NNP Doc_19581773_773_782_Chemical))))))) (. .)))
19581773	6	(S1 (S (S (NP (NP (DT The) (NN Doc_19581773_788_805_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_19581773_845_867_Chemical)) (CC and) (NP (NNP Doc_19581773_872_881_Chemical)))) (PP (IN for) (NP (NNP Doc_19581773_886_889_Disease))))))) (VP (AUX is) (ADVP (RB very) (RB rarely)) (VP (VBN reported)))) (: ;) (S (ADVP (RB therefore)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (DT this) (NN case)) (PP (IN with) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (DT the) (JJ various) (NN eye) (NNS complications)) (PP (IN of) (NP (JJ Doc_19581773_997_1000_Chemical) (NN therapy))))))))) (. .)))
19631624	0	(S1 (NP (NP (NN Doc_19631624_0_28_Disease)) (PP (IN in) (NP (NP (JJ Doc_19631624_32_39_Chemical) (NNS users)) (CC and) (NP (PRP$ their) (JJ neural) (NNS correlates)))) (PP (IN during) (NP (DT a) (JJ face-learning) (NN task))) (. .)))
19631624	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (ADVP (RB consistently)) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ Doc_19631624_139_146_Chemical) (NNS users)) (VP (VBP display) (NP (JJ Doc_19631624_161_195_Disease) (NN performance)))))))) (. .)))
19631624	2	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ working) (NN memory) (NN processing)) (PP (IN in) (NP (JJ Doc_19631624_251_258_Chemical) (NNS users)))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ neural) (NNS alterations)) (PP (IN in) (NP (JJ hippocampal) (NN and/or) (NN cortical) (NNS regions))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (JJ functional) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NN fMRI)) (-RRB- -RRB-)))))))))))))) (. .)))
19631624	3	(S1 (S (S (VP (VBG Using) (NP (NP (JJ functional) (NN imaging)) (CC and) (NP (DT a) (JJ face-learning) (NN task))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (JJ neural) (NNS correlates)) (PP (IN of) (S (VP (VP (VBG encoding)) (CC and) (VP (VBG recalling) (NP (JJ face-name) (NNS associations)) (PP (IN in) (NP (NP (CD 20) (JJ recreational) (NN drug) (NNS users)) (SBAR (WHNP (WP$ whose) (NN predominant)) (S (NP (NN drug) (NN use)) (VP (AUX was) (NP (NP (NNP Doc_19631624_616_623_Chemical)) (CC and) (NP (CD 20) (NNS controls)))))))))))))) (. .)))
19631624	4	(S1 (S (S (VP (TO To) (VP (VB address) (NP (NP (DT the) (JJ potential) (JJ confounding) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ Doc_19631624_693_701_Chemical) (NN use)) (PP (IN of) (NP (DT the) (JJ Doc_19631624_713_720_Chemical) (VBG using) (NN group))))))))) (, ,) (NP (DT a) (JJ second) (NN analysis)) (VP (VBD included) (NP (NP (CD 14) (ADJP (RB previously) (VBN tested)) (JJ Doc_19631624_782_790_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (NNP Nestor)) (, ,) (NP (NP (NNP L.) (, ,) (NNP Roberts) (, ,) (NNP G.) (, ,) (NNP Garavan) (, ,) (NNP H.) (, ,) (NNP Hester) (, ,) (NNP R.)) (, ,) (NP (CD 2008)))))) (. .)))
19631624	5	(S1 (NP (NP (NN Doc_19631624_854_885_Disease)) (: :) (NP (NP (NP (JJ parahippocampal) (NN Doc_19631624_903_916_Disease)) (CC and) (NP (JJ frontocortical) (NN hypoactivity))) (PP (IN in) (NP (JJ Doc_19631624_952_960_Chemical) (NNS users)))) (. .)))
19631624	6	(S1 (NP (NNP Neuroimage) (CD 40) (, ,) (CD 1328-1339) (-RRB- -RRB-) (. .)))
19631624	7	(S1 (S (NP (NN Doc_19631624_995_1002_Chemical) (NNS users)) (VP (VBD performed) (ADVP (RB significantly) (RBR worse)) (PP (IN in) (NP (NN learning) (CC and) (NN memory))) (PP (VBN compared) (PP (TO to) (NP (NP (NNS controls)) (CC and) (NP (JJ Doc_19631624_1087_1095_Chemical) (NNS users)))))) (. .)))
19631624	8	(S1 (S (NP (NP (DT A) (NN conjunction) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN encode) (CC and) (NN recall) (NNS phases)) (PP (IN of) (NP (DT the) (NN task)))))) (VP (VBD revealed) (NP (NNP Doc_19631624_1179_1186_Chemical-specific) (NNP Doc_19631624_1196_1209_Disease)) (PP (IN in) (NP (JJ bilateral) (JJ frontal) (NNS regions))) (, ,) (VP (VBN left) (UCP (ADJP (JJ temporal)) (, ,) (ADJP (JJ right) (JJ parietal)) (, ,) (ADJP (JJ bilateral) (JJ temporal)) (, ,) (CC and) (NP (JJ bilateral) (JJ occipital) (NN brain) (NNS regions))))) (. .)))
19631624	9	(S1 (S (NP (JJ Doc_19631624_1330_1337_Chemical-specific) (NN hypoactivity)) (VP (VP (AUX was) (ADJP (JJ evident) (PP (IN in) (NP (NP (DT the) (ADJP (RB right) (JJ dorsal)) (NNP anterior) (JJ cingulated) (NN cortex)) (PRN (-LRB- -LRB-) (NP (NNP ACC)) (-RRB- -RRB-)))))) (CC and) (VP (VBD left) (NP (JJ posterior) (JJ cingulated) (NN cortex)))) (. .)))
19631624	10	(S1 (S (PP (IN In) (NP (DT both) (NNP Doc_19631624_1471_1478_Chemical) (CC and) (NNP Doc_19631624_1483_1491_Chemical) (NNS groups))) (NP (NN brain) (NN activation)) (VP (AUX was) (VP (VP (VBN decreased) (PP (IN in) (NP (DT the) (JJ right) (JJ medial) (JJ frontal) (NN gyrus)))) (, ,) (VP (VBN left) (NP (JJ parahippocampal) (NN gyrus))) (, ,) (VP (VBN left) (NP (JJ dorsal) (JJ cingulate) (NN gyrus))) (, ,) (CC and) (VP (VBD left) (NP (NN caudate))))) (. .)))
19631624	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP elucidated) (NP (NP (JJ Doc_19631624_1665_1672_Chemical-related) (NNS deficits)) (, ,) (SBAR (RB only) (WHNP (NP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD might) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (JJ Doc_19631624_1733_1741_Chemical) (NN use)))))))))) (. .)))
19631624	12	(S1 (S (NP (DT These) (JJ Doc_19631624_1753_1760_Chemical-specific) (NNS effects)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN vulnerability)) (PP (IN of) (NP (JJ isocortical) (CC and) (JJ allocortical) (NNS regions))) (PP (TO to) (NP (NP (DT the) (JJ Doc_19631624_1861_1871_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_19631624_1883_1890_Chemical)))))))))) (. .)))
19657887	0	(S1 (NP (NP (NP (JJ Doc_19657887_0_10_Chemical-like) (NN syndrome)) (PP (IN after) (NP (NNP Doc_19657887_31_49_Chemical) (JJ professional) (NN skin) (NN exposure)))) (: :) (NP (NP (CD two) (NN case) (NNS reports)) (PP (IN in) (NP (NNP France)))) (. .)))
19657887	1	(S1 (S (NP (NN Doc_19657887_106_124_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN plant) (NN growth) (NN regulator)) (VP (VBN used) (PP (IN in) (NP (NN agriculture))) (S (VP (TO to) (VP (VB induce) (NP (NNP bud) (NN break)) (PP (IN in) (NP (NN fruit) (NNS trees))))))))) (. .)))
19657887	2	(S1 (S (NP (NP (NN Contact)) (PP (IN with) (NP (DT the) (NN skin)))) (VP (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (JJ percutaneous) (NN absorption)) (PP (IN of) (NP (NP (DT the) (NN substance)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (JJ Doc_19657887_300_308_Chemical) (NN dehydrogenase))))))))))) (CC and) (VP (MD can) (VP (VB induce) (NP (JJ Doc_19657887_338_350_Chemical) (NN syndrome)) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (JJ Doc_19657887_371_378_Chemical) (NN use)))))))) (. .)))
19657887	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN report)))) (VP (AUX is) (S (VP (TO to) (VP (VB describe) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (DT a) (JJ Doc_19657887_441_451_Chemical-like) (NN syndrome)))) (PP (VBG following) (NP (NP (JJ occupational) (NN exposure)) (PP (TO to) (NP (NNP Doc_19657887_501_519_Chemical))))))))) (. .)))
19657887	4	(S1 (S (NP (DT The) (JJ first) (NN case)) (VP (VBD involved) (NP (NP (DT a) (JJ 59-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (NNP Doc_19657887_572_578_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NNP Doc_19657887_595_613_Chemical))))) (, ,)) (PP (IN without) (NP (NN protection))) (PP (IN after) (NP (NN consuming))) (NP (NP (DT a) (JJ large) (NN amount)) (PP (IN of) (NP (NNP Doc_19657887_668_675_Chemical)))) (PP (IN during) (NP (DT a) (NN meal)))))))) (. .)))
19657887	5	(S1 (S (PP (IN In) (NP (NP (QP (JJR less) (IN than) (CD 1)) (NN hour)) (PP (IN after) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NNP Doc_19657887_734_741_Chemical))))))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (NN malaise)) (PP (IN with) (NP (NP (NNP Doc_19657887_769_789_Disease)) (, ,) (NP (NNP Doc_19657887_791_802_Disease)) (, ,) (CC and) (NP (NNP Doc_19657887_808_815_Disease))))) (. .)))
19657887	6	(S1 (S (NP (NNS Manifestations)) (VP (VBD regressed) (ADVP (RB spontaneously)) (PP (IN under) (NP (NN surveillance))) (PP (IN in) (NP (DT the) (NN hospital)))) (. .)))
19657887	7	(S1 (S (NP (DT The) (JJ second) (NN case)) (VP (VBD occurred) (PP (IN in) (NP (DT a) (JJ 55-year-old) (NN farmer))) (PP (VBG following) (NP (NP (NN cutaneous) (NN contact)) (PP (IN with) (NP (NNP Doc_19657887_974_980_Chemical)))))) (. .)))
19657887	8	(S1 (S (PP (NP (CD Five) (NNS hours)) (IN after) (NP (NN exposure))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (JJ Doc_19657887_1022_1032_Chemical-like) (NN syndrome)) (PP (IN with) (NP (NP (NNP Doc_19657887_1052_1060_Disease)) (, ,) (NP (NNP Doc_19657887_1062_1073_Disease)) (, ,) (CC and) (NP (NNP Doc_19657887_1079_1099_Disease)))) (PP (IN after) (NP (NP (NN consuming) (CD three) (NNS glasses)) (PP (IN of) (NP (NN wine)))))) (. .)))
19657887	9	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (ADVP (RB spontaneously)) (PP (IN in) (NP (CD 3) (NNS hours))) (PP (IN under) (NP (NP (NN surveillance)) (PP (IN in) (NP (DT the) (NN hospital)))))) (. .)))
19657887	10	(S1 (S (NP (DT These) (NNS cases)) (VP (VBP confirm) (NP (NP (DT the) (NN necessity)) (PP (IN of) (S (VP (VBG avoiding) (NP (NN Doc_19657887_1268_1275_Chemical) (NN consumption)) (SBAR (IN as) (S (VP (VBN recommended) (PP (IN in) (NP (NP (DT the) (NNS instructions)) (PP (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_19657887_1334_1340_Chemical))))) (CC and) (PP (IN of) (S (VP (VBG preventing) (NP (JJ cutaneous) (NN contact)) (PP (IN during) (NP (NN use))))))))))))))))) (. .)))
1967484	0	(S1 (NP (JJ Doc_1967484_0_9_Chemical-induced) (NN Doc_1967484_18_34_Disease) (. .)))
1967484	1	(S1 (S (NP (NN Doc_1967484_36_45_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ D2-receptor) (NN antagonist)) (PP (IN with) (NP (UCP (JJ antipsychotic) (CC and) (JJ Doc_1967484_107_121_Chemical)) (NNS properties))))) (. .)))
1967484	2	(S1 (S (SBAR (IN Although) (S (ADVP (RB initially)) (VP (VBD thought) (S (VP (TO to) (VP (AUX be) (ADJP (JJ free) (PP (IN of) (NP (JJ extrapyramidal) (NN side) (NNS effects)))))))))) (, ,) (NP (NNP Doc_1967484_204_213_Chemical-induced) (NNP Doc_1967484_222_240_Disease) (CC and) (NNP Doc_1967484_245_257_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB occasionally))))) (. .)))
1967484	3	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (JJ 37-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ persistent) (JJ segmental) (NN Doc_1967484_355_363_Disease)) (PP (IN within) (NP (CD 2) (NNS months))) (PP (IN after) (S (VP (VBG starting) (NP (JJ Doc_1967484_395_404_Chemical) (NN therapy)))))))))) (. .)))
1967484	4	(S1 (S (NP (PRP We)) (VP (MD could) (RB not) (VP (VB find) (NP (NP (DT any) (JJ previous) (NNS reports)) (PP (IN of) (NP (NNP Doc_1967484_456_465_Chemical-induced) (NNP Doc_1967484_474_490_Disease)))))) (. .)))
19729346	0	(S1 (NP (NP (NP (JJ Comparative) (NN cognitive)) (CC and) (NP (JJ subjective) (NN side) (NNS effects))) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_71_80_Chemical))) (PP (IN in) (NP (JJ healthy) (UCP (JJ middle-aged) (CC and) (JJR older)) (NNS adults))) (. .)))
19729346	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD measured) (NP (NP (DT the) (ADJP (JJ objective) (CC and) (JJ subjective)) (JJ neurocognitive) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_238_247_Chemical))))) (PP (IN in) (NP (NP (JJ healthy) (, ,) (ADJP (ADJP (JJR older)) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CD 65)) (NNS years)) (-RRB- -RRB-)) (, ,) (CC and) (ADJP (JJ middle-aged) (PRN (-LRB- -LRB-) (NP (QP (CD 35) (TO to) (CD 55)) (NNS years)) (-RRB- -RRB-)))) (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (VP (VBG suffering) (PP (IN from) (NP (ADJP (JJ chronic) (CC or) (JJ significant)) (JJ daily) (NNP Doc_19729346_377_381_Disease))))))))))) (. .)))
19729346	2	(S1 (S (NP (NN Seventy-one) (NNS participants)) (VP (VP (VBD completed) (NP (CD 2) (JJ separate) (NN study) (NNS days))) (CC and) (VP (AUX were) (ADJP (JJ blind) (PP (TO to) (NP (NP (NN medication) (NN condition)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (, ,) (NP (JJ 10-mg) (NNP Doc_19729346_495_504_Chemical))) (-RRB- -RRB-))))))) (. .)))
19729346	3	(S1 (S (S (NP (NN Plasma) (JJ Doc_19729346_514_523_Chemical) (NN concentration)) (VP (VBD peaked) (PP (IN between) (NP (CD 60) (CC and) (CD 90) (NNS minutes))) (NP (NN postdose)))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .01)) (-RRB- -RRB-)) (CC and) (S (NP (NP (NN pupil) (NN size)) (, ,) (NP (NP (DT an) (NN indication)) (PP (IN of) (NP (NP (JJ physiological) (NNS effects)) (PP (IN of) (NP (DT the) (NN medication)))))) (, ,)) (VP (VBD peaked) (PP (IN at) (NP (QP (RB approximately) (CD 90) (TO to) (CD 120)) (NNS minutes))) (NP (NP (NN postdose)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .01)) (-RRB- -RRB-))))) (. .)))
19729346	4	(S1 (S (NP (JJ Significant) (NNP Doc_19729346_738_815_Disease)) (VP (AUX were) (VP (VBN observed) (PP (IN at) (NP (ADJP (CD 1) (NN hour)) (NN postdose))) (PP (VBN compared) (PP (TO to) (NP (NP (NN baseline)) (PP (IN for) (NP (NP (DT both) (NN age) (NNS groups)) (PP (IN with) (NP (NP (DT a) (NN trend)) (PP (IN toward) (NP (NP (NN return)) (PP (TO to) (NP (NN baseline))))) (PP (IN by) (NP (CD 5) (NNS hours) (NN postdose)))))))))))) (. .)))
19729346	5	(S1 (S (PP (IN For) (NP (RB almost) (DT all) (JJ cognitive) (NNS measures))) (, ,) (NP (EX there)) (VP (AUX were) (NP (DT no) (NN medication)) (PP (IN by) (NP (NP (JJ age-interaction) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ indicates) (SBAR (IN that) (S (NP (DT the) (CD 2) (NN age) (NNS groups)) (VP (VBD exhibited) (NP (JJ similar) (NNS responses)) (PP (TO to) (NP (DT the) (NN medication) (NN challenge)))))))))))) (. .)))
19729346	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (PP (IN for) (NP (NP (JJ healthy) (JJR older) (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (RB not) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_19729346_1210_1222_Disease))))))))) (, ,) (NP (NP (JJ neurocognitive) (CC and) (JJ pharmacodynamic) (NNS changes)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT a) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_1316_1325_Chemical)))))))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN for) (NP (JJ middle-aged) (NNS adults))))))))))) (. .)))
19729346	7	(S1 (S (NP (NN Study) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism) (, ,) (JJ neurocognitive) (NNS effects)) (, ,) (CC and) (NP (NP (JJ physical) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ oral) (NNP Doc_19729346_1496_1505_Chemical))))) (VP (AUX are) (ADJP (JJ similar) (PP (IN for) (NP (NP (JJ healthy) (JJ middle-aged)) (CC and) (NP (JJR older) (NNS adults))))))))) (. .)))
19729346	8	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNS clinicians)) (VP (MD should) (RB not) (VP (VB avoid) (S (VP (VBG prescribing) (NP (JJ oral) (NNS opioids)) (PP (TO to) (NP (NP (JJR older) (NNS adults)) (VP (VBN based) (PP (IN on) (NP (DT the) (NN belief) (SBAR (IN that) (S (NP (JJR older) (NNS adults)) (VP (AUX are) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN for) (NP (NP (JJ side) (NNS effects)) (PP (IN than) (NP (JJR younger) (NNS adults))))))))))))))))))) (. .)))
19759529	0	(S1 (S (NP (DT The) (JJ Doc_19759529_4_11_Chemical) (JJ transporter-1) (NN inhibitor) (NN Doc_19759529_36_45_Chemical)) (VP (VBZ displays) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ specific)) (JJ antipsychotic-like) (NN profile)) (PP (IN in) (NP (UCP (JJ normal) (CC and) (NNP transgenic)) (NNS mice))))) (. .)))
19759529	1	(S1 (S (NP (NN Doc_19759529_138_151_Disease)) (VP (AUX has) (VP (AUX been) (ADVP (RB initially)) (VP (VBN associated) (PP (IN with) (NP (NP (NN dysfunction)) (PP (IN in) (NP (JJ Doc_19759529_202_210_Chemical) (NN neurotransmission)))))))) (. .)))
19759529	2	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP (NP (NNS antagonists)) (PP (IN of) (NP (DT the) (NNP Doc_19759529_279_288_Chemical) (NNP Doc_19759529_289_309_Chemical) (-LRB- -LRB-) (NNP Doc_19759529_311_315_Chemical) (-RRB- -RRB-) (NN receptor)))) (VP (VBP produce) (NP (NP (JJ Doc_19759529_334_347_Disease-like) (NNS symptoms)) (PP (IN in) (NP (NNS humans)))))))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN idea)) (PP (IN of) (NP (NP (DT a) (NN dysfunctioning)) (PP (IN of) (NP (DT the) (JJ glutamatergic) (NN system))) (PP (IN via) (NP (PRP$ its) (JJ Doc_19759529_448_452_Chemical) (NN receptor))))))))) (. .)))
19759529	3	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (VBG growing) (NN interest)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ pharmacological) (NNS agents))) (PP (IN with) (NP (NP (JJ potential) (JJ antipsychotic) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (VB enhance) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ glutamatergic) (NN system)))) (PP (IN via) (NP (NP (DT a) (NN modulation)) (PP (IN of) (NP (DT the) (JJ Doc_19759529_667_671_Chemical) (NN receptor)))))))))))))) (. .)))
19759529	4	(S1 (SINV (PP (IN Among) (NP (PRP them))) (VP (AUX are) (NP (NP (JJ Doc_19759529_697_704_Chemical) (NN transporter-1)) (PRN (-LRB- -LRB-) (NP (NNP GlyT1)) (-RRB- -RRB-)))) (NP (NP (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19759529_746_755_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB indirectly)) (VP (VB enhance) (NP (JJ Doc_19759529_782_786_Chemical) (NN receptor) (NN function)) (PP (IN by) (S (VP (VBG increasing) (NP (DT the) (JJ Doc_19759529_823_830_Chemical) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN co-agonist)) (PP (IN for) (NP (DT the) (JJ Doc_19759529_853_857_Chemical) (NN receptor)))) (-RRB- -RRB-)) (NNS levels)) (PP (IN in) (NP (DT the) (NN synapse)))))))))))) (. .)))
19759529	5	(S1 (S (NP (DT This) (NN study)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG investigating) (NP (NP (DT the) (JJ potential) (JJ antipsychotic-like) (NNS properties)) (PP (IN of) (NP (NNP Doc_19759529_972_981_Chemical))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ particular) (NN focus)) (PP (IN on) (NP (NP (NNS models)) (PP (IN of) (NP (NNP Doc_19759529_1020_1033_Disease))))) (, ,) (VP (VBG involving) (NP (NP (NP (DT either) (NN drug) (NN challenge)) (PRN (-LRB- -LRB-) (NP (NN ie)) (, ,) (NP (NNP Doc_19759529_1072_1083_Chemical) (CC and) (NNP Doc_19759529_1088_1094_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP transgenic) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD ie)) (, ,) (NP (NP (NP (NP (NNP Doc_19759529_1120_1124_Chemical) (NNP Nr1)) (PRN (-LRB- -LRB-) (JJ neo-/-) (-RRB- -RRB-))) (CC and) (NP (NNP DAT))) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-))) (-RRB- -RRB-)))))))))))) (. .)))
19759529	6	(S1 (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP Doc_19759529_1172_1181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-30) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-))) (VP (VP (VBD blocked) (NP (NP (NNP Doc_19759529_1209_1222_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ non-competitive) (JJ Doc_19759529_1254_1258_Chemical) (NN receptor) (NN antagonist)) (, ,) (NP (NNP Doc_19759529_1280_1286_Chemical))))))) (CC and) (VP (ADVP (RB partially)) (VBD reversed) (NP (NP (JJ spontaneous) (NN Doc_19759529_1322_1335_Disease)) (PP (IN of) (NP (NNP Doc_19759529_1339_1343_Chemical) (NNP Nr1) (PRN (-LRB- -LRB-) (JJ neo-/-) (-RRB- -RRB-)) (NNS mice))))))))) (. .)))
19759529	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_19759529_1375_1384_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB affect) (S (NP (NNP Doc_19759529_1402_1415_Disease)) (VP (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19759529_1427_1438_Chemical)))) (CC or) (VP (ADVP (RB naturally)) (VBN observed) (PP (IN in) (NP (NP (JJ Doc_19759529_1464_1472_Chemical) (NN transporter) (PRN (-LRB- -LRB-) (NP (NP (NNP DAT)) (PRN (-LRB- -LRB-) (NP (NN -/-)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NN knockout) (NNS mice)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-30) (CD mg/kg)) (NNS p.o.)) (-RRB- -RRB-))))))))))) (. .)))
19759529	8	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NP (NP (DT both) (JJ classical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19759529_1559_1570_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ atypical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19759529_1586_1596_Chemical) (, ,) (NNP Doc_19759529_1598_1607_Chemical) (CC and) (NNP Doc_19759529_1612_1624_Chemical)) (-RRB- -RRB-)) (NNS antipsychotics))) (VP (AUX were) (ADJP (JJ effective)) (PP (IN in) (NP (NP (PDT all) (DT these) (NNS models)) (PP (IN of) (NP (NNP Doc_19759529_1679_1692_Disease)))))) (. .)))
19759529	9	(S1 (S (ADVP (RB However)) (, ,) (PP (IN unlike) (NP (DT these) (JJ latter))) (, ,) (NP (NNP Doc_19759529_1724_1733_Chemical)) (VP (AUX did) (RB not) (VP (VB produce) (NP (NP (NNP Doc_19759529_1750_1759_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN retention)) (PP (IN on) (NP (DT the) (NN bar) (NN test)))) (-RRB- -RRB-))) (ADVP (RB up) (PP (TO to) (NP (QP (CD 30) (CD mg/kg)) (NNS p.o.)))) (ADVP (RB Together)) (S (NP (DT these) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ GlyT1) (NN inhibitor)) (, ,) (NP (NNP Doc_19759529_1863_1872_Chemical)) (, ,)) (VP (VBZ produces) (NP (NP (JJ antipsychotic-like) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP differ) (PP (IN from) (S (NP (DT those)) (VP (VP (VBN observed) (PP (IN with) (NP (NP (NNS compounds)) (VP (ADVP (RB primarily)) (VBG targeting) (NP (DT the) (JJ dopaminergic) (NN system)))))) (, ,) (CC and) (VP (AUX has) (NP (DT a) (JJ reduced) (JJ side-effect) (NN potential)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (DT these) (JJ latter) (NNS drugs))))))))))))))))))))) (. .)))
19767176	0	(S1 (S (NP (NN Doc_19767176_0_27_Chemical)) (VP (VBZ protects) (NP (NP (DT the) (JJ piriform) (NN cortex)) (PP (IN in) (NP (DT the) (NNP Doc_19767176_64_75_Chemical) (NNP Doc_19767176_76_94_Disease) (NN model))))) (. .)))
19767176	1	(S1 (S (NP (NP (NNP Doc_19767176_102_129_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19767176_131_135_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (NP (NP (DT a) (JJ dual) (NN mechanism)) (PP (IN of) (NP (NN action)))) (PP (IN as) (NP (NP (NP (DT an) (NN antioxidant)) (CC and) (NP (DT an) (NN inhibitor))) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN kappa-beta)))))) (. .)))
19767176	2	(S1 (S (ADVP (DT Both)) (, ,) (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_19767176_272_278_Chemical) (NNS species)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ severe) (NN Doc_19767176_353_368_Disease)) (PP (IN in) (NP (JJ different) (NNS sub-regions)) (PP (IN of) (NP (DT the) (NN hippocampus))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT the) (VBG surrounding) (NNS cortices))))))))) (. .)))
19767176	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_19767176_467_471_Chemical))) (PP (IN on) (NP (JJ Doc_19767176_475_493_Disease-associated) (NN cell) (NN loss))) (PP (IN in) (NP (DT the) (ADJP (JJ hippocampus) (CC and) (JJ piriform)) (NN cortex)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT the) (NN rat)) (VP (VBN fractionated) (NP (JJ Doc_19767176_592_603_Chemical) (NN model))))))) (. .)))
19767176	4	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (CD 150)))) (VP (VP (VBD mg/kg) (NP (NNP Doc_19767176_636_640_Chemical)) (ADVP (RB before))) (CC and) (VP (PP (VBG following) (NP (NNP Doc_19767176_662_680_Disease))) (ADVP (RB significantly)) (VBD increased) (NP (DT the) (NN mortality) (NN rate)) (PP (TO to) (NP (CD 100) (NN %))))) (. .)))
19767176	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (CD 50) (NNS mg/kg)) (NP (NP (NNP Doc_19767176_760_764_Chemical)) (PRN (-LRB- -LRB-) (NP (NN low-dose)) (-RRB- -RRB-)))))) (VP (AUX did) (RB not) (VP (VB exert) (NP (NP (JJ major) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT a) (NN Doc_19767176_828_846_Disease)) (CC or) (NP (DT the) (NN mortality) (NN rate))))))))) (. .)))
19767176	6	(S1 (S (PP (IN In) (NP (JJ vehicle-treated) (NNS rats))) (, ,) (NP (NNP Doc_19767176_895_913_Disease)) (VP (VBD caused) (NP (JJ pronounced) (NN Doc_19767176_932_947_Disease)) (PP (IN in) (NP (NP (DT the) (JJ piriform) (NN cortex)) (VP (VBG comprising) (NP (NP (DT both) (JJ pyramidal) (NNS cells)) (CC and) (NP (NNS interneurons))))))) (. .)))
19767176	7	(S1 (S (NP (JJ Low-dose) (JJ Doc_19767176_1030_1034_Chemical) (NN treatment)) (ADVP (RB almost) (RB completely)) (VP (VBD protected) (PP (IN from) (NP (NNS lesions))) (PP (IN in) (NP (DT the) (JJ piriform) (NN cortex)))) (. .)))
19767176	8	(S1 (S (NP (NP (DT A) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (JJ neuronal) (NN density)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN hilar) (NN formation)))))) (VP (AUX was) (VP (VBN identified) (PP (IN in) (NP (NP (JJ vehicle-) (CC and) (JJ Doc_19767176_1219_1223_Chemical-treated) (NNS rats)) (VP (VBG following) (NP (NNP Doc_19767176_1247_1265_Disease))))))) (. .)))
19767176	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (NN NF-kappaB) (NN inhibitor) (CC and) (NN antioxidant) (NN Doc_19767176_1322_1326_Chemical)) (VP (VBD protected) (NP (DT the) (JJ piriform) (NN cortex)) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB affect) (NP (JJ hilar) (NN Doc_19767176_1390_1403_Disease))))))) (. .)))
19767176	10	(S1 (S (NP (DT These) (NNS data)) (VP (MD might) (VP (VB indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_19767176_1463_1469_Chemical) (NNS species)) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))) (VP (VBZ plays) (NP (NP (DT a) (RBR more) (JJ central) (NN role)) (PP (IN in) (NP (NP (NNP Doc_19767176_1535_1542_Disease-associated) (NNP Doc_19767176_1554_1569_Disease)) (PP (IN in) (NP (DT the) (JJ temporal) (NN cortex)))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (JJ hippocampal) (NN hilus))))))))))) (. .)))
19767176	11	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ future) (NNS investigations)) (VP (AUX are) (ADJP (JJ necessary) (S (VP (TO to) (ADVP (RB exactly)) (VP (VB analyze) (NP (NP (DT the) (JJ biochemical) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_19767176_1731_1735_Chemical)) (VP (VBN exerted) (NP (PRP$ its) (JJ beneficial) (NNS effects)) (PP (IN in) (NP (DT the) (JJ piriform) (NN cortex)))))))))))) (. .)))
19803309	0	(S1 (NP (NP (NP (NNS Anaesthetists) (POS ')) (NN nightmare)) (: :) (NP (NP (NN Doc_19803309_26_40_Disease)) (PP (IN after) (NP (NN induction))) (PP (IN in) (NP (NP (DT an) (JJ undiagnosed) (NN case)) (PP (IN of) (NP (NNP Doc_19803309_83_101_Disease)))))) (. .)))
19803309	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (JJ undiagnosed) (NN case)) (PP (IN of) (NP (NNP Doc_19803309_136_154_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ 24-year-old) (ADJP (RB previously) (JJ healthy)) (NN primigravida)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NN life)) (VP (VBG threatening) (NP (NNP Doc_19803309_236_250_Disease)))) (PP (VBG following) (NP (NP (DT a) (JJ standard) (NN dose)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_19803309_292_305_Chemical))) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))))))))))))) (. .)))
19803309	2	(S1 (S (NP (CC Neither) (NP (DT the) (NN patient)) (CC nor) (NP (DT the) (NN anaesthetist))) (VP (AUX was) (ADJP (JJ aware) (PP (IN of) (NP (DT the) (NN diagnosis)))) (SBAR (IN before) (S (NP (DT this) (ADJP (RB potentially) (JJ lethal)) (NN complication)) (VP (VBD occurred))))) (. .)))
19820426	0	(S1 (NP (NP (JJ Twin) (JJ preterm) (NNS neonates)) (PP (IN with) (NP (NNP Doc_19820426_27_43_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_19820426_55_74_Chemical) (NN therapy)))) (. .)))
19820426	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ twin) (NNS neonates)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (ADVP (RB prematurely)) (PP (IN at) (NP (NP (CD 32) (NNS weeks)) (PP (IN of) (NP (NN gestation))))) (PP (TO to) (NP (NP (DT a) (NN mother)) (PP (IN with) (NP (NNP Doc_19820426_176_214_Disease))))))))))) (. .)))
19820426	2	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NNP twins)))) (VP (VBD developed) (ADJP (JJ complete)) (SBAR (S (NP (NNP Doc_19820426_252_263_Disease) (CC and) (NNP Doc_19820426_268_290_Disease)) (VP (VBD related) (PP (TO to) (NP (NP (JJ Doc_19820426_302_321_Chemical) (NN therapy)) (, ,) (NP (DT a) (VBN boosted) (JJ protease-inhibitor) (NN agent)) (, ,))) (SBAR (IN while) (S (NP (DT the) (JJ other) (JJ twin)) (VP (VBD developed) (NP (JJ mild) (NN Doc_19820426_403_414_Disease))))))))) (. .)))
19820426	3	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (NN caution)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_19820426_451_470_Chemical))) (PP (IN in) (NP (DT the) (JJ immediate) (JJ neonatal) (NN period)))))) (. .)))
19843802	0	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNS drugs)) (VP (VBP disappear) (PP (IN from) (NP (DT the) (NN patient)))))) (: :) (NP (NP (NN elimination)) (PP (IN of) (NP (JJ intravenous) (NN medication))) (PP (IN by) (NP (NN hemodiafiltration)))) (. .)))
19843802	1	(S1 (S (PP (NP (JJ Twenty-three) (NNS hours)) (IN after) (NP (NN heart) (NN transplantation))) (, ,) (NP (JJ life-threatening) (JJ acute) (NN Doc_19843802_170_189_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG requiring) (NP (NP (JJ continuous) (JJ venovenous) (NN hemodiafiltration)) (PRN (-LRB- -LRB-) (NP (NNP CVVHDF)) (-RRB- -RRB-)))))))) (. .)))
19843802	2	(S1 (S (NP (NP (NP (NP (JJ Increasing) (NNS doses)) (PP (IN of) (NP (NNP Doc_19843802_297_311_Chemical)))) (, ,) (NP (NNS sedatives)) (, ,) (CC and) (NP (NN muscle) (NNS relaxants))) (VP (VBN administered) (PP (IN through) (NP (DT a) (JJ central) (JJ venous) (NN catheter))))) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
19843802	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (NN bolus)) (PP (IN of) (NP (NNP Doc_19843802_430_441_Chemical))) (VP (VBN injected) (PP (IN through) (NP (DT an) (JJ alternative) (NN catheter))))) (VP (VBD provoked) (NP (DT a) (JJ Doc_19843802_494_506_Disease) (NN crisis))) (. .)))
19843802	4	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN interference)) (PP (IN with) (NP (DT the) (JJ central) (JJ venous) (NN infusion))) (PP (IN by) (NP (DT the) (NN dialysis) (NN catheter)))) (VP (AUX was) (VP (VBN suspected))) (. .)))
19843802	5	(S1 (S (S (NP (DT The) (NNS catheters)) (VP (AUX were) (VP (VBN changed)))) (, ,) (CC and) (S (NP (NNS hemodynamics)) (VP (VBD stabilized) (PP (IN at) (NP (JJR lower) (NNP Doc_19843802_672_685_Chemical) (NNS doses))))) (. .)))
19843802	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP IV) (NNS drugs)))) (VP (AUX are) (ADJP (JJ inadequate)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNS CVVHDF)))))))) (, ,) (NP (NP (NN interference)) (PP (IN with) (NP (NP (JJ adjacent) (NNS catheters)) (VP (VBG resulting) (PP (IN in) (NP (NP (NN elimination)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN by) (NP (NNP CVVHDF))))))))) (VP (MD should) (VP (AUX be) (VP (VBN suspected)))) (. .)))
1987816	0	(S1 (FRAG (NP (NP (ADJP (RBR Less) (JJ frequent)) (JJ Doc_1987816_14_21_Chemical) (NN administration)) (CC and) (NP (JJR lower) (NN urine) (NN volume))) (. .)))
1987816	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNS patients)) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NNP Doc_1987816_153_160_Chemical))))) (PP (IN on) (NP (DT a) (JJ once-per-day) (NN schedule))))) (VP (AUX have) (NP (NP (JJR lower) (NN urine) (NNS volumes)) (SBAR (IN than) (SINV (AUX do) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ multiple) (NNS doses)) (PP (IN per) (NP (NN day)))))))))))))))) (. .)))
1987816	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ cross-sectional) (NN study)) (PP (IN of) (NP (NP (CD 85) (NNS patients)) (PP (IN from) (NP (NP (DT a) (JJ Doc_1987816_327_334_Chemical) (NN clinic)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ different) (NN dose) (NNS schedules))))))))))) (. .)))
1987816	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (JJ Doc_1987816_439_446_Chemical) (NN level)) (, ,) (NP (JJ Doc_1987816_454_464_Chemical) (NN clearance)) (, ,) (NP (NN urine) (NN volume)) (, ,) (CC and) (NP (NN maximum) (NN osmolality)))))))) (. .)))
1987816	4	(S1 (S (NP (NP (JJ Multiple) (JJ daily) (NNS doses)) (PP (IN of) (NP (NNP Doc_1987816_547_554_Chemical)))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJR higher) (NN urine) (NNS volumes))))) (. .)))
1987816	5	(S1 (S (NP (NP (DT The) (NN dosing) (NN schedule)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (JJ Doc_1987816_631_638_Chemical) (NN treatment)))) (, ,) (CC and) (NP (NP (JJ daily) (NN dose)) (PP (IN of) (NP (NNP Doc_1987816_668_675_Chemical))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (JJ maximum) (NN osmolality)) (CC or) (NP (JJ Doc_1987816_713_723_Chemical) (NN clearance))))) (. .)))
1987816	6	(S1 (S (NP (NN Urine) (NN volume)) (VP (MD can) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (S (VP (VBG giving) (NP (NNP Doc_1987816_786_793_Chemical) (ADJP (RB once) (JJ daily)) (NN and/or)) (PP (IN by) (S (VP (VBG lowering) (NP (DT the) (JJ total) (JJ daily) (NN dose))))))))))) (. .)))
1987816	7	(S1 (S (NP (JJ Doc_1987816_846_853_Chemical-induced) (NNP Doc_1987816_862_870_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJ related) (PP (TO to) (NP (NN extrarenal)))) (CONJP (RB as) (RB well) (IN as)) (PP (TO to) (NP (JJ renal) (NNS effects)))))))) (. .)))
19884587	0	(S1 (NP (NP (NP (JJ Antibacterial) (NN medication) (NN use)) (PP (IN during) (NP (NP (NN pregnancy)) (CC and) (NP (NN risk)))) (PP (IN of) (NP (NNP Doc_19884587_58_71_Disease)))) (: :) (NP (NNP National) (NNP Doc_19884587_82_95_Disease) (NNP Prevention) (NNP Study)) (. .)))
19884587	1	(S1 (FRAG (S (VP (TO To) (VP (VB estimate) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (JJ antibacterial) (NNS medications)) (CC and) (NP (JJ selected) (NN Doc_19884587_200_213_Disease)))))))) (. .)))
19884587	2	(S1 (NP (NP (NP (NN DESIGN)) (, ,) (NP (NN SETTING)) (, ,) (CC AND) (NP (NNS PARTICIPANTS))) (: :) (NP (NP (JJ Population-based) (, ,) (JJ multisite) (, ,) (JJ case-control) (NN study)) (PP (IN of) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (NNS pregnancies)) (VP (VBN affected) (PP (IN by) (NP (NP (CD 1)) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 30)) (JJ eligible) (JJ major) (NN Doc_19884587_372_385_Disease)) (VP (VBN identified) (PP (IN via) (NP (NP (NNP Doc_19884587_401_413_Disease) (NN surveillance) (NNS programs)) (PP (IN in) (NP (NP (NP (CD 10) (NNS states)) (PRN (-LRB- -LRB-) (NP (NNP n) (QP (SYM =) (CD 13) (CD 155))) (-RRB- -RRB-))) (CC and) (NP (NP (NN control) (NNS women)) (ADJP (RB randomly) (VBN selected)) (PP (IN from) (NP (NP (DT the) (JJ same) (NN geographical) (NNS regions)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4941)) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
19884587	3	(S1 (NP (NP (JJ MAIN) (NN EXPOSURE)) (: :) (NP (NP (JJ Reported) (JJ maternal) (NN use)) (PP (IN of) (NP (NP (NNS antibacterials)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN month)) (PP (IN before) (NP (NN pregnancy))) (PP (IN through) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ first) (NN trimester)))))) (-RRB- -RRB-))))) (. .)))
19884587	4	(S1 (NP (NP (JJ MAIN) (NN OUTCOME) (NN MEASURE)) (: :) (NP (NP (NP (NNS Odds) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NNP ORs)) (-RRB- -RRB-))) (VP (VBG measuring) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (JJ antibacterial) (NN use)) (CC and) (NP (NP (VBN selected) (NN Doc_19884587_772_785_Disease)) (VP (VBN adjusted) (PP (IN for) (NP (JJ potential) (NNS confounders)))))))))) (. .)))
19884587	5	(S1 (S (NP (NP (DT The) (VBN reported) (NN use)) (PP (IN of) (NP (NNS antibacterials)))) (VP (VBD increased) (PP (IN during) (NP (NN pregnancy))) (, ,) (S (VP (VBG peaking) (PP (IN during) (NP (DT the) (JJ third) (NN month)))))) (. .)))
19884587	6	(S1 (S (NP (NNP Doc_19884587_926_938_Chemical)) (VP (AUX were) (ADJP (ADJP (JJ associated) (PP (IN with) (NP (NNP Doc_19884587_960_971_Disease)))) (PRN (-LRB- -LRB-) (NP (NP (ADJP (JJ adjusted) (CC OR) (JJ -LSB-AOR)) (JJ -RSB-) (SYM =) (CD 3.4)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-))) (, ,) (NP (CD 1.3-8.8)) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1038_1069_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 3.2)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 1.3-7.6))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1100_1124_Disease)) (PRN (-LRB- -LRB-) (NP (NNP AOR) (SYM =) (CD 2.7)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NNS CI)) (, ,) (NP (CD 1.3-5.6))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1155_1170_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 8.0)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 2.7-23.5))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1202_1228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP AOR) (SYM =) (CD 2.5)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NNS CI)) (, ,) (NP (CD 1.0-5.9))) (-RRB- -RRB-)) (, ,) (CC and) (ADJP (JJ Doc_19884587_1263_1283_Disease))) (PRN (-LRB- -LRB-) (NP (NP (NNP AOR) (SYM =) (CD 2.4)) (: ;) (NP (ADJP (CD 95) (NN %)) (NNS CI))) (, ,) (NP (CD 1.1-5.4)) (-RRB- -RRB-))) (. .)))
19884587	7	(S1 (S (NP (NNP Doc_19884587_1314_1329_Chemical)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNP Doc_19884587_1351_1363_Disease) (CC or) (NNP Doc_19884587_1367_1381_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 3.7)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.1-12.2))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1413_1444_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 4.2)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.9-9.1))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_19884587_1475_1496_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 1.9)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.1-3.4))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_19884587_1531_1540_Disease)))) (PP (IN with) (NP (NP (NNP Doc_19884587_1546_1558_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 2.1)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.2-3.9))) (-RRB- -RRB-)))))) (. .)))
19884587	8	(S1 (NP (NP (JJ Other) (JJ antibacterial) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (SBAR (S (NP (NNS associations)) (VP (VBD included) (NP (NP (NP (NNP Doc_19884587_1650_1663_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS defects)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1677_1688_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1701_1715_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_19884587_1732_1742_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-)))))))))) (. .)))
19884587	9	(S1 (S (ADVP (RB Reassuringly)) (, ,) (NP (NP (NNP Doc_19884587_1782_1793_Chemical)) (, ,) (NP (NNP Doc_19884587_1795_1808_Chemical)) (, ,) (CC and) (NP (NNP Doc_19884587_1814_1828_Chemical))) (, ,) (SBAR (IN although) (S (VP (VBN used) (ADVP (RB commonly)) (PP (IN by) (NP (JJ pregnant) (NNS women)))))) (, ,) (VP (AUX were) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ many) (NNP Doc_19884587_1902_1915_Disease))))) (. .)))
19884587	10	(S1 (S (NP (NP (NNP Doc_19884587_1917_1929_Chemical)) (CC and) (NP (NNP Doc_19884587_1934_1949_Chemical))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJ several) (NNP Doc_19884587_1979_1992_Disease))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (JJ additional) (NN scrutiny)))))))) (. .)))
19889778	0	(S1 (NP (NP (NN Differential) (NN impact)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS mutations) (NNP G145R) (CC and) (NNP P120T))) (PP (IN on) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_85_95_Chemical-resistant) (UCP (JJ Doc_19889778_106_133_Chemical-positive) (CC and) (JJ -negative)) (NNS strains))))) (. .)))
19889778	1	(S1 (S (NP (NP (NP (JJ Immune) (NN escape) (NNS variants)) (PP (IN of) (NP (DT the) (NNP Doc_19889778_196_207_Disease) (NN virus)))) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-))) (VP (VBP represent) (NP (DT an) (VBG emerging) (JJ clinical) (NN challenge)) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN vaccine) (NN escape)) (, ,) (NP (NN HBV) (NN reactivation)) (, ,) (CC and) (NP (NP (NN failure)) (PP (IN of) (NP (JJ diagnostic) (NNS tests)))))))))))) (. .)))
19889778	2	(S1 (S (NP (JJ Recent) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJ preferential) (NN selection)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS mutants))) (PP (IN in) (NP (NP (JJ distinct) (JJ peripheral) (NN blood) (NN leukocyte) (NNS compartments)) (PP (IN of) (NP (JJ infected) (NNS individuals))))))) (. .)))
19889778	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (ADVP (RB systematically)) (VBD analyzed) (NP (NP (DT the) (JJ functional) (NN impact)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ prevalent)) (JJ immune) (NN escape) (NNS variants)) (, ,) (NP (DT the) (NN sG145R) (CC and) (NN sP120T) (NNS mutants)) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ viral) (NN replication) (NN efficacy)) (CC and) (NP (NP (JJ antiviral) (NN drug) (NN susceptibility)) (PP (IN of) (NP (NP (JJ common) (JJ treatment-associated) (NNS mutants)) (PP (IN with) (NP (NP (NN resistance)) (PP (TO to) (NP (NP (NNP Doc_19889778_774_784_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19889778_786_789_Chemical)) (-RRB- -RRB-)) (NP (JJ and/or) (JJ Doc_19889778_798_803_Chemical) (NN negativity))))))))))))) (. .)))
19889778	4	(S1 (S (NP (NP (JJ Replication-competent) (JJ HBV) (NNS strains)) (PP (IN with) (NP (NP (NN sG145R)) (CC or) (NP (NP (ADJP (JJ sP120T) (CC and) (JJ Doc_19889778_876_879_Chemical)) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN rtM204I) (CC or) (NNS rtL180M/rtM204V)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN generated) (PP (IN on) (NP (NP (DT an) (JJ Doc_19889778_941_946_Chemical-positive)) (CC and) (NP (DT an) (JJ Doc_19889778_963_968_Chemical-negative) (NN background)))) (PP (IN with) (NP (NP (NP (NN precore)) (PRN (-LRB- -LRB-) (NP (NN PC)) (-RRB- -RRB-))) (CC and) (NP (JJ basal) (NN core) (NN promoter) (PRN (-LRB- -LRB-) (NP (NNP BCP)) (-RRB- -RRB-)) (NNS mutants)))))) (. .)))
19889778	5	(S1 (S (S (NP (DT The) (JJ sG145R) (NN mutation)) (VP (VP (ADVP (RB strongly)) (VBD reduced) (NP (JJ Doc_19889778_1083_1088_Chemical) (NNS levels))) (CC and) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (ADVP (RB fully)) (VB restore) (NP (NP (DT the) (VBN impaired) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_1154_1157_Chemical-resistant) (NN HBV) (NNS mutants)))) (PP (TO to) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ wild-type) (NNS HBV)))))))))))) (, ,) (CC and) (S (NP (NNP PC) (CC or) (NNP BCP) (NNS mutations)) (VP (ADVP (RB further)) (VBD enhanced) (NP (JJ viral) (NN replication)))) (. .)))
19889778	6	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ sP120T) (NN substitution)) (ADVP (RB also)) (VP (VBN impaired) (NP (JJ Doc_19889778_1319_1324_Chemical) (NN secretion))))) (, ,) (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB enhance) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_1374_1377_Chemical-resistant) (NNS clones)))))) (. .)))
19889778	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ concomitant) (NN occurrence)) (PP (IN of) (NP (NP (NP (JJ Doc_19889778_1435_1440_Chemical) (NN negativity)) (PRN (-LRB- -LRB-) (NP (NNP PC/BCP)) (-RRB- -RRB-))) (, ,) (NP (NN sP120T)) (, ,) (CC and) (NP (JJ Doc_19889778_1474_1477_Chemical) (NN resistance))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN restoration)) (PP (IN of) (NP (NN replication))) (PP (TO to) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ wild-type) (NNS HBV)))))))) (. .)))
19889778	8	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS clones)) (PP (IN with) (NP (NP (JJ combined) (JJ immune) (NN escape)) (CC and) (NP (JJ Doc_19889778_1606_1609_Chemical) (NN resistance) (NNS mutations)))))) (, ,) (NP (DT the) (NNP Doc_19889778_1636_1646_Chemical) (NNS analogues) (NNP Doc_19889778_1657_1665_Chemical) (CC and) (NNP Doc_19889778_1670_1679_Chemical)) (VP (VBD remained) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG suppressing) (NP (JJ viral) (NN replication)) (PP (IN in) (NP (NN vitro)))))))) (. .)))
19889778	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP reveal) (NP (NP (DT the) (NN differential) (NN impact)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS variants))) (PP (IN on) (NP (NP (DT the) (NN replication) (CC and) (NN drug) (NN susceptibility)) (PP (IN of) (NP (JJ complex) (NN HBV) (NNS mutants)))))) (, ,) (S (VP (VBG supporting) (NP (NP (DT the) (NN need)) (PP (IN of) (NP (NP (JJ close) (NN surveillance)) (CC and) (NP (NN treatment) (NN adjustment))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (JJ distinct) (JJ mutational) (NNS patterns)))))))))) (. .)))
1992636	0	(S1 (S (NP (NN Doc_1992636_0_16_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1992636_44_54_Chemical)))))) (. .)))
1992636	1	(S1 (S (NP (NN Doc_1992636_56_66_Chemical)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN drug)) (VP (VBN designed) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (JJ final) (NN step)) (PP (IN in) (NP (NP (DT the) (NN acid) (NN secretory) (NN process)) (PP (IN within) (NP (DT the) (JJ parietal) (NN cell)))))))))))) (. .)))
1992636	2	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (RB extremely) (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1992636_238_258_Disease)) (, ,) (NP (NNP Doc_1992636_260_278_Disease)) (, ,) (CC and) (NP (DT the) (NNP Doc_1992636_288_314_Disease)))))))))))) (. .)))
1992636	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ clinical) (NN experience)) (PP (IN with) (NP (NNP Doc_1992636_350_360_Chemical)))) (VP (AUX is) (ADVP (RB still)) (VP (VBN limited))))) (, ,) (NP (JJ many) (VBN controlled) (NNS studies)) (VP (AUX have) (VP (VBN established) (NP (NP (DT the) (JJ short-term) (NN safety)) (PP (IN of) (NP (DT this) (NN drug)))))) (. .)))
1992636	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ serious) (JJ short-term) (JJ adverse) (NN reaction)) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_1992636_538_548_Chemical)) (: :) (NP (NNP Doc_1992636_550_566_Disease)))))))))) (. .)))
1992636	5	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (NP (NN weakness)) (, ,) (NP (NN Doc_1992636_600_608_Disease)) (, ,) (CC and) (NP (NP (NN Doc_1992636_614_633_Disease)) (NP (CD 2) (NNS days)))) (PP (IN after) (S (VP (VBG starting) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_1992636_669_679_Chemical)))))))) (. .)))
1992636	6	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN therapy))))) (, ,) (S (NP (PRP$ her) (NN hematocrit)) (VP (AUX had) (VP (VBN decreased) (PP (IN from) (NP (QP (CD 44.1) (NN %) (TO to) (CD 20.4)) (NN %)))))) (, ,) (CC and) (S (NP (PRP she)) (VP (AUX had) (NP (NP (DT a) (JJ positive) (JJ direct) (NNP Coombs) (NN antiglobulin) (NN test)) (CC and) (NP (DT an) (JJ elevated) (JJ indirect) (NN Doc_1992636_854_863_Chemical))))) (. .)))
1992636	7	(S1 (S (SBAR (IN After) (S (NP (PRP she)) (VP (VBN discontinued) (NP (DT the) (NNP Doc_1992636_892_902_Chemical))))) (, ,) (NP (PRP$ her) (NN hemoglobin) (CC and) (NN hematocrit)) (ADVP (RB gradually)) (VP (VBD returned) (PP (TO to) (NP (JJ normal)))) (. .)))
1992636	8	(S1 (NP (DT The) (NN mechanism) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_1992636_987_997_Chemical)) (VP (VBD caused) (SBAR (S (S (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_1992636_1019_1035_Disease)) (VP (AUX is) (ADJP (JJ uncertain)))) (, ,) (CC but) (S (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (VP (VBD alerted) (PP (TO to) (NP (DT this) (JJ possible) (JJ adverse) (NN effect)))))))))))) (. .)))
19957053	0	(S1 (FRAG (NP (NN Doc_19957053_0_13_Chemical)) (CC but) (RB not) (NP (NP (NNP Doc_19957053_22_31_Chemical) (NNP Doc_19957053_32_64_Disease)) (VP (VBG following) (NP (JJ anesthesia-induced) (NNP Doc_19957053_94_105_Disease)))) (. .)))
19957053	1	(S1 (S (NP (NN Vasopressor) (NNS agents)) (VP (AUX are) (VP (VBN used) (S (VP (TO to) (VP (VB correct) (NP (JJ anesthesia-induced) (NN Doc_19957053_177_188_Disease))))))) (. .)))
19957053	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_19957053_216_229_Chemical) (CC and) (NNP Doc_19957053_234_243_Chemical))) (PP (IN on) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-))))) (PP (VBG following) (NP (JJ anesthesia-induced) (NNP Doc_19957053_312_323_Disease)))) (. .)))
19957053	3	(S1 (S (S (VP (VBG Following) (NP (NP (NN induction)) (PP (IN of) (NP (NN anesthesia))) (PP (IN by) (NP (NP (NNP Doc_19957053_371_379_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.15) (NNS mg) (NN kg) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-) (-RRB- -RRB-)) (CC and) (NNP Doc_19957053_401_409_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg)) (NNS kg)) (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-))))))) (, ,) (NP (CD 13) (NNS patients)) (VP (VBD received) (SBAR (S (NP (NP (NP (NNP Doc_19957053_448_461_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.1) (CD mg)) (NNP iv)) (-RRB- -RRB-))) (CC and) (NP (CD 12) (NNS patients))) (VP (VBD received) (NP (NP (NNP Doc_19957053_499_508_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg)) (NNP iv)) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB restore) (VP (VB mean) (NP (NP (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))))))))))) (. .)))
19957053	4	(S1 (S (NP (NP (NP (NN Heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-)) (, ,) (NP (NN MAP)) (, ,) (NP (NNP Doc_19957053_583_589_Disease) (NN volume)) (PRN (-LRB- -LRB-) (NP (NNP SV)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ cardiac) (NN output)) (PRN (-LRB- -LRB-) (NP (NNP CO)) (-RRB- -RRB-))) (, ,)) (CC and) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN registered))) (. .)))
19957053	5	(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NNS anesthesia)))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_19957053_730_763_Disease) (NN concomitant)) (PP (IN with) (NP (NP (DT an) (NN elevation)) (PP (IN in) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))))))))) (. .)))
19957053	6	(S1 (S (PP (IN After) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_19957053_831_844_Chemical))))) (, ,) (NP (NN MAP)) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 51) (NN +/-)) (NP (QP (CD 12) (TO to) (CD 81)) (JJ +/-) (CD 13) (NNS mmHg))) (: ;) (NP (NNP P) (NNP <) (CD 0.001)) (: ;) (NP (JJ mean) (JJ +/-) (NN SD))) (-RRB- -RRB-))) (. .)))
19957053	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (ADJP (ADJP (CD 14) (NN %)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (QP (CD 70) (JJ +/-) (CD 8) (NN %) (TO to) (CD 60) (NN +/-))) (NP (CD 7) (NN %)))) (-RRB- -RRB-))) (NN reduction)) (PP (IN in) (NP (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))) (VP (VBN followed) (PP (IN with) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NNP CO)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.7) (NN +/-)) (ADJP (QP (CD 1.1) (TO to) (CD 3.4) (NN +/-)) (NP (NP (CD 0.9) (NNP l) (NN min)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))))) (-RRB- -RRB-))))))) (. .)))
19957053	8	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_19957053_1085_1094_Chemical)))) (VP (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ similar) (NN increase)) (PP (IN in) (NP (NN MAP))) (PRN (-LRB- -LRB-) (NP (NP (CD 53) (NN +/-)) (NP (QP (CD 9) (TO to) (CD 79)) (JJ +/-) (CD 8) (NNS mmHg))) (: ;) (VP (VBG P) (NP (NNP <) (CD 0.001))) (-RRB- -RRB-))))) (, ,) (VP (VBD restored) (NP (NP (NNP CO)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 3.2) (NN +/-) (QP (CD 1.2) (TO to) (CD 5.0))) (JJ +/-) (CD 1.3) (NNP l) (NN min)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBD preserved) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (. .)))
19957053	9	(S1 (S (S (NP (NP (DT The) (NN utilization)) (PP (IN of) (NP (NNP Doc_19957053_1276_1289_Chemical)))) (VP (TO to) (VP (VB correct) (NP (NP (NNP Doc_19957053_1301_1312_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNS anesthesia)))))))) (VP (AUX has) (NP (NP (DT a) (JJ negative) (NN impact)) (PP (IN on) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (SBAR (IN while) (S (NP (NNP Doc_19957053_1375_1384_Chemical)) (VP (VBZ maintains) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (ADJP (RB potentially) (JJ related) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP CO))))))))))) (. .)))
20003049	0	(S1 (NP (NP (VBN Prolonged) (NN elevation)) (PP (IN of) (NP (NN plasma) (NNP Doc_20003049_30_40_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ cardiac) (NN transplant) (NN patient)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (NN history)) (PP (IN of) (NP (NP (NNP Doc_20003049_101_108_Chemical-induced) (NNP Doc_20003049_117_133_Disease)) (PP (IN with) (NP (NNP Doc_20003049_139_149_Disease))))))))) (. .)))
20003049	1	(S1 (S (NP (NP (JJ Direct) (NN thrombin) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP DTIs)) (-RRB- -RRB-))) (VP (VBP provide) (NP (NP (DT an) (JJ alternative) (NN method)) (PP (IN of) (NP (NN anticoagulation)))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NP (JJ Doc_20003049_277_284_Chemical-induced) (NNP Doc_20003049_293_309_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20003049_311_314_Disease)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NNP Doc_20003049_319_322_Disease)) (PP (IN with) (NP (NNP Doc_20003049_328_338_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_20003049_340_344_Disease)) (-RRB- -RRB-))))) (VP (VBG undergoing) (NP (NP (JJ cardiopulmonary) (NN bypass)) (PRN (-LRB- -LRB-) (NP (NNP CPB)) (-RRB- -RRB-))))))))) (. .)))
20003049	2	(S1 (S (PP (IN In) (NP (DT the) (JJ following) (NN report))) (, ,) (NP (NP (DT a) (JJ 65-year-old) (NN Doc_20003049_426_440_Disease) (NN patient)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (NN history)) (PP (IN of) (NP (NNP Doc_20003049_477_481_Disease)))))) (VP (AUX was) (VP (VBN administered) (NP (NNP Doc_20003049_499_509_Chemical)) (PP (IN for) (NP (NN anticoagulation))) (PP (IN on) (NP (NN bypass))) (PP (IN during) (NP (NN heart) (NN transplantation))))) (. .)))
20003049	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD required) (NP (NP (JJ massive) (NN transfusion) (NN support)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 55) (NNS units)) (PP (IN of) (NP (JJ red) (NN blood) (NNS cells)))) (, ,) (NP (NP (CD 42) (NNS units)) (PP (IN of) (NP (NP (JJ fresh-frozen) (NN plasma)) (, ,) (NP (NP (CD 40) (NNS units)) (PP (IN of) (NP (NN cryoprecipitate)))) (, ,) (NP (NP (CD 40) (NNS units)) (PP (IN of) (NP (NNS platelets)))) (, ,) (CC and) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (JJ recombinant) (NN Factor) (NNS VIIa)))))))) (-RRB- -RRB-)) (PP (IN for) (NP (JJ severe) (NNP Doc_20003049_789_830_Disease))))) (. .)))
20003049	4	(S1 (S (S (VP (VB STUDY) (NP (NN DESIGN) (CC AND) (NNS METHODS)))) (: :) (S (NP (NP (NN Plasma) (NNS samples)) (PP (IN from) (PP (IN before) (CC and) (IN after) (NP (NN CPB))))) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB postoperatively)) (PP (IN for) (NP (NP (JJ Doc_20003049_933_943_Chemical) (NN concentration)) (VP (VBG using) (NP (DT a) (VBN modified) (NN ecarin) (NN clotting) (NN time) (-LRB- -LRB-) (NN ECT) (-RRB- -RRB-) (NN assay)))))))) (. .)))
20003049	5	(S1 (S (S (NP (NP (RB Unexpectedly) (JJ high) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_20003049_1054_1064_Chemical)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT these) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 0-32) (NNS microg/mL)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ prolonged) (NN plasma) (JJ Doc_20003049_1144_1154_Chemical) (NN half) (NN life)) (PRN (-LRB- -LRB-) (NNP t) (-LRB- -LRB-) (NN 1/2) (-RRB- -RRB-) (-RRB- -RRB-)) (PP (IN of) (NP (CD 514) (NNS minutes)))) (VP (AUX was) (ADJP (JJ observed)) (PRN (-LRB- -LRB-) (VP (VBN published) (NP (NP (NP (NN elimination) (NNS t)) (PRN (-LRB- -LRB-) (NP (CD 1/2)) (-RRB- -RRB-)) (VP (AUX is) (ADJP (NP (CD 39-51) (NNS minutes)) (JJ -LSB-<)))) (CC or) (NP (NP (QP (SYM =) (CD 181)) (NNS minutes)) (PP (IN with) (NP (NNP Doc_20003049_1274_1292_Disease) (NNS -RSB-)))))) (-RRB- -RRB-)))) (. .)))
20003049	6	(S1 (S (NP (NP (NP (NN Correlation)) (PP (IN of) (NP (NP (NN plasma) (JJ Doc_20003049_1331_1341_Chemical) (NN concentration)) (CC versus) (NP (NP (DT the) (NN patient) (POS 's)) (JJ coagulation) (NNS variables))))) (CC and) (NP (JJ clinical) (NN course))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ prolonged) (JJ elevated) (NNS levels)) (PP (IN of) (NP (NN plasma) (NN Doc_20003049_1468_1478_Chemical)))) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NP (DT the) (NN patient) (POS 's)) (VBN extended) (NN Doc_20003049_1526_1538_Disease))))))))) (. .)))
20003049	7	(S1 (S (SBAR (IN Because) (S (NP (NNS DTIs)) (VP (AUX do) (RB not) (VP (AUX have) (NP (NN reversal) (NNS agents)))))) (, ,) (NP (NP (JJ surgical) (NNS teams)) (CC and) (NP (NN transfusion) (NNS services))) (VP (MD should) (VP (VB remain) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ massive) (NN transfusion) (NNS events)))))) (PP (IN during) (NP (NP (NN anticoagulation)) (PP (IN with) (NP (DT these) (NNS agents))))))) (. .)))
20003049	8	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (SBAR (S (VP (TO to) (VP (VB measure) (NP (NP (NN plasma) (JJ Doc_20003049_1776_1786_Chemical) (NN concentration)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (NN CPB)) (CC and) (NP (JJ extended) (NN Doc_20003049_1836_1848_Disease))))))))))))) (. .)))
20067456	0	(S1 (NP (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (DT the) (JJ adjunctive) (NNP Doc_20067456_30_39_Chemical))) (PP (IN on) (NP (NP (JJ male) (NN Doc_20067456_48_66_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT a) (NNP Doc_20067456_80_118_Chemical))))))) (: :) (NP (DT a) (JJ double-blind) (ADJP (JJ placebo-controlled) (CC and) (JJ randomized)) (NN study)) (. .)))
20067456	1	(S1 (S (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (JJ adjunctive) (JJ Doc_20067456_238_247_Chemical) (NN sustained-release)) (PRN (-LRB- -LRB-) (NP (NNP SR)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ male) (NNP Doc_20067456_279_297_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20067456_299_301_Disease)) (-RRB- -RRB-)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (NNP Doc_20067456_316_354_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20067456_356_360_Chemical)) (-RRB- -RRB-)))))))) (, ,) (PP (IN as) (NP (NNP Doc_20067456_366_368_Disease)))))) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN side-effect)) (PP (IN of) (NP (NNP Doc_20067456_396_401_Chemical)))))) (CC and) (S (NP (DT the) (ADJP (RBS most) (JJ effective)) (NNS treatments)) (VP (AUX have) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN determined))))))) (. .)))
20067456	2	(S1 (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (DT The) (JJ randomized) (NN sample)) (VP (VBN consisted) (PP (IN of) (NP (NP (CD 234) (JJ euthymic) (NNS men)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NP (DT some) (NN type)) (PP (IN of) (NP (NNP Doc_20067456_569_573_Chemical)))))))))))) (. .)))
20067456	3	(S1 (S (NP (DT The) (NNS men)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (NNP Doc_20067456_609_618_Chemical) (NNP SR)) (PRN (-LRB- -LRB-) (NP (QP (CD 150) (CD mg)) (RB twice) (JJ daily)) (, ,) (NP (CD 117)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (RB twice) (JJ daily)) (, ,) (NP (CD 117)) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 12) (NNS weeks))))) (. .)))
20067456	4	(S1 (S (NP (NN Efficacy)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT the) (JJ Clinical) (JJ Global) (JJ Impression-Sexual) (NN Function)) (PRN (-LRB- -LRB-) (NP (NNP CGI-SF)) (: ;) (NP (DT the) (JJ primary) (NN outcome) (NN measure)) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NNP International) (NNP Index)) (PP (IN of) (NP (NP (NP (NNP Erectile) (NN Function)) (PRN (-LRB- -LRB-) (NP (NN IIEF)) (-RRB- -RRB-)) (, ,) (NP (NNP Arizona) (JJ Sexual) (NN Experience) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NNP ASEX)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NNP Doc_20067456_904_924_Disease) (NN Inventory))) (PP (IN of) (NP (NNP Treatment) (NN Satisfaction))))) (PRN (-LRB- -LRB-) (NP (NNP EDITS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (JJ secondary) (NN outcome) (NNS measures)) (-RRB- -RRB-))))))) (. .)))
20067456	5	(S1 (S (NP (NNS Participants)) (VP (AUX were) (VP (VBN followed) (ADVP (RB biweekly)) (PP (IN during) (NP (NN study) (NN period))))) (. .)))
20067456	6	(S1 (S (PP (IN After) (NP (NP (CD 12) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (DT the) (JJ mean) (PRN (-LRB- -LRB-) (CD sd) (-RRB- -RRB-)) (NNS scores)) (PP (IN for) (NP (NNP CGI-SF)))) (VP (AUX were) (ADJP (RB significantly) (JJR lower)) (, ,) (ADVP (FW i.e.) (JJR better)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NNP Doc_20067456_1180_1189_Chemical) (NNP SR))))) (, ,) (PP (IN at) (NP (NP (NP (CD 2.4)) (PRN (-LRB- -LRB-) (NP (CD 1.2)) (-RRB- -RRB-)) (, ,) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (, ,) (PP (IN at) (NP (CD 3.9)))) (-LRB- -LRB-) (NP (CD 1.1)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP P=) (CD 0.01)) (-RRB- -RRB-)))) (. .)))
20067456	7	(S1 (S (NP (NP (NNS Men)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_20067456_1276_1285_Chemical)))))) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (PP (IN in) (NP (NP (DT the) (JJ total) (NN IIEF) (NN score)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 54.4) (NN %)) (NNP vs) (CD 1.2) (NN %)) (: ;) (NP (NNP P=) (CD 0.003))) (-RRB- -RRB-)))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (CD five) (JJ different) (NNS domains)) (PP (IN of) (NP (DT the) (NN IIEF)))))))) (. .)))
20067456	8	(S1 (S (NP (JJ Total) (NN ASEX) (NNS scores)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (, ,) (PP (FW i.e.) (ADVP (RB better))) (, ,))) (PP (IN among) (NP (NP (NNS men)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_20067456_1491_1500_Chemical)) (PP (IN than) (NP (NN placebo)))))))) (, ,) (PP (IN at) (NP (NP (NP (CD 15.5) (-LRB- -LRB-) (CD 4.3) (-RRB- -RRB-) (NNP vs) (CD 21.5)) (-LRB- -LRB-) (NP (CD 4.7)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.002)) (-RRB- -RRB-))))) (. .)))
20067456	9	(S1 (S (NP (DT The) (JJ EDITS) (NNS scores)) (VP (AUX were) (NP (NP (NP (NP (CD 67.4)) (PRN (-LRB- -LRB-) (NP (CD 10.2)) (-RRB- -RRB-) (PP (IN for) (NP (DT the) (NNP Doc_20067456_1597_1606_Chemical))))) (CC and) (NP (NP (CD 36.3)) (PRN (-LRB- -LRB-) (NP (CD 11.7)) (-RRB- -RRB-)))) (PP (IN for) (NP (DT the) (NN placebo) (NN group))) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.001)) (-RRB- -RRB-)))) (. .)))
20067456	10	(S1 (S (NP (NP (DT The) (NN ASEX) (NN score)) (CC and) (NP (JJ CGI-SF) (NN score))) (VP (AUX were) (VP (VBN correlated) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.003)) (-RRB- -RRB-)))) (. .)))
20067456	11	(S1 (S (PP (IN In) (NP (JJ linear) (JJ regression) (NNS analyses))) (NP (DT the) (JJ CGI-SF) (NN score)) (VP (AUX was) (RB not) (VP (VBN affected) (ADVP (RB significantly)) (PP (IN by) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_20067456_1814_1816_Disease)) (, ,) (NP (NP (NP (NN type)) (PP (IN of) (NP (NNP Doc_20067456_1826_1830_Chemical))) (VP (VBN used))) (CC and) (NP (NN age))))))))) (. .)))
20067456	12	(S1 (S (NP (NN Doc_20067456_1858_1867_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (JJ male) (NN Doc_20067456_1903_1905_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20067456_1917_1922_Chemical)))))))) (. .)))
20067456	13	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (JJ empirical) (NN support)) (PP (IN for) (S (VP (VBG conducting) (NP (NP (DT a) (JJ further) (NN study)) (PP (IN of) (NP (NN Doc_20067456_1998_2007_Chemical))))))))) (. .)))
20080419	0	(S1 (NP (NP (NP (NP (NN Prevention)) (PP (IN of) (NP (NNP Doc_20080419_14_22_Disease)))) (CC and) (NP (NP (NN reorganization)) (PP (IN of) (NP (JJ hippocampal) (NNS functions))))) (PP (IN by) (NP (NP (NN transplantation)) (PP (IN of) (NP (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN in) (NP (NP (DT the) (JJ acute) (NN phase)) (PP (IN of) (NP (JJ experimental) (NNP Doc_20080419_142_150_Disease))))))))) (. .)))
20080419	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (JJ therapeutic) (NN potential)) (PP (IN of) (NP (NP (NN bone) (NN marrow) (NN mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP BMCs)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_20080419_263_271_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20080419_283_294_Chemical))) (PP (IN in) (NP (NNS rats))))))) (. .)))
20080419	2	(S1 (S (NP (NP (NNS BMCs)) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ green) (JJ fluorescent) (NN protein) (PRN (-LRB- -LRB-) (NP (NNP GFP)) (-RRB- -RRB-)) (NNP transgenic) (NNS mice)) (CC or) (NP (NNS rats)))))) (VP (AUX were) (VP (VBN transplanted) (ADVP (RB intravenously)) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NNP Doc_20080419_430_448_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20080419_450_452_Disease)) (-RRB- -RRB-)))))))) (. .)))
20080419	3	(S1 (S (NP (NP (NNP Doc_20080419_455_485_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20080419_487_490_Disease)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN monitored) (S (VP (VBG using) (NP (NP (NNP Racine) (POS 's)) (NNP Doc_20080419_522_529_Disease) (NN severity) (NN scale)))))) (. .)))
20080419	4	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (NP (DT the) (NNS rats)) (PP (IN in) (NP (DT the) (JJ saline-treated) (NNP Doc_20080419_584_593_Disease) (NN control) (NN group)))))) (VP (VBD developed) (NP (NNP Doc_20080419_618_621_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NP (NN none)) (PP (IN of) (NP (DT the) (JJ BMC-treated) (JJ Doc_20080419_655_664_Disease) (NNS animals)))) (VP (AUX had) (NP (NNP Doc_20080419_677_685_Disease)) (PP (IN in) (NP (NP (DT the) (JJ short) (NN term)) (PRN (-LRB- -LRB-) (NP (NP (CD 15) (NNS days)) (PP (IN after) (NP (NN transplantation)))) (-RRB- -RRB-)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (DT the) (NNP BMC) (NN source)))))))) (. .)))
20080419	5	(S1 (S (PP (IN Over) (NP (NP (DT the) (JJ long-term) (NN chronic) (NN phase)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NNS days)) (PP (IN after) (NP (NN transplantation)))) (-RRB- -RRB-)))) (, ,) (NP (NP (QP (RB only) (CD 25)) (NN %)) (PP (IN of) (NP (JJ BMC-treated) (JJ Doc_20080419_858_867_Disease) (NNS animals)))) (VP (VP (AUX had) (NP (NNP Doc_20080419_880_888_Disease))) (, ,) (CC but) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN frequency)) (CC and) (NP (NN duration)))) (PP (VBN compared) (PP (TO to) (NP (DT the) (NNP Doc_20080419_946_955_Disease) (NN control) (NN group))))) (. .)))
20080419	6	(S1 (S (NP (NP (DT The) (NN density)) (PP (IN of) (NP (JJ hippocampal) (NNS neurons))) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNS BMCs))))))))) (VP (AUX was) (ADVP (RB markedly)) (VP (VBN preserved))) (. .)))
20080419	7	(S1 (S (PP (IN At) (NP (JJ hippocampal) (NNP Schaeffer) (NN collateral-CA1) (NNS synapses))) (, ,) (NP (JJ long-term) (NN potentiation)) (VP (AUX was) (VP (VBN preserved) (PP (IN in) (NP (JJ BMC-transplanted) (NNS rats))) (PP (VBN compared) (PP (TO to) (NP (JJ Doc_20080419_1197_1206_Disease) (NNS controls)))))) (. .)))
20080419	8	(S1 (S (NP (DT The) (JJ donor-derived) (NNP GFP) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NNS cells)) (VP (AUX were) (ADVP (RB rarely)) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (JJ transplanted) (JJ Doc_20080419_1296_1305_Disease) (NNS rats))))))) (. .)))
20080419	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NNS BMCs)))) (VP (MD can) (VP (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ chronic) (NNP Doc_20080419_1386_1394_Disease))))) (, ,) (VP (VB reduce) (NP (NN Doc_20080419_1403_1416_Disease))) (, ,) (CC and) (VP (VB influence) (NP (NP (DT the) (NN reorganization)) (PP (IN of) (NP (DT the) (JJ hippocampal) (JJ neuronal) (NN network))))))) (. .)))
20080983	0	(S1 (NP (NP (JJ Normalizing) (NNS effects)) (PP (IN of) (NP (NNP Doc_20080983_23_32_Chemical))) (PP (IN on) (NP (NP (NN sleep)) (PP (IN in) (NP (JJ chronic) (JJ Doc_20080983_53_60_Chemical) (NNS users))))) (. .)))
20080983	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ morning-dosed) (NNP Doc_20080983_157_166_Chemical))) (PP (IN on) (NP (NN sleep))))) (CC and) (VP (VB Doc_20080983_180_198_Disease) (PP (IN in) (NP (JJ chronic) (JJ Doc_20080983_210_217_Chemical) (NNS users)))))))) (. .)))
20080983	2	(S1 (S (NP (CD Twenty) (JJ Doc_20080983_240_247_Chemical-dependent) (NNS participants)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (NNP Doc_20080983_305_314_Chemical)) (, ,) (NP (NP (CD 400) (NNS mg)) (PRN (-LRB- -LRB-) (NP (NNP N=10)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP N=10)) (-RRB- -RRB-)))) (NP (DT every) (NN morning)) (PP (IN at) (NP (CD 7:30) (RB a.m.))) (PP (IN for) (NP (NP (CD 16) (NNS days)) (PP (IN in) (NP (DT an) (JJ inpatient) (, ,) (JJ double-blind) (JJ randomized) (NN trial)))))))))) (. .)))
20080983	3	(S1 (S (NP (NNS Participants)) (VP (VBD underwent) (NP (JJ polysomnographic) (NN sleep) (NNS recordings)) (PP (IN on) (NP (NNS days))) (NP (NP (QP (CD 1) (TO to) (CD 3))) (, ,) (NP (QP (CD 7) (TO to) (CD 9))) (, ,) (CC and) (NP (NP (QP (CD 14) (TO to) (CD 16))) (PRN (-LRB- -LRB-) (NP (NP (JJ first) (, ,) (ADJP (JJ second) (, ,) (CC and) (JJ third)) (NNS weeks)) (PP (IN of) (NP (NN abstinence)))) (-RRB- -RRB-))))) (. .)))
20080983	4	(S1 (S (NP (DT The) (JJ Multiple) (NNP Sleep) (NNP Latency) (NN Test)) (VP (AUX was) (VP (VBN performed) (PP (IN at) (NP (NP (CD 11:30) (RB a.m.)) (, ,) (NP (CD 2:00) (RB p.m.)) (, ,) (CC and) (NP (CD 4:30) (RB p.m.)))) (PP (IN on) (NP (NNS days))) (NP (NP (CD 2)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 15))))) (. .)))
20080983	5	(S1 (S (PP (IN For) (NP (NP (NN comparison)) (PP (IN of) (NP (NN sleep) (NN architecture) (NNS variables))))) (, ,) (NP (CD 12) (JJ healthy) (NN comparison) (NNS participants)) (VP (VBD underwent) (NP (NP (DT a) (JJ single) (NN night)) (PP (IN of) (NP (JJ experimental) (NN polysomnography))) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NP (CD 1) (NN night)) (PP (IN of) (NP (NN accommodation) (NN polysomnography))))))))) (. .)))
20080983	6	(S1 (S (NP (NP (JJ Progressive) (NN abstinence)) (PP (IN from) (NP (NNP Doc_20080983_919_926_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBG worsening)) (PP (IN of) (NP (DT all) (JJ measured) (JJ polysomnographic) (NN sleep) (NNS outcomes))))))) (. .)))
20080983	7	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN placebo)))) (, ,) (NP (NNP Doc_20080983_1029_1038_Chemical)) (VP (VBD decreased) (NP (NP (JJ nighttime) (NN sleep) (NN latency)) (CC and) (NP (VBN increased) (JJ slow-wave) (NN sleep) (NN time))) (PP (IN in) (NP (JJ Doc_20080983_1111_1118_Chemical-dependent) (NNS participants)))) (. .)))
20080983	8	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_20080983_1157_1166_Chemical)))) (VP (VP (VBD interacted) (PP (IN with) (NP (DT the) (NN abstinence) (NN week)))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJR longer) (JJ total) (NN sleep) (NN time)) (CC and) (NP (JJR shorter) (NN REM) (NN sleep) (NN latency)))) (PP (IN in) (NP (NP (DT the) (JJ third) (NN week)) (PP (IN of) (NP (NN abstinence)))))))) (. .)))
20080983	9	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ slow-wave) (NN sleep) (NN time)) (, ,) (NP (JJ total) (NN sleep) (NN time)) (, ,) (CC and) (NP (NP (NN sleep) (NN latency)) (PP (IN in) (NP (NNP Doc_20080983_1389_1396_Chemical-dependent)))) (CC and) (NP (JJ healthy) (NNS participants))))) (VP (VBD revealed) (NP (NP (DT a) (JJ normalizing) (NN effect)) (PP (IN of) (NP (NNP Doc_20080983_1465_1474_Chemical))) (PP (IN in) (NP (JJ Doc_20080983_1478_1485_Chemical-dependent) (NNS participants))))) (. .)))
20080983	10	(S1 (S (NP (NN Doc_20080983_1510_1519_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (JJ daytime) (NN sleep) (NN latency))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT the) (JJ Multiple) (NNP Sleep) (NNP Latency) (NN Test)) (, ,) (CC and) (NP (NP (DT a) (ADJP (RB nearly) (JJ significant)) (NN decrease)) (PP (IN in) (NP (JJ subjective) (NN Doc_20080983_1669_1687_Disease))))))))))) (. .)))
20080983	11	(S1 (S (NP (JJ Morning-dosed) (NNP Doc_20080983_1716_1725_Chemical)) (VP (VP (VBZ promotes) (NP (JJ nocturnal) (NN sleep))) (, ,) (VP (VBZ normalizes) (NP (NN sleep) (NN architecture))) (, ,) (CC and) (VP (VBZ decreases) (NP (NP (NN Doc_20080983_1797_1815_Disease)) (PP (IN in) (NP (JJ abstinent) (JJ Doc_20080983_1829_1836_Chemical) (NNS users)))))) (. .)))
20080983	12	(S1 (S (NP (DT These) (NNS effects)) (VP (MD may) (VP (AUX be) (ADJP (JJ relevant)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_20080983_1894_1901_Chemical) (NN dependence))))))) (. .)))
20084309	0	(S1 (NP (NP (NP (NN Safety)) (PP (IN of) (NP (JJ transesophageal) (NN echocardiography))) (PP (IN in) (NP (NNS adults)))) (: :) (NP (NP (NN study)) (PP (IN in) (NP (DT a) (JJ multidisciplinary) (NN hospital)))) (. .)))
20084309	1	(S1 (S (NP (NN TEE)) (VP (AUX is) (NP (NP (NP (DT a) (JJ semi-invasive) (NN tool)) (VP (ADVP (RB broadly)) (VBN used))) (CC and) (NP (NP (PRP$ its) (NN utilization)) (VP (VBN associated) (S (VP (TO to) (VP (VB sedatives) (SBAR (S (NP (NNS drugs)) (VP (MD might) (S (VP (TO to) (VP (VB affect) (NP (DT the) (NN procedure) (NN safety))))))))))))))) (. .)))
20084309	2	(S1 (FRAG (S (VP (TO to) (VP (VB analyze) (NP (NP (NNS aspects)) (PP (IN of) (NP (NP (NN TEE) (NN safety)) (VP (VBN associated) (PP (TO to) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NP (NNP Doc_20084309_303_312_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_314_316_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20084309_322_332_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_334_336_Chemical)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NNS variables)) (PP (IN on) (NP (DT the) (NN event) (NN rate))))))))))))))) (. .)))
20084309	3	(S1 (NP (NP (JJ prospective) (NN study)) (PP (IN with) (NP (NP (CD 137) (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (VBD underwent) (NP (NN TEE)) (PP (IN with) (NP (NP (NNP Doc_20084309_469_471_Chemical)) (VP (VBN associated) (PP (TO to) (NP (JJ moderate) (NN sedation))))))))))) (. .)))
20084309	4	(S1 (S (S (NP (PRP We)) (VP (VBD analyzed) (NP (DT the) (JJ following) (NNS events)))) (: :) (S (NP (NNS complications)) (VP (VBD related) (PP (PP (IN with) (NP (DT the) (JJ topical) (NN anesthesia))) (, ,) (PP (IN with) (NP (JJ Doc_20084309_595_597_Chemical) (NN use))) (CC and) (PP (IN with) (NP (DT the) (NN procedure)))))) (. .)))
20084309	5	(S1 (S (S (NP (JJ Uni-) (CC and) (JJ multivariate) (NNS analyses)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT the) (JJ clinical) (NNS variables)))))))))) (: :) (S (NP (NP (NN age) (, ,) (NN sex) (, ,) (NNP Doc_20084309_726_732_Disease) (, ,) (NNP Doc_20084309_734_748_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_750_752_Disease)) (-RRB- -RRB-)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (NN test)))) (, ,)) (NP (NP (NP (NNP Doc_20084309_777_797_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_799_801_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NNP Doc_20084309_811_813_Chemical) (NN dose)))) (. .)))
20084309	6	(S1 (S (NP (NP (DT All) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 65+/-16) (NNS yrs)) (: ;) (NP (ADJP (CD 58) (NN %)) (NNS males))) (-RRB- -RRB-))) (VP (VBD finished) (NP (DT the) (NN examination))) (. .)))
20084309	7	(S1 (S (NP (NP (DT The) (JJ mean) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_20084309_911_913_Chemical)) (CC and) (NP (NNP Doc_20084309_918_920_Chemical))))) (VP (AUX were) (NP (NP (CD 4.3+/-1.9) (NN mg)) (CC and) (NP (CD 0.28+/-0.2) (NN mg))) (, ,) (ADVP (RB respectively))) (. .)))
20084309	8	(S1 (S (NP (NP (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (NN examination)))) (CC and) (NP (DT the) (JJ mean) (NN ejection) (NN fraction))) (PRN (-LRB- -LRB-) (NP (NNP EF)) (-RRB- -RRB-))) (VP (AUX were) (NP (NP (CD 16.4+/-6.1) (NNS minutes)) (CC and) (NP (CD 60+/-9) (NN %))) (, ,) (ADVP (RB respectively))) (. .)))
20084309	9	(S1 (S (S (NP (NP (JJ Mild) (NNP Doc_20084309_1096_1103_Disease)) (PRN (-LRB- -LRB-) (NP (CD SO2<90) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN event)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))))) (: ;) (S (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD presented) (NP (NP (JJ transient) (NNP Doc_20084309_1191_1198_Disease) (ADJP (JJ due) (PP (TO to) (NP (JJ upper) (NNP Doc_20084309_1212_1230_Disease))) (PP (IN by) (NP (NP (NN probe) (NN introduction)) (CC and) (NP (NP (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 5.8) (NN %)) (-RRB- -RRB-)))))) (JJ due)) (PP (TO to) (NP (NNP Doc_20084309_1273_1280_Disease))) (VP (VBD caused) (PP (IN by) (NP (NNP Doc_20084309_1291_1293_Chemical) (NN use))))))) (. .)))
20084309	10	(S1 (S (NP (NP (JJ Transient) (NNP Doc_20084309_1309_1320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SAP<90mmHg)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 0.7) (NN %)) (-RRB- -RRB-))))) (. .)))
20084309	11	(S1 (S (NP (DT The) (JJ multivariate) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NP (JJ severe) (NNP Doc_20084309_1409_1411_Disease)) (, ,) (NP (NP (NNP Doc_20084309_1413_1415_Disease)) (PRN (-LRB- -LRB-) (NP (CD EF<45) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_20084309_1443_1445_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP >5mg)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NNS events)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))))))))) (. .)))
20084309	12	(S1 (S (S (NP (DT The) (NN EF)) (VP (AUX was) (NP (CD 40) (NN %)) (, ,) (PP (IN in) (NP (NP (NP (DT the) (NN group)) (PP (IN with) (NP (NNP Doc_20084309_1526_1528_Disease)))) (CC and) (NP (NP (CD 44) (NN %)) (PP (IN in) (NP (NP (DT the) (NN group)) (PP (IN with) (NP (JJ severe) (NN Doc_20084309_1562_1564_Disease)))))))))) (CC and) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (NP (NP (DT a) (NN factor)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NNS events)) (PP (IN in) (NP (DT the) (JJ last) (NN group)))))))))) (. .)))
20084309	13	(S1 (S (NP (NP (NN TEE)) (PP (IN with) (NP (NN sedation)))) (VP (VBZ presents) (NP (NP (DT a) (JJ low) (NN rate)) (PP (IN of) (NP (NNS events))))) (. .)))
20084309	14	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ severe) (NNS events)))) (CC and) (S (NP (EX there)) (VP (AUX was) (NP (DT no) (NN need) (S (VP (TO to) (VP (VB interrupt) (NP (DT the) (NNS examinations)))))))) (. .)))
2008831	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ direct) (NN intracoronary) (NN administration)) (PP (IN of) (NP (NNP Doc_2008831_49_65_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (CC and) (IN without) (NP (NNP Doc_2008831_95_109_Disease))))))) (. .)))
2008831	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN intracoronary) (NN administration)) (PP (IN of) (NP (NNP Doc_2008831_158_174_Chemical)))))) (VP (AUX were) (VP (VBN studied) (PP (PP (IN in) (NP (NP (NP (CD 21) (NNS patients)) (PP (IN with) (NP (NNP Doc_2008831_208_222_Disease)))) (CC and) (NP (NP (CD 22) (NNS patients)) (PP (IN with) (NP (JJ atypical) (NNP Doc_2008831_253_263_Disease)))))) (CC and) (PP (IN in) (NP (NP (NNS others)) (PP (IN without) (NP (NP (NNP Doc_2008831_286_301_Disease)) (PRN (-LRB- -LRB-) (NP (NN control) (NN group)) (-RRB- -RRB-))))))))) (. .)))
2008831	2	(S1 (S (NP (NN Doc_2008831_319_335_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB continuously)) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (QP (NP (CD 10) (NN micrograms/min)) (IN up) (TO to) (CD 50)) (NNS micrograms))))))) (. .)))
2008831	3	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NNP Doc_2008831_439_453_Disease))))) (, ,) (NP (NNP Doc_2008831_455_469_Disease)) (VP (AUX was) (VP (VBN provoked) (PP (IN at) (NP (NP (DT a) (JJ mean) (NN dose)) (PP (IN of) (NP (NP (CD 28) (JJ +/-) (CD 13) (NNS micrograms)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (-RRB- -RRB-)))))))) (. .)))
2008831	4	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (NP (NP (DT neither) (JJ ischemic) (NNP ST) (NN change)) (CC nor) (NP (VBN localized) (NN Doc_2008831_599_604_Disease))) (VP (VBD occurred)) (. .)))
2008831	5	(S1 (S (NP (NP (DT The) (JJ basal) (NN tone)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ left) (JJ coronary) (NN artery))))))) (. .)))
2008831	6	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (NP (NN vasoconstriction)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ left) (JJ coronary) (NN artery))))))) (. .)))
2008831	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (JJ Doc_2008831_877_882_Disease) (NN provocation) (NNS tests)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP use) (NP (NP (DT an) (JJ intracoronary) (NN injection)) (PP (IN of) (NP (NP (DT a) (ADJP (RB relatively) (JJ low)) (NN dose)) (PP (IN of) (NP (NNP Doc_2008831_967_983_Chemical))))))))) (, ,)) (VP (AUX have) (NP (NP (DT a) (JJ high) (NN sensitivity)) (PP (IN in) (NP (NNP Doc_2008831_1012_1026_Disease)))))) (CC and) (S (NP (NP (DT the) (NN vasoreactivity)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))) (VP (MD may) (VP (AUX be) (ADJP (JJR greater) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ other) (JJ coronary) (NNS arteries)))))))))))) (. .)))
20098969	0	(S1 (NP (NP (NP (JJ Oral) (NNS manifestations)) (PP (IN of) (NP (`` ``) (NNP Doc_20098969_24_34_Disease) ('' '')))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
20098969	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (NP (DT the) (NN documentation)) (PP (IN of) (NP (DT this) (JJ clinical) (NN case)))))) (VP (AUX is) (S (VP (TO to) (VP (VB make) (NP (NP (NP (NNS clinicians)) (ADJP (JJ aware) (PP (IN of) (`` ``) (NP (NNP Doc_20098969_140_150_Disease)) ('' '')))) (CC and) (NP (NP (DT the) (JJ medical) (NNS risks)) (VP (VBN associated) (PP (IN with) (NP (DT this) (JJ serious) (NN condition)))))))))) (. .)))
20098969	2	(S1 (S (NP (NN Doc_20098969_226_241_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB very) (JJ addictive)) (, ,) (JJ powerful) (NN stimulant)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ increases) (NP (ADJP (JJ wakefulness) (CC and) (JJ physical)) (NN activity))) (CC and) (VP (MD can) (VP (VB produce) (NP (NP (JJ other) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20098969_369_389_Disease)) (, ,) (NP (NNP Doc_20098969_391_403_Disease)) (, ,) (NP (NNP Doc_20098969_405_419_Disease)) (, ,) (CC and) (NP (NNP Doc_20098969_425_441_Disease)))))))))))) (. .)))
20098969	3	(S1 (S (NP (NP (JJ Dental) (NNS patients)) (VP (VBG abusing) (NP (NNP Doc_20098969_467_482_Chemical)))) (VP (MD can) (VP (VB present) (PP (IN with) (NP (NP (NP (JJ poor) (JJ oral) (NN hygiene)) (, ,) (NP (NP (NNP Doc_20098969_519_529_Disease)) (, ,) (NP (NP (JJ rampant) (NNP Doc_20098969_539_545_Disease)) (PRN (-LRB- -LRB-) (`` ``) (NP (NNP Doc_20098969_548_558_Disease)) ('' '') (-RRB- -RRB-)))) (, ,)) (CC and) (NP (JJ excessive) (NN Doc_20098969_576_586_Disease)))))) (. .)))
20098969	4	(S1 (S (NP (NP (JJ Oral) (NN rehabilitation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG using) (NP (NNP Doc_20098969_626_641_Chemical)))))) (VP (MD can) (VP (AUX be) (ADJP (JJ challenging)))) (. .)))
20098969	5	(S1 (NP (NP (NN CASE) (NN DESCRIPTION)) (: :) (NP (NP (DT A) (JJ 30-year-old) (NNP Caucasian) (NN woman)) (VP (VBN presented) (PP (IN with) (NP (NP (JJ dental) (NNP Doc_20098969_732_736_Disease)) (, ,) (NP (NNP Doc_20098969_738_748_Disease)) (, ,) (CC and) (NP (JJ self-reported) (JJ poor) (NNS esthetics)))))) (. .)))
20098969	6	(S1 (S (NP (NP (DT A) (JJ comprehensive) (NN examination)) (PP (VBG including) (NP (NP (PRP$ her) (JJ medical) (NN history)) (, ,) (NP (JJ panoramic) (NN radiograph)) (, ,) (CC and) (NP (JJ intraoral) (NN examination))))) (VP (VBD revealed) (NP (NP (CD 19) (NNP Doc_20098969_903_918_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (RB not) (ADJP (RB very) (JJ common)) (PP (IN for) (NP (DT a) (JJ healthy) (NN adult)))))))) (. .)))
20098969	7	(S1 (S (NP (PRP She)) (VP (VP (VBD reported) (NP (NP (PRP$ her) (NN use)) (PP (IN of) (NP (NNP Doc_20098969_990_1005_Chemical)))) (PP (IN for) (NP (CD five) (NNS years)))) (CC and) (VP (AUX had) (RB not) (VP (VBN experienced) (NP (DT any) (JJ major) (NN Doc_20098969_1055_1071_Disease)) (SBAR (IN before) (S (NP (PRP she)) (VP (VBD started) (S (VP (VBG using) (NP (DT the) (NN drug)))))))))) (. .)))
20098969	8	(S1 (S (NP (NP (NP (DT The) (NN patient) (POS 's)) (JJ medical) (CC and) (JJ dental) (NNS histories)) (PP (IN along) (PP (IN with) (NP (JJ radiographic) (CC and) (JJ clinical) (NNS findings))))) (VP (VBP lead) (PP (TO to) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (`` ``) (NP (NNP Doc_20098969_1229_1239_Disease)))))) (. .) ('' '')))
20098969	9	(S1 (S (SBAR (IN Although) (S (NP (NP (CD three) (JJ different) (JJ dental) (NN treatment) (NNS modalities)) (PRN (-LRB- -LRB-) (ADVP (RB either)) (ADJP (ADJP (JJ conventional)) (CC or) (ADJP (JJ implant-supported))) (-RRB- -RRB-))) (VP (AUX have) (VP (AUX been) (VP (VBN offered) (PP (TO to) (NP (DT the) (NN patient))) (PP (IN since) (NP (NNP August) (CD 2007)))))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (VB initiate) (NP (DT any) (NN treatment)))))) (. .)))
20098969	10	(S1 (NP (NP (JJ CLINICAL) (NN SIGNIFICANCE)) (: :) (S (NP (NP (DT This) (JJ clinical) (NN case)) (VP (VBG showing) (NP (NP (JJ oral) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_20098969_1510_1520_Disease)))))) (VP (AUX was) (VP (VBN presented) (S (VP (TO to) (VP (VB help) (S (NP (JJ dental) (NNS practitioners)) (VP (VB recognize) (CC and) (VB manage) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (AUX be) (VP (VBG abusing) (NP (NN Doc_20098969_1613_1629_Chemical)))))))))))))))) (. .)))
20098969	11	(S1 (S (NP (JJ Dental) (NNS practitioners)) (ADVP (RB also)) (VP (MD may) (VP (AUX be) (ADJP (JJ skeptical) (PP (IN about) (NP (NP (DT the) (NN reliability)) (PP (IN of) (NP (NP (NN appointment)) (VP (VBG keeping) (PP (IN by) (NP (DT these) (NNS patients))))))))) (, ,) (SBAR (IN as) (S (NP (PRP they)) (ADVP (RB frequently)) (VP (VBP miss) (NP (PRP$ their) (NNS appointments)) (PP (IN without) (NP (JJ reasonable) (NN justification)))))))) (. .)))
20196116	0	(S1 (NP (NP (JJ Doc_20196116_0_16_Chemical) (JJ therapy-induced) (NN Doc_20196116_33_52_Disease)) (: :) (NP (NP (NN magnitude)) (, ,) (NP (NN profile)) (, ,) (NP (NN prognosis)) (, ,) (CC and) (NP (NP (NNS predictors)) (PP (IN of) (NP (NN outcome))))) (. .)))
20196116	1	(S1 (S (NP (NP (JJ Doc_20196116_112_128_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP ATT)) (-RRB- -RRB-))) (VP (VBD -associated) (SBAR (S (NP (NP (NNP Doc_20196116_154_173_Disease)) (PRN (-LRB- -LRB-) (NP (NN ATT-Doc_20196116_179_182_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT the) (JJ commonest) (JJ drug-induced) (NN Doc_20196116_214_217_Disease)) (PP (IN in) (NP (NNP South) (NNP Asia)))))))) (. .)))
20196116	2	(S1 (S (NP (NP (JJ Prospective) (NNS studies)) (PP (IN on) (NP (NN ATT-Doc_20196116_260_263_Disease)))) (VP (AUX are) (VP (VBG lacking))) (. .)))
20196116	3	(S1 (S (NP (DT The) (JJ current) (NN study)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NN magnitude)) (, ,) (NP (JJ clinical) (NN course)) (, ,) (NP (NN outcome)) (, ,) (CC and) (NP (JJ prognostic) (NNS factors))) (PP (IN in) (NP (NN ATT-Doc_20196116_390_393_Disease)))) (. .)))
20196116	4	(S1 (S (S (PP (PP (IN From) (NP (NNP January) (CD 1986))) (PP (TO to) (NP (NNP January) (CD 2009)))) (, ,) (NP (CD 1223) (JJ consecutive) (NNP Doc_20196116_447_450_Disease) (NNS patients)) (VP (AUX were) (VP (VBN evaluated)))) (: :) (S (NP (NP (NNP ATT)) (ADVP (RB alone))) (VP (AUX was) (NP (NP (DT the) (NN cause)) (PP (IN in) (NP (CD 70) (PRN (-LRB- -LRB-) (NP (CD 5.7) (NN %)) (-RRB- -RRB-)) (NNS patients)))))) (. .)))
20196116	5	(S1 (S (NP (NP (DT Another) (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 1.2) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (NN ATT)) (CC and) (NP (JJ simultaneous) (NN Doc_20196116_566_591_Disease)))) (. .)))
20196116	6	(S1 (S (PP (IN In) (NP (CD 44) (PRN (-LRB- -LRB-) (NP (CD 62.8) (NN %)) (-RRB- -RRB-)) (NNS patients))) (, ,) (NP (NNP ATT)) (VP (AUX was) (VP (VBN prescribed) (ADVP (RB empirically)) (PP (IN without) (NP (NP (JJ definitive) (NN evidence)) (PP (IN of) (NP (NNP Doc_20196116_679_691_Disease))))))) (. .)))
20196116	7	(S1 (S (S (NP (JJ ATT-Doc_20196116_697_700_Disease) (NNS patients)) (VP (AUX were) (ADJP (ADJP (JJR younger)) (PRN (-LRB- -LRB-) (NP (QP (CD 32.87) (CD -LSB-+/-15.8)) (JJ -RSB-) (NNS years)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (NP (CD 49)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (NP (NNS women)))) (. .)))
20196116	8	(S1 (S (S (NP (JJS Most)) (VP (AUX had) (NP (JJ hyperacute) (NN presentation)))) (: ;) (S (NP (DT the) (JJ median) (NNP Doc_20196116_826_833_Disease) (NNP Doc_20196116_834_848_Disease) (NN interval)) (VP (AUX was) (NP (CD 4.5) (-LRB- -LRB-) (NN 0-30) (-RRB- -RRB-) (NNS days)))) (. .)))
20196116	9	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NNP ATT))) (PP (IN before) (NP (NNP Doc_20196116_913_916_Disease)))) (VP (AUX was) (NP (CD 30) (-LRB- -LRB-) (CD 7-350) (-RRB- -RRB-) (NNS days))) (. .)))
20196116	10	(S1 (S (PP (IN At) (NP (NN presentation))) (, ,) (NP (JJ advanced) (NNP Doc_20196116_964_978_Disease) (CC and) (NNP Doc_20196116_983_997_Disease)) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (NP (NP (NP (CD 51)) (PRN (-LRB- -LRB-) (NP (CD 76) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 29)) (PRN (-LRB- -LRB-) (NP (CD 41.4) (NN %)) (-RRB- -RRB-)))) (NNS patients))) (, ,) (ADVP (RB respectively))) (. .)))
20196116	11	(S1 (NP (NNP Doc_20196116_1062_1084_Disease) (, ,) (NNP Doc_20196116_1086_1094_Disease) (, ,) (NNP Doc_20196116_1096_1105_Disease) (, ,) (S (CC and) (NP (NNP Doc_20196116_1111_1130_Disease)) (VP (AUX were) (VP (VBN documented) (PP (IN in) (NP (NP (NP (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 7.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 37.1) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD seven) (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-) (NNS patients)) (, ,) (ADVP (RB respectively)))))) (. .))))
20196116	12	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NP (NP (JJ Doc_20196116_1242_1253_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HEV)) (-RRB- -RRB-))) (CC and) (NP (JJ non-A) (JJ non-E-induced) (NN Doc_20196116_1290_1293_Disease))))) (, ,) (NP (JJ ATT-Doc_20196116_1299_1302_Disease) (NNS patients)) (VP (AUX had) (NP (ADJP (RB nearly) (JJ similar)) (NNS presentations)) (PP (IN except) (PP (IN for) (NP (NP (NP (JJR older) (NN age)) (CC and) (NP (JJR less) (NN elevation))) (PP (IN of) (NP (NN liver) (NNS enzymes))))))) (. .)))
20196116	13	(S1 (S (S (NP (NP (DT The) (NN mortality) (NN rate)) (PP (IN among) (NP (NNS patients))) (PP (IN with) (NP (NN ATT-Doc_20196116_1446_1449_Disease)))) (VP (AUX was) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (NP (CD 67.1) (NN %)) (, ,) (NP (NNP n) (SYM =) (CD 47))) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (QP (RB only) (CD 23)) (PRN (-LRB- -LRB-) (NP (CD 32.9) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (VBD recovered) (PP (IN with) (NP (JJ medical) (NN treatment))))) (. .)))
20196116	14	(S1 (S (PP (IN In) (NP (NN multivariate) (NN analysis))) (, ,) (NP (CD three) (NNS factors)) (ADVP (RB independently)) (VP (VBD predicted) (NP (NP (NN mortality)) (: :) (NP (NP (NP (JJ serum) (NNP Doc_20196116_1620_1629_Chemical)) (PRN (-LRB- -LRB-) (NP (CD >or=10.8) (NN mg/dL)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ prothrombin) (NN time) (PRN (-LRB- -LRB-) (NNP PT) (-RRB- -RRB-)) (NN prolongation)) (PRN (-LRB- -LRB-) (NP (CD >or=26) (NNS seconds)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN grade) (NNP III/IV) (NNP Doc_20196116_1718_1732_Disease)))) (PP (IN at) (NP (NN presentation)))) (. .)))
20196116	15	(S1 (S (NP (NN ATT-Doc_20196116_1766_1769_Disease)) (VP (VP (VBD constituted) (NP (NP (CD 5.7) (NN %)) (PP (IN of) (NP (NNP Doc_20196116_1790_1793_Disease)))) (PP (IN at) (NP (PRP$ our) (NN center)))) (CC and) (VP (AUX had) (NP (DT a) (JJ high) (NN mortality) (NN rate)))) (. .)))
20196116	16	(S1 (S (SBAR (IN Because) (S (NP (DT the) (NN mortality) (NN rate)) (VP (AUX is) (ADJP (RB so) (JJ high))))) (, ,) (NP (NP (VBG determining)) (SBAR (WHNP (WDT which) (NNS factors)) (S (VP (AUX are) (NP (NNS predictors)))))) (VP (AUX is) (ADJP (RBR less) (JJ important))) (. .)))
20196116	17	(S1 (S (NP (NP (DT A) (JJ high) (NN proportion)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (VP (VBN consumed) (NP (NN ATT)) (ADVP (RB empirically)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (VP (AUX been) (VP (VBN prevented))))))))) (. .)))
2024540	0	(S1 (NP (NP (NP (NP (NN Design)) (CC and) (NP (NN analysis))) (PP (IN of) (NP (DT the) (NN HYPREN-trial)))) (: :) (NP (NP (NN safety)) (PP (IN of) (NP (NNP Doc_2024540_51_60_Chemical) (CC and) (NNP Doc_2024540_65_73_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN treatment) (NN phase)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2024540_122_146_Disease)))))))) (. .)))
2024540	1	(S1 (S (PP (IN Since) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_2024540_174_220_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ adjunctive) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2024540_268_292_Disease))))))))) (, ,) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ severe) (NNP Doc_2024540_310_321_Disease))) (, ,) (PP (ADVP (RB especially)) (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NN treatment))))) (, ,)) (VP (AUX have) (ADVP (RB occasionally)) (VP (AUX been) (VP (VBN reported)))) (. .)))
2024540	2	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (DT the) (NNP Doc_2024540_426_439_Chemical) (NNP Doc_2024540_440_449_Chemical)))) (NP (DT a) (NN multicenter) (, ,) (VBN randomized) (, ,) (JJ Doc_2024540_477_485_Chemical-controlled) (NN trial))))) (VP (AUX was) (VP (VBN designed) (S (NP (DT that)) (VP (VBN compared) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ symptomatic) (NNP Doc_2024540_572_583_Disease)))) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NN treatment))))))))) (. .)))
2024540	3	(S1 (S (NP (NN Trial) (NN medication)) (VP (AUX was) (NP (QP (CD 2.5) (CD mg) (NN Doc_2024540_643_652_Chemical) (CC or) (CD 0.5)) (NN Doc_2024540_660_668_Chemical))) (. .)))
2024540	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (NP (NP (JJ 1210) (NNS inpatients)) (PP (IN with) (NP (NP (NNP New) (NNP York) (NNP Heart) (NNP Association)) (PRN (-LRB- -LRB-) (NP (NNP NYHA)) (-RRB- -RRB-)) (NP (JJ functional) (NN class) (NNP II)) (CC and) (NP (NNP III)))))) (. .)))
2024540	5	(S1 (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_2024540_790_799_Chemical)) (VP (VBD experienced) (ADVP (RB clinically) (CC and) (RB statistically) (ADVP (RB significantly) (RBR less))) (NP (JJ symptomatic) (NNP Doc_2024540_872_883_Disease)) (PRN (-LRB- -LRB-) (NP (CD 5.2) (NN %)) (-RRB- -RRB-)) (PP (IN than) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_2024540_922_930_Chemical))))))) (PRN (-LRB- -LRB-) (NP (CD 12.9) (NN %)) (-RRB- -RRB-)))))))) (. .)))
2024540	6	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recovered)) (. .)))
2024540	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2024540_1001_1010_Chemical)))) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated)))) (CC and) (S (NP (PRP it)) (VP (AUX is) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ unreasonable) (S (VP (TO to) (VP (VB restrict) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_2024540_1110_1119_Chemical)))) (PP (TO to) (NP (NNS inpatients))))))))))))) (. .)))
20470218	0	(S1 (S (VP (VB Doc_20470218_0_36_Disease) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_20470218_57_85_Disease))))) (PP (IN in) (NP (DT a) (JJ single) (JJ pediatric) (NN institution)))) (. .)))
20470218	1	(S1 (S (NP (NP (NN Doc_20470218_121_163_Disease)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NN childhood) (NNP Doc_20470218_194_222_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20470218_224_227_Disease)) (-RRB- -RRB-))))))) (VP (VBP remain) (NP (DT a) (JJ challenging) (JJ clinical) (NN problem))) (. .)))
20470218	2	(S1 (S (NP (NP (NN Outcome) (NN improvement)) (PP (IN with) (NP (ADJP (RBR more) (JJ intensive)) (NN chemotherapy)))) (VP (AUX has) (ADVP (RB significantly)) (VP (VBN increased) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ adverse) (NNS events)))))) (. .)))
20470218	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD analyzed) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20470218_432_458_Disease)))) (PP (IN during) (NP (NP (JJ Doc_20470218_466_469_Disease) (NN treatment)) (PP (IN in) (NP (DT a) (JJ single) (JJ pediatric) (NN institution))))) (, ,) (S (VP (VBG focusing) (PP (IN on) (NP (JJ clinical) (, ,) (ADJP (ADJP (JJ radiological)) (, ,) (CC and) (ADJP (JJ electrophysiological))) (NNS findings)))))) (. .)))
20470218	4	(S1 (S (NP (NN Exclusion) (NNS criteria)) (VP (VBD included) (NP (NNP CNS) (NNP Doc_20470218_618_639_Disease)) (PP (IN at) (NP (NP (NN diagnosis)) (, ,) (NP (JJ therapy-related) (NN Doc_20470218_670_691_Disease)) (, ,) (NP (JJ late-onset) (NN Doc_20470218_704_718_Disease)) (, ,) (CC or) (NP (JJ long-term) (NN Doc_20470218_733_755_Disease))))) (. .)))
20470218	5	(S1 (S (PP (IN During) (NP (DT a) (JJ 9-year) (NN period))) (, ,) (NP (PRP we)) (ADVP (RB retrospectively)) (VP (VBD collected) (NP (NP (CD 27) (JJ neurological) (NNS events)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (ADJP (RB as) (JJ many)) (NNS patients))) (, ,) (PP (IN from) (NP (NP (CD 253) (NNS children)) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (JJ Doc_20470218_894_897_Disease) (JJ front-line) (NN protocol))))))) (. .)))
20470218	6	(S1 (S (NP (NNS CNS) (NNS complications)) (VP (VBD included) (NP (NP (JJ posterior) (JJ reversible) (NN Doc_20470218_967_986_Disease) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20470218_1006_1012_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 5)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20470218_1022_1044_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)) (, ,) (NP (JJ high-dose) (NNP Doc_20470218_1064_1076_Chemical) (NNP Doc_20470218_1077_1085_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NP (NN syndrome)) (PP (IN of) (NP (NNP Doc_20470218_1107_1151_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ other) (JJ unclassified) (NNS events)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-))))) (. .)))
20470218	7	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS CNS) (NNS complications)) (VP (VP (AUX are) (NP (JJ frequent) (NNS events)) (PP (IN during) (NP (JJ Doc_20470218_1260_1263_Disease) (NN therapy)))) (, ,) (CC and) (VP (VBP require) (NP (NP (JJ rapid) (NN detection)) (CC and) (NP (JJ prompt) (NN treatment))) (S (VP (TO to) (VP (VB limit) (NP (JJ permanent) (NN damage))))))) (. .)))
20477932	0	(S1 (NP (NP (NP (JJ Doc_20477932_0_7_Chemical) (NNS causes)) (ADJP (JJ Doc_20477932_15_46_Disease) (PP (IN in) (NP (NNS rats))))) (: :) (NP (NP (NP (NN involvement)) (PP (IN of) (NP (JJ nuclear) (UCP (NN factor) (NN kappa) (NNP B) (CC and) (JJ oxidative)) (NN stress)))) (, ,) (CC and) (NP (NP (NN prevention)) (PP (IN by) (NP (NNP Doc_20477932_134_144_Chemical))))) (. .)))
20477932	1	(S1 (S (S (NP (JJ Different) (NNS mechanisms)) (VP (AUX have) (VP (AUX been) (VP (VBN suggested) (PP (IN for) (NP (NNP Doc_20477932_191_198_Chemical) (NNP Doc_20477932_199_207_Disease))) (PP (VBG including) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ oxidative) (NN stress))))))))) (CC but) (S (NP (NP (DT the) (NN association)) (PP (IN between) (NP (JJ oxidative) (NN status))) (PP (IN in) (NP (NP (DT the) (NN brain)) (CC and) (NP (JJ Doc_20477932_312_319_Chemical) (NN induced-behaviour))))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood)))) (. .)))
20477932	2	(S1 (S (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP NFkappaB)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT a) (NN sensor)) (PP (IN of) (NP (JJ oxidative) (NN stress))))) (CC and) (VP (VBZ participates) (PP (IN in) (NP (NP (NN memory) (NN formation)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (NN drug) (NN Doc_20477932_494_502_Disease)) (CC and) (NP (NN addiction) (NNS mechanisms))))))))))))) (. .)))
20477932	3	(S1 (S (ADVP (RB Therefore)) (NP (NP (NP (JJ NFkappaB) (NN activity)) (, ,) (NP (JJ oxidative) (NN stress)) (, ,) (NP (JJ neuronal) (JJ Doc_20477932_585_597_Chemical) (FW synthase) (PRN (-LRB- -LRB-) (NP (NN nNOS)) (-RRB- -RRB-)) (NN activity)) (, ,) (NP (JJ spatial) (NN learning)) (CC and) (NP (NN memory))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_20477932_677_687_Chemical)) (, ,) (NP (NP (DT a) (ADJP (RB previously) (VBN proposed)) (NN therapy)) (PP (IN for) (NP (NNP Doc_20477932_723_740_Disease)))) (, ,))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_20477932_785_792_Chemical) (NN administration))) (PP (IN in) (NP (NNS rats))))))) (. .)))
20477932	4	(S1 (S (NP (NN NFkappaB) (NN activity)) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (NP (NP (DT the) (JJ frontal) (NN cortex)) (PP (IN of) (NP (JJ Doc_20477932_874_881_Chemical) (VBN treated) (NNS rats)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (JJ Doc_20477932_907_910_Chemical) (NN concentration)) (CC and) (NP (JJ Doc_20477932_929_940_Chemical) (NN peroxidase) (NN activity))) (PP (IN in) (NP (DT the) (NN hippocampus)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN nNOS) (NN activity)) (PP (IN in) (NP (DT the) (NN hippocampus)))) (VP (AUX was) (VP (VBN increased))))))) (. .)))
20477932	5	(S1 (S (NP (NP (NN Memory) (NN retrieval)) (PP (IN of) (NP (NP (NNS experiences)) (VP (VBN acquired) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_20477932_1087_1094_Chemical) (NN administration)))))))) (VP (AUX was) (VP (VP (VBN impaired)) (CC and) (VP (ADVP (RB negatively)) (VBN correlated) (PP (IN with) (NP (NN NFkappaB) (NN activity))) (PP (IN in) (NP (DT the) (JJ frontal) (NN cortex)))))) (. .)))
20477932	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN learning)) (PP (IN of) (NP (JJ new) (NNS tasks)))) (VP (VP (AUX was) (VP (VBN enhanced))) (CC and) (VP (VBD correlated) (PP (IN with) (NP (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN nNOS) (NN activity)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN of) (NP (JJ Doc_20477932_1313_1324_Chemical) (NN peroxidase)))))))) (. .)))
20477932	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NN evidence)) (PP (IN for) (NP (NP (NP (DT a) (JJ possible) (JJ mechanistic) (NN role)) (PP (IN of) (NP (NN oxidative)))) (CC and) (NP (NP (NP (JJ nitrosative) (NN stress)) (CC and) (NP (NN NFkappaB))) (PP (IN in) (NP (NP (DT the) (NNS alterations)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20477932_1479_1486_Chemical)))))))))) (. .)))
20477932	8	(S1 (S (NP (NN Doc_20477932_1488_1498_Chemical)) (VP (VBD prevented) (SBAR (S (NP (PDT all) (DT the) (NNS alterations)) (VP (VBD observed)))) (, ,) (S (VP (VBG showing) (NP (JJ novel) (JJ neuroprotective) (NNS properties))))) (. .)))
20520283	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NNP Doc_20520283_23_32_Chemical))) (PP (IN in) (NP (NP (DT a) (ADJP (JJ placebo-) (CC and) (JJ Doc_20520283_51_62_Chemical-controlled)) (NN trial)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (NN exacerbation)) (PP (IN of) (NP (NNP Doc_20520283_119_132_Disease))))))))) (. .)))
20520283	1	(S1 (S (NP (NNP Doc_20520283_134_143_Chemical)) (VP (AUX is) (VP (VBN approved) (PP (IN by) (NP (DT the) (NNP Food) (CC and) (NNP Drugs) (NNP Administration))) (PP (IN in) (NP (NP (NNS adults)) (PP (PP (IN for) (NP (NP (JJ acute) (NN treatment)) (PP (IN of) (NP (NNP Doc_20520283_226_239_Disease))))) (CC or) (PP (IN of) (NP (NP (UCP (NNP Doc_20520283_246_251_Disease) (CC or) (JJ mixed)) (NNS episodes)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_20520283_286_304_Disease))) (PP (IN with))))) (CC or) (PP (IN without) (NP (JJ Doc_20520283_321_330_Disease) (NNS features)))))))) (. .)))
20520283	2	(S1 (S (PP (IN In) (NP (DT a) (JJ double-blind) (JJ 6-week) (NN trial))) (, ,) (NP (NP (CD 458) (NNS patients)) (PP (IN with) (NP (JJ acute) (NNP Doc_20520283_397_410_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (JJ fixed-dose) (NN treatment)) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_463_472_Chemical)) (PP (IN at) (NP (CD 5) (CD mg) (RB twice) (JJ daily) (-LRB- -LRB-) (NN BID) (-RRB- -RRB-)))) (, ,) (NP (NP (NNP Doc_20520283_500_509_Chemical)) (PP (IN at) (NP (NP (QP (CD 10) (CD mg)) (NN BID)) (, ,) (NP (NN placebo)) (, ,)))) (CC or) (NP (NP (NNP Doc_20520283_536_547_Chemical)) (PP (IN at) (NP (NP (QP (CD 4) (CD mg)) (NN BID)) (PRN (-LRB- -LRB-) (S (VP (TO to) (VP (VB verify) (NP (JJ assay) (NN sensitivity))))) (-RRB- -RRB-))))))))))) (. .)))
20520283	3	(S1 (FRAG (PP (IN With) (NP (NP (JJ last) (NNS observations)) (VP (VBN carried) (ADVP (RB forward)) (PRN (-LRB- -LRB-) (NN LOCF) (-RRB- -RRB-) (, ,)) (VP (VB mean) (NP (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NN Scale)) (NP (JJ total) (NN score) (NNS reductions)) (PP (IN from) (NP (NN baseline))) (S (VP (TO to) (VP (VB endpoint) (SBAR (S (VP (AUX were) (ADJP (ADJP (ADJP (RB significantly) (JJR greater) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_761_770_Chemical)) (PP (IN at) (NP (QP (CD 5) (CD mg)) (NN BID))) (PRN (-LRB- -LRB-) (NP (CD -16.2)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_20520283_795_806_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD -15.4)) (-RRB- -RRB-))) (PP (IN than) (NP (NN placebo)))))))))))))) (PRN (-LRB- -LRB-) (NP (CD -10.7)) (: ;) (NP (DT both) (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)) (: ;) (S (S (VP (VBG using) (NP (JJ mixed) (NN model)) (PP (IN for) (NP (NP (VBN repeated) (NNS measures)) (PRN (-LRB- -LRB-) (JJ MMRM) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNS changes)) (PP (IN at) (NP (NN day) (CD 42)))) (VP (AUX were) (ADJP (ADJP (ADJP (RB significantly) (JJR greater) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_950_959_Chemical)) (PP (IN at) (NP (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)) (PRN (-LRB- -LRB-) (NP (CD -21.3) (CC and) (CD -19.4)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))))) (CC and) (NP (NNP Doc_20520283_1015_1026_Chemical))))) (PRN (-LRB- -LRB-) (CD -20.0) (-RRB- -RRB-))) (PP (IN than) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD -14.6)) (: ;) (NP (DT all) (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
20520283	4	(S1 (S (S (PP (IN On) (NP (DT the) (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NNP Scale) (JJ positive) (NN subscale))) (, ,) (NP (DT all) (NNS treatments)) (VP (AUX were) (ADJP (JJ superior) (PP (TO to) (NP (NP (NN placebo)) (PP (IN with) (NP (NNP LOCF) (CC and) (NNP MMRM)))))))) (: ;) (S (NP (NP (NNP Doc_20520283_1194_1203_Chemical)) (PP (IN at) (NP (CD 5) (JJ mg) (NN BID)))) (VP (AUX was) (ADJP (JJ superior) (PP (TO to) (NP (NN placebo)))) (PP (PP (IN on) (NP (NP (DT the) (JJ negative) (NN subscale)) (PP (IN with) (NP (NN MMRM))))) (CC and) (PP (IN on) (NP (NP (DT the) (JJ general) (NN psychopathology) (NN subscale)) (PP (IN with) (NP (NNP LOCF) (CC and) (NNP MMRM)))))))) (. .)))
20520283	5	(S1 (S (NP (NP (JJ Treatment-related) (JJ adverse) (NNS events)) (PRN (-LRB- -LRB-) (NP (NNP AEs)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 44) (NN %)) (CC and) (NP (CD 52) (NN %)) (, ,) (NP (CD 57) (NN %)) (, ,) (CC and) (NP (NP (CD 41) (NN %)) (PP (IN of) (NP (NP (NP (DT the) (NNP Doc_20520283_1423_1432_Chemical)) (PP (IN at) (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)))) (, ,) (NP (NNP Doc_20520283_1453_1464_Chemical)) (, ,) (CC and) (NP (NN placebo) (NNS groups))))) (, ,) (ADVP (RB respectively))))) (. .)))
20520283	6	(S1 (S (NP (NNP Doc_20520283_1500_1523_Disease)) (VP (VBD reported) (SBAR (IN as) (S (NP (NNS AEs)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 15) (NN %)) (CC and) (NP (CD 18) (NN %)) (, ,) (NP (CD 34) (NN %)) (, ,) (CC and) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NP (NP (DT the) (NNP Doc_20520283_1585_1594_Chemical)) (PP (IN at) (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)))) (, ,) (NP (NNP Doc_20520283_1615_1626_Chemical)) (, ,) (CC and) (NP (NN placebo) (NNS groups))))) (, ,) (ADVP (RB respectively)))))))) (. .)))
20520283	7	(S1 (S (PP (IN Across) (NP (DT all) (NNS groups))) (, ,) (NP (NP (QP (DT no) (RBR more) (IN than) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (ADJP (RB clinically) (JJ significant)) (NN weight) (NN change))) (. .)))
20520283	8	(S1 (S (S (NP (ADJP (NN Post) (FW hoc)) (NNS analyses)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN efficacy)) (VP (AUX was) (ADJP (JJ similar) (PP (IN with) (NP (NP (NNP Doc_20520283_1810_1819_Chemical)) (CC and) (NP (NNP Doc_20520283_1824_1835_Chemical)))))))))) (: ;) (S (NP (JJR greater) (NNS contrasts)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (NNS AEs)) (, ,) (ADVP (RB especially)) (NP (NNP Doc_20520283_1884_1907_Disease))))))) (. .)))
20528871	0	(S1 (S (VP (VB Salvage) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_20528871_21_31_Chemical)) (, ,) (NP (NNP Doc_20528871_33_42_Chemical)) (, ,) (CC and) (NP (NNP Doc_20528871_48_64_Chemical))))) (PP (IN in) (NP (JJ relapsed/refractory) (JJ paediatric) (NN Doc_20528871_99_142_Disease)))) (. .)))
20528871	1	(S1 (S (NP (NP (NP (DT A) (NN combination)) (PP (IN of) (NP (NP (CD 5) (NNP d)) (PP (IN of) (NP (NP (NNP Doc_20528871_168_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_180_184_Chemical)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (CD 5) (NNP d)) (PP (IN of) (NP (NP (NP (NNP Doc_20528871_198_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_209_211_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20528871_217_233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_235_238_Chemical)) (-RRB- -RRB-)))))))) (CC and) (NP (JJ prophylactic) (JJ intrathecal) (NN chemotherapy))) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (NN salvage) (NN therapy)) (PP (IN in) (NP (NP (CD seven) (NNS children)) (PP (IN with) (NP (ADJP (JJ refractory) (CC or) (JJ relapsed)) (NNP Doc_20528871_356_384_Disease))))))))) (. .)))
20528871	2	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ side) (NNS effects)) (ADJP (JJ attributable) (PP (TO to) (NP (DT the) (NNP Doc_20528871_435_439_Chemical))))) (VP (VBD included) (NP (NNP Grade) (CD 2) (CC and) (CD 3)) (UCP (JJ sensory) (CC and) (NN motor) (NNP Doc_20528871_481_491_Disease) (CC and) (NNP Doc_20528871_496_516_Disease))) (. .)))
20528871	3	(S1 (S (NP (NN Doc_20528871_518_541_Disease)) (VP (AUX was) (ADJP (ADJP (JJR greater) (PP (IN for) (NP (DT the) (NN combination)))) (PP (IN than) (NP (NP (NNP Doc_20528871_579_583_Chemical)) (ADVP (RB alone))))) (, ,) (SBAR (IN although) (S (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN neutrophil)) (CC and) (NP (NN platelet) (NN recovery))))) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (JJ other) (NN salvage) (NNS therapies)))))))) (. .)))
20528871	4	(S1 (S (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT some) (NN response)) (PP (TO to) (NP (DT the) (VBN combined) (NN therapy)))))) (CC and) (S (NP (NP (CD five)) (PP (IN of) (NP (DT the) (CD seven)))) (VP (VBD went) (PP (IN into) (NP (JJ complete) (NN remission))) (PP (IN after) (NP (NP (QP (CD one) (CC or) (CD two)) (NNS courses)) (PP (IN of) (NP (NNP Doc_20528871_827_831_Chemical/Doc_20528871_832_834_Chemical/Doc_20528871_835_838_Chemical))))))) (. .)))
20528871	5	(S1 (S (NP (PRP$ Our) (NN experience)) (VP (VBZ supports) (NP (NP (DT the) (NN safety)) (PP (IN of) (S (VP (VBG giving) (NP (NNP Doc_20528871_885_889_Chemical)) (PP (IN as) (NP (NP (NN salvage) (NN therapy)) (PP (IN in) (NP (NN synchrony))) (PP (IN with) (NP (NNP Doc_20528871_927_936_Chemical) (CC and) (NNP Doc_20528871_941_957_Chemical))))))))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_20528871_968_989_Disease)) (VP (MD must) (VP (AUX be) (VP (ADVP (RB closely)) (VBN monitored))))))) (. .)))
2054792	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_2054792_10_20_Chemical)))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ whole) (NN body) (NN Doc_2054792_46_58_Disease)) (PP (IN on) (NP (NP (NNP Doc_2054792_62_67_Disease)) (CC and) (NP (JJ normal) (NNS tissues))))))) (. .)))
2054792	1	(S1 (S (NP (NP (JJ Thermal) (NN enhancement)) (PP (IN of) (NP (NP (JJ Doc_2054792_111_121_Chemical-mediated) (NN antitumor) (NN activity)) (CC and) (NP (JJ normal) (NN tissue) (NN Doc_2054792_168_178_Disease)))) (PP (IN by) (NP (JJ whole) (NN body) (NN Doc_2054792_193_205_Disease)))) (VP (AUX were) (VP (VBN compared) (S (VP (VBG using) (NP (DT a) (NNP F344) (NN rat) (NN model)))))) (. .)))
2054792	2	(S1 (S (NP (NN Antitumor) (NN activity)) (VP (AUX was) (VP (VBN studied) (S (VP (VBG using) (NP (DT a) (JJ Doc_2054792_283_288_Disease) (NN growth) (NN delay) (NN assay)))))) (. .)))
2054792	3	(S1 (S (NP (NP (NP (JJ Acute) (JJ normal) (NN tissue) (NNP Doc_2054792_329_339_Disease)) (PRN (-LRB- -LRB-) (NP (FW i.e.)) (, ,) (NP (NP (NNP Doc_2054792_347_357_Disease)) (CC and) (NP (NNP Doc_2054792_362_378_Disease))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ late) (JJ normal) (NN tissue) (NNP Doc_2054792_403_413_Disease)) (PRN (-LRB- -LRB-) (NP (FW i.e.)) (, ,) (NP (NNP Doc_2054792_421_449_Disease)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN evaluated) (PP (PP (IN by) (NP (JJ functional/physiological) (NNS assays))) (CC and) (PP (IN by) (NP (JJ morphological) (NNS techniques)))))) (. .)))
2054792	4	(S1 (S (NP (NP (JJ Whole) (NN body) (NNP Doc_2054792_545_557_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NN min)) (PP (IN at) (NP (CD 41.5) (NNS degrees))) (X (SYM C))) (-RRB- -RRB-))) (VP (VBD enhanced) (NP (NP (DT both) (JJ Doc_2054792_600_610_Chemical-mediated) (NN antitumor) (NN activity)) (CC and) (NP (JJ toxic) (NN side) (NNS effects)))) (. .)))
2054792	5	(S1 (S (NP (DT The) (JJ thermal) (NN enhancement) (NN ratio)) (VP (VBD calculated) (SBAR (IN for) (S (NP (NN antitumor) (NN activity)) (VP (AUX was) (NP (CD 1.6)))))) (. .)))
2054792	6	(S1 (S (NP (NP (JJ Thermal) (NN enhancement) (NNS ratios)) (VP (VBN estimated) (PP (IN for) (NP (`` ``) (JJ acute) ('' '') (NN hematological) (NNS changes))))) (VP (AUX were) (NP (CD 1.3)) (, ,) (SBAR (IN whereas) (S (NP (DT those)) (VP (VBN estimated) (PP (IN for) (NP (NP (`` ``) (JJ late) ('' '') (NN damage)) (PRN (-LRB- -LRB-) (VP (VBN based) (PP (IN on) (NP (JJ morphological) (NNP Doc_2054792_883_908_Disease)))) (-RRB- -RRB-)) (VP (VBN varied) (PP (IN between) (NP (CD 2.4) (CC and) (CD 4.3)))))))))) (. .)))
2054792	7	(S1 (S (ADVP (RB Thus)) (, ,) (SBAR (IN while) (S (NP (JJ whole) (NN body) (NN Doc_2054792_961_973_Disease)) (VP (VBZ enhances) (NP (JJ Doc_2054792_983_993_Chemical-mediated) (NN antitumor) (NN effect))))) (, ,) (S (NP (JJ normal) (NN tissue) (NN Doc_2054792_1035_1043_Disease)) (VP (AUX is) (ADVP (RB also)) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ potential) (JJ therapeutic) (NN gain)) (PP (IN of) (NP (DT the) (VBN combined) (NN modality) (NN treatment)))) (VP (AUX is) (VP (VBN eroded)))) (. .)))
20588063	0	(S1 (NP (NP (NN Permeability)) (, ,) (NP (JJ ultrastructural) (NNS changes)) (, ,) (CC and) (NP (NP (NN distribution)) (PP (IN of) (NP (NN novel) (NNS proteins))) (PP (IN in) (NP (NP (DT the) (JJ glomerular) (NN barrier)) (PP (IN in) (NP (JJ early) (NNP Doc_20588063_109_134_Chemical) (NNP Doc_20588063_135_144_Disease)))))) (. .)))
20588063	1	(S1 (NP (NP (NNS BACKGROUND/AIMS)) (: :) (S (NP (PRP It)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear)) (SBAR (WHNP (WP what)) (S (VP (VBZ happens) (PP (IN in) (NP (DT the) (NN glomerulus))) (SBAR (WHADVP (WRB when)) (S (NP (NN Doc_20588063_219_230_Disease)) (VP (VBZ starts))))))))) (. .)))
20588063	2	(S1 (S (S (S (VP (VBG Using) (NP (NNP Doc_20588063_245_270_Chemical) (NNP Doc_20588063_271_280_Disease) (PRN (-LRB- -LRB-) (NP (NNP PAN)) (-RRB- -RRB-)) (NNS rats)))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (JJ early) (NN ultrastructural)) (CC and) (NP (NP (JJ permeability) (NNS changes)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ podocyte-associated) (NNS molecules)) (ADJP (JJ nephrin) (, ,) (JJ a-actinin) (, ,) (JJ dendrin)))))))))))) (, ,) (CC and) (S (ADVP (RB plekhh2)) (, ,) (NP (NP (DT the) (JJ last) (CD two)) (PP (IN of) (NP (WDT which)))) (VP (AUX were) (ADVP (RB only) (RB recently)) (VP (VBN discovered) (PP (IN in) (NP (NNS podocytes)))))) (. .)))
20588063	3	(S1 (S (S (VP (VBG Using) (NP (JJ immune) (NNS stainings)))) (, ,) (NP (JJ semiquantitative) (NN measurement)) (VP (AUX was) (VP (VBN performed) (PP (IN under) (NP (DT the) (NNP electron) (NN microscope))))) (. .)))
20588063	4	(S1 (S (NP (NN Permeability)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (JJ isolated) (NN kidney) (NN perfusion)) (PP (IN with) (NP (NNP tracers))))))) (. .)))
20588063	5	(S1 (S (NP (NP (JJ Possible) (NNS effects)) (PP (IN of) (NP (NN ACE) (NN inhibition)))) (VP (AUX were) (VP (VBN tested))) (. .)))
20588063	6	(S1 (S (PP (IN By) (NP (NN day) (CD 2))) (, ,) (NP (NP (DT some) (JJ patchy) (NN foot) (NN process) (NN effacement)) (, ,) (CC but) (NP (DT no) (NNP Doc_20588063_816_827_Disease)) (, ,)) (VP (VBD appeared)) (. .)))
20588063	7	(S1 (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN nephrin)))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (DT both) (JJ diseased) (CC and) (JJ normal) (NNS areas))))) (. .)))
20588063	8	(S1 (S (NP (DT The) (JJ other) (NNS proteins)) (VP (VBD showed) (NP (NP (JJ few) (NNS changes)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN limited) (PP (TO to) (NP (JJ diseased) (NNS areas))))))))) (. .)))
20588063	9	(S1 (S (PP (IN By) (NP (NN day) (CD 4))) (, ,) (S (NP (NN foot) (NN process) (NN effacement)) (VP (AUX was) (ADJP (JJ complete)))) (CC and) (S (NP (NNP Doc_20588063_1036_1047_Disease)) (VP (VBD appeared) (PP (IN in) (NP (NN parallel))) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NN size) (NN barrier) (NN damage))))))) (. .)))
20588063	10	(S1 (S (NP (NN Nephrin)) (VP (VBD decreased) (ADVP (RB further)) (, ,) (SBAR (IN while) (S (S (NP (NP (NN dendrin)) (CC and) (NP (NN plekhh2))) (ADVP (RB also)) (VP (VBD decreased))) (CC but) (S (NP (NN a-actinin)) (VP (VBD remained) (ADJP (JJ unchanged))))))) (. .)))
20588063	11	(S1 (S (NP (NN ACE) (NN inhibition)) (VP (AUX had) (NP (DT no) (JJ significant) (JJ protective) (NN effect))) (. .)))
20588063	12	(S1 (S (NP (NNP PAN) (NNS glomeruli)) (ADVP (RB already)) (VP (VBD showed) (NP (JJ significant) (NN pathology)) (PP (IN by) (NP (NN day) (CD 4))) (, ,) (PP (IN despite) (NP (ADJP (RB relatively) (JJ mild)) (NN Doc_20588063_1357_1368_Disease)))) (. .)))
20588063	13	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN preceded) (PP (IN by) (NP (JJ altered) (NN nephrin) (NN expression))) (, ,) (S (VP (VBG supporting) (NP (NP (PRP$ its) (JJ pivotal) (NN role)) (PP (IN in) (NP (JJ podocyte) (NNS morphology)))))))) (. .)))
20588063	14	(S1 (S (NP (NP (DT The) (JJ novel) (NNS proteins)) (VP (VBN dendrin) (CC and) (VBN plekhh2))) (VP (AUX were) (DT both) (VP (VBN reduced) (, ,) (PP (VBG suggesting) (NP (NP (NNS roles)) (PP (IN in) (NP (NNP PAN))))) (, ,) (SBAR (IN whereas) (S (NP (NN a-actinin)) (VP (AUX was) (ADJP (JJ unchanged))))))) (. .)))
20619828	0	(S1 (NP (NP (DT A) (NN novel)) (, ,) (NP (NP (JJ multiple) (NN symptom) (NN model)) (PP (IN of) (NP (NNP Doc_20619828_35_70_Disease))) (PP (IN in) (NP (NNS animals)))) (. .)))
20619828	1	(S1 (S (NP (NP (JJ Current) (NN animal) (NNS models)) (PP (IN of) (NP (NP (NNP Doc_20619828_120_149_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20619828_151_154_Disease)) (-RRB- -RRB-))))) (ADVP (RB typically)) (VP (VBP involve) (NP (NP (JJ acute) (, ,) (JJ drug-induced) (NN symptom) (NN provocation)) (CC or) (NP (NP (DT a) (JJ genetic) (NN association)) (PP (IN with) (NP (NP (NNS stereotypies)) (CC or) (NP (NN Doc_20619828_260_267_Disease))))))) (. .)))
20619828	2	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (JJ current) (NNS models)))) (VP (VBP demonstrate) (NP (JJ multiple) (JJ Doc_20619828_319_322_Disease-like) (NNS behaviors))) (. .)))
20619828	3	(S1 (S (NP (JJ Neonatal) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJ tricyclic) (NNP Doc_20619828_394_408_Chemical) (NNP Doc_20619828_409_421_Chemical)) (CC or) (NP (NP (NN vehicle)) (PP (IN between) (NP (NP (NNS days) (CD 9) (CC and) (CD 16)) (ADJP (ADJP (RB twice) (JJ daily)) (CC and) (ADJP (RB behaviorally) (VBN tested) (PP (IN in) (NP (NN adulthood)))))))))))) (. .)))
20619828	4	(S1 (S (NP (NP (JJ Doc_20619828_514_526_Chemical) (NN exposure)) (PP (IN in) (NP (JJ immature) (NNS rats)))) (VP (VBD produced) (NP (NP (JJ significant) (ADJP (JJ behavioral) (CC and) (JJ biochemical)) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBP include) (NP (NP (NP (JJ enhanced) (NNP Doc_20619828_631_638_Disease)) (PRN (-LRB- -LRB-) (NP (JJ elevated) (CC plus) (NN maze) (CC and) (NN marble)) (VBG burying) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_20619828_680_704_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN perseveration)) (PP (IN in) (NP (DT the) (JJ spontaneous) (NN alternation) (NN task)))) (CC and) (NP (VBN impaired) (NN reversal) (NN learning))) (-RRB- -RRB-))) (, ,) (NP (VBG working) (NNP Doc_20619828_797_814_Disease) (PRN (-LRB- -LRB-) (NP (NN e.g.)) (, ,) (NP (JJ win-shift) (NN paradigm)) (-RRB- -RRB-)) (, ,) (NNP Doc_20619828_843_851_Disease)) (, ,) (CC and) (NP (NNP Doc_20619828_857_884_Disease)))))))) (. .)))
20619828	5	(S1 (S (NP (JJ Doc_20619828_886_894_Chemical) (NNP D2) (NNS receptors)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (DT the) (NN striatum))) (, ,) (SBAR (IN whereas) (S (NP (NP (JJ Doc_20619828_947_956_Chemical) (NNS 2C)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ Doc_20619828_969_978_Chemical) (NNS 1A)) (, ,) (NP (NNS receptors))) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (DT the) (JJ orbital) (JJ frontal) (NN cortex))))))) (. .)))
20619828	6	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN demonstration)) (PP (IN of) (NP (NP (JJ multiple) (NNS symptoms)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ Doc_20619828_1123_1126_Disease-like) (NN profile)) (PP (IN in) (NP (NNS animals)))))))))) (. .)))
20619828	7	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT these) (NNS behaviors)) (VP (AUX are) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ biochemical) (NNS changes)) (PP (IN in) (NP (NP (NN brain) (NNS regions)) (VP (ADVP (RB previously)) (VBN identified) (PP (IN as) (NP (NP (JJ relevant)) (PP (TO to) (NP (NNP Doc_20619828_1271_1274_Disease)))))))))))) (. .)))
20619828	8	(S1 (S (NP (NP (DT This) (JJ novel) (NN model)) (PP (IN of) (NP (NNP Doc_20619828_1296_1299_Disease)))) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (NN drug) (NN exposure)) (PP (IN during) (NP (DT a) (JJ sensitive) (NN period)))) (VP (MD can) (VP (VB program) (NP (JJ disease-like) (NNS systems)) (ADVP (RB permanently)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN current)) (CC and) (NP (NP (JJ future) (JJ therapeutic) (NNS strategies)) (PP (IN for) (NP (NP (DT this)) (CC and) (NP (JJ other) (NN Doc_20619828_1499_1520_Disease))))))))))))))))) (. .)))
20621845	0	(S1 (S (NP (NP (NN Elevation)) (PP (IN of) (NP (CD ADAM10) (, ,) (CD ADAM17) (, ,) (CD MMP-2) (CC and) (CD MMP-9) (NN expression))) (PP (IN with) (NP (NN media) (NN degeneration)))) (VP (VBZ features) (NP (NP (JJ Doc_20621845_89_94_Chemical-induced) (NN Doc_20621845_103_127_Disease)) (PP (IN in) (NP (DT a) (NN rat) (NN model))))) (. .)))
20621845	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (VP (TO to) (VP (VB establish) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NNP Doc_20621845_205_229_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_231_234_Disease)) (-RRB- -RRB-))))) (PP (IN by) (NP (JJ Doc_20621845_239_255_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_257_264_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_20621845_274_289_Disease))))) (CC and) (VP (TO to) (VP (VB explore) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NP (NP (DT a) (NN disintegrin) (CC and) (NN metalloproteinase)) (PRN (-LRB- -LRB-) (NP (NNP ADAM)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP matrix) (NNS metalloproteinases)) (PRN (-LRB- -LRB-) (NP (NNP MMPs)) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ their) (JJ endogenous) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP TIMPs)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNP Doc_20621845_447_450_Disease) (NN formation)))))))))) (. .)))
20621845	2	(S1 (S (NP (NP (JJ Thoracic) (NN aorta)) (PP (IN of) (NP (JJ male) (NNP Sprague-Dawley) (NNS rats)))) (VP (AUX was) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ 0.5M) (NN Doc_20621845_534_541_Chemical)) (CC or) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_560_564_Chemical)) (-RRB- -RRB-))))))) (. .)))
20621845	3	(S1 (S (PP (IN After) (NP (NNS 12weeks))) (, ,) (S (NP (NNS animals)) (VP (AUX were) (VP (VBN euthanized)))) (, ,) (CC and) (S (NP (NP (JJ Doc_20621845_611_618_Chemical-treated)) (, ,) (NP (NP (JJ Doc_20621845_628_635_Chemical-untreated)) (PRN (-LRB- -LRB-) (NP (CD n=12)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_20621845_657_661_Chemical-treated) (JJ aortic) (NNS segments)) (PRN (-LRB- -LRB-) (NP (CD n=12)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN histological)) (CC and) (NP (JJ molecular) (NNS assessments))))))) (. .)))
20621845	4	(S1 (S (S (NP (NN MMP-TIMP) (CC and) (NNP ADAM) (NNS mRNAs)) (VP (AUX were) (ADVP (RB semi-quantitatively)) (VP (VBN analyzed)))) (CC and) (S (NP (NN protein) (NNS expressions)) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NN immunohistochemistry)))))) (. .)))
20621845	5	(S1 (S (PP (IN Despite) (NP (NP (JJ similar) (JJ external) (NNS diameters)) (PP (IN among) (NP (ADJP (JJ Doc_20621845_925_932_Chemical-treated) (, ,) (JJ non-Doc_20621845_946_953_Chemical-treated) (CC and) (JJ Doc_20621845_966_970_Chemical-treated)) (NNS segments))))) (, ,) (NP (NP (NP (JJ aneurymal) (NN alteration)) (PRN (-LRB- -LRB-) (NP (NP (NN n=6)) (, ,) (NP (CD 50) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS media) (NN degeneration)) (PP (IN with) (NP (JJ regional) (NN disruption)))) (, ,) (NP (NP (NN fragmentation)) (PP (IN of) (NP (JJ elastic) (NN fiber)))) (, ,) (CC and) (NP (VBN increased) (NN collagen) (NN deposition)) (PRN (-LRB- -LRB-) (NP (NP (CD n=12)) (, ,) (NP (CD 100) (NN %))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN demonstrated) (PP (IN in) (NP (JJ Doc_20621845_1167_1174_Chemical-treated) (NNS segments))))) (. .)))
20621845	6	(S1 (S (NP (NN MMP-2) (, ,) (NN MMP-9) (, ,) (NN ADAM-10) (CC and) (NN ADAM-17) (NN mRNA) (NNS levels)) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (NP (JJ Doc_20621845_1257_1264_Chemical-treated) (NNS segments)) (PRN (-LRB- -LRB-) (NP (DT all) (CD p<0.01)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (NNS trends)) (PP (IN of) (NP (NP (NN elevation)) (PP (IN in) (NP (JJ Doc_20621845_1324_1331_Chemical-untreated) (NNS segments))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (JJ Doc_20621845_1369_1373_Chemical-treated) (NNS segments)))))))) (. .)))
20621845	7	(S1 (S (NP (NN Immunohistochemistry)) (VP (VP (VBD displayed) (ADVP (RB significantly)) (NP (NP (VBN increased) (NNS expressions)) (PP (IN of) (NP (JJ MMP-2) (, ,) (CD MMP-9) (, ,) (CD ADAM-10) (CC and) (CD ADAM-17)))) (PRN (-LRB- -LRB-) (NP (DT all) (CD p<0.01)) (-RRB- -RRB-)) (PP (IN in) (NP (NN intima)))) (CC and) (VP (NNS media) (PP (IN for) (NP (JJ Doc_20621845_1533_1540_Chemical-treated) (NNS segments))))) (. .)))
20621845	8	(S1 (S (NP (NP (NN TIMP) (NNS mRNA)) (CC and) (NP (NN tissue) (NNS levels))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB obviously)) (PP (IN among) (NP (DT the) (CD three) (JJ aortic) (NNS segments))))) (. .)))
20621845	9	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ establishes) (NP (DT a) (JJ Doc_20621845_1682_1685_Disease) (NN model)) (PP (IN by) (NP (NP (JJ periarterial) (JJ Doc_20621845_1708_1715_Chemical) (NN exposure)) (PP (IN in) (NP (NNS rats)))))) (, ,) (CC and) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ significant) (NN elevation)) (PP (IN of) (NP (NN expression))) (PP (IN of) (NP (CD MMP-2) (, ,) (CD MMP-9) (, ,) (CD ADAM10) (CC and) (CD ADAM17)))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ vascular) (NN remodeling))))))) (. .)))
20633755	0	(S1 (S (NP (NNP Doc_20633755_0_13_Chemical)) (VP (VBN induced) (NP (JJ prolonged) (NNP Doc_20633755_32_37_Disease)) (PP (IN in) (NP (DT a) (JJ patient) (NN receiving) (NN electroconvulsive) (NN therapy)))) (. .)))
20633755	1	(S1 (S (NP (NN Doc_20633755_88_101_Chemical)) (VP (VBZ causes) (NP (JJ prolonged) (NN Doc_20633755_119_124_Disease)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ pseudocholinesterase) (NN enzyme)) (VP (VBZ gets) (VP (VBN deactivated) (PP (IN by) (NP (NNP Doc_20633755_193_222_Chemical)))))))))) (. .)))
20633755	2	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (DT a) (JJ similar) (NN incident)) (PP (IN in) (NP (NP (DT a) (ADJP (RB severely) (JJ Doc_20633755_274_283_Disease)) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ electroconvulsive) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN ECT)) (-RRB- -RRB-))))))))) (. .)))
20633755	3	(S1 (S (NP (NP (JJ Prolonged) (NN Doc_20633755_348_353_Disease)) (PP (IN in) (NP (PRP$ our) (NN case)))) (VP (VBD ensued) (SBAR (IN because) (S (NP (NP (DT the) (NN information)) (PP (IN about) (NP (NP (JJ suicidal) (NN attempt)) (PP (IN by) (NP (NNP Doc_20633755_423_434_Chemical)))))) (VP (AUX was) (VP (VBN concealed) (PP (IN from) (NP (DT the) (VBG treating) (NN team)))))))) (. .)))
20667451	0	(S1 (S (NP (NN Doc_20667451_0_8_Chemical)) (VP (VBZ ameliorates) (NP (NP (NNP Doc_20667451_21_42_Disease)) (CC and) (NP (JJ oxidative) (NN damage))) (PP (IN in) (NP (ADJP (JJ Doc_20667451_67_81_Chemical) (CC and) (JJ Doc_20667451_86_99_Chemical)) (VBN administered) (NNS rats)))) (. .)))
20667451	1	(S1 (S (NP (NP (DT The) (JJ antiepileptic) (NNS drugs)) (, ,) (NP (NP (NNP Doc_20667451_144_158_Chemical)) (CC and) (NP (NNP Doc_20667451_163_176_Chemical)))) (VP (AUX are) (VP (ADVP (RB well)) (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_20667451_201_221_Disease)) (PP (IN on) (NP (JJ chronic) (NN use)))))))) (. .)))
20667451	2	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (JJ free) (JJ radical) (NN generation)))) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ important) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_20667451_336_356_Disease))))))) (PP (IN by) (NP (JJ antiepileptic) (NNS drugs)))))) (. .)))
20667451	3	(S1 (S (NP (NN Doc_20667451_381_389_Chemical)) (VP (AUX has) (VP (VBN shown) (NP (NP (NN antioxidant)) (, ,) (NP (NN anti-inflammatory)) (CC and) (NP (JJ neuro-protective) (NNS properties))))) (. .)))
20667451	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ chronic) (NNP Doc_20667451_546_554_Chemical) (NN administration))) (PP (IN on) (NP (NP (NNP Doc_20667451_573_587_Chemical-)) (CC and) (NP (NNP Doc_20667451_593_606_Chemical-induced) (NNP Doc_20667451_615_635_Disease)))))) (CC and) (VP (VB oxidative) (NP (NP (NN stress)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
20667451	5	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS interactions)) (PP (IN of) (NP (NNP Doc_20667451_698_706_Chemical))) (PP (IN with) (NP (NP (NNP Doc_20667451_712_726_Chemical)) (CC and) (NP (NNP Doc_20667451_731_744_Chemical))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN studied))) (. .)))
20667451	6	(S1 (S (NP (NNS Vehicle/drugs)) (VP (AUX were) (VP (VBN administered) (ADVP (RB daily)) (PP (IN for) (NP (NP (NNS 21days)) (PP (TO to) (NP (JJ male) (JJ Wistar) (NNS rats))))))) (. .)))
20667451	7	(S1 (S (NP (NP (JJ Passive) (NN avoidance) (NNS paradigm)) (CC and) (NP (JJ elevated) (CC plus) (NN maze) (NN test))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NN cognitive) (NN function))))))) (. .)))
20667451	8	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN study) (NN period))))) (, ,) (NP (NP (NNP serum) (NNP Doc_20667451_963_977_Chemical) (CC and) (NNP Doc_20667451_982_995_Chemical)) (, ,) (NP (JJ whole) (NN brain) (NN Doc_20667451_1009_1024_Chemical)) (CC and) (NP (VBN reduced) (JJ Doc_20667451_1037_1048_Chemical) (NNS levels))) (VP (AUX were) (VP (VBN estimated))) (. .)))
20667451	9	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_20667451_1094_1108_Chemical)) (CC and) (NP (NNP Doc_20667451_1113_1126_Chemical)))) (PP (IN for) (NP (NNS 21days)))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN Doc_20667451_1159_1192_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (DT an) (VBN increased) (NN oxidative) (NN stress)))) (. .)))
20667451	10	(S1 (S (NP (JJ Concomitant) (JJ Doc_20667451_1247_1255_Chemical) (NN administration)) (VP (VP (VBD prevented) (NP (DT the) (NNP Doc_20667451_1285_1305_Disease))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (VBN increased) (JJ oxidative) (NN stress)) (VP (VBN induced) (PP (IN by) (NP (DT these) (JJ antiepileptic) (NNS drugs))))))) (. .)))
20667451	11	(S1 (S (NP (JJ Doc_20667451_1389_1397_Chemical) (NN co-administration)) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (DT any) (JJ significant) (NN alteration)) (PP (IN in) (NP (NP (DT the) (JJ serum) (NNS concentrations)) (PP (IN of) (NP (NP (DT both) (NNP Doc_20667451_1493_1507_Chemical)) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_20667451_1519_1532_Chemical))))))))) (. .)))
20667451	12	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_20667451_1558_1566_Chemical)) (VP (AUX has) (NP (JJ beneficial) (NN effect)) (PP (IN in) (S (VP (VBG mitigating) (NP (NP (DT the) (ADJP (JJ Doc_20667451_1607_1643_Disease) (CC and) (JJ oxidative)) (NN damage)) (PP (IN in) (NP (NNS rats))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_20667451_1686_1700_Chemical)) (CC and) (NP (NNP Doc_20667451_1705_1718_Chemical)))))) (PP (IN without) (S (VP (ADVP (RB significantly)) (VBG altering) (NP (PRP$ their) (NN serum) (NNS concentrations)))))))))))) (. .)))
20667451	13	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_20667451_1804_1812_Chemical)) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (NP (NP (DT a) (JJ potential) (ADJP (JJ safe) (CC and) (JJ effective)) (NN adjuvant)) (PP (TO to) (NP (NNP Doc_20667451_1877_1891_Chemical)))) (CC and) (NP (NP (JJ Doc_20667451_1896_1909_Chemical) (NN therapy)) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_20667451_1932_1952_Disease))))))) (VP (VBN associated) (PP (IN with) (NP (DT these) (NNS drugs)))))))))))) (. .)))
20698227	0	(S1 (SQ (MD Can) (NP (NN angiogenesis)) (VP (AUX be) (NP (NP (DT a) (NN target)) (PP (IN of) (NP (NN treatment)))) (PP (IN for) (NP (NNP Doc_20698227_46_55_Chemical) (NNP associated) (NNP Doc_20698227_67_83_Disease)))) (. ?)))
20698227	1	(S1 (NP (NP (NNS BACKGROUND/AIMS)) (: :) (S (S (ADVP (RB Recently)) (NP (NNP Doc_20698227_111_120_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB inhibit) (NP (NNS angiogenesis))))))))) (CC and) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NN angiogenesis) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20698227_208_217_Chemical)) (CC and) (NP (NNP Doc_20698227_222_231_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB cause) (NP (JJ acute) (NNP Doc_20698227_263_272_Disease)))))))))) (. .)))
20698227	2	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (NN hemoglobin) (, ,) (NN haptoglobin) (CC and) (NN angiogenesis) (JJ soluble) (NNS markers)) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX are) (ADJP (JJ modifiable))) (CC and) (VP (MD can) (VP (VB help) (PP (IN in) (S (VP (VBG developing) (NP (NNS strategies)) (PP (IN against) (NP (NNP Doc_20698227_458_464_Disease))))))))))))))))))))) (. .)))
20698227	3	(S1 (S (NP (NP (CD Fourteen) (NNS patients)) (NP (NNP Doc_20698227_493_536_Disease))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (NNP Doc_20698227_553_582_Chemical)) (CC and) (NP (NNP Doc_20698227_587_596_Chemical)))))) (. .)))
20698227	4	(S1 (S (NP (NP (JJ Serum) (NN hemoglobin) (, ,) (NN haptoglobin) (CC and) (NN angiogenesis) (NNS markers)) (PP (IN of) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (CC and) (NP (NN angiopoetin-2))))) (VP (AUX were) (VP (VBN investigated) (PP (IN before) (CC and) (PP (IN after) (NP (NN therapy)))))) (. .)))
20698227	5	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ haptoglobin) (NNS levels))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN treatment) (NN period))))))) (. .)))
20698227	6	(S1 (S (NP (NN Hemoglobin) (NNS levels)) (ADVP (RB also)) (VP (VP (VBN decreased)) (CC but) (VP (ADJP (JJ insignificantly)) (PP (IN by) (NP (NN treatment))))) (. .)))
20698227	7	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (IN with) (NP (DT the) (NN literature))))) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN angiogenesis) (NNS factors)))) (VP (AUX did) (RB not) (VP (NN change) (ADVP (RB significantly)) (PP (IN by) (NP (NP (NNP Doc_20698227_1024_1044_Chemical)) (CC and) (NP (JJ Doc_20698227_1049_1058_Chemical) (NN therapy)))))) (. .)))
20698227	8	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT no) (NN correlation)) (PP (IN of) (NP (JJ angiogenesis) (JJ soluble) (NNS markers))) (PP (IN with) (NP (DT either) (NN hemoglobin) (CC or) (NN haptoglobin))))) (. .)))
20698227	9	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN study)) (PP (IN in) (NP (NP (DT the) (NN literature)) (VP (VBG investigating) (NP (NP (DT a) (NN link)) (PP (IN between) (NP (NP (JJ angiogenesis) (JJ soluble) (NNS markers)) (CC and) (NP (NNP Doc_20698227_1279_1288_Chemical)))))))) (VP (VBN induced) (NP (NNP Doc_20698227_1297_1303_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20698227_1321_1332_Disease))))))))) (CC and) (S (NP (PRP we)) (VP (MD could) (RB not) (VP (VB find) (NP (DT any) (NN relation))))) (. .)))
20698227	10	(S1 (S (NP (NP (JJ Future) (NN research)) (PP (IN with) (NP (NP (JJR larger) (NN number)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX is) (VP (VBN needed) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (NP (NP (JJ modifiable) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB improve) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (JJ Doc_20698227_1489_1498_Chemical) (NN therapy)))))))))))))) (. .)))
2070391	0	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NN injection)))) (VP (NNP Doc_2070391_23_27_Disease) (S (VP (VBG using) (NP (JJ buffered) (NN Doc_2070391_43_52_Chemical)) (PP (IN as) (NP (NP (DT a) (JJ local) (NN anesthetic)) (PP (IN before) (NP (JJ cardiac) (NN catheterization)))))))) (. .)))
2070391	1	(S1 (S (NP (JJ Previous) (NNS reports)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NN Doc_2070391_144_148_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_2070391_182_191_Chemical))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ acidic) (NN pH)) (PP (IN of) (NP (DT the) (NN solution))))))))))) (. .)))
2070391	2	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (DT a) (JJ buffering) (NN solution)) (SBAR (S (VP (TO to) (VP (VB adjust) (NP (NP (DT the) (NN pH)) (PP (IN of) (NP (NNP Doc_2070391_310_319_Chemical)))) (PP (IN into) (NP (DT the) (JJ physiologic) (NN range)))))))))) (VP (MD would) (VP (VB reduce) (NP (NNP Doc_2070391_360_364_Disease)) (PP (IN during) (NP (NN injection)))))))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (DT a) (JJ blinded) (JJ randomized) (NN study)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ cardiac) (NN catheterization)))))) (. .)))
2070391	3	(S1 (S (NP (CD Twenty) (NNS patients)) (VP (VP (AUX were) (VP (VBN asked) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_2070391_526_530_Disease)))) (PP (IN after) (S (VP (VBG receiving) (NP (JJ standard) (NN Doc_2070391_556_565_Chemical)) (PP (IN in) (NP (CD one) (JJ femoral) (NN area))))))))))) (CC and) (VP (VBD buffered) (NP (NNP Doc_2070391_599_608_Chemical)) (PP (IN in) (NP (DT the) (JJ opposite) (JJ femoral) (NN area))))) (. .)))
2070391	4	(S1 (S (NP (NP (DT The) (JJ mean) (JJ Doc_2070391_648_652_Disease) (NN score)) (PP (IN for) (NP (JJ buffered) (NNP Doc_2070391_672_681_Chemical)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT the) (JJ mean) (NN score)) (PP (IN for) (NP (NP (JJ standard) (NNP Doc_2070391_739_748_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 2.7) (NN +/-) (QP (CD 1.9) (CC vs.) (CD 3.8) (JJR +/-) (CD 2.2))) (, ,) (NP (NNP P) (SYM =) (CD 0.03))) (-RRB- -RRB-)))))))) (. .)))
2070391	5	(S1 (S (NP (NP (DT The) (JJ pH) (NN adjustment)) (PP (IN of) (NP (JJ standard) (NNP Doc_2070391_820_829_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN accomplished) (ADVP (RB easily)) (PP (IN in) (NP (DT the) (NN catheterization) (NN laboratory))) (PP (IN before) (NP (NP (NN injection)) (CC and) (NP (NP (NNS results)) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2070391_942_946_Disease)) (VP (VBG occurring) (PP (IN during) (NP (NP (DT the) (NN infiltration)) (PP (IN of) (NP (NNS tissues)))))))))))))))) (. .)))
2071257	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_2071257_10_44_Chemical))) (PP (IN on) (NP (NNP Doc_2071257_48_55_Disease)))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_2071257_66_77_Chemical)))) (. .)))
2071257	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2071257_136_169_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2071257_171_182_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNP Doc_2071257_187_204_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2071257_216_227_Chemical))) (PP (IN in) (NP (NN man)))))))))))) (. .)))
2071257	2	(S1 (S (NP (JJ Thirty-two) (JJ healthy) (JJ young) (NNS volunteers)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (CD four) (JJ different) (NNS groups))))) (. .)))
2071257	3	(S1 (S (NP (PRP They)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (ADJP (CD ten) (NN day)) (NN pretreatment)) (PP (IN with) (NP (NP (DT either) (NNP Doc_2071257_373_384_Chemical)) (CC or) (NP (NN placebo) (, ,) (NN p.o.) (, ,) (CC and) (PP (IN on) (NP (NP (DT the) (JJ eleventh) (NN day)) (CC either) (NP (NNP Doc_2071257_434_445_Chemical)) (CC or) (NP (NN placebo)))) (, ,) (NP (NP (NNP i.m.)) (NP (RB Before) (CC and) (CD 0.5) (, ,) (CD 1) (, ,) (CD 2) (, ,) (CD 3))) (, ,)) (CC and) (NP (CD 6) (NNP h))))) (SBAR (IN after) (NN injection) (S (NP (DT the) (NNS subjects)) (VP (AUX were) (VP (VBN given) (NP (NP (NN attention)) (CC and) (NP (JJ mnemonic) (NNS tests))))))))) (. .)))
2071257	4	(S1 (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NN drug)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB antagonize) (NP (NP (NNP Doc_2071257_638_672_Disease)) (VP (VBN induced) (PP (IN by) (NP (NN Doc_2071257_684_695_Chemical))))))))))))) (. .)))
20722491	0	(S1 (NP (NP (NP (NN Safety)) (PP (IN of) (NP (NNP Doc_20722491_10_22_Chemical)))) (: :) (NP (DT a) (NN review)) (. .)))
20722491	1	(S1 (NP (NP (NP (NN IMPORTANCE)) (PP (IN OF) (NP (DT THE) (NN FIELD)))) (: :) (S (NP (NP (NNP Doc_20722491_59_76_Chemical)) (, ,) (PP (IN in) (NP (NP (JJ particular) (NNP Doc_20722491_92_106_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20722491_108_112_Chemical)) (-RRB- -RRB-)))) (, ,)) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (NN mainstay)) (PP (IN of) (NP (NN treatment)))) (PP (IN for) (NP (NP (JJ several) (JJ solid) (NN Doc_20722491_169_175_Disease)) (, ,) (PP (VBG including) (NP (NNP Doc_20722491_187_231_Disease))) (, ,))) (PP (IN for) (NP (QP (RB >) (CD 40)) (NNS years)))))) (. .)))
20722491	2	(S1 (S (S (NP (NNS AREAS)) (VP (VBN COVERED) (PP (IN IN) (NP (DT THIS) (NN REVIEW))))) (: :) (S (NP (DT This) (NN article)) (VP (VBZ reviews) (NP (NP (DT the) (NN pharmacology) (CC and) (NN efficacy)) (PP (IN of) (NP (NNP Doc_20722491_333_345_Chemical))) (PP (IN with) (NP (NP (DT a) (JJ special) (NN emphasis)) (PP (IN on) (NP (PRP$ its) (NN safety)))))))) (. .)))
20722491	3	(S1 (SBARQ (WHNP (WP WHAT)) (S (S (NP (DT THE) (NN READER)) (VP (MD WILL) (VP (VB GAIN)))) (: :) (S (NP (DT The) (NN reader)) (VP (MD will) (VP (VB gain) (ADVP (RB better)) (NP (NNP insight)) (PP (IN into) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (NNP Doc_20722491_467_479_Chemical)) (PP (IN in) (NP (NP (JJ special) (NNS populations)) (PP (JJ such) (IN as) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN age)) (, ,) (NP (NNP Doc_20722491_539_563_Disease)))))))))))))))) (. .)))
20722491	4	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VB explore) (NP (NP (NP (JJ different) (NN dosing)) (CC and) (NP (NNS schedules))) (PP (IN of) (NP (NNP Doc_20722491_615_627_Chemical) (NN administration))))) (. .)))
20722491	5	(S1 (S (S (VP (VB TAKE) (NP (NN HOME) (NN MESSAGE)))) (: :) (S (NP (NNP Doc_20722491_663_675_Chemical)) (VP (VP (AUX is) (NP (NP (DT an) (JJ oral) (NN prodrug)) (PP (IN of) (NP (NNP Doc_20722491_698_702_Chemical))))) (CC and) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VP (VB fulfill) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (DT a) (ADJP (RBR more) (JJ convenient)) (NN therapy))))) (CC and) (VP (VB provide) (NP (DT an) (JJ improved) (NN safety/efficacy) (NN profile)))))))))) (. .)))
20722491	6	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (VBN shown) (NP (NP (JJ promising) (NNS results)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (JJ chemotherapeutic) (NNS agents)) (PP (IN in) (NP (NNP Doc_20722491_913_998_Disease))))))))))) (. .)))
20722491	7	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (RB commonly) (VBN reported)) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20722491_1044_1056_Chemical)))) (VP (AUX are) (NP (NNP Doc_20722491_1061_1069_Disease) (, ,) (NNP Doc_20722491_1071_1077_Disease) (, ,) (NNP Doc_20722491_1079_1087_Disease) (, ,) (NNP Doc_20722491_1089_1099_Disease) (CC and) (NNP Doc_20722491_1104_1122_Disease))) (. .)))
20722491	8	(S1 (S (NP (NN Doc_20722491_1124_1136_Chemical)) (VP (VP (AUX has) (NP (DT a) (JJ well-established) (NN safety) (NN profile))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN given) (ADVP (RB safely)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN age)) (, ,) (NP (NNP Doc_20722491_1230_1260_Disease)))))))))) (. .)))
20880751	0	(S1 (NP (NP (NP (JJ Doc_20880751_0_8_Chemical-induced) (NN Doc_20880751_17_28_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20880751_46_65_Disease)))))) (: :) (S (VP (VBG filling) (NP (DT the) (JJ bench-to-bedside) (NN gap)))) (. .)))
20880751	1	(S1 (S (NP (NN Doc_20880751_101_109_Chemical)) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (JJ effective)) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_20880751_158_177_Disease))))))) (. .)))
20880751	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (DT this) (JJ Doc_20880751_214_222_Chemical) (NN precursor)))) (VP (AUX is) (VP (VBN complicated) (PP (IN by) (NP (NP (RB highly) (VBG disabling) (NNS fluctuations)) (CC and) (NP (NN Doc_20880751_285_296_Disease)))))) (. .)))
20880751	3	(S1 (S (SBAR (IN Although) (S (NP (NP (NN preclinical)) (CC and) (NP (JJ clinical) (NNS findings))) (VP (VBP suggest) (NP (NP (JJ pulsatile) (NN stimulation)) (PP (IN of) (NP (JJ striatal) (JJ postsynaptic) (NNS receptors)))) (PP (IN as) (NP (NP (DT a) (JJ key) (NN mechanism)) (VP (VBG underlying) (NP (JJ Doc_20880751_436_444_Chemical-induced) (NNP Doc_20880751_453_464_Disease)))))))) (, ,) (NP (PRP$ their) (NN pathogenesis)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
20880751	4	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (, ,) (NP (NP (NN evidence)) (PP (IN from) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20880751_551_570_Disease)))))) (VP (AUX has) (VP (VBN provided) (NP (JJ important) (NN information)) (S (VP (TO to) (VP (VP (VB understand) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ specific) (NN receptor))))) (CC and) (VP (VB post-receptor) (NP (NP (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20880751_721_741_Disease)))))))))))) (. .)))
20880751	5	(S1 (S (NP (NP (JJ Recent) (JJ preclinical) (CC and) (JJ clinical) (NNS data)) (PP (IN from) (NP (NP (JJ promising) (NNS lines)) (PP (IN of) (NP (NN research)))))) (VP (VBP focus) (PP (IN on) (NP (NP (DT the) (NN differential) (NN role)) (PP (IN of) (NP (NP (JJ presynaptic) (CC versus) (JJ postsynaptic) (NNS mechanisms)) (, ,) (NP (JJ Doc_20880751_891_899_Chemical) (NN receptor) (NNS subtypes)) (, ,) (NP (ADJP (JJ ionotropic) (CC and) (JJ metabotropic)) (JJ Doc_20880751_947_956_Chemical) (NNS receptors)) (, ,) (CC and) (NP (JJ non-dopaminergic) (NN neurotransmitter) (NNS systems)))) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20880751_1040_1048_Chemical-induced) (NNP Doc_20880751_1057_1068_Disease)))))))) (. .)))
20882060	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ pallidal) (NNP Doc_20882060_20_31_Chemical))) (PP (IN on) (NP (NNP Doc_20882060_35_46_Chemical-induced) (NNP Doc_20882060_55_77_Disease)))) (: :) (NP (ADJP (JJ behavioral) (CC and) (JJ electrophysiological)) (NNS studies)) (. .)))
20882060	1	(S1 (S (NP (DT The) (JJ globus) (NN pallidus)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NN movement) (NN regulation)))) (. .)))
20882060	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (S (NP (DT the) (JJ globus) (NN pallidus)) (VP (VBZ receives) (NP (JJ neurotensinergic) (NN innervation)) (PP (IN from) (NP (DT the) (NN striatum))))) (, ,) (CC and) (S (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (DT a) (JJ Doc_20882060_348_359_Chemical) (NN analog)))) (VP (MD could) (VP (VB produce) (NP (JJ antiparkinsonian) (NNS effects))))))))) (. .)))
20882060	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ pallidal) (NNP Doc_20882060_470_481_Chemical))) (PP (IN on) (NP (JJ Doc_20882060_485_496_Chemical-induced) (NN Doc_20882060_505_526_Disease)))))))) (. .)))
20882060	4	(S1 (S (NP (NP (JJ Behavioral) (NNS experiments)) (CC and) (NP (JJ electrophysiological) (NNS recordings))) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (DT the) (JJ present) (NN study))))) (. .)))
20882060	5	(S1 (S (NP (NP (JJ Bilateral) (NNS infusions)) (PP (IN of) (NP (NNP Doc_20882060_665_676_Chemical))) (PP (IN into) (NP (DT the) (JJ globus) (NNS pallidus)))) (VP (VBD reversed) (NP (JJ Doc_20882060_711_722_Chemical-induced) (NN Doc_20882060_731_753_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
20882060	6	(S1 (S (NP (JJ Electrophysiological) (NNS recordings)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_20882060_825_836_Chemical)))) (VP (VBN induced) (NP (NP (NN excitation)) (PP (IN of) (NP (JJ pallidal) (NNS neurons)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ systemic) (JJ Doc_20882060_904_915_Chemical) (NN administration))))))))) (. .)))
20882060	7	(S1 (S (NP (DT The) (NNP Doc_20882060_936_974_Chemical) (NNP Doc_20882060_975_982_Chemical)) (VP (VBD blocked) (NP (CC both) (NP (DT the) (JJ behavioral)) (CC and) (NP (NP (DT the) (JJ electrophysiological) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20882060_1059_1070_Chemical))))))) (. .)))
20882060	8	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ pallidal) (JJ Doc_20882060_1107_1118_Chemical) (NNS receptors)))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_20882060_1148_1159_Chemical-induced) (NN antiparkinsonian) (NNS effects)))))) (. .)))
2096243	0	(S1 (NP (JJ Doc_2096243_0_8_Chemical-induced) (NN Doc_2096243_17_41_Disease) (. .)))
2096243	1	(S1 (S (NP (NN Doc_2096243_43_66_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (JJ 29-year-old) (NN female)) (PP (IN in) (NP (DT the) (JJ prognostic) (NN period))))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_2096243_148_156_Chemical-induced) (NNP Doc_2096243_165_184_Disease))))))) (. .)))
2096243	2	(S1 (S (NP (NP (NNS Symptoms)) (PP (JJ such) (IN as) (NP (NP (NN euphoria)) (, ,) (NP (JJ emotional) (NN lability)) (CC and) (NP (JJ puerile) (NN attitude)))) (VP (VBN noted) (PP (IN in) (NP (DT the) (NN patient))))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (NP (NNP Doc_2096243_292_320_Disease))) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS criteria)) (VP (VBN defined) (PP (IN in) (NP (DT the) (NN DSM-III-R))))))))) (. .)))
2096243	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT a) (NN Doc_2096243_396_417_Disease))))) (. .)))
2096243	4	(S1 (S (NP (NN Brain) (NNS CT)) (VP (VBD revealed) (NP (DT a) (JJ periventricular) (JJ low) (NN density) (NN area)) (PP (IN in) (NP (NP (NP (DT the) (JJ frontal) (JJ white) (NN matter)) (CC and) (NP (JJ moderate) (NN dilatation))) (PP (IN of) (NP (DT the) (JJ lateral) (NNS ventricles))))) (PP (ADVP (RB especially)) (IN at) (NP (DT the) (JJ bilateral) (NNP anterior) (NNS horns)))) (. .)))
2096243	5	(S1 (S (ADVP (RB Consequently)) (, ,) (NP (NNP Doc_2096243_608_616_Chemical-induced) (NNP Doc_2096243_625_644_Disease)) (VP (MD may) (ADVP (RB uncommonly)) (VP (VB result) (PP (IN in) (NP (NNP Doc_2096243_670_698_Disease))) (PP (IN in) (NP (DT the) (JJ residual) (NN state))))) (. .)))
2096243	6	(S1 (S (NP (PRP It)) (VP (MD may) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (DT the) (NNP Doc_2096243_750_787_Disease)))))) (. .)))
21029050	0	(S1 (S (VP (VB Butyrylcholinesterase) (NP (NN gene) (NNS mutations)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN prolonged) (NN Doc_21029050_64_69_Disease)) (PP (IN after) (NP (NP (NNP Doc_21029050_76_91_Chemical)) (PP (IN for) (NP (JJ electroconvulsive) (NN therapy)))))))))) (. .)))
21029050	1	(S1 (S (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ electroconvulsive) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN ECT)) (-RRB- -RRB-))))) (ADVP (RB often)) (VP (VBP receive) (NP (NNP Doc_21029050_201_216_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ anesthetic) (NN procedure)))))) (. .)))
21029050	2	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NN action)))) (VP (MD may) (VP (AUX be) (VP (VBN prolonged) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ genetic) (NNS variants)) (PP (IN of) (NP (NP (DT the) (JJ butyrylcholinesterase) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP BChE)) (-RRB- -RRB-)))))))) (, ,) (S (NP (DT the) (RBS most) (JJ common)) (VP (AUXG being) (NP (NP (DT the) (NNPS K-)) (CC and) (NP (DT the) (NNPS A-variants)))))))) (. .)))
21029050	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (NP (JJ genetic) (NNS variants)) (PP (IN in) (NP (NN butyrylcholinesterase) (NN gene))) (PRN (-LRB- -LRB-) (NP (NNP BCHE)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (JJ prolonged) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_21029050_600_615_Chemical))) (PP (IN after) (NP (NN ECT))))))))))))) (. .)))
21029050	4	(S1 (S (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 13) (NNS patients)))) (VP (AUX were) (VP (VBN referred) (PP (TO to) (NP (DT the) (JJ Danish) (NNP Cholinesterase) (NN Research) (NN Unit))) (PP (IN after) (NP (NN ECT))) (PP (IN during) (NP (CD 38) (NNS months))))) (. .)))
21029050	5	(S1 (S (NP (PRP We)) (VP (VBD determined) (SBAR (S (NP (NP (DT the) (NNP BChE) (NN activity)) (CC and) (NP (NP (NP (DT the) (NN BCHE) (NN genotype)) (VP (VBG using) (NP (JJ molecular) (JJ genetic) (NNS methods)))) (, ,) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_847_852_Disease)))) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (NP (JJ sufficient) (JJ spontaneous) (NN ventilation)) (CC and) (NP (IN whether) (NN neuromuscular) (NN monitoring))))))) (VP (AUX was) (VP (VBN used)))))) (. .)))
21029050	6	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_960_965_Disease)))) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (VBN published) (NNS data)) (PP (IN on) (NP (JJ normal) (NNS subjects))))))) (. .)))
21029050	7	(S1 (S (PP (IN in) (NP (CD 11) (NNS patients))) (, ,) (NP (NNS mutations)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (NN BCHE) (NN gene))) (, ,) (S (NP (DT the) (NN K-variant)) (VP (AUXG being) (NP (DT the) (RBS most) (JJ frequent)))))) (. .)))
21029050	8	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_1138_1143_Disease)))) (VP (AUX was) (NP (CD 5-15) (NN min)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 3-5.3) (NN min)) (PP (IN from) (NP (DT the) (NN literature))))))) (. .)))
21029050	9	(S1 (S (NP (JJ Severe) (NN distress)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (NN recovery) (NN phase)) (PP (IN in) (NP (CD two) (NNS patients))))))) (. .)))
21029050	10	(S1 (S (NP (JJ Neuromuscular) (NN monitoring)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (CD two) (NNS patients))))) (. .)))
21029050	11	(S1 (S (NP (NP (CD eleven)) (PP (IN of) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NP (DT a) (VBN prolonged) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_21029050_1391_1406_Chemical)))))))))) (VP (AUX had) (NP (NNS mutations)) (PP (IN in) (NP (NNP BCHE))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ possible) (NN reason)) (PP (IN for) (NP (NP (DT a) (JJ prolonged) (NN period)) (PP (IN of) (NP (NNP Doc_21029050_1500_1505_Disease)))))))))))) (. .)))
21029050	12	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (JJ objective) (JJ neuromuscular) (NN monitoring)) (PP (IN during) (NP (DT the) (JJ first) (NN ECT)))) (. .)))
220563	0	(S1 (NP (NNP Doc_220563_0_19_Chemical) (CC and) (NNP Doc_220563_24_45_Disease) (. .)))
220563	1	(S1 (S (NP (NN Doc_220563_47_68_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN noted) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NP (NNP Doc_220563_118_137_Chemical)) (, ,) (NP (NP (DT a) (NN drug)) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (NNP France))) (PRN (-LRB- -LRB-) (CC and) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT the) (JJ prophylactic) (NN treatment)) (PP (IN of) (NP (NNP Doc_220563_248_263_Disease)))))))))))))) (. .)))
220563	2	(S1 (S (PP (IN In) (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (DT this) (NN complication))))) (, ,) (NP (NP (NP (DT the) (JJ marked) (NN slowing)) (PP (IN of) (NP (NN motor) (NN nerve) (NN conduction) (NN velocity)))) (CC and) (NP (DT the) (JJ electromyographic) (NNS changes))) (VP (VBP imply) (ADVP (RB mainly)) (NP (DT a) (NN Doc_220563_407_429_Disease))) (. .)))
220563	3	(S1 (S (NP (NN Improvement)) (VP (AUX was) (VP (VBN noted) (PP (IN with) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))))))) (. .)))
220563	4	(S1 (S (PP (IN In) (NP (DT a) (JJ few) (NNS cases))) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ active) (NN denervation)))) (VP (VBD signified) (NP (NP (DT a) (JJ poor) (NN prognosis)) (, ,) (PP (IN with) (NP (JJ only) (JJ slight) (NN improvement))))) (. .)))
220563	5	(S1 (S (NP (NP (DT The) (JJ underlying) (NN mechanism)) (VP (VBG causing) (NP (DT the) (NNP Doc_220563_625_635_Disease)))) (VP (AUX is) (ADJP (ADVP (RB not) (CC yet) (RB fully)) (VBN known)) (, ,) (SBAR (IN although) (S (NP (DT some) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (NP (DT a) (NN lipid) (NN storage) (NN process)))))))))) (. .)))
2224762	0	(S1 (NP (NP (DT A) (NN phase)) (NP (NP (PRP I) (NN study)) (PP (IN of) (NP (NNP Doc_2224762_19_51_Chemical)))) (. .)))
2224762	1	(S1 (NP (NP (NP (JJ Clinical) (NNS pharmacology)) (CC and) (NP (NNS pharmacokinetics))) (. .)))
2224762	2	(S1 (S (NP (NP (DT A) (NN Phase) (NN I) (NN study)) (PP (IN of) (NP (NP (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (JJ bolus) (NNP Doc_2224762_139_171_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2224762_173_184_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (AUX done) (PP (IN in) (NP (NP (CD 55) (NNS patients)) (PP (IN in) (NP (NP (JJ good) (NN performance) (NN status)) (PP (IN with) (NP (JJ refractory) (NN Doc_2224762_253_259_Disease))))))))) (. .)))
2224762	3	(S1 (S (S (NP (NN Twenty-six)) (VP (AUX had) (NP (NP (JJ minimal) (JJ prior) (NN therapy)) (PRN (-LRB- -LRB-) (NP (JJ good) (NN risk)) (-RRB- -RRB-))))) (, ,) (S (NP (CD 23)) (VP (AUX had) (NP (NP (JJ extensive) (JJ prior) (NN therapy)) (PRN (-LRB- -LRB-) (NP (JJ poor) (NN risk)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (CD six)) (VP (AUX had) (NP (NN Doc_2224762_367_399_Disease)))) (. .)))
2224762	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 167) (NNS courses))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 15) (TO to) (CD 70)) (NNS mg/m2)))))) (VP (AUX were) (ADJP (JJ evaluable))) (. .)))
2224762	5	(S1 (S (S (NP (NP (JJ Maximum) (JJ tolerated) (NN dose)) (PP (IN in) (NP (JJ good-risk) (NNS patients)))) (VP (AUX was) (NP (CD 70) (NN mg/m2)))) (, ,) (CC and) (S (PP (IN in) (NP (JJ poor-risk) (NNS patients))) (, ,) (NP (CD 60) (NNS mg/m2))) (. .)))
2224762	6	(S1 (S (NP (DT The) (JJ dose-limiting) (NN toxic) (NN effect)) (VP (AUX was) (NP (JJ transient) (JJ noncumulative) (NN Doc_2224762_622_638_Disease))) (. .)))
2224762	7	(S1 (S (S (NP (NNP Granulocyte) (NNP nadir)) (VP (AUX was) (PP (IN on) (NP (NN day) (CD 14))))) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 4-22)) (-RRB- -RRB-)) (. .)))
2224762	8	(S1 (S (NP (ADJP (RBR Less) (JJ frequent)) (JJ toxic) (NNS effects)) (VP (VBD included) (NP (NP (NNP Doc_2224762_724_740_Disease)) (, ,) (NP (NNP Doc_2224762_742_748_Disease)) (, ,) (NP (NNP Doc_2224762_750_756_Disease)) (, ,) (NP (JJ mild) (NNP Doc_2224762_763_771_Disease)) (, ,) (NP (NNP Doc_2224762_773_782_Disease)) (, ,) (CC and) (NP (NNP Doc_2224762_788_797_Disease)))) (. .)))
2224762	9	(S1 (S (NP (NN Doc_2224762_799_815_Disease)) (VP (AUX was) (ADVP (RBR more)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2224762_842_861_Disease)))))) (. .)))
2224762	10	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS analyses)) (PP (IN in) (NP (CD 21) (NNS patients)))) (VP (VBD revealed) (SBAR (S (NP (NNP Doc_2224762_912_923_Chemical) (NN plasma) (NNS T)) (VP (VBD 1/2) (NP (NP (NN alpha)) (PRN (-LRB- -LRB-) (NP (JJ +/-) (FW SE)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 2.5) (JJ +/-) (CD 0.85) (NNS minutes)))) (, ,) (S (VP (VP (VBG T) (NP (NP (JJ beta) (NNS 1/2)) (PP (IN of) (NP (CD 25.6) (JJ +/-) (CD 6.5) (NNS minutes))))) (, ,) (CC and) (VP (VBG T) (NP (NP (CD 1/2) (NN gamma)) (PP (IN of) (NP (CD 23.6) (JJ +/-) (CD 7.6) (NNS hours))))))))))) (. .)))
2224762	11	(S1 (S (S (NP (NP (DT The) (NN area)) (PP (IN under) (NP (DT the) (NN curve)))) (VP (AUX was) (NP (NP (CD 537) (NN +/-) (CD 149) (NNP ng/ml) (NNP x) (NNS hours)) (, ,) (NP (NP (NP (NP (NN volume)) (PP (IN of) (NP (NP (NN distribution)) (PRN (-LRB- -LRB-) (NP (NNP Vd)) (-RRB- -RRB-))))) (NP (CD 3504) (NNS +/-))) (NP (CD 644) (NNS l/m2)))))) (, ,) (CC and) (S (NP (NP (JJ total) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP ClT)) (-RRB- -RRB-))) (VP (AUX was) (NP (QP (CD 204) (CD +)) (QP (CD 39.3) (CD l/hour/m2))))) (. .)))
2224762	12	(S1 (S (S (NP (NP (NNP Doc_2224762_1207_1219_Chemical)) (, ,) (NP (NNP Doc_2224762_1221_1232_Chemical)) (, ,) (NP (NNP Doc_2224762_1234_1247_Chemical)) (, ,) (CC and) (NP (NNP Doc_2224762_1253_1282_Chemical))) (VP (AUX were) (NP (NP (DT the) (NNS metabolites)) (VP (VBN detected) (PP (IN in) (NP (NN plasma))))))) (CC and) (S (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NNP Doc_2224762_1341_1352_Chemical)))) (VP (AUX was) (ADJP (ADJP (JJR less) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NNS metabolites))))))))) (. .)))
2224762	13	(S1 (S (NP (NP (JJ Urinary) (NN excretion)) (PP (IN of) (NP (NNP Doc_2224762_1430_1441_Chemical))) (PP (IN in) (NP (DT the) (JJ first) (CD 24) (NNS hours)))) (VP (AUX was) (UCP (ADVP (RBR less) (IN than)) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (CD 10) (NN %)))))) (. .)))
2224762	14	(S1 (S (NP (NN Activity)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (NNP Doc_2224762_1517_1529_Disease)) (, ,) (NP (NNP Doc_2224762_1531_1545_Disease)) (, ,) (CC and) (NP (NNP Doc_2224762_1551_1571_Disease)))))) (. .)))
2224762	15	(S1 (S (NP (NP (DT The) (VBN recommended) (NN starting) (NN dose)) (PP (IN for) (NP (NN Phase) (NNP II) (NNS trials)))) (VP (AUX is) (NP (NP (CD 60) (JJ mg/m2) (NNP IV) (NN bolus)) (NP (DT every) (CD 3) (NNS weeks)))) (. .)))
2234245	0	(S1 (NP (NP (NN Doc_2234245_0_28_Disease)) (PP (IN in) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2234245_64_79_Chemical))))) (. .)))
2234245	1	(S1 (S (PP (IN During) (NP (NP (DT an) (JJ 18-month) (NN period)) (PP (IN of) (NP (NN study))))) (NP (NP (CD 41) (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_2234245_151_166_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 10-40) (NN mg/kg)) (NP (CD BW/3) (NNS times) (JJ weekly))) (-RRB- -RRB-))) (PP (IN for) (NP (DT the) (JJ first) (NN time))))) (VP (AUX were) (VP (VBN monitored) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NP (NNP Doc_2234245_250_270_Disease.) (CD 6) (NNS patients)) (VP (VBN presented) (NP (NP (JJ clinical) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_2234245_314_341_Disease))))))))))) (. .)))
2234245	2	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ detailed) (NN ophthalmologic)) (CC and) (NP (JJ audiologic) (NNS studies))) (VP (VBD disclosed) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (QP (CD 7) (JJR more)) (JJ asymptomatic) (NNS patients))))) (. .)))
2234245	3	(S1 (S (NP (NN Doc_2234245_457_472_Disease)) (VP (VP (AUX was) (PP (IN of) (NP (JJ retinal) (NN origin)))) (CC and) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ tritan-type) (NN Doc_2234245_534_548_Disease)) (, ,) (VP (ADVP (RB sometimes)) (VBN associated) (PP (IN with) (NP (NP (NNP Doc_2234245_576_599_Disease)) (CC and) (NP (NNP Doc_2234245_604_631_Disease)))))))))) (. .)))
2234245	4	(S1 (S (NP (NN Doc_2234245_633_650_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (NN mid-)) (PP (TO to) (NP (JJ high-frequency) (NNP Doc_2234245_697_724_Disease)))) (CC and) (NP (NP (DT the) (NN lesion) (AUX was)) (PP (IN of) (NP (DT the) (JJ cochlear) (NN type)))))))) (. .)))
2234245	5	(S1 (S (NP (JJ Doc_2234245_766_781_Chemical) (NN withdrawal)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ complete) (NN recovery)) (PP (IN of) (NP (JJ visual) (NN function))))) (PP (IN in) (NP (NP (NP (NP (NP (CD 1) (JJ patient) (CC and) (JJ partial) (NN recovery)) (PP (IN in) (NP (NNP 3)))) (, ,) (CC and) (NP (NP (DT a) (JJ complete) (NN reversal)) (PP (IN of) (NP (NNP Doc_2234245_911_923_Disease))))) (PP (IN in) (NP (CD 3) (NNS patients)))) (CC and) (NP (NP (JJ partial) (NN recovery)) (PP (IN in) (NP (NNP 3))))))) (. .)))
2234245	6	(S1 (S (NP (DT This) (NN Doc_2234245_970_978_Disease)) (VP (VP (VBD appeared) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (JJR higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_2234245_1030_1045_Chemical)))))))) (CC or) (VP (VBD coincided) (PP (IN with) (NP (NP (DT the) (NN normalization)) (PP (IN of) (NP (JJ ferritin) (CC or) (JJ Doc_2234245_1097_1106_Chemical) (NN serum) (NNS levels))))))) (. .)))
2234245	7	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_2234245_1144_1164_Disease)) (VP (AUX is) (RB not) (NP (NP (DT an) (JJ infrequent) (NN complication)) (PP (IN in) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NN Doc_2234245_1234_1249_Chemical)))))))))) (. .)))
2234245	8	(S1 (S (NP (JJ Periodical) (NNP audiovisual) (NN monitoring)) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN on) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (DT the) (NN drug)) (PP (IN in) (NP (NN order)))))) (S (VP (TO to) (VP (VB detect) (NP (JJ adverse) (NNS effects)) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (ADJP (JJ possible)))))))))) (. .)))
2265898	0	(S1 (S (NP (JJ Serial) (NN Doc_2265898_7_15_Disease)) (VP (VBD caused) (PP (IN by) (NP (NNP Doc_2265898_26_44_Chemical) (NN administration))) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PP (IN on) (NP (NN hemodialysis)))))) (. .)))
2265898	1	(S1 (S (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (JJ similar) (JJ clinical) (NNS features)))) (VP (AUX are) (VP (VBN presented)))) (: :) (S (S (NP (DT both) (NNS patients)) (VP (VP (AUX had) (NP (NNP Doc_2265898_170_191_Disease)) (, ,) (PP (IN on) (NP (NN hemodialysis))) (PP (IN for) (NP (JJ many) (NNS years)))) (CC but) (VP (ADVP (RB recently)) (VBN begun) (PP (IN on) (NP (DT a) (JJ high-flux) (NN dialyzer)))))) (: ;) (S (NP (DT both)) (VP (AUX had) (VP (AUX been) (VP (VBG receiving) (NP (DT a) (JJ Doc_2265898_294_312_Chemical) (NN preparation)))))) (: ;) (CC and) (S (NP (DT both)) (VP (AUX had) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_2265898_352_364_Disease)) (CC and) (NP (NP (JJ recurrent) (NNP Doc_2265898_379_387_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (JJ refractory) (PP (TO to) (NP (NNS anticonvulsants)))))))))))))) (. .)))
2265898	2	(S1 (S (S (NP (DT The) (JJ first) (NN patient)) (VP (VBD died) (PP (IN without) (NP (DT a) (NN diagnosis))))) (: ;) (S (NP (DT the) (JJ second) (NN patient)) (VP (AUX had) (NP (DT a) (JJ dramatic) (NN recovery)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2265898_550_560_Chemical))))))) (. .)))
2265898	3	(S1 (S (NP (DT Neither) (NN patient)) (VP (AUX was) (VP (VBN considered) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ renal) (NN state) (ADJP (RB sufficiently) (JJ severe)) (NN enough)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (PRP$ their) (NN presentation)))))))))))) (. .)))
2266990	0	(S1 (NP (NP (NNP Randomized)) (, ,) (NP (NP (JJ double-blind) (NN trial)) (PP (IN of) (NP (NNP Doc_2266990_34_42_Chemical))) (PP (IN in) (NP (NNP Doc_2266990_46_64_Disease)))) (. .)))
2266990	1	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NN growth) (NN hormone)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_141_149_Disease))) (PP (IN in) (NP (NNP Doc_2266990_153_171_Disease)))))))))))) (. .)))
2266990	2	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ 12-month) (JJ controlled) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_2266990_217_225_Chemical)) (, ,) (NP (DT a) (JJ putative) (NN growth) (NN hormone) (NN secretion) (NN inhibitor)) (, ,))) (PP (IN in) (NP (NP (CD 83) (NNS boys)) (PP (IN with) (NP (NNP Doc_2266990_290_308_Disease))))))) (. .)))
2266990	3	(S1 (S (S (NP (NP (NN Muscle) (NN strength)) (, ,) (NP (NNS contractures)) (, ,) (NP (JJ functional) (NN ability)) (CC and) (NP (JJ pulmonary) (NN function))) (VP (AUX were) (VP (VBN tested) (PP (IN at) (NP (NN baseline)))))) (, ,) (CC and) (S (NP (QP (CD 6) (CC and) (CD 12)) (NNS months)) (PP (IN after) (NP (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2266990_449_457_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/d)) (-RRB- -RRB-))) (CC or) (NP (NN placebo))))) (. .)))
2266990	4	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (NN power)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 0.90)))) (SBAR (S (VP (TO to) (VP (VB detect) (NP (DT a) (NN slowing)) (PP (TO to) (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (NP (DT the) (VBN expected) (NN rate)) (PP (IN of) (NP (NP (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_605_613_Disease))))))))) (PP (IN at) (S (VP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.05)))))))))))))))) (. .)))
2266990	5	(S1 (S (NP (NN Doc_2266990_635_643_Chemical)) (VP (AUX did) (RB not) (VP (VB benefit) (NP (NN strength)) (PP (IN at) (NP (NP (DT any) (NN point)) (PP (IN in) (NP (DT the) (NN study))))))) (. .)))
2266990	6	(S1 (S (S (NP (NP (NN Side) (NNS effects)) (ADJP (JJ attributable) (PP (TO to) (NP (NNP Doc_2266990_725_733_Chemical))))) (VP (VBD included) (NP (NP (NNP Doc_2266990_743_761_Disease)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_2266990_769_778_Disease)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-)) (, ,) (NP (JJ behavioral) (NN change)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (NNP Doc_2266990_815_840_Disease) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-)) (: ;)) (NNP Doc_2266990_848_856_Chemical) (NN dosage)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
2266990	7	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_2266990_910_918_Chemical))) (PP (IN on) (NP (CD GH) (NN secretion)))) (VP (AUX was) (VP (VBN estimated) (ADVP (RB indirectly)) (PP (IN by) (S (VP (VBG comparing) (NP (NP (NP (DT the) (JJ postabsorptive) (JJ IGF-I) (NNS levels)) (VP (VBN obtained) (NP (NN following) (CD 3) (, ,) (CD 6) (, ,) (CD 9)))) (, ,) (CC and) (NP (CD 12) (NNS months))) (PP (IN in) (NP (NP (DT the) (NNP Doc_2266990_1054_1062_Chemical)) (VP (VBN treated) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN placebo) (NNS groups))))))))))))) (. .)))
2266990	8	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_2266990_1112_1120_Chemical-treated) (NNS patients)) (VP (VP (VBD gained) (NP (JJR less) (NN weight))) (CC and) (VP (NP (NN height)) (PP (IN than) (NP (JJ placebo-treated) (NNS patients))))))) (, ,) (NP (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (JJ IGF-I) (NNS levels)))) (VP (AUX was) (VP (VBN observed))) (. .)))
2266990	9	(S1 (S (NP (JJ Doc_2266990_1251_1259_Chemical) (NNS doses)) (VP (RB not) (VB slow) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_1294_1302_Disease))) (PP (IN in) (NP (NNP Doc_2266990_1306_1324_Disease))))) (. .)))
2273650	0	(S1 (NP (NP (NN Facilitation)) (PP (IN of) (NP (NN memory) (NN retrieval))) (PP (IN by) (NP (NP (JJ pre-test) (NN Doc_2273650_45_53_Chemical)) (CC and) (NP (NP (PRP$ its) (NN state) (NN dependency)) (PP (IN in) (NP (NP (DT the) (JJ step-through) (NN type) (NN passive) (NN avoidance)) (VP (VBG learning) (NP (NN test)) (PP (IN in) (NP (NNS mice))))))))) (. .)))
2273650	1	(S1 (S (S (NP (NP (NN Doc_2273650_145_152_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_2273650_165_176_Chemical)) (CC and) (NP (NNP Doc_2273650_181_194_Chemical)))))) (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_2273650_212_220_Chemical))) (S (VP (VBN given) (NP (CD 30) (NN min)) (PP (IN before) (NP (NP (DT the) (NN test) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN pre-test)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (JJ pre-test) (NNP Doc_2273650_281_289_Chemical)) (ADVP (RB also)) (VP (VBD facilitated) (NP (DT the) (NN memory) (NN retrieval)) (PP (IN in) (NP (NP (DT the) (NNS animals)) (VP (VBN administered) (NP (NNP Doc_2273650_356_364_Chemical)) (PP (IN during) (NP (DT the) (NN training) (NN trial)))))))) (. .)))
2273650	2	(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (JJ pre-test) (NNP Doc_2273650_412_423_Chemical)) (ADVP (RB partially)) (VP (VBD reversed) (NP (DT the) (JJ Doc_2273650_447_458_Chemical-induced) (NNP Doc_2273650_467_474_Disease)) (, ,) (FRAG (CC but) (RB not) (ADVP (RB significantly))))) (: ;) (CC and) (S (NP (JJ pre-test) (NNP Doc_2273650_512_525_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB reverse) (NP (DT the) (JJ Doc_2273650_548_561_Chemical-induced) (NNP Doc_2273650_570_577_Disease))))))) (. .)))
2273650	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN facilitation)) (PP (IN of) (NP (NN memory) (NN retrieval))) (PP (IN by) (NP (JJ pre-test) (NNP Doc_2273650_655_663_Chemical)))) (VP (MD might) (VP (AUX be) (NP (NP (DT the) (JJ direct) (NN action)) (PP (IN of) (NP (NNP Doc_2273650_694_702_Chemical)))) (PP (RB rather) (IN than) (NP (DT a) (ADJP (NN state) (JJ dependent)) (NN effect)))))))) (. .)))
227508	0	(S1 (S (NP (NN Doc_227508_0_8_Chemical)) (VP (VBZ reverses) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NNP Doc_227508_49_58_Chemical))))) (. .)))
227508	1	(S1 (S (PP (IN In) (NP (JJ unanesthetized) (, ,) (ADJP (RB spontaneously) (JJ Doc_227508_93_105_Disease)) (NNS rats))) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (VP (VBN produced) (PP (IN by) (NP (NP (JJ intravenous) (NNP Doc_227508_181_190_Chemical)) (, ,) (NP (QP (CD 5) (TO to) (CD 20)) (NN micrograms/kg)) (, ,))))) (VP (AUX was) (VP (VBD inhibited) (CC or) (VBN reversed) (PP (IN by) (NP (NP (NNP Doc_227508_244_252_Chemical)) (, ,) (NP (QP (CD 0.2) (TO to) (CD 2)) (NN mg/kg)))))) (. .)))
227508	2	(S1 (S (NP (NP (DT The) (JJ Doc_227508_274_285_Disease) (NN effect)) (PP (IN of) (NP (QP (CD 100) (CD mg/kg)) (NN Doc_227508_306_322_Chemical)))) (VP (AUX was) (ADVP (RB also)) (VP (ADVP (RB partially)) (VBN reversed) (PP (IN by) (NP (NNP Doc_227508_354_362_Chemical))))) (. .)))
227508	3	(S1 (S (NP (NN Doc_227508_364_372_Chemical)) (ADVP (RB alone)) (VP (AUX did) (RB not) (VP (VB affect) (ADVP (RB either)) (NP (NP (NN blood) (NN pressure)) (CC or) (NP (NN heart) (NN rate))))) (. .)))
227508	4	(S1 (S (PP (IN In) (NP (NP (NN brain) (NNS membranes)) (PP (IN from) (NP (ADJP (RB spontaneously) (JJ Doc_227508_469_481_Disease)) (NNS rats))))) (NP (NNP Doc_227508_487_496_Chemical)) (, ,) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-)) (TO to) (CD 10)) (PRN (-LRB- -LRB-) (JJ -5) (-RRB- -RRB-)) (NP (NNP M)) (, ,)) (VP (AUX did) (RB not) (VP (VB influence) (S (VP (VP (VB stereoselective) (ADJP (JJ binding) (PP (IN of) (NP (NP (NP (NP (NNP Doc_227508_563_576_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 8) (NNS nM)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_227508_589_597_Chemical))) (, ,) (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -4) (-RRB- -RRB-))) (NP (NNP M))))) (, ,) (VP (AUX did) (RB not) (VP (VB influence) (ADJP (JJ Doc_227508_637_646_Chemical-suppressible) (PP (VBG binding) (PP (IN of) (NP (NP (NNP Doc_227508_671_695_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN nM)) (-RRB- -RRB-)))))))))))) (. .)))
227508	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_227508_750_762_Disease)) (NNS rats))) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ central) (NN alpha-adrenoceptor) (NN stimulation)))) (VP (VBP involve) (NP (NP (NN activation)) (PP (IN of) (NP (NN opiate) (NNS receptors)))))))) (. .)))
227508	6	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_227508_865_873_Chemical) (CC and) (NNP Doc_227508_878_887_Chemical)) (VP (AUX do) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (DT the) (JJ same) (NN receptor) (NN site)))))))))) (, ,) (NP (DT the) (JJ observed) (JJ functional) (NN antagonism)) (VP (VBZ suggests) (NP (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (DT an) (JJ endogenous) (NN opiate)) (PP (IN by) (NP (NNP Doc_227508_1026_1035_Chemical) (CC or) (NNP Doc_227508_1039_1055_Chemical)))))) (CC and) (NP (NP (DT the) (JJ possible) (NN role)) (PP (IN of) (NP (DT the) (NN opiate))) (PP (IN in) (NP (NP (DT the) (JJ central) (NN control)) (PP (IN of) (NP (JJ sympathetic) (NN tone)))))))) (. .)))
230316	0	(S1 (NP (NP (NP (NN Doc_230316_0_13_Disease)) (PP (IN of) (NP (NNP Doc_230316_17_46_Chemical)))) (: :) (NP (NP (JJ clinical) (NN analysis)) (PP (IN of) (NP (NP (NNS cases)) (VP (VBN reported) (PP (IN outside) (NP (NNP Japan))))))) (. .)))
230316	1	(S1 (S (NP (DT An) (NN analysis)) (VP (AUX is) (VP (VBN presented) (PP (IN of) (NP (NP (CD 220) (NNS cases)) (PP (IN of) (NP (JJ possible) (NN Doc_230316_149_159_Disease) (NNS reactions))))) (PP (TO to) (NP (NP (NNP Doc_230316_173_202_Chemical)) (VP (VBN reported) (PP (IN from) (PP (IN outside) (NP (NNP Japan))))))))) (. .)))
230316	2	(S1 (S (PP (PP (IN In) (NP (NP (CD 80) (NNS cases)) (SBAR (S (NP (JJ insufficient) (NN information)) (VP (AUX was) (ADJP (JJ available) (PP (IN for) (NP (JJ adequate) (NN comment))))))))) (CC and) (PP (IN in) (NP (CD 29)))) (NP (NP (DT a) (NN relationship)) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_230316_354_364_Chemical)))))) (VP (MD could) (VP (AUX be) (VP (VBN excluded)))) (. .)))
230316	3	(S1 (S (PP (IN Of) (NP (DT the) (NN remainder))) (, ,) (NP (NP (DT a) (NN relationship)) (PP (TO to) (NP (NNP Doc_230316_420_430_Chemical)))) (VP (AUX was) (VP (VBN considered) (ADJP (ADJP (JJ probable) (PP (IN in) (NP (CD 42)))) (CC and) (ADJP (JJ possible) (PP (IN in) (NP (CD 69) (NNS cases))))))) (. .)))
230316	4	(S1 (S (PP (IN In) (NP (NP (CD six)) (PP (IN of) (NP (DT the) (JJ probable) (NNS cases))))) (NP (DT the) (NNP Doc_230316_520_544_Disease)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT an) (JJ acute) (JJ reversible) (NN Doc_230316_578_592_Disease)) (VP (ADVP (RB usually)) (VBN related) (PP (TO to) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_230316_644_654_Chemical))) (PP (IN over) (NP (DT a) (JJ short) (NN period))))))))))) (. .)))
230316	5	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NN manifestation)) (, ,) (VP (VBN observed) (PP (IN in) (NP (CD 15) (JJ further) (NNS cases)))) (, ,)) (VP (AUX was) (VP (VBN isolated) (NP (NN Doc_230316_750_763_Disease)))) (. .)))
230316	6	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RBS most) (RB frequently)) (VP (VBN found) (PP (IN in) (NP (NP (NNS children)) (, ,) (SBAR (WHNP (NP (DT many)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (VP (VBN received) (NP (NNP Doc_230316_835_845_Chemical)) (PP (IN as) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_230316_863_891_Disease))))))))))))) (. .)))
230316	7	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (NNS cases))) (, ,) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_230316_934_944_Disease)) (, ,) (NP (NNP Doc_230316_946_964_Disease)) (, ,) (CC and) (NP (NNP Doc_230316_970_991_Disease))))) (VP (AUX was) (NP (DT the) (ADJP (RBS most) (JJ common)) (NN manifestation))) (. .)))
230316	8	(S1 (S (NP (NP (JJ Isolated) (NNP Doc_230316_1036_1046_Disease) (CC or) (NNP Doc_230316_1050_1071_Disease)) (, ,) (CC or) (NP (NP (DT these) (NNS manifestations)) (VP (VBG occurring) (ADVP (RB together)))) (, ,)) (VP (AUX were) (ADJP (JJ infrequent))) (. .)))
230316	9	(S1 (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (DT all) (NNS manifestations)))) (PRN (-LRB- -LRB-) (PP (IN except) (NP (JJ toxic) (NNP Doc_230316_1180_1194_Disease))) (-RRB- -RRB-)) (VP (AUX was) (ADVP (RB usually)) (NP (NN subacute)) (, ,) (PP (IN with) (NP (JJ subsequent) (JJ partial) (NN recovery)))) (. .)))
230316	10	(S1 (S (NP (JJR Older) (NNS subjects)) (VP (VBD tended) (S (VP (TO to) (VP (VB display) (NP (JJR more) (NN side) (NNS effects)))))) (. .)))
230316	11	(S1 (S (S (NP (NP (DT The) (JJ full) (NN syndrome)) (PP (IN of) (NP (JJ subacute) (NNP Doc_230316_1334_1356_Disease)))) (VP (AUX was) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NNS women))))) (, ,) (CC but) (S (NP (PRP they)) (VP (VBD tended) (S (VP (TO to) (VP (AUX have) (VP (VBN taken) (NP (NP (JJR greater) (NNS quantities)) (PP (IN of) (NP (DT the) (NN drug)))))))))) (. .)))
2304736	0	(S1 (NP (JJ Doc_2304736_0_8_Chemical-induced) (NN Doc_2304736_17_36_Disease) (. .)))
2304736	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (JJ genuine) (NN Doc_2304736_56_75_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_2304736_83_91_Chemical)) (, ,) (NP (DT a) (JJ common) (NN antihypertensive) (NN drug)) (, ,))))))) (VP (AUX is) (VP (VBN presented))) (. .)))
2304736	2	(S1 (S (NP (NN Doc_2304736_139_147_Chemical)) (VP (VBZ exerts) (NP (PRP$ its) (JJ antihypertensive) (NNS effects)) (PP (IN through) (NP (NP (NN vasodilatation)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ selective) (NN blockade)) (PP (IN of) (NP (JJ postsynaptic) (JJ alpha-1) (JJ adrenergic) (NNS receptors))))))))) (. .)))
2304736	3	(S1 (S (PP (IN As) (NP (DT an) (NN alpha-blocker))) (, ,) (NP (PRP it)) (ADVP (RB also)) (VP (VBZ exerts) (NP (NP (DT a) (JJ significant) (JJ relaxant) (NN effect)) (PP (IN on) (NP (DT the) (NN bladder) (NN neck) (CC and) (NN urethra))))) (. .)))
2304736	4	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ clinical) (NN course)) (VP (AUX is) (VP (VP (VBN described)) (CC and) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ initial) (JJ urodynamic) (NNS studies) (NN while)) (PP (IN on) (NP (NP (NNP Doc_2304736_480_488_Chemical)) (CC and) (NP (JJ subsequent) (NNS studies)))))) (SBAR (IN while) (S (VP (VBG taking) (NP (NNP Doc_2304736_525_534_Chemical)))))))) (. .)))
2304736	5	(S1 (S (NP (PRP$ Her) (NNP Doc_2304736_540_552_Disease)) (VP (VBN resolved) (PP (IN with) (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN medication)))))) (. .)))
2304736	6	(S1 (S (NP (NP (DT The) (NN restoration)) (PP (IN of) (NP (NN continence)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ substantial) (NN rise)) (PP (IN in) (NP (NP (JJ maximum) (JJ urethral) (NN pressure)) (, ,) (NP (NN maximum) (NN urethral) (NN closure) (NN pressure)) (, ,) (CC and) (NP (JJ functional) (JJ urethral) (NN length)))))))) (. .)))
2304736	7	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP present) (PP (IN with) (NP (NNP Doc_2304736_784_803_Disease))) (SBAR (IN while) (S (VP (VBG taking) (NP (NN Doc_2304736_817_825_Chemical))))))))) (VP (MD should) (VP (VB change) (NP (PRP$ their) (JJ antihypertensive) (NN medication)) (PP (IN before) (S (VP (VBG considering) (NP (NN surgery))))) (, ,) (SBAR (IN because) (S (NP (PRP$ their) (NN Doc_2304736_916_928_Disease)) (VP (MD may) (VP (VB resolve) (ADVP (RB spontaneously)) (PP (IN with) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN drug) (NN therapy))))))))))) (. .)))
2312209	0	(S1 (S (VP (VB Doc_2312209_0_21_Disease) (S (VP (VBG following) (NP (NP (NN sublingual) (NN administration)) (PP (IN of) (NP (NNP Doc_2312209_61_81_Chemical))))))) (. .)))
2312209	1	(S1 (S (NP (NP (DT A) (NN 78-year-old)) (PP (IN with) (NP (VBN healed) (JJ septal) (NN Doc_2312209_116_124_Disease)))) (VP (VBD suffered) (NP (NP (DT a) (JJ recurrent) (NN Doc_2312209_146_167_Disease)) (PP (IN of) (NP (DT the) (NNP anterior) (NN wall)))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2312209_221_241_Chemical) (CD 5))) (VP (VBN mg) (ADVP (RB sublingually)))))) (. .)))
2312209	2	(S1 (S (PP (IN After) (S (VP (VBG detailing) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNS events))))))) (, ,) (NP (PRP we)) (VP (VB discuss) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ paradoxical) (JJ coronary) (NNP Doc_2312209_343_348_Disease)) (CC and) (NP (NNP Doc_2312209_353_364_Disease-mediated) (NNP Doc_2312209_374_393_Disease)))) (VP (VBG occurring) (NP (ADJP (JJ downstream) (TO to) (JJ significant)) (NNP Doc_2312209_430_456_Disease)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_2312209_483_511_Disease)))))))) (. .)))
2334618	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS effects)) (PP (IN of) (NP (NP (JJ i.v.) (NNS infusions)) (PP (IN of) (NP (NP (NNP Doc_2334618_59_67_Chemical)) (CC and) (NP (JJ regional) (NNS analgesia)))))))) (PP (IN by) (NP (JJ extradural) (NN block))) (. .)))
2334618	1	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (JJ respiratory) (NN Doc_2334618_155_161_Disease)))) (VP (AUX was) (VP (VBN compared) (PP (IN between) (NP (NP (NP (CD five) (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ continuous) (JJ i.v.) (NN infusion)) (PP (IN of) (NP (NNP Doc_2334618_237_245_Chemical)))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 73.6) (NN mg)))) (-RRB- -RRB-)))) (CC and) (NP (NP (CD five) (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ continuous) (JJ extradural) (NN infusion)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_2334618_331_342_Chemical))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 192) (NN mg)))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ 24-h) (NN period)) (PP (VBG following) (NP (JJ upper) (JJ abdominal) (NN surgery))))))))))) (. .)))
2334618	2	(S1 (S (S (NP (NN Monitoring)) (VP (VBN consisted) (PP (IN of) (NP (NN airflow) (NN detection))) (PP (IN by) (NP (DT a) (JJ Doc_2334618_458_472_Chemical) (NN analyser))))) (, ,) (S (NP (NN chest) (NN wall) (NN movement)) (VP (VBN detected) (PP (IN by) (NP (JJ pneumatic) (NNS capsules))))) (, ,) (CC and) (S (NP (JJ continuous) (NN electrocardiograph)) (VP (VBD recorded) (PP (IN with) (NP (DT a) (NNP Holter) (JJ ambulatory) (NN monitor))))) (. .)))
2334618	3	(S1 (S (NP (NP (DT Both) (NNP Doc_2334618_617_666_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT a) (JJ Doc_2334618_733_741_Chemical) (NN infusion)))))))) (. .)))
2334618	4	(S1 (S (NP (EX There)) (VP (AUX was) (ADVP (RB also)) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_2334618_789_805_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2334618_829_854_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (JJ Doc_2334618_881_889_Chemical) (NN infusion) (NN group))))) (. .)))
234669	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_234669_11_24_Chemical))) (PP (IN on) (NP (NP (DT the) (NN threshold)) (PP (IN for) (S (VP (VBG initiating) (NP (NNP Doc_234669_57_81_Disease)) (PP (IN during) (NP (NN Doc_234669_89_108_Disease)))))))) (. .)))
234669	1	(S1 (S (NP (NN Doc_234669_110_129_Disease)) (VP (AUX have) (ADVP (RB frequently)) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NNP Doc_234669_180_199_Disease)))))))) (. .)))
234669	2	(S1 (S (NP (NP (DT The) (JJ possible) (JJ additive) (NN role)) (PP (IN of) (NP (JJ pharmacologic) (NNS agents))) (PP (IN in) (S (VP (VBG precipitating) (NP (NN Doc_234669_269_289_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_234669_307_326_Disease))))))))) (VP (AUX has) (ADVP (RB only) (RB recently)) (VP (AUX been) (VP (VBN emphasized)))) (. .)))
234669	3	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_234669_377_390_Chemical))) (PP (IN on) (NP (DT the) (NNP Doc_234669_398_422_Disease) (NN threshold))) (PP (PP (IN during) (NP (JJ normal) (JJ acid-base) (NNS conditions))) (CC and) (PP (IN during) (NP (NNP Doc_234669_479_498_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (JJ anesthetized) (JJ open) (NN chest) (NNS dogs))))) (. .)))
234669	4	(S1 (S (NP (DT The) (NNP Doc_234669_549_573_Disease) (NN threshold)) (VP (AUX was) (VP (VBN measured) (PP (IN by) (S (VP (VBG passing) (NP (NP (DT a) (JJ gated) (NN train)) (PP (IN of) (NP (CD 12) (JJ constant) (JJ current) (NNS pulses)))) (PP (IN through) (NP (NP (DT the) (JJ ventricular) (NN myocardium)) (PP (IN during) (NP (NP (DT the) (JJ vulnerable) (NN period)) (PP (IN of) (NP (DT the) (JJ cardiac) (NN cycle)))))))))))) (. .)))
234669	5	(S1 (S (PP (IN During) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_234669_761_774_Chemical))))) (, ,) (NP (DT the) (NNP Doc_234669_780_804_Disease) (NN threshold)) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (CD 30) (TO to) (CD 40)) (NN percent)) (PP (IN of) (NP (DT the) (NN control))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ pH) (CC and) (JJ partial) (NNS pressures)) (PP (IN of) (NP (NP (NP (NNP Doc_234669_895_901_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_234669_903_906_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_234669_912_926_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_234669_928_931_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN kept) (PP (IN within) (NP (JJ normal) (NNS limits))))))))) (. .)))
234669	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_234669_970_989_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_234669_1006_1021_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB pH) (CD 7.05) (TO to) (CD 7.25))) (: ;) (NP (NP (QP (CD PC02) (CD 70) (TO to) (CD 100)) (NNS mm)) (NP (NNP Hg))) (: :) (NP (NP (QP (CD P02) (CD 20) (TO to) (CD 40)) (NNS mm)) (NP (NNP Hg)))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_234669_1095_1108_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (ADJP (RB even) (JJR greater)) (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_234669_1149_1173_Disease) (NN threshold)) (PP (TO to) (NP (NP (CD 60) (NN percent)) (PP (IN of) (NP (DT the) (NN control) (NN level)))))))))) (. .)))
234669	7	(S1 (S (NP (DT These) (NNS experiments)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR (IN although) (S (NP (JJ many) (NNS factors)) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (VBN increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_234669_1318_1341_Disease))) (PP (IN in) (NP (NNP Doc_234669_1345_1364_Disease))))))))) (, ,) (NP (NP (JJ pharmacologic) (NNS agents)) (, ,) (ADJP (RB particularly) (JJ Doc_234669_1401_1414_Chemical)) (, ,)) (VP (MD may) (VP (VB play) (NP (DT a) (JJ significant) (NN role))))))) (. .)))
2348231	0	(S1 (S (S (NP (NP (NNP Doc_2348231_0_14_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2348231_16_23_Chemical)) (-RRB- -RRB-))) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (JJ Doc_2348231_42_54_Chemical-induced) (JJ coronary) (NN Doc_2348231_72_81_Disease))))) (: :) (S (NP (NNS implications)) (PP (IN for) (NP (JJ Doc_2348231_100_112_Chemical-Doc_2348231_113_121_Chemical-201) (JJ myocardial) (NN imaging)))) (. .)))
2348231	1	(S1 (S (NP (CD Doc_2348231_146_158_Chemical-Doc_2348231_159_167_Chemical-201) (NN imaging)) (VP (AUX is) (ADVP (RB often)) (VP (VBN performed) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ unable) (S (VP (TO to) (VP (VB exercise) (PP (IN because) (IN of) (NP (NN Doc_2348231_241_268_Disease))))))))))) (. .)))
2348231	2	(S1 (S (NP (NP (DT Many)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX are) (VP (VBG taking) (NP (NP (NP (NNP Doc_2348231_304_318_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2348231_320_327_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ Doc_2348231_332_346_Chemical) (NN derivative)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB improve) (NP (NN Doc_2348231_376_401_Disease)))))))))) (. .)))
2348231	3	(S1 (S (SBAR (IN Whether) (S (NP (NNP Doc_2348231_411_425_Chemical)) (VP (VP (VBZ inhibits) (NP (JJ Doc_2348231_435_447_Chemical-induced) (JJ coronary) (NN Doc_2348231_465_474_Disease)) (PP (IN like) (NP (NP (JJ other) (JJ Doc_2348231_486_501_Chemical)) (PP (JJ such) (IN as) (NP (NNP Doc_2348231_510_522_Chemical)))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN stopped) (ADVP (RB prior) (PP (TO to) (NP (CD Doc_2348231_554_566_Chemical-Doc_2348231_567_575_Chemical-201) (NN imaging)))))))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
2348231	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ hyperemic) (NN response)) (PP (TO to) (NP (NNP Doc_2348231_648_660_Chemical)))) (PP (IN in) (NP (CD seven) (JJ open-chest) (JJ anesthetized) (NNS dogs))) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_2348231_730_744_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 7.5)) (, ,) (CC or) (NP (CD 15) (JJ mg/kg) (NNS i.v.))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_2348231_775_787_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-)))))))) (. .)))
2348231	5	(S1 (S (NP (NN Baseline) (NN circumflex) (JJ coronary) (NN blood) (NNS flows)) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN among) (NP (NN treatment) (NNS groups))))) (. .)))
2348231	6	(S1 (S (NP (NNP Doc_2348231_898_910_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (JJ coronary) (NN blood) (NN flow)) (PP (IN before) (CC and) (IN after) (NP (NP (QP (CD 7.5) (CC or) (CD 15)) (NN mm/kg)) (PP (IN i.v.) (NP (NP (NNP Doc_2348231_993_1007_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.002))) (-RRB- -RRB-))))))) (. .)))
2348231	7	(S1 (S (CC Neither) (NP (NP (NN dose)) (PP (IN of) (NP (NNP Doc_2348231_1045_1059_Chemical)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (DT the) (JJ Doc_2348231_1088_1100_Chemical-induced) (NN Doc_2348231_1109_1118_Disease)) (, ,) (SBAR (IN while) (S (NP (JJ peak) (JJ coronary) (NN blood) (NN flow)) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN after) (NP (NP (NNP Doc_2348231_1181_1193_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))))) (. .)))
2348231	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_2348231_1231_1246_Chemical)) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (JJ Doc_2348231_1264_1276_Chemical-induced) (JJ coronary) (NN Doc_2348231_1294_1303_Disease)) (ADVP (RB even)) (PP (IN at) (NP (JJ high) (NNS doses)))))))) (. .)))
2355241	0	(S1 (NP (NP (NP (NN Cause)) (PP (IN of) (NP (NNP Doc_2355241_9_14_Disease))) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2355241_35_54_Disease)))))) (: :) (NP (NP (DT a) (JJ rare) (NN mortality)) (ADJP (JJ due) (PP (TO to) (NP (NN Doc_2355241_80_100_Disease))))) (. .)))
2355241	1	(S1 (S (NP (NP (NNS Causes)) (PP (IN of) (NP (NNP Doc_2355241_112_117_Disease))) (, ,) (PP (IN with) (NP (NP (JJ special) (NN reference)) (PP (TO to) (NP (NNP Doc_2355241_145_165_Disease))))) (, ,)) (PP (IN among) (NP (NP (CD 240) (NNS patients)) (PP (IN with) (NP (ADJP (RB pathologically) (VBN verified)) (NNP Doc_2355241_215_234_Disease))))) (VP (AUX were) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (DT the) (NNS Annuals)) (PP (IN of) (NP (NP (DT the) (JJ Pathological) (NNP Autopsy) (NNS Cases)) (PP (IN in) (NP (NNP Japan))))) (PP (PP (IN from) (NP (CD 1981))) (PP (TO to) (NP (CD 1985))))))))) (. .)))
2355241	2	(S1 (S (NP (NP (DT The) (JJ leading) (NNS causes)) (PP (IN of) (NP (NNP Doc_2355241_355_360_Disease)))) (VP (AUX were) (NP (NP (NP (NNP Doc_2355241_366_375_Disease) (CC and) (NNP Doc_2355241_380_390_Disease)) (PRN (-LRB- -LRB-) (NP (CD 44.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ malignant) (NNP Doc_2355241_410_419_Disease) (PRN (-LRB- -LRB-) (NP (CD 11.6) (NN %)) (-RRB- -RRB-) (, ,)) (NNP Doc_2355241_429_443_Disease)) (PRN (-LRB- -LRB-) (NP (CD 4.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_2355241_452_471_Disease) (PRN (-LRB- -LRB-) (NP (CD 3.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2355241_483_494_Disease) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))))) (. .)))
2355241	3	(S1 (S (NP (NN Doc_2355241_503_523_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ 11th) (ADJP (RBS most) (JJ frequent)) (NN cause)) (PP (IN of) (NP (NNP Doc_2355241_560_565_Disease)))) (, ,) (S (VP (VBG accounting) (PP (IN for) (NP (NP (QP (RB only) (CD 0.8)) (NN %)) (PP (IN of) (NP (NNP Doc_2355241_595_601_Disease))))) (PP (IN among) (NP (DT the) (NNS patients))))) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX was) (NP (NP (DT the) (JJ 5th) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (NNP Doc_2355241_666_671_Disease)))) (PP (IN among) (NP (NP (DT the) (JJ Japanese) (JJ general) (NN population)) (PP (IN in) (NP (CD 1985))))))))) (. .)))
2355241	4	(S1 (S (NP (NP (DT The) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_2355241_740_760_Disease))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NP (NNP Doc_2355241_775_780_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2355241_798_817_Disease)))))))))) (VP (MD may) (VP (VB reflect) (NP (NP (NP (DT the) (JJ Doc_2355241_834_845_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2355241_856_864_Chemical)))) (CC and) (NP (NP (DT a) (JJ Doc_2355241_871_882_Disease) (NN mechanism)) (PP (JJ due) (TO to) (NP (NP (VBN reduced) (JJ Doc_2355241_908_921_Chemical) (NNS levels)) (PP (IN in) (NP (DT the) (NNP Doc_2355241_936_948_Disease) (NN brain))))))))) (. .)))
2375138	0	(S1 (NP (JJ Possible) (JJ intramuscular) (JJ Doc_2375138_23_32_Chemical-associated) (NNP Doc_2375138_44_68_Disease) (CC and) (NNP Doc_2375138_73_78_Disease) (. .)))
2375138	1	(S1 (S (NP (NN Doc_2375138_80_103_Chemical)) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN used) (PP (IN for) (NP (UCP (JJ dental) (CC or) (JJ endoscopic)) (NNS procedures))))) (. .)))
2375138	2	(S1 (S (SBAR (IN Although) (S (ADVP (RB generally)) (VP (VBD consisted) (ADJP (JJ safe)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NN intramuscularly)))))))) (, ,) (NP (JJ intravenous) (NN administration)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_2375138_265_306_Disease))))))) (. .)))
2375138	3	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT the) (JJ first) (JJ published) (NN case)) (PP (IN of) (NP (NP (NNP Doc_2375138_358_382_Disease)) (CC and) (NP (NNP Doc_2375138_387_392_Disease)))) (VP (VBN associated) (PP (IN with) (NP (NP (NN intramuscular) (NN administration)) (PP (IN of) (NP (NNP Doc_2375138_441_450_Chemical)))))))) (. .)))
2375138	4	(S1 (S (NP (NP (NN Information)) (VP (VBG regarding) (NP (JJ Doc_2375138_474_483_Chemical) (NN use)))) (VP (AUX is) (VP (VBN reviewed) (S (VP (TO to) (VP (VB provide) (NP (NN recommendation)) (PP (IN for) (NP (JJ safe) (NN administration)))))))) (. .)))
2385256	0	(S1 (S (NP (NN Doc_2385256_0_17_Disease)) (VP (VBG presenting) (PP (IN as) (NP (NN weakness))) (PP (IN after) (NP (NNP Doc_2385256_47_56_Chemical) (NN administration)))) (. .)))
2385256	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (DT no) (JJ prior) (NN history)) (PP (IN of) (NP (NNP Doc_2385256_119_140_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD became) (ADJP (RB virtually) (JJ Doc_2385256_162_174_Disease)) (PP (IN after) (NP (NP (JJ parenteral) (JJ Doc_2385256_192_201_Chemical) (NN administration)) (PP (IN for) (NP (NNP Doc_2385256_221_233_Disease)))))))))))) (. .)))
2385256	2	(S1 (S (NP (DT The) (NN serum) (JJ Doc_2385256_245_254_Chemical) (NN concentration)) (VP (AUX was) (NP (NP (CD 3.0) (NN mEq/L)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated))))))) (. .)))
2385256	3	(S1 (S (S (NP (DT The) (NNP Doc_2385256_321_330_Chemical)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (PRP she)) (VP (VBD recovered) (PP (IN over) (NP (DT a) (JJ few) (NNS days))))) (. .)))
2385256	4	(S1 (S (SBAR (IN While) (S (NP (PRP she)) (VP (AUX was) (ADJP (JJ weak))))) (, ,) (NP (JJ 2-Hz) (JJ repetitive) (NN stimulation)) (VP (VBD revealed) (NP (DT a) (NN decrement)) (PP (IN without) (NP (JJ significant) (NN facilitation))) (PP (PP (IN at) (NP (JJ rapid) (NNS rates))) (CC or) (PP (IN after) (NP (NN exercise)))) (, ,) (S (VP (VBG suggesting) (NP (NN Doc_2385256_525_560_Disease))))) (. .)))
2385256	5	(S1 (S (SBAR (IN After) (S (NP (PRP$ her) (NN strength)) (VP (VBD returned)))) (, ,) (S (NP (JJ repetitive) (NN stimulation)) (VP (AUX was) (ADJP (JJ normal)))) (, ,) (CC but) (S (NP (JJ single) (NN fiber) (NNP EMG)) (VP (VBD revealed) (NP (VBN increased) (NN jitter) (CC and) (VBG blocking)))) (. .)))
2385256	6	(S1 (S (NP (PRP$ Her) (JJ Doc_2385256_691_704_Chemical) (NN receptor) (NN antibody) (NN level)) (VP (AUX was) (ADJP (RB markedly) (JJ elevated))) (. .)))
2385256	7	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_2385256_761_770_Disease) (IN after) (NNP Doc_2385256_777_786_Chemical) (NN administration)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ known) (NN Doc_2385256_844_861_Disease)))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ initial) (CC or) (JJ only) (NN manifestation)) (PP (IN of) (NP (DT the) (NN disease)))))))))) (. .)))
2385256	8	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (RB unusually) (JJ sensitive) (PP (TO to) (NP (NP (DT the) (JJ neuromuscular) (NNS effects)) (PP (IN of) (NP (NNP Doc_2385256_1024_1033_Chemical)))))))))) (VP (MD should) (VP (AUX be) (VP (VBN suspected) (PP (IN of) (S (VP (AUXG having) (NP (DT an) (JJ underlying) (NN Doc_2385256_1078_1116_Disease)))))))) (. .)))
2396046	0	(S1 (NP (NP (DT No) (NN enhancement)) (PP (IN by) (NP (NP (NNP Doc_2396046_18_31_Chemical)) (PP (IN of) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (NP (DT a) (JJ Doc_2396046_66_73_Chemical-devoid) (NN diet)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
2396046	1	(S1 (S (NP (DT An) (NN experiment)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NN inclusion)) (PP (IN of) (NP (NNP Doc_2396046_155_168_Chemical))) (PP (IN in) (NP (DT a) (JJ Doc_2396046_174_181_Chemical-devoid) (NN diet)))) (VP (MD would) (VP (VB increase) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (DT the) (NN diet))))))))))))) (. .)))
2396046	2	(S1 (S (NP (NP (NNS Groups)) (PP (IN of) (NP (JJ 5-week) (JJ old) (NN male) (JJ Fischer-344) (NNS rats)))) (VP (AUX were) (VP (VBN fed) (PP (IN for) (NP (NP (CD 7-25) (NNS months)) (VP (VBN semipurified) (NP (NP (JJ Doc_2396046_329_336_Chemical-devoid) (CC or) (JJ Doc_2396046_347_354_Chemical-supplemented) (NNS diets)) (, ,) (VP (VBG containing) (NP (ADJP (QP (CC or) (RB not) (CD 0.06)) (NN %)) (NNP Doc_2396046_399_412_Chemical))))))))) (. .)))
2396046	3	(S1 (S (NP (NP (DT No) (JJ hepatic) (JJ preneoplastic) (NNS nodules) (CC or) (NN Doc_2396046_450_475_Disease)) (VP (VBN developed) (PP (IN in) (NP (NNS rats))))) (VP (VBN fed) (NP (DT the) (JJ plain) (JJ Doc_2396046_508_515_Chemical-supplemented) (NN diet)) (, ,) (SBAR (IN while) (S (NP (NP (CD one) (JJ preneoplastic) (NN nodule)) (CC and) (NP (CD one) (NN Doc_2396046_574_598_Disease))) (VP (VBD developed) (PP (IN in) (NP (NP (CD two) (NNS rats)) (VP (VBN fed) (NP (NP (DT the) (JJ same) (NN diet)) (VP (VBG containing) (NP (NNP Doc_2396046_650_663_Chemical))))))))))) (. .)))
2396046	4	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (PP (IN of) (NP (JJ preneoplastic) (NNS nodules))) (CC and) (PP (IN of) (NP (NNP Doc_2396046_711_736_Disease))))) (VP (AUX was) (NP (NP (NP (NP (CD 10) (NN %)) (CC and) (NP (CD 37) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN in) (NP (NNS rats))) (VP (VBN fed) (NP (DT the) (ADJP (RB plain) (JJ Doc_2396046_790_797_Chemical-devoid)) (NN diet)))) (, ,) (CC and) (NP (NP (NP (CD 17) (NN %)) (CC and) (NP (CD 30) (NN %)) (, ,)) (PP (IN in) (NP (NNS rats))) (VP (VBN fed) (NP (DT the) (JJ Doc_2396046_844_857_Chemical-containing) (JJ Doc_2396046_869_876_Chemical-devoid) (NN diet)))))) (. .)))
2396046	5	(S1 (S (NP (DT The) (NNS results)) (VP (VBN evinced) (NP (NP (DT no) (NN enhancement)) (PP (IN of) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (DT the) (JJ Doc_2396046_961_968_Chemical-devoid) (NN diet)))))) (PP (IN by) (NP (NNP Doc_2396046_984_997_Chemical)))) (. .)))
2396046	6	(S1 (S (NP (JJ Sporadic) (JJ neoplastic) (NNS lesions)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS organs)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS animals)))))))))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (DT the) (NN diet) (NN fed)))))) (. .)))
2425813	0	(S1 (S (PP (IN On) (NP (NP (CD two) (JJ paradoxical) (NNS side-effects)) (PP (IN of) (NP (NP (NNP Doc_2425813_35_47_Chemical)) (PP (IN in) (NP (NNS rats))))))) (, ,) (NP (JJ ribosomal) (NNP RNA)) (VP (VP (VBZ biosyntheses)) (, ,) (CC and) (NP (NP (DT a) (NN mechanism)) (PP (IN of) (NP (NN action))))) (. .)))
2425813	1	(S1 (S (NP (NP (NNP Doc_2425813_112_129_Disease)) (CC and) (NP (NNP Doc_2425813_134_148_Disease))) (VP (VBD occurred) (PP (IN in) (NP (JJ Wistar) (NNS rats))) (PP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_2425813_218_230_Chemical)))))) (. .)))
2425813	2	(S1 (S (PP (IN In) (NP (DT the) (NN liver))) (NP (NP (NP (PDT both) (DT the) (NN content)) (PP (IN of) (NP (NNP RNA)))) (CC and) (NP (NP (DT the) (NN biosynthesis)) (PP (IN of) (NP (JJ ribosomal) (NNP RNA))))) (VP (VBD increased) (SBAR (IN while) (S (NP (DT both) (NP (DT the) (NNP RNA) (NN content)) (CC and) (NP (JJ ribosomal) (NNP RNA)) (NNS biosynthesis)) (VP (AUX were) (VP (VBN reduced) (PP (IN in) (NP (DT the) (JJ gastrocnemius) (NN muscle)))))))) (. .)))
2425813	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT the) (NN drug)) (VP (VBD acted) (PP (IN in) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ tissue-specific)) (NN manner)) (SBAR (S (VP (TO to) (VP (VP (VB enhance) (NP (NP (JJ ribosomal) (NNP RNA)) (NN synthesis)) (PP (IN in) (NP (DT the) (NN liver)))) (CC and) (VP (VB depress) (NP (JJ such) (NN synthesis)) (PP (IN in) (NP (DT the) (NN muscle))))))))))))))) (. .)))
2425813	4	(S1 (S (NP (DT This) (NN view)) (VP (VBZ supports) (NP (DT the) (NN contention) (SBAR (IN that) (S (NP (DT the) (NP (NN liver)) (CC and) (NP (NN muscle))) (VP (AUX are) (NP (NP (JJ independent) (NNS sites)) (PP (IN of) (NP (JJ Doc_2425813_670_682_Chemical) (NN action))))))))) (. .)))
2440413	0	(S1 (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2440413_24_51_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_53_60_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ pharmacologically-induced) (NNP Doc_2440413_91_99_Disease))) (. .)))
2440413	1	(S1 (S (NP (NP (NP (NNP Doc_2440413_101_128_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_130_139_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ active) (NN ingredient)) (PP (IN of) (NP (DT the) (JJ insecticide) (NNP Doc_2440413_183_190_Chemical)))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB decrease) (NP (JJ Doc_2440413_219_226_Disease) (NN threshold)) (PP (TO to) (NP (JJ pentylenetrazol) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_257_260_Chemical)) (-RRB- -RRB-)) (NNP 3) (NNP h))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_2440413_284_293_Chemical)))))) (CC and) (VP (ADVP (RB conversely)) (VB increase) (NP (NN threshold)) (PP (TO to) (NP (JJ Doc_2440413_331_334_Chemical-induced) (NX (NNP Doc_2440413_343_351_Disease) (CD 24) (NNP h)))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_2440413_375_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Vohland) (FW et) (NNP al.) (CD 1981)) (-RRB- -RRB-))))))))))))) (. .)))
2440413	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (JJ other) (JJ Doc_2440413_457_464_Disease-inducing) (NNS agents)))))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NNS mice))) (NP (CD 1) (CC and) (CD 24) (NNP h)) (PP (IN after) (NP (NP (JJ intraperitoneal) (NN administration)) (PP (IN of) (NP (QP (CD 80) (CD mg/kg)) (NN Doc_2440413_560_569_Chemical))))))) (. .)))
2440413	3	(S1 (S (NP (NP (CD One) (NN hour)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2440413_608_617_Chemical)))))) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ Doc_2440413_635_642_Disease-inducing) (NNS agents)))) (VP (AUX was) (VP (VBN increased) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (PRP$ their) (NN mechanism)))) (, ,) (SBAR (IN while) (S (NP (NP (CD 24) (NNP h) (IN after) (NNP Doc_2440413_722_731_Chemical)) (NP (DT a) (NN differential) (NN response))) (VP (AUX was) (VP (VBN observed))))))) (. .)))
2440413	4	(S1 (S (S (NP (NP (NN Doc_2440413_770_777_Disease) (NN activity)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_2440413_794_797_Chemical)) (CC and) (NP (NP (NNP Doc_2440413_802_812_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_814_817_Chemical)) (-RRB- -RRB-))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN decreased)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_2440413_857_864_Disease) (NN activity)) (VP (ADVP (RB due) (PP (TO to) (NP (NP (NP (NP (NNP Doc_2440413_881_905_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_907_910_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_2440413_913_924_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_926_929_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_2440413_932_986_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_988_992_Chemical)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_2440413_998_1008_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_1010_1013_Chemical)) (-RRB- -RRB-))))) (AUX was) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NN control)))))) (. .)))
2440413	5	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (NNP Doc_2440413_1057_1066_Chemical) (, ,) (NNP Doc_2440413_1068_1085_Chemical) (CC and) (NNP Doc_2440413_1090_1100_Chemical)) (VP (AUX were) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NNP Doc_2440413_1123_1130_Chemical) (VBG binding)) (PP (IN in) (NP (NN mouse) (JJ whole) (NN brain))) (, ,) (PP (IN with) (NP (NP (CD IC50) (NNS values)) (PP (IN of) (NP (CD 4.6) (, ,) (CD 404) (CC and) (CD 9.4) (NN microM))))) (, ,) (ADVP (RB respectively))))))) (. .)))
2440413	6	(S1 (S (NP (NP (NNP Doc_2440413_1220_1223_Chemical)) (, ,) (NP (NNP Doc_2440413_1225_1228_Chemical)) (, ,) (NP (NNP Doc_2440413_1230_1234_Chemical)) (, ,) (CC and) (NP (NNP Doc_2440413_1240_1243_Chemical))) (VP (VBD showed) (NP (NP (DT no) (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_2440413_1268_1275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_1277_1306_Chemical)) (-RRB- -RRB-))))) (PP (VBG binding) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 100) (NN micron))))))) (. .)))
2440413	7	(S1 (S (NP (DT The) (JJ pharmacological) (NN challenge) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN tolerance)) (VP (MD may) (VP (VB occur) (PP (TO to) (NP (NP (JJ Doc_2440413_1420_1427_Disease) (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_2440413_1448_1451_Chemical)) (CC and) (NP (NNP Doc_2440413_1456_1459_Chemical) (CD 24) (NNP h)))) (PP (IN after) (NP (NNP Doc_2440413_1471_1480_Chemical)))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN response)) (PP (TO to) (NP (RB only) (DT these) (CD two) (JJ Doc_2440413_1519_1526_Disease-inducing) (NNS agents)))) (VP (AUX is) (VP (VBN decreased)))))))))) (. .)))
2440413	8	(S1 (S (NP (NP (DT The)) (PP (IN in) (NP (NN vitro) (NNS data)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN site)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NNP Doc_2440413_1629_1636_Disease) (NN activity) (CD 24))) (NP (NNP h) (IN after) (NNP Doc_2440413_1657_1666_Chemical)))))) (VP (MD may) (VP (AUX be) (NP (DT the) (JJ Doc_2440413_1678_1682_Chemical-A) (JJ receptor-linked) (NN chloride) (NN channel))))))) (. .)))
2445283	0	(S1 (NP (NP (NP (NN Tolerance)) (CC and) (NP (JJ antiviral) (NN effect))) (PP (IN of) (NP (NNP Doc_2445283_34_43_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2445283_61_88_Disease))))) (. .)))
2445283	1	(S1 (S (NP (NP (NN Tolerance)) (CC and) (NP (NP (JJ antiviral) (NN effect)) (PP (IN of) (NP (NNP Doc_2445283_124_133_Chemical))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 6) (NNS patients))) (PP (IN with) (NP (NP (NP (NNP Doc_2445283_165_192_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2445283_194_197_Disease)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 8)) (NNS days)) (PP (IN of) (NP (NN evolution))))))))) (. .)))
2445283	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_2445283_251_260_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN neutralization)) (PP (IN of) (NP (NNP Doc_2445283_293_300_Disease)))) (CC and) (NP (NP (DT a) (NN drop)) (PP (IN of) (NP (JJ endogenous) (NNP interferon) (NNS titers))))))) (. .)))
2445283	3	(S1 (S (NP (NP (DT The) (JJ average) (NN time)) (PP (IN of) (NP (NNP Doc_2445283_365_370_Disease)))) (VP (AUX was) (VP (VBN delayed))) (. .)))
2445283	4	(S1 (S (NP (DT A) (JJ reversible) (NN Doc_2445283_397_403_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ only) (JJ adverse) (NN effect)) (VP (VBN observed)))) (. .)))
2445283	5	(S1 (S (PP (IN From) (NP (DT these) (NNS results))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NNP Doc_2445283_479_488_Chemical)) (VP (AUX has) (NP (NP (DT an) (JJ antiviral) (NN effect)) (PP (IN in) (NP (NP (JJ advanced) (NNS cases)) (PP (IN of) (NP (NNP Doc_2445283_534_537_Disease))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NNP Doc_2445283_548_554_Disease)) (, ,) (NP (NP (DT the) (JJ only) (JJ secondary) (NN reaction)) (VP (VBN observed))) (, ,)) (VP (MD can) (VP (AUX be) (ADVP (RB easily)) (VP (VBN managed)))))))) (. .)))
2445283	6	(S1 (S (NP (NP (DT The) (JJ possible) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_2445283_651_660_Chemical))) (PP (IN during) (NP (NP (DT the) (JJ initial) (NNS days)) (PP (IN of) (NP (NNP Doc_2445283_688_691_Disease)))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
2476560	0	(S1 (SQ (AUX Is) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_2476560_20_27_Disease)))) (ADJP (JJ hazardous)) (. ?)))
2476560	1	(S1 (S (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NNP Doc_2476560_53_60_Disease)))) (VP (AUX is) (ADVP (RB usually)) (VP (VBN initiated) (PP (IN by) (NP (JJ general) (NNS practitioners)))))) (: ;) (S (NP (JJS most)) (VP (VBP consider) (NP (NP (NNP Doc_2476560_122_129_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2476560_131_157_Chemical)) (-RRB- -RRB-))) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN choice)))))) (. .)))
2476560	2	(S1 (S (S (NP (NN Doc_2476560_184_191_Chemical)) (VP (AUX is) (ADVP (RB also)) (ADVP (RB widely)) (VP (VBN used) (PP (IN as) (NP (DT an) (ADJP (JJ agricultural) (CC and) (JJ industrial)) (NN pesticide)))))) (, ,) (CC and) (S (PP (IN as) (NP (DT a) (NN result))) (NP (NP (DT the) (JJ toxic) (NN profile)) (PP (IN of) (NP (DT this) (NN insecticide)))) (VP (AUX is) (VP (ADVP (RB well)) (VBN understood)))) (. .)))
2476560	3	(S1 (S (NP (NN Evidence)) (VP (AUX is) (VP (VBG accumulating) (SBAR (IN that) (S (NP (NNP Doc_2476560_361_368_Chemical)) (VP (VP (MD can) (VP (AUX be) (ADJP (JJ Doc_2476560_376_411_Disease)))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NN Doc_2476560_439_455_Disease))))))))))) (. .)))
2476560	4	(S1 (S (NP (NP (NNS Preparations)) (VP (VBG containing) (NP (NNP Doc_2476560_481_488_Chemical)))) (VP (VP (VBP continue) (S (VP (TO to) (VP (AUX be) (VP (VBN sold) (PP (IN over) (NP (DT the) (NN counter)))))))) (CC and) (VP (MD may) (VP (VB represent) (NP (NP (DT a) (NN hazard)) (PP (TO to) (NP (ADJP (RB poorly) (VBN informed)) (NNS patients))))))) (. .)))
2476560	5	(S1 (S (NP (DT This) (NN literature) (NN review)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ general) (NNS practitioners)) (VP (MD should) (VP (VP (VB prescribe) (NP (NP (NNS scabicides)) (PP (IN with) (NP (NP (VBN increased) (NN caution)) (PP (IN for) (NP (JJ certain) (JJ at-risk) (NNS groups))))))) (, ,) (CC and) (VP (VB give) (NP (NP (JJ adequate) (NNS warnings)) (VP (VBG regarding) (NP (JJ potential) (NN Doc_2476560_767_775_Disease)))))))))) (. .)))
2484011	0	(S1 (NP (NP (NN Mouse) (JJ strain-dependent) (NN effect)) (PP (IN of) (NP (NNP Doc_2484011_33_43_Chemical))) (PP (IN on) (NP (NP (NN motility)) (CC and) (NP (NN brain) (JJ biogenic) (NN Doc_2484011_75_81_Chemical)))) (. .)))
2484011	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_2484011_97_121_Chemical)) (, ,) (NP (NP (VBN injected) (NN i.p.)) (PP (IN in) (NP (NP (CD 6) (NNS increments)) (PP (IN of) (NP (NP (CD 100) (NNS mg/kg)) (NP (DT each)))))) (PP (IN over) (NP (CD 30) (NNS hr)))) (, ,))) (PP (IN on) (NP (NP (NN mouse) (NN motility) (CC and) (JJ whole) (NN brain) (NN content)) (PP (IN of) (NP (JJ selected) (JJ biogenic) (JJ Doc_2484011_246_252_Chemical) (CC and) (JJ major) (NNS metabolites)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (CD 4) (NNS strains)) (PP (IN of) (NP (NNS mice))))))) (. .)))
2484011	2	(S1 (S (NP (DT These)) (VP (AUX were) (NP (NP (DT the) (NNP albino) (NNP Sprague-Dawley) (NNP ICR) (CC and) (NNP BALB/C)) (, ,) (NP (DT the) (JJ black) (NNP C57BL/6)) (CC and) (NP (DT the) (JJ brown) (JJ CDF-I) (NN mouse) (NNS strains)))) (. .)))
2484011	3	(S1 (S (NP (JJ Doc_2484011_415_425_Chemical) (NN treatment)) (VP (VBD produced) (NP (NP (DT a) (JJ biphasic) (NN effect)) (PP (IN on) (NP (NN mouse) (NN motility))))) (. .)))
2484011	4	(S1 (S (NP (NP (DT The) (JJ initial) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2484011_502_512_Chemical) (NNP Doc_2484011_513_522_Disease) (NN locomotor) (NN activity)) (PP (IN in) (NP (DT all) (NN mouse) (NNS strains)))))) (VP (VBD studied) (PP (IN with) (S (NP (DT the) (CD BALB/C) (NNS mice)) (VP (AUXG being) (NP (DT the) (RBS most) (JJ sensitive)))))) (. .)))
2484011	5	(S1 (S (NP (JJ Subsequent) (NNP Doc_2484011_629_639_Chemical) (NNS treatments)) (VP (VBD produced) (NP (NP (NN enhancement)) (PP (IN of) (NP (NN motility)))) (PP (IN from) (NP (JJ corresponding) (NN control))) (PP (IN in) (NP (DT all) (NN mouse) (NNS strains))) (PP (IN with) (S (NP (DT the) (CD BALB/C) (NNS mice)) (VP (AUXG being) (ADJP (DT the) (JJS least) (JJ sensitive)))))) (. .)))
2484011	6	(S1 (S (NP (DT The) (NN locomotor) (NN activity)) (VP (AUX was) (VP (VBN decreased) (PP (IN from) (NP (NP (JJ corresponding) (NNS controls)) (PP (IN in) (NP (NP (DT all) (NNS strains)) (VP (VBN studied)))) (, ,) (PP (IN except) (PP (IN for) (NP (DT the) (NNP ICR) (NNS mice)))))) (, ,) (PP (IN during) (NP (NP (DT an) (JJ overnight) (JJ drug-free) (NN period)) (PP (VBG following) (NP (DT the) (JJ fourth) (JJ Doc_2484011_952_962_Chemical) (NN treatment))))))) (. .)))
2484011	7	(S1 (S (NP (NP (NN Readministration)) (PP (IN of) (NP (NNP Doc_2484011_994_1004_Chemical)))) (, ,) (PP (IN after) (NP (DT a) (JJ drug-free) (JJ overnight) (NN period))) (, ,) (VP (VBD increased) (NP (NN motility)) (PP (IN from) (NP (JJ respective) (NN saline) (NN control))) (PP (IN in) (NP (NP (DT all) (NNS strains)) (PP (IN with) (NP (NP (NN exception)) (PP (IN of) (NP (NP (DT the) (JJ BALB/C) (NNS mice)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_2484011_1147_1170_Disease)) (VP (VBD occurred))))))))))) (. .)))
2484011	8	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_2484011_1196_1206_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (JJ whole) (NN brain) (NN Doc_2484011_1233_1241_Chemical) (NNS levels)))) (CC but) (VP (VBD decreased) (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NNP Doc_2484011_1278_1308_Chemical)))) (PP (IN in) (NP (NP (DT the) (JJ BALB/C) (NNS mice)) (VP (VBN compared) (S (VP (TO to) (VP (VB saline) (NP (NN control)))))))))) (. .)))
2484011	9	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NN brain) (JJ Doc_2484011_1374_1389_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NN saline) (NN control))) (PP (IN by) (NP (NP (NNP Doc_2484011_1441_1451_Chemical)) (PP (IN in) (NP (DT the) (JJ BALB/C) (NNS mice))))))) (. .)))
2484011	10	(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBP suggest) (NP (NP (DT a) (JJ strain-dependent) (NN effect)) (PP (IN of) (NP (NNP Doc_2484011_1521_1531_Chemical))) (PP (IN on) (NP (NN motility))))) (CC and) (VP (VBP indicate) (NP (NP (DT a) (NN differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ acute) (CC and) (JJ multiple) (NN dose) (NNS regimens)) (VP (VBN used))))))) (. .)))
2484011	11	(S1 (S (NP (DT The) (JJ BALB/C) (NN mouse)) (VP (VP (AUX was) (NP (DT the) (ADJP (RBS most) (JJ sensitive)) (NN strain))) (CC and) (VP (MD could) (VP (VB serve) (PP (IN as) (NP (NP (DT the) (NN strain)) (PP (IN of) (NP (NN choice))) (PP (IN for) (S (VP (VBG evaluating) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_2484011_1749_1759_Chemical)))))))))))) (. .)))
2484011	12	(S1 (S (NP (NP (DT The) (JJ biochemical) (NNS results)) (PP (IN of) (NP (NP (NN brain) (NN biogenic) (NNP Doc_2484011_1803_1809_Chemical)) (PP (IN of) (NP (JJ BALB/C) (NN mouse) (NN strain)))))) (VP (VBP suggest) (NP (NP (NP (DT a) (JJ probable) (NN decrease)) (PP (IN of) (NP (NP (JJ Doc_2484011_1864_1877_Chemical) (NN turnover) (NN rate) (NN and/or) (NN metabolism)) (PP (IN by) (NP (JJ monoamine) (NN oxidase)))))) (CC and) (NP (NP (DT a) (VBG resulting) (NN increase)) (PP (IN in) (NP (NP (NNP O-methylation)) (PP (IN of) (NP (NNP Doc_2484011_1976_1990_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (DT a) (NN Doc_2484011_2015_2036_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_2484011_2047_2057_Chemical)) (PP (IN in) (NP (DT the) (CD BALB/C) (NNS mice))))))))))))))))) (. .)))
2505783	0	(S1 (NP (NP (NP (NN Doc_2505783_0_18_Chemical)) (CC and) (NP (NP (PRP$ its) (NN contribution)) (PP (TO to) (NP (NN urotoxicity))))) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_2505783_77_93_Chemical)) (CC or) (NP (NNP Doc_2505783_97_107_Chemical)))) (. .)))
2505783	1	(S1 (NP (NP (DT An) (JJ experimental) (NN study/short) (NN communication)) (. .)))
2505783	2	(S1 (S (S (VP (VBN Based) (PP (IN on) (NP (JJ clinical) (NNS data))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NNP Doc_2505783_192_210_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2505783_212_215_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN metabolite)) (PP (IN of) (NP (JJ oxazaphosphorine) (NNS cytostatics))))))))))) (, ,) (NP (DT an) (JJ experimental) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_2505783_349_352_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2505783_375_395_Disease)))))))))) (. .)))
2505783	3	(S1 (S (NP (DT The) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_2505783_423_426_Chemical)) (PP (IN after) (NP (CD i.v.) (NN administration))) (VP (AUX does) (RB not) (VP (VB contribute) (PP (TO to) (NP (NN Doc_2505783_476_490_Disease)))))))) (. .)))
2505783	4	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN instilled) (ADVP (RB directly)) (PP (IN into) (NP (DT the) (NN bladder)))))) (, ,) (NP (NNP Doc_2505783_534_537_Chemical)) (VP (VBZ exerts) (NP (JJ urotoxic) (NNS effects)))) (, ,) (S (NP (PRP it)) (VP (AUX is) (, ,) (ADVP (RB however)) (, ,) (ADJP (JJ susceptible) (PP (TO to) (NP (NP (NN detoxification)) (PP (IN with) (NP (NNP Doc_2505783_614_619_Chemical)))))))) (. .)))
2515254	0	(S1 (NP (NP (NP (NN Source)) (PP (IN of) (NP (NP (NN Doc_2515254_10_14_Disease)) (CC and) (NP (JJ primitive) (NN dysfunction)))) (PP (IN in) (NP (NNP Doc_2515254_44_52_Disease)))) (: :) (NP (DT an) (JJ identical) (NN site)) (. ?)))
2515254	1	(S1 (S (NP (CD Twenty) (JJ common) (NNP Doc_2515254_87_95_Disease) (NNS patients)) (VP (VBD received) (NP (NP (DT a) (NN one)) (VP (VBN sided) (NP (NP (NP (JJ frontotemporal) (NN application)) (PP (IN of) (NP (NNP Doc_2515254_156_169_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS patients)) (-RRB- -RRB-)) (CC or) (NP (NP (NN placebo) (NN ointment)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS patients)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT a) (JJ double) (JJ blind) (NN study)))))) (. .)))
2515254	2	(S1 (S (NP (JJ Early) (NN onset) (NN Doc_2515254_255_263_Disease) (NNS attacks)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2515254_288_301_Chemical))) (PP (IN in) (NP (NP (NP (CD seven)) (PP (IN out) (PP (IN of) (NP (CD 10) (NNS patients))))) (CC versus) (NP (NP (DT no) (NN patient)) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))))) (. .)))
2515254	3	(S1 (S (NP (NP (QP (RB Subsequently) (CD 20)) (JJ Doc_2515254_386_394_Disease) (NNS patients)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT an) (JJ early) (NN onset) (NN attack)) (PP (IN with) (NP (JJ frontotemporal) (NNP Doc_2515254_461_474_Chemical))))))) (, ,)) (VP (VBD received) (NP (DT the) (NN drug)) (PP (IN in) (NP (NP (DT a) (JJ second) (NN induction) (NN test)) (PP (IN at) (NP (JJ other) (NN body) (NNS areas)))))) (. .)))
2515254	4	(S1 (S (NP (DT No) (JJ early) (NN onset) (NN Doc_2515254_557_565_Disease)) (VP (AUX was) (VP (VBN observed))) (. .)))
2515254	5	(S1 (S (ADVP (RB Thus)) (NP (NP (DT the) (JJ Doc_2515254_589_597_Disease-inducing) (NN effect)) (PP (IN of) (NP (NNP Doc_2515254_617_630_Chemical)))) (VP (VBZ seems) (S (VP (TO to) (VP (VB depend) (PP (IN on) (NP (NP (JJ direct) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (JJ habitual) (NN site)) (PP (IN of) (NP (NNP Doc_2515254_693_697_Disease))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (JJ frontotemporal) (NN region)) (VP (AUX is) (PP (IN of) (NP (JJ crucial) (NN importance))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT a) (JJ Doc_2515254_790_798_Disease) (NN crisis)))))))))))))) (. .)))
2515254	6	(S1 (S (NP (DT This)) (VP (AUX is) (RB not) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ CNS) (NN origin)) (PP (IN of) (NP (NN Doc_2515254_851_859_Disease) (NN attack))))))) (. .)))
2522601	0	(S1 (S (NP (NP (NN Doc_2522601_0_16_Disease)) (PP (TO to) (NP (NNP Doc_2522601_20_33_Chemical)))) (VP (VBG presenting) (PP (IN with) (NP (NP (DT a) (NNP Doc_2522601_52_70_Disease)) (, ,) (NP (NNP Doc_2522601_72_84_Disease)) (, ,) (NP (NNP Doc_2522601_86_98_Disease)) (, ,) (CC and) (NP (NNP Doc_2522601_104_117_Disease))))) (. .)))
2522601	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_2522601_147_163_Disease)) (VP (TO to) (VP (VB Doc_2522601_167_180_Chemical) (VP (VBN presented) (PP (IN with) (NP (NP (JJ generalized) (NNP Doc_2522601_208_220_Disease)) (, ,) (NP (DT a) (JJ severe) (NN Doc_2522601_231_249_Disease)) (, ,) (NP (NNP Doc_2522601_251_263_Disease)) (, ,) (NP (NNP Doc_2522601_265_277_Disease)) (, ,) (CC and) (NP (NNP Doc_2522601_283_296_Disease))))))))))) (. .)))
2522601	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (NP (PDT such) (DT an) (JJ unusual) (NN reaction)) (PP (TO to) (NP (NNP Doc_2522601_354_367_Chemical))))))) (. .)))
2549018	0	(S1 (NP (NP (JJ Doc_2549018_0_10_Chemical-induced) (NNP Doc_2549018_19_28_Disease)) (: :) (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ theoretical))) (NNS implications)) (. .)))
2549018	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2549018_93_103_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_2549018_125_154_Disease)) (CC or) (NP (NNP Doc_2549018_158_174_Disease)))))))) (VP (VBD developed) (NP (NN Doc_2549018_185_194_Disease))) (. .)))
2549018	2	(S1 (S (NP (NP (DT The) (JJ typical) (JJ Doc_2549018_208_218_Chemical-induced) (NNS symptoms)) (PP (IN of) (NP (NP (NN restlessness)) (, ,) (NP (JJ constant) (NN pacing)) (, ,) (NP (NP (JJ purposeless) (NNS movements)) (PP (IN of) (NP (NP (DT the) (NNS feet)) (CC and) (NP (NNS legs))))) (, ,) (CC and) (NP (JJ marked) (NN Doc_2549018_325_332_Disease))))) (VP (AUX were) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_2549018_390_399_Disease))))))) (. .)))
2549018	3	(S1 (S (NP (NP (CD Three) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ neuroleptic-induced) (NN Doc_2549018_456_465_Disease)) (PP (IN in) (NP (DT the) (NN past)))))))) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_2549018_508_518_Chemical-induced) (NNP Doc_2549018_527_536_Disease)))) (VP (AUX were) (ADJP (JJ identical)) (, ,) (SBAR (IN although) (S (ADJP (RB somewhat) (JJR milder)))))))) (. .)))
2549018	4	(S1 (S (NP (NN Doc_2549018_579_588_Disease)) (VP (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ common) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_2549018_628_638_Chemical)))))))) (CC and) (VP (ADVP (RB generally)) (VBD responded) (ADVP (RB well)) (PP (TO to) (NP (NN treatment))) (PP (IN with) (NP (NP (DT the) (JJ beta-adrenergic) (NN antagonist) (NN Doc_2549018_717_728_Chemical)) (, ,) (NP (NN dose) (NN reduction)) (, ,) (CC or) (NP (DT both)))))) (. .)))
2549018	5	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_2549018_780_790_Chemical-induced) (NNP Doc_2549018_799_808_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (ADJP (RB serotonergically) (VBN mediated)) (NN inhibition)) (PP (IN of) (NP (JJ dopaminergic) (NN neurotransmission)))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (NNP Doc_2549018_929_939_Chemical-induced) (NNP Doc_2549018_948_957_Disease)) (CC and) (NP (JJ tricyclic) (JJ Doc_2549018_972_986_Chemical-induced) (`` ``) (NNS jitteriness) ('' ''))))) (VP (MD may) (VP (AUX be) (ADJP (JJ identical)))))))) (. .)))
2559236	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (S (VP (VBG converting) (NP (JJ enzyme) (NN inhibition)) (PP (IN on) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_2559236_56_66_Chemical-induced) (NNP Doc_2559236_75_86_Disease)))))))) (. .)))
2559236	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT the) (VBG converting) (NN enzyme) (NN inhibitor) (-LRB- -LRB-) (NNP CEI) (-RRB- -RRB-) (NNP Doc_2559236_140_149_Chemical)))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ Munich-Wistar) (NNS rats)) (PP (IN with) (NP (JJ established) (NNP Doc_2559236_202_212_Chemical) (NNP Doc_2559236_213_222_Disease))))))) (. .)))
2559236	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VP (VBN given) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_2559236_257_267_Chemical))))) (CC and) (VP (ADVP (NP (CD one) (NN month)) (RB later)) (VBN divided) (PP (IN into) (NP (NP (CD four) (NNS groups)) (VP (VBN matched) (PP (IN for) (NP (NP (NN Doc_2559236_325_336_Disease)) (, ,) (NP (NN blood) (NN pressure)) (, ,) (CC and) (NP (NN plasma) (NN albumin) (NN concentration)))))))))) (. .)))
2559236	3	(S1 (S (NP (NNS Groups) (CD 1) (CC and) (CD 3)) (VP (VBD remained) (ADJP (JJ untreated)) (SBAR (IN while) (S (NP (NNS groups) (CD 2) (CC and) (CD 4)) (VP (VBD received) (NP (NNP Doc_2559236_452_461_Chemical)))))) (. .)))
2559236	4	(S1 (S (NP (NNS Groups) (CD 1) (CC and) (CD 2)) (VP (VBD underwent) (NP (NN micropuncture) (NNS studies)) (PP (IN after) (NP (CD 10) (NNS days)))) (. .)))
2559236	5	(S1 (S (NP (DT These) (JJ short-term) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_2559236_562_571_Chemical)) (VP (VBD reduced) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NP (CD 101) (ADJP (JJ +/-) (NP (CD 2) (CC vs.) (CD 124))) (JJ +/-) (CD 3) (NN mm)) (ADJP (NNP Hg) (, ,) (NN group) (CD 2) (CC vs.) (CD 1)) (, ,) (VP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.05))))) (-RRB- -RRB-)) (CC and) (NP (JJ glomerular) (JJ capillary) (NN pressure)) (PRN (-LRB- -LRB-) (NP (QP (CD 54) (JJ +/-) (CD 1) (CC vs.) (CD 61)) (JJ +/-) (CD 2) (JJ mm) (NNP Hg)) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (PP (IN without) (S (VP (VBG reducing) (NP (NP (NP (NNP Doc_2559236_768_779_Disease)) (PRN (-LRB- -LRB-) (NP (CD 617) (ADJP (JJ +/-) (NP (CD 50) (CC vs.) (CD 570))) (JJ +/-) (CD 47) (NN mg/day)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP GFR)) (PRN (-LRB- -LRB-) (NP (CD 1.03) (ADJP (JJ +/-) (NP (CD 0.04) (CC vs.) (CD 1.04))) (JJ +/-) (CD 0.11) (NN ml/min)) (-RRB- -RRB-))))))))))) (. .)))
2559236	6	(S1 (S (NP (NNS Groups) (CD 3) (CC and) (CD 4)) (VP (AUX were) (VP (VBN studied) (PP (PP (IN at) (NP (CD four))) (CC and) (PP (IN at) (NP (CD six) (NNS months)))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_2559236_942_951_Chemical))) (PP (IN on) (NP (NP (NN progression)) (PP (IN of) (NP (NP (NNP Doc_2559236_970_982_Disease)) (PP (IN in) (NP (NNP Doc_2559236_986_996_Chemical) (NNP Doc_2559236_997_1006_Disease))))))))))))) (. .)))
2559236	7	(S1 (S (NP (JJ Chronic) (JJ Doc_2559236_1016_1025_Chemical) (NN treatment)) (VP (VBD reduced) (NP (NN blood) (NN pressure)) (PP (IN without) (S (VP (VBG reducing) (NP (NN Doc_2559236_1076_1087_Disease)) (PP (IN in) (NP (NN group) (CD 4))))))) (. .)))
2559236	8	(S1 (S (NP (NP (JJ Untreated) (NN group)) (NP (CD 3) (NNS rats))) (VP (VBD exhibited) (NP (NP (DT a) (JJ progressive) (NN reduction)) (PP (IN in) (NP (NP (NNP GFR)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 0.35) (NN +/-)) (NP (CD 0.08) (NN ml/min))) (PP (IN at) (NP (CD 4) (NNS months)))) (, ,) (NP (NP (CD 0.27) (NN +/-) (CD 0.07) (NN ml/min)) (NP (QP (IN at) (CD 6)) (NNS months)))) (-RRB- -RRB-)))))) (. .)))
2559236	9	(S1 (S (NP (JJ Doc_2559236_1234_1243_Chemical) (NN treatment)) (VP (VP (VBD blunted)) (CC but) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NNP GFR)) (PP (IN in) (NP (NN group) (CD 4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 0.86) (NN +/-)) (NP (CD 0.15) (NN ml/min))) (PP (IN at) (NP (CD 4) (NNS months)))) (, ,) (NP (NP (NP (CD 0.69) (NN +/-)) (NP (CD 0.13) (NN ml/min))) (PP (IN at) (NP (CD 6) (NNS months)))) (, ,) (NP (DT both) (JJ P) (QP (JJR less) (IN than) (CD 0.05))) (CC vs.) (NP (NN group) (CD 3))) (-RRB- -RRB-)))))))) (. .)))
2559236	10	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NNS GFR)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2559236_1471_1491_Disease))) (PP (IN in) (NP (NP (DT both) (ADJP (VBN treated) (CC and) (JJ untreated)) (NNS rats.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2572625	0	(S1 (FRAG (NP (JJ Doc_2572625_0_11_Chemical-induced) (JJ acute) (NN Doc_2572625_26_35_Disease)) (. .)))
2572625	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (JJ acute) (NN Doc_2572625_89_98_Disease)) (PP (IN with) (NP (NNP Doc_2572625_104_137_Disease)))) (, ,) (NP (CD 7) (NNS months))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2572625_185_196_Chemical)) (, ,) (NP (DT a) (JJ Doc_2572625_200_215_Chemical) (NN derivative))))))))))))))) (. .)))
2572625	2	(S1 (S (NP (JJ Doc_2572625_228_239_Chemical) (NN withdrawal)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (JJ prompt) (NN recovery))))) (. .)))
2572625	3	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (JJ several) (NNP Doc_2572625_314_329_Chemical))) (, ,) (VP (ADVP (RB chemically)) (VBN related) (PP (TO to) (NP (NNP Doc_2572625_353_364_Chemical)))) (, ,)) (VP (VP (AUX did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NN recovery))))) (CC and) (VP (AUX did) (RB not) (VP (VB induce) (NP (NP (DT any) (NN relapse)) (PP (IN of) (NP (NNP Doc_2572625_432_441_Disease))))))) (. .)))
2572625	4	(S1 (S (NP (DT This) (NN observation)) (VP (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP Doc_2572625_471_482_Chemical)) (VP (MD can) (VP (VB induce) (NP (JJ acute) (NN Doc_2572625_500_509_Disease))))))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (JJ cross) (NN Doc_2572625_546_560_Disease)) (PP (IN between) (NP (NP (NNP Doc_2572625_569_580_Chemical)) (CC and) (NP (JJ several) (NNP Doc_2572625_593_608_Chemical)))))))))) (. .)))
2578334	0	(S1 (S (NP (JJ Doc_2578334_0_13_Chemical) (NNS potentiates)) (VP (VBP Doc_2578334_26_59_Disease) (PP (IN in) (NP (NN rat) (NN liver)))) (. .)))
2578334	1	(S1 (S (VP (TO To) (VP (VB test) (NP (NP (DT the) (NN validity)) (PP (IN of) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NNP DNA)))) (VP (VBZ plays) (NP (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NP (DT the) (NNP Doc_2578334_172_206_Disease) (PRN (, ,) (S (NP (NP (NNP Doc_2578334_208_221_Chemical) (-LRB- -LRB-) (NNP Doc_2578334_223_228_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN DNA) (NN methylation)))) (, ,)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (NNS rats)) (PP (IN during) (NP (NP (DT the) (NN phase)) (PP (IN of) (NP (NN repair) (NN synthesis))) (VP (VBN induced) (PP (IN by) (NP (DT the) (CD three) (NNS carcinogens))))))))))) (, ,)) (NNP Doc_2578334_364_379_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NNS mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2578334_393_415_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NNS mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2578334_431_452_Chemical))))) (-LRB- -LRB-) (NP (NNP Doc_2578334_454_461_Chemical)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS mg/kg)) (-RRB- -RRB-)))))))))) (. .)))
2578334	2	(S1 (S (NP (NP (DT The) (VBN initiated) (NNS hepatocytes)) (PP (IN in) (NP (DT the) (NN liver)))) (VP (AUX were) (VP (VBN assayed) (PP (IN as) (NP (NP (DT the) (JJ gamma-glutamyltransferase) (-LRB- -LRB-) (NN gamma-GT) (-RRB- -RRB-) (JJ positive) (NN foci)) (VP (VBN formed) (PP (VBG following) (NP (NP (DT a) (JJ 2-week) (NN selection) (NN regimen)) (VP (VBG consisting) (PP (IN of) (NP (NP (JJ dietary) (ADJP (CD 0.02) (NN %)) (NN Doc_2578334_658_679_Chemical)) (VP (VBN coupled) (PP (IN with) (NP (NP (DT a) (JJ necrogenic) (NN dose)) (PP (IN of) (NP (NNP Doc_2578334_714_718_Chemical)))))))))))))))) (. .)))
2578334	3	(S1 (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN with) (NP (DT all) (CD three) (NNS carcinogens))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_2578334_801_806_Chemical))) (PP (IN during) (NP (NN repair) (NN synthesis)))) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (VBN initiated) (NNS hepatocytes))) (, ,) (PP (IN for) (NP (NN example)))) (NP (CD 10-20) (NN foci/cm2)) (PP (IN in) (NP (NP (JJ Doc_2578334_911_916_Chemical) (CC and) (JJ carcinogen-treated) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ 3-5) (NNS foci/cm2)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NN carcinogen) (RB only))))))))))))))) (. .)))
2578334	4	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_2578334_1028_1051_Chemical))) (PP (IN during) (NP (NP (DT the) (NN repair) (NN synthesis)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2578334_1091_1098_Chemical))))))) (ADVP (RB further)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (CD 0.019) (JJ mol) (NN %)) (PP (IN of) (NP (NP (JJ Doc_2578334_1134_1142_Chemical) (NNS residues)) (PP (IN in) (NP (NNP DNA)))))) (VP (AUX were) (VP (VBN substituted) (PP (IN by) (NP (DT the) (NN analogue))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NN incorporation)) (PP (IN of) (NP (NNP Doc_2578334_1226_1231_Chemical)))) (VP (VBZ occurs) (PP (IN during) (NP (NN repair) (NN synthesis))))))))))))) (. .)))
2578334	5	(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (NN carcinogen))))) (, ,) (NP (NNP Doc_2578334_1298_1303_Chemical)) (VP (VBN given) (PP (IN after) (NP (NP (DT a) (CD two) (NNS thirds)) (SBAR (S (NP (JJ partial) (NN hepatectomy)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (PRP$ its) (NN incorporation)) (VP (MD should) (VP (AUX be) (NP (NN maximum)))))) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (DT any) (JJ gamma-GT) (JJ positive) (NNS foci))))))))))) (. .)))
2578334	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NNP DNA)))) (ADVP (FW per) (FW se)) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ sufficient) (PP (IN for) (NP (NN initiation))))))))) (. .)))
2578334	7	(S1 (S (ADVP (RB Perhaps)) (NP (CD two) (NNS events)) (VP (MD might) (VP (AUX be) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NN initiation)) (, ,) (NP (NP (DT the) (JJ first)) (VP (VBN caused) (PP (IN by) (NP (DT the) (NN carcinogen))))) (CC and) (NP (NP (DT a) (NN second)) (VP (VBG involving) (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NN DNA))))))))))) (. .)))
26094	0	(S1 (NP (NP (NP (JJ Antihypertensive) (NNS drugs)) (CC and) (NP (NN Doc_26094_27_37_Disease))) (: :) (NP (DT a) (NN reappraisal)) (. .)))
26094	1	(S1 (S (NP (NP (JJ Eighty-nine) (JJ new) (NN referral) (NN Doc_26094_79_91_Disease) (NNS out-patients)) (CC and) (NP (CD 46) (JJ new) (NN referral) (NN non-Doc_26094_129_141_Disease)) (CONJP (RB chronically) (RB physically)) (NP (JJ ill) (NNS out-patients))) (VP (VBD completed) (NP (DT a) (NN mood) (NN rating) (NN scale)) (PP (IN at) (NP (JJ regular) (NNS intervals))) (PP (IN for) (NP (CD one) (NN year)))) (. .)))
26094	2	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (NP (DT a) (JJ high) (NN prevalence)) (PP (IN of) (NP (NNP Doc_26094_287_297_Disease)))) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNS patients))))) (, ,) (PP (IN with) (NP (NP (DT no) (NN preponderance)) (PP (IN in) (NP (DT the) (NNP Doc_26094_355_367_Disease) (NN group)))))) (. .)))
26094	3	(S1 (S (NP (NP (JJ Doc_26094_375_387_Disease) (NNS patients)) (PP (IN with) (NP (JJ Doc_26094_402_413_Disease) (NNS histories)))) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN prevalence)) (PP (IN of) (NP (NNP Doc_26094_451_461_Disease))) (PP (IN than) (NP (DT the) (NN comparison) (NNS patients))))) (. .)))
26094	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (DT a) (JJ significant) (NN number)) (PP (IN of) (NP (NNP Doc_26094_542_553_Disease))) (VP (VBG occurring) (PP (IN in) (NP (NP (JJ Doc_26094_567_578_Chemical) (VBN treated) (NNS patients)) (PP (IN with) (NP (JJ Doc_26094_601_612_Disease) (NNS histories)))))))))) (. .)))
2611118	0	(S1 (S (NP (NN Doc_2611118_0_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_2611118_41_58_Chemical) (NN therapy)))) (. .)))
2611118	1	(S1 (S (NP (NP (NNP Doc_2611118_68_85_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2611118_87_95_Chemical)) (, ,) (NP (NNP Geigy) (NNP Pharmaceuticals)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ non-steroidal) (JJ anti-inflammatory) (NN derivative)) (PP (IN of) (NP (NNP Doc_2611118_171_188_Chemical))))) (. .)))
2611118	2	(S1 (S (SBAR (IN Although) (S (ADJP (RB generally) (JJ well-tolerated)))) (, ,) (NP (JJ asymptomatic) (NNP Doc_2611118_238_269_Disease)) (VP (VP (AUX have) (VP (AUX been) (VP (VBN recorded)))) (CC and) (, ,) (ADVP (RBR less) (RB commonly)) (, ,) (S (NP (JJ severe) (NN Doc_2611118_316_325_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2611118_337_347_Chemical)))))) (. .)))
2611118	3	(S1 (S (NP (NP (DT The) (NN patient)) (VP (VBN described))) (VP (VBD developed) (NP (NP (NAC (NNP Doc_2611118_381_405_Disease) (PP (IN after) (NP (CD six) (NNS months)))) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_2611118_436_453_Chemical)) (SBAR (WHNP (WDT which)) (S (VP (VBD progressed) (PP (IN despite) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (DT the) (NN drug))))))))) (, ,) (NP (NP (DT a) (NN finding)) (VP (RB not) (ADVP (RB previously)) (VBN reported))))))) (. .)))
2632720	0	(S1 (NP (NP (NNP Arterial) (NNP Doc_2632720_9_21_Disease)) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (JJ prolonged) (JJ Doc_2632720_53_65_Chemical) (NN treatment))))) (. .)))
2632720	1	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 14) (NNS patients)) (PP (IN with) (NP (NNP Doc_2632720_101_119_Disease))) (VP (VBN treated) (PP (IN on) (NP (DT a) (JJ long-term) (NN basis))) (PP (IN with) (NP (NNP Doc_2632720_154_166_Chemical))))))) (VP (VBD developed) (NP (JJ sustained) (NN Doc_2632720_187_199_Disease))) (. .)))
2632720	2	(S1 (S (S (PP (IN In) (NP (DT both) (NNS cases))) (NP (JJ normal) (UCP (NN plasma) (CC and) (JJ urinary)) (JJ free) (NN Doc_2632720_246_254_Chemical) (NNS levels)) (VP (AUX had) (VP (AUX been) (VP (VBN achieved) (PP (VBG following) (NP (JJ Doc_2632720_290_302_Chemical) (NN therapy))))))) (, ,) (CC yet) (S (NP (JJ continuous) (NN blood) (NN pressure) (NN monitoring)) (VP (VBD demonstrated) (NP (NP (NP (NNP Doc_2632720_366_378_Disease) (CD 31)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 52) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 2)) (-RRB- -RRB-)))) (PP (IN after) (NP (NN treatment))))) (. .)))
2632720	3	(S1 (S (PP (IN In) (NP (NN patient) (CD 1))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_2632720_467_486_Chemical)) (CC and) (NP (NNP Doc_2632720_491_507_Chemical))))) (VP (AUX were) (ADJP (JJ elevated))) (. .)))
2632720	4	(S1 (S (PP (IN In) (NP (NN patient) (CD 2))) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT both) (NNP Doc_2632720_572_591_Chemical) (CC and) (NNP Doc_2632720_596_612_Chemical) (NNS levels))))))) (, ,) (NP (NN plasma) (NN Doc_2632720_628_639_Chemical) (NNS values)) (VP (AUX were) (VP (VBN raised) (, ,) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN suppression)) (PP (IN of) (NP (JJ renin) (NNS levels))))))) (. .)))
2632720	5	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_2632720_770_782_Chemical)))))) (VP (MD may) (VP (VB induce) (NP (NP (JJ enzyme) (NN blockade)) (VP (VBG leading) (PP (TO to) (NP (JJ mineralocorticoid-related) (NN Doc_2632720_847_859_Disease)))))))))) (. .)))
2670794	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NNP Doc_2670794_27_38_Chemical)))))) (VP (VBG converting) (NP (NP (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2670794_58_67_Chemical)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (NNP Doc_2670794_72_105_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_2670794_113_138_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
2670794	1	(S1 (S (NP (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NNP Doc_2670794_164_189_Disease)))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN fibrinolysis))))) (PP (IN by) (NP (NP (NP (NN injection)) (PP (IN of) (NP (NN thrombin)))) (CC and) (NP (NP (NNP Doc_2670794_250_265_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2670794_267_271_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN rat)))) (VP (VBZ gives) (NP (NN rise)) (PP (TO to) (NP (NNP Doc_2670794_298_331_Disease))) (S (VP (VBG resembling) (SBAR (IN that) (S (VP (VBG occurring) (PP (IN after) (NP (NP (NNP Doc_2670794_364_370_Disease) (CC or) (NNP Doc_2670794_374_380_Disease)) (PP (IN in) (NP (NN man))))))))))) (. .)))
2670794	2	(S1 (S (NP (NP (NN Injection)) (PP (IN of) (NP (NP (NP (NNP Doc_2670794_402_411_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ Doc_2670794_439_450_Chemical) (VBG converting) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NN ACE)) (-RRB- -RRB-))))) (, ,)))) (VP (VBD reduced) (NP (DT both) (NNP Doc_2670794_489_522_Disease)) (PP (IN in) (NP (DT this) (NN rat) (NN model)))) (. .)))
2670794	3	(S1 (S (S (NP (DT The) (NN lung) (NNS weights)) (VP (AUX were) (ADJP (JJR lower)))) (CC and) (S (NP (NNP PaO2)) (VP (AUX was) (VP (VBN improved) (PP (IN in) (NP (NNS rats))) (PP (VBN given) (NP (DT this) (JJ enzyme-blocking) (NN agent)))))) (. .)))
2670794	4	(S1 (S (NP (NP (DT The) (NNS contents)) (PP (IN of) (NP (NN albumin))) (PP (IN in) (NP (DT the) (NNS lungs)))) (VP (AUX were) (RB not) (VP (VBN changed) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP Doc_2670794_705_714_Chemical)) (VP (AUX did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN extravasation)) (PP (IN of) (NP (NN protein)))))))))))) (. .)))
2670794	5	(S1 (S (NP (NN Doc_2670794_763_775_Disease)) (SBAR (IN as) (S (VP (VBN reflected) (PP (IN by) (NP (DT an) (NN increase))) (PP (PP (IN in) (NP (JJ serum) (NNP Doc_2670794_813_817_Chemical))) (CC and) (PP (IN in) (NP (NN kidney) (NN weight))))))) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NNP Doc_2670794_856_865_Chemical))))) (. .)))
2670794	6	(S1 (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN fibrin))) (PP (IN in) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (ADVP (RB also)) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (VBD received) (NP (NP (NN thrombin)) (CC and) (NP (NP (NNP Doc_2670794_975_979_Chemical)) (ADVP (RB alone)))))))))))) (. .)))
2670794	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2670794_1023_1032_Chemical))) (PP (IN on) (NP (DT the) (NNS lungs)))) (VP (MD may) (VP (AUX be) (ADJP (JJ attributable) (PP (TO to) (NP (NP (DT a) (JJ vasodilatory) (NN effect)) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (VBG circulating) (NN level)) (PP (IN of) (NP (NNP Doc_2670794_1138_1153_Chemical)))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNP Doc_2670794_1173_1185_Chemical)) (PRN (-LRB- -LRB-) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_2670794_1215_1225_Chemical)))))) (-RRB- -RRB-))))))))))))))))) (. .)))
2670794	8	(S1 (S (NP (NNP Doc_2670794_1228_1237_Chemical)) (VP (MD may) (, ,) (PP (IN by) (NP (DT the) (JJ same) (NN mechanism))) (, ,) (VP (VB reduce) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (JJ glomerular) (NN filtration)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB occur) (PP (IN after) (NP (NP (DT an) (NN injection)) (PP (IN of) (NP (NN thrombin))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG diminishing) (NP (NP (DT the) (NN aggregation)) (PP (IN of) (NP (NP (JJ fibrin) (NNS monomers)) (PP (IN in) (NP (DT the) (NNS glomeruli)))))))) (, ,) (PP (IN with) (NP (DT the) (NN result) (SBAR (IN that) (S (S (NP (JJR less) (NN fibrin)) (VP (MD will) (VP (AUX be) (VP (VBD deposited))))) (CC and) (S (ADVP (RB thus) (RBR less)) (NP (NNP Doc_2670794_1504_1517_Disease)) (VP (MD will) (VP (AUX be) (VP (VBN produced))))))))))))))))))))) (. .)))
2673163	0	(S1 (S (NP (NN Doc_2673163_0_6_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_2673163_23_30_Chemical) (NN use)))) (. .)))
2673163	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD eight) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ Doc_2673163_71_78_Chemical) (NN use)) (VP (AUX was) (VP (VBN related) (S (VP (TO to) (VP (VB Doc_2673163_98_104_Disease) (CC and) (VB review) (NP (CD 39) (NNS cases)) (PP (IN from) (NP (DT the) (NN literature)))))))))))) (. .)))
2673163	2	(S1 (S (S (PP (IN Among) (NP (DT these) (CD 47) (NNS patients))) (NP (DT the) (JJ mean) (PRN (-LRB- -LRB-) (NP (JJ +/-) (NN SD)) (-RRB- -RRB-)) (NN age)) (VP (AUX was) (NP (CD 32.5) (JJ +/-) (CD 12.1) (NNS years)))) (: ;) (S (NP (NP (CD 76) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 34/45)) (-RRB- -RRB-))) (VP (AUX were) (NP (NNS men)))) (. .)))
2673163	3	(S1 (S (NP (NN Doc_2673163_239_245_Disease)) (VP (VBD followed) (NP (NP (JJ Doc_2673163_255_262_Chemical) (NN use)) (PP (IN by) (NP (ADJP (JJ inhalation) (, ,) (JJ intranasal) (, ,) (JJ intravenous) (, ,) (CC and) (JJ intramuscular)) (NNS routes))))) (. .)))
2673163	4	(S1 (S (S (NP (NP (NNP Doc_2673163_333_355_Disease)) (CC or) (NP (NNP Doc_2673163_359_386_Disease))) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (NP (CD 17)) (PP (IN of) (NP (NP (CD 32) (NNS patients)) (VP (VBN studied) (UCP (ADVP (RB angiographically)) (CC or) (PP (IN at) (NP (NN autopsy))))))))))) (: ;) (S (NP (NNP Doc_2673163_461_480_Disease)) (VP (AUX was) (ADJP (JJ present)) (PP (IN in) (NP (CD two) (NNS patients))))) (. .)))
2673163	5	(S1 (S (NP (NN Doc_2673163_510_529_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 10) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_2673163_561_585_Disease)) (PP (IN in) (NP (CD 22))) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_2673163_603_626_Disease)) (PP (IN in) (NP (CD 13))) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-))))))) (. .)))
2673163	6	(S1 (S (S (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NP (DT the) (JJ apparent) (NN incidence)) (PP (IN of) (NP (NNP Doc_2673163_695_701_Disease)))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_2673163_713_720_Chemical) (NN use))))) (VP (AUX is) (VP (VBG increasing))))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNP Doc_2673163_744_751_Chemical-associated) (NNP Doc_2673163_763_769_Disease)) (VP (VBZ occurs) (ADVP (RB primarily)) (PP (IN in) (NP (JJ young) (NNS adults))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNP Doc_2673163_808_814_Disease)) (VP (MD may) (VP (VB follow) (NP (DT any) (NN route)) (PP (IN of) (NP (NNP Doc_2673163_839_846_Chemical) (NN administration)))))) (: ;) (S (NP (NP (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NNP Doc_2673163_867_873_Disease)) (PP (IN after) (NP (JJ Doc_2673163_880_887_Chemical) (NN use)))) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_2673163_922_944_Disease) (CC and) (NNP Doc_2673163_949_976_Disease)))))) (: ;) (CC and) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ Doc_2673163_989_996_Chemical-associated) (NNP Doc_2673163_1008_1014_Disease)))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_2673163_1033_1056_Disease)))) (VP (VBZ exceeds) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_2673163_1073_1092_Disease))))) (. .)))
2696505	0	(S1 (NP (NP (DT A) (JJ randomized) (NN comparison)) (PP (IN of) (NP (NP (NNP Doc_2696505_27_36_Chemical)) (CC and) (NP (NNP Doc_2696505_41_54_Chemical)))) (PP (IN for) (NP (VBN induced) (NN Doc_2696505_67_78_Disease))) (. .)))
2696505	1	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (NN study))) (, ,) (NP (NP (NNP Doc_2696505_103_112_Chemical-induced) (NNP Doc_2696505_121_132_Disease)) (CC and) (NP (NNP Doc_2696505_137_150_Chemical-induced) (NNP Doc_2696505_159_170_Disease))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NP (CD 20) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 10)) (PP (IN in) (NP (DT each) (NN group)))) (-RRB- -RRB-))) (VP (VBN scheduled) (PP (IN for) (NP (JJ major) (JJ orthopedic) (NNS procedures)))))))) (. .)))
2696505	2	(S1 (S (NP (DT Each) (NN patient)) (VP (AUX was) (VP (VBN subjected) (PP (TO to) (NP (NP (DT an) (JJ identical) (JJ anesthetic) (NN protocol)) (CC and) (NP (NP (NP (JJ similar) (JJ drug-induced) (NNP Doc_2696505_350_392_Disease)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (TO to) (CD 55)) (NNS mmHg)) (-RRB- -RRB-))))))) (. .)))
2696505	3	(S1 (S (S (NP (JJ Nitroprusside) (NN infusion)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (NN Doc_2696505_491_532_Disease)))))) (: ;) (S (NP (NN rebound)) (NP (NNP Doc_2696505_542_554_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (CD three) (NNS patients))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_2696505_611_624_Chemical)))))))) (. .)))
2696505	4	(S1 (S (NP (JJ Doc_2696505_626_635_Chemical) (NN administration)) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS findings))))))) (. .)))
2696505	5	(S1 (S (NP (NNP Arterial) (NNP Doc_2696505_707_710_Chemical)) (VP (VBD decreased) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
2696505	6	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_2696505_759_768_Chemical)) (VP (VBZ offers) (NP (NNS advantages)) (PP (IN over) (NP (NN Doc_2696505_792_805_Chemical)))))))) (. .)))
2802551	0	(S1 (S (NP (JJ Doc_2802551_0_6_Chemical) (NN status)) (VP (VBZ influences) (NP (NP (JJ chronic) (JJ Doc_2802551_33_47_Chemical) (NN Doc_2802551_48_62_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
2802551	1	(S1 (S (NP (NP (DT The) (JJ Doc_2802551_76_87_Disease) (NN potential)) (PP (IN of) (NP (NNP Doc_2802551_101_115_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN mg/kg)) (PP (IN per) (NP (NN day))) (PP (ADVP (RB intraperitoneally)) (IN for) (NP (CD 3) (NNS weeks)))) (-RRB- -RRB-)) (VP (AUX has) (VP (AUX been) (VP (VBN investigated) (PP (IN in) (NP (ADJP (JJ salt-depleted) (, ,) (JJ normal-salt) (, ,) (CC and) (JJ salt-loaded)) (NNS rats)))))) (. .)))
2802551	2	(S1 (S (PP (IN In) (NP (JJ salt-depleted) (NNS rats))) (, ,) (NP (NNP Doc_2802551_262_276_Chemical)) (VP (VBD decreased) (NP (JJ Doc_2802551_287_297_Chemical) (NN clearance)) (ADVP (RB linearly)) (PP (IN with) (NP (NN time))) (, ,) (PP (IN with) (NP (NP (DT an) (ADJP (CD 85) (NN %)) (NN reduction)) (PP (IN by) (NP (NN week) (CD 3)))))) (. .)))
2802551	3	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (JJ normal-salt) (NNS rats))) (NP (NNP Doc_2802551_394_404_Chemical) (NN clearance)) (VP (VP (AUX was) (VP (VBN decreased))) (CC but) (VP (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (PP (PP (IN at) (NP (NN week) (CD 2) (CC and) (CD 3))) (, ,) (CC and) (PP (IN in) (NP (NP (JJ salt-loaded) (NNS rats)) (SBAR (S (NP (NNP Doc_2802551_493_503_Chemical) (NN clearance)) (VP (VP (AUX did) (RB not) (VP (VB change) (PP (IN for) (NP (CD 2) (NNS weeks))))) (CC and) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (CD 43) (NN %))) (PP (IN at) (NP (NN week) (CD 3))))))))))))) (. .)))
2802551	4	(S1 (S (NP (NP (DT All) (NNS rats)) (PP (IN in) (NP (DT the) (JJ Doc_2802551_593_599_Chemical-depleted) (NN group)))) (VP (AUX had) (NP (NP (JJ histopathological) (NN evidence)) (PP (IN of) (NP (NP (JJ patchy) (JJ tubular) (JJ cytoplasmic) (NN degeneration)) (PP (IN in) (NP (NP (NNS tubules)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (DT any) (NN normal-salt)) (CC or) (NP (JJ salt-loaded) (NN rat)))))))))))))) (. .)))
2802551	5	(S1 (S (NP (NP (NNS Concentrations)) (PP (IN of) (NP (NNP Doc_2802551_779_793_Chemical))) (PP (IN in) (NP (NN plasma)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different)) (PP (IN among) (NP (DT the) (CD three) (NNS groups))) (PP (IN at) (NP (DT any) (NN time))) (PP (IN during) (NP (DT the) (NN study)))) (. .)))
2802551	6	(S1 (S (ADVP (RB However)) (, ,) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (CD 3) (NNS weeks))))) (, ,) (NP (NP (JJ Doc_2802551_922_936_Chemical) (NNS levels)) (PP (IN in) (NP (DT the) (NNS kidneys) (CC and) (NN liver)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (ADJP (JJ salt-depleted) (CC and) (JJ normal-salt)) (NNS rats)))) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (JJ salt-loaded) (NNS rats)))))) (, ,) (PP (IN with) (NP (NP (JJ plasma/kidney) (NNS ratios)) (PP (IN of) (NP (NP (CD 21)) (, ,) (NP (CD 14)) (, ,) (CC and) (NP (NP (CD 8)) (PP (IN in) (NP (UCP (ADJP (JJ salt-depleted)) (, ,) (ADJP (JJ normal-salt)) (, ,) (CC and) (JJ salt-loaded)) (NNS rats)))) (, ,) (ADVP (RB respectively))))))) (. .)))
2802551	7	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (JJ Doc_2802551_1204_1214_Chemical) (NN clearance)) (CC and) (NP (JJ renal) (JJ Doc_2802551_1235_1249_Chemical) (NN accumulation))))) (PP (IN after) (NP (JJ chronic) (NNP Doc_2802551_1277_1291_Chemical) (NN administration))) (VP (AUX were) (VP (VP (VBN enhanced) (PP (IN by) (NP (NN salt) (NN depletion)))) (CC and) (VP (VBN attenuated) (PP (IN by) (NP (NP (JJ Doc_2802551_1357_1363_Chemical) (NN loading)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
2870085	0	(S1 (NP (NP (NN Doc_2870085_0_9_Chemical)) (: :) (NP (NP (DT an) (JJ ultra-short-acting) (NN beta-adrenergic)) (VP (VBG blocking) (NP (NN agent)))) (. .)))
2870085	1	(S1 (S (NP (NP (NNP Doc_2870085_65_74_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2870085_76_84_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ nonselective) (, ,) (JJ competitive) (, ,) (JJ ultra-short-acting) (JJ beta-adrenergic) (VBG blocking) (NN agent)) (, ,) (PP (IN without) (NP (DT any) (JJ intrinsic) (NN sympathomimetic) (NN activity))))) (. .)))
2870085	2	(S1 (S (NP (NN Doc_2870085_217_226_Chemical)) (VP (VP (AUX is) (VP (VBN metabolized) (PP (IN by) (NP (NN plasma) (NNS esterases))))) (CC and) (VP (AUX has) (NP (NP (DT an) (NN elimination) (NN half-life)) (PP (IN of) (NP (QP (RB approximately) (CD 6.5)) (NNS minutes)))))) (. .)))
2870085	3	(S1 (S (NP (DT This) (NN agent)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN in) (NP (JJ healthy) (NNS volunteers))) (PP (IN at) (NP (QP (NNS doses) (IN up) (TO to) (CD 100)) (NN micrograms/kg/min))))) (. .)))
2870085	4	(S1 (S (PP (IN In) (NP (JJ long-term) (NN infusion) (NNS studies))) (, ,) (NP (NNP Doc_2870085_446_455_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN at) (NP (NP (DT the) (JJ effective) (NN beta-blocking) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN micrograms/kg/min)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (IN up) (TO to) (CD seven)) (NNS days))))) (. .)))
2870085	5	(S1 (S (NP (JJ Doc_2870085_555_564_Chemical) (NN blood) (NNS concentrations)) (VP (VBD increased) (ADVP (RB linearly)) (PP (IN with) (S (VP (VBG increasing) (NP (NP (NN dose) (CC and) (JJ good) (NN correlation) (VBZ exists)) (PP (IN between) (NP (NP (NN blood) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_2870085_686_695_Chemical)) (CC and) (NP (JJ beta-adrenergic) (NN blockade))))))))))) (. .)))
2870085	6	(S1 (S (NP (NN Doc_2870085_726_735_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN attenuation)) (PP (IN of) (NP (NNP Doc_2870085_777_790_Chemical-induced) (NNP Doc_2870085_799_810_Disease))))) (. .)))
2870085	7	(S1 (S (NP (NP (ADJP (ADJP (JJ Electrophysiologic)) (CC and) (ADJP (JJ hemodynamic))) (NNS effects)) (PP (IN of) (NP (NNP Doc_2870085_858_867_Chemical)))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NN beta) (NNS blockers))))))) (. .)))
2870085	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (IN with) (NP (JJ other) (NN beta) (NNS blockers))))) (, ,) (NP (JJ Doc_2870085_951_960_Chemical-induced) (NNS effects)) (VP (VBP reverse) (ADVP (RB rapidly)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 30) (NNS minutes))) (-RRB- -RRB-)) (VP (VBG following) (NP (NN discontinuation)) (PP (IN because) (IN of) (NP (PRP$ its) (JJ short) (NN half-life))))) (. .)))
2870085	9	(S1 (S (NP (NN Doc_2870085_1071_1080_Chemical)) (ADVP (RB effectively)) (VP (VBD reduced) (NP (NN heart) (NN rate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2870085_1129_1161_Disease)))))) (. .)))
2870085	10	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2870085_1180_1195_Disease))))) (, ,) (NP (JJ Doc_2870085_1197_1206_Chemical) (NN infusion)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ safe) (CC and) (JJ effective)) (PP (IN in) (S (VP (VBG controlling) (NP (NN Doc_2870085_1266_1276_Disease)))))))))) (. .)))
2870085	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_2870085_1299_1308_Chemical)) (VP (AUX is) (NP (DT a) (JJ potent) (, ,) (JJ well-tolerated) (, ,) (JJ ultra-short-acting) (JJ beta-adrenergic) (VBG blocking) (NN agent))))))) (. .)))
2870085	12	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_2870085_1396_1405_Chemical))) (PP (IN in) (NP (DT the) (JJ critical) (NN care) (NN setting)))) (VP (AUX is) (ADVP (RB currently)) (VP (VBG undergoing) (NP (NN investigation)))) (. .)))
2887062	0	(S1 (S (ADVP (JJ Immunohistochemical)) (, ,) (NP (NP (NNP electron) (JJ microscopic) (CC and) (JJ morphometric) (NNS studies)) (PP (IN of) (NP (JJ Doc_2887062_70_78_Chemical-induced) (NN rat)))) (VP (VBP Doc_2887062_91_104_Disease) (PP (IN after) (NP (JJ Doc_2887062_111_124_Chemical) (NN treatment)))) (. .)))
2887062	1	(S1 (S (S (VP (TO To) (VP (VB clarify) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2887062_162_175_Chemical))) (PP (IN on) (NP (NP (JJ Doc_2887062_179_191_Disease) (NNS cells)) (PP (IN in) (NP (NN vivo))))))))) (, ,) (NP (ADJP (JJ immunohistochemical) (, ,) (JJ ultrastructural) (CC and) (JJ morphometrical)) (NNS analyses)) (VP (AUX were) (VP (VBN applied) (PP (TO to) (NP (JJ Doc_2887062_288_296_Chemical-induced) (NN rat) (NN Doc_2887062_309_321_Disease) (NNS cells) (NX (NX (CD 1) (NNP h)) (CC and) (NX (CD 6) (NNP h))))) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2887062_359_372_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 3) (NN mg/kg)) (PP (IN of) (NP (NN body) (NN weight)))) (-RRB- -RRB-)))))))) (. .)))
2887062	2	(S1 (S (NP (CD One) (NNP h)) (PP (IN after) (NP (NN treatment))) (, ,) (NP (NN serum) (NN prolactin) (NNS levels)) (VP (VBD decreased) (ADVP (RB markedly))) (. .)))
2887062	3	(S1 (S (NP (NNP Electron) (JJ microscopy)) (VP (VBD disclosed) (NP (NP (JJ many) (NN secretory) (NNS granules)) (, ,) (NP (ADJP (RB slightly) (JJ distorted)) (JJ rough) (JJ endoplasmic) (NN reticulum)) (, ,) (CC and) (NP (ADJP (RB partially) (VBN dilated)) (NNP Golgi) (NNS cisternae))) (PP (IN in) (NP (DT the) (JJ Doc_2887062_613_625_Disease) (NNS cells)))) (. .)))
2887062	4	(S1 (S (NP (JJ Morphometric) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ secretory) (NNS granules)))) (VP (VBD increased) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ cytoplasmic) (NNS microtubules)))) (VP (VBD decreased)))))))) (. .)))
2887062	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (VBN lowered) (NN serum) (NN prolactin) (NNS levels)) (PP (IN in) (NP (NP (DT the) (JJ early) (NN phase)) (PP (IN of) (NP (JJ Doc_2887062_866_879_Chemical) (NN treatment)))))) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT an) (VBN impaired) (NN secretion)) (PP (IN of) (NP (NN prolactin))) (ADJP (JJ due) (PP (TO to) (NP (NP (VBG decreasing) (NNS numbers)) (PP (IN of) (NP (JJ cytoplasmic) (NNS microtubules))))))))))))) (. .)))
2887062	6	(S1 (S (PP (IN At) (NP (NP (CD 6) (NNP h)) (PP (IN after) (NP (NN injection))))) (, ,) (NP (NN serum) (NN prolactin) (NNS levels)) (VP (AUX were) (ADVP (RB still)) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NNS controls)))))) (. .)))
2887062	7	(S1 (S (NP (NP (DT The) (JJ Doc_2887062_1095_1107_Disease) (NNS cells)) (PP (IN at) (NP (DT this) (NN time)))) (VP (AUX were) (VP (ADVP (RB well)) (VBN granulated) (, ,) (PP (IN with) (NP (NP (JJ vesiculated) (JJ rough) (JJ endoplasmic) (NN reticulum)) (CC and) (NP (ADJP (RB markedly) (VBN dilated)) (NNP Golgi) (NNS cisternae)))))) (. .)))
2887062	8	(S1 (S (NP (NNP Electron) (JJ microscopical) (NN immunohistochemistry)) (VP (VBD revealed) (NP (NP (JJ positive) (NN reaction) (NNS products)) (VP (VBN noted) (PP (IN on) (NP (NP (NP (DT the) (JJ secretory) (NNS granules)) (, ,) (NP (NNP Golgi) (NNS cisternae)) (, ,) (CC and) (NP (JJ endoplasmic) (NN reticulum))) (PP (IN of) (NP (DT the) (JJ untreated) (NN rat) (NN Doc_2887062_1409_1421_Disease) (NNS cells)))))))) (. .)))
2887062	9	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ only) (NN secretory) (NNS granules)) (VP (VBD showed) (NP (NP (DT the) (JJ positive) (NN reaction) (NNS products)) (PP (IN for) (S (VP (VBG prolactin) (NP (CD 6) (NNP h)) (PP (IN after) (NP (NP (JJ Doc_2887062_1524_1537_Chemical) (NN treatment)) (PP (IN of) (NP (DT the) (JJ Doc_2887062_1555_1562_Disease) (NNS cells)))))))))) (. .)))
2887062	10	(S1 (S (NP (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ secretory) (NNS granules)))))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN volume) (NNS densities)) (PP (IN of) (NP (NP (JJ rough) (JJ endoplasmic) (NN reticulum)) (CC and) (NP (NNS microtubules)))))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ morphometric) (NN analysis))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP Doc_2887062_1770_1783_Chemical)) (VP (VBZ inhibits) (NP (NP (NN protein) (NN synthesis)) (CONJP (RB as) (RB well) (IN as)) (NP (NN bringing))) (PP (IN about) (NP (NP (DT a) (NN disturbance)) (PP (IN of) (NP (DT the) (JJ prolactin) (NN secretion)))))))))))) (. .)))
2894766	0	(S1 (NP (JJ Doc_2894766_0_13_Chemical-induced) (NN Doc_2894766_22_41_Disease) (. .)))
2894766	1	(S1 (S (NP (NP (NNP Doc_2894766_43_54_Disease)) (, ,) (NP (JJ bilateral) (NNP Doc_2894766_66_83_Disease)) (, ,) (NP (NP (JJ echocardiographic) (NN evidence)) (PP (IN of) (NP (NNP Doc_2894766_115_132_Disease)))) (, ,) (CC and) (NP (JJ positive) (NNS autoantibodies))) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ 43-year-old) (NN man)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (S (VP (VBG receiving) (NP (JJ long-term) (JJ Doc_2894766_222_235_Chemical) (NN therapy)) (PP (IN for) (NP (JJ chronic) (NN Doc_2894766_256_274_Disease))))))))))) (. .)))
2894766	2	(S1 (S (PP (IN After) (NP (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NNP Doc_2894766_299_312_Chemical)))) (CC and) (NP (NP (NN completion)) (PP (IN of) (NP (NP (DT a) (JJ six-week) (NN course)) (PP (IN of) (NP (NNS corticosteroids)))))))) (, ,) (NP (DT these) (NNS problems)) (VP (VBN resolved) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (CD four) (TO to) (CD six)) (NNS months)))))) (. .)))
2894766	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (AUX had) (NP (NP (NNP Doc_2894766_467_480_Chemical-induced) (NNP Doc_2894766_489_494_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD manifested) (PP (IN with) (NP (NP (NN Doc_2894766_518_527_Disease)) (CC and) (NP (JJ pulmonary) (JJ parenchymal) (NN involvement)))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ joint) (NNS symptoms)))))))))))))) (. .)))
2894766	4	(S1 (S (NP (NP (NNS Physicians)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (NP (NNP Doc_2894766_619_632_Chemical)) (S (VP (TO to) (VP (VB treat) (NP (NNS patients)) (PP (IN with) (NP (NN Doc_2894766_656_682_Disease)))))))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NNP Doc_2894766_715_728_Chemical-induced) (NNP Doc_2894766_737_751_Disease)))))))) (. .)))
2924746	0	(S1 (NP (NP (NP (JJ Chronic) (JJ Doc_2924746_8_21_Chemical) (NN treatment)) (PP (IN in) (NP (DT the) (NN rat)))) (: :) (NP (NP (NN efficacy)) (, ,) (NP (NN Doc_2924746_54_62_Disease)) (, ,) (CC and) (NP (NP (NN effect)) (PP (IN on) (NP (NN plasma) (CC and) (NN tissue) (NN Doc_2924746_96_102_Chemical) (NNS concentrations))))) (. .)))
2924746	1	(S1 (S (NP (JJ Doc_2924746_119_125_Chemical) (NN depletion)) (VP (AUX has) (ADVP (RB often)) (VP (AUX been) (NP (NP (DT a) (NN problem)) (PP (IN in) (NP (JJ chronic) (JJ antiepileptic) (NN drug) (PRN (-LRB- -LRB-) (JJ AED) (-RRB- -RRB-)) (NN therapy)))))) (. .)))
2924746	2	(S1 (S (NP (NP (NP (NNP Doc_2924746_206_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2924746_221_224_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN AED)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (DT some) (JJ clinical) (NNS studies)))))) (. .)))
2924746	3	(S1 (S (NP (DT A) (NN rat) (NN model)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ chronic) (JJ Doc_2924746_354_357_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ Doc_2924746_371_377_Chemical) (NNS concentrations)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
2924746	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NN course)) (PP (IN of) (S (VP (VBG developing) (NP (DT this) (NN model))))))) (, ,) (NP (NP (DT a) (JJ common) (NN vehicle)) (, ,) (NP (NNP Doc_2924746_463_479_Chemical)) (, ,) (PP (IN by) (NP (NP (PRP itself)) (PP (IN in) (NP (JJ high) (NNS doses))))) (, ,)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB exhibit) (NP (JJ protective) (NNS properties)) (PP (IN against) (S (VP (VP (VBN induced) (NP (NNP Doc_2924746_565_573_Disease))) (CC and) (VP (VBD inhibited) (NP (NN Doc_2924746_588_599_Disease))))))))))) (. .)))
2924746	5	(S1 (S (NP (NP (NN Doc_2924746_601_609_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_2924746_621_644_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2924746_646_650_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN measure)) (PP (IN of) (NP (NN protection)))) (PP (IN by) (NP (NNP Doc_2924746_716_719_Chemical))) (SBAR (IN than) (S (NP (NNP Doc_2924746_725_733_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ maximal) (NN electroshock)) (PRN (-LRB- -LRB-) (NP (NNP MES)) (-RRB- -RRB-)))))))))))) (. .)))
2924746	6	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_2924746_796_799_Chemical))) (PP (IN as) (NP (DT an) (JJ aqueous) (NN suspension))) (NP (DT every) (CD 8) (NNP h)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 250) (NNS mg/kg)))))) (VP (VP (AUX was) (ADJP (RB continuously) (JJ protective) (PP (IN against) (NP (JJ Doc_2924746_894_898_Chemical-induced) (NNP Doc_2924746_907_915_Disease))))) (CC and) (VP (AUX was) (ADJP (RB minimally) (JJ toxic) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NNP Doc_2924746_955_966_Disease))) (PP (IN over) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))))))) (. .)))
2924746	7	(S1 (S (NP (NP (DT The) (JJ Doc_2924746_998_1001_Chemical) (NNS levels)) (VP (VBN measured) (PP (IN in) (NP (NP (NP (NN plasma)) (CC and) (NP (NN brain))) (PP (IN of) (NP (DT these) (NNS animals))))))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX were) (PP (IN below) (NP (NP (DT those)) (VP (ADVP (RB normally)) (VBN considered) (S (ADJP (JJ protective))))))) (. .)))
2924746	8	(S1 (S (NP (NP (DT This) (NN treatment)) (PP (IN with) (NP (NNP Doc_2924746_1134_1137_Chemical)))) (VP (VP (AUX had) (NP (NP (DT no) (JJ apparent) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (JJ Doc_2924746_1172_1178_Chemical) (NNS concentrations)) (PP (IN in) (NP (DT the) (NN rat))))))) (, ,) (CC and) (, ,) (ADVP (RB indeed)) (, ,) (S (NP (DT the) (NNP Doc_2924746_1223_1229_Chemical) (NN concentration)) (VP (VBN increased) (PP (IN in) (NP (NN liver))) (PP (PP (IN after) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (CC and) (PP (IN in) (NP (NN plasma)))) (PP (IN at) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
2950248	0	(S1 (NP (JJ Doc_2950248_0_12_Chemical-induced) (NN Doc_2950248_21_40_Disease) (. .)))
2950248	1	(S1 (S (NP (NP (NN Doc_2950248_42_48_Disease)) (CC and) (NP (JJ ischemic) (NN electrocardiographic) (NNS changes))) (VP (VBD occurred) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NNP Doc_2950248_129_141_Chemical))) (PP (IN in) (NP (NP (CD four) (NNS patients)) (VP (VBG awaiting) (NP (JJ urgent) (JJ myocardial) (NN revascularization) (NNS procedures)))))))) (. .)))
2950248	2	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (JJ preoperative) (JJ Doc_2950248_305_317_Chemical) (NN therapy))))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_2950248_336_348_Chemical-induced) (NNP Doc_2950248_357_376_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB occur) (PP (IN in) (NP (NP (NNS animals)) (CC and) (NP (NNS humans)))) (PP (IN with) (NP (NN Doc_2950248_435_458_Disease)))))))))))))) (. .)))
2950248	3	(S1 (S (S (NP (JJ Epicardial) (JJ coronary) (NN collateral) (NNS vessels)) (VP (AUX were) (VP (VBN demonstrated) (PP (IN in) (NP (DT all) (CD four) (NNS patients)))))) (: ;) (S (NP (DT a) (JJ coronary) (`` ``) (VB steal) ('' '') (NN phenomenon)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (JJ Doc_2950248_597_609_Chemical-induced) (NN Doc_2950248_618_626_Disease)) (VP (VBN observed)))))))) (. .)))
2951327	0	(S1 (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN sympathoadrenal) (NN activity))) (PP (IN by) (NP (NP (JJ atrial) (JJ natriuretic) (NN factor)) (PP (IN in) (NP (NNS dogs))))) (. .)))
2951327	1	(S1 (S (PP (IN In) (NP (NP (CD six) (JJ conscious) (, ,) (JJ trained) (NNS dogs)) (, ,) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (JJ normal) (JJ Doc_2951327_132_138_Chemical) (NN intake)) (PP (IN of) (NP (QP (CD 2) (TO to) (CD 4)) (NN mEq/kg/day)))))))) (, ,) (NP (JJ sympathetic) (NN activity)) (VP (AUX was) (VP (VBN assessed) (PP (IN as) (NP (NP (DT the) (NN release) (NN rate)) (PP (IN of) (NP (NNP Doc_2951327_225_239_Chemical) (CC and) (NNP Doc_2951327_244_255_Chemical))))) (PP (IN during) (NP (NP (JJ 15-minute) (JJ i.v.) (NNS infusions)) (PP (IN of) (NP (JJ human) (JJ alpha-atrial) (NN natriuretic) (NN factor))))))) (. .)))
2951327	2	(S1 (S (NP (NP (JJ Mean) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN percentage)) (PP (IN of) (NP (NN control) (NN +/-) (NN SEM))))) (-RRB- -RRB-)) (PP (IN during) (NP (NP (JJ randomized) (NNS infusions)) (PP (IN of) (NP (CD 0.03))))) (, ,) (CD 0.1) (, ,) (CD 0.3) (, ,) (CC or) (NP (CD 1.0) (NN microgram/kg/min))) (VP (AUX was) (NP (NP (QP (CD 99) (CD +/-)) (CD 1)) (, ,) (NP (NP (CD 95) (NN +/-)) (SBAR (S (NP (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 93) (NN +/-)) (NP (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (CD 79) (NN +/-) (CD 6) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))) (, ,) (CC but) (NP (DT no) (NNP Doc_2951327_588_599_Disease)) (CC and) (NP (NP (DT no) (NN augmentation)) (PP (IN of) (NP (NP (DT the) (JJ Doc_2951327_627_641_Chemical) (NN release) (NN rate)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 0.3)) (NN microgram/kg/min)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN observed)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (JJ comparable) (NNP Doc_2951327_734_745_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2951327_757_768_Chemical) (CC or) (NNP Doc_2951327_772_785_Chemical))))))))))))) (. .)))
2951327	3	(S1 (S (NP (NP (DT The) (NN release) (NN rate)) (PP (IN of) (NP (NNP Doc_2951327_807_818_Chemical))) (PRN (-LRB- -LRB-) (NP (NN control)) (, ,) (NP (CD 6.7) (NN +/-) (CD 0.6) (NN ng/kg/min)) (-RRB- -RRB-))) (VP (VBD declined) (ADVP (RB immediately)) (PP (IN during) (NP (NP (NNS infusions)) (PP (IN of) (NP (JJ atrial) (JJ natriuretic) (NN factor))))) (PP (TO to) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (NP (CD 49) (NN +/-) (CD 5) (NN %)) (PP (IN of) (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))))) (PP (IN during) (NP (CD 0.1) (NN microgram/kg/min))) (CC and) (PP (TO to) (NP (NP (NP (NP (CD 63) (NN +/-)) (NP (CD 5) (NN %))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (QP (JJR greater) (IN than) (CD p)) (JJR greater)) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 95) (NN +/-)) (ADJP (CD 13) (NN %) (PRN (-LRB- -LRB-) (ADJP (RB not) (JJ significant)) (-RRB- -RRB-)) (PP (IN during) (NP (CD 0.3) (CC or) (CD 1.0) (NN microgram/kg/min))))))))) (. .)))
2951327	4	(S1 (S (NP (NP (JJ Steady) (NN state) (NN arterial) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ atrial) (JJ natriuretic) (NN factor)))) (VP (AUX were) (NP (NP (CD 39) (JJ +/-) (CD 10) (NNS pg/ml)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (PP (IN during) (NP (NP (NP (NNS infusions)) (PP (IN of) (NP (NN saline)))) (CC and) (NP (NP (NP (NP (NP (CD 284) (NN +/-)) (NP (CD 24) (NNS pg/ml))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 1520) (NN +/-)) (NP (CD 300) (NNS pg/ml))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (QP (CD 0.03) (CC and) (CD 0.1)) (JJ microgram/kg/min) (NNS infusions)) (PP (IN of) (NP (DT the) (NN factor.))) (PRN (-LRB- -LRB-) (VP (ADVP (JJ ABSTRACT)) (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-))))))))))
3015567	0	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ immunoreactive) (JJ corticotropin-releasing) (NN factor)))) (VP (VBP secretion) (PP (IN into) (NP (DT the) (JJ hypophysial-portal) (NN circulation))) (PP (IN by) (NP (JJ delayed) (JJ glucocorticoid) (NN feedback)))) (. .)))
3015567	1	(S1 (S (NP (JJ Doc_3015567_146_159_Chemical-induced) (NNP Doc_3015567_168_179_Disease)) (VP (VBZ evokes) (NP (NP (JJ ACTH) (NN secretion)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB primarily)) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ enhanced) (NN secretion)) (PP (IN of) (NP (NP (JJ immunoreactive) (NN corticotropin-releasing) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN irCRF)) (-RRB- -RRB-)))))) (PP (IN into) (NP (DT the) (JJ hypophysial-portal) (NN circulation))))))))) (. .)))
3015567	2	(S1 (S (NP (NP (JJ Portal) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (CC neither) (NP (NNP Doc_3015567_390_410_Chemical)) (CC nor) (NP (NNP Doc_3015567_415_423_Chemical))))) (VP (AUX are) (VP (ADVP (RB significantly)) (VBN altered) (PP (IN in) (NP (DT this) (NN paradigm))))) (. .)))
3015567	3	(S1 (S (NP (NP (NN Application)) (PP (IN of) (NP (DT a) (JJ delayed) (NN feedback) (NN signal)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (DT a) (JJ 2-h) (JJ systemic) (JJ Doc_3015567_540_554_Chemical) (NN infusion)) (PP (IN in) (NP (NP (JJ Doc_3015567_567_575_Chemical-anesthetized) (NNS rats)) (PP (IN with) (NP (NP (JJ pharmacological) (NN blockade)) (PP (IN of) (NP (JJ glucocorticoid) (NN synthesis))))))))))) (, ,) (VP (AUX is) (PP (IN without) (NP (NN effect))) (PP (IN on) (NP (NP (DT the) (JJ resting) (NN secretion)) (PP (IN of) (NP (NNP Doc_3015567_699_719_Chemical) (CC and) (NNP Doc_3015567_724_732_Chemical))))) (PP (IN at) (NP (NP (DT any) (JJ Doc_3015567_740_754_Chemical) (NN feedback)) (SBAR (S (NP (NN dose)) (VP (VBD tested))))))) (. .)))
3015567	4	(S1 (S (NP (NN Resting) (NN irCRF) (NNS levels)) (VP (AUX are) (VP (VBN suppressed) (ADVP (RB only)) (PP (IN at) (NP (NP (DT the) (JJS highest) (JJ Doc_3015567_833_847_Chemical) (NN infusion) (NN rate)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (JJ systemic) (JJ Doc_3015567_890_904_Chemical) (NNS levels)) (PP (IN of) (NP (CD 40) (NN micrograms/dl)))))))))))) (. .)))
3015567	5	(S1 (S (NP (NP (NN Suppression)) (PP (IN of) (NP (NN irCRF) (NN secretion))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ Doc_3015567_979_992_Chemical-induced) (NNP Doc_3015567_1001_1012_Disease)))))) (VP (VP (AUX is) (VP (VBN observed))) (CC and) (VP (VBZ occurs) (PP (IN at) (NP (NP (DT a) (NN plasma) (JJ Doc_3015567_1048_1062_Chemical) (NN level)) (PP (IN between) (NP (CD 8-12) (CD micrograms/dl))))))) (. .)))
3015567	6	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP provide) (NP (NP (JJ further) (NN evidence)) (PP (IN for) (NP (NP (DT a) (JJ strong) (JJ central) (NN component)) (PP (IN of) (NP (NP (DT the) (JJ delayed) (NN feedback) (NN process)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (NP (NN modulation)) (PP (IN of) (NP (NN irCRF) (NN release))))))))))))))) (. .)))
3031535	0	(S1 (NP (NP (JJ Noradrenergic) (NN involvement)) (PP (IN in) (NP (NNP Doc_3031535_29_38_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_50_78_Chemical)))) (. .)))
3031535	1	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ catecholaminergic) (NN system))) (PP (IN in) (NP (NP (DT the) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3031535_175_203_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3031535_205_208_Chemical)) (-RRB- -RRB-))))))))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NN pretreatment)) (PP (PP (IN with) (NP (NP (NNP Doc_3031535_243_260_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3031535_262_268_Chemical)) (-RRB- -RRB-)))) (CC or) (PP (IN with) (NP (NP (NNP Doc_3031535_278_289_Chemical)) (CC and) (NP (NNP Doc_3031535_294_300_Chemical)))))) (CC and) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus))))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (NNS rats))))) (. .)))
3031535	2	(S1 (S (NP (NP (DT The) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NNP Doc_3031535_392_395_Chemical)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3031535_443_449_Chemical)))))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus))))))) (CC but) (PP (RB not) (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3031535_527_538_Chemical)) (CC and) (NP (NNP Doc_3031535_543_549_Chemical)))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NN control) (NNS rats)))))))) (. .)))
3031535	3	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (NP (DT the) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NNP Doc_3031535_628_639_Chemical)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3031535_687_698_Chemical)) (CC and) (NP (NNP Doc_3031535_703_709_Chemical))))))) (CC but) (RB not) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3031535_739_745_Chemical)))))) (CC or) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NNS coeruleus)))))))))) (. .)))
3031535	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ noradrenergic) (NNS neurons)) (VP (AUX have) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NP (NNP Doc_3031535_891_900_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_912_915_Chemical)))))))) (, ,) (SBAR (IN whereas) (S (NP (JJ dopaminergic) (NNS neurons)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (NNP Doc_3031535_963_972_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_984_995_Chemical))))))))))))) (. .)))
3070035	0	(S1 (NP (NP (NN Reversibility)) (PP (IN of) (NP (NNP Doc_3070035_17_26_Chemical-induced) (NNP Doc_3070035_35_54_Disease))) (PP (IN after) (NP (NP (VBN prolonged) (NN use)) (PP (IN in) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NNP Doc_3070035_97_122_Disease))))))) (. .)))
3070035	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NN Doc_3070035_151_163_Disease)) (PP (IN with) (NP (NP (DT an) (JJ occluded) (JJ renal) (NN artery)) (PP (TO to) (NP (NP (DT a) (JJ solitary) (NN kidney)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3070035_230_268_Disease)) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3070035_294_303_Chemical)))))))))))))))) (. .)))
3070035	2	(S1 (S (NP (PRP$ His) (JJ renal) (NN function)) (VP (VP (VBD remained) (ADJP (ADJP (JJ impaired)) (CC but) (ADJP (JJ stable))) (PP (IN during) (NP (NP (NP (CD 2) (NNS years) (POS ')) (NN treatment)) (PP (IN with) (NP (NNP Doc_3070035_384_393_Chemical)))))) (CC but) (VP (VBD returned) (PP (TO to) (NP (JJ pre-treatment) (NNS levels))) (PP (ADVP (RB soon)) (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug))))))) (. .)))
3070035	3	(S1 (S (NP (DT This)) (VP (VP (VBZ indicates) (NP (NP (NN reversibility)) (PP (IN in) (NP (NNP Doc_3070035_497_506_Chemical-induced) (NNP Doc_3070035_515_528_Disease)))) (PP (ADVP (RB even)) (IN after) (NP (PRP$ its) (JJ prolonged) (NN use)))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT no) (JJ organic) (NN damage)) (VP (VBZ occurs) (PP (TO to) (NP (NP (JJ glomerular) (NNS arterioles)) (VP (VBG following) (NP (JJ chronic) (NN ACE) (NN inhibition)))))))))) (. .)))
3076126	0	(S1 (S (NP (NNP HMG) (NNP CoA) (NN reductase)) (VP (VBZ inhibitors)) (. .)))
3076126	1	(S1 (FRAG (NP (JJ Current) (JJ clinical) (NN experience)) (. .)))
3076126	2	(S1 (S (NP (NP (NNP Doc_3076126_59_69_Chemical)) (CC and) (NP (NNP Doc_3076126_74_85_Chemical))) (VP (AUX are) (NP (NP (DT the) (CD 2) (JJ best-known) (NNS members)) (PP (IN of) (NP (NP (DT the) (NN class)) (PP (IN of) (NP (JJ hypolipidaemic) (NNS agents))) (VP (VBN known) (PP (IN as) (NP (NNP HMG) (NNP CoA) (NN reductase) (NNS inhibitors)))))))) (. .)))
3076126	3	(S1 (S (S (NP (NP (JJ Clinical) (NN experience)) (PP (IN with) (NP (NNP Doc_3076126_217_227_Chemical)))) (VP (VBZ includes) (PP (IN over) (NP (NP (CD 5000) (NNS patients)) (, ,) (SBAR (WHNP (CD 700) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (NP (CD 2) (NNS years)) (CC or) (NP (JJR more))))))))))))) (, ,) (CC and) (S (NP (NP (NN experience)) (PP (IN with) (NP (NNP Doc_3076126_328_339_Chemical)))) (VP (VBZ includes) (PP (IN over) (NP (NP (CD 3500) (NNS patients)) (, ,) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (CD 350)) (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (CD 18) (NNS months) (QP (CC or) (JJR more))))))))))))) (. .)))
3076126	4	(S1 (S (NP (NN Doc_3076126_422_432_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN marketed) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))) (PP (IN for) (NP (IN over) (CD 6) (NNS months)))))) (. .)))
3076126	5	(S1 (S (NP (DT Both) (NNS agents)) (VP (VBP show) (NP (JJ substantial) (JJ clinical) (NN efficacy)) (, ,) (PP (IN with) (NP (NP (NNS reductions)) (PP (PP (IN in) (NP (NP (JJ total) (NN Doc_3076126_564_575_Chemical)) (PP (IN of) (NP (QP (IN over) (CD 30)) (NN %))))) (CC and) (PP (IN in) (NP (NP (NN LDL-Doc_3076126_599_610_Chemical)) (PP (IN of) (NP (CD 40) (NN %))) (PP (IN in) (NP (JJ clinical) (NNS studies))))))))) (. .)))
3076126	6	(S1 (S (NP (NP (JJ Modest) (NNS increases)) (PP (IN in) (NP (NP (JJ HDL-Doc_3076126_663_674_Chemical) (NNS levels)) (PP (IN of) (NP (QP (RB about) (CD 10)) (NN %)))))) (VP (AUX are) (ADVP (RB also)) (VP (VBN reported))) (. .)))
3076126	7	(S1 (S (NP (NP (JJ Clinical) (NN tolerability)) (PP (IN of) (NP (DT both) (NNS agents)))) (VP (AUX has) (VP (AUX been) (ADJP (JJ good)) (, ,) (PP (IN with) (NP (NP (QP (JJR fewer) (IN than) (CD 3)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN withdrawn) (PP (IN from) (NP (NN treatment))) (PP (IN because) (IN of) (NP (JJ clinical) (JJ adverse) (NNS experiences)))))))))) (. .)))
3076126	8	(S1 (S (NP (NP (JJ Ophthalmological) (NNS examinations)) (PP (IN in) (NP (QP (IN over) (CD 1100)) (NNS patients))) (VP (VBN treated) (PP (IN with) (NP (CD one) (CC or) (DT the) (JJ other) (NN agent))))) (VP (AUX have) (VP (VP (VBN revealed) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (JJ significant) (JJ short) (NN term))))) (PRN (-LRB- -LRB-) (NP (QP (RB up) (TO to) (CD 2)) (NNS years)) (-RRB- -RRB-)) (NP (JJ cataractogenic) (NN potential)))) (. .)))
3076126	9	(S1 (S (NP (NP (QP (CD One) (TO to) (CD 2)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX have) (NP (NP (NNS elevations)) (PP (IN of) (NP (NN serum) (NNS transaminases))) (PP (TO to) (NP (NP (QP (JJR greater) (IN than) (CD 3) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal))))))) (. .)))
3076126	10	(S1 (S (NP (DT These) (NNS episodes)) (VP (AUX are) (ADJP (ADJP (JJ asymptomatic)) (CC and) (ADJP (JJ reversible))) (SBAR (WHADVP (WRB when)) (S (NP (NN therapy)) (VP (AUX is) (VP (VBN discontinued)))))) (. .)))
3076126	11	(S1 (S (NP (NP (JJ Minor) (NNS elevations)) (PP (IN of) (NP (JJ Doc_3076126_1254_1262_Chemical) (NN kinase) (NNS levels)))) (VP (AUX are) (VP (VBN reported) (PP (IN in) (NP (NP (QP (RB about) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
3076126	12	(S1 (S (NP (NP (NN Doc_3076126_1315_1323_Disease)) (, ,) (VP (VBN associated) (PP (PP (IN in) (NP (NP (DT some) (NNS cases)) (PP (IN with) (NP (NNP Doc_3076126_1355_1368_Disease))))) (, ,) (CC and) (PP (IN in) (NP (NP (CD 2) (NNS cases)) (PP (IN with) (NP (JJ transient) (NNP Doc_3076126_1400_1413_Disease))))))) (, ,)) (VP (AUX has) (VP (AUX been) (ADVP (RB rarely)) (VP (VBN reported) (PP (IN with) (NP (NNP Doc_3076126_1445_1455_Chemical))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBN treated) (PP (IN with) (NP (NNP Doc_3076126_1507_1518_Chemical) (, ,) (NNP Doc_3076126_1520_1531_Chemical) (CC or) (NNP Doc_3076126_1535_1541_Chemical))))))))) (. .)))
3076126	13	(S1 (S (NP (NP (NNP Doc_3076126_1543_1553_Chemical)) (CC and) (NP (NNP Doc_3076126_1558_1569_Chemical))) (VP (AUX are) (NP (DT both) (JJ effective) (CC and) (JJ well-tolerated) (NNS agents)) (PP (IN for) (S (VP (VBG lowering) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_3076126_1653_1664_Chemical)))))))) (. .)))
3076126	14	(S1 (S (SBAR (IN As) (S (NP (JJR wider) (NN use)) (VP (VBZ confirms) (NP (PRP$ their) (NN safety) (NN profile))))) (, ,) (NP (PRP they)) (VP (MD will) (VP (VB gain) (S (VP (VBG increasing) (NP (NN importance)) (PP (IN in) (NP (NP (DT the) (JJ therapeutic) (NN approach)) (PP (TO to) (NP (NP (NNP Doc_3076126_1778_1799_Disease)) (CC and) (NP (PRP$ its) (NNS consequences)))))))))) (. .)))
3101906	0	(S1 (S (NP (JJ Hepatic) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3101906_34_46_Chemical))) (PP (IN in) (NP (DT the) (NNP United) (NNP Kingdom)))) (. .)))
3101906	1	(S1 (S (NP (NN Doc_3101906_70_82_Chemical)) (VP (AUX was) (VP (VBN introduced) (PP (IN in) (NP (NP (DT the) (NNP United) (NNP Kingdom)) (PP (IN in) (NP (CD 1981))))))) (. .)))
3101906	2	(S1 (S (PP (IN By) (NP (NNP November) (CD 1984))) (NP (NP (DT the) (NN Committee)) (PP (IN on) (NP (NP (NNP Safety)) (PP (IN of) (NP (NNP Medicines)))))) (VP (AUX had) (VP (VBN received) (NP (NP (CD 82) (NNS reports)) (PP (IN of) (NP (NP (JJ possible) (NN Doc_3101906_219_233_Disease)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN drug))))))) (, ,) (PP (VBG including) (NP (CD five) (NN Doc_3101906_275_281_Disease))))) (. .)))
3101906	3	(S1 (S (NP (NP (DT An) (NN analysis)) (PP (IN of) (NP (NP (DT the) (CD 75) (NNS cases)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (ADVP (RB adequately)) (VP (VBN followed) (PRT (RP up)))))))))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (CD 16)) (, ,) (PP (VBG including) (NP (CD three) (NN Doc_3101906_383_389_Disease))) (, ,)) (VP (AUX were) (ADVP (RB probably)) (VP (VBN related) (PP (TO to) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (NN drug)))))))))) (. .)))
3101906	4	(S1 (S (PP (IN Of) (NP (DT the) (NN remainder))) (, ,) (S (NP (CD 48)) (VP (AUX were) (ADJP (ADVP (RB possibly)) (VBN related) (PP (TO to) (NP (NN treatment)))))) (, ,) (S (NP (CD five)) (VP (AUX were) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (ADVP (RB so)))))))) (, ,) (CC and) (S (NP (CD six)) (VP (AUX were) (ADJP (JJ unclassifiable)))) (. .)))
3101906	5	(S1 (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (NNS patients))) (PP (IN in) (NP (DT the) (CD 16) (JJ probable) (NNS cases)))) (VP (AUX was) (NP (CD 57.9)) (, ,) (PP (IN with) (S (NP (NNP Doc_3101906_621_635_Disease)) (VP (AUXG being) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NNS women))))))) (. .)))
3101906	6	(S1 (S (NP (NP (DT The) (JJ average) (NN duration)) (PP (IN of) (NP (NN treatment))) (PP (IN before) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3101906_718_726_Disease)))))) (VP (AUX was) (NP (CD 61) (NNS days))) (. .)))
3101906	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (ADJP (RB well) (VBN validated)) (NNS cases)))) (VP (VBD occurred) (PP (IN within) (NP (DT the) (JJ first) (CD 10) (NNS days))) (PP (IN after) (NP (NN treatment)))) (. .)))
3101906	8	(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NN serum) (NN liver) (NN function) (NNS tests)))) (VP (VBD suggested) (NP (NNP Doc_3101906_878_899_Disease)) (PP (IN in) (NP (CD 10))) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)))) (: ;) (S (NP (DT the) (NN rest)) (VP (VBD showed) (NP (DT a) (JJ mixed) (NN pattern)))) (. .)))
3101906	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ histological) (NN examination)) (PP (IN of) (NP (DT the) (NN liver)))))) (ADVP (RB often)) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_3101906_1037_1048_Disease))))) (. .)))
3101906	10	(S1 (S (NP (NP (DT The) (NNS characteristics)) (PP (IN of) (NP (DT the) (CD 48) (NNS patients))) (PP (IN in) (NP (DT the) (JJ possible) (NNS cases)))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
3101906	11	(S1 (S (NP (NP (JJ Allergic) (NNS manifestations)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_3101906_1157_1161_Disease)) (CC and) (NP (NNP Doc_3101906_1166_1178_Disease))))) (VP (AUX were) (ADJP (JJ rare))) (. .)))
3101906	12	(S1 (S (NP (NN Doc_3101906_1190_1199_Disease)) (VP (AUX was) (ADVP (RB usually)) (ADJP (JJ reversible)) (SBAR (WHADVP (WRB when)) (S (NP (NN treatment)) (VP (AUX was) (VP (VBN stopped) (, ,) (PP (IN with) (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN liver) (NN function) (NNS tests)))) (VP (VBG returning) (PP (TO to) (NP (JJ normal))) (PP (IN after) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 3.1) (NNS months))))))))))))) (. .)))
3101906	13	(S1 (S (PP (IN In) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (CD three) (NNP Doc_3101906_1364_1370_Disease)) (VP (ADVP (RB probably)) (VBN associated) (PP (IN with) (NP (JJ Doc_3101906_1396_1408_Chemical) (NN treatment)))))))) (NP (DT the) (NN drug)) (VP (AUX had) (VP (AUX been) (VP (VBN continued) (PP (IN after) (NP (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3101906_1466_1474_Disease)))) (CC and) (NP (NP (JJ other) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_3101906_1497_1506_Disease))))))))) (. .)))
3101906	14	(S1 (S (NP (NP (ADJP (JJ Clinical) (CC and) (JJ biochemical)) (NN monitoring)) (PP (IN at) (NP (JJ regular) (NNS intervals))) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_3101906_1581_1590_Disease)))))) (VP (AUX is) (VP (VBN advised) (PP (IN during) (NP (NP (JJ long) (NN term) (NN treatment)) (PP (IN with) (NP (NNP Doc_3101906_1634_1646_Chemical))))) (S (VP (TO to) (VP (VB prevent) (NP (JJ possible) (JJ serious) (NN Doc_3101906_1675_1689_Disease))))))) (. .)))
3107448	0	(S1 (NP (JJ Doc_3107448_0_9_Chemical-induced) (NN Doc_3107448_18_27_Disease) (. .)))
3107448	1	(S1 (S (NP (NP (JJ Drug-induced) (NNP Doc_3107448_42_56_Disease)) (, ,) (PP (IN although) (NP (NN common))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (ADVP (RB only) (RB infrequently)) (PP (IN with) (NP (NNP Doc_3107448_116_129_Chemical)))))) (. .)))
3107448	2	(S1 (S (PP (IN For) (NP (NP (NNP Doc_3107448_135_144_Chemical)) (, ,) (NP (DT a) (JJ second-generation) (NN Doc_3107448_166_178_Chemical)))) (, ,) (NP (NP (QP (RB only) (CD two)) (JJ brief) (NNS reports)) (PP (IN of) (NP (NNP Doc_3107448_206_220_Disease)))) (VP (VBP exist)) (. .)))
3107448	3	(S1 (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (NNP Doc_3107448_246_271_Disease)))) (VP (VBD developed) (NP (DT an) (NN Doc_3107448_285_314_Disease)) (PP (ADVP (RB soon)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_3107448_340_349_Chemical) (NN therapy)))))) (. .)))
3107448	4	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ serologic) (NN evidence)) (PP (IN of) (NP (NNP Doc_3107448_394_409_Disease)))))) (, ,) (CC and) (S (NP (DT a) (NN liver) (NN biopsy) (NN sample)) (VP (VBD showed) (NP (NP (DT a) (JJ histologic) (NN pattern)) (ADJP (JJ consistent) (PP (IN with) (NP (NN Doc_3107448_481_503_Disease))))))) (. .)))
3107448	5	(S1 (S (CC Both) (NP (NNS patients)) (VP (VP (VBD recovered) (ADVP (RB quickly)) (PP (IN after) (S (VP (VBG stopping) (NP (JJ Doc_3107448_552_561_Chemical) (NN therapy)))))) (CC and) (VP (AUX have) (VP (VBN remained) (ADVP (RB well)) (PP (IN for) (NP (NP (DT a) (JJ follow-up) (NN period)) (PP (IN of) (NP (CD 1) (NN year)))))))) (. .)))
3107448	6	(S1 (S (NP (NN Doc_3107448_627_636_Chemical)) (VP (MD can) (VP (VB produce) (NP (NP (DT an) (NN Doc_3107448_652_680_Disease)) (PP (IN in) (NP (DT some) (NNS persons)))))) (. .)))
3125768	0	(S1 (S (NP (JJ Intracranial) (NN pressure)) (VP (VBZ increases) (PP (IN during) (NP (NNP Doc_3125768_39_49_Chemical-induced) (NNP Doc_3125768_58_66_Disease)))) (. .)))
3125768	1	(S1 (S (NP (NP (JJ Intracranial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP ICP)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN during) (NP (NP (JJ Doc_3125768_116_126_Chemical-induced) (NN Doc_3125768_135_143_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
3125768	2	(S1 (S (NP (CD Ten) (NNS rats)) (VP (AUX had) (NP (NP (NN arterial)) (, ,) (NP (NP (JJ central) (NNS venous)) (PRN (-LRB- -LRB-) (NP (NNP CVP)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ subdural) (NNS cannulae)) (VP (VBN inserted) (PP (IN under) (NP (JJ Doc_3125768_235_244_Chemical) (NN anesthesia))))))) (. .)))
3125768	3	(S1 (S (NP (DT The) (NNS animals)) (VP (AUX were) (ADJP (RB mechanically) (VBN ventilated) (S (VP (TO to) (VP (VB achieve) (NP (NN normocarbia)))))) (PRN (-LRB- -LRB-) (NP (QP (CD PCO2) (SYM =) (CD 42) (CD +/-) (CD 1)) (NN mmHg)) (, ,) (NP (JJ mean) (FW +/-) (FW SE)) (-RRB- -RRB-))) (. .)))
3125768	4	(S1 (S (PP (VBG Following) (NP (NN instrumentation))) (, ,) (S (NP (NNP Doc_3125768_385_394_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NP (NNP Doc_3125768_416_426_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 125) (NN mu/kg)) (-RRB- -RRB-))) (VP (VBN administered) (NP (NNP iv)) (PP (IN during) (NP (NN emergence))) (PP (IN from) (NP (JJ Doc_3125768_477_486_Chemical) (NNS anesthesia))))) (. .)))
3125768	5	(S1 (S (PP (IN In) (NP (NP (DT the) (CD five) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (NP (NN Doc_3125768_531_547_Disease))))))) (, ,) (NP (NNP ICP) (CC and) (NNP CVP)) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN above) (NP (NN baseline))) (PRN (-LRB- -LRB-) (NP (JJ delta) (NNP ICP) (CD 7.5) (NN +/-) (CD 1.0) (NN mmHg)) (, ,) (NP (NN delta) (NN CVP)) (NP (CD 5.9) (NN +/-) (QP (CD 1.3) (CD mmHg))) (-RRB- -RRB-))) (. .)))
3125768	6	(S1 (S (NP (DT These) (NNS variables)) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3125768_700_708_Disease)) (VP (AUX was) (VP (VBN abolished) (PP (IN with) (NP (NN Doc_3125768_728_738_Chemical)))))))) (. .)))
3125768	7	(S1 (S (PP (IN In) (NP (NP (CD five) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB become) (ADJP (JJ rigid)))))))) (, ,) (NP (NP (NNP ICP)) (CC and) (NP (NNP CVP))) (VP (AUX did) (RB not) (VP (VB change) (NP (JJ following) (NN Doc_3125768_817_827_Chemical)))) (. .)))
3125768	8	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3125768_861_869_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN prevented) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_3125768_895_905_Chemical)) (, ,) (CC and) (, ,) (ADVP (RB presumably)) (, ,) (NP (JJ other) (NNS opiates)) (, ,)) (VP (AUX are) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ anesthetic) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ICP) (NNS problems))))))))))))))))) (. .)))
3173179	0	(S1 (NP (NP (JJ Doc_3173179_0_9_Chemical) (NN withdrawal)) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_3173179_44_65_Disease))) (PP (IN in) (NP (NP (DT a) (NNP Doc_3173179_71_83_Disease) (NN woman)) (PP (IN with) (NP (DT a) (JJ normal) (JJ coronary) (NN angiogram))))))) (. .)))
3173179	1	(S1 (S (NP (NN Doc_3173179_124_133_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective)) (CC and) (NP (JJ relatively-safe) (JJ antihypertensive) (NN drug)))) (. .)))
3173179	2	(S1 (S (NP (JJ Serious) (JJ adverse) (NNS effects)) (VP (VP (AUX are) (ADJP (JJ uncommon))) (CC and) (VP (ADVP (RB mainly)) (AUX have) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NNP Doc_3173179_266_276_Disease)) (PP (IN of) (NP (NP (JJ cardiac) (NN contractility)) (CC and) (NP (NN conduction)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX is) (VP (VBN combined) (PP (IN with) (NP (JJ beta-blocking) (NNS agents))))))))))))) (. .)))
3173179	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNP Doc_3173179_408_429_Disease)) (VP (VBD coincided) (PP (IN with) (NP (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_3173179_465_474_Chemical)))) (CC and) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3173179_497_506_Chemical)))))) (PP (IN in) (NP (NP (DT a) (ADJP (RB previously) (JJ asymptomatic)) (NN woman)) (PP (IN with) (NP (JJ severe) (NN Doc_3173179_554_566_Disease)))))))))) (. .)))
3173179	4	(S1 (S (NP (NP (JJ Possible) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP involve) (NP (NP (DT a) (JJ Doc_3173179_603_612_Chemical-related) (NN increase)) (PP (IN in) (NP (JJ platelet) (NN and/or) (NN vascular) (NN alpha) (NN 2-adrenoreceptor) (NN affinity))) (PP (IN for) (NP (NNP Doc_3173179_694_708_Chemical)))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
3173180	0	(S1 (NP (NP (NN Doc_3173180_0_27_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3173180_49_62_Chemical))))) (. .)))
3173180	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ describes) (NP (NP (DT the) (JJ clinical) (NNS features)) (PP (IN of) (NP (CD six) (NNS children))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT the) (NN Doc_3173180_141_168_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3173180_190_203_Chemical)))))))))) (. .)))
3173180	2	(S1 (S (NP (DT These) (NNS children)) (VP (VP (AUX were) (ADJP (JJR older))) (CC and) (VP (AUX were) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (VP (VBN undergone) (NP (NP (JJ recent) (NN bowel) (NN surgery)) (SBAR (WHNP (IN than)) (S (VP (AUX are) (NP (NP (JJ other) (NNS children)) (PP (IN with) (NP (DT this) (NN condition))))))))))))))) (. .)))
3173180	3	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNP Doc_3173180_361_374_Chemical))) (PP (IN in) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (DT the) (NNP Doc_3173180_399_426_Disease)))))) (VP (AUX is) (RB not) (VP (VBN established) (ADVP (RB firmly)))))) (, ,) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (S (VP (VBG sensitizing) (NP (NNS tissues)) (PP (TO to) (NP (NP (NN oxidation) (NN injury)) (CC and) (NP (NP (DT the) (VBN reported) (NN evidence)) (PP (IN of) (NP (NP (JJ oxidation) (NNS changes)) (PP (IN in) (NP (DT the) (NNP Doc_3173180_575_602_Disease)))))))))))) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN link)) (PP (IN between) (NP (NP (JJ Doc_3173180_635_648_Chemical) (NN treatment)) (CC and) (NP (NP (DT some) (NNS cases)) (PP (IN of) (NP (DT the) (NNP Doc_3173180_681_708_Disease)))))))) (. .)))
3187073	0	(S1 (NP (NP (JJ Adverse) (JJ cardiac) (NNS effects)) (PP (IN during) (NP (NP (JJ induction) (JJ chemotherapy) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_3187073_69_79_Chemical)) (CC and) (NP (NNP Doc_3187073_84_98_Chemical)))))) (. .)))
3187073	1	(S1 (S (NP (NP (NN Survival)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NNP Doc_3187073_136_159_Disease)) (CC and) (NP (NNP Doc_3187073_164_184_Disease))))))) (VP (AUX is) (ADJP (JJ poor) (PP (IN with) (NP (JJ radiotherapy) (NN and/or) (NN surgery))))) (. .)))
3187073	2	(S1 (S (ADVP (RB Obviously)) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (JJ effective) (NN chemotherapy))))) (. .)))
3187073	3	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NP (NNP Doc_3187073_304_314_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-120) (NN mg/m2BSA)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3187073_337_341_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg/m2BSA)) (PP (JJ daily) (IN as) (NP (DT a) (JJ continuous) (NN infusion))) (PP (IN during) (NP (CD 5) (NNS days)))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN given) (PP (TO to) (NP (NP (CD 76) (NNS patients)) (PP (IN before) (NP (NN radiotherapy) (CC and) (NN surgery))))))) (. .)))
3187073	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (JJ adverse) (JJ cardiac) (NNS effects)) (PP (TO to) (NP (DT this) (NN treatment)))))))))) (. .)))
3187073	5	(S1 (S (PP (IN Before) (NP (NN treatment))) (NP (DT all) (NNS patients)) (VP (VP (AUX had) (NP (DT a) (JJ cardiac) (NN evaluation))) (CC and) (VP (PP (IN during) (NP (NN treatment) (NN serial) (NN ECG) (NNS recordings))) (AUX were) (VP (VBN performed)))) (. .)))
3187073	6	(S1 (S (PP (IN In) (NP (DT the) (JJ pre-treatment) (NN evaluation))) (, ,) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_727_749_Disease)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (CD 33) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-)))))) (. .)))
3187073	7	(S1 (S (PP (IN During) (NP (NN treatment))) (, ,) (NP (JJ adverse) (JJ cardiac) (NNS effects)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (CD 14) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-)))))) (. .)))
3187073	8	(S1 (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX was) (NP (NP (NP (DT the) (JJ same)) (PP (IN as) (PP (IN for) (NP (DT the) (JJ entire) (NN group))))) (, ,) (NP (CD 64) (NNS years)))) (. .)))
3187073	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_3187073_957_971_Disease)))) (VP (AUX was) (RB not) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_1013_1035_Disease)))))))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (ADJP (IN without) (PP (IN in) (NP (DT the) (JJ pre-treatment) (NN evaluation))))))))) (. .)))
3187073	10	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_1116_1130_Disease)))) (VP (AUX were) (NP (NP (NNP Doc_3187073_1136_1146_Disease)) (, ,) (NP (JJ ST-T) (NN wave) (NNS changes)) (CC and) (NP (NNP Doc_3187073_1170_1189_Disease)))) (. .)))
3187073	11	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (NP (NNP Doc_3187073_1212_1236_Disease)) (PP (IN in) (NP (CD one) (NN patient)))) (CC and) (NP (NP (NNP Doc_3187073_1256_1268_Disease)) (PP (IN in) (NP (DT another)))))))) (. .)))
3187073	12	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN on) (NP (JJ Doc_3187073_1314_1318_Chemical) (NN treatment)))) (VP (MD should) (VP (AUX be) (PP (IN under) (NP (JJ close) (NN supervision))))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN treatment)) (VP (MD should) (VP (AUX be) (ADJP (JJ discontinued)) (SBAR (IN if) (S (NP (NP (NNP Doc_3187073_1412_1422_Disease)) (CC or) (NP (NNP Doc_3187073_1426_1441_Disease))) (VP (AUX is) (ADJP (JJ observed)))))))))))) (. .)))
3192036	0	(S1 (NP (NP (NN Doc_3192036_0_5_Disease)) (PP (IN from) (NP (NN chemotherapy))) (PP (IN in) (NP (NNP Doc_3192036_27_60_Disease))) (. .)))
3192036	1	(S1 (S (NP (JJ Multiple) (JJ cytotoxic) (NN drug) (NN administration)) (VP (AUX is) (NP (NP (DT the) (ADJP (RB generally) (JJ accepted)) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ high-risk) (NN stage)) (PP (IN of) (NP (NN Doc_3192036_175_190_Disease))))))))) (. .)))
3192036	2	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT this) (NN principle)))) (NP (NP (DT a) (JJ 27-year) (JJ old) (NN woman)) (, ,) (VP (VBN classified) (PP (IN as) (NP (AUXG being))) (PP (IN in) (NP (NP (DT the) (JJ high-risk) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP Goldstein) (CC and) (NNP Berkowitz) (NN score)) (: :) (NP (CD 11))) (-RRB- -RRB-))))) (, ,)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ multiple) (JJ cytotoxic) (NNS drugs))))) (. .)))
3192036	3	(S1 (S (NP (DT The) (JJ multiple) (NN drug) (NN schema)) (VP (VBD consisted) (PP (IN of) (: :) (NP (NP (NNP Doc_3192036_399_408_Chemical) (CD 16.213)) (, ,) (NP (NNP Doc_3192036_417_429_Chemical)) (, ,) (NP (NNP Doc_3192036_431_447_Chemical)) (, ,) (NP (NNP Doc_3192036_449_460_Chemical)) (, ,) (CC and) (NP (NNP Doc_3192036_466_475_Chemical))))) (. .)))
3192036	4	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (DT the) (NN schedule))))) (, ,) (NP (NP (JJ moderate) (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_3192036_534_546_Chemical)) (, ,) (NP (NNP Doc_3192036_548_557_Chemical)) (CC and) (NP (NNP Doc_3192036_562_578_Chemical))))) (VP (AUX were) (VP (VBN administered))) (. .)))
3192036	5	(S1 (S (PP (IN Within) (NP (NP (CD 8) (NNS hours)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy))))))) (NP (DT the) (NN patient)) (VP (VBD died) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN picture)) (VP (VBG resembling) (NP (JJ massive) (NNP Doc_3192036_701_722_Disease)) (PP (JJ due) (TO to) (NP (JJ choriocarcinomic) (NN tissue) (NNS plugs)))))) (, ,) (S (ADVP (RB probably)) (VP (VBG originating) (PP (IN from) (NP (DT the) (NN uterus)))))) (. .)))
3192036	6	(S1 (S (S (NP (NP (NN Formation)) (PP (IN of) (NP (DT these) (NNS plugs)))) (VP (AUX was) (ADJP (RB probably) (JJ due) (PP (TO to) (NP (JJ extensive) (NNP Doc_3192036_854_859_Disease) (NNP Doc_3192036_860_868_Disease)))) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (DT the) (NNS walls)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN uterine) (NNS veins)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ open) (NN exchange)) (PP (IN of) (NP (NP (JJ Doc_3192036_961_966_Disease) (NNS plugs)) (PP (TO to) (NP (DT the) (JJ vascular) (NNS spaces)))))))))))))))))) (: ;) (S (NP (NP (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_3192036_1009_1014_Disease) (NN tissue) (NN coherence)) (ADJP (JJ secondary) (TO to) (JJ chemotherapy))))) (VP (MD may) (VP (AUX have) (VP (ADVP (RB further)) (VBN contributed) (PP (TO to) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNP Doc_3192036_1107_1112_Disease) (NNS emboli))))))))) (. .)))
3192036	7	(S1 (S (PP (IN In) (NP (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ close) (NN time) (NN association)) (PP (IN between) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN chemotherapy)))))))) (CC and) (NP (NP (DT the) (JJ acute) (NN onset)) (PP (IN of) (NP (JJ massive) (NNP Doc_3192036_1224_1232_Disease)))))) (NP (NP (JJ other) (NNS explanations)) (, ,) (PP (JJ such) (IN as) (NP (JJ spontaneous) (NNP Doc_3192036_1273_1281_Disease))) (, ,)) (VP (MD must) (VP (AUX be) (VP (VBN considered) (S (ADJP (RBR less) (JJ likely)))))) (. .)))
3192036	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ large) (NN Doc_3192036_1335_1347_Disease) (NNS loads)))) (VP (AUX are) (, ,) (PP (VBG according) (PP (TO to) (NP (JJ existing) (NNS classifications)))) (, ,) (PP (IN at) (NP (NP (JJ high) (NN risk)) (SBAR (S (VP (VP (TO to) (VP (VB die))) (CC and) (VP (TO to) (VP (VB develop) (NP (NN drug) (NN resistance)))))))))) (. .)))
3192036	9	(S1 (S (PP (IN Notwithstanding) (NP (DT these) (NNS facts))) (NP (PRP$ our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT these) (NNS patients)) (VP (MD might) (VP (VB benefit) (PP (IN from) (NP (ADJP (RB relatively) (JJ mild)) (JJ initial) (NN treatment))) (, ,) (ADJP (RB especially) (JJ true) (PP (IN for) (NP (NP (NNS patients)) (VP (RB not) (ADVP (RB previously)) (VBN exposed) (PP (TO to) (NP (DT this) (NN drug)))))))))))) (. .)))
3192036	10	(S1 (NP (NP (JJ Close) (NN observation)) (PP (IN of) (NP (DT the) (NN response) (NN status))) (UCP (DT both) (ADVP (RB clinically)) (CC and) (SBAR (IN with) (S (NP (NN beta-hCG) (NNS values)) (VP (MD may) (VP (VB indicate) (SBAR (IN whether) (CC and) (SBAR (WHADVP (WRB when)) (S (NP (JJR more) (JJ agressive) (NN combination) (NN chemotherapy)) (VP (MD should) (VP (AUX be) (VP (VBN started.) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))))))))
322550	0	(S1 (S (NP (NP (JJ Pulmonary) (NN shunt)) (CC and) (NP (JJ cardiovascular) (NNS responses))) (VP (TO to) (VP (VB CPAP) (PP (IN during) (NP (JJ Doc_322550_60_73_Chemical-induced) (NN Doc_322550_82_93_Disease))))) (. .)))
322550	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ continuous) (JJ positive) (NN airway) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN CPAP)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ cardiovascular) (NNS dynamics)) (CC and) (NP (NP (JJ pulmonary) (NN shunt)) (PRN (-LRB- -LRB-) (NP (NNP QS/QT)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (CD 12) (NNS dogs))) (PP (IN before) (CC and) (IN during) (NP (NP (JJ Doc_322550_255_275_Chemical) (NN infusion)) (SBAR (WHNP (WDT that)) (S (VP (VBD decreased) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (NP (NP (CD 40-50)) (PP (IN per) (NP (NN cent))))))))))) (. .)))
322550	2	(S1 (S (PP (IN Before) (NP (JJ Doc_322550_352_365_Chemical) (NN infusion))) (, ,) (NP (CD 5) (JJ cm) (NNP Doc_322550_381_384_Chemical) (NN CPAP)) (VP (ADVP (RB significantly)) (, ,) (VP (VBD P) (NP (QP (JJR less) (IN than) (CD .05)))) (, ,) (VP (VBD decreased) (NP (JJ arterial) (NN blood) (NN pressure))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB significantly)) (VB alter) (NP (NP (NN heart) (NN rate)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (NP (JJ systemic) (JJ vascular) (NN resistance)) (, ,) (CC or) (NP (NN QS/QT)))))) (. .)))
322550	3	(S1 (S (NP (NP (CD Ten) (JJ cm) (NNP Doc_322550_564_567_Chemical) (NN CPAP)) (PP (IN before) (NP (JJ Doc_322550_580_593_Chemical) (NN infusion)))) (VP (VP (VBD produced) (NP (DT a) (JJ further) (NN Doc_322550_622_657_Disease))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NP (NNP Doc_322550_701_725_Disease)) (CC and) (NP (NNP QS/QT)))))) (. .)))
322550	4	(S1 (S (S (NP (NN Doc_322550_737_750_Chemical)) (VP (VBD caused) (NP (NP (JJ significant) (NNP Doc_322550_770_806_Disease) (CC and) (JJ systemic) (NN vascular) (NN resistance)) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NN heart) (NN rate))))))) (, ,) (CC but) (S (VP (AUX did) (RB not) (VP (VB change) (NP (JJ cardiac) (NN output) (CC or) (NNS QS/QT))))) (. .)))
322550	5	(S1 (S (NP (NP (CD Five) (JJ cm) (JJ Doc_322550_921_924_Chemical) (NN CPAP)) (PP (IN during) (NP (NNP Doc_322550_937_950_Chemical)))) (VP (AUX did) (RB not) (ADVP (RB further)) (VP (VB alter) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ above-mentioned) (NNS variables)))))) (. .)))
322550	6	(S1 (S (ADVP (RB However)) (, ,) (NP (CD 10) (NN cm) (JJ Doc_322550_1026_1029_Chemical) (NN CPAP)) (VP (VBD decreased) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (CC and) (NP (NN QS/QT)))) (. .)))
322550	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ Doc_322550_1122_1135_Chemical) (NN infusion) (NNS rates)) (SBAR (WHNP (WDT that)) (S (VP (VB decrease) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN by) (NP (NP (CD 40-50)) (PP (IN per) (NP (NN cent))))))))) (VP (AUX do) (RB not) (VP (VB change) (NP (NP (JJ cardiac) (NN output)) (CC or) (NP (NNS QS/QT)))))))) (. .)))
322550	8	(S1 (S (PP (IN During) (NP (JJ Doc_322550_1258_1271_Chemical) (NN infusion))) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (NN CPAP)))) (VP (AUX do) (RB not) (ADVP (RB markedly)) (VP (VB alter) (NP (JJ cardiovascular) (NNS dynamics)))) (, ,) (CC but) (S (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NNP CPAP)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN cm) (NNP Doc_322550_1378_1381_Chemical)) (-RRB- -RRB-))))) (, ,) (SBAR (IN while) (S (VP (VBG decreasing) (NP (NN QS/QT))))) (, ,) (VP (VBP produce) (NP (JJ marked) (NN Doc_322550_1423_1478_Disease)))) (. .)))
3341566	0	(S1 (S (NP (JJ Systolic) (NN pressure) (NN variation)) (VP (AUX is) (ADJP (ADJP (JJR greater)) (PP (IN during) (NP (NNP Doc_3341566_46_56_Disease))) (PP (IN than) (PP (IN during) (NP (NP (JJ Doc_3341566_69_89_Chemical-induced) (NN Doc_3341566_98_109_Disease)) (PP (IN in) (NP (VBN ventilated) (NNS dogs)))))))) (. .)))
3341566	1	(S1 (S (NP (NP (DT The) (JJ systolic) (NN pressure) (NN variation)) (PRN (-LRB- -LRB-) (NP (NNP SPV)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (NP (DT the) (JJ maximal) (CC and) (JJ minimal) (NNS values)) (PP (IN of) (NP (DT the) (JJ systolic) (NN blood) (NN pressure)))))) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-)) (PP (IN after) (NP (CD one) (JJ positive-pressure) (NN breath)))))) (, ,)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (VBN ventilated) (NNS dogs)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_3341566_349_360_Disease)))))))) (. .)))
3341566	2	(S1 (S (NP (JJ Mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (VBN decreased) (PP (TO to) (NP (CD 50) (NN mm))) (NP (NNP Hg)) (PP (IN for) (NP (CD 30) (NNS minutes))) (PP (CC either) (PP (IN by) (NP (NP (NNP Doc_3341566_436_446_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3341566_448_451_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_3341566_489_509_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3341566_511_514_Chemical)) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-))))))))) (. .)))
3341566	3	(S1 (S (PP (IN During) (NP (NNP Doc_3341566_531_534_Disease-induced) (NNP Doc_3341566_543_554_Disease))) (NP (DT the) (JJ cardiac) (NN output)) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (CC and) (ADJP (NP (JJ systemic) (NN vascular) (NN resistance)) (JJR higher))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_664_667_Chemical) (NN group))))))) (. .)))
3341566	4	(S1 (S (NP (NP (DT The) (JJ systemic) (, ,) (JJ central) (NNS venous)) (, ,) (NP (NN pulmonary) (NN capillary) (NN wedge) (NNS pressures)) (, ,) (CC and) (NP (NN heart) (NNS rates)) (, ,)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT the) (CD two) (NNS groups)))) (. .)))
3341566	5	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS changes)) (PP (IN in) (NP (DT the) (JJ arterial) (NN pressure) (NN waveform)))))) (VP (VBD enabled) (NP (NP (NN differentiation)) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
3341566	6	(S1 (S (NP (NP (DT The) (NN SPV)) (PP (IN during) (NP (NNP Doc_3341566_924_935_Disease)))) (VP (AUX was) (NP (QP (CD 15.7) (JJR +/-) (CD 6.7) (CD mm)) (NNP Hg)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_966_969_Disease) (NN group))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 9.1) (NN +/-)) (NP (NP (QP (CD 2.0) (CD mm)) (NNP Hg)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_1016_1019_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.02))) (-RRB- -RRB-))))))) (. .)))
3341566	7	(S1 (S (NP (NP (DT The) (JJ delta) (NN down)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (NN measure)) (PP (IN of) (NP (NN decrease))) (PP (IN of) (NP (NNP SBP)))) (PP (IN after) (NP (DT a) (JJ mechanical) (NN breath)))))) (, ,)) (VP (AUX was) (NP (NP (NP (QP (CD 20.3) (JJ +/-) (CD 8.4) (CC and) (CD 10.1) (NN +/-))) (NP (CD 3.8) (JJ mm) (NNP Hg))) (PP (IN in) (NP (DT the) (NNP Doc_3341566_1176_1179_Disease) (CC and) (NNP Doc_3341566_1184_1187_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (NNP Doc_3341566_1217_1228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.02))) (-RRB- -RRB-))))) (. .)))
3341566	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN SPV)) (CC and) (NP (DT the) (NN delta)))) (ADVP (RB down))) (VP (AUX are) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (DT a) (JJ Doc_3341566_1334_1345_Disease) (NN state)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ predominant) (NN decrease)) (PP (IN in) (NP (NN preload)))))))))))))) (. .)))
3341566	9	(S1 (S (NP (PRP They)) (VP (AUX are) (ADVP (RB thus)) (ADJP (RBR more) (JJ important)) (PP (IN during) (NP (JJ absolute) (NN Doc_3341566_1439_1450_Disease))) (PP (IN than) (PP (IN during) (NP (JJ deliberate) (NNP Doc_3341566_1474_1485_Disease))))) (. .)))
3358181	0	(S1 (NP (NP (NP (NN Doc_3358181_0_28_Disease)) (PP (IN during) (NP (JJ cesarean) (NN section))) (PP (IN after) (NP (JJ Doc_3358181_59_68_Chemical) (NN therapy)))) (: :) (NP (NP (NN interaction)) (PP (IN with) (NP (NNS anesthetics)))) (. .)))
3358181	1	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (SBAR (IN that) (S (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3358181_154_163_Chemical)) (PP (IN for) (NP (NNP Doc_3358181_168_181_Disease))))) (VP (MD may) (VP (VB risk) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NP (DT the) (JJ residual) (JJ betamimetic) (NNS effects)) (PP (IN of) (NP (NNP Doc_3358181_248_257_Chemical)))) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS anesthetics))))))) (PP (IN during) (NP (JJ cesarean) (NN section)))))))) (. .)))
3358181	2	(S1 (S (NP (JJ Such) (NNS interactions)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_3358181_354_382_Disease))) (PP (ADVP (RB even)) (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NNP Doc_3358181_422_431_Chemical))))))))) (. .)))
3358181	3	(S1 (S (NP (JJ Preoperative) (NN assessment)) (VP (MD should) (VP (VB focus) (PP (IN on) (NP (NP (JJ cardiovascular) (NN status)) (CC and) (NP (NN serum) (JJ Doc_3358181_505_514_Chemical) (NN level)))))) (. .)))
3358181	4	(S1 (S (NP (NP (NN Delaying) (NN induction)) (PP (IN of) (NP (NN anesthesia)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB whenever)) (FRAG (ADJP (JJ possible))))))) (. .)))
3358181	5	(S1 (S (NP (NP (JJ Careful) (NN fluid) (NN administration)) (CC and) (NP (NP (JJ cautious) (NN use)) (PP (IN of) (NP (NP (JJ titrated) (NNS doses)) (PP (IN of) (NP (NNP Doc_3358181_662_671_Chemical))))))) (VP (AUX are) (VP (VBN advised))) (. .)))
3358181	6	(S1 (S (PP (IN After) (NP (NP (NN delivery)) (PP (IN of) (NP (DT the) (NN infant))))) (, ,) (NP (EX there)) (VP (MD should) (VP (AUX be) (NP (NP (DT no) (NN contraindication)) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT an) (JJ alpha-adrenergic) (NN vasopressor)) (PP (JJ such) (IN as) (NP (NNP Doc_3358181_805_818_Chemical))))) (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_3358181_828_839_Disease) (NNS patients)) (PP (IN with) (NP (NN Doc_3358181_854_865_Disease))))))))))) (. .)))
3371379	0	(S1 (NP (NNP Doc_3371379_0_9_Chemical-induced) (NNP Doc_3371379_18_31_Chemical) (NNP Doc_3371379_32_45_Disease) (. .)))
3371379	1	(S1 (NP (NP (NP (DT A) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
3371379	2	(S1 (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3371379_97_110_Chemical) (NNP Doc_3371379_111_124_Disease))) (PP (IN after) (NP (NP (JJ combined) (NN treatment)) (PP (IN with) (NP (NNP Doc_3371379_155_164_Chemical)))))))) (VP (VBD showed) (NP (JJ complete) (NN recovery)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (JJ Doc_3371379_219_226_Chemical) (NN entry) (NN blocker)))))) (. .)))
3371379	3	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_3371379_249_258_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_3371379_279_292_Chemical)))))) (VP (MD should) (VP (CC either) (VP (AUX be) (VP (VBN avoided))) (CC or) (VP (VBN prescribed) (ADVP (RB only)) (PP (IN with) (NP (NP (JJ appropriate) (NN adjustment)) (PP (IN of) (NP (NP (DT the) (JJ Doc_3371379_372_385_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (ADVP (RB usually)) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (JJ Doc_3371379_417_430_Chemical) (NN dose))) (PP (IN by) (NP (CD one) (NN half)))) (-RRB- -RRB-))))))))) (. .)))
3403780	0	(S1 (NP (NP (JJ Doc_3403780_0_11_Chemical-associated) (NNP Doc_3403780_23_27_Disease)) (, ,) (NP (NNP Doc_3403780_29_47_Disease)) (, ,) (NP (NNP Doc_3403780_49_74_Disease)) (. .)))
3403780	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (NNP Doc_3403780_86_104_Disease)) (, ,) (NP (NNP Doc_3403780_106_145_Disease) (JJ following) (JJ Doc_3403780_156_167_Chemical) (NN ingestion))))) (VP (AUX is) (VP (VBN presented))) (. .)))
3403780	2	(S1 (S (NP (NP (DT The) (JJ diagnostic) (NN difficulty)) (PP (IN at) (NP (NN presentation)))) (VP (AUX is) (VP (VBN highlighted))) (. .)))
3403780	3	(S1 (S (NP (JJ Continuous) (JJ arteriovenous) (NN haemofiltration)) (VP (VBD proved) (NP (NP (DT a) (JJ valuable) (NN means)) (PP (IN of) (S (VP (VBG maintaining) (NP (NP (NN fluid)) (CC and) (NP (NN electrolyte) (NN balance)))))))) (. .)))
3403780	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered)) (. .)))
3409645	0	(S1 (NP (NP (NN Doc_3409645_0_18_Disease)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3409645_39_48_Disease))))) (. .)))
3409645	1	(S1 (S (NP (NP (DT The) (NN relationship)) (PP (IN of) (NP (NP (NNP Doc_3409645_70_79_Disease)) (CC and) (NP (NNP Doc_3409645_84_102_Disease))))) (VP (AUX was) (VP (VBN investigated) (PP (IN among) (NP (NP (CD 169) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_3409645_144_164_Disease)) (, ,) (NP (NNP Doc_3409645_166_180_Disease)) (CC and) (NP (NNP Doc_3409645_185_204_Disease)))) (, ,) (SBAR (WHNP (CD 130) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (ADJP (JJ pair-matched) (PP (TO to) (NP (NNS controls))))))))))) (. .)))
3409645	2	(S1 (S (NP (NP (NNS Assessments)) (PP (IN of) (NP (NP (JJ marital) (NN happiness)) (CC and) (NP (NNP Doc_3409645_286_300_Disease))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN made) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ CES-D)) (CC and) (NP (DT the) (NNP Azrin) (JJ Marital) (NN Happiness) (NN Scale))) (PRN (-LRB- -LRB-) (NP (NNP AMHS)) (-RRB- -RRB-))))))) (. .)))
3409645	3	(S1 (S (NP (NNP Doc_3409645_378_397_Disease)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ common) (PP (IN among) (NP (NP (NP (NNS patients)) (CC and) (NP (NNS controls))) (, ,) (NP (NP (DT the) (NN majority)) (PP (IN in) (S (NP (DT both) (NNS groups)) (VP (VBG reporting) (NP (QP (CD one) (CC or) (JJR more)) (NNS dysfunctions)))))))))))))) (. .)))
3409645	4	(S1 (S (NP (NN Doc_3409645_515_524_Disease)) (VP (VP (AUX was) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NP (JJ male) (NNS patients)) (PP (IN than) (NP (NNS controls)))))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN co-morbidity)) (CC and) (NP (NP (DT the) (NN taking)) (PP (IN of) (NP (NNP Doc_3409645_642_654_Chemical))))))))))))) (. .)))
3409645	5	(S1 (S (NP (NN Doc_3409645_656_670_Disease)) (VP (VP (AUX was) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NNS patients)))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (PP (IN with) (NP (JJ certain) (JJ sexual) (NNS difficulties))) (, ,) (CC but) (RB not) (PP (IN with) (NP (NNP Doc_3409645_768_777_Disease))))))) (. .)))
3409645	6	(S1 (S (NP (JJ Marital) (NN unhappiness)) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (JJ AMHS) (NNS scores)))))) (, ,) (VP (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3409645_853_862_Disease))))) (CC but) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NN Doc_3409645_887_905_Disease)) (, ,) (NP (JJ sexual) (NN dissatisfaction)) (CC and) (NP (JJ being) (NN female))))))) (. .)))
3412544	0	(S1 (SQ (AUX Does) (NP (NNP Doc_3412544_5_16_Chemical)) (VP (VB cause) (NP (NP (NNP Doc_3412544_23_40_Disease)) (CC or) (NP (NNP Doc_3412544_44_68_Disease)))) (. ?)))
3412544	1	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NNP Doc_3412544_93_117_Disease)) (CC or) (NP (NNP Doc_3412544_121_166_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NP (NN consumption)) (PP (IN of) (NP (DT either) (NNP Doc_3412544_205_215_Chemical) (CC or) (NNP Doc_3412544_219_230_Chemical))))))) (VP (AUX was) (VP (VBN calculated) (PP (IN from) (NP (NP (NNS data)) (VP (VBN acquired) (PP (IN by) (NP (NN questionnaire))) (PP (IN from) (NP (NP (CD 381) (NNS cases)) (CC and) (NP (CD 808) (NNS controls))))))))) (. .)))
3412544	2	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_3412544_327_351_Disease)))) (VP (AUX was) (VP (VBN increased) (ADJP (RB nearly) (JJ 20-fold)) (PP (IN by) (NP (NP (NN consumption)) (PP (IN of) (NP (NP (NNP Doc_3412544_399_409_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBD increased) (NP (DT the) (NN risk)) (PP (PP (IN for) (NP (NNP Doc_3412544_445_483_Disease))) (CC but) (RB not) (PP (IN for) (NP (NNP Doc_3412544_496_511_Disease))))))))))))) (. .)))
3412544	3	(S1 (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (PRP we)) (VP (AUX were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB substantiate) (NP (DT an) (VBN increased) (NN risk)) (PP (IN from) (NP (NP (NP (JJ Doc_3412544_580_591_Chemical) (NN consumption)) (PP (IN for) (NP (NNP Doc_3412544_608_632_Disease)))) (CC or) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNP Doc_3412544_649_656_Disease)))))) (SBAR (IN although) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN suggestion)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NNP Doc_3412544_712_732_Disease)))))))))))))) (. .)))
3425586	0	(S1 (NP (NP (JJ Doc_3425586_0_7_Chemical-associated) (NNP Heinz) (NN body) (NNP Doc_3425586_30_46_Disease)) (PP (IN in) (NP (NP (DT a) (JJ Cambodian) (NN woman)) (PP (IN with) (NP (NN hemoglobin) (NN E) (NN trait))))) (. .)))
3425586	1	(S1 (S (NP (NP (DT A) (JJ Cambodian) (NN woman)) (PP (IN with) (NP (NN hemoglobin) (NN E) (NN trait) (PRN (-LRB- -LRB-) (NP (NNP AE)) (-RRB- -RRB-)) (CC and) (NNP Doc_3425586_144_151_Disease)))) (VP (VBD developed) (NP (DT a) (NNP Heinz) (NN body) (NN Doc_3425586_175_191_Disease)) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3425586_215_222_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/day)) (-RRB- -RRB-)))) (VP (ADVP (RB not) (RB usually)) (VBN associated) (PP (IN with) (NP (JJ clinical) (NN Doc_3425586_272_281_Disease))))))))) (. .)))
3425586	2	(S1 (S (NP (NP (PRP$ Her) (JJ red) (NN blood) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP RBCs)) (-RRB- -RRB-))) (VP (AUX had) (VP (VP (VBN increased) (NP (JJ incubated) (NNP Heinz) (NN body) (NN formation))) (, ,) (VP (VBN decreased) (NP (NP (JJ reduced) (NNP Doc_3425586_374_385_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3425586_387_390_Chemical)) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBN decreased) (NP (JJ Doc_3425586_407_410_Chemical) (NN stability))))) (. .)))
3425586	3	(S1 (S (NP (NP (DT The) (JJ Doc_3425586_426_443_Chemical) (NN shunt) (NN activity)) (PP (IN of) (NP (DT the) (JJ Doc_3425586_466_473_Chemical-exposed) (NN AE) (NNS RBCs)))) (VP (AUX was) (VP (VBN increased) (PP (VBN compared) (PP (TO to) (NP (JJ normal) (NNS RBCs)))))) (. .)))
3425586	4	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ AE) (NNS RBCs)) (PP (IN from) (NP (DT an) (NN individual))) (VP (RB not) (VBG taking) (NP (NNP Doc_3425586_580_587_Chemical)))) (VP (AUX had) (VP (VBN increased) (NP (JJ incubated) (NNP Heinz) (NN body) (NN formation)))))) (, ,) (NP (NP (DT the) (JJ Doc_3425586_638_641_Chemical) (NN content)) (CC and) (NP (JJ Doc_3425586_654_657_Chemical) (NN stability))) (VP (AUX were) (ADJP (JJ normal))) (. .)))
3425586	5	(S1 (S (NP (NP (DT The) (JJ Doc_3425586_685_702_Chemical) (NN shunt) (NN activity)) (PP (IN of) (NP (DT the) (JJ non-Doc_3425586_729_736_Chemical-exposed) (NN AE) (NNS RBCs)))) (VP (AUX was) (VP (VBN decreased) (PP (VBN compared) (PP (TO to) (NP (JJ normal) (NNS RBCs)))))) (. .)))
3425586	6	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NN AE) (NNS RBCs)) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN sensitivity)) (PP (TO to) (NP (JJ oxidant) (NN stress)))) (PP (DT both) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))) (, ,) (SBAR (IN since) (S (NP (NNP Doc_3425586_897_904_Chemical)) (VP (AUX does) (RB not) (VP (VB cause) (NP (NNP Doc_3425586_920_936_Disease)) (PP (IN at) (NP (NP (DT this) (NN dose)) (PP (IN in) (NP (ADJP (RB hematologically) (JJ normal)) (NNS individuals)))))))))) (. .)))
3425586	7	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN influx)) (PP (IN of) (NP (NNP Southeast) (NNPS Asians))) (PP (IN into) (NP (DT the) (NNP United) (NNPS States))))) (, ,) (NP (JJ oxidant) (NNS medications)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (, ,) (SBAR (ADVP (RB especially)) (IN if) (S (NP (DT an) (NN Doc_3425586_1116_1125_Disease)) (VP (AUX is) (ADJP (JJ present))))) (, ,) (PP (IN in) (NP (NP (NNS individuals)) (PP (IN of) (NP (JJ ethnic) (NNS backgrounds))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN prevalence)) (PP (IN of) (NP (NN hemoglobin) (NN E)))))))))))) (. .)))
3437726	0	(S1 (NP (NP (JJ Severe) (NNS complications)) (PP (IN of) (NP (JJ antianginal) (NN drug) (NN therapy))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN identified) (PP (IN as) (NP (NP (DT a) (JJ poor) (NN metabolizer)) (PP (IN of) (NP (NP (NNP Doc_3437726_98_108_Chemical)) (, ,) (NP (NNP Doc_3437726_110_121_Chemical)) (, ,) (NP (NNP Doc_3437726_123_132_Chemical)) (, ,) (CC and) (NP (NNP Doc_3437726_138_147_Chemical))))))))) (. .)))
3437726	1	(S1 (S (NP (NP (DT A) (JJ 47-year-old) (NN patient)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_3437726_186_209_Disease))))) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NP (DT the) (NNS CCU)) (PP (IN in) (NP (NP (NNP Doc_3437726_237_242_Disease)) (PP (IN with) (NP (NNP III))))))))) (. .)))
3437726	2	(S1 (NP (NP (NN Doc_3437726_253_261_Disease)) (, ,) (NP (JJ severe) (NN Doc_3437726_270_281_Disease)) (, ,) (CC and) (NP (NNP Doc_3437726_287_321_Disease)) (. .)))
3437726	3	(S1 (S (NP (NP (ADVP (NP (CD One) (NN week)) (RB prior) (PP (TO to) (NP (NN admission)))) (DT a) (NN therapy)) (PP (IN with) (NP (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NNP Doc_3437726_384_394_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 100) (CD mg)) (NNS t.i.d.)) (CC and) (NP (QP (RB then) (CD 100) (CD mg)) (NNS b.i.d.))) (-RRB- -RRB-))))) (VP (AUX had) (VP (AUX been) (VP (VBN initiated)))) (. .)))
3437726	4	(S1 (S (NP (NP (CD Two) (NNS days)) (PP (IN before) (NP (NP (NN admission) (NN Doc_3437726_480_489_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 60) (CD mg)) (NNS b.i.d.)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN prescribed) (PP (IN in) (NP (NN addition))))) (. .)))
3437726	5	(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (DT a) (NN blood) (NN sample)))) (VP (VBD revealed) (NP (NP (ADJP (RB unusually) (JJ high)) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_3437726_609_619_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (JJR greater) (IN than) (CD 3000)) (NN ng/ml)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3437726_650_659_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 526) (NN ng/ml)) (-RRB- -RRB-))))))) (. .)))
3437726	6	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (PP (IN within) (NP (CD 1) (NN week))) (PP (VBG following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (JJ antianginal) (NN therapy)))))) (. .)))
3437726	7	(S1 (S (ADVP (NP (CD Three) (NNS months)) (RB later)) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN exposed) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3437726_822_832_Chemical)) (, ,) (NP (NNP Doc_3437726_834_843_Chemical)) (, ,) (NP (NP (NNP Doc_3437726_845_856_Chemical)) (PRN (-LRB- -LRB-) (SBAR (IN since) (S (NP (PRP he)) (VP (AUX had) (VP (VBN received) (NP (DT this) (NN drug)) (PP (IN in) (NP (DT the) (NN past))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3437726_908_917_Chemical)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN probe)) (PP (IN for) (NP (NP (DT the) (JJ Doc_3437726_938_950_Chemical/Doc_3437726_951_960_Chemical) (NN type) (NN polymorphism)) (PP (IN of) (NP (JJ oxidative) (NN drug) (NN metabolism))))))) (-RRB- -RRB-))))))))) (. .)))
3437726	8	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (PRP he)) (VP (AUX was) (NP (NP (DT a) (JJ poor) (NN metabolizer)) (PP (IN of) (NP (DT all) (CD four) (NNS drugs)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (PRP$ their) (NN metabolism)) (VP (AUX is) (PP (IN under) (NP (DT the) (JJ same) (JJ genetic) (NN control))))))))))))) (. .)))
3437726	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (VP (VBG belonging) (PP (TO to) (NP (NP (DT the) (JJ poor-metabolizer) (NN phenotype)) (PP (IN of) (NP (JJ Doc_3437726_1208_1217_Chemical/Doc_3437726_1218_1230_Chemical) (NN polymorphism))) (PP (IN in) (NP (NP (NN drug) (NN metabolism)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ constitutes) (NP (NP (CD 6.4) (NN %)) (PP (IN of) (NP (DT the) (JJ German) (NN population))))))) (, ,))))))) (VP (MD may) (VP (VB experience) (NP (NNP Doc_3437726_1328_1350_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (ADVP (RB alone))))))))))))) (. .)))
3437726	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (DT these) (ADJP (RB frequently) (VBN used)) (NNS drugs)))) (VP (AUX is) (VP (VBN expected) (S (VP (TO to) (VP (AUX be) (ADJP (RB especially) (JJ harmful)) (PP (IN in) (NP (NP (DT this) (NN subgroup)) (PP (IN of) (NP (NNS patients)))))))))) (. .)))
347884	0	(S1 (NP (NP (NP (JJ Clinical) (NNS experiences)) (PP (IN in) (NP (NP (DT an) (NN open)) (CC and) (NP (DT a) (JJ double-blind) (NN trial))))) (. .)))
347884	1	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD sixty) (NNS patients)))) (VP (AUX were) (VP (VBN trated) (PP (IN with) (NP (NNP Doc_347884_101_112_Chemical))) (ADVP (RB first)) (PP (IN in) (NP (NP (JJ open) (NNS conditions)) (PRN (-LRB- -LRB-) (NP (CD 20) (NNS patients)) (-RRB- -RRB-)))) (, ,) (ADVP (RB then)) (PP (IN on) (NP (NP (DT a) (JJ double) (JJ blind) (NN basis)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS patients)) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_347884_201_212_Chemical))) (PP (IN as) (NP (DT the) (NN reference) (NN substance))))) (. .)))
347884	2	(S1 (S (S (NP (DT The) (JJ open) (NN study)) (VP (VBD lasted) (PP (IN for) (NP (CD four) (NNS weeks))))) (: ;) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN administrated) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (QP (CD 1) (CD mg)) (NNS tablets)))))))) (. .)))
347884	3	(S1 (S (NP (NP (DT The) (JJ daily) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (JJ initial) (NN dose)) (: :) (NP (CD 1) (NN mg)) (: ;) (NP (NP (JJ mean) (NN dose)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN trial)))))) (: :) (NP (CD 4.47) (NN mg))) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB always)) (VP (VBN administered) (PP (IN in) (NP (CD one) (JJ single) (NN dose))))) (. .)))
347884	4	(S1 (S (S (NP (NN Nineteen) (NNS patients)) (VP (VBD finished) (NP (DT the) (NN trial)))) (, ,) (CC and) (S (PP (IN in) (NP (CD 18) (NNS cases))) (NP (DT the) (JJ therapeutic) (NN result)) (VP (AUX was) (VP (VBN considered) (S (ADJP (RB very) (JJ good) (TO to) (JJ good)))))) (. .)))
347884	5	(S1 (S (NP (DT These) (NNS results)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (JJ statistical) (NN analysis))))) (. .)))
347884	6	(S1 (S (S (NP (CD Nine) (NNS patients)) (VP (VBD exhibited) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (NP (NNP Doc_347884_665_700_Disease)))))))) (: ;) (S (NP (DT no) (JJ other) (NN side) (NNS effects)) (VP (AUX were) (VP (VBN observed)))) (. .)))
347884	7	(S1 (S (NP (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (JJ detailed) (NN laboratory) (NNS tests)))) (CC and) (NP (NP (NNS evaluations)) (PP (IN of) (NP (JJ various) (UCP (JJ quantitative) (CC and) (JJ qualitative)) (NN tolerability) (NNS parameters))))) (VP (AUX were) (RB not) (ADJP (JJ indicative) (PP (IN of) (NP (JJ toxic) (NNS effects))))) (. .)))
347884	8	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ double) (JJ blind) (NN study)) (PP (IN with) (NP (NNP Doc_347884_929_940_Chemical))))) (, ,) (NP (DT both) (NNS substances)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB highly) (JJ effective) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_347884_1012_1082_Disease))))))))))) (. .)))
347884	9	(S1 (S (NP (NP (JJ Certain) (NNS clues)) (, ,) (PP (VBG including) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN action))))) (, ,)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (ADJP (JJ indicative) (PP (IN of) (NP (NP (DT the) (NN superiority)) (PP (IN of) (NP (NNP Doc_347884_1174_1185_Chemical)))))))))) (. .)))
347884	10	(S1 (S (NP (DT No) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (JJ side) (NNS effects)) (CC and) (NP (JJ general) (NN tolerability)))))))) (. .)))
3496378	0	(S1 (NP (NP (VBN Prolonged) (NN Doc_3496378_10_21_Disease)) (PP (IN after) (NP (JJ Doc_3496378_28_42_Chemical-induced) (JJ acute) (NN Doc_3496378_57_66_Disease))) (. .)))
3496378	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_3496378_108_122_Chemical-induced) (NNP Doc_3496378_131_140_Disease)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (JJ prolonged) (JJ anicteric) (NN Doc_3496378_177_188_Disease))))))))))) (. .)))
3496378	2	(S1 (S (NP (NN Doc_3496378_190_198_Disease)) (VP (VP (VBD occurred) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_3496378_232_246_Chemical))) (PP (IN for) (NP (CD 7) (NN days)))))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3496378_282_299_Disease)))))) (. .)))
3496378	3	(S1 (S (NP (NN Doc_3496378_301_309_Disease)) (VP (VP (VBD disappeared) (PP (IN within) (NP (CD 3) (NNS months)))) (CC but) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (VBN prolonged) (JJ anicteric) (NN Doc_3496378_378_389_Disease)) (VP (VBN marked) (PP (IN by) (NP (NP (JJ Doc_3496378_400_408_Disease) (CC and) (JJ high) (NNS levels)) (PP (IN of) (NP (NP (JJ alkaline) (NN phosphatase)) (CC and) (NP (JJ gammaglutamyltransferase) (NNS activities)))))))))))) (. .)))
3496378	4	(S1 (S (ADVP (RB Finally)) (, ,) (S (NP (NNP Doc_3496378_499_507_Disease)) (VP (VBD disappeared) (PP (IN within) (NP (CD 19) (NNS months))))) (, ,) (CC and) (S (NP (NN liver) (NNS tests)) (VP (VBD returned) (PP (TO to) (NP (QP (RB normal) (CD 27)) (NNS months))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3496378_602_611_Disease))))))) (. .)))
3496378	5	(S1 (S (NP (DT This) (NN observation)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (JJ prolonged) (NN Doc_3496378_658_669_Disease)) (VP (MD can) (VP (VB follow) (NP (JJ Doc_3496378_681_695_Chemical-induced) (JJ acute) (NN Doc_3496378_710_719_Disease))))))) (. .)))
3503576	0	(S1 (NP (NP (JJ Serial) (NNS studies)) (PP (IN of) (NP (NNP Doc_3503576_18_40_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_3503576_63_75_Chemical) (NN therapy))))) (. .)))
3503576	1	(S1 (S (NP (NN Doc_3503576_85_118_Disease)) (VP (AUX was) (ADVP (RB previously)) (VP (VBN documented) (PP (IN in) (NP (NP (QP (CD 42) (IN of) (CD 89)) (NNS patients)) (PP (IN with) (NP (JJ transfusion-dependent) (NNP Doc_3503576_193_199_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (JJ Doc_3503576_219_223_Chemical) (NN chelation) (NN therapy)) (PP (IN with) (NP (JJ daily) (JJ subcutaneous) (NNP Doc_3503576_266_278_Chemical))))))))))) (. .)))
3503576	2	(S1 (S (NP (NP (JJ Twenty-two) (NNS patients)) (PP (IN in) (NP (DT the) (VBN affected) (NN group)))) (VP (AUX had) (UCP (ADJP (JJ Doc_3503576_326_415_Disease)) (CC and) (PP (IN in) (NP (NP (DT the) (NN hearing) (NN threshold) (NNS levels)) (PP (IN of) (NP (QP (CD 30) (TO to) (CD 100)) (NNS decibels))))))) (. .)))
3503576	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (S (NP (JJ Doc_3503576_480_492_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (JJ serial) (NNS studies)) (VP (AUX were) (VP (VBN performed)))))) (, ,) (S (NP (NP (NNS audiograms)) (PP (IN in) (NP (CD seven) (NNS cases)))) (VP (VBN reverted) (PP (TO to) (ADJP (ADJP (JJ normal)) (CC or) (ADJP (RB near) (JJ normal)))) (PP (IN within) (NP (QP (CD two) (TO to) (CD three)) (NNS weeks))))) (, ,) (CC and) (S (NP (NP (CD nine)) (PP (IN of) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NNS symptoms)))))) (VP (VBD became) (ADJP (JJ asymptomatic)))) (. .)))
3503576	4	(S1 (S (S (NP (NP (NNS Audiograms)) (PP (IN from) (NP (CD 15) (NNS patients)))) (VP (VBD remained) (ADJP (JJ abnormal)))) (CC and) (S (NP (CD four) (NNS patients)) (VP (VBD required) (NP (NN hearing) (NNS aids)) (PP (IN because) (IN of) (NP (NN Doc_3503576_796_816_Disease))))) (. .)))
3503576	5	(S1 (S (SBAR (IN Since) (S (NP (NP (CD 18)) (PP (IN of) (NP (DT the) (CD 22) (NNS patients)))) (VP (AUX were) (ADVP (RB initially)) (VP (VBG receiving) (NP (JJ Doc_3503576_871_883_Chemical) (NNS doses)) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (NP (DT the) (RB commonly) (VBN recommended) (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN dose))))))))))) (, ,) (S (NP (NN therapy)) (VP (AUX was) (VP (VBN restarted) (PP (IN with) (NP (NP (JJR lower) (NNS doses)) (, ,) (NP (NP (QP (RB usually) (CD 50)) (NNS mg/kg)) (PP (IN per) (NP (NN dose)))) (CC or) (NP (JJR less)))) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_3503576_1048_1068_Disease))))))))) (, ,) (CC and) (S (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (CD two) (NNS cases))))) (NP (DT no) (JJ further) (NN Doc_3503576_1117_1125_Disease)) (VP (AUX was) (VP (VBN demonstrated)))) (. .)))
3503576	6	(S1 (S (NP (NP (NP (JJ Auditory) (NN deterioration)) (CC and) (NP (NN improvement))) (, ,) (VP (VBN demonstrated) (ADVP (RB serially)) (PP (IN in) (NP (NP (JJ individual) (NNS patients)) (VP (VP (VBG receiving)) (CC and) (RB not) (VP (VBG receiving) (NP (NP (NNP Doc_3503576_1257_1269_Chemical)) (, ,) (ADVP (RB respectively)))))))) (, ,)) (VP (VBD provided) (NP (JJ convincing) (NN evidence)) (PP (IN for) (NP (NP (DT a) (JJ cause-and-effect) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_3503576_1354_1366_Chemical) (NN administration)) (CC and) (NP (NNP Doc_3503576_1386_1397_Disease))))))) (. .)))
3503576	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (NP (DT a) (NN plan)) (PP (IN of) (NP (NN management)))) (VP (AUX was) (VP (VBN developed) (SBAR (WHNP (WDT that)) (S (VP (VBZ allows) (NP (NP (ADJP (JJ effective) (CC yet) (JJ safe)) (NN administration)) (PP (IN of) (NP (NNP Doc_3503576_1504_1516_Chemical))))))))) (. .)))
3503576	8	(S1 (S (NP (NP (DT A) (NN dose)) (PP (IN of) (NP (CD 50) (NN mg/kg)))) (VP (AUX is) (VP (VBN recommended) (PP (IN in) (NP (NP (DT those)) (PP (IN without) (NP (NN audiogram) (NNS abnormalities))))))) (. .)))
3503576	9	(S1 (S (PP (IN With) (NP (JJ mild) (NN Doc_3503576_1604_1612_Disease))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (TO to) (NP (QP (CD 30) (CC or) (CD 40)) (NNS mg/kg))) (PP (IN per) (NP (NN dose)))) (VP (MD should) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN reversal)) (PP (IN of) (NP (DT the) (JJ abnormal) (NNS results))) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (CD four) (NNS weeks))))))) (. .)))
3503576	10	(S1 (S (NP (JJ Moderate) (NNS abnormalities)) (VP (VBP require) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NNP Doc_3503576_1780_1792_Chemical)))) (PP (TO to) (NP (NP (CD 25) (NNS mg/kg)) (PP (IN per) (NP (NN dose))) (PP (IN with) (NP (JJ careful) (NN monitoring)))))) (. .)))
3503576	11	(S1 (S (PP (IN In) (NP (NP (DT those)) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_3503576_1865_1877_Disease))))))) (, ,) (S (NP (DT the) (NN drug)) (VP (MD should) (VP (AUX be) (VP (VBN stopped) (PP (IN for) (NP (CD four) (NNS weeks))))))) (, ,) (CC and) (S (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN audiogram)) (VP (AUX is) (ADJP (ADJP (JJ stable)) (CC or) (ADJP (JJ improved)))))) (, ,) (NP (NN therapy)) (VP (MD should) (VP (AUX be) (VP (VBN restarted) (PP (IN at) (NP (NP (QP (CD 10) (TO to) (CD 25)) (NNS mg/kg)) (PP (IN per) (NP (NN dose))))))))) (. .)))
3503576	12	(S1 (S (NP (JJ Serial) (NNS audiograms)) (VP (MD should) (VP (AUX be) (VP (VP (VBN performed) (NP (DT every) (CD six) (NNS months)) (PP (IN in) (NP (NP (DT those)) (PP (IN without) (NP (NNS problems)))))) (CC and) (VP (ADVP (RBR more) (RB frequently)) (PP (PP (IN in) (NP (NP (JJ young) (NNS patients)) (PP (IN with) (NP (JJ normal) (NN serum) (NN ferritin) (NNS values))))) (CC and) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_3503576_2195_2215_Disease)))))))))) (. .)))
354896	0	(S1 (NP (JJ Doc_354896_0_9_Chemical-induced) (NN Doc_354896_18_34_Disease) (. .)))
354896	1	(S1 (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 50-mg) (NN bolus)) (PP (IN of) (NP (NNP Doc_354896_90_99_Chemical))) (PP (IN in) (NP (DT a) (JJ 67-year-old) (NN man)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ profound) (NN Doc_354896_142_152_Disease)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ sinoatrial) (CC and) (JJ atrioventricular) (JJ nodal) (NNS pacemakers)))))))) (. .)))
354896	2	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT no) (JJ apparent) (VBN associated) (NNS conditions)) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (AUX have) (VP (VBN predisposed) (NP (PRP him)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_354896_331_347_Disease))))))))))))) (: ;) (S (CC and) (, ,) (ADVP (RB thus)) (, ,) (NP (DT this)) (ADVP (RB probably)) (VP (VBD represented) (NP (NP (DT a) (JJ true) (NN idiosyncrasy)) (PP (TO to) (NP (NNP Doc_354896_409_418_Chemical)))))) (. .)))
3560095	0	(S1 (NP (NP (NN Doc_3560095_0_12_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3560095_33_62_Disease))))) (. .)))
3560095	1	(S1 (S (NP (NP (CD Thirty-four) (NNS patients)) (PP (IN with) (NP (NNP Doc_3560095_90_119_Disease))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3560095_143_155_Chemical))) (PP (IN at) (NP (NP (DT a) (JJ maximum) (NN dose)) (PP (IN of) (NP (CD 4) (NN mg/kg/day))))))))) (, ,)) (VP (AUX had) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS decreases)) (PP (IN from) (NP (NN baseline)))) (PP (IN in) (NP (CD 6) (JJ Doc_3560095_249_258_Disease) (NNS indices))) (PP (IN after) (NP (NP (CD 12) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (. .)))
3560095	2	(S1 (S (NP (NNS Improvements)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNP Doc_3560095_336_349_Disease)) (, ,) (NP (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_3560095_367_375_Disease) (CC and) (NNP Doc_3560095_380_390_Disease)))) (, ,) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN walk) (CD 50) (NNS feet)))) (, ,) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_3560095_434_451_Disease)))) (CC and) (NP (NP (DT the) (NN circumference)) (PP (IN of) (NP (DT the) (JJ left) (NN knee))))))))))) (. .)))
3560095	3	(S1 (S (S (NP (DT The) (ADJP (ADVP (RBS most) (RB frequently)) (JJ observed)) (NN side) (NN effect)) (VP (AUX was) (NP (NP (NNP Doc_3560095_537_555_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (NNS patients)))) (-RRB- -RRB-))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ other) (NN evidence)) (PP (IN of) (NP (NNP Doc_3560095_615_645_Disease)))) (PP (IN in) (NP (DT these) (NNS patients))))) (. .)))
3560095	4	(S1 (S (NP (CD One) (NN patient)) (VP (AUX was) (ADVP (RB prematurely)) (VP (VBN discontinued) (PP (IN from) (NP (DT the) (NN study))) (PP (IN for) (NP (JJ severe) (NNP Doc_3560095_732_740_Disease) (CC and) (NNP Doc_3560095_745_759_Disease))))) (. .)))
3560095	5	(S1 (S (NP (JJS Most) (NN side) (NNS effects)) (VP (VP (AUX were) (ADJP (JJ mild))) (CC and) (VP (VBD related) (PP (TO to) (NP (DT the) (JJ GI) (NN tract))))) (. .)))
3560096	0	(S1 (S (NP (NN Doc_3560096_0_12_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3560096_29_37_Chemical) (NN therapy)))) (. .)))
3560096	1	(S1 (S (NP (NN Doc_3560096_47_59_Disease)) (VP (AUX has) (ADVP (RB recently)) (VP (AUX been) (VP (VBN recognized) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NP (NP (JJ nonsteroidal) (NN antiinflammatory) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP NSAID)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NNP Doc_3560096_163_175_Chemical)))))))))) (. .)))
3560096	2	(S1 (S (NP (JJ Several) (JJ recent) (NNS studies)) (VP (AUX have) (VP (VBN stressed) (NP (NP (DT the) (JJ renal) (NN sparing) (NNS features)) (PP (IN of) (NP (NNP Doc_3560096_244_252_Chemical)))) (, ,) (PP (VBG owing) (PP (TO to) (NP (NP (PRP$ its) (NN lack)) (PP (IN of) (NP (NN interference))) (PP (IN with) (NP (JJ renal) (JJ Doc_3560096_299_311_Chemical) (NN synthesis)))))))) (. .)))
3560096	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 4) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NNP Doc_3560096_354_366_Disease)) (VP (VBG ranging) (PP (IN from) (NP (CD 6.1))) (PP (TO to) (NP (QP (CD 6.9) (CD mEq/l)))))) (VP (VBD developed) (PP (IN within) (NP (NP (QP (CD 3) (TO to) (CD 8)) (NNS days)) (PP (IN of) (NP (NNP Doc_3560096_429_437_Chemical) (NN administration)))))))))) (. .)))
3560096	4	(S1 (S (PP (IN In) (NP (NP (DT all)) (PP (IN of) (NP (PRP them))))) (NP (JJ normal) (NN serum) (NN Doc_3560096_482_491_Chemical) (NNS levels)) (VP (VBD reached) (PP (IN within) (NP (NP (QP (CD 2) (TO to) (CD 4)) (NNS days)) (PP (IN of) (NP (NN stopping) (NN Doc_3560096_538_546_Chemical)))))) (. .)))
3560096	5	(S1 (S (PP (IN As) (NP (NP (DT no) (JJ other) (NNS medications)) (VP (VBN known) (S (VP (TO to) (VP (VB effect) (SBAR (S (NP (NN serum) (NNP Doc_3560096_594_603_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN given) (ADVP (RB concomitantly))))))))))))) (, ,) (NP (NP (DT this) (NN course)) (PP (IN of) (NP (NNS events)))) (VP (AUX is) (ADJP (JJ suggestive) (PP (IN of) (NP (NP (DT a) (JJ cause-and-effect) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_3560096_713_721_Chemical)) (CC and) (NP (NNP Doc_3560096_726_738_Disease)))))))) (. .)))
3560096	6	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ initial) (NNS hopes)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_3560096_792_800_Chemical)) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ adverse) (JJ renal) (NNS effects)) (PP (IN of) (NP (JJ other) (NNS NSAID))))))))))) (VP (AUX are) (ADVP (RB probably)) (RB not) (ADJP (JJ justified)))))) (. .)))
3564823	0	(S1 (S (NP (JJ Drug-induced) (NN arterial) (NN Doc_3564823_22_27_Disease)) (VP (VBN relieved) (PP (IN by) (NP (NNP Doc_3564823_40_49_Chemical)))) (. .)))
3564823	1	(S1 (S (NP (NN Case)) (VP (VBP report)) (. .)))
3564823	2	(S1 (S (PP (VBG Following) (NP (NP (JJ major) (NN intracranial) (NN surgery)) (PP (IN in) (NP (DT a) (JJ 35-year-old) (NN man))))) (, ,) (NP (NNP Doc_3564823_123_139_Chemical)) (VP (AUX was) (ADVP (RB intravenously)) (VP (VBN infused) (S (VP (TO to) (VP (VB minimize) (NP (NNP Doc_3564823_178_196_Disease))))))) (. .)))
3564823	3	(S1 (S (NP (NP (JJ Intense) (NN Doc_3564823_206_215_Disease)) (PP (IN with) (NP (VBN threatened) (NNP Doc_3564823_232_240_Disease)))) (VP (VBD arose) (PP (IN in) (NP (NP (DT the) (NN arm)) (VP (VBN used) (PP (IN for) (NP (DT the) (NN infusion))))))) (. .)))
3564823	4	(S1 (S (PP (IN Since) (NP (NP (DT the) (JJ cranial) (NN condition)) (VP (VBN precluded) (NP (NP (NN use)) (PP (IN of) (NP (ADJP (RBR more) (JJ usual)) (NNS methods))))))) (, ,) (NP (NNP Doc_3564823_346_355_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB intra-arterially)) (, ,) (PP (IN with) (NP (NP (JJ careful) (JJ cardiovascular) (NN monitoring)) (, ,) (SBAR (S (VP (TO to) (VP (VB counteract) (NP (DT the) (NNP Doc_3564823_442_451_Disease)))))))))) (. .)))
3564823	5	(S1 (S (NP (DT The) (NN treatment)) (VP (AUX was) (ADVP (RB rapidly)) (ADJP (JJ successful))) (. .)))
3615541	0	(S1 (NP (NP (JJ Regional) (NN localization)) (PP (IN of) (NP (NP (DT the) (NN antagonism)) (PP (IN of) (NP (NNP Doc_3615541_43_54_Chemical-induced) (NNP Doc_3615541_63_76_Disease))))) (PP (IN by) (NP (JJ intracerebral) (JJ Doc_3615541_94_104_Chemical) (NNS injections))) (. .)))
3615541	1	(S1 (S (S (NP (NN Doc_3615541_117_127_Chemical) (NNS receptors)) (VP (AUX are) (VP (VBN found) (PP (IN in) (NP (DT the) (NN brain)))))) (, ,) (CC and) (S (NP (NP (JJ intracerebral) (NNS infusions)) (PP (IN of) (NP (NNP Doc_3615541_193_203_Chemical)))) (VP (MD can) (VP (VB produce) (NP (JJ behavioral) (NNS effects))))) (. .)))
3615541	2	(S1 (FRAG (SBAR (IN Among) (S (NP (DT these) (JJ behavioral) (NNS effects)) (VP (AUX are) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN food) (NN intake)))) (CC and) (NP (NP (NNS decreases)) (PP (IN in) (NP (JJ Doc_3615541_313_324_Chemical-induced) (NN locomotor) (NN activity)))))))) (. .)))
3615541	3	(S1 (S (PP (IN In) (NP (JJ previous) (NNS experiments))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NNS decreases)) (PP (IN in) (NP (NN food) (NN intake)))) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ local) (NN administration)) (PP (IN of) (NP (NNP Doc_3615541_456_466_Chemical))))) (PP (PP (IN into) (NP (JJ several) (JJ hypothalamic) (NNS sites))) (CC and) (PP (IN into) (NP (DT the) (NN nucleus) (NNS accumbens))))))))) (. .)))
3615541	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN experiment))) (NP (NNP Doc_3615541_557_567_Chemical)) (VP (VBD decreased) (NP (NN locomotor) (NN activity)) (SBAR (WHADVP (WRB when)) (S (ADVP (RB locally)) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (JJ same) (NNS sites)) (SBAR (WHADVP (WRB where)) (S (NP (PRP it)) (VP (VBZ decreases) (NP (NN food) (NN intake))))))))))) (. .)))
3615541	5	(S1 (S (NP (NP (DT The) (NNS areas)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_3615541_687_697_Chemical)) (VP (AUX is) (ADJP (RBS most) (JJ effective) (PP (IN in) (S (VP (VBG decreasing) (NP (NN locomotor) (NN activity)))))))))) (VP (AUX are) (VP (VBN located) (PP (IN in) (NP (DT the) (NN hypothalamus) (CC and) (NN nucleus) (NNS accumbens))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT these) (NNS areas)) (VP (AUX are) (NP (NP (DT the) (JJ major) (NNS sites)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_3615541_865_875_Chemical)))))) (PP (IN in) (S (VP (VBG inhibiting) (NP (JJ Doc_3615541_890_901_Chemical-induced) (JJ locomotor) (NN activity)))))))))))) (. .)))
3629586	0	(S1 (NP (NP (NP (DT The) (JJ hematologic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_3629586_27_36_Chemical)) (CC and) (NP (NNP Doc_3629586_41_51_Chemical)))) (PP (IN in) (NP (DT the) (NN dog)))) (: :) (NP (NP (DT a) (JJ potential) (NN model)) (PP (IN of) (NP (NNP Doc_3629586_85_98_Chemical) (NNP Doc_3629586_99_113_Disease))) (PP (IN in) (NP (NN man)))) (. .)))
3629586	1	(S1 (S (S (NP (NN Doc_3629586_122_135_Chemical) (NNS antibiotics)) (VP (VBP cause) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNP Doc_3629586_167_191_Disease)))) (PP (IN in) (NP (NN man))))) (, ,) (NP (NP (DT the) (NNS pathogeneses) (CC and) (NNS hematopathology)) (PP (IN of) (NP (WDT which)))) (VP (VBP remain) (ADJP (RB poorly) (VBN characterized))) (. .)))
3629586	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (NP (DT a) (JJ well-defined) (NN animal) (NN model)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT these) (NNP Doc_3629586_338_354_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN studied)))))))))) (. .)))
3629586	3	(S1 (S (PP (IN In) (NP (CD four) (JJ subacute) (NNP Doc_3629586_388_396_Disease) (NNS studies))) (, ,) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3629586_440_449_Chemical)) (CC or) (NP (NNP Doc_3629586_453_463_Chemical)))) (PP (TO to) (NP (JJ beagle) (NNS dogs)))) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_3629586_516_522_Disease)) (, ,) (NP (NNP Doc_3629586_524_535_Disease)) (, ,) (CC and) (NP (NNP Doc_3629586_541_557_Disease)))) (PP (IN after) (NP (NP (JJ 1-3) (NNS months)) (PP (IN of) (NP (NN treatment))))))) (. .)))
3629586	4	(S1 (S (NP (DT A) (JJ nonregenerative) (NN Doc_3629586_607_613_Disease)) (VP (VP (AUX was) (NP (NP (DT the) (ADJP (JJS most) (VBG compromising))) (PP (IN of) (NP (DT the) (NNP Doc_3629586_647_657_Disease))))) (CC and) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NP (NNS dogs)) (VP (VBG receiving) (NP (NP (CD 400-500) (NNS mg/kg)) (ADJP (JJ Doc_3629586_724_733_Chemical) (CC or) (JJ 540-840))) (PP (IN mg/kg) (NP (NNP Doc_3629586_751_761_Chemical)))))))))) (. .)))
3629586	5	(S1 (S (S (NP (DT All) (CD three) (NN Doc_3629586_773_783_Disease)) (VP (AUX were) (NP (NP (ADJP (RB completely) (JJ reversible)) (JJ following) (NN cessation)) (PP (IN of) (NP (NN treatment)))))) (: ;) (S (NP (NP (DT the) (NN time)) (VP (VBN required) (PP (IN for) (NP (NP (NN recovery)) (PP (IN of) (NP (DT the) (NN erythron)))))) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 1)) (NN month)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (RB considerably) (JJR longer)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (NNS granulocytes) (CC and) (NNS platelets)) (PRN (-LRB- -LRB-) (NP (NP (NNS hours)) (PP (TO to) (NP (DT a) (JJ few) (NNS days)))) (-RRB- -RRB-))))))))) (. .)))
3629586	6	(S1 (S (S (PP (IN Upon) (NP (NP (NN rechallenge)) (PP (IN with) (NP (DT either) (NNP Doc_3629586_1036_1049_Chemical))))) (, ,) (NP (DT the) (NNP Doc_3629586_1055_1075_Disease)) (VP (AUX was) (VP (VBN reproduced) (PP (IN in) (NP (NP (JJS most) (NNS dogs)) (VP (VBN tested))))))) (: ;) (S (NP (NNP Doc_3629586_1112_1121_Chemical) (PRN (-LRB- -LRB-) (CC but) (ADJP (RB not) (JJ Doc_3629586_1131_1141_Chemical)) (-RRB- -RRB-)) (JJ -treated) (NNS dogs)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB substantially) (VBN reduced)) (NN induction) (NN period)) (PRN (-LRB- -LRB-) (NP (CD 15) (JJ +/-) (CD 5) (NNS days)) (-RRB- -RRB-))) (PP (VBN compared) (PP (TO to) (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ first) (NN exposure)) (PP (TO to) (NP (NP (DT the) (NN drug)) (PRN (-LRB- -LRB-) (NP (CD 61) (JJ +/-) (CD 24) (NNS days)) (-RRB- -RRB-)))))))))) (. .)))
3629586	7	(S1 (S (NP (DT This) (NN observation)) (, ,) (PP (IN along) (PP (IN with) (NP (NP (DT the) (JJ rapid) (NN rate)) (PP (IN of) (NP (NN decline))) (PP (IN in) (NP (NP (JJ red) (NN cell) (NN mass) (NNS parameters)) (PP (IN of) (NP (JJ affected) (NNS dogs)))))))) (, ,) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (DT a) (NNP Doc_3629586_1406_1415_Disease) (NN component)) (VP (VBD complicated) (NP (DT the) (JJ red) (NN cell) (NN production) (NN problem))))) (CC and) (SBAR (IN that) (S (NP (JJ multiple) (JJ toxicologic) (NNS mechanisms)) (VP (VBD contributed) (PP (TO to) (NP (DT the) (NNP Doc_3629586_1530_1539_Disease)))))))) (. .)))
3629586	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_3629586_1594_1603_Chemical) (CC or) (NNP Doc_3629586_1607_1617_Chemical))) (PP (TO to) (NP (NNS dogs)))))) (VP (MD can) (VP (VB induce) (NP (NP (NN Doc_3629586_1637_1651_Disease)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (JJ Doc_3629586_1667_1680_Chemical-induced) (NNP Doc_3629586_1689_1705_Disease)) (VP (VP (VBN described) (PP (IN in) (NP (NN man)))) (CC and) (ADVP (RB thus)) (VP (VBZ provides) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (S (VP (VBG studying) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (DT these) (NNS disorders))))))))))))))))))) (. .)))
3676049	0	(S1 (NP (NP (NP (JJ Cerebral) (NN blood) (NN flow)) (CC and) (NP (NN metabolism))) (PP (IN during) (NP (NP (NNP Doc_3676049_42_52_Chemical-induced) (NNP Doc_3676049_61_72_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN subjected) (PP (TO to) (NP (NP (NN surgery)) (PP (IN for) (NP (NNP Doc_3676049_110_128_Disease)))))))))) (. .)))
3676049	1	(S1 (S (NP (NP (JJ Cerebral) (NN blood) (NN flow)) (CC and) (NP (NP (JJ cerebral) (JJ metabolic) (NN rate)) (PP (IN for) (NP (NNP Doc_3676049_182_188_Chemical))))) (VP (AUX were) (VP (VBN measured) (PP (IN during) (NP (NP (JJ Doc_3676049_210_220_Chemical-induced) (NN Doc_3676049_229_240_Disease)) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (VP (VBN subjected) (PP (TO to) (NP (NP (NN craniotomy)) (PP (IN for) (NP (NP (NN clipping)) (PP (IN of) (NP (DT a) (NNP Doc_3676049_298_315_Disease)))))))))))))) (. .)))
3676049	2	(S1 (S (NP (NN Flow) (CC and) (NN metabolism)) (VP (AUX were) (VP (VBN measured) (NP (CD 5-13) (NNS days)) (PP (IN after) (NP (DT the) (NNP Doc_3676049_371_395_Disease))) (PP (IN by) (NP (NP (DT a) (NN modification)) (PP (IN of) (NP (DT the) (JJ classical) (NNP Kety-Schmidt) (NN technique))))) (S (VP (VBG using) (NP (NP (JJ Doc_3676049_460_465_Chemical-133) (NNS i.v.)) (SBAR (S (NP (NNP Anaesthesia)) (VP (AUX was) (VP (VBN maintained) (PP (IN with) (NP (NP (DT an) (VBN inspired) (JJ Doc_3676049_519_529_Chemical) (NN concentration)) (PP (IN of) (NP (NP (NP (CD 0.75) (NN %)) (PRN (-LRB- -LRB-) (CC plus) (NP (NP (NP (CD 67) (NN %)) (NP (NNP Doc_3676049_563_576_Chemical))) (PP (IN in) (NP (NNP Doc_3676049_580_586_Chemical)))) (-RRB- -RRB-)) (, ,) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NNS CBF) (CC and) (NNS CMRO2)) (VP (AUX were) (NP (NP (CD 34.3) (NN +/-) (QP (CD 2.1) (CD ml/100))) (ADJP (NNP g) (JJ min-1))))))) (CC and) (NP (NP (CD 2.32) (NN +/-)) (NP (NP (CD 0.16) (CD ml/100) (NNP g) (NN min-1)) (PP (IN at) (NP (NP (NNP PaCO2) (CD 4.1) (NN +/-) (CD 0.1) (NN kPa)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NN SEM)) (-RRB- -RRB-))))))))))))))))))) (. .)))
3676049	3	(S1 (S (NP (NP (JJ Controlled) (NN Doc_3676049_734_745_Disease)) (PP (TO to) (NP (NP (DT an) (JJ average) (NN MAP)) (PP (IN of) (NP (CD 50-55) (NN mm) (NNP Doc_3676049_776_778_Chemical)))))) (VP (VP (AUX was) (VP (VBN induced) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_3676049_817_827_Chemical))))))))) (, ,) (CC and) (VP (VBD maintained) (PP (IN at) (NP (NP (DT an) (VBN inspired) (NN concentration)) (PP (IN of) (NP (CD 2.2) (NNS +/-))))) (NP (CD 0.2) (NN %)))) (. .)))
3676049	4	(S1 (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NNS CMRO2)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 1.73) (NN +/-))) (NP (QP (CD 0.16) (CD ml/100)) (NNP g) (NNS min-1)) (-RRB- -RRB-)))))) (, ,) (SBAR (IN while) (S (NP (NNP CBF)) (VP (AUX was) (ADJP (JJ unchanged)))))) (. .)))
3676049	5	(S1 (S (PP (IN After) (NP (NP (DT the) (NN clipping)) (PP (IN of) (NP (DT the) (NNP Doc_3676049_1025_1033_Disease))))) (NP (DT the) (JJ Doc_3676049_1038_1048_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (CD 0.75) (NN %))))) (. .)))
3676049	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN CBF)))) (, ,) (SBAR (IN although) (S (NP (NN CMRO2)) (VP (AUX was) (ADJP (JJ unchanged)) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ pre-Doc_3676049_1174_1185_Disease) (NNS values)))))))) (. .)))
3676049	7	(S1 (S (NP (DT These) (NNS changes)) (VP (MD might) (VP (VB offer) (NP (NN protection)) (PP (TO to) (NP (NN brain) (NN tissue))) (PP (IN during) (NP (NP (NNS periods)) (PP (IN of) (NP (VBN induced) (NNP Doc_3676049_1273_1284_Disease))))))) (. .)))
3693336	0	(S1 (NP (NP (JJ Doc_3693336_0_9_Chemical-induced) (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ secondary) (NN Doc_3693336_46_51_Disease))) (PP (IN in) (NP (DT a) (JJ Doc_3693336_57_66_Disease) (NN patient))) (. .)))
3693336	1	(S1 (S (NP (NP (JJ Large) (NNS doses)) (PP (IN of) (NP (NNP Doc_3693336_91_100_Chemical)))) (ADVP (RB repeatedly)) (VP (VBN induced) (NP (NP (JJ brief) (NNS episodes)) (PP (IN of) (NP (NNP Doc_3693336_138_143_Disease)))) (PP (IN in) (NP (DT a) (JJ Doc_3693336_149_158_Disease) (JJ elderly) (NN woman)))) (. .)))
3693336	2	(S1 (S (NP (NP (NNS Features)) (PP (IN of) (NP (NP (NNP Doc_3693336_186_209_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3693336_211_219_Disease)) (-RRB- -RRB-))))) (VP (AUX were) (RB not) (ADJP (JJ present))) (. .)))
3693336	3	(S1 (S (NP (JJ Doc_3693336_239_244_Disease) (NN excitement)) (VP (AUX was) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_3693336_302_311_Chemical))))))))) (. .)))
3693336	4	(S1 (S (NP (NP (DT The) (JJ possible) (NN contribution)) (PP (IN of) (NP (DT the) (JJ Doc_3693336_346_354_Chemical) (NN group))) (PP (TO to) (NP (NNS changes))) (PP (IN in) (NP (JJ affective) (NN status)))) (VP (AUX is) (VP (VBN discussed))) (. .)))
3714122	0	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NNP Doc_3714122_24_34_Disease)))) (VP (VBP esterase) (NP (NP (NP (NN inhibition)) (CC and) (NP (JJ Doc_3714122_59_66_Chemical-induced) (NN Doc_3714122_75_93_Disease))) (PP (IN in) (NP (NNS rats))))) (. .)))
3714122	1	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_3714122_127_145_Disease)) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_3714122_164_174_Disease) (NN esterase)) (CC or) (NP (NP (JJ Doc_3714122_187_197_Disease) (NN target) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP NTE)) (-RRB- -RRB-))))))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NP (NNS rats)) (VP (ADVP (RB acutely)) (VBN exposed) (PP (TO to) (NP (NP (NP (NNP Doc_3714122_258_265_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3714122_267_310_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (NNP Doc_3714122_315_325_Disease) (NNP Doc_3714122_326_341_Chemical))))))))) (. .)))
3714122	2	(S1 (S (NP (NN Brain) (CC and) (NN spinal) (NN cord) (NN NTE) (NNS activities)) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (JJ Long-Evans) (JJ male) (NNS rats)) (ADJP (CD 1) (NN hr) (JJ post-exposure) (PP (TO to) (NP (NP (JJ various) (NNS dosages)) (PP (IN of) (NP (NP (NNP Doc_3714122_459_466_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN ip)) (, ,) (NP (CD 1-15) (NNS mg/kg))) (-RRB- -RRB-))))))))))) (. .)))
3714122	3	(S1 (S (NP (DT These) (NNS data)) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (ADJP (RB histologically) (VBN scored)) (JJ cervical) (NN Doc_3714122_548_559_Disease))) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NP (ADJP (RB similarly) (VBN dosed)) (NNS rats)) (VP (VBN sampled) (ADVP (NP (CD 14-21) (NNS days)) (RB post-exposure))))))))) (. .)))
3714122	4	(S1 (S (NP (NP (DT Those) (NNS dosages)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (QP (CD 10) (CD mg/kg))))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD inhibited))))) (VP (VBP mean) (SBAR (S (NP (NP (JJ NTE) (NN activity)) (PP (IN in) (NP (NP (DT the) (JJ spinal) (NN cord)) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (ADJP (JJ equal) (PP (TO to) (NP (CD 73) (NN %)))) (CC and) (ADJP (NP (NN brain)) (JJR greater))))))) (ADVP (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (CD 67) (NN %)) (PP (IN of) (NP (NN control) (NNS values)))))) (VP (VBD produced) (NP (JJ severe) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 3)))) (-RRB- -RRB-)) (JJ cervical) (NN cord) (NN pathology)) (PP (IN in) (NP (NP (CD 85) (NN %)) (PP (IN of) (NP (DT the) (NNS rats))))))))) (. .)))
3714122	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS dosages)) (PP (IN of) (NP (NNP Doc_3714122_939_946_Chemical))) (PRN (-LRB- -LRB-) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 5) (NN mg/kg)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBD inhibited) (NP (NP (JJ mean) (JJ NTE) (NN activity)) (PP (IN in) (NP (JJ spinal) (NN cord)))))))) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (CD 61) (NN %)) (CC and) (NP (NN brain))))) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 60) (NN %)))) (VP (VBD produced) (NP (NP (DT this) (NN degree)) (PP (IN of) (NP (NNP Doc_3714122_1114_1125_Disease)))) (PP (IN in) (NP (NP (QP (RB only) (CD 9)) (NN %)) (PP (IN of) (NP (DT the) (NNS animals)))))) (. .)))
3714122	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT a) (JJ critical) (NN percentage)) (PP (IN of) (NP (NP (JJ NTE) (NN inhibition)) (PP (IN in) (NP (NP (NN brain) (CC and) (NN spinal) (NN cord)) (VP (VBN sampled) (PP (ADVP (RB shortly)) (IN after) (NP (NNP Doc_3714122_1265_1272_Chemical) (NN exposure))))))))) (VP (MD can) (VP (VB predict) (NP (NNP Doc_3714122_1294_1312_Disease)) (PP (IN in) (NP (NNS rats))) (ADVP (NP (JJ several) (NNS weeks)) (RB later))))))) (. .)))
3719553	0	(S1 (NP (NP (NN Doc_3719553_0_17_Disease)) (PP (TO to) (NP (JJ Doc_3719553_21_35_Chemical) (NN infusion))) (. .)))
3719553	1	(S1 (S (NP (NP (DT An) (NN Doc_3719553_49_66_Disease)) (VP (VBG consisting) (PP (IN of) (NP (NNP Doc_3719553_81_100_Disease) (ADJP (JJ secondary) (TO to) (JJ continuous)) (NN infusion) (NN Doc_3719553_134_148_Chemical))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ recurrent) (NNP Doc_3719553_186_214_Disease)) (, ,) (NP (NNP Doc_3719553_216_225_Disease)) (, ,) (CC and) (NP (NNP Doc_3719553_231_240_Chemical-induced) (NNP Doc_3719553_249_272_Disease))))))) (. .)))
3719553	2	(S1 (S (NP (DT This) (NN reaction)) (VP (VBD occurred) (PP (IN during) (NP (NP (DT the) (JJ sixth) (CC and) (JJ seventh) (NNS courses)) (PP (IN of) (NP (JJ infusional) (NNS chemotherapy)))))) (. .)))
3719553	3	(S1 (S (NP (NP (JJ Oral) (NNP Doc_3719553_367_382_Chemical)) (CC and) (NP (NNP Doc_3719553_387_397_Chemical))) (VP (AUX were) (ADJP (JJ ineffective)) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (DT the) (NNP Doc_3719553_451_468_Disease)))))))) (. .)))
3719553	4	(S1 (S (NP (NP (NN Discontinuance)) (PP (IN of) (NP (JJ effective) (NN chemotherapy))) (PP (IN in) (NP (DT this) (NN patient))) (PP (IN during) (NP (JJ partial) (NN remission)))) (VP (VBD resulted) (PP (IN in) (NP (JJ fatal) (NN disease) (NN progression)))) (. .)))
3750012	0	(S1 (S (NP (NN Doc_3750012_0_17_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_3750012_28_41_Chemical)) (CC and) (NP (NP (JJ Doc_3750012_46_57_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_3750012_70_90_Disease))))))) (. .)))
3750012	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN described) (NP (NP (DT a) (JJ unique) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (ADJP (JJ reversible) (CC and) (JJ dose-related)) (NN Doc_3750012_163_180_Disease)) (PP (IN after) (NP (NP (NNP Doc_3750012_187_200_Chemical) (CC and) (NNP Doc_3750012_205_216_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_3750012_229_249_Disease))))))))))) (. .)))
3750012	2	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_3750012_260_273_Chemical) (NN receptor) (NNS antibodies)) (VP (AUX were) (RB not) (ADJP (JJ detectable))))) (, ,) (NP (DT the) (NN time) (NN course)) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (DT an) (JJ autoimmune) (NN process))))) (. .)))
3780846	0	(S1 (FRAG (PP (IN On) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN tolerance))) (PP (TO to) (NP (NP (DT the) (NNP Doc_3780846_57_74_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3780846_87_95_Chemical))) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
3780846	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NN tolerance))) (PP (TO to) (NP (NP (DT the) (NNP Doc_3780846_141_158_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3780846_171_179_Chemical))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))))) (. .)))
3780846	2	(S1 (S (NP (NP (JJ Saline-pretreated) (NNS controls)) (PP (VBN given) (NP (NP (DT a) (NN test) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3780846_249_257_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))))))) (VP (VBD showed) (NP (NP (DT a) (JJ pronounced) (NN Doc_3780846_294_302_Disease)) (VP (VBN recorded) (PP (IN as) (NP (NP (NN tonic) (NN activity)) (PP (IN in) (NP (DT the) (NN electromyogram)))))))) (. .)))
3780846	3	(S1 (S (S (NP (NP (NNS Rats)) (VP (VP (VBN treated) (PP (IN for) (NP (NP (CD 11) (NNS days)) (PP (IN with) (NP (NNP Doc_3780846_383_391_Chemical)))))) (CC and) (VP (VBN withdrawn) (PP (IN for) (NP (JJ 36-40) (NNP h)))))) (VP (VBD showed) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN tolerance)))))))) (: :) (S (NP (NP (RB about) (NN half)) (PP (IN of) (NP (DT the) (NNS animals)))) (VP (VBD showed) (NP (NP (DT a) (NN Doc_3780846_505_513_Disease)) (PP (IN after) (NP (NP (DT the) (NN test) (NN dose)) (PP (IN of) (NP (NNP Doc_3780846_537_545_Chemical))))) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX was) (RB not) (ADJP (RB significantly) (JJR less)) (PP (IN than) (PP (IN in) (NP (DT the) (NNS controls))))) (CC and) (VP (AUX were) (ADJP (JJ Doc_3780846_608_616_Disease)) (PRN (-LRB- -LRB-) (NP (DT A) (NN group)) (-RRB- -RRB-))))))))) (. .)))
3780846	4	(S1 (S (NP (DT The) (JJ other) (NNS rats)) (VP (VBD showed) (NP (NP (NP (DT a) (JJ strong) (NN decrease)) (PP (IN in) (NP (DT the) (NNP Doc_3780846_675_683_Disease)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ stereotyped)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-)))))) (S (VP (VBG licking) (NP (NP (NN and/or) (NN gnawing)) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NNP Doc_3780846_760_768_Disease) (CC or) (NNP Doc_3780846_772_784_Disease) (PRN (-LRB- -LRB-) (NP (NNP K)) (-RRB- -RRB-)) (NN behaviour)) (PRN (-LRB- -LRB-) (NP (NNP AS/KS) (NN group)) (-RRB- -RRB-))))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ dopaminergic) (NN activation))))))) (. .)))
3780846	5	(S1 (S (NP (DT The) (NNP Doc_3780846_863_871_Disease)) (VP (AUX was) (ADVP (RB considerably)) (VP (VBN decreased) (PP (IN in) (NP (DT both) (NNS groups))) (PP (IN after) (NP (NP (CD 20) (NNS days) (POS ')) (NN treatment))))) (. .)))
3780846	6	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ further) (NN series)) (PP (IN of) (NP (NNS experiments))))) (, ,) (NP (NP (NNP Doc_3780846_976_987_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NN order))) (S (VP (VP (TO to) (VP (VB block) (NP (DT the) (JJ dopaminergic) (NN activation)))) (CC and) (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (JJ real) (NN degree)) (PP (IN of) (NP (DT the) (NN tolerance))) (PP (TO to) (NP (DT the) (NNP Doc_3780846_1116_1124_Disease)))) (PP (IN without) (NP (DT any) (JJ dopaminergic) (NN interference))))))))) (. .)))
3780846	7	(S1 (S (NP (NN Doc_3780846_1164_1175_Chemical)) (VP (VBD enhanced) (NP (DT the) (NN Doc_3780846_1189_1197_Disease)) (PP (IN in) (NP (DT the) (NNP A) (NN group)))) (. .)))
3780846	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN level)) (PP (IN in) (NP (DT the) (NNP AS/KS) (NN group)))) (VP (VBD remained) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (DT the) (NNP A) (NN group)))))) (. .)))
3780846	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_3780846_1326_1334_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN assumed) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NP (DT an) (NN action)) (PP (IN of) (NP (NNP Doc_3780846_1379_1387_Chemical)))))) (PP (IN in) (NP (DT the) (NN striatum)))))))))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN antagonized) (PP (IN by) (NP (NP (DT another) (NN process)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ dopaminergic) (NN activation)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))) (. .)))
3780846	10	(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (EX there)) (VP (VBZ occurs) (NP (DT some) (JJ real) (NN tolerance)) (PP (TO to) (NP (DT this) (NN effect)))) (. .)))
3780846	11	(S1 (S (NP (NP (NP (NP (DT The) (JJ rapid) (NNS alternations)) (PP (IN of) (NP (NNP Doc_3780846_1584_1592_Disease)))) (CC and) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (JJ dopaminergic) (NN activation))))) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NNS animals)) (PP (IN of) (NP (DT the) (NNP AS/KS) (NN group))))))) (VP (MD might) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ rapid) (NNS shifts)) (PP (IN in) (NP (NP (DT the) (NN predominance)) (PP (IN of) (NP (JJ various) (JJ DA-innervated) (NNS structures)))))))))) (. .)))
3782049	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ massive) (NNP Doc_3782049_18_32_Disease) (VBG following) (NNP Doc_3782049_43_52_Chemical) (NN administration))) (. .)))
3782049	1	(S1 (S (NP (NN Doc_3782049_69_83_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ lethal)) (NN syndrome)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_3782049_122_133_Disease) (NNS patients)) (VP (VBP seem) (VP (VBN predisposed) (S (VP (TO to) (VP (VB develop)))))))))) (. .)))
3782049	2	(S1 (S (NP (NP (DT The) (JJ clinical) (NNS signs) (CC and) (NNS symptoms)) (, ,) (NP (JJ typical) (NN laboratory) (NNS features)) (, ,) (CC and) (NP (NP (NNS complications)) (PP (IN of) (NP (NNP Doc_3782049_255_269_Disease))))) (VP (AUX are) (VP (VBN presented))) (. .)))
3782049	3	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (DT a) (JJ Doc_3782049_299_312_Disease) (NN patient)))) (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (VB illustrate) (NP (NP (JJ massive) (NN Doc_3782049_355_369_Disease)) (CC and) (NP (JJ subsequent) (NN Doc_3782049_385_404_Disease))) (PP (VBG following) (NP (NNP Doc_3782049_415_424_Chemical) (NN administration)))))))) (. .)))
3782049	4	(S1 (S (NP (NP (NNS Physicians)) (SBAR (WHNP (WP who)) (S (VP (VBP prescribe) (NP (NN Doc_3782049_466_475_Chemical)))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN reaction)))))) (. .)))
3800626	0	(S1 (FRAG (NP (NN Doc_3800626_0_42_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_3800626_50_61_Chemical-induced) (NNP Doc_3800626_70_86_Disease))) (. .)))
3800626	1	(S1 (S (NP (NN Doc_3800626_88_104_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ common) (, ,) (JJ well-known) (NN side) (NN effect)) (PP (IN of) (NP (JJ repeated) (JJ Doc_3800626_153_164_Chemical) (NN injection))))) (. .)))
3800626	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_3800626_185_207_Disease)) (PP (JJ due) (TO to) (NP (NP (JJ fibrotic) (NN muscle)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_3800626_243_254_Chemical-induced) (NNP Doc_3800626_263_271_Disease)))))) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported)))) (. .)))
3800626	3	(S1 (S (PP (IN In) (NP (NP (NP (DT a) (JJ 37-year-old) (NN woman)) (PP (IN with) (NP (NP (VBN documented) (JJ Doc_3800626_345_356_Chemical-induced) (NN Doc_3800626_365_381_Disease)) (PP (IN of) (NP (NP (NNS triceps)) (CC and) (NP (JJ deltoid) (NNS muscles)))) (ADVP (RB bilaterally))))) (CC and) (NP (NP (DT a) (JJ three-week) (NN history)) (PP (IN of) (NP (JJ right) (NN wrist) (NN drop)))))) (, ,) (NP (JJ electrodiagnostic) (NN examination)) (VP (VBD showed) (NP (NP (DT a) (ADJP (JJ severe) (CC but) (JJ partial)) (NN lesion)) (PP (IN of) (NP (DT the) (JJ right) (JJ radial) (NN nerve) (NN distal))) (PP (TO to) (NP (DT the) (NNS branches)))) (PP (TO to) (NP (DT the) (NNS triceps))) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (DT the) (NNP Doc_3800626_620_636_Disease)))))) (. .)))
3800626	4	(S1 (S (NP (NN Surgery)) (VP (VBD revealed) (NP (DT the) (JJ right) (JJ radial) (NN nerve) (S (VP (TO to) (VP (AUX be) (ADVP (RB severely)) (VP (VBN compressed) (PP (IN by) (NP (NP (DT the) (ADJP (RB densely) (JJ fibrotic)) (NN lateral) (NN head)) (PP (IN of) (NP (DT the) (NNS triceps))))))))))) (. .)))
3800626	5	(S1 (S (NP (NP (NN Decompression)) (CC and) (NP (NN neurolysis))) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (JJ good) (JJ subsequent) (NN recovery)) (PP (IN of) (NP (NN function))))))) (. .)))
3827439	0	(S1 (NP (NP (JJ Recurrent) (JJ reversible) (NN Doc_3827439_21_40_Disease)) (PP (IN from) (NP (NNP Doc_3827439_46_58_Chemical))) (. .)))
3827439	1	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NP (JJ cryptogenic) (NN Doc_3827439_87_96_Disease)) (CC and) (NP (VBN disseminated) (NN Doc_3827439_114_128_Disease))))) (VP (VBD developed) (NP (NNP Doc_3827439_139_158_Disease)) (ADVP (RB immediately)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_3827439_203_217_Chemical))) (PP (IN on) (NP (CD four) (JJ separate) (NNS occasions)))))) (. .)))
3827439	2	(S1 (S (NP (NP (NP (DT The) (NN abruptness)) (PP (IN of) (NP (DT the) (NNP Doc_3827439_268_281_Disease)))) (CC and) (NP (NP (PRP$ its) (NN reversibility)) (PP (IN within) (NP (NNS days))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ functional) (NN component)) (PP (TO to) (NP (DT the) (NNP Doc_3827439_370_387_Disease)))))))) (. .)))
3827439	3	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (IN that) (S (NP (NNP Doc_3827439_405_417_Chemical)) (, ,) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ reduced) (JJ effective) (NN arterial) (NN volume))))) (, ,) (VP (MD may) (VP (VBP activate) (ADVP (RB tubuloglomerular)) (NP (NN feedback)) (, ,) (S (ADVP (RB thereby)) (VP (VBG contributing) (PP (TO to) (NP (NNP Doc_3827439_536_555_Disease)))))))))) (. .)))
3828020	0	(S1 (NP (NP (NN Doc_3828020_0_19_Disease)) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NNP Doc_3828020_47_66_Chemical))))) (. .)))
3828020	1	(S1 (S (NP (NP (NP (NNP Doc_3828020_68_87_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3828020_89_92_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ synthetic) (NN sympathomimetic)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (RB structurally) (JJ similar) (PP (TO to) (NP (NNP Doc_3828020_155_166_Chemical)))))))) (, ,)) (VP (AUX is) (ADJP (JJ available)) (PP (IN over) (NP (NP (DT the) (NN counter)) (PP (IN in) (NP (NP (NNS anorectics)) (, ,) (NP (JJ nasal) (NNS congestants)) (, ,) (CC and) (NP (JJ cold) (NNS preparations))))))) (. .)))
3828020	2	(S1 (S (NP (PRP$ Its) (JJ prolonged) (NN use) (CC or) (NN overuse)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_3828020_309_317_Disease)) (, ,) (NP (NNP Doc_3828020_319_343_Disease)) (, ,) (NP (NNP Doc_3828020_345_370_Disease)) (, ,) (CC and) (NP (JJ nonhemorrhagic) (NNP Doc_3828020_391_410_Disease))))))) (. .)))
3828020	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (DT a) (NN Doc_3828020_463_482_Disease)) (PP (IN after) (S (VP (VBG taking) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NN Doc_3828020_518_521_Chemical)))))))))))))) (. .)))
3856631	0	(S1 (NP (NP (NN Remission) (NN induction)) (PP (IN of) (NP (NNP Doc_3856631_23_41_Disease))) (PP (IN with) (NP (JJ high-dose) (JJ intravenous) (NNP Doc_3856631_69_81_Chemical))) (. .)))
3856631	1	(S1 (S (NP (NP (CD Twenty) (NNS children)) (PP (IN with) (NP (NNP Doc_3856631_104_132_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3856631_147_164_Disease)))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ high-dose) (JJ intravenous) (JJ Doc_3856631_207_219_Chemical) (NN regimen)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB achieve) (CC and) (VB maintain) (NP (NP (NNP CSF) (NNP Doc_3856631_274_286_Chemical) (NNS concentrations)) (PP (IN of) (NP (CD 10) (-LRB- -LRB-) (NN -5) (-RRB- -RRB-) (NNS mol/L)))) (PP (IN without) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (JJ concomitant) (JJ intrathecal) (NN dosing)))))))))))))))) (. .)))
3856631	2	(S1 (S (NP (DT The) (NNP Doc_3856631_375_387_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 6,000) (NNS mg/m2))))) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD one) (NN hour))) (VP (VBN followed) (PP (IN by) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (CD 1,200) (NNS mg/m2/h))) (PP (IN for) (NP (CD 23) (NNS hours)))))))))) (. .)))
3856631	3	(S1 (S (NP (JJ Doc_3856631_518_528_Chemical) (NN rescue)) (VP (AUX was) (VP (VBN initiated) (NP (NP (NP (CD 12) (NNS hours)) (PP (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (NN infusion)) (PP (IN with) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 200) (NNS mg/m2))))) (VP (VBN followed) (PP (IN by) (NP (NP (NP (CD 12) (NN mg/m2)) (NP (QP (DT every) (CD three)) (NNS hours))) (PP (IN for) (NP (CD six) (NNS doses))))))))))) (CC and) (RB then) (NP (DT every) (CD six) (NNS hours))) (SBAR (IN until) (S (NP (DT the) (NN plasma) (JJ Doc_3856631_717_729_Chemical) (NN level)) (VP (VBD decreased) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 1)) (NNP X) (CD 10) (-LRB- -LRB-) (NN -7) (-RRB- -RRB-) (NN mol/L)))))))) (. .)))
3856631	4	(S1 (S (NP (NP (DT The) (JJ mean) (JJ steady-state) (NN plasma)) (CC and) (NP (NNP CSF) (NNP Doc_3856631_814_826_Chemical) (NNS concentrations))) (VP (VBD achieved) (SBAR (S (VP (AUX were) (NP (NP (CD 1.1) (NNP X) (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NN mol/L)) (CC and) (NP (CD 3.6) (NNP X) (CD 10) (-LRB- -LRB-) (NN -5) (-RRB- -RRB-) (NN mol/L))) (, ,) (ADVP (RB respectively)))))) (. .)))
3856631	5	(S1 (S (NP (DT All) (CD 20) (NNS patients)) (VP (VBD responded) (PP (TO to) (NP (DT this) (NN regimen))) (, ,) (SBAR (S (S (NP (NP (NNS 16/20)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (VP (VBD achieved) (NP (DT a) (JJ complete) (NN remission)))) (, ,) (CC and) (S (NP (CD 20) (NN %)) (VP (VBD obtained) (NP (DT a) (JJ partial) (NN remission))))))) (. .)))
3856631	6	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN Doc_3856631_1053_1063_Disease)) (VP (VBD encountered) (SBAR (S (VP (AUX were) (NP (NP (JJ transient) (NN serum) (NN transaminase)) (CC and) (NP (NP (JJ Doc_3856631_1114_1123_Chemical) (NNS elevations)) (, ,) (NP (NP (NNP Doc_3856631_1136_1147_Disease)) (, ,) (CC and) (NP (NNP Doc_3856631_1153_1162_Disease))))))))) (. .)))
3856631	7	(S1 (S (NP (CD One) (NN patient)) (VP (VP (AUX had) (NP (NP (JJ focal) (NN Doc_3856631_1186_1194_Disease)) (CC and) (NP (NNP Doc_3856631_1199_1220_Disease)))) (CC but) (VP (VBD recovered) (ADVP (RB completely)))) (. .)))
3856631	8	(S1 (S (NP (JJ High-dose) (JJ intravenous) (NN Doc_3856631_1269_1281_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN remission))) (PP (IN after) (NP (NP (JJ meningeal) (NN relapse)) (PP (IN in) (NP (NNP Doc_3856631_1366_1394_Disease))))))))) (. .)))
3865016	0	(S1 (NP (NP (NN Interaction)) (PP (IN of) (NP (NNP Doc_3865016_15_28_Chemical))) (PP (IN with) (NP (JJ antineoplastic) (NNS agents))) (. .)))
3865016	1	(S1 (S (NP (NP (DT A) (JJ synergistic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3865016_81_90_Chemical)) (CC and) (NP (NNP Doc_3865016_95_108_Chemical))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_3865016_140_168_Disease)) (PP (IN in) (NP (NN relapse))))))))) (. .)))
3865016	2	(S1 (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3865016_215_224_Chemical)) (CC and) (NP (NNP Doc_3865016_229_242_Chemical))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN eradication)) (PP (IN of) (NP (NP (JJ hitherto) (JJ refractory) (NN Doc_3865016_290_311_Disease)) (PP (IN of) (NP (NN bone) (NN marrow)))))))) (. .)))
3865016	3	(S1 (S (NP (NP (JJ Severe) (JJ side) (NNS effects)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ mental) (NNP Doc_3865016_367_376_Disease)) (CC and) (NP (JJ progressive) (NNP Doc_3865016_393_411_Disease))))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBP point) (PP (TO to) (NP (DT an) (NN enhancement))) (PP (CONJP (RB not) (RB only)) (PP (IN of) (NP (JJ antineoplastic) (NNS effects))) (CONJP (CC but) (RB also)) (PP (IN of) (NP (NP (NNP Doc_3865016_493_501_Disease)) (PP (IN in) (NP (JJ normal) (NNS tissues))))))) (. .)))
3865016	4	(S1 (S (NP (DT This) (NN report)) (VP (VBZ demonstrates) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (SBAR (WHNP (IN that)) (S (NP (NP (DT the) (JJ pharmacodynamic) (NNS properties)) (PP (IN of) (NP (NNP Doc_3865016_604_617_Chemical)))) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN confined) (ADVP (RB strictly)) (PP (TO to) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ normal) (JJ T-cell) (NNS functions))))))))))))) (. .)))
3970039	0	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (NNP Doc_3970039_13_22_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3970039_40_60_Disease)))))) (VP (VBD exposed) (PP (TO to) (NP (JJ different) (NN treatment) (NNS regimens)))) (. .)))
3970039	1	(S1 (S (NP (JJ Immunosuppressive) (NNS drugs)) (VP (AUX have) (VP (AUX been) (VP (VBN used) (PP (IN during) (NP (NP (DT the) (JJ last) (CD 30) (NNS years)) (PP (IN in) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_3970039_203_223_Disease)))))))))))) (. .)))
3970039	2	(S1 (S (NP (NP (DT The) (NNS drugs)) (ADJP (RB commonly) (VBN used))) (VP (AUX are) (NP (NP (NP (NNP Doc_3970039_253_269_Chemical) (CC and) (NNP Doc_3970039_274_286_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3970039_288_305_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3970039_308_320_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_3970039_322_328_Chemical) (NN analogue)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3970039_344_356_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_3970039_358_368_Chemical) (NN analogue)) (-RRB- -RRB-))))) (. .)))
3970039	3	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (DT all) (CD four) (JJ immunosuppressive) (NNS drugs)) (VP (MD can) (VP (VB reduce) (NP (NN Doc_3970039_447_456_Disease))))))))) (, ,) (CC but) (S (NP (NN disease) (NN activity)) (ADVP (RB almost) (RB always)) (VP (VBZ recurs) (SBAR (IN after) (S (NP (NN therapy)) (VP (AUX is) (VP (VBN stopped))))))) (. .)))
3970039	4	(S1 (S (SBAR (IN Since) (S (NP (JJ adverse) (NNS reactions)) (VP (AUX are) (ADJP (JJ frequent))))) (, ,) (NP (NP (QP (JJR less) (IN than) (CD 50)) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (AUX are) (ADJP (JJ able) (S (VP (TO to) (VP (VB continue) (NP (NP (DT a) (JJ particular) (NN drug)) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year))))))))) (. .)))
3970039	5	(S1 (S (SBAR (IN Since) (S (NP (PRP it)) (VP (VBZ takes) (NP (QP (CD three) (TO to) (CD 12)) (NNS months)) (S (VP (TO to) (VP (VB achieve) (NP (JJ maximal) (NNS effects)))))))) (, ,) (NP (NP (DT those) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (JJ unable)) (S (VP (TO to) (VP (VB continue) (NP (DT the) (NN drug))))))))) (VP (VBP receive) (NP (NP (JJ little) (NN benefit)) (PP (IN from) (NP (PRP it))))) (. .)))
3970039	6	(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3970039_827_844_Chemical))))) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_3970039_886_915_Disease)))))))) (, ,) (CC and) (S (NP (DT both) (NNP Doc_3970039_926_943_Chemical) (CC and) (NNP Doc_3970039_948_960_Chemical)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3970039_1000_1022_Disease)))))))) (. .)))
3970039	7	(S1 (S (NP (JJ Doc_3970039_1024_1040_Chemical) (NN therapy)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_3970039_1071_1095_Disease))))) (. .)))
3970039	8	(S1 (S (S (NP (EX There)) (VP (AUX have) (VP (AUX been) (NP (NP (JJ several) (JJ long-term) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3970039_1156_1176_Disease))))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3970039_1190_1202_Chemical)) (CC and) (NP (NNP Doc_3970039_1207_1223_Chemical))))))))) (CC and) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (JJ common) (NNP Doc_3970039_1264_1271_Disease)))))) (VP (AUX is) (RB not) (VP (VBN increased)))) (. .)))
3970039	9	(S1 (S (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (DT the) (JJ possible) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_3970039_1329_1339_Disease))))) (PP (IN in) (NP (NNP Doc_3970039_1343_1363_Disease)))) (VP (AUX are) (ADVP (RB still)) (VP (AUXG being) (VP (VBN collected))))) (, ,) (CC and) (S (SBAR (IN until) (S (NP (JJ further) (NN information)) (VP (AUX is) (ADJP (JJ available))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ immunosuppressive) (NNS drugs)) (, ,) (ADVP (RB particularly)) (NP (NNP Doc_3970039_1484_1501_Chemical)) (, ,))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3970039_1523_1543_Disease)))))) (VP (MD should) (VP (AUX be) (VP (VBN reserved) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (JJ progressive) (NN disease)) (CC or) (NP (JJ life-threatening) (NNS complications)))))))))) (. .)))
3985451	0	(S1 (S (NP (JJ Doc_3985451_0_8_Chemical-induced) (NNS iliopsoas)) (VP (VBP Doc_3985451_27_37_Disease) (PP (IN with) (NP (JJ subsequent) (NNP Doc_3985451_54_73_Disease)))) (. .)))
3985451	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 28-year-old) (NN man)) (PP (IN on) (NP (NP (JJ chronic) (JJ Doc_3985451_127_135_Chemical) (NN therapy)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD sustained) (NP (DT a) (JJ minor) (NN Doc_3985451_166_177_Disease))) (CC and) (VP (VBD developed) (NP (NP (VBG increasing) (NN Doc_3985451_203_207_Disease)) (CC and) (NP (NP (DT a) (JJ flexure) (NN Doc_3985451_222_233_Disease)) (PP (IN of) (NP (DT the) (JJ right) (NN hip))))))))))))))) (. .)))
3985451	2	(S1 (S (NP (JJ Surgical) (NN exploration)) (VP (VBD revealed) (NP (NP (DT an) (JJ iliopsoas) (NN Doc_3985451_295_303_Disease)) (CC and) (NP (JJ femoral) (NN Doc_3985451_316_332_Disease))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (DT a) (NNP Doc_3985451_349_368_Disease) (CC and) (NNP Doc_3985451_373_409_Disease)))))) (. .)))
3985451	3	(S1 (S (S (NP (JJ Anticoagulant-induced) (NN Doc_3985451_433_452_Disease)) (VP (VBZ represents) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN form)) (PP (IN of) (NP (JJ Doc_3985451_488_496_Chemical-induced) (NNP Doc_3985451_505_526_Disease)))))) (: ;) (S (NP (PRP it)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (JJ severe) (NNP Doc_3985451_558_562_Disease)) (PP (IN in) (NP (DT the) (JJ inguinal) (NN region)))) (, ,) (NP (NP (VBG varying) (NNS degrees)) (PP (IN of) (NP (NNP Doc_3985451_606_634_Disease)))) (, ,) (CC and) (NP (NP (JJ flexure) (NNP Doc_3985451_648_659_Disease)) (PP (IN of) (NP (DT the) (VBN involved) (NN extremity))))))))) (. .)))
3997294	0	(S1 (NP (NP (NN Pneumonitis)) (PP (IN with) (NP (NP (NNP Doc_3997294_17_49_Disease)) (CC and) (NP (NNP Doc_3997294_54_64_Disease)))) (PP (IN during) (NP (JJ Doc_3997294_72_82_Chemical) (NN therapy))) (. .)))
3997294	1	(S1 (S (NP (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NNP Doc_3997294_107_125_Disease)))) (CC and) (NP (VBN implanted) (NN pacemaker))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3997294_167_177_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NN maximum) (NN dose)) (NP (CD 1000) (NN mg))) (, ,) (NP (NN maintenance) (NN dose)) (NP (QP (CD 800) (CD mg)) (NN daily)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 10) (NNS months))) (, ,) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (NNP Doc_3997294_262_295_Disease))))))) (. .)))
3997294	2	(S1 (S (NP (PRP He)) (VP (VBD developed) (NP (NP (NNP Doc_3997294_310_321_Disease)) (, ,) (NP (NNP Doc_3997294_323_356_Disease)) (, ,) (CC and) (NP (DT a) (ADVP (RB predominantly)) (NN Doc_3997294_378_403_Disease)))) (. .)))
3997294	3	(S1 (S (NP (JJ Immediate) (CC but) (JJ gradual) (NN improvement)) (VP (VBD followed) (NP (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3997294_462_472_Chemical)))) (CC and) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3997294_492_504_Chemical)))))) (. .)))
3997294	4	(S1 (S (NP (NP (NN Review)) (PP (IN of) (NP (NP (DT this)) (CC and) (NP (ADJP (RB previously) (VBN reported)) (NNS cases))))) (VP (VBZ indicates) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NP (JJ early) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3997294_593_603_Chemical) (NNP Doc_3997294_604_615_Disease)))) (, ,) (NP (NP (JJ immediate) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3997294_641_651_Chemical)))) (, ,) (CC and) (NP (JJ prompt) (CC but) (JJ continued) (JJ Doc_3997294_678_685_Chemical) (NN therapy)))) (S (VP (TO to) (VP (VB ensure) (NP (JJ full) (NN recovery))))))) (. .)))
4008111	0	(S1 (NP (JJ Doc_4008111_0_10_Chemical-induced) (NN Doc_4008111_19_35_Disease) (. .)))
4008111	1	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NNP Doc_4008111_49_65_Disease)) (PP (JJ due) (TO to) (NP (JJ chronic) (NNP Doc_4008111_81_91_Chemical) (NN administration))) (PP (IN in) (NP (NP (DT a) (JJ 5-year-old) (NN boy)) (PP (IN with) (NP (NP (NNP Doc_4008111_132_154_Disease)) (, ,) (NP (NNP Doc_4008111_156_186_Disease)) (CC and) (NP (NNP Doc_4008111_191_219_Disease))))))) (. .)))
4008111	2	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NNP Doc_4008111_248_258_Chemical)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT the) (NN disappearance)) (PP (IN of) (NP (DT the) (NNP Doc_4008111_296_312_Disease)))) (CC and) (NP (NP (DT the) (NN persistence)) (PP (IN of) (NP (JJ asymptomatic) (NNP Doc_4008111_349_366_Disease))))))) (. .)))
4027862	0	(S1 (NP (NP (NP (JJ Doc_4027862_0_11_Chemical-induced) (NN Doc_4027862_20_28_Disease)) (PP (IN at) (NP (`` ``) (JJ subtherapeutic) ('' '') (NNS concentrations)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
4027862	1	(S1 (S (NP (NP (DT An) (JJ elderly) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (JJ low) (NN dose) (NN Doc_4027862_121_132_Chemical))))) (VP (VBD developed) (NP (DT a) (NN Doc_4027862_145_153_Disease)) (SBAR (IN while) (S (NP (PRP$ her) (NN plasma) (NN level)) (VP (AUX was) (PP (IN in) (NP (DT the) (`` ``) (JJ subtherapeutic) ('' '') (NN range))))))) (. .)))
4027862	2	(S1 (S (NP (NP (NN Doc_4027862_212_220_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (VP (VBN induced) (PP (IN by) (NP (JJ tricyclic) (NN drug) (NN therapy))) (PP (IN in) (NP (DT the) (JJ elderly)))))))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (NNS tricyclics)) (PP (IN with) (NP (JJ low) (JJ anticholinergic) (NN potency)))))))) (. .)))
4027862	3	(S1 (S (NP (NP (JJ Therapeutic) (NNS ranges)) (PP (IN for) (NP (NNP Doc_4027862_370_385_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN derived) (PP (IN from) (NP (JJ general) (NN adult) (NN population) (NNS studies))))))))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ appropriate) (PP (IN for) (NP (DT the) (JJ elderly)))))) (. .)))
4027862	4	(S1 (S (NP (NP (JJ Further) (NNS studies)) (PP (IN of) (NP (RB specifically) (JJ elderly) (NNS patients)))) (VP (AUX are) (ADVP (RB now)) (VP (VBN required) (S (VP (TO to) (VP (VB establish) (NP (ADJP (ADJP (JJR safer)) (CC and) (ADJP (RBR more) (JJ appropriate))) (NNS guidelines)) (PP (IN for) (NP (NN drug) (NN therapy)))))))) (. .)))
4071154	0	(S1 (NP (NP (JJ Doc_4071154_0_12_Chemical-induced) (NN Doc_4071154_21_40_Disease)) (: :) (NP (NP (NN recurrence)) (PP (IN on) (NP (NN rechallenge)))) (. .)))
4071154	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN reported) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (JJ oliguric) (NN Doc_4071154_111_124_Disease)) (PP (IN with) (NP (NNP Doc_4071154_130_142_Disease)))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_4071154_161_170_Disease)) (, ,) (NP (NNP Doc_4071154_172_179_Disease)) (, ,) (CC and) (NP (NNP Doc_4071154_185_198_Disease)))) (PP (IN after) (NP (JJ Doc_4071154_205_217_Chemical) (NN therapy))))))) (. .)))
4071154	2	(S1 (S (NP (NP (JJ Prompt) (NN restoration)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (VBD followed) (NP (NN drug) (NN withdrawal)) (, ,) (SBAR (IN while) (S (NP (NP (NN re-exposure)) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_4071154_328_340_Chemical)))))) (VP (VBD caused) (NP (NP (NN recurrence)) (PP (IN of) (NP (JJ acute) (JJ reversible) (NN Doc_4071154_379_387_Disease)))))))) (. .)))
4071154	3	(S1 (S (NP (PRP$ Our) (NN case)) (VP (VBZ supports) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ endogenous) (JJ renal) (NN Doc_4071154_444_458_Chemical)) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (JJ renal) (NN blood) (NN flow))))) (SBAR (WHADVP (WRB when)) (S (S (VP (VBG circulating) (NP (NN plasma) (NN volume)))) (VP (AUX is) (VP (VBN diminished)))))))))) (. .)))
4071154	4	(S1 (S (SBAR (IN Since) (S (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS agents)) (VP (VP (VBP interfere) (PP (IN with) (NP (DT this) (JJ compensatory) (NN mechanism)))) (CC and) (VP (MD may) (VP (VB cause) (NP (NN Doc_4071154_657_676_Disease))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (JJ such) (NNS patients)))))) (. .)))
424937	0	(S1 (NP (NP (NNS Patterns)) (PP (IN of) (NP (NNP Doc_424937_12_26_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_424937_38_48_Chemical)))) (. .)))
424937	1	(S1 (S (NP (NP (CD Twelve) (NNS patients)) (PP (IN with) (NP (NNP Doc_424937_71_84_Disease))) (VP (VBN related) (PP (TO to) (NP (NNP Doc_424937_96_106_Chemical))))) (VP (AUX were) (VP (VBN seen) (PP (IN between) (NP (NP (CD 1967)) (CC and) (NP (CD 1977)))))) (. .)))
424937	2	(S1 (S (NP (NN Illness)) (VP (VBD occurred) (PP (IN within) (NP (NP (JJ 1--9) (NNS weeks)) (PP (IN of) (NP (NP (NN commencement)) (PP (IN of) (NP (NN therapy))))))) (PP (IN in) (NP (NP (CD 9) (NNS patients)) (, ,) (NP (NP (DT the) (JJ remaining) (CD 3) (NNS patients)) (VP (AUXG having) (VP (VBN received) (NP (NP (DT the) (NN drug)) (PP (IN for) (NP (NP (CD 13) (NNS months)) (, ,) (NP (CD 15) (NNS months)) (CC and) (NP (CD 7) (NNS years))))) (PP (IN before) (S (VP (VBG experiencing) (NP (NNS symptoms))))))))))) (. .)))
424937	3	(S1 (S (NP (NP (NN Doc_424937_334_342_Disease)) (PP (IN with) (NP (NN tender) (NN Doc_424937_355_367_Disease)))) (, ,) (S (ADVP (RB usually)) (VP (VP (VBN preceded) (PP (IN by) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NN malaise)) (, ,) (NP (NNP Doc_424937_410_418_Disease) (, ,) (NNP Doc_424937_420_426_Disease) (CC and) (NNP Doc_424937_431_439_Disease)) (, ,)))))) (CC and) (VP (VBN associated) (PP (IN with) (NP (JJ upper) (NNP Doc_424937_467_481_Disease)))))) (, ,) (VP (AUX was) (NP (NP (DT an) (JJ invariable) (NN finding)) (PP (IN in) (NP (DT all) (NNS patients))))) (. .)))
424937	4	(S1 (S (NP (JJ Biochemical) (NN liver) (NN function) (NNS tests)) (VP (VP (VBD indicated) (NP (JJ hepatocellular) (NNP Doc_424937_584_592_Disease))) (CC and) (VP (VBD correlated) (PP (IN with) (NP (NP (JJ histopathological) (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_424937_643_657_Disease)) (, ,) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (SBAR (WHNP (WDT which)) (S (VP (VBD ranged) (PP (IN from) (NP (NP (NNP Doc_424937_693_705_Disease) (CC and) (JJ focal) (JJ hepatocellular) (NN Doc_424937_731_739_Disease)) (PP (TO to) (NP (NNP Doc_424937_743_767_Disease)))))))))))))))) (. .)))
424937	5	(S1 (S (NP (JJS Most) (NNS patients)) (VP (VBD showed) (ADJP (JJ moderate) (TO to) (JJ severe)) (NP (NNP Doc_424937_809_824_Disease) (CC or) (NNP Doc_424937_828_852_Disease)) (PP (IN with) (NP (JJ associated) (NNP Doc_424937_869_880_Disease)))) (. .)))
424937	6	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN withdrawn) (PP (IN on) (NP (NN presentation))) (PP (TO to) (NP (NN hospital))) (PP (IN in) (NP (CD 11) (NNS patients))) (, ,) (PP (IN with) (NP (NP (JJ rapid) (JJ clinical) (NN improvement)) (PP (IN in) (NP (CD 9))))))) (. .)))
424937	7	(S1 (S (S (NP (CD One) (NN patient)) (VP (VBD died) (, ,) (S (VP (AUXG having) (VP (VBN presented) (PP (IN in) (NP (NNP Doc_424937_1025_1040_Disease)))))))) (, ,) (CC and) (S (NP (NP (DT another)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_424937_1075_1085_Chemical)) (PP (IN for) (NP (CD 7) (NNS years)))))))) (, ,)) (VP (VBD showed) (NP (JJR slower) (JJ clinical) (CC and) (JJ biochemical) (NN resolution)) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (JJ several) (NNS months))))))) (. .)))
424937	8	(S1 (S (NP (NP (DT The) (VBG remaining) (NN patient)) (PP (IN in) (NP (DT the) (NN series)))) (VP (VBD developed) (NP (NN Doc_424937_1228_1247_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX was) (ADVP (RB accidentally)) (VP (VBN recommenced) (NP (CD 1) (NN year)) (PP (IN after) (NP (NP (DT a) (JJ prior) (NN episode)) (PP (IN of) (NP (NNP Doc_424937_1323_1333_Chemical-induced) (NNP Doc_424937_1342_1351_Disease)))))))))) (. .)))
424937	9	(S1 (S (PP (PP (IN In) (NP (DT this) (JJ latter) (NN patient))) (, ,) (CC and) (PP (IN in) (NP (CD 2) (NNS others)))) (, ,) (NP (NP (DT the) (JJ causal) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_424937_1426_1436_Chemical)) (CC and) (NP (NNP Doc_424937_1441_1460_Disease))))) (VP (AUX was) (VP (VBN proved) (PP (IN with) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_424937_1495_1504_Disease))))) (PP (IN within) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NP (NN re-exposure)) (PP (TO to) (NP (DT the) (NN drug))))))))) (. .)))
435349	0	(S1 (FRAG (NP (NP (JJ Doc_435349_0_13_Chemical) (NN infusion) (NN rate)) (CC and) (NP (JJ observed) (NN Doc_435349_41_55_Disease))) (. .)))
435349	1	(S1 (NP (DT A) (JJ dose-response) (NN study) (. .)))
435349	2	(S1 (S (NP (NP (NNP Doc_435349_80_102_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_435349_104_107_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (NP (QP (CD i.v.) (TO to) (CD 36)) (JJ adult) (NNS males)) (PP (IN at) (NP (NP (CD six) (NNS rates)) (: :) (NP (QP (CD 0.25) (CD mg) (NN s-1) (TO to) (CD 20) (CD mg) (NN s-1))))))) (. .)))
435349	3	(S1 (S (NP (DT The) (NN infusion)) (VP (AUX was) (VP (VBN discontinued) (ADVP (RB either)) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ muscular) (NN response)) (PP (TO to) (NP (NP (JJ Doc_435349_265_272_Disease) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ ulnar) (NN nerve))))))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_435349_312_315_Chemical) (CD 120) (NN mg)) (VP (AUX was) (VP (VBN exceeded)))))))) (. .)))
435349	4	(S1 (S (NP (CD Six) (JJ additional) (NNS patients)) (VP (VBD received) (NP (DT a) (JJ 30-mg) (NN i.v.) (NN bolus) (NN dose))) (. .)))
435349	5	(S1 (S (NP (NP (NN Doc_435349_395_409_Disease)) (PP (IN in) (NP (NP (CD six) (NNS areas)) (PP (IN of) (NP (DT the) (NN body)))))) (VP (AUX were) (VP (VP (VBN scored) (PP (IN from) (NP (NP (CD 0)) (PP (TO to) (NP (CD 3)))))) (CC and) (VP (VBN summated) (PP (IN as) (NP (DT a) (JJ total) (JJ Doc_435349_483_496_Disease) (NN score)))))) (. .)))
435349	6	(S1 (S (NP (NP (DT The) (NNS times)) (PP (TO to) (NP (NP (JJ first) (NN Doc_435349_523_536_Disease)) (, ,) (NP (JJ Doc_435349_538_544_Disease) (NN suppression)) (CC and) (NP (JJ Doc_435349_561_568_Disease) (NN suppression))))) (VP (AUX were) (ADVP (RB inversely)) (VP (VBN related) (PP (TO to) (NP (DT the) (NN infusion) (NNS rates))))) (. .)))
435349	7	(S1 (S (NP (NP (NP (NN Doc_435349_627_641_Disease)) (PP (IN in) (NP (DT the) (CD six) (NNS areas)))) (CC and) (NP (DT the) (JJ total) (NN Doc_435349_673_686_Disease) (NN score))) (VP (AUX were) (VP (VBN related) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN infusion))))))) (. .)))
435349	8	(S1 (S (NP (NP (NP (JJ Total) (JJ Doc_435349_746_759_Disease) (NNS scores)) (PP (IN in) (NP (DT the) (JJ 30-mg) (NN bolus) (NN group)))) (CC and) (NP (DT the) (JJ 5-mg) (ADJP (JJ s-1) (CC and) (JJ 20-mg)) (NN s-1) (NN infusion) (NNS groups))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different))) (. .)))
4812392	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_4812392_13_22_Disease))) (PP (IN with) (NP (NNP Doc_4812392_28_40_Chemical))) (. .)))
4812392	1	(S1 (S (NP (JJ Doc_4812392_42_54_Chemical) (NN treatment)) (VP (VBD benefited) (NP (CD 19)) (PRN (-LRB- -LRB-) (NP (CD 66) (NN %)) (-RRB- -RRB-)) (PP (IN out) (PP (IN of) (NP (NP (CD 29) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ severe) (NN Doc_4812392_125_134_Disease)))))))) (. .)))
4812392	2	(S1 (S (S (NP (JJ Haematological) (NNS complications)) (VP (AUX were) (RB not) (ADJP (JJ troublesome)))) (CC and) (S (NP (NP (NNS results)) (PP (IN of) (NP (JJ biochemical) (NN liver) (NN function) (NNS tests)))) (VP (VBD remained) (ADJP (JJ normal)))) (. .)))
4812392	3	(S1 (S (NP (JJ Minimal) (NN Doc_4812392_259_270_Disease)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (NP (CD two) (NNS cases)) (CC and) (NP (JJ portal) (NN Doc_4812392_304_312_Disease))) (PP (IN of) (NP (NP (DT a) (JJ reversible) (NN degree)) (PP (IN in) (NP (CD eight))))))))) (. .)))
4812392	4	(S1 (S (NP (NN Liver) (NNS biopsies)) (VP (MD should) (VP (AUX be) (VP (VBN undertaken) (PP (IN at) (NP (JJ regular) (NNS intervals))) (SBAR (IN if) (S (NP (JJ Doc_4812392_406_418_Chemical) (NN therapy)) (VP (AUX is) (VP (VBN continued) (SBAR (IN so) (S (NP (DT that) (JJ structural) (NN Doc_4812392_459_471_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN detected) (PP (IN at) (NP (DT an) (JJ early) (CC and) (JJ reversible) (NN stage))))))))))))))) (. .)))
567256	0	(S1 (S (NP (NN Doc_567256_0_25_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_567256_42_60_Chemical)))) (. .)))
567256	1	(S1 (S (NP (NN Doc_567256_62_87_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ 76-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (NP (DT a) (JJ well-differentiated) (NN Doc_567256_165_192_Disease)) (PP (IN with) (NP (NNP Doc_567256_198_216_Chemical))) (PP (IN for) (NP (CD 13) (NNS years))))))))))))) (. .)))
567256	2	(S1 (S (NP (NN Doc_567256_231_243_Disease)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ present)) (PP (IN within) (NP (NP (NN pulmonary)) (CC and) (NP (JJ renal) (NN arteries))))) (. .)))
567256	3	(S1 (S (NP (DT The) (NN possibility) (SBAR (IN that) (S (NP (DT the) (NNP Doc_567256_323_344_Disease)) (VP (MD might) (VP (VB represent) (NP (JJ independent) (JJ primary) (NN Doc_567256_381_387_Disease))))))) (VP (AUX is) (VP (VBN considered))) (. .)))
603022	0	(S1 (NP (NP (NNP Doc_603022_0_25_Chemical)) (, ,) (NP (DT a) (ADJP (RBR longer) (JJ acting)) (NN anticholinesterase) (NN drug)) (, ,) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT the) (JJ central) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_603022_111_122_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_603022_124_132_Chemical)) (-RRB- -RRB-)))))))) (. .)))
603022	1	(S1 (S (NP (NP (NNP Doc_603022_135_160_Chemical)) (, ,) (NP (NP (DT an) (JJ anticholinesterase) (NN drug)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG penetrating) (NP (DT the) (NN blood-brain) (NN barrier))))))) (, ,)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG demonstrating) (NP (NP (JJ central) (NNS effects)) (PP (IN of) (NP (NNP Doc_603022_292_303_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_603022_305_313_Chemical)) (-RRB- -RRB-)) (NNP Doc_603022_315_325_Disease))))))))) (. .)))
603022	2	(S1 (S (NP (PRP It)) (VP (VP (AUX is) (ADVP (RB longer)) (VP (VBG acting) (PP (IN than) (NP (NNP Doc_603022_352_365_Chemical))))) (CC and) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (NN anaesthesia))) (S (VP (TO to) (VP (VB reverse) (NP (DT the) (JJ non-depolarizing) (NN neuromuscular) (NN block)))))))) (. .)))
603022	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS studies)) (PP (IN into) (NP (NP (DT the) (NN dose)) (ADJP (JJ necessary) (PP (TO to) (S (VP (VBG combating) (NP (JJ Doc_603022_500_511_Chemical) (NN intoxication))))))))) (VP (AUX are) (VP (VBN indicated))) (. .)))
6103707	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (JJ subjective) (NNS effects)) (CC and) (NP (NN plasma) (NNS concentrations)))) (VP (VBG following) (NP (NP (JJ oral) (CC and) (NNP i.m.) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6103707_105_118_Chemical)) (PP (IN in) (NP (NNS volunteers))))))) (. .)))
6103707	1	(S1 (S (NP (NP (NNP Doc_6103707_134_147_Chemical) (CD 0.5) (, ,) (CD 1.0)) (CC or) (NP (CD 2.0) (NNS mg))) (VP (AUX was) (VP (VBN given) (PP (IN by) (NP (DT the) (JJ oral) (CC or) (NNP i.m.) (NNS routes))) (PP (TO to) (NP (NP (NP (NNS groups)) (PP (IN of) (NP (NNS volunteers)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (VP (VBN compared))))))) (. .)))
6103707	2	(S1 (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX were) (VP (VBN estimated) (PP (IN by) (NP (JJ gas-liquid) (NN chromatography))) (, ,) (PP (IN in) (NP (NP (DT a) (JJR smaller) (NN number)) (PP (IN of) (NP (DT the) (NNS subjects))))))) (. .)))
6103707	3	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ striking)) (NN effect)) (VP (AUX was) (NP (NP (NN sedation)) (SBAR (WHNP (WDT which)) (S (VP (VBD increased) (PP (IN with) (NP (DT the) (NN dose))) (, ,) (S (NP (CD 2) (NN mg)) (VP (VBG producing) (NP (JJ deep) (NN sleep)) (SBAR (IN although) (S (NP (DT the) (NNS subjects)) (VP (MD could) (ADVP (RB still)) (VP (AUX be) (VP (VBN aroused))))))))))))) (. .)))
6103707	4	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP i.m.) (NN administration)))) (VP (AUX were) (UCP (ADJP (JJ apparent) (JJR earlier)) (CC and) (VP (ADVP (RB sometimes)) (VBN lasted) (ADVP (RBR longer) (PP (IN than) (NP (NP (DT those)) (VP (VBG following) (NP (JJ oral) (NN administration))))))))) (. .)))
6103707	5	(S1 (S (NP (NN Doc_6103707_638_647_Disease)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ marked) (PP (IN than) (NP (NN sedation)))) (, ,) (CC but) (ADJP (JJ increased) (PP (IN with) (NP (DT the) (NN dose)))))) (. .)))
6103707	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (NNP Doc_6103707_718_722_Disease) (IN on) (NNP i.m.) (NN injection)) (PP (IN of) (NP (NNP Doc_6103707_744_757_Chemical)))) (ADVP (ADVP (RB significantly) (RBR more) (RB often)) (PP (IN than) (PP (IN with) (NP (JJ isotonic) (NN saline)))))) (. .)))
6103707	7	(S1 (S (NP (NN Plasma) (NNS concentrations)) (VP (VP (VBN varied) (PP (IN with) (NP (NP (NN dose)) (CC and) (NP (NN route))))) (CC and) (VP (VBD corresponded) (ADVP (RB qualitatively)) (PP (IN with) (NP (DT the) (JJ subjective) (NNS effects))))) (. .)))
6103707	8	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (ADVP (RB still)) (ADJP (JJ present)) (PP (IN in) (NP (JJ measurable) (NNS quantities))) (PP (IN after) (NP (NP (CD 24) (NNP h)) (PP (ADVP (RB even)) (IN with) (NP (DT the) (JJS smallest) (NN dose)))))) (. .)))
6133211	0	(S1 (NP (NP (JJ Possible) (NN teratogenicity)) (PP (IN of) (NP (NNP Doc_6133211_27_41_Chemical))) (. .)))
6133211	1	(S1 (S (NP (NP (CD Three) (NNS infants)) (, ,) (VP (VBN born) (PP (IN of) (NP (CD two) (NNS mothers))) (PP (IN with) (NP (NP (NNP Doc_6133211_83_109_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_6133211_138_152_Chemical))) (PP (IN throughout) (NP (NN pregnancy))))))))) (, ,)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (JJ major) (NN Doc_6133211_200_220_Disease))))))) (. .)))
6133211	2	(S1 (S (PP (IN In) (NP (DT the) (NNP singleton) (NN pregnancy))) (, ,) (S (NP (DT the) (NN mother)) (VP (AUX had) (NP (NN Doc_6133211_265_283_Disease)))) (, ,) (CC and) (S (NP (NP (DT the) (NN infant)) (, ,) (NP (DT a) (NN male)) (, ,)) (VP (AUX had) (NP (NP (NN Doc_6133211_313_337_Disease)) (CC and) (NP (DT a) (NN Doc_6133211_344_369_Disease))))) (. .)))
6133211	3	(S1 (S (PP (IN In) (NP (DT the) (JJ twin) (NN pregnancy))) (, ,) (NP (DT the) (NN mother)) (VP (AUX had) (NP (NN Doc_6133211_409_424_Disease))) (. .)))
6133211	4	(S1 (S (NP (NP (DT The) (JJ first) (JJ twin)) (, ,) (NP (DT a) (NN female)) (, ,)) (VP (AUX had) (NP (NP (DT a) (JJ left) (NN Doc_6133211_463_496_Disease)) (CC and) (NP (DT a) (NN Doc_6133211_503_533_Disease)))) (. .)))
6133211	5	(S1 (S (NP (NP (DT The) (JJ second) (JJ twin)) (, ,) (NP (DT a) (NN male)) (, ,)) (VP (AUX had) (NP (NP (DT some) (NNS features)) (PP (IN of) (NP (NP (NNP Doc_6133211_581_596_Disease)) (, ,) (NP (NNP Doc_6133211_598_615_Disease)) (, ,) (NP (NNP Doc_6133211_617_643_Disease)) (, ,) (CC and) (NP (NNP Doc_6133211_649_668_Disease)))))) (. .)))
6133211	6	(S1 (S (PP (IN Despite) (NP (NP (NNS reports)) (PP (TO to) (NP (DT the) (NN contrary))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_6133211_724_738_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ teratogenic)))))))) (. .)))
6203452	0	(S1 (S (NP (NP (NN Doc_6203452_0_26_Disease)) (CC and) (NP (NN Doc_6203452_31_44_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ antineoplastic) (NN chemotherapy)))) (. .)))
6203452	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NNP Doc_6203452_109_118_Disease)))) (VP (VBD developed) (NP (NP (NNP Doc_6203452_129_155_Disease)) (PRN (-LRB- -LRB-) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_6203452_174_193_Disease)) (, ,) (NP (NNP Doc_6203452_195_228_Disease)) (, ,) (CC and) (ADVP (RB usually)) (NP (NNP Doc_6203452_242_258_Disease))))) (-RRB- -RRB-))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6203452_281_290_Chemical)) (, ,) (NP (NNP Doc_6203452_292_301_Chemical)) (, ,) (CC and) (NP (DT a) (NNP Doc_6203452_309_323_Chemical))))))) (. .)))
6203452	2	(S1 (S (NP (CD One) (NN patient)) (VP (AUX had) (NP (NP (NNP Doc_6203452_341_376_Disease)) (, ,) (NP (NP (NP (CD three)) (NP (DT the) (NNP Doc_6203452_388_413_Disease))) (, ,) (CC and) (NP (NP (CD one)) (NP (NP (DT an) (JJ apparent) (NN forme) (NN fruste)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS disorders)))))))))) (. .)))
6203452	3	(S1 (S (NP (NP (JJ Histologic) (NN examination)) (PP (IN of) (NP (DT the) (JJ renal) (NN tissue)))) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_6203452_537_562_Disease)))) (, ,) (S (ADVP (RB primarily)) (VP (VBG affecting) (NP (NP (DT the) (JJ small) (NNS arteries)) (, ,) (NP (NNS arterioles)) (, ,) (CC and) (NP (NNS glomeruli)))))) (. .)))
6203452	4	(S1 (S (SBAR (IN Because) (S (NP (DT each) (NN patient)) (VP (VP (AUX was) (ADJP (JJ Doc_6203452_656_661_Disease-free))) (CC or) (VP (AUX had) (NP (RB only) (DT a) (JJ small) (NN Doc_6203452_687_692_Disease)) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT this) (NN syndrome))))))))) (, ,) (NP (DT the) (NNP Doc_6203452_728_754_Disease)) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN induced) (PP (IN by) (NP (NN chemotherapy))))))) (. .)))
6203452	5	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (DT this) (ADJP (RB potentially) (JJ fatal)) (NN complication)))) (VP (MD may) (VP (AUX be) (VP (VBN delayed) (CC or) (VBN missed) (SBAR (IN if) (S (NP (NP (JJ renal) (NN tissue)) (CC or) (NP (DT the) (JJ peripheral) (NN blood) (NN smear))) (VP (AUX is) (RB not) (VP (VBN examined))))) (, ,) (SBAR (IN because) (S (NP (NNP Doc_6203452_939_952_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN ascribed) (PP (TO to) (NP (NNP Doc_6203452_972_981_Chemical) (NNP Doc_6203452_982_996_Disease) (CC and) (DT the) (NNP Doc_6203452_1005_1011_Disease) (CC and) (NNP Doc_6203452_1016_1032_Disease))) (PP (TO to) (NP (JJ drug-induced) (NN Doc_6203452_1049_1072_Disease))))))))))) (. .)))
6209318	0	(S1 (NP (NP (NP (NNP International) (NNP Doc_6209318_14_24_Chemical)) (CC and) (NP (NN placebo) (NN antiarrhythmic) (JJ coronary) (NN trial))) (: :) (NP (NP (NNP I.) (NNP Report)) (PP (IN on) (NP (NP (NNP Doc_6209318_81_91_Disease)) (CC and) (NP (JJ other) (NNS findings))))) (. .)))
6209318	1	(S1 (NP (NNP Impact) (NNP Research) (NNP Group) (. .)))
6209318	2	(S1 (S (NP (NP (DT The) (JJ antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ sustained) (NN release) (NN form)) (PP (IN of) (NP (NP (NNP Doc_6209318_195_205_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6209318_207_225_Chemical)) (-RRB- -RRB-))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (NN placebo) (NN trial)) (PP (IN in) (NP (CD 630) (NNS patients))) (PP (IN with) (NP (JJ recent) (VBN documented) (NN Doc_6209318_313_334_Disease))))))) (. .)))
6209318	3	(S1 (S (NP (DT The) (JJ primary) (NN response) (NN variable)) (VP (VP (AUX was) (VP (VBN based) (PP (IN on) (NP (NP (JJ central) (NN reading)) (PP (IN of) (NP (ADJP (CD 24) (NN hour)) (JJ ambulatory) (JJ electrocardiographic) (NNS recordings))))))) (CC and) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (QP (CD 30) (CC or) (JJR more)) (JJ single) (JJ premature) (NN ventricular) (NNS complexes))) (PP (IN in) (NP (QP (DT any) (CD two)) (JJ consecutive) (CD 30) (JJ minute) (NNS blocks)))) (CC or) (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS runs)) (PP (IN of) (NP (QP (CD two) (CC or) (JJR more)) (JJ premature) (NN ventricular) (NNS complexes))) (PP (IN in) (NP (DT the) (JJ entire) (ADJP (CD 24) (NN hour)) (JJ electrocardiographic) (NN recording))))))))) (. .)))
6209318	4	(S1 (S (S (NP (NP (JJ Large) (NNS differences)) (, ,) (VP (VBN regarded) (PP (IN as) (ADJP (RB statistically) (JJ significant)))) (, ,) (PP (IN between) (NP (DT the) (JJ Doc_6209318_767_777_Chemical) (CC and) (NN placebo) (NNS groups)))) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (DT that) (NN end) (NN point))) (PP (IN at) (NP (NP (NNS months)) (CD 1) (CC and) (CD 4)))))) (, ,) (CC but) (S (NP (JJ only) (NNS trends)) (VP (AUX were) (VP (VBN observed) (PP (IN at) (NP (NN month) (CD 12)))))) (. .)))
6209318	5	(S1 (S (NP (DT These) (NNS differences)) (VP (AUX were) (VP (VBN observed) (SBAR (RB even) (IN though) (S (NP (NP (DT the) (JJ serum) (JJ Doc_6209318_942_952_Chemical) (NNS levels)) (VP (VBN obtained) (PP (IN in) (NP (DT this) (NN study))))) (VP (AUX were) (ADJP (ADJP (RB generally) (JJR lower)) (PP (IN than) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN used) (NP (NP (DT the) (JJ regular) (NN form)) (PP (IN of) (NP (DT the) (NN drug))))))))))))))))))) (. .)))
6209318	6	(S1 (S (S (NP (EX There)) (VP (AUX were) (ADJP (RBR more) (JJ Doc_6209318_1096_1102_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_6209318_1110_1120_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (CD 7.6) (NN %)) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD 4.8) (NN %)) (-RRB- -RRB-)))) (: ;) (S (NP (DT the) (NN difference)) (VP (AUX was) (RB not) (ADJP (RB statistically) (JJ significant)))) (. .)))
6209318	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ coronary) (NNS events)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
6209318	8	(S1 (S (NP (NP (ADJP (RB Previously) (VBN recognized)) (NN side) (NNS effects)) (, ,) (ADVP (RB particularly)) (NP (NP (NNP Doc_6209318_1328_1334_Disease)) (CC and) (NP (NNP Doc_6209318_1339_1364_Disease))) (, ,)) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (DT the) (NNP Doc_6209318_1392_1402_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))) (. .)))
6229975	0	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NN heart)))) (VP (VBP size) (PP (IN during) (NP (NP (JJ long-term) (JJ Doc_6229975_39_46_Chemical) (NN treatment)) (PP (IN after) (NP (NNP Doc_6229975_63_84_Disease)))))) (. .)))
6229975	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ long-term) (JJ Doc_6229975_110_117_Chemical) (NN treatment))) (PP (IN on) (NP (NN heart) (NN size))) (PP (IN after) (NP (NNP Doc_6229975_148_169_Disease)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (NP (NN X-ray))) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (NN study)) (PP (VBG including) (NP (NP (CD 241) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo) (CD 126)) (, ,) (NP (NNP Doc_6229975_254_261_Chemical) (CD 115))) (-RRB- -RRB-)))))))) (. .)))
6229975	2	(S1 (S (NP (DT The) (JJ follow-up) (NN period)) (VP (AUX was) (NP (CD 12) (NNS months))) (. .)))
6229975	3	(S1 (S (NP (DT The) (JJ Doc_6229975_308_315_Chemical-treated) (NNS patients)) (VP (VBD showed) (NP (NP (DT a) (ADJP (JJ small) (CC but) (JJ significant)) (NN increase)) (PP (IN in) (NP (NN heart) (NN size))) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (NN contrast))) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))))) (. .)))
6229975	4	(S1 (S (NP (DT These) (NNS differences)) (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (JJ Doc_6229975_484_491_Chemical-induced) (NN Doc_6229975_500_511_Disease)) (CC and) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (JJ end-diastolic) (NN volume))))))))) (. .)))
6229975	5	(S1 (S (NP (NP (DT The) (JJ Doc_6229975_569_576_Chemical-related) (NN increase)) (PP (IN in) (NP (NN heart) (NN size)))) (VP (AUX was) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (JJ normal) (CC and) (JJ borderline) (NN heart) (NN size))))) (. .)))
6229975	6	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6229975_694_706_Disease))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN heart) (NN size)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
6229975	7	(S1 (S (PP (IN After) (NP (NN re-Doc_6229975_772_782_Disease))) (, ,) (NP (NN heart) (NN size)) (VP (VP (VBD increased) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (CC and) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT the) (NNP Doc_6229975_856_863_Chemical) (NN group))))) (. .)))
6286738	0	(S1 (NP (NP (NNP Doc_6286738_0_10_Chemical) (NNP Doc_6286738_11_19_Disease)) (PP (IN in) (NP (NN dairy) (NNS cows))) (. .)))
6286738	1	(S1 (S (NP (NP (JJ Large) (JJ parenteral) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6286738_61_71_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (TO to) (CD 17.5)) (NNP x) (CD 10) (-LRB- -LRB-) (CD 6) (-RRB- -RRB-) (NNP IU) (NNP Doc_6286738_95_105_Chemical)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJ prolonged) (NNP Doc_6286738_138_151_Disease) (, ,) (NNP Doc_6286738_153_170_Disease) (, ,) (CC and) (JJ large) (NNS increases)) (PP (IN of) (NP (NNP Doc_6286738_195_205_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS metabolites)) (PP (IN in) (NP (NP (DT the) (NN blood) (NN plasma)) (PP (IN of) (NP (NP (JJ nonlactating) (NN nonpregnant)) (CC and) (NP (JJ pregnant) (NNP Jersey) (NNS cows))))))))))) (. .)))
6286738	2	(S1 (S (NP (JJ Doc_6286738_300_307_Chemical) (NNS concentrations)) (NP (CD 1) (NN day) (NN postpartum)) (VP (AUX were) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS cows)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6286738_373_383_Chemical))) (PP (IN about) (NP (NP (CD 32) (NNS days)) (ADJP (ADJP (JJ prepartum)) (PRN (-LRB- -LRB-) (NP (QP (CD 8.8) (CD mg/100)) (NNS ml)) (-RRB- -RRB-))))))))) (PP (IN than) (PP (IN in) (NP (NP (NN control) (NNS cows)) (PRN (-LRB- -LRB-) (NP (QP (CD 5.5) (CD mg/100)) (NNS ml)) (-RRB- -RRB-))))))) (. .)))
6286738	3	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS cows)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6286738_492_502_Chemical))))))) (VP (VBD showed) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_6286738_519_529_Disease)))) (PP (IN during) (NP (DT the) (JJ peripartal) (NN period))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (CD 22) (NN %)) (PP (IN of) (NP (DT the) (NN control) (NNS cows)))) (VP (VBD developed) (NP (NP (JJ clinical) (NNS signs)) (PP (IN of) (NP (NNP Doc_6286738_621_631_Disease)))) (PP (IN during) (NP (DT this) (NN period))))) (. .)))
6286738	4	(S1 (S (S (NP (NP (NNS Signs)) (PP (IN of) (NP (NNP Doc_6286738_661_671_Chemical) (NNP Doc_6286738_672_680_Disease)))) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (S (VP (VBG nonlactating) (NP (JJ nonpregnant) (NNS cows)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ pregnant) (NNS cows)) (VP (ADVP (RB commonly)) (VBN developed) (NP (NP (JJ severe) (NNS signs)) (PP (IN of) (NP (NP (NNP Doc_6286738_791_801_Chemical) (NNP Doc_6286738_802_810_Disease)) (CC and) (NP (NP (CD 10)) (PP (IN of) (NP (CD 17) (NNS cows))))))))) (VP (VBD died))) (. .)))
6286738	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ widespread) (JJ metastatic) (NN calcification)) (PP (IN in) (NP (NP (DT the) (NNS cows)) (SBAR (WHNP (WDT that)) (S (VP (VBD died)))))))) (. .)))
6286738	6	(S1 (S (PP (IN Because) (IN of) (NP (NP (NP (DT the) (JJ extreme) (NN Doc_6286738_927_935_Disease)) (PP (IN of) (NP (NNP Doc_6286738_939_949_Chemical))) (PP (IN in) (NP (JJ pregnant) (NNP Jersey) (NNS cows)))) (CC and) (NP (NP (DT the) (JJ low) (NN margin)) (PP (IN of) (NP (NN safety))) (PP (IN between) (NP (NP (NNS doses)) (PP (IN of) (NP (NNP Doc_6286738_1020_1030_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBP prevent) (NP (NNP Doc_6286738_1044_1054_Disease) (CC and) (NNS doses)) (SBAR (IN that) (S (VP (VB induce) (NP (NNP Doc_6286738_1077_1087_Disease))))))))))))) (, ,) (NP (PRP we)) (VP (VBD concluded) (SBAR (IN that) (S (NP (JJ Doc_6286738_1107_1117_Chemical) (NN cannot)) (VP (AUX be) (VP (VBN used) (ADVP (RB practically)) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_6286738_1156_1166_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN injected) (NP (JJ several) (NNS weeks)) (NP (NN prepartum))))))))))))) (. .)))
6287825	0	(S1 (S (NP (NN Doc_6287825_0_29_Disease)) (ADVP (RB as)) (VP (VBN seen) (PP (IN in) (NP (DT the) (NNP Nigerian) (NNP African)))) (. .)))
6287825	1	(S1 (S (NP (NP (DT The) (JJ anatomical) (CC and) (JJ aetiological) (NNS diagnoses)) (PP (IN of) (NP (NNP Doc_6287825_108_132_Disease))) (PP (VBG excluding) (NP (NP (PRP$ its) (JJ primary) (JJ benign) (CC and) (JJ malignant) (NNS disorders)) (, ,) (VP (ADVP (RB as)) (VBN seen) (PP (IN in) (NP (CD 358) (NNS Nigerians))))))) (VP (AUX are) (VP (VBN presented))) (. .)))
6287825	2	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (DT a) (JJ male) (NN preponderance)))) (CC and) (S (NP (DT the) (JJ peak) (NN incidence)) (VP (AUX is) (PP (IN in) (NP (DT the) (JJ fourth) (NN decade))))) (. .)))
6287825	3	(S1 (S (NP (NN Doc_6287825_305_329_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ commonest) (NN presentation)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-)))) (. .)))
6287825	4	(S1 (S (NP (NN Doc_6287825_368_392_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ commonest) (JJ identifiable) (NN cause)) (PRN (-LRB- -LRB-) (NP (CD 15.6) (NN %)) (-RRB- -RRB-))) (, ,) (S (VP (VBG accounting) (PP (IN for) (NP (NP (NN half)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PP (IN with) (NP (NNP Doc_6287825_477_493_Disease)))))))))) (. .)))
6287825	5	(S1 (S (NP (NP (NN Doc_6287825_495_516_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_6287825_524_546_Disease)) (PP (IN of) (NP (NNP Doc_6287825_550_558_Chemical) (CC and) (NNP Doc_6287825_563_573_Chemical))))))) (VP (VP (AUX was) (ADJP (JJ common)) (PRN (-LRB- -LRB-) (NP (CD 10.1) (NN %)) (-RRB- -RRB-))) (CC and) (VP (VBD presented) (ADVP (RB mainly)) (PP (IN as) (NP (JJ sensory) (CC and) (NNP Doc_6287825_629_653_Disease))))) (. .)))
6287825	6	(S1 (S (NP (NN Doc_6287825_655_672_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NNP Doc_6287825_696_716_Disease))))) (. .)))
6287825	7	(S1 (S (NP (NN Doc_6287825_718_727_Chemical)) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ frequent)) (NN agent)) (PP (IN in) (NP (JJ drug-induced) (NNP Doc_6287825_772_782_Disease))))) (. .)))
6287825	8	(S1 (S (S (NP (NP (NNP Doc_6287825_784_792_Disease)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (RB not) (NP (NP (DT an) (JJ uncommon) (NN cause)) (PP (IN of) (NP (NNP Doc_6287825_828_846_Disease))) (PP (IN although) (NP (NP (NNP Doc_6287825_856_868_Disease)) (VP (VBG arising) (PP (IN from) (NP (DT the) (JJ reticuloendothelial) (NN system))))))))) (CC or) (S (NP (NP (VBN related) (NNS structures)) (PP (IN of) (NP (DT the) (NN head) (CC and) (NN neck)))) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-)))) (. .)))
6287825	9	(S1 (S (PP (IN In) (NP (NP (CD 26.5) (NN %)) (PP (IN of) (NP (PDT all) (DT the) (NNS cases))))) (, ,) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (DT the) (NNP Doc_6287825_1030_1040_Disease)))) (VP (AUX was) (ADJP (JJ undetermined))) (. .)))
6287825	10	(S1 (S (NP (NP (NN Heredofamilial)) (CC and) (NP (NN Doc_6287825_1078_1105_Disease))) (VP (AUX were) (ADJP (JJ rare))) (. .)))
6287825	11	(S1 (S (NP (NP (DT Some)) (PP (IN of) (NP (DT the) (NNS factors))) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ clinical) (NN presentation) (CC and) (NN pathogenesis)) (PP (IN of) (NP (DT the) (NNP Doc_6287825_1198_1210_Disease))))))) (VP (AUX are) (ADVP (RB briefly)) (VP (VBN discussed))) (. .)))
6308277	0	(S1 (NP (NP (NN Reduction)) (PP (IN in) (NP (NNP Doc_6308277_13_21_Chemical) (NNP Doc_6308277_22_30_Disease))) (PP (IN by) (NP (NNP Doc_6308277_34_47_Chemical))) (. .)))
6308277	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (ADVP (RB allegedly)) (VP (VBD consumed) (NP (NP (CD 100) (NNS tablets)) (PP (IN of) (NP (NP (DT an) (JJ over-the-counter) (JJ analgesic)) (VP (VBG containing) (NP (NP (NNP Doc_6308277_138_161_Chemical)) (, ,) (NP (NNP Doc_6308277_163_171_Chemical)) (, ,) (CC and) (NP (NNP Doc_6308277_177_190_Chemical))))))))))) (VP (VBD displayed) (NP (DT no) (JJ significant) (NNS CNS) (NN stimulation)) (PP (IN despite) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (CD 175) (NNS micrograms)) (PP (IN of) (NP (NNP Doc_6308277_274_282_Chemical))) (PP (IN per) (NP (NP (NN mL)) (PP (IN of) (NP (NN serum)))))))))) (. .)))
6308277	2	(S1 (S (SBAR (IN Because) (S (NP (NNS salicylates)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB augment) (NP (NP (DT the) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_6308277_377_385_Chemical))) (PP (IN on) (NP (DT the) (NNS CNS)))))))))))) (, ,) (NP (NN attention)) (VP (AUX was) (VP (VBN focused) (PP (IN on) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_6308277_460_473_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 52) (NN micrograms/mL)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NP (DT the) (NNS CNS) (NN Doc_6308277_509_517_Disease)) (PP (IN of) (NP (NNP Doc_6308277_521_529_Chemical))))))))))) (. .)))
6308277	3	(S1 (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ DBA/2J) (NNS mice)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (: :) (S (LST (LS 1)) (-RRB- -RRB-) (VP (VBP pretreatment) (SBAR (IN with) (S (NP (NP (NNP Doc_6308277_588_601_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBN increased) (NP (NP (DT the) (NN interval)) (PP (IN between) (NP (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6308277_667_675_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 300) (TO to) (CD 450) (CD mg/kg)) (NN IP)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (JJ fatal) (NNP Doc_6308277_721_732_Disease))))))) (PP (IN by) (NP (NP (DT a) (NN factor)) (PP (IN of) (NP (QP (RB about) (CD two))))))))))) (PRN (: ;) (CC and) (NP (CD 2)) (-RRB- -RRB-)) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6308277_784_797_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 75) (NNS mg/kg)) (-RRB- -RRB-))) (VP (VBD reduced) (SBAR (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ audiogenic) (NNP Doc_6308277_845_853_Disease)))) (VP (VBD produced) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_6308277_882_890_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 12.5) (TO to) (CD 75) (CD mg/kg)) (NNS IP)) (-RRB- -RRB-))))))))))))) (. .)))
6308277	4	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (JJ sound-induced) (NNP Doc_6308277_945_953_Disease))) (PP (IN after) (NP (CD 12.5) (CC or) (CD 25)))) (VP (VBD mg/kg) (SBAR (S (NP (NNP Doc_6308277_977_985_Chemical)) (VP (AUX was) (VP (VBN reduced) (PP (IN from) (NP (QP (CD 50) (TO to) (CD 5)) (NN %))) (PP (IN by) (NP (NNP Doc_6308277_1015_1028_Chemical)))))))) (. .)))
6308277	5	(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_6308277_1048_1056_Chemical))))) (, ,) (NP (NP (NNP Doc_6308277_1058_1071_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 300)) (NN mg/kg)) (-RRB- -RRB-))) (VP (VP (AUX did) (RB not) (VP (VB modify) (NP (NP (DT the) (NN Doc_6308277_1109_1117_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ maximal) (NN electroshock))))))) (CC and) (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ convulsant) (NN dose)) (PP (IN of) (NP (NNP Doc_6308277_1191_1208_Chemical))) (PP (IN in) (NP (NP (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (NNS tests)) (VP (VBN performed) (PP (IN by) (NP (NP (DT the) (JJ Anticonvulsant) (NN Screening) (NN Project)) (PP (IN of) (NP (NNS NINCDS))))))) (-RRB- -RRB-)))))))) (. .)))
6308277	6	(S1 (S (NP (NP (NN Doc_6308277_1286_1299_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 150)) (NN micrograms/mL)) (-RRB- -RRB-))) (VP (AUX did) (RB not) (VP (VB retard) (NP (NP (DT the) (NN incorporation)) (PP (IN of) (NP (JJ radioactive) (NNP Doc_6308277_1374_1383_Chemical)))) (PP (IN into) (NP (NNP Doc_6308277_1389_1392_Chemical))) (PP (IN in) (NP (NP (NNS slices)) (PP (IN of) (NP (NN rat) (NN cerebral) (NN cortex))))))) (. .)))
6308277	7	(S1 (S (ADVP (RB Thus)) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_6308277_1455_1468_Chemical)) (VP (VBZ antagonizes) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_6308277_1496_1504_Chemical)))) (PP (IN in) (NP (DT the) (NNS CNS))))))) (VP (VBZ remains) (ADJP (JJ unknown))) (. .)))
6386793	0	(S1 (NP (NP (DT A) (JJ double-blind) (NN study)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_6386793_51_74_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ major) (NN Doc_6386793_101_120_Disease))))))) (. .)))
6386793	1	(S1 (S (PP (IN In) (NP (DT a) (JJ 6-week) (JJ double-blind) (JJ parallel) (NN treatment) (NN study))) (, ,) (NP (NP (NNP Doc_6386793_173_182_Chemical)) (CC and) (NP (NNP Doc_6386793_187_200_Chemical))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (CD 33) (JJ Doc_6386793_249_258_Disease) (NNS outpatients))))))))) (. .)))
6386793	2	(S1 (S (S (NP (NP (NNP Doc_6386793_272_281_Chemical)) (CC and) (NP (NNP Doc_6386793_286_299_Chemical))) (VP (AUX were) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG alleviating) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_6386793_354_372_Disease)))))))))) (, ,) (CC and) (S (NP (DT both)) (VP (AUX were) (ADJP (RB significantly) (JJ superior) (PP (TO to) (NP (NN placebo)))))) (. .)))
6386793	3	(S1 (S (NP (NP (NP (DT The) (JJ overall) (NN incidence)) (PP (IN of) (NP (NN side) (NNS effects)))) (CC and) (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_6386793_495_509_Disease)) (, ,) (NP (NNP Doc_6386793_511_520_Disease)) (, ,) (CC and) (NP (NN drowsiness)))))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR less) (PP (IN with) (NP (NNP Doc_6386793_566_575_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_6386793_586_599_Chemical)))))) (. .)))
6386793	4	(S1 (S (NP (NN Doc_6386793_601_610_Chemical)) (ADVP (RB also)) (VP (VBD produced) (NP (NP (JJR fewer) (NNS CNS)) (CC and) (NP (JJ cardiovascular) (NNS effects)))) (. .)))
6386793	5	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB clinically) (JJ important)) (NNS changes)) (PP (IN in) (NP (NN laboratory) (NNS parameters))))) (. .)))
6386793	6	(S1 (S (NP (NN Doc_6386793_732_741_Chemical)) (ADVP (RB thus)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (JJ Doc_6386793_776_790_Chemical) (NN drug)) (VP (VBN associated) (PP (IN with) (NP (NP (JJR fewer) (NN side) (NNS effects)) (PP (IN than) (NP (NP (NNP Doc_6386793_836_849_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_6386793_870_879_Disease) (NNS outpatients)))))))))))))))) (. .)))
6387529	0	(S1 (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_6387529_22_30_Chemical) (CC and) (NNP Doc_6387529_35_46_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6387529_64_78_Disease)) (CC and) (NP (NNP Doc_6387529_83_94_Disease)))))) (. .)))
6387529	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_6387529_125_133_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 10) (NNS mg)) (CC and) (NP (NP (DT a) (JJ median) (NN dose)) (PP (IN of) (NP (CD 30) (NN mg/day)))))) (PP (IN for) (NP (CD 2) (NNS weeks)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_6387529_204_215_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 80) (NNS mg)) (CC and) (NP (NP (DT a) (JJ median) (NN dose)) (PP (IN of) (NP (CD 240) (NN mg/day)))))) (PP (IN for) (NP (CD 2) (NNS weeks)))) (-RRB- -RRB-))))))) (PP (IN on) (NP (NP (JJ psychological) (NN performance)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (NNP Doc_6387529_329_344_Disease) (CC and) (NNP Doc_6387529_349_360_Disease)))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (CC and) (NN crossover) (NN design))))) (. .)))
6387529	2	(S1 (S (S (NP (DT Both) (NNS drugs)) (VP (VBP Doc_6387529_442_472_Disease))) (CC but) (S (NP (DT the) (NN decrease)) (VP (AUX was) (ADJP (JJR greater) (PP (IN for) (NP (NNP Doc_6387529_506_514_Chemical))) (PP (IN than) (NP (NNP Doc_6387529_520_531_Chemical)))))) (. .)))
6387529	3	(S1 (S (NP (NP (NN Doc_6387529_533_570_Disease)) (CC but) (NP (DT the) (CD two) (NNS drugs))) (VP (AUX did) (RB not) (VP (VB differ))) (. .)))
6387529	4	(S1 (S (NP (NNS Patients)) (VP (VBD tapped) (ADVP (RBR faster)) (PP (IN after) (NP (NNP Doc_6387529_634_645_Chemical))) (SBAR (IN than) (S (NP (NNP Doc_6387529_651_659_Chemical) (CC and) (PRP they)) (VP (AUX were) (ADJP (RBR more) (JJ sedated)) (PP (IN after) (NP (NP (NNP Doc_6387529_693_701_Chemical)) (PP (IN than) (NP (NNP Doc_6387529_707_718_Chemical))))))))) (. .)))
6387529	5	(S1 (S (PP (IN After) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NNS patients)) (VP (VBD tested) (NP (JJ 5-8) (NNP h)) (SBAR (IN after) (S (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN medication)))) (VP (AUX did) (RB not) (VP (VB show) (NP (NP (DT any) (NN decrement)) (PP (IN of) (NP (NN performance))))))))) (. .)))
6387529	6	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN found) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))))) (. .)))
6387529	7	(S1 (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (NNS drugs)))) (VP (AUX was) (RB not) (VP (VBN reflected) (PP (IN in) (NP (JJ prolonged) (NNP Doc_6387529_973_994_Disease))))) (. .)))
6466532	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (NNP i.v.) (NNP Doc_6466532_19_33_Chemical) (CC and) (NNP Doc_6466532_38_46_Chemical)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_6466532_68_79_Disease) (CC and) (NNP Doc_6466532_84_95_Disease) (NN following)))))))) (VP (VBD repeated) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6466532_124_137_Chemical)) (PP (IN in) (NP (NNS children))))))) (. .)))
6466532	1	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_6466532_190_204_Chemical) (CD 5)))) (CC and) (NP (NP (ADJP (ADJP (NP (CD 10) (NNS micrograms)) (JJ kg-1)) (CC and) (ADJP (NP (QP (JJ Doc_6466532_234_242_Chemical) (CD 10) (CC and) (CD 20)) (NNS micrograms)) (JJ kg-1))) (NNS i.v.)) (PP (ADVP (RB immediately)) (IN before) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN anaesthesia)))))))) (, ,) (SBAR (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_6466532_334_344_Disease) (CC and) (NNP Doc_6466532_349_360_Disease) (JJ following) (VBN repeated) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6466532_389_402_Chemical)) (PP (IN in) (NP (NNS children)))))))))) (, ,)) (VP (AUX was) (VP (VBN studied))) (. .)))
6466532	2	(S1 (S (NP (DT A) (NN control) (NN group)) (VP (AUX was) (VP (VBN included) (PP (IN for) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (JJR lower) (NN dose) (NN range)) (PP (IN of) (NP (NP (NNP Doc_6466532_502_516_Chemical)) (CC and) (NP (NNP Doc_6466532_521_529_Chemical)))))))))) (. .)))
6466532	3	(S1 (S (S (NP (NP (DT A) (NN frequency)) (PP (IN of) (NP (NP (NNP Doc_6466532_546_557_Disease)) (PP (IN of) (NP (CD 50) (NN %)))))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (, ,) (CC but) (S (NP (DT this)) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT the) (NN frequency))) (PP (IN with) (NP (DT the) (JJ active) (NNS drugs)))))) (. .)))
6466532	4	(S1 (S (NP (NP (NN Doc_6466532_680_691_Disease)) (PRN (-LRB- -LRB-) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN heart) (NN rate))) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 50)) (NN beat) (NN min-1)))))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN prevented) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJR larger) (NN dose)) (PP (IN of) (NP (DT either) (JJ active) (NN drug)))) (VP (AUX was) (VP (VBN used))))))) (. .)))
6466532	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (S (NP (DT either) (NNP Doc_6466532_854_868_Chemical) (CD 10)) (VP (VBZ micrograms) (ADJP (JJ kg-1)))) (CC or) (S (NP (NNP Doc_6466532_891_899_Chemical) (CD 20)) (VP (VBZ micrograms) (SBAR (S (NP (JJ kg-1) (NNS i.v.)) (VP (MD should) (ADVP (RB immediately)) (VP (VB precede) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (, ,) (PP (IN in) (NP (NNS children)))) (, ,) (SBAR (IN if) (S (NP (NP (DT the) (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_6466532_1024_1037_Chemical)))) (VP (AUX is) (VP (VBN anticipated))))))))))))))) (. .)))
6503301	0	(S1 (NP (NP (NN Doc_6503301_0_28_Disease)) (PP (IN after) (NP (NP (JJ Doc_6503301_35_46_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6503301_56_60_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNP Doc_6503301_66_74_Disease))) (. .)))
6503301	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6503301_86_121_Disease))) (PP (IN with) (NP (JJ fatal) (NN outcome))) (PP (IN after) (NP (NNP Doc_6503301_147_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_6503301_160_164_Chemical)) (-RRB- -RRB-)) (NN therapy))) (PP (IN for) (NP (NNP Doc_6503301_178_186_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
6503301	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ fulminant) (JJ clinical) (NN course)) (PP (IN from) (NP (NP (NN start)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN until) (NP (NNP Doc_6503301_267_272_Disease))))))))) (. .)))
6503301	3	(S1 (S (PP (IN At) (NP (NN autopsy))) (NP (DT the) (NN liver)) (VP (AUX was) (ADJP (ADJP (JJ enlarged)) (CC and) (ADJP (JJ firm))) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_6503301_331_348_Disease)))))) (. .)))
6503301	4	(S1 (S (NP (ADJP (JJ Small-) (CC and) (JJ medium-sized)) (JJ hepatic) (NNS veins)) (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_6503301_404_414_Disease))))) (. .)))
6503301	5	(S1 (S (NP (JJ Eosinophilic) (NNS infiltrations)) (VP (AUX were) (VP (VBN found) (PP (IN around) (NP (DT the) (NNS vessels))))) (. .)))
6503301	6	(S1 (S (S (NP (NP (JJ Published) (NNS cases)) (PP (IN from) (NP (DT the) (NN literature)))) (VP (AUX are) (VP (VBN reviewed)))) (CC and) (S (NP (JJ pertinent) (NNS features)) (VP (VBN discussed))) (. .)))
6518066	0	(S1 (NP (NP (NP (JJ Maternal) (NN Doc_6518066_9_16_Chemical)) (CC and) (NP (JJ neonatal) (NN Doc_6518066_30_47_Disease))) (: :) (NP (NP (NN evaluation)) (PP (IN with) (NP (JJ cross-sectional) (NN echocardiography)))) (. .)))
6518066	1	(S1 (S (NP (JJ Cross-sectional) (NN echocardiography)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (CD two) (NNS neonates)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD ingested) (NP (NNP Doc_6518066_189_196_Chemical)) (PP (IN during) (NP (NN pregnancy)))))))))))) (. .)))
6518066	2	(S1 (S (PP (IN In) (NP (CD one) (NN infant))) (, ,) (NP (NP (NNP Doc_6518066_230_247_Disease)) (PP (IN of) (NP (DT the) (JJ tricuspid) (NN valve)))) (VP (AUX was) (VP (VBN identified))) (. .)))
6518066	3	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (NN infant))) (NP (JJ cross-sectional) (NN echocardiography)) (VP (VBD provided) (NP (NN reassurance)) (SBAR (IN that) (S (NP (DT the) (NN infant)) (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_6518066_390_407_Disease))))))) (. .)))
6518066	4	(S1 (S (NP (NP (JJ Cross-sectional) (JJ echocardiographic) (NN screening)) (PP (IN of) (NP (NP (NNS newborns)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_6518066_476_483_Chemical))) (PP (IN during) (NP (NN gestation))))))) (VP (MD can) (VP (VB provide) (NP (NP (ADJP (RB highly) (JJ accurate)) (, ,) (JJ noninvasive) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NNP Doc_6518066_583_590_Chemical-induced) (NNP Doc_6518066_599_620_Disease)))))))) (. .)))
6534871	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NN training))) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ experimental) (NNP Doc_6534871_50_71_Disease)) (PP (IN in) (NP (VBG aging) (NNS rats))))))) (. .)))
6534871	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN exercise))) (PP (IN on) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_6534871_130_143_Chemical-induced) (NNP Doc_6534871_152_173_Disease)))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (NP (JJ female) (NN albino) (NNS rats)) (PP (IN of) (NP (CD 20,40,60)))) (CC and) (NP (NP (CD 80) (NNS weeks)) (PP (IN of) (NP (NN age)))))))) (. .)))
6534871	2	(S1 (S (NP (DT The) (NNS rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VBP swim) (PP (PP (IN for) (NP (DT a) (JJ specific) (NN duration))) (CC and) (PP (IN for) (NP (DT a) (JJ particular) (NN period))))))))) (. .)))
6534871	3	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP Doc_6534871_343_351_Disease)))) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (JJ histological) (NNS methods))))) (. .)))
6534871	4	(S1 (S (NP (NP (NNS Elevations)) (PP (IN in) (NP (DT the) (NN serum)))) (VP (VP (VBD GOT)) (CC and) (VP (VBD GPT) (SBAR (S (VP (AUX were) (ADJP (JJ maximum)) (PP (IN in) (NP (NP (DT the) (NN sedentary-Doc_6534871_458_472_Chemical) (CC and) (NN minimum)) (PP (IN in) (NP (DT the) (NNS exercise-controls)))))))))) (. .)))
6534871	5	(S1 (S (NP (NP (DT These) (NNS changes)) (PP (IN in) (NP (DT the) (JJ serum) (NNS transaminases)))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (JJ corresponding) (NNS depletions)) (PP (IN in) (NP (DT the) (JJ cardiac) (NNP GOT) (CC and) (NNP GPT))))))) (. .)))
6534871	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NN age)) (VP (AUX was) (VP (VBN seen) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NNS responses)) (VP (VBN exhibited) (PP (IN by) (NP (DT the) (JJ young) (CC and) (JJ old) (NNS rats))))))))))) (. .)))
6534871	7	(S1 (S (NP (NP (NNS Studies)) (VP (VBG dealing) (PP (IN with) (NP (NNP Doc_6534871_738_759_Disease))))) (VP (AUX are) (ADJP (RBR more) (JJ informative)) (SBAR (WHADVP (WRB when)) (S (VP (VBN dealt) (PP (IN with) (NP (NN age))))))) (. .)))
6538499	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6538499_10_33_Chemical))) (PP (IN on) (NP (NP (NNP Doc_6538499_37_47_Chemical) (NNP Doc_6538499_48_56_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
6538499	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ organic) (JJ solvent)) (, ,) (NP (NP (NNP Doc_6538499_111_134_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6538499_136_143_Chemical)) (-RRB- -RRB-))) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ toxic) (NN action)) (PP (IN of) (NP (NP (DT an) (ADJP (ADJP (JJ acute)) (CC or) (ADJP (JJ chronic))) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6538499_204_214_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6538499_216_219_Chemical)) (-RRB- -RRB-))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNS mice))))) (. .)))
6538499	2	(S1 (S (NP (NN Doc_6538499_244_251_Chemical)) (ADVP (RB impressively)) (VP (VBD decreased) (NP (NP (DT both) (JJ acute) (NN high-dose)) (CC and) (NP (JJ chronic) (JJ low-dose-Doc_6538499_317_320_Chemical-associated) (NN lethality)))) (. .)))
6538499	3	(S1 (S (NP (JJ Light) (JJ microscopic) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN protection)) (PP (IN against) (NP (NNP Doc_6538499_410_413_Chemical-induced) (NNP Doc_6538499_422_455_Disease))))) (. .)))
6538499	4	(S1 (S (NP (JJ Such) (NN treatment)) (VP (AUX did) (RB not) (VP (VB diminish) (NP (NP (DT the) (JJ Doc_6538499_493_496_Chemical) (NN antitumor) (NN activity)) (PP (PP (IN in) (NP (NNP Doc_6538499_519_533_Disease))) (CC and) (PP (IN in) (NP (NNP Doc_6538499_541_562_Disease))))))) (. .)))
6634932	0	(S1 (NP (NP (NP (JJ Sublingual) (NN absorption)) (PP (IN of) (NP (DT the) (JJ Doc_6634932_29_48_Chemical) (JJ antiarrhythmic) (NN agent)))) (, ,) (NP (NNP Doc_6634932_71_77_Chemical)) (. .)))
6634932	1	(S1 (S (NP (NP (NP (NNP Doc_6634932_79_85_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6634932_87_110_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ quaternary) (JJ antiarrhythmic) (NN agent)) (, ,)) (VP (AUX was) (VP (VBN administered) (ADVP (RB sublingually)) (PP (TO to) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_6634932_191_198_Chemical-induced) (NNP Doc_6634932_207_231_Disease))))))) (. .)))
6634932	2	(S1 (S (NP (CC Both) (NP (JJ anti-arrhythmic) (NN efficacy)) (CC and) (NP (NN bioavailability))) (VP (AUX were) (PP (VBN compared) (PP (TO to) (NP (JJ oral) (NN drug))))) (. .)))
6634932	3	(S1 (S (NP (NNP Sublingual) (NNP Doc_6634932_322_328_Chemical)) (VP (VBD converted) (NP (NNP Doc_6634932_339_362_Disease)) (PP (TO to) (NP (JJ sinus) (NN rhythm))) (PP (IN in) (NP (DT all) (CD 5) (NNS dogs)))) (. .)))
6634932	4	(S1 (S (NP (NP (DT The) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration) (NN time) (NN curve))) (PP (IN at) (NP (CD 90) (NN min)))) (VP (AUX was) (ADJP (ADJP (QP (CD 4-12) (NNS times)) (JJR greater)) (PP (IN than) (PP (IN for) (NP (JJ oral) (NN drug))))) (, ,) (S (VP (VP (VBG suggesting) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT an) (JJ absorption-limiting) (NN process)) (PP (IN in) (NP (DT the) (NN intestine))))))) (, ,) (CC and) (VP (VBG providing) (NP (NP (DT an) (JJ alternate) (NN form)) (PP (IN of) (NP (NP (NN administration)) (PP (IN for) (NP (JJ quaternary) (NNS drugs)))))))))) (. .)))
6640832	0	(S1 (S (NP (JJ Early) (NN adjuvant)) (VP (NNP Doc_6640832_15_25_Chemical) (PP (IN in) (NP (JJ superficial) (NNP Doc_6640832_41_58_Disease)))) (. .)))
6640832	1	(S1 (S (NP (DT A) (NN multicenter) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (CD 110) (NNS patients))) (PP (IN with) (NP (JJ superficial) (JJ transitional) (NN cell) (NN Doc_6640832_145_169_Disease))))) (. .)))
6640832	2	(S1 (S (NP (NP (NN Doc_6640832_171_181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg/50)) (NN ml)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravesically)) (PP (IN within) (NP (NP (CD 24) (NNP h)) (PP (IN after) (NP (NP (JJ transurethral) (NN resection)) (PP (IN of) (NP (NNP TA-T1) (PRN (-LRB- -LRB-) (NP (NNP O-A)) (-RRB- -RRB-)) (NNP Doc_6640832_285_299_Disease))))))))) (. .)))
6640832	3	(S1 (S (NP (NN Instillation)) (VP (AUX was) (VP (VP (VBN repeated) (ADVP (RB twice)) (PP (IN during) (NP (DT the) (JJ first) (NN week)))) (, ,) (VP (ADVP (RB then)) (JJ weekly) (PP (IN during) (NP (DT the) (JJ first) (NN month)))) (CC and) (VP (ADVP (RB afterwards)) (JJ monthly) (PP (IN for) (NP (CD 1) (NN year)))))) (. .)))
6640832	4	(S1 (S (S (NP (DT The) (NN tolerance)) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (DT these) (CD 110) (NNS patients)))))) (, ,) (CC and) (S (NP (CD 29) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (JJ local) (NNS side-effects))))) (. .)))
6640832	5	(S1 (S (PP (IN In) (NP (NP (CD 24)) (PP (IN of) (NP (DT these) (NNS patients))))) (NP (JJ chemical) (NNP Doc_6640832_561_569_Disease)) (VP (AUX was) (ADJP (JJ severe) (RB enough) (SBAR (IN for) (S (NP (PRP them)) (VP (TO to) (VP (VB drop) (PP (IN out) (PP (IN of) (NP (DT the) (NN study)))))))))) (. .)))
6640832	6	(S1 (S (NP (DT No) (JJ systemic) (NNS side-effects)) (VP (AUX were) (VP (VBN observed))) (. .)))
6640832	7	(S1 (S (NP (NN Recurrence)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 82) (JJ evaluable) (NNS patients))) (PP (PP (IN after) (NP (NP (CD 1) (NN year)) (PP (IN of) (NP (NN follow-up))))) (CC and) (PP (IN in) (NP (NP (CD 72) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (NP (CD 2-3) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 32) (NNS months)) (-RRB- -RRB-)))))))))) (. .)))
6640832	8	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 82) (NNS patients)) (VP (VBN studied) (PP (IN after) (NP (CD 1) (NN year)))))) (, ,) (NP (CD 23)) (VP (AUX had) (NP (NP (NN primary)) (CC and) (NP (CD 59) (NN recurrent) (NN disease)))) (. .)))
6640832	9	(S1 (S (PP (IN Of) (NP (DT the) (CD 82) (JJ evaluable) (NNS patients))) (, ,) (NP (CD 50)) (VP (AUX did) (RB not) (VP (VB show) (NP (DT any) (NN recurrence)) (PP (IN after) (NP (NP (CD 1) (NN year)) (PRN (-LRB- -LRB-) (NP (CD 61) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN while) (NP (NP (CD 32)) (VP (VBN presented) (PP (IN with) (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS recurrences)) (PRN (-LRB- -LRB-) (NP (CD 39) (NN %)) (-RRB- -RRB-))))))))) (. .)))
6640832	10	(S1 (S (PP (IN Of) (NP (DT these) (NNS recurrences))) (, ,) (NP (CD 27)) (VP (AUX were) (NP (NNP T1) (NNP Doc_6640832_1048_1054_Disease)) (SBAR (IN while) (S (NP (CD five)) (VP (VBD progressed) (PP (TO to) (NP (RBR more) (ADJP (RB highly) (JJ invasive)) (NNS lesions))))))) (. .)))
6640832	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ free) (PP (IN of) (NP (NN recurrence)))) (PP (IN during) (NP (DT the) (JJ first) (NN year)))))))) (, ,) (NP (CD 80) (NN %)) (VP (VBD remained) (ADJP (JJ Doc_6640832_1187_1192_Disease-free)) (PP (IN during) (NP (DT the) (ADJP (JJ 2-) (TO to) (JJ 3-year)) (JJ follow-up) (NN period)))) (. .)))
6640832	12	(S1 (S (PP (IN Of) (NP (NP (DT the) (NNS patients)) (VP (VBG developing) (NP (QP (CD one) (CC or) (JJR more)) (NNS recurrences)) (PP (IN during) (NP (DT the) (JJ first) (NN year)))))) (, ,) (NP (QP (RB only) (CD 50)) (NN %)) (VP (VBD presented) (PP (IN with) (NP (JJ further) (NN recurrence))) (SBAR (IN once) (S (NP (DT the) (NNS instillations)) (VP (AUX were) (VP (VBN stopped)))))) (. .)))
6640832	13	(S1 (S (NP (NP (DT The) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_6640832_1419_1429_Chemical)))) (VP (VP (VBZ appears) (ADJP (JJ obvious))) (CC and) (VP (MD might) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (NP (DT the) (NN drug)) (NP (PRP itself))) (, ,) (NP (NP (DT the) (JJ early) (CC and) (JJ repeated) (NNS instillations)) (PP (IN after) (NP (NN TUR)))) (, ,) (CC or) (NP (DT both)))))))) (. .)))
6666578	0	(S1 (NP (NP (JJ Doc_6666578_0_15_Chemical-induced) (NN Doc_6666578_24_34_Disease)) (PP (IN in) (NP (NNS rats))) (. .)))
6666578	1	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ high) (NN dose) (NN Doc_6666578_68_83_Chemical) (NN treatment))) (PP (PP (IN on) (NP (NP (JJ aortic) (NN permeability)) (PP (TO to) (NP (NN albumin))))) (CC and) (PP (IN on) (NP (NP (DT the) (NN ultrastructure)) (PP (IN of) (NP (DT the) (NN vessel)))))) (. .)))
6666578	2	(S1 (S (NP (JJ Male) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_6666578_212_227_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6666578_229_234_Chemical)) (-RRB- -RRB-)))) (NP (CD 500) (NN mg/kg/day)) (PP (IN for) (NP (QP (CD 10) (CC or) (CD 42)) (NNS days))))) (. .)))
6666578	3	(S1 (S (NP (NN Pair) (NN fed) (NNS rats)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
6666578	4	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ aortic) (NNS morphology)))) (VP (AUX were) (VP (VBN examined) (PP (IN by) (NP (NP (NN light-)) (CC and) (NP (NP (JJ transmission-electron) (NN microscopy)) (PRN (-LRB- -LRB-) (NP (NNP TEM)) (-RRB- -RRB-))))))) (. .)))
6666578	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (JJ endothelial) (NN permeability)) (CC and) (NP (NP (DT the) (NN penetration)) (PP (IN through) (NP (NP (DT the) (JJ aortic) (NN wall)) (PP (IN of) (NP (NN albumin))))))) (VP (AUX were) (VP (VBN studied) (NP (NP (CD 10) (NNS minutes)) (, ,) (NP (CD 24) (CC and) (CD 48) (NNS hours))) (PP (IN after) (NP (NP (NN i.) (CC v.) (NN injection)) (PP (IN of) (NP (JJ human) (NN serum) (NN 131I-albumin))))) (PRN (-LRB- -LRB-) (FW 131I-HSA) (-RRB- -RRB-)))) (. .)))
6666578	6	(S1 (S (NP (NN TEM)) (VP (VBD revealed) (NP (NP (JJ extensive) (NN elastolysis)) (PP (IN in) (NP (NP (DT the) (JJ arterial) (NN wall)) (PP (IN of) (NP (JJ Doc_6666578_659_664_Chemical-treated) (NNS rats))))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NN crosslink) (NN formation)))))))) (. .)))
6666578	7	(S1 (S (PP (IN In) (NP (JJ experimental) (NNS animals))) (NP (NP (JJ excess) (NN deposition)) (PP (IN of) (NP (NN collagen) (CC and) (NNS glycoaminoglycans)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (ADJP (JJ subendothelial) (CC and) (JJ medial)) (NN layer)) (PP (IN of) (NP (DT the) (JJ aortic) (NN wall))))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (JJ prominent) (JJ basal) (NN membrane) (NN substance)) (PP (IN around) (NP (JJ aortic) (JJ smooth) (NN muscle) (NNS cells))))))) (. .)))
6666578	8	(S1 (S (NP (NP (DT The) (NN aorta/serum-ratio)) (CC and) (NP (NP (DT the) (JJ radioactive) (NN build-up)) (PP (NP (CD 24) (CC and) (CD 48) (NNS hours)) (IN after) (NP (NN injection))) (PP (IN of) (NP (FW 131I-HSA))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6666578_1103_1108_Chemical))) (PP (IN for) (NP (CD 42) (NNS days)))))) (, ,) (S (VP (VBG indicating) (NP (NP (DT an) (VBN impeded) (JJ transmural) (NN transport)) (PP (IN of) (NP (NNP tracer))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (JJ steric) (NN exclusion) (NN effect)) (PP (IN of) (NP (JJ abundant) (NNP Doc_6666578_1236_1247_Chemical))))))))))))))) (. .)))
6666578	9	(S1 (S (S (NP (DT The) (JJ endothelial) (NN ultrastructure)) (VP (AUX was) (ADJP (JJ unaffected)) (PP (IN by) (NP (NNP Doc_6666578_1298_1303_Chemical))))) (, ,) (CC and) (S (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ aortic) (JJ 131I-HSA) (NN radioactivity)) (CC or) (NP (NN aorta/serum-ratio))))) (VP (AUX were) (VP (VBN recorded) (PP (IN between) (NP (UCP (JJ experimental) (CC and) (NN control)) (NNS groups))) (SBAR (NP (CD 10) (NNS minutes)) (IN after) (S (NP (NNP tracer)) (VP (NN injection) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (NN permeability)) (PP (IN of) (NP (NP (DT the) (JJ endothelial) (NN barrier)) (PP (TO to) (NP (NN albumin)))))) (VP (VBD remained) (ADJP (JJ unaffected)) (PP (IN by) (NP (JJ Doc_6666578_1561_1566_Chemical) (NN treatment)))))))))))))) (. .)))
6666578	10	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_6666578_1654_1659_Chemical)))))) (VP (MD may) (VP (VB induce) (NP (DT a) (JJ fibroproliferative) (NN response)) (PP (IN in) (NP (NN rat) (NN aorta))) (, ,) (PP (ADVP (RB possibly)) (IN by) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN cross-linking)) (PP (IN of) (NP (NN collagen) (CC and) (NN elastin))))))))))))) (. .)))
6692345	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6692345_10_17_Chemical))) (PP (IN on) (NP (NP (JJ Doc_6692345_21_66_Chemical-induced) (JJ epithelial) (NN proliferation)) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder) (CC and) (NN forestomach)) (PP (IN of) (NP (DT the) (NN rat))))))) (. .)))
6692345	1	(S1 (S (NP (NP (DT The) (NN co-administration)) (PP (IN of) (NP (NNP Doc_6692345_176_183_Chemical))) (PP (IN with) (NP (NP (NNP Doc_6692345_189_234_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6692345_236_241_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (VBN reduced) (NN incidence)) (PP (IN of) (NP (JJ Doc_6692345_286_291_Chemical-induced) (NN Doc_6692345_300_318_Disease)))) (CC but) (NP (NP (DT a) (JJ concomitant) (NN induction)) (PP (IN of) (NP (NNP Doc_6692345_350_368_Disease))))))) (. .)))
6692345	2	(S1 (S (NP (DT An) (JJ autoradiographic) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (JJ male) (JJ F-344) (NNS rats)) (VP (VBN fed) (NP (NP (NN diet)) (VP (VBG containing) (NP (NNP Doc_6692345_449_454_Chemical)) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (ADJP (CD 0.2) (NN %)) (NN and/or) (NN Doc_6692345_481_488_Chemical))))))) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (CD 0.5) (NN %))))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_6692345_534_541_Chemical)))) (PP (IN on) (NP (NP (DT the) (VBN increased) (NN cell) (NN proliferation)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6692345_589_594_Chemical))) (PP (IN in) (NP (DT the) (NN forestomach) (CC and) (NN bladder)))))))))))))) (. .)))
6692345	3	(S1 (S (NP (NP (JJ Doc_6692345_627_632_Chemical-induced) (NN cell) (NN proliferation)) (PP (IN in) (NP (DT the) (NN bladder)))) (VP (AUX was) (UCP (VP (ADVP (RB significantly)) (VBN suppressed) (PP (IN by) (NP (JJ Doc_6692345_707_714_Chemical) (NN co-administration))) (PP (IN after) (NP (CD 4) (NNS weeks)))) (CC but) (RB not) (PP (IN after) (NP (CD 12) (NNS weeks))))) (. .)))
6692345	4	(S1 (S (PP (PP (IN In) (NP (DT the) (NN forestomach))) (, ,) (CC and) (ADVP (RB also)) (PP (IN in) (NP (DT the) (NN liver)))) (, ,) (NP (NNP Doc_6692345_814_821_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ Doc_6692345_841_846_Chemical-induced) (NN increase)) (PP (IN in) (S (VP (VBG labeling) (NP (NN index)))))))) (. .)))
6692345	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN carcinogenicity) (NN experiment)) (VP (VBG suggesting) (SBAR (SBAR (IN that) (S (NP (JJ different) (NNS mechanisms)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_6692345_1007_1012_Chemical) (NNP Doc_6692345_1013_1027_Disease)) (PP (IN in) (NP (DT the) (NN bladder) (CC and) (NN forestomach))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_6692345_1069_1076_Chemical) (POS 's)) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_6692345_1089_1094_Chemical)) (PP (IN in) (NP (DT the) (NN forestomach)))))) (VP (AUX is) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (JJ irritant) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN cell) (NN proliferation)))))))))))))))) (. .)))
6692345	6	(S1 (S (ADVP (RB Also)) (, ,) (NP (EX there)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (NN adaptation)) (PP (IN by) (NP (NP (DT the) (NNS rats)) (PP (TO to) (NP (NP (DT the) (JJ chronic) (NN ingestion)) (PP (IN of) (NP (NN Doc_6692345_1273_1280_Chemical)))))))))))) (. .)))
6727060	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6727060_10_28_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_6727060_39_53_Chemical)))) (. .)))
6727060	1	(S1 (S (NP (NN Doc_6727060_55_85_Disease)) (VP (VBD appeared) (PP (IN in) (NP (NP (DT the) (NN mouth) (, ,) (NN tongue) (, ,) (NN neck) (CC and) (NN abdomen)) (PP (IN of) (NP (DT a) (JJ 64-year-old) (JJ male) (NN patient))))) (SBAR (IN after) (S (NP (PRP he)) (VP (VBD took) (NP (NNP Doc_6727060_178_192_Chemical)) (PP (IN for) (NP (NNP Doc_6727060_197_222_Disease))) (PP (IN in) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NP (CD 30) (NNS mg)) (PP (IN per) (NP (NN day))))) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (QP (RB about) (CD 260)) (NNS days))))))))))) (. .)))
6727060	2	(S1 (S (NP (DT The) (NNS symptoms)) (VP (VBD exacerbated) (PP (TO to) (NP (DT a) (NN maximum))) (PP (IN in) (NP (DT a) (NN month)))) (. .)))
6727060	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6727060_343_357_Chemical) (NN administration)) (VP (AUX was) (VP (VBN discontinued))))) (, ,) (NP (DT the) (NN Doc_6727060_395_413_Disease)) (ADVP (RB gradually)) (VP (VBD improved) (PP (TO to) (NP (DT a) (JJ considerable) (NN extent)))) (. .)))
6727060	4	(S1 (S (NP (NP (NN Attention)) (PP (TO to) (NP (NP (DT the) (JJ possible) (NN induction)) (PP (IN of) (NP (JJ specific) (NNP Doc_6727060_507_525_Disease)))))) (VP (AUX is) (VP (VBN called) (PP (IN for)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))) (. .)))
6747681	0	(S1 (S (NP (JJ Intra-arterial) (NNP Doc_6747681_15_19_Chemical)) (VP (VBZ chemotherapy) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_6747681_50_67_Disease)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))) (. .)))
6747681	1	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (JJ rapid) (JJ systemic) (NN clearance)) (PP (IN of) (NP (NP (NNP Doc_6747681_142_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6747681_148_185_Chemical)) (-RRB- -RRB-)))))) (, ,) (NP (JJ intra-arterial) (NN administration)) (VP (MD should) (VP (VB provide) (NP (NP (DT a) (JJ substantial) (NN advantage)) (PP (IN over) (NP (NP (JJ intravenous) (NN administration)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_6747681_310_327_Disease)))))))))) (. .)))
6747681	2	(S1 (S (NP (JJ Thirty-six) (NNS patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_6747681_367_371_Chemical) (QP (DT every) (CD 6) (TO to) (CD 8)) (NNS weeks))) (, ,) (PP (CC either) (PP (IN by) (NP (NP (JJ transfemoral) (NN catheterization)) (PP (IN of) (NP (NP (DT the) (JJ internal) (NN carotid)) (CC or) (NP (JJ vertebral) (NN artery)))))) (CC or) (PP (IN through) (NP (DT a) (ADJP (RB fully) (JJ implantable)) (NN intracarotid) (NN drug) (NN delivery) (NN system)))) (, ,) (PP (VBG beginning) (PP (IN with) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 200) (JJ mg/sq) (NNP m) (NN body) (NN surface) (NN area)))))))) (. .)))
6747681	3	(S1 (S (NP (NP (CD Twelve) (NNS patients)) (PP (IN with) (NP (NP (NNP Grade) (NNP III)) (CC or) (NP (NNP IV) (NNP Doc_6747681_634_646_Disease))))) (VP (AUX were) (VP (VBN treated) (PP (IN after) (NP (NP (JJ partial) (NN resection)) (PP (IN of) (NP (DT the) (NNP Doc_6747681_691_696_Disease))))) (PP (IN without) (NP (JJ prior) (NN radiation) (NN therapy))))) (. .)))
6747681	4	(S1 (S (PP (IN After) (NP (NP (QP (CD two) (TO to) (CD seven)) (NNS cycles)) (PP (IN of) (NP (NN chemotherapy))))) (, ,) (NP (CD nine) (NNS patients)) (VP (VBD showed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_6747681_808_813_Disease) (NN size)) (CC and) (NP (VBG surrounding) (NN Doc_6747681_835_840_Disease)))) (PP (IN on) (NP (JJ contrast-enhanced) (JJ computerized) (NN tomography) (NNS scans))))) (. .)))
6747681	5	(S1 (S (PP (IN In) (NP (DT the) (CD nine) (NNS responders))) (, ,) (NP (NP (JJ median) (NN duration)) (PP (IN of) (NP (JJ chemotherapy) (NN response))) (PP (IN from) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN operation)))))) (VP (AUX was) (NP (NP (CD 25) (NNS weeks)) (PRN (-LRB- -LRB-) (VP (VBP range) (NP (CD 12)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 91)) (NNS weeks)))) (-RRB- -RRB-)))) (. .)))
6747681	6	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NN survival))) (PP (IN in) (NP (DT the) (CD 12) (NNS patients)))) (VP (AUX was) (NP (NP (CD 54) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NP (NN range) (CD 21)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 156)) (NNS weeks)))) (-RRB- -RRB-))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ 18-month) (NN survival) (NN rate)) (PP (IN of) (NP (CD 42) (NN %)))))) (. .)))
6747681	7	(S1 (S (NP (NP (JJ Twenty-four) (NNS patients)) (PP (IN with) (NP (JJ recurrent) (NNP Grade) (NNP I))) (PP (TO to) (NP (NP (NNP IV) (NNP Doc_6747681_1220_1232_Disease)) (, ,) (SBAR (WHNP (WP$ whose) (NN resection) (CC and) (NN irradiation) (NN therapy)) (S (VP (AUX had) (VP (VBN failed))))) (, ,)))) (VP (VBD received) (NP (NP (QP (CD two) (TO to) (CD eight)) (NNS courses)) (PP (IN of) (NP (JJ intra-arterial) (JJ Doc_6747681_1334_1338_Chemical) (NN therapy))))) (. .)))
6747681	8	(S1 (S (NP (NP (CD Seventeen)) (PP (IN of) (NP (DT these)))) (VP (VP (AUX had) (NP (DT a) (NN response))) (CC or) (VP (AUX were) (ADJP (JJ stable)) (PP (IN for) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (NP (CD 20) (NNS weeks)) (PRN (-LRB- -LRB-) (VP (VBP range) (NP (CD 6)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 66)) (NNS weeks)))) (-RRB- -RRB-)))))))) (. .)))
6747681	9	(S1 (S (NP (DT The) (NN catheterization) (NN procedure)) (VP (AUX is) (ADJP (JJ safe)) (, ,) (PP (IN with) (NP (NP (DT no) (JJ immediate) (NN complication)) (PP (IN in) (NP (NP (CD 111) (NNS infusions)) (PP (IN of) (NP (NNP Doc_6747681_1545_1549_Chemical)))))))) (. .)))
6747681	10	(S1 (S (NP (NP (DT A) (JJ delayed) (NN complication)) (PP (IN in) (NP (CD nine) (NNS patients)))) (VP (AUX has) (VP (AUX been) (NP (NP (JJ unilateral) (NN Doc_6747681_1611_1625_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (DT a) (NN Doc_6747681_1641_1659_Disease))))))) (. .)))
6747681	11	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NNP Doc_6747681_1678_1689_Disease)))) (VP (VBD decreased) (SBAR (IN after) (S (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (JJ Doc_6747681_1731_1738_Chemical) (NN diluent)))) (VP (AUX was) (VP (VBN lowered)))))) (. .)))
6773726	0	(S1 (NP (NP (NN Provocation)) (PP (IN of) (NP (JJ postural) (NNP Doc_6773726_24_35_Disease))) (PP (IN by) (NP (NP (NNP Doc_6773726_39_52_Chemical)) (PP (IN in) (NP (NNP Doc_6773726_56_85_Disease))))) (. ?)))
6773726	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_6773726_101_114_Chemical))) (PP (IN on) (NP (NP (NN heart) (NN rate)) (CC and) (NP (JJ systolic) (NN blood) (NN pressure))))) (VP (AUX was) (VP (VBN compared) (PP (IN in) (NP (NP (CD 5) (JJ normal) (NNS subjects)) (, ,) (NP (NP (CD 12) (JJ Doc_6773726_195_203_Disease) (NNS subjects)) (PP (IN without) (NP (NNP Doc_6773726_221_241_Disease)))) (, ,) (CC and) (NP (NP (CD 5) (JJ Doc_6773726_249_257_Disease) (NNS subjects)) (PP (IN with) (NP (NNP Doc_6773726_272_292_Disease)))))))) (. .)))
6773726	2	(S1 (S (NP (NP (DT The) (NN magnitude) (CC and) (NN time) (NN course)) (PP (IN of) (NP (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (JJ systolic) (NN blood) (NN pressure)))))) (PP (IN after) (NP (NNP Doc_6773726_404_417_Chemical)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN in) (NP (NP (DT the) (JJ normal) (CC and) (JJ Doc_6773726_449_457_Disease) (NNS subjects)) (PP (IN without) (NP (NNP Doc_6773726_475_495_Disease)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (DT a) (JJR lesser) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate)))) (CC and) (NP (NP (DT a) (JJR greater) (NN decrease)) (PP (IN in) (NP (JJ systolic) (NN blood) (NN pressure))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (JJ Doc_6773726_603_611_Disease) (NNS subjects)) (PP (IN with) (NP (NNP Doc_6773726_626_646_Disease))))))))) (. .)))
6773726	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN caution)) (VP (MD should) (VP (AUX be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NN vasodilator) (NNS drugs)) (PP (IN in) (NP (NP (JJ Doc_6773726_745_753_Disease) (NNS patients)) (, ,) (ADVP (RB particularly)) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_6773726_788_808_Disease)))))))))))))))) (. .)))
6861444	0	(S1 (S (NP (NN Blood)) (VP (VBP pressure) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ chronic) (JJ low-dose) (JJ intrarenal) (JJ Doc_6861444_55_68_Chemical) (NN infusion)) (PP (IN in) (NP (JJ conscious) (NNS rats))))))) (. .)))
6861444	1	(S1 (S (NP (NP (JJ Doc_6861444_97_112_Chemical) (NN solution)) (PRN (-LRB- -LRB-) (NP (CD 0.9) (NN %)) (-RRB- -RRB-)) (CC or) (NP (NP (NNP Doc_6861444_132_145_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 4) (, ,) (CD 12) (CC and) (CD 36) (NNS micrograms)))))) (JJ h-1) (JJ kg-1)) (VP (AUX was) (VP (VBN infused) (PP (IN for) (NP (CD five) (JJ consecutive) (NNS days))) (, ,) (ADVP (ADVP (RB either) (RB intrarenally) (-LRB- -LRB-) (PP (IN by) (NP (DT a) (JJ new) (NN technique))) (-RRB- -RRB-)) (CC or) (ADVP (RB intravenously))) (PP (IN into) (NP (NNS rats))) (PP (IN with) (NP (NP (CD one) (NN kidney)) (VP (VBN removed)))))) (. .)))
6861444	2	(S1 (S (NP (NP (JJ Intrarenal) (NN infusion)) (PP (IN of) (NP (NNP Doc_6861444_346_359_Chemical)))) (VP (VBD caused) (NP (NN Doc_6861444_367_379_Disease)) (PP (IN at) (NP (NP (NNS doses)) (SBAR (WHNP (WDT which)) (S (VP (AUX did) (RB not) (VP (AUX do) (ADVP (RB so)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN infused) (ADVP (RB intravenously)))))) (. .)))
6861444	3	(S1 (S (NP (NP (NN Intrarenal)) (VP (VBN compared) (PP (IN with) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_6861444_486_499_Chemical))))))) (VP (VBD caused) (NP (NP (JJR higher) (NN plasma) (NN Doc_6861444_521_534_Chemical) (NNS concentrations)) (CC and) (NP (NP (DT a) (NN shift)) (PP (IN of) (NP (DT the) (NN plasma) (JJ Doc_6861444_576_589_Chemical) (NN concentration-blood) (NN pressure) (NN effect) (NN curve))) (PP (IN towards) (NP (JJR lower) (NN plasma) (JJ Doc_6861444_653_666_Chemical) (NNS levels)))))) (. .)))
6861444	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_6861444_702_714_Disease)) (PP (IN after) (NP (JJ chronic) (JJ intrarenal) (JJ Doc_6861444_740_753_Chemical) (NN infusion)))) (VP (AUX is) (VP (VBN produced) (PP (PP (IN by) (NP (NP (ADJP (RB relatively) (JJR higher)) (NNS levels)) (PP (IN of) (NP (VBG circulating) (NNP Doc_6861444_818_831_Chemical))))) (CC and) (PP (IN by) (NP (NP (VBG triggering)) (PP (IN of) (NP (DT an) (JJ additional) (NN intrarenal) (NN pressor) (NN mechanism))))))))))) (. .)))
6888657	0	(S1 (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (NNP Doc_6888657_20_28_Chemical-induced) (NNP Doc_6888657_37_60_Disease)) (PP (IN in) (NP (DT the) (NNP Fischer) (CD 344) (NN rat))))) (. .)))
6888657	1	(S1 (S (NP (NN Doc_6888657_85_101_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN in) (NP (CD F344) (JJ female) (NNS rats))) (PP (IN by) (NP (NP (JJ chronic) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6888657_161_179_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_6888657_181_184_Chemical)) (, ,) (NP (CD 8-10) (NN mg))) (-RRB- -RRB-)))) (VP (VBN implanted) (ADVP (RB subcutaneously)) (PP (IN in) (NP (JJ silastic) (NNS capsules)))))))) (. .)))
6888657	2	(S1 (S (PP (IN Over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (CD 1-150) (NNS days)) (PP (IN of) (NP (JJ Doc_6888657_272_275_Chemical) (NN treatment))))))) (, ,) (S (NP (NP (NNS pairs)) (PP (IN of) (NP (NP (NN control)) (CC and) (NP (JJ Doc_6888657_308_311_Chemical-treated) (NNS rats))))) (VP (AUX were) (VP (VBN sacrificed)))) (, ,) (CC and) (S (NP (PRP$ their) (NNS pituitaries)) (VP (VBD dissociated) (ADVP (RB enzymatically)) (PP (IN into) (NP (JJ single-cell) (NNS preparations))))) (. .)))
6888657	3	(S1 (S (NP (DT The) (NN cell) (NNS populations)) (VP (AUX were) (VP (VBN examined) (PP (VBG regarding) (NP (NP (JJ total) (NN cell) (NN recovery)) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ gland) (NN weight)) (, ,) (NP (JJ intracellular) (NN prolactin) (PRN (-LRB- -LRB-) (NNP PRL) (-RRB- -RRB-)) (NN content)) (CC and) (NP (NP (JJ subsequent) (NN release)) (PP (IN in) (NP (NP (JJ primary) (NN culture)) (, ,) (NP (JJ immunocytochemical) (NN PRL) (NN staining)) (, ,) (NP (NP (NN density) (NN and/or) (NN size) (NNS alterations)) (PP (IN via) (NP (NP (NN separation)) (PP (PP (IN on) (NP (NNP Ficoll-Hypaque))) (CC and) (PP (IN by) (NP (NN unit) (NN gravity) (NN sedimentation))))))) (, ,) (CC and) (NP (NN cell) (NN cycle) (NN analysis)) (, ,)))))) (PP (IN after) (NP (JJ Doc_6888657_761_772_Chemical) (NN DNA) (NN staining))) (, ,) (PP (IN by) (NP (NN laser) (NN flow) (NN cytometry)))))))) (. .)))
6888657	4	(S1 (S (NP (NP (JJ Total) (NN cell) (NNS yields)) (PP (IN from) (NP (JJ Doc_6888657_835_838_Chemical-treated) (NNS pituitaries)))) (VP (VBN increased) (PP (IN from) (NP (QP (CD 1.3) (NNS times)) (NN control) (NNS yields))) (PP (IN at) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (TO to) (NP (QP (CD 58.9) (NNS times)) (NN control) (NNS values))) (PP (IN by) (NP (NN day) (CD 150)))) (. .)))
6888657	5	(S1 (S (S (NP (JJ Intracellular) (NN PRL) (NN content)) (VP (VBN ranged) (PP (IN from) (NP (QP (CD 1.9) (TO to) (CD 9.4) (NNS times)) (NN control) (NNS levels))))) (, ,) (CC and) (S (NP (NP (NN PRL) (NN release)) (PP (IN in) (NP (NN vitro)))) (VP (AUX was) (ADVP (RB significantly) (CC and) (RB consistently)) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NNS controls)))) (, ,) (PP (IN after) (NP (NP (QP (IN at) (JJS least) (CD 8)) (NNS days)) (PP (IN of) (NP (NNP Doc_6888657_1141_1144_Chemical) (NN exposure))))))) (. .)))
6888657	6	(S1 (S (PP (IN Beyond) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NNP Doc_6888657_1172_1175_Chemical) (NN exposure))))) (, ,) (NP (NP (DT the) (ADJP (RB immunochemically) (JJ PRL-positive)) (NN proportion)) (PP (IN of) (NP (NNS cells)))) (VP (VBD increased) (PP (TO to) (NP (NP (QP (IN over) (CD 50)) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NN population)))))) (. .)))
6888657	7	(S1 (S (NP (NP (VBN Increased) (NN density) (NN and/or) (NN size)) (CC and) (NP (NN PRL) (NN content))) (VP (AUX were) (VP (VBN indicated) (PP (IN for) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NN PRL) (NN cell) (NN population))) (PP (IN in) (NP (NP (DT both) (NNS types)) (PP (IN of) (NP (NN separation) (NNS protocols))))))))) (. .)))
6888657	8	(S1 (S (NP (NP (PDT All) (DT these) (NNS effects)) (PP (IN of) (NP (NNP Doc_6888657_1452_1455_Chemical)))) (VP (AUX were) (ADJP (RBR more) (JJ pronounced)) (PP (IN among) (NP (ADJP (RB previously) (VBN ovariectomized)) (NNS animals)))) (. .)))
6888657	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP extend) (NP (NP (DT the) (NNS findings)) (PP (IN of) (NP (JJ other) (NNS investigators)))) (, ,) (S (ADVP (RB further)) (VP (VBG establishing) (NP (DT the) (JJ Doc_6888657_1596_1599_Chemical-induced) (NN Doc_6888657_1608_1613_Disease)) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (NP (NN study)) (PP (IN of) (NP (NNP PRL) (JJ cellular) (NN control) (NNS mechanisms)))))))))) (. .)))
7053303	0	(S1 (NP (NP (NP (NN Age)) (CC and) (NP (JJ renal) (NN clearance))) (PP (IN of) (NP (NNP Doc_7053303_27_37_Chemical))) (. .)))
7053303	1	(S1 (S (PP (IN In) (NP (NP (NP (CD 35) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NNS ages)) (NP (QP (CD 20) (TO to) (CD 86)) (NN yr))) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NNP Doc_7053303_83_93_Chemical)) (ADVP (RB therapeutically))))) (NP (NP (CD two) (NN serum) (NNS samples)) (CC and) (NP (NP (DT all) (NN urine)) (VP (VBN formed) (PP (IN in) (NP (DT the) (NN interim)))))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN analysis)) (PP (IN of) (NP (NNP Doc_7053303_195_205_Chemical))))) (PP (PP (IN by) (NP (JJ high-pressure) (NN liquid) (NN chromatography))) (CC and) (PP (IN for) (NP (NNP Doc_7053303_253_263_Chemical)))))) (. .)))
7053303	2	(S1 (S (NP (JJ Doc_7053303_265_275_Chemical) (NN clearance)) (VP (VBD decreased) (PP (IN with) (NP (NN age)))) (. .)))
7053303	3	(S1 (S (NP (NP (DT The) (VBN extrapolated) (JJ 6-hr) (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_7053303_351_361_Chemical))) (PP (IN per) (NP (NN unit) (NN dose)))) (, ,) (PP (IN after) (NP (JJ intravenous) (NNP Doc_7053303_395_405_Chemical))) (, ,) (VP (VBD increased) (PP (IN with) (NP (NP (NN age)) (PP (IN of) (NP (DT the) (NNS patients)))))) (. .)))
7053303	4	(S1 (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (JJ Doc_7053303_456_466_Chemical) (NN clearance))) (PP (TO to) (NP (NP (JJ Doc_7053303_480_490_Chemical) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP Rc)) (-RRB- -RRB-))))) (VP (VBD averaged) (NP (QP (CD 4.8) (CD +/-)) (CD 2.0)) (, ,) (S (VP (VBG indicating) (NP (NP (JJ net) (JJ tubular) (NN secretion)) (PP (IN for) (NP (NNP Doc_7053303_565_575_Chemical))))))) (. .)))
7053303	5	(S1 (S (NP (NNP Rc)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (UCP (ADJP (JJ independent) (PP (IN of) (NP (NN age)))) (CC and) (VP (VBN decreased) (PP (IN with) (S (VP (VBG increasing) (NP (NP (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_7053303_665_675_Chemical)))))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN secretion)) (PP (IN of) (NP (NNP Doc_7053303_706_716_Chemical)))) (VP (AUX is) (NP (DT a) (JJ saturable) (NN process)))))))) (. .)))
7053303	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (QP (RB only) (CD one)) (NN case)) (PP (IN of) (NP (NNP Doc_7053303_768_776_Disease)))) (PP (ADVP (RB possibly)) (JJ due) (PP (TO to) (NP (NP (NNP Doc_7053303_793_803_Chemical)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (DT a) (NN drug) (NN level)) (PP (IN of) (NP (CD 1.9) (NNS microgram/ml))))) (NP (NP (CD 6) (NN hr)) (PP (IN after) (NP (DT a) (NN dose)))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (CD 13) (NNS patients)) (PP (IN without) (NP (NNP Doc_7053303_896_919_Disease)))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (JJ Doc_7053303_928_938_Chemical) (NNS levels)) (PP (IN above) (NP (CD 1.25) (CD microgram/ml))))))))))))) (. .)))
7053303	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ high) (JJ Doc_7053303_982_992_Chemical) (NNS levels)) (ADVP (RB alone))) (VP (AUX do) (RB not) (ADVP (RB always)) (VP (VB induce) (NP (NN Doc_7053303_1027_1035_Disease)))) (. .)))
7083920	0	(S1 (NP (NP (JJ Further) (NNS observations)) (PP (IN on) (NP (NP (DT the) (JJ electrophysiologic) (NNS effects)) (PP (IN of) (NP (JJ oral) (JJ Doc_7083920_63_73_Chemical) (NN therapy))))) (. .)))
7083920	1	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN presented) (PP (IN of) (NP (NP (DT a) (JJ reversible) (NN Doc_7083920_119_137_Disease)) (VP (VBG occurring) (PP (IN under) (NP (NP (JJ Doc_7083920_154_164_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_7083920_179_197_Disease))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN without) (NP (JJ clear) (NN Doc_7083920_225_266_Disease)))))))))) (. .)))
7083920	2	(S1 (S (NP (PRP$ His) (NN bundle) (NNS recordings)) (VP (VBD showed) (NP (DT an) (NN Doc_7083920_300_318_Disease)) (PP (IN with) (NP (NP (JJ intermittent) (NN exit) (NN block)) (CC and) (NP (NP (NP (ADJP (RB greatly) (VBN prolonged)) (NN BH)) (CC and) (NP (JJ HV) (NNS intervals))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 40) (CC and) (CD 100) (NN msec))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))) (. .)))
7083920	3	(S1 (S (PP (NP (CD Thirty) (NNS days)) (IN after) (NP (JJ Doc_7083920_441_451_Chemical) (NN discontinuation))) (, ,) (NP (PRP$ His) (NN bundle) (NNS electrograms)) (VP (VBD showed) (NP (NN Doc_7083920_500_514_Disease)) (PP (IN without) (NP (NP (NN intra-Hisian)) (CC or) (NP (JJ infra-Hisian) (NN delay))))) (. .)))
7083920	4	(S1 (S (NP (NNP Doc_7083920_559_569_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN during) (NP (NP (JJ long-term) (JJ oral) (NN therapy)) (PP (IN in) (NP (NNS patients))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ clear) (JJ intraventricular) (NN conduction) (NNS defects))))))))) (. .)))
7088431	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_7088431_15_40_Disease))) (PP (IN in) (NP (NP (JJ Doc_7088431_44_47_Chemical-exposed) (NN offspring)) (PP (IN under) (NP (NN observation))))) (. .)))
7088431	1	(S1 (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NNP Doc_7088431_98_137_Disease))) (VP (VBN detected) (PP (IN at) (NP (NN follow-up))) (PP (IN in) (NP (NP (JJ young) (NNS women)) (VP (VBN exposed) (PP (IN in) (NP (NN utero))) (PP (TO to) (NP (NNP Doc_7088431_195_213_Chemical)))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
7088431	2	(S1 (S (S (NP (NP (CD One) (NN patient)) (, ,) (VP (VBN aged) (NP (CD 23))) (, ,)) (VP (AUX had) (VP (AUX been) (VP (VBN followed) (PP (IN for) (NP (CD 2) (NNS years))) (SBAR (IN before) (S (NP (NNP Doc_7088431_287_296_Disease)) (VP (AUX was) (VP (VBN diagnosed))))))))) (: ;) (S (NP (NP (DT the) (JJ second) (NN patient)) (, ,) (VP (VBN aged) (NP (CD 22))) (, ,)) (VP (AUX had) (VP (AUX been) (VP (VBN seen) (PP (IN on) (NP (NP (DT a) (JJ regular) (NN basis)) (PP (IN for) (NP (NP (CD 5) (NNS years)) (, ,) (NP (CD 8) (NNS months)))))))))) (. .)))
7088431	3	(S1 (S (PP (IN In) (NP (DT both) (NNS instances))) (, ,) (NP (NP (NN suspicion)) (PP (IN of) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_7088431_445_454_Disease)))))) (VP (AUX was) (VP (VBN aroused) (PP (IN by) (NP (NP (DT the) (NN palpation)) (PP (IN of) (NP (DT a) (JJ small) (NN nodule))) (PP (IN in) (NP (DT the) (JJ vaginal) (NN fornix))))))) (. .)))
7088431	4	(S1 (S (S (NP (NN Hysterosalpingography)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (DT both) (NNS patients)))))) (CC and) (, ,) (S (PP (IN in) (NP (CD 1) (NN instance))) (, ,) (NP (DT an) (JJ abnormal) (NN x-ray) (NN film)) (VP (AUX was) (VP (VBN reflected) (PP (IN by) (NP (NP (DT the) (JJ gross) (NN appearance)) (PP (IN of) (NP (NP (DT the) (JJ uterine) (NN cavity)) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ surgical) (NNS specimen))))))))))) (. .)))
7199841	0	(S1 (S (NP (NP (JJ Neurologic) (NNS effects)) (PP (IN of) (NP (NP (NN subarachnoid) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_7199841_53_72_Chemical)) (, ,) (NP (NNP Doc_7199841_74_85_Chemical)) (, ,) (CC and) (NP (JJ low) (NNS pH))))))) (ADVP (RB normal)) (VP (VBP saline) (PP (IN in) (NP (NNS dogs)))) (. .)))
7199841	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ neurologic) (NNS consequences)) (PP (IN of) (NP (NP (JJ deliberate) (NN subarachnoid) (NN injection)) (PP (IN of) (NP (NP (JJ large) (NNS volumes)) (PP (IN of) (NP (NP (NNP Doc_7199841_248_267_Chemical)) (PP (IN in) (NP (JJ experimental) (NNS animals)))))))))))))) (. .)))
7199841	2	(S1 (S (NP (NP (DT The) (JJ possible) (NN role)) (PP (IN of) (NP (NP (JJ low) (NNS pH)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ total) (NN volume)))) (PP (IN as) (NP (JJ potential) (NNS factors))) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_7199841_377_390_Disease)))))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
7199841	3	(S1 (S (NP (NP (DT The) (CD 65) (NNS dogs)) (PP (IN in) (NP (DT the) (NN study)))) (VP (VBD received) (NP (NP (NNS injections)) (PP (IN in) (NP (DT the) (JJ subarachnoid) (NN space)))) (SBAR (IN as) (S (VP (VBZ follows) (: :) (NP (NP (NP (QP (CD 6) (TO to) (CD 8) (NN ml))) (PP (IN of) (NP (NNP Doc_7199841_502_513_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 15)) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_7199841_524_543_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 20)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (JJ low) (JJ pH) (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 3.0)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 20)) (-RRB- -RRB-)) (, ,) (CC or) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 10)) (-RRB- -RRB-)))))))) (. .)))
7199841	4	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 20) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (JJ subarachnoid) (NN injection)) (PP (IN of) (NP (NNP Doc_7199841_679_698_Chemical) (CD seven))))))))) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %)) (-RRB- -RRB-)) (VP (VBD developed) (NP (JJ hind-limb) (NN Doc_7199841_731_740_Disease))) (. .)))
7199841	5	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_7199841_776_787_Chemical)) (, ,) (NP (NP (JJ normal) (NN saline)) (, ,) (CC or) (NP (JJ normal) (NN saline)))))))))) (VP (VBD titrated) (PP (TO to) (NP (DT a) (NN pH) (CD 3.0) (VBN developed) (NN hind-limb) (NN Doc_7199841_862_871_Disease)))) (. .)))
7199841	6	(S1 (S (S (PP (IN Of) (NP (NP (DT the) (CD 15) (JJ spinal) (NNS cords)) (PP (IN of) (NP (NP (DT the) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NNP Doc_7199841_925_944_Chemical))))))))) (, ,) (NP (CD 13)) (VP (VBD showed) (NP (NNP Doc_7199841_956_972_Disease)))) (: ;) (S (NP (DT the) (NX (NX (NN nerve) (NNS roots)) (CC and) (NX (NN subarachnoid) (NNS vessels)))) (VP (AUX were) (ADJP (JJ normal)))) (. .)))
7199841	7	(S1 (S (NP (NP (DT The) (JJ spinal) (NNS cords)) (PP (IN of) (NP (DT the) (NNS animals))) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NP (NNP Doc_7199841_1074_1085_Chemical) (, ,) (JJ low) (JJ pH) (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 3.0)) (-RRB- -RRB-))) (, ,) (CC or) (NP (JJ normal) (NN saline))))))) (VP (AUX did) (RB not) (VP (VB show) (NP (JJ abnormal) (NNS findings)))) (. .)))
7234705	0	(S1 (S (NP (JJ Doc_7234705_0_12_Chemical-induced) (NNS polymorphous)) (VP (VBP Doc_7234705_34_57_Disease)) (. .)))
7234705	1	(S1 (S (NP (NP (CD Seven) (NNS cases)) (PP (IN of) (NP (JJ Doc_7234705_74_86_Chemical-induced) (JJ polymorphous) (NN Doc_7234705_108_131_Disease)))) (VP (AUX are) (VP (VBN presented))) (. .)))
7234705	2	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (, ,) (NP (JJ polymorphous) (NNP Doc_7234705_178_201_Disease)) (VP (VBD appeared) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (QP (CD 200) (TO to) (CD 400)) (NNS mg)) (PP (IN of) (NP (NNP Doc_7234705_264_276_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ sustained) (NNP Doc_7234705_308_331_Disease)))))))))) (. .)))
7234705	3	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (CD three) (NNS patients))) (, ,) (NP (NNP Doc_7234705_366_378_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ chronic) (NNP Doc_7234705_428_462_Disease) (CC or) (NNP Doc_7234705_466_480_Disease))))))) (. .)))
7234705	4	(S1 (S (NP (DT These) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_7234705_501_517_Disease) (CC and) (NN recurrent) (NN Doc_7234705_532_539_Disease)) (ADJP (JJ due) (PP (TO to) (NP (JJ polymorphous) (NNP Doc_7234705_560_583_Disease)))))) (. .)))
7234705	5	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (, ,) (NP (DT the) (NNP Doc_7234705_607_617_Disease)) (VP (VP (AUX was) (ADVP (RB rapidly)) (VP (VBN diagnosed))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (NN disappearance)) (PP (IN of) (NP (NP (JJ further) (NNS episodes)) (PP (IN of) (NP (DT the) (NNP Doc_7234705_698_708_Disease))))))))) (. .)))
7234705	6	(S1 (S (PP (IN In) (NP (CD two) (NNS patients))) (, ,) (NP (NP (DT the) (NNP Doc_7234705_731_741_Disease)) (VP (VBN degenerated) (PP (IN into) (NP (NP (JJ irreversible) (NN Doc_7234705_772_796_Disease)) (CC and) (NP (DT both) (NNS patients)))))) (VP (VBD died)) (. .)))
7234705	7	(S1 (S (S (PP (IN In) (NP (DT the) (JJ seventh) (NN patient))) (, ,) (NP (DT a) (JJ permanent) (NN ventricular) (NN pacemaker)) (VP (AUX was) (VP (VBN inserted)))) (CC and) (, ,) (S (PP (IN despite) (NP (NP (NN continuation)) (PP (IN of) (NP (JJ Doc_7234705_921_933_Chemical) (NN therapy))))) (, ,) (NP (JJ polymorphous) (NN Doc_7234705_956_979_Disease)) (VP (AUX did) (RB not) (VP (VB reoccur)))) (. .)))
7234705	8	(S1 (S (NP (DT These) (CD seven) (NNS cases)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_7234705_1032_1044_Chemical)) (VP (MD can) (VP (VB produce) (NP (NP (DT an) (VBN acquired) (NN Doc_7234705_1069_1091_Disease)) (PP (IN with) (NP (JJ polymorphous) (NN Doc_7234705_1110_1133_Disease))))))))) (. .)))
7248170	0	(S1 (NP (NP (NP (JJ Doc_7248170_0_14_Chemical-induced) (NN Doc_7248170_23_47_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (: :) (NP (NP (PRP$ its) (NN relationship)) (PP (TO to) (NP (NNP Doc_7248170_80_100_Chemical-induced) (NNP Doc_7248170_109_118_Disease)))) (. .)))
7248170	1	(S1 (S (NP (NP (DT The) (NN yield)) (PP (IN of) (NP (JJ severe) (NNP Doc_7248170_140_162_Disease) (PRN (-LRB- -LRB-) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (JJ shrunken) (ADJP (RB finely) (JJ nodular)) (NN liver)) (PP (IN with) (NP (JJ micronodular) (NN histology)))))) (, ,)) (NNP Doc_7248170_236_243_Disease)))) (NP (NP (QP (JJR greater) (IN than) (CD 30)) (NN ml)) (, ,) (NP (NP (NN plasma) (NN albumin)) (QP (JJR less) (IN than) (CD 2.2) (CD g/dl))) (, ,) (NP (NP (NNP Doc_7248170_299_311_Disease) (CD 2-3) (NNS times)) (ADJP (JJ normal))) (, ,) (CC and) (NP (NP (NP (JJ testicular) (NN Doc_7248170_345_352_Disease)) (PRN (ADVP (RB approximately)) (NP (DT half) (JJ normal) (NN weight)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (CD 12) (NNS doses)) (PP (IN of) (NP (NNP Doc_7248170_405_425_Chemical))))) (VP (VBN given) (ADVP (RB intragastrically)) (PP (IN in) (NP (DT the) (JJ Doc_7248170_456_470_Chemical-primed) (NN rat)))))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (CD 25) (NN %))) (PP (TO to) (NP (CD 56) (NN %))) (PP (IN by) (S (VP (VBG giving) (NP (NP (DT the) (JJ initial) (`` ``) (JJ calibrating) ('' '') (NN dose)) (PP (IN of) (NP (NNP Doc_7248170_556_576_Chemical)))) (PP (IN at) (NP (NP (DT the) (NN peak)) (PP (IN of) (NP (DT the) (JJ Doc_7248170_596_610_Chemical-induced) (NNP Doc_7248170_619_643_Disease)))))))))) (. .)))
7248170	2	(S1 (S (PP (IN At) (NP (DT this) (NN point))) (NP (PRP it)) (VP (AUX was) (VP (VBN assumed) (SBAR (IN that) (S (NP (DT the) (JJ cytochrome) (JJ P450/Doc_7248170_699_703_Chemical) (JJ toxic) (NN state)) (VP (AUX was) (ADJP (DT both) (ADJP (JJ maximal)) (CC and) (ADJP (JJ stable)))))))) (. .)))
7248170	3	(S1 (S (S (NP (NP (DT The) (JJ optimal) (NN rat) (NN size)) (SBAR (S (VP (TO to) (VP (VB begin) (NP (NNP Doc_7248170_775_789_Chemical))))))) (VP (AUX was) (VP (VBN determined) (PP (IN as) (NP (NP (CD 100)) (NP (NNP g))))))) (, ,) (CC and) (S (NP (NP (DT this) (NN size)) (PP (IN as) (NP (DT a) (NN group)))) (VP (AUX had) (NP (NP (DT a) (JJ mean) (JJ maximum) (JJ relative) (NN liver) (NN weight) (NN increase)) (ADJP (ADJP (NP (CD 47) (NN %)) (JJR greater)) (PP (IN than) (NP (NP (JJ normal) (NNS rats)) (PP (IN of) (NP (DT the) (JJ same) (NN body) (NN weight))))))))) (. .)))
7248170	4	(S1 (S (NP (NP (DT The) (JJ optimal) (NN time)) (PP (IN for) (NP (NP (DT the) (JJ initial) (NN dose)) (PP (IN of) (NP (NNP Doc_7248170_985_1005_Chemical)))))) (VP (AUX was) (PP (IN after) (NP (NP (CD 14) (NNS days)) (PP (IN on) (NP (NNP Doc_7248170_1027_1041_Chemical)))))) (. .)))
7265370	0	(S1 (S (NP (NNP Doc_7265370_0_11_Chemical) (NNP Doc_7265370_12_27_Disease)) (VP (VBD complicating) (NP (JJ Doc_7265370_41_48_Chemical) (NN therapy))) (. .)))
7265370	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_7265370_68_79_Chemical) (NNP Doc_7265370_80_95_Disease)))) (VP (AUX is) (VP (VBN reported) (PP (IN in) (NP (DT a) (NN man))) (PP (IN after) (NP (NP (CD 4) (NNS years)) (PP (IN of) (NP (NP (JJ Doc_7265370_134_165_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_7265370_178_190_Disease))))))))) (. .)))
7265370	2	(S1 (S (NP (DT The) (NN stone)) (VP (VP (VBD passed) (ADVP (RB spontaneously))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB contain) (NP (NP (DT a) (JJ Doc_7265370_250_261_Chemical) (NN metabolite)) (VP (VBN admixed) (PP (IN with) (NP (NN Doc_7265370_286_301_Chemical))))))))))) (. .)))
7265370	3	(S1 (S (S (NP (NP (NNS Factors)) (VP (VBG affecting) (NP (NNP Doc_7265370_321_332_Chemical) (NNP Doc_7265370_333_348_Disease)))) (VP (AUX are) (VP (VBN discussed)))) (CC and) (S (NP (CD 2) (ADJP (RB previously) (VBN reported)) (NNS cases)) (VP (AUX are) (VP (VBN reviewed)))) (. .)))
7269015	0	(S1 (NP (JJ Doc_7269015_0_8_Chemical-induced) (NN Doc_7269015_17_37_Disease) (. .)))
7269015	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (DT a) (JJ Doc_7269015_51_59_Chemical-induced) (NN Doc_7269015_68_87_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
7269015	2	(S1 (S (NP (JJ Spontaneous) (NN resolution)) (VP (VBD occurred) (PP (VBG following) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
7269015	3	(S1 (S (S (NP (NP (DT The) (NN similarity)) (PP (IN between) (NP (NP (DT the) (JJ histologic) (NNS appearances)) (PP (IN of) (NP (NP (NNP Doc_7269015_219_227_Chemical) (NNP Doc_7269015_228_236_Disease)) (CC and) (NP (UCP (DT both) (NN radiation) (CC and) (JJ Doc_7269015_260_276_Chemical-induced)) (NNP Doc_7269015_285_293_Disease))))))) (VP (AUX is) (VP (VBN discussed)))) (CC and) (S (NP (DT the) (NN world) (NN literature)) (VP (VBN reviewed))) (. .)))
7269015	4	(S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ known) (NN tendency)) (PP (IN of) (NP (NNP Doc_7269015_375_383_Chemical))) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ cellular) (NN atypia)) (CC and) (NP (NNP Doc_7269015_414_423_Disease))) (PP (IN in) (NP (JJ other) (NNS sites)))))))))) (, ,) (NP (JJ periodic) (NN urinary) (NN cytology)) (VP (AUX is) (VP (VBN suggested) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ long-term) (NN therapy))))))) (. .)))
7292072	0	(S1 (NP (NP (NNP Variant) (NNP Doc_7292072_8_31_Disease)) (PP (IN in) (NP (NNP Doc_7292072_35_46_Chemical) (NNP Doc_7292072_47_55_Disease))) (. .)))
7292072	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ variant) (NN Doc_7292072_85_108_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7292072_120_131_Chemical) (NNP Doc_7292072_132_140_Disease)))))))) (. .)))
7292072	2	(S1 (S (NP (NP (JJ Unusual) (NNS features)) (PP (IN of) (NP (DT the) (NNP Doc_7292072_166_176_Disease)))) (VP (AUX are) (NP (NP (JJ repetitive) (NN group) (NN beating)) (, ,) (NP (NP (JJ progressive) (NN shortening)) (PP (IN of) (NP (DT the) (JJ R-R) (NN interval)))) (, ,) (NP (NP (JJ progressive) (NN widening)) (PP (IN of) (NP (NP (DT the) (NNS QRS)) (ADJP (JJ complex) (PP (IN with) (NP (NP (JJ eventual) (NN failure)) (PP (IN of) (NP (NN intraventricular) (NN conduction))))))))) (, ,) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN direction)) (PP (IN of) (NP (DT the) (NNP QRS) (NN axis)))))))) (. .)))
7292072	3	(S1 (S (NP (NP (NN Recognition)) (PP (IN of) (NP (JJ variant) (NNP Doc_7292072_410_433_Disease)))) (VP (AUX is) (ADJP (JJ important)) (SBAR (IN because) (S (NP (NN therapy)) (VP (VBZ differs) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (JJ classic) (NN Doc_7292072_492_515_Disease))))))))) (. .)))
7352670	0	(S1 (S (NP (NN Rebound)) (VP (VBP Doc_7352670_8_20_Disease) (SBAR (IN after) (S (NP (NNP Doc_7352670_27_47_Chemical)) (VP (VBD prevented) (PP (IN by) (NP (NNP Doc_7352670_61_70_Chemical))) (PP (IN in) (NP (NNS rats))))))) (. .)))
7352670	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (DT the) (JJ renin--Doc_7352670_103_114_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (PP (IN during) (NP (NP (NNP Doc_7352670_166_175_Chemical) (NNP anesthesia)) (CC and) (NP (NP (NNP Doc_7352670_191_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7352670_213_216_Chemical)) (-RRB- -RRB-)))))))))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_7352670_226_237_Disease)) (VP (AUX was) (VP (VBN evaluated)))))) (. .)))
7352670	2	(S1 (S (NP (NN Control) (NNS rats)) (VP (VBD received) (NP (NP (JJ Doc_7352670_275_284_Chemical) (NNS anesthesia)) (PRN (-LRB- -LRB-) (NP (CD 1) (NNP MAC)) (-RRB- -RRB-)) (PP (IN for) (NP (CD one) (NN hour))) (, ,) (VP (VBN followed) (PP (IN by) (NP (JJ Doc_7352670_330_333_Chemical) (NN infusion)))) (, ,)) (NP (CD 40) (NN microgram/kg/min)) (, ,) (PP (IN for) (NP (CD 30) (NN min))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 30-min) (NN recovery) (NN period))))) (. .)))
7352670	3	(S1 (S (NP (NP (DT A) (JJ second) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (VP (AUX was) (VP (VBN treated) (ADVP (RB identically)))) (CC and) (PRN (, ,) (PP (IN in) (NP (NN addition))) (, ,)) (VP (VBD received) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_7352670_504_513_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ competitive) (NN inhibitor)) (PP (IN of) (NP (NNP Doc_7352670_542_556_Chemical)))) (-RRB- -RRB-))))) (PP (IN throughout) (NP (DT the) (JJ experimental) (NN period))))) (. .)))
7352670	4	(S1 (S (PP (IN In) (NP (DT each) (NN group))) (, ,) (NP (JJ Doc_7352670_609_612_Chemical) (NN infusion)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ initial) (NN decrease)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (PP (IN from) (NP (NP (CD 86) (NNS torr)) (CC and) (NP (CD 83) (NNS torr)))))))) (, ,) (ADVP (RB respectively)) (, ,) (PP (TO to) (NP (CD 48) (NN torr)))) (. .)))
7352670	5	(S1 (S (PP (IN During) (NP (DT the) (JJ Doc_7352670_735_738_Chemical) (NN infusion))) (NP (DT the) (NN control) (NNS animals)) (VP (VBD demonstrated) (NP (DT a) (JJ progressive) (NN Doc_7352670_795_821_Disease)) (PP (TO to) (NP (QP (CD 61) (CD torr)))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ Doc_7352670_846_855_Chemical-treated) (NNS animals)) (VP (VBD showed) (NP (DT no) (NN change)))))) (. .)))
7352670	6	(S1 (S (PP (VBG Following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_7352670_919_922_Chemical))))) (, ,) (NP (NP (NN blood) (NN pressure)) (PP (IN in) (NP (DT the) (NN control) (NNS animals)))) (VP (VBD rebounded) (PP (TO to) (NP (CD 94) (CD torr))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (CD 78) (NN torr)) (PP (IN in) (NP (DT the) (JJ Doc_7352670_1016_1025_Chemical-treated) (NNS rats))))))))) (. .)))
7352670	7	(S1 (S (NP (DT This) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (PP (IN with) (NP (JJ stable) (JJ Doc_7352670_1078_1087_Chemical) (NN anesthesia))) (, ,) (NP (NP (NP (DT the) (JJ partial) (NN recovery)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (PP (IN during) (NP (JJ Doc_7352670_1146_1149_Chemical) (NN infusion)))))) (CC and) (NP (NP (DT the) (JJ post-Doc_7352670_1172_1175_Chemical) (NN rebound)) (PP (IN of) (NP (NN blood) (NN pressure))))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB completely)) (VBN blocked) (PP (IN by) (NP (NNP Doc_7352670_1231_1240_Chemical))))))))) (. .)))
7352670	8	(S1 (S (NP (DT This)) (VP (VBZ demonstrates) (NP (NP (DT the) (NN participation)) (PP (IN of) (NP (DT the) (JJ renin--Doc_7352670_1292_1303_Chemical) (NN system))) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (VBN combined) (JJ Doc_7352670_1340_1351_Disease) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7352670_1363_1372_Chemical)) (CC and) (NP (NNP Doc_7352670_1377_1380_Chemical)))))))))) (. .)))
7420681	0	(S1 (NP (NP (JJ Clinical) (NNP Doc_7420681_9_23_Disease)) (PP (IN of) (NP (NP (NNP Doc_7420681_27_37_Chemical)) (CC and) (NP (NNP Doc_7420681_42_52_Chemical)))) (. .)))
7420681	1	(S1 (NP (DT A) (JJ prospective) (NN study) (. .)))
7420681	2	(S1 (S (NP (NP (QP (RB Nearly) (CD 3.2) (CD million)) (NNS people)) (PP (IN in) (NP (DT this) (NN country)))) (VP (VBP receive) (NP (JJ Doc_7420681_125_139_Chemical) (NNS antibiotics)) (ADVP (RB annually))) (. .)))
7420681	3	(S1 (S (NP (NP (NNP Doc_7420681_162_180_Chemical)) (CC and) (NP (NNP Doc_7420681_185_203_Chemical))) (VP (VBP continue) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (NNP Doc_7420681_228_239_Disease)) (CC and) (NP (NNP Doc_7420681_244_258_Disease))) (PP (IN in) (NP (DT both) (ADJP (JJ animal) (CC and) (JJ clinical)) (NNS studies))))))) (. .)))
7420681	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (CD 62) (NNS patients)) (SBAR (WHNP (IN with)) (S (VP (VP (VBN confirmed) (NP (JJ initial) (JJ normal) (JJ renal) (NN function))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (QP (CD 2) (TO to) (CD 5)) (NN mg/kg/day)) (PP (IN of) (NP (NNP Doc_7420681_405_423_Chemical) (CC or) (NNP Doc_7420681_427_445_Chemical))))) (PP (IN for) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (CD seven) (NNS days)))))))))) (VP (AUX were) (VP (VBN followed) (PRT (RP up)) (ADVP (RB prospectively)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_7420681_528_542_Chemical-related) (NNP Doc_7420681_551_564_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (JJ one-third) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN function)))))))))))) (. .)))
7420681	5	(S1 (S (PP (IN In) (NP (DT these) (CD 62) (NNS patients))) (, ,) (NP (NP (DT no) (JJ other) (NNS causes)) (PP (IN for) (NP (NNP Doc_7420681_669_682_Disease)))) (VP (MD could) (VP (AUX be) (VP (VBN identified)))) (. .)))
7420681	6	(S1 (S (NP (NP (NP (NP (CD Five)) (PP (IN of) (NP (CD 33))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (DT the) (JJ Doc_7420681_728_738_Chemical-treated) (NNS patients)))) (CC and) (NP (NP (CD 16)) (PP (IN of) (NP (CD 29))) (PRN (-LRB- -LRB-) (NP (CD 55.2) (NN %)) (-RRB- -RRB-)))) (PP (IN of) (NP (DT the) (JJ Doc_7420681_784_794_Chemical-treated) (NNS patients)))) (VP (AUX had) (NP (NNP Doc_7420681_816_829_Disease))) (. .)))
7420681	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_7420681_837_847_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_7420681_868_881_Disease))) (ADVP (QP (JJR more) (IN than) (CD three) (NNS times)) (RB as) (RB often) (SBAR (IN as) (S (VP (AUX was) (ADJP (JJ Doc_7420681_920_930_Chemical)))))))) (. .)))
7423039	0	(S1 (NP (NP (JJ Metabolic) (NN involvement)) (PP (IN in) (NP (NNP Doc_7423039_25_35_Chemical) (NNP Doc_7423039_36_50_Disease))) (. .)))
7423039	1	(S1 (S (NP (NP (DT The) (JJ Doc_7423039_56_67_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_7423039_79_89_Chemical)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (JJ mammalian) (JJ myocardial) (NNS cells)) (PP (IN in) (NP (NN culture))))) (PP (IN as) (NP (DT a) (NN model) (NN system))))) (. .)))
7423039	2	(S1 (S (NP (NN Doc_7423039_163_173_Chemical)) (VP (VBD inhibited) (NP (NP (NN cell) (NN growth)) (CC and) (NP (NP (DT the) (JJ rhythmic) (NNS contractions) (NN characteristic)) (PP (IN of) (NP (JJ myocardial) (NNS cells))) (PP (IN in) (NP (NN culture)))))) (. .)))
7423039	3	(S1 (S (S (NP (NP (DT A) (JJ possible) (NN involvement)) (PP (IN of) (NP (NN energy) (NN metabolism)))) (VP (AUX was) (VP (VBN suggested) (ADVP (RB previously))))) (, ,) (CC and) (S (PP (IN in) (NP (DT this) (NN study))) (NP (NP (DT the) (JJ adenylate) (NN energy) (NN charge)) (CC and) (NP (JJ Doc_7423039_393_411_Chemical) (JJ mole) (NN fraction))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (DT the) (JJ Doc_7423039_449_459_Chemical-treated) (NNS cells)))))) (. .)))
7423039	4	(S1 (S (NP (DT The) (NN adenylate) (NN energy) (NN charge)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB significantly)) (VBN decreased))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ Doc_7423039_554_571_Chemical) (NN mole) (NN fraction)) (VP (AUX was) (ADJP (JJ unchanged))))))) (. .)))
7423039	5	(S1 (S (NP (JJ Such) (NN disparity)) (VP (VBZ suggests) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (JJ Doc_7423039_642_650_Chemical) (NN phosphokinase))))) (. .)))
7423039	6	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (QP (CD 1) (CD mM)) (ADJP (JJ Doc_7423039_687_696_Chemical) (PP (TO to) (NP (DT the) (JJ myocardial) (NN cell)))) (NNS cultures)))) (ADVP (RB markedly)) (VP (VBZ increases) (NP (DT the) (JJ Doc_7423039_752_755_Chemical) (NN concentration)) (PP (IN through) (NP (NP (DT a) (NN pathway)) (VP (ADVP (RB reportedly)) (VBG leading) (PP (TO to) (NP (DT a) (JJ compartmentalized) (NN Doc_7423039_830_833_Chemical) (NN pool))))))) (. .)))
7423039	7	(S1 (S (PP (IN In) (NP (DT the) (JJ Doc_7423039_847_857_Chemical-treated) (NNS cells))) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_7423039_889_898_Chemical)))) (VP (VP (VBD increased) (NP (DT the) (JJ adenylate) (NN charge))) (CC and) (VP (, ,) (ADVP (JJ concomitant) (PP (IN with) (NP (NP (DT this) (NN inrcease)) (, ,) (NP (NP (DT the) (NNS cells) (POS ')) (JJ functional) (NN integrity))))) (, ,) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NP (NN percentage)) (PP (IN of) (NP (NN beating) (NNS cells)))) (CC and) (NP (NP (NN rate)) (PP (IN of) (NP (NNS contractions)))))))) (, ,) (AUX was) (VP (VBN maintained)))) (. .)))
7444978	0	(S1 (NP (NP (JJ Age-dependent) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN rat))) (PP (TO to) (NP (NP (JJ Doc_7444978_40_50_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_7444978_62_74_Chemical))))) (. .)))
7444978	1	(S1 (S (NP (NP (JJ Doc_7444978_76_88_Chemical) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NP (CD 300) (NN mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (PP (IN for) (NP (JJ various) (NNS periods))) (PP (PP (IN into) (NP (JJ preweanling) (NNS rats))) (CC and) (PP (IN for) (NP (CD 3) (NNS weeks)))) (PP (IN into) (NP (VBG weanling) (NNS rats))))) (. .)))
7444978	2	(S1 (S (PP (VBG Beginning) (PP (IN at) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN age)))))) (, ,) (NP (NP (NN body) (NN movement)) (CC and) (NP (NN hearing))) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (QP (CD 6) (CC and) (RB up) (TO to) (CD 17)) (NNS weeks))) (, ,) (ADVP (RB respectively)))) (. .)))
7444978	3	(S1 (S (S (NP (NNP Doc_7444978_313_331_Disease) (CC and) (NNP Doc_7444978_336_344_Disease)) (VP (VBD occurred) (ADVP (RB only)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN during) (NP (DT the) (JJ preweaning) (NN period)))))))) (: ;) (S (PP (IN within) (NP (DT this) (NN period))) (NP (DT the) (JJS greatest) (NNS sensitivities)) (PP (IN for) (NP (DT these) (NNS abnormalities))) (VP (VBD occurred) (PP (IN from) (NP (NP (QP (CD 2) (TO to) (CD 11-17))) (CC and) (NP (NP (QP (CD 5) (TO to) (CD 11)) (NNS days)) (PP (IN of) (NP (NN age)))))) (, ,) (ADVP (RB respectively)) (, ,) (S (VP (VBG indicating) (SBAR (S (IN that) (NP (DT the) (NN cochlea)) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (NNP Doc_7444978_588_600_Chemical)))) (PP (IN than) (NP (NP (DT the) (NN site)) (ADJP (PRN (-LRB- -LRB-) (ADJP (JJ vestibular) (CC or) (JJ central)) (-RRB- -RRB-)) (JJ responsible) (PP (IN for) (NP (DT the) (NNP Doc_7444978_659_670_Disease)))))))))))))) (. .)))
7449470	0	(S1 (NP (NP (JJ Late) (, ,) (JJ late) (NNP Doc_7449470_11_22_Chemical) (NNP Doc_7449470_23_37_Disease)) (. .)))
7449470	1	(S1 (S (NP (NN Doc_7449470_39_55_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN complication)) (SBAR (WHNP (WDT which)) (S (VP (VBZ limits) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_7449470_104_114_Chemical)))) (PP (IN as) (NP (DT a) (JJ chemotherapeutic) (NN agent)))))))) (. .)))
7449470	2	(S1 (S (NP (NN Doc_7449470_144_158_Disease)) (VP (AUX is) (ADJP (JJ frequent)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ total) (NN dose)) (VP (VP (VBZ exceeds) (NP (CD 600) (NN mg/m2))) (CC and) (VP (VBZ occurs) (PP (IN within) (NP (QP (CD one) (TO to) (CD six)) (NNS months))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy)))))))))) (. .)))
7449470	3	(S1 (S (NP (DT A) (NN patient)) (VP (AUX is) (VP (VBN reported) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ progressive) (UCP (NNP Doc_7449470_321_335_Disease) (CD two) (CC and) (JJ one-half)) (NNS years)) (PP (IN after) (S (VP (VBG receiving) (NP (NP (CD 580) (NN mg/m2)) (SBAR (WHNP (WDT which)) (S (ADVP (RB apparently)) (VP (VBZ represents) (NP (JJ late) (, ,) (JJ late) (NNP Doc_7449470_424_438_Disease)))))))))))))) (. .)))
7453952	0	(S1 (NP (NP (NN Attenuation)) (PP (IN of) (NP (DT the) (JJ Doc_7453952_19_26_Chemical-induced) (NN Doc_7453952_35_67_Disease))) (PP (IN by) (NP (NP (NNP Doc_7453952_71_80_Chemical)) (PP (IN in) (NP (NNS rats))))) (. .)))
7453952	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_7453952_104_113_Chemical))) (PP (PP (IN on) (NP (NNP Doc_7453952_117_124_Chemical-induced) (NNP Doc_7453952_133_143_Disease) (CC and) (NNP Doc_7453952_148_156_Disease))) (CC and) (PP (IN on) (NP (NP (DT the) (JJ Doc_7453952_168_175_Chemical) (NN concentration)) (PP (IN in) (NP (DT the) (NN plasma) (, ,) (NN brain) (, ,) (NN kidney) (, ,) (NN thyroid) (CC and) (JJ red) (NN blood) (NNS cells))))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (NNS rats)) (, ,) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NNP Doc_7453952_299_303_Chemical)))))))) (. .)))
7453952	2	(S1 (S (S (NP (NNP Doc_7453952_305_314_Chemical)) (VP (VBD reduced) (NP (NP (DT the) (NN drinking) (CC and) (NN urine) (NN volume)) (PP (IN of) (NP (NNS rats)))) (PP (IN in) (NP (NP (NP (DT an) (JJ acute)) (PRN (-LRB- -LRB-) (NP (QP (CD 6) (CC or) (CD 12)) (NNP h)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT a) (NN subacute)) (-LRB- -LRB-) (NP (CD 3) (NNS days)) (-RRB- -RRB-)) (NP (NN experiment.) (CD 6) (NNP h))))) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_7453952_453_462_Chemical))))))) (, ,) (NP (DT a) (NN reduction)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ Doc_7453952_496_503_Chemical) (NN content)) (PP (PP (IN of) (NP (DT the) (JJ renal) (NN medulla))) (CC but) (RB not) (PP (IN in) (NP (NP (DT the) (JJ other) (NNS organs)) (VP (VBN studied))))))))) (. .)))
7453952	3	(S1 (S (PP (IN At) (NP (CD 12) (NNP h))) (, ,) (NP (PDT all) (DT the) (NNS tissues)) (VP (VBD showed) (NP (NP (DT a) (JJ slight) (NN increase)) (PP (IN in) (NP (JJ Doc_7453952_623_630_Chemical) (NNS levels))))) (. .)))
7453952	4	(S1 (S (PP (IN After) (NP (NP (CD 3) (NNS days)) (PP (IN of) (NP (VBN combined) (NN treatment))))) (, ,) (NP (NP (DT a) (JJ marked) (NN elevation)) (PP (IN in) (NP (UCP (NN plasma) (CC and) (NN tissue)) (JJ Doc_7453952_715_722_Chemical) (NNS levels)))) (VP (VBD accompanied) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN water) (NN intake))))) (. .)))
7453952	5	(S1 (S (PP (IN In) (NP (PDT all) (DT the) (NNS experiments))) (, ,) (NP (NP (DT the) (NN attenuation)) (PP (IN of) (NP (DT the) (JJ Doc_7453952_818_825_Chemical-induced) (NNP Doc_7453952_834_866_Disease))) (PP (IN by) (NP (NNP Doc_7453952_870_879_Chemical)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN ratio)) (PP (IN between) (NP (NP (NP (DT the) (JJ Doc_7453952_936_943_Chemical) (NN concentration)) (PP (IN in) (NP (DT the) (JJ renal) (NN medulla)))) (CC and) (NP (NP (PRP$ its) (NNS levels)) (PP (IN in) (NP (DT the) (NN blood))))))))) (CC and) (NP (NP (DT an) (NN elevation)) (PP (IN in) (NP (DT the) (NN plasma) (NN Doc_7453952_1038_1047_Chemical) (NN level)))))))) (. .)))
7453952	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NP (JJ acute) (NNP Doc_7453952_1082_1091_Chemical) (NN administration)) (PP (TO to) (NP (NP (JJ Doc_7453952_1110_1117_Chemical-treated) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_7453952_1150_1160_Disease)) (CC and) (NP (NNP Doc_7453952_1165_1173_Disease)))))))) (VP (MD might) (VP (VB relieve) (NP (DT these) (NNS patients))))) (CC but) (S (NP (VBN prolonged) (NNP Doc_7453952_1217_1226_Chemical) (NN supplementation)) (VP (VP (MD would) (VP (VB result) (PP (IN in) (NP (JJ elevated) (JJ Doc_7453952_1268_1275_Chemical) (NNS levels))))) (CC and) (VP (MD might) (VP (AUX be) (ADJP (JJ hazardous)))))))))) (. .)))
7468724	0	(S1 (S (NP (NN Doc_7468724_0_28_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_7468724_45_56_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_7468724_71_84_Disease)))))) (. .)))
7468724	1	(S1 (S (NP (JJ Severe) (NN Doc_7468724_93_121_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (CD eight) (IN of) (CD 160)) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7468724_169_180_Chemical))) (PP (IN for) (NP (NN Doc_7468724_185_198_Disease))))))) (. .)))
7468724	2	(S1 (S (NP (JJ Associated) (JJ corticosteroid) (NN therapy) (CC and) (JJ twin) (NNS gestations)) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (VP (VBG predisposing) (NP (NNS factors))))))) (. .)))
7468724	3	(S1 (S (NP (NP (JJ Potential) (NNS mechanisms)) (PP (IN of) (NP (DT the) (NN pathophysiology)))) (VP (AUX are) (ADVP (RB briefly)) (VP (VBN discussed))) (. .)))
7504976	0	(S1 (S (S (NP (NNP Doc_7504976_0_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ antithyroid) (NNS drugs))))) (: :) (S (NP (CD four) (NNS cases)) (VP (VBG including) (NP (CD one)) (PP (IN with) (NP (NP (NN cross-reactivity)) (PP (IN between) (NP (NP (NNP Doc_7504976_101_112_Chemical)) (CC and) (NP (NNP Doc_7504976_117_133_Chemical)))))))) (. .)))
7504976	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_7504976_199_222_Disease)))) (PP (VBN encountered) (PP (IN with) (NP (JJ antithyroid) (NNS drugs))))))))) (. .)))
7504976	2	(S1 (S (NP (NP (NN Retrospective) (NN review)) (PP (IN of) (NP (NP (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 236) (NNS patients)) (PP (IN with) (NP (NNP Doc_7504976_329_344_Disease)))))))) (VP (VBD admitted) (PP (IN in) (NP (NP (PRP$ our) (NN department)) (PRN (-LRB- -LRB-) (NP (NP (NNS in-)) (CC or) (NP (NNS out-patients))) (-RRB- -RRB-)))) (PP (IN from) (NP (CD 1986))) (PP (TO to) (NP (CD 1992)))) (. .)))
7504976	3	(S1 (S (NP (NP (CD Four) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 1.7) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN identified) (PP (IN with) (NP (NP (NNP Doc_7504976_464_479_Disease)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (ADVP (RB reasonably)) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ antithyroid) (NN agent)))))))))))))) (. .)))
7504976	4	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (NN Doc_7504976_569_590_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_7504976_602_613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7504976_615_628_Chemical)) (-RRB- -RRB-))))))) (. .)))
7504976	5	(S1 (S (NP (CD Two) (NNS others)) (VP (AUX had) (NP (DT a) (JJ mixed) (PRN (-LRB- -LRB-) (ADJP (JJ Doc_7504976_655_666_Disease) (CC and) (JJ cytolytic)) (-RRB- -RRB-)) (NN Doc_7504976_682_691_Disease)) (PP (VBG following) (NP (NN Doc_7504976_702_713_Chemical)))) (. .)))
7504976	6	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (JJ latter) (CD two) (NNS patients)))) (ADVP (RB further)) (VP (VBD experienced) (NP (NP (DT a) (JJ cytolytic) (NN Doc_7504976_778_787_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (SBAR (IN after) (S (NP (NP (NNP Doc_7504976_809_825_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7504976_827_835_Chemical)) (-RRB- -RRB-))) (VP (AUX had) (VP (VBN replaced) (NP (NNP Doc_7504976_850_861_Chemical))))))))))) (. .)))
7504976	7	(S1 (S (NP (NP (JJ Biological) (NNS features)) (PP (IN of) (NP (NNP Doc_7504976_886_895_Disease)))) (VP (VBD disappeared) (PP (IN in) (NP (DT all) (NNS cases))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (VBN incriminated) (NN drug))))) (, ,) (SBAR (IN while) (S (NP (JJ biliary) (, ,) (JJ viral) (CC and) (JJ immunological) (NNS searches)) (VP (AUX were) (ADJP (JJ negative)))))) (. .)))
7504976	8	(S1 (S (NP (NP (QP (RB Only) (CD 2)) (NNS patients)) (PP (IN of) (NP (PRP$ our) (NN retrospective) (NN study)))) (VP (VBD experienced) (NP (DT a) (ADJP (ADJP (JJ mild)) (CC or) (ADJP (JJ severe))) (NN Doc_7504976_1098_1109_Disease))) (. .)))
7504976	9	(S1 (S (NP (NN Doc_7504976_1123_1138_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ potential) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ antithyroid) (NNS drugs))) (SBAR (WHNP (WDT which)) (S (VP (VBZ warrants) (, ,) (PP (IN as) (PP (IN for) (NP (NP (JJ haematological) (NNS disturbances)) (, ,) (NP (DT a) (JJ pre-therapeutic) (NN determination)) (CC and) (NP (NP (DT a) (JJ careful) (NN follow-up)) (PP (IN of) (NP (JJ relevant) (JJ biological) (NNS markers)))))))))))) (. .)))
7504976	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_7504976_1340_1354_Disease)) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN restricted) (PP (TO to) (NP (NP (CD one) (NN class)) (PP (IN of) (NP (JJ antithyroid) (NNS agents)))))))) (. .)))
7516729	0	(S1 (S (NP (NP (JJ Interactive) (NNS effects)) (PP (IN of) (NP (NP (NNS variations)) (PP (IN in) (NP (NP (JJ -LSB-Doc_7516729_38_40_Chemical) (JJ -RSB-) (NNS o)) (CC and) (NP (JJ -LSB-Doc_7516729_48_50_Chemical) (NNS -RSB-))))))) (VP (VBP o) (PP (IN on) (NP (NN rat) (JJ atrial) (JJ spontaneous) (NN frequency)))) (. .)))
7516729	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (S (VP (VBG varying) (NP (NP (DT the) (JJ extracellular) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_7516729_149_151_Chemical) (CC and) (NNP Doc_7516729_156_158_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (JJ -LSB-Doc_7516729_161_163_Chemical) (JJ -RSB-) (NNS o)) (CC and) (NP (JJ -LSB-Doc_7516729_171_173_Chemical) (JJ -RSB-) (NNS o))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT both)) (, ,) (NP (NP (NP (DT the) (JJ spontaneous) (NN beating)) (CC and) (NP (DT the) (JJ negative) (JJ chronotropic) (NN action))) (PP (IN of) (NP (NNP Doc_7516729_250_259_Chemical)))) (, ,)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (DT the) (VBN isolated) (NN rat) (NN atria))))) (. .)))
7516729	2	(S1 (S (NP (NP (JJ Basal) (NN frequency)) (PRN (-LRB- -LRB-) (NP (NN BF)) (-RRB- -RRB-)) (VP (VBN evaluated) (PP (IN by) (NP (NN surface) (NN electrogram))))) (VP (AUX was) (NP (NP (CD 223) (NN +/-) (QP (CD 4) (CD beats/min.))) (PP (IN in) (NP (NP (NN control) (NN Krebs-Ringer)) (VP (VBG containing) (NP (QP (CD 137) (CD mM)) (NX (NX (NNP Doc_7516729_422_424_Chemical)) (CC and) (NX (NX (CD 1.35) (JJ mM) (NNP Doc_7516729_437_439_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP N)) (-RRB- -RRB-)))))))))) (. .)))
7516729	3	(S1 (S (NP (PRP It)) (VP (VBD decreased) (PP (IN by) (NP (CD 16) (NN +/-))) (NP (CD 3) (NN %)) (PP (IN by) (S (VP (VBG lowering) (NP (JJ -LSB-Doc_7516729_484_486_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (CD 78) (NNS mM)) (PRN (-LRB- -LRB-) (NP (NNP LNa)) (-RRB- -RRB-)) (, ,) (NP (NP (CD 23) (NN +/-)) (NP (CD 2) (NN %))))) (PP (IN by) (S (VP (VBG lowering) (NP (NP (ADJP (RB simultaneously) (JJ -LSB-Doc_7516729_543_545_Chemical)) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (CD 78) (NNS mM)) (CC and) (NP (JJ -LSB-Doc_7516729_562_564_Chemical) (JJ -RSB-) (NNS o))))) (PP (TO to) (NP (NP (NP (CD 0.675) (NNS mM)) (PRN (-LRB- -LRB-) (NP (NNP LNa+LCa)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 31) (NNS +/-)) (NP (CD 5) (NN %))))) (PP (IN by) (S (VP (VP (VBG lowering) (NP (JJ -LSB-Doc_7516729_616_618_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (CD 78) (NN mM)))) (CC plus) (VP (VBG increasing) (NP (JJ -LSB-Doc_7516729_647_649_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (QP (CD 3.6) (CD mM))) (PRN (-LRB- -LRB-) (NP (NNP LNa+HCa)) (-RRB- -RRB-))))))))))))))) (. .)))
7516729	4	(S1 (S (S (PP (IN At) (NP (JJ normal) (JJ -LSB-Doc_7516729_684_686_Chemical) (JJ -RSB-) (NN o))) (, ,) (NP (NP (NP (NP (NN decrease)) (PRN (-LRB- -LRB-) (NP (CD 0.675) (NNS mM)) (-RRB- -RRB-))) (CC or) (NP (NP (NN increase)) (PRN (-LRB- -LRB-) (NP (CD 3.6) (NNS mM)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ -LSB-Doc_7516729_735_737_Chemical) (JJ -RSB-) (NNS o)))) (VP (AUX did) (RB not) (VP (VB modify) (NP (NN BF))))) (: ;) (S (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (CD ten) (NNS times)) (-LRB- -LRB-) (NP (CD 0.135) (NNS mM)) (PP (IN of) (NP (JJ normal) (JJ -LSB-Doc_7516729_805_807_Chemical) (JJ -RSB-) (NNS o)))))) (VP (AUX was) (ADJP (JJ effective) (S (VP (TO to) (VP (VB reduce) (NP (NN BF)) (PP (IN by) (NP (NP (CD 40) (NN +/-)) (NP (CD 13) (NN %)))))))))) (. .)))
7516729	5	(S1 (S (NP (DT All) (JJ negative) (JJ chronotropic) (NNS effects)) (VP (AUX were) (ADJP (JJ BF-dependent))) (. .)))
7516729	6	(S1 (S (NP (NP (JJ Dose-dependent) (NN Doc_7516729_920_931_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7516729_943_952_Chemical))))) (VP (AUX was) (VP (VBN potentiated) (PP (IN by) (NP (NP (NNP LNa)) (, ,) (NP (NNP LCa)) (, ,) (CC and) (NP (NNP HCa)))))) (. .)))
7516729	7	(S1 (S (NP (NP (ADJP (ADJP (JJ Independent)) (CC but) (ADJP (RB not) (JJ additive))) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7516729_1031_1033_Chemical)) (CC and) (NP (NNP Doc_7516729_1038_1040_Chemical))))) (VP (AUX are) (VP (VBN shown) (PP (IN by) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NP (DT the) (NNS values)) (PP (IN of) (NP (NP (JJ -LSB-Doc_7516729_1082_1091_Chemical) (JJ -RSB-) (NNS o)) (VP (VBN needed) (S (VP (TO to) (VP (VB reduce) (NP (NN BF)) (PP (IN by) (NP (NP (CD 30) (NN %)) (PRN (-LRB- -LRB-) (NP (CD IC30)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT the) (JJ following) (NN order)) (PP (IN of) (NP (JJ inhibitory) (NN potency)))))))))))) (: :) (NP (NNP LNa) (NNP >) (NNP LCa) (NNP >) (NNP HCa) (NNP >) (NNP N)))))) (, ,) (S (VP (VBG resulting) (NP (NP (NN LNa+HCa)) (ADJP (JJ similar) (PP (TO to) (NP (NNP LNa))))))))) (. .)))
7516729	8	(S1 (S (NP (DT The) (JJ -LSB-Doc_7516729_1236_1245_Chemical) (NN -RSB-)) (VP (VBD o) (SBAR (IN that) (S (NP (NP (VBN arrested) (JJ atrial) (NN beating)) (PRN (-LRB- -LRB-) (NP (NNP AC)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (VP (VBN potentiated) (PP (IN with) (NP (NP (DT the) (NN order) (NN LNa)) (X (SYM =) (X (NP (NNP LNa+LCa) (SYM =) (NNP LNa+HCa) (SYM =) (NNP LCa) (NNPS >) (NNP HCa)) (SYM =)) (NP (NNP N)))))))))) (. .)))
7516729	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (VP (VB rat) (NP (JJ atrial) (JJ spontaneous) (NN beating)))) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ dependent)) (PP (IN on) (NP (JJ -LSB-Doc_7516729_1438_1440_Chemical) (JJ -RSB-) (NNS o))) (PP (IN than) (PP (IN on) (NP (NP (JJ -LSB-Doc_7516729_1452_1454_Chemical) (JJ -RSB-) (NNS o)) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (QP (CD +/-) (CD 50)) (NN %)) (PP (IN of) (NP (PRP$ their) (JJ normal) (NN concentration))))))))))))))) (. .)))
7516729	10	(S1 (S (ADVP (RB Also)) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (JJ Doc_7516729_1534_1543_Chemical) (NNS effects))) (PP (IN on) (NP (JJ atrial) (NN beating)))) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ pronounced)) (PP (IN at) (NP (NNP LNa))) (PP (IN than) (PP (IN at) (NP (NNP LCa.))))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
7582165	0	(S1 (NP (NP (NP (NN Pseudo-Doc_7582165_7_25_Disease)) (PP (TO to) (NP (NNP Doc_7582165_29_44_Chemical)))) (: :) (NP (NP (NN diagnosis)) (CC and) (NP (NNS alternatives))) (. .)))
7582165	1	(S1 (S (NP (NP (CD Two) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ parenteral) (NNP Doc_7582165_111_124_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Triniol)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7582165_139_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Sedionbel)) (-RRB- -RRB-))))))) (VP (AUX are) (VP (VBN described))) (. .)))
7582165	2	(S1 (S (NP (NP (DT A) (JJ few) (NNS minutes)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNS drugs)))))) (, ,) (NP (PRP they)) (VP (VBD presented) (NP (NP (NP (NNP Doc_7582165_244_253_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNS patients)) (CD 1) (CC and) (CD 2)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7582165_277_291_Disease)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 1)) (-RRB- -RRB-))))) (. .)))
7582165	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (NP (DT the) (NNS patients) (POS ')) (NNS reactions)) (, ,) (SBAR (SBAR (S (NP (DT the) (JJ immunological) (NNS mechanisms)) (VP (VBN involved)))) (CC and) (SBAR (IN whether) (S (NP (DT these) (NNS patients)) (VP (MD would) (VP (AUX be) (ADJP (JJ able) (S (VP (TO to) (VP (VB tolerate) (NP (NP (DT any) (NN kind)) (PP (IN of) (NP (NN corticoid)))))))))))))))))))) (. .)))
7582165	4	(S1 (S (NP (NP (NP (JJ Clinical) (NNS examinations)) (CC and) (NP (ADJP (NN skin) (, ,) (JJ oral) (CC and) (JJ parenteral)) (NNS challenges))) (PP (IN with) (NP (JJ different) (NNP Doc_7582165_577_592_Chemical) (CC and) (NNP ELISA) (NNS tests)))) (VP (AUX were) (VP (VBN performed))) (. .)))
7582165	5	(S1 (S (PP (IN In) (NP (DT the) (CD two) (NNS patients))) (, ,) (NP (NP (NN skin) (CC and) (NNP ELISA) (NNS tests)) (PP (IN with) (NP (NNP Doc_7582165_672_685_Chemical)))) (VP (AUX were) (ADJP (JJ negative)) (, ,) (SBAR (IN as) (S (VP (AUX was) (NP (DT the) (JJ prick) (NN test)) (PP (IN with) (NP (NP (DT each)) (PP (IN of) (NP (PRP$ its) (NNS excipients))))))))) (. .)))
7582165	6	(S1 (S (NP (NP (DT A) (JJ single-blind) (JJ parenteral) (NN challenge)) (PP (IN with) (NP (NNP Triniol)))) (VP (AUX was) (ADJP (ADJP (JJ positive) (PP (IN in) (NP (NP (DT both) (NNS patients)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (CD 1) (NN ml)) (PP (IN of) (NP (DT the) (NN drug)))))))))) (, ,) (CC and) (ADJP (JJ negative) (PP (IN with) (NP (PRP$ its) (NNS excipients)))))) (. .)))
7582165	7	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD carried) (PRT (RP out)) (NP (NP (JJ oral) (CC and) (JJ parenteral) (NNS challenges)) (PP (IN with) (NP (JJ other) (NNP Doc_7582165_973_988_Chemical))))) (CC and) (VP (VBD found) (NP (NN intolerance)) (PP (TO to) (NP (NP (DT some)) (PP (IN of) (NP (PRP them))))))) (. .)))
7582165	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_7582165_1055_1068_Chemical)) (VP (VBD caused) (NP (JJ pseudoallergic) (NNS reactions)) (PP (IN in) (NP (PRP$ our) (NNS patients))))))) (. .)))
7582165	9	(S1 (S (S (NP (NP (NNS Corticosteroids)) (ADJP (JJ different) (PP (IN from) (NP (NNP Doc_7582165_1149_1162_Chemical))))) (ADVP (RB also)) (VP (VBD produced) (NP (NNP Doc_7582165_1177_1193_Disease) (NNS reactions)) (PP (IN in) (NP (DT these) (NNS patients))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT a) (JJ few)) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (VP (VBN tolerated)))) (. .)))
7582165	10	(S1 (S (NP (NP (DT The) (JJ basic) (NNS mechanisms)) (PP (IN of) (NP (DT those) (NNS reactions)))) (VP (AUX are) (RB not) (ADVP (RB yet)) (ADVP (RB fully)) (VP (VBN understood))) (. .)))
7582165	11	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (NP (DT a) (NN pseudo-Doc_7582165_1387_1394_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7582165_1405_1418_Chemical)))))))) (. .)))
7628595	0	(S1 (S (NP (NP (NN Study)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNP Doc_7628595_21_32_Chemical)) (CC and) (NP (NNP Doc_7628595_37_49_Chemical))))))) (VP (VBP supplementation) (PP (IN in) (S (VP (VBG preventing) (NP (NP (JJ hematologic) (NN Doc_7628595_92_100_Disease)) (PP (IN of) (NP (NNP Doc_7628595_104_114_Chemical)))))))) (. .)))
7628595	1	(S1 (S (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_7628595_186_197_Chemical) (CC and) (NNP Doc_7628595_202_214_Chemical) (NN supplementation))) (PP (IN in) (S (VP (VBG preventing) (NP (JJ Doc_7628595_245_255_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7628595_257_260_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_7628595_270_293_Disease))))))))))) (. .)))
7628595	2	(S1 (S (NP (NP (JJ Seventy-five) (JJ Doc_7628595_308_351_Disease) (NNS patients)) (PP (IN with) (NP (CD CD4+) (NN cell) (NNS counts)))) (VP (VBD <) (SBAR (S (NP (NNS 500/mm3)) (VP (AUX were) (VP (VBN randomized) (UCP (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (NNP Doc_7628595_427_430_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 500) (CD mg)) (NN daily)) (-RRB- -RRB-))) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN I)) (, ,) (NP (NNP n) (SYM =) (CD 38))) (-RRB- -RRB-))))) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NNP Doc_7628595_493_505_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg)) (NN daily)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ intramascular) (NNP Doc_7628595_538_549_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NNS micrograms) (JJ monthly)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN group) (NNP II)) (, ,) (NP (NNP n) (SYM =) (CD 37)) (-RRB- -RRB-))))))))))))) (. .)))
7628595	3	(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (CD 15) (NNS patients)) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))) (PRN (-LRB- -LRB-) (NP (NP (NN noncompliance) (CD 14)) (, ,) (NP (NNP Doc_7628595_665_670_Disease) (CD 1))) (-RRB- -RRB-))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (NP (CD 60) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 31)) (PP (IN in) (NP (NN group) (NN I)))) (CC and) (NP (NP (CD 29)) (PP (IN in) (NP (NN group) (NNP II))))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ eligible) (PP (IN for) (NP (NN analysis)))))) (. .)))
7628595	4	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN between) (NP (NNS groups)))) (VP (AUX were) (VP (VBN found) (PP (IN at) (NP (NN enrollment))))) (. .)))
7628595	5	(S1 (S (S (PP (IN During) (NP (DT the) (NN study))) (, ,) (NP (NNP Doc_7628595_842_853_Chemical) (CC and) (NNP Doc_7628595_858_864_Chemical) (NNS levels)) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN group) (NNP II) (NNS patients))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NN hemoglobin)) (, ,) (NP (JJ hematocrit) (, ,) (JJ mean) (NN corpuscular) (NN volume)) (, ,) (CC and) (NP (NN white-cell) (, ,) (NN neutrophil) (CC and) (NN platelet) (NNS counts))))) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (NNS groups)) (PP (IN at) (NP (CD 3) (, ,) (CD 6) (, ,) (CD 9) (CC and) (CD 12) (NNS months)))))))) (. .)))
7628595	6	(S1 (S (NP (NP (JJ Severe) (JJ hematologic) (NN Doc_7628595_1117_1125_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN neutrophil) (NN count) (NNP <) (JJ 1000/mm3) (NN and/or) (NN hemoglobin) (NN <)) (NP (CD 8) (NN g/dl))) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 4) (NNS patients)) (VP (VBN assigned) (PP (TO to) (NP (NP (NN group) (NN I)) (CC and) (NP (NP (CD 7)) (VP (VBN assigned) (PP (TO to) (NP (NN group) (NNP II))))))))))) (. .)))
7628595	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_7628595_1287_1298_Chemical) (CC or) (NNP Doc_7628595_1302_1308_Chemical) (NNS levels)) (CC and) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_7628595_1335_1351_Disease)))))))) (. .)))
7628595	8	(S1 (S (NP (NP (ADJP (JJ Doc_7628595_1353_1364_Chemical) (CC and) (JJ Doc_7628595_1369_1381_Chemical)) (NN supplementation)) (PP (IN of) (NP (JJ Doc_7628595_1401_1404_Chemical) (NN therapy)))) (VP (AUX does) (RB not) (VP (VB seem) (ADJP (JJ useful) (PP (IN in) (S (VP (VP (VBG preventing)) (CC or) (VP (VBG reducing) (NP (NP (JJ Doc_7628595_1460_1463_Chemical-induced) (NN Doc_7628595_1472_1485_Disease)) (PP (IN in) (NP (DT the) (JJ overall) (VBN treated) (NN population))))))))) (, ,) (SBAR (IN although) (S (NP (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN in) (NP (NP (JJ certain) (NNS subgroups)) (PP (IN of) (NP (NNS patients)))))) (ADVP (RB cannot)) (VP (AUX be) (VP (VBN excluded))))))) (. .)))
7802851	0	(S1 (NP (NP (NP (NN Safety)) (CC and) (NP (NN side-effects))) (PP (IN of) (NP (NNP Doc_7802851_27_37_Chemical))) (. .)))
7802851	1	(S1 (NP (NP (VBN Controlled) (NN study)) (PP (IN in) (NP (NP (NNP Doc_7802851_59_70_Disease)) (PP (IN with) (NP (NNP Doc_7802851_76_90_Disease))))) (. .)))
7802851	2	(S1 (S (NP (NP (DT The) (JJ widespread) (NN use)) (PP (IN of) (NP (NNP Doc_7802851_126_141_Chemical)))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (JJ increasing) (NN recognition)) (PP (IN of) (NP (PRP$ their) (JJ unwanted) (NNS effects))))))) (. .)))
7802851	3	(S1 (S (NP (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NP (NNP Doc_7802851_219_229_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NNP Doc_7802851_245_259_Disease))) (PP (IN with) (NP (NNP Doc_7802851_265_276_Disease))))))) (, ,) (CC and) (NP (DT the) (JJ side-effect) (CC and) (JJ adverse) (NN effect) (NNS profiles)) (PP (IN of) (NP (DT both) (NN drug) (NNS groups)))) (VP (AUX were) (VP (VBN measured))) (. .)))
7802851	4	(S1 (S (PP (IN In) (NP (NNP London) (CC and) (NNP Toronto))) (NP (NP (CD 154) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD met) (NP (NP (JJ DSM-III) (NNS criteria)) (PP (IN for) (NP (NNP Doc_7802851_433_447_Disease)))) (PP (IN with) (NP (NNP Doc_7802851_453_464_Disease))))))) (VP (AUX were) (VP (VBN randomised) (PP (TO to) (NP (NP (NN Doc_7802851_484_494_Chemical)) (CC or) (NP (NN placebo)))))) (. .)))
7802851	5	(S1 (S (NP (NP (NNS Subjects)) (PP (IN in) (NP (DT each) (NN drug) (NN group)))) (ADVP (RB also)) (VP (VBD received) (ADVP (RB either)) (NP (NP (NN exposure)) (CC or) (NP (NN relaxation)))) (. .)))
7802851	6	(S1 (S (NP (NN Treatment)) (VP (VP (AUX was) (PP (IN from) (NP (NNS weeks))) (ADVP (CD 0) (TO to) (CD 8))) (CC and) (VP (AUX was) (ADVP (RB then)) (ADJP (JJ tapered) (PP (IN from) (NP (NNS weeks) (QP (CD 8) (TO to) (CD 16))))))) (. .)))
7802851	7	(S1 (S (NP (JJ Mean) (JJ Doc_7802851_667_677_Chemical) (NN dose)) (VP (AUX was) (NP (CD 5) (NN mg)) (ADVP (RB daily))) (. .)))
7802851	8	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN placebo) (NNS subjects)))) (, ,) (NP (NNP Doc_7802851_731_741_Chemical) (NNS patients)) (VP (VBD developed) (NP (NP (JJR more) (JJ adverse) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (NP (CD 21) (NN %)) (CC v.) (NP (CD 0) (NN %))) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_7802851_799_809_Disease)) (, ,) (NP (NNP Doc_7802851_811_819_Disease)) (, ,) (NP (NN disinhibition)) (CC and) (NP (NNP Doc_7802851_839_849_Disease)))) (: ;) (CC and) (NP (JJR more) (NNS side-effects)) (, ,) (ADVP (RB particularly)) (NP (NP (NN sedation)) (, ,) (NP (NNP Doc_7802851_897_909_Disease) (, ,) (NNP Doc_7802851_911_926_Disease) (, ,) (NNP Doc_7802851_928_939_Disease) (CC and) (NNP Doc_7802851_944_950_Disease))))) (. .)))
7802851	9	(S1 (S (NP (NNS Side-effects)) (VP (VP (VBD tended) (S (VP (TO to) (VP (VB diminish) (PP (IN during) (NP (NN treatment))))))) (CC but) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN at) (NP (NN week) (CD 8))))) (. .)))
7802851	10	(S1 (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (DT the) (JJ drop-out) (NN rate)) (VP (AUX was) (ADJP (JJ low))) (. .)))
7802851	11	(S1 (S (S (NP (NN Doc_7802851_1091_1101_Chemical)) (VP (VBD caused) (NP (NP (NNS side-effects)) (CC and) (NP (JJ adverse) (NNS effects))) (PP (IN during) (NP (NN treatment))))) (CC but) (S (NP (JJ many) (NNS patients)) (VP (AUX were) (ADJP (JJ willing) (S (VP (TO to) (VP (VB accept) (NP (DT these)))))))) (. .)))
7834920	0	(S1 (S (NP (JJ Crescentic) (NN fibrillary) (NN Doc_7834920_22_40_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ intermittent) (JJ Doc_7834920_70_78_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_7834920_91_113_Disease)))))) (. .)))
7834920	1	(S1 (S (NP (DT This) (NN case) (NN study)) (VP (VBZ reveals) (NP (NP (DT an) (JJ unusual) (NN finding)) (PP (IN of) (NP (NP (RB rapidly) (JJ proliferative) (JJ crescentic) (NN Doc_7834920_194_212_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7834920_239_247_Chemical)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT no) (JJ other) (JJ identifiable) (NNS causes)) (PP (IN for) (S (VP (VBG developing) (NP (DT this) (NN disease))))))))))))))))) (. .)))
7834920	2	(S1 (S (NP (DT This) (NN patient)) (VP (VP (VBD underwent) (NP (NP (DT a) (JJ 10-month) (NN regimen)) (PP (IN of) (NP (NP (NNP Doc_7834920_359_367_Chemical)) (CC and) (NP (NNP Doc_7834920_372_381_Chemical)))) (PP (IN for) (NP (NNP Doc_7834920_386_408_Disease))))) (CC and) (VP (AUX was) (VP (VBN discovered) (S (VP (TO to) (VP (AUX have) (VP (VBN developed) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ severe) (NNP Doc_7834920_462_475_Disease) (CD five) (NNS weeks)))) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NN therapy)))))))))))) (. .)))
7834920	3	(S1 (S (NP (JJ Renal) (NN biopsy)) (VP (VBD revealed) (NP (NP (JJ severe) (NN Doc_7834920_545_563_Disease)) (PP (IN with) (NP (NP (NNS crescents)) (, ,) (NP (NNP electron) (JJ dense) (NN fibrillar) (NNS deposits)) (CC and) (NP (JJ moderate) (JJ lymphocytic) (NN interstitial) (VB infiltrate)))))) (. .)))
7834920	4	(S1 (S (NP (NP (JJ Other) (JJ possible) (NNS causes)) (PP (IN of) (NP (ADJP (RB rapidly) (JJ progressive)) (NN Doc_7834920_709_727_Disease)))) (VP (AUX were) (VP (VP (VBN investigated)) (CC and) (VP (VBD ruled) (PRT (RP out))))) (. .)))
7834920	5	(S1 (S (NP (DT This) (NN report)) (VP (VBZ documents) (NP (NP (DT the) (JJ unusual) (NN occurrence)) (PP (IN of) (NP (RB rapidly) (JJ progressive) (NNP Doc_7834920_829_847_Disease))) (PP (IN with) (NP (NP (NNS crescents)) (CC and) (NP (JJ fibrillar) (NN Doc_7834920_877_895_Disease))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7834920_922_930_Chemical))))))) (. .)))
7858459	0	(S1 (S (NP (JJ Acute) (NN Doc_7858459_6_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ high-dose) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_7858459_51_65_Chemical)) (CC and) (NP (NNP Doc_7858459_70_82_Chemical))))))) (. .)))
7858459	1	(S1 (S (NP (DT A) (JJ 61-year-old) (NN man)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NN combination) (NNS chemotherapy)) (VP (VBG incorporating) (NP (NP (NNP Doc_7858459_158_169_Chemical)) (, ,) (NP (NNP Doc_7858459_171_180_Chemical)) (, ,) (NP (NP (JJ high-dose) (NNP Doc_7858459_192_206_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2,250) (CD mg/m2/24)) (NNS hours)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7858459_234_246_Chemical))) (PP (IN for) (NP (DT an) (JJ inoperable) (NN Doc_7858459_265_287_Disease)))))))) (. .)))
7858459	2	(S1 (S (NP (PRP He)) (VP (VP (VBD developed) (NP (NP (JJ acute) (JJ neurologic) (NNS symptoms)) (PP (IN of) (NP (JJ mental) (NNP Doc_7858459_338_347_Disease) (, ,) (NNP Doc_7858459_349_363_Disease) (CC and) (NNP Doc_7858459_368_380_Disease))))) (, ,) (CC and) (ADVP (RB then)) (VP (VBN lapsed) (PP (IN into) (NP (NP (DT a) (JJ deep) (NN Doc_7858459_410_414_Disease)) (, ,) (VP (VBG lasting) (PP (IN for) (NP (QP (RB approximately) (CD 40)) (NNS hours))) (PP (IN during) (NP (NP (DT the) (JJ first) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_7858459_484_498_Chemical) (CC and) (NNP Doc_7858459_503_515_Chemical) (NN infusion)))))))))) (. .)))
7858459	3	(S1 (S (NP (DT This) (NN complication)) (VP (VBD reappeared) (PP (IN on) (NP (NN day) (CD 25))) (PP (IN during) (NP (NP (DT the) (JJ second) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_7858459_591_605_Chemical)) (CC and) (NP (NNP Doc_7858459_610_622_Chemical)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADVP (RB then)) (NP (NP (DT the) (JJ only) (NNS drugs)) (VP (VBN given))))))))) (. .)))
7858459	4	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_7858459_670_682_Chemical)) (VP (AUX was) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (DT this) (NN condition))))))))))) (, ,) (NP (NNP Doc_7858459_734_747_Disease)) (PP (JJ due) (TO to) (NP (JJ high-dose) (NNP Doc_7858459_765_779_Chemical))) (VP (AUX was) (ADJP (RB highly) (VBN suspected))) (. .)))
7858459	5	(S1 (S (NP (NP (DT The) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_7858459_822_836_Chemical) (NNP Doc_7858459_837_850_Disease)))) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (DT a) (NNP Krebs) (NN cycle) (NN blockade)) (PP (IN by) (NP (NP (NNP Doc_7858459_891_904_Chemical)) (CC and) (NP (NNP Doc_7858459_909_922_Chemical))))) (, ,) (NP (JJ Doc_7858459_924_932_Chemical) (NN deficiency)) (, ,) (CC or) (NP (JJ Doc_7858459_948_961_Chemical) (NN dehydrogenase) (NN deficiency))))))) (. .)))
7858459	6	(S1 (S (NP (JJ High-dose) (JJ Doc_7858459_998_1012_Chemical/Doc_7858459_1013_1025_Chemical) (NN infusion) (NN therapy)) (VP (AUX has) (ADVP (RB recently)) (VP (VBN become) (NP (NP (DT a) (JJ popular) (NN regimen)) (PP (IN for) (NP (JJ various) (NNP Doc_7858459_1093_1100_Disease)))))) (. .)))
7858459	7	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ necessary)) (SBAR (IN that) (S (NP (DT both) (NNS oncologists) (CC and) (NNS neurologists)) (VP (AUX be) (ADJP (RB fully) (JJ aware) (PP (IN of) (NP (DT this) (JJ unusual) (NN complication)))))))) (. .)))
7862923	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (S (VP (VBG switching) (NP (NN Doc_7862923_20_33_Chemical)) (PP (TO to) (NP (NNP Doc_7862923_37_50_Chemical)))))) (PP (IN on) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NNS neuroleptics))))) (. .)))
7862923	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
7862923	2	(S1 (S (NP (NN Doc_7862923_104_117_Chemical)) (VP (AUX was) (VP (VBN switched) (PP (TO to) (NP (NP (PRP$ its) (JJ 10-keto) (NN analogue) (NN Doc_7862923_155_168_Chemical)) (PP (IN among) (NP (NP (CD six) (JJ difficult-to-treat) (NNP Doc_7862923_198_211_Disease) (CC or) (NNP Doc_7862923_215_232_Disease) (NNS patients)) (VP (VBG using) (NP (RB concomitantly) (NNP Doc_7862923_262_273_Chemical) (, ,) (NNP Doc_7862923_275_289_Chemical) (CC or) (NNP Doc_7862923_293_302_Chemical))))))))) (. .)))
7862923	3	(S1 (S (NP (DT This) (NN change)) (VP (VBD resulted) (PP (IN within) (NP (JJ 2-4) (NNS weeks))) (PP (IN in) (NP (NP (NP (DT the) (ADJP (CD 50-200) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT these) (NNS neuroleptics)))))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_7862923_431_454_Disease))))))) (. .)))
7862923	4	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD showed) (NP (DT any) (JJ clinical) (NN deteriotation)) (PP (IN during) (NP (DT the) (JJ following) (JJ 3-6) (NNS months)))) (. .)))
7862923	5	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN case)))) (VP (VBP report) (SBAR (S (VP (VBP support) (NP (NP (DT the) (NN idea)) (SBAR (WHNP (WDT that)) (S (PP (IN in) (NP (NP (NN contrast)) (PP (IN with) (NP (NNP Doc_7862923_615_628_Chemical) (NNP Doc_7862923_629_642_Chemical))))) (VP (AUX does) (RB not) (VP (VB induce) (NP (NP (DT the) (JJ hepatic) (JJ microsomal) (NN enzyme) (NNS systems)) (VP (VBG regulating) (NP (NP (DT the) (NN inactivation)) (PP (IN of) (NP (JJ antipsychotic) (NNS drugs))))))))))))))) (. .)))
7881871	0	(S1 (NP (NP (NN Time) (NN course)) (PP (IN of) (NP (NN lipid) (NN peroxidation))) (PP (IN in) (NP (NNP Doc_7881871_37_62_Chemical-induced) (NNP Doc_7881871_71_82_Disease))) (. .)))
7881871	1	(S1 (S (NP (JJ Reactive) (JJ Doc_7881871_93_99_Chemical) (NNS species)) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ acute) (NNP Doc_7881871_158_183_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7881871_185_188_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_7881871_198_209_Disease))))) (, ,) (PP (IN with) (NP (NP (NNS antioxidants)) (VP (ADVP (RB significantly)) (VBG reducing) (NP (DT the) (NNP Doc_7881871_256_267_Disease)))))))) (. .)))
7881871	2	(S1 (S (NP (NP (DT The) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (NP (NN lipid) (NN peroxidation)) (PP (IN in) (NP (DT the) (NN kidney)))) (CC and) (NP (NNP Doc_7881871_340_351_Disease))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
7881871	3	(S1 (S (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (NNP IV) (NN injection)) (PP (IN of) (NP (NNP Doc_7881871_428_453_Chemical))))) (, ,) (PRN (-LRB- -LRB-) (NP (NNP Doc_7881871_456_459_Chemical)) (, ,) (NP (CD 7.5) (NN mg/kg)) (-RRB- -RRB-))))) (CC and) (S (NP (CD 24) (NN hour) (NN urine) (NNS samples)) (VP (AUX were) (VP (VBN obtained) (ADVP (RB prior)) (S (VP (TO to) (VP (VB sacrifice) (PP (IN on) (NP (NP (NNS days) (CD 3,5,7,10,17,27,41)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (PP (JJ 5-10) (IN per) (NP (NN group)))) (-RRB- -RRB-)))))))))) (. .)))
7881871	4	(S1 (S (NP (DT The) (NNS kidneys)) (VP (AUX were) (VP (VBN removed) (, ,) (PP (VBN flushed) (PP (IN with) (NP (NN ice) (JJ cold) (NN TRIS) (NN buffer)))))) (. .)))
7881871	5	(S1 (S (NP (NP (NN Kidney) (NNS cortices)) (PP (IN from) (NP (DT each) (NN animal)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB prepare) (NP (NNS homogenates))))))) (. .)))
7881871	6	(S1 (S (NP (NN Tissue) (NN lipid) (NN peroxidation)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (JJ whole) (NNS homogenates))) (PP (CONJP (RB as) (RB well) (IN as)) (IN in) (NP (NP (NN lipid) (NNS extracts)) (PP (IN from) (NP (NP (NNS homogenates)) (PP (IN as) (NP (JJ Doc_7881871_816_835_Chemical) (JJ reactive) (NNS substances))))))))) (. .)))
7881871	7	(S1 (S (S (NP (NN Doc_7881871_857_868_Disease)) (VP (AUX was) (ADJP (JJ evident)) (PP (IN at) (NP (NN day) (CD 5))))) (, ,) (VP (VP (VBD peaked) (PP (IN at) (NP (NN day) (CD 7)))) (CC and) (VP (VBD persisted) (PP (TO to) (NP (NN day) (CD 27))))) (. .)))
7881871	8	(S1 (S (NP (NP (NN Lipid) (NN peroxidation)) (PP (IN in) (NP (NNS homogenates)))) (VP (VP (AUX was) (ADVP (RB maximal)) (PP (IN at) (NP (NN day) (CD 3)))) (CC and) (VP (VBD declined) (ADVP (RB rapidly)) (S (VP (TO to) (VP (VB control) (NP (NNS levels)) (PP (IN by) (NP (NN day) (CD 17)))))))) (. .)))
7881871	9	(S1 (S (NP (DT This) (NN study)) (VP (VBZ supports) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN lipid) (NN peroxidation))) (PP (IN in) (S (VP (VBG mediating) (NP (NP (DT the) (NN Doc_7881871_1105_1123_Disease)) (PP (IN in) (NP (NNP Doc_7881871_1127_1130_Chemical) (NNP Doc_7881871_1131_1142_Disease))))))))) (. .)))
7890216	0	(S1 (NP (NP (NP (NN Composition)) (PP (IN of) (NP (NNP Doc_7890216_15_34_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_7890216_51_61_Chemical))))) (: :) (NP (NP (NN response)) (PP (TO to) (NP (JJ oral) (NNP Doc_7890216_80_100_Chemical)))) (. .)))
7890216	1	(S1 (S (NP (NP (NNP Doc_7890216_102_112_Chemical)) (, ,) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NNP Doc_7890216_141_151_Disease)))) (, ,)) (VP (VBZ induces) (NP (NN Doc_7890216_161_180_Disease)) (PP (IN in) (NP (NP (CD 13-60) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
7890216	2	(S1 (S (SBAR (IN Because) (S (NP (NP (NN knowledge)) (PP (IN of) (NP (NN stone) (NN composition)))) (VP (AUX is) (ADJP (JJ essential) (PP (IN for) (NP (NP (NNS studies)) (PP (IN of) (NP (PRP$ their) (NN pathogenesis) (, ,) (NN treatment) (, ,) (CC and) (NN prevention))))))))) (, ,) (NP (DT this)) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (NP (NP (JJ direct) (CC and) (JJ indirect) (NNS methods)) (PP (IN in) (NP (NP (CD 14) (JJ Doc_7890216_377_387_Chemical) (VBN treated) (JJ Doc_7890216_396_407_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_7890216_422_433_Disease))))))))) (. .)))
7890216	3	(S1 (S (S (NP (NP (JJ Chemical) (NN analysis)) (PP (IN of) (NP (NNP Doc_7890216_456_467_Disease)))) (VP (VBD retrieved) (PP (IN at) (NP (NN cholecystectomy))) (PP (IN from) (NP (CD two) (NNS patients))))) (, ,) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP they)) (VP (VBD contained) (NP (NP (CD 71) (NN %)) (CC and) (NP (CD 87) (NN %))) (NP (NNP Doc_7890216_555_566_Chemical)) (PP (IN by) (NP (NN weight))))))) (. .)))
7890216	4	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (CD 12) (NNS patients))) (, ,) (NP (NP (JJ localised) (JJ computed) (NN tomography)) (PP (IN of) (NP (DT the) (NN gall) (NN bladder)))) (VP (VBD showed) (SBAR (IN that) (S (NP (CD eight)) (VP (AUX had) (NP (NNS stones)) (PP (IN with) (NP (NP (JJ maximum) (JJ attenuation) (NNS scores)) (PP (IN of) (NP (NP (QP (CD <) (CD 100)) (NNP Hounsfield) (NNS units)) (PRN (-LRB- -LRB-) (S (NP (NP (NNS values)) (PP (IN of) (NP (QP (CD <) (CD 100)) (NNS HU)))) (VP (VBP predict) (NP (JJ Doc_7890216_773_784_Chemical) (JJ rich) (, ,) (JJ dissolvable) (NNS stones)))) (-RRB- -RRB-)))))))))) (. .)))
7890216	5	(S1 (S (NP (NN Gall) (NN bladder) (NN bile)) (VP (AUX was) (VP (VBN obtained) (PP (IN by) (NP (NP (NN ultrasound)) (VP (VBN guided)))) (, ,) (NP (NP (JJ fine) (NN needle) (NN puncture)) (PP (IN from) (NP (CD six) (NNS patients)))))) (. .)))
7890216	6	(S1 (S (S (NP (DT All) (CD six) (NNS patients)) (VP (AUX had) (VP (VBN supersaturated) (NP (JJ bile) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NP (NP (NP (PRN (-LRB- -LRB-) (NP (NNP SEM)) (-RRB- -RRB-)) (NNP Doc_7890216_958_969_Chemical) (NN saturation) (NN index)) (PP (IN of) (NP (CD 1.19)))) (-LRB- -LRB-) (NP (CD 0.08)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NN range) (CD 1.01-1.53)) (-RRB- -RRB-)))) (-RRB- -RRB-) (S (CC and) (NP (DT all)) (VP (AUX had) (NP (NP (ADJP (RB abnormally) (JJ rapid)) (JJ Doc_7890216_1050_1061_Chemical) (JJ microcrystal) (NN nucleation) (NNS times)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD <) (CD 4)) (NNS days)) (PRN (-LRB- -LRB-) (NN range) (NN 1-4) (-RRB- -RRB-))) (-RRB- -RRB-))))) (, ,)) (NN whilst)) (PP (IN in) (NP (CD four)))))) (, ,) (NP (DT the) (NN bile)) (VP (VBD contained) (NP (JJ Doc_7890216_1151_1162_Chemical) (NNS microcrystals)) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG sampling))))) (. .)))
7890216	7	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 12) (NNS patients)) (VP (VBN considered) (PP (IN for) (NP (JJ oral) (NNP Doc_7890216_1244_1264_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7890216_1266_1270_Chemical)) (-RRB- -RRB-)) (NN treatment)))))) (, ,) (NP (CD two)) (VP (VP (AUX had) (NP (DT a) (VBN blocked) (JJ cystic) (NN duct))) (CC and) (VP (AUX were) (RB not) (VP (VBD started) (PP (IN on) (NP (NNP Doc_7890216_1337_1341_Chemical))) (SBAR (IN while) (S (NP (PRP one)) (VP (AUX was) (VP (VBN lost) (S (VP (TO to) (VP (VB follow) (PRT (RP up)))))))))))) (. .)))
7890216	8	(S1 (S (PP (IN After) (NP (NP (CD one) (NN year)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (CD five)) (PP (IN of) (NP (DT the) (JJ remaining) (CD nine) (NNS patients)))) (VP (VBD showed) (NP (DT either) (ADJP (ADJP (ADJP (JJ partial)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ complete)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)))) (NNP Doc_7890216_1490_1500_Disease) (NN dissolution)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP$ their) (NNS stones)) (VP (AUX were) (ADJP (NNP Doc_7890216_1548_1559_Chemical) (JJ rich)))))))) (. .)))
7890216	9	(S1 (NP (NP (NP (DT This) (NNS corresponds)) (, ,) (PP (IN by) (NP (JJ actuarial) (PRN (-LRB- -LRB-) (NP (NN life) (NN table)) (-RRB- -RRB-)) (NN analysis))) (, ,)) (PP (TO to) (NP (NP (DT a) (JJ combined) (JJ Doc_7890216_1634_1644_Disease) (NN dissolution) (NN rate)) (PP (IN of) (NP (CD 58.3))) (PRN (-LRB- -LRB-) (NP (CD 15.9) (NN %)) (-RRB- -RRB-)))) (. .)))
7890216	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNP Doc_7890216_1694_1704_Chemical)) (VP (VBN induced) (NP (NNP Doc_7890216_1713_1724_Disease)))) (VP (AUX are) (ADJP (ADJP (RB generally) (JJ small)) (, ,) (ADJP (JJ multiple)) (, ,) (CC and) (ADJP (JJ Doc_7890216_1760_1771_Chemical) (JJ rich))) (SBAR (IN although) (S (, ,) (PP (IN in) (NP (NP (NN common)) (PP (IN with) (NP (JJ spontaneous) (NNP Doc_7890216_1814_1832_Disease))))) (, ,) (PP (IN at) (NP (NN presentation))) (NP (DT some) (NNS patients)) (VP (MD will) (VP (AUX have) (NP (NP (DT a) (VBN blocked) (JJ cystic) (NN duct)) (CC and) (NP (NP (DT some) (NN Doc_7890216_1905_1916_Disease)) (VP (VBG containing) (NP (NNP Doc_7890216_1928_1935_Chemical)))))))))) (. .)))
7919560	0	(S1 (S (NP (NP (NN Doc_7919560_0_19_Disease)) (CC and) (NP (NN Doc_7919560_24_52_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_63_73_Chemical)))) (. .)))
7919560	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_7919560_106_125_Disease)) (CC and) (NP (NNP Doc_7919560_130_158_Disease)))))))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_169_179_Chemical)))) (. .)))
7919560	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (S (NP (DT A) (JJ 13-year-old) (NN boy)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7919560_230_240_Chemical)) (CC and) (NP (NNP Doc_7919560_245_255_Chemical)))) (PP (IN because) (IN of) (NP (VBN suspected) (NN Doc_7919560_277_287_Disease)))))) (. .)))
7919560	3	(S1 (S (NP (NNS Medications)) (VP (AUX were) (VP (VBN discontinued) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NNP Doc_7919560_324_343_Disease)) (CC and) (NP (NNP Doc_7919560_348_372_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_383_394_Disease))))) (VP (VBD occurred)))))) (. .)))
7919560	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7919560_434_452_Chemical))))) (CC and) (VP (ADVP (RB gradually)) (VBN improved))) (. .)))
7919560	5	(S1 (S (NP (NP (JJ Macrophage-migration) (NN inhibition) (PRN (-LRB- -LRB-) (NP (NNP MIF)) (-RRB- -RRB-)) (NN test)) (PP (IN with) (NP (NNP Doc_7919560_525_535_Chemical)))) (VP (AUX was) (ADJP (JJ positive))) (. .)))
7919560	6	(S1 (S (SBAR (IN After) (S (NP (NP (RBS most) (JJ Doc_7919560_573_583_Disease)) (PP (VBG causing) (NP (NP (NNP Doc_7919560_592_611_Disease)) (CC and) (NP (NNP Doc_7919560_616_627_Disease))))) (VP (AUX were) (VP (VBN ruled) (PRT (RP out)))))) (, ,) (NP (DT a) (NN Doc_7919560_646_676_Disease)) (VP (AUX was) (VP (VBN suspected))) (. .)))
7919560	7	(S1 (S (NP (NP (JJ Positive) (NN MIF) (NN test)) (PP (IN for) (NP (NNP Doc_7919560_714_724_Chemical)))) (VP (VBD showed) (NP (NP (NN sensitization)) (PP (IN of) (NP (NP (DT the) (NN patient) (POS 's)) (NNS lymphocytes))) (PP (TO to) (NP (NNP Doc_7919560_778_788_Chemical))))) (. .)))
7919560	8	(S1 (S (NP (NN Doc_7919560_803_831_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC and) (JJ dangerous)) (NN manifestation)) (PP (IN of) (NP (NNP Doc_7919560_873_880_Disease))) (PP (TO to) (NP (NNP Doc_7919560_884_895_Chemical))))) (. .)))
7930386	0	(S1 (S (NP (JJ Doc_7930386_0_12_Chemical-induced) (NNP Doc_7930386_21_38_Disease)) (VP (AUX does) (RB not) (VP (VB impair) (NP (PRP$ its) (JJ prolactin-releasing) (NN action)))) (. .)))
7930386	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNP Doc_7930386_143_160_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7930386_173_185_Chemical) (NN administration)))) (, ,)))) (PP (IN on) (NP (NP (DT the) (JJ secretory) (NN rate)) (PP (IN of) (NP (NP (NN prolactin)) (PRN (-LRB- -LRB-) (NP (NN PRL)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (DT the) (JJ direct) (NN drug) (NN effect)))))))))))) (. .)))
7930386	2	(S1 (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (JJ supine) (NNS subjects)))) (VP (AUX were) (VP (VBN studied) (PP (IN under) (NP (NP (JJ placebo-controlled) (NNS conditions)) (, ,) (NP (NP (NP (CD one)) (PP (IN during) (NP (NP (DT the) (NN night)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG sleeping) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN at) (NP (JJ daytime))))) (, ,))) (FRAG (WHADVP (WRB when) (RB awake))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-)))) (. .)))
7930386	3	(S1 (S (NP (DT Each) (NN subject)) (VP (VBD received) (NP (NP (DT a) (JJ single) (CD 50) (JJ mg) (NN dose)) (PP (IN of) (NP (NNP Doc_7930386_497_509_Chemical)))) (S (VP (VBN given) (NP (QP (RB orally) (CD 2)) (NNS hours)) (PP (IN before) (NP (NN blood) (NN collection)))))) (. .)))
7930386	4	(S1 (S (NP (NN Plasma) (NN PRL) (NNS concentrations)) (VP (AUX were) (VP (VBN analysed) (PP (IN at) (NP (NP (NP (CD 10) (JJ min) (NNS intervals)) (CC and) (NP (JJ underlying) (NN secretory) (NNS rates))) (VP (VBN calculated) (PP (IN by) (NP (DT a) (JJ deconvolution) (NN procedure)))))))) (. .)))
7930386	5	(S1 (S (PP (IN For) (NP (DT both) (NNS experiments))) (NP (DT the) (NN drug) (NN intake)) (VP (VBD led) (PP (TO to) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NN PRL) (NN secretion))))) (, ,) (S (VP (VBG acting) (ADVP (RB preferentially)) (PP (IN on) (NP (NN tonic) (NN secretion))) (SBAR (IN as) (S (NP (NP (NN pulse) (NN amplitude)) (CC and) (NP (NN frequency))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (S (VP (VBG corresponding) (NP (NN control) (NNS values)))))))))))) (. .)))
7930386	6	(S1 (S (PP (IN During) (NP (DT the) (NN night))) (NP (NNP Doc_7930386_927_939_Chemical) (NN ingestion)) (VP (VBD altered) (NP (DT the) (JJ complete) (NN sleep) (NN architecture)) (SBAR (IN in) (IN that) (S (NP (PRP it)) (VP (VP (VBD suppressed) (NP (NP (NN REM) (NN sleep)) (CC and) (NP (DT the) (NN sleep) (NNS cycles)))) (CC and) (VP (VBN induced) (NP (JJ increased) (NN wakefulness))))))) (. .)))
7930386	7	(S1 (S (SBAR (IN As) (S (NP (NP (DT the) (JJ relative) (NN increase)) (PP (IN in) (NP (NP (NN PRL) (NN secretion)) (VP (VBN expressed) (PP (IN as) (NP (NP (DT a) (NN percentage)) (PP (IN of) (NP (DT the) (NN mean))))))))) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB differ) (PP (IN between) (NP (NP (DT the) (NN night) (CC and) (NN day) (NN time) (NNS studies)) (PRN (-LRB- -LRB-) (NP (CD 46) (JJ +/-) (NP (CD 19) (NN %)) (NNP vs) (CD 34) (NN +/-) (CD 10) (NN %)) (-RRB- -RRB-)))))))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN concluded) (SBAR (IN that) (S (NP (DT the) (JJ observed) (NNP Doc_7930386_1292_1309_Disease)) (VP (AUX did) (RB not) (VP (VB interfere) (PP (IN with) (NP (DT the) (NN drug) (NN action))) (ADVP (FW per) (FW se))))))))) (. .)))
7930386	8	(S1 (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NN REM) (NN sleep)))) (VP (AUX was) (VP (VBN shown) (S (RB not) (VP (TO to) (VP (AUX be) (NP (DT a) (VBG determining) (NN factor)) (ADVP (RB either)) (PP (IN for) (NP (NP (JJ secretory) (NN pulse) (NN amplitude)) (CC and) (NP (NN frequency)))) (PRN (, ,) (ADVP (RB as)) (, ,)) (SBAR (IN for) (S (NP (DT both)) (, ,) (VP (VBP mean) (SBAR (S (NP (NN nocturnal) (NNS values)) (VP (AUX were) (UCP (ADJP (JJ similar) (PP (IN with))) (CC and) (PP (IN without) (NP (JJ prior) (JJ Doc_7930386_1548_1560_Chemical) (NN ingestion))))))))))))))) (. .)))
7977601	0	(S1 (NP (NP (NN Survey)) (PP (IN of) (NP (NP (NNS complications)) (PP (IN of) (NP (NP (JJ Doc_7977601_27_44_Chemical) (NN angiography)) (PP (IN in) (NP (NNP Japan))))))) (. .)))
7977601	1	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NNP Doc_7977601_103_120_Chemical)))) (PP (IN for) (NP (NN use))) (PP (IN in) (NP (JJ fundus) (NN angiography)))) (. .)))
7977601	2	(S1 (S (NP (PRP We)) (VP (VBD sent) (NP (NP (DT a) (NN questionnaire)) (VP (VBG concerning) (NP (NP (NNS complications)) (PP (IN of) (NP (NNP Doc_7977601_213_230_Chemical)))))) (PP (TO to) (NP (CD 32) (NNS institutions))) (PP (IN in) (NP (NP (NNP Japan)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN selected) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (NN client) (NN list)) (PP (IN from) (NP (NP (DT the) (NNP Topcon) (NN Company)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ manufactures) (NP (DT the) (JJ Doc_7977601_360_377_Chemical) (JJ fundus) (NN camera)))))))))))))))))) (. .)))
7977601	3	(S1 (S (NP (NP (NNS Ophthalmologists)) (PP (IN at) (NP (CD 15) (NNS institutions)))) (VP (VBD responded) (, ,) (S (VP (VBG reporting) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 3,774) (JJ Doc_7977601_476_493_Chemical) (NNS angiograms)) (VP (VBN performed) (PP (IN on) (NP (NP (CD 2,820) (NNS patients)) (PP (IN between) (NP (NP (NNP June) (CD 1984)) (CC and) (NP (NNP September) (CD 1992))))))))))))) (. .)))
7977601	4	(S1 (S (PP (IN Before) (NP (NP (NN angiography)) (, ,) (NP (NN intradermal)) (CC or) (NP (JJ intravenous) (JJ Doc_7977601_618_635_Chemical) (NN testing)))) (, ,) (CC or) (S (NP (DT both)) (VP (AUX was) (VP (VBN performed) (PP (IN at) (NP (NP (CD 13)) (PP (IN of) (NP (CD 15) (NNS institutions)))))))) (. .)))
7977601	5	(S1 (S (PP (IN For) (NP (CD three) (NNS patients))) (, ,) (NP (DT the) (NN decision)) (VP (AUX was) (VP (VBN made) (S (RB not) (VP (TO to) (VP (VB proceed) (PP (IN with) (NP (NN angiography))) (PP (IN after) (NP (JJ positive) (JJ preangiographic) (NN testing)))))))) (. .)))
7977601	6	(S1 (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (NNP Doc_7977601_821_838_Chemical))) (VP (VBN used) (PP (IN for) (NP (NN angiography))))) (VP (VBN varied) (PP (IN from) (NP (QP (CD 25) (TO to) (CD 75)) (NN mg))) (, ,) (PP (VBG depending) (PP (IN upon) (NP (DT the) (NN institution))))) (. .)))
7977601	7	(S1 (S (NP (EX There)) (VP (VP (AUX were) (NP (NP (CD 13) (NNS cases)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (CD 0.34) (NN %)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (CD ten) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX were) (NP (NP (JJ mild) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_7977601_1008_1014_Disease) (, ,) (NNP Doc_7977601_1016_1025_Disease) (, ,) (NNP Doc_7977601_1027_1037_Disease) (, ,) (NNP Doc_7977601_1039_1048_Disease) (, ,) (CC and) (NN urgency)) (PP (TO to) (NP (VB defecate))))))))))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB require) (NP (NN treatment))))) (. .)))
7977601	8	(S1 (S (S (ADVP (RB Also)) (VP (VBN recorded))) (VP (AUX were) (NP (NP (NP (CD one) (NN case)) (PP (IN of) (NP (NP (NNP Doc_7977601_1137_1141_Disease)) (PP (IN of) (NP (DT the) (NN vein))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD required) (NP (NN treatment)))))))) (, ,) (CC and) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_7977601_1198_1209_Disease)))))) (. .)))
7977601	9	(S1 (S (NP (DT The) (CD two) (JJ Doc_7977601_1219_1230_Disease) (NNS patients)) (VP (VBD required) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_7977601_1263_1268_Disease))))) (. .)))
7977601	10	(S1 (S (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (NP (NN frequency)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PP (TO to) (NP (NNP Doc_7977601_1333_1350_Chemical))))) (PP (IN with) (NP (NP (DT the) (ADJP (RB previously) (VBN reported)) (NN frequency)) (PP (IN of) (NP (NP (JJ such) (NNS reactions)) (PP (TO to) (NP (NNP Doc_7977601_1411_1429_Chemical)))))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NNP Doc_7977601_1445_1462_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ safe)) (PP (IN as) (NP (NNP Doc_7977601_1476_1487_Chemical)))) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NN angiography))))))))) (. .)))
7988234	0	(S1 (S (NP (NN Doc_7988234_0_10_Disease)) (VP (VBG following) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_7988234_55_65_Chemical))))) (. .)))
7988234	1	(S1 (S (NP (DT A) (JJ 72-year-old) (NN woman)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN with) (NP (NP (`` ``) (NN flash) ('' '') (NN Doc_7988234_129_144_Disease)) (, ,) (VP (VBN preceded) (PP (IN by) (NP (NNP Doc_7988234_158_168_Disease)))) (, ,) (VP (VBG requiring) (NP (NN intubation))))))) (. .)))
7988234	2	(S1 (S (NP (PRP$ Her) (JJ medical) (NN history)) (VP (VBD included) (NP (NNP Doc_7988234_221_244_Disease)) (PP (IN with) (NP (NP (JJ previous) (NNP Doc_7988234_259_281_Disease)) (, ,) (NP (NNP Doc_7988234_283_295_Disease)) (, ,) (CC and) (NP (NNP Doc_7988234_301_318_Disease))))) (. .)))
7988234	3	(S1 (S (NP (NP (DT A) (NN history)) (PP (IN of) (NP (NNP Doc_7988234_333_343_Disease) (JJ secondary))) (PP (TO to) (NP (JJ Doc_7988234_357_367_Chemical) (NN therapy)))) (VP (AUX was) (VP (VBN elicited))) (. .)))
7988234	4	(S1 (S (NP (JJ Current) (NNS medications)) (VP (AUX did) (RB not) (VP (VB include) (NP (NP (JJ Doc_7988234_426_437_Chemical-converting) (NN enzyme) (NNS inhibitors)) (CC or) (NP (NNS beta-blockers))))) (. .)))
7988234	5	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (DT no) (JJ previous) (JJ beta-blocking) (NN drug) (NN exposure))) (. .)))
7988234	6	(S1 (S (PP (IN During) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NP (NN hospitalization)) (PRN (-LRB- -LRB-) (PP (IN while) (NP (NN intubated))) (-RRB- -RRB-)))))) (, ,) (NP (JJ intravenous) (NNP Doc_7988234_605_615_Chemical)) (VP (AUX was) (VP (VBN given) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ severe) (NN Doc_7988234_647_657_Disease))))))) (. .)))
7988234	7	(S1 (S (NP (DT The) (NNP Doc_7988234_663_673_Disease)) (VP (VBD resolved) (PP (IN after) (NP (NN therapy))) (PP (IN with) (NP (NP (JJ intravenous) (NN Doc_7988234_714_722_Chemical)) (CC and) (NP (JJ Doc_7988234_727_742_Chemical) (NN hydrochloride))))) (. .)))
8073369	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8073369_10_17_Chemical))) (PP (IN on) (NP (DT the) (JJ developing) (NN chick) (NN embryo))) (. .)))
8073369	1	(S1 (S (NP (NP (NNP Doc_8073369_50_57_Chemical)) (, ,) (NP (NP (DT an) (NN alkaloid)) (PP (IN from) (NP (NP (JJ Conium) (NN maculatum)) (PRN (-LRB- -LRB-) (NP (NN poison) (NN hemlock)) (-RRB- -RRB-))))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (JJ teratogenic)) (PP (IN in) (NP (NN livestock))))))))) (. .)))
8073369	2	(S1 (S (NP (DT The) (JJ major) (JJ teratogenic) (NN outcome)) (VP (AUX is) (ADJP (JJ Doc_8073369_191_205_Disease)) (, ,) (PP (ADVP (RB presumably)) (JJ due) (PP (TO to) (NP (JJ nicotinic) (NN receptor) (NN blockade))))) (. .)))
8073369	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_8073369_263_270_Chemical)) (VP (VP (AUX has) (VP (VBN failed) (S (VP (TO to) (VP (VB produce) (NP (NP (NN Doc_8073369_293_307_Disease)) (PP (IN in) (NP (NNS rats) (CC or) (NNS mice))))))))) (CC and) (VP (AUX is) (ADVP (RB only)) (ADJP (RB weakly) (JJ teratogenic) (PP (IN in) (NP (NNS rabbits)))))) (. .)))
8073369	4	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB evaluate)) (CC and) (VP (VB compare) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_8073369_436_443_Chemical)) (CC and) (NP (NNP Doc_8073369_448_456_Chemical)))) (PP (IN in) (NP (DT the) (VBG developing) (NN chick))))))))) (. .)))
8073369	5	(S1 (S (NP (NP (NNS Concentrations)) (PP (IN of) (NP (NNP Doc_8073369_500_507_Chemical) (CC and) (NNP Doc_8073369_512_520_Chemical) (NN sulfate)))) (VP (AUX were) (ADVP (NP (NP (CD 0.015) (NN %)) (, ,) (NP (CD 0.03) (NN %)) (, ,) (NP (CD 0.075) (NN %)) (, ,) (NP (CD 0.15) (NN %)) (, ,) (NP (CD 0.75) (NN %)) (, ,) (NP (CD 1.5) (NN %)) (, ,) (NP (CD 3) (NN %)) (, ,) (CC and) (NP (CD 6) (NN %)) (CC and) (NP (CD 1) (NN %)) (, ,) (NP (CD 5) (NN %)) (, ,) (CC and) (NP (CD 10) (NN %)) (, ,)) (RB respectively))) (. .)))
8073369	6	(S1 (S (NP (DT Both) (NNS compounds)) (VP (VBD caused) (NP (NP (NN Doc_8073369_645_657_Disease)) (CC and) (NP (NN lethality))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
8073369	7	(S1 (S (S (NP (NP (DT All) (NNS concentrations)) (PP (IN of) (NP (JJ Doc_8073369_722_730_Chemical) (NN sulfate)))) (VP (VBD caused) (NP (DT some) (NN lethality)))) (CC but) (S (NP (NP (DT a) (ADJP (RB no) (NN effect)) (NN level)) (PP (IN for) (NP (NNP Doc_8073369_787_794_Chemical) (CD lethality)))) (VP (AUX was) (NP (CD 0.75) (NN %)))) (. .)))
8073369	8	(S1 (S (NP (NP (DT The) (NNP Doc_8073369_820_832_Disease)) (VP (VBN caused) (PP (IN by) (NP (DT both) (NNP Doc_8073369_848_855_Chemical) (CC and) (NNP Doc_8073369_860_868_Chemical) (NN sulfate))))) (VP (AUX were) (ADJP (JJ Doc_8073369_882_932_Disease))) (. .)))
8073369	9	(S1 (S (S (NP (NP (DT No) (JJ histopathological) (NNS alterations)) (CC or) (NP (NP (NNS differences)) (PP (IN in) (NP (NN bone) (NN formation))))) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NNS limbs) (CC or) (NNS toes)) (PP (IN of) (NP (NP (DT any) (NNS chicks)) (PP (IN from) (NP (DT any) (NN group)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ extensive) (NN Doc_8073369_1080_1098_Disease)) (VP (VBD occurred) (PP (IN in) (NP (DT all) (JJ Doc_8073369_1115_1123_Chemical) (JJ sulfate-treated) (NNS chicks))))) (. .)))
8073369	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (ADJP (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NNS <)) (CC or) (NP (SYM =) (CD 0.01))) (-RRB- -RRB-))) (NN decrease)) (PP (IN in) (NP (NN movement))) (PP (IN in) (NP (NP (NNP Doc_8073369_1226_1233_Chemical)) (CC and) (NP (JJ Doc_8073369_1238_1246_Chemical) (JJ sulfate) (VBN treated) (NNS chicks))))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN ultrasound))))))) (. .)))
8073369	11	(S1 (S (S (NP (NN Control) (NNS chicks)) (VP (AUX were) (PP (IN in) (NP (NN motion))) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 33.67) (NN %)) (PP (IN of) (NP (DT the) (NN time)))))) (, ,) (SBAR (IN while) (S (NP (JJ Doc_8073369_1369_1376_Chemical-treated) (NNS chicks)) (VP (AUX were) (ADVP (RB only)) (VP (VBG moving) (NP (NP (CD 8.95) (NN %)) (PP (IN of) (NP (DT a) (JJ 5-min) (NN interval)))))))))) (, ,) (CC and) (S (NP (DT no) (NN movement)) (VP (AUX was) (VP (VBN observed) (PP (IN for) (NP (JJ Doc_8073369_1469_1477_Chemical) (JJ sulfate) (VBN treated) (NNS chicks)))))) (. .)))
8073369	12	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (DT the) (JJ chick) (NN embryo)) (VP (VBZ provides) (NP (NP (DT a) (ADJP (ADJP (JJ reliable)) (CC and) (ADJP (JJ simple))) (JJ experimental) (NN animal) (NN model)) (PP (IN of) (NP (JJ Doc_8073369_1591_1598_Chemical-induced) (NN Doc_8073369_1607_1621_Disease))))) (. .)))
8073369	13	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (DT this) (NN model)))) (VP (VBP support) (NP (NP (DT a) (NN mechanism)) (VP (VBG involving) (NP (NP (JJ nicotinic) (NN receptor) (NN blockade)) (PP (IN with) (NP (JJ subsequent) (VBN decreased) (JJ fetal) (NN movement))))))) (. .)))
8092427	0	(S1 (NP (NP (JJ Immediate) (NN Doc_8092427_10_28_Disease)) (PP (TO to) (NP (NNP Doc_8092427_32_43_Chemical))) (. .)))
8092427	1	(S1 (S (NP (NP (DT A) (JJ large) (NN group)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (VBN suspected) (NNP Doc_8092427_86_104_Disease))) (PP (TO to) (NP (JJ Doc_8092427_108_119_Chemical) (NNS antibiotics)))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
8092427	2	(S1 (S (NP (DT A) (VBN detailed) (JJ clinical) (NN history)) (, ,) (ADVP (RB together) (PP (IN with) (NP (NN skin) (NNS tests)))) (, ,) (NP (NP (NP (NN RAST)) (PRN (-LRB- -LRB-) (NP (JJ radioallergosorbent) (NN test)) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ controlled) (NN challenge) (NNS tests)) (, ,)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB establish) (SBAR (IN whether) (S (NP (NP (NNS patients)) (ADJP (JJ Doc_8092427_306_314_Disease) (PP (TO to) (NP (JJ Doc_8092427_318_329_Chemical) (NNS antibiotics))))) (VP (VP (AUX had) (NP (NP (JJ selective) (JJ immediate) (NNP Doc_8092427_366_374_Disease) (NNS responses)) (PP (TO to) (NP (NP (NNP Doc_8092427_388_399_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_401_403_Chemical)) (-RRB- -RRB-)))))) (CC or) (VP (AUX were) (ADJP (JJ cross-reacting) (PP (IN with) (NP (JJ other) (JJ Doc_8092427_439_449_Chemical) (NNS derivatives))))))))))))) (. .)))
8092427	3	(S1 (S (NP (NN Skin) (NNS tests)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (NP (NNP Doc_8092427_494_525_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_527_534_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_8092427_537_555_Chemical)) (, ,) (NP (NP (NNP Doc_8092427_557_573_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_575_577_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_8092427_580_590_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_592_595_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_8092427_602_604_Chemical)))))) (. .)))
8092427	4	(S1 (S (NP (NP (NN RAST)) (PP (IN for) (NP (NP (NNP Doc_8092427_615_622_Chemical)) (CC and) (NP (NNP Doc_8092427_627_629_Chemical-PLL))))) (VP (AUX was) (VP (AUX done))) (. .)))
8092427	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT both) (NN skin) (NN test) (CC and) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_677_680_Chemical)))) (VP (AUX were) (ADJP (JJ negative))))) (, ,) (NP (JJ single-blind) (, ,) (JJ placebo-controlled) (NN challenge) (NNS tests)) (VP (AUX were) (ADVP (RB done)) (S (VP (TO to) (VP (VB ensure) (NP (NP (NP (NN tolerance)) (PP (IN of) (NP (NNP Doc_8092427_778_780_Chemical)))) (CC or) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NNP Doc_8092427_799_801_Chemical))))))))) (. .)))
8092427	6	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 177) (NNS patients)))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (NP (NNP Doc_8092427_845_853_Disease))) (PP (TO to) (NP (JJ Doc_8092427_857_868_Chemical) (NNS antibiotics))))) (. .)))
8092427	7	(S1 (S (NP (PRP We)) (VP (VBD selected) (NP (NP (DT the) (CD 54) (ADJP (-LRB- -LRB-) (NP (CD 30.5) (NN %)) (-RRB- -RRB-)) (NNS cases)) (PP (IN of) (NP (JJ immediate) (JJ Doc_8092427_928_930_Chemical) (NN Doc_8092427_931_938_Disease))) (PP (IN with) (NP (NP (JJ good) (NN tolerance)) (PP (IN of) (NP (NNP Doc_8092427_962_964_Chemical))))))) (. .)))
8092427	8	(S1 (S (NP (NN Doc_8092427_966_977_Disease)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (NP (CD 37) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 69) (NN %)) (-RRB- -RRB-)) (, ,) (NP (DT the) (JJ other) (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 31) (NN %)) (-RRB- -RRB-))) (VP (AUXG having) (NP (JJ Doc_8092427_1035_1044_Disease) (NN and/or) (NN Doc_8092427_1052_1062_Disease))))))) (. .)))
8092427	9	(S1 (S (S (NP (PDT All) (DT the) (NNS patients)) (VP (AUX were) (NP (NP (NN skin) (NN test) (NN negative)) (PP (TO to) (NP (NNP Doc_8092427_1108_1111_Chemical)))))) (: ;) (S (NP (NP (CD 49)) (PP (IN of) (NP (CD 51))) (PRN (-LRB- -LRB-) (NP (CD 96) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (RB also) (JJ negative) (PP (TO to) (NP (NP (NNP Doc_8092427_1150_1153_Disease)) (, ,) (CC and) (NP (NP (QP (CD 44) (IN of) (CD 46))) (PRN (-LRB- -LRB-) (NP (CD 96) (NN %)) (-RRB- -RRB-)))))) (PP (TO to) (NP (NNP Doc_8092427_1177_1179_Chemical))))) (. .)))
8092427	10	(S1 (S (NP (NP (NN Skin) (NNS tests)) (PP (IN with) (NP (NNP Doc_8092427_1197_1199_Chemical)))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN in) (NP (CD 34) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (. .)))
8092427	11	(S1 (S (NP (JJS RAST)) (VP (AUX was) (ADJP (JJ positive)) (PP (IN for) (NP (NNP Doc_8092427_1258_1260_Chemical))) (PP (PP (IN in) (NP (NP (CD 22) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 41) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (NNP Doc_8092427_1289_1292_Chemical)) (PP (IN in) (NP (NP (QP (RB just) (CD 5))) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-))))))) (. .)))
8092427	12	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NN sera))) (PP (IN with) (NP (NP (JJ negative) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_1349_1351_Chemical)))))) (VP (AUX were) (ADJP (JJ positive) (TO to) (JJ Doc_8092427_1369_1372_Chemical))) (. .)))
8092427	13	(S1 (S (S (NP (NP (NN Challenge) (NNS tests)) (PP (IN with) (NP (NNP Doc_8092427_1395_1397_Chemical)))) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (CD 23) (NNS subjects))) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB establish) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NP (JJ immediate) (NN Doc_8092427_1474_1491_Disease)) (PP (TO to) (NP (NNP Doc_8092427_1495_1497_Chemical)))))))))))) (, ,) (CC and) (S (PP (IN in) (NP (NP (CD 15) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 28) (NN %)) (-RRB- -RRB-)))) (NP (NP (DT both) (NN skin) (NN test) (CC and) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_1549_1551_Chemical)))) (VP (AUX were) (ADJP (JJ negative)))) (. .)))
8092427	14	(S1 (S (NP (NN Doc_8092427_1567_1569_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN by) (NP (DT all) (CD 54) (NNS patients))))) (. .)))
8092427	15	(S1 (S (NP (PRP We)) (VP (VBP describe) (SBAR (S (NP (NP (DT the) (JJS largest) (NN group)) (PP (IN of) (NP (NP (JJ Doc_8092427_1642_1644_Chemical-Doc_8092427_1645_1653_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN tolerated) (NP (NNP Doc_8092427_1682_1684_Chemical))))))))) (VP (VBD reported) (ADVP (RB so) (RB far)))))) (. .)))
8092427	16	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (MD can) (VP (AUX be) (VP (VBN achieved) (SBAR (RB only) (IN if) (S (NP (JJ specific) (JJ Doc_8092427_1763_1765_Chemical-related) (NNS reagents)) (VP (AUX are) (VP (VBN employed)))))))) (. .)))
8092427	17	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (ADJP (JJ necessary) (S (VP (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ exact) (NN extent)) (PP (IN of) (NP (DT this) (NN problem)))))) (CC and) (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ diagnostic) (NNS methods)))))))))) (. .)))
809711	0	(S1 (NP (NP (NN Reversal)) (PP (IN by) (NP (NP (NNP Doc_809711_12_25_Chemical)) (PP (IN of) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_809711_67_80_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_809711_98_125_Disease))))))))) (. .)))
809711	1	(S1 (S (NP (NN Doc_809711_127_140_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (JJ ST-segment) (NN elevation)) (PP (IN during) (NP (NP (NNP Doc_809711_194_221_Disease)) (, ,) (NP (NP (DT an) (NN effect)) (VP (VBN potentiated) (PP (IN in) (NP (DT the) (NN dog))) (PP (IN by) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP reverse) (NP (JJ Doc_809711_279_292_Chemical-induced) (NN Doc_809711_301_312_Disease))))))))))))))))) (. .)))
809711	2	(S1 (S (NP (PRP$ Our) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ combined) (NN Doc_809711_374_387_Chemical)) (CC and) (NP (JJ Doc_809711_392_405_Chemical) (NN therapy)))))))))) (. .)))
809711	3	(S1 (S (NP (NP (CD Ten) (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ transmural) (NNP Doc_809711_450_472_Disease)))) (VP (VBD received) (NP (NP (JJ intravenous) (NNP Doc_809711_494_507_Chemical)) (, ,) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN from) (NP (NP (QP (CD 107) (JJ +/-) (CD 6) (TO to) (CD 85)) (JJ +/-) (CD 6) (NNS mm)) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))))))) (, ,)) (PP (IN for) (NP (CD 60) (NNS minutes)))) (. .)))
809711	4	(S1 (S (NP (NN Left) (NN ventricular) (VBG filling) (NN pressure)) (VP (VBD decreased) (PP (IN from) (NP (CD 19) (NN +/-))) (, 2) (PP (TO to) (NP (NP (CD 11) (NNS +/-)) (NP (NP (QP (CD 2) (CD mm)) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
809711	5	(S1 (S (NP (NP (NNP SigmaST)) (, ,) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (JJ ST-segment) (NNS elevations))) (PP (IN in) (NP (CD 16) (JJ precordial) (NNS leads)))) (, ,)) (VP (VBD decreased) (PRN (-LRB- -LRB-) (PP (FW P) (NP (QP (JJR less) (IN than) (CD 0.02)))) (-RRB- -RRB-)) (PP (IN with) (NP (JJ intravenous) (NNP Doc_809711_832_845_Chemical)))) (. .)))
809711	6	(S1 (S (NP (NP (JJ Subsequent) (NN addition)) (PP (IN of) (NP (NP (JJ Doc_809711_870_883_Chemical) (NN infusion)) (, ,) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB re-elevate) (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (TO to) (NP (NP (CD 106) (NNS +/-)) (NP (NP (QP (CD 4) (CD mm)) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 30) (NNS minutes))))))) (, ,)))) (VP (VBD increased) (NP (JJ left) (NN ventricular) (VBG filling) (NN pressure)) (PP (TO to) (NP (CD 17) (NN +/-))) (, 2) (S (VP (VP (VBG mm) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (CC and) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (JJS sigmaST)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
809711	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN addition)) (PP (IN of) (NP (NNP Doc_809711_1176_1189_Chemical))) (PP (TO to) (NP (NNP Doc_809711_1193_1206_Chemical)))) (VP (AUX is) (RB not) (ADJP (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_809711_1259_1286_Disease))))))))))) (. .)))
8170551	0	(S1 (NP (NP (JJ Doc_8170551_0_13_Chemical-induced) (NNP Doc_8170551_22_37_Disease)) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_8170551_69_92_Disease)))))) (. .)))
8170551	1	(S1 (S (NP (JJ Carbonic) (NN anhydrase) (NNS inhibitors)) (VP (MD can) (VP (VB cause) (NP (NN Doc_8170551_134_149_Disease)))) (. .)))
8170551	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD 20) (NNS patients)) (VP (VBG receiving) (NP (JJ long-term) (JJ carbonic) (NN anhydrase) (NN inhibitor) (NN treatment)) (PP (IN for) (NP (JJ periodic) (NNP Doc_8170551_246_255_Disease) (CC and) (NNP Doc_8170551_260_268_Disease)))))) (. .)))
8170551	3	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN on) (NP (NNP Doc_8170551_288_301_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NN Doc_8170551_318_331_Disease))) (. .)))
8170551	4	(S1 (S (S (NP (JJ Extracorporeal) (NN lithotripsy)) (ADVP (RB successfully)) (VP (VBD removed) (NP (DT a) (NN Doc_8170551_383_397_Disease)) (PP (IN in) (NP (CD one) (NN patient))))) (CC and) (S (NP (NN surgery)) (VP (VBD removed) (NP (DT a) (JJ staghorn) (NN Doc_8170551_444_452_Disease)) (PP (IN in) (NP (DT another))) (, ,) (S (VP (VBG permitting) (NP (JJ continued) (NN treatment)))))) (. .)))
8170551	5	(S1 (S (NP (JJ Renal) (NN function)) (VP (VBD remained) (ADJP (JJ normal)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
8170551	6	(S1 (S (NP (NN Doc_8170551_545_560_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NNP Doc_8170551_582_595_Chemical))))) (CC but) (VP (AUX does) (RB not) (VP (VB preclude) (NP (PRP$ its) (NN use))))) (. .)))
8231633	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ Doc_8231633_11_18_Chemical) (NN channel) (NNS blockers))) (PP (IN on) (NP (NNP Doc_8231633_39_50_Chemical-induced) (NNP Doc_8231633_59_67_Disease))) (. .)))
8231633	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ Doc_8231633_131_138_Chemical) (NN channel) (NNS blockers))) (PP (IN on) (NP (JJ Doc_8231633_159_170_Chemical-induced) (JJ acute) (NN Doc_8231633_185_193_Disease)))))))) (. .)))
8231633	2	(S1 (S (PP (IN For) (NP (NP (DT each)) (PP (IN of) (NP (NP (NP (DT the) (CD three) (VBN tested) (NNP Doc_8231633_224_231_Chemical) (NN channel) (NNS blockers)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8231633_250_259_Chemical) (, ,) (NNP Doc_8231633_261_270_Chemical) (CC and) (NNP Doc_8231633_275_283_Chemical)) (-RRB- -RRB-)) (SBAR (S (NP (NP (CD 6) (NNS groups)) (PP (IN of) (NP (NNS mice)))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (NP (CD two) (JJ different) (NNS doses)) (, ,) (PP (FW i.e.) (NP (CD 2) (CC and) (CD 10) (NNS mg/kg/i.p.))) (, ,)) (CC or) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NN saline)))))) (PP (IN for) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))))))))) (: ;) (NP (CD 15) (NNS minutes)))))) (ADVP (RB later)) (, ,) (NP (PDT all) (DT the) (NNS animals)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (DT a) (JJ single) (CD 50) (JJ mg/kg/i.p.) (NN dose)) (PP (IN of) (NP (NNP Doc_8231633_510_521_Chemical))))))) (. .)))
8231633	3	(S1 (S (NP (NP (DT The) (JJ convulsant) (NN activity)) (, ,) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN latency))) (PP (TO to) (NP (NN convulse)))) (CC and) (NP (DT the) (NN mortality) (NN rate))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (DT each) (NN group))))) (. .)))
8231633	4	(S1 (S (NP (DT The) (JJ local) (JJ anesthetic-induced) (NN mortality)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN by) (NP (DT the) (CD three) (JJ different) (JJ Doc_8231633_722_729_Chemical) (NN channel) (NNS blockers))))) (. .)))
8231633	5	(S1 (S (S (NP (NP (DT The) (JJ convulsant) (NN activity)) (PP (IN of) (NP (NNP Doc_8231633_775_786_Chemical)))) (VP (AUX was) (RB not) (ADVP (RB significantly)) (VP (VBN modified)))) (CC but) (S (NP (NNP Doc_8231633_822_829_Chemical) (NN channel) (NNS blockers)) (VP (VBD decreased) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN latency))) (SBAR (S (VP (TO to) (VP (VB obtain) (NP (JJ Doc_8231633_887_898_Chemical-induced) (NNP Doc_8231633_907_918_Disease))))))))) (: ;) (S (NP (DT this) (NN effect)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ pronounced)) (PP (IN with) (NP (NNP Doc_8231633_957_965_Chemical)))))) (. .)))
8302922	0	(S1 (S (NP (NP (JJ Epidural) (NN blood) (NN flow)) (PP (IN during) (NP (NP (NNP Doc_8302922_27_43_Chemical)) (CC or) (NP (NNP Doc_8302922_47_59_Chemical))))) (VP (VBN induced) (NP (NNP Doc_8302922_68_79_Disease))) (. .)))
8302922	1	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NNP Doc_8302922_107_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8302922_125_129_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_8302922_134_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8302922_148_151_Chemical)) (-RRB- -RRB-))))) (VP (VBN induced) (NP (NNP Doc_8302922_161_172_Disease))) (PP (IN on) (NP (NP (JJ epidural) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NNP EBF)) (-RRB- -RRB-))))) (PP (IN during) (NP (NN spinal) (NN surgery)))))) (, ,) (NP (NNP EBF)) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (NP (DT the) (NN heat) (NN clearance) (NN method)) (PP (IN in) (NP (NP (CD 30) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ postero-lateral) (NN interbody) (NN fusion)) (PP (IN under) (NP (JJ Doc_8302922_342_352_Chemical) (NN anaesthesia))))))))))))) (. .)))
8302922	2	(S1 (S (S (NP (NP (DT An) (JJ initial) (NN dose)) (PP (IN of) (NP (NP (NP (CD 0.1) (NN microgram.kg-1.min-1)) (PP (IN of) (NP (NP (NNP Doc_8302922_413_417_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NNS patients)) (-RRB- -RRB-))))) (, ,) (CC or) (NP (NP (CD 10) (NN micrograms.kg-1.min-1)) (PP (IN of) (NP (NP (NNP Doc_8302922_464_467_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NNS patients)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PP (IN after) (NP (DT the) (JJ dural) (NN opening)))))) (CC and) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN adjusted) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT the) (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (PP (IN at) (NP (QP (RB about) (CD 60)) (NN mmHg))))))))) (. .)))
8302922	3	(S1 (S (NP (DT The) (NNP Doc_8302922_636_647_Disease) (NN drug)) (VP (AUX was) (VP (VBN discontinued) (PP (IN at) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (DT the) (JJ operative) (NN procedure))))))) (. .)))
8302922	4	(S1 (S (PP (IN After) (S (VP (VBG starting) (NP (NNP Doc_8302922_731_735_Chemical) (CC or) (NNP Doc_8302922_739_742_Chemical))))) (, ,) (S (NP (NP (NP (NN MAP)) (CC and) (NP (NN rate) (NN pressure) (NN product))) (PRN (-LRB- -LRB-) (NP (NNP RPP)) (-RRB- -RRB-))) (VP (VBD decreased) (ADVP (RB significantly)) (PP (VBN compared) (PP (IN with) (NP (NP (NN preinfusion) (NNS values)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.01)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NNP Doc_8302922_867_878_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_8302922_886_890_Chemical))))))) (VP (VBD remained) (ADJP (JJ constant)) (PP (IN until) (NP (CD 60) (NN min))) (PP (IN after) (NP (PRP$ its) (NN discontinuation))))) (. .)))
8302922	5	(S1 (S (NP (NP (NN Heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN HR)) (-RRB- -RRB-))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN in) (NP (DT either) (NN group))))) (. .)))
8302922	6	(S1 (S (NP (NNP EBFF)) (VP (AUX did) (RB not) (VP (VB change) (PP (IN during) (NP (JJ Doc_8302922_1024_1028_Chemical) (NN infusion))) (SBAR (IN whereas) (S (PP (IN in) (NP (DT the) (NNP Doc_8302922_1053_1056_Chemical) (NN group))) (, ,) (NP (NNP EBF)) (VP (VBD decreased) (ADVP (RB significantly) (NP (QP (IN at) (CD 30) (CC and) (CD 60) (NN min)))) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NNP Doc_8302922_1128_1131_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (NN preinfusion)) (: :) (NP (NP (CD 45.9) (JJ +/-) (CD 13.9) (NNS ml/100g/min.)) (ADJP (CD 30) (NN min))) (: :) (NP (NP (NP (CD 32.3) (NN +/-)) (NP (QP (CD 9.9) (CD ml/100)) (NN g/min))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))) (. .)) (NP (NP (CD 60) (NN min)) (: :) (NP (NP (NP (CD 30) (NN +/-)) (NP (CD 7.5) (CD ml/100) (NN g/min))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)))) (-RRB- -RRB-))))))) (. .)))
8302922	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_8302922_1291_1295_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ preferable) (PP (TO to) (NP (NNP Doc_8302922_1317_1320_Chemical)))) (PP (IN for) (NP (NP (JJ Doc_8302922_1325_1336_Disease) (NNS anaesthesia)) (PP (IN in) (NP (NN spinal) (NN surgery))))) (SBAR (IN because) (S (NP (NNP Doc_8302922_1375_1378_Chemical)) (VP (VBD decreased) (NP (NN EBF)))))))))) (. .)))
8319760	0	(S1 (S (NP (NN Doc_8319760_0_7_Chemical)) (VP (VBZ prevents) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8319760_36_61_Chemical-induced) (NNP Doc_8319760_70_79_Disease))))) (. .)))
8319760	1	(S1 (S (NP (NP (DT The) (NN appearance)) (PP (IN of) (NP (NNP Doc_8319760_99_118_Disease))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8319760_127_138_Disease)) (, ,) (NP (NNP Doc_8319760_140_155_Disease)) (, ,) (NP (NNP Doc_8319760_157_177_Disease)) (CC and) (NP (NP (NN increase)) (PP (IN in) (NP (NNP Doc_8319760_194_213_Chemical))))))) (, ,) (S (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_8319760_247_272_Chemical))))))) (VP (AUX was) (RB markedly) (VP (VBD inhibited) (PP (IN by) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_8319760_322_329_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8319760_331_339_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ novel) (JJ Doc_8319760_350_364_Chemical) (NN receptor) (NN antagonist)) (, ,))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (QP (CD 1) (CC or) (CD 2) (CD mg/kg))) (PP (IN per) (NP (NN day))))))))) (. .)))
8319760	2	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN involvement)) (PP (IN of) (NP (DT the) (JJ renin-Doc_8319760_477_488_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_8319760_518_543_Chemical-induced) (NN Doc_8319760_552_561_Disease))))))) (. .)))
8372922	0	(S1 (S (NP (NP (NN Neuroplasticity)) (PP (IN of) (NP (DT the) (NN adult)))) (VP (VBP primate) (NP (NN auditory) (NN cortex)) (PP (VBG following) (NP (JJ cochlear) (NN Doc_8372922_72_84_Disease)))) (. .)))
8372922	1	(S1 (S (NP (JJ Tonotopic) (NN organization)) (VP (AUX is) (NP (NP (DT an) (JJ essential) (NN feature)) (PP (IN of) (NP (NP (DT the) (JJ primary) (NN auditory) (NN area)) (PRN (-LRB- -LRB-) (NP (NNP A1)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ primate) (NN cortex))))))) (. .)))
8372922	2	(S1 (S (PP (IN In) (NP (NP (NNP A1)) (PP (IN of) (NP (NN macaque) (NNS monkeys))))) (, ,) (S (NP (JJ low) (NNS frequencies)) (VP (AUX are) (VP (VBN represented) (ADVP (RB rostrolaterally))))) (CC and) (S (NP (JJ high) (NNS frequencies)) (VP (AUX are) (VP (VBN represented) (ADVP (RB caudomedially))))) (. .)))
8372922	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NNS changes)) (VP (VBP occur) (PP (IN in) (NP (NP (DT this) (JJ tonotopic) (NN organization)) (VP (VBG following) (NP (JJ cochlear) (NN Doc_8372922_422_434_Disease)))))))))))) (. .)))
8372922	4	(S1 (S (PP (IN Under) (NP (NN anesthesia))) (, ,) (S (NP (NP (DT the) (JJ superior) (JJ temporal) (NN gyrus)) (PP (IN of) (NP (NN adult) (NN macaque) (NNS monkeys)))) (VP (AUX was) (VP (VBN exposed)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ tonotopic) (NN organization)) (PP (IN of) (NP (NNP A1)))) (VP (AUX was) (VP (VBN mapped) (S (VP (VBG using) (NP (JJ conventional) (NN microelectrode) (NN recording) (NNS techniques))))))) (. .)))
8372922	5	(S1 (S (PP (VBG Following) (NP (NN recovery))) (, ,) (NP (DT the) (NNS monkeys)) (VP (AUX were) (ADVP (RB selectively)) (VP (VBN deafened) (PP (IN for) (NP (NP (JJ high) (NNS frequencies)) (VP (VBG using) (NP (NP (NNP Doc_8372922_709_718_Chemical)) (CC and) (NP (NNP Doc_8372922_723_733_Chemical)))))))) (. .)))
8372922	6	(S1 (S (NP (NP (DT The) (JJ actual) (NNS frequencies)) (VP (VBN deafened))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ tone-burst) (JJ elicited) (NN auditory) (NN brainstem) (NNS responses))))))) (. .)))
8372922	7	(S1 (S (PP (NP (CD Three) (NNS months)) (IN after) (NP (NN deafening))) (, ,) (NP (NNP A1)) (VP (AUX was) (VP (VBN remapped))) (. .)))
8372922	8	(S1 (S (NP (NP (NN Postmortem) (NN cytoarchitectural) (NNS features)) (VP (VBG identifying) (NP (NNP A1)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (DT the) (JJ electrophysiologic) (NNS data))))) (. .)))
8372922	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (VBN deprived) (NN area)) (PP (IN of) (NP (NNP A1)))) (VP (VP (VBZ undergoes) (NP (JJ extensive) (NN reorganization))) (CC and) (VP (VBZ becomes) (ADJP (JJ responsive) (PP (TO to) (NP (JJ intact) (JJ cochlear) (NNS frequencies))))))))) (. .)))
8372922	10	(S1 (S (NP (NP (DT The) (NN region)) (PP (IN of) (NP (NN cortex))) (SBAR (WHNP (WDT that)) (S (VP (VBZ represents) (NP (DT the) (JJ low) (NNS frequencies)))))) (VP (AUX was) (RB not) (ADVP (RB obviously)) (VP (VBN affected) (PP (IN by) (NP (DT the) (JJ cochlear) (NN Doc_8372922_1238_1250_Disease))))) (. .)))
8386779	0	(S1 (S (NP (JJ Doc_8386779_0_18_Chemical) (NNS alleviates)) (VP (VBP Doc_8386779_30_41_Disease) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intracavernous) (NNS injections)) (PP (IN for) (NP (NNP Doc_8386779_83_103_Disease))))))) (. .)))
8386779	1	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_8386779_140_151_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ intracorporeal) (NNS injections))))) (VP (MD could) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN acidity)) (PP (IN of) (NP (DT the) (NN medication))))))))))))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (NP (DT a) (JJ randomized) (NN study)) (VP (VBG comparing) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8386779_300_311_Disease))) (PP (VBG following) (NP (JJ intracorporeal) (NNS injections)))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_8386779_380_398_Chemical))) (PP (TO to) (NP (DT the) (JJ intracorporeal) (NNS medications))))))))) (. .)))
8386779	2	(S1 (NP (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 38) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (TO to) (NP (PRP$ our) (NN clinic))) (SBAR (IN with) (S (NP (NNP Doc_8386779_502_511_Disease)) (VP (VBD received) (NP (NP (CD 0.2) (NN ml.)) (PP (IN of) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (CD 3) (NNS drugs))))))))))))))) (: :) (NP (NP (CD 6) (NN mg.)) (NP (NP (NP (NNP Doc_8386779_564_574_Chemical)) (, ,) (NP (CD 100) (JJ micrograms.) (NNP Doc_8386779_592_604_Chemical)) (CC and) (NP (CD 10) (JJ micrograms.) (NNP Doc_8386779_624_640_Chemical))) (PP (IN with) (PRN (-LRB- -LRB-) (NP (CD pH) (CD 7.05)) (-RRB- -RRB-)) (CC or) (PP (IN without) (PRN (-LRB- -LRB-) (NP (QP (CD pH) (CD 4.17))) (-RRB- -RRB-)) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_8386779_693_711_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.03) (CD mEq) (. .)) (-RRB- -RRB-))))) (. .)))
8386779	3	(S1 (S (IN Of) (NP (NP (DT the) (CD 19) (NNS patients)) (PP (IN without) (NP (NNP Doc_8386779_752_770_Chemical)))) (VP (VBD added) (PP (TO to) (NP (DT the) (NN medication) (CD 11))) (SBAR (S (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_8386779_818_829_Disease))) (ADVP (JJ due) (PP (TO to) (NP (DT the) (NN medication)))) (, ,) (SBAR (IN while) (S (NP (NP (QP (RB only) (CD 1))) (PP (IN of) (NP (NP (DT the) (CD 19) (NNS men)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_8386779_898_916_Chemical)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_8386779_931_942_Disease)))))))))))))))))) (. .)))
8386779	4	(S1 (S (PP (IN From) (NP (DT these) (NNS data))) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NNP Doc_8386779_981_992_Disease) (JJ following) (NN intracorporeal) (NNS injections)) (VP (AUX is) (ADVP (RBS most) (JJ likely)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN acidity)) (PP (IN of) (NP (NP (DT the) (NN medication)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (AUX be) (VP (VBN overcome) (PP (IN by) (S (VP (VBG elevating) (NP (DT the) (NN pH)) (PP (TO to) (NP (DT a) (JJ neutral) (NN level)))))))))))))))))))) (. .)))
8387218	0	(S1 (NP (NP (DT The) (NN use) (CC and) (NN Doc_8387218_12_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_8387218_24_34_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_36_39_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_8387218_44_65_Disease) (NNS individuals) (NN intolerant))) (PP (TO to) (NP (NNP Doc_8387218_92_102_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_104_107_Chemical)) (-RRB- -RRB-))))
8387218	1	(S1 (S (NP (NP (QP (CD One) (CD hundred))) (CC and) (NP (NP (JJ fifty-one) (NNS patients)) (ADJP (JJ intolerant) (PP (TO to) (NP (NP (NNP Doc_8387218_158_168_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_170_173_Chemical)) (-RRB- -RRB-))))))) (VP (VBD received) (NP (NP (NNP Doc_8387218_184_194_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_196_199_Chemical)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (DT a) (JJ maximum) (NN dose)) (PP (IN of) (NP (CD 12.5) (NN mg/kg/day)))))) (. .)))
8387218	2	(S1 (S (NP (JJ Patient) (NN response)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NN count)) (, ,) (NP (NNP HIV) (CD p24) (NN antigen)) (, ,) (NP (NN weight)) (, ,) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))))))))) (. .)))
8387218	3	(S1 (S (S (NP (CD Seventy) (NNS patients)) (VP (VBD developed) (NP (JJ major) (JJ Doc_8387218_394_418_Disease) (NN whilst)) (PP (IN on) (NP (NN therapy))))) (: ;) (S (NP (DT this)) (VP (AUX was) (NP (NP (DT the) (JJ first) (JJ Doc_8387218_457_461_Disease) (NN diagnosis)) (PP (IN in) (NP (CD 17)))))) (. .)))
8387218	4	(S1 (S (NP (NP (ADJP (RB Only) (JJ minor)) (NNS changes)) (PP (IN in) (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NN count)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_8387218_547_551_Disease) (NNS patients))) (, ,) (SBAR (IN although) (S (NP (DT a) (ADJP (RBR more) (JJ significant)) (NN rise)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJR earlier) (NNS stages)) (PP (IN of) (NP (NN disease)))))))))))) (. .)))
8387218	5	(S1 (S (S (NP (NP (IN Of) (DT those) (JJ positive)) (PP (IN for) (NP (NP (CD p24) (NN antigen)) (PP (IN at) (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (DT the) (NN study))))) (NP (CD 67) (NN %))))) (VP (VBD showed) (NP (DT a) (JJ positive) (NN response)))) (, ,) (CC and) (S (NP (DT this)) (VP (AUX was) (ADJP (RBS most) (JJ likely) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NNS counts)) (PP (IN above) (NP (CD 100) (CD mm3)))))))))) (. .)))
8387218	6	(S1 (S (NP (DT A) (JJ positive) (NN weight) (NN response)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 16) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8387218	7	(S1 (S (NP (JJS Most) (NNS patients)) (VP (VBD showed) (NP (NP (NP (NN improvement)) (PP (IN in) (NP (JJ individual) (NNS parameters)))) (CC and) (NP (NP (JJ global) (NN score)) (PP (IN of) (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))))))) (. .)))
8387218	8	(S1 (S (NP (NP (JJ Adverse) (NNS reactions)) (ADJP (ADVP (RB possibly)) (JJ attributable) (PP (TO to) (NP (NNP Doc_8387218_1022_1032_Chemical))))) (VP (AUX were) (ADJP (JJ common))) (. .)))
8387218	9	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN side-effect)) (VP (AUX was) (NP (NP (NNP Doc_8387218_1078_1087_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))) (PP (IN in) (NP (CD 19) (NNS individuals)))))))))) (. .)))
8387218	10	(S1 (S (NP (NN Doc_8387218_1147_1168_Disease)) (VP (VP (VBD occurred) (PP (IN in) (NP (CD 12) (NNS patients)))) (CC and) (VP (NP (NNP Doc_8387218_1197_1209_Disease)) (PP (IN in) (NP (CD six))))) (. .)))
8387218	11	(S1 (S (NP (JJ Thirteen) (NNS patients)) (VP (VBD developed) (NP (NP (DT a) (VBN raised) (NN serum) (NN amylase)) (PP (IN without) (NP (NN Doc_8387218_1277_1291_Disease))))) (. .)))
8387218	12	(S1 (S (S (NP (CD Seven) (NNS patients)) (VP (VBD developed) (NP (NP (JJ Doc_8387218_1318_1342_Disease) (NN characteristic)) (PP (IN of) (NP (NNP Doc_8387218_1361_1369_Disease)))))) (CC but) (S (NP (DT these)) (VP (VP (AUX were) (ADJP (JJ mild))) (, ,) (VP (AUX did) (RB not) (VP (VB require) (NP (NN treatment)))) (CC and) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN on) (S (VP (VBG ceasing) (NP (NNP Doc_8387218_1451_1461_Chemical)))))))) (. .)))
8410052	0	(S1 (NP (NP (JJ Immunohistochemical) (NNS studies)) (PP (IN with) (NP (NNS antibodies))) (PP (TO to) (NP (JJ neurofilament) (NNS proteins))) (PP (IN on) (NP (NP (NNP Doc_8410052_73_86_Disease)) (PP (IN in) (NP (NP (JJ experimental) (JJ focal) (NNS lesions)) (PP (IN in) (NP (NN rat))))))) (. .)))
8410052	1	(S1 (S (NP (NP (NN Immunohistochemistry)) (PP (IN with) (NP (NP (JJ monoclonal) (NNS antibodies)) (PP (IN against) (NP (NP (JJ neurofilament) (PRN (-LRB- -LRB-) (NP (NNP NF)) (-RRB- -RRB-)) (NNS proteins)) (PP (IN of) (NP (NP (JJ middle) (CC and) (JJ high) (JJ molecular) (NN weight) (NN class)) (, ,) (ADJP (JJ NF-M) (CC and) (JJ NF-H)) (, ,)))))))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (NP (NN Doc_8410052_285_298_Disease)) (PP (IN in) (NP (NP (DT the) (NN borderzone)) (PP (IN of) (NP (NP (JJ focal) (NNS lesions)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
8410052	2	(S1 (S (NP (JJ Focal) (NN Doc_8410052_349_369_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_8410052_398_405_Chemical))) (PP (PP (IN at) (NP (NN acid) (NN pH))) (CC or) (PP (IN by) (NP (NP (NN stab)) (VP (VBN caused) (PP (IN by) (NP (NN needle) (NN insertion))))))))))) (. .)))
8410052	3	(S1 (S (NP (NN Doc_8410052_456_500_Disease)) (VP (AUX were) (VP (VBN evoked) (PP (IN by) (NP (JJ prolonged) (JJ Doc_8410052_526_537_Chemical-induced) (NN Doc_8410052_546_564_Disease))))) (. .)))
8410052	4	(S1 (S (NP (NP (JJ Immunohistochemical) (NN staining)) (PP (IN for) (NP (NNS NFs)))) (VP (VBD showed) (NP (NP (JJ characteristic) (NN terminal) (NNS clubs)) (PP (IN of) (NP (NNS axons)))) (PP (IN in) (NP (NP (DT the) (NN borderzone)) (PP (IN of) (NP (NNS lesions)))))) (. .)))
8410052	5	(S1 (S (NP (NP (NNS Differences)) (PP (IN in) (NP (DT the) (VBG labelling) (NN pattern)))) (VP (VBD occurred) (PP (IN with) (NP (NP (JJ different) (NNS antibodies)) (SBAR (WHNP (WDT which)) (S (ADVP (RB apparently)) (VP (VBD depended) (PP (IN on) (NP (NP (JJ molecular) (NN weight) (NN class)) (PP (IN of) (NP (NP (NNS NFs)) (CC and) (NP (NN phosphorylation) (NN state)))))))))))) (. .)))
8410052	6	(S1 (S (NP (NP (DT These) (JJ immunohistochemical) (NNS changes)) (PP (IN of) (NP (NNS NFs)))) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NP (NNP Doc_8410052_904_917_Disease)) (PP (IN in) (NP (NP (JJ various) (JJ experimental) (NN Doc_8410052_942_951_Disease)) (CC or) (NP (JJ ischemic) (NNS lesions)))))))))) (. .)))
84204	0	(S1 (S (NP (NP (JJ Pharmacokinetic) (CC and) (JJ clinical) (NNS studies)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ Doc_84204_54_64_Chemical-associated) (JJ mental) (NNP Doc_84204_83_92_Disease.) (CD 15) (NNS cases)) (PP (IN of) (NP (JJ Doc_84204_106_116_Chemical-associated) (JJ mental) (NN Doc_84204_135_144_Disease)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
84204	1	(S1 (S (PP (IN In) (NP (NN order) (SBAR (IN that) (S (NP (DT this) (NN syndrome)) (VP (MD might) (VP (AUX be) (VP (VBN investigated) (SBAR (S (NP (NP (NNS changes)) (PP (IN in) (NP (JJ mental) (NN status))) (PRN (-LRB- -LRB-) (NP (NNP M.S.)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NP (NN serum) (NNS concentrations)) (CC and) (NP (JJ renal) (CC and) (JJ hepatic) (NN function)))) (PP (IN in) (NP (CD 36) (NNS patients)))))))))))))) (, ,) (S (NP (CD 30) (NNS patients)) (VP (AUX had) (NP (DT no) (JJ M.S.) (NN change)) (PP (IN on) (NP (NNP Doc_84204_370_380_Chemical))))) (CC and) (S (NP (CD 6)) (VP (AUX had) (ADJP (JJ moderate) (PP (TO to) (NP (JJ severe) (NNS changes)))))) (. .)))
84204	2	(S1 (S (NP (DT These) (CD 6) (NNS patients)) (VP (AUX had) (NP (NP (NP (DT both) (NNP Doc_84204_445_472_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_84204_504_514_Chemical) (NNS trough-concentrations)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 1.25)) (NNS microgram/ml)))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (. .)))
84204	3	(S1 (S (NP (NP (DT The) (NN severity)) (PP (IN of) (NP (JJ M.S.) (NNS changes)))) (VP (VBD increased) (SBAR (IN as) (S (NP (NNS trough-concentrations)) (VP (VBD rose) (, ,) (SBAR (S (NP (CD 5) (NNS patients)) (VP (AUX had) (NP (JJ lumbar) (NN puncture))))))))) (. .)))
84204	4	(S1 (S (S (NP (NP (DT The) (JJ cerebrospinal) (JJ fluid) (: :) (NN serum) (NN ratio)) (PP (IN of) (NP (NNP Doc_84204_730_740_Chemical) (NNS concentrations)))) (VP (VP (AUX was) (VP (VBN 0.24:1))) (CC and) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NNP Doc_84204_786_796_Chemical)) (VP (VBZ passes) (NP (DT the) (JJ blood-brain) (NN barrier)))))))) (: ;) (S (NP (PRP it)) (ADVP (RB also)) (VP (VBZ raises) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NNP M.S.) (NNS changes)) (VP (AUX are) (ADJP (JJ due) (PP (TO to) (NP (NP (NN blockade)) (PP (IN of) (NP (NP (NNP Doc_84204_901_910_Chemical) (NNP H2-receptors)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))))))) (. .)))
84204	5	(S1 (S (NP (NP (NP (NNS Patients)) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (DT both) (VBN raised) (NNS trough-concentrations))))))) (CC and) (NP (JJ mental) (NN Doc_84204_1024_1033_Disease))) (VP (AUX are) (NP (NP (DT those)) (PP (IN with) (NP (DT both) (JJ severe) (NNP Doc_84204_1061_1090_Disease))))) (. .)))
84204	6	(S1 (S (NP (PRP They)) (VP (VP (MD should) (VP (AUX be) (VP (ADVP (RB closely)) (VBN observed)))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN given) (NP (NP (JJ reduced) (NNS doses)) (PP (IN of) (NP (NNP Doc_84204_1161_1171_Chemical)))))))) (. .)))
8421099	0	(S1 (NP (NP (JJ Prospective) (NN study)) (PP (IN of) (NP (NP (DT the) (JJ long-term) (NNS effects)) (PP (IN of) (NP (NP (NN somatostatin) (NN analog)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8421099_67_77_Chemical)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (JJ gallbladder) (NN function)) (CC and) (NP (NP (NNP Doc_8421099_107_116_Disease) (NN formation)) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8421099_138_149_Disease) (NNS patients)))))) (. .)))
8421099	1	(S1 (S (NP (DT This) (NN article)) (VP (VBZ reports) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJR gallbladder) (NN function)) (VP (VBN examined) (PP (IN by) (NP (NN ultrasonography))) (PP (IN in) (NP (NP (CD 20) (JJ Chinese) (NNS patients)) (PP (IN with) (NP (JJ active) (NNP Doc_8421099_280_290_Disease))) (VP (VBN treated) (PP (IN with) (NP (NP (CD sc) (NN injection)) (PP (IN of) (NP (DT the) (NN somatostatin) (NN analog) (NNP Doc_8421099_344_354_Chemical))))) (PP (IN in) (NP (NP (NNS dosages)) (PP (IN of) (NP (NP (CD 300-1500) (NN micrograms/day)) (PP (IN for) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (NP (CD 24.2) (NN +/-)) (NP (CD 13.9) (NNS months)))))))))))))))))) (. .)))
8421099	2	(S1 (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_8421099_451_461_Chemical))))) (, ,) (S (NP (CD 17) (NNS patients)) (VP (VBD developed) (NP (NN sludge)))) (, ,) (S (NP (CD 10)) (VP (AUX had) (NP (NN Doc_8421099_500_510_Disease)))) (, ,) (CC and) (S (NP (CD 1)) (VP (VBD developed) (NP (NP (NN Doc_8421099_528_547_Disease)) (VP (VBG requiring) (NP (NN surgery)))))) (. .)))
8421099	3	(S1 (S (PP (IN In) (NP (NP (DT all)) (PP (IN of) (NP (NP (CD 7) (NNS patients)) (VP (VBN examined) (ADVP (RB acutely))))))) (, ,) (NP (NN gallbladder) (NN contractility)) (VP (AUX was) (VP (VBD inhibited) (PP (IN after) (NP (DT a) (JJ single) (JJ 100-micrograms) (NN injection))))) (. .)))
8421099	4	(S1 (S (PP (IN In) (NP (NP (CD 8) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (CD 24) (NNS weeks)))))) (, ,) (NP (JJ gallbladder) (NN contractility)) (VP (VBD remained) (NP (NNP Doc_8421099_759_768_Disease)) (PP (IN throughout) (NP (NN therapy)))) (. .)))
8421099	5	(S1 (S (PP (IN After) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_8421099_809_819_Chemical))) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PP (IN without) (NP (NNP Doc_8421099_843_853_Disease))))))) (, ,) (NP (NP (CD 8) (NNS patients)) (VP (VBN assessed))) (VP (AUX had) (NP (NP (NN return)) (PP (IN of) (NP (JJ normal) (NN gallbladder) (NN contractility))) (PP (IN within) (NP (CD 1) (NN month))))) (. .)))
8421099	6	(S1 (S (PP (IN In) (NP (NP (CD 8)) (PP (IN of) (NP (NP (DT the) (JJ remaining) (CD 10) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_8421099_986_996_Disease)) (PP (IN during) (NP (NN treatment)))))))))) (, ,) (NP (JJ gallbladder) (NN contractility)) (VP (VP (VBD normalized) (PP (IN in) (NP (NP (CD 5) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 3)) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (VP (AUX has) (NP (NP (NN disappearance)) (PP (IN of) (NP (PRP$ their) (NNS stones)))) (PP (IN within) (NP (CD 3) (NNS weeks))))))) (-RRB- -RRB-))))) (, ,) (CC and) (VP (VBD remained) (NP (NNP Doc_8421099_1141_1150_Disease)) (PP (IN in) (NP (NP (CD 3)) (PRN (-LRB- -LRB-) (NP (NP (CD 2)) (PP (IN of) (SBAR (WHNP (WP whom)) (S (VP (AUX had) (NP (NP (NNS stones)) (ADJP (JJ present) (PP (IN at) (NP (CD 6) (NNS months)))))))))) (-RRB- -RRB-)))))) (. .)))
8421099	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN gallbladder) (NN contractility)))) (VP (AUX is) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (JJ successive) (NN formation)) (PP (IN of) (NP (JJ bile) (NN sludge) (, ,) (NNP Doc_8421099_1327_1337_Disease) (, ,) (CC and) (NNP Doc_8421099_1343_1356_Disease)))))) (PP (IN during) (NP (NP (JJ Doc_8421099_1364_1374_Chemical) (NN therapy)) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8421099_1394_1405_Disease) (NNS patients))))))))) (. .)))
8421099	8	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (ADJP (RB very) (JJ important) (S (VP (TO to) (VP (VB follow) (NP (NP (DT the) (NNS changes)) (PP (IN of) (NP (NN gallbladder) (NN function)))) (PP (IN during) (NP (NP (JJ long-term) (JJ Doc_8421099_1510_1520_Chemical) (NN therapy)) (PP (IN of) (NP (JJ Doc_8421099_1532_1543_Disease) (NNS patients)))))))))) (. .)))
8423889	0	(S1 (NP (NP (NN Increase)) (PP (IN of) (NP (NNP Doc_8423889_12_32_Disease))) (PP (IN after) (NP (JJ Doc_8423889_39_49_Chemical) (NN medication))) (. .)))
8423889	1	(S1 (S (NP (NN Doc_8423889_62_72_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ clinical) (NN feature)) (PP (IN of) (NP (NNP Doc_8423889_104_123_Disease))))) (. .)))
8423889	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (VBN increased) (NN amount)) (PP (IN of) (NP (NNP Doc_8423889_159_175_Disease))) (PP (IN in) (NP (CD four) (NNS patients)))) (PP (IN with) (NP (NNP Doc_8423889_198_228_Disease))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NNP Doc_8423889_251_265_Chemical) (NNP Doc_8423889_266_276_Chemical)))))) (. .)))
8423889	3	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (JJ Doc_8423889_319_327_Chemical-antagonistic) (NN capacity)) (PP (IN of) (NP (NNP Doc_8423889_353_363_Chemical))) (PP (IN in) (NP (NNP Doc_8423889_367_386_Disease) (NNS patients)))))) (VP (MD must) (VP (AUX be) (VP (VBN considered)))) (. .)))
8437969	0	(S1 (S (NP (NN Doc_8437969_0_12_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ continuous-infusion) (NNP Doc_8437969_49_59_Chemical)))) (. .)))
8437969	1	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ intermittent) (JJ intravenous) (NNS infusions)) (PP (IN of) (NP (NNP Doc_8437969_121_131_Chemical)))))) (VP (AUX is) (ADVP (RB infrequently)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8437969_183_199_Disease))))))) (. .)))
8437969	2	(S1 (S (NP (NP (NP (DT A) (JJ 40-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_8437969_224_232_Disease)))) (CC and) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_8437969_251_266_Disease))))) (VP (VBD developed) (NP (NP (JJ recurrent) (, ,) (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ apparent) (NN Doc_8437969_315_327_Disease)))) (SBAR (IN while) (S (VP (VBG receiving) (NP (JJ continuous-infusion) (NNP Doc_8437969_364_374_Chemical) (CD 50) (NN mg/hour)))))) (. .)))
8437969	3	(S1 (S (NP (DT The) (NNP Doc_8437969_391_402_Disease)) (VP (AUX were) (ADVP (RB temporally)) (VP (VP (VBN related) (PP (TO to) (NP (NNP Doc_8437969_430_440_Chemical) (NN administration)))) (, ,) (VP (VBN disappeared) (PP (IN after) (NP (NN dechallenge)))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB recur) (PP (IN during) (NP (JJ Doc_8437969_513_523_Chemical) (NN treatment))))))) (. .)))
8437969	4	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8437969_570_582_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ continuous-infusion) (NN Doc_8437969_619_629_Chemical)))))))) (. .)))
8558192	0	(S1 (NP (NP (NN Phase) (NNP II) (NN trial)) (PP (IN of) (NP (NNP Doc_8558192_18_29_Chemical))) (PP (IN in) (NP (JJ metastatic) (NNP Doc_8558192_44_78_Disease))) (. .)))
8558192	1	(S1 (S (NP (NP (NNP European) (NNP Organization)) (PP (IN for) (NP (NP (NP (NNP Research)) (CC and) (NP (NNP Treatment))) (PP (IN of) (NP (NNP Doc_8558192_132_138_Disease) (NNP Gastrointestinal)))))) (VP (VBP Treat) (NP (NNP Doc_8558192_162_168_Disease) (NNP Cooperative) (NNP Group))) (. .)))
8558192	2	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN response) (NN rate)) (CC and) (NP (NP (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_8558192_248_259_Chemical)))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8558192_261_264_Chemical)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ single) (NN agent)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_8558192_311_345_Disease)))))) (. .)))
8558192	3	(S1 (S (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (JJ Forty-six) (NN eligible) (NNS patients)) (PP (IN with) (NP (JJ measurable) (NNS lesions)))) (VP (VP (AUX were) (VP (VBN included))) (CC and) (VP (AUX were) (ADJP (JJ stratified)) (PP (VBG according) (PP (TO to) (NP (JJ previous) (NN chemotherapy)))))) (. .)))
8558192	4	(S1 (S (NP (NP (NP (CD Thirty) (NNS patients)) (PP (IN without) (NP (JJ prior) (NN chemotherapy)))) (CC and) (NP (NP (CD 16)) (VP (VBN pretreated) (PP (IN with) (NP (JJ Doc_8558192_557_566_Chemical-based) (NN chemotherapy)))))) (VP (AUX were) (ADJP (JJ assessable) (PP (IN for) (NP (NP (NN Doc_8558192_606_614_Disease)) (CC and) (NP (NN response)))))) (. .)))
8558192	5	(S1 (S (NP (NN Doc_8558192_629_632_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB weekly)) (PP (IN as) (NP (DT a) (JJ 25-mg/m2) (JJ short) (JJ intravenous) (-LRB- -LRB-) (NN i.v.) (-RRB- -RRB-) (NN infusion))))) (. .)))
8558192	6	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)))) (PP (IN without) (NP (JJ prior) (NN chemotherapy)))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN response)) (-LRB- -LRB-) (NP (NNP PR)) (-RRB- -RRB-) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-)) (, ,) (NP (QP (CD 8) (NN %) (TO to) (CD 39) (NN %)))) (-RRB- -RRB-)))) (. .)))
8558192	7	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NN response)))) (VP (AUX was) (NP (NP (CD 21) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (QP (CD 17) (TO to) (CD 28))) (-RRB- -RRB-)))) (. .)))
8558192	8	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (NP (NP (CD 16) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ prior) (NN chemotherapy)))))) (VP (AUX had) (NP (NP (DT a) (JJ complete) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (CD 31) (NNS weeks) (POS ')) (NN duration)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN CI)) (, ,) (NP (QP (CD 0) (NN %) (TO to) (CD 30) (NN %)))) (-RRB- -RRB-)))))) (. .)))
8558192	9	(S1 (S (NP (NP (DT The) (JJ overall) (NN response) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP World) (NNP Health) (NNP Organization)) (NP (JJ -LSB-WHO) (JJ -RSB-) (NNS criteria)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 15) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN CR)) (, ,) (NP (NP (NP (CD 2) (NN %)) (: ;) (NP (NNP PR) (CD 13) (NN %)) (: ;) (NP (ADJP (CD 95) (NN %)) (NNS CI))) (, ,) (NP (QP (CD 6) (NN %) (TO to) (CD 29) (NN %))))) (-RRB- -RRB-)))) (. .)))
8558192	10	(S1 (S (NP (NP (DT The) (JJ median) (NN dose-intensity)) (PRN (-LRB- -LRB-) (NP (NNP DI)) (-RRB- -RRB-))) (VP (AUX was) (NP (CD 20) (NN mg/m2/wk))) (. .)))
8558192	11	(S1 (S (S (NP (NN Doc_8558192_1189_1192_Chemical)) (VP (AUX was) (VP (ADVP (RB well)) (VBN tolerated)))) (CC and) (S (NP (NP (CD zero) (NNS instances)) (PP (IN of) (NP (WP WHO) (NN grade))) (NP (CD 4) (JJ nonhematologic) (NNP Doc_8558192_1261_1269_Disease))) (VP (VBD occurred))) (. .)))
8558192	12	(S1 (S (NP (NP (NP (QP (IN At) (JJS least) (CD one)) (NN episode)) (PP (IN of) (NP (NN grade) (CD 3)))) (CC or) (NP (CD 4) (NN Doc_8558192_1317_1333_Disease))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 59) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8558192	13	(S1 (S (S (NP (NP (DT A) (NN grade)) (NP (QP (CD 2) (CC or) (CD 3)) (NN Doc_8558192_1378_1387_Disease))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 16) (NN %)) (PP (IN of) (NP (NNS patients))))))) (, ,) (CC but) (S (NP (DT no) (JJ toxic) (NN Doc_8558192_1430_1436_Disease)) (VP (VBD occurred))) (. .)))
8558192	14	(S1 (S (S (NP (JJ Other) (NN side) (NNS effects)) (VP (AUX were) (ADJP (JJ rare)))) (, ,) (CC and) (S (NP (NNP Doc_8558192_1481_1505_Disease)) (VP (AUX has) (VP (AUX been) (ADJP (JJ minor)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %) (NN grade) (CD 1)) (-RRB- -RRB-))))) (. .)))
8558192	15	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_8558192_1573_1576_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ active) (NN agent)) (PP (IN in) (NP (JJ metastatic) (NN Doc_8558192_1610_1644_Disease)))))))) (. .)))
8558192	16	(S1 (S (PP (VBN Given) (NP (NP (PRP$ its) (JJ excellent) (NN tolerance) (NN profile)) (CC and) (NP (JJ low) (NN Doc_8558192_1692_1700_Disease)))) (, ,) (NP (NP (JJ further) (NN evaluation)) (PP (IN of) (NP (NNP Doc_8558192_1724_1727_Chemical))) (PP (IN in) (NP (NN combination) (NN therapy)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
8590259	0	(S1 (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PP (IN of) (NP (JJ Doc_8590259_35_58_Chemical) (JJ ophthalmic) (NN solution))))) (. .)))
8590259	1	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (JJ adverse) (NNS reactions)) (PP (IN of) (NP (NNP Doc_8590259_132_145_Chemical)))) (PP (IN in) (NP (CD 20) (JJ normal) (NNS volunteers))) (PP (IN by) (S (VP (VBG instilling) (NP (NP (DT a) (JJ single) (NN drop)) (PP (IN of) (NP (ADJP (CD 1) (NN %)) (NN Doc_8590259_204_217_Chemical))) (PP (IN in) (NP (PRP$ their) (JJ right) (NNS eyes)))))))) (. .)))
8590259	2	(S1 (S (NP (NP (NNS Examinations)) (, ,) (PP (VBG including) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NN pulse) (NN rate)) (, ,) (NP (FW conjunctiva)) (CC and) (NP (NP (NP (NN cornea)) (, ,) (NP (NN intraocular) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP IOP)) (-RRB- -RRB-)) (, ,) (NP (NN pupil) (NN diameter)) (, ,)) (NN basal) (S (VP (VB tear) (NP (NP (NP (NN secretion)) (CC and) (NP (NN margin) (JJ reflex) (NN distance))) (PP (IN of) (NP (DT both) (ADJP (JJ upper) (CC and) (JJR lower)) (NNS eyelids))))))))) (, ,)) (VP (VP (AUX were) (VP (VBN performed) (ADVP (RB prior)) (PP (TO to) (NP (NN entry))))) (CC and) (VP (PP (IN at) (NP (NP (CD 1) (, ,) (CD 3) (, ,) (CD 5) (CC and) (CD 7) (NNS hours)) (PP (IN after) (NP (NN instillation))))))) (. .)))
8590259	3	(S1 (S (NP (DT The) (JJ Doc_8590259_521_539_Disease) (NNS effects)) (VP (VP (AUX were) (ADJP (RB statistically) (JJ significant)) (PP (IN for) (NP (NP (JJ Doc_8590259_583_596_Chemical-treated) (NNS eyes)) (PP (IN throughout) (NP (DT the) (NN study)))))) (CC and) (ADVP (RB also)) (VP (ADJP (RB statistically) (JJ significant)) (PP (IN for) (NP (NP (JJ contralateral) (NNS eyes)) (PP (IN from) (NP (NP (CD three) (NNS hours)) (PP (IN after) (NP (NP (JJ topical) (NN administration)) (PP (IN of) (NP (ADJP (CD 1) (NN %)) (NNP Doc_8590259_741_754_Chemical))))))))))) (. .)))
8590259	4	(S1 (S (NP (NN Doc_8590259_756_792_Disease)) (VP (AUX were) (UCP (ADVP (RB statistically)) (, ,) (CC but) (RB not) (ADJP (RB clinically) (, ,) (JJ significant)))) (. .)))
8590259	5	(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (JJ diastolic) (NN blood) (NN pressure)) (, ,) (NP (NN pulse) (NN rate)) (CC and) (NP (NN basal))))) (VP (VB tear) (NP (NN secretion)))) (VP (AUX were) (VP (VBN noted))) (. .)))
8590259	6	(S1 (S (NP (NP (NN Doc_8590259_946_968_Disease)) (CC and) (NP (NN Doc_8590259_973_982_Disease))) (VP (AUX were) (ADVP (RB commonly)) (VP (VBN found))) (. .)))
8590259	7	(S1 (S (NP (JJ Upper) (NN lid) (NN retraction)) (VP (AUX was) (ADVP (RB frequently)) (VP (VBN noted))) (. .)))
8590259	8	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NNS elevations)) (PP (IN of) (NP (DT the) (JJ upper) (NN lid) (NN margin))) (PP (IN in) (NP (JJS most) (NNS subjects)))) (VP (VP (AUX were) (RB not) (NP (QP (JJR more) (IN than) (CD 2)) (NN mm))) (CC and) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (JJ noticeable) (NN change)) (PP (IN in) (NP (NN appearance))))))))) (, ,) (NP (CD one) (NN subject)) (VP (VP (VBD suffered) (PP (IN from) (NP (JJ mechanical) (NNP Doc_8590259_1221_1230_Disease)))) (CC and) (VP (VBD marked) (NP (NNP Doc_8590259_1242_1258_Disease) (CD 3) (NNS hours)) (PP (IN after) (NP (NP (NN instillation)) (PP (IN of) (NP (DT the) (NN medication))))))) (. .)))
8590259	9	(S1 (S (NP (DT This)) (VP (MD may) (ADVP (RB well)) (VP (AUX be) (NP (NP (DT a) (ADJP (RB particularly) (JJ notable)) (NN finding)) (PP (IN in) (NP (JJ Asian) (NNS people)))))) (. .)))
8595686	0	(S1 (NP (NP (JJ Doc_8595686_0_11_Chemical) (NN pretreatment)) (PP (IN for) (NP (NP (NNP Doc_8595686_29_37_Chemical) (NN injection) (NNP Doc_8595686_48_52_Disease)) (PP (IN in) (NP (JJ ambulatory) (NNS patients))))) (. .)))
8595686	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (JJ Doc_8595686_101_109_Chemical) (NN injection) (NN Doc_8595686_120_124_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ ambulatory) (NN anaesthesia))))))) (. .)))
8595686	2	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN trial))) (, ,) (NP (CD 90) (NNS women)) (VP (AUX were) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (NN one)) (PP (IN of) (NP (CD three) (NNS treatments)))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP Doc_8595686_307_315_Chemical))))))))))) (. .)))
8595686	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (NNP Group) (NNP C)))) (VP (VBD received) (NP (NP (QP (CD 2) (CD ml)) (JJ normal) (NN saline)) (, ,) (NP (NP (NNP Group) (NNP L)) (, ,) (NP (NP (CD 2) (NN ml)) (, ,) (NP (NP (NNP Doc_8595686_381_390_Chemical) (CD 2) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg)) (-RRB- -RRB-)))) (CC and) (NP (NP (NNP Group) (NNP T)) (, ,) (NP (NP (QP (CD 2) (CD ml)) (NNP Doc_8595686_420_431_Chemical) (CD 2.5) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-))))))) (. .)))
8595686	4	(S1 (S (NP (JJ Venous) (NN discomfort)) (VP (AUX was) (VP (VBN assessed) (PP (IN with) (NP (NP (DT a) (JJ visual) (NN analogue) (NN scale)) (PRN (-LRB- -LRB-) (INTJ (UH VAS)) (-RRB- -RRB-)))) (NP (JJ 5-15) (NNP sec)) (PP (IN after) (S (VP (VBG commencing) (NP (NP (JJ Doc_8595686_538_546_Chemical) (NN administration)) (VP (VBG using) (NP (NP (DT an) (NN infusion) (NN pump)) (PRN (-LRB- -LRB-) (NP (NN rate) (CD 1000) (NN micrograms.kg-1.min-1)) (-RRB- -RRB-)))))))))) (. .)))
8595686	5	(S1 (S (NP (NN Doc_8595686_620_641_Disease)) (VP (VBD occurred) (PP (IN in) (NP (JJ 60-90) (NNP sec)))) (. .)))
8595686	6	(S1 (S (S (NP (NP (NP (JJ Visual) (JJ analogue) (NNS scores)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (-RRB- -RRB-))) (PP (IN during) (NP (NN induction)))) (VP (AUX were) (ADJP (ADJP (JJR lower) (PP (IN in) (NP (NP (NNS Groups)) (NX (NX (NX (NNP L)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.3) (CD +/-)) (CD 2.5)) (-RRB- -RRB-))) (CC and) (NX (NX (NNP T)) (PRN (-LRB- -LRB-) (NP (QP (CD 4.1) (CD +/-)) (CD 2.7)) (-RRB- -RRB-))))))) (PP (IN than) (PP (IN in) (NP (NNP Group) (NNP C))))) (PRN (-LRB- -LRB-) (NP (QP (CD 5.6) (CD +/-)) (CD 2.3)) (-RRB- -RRB-)))) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.0031)))) (. .)))
8595686	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ venous) (NN discomfort)))) (VP (VP (AUX was) (ADJP (ADJP (ADJP (JJR lower) (PP (IN in) (NP (NNP Group) (NNP L)))) (PRN (-LRB- -LRB-) (NP (NP (CD 76.6) (NN %)) (: ;) (NP (CD P) (NNS <))) (NP (CD 0.05)) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (NNP Group) (NNP C))))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN %)) (-RRB- -RRB-))) (CC but) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NP (NNP Group) (NNP T)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %)) (-RRB- -RRB-)))))) (. .)))
8595686	8	(S1 (S (NP (NP (DT The) (JJ VAS) (NNS scores)) (PP (IN for) (NP (NP (NN recall)) (PP (IN of) (NP (NNP Doc_8595686_983_987_Disease))))) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (DT the) (NNP VAS) (NNS scores))) (PP (IN during) (NP (NP (NN induction)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.7045)) (: ;) (NP (QP ($ P) (CD <) (CD 0.0001))) (-RRB- -RRB-)))))) (. .)))
8595686	9	(S1 (S (NP (NN Recovery) (NN room) (NN discharge) (NNS times)) (VP (AUX were) (ADJP (JJ similar)) (: :) (NP (NP (NP (NNP C)) (PRN (-LRB- -LRB-) (NP (NP (CD 75.9) (NN +/-)) (NP (CD 19.4) (NN min))) (-RRB- -RRB-))) (: ;) (NP (NP (NNP L) (CD 73.6)) (PRN (NP (QP (CD +/-) (CD 21.6)) (NN min)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP T)) (PRN (-LRB- -LRB-) (NP (CD 77.1) (NN +/-) (CD 18.9) (NN min)) (-RRB- -RRB-))))) (. .)))
8595686	10	(S1 (S (S (VP (VBG Assessing) (NP (PRP$ their) (JJ overall) (NN satisfaction)))) (, ,) (NP (CD 89.7) (NN %)) (VP (MD would) (VP (VB choose) (NP (JJ Doc_8595686_1257_1265_Chemical) (NN anaesthesia)) (ADVP (RB again)))) (. .)))
8595686	11	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_8595686_1302_1311_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_8595686_1350_1358_Chemical) (NN injection) (NNP Doc_8595686_1369_1373_Disease))) (PP (IN in) (NP (JJ ambulatory) (NNS patients)))) (SBAR (IN whereas) (S (NP (NNP Doc_8595686_1405_1416_Chemical)) (ADVP (RB only)) (VP (VBZ reduces) (NP (PRP$ its) (NN severity))))))))) (. .)))
8638206	0	(S1 (NP (NP (JJ Persistent) (NN Doc_8638206_11_20_Disease)) (PP (IN after) (NP (NP (VBN prolonged) (NN use)) (PP (IN of) (NP (NNP Doc_8638206_44_54_Chemical))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNS corticosteroids))))))) (. .)))
8638206	1	(S1 (S (NP (NP (JJ Neuromuscular) (VBG blocking) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP NMBAs)) (-RRB- -RRB-))) (VP (AUX are) (ADVP (RB often)) (VP (VBN used) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG requiring) (NP (JJ prolonged) (JJ mechanical) (NN ventilation))))))) (. .)))
8638206	2	(S1 (S (NP (NP (NNS Reports)) (PP (IN of) (NP (JJ persistent) (NN Doc_8638206_222_231_Disease))) (PP (IN after) (NP (NP (DT the) (NN discontinuance)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (AUX have) (ADVP (RBS most) (RB often)) (VP (VBN involved) (NP (NP (JJ aminosteroid-based) (NNS NMBAs)) (PP (JJ such) (IN as) (NP (NNP Doc_8638206_330_348_Chemical)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNS corticosteroids)))))))))) (. .)))
8638206	3	(S1 (S (NP (NP (NNP Doc_8638206_408_427_Chemical)) (, ,) (NP (NP (NP (DT a) (NN short-acting)) (NP (NNP Doc_8638206_444_464_Chemical) (NNP NMBA))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN eliminated) (ADVP (RB independently) (PP (IN of) (NP (JJ renal) (CC or) (JJ hepatic) (NN function))))))))) (, ,)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (JJ persistent) (NN Doc_8638206_574_583_Disease))) (, ,) (FRAG (CC but) (RB only) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN with) (NP (NNS corticosteroids)))))))))) (. .)))
8638206	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8638206_646_656_Chemical-related) (NNP Doc_8638206_665_674_Disease)) (VP (VBG persisting) (PP (IN for) (NP (QP (RB approximately) (CD 50)) (NNS hours))) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (RB not) (VP (VBN treated) (PP (IN with) (NP (NNS corticosteroids)))))))))))))) (. .)))
8643971	0	(S1 (NP (NP (NP (DT A) (NN phase) (NNP I/II) (NN study)) (PP (IN of) (NP (NP (NNP Doc_8643971_22_32_Chemical)) (CC plus) (NP (NNP Doc_8643971_38_47_Chemical)))) (PP (IN as) (NP (JJ first-line) (NN therapy))) (PP (IN for) (NP (NNP Doc_8643971_74_95_Disease)))) (: :) (NP (JJ preliminary) (NNS results)) (. .)))
8643971	1	(S1 (S (NP (NP (JJ Improved) (NNS outcomes)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8643971_156_180_Disease)))))) (VP (VBP require) (NP (NP (NNS investigations)) (PP (IN of) (NP (JJ new) (NNS drugs))) (PP (IN for) (NP (JJ induction) (NN therapy))))) (. .)))
8643971	2	(S1 (S (S (NP (NP (JJ Preliminary) (NNS results)) (PP (IN of) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN study)) (PP (IN of) (NP (NP (JJ single-agent) (NNP Doc_8643971_323_333_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8643971_335_340_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-))))))) (VP (VBD reported) (NP (DT a) (ADJP (CD 37) (NN %)) (NN response) (NN rate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8643971_433_453_Disease))))))) (, ,) (CC and) (S (NP (DT the) (JJ Doc_8643971_463_473_Chemical/Doc_8643971_474_483_Chemical) (NN combination)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN used) (ADVP (RB successfully))))) (CC and) (VP (AUX has) (VP (ADVP (RB significantly)) (VBN improved) (NP (NP (JJ median) (NN response) (NN duration)) (PP (IN in) (NP (NNP Doc_8643971_582_596_Disease) (NNS patients)))))))) (. .)))
8643971	3	(S1 (S (NP (PRP We)) (VP (VBD initiated) (NP (NP (DT a) (NN phase) (NNP I/II) (NN trial)) (SBAR (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN response) (CC and) (NN Doc_8643971_669_677_Disease)) (PP (IN of) (S (VP (VBG escalating) (NP (NP (JJ Doc_8643971_692_702_Chemical) (NNS doses)) (VP (VBN combined) (PP (IN with) (NP (JJ fixed-dose) (NNP Doc_8643971_734_743_Chemical))) (PP (IN with) (NP (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor) (NN support)) (PP (IN in) (NP (NNS patients))))) (PP (IN with) (NP (JJ untreated) (ADJP (RB locally) (VBN advanced)) (JJ inoperable) (NN Doc_8643971_850_873_Disease))))))))))))))) (. .)))
8643971	4	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (NP (NP (CD 23) (NNS men)) (PP (IN with) (NP (NP (DT a) (JJ median) (NN age)) (PP (IN of) (NP (NP (CD 50) (NNS years)) (CC and) (NP (JJ good) (NN performance) (NN status))))))) (VP (AUX have) (VP (VBN entered) (NP (DT the) (NN trial)))) (. .)))
8643971	5	(S1 (S (NP (JJ Primary) (NN Doc_8643971_981_986_Disease) (NNS sites)) (VP (AUX were) (NP (NP (NP (NP (NN oropharynx)) (, ,) (NP (CD 10) (NNS patients))) (: ;) (NP (NP (NN hypopharynx)) (, ,) (NP (CD four))) (: ;) (NP (NP (NN larynx)) (, ,) (NP (CD two))) (: ;) (NP (NP (JJ oral) (NN cavity)) (, ,) (NP (CD three))) (: ;) (NP (NP (JJ unknown) (NN primary)) (, ,) (NP (CD two))) (: ;) (CC and) (NP (NP (JJ nasal) (NN cavity)) (CC and) (NP (JJ parotid) (NN gland)))) (, ,) (NP (NP (CD one)) (NP (DT each))))) (. .)))
8643971	6	(S1 (S (NP (QP (IN Of) (CD 20)) (NNS patients)) (VP (VBP evaluable) (PP (IN for) (NP (NNP Doc_8643971_1172_1180_Disease))) (, ,) (SBAR (S (S (NP (CD four)) (VP (AUX had) (VP (VB stage) (NP (NNP III))))) (CC and) (S (NP (CD 16)) (VP (AUX had) (VP (VB stage) (NP (NNP IV) (NN disease)))))))) (. .)))
8643971	7	(S1 (S (NP (NP (NN Treatment)) (, ,) (VP (VBN given) (NP (NP (DT every) (CD 21) (NNS days)) (PP (IN for) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD three) (NNS cycles))))))) (, ,) (VP (VBN consisted) (PP (IN of) (NP (NNP Doc_8643971_1305_1315_Chemical))) (PP (IN by) (NP (JJ 3-hour) (NN infusion))))) (VP (VBD followed) (NP (DT the) (JJ next) (NN day)) (PP (IN by) (NP (NP (DT a) (JJ fixed) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_8643971_1376_1385_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN mg/m2)) (-RRB- -RRB-))))))) (. .)))
8643971	8	(S1 (S (S (NP (DT The) (NN dose) (NNS levels)) (VP (VB incorporate) (S (VP (VBG escalating) (NP (JJ Doc_8643971_1437_1447_Chemical) (NNS doses)))))) (, ,) (CC and) (S (NP (NP (JJ intrapatient) (NNS escalations)) (PP (IN within) (NP (DT a) (VBN given) (NN dose) (NN level)))) (VP (AUX are) (VP (VBN permitted) (SBAR (IN if) (S (NP (NNP Doc_8643971_1527_1535_Disease)) (VP (VBZ permits))))))) (. .)))
8643971	9	(S1 (S (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT this) (NN writing))))) (, ,) (NP (NP (NN dose) (NN level) (CD 4)) (PRN (-LRB- -LRB-) (NP (NP (CD 260)) (, ,) (NP (CD 270)) (, ,) (CC and) (NP (CD 280) (NN mg/m2))) (-RRB- -RRB-))) (VP (AUX is) (VP (AUXG being) (VP (VBN evaluated))))) (: ;) (S (NP (NP (CD three) (NNS patients)) (PP (IN from) (NP (DT this) (NN level)))) (VP (AUX are) (ADJP (JJ evaluable)))) (. .)))
8643971	10	(S1 (S (PP (IN With) (NP (NP (JJ Doc_8643971_1684_1694_Chemical) (NNS doses)) (PP (IN of) (NP (NP (CD 200) (NNS mg/m2)) (CC and) (NP (JJR higher)))))) (, ,) (NP (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor)) (NP (CD 5) (NN micrograms/kg/d))) (VP (AUX is) (VP (VBN given) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 4) (IN through) (CD 12)) (-RRB- -RRB-)))) (. .)))
8643971	11	(S1 (S (PP (IN Of) (NP (NP (CD 18) (NNS patients)) (ADJP (JJ evaluable) (PP (IN for) (NP (NN response)))))) (, ,) (NP (NP (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 39) (NN %)) (-RRB- -RRB-))) (VP (VBD achieved) (SBAR (S (NP (NP (DT a) (JJ complete) (NN response)) (CC and) (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-)))) (VP (VBD achieved) (NP (DT a) (JJ partial) (NN response)))))) (. .)))
8643971	12	(S1 (S (S (NP (CD Three) (NNS patients)) (VP (AUX had) (NP (DT no) (NN change)))) (CC and) (S (NP (NN disease)) (VP (VBD progressed) (PP (IN in) (NP (CD two))))) (. .)))
8643971	13	(S1 (S (NP (DT The) (JJ overall) (NN response) (NN rate)) (VP (AUX is) (NP (CD 72) (NN %))) (. .)))
8643971	14	(S1 (S (NP (CD Eleven) (VBG responding) (NNS patients)) (VP (AUX had) (NP (NP (JJ subsequent) (NN surgery/radiotherapy)) (CC or) (NP (JJ radical) (NN radiotherapy)))) (. .)))
8643971	15	(S1 (S (NP (CD Two) (JJ pathologic) (JJ complete) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN achieved) (NP (JJ clinical) (JJ complete) (NNS responses)))))))))) (. .)))
8643971	16	(S1 (S (S (NP (NP (NNP Doc_8643971_2223_2231_Disease)) (, ,) (NP (NNP Doc_8643971_2233_2245_Disease)) (, ,) (CC and) (NP (NNP Doc_8643971_2251_2262_Disease/Doc_8643971_2263_2271_Disease))) (VP (AUX have) (VP (VBN occurred) (ADVP (RB frequently))))) (, ,) (CC but) (S (PP (IN with) (NP (NP (CD one) (NN exception)) (-LRB- -LRB-) (NP (DT a) (NN grade) (CD 3) (NNP Doc_8643971_2332_2339_Disease)) (-RRB- -RRB-))) (NP (PRP they)) (VP (AUX have) (VP (AUX been) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2))))) (. .)))
8643971	17	(S1 (S (NP (DT No) (JJ dose-limiting) (JJ hematologic) (NN Doc_8643971_2399_2407_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN seen)))) (. .)))
8643971	18	(S1 (S (S (NP (NN Doc_8643971_2423_2433_Chemical/Doc_8643971_2434_2443_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN first-line) (NN regimen)) (PP (IN for) (NP (ADJP (RB locoregionally) (VBN advanced)) (NNP Doc_8643971_2507_2527_Disease)))))) (CC and) (S (NP (VBN continued) (NN study)) (VP (AUX is) (VP (VBN warranted)))) (. .)))
8643971	19	(S1 (S (NP (NNS Results)) (ADVP (RB thus) (RB far)) (VP (VBP suggest) (NP (NP (DT no) (JJ dose-response) (NN effect)) (PP (IN for) (NP (NP (JJ Doc_8643971_2615_2625_Chemical) (NNS doses)) (PP (IN above) (NP (QP (CD 200) (CD mg/m2)))))))) (. .)))
8649546	0	(S1 (NP (NP (NN Improvement)) (PP (IN of) (NP (NNP Doc_8649546_15_23_Chemical-induced) (NNP Doc_8649546_32_42_Disease))) (PP (IN by) (NP (NP (NNP Doc_8649546_46_57_Chemical)) (PP (IN in) (NP (NNP Doc_8649546_61_80_Disease))))) (. .)))
8649546	1	(S1 (S (NP (NP (CD Seven) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_8649546_112_131_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8649546_133_135_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (ADJP (RB severely) (VBG disabling)) (NNP Doc_8649546_161_171_Disease))))) (VP (VBD received) (NP (JJ low-dose) (NN Doc_8649546_190_201_Chemical)) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (DT the) (ADJP (RB currently) (JJ used)) (JJ medical) (NN treatment)))))) (. .)))
8649546	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (ADJP (CD 40) (NN %)) (NN improvement)) (PP (IN in) (NP (NP (DT the) (JJ Doc_8649546_304_314_Disease) (NN score)) (PP (IN without) (NP (NP (NN increase)) (PP (IN of) (NP (NNP Doc_8649546_341_353_Disease) (NNP Doc_8649546_354_370_Disease))))))))) (. .)))
8649546	3	(S1 (S (NP (ADJP (JJ Ballistic) (CC and) (JJ choreic)) (NNP Doc_8649546_394_404_Disease)) (VP (AUX were) (ADVP (RB markedly)) (VP (VBN ameliorated) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_8649546_440_448_Disease)) (VP (AUX was) (RB not)))))) (. .)))
8649546	4	(S1 (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNS beta-blockers)))))) (VP (MD may) (VP (VB improve) (NP (JJ Doc_8649546_540_548_Chemical-induced) (JJ ballistic) (CC and) (JJ choreic) (NN Doc_8649546_579_589_Disease)) (PP (IN in) (NP (NN Doc_8649546_593_595_Disease)))))))) (. .)))
8669433	0	(S1 (NP (NP (NP (JJ Habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_16_29_Chemical))) (PP (IN as) (NP (DT a) (NN risk) (NN factor))) (PP (IN for) (NP (NNP Doc_8669433_51_72_Disease)))) (: :) (NP (NP (DT a) (NN comparison)) (PP (IN with) (NP (NNP Doc_8669433_92_102_Chemical)))) (. .)))
8669433	1	(S1 (S (NP (NP (CD Six) (JJ epidemiologic) (NNS studies)) (PP (IN in) (NP (NP (DT the) (NNP United) (NNPS States)) (CC and) (NP (NNP Europe))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_192_202_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_8669433_241_262_Disease)) (CC and) (NP (NP (NNP Doc_8669433_267_290_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8669433_292_296_Disease)) (-RRB- -RRB-))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (QP (CD 4) (TO to) (CD 19))))))))))))) (. .)))
8669433	2	(S1 (S (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT these)) (CC and) (NP (JJ other) (NNS studies)))))) (, ,) (NP (NNP Doc_8669433_385_395_Chemical)) (VP (AUX has) (ADVP (RB now)) (VP (AUX been) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT the) (NN market)) (PP (IN in) (NP (JJS most) (NNS countries)))))))) (. .)))
8669433	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD three) (NN case) (NN control) (NNS studies)) (, ,) (NP (NP (CD one) (DT each)) (PP (IN in) (NP (NP (NNP North) (NNP Carolina)) (, ,) (NP (JJ northern) (NNP Maryland)) (, ,) (CC and) (NP (NP (NNP West) (NNP Berlin)) (, ,) (NP (NNP Germany)))))) (, ,)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_592_605_Chemical)))) (VP (AUX is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_8669433_630_651_Disease)) (CC and) (NP (NNP Doc_8669433_656_660_Disease)))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (QP (CD 2) (TO to) (CD 4))))))))))))) (. .)))
8669433	4	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT both) (NP (NNP Doc_8669433_739_749_Chemical)) (CC and) (NP (NNP Doc_8669433_754_767_Chemical))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN burden)) (PP (IN of) (NP (NNP Doc_8669433_800_804_Disease))))) (, ,) (PP (IN with) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT the) (JJ latter)))) (VP (AUXG being) (ADJP (ADJP (RB somewhat) (JJR less)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ former)))))))))))))) (. .)))
8669433	5	(S1 (S (NP (NP (DT This) (JJ apparent) (NN difference)) (PP (IN in) (NP (NN risk)))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_8669433_945_956_Disease) (NN potential)) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (NP (PRP themselves))))))))))) (. .)))
8669433	6	(S1 (S (NP (DT A) (ADJP (RBR lower) (JJ relative)) (NN risk)) (VP (MD would) (VP (AUX be) (VP (VBN expected) (PP (IN for) (NP (NNP Doc_8669433_1036_1049_Chemical))) (SBAR (IN if) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS analgesics)))))))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT either) (NN agent)) (ADVP (RB alone))))))))))))) (. .)))
8669433	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_8669433_1167_1180_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (DT both) (PP (IN as) (NP (DT a) (JJ single) (NN agent))) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS analgesics)))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_8669433_1268_1278_Chemical)) (VP (AUX was) (ADJP (JJ available)) (PP (ADVP (RB only)) (IN in) (NP (NNS combinations))))))))) (. .)))
8669433	8	(S1 (S (S (NP (NP (DT The) (NN possibility)) (SBAR (WHNP (IN that)) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_1352_1365_Chemical)))) (ADVP (RB alone)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_8669433_1394_1398_Disease)))))))) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB clearly)) (VP (VBN demonstrated))))) (, ,) (CC but) (S (NP (NN cannot)) (VP (AUX be) (VP (VBN dismissed)))) (. .)))
8682684	0	(S1 (NP (JJ Doc_8682684_0_13_Chemical-induced) (NN Doc_8682684_22_33_Disease) (. .)))
8682684	1	(S1 (S (PP (IN Through) (NP (NP (CD 30) (NNS years)) (PP (IN of) (NP (JJ widespread) (NN use))))) (, ,) (NP (NNP Doc_8682684_71_84_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (ADJP (RB remarkably) (JJ safe)) (NN medication)) (PP (IN in) (NP (JJ therapeutic) (NNS dosages)))))))))) (. .)))
8682684	2	(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NNP Doc_8682684_177_190_Chemical))) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NN Doc_8682684_202_227_Disease))))))) (VP (AUX is) (ADJP (RB very) (JJ low))) (. .)))
8682684	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_8682684_250_263_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB produce) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8682684_309_320_Disease))) (, ,) (PP (VBG including) (NP (NNP Doc_8682684_332_343_Disease))))))) (, ,) (PP (IN in) (NP (JJ sensitive) (NNS individuals)))))) (. .)))
8682684	4	(S1 (S (NP (DT This) (NN article)) (VP (VBZ describes) (NP (NP (CD two) (JJ Doc_8682684_398_412_Disease) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (JJ transient) (NNS episodes)) (PP (IN of) (NP (NNP Doc_8682684_452_463_Disease)))) (ADVP (RB reproducibly)) (VP (VBD developed) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8682684_511_524_Chemical)))))))))) (. .)))
8682684	5	(S1 (S (NP (NP (JJ Other) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8682684_544_562_Disease)))) (VP (AUX were) (RB not) (ADJP (RB clinically) (JJ detectable))) (. .)))
8682684	6	(S1 (S (NP (DT The) (NNP Doc_8682684_599_610_Disease) (NNS episodes)) (VP (AUX were) (ADJP (JJ severe) (RB enough) (S (VP (TO to) (VP (VB require) (NP (NN vasopressor) (NN administration))))))) (. .)))
8682684	7	(S1 (S (NP (DT The) (NNS reports)) (VP (VBP illustrate) (NP (DT the) (NN need) (SBAR (IN for) (S (NP (NNS clinicians)) (VP (TO to) (VP (VB consider) (NP (NNP Doc_8682684_737_750_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_8682684_768_779_Disease)) (PP (IN of) (NP (JJ unknown) (NN origin))))))))))))) (. .)))
8690168	0	(S1 (NP (NP (NN Reduction)) (PP (IN of) (NP (NP (JJ Doc_8690168_13_29_Chemical-associated) (JJ anionic) (NNS sites)) (PP (IN in) (NP (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NNP Doc_8690168_104_118_Chemical-induced) (NNP Doc_8690168_127_147_Disease))))))) (. .)))
8690168	1	(S1 (S (NP (NP (JJ Doc_8690168_149_165_Chemical-associated) (JJ anionic) (NNS sites)) (PP (IN in) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NNS rats))) (PP (NP (CD 8) (NNS months)) (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_8690168_276_284_Disease))))) (PP (PP (IN by) (NP (NNP Doc_8690168_288_302_Chemical))) (CC and) (PP (IN in) (NP (JJ age-) (NNP adn) (JJ sex-matched) (NN control) (NNS rats)))) (, ,) (S (VP (VBG employing) (NP (DT the) (JJ cationic) (NN dye) (NN Doc_8690168_372_387_Chemical)))))) (. .)))
8690168	2	(S1 (S (NP (NP (JJ Morphometric) (NN analysis)) (PP (IN at) (NP (DT the) (JJ ultrastructural) (NN level)))) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (DT a) (JJ computerized) (NN image) (NN processor)))))) (. .)))
8690168	3	(S1 (S (NP (NP (DT The) (JJ Doc_8690168_496_512_Chemical) (NN specificity)) (PP (IN of) (NP (DT the) (JJ Doc_8690168_532_547_Chemical) (NN staining)))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN by) (NP (NP (JJ Doc_8690168_577_594_Chemical-degrading) (NNS enzymes)) (, ,) (VP (VBG showing) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (DT the) (NNS sections)) (PP (IN with) (NP (NN heparitinase)))))) (VP (VBD abolished) (NP (DT all) (NN staining)) (, ,) (SBAR (IN whereas) (S (NP (NNP chondroitinase) (NNP ABC)) (VP (AUX had) (NP (DT no) (NN effect))))))))))))) (. .)))
8690168	4	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (JJ anionic) (NNS sites)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 74) (NN %)) (PP (IN in) (NP (NNP Doc_8690168_778_786_Disease)))) (CC and) (NP (NP (CD 81) (NN %)) (PP (IN in) (NP (NN control) (NNS rats))))) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN found) (PP (IN within) (NP (NP (DT the) (JJ lamina) (NN rara) (NN externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane))))))) (. .)))
8690168	5	(S1 (S (NP (NP (DT A) (NN minority)) (PP (IN of) (NP (JJ anionic) (NNS sites)))) (VP (VP (AUX were) (VP (VBN scattered) (PP (IN throughout) (NP (DT the) (FW lamina) (FW densa) (CC and) (FW lamina) (FW rara) (FW interna))))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR smaller)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (DT the) (FW lamina) (FW rara) (FW externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD p<0.001) (CC and) (CD p<0.01)) (PP (IN for) (NP (NP (NNP Doc_8690168_1116_1124_Disease)) (CC and) (NP (NN control) (NNS rats))))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))) (. .)))
8690168	6	(S1 (S (NP (NN Doc_8690168_1158_1166_Disease) (NNS rats)) (ADVP (RB progressively)) (VP (VBD developed) (NP (NNP Doc_8690168_1196_1207_Disease)) (S (VP (VBG reaching) (NP (NP (CD 40.3)) (PRN (-LRB- -LRB-) (NP (CD 32.2-62.0)) (-RRB- -RRB-))) (NP (CD mg/24) (NNP h)) (PP (IN after) (NP (CD 8) (NNS months))) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN control) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.8)) (PRN (-LRB- -LRB-) (NP (CD 0.2-0.9)) (-RRB- -RRB-)) (NP (CD mg/24) (NNP h))) (, ,) (NP (CD p<0.002))) (-RRB- -RRB-))))))))) (. .)))
8690168	7	(S1 (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ Doc_8690168_1358_1374_Chemical) (JJ anionic) (NNS sites)) (CC and) (NP (NP (DT the) (JJ total) (JJ anionic) (NN site) (NN surface)) (PRN (-LRB- -LRB-) (S (NP (NP (NN number)) (PP (IN of) (NP (JJ anionic) (NNS sites)))) (VP (SYM x) (VP (VB mean) (NP (JJ anionic) (NN site) (NN surface))))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (FW lamina) (FW rara) (FW externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))) (VP (AUX was) (VP (VBN reduced) (PP (PP (IN by) (NP (NP (CD 19) (NN %)) (PRN (-LRB- -LRB-) (NP (CD p<0.021)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (CD p<0.02)) (-RRB- -RRB-))))) (, ,) (ADVP (RB respectively)))) (. .)))
8690168	8	(S1 (S (NP (NP (NP (NP (NN Number)) (CC and) (NP (JJ total) (JJ anionic) (NN site) (NN surface))) (PP (IN in) (NP (NP (DT the) (VBG remaining) (NN part)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))) (-LRB- -LRB-) (NP (FW lamina) (FW densa) (CC and) (FW lamina) (FW rara) (FW interna)) (-RRB- -RRB-)) (VP (AUX were) (RB not) (ADJP (RB significantly) (VBN changed))) (. .)))
8690168	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ Doc_8690168_1792_1806_Chemical-Doc_8690168_1807_1815_Disease) (NNS rats)) (PP (IN with) (NP (DT an) (VBN increased) (NN urinary) (NN albumin) (NN excretion))))) (, ,) (NP (DT a) (VBN reduced) (JJ Doc_8690168_1876_1892_Chemical) (NN charge) (NN barrier/density)) (VP (AUX is) (VP (VBN found) (PP (IN at) (NP (NP (DT the) (FW lamina) (FW rara) (NNS externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))))))) (. .)))
869641	0	(S1 (NP (NP (NN Mediation)) (PP (IN of) (NP (JJ enhanced) (JJ reflex) (NN vagal) (NN Doc_869641_35_46_Disease))) (PP (IN by) (NP (NNP Doc_869641_50_56_Chemical))) (PP (IN via) (NP (NP (JJ central) (JJ Doc_869641_69_77_Chemical) (NN formation)) (PP (IN in) (NP (NNS dogs))))) (. .)))
869641	1	(S1 (S (NP (NP (NN Doc_869641_97_103_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))) (PP (IN after) (NP (NP (JJ extracerebral) (NN decarboxylase) (NN inhibition)) (PP (IN with) (NP (NP (NNP Doc_869641_209_215_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 25) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ anesthetize) (JJ Doc_869641_247_250_Chemical-inhibited) (NNS dogs)))) (. .)))
869641	2	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ reflex) (NN Doc_869641_287_298_Disease)) (VP (VBN caused) (PP (IN by) (NP (VBN injected) (NNP Doc_869641_318_332_Chemical))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN enhanced) (PP (IN by) (NP (NNP Doc_869641_363_369_Chemical))) (, ,) (SBAR (S (NP (NNP Doc_869641_371_401_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (CC or) (NP (NP (JJ reflex) (NNS responses)) (PP (TO to) (NP (NNP Doc_869641_469_483_Chemical))))))))))) (. .)))
869641	3	(S1 (S (NP (NP (NNP Doc_869641_485_491_Chemical)) (, ,) (NP (DT a) (JJ Doc_869641_495_503_Chemical-beta-oxidase) (NN inhibitor)) (, ,)) (VP (AUX did) (RB not) (VP (AUX have) (NP (DT any) (NN effect)) (PP (IN on) (NP (NP (DT the) (ADJP (JJ Doc_869641_559_570_Disease) (, ,) (JJ Doc_869641_572_583_Disease) (CC or) (JJ reflex-enhancing)) (NN effect)) (PP (IN of) (NP (NNP Doc_869641_614_620_Chemical))))))) (. .)))
869641	4	(S1 (S (S (NP (NN Doc_869641_622_630_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_869641_661_667_Chemical)))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))))) (CC but) (S (NP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (NNS reflexes)))))) (. .)))
869641	5	(S1 (S (NP (NP (NN Removal)) (PP (IN of) (NP (DT the) (JJ carotid) (NNS sinuses)))) (VP (VP (VBD caused) (NP (NP (DT an) (JJ elevation) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (CC and) (VP (VBD abolished) (NP (NP (DT the) (JJ negative) (JJ chronotropic) (NN effect)) (PP (IN of) (NP (NN Doc_869641_884_898_Chemical)))))) (. .)))
869641	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_869641_909_915_Chemical)) (VP (VBD restored) (SBAR (S (NP (NP (DT the) (NN Doc_869641_929_940_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_869641_951_965_Chemical))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (S (VP (VBG decreasing) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NP (NN heart)) (PP (FW rate.) (NP (NNP Doc_869641_1023_1028_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-))))))))))) (VP (VP (VBD decreased) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (CC and) (VP (VBD decreased) (NP (DT the) (JJ reflex) (NN Doc_869641_1109_1120_Disease)) (PP (TO to) (NP (NNP Doc_869641_1124_1138_Chemical)))))))) (. .)))
869641	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_869641_1161_1167_Chemical)) (VP (VBZ enhances) (NP (JJ reflex) (NN Doc_869641_1184_1195_Disease)) (PP (IN through) (NP (JJ central) (JJ alpha-receptor) (NN stimulation)))))))) (. .)))
869641	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (NNS effects)) (VP (VP (AUX are) (VP (VBN mediated) (PP (IN through) (NP (NNP Doc_869641_1286_1294_Chemical) (CONJP (RB rather) (IN than)) (NNP Doc_869641_1307_1321_Chemical))))) (CC and) (VP (AUX do) (RB not) (VP (VB require) (NP (DT the) (JJ carotid) (JJ sinus) (NNS baroreceptors))))) (. .)))
8701950	0	(S1 (S (NP (NN Doc_8701950_0_33_Disease)) (VP (VBD complicating) (NP (NNP Doc_8701950_47_52_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_54_64_Chemical)) (-RRB- -RRB-)) (NN therapy))) (. .)))
8701950	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 3) (NNS episodes)) (PP (IN of) (NP (NP (NNP Doc_8701950_101_134_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_136_140_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (CD 2) (JJ solid) (NN organ) (NNS recipients)) (PP (IN under) (NP (NNP Doc_8701950_176_181_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_183_193_Chemical)) (-RRB- -RRB-)) (NN therapy)))))) (. .)))
8701950	2	(S1 (S (PP (IN In) (NP (DT both) (NNS cases))) (, ,) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_8701950_238_243_Chemical)))) (CC and) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN plasma) (NN exchange)) (, ,) (NP (JJ fresh) (JJ frozen) (NN plasma) (NN replacement)) (, ,) (NP (NNP Doc_8701950_313_328_Chemical)) (, ,) (NP (NNP Doc_8701950_330_337_Chemical)) (, ,) (CC and) (NP (NNP Doc_8701950_343_355_Chemical)))))) (VP (VBD led) (PP (TO to) (NP (NP (NN resolution)) (PP (IN of) (NP (NNP Doc_8701950_377_381_Disease)))))) (. .)))
8701950	3	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP (NP (NN reintroduction)) (PP (IN of) (NP (NNP Doc_8701950_417_422_Chemical)))) (VP (VBD led) (PP (TO to) (NP (NP (JJ rapid) (NN recurrence)) (PP (IN of) (NP (NNP Doc_8701950_450_454_Disease)))))) (. .)))
8701950	4	(S1 (S (S (NP (JJ Doc_8701950_456_461_Chemical-associated) (NN Doc_8701950_473_477_Disease)) (VP (AUX is) (ADVP (RB probably)) (ADJP (JJ rare)))) (CC but) (S (NP (NNS physicians)) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ severe) (NN complication))))))) (. .)))
8701950	5	(S1 (S (PP (PP (IN In) (NP (PRP$ our) (NN experience))) (CC and) (PP (VBG according) (PP (TO to) (NP (DT the) (NN literature))))) (, ,) (NP (NNP Doc_8701950_604_609_Chemical)) (VP (AUX does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB cross-react) (PP (IN with) (NP (NP (NP (NNP Doc_8701950_644_657_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_659_662_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (JJ immuno-suppressive) (NN drug)) (VP (ADVP (RB already)) (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_8701950_716_720_Disease)))))))))))))) (. .)))
8739323	0	(S1 (FRAG (NP (NP (NP (NN Effect)) (PP (IN of) (NP (DT some) (JJ anticancer) (NNS drugs)))) (CC and) (NP (NP (VBN combined) (NN chemotherapy)) (PP (IN on) (NP (NNP Doc_8739323_61_75_Disease))))) (. .)))
8739323	1	(S1 (S (NP (NP (DT The) (NNP Doc_8739323_81_92_Disease) (NN action)) (PP (IN of) (NP (NP (NN anticancer) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NP (NNP Doc_8739323_128_143_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_145_147_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_8739323_150_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_164_167_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_8739323_170_184_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_186_190_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_8739323_196_212_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_214_216_Chemical)) (-RRB- -RRB-)))))) (VP (VBN administered) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination) (JJ -LSB-Doc_8739323_256_259_Chemical) (NN +) (NNP Doc_8739323_262_266_Chemical) (NNP +) (NNP Doc_8739323_269_271_Chemical) (PRN (-LRB- -LRB-) (NP (NNP CMF)) (-RRB- -RRB-)) (NN -RSB-)))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS experiments)) (PP (IN on) (NP (NNP Wistar) (NNS rats))))))) (. .)))
8739323	2	(S1 (S (PP (IN After) (NP (NN drug) (NN administration))) (, ,) (NP (NP (JJ Doc_8739323_351_361_Chemical) (NNS concentrations)) (PP (PP (IN in) (NP (DT the) (NN plasma))) (CC and) (PP (IN in) (NP (NP (DT the) (NN urine)) (PP (IN of) (NP (DT the) (NNS rats))))))) (VP (AUX were) (VP (VP (VBN determined)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ Doc_8739323_448_458_Chemical) (NN clearance)))) (. .)))
8739323	3	(S1 (S (NP (NP (JJ Histopathologic) (NN evaluation)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN performed))) (. .)))
8739323	4	(S1 (S (PP (IN After) (NP (NNP Doc_8739323_538_541_Chemical) (NN administration))) (NP (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0228)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN plasma) (NN Doc_8739323_607_617_Chemical) (NN concentration)))) (CC and) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (JJ Doc_8739323_675_685_Chemical) (NN clearance))))) (VP (AUX was) (VP (VBN noted) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))) (. .)))
8739323	5	(S1 (S (PP (IN After) (NP (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_756_758_Chemical) (, ,) (NNP Doc_8739323_760_764_Chemical) (CC and) (NNP Doc_8739323_769_771_Chemical)))) (CC neither) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (JJ Doc_8739323_820_830_Chemical) (NN concentration)))) (CC nor) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_8739323_864_874_Chemical)))))) (NP (NN clearance)) (VP (AUX was) (VP (VBN observed) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (NN group)) (VP (VBG receiving) (NP (DT no) (NNS cytostatics)))))))) (. .)))
8739323	6	(S1 (S (PP (VBG Following) (NP (NP (NN polytherapy)) (PP (VBG according) (PP (TO to) (NP (DT the) (NN CMF) (NN regimen)))))) (, ,) (S (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0343)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ Doc_8739323_1051_1061_Chemical) (NN clearance)))) (VP (AUX was) (VP (VBN found)))) (, ,) (CC but) (S (NP (JJ Doc_8739323_1087_1097_Chemical) (NN concentration)) (VP (AUX did) (RB not) (VP (VB increase) (ADVP (RB significantly)) (PP (VBN compared) (PP (TO to) (NP (NNS controls))))))) (. .)))
8739323	7	(S1 (S (S (NP (NN Doc_8739323_1165_1167_Chemical)) (VP (VBD caused) (NP (NN Doc_8739323_1175_1195_Disease)) (PP (IN in) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NNS rats))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB cause) (NP (DT this) (NN complication)) (SBAR (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_8739323_1270_1274_Chemical)) (CC and) (NP (NNP Doc_8739323_1279_1282_Chemical)))))))))) (. .)))
8739323	8	(S1 (S (NP (JJ Histologic) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NN rat) (NNS kidneys))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_1353_1356_Chemical) (, ,) (NNP Doc_8739323_1358_1360_Chemical) (CC and) (NNP Doc_8739323_1365_1367_Chemical))))) (, ,) (SBAR (IN while) (S (NP (DT no) (JJ such) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (JJ Doc_8739323_1409_1413_Chemical) (CC and) (JJ joint) (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_1442_1445_Chemical) (NNP +) (NNP Doc_8739323_1448_1452_Chemical) (NNP +) (NNP Doc_8739323_1455_1457_Chemical))) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))))))))) (. .)))
8739323	9	(S1 (S (NP (PRP$ Our) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN Doc_8739323_1506_1520_Disease)) (PP (IN of) (NP (NNP Doc_8739323_1524_1527_Chemical) (NNP +) (NNP Doc_8739323_1530_1534_Chemical) (NNP +) (NNP Doc_8739323_1537_1539_Chemical))) (VP (VBN administered) (ADVP (RB jointly)))) (VP (AUX is) (ADJP (ADJP (JJR lower)) (PP (IN than) (PP (IN in) (NP (NN monotherapy))))))))) (. .)))
8741744	0	(S1 (S (NP (DT The) (JJ interpeduncular) (NN nucleus)) (VP (VBZ regulates) (NP (NP (NP (NNP Doc_8741744_38_46_Chemical) (POS 's)) (NNS effects)) (PP (IN on) (NP (JJ free-field) (NN activity))))) (. .)))
8741744	1	(S1 (S (NP (JJ Partial) (NNS lesions)) (VP (AUX were) (VP (VBN made) (PP (IN with) (NP (NNP Doc_8741744_112_123_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ interpeduncular) (NN nucleus)) (PP (IN of) (NP (NP (DT the) (JJ ventral) (NN midbrain)) (PP (IN of) (NP (DT the) (NN rat))))))))) (. .)))
8741744	2	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ sham-operated) (NNS controls)))) (, ,) (NP (NNS lesions)) (ADVP (RB significantly)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.25)) (-RRB- -RRB-) (VP (VBD blunted) (SBAR (S (NP (DT the) (JJ early) (PRN (-LRB- -LRB-) (NP (CD <60) (NN min)) (-RRB- -RRB-)) (JJ free-field) (NN Doc_8741744_301_323_Disease)) (VP (VP (VBD caused) (PP (IN by) (NP (NP (NNP Doc_8741744_334_342_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 0.5) (CD mg)) (NNS kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (, ,) (NP (NNP i.m.))) (-RRB- -RRB-))))) (, ,) (VP (VBD enhanced) (NP (DT the) (JJ later) (PRN (-LRB- -LRB-) (NP (CD 60-120) (NN min)) (-RRB- -RRB-)) (JJ Doc_8741744_398_406_Chemical-induced) (NNP Doc_8741744_415_428_Disease))) (, ,) (CC and) (VP (VBD raised) (NP (JJ spontaneous) (JJ nocturnal) (NN activity))))))) (. .)))
8741744	3	(S1 (S (NP (NNS Lesions)) (VP (VBD reduced) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ immunohistological) (NN staining)))) (PP (PP (IN for) (NP (NP (JJ Doc_8741744_535_542_Chemical) (NN acetyltransferase)) (PP (IN in) (NP (NP (DT the) (JJ interpeduncular) (NN nucleus)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.025)) (-RRB- -RRB-)))))) (, ,) (CC but) (RB not) (PP (IN for) (NP (NP (JJ Doc_8741744_616_624_Chemical) (NN hydroxylase)) (PP (IN in) (NP (DT the) (VBG surrounding) (JJ catecholaminergic) (JJ A10) (NN region))))))) (. .)))
8741744	4	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (JJ interpeduncular) (NN nucleus)) (VP (VP (VBZ mediates) (NP (NP (JJ nicotinic) (NN Doc_8741744_750_760_Disease)) (PP (IN of) (NP (NN locomotor) (NN activity))))) (CC and) (VP (VBZ dampens) (NP (NP (JJ nicotinic) (JJ arousal) (NNS mechanisms)) (VP (VBN located) (ADVP (RB elsewhere)) (PP (IN in) (NP (DT the) (NN brain)))))))))) (. .)))
8752018	0	(S1 (NP (NP (NP (JJ Doc_8752018_0_7_Chemical-associated) (NN Doc_8752018_19_52_Disease)) (VP (VBN reduced) (PP (IN by) (NP (NP (DT a) (NN switch)) (PP (TO to) (NP (NNP Doc_8752018_76_93_Chemical))))))) (: :) (NP (DT a) (NN case) (NN series)) (. .)))
8752018	1	(S1 (S (NP (NN Doc_8752018_122_129_Chemical)) (VP (VBZ remains) (NP (NP (DT a) (JJ first-line) (NN treatment)) (PP (IN for) (NP (NP (DT the) (JJ acute) (CC and) (NN maintenance) (NN treatment)) (PP (IN of) (NP (NNP Doc_8752018_204_220_Disease))))))) (. .)))
8752018	2	(S1 (S (SBAR (IN Although) (S (NP (JJ much)) (VP (AUX has) (VP (AUX been) (VP (VBN written) (PP (IN about) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (DT the) (ADJP (RBR more) (JJ common)) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_8752018_312_319_Chemical))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8752018_329_337_Disease)) (CC and) (NP (NNP Doc_8752018_342_348_Disease))))))))))))) (, ,) (NP (NP (ADJP (RBR more) (JJ subtle)) (JJ Doc_8752018_362_369_Chemical) (JJ side) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8752018_391_409_Disease)) (, ,) (NP (NNP Doc_8752018_411_429_Disease)) (, ,) (CC and) (NP (NNP Doc_8752018_435_457_Disease))))) (VP (VBP remain) (ADJP (JJ understudied))) (. .)))
8752018	3	(S1 (S (NP (DT This) (NN report)) (VP (VBZ summarizes) (NP (PRP$ our) (NN experience)) (PP (IN in) (S (VP (VBG switching) (NP (NNP Doc_8752018_530_537_Disease) (NNS patients)) (PP (IN from) (NP (NNP Doc_8752018_552_559_Chemical))) (PP (TO to) (NP (NNP Doc_8752018_563_580_Chemical))) (S (VP (TO to) (VP (VB alleviate) (NP (JJ such) (NN Doc_8752018_599_635_Disease))))))))) (. .)))
8752018	4	(S1 (FRAG (ADJP (JJ Open)) (, ,) (NP (NN case) (NN series) (NN design)) (. .)))
8752018	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD seven) (NNS cases)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN substitution)) (PP (IN of) (NP (NNP Doc_8752018_724_731_Chemical))) (PRN (, ,) (ADVP (DT either) (RB fully) (CC or) (RB partially)) (, ,)) (PP (IN with) (NP (NNP Doc_8752018_765_782_Chemical)))) (VP (AUX was) (ADJP (RB extremely) (JJ helpful)) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN Doc_8752018_821_866_Disease)) (VP (VBN attributed) (PP (TO to) (NP (NNP Doc_8752018_881_888_Chemical))) (PP (IN in) (NP (PRP$ our) (NNP Doc_8752018_896_903_Disease) (NNS patients))))))))))))) (. .)))
8752018	6	(S1 (S (PP (IN In) (NP (DT this) (JJ preliminary) (NN report))) (, ,) (NP (NNP Doc_8752018_954_971_Chemical)) (VP (AUX was) (NP (NP (DT a) (JJ superior) (NN alternative)) (PP (TO to) (NP (NNP Doc_8752018_1002_1009_Chemical))) (PP (IN in) (NP (NP (JJ Doc_8752018_1013_1020_Disease) (NNS patients)) (VP (VBG experiencing) (NP (NP (NNP Doc_8752018_1043_1061_Disease)) (, ,) (NP (NNP Doc_8752018_1063_1081_Disease)) (, ,) (CC and) (NP (NNP Doc_8752018_1087_1109_Disease)))))))) (. .)))
8829025	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8829025_10_20_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (NN liver) (NN transplant) (NNS recipients)) (VP (VBG receiving) (NP (NNP Doc_8829025_80_90_Chemical))))))) (. .)))
8829025	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_8829025_106_116_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (NN liver) (NN transplant) (NNS recipients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NN Doc_8829025_185_195_Chemical))))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN between) (NP (NP (NNP January) (CD 1992)) (CC and) (NP (NNP January) (CD 1996)))))) (. .)))
8829025	2	(S1 (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_8829025_282_292_Chemical)))))) (VP (AUX were) (VP (VBN compared) (PP (IN over) (NP (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 1) (NN year)))) (, ,) (NP (NP (CD one) (NN group)) (VP (VBG comprising) (NP (NP (NP (JJ Doc_8829025_353_365_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NNP Doc_8829025_394_404_Chemical))))))) (, ,) (CC and) (NP (NP (DT the) (JJ other) (VBG comprising) (NN nonhypertensive) (NNS patients)) (VP (RB not) (VBG receiving) (NP (NNP Doc_8829025_470_480_Chemical))))))))))) (. .)))
8829025	3	(S1 (S (NP (NP (DT The) (NN time)) (PP (IN from) (NP (NN transplant))) (PP (TO to) (NP (NN baseline)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
8829025	4	(S1 (S (NP (NN Doc_8829025_548_558_Chemical)) (ADVP (RB significantly)) (VP (VBD improved) (NP (NN kidney) (NN function)) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (DT a) (JJ significant) (VBG lowering)) (PP (IN of) (NP (JJ serum) (JJ Doc_8829025_646_656_Chemical) (NNS levels))))) (PP (IN at) (NP (QP (CD 6) (CC and) (CD 12)) (NNS months))))))) (. .)))
8829025	5	(S1 (S (NP (NP (DT The) (ADJP (JJ observed) (JJ positive)) (NN impact)) (PP (IN of) (NP (NNP Doc_8829025_716_726_Chemical))) (PP (IN on) (S (VP (VBG reducing) (NP (NP (DT the) (NN Doc_8829025_743_757_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8829025_774_784_Chemical))) (PP (IN in) (NP (NN liver) (NN transplant) (NNS recipients))))))))) (VP (MD should) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN factor)) (PP (IN in) (S (VP (VBG selecting) (NP (NP (DT an) (NN agent)) (SBAR (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_8829025_877_889_Disease)) (PP (IN in) (NP (DT this) (NN population)))))))))))))) (. .)))
88336	0	(S1 (S (NP (NP (NP (NN Alpha)) (CC and) (NP (NN beta) (NN Doc_88336_15_19_Disease))) (PP (IN in) (NP (NN drug) (NN intoxication)))) (VP (JJ uncomplicated) (PP (IN by) (NP (NNP Doc_88336_58_74_Disease)))) (. .)))
88336	1	(S1 (S (NP (NP (CD Four) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN rendered) (NP (NP (NNP Doc_88336_108_116_Disease)) (CC or) (NP (NNP Doc_88336_120_129_Disease))) (PP (IN by) (NP (NN drug) (NN intoxication))))))) (, ,) (CC but) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (ADJP (JJ hypoxic))))) (, ,))) (VP (AUX are) (VP (VBN described))) (. .)))
88336	2	(S1 (S (S (NP (CD Three) (NNS patients)) (VP (VBD received) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_88336_231_246_Chemical)))) (PP (IN for) (NP (NNP Doc_88336_251_258_Chemical) (NNP Doc_88336_259_278_Disease))))) (, ,) (CC and) (S (NP (CD one)) (VP (VBD took) (NP (NP (DT a) (JJ suicidal) (NN Doc_88336_304_312_Disease)) (PP (IN of) (NP (NNP Doc_88336_316_326_Chemical)))))) (. .)))
88336	3	(S1 (S (NP (NP (NP (DT The) (NN patient)) (PP (IN with) (NP (NNP Doc_88336_345_355_Chemical) (NNP Doc_88336_356_364_Disease)))) (CC and) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT those)) (PP (IN with) (NP (JJ Doc_88336_387_402_Chemical) (NN intoxication))))))) (VP (VBD conformed) (PP (TO to) (NP (NP (DT the) (NNS criteria)) (PP (IN of) ('' ') (NP (NN alpha))) (NP (NNP Doc_88336_452_456_Disease) (POS ')))) (, ,) (S (VP (VBG showing) (NP (NP (JJ non-reactive) (JJ generalized) (CC or) (JJ frontally) (NN predominant) (NN alpha) (NN activity)) (PP (IN in) (NP (DT the) (NNP EEG))))))) (. .)))
88336	4	(S1 (S (NP (NP (DT The) (JJ fourth) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (ADJP (JJ unconscious)) (PP (IN after) (NP (NNP Doc_88336_589_604_Chemical) (NN administration))))))) (VP (VBP exhibite) (NP (NP (JJ generalized) (JJ non-reactive) (NN activity)) (PP (IN in) (NP (DT the) (JJ slow) (NN beta) (NN range))))) (. .)))
88336	5	(S1 (S (NP (DT All) (CD four)) (VP (VBD recovered) (ADVP (RB completely)) (PP (IN without) (NP (NNP Doc_88336_725_746_Disease))) (PP (VBG following) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (DT the) (VBG offending) (NNS agents)))))) (. .)))
88336	6	(S1 (S (NP (NP (DT The) (NNS similarities)) (PP (IN between) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ structural) (NNS lesions)))) (CC and) (NP (NP (JJ pharmacological) (NN Doc_88336_876_886_Disease)) (PP (IN of) (NP (DT the) (NN brain))))))) (VP (VBP stem) (SBAR (S (NP (JJ reticular) (NN formation)) (VP (AUX are) (VP (VBN discussed)))))) (. .)))
88336	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (PP (IN in) (NP (DT both) (NNS situations))) (NP (JJ disturbed) (JJ reticulo-thalamic) (NNS interactions)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN alpha) (NN Doc_88336_1064_1068_Disease)))))))))) (. .)))
88336	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (DT this) (ADJP (ADJP (JJ electroencephalographic)) (CC and) (ADJP (JJ behavioural))) (NN picture)) (VP (AUX is) (VP (VBN seen) (PP (IN in) (NP (NN drug) (NN intoxication))) (, ,) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ significant) (NNP Doc_88336_1209_1219_Disease))))))))) (, ,) (NP (DT a) (JJ favourable) (NN outcome)) (VP (MD may) (VP (AUX be) (VP (VBN anticipated)))))))) (. .)))
8864707	0	(S1 (NP (NP (JJ Magnetic) (NN resonance) (NN volumetry)) (PP (IN of) (NP (DT the) (NN cerebellum))) (PP (IN in) (NP (NP (JJ Doc_8864707_50_59_Disease) (NNS patients)) (PP (IN after) (NP (NNP Doc_8864707_75_84_Chemical) (NNP Doc_8864707_85_96_Disease))))) (. .)))
8864707	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (JJ Doc_8864707_161_170_Chemical) (NN medication)) (CC and) (NP (NN Doc_8864707_186_204_Disease))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ clinical) (NN intoxication))))))))))))))) (. .)))
8864707	2	(S1 (S (NP (NP (NP (CD Five) (NNS females)) (CC and) (NP (CD 6) (NNS males))) (, ,) (NP (NP (CD 21-59) (NNS years)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (AUX were) (VP (VBN examined) (PP (IN with) (NP (NP (DT a) (JJ 1.5-T) (NN whole-body) (NN system)) (VP (VBG using) (NP (DT a) (JJ circular) (JJ polarized) (NN head) (NN coil))))))) (. .)))
8864707	3	(S1 (S (NP (JJ Conventional) (NN spin) (VB echo) (NNS images)) (VP (AUX were) (VP (VBN acquired) (PP (IN in) (NP (DT the) (NN sagittal) (CC and) (NN transverse) (NN orientation))))) (. .)))
8864707	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD performed) (SBAR (S (S (NP (DT a) (JJ high-resolution) (NN 3D) (NN gradient)) (VP (VBP echo))) (, ,) (S (NP (NP (JJ T1-weighted) (NNS sequences)) (PP (IN at) (NP (DT a) (NN 1-mm)))) (VP (VBP slice) (NP (NN thickness))))))) (. .)))
8864707	5	(S1 (S (NP (DT The) (NNS images)) (VP (AUX were) (ADVP (RB subsequently)) (VP (VBN processed) (S (VP (TO to) (VP (VB obtain) (NP (JJ volumetric) (NNS data)) (PP (IN for) (NP (DT the) (NN cerebellum)))))))) (. .)))
8864707	6	(S1 (S (NP (NP (JJ Cerebellar) (NN volume)) (PP (IN for) (NP (DT the) (JJ patient) (NN group)))) (VP (VBD ranged) (PP (IN between) (NP (NP (CD 67.66)) (CC and) (NP (NP (QP (CD 131.08) (CD ml))) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 108.9) (NNS ml)) (-RRB- -RRB-)))))) (. .)))
8864707	7	(S1 (S (PP (IN In) (NP (NN addition))) (NP (CD 3D) (NN gradient)) (VP (VBP echo) (SBAR (S (NP (NP (NN data) (NNS sets)) (PP (IN from) (NP (CD 10) (JJ healthy) (NN male) (CC and) (CD 10) (JJ healthy) (JJ female) (JJ age-matched) (NNS volunteers)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB compare) (NP (JJ cerebellar) (NNS volumes)))))))))) (. .)))
8864707	8	(S1 (S (S (VP (VBG Using) (NP (JJ linear) (NN regression)))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (DT no) (NN correlation)) (VP (VBZ exists) (PP (IN between) (NP (NP (JJ Doc_8864707_979_986_Disease) (NN duration)) (, ,) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ Doc_8864707_1010_1019_Chemical) (NN serum) (NNS levels)))) (CC and) (NP (JJ cerebellar) (NN volume)))))))) (. .)))
8864707	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ multiple) (NN regression)) (PP (IN for) (NP (NP (DT the) (JJ daily) (NN dosage)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NP (JJ Doc_8864707_1119_1128_Chemical) (NN treatment)) (CC and) (NP (JJ cerebellar) (NN volume)))))))) (VP (VBD revealed) (NP (NP (DT a) (NN correlation)) (PP (IN of) (NP (DT these) (NNS parameters))))) (. .)))
8864707	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (NP (NNP Doc_8864707_1222_1231_Chemical) (NNP Doc_8864707_1232_1242_Disease)) (VP (AUX does) (RB not) (ADVP (RB necessarily)) (VP (VB result) (PP (IN in) (NP (NNP Doc_8864707_1274_1292_Disease)))))) (CC and) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (JJ Doc_8864707_1317_1326_Chemical) (NN medication)) (VP (AUX was) (NP (NP (DT the) (JJ only) (NN cause)) (PP (IN of) (NP (NNP Doc_8864707_1360_1378_Disease)))) (PP (IN in) (NP (DT the) (VBG remaining) (NNS patients)))))))))))) (. .)))
8864707	11	(S1 (S (NP (NP (JJ Quantitative) (JJ morphometric) (NNS studies)) (PP (IN of) (NP (DT the) (NN cerebellum)))) (VP (VBP provide) (NP (NP (JJ valuable) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_8864707_1509_1529_Disease))))))) (. .)))
891050	0	(S1 (NP (NP (JJ Late) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function))) (PP (IN in) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (DT the) (NNP Doc_891050_52_77_Disease))))) (. .)))
891050	1	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN reported) (PP (IN of) (NP (NP (DT the) (NNP Doc_891050_105_130_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_891050_132_135_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN woman)) (VP (VBG taking) (NP (NNP Doc_891050_155_174_Chemical))))))) (. .)))
891050	2	(S1 (S (S (NP (PRP She)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_891050_197_204_Chemical)) (, ,) (NP (NNP Doc_891050_206_218_Chemical)) (CC and) (NP (NNS hemodialysis))))))) (: ;) (CC and) (S (PP (IN after) (NP (QP (JJR more) (IN than) (CD three)) (NNS months))) (, ,) (S (NP (PRP$ her) (JJ urinary) (NN output)) (VP (VBD rose) (PP (IN above) (NP (NP (CD 500) (NN ml)) (: ;) (CC and) (NP (CD six) (NNS months)))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_891050_343_349_Disease))))))) (, ,) (NP (NN dialysis) (NN treatment)) (VP (AUX was) (VP (VBN stopped)))) (. .)))
891050	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ emphasizes) (NP (DT the) (NN possibility) (SBAR (SBAR (IN that) (S (NP (NP (NN Doc_891050_425_428_Disease)) (PP (IN in) (NP (NNS adults)))) (VP (AUX is) (RB not) (ADJP (RB invariably) (JJ irreversible))))) (CC and) (SBAR (IN that) (S (, ,) (PP (IN despite) (NP (JJ prolonged) (NN Doc_891050_498_506_Disease))) (, ,) (NP (NP (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (MD can) (VP (AUX be) (VP (VBN obtained))))))))) (. .)))
891050	4	(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (NN adult) (NNS patients)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_891050_593_596_Disease)))))) (, ,) (NP (NN dialysis)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN discontinued) (ADVP (RB prematurely)))))) (: ;) (S (ADVP (RB moreover)) (, ,) (NP (NP (JJ bilateral) (NN nephrectomy)) (, ,) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ severe) (NNP Doc_891050_704_716_Disease)) (CC and) (NP (NNP Doc_891050_721_754_Disease)))))) (, ,)) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN with) (NP (NN caution))))))) (. .)))
8919272	0	(S1 (NP (NP (JJ Morphological) (NNS features)) (PP (IN of) (NP (NNP Doc_8919272_26_40_Disease))) (PP (IN after) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ antiepileptic) (NN drug) (NN Doc_8919272_96_105_Chemical)) (PP (TO to) (NP (NNS rats))))))) (. .)))
8919272	1	(S1 (NP (NP (DT A) (NN transmission) (NNP electron) (JJ microscopic) (NN study)) (PP (IN of) (NP (NNS capillaries))) (PP (IN in) (NP (DT the) (JJ cerebellar) (NN cortex))) (. .)))
8919272	2	(S1 (S (NP (NP (JJ Long-term) (JJ intragastric) (NN application)) (PP (IN of) (NP (NP (DT the) (JJ antiepileptic) (NN drug)) (NP (NNP Doc_8919272_259_275_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Vupral) (`` ``) (NNP Polfa) ('' '')) (-RRB- -RRB-)) (PP (IN at) (NP (NP (DT the) (JJ effective) (NN dose)) (PP (IN of) (NP (QP (CD 200) (CD mg/kg)) (NNP b.) (NNP w.) (ADJP (RB once) (JJ daily) (PP (TO to) (NP (NP (NNS rats)) (PP (IN for) (NP (CD 1) (, ,) (CD 3) (, ,) (CD 6) (, ,) (CD 9) (CC and) (CD 12) (NNS months)))))))))))))) (VP (VBD revealed) (NP (NP (NNP Doc_8919272_391_413_Disease)) (VP (VBG indicating) (NP (NP (NNP Doc_8919272_425_442_Disease)) (PRN (-LRB- -LRB-) (NP (`` ``) (NP (NNP Doc_8919272_445_454_Chemical) (NNP Doc_8919272_455_469_Disease)) ('' '')) (-RRB- -RRB-)))))) (. .)))
8919272	3	(S1 (S (NP (NP (DT The) (JJ first) (JJ ultrastructural) (NNS changes)) (PP (IN in) (NP (NP (JJ structural) (NNS elements)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain-barrier)) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)))))) (PP (IN in) (NP (DT the) (JJ cerebellar) (NN cortex)))) (VP (AUX were) (ADJP (JJ detectable)) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (DT the) (NN experiment)))))) (. .)))
8919272	4	(S1 (S (NP (PRP They)) (VP (VP (VBD became) (ADJP (RBR more) (JJ severe)) (PP (IN in) (NP (NP (DT the) (JJ later) (NNS months)) (PP (IN of) (NP (DT the) (NN experiment)))))) (, ,) (CC and) (VP (AUX were) (ADJP (RBS most) (JJ severe)) (PP (IN after) (NP (CD 12) (NNS months))) (, ,) (VP (VBN located) (ADVP (RB mainly)) (PP (IN in) (NP (NP (DT the) (JJ molecular) (NN layer)) (PP (IN of) (NP (DT the) (JJ cerebellar) (NN cortex)))))))) (. .)))
8919272	5	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (NN capillary)))) (VP (VBD included) (NP (NP (NN Doc_8919272_837_845_Disease)) (PP (IN of) (NP (JJ endothelial) (NNS cells))))) (. .)))
8919272	6	(S1 (S (NP (NP (NNS Organelles)) (PP (IN of) (NP (NP (NP (DT these) (NNS cells)) (, ,) (PP (IN in) (NP (NP (JJ particular) (DT the) (NN mitochondria)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN number) (CC and) (NN size)) (, ,) (NP (NP (JJ distinct) (NN degeneration)) (PP (IN of) (NP (PRP$ their) (NNP matrix) (CC and) (NNS cristae)))) (-RRB- -RRB-))))) (CC and) (NP (NNP Golgi) (NN apparatus))))) (VP (AUX were) (VP (VBN altered))) (. .)))
8919272	7	(S1 (S (NP (NP (JJ Reduced) (NN size)) (PP (IN of) (NP (NP (JJ capillary) (NNS lumen)) (CC and) (NP (NN occlusion))))) (VP (AUX were) (VP (VBN caused) (PP (IN by) (NP (NP (JJ swollen) (JJ endothelial) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (NP (NP (JJ Doc_8919272_1136_1143_Chemical) (NNS protrusions)) (CC and) (NP (JJ swollen) (NNS microvilli)))))))))) (. .)))
8919272	8	(S1 (S (NP (NP (NN Pressure)) (PP (IN on) (NP (DT the) (NN vessel) (NN wall)))) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (JJ enlarged) (JJ perivascular) (NN astrocytic) (NNS processes))))) (. .)))
8919272	9	(S1 (S (NP (NP (NNS Fragments)) (PP (IN of) (NP (JJ Doc_8919272_1281_1289_Disease) (NN endothelial) (NNS cells)))) (VP (AUX were) (UCP (PP (IN in) (NP (DT the) (JJ vascular) (NNS lumens))) (CC and) (SBAR (IN in) (S (NP (DT these) (EX there)) (VP (AUX was) (NP (NP (NP (NN loosening)) (CC and) (NP (NN breaking))) (PP (IN of) (NP (JJ tight) (JJ cellular) (NNS junctions))))))))) (. .)))
8919272	10	(S1 (S (NP (NP (NN Damage)) (PP (TO to) (NP (DT the) (JJ vascular) (NN basement) (NNS lamina)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed))) (. .)))
8919272	11	(S1 (S (NP (NP (NN Damage)) (PP (TO to) (NP (DT the) (NN capillary)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ marked) (NN damage)) (PP (TO to) (NP (JJ neuroglial) (NNS cells))))) (, ,) (ADVP (RB mainly)) (S (VP (TO to) (VP (VB perivascular) (NP (NP (NNS processes)) (PP (IN of) (NP (NNS astrocytes))))))))) (. .)))
8919272	12	(S1 (S (NP (NP (NP (DT The) (NN proliferation)) (PP (IN of) (NP (NP (NNS astrocytes)) (PRN (-LRB- -LRB-) (NP (NP (NNP Bergmann) (POS 's)) (PP (IN in) (NP (JJ particular)))) (-RRB- -RRB-))))) (CC and) (NP (NP (RB occasionally)) (PP (IN of) (NP (NNS oligodendrocytes))))) (VP (AUX was) (VP (VBN found))) (. .)))
8919272	13	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NNS elements)) (PP (IN of) (NP (DT the) (NNP BBB)))))) (VP (VBD coexisted) (PP (IN with) (NP (NP (JJ marked) (NNS lesions)) (PP (IN of) (NP (NP (NNS neurons)) (PP (IN of) (NP (NP (DT the) (NN cerebellum)) (PRN (-LRB- -LRB-) (S (NP (NNP Purkinje) (NNS cells)) (VP (AUX are) (NP (JJS earliest)))) (-RRB- -RRB-))))))))) (. .)))
8919272	14	(S1 (S (PP (IN In) (NP (NNP electron) (NNS micrographs))) (NP (NP (DT both) (ADJP (ADJP (JJ Doc_8919272_1871_1878_Chemical)) (CC and) (ADJP (JJ antiluminal))) (NNS sides)) (PP (IN of) (NP (NP (DT the) (NNP BBB)) (PP (IN of) (NP (DT the) (JJ cerebellar) (NN cortex)))))) (VP (AUX had) (NP (JJ similar) (NNS lesions))) (. .)))
8919272	15	(S1 (S (NP (NP (DT The) (JJ possible) (NN influence)) (PP (IN of) (NP (NP (DT the) (NNP Doc_8919272_1988_2002_Disease)) (PRN (, ,) (ADVP (RB mainly)) (NP (NNP Doc_8919272_2011_2025_Disease)) (, ,)))) (PP (IN upon) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8919272_2051_2060_Chemical) (NNP Doc_8919272_2061_2075_Disease)))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
8953972	0	(S1 (S (NP (JJ Fatal) (NN Doc_8953972_6_27_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prehospital) (NN use)) (PP (IN of) (NP (NNP Doc_8953972_63_74_Chemical)))))) (. .)))
8953972	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ paramedic) (NN misjudgment)) (PP (IN in) (NP (NP (DT the) (NN execution)) (PP (IN of) (NP (NP (DT a) (NN protocol)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8953972_171_188_Disease))))))) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8953972_202_217_Disease)) (PP (IN with) (NP (NNP Doc_8953972_223_231_Disease))))))))))))) (. .)))
8953972	2	(S1 (S (NP (NP (NP (DT The) (JJ sudden) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_8953972_253_273_Disease)) (, ,) (NP (NNP Doc_8953972_275_279_Disease)) (, ,)))) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (DT a) (JJ new) (NN medicine))))) (VP (VBD led) (NP (NP (DT the) (CD two) (NNS paramedics)) (PP (IN on) (NP (DT the) (NN scene)))) (S (VP (TO to) (VP (VB administer) (NP (JJ subcutaneous) (NNP Doc_8953972_376_387_Chemical)))))) (. .)))
8953972	3	(S1 (S (ADVP (RB Subsequently)) (, ,) (NP (NP (JJ acute) (NN Doc_8953972_409_423_Disease)) (CC and) (NP (JJ fatal) (NN Doc_8953972_434_457_Disease))) (VP (VBD occurred)) (. .)))
8953972	4	(S1 (S (S (NP (NNP Doc_8953972_468_479_Chemical)) (VP (AUX has) (NP (NP (DT a) (VBN proven) (NN role)) (PP (IN in) (NP (NNP Doc_8953972_501_515_Disease))) (PP (IN in) (NP (JJ prehospital) (NN care)))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NN use)) (PP (IN by) (NP (NNS paramedics))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ suspected) (NNP Doc_8953972_591_608_Disease)) (CC and) (NP (JJ severe) (NNP Doc_8953972_620_632_Disease))))))) (VP (MD should) (VP (AUX be) (VP (VBN viewed) (PP (IN with) (NP (NN caution))))))) (. .)))
8955532	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (JJ Doc_8955532_22_32_Chemical) (JJ B2) (NNS receptors))))) (PP (IN in) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NNP Doc_8955532_100_112_Disease))))))) (. .)))
8955532	1	(S1 (S (NP (NP (JJ Cellular) (NNS mechanisms)) (SBAR (WHNP (WDT which)) (S (VP (VBP account) (PP (IN for) (NP (NN disruption))) (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NN Doc_8955532_200_212_Disease))))))) (VP (AUX are) (RB not) (ADJP (JJ clear))) (. .)))
8955532	2	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NN synthesis/release)) (PP (IN of) (NP (NNP Doc_8955532_301_311_Chemical)))))) (S (VP (TO to) (VP (VBP activate) (NP (JJ B2) (NNS receptors)) (PP (IN in) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NN Doc_8955532_391_403_Disease)))))))))))))) (. .)))
8955532	3	(S1 (S (NP (NP (NN Permeability)) (PP (IN of) (NP (DT the) (JJ blood-brain) (NN barrier)))) (VP (AUX was) (VP (VBN quantitated) (PP (IN by) (NP (NP (NN clearance)) (PP (IN of) (NP (JJ fluorescent-labeled) (NNP Doc_8955532_497_504_Chemical))))) (PP (IN before) (CC and) (IN during) (NP (NP (JJ Doc_8955532_523_536_Chemical-induced) (JJ acute) (NN Doc_8955532_551_563_Disease)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NN vehicle)) (CC and) (NP (NP (NNP Doc_8955532_597_604_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN microM)) (-RRB- -RRB-)))))))))))) (. .)))
8955532	4	(S1 (S (NP (JJ Doc_8955532_619_632_Chemical) (NN infusion)) (VP (VBD increased) (NP (NP (JJ arterial) (NN pressure)) (, ,) (NP (JJ arteriolar) (NN diameter)) (CC and) (NP (NP (NN clearance)) (PP (IN of) (NP (JJ fluorescent) (NNP Doc_8955532_720_727_Chemical))))) (PP (IN by) (NP (DT a) (JJ similar) (NN magnitude))) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
8955532	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN disruption)) (PP (IN of) (NP (DT the) (JJ blood-brain) (NN barrier))) (PP (IN during) (NP (JJ acute) (NNP Doc_8955532_846_858_Disease)))) (VP (AUX is) (RB not) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN synthesis/release)) (PP (IN of) (NP (NNP Doc_8955532_902_912_Chemical))) (S (VP (TO to) (VP (VBP activate) (NP (JJ B2) (NNS receptors)))))))))))) (. .)))
8996652	0	(S1 (NP (NP (NN Risk) (NNS factors)) (PP (IN of) (NP (NP (NNP Doc_8996652_16_42_Disease)) (PP (IN in) (NP (JJ preterm) (NNS infants))))) (. .)))
8996652	1	(S1 (S (PP (IN Among) (NP (NP (CD 547) (JJ preterm) (NNS infants)) (PP (IN of) (NP (QP (CD <) (CC or) (SYM =) (CD 34) (NNS weeks)) (NN gestation))) (VP (VBN born) (PP (IN between) (NP (NP (CD 1987)) (CC and) (NP (CD 1991))))))) (, ,) (NP (NP (CD 8) (NNS children)) (PRN (-LRB- -LRB-) (NP (CD 1.46) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (JJ severe) (JJ progressive) (CC and) (JJ bilateral) (NN Doc_8996652_208_234_Disease))) (. .)))
8996652	2	(S1 (S (NP (NP (JJ Perinatal) (NN risk) (NNS factors)) (PP (IN of) (NP (NP (NNS infants)) (PP (IN with) (NP (NNP Doc_8996652_275_287_Disease)))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (CD two) (NN control) (NNS groups))) (VP (VBN matched) (PP (PP (IN for) (NP (NP (NN gestation)) (CC and) (NP (NN birth) (NN weight)))) (CC and) (PP (IN for) (NP (JJ perinatal) (NNS complications))))))))) (. .)))
8996652	3	(S1 (S (NP (PRP$ Our) (NNS observations)) (VP (VBD demonstrated) (NP (NP (DT an) (NN association)) (PP (IN of) (NP (NNP Doc_8996652_455_467_Disease))) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (JJ perinatal) (NNS complications))))))) (. .)))
8996652	4	(S1 (S (NP (NN Doc_8996652_520_531_Disease)) (VP (VBD appeared) (ADJP (RB closely) (VBN related) (PP (TO to) (NP (NP (DT a) (VBN prolonged) (NN administration)) (CC and) (NP (NP (JJR higher) (JJ total) (NN dose)) (PP (IN of) (NP (NP (JJ Doc_8996652_612_620_Disease) (NNS drugs)) (, ,) (ADVP (RB particularly)) (NP (NP (NNP Doc_8996652_641_656_Chemical)) (CC and) (NP (NNP Doc_8996652_661_671_Chemical)))))))))) (. .)))
8996652	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (ADVP (RB strongly)) (VP (VBP recommend) (S (VP (TO to) (VP (ADVP (RB prospectively) (CC and) (RB regularly)) (VB perform) (NP (NP (JJ audiologic) (NN assessment)) (PP (IN in) (NP (JJ sick) (JJ preterm) (NNS children)))) (SBAR (IN as) (S (NP (NNP Doc_8996652_793_805_Disease)) (VP (AUX is) (PP (PP (IN of) (NP (JJ delayed) (NN onset))) (CC and) (PP (IN in) (NP (JJS most) (NNS cases)))) (ADJP (JJ bilateral) (CC and) (JJ severe))))))))) (. .)))
9034419	0	(S1 (S (NP (NN Doc_9034419_0_7_Disease)) (VP (VBG resulting) (PP (IN from) (NP (DT a) (JJ Doc_9034419_25_36_Chemical) (NN Doc_9034419_37_45_Disease)))) (. .)))
9034419	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9034419_78_89_Chemical) (NNP Doc_9034419_90_98_Disease))))))) (. .)))
9034419	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 40-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_9034419_139_155_Disease))) (SBAR (S (VP (VBD took) (NP (NP (DT an) (NN Doc_9034419_164_172_Disease)) (PP (IN of) (NP (NNP Doc_9034419_176_187_Chemical)))) (PP (IN in) (NP (DT an) (JJ apparent) (NN suicide) (NN attempt))))))) (. .)))
9034419	3	(S1 (S (PP (IN After) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (CD 26) (JJ Doc_9034419_246_257_Chemical) (NN 50-mg) (NNS tablets))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD experienced) (NP (DT a) (VBN witnessed) (JJ generalized) (NN Doc_9034419_321_328_Disease))) (. .)))
9034419	4	(S1 (S (S (NP (PRP She)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (JJ medical) (JJ intensive) (NN care) (NN unit)))))) (, ,) (S (NP (NNP Doc_9034419_383_394_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (DT no) (JJ further) (NNS sequelae)) (VP (AUX were) (VP (VBN seen)))) (. .)))
9034419	5	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NNP Doc_9034419_513_524_Chemical) (NNP Doc_9034419_525_533_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (DT a) (JJ generalized) (NN Doc_9034419_565_572_Disease)))))))) (. .)))
9034419	6	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (NP (NP (JJ nonoverdose) (NNS pharmacokinetics)) (CC and) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NNP Doc_9034419_636_647_Chemical)))) (CC and) (NP (NP (DT the) (JJ potential) (NNS risks)) (PP (IN of) (NP (JJ available) (NNS interventions))))))) (, ,) (NP (DT no) (JJ emergent) (NN therapy)) (VP (AUX was) (VP (VBN instituted))) (. .)))
9034419	7	(S1 (S (NP (NP (DT The) (JJ Doc_9034419_753_764_Chemical) (NN Doc_9034419_765_773_Disease)) (PP (IN in) (NP (PRP$ our) (NN patient)))) (VP (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ single) (NN episode)) (PP (IN of) (NP (JJ generalized) (NNP Doc_9034419_833_840_Disease)))))) (CC but) (VP (VBD elicited) (NP (DT no) (JJ further) (NNS sequelae)))) (. .)))
9088814	0	(S1 (S (NP (NP (JJ Combined) (NNS effects)) (PP (IN of) (NP (NP (JJ prolonged) (JJ Doc_9088814_30_46_Chemical-induced) (NN Doc_9088814_55_66_Disease)) (CC and) (NP (NNP Doc_9088814_71_84_Disease)))) (PP (IN on) (NP (JJ human) (NN hepatic)))) (VP (VBP function)) (. .)))
9088814	1	(S1 (S (NP (NP (JJ Combined) (NNS effects)) (PP (IN of) (NP (JJ prolonged) (NNP Doc_9088814_142_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9088814_160_164_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_9088814_174_185_Disease) (CC and) (NNP Doc_9088814_190_203_Disease))) (PP (IN on) (NP (JJ hepatic) (NN function)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (CD 30) (NNS patients)) (VP (VBG undergoing) (NP (NN hip) (NN surgery))))))) (. .)))
9088814	2	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD three) (NNS groups)) (: ;) (NP (NP (NP (DT those)) (SBAR (IN in) (S (NP (NP (NN group) (DT A)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (JJ controlled) (NNP Doc_9088814_392_403_Disease)) (ADVP (RB alone))))))))) (, ,) (NP (NP (DT those)) (PP (IN in) (NP (NP (NN group) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (TO to) (NP (NNP Doc_9088814_440_453_Disease)) (ADVP (RB alone))))) (CC and) (NP (NP (DT those)) (PP (IN in) (NP (NN group) (NN C))))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (PP (TO to) (NP (DT both) (JJ controlled) (NNP Doc_9088814_509_520_Disease) (CC and) (NNP Doc_9088814_525_538_Disease))))) (. .)))
9088814	3	(S1 (S (S (NP (NP (NN Doc_9088814_540_553_Disease)) (PP (IN in) (NP (NNS groups) (NNP B) (CC and) (NNP C)))) (VP (AUX was) (VP (VBN produced) (PP (IN by) (S (VP (VP (VBG withdrawing) (NP (NP (QP (RB approximately) (CD 1000)) (NNS mL)) (PP (IN of) (NP (NN blood))))) (CC and) (VP (VBG replacing) (NP (PRP it)) (PP (IN with) (NP (NP (DT the) (JJ same) (NN amount)) (PP (IN of) (NP (JJ Doc_9088814_672_679_Chemical) (NN solution)))))))))))) (, ,) (CC and) (S (NP (JJ final) (NN haematocrit) (NNS values)) (VP (AUX were) (NP (QP (CD 21) (CC or) (CD 22)) (NN %)))) (. .)))
9088814	4	(S1 (S (NP (NP (JJ Controlled) (NN Doc_9088814_746_757_Disease)) (PP (IN in) (NP (NP (NNS groups)) (X (DT A) (CC and) (SYM C))))) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_9088814_793_797_Chemical))) (S (VP (TO to) (VP (VB maintain) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN at) (NP (CD 55) (NN mmHg))) (PP (IN for) (NP (CD 180) (NN min)))))))) (. .)))
9088814	5	(S1 (S (NP (NNS Measurements)) (VP (VBD included) (NP (NP (NP (JJ arterial) (JJ ketone) (NN body) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NNP AKBR)) (, ,) (NP (NNP Doc_9088814_919_932_Chemical/Doc_9088814_933_950_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ clinical) (JJ hepatic) (NN function) (NNS parameters)))) (. .)))
9088814	6	(S1 (S (NP (JJ AKBR) (CC and) (JJ biological) (JJ hepatic) (NN function) (NNS tests)) (VP (VBD showed) (NP (DT no) (NN change)) (PP (IN throughout) (NP (NP (DT the) (NN time) (NN course)) (PP (IN in) (NP (NP (NNS groups)) (X (DT A) (CC and) (SYM B))))))) (. .)))
9088814	7	(S1 (S (PP (IN In) (NP (NN group) (NN C))) (, ,) (NP (NNP AKBR)) (VP (VBD showed) (SBAR (S (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (PP (IN at) (NP (NP (CD 120) (NN min)) (PRN (-LRB- -LRB-) (NP (JJ -40) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (IN at) (NP (CD 180) (NN min)))) (PRN (-LRB- -LRB-) (NP (CD -49) (NN %)) (-RRB- -RRB-)) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NNP Doc_9088814_1206_1217_Disease) (CC and) (PP (IN at) (NP (NP (NP (CD 60) (NN min)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-) (PP (IN after) (NP (NP (NN recovery)) (PP (IN of) (NP (NN normotension))))) (, ,))) (CC and) (NP (NNP SGOT)))) (, ,) (NN SGPT) (, ,) (NN LDH) (CC and) (JJ total) (NNP Doc_9088814_1301_1310_Chemical)))))) (VP (VBD showed) (NP (JJ significant) (NNS increases)) (PP (IN after) (NP (NN operation))))))) (. .)))
9088814	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (VBN prolonged) (NN combination)) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 120)) (NN min)) (PP (IN of) (NP (NP (JJ Doc_9088814_1430_1434_Chemical-induced) (NNP Doc_9088814_1443_1454_Disease)) (CC and) (NP (JJ moderate) (NNP Doc_9088814_1468_1481_Disease))))))) (VP (MD would) (VP (VB cause) (NP (NN Doc_9088814_1494_1524_Disease))))))) (. .)))
9100294	0	(S1 (S (NP (NP (NN Doc_9100294_0_26_Disease)) (PP (IN in) (NP (NN rat) (NNS fetuses)))) (VP (VBD exposed) (PP (TO to) (NP (JJ Doc_9100294_53_60_Chemical) (NN channel) (NNS blockers)))) (. .)))
9100294	1	(S1 (S (NP (JJ Preclinical) (JJ toxicologic) (NN investigation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT a) (JJ new) (JJ Doc_9100294_138_145_Chemical) (NN channel) (NN blocker)) (, ,) (NP (NNP Doc_9100294_163_173_Chemical)) (, ,)) (VP (VBN induced) (NP (NNP Doc_9100294_183_209_Disease)) (PP (IN in) (NP (NP (NN rat) (NNS fetuses)) (VP (VBN exposed) (PP (TO to) (NP (DT this) (NN agent))) (PP (IN during) (NP (NN organogenesis)))))))))) (. .)))
9100294	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (JJ Doc_9100294_335_342_Chemical) (NN channel) (NNS blockers)) (PP (IN in) (NP (NN general)))) (VP (VB induce) (NP (NNP Doc_9100294_378_406_Disease)) (S (VP (VBG indicating) (NP (DT a) (JJ pharmacologic) (NN class) (NN effect))))))))))))) (. .)))
9100294	3	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD three) (JJ Doc_9100294_465_472_Chemical) (NN channel) (NNS blockers)) (PP (IN of) (NP (NP (JJ different) (NN structure)) (, ,) (NP (NP (NNP Doc_9100294_514_524_Chemical)) (, ,) (NP (NNP Doc_9100294_526_535_Chemical)) (, ,) (CC and) (NP (NNP Doc_9100294_541_550_Chemical))) (, ,)))) (PP (IN along) (PP (IN with) (NP (DT the) (JJ new) (NN agent))))) (. .)))
9100294	4	(S1 (S (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN administered) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ Doc_9100294_623_630_Chemical) (NN channel) (NNS blockers)))) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (JJ cardiac) (NNS morphogenesis)))))))) (CC and) (S (NP (DT the) (NN offspring)) (VP (VBD examined) (PP (IN on) (NP (NP (NN day) (CD 20)) (PP (IN of) (NP (NP (NN gestation)) (PP (IN for) (NP (NNP Doc_9100294_745_773_Disease))))))))) (. .)))
9100294	5	(S1 (S (S (NP (NP (DT A) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_9100294_794_822_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (CD four) (JJ Doc_9100294_871_878_Chemical) (NN channel) (NNS blockers)))))))))) (, ,) (CC but) (S (NP (DT this) (NN incidence)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (ADVP (RB only)) (PP (IN for) (NP (NP (NNP Doc_9100294_955_964_Chemical)) (CC and) (NP (NNP Doc_9100294_969_979_Chemical)))))) (. .)))
9100294	6	(S1 (S (NP (DT All) (CD four) (NNS agents)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NN aortic) (NN arch) (VBG branching) (NNS variants))) (, ,) (SBAR (IN although) (S (VP (ADVP (RB significantly)) (VBD increased) (ADVP (RB only)) (PP (IN for) (NP (NP (NNP Doc_9100294_1092_1102_Chemical)) (CC and) (NP (NNP Doc_9100294_1107_1116_Chemical))))))))) (. .)))
9195768	0	(S1 (NP (NP (DT The) (NN site)) (PP (IN of) (NP (NP (JJ common) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_9195768_35_46_Chemical))))) (. .)))
9195768	1	(S1 (S (S (NP (NP (NN Doc_9195768_48_67_Disease)) (VP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ subcutaneous) (NNP Doc_9195768_102_113_Chemical)))))) (VP (AUX are) (ADJP (JJ common)))) (, ,) (CC but) (S (PP (IN of) (NP (JJ uncertain) (NN origin)))) (. .)))
9195768	2	(S1 (S (NP (PRP They)) (VP (VP (AUX are) (ADJP (ADVP (RB almost) (RB always)) (JJ benign))) (, ,) (CC but) (VP (MD can) (VP (AUX be) (VP (VBN mistaken) (PP (IN for) (NP (NP (DT a) (JJ serious) (JJ adverse) (NN event)) (PP (IN by) (NP (DT the) (NN patient))))))))) (. .)))
9195768	3	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX are) (VP (VBN presented) (PP (IN with) (NP (NNP Doc_9195768_278_308_Disease))) (PP (VBN limited) (PP (TO to) (NP (NP (NNS areas)) (PP (IN of) (NP (NP (NN heat) (NN exposure)) (CC or) (NP (NN Doc_9195768_346_353_Disease))))))))) (. .)))
9195768	4	(S1 (S (PP (IN In) (NP (DT these) (NNS individuals))) (, ,) (NP (NN side) (NNS effects)) (VP (AUX are) (ADVP (RBS most) (JJ likely)) (VP (VBN generated) (ADVP (RB superficially)) (PP (IN in) (NP (DT the) (NN skin))))) (. .)))
9199746	0	(S1 (NP (NP (NNP Macula) (NNP Doc_9199746_7_15_Disease)) (PP (IN after) (NP (JJ intravitreal) (NNP Doc_9199746_35_43_Chemical))) (. .)))
9199746	1	(S1 (S (SBAR (IN Although) (S (NP (JJ intravitreal) (NNP Doc_9199746_79_94_Chemical)) (VP (AUX have) (NP (ADJP (RB substantially) (VBN improved)) (JJ visual) (NN prognosis)) (PP (IN in) (NP (NNP Doc_9199746_143_158_Disease)))))) (, ,) (ADVP (RB macular)) (NP (NNP Doc_9199746_168_178_Disease)) (VP (MD may) (VP (VB impair) (NP (JJ full) (JJ visual) (NN recovery)))) (. .)))
9199746	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ presumed) (NNP Doc_9199746_251_259_Chemical) (NNP Doc_9199746_260_276_Disease)))) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_9199746_302_310_Chemical)) (CC and) (NP (NNP Doc_9199746_315_325_Chemical)))) (PP (IN for) (NP (JJ alpha-haemolytic) (NNP Doc_9199746_347_376_Disease)))))) (. .)))
9199746	3	(S1 (S (NP (NN Doc_9199746_387_402_Disease)) (VP (VBN resolved) (PP (IN with) (NP (NN improvement))) (PP (IN in) (NP (NP (JJ visual) (NN acuity)) (PP (TO to) (NP (CD 6/24))))) (PP (IN at) (NP (CD three) (NNS months)))) (. .)))
9199746	4	(S1 (S (NP (JJ Fundus) (JJ Doc_9199746_478_489_Chemical) (NN angiography)) (VP (VBD confirmed) (NP (NP (JJ macular) (JJ capillary) (NN closure)) (CC and) (NP (NN Doc_9199746_542_556_Disease)))) (. .)))
9199746	5	(S1 (S (ADVP (RB Currently)) (NP (JJ accepted) (JJ intravitreal) (JJ antibiotic) (NNS regimens)) (VP (MD may) (VP (VP (VB cause) (NP (NN Doc_9199746_633_649_Disease))) (CC and) (VP (VB macular) (NP (NNP Doc_9199746_662_671_Disease))))) (. .)))
9199746	6	(S1 (S (NP (NP (NN Treatment) (NNS strategies)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG avoiding) (NP (NN Doc_9199746_712_728_Disease))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
9245658	0	(S1 (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_9245658_12_20_Chemical))) (PP (IN in) (NP (JJ smoking-related) (NNP Doc_9245658_40_62_Disease))) (. .)))
9245658	1	(S1 (S (NP (NN Doc_9245658_64_72_Chemical)) (VP (VP (VBZ activates) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system))) (CC and) (VP (PP (IN in) (NP (DT this) (NN way))) (MD could) (VP (VB contribute) (PP (TO to) (NP (NN Doc_9245658_150_172_Disease)))))) (. .)))
9245658	2	(S1 (S (S (NP (NP (NN Animal) (NNS studies)) (CC and) (NP (JJ mechanistic) (NNS studies))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9245658_227_235_Chemical)) (VP (MD could) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG accelerating) (NP (NNP Doc_9245658_270_285_Disease))))))))))) (, ,) (CC but) (S (NP (NP (NN evidence)) (PP (IN among) (NP (NNS humans)))) (VP (AUX is) (ADJP (RB too) (JJ inadequate) (S (VP (TO to) (VP (AUX be) (ADJP (JJ definitive) (PP (IN about) (NP (PDT such) (DT an) (NN effect)))))))))) (. .)))
9245658	3	(S1 (S (ADVP (RB Almost) (RB certainly)) (, ,) (NP (NP (NNP Doc_9245658_388_396_Chemical)) (PP (IN via) (NP (PRP$ its) (JJ hemodynamic) (NNS effects)))) (VP (VBZ contributes) (PP (TO to) (NP (JJ acute) (JJ cardiovascular) (NNS events))) (, ,) (SBAR (IN although) (S (NP (JJ current) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9245658_524_532_Chemical)))) (VP (AUX are) (ADJP (ADVP (RB much) (RBR less)) (JJ important)) (SBAR (IN than) (S (VP (AUX are) (NP (NP (NP (DT the) (JJ prothrombotic) (NNS effects)) (PP (IN of) (NP (NN cigarette) (NN smoking)))) (CC or) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9245658_631_646_Chemical))))))))))))))) (. .)))
9245658	4	(S1 (S (NP (NN Doc_9245658_648_656_Chemical)) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN Doc_9245658_684_694_Disease)) (PP (IN among) (NP (NNS humans))))))))) (. .)))
9245658	5	(S1 (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN of) (NP (NP (NP (NN pipe) (NNS smokers)) (CC and) (NP (NNS people))) (VP (VBG using) (NP (JJ transdermal) (NNP Doc_9245658_771_779_Chemical)))))) (VP (VBP support) (NP (DT the) (NN idea) (SBAR (IN that) (S (NP (NP (NNS toxins)) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_9245658_820_828_Chemical))))) (VP (AUX are) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NNS causes)) (PP (IN of) (NP (JJ acute) (JJ cardiovascular) (NNS events))))))))) (. .)))
9245658	6	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN dose) (NN response)) (PP (IN for) (NP (NP (JJ cardiovascular) (NNS events)) (PP (IN of) (NP (NNP Doc_9245658_947_955_Chemical)))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ flat))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (SBAR (IN if) (S (NP (NNP Doc_9245658_995_1003_Chemical)) (VP (AUX is) (VP (VBN involved))))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (MD might) (VP (AUX be) (VP (VBN seen) (PP (IN with) (NP (ADJP (RB relatively) (JJ low-level)) (NN cigarette) (NNS exposures))))))))))) (. .)))
9249847	0	(S1 (S (VP (ADVP (RB Iatrogenically)) (VBN induced) (NP (JJ intractable) (NNP Doc_9249847_35_73_Disease)) (PP (IN after) (NP (NP (NNP Doc_9249847_80_89_Chemical)) (CC and) (NP (NN catheter) (NN ablation)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_9249847_130_160_Disease)) (CC and) (NP (NNP Doc_9249847_165_198_Disease))))))) (. .)))
9249847	1	(S1 (S (PP (IN In) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_9249847_218_230_Disease)) (CC and) (NP (NNP Doc_9249847_235_268_Disease)))))) (, ,) (NP (NP (JJ intractable) (NNP Doc_9249847_282_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9249847_322_326_Disease)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB iatrogenically)) (VP (VBN induced))) (. .)))
9249847	2	(S1 (S (NP (NP (NNS QRS)) (PP (IN without) (NP (NN preexcitation))) (, ,) (VP (VBN caused) (PP (IN by) (NP (JJ junctional) (NN escape) (NNS beats))) (PP (IN after) (NP (NP (JJ Doc_9249847_423_432_Chemical) (CC or) (JJ unidirectional) (NN antegrade) (NN block)) (PP (IN of) (NP (JJ accessory) (NN pathway))))) (PP (IN after) (NP (NN catheter) (NN ablation)))) (, ,)) (VP (VBD established) (NP (JJ frequent) (JJ Doc_9249847_534_538_Disease) (NN attack))) (. .)))
9284778	0	(S1 (S (NP (NP (NN Epidemic)) (PP (IN of) (NP (NNP Doc_9284778_12_25_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9284778_36_60_Chemical))))) (VP (VBD used) (PP (IN as) (NP (NP (JJ Doc_9284778_69_74_Chemical-sparing) (NNS substitutes)) (PP (IN of) (NP (NNP Doc_9284778_98_117_Chemical)))))) (. .)))
9284778	1	(S1 (S (NP (NP (NNP Doc_9284778_131_155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_157_162_Chemical)) (-RRB- -RRB-))) (VP (AUX are) (VP (VBN used) (ADVP (RB increasingly)) (PP (IN in) (NP (NN industry))) (PP (IN as) (NP (NP (NNS substitutes)) (PP (IN for) (NP (NP (NNP Doc_9284778_217_222_Chemical-depleting) (NNP Doc_9284778_233_252_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_254_258_Chemical)) (-RRB- -RRB-)))))))) (. .)))
9284778	2	(S1 (S (NP (NP (JJ Limited) (NNS studies)) (PP (IN in) (NP (NNS animals)))) (VP (VBP indicate) (NP (NP (JJ potential) (NN Doc_9284778_307_321_Disease)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (DT these) (NNS compounds))))))) (. .)))
9284778	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT an) (NN epidemic)) (PP (IN of) (NP (NNP Doc_9284778_381_394_Disease))) (PP (IN in) (NP (NP (CD nine) (JJ industrial) (NNS workers)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (VP (VBN repeated) (NP (JJ accidental) (NN exposure)) (PP (TO to) (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (NP (NP (NNP Doc_9284778_479_513_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_515_523_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9284778_529_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_565_573_Chemical)) (-RRB- -RRB-)))))))))))))))) (. .)))
9284778	4	(S1 (S (NP (DT All) (CD nine) (JJ exposed) (NNS workers)) (VP (AUX were) (VP (VBN affected) (PP (TO to) (NP (JJ various) (NNS degrees))))) (. .)))
9284778	5	(S1 (S (NP (DT Both) (NNS compounds)) (VP (AUX are) (VP (VBN metabolised) (PP (IN in) (NP (DT the) (JJ same) (NN way))) (PP (IN as) (NP (NP (NP (NNP Doc_9284778_685_723_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_725_734_Chemical)) (-RRB- -RRB-)) (SBAR (S (VP (TO to) (VP (VB form) (NP (JJ reactive) (JJ Doc_9284778_753_768_Chemical) (NN halide) (NNS intermediates))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNP Doc_9284778_825_839_Disease)) (PP (IN of) (NP (NNP Doc_9284778_843_852_Chemical)))))))))))))) (. .)))
9284778	6	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB test) (SBAR (IN whether) (S (NP (NNP Doc_9284778_879_896_Chemical)) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_9284778_919_932_Disease))))))))))) (. .)))
9284778	7	(S1 (S (PP (IN For) (NP (CD one))) (NP (NP (ADJP (RB severely) (VBN affected)) (NN worker) (NN liver) (NN biopsy) (CC and) (JJ immunohistochemical) (NNS stainings)) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ Doc_9284778_1043_1058_Chemical) (NN protein) (NNS adducts)))))) (VP (AUX were) (VP (AUX done))) (. .)))
9284778	8	(S1 (S (NP (NP (DT The) (NN serum)) (PP (IN of) (NP (NP (CD six) (JJ affected) (NNS workers)) (CC and) (NP (CD five) (NNS controls))))) (VP (AUX was) (VP (VBN tested) (PP (IN for) (NP (NP (NNS autoantibodies)) (SBAR (WHNP (WDT that)) (S (VP (VBP react) (PP (IN with) (NP (NP (NP (JJ human) (NN liver) (JJ cytochrome-P450) (NNS 2E1)) (PRN (-LRB- -LRB-) (NP (CD P450) (NNS 2E1)) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (CD P58) (NN protein)) (JJ disulphide) (JJ isomerase) (NN isoform)) (PRN (-LRB- -LRB-) (NP (NNP P58)) (-RRB- -RRB-)))))))))))) (. .)))
9284778	9	(S1 (S (NP (DT The) (NN liver) (NN biopsy) (NN sample)) (VP (VBD showed) (NP (NP (JJ hepatocellular) (NN Doc_9284778_1335_1343_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (ADJP (JJ prominent)) (PP (IN in) (NP (NN perivenular) (NN zone) (CD three)))) (CC and) (VP (VBD extended) (ADVP (RB focally) (PP (IN from) (NP (JJ portal) (NNS tracts)))) (PP (TO to) (NP (NP (NP (JJ portal) (NNS tracts)) (CC and) (NP (JJ centrilobular) (NNS areas))) (PRN (-LRB- -LRB-) (PP (VBG bridging) (NP (NNP Doc_9284778_1481_1489_Disease))) (-RRB- -RRB-)))))))))) (. .)))
9284778	10	(S1 (S (NP (JJ Doc_9284778_1492_1507_Chemical-adducted) (NNS proteins)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (VBG surviving) (NNS hepatocytes))))) (. .)))
9284778	11	(S1 (S (NP (NP (NNS Autoantibodies)) (PP (IN against) (NP (NNP P450) (CD 2E1) (CC or) (CD P58))) (, ,) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NNP Doc_9284778_1633_1652_Disease)))) (, ,)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (CD five) (JJ affected) (NNS workers))))))) (. .)))
9284778	12	(S1 (S (NP (NP (VBN Repeated) (NN exposure)) (PP (IN of) (NP (JJ human) (NNS beings))) (PP (TO to) (NP (NNP Doc_9284778_1760_1777_Chemical)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_9284778_1800_1812_Disease))) (PP (IN in) (NP (NP (DT a) (JJ large) (NN proportion)) (PP (IN of) (NP (DT the) (VBN exposed) (NN population))))))) (. .)))
9284778	13	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ exact) (NN mechanism)) (PP (IN of) (NP (NP (NNP Doc_9284778_1894_1908_Disease)) (PP (IN of) (NP (DT these) (NNS agents)))))) (VP (AUX is) (RB not) (VP (VBN known))))) (, ,) (NP (DT the) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_9284778_1964_1979_Chemical-altered) (NN liver) (NNS proteins)) (VP (AUX are) (VP (VBN involved)))))) (. .)))
9284778	14	(S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (ADJP (RB potentially) (JJ widespread)) (NN use)) (PP (IN of) (NP (DT these) (NNS compounds))))))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB develop) (NP (JJR safer) (NNS alternatives)))))))) (. .)))
9293063	0	(S1 (S (NP (NN Doc_9293063_0_19_Disease)) (VP (VBG occurring) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NNP Doc_9293063_75_82_Chemical)))))) (. .)))
9293063	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9293063_104_123_Disease))) (SBAR (WHNP (WDT which)) (S (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (PP (IN on) (NP (JJ long-term) (JJ Doc_9293063_179_186_Chemical) (NN treatment)))))))))))))) (. .)))
9293063	2	(S1 (S (NP (JJ Such) (NNS patients)) (VP (MD should) (VP (AUX be) (PP (IN under) (NP (JJ close) (NN follow-up))) (, ,) (PP (ADVP (RB preferably)) (IN with) (NP (NP (JJ periodic) (NN ultrasound) (NN examination)) (PP (IN of) (NP (DT the) (NN liver))))))) (. .)))
9293063	3	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN patient)) (VP (VBZ develops) (NP (DT a) (NN Doc_9293063_333_343_Disease))))) (, ,) (PP (IN because) (IN of) (NP (NP (JJ non-specific) (JJ clinical) (NNS features)) (CC and) (NP (NN imaging) (NNS appearances)))) (, ,) (NP (NN biopsy)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ only) (NN way)) (SBAR (S (VP (TO to) (VP (VB achieve) (NP (DT a) (JJ definitive) (NN diagnosis))))))))) (. .)))
9334596	0	(S1 (NP (NP (NP (JJ Endocrine) (NN screening)) (PP (IN in) (NP (CD 1,022) (NNS men))) (PP (IN with) (NP (NNP Doc_9334596_38_58_Disease)))) (: :) (NP (NP (JJ clinical) (NN significance)) (CC and) (NP (JJ cost-effective) (NN strategy))) (. .)))
9334596	1	(S1 (S (NP (PRP We)) (VP (VP (VBN reviewed) (NP (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ serum) (NNP Doc_9334596_153_165_Chemical)))) (CC and) (NP (NN prolactin) (NN determination))) (PP (IN in) (NP (NP (CD 1,022) (NNS patients)) (VP (VBN referred) (PP (IN because) (IN of) (NP (NNP Doc_9334596_232_252_Disease))))))) (CC and) (VP (VBN compared) (NP (DT the) (NNS data)) (PP (IN with) (NP (NP (NN history)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (JJ physical) (NN examination)))) (, ,) (NP (JJ other) (JJ etiological) (NNS investigations)) (CC and) (NP (NP (NNS effects)) (PP (IN of) (NP (JJ endocrine) (NN therapy))))))) (S (VP (VP (TO to) (VP (VB refine) (NP (NP (DT the) (NNS rules)) (PP (IN of) (NP (JJ cost-effective) (NN endocrine) (NN screening)))))) (CC and) (VP (TO to) (VP (VB pinpoint) (NP (NP (JJ actual) (NN responsibility)) (PP (IN for) (NP (JJ hormonal) (NNS abnormalities))))))))) (. .)))
9334596	2	(S1 (S (NP (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NNP Doc_9334596_535_547_Chemical)) (CC and) (NP (NNP prolactin)))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NN radioimmunoassay))))) (. .)))
9334596	3	(S1 (S (S (NP (DT Every) (NN patient)) (VP (AUX was) (VP (VBN screened) (PP (IN for) (NP (NNP Doc_9334596_630_642_Chemical)))))) (CC and) (S (NP (CD 451)) (VP (AUX were) (VP (VBN screened) (PP (IN for) (NP (NN prolactin))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NNP Doc_9334596_695_712_Disease)) (, ,) (NP (NNP Doc_9334596_714_726_Disease)) (CC or) (NP (NNP Doc_9334596_730_742_Chemical)))))) (NP (QP (JJR less) (IN than) (CD 4)) (NN ng./ml))))) (. .)))
9334596	4	(S1 (S (NP (NN Determination)) (VP (AUX was) (VP (VBN repeated) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (JJ abnormal) (JJ first) (NNS results))))))) (. .)))
9334596	5	(S1 (S (NP (NNP Prolactin) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (JJ previous) (JJ personal) (NN cohort)) (PP (IN of) (NP (NP (JJ 1,340) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9334596_921_941_Disease)) (CC and) (NP (JJ systematic) (NN prolactin) (NN determination)))))))))))) (. .)))
9334596	6	(S1 (S (NP (NP (JJ Main) (JJ clinical) (NNS criteria)) (VP (VBN tested) (PP (VBG regarding) (NP (NN efficiency))) (PP (IN in) (NP (NN hormone) (NN determination))))) (VP (AUX were) (NP (NP (NNP Doc_9334596_1063_1080_Disease)) (, ,) (NP (JJ small) (NNS testes)) (CC and) (NP (NNP Doc_9334596_1099_1111_Disease)))) (. .)))
9334596	7	(S1 (S (NP (JJ Endocrine) (NN therapy)) (VP (VBD consisted) (PP (IN of) (NP (NP (NNP Doc_9334596_1144_1166_Chemical) (CC or) (JJ human) (JJ chorionic) (NN gonadotropin)) (PP (IN for) (NP (NP (NNP Doc_9334596_1203_1215_Disease)) (CC and) (NP (NNP Doc_9334596_1220_1233_Chemical)))) (PP (IN for) (NP (NNP Doc_9334596_1238_1256_Disease)))))) (. .)))
9334596	8	(S1 (S (NP (NN Doc_9334596_1267_1279_Chemical)) (VP (AUX was) (UCP (NP (NP (QP (JJR less) (IN than) (CD 3)) (NN ng./ml.)) (PP (IN in) (NP (CD 107) (NNS patients)))) (CC but) (ADJP (JJ normal) (PP (IN in) (NP (CD 40) (NN %))) (PP (IN at) (NP (NN repeat) (NN determination)))))) (. .)))
9334596	9	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (ADJP (RB repeatedly) (JJ low)) (NNP Doc_9334596_1396_1408_Chemical)))) (VP (VBN increased) (PP (IN with) (NP (NN age))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 4) (NN %)) (PP (IN before) (NP (NN age)))) (NP (CD 50) (NNS years))) (CC and) (NP (NP (CD 9) (NN %)) (NP (CD 50) (NNS years) (QP (CC or) (JJR older))))) (-RRB- -RRB-))) (. .)))
9334596	10	(S1 (S (NP (CD Two) (NNP Doc_9334596_1483_1499_Disease)) (VP (AUX were) (VP (VBN discovered) (PP (IN after) (NP (JJ Doc_9334596_1522_1534_Chemical) (NN determination))))) (. .)))
9334596	11	(S1 (S (NP (NP (JJS Most)) (PP (IN of) (NP (DT the) (JJ other) (JJ low) (NNP Doc_9334596_1572_1584_Chemical) (NNS levels)))) (VP (VBD seemed) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (JJ nonorganic) (NNP Doc_9334596_1625_1649_Disease))) (PP (IN because) (IN of) (NP (NP (JJ normal) (NN serum) (NN luteinizing) (NN hormone) (CC and) (NN prolactin)) (CC and) (S (VP (TO to) (VP (AUX have) (NP (NP (RB only) (DT a) (JJ small) (NN role)) (PP (IN in) (NP (NP (NNP Doc_9334596_1741_1761_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ definite) (NN improvement)) (PP (IN in) (NP (NP (NP (NP (QP (RB only) (CD 16) (IN of) (CD 44) (CD -LSB-36)) (NN %)) (NN -RSB-)) (PP (IN after) (NP (JJ androgen) (NN therapy)))) (, ,) (NP (NP (JJ normal) (UCP (NN morning) (CC or) (JJ nocturnal)) (NNS erections)) (PP (IN in) (NP (CD 30) (NN %)))) (CC and) (NP (JJ definite) (JJ vasculogenic) (NNS contributions)))) (PP (IN in) (NP (CD 42) (NN %)))) (-RRB- -RRB-)))))))))))))) (. .)))
9334596	12	(S1 (S (S (VP (VBG Determining) (NP (NN Doc_9334596_1937_1949_Chemical)) (PP (ADVP (RB only)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_9334596_1967_1984_Disease) (CC or) (JJ abnormal) (JJ physical) (NN examination))))))) (VP (MD would) (VP (AUX have) (VP (VBN missed) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PP (IN with) (NP (JJ low) (NNP Doc_9334596_2062_2074_Chemical))) (, ,) (PP (VBG including) (NP (NP (CD 37) (NN %)) (PP (IN of) (NP (NP (DT those)) (VP (ADVP (RB subsequently)) (VBN improved) (PP (IN by) (NP (JJ androgen) (NN therapy)))))))))))))) (. .)))
9334596	13	(S1 (S (NP (NN Prolactin)) (VP (VP (VBD exceeded) (NP (CD 20) (NN ng./ml.)) (PP (IN in) (NP (CD 5) (NN men)))) (CC and) (VP (AUX was) (ADJP (JJ normal) (PP (IN in) (NP (CD 2)))) (PP (IN at) (NP (NN repeat) (NN determination))))) (. .)))
9334596	14	(S1 (S (NP (QP (RB Only) (CD 1)) (NN Doc_9334596_2233_2245_Disease)) (VP (AUX was) (VP (VBN discovered))) (. .)))
9334596	15	(S1 (S (NP (DT These) (NNS data)) (VP (AUX are) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT those)) (SBAR (S (NP (PRP we)) (VP (VBD found) (PP (IN during) (NP (NP (DT the) (JJ last) (CD 2) (NNS decades)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ overall) (NN prolactin)) (NP (QP (JJR greater) (IN than) (CD 20)) (NNS ng./ml.))) (PP (IN in) (NP (NP (CD 1.86) (NN %)) (PP (IN of) (NP (CD 1,821) (NNS patients)))))) (, ,) (NP (NP (NNP Doc_9334596_2400_2413_Disease)) (PP (IN in) (NP (CD 7)))) (, ,) (NP (CD 0.38) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
9334596	16	(S1 (S (NP (NNP Doc_9334596_2428_2441_Chemical)) (VP (AUX was) (ADVP (RB definitely)) (ADJP (JJ effective)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN with) (NP (NP (NP (NN prolactin)) (NP (QP (JJR greater) (IN than) (CD 35)) (NNS ng./ml)) (. .)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 8) (IN of) (CD 12))) (VP (VBN compared) (PP (TO to) (NP (QP (RB only) (CD 9) (IN of) (CD 22)) (NNS cases))) (PP (IN with) (NP (NP (NN prolactin)) (PP (IN between) (NP (CD 20) (CC and) (CD 35) (NNS ng./ml)))))) (. .)) (-RRB- -RRB-))))))) (. .)))
9334596	17	(S1 (S (NP (NN Doc_9334596_2598_2610_Chemical)) (VP (AUX was) (ADJP (JJ low)) (PP (IN in) (NP (NP (QP (JJR less) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (NNS cases))))) (PP (IN with) (S (VP (VBG prolactin) (NP (QP (JJR greater) (IN than) (CD 35)) (NN ng./ml)))))) (. .)))
9334596	18	(S1 (S (NP (NP (JJ Low) (NNS prevalences) (CC and) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ low) (NN Doc_9334596_2732_2744_Chemical)) (CC and) (NP (JJ high) (NN prolactin))) (PP (IN in) (NP (NNP Doc_9334596_2767_2787_Disease)))))) (VP (VBP cannot) (S (VP (VB justify) (NP (PRP$ their) (JJ routine) (NN determination))))) (. .)))
9334596	19	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ cost-effective) (NN screening) (NNS strategies)) (VP (VBD recommended) (SBAR (S (ADVP (RB so) (RB far)) (VP (VBD missed) (NP (NP (QP (CD 40) (TO to) (CD 50)) (NN %)) (PP (IN of) (NP (NNS cases)))) (PP (VBN improved) (PP (IN with) (NP (NP (JJ endocrine) (NN therapy)) (CC and) (NP (DT the) (NNP Doc_9334596_2962_2978_Disease))))))))) (. .)))
9334596	20	(S1 (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP advocate) (SBAR (SBAR (IN that) (S (NP (NP (RB before) (NN age)) (ADJP (NP (CD 50) (NNS years)) (JJ Doc_9334596_3021_3033_Chemical))) (VP (AUX be) (VP (VBN determined) (ADVP (RB only)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_9334596_3065_3082_Disease)) (CC and) (NP (JJ abnormal) (JJ physical) (NN examination)))))))))) (CC but) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX be) (VP (VBN measured) (PP (IN in) (NP (DT all) (NN men) (QP (JJR older) (IN than) (CD 50)) (NNS years))))))))) (. .)))
9334596	21	(S1 (S (NP (NNP Prolactin)) (VP (MD should) (VP (AUX be) (VP (VBN determined) (PP (ADVP (RB only)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_9334596_3221_3238_Disease)) (, ,) (NP (NNP Doc_9334596_3240_3252_Disease) (NN and/or) (NNP Doc_9334596_3260_3272_Chemical)))))) (ADVP (RBR less) (PP (IN than) (NP (CD 4) (NN ng./ml))))))) (. .)))
9351491	0	(S1 (NP (NP (JJ Extrapyramidal) (JJ side) (NNS effects)) (PP (IN with) (NP (NP (NNP Doc_9351491_33_44_Chemical)) (CC and) (NP (NNP Doc_9351491_49_60_Chemical)))) (PP (IN at) (NP (JJ comparable) (NNP D2) (NN receptor) (NN occupancy) (NNS levels))) (. .)))
9351491	1	(S1 (S (NP (NN Doc_9351491_105_116_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ antipsychotic) (NN drug)) (PP (IN with) (NP (NP (JJ high) (NN affinity)) (PP (IN at) (NP (NNP Doc_9351491_164_172_Chemical) (NNP D2) (CC and) (NNP Doc_9351491_180_195_Chemical) (NNS receptors))))))) (. .)))
9351491	2	(S1 (S (S (NP (JJ Previous) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (NNP Doc_9351491_252_263_Chemical) (POS 's)) (JJ pharmacologic) (NN profile)) (VP (MD may) (VP (VB produce) (NP (NP (NP (VBN improved) (NN efficacy)) (PP (IN for) (NP (JJ negative) (NNP Doc_9351491_331_349_Disease)))) (CC and) (NP (NP (VBN decreased) (NN propensity)) (PP (IN for) (NP (JJ extrapyramidal) (NN side) (NNS effects)))))))))))) (: ;) (S (NP (NNS features)) (VP (VBN shared) (PP (IN by) (NP (NP (NN so-called) (POS ')) (JJ atypical) ('' ') (NNS neuroleptics))))) (. .)))
9351491	3	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN if) (S (NP (JJ routine) (JJ Doc_9351491_486_497_Chemical) (NN treatment)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ unique) (NN degree)) (PP (IN of) (NP (NP (NNP D2) (NN receptor) (NN occupancy)) (CC and) (NP (NP (NN pattern)) (PP (IN of) (NP (JJ clinical) (NNS effects))))))))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (JJ -LSB-123I) (JJ -RSB-) (NN IBZM) (NN SPECT)) (S (VP (TO to) (VP (VB determine) (NP (JJ D2) (NN occupancy)) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ routine) (JJ clinical) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_9351491_703_714_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 12)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9351491_727_738_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))))))))))))) (. .)))
9351491	4	(S1 (S (NP (DT Both) (NNP Doc_9351491_753_764_Chemical) (CC and) (NNP Doc_9351491_769_780_Chemical)) (VP (VBD produced) (NP (NP (NNP D2) (NN occupancy) (NNS levels)) (PP (IN between) (NP (QP (RB approximately) (CD 60) (CC and) (CD 90)) (NN %)))) (PP (IN at) (NP (JJ standard) (JJ clinical) (NNS doses)))) (. .)))
9351491	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NN occupancy) (NNS levels)) (VP (VBN obtained) (PP (IN with) (NP (NP (NNP Doc_9351491_946_957_Chemical)) (CC or) (NP (NNP Doc_9351491_961_972_Chemical))))))))) (. .)))
9351491	6	(S1 (S (NP (NN Doc_9351491_974_999_Disease)) (VP (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_9351491_1038_1049_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9351491_1060_1071_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-)))))))))) (CC and) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NP (NN occupancy) (NNS levels)) (PP (IN above) (NP (CD 60) (NN %)))))))) (. .)))
9351491	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS observations)))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (JJ 5-HT2) (NN blockade)) (VP (VBD obtained) (PP (IN with) (NP (NNP Doc_9351491_1205_1216_Chemical))) (PP (IN at) (NP (NP (JJ D2) (NN occupancy) (NNS rates)) (PP (IN of) (NP (CD 60) (NN %)))))))) (CC and) (SBAR (IN above) (S (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (JJ extrapyramidal) (NN side) (NNS effects))))))))))))))) (. .)))
9390208	0	(S1 (NP (NP (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (ADJP (RB previously) (VBN treated)) (NN metastatic) (NNP Doc_9390208_43_56_Disease))) (PP (IN by) (NP (NNP Doc_9390208_60_72_Chemical)))) (CC and) (NP (JJ 48-hour) (JJ continuous) (NN infusion))) (PP (IN of) (NP (NP (JJ high-dose) (NNP Doc_9390208_118_122_Chemical)) (CC and) (NP (NP (NNP Doc_9390208_127_137_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_139_142_Chemical)) (-RRB- -RRB-)))))) (: :) (NP (NP (JJ low) (JJ palliative) (NN benefit)) (CC and) (NP (JJ high) (JJ treatment-related) (NN Doc_9390208_195_203_Disease))) (. .)))
9390208	1	(S1 (S (PP (IN For) (NP (ADJP (RB previously) (VBN treated)) (JJ advanced) (NN Doc_9390208_237_250_Disease))) (, ,) (NP (EX there)) (VP (AUX is) (NP (DT no) (JJ standard) (NN second-line) (NN therapy))) (. .)))
9390208	2	(S1 (S (NP (NP (NN Combination) (NNS chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_9390208_324_336_Chemical)) (, ,) (NP (NP (JJ high-dose) (NNP Doc_9390208_348_362_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_364_368_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9390208_374_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_386_397_Chemical)) (-RRB- -RRB-)))))) (VP (AUX had) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (RB well) (JJ tolerated))) (NN regimen)))))) (. .)))
9390208	3	(S1 (S (PP (PP (IN From) (NP (NNP October) (CD 1993))) (PP (TO to) (NP (NNP November) (CD 1995)))) (, ,) (NP (PRP we)) (VP (VBD treated) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NP (NP (ADJP (RB previously) (JJ chemotherapy-treated)) (JJ metastatic) (NN Doc_9390208_568_581_Disease)) (PP (IN by) (NP (NP (NNP Doc_9390208_585_597_Chemical)) (, ,) (NP (CD 12) (NN mg/m2)) (, ,))) (PP (IN on) (NP (NN day) (CD 1)))) (CC and) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_9390208_645_649_Chemical)) (, ,) (NP (CD 3000) (NN mg/m2)) (, ,))))))) (ADVP (RB together)) (PP (IN with) (NP (NP (NNP Doc_9390208_677_687_Chemical)) (, ,) (NP (CD 300) (NN mg/m2)) (, ,))) (PP (IN for) (NP (CD 48))) (NP (NNP h)) (PP (PP (IN from) (NP (NN day) (CD 1))) (PP (TO to) (NP (CD 2))))) (. .)))
9390208	4	(S1 (S (NP (NP (DT Each) (NN course)) (PP (IN of) (NP (NN chemotherapy)))) (VP (AUX was) (VP (VBN given) (NP (DT every) (CD 4) (NNS weeks)))) (. .)))
9390208	5	(S1 (S (NP (NP (JJS Most)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX had) (NP (NP (JJR more)) (PP (IN than) (NP (CD two) (JJ metastatic) (NNS sites)))) (, ,) (PP (IN with) (NP (NN lung) (NN metastasis) (NN predominant)))) (. .)))
9390208	6	(S1 (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9390208_909_922_Chemical)))))) (. .)))
9390208	7	(S1 (S (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (ADVP (RB previously)) (VP (VBN received) (NP (NN radiotherapy))))) (CC and) (S (NP (CD seven)) (VP (AUX had) (VP (VBN received) (NP (NN hormone) (NN therapy))))) (. .)))
9390208	8	(S1 (S (S (NP (NP (JJ Median) (NN number)) (PP (IN of) (NP (NP (NNS courses)) (PP (IN of) (NP (NNP Doc_9390208_1044_1055_Chemical))))) (VP (VBN given))) (VP (AUX was) (NP (CD six)))) (CC and) (S (NP (NP (DT the) (JJ median) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_9390208_1104_1116_Chemical)))) (VP (AUX was) (NP (CD 68.35) (NN mg/m2)))) (. .)))
9390208	9	(S1 (S (S (NP (CD One) (NN patient)) (VP (AUX had) (NP (JJ complete) (NN response)))) (, ,) (S (NP (CD seven)) (VP (AUX had) (NP (NN stable) (NN disease)))) (, ,) (S (NP (NN none)) (VP (AUX had) (NP (JJ partial) (NN response)))) (CC and) (S (NP (CD five)) (VP (AUX had) (NP (JJ progressive) (NN disease)))) (. .)))
9390208	10	(S1 (S (NP (DT The) (JJ overall) (JJ objective) (NN response) (NN rate)) (VP (AUX was) (NP (CD 7.6) (NN %))) (. .)))
9390208	11	(S1 (S (NP (DT The) (JJ median) (NN follow-up) (NN period)) (VP (AUX was) (NP (CD 14) (NNS months))) (. .)))
9390208	12	(S1 (S (NP (JJ Median) (NN survival)) (VP (AUX was) (NP (CD 16) (NNS months))) (. .)))
9390208	13	(S1 (S (NP (JJ Median) (NN progression-free) (NN survival)) (VP (AUX was) (NP (CD 5) (NNS months))) (. .)))
9390208	14	(S1 (S (NP (DT A) (JJ complete) (NN responder)) (VP (AUX had) (NP (JJ relapse-free) (NN survival)) (PP (IN up) (PP (TO to) (NP (CD 17) (NNS months))))) (. .)))
9390208	15	(S1 (S (NP (JJ Major) (NN Doc_9390208_1492_1502_Disease)) (VP (AUX were) (NP (NP (NNP Doc_9390208_1508_1522_Disease)) (CC and) (NP (NNP Doc_9390208_1527_1537_Disease)))) (. .)))
9390208	16	(S1 (S (S (NP (CD Eight) (NNS patients)) (VP (AUX were) (ADJP (JJ dead)) (PP (IN in) (NP (DT the) (JJ last) (NN follow-up))))) (: ;) (S (NP (NP (CD two)) (PP (IN of) (NP (PRP them)))) (VP (VBD died) (PP (IN of) (NP (JJ treatment-related) (NNP Doc_9390208_1625_1633_Disease))))) (. .)))
9390208	17	(S1 (S (NP (DT The) (NNP Doc_9390208_1639_1650_Chemical)) (VP (VP (VBZ achieves) (NP (JJ little) (JJ palliative) (NN benefit))) (CC and) (VP (VBZ induces) (NP (JJ severe) (NN Doc_9390208_1705_1713_Disease)) (PP (IN at) (NP (DT a) (ADJP (RB fairly) (JJ high)) (NN rate))))) (. .)))
9390208	18	(S1 (S (NP (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT this) (NN regimen)) (PP (TO to) (NP (NP (JJ Doc_9390208_1771_1784_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN by) (NP (NN chemotherapy))))))))))))) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_9390208_1847_1870_Disease))))) (VP (VBZ requires) (NP (JJ careful) (NN attention))) (. .)))
9401499	0	(S1 (NP (NP (JJ Doc_9401499_0_11_Chemical-induced) (NN Doc_9401499_20_35_Disease)) (: :) (NP (NP (NP (NN report)) (PP (IN of) (NP (CD three) (JJ Chinese) (NNS patients)))) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))) (. .)))
9401499	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (S (NP (NP (CD three) (JJ Chinese) (NNS patients)) (PP (IN with) (NP (NNP Doc_9401499_143_154_Chemical-induced) (NNP Doc_9401499_163_178_Disease)))) (VP (AUX were) (VP (VBN reported)))) (CC and) (S (NP (NP (DT another) (CD 13) (NNS patients)) (PP (IN in) (NP (DT the) (JJ English) (NN literature)))) (VP (AUX were) (VP (VBN reviewed)))) (. .)))
9401499	2	(S1 (S (NP (PRP We)) (VP (VBD attempted) (S (VP (TO to) (VP (VP (VB find) (NP (VBG underlying) (NNS similarities))) (, ,) (VP (VB evaluate) (NP (DT the) (NN risk) (NNS factors))) (, ,) (CC and) (VP (VB identify) (NP (NP (JJ appropriate) (NN treatment)) (PP (IN for) (NP (DT this) (NN complication))))))))) (. .)))
9401499	3	(S1 (S (S (NP (NP (DT All)) (CC but) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS patients))))) (VP (AUX were) (ADVP (RB over)) (ADJP (NP (CD 60) (NNS years)) (JJ old)))) (, ,) (CC and) (S (NP (NP (DT the) (CD 6)) (SBAR (WHNP (WP who)) (S (VP (VBD died))))) (VP (AUX were) (ADJP (ADJP (NP (DT all)) (JJR older)) (PP (IN than) (NP (CD 65)))))) (. .)))
9401499	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (JJ old) (NN age)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (S (VP (VBG developing) (NP (DT this) (NN complication)))))))) (. .)))
9401499	5	(S1 (S (NP (NN Doc_9401499_558_573_Disease)) (VP (VBD occurred) (SBAR (NP (CD 3-20) (NNS weeks)) (IN after) (S (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NNP Doc_9401499_614_625_Chemical)) (, ,) (NP (NP (ADJP (RB so) (JJ frequent)) (NN examination)) (PP (IN of) (NP (JJ white) (NN cell) (NN count)))))) (PP (IN during) (NP (NN treatment)))) (VP (AUX is) (VP (VBN recommended)))))) (. .)))
9401499	6	(S1 (S (NP (EX There)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT no) (JJ direct) (NN correlation)) (PP (IN between) (NP (NP (NP (DT the) (NN dose) (CC or) (NN duration)) (VP (VBN used))) (CC and) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NN Doc_9401499_799_822_Disease))))))))))) (. .)))
9401499	7	(S1 (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NP (JJ Doc_9401499_838_849_Chemical-induced) (NN Doc_9401499_858_873_Disease)) (PP (IN with) (NP (JJ colony-stimulating) (NNS factors)))))) (VP (VBD seemed) (S (VP (TO to) (VP (AUX have) (NP (JJ little) (NN effect)))))) (. .)))
9401499	8	(S1 (S (NP (DT The) (NN fact) (SBAR (IN that) (S (NP (NP (CD 5)) (PP (IN of) (NP (NP (DT the) (CD 6) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ concurrent) (JJ Doc_9401499_994_1001_Chemical) (NN channel) (NNS blockers)))))))) (VP (VBD died))))) (, ,) (VP (MD should) (VP (VB alert) (NP (NP (NNS clinicians)) (SBAR (S (VP (TO to) (VP (AUX be) (ADJP (RBR more) (JJ cautious)) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (DT these) (CD two) (NNS drugs)))))))))) (ADVP (RB simultaneously)))) (. .)))
9406968	0	(S1 (NP (NP (NN Upregulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ Doc_9406968_34_45_Chemical) (NN gene))))) (PP (IN in) (NP (NP (DT the) (ADJP (JJ paraventricular) (CC and) (JJ supraoptic)) (NN nuclei)) (PP (IN of) (NP (DT the) (JJ Doc_9406968_103_110_Chemical-induced) (JJ Doc_9406968_119_137_Disease) (NN rat))))) (. .)))
9406968	1	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NNP Doc_9406968_161_181_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9406968_183_186_Chemical)) (-RRB- -RRB-)) (NN gene))) (PP (IN in) (NP (NP (NP (DT the) (NN paraventricular)) (PRN (-LRB- -LRB-) (NP (NNP PVN)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ supraoptic) (NNS nuclei)) (PRN (-LRB- -LRB-) (NP (NN SON)) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NNS rats))) (PP (IN with) (NP (NP (NNP Doc_9406968_280_287_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9406968_289_291_Chemical)) (-RRB- -RRB-)))) (NP (JJ -induced) (NNP Doc_9406968_301_309_Disease)) (, ,) (S (VP (VBG using) (PP (IN in) (NP (NP (JJ situ) (NN hybridization) (NN histochemistry)) (CC and) (NP (NN radioimmunoassay)))))))) (. .)))
9406968	2	(S1 (S (NP (NP (DT The) (JJ male) (NNP Wistar) (NNS rats) (NN consuming)) (NP (DT a) (NN diet)) (SBAR (WHNP (WDT that)) (S (VP (VBD contained) (NP (NP (NNP Doc_9406968_429_433_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mmol/kg)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 4) (NNS weeks))))))) (VP (VBD developed) (NP (JJ marked) (NN Doc_9406968_476_484_Disease))) (. .)))
9406968	3	(S1 (S (NP (DT The) (JJ Doc_9406968_490_492_Chemical-treated) (NNS rats)) (VP (VBD produced) (NP (NP (DT a) (JJ large) (NN volume)) (PP (IN of) (NP (JJ hypotonic) (NN urine))) (PP (IN with) (NP (JJ low) (JJ ionic) (NNS concentrations))))) (. .)))
9406968	4	(S1 (S (NP (NN Plasma) (NN Doc_9406968_587_593_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADVP (RB slightly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_9406968_652_654_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (NNS controls)))))))))))) (. .)))
9406968	5	(S1 (S (NP (NP (NP (NN Plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_9406968_725_728_Chemical)))) (CC and) (NP (NP (NNS transcripts)) (PP (IN of) (NP (JJ Doc_9406968_748_751_Chemical) (NN gene))) (PP (IN in) (NP (DT the) (NNP PVN) (CC and) (NNP SON))))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_9406968_812_814_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (. .)))
9406968	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9406968_879_890_Disease)) (VP (VBP and/or) (SBAR (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ visceral) (NN afferent) (NNS inputs)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_9406968_983_986_Chemical)) (CC and) (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NP (JJ Doc_9406968_1011_1014_Chemical) (NN gene) (NN expression)) (PP (IN in) (NP (DT the) (NNP PVN))))))))) (CC and) (NP (NP (DT the) (NN SON)) (PP (IN of) (NP (DT the) (JJ Doc_9406968_1061_1063_Chemical-induced) (NNP Doc_9406968_1072_1090_Disease) (NN rat)))))))))))))) (. .)))
9495837	0	(S1 (NP (NP (NP (NN Antinociceptive)) (CC and) (NP (JJ antiamnesic) (NNS properties))) (PP (IN of) (NP (DT the) (JJ presynaptic) (JJ cholinergic) (NN amplifier) (NNP Doc_9495837_84_88_Chemical))) (. .)))
9495837	1	(S1 (S (NP (NP (DT The) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_9495837_120_162_Chemical) (JJ -LSB-) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_9495837_170_174_Chemical) (NNS -RSB-)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-40) (CD mg)) (JJ kg-1) (NNP s.c.)) (: ;) (NP (NP (QP (CD 30-60) (CD mg)) (JJ kg-1) (NNS p.o.)) (: ;) (NP (QP (CD 10-30) (CD mg)) (JJ kg-1) (NNS i.v.)) (: ;) (NP (CD 10-30) (JJ micrograms/mouse) (NNS i.c.v.))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VP (VBN examined) (PP (IN in) (NP (NP (NP (NNS mice) (, ,) (NNS rats) (CC and) (NN guinea) (NNS pigs)) (PP (IN by) (NP (NN use))) (PP (IN of) (NP (DT the) (JJ hot-plate) (, ,) (JJ abdominal-constriction) (, ,) (JJ tail-flick) (CC and) (JJ paw-pressure) (NNS tests))) (. .)) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (JJ -Doc_9495837_401_405_Chemical) (NN antinociception)) (VP (VBD peaked) (NP (CD 15) (NN min)) (PP (IN after) (NP (NN injection))))))) (CC and) (ADVP (RB then)) (VP (ADVP (RB slowly)) (VBN diminished)))) (. .)))
9495837	2	(S1 (S (NP (NP (DT The) (NN antinociception)) (VP (VBN produced) (PP (IN by) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NN -Doc_9495837_518_522_Chemical))))) (VP (AUX was) (UCP (VP (VBN prevented) (PP (IN by) (NP (NP (DT the) (JJ unselective) (JJ muscarinic) (NN antagonist) (NNP Doc_9495837_578_586_Chemical)) (, ,) (NP (DT the) (JJ M1-selective) (NNS antagonists) (NNP Doc_9495837_617_628_Chemical) (CC and) (NNP Doc_9495837_633_644_Chemical)) (CC and) (NP (DT the) (JJ Doc_9495837_653_666_Chemical) (NN depletor) (NNP Doc_9495837_676_691_Chemical))))) (, ,) (CC but) (PP (RB not) (IN by) (NP (NP (DT the) (JJ opioid) (NN antagonist) (NNP Doc_9495837_726_734_Chemical)) (, ,) (NP (DT the) (NNP Doc_9495837_740_764_Chemical) (NN antagonist) (NNP Doc_9495837_776_821_Chemical)) (, ,) (NP (DT the) (NNP H3) (NN agonist) (NNP Doc_9495837_838_863_Chemical)) (, ,) (NP (DT the) (NNP D2) (NN antagonist) (NNP Doc_9495837_883_893_Chemical)) (, ,) (NP (DT the) (JJ Doc_9495837_899_919_Chemical) (JJ antagonist) (NNP Doc_9495837_931_997_Chemical) (NN hydrochloride)) (, ,) (NP (DT the) (JJ Doc_9495837_1017_1037_Chemical) (JJ antagonist) (NNP Doc_9495837_1049_1105_Chemical) (NN hydrobromide)) (CC and) (NP (DT the) (NNS polyamines) (NN depletor) (NNP Doc_9495837_1147_1156_Chemical)))))) (. .)))
9495837	3	(S1 (S (NP (NP (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN postulated) (PP (IN that) (NP (NP (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-) (NN -Doc_9495837_1211_1215_Chemical)) (VP (VBN exerted) (NP (NP (DT an) (JJ antinociceptive) (NN effect)) (VP (VBD mediated) (PP (IN by) (NP (NP (DT a) (JJ central) (NN potentiation)) (PP (IN of) (NP (JJ cholinergic) (NN transmission))))))))))))) (. .)) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_9495837_1320_1324_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-40) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (VB prevent) (S (VP (NNP Doc_9495837_1366_1373_Disease) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_9495837_1385_1396_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9495837_1418_1429_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN mouse) (NN passive-avoidance) (NN test))))))))))) (. .)))
9495837	4	(S1 (S (NP (NP (JJ Affinity) (NNS profiles)) (PP (IN of) (NP (NP (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-) (NN -Doc_9495837_1511_1515_Chemical)) (PP (IN for) (NP (JJ muscarinic) (NN receptor) (NNS subtypes))))) (, ,) (VP (VBN determined) (PP (IN by) (NP (NP (JJ functional) (NNS studies)) (PRN (-LRB- -LRB-) (NP (NP (NN rabbit) (NN vas) (NNS deferens)) (PP (IN for) (NP (NP (NNP M1)) (, ,) (NP (NP (NN guinea) (NN pig) (NN atrium)) (PP (IN for) (NP (NNP M2))))))) (, ,) (NP (NP (NN guinea) (NN pig) (NN ileum)) (PP (IN for) (NP (NP (NNP M3)) (CC and) (NP (NP (JJ immature) (NN guinea) (NN pig) (NN uterus)) (PP (IN for) (NP (JJ putative) (NNP M4))))))) (-RRB- -RRB-))))) (, ,)) (VP (AUX have) (VP (VBN shown) (NP (NP (DT an) (NNP M4/M1) (NN selectivity) (NN ratio)) (PP (IN of) (NP (CD 10.2))) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN antinociception)) (CC and) (NP (NP (DT the) (JJ anti-Doc_9495837_1820_1827_Disease) (NN effect)) (VP (VBN induced) (PP (IN by) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NN -Doc_9495837_1852_1856_Chemical))) (PP (IN through) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ Doc_9495837_1880_1893_Chemical) (JJ extracellular) (NNS levels))))))))))))))))) (. .)))
9495837	5	(S1 (S (PP (IN In) (NP (DT the) (ADJP (JJ antinociceptive) (CC and) (JJ antiamnesic)) (NN dose) (NN range))) (, ,) (NP (-LRB- -LRB-) (NN +/-) (-RRB- -RRB-) (NN -Doc_9495837_1973_1977_Chemical)) (VP (AUX did) (RB not) (VP (VB impair) (NP (NP (NN mouse) (NN performance)) (VP (VBN evaluated) (PP (IN by) (NP (NP (DT the) (JJ rota-rod) (NN test)) (CC and) (NP (NNP Animex) (NN apparatus)))))))) (. .)))
9522143	0	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ different) (JJ anaesthetic) (NNS agents))) (PP (IN in) (NP (NP (NNP Doc_9522143_46_58_Disease)) (VP (VBG following) (NP (JJ spinal) (NN anaesthesia))))) (. .)))
9522143	1	(S1 (S (NP (NP (DT The) (NN cause)) (PP (IN of) (NP (NNP Doc_9522143_102_114_Disease))) (PP (IN after) (NP (JJ spinal) (NNS anaesthesia)))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
9522143	2	(S1 (S (PP (IN Up) (PP (IN until) (NP (RB now)))) (, ,) (NP (NP (DT the) (JJ only) (NN factor)) (VP (VBN studied))) (VP (AUX has) (VP (AUX been) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN diameter)) (PP (IN of) (NP (DT the) (JJ spinal) (NN needle))))) (PP (IN on) (NP (JJ post-operative) (NN Doc_9522143_265_291_Disease)))))) (. .)))
9522143	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB describe) (NP (DT this) (NN Doc_9522143_336_348_Disease)))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (JJ other) (NNS factors)) (VP (VBG influencing) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN Doc_9522143_408_420_Disease))))))))))) (. .)))
9522143	4	(S1 (S (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (CD 22) (JJ similar) (NNS patients)))) (VP (AUX were) (VP (VBN studied)))) (: :) (S (NP (CD one) (NN group)) (VP (VBD received) (NP (NP (CD 6) (JJ mL) (NNP Doc_9522143_494_504_Chemical) (CD 2) (NN %)) (: ;) (CC and) (NP (DT the) (JJ other) (VBN received) (ADJP (CD 3) (NN mL)) (JJ Doc_9522143_537_548_Chemical) (CD 0.5) (NN %))))) (. .)))
9522143	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBN given) (NP (NNP Doc_9522143_570_580_Chemical)))) (VP (AUX were) (ADJP (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB develop) (NP (NNP Doc_9522143_609_621_Disease)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (IN out) (IN of) (CD 22))) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those)) (VP (VBN given) (NP (NNP Doc_9522143_654_665_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (IN out) (IN of) (CD 22))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
9522143	6	(S1 (S (NP (NP (DT The) (JJ average) (NN Doc_9522143_704_716_Disease)) (PP (IN for) (NP (NN speech) (NNS frequencies)))) (VP (AUX was) (NP (QP (RB about) (CD 10)) (NN dB)) (PP (IN after) (NP (NP (NNP Doc_9522143_762_772_Chemical)) (CC and) (NP (NP (CD 15)) (VP (VBN dB) (PP (IN after) (NP (NNP Doc_9522143_789_800_Chemical)))))))) (. .)))
9522143	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD complained) (PP (IN of) (NP (JJ subjective) (NNP Doc_9522143_848_860_Disease)))) (. .)))
9522143	8	(S1 (S (NP (NP (JJ Long-term) (NN follow-up)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX was) (RB not) (ADJP (JJ possible))) (. .)))
9522152	0	(S1 (S (NP (NP (DT A) (JJ transient) (JJ Doc_9522152_12_32_Disease) (JJ following) (NN intrathecal) (NN injection)) (PP (IN of) (NP (CD 1) (NN %)))) (VP (VBP hyperbaric) (NP (NNP Doc_9522152_82_93_Chemical)) (PP (IN for) (NP (JJ unilateral) (NN spinal) (NN anaesthesia)))) (. .)))
9522152	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ transient) (NNP Doc_9522152_161_181_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (NP (JJ unilateral) (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (NP (CD 8) (NN mg)) (PP (IN of) (NP (NP (ADJP (CD 1) (NN %)) (JJ hyperbaric) (NN Doc_9522152_259_270_Chemical)) (VP (ADVP (RB slowly)) (VBN injected) (PP (IN through) (NP (DT a) (JJ 25-gauge) (JJ pencil-point) (NN spinal) (NN needle))))))))))))))) (. .)))
9522152	2	(S1 (S (S (NP (DT The) (NN surgery) (CC and) (NNS anaesthesia)) (VP (VP (AUX were) (ADJP (JJ uneventful))) (, ,) (CC but) (VP (NP (CD 3) (NNS days)) (PP (IN after) (NP (NN surgery)))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD reported) (NP (NP (DT an) (NN area)) (PP (IN of) (NP (NN hypoaesthesia)))) (PP (IN over) (NP (NP (JJ L3-L4) (NNS dermatomes)) (PP (IN of) (NP (NP (DT the) (NN leg)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (VP (AUX been) (VP (VBN operated) (PRT (RP on)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9522152_512_538_Disease)) (-RRB- -RRB-)) (PP (IN without) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ muscular) (NN strength))))))))))))))) (. .)))
9522152	3	(S1 (S (NP (NP (NN Sensation)) (PP (IN in) (NP (DT this) (NN area)))) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN over) (NP (DT the) (JJ following) (CD 2) (NNS weeks)))) (. .)))
9522152	4	(S1 (S (NP (NP (JJ Prospective) (JJ multicentre) (NNS studies)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN population)) (CC and) (NP (DT a) (JJ long) (NN follow-up))))) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (DT this) (JJ unusual) (NN side) (NN effect)))))))))) (. .)))
9522152	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT a) (JJ low) (NN solution) (NN concentration)) (VP (MD should) (VP (AUX be) (VP (VBN preferred) (PP (IN for) (NP (NP (JJ unilateral) (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (NP (DT a) (JJ hyperbaric) (JJ anaesthetic) (NN solution)) (PRN (-LRB- -LRB-) (SBAR (IN if) (S (NP (NP (JJ pencil-point) (NN needle)) (CC and) (NP (JJ slow) (NN injection) (NN rate))) (VP (AUX are) (VP (VBN employed))))) (-RRB- -RRB-)))))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB minimize) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT a) (VBN localized) (JJ high) (JJ peak) (JJ anaesthetic) (NN concentration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB lead) (PP (TO to) (NP (DT a) (JJ transient) (NN Doc_9522152_1135_1155_Disease)))))))))))))))))))) (. .)))
9523805	0	(S1 (NP (NP (NP (NN Doc_9523805_0_29_Disease)) (PP (IN after) (NP (JJ spinal) (NNS anesthesia)))) (: :) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN with) (NP (NP (NNP Doc_9523805_78_88_Chemical)) (CC and) (NP (NNP Doc_9523805_93_104_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_9523805_115_124_Chemical))))) (. .)))
9523805	1	(S1 (S (NP (JJ Recent) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNP Doc_9523805_168_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9523805_199_203_Disease)) (-RRB- -RRB-))) (ADVP (RB frequently)) (VP (VP (VBP follow) (NP (JJ Doc_9523805_223_232_Chemical) (JJ spinal) (NNS anesthesia))) (CC but) (VP (AUX are) (ADJP (JJ infrequent) (PP (IN with) (NP (NNP Doc_9523805_275_286_Chemical))))))))) (. .)))
9523805	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN identification)) (PP (IN of) (NP (NP (DT a) (JJ short-acting) (JJ local) (NN anesthetic)) (SBAR (S (VP (TO to) (VP (VB substitute) (PP (IN for) (NP (NNP Doc_9523805_365_374_Chemical))) (PP (IN for) (NP (JJ brief) (JJ surgical) (NNS procedures)))))))))) (VP (VBZ remains) (NP (DT an) (JJ important) (NN goal))) (. .)))
9523805	3	(S1 (S (NP (NN Doc_9523805_432_442_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ amide) (JJ local) (NN anesthetic)) (PP (IN with) (NP (NP (DT a) (NN duration)) (PP (IN of) (NP (NN action))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9523805_517_526_Chemical)))))))))) (. .)))
9523805	4	(S1 (S (ADVP (RB Accordingly)) (, ,) (NP (DT the) (JJ present) (, ,) (JJ prospective) (JJ double-blind) (NN study)) (VP (VBZ compares) (NP (NNP Doc_9523805_594_604_Chemical)) (PP (IN with) (NP (NP (NNP Doc_9523805_610_619_Chemical)) (CC and) (NP (NNP Doc_9523805_624_635_Chemical)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NP (NN duration)) (PP (IN of) (NP (NN action)))) (CC and) (NP (NP (JJ relative) (NN risk)) (PP (IN of) (NP (NNP Doc_9523805_692_696_Disease))))))))) (. .)))
9523805	5	(S1 (S (NP (NP (CD Ninety) (NNS patients)) (PP (JJ classified) (IN as) (NP (NP (NP (NNP American) (NNP Society)) (PP (IN of) (NP (NNP Anesthesiologists) (JJ physical) (NN status) (NN I)))) (CC or) (NP (NNP II)))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN scheduled) (PP (IN for) (NP (JJ short) (JJ gynecologic) (NNS procedures))) (PP (IN under) (NP (JJ spinal) (NN anesthesia)))))))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 2.5) (NNS ml)) (NP (NP (NP (NP (CD 2) (NN %)) (NP (NNP Doc_9523805_920_929_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_938_945_Chemical)))) (, ,) (NP (NP (NP (CD 2) (NN %)) (NP (NNP Doc_9523805_950_960_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_969_976_Chemical)))) (, ,) (CC or) (NP (NP (NP (CD 0.5) (NN %)) (NP (NNP Doc_9523805_986_997_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_1006_1013_Chemical))))))))))) (. .)))
9523805	6	(S1 (S (NP (DT All) (NNS solutions)) (VP (AUX were) (VP (VBN provided) (PP (IN in) (NP (JJ blinded) (NNS vials))) (PP (IN by) (NP (DT the) (NN hospital) (NN pharmacy))))) (. .)))
9523805	7	(S1 (S (NP (NP (NNS Details)) (PP (IN of) (NP (NP (JJ spinal) (NN puncture)) (, ,) (NP (NP (NP (NN extension)) (CC and) (NP (NN regression))) (PP (IN of) (NP (NN spinal) (NN block)))) (, ,) (CC and) (NP (NP (DT the) (NNS times)) (SBAR (S (VP (TO to) (VP (VB reach) (NP (NN discharge) (NNS criteria)))))))))) (VP (AUX were) (VP (VBN noted))) (. .)))
9523805	8	(S1 (S (PP (IN In) (NP (NP (DT the) (NN evening)) (PP (IN of) (NP (NN postoperative) (NN day) (CD 1))))) (, ,) (NP (NNS patients)) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NN Doc_9523805_1277_1281_Disease))) (PP (IN by) (NP (NP (NP (DT a) (NN physician)) (ADJP (JJ unaware) (PP (IN of) (NP (NP (DT the) (NN drug)) (VP (VBN administered)))))) (CC and) (NP (NP (DT the) (NNS details)) (PP (IN of) (NP (DT the) (JJ anesthetic) (NN procedure)))))))) (. .)))
9523805	9	(S1 (S (NP (NP (CD Nine)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_9523805_1414_1423_Chemical)))))) (VP (VBD experienced) (NP (NP (NNP Doc_9523805_1436_1440_Disease)) (, ,) (NP (NP (CD 1)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (SBAR (S (S (NP (NP (NNP Doc_9523805_1469_1479_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.03)) (-RRB- -RRB-))) (VP (AUX had) (NP (PRP them)))) (, ,) (CC and) (S (NP (NP (NN none)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_9523805_1535_1546_Chemical)))))) (VP (AUX had) (NP (NN Doc_9523805_1551_1555_Disease)))))))))))) (. .)))
9523805	10	(S1 (S (NP (NP (NNS Times)) (VP (VP (TO to) (VP (VB ambulate))) (CC and) (VP (TO to) (VP (VB void))))) (VP (VP (AUX were) (ADJP (JJ similar)) (PP (IN after) (NP (NP (NNP Doc_9523805_1606_1615_Chemical)) (CC and) (NP (NP (NNP Doc_9523805_1620_1630_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 150) (CC vs.) (CD 165) (NN min) (CC and) (CD 238) (CC vs.) (CD 253)) (NN min)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))) (CC but) (VP (VBN prolonged) (PP (IN after) (NP (NP (NNP Doc_9523805_1703_1714_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 200) (CC and) (CD 299)) (NN min)) (, ,) (ADVP (RB respectively))) (: ;) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
9523805	11	(S1 (S (NP (NN Doc_9523805_1771_1781_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ preferable) (TO to) (JJ Doc_9523805_1803_1812_Chemical)) (PP (IN for) (NP (JJ short) (JJ surgical) (NNS procedures))) (SBAR (IN because) (S (NP (PRP it)) (VP (AUX has) (NP (NP (NP (DT a) (JJ similar) (NN duration)) (PP (IN of) (NP (NN action)))) (CC but) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (NNP Doc_9523805_1912_1916_Disease)))))))))) (. .)))
9587734	0	(S1 (S (NP (JJ Doc_9587734_0_13_Chemical-induced) (NNP Doc_9587734_22_36_Disease) (CC and) (NNP Doc_9587734_41_46_Disease)) (VP (VBG following) (NP (NP (CD 5) (NNS days)) (PP (IN of) (NP (NN immobilization))))) (. .)))
9587734	1	(S1 (S (NP (DT The) (JJ present) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_9587734_122_136_Disease)) (CC and) (NP (JJ subsequent) (NNP Doc_9587734_152_157_Disease))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_9587734_173_186_Disease))) (PP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_9587734_208_221_Chemical))) (PP (IN in) (NP (DT a) (JJ 23-year-old) (JJ Malawian) (NN woman)))))))) (. .)))
9587734	2	(S1 (S (PP (NP (CD Five) (NNS days)) (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_9587734_300_310_Disease))))))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD aspirated) (NP (NN stomach) (NNS contents))) (CC and) (VP (VBD needed) (NP (JJ endotracheal) (NN intubation)))) (. .)))
9587734	3	(S1 (S (NP (NP (CD Forty) (NNS seconds)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_9587734_420_433_Chemical)) (, ,) (NP (NNP Doc_9587734_435_446_Disease)) (CC and) (NP (NNP Doc_9587734_451_465_Disease))))))) (VP (VBD occurred)) (. .)))
9587734	4	(S1 (S (NP (NP (NNS Attempts)) (SBAR (S (VP (TO to) (VP (VB resuscitate) (NP (DT the) (NN patient))))))) (VP (AUX were) (RB not) (ADJP (JJ successful))) (. .)))
9587734	5	(S1 (S (NP (NP (DT The) (NN serum) (NN level)) (PP (IN of) (NP (NNP Doc_9587734_552_561_Chemical)))) (VP (AUX was) (VP (VBN observed) (S (VP (TO to) (VP (AUX be) (ADJP (CD 8.4) (NN mequiv) (JJ L-1))))))) (. .)))
9587734	6	(S1 (S (ADVP (RB Apart) (PP (IN from) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN level)) (PP (IN of) (NP (NN consciousness)))))))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS signs)) (PP (PP (IN of) (NP (NN motor) (NN neurone) (NN damage))) (CC or) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ other) (JJ known) (NN predisposing) (NNS conditions)) (PP (IN for) (NP (NNP Doc_9587734_764_777_Disease))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_9587734_810_823_Chemical)))))))))))) (. .)))
9587734	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN postulated) (SBAR (IN that) (S (NP (PRP$ her) (NN Doc_9587734_851_856_Disease)) (VP (AUX was) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9587734_871_887_Disease))) (PP (TO to) (NP (NP (NNP Doc_9587734_891_904_Chemical)) (, ,) (VP (VBN associated) (PP (IN with) (NP (PRP$ her) (JJ 5-day) (NN immobilization)))))))))))) (. .)))
9625142	0	(S1 (S (NP (NP (JJ Acute) (NNP Doc_9625142_6_15_Disease)) (, ,) (NP (NNP Doc_9625142_17_44_Disease)) (, ,) (CC and) (NP (NNP Doc_9625142_50_72_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9625142_84_95_Chemical)))) (. .)))
9625142	1	(S1 (S (NP (DT An) (JJ 80-yr-old) (NN man)) (VP (VBD developed) (NP (JJ acute) (NN Doc_9625142_130_139_Disease)) (PP (ADVP (RB shortly)) (IN after) (S (VP (VBG ingesting) (NP (JJ oral) (NNP Doc_9625142_169_180_Chemical)))))) (. .)))
9625142	2	(S1 (S (SBAR (IN Although) (S (NP (DT the) (NNS transaminases)) (ADVP (RB gradually)) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (S (VP (VBG withholding) (NP (DT the) (JJ Doc_9625142_262_273_Chemical) (JJ antibiotic)))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (JJ gradual) (NN increase)) (PP (IN in) (NP (JJ serum) (NNP Doc_9625142_324_333_Chemical)))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN hemoglobin) (NN concentration)) (VP (VBN caused) (PP (IN by) (NP (DT an) (NNP Doc_9625142_390_417_Disease) (CC and) (NNP Doc_9625142_422_444_Disease))))))))) (. .)))
9625142	3	(S1 (S (NP (DT These)) (VP (VBD responded) (PP (TO to) (NP (NP (JJ systemic) (NN Doc_9625142_474_482_Chemical)) (CC and) (NP (NNS immunoglobulins))))) (. .)))
9625142	4	(S1 (S (PP (IN Despite) (NP (NP (DT the) (JJ widespread) (NN use)) (PP (IN of) (NP (DT these) (NNS agents))))) (NP (NP (DT this) (NNP triad)) (PP (IN of) (NP (NN side) (NNS effects)))) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (JJ Doc_9625142_626_637_Chemical) (NNS antibiotics)))))))) (. .)))
9653867	0	(S1 (NP (NP (JJ Doc_9653867_0_9_Chemical) (NN abuse)) (: :) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NNP Doc_9653867_36_50_Disease))) (PP (IN in) (NP (NN pregnancy)))) (. .)))
9653867	1	(S1 (S (NP (NP (NP (NN Doc_9653867_65_81_Disease)) (CC and) (NP (DT the) (JJ associated) (NN behavioural) (NNS problems))) (CC and) (NP (NNP Doc_9653867_126_136_Disease))) (VP (AUX are) (ADJP (JJ uncommon)) (PP (IN in) (NP (NN pregnancy)))) (. .)))
9653867	2	(S1 (FRAG (SBAR (SBAR (WHADVP (WRB When)) (S (NP (PRP they)) (VP (AUX do) (VP (VB occur) (SBAR (S (NP (PRP they)) (VP (AUX are) (ADVP (RB often)) (ADJP (JJ unrecognized)) (PP (IN because) (IN of) (NP (NN denial)))))))))) (CC but) (SBAR (WHADVP (WRB when)) (S (NP (JJ significant)) (VP (MD may) (VP (VB pose) (NP (DT a) (NN risk)) (PP (TO to) (NP (NP (PDT both) (DT the) (NN mother)) (CC and) (NP (PRP her) (NN fetus))))))))) (. .)))
9653867	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS problems))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (VP (VBN encountered) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_9653867_381_397_Disease)) (PP (IN in) (NP (NN pregnancy))))) (, ,) (PP (VBG including) (NP (NP (ADJP (JJ prolonged) (CC and) (JJ recurrent)) (JJ metabolic) (NNS disturbances)) (CC and) (NP (JJ diuretic) (NN abuse))))))))))))) (. .)))
9653867	4	(S1 (S (PP (IN In) (NP (NN particular))) (NP (PRP it)) (VP (VP (VBZ illustrates) (NP (NP (DT the) (NNS derangements)) (PP (IN of) (NP (NP (JJ thyroid) (NN function)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ pregnant) (NNS women)) (PP (IN with) (NP (NNP Doc_9653867_583_599_Disease)))))))))) (CC and) (VP (VBZ reminds) (NP (PRP us)) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (NN cause)) (PP (IN for) (NP (NNP Doc_9653867_637_651_Disease)))) (VP (VBZ remains) (ADJP (JJ obscure))))) (, ,) (NP (JJ Doc_9653867_669_678_Chemical) (NN abuse)) (VP (MD should) (VP (AUX be) (VP (VP (VBN considered)) (CC and) (VP (VBN explored))))))))) (. .)))
9660111	0	(S1 (S (NP (JJ Repeated) (NNP Doc_9660111_9_21_Chemical)) (VP (VBZ induces) (NP (NP (JJ Doc_9660111_30_38_Chemical) (NN D2/D3)) (CC and) (NP (JJ alpha1-adrenergic) (NN up-regulation)))) (. .)))
9660111	1	(S1 (SINV (S (NP (NP (NP (NNP Doc_9660111_82_94_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9660111_96_99_Chemical)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ shows) (NP (DT a) (JJ clinical) (JJ Doc_9660111_125_139_Chemical) (NN activity))))) (, ,)) (VP (VP (AUX is) (ADVP (RB chemically)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9660111_175_185_Chemical))))) (CC but) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (NP (DT the) (NN reuptake)) (PP (IN of) (NP (NP (NNP Doc_9660111_223_236_Chemical)) (CC and) (NP (NNP Doc_9660111_241_260_Chemical))))))))) (, ,) (CC nor) (AUX does) (NP (PRP it)) (VP (VB induce) (NP (JJ beta-adrenergic) (NN down-regulation))) (. .)))
9660111	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (PRP$ its) (JJ Doc_9660111_335_349_Chemical) (NN activity)))) (VP (AUX is) (ADVP (RB still)) (NP (NN unknown))) (. .)))
9660111	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (SBAR (IN whether) (S (S (NP (NNP Doc_9660111_430_433_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ adaptive) (NNS changes)) (PP (IN in) (NP (DT the) (JJ dopaminergic) (CC and) (JJ alpha1-adrenergic) (NNS systems))) (, ,) (VP (VBN demonstrated) (PP (IN by) (NP (PRP us))))) (ADVP (RB previously)) (PP (IN for) (NP (JJ various) (NNP Doc_9660111_580_595_Chemical)))))))))))))) (. .)))
9660111	4	(S1 (S (NP (NNP Doc_9660111_597_600_Chemical)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (JJ male) (JJ Wistar) (NNS rats)) (CC and) (NP (JJ male) (NNP Albino) (NNP Swiss) (NNS mice)))) (ADVP (RB perorally)) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 14) (NNS days))))) (. .)))
9660111	5	(S1 (S (PP (IN In) (NP (DT the) (JJ acute) (NN experiment))) (NP (NP (NNP Doc_9660111_717_720_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ given) (NN i.p.)) (-RRB- -RRB-))) (VP (VP (AUX does) (RB not) (VP (VB antagonize) (NP (NP (DT the) (NNP Doc_9660111_758_767_Chemical) (NNP Doc_9660111_768_779_Disease)) (PP (IN in) (NP (NNS mice)))))) (CC and) (VP (AUX does) (RB not) (VP (VB potentiate) (NP (NP (DT the) (JJ Doc_9660111_816_835_Chemical) (NN head) (NNS twitches)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9660111	6	(S1 (S (NP (NP (NN Doc_9660111_859_862_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)) (PP (TO to) (NP (NNS rats))))) (VP (VBZ increases) (NP (NP (DT the) (NN locomotor) (NN Doc_9660111_912_925_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9660111_937_950_Chemical)) (, ,) (NP (NNP Doc_9660111_952_962_Chemical)) (CC and) (NP (NP (-LRB- -LRB-) (NNP +) (-RRB- -RRB-) (NN -7-hydroxy-dipropyloaminotetralin)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9660111_1005_1013_Chemical) (NNP D2) (CC and) (NNP D3) (NNS effects)) (-RRB- -RRB-)))))))) (. .)))
9660111	7	(S1 (S (NP (NP (DT The) (NNS stereotypies)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9660111_1062_1075_Chemical)) (CC or) (NP (NNP Doc_9660111_1079_1090_Chemical)))))) (VP (AUX are) (RB not) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_9660111_1114_1117_Chemical))))) (. .)))
9660111	8	(S1 (S (NP (PRP It)) (VP (VBZ increases) (NP (NP (DT the) (JJ behaviour) (NN stimulation)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_9660111_1168_1181_Chemical)))) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB intraventricularly))) (-RRB- -RRB-)) (PP (IN in) (NP (NNS rats))) (, ,) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT the) (JJ open) (NN field) (NN test)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNP Doc_9660111_1266_1280_Disease)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_9660111_1291_1300_Chemical))) (PP (IN in) (NP (NNS mice))))) (, ,) (CC both) (NP (NP (DT these) (NNS effects)) (VP (AUXG being) (VP (VBN mediated) (PP (IN by) (NP (DT an) (JJ alpha1-adrenergic) (NN receptor))))))))))) (. .)))
9660111	9	(S1 (S (NP (PRP It)) (VP (MD may) (VP (AUX be) (VP (VBN concluded) (SBAR (IN that) (S (, ,) (PP (IN like) (NP (NP (JJ other) (JJ tricyclic) (NN Doc_9660111_1425_1440_Chemical)) (VP (VBN studied) (ADVP (RB previously))))) (, ,) (S (NP (NNP Doc_9660111_1461_1464_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (VBZ increases) (NP (NP (NP (DT the) (NN responsiveness)) (PP (IN of) (NP (NP (NN brain) (NNP Doc_9660111_1520_1528_Chemical) (NNP D2)) (CC and) (NP (NP (NNP D3)) (PRN (-LRB- -LRB-) (NP (NP (JJ locomotor) (NN activity)) (CC but) (NP (RB not) (JJ stereotypy))) (-RRB- -RRB-)))))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ alpha1-adrenergic) (NNS receptors))) (PP (TO to) (NP (PRP$ their) (NNS agonists))))))))) (. .)))
9660111	10	(S1 (S (NP (DT A) (NN question)) (VP (VBZ arises) (SBAR (IN whether) (S (NP (DT the) (JJ reuptake) (NN inhibition)) (VP (AUX is) (PP (IN of) (NP (NP (DT any) (NN importance)) (PP (TO to) (NP (NP (DT the) (JJ adaptive) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (JJ repeated) (NNP Doc_9660111_1752_1767_Chemical)))))))) (, ,) (S (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (JJ Doc_9660111_1805_1819_Chemical) (NN activity))))))))))))) (. .)))
9672936	0	(S1 (NP (NP (JJ Doc_9672936_0_9_Chemical-associated) (NNP Doc_9672936_21_28_Disease)) (PP (IN in) (NP (NP (DT a) (JJ healthy) (JJ adolescent) (NN receiving) (NN Doc_9672936_63_72_Chemical)) (PP (IN for) (NP (JJ Doc_9672936_77_95_Disease) (NN control))))) (. .)))
9672936	1	(S1 (S (NP (DT A) (JJ healthy) (JJ 17-year-old) (NN male)) (VP (VBD received) (NP (NP (JJ standard) (JJ intermittent) (NNS doses)) (PP (IN of) (NP (NNP Doc_9672936_172_181_Chemical)))) (PP (IN via) (NP (NP (DT a) (JJ patient-controlled) (NN analgesia) (PRN (-LRB- -LRB-) (NP (NNP PCA)) (-RRB- -RRB-)) (NN pump)) (PP (IN for) (NP (NP (NN management)) (PP (IN of) (NP (JJ Doc_9672936_246_264_Disease) (NN control)))))))) (. .)))
9672936	2	(S1 (S (NP (NNP Twenty-three) (NNP h)) (ADVP (RB postoperatively)) (NP (PRP he)) (VP (VBD developed) (NP (DT a) (JJ brief) (JJ self-limited) (NN Doc_9672936_339_346_Disease))) (. .)))
9672936	3	(S1 (S (NP (DT Both) (NN plasma) (NNP Doc_9672936_360_369_Chemical) (CC and) (NNP Doc_9672936_374_386_Chemical)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (NP (DT the) (NN range)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NNS manifestations)) (PP (IN of) (NP (JJ central) (JJ nervous) (NN system) (NN excitation))))))))) (. .)))
9672936	4	(S1 (S (NP (NP (DT No) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP CNS) (NNP Doc_9672936_522_530_Disease)))) (VP (AUX were) (VP (VBN identified))) (. .)))
9672936	5	(S1 (S (NP (DT This) (NN method)) (VP (VBD allowed) (NP (NP (JJ frequent) (NN self-dosing)) (PP (IN of) (NP (NNP Doc_9672936_592_601_Chemical))) (PP (IN at) (NP (NP (JJ short) (NN time) (NNS intervals)) (CC and) (NP (NP (JJ rapid) (NN accumulation)) (PP (IN of) (NP (NP (NNP Doc_9672936_652_661_Chemical)) (CC and) (NP (NNP Doc_9672936_666_678_Chemical))))))))) (. .)))
9672936	6	(S1 (S (NP (NP (DT The) (JJ routine) (NN use)) (PP (IN of) (NP (NNP Doc_9672936_699_708_Chemical))) (PP (IN via) (NP (NP (NNP PCA) (RB even)) (PP (IN for) (NP (DT a) (JJ brief) (NN postoperative) (NN analgesia)))))) (VP (MD should) (VP (AUX be) (VP (VBN reconsidered)))) (. .)))
9698967	0	(S1 (S (NP (NP (DT An) (JJ unusual) (JJ toxic) (NN reaction)) (PP (TO to) (NP (NN axillary)))) (VP (VBP block) (PP (IN by) (NP (NP (NNP Doc_9698967_47_58_Chemical)) (PP (IN with) (NP (NNP Doc_9698967_64_74_Chemical)))))) (. .)))
9698967	1	(S1 (S (NP (NP (DT An) (NN Doc_9698967_79_105_Disease)) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_9698967_122_141_Disease) (, ,) (NNP Doc_9698967_143_152_Disease) (, ,) (NNP Doc_9698967_154_177_Disease) (CC and) (NNP Doc_9698967_182_203_Disease)))) (, ,)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT an) (JJ elderly)) (, ,) (NP (NNP ASA) (NN classification) (NN group) (NNP II)) (, ,) (NP (ADJP (RB cardiovascularly) (VBN medicated)) (JJ male)) (, ,) (NP (NP (CD 12) (NN min)) (PP (IN after) (NP (NP (NN performance)) (PP (IN of) (NP (JJ axillary) (NN block))) (PP (IN with) (NP (NP (NNP Doc_9698967_343_354_Chemical) (CD 850) (NNS mg)) (VP (VBG containing) (NP (NNP Doc_9698967_373_383_Chemical) (CD 0.225)) (ADVP (RB mg)) (, ,) (PP (IN for) (NP (NP (NN correction)) (PP (IN of) (NP (NNP Doc_9698967_412_435_Disease))))))))))))))) (. .)))
9698967	2	(S1 (S (S (PP (IN After) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9698967_473_482_Chemical)) (, ,) (NP (NNP Doc_9698967_484_494_Chemical)) (CC and) (NP (NNP Doc_9698967_499_508_Chemical)))))) (NP (NP (DT the) (NN patient) (POS 's)) (NN condition)) (VP (VBD improved))) (, ,) (CC and) (S (ADVP (NP (CD 15) (NN min)) (RB later)) (NP (PRP he)) (VP (VBD woke) (PRT (RP up)))) (. .)))
9698967	3	(S1 (S (S (NP (DT The) (NN block)) (VP (AUX was) (ADJP (JJ successful)))) (CC and) (S (NP (NN surgery)) (VP (AUX was) (VP (VBN conducted) (SBAR (IN as) (S (VP (VBN scheduled) (PP (IN despite) (S (VP (VBG persisting) (NP (NN Doc_9698967_655_674_Disease))))))))))) (. .)))
9698967	4	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD refused) (NP (CD DC) (NN cardioversion))) (CC and) (VP (AUX was) (VP (VBN treated) (ADVP (RB medically))))) (. .)))
9698967	5	(S1 (S (NP (NP (NP (PDT Both) (DT the) (JJ temporal) (NN relationship)) (PP (IN of) (NP (NNS events)))) (CC and) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN treatment))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (JJ rapid) (JJ systemic) (NN absorption)) (PP (IN of) (NP (NNP Doc_9698967_872_883_Chemical))) (PP (IN with) (NP (NP (JJ Doc_9698967_889_899_Chemical) (NN and/or) (NN interaction)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN with) (NP (NP (DT the) (NN patient) (POS 's)) (JJ cardiovascular) (NNS medications)))))) (VP (AUX were) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (JJ perioperative) (NNS complications)))))))) (. .)))
9721172	0	(S1 (NP (NP (NP (JJ Drug-associated) (JJ acute-onset) (NN Doc_9721172_28_47_Disease)) (CC and) (NP (NNP Doc_9721172_52_77_Disease))) (PP (IN in) (NP (DT a) (NN child))) (. .)))
9721172	1	(S1 (S (NP (JJ Acute) (NN Doc_9721172_96_115_Disease) (NN syndrome)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ established)) (NN cause)) (PP (IN of) (NP (NP (JJ progressive) (NNP Doc_9721172_172_183_Disease)) (PP (IN in) (NP (NNS adults)))))) (, ,) (VP (AUX is) (ADVP (RBS most) (RB often)) (ADJP (NN drug) (CC or) (NN toxin) (VBN related))) (, ,) (CC and) (VP (AUX is) (PP (IN of) (NP (JJ unknown) (NNS pathogenesis))))) (. .)))
9721172	2	(S1 (S (NP (PRP It)) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN reported) (ADVP (RB previously)) (PP (IN in) (NP (NNS children)))))) (. .)))
9721172	3	(S1 (S (NP (NN Doc_9721172_313_337_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-recognized) (JJ immune) (JJ complex-mediated) (NN Doc_9721172_383_399_Disease) (NN reaction)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ affects) (NP (DT all) (NN age) (NNS groups))) (, ,) (VP (AUX is) (NP (NP (NN drug) (CC or) (NN Doc_9721172_449_458_Disease)) (VP (VBN induced)))) (, ,) (CC and) (VP (AUX has) (NP (JJ classic) (ADJP (JJ systemic) (, ,) (JJ mucosal) (, ,) (CC and) (JJ dermatologic)) (NNS manifestations)))))))) (. .)))
9721172	4	(S1 (S (S (NP (NP (DT A) (ADJP (RB previously) (JJ healthy)) (NN child)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ acute) (, ,) (JJ severe) (, ,) (RB rapidly) (JJ progressive) (NNP Doc_9721172_612_640_Disease)) (PP (ADVP (RB shortly)) (IN after) (NP (NN Doc_9721172_655_679_Disease))))))) (VP (AUX is) (VP (VBN described)))) (: ;) (S (NP (DT this)) (VP (AUX was) (ADVP (RB temporally)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_9721172_730_739_Chemical) (NN use)))))) (. .)))
9721172	5	(S1 (S (PP (IN Despite) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_9721172_766_786_Chemical)) (, ,) (NP (NNP Doc_9721172_788_798_Chemical)) (, ,) (CC and) (ADVP (RB then)) (NP (NNP Doc_9721172_809_819_Chemical)))))) (, ,) (NP (PRP$ her) (NN Doc_9721172_825_844_Disease)) (VP (AUX was) (VP (VBG unrelenting) (, ,) (SBAR (IN with) (S (NP (NNP Doc_9721172_867_876_Disease)) (VP (VBN shown) (PP (IN by) (NP (NN biopsy))) (PP (NP (CD 6) (NNS months)) (IN after) (NP (NN presentation)))))))) (. .)))
9721172	6	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBZ documents) (NP (NP (JJ acute) (JJ drug-related) (NN Doc_9721172_961_989_Disease)) (PP (IN in) (NP (DT the) (JJ pediatric) (NN age) (NN group))))) (CC and) (VP (VBZ suggests) (NP (NP (JJ shared) (JJ immune) (NNS mechanisms)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT both) (NNP Doc_9721172_1083_1107_Disease) (CC and) (NNP Doc_9721172_1112_1140_Disease)))))))) (. .)))
9727773	0	(S1 (S (NP (NP (JJ High) (NN incidence)) (PP (IN of) (NP (NNP Doc_9727773_18_48_Disease)))) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_9727773_65_86_Chemical)) (PP (IN in) (NP (NNP Belgium)))))) (. .)))
9727773	1	(S1 (S (NP (NN Doc_9727773_99_129_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (, ,) (JJ progressive) (CC and) (JJ incurable)) (NN disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN intake)) (PP (IN of) (NP (JJ Doc_9727773_221_241_Chemical) (NNS drugs)))))))))))) (. .)))
9727773	2	(S1 (S (NP (NP (DT The) (NN importance)) (PP (IN of) (NP (DT this) (NN association)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNP Belgium))) (SBAR (IN while) (S (NP (DT this) (NN country)) (ADVP (RB still)) (VP (AUX had) (NP (DT no) (NN restriction)) (PP (IN on) (NP (NP (DT the) (NN prescription)) (PP (IN of) (NP (NNP Doc_9727773_376_397_Chemical)))))))))) (. .)))
9727773	3	(S1 (S (NP (NP (NP (JJ Thirty-five) (NNS patients)) (PP (IN with) (NP (NNP Doc_9727773_425_455_Disease)))) (CC and) (NP (CD 85) (VBN matched) (NNS controls))) (VP (AUX were) (VP (VBN recruited) (PP (IN over) (NP (NP (CD 32) (NNS months)) (PRN (-LRB- -LRB-) (JJ 1992-1994) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Belgium))))) (. .)))
9727773	4	(S1 (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NNP Doc_9727773_546_567_Chemical)))) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NN hospital) (NNS records)) (CC and) (NP (JJ standardized) (NN interview)))))))) (. .)))
9727773	5	(S1 (S (NP (NP (NN Twenty-three)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (ADVP (RB previously)) (VP (VBN taken) (ADJP (JJ Doc_9727773_692_713_Chemical) (, ,) (RB mainly) (JJ Doc_9727773_722_735_Chemical) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (QP (RB only) (CD 5))) (PP (IN of) (NP (NP (DT the) (NNS controls)) (PRN (-LRB- -LRB-) (NP (QP (CD 66) (CC versus) (CD 6)) (NN %)) (, ,) (NP (CD p<0.0001)) (-RRB- -RRB-)))))))))))) (. .)))
9727773	6	(S1 (S (NP (NP (NP (CD Five) (NNS patients)) (VP (VBN died) (PP (IN before) (NP (DT the) (NN interview))))) (, ,) (NP (NP (DT all)) (PP (IN of) (NP (PRP them))))) (VP (AUX had) (VP (VBN taken) (NP (NNP Doc_9727773_866_887_Chemical)))) (. .)))
9727773	7	(S1 (S (PP (IN In) (NP (NP (CD 8) (NNS patients)) (SBAR (S (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_9727773_920_950_Disease)))) (VP (AUX was) (ADJP (JJ uncertain))))))) (, ,) (NP (NP (CD 5)) (PP (IN of) (NP (PRP them)))) (VP (AUX had) (VP (VBN taken) (NP (NN Doc_9727773_986_1007_Chemical)))) (. .)))
9727773	8	(S1 (S (NP (NP (DT The) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_9727773_1046_1067_Chemical))))))))) (VP (VBD tended) (S (VP (VP (TO to) (VP (AUX be) (PP (IN on) (NP (NN average))) (ADVP (ADVP (RBR more) (RB severely)) (JJ ill)))) (, ,) (CC and) (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR shorter) (JJ median) (NN delay)) (PP (IN between) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNS symptoms)) (CC and) (NP (NN diagnosis)))))))))))) (. .)))
9727773	9	(S1 (S (NP (NP (DT A) (NN policy)) (PP (IN of) (NP (NP (JJ unrestricted) (NN prescription)) (PP (IN of) (NP (NNP Doc_9727773_1228_1249_Chemical)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (JJ associated) (NNP Doc_9727773_1293_1323_Disease))))))) (. .)))
9727773	10	(S1 (S (NP (NP (NN Intake)) (PP (IN of) (NP (NNP Doc_9727773_1335_1356_Chemical)))) (VP (MD may) (VP (VB accelerate) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (DT the) (NN disease)))))) (. .)))
9746003	0	(S1 (NP (NP (JJ Inappropriate) (NN use)) (PP (IN of) (NP (NP (NNP Doc_9746003_21_34_Chemical)) (CC and) (NP (NNP Doc_9746003_39_49_Chemical)))) (PP (IN in) (NP (JJ typical) (NNP Doc_9746003_61_77_Disease))) (. .)))
9746003	1	(S1 (S (NP (NP (NNP Doc_9746003_79_92_Chemical)) (CC and) (NP (NNP Doc_9746003_97_107_Chemical))) (VP (AUX are) (VP (VBN contraindicated) (PP (IN in) (NP (JJ typical) (NN Doc_9746003_139_155_Disease))))) (. .)))
9746003	2	(S1 (S (PP (IN Of) (NP (NP (CD 18) (JJ consecutive) (NNS referrals)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (JJ resistant) (JJ typical) (NNS absences))))))) (ADVP (RB only)) (, ,) (NP (CD eight)) (VP (AUX were) (UCP (VP (ADVP (RB erroneously)) (VBN treated) (PP (IN with) (NP (NNP Doc_9746003_271_284_Chemical)))) (CC either) (RB as) (ADJP (JJ monotherapy)) (CC or) (PP (IN as) (NP (DT an) (JJ add-on))))) (. .)))
9746003	3	(S1 (S (NP (NN Doc_9746003_324_334_Chemical)) (VP (AUX was) (ADVP (RB also)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (CD two) (NNS children))))))) (. .)))
9746003	4	(S1 (S (S (NP (NP (NN Frequency)) (PP (IN of) (NP (NNS absences)))) (VP (VBD increased) (PP (IN in) (NP (CD four) (NNS children))) (PP (VBN treated) (PP (IN with) (NP (NNP Doc_9746003_445_458_Chemical)))))) (CC and) (S (NP (NP (CD two)) (PP (IN of) (NP (DT these)))) (VP (VBD developed) (NP (NP (NNP Doc_9746003_486_501_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN on) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_9746003_535_548_Chemical))))))))))) (. .)))
9746003	5	(S1 (S (NP (NNS Absences)) (VP (AUX were) (VP (VBN aggravated) (PP (IN in) (NP (NP (DT both) (NNS cases)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_9746003_595_605_Chemical)) (VP (AUX was) (VP (VBN added) (PRT (RP on)) (PP (TO to) (NP (JJ concurrent) (NN treatment))))))))))) (. .)))
9746003	6	(S1 (S (NP (NP (JJ Optimal) (NN control)) (PP (IN of) (NP (DT the) (NNS absences)))) (VP (AUX was) (VP (VBN achieved) (PP (IN with) (NP (NP (NP (NNP Doc_9746003_694_710_Chemical)) (, ,) (NP (NNP Doc_9746003_712_723_Chemical)) (, ,) (CC or) (NP (NNP Doc_9746003_728_740_Chemical))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination)))))))) (. .)))
9754849	0	(S1 (S (NP (NN Doc_9754849_0_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ rapid) (NN adjustment)) (PP (TO to) (NP (NNP Doc_9754849_61_70_Chemical)))))) (. .)))
9754849	1	(S1 (S (NP (NN Doc_9754849_72_98_Disease)) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (NP (JJ occasional) (NNP Doc_9754849_126_148_Disease)) (PP (IN during) (NP (NP (NNS intoxications)) (PP (IN with) (NP (UCP (JJ Doc_9754849_175_182_Chemical) (CC but) (RB not)) (NNS opiates)))))))))) (. .)))
9754849	2	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN of) (NP (NN euphoria)))))) (CC and) (S (NP (NNP Doc_9754849_238_262_Disease)) (VP (ADVP (DT both) (RB transiently)) (VBN induced) (PP (IN by) (NP (NP (JJ rapid) (NN adjustment)) (PP (TO to) (NP (NP (DT the) (JJ selective) (JJ mu-opioid) (NN receptor) (NN agonist) (NNP Doc_9754849_352_361_Chemical)) (PP (IN in) (NP (NP (DT an) (NN inpatient)) (VP (ADVP (RB previously)) (VBG abusing) (NP (NP (NNP Doc_9754849_397_404_Chemical)) (CC and) (NP (NNP Doc_9754849_409_416_Chemical)))))))))))) (. .)))
9754849	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ minor) (NNP EEG) (NNS abnormalities)) (VP (VBD occurred)) (. .)))
9754849	4	(S1 (S (NP (JJ Possible) (JJ underlying) (NN neurobiological) (NNS phenomena)) (VP (AUX are) (VP (VBN discussed))) (. .)))
9766615	0	(S1 (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (DT the) (JJ atypical) (NNS antipsychotics))) (. .)))
9766615	1	(S1 (NP (NP (NNP Collaborative) (NNP Working) (NNP Group)) (PP (IN on) (NP (JJ Clinical) (NN Trial) (NNS Evaluations))) (. .)))
9766615	2	(S1 (S (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (NNS antipsychotics)))) (ADVP (RB often)) (VP (VBP lead) (S (VP (TO to) (VP (VB noncompliance))))) (. .)))
9766615	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNS clinicians)) (VP (MD should) (VP (VP (VB address) (NP (NP (NP (NNS patients) (POS ')) (NNS concerns)) (PP (IN about) (NP (JJ adverse) (NNS effects))))) (CC and) (VP (VB attempt) (S (VP (TO to) (VP (VB choose) (NP (NP (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB improve) (NP (NP (NP (NP (PRP$ their) (NNS patients) (POS ')) (NN quality)) (PP (IN of) (NP (NN life)))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ overall) (NN health)))))))))))))) (. .)))
9766615	4	(S1 (S (NP (NP (DT The) (JJ side) (NN effect) (NNS profiles)) (PP (IN of) (NP (DT the) (JJ atypical) (NNS antipsychotics)))) (VP (AUX are) (ADJP (ADJP (RBR more) (JJ advantageous)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ conventional) (NNS neuroleptics))))))) (. .)))
9766615	5	(S1 (S (NP (JJ Conventional) (NNS agents)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ unwanted) (JJ central) (JJ nervous) (NN system) (NNS effects)) (, ,) (PP (VBG including) (NP (NP (NP (NNP Doc_9766615_568_591_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9766615_593_596_Disease)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9766615_599_617_Disease)) (, ,) (NP (NP (NN sedation)) (, ,) (CC and) (NP (NP (JJ possible) (NN impairment)) (PP (IN of) (NP (DT some) (JJ cognitive) (NNS measures)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ cardiac) (NNS effects))) (, ,) (NP (NNP Doc_9766615_709_732_Disease)) (, ,) (NP (JJ hepatic) (NNS changes)) (, ,) (NP (NN anticholinergic) (NN side) (NNS effects)) (, ,) (NP (NNP Doc_9766615_781_799_Disease)) (, ,) (CC and) (NP (NNP Doc_9766615_805_816_Disease)))))))) (. .)))
9766615	6	(S1 (S (S (NP (DT The) (JJR newer) (JJ atypical) (NNS agents)) (VP (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN risk)) (PP (IN of) (NP (NNP Doc_9766615_865_868_Disease))))) (, ,) (CC but) (VP (AUX are) (VP (VBN associated) (PP (IN in) (NP (VBG varying) (NNS degrees))) (PP (IN with) (NP (NP (NN sedation)) (, ,) (NP (JJ cardiovascular) (NNS effects)) (, ,) (NP (JJ anticholinergic) (NNS effects)))))))) (, ,) (NP (NP (NNP Doc_9766615_972_983_Disease)) (, ,) (NP (NNP Doc_9766615_985_1003_Disease)) (, ,) (NP (JJ hepatic) (NNS effects)) (, ,)) (VP (VBD lowered) (NP (NP (NP (JJ Doc_9766615_1030_1037_Disease) (NN threshold)) (PRN (-LRB- -LRB-) (ADVP (RB primarily)) (NP (NNP Doc_9766615_1059_1068_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_9766615_1075_1090_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9766615_1092_1101_Chemical) (RB only)) (-RRB- -RRB-))))) (. .)))
9766615	7	(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ specific) (JJ adverse) (NNS effects)))) (VP (VBP differ) (PP (IN among) (NP (DT the) (JJ various) (NNS atypicals)))))) (, ,) (NP (DT the) (NN clinician)) (VP (MD should) (ADVP (RB carefully)) (VP (VB consider) (SBAR (WHNP (WDT which)) (S (NP (NN side) (NNS effects)) (VP (AUX are) (ADJP (RBS most) (JJ likely) (S (VP (TO to) (VP (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN individual) (POS 's)) (NN dissatisfaction)))) (CC and) (VP (VB noncompliance) (PP (IN before) (S (VP (VBG choosing) (NP (NP (DT an) (NN antipsychotic)) (PP (IN for) (NP (DT a) (JJ particular) (NN patient))))))))))))))))) (. .)))
9812111	0	(S1 (NP (NP (DT A) (JJ randomized) (, ,) (JJ placebo-controlled) (NN dose-comparison) (NN trial)) (PP (IN of) (NP (NNP Doc_9812111_58_69_Chemical))) (PP (IN for) (NP (NP (NP (NNP Doc_9812111_74_83_Disease)) (CC and) (NP (NNP Doc_9812111_88_108_Disease))) (PP (IN in) (NP (NNP Doc_9812111_112_131_Disease))))) (. .)))
9812111	1	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN efficacy) (CC and) (NN side) (NNS effects)) (PP (IN of) (NP (NP (NP (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_9812111_228_239_Chemical)))) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9812111_272_281_Disease) (CC and) (NNP Doc_9812111_286_306_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9812111_324_343_Disease))))))))))))))))) (. .)))
9812111	2	(S1 (S (PP (IN In) (NP (DT a) (JJ 6-week) (NN random-assignment))) (, ,) (NP (NP (NP (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN phase)) (NP (DT A)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9812111_434_445_Chemical)) (, ,) (NP (NP (CD 2-3) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (JJ standard) (NN dose)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_9812111_479_490_Chemical)) (, ,) (NP (NP (CD 0.50-0.75) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (JJ low) (NN dose)) (-RRB- -RRB-))) (, ,)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (CD 71) (NNS outpatients)) (PP (IN with) (NP (NNP Doc_9812111_558_577_Disease))))))) (. .)))
9812111	3	(S1 (S (PP (IN For) (NP (NP (DT the) (JJ subsequent) (JJ 6-week) (NN double-blind) (NN crossover) (NN phase)) (PRN (-LRB- -LRB-) (NP (NN phase) (NN B)) (-RRB- -RRB-)))) (, ,) (S (NP (NP (NNS patients)) (VP (VBG taking) (NP (ADJP (JJ standard-) (CC or) (JJ low-dose)) (NNP Doc_9812111_683_694_Chemical)))) (VP (AUX were) (VP (VBN switched) (PP (TO to) (NP (NN placebo)))))) (, ,) (CC and) (S (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN placebo)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (ADJP (JJ standard-) (CC or) (JJ low-dose)) (NNP Doc_9812111_797_808_Chemical)))))) (. .)))
9812111	4	(S1 (S (PP (IN For) (NP (NP (DT the) (CD 60) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD completed) (NP (NN phase) (DT A))))))) (, ,) (NP (JJ standard-dose) (NNP Doc_9812111_876_887_Chemical)) (VP (AUX was) (ADJP (ADJP (JJ efficacious)) (CC and) (ADJP (JJ superior) (PP (TO to) (NP (NP (DT both) (JJ low-dose) (NN Doc_9812111_934_945_Chemical) (CC and) (NN placebo)) (PP (IN for) (NP (NP (NNS scores)) (PP (PP (IN on) (NP (DT the) (JJ Brief) (NNP Psychiatric) (NNP Rating) (NNP Scale) (NNP Doc_9812111_1007_1016_Disease) (NN factor))) (CC and) (PP (IN on) (NP (NNP Doc_9812111_1031_1052_Disease))))))))))) (. .)))
9812111	5	(S1 (S (NP (NP (NN Response) (NNS rates)) (VP (VBG according) (PP (TO to) (NP (NP (CD three) (NNS sets)) (PP (IN of) (NP (NNS criteria))))))) (VP (AUX were) (ADJP (ADJP (JJR greater)) (PP (IN with) (NP (NP (DT the) (JJ standard) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 55) (NN %)) (NP (CD -60) (NN %))) (-RRB- -RRB-)))) (PP (IN than) (NP (NP (NP (DT the) (JJ low) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (NP (CD -35) (NN %))) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (NP (CD -30) (NN %))) (-RRB- -RRB-))))))) (. .)))
9812111	6	(S1 (S (NP (NP (DT The) (NN advantage)) (PP (IN of) (NP (JJ standard) (NN dose))) (PP (IN over) (NP (JJ low) (NN dose)))) (VP (AUX was) (VP (VBN replicated) (PP (IN in) (NP (NN phase) (NN B))))) (. .)))
9812111	7	(S1 (S (PP (IN In) (NP (NN phase) (DT A))) (, ,) (NP (NNP Doc_9812111_1286_1306_Disease)) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (ADJP (JJR greater) (PP (IN with) (NP (DT the) (JJ standard) (NN dose))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ other) (CD two) (NNS conditions)))))))) (, ,) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (DT a) (NN subgroup)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (ADJP (JJ moderate) (TO to) (JJ severe)) (NNS signs)))))))) (. .)))
9812111	8	(S1 (S (NP (NNP Low-dose) (NNP Doc_9812111_1472_1483_Chemical)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN from) (NP (NN placebo))) (PP (IN on) (NP (NP (DT any) (NN measure)) (PP (IN of) (NP (NP (NN efficacy)) (CC or) (NP (NN side) (NNS effects)))))))) (. .)))
9812111	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBD indicated) (NP (NP (DT a) (JJ favorable) (JJ therapeutic) (NN profile)) (PP (IN for) (NP (NNP Doc_9812111_1627_1638_Chemical)))) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 2-3) (NN mg/day))))) (, ,) (SBAR (IN although) (S (NP (DT a) (NN subgroup)) (VP (VBD developed) (ADVP (JJ moderate) (PP (TO to) (NP (JJ severe) (NN Doc_9812111_1712_1732_Disease)))))))) (. .)))
9812111	10	(S1 (S (NP (NP (DT A) (JJ starting) (NN dose)) (PP (IN of) (NP (CD 1) (NN mg/day))) (PP (IN with) (NP (JJ gradual) (, ,) (JJ upward) (NN dose) (NN titration)))) (VP (AUX is) (VP (VBN recommended))) (. .)))
9812111	11	(S1 (S (NP (NP (DT The) (JJ narrow) (JJ therapeutic) (NN window)) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_9812111_1858_1869_Chemical))))) (VP (MD may) (ADVP (RB also)) (VP (VB apply) (PP (TO to) (NP (NP (JJ other) (NNS neuroleptics)) (VP (VBN used) (PP (IN in) (NP (NP (JJ Doc_9812111_1915_1934_Disease) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9812111_1949_1958_Disease)) (CC and) (NP (NNP Doc_9812111_1963_1983_Disease))))))))))) (. .)))
983936	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP Doc_983936_11_31_Chemical)) (, ,) (NP (NNP Doc_983936_33_45_Chemical)) (, ,) (CC and) (NP (NNP Doc_983936_51_65_Chemical)))) (PP (IN on) (NP (NP (NNP Doc_983936_69_80_Chemical-induced) (NNP Doc_983936_89_106_Disease)) (PP (IN in) (NP (NNS dogs))))) (. .)))
983936	1	(S1 (S (NP (NP (DT A) (JJ reproducible) (NN model)) (PP (IN for) (S (VP (VBG producing) (NP (JJ diffuse) (NN Doc_983936_159_176_Disease)))))) (PRN (-LRB- -LRB-) (NP (JJ Doc_983936_178_189_Chemical) (NN infusion)) (-RRB- -RRB-)) (VP (AUX has) (VP (AUX been) (VP (VBN developed) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ cardioprotective) (NNS effects)) (PP (IN of) (NP (NP (NNS agents)) (CC or) (NP (NNS maneuvers)))) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB alter) (NP (NP (DT the) (NN evolution)) (PP (IN of) (NP (JJ acute) (NNP Doc_983936_321_342_Disease))))))))))))))) (. .)))
983936	2	(S1 (S (NP (NP (NNS Infusions)) (PP (IN of) (NP (NNP Doc_983936_357_368_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN mug)) (PP (IN per) (NP (FW kilogram) (FW per) (NN minute))) (PP (IN for) (NP (CD 6) (NNS hours)))) (-RRB- -RRB-))) (VP (VBD increased) (NP (JJ Doc_983936_423_435_Chemical) (NNS uptakes)) (PP (IN into) (NP (NP (JJ intact) (NN myocardium)) (CC and) (NP (NP (DT each)) (PP (IN of) (NP (PRP$ its) (JJ subcellular) (NNS components)))))) (PP (IN with) (S (NP (DT the) (JJ mitochondrial) (NN fraction)) (VP (VBG showing) (NP (DT the) (ADJP (RBS most) (JJ consistent)) (NNS changes)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-infused) (NN control) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4,957) (CC vs.) (CD 827)) (NNS counts)) (PP (IN per) (NP (NN minute))) (PP (IN per) (NP (NP (NN gram)) (PP (IN of) (NP (VBN dried) (NN tissue) (CC or) (NN fraction)))))) (-RRB- -RRB-))))))))))) (. .)))
983936	3	(S1 (S (NP (NP (JJ Myocardial) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_983936_723_730_Chemical)))) (ADVP (RB also)) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12.0) (CC vs.) (CD 5.0) (JJR mg.per) (CD 100)) (NNP Gm.)) (PP (IN of) (NP (JJ fat-free) (JJ dry) (NN weight)))) (-RRB- -RRB-))) (. .)))
983936	4	(S1 (S (NP (NP (NP (NNS Infusions)) (PP (IN of) (NP (NNP Doc_983936_827_843_Chemical))) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB raise) (NP (JJ serum) (JJ Doc_983936_870_877_Chemical) (NNS concentrations)))))) (QP (CD 2) (CD mEq.))) (PP (IN per) (NP (NN liter)))) (VP (VBD failed) (S (VP (TO to) (VP (VB increase) (NP (JJ Doc_983936_929_936_Chemical) (NN influx)) (PP (IN into) (NP (DT the) (JJ myocardial) (NN cell))))))) (. .)))
983936	5	(S1 (S (NP (JJ Mitochondrial) (JJ Doc_983936_984_996_Chemical) (NNS uptakes)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN decreased) (UCP (PP (IN in) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_983936_1061_1081_Chemical) (CC or) (NNP Doc_983936_1085_1097_Chemical)))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_983936_1106_1120_Chemical)) (VP (AUX was) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (JJ Doc_983936_1138_1149_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (CD 2,682,2,803) (, ,) (CC and) (CD 3,424) (NNS counts)) (PP (IN per) (NP (NN minute))) (PP (IN per) (NP (NP (NN gram)) (PP (IN of) (NP (VBN dried) (NN fraction)))))) (, ,) (RB respectively) (-RRB- -RRB-))))))))))) (. .)))
983936	6	(S1 (S (NP (JJ Myocardial) (JJ Doc_983936_1255_1262_Chemical) (NNS concentrations)) (ADVP (RB also)) (VP (AUX were) (ADJP (VBN decreased) (PRN (-LRB- -LRB-) (NP (NP (CD 11.2)) (, ,) (NP (CD 8.3)) (, ,) (CC and) (NP (NP (CD 8.9) (NN mg.)) (PP (IN per) (NP (NP (CD 100) (NNP Gm.)) (PP (IN of) (NP (JJ fat-free) (JJ dry) (NN weight)))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (CD three) (NN treatment) (NNS groups))) (, ,) (S (VP (AUXG being) (VP (ADVP (RB significantly)) (VBN decreased) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ last) (CD two))))))) (. .)))
983936	7	(S1 (S (NP (NP (NN Evidence)) (PP (IN of) (NP (JJ microscopic) (NN damage)))) (VP (AUX was) (VP (VBN graded) (PP (IN as) (ADJP (RBR less) (JJ severe))) (PP (IN in) (NP (DT the) (CD three) (NN treatment) (NNS groups))))) (. .)))
983936	8	(S1 (S (NP (NP (NNP Doc_983936_1543_1563_Chemical)) (, ,) (NP (NNP Doc_983936_1565_1577_Chemical)) (, ,) (CC and) (NP (NNP Doc_983936_1583_1597_Chemical))) (DT all) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (NP (JJ cardioprotective) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN tested) (PP (IN in) (NP (DT this) (NN model)))))))))) (. .)))
9855119	0	(S1 (S (NP (NP (ADJP (JJ Clinical) (CC and) (JJ histopathologic)) (NN examination)) (PP (IN of) (NP (JJ renal) (NNS allografts)))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9855119_74_84_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9855119_86_91_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN year)))) (. .)))
9855119	1	(S1 (S (NP (PRP We)) (ADVP (RB clinically) (CC and) (RB pathologically)) (VP (VBD analyzed) (NP (NP (JJ renal) (NNS allografts)) (PP (IN from) (NP (NP (QP (CD 1) (CD 9)) (JJ renal) (NN transplant) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9855119_235_245_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9855119_247_252_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 1)) (NN year)))))))) (. .)))
9855119	2	(S1 (S (NP (NP (JJ Twenty-six) (JJ renal) (NN allograft) (NN biopsy) (NNS specimens)) (PP (IN from) (NP (NP (QP (CD 1) (CD 9)) (JJ renal) (NN transplant) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NNS transplantations)) (PP (IN between) (NP (NP (CD 1991)) (CC and) (NP (CD 1993)))))))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
9855119	3	(S1 (S (S (NP (JJ Thirteen) (NNS biopsies)) (VP (AUX were) (VP (VBN performed) (PP (IN from) (NP (JJ stable) (VBG functioning) (JJ renal) (NNS allografts))) (PP (IN with) (NP (NP (JJ informed) (NN consent)) (PRN (-LRB- -LRB-) (NP (JJ nonepisode) (NN biopsy)) (-RRB- -RRB-))))))) (CC and) (S (NP (DT the) (JJ other) (CD 13)) (VP (AUX were) (PP (IN from) (NP (NP (JJ dysfunctional) (JJ renal) (NNS allografts)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN indication)) (PP (IN for) (NP (NP (NN biopsy)) (PRN (-LRB- -LRB-) (NP (NN episode) (NN biopsy)) (-RRB- -RRB-)))))))))) (. .)))
9855119	4	(S1 (S (NP (NP (DT The) (JJ main) (JJ pathologic) (NNS diagnoses)) (PRN (-LRB- -LRB-) (S (NP (DT some)) (VP (VBP overlap))) (-RRB- -RRB-))) (VP (AUX were) (NP (NP (JJ acute) (NN rejection)) (PRN (-LRB- -LRB-) (NP (NNP AR)) (: ;) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)) (, ,) (NP (NN chronic) (NN rejection)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (: ;) (NP (CD n=5)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP AR+CR)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =4)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ recurrent) (NNP Doc_9855119_804_819_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =5)) (-RRB- -RRB-))) (, ,) (NP (JJ normal) (NNS findings)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =2)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ minimal-type) (NN chronic) (NNP Doc_9855119_873_878_Chemical) (NNP Doc_9855119_879_890_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)))) (, ,) (CC and) (NP (JJ mild-type) (NNP Doc_9855119_914_919_Chemical) (NNP Doc_9855119_920_931_Disease))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 11)) (-RRB- -RRB-)))) (. .)))
9855119	5	(S1 (S (PP (IN Of) (NP (DT the) (JJ nonepisode) (NNS biopsies))) (, ,) (NP (QP (CD 7) (CC and) (CD 4)) (NNS biopsies)) (VP (VBD showed) (NP (NP (NN minimal-type)) (CC and) (NP (JJ mild-type) (NN chronic) (NNP Doc_9855119_1029_1034_Chemical) (NNP Doc_9855119_1035_1046_Disease))) (, ,) (ADVP (RB respectively))) (. .)))
9855119	6	(S1 (S (NP (JJ Chronic) (NNP Doc_9855119_1070_1075_Chemical) (NNP Doc_9855119_1076_1087_Disease)) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (JJ rough) (CC and) (JJ foamy) (JJ tubular) (NN vacuolization)) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS biopsies)) (-RRB- -RRB-))) (, ,) (NP (NP (NN arteriolopathy)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN angiodegeneration)) (PP (IN of) (NP (DT the) (JJ arteriolar) (NN wall)))) (: ;) (NP (CD 20) (NNS biopsies))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9855119_1225_1259_Disease) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS biopsies)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ striped) (NN form)) (PP (IN of) (NP (NP (NNP Doc_9855119_1297_1318_Disease)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS biopsies)) (-RRB- -RRB-)))))))) (. .)))
9855119	7	(S1 (S (NP (NP (DT The) (JJ serum) (JJ Doc_9855119_1344_1354_Chemical) (NNS levels)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (JJ mild-type) (NN chronic) (NNP Doc_9855119_1399_1404_Chemical) (NNP Doc_9855119_1405_1416_Disease) (NN group))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (ADJP (CD 7) (NN episode)) (NNS biopsies))))) (, ,)) (VP (AUX were) (ADJP (ADJP (RB statistically) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (JJ minimum-type) (NN chronic) (NN Doc_9855119_1524_1529_Chemical-Doc_9855119_1530_1541_Disease) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.001)) (-RRB- -RRB-))) (. .)))
9855119	8	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NN chronic) (NNP Doc_9855119_1610_1615_Chemical) (NNP Doc_9855119_1616_1627_Disease)) (VP (VBZ consists) (ADVP (RB primarily)) (PP (IN of) (NP (NP (NN arteriolopathy)) (VP (VBG manifesting) (PP (IN as) (NP (NP (JJ insudative) (NN hyalinosis)) (PP (IN of) (NP (DT the) (JJ arteriolar) (NN wall)))))))))))) (, ,) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN mild-type) (NN chronic) (NNP Doc_9855119_1762_1767_Chemical) (NNP Doc_9855119_1768_1779_Disease)) (VP (AUX is) (NP (NP (DT a) (NN condition)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN allograft) (NN function))))))))))))))) (. .)))
9862868	0	(S1 (NP (NP (JJ Different) (NN lobular) (NNS distributions)) (PP (IN of) (NP (NP (JJ altered) (JJ hepatocyte) (JJ tight) (NNS junctions)) (PP (IN in) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NNP Doc_9862868_87_128_Disease))))))) (. .)))
9862868	1	(S1 (S (NP (NP (NP (JJ Hepatocyte) (JJ tight) (NNS junctions)) (PRN (-LRB- -LRB-) (NP (NNP TJs)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (RB only) (JJ intercellular) (NN barrier)) (PP (IN between) (NP (NP (DT the) (NN sinusoidal)) (CC and) (NP (DT the) (JJ canalicular) (NNS spaces))))) (, ,)) (VP (VBP play) (NP (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NN bile) (NN formation))))) (. .)))
9862868	2	(S1 (S (SBAR (IN Although) (S (NP (NN hepatocyte) (NNS TJs)) (VP (AUX are) (VP (VBN impaired) (PP (IN in) (NP (NNP Doc_9862868_321_332_Disease))))))) (, ,) (NP (NP (NNS attempts)) (SBAR (S (VP (TO to) (VP (VB localize) (NP (NP (DT the) (JJ precise) (NN site)) (PP (IN of) (NP (JJ hepatocyte) (JJ TJ) (NN damage)))) (PP (IN by) (NP (JJ freeze-fracture) (NNP electron) (NN microscopy)))))))) (VP (AUX have) (VP (VBN produced) (NP (JJ limited) (NN information)))) (. .)))
9862868	3	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (JJ several) (JJ TJ-associated) (NNS proteins)) (PP (IN like) (NP (NP (NN ZO-1)) (CC and) (NP (NN 7H6))))) (VP (AUX have) (VP (AUX been) (VP (VP (VBN identified)) (CC and) (VP (VBN characterized))))) (. .)))
9862868	4	(S1 (S (NP (NP (NN Immunolocalization)) (PP (IN of) (NP (NNS 7H6)))) (VP (VBZ appears) (S (VP (TO to) (ADVP (RB closely)) (VP (VB correlate) (PP (IN with) (NP (JJ paracellular) (NN permeability))))))) (. .)))
9862868	5	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NP (NP (NNP Doc_9862868_678_702_Disease)) (PP (IN by) (NP (NNP Doc_9862868_706_723_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9862868_725_727_Chemical)) (-RRB- -RRB-)) (NN treatment)))) (CC and) (NP (NP (NP (NNP Doc_9862868_743_767_Disease)) (PP (IN by) (NP (JJ bile) (NN duct) (NN ligation)))) (PRN (-LRB- -LRB-) (NP (NNP BDL)) (-RRB- -RRB-)))))) (S (VP (TO to) (ADVP (RB precisely)) (VP (VB determine) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (JJ TJ) (NN damage)))))))) (. .)))
9862868	6	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (JJ hepatocyte) (NNS TJs)))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (S (VP (VP (VBG double-immunolabeling) (PP (IN for) (NP (NN 7H6)))) (CC and) (VP (ADVP (JJ ZO-1)) (VBG using) (NP (DT a) (JJ confocal) (NN laser) (VBG scanning) (NN microscope)))))))) (. .)))
9862868	7	(S1 (S (PP (IN In) (NP (NN control) (NNS rats))) (, ,) (NP (NP (NN immunostaining)) (PP (IN for) (NP (NP (NN 7H6)) (CC and) (NP (NN ZO-1))))) (VP (VBD colocalized) (S (VP (TO to) (VP (VB outline) (NP (JJ bile) (NNS canaliculi)) (PP (IN in) (NP (DT a) (JJ continuous) (NN fashion))))))) (. .)))
9862868	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN 7H6)) (CC and) (NP (JJ ZO-1) (NN immunostaining))) (VP (AUX was) (ADJP (RBR more) (JJ discontinuous)) (, ,) (S (VP (VBG outlining) (NP (DT the) (JJ bile) (NNS canaliculi)) (PP (IN after) (NP (NN BDL)))))) (. .)))
9862868	9	(S1 (S (NP (NP (NN Immunostaining)) (PP (IN for) (NP (NN 7H6))) (, ,) (ADJP (RB not) (JJ ZO-1)) (, ,)) (VP (VP (VBD decreased)) (CC and) (ADVP (RB predominantly)) (VP (VBD appeared) (PP (IN as) (NP (JJ discrete) (NNS signals))) (PP (IN in) (NP (NP (DT the) (JJ submembranous) (NN cytoplasm)) (PP (IN of) (NP (JJ periportal) (NNS hepatocytes))) (PP (IN after) (NP (NNP BDL))))))) (. .)))
9862868	10	(S1 (S (PP (IN After) (NP (JJ Doc_9862868_1356_1358_Chemical) (NN treatment))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (S (VP (VBG immunostaining) (PP (IN for) (NP (NP (NN 7H6)) (CC and) (NP (NN ZO-1)))))))) (VP (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (JJ periportal) (NNS hepatocytes))))))) (PP (IN after) (NP (NNP BDL)))) (, ,) (CC but) (VP (VBN distributed) (ADVP (RBR more) (RB diffusely)) (PP (IN throughout) (NP (DT the) (NN lobule))))) (. .)))
9862868	11	(S1 (S (NP (DT This) (NN study)) (VP (AUX is) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB demonstrate) (SBAR (IN that) (S (NP (NP (NN impairment)) (PP (IN of) (NP (JJ hepatocyte) (NNS TJs)))) (VP (VP (VBZ occurs) (ADVP (RB heterogenously)) (PP (IN in) (NP (DT the) (NN liver) (NN lobule))) (PP (IN after) (NP (NN BDL)))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP BDL) (CC and) (NNP Doc_9862868_1682_1684_Chemical) (NNS treatments)) (VP (VBP produce) (NP (NP (JJ different) (NN lobular) (NNS distributions)) (PP (IN of) (NP (VBN increased) (JJ paracellular) (NN permeability))))))))))))))))) (. .)))
9869257	0	(S1 (S (NP (NP (NN Memory) (NN facilitation) (CC and) (NN stimulation)) (PP (IN of) (NP (JJ endogenous) (NN nerve) (NN growth)))) (VP (VB factor) (NP (NN synthesis)) (PP (IN by) (NP (DT the) (NNP Doc_9869257_87_100_Chemical) (NNP releaser) (NNP Doc_9869257_110_114_Chemical)))) (. .)))
9869257	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_9869257_131_135_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9869257_137_178_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT the) (NNP Doc_9869257_185_198_Chemical) (NN releaser)) (, ,))) (PP (IN on) (NP (NP (NN memory) (NNS processes)) (CC and) (NP (NN nerve) (NN growth) (NN factor) (-LRB- -LRB-) (NN NGF) (-RRB- -RRB-) (NN synthesis))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
9869257	2	(S1 (S (PP (IN In) (NP (DT the) (NN mouse) (NN passive-avoidance) (NN test))) (, ,) (NP (NP (NP (NNP Doc_9869257_322_326_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10-30) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN administered) (CD 20) (NN min)) (PP (IN before) (NP (DT the) (NN training) (NN session)))) (, ,)) (VP (VBD prevented) (NP (NNP Doc_9869257_407_414_Disease)) (S (VP (VBN induced) (PP (IN by) (NP (NP (PDT both) (DT the) (JJ non) (JJ selective) (JJ antimuscarinic) (NN drug) (NNP Doc_9869257_469_480_Chemical)) (CC and) (NP (DT the) (JJ M1-selective) (JJ antagonist) (NNP Doc_9869257_513_525_Chemical))))))) (. .)))
9869257	3	(S1 (S (PP (IN In) (NP (DT the) (JJ same) (JJ experimental) (NNS conditions))) (, ,) (NP (NP (NNP Doc_9869257_564_568_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 5-20) (NN microg)) (PP (IN per) (NP (NN mouse)))) (, ,) (NP (NNP i.c.v.)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB prevent) (NP (JJ antimuscarine-induced) (NNP Doc_9869257_648_655_Disease)))))) (, ,) (S (VP (VBG demonstrating) (NP (NP (DT a) (JJ central) (NN localization)) (PP (IN of) (NP (DT the) (NN activity))))))) (. .)))
9869257	4	(S1 (S (PP (IN At) (NP (DT the) (JJS highest) (JJ effective) (NNS doses))) (, ,) (S (NP (NNP Doc_9869257_743_747_Chemical)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ collateral) (NNS symptoms)) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (DT the) (NNP Irwin) (NN test))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB modify) (NP (JJ spontaneous) (NN motility) (CC and) (NN inspection) (NN activity)) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (DT the) (JJ hole-board) (NN test))))))))) (. .)))
9869257	5	(S1 (S (NP (NN Doc_9869257_923_927_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NNS NGF)) (VP (VBN secreted) (PP (IN in) (NP (NN vitro))) (PP (IN by) (NP (NNS astrocytes))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))))))))) (. .)))
9869257	6	(S1 (S (NP (NP (DT The) (JJ maximal) (CD NGF) (NNS contents)) (VP (VBN obtained) (PP (IN by) (NP (NNP Doc_9869257_1069_1073_Chemical))))) (VP (AUX were) (ADJP (JJ 17.6-fold) (PP (IN of) (NP (DT the) (NN control) (NN value))))) (. .)))
9869257	7	(S1 (S (PP (IN During) (NP (NN culture))) (, ,) (NP (DT no) (JJ morphological) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN at) (NP (NP (JJ effective) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_9869257_1194_1198_Chemical))))))) (. .)))
9869257	8	(S1 (S (NP (DT The) (JJ current) (NN work)) (VP (VBZ indicates) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_9869257_1242_1246_Chemical))) (S (VP (TO to) (VP (VP (VB induce) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN on) (NP (JJ cognitive) (NNS processes))))) (CC and) (VP (VB stimulate) (NP (NP (NN activity)) (PP (IN of) (NP (NN NGF) (NN synthesis))) (PP (IN in) (NP (JJ astroglial) (NNS cells)))))))))) (. .)))
9869257	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_9869257_1371_1375_Chemical)) (VP (MD could) (VP (VB represent) (NP (NP (DT a) (JJ potential) (JJ useful) (NN drug)) (ADJP (JJ able) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (JJ impaired) (JJ cognitive) (NNS processes))))))))))) (. .)))
9931093	0	(S1 (S (NP (NP (NNS Mechanisms)) (PP (IN of) (NP (NP (NP (NNP Doc_9931093_14_20_Chemical-induced) (NNP Doc_9931093_29_41_Disease)) (PP (IN in) (NP (DT the) (NN rat.) (NN -Doc_9931093_55_65_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_9931093_67_73_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (NP (DT a) (JJ powerful) (, ,) (ADJP (RB widely) (VBN used)) (NN immunosuppressant))) (. .)))
9931093	1	(S1 (S (NP (NP (DT The) (JJ clinical) (NN utility)) (PP (IN of) (NP (NNP Doc_9931093_145_151_Chemical)))) (VP (AUX is) (VP (VBN complicated) (PP (IN by) (NP (NP (JJ substantial) (NN Doc_9931093_182_194_Disease)) (CC and) (NP (NN Doc_9931093_199_213_Disease)))))) (. .)))
9931093	2	(S1 (S (S (VP (TO To) (VP (VB clarify) (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (JJ Doc_9931093_244_250_Chemical-induced) (NNP Doc_9931093_259_271_Disease)))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ chronic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9931093_307_313_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (JJ endothelin-1) (PRN (-LRB- -LRB-) (JJ ET-1) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN of) (NP (NP (JJ ET-1) (CC and) (JJ endothelin-converting) (NN enzyme-1)) (PRN (-LRB- -LRB-) (JJ ECE-1) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (JJ endothelial) (NNP Doc_9931093_446_458_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNS eNOS)) (-RRB- -RRB-))) (NN activity)))) (, ,) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN of) (NP (NP (NNS eNOS)) (CC and) (NP (JJ C-type) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP CNP)) (-RRB- -RRB-)) (PP (IN in) (NP (NN rat) (NN blood) (NNS vessels)))))))))))) (. .)))
9931093	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (JJ specific) (NN endothelin) (NN type)))) (NP (NP (DT A) (NN receptor) (NN antagonist) (NN Doc_9931093_657_666_Chemical)) (PP (IN on) (NP (NP (NNP Doc_9931093_670_676_Chemical-induced) (NNP Doc_9931093_685_697_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (AUX was) (VP (VBN studied))) (. .)))
9931093	4	(S1 (S (NP (NP (NNP Doc_9931093_719_725_Chemical)) (, ,) (NP (NP (CD 5) (JJ mg.) (JJ kg-1.) (NN d-1)) (VP (VBN given) (PP (IN for) (NP (CD 4) (NNS weeks))))) (, ,)) (VP (VP (VBD elevated) (NP (NP (NN blood) (NN pressure)) (PP (IN from) (NP (QP (CD 102+/-13) (TO to) (CD 152+/-15)) (NNS mm)))) (NP (NNP Hg))) (CC and) (VP (VBD increased) (NP (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NN ET-1)))) (CC and) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ ET-1) (NNS mRNA))) (PP (IN in) (NP (NP (DT the) (JJ mesenteric) (NN artery)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 240) (NN %) (CC and) (CD 230) (NN %))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
9931093	5	(S1 (S (NP (JJ Little) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ ECE-1) (NN mRNA)) (CC and) (NP (JJ CNP) (NN mRNA)))))))) (. .)))
9931093	6	(S1 (S (NP (NN Doc_9931093_1011_1017_Chemical)) (VP (VBD decreased) (NP (NP (NN eNOS) (NN activity)) (CC and) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN eNOS) (NNS mRNA))) (PP (IN in) (NP (NP (DT the) (NN aorta)) (PRN (-LRB- -LRB-) (NP (NP (CD 48) (NN %)) (CC and) (NP (CD 55) (NN %))) (, ,) (RB respectively) (-RRB- -RRB-))))))) (. .)))
9931093	7	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9931093_1134_1143_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg.) (NN kg-1.) (NN d-1)) (-RRB- -RRB-))))) (VP (VBD prevented) (NP (JJ Doc_9931093_1173_1179_Chemical-induced) (NNP Doc_9931093_1188_1200_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
9931093	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9931093_1238_1244_Chemical)) (VP (MD may) (VP (VB increase) (NP (NN blood) (NN pressure)) (PP (CONJP (RB not) (RB only)) (PP (IN by) (S (VP (VBG increasing) (NP (JJ ET-1) (NN production))))) (CONJP (CC but) (RB also)) (PP (IN by) (S (VP (VBG decreasing) (NP (JJ Doc_9931093_1335_1337_Chemical) (NN synthesis)) (PP (IN in) (NP (DT the) (NN vasculature)))))))))))) (. .)))
10027919	0	(S1 (S (NP (JJ Doc_10027919_0_16_Chemical) (NNS suppresses)) (VP (VBP Doc_10027919_28_57_Disease) (PP (IN without) (S (VP (VBG inducing) (NP (NN Doc_10027919_75_92_Disease)) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_10027919_106_119_Disease))))))))) (. .)))
10027919	1	(S1 (S (NP (JJ Doc_10027919_133_143_Chemical) (NN therapy)) (VP (VP (VBZ suppresses) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (JJ parathyroid) (NN hormone)))) (PRN (-LRB- -LRB-) (NP (NNP PTH)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10027919_222_235_Disease)))))) (CC but) (VP (AUX has) (NP (NP (JJ several) (NNS drawbacks)) (, ,) (PP (VBG including) (NP (NP (JJ Doc_10027919_273_286_Disease) (NN and/or)) (VP (VBD marked) (NP (NNP Doc_10027919_301_329_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NNP Doc_10027919_349_370_Disease)))))))))))) (. .)))
10027919	2	(S1 (S (NP (NP (DT A) (JJ new) (JJ Doc_10027919_378_387_Chemical) (NN analogue)) (, ,) (NP (NP (NNP Doc_10027919_398_414_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10027919_416_419_Chemical)) (-RRB- -RRB-))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX have) (NP (JJ promising) (NNS characteristics)))))))) (. .)))
10027919	3	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10027919_526_529_Chemical))) (PP (IN on) (NP (NP (NP (JJ serum) (JJ PTH) (NNS levels)) (CC and) (NP (NN bone) (NN turnover))) (PP (IN in) (NP (NP (NNS states)) (PP (IN of) (NP (NP (JJ normal)) (CC or) (NP (NNP Doc_10027919_591_614_Disease)))))))))))))) (. .)))
10027919	4	(S1 (S (NP (CD Sixty) (NNS dogs)) (VP (AUX were) (ADJP (ADJP (ADJP (RB either) (JJ nephrectomized)) (PRN (-LRB- -LRB-) (NP (NNP Nx)) (, ,) (NP (NNP N) (SYM =) (CD 38)) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ sham-operated)) (PRN (-LRB- -LRB-) (NP (NNP Sham)) (, ,) (NP (NNP N) (SYM =) (CD 22)) (-RRB- -RRB-))))) (. .)))
10027919	5	(S1 (S (NP (DT The) (NNS animals)) (VP (VBD received) (NP (JJ supplemental) (NNP Doc_10027919_743_752_Chemical)) (S (VP (TO to) (VP (VB enhance) (NP (JJ PTH) (NN secretion)))))) (. .)))
10027919	6	(S1 (S (S (PP (NP (CD Fourteen) (NNS weeks)) (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (JJ Doc_10027919_813_822_Chemical) (NN supplementation))))) (, ,) (NP (NP (NN half)) (PP (IN of) (NP (DT the) (NNP Nx) (CC and) (NNP Sham) (NNS dogs)))) (VP (VBD received) (NP (NP (NNS doses)) (PP (IN of) (NP (NNP Doc_10027919_887_890_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD three) (NNS times)) (PP (IN per) (NP (NN week)))) (-RRB- -RRB-))))) (: ;) (S (NP (DT the) (JJ other) (NN half)) (VP (AUX were) (VP (VBN given) (NP (NN vehicle)) (PP (IN for) (NP (CD 60) (NNS weeks)))))) (. .)))
10027919	7	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (NP (DT the) (NN treatment) (NNS modalities)) (PP (IN for) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NNS animals)))))) (VP (AUX were) (VP (VBN crossed) (PRT (RP over)) (PP (IN for) (NP (DT an) (JJ additional) (CD eight) (NNS months))))) (. .)))
10027919	8	(S1 (S (S (NP (NP (JJ Biochemical) (CC and) (JJ hormonal) (NNS indices)) (PP (IN of) (NP (NP (NNP Doc_10027919_1110_1117_Chemical)) (CC and) (NP (NN bone) (NN metabolism))))) (VP (AUX were) (VP (VBN measured) (PP (IN throughout) (NP (DT the) (NN study)))))) (, ,) (CC and) (S (NP (NN bone) (NNS biopsies)) (VP (AUX were) (VP (AUX done) (PP (PP (IN at) (NP (NP (NN baseline)) (, ,) (NP (NP (NP (CD 60) (NNS weeks)) (PP (IN after) (NP (NNP Doc_10027919_1230_1233_Chemical)))) (CC or) (NP (NN vehicle) (NN treatment))))) (, ,) (CC and) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ crossover) (NN period))))))))) (. .)))
10027919	9	(S1 (S (PP (IN In) (NP (JJ Nx) (NNS dogs))) (, ,) (NP (NNP Doc_10027919_1317_1320_Chemical)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN serum) (NN PTH) (NNS levels)) (PP (ADVP (RB soon)) (IN after) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_10027919_1390_1409_Disease)))))) (. .)))
10027919	10	(S1 (S (PP (IN In) (NP (JJ long-standing) (NNP Doc_10027919_1428_1457_Disease))) (, ,) (NP (NP (NNP Doc_10027919_1459_1462_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.03) (NN microg/kg)) (-RRB- -RRB-))) (VP (VBD stabilized) (NP (NN serum) (NN PTH) (NNS levels)) (PP (IN during) (NP (DT the) (JJ first) (NNS months)))) (. .)))
10027919	11	(S1 (S (S (NP (NN Serum) (NN PTH) (NNS levels)) (VP (VBD rose) (ADVP (RB thereafter)))) (, ,) (CC but) (S (NP (DT the) (NN rise)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ pronounced)) (PP (VBN compared) (PP (IN with) (NP (NN baseline)))) (PP (IN than) (NP (NP (DT the) (NN rise)) (VP (VBN seen) (PP (IN in) (NP (JJ Nx) (NN control))))))))) (. .)))
10027919	12	(S1 (S (NP (DT These) (NNS effects)) (VP (AUX were) (VP (VBN accompanied) (PP (IN by) (NP (NP (NNS episodes)) (PP (IN of) (NP (NP (NNP Doc_10027919_1703_1716_Disease)) (CC and) (NP (NNP Doc_10027919_1721_1738_Disease)))))))) (. .)))
10027919	13	(S1 (S (PP (IN In) (NP (NP (NNS animals)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function))))) (, ,) (NP (NNP Doc_10027919_1779_1782_Chemical)) (VP (VBN induced) (NP (NP (DT a) (JJ transient) (NN decrease)) (PP (IN in) (NP (JJ serum) (JJ PTH) (NNS levels)))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.1) (NN microg/kg))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (RB not) (VP (VBN sustained) (PP (IN with) (NP (NP (VBG lowering)) (PP (IN of) (NP (DT the) (NNS doses)))))))))))) (. .)))
10027919	14	(S1 (S (PP (IN In) (NP (NNP Nx) (NNS dogs))) (, ,) (NP (NNP Doc_10027919_1924_1927_Chemical)) (VP (VP (VBD reversed) (NP (NP (JJ abnormal) (NN bone) (NN formation)) (PRN (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_10027919_1970_1983_Disease)) (CC and) (NP (NNP Doc_10027919_1988_1996_Disease)))) (, ,)))) (CC but) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB alter) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN bone) (NN turnover))))))) (. .)))
10027919	15	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_10027919_2071_2074_Chemical)) (VP (VBD improved) (NP (NN mineralization) (NN lag) (NN time)) (, ,) (PRN (-LRB- -LRB-) (INTJ (DT that) (AUX is)) (, ,) (NP (NP (DT the) (NN rate)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (NN osteoid)) (VP (VBZ mineralizes))))) (-RRB- -RRB-)) (PP (IN in) (NP (DT both) (NNP Nx) (CC and) (NNP Sham) (NNS dogs)))) (. .)))
10027919	16	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (RB even) (IN though) (S (NP (NNP Doc_10027919_2237_2240_Chemical)) (VP (AUX does) (RB not) (ADVP (RB completely)) (VP (VB prevent) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_10027919_2287_2300_Disease))) (PP (IN in) (NP (NP (JJ experimental) (NNS dogs)) (PP (IN with) (NP (NNP Doc_10027919_2327_2346_Disease)))))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NP (NN use)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_10027919_2386_2415_Disease))))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VP (AUX does) (RB not) (VP (VB induce) (NP (NNP Doc_10027919_2443_2460_Disease)))) (CC and) (PRN (, ,) (ADVP (RB therefore)) (, ,)) (VP (AUX does) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10027919_2507_2528_Disease)))))))))))))) (. .)))
10074612	0	(S1 (FRAG (NP (NP (NNP Doc_10074612_0_11_Disease)) (, ,) (NP (NNP Doc_10074612_13_24_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_30_38_Disease))) (PP (IN after) (NP (NP (JJ high-dose) (JJ intravenous) (NN Doc_10074612_67_85_Chemical)) (PP (IN in) (NP (DT a) (JJ monitored) (NN patient))))) (. .)))
10074612	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_10074612_130_141_Disease)) (, ,) (NP (NNP Doc_10074612_143_154_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_160_168_Disease))))) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_10074612_215_233_Chemical))))) (PP (IN in) (NP (NP (DT a) (JJ 73-year-old) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ electrocardiographic) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-)) (NN monitoring)) (PP (IN throughout) (NP (DT the) (NN episode))))))))) (. .)))
10074612	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_10074612_358_366_Disease) (NNP Doc_10074612_367_382_Disease))) (ADVP (NP (CD 9) (NNS years)) (RB earlier)))) (. .)))
10074612	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NP (DT a) (NN Doc_10074612_432_456_Disease)) (PP (IN with) (NP (NP (NNP Doc_10074612_462_472_Disease)) (, ,) (ADVP (RB rapidly) (JJ progressive)) (NP (NNP Doc_10074612_494_507_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_513_522_Disease)))) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (JJ mechanical) (NN ventilation)) (PP (IN in) (NP (DT the) (JJ intensive) (NN care) (NN unit)))))))))) (. .)))
10074612	4	(S1 (S (PP (IN After) (S (VP (VBG receiving) (NP (JJ advanced) (NN cardiopulmonary) (NN resuscitation))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD recovered) (NP (JJ cardiac) (NN rhythm))) (. .)))
10074612	5	(S1 (S (NP (DT The) (NNS ECG)) (VP (VBD showed) (NP (NP (DT a) (JJ junctional) (NN rhythm)) (PP (IN without) (NP (NN Doc_10074612_725_747_Disease))))) (. .)))
10074612	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ reviews) (NP (NP (DT the) (JJ current) (VBN proposed) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_10074612_803_815_Disease)))) (PP (IN after) (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NP (JJ intravenous) (NNP Doc_10074612_849_867_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10074612_869_873_Chemical)) (-RRB- -RRB-))))))) (. .)))
10074612	7	(S1 (S (NP (DT These) (NNS mechanisms)) (VP (AUX are) (RB not) (ADVP (RB well)) (VP (VBN understood) (SBAR (IN because) (S (, ,) (PP (IN in) (NP (JJS most) (NNS cases))) (, ,) (NP (DT the) (NNS patients)) (VP (AUX were) (RB not) (VP (VBN monitored) (PP (IN at) (NP (NP (DT the) (NN moment)) (PP (IN of) (NP (DT the) (NN event))))))))))) (. .)))
10074612	8	(S1 (S (S (NP (NP (JJ Rapid) (NN infusion)) (CC and) (NP (JJ underlying) (NN Doc_10074612_1031_1046_Disease))) (VP (AUX were) (NP (JJ important) (NN risk) (NNS factors)) (PP (IN in) (NP (NP (DT the) (NN case)) (VP (VBN reported) (ADVP (RB here))))))) (, ,) (CC and) (S (NP (DT the) (NNS authors)) (VP (VB discount) (NP (NNP Doc_10074612_1127_1149_Disease)) (PP (IN as) (NP (DT the) (JJ main) (NN mechanism))))) (. .)))
10091616	0	(S1 (FRAG (S (VP (VBG Worsening) (PP (IN of) (NP (NNP Doc_10091616_13_21_Chemical-induced) (NNP Doc_10091616_30_41_Disease))) (PP (IN by) (NP (UCP (NN motor) (CC and) (JJ mental)) (NNS tasks))))) (. .)))
10091616	1	(S1 (S (NP (NP (CD Ten) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NNP Doc_10091616_90_109_Disease)))))) (PP (IN with) (S (VP (VBG disabling) (NP (NNP Doc_10091616_125_135_Disease))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (NN study) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ mental) (PRN (-LRB- -LRB-) (NP (JJ mental) (NN calculation)) (-RRB- -RRB-)) (CC and) (NN motor) (PRN (-LRB- -LRB-) (S (NP (NP (NP (NN flexion/extension)) (PP (IN of) (NP (JJ right) (NNS fingers)))) (, ,) (NP (NP (NN flexion/extension)) (PP (IN of) (NP (NN left) (NNS fingers)))) (, ,) (NP (NP (NN flexion/extension)) (PP (IN of) (NP (DT the) (NN neck)))) (, ,)) (VP (VBG speaking) (ADVP (RB aloud)))) (-RRB- -RRB-)) (NNS tasks)))) (PP (IN on) (NP (NP (DT the) (VBG worsening)) (PP (IN of) (NP (JJ peak-dose) (NNP Doc_10091616_381_391_Disease))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT an) (JJ effective) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_10091616_448_459_Chemical)))))))))))))))) (. .)))
10091616	2	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NP (DT the) (NN score)) (PP (IN at) (NP (NP (NN rest)) (PRN (-LRB- -LRB-) (NP (CD 1.3+/-0.3)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (JJ significant) (NN aggravation)) (PP (IN of) (NP (DT the) (NNP Doc_10091616_539_549_Disease) (NN score)))) (VP (AUX was) (VP (VBN observed) (PP (IN during) (S (VP (VP (VBG speaking) (NP (NP (RB aloud)) (PRN (-LRB- -LRB-) (NP (CD 5.2+/-1.1)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)) (, ,) (NP (NP (NNS movements)) (PP (IN of) (NP (NN right)))) (PRN (-LRB- -LRB-) (NP (CD 4.5+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)))) (CC and) (VP (VBD left) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 3.7+/-0.8)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)) (NNS fingers)) (, ,) (NP (NP (NP (NNS movements)) (PP (IN of) (NP (DT the) (NN neck)))) (PRN (-LRB- -LRB-) (NP (CD 5.1+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ mental) (NN calculation)) (PRN (-LRB- -LRB-) (NP (CD 3.1+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)))))))))) (. .)))
10091616	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN activation) (NNS tasks)) (PP (JJ such) (IN as) (`` ``) (S (VP (VBG speaking) (ADVP (RB aloud)))) ('' ''))) (VP (MD could) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (JJ objective) (NN assessment)) (PP (IN of) (NP (JJ Doc_10091616_887_897_Disease) (NN severity))))))))))) (. .)))
10193809	0	(S1 (NP (NP (NN Urine) (JJ N-acetyl-beta-D-glucosaminidase--a) (NN marker)) (PP (IN of) (NP (JJ tubular) (NN damage))) (. ?)))
10193809	1	(S1 (S (PP (IN Although) (NP (NP (DT an) (NN indicator)) (PP (IN of) (NP (NNP Doc_10193809_104_129_Disease))))) (, ,) (NP (DT an) (JJ increased) (NN urinary) (NN N-acetyl-beta-D-glucosaminidase) (-LRB- -LRB-) (NN NAG) (-RRB- -RRB-) (NN activity)) (VP (MD might) (VP (VB reflect) (NP (NP (JJ increased) (JJ lysosomal) (NN activity)) (PP (IN in) (NP (JJ renal) (JJ tubular) (NNS cells)))))) (. .)))
10193809	2	(S1 (S (NP (NP (NNP Doc_10193809_275_300_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193809_302_305_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NNP Sprague) (NNP Dawley) (NNS rats) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_10193809_357_368_Disease))))))))) (. .)))
10193809	3	(S1 (S (NP (NP (JJ Total) (NN protein)) (, ,) (NP (NN albumin)) (, ,) (NP (NN NAG) (NN activity)) (CC and) (NP (NN protein) (JJ electrophoretic) (NN pattern))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ daily) (NN urine) (NNS samples)) (PP (IN for) (NP (CD 33) (NNS days))))))) (. .)))
10193809	4	(S1 (S (NP (NP (DT The) (JJ morphological) (NN appearance)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (VP (VBN examined) (PP (IN on) (NP (NP (NNS days) (CD three) (, ,) (CD four) (, ,) (CD six) (, ,) (CD eight) (CC and) (CD thirty) (CD three)) (CC and) (NP (NP (DT the) (NN NAG) (NN isoenzyme) (NNS patterns)) (PP (IN on) (NP (NNS days) (CD zero) (, ,) (CD four) (, ,) (CD eight) (CC and) (CD thirty) (CD three)))))))) (. .)))
10193809	5	(S1 (S (PP (VBG Following) (NP (NP (JJ intravenous) (JJ Doc_10193809_705_708_Chemical) (NN urine) (NN volume)) (CC and) (NP (NN urine)))) (NP (NN NAG) (NN activity)) (VP (VP (VBD increased) (ADVP (RB significantly)) (PP (IN by) (NP (NN day) (CD two)))) (, ,) (CC but) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN by) (NP (NN day) (CD four))))) (. .)))
10193809	6	(S1 (S (PP (IN After) (NP (NN day) (CD four))) (NP (DT all) (VBN treated) (NNS animals)) (VP (VBD exhibited) (NP (NP (DT a) (JJ marked) (NN rise)) (PP (IN in) (NP (NP (NN urine) (NN albumin)) (, ,) (NP (JJ total) (NN protein) (NN excretion)) (CC and) (NP (NN NAG) (NN activity)))))) (. .)))
10193809	7	(S1 (S (NP (NNP Electrophoresis)) (VP (VBD showed) (NP (NP (DT a) (JJ generalised) (NN increase)) (PP (IN in) (NP (NP (NN middle)) (CC and) (NP (JJ high) (JJ molecular) (NN weight) (NN urine) (NNS proteins)))) (PP (IN from) (NP (NN day) (CD four) (NNS onwards))))) (. .)))
10193809	8	(S1 (S (NP (NN Protein) (NNS droplets)) (ADVP (RB first)) (VP (VBD appeared) (ADJP (JJ prominent)) (PP (IN in) (NP (NP (JJ tubular) (NNS cells)) (PP (IN on) (NP (NN day) (CD four)))))) (. .)))
10193809	9	(S1 (S (NP (NP (JJ Peak) (NN urine) (NN NAG) (NN activity)) (CC and) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN NAG) (NN isoenzyme) (NN pattern))))) (VP (VBD coincided) (PP (IN with) (NP (PDT both) (NP (DT the) (JJ peak) (NN Doc_10193809_1219_1230_Disease)) (CC and) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (JJ intracellular) (NN protein)) (CC and) (NP (NP (NN NAG) (NNS droplets)) (PRN (-LRB- -LRB-) (NP (NN day) (CD six) (NNS onwards)) (-RRB- -RRB-))))))))) (. .)))
10193809	10	(S1 (S (NP (DT This) (NN animal) (NN model)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ lysosomal) (NN turnover)) (CC and) (ADVP (RB hence)) (NP (NN urine) (NN NAG) (NN activity)) (, ,)))) (VP (VBZ occurs) (SBAR (WHADVP (WRB when)) (S (NP (JJ increased) (NN protein)) (VP (AUX is) (VP (VBN presented) (PP (TO to) (NP (DT the) (JJ tubular) (NNS cells))))))))))) (. .)))
10193809	11	(S1 (S (NP (NN Urine) (NN NAG) (NN activity)) (VP (VP (AUX is) (ADVP (RB thus)) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (JJ altered) (NN function))) (PP (IN in) (NP (DT the) (JJ renal) (NNS tubules))))) (CC and) (RB not) (ADVP (RB simply)) (NP (NP (DT an) (NN indicator)) (PP (IN of) (NP (NN damage))))) (. .)))
10225068	0	(S1 (NP (NP (NP (NN Doc_10225068_0_21_Disease)) (PP (IN after) (NP (NP (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_66_76_Chemical)))))) (: :) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (NNP Doc_10225068_103_124_Disease))))) (VP (VBN reported) (PP (TO to) (NP (DT the) (NNP Swedish) (NNP Pharmaceutical) (NNP Insurance) (NN 1993-1997))))) (. .)))
10225068	1	(S1 (S (NP (NP (CD Six) (NNS cases)) (PP (IN of) (NP (NNP Doc_10225068_198_219_Disease))) (PP (IN with) (NP (VBG varying) (NN severity)))) (VP (AUX were) (VP (VBN reported) (PP (TO to) (NP (DT the) (NNP Swedish) (NNP Pharmaceutical) (NNP Insurance))) (PP (IN during) (NP (DT the) (NN period) (CD 1993-1997))))) (. .)))
10225068	2	(S1 (S (NP (DT All)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (JJ spinal) (NNS anaesthesia)) (VP (VBG using) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_389_399_Chemical))))))) (. .)))
10225068	3	(S1 (S (S (NP (CD Five) (NNS cases)) (VP (AUX had) (NP (JJ single-shot) (NN spinal) (NN anaesthesia)))) (CC and) (S (NP (PRP one)) (VP (AUX had) (NP (NP (DT a) (NN repeat) (NN spinal) (NN anaesthetic)) (ADJP (JJ due) (PP (TO to) (NP (JJ inadequate) (NN block))))))) (. .)))
10225068	4	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (JJ Doc_10225068_538_548_Chemical) (VBN administered)))) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 60) (TO to) (CD 120)) (NNS mg)))) (. .)))
10225068	5	(S1 (S (NP (NP (CD Three)) (PP (IN of) (NP (DT the) (NNS cases)))) (VP (AUX were) (ADVP (RBS most) (JJ likely)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ direct) (NN Doc_10225068_641_654_Disease)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_672_682_Chemical))))))) (. .)))
10225068	6	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (CD 3) (NNS cases))) (, ,) (S (NP (JJ direct) (NN Doc_10225068_713_726_Disease)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ probable)))) (, ,) (CC but) (S (ADVP (RB unfortunately)) (NP (NN radiological) (NNS investigations)) (VP (AUX were) (RB not) (VP (AUX done) (S (VP (TO to) (ADVP (RB definitely)) (VP (VB exclude) (NP (DT a) (JJ compressive) (NN aetiology)))))))) (. .)))
10225068	7	(S1 (S (NP (DT All) (NNS cases)) (VP (VBD sustained) (NP (JJ permanent) (NN Doc_10225068_883_904_Disease))) (. .)))
10225068	8	(S1 (S (NP (PRP We)) (VP (VBP recommend) (SBAR (IN that) (S (NP (JJ hyperbaric) (NNP Doc_10225068_935_945_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN administered) (PP (PP (IN in) (NP (NP (NNS concentrations)) (ADJP (ADJP (RB not) (JJR greater)) (PP (IN than) (NP (CD 2) (NN %)))))) (CC and) (PP (IN at) (NP (NP (DT a) (JJ total) (NN dose)) (VP (ADVP (RB preferably) (RB not)) (VBG exceeding) (NP (CD 60) (NN mg)))))))))))) (. .)))
10328196	0	(S1 (NP (NP (NP (JJ Systemic) (JJ Doc_10328196_9_17_Disease) (JJ following) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_10328196_46_55_Chemical)) (PRN (-LRB- -LRB-) (ADVP (RB formerly)) (NP (NNP Doc_10328196_66_75_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNP Doc_10328196_81_90_Disease)))) (: :) (NP (NP (NN association)) (PP (IN of) (NP (NNP Doc_10328196_107_130_Disease))) (PP (IN with) (NP (NP (NNS apoptosis)) (PP (IN of) (NP (JJ lesional) (NNS lymphocytes)))))) (. .)))
10328196	1	(S1 (S (NP (NP (NNP Doc_10328196_183_192_Chemical)) (PRN (-LRB- -LRB-) (NP (ADVP (RB formerly)) (NNP Doc_10328196_203_212_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ immunosuppressive) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ interferes) (PP (IN with) (NP (JJ T-cell) (NN activation)))))))) (. .)))
10328196	2	(S1 (S (SBAR (IN After) (S (NP (NP (CD 2) (NNS individuals)) (PP (IN with) (NP (NNP Doc_10328196_309_318_Disease)))) (VP (VBD developed) (NP (DT a) (NNP Doc_10328196_331_354_Disease) (VBG following) (NN treatment)) (PP (IN with) (NP (NP (JJ oral) (JJ Doc_10328196_385_394_Chemical) (JJ lesional) (NN skin) (NNS cells)) (CC and) (NP (VBN activated) (JJ peripheral) (NN blood) (NNS cells))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis))))))) (. .)))
10328196	3	(S1 (S (NP (NP (DT A) (JJ keratome) (NN skin) (NN specimen)) (PP (IN from) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (JJ Doc_10328196_553_562_Chemical-induced) (NNP Doc_10328196_571_594_Disease)))))) (VP (AUX had) (NP (NP (DT a) (JJ 2.3-fold) (NN increase)) (PP (IN in) (NP (NP (NN percentage)) (PP (IN of) (NP (NP (JJ apoptotic) (NNS cells)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 48) (NN %))) (-RRB- -RRB-))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT an) (JJ unaffected) (JJ Doc_10328196_689_698_Chemical-treated) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_10328196_720_729_Disease)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-)))))))) (. .)))
10328196	4	(S1 (S (NP (NP (VBN Activated) (JJ peripheral) (NN blood) (NN T) (NNS cells)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10328196_791_800_Disease)))))) (VP (VBD tended) (S (VP (TO to) (VP (VB exhibit) (NP (NP (JJR greater) (JJ spontaneous) (CC or) (JJ Doc_10328196_842_855_Chemical-induced) (NN apoptosis)) (SBAR (IN than) (S (VP (AUX did) (NP (JJ normal) (NN T) (NNS cells)))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_10328196_931_940_Chemical))))))))) (. .)))
10328196	5	(S1 (S (NP (NP (JJ Severe) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_10328196_981_990_Chemical)))) (VP (VBP include) (NP (NP (NNP Doc_10328196_999_1004_Disease)) (, ,) (NP (NNP Doc_10328196_1006_1012_Disease)) (, ,) (CC and) (NP (NNP Doc_10328196_1018_1041_Disease)))) (. .)))
10328196	6	(S1 (S (NP (DT These) (NNS symptoms)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ drug-induced) (NNS apoptosis)) (PP (IN of) (NP (NP (JJ lesional) (NNS leukocytes)) (, ,) (NP (ADJP (RB especially) (VBN activated)) (NN T) (NNS lymphocytes)) (, ,) (CC and) (ADVP (RB possibly)) (NP (NP (NN release)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))))))))))) (. .)))
10328196	7	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_10328196_1239_1248_Disease)))) (VP (MD may) (VP (VB develop) (NP (NN Doc_10328196_1261_1275_Disease)) (PP (IN from) (NP (JJ various) (JJ systemic) (NNS therapies))))))) (, ,) (NP (JJ clinical) (NN monitoring)) (VP (AUX is) (ADJP (JJ advisable)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10328196_1360_1381_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN treated) (PP (IN with) (NP (JJ immune) (NNS modulators)))))))))) (. .)))
10354657	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_10354657_10_17_Chemical) (NN maintenance) (NN therapy))) (PP (IN on) (NP (NP (NN thyroid)) (CC and) (NP (NN parathyroid) (NN function)))) (. .)))
10354657	1	(S1 (S (VP (TO To) (VP (VB assess) (NP (NP (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_10354657_116_123_Chemical) (NN maintenance) (NN therapy))) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN thyroid) (, ,) (NN parathyroid) (CC and) (NN ion) (NNS alterations))))))))) (. .)))
10354657	2	(S1 (S (NP (DT These)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ Doc_10354657_259_266_Chemical) (NN therapy)) (, ,) (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (CC and) (NP (NP (NN family) (NN history)) (PRN (-LRB- -LRB-) (SBAR (IN whether) (CC or) (RB not) (S (NP (DT the) (NN patient)) (VP (AUX had) (NP (DT a) (JJ first-degree) (NN relative)) (PP (IN with) (NP (NNP Doc_10354657_366_381_Disease)))))) (-RRB- -RRB-))))))))))) (. .)))
10354657	3	(S1 (NP (JJ Prospective) (NN study) (. .)))
10354657	4	(S1 (NP (NP (JJ Affective) (NNS Disorders)) (NP (NP (NNP Clinic)) (PP (IN at) (NP (NP (NP (NNP St.) (NNP Mary) (POS 's)) (NNP Hospital)) (, ,) (NP (NNP Montreal))))) (. .)))
10354657	5	(S1 (NP (NP (NP (QP (CD One) (CD hundred) (CC and) (CD one)) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 28) (NNS men)) (CC and) (NP (CD 73) (NNS women))) (-RRB- -RRB-))) (PP (IN with) (S (NP (NNP Doc_10354657_547_563_Disease)) (VP (VBG receiving) (NP (NP (JJ Doc_10354657_574_581_Chemical) (NN maintenance) (NN therapy)) (VP (VBG ranging) (PP (IN from) (NP (CD 1) (NN year) (POS 's))))) (PP (TO to) (NP (NP (CD 32) (NNS years) (POS ')) (NN duration)))))) (. .)))
10354657	6	(S1 (S (NP (DT The) (NN control) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (CD 82) (NNS patients))) (PP (IN with) (NP (NP (DT no) (JJ Doc_10354657_698_709_Disease) (CC or) (JJ endocrinological) (NNS diagnoses)) (PP (IN from) (NP (NP (DT the) (NN hospital) (POS 's)) (JJ out-patient) (NNS clinics)))))) (. .)))
10354657	7	(S1 (S (S (NP (NN OUTCOME)) (VP (VBZ MEASURES))) (: :) (S (NP (NP (NN Laboratory) (NNS analyses)) (PP (IN of) (NP (NNP Doc_10354657_822_829_Chemical) (, ,) (NNP Doc_10354657_831_840_Chemical) (CC and) (JJ thyroid-stimulating) (NN hormone) (NNS levels)))) (VP (VBD performed) (PP (IN before) (S (VP (VP (VBG beginning) (NP (JJ Doc_10354657_907_914_Chemical) (NN therapy))) (CC and) (VP (PP (IN at) (NP (JJ biannual) (NN follow-up))))))))) (. .)))
10354657	8	(S1 (S (NP (NN Doc_10354657_959_973_Disease)) (VP (VBD developed) (PP (IN in) (NP (CD 40) (NNS patients))) (, ,) (S (VP (VBG excluding) (NP (NP (CD 8) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ Doc_10354657_1030_1041_Disease)) (PP (IN at) (NP (NN baseline)))))))))) (. .)))
10354657	9	(S1 (S (NP (NP (DT All) (NNS patients)) (VP (AUXG having) (NP (NP (JJ first-degree) (NNS relatives)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_10354657_1110_1125_Disease))))))) (VP (AUX had) (NP (NP (JJ accelerated) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_10354657_1151_1165_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.7) (NNS years)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (JJ Doc_10354657_1192_1199_Chemical) (NN therapy)))))) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS patients)) (PP (IN without) (NP (NP (DT a) (NN family) (NN history)) (PRN (-LRB- -LRB-) (NP (NP (CD 8.6) (NNS years)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (JJ Doc_10354657_1283_1290_Chemical) (NN therapy)))))) (-RRB- -RRB-)))))))) (. .)))
10354657	10	(S1 (S (NP (NP (NNS Women)) (PP (IN over) (NP (NP (CD 60) (NNS years)) (PP (IN of) (NP (NN age)))))) (VP (AUX were) (VP (ADVP (RBR more) (RB often)) (JJ affected) (PP (IN by) (NP (NNP Doc_10354657_1356_1370_Disease))) (PP (IN than) (NP (NP (NNS women)) (PP (IN under) (NP (NP (NP (CD 60) (NNS years)) (PP (IN of) (NP (NN age)))) (PRN (-LRB- -LRB-) (NP (NP (CD 34.6) (NN %)) (CC versus) (NP (CD 31.9) (NN %))) (-RRB- -RRB-)))))))) (. .)))
10354657	11	(S1 (S (NP (NP (JJ Doc_10354657_1426_1435_Chemical) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ Doc_10354657_1458_1465_Chemical) (NN treatment)))))) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN from) (NP (JJ baseline) (NNS levels)))) (. .)))
10354657	12	(S1 (S (PP (IN After) (NP (JJ Doc_10354657_1519_1526_Chemical) (NN treatment))) (, ,) (NP (JJ Doc_10354657_1538_1545_Chemical) (NNS levels)) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT either) (NX (NX (NN baseline) (NNS levels)) (CC or) (NX (NN control) (NNS levels))))))) (. .)))
10354657	13	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ Doc_10354657_1618_1625_Chemical) (NN treatment)) (VP (VBN counteracted) (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NN Doc_10354657_1672_1679_Chemical) (NNS levels)) (VP (VBN associated) (PP (IN with) (NP (NN aging))))))) (. .)))
10354657	14	(S1 (S (NP (NNP Familial) (NNP Doc_10354657_1732_1747_Disease)) (VP (AUX is) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NP (NNP Doc_10354657_1769_1783_Disease)) (CC and) (NP (NNP Doc_10354657_1788_1801_Disease)))) (PP (IN during) (NP (JJ Doc_10354657_1809_1816_Chemical) (NN therapy))))) (. .)))
10411803	0	(S1 (S (NP (JJ Severe) (JJ immune) (NN Doc_10411803_14_30_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prophylactic) (NN use)) (PP (IN of) (NP (NNP Doc_10411803_67_76_Chemical))) (PP (IN in) (NP (NP (NN obstetric)) (CC and) (NP (JJ gynecologic) (NNS procedures))))))) (. .)))
10411803	1	(S1 (S (NP (NP (NN Second-) (CC and) (NN third-generation) (NN Doc_10411803_147_161_Chemical)) (, ,) (NP (RB especially) (NNP Doc_10411803_174_183_Chemical)) (, ,)) (VP (AUX are) (ADVP (RB increasingly)) (VP (VBN associated) (PP (IN with) (NP (JJ severe) (, ,) (ADJP (RB sometimes) (JJ fatal)) (JJ immune) (NN Doc_10411803_249_265_Disease))))) (. .)))
10411803	2	(S1 (S (NP (PRP We)) (VP (VBD noticed) (SBAR (IN that) (S (NP (NP (CD 10)) (PP (IN of) (NP (NP (PRP$ our) (CD 35) (NNS cases)) (PP (IN of) (NP (NNP Doc_10411803_305_314_Chemical-induced) (NNP Doc_10411803_323_340_Disease)))))) (VP (AUX were) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (JJ Doc_10411803_375_384_Chemical) (NN prophylactically)) (PP (IN for) (NP (ADJP (JJ obstetric) (CC and) (JJ gynecologic)) (NNS procedures))))))))))))) (. .)))
10411803	3	(S1 (S (NP (NP (CD Eight)) (PP (IN of) (NP (NP (DT these) (NNS cases)) (PP (IN of) (NP (JJ severe) (JJ immune) (NN Doc_10411803_482_498_Disease)))))) (VP (AUX are) (VP (VBN described))) (. .)))
10414674	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (PP (IN on) (NP (NP (NN hemostasis)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10414674_79_113_Disease))))))) (. .)))
10414674	1	(S1 (S (NP (JJ Platelet) (NN function)) (VP (AUX is) (VP (VBN impaired) (PP (IN by) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAIDs)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ prominent) (JJ anti-inflammatory) (NNS properties))))) (. .)))
10414674	2	(S1 (S (NP (NP (PRP$ Their) (NN safety)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ intracranial) (NN surgery)))))) (VP (AUX is) (PP (IN under) (NP (NN debate)))) (. .)))
10414674	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Doc_10414674_327_361_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_363_366_Disease)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (ADVP (RB either)) (NP (NP (NNP Doc_10414674_402_412_Chemical)) (, ,) (NP (NP (CD 100) (NN mg)) (, ,) (NP (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day))) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_441_451_Chemical) (NN group)) (, ,) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-))) (CC or) (NP (DT a) (JJ weak) (NN NSAID))) (, ,) (NP (NNP Doc_10414674_483_496_Chemical)) (, ,) (NP (CD 1) (NNP g)) (, ,) (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_522_535_Chemical) (NN group)) (, ,) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)) (S (VP (VBG starting) (PP (ADVP (RB immediately)) (IN after) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10414674_594_604_Disease) (NNP Doc_10414674_605_608_Disease))))))))) (. .)))
10414674	4	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN continued) (PP (IN for) (NP (NP (CD 3) (NNS days)) (ADVP (RB postoperatively)))))) (. .)))
10414674	5	(S1 (S (NP (NN Test) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN taken) (PP (IN before) (NP (NP (NN treatment) (CC and) (NN surgery)) (CONJP (RB as) (RB well) (IN as)))) (PP (IN on) (NP (DT the) (JJ first) (, ,) (ADJP (JJ third) (, ,) (CC and) (JJ fifth)) (JJ postoperative) (NNS mornings))))) (. .)))
10414674	6	(S1 (S (NP (NP (NNP Maximal) (NNP Doc_10414674_795_815_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (CD 6) (NN microM)) (PP (IN of) (NP (NNP Doc_10414674_839_860_Chemical))))))) (VP (VBD decreased) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10414674_895_905_Chemical)))))) (. .)))
10414674	7	(S1 (S (NP (NN Aggregation)) (VP (AUX was) (ADJP (ADJP (ADJP (ADJP (JJR lower)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .05)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP Doc_10414674_946_956_Chemical) (NN group)))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP Doc_10414674_975_988_Chemical) (NN group))))) (PP (RB just) (PP (IN before) (NP (NN surgery))) (CC and) (PP (IN on) (NP (DT the) (JJ third) (JJ postoperative) (NN day))))) (. .)))
10414674	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ maximal) (NNP Doc_10414674_1072_1092_Disease)) (VP (VBD increased) (PP (IN in) (NP (NP (DT the) (JJ Doc_10414674_1110_1123_Chemical) (NN group)) (PP (IN on) (NP (DT the) (JJ third) (JJ postoperative) (NN day))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ pretreatment) (NN Doc_10414674_1195_1215_Disease) (NNS results)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .05))) (-RRB- -RRB-)))))))) (. .)))
10414674	9	(S1 (S (NP (NP (CD One) (NN patient)) (PP (IN in) (NP (DT the) (NNP Doc_10414674_1254_1264_Chemical) (NN group)))) (VP (VBD developed) (NP (DT a) (JJ postoperative) (NN intracranial) (NN Doc_10414674_1310_1318_Disease))) (. .)))
10414674	10	(S1 (S (NP (NP (NN Coagulation)) (PRN (-LRB- -LRB-) (NP (NP (NN prothrombin) (NN time) (NN -LSB-PT) (NN -RSB-)) (, ,) (NP (VBN activated) (JJ partial) (NN thromboplastin) (NN time) (JJ -LSB-APPT) (NN -RSB-)) (, ,) (NP (NN fibrinogen) (NN concentration)) (, ,) (CC and) (NP (JJ antithrombin) (NNP III) (NN -LSB-AT) (NNP III) (NN -RSB-))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ comparable)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (. .)))
10414674	11	(S1 (S (S (ADJP (ADJP (JJ Doc_10414674_1498_1508_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_10414674_1517_1530_Chemical)))) (VP (VBN impaired) (NP (NN platelet) (NN function)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10414674_1575_1578_Disease)))))) (. .)))
10414674	12	(S1 (S (SBAR (IN If) (S (NP (NNP Doc_10414674_1583_1593_Chemical)) (VP (AUX is) (VP (VBN used) (PP (IN before) (NP (NN surgery))) (PP (IN on) (NP (JJ cerebral) (NN Doc_10414674_1629_1645_Disease))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB pose) (NP (NP (DT an) (JJ additional) (NN risk) (NN factor)) (PP (IN for) (NP (NN Doc_10414674_1689_1699_Disease)))))) (. .)))
10523326	0	(S1 (NP (NP (JJ Doc_10523326_0_12_Chemical) (NN synthase) (NN expression)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_10523326_50_54_Chemical-induced) (NNP Doc_10523326_63_75_Disease))))) (. .)))
10523326	1	(S1 (S (NP (PRP We)) (ADVP (RB recently)) (VP (VP (VBD showed) (NP (NP (JJ elevated) (JJ reactive) (JJ Doc_10523326_114_120_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-)))) (, ,) (VP (VBD reduced) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NP (JJ Doc_10523326_165_167_Chemical) (NNS metabolites)) (PRN (-LRB- -LRB-) (NP (NNP NOx)) (-RRB- -RRB-)))))) (, ,) (CC and) (VP (VBD increased) (NP (JJ Doc_10523326_201_203_Chemical) (NN sequestration)) (PP (IN as) (NP (NNP Doc_10523326_221_234_Chemical))) (PP (IN in) (NP (NP (JJ various) (NNS tissues)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_10523326_267_271_Chemical-induced) (NNP Doc_10523326_280_292_Disease))))))))) (. .)))
10523326	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB discern) (SBAR (IN whether) (S (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (JJ urinary) (NN NOx))) (PP (IN in) (NP (NNP Doc_10523326_369_373_Chemical-induced) (NNP Doc_10523326_382_394_Disease)))) (VP (AUX is) (, ,) (PP (IN in) (NP (NN part))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (JJ depressed) (JJ Doc_10523326_425_427_Chemical) (NN synthase) (PRN (-LRB- -LRB-) (NP (NNP NOS)) (-RRB- -RRB-)) (NN expression)))))))))))) (. .)))
10523326	3	(S1 (S (NP (JJ Male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (DT a) (JJ Doc_10523326_508_512_Chemical-treated) (NN group)) (PRN (-LRB- -LRB-) (VP (VBN given) (NP (NP (NNP Doc_10523326_534_546_Chemical)) (, ,) (NP (CD 100) (CD ppm)) (, ,)) (PP (IN in) (NP (NP (NN drinking) (NN water)) (CC and) (NP (JJ regular) (NN rat) (NN chow))))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN group)) (VP (VBN given) (NP (ADJP (JJ Doc_10523326_612_616_Chemical) (CC and) (JJ Doc_10523326_621_630_Chemical-fortified)) (NN chow)))) (, ,) (CC or) (NP (NP (DT a) (JJ normal) (NN control) (NN group)) (PP (VBN given) (NP (NP (DT either) (JJ regular) (NN food)) (CC and) (NP (NP (NP (NN water)) (CC or) (NP (JJ Doc_10523326_712_721_Chemical-fortified) (NN food))) (PP (IN for) (NP (CD 12) (NNS weeks))))))))))) (. .)))
10523326	4	(S1 (S (NP (NP (JJ Tail) (NN blood) (NN pressure)) (, ,) (NP (JJ urinary) (NN NOx) (NN excretion)) (, ,) (NP (NP (NN plasma)) (SBAR (S (NP (NP (NNP Doc_10523326_802_817_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10523326_819_822_Chemical)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (ADJP (JJ endothelial) (CC and) (JJ inducible)) (NNS NOS)) (PRN (-LRB- -LRB-) (NP (NP (NNS eNOS)) (CC and) (NP (NNS iNOS))) (-RRB- -RRB-)))) (VP (VBZ isotypes) (PP (IN in) (NP (DT the) (NN aorta))))))) (CC and) (NP (NN kidney))) (VP (AUX were) (VP (VBN measured))) (. .)))
10523326	5	(S1 (S (NP (DT The) (JJ Doc_10523326_927_931_Chemical-treated) (NN group)) (VP (VBD exhibited) (NP (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN plasma) (JJ Doc_10523326_992_995_Chemical) (NN concentration))))) (, ,) (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (JJ urinary) (NN NOx) (NN excretion)))) (, ,) (CC and) (NP (NP (DT a) (JJ paradoxical) (NN rise)) (PP (IN in) (NP (NP (JJ vascular) (CC and) (JJ renal) (NN tissue) (NNS eNOS)) (CC and) (NP (NN iNOS) (NN expression))))))) (. .)))
10523326	6	(S1 (S (NP (JJ Doc_10523326_1122_1131_Chemical) (NN supplementation)) (VP (VP (VBD ameliorated) (NP (NNP Doc_10523326_1160_1172_Disease))) (, ,) (VP (VBD lowered) (NP (NN plasma) (JJ Doc_10523326_1189_1192_Chemical) (NN concentration))) (, ,) (CC and) (VP (VBD raised) (NP (JJ urinary) (NN NOx) (NN excretion)) (SBAR (IN while) (S (VP (ADVP (RB significantly)) (VBG lowering) (NP (NP (NN vascular)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ renal) (, ,) (NN tissue) (NNS eNOS) (CC and) (NNS iNOS) (NN expression)))))))) (. .)))
10523326	7	(S1 (S (NP (JJ Doc_10523326_1328_1337_Chemical) (NN supplementation)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT either) (NN blood) (NN pressure)) (, ,) (NP (NN plasma) (NN Doc_10523326_1401_1404_Chemical)) (, ,) (CC or) (NP (NN NOS) (NN expression)))) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (. .)))
10523326	8	(S1 (S (NP (DT The) (NN study)) (ADVP (RB also)) (VP (VBD revealed) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NNP NOS) (JJ enzymatic) (NN activity))) (PP (IN by) (NP (NNP Doc_10523326_1522_1526_Chemical))) (PP (IN in) (NP (JJ cell-free) (NNS preparations))))) (. .)))
10523326	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNP Doc_10523326_1569_1573_Chemical-induced) (NNP Doc_10523326_1582_1594_Disease)) (PP (IN in) (NP (DT this) (NN model)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ compensatory) (NN upregulation)) (PP (IN of) (NP (NP (ADJP (JJ renal) (CC and) (JJ vascular)) (NNS eNOS)) (CC and) (NP (NN iNOS) (NN expression)))))))) (. .)))
10523326	10	(S1 (S (NP (DT This)) (VP (AUX is) (, ,) (PP (IN in) (NP (NN part))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ ROS-mediated) (JJ Doc_10523326_1743_1745_Chemical) (NN inactivation)) (, ,) (NP (NP (JJ Doc_10523326_1760_1764_Chemical-associated) (NN inhibition)) (PP (IN of) (NP (NN NOS) (NN activity)))) (, ,) (CC and) (NP (NP (RB perhaps) (JJ stimulatory) (NNS actions)) (PP (IN of) (NP (NP (VBN increased) (JJ shear) (NN stress)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10523326_1878_1890_Disease))))))))))) (. .)))
10524660	0	(S1 (S (NP (NN Doc_10524660_0_19_Chemical)) (VP (VBZ induces) (NP (NP (NNS attacks)) (PP (IN of) (NP (NNP Doc_10524660_39_60_Disease)))) (PP (IN in) (NP (NP (NNS sufferers)) (PP (IN of) (NP (NNP Doc_10524660_77_95_Disease)))))) (. .)))
10524660	1	(S1 (S (NP (NP (NNP Doc_10524660_97_115_Disease)) (CC and) (NP (NNP Doc_10524660_120_141_Disease))) (VP (AUX have) (NP (DT the) (JJ same) (JJ Doc_10524660_156_160_Disease) (NN phase)) (, ,) (S (ADVP (RB thus)) (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NNP Doc_10524660_189_207_Disease)) (CC and) (NP (NNP Doc_10524660_212_233_Disease))) (VP (NN share) (NP (NP (DT a) (JJ common) (NN pathway)) (PP (IN of) (NP (NN nociception)))))))))) (. .)))
10524660	2	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (, ,) (NP (VBG increasing) (NN evidence)) (VP (AUX has) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN messenger) (NN molecule) (NNP Doc_10524660_352_364_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10524660_366_368_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ Doc_10524660_385_389_Disease) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_10524660_404_425_Disease))))))))))) (. .)))
10524660	3	(S1 (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB clarify) (SBAR (S (IN whether) (NP (DT the) (JJ same)) (VP (AUX is) (ADJP (JJ true)) (PP (IN for) (NP (NNP Doc_10524660_476_494_Disease))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ present) (NN study)) (SBAR (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ Doc_10524660_533_541_Disease) (NN response)) (PP (TO to) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_10524660_578_597_Chemical) (-LRB- -LRB-) (NNP Doc_10524660_599_602_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (NN microg/kg/min)) (PP (IN for) (NP (CD 20) (NN min)))) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (CD 12) (NNS sufferers)) (PP (IN of) (NP (NNP Doc_10524660_654_672_Disease))))))))))) (. .))))))))
10524660	4	(S1 (S (NP (DT The) (JJ specific) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB elucidate) (SBAR (IN whether) (S (NP (NP (DT an) (NN aura) (NN and/or) (DT an) (NN attack)) (PP (IN of) (NP (NNP Doc_10524660_744_765_Disease)))) (VP (MD could) (VP (AUX be) (VP (VBN induced)))))))))) (. .)))
10524660	5	(S1 (S (NP (CD Fourteen) (JJ healthy) (NNS subjects)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
10524660	6	(S1 (S (NP (NN Aura) (NNS symptoms)) (VP (AUX were) (RB not) (VP (VBN elicited) (PP (IN in) (NP (DT any) (NN subject))))) (. .)))
10524660	7	(S1 (S (NP (NN Doc_10524660_878_886_Disease)) (VP (AUX was) (ADJP (RBR more) (JJ severe)) (PP (IN in) (NP (NNP Doc_10524660_906_917_Disease))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NNS controls)) (PP (IN during) (CC and) (PP (ADVP (RB immediately)) (IN after) (NP (NP (JJ Doc_10524660_968_971_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (CD p=0.037)) (-RRB- -RRB-)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (DT the) (JJ following) (CD 11) (NNP h)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.008)) (-RRB- -RRB-))))))))) (. .)))
10524660	8	(S1 (S (PP (IN In) (NP (DT the) (NNS controls))) (, ,) (NP (DT the) (JJ Doc_10524660_1062_1065_Chemical-induced) (NN Doc_10524660_1074_1082_Disease)) (ADVP (RB gradually)) (VP (VBD disappeared) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NNP Doc_10524660_1117_1128_Disease))) (NP (JJ peak) (JJ Doc_10524660_1134_1142_Disease) (NN intensity)) (VP (VBD occurred) (PP (IN at) (NP (NP (DT a) (JJ mean) (NN time)) (PP (IN of) (NP (CD 240) (JJ min) (NN post-infusion))))))))) (. .)))
10524660	9	(S1 (S (PP (IN At) (NP (DT this) (NN time))) (NP (NP (DT the) (VBN induced) (NN Doc_10524660_1228_1236_Disease)) (PP (IN in) (NP (QP (CD 6) (IN of) (CD 12)) (NN Doc_10524660_1248_1259_Disease)))) (VP (VBD fulfilled) (NP (NP (DT the) (JJ diagnostic) (NNS criteria)) (PP (IN for) (NP (NP (NNP Doc_10524660_1298_1319_Disease)) (PP (IN of) (NP (DT the) (NNP International) (NNP Doc_10524660_1341_1349_Disease) (NNP Society))))))) (. .)))
10524660	10	(S1 (S (NP (DT The) (NNS results)) (ADVP (RB therefore)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_10524660_1394_1396_Chemical)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ Doc_10524660_1416_1420_Disease) (NNS mechanisms)) (PP (IN of) (NP (NN Doc_10524660_1435_1453_Disease)))))))))) (. .)))
10524660	11	(S1 (S (SBAR (IN Since) (S (NP (JJ cortical) (VBG spreading) (NN Doc_10524660_1480_1490_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB liberate) (NP (NNP Doc_10524660_1518_1520_Chemical)) (PP (IN in) (NP (NNS animals))))))))))) (, ,) (NP (DT this) (NN finding)) (VP (MD may) (VP (VB help) (S (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN coupling)) (PP (IN between) (NP (NN cortical)))))) (VP (VBG spreading) (NP (NNP Doc_10524660_1616_1626_Disease) (CC and) (NNP Doc_10524660_1631_1639_Disease)) (PP (IN in) (NP (NNP Doc_10524660_1643_1661_Disease))))))) (. .)))
10533019	0	(S1 (NP (NP (JJ Rapid) (NN reversal)) (PP (IN of) (NP (JJ life-threatening) (JJ Doc_10533019_35_44_Chemical-induced) (NN Doc_10533019_53_59_Disease))) (PP (IN with) (NP (NNP Doc_10533019_65_81_Chemical))) (. .)))
10533019	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_10533019_119_125_Disease)) (PP (IN with) (NP (JJ sudden) (NN Doc_10533019_138_156_Disease))) (PP (IN after) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10533019_191_200_Chemical)))))))))) (. .)))
10533019	2	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_10533019_224_240_Chemical)))) (ADVP (RB rapidly)) (VP (VBD resolved) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_10533019_272_278_Disease)) (PP (IN with) (NP (NP (JJ prompt) (NN recovery)) (PP (IN of) (NP (NN respiratory) (NN function))))) (, ,) (S (VP (VBG averting) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (ADJP (RBR more) (JJ aggressive)) (NN airway) (NN management)) (CC and) (NP (JJ ventilatory) (NN support)))))))) (. .)))
10533019	3	(S1 (S (NP (DT The) (NN emergency) (NN physician)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (SBAR (IN that) (S (NP (JJ life-threatening) (NN Doc_10533019_468_474_Disease)) (VP (MD may) (VP (VB accompany) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10533019_523_532_Chemical)))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_10533019_542_558_Chemical)) (VP (MD may) (VP (AUX be) (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ effective))) (NN remedy)))))))))) (. .)))
10539815	0	(S1 (NP (NP (NP (NNS Predictors)) (PP (IN of) (NP (NNP Doc_10539815_14_38_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_56_69_Disease))) (PP (IN during) (NP (JJ Doc_10539815_77_88_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)))))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (DT the) (NNS studies))) (PP (IN of) (NP (NNP Doc_10539815_154_182_Disease))) (PRN (-LRB- -LRB-) (NP (NNP SOLVD)) (-RRB- -RRB-)))))
10539815	1	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_10539815_212_223_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)) (VP (VBZ reduces) (NP (NN mortality) (NNS rates)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_10539815_301_325_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10539815_327_330_Disease)) (-RRB- -RRB-))))))))) (, ,) (NP (PRP it)) (VP (MD may) (ADVP (RB also)) (VP (VB cause) (NP (NN Doc_10539815_351_375_Disease)))) (. .)))
10539815	2	(S1 (S (NP (JJ Little) (NN information)) (VP (AUX is) (ADJP (JJ available)) (S (VP (TO to) (VP (VB predict) (SBAR (WHNP (WDT which)) (S (NP (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NP (JJS highest) (NN risk)) (PP (IN for) (NP (DT this) (NN complication)))))))))))) (. .)))
10539815	3	(S1 (FRAG (S (VP (TO To) (VP (VB quantify) (NP (NP (JJ specific) (JJ clinical) (NNS predictors)) (PP (IN of) (NP (NNP Doc_10539815_533_560_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_578_581_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN prescribed) (NP (JJ Doc_10539815_601_612_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)))))))))))) (. .)))
10539815	4	(S1 (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NNS data)) (PP (IN from) (NP (NP (DT the) (NNPS Studies)) (PP (IN of) (NP (NP (NP (NNP Doc_10539815_695_723_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SOLVD)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NNP Doc_10539815_789_798_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_10539815_820_823_Disease)))))))))))) (. .)))
10539815	5	(S1 (S (NP (EX There)) (VP (AUX were) (VP (VP (ADVP (NP (CD 3379) (NNS patients)) (RB randomly)) (VBN assigned) (PP (TO to) (NP (NNP Doc_10539815_871_880_Chemical))) (PP (IN with) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 974) (NN days)))))) (CC and) (VP (ADVP (NP (CD 3379) (NNS patients)) (RB randomly)) (VBN assigned) (PP (TO to) (NP (NN placebo))) (PP (IN with) (NP (NP (DT a) (JJ mean) (NN follow-up)) (PP (IN of) (NP (CD 967) (NNS days)))))))) (. .)))
10539815	6	(S1 (S (NP (NN Doc_10539815_999_1023_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (JJ serum) (NNP Doc_10539815_1055_1065_Chemical) (CD >/=0.5) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 44) (NNS micromol/L)) (-RRB- -RRB-)))) (PP (IN from) (NP (NN baseline))))))) (. .)))
10539815	7	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (JJ time-to-event) (NN analysis)) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ potential) (NNS predictors)) (PP (IN of) (NP (NN decrease)))) (PP (IN in) (NP (NP (JJ renal) (NN function)) (PP (VBG including) (NP (NP (NN age)) (, ,) (NP (NN baseline) (NN ejection) (NN fraction)) (, ,) (NP (NN baseline) (NN Doc_10539815_1256_1266_Chemical)) (, ,) (NP (NP (JJ low) (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (CD <100) (NN mm) (NNP Hg)) (-RRB- -RRB-)) (, ,) (NP (NP (NN history)) (PP (IN of) (NP (NP (NNP Doc_10539815_1321_1333_Disease)) (, ,) (NP (NNP Doc_10539815_1335_1343_Disease)) (, ,)))) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NN antiplatelet))))) (, ,) (NP (NNP Doc_10539815_1370_1378_Chemical)) (, ,) (CC and) (NP (NN beta-blocker) (NN therapy)))))))))) (. .)))
10539815	8	(S1 (S (NP (NP (NNS Patients)) (VP (ADVP (RB randomly)) (VBN assigned) (PP (TO to) (NP (NNP Doc_10539815_1445_1454_Chemical))))) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 33) (NN %)) (JJR greater) (NN likelihood)) (PP (IN of) (NP (NNP Doc_10539815_1487_1511_Disease))) (PP (IN than) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD =.003)) (-RRB- -RRB-)))))) (. .)))
10539815	9	(S1 (S (PP (IN By) (NP (NN multivariate) (NN analysis))) (, ,) (PP (IN in) (NP (DT both) (DT the) (UCP (NN placebo) (CC and) (JJ Doc_10539815_1587_1596_Chemical)) (NNS groups))) (NP (NP (JJR older) (NN age)) (, ,) (NP (JJ Doc_10539815_1615_1623_Chemical) (NN therapy)) (, ,) (CC and) (NP (NNP Doc_10539815_1637_1645_Disease))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10539815_1667_1691_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN beta-blocker) (NN therapy)) (CC and) (NP (JJR higher) (NN ejection) (NN fraction))) (VP (AUX were) (ADJP (JJ renoprotective))))))) (. .)))
10539815	10	(S1 (S (NP (JJR Older) (NN age)) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NNP Doc_10539815_1831_1855_Disease)) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (, ,) (CC but) (VP (ADVP (RB significantly)) (ADJP (RBR more) (RB so) (PP (IN in) (NP (NP (DT the) (NNP Doc_10539815_1905_1914_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10539815_1922_1931_Chemical)) (: :) (NP (NP (NP (NP (NN risk) (NN ratio) (NN -LSB-RR)) (JJ -RSB-) (CD 1.42)) (PP (IN per) (NP (CD 10) (NNS years)))) (, ,) (NP (NP (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (JJ -RSB-) (NN 1.32-1.52)) (PP (IN with) (NP (NNP Doc_10539815_2012_2021_Chemical)))) (: ;) (NP (NN placebo)) (: :) (NP (QP (CD RR) (CD 1.18)))) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.12-1.25)))) (-RRB- -RRB-))))))) (. .)))
10539815	11	(S1 (S (NP (JJ Doc_10539815_2060_2068_Chemical) (NN therapy)) (VP (AUX was) (ADVP (RB likewise)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2124_2148_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_10539815_2156_2165_Chemical) (NN group))))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.89)) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.70-2.08))) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.35)) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.09-1.66))) (-RRB- -RRB-)))) (. .)))
10539815	12	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_10539815_2267_2276_Chemical)) (VP (AUX had) (NP (NP (DT a) (JJ relative) (JJ renoprotective) (NN effect)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.33)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.13-1.53))) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN with) (NP (NN placebo)))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.96)) (, ,) (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.57-2.44)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_2409_2417_Disease)))))) (. .)))
10539815	13	(S1 (S (NP (NP (DT A) (JJR lower) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2435_2451_Disease)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (DT both) (NNS groups))) (PP (IN with) (NP (NP (NP (NN beta-blocker) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.70)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.57-0.85))) (-RRB- -RRB-))) (CC and) (NP (NP (JJR higher) (NN baseline) (NN ejection) (NN fraction)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD RR) (CD 0.93)) (IN per) (ADJP (CD 5) (NN %)) (NN increment)) (, ,) (NP (CD 95) (NN %) (QP (RB CI) (CD 0.91-0.) (CD 96)))) (-RRB- -RRB-))))))) (. .)))
10539815	14	(S1 (S (NP (JJ Doc_10539815_2628_2637_Chemical) (NN use)) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD 33) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2679_2703_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_2721_2724_Disease))))))))) (. .)))
10539815	15	(S1 (S (NP (NP (JJ Doc_10539815_2726_2734_Chemical) (NN use)) (CC and) (NP (JJ advanced) (NN age))) (VP (VBD increased) (NP (DT this) (NN risk))) (. .)))
10539815	16	(S1 (S (S (NP (NN Doc_10539815_2777_2785_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2827_2843_Disease))))) (PP (IN in) (NP (DT all) (NNS patients))) (PP (IN with) (NP (NNP Doc_10539815_2865_2868_Disease)))))) (, ,) (CC but) (S (S (NP (DT this) (NN risk)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (DT the) (NNP Doc_10539815_2903_2912_Chemical) (NN group))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group.) (NN beta-Blocker) (NN therapy))))))) (CC and) (S (NP (JJR higher) (NN ejection) (NN fraction)) (VP (AUX were) (ADJP (JJ renoprotective) (PP (IN in) (NP (DT all) (NNS patients)))) (ADVP (RB regardless) (PP (IN of) (NP (NN therapy))))))) (. .)))
10565806	0	(S1 (S (NP (JJ Doc_10565806_0_9_Disease-like) (NN syndrome)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10565806_35_45_Chemical)))) (. .)))
10565806	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NP (DT a) (ADJP (RB not) (RB otherwise) (JJ specified)) (NNP Doc_10565806_120_138_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DSM-IV)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_10565806_162_171_Disease)) (PP (ADVP (RB shortly)) (IN after) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (JJ Doc_10565806_206_216_Chemical) (NN treatment)))))))))))))) (. .)))
10692744	0	(S1 (NP (JJ Doc_10692744_0_13_Chemical-induced) (NN Doc_10692744_22_40_Disease) (. .)))
10692744	1	(S1 (S (NP (NP (JJ Acute) (NN Doc_10692744_48_57_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10692744_69_82_Chemical))))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB well) (VBN known)) (JJ adverse) (NN drug) (NN reaction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10692744_138_154_Disease))))))) (. .)))
10692744	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_10692744_176_189_Chemical-induced) (NN Doc_10692744_198_216_Disease)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function))))) (, ,) (S (VP (TO to) (VP (VB highlight) (NP (NP (JJ predisposing) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADVP (RB frequently)) (VP (VBN overlooked)))))))))) (. .)))
10728962	0	(S1 (NP (NP (NN Doc_10728962_0_11_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_10728962_32_41_Chemical-induced) (NNP Doc_10728962_50_61_Disease)) (PP (IN in) (NP (JJ severe) (NNP Doc_10728962_72_85_Disease))))))) (. .)))
10728962	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (JJ phosphodiesterase) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NNP Doc_10728962_135_144_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_10728962_172_185_Disease)))))) (VP (AUX is) (VP (ADVP (RB frequently)) (VBN restricted) (SBAR (IN because) (S (NP (PRP they)) (VP (VBP cause) (NP (NP (NN vasodilation)) (CC and) (NP (NN Doc_10728962_247_258_Disease)))))))) (. .)))
10728962	2	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ decompensated) (NN Doc_10728962_291_304_Disease)) (PP (IN with) (NP (NNP Doc_10728962_310_321_Disease))) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_10728962_343_352_Chemical))))))) (, ,) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNP Doc_10728962_367_378_Chemical)))) (VP (VBN restored) (NP (NN blood) (NN pressure)) (PP (IN without) (S (VP (VBG inhibiting) (NP (NP (DT the) (JJ inotropic) (NN effect)) (PP (IN of) (NP (NNP Doc_10728962_446_455_Chemical)))))))) (. .)))
10743694	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (JJ Doc_10743694_13_23_Chemical-related) (JJ adverse) (NNS effects))) (PP (IN by) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_10743694_65_77_Chemical))) (PP (IN in) (NP (NN liver) (NN transplant) (NNS recipients))))) (. .)))
10743694	1	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ Doc_10743694_115_125_Chemical) (NN side) (NNS effects)) (VP (VBP persist) (PP (IN despite) (NP (NN dose) (NN reduction)))))) (, ,) (NP (NP (NN conversion)) (PP (TO to) (NP (NP (JJ Doc_10743694_185_197_Chemical-based) (NN immunosuppression)) (PRN (-LRB- -LRB-) (NP (NNP CyA)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ necessary))) (. .)))
10743694	2	(S1 (S (NP (PRP We)) (VP (VBD characterized) (NP (NP (NP (JJ Doc_10743694_259_269_Chemical) (JJ side) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (VBD warranted) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (, ,) (CC and) (NP (NNS outcomes))) (PP (IN after) (NP (NN conversion)))) (. .)))
10743694	3	(S1 (S (PP (IN Of) (NP (NP (CD 388) (NN liver) (NNS recipients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_10743694_395_405_Chemical)) (PP (IN as) (NP (JJ primary) (NN immunosuppression)))))))) (, ,) (NP (CD 70)) (VP (VBD required) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP CyA))))) (. .)))
10743694	4	(S1 (S (NP (PRP We)) (VP (VBD recorded) (NP (NN indication)) (PP (IN for) (NP (NN conversion))) (, ,) (SBAR (IN whether) (S (NP (NN conversion)) (VP (AUX was) (ADJP (JJ early) (CC or) (JJ late)) (PP (IN after) (NP (NP (NN transplantation)) (, ,) (NP (JJ Doc_10743694_566_576_Chemical) (NN dose)) (CC and) (NP (NN trough) (NN blood) (NN level)))) (PP (IN at) (NP (NP (NN conversion)) (, ,) (CC and) (NP (NP (NN incidence)) (PP (IN of) (NP (NN rejection))) (PP (IN after) (NP (NN conversion)))))))))) (. .)))
10743694	5	(S1 (S (NP (NN Conversion)) (VP (AUX was) (ADJP (ADJP (JJ early) (PP (IN in) (NP (NP (CD 29) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 41.4) (NN %)) (-RRB- -RRB-))))) (CC and) (ADJP (JJ late) (PP (IN in) (NP (NP (CD 41)) (PRN (-LRB- -LRB-) (NP (CD 58.6) (NN %)) (-RRB- -RRB-))))))) (. .)))
10743694	6	(S1 (S (S (NP (NP (NNS Indications)) (PP (IN for) (NP (JJ early) (NN conversion)))) (VP (AUX were) (NP (NP (NP (NNP Doc_10743694_771_784_Disease) (PRN (-LRB- -LRB-) (CD 20) (-RRB- -RRB-) (, ,)) (NNP Doc_10743694_791_828_Disease)) (-LRB- -LRB-) (NP (NNP Doc_10743694_830_834_Disease)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_841_855_Disease)) (PRN (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_861_891_Disease)) (PRN (-LRB- -LRB-) (CD 6) (-RRB- -RRB-)) (, ,) (CC and) (NP (NNP Doc_10743694_901_915_Disease))) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)))) (, ,) (CC and) (S (PP (IN for) (NP (JJ late) (NN conversion))) (VP (AUX were) (NP (NP (NP (NNP Doc_10743694_950_963_Disease)) (PRN (-LRB- -LRB-) (NP (CD 15)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_970_974_Disease)) (PRN (-LRB- -LRB-) (CD 12) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_981_995_Disease)) (PRN (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1001_1012_Disease)) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1018_1032_Disease)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1038_1078_Disease)) (-LRB- -LRB-) (NP (NNP Doc_10743694_1080_1084_Disease)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1091_1105_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1111_1127_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NNP Doc_10743694_1137_1145_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
10743694	7	(S1 (S (NP (DT All) (JJ early-conversion) (NNS patients)) (VP (VBD showed) (NP (NP (NN improvement/resolution)) (PP (IN of) (NP (NNS symptoms))))) (. .)))
10743694	8	(S1 (S (S (PP (IN Among) (NP (NN late-conversion) (NNS patients))) (, ,) (NP (NP (CD 37)) (PRN (-LRB- -LRB-) (NP (CD 90.2) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NN improvement/resolution)))) (: ;) (S (PP (IN in) (NP (NP (CD 4)) (PRN (-LRB- -LRB-) (NP (CD 9.8) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (VBD persisted))) (. .)))
10743694	9	(S1 (S (NP (DT The) (JJ overall) (NN rejection) (NN rate)) (VP (AUX was) (NP (CD 30) (NN %))) (. .)))
10743694	10	(S1 (S (NP (NP (JJ Sixty-two) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 88.6) (NN %)) (-RRB- -RRB-))) (VP (AUX are) (ADJP (JJ alive)) (PP (IN with) (S (VP (VBG functioning) (NP (NNS grafts)) (PP (NP (NP (CD 686) (JJ +/-) (CD 362) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 154-1433) (NNS days))) (-RRB- -RRB-))) (IN after) (NP (NN conversion))))))) (. .)))
10743694	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ Doc_10743694_1495_1505_Chemical) (NN side) (NNS effects)) (VP (AUX are) (ADJP (JJ unresponsive) (PP (TO to) (NP (NN dose) (NN reduction))))))) (, ,) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP CyA)))) (VP (MD can) (VP (AUX be) (VP (VBN accomplished) (ADVP (RB safely)) (, ,) (PP (IN with) (NP (NP (NP (DT no) (VBN increased) (NN risk)) (PP (IN of) (NP (NN rejection)))) (CC and) (NP (JJ excellent) (JJ long-term) (NN outcome))))))) (. .)))
1079693	0	(S1 (NP (NP (JJ Ocular) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_1079693_25_54_Disease))) (. .)))
1079693	1	(S1 (S (NP (PRP We)) (VP (VBD followed) (NP (NP (CD 210) (NNS cases)) (PP (IN of) (NP (NNP Doc_1079693_81_110_Disease)))) (ADVP (RB closely)) (PP (IN for) (NP (CD eleven) (NNS years)))) (. .)))
1079693	2	(S1 (S (NP (NP (NN Thirty-six)) (PP (IN of) (NP (NP (DT the) (CD 210) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 17.2) (NN %)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (NN Doc_1079693_186_199_Disease))) (. .)))
1079693	3	(S1 (S (NP (NN Doc_1079693_201_214_Disease)) (VP (AUX was) (VP (VBN seen) (ADVP (RBS most) (RB frequently)) (PP (IN in) (NP (NP (JJ young) (JJ female) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 0) (TO to) (CD 4)) (NNS years)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT the) (JJ monoarticular) (CC or) (JJ pauciatricular) (NN form)) (PP (IN of) (NP (DT the) (NNP Doc_1079693_333_342_Disease))))))) (. .)))
1079693	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD 30) (NN %)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_1079693_383_390_Disease)) (PP (IN after) (NP (NP (CD 16) (NNS years)) (PP (IN of) (NP (NN age)))))) (. .)))
1079693	5	(S1 (S (SBAR (IN Although) (S (NP (NP (CD 61) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (DT a) (JJ noncontributory) (JJ ocular) (NN history)) (PP (IN on) (NP (NN entry)))))) (, ,) (NP (CD 42) (NN %)) (VP (AUX had) (NP (JJ active) (NN Doc_1079693_501_508_Disease)) (PP (IN on) (NP (NN entry)))) (. .)))
1079693	6	(S1 (S (NP (PRP$ Our) (NN approach)) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG detecting) (NP (NP (NP (NNP Doc_1079693_559_566_Disease)) (PP (IN in) (NP (JJ new) (NNS cases)))) (CC and) (NP (NP (NNS exacerbations)) (PP (IN of) (NP (NP (NNP Doc_1079693_601_608_Disease)) (PP (IN in) (NP (JJ established) (NNS cases)))))))))))) (. .)))
1079693	7	(S1 (S (NP (NP (JJ Forty-four) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1079693_667_674_Disease)))))) (VP (AUX had) (NP (NP (QP (CD one) (CC or) (JJR more)) (JJ identifiable) (NNS signs)) (CC or) (NP (NP (NNS symptoms)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ red) (NN eye)) (, ,) (NP (NP (NP (NNP Doc_1079693_740_751_Disease)) (, ,) (NP (NNP Doc_1079693_753_776_Disease)) (, ,) (CC or) (NP (NNP Doc_1079693_781_792_Disease)) (, ,)) (PP (IN in) (NP (NP (NN order)) (PP (IN of) (NP (VBG decreasing) (NN frequency))))))))))) (. .)))
1079693	8	(S1 (S (PP (ADVP (RB Even)) (IN after) (NP (NP (JJ early) (NN detection)) (CC and) (NP (JJ prompt) (NN treatment)))) (, ,) (NP (NP (CD 41) (NN %)) (PP (IN of) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_1079693_893_900_Disease)))))) (VP (AUX did) (RB not) (VP (VB respond) (PP (TO to) (NP (NP (QP (JJR more) (IN than) (CD six)) (NNS months)) (PP (IN of) (NP (NP (JJ intensive) (JJ topical) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_1079693_977_992_Chemical)) (CC and) (NP (NNS mydriatics)))))))))) (. .)))
1079693	9	(S1 (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ dramatic) (NN decrease)) (PP (IN in) (NP (NP (DT the) (ADJP (CD 50) (NN %)) (NN incidence)) (PP (IN of) (NP (NP (JJ blinding) (NNS complications)) (PP (IN of) (NP (NNP Doc_1079693_1103_1110_Disease))))) (VP (VBN cited) (PP (IN in) (NP (JJR earlier) (NNS studies)))))))) (. .)))
1079693	10	(S1 (S (NP (NP (NNP Doc_1079693_1137_1145_Disease)) (CC and) (NP (NNP Doc_1079693_1150_1166_Disease))) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (RB only) (CD 22) (CC and) (CD 13)) (NN %)) (PP (IN of) (NP (PRP$ our) (NN group))))) (, ,) (ADVP (RB respectively))) (. .)))
1079693	11	(S1 (S (NP (PRP We)) (VP (VP (VBD used) (NP (NP (NNP Doc_1079693_1231_1242_Chemical)) (CC or) (NP (NNP Doc_1079693_1246_1264_Chemical))) (PP (IN in) (NP (NP (CD 173)) (PP (IN of) (NP (CD 210) (NNS cases)))))) (CC and) (VP (VBD found) (NP (NP (QP (RB only) (CD one)) (NN case)) (PP (IN of) (NP (NNP Doc_1079693_1312_1329_Disease))) (ADJP (JJ attributable) (PP (TO to) (NP (DT these) (NNS drugs))))))) (. .)))
1079693	12	(S1 (S (S (NP (ADJP (RB Systemically) (VBN administered)) (NNP Doc_1079693_1385_1400_Chemical)) (VP (AUX were) (VP (VBN used) (PP (IN in) (NP (QP (CD 75) (IN of) (CD 210)) (NNS cases)))))) (: ;) (S (NP (NP (DT a) (JJ significant) (NN number)) (PP (IN of) (NP (JJ posterior) (NN subcapsular) (NN Doc_1079693_1477_1486_Disease)))) (VP (AUX was) (VP (VBN found)))) (. .)))
1079693	13	(S1 (S (NP (JJ Typical) (JJ Doc_1079693_1506_1526_Disease) (NN sicca)) (VP (VBD developed) (PP (IN in) (NP (NP (CD three)) (PP (IN of) (NP (DT the) (JJ Doc_1079693_1559_1566_Disease) (NNS cases)))))) (. .)))
1079693	14	(S1 (S (NP (NP (DT This) (NN association)) (PP (IN with) (NP (NP (NNP Doc_1079693_1596_1603_Disease)) (CC and) (NP (NNP JRA))))) (VP (AUX was) (RB not) (VP (VBN noted) (ADVP (RB previously)))) (. .)))
1079693	15	(S1 (S (NP (NP (JJ Surgical) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1079693_1660_1669_Disease)) (, ,) (NP (NNP Doc_1079693_1671_1687_Disease)) (, ,) (CC and) (NP (NNP Doc_1079693_1693_1701_Disease))))) (VP (VBD achieved) (NP (ADJP (RB uniformly) (JJ discouraging)) (NNS results))) (. .)))
10840460	0	(S1 (NP (NP (NP (JJ Doc_10840460_0_16_Chemical-induced) (NN Doc_10840460_25_33_Disease)) (PP (IN in) (NP (JJ freely-moving) (JJ conscious) (NNS rats)))) (: :) (NP (NP (JJ behavioral) (NN approach)) (PP (TO to) (NP (NP (DT a) (JJ new) (NN model)) (PP (IN of) (NP (NNP Doc_10840460_105_118_Disease)))))) (. .)))
10840460	1	(S1 (FRAG (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_10840460_151_164_Disease)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG using) (NP (DT a) (JJ behavioral) (NN approach)))))))) (. .)))
10840460	2	(S1 (S (NP (NP (NP (NNP Doc_10840460_202_218_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10840460_220_222_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (JJ antitumoral) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB produce) (NP (NP (JJ toxic) (NNS effects)) (PP (IN on) (NP (DT the) (NN bladder) (NN wall)))) (PP (IN through) (NP (PRP$ its) (JJ main) (JJ toxic) (NN metabolite) (NN Doc_10840460_331_339_Chemical)))))))) (, ,)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_10840460_360_368_Disease))))))) (. .)))
10840460	3	(S1 (NP (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (S (NP (NNP Doc_10840460_393_395_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 50) (, ,) (CD 100) (CC and) (CD 200) (JJ mg./kg.) (NNS i.p.)) (PP (TO to) (NP (JJ male) (NNS rats)))))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN behavior)) (VP (VBD observed) (CC and) (VBD scored)))) (. .)))
10840460	4	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10840460_523_531_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.5) (TO to) (CD 4) (CD mg./kg.)) (NN i.v.)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ Doc_10840460_559_561_Chemical-induced) (JJ behavioral) (NNS modifications)))) (VP (AUX were) (VP (VBN tested) (S (VP (VBN administered) (UCP (ADVP (RB alone)) (CC and) (PP (IN after) (NP (NP (NNP Doc_10840460_636_644_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (RB mg./kg.) (NNP s.c.)) (-RRB- -RRB-))))))))) (. .)))
10840460	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (NP (CD 90) (NNS minutes)) (IN after) (NP (NP (JJ Doc_10840460_693_695_Chemical) (NN injection)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (, ,) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10840460_749_757_Chemical)))))))))))) (, ,) (NP (DT the) (NN bladder)) (VP (AUX was) (VP (VBN removed) (PP (IN in) (NP (NP (DT some) (NNS rats)) (PP (IN for) (NP (JJ histological) (NN examination))))))) (. .)))
10840460	6	(S1 (S (ADVP (RB Finally)) (PRN (, ,) (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP (DT the) (NN bladder)) (VP (AUX is) (ADJP (JJ essential) (PP (IN for) (NP (DT the) (JJ Doc_10840460_881_883_Chemical-induced) (JJ behavioral) (NNS modifications)))))))))) (, ,)) (NP (JJ female) (NNS rats)) (ADVP (RB also)) (VP (VBD received) (NP (NNP Doc_10840460_944_946_Chemical)) (PP (IN at) (S (NP (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 200) (CD mg./kg.)) (NNS i.p.)) (PP (CC and) (PP (IN of) (NP (NP (NP (CD 20) (NN mg.)) (PP (IN by) (NP (DT the) (JJ intravesical) (NN route)))) (, ,) (CC and) (NP (NP (NNP Doc_10840460_1021_1029_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 0.5) (NN mg.)) (PP (IN by) (NP (DT the) (JJ intravesical) (NN route)))))))))) (CC and) (PP (IN of) (NP (QP (CD 5) (CD mg./kg.)) (NN i.v.) (NNS RESULTS))))))) (: :) (NP (NP (NNP Doc_10840460_1107_1109_Chemical)) (VP (ADVP (RB dose-relatedly)) (VBN induced) (S (VP (VBN marked) (NP (NP (JJ behavioral) (NNS modifications)) (PP (IN in) (NP (JJ male) (NNS rats)))))))) (: :)) (VP (VBG breathing) (NP (NN rate) (NN decrease))))) (, ,) (S (VP (VBG closing) (PP (IN of) (NP (NP (DT the) (NNS eyes)) (CC and) (NP (NP (NN occurrence)) (PP (IN of) (NP (JJ specific) (NNS postures))))))))) (. .)))
10840460	7	(S1 (S (NP (NN Doc_10840460_1261_1269_Chemical)) (ADVP (RB dose-dependently)) (VP (VBD reversed) (NP (DT these) (NNP Doc_10840460_1302_1322_Disease))) (. .)))
10840460	8	(S1 (S (NP (NP (DT A) (NN dose)) (PP (IN of) (NP (CD 0.5) (NN mg./kg.)))) (VP (VBD produced) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (QP (RB almost) (CD 50)) (NN %)) (PP (IN of) (NP (NP (DT the) (JJ behavioral) (NN score)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10840460_1416_1418_Chemical) (CD 200) (NN mg./kg)))))))))) (. .)))
10840460	9	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (ADVP (RB completely)) (VP (VBN prevented) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10840460_1489_1497_Chemical))))))) (. .)))
10840460	10	(S1 (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10840460_1532_1540_Chemical))))))) (, ,) (NP (NP (JJ histological) (NNS modifications)) (PP (IN of) (NP (DT the) (NN bladder) (NN wall))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN chorionic)) (CC and) (NP (NN muscle) (NN layer) (NN Doc_10840460_1625_1630_Disease)))) (, ,)) (VP (AUX were) (VP (VBN observed))) (. .)))
10840460	11	(S1 (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (NNP Doc_10840460_1663_1665_Chemical)) (ADVP (NP (CD 200) (NNS mg./kg.)) (RB i.p.)) (VP (VBD produced) (NP (NP (DT the) (JJ same) (JJ marked) (JJ behavioral) (NNS modifications)) (PP (IN as) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (JJ male) (NNS rats)))))))) (. .)))
10840460	12	(S1 (S (S (VP (VBN Administered) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 20) (NNS mg.))))) (ADVP (RB intravesically)))) (, ,) (NP (NNP Doc_10840460_1816_1818_Chemical)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ behavioral) (NNS effects)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_10840460_1867_1875_Chemical)) (ADVP (NP (QP (IN at) (CD 0.5)) (NNS mg.)) (RB intravesically)) (VP (VBN induced) (NP (NP (JJ behavioral) (NNS modifications)) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT those)) (PP (IN under) (NP (NNP Doc_10840460_1960_1962_Chemical) (CD 200) (NN mg./kg.) (NNS i.p.))))))) (, ,) (PP (IN with) (NP (DT the) (JJ same) (JJ maximal) (NNS levels)))))))) (. .)))
10840460	13	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_10840460_2023_2031_Chemical) (CD 5)) (VP (VBD mg./kg.) (SBAR (S (NP (NN i.v.)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ behavioral) (NNS effects)) (ADVP (IN at) (DT all))))))) (. .)))
10840460	14	(S1 (S (ADVP (RB Overall)) (, ,) (NP (DT these) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT this) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ Doc_10840460_2171_2173_Chemical-induced) (NNP Doc_10840460_2182_2190_Disease)))) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ interesting) (JJ new) (JJ behavioral) (NN model)) (PP (IN of) (NP (JJ inflammatory) (NNP Doc_10840460_2250_2263_Disease)))))))) (, ,) (S (VP (VBG allowing) (NP (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (DT these) (NNP Doc_10840460_2306_2323_Disease)))) (CC and) (NP (NP (RB thus) (DT a) (ADJP (RBR better) (JJ therapeutic)) (NN approach)) (PP (TO to) (NP (PRP them)))))))) (. .)))
10910842	0	(S1 (S (NP (JJ Doc_10910842_0_12_Chemical-induced) (NN Doc_10910842_21_39_Disease)) (VP (AUX is) (VP (VBN caused) (ADVP (RBR more)) (PP (IN by) (NP (NNP Doc_10910842_58_65_Disease))) (PP (IN than) (PP (IN by) (NP (JJ altered) (JJ Doc_10910842_82_95_Chemical) (NN receptor) (NN expression)))))) (. .)))
10910842	1	(S1 (S (NP (NP (JJ Large) (NNS doses)) (PP (IN of) (NP (NNS glucocorticoids)))) (VP (MD can) (VP (VB alter) (NP (NP (NN muscle)) (UCP (NNP physiology) (CC and) (ADJP (JJ susceptibility) (PP (TO to) (NP (JJ neuromuscular) (VBG blocking) (NNS drugs))) (PP (IN by) (NP (NP (NNS mechanisms)) (VP (RB not) (ADVP (RB clearly)) (VBN understood))))))))) (. .)))
10910842	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (JJ moderate) (CC and) (JJ large)) (NNS doses)) (PP (IN of) (NP (NNP Doc_10910842_324_336_Chemical))) (PP (IN on) (NP (NP (NN muscle) (NN function)) (CC and) (NP (NN pharmacology))))))) (, ,) (CC and) (NP (NP (PRP$ their) (NN relationship)) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN muscle) (NN size)) (CC and) (NP (JJ Doc_10910842_427_440_Chemical) (NN receptor) (PRN (-LRB- -LRB-) (NNP AChR) (-RRB- -RRB-)) (NN expression))))))))) (. .)))
10910842	3	(S1 (S (PP (IN With) (NP (JJ institutional) (NN approval))) (, ,) (NP (CD 35) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ daily) (JJ subcutaneous) (NNS doses)) (PP (IN of) (NP (NP (NP (QP (CD 10) (CD mg/kg)) (NNP Doc_10910842_593_605_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P10) (NN group)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 100) (NNS mg/kg)) (NP (NP (NNP Doc_10910842_629_641_Chemical)) (PRN (-LRB- -LRB-) (NP (CD P100) (NN group)) (-RRB- -RRB-)))) (, ,) (CC or) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NN saline))) (PRN (-LRB- -LRB-) (NP (NNP S) (NN group)) (-RRB- -RRB-)))))) (PP (IN for) (NP (CD 7) (NNS days)))))))) (. .)))
10910842	4	(S1 (S (NP (NP (DT A) (JJ fourth) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (AUX was) (ADJP (NN pair) (VBN fed)) (PRN (-LRB- -LRB-) (S (NP (NN food)) (VP (VBN restricted))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (CD P100) (NNS rats)) (PP (IN for) (NP (NP (CD 7) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD FR) (NN group)) (-RRB- -RRB-))))))) (. .)))
10910842	5	(S1 (S (PP (IN On) (NP (NNP Day) (CD 8))) (, ,) (NP (NP (DT the) (JJ nerve-evoked) (NN peak) (VB twitch) (NNS tensions)) (, ,) (NP (NNP Doc_10910842_852_859_Disease) (NNS tensions)) (, ,) (CC and) (NP (NN fatigability)) (, ,) (CC and) (NP (NP (DT the) (JJ dose-response) (NNS curves)) (PP (IN of) (NP (NNP Doc_10910842_920_934_Chemical))) (PP (IN in) (NP (DT the) (ADJP (FW tibialis) (FW cranialis)) (NN muscle))))) (VP (AUX were) (VP (VP (VBN measured) (PP (IN in) (NP (NN vivo)))) (CC and) (VP (VBN related) (PP (TO to) (NP (NP (NN muscle) (NN mass) (CC or) (NN expression)) (PP (IN of) (NP (NNS AChRs)))))))) (. .)))
10910842	6	(S1 (S (NP (NP (NN Rate)) (PP (IN of) (NP (NN body) (NN weight) (NN gain)))) (VP (AUX was) (VP (VBN depressed) (PP (IN in) (NP (DT the) (NNP P100) (, ,) (NNP FR) (, ,) (CC and) (NNP P10) (NNS groups))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	7	(S1 (S (NP (NNP Tibialis) (NN muscle) (NN mass)) (VP (AUX was) (ADJP (JJR smaller)) (PP (IN in) (NP (DT the) (NNP P100) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP P10) (CC or) (NNP S) (NNS groups))))) (. .)))
10910842	8	(S1 (S (S (S (NP (DT The) (JJ evoked) (NN peak)) (VP (VB twitch))) (CC and) (S (NP (JJ Doc_10910842_1246_1253_Disease) (NNS tensions)) (VP (AUX were) (ADJP (ADJP (JJR less) (PP (IN in) (NP (DT the) (NNP P100) (NN group)))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP P10) (CC or) (NNP S) (NNS groups)))))))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NN tension)) (PP (IN per) (NP (NP (NN milligram)) (PP (IN of) (NP (NN muscle) (NN mass)))))) (VP (AUX was) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (NNP P100) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	9	(S1 (S (NP (NP (DT The) (ADJP (CD 50) (NN %)) (JJ effective) (NN dose)) (PP (IN of) (NP (NNP Doc_10910842_1443_1457_Chemical))) (PRN (-LRB- -LRB-) (NP (CD microg/kg)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NN tibialis) (NN muscle)))) (VP (AUX was) (ADJP (ADJP (JJR smaller) (PP (IN in) (NP (NP (DT the) (NNP P10)) (PRN (-LRB- -LRB-) (NP (QP (CD 33.6) (CD +/-)) (CD 5.4)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN in) (NP (NP (NP (DT the) (NNP S)) (PRN (-LRB- -LRB-) (NP (QP (CD 61.9) (CD +/-)) (CD 5.0)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NNP P100) (PRN (-LRB- -LRB-) (NP (QP (CD 71.3) (CD +/-)) (CD 9.6)) (-RRB- -RRB-)) (NNS groups))))))) (. .)))
10910842	10	(S1 (S (NP (JJ AChR) (NN expression)) (VP (AUX was) (ADJP (ADJP (JJR less)) (PP (IN in) (NP (DT the) (NNP P10) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	11	(S1 (S (NP (DT The) (JJ evoked) (NNS tensions)) (VP (VBD correlated) (PP (IN with) (NP (NP (NN muscle) (NN mass)) (PRN (-LRB- -LRB-) (NP (NN r) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (SYM =) (CD 0.32)) (, ,) (NP (NNP P) (QP (CD <) (CD 0.001))) (-RRB- -RRB-)))) (, ,) (ADVP (RB however)) (, ,) (PP (RB not) (PP (IN with) (NP (NP (NN expression)) (PP (IN of) (NP (NNP AChR))))))) (. .)))
10910842	12	(S1 (S (NP (NP (DT The) (ADJP (CD 50) (NN %)) (JJ effective) (NN dose)) (PP (IN of) (NP (NNP Doc_10910842_1796_1810_Chemical)))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NN muscle) (NN mass)) (CC or) (NP (NN AChR) (NN expression)))))) (. .)))
10910842	13	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_10910842_1895_1920_Disease)) (PP (IN after) (NP (NNP Doc_10910842_1927_1939_Chemical)))) (VP (VP (AUX is) (ADJP (JJ dose-dependent))) (, ,) (CC and) (VP (VP (VBZ derives) (ADVP (RB primarily)) (PP (IN from) (NP (NNP Doc_10910842_1986_2000_Disease)))) (CC and) (VP (VBZ derives) (ADVP (RBR less) (RB so)) (PP (IN from) (NP (NP (NNS changes)) (PP (IN in) (NP (CD AChR) (NN expression))))))))))) (. .)))
10910842	14	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ chronic) (NN glucocorticoid) (NN therapy) (NNS alters)) (VP (VBP neuromuscular) (NP (NP (NNP physiology)) (CC and) (NP (NNS pharmacology))))))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
10910842	15	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ observed) (NNS effects)) (VP (VP (AUX are) (ADJP (JJ dose-dependent))) (CC and) (VP (VBP derive) (ADVP (RB primarily)) (PP (IN from) (NP (NNP Doc_10910842_2267_2281_Disease)))) (CC and) (VP (VBP derive) (ADVP (RBR less)) (PP (IN from) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ Doc_10910842_2314_2327_Chemical) (NN receptor) (NN expression)))))))))) (. .)))
11009181	0	(S1 (NP (NP (NN Doc_11009181_0_11_Chemical)) (: :) (NP (NP (DT an) (VBN underutilized) (NN therapy)) (PP (IN for) (NP (NNP Doc_11009181_42_61_Disease)))) (. .)))
11009181	1	(S1 (S (NP (NN Doc_11009181_63_74_Chemical)) (VP (AUX was) (NP (NP (DT the) (JJ first) (JJ dopaminergic) (NN drug)) (VP (ADVP (RB ever)) (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN Doc_11009181_138_157_Disease)))))))))) (. .)))
11009181	2	(S1 (S (SBAR (IN While) (S (NP (JJ powerful) (NN antiparkinsonian) (NNS effects)) (VP (AUX had) (VP (AUX been) (VP (VBN observed) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (CD 1951))))))))) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN of) (S (VP (VBG treating) (NP (JJ fluctuating) (NNP Doc_11009181_273_292_Disease)) (PP (IN by) (NP (NP (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_11009181_327_338_Chemical))))))))) (VP (AUX has) (ADVP (RB only)) (ADVP (RB recently)) (VP (VBN become) (NP (NP (DT the) (NN subject)) (PP (IN of) (NP (JJ systematic) (NN study)))))) (. .)))
11009181	3	(S1 (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (JJ small) (NN scale) (JJ clinical) (NNS trials)))) (VP (AUX have) (ADVP (RB unequivocally)) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ intermittent) (JJ subcutaneous) (NNP Doc_11009181_493_504_Chemical) (NNS injections)) (VP (VBP produce) (NP (JJ antiparkinsonian) (NN benefit)) (ADVP (RB close)) (SBAR (SBAR (IN if) (S (ADJP (RB not) (JJ identical) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (NNP Doc_11009181_590_598_Chemical))))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_11009181_608_619_Chemical) (NN rescue) (NNS injections)) (VP (MD can) (ADVP (RB reliably)) (VP (VB revert) (NP (NNS off-periods)) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ complex) (JJ on-off) (NN motor) (NNS swings))))))))))))))) (. .)))
11009181	4	(S1 (S (NP (ADJP (JJ Continuous) (JJ subcutaneous)) (JJ Doc_11009181_745_756_Chemical) (NNS infusions)) (VP (MD can) (VP (VB reduce) (NP (JJ daily) (NN off-time)) (PP (IN by) (NP (QP (JJR more) (IN than) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJR stronger) (NN effect)) (PP (IN than) (NP (NP (DT that)) (VP (ADVP (RB generally)) (VBN seen) (PP (IN with) (NP (NP (JJ add-on) (NN therapy)) (PP (IN with) (NP (NP (JJ oral) (JJ Doc_11009181_930_938_Chemical) (NNS agonists)) (CC or) (NP (JJ COMT) (NNS inhibitors)))))))))))))))))))) (. .)))
11009181	5	(S1 (S (NP (NP (JJ Extended) (JJ follow-up) (NNS studies)) (PP (IN of) (NP (QP (RB up) (TO to) (CD 8)) (NNS years)))) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (JJ long-term) (NN persistence)) (PP (IN of) (NP (JJ Doc_11009181_1055_1066_Chemical) (NN efficacy)))))) (. .)))
11009181	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (AUX is) (NP (JJ convincing) (JJ clinical) (NN evidence) (SBAR (IN that) (S (NP (NP (NN monotherapy)) (PP (IN with) (NP (JJ continuous) (JJ subcutaneous) (NNP Doc_11009181_1174_1185_Chemical) (NNS infusions)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ marked) (NNS reductions)) (PP (IN of) (S (VP (VBG preexisting) (NP (JJ Doc_11009181_1248_1256_Chemical-induced) (NN Doc_11009181_1265_1276_Disease))))))))))))) (. .)))
11009181	7	(S1 (S (NP (NP (DT The) (JJ main) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_11009181_1316_1327_Chemical) (NN treatment)))) (VP (AUX are) (ADJP (JJ related) (PP (TO to) (NP (JJ cutaneous) (NN tolerability) (NNS problems)))) (, ,) (SBAR (IN whereas) (S (NP (NN sedation) (CC and) (NN Doc_11009181_1407_1418_Disease) (NNS complications)) (VP (VBP play) (NP (DT a) (JJR lesser) (NN role)))))) (. .)))
11009181	8	(S1 (S (PP (VBN Given) (NP (NP (DT the) (JJ marked) (NN degree)) (PP (IN of) (NP (NP (NN efficacy)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_11009181_1505_1516_Chemical) (NN treatment))))) (PP (IN in) (S (VP (VBG fluctuating) (NP (NNP Doc_11009181_1542_1561_Disease))))))) (, ,) (NP (DT this) (NN approach)) (VP (VBZ seems) (S (VP (TO to) (VP (VB deserve) (NP (ADJP (RBR more) (JJ widespread)) (JJ clinical) (NN use)))))) (. .)))
11022397	0	(S1 (FRAG (S (VP (VBG Probing) (NP (JJ peripheral) (CC and) (JJ central) (JJ cholinergic) (NN system) (NNS responses)))) (. .)))
11022397	1	(S1 (S (S (NP (NP (DT The) (JJ pharmacological) (NN response)) (PP (TO to) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP act) (PP (IN on) (NP (NP (DT the) (JJ cholinergic) (NN system)) (PP (IN of) (NP (DT the) (NN iris))))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB predict) (NP (NNS deficits)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN functioning)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS diseases)) (PP (JJ such) (IN as) (NP (NNP Doc_11022397_250_269_Disease))))))))))))))) (, ,) (CC yet) (S (NP (NP (NNS correlations)) (PP (IN between) (NP (JJ central) (CC and) (JJ peripheral) (NNS responses)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (ADVP (RB properly)) (VBN studied))))) (. .)))
11022397	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ normal) (NN aging))) (PP (IN on) (NP (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (JJ Doc_11022397_419_430_Chemical-induced) (NN increase)) (PP (IN in) (NP (NN pupil) (NN diameter)))) (, ,) (CC and) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN reversal)) (PP (IN of) (NP (NP (DT this) (NN effect)) (PP (IN with) (NP (NNP Doc_11022397_508_519_Chemical)))))))))) (. .)))
11022397	3	(S1 (S (NP (NN Doc_11022397_521_532_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ positive) (NN control)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (JJ age-dependent) (NNS changes)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN functioning)) (PP (IN in) (NP (DT the) (JJ elderly))))))))))))) (. .)))
11022397	4	(S1 (S (NP (JJ Randomized) (NN double-blind)) (VP (VBD controlled) (NP (NN trial))) (. .)))
11022397	5	(S1 (S (NP (NP (NP (CD Ten) (JJ healthy) (JJ elderly)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age) (CD 70)) (-RRB- -RRB-))) (CC and) (NP (CD 9) (JJ young))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NN age) (CD 33)))) (-RRB- -RRB-)) (VP (NNS volunteers)) (. .)))
11022397	6	(S1 (S (NP (NN Pupil) (NN diameter)) (VP (AUX was) (VP (VBN monitored) (S (VP (VBG using) (NP (NP (DT a) (JJ computerized) (JJ infrared) (NN pupillometer)) (PP (IN over) (NP (CD 4) (NNS hours)))))))) (. .)))
11022397	7	(S1 (S (NP (DT The) (NN study)) (VP (VBD involved) (NP (CD 4) (NNS sessions))) (. .)))
11022397	8	(S1 (S (PP (IN In) (NP (CD 1) (NN session))) (, ,) (NP (NP (NNP Doc_11022397_929_940_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.01) (NN %))) (-RRB- -RRB-))) (VP (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (CD one) (NN eye))))) (CC and) (VP (NP (NN placebo)) (PP (TO to) (NP (DT the) (JJ other))))) (. .)))
11022397	9	(S1 (S (PP (IN In) (NP (DT another) (NN session))) (, ,) (NP (NP (NNP Doc_11022397_1034_1045_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.01) (NN %))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT both) (NNS eyes))) (, ,) (S (VP (VBN followed) (ADVP (NP (CD 23) (NNS minutes)) (RB later)) (PP (IN by) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (NP (NNP Doc_11022397_1144_1155_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.1) (NN %))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD one) (NN eye)) (CC and) (NP (NP (NN placebo)) (PP (TO to) (NP (DT the) (JJ other)))))))))))) (. .)))
11022397	10	(S1 (S (NP (DT All) (NN eye) (NNS drops)) (VP (AUX were) (VP (VBN given) (PP (IN in) (NP (DT a) (JJ randomized) (NN order))))) (. .)))
11022397	11	(S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS sessions))) (, ,) (S (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11022397_1300_1311_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg)) (, ,) (NP (NN intravenously)) (-RRB- -RRB-))) (CC or) (NP (NN placebo))) (VP (AUX was) (VP (VBN administered)))) (, ,) (CC and) (S (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NN word) (NN recall)))) (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test)) (PP (IN over) (NP (CD 2) (NNS hours)))))))) (. .)))
11022397	12	(S1 (NP (NP (NN OUTCOME) (NNS MEASURES)) (: :) (NP (NP (NP (NN Pupil) (NN size)) (PP (IN at) (NP (NN time) (NNS points))) (PP (IN after) (NP (NN administration))) (PP (IN of) (NP (NP (NNP Doc_11022397_1535_1546_Chemical)) (CC and) (NP (NNP Doc_11022397_1551_1562_Chemical))))) (: ;) (NP (JJ Doc_11022397_1564_1575_Chemical-induced) (NNP Doc_11022397_1584_1609_Disease))) (. .)))
11022397	13	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NP (JJ elderly) (CC and) (JJ young) (NNS volunteers)) (PP (IN in) (NP (NP (JJ pupillary) (NN response)) (PP (TO to) (NP (NNP Doc_11022397_1718_1729_Chemical))))) (PP (IN at) (NP (DT any) (NN time) (NN point)))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD >) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
11022397	14	(S1 (S (NP (DT The) (JJ elderly) (NN group)) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (JJR greater)) (JJ Doc_11022397_1806_1817_Chemical-induced) (JJ net) (NN decrease)) (PP (IN in) (NP (NN pupil) (NN size)))) (PP (NP (CD 85) (, ,) (CD 125) (, ,) (CD 165) (CC and) (CD 215) (NNS minutes)) (IN after) (NP (NN administration))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ young) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
11022397	15	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (JJ young) (NN group)))) (, ,) (NP (DT the) (JJ elderly) (NN group)) (VP (AUX had) (NP (JJR greater) (JJ Doc_11022397_2007_2018_Chemical-induced) (NNP Doc_11022397_2027_2052_Disease) (CD 60) (, ,) (CD 90) (CC and) (CD 120) (NNS minutes)) (PP (IN after) (NP (NP (NN administration)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
11022397	16	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT an) (JJ age-related) (JJ pupillary) (NN response)) (PP (TO to) (NP (NNP Doc_11022397_2167_2178_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (RB not) (VP (VBN found) (PP (IN with) (NP (NN Doc_11022397_2202_2213_Chemical))))))))) (. .)))
11022397	17	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_11022397_2221_2232_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB assess) (NP (NNS variations)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN function)) (PP (IN in) (NP (JJ elderly) (NNS patients))))))))))) (. .)))
11027904	0	(S1 (NP (NP (NN Doc_11027904_0_4_Disease) (NNS responses)) (PP (IN in) (NP (JJ Doc_11027904_18_27_Chemical-maintained) (JJ opioid) (NNS abusers))) (. .)))
11027904	1	(S1 (S (S (VP (VBG Providing) (NP (NNP Doc_11027904_65_69_Disease) (NN management)) (PP (IN for) (NP (JJ known) (JJ opioid) (NNS abusers))))) (VP (AUX is) (NP (DT a) (JJ challenging) (JJ clinical) (NN task)) (, ,) (PP (IN in) (NP (NN part))) (SBAR (IN because) (S (NP (RB little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (PRP$ their) (JJ Doc_11027904_182_186_Disease) (NN experience)) (CC and) (NP (JJ analgesic) (NNS requirements))))))))) (. .)))
11027904	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB describe) (NP (NP (JJ Doc_11027904_262_266_Disease) (NN tolerance)) (CC and) (NP (JJ analgesic) (NN response))) (PP (IN in) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (NNP Doc_11027904_315_329_Disease))) (VP (VBN stabilized) (PP (IN in) (NP (NP (JJ Doc_11027904_344_353_Chemical-maintenance) (PRN (-LRB- -LRB-) (NP (NNP MM)) (-RRB- -RRB-)) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 60)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (VBN matched) (JJ nondependent) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 60)) (-RRB- -RRB-)))))))))))))) (. .)))
11027904	3	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ two-way) (JJ factorial) (NN design))))) (, ,) (NP (NP (NN tolerance)) (PP (TO to) (NP (JJ cold-pressor) (PRN (-LRB- -LRB-) (NP (NNP CP)) (-RRB- -RRB-)) (NNP Doc_11027904_543_547_Disease)))) (VP (AUX was) (VP (VBN examined) (, ,) (PP (DT both) (IN before) (CC and) (IN after) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (JJ common) (NN opioid)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027904_643_656_Chemical) (CD 2) (CD mg)) (-RRB- -RRB-))) (CC and) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027904_699_708_Chemical) (CD 10) (CD mg)) (-RRB- -RRB-)) (JJ analgesic) (NNS agents)))))))) (. .)))
11027904	4	(S1 (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN MM) (NNS individuals)) (VP (AUX were) (NP (NP (ADJP (RB significantly) (JJR less)) (NN tolerant)) (PP (IN of) (NP (NNP CP) (NNP Doc_11027904_808_812_Disease)))) (PP (IN than) (NP (NN control) (NNS subjects))) (, ,) (S (VP (VBG replicating) (NP (JJ previous) (NN work)))))))) (. .)))
11027904	5	(S1 (S (NP (JJ Analgesic) (NNS effects)) (VP (AUX were) (UCP (ADJP (JJ significant)) (CC neither) (PP (IN for) (NP (NP (NN medication)) (CC nor) (NP (NN group)))))) (. .)))
11027904	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ MM) (NN opioid) (NNS abusers)) (VP (VBP represent) (NP (NP (DT a) (JJ Doc_11027904_987_1002_Disease) (NN subset)) (PP (IN of) (NP (JJ clinical) (NNS patients)))))))) (. .)))
11027904	7	(S1 (S (NP (NP (PRP$ Their) (NNS complaints)) (PP (IN of) (NP (NNP Doc_11027904_1052_1056_Disease)))) (VP (MD should) (VP (AUX be) (VP (VP (VBN evaluated) (ADVP (RB seriously))) (CC and) (VP (VBN managed) (ADVP (RB aggressively)))))) (. .)))
11058428	0	(S1 (S (NP (NNP High-dose) (NNP Doc_11058428_10_28_Chemical)) (VP (MD may) (VP (AUX do) (NP (NP (JJR more) (NN harm)) (PP (IN for) (NP (NNP Doc_11058428_50_68_Disease)))))) (. .)))
11058428	1	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (ADJP (NNP National) (JJ Acute)) (NNP Doc_11058428_100_118_Disease) (NNP Studies)) (PRN (-LRB- -LRB-) (NP (NNP NASCIS)) (-RRB- -RRB-)))) (, ,) (NP (JJ high-dose) (NNP Doc_11058428_147_165_Chemical)) (VP (VBD became) (NP (NP (DT the) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (DT the) (JJ acute) (NN Doc_11058428_208_226_Disease))))) (. .)))
11058428	2	(S1 (S (PP (IN In) (NP (DT the) (NN NASCIS))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN mention)) (VP (VBG regarding) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ acute) (NNP Doc_11058428_299_313_Chemical) (NNP Doc_11058428_314_322_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBP high-dose) (SBAR (S (NP (NNP Doc_11058428_338_356_Chemical)) (VP (MD may) (VP (VB cause)))))))))) (. .)))
11058428	3	(S1 (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (NNP Doc_11058428_382_400_Chemical))) (VP (VBN recommended) (PP (IN by) (NP (DT the) (NNP NASCIS) (CD 3))))) (VP (AUX is) (S (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NNP Doc_11058428_452_460_Chemical)))) (ADVP (RB ever)) (VP (AUXG being) (VP (VBN used) (PP (IN during) (NP (NP (DT a) (JJ 2-day) (NN period)) (PP (IN for) (NP (DT any) (JJ clinical) (NN condition))))))))) (. .)))
11058428	4	(S1 (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (VB cause) (NP (NP (DT some) (NN Doc_11058428_565_585_Disease)) (PP (IN of) (NP (JJ Doc_11058428_589_607_Disease) (NNS patients))))))))) (. .)))
11058428	5	(S1 (S (ADVP (RB Further)) (, ,) (S (NP (NNP Doc_11058428_627_634_Chemical) (NNP Doc_11058428_635_643_Disease)) (VP (VBZ recovers) (ADVP (RB naturally)))) (CC and) (S (NP (NP (DT the) (JJ neurological) (NN improvement)) (VP (VBN shown) (PP (IN in) (NP (DT the) (NN NASCIS))))) (VP (MD may) (VP (AUX be) (NP (NP (NP (RB just) (DT a) (NN recording)) (PP (IN of) (NP (NP (DT this) (JJ natural) (NN motor) (NN recovery)) (PP (IN from) (NP (DT the) (NNP Doc_11058428_780_787_Chemical) (NNP Doc_11058428_788_796_Disease)))))) (, ,) (CONJP (RB instead) (IN of)) (NP (NP (DT any) (NN protection)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_11058428_829_847_Chemical)) (VP (VBZ offers) (PP (TO to) (NP (DT the) (NNP Doc_11058428_862_880_Disease))))))))))) (. .)))
11058428	6	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN discussion)) (VP (VBG considering) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_11058428_966_984_Chemical)) (VP (VBN recommended) (PP (IN by) (NP (NNP NASCIS))))) (VP (MD may) (VP (VB cause) (NP (JJ acute) (JJ Doc_11058428_1023_1037_Chemical) (NN Doc_11058428_1038_1046_Disease)))))))))) (. .)))
11063349	0	(S1 (NP (NP (NP (NN Conversion)) (PP (TO to) (NP (JJ Doc_11063349_14_23_Chemical) (NN immunosuppression))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients)))) (: :) (NP (NP (NN report)) (PP (IN of) (NP (DT an) (JJ initial) (NN experience)))) (. .)))
11063349	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_11063349_171_175_Chemical) (NN conversion))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NP (NNP Doc_11063349_210_222_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_224_227_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_11063349_232_242_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_244_247_Chemical)) (-RRB- -RRB-)) (NNP Doc_11063349_249_257_Disease))))))))))) (. .)))
11063349	2	(S1 (S (NP (CD Twenty) (JJ renal) (NN transplant) (NNS recipients)) (VP (AUX were) (VP (VBN switched) (PP (TO to) (NP (NP (NP (JJ fixed) (NN dose) (NNP Doc_11063349_331_340_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_342_346_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/day)) (-RRB- -RRB-)))) (NP (QP (CD 0) (TO to) (CD 204) (NNS months)) (NN posttransplant)))) (. .)))
11063349	3	(S1 (S (NP (NN Drug) (NN monitoring)) (VP (AUX was) (RB not) (ADVP (RB initially)) (VP (VBN used) (S (VP (TO to) (VP (VB adjust) (NP (NNS doses))))))) (. .)))
11063349	4	(S1 (S (NP (NP (DT The) (NNS indications)) (PP (IN for) (NP (NN switch)))) (VP (AUX were) (NP (NP (NP (JJ chronic) (NNP Doc_11063349_487_490_Chemical) (CC or) (NNP Doc_11063349_494_497_Chemical) (NNP Doc_11063349_498_512_Disease)) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ acute) (NNP Doc_11063349_525_528_Chemical) (CC or) (NNP Doc_11063349_532_535_Chemical) (NNP Doc_11063349_536_544_Disease)) (PRN (-LRB- -LRB-) (CD 3) (-RRB- -RRB-))) (, ,) (NP (NP (JJ severe) (NNP Doc_11063349_557_575_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_11063349_581_624_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_626_630_Disease)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN remission)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NNP Doc_11063349_654_668_Disease))) (PP (IN in) (NP (CD 1)))) (. .)))
11063349	5	(S1 (S (NP (NN Follow-up)) (VP (AUX is) (NP (QP (CD 7) (TO to) (CD 24)) (NNS months))) (. .)))
11063349	6	(S1 (S (PP (IN In) (NP (NP (DT the) (CD 12) (NNS patients)) (VP (VBN switched) (PP (IN because) (IN of) (NP (NN chronic) (NN Doc_11063349_760_774_Disease)))))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ serum) (NNP Doc_11063349_817_827_Chemical) (CD -LSB-233+/-34))) (PP (TO to) (NP (CD 210+/-56) (NN micromol/liter)))) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (PP (IN at) (NP (QP (CD 6) (NNS months)) (NN -RSB-)))) (. .)))
11063349	7	(S1 (S (NP (NN Doc_11063349_888_906_Disease)) (VP (VBD improved) (PP (IN in) (NP (CD two) (NNS patients)))) (. .)))
11063349	8	(S1 (S (NP (NP (DT No) (NN relapse)) (PP (IN of) (NP (NNP Doc_11063349_947_951_Disease)))) (VP (AUX was) (VP (VBN observed))) (. .)))
11063349	9	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD developed) (SBAR (S (NP (NP (NP (NNP Doc_11063349_990_999_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD two) (NNP Doc_11063349_1005_1035_Disease)) (, ,) (NP (NP (CD one) (NN Doc_11063349_1041_1065_Disease)) (PP (IN with) (NP (JJ polyclonal) (JJ Doc_11063349_1082_1086_Disease) (NN lung) (VB infiltrate))))) (-RRB- -RRB-))) (CC and) (NP (CD two))) (VP (AUX had) (NP (NN Doc_11063349_1116_1140_Disease)))))) (. .)))
11063349	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (NNS deaths))) (. .)))
11063349	11	(S1 (S (NP (NN Doc_11063349_1164_1168_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN in) (NP (CD four) (NNS patients))) (, ,) (PP (IN because) (IN of) (NP (NP (NP (NNP Doc_11063349_1215_1224_Disease)) (PP (IN in) (NP (CD two)))) (, ,) (NP (NP (NNP Doc_11063349_1233_1237_Disease)) (PP (IN in) (NP (CD one)))) (, ,) (CC and) (NP (NP (JJ oral) (NNP Doc_11063349_1255_1269_Disease)) (PP (IN in) (NP (CD one)))))))) (. .)))
11063349	12	(S1 (S (NP (NN Doc_11063349_1278_1282_Chemical) (NNS levels)) (VP (AUX were) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (CD >15) (NN ng/ml)) (-RRB- -RRB-)) (PP (IN in) (NP (QP (CD 7) (IN of) (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 54) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (. .)))
11063349	13	(S1 (S (NP (JJ Doc_11063349_1352_1356_Chemical) (NN conversion)) (VP (VBZ provides) (NP (JJ adequate) (NN immunosuppression)) (S (VP (TO to) (VP (VB enable) (NP (JJ Doc_11063349_1414_1417_Chemical) (NN withdrawal)))))) (. .)))
11063349	14	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG converting) (NP (NNS patients)) (PP (TO to) (NP (JJ Doc_11063349_1467_1471_Chemical) (NN drug) (NNS levels)))))) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (S (VP (TO to) (VP (VB avoid) (SBAR (S (NP (NP (NN over-immunosuppression)) (CC and) (NP (JJ adequate) (ADJP (JJ antiviral) (CC and) (JJ Doc_11063349_1563_1593_Disease)) (NNS prophylaxis))) (VP (MD should) (VP (AUX be) (VP (VBN given)))))))))))) (. .)))
11077455	0	(S1 (NP (NP (NN Electro-oculography)) (, ,) (NP (NN electroretinography)) (, ,) (NP (JJ visual) (JJ evoked) (NNS potentials)) (, ,) (CC and) (NP (NP (JJ multifocal) (NN electroretinography)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11077455_120_130_Chemical-attributed) (NNP Doc_11077455_142_167_Disease)))))) (. .)))
11077455	1	(S1 (S (NP (NP (NNP Symptomatic) (NNP Doc_11077455_190_215_Disease)) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11077455_246_256_Chemical))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported)))) (. .)))
11077455	2	(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (JJ visual) (NNS fields)) (CC and) (NP (NP (JJ visual) (NN electrophysiology)) (PP (IN of) (NP (CD eight) (NNS patients))) (PP (IN with) (NP (NP (VBN known) (JJ Doc_11077455_383_393_Chemical-attributed) (NNP Doc_11077455_405_422_Disease)) (, ,) (SBAR (WHNP (WHNP (CD three)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (VP (VBN reported) (ADVP (RB previously))))))))))) (. .)))
11077455	3	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (ADVP (RB no) (RBR longer)) (VP (VBG receiving) (NP (NN Doc_11077455_509_519_Chemical)))) (. .)))
11077455	4	(S1 (S (NP (DT The) (JJ central) (CC and) (JJ peripheral) (NNS fields)) (VP (AUX were) (VP (VBN examined) (PP (IN with) (NP (DT the) (NNP Humphrey) (JJ Visual) (NN Field) (NN Analyzer))))) (. .)))
11077455	5	(S1 (S (NP (NP (JJ Full) (JJ visual) (NN electrophysiology)) (, ,) (PP (VBG including) (NP (NP (NP (NN flash) (NN electroretinography)) (PRN (-LRB- -LRB-) (NP (NNP ERG)) (-RRB- -RRB-))) (, ,) (NP (NN pattern) (NN electroretinography)) (, ,) (NP (NP (JJ multifocal) (NN ERG)) (VP (VBG using) (NP (DT the) (NN VERIS) (NN system)))) (, ,) (NP (NN electro-oculography)) (, ,) (CC and) (NP (ADJP (NN flash) (CC and) (NN pattern)) (JJ visual) (JJ evoked) (NNS potentials)))) (, ,)) (VP (AUX was) (VP (VBN undertaken))) (. .)))
11077455	6	(S1 (S (NP (CD Seven) (NNS patients)) (VP (VBD showed) (NP (JJ marked) (NN Doc_11077455_884_909_Disease)) (PP (IN with) (NP (NP (DT some) (NN sparing)) (PP (IN of) (NP (DT the) (JJ temporal) (JJ visual) (NN field)))))) (. .)))
11077455	7	(S1 (FRAG (NP (DT The) (JJ eighth) (JJ exhibited) (JJ concentric) (NN constriction)) (. .)))
11077455	8	(S1 (S (S (NP (JJS Most) (JJ electrophysiological) (NNS responses)) (VP (AUX were) (ADVP (RB usually)) (ADVP (RB just)) (PP (IN within) (NP (JJ normal) (NNS limits))))) (: ;) (S (NP (CD two) (NNS patients)) (VP (AUX had) (NP (JJ subnormal) (NNP Arden) (JJ electro-oculography) (NNS indices)))) (: ;) (CC and) (S (NP (CD one) (NN patient)) (VP (VBD showed) (NP (DT an) (ADJP (RB abnormally) (VBN delayed)) (NN photopic) (NN b) (NN wave)))) (. .)))
11077455	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (CD five) (NNS patients)) (VP (VBN showed) (NP (JJ delayed) (JJ 30-Hz) (NN flicker) (NN b) (NNS waves)))) (, ,) (CC and) (NP (CD seven) (NNS patients))) (VP (VBD showed) (NP (JJ delayed) (NN oscillatory) (NNS potentials))) (. .)))
11077455	10	(S1 (S (NP (NNP Multifocal) (NNP ERG)) (VP (VBD showed) (NP (NP (NNS abnormalities)) (SBAR (WHNP (WDT that)) (S (ADVP (RB sometimes)) (VP (VP (VBD correlated) (PP (IN with) (NP (DT the) (JJ visual) (NN field) (NN appearance)))) (CC and) (VP (VBD confirmed) (SBAR (IN that) (S (NP (DT the) (NN deficit)) (VP (VBZ occurs) (PP (IN at) (NP (DT the) (JJ retinal) (NN level)))))))))))) (. .)))
11077455	11	(S1 (S (NP (JJ Marked) (NN Doc_11077455_1497_1522_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_11077455_1553_1563_Chemical) (NN therapy)))))))) (. .)))
11077455	12	(S1 (S (NP (NP (DT The) (NN field) (NNS defects)) (CC and) (NP (DT some) (NN electrophysiological) (NNS abnormalities))) (VP (VBP persist) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_11077455_1648_1658_Chemical) (NN therapy)) (VP (AUX is) (VP (VBN withdrawn)))))) (. .)))
11078231	0	(S1 (S (VP (VBP Doc_11078231_0_19_Disease) (PP (JJ due) (TO to) (NP (NNP Doc_11078231_27_48_Disease))) (PP (IN during) (NP (JJ Doc_11078231_56_66_Chemical) (NN stress) (NN echocardiography)))) (. .)))
11078231	1	(S1 (S (NP (NP (JJ Doc_11078231_92_102_Chemical) (NN stress) (NN echocardiography)) (PRN (-LRB- -LRB-) (NP (NN DSE)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ useful)) (CC and) (ADJP (JJ safe))) (NN provocation) (NN test)) (PP (IN for) (NP (NNP Doc_11078231_175_194_Disease))))) (. .)))
11078231	2	(S1 (S (PP (IN Until) (NP (RB now))) (, ,) (S (NP (DT the) (NN test)) (VP (AUX has) (VP (AUX been) (VP (VBN focused) (PP (ADVP (RB only)) (IN on) (NP (NP (DT the) (JJ organic) (NN lesion)) (PP (IN in) (NP (DT the) (JJ coronary) (NN artery))))))))) (, ,) (CC and) (S (NP (JJ positive) (NN DSE)) (VP (AUX has) (VP (VBN indicated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ significant) (JJ fixed) (NN Doc_11078231_349_373_Disease))))))) (. .)))
11078231	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (NP (JJ Doc_11078231_426_445_Disease) (NN due)) (PP (TO to) (NP (NNP Doc_11078231_453_467_Disease)))) (VP (AUX is) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11078231_482_492_Chemical))))))))))) (. .)))
11078231	4	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NN DSE)) (PP (IN on) (NP (CD 51) (NNS patients))) (PP (PP (IN with) (NP (NNP Doc_11078231_531_554_Disease))) (CC but) (PP (IN without) (NP (JJ significant) (JJ fixed) (NN Doc_11078231_585_609_Disease))))) (. .)))
11078231	5	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (JJ Doc_11078231_628_635_Disease) (NNS attacks)) (PP (IN at) (NP (NP (NN rest)) (PP (IN with) (NP (NP (NNP ST) (NN elevation)) (PP (IN on) (NP (NP (DT the) (NN electrocardiogram)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11078231_696_710_Disease)) (-RRB- -RRB-))))))))) (. .)))
11078231	6	(S1 (S (S (NP (JJ Coronary) (NN spasm)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NN intracoronary) (NN injection)) (PP (IN of) (NP (NNP Doc_11078231_770_783_Chemical)))))))) (, ,) (CC and) (S (NP (DT no) (JJ fixed) (NN Doc_11078231_798_822_Disease)) (VP (AUX was) (VP (VBN documented) (PP (IN on) (NP (NP (NNS angiograms)) (PP (IN in) (NP (DT all) (NNS patients)))))))) (. .)))
11078231	7	(S1 (S (NP (NN DSE)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (JJ intravenous) (JJ Doc_11078231_904_914_Chemical) (NN infusion))) (PP (IN with) (NP (NP (DT an) (JJ incremental) (NNS doses)) (PP (IN of) (NP (CD 5) (, ,) (CD 10) (, ,) (CD 20) (, ,) (CD 30) (, ,) (CC and) (CD 40) (NN microg/kg/min))))) (NP (DT every) (CD 5) (NNS minutes)))) (. .)))
11078231	8	(S1 (S (PP (IN Of) (NP (DT the) (CD 51) (NNS patients))) (, ,) (NP (CD 7) (NNS patients)) (VP (VBD showed) (NP (NN asynergy)) (PP (IN with) (NP (NNP ST) (NN elevation)))) (. .)))
11078231	9	(S1 (S (S (NP (NP (DT All) (CD 7) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 13.7) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NN Doc_11078231_1099_1109_Disease)) (PP (IN during) (NP (NN asynergy))))) (, ,) (CC and) (S (NP (DT both) (JJ Doc_11078231_1136_1146_Disease) (CC and) (JJ electrocardiographic) (NNS changes)) (VP (AUX were) (VP (VBN preceded) (PP (IN by) (NP (NN asynergy)))))) (. .)))
11078231	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_11078231_1236_1246_Chemical)) (VP (MD can) (VP (VB provoke) (NP (NNP Doc_11078231_1259_1273_Disease)) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NNP Doc_11078231_1296_1319_Disease)))))))))) (. .)))
11078231	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN DSE)) (VP (AUX is) (VP (VP (VBN performed) (S (VP (TO to) (VP (VB evaluate) (NP (NNP Doc_11078231_1355_1378_Disease)))))) (, ,) (CONJP (RB not) (RB only)) (VP (VBN fixed) (NP (NNP Doc_11078231_1395_1412_Disease))))))) (, ,) (CC but) (ADVP (RB also)) (NP (NNP Doc_11078231_1423_1437_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT a) (NN genesis)) (PP (IN of) (NP (NN asynergy)))))))) (. .)))
11079278	0	(S1 (NP (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ intravenous) (NNP Doc_11079278_22_32_Chemical)) (CC or) (NP (JJ intravenous) (NNP Doc_11079278_48_58_Chemical))))) (CC plus) (NP (NN glucagon))) (PP (IN on) (NP (NNP Doc_11079278_76_86_Chemical-induced) (NNP Doc_11079278_95_114_Disease))) (. .)))
11079278	1	(S1 (FRAG (NP (NN STUDY) (NN OBJECTIVE)) (: :) (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_11079278_160_170_Chemical))) (PP (IN on) (NP (NP (JJ Doc_11079278_174_184_Chemical) (NN stress) (VBG testing)) (PP (IN with) (NP (JJ Doc_11079278_205_229_Chemical) (JJ single-photon) (NN emission) (VBD computed) (JJ tomography) (NN imaging) (CC and) (NN ST-segment) (NN monitoring))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ intravenous) (NN glucagon))) (PP (IN on) (NP (NP (NNP Doc_11079278_360_370_Chemical) (POS 's)) (NNS effects)))))))) (. .)))
11079278	2	(S1 (NP (NP (NN Randomized)) (, ,) (NP (NN double-blind)) (, ,) (NP (JJ placebo-controlled) (NN trial)) (. .)))
11079278	3	(S1 (FRAG (NP (NN Community) (NN hospital)) (. .)))
11079278	4	(S1 (NP (NP (JJ Twenty-two) (NNS patients)) (PP (IN with) (NP (JJ known) (JJ reversible) (NN perfusion) (NNS defects))) (. .)))
11079278	5	(S1 (S (NP (NNS Patients)) (VP (VBD underwent) (NP (NP (JJ Doc_11079278_575_585_Chemical) (NN stress) (NNS tests)) (PP (IN per) (NP (JJ standard) (NN protocol))))) (. .)))
11079278	6	(S1 (S (SBAR (IN Before) (S (NP (NNP Doc_11079278_629_639_Chemical)) (VP (AUX was) (VP (VBN begun))))) (, ,) (S (NP (DT no) (NN therapy)) (VP (AUX was) (VP (VBN given) (PP (IN during) (NP (DT the) (JJ first) (NN visit)))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (AUX were) (VP (VBN randomized) (PP (IN on) (NP (JJ subsequent) (NNS visits))) (S (VP (TO to) (VP (VP (VB receive) (NP (NNP Doc_11079278_757_767_Chemical) (CC or) (NNP Doc_11079278_771_781_Chemical))) (CC plus) (VP (VB glucagon) (NP (CD 1) (NN mg))))))))) (. .)))
11079278	7	(S1 (S (NP (NN Doc_11079278_802_812_Chemical)) (VP (AUX was) (VP (VBN dosed) (S (VP (TO to) (VP (VB achieve) (NP (DT a) (JJ resting) (NNP Doc_11079278_844_857_Chemical) (NN heart) (NN rate)) (PP (IN below) (NP (NP (CD 65) (NN beats/minute)) (CC or) (NP (NP (DT a) (JJ total) (JJ intravenous) (NN dose)) (PP (IN of) (NP (CD 20) (NN mg))))))))))) (. .)))
11079278	8	(S1 (FRAG (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (NP (NNP Doc_11079278_960_970_Chemical)) (VP (VP (VBD reduced) (NP (NN maximum) (NN heart) (NN rate)) (NP (CD 31) (NN %))) (, ,) (VP (VBD summed) (NP (NN stress) (NNS scores)) (NP (CD 29) (NN %))) (, ,) (CC and) (VP (VBD summed) (NP (NN difference) (NNS scores)) (NP (CD 43) (NN %)) (PP (IN versus) (NP (NN control)))))) (. .)))
11079278	9	(S1 (S (NP (NP (NN Doc_11079278_1078_1088_Chemical)) (CC plus) (NP (NN glucagon))) (ADVP (RB also)) (VP (VBD reduced) (NP (DT the) (NN maximum) (NN heart) (NN rate)) (NP (CD 29) (NN %)) (PP (IN versus) (NP (NN control)))) (. .)))
11079278	10	(S1 (S (VP (VP (VBD Summed) (NP (NN stress))) (CC and) (VP (VBD summed) (SBAR (S (NP (NN difference) (NNS scores)) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN reduced) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (AUX were) (ADVP (NP (NP (CD 18) (NN %)) (CC and) (NP (CD 30) (NN %))) (JJR lower)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN than) (NP (NN control)))))))))))) (. .)))
11079278	11	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (DT any) (NN parameter)) (PP (IN between) (NP (NP (NNP Doc_11079278_1363_1373_Chemical)) (CC and) (NP (NNP Doc_11079278_1378_1388_Chemical-glucagon)))))))) (. .)))
11079278	12	(S1 (S (PP (IN During) (NP (JJ Doc_11079278_1418_1428_Chemical) (NN stress) (NN testing))) (, ,) (NP (NNP Doc_11079278_1445_1455_Chemical)) (VP (VP (VBZ attenuates)) (CC or) (VP (VBZ eliminates) (NP (NP (NN evidence)) (PP (IN of) (NP (NN Doc_11079278_1493_1512_Disease)))))) (. .)))
11079278	13	(S1 (S (NP (NN Glucagon) (CD 1) (NN mg)) (, ,) (SBAR (IN although) (S (ADJP (RB somewhat) (JJ effective)))) (, ,) (VP (AUX does) (RB not) (VP (VB correct) (NP (DT this) (NN effect)) (PP (TO to) (NP (DT the) (NN extent) (SBAR (IN that) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN administered) (ADVP (RB clinically))))))))))) (. .)))
11099450	0	(S1 (NP (NP (NN Evidence)) (PP (IN of) (NP (JJ functional) (NN somatotopy))) (PP (IN in) (NP (NNP GPi))) (PP (IN from) (NP (NP (NNS results)) (PP (IN of) (NP (NN pallidotomy))))) (. .)))
11099450	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (JJ functional) (NN anatomy)) (PP (IN of) (NP (NP (DT the) (JJ globus) (JJ pallidus) (NNS internus)) (PRN (-LRB- -LRB-) (NP (NNP GPi)) (-RRB- -RRB-))))) (PP (IN by) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ unilateral) (NN pallidotomy))) (PP (IN on) (NP (NP (NP (NNP Doc_11099450_227_239_Disease) (POS ')) (JJ off) ('' ') (NNS signs)) (CC and) (NP (NP (NNP Doc_11099450_256_264_Chemical-induced) (NNP Doc_11099450_273_284_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11099450_286_289_Disease)) (-RRB- -RRB-))))))))))))) (. .)))
11099450	2	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (JJ significant) (JJ positive) (NNS correlations)) (PP (IN between) (NP (NP (DT the) (JJ preoperative) (NNP Doc_11099450_360_368_Chemical) (NN responsiveness)) (PP (IN of) (NP (NP (NN motor) (NNS signs)) (CC and) (NP (NP (DT the) (NNP Doc_11099450_407_415_Chemical) (NN responsiveness)) (PP (IN of) (NP (NP (NNS scores)) (PP (IN in) (NP (NP (VBN timed) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (NNP Core) (NNP Assessment) (NNP Program)) (PP (IN for) (NP (NNP Intracerebral) (NNP Transplantations)))) (-RRB- -RRB-)))))))))))) (PP (IN in) (NP (NP (DT the) (JJ contralateral) (NNS limbs)) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (DT these) (NNS scores))) (PP (IN after) (NP (NN surgery)))))) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN with) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NNP Doc_11099450_652_655_Disease)))))))))) (. .)))
11099450	3	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (NP (NP (DT a) (ADJP (RB highly) (JJ significant)) (NN correlation)) (PRN (-LRB- -LRB-) (NP (NNP P)) (: :) (NP (NP (NNP <) (CD 0.0001)) (, ,) (NP (NN r) (SYM =) (CD 0.8))) (-RRB- -RRB-)) (PP (IN between) (NP (NP (DT the) (NN volume)) (PP (IN of) (NP (NP (NP (DT the) (JJ ventral) (NN lesion)) (PP (IN in) (NP (DT the) (NNP GPi)))) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NNP Doc_11099450_802_805_Disease))) (PP (IN in) (NP (DT the) (JJ contralateral) (NNS limbs))))))))) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (NP (NP (DT the) (JJ ventral) (NN volume)) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NP (NP (NNP Doc_11099450_917_929_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))))))) (. .)))
11099450	4	(S1 (S (NP (NP (DT The) (NNS volumes)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN lesion) (NN cylinder)) (CC and) (NP (DT the) (JJ dorsal) (NN lesion))))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (DT either) (NNP Doc_11099450_1051_1062_Disease) (CC or) (NNP Doc_11099450_1066_1078_Disease) (POS ')) (JJ off) ('' ') (NNS signs))))))) (. .)))
11099450	5	(S1 (S (S (NP (NP (DT The) (NN differential) (JJ predictive) (NN value)) (PP (IN of) (NP (NNP Doc_11099450_1129_1137_Chemical)))) (VP (VBP responsiveness) (PP (IN for) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (NP (NNP Doc_11099450_1172_1184_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))) (CC and) (S (NP (NP (NNP Doc_11099450_1201_1204_Disease)) (CC and) (NP (NP (DT the) (JJ different) (NNS correlations)) (PP (IN of) (NP (NP (JJ ventral) (NN lesion) (NN volume)) (PP (IN with) (NP (NP (NP (NNP Doc_11099450_1266_1277_Disease) (CC and) (NNP Doc_11099450_1282_1294_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ different) (ADJP (JJ anatomical) (CC or) (JJ pathophysiological)) (NNS substrates)) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NP (NP (NNP Doc_11099450_1416_1428_Disease) (POS ')) (JJ off) ('' ') (NNS signs)) (CC and) (NP (NNP Doc_11099450_1445_1456_Disease))))))))))))) (. .)))
11099450	6	(S1 (S (SBAR (IN Whereas) (S (NP (NP (NNS cells)) (PP (IN in) (NP (NP (DT a) (JJR wider) (NN area)) (PP (IN of) (NP (DT the) (NNP GPi)))))) (VP (MD may) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (NNP Doc_11099450_1520_1532_Disease)))))))) (, ,) (NP (DT the) (JJ ventral) (NNP GPi)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ crucial)) (PP (IN for) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NN Doc_11099450_1595_1598_Disease))))))))) (. .)))
11099450	7	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP$ our) (NNS observations)) (VP (AUX are) (NP (NP (JJ additional) (NN proof)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NN somatotopy)) (PP (IN of) (NP (DT the) (NNS systems))) (PP (IN within) (NP (NP (DT the) (NNS GPi)) (SBAR (WHNP (WDT that)) (S (VP (VB mediate) (NP (NP (NNP Doc_11099450_1726_1738_Disease) (CC and) (NNP Doc_11099450_1743_1754_Disease)) (, ,) (ADVP (RB especially))) (PP (IN along) (NP (NP (DT the) (JJ dorsoventral) (NN trajectory)) (VP (VBN used) (PP (IN in) (NP (NN pallidotomy)))))))))))))))))) (. .)))
11099450	8	(S1 (S (NP (NP (DT The) (NN outcome)) (PP (IN of) (NP (NP (NN pallidotomy)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN lesion)) (VP (VBZ involves) (NP (DT the) (JJ ventral) (CC and) (JJ dorsal) (NNS GPi)))))))) (VP (MD could) (VP (AUX be) (NP (NP (DT the) (JJ net) (NN effect)) (PP (IN of) (NP (NN alteration)))) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNS pathways)) (SBAR (WHNP (WDT which)) (S (VP (VP (VB mediate) (NP (JJ different) (NNS symptoms))) (, ,) (CC and) (ADVP (RB hence)) (VP (MD could) (VP (AUX be) (ADJP (JJ variable))))))))))))) (. .)))
11185967	0	(S1 (NP (NP (NN Screening)) (PP (IN for) (NP (NN stimulant) (NN use))) (PP (IN in) (NP (NN adult) (NN emergency) (NN department) (NN Doc_11185967_58_65_Disease) (NNS patients))) (. .)))
11185967	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ positive) (NN plasma) (NN drug) (NN screening))) (PP (IN for) (NP (NNP Doc_11185967_185_192_Chemical) (CC or) (NNP Doc_11185967_196_207_Chemical))) (PP (IN in) (NP (NN adult) (NN emergency) (NN department) (JJ Doc_11185967_238_245_Disease) (NNS patients)))))))) (. .)))
11185967	2	(S1 (S (NP (DT This) (JJ prospective) (NN study)) (VP (VBN evaluated) (NP (NP (JJ consecutive) (NN eligible) (NN Doc_11185967_319_326_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (NN plasma) (NN sample)) (VP (VBN collected) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (PRP$ their) (JJ clinical) (NN evaluation)))))))))))) (. .)))
11185967	3	(S1 (S (NP (NN Plasma)) (VP (AUX was) (VP (VBN tested) (PP (IN for) (NP (NP (NNP Doc_11185967_430_441_Chemical)) (CC and) (NP (NP (DT the) (JJ Doc_11185967_450_457_Chemical) (NN metabolite) (NNP Doc_11185967_469_484_Chemical)) (VP (VBG using) (NP (JJ enzyme-mediated) (NN immunoassay) (NN methodology)))))))) (. .)))
11185967	4	(S1 (S (NP (NP (NN Plasma) (NNS samples)) (PP (IN with) (NP (NP (JJ Doc_11185967_552_567_Chemical) (QP (JJR greater) (IN than) (CD 150) (CD ng/mL))) (CC or) (NP (DT an) (JJ Doc_11185967_597_608_Chemical) (QP (JJR greater) (IN than) (CD 500) (CD ng/mL)))))) (VP (AUX were) (VP (VBN defined) (PP (IN as) (NP (NN positive))))) (. .)))
11185967	5	(S1 (S (S (NP (NP (NN Patient) (NNS demographics)) (, ,) (NP (NP (NN history)) (PP (IN of) (NP (VBG underlying) (NN drug) (CC or) (JJ Doc_11185967_710_717_Chemical-related) (NN Doc_11185967_726_733_Disease) (NN disorder)))) (, ,)) (VP (VBD estimated) (NP (NN time)) (PP (PP (IN from) (NP (NNP Doc_11185967_764_771_Disease))) (PP (TO to) (NP (NP (NN sample) (NN collection)) (, ,) (NP (NN history)) (CC or) (NP (NP (NN suspicion)) (PP (IN of) (NP (NNP Doc_11185967_818_846_Disease))))))) (, ,) (S (NP (NP (NNS results)) (PP (IN of) (NP (JJ clinical) (NN urine)))) (VP (VBG testing) (PP (IN for) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse))))))))) (, ,) (CC and) (S (NP (JJ assay) (NNS results)) (VP (AUX were) (VP (VBN recorded) (PP (IN without) (NP (NN patient) (NNS identifiers)))))) (. .)))
11185967	6	(S1 (S (S (NP (QP (CD Fourteen) (IN of) (CD 248)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.6) (NN %)) (, ,) (NP (NP (NP (CD 95) (NN %)) (NN CI) (CD 2.7) (NN %)) (NP (CD -8.5) (NN %)))) (-RRB- -RRB-)) (NN plasma) (NNS samples)) (VP (AUX were) (ADJP (JJ positive) (PP (IN by) (NP (NP (JJ immunoassay) (NN testing)) (PP (IN for) (NP (NNP Doc_11185967_1069_1084_Chemical)))))))) (CC and) (S (NP (NP (DT no) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NP (CD 0) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NP (QP (CD CI) (CD 0-1.2)) (NN %)))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN for) (NP (NNP Doc_11185967_1138_1149_Chemical))))) (. .)))
11185967	7	(S1 (S (NP (JJ Positive) (NN test) (NNS results)) (VP (AUX were) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NP (JJ patient) (NNS visits)) (SBAR (WHADVP (WRB where)) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN history) (CC or) (NN suspicion)) (PP (IN of) (NP (NNP Doc_11185967_1250_1278_Disease))))))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.0005))) (-RRB- -RRB-))))) (. .)))
11185967	8	(S1 (S (PP (IN During) (NP (DT this) (NN study) (NN period))) (, ,) (NP (NP (JJ routine) (NN plasma) (NN screening)) (PP (IN for) (NP (NP (NNP Doc_11185967_1361_1368_Chemical)) (CC and) (NP (NNP Doc_11185967_1373_1385_Chemical)))) (PP (IN in) (NP (NN adult) (NN Doc_11185967_1395_1402_Disease) (NNS patients)))) (VP (AUX had) (NP (DT a) (JJ low) (NN yield))) (. .)))
11185967	9	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (JJ routine) (NN plasma) (NN screening)) (VP (MD would) (VP (VB yield) (NP (NP (JJ few) (NNS cases)) (PP (IN of) (NP (NN stimulant) (NN drug))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (EX there)) (VP (AUX was) (RB neither) (NP (NP (DT a) (NN history) (CC nor) (NN suspicion)) (PP (IN of) (NP (NNP Doc_11185967_1561_1571_Disease))) (PP (IN in) (NP (DT this) (NN population)))))))))) (. .)))
11195262	0	(S1 (NP (NP (NN Contribution)) (PP (IN of) (NP (NNP Doc_11195262_16_32_Chemical))) (PP (TO to) (NP (DT the) (NNP Doc_11195262_40_99_Disease))) (. .)))
11195262	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 62-year-old) (NN man)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN administered) (NP (NP (NNP Doc_11195262_162_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11195262_180_183_Chemical)) (-RRB- -RRB-))))))) (CC and) (SBAR (WHNP (WP who)) (S (ADVP (RB subsequently)) (VP (VBD developed) (NP (NP (DT the) (NNP Doc_11195262_220_279_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11195262_281_286_Disease)) (-RRB- -RRB-))))))))))) (. .)))
11195262	2	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_11195262_308_311_Chemical)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ idiopathic) (JJ generalized) (NN Doc_11195262_352_376_Disease))))) (SBAR (IN since) (S (NP (PRP he)) (VP (AUX was) (ADJP (NP (CD 56) (NNS years)) (JJ old)))))))) (. .)))
11195262	3	(S1 (S (PP (IN After) (S (VP (VBG substituting) (NP (NNP Doc_11195262_423_426_Chemical)) (PP (IN with) (NP (NNP Doc_11195262_432_442_Chemical)))))) (, ,) (NP (DT the) (JJ serum) (JJ Doc_11195262_454_460_Chemical) (NN level)) (VP (VBD returned) (PP (TO to) (NP (JJ normal)))) (. .)))
11195262	4	(S1 (S (NP (PRP We)) (VP (VBP consider) (S (NP (NP (DT this) (NN episode)) (PP (IN of) (NP (NNP Doc_11195262_515_520_Disease)))) (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNS factors)) (PP (VBG including) (NP (NP (DT a) (NN Doc_11195262_578_616_Disease)) (CC and) (NP (NP (DT the) (JJ long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_11195262_653_656_Chemical))))))))))))))) (. .)))
11208990	0	(S1 (NP (NP (NNP Association)) (PP (IN of) (NP (NP (JJ Doc_11208990_15_27_Chemical) (NN production)) (CC and) (NP (NN apoptosis)))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ experimental) (NNP Doc_11208990_80_91_Disease))))) (. .)))
11208990	1	(S1 (S (PP (IN In) (NP (JJ recent) (NNS studies))) (NP (NP (VBN increased) (NNS amounts)) (PP (IN of) (NP (NP (NP (NNP Doc_11208990_144_156_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11208990_158_160_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNS apoptosis))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ various) (JJ pathological) (NNS conditions)) (PP (IN in) (NP (DT the) (NN kidney)))))))) (. .)))
11208990	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN studied) (NP (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_11208990_275_277_Chemical)))) (CC and) (NP (NP (PRP$ its) (NN association)) (PP (IN with) (NP (NNS apoptosis))))) (PP (IN in) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_11208990_341_359_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11208990_393_403_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11208990_405_408_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
11208990	3	(S1 (S (NP (NP (DT The) (NN alteration)) (PP (IN in) (NP (DT the) (JJ Doc_11208990_442_444_Chemical) (NN pathway)))) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG measuring) (NP (JJ Doc_11208990_479_486_Chemical) (NNS levels)) (PP (PP (IN in) (NP (NN serum/urine))) (CC and) (PP (IN by) (S (VP (VBG evaluating) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJ vascular) (NN reactivity)) (PP (IN of) (NP (DT the) (VBN isolated) (JJ perfused) (NN rat) (NN kidney) (PRN (-LRB- -LRB-) (NP (NNP IPRK)) (-RRB- -RRB-)) (NN system))))))))))))))) (. .)))
11208990	4	(S1 (S (NP (NNS Rats)) (VP (AUX were) (ADJP (JJ stratified) (PP (IN into) (NP (NP (NN control) (NNS groups)) (CC and) (NP (JJ Doc_11208990_658_661_Chemical-induced) (JJ Doc_11208990_670_681_Disease) (NNS groups)))))) (. .)))
11208990	5	(S1 (S (NP (DT These) (CD two) (NNS groups)) (VP (AUX were) (ADVP (RB then)) (VP (VBN divided) (PP (IN into) (NP (: :) (NP (NP (NN group) (CD 1)) (, ,) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NN saline))))) (: ;) (CC and) (NP (NP (NN group) (CD 2)) (, ,) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NP (NNP Doc_11208990_797_811_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11208990_813_815_Chemical)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (JJ inducible-Doc_11208990_860_862_Chemical) (NN synthase))))))))))))))) (. .)))
11208990	6	(S1 (S (PP (IN On) (NP (NN day) (CD 21))) (, ,) (NP (NNS rats)) (VP (AUX were) (VP (VBN sacrificed) (PP (IN after) (S (VP (VBG obtaining) (NP (NP (NN material)) (PP (IN for) (NP (JJ biochemical) (NN analysis))))))))) (. .)))
11208990	7	(S1 (S (NP (NP (JJ Histopathological) (NN examination)) (PP (IN of) (NP (NP (DT the) (NNS kidneys)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11208990_1031_1034_Chemical))))))))) (VP (VBD revealed) (NP (NP (JJ focal) (NNS areas)) (PP (IN of) (NP (NP (NNP Doc_11208990_1059_1082_Disease)) (CC and) (NP (JJ mild) (NNP Doc_11208990_1092_1123_Disease)))))) (. .)))
11208990	8	(S1 (S (NP (PRP They)) (ADVP (RB also)) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NNS levels)) (PP (IN of) (NP (NNP Doc_11208990_1170_1181_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control)) (CC and) (NP (NP (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
11208990	9	(S1 (S (NP (NN Urine) (NN Doc_11208990_1243_1250_Chemical) (NNS levels)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1294_1297_Chemical-Doc_11208990_1298_1309_Disease) (NN group))) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
11208990	10	(S1 (S (PP (IN In) (NP (DT the) (NNP IPRK) (NNP Doc_11208990_1340_1353_Chemical) (CC and) (NNP Doc_11208990_1358_1371_Chemical))) (NP (VBN related) (NNS responses)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN impaired) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1425_1428_Chemical-Doc_11208990_1429_1440_Disease) (NN group))))) (. .)))
11208990	11	(S1 (S (NP (NN Apoptosis)) (VP (AUX was) (RB not) (VP (VBN detected) (PP (IN in) (NP (NNS controls))))) (. .)))
11208990	12	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1504_1507_Chemical-Doc_11208990_1508_1519_Disease) (NN group))) (, ,) (NP (JJ numerous) (NN apoptotic) (NNS cells)) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ tubulointerstitial) (NNS areas))))) (. .)))
11208990	13	(S1 (S (NP (JJ Double) (NN staining)) (VP (VBD revealed) (NP (NP (JJ numerous) (JJ interstitial) (NN apoptotic) (NNS cells)) (SBAR (S (VP (TO to) (VP (VB stain) (PP (IN for) (NP (NP (NNP ED1)) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NNS monocytes/macrophages)))))))))))) (. .)))
11208990	14	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_11208990_1733_1735_Chemical)))) (VP (VP (VBD prevented) (NP (NP (DT the) (NN impairment)) (PP (IN of) (NP (JJ renal) (JJ vascular) (NN bed) (NNS responses))))) (CC and) (VP (VBD reduced) (NP (NP (DT both) (NN urine) (JJ Doc_11208990_1816_1823_Chemical) (NNS levels)) (CC and) (NP (NP (NNS apoptosis)) (PP (TO to) (NP (NN control) (NNS levels))))))) (. .)))
11208990	15	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NNP Doc_11208990_1913_1915_Chemical)) (CC and) (NP (NNS apoptosis))))) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT the) (JJ Doc_11208990_1971_1974_Chemical-induced) (NN Doc_11208990_1983_1992_Disease))))))))) (. .)))
11226639	0	(S1 (NP (NP (JJ Dual) (NNS effects)) (PP (IN of) (NP (NNP Doc_11226639_16_25_Chemical))) (PP (IN on) (NP (NP (NNP Doc_11226639_29_40_Chemical-induced) (NNP Doc_11226639_49_57_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
11226639	1	(S1 (S (S (NP (NN Doc_11226639_67_76_Chemical)) (VP (VBZ affects) (NP (DT the) (NN circadian) (NN sleep/wake) (NN cycle)))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ clear)) (SBAR (IN whether) (S (NP (PRP it)) (VP (MD may) (VP (VB influence) (NP (JJ drug-induced) (NN Doc_11226639_175_183_Disease)))))))) (. .)))
11226639	2	(S1 (S (NP (NN Doc_11226639_185_203_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intraperitoneally)) (PP (IN into) (NP (NP (JJ male) (NNS rats)) (VP (VBN pre-treated) (PP (IN with) (NP (NP (NNP Doc_11226639_271_280_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.05) (, ,) (CD 0.5) (, ,) (CD 5) (CC and) (CD 50) (NN mg/kg)) (-RRB- -RRB-))))))))) (. .)))
11226639	3	(S1 (S (NP (NP (JJ Doc_11226639_310_319_Chemical) (NN pre-treatment)) (VP (VBN affected) (PP (IN in) (NP (DT a) (JJ dual) (NN manner))) (NP (NNP Doc_11226639_360_371_Chemical) (NNP Doc_11226639_372_380_Disease)))) (, ,) (ADVP (RB however)) (, ,) (NP (DT no) (JJ dose-effect) (NN correlation)) (VP (AUX was) (VP (VBN found))) (. .)))
11226639	4	(S1 (S (PP (IN In) (NP (NN particular))) (, ,) (NP (JJ low) (NNS doses)) (VP (VP (VBD reduced) (NP (DT the) (NN latency)) (PP (TO to))) (CC and) (VP (VBN prolonged) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_11226639_507_518_Chemical) (NNP Doc_11226639_519_527_Disease)))))) (. .)))
11226639	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11226639_562_571_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-))))) (VP (VP (VBD caused) (NP (NP (DT a) (JJ paradoxical) (NN increase)) (PP (IN in) (NP (DT the) (NN latency))))) (CC and) (VP (VBD produced) (NP (NP (NP (DT a) (JJ sustained) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_11226639_682_690_Disease)))))) (, ,) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN mortality) (NN rate))))))) (. .)))
11226639	6	(S1 (S (NP (NNP Doc_11226639_727_736_Chemical) (CD 0.5) (CC and) (CD 5)) (ADVP (RB mg/kg)) (VP (VBD influenced) (NP (NP (DT the) (NN duration)) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN latency)) (PP (IN of) (NP (NNP Doc_11226639_800_808_Chemical-) (CC or) (NNP Doc_11226639_813_821_Chemical-induced) (NNP Doc_11226639_830_838_Disease)))))) (. .)))
11226639	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ dual) (NN action)) (PP (IN of) (NP (NNP Doc_11226639_865_874_Chemical))) (PP (IN on) (NP (JJ pharmacological) (NNP Doc_11226639_894_902_Disease)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ specific)) (PP (IN for) (NP (NP (DT the) (JJ Doc_11226639_932_943_Chemical) (NN mechanism)) (PP (IN of) (NP (NN action))))))))) (. .)))
11230490	0	(S1 (S (NP (JJ Reduced) (NNP Doc_11230490_8_22_Disease)) (VP (CC and) (VP (VBD preserved) (NP (NP (NN antitumor) (NN efficacy)) (PP (IN of) (NP (JJ liposome-encapsulated) (NNP Doc_11230490_81_92_Chemical) (CC and) (NNP Doc_11230490_97_113_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ conventional) (NNP Doc_11230490_141_152_Chemical)) (CC and) (NP (NNP Doc_11230490_157_173_Chemical))))) (PP (IN in) (NP (NP (DT a) (JJ randomized) (, ,) (JJ multicenter) (NN trial)) (PP (IN of) (NP (JJ metastatic) (NNP Doc_11230490_223_236_Disease))))))) (. .)))
11230490	1	(S1 (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_11230490_268_274_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ liposome-encapsulated) (NNP Doc_11230490_298_309_Chemical)) (: ;) (NP (NP (NNP The) (NNP Liposome) (NNP Company)) (, ,) (NP (NN Elan) (NN Corporation)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_11230490_386_402_Chemical)))))) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NNP Doc_11230490_425_436_Chemical) (NNP Doc_11230490_437_451_Disease)) (SBAR (IN while) (S (VP (VBG providing) (NP (JJ comparable) (NN antitumor) (NN efficacy)) (PP (IN in) (NP (NP (JJ first-line) (NN treatment)) (PP (IN of) (NP (NP (JJ metastatic) (NNP Doc_11230490_536_549_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11230490_551_554_Disease)) (-RRB- -RRB-)))))))))))))) (. .)))
11230490	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NP (QP (CD Two) (CD hundred)) (JJ ninety-seven) (NNS patients)) (PP (IN with) (NP (NNP Doc_11230490_618_621_Disease)))) (CC and) (NP (NP (DT no) (JJ prior) (NN chemotherapy)) (PP (IN for) (NP (JJ metastatic) (NN disease))))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (CD 60) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (NNP Doc_11230490_719_725_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP M)) (-RRB- -RRB-))) (CC or) (NP (JJ conventional) (NNP Doc_11230490_746_757_Chemical))))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))))) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (CD 600) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (NNP Doc_11230490_798_814_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP C)) (-RRB- -RRB-))) (, ,) (NP (NP (DT every) (CD 3) (NNS weeks)) (PP (IN until) (NP (NN disease) (NN progression)))) (CC or) (NP (JJ unacceptable) (NNP Doc_11230490_876_884_Disease)))))))))) (. .)))
11230490	3	(S1 (S (NP (NN Doc_11230490_886_900_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN by) (NP (NP (NNS reductions)) (PP (IN in) (NP (JJ left-ventricular) (NN ejection) (NN fraction))) (, ,) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ serial) (JJ multigated) (NN radionuclide) (NN angiography) (NNS scans)) (, ,) (CC or) (NP (NP (NNP Doc_11230490_1031_1055_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11230490_1057_1060_Disease)) (-RRB- -RRB-)))))))))) (. .)))
11230490	4	(S1 (S (NP (JJ Antitumor) (NN efficacy)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (NP (JJ objective) (NNP Doc_11230490_1108_1113_Disease) (NN response) (NNS rates)) (PRN (-LRB- -LRB-) (NP (NNP World) (NNP Health) (NNP Organization) (NNS criteria)) (-RRB- -RRB-))) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (NP (NN progression)) (, ,) (CC and) (NP (NN survival))))))))) (. .)))
11230490	5	(S1 (S (NP (NP (NP (CD Six) (NN percent)) (PP (IN of) (NP (NNP MC) (NNS patients)))) (CC versus) (NP (NP (NP (CD 21) (NN %)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (NNP Doc_11230490_1274_1277_Disease))))) (-RRB- -RRB-))) (PP (IN of) (NP (NN AC) (NNS patients))))) (VP (VBD developed) (NP (NP (NNP Doc_11230490_1304_1318_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD =.0002)) (-RRB- -RRB-)))) (. .)))
11230490	6	(S1 (S (NP (NP (JJ Median) (JJ cumulative) (JJ Doc_11230490_1349_1360_Chemical) (NN dose)) (PP (IN at) (NP (NN onset)))) (VP (AUX was) (NP (NP (QP (JJR more) (IN than) (CD 2,220)) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP MC) (CC versus) (CD 480) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP AC)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (CD =.0001)) (, ,) (NP (NN hazard) (NN ratio)) (, ,) (NP (CD 5.04))) (-RRB- -RRB-)))))))) (. .)))
11230490	7	(S1 (S (NP (NNP MC) (NNS patients)) (ADVP (RB also)) (VP (VBD experienced) (NP (JJR less) (NN grade) (CD 4) (NN Doc_11230490_1510_1521_Disease))) (. .)))
11230490	8	(S1 (UCP (S (NP (NP (JJ Antitumor) (NN efficacy)) (PP (IN of) (NP (NNP MC) (CC versus) (NNP AC)))) (VP (AUX was) (ADJP (JJ comparable)))) (: :) (NP (NP (JJ objective) (NN response) (NNS rates)) (, ,) (NP (NP (NP (NP (CD 43) (NN %)) (PP (IN versus) (NP (CD 43) (NN %)))) (: ;) (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN progression)) (, ,) (NP (CD 5.1) (NN %)) (CC versus) (NP (CD 5.5) (NNS months))))) (: ;) (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN treatment) (NN failure)) (, ,) (NP (QP (CD 4.6) (CC versus) (CD 4.4)) (NNS months))))) (: ;) (CC and) (NP (JJ median) (NN survival))) (, ,) (NP (QP (CD 19) (CC versus) (CD 16)) (NNS months)))) (. .)))
11230490	9	(S1 (S (NP (NNP Doc_11230490_1779_1785_Chemical)) (VP (VP (VBZ improves) (NP (NP (DT the) (JJ therapeutic) (NN index)) (PP (IN of) (NP (NNP Doc_11230490_1820_1831_Chemical)))) (PP (IN by) (S (VP (VP (ADVP (RB significantly)) (VBG reducing) (NP (NNP Doc_11230490_1858_1872_Disease))) (CC and) (VP (NN grade) (NP (CD 4) (NN Doc_11230490_1885_1896_Disease))))))) (CC and) (VP (VBZ provides) (NP (JJ comparable) (NN antitumor) (NN efficacy)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_11230490_1971_1987_Chemical))))) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NNP Doc_11230490_2014_2017_Disease)))))))))) (. .)))
11243580	0	(S1 (NP (NP (DT The) (NN role)) (PP (IN of) (NP (JJ nitrergic) (NN system))) (PP (IN in) (NP (NP (NNP Doc_11243580_32_41_Chemical-induced) (NNP Doc_11243580_50_60_Disease)) (PP (IN in) (NP (DT the) (NN mouse))))) (. .)))
11243580	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_11243580_90_121_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11243580_123_129_Chemical)) (-RRB- -RRB-)) (NP (DT a) (NNP Doc_11243580_133_145_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11243580_147_149_Chemical)) (-RRB- -RRB-)) (NN synthase) (NN inhibitor))) (CC and) (NP (NP (NNP Doc_11243580_174_184_Chemical)) (, ,) (NP (DT a) (JJ Doc_11243580_188_190_Chemical) (NN precursor)) (, ,))))) (VP (AUX were) (VP (VBN investigated) (PP (IN on) (NP (NNP Doc_11243580_223_232_Chemical-induced) (NNP Doc_11243580_241_252_Disease))))) (. .)))
11243580	2	(S1 (S (PP (IN In) (NP (DT the) (JJ first) (NN experiment))) (, ,) (NP (NP (CD four) (NNS groups)) (PP (IN of) (NP (NNS mice)))) (VP (VBD received) (NP (NP (JJ physiological) (NN saline)) (PRN (-LRB- -LRB-) (NP (CD 0.9) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP Doc_11243580_337_347_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 300) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_11243580_367_373_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_11243580_396_404_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively)))) (. .)))
11243580	3	(S1 (S (PP (NP (CD Thirty) (NNS minutes)) (IN after) (NP (DT these) (NNS injections))) (, ,) (NP (DT all) (NNS mice)) (VP (VBD received) (NP (NP (NNP Doc_11243580_487_496_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN mg/kg)) (, ,) (NP (NN i.p.))) (-RRB- -RRB-)))) (. .)))
11243580	4	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ second) (NN experiment)) (, ,) (NP (NP (CD four) (NNS groups)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN received) (NP (JJ similar) (NN treatment)) (PP (IN in) (NP (DT the) (JJ first) (NN experiment))))))) (, ,) (CC and) (NP (NP (CD 30) (NN min)) (PP (IN after) (NP (DT these) (NNS injections)))))) (, ,) (NP (DT all) (NNS mice)) (VP (VBD received) (NP (NP (DT a) (JJR higher) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11243580_683_692_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN mg/kg)) (-RRB- -RRB-)))))) (. .)))
11243580	5	(S1 (S (NP (NP (NP (NNP Doc_11243580_705_711_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (CD mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_11243580_734_742_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11243580_794_803_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-))) (NP (JJ -induced) (NNP Doc_11243580_823_834_Disease))) (. .)))
11243580	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT the) (JJ Doc_11243580_853_863_Chemical) (NN treatment)) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ Doc_11243580_901_910_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 80) (NN mg/kg)) (, ,) (NP (NNP i.p.))) (-RRB- -RRB-)) (JJ -induced) (NN Doc_11243580_936_947_Disease)))) (ADVP (RB significantly))) (. .)))
11243580	7	(S1 (S (NP (DT These) (NNS results)) (VP (MD may) (VP (VB suggest) (SBAR (IN that) (S (NP (NNP Doc_11243580_994_996_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ proconvulsant) (NN mediator)) (PP (IN in) (NP (JJ Doc_11243580_1028_1037_Chemical-induced) (NN Doc_11243580_1046_1057_Disease))))))))) (. .)))
11245434	0	(S1 (S (NP (NN Erythropoietin)) (VP (VBZ restores) (NP (NP (DT the) (JJ Doc_11245434_28_34_Disease-induced) (NN reduction)) (PP (IN in) (NP (NP (NNP Doc_11245434_56_72_Chemical) (NNP Doc_11245434_73_85_Disease)) (PP (IN in) (NP (NN rat) (NN Doc_11245434_93_99_Disease))))))) (. .)))
11245434	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NN Doc_11245434_152_158_Disease) (NN prevention))) (PP (IN by) (NP (JJ recombinant) (JJ human) (NN erythropoietin) (PRN (-LRB- -LRB-) (NN rHuEPO) (-RRB- -RRB-)) (NN treatment))) (PP (IN on) (NP (NP (DT the) (NNP Doc_11245434_232_244_Disease)) (PP (IN of) (NP (NNP Doc_11245434_248_264_Chemical))) (PP (IN in) (NP (JJ solid) (JJ experimental) (NN Doc_11245434_287_293_Disease)))))))))) (. .)))
11245434	2	(S1 (S (NP (NN Doc_11245434_295_301_Disease)) (VP (AUX was) (VP (VBN induced) (S (VP (VBG using) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11245434_337_348_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-)))) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (DT a) (JJ long-lasting) (NN reduction)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN hemoglobin) (NN concentration))))))))))) (. .)))
11245434	3	(S1 (S (PP (IN In) (NP (DT a) (JJ second) (NN group))) (, ,) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11245434_480_486_Disease)))) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN rHuEPO)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NN IU/kg)) (-RRB- -RRB-)) (VP (VBN administered) (NP (NNP s.c.) (CD three)) (S (VP (NN times/week) (S (VP (VBG starting) (NP (CD 7) (NNS days)) (PP (IN before) (NP (JJ Doc_11245434_582_593_Chemical) (NN application)))))))))))) (. .)))
11245434	4	(S1 (S (PP (NP (CD Four) (NNS days)) (IN after) (NP (JJ Doc_11245434_623_634_Chemical) (NN treatment))) (, ,) (NP (NP (NNP Doc_11245434_646_652_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN DS-Doc_11245434_657_664_Disease)) (PP (IN of) (NP (DT the) (NN rat)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN implanted) (NP (NNP s.c.)) (PP (IN onto) (NP (DT the) (JJ hind) (NN food) (NN dorsum))))) (. .)))
11245434	5	(S1 (S (NP (CC Neither) (NP (NNP Doc_11245434_732_743_Chemical)) (CC nor) (NP (NN rHuEPO) (NN treatment))) (VP (VBD influenced) (NP (NNP Doc_11245434_776_781_Disease) (NN growth) (NN rate)) (ADVP (FW per) (FW se))) (. .)))
11245434	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_11245434_807_813_Disease)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11245434_849_865_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-)) (NP (CD 5) (NNS days)))) (PP (IN after) (NP (NN implantation))))))) (, ,) (NP (NP (DT a) (NN growth) (NN delay)) (PP (IN with) (NP (NP (DT a) (JJ subsequent) (NN regrowth)) (PP (IN of) (NP (DT the) (NNP Doc_11245434_958_964_Disease)))))) (VP (AUX was) (VP (VBN observed))) (. .)))
11245434	7	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_11245434_986_992_Disease) (NN group))) (, ,) (NP (DT the) (NN growth) (NN delay)) (VP (AUX was) (ADJP (RB significantly) (JJR shorter)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ nonanemic) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 13.3) (NNS days)) (CC versus) (NP (CD 8.6) (NNS days))) (-RRB- -RRB-)))))) (. .)))
11245434	8	(S1 (S (PP (IN In) (NP (NP (DT the) (NN group)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_11245434_1124_1130_Disease)) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (JJ rHuEPO) (NN treatment))))))))) (, ,) (NP (NN growth) (NN delay)) (VP (AUX was) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ nonanemic) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 13.3) (NNS days)) (-RRB- -RRB-)))))))) (. .)))
11245434	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ chemotherapy-induced) (NN Doc_11245434_1287_1293_Disease)) (VP (VBZ reduces) (NP (NP (NNP Doc_11245434_1302_1314_Disease)) (PP (IN of) (NP (NNP Doc_11245434_1318_1334_Chemical)))) (PP (IN in) (NP (NNP Doc_11245434_1338_1344_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN correction)) (PP (IN of) (NP (NNP Doc_11245434_1368_1374_Disease))) (PP (IN by) (NP (NP (JJ rHuEPO) (NN treatment)) (PRN (-LRB- -LRB-) (NP (JJ epoetin) (NN alpha)) (-RRB- -RRB-))))) (VP (VBZ increases) (NP (DT the) (NN sensitivity)) (, ,) (ADVP (RB probably)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT an) (VBN improved) (JJ Doc_11245434_1474_1480_Chemical) (NN supply)) (PP (TO to) (NP (NNP Doc_11245434_1491_1496_Disease) (NN tissue)))))))))))))) (. .)))
11271907	0	(S1 (S (NP (JJ Fatal) (NN Doc_11271907_6_30_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_11271907_44_60_Chemical) (NN therapy)))) (. .)))
11271907	1	(S1 (S (NP (NN Doc_11271907_70_94_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ important)) (NN complication)) (PP (IN of) (NP (JJ Doc_11271907_135_151_Chemical) (NN therapy))))) (. .)))
11271907	2	(S1 (S (NP (NP (JJ Echocardiographic) (NN identification)) (PP (IN of) (NP (DT the) (NN disorder)))) (VP (MD can) (VP (AUX be) (VP (VBN made)))) (. .)))
11271907	3	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (IN that) (S (NP (NP (DT the) (NN ultrasound) (NNS features)) (PP (IN of) (NP (DT this) (NN disorder)))) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN reported))))))) (. .)))
11282081	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_11282081_11_20_Chemical))) (PP (IN on) (NP (NP (NNP Doc_11282081_24_43_Disease)) (CC and) (NP (NP (PRP$ its) (JJ electrophysiological) (NNS determinants)) (PP (IN in) (NP (NNS dogs)))))) (. .)))
11282081	1	(S1 (S (NP (JJ Doc_11282081_107_125_Disease-induced) (NN remodeling)) (VP (VP (VBZ promotes) (NP (NP (DT the) (NN occurrence) (CC and) (NN maintenance)) (PP (IN of) (NP (NP (NNP Doc_11282081_188_207_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11282081_209_211_Disease)) (-RRB- -RRB-)))))) (CC and) (VP (VBZ decreases) (NP (NNP L-type) (NNP Doc_11282081_234_236_Chemical) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-)) (NN current)))) (. .)))
11282081	2	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB also)) (NP (DT a) (JJ clinical) (NN suggestion) (SBAR (IN that) (S (NP (JJ acute) (NNP L-type) (NNP Doc_11282081_304_306_Chemical) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN channel) (NN blockade)) (VP (MD can) (VP (VB promote) (NP (NP (NNP Doc_11282081_339_341_Disease)) (, ,) (NP (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ Doc_11282081_362_364_Disease) (VBG promoting) (NN effect)) (PP (IN of) (NP (NNP Doc_11282081_385_387_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-)) (NN channel) (NN inhibition))))))))) (. .)))
11282081	3	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ potential) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_11282081_461_463_Disease) (NN promotion))) (PP (IN by) (NP (JJ Doc_11282081_477_479_Chemical) (PRN (-LRB- -LRB-) (JJ 2+) (-RRB- -RRB-)) (NN channel) (NNS blockers))))))) (, ,) (NP (PRP we)) (VP (VBN administered) (NP (NNP Doc_11282081_518_527_Chemical)) (PP (TO to) (NP (JJ Doc_11282081_531_539_Chemical-Doc_11282081_540_550_Chemical) (JJ anesthetized) (NNS dogs)))) (. .)))
11282081	4	(S1 (S (S (NP (NN Doc_11282081_570_579_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN comparison) (NN drug) (CC and) (NN autonomic) (NN blockade)) (PP (IN with) (NP (NNP Doc_11282081_638_646_Chemical)))))))) (CC and) (S (NP (NNP Doc_11282081_651_658_Chemical)) (VP (AUX was) (VP (VBN applied) (PP (IN in) (NP (DT some) (NNS experiments)))))) (. .)))
11282081	5	(S1 (S (NP (NP (JJ Epicardial) (NN mapping)) (PP (IN with) (NP (CD 240) (JJ epicardial) (NNS electrodes)))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NN activation)) (PP (IN during) (NP (NN Doc_11282081_781_783_Disease)))))))) (. .)))
11282081	6	(S1 (S (NP (NN Doc_11282081_794_803_Chemical)) (VP (VBD caused) (NP (NNP Doc_11282081_811_813_Disease) (NN promotion)) (PP (IN in) (NP (CD six) (NNS dogs))) (, ,) (S (VP (VBG increasing) (NP (NP (JJ mean) (NN duration)) (PP (IN of) (NP (NNP Doc_11282081_865_867_Disease))) (VP (VBN induced) (PP (IN by) (NP (NN burst) (NN pacing))))))) (, ,) (PP (PP (IN from) (NP (NP (JJ 8+/-4) (NNP s)) (PRN (-LRB- -LRB-) (FW mean+/-S.E.) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NP (CD 95+/-39) (NNP s)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01) (FW vs.) (NN control)) (-RRB- -RRB-)) (PP (IN at) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 0.1) (NN mg/kg)))))) (CC and) (NP (NP (CD 228+/-101) (NNP s)) (PRN (-LRB- -LRB-) (NP (NNP P<0.0005) (FW vs.) (NN control)) (-RRB- -RRB-)))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.2) (NN mg/kg)))))) (. .)))
11282081	7	(S1 (S (NP (JJ Underlying) (NN electrophysiological) (NNS mechanisms)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NN detail))) (PP (PP (IN in) (NP (NP (CD five) (JJ additional) (NNS dogs)) (PP (IN under) (NP (NN control) (NNS conditions))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NNP Doc_11282081_1205_1214_Chemical)))))))))) (. .)))
11282081	8	(S1 (S (PP (IN In) (NP (DT these) (NNS experiments))) (, ,) (NP (NNP Doc_11282081_1238_1247_Chemical)) (VP (VP (VBN shortened) (NP (NP (JJ mean) (JJ effective) (JJ refractory) (NN period)) (PRN (-LRB- -LRB-) (NP (NNP ERP)) (-RRB- -RRB-))) (PP (IN from) (NP (CD 122+/-5))) (PP (TO to) (NP (NP (JJ 114+/-4) (NNS ms)) (PRN (-LRB- -LRB-) (NP (NNP P<0.02)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (DT a) (NN cycle) (NN length)) (PP (IN of) (NP (CD 300) (NNS ms)))))) (, ,) (VP (VBD decreased) (NP (NP (NNP ERP) (CD heterogeneity)) (PRN (-LRB- -LRB-) (PP (IN from) (ADJP (JJ 15+/-1) (PP (TO to) (NP (CD 10+/-1) (NN %))))) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)))) (, ,) (VP (ADVP (RB heterogeneously)) (VBN accelerated) (NP (JJ atrial) (NN conduction))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (NN cycle) (NN length)) (PP (IN of) (NP (NP (NNP Doc_11282081_1504_1506_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN 94+/-4)) (PP (TO to) (NP (JJ 84+/-3) (NNS ms)))) (, ,) (NP (NNP P<0.005)) (-RRB- -RRB-))))))) (. .)))
11282081	9	(S1 (S (NP (NNP Doc_11282081_1539_1548_Chemical)) (VP (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (NN ERP)) (, ,) (NP (NNP Doc_11282081_1569_1571_Disease) (NN cycle) (NN length)) (CC or) (NP (JJ Doc_11282081_1588_1590_Disease) (NN duration))))) (, ,) (CC but) (VP (VBD produced) (NP (NP (NN conduction) (NN acceleration)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_11282081_1664_1673_Chemical)) (PRN (-LRB- -LRB-) (NP (NN n=5)) (-RRB- -RRB-))))))))))) (. .)))
11282081	10	(S1 (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ autonomic) (NN blockade))))) (, ,) (NP (NNP Doc_11282081_1720_1729_Chemical)) (VP (VP (VBD failed) (S (VP (TO to) (VP (VB promote) (NP (NNP Doc_11282081_1748_1750_Disease)))))) (CC and) (VP (VBD increased)) (, ,) (CONJP (RB rather) (IN than)) (VP (VBG decreasing) (, ,) (NP (NN refractoriness)))) (. .)))
11282081	11	(S1 (S (NP (CC Neither) (NP (NNP Doc_11282081_1814_1823_Chemical)) (CC nor) (NP (NNP Doc_11282081_1828_1837_Chemical))) (VP (VBD affected) (NP (JJ atrial) (NN conduction)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ autonomic) (NN blockade)))))) (. .)))
11282081	12	(S1 (S (NP (JJ Epicardial) (NN mapping)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_11282081_1938_1947_Chemical)) (VP (VBD promoted) (NP (NNP Doc_11282081_1957_1959_Disease)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ simultaneous) (NNS wavefronts)) (VP (VBN reflected) (PP (IN by) (NP (NP (JJ separate) (NNS zones)) (PP (IN of) (NP (NN reactivation))))) (PP (IN in) (NP (DT each) (NN cycle)))))))))))))) (. .)))
11282081	13	(S1 (S (NP (NNP Doc_11282081_2084_2093_Chemical)) (VP (VBZ promotes) (NP (NP (NN Doc_11282081_2103_2105_Disease)) (PP (IN in) (NP (JJ normal) (NNS dogs)))) (PP (IN by) (S (VP (VBG promoting) (NP (JJ multiple) (NN circuit) (NN reentry))))) (, ,) (S (NP (DT an) (NN effect)) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ intact) (JJ autonomic) (NN tone)) (CC and) (NP (NP (RB not)) (VP (VBN shared) (PP (IN by) (NP (NNP Doc_11282081_2223_2232_Chemical)))))))))) (. .)))
11284996	0	(S1 (S (NP (NNP Calcitonin)) (VP (VBD gene-related) (NP (NN peptide) (NNS levels)) (PP (IN during) (NP (NP (JJ Doc_11284996_46_58_Chemical-induced) (NN Doc_11284996_67_75_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_11284996_101_122_Disease)))))))) (. .)))
11284996	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (NNP Doc_11284996_150_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11284996_164_166_Chemical)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NNP Doc_11284996_176_184_Disease)) (PP (IN in) (NP (NNP Doc_11284996_188_205_Disease))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN release)) (PP (IN of) (NP (NP (JJ calcitonin) (JJ gene-related) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP CGRP)) (-RRB- -RRB-)))))))))))))) (. .)))
11284996	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NNP CGRP)))) (PP (IN during) (NP (NP (NNP Doc_11284996_354_362_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNP Doc_11284996_378_380_Chemical) (NN donor) (NNP Doc_11284996_387_406_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11284996_408_411_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_11284996_441_462_Disease)) (CC and) (NP (CD 16) (JJ healthy) (NNS controls))))))))))))) (. .)))
11284996	3	(S1 (S (NP (DT The) (NNS subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (CD 0.5) (NN microg/kg/min) (NN Doc_11284996_554_557_Chemical) (CC or) (NN placebo)) (PP (IN over) (NP (NP (CD 20) (NN min)) (PP (IN on) (NP (CD two) (JJ Doc_11284996_588_596_Disease-free) (NNS days)))))))))) (. .)))
11284996	4	(S1 (S (NP (NN Blood) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN at) (NP (NN baseline) (, ,) (CD 10) (, ,) (CD 20) (CC and) (CD 60) (NN min))) (PP (IN after) (NP (NP (NN start)) (PP (IN of) (NP (NN infusion))))))) (. .)))
11284996	5	(S1 (S (S (NP (DT Both) (NNS patients) (CC and) (NNS controls)) (VP (VBD developed) (NP (ADJP (RB significantly) (JJR stronger)) (JJ immediate) (NN Doc_11284996_763_771_Disease)) (PP (IN on) (NP (NP (DT the) (JJ Doc_11284996_779_782_Chemical) (NN day)) (ADVP (IN than) (PP (IN on) (NP (DT the) (NN placebo) (NN day)))))))) (CC and) (S (NP (DT the) (NNP Doc_11284996_819_827_Disease)) (VP (AUX was) (ADJP (ADJP (RB significantly) (RBR more) (JJ pronounced)) (PP (IN in) (NP (NNS patients))) (PP (IN than) (PP (IN in) (NP (NNS controls))))))) (. .)))
11284996	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN CGRP) (NN curve)))))) (PRN (-LRB- -LRB-) (NP (NNP AUCCGRP)) (-RRB- -RRB-)) (PP (IN on) (NP (NP (NNP Doc_11284996_967_970_Chemical) (FW vs.) (NN placebo) (NN day)) (PP (IN in) (NP (NP (NP (DT either) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP P=0.65)) (-RRB- -RRB-))) (CC or) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.48)) (-RRB- -RRB-)))))))) (. .)))
11284996	7	(S1 (S (NP (NP (DT The) (NNP AUCCGRP)) (VP (VBN recorded) (PP (IN on) (NP (DT the) (JJ Doc_11284996_1065_1068_Chemical) (NN day))))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (NP (NNS patients)) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.36)) (-RRB- -RRB-))))))) (. .)))
11284996	8	(S1 (S (PP (DT Both) (IN in) (NP (NP (NNS patients)) (CC and) (NP (NNS controls)))) (, ,) (NP (NNP CGRP) (NNS levels)) (VP (VBD changed) (ADVP (RB significantly)) (PP (IN over) (NP (NN time))) (, ,) (PP (IN on) (NP (NP (PDT both) (DT the) (JJ Doc_11284996_1216_1219_Chemical) (CC and) (NN placebo) (NNS days)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
11284996	9	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ Doc_11284996_1282_1284_Chemical-induced) (JJ immediate) (NN Doc_11284996_1303_1311_Disease)) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NN release)) (PP (IN of) (NP (NN CGRP)))))))))) (. .)))
11302406	0	(S1 (NP (JJ Doc_11302406_0_11_Chemical-induced) (NN Doc_11302406_20_38_Disease) (. .)))
11302406	1	(S1 (S (VP (TO To) (VP (VP (VB present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ Doc_11302406_72_83_Chemical-associated) (NNP Doc_11302406_95_113_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11302406_115_118_Disease)) (-RRB- -RRB-)))))) (CC and) (VP (VB discuss) (NP (NP (NP (NNP Doc_11302406_132_143_Chemical) (POS 's)) (NN role)) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_11302406_162_165_Disease))))))))) (. .)))
11302406	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 68-year-old) (JJ white) (NN woman)) (PP (IN with) (NP (NP (NNP Candida) (NNS glabrata)) (VP (VBN isolated) (PP (IN from) (NP (NP (DT a) (JJ presacral) (NN abscess)) (VP (VBN developed) (PP (NP (NNP Doc_11302406_273_276_Disease) (CD eight) (NNS days)) (IN after) (S (VP (VBG commencing) (NP (JJ oral) (NNP Doc_11302406_310_321_Chemical)) (SBAR (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_11302406_364_367_Disease))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_11302406_379_402_Disease)) (, ,) (NP (NNP Doc_11302406_404_418_Disease)) (, ,) (NP (NNP Doc_11302406_420_444_Disease)) (, ,) (CC and) (NP (NP (JJ electrolyte) (NNS abnormalities)) (SBAR (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11302406_535_546_Chemical) (CC and) (NNP Doc_11302406_551_554_Disease))))))))))))))))))))))))) (. .)))
11302406	3	(S1 (S (S (NP (DT The) (NNP Doc_11302406_560_563_Disease)) (VP (VBD resolved) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11302406_578_589_Chemical)) (VP (AUX was) (VP (VBN discontinued))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (DT the) (NN patient)) (VP (VBD continued) (S (VP (TO to) (VP (VP (AUX have) (NP (NNP Doc_11302406_647_681_Disease))) (CC and) (VP (VBD nonsustained) (NP (NP (NNP Doc_11302406_699_722_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11302406_724_728_Disease)) (-RRB- -RRB-))) (PP (IN until) (NP (CD six) (NNS days))) (PP (IN after) (NP (NN drug) (NN cessation) (NN DISCUSSION))))))))) (: :) (S (NP (NP (NN Use)) (PP (IN of) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale)))) (VP (VBZ indicates) (NP (NP (DT a) (JJ probable) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_11302406_868_879_Chemical)) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11302406_903_906_Disease))))))))))) (. .)))
11302406	4	(S1 (S (NP (DT The) (JJ possible) (NN mechanism)) (VP (AUX is) (NP (NP (NN Doc_11302406_934_944_Disease)) (PP (IN of) (NP (ADJP (RB rapidly) (VBG activating)) (JJ delayed) (NNP rectifier) (NNP Doc_11302406_985_994_Chemical) (NNS currents))))) (. .)))
11302406	5	(S1 (S (PP (IN In) (NP (PRP$ our) (NN patient))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ other) (NN etiology)) (VP (VBN identified) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB explain) (NP (NNP Doc_11302406_1079_1094_Disease) (CC or) (NNP Doc_11302406_1098_1101_Disease)) (NP (NP (DT The) (JJ complete) (NN disappearance)) (PP (IN of) (NP (NNP Doc_11302406_1132_1136_Disease) (CC and) (NNP Doc_11302406_1141_1175_Disease))) (VP (VBN followed) (PP (IN by) (NP (NP (NN normalization)) (PP (IN of) (NP (CD QT) (NN interval))))) (SBAR (IN after) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN stopped) (ADVP (RB strongly)) (S (VP (VBZ suggests) (ADJP (JJ Doc_11302406_1262_1273_Chemical) (PP (IN as) (NP (DT the) (NN etiology))))))))))))))))))) (. .)))
11302406	6	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (NNP Doc_11302406_1336_1347_Chemical)) (, ,) (PP (ADVP (RB even)) (IN at) (NP (JJ low) (NNS doses))) (, ,) (VP (MD may) (VP (VB cause) (NP (NN Doc_11302406_1378_1409_Disease)) (, ,) (PP (VBG leading) (PP (TO to) (NP (NNP Doc_11302406_1422_1425_Disease))))))))))) (. .)))
11302406	7	(S1 (S (NP (JJ Serial) (JJ electrocardiographic) (NN monitoring)) (VP (MD may) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11302406_1489_1500_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NN Doc_11302406_1549_1572_Disease))))))))))))))))) (. .)))
11337188	0	(S1 (S (NP (NN Doc_11337188_0_37_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11337188_54_63_Chemical)))) (. .)))
11337188	1	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11337188_104_113_Chemical))) (PP (IN for) (NP (CD one) (NN week))) (PP (IN because) (IN of) (NP (NNP Doc_11337188_138_170_Disease))))))) (, ,)) (VP (VBD developed) (NP (ADJP (JJ Doc_11337188_182_195_Disease) (CC and) (JJ diffuse) (, ,) (JJ symmetric) (, ,) (JJ palpable)) (NN Doc_11337188_229_245_Disease)) (PP (IN on) (NP (PRP$ his) (NNS feet)))) (. .)))
11337188	2	(S1 (S (NP (NN Doc_11337188_259_276_Disease)) (VP (AUX were) (VP (VBN noted) (PP (IN on) (NP (PRP$ his) (NNS fingers))))) (. .)))
11337188	3	(S1 (S (NP (NN Skin) (NNS biopsies)) (VP (VBD showed) (NP (NP (NNS findings) (JJ diagnostic)) (PP (IN of) (NP (NNP Doc_11337188_348_375_Disease))))) (. .)))
11337188	4	(S1 (S (S (NP (NN Doc_11337188_377_386_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11337188_433_448_Chemical)))))) (. .)))
11337188	5	(S1 (S (S (NP (DT The) (NNP Doc_11337188_454_458_Disease)) (VP (VBD disappeared) (PP (IN after) (NP (CD three) (NNS weeks))))) (CC and) (S (NP (JJ renal) (NN function)) (VP (VBD returned) (PP (TO to) (ADJP (JJ normal))))) (. .)))
11337188	6	(S1 (S (NP (NN Doc_11337188_528_555_Disease)) (VP (VBZ presents) (PP (IN as) (NP (NP (JJ palpable) (NN Doc_11337188_577_584_Disease)) (PP (IN of) (NP (NP (DT the) (JJR lower) (NNS extremities)) (VP (ADVP (RB often)) (VBN accompanied) (PP (IN by) (NP (NP (NNP Doc_11337188_631_645_Disease)) (, ,) (NP (NNP Doc_11337188_647_657_Disease)) (, ,) (CC and) (NP (NNP Doc_11337188_663_680_Disease)))))))))) (. .)))
11337188	7	(S1 (S (NP (NP (JJ Etiologic) (NNS factors)) (CC or) (NP (JJ associated) (NNS disorders))) (VP (VBP include) (NP (NP (NNP Doc_11337188_732_742_Disease)) (, ,) (NP (NNP medications)) (, ,) (NP (NNP Doc_11337188_757_782_Disease)) (CC and) (NP (NNP Doc_11337188_787_796_Disease)))) (. .)))
11337188	8	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT half)) (PP (IN of) (NP (DT the) (NNS cases))))) (NP (DT no) (JJ etiologic) (NN factor)) (VP (AUX is) (VP (VBN identified))) (. .)))
11337188	9	(S1 (S (S (ADVP (RB Usually)) (NP (PRP it)) (VP (AUX is) (NP (DT a) (JJ self-limited) (NN disorder)))) (, ,) (CC but) (S (NP (JJ Doc_11337188_906_920_Chemical) (NN therapy)) (VP (MD may) (VP (AUX be) (VP (VBN needed) (PP (IN in) (NP (JJ life-threatening) (NNS cases))) (SBAR (IN since) (S (NP (NP (JJ early) (NN treatment)) (PP (IN with) (NP (NNP Doc_11337188_996_1011_Chemical))) (PP (IN in) (NP (JJ severe) (NNS cases)))) (VP (MD can) (VP (VB prevent) (NP (NNS complications)))))))))) (. .)))
11337188	10	(S1 (S (NP (NN Doc_11337188_1055_1064_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN included) (PP (IN among) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN Doc_11337188_1115_1142_Disease))))))))))) (. .)))
1141447	0	(S1 (NP (NP (DT The) (JJ renal) (NN pathology)) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_1141447_33_40_Chemical-induced) (NNP Doc_1141447_49_67_Disease))))) (. .)))
1141447	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_1141447_79_86_Chemical-induced) (NNP Doc_1141447_95_113_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
1141447	2	(S1 (S (NP (IN At) (JJ necropsy) (NN microscopy)) (VP (VBD shoed) (NP (ADJP (JJ unique) (CC and) (JJ extensive)) (NN damage)) (PP (TO to) (NP (NP (NNS cells)) (VP (VBG lining) (NP (DT the) (JJ distal) (NN nephron)))))) (. .)))
1141447	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT these) (NNS changes)) (VP (VBP represent) (NP (NP (DT a) (JJ specific) (JJ toxic) (NN effect)) (PP (IN of) (NP (NNP Doc_1141447_292_299_Chemical))) (, ,) (VP (VBN reported) (ADVP (RB here)) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (PP (IN in) (NP (NN man)))))))))))) (. .)))
11467664	0	(S1 (S (NP (NN Doc_11467664_0_20_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11467664_48_57_Chemical)))))) (. .)))
11467664	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_11467664_93_113_Disease)) (PP (ADVP (RB shortly)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11467664_157_180_Chemical)))))))))) (. .)))
11467664	2	(S1 (S (NP (NP (NN Ultrasound)) (PP (IN of) (NP (DT the) (NN liver) (CC and) (NN abdominal) (NNS CT)))) (VP (AUX were) (ADJP (JJ normal))) (. .)))
11467664	3	(S1 (S (NP (DT An) (NN ERCP)) (VP (VBD showed) (NP (JJ normal) (JJ biliary) (NN anatomy))) (. .)))
11467664	4	(S1 (S (NP (DT A) (JJ percutaneous) (NN liver) (NN biopsy)) (VP (AUX was) (VP (VBN obtained) (S (VP (VBG showing) (NP (JJ marked) (NN Doc_11467664_331_342_Disease)))) (, ,) (PP (IN with) (NP (NP (JJ portal) (NN Doc_11467664_356_361_Disease)) (, ,) (NP (JJ ductular) (NN proliferation)) (, ,) (CC and) (NP (JJ acute) (NN Doc_11467664_397_409_Disease)))))) (. .)))
11467664	5	(S1 (S (S (NP (NN Doc_11467664_411_434_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_11467664_471_479_Disease)) (VP (VBD resolved) (ADVP (RB slowly)) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (JJ several) (NNS months))))))) (. .)))
11467664	6	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (PRP$ his) (NNP Doc_11467664_552_560_Disease) (CD 2) (NN wk)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11467664_590_599_Chemical))))))))) (, ,) (NP (PRP we)) (VP (VBP believe) (SBAR (IN that) (S (NP (DT this) (NN case)) (VP (VBZ represents) (NP (NP (DT an) (NN example)) (PP (IN of) (NP (NP (NNP Doc_11467664_652_661_Chemical-associated) (NNP Doc_11467664_673_687_Disease)) (, ,) (NP (NP (DT the) (JJ first) (JJ such) (NN case)) (VP (VBD reported)))))))))) (. .)))
11524350	0	(S1 (NP (NP (NP (JJ Systemic) (NN Doc_11524350_9_17_Disease)) (CC and) (NP (NN resuscitation))) (PP (IN in) (NP (NP (NNP Doc_11524350_39_50_Chemical-)) (, ,) (NP (NNP Doc_11524350_53_68_Chemical-)) (, ,) (CC or) (NP (JJ Doc_11524350_74_85_Chemical-infused) (NNS rats)))) (. .)))
11524350	1	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (JJ systemic) (NN Doc_11524350_125_133_Disease)) (PP (IN of) (NP (NP (NNP Doc_11524350_137_148_Chemical)) (, ,) (NP (NNP Doc_11524350_150_165_Chemical)) (, ,) (CC and) (NP (NNP Doc_11524350_171_182_Chemical)))) (PP (IN in) (NP (JJ anesthetized) (NNS rats))))) (. .)))
11524350	2	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD compared) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB resuscitate) (NP (NNS rats)))))) (PP (IN after) (NP (NP (JJ lethal) (NNS doses)) (PP (IN of) (NP (DT these) (JJ local) (NNS anesthetics)))))) (. .)))
11524350	3	(S1 (S (NP (NNP Doc_11524350_301_312_Chemical) (, ,) (NNP Doc_11524350_314_329_Chemical) (, ,) (CC or) (NNP Doc_11524350_334_345_Chemical)) (VP (AUX was) (VP (VBN infused) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (QP (CD 2) (CD mg.)) (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (. .) (VP (VB min) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (NP (NN electrocardiogram)) (, ,) (NP (NN electroencephalogram)) (, ,) (CC and) (NP (JJ arterial) (NN pressure))) (VP (AUX were) (ADVP (RB continuously)) (VP (VBN monitored)))))))) (. .)))
11524350	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_11524350_496_504_Disease)) (VP (AUX was) (VP (VBN recorded))))) (, ,) (S (NP (NN drug) (NN infusion)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (DT a) (JJ resuscitation) (NN sequence)) (VP (AUX was) (VP (VBN begun)))) (. .)))
11524350	5	(S1 (S (NP (NN Doc_11524350_585_596_Chemical) (CD 0.01) (NN mg/kg)) (VP (AUX was) (VP (VBN administered) (PP (IN at) (NP (JJ 1-min) (NNS intervals))) (SBAR (IN while) (S (NP (JJ external) (JJ cardiac) (NNS compressions)) (VP (AUX were) (VP (VBN applied))))))) (. .)))
11524350	6	(S1 (S (NP (NN Resuscitation)) (VP (AUX was) (VP (VBN considered) (S (ADJP (JJ successful))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ systolic) (JJ arterial) (NN pressure) (NN >)) (CC or) (NP (NP (CD =100) (NN mm)) (NP (NNP Hg)))) (VP (AUX was) (VP (VBN achieved) (PP (IN within) (NP (CD 5) (NN min))))))))) (. .)))
11524350	7	(S1 (S (NP (NP (DT The) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_11524350_835_850_Chemical)) (CC and) (NP (NNP Doc_11524350_855_866_Chemical)))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NN Doc_11524350_881_889_Disease)))))) (VP (VP (AUX were) (ADJP (JJ similar))) (CC and) (VP (AUX were) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11524350_933_944_Chemical)))))))) (. .)))
11524350	8	(S1 (S (S (NP (NP (DT The) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_11524350_970_985_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (NNP Doc_11524350_1000_1012_Disease)) (CC and) (NP (NNP Doc_11524350_1017_1025_Disease))))))) (VP (AUX were) (ADJP (ADJP (JJR smaller)) (PP (IN than) (NP (NP (DT the) (JJ corresponding) (NNS doses)) (PP (IN of) (NP (NNP Doc_11524350_1071_1082_Chemical)))))))) (, ,) (CC but) (S (NP (PRP they)) (VP (AUX were) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11524350_1119_1130_Chemical)))))))) (. .)))
11524350	9	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ successful) (NNS resuscitations)))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN among) (NP (NNS groups))))) (. .)))
11524350	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (JJR smaller) (NN dose)) (PP (IN of) (NP (NNP Doc_11524350_1228_1239_Chemical)))) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (DT the) (NNP Doc_11524350_1260_1271_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ other) (NNS groups)))))) (. .)))
11524350	11	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ systemic) (NN Doc_11524350_1334_1342_Disease)) (PP (IN of) (NP (NNP Doc_11524350_1346_1361_Chemical)))) (VP (AUX is) (ADJP (JJ intermediate) (PP (IN between) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_11524350_1394_1405_Chemical) (CC and) (NNP Doc_11524350_1410_1421_Chemical)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN at) (NP (DT the) (JJ same) (NN rate))))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_11524350_1466_1477_Chemical-induced) (NNP Doc_11524350_1486_1500_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RBR more) (JJ susceptible) (PP (TO to) (NP (NP (NN treatment)) (PP (IN than) (NP (NP (DT that)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11524350_1566_1577_Chemical) (CC or) (NNP Doc_11524350_1581_1596_Chemical))))))))))))))))) (. .)))
11573852	0	(S1 (NP (NP (JJ Doc_11573852_0_14_Chemical-induced) (NN Doc_11573852_23_31_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_11573852_50_54_Disease))))) (. .)))
11573852	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ multiple) (NNS episodes)) (PP (IN of) (NP (JJ Doc_11573852_108_115_Disease) (NN activity)))))) (PP (IN in) (NP (NP (DT an) (NNP Doc_11573852_131_135_Disease) (NN patent)) (VP (VBG following) (NP (JJ Doc_11573852_153_167_Chemical) (NN infusion)))))))) (. .)))
11573852	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 46-year-old) (JJ African-American) (NN man)) (VP (VBN experienced) (NP (JJ recurrent) (NNP Doc_11573852_249_267_Disease)) (PP (IN during) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_11573852_299_313_Chemical)) (, ,) (ADVP (RB then)) (NP (NNP petit) (NN mal) (NN Doc_11573852_330_338_Disease)))))) (SBAR (IN as) (S (S (NP (DT the) (NN infusion)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (DT the) (NN drug) (NNS concentrations)) (VP (VBN decreased) (PP (IN with) (NP (NN time))))))))) (. .)))
11573852	3	(S1 (S (NP (NP (DT The) (NNS patients)) (JJ concurrent) (NNS medications)) (VP (VBD included) (NP (NNP Doc_11573852_461_471_Chemical) (, ,) (NNP Doc_11573852_473_484_Chemical) (, ,) (NNP Doc_11573852_486_498_Chemical) (, ,) (NNP Doc_11573852_500_514_Chemical) (, ,) (CC and) (NNP Doc_11573852_520_536_Chemical))) (. .)))
11573852	4	(S1 (S (PP (IN Despite) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_11573852_564_573_Chemical)) (CC and) (NP (NNP Doc_11573852_578_587_Chemical)))))) (, ,) (NP (DT the) (NNP Doc_11573852_593_601_Disease)) (VP (VP (VBD persisted)) (CC and) (VP (VBD occurred) (ADVP (RB only)) (PP (IN during) (NP (NNP Doc_11573852_637_650_Chemical) (NN administration))))) (. .)))
11573852	5	(S1 (S (NP (NP (NP (NNP Doc_11573852_679_683_Disease)) (CC and) (NP (NNP Doc_11573852_688_711_Disease))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (NP (DT the) (NN patient)) (VP (AUX had)))) (, ,)) (VP (MD can) (ADVP (RB potentially)) (VP (VB cause) (NP (NN Doc_11573852_766_774_Disease)))) (. .)))
11573852	6	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_11573852_805_818_Disease)))))) (: ;) (S (NP (NP (JJ Doc_11573852_820_827_Chemical) (NN intake)) (CONJP (RB as) (RB well) (IN as)) (NP (NN withdrawal))) (VP (MD can) (ADVP (RB also)) (VP (VB cause) (NP (NN Doc_11573852_872_880_Disease))))) (. .)))
11573852	7	(S1 (S (NP (NN Doc_11573852_882_892_Chemical)) (ADVP (RB also)) (VP (AUX has) (NP (NP (DT a) (NN potential)) (PP (IN for) (S (VP (VBG inducing) (NP (NN Doc_11573852_927_935_Disease))))))) (. .)))
11573852	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT these) (JJ other) (JJ potential) (NNS causes)) (PP (IN of) (NP (NNP Doc_11573852_978_985_Disease)))) (VP (AUX were) (VP (VBN ruled) (PRT (RP out)))) (. .)))
11573852	9	(S1 (S (NP (NP (DT The) (NN time) (NN course)) (PP (IN of) (NP (NNS events)))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_11573852_1043_1057_Chemical)) (VP (AUX was) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_11573852_1079_1087_Disease))) (PP (IN in) (NP (DT this) (NNP Doc_11573852_1096_1100_Disease) (NN patient)))))))) (. .)))
11573852	10	(S1 (S (NP (NN Doc_11573852_1123_1137_Chemical)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ probable) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_11573852_1176_1184_Disease)))))))) (. .)))
11573852	11	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (S (NP (NP (QP (RB only) (CD three)) (NNS cases)) (PP (IN of) (NP (NNP Doc_11573852_1215_1223_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11573852_1240_1254_Chemical))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))))))) (, ,) (CC but) (S (NP (NN healthcare) (NNS providers)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (DT this) (JJ rare) (JJ adverse) (NN effect))))))))) (. .)))
11583940	0	(S1 (NP (NP (NP (NNP Doc_11583940_0_9_Chemical)) (CC and) (NP (NNP Doc_11583940_14_35_Chemical))) (PP (IN for) (NP (NP (JJ calcineurin-free) (NN immunosuppression)) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients))))) (. .)))
11583940	1	(S1 (S (NP (NP (JJ Calcineurin) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_11583940_139_151_Chemical)) (CC and) (NP (NNP Doc_11583940_156_166_Chemical)))) (, ,)) (VP (AUX have) (VP (AUX been) (ADJP (JJ available)) (PP (IN for) (NP (QP (RB almost) (CD 20)) (NNS years))))) (. .)))
11583940	2	(S1 (S (SBAR (IN Although) (S (NP (DT these) (NNS drugs)) (VP (VP (AUX are) (ADJP (RB highly) (JJ effective))) (CC and) (VP (VB represent) (NP (NP (DT the) (NN mainstay)) (PP (IN of) (NP (NN transplant) (NN immunosuppression)))))))) (, ,) (NP (PRP they)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (JJ acute)) (CC and) (ADJP (JJ chronic))) (NN Doc_11583940_354_368_Disease))))) (. .)))
11583940	3	(S1 (S (S (NP (NP (JJ Acute) (NNP Doc_11583940_376_390_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ occurs) (PP (IN in) (NP (DT the) (JJ early) (NN period))) (PP (IN after) (NP (NN transplantation)))))) (, ,)) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NN dialysis))))))) (, ,) (CC and) (S (NP (NN chronic) (NN Doc_11583940_496_510_Disease)) (VP (MD may) (ADVP (RB eventually)) (VP (VB result) (PP (IN in) (NP (NN graft) (NN loss)))))) (. .)))
11583940	4	(S1 (S (NP (ADJP (JJ Acute) (CC and) (JJ chronic)) (NNP Doc_11583940_566_580_Disease)) (VP (AUX is) (VP (VBG becoming) (ADJP (RBR more) (JJ common)) (PP (IN as) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ marginal) (NNS kidneys))) (PP (IN for) (NP (NN transplantation) (NNS increases))))))) (. .)))
11583940	5	(S1 (S (NP (NP (CD Two) (ADJP (RB recently) (JJ available)) (NN immunosuppressive) (NNS agents)) (, ,) (NP (NP (NNP Doc_11583940_716_737_Chemical)) (CC and) (NP (NP (NNP Doc_11583940_742_751_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11583940_753_762_Chemical)) (-RRB- -RRB-)))) (, ,)) (VP (AUX have) (NP (DT no) (NN Doc_11583940_773_787_Disease))) (. .)))
11583940	6	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS agents)))))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ new) (NNS paradigms)) (PP (IN of) (NP (JJ immunosuppressive) (NN therapy))))))))) (. .)))
11583940	7	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ reviews) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ clinical) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN investigated) (NP (NP (DT these) (JJ new) (NNS approaches)) (PP (TO to) (NP (NN immunosuppression)))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients))))))))))) (. .)))
11694026	0	(S1 (NP (NP (NN Tolerability)) (PP (IN of) (NP (NP (NNP Doc_11694026_16_26_Chemical)) (CC and) (NP (NNP Doc_11694026_31_42_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11694026_60_65_Chemical-induced) (NNP Doc_11694026_74_83_Disease/Doc_11694026_84_94_Disease))))) (. .)))
11694026	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBN evaluated) (NP (NP (DT the) (NN tolerance)) (PP (IN of) (NP (NP (NNP Doc_11694026_140_150_Chemical)) (CC and) (NP (NNP Doc_11694026_155_166_Chemical)))) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (ADJP (JJ cutaneous) (, ,) (JJ respiratory) (CC and) (JJ anaphylactoid)) (NNS reactions)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_11694026_246_282_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11694026_284_290_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
11694026	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD investigated) (NP (NP (NN tolerability) (CC and) (NN reliability)) (PP (IN of) (NP (NP (NNP Doc_11694026_355_365_Chemical)) (CC and) (NP (NNP Doc_11694026_370_381_Chemical))))) (PP (IN in) (NP (NP (DT a) (ADJP (RB very) (JJ large)) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT an) (JJ exclusive) (JJ well-documented) (NN history)) (PP (IN of) (NP (NNP Doc_11694026_462_467_Chemical-induced) (NNP Doc_11694026_476_485_Disease/Doc_11694026_486_496_Disease)))))))))) (. .)))
11694026	3	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBN evaluated) (SBAR (IN whether) (S (NP (DT some) (NNS factors)) (VP (AUX have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN reaction))) (PP (TO to) (NP (NP (NNP Doc_11694026_600_611_Chemical)) (CC and) (NP (NNP Doc_11694026_616_626_Chemical))))))))))))) (. .)))
11694026	4	(S1 (S (NP (NP (DT A) (JJ single-placebo-controlled) (JJ oral) (NN challenge) (NN procedure)) (PP (IN with) (NP (NP (NNP Doc_11694026_686_696_Chemical)) (CC or) (NP (NNP Doc_11694026_700_711_Chemical))))) (VP (AUX was) (VP (VBN applied) (PP (TO to) (NP (CD 829) (NNS patients))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_11694026_758_763_Chemical-induced) (NNP Doc_11694026_772_781_Disease/Doc_11694026_782_792_Disease))))))) (. .)))
11694026	5	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 75/829) (PRN (-LRB- -LRB-) (NP (CD 9.4) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD experienced) (NP (NP (NNS reactions)) (PP (TO to) (NP (NP (NNP Doc_11694026_853_863_Chemical)) (CC or) (NP (NNP Doc_11694026_867_878_Chemical)))))) (. .)))
11694026	6	(S1 (S (IN Of) (NP (NP (DT the) (CD 715) (NNS patients)) (VP (VBN tested) (PP (IN with) (NP (NP (NNP Doc_11694026_912_922_Chemical) (CD 62)) (PRN (-LRB- -LRB-) (NP (CD 8.6) (NN %)) (-RRB- -RRB-)))))) (VP (VBD showed) (NP (DT a) (JJ positive) (NN test)) (, ,) (SBAR (IN while) (S (NP (NP (QP (IN of) (CD 114)) (NNS subjects)) (VP (VBN submitted) (PP (TO to) (NP (DT the) (NN challenge))) (PP (IN with) (NP (NP (NNP Doc_11694026_1011_1022_Chemical)) (, ,) (NP (NP (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 9.6) (NN %)) (-RRB- -RRB-))))))) (VP (AUX did) (RB not) (VP (VB tolerate) (NP (DT this) (NN drug))))))) (. .)))
11694026	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NP (CD 18.28) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ chronic) (NNP Doc_11694026_1120_1129_Disease)))))))) (CC and) (NP (NP (CD 11.8) (NN %)) (PP (IN of) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (DT an) (NN history)) (PP (IN of) (NP (NP (NNP Doc_11694026_1171_1176_Chemical-induced) (NNP Doc_11694026_1185_1194_Disease/Doc_11694026_1195_1205_Disease) (CC or) (NNP Doc_11694026_1209_1219_Disease)) (ADVP (RB alone)))) (PRN (-LRB- -LRB-) (PP (IN with) (CC or) (IN without) (NP (JJ chronic) (NNP Doc_11694026_1251_1260_Disease))) (-RRB- -RRB-)))))))) (VP (VBD resulted) (S (VP (TO to) (VP (AUX be) (ADJP (JJ intolerant) (PP (TO to) (NP (JJ alternative) (NNS drugs)))))))) (. .)))
11694026	8	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP confirm) (NP (NP (DT the) (JJ good) (NN tolerability)) (PP (IN of) (NP (NP (NNP Doc_11694026_1371_1381_Chemical)) (CC and) (NP (NNP Doc_11694026_1386_1397_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (NP (NN Doc_11694026_1426_1435_Disease/Doc_11694026_1436_1446_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_11694026_1457_1463_Chemical)))))))))))) (. .)))
11694026	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN reaction)) (PP (TO to) (NP (DT these) (JJ alternative) (NN study) (NNS drugs)))))) (VP (VP (AUX is) (ADVP (RB statistically)) (VP (VBN increased) (PP (IN by) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ chronic) (NNP Doc_11694026_1579_1588_Disease))))))) (CC and) (VP (PRN (, ,) (PP (IN above) (NP (DT all))) (, ,)) (PP (IN by) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_11694026_1621_1626_Chemical-induced) (NNP Doc_11694026_1635_1645_Disease))))))) (. .)))
11704023	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NN aqueous) (CC and) (NN gellan)))) (VP (VBP ophthalmic) (ADJP (JJ Doc_11704023_44_51_Chemical) (PP (IN with) (NP (NN placebo)))) (PP (IN on) (NP (NP (DT the) (JJ 24-hour) (NN heart) (NN rate) (NN response)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_11704023_129_137_Disease)))))))))) (. .)))
11704023	1	(S1 (S (NP (JJ Topical) (NN beta-blocker) (NN treatment)) (VP (AUX is) (NP (NP (JJ routine) (NN therapy)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11704023_233_241_Disease))))))))) (. .)))
11704023	2	(S1 (S (NP (NP (NN Therapy) (NNS results)) (PP (IN in) (NP (JJ systemic) (NN absorption)))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN resting)) (CC and) (NP (JJ peak) (NN heart) (NN rate))))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN quantified)))) (. .)))
11704023	3	(S1 (S (NP (DT This) (NN trial)) (VP (VBN evaluated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN placebo)) (, ,) (NP (NP (CD 0.5) (NN %)) (ADJP (JJ aqueous) (NP (NP (NNP Doc_11704023_437_444_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11704023_446_453_Chemical) (NN solution)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (ADJP (CD 0.5) (NN %)) (JJ Doc_11704023_475_482_Chemical) (NN suspension)) (SBAR (WHNP (WDT that)) (S (VP (VBZ forms) (NP (NP (DT a) (NN gel)) (PP (IN on) (NP (NN application))) (PP (TO to) (NP (NP (DT the) (NN conjunctiva)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11704023_546_553_Chemical) (NN gellan)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (DT the) (JJ 24-hour) (NN heart) (NN rate)) (PP (IN in) (S (NP (NNS patients)) (ADVP (RB currently)) (VP (AUXG being) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_11704023_628_636_Disease))) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (JJ mean) (NN heart) (NN rate))))))))))))))))))))) (. .)))
11704023	4	(S1 (S (NP (NP (JJ Forty-three) (NNP Caucasian) (NNS patients)) (PP (IN with) (NP (JJ primary) (NNP Doc_11704023_736_755_Disease) (CC or) (NNP Doc_11704023_759_778_Disease))) (PP (IN with) (NP (NP (DT a) (JJ mean) (PRN (-LRB- -LRB-) (JJ +/-SD) (-RRB- -RRB-)) (NN age)) (PP (IN of) (NP (CD 63) (-LRB- -LRB-) (JJ +/-8) (-RRB- -RRB-) (NNS years)))))) (VP (VP (AUX were) (VP (VBN randomized))) (CC and) (VP (VBD crossed) (PP (IN over) (PP (IN in) (NP (NP (DT a) (JJ double-masked) (NN manner)) (PP (TO to) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (NN morning) (CC and) (NN evening)) (PP (IN in) (NP (DT both) (NNS eyes)))) (-RRB- -RRB-)) (, ,)) (NNP Doc_11704023_954_961_Chemical) (NN solution)) (PRN (-LRB- -LRB-) (NP (NP (NN morning) (CC and) (NN evening)) (PP (IN in) (NP (DT both) (NNS eyes)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (JJ Doc_11704023_1010_1017_Chemical) (NN gellan)) (PRN (-LRB- -LRB-) (NP (NP (NN morning)) (PP (IN in) (NP (NP (DT both) (NNS eyes)) (PP (IN with) (NP (NN placebo))) (PP (IN in) (NP (DT the) (NN evening)))))) (-RRB- -RRB-)))))))))))))) (. .)))
11704023	5	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ 13th) (NN day)) (PP (IN of) (NP (DT each) (NN period))))) (, ,) (NP (NN heart) (NN rate)) (VP (AUX was) (VP (VBN recorded) (ADVP (RB continuously)) (PP (IN during) (NP (DT a) (JJ typical) (, ,) (JJ ambulant) (JJ 24-hour) (NN period))))) (. .)))
11704023	6	(S1 (S (S (NP (NP (DT Both) (JJ Doc_11704023_1203_1210_Chemical) (NN solution)) (CC and) (NP (JJ Doc_11704023_1224_1231_Chemical) (NN gellan))) (VP (VBD reduced) (NP (DT the) (JJ mean) (JJ 24-hour) (NN heart) (NN rate)) (PP (VBN compared) (PP (IN with) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NNS <)) (CC or) (NP (SYM =) (CD .001))) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (DT this) (NN reduction)) (VP (AUX was) (VP (RBS most) (VBN pronounced) (PP (IN during) (NP (NP (DT the) (JJ daytime)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD -7.5) (NN %)) (NN change)) (PP (IN in) (NP (NP (JJ mean) (NN heart) (NN rate)) (, ,) (NP (CD -5.7) (NN beats/min))))) (-RRB- -RRB-))))))) (. .)))
11704023	7	(S1 (S (NP (JJ Doc_11704023_1423_1430_Chemical) (NN gellan)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB numerically) (CC but) (RB not) (ADJP (RB significantly) (JJR smaller))) (NN reduction)) (PP (IN in) (NP (JJ 24-hour) (NN heart) (NN rate)))) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ Doc_11704023_1536_1543_Chemical) (NN solution))))) (. .)))
11704023	8	(S1 (S (S (PP (IN During) (NP (DT the) (NN night))) (, ,) (NP (NP (DT the) (JJ mean) (JJ 12-hour) (NN heart) (NN rate)) (PP (IN on) (NP (NP (NN placebo)) (CC and) (NP (JJ Doc_11704023_1615_1622_Chemical) (NN gellan))))) (VP (AUX were) (ADJP (ADJP (DT both) (RB significantly) (JJR less)) (PP (IN than) (PP (IN on) (NP (JJ Doc_11704023_1667_1674_Chemical) (NN solution))))))) (: ;) (S (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (UCP (NN solution) (CC and) (JJ gellan)) (NNS treatments)))) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .01)) (-RRB- -RRB-)))) (. .)))
11704023	9	(S1 (S (NP (NP (DT Both) (JJ Doc_11704023_1798_1805_Chemical) (NN solution)) (CC and) (NP (JJ Doc_11704023_1819_1826_Chemical) (NN gellan) (NN decrease))) (NP (DT the) (JJ mean) (JJ 24-hour) (NN heart) (NN rate)) (VP (VBN compared) (PP (IN with) (NP (NN placebo)))) (. .)))
11704023	10	(S1 (S (NP (DT This) (NN response)) (VP (AUX was) (VP (RBS most) (VBN pronounced) (PP (IN during) (NP (DT the) (JJ active) (JJ daytime) (NN period))))) (. .)))
11704023	11	(S1 (S (NP (DT These) (NNS data)) (VP (VB quantify) (NP (NP (DT the) (JJ modest) (NN Doc_11704023_1993_2004_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ ophthalmic) (NN beta-blocker) (NN therapy)) (PP (IN in) (NP (NP (DT a) (JJ typical) (JJ patient) (NN population)) (PP (IN on) (NP (NN therapy))) (PP (IN for) (NP (NNP Doc_11704023_2100_2108_Disease)))))))))) (. .)))
11704023	12	(S1 (S (SBAR (IN Although) (S (NP (NN exercise) (NN performance)) (VP (AUX was) (RB not) (VP (VBN assessed) (PP (IN in) (NP (DT this) (NN trial))))))) (, ,) (NP (NP (NNS reductions)) (PP (IN of) (NP (DT this) (NN magnitude)))) (VP (MD should) (RB not) (VP (AUX have) (NP (JJ substantial) (JJ clinical) (NNS consequences)))) (. .)))
11705128	0	(S1 (NP (NP (NP (NN Management) (NNS strategies)) (PP (IN for) (NP (JJ Doc_11705128_26_35_Chemical-induced) (NN Doc_11705128_44_60_Disease))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11705128_81_92_Disease)))))) (: :) (NP (ADJP (JJ clinical) (CC and) (JJ economic)) (NNS implications)) (. .)))
11705128	1	(S1 (S (ADVP (RB Recently)) (NP (VBN published) (NNS studies)) (VP (AUX have) (VP (VP (VBN demonstrated) (NP (NP (VBN increased) (NN efficacy) (CC and) (NN cost-effectiveness)) (PP (IN of) (NP (NN combination) (NN therapy))) (PP (IN with) (NP (NNP interferon))))) (CC and) (VP (ADJP (JJ alpha-2b/Doc_11705128_281_290_Chemical)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_11705128_305_321_Chemical) (NN monotherapy)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11705128_354_373_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11705128_375_378_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
11705128	2	(S1 (S (NP (NN Combination) (NN therapy)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB clinically) (JJ important)) (JJ adverse) (NN effect)) (: :) (NP (NP (JJ Doc_11705128_459_468_Chemical-induced) (NNP Doc_11705128_477_493_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11705128_495_499_Disease)) (-RRB- -RRB-))))))) (. .)))
11705128	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ direct) (NN health-care) (NNS costs)) (CC and) (NP (NP (NN management)) (PP (IN of) (NP (NNP Doc_11705128_593_597_Disease))))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_11705128_618_621_Disease))) (PP (IN in) (NP (DT a) (JJ clinical) (NN trial) (NN setting))))))))) (. .)))
11705128	4	(S1 (S (NP (DT A) (JJ systematic) (NN literature) (NN review)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB synthesize) (NP (NP (NN information)) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC and) (NN management)) (PP (IN of) (NP (NN Doc_11705128_766_770_Disease))))))))))) (. .)))
11705128	5	(S1 (S (NP (JJ Decision-analytic) (NNS techniques)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (NN Doc_11705128_844_848_Disease))))))))))) (. .)))
11705128	6	(S1 (S (NP (NN Uncertainty)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NN sensitivity) (NNS analyses)))))) (. .)))
11705128	7	(S1 (S (NP (NP (NN Doc_11705128_913_917_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN hemoglobin))) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 100)) (NNS g/L)))))) (, ,)) (VP (VBZ occurs) (PP (IN in) (NP (NP (QP (RB approximately) (CD 7) (NN %) (TO to) (CD 9) (NN %))) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN combination) (NN therapy))))))))) (. .)))
11705128	8	(S1 (S (NP (NP (DT The) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (NN management))) (PP (IN of) (NP (NNP Doc_11705128_1096_1100_Disease)))) (VP (AUX is) (NP (NP (NP (NN reduction)) (CC or) (NP (NN discontinuation))) (PP (IN of) (NP (DT the) (JJ Doc_11705128_1140_1149_Chemical) (NN dosage))))) (. .)))
11705128	9	(S1 (S (NP (PRP We)) (VP (VBD estimated) (NP (NP (DT the) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_11705128_1222_1226_Disease) (S (VP (TO to) (VP (AUX be) (NP (NP (CD 170)) (PP (IN per) (NP (NP (NN patient)) (VP (VBG receiving) (NP (NN combination) (NN therapy)) (PP (IN per) (NP (NP (JJ 48-week) (NN treatment) (NN course)) (PRN (-LRB- -LRB-) (NN range) (NN 68-) (NN 692) (-RRB- -RRB-))))))))))))))))) (. .)))
11705128	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ one-way) (NN sensitivity) (NNS analyses)))) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 57) (TO to) (CD 317))))) (. .)))
11705128	11	(S1 (S (PP (IN In) (NP (NN comparison))) (, ,) (NP (NP (DT the) (NN cost)) (PP (IN of) (NP (NP (CD 48) (NNS weeks)) (PP (IN of) (NP (NN combination) (NN therapy)))))) (VP (AUX is) (NP (CD 16,459))) (. .)))
11705128	12	(S1 (S (NP (NP (DT The) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_11705128_1535_1539_Disease)))))) (VP (AUX is) (NP (NP (NP (CD 1) (NN %)) (PRN (-LRB- -LRB-) (NP (NN 170/) (CD 16,459)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug) (NN treatment) (NNS costs))))) (. .)))
11705128	13	(S1 (S (NP (NNS Questions)) (VP (VBP remain) (PP (IN about) (NP (NP (NP (DT the) (JJ optimal) (NN dose)) (PP (IN of) (NP (NNP Doc_11705128_1629_1638_Chemical)))) (CC and) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11705128_1660_1664_Disease)))))) (PP (IN in) (NP (DT a) (JJ real-world) (NN population)))) (. .)))
11705128	14	(S1 (S (PP (IN Despite) (NP (DT these) (NNS uncertainties))) (, ,) (NP (NP (DT this) (JJ initial) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (NNP Doc_11705128_1777_1781_Disease)))))))) (VP (VBZ provides) (NP (NP (DT an) (NN estimate)) (PP (IN of) (NP (NP (DT the) (NN cost) (CC and) (NN management) (NNS implications)) (PP (IN of) (NP (DT this) (ADJP (RB clinically) (JJ important)) (JJ adverse) (NN effect))))))) (. .)))
11752998	0	(S1 (NP (NP (JJ Preliminary) (NN efficacy) (NN assessment)) (PP (IN of) (NP (NP (JJ intrathecal) (NN injection)) (PP (IN of) (NP (NP (DT an) (JJ American) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_87_96_Chemical))) (PP (IN in) (NP (NNS humans))))))) (. .)))
11752998	1	(S1 (S (NP (NP (JJ Preclinical) (NNS studies)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_11752998_155_164_Chemical)))) (VP (VBP suggest) (SBAR (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11752998_213_235_Disease)) (PP (IN in) (NP (NP (NNS humans)) (, ,) (CC and) (NP (JJ preliminary) (NNS studies)))) (PP (IN in) (NP (NNS volunteers) (CC and) (NNS patients))))))) (SBAR (IN with) (S (NP (NP (DT a) (JJ Swedish) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_328_337_Chemical)))) (VP (VBZ suggests) (SBAR (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (PP (IN in) (NP (NNP Doc_11752998_370_386_Disease) (NNS states))) (CC but) (RB not) (PP (IN with) (NP (JJ acute) (JJ noxious) (NN stimulation))))))))))))))))) (. .)))
11752998	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB screen) (PP (IN for) (NP (NP (NN efficacy)) (PP (IN of) (NP (NP (DT a) (JJ different) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_517_526_Chemical))) (VP (VBN marketed) (PP (IN in) (NP (DT the) (NNP US)))))))) (, ,) (S (VP (VBG using) (NP (PDT both) (NP (JJ acute) (JJ noxious) (NN stimulation)) (CC and) (NP (JJ Doc_11752998_588_597_Chemical-evoked) (JJ mechanical) (NN Doc_11752998_616_632_Disease))))))))) (. .)))
11752998	3	(S1 (S (PP (VBG Following) (NP (NP (NNP Food) (CC and) (NNP Drug) (NNP Administration) (CC and) (JJ institutional) (NN review) (NN board) (NN approval)) (CC and) (NP (JJ written) (JJ informed) (NN consent)))) (, ,) (NP (CD 65) (NNS volunteers)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (CD two) (NNS trials)) (: :) (NP (NP (NP (DT an) (JJ open-label) (, ,) (JJ dose-escalating) (NN trial)) (PP (IN with) (NP (NP (JJ intrathecal) (JJ Doc_11752998_848_857_Chemical) (NNS doses)) (PP (IN of) (NP (CD 0.25-2.0) (NN mg)))))) (CC and) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_11752998_927_936_Chemical)) (, ,) (NP (CD 2) (NN mg)))))))))) (. .)))
11752998	4	(S1 (S (S (NP (JJ Cerebrospinal) (NN fluid)) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (JJ pharmacokinetic) (NN analysis)))))) (, ,) (CC and) (S (NP (NP (JJ Doc_11752998_1011_1015_Disease) (NNS ratings)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ acute) (NN heat) (NNS stimuli)) (CC and) (NP (NP (NNS areas)) (PP (IN of) (NP (NNP Doc_11752998_1071_1094_Disease) (CC and) (NNP Doc_11752998_1099_1108_Disease))) (PP (IN after) (NP (JJ intradermal) (JJ Doc_11752998_1127_1136_Chemical) (NN injection))))))))) (VP (AUX were) (VP (VBN determined)))) (. .)))
11752998	5	(S1 (S (NP (NNP Doc_11752998_1173_1182_Chemical)) (VP (VP (VBD produced) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ Doc_11752998_1205_1209_Disease) (NN report)))) (PP (TO to) (NP (JJ acute) (JJ noxious) (JJ thermal) (CC or) (NN chemical) (NN stimulation)))) (CC but) (VP (VBD reduced) (NP (NP (NNP Doc_11752998_1278_1301_Disease)) (CC and) (NP (NNP Doc_11752998_1306_1315_Disease))) (PP (IN from) (NP (NP (JJ intradermal) (JJ Doc_11752998_1333_1342_Chemical) (NN injection)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 24)) (NNP h))))))) (. .)))
11752998	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN residence) (NN time)) (PP (IN of) (NP (NNP Doc_11752998_1403_1412_Chemical))) (PP (IN in) (NP (JJ cerebrospinal) (NN fluid)))) (VP (AUX was) (ADJP (ADJP (JJ short)) (PRN (-LRB- -LRB-) (VP (VBG <) (NP (CD 4) (NNP h))) (-RRB- -RRB-)))) (. .)))
11752998	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (NP (NP (JJ selective) (NN inhibition)) (PP (IN by) (NP (NP (JJ intrathecal) (NNP Doc_11752998_1523_1532_Chemical)) (PP (IN of) (NP (NNP Doc_11752998_1536_1552_Disease))))) (, ,) (VP (VBN presumed) (S (VP (TO to) (VP (VB reflect) (NP (NP (JJ central) (NN sensitization)) (PP (IN in) (NP (NNS humans)))) (PP (IN after) (NP (JJ peripheral) (JJ Doc_11752998_1623_1632_Chemical) (NN injection))))))))) (. .)))
11752998	8	(S1 (S (NP (DT The) (JJ long-lasting) (NN effect)) (VP (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ preliminary) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_11752998_1749_1765_Disease)))))))))))) (CC and) (VP (AUX is) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ prolonged) (NN residence)) (PP (IN of) (NP (NNP Doc_11752998_1807_1816_Chemical))) (PP (IN in) (NP (JJ cerebrospinal) (NN fluid)))))))) (. .)))
11827497	0	(S1 (NP (NNP Delayed-onset) (NNP Doc_11827497_14_21_Chemical-induced) (NNP Doc_11827497_30_46_Disease) (. .)))
11827497	1	(S1 (S (NP (JJ Doc_11827497_60_67_Chemical-induced) (NN Doc_11827497_76_92_Disease)) (VP (VBZ presents) (NP (QP (CD 5) (TO to) (CD 12)) (NNS days)) (PP (IN after) (NP (NNP Doc_11827497_121_128_Chemical) (NN exposure))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NNP Doc_11827497_155_187_Disease))))) (. .)))
11827497	2	(S1 (S (NP (NP (NP (JJ Delayed) (NN recognition)) (CC and) (NP (NN treatment))) (PP (IN of) (NP (NNP Doc_11827497_226_233_Chemical-induced) (NNP Doc_11827497_242_258_Disease)))) (VP (VBP contribute) (PP (TO to) (NP (JJ poor) (NN patient) (NNS outcomes)))) (. .)))
11827497	3	(S1 (FRAG (S (VP (TO To) (VP (VP (VB describe)) (CC and) (VP (VB increase) (NP (NP (NN awareness)) (PP (IN of) (NP (NP (DT a) (JJ clinical) (NN scenario)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (NN onset) (CC or) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_11827497_405_412_Chemical-induced) (NNP Doc_11827497_421_437_Disease)))) (VP (AUX are) (VP (VBN delayed)))))))))))) (. .)))
11827497	4	(S1 (NP (NN Retrospective) (NN case) (NN series) (. .)))
11827497	5	(S1 (NP (NP (NP (CD Three) (JJ large) (JJ urban) (NNS hospitals)) (-LRB- -LRB-) (PP (IN with) (NP (JJ active) (JJ cardiovascular) (NN surgery) (NNS programs))) (-RRB- -RRB-)) (. .)))
11827497	6	(S1 (S (NP (CD 14) (NNS patients)) (VP (VBN seen) (PP (IN over) (NP (NP (DT a) (JJ 3-year) (NN period)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_11827497_626_633_Chemical-induced) (NNP Doc_11827497_642_658_Disease)) (VP (VBD became) (ADJP (JJ apparent)) (PP (IN on) (NP (NP (VBN delayed) (NN presentation)) (PP (IN with) (NP (JJ Doc_11827497_704_718_Disease) (NNS complications))))))))))) (. .)))
11827497	7	(S1 (NP (NP (NN Platelet) (NNS counts)) (, ,) (NP (NP (NN onset)) (PP (IN of) (NP (ADJP (RB objectively) (VBN determined)) (NNP Doc_11827497_797_812_Disease)))) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (NP (JJ Doc_11827497_825_832_Chemical-induced) (NN platelet) (NN factor)) (SBAR (S (NP (CD 4) (NN antibody)) (VP (VBZ tests))))))) (, ,) (CC and) (NP (NNS outcomes)) (. .)))
11827497	8	(S1 (S (NP (NNS Patients)) (VP (VBD went) (ADVP (RB home)) (PP (IN after) (NP (NP (NNS hospitalizations)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN included) (NP (JJ Doc_11827497_958_965_Chemical) (JJ exposure--in) (JJS most) (NNS cases)))))))) (, ,) (PP (IN with) (NP (NP (DT no) (NNP Doc_11827497_999_1015_Disease) (NN recognized--only)) (SBAR (S (VP (TO to) (VP (VB return) (PP (TO to) (NP (NP (DT the) (NN hospital)) (PRN (-LRB- -LRB-) (NP (NN median)) (, ,) (NP (NN day) (CD 14)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ Doc_11827497_1081_1095_Disease) (NNS complications)))))))))) (. .)))
11827497	9	(S1 (S (NP (NN Doc_11827497_1111_1124_Disease)) (VP (AUX were) (ADJP (ADJP (ADJP (JJ venous)) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNS patients)) (, ,) (NP (NP (CD 7)) (PP (IN with) (NP (NNP Doc_11827497_1158_1174_Disease))))) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ arterial)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS patients)) (-RRB- -RRB-))) (CC or) (DT both))) (. .)))
11827497	10	(S1 (S (NP (NN Platelet) (NNS counts)) (VP (AUX were) (ADVP (RB mildly)) (VP (VBN decreased) (PP (IN in) (NP (QP (DT all) (CC but) (CD 2)) (NNS patients))) (PP (IN on) (NP (JJ second) (NN presentation))))) (. .)))
11827497	11	(S1 (S (PP (IN On) (NP (NN readmission))) (, ,) (NP (CD 11) (NNS patients)) (VP (VBD received) (NP (NP (JJ therapeutic) (NNP Doc_11827497_1343_1350_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBD worsened) (NP (NP (DT the) (NNS patients) (POS ')) (JJ clinical) (NN condition))) (CC and) (PRN (, ,) (PP (IN in) (NP (QP (DT all) (CD 11)) (NNS cases))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (JJ platelet) (NN count)) (PRN (-LRB- -LRB-) (S (S (S (VP (VB mean) (PP (IN at) (NP (NN readmission))))) (, ,) (S (NP (NP (CD 143) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ cells/L))) (: ;) (S (VP (VB mean) (NP (NNP nadir)) (PP (IN after) (NP (JJ Doc_11827497_1511_1518_Chemical) (NN re-exposure)))))) (, ,) (NP (NP (CD 39) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ cells/L))) (-RRB- -RRB-))))))))) (. .)))
11827497	12	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (JJ serologic) (NNS tests))) (PP (IN for) (NP (JJ Doc_11827497_1584_1591_Chemical-induced) (NNS antibodies)))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
11827497	13	(S1 (S (NP (JJ Subsequent) (NNS treatments)) (VP (VBD included) (NP (NP (NP (ADJP (NP (NP (NP (JJ alternative) (NNS anticoagulants)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ thrombolytic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS patients)) (-RRB- -RRB-))) (, ,)) (JJ inferior)) (FW vena) (FW cava) (NNS filters)) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS patients)) (-RRB- -RRB-))) (CC and) (, ,) (ADVP (RB eventually)) (, ,) (NP (NP (NNP Doc_11827497_1805_1813_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))))) (. .)))
11827497	14	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD died)) (. .)))
11827497	15	(S1 (S (NP (JJ Delayed-onset) (JJ Doc_11827497_1877_1884_Chemical-induced) (NN Doc_11827497_1893_1909_Disease)) (VP (AUX is) (ADVP (RB increasingly)) (VP (AUXG being) (VP (VBN recognized)))) (. .)))
11827497	16	(S1 (S (S (S (VP (TO To) (VP (VB avoid) (NP (JJ disastrous) (NNS outcomes))))) (, ,) (NP (NNS physicians)) (VP (MD must) (VP (VB consider) (NP (JJ Doc_11827497_1999_2006_Chemical-induced) (NNP Doc_11827497_2015_2031_Disease)) (SBAR (WHADVP (WRB whenever)) (S (NP (DT a) (ADJP (RB recently) (VBN hospitalized)) (NN patient)) (VP (VBZ returns) (PP (IN with) (NP (NN Doc_11827497_2086_2101_Disease))))))))) (: ;) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NP (JJ alternative) (NNS anticoagulants)) (, ,) (ADJP (RB not) (JJ Doc_11827497_2148_2155_Chemical)) (, ,)))) (VP (MD should) (VP (AUX be) (VP (VBN initiated))))) (. .)))
11838826	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_11838826_13_24_Chemical-induced) (NNP Doc_11838826_33_51_Disease))) (PP (IN with) (NP (NP (DT a) (JJ Doc_11838826_59_67_Chemical) (NN agonist)) (PP (IN in) (NP (NNS children))))) (. .)))
11838826	1	(S1 (S (NP (NP (NP (NNP Doc_11838826_101_112_Chemical)) (, ,) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (DT both) (NN serotonergic)))) (PRN (-LRB- -LRB-) (NP (NN 5HT2A)) (-RRB- -RRB-))) (CC and) (NP (JJ dopaminergic) (NNP D2) (NNS receptors))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_11838826_212_230_Disease)) (PP (IN in) (NP (NNS adults) (CC and) (NNS children))))))) (. .)))
11838826	2	(S1 (S (NP (NP (ADJP (RB Chronically) (JJ elevated)) (NN prolactin) (NNS levels)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_11838826_310_323_Disease)))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (VBN arrested) (NN growth)) (CC and) (NP (NP (NN development)) (VP (VBG resulting) (PP (IN in) (NP (DT either) (JJ Doc_11838826_399_414_Disease) (CC or) (JJ short) (NN stature)))))))))) (. .)))
11838826	3	(S1 (S (NP (DT These) (NNS possibilities)) (VP (VBP stress) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG developing) (NP (NP (DT a) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (JJ effective))) (NN approach)) (PP (TO to) (NP (JJ drug-induced) (NNP Doc_11838826_535_553_Disease))) (PP (IN in) (NP (NN youth))))))))) (. .)))
11838826	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ successful) (NN treatment)) (PP (IN of) (NP (NNP Doc_11838826_602_613_Chemical-induced) (NNP Doc_11838826_622_640_Disease))) (PP (IN with) (NP (NP (NNP Doc_11838826_646_657_Chemical)) (PP (IN in) (NP (NN youth))))))) (. .)))
11838826	5	(S1 (S (NP (PRP We)) (VP (VBD undertook) (NP (NP (DT a) (JJ retrospective) (NN case) (NN review)) (PP (IN of) (NP (NP (CD four) (NNS children)) (PP (IN with) (NP (NP (NNP Doc_11838826_740_751_Chemical-induced) (NNP Doc_11838826_760_778_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11838826_792_803_Chemical)))))))))) (. .)))
11838826	6	(S1 (S (NP (NP (CD Four) (NNS males)) (PRN (-LRB- -LRB-) (NP (NN age) (NN 6-11) (NNS years)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNP Diagnostic) (CC and) (NNP Statistical) (NNP Manual)) (PP (IN of) (NP (NNP Doc_11838826_884_900_Disease) (PRN (-LRB- -LRB-) (NP (JJ fourth) (NN edition)) (-RRB- -RRB-)) (NNP Doc_11838826_918_934_Disease) (CC or) (NNP Doc_11838826_938_947_Disease))))) (, ,) (PP (IN with) (NP (NP (JJ Doc_11838826_954_965_Chemical-induced) (NNS elevations)) (PP (IN in) (NP (NP (JJ serum) (NN prolactin) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 57.5-129) (NNS ng/mL)) (, ,) (NP (JJ normal) (NN 5-15) (NNS ng/mL)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11838826_1066_1077_Chemical))) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN dose)) (NP (CD 2.13) (NN +/-) (CD 0.09) (NN mg/week)) (-RRB- -RRB-)))) (. .)))
11838826	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN serum) (NN prolactin) (NNS levels)) (VP (VBD normalized) (PP (IN in) (NP (DT all) (CD four) (NNS subjects)))))) (PRN (-LRB- -LRB-) (VP (VB mean) (NP (CD 11.2) (NN +/-)) (NP (CD 10.9) (NN ng/mL))) (-RRB- -RRB-)) (, ,) (NP (DT the) (NNP Doc_11838826_1205_1216_Chemical) (NN dose)) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (CD 1) (NN mg/week))) (PP (IN in) (NP (NP (CD three)) (PP (IN of) (NP (CD four) (NNS subjects))))))) (. .)))
11838826	8	(S1 (S (S (NP (NP (DT The) (JJ mean) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NNP Doc_11838826_1308_1319_Chemical)))) (VP (AUX was) (NP (NP (CD 523.5) (NN +/-)) (NP (CD 129.7) (NNS days))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ mean) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NNP Doc_11838826_1384_1395_Chemical)))) (VP (AUX was) (NP (NP (CD 788.5) (NN +/-)) (NP (CD 162.5) (NNS days))))) (. .)))
11838826	9	(S1 (S (NP (NN Doc_11838826_1422_1433_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN without) (NP (JJ adverse) (NNS effects))))) (. .)))
11838826	10	(S1 (S (S (NP (NN Doc_11838826_1491_1502_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11838826_1538_1549_Chemical-induced) (NNP Doc_11838826_1558_1576_Disease)) (PP (IN in) (NP (NN youth)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ further) (NN research)) (VP (AUX is) (VP (VBN needed)))) (. .)))
11847945	0	(S1 (NP (NP (JJ Acute) (NN Doc_11847945_6_27_Disease)) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_11847945_46_56_Chemical))))) (. .)))
11847945	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_11847945_95_116_Disease))) (PP (VBG following) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (JJ inhalational) (JJ anesthetic) (NN Doc_11847945_167_177_Chemical))))))))) (. .)))
11847945	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (S (NP (NP (DT A) (JJ 70-year-old) (JJ healthy) (NN woman)) (PP (IN from) (NP (NNP Iraq)))) (VP (VBD developed) (NP (JJ acute) (NNP Doc_11847945_247_268_Disease) (CD 3) (NNS weeks)) (PP (VBG following) (NP (NP (NN repair)) (PP (IN of) (NP (DT the) (JJ right) (NN rotator))) (S (VP (VB cuff) (PP (IN under) (NP (JJ general) (NNS anesthesia))))))))) (. .)))
11847945	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ viral)) (, ,) (ADJP (JJ autoimmune)) (, ,) (CC or) (ADJP (JJ metabolic))) (NNS causes)) (PP (IN of) (NP (NNP Doc_11847945_414_423_Disease))))))) (. .)))
11847945	4	(S1 (S (NP (DT No) (JJ other) (NNS medications)) (VP (AUX were) (VP (VBN involved) (PP (IN except) (PP (IN for) (NP (NP (NNP Doc_11847945_471_479_Chemical)) (PP (IN for) (NP (NNP Doc_11847945_484_493_Disease)))))))) (. .)))
11847945	5	(S1 (S (NP (DT The) (NNP Doc_11847945_499_506_Chemical) (NN aminotransferase)) (VP (AUX was) (ADJP (JJ elevated) (PP (TO to) (NP (NP (NP (DT a) (JJ peak) (NN concentration)) (PP (IN of) (NP (CD 1533) (NN U/L)))) (CC and) (NP (NP (DT the) (NN serum)) (SBAR (S (NP (NNP Doc_11847945_587_596_Chemical)) (VP (VBD reached) (NP (NP (DT a) (NN peak)) (PP (IN of) (NP (CD 17.0) (NN mg/dL)))))))))))) (. .)))
11847945	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ slow) (NN improvement)) (PP (IN over) (NP (CD 4) (NNS months))))) (. .)))
11847945	7	(S1 (S (NP (NP (JJ Accidental) (NN reexposure)) (PP (IN by) (NP (DT the) (NN patient))) (PP (TO to) (NP (NNP Doc_11847945_709_717_Chemical)))) (VP (AUX was) (ADJP (JJ uneventful))) (. .)))
11847945	8	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ histologic))) (NN picture)) (PP (IN of) (NP (DT this) (NN case)))) (VP (VBZ resembles) (NP (NP (NNP Doc_11847945_805_824_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (NP (DT a) (JJ significant) (NN mortality) (NN rate))))))) (. .)))
11847945	9	(S1 (S (NP (NP (NNP Doc_11847945_879_889_Chemical)) (, ,) (NP (DT a) (JJ common) (JJ anesthetic) (NN agent)) (, ,)) (VP (MD can) (VP (VB cause) (NP (JJ severe) (NN Doc_11847945_935_956_Disease)))) (. .)))
11858397	0	(S1 (S (NP (NN Doc_11858397_0_18_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11858397_30_44_Chemical))) (PP (IN in) (NP (DT an) (JJ elderly) (NN woman))) (PP (IN with) (S (VP (VBG preexisting) (NP (JJ complete) (NN Doc_11858397_91_115_Disease)))))) (. .)))
11858397	1	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (VBG growing) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN implicated) (PP (IN in) (NP (NP (VBN acquired) (NNP Doc_11858397_173_189_Disease)) (CC and) (NP (NNP Doc_11858397_194_212_Disease))))))))) (. .)))
11858397	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ torsadogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_11858397_253_267_Chemical)) (, ,) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN antiemetic)) (CC and) (NP (JJ prokinetic) (NN drug))) (, ,)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))) (, ,) (PP (IN despite) (NP (NP (PRP$ its) (NN chemical) (NN similarity)) (PP (TO to) (NP (NNP Doc_11858397_393_405_Chemical)))))))) (. .)))
11858397	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (JJ 92-year-old) (NN woman)) (PP (IN with) (S (VP (VBG preexisting) (NP (NP (JJ complete) (NNP Doc_11858397_466_490_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_11858397_505_523_Disease)) (PP (IN after) (NP (NP (JJ intravenous) (CC and) (JJ oral) (NN administration)) (PP (IN of) (NP (NNP Doc_11858397_569_583_Chemical))))))))))))))) (. .)))
11858397	4	(S1 (S (NP (DT This) (NN patient)) (ADVP (RB also)) (VP (VBD developed) (NP (NN Doc_11858397_613_631_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_11858397_637_646_Chemical)) (CC and) (NP (NNP Doc_11858397_651_663_Chemical))) (VP (AUX were) (VP (VBN given) (ADVP (RB simultaneously))))))) (. .)))
11858397	5	(S1 (S (NP (DT These) (CD two) (NNS episodes)) (VP (AUX were) (VP (VBN suppressed) (ADVP (RB successfully)) (PP (IN after) (S (VP (VP (VBG discontinuing) (NP (DT the) (VBG offending) (NNS drugs))) (CC and) (VP (VBG administering) (NP (NN class) (NN IB) (NNS drugs)))))))) (. .)))
11858397	6	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN documentation)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_11858397_850_864_Chemical)) (VP (VBZ provokes) (NP (NNP Doc_11858397_874_892_Disease)) (ADVP (RB clinically))))))) (. .)))
11858397	7	(S1 (S (NP (NN Doc_11858397_905_919_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (NNP Doc_11858397_973_991_Disease)))))))) (. .)))
11860278	0	(S1 (S (NP (NNP Doc_11860278_0_8_Chemical) (NNP D2) (NN receptor) (VBG signaling)) (VP (VBZ controls) (NP (NP (JJ neuronal) (NN cell) (NN death)) (VP (VBN induced) (PP (IN by) (NP (NP (NN muscarinic)) (CC and) (NP (JJ glutamatergic) (NNS drugs))))))) (. .)))
11860278	1	(S1 (S (NP (NP (NNP Doc_11860278_107_115_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860278_117_119_Chemical)) (-RRB- -RRB-))) (, ,) (PP (IN through) (NP (NNP D1/D2) (JJ receptor-mediated) (VBG signaling))) (, ,) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NNP Doc_11860278_202_220_Disease))) (VP (VBG arising) (PP (IN in) (NP (DT the) (JJ limbic) (NN system))))))) (. .)))
11860278	2	(S1 (S (NP (NP (NN Doc_11860278_251_265_Disease)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ neuronal) (NN cell) (NN death)) (PP (IN in) (NP (DT the) (JJ affected) (NNS areas))))))) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN consequence)) (PP (IN of) (NP (NNP Doc_11860278_345_353_Disease))) (PP (IN at) (NP (DT the) (JJ cellular) (NN level))))) (. .)))
11860278	3	(S1 (S (PP (IN In) (NP (DT this) (NN respect))) (, ,) (NP (RB little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ Doc_11860278_428_430_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ Doc_11860278_462_470_Disease-induced) (JJ neuronal) (NN cell) (NN death))))))))) (. .)))
11860278	4	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP analyze) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_11860278_534_542_Disease) (CC and) (NNP Doc_11860278_547_560_Disease))) (PP (IN in) (NP (NP (NNP D2R) (JJ -/-) (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (DT the) (JJ cholinergic) (NN agonist) (NN Doc_11860278_614_625_Chemical)))))))) (. .)))
11860278	5	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (DT these) (NNS results)) (PP (IN with) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN obtained) (PP (IN with) (NP (NP (NP (NNP Doc_11860278_689_700_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860278_702_704_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (JJ Doc_11860278_716_725_Chemical) (NN agonist)))))))) (. .)))
11860278	6	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NNP D2R) (NN -/-) (NNS mice)) (VP (VBP develop) (NP (NNP Doc_11860278_769_777_Disease)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX are) (RB not) (ADJP (JJ epileptogenic)) (PP (IN for) (NP (JJ WT) (NNS littermates)))) (CC and) (VP (VBP show) (NP (JJR greater) (NN Doc_11860278_864_877_Disease))))))))))) (. .)))
11860278	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_11860278_888_899_Chemical-induced) (NNP Doc_11860278_908_916_Disease)) (VP (VBP result) (PP (IN in) (NP (NP (DT a) (ADJP (RBR more) (JJ widespread)) (JJ neuronal) (NN death)) (PP (IN in) (NP (DT both) (NNP WT) (CC and) (NNP D2R) (JJ -/-) (NNS brains))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NNP Doc_11860278_1007_1009_Chemical)))))))) (. .)))
11860278	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP D2R)))) (VP (VBZ lowers) (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NP (NNP Doc_11860278_1061_1069_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT both) (NNP Doc_11860278_1086_1095_Chemical) (CC and) (NNP Doc_11860278_1100_1113_Chemical)))))))) (. .)))
11860278	9	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ dopaminergic) (NN control)) (PP (IN of) (NP (JJ Doc_11860278_1153_1161_Disease-induced) (NNP Doc_11860278_1170_1187_Disease)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ distinct) (NNS interactions)) (PP (IN of) (NP (NNP D2R) (VBG signaling))) (PP (IN with) (NP (DT these) (CD two) (NNS neurotransmitters)))))))))) (. .)))
11860495	0	(S1 (S (NP (JJ Doc_11860495_0_7_Chemical) (NN structure) (CC and) (NN pharmacological) (NNS properties)) (VP (VBP determine) (NP (NP (DT the) (JJ anti-Doc_11860495_68_75_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_87_108_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ passive) (NN avoidance) (NN task)) (PP (IN in) (NP (NNS rats))))))) (. .)))
11860495	1	(S1 (S (NP (NP (NNP Doc_11860495_148_169_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860495_171_176_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (VBN generated) (NP (NN interest)) (SBAR (IN as) (S (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN memory-enhancing)))) (VP (VBZ neurosteroids) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN in) (NP (JJ rodent) (VBG learning) (NNS studies))))))) (, ,) (PP (IN with) (NP (JJ particular) (NN importance))) (PP (IN in) (NP (DT the) (JJ ageing) (NN process)))))))) (. .)))
11860495	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT this) (JJ endogenous) (NN Doc_11860495_390_397_Chemical)) (VP (VBZ enhances) (NP (NN memory) (NN formation)))))) (VP (AUX is) (VP (VBN hypothesized) (S (VP (TO to) (VP (VB involve) (NP (NP (NNS actions)) (PP (IN on) (NP (ADJP (JJ glutamatergic) (CC and) (JJ GABAergic)) (NNS systems))))))))) (. .)))
11860495	3	(S1 (S (NP (DT This) (NN hypothesis)) (VP (VBZ stems) (PP (IN from) (NP (NNS findings))) (SBAR (IN that) (S (NP (NNP Doc_11860495_540_545_Chemical)) (VP (AUX is) (NP (NP (NP (DT a) (JJ potent) (JJ positive) (NN modulator)) (PP (IN of) (NP (NP (JJ Doc_11860495_580_600_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS NMDARs)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (JJ negative) (NN modulator)) (PP (IN of) (NP (NP (NNP Doc_11860495_648_671_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860495_686_690_Chemical)) (-LRB- -LRB-) (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (-RRB- -RRB-)))))))))) (. .)))
11860495	4	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_11860495_708_713_Chemical)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ Doc_11860495_737_744_Disease-like) (NNS effects)) (PP (IN of) (NP (ADJP (ADJP (JJ NMDAR) (CC and) (JJ Doc_11860495_771_775_Chemical)) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-))) (NN R) (NNS ligands))))))))) (. .)))
11860495	5	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (DT this) (NN hypothesis))))) (, ,) (NP (NP (DT the) (JJ present) (NN study)) (PP (IN in) (NP (NNS rats)))) (VP (VBD examined) (NP (NP (DT the) (JJ memory-altering) (NNS abilities)) (PP (IN of) (NP (NP (JJ structural) (NNS analogs)) (PP (IN of) (NP (NP (NNP Doc_11860495_911_916_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN modulation)) (PP (IN of) (NP (NNP NMDAR) (FW and/or) (NNP Doc_11860495_967_971_Chemical))))) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NP (NN R) (NN function))))))))))) (. .)))
11860495	6	(S1 (S (NP (NP (DT The) (NNS analogs)) (VP (VBN tested))) (VP (AUX were) (: :) (NP (NP (NNP Doc_11860495_1011_1039_Chemical) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (JJ inactive)) (PP (IN at) (NP (NP (NP (NP (NNP Doc_11860495_1070_1074_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_11860495_1093_1155_Chemical)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (DT both) (NNP Doc_11860495_1178_1182_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))))) (, ,)) (CC and) (NP (DT a) (ADJP (ADJP (RB newly) (VBN synthesized)) (-LRB- -LRB-)))))))) (: -)) (-RRB- -RRB-)) (NNP Doc_11860495_1229_1234_Chemical) (NN enantiomer)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ identical) (PP (TO to) (NP (NP (NNP Doc_11860495_1269_1274_Chemical)) (PP (IN in) (NP (NP (NNS effects)) (PP (IN on) (NP (NNP Doc_11860495_1289_1293_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))))))))))) (. .)))
11860495	7	(S1 (S (NP (NP (DT The) (JJ memory-enhancing) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_11860495_1344_1349_Chemical)) (CC and) (NP (PRP$ its) (NNS analogs))))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (NP (DT the) (JJ passive) (NN avoidance) (NN task)) (VP (VBG using) (NP (NP (DT the) (NN model)) (PP (IN of) (NP (JJ Doc_11860495_1427_1438_Chemical-induced) (NN Doc_11860495_1447_1454_Disease))))))))) (. .)))
11860495	8	(S1 (S (NP (CC Both) (NP (NNP Doc_11860495_1461_1466_Chemical)) (CC and) (NP (PRP$ its) (-LRB- -LRB-) (: -) (-RRB- -RRB-) (NN enantiomer))) (VP (VBD blocked) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_1513_1524_Chemical))))) (. .)))
11860495	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (, ,) (PP (IN unlike) (NP (NNP Doc_11860495_1556_1561_Chemical))) (, ,) (NP (NP (NNP Doc_11860495_1563_1591_Chemical)) (CC and) (NP (NNP Doc_11860495_1596_1620_Chemical))) (VP (VBD failed) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_11860495_1651_1662_Chemical))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (S (VP (VBG altering) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (JJ Doc_11860495_1707_1711_Chemical) (NNS receptors)))))) (VP (VBZ diminishes) (NP (NP (DT the) (JJ memory-enhancing) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_1765_1770_Chemical))))))))))))) (. .)))
11860495	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN enantioselectivity)) (VP (AUX was) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ natural) (NNP Doc_11860495_1844_1849_Chemical))) (S (VP (TO to) (VP (AUX be) (ADJP (NP (NP (DT an) (NN order)) (PP (IN of) (NP (NN magnitude)))) (RBR more) (JJ effective) (PP (IN than) (NP (NP (PRP$ its) (JJ synthetic) (NN enantiomer)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ Doc_11860495_1936_1947_Chemical-induced) (NN Doc_11860495_1956_1963_Disease))))))))))))))) (. .)))
11860495	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP identify) (NP (NP (DT a) (JJ novel) (NN neuropharmacological) (NN site)) (PP (IN for) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NN memory) (NNS processes))) (PP (IN by) (NP (JJ neuroactive) (NNP Doc_11860495_2076_2084_Chemical))))))) (. .)))
11861791	0	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ Doc_11861791_14_30_Chemical) (NN polymerase)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_11861791_72_83_Chemical-induced) (NNP Doc_11861791_92_105_Disease)))))) (. .)))
11861791	1	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (JJ enzyme) (JJ Doc_11861791_140_156_Chemical) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NNP PARP)) (-RRB- -RRB-)))) (PP (IN by) (NP (JJ oxidant-mediated) (NN DNA) (NN damage)))) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN pathway)) (PP (IN of) (NP (NP (NN cell) (NN dysfunction)) (CC and) (NP (NN tissue) (NN injury))))) (PP (IN in) (NP (NP (NNS conditions)) (VP (VBN associated) (PP (IN with) (NP (JJ oxidative) (NN stress))))))) (. .)))
11861791	2	(S1 (S (NP (VBN Increased) (NN oxidative) (NN stress)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN factor)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNP Doc_11861791_379_393_Disease)) (PP (IN of) (NP (NP (NP (NNP Doc_11861791_397_408_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11861791_410_413_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (NN antitumor)) (ADJP (NNP Doc_11861791_440_453_Chemical) (JJ antibiotic)))))))))) (. .)))
11861791	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NNP PARP)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (DT the) (JJ Doc_11861791_538_541_Chemical-induced) (NN Doc_11861791_550_564_Disease)))))))) (. .)))
11861791	4	(S1 (S (S (VP (VBG Using) (NP (NP (DT a) (JJ dual) (NN approach)) (PP (IN of) (NP (JJ PARP-1) (NN suppression)))) (, ,) (PP (IN by) (NP (NP (JJ genetic) (NN deletion)) (CC or) (NP (NP (JJ pharmacological) (NN inhibition)) (PP (IN with) (NP (DT the) (JJ phenanthridinone) (NN PARP) (NN inhibitor) (NNP Doc_11861791_702_706_Chemical)))))))) (, ,) (NP (PRP we)) (ADVP (RB now)) (VP (VBP demonstrate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP PARP))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11861791_766_785_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11861791_797_800_Chemical)))))))) (. .)))
11861791	5	(S1 (S (NP (NN PARP-1+/+) (CC and) (NN PARP-1-/-) (NNS mice)) (VP (VBD received) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11861791_862_865_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 25) (CD mg/kg)) (NNS i.p)) (-RRB- -RRB-)))))) (. .)))
11861791	6	(S1 (S (PP (NP (CD Five) (NNS days)) (IN after) (NP (NNP Doc_11861791_898_901_Chemical) (NN administration))) (, ,) (NP (JJ left) (NN ventricular) (NN performance)) (VP (VP (AUX was) (VP (ADVP (RB significantly)) (VBN depressed) (PP (IN in) (NP (JJ PARP-1+/+) (NNS mice))))) (, ,) (CC but) (VP (ADJP (RB only) (PP (TO to) (NP (DT a) (JJR smaller) (NN extent)))) (PP (IN in) (NP (JJ PARP-1-/-) (NNS ones))))) (. .)))
11861791	7	(S1 (S (NP (JJ Similar) (NNS experiments)) (VP (AUX were) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ BALB/c) (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NP (NN Doc_11861791_1105_1109_Chemical)) (CC or) (NP (NN vehicle))))))))) (. .)))
11861791	8	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (DT a) (NN Doc_11861791_1139_1143_Chemical)))) (VP (VP (ADVP (RB significantly)) (VBN improved) (NP (NNP Doc_11861791_1167_1186_Disease))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (DT the) (NNS animals)))))) (. .)))
11861791	9	(S1 (S (PP (IN In) (NP (NN addition))) (NP (NNP Doc_11861791_1242_1246_Chemical)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (NP (DT the) (JJ Doc_11861791_1273_1276_Chemical-induced) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ serum) (JJ Doc_11861791_1307_1314_Chemical) (NN dehydrogenase)) (CC and) (NP (JJ Doc_11861791_1333_1341_Chemical) (NN kinase) (NNS activities))))) (CC but) (NP (NP (RB not) (JJ metalloproteinase) (NN activation)) (PP (IN in) (NP (DT the) (NN heart)))))) (. .)))
11861791	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP PARP) (NN activation)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NNP Doc_11861791_1452_1466_Disease)) (PP (IN of) (NP (NNP Doc_11861791_1470_1473_Chemical)))))) (. .)))
11861791	11	(S1 (S (NP (NN PARP) (NNS inhibitors)) (VP (MD may) (VP (VB exert) (NP (JJ protective) (NNS effects)) (PP (IN against) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ severe) (NNP Doc_11861791_1554_1575_Disease))) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ Doc_11861791_1596_1599_Chemical) (NN treatment)))))))) (. .)))
11868798	0	(S1 (NP (NP (NN Doc_11868798_0_14_Chemical)) (: :) (SQ (AUX is) (NP (PRP it)) (NP (NP (DT a) (JJ novel) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_11868798_57_71_Chemical-related) (NNP Doc_11868798_80_91_Disease))) (PP (IN in) (NP (NNP Doc_11868798_95_101_Disease) (NNS patients)))))) (. ?))))
11868798	1	(S1 (S (NP (NN Doc_11868798_123_137_Disease)) (VP (AUX is) (NP (NP (DT the) (JJ major) (JJ adverse) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_11868798_169_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11868798_185_188_Chemical)) (-RRB- -RRB-))))) (, ,) (S (ADVP (RB often)) (VP (VBG limiting) (NP (NP (NN administration)) (PP (IN of) (NP (JJ full) (NN dosage))))))) (. .)))
11868798	2	(S1 (S (NP (JJ Selective) (JJ distal) (JJ tubular) (NN epithelial) (NN Doc_11868798_273_281_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ profound) (JJ Doc_11868798_323_332_Chemical) (NN wasting)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ clinical) (NN side) (NN effect)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11868798_396_399_Chemical)))))))))))))) (. .)))
11868798	3	(S1 (S (NP (JJ Doc_11868798_401_410_Chemical) (NN depletion)) (ADVP (RB also)) (VP (VBZ potentiates) (NP (NP (DT the) (JJ tubular) (NN Doc_11868798_450_458_Disease)) (PP (IN of) (NP (NNP Doc_11868798_462_465_Chemical))))) (. .)))
11868798	4	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_11868798_516_530_Chemical))) (S (VP (VP (TO to) (VP (VB reduce) (NP (JJ Doc_11868798_541_550_Chemical) (NNS requirements)))) (CC and) (VP (TO to) (VP (VB prevent) (NP (NP (NN Doc_11868798_579_590_Disease)) (PP (IN in) (NP (NP (JJ Doc_11868798_594_605_Disease) (NNS patients)) (PP (IN on) (NP (JJ Doc_11868798_618_621_Chemical) (NN treatment)))))))))))))))) (. .)))
11868798	5	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NP (CD 26) (NNS patients)) (PP (IN with) (NP (JJ various) (NNP Doc_11868798_681_704_Disease)))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VP (VB receive) (NP (DT either) (JJ intravenous) (NN Doc_11868798_751_754_Chemical)) (ADVP (RB alone))) (CC or) (VP (NP (NP (NNP Doc_11868798_764_767_Chemical)) (CC and) (NP (JJ oral) (NNP Doc_11868798_777_791_Chemical) (CD 100))) (S (VP (VBG mg) (ADVP (RB twice) (RB daily)) (SBAR (WHADVP (WRB when)) (S (VP (VBG developing) (NP (DT a) (VBN proven) (CC or) (VBN suspected) (NN Doc_11868798_849_865_Disease))))))))))))) (. .)))
11868798	6	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ concomitant) (NNP Doc_11868798_907_910_Chemical) (CC and) (NNP Doc_11868798_915_929_Chemical)))) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN plasma) (NN Doc_11868798_962_971_Chemical) (NNS levels)) (PP (IN than) (NP (NP (DT those)) (VP (VBG receiving) (NP (NNP Doc_11868798_1000_1003_Chemical)) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (FRAG (X (FW P) (SYM =)) (NP (CD 0.0027))) (-RRB- -RRB-))))))) (. .)))
11868798	7	(S1 (S (NP (NP (DT Those) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_11868798_1049_1052_Chemical)) (CC and) (NP (NNP Doc_11868798_1057_1071_Chemical))))) (VP (VBD required) (NP (ADJP (RB significantly) (JJR less)) (JJ Doc_11868798_1100_1109_Chemical) (NN supplementation)) (S (VP (TO to) (VP (VB maintain) (NP (PRP$ their) (NN plasma) (NN Doc_11868798_1151_1160_Chemical)) (PP (IN within) (NP (NP (DT the) (JJ normal) (NN range)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.022)) (-RRB- -RRB-)))))))) (. .)))
11868798	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (JJ urinary) (JJ Doc_11868798_1216_1225_Chemical) (NNS losses)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR less) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_11868798_1279_1282_Chemical)) (CC and) (NP (NNP Doc_11868798_1287_1301_Chemical))))))) (PP (IN than) (NP (NP (DT those)) (VP (VBG receiving) (NP (NNP Doc_11868798_1323_1326_Chemical)) (ADVP (RB alone)))))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.040)) (-RRB- -RRB-))) (. .)))
11868798	9	(S1 (S (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_11868798_1381_1395_Chemical)) (VP (MD can) (VP (VP (VB reduce) (NP (JJ Doc_11868798_1407_1416_Chemical) (NNS requirements))) (CC and) (VP (VB prevent) (NP (NN Doc_11868798_1442_1453_Disease)) (PP (IN by) (S (VP (VBG reducing) (NP (NP (JJ urinary) (JJ Doc_11868798_1474_1483_Chemical) (NN loss)) (PP (IN in) (NP (NNP Doc_11868798_1492_1503_Disease) (NNS patients))) (PP (IN on) (NP (JJ Doc_11868798_1516_1519_Chemical) (NN treatment))))))))))))) (. .)))
11890511	0	(S1 (S (NP (NN Doc_11890511_0_20_Disease)) (VP (VBZ occurs) (NP (JJ following) (NN substantia) (NN nigra) (NNS lesions)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
11890511	1	(S1 (S (NP (JJ Erectile) (NN function)) (VP (AUX was) (VP (VBN assessed) (NP (CD 6) (NNS weeks)) (PP (VBG following) (NP (NP (JJ uni-) (CC and) (JJ bilateral) (NNS injections)) (PP (IN of) (NP (NNP Doc_11890511_157_174_Chemical))) (PP (IN in) (NP (NP (DT the) (NN substantia) (NN nigra) (NN nucleus)) (PP (IN of) (NP (DT the) (NN brain))))))))) (. .)))
11890511	2	(S1 (S (NP (JJ Behavioral) (JJ Doc_11890511_232_243_Chemical-induced) (NN penile) (NNS erections)) (VP (VP (AUX were) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (NN 5/8)) (-RRB- -RRB-)))) (CC and) (VP (VBD increased) (PRN (-LRB- -LRB-) (ADVP (RB 3/8)) (-RRB- -RRB-)) (PP (IN in) (NP (ADJP (JJ uni-) (CC and) (JJ bilateral)) (JJ lesioned) (NNS animals))))) (. .)))
11890511	3	(S1 (S (NP (NP (JJ Intracavernous) (NNS pressures)) (, ,) (PP (VBG following) (NP (NP (JJ electrical) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ cavernous) (NN nerve))))) (, ,)) (VP (VBN decreased) (PP (IN in) (NP (JJ lesioned) (NNS animals)))) (. .)))
11890511	4	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (JJ substantia) (NNS nigra)))) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NN histology))))) (. .)))
11890511	5	(S1 (S (NP (NP (NN Concentration)) (PP (IN of) (NP (NP (NNP Doc_11890511_540_548_Chemical)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (VP (AUX were) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (NN substantia) (NN nigra) (JJ lesioned) (NNS rats))))))) (. .)))
11890511	6	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (NN substantia) (NN nigra)))) (VP (VP (AUX are) (ADVP (RB therefore)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11890511_697_717_Disease))) (PP (IN in) (NP (NNS rats))))) (CC and) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN model)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (NN Doc_11890511_760_780_Disease)) (PP (IN in) (NP (NNP Doc_11890511_784_803_Disease))))))))))))) (. .)))
11900788	0	(S1 (NP (NP (JJ Doc_11900788_0_8_Chemical) (NN potentiation)) (PP (IN of) (NP (NP (NNP Doc_11900788_25_33_Chemical-induced) (NNP Doc_11900788_42_51_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11900788	1	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NNS effects)) (PP (IN of) (NP (NNP Doc_11900788_94_102_Chemical))) (PP (IN on) (NP (NNP Doc_11900788_106_115_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_127_135_Chemical))) (PP (IN in) (NP (NNS mice))))) (VP (AUX have) (VP (AUX been) (VP (VBN investigated)))) (. .)))
11900788	2	(S1 (S (S (ADJP (ADJP (JJ Doc_11900788_168_176_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_11900788_185_193_Chemical)))) (VP (VBN induced) (NP (DT a) (JJ dose-dependent) (NN Doc_11900788_219_228_Disease))) (. .)))
11900788	3	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (NNP Doc_11900788_246_254_Chemical)))) (VP (AUX was) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_11900788_274_282_Chemical))))) (. .)))
11900788	4	(S1 (S (NP (NP (JJ Intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_11900788_318_326_Chemical) (, ,) (NNP Doc_11900788_328_336_Chemical) (, ,) (NNP Doc_11900788_338_350_Chemical) (, ,) (CC and) (NNP Doc_11900788_356_369_Chemical))) (PP (TO to) (NP (NNS mice)))) (VP (VBD reduced) (NP (NP (NN Doc_11900788_386_395_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11900788_424_432_Chemical)) (PP (IN with) (NP (NNP Doc_11900788_438_446_Chemical)))))))))) (. .)))
11900788	5	(S1 (S (NP (NP (JJ Intracerebroventricular) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11900788_485_493_Chemical)) (, ,) (NP (NNP Doc_11900788_495_508_Chemical)) (, ,) (CC and) (NP (NNP Doc_11900788_514_522_Chemical))))) (ADVP (RB also)) (VP (VBD decreased) (NP (NP (NN Doc_11900788_538_547_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_559_567_Chemical) (CC plus) (NNP Doc_11900788_573_581_Chemical)))))) (. .)))
11900788	6	(S1 (S (NP (NP (NP (JJ Intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_11900788_617_625_Chemical)))) (, ,) (CC but) (NP (NP (RB not) (JJ intraperitoneal) (CC or) (JJ intracerebroventricular) (NN injection)) (PP (IN of) (NP (NNP Doc_11900788_691_704_Chemical)))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11900788_747_755_Chemical))))))) (. .)))
11900788	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NNP Doc_11900788_779_787_Chemical) (NNP Doc_11900788_788_797_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN elicited) (PP (IN by) (NP (NP (NN opioid)) (CC and) (NP (JJ cholinergic) (NNS receptors)))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN potentiation)) (PP (IN of) (NP (NNP Doc_11900788_875_883_Chemical))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_895_903_Chemical))))) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (VP (VBN mediated) (PP (IN through) (NP (JJ cholinergic) (NN receptor) (NNS mechanisms))))))))))) (. .)))
11912119	0	(S1 (NP (NP (NP (NN Force) (NN overflow)) (CC and) (NP (JJ Doc_11912119_19_27_Chemical-induced) (NN Doc_11912119_36_47_Disease))) (PP (IN in) (NP (NNP Doc_11912119_51_70_Disease))) (. .)))
11912119	1	(S1 (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (NN force) (NN coordination)) (PP (IN of) (NP (DT the) (NN hand))) (PP (IN in) (NP (NP (NNP Doc_11912119_118_137_Disease)) (CC and) (NP (PRP$ its) (NN relationship))))) (PP (TO to) (NP (NP (NN motor) (NNS complications)) (PP (IN of) (NP (JJ Doc_11912119_185_193_Chemical) (NN therapy))))) (, ,) (PP (ADVP (RB particularly)) (TO to) (NP (NP (NNP Doc_11912119_219_227_Chemical-induced) (NNP Doc_11912119_236_247_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11912119_249_252_Disease)) (-RRB- -RRB-))))) (. .)))
11912119	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (NNP Doc_11912119_280_299_Disease) (NNS patients)))) (PP (IN with) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11912119_315_334_Disease) (NNP +) (NNP Doc_11912119_337_340_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 23))) (-RRB- -RRB-)) (CC and) (PP (IN without) (NP (NP (NP (NNP Doc_11912119_362_370_Chemical-induced) (NNP Doc_11912119_379_390_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11912119_392_411_Disease)) (: -) (NP (NP (NNP Doc_11912119_414_417_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 10))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ age-matched) (JJ healthy) (NNS controls)))))) (. .)))
11912119	3	(S1 (S (NP (NP (DT The) (NN motor) (NN score)) (PP (IN of) (NP (NP (DT the) (JJ Unified) (NNP Doc_11912119_493_512_Disease) (NN Rating) (NN Scale)) (, ,) (NP (DT a) (NNP Doc_11912119_529_539_Disease) (NN score)) (CC and) (NP (NN force)))) (PP (IN in) (NP (DT a) (JJ grip-lift) (NN paradigm)))) (VP (AUX were) (VP (VBN assessed) (PP (IN ON) (CC and) (IN OFF) (NP (NNP Doc_11912119_605_613_Chemical))))) (. .)))
11912119	4	(S1 (S (NP (NP (DT A) (JJ pathological) (NN increase)) (PP (IN of) (NP (NNS forces)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NN ON-state))) (PP (IN in) (NP (NP (NNP Doc_11912119_673_692_Disease) (NNP +) (NNP Doc_11912119_695_698_Disease)) (ADVP (RB only)))))) (. .)))
11912119	5	(S1 (S (PP (IN In) (NP (NNP Doc_11912119_708_727_Disease) (NNP +) (NNP Doc_11912119_730_733_Disease))) (, ,) (NP (NP (DT the) (NN force)) (VP (VBN involved) (PP (IN in) (S (VP (VBG pressing) (PRT (RP down)) (NP (DT the) (NN object)) (PP (IN before) (NP (NN lifting)))))))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN by) (NP (NP (NNP Doc_11912119_828_836_Chemical)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (CD 61) (NN %))) (, ,) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
11912119	6	(S1 (S (NP (NP (DT An) (NN overshooting)) (PP (IN of) (NP (JJ peak) (NN grip) (NN force))) (PP (PP (IN by) (NP (NP (CD 51) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (JJ static) (NN grip) (NN force)))) (PP (IN by) (NP (CD 45) (NN %))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.01)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT the) (NN ON-))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ OFF-drug) (NN condition)))))) (. .)))
11912119	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT no) (JJ excessive) (NN force)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNP Doc_11912119_1060_1079_Disease)) (: -) (NP (NNP Doc_11912119_1082_1085_Disease)))))) (. .)))
11912119	8	(S1 (S (NP (NP (JJ Peak) (NN grip) (NN force)) (PP (IN in) (NP (NN ON-state)))) (VP (AUX was) (ADVP (NP (NP (CD 140) (NN %)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))) (JJR higher)) (PP (IN in) (NP (NNP Doc_11912119_1145_1164_Disease) (NNP +) (NNP Doc_11912119_1167_1170_Disease))) (PP (IN than) (PP (IN in) (NP (NP (NNP Doc_11912119_1179_1198_Disease)) (: -) (NP (NNP Doc_11912119_1201_1204_Disease))))) (, ,) (SBAR (IN while) (S (NP (JJ static) (NN grip) (NN force)) (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (NP (CD 138) (NN %)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))) (PP (IN between) (NP (NNS groups)))))))) (. .)))
11912119	9	(S1 (S (NP (NP (NN Severity)) (PP (IN of) (NP (JJ peak-dose) (NNP Doc_11912119_1301_1312_Disease)))) (VP (AUX was) (ADVP (RB strongly)) (VP (VBN correlated) (PP (IN with) (NP (NN grip) (NN force))) (PP (IN in) (NP (NP (NN ON-state)) (PRN (-LRB- -LRB-) (NP (NP (NP (SYM r)) (NP (SYM =) (CD 0.79))) (PP (IN with) (NP (NN peak) (NN force)))) (, ,) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
11912119	10	(S1 (S (NP (DT No) (NN correlation)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NNS forces)) (CC and) (NP (DT the) (NN motor) (NN score)))) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (NP (DT the) (JJ daily) (NN dose)) (PP (IN of) (NP (JJ dopaminergic) (NN medication)))))))) (. .)))
11912119	11	(S1 (S (NP (NN Force) (NN excess)) (VP (AUX was) (ADVP (RB only)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_11912119_1573_1576_Disease)) (CC and) (NP (NN motor) (NNS fluctuations)))))))) (. .)))
11912119	12	(S1 (S (NP (DT A) (JJ close) (NN relationship)) (VP (AUX was) (VP (VBN seen) (PP (IN between) (NP (NP (DT the) (NN overshooting)) (PP (IN of) (NP (NP (NNS forces)) (CC and) (NP (NNP Doc_11912119_1670_1681_Disease)))) (PP (IN in) (NP (DT the) (JJ ON-drug) (NN condition))))))) (. .)))
11912119	13	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (NP (DT both) (NP (NNP Doc_11912119_1731_1734_Disease)) (CC and) (NP (NN grip))) (VP (VBP force) (NP (NP (JJ excess) (NN share) (JJ common) (JJ pathophysiological) (NNS mechanisms)) (VP (VBN related) (PP (TO to) (NP (NN motor) (NNS fluctuations))))))))) (. .)))
11999899	0	(S1 (NP (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_11999899_22_28_Chemical))) (PP (IN on) (NP (JJ Doc_11999899_32_41_Chemical-treated) (NNS mice)))) (. .)))
11999899	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_11999899_71_82_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11999899_84_90_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ noncompetitive) (NNP Doc_11999899_110_130_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11999899_132_136_Chemical)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (, ,)))) (VP (AUX were) (VP (VBN studied) (PP (IN on) (NP (NP (JJ Doc_11999899_175_183_Chemical-related) (NNS behaviors)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_11999899_213_222_Chemical) (NNS treatments)))))))) (. .)))
11999899	2	(S1 (S (NP (DT This) (NN study)) (VP (VBZ focuses) (PP (IN on) (NP (NP (JJ behavioral) (NNS syndromes)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VBN used) (PP (IN as) (NP (NP (NP (NNS models)) (PP (IN for) (NP (NP (NNP Doc_11999899_306_325_Disease)) (, ,) (CC or) (NP (NNP Doc_11999899_330_348_Disease)) (, ,)))) (CC and) (NP (NP (PRP$ its) (NN response)) (PP (IN after) (NP (JJ glutamatergic) (NN blockage))))))))))))) (. .)))
11999899	3	(S1 (S (NP (NP (NNP Doc_11999899_397_406_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (VP (VBN administered) (PP (IN once) (NP (NP (DT every) (JJ other) (NN day)) (PP (IN for) (NP (CD 4) (NNS days)))))) (, ,)) (VP (VBD produced) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_11999899_486_506_Disease)) (, ,) (NP (NP (NP (NN tongue) (NN protrusion)) (CC and) (NP (JJ vacuous) (VBG chewing))) (PP (IN in) (NP (NNS mice)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (NP (NP (NNS signs)) (ADJP (JJ indicative) (PP (IN of) (NP (NNP Doc_11999899_585_603_Disease)))))))))))) (. .)))
11999899	4	(S1 (S (NP (NN Doc_11999899_605_614_Chemical)) (ADVP (RB also)) (VP (VBD produced) (NP (NP (NP (NNP Doc_11999899_629_635_Disease)) (CC and) (NP (NNP Doc_11999899_640_649_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (NP (NP (NNS signs)) (PP (JJ suggestive) (IN of) (NP (NNP Doc_11999899_681_700_Disease))))))))) (. .)))
11999899	5	(S1 (S (NP (NP (NN Doc_11999899_702_708_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (S (VP (VBN administered) (NP (CD 30) (NN min)) (PP (IN before) (NP (DT the) (JJ observation) (NN test))))) (, ,) (VP (VBD prevented) (NP (NP (DT the) (JJ vacuous) (VBG chewing) (NNS movements)) (, ,) (NP (NN tongue) (NNS protrusions)) (CC and) (NP (NP (NNP Doc_11999899_835_844_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11999899_856_865_Chemical))))))) (. .)))
11999899	6	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_11999899_876_882_Chemical) (NN injection)) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN of) (NP (NNP Doc_11999899_928_934_Disease))) (PP (IN in) (NP (JJ Doc_11999899_938_947_Chemical-treated) (NNS mice))))) (. .)))
11999899	7	(S1 (S (NP (NP (NP (NNP Doc_11999899_962_971_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg))) (-RRB- -RRB-))) (, ,) (VP (VP (VBN administered) (NP (CD 90) (NN min)) (PP (IN before) (NP (DT the) (NN test)))) (CC and) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_11999899_1035_1045_Chemical) (NN injection)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-)))) (NP (CD 5) (NN min)) (PP (IN before) (NP (DT the) (NN test))))) (, ,)) (VP (AUX did) (RB not) (VP (VB produce) (NP (NNP Doc_11999899_1107_1122_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11999899	8	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NNP Doc_11999899_1151_1160_Chemical) (VBN induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_11999899_1182_1188_Disease)) (CC and) (NP (NNP Doc_11999899_1193_1202_Disease))))) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (NP (NNS mice)))))) (. .)))
11999899	9	(S1 (S (NP (JJ Doc_11999899_1229_1235_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-)) (NN administration)) (VP (VBD attenuated) (NP (NP (DT the) (NNP Doc_11999899_1278_1287_Disease) (CC and) (NNP Doc_11999899_1292_1298_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11999899_1310_1319_Chemical)))))) (. .)))
11999899	10	(S1 (S (NP (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_11999899_1339_1348_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (NP (CD 24) (NNP h)) (PP (IN before) (NP (DT the) (NN observation) (NN test)))) (VP (VBD produced) (NP (NP (NP (NNS increases)) (PP (IN in) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NN protrusion))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS increases)) (PP (IN in) (NP (NNP Doc_11999899_1487_1493_Disease) (CC and) (NNP Doc_11999899_1498_1507_Disease)))) (, ,)) (PP (IN whereas) (NP (NNP Doc_11999899_1517_1523_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NNS mg/kg)) (-RRB- -RRB-)) (NN injection))) (NP (CD 90) (NN min)) (SBAR (IN before) (S (NP (DT the) (NN test)) (VP (VBD reversed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11999899_1593_1602_Chemical)))))))) (. .)))
11999899	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_11999899_1628_1637_Chemical)) (VP (VBZ produces) (ADJP (ADJP (JJ different)) (CC and) (ADJP (JJ Doc_11999899_1661_1679_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX are) (ADJP (VBN related) (PP (TO to) (NP (NP (NN dose) (CC and) (NN schedule)) (VP (VBN employed)))))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NNP Doc_11999899_1754_1766_Disease-like) (CC and) (NNP Doc_11999899_1776_1794_Disease) (NNS signs))))))))))))) (. .)))
11999899	12	(S1 (S (NP (NP (DT The) (JJ glutamatergic) (NN blockage)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_11999899_1841_1845_Chemical))))) (VP (MD can) (VP (VB restore) (NP (NP (DT these) (NNS signs)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (, ,) (NP (NN tongue) (NNS protrusions)) (, ,) (NP (NNP Doc_11999899_1926_1935_Disease)) (CC and) (NP (NNP Doc_11999899_1940_1946_Disease))))) (PP (VBG according) (PP (TO to) (NP (DT the) (VBN employed) (NN model)))))) (. .)))
12013711	0	(S1 (NP (NP (JJ Doc_12013711_0_11_Chemical-associated) (, ,) (JJ benign) (JJ transient) (NNP Doc_12013711_41_60_Disease)) (PP (IN in) (NP (NP (JJ Doc_12013711_64_77_Disease) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ past) (NN history)) (PP (IN of) (NP (JJ Doc_12013711_110_113_Chemical) (NN abuse))))))) (. .)))
12013711	1	(S1 (S (NP (NP (CD Two) (JJ Doc_12013711_125_138_Disease) (NNS patients)) (, ,) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ prior) (NN history)) (PP (IN of) (NP (JJ Doc_12013711_176_179_Chemical) (NN abuse))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB previously)) (VP (VBN developed) (NP (NN Doc_12013711_219_222_Disease)) (PP (IN with) (NP (JJ classic) (NNS antipsychotics)))))))) (, ,)) (VP (AUX were) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12013711_283_294_Chemical))))) (. .)))
12013711	2	(S1 (S (NP (PRP They)) (DT both) (VP (VBD reported) (NP (NP (JJ short) (NNS episodes)) (PP (IN of) (NP (JJ transient) (NNP Doc_12013711_343_362_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG starting) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_12013711_421_432_Chemical))))))))))) (. .)))
12013711	3	(S1 (S (NP (DT This) (NN imagery)) (VP (VBD resembled) (SBAR (S (NP (NNP Doc_12013711_457_476_Disease)) (ADVP (RB previously)) (VP (VBN experienced) (PP (IN as) (NP (NP (`` ``) (NNS flashbacks) ('' '')) (VP (VBN related) (PP (TO to) (NP (JJ prior) (JJ Doc_12013711_533_536_Chemical) (NN consumption)))))))))) (. .)))
12013711	4	(S1 (S (S (NP (JJ Doc_12013711_550_561_Chemical) (NN administration)) (VP (AUX was) (VP (VBN continued)))) (CC and) (S (NP (DT the) (NN Doc_12013711_599_618_Disease)) (ADVP (RB gradually)) (VP (VBD wore) (PRT (RP off)))) (. .)))
12013711	5	(S1 (S (PP (IN During) (NP (DT a) (JJ six-month) (JJ follow-up) (NN period))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN recurrence)) (PP (IN of) (NP (NNP Doc_12013711_703_722_Disease))))) (. .)))
12013711	6	(S1 (S (NP (DT This) (NN phenomenon)) (VP (MD may) (VP (AUX be) (VP (VBN interpreted) (PP (IN as) (NP (NP (DT a) (ADJP (ADJP (JJ benign)) (, ,) (ADJP (JJ short-term)) (CC and) (ADJP (JJ self-limiting))) (NN side) (NN effect)) (SBAR (WHNP (WDT which)) (S (VP (AUX does) (RB not) (VP (VP (VB contraindicate) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12013711_854_865_Chemical))))) (CC or) (VP (VB interfere) (PP (IN with) (NP (NN treatment))))))))))))) (. .)))
12013711	7	(S1 (S (NP (NP (NNS Conclusions)) (VP (VBN based) (PP (IN on) (NP (CD two) (NN case) (NNS reports))))) (VP (MD should) (VP (AUX be) (VP (VBN taken) (PP (IN with) (NP (JJ appropriate) (NN caution)))))) (. .)))
12042105	0	(S1 (NP (JJ Doc_12042105_0_10_Chemical-induced) (NN Doc_12042105_19_34_Disease) (. .)))
12042105	1	(S1 (S (NP (NN Doc_12042105_36_46_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB recently) (VBN developed)) (JJ antiepileptic) (NN medication)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBG becoming) (NP (NP (JJR more)) (VP (ADVP (RB widely)) (VBN prescribed) (PP (IN because) (IN of) (NP (PRP$ its) (NN efficacy))) (PP (IN in) (S (VP (VBG treating) (NP (NNP Doc_12042105_172_191_Disease))))))))))))) (. .)))
12042105	2	(S1 (S (NP (NNS Urologists)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (DT this) (NN medication)) (VP (MD can) (VP (VB cause) (NP (NN Doc_12042105_251_269_Disease)) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ carbonic) (NN anhydrase))))))))))))))) (. .)))
12042105	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT a) (JJ distal) (JJ tubular) (NN acidification) (NN defect)) (VP (MD may) (VP (VB result) (, ,) (S (ADVP (RB thus)) (VP (VBG impairing) (NP (NP (DT the) (JJ normal) (JJ compensatory) (NN drop)) (PP (IN in) (NP (NN urine) (NNP pH.))) (SBAR (S (NP (DT These) (NNS factors)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12042105_494_511_Chemical) (NNP Doc_12042105_512_527_Disease)))))))))))))) (. .)))
12042105	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_12042105_562_572_Chemical-induced) (NNP Doc_12042105_581_596_Disease))) (PP (IN in) (NP (DT the) (JJ urologic) (NN literature))))) (. .)))
12091028	0	(S1 (NP (NP (NN Doc_12091028_0_8_Chemical)) (PP (IN in) (NP (NP (JJ war/tropical) (NN surgery)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ final) (NN tribute)) (PP (TO to) (NP (DT the) (JJ racemic) (NN mixture)))) (-RRB- -RRB-)))) (. .)))
12091028	1	(S1 (S (NP (NP (DT A) (NN technique)) (PP (IN of) (NP (NP (JJ continuous) (JJ intravenous) (NNS anaesthesia)) (PP (IN with) (NP (NNP Doc_12091028_130_138_Chemical)))))) (VP (VP (AUX was) (VP (VBN used) (ADVP (RB successfully)) (PP (IN during) (NP (DT the) (NNP Somalia) (JJ civil) (NN war))) (PP (IN in) (NP (CD 1994))))) (CC and) (VP (PP (IN in) (NP (JJ north) (NNP Uganda))) (PP (IN in) (NP (CD 1999))) (PP (IN for) (NP (NP (CD 64) (NNS operations)) (PP (IN in) (NP (CD 62) (NNS patients))) (, ,) (VP (VBN aged) (PP (IN from) (NP (QP (CD 6) (NNS weeks) (TO to) (CD 70)) (NNS years)))) (, ,) (PP (VBG undergoing) (NP (NP (NN limb) (CC and) (NN abdominal) (NN surgery)) (PP (VBG including) (NP (NP (JJ caesarian) (NNS sections)) (CC and) (NP (NP (NNS interventions)) (PP (IN in) (NP (NNS neonates)))))))))))) (. .)))
12091028	2	(S1 (S (NP (NP (NNS Operations)) (VP (VBG lasting) (PRT (RP up)) (PP (TO to) (NP (CD 2h))))) (VP (MD could) (VP (AUX be) (VP (VBN performed) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ sophisticated) (NN equipment)) (PP (JJ such) (IN as) (NP (NP (NN pulse) (NNS oximeters)) (CC or) (NP (NP (NNS ventilators)) (PP (IN in) (NP (NNS patients)))))))))) (PP (IN on) (NP (NP (JJ spontaneous) (NN ventilation) (NN breathing) (NN air/Doc_12091028_570_576_Chemical)) (ADVP (RB only))))))) (. .)))
12091028	3	(S1 (S (PP (IN After) (NP (NP (NP (NN premedication)) (PP (IN with) (NP (NP (NNP Doc_12091028_608_616_Chemical)) (, ,) (NP (NNP Doc_12091028_618_632_Chemical)) (CC and) (NP (JJ local) (NNS anaesthesia))))) (, ,) (CC and) (NP (NP (NN induction)) (PP (IN with) (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NNP Doc_12091028_693_701_Chemical)))))))) (, ,) (NP (NP (DT a) (NN maintenance) (NN dose)) (PP (IN of) (NP (NP (CD 10-20) (NN microg/kg/min)) (PP (IN of) (NP (NNP Doc_12091028_748_756_Chemical)))))) (VP (VBD proved) (ADJP (JJ safe) (CC and) (JJ effective))) (. .)))
12091028	4	(S1 (S (NP (NN Emphasis)) (VP (AUX was) (VP (VBN placed) (PP (IN on) (NP (JJ bedside) (JJ clinical) (NN monitoring))) (, ,) (S (VP (VBG relying) (ADVP (RB heavily)) (PP (IN on) (NP (DT the) (NN heart) (NN rate))))))) (. .)))
12091028	5	(S1 (S (NP (NP (NN Doc_12091028_871_879_Chemical)) (, ,) (SBAR (IN unless) (FRAG (ADJP (JJ contraindicated) (CC or) (JJ risky)))) (, ,)) (VP (VBZ remains) (NP (NP (DT the) (RB only) (JJ necessary) (JJ complementary) (NN drug)) (PP (TO to) (NP (NNP Doc_12091028_963_971_Chemical)))) (SBAR (IN as) (S (NP (PRP it)) (VP (VP (VBZ buffers) (NP (PRP$ its) (JJ cardiovascular) (NN response))) (CC and) (VP (VBZ decreases) (NP (NP (DT the) (NN duration) (CC and) (NN intensity)) (PP (IN of) (NP (ADJP (JJ operative) (CC and) (JJ postoperative)) (NNP Doc_12091028_1086_1100_Disease))))))))) (. .)))
12091028	6	(S1 (S (NP (JJ Local) (JJ anaesthetic) (NNS blocks)) (VP (AUX were) (ADJP (JJ useful)) (PP (IN in) (S (VP (VBG decreasing) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (JJ postoperative) (NN Doc_12091028_1187_1196_Disease)))))))) (. .)))
12091028	7	(S1 (S (NP (DT An) (NN antisialogue)) (VP (AUX was) (ADJP (RB usually) (JJ unnecessary)) (PP (IN in) (NP (NP (NNS operations)) (VP (VBG lasting) (NP (QP (RB up) (TO to) (CD 2)) (NNP h))))) (, ,) (S (NP (NNP Doc_12091028_1271_1285_Chemical)) (VP (AUXG being) (NP (NP (DT the) (JJS best) (NN choice)) (PP (IN for) (NP (NP (PRP$ its) (JJS lowest) (NN psychotropic)) (CC and) (NP (JJ chronotropic) (NNS effects))))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (DT a) (JJ hot) (NN climate)))) (. .)))
12091028	8	(S1 (S (NP (NP (NN Experience)) (PP (IN in) (NP (JJ war/tropical) (NNS settings)))) (VP (VBZ suggests) (SBAR (S (NP (DT this) (NN technique)) (VP (MD could) (VP (AUX be) (ADJP (JJ useful) (PP (PP (IN in) (NP (NP (JJ civilian) (NNS contexts)) (PP (JJ such) (IN as) (NP (JJ outdoor) (JJ life-saving) (NN emergency) (NN surgery))))) (CC or) (PP (IN in) (NP (NP (NN mass) (NNS casualties)) (SBAR (WHADVP (WRB where)) (, ,) (S (NP (NP (JJ e.g.) (NN amputation)) (CC and) (NP (JJ rapid) (NN extrication))) (VP (AUX were) (VP (VBN required)))))))))))))) (. .)))
12093990	0	(S1 (NP (NP (JJ Intravenous) (JJ Doc_12093990_12_21_Chemical) (NN treatment)) (PP (IN for) (NP (NP (JJ severe) (NN Doc_12093990_43_61_Disease)) (PP (IN in) (NP (JJ immunocompromised) (NNS children))))) (. .)))
12093990	1	(S1 (S (NP (NN Adenovirus)) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN cause)) (PP (IN of) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))))) (PP (IN in) (NP (DT the) (JJ immunocompromised) (NN host)))) (. .)))
12093990	2	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_220_238_Disease))) (PP (IN in) (NP (NNS pediatrics)))) (VP (AUX is) (VP (VBG increasing) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (VBG growing) (NNS numbers)) (PP (IN of) (NP (JJ immunocompromised) (NNS children))))) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN case) (NN fatality) (NNS rates)) (ADJP (RB as) (JJ high) (PP (IN as) (NP (QP (CD 50) (NN %) (TO to) (CD 80) (NN %)))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))))))))) (. .)))
12093990	3	(S1 (S (NP (EX There)) (VP (VP (AUX are) (NP (DT no) (JJ approved) (JJ antiviral) (NNS agents)) (PP (IN with) (NP (NP (VBN proven) (NN efficacy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_490_508_Disease)))))))) (, ,) (CC nor) (VP (AUX are) (ADVP (RB there)) (NP (NP (DT any) (JJ prospective) (JJ randomized) (, ,) (JJ controlled) (NNS trials)) (PP (IN of) (NP (ADJP (RB potentially) (JJ useful)) (JJ anti-adenovirus) (NNS therapies)))))) (. .)))
12093990	4	(S1 (S (NP (NP (JJ Apparent) (JJ clinical) (NN success)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_672_690_Disease)))))) (VP (AUX is) (VP (VBN limited) (PP (TO to) (NP (NP (DT a) (JJ few) (NN case) (NNS reports)) (CC and) (NP (JJ small) (NNS series)))))) (. .)))
12093990	5	(S1 (S (NP (NN Experience)) (VP (AUX is) (ADJP (JJS greatest) (PP (IN with) (NP (JJ intravenous) (NNP Doc_12093990_782_791_Chemical) (CC and) (NNP Doc_12093990_796_805_Chemical))))) (. .)))
12093990	6	(S1 (S (NP (NP (NNP Doc_12093990_807_816_Chemical)) (, ,) (NP (DT a) (JJ Doc_12093990_820_829_Chemical) (NN analogue)) (, ,)) (VP (AUX has) (NP (NP (JJ broad) (JJ antiviral) (NN activity)) (PP (IN against) (NP (DT both) (NNP RNA) (CC and) (NNP DNA) (NNS viruses)))) (, ,) (PP (VBG including) (NP (NP (VBN documented) (NN activity)) (PP (IN against) (NP (NN adenovirus))) (PP (IN in) (NP (NN vitro)))))) (. .)))
12093990	7	(S1 (S (NP (NN Doc_12093990_962_971_Chemical)) (VP (AUX is) (VP (VP (VBN licensed) (PP (IN in) (NP (JJ aerosol) (NN form))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12093990_1021_1058_Disease)))))) (, ,) (CC and) (VP (ADVP (RB orally)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP interferon))) (S (VP (TO to) (VP (VB treat) (SBAR (S (NP (ADJP (NNP Doc_12093990_1111_1122_Disease.) (JJ Intravenous)) (NNP Doc_12093990_1136_1145_Chemical)) (VP (AUX is) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN choice))) (PP (IN for) (NP (NNP Doc_12093990_1177_1217_Disease))))))))))))) (. .)))
12093990	8	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_12093990_1265_1274_Chemical)))) (VP (AUX is) (NP (JJ reversible) (JJ mild) (NN Doc_12093990_1294_1300_Disease))) (. .)))
12093990	9	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_12093990_1313_1322_Chemical))) (PP (IN in) (NP (JJ severe) (NNP Doc_12093990_1333_1353_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN limited) (PP (IN by) (NP (NP (JJ adverse) (NNS effects)) (, ,) (SBAR (WHNP (WHNP (DT the) (RBS most) (JJ significant)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX is) (NP (NN Doc_12093990_1424_1438_Disease)))))))))) (. .)))
12093990	10	(S1 (S (NP (PRP We)) (VP (VP (VBP report) (NP (NP (PRP$ our) (NN experience)) (PP (IN with) (NP (JJ intravenous) (JJ Doc_12093990_1493_1502_Chemical) (NN therapy))) (PP (IN for) (NP (JJ severe) (NN Doc_12093990_1522_1540_Disease)))) (PP (IN in) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ immunocompromised) (NNS children)))))) (CC and) (VP (VB review) (NP (DT the) (NN literature)))) (. .)))
12093990	11	(S1 (NP (NP (NNS DESIGN/METHODS)) (: :) (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBN reviewed) (NP (NP (DT the) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 5) (NNS children)) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NNP Doc_12093990_1713_1722_Chemical))) (PP (IN for) (NP (VBN documented) (JJ severe) (NN Doc_12093990_1745_1763_Disease))))))))) (. .)))
12093990	12	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ adenovirus) (NN Doc_12093990_1799_1819_Disease)) (PP (IN after) (NP (NP (JJ cardiac)) (CC and) (NP (NN bone) (NN marrow) (NNS transplants)))) (, ,) (ADVP (RB respectively))) (. .)))
12093990	13	(S1 (S (NP (DT The) (NN bone) (NN marrow) (NN transplant) (NN patient)) (ADVP (RB also)) (VP (VBD received) (NP (NP (JJ intravenous) (NN Doc_12093990_1938_1947_Chemical)) (PP (IN for) (NP (JJ progressive) (VBN disseminated) (NN disease))))) (. .)))
12093990	14	(S1 (S (S (NP (DT An) (JJ additional) (CD 3) (NNS children)) (VP (VBD developed) (NP (NNP Doc_12093990_2021_2041_Disease)))) (: ;) (S (NP (CD 2)) (VP (AUX were) (NP (NP (NNS neonates)) (, ,) (SBAR (WHNP (CD 1) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (NP (JJ partial) (NN Doc_12093990_2082_2099_Disease)))))))) (. .)))
12093990	15	(S1 (S (NP (DT The) (VBG remaining) (NN infant)) (VP (AUX had) (ADVP (RB recently)) (VP (VBN undergone) (NP (DT a) (JJ cardiac) (NN transplant)))) (. .)))
12093990	16	(S1 (S (NP (JJ Intravenous) (NNP Doc_12093990_2179_2188_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN on) (NP (DT a) (JJ compassionate-use) (NN protocol))))) (. .)))
12093990	17	(S1 (S (NP (NP (JJ Complete) (JJ clinical) (NN recovery)) (VP (VBN followed) (ADVP (RB later)) (PP (IN by) (NP (JJ viral) (NN clearance))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 2) (NNS children)) (: :) (NP (NP (NP (DT the) (JJ cardiac) (NN transplant) (NN recipient)) (PP (IN with) (NP (JJ adenovirus) (NN Doc_12093990_2386_2406_Disease)))) (CC and) (NP (NP (DT the) (JJ immunocompetent) (NN neonate)) (PP (IN with) (NP (NNP Doc_12093990_2444_2464_Disease))))))))) (. .)))
12093990	18	(S1 (S (NP (DT The) (JJ remaining) (CD 3) (NNS children)) (VP (VBD died) (PP (IN of) (NP (NNP Doc_12093990_2499_2517_Disease)))) (. .)))
12093990	19	(S1 (S (NP (JJ Intravenous) (JJ Doc_12093990_2531_2540_Chemical) (NN therapy)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
12093990	20	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_12093990_2576_2585_Chemical))) (PP (IN in) (NP (CD 1) (NN child)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_12093990_2617_2642_Disease)) (CC and) (NP (NNP Doc_12093990_2647_2658_Disease)))))) (. .)))
12093990	21	(S1 (S (NP (NP (PRP$ Our) (NN series)) (PP (IN of) (NP (NNS patients)))) (VP (AUX is) (NP (NP (NN representative)) (PP (IN of) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (NP (JJ immunocompromised) (NNS children)) (PP (IN at) (NP (NP (JJS greatest) (NN risk)) (PP (IN for) (NP (NP (JJ severe) (NN Doc_12093990_2787_2805_Disease)) (, ,) (NP (RB namely) (JJ solid-organ) (CC and) (NN bone) (NN marrow) (NN transplant) (NNS recipients)) (, ,) (NP (NNS neonates)) (, ,) (CC and) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_12093990_2893_2909_Disease)))))))))))))) (. .)))
12093990	22	(S1 (S (SBAR (IN Although) (S (NP (JJ intravenous) (NNP Doc_12093990_2932_2941_Chemical)) (VP (AUX was) (RB not) (ADJP (JJ effective)) (PP (IN for) (NP (NP (DT all) (NNS children)) (PP (IN with) (NP (JJ severe) (NNP Doc_12093990_2989_3007_Disease))))) (PP (PP (IN in) (NP (DT this) (NN series))) (CC or) (PP (IN in) (NP (DT the) (NN literature))))))) (, ,) (NP (NN therapy)) (VP (AUX is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (NN benefit))) (SBAR (IN if) (S (VP (VBN begun) (ADVP (RB late)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NNP Doc_12093990_3117_3126_Disease))))))))))))) (. .)))
12093990	23	(S1 (S (NP (NP (JJ Early) (NN identification)) (, ,) (VP (VBN eg) (PP (IN by) (NP (NP (NN polymerase) (NN chain) (NN reaction)) (PP (IN of) (NP (DT those) (NNS patients))))) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (NP (VBN disseminated) (NN Doc_12093990_3224_3242_Disease))))))) (VP (MD may) (VP (VB permit) (NP (NP (RBR earlier) (JJ antiviral) (NN treatment)) (CC and) (NP (NP (JJR better) (NN evaluation)) (PP (IN of) (NP (JJ therapeutic) (NN response))))))) (. .)))
12093990	24	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 5) (NNS children)) (PP (IN with) (NP (JJ severe) (NNP Doc_12093990_3372_3390_Disease))) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NN Doc_12093990_3416_3425_Chemical))))))) (VP (VBD recovered)) (. .)))
12093990	25	(S1 (S (NP (NP (DT The) (NN availability)) (PP (IN of) (NP (NP (JJR newer) (JJ rapid) (JJ diagnostic) (NNS techniques)) (, ,) (PP (JJ such) (IN as) (NP (NN polymerase) (NN chain) (NN reaction))) (, ,)))) (VP (MD may) (VP (VB make) (NP (NP (JJR earlier) (, ,) (ADJP (RBR more) (JJ effective)) (NN treatment)) (PP (IN of) (NP (JJ Doc_12093990_3573_3593_Disease) (JJ possible)))))) (. .)))
12093990	26	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN seriousness)) (CC and) (NP (NP (VBG increasing) (NN prevalence)) (PP (IN of) (NP (NNP Doc_12093990_3655_3673_Disease))) (PP (IN in) (NP (NP (JJ certain) (NNS hosts)) (, ,) (ADVP (RB especially)) (NP (NNS children))))))) (, ,) (NP (NP (DT a) (JJ large) (, ,) (JJ multicenter) (JJ clinical) (NN trial)) (PP (IN of) (NP (NP (ADJP (RB potentially) (JJ useful)) (JJ anti-adenoviral) (NNS therapies)) (, ,) (PP (JJ such) (IN as) (NP (JJ intravenous) (NNP Doc_12093990_3818_3827_Chemical))) (, ,)))) (VP (AUX is) (ADVP (RB clearly)) (VP (VBN required) (S (VP (TO to) (VP (VB demonstrate) (NP (DT the) (ADJP (ADJP (RBS most) (JJ effective)) (CC and) (ADJP (RBS least) (JJ toxic))) (NN therapy))))))) (. .)))
12101159	0	(S1 (S (S (VP (VBN Delayed) (NP (NNP Doc_12101159_8_17_Disease) (NNP Doc_12101159_18_32_Disease)) (PP (IN after) (NP (NNP Doc_12101159_39_48_Chemical) (NNP Doc_12101159_49_57_Disease))))) (: ;) (S (NP (NP (NN resuscitation)) (PP (IN with) (NP (JJ high) (NN dose)))) (ADJP (JJ intravenous) (JJ Doc_12101159_100_107_Chemical))) (. .)))
12101159	1	(S1 (S (NP (DT A) (CD 51) (NN year) (JJ old) (NN man)) (VP (VBD took) (NP (DT a) (JJ mixed) (NN Doc_12101159_140_148_Disease)) (PP (VBG including) (NP (NP (NP (CD 1.8-3.6) (NNP g)) (PP (IN of) (NP (NNP Doc_12101159_172_181_Chemical)))) (, ,) (NP (NNP Doc_12101159_183_194_Chemical)) (, ,) (NP (NNP Doc_12101159_196_203_Chemical)) (, ,) (NP (NNP Doc_12101159_205_215_Chemical) (NNP Doc_12101159_216_223_Chemical)) (, ,) (CC and) (NP (NNP Doc_12101159_229_236_Chemical))))) (. .)))
12101159	2	(S1 (S (NP (PRP He)) (ADVP (RB initially)) (VP (VP (VBD presented) (PP (TO to) (NP (NN hospital))) (PP (IN after) (NP (NP (CD six) (NNS hours)) (PP (IN with) (NP (JJ mild) (NN Doc_12101159_299_310_Disease)))))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (VBN activated) (NN charcoal)) (CC and) (NP (JJ intravenous) (NNS fluids))))))) (. .)))
12101159	3	(S1 (S (PP (NP (CD Eighteen) (NNS hours)) (IN after) (NP (DT the) (NNP Doc_12101159_400_408_Disease))) (NP (PRP he)) (VP (AUX had) (NP (CD two) (JJ generalised) (NN Doc_12101159_432_453_Disease))) (. .)))
12101159	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (VBD remained) (ADJP (JJ unresponsive) (PP (IN with) (NP (NP (JJ junctional) (NNP Doc_12101159_505_516_Disease)) (, ,) (NP (JJ unrecordable) (NN blood) (NN pressure)) (, ,))))) (CC and) (VP (ADVP (RB then)) (VBD became) (NP (NNP Doc_12101159_563_572_Disease)))) (. .)))
12101159	5	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN resuscitated) (S (PP (IN with) (NP (JJ high) (NN dose))) (-LRB- -LRB-) (NP (CD 13.5) (NNP g)) (-RRB- -RRB-) (NP (NP (JJ intravenous) (NNP Doc_12101159_630_637_Chemical)) (CC and) (NP (NP (NNP Doc_12101159_642_652_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12101159_654_665_Chemical)) (-RRB- -RRB-))))))) (. .)))
12101159	6	(S1 (S (NP (PRP He)) (VP (VBD required) (NP (NP (JJ inotropic) (NN support)) (CC and) (NP (JJ temporary) (NN pacing))) (PP (IN over) (NP (DT the) (JJ next) (CD 48) (NNS hours)))) (. .)))
12101159	7	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (JJ aggressive) (JJ high) (NN dose) (JJ intravenous) (JJ Doc_12101159_815_822_Chemical) (NN therapy))) (PP (IN in) (NP (JJ severe) (NNP Doc_12101159_841_850_Chemical) (NNP Doc_12101159_851_859_Disease)))) (, ,) (PP (ADVP (RB particularly)) (IN with) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_12101159_892_900_Disease))))))))) (. .)))
12101159	8	(S1 (S (NP (PRP It)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (ADVP (RB early)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_12101159_944_958_Disease))))) (PP (IN after) (NP (NNP Doc_12101159_965_974_Chemical) (NNP Doc_12101159_975_983_Disease)))))) (. .)))
12101159	9	(S1 (S (NP (DT The) (NN case)) (ADVP (RB also)) (VP (VBZ highlights) (NP (NP (DT the) (NNS problems)) (PP (IN with) (NP (JJ delayed) (NN Doc_12101159_1036_1044_Disease)))) (SBAR (WHADVP (WRB when)) (S (NP (JJ whole) (NN bowel) (NN irrigation)) (VP (AUX is) (RB not) (VP (VBN administered)))))) (. .)))
12109865	0	(S1 (NP (NP (NN Doc_12109865_0_28_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))))) (. .)))
12109865	1	(S1 (S (NP (NP (DT The) (NN interruption)) (PP (IN of) (NP (JJ oral) (NN anticoagulant) (PRN (-LRB- -LRB-) (NP (NNP OAC)) (-RRB- -RRB-)) (NN administration)))) (VP (AUX is) (ADVP (RB sometimes)) (VP (VBN indicated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))) (, ,) (PP (ADVP (RB mainly)) (IN before) (NP (NP (NN noncardiac) (NN surgery)) (, ,) (NP (JJ non-surgical) (NNS interventions)) (, ,) (CC and) (NP (NN pregnancy)))))) (. .)))
12109865	2	(S1 (S (NP (NP (NNP Doc_12109865_303_325_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12109865_327_329_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB currently)) (NP (NP (DT the) (NN substitute)) (PP (IN for) (NP (VBN selected) (NNS patients))))) (. .)))
12109865	3	(S1 (S (NP (NP (NNP Doc_12109865_382_410_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12109865_412_416_Chemical)) (-RRB- -RRB-))) (VP (VP (VBZ offers) (NP (NP (JJ theoretical) (NNS advantages)) (PP (IN over) (NP (NNP Doc_12109865_453_455_Chemical))))) (, ,) (CC but) (VP (AUX is) (RB not) (ADVP (RB currently)) (VP (VBN considered) (PP (IN in) (NP (JJ clinical) (NNS guidelines))) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (NNP Doc_12109865_533_535_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ prosthetic) (NNS valves)))))))))) (. .)))
12109865	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB review) (NP (NP (DT the) (NNS data)) (VP (VBN accumulated) (ADVP (RB so) (RB far)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12109865_669_673_Chemical))) (PP (IN in) (NP (DT this) (JJ patient) (NN population))))))))) (CC and) (VP (TO to) (VP (VB discuss) (NP (NP (PRP$ its) (NN applicability)) (PP (IN in) (NP (JJ common) (NN practice))))))))) (. .)))
12109865	5	(S1 (S (PP (IN For) (NP (DT this) (NN paper))) (, ,) (NP (NP (DT the) (JJ current) (JJ medical) (NN literature)) (PP (IN on) (NP (NNP Doc_12109865_813_817_Chemical))) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves)))) (VP (AUX was) (ADVP (RB extensively)) (VP (VBN reviewed))) (. .)))
12109865	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD eight) (NN series)) (CC and) (NP (CD six) (NN case) (NNS reports)))) (. .)))
12109865	7	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS studies)))) (VP (AUX was) (VP (VBN randomized)))) (, ,) (CC and) (S (NP (RB only) (CD one)) (VP (AUX was) (ADJP (JJ prospective)))) (. .)))
12109865	8	(S1 (S (NP (NP (NNS Data)) (SBAR (S (VP (TO to) (VP (VB establish) (NP (DT the) (JJ Doc_12109865_1028_1042_Disease) (NN risk))))))) (VP (AUX were) (ADJP (JJ incomplete))) (. .)))
12109865	9	(S1 (S (PP (IN After) (NP (VBG excluding) (NN case) (NNS reports))) (, ,) (NP (DT the) (JJ following) (NNS groups)) (VP (AUX were) (VP (VBN constructed) (UCP (: :) (ADJP (ADJP (NP (NP (LST (-LRB- -LRB-) (DT a) (-RRB- -RRB-)) (NP (JJ short-term) (NN administration)) (, ,) (PP (IN after) (NP (NN valve) (NN insertion)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 212)) (-RRB- -RRB-)) (: ;) (NP (NP (PRN (-LRB- -LRB-) (NP (NNP b)) (-RRB- -RRB-)) (JJ short-term) (, ,) (JJ perioperative) (PRN (-LRB- -LRB-) (NP (NN noncardiac)) (-RRB- -RRB-)) (JJ /periprocedural)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 114)) (-RRB- -RRB-)) (: ;)) (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (JJ long-term)) (, ,) (ADJP (JJ due) (S (VP (TO to) (VP (VB intolerance) (PP (TO to) (NP (NP (NNP OAC)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 16)) (-RRB- -RRB-)) (: ;) (ADJP (PRN (-LRB- -LRB-) (NP (NNP d)) (-RRB- -RRB-)) (JJ long-term)) (, ,))) (PP (IN in) (NP (NN pregnancy))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)))))) (. .)))
12109865	10	(S1 (S (S (NP (NP (DT The) (NN incidence) (NN rate)) (PP (IN of) (NP (NNP Doc_12109865_1378_1393_Disease)))) (VP (AUX was) (NP (NP (NP (CD 0.9) (NN %)) (PP (IN for) (NP (PDT all) (DT the) (NNS studies) (CC and) (CD 0.5) (, ,) (CD 0) (, ,) (CD 20)))) (, ,) (CC and) (NP (NP (CD 0) (NN %)) (PP (IN in) (NP (NNS groups)))) (DT a)) (, ,) (NP (NP (NNP b)) (, ,) (NP (NNP c)) (, ,) (CC and) (NP (NNP d)) (, ,) (ADVP (RB respectively))))) (: ;) (S (PP (IN for) (NP (NNP Doc_12109865_1490_1500_Disease))) (, ,) (NP (DT the) (JJ overall) (NN rate)) (VP (AUX was) (NP (NP (CD 3.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.8)) (, ,) (NP (CD 2.6)) (, ,) (NP (CD 10)) (, ,) (CC and) (NP (NP (CD 0) (NN %)) (PP (IN for) (NP (DT the) (JJ respective) (NNS groups))))) (-RRB- -RRB-))))) (. .)))
12109865	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))) (, ,) (NP (JJ short-term) (JJ Doc_12109865_1644_1648_Chemical) (NN therapy)) (VP (VBZ compares) (ADVP (RB favorably)) (PP (IN with) (NP (NNP Doc_12109865_1681_1683_Chemical)))) (. .)))
12109865	12	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NN mid-)) (CC and) (NP (JJ long-term) (JJ Doc_12109865_1712_1716_Chemical) (NN administration)))) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX are) (ADJP (JJ sparse))) (. .)))
12109865	13	(S1 (S (NP (JJ Further) (JJ randomized) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB confirm) (NP (NP (DT the) (NN safety)) (CC and) (NP (JJ precise) (NNS indications))) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12109865_1861_1865_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves)))))))))))) (. .)))
12139551	0	(S1 (NP (NP (NP (NN Doc_12139551_0_14_Disease)) (PP (IN after) (NP (JJ intravenous) (NNP Doc_12139551_33_47_Chemical)))) (: -) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (CD five) (JJ repeated) (NNS injections)) (PP (IN of) (NP (NNP Doc_12139551_88_102_Chemical))))) (VP (VBG causing) (NP (NP (CD five) (NNS episodes)) (PP (IN of) (NP (NNP Doc_12139551_128_142_Disease)))))) (. .)))
12139551	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHADVP (WRB where)) (S (NP (NP (JJ intravenous) (NN injection)) (PP (IN of) (NP (NNP Doc_12139551_197_211_Chemical)))) (VP (AUX was) (ADVP (RB immediately)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_12139551_240_248_Disease))) (ADVP (RB repeatedly)))))))) (. .)))
12139551	2	(S1 (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NNP Doc_12139551_282_296_Chemical) (CD 10) (NNS mg)) (PP (IN i.v.) (NP (CD five) (NNS times))) (PP (IN during) (NP (NP (CD 48)) (NP (NNP h))))) (. .)))
12139551	3	(S1 (S (PP (IN After) (S (VP (VP (VBG interviewing) (NP (DT the) (VBG attending) (NNS nurses))) (CC and) (VP (VBG reviewing) (NP (DT the) (VBN written) (NN documentation)))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NP (DT every) (NN administration)) (PP (IN of) (NP (NNP Doc_12139551_454_468_Chemical)))) (VP (AUX was) (ADVP (RB immediately)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (PRP s))) (-RRB- -RRB-)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_12139551_508_516_Disease)))))))) (. .)))
12139551	4	(S1 (S (S (NP (DT The) (NNP Doc_12139551_522_530_Disease)) (VP (VBD lasted) (SBAR (S (NP (NN 15-30)) (VP (VBZ s) (PP (IN on) (NP (CD four) (NNS occasions)))))))) (, ,) (S (PP (IN on) (NP (CD one) (NN occasion))) (NP (PRP it)) (VP (VBD lasted) (NP (CD 2) (NN min)))) (. .)))
12139551	5	(S1 (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NP (JJ Doc_12139551_619_627_Chemical) (JJ 0.5-1) (NN mg)) (CC and) (NP (NN chest) (NNS compressions))) (, ,) (SBAR (IN before) (S (NP (JJ sinus) (NN rhythm)) (ADVP (RB again)) (VP (VBD took) (PRT (RP over)))))) (. .)))
12139551	6	(S1 (S (NP (PRP We)) (VP (VB interpret) (NP (DT this)) (PP (IN as) (NP (NP (NNS episodes)) (PP (IN of) (NP (NNP Doc_12139551_731_745_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_12139551_756_770_Chemical))))))) (. .)))
12139551	7	(S1 (S (NP (NP (NP (DT The) (JJ rapid) (NN injection)) (PP (IN via) (NP (DT the) (JJ central) (JJ venous) (NN route)))) (CC and) (NP (NP (DT the) (JJ concomitant) (VBG tapering)) (PP (IN of) (NP (JJ Doc_12139551_853_861_Chemical) (NN infusion))))) (VP (MD might) (VP (AUX have) (VP (VBN contributed) (PP (IN in) (S (VP (VBG precipitating) (NP (DT the) (JJ adverse) (NN drug) (NN reaction)))))))) (. .)))
12180796	0	(S1 (S (NP (NP (JJ Immunohistochemical) (NN study)) (PP (IN on) (NP (NP (JJ inducible) (NN type)) (PP (IN of) (NP (NP (NP (NNP Doc_12180796_47_59_Chemical)) (PRN (-LRB- -LRB-) (NP (NNS iNOS)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ basic) (NN fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (CD bFGF)) (-RRB- -RRB-)) (CC and) (NP (NNP Doc_12180796_110_115_Disease) (NN growth) (NN factor-beta1)) (PRN (-LRB- -LRB-) (JJ TGF-beta1) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNP Doc_12180796_151_160_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNP Doc_12180796_180_190_Chemical) (CC and) (NNP Doc_12180796_195_207_Chemical))))))) (, ,)))))) (VP (VBZ vasodilators)) (. .)))
12180796	1	(S1 (S (NP (NP (NP (NN Doc_12180796_223_232_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNS vasodilators))))) (, ,) (NP (NNP Doc_12180796_266_276_Chemical) (CC and) (NNP Doc_12180796_281_293_Chemical)) (, ,)) (VP (AUX was) (VP (VBN examined) (ADVP (RB immunohistochemically)) (PP (IN for) (NP (NP (NNS expressions)) (PP (IN of) (NP (NP (JJ inducible) (NN type)) (PP (IN of) (NP (NP (NP (NNP Doc_12180796_367_379_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNS iNOS)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ basic) (JJ fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (CD bFGF)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_12180796_439_444_Disease) (NN growth) (NNS factor-beta1)) (PRN (-LRB- -LRB-) (NP (NNP TGF-beta1)) (-RRB- -RRB-))))))))))) (. .)))
12180796	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VP (VBN administered) (NP (NNP Doc_12180796_501_511_Chemical)) (PP (IN for) (NP (CD 24) (NNS hours))) (PP (IN by) (NP (JJ intravenous) (NN infusion))) (PP (IN with))) (CC or) (VP (PP (IN without) (S (VP (VBG following) (NP (NP (JJ repeated) (JJ daily) (JJ oral) (NNS administrations)) (PP (IN of) (NP (NNP Doc_12180796_614_626_Chemical)))))))))) (. .)))
12180796	3	(S1 (S (S (ADVP (RB Irrespective) (PP (IN of) (NP (NNP Doc_12180796_644_656_Chemical) (NN administration)))) (, ,) (NP (NNS iNOS) (NNS antigens)) (VP (AUX were) (ADJP (RB remarkably) (JJ abundant)) (PP (IN in) (NP (NP (NP (JJ ED-1-positive) (NNS cells)) (PP (IN on) (NP (NN day) (CD 5)))) (CC and) (NP (NP (CD 8) (NN post-Doc_12180796_755_765_Chemical-infusion)) (PRN (-LRB- -LRB-) (NP (NNP DPI)) (-RRB- -RRB-))))))) (: ;) (S (NP (CD bFGF) (NNS antigens)) (VP (AUX were) (ADJP (RB remarkably) (JJ abundant)) (PP (IN in) (NP (NP (JJ ED-1-positive) (NNS cells)) (PP (IN on) (NP (QP (CD 1) (CC and) (CD 3)) (NNP DPI))))))) (: ;) (S (NP (JJ TGF-beta1) (NNS antigens)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ ED-1-positive) (NNS cells))) (PP (IN on) (CC and) (IN after) (NP (CD 5) (NNP DPI)))))) (. .)))
12180796	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT the) (JJ peak) (NN expression)) (PP (IN of) (NP (NN iNOS) (NN antigen)))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT that)) (PP (IN of) (NP (CD bFGF) (NN antigen)))))))) (, ,) (CC and) (S (NP (NNS bFGF)) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (JJ suppressive) (NN effect)) (PP (IN on) (NP (NP (NNS iNOS) (NN expression)) (PP (IN in) (NP (DT these) (NN rat) (NNP Doc_12180796_1108_1117_Disease) (NNS models)))))))))))) (. .)))
12180796	5	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NN TGF-beta1)) (VP (AUX was) (RB not) (VP (VBN considered) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ suppressive) (NN effect)) (PP (IN on) (NP (NP (NN iNOS) (NN expression)) (PP (IN in) (NP (DT these) (NNS models))))))))))) (. .)))
12231232	0	(S1 (NP (NP (DT The) (NN striatum)) (PP (IN as) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (NP (JJ anti-rigor) (NNS effects)) (PP (IN of) (NP (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (NN mGluR1)))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT an) (NN agonist)) (PP (IN of) (NP (NN group) (NNP II) (JJ metabotropic) (NN Doc_12231232_120_129_Chemical) (NNS receptors)))))))))) (. .)))
12231232	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (SBAR (IN whether) (S (NP (NP (NP (NP (DT the) (JJ metabotropic) (NN receptor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN mGluR1)) (-RRB- -RRB-))) (CC and) (NP (NN group) (NNP II) (NNS mGluRs))) (, ,) (VP (VBN localized) (PP (IN in) (NP (DT the) (NN striatum)))) (, ,)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ antiparkinsonian-like) (NNS effects)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
12231232	2	(S1 (S (NP (NP (NP (NNP Doc_12231232_334_345_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NP (NP (NNP Doc_12231232_367_379_Disease-like) (NNP Doc_12231232_385_400_Disease)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (DT an) (VBN increased) (NN resistance)) (PP (IN of) (NP (NP (DT a) (NN rat) (POS 's)) (JJ hind) (NN foot))) (PP (TO to) (NP (NP (JJ passive) (NN flexion)) (CC and) (NP (NP (NN extension)) (PP (IN at) (NP (NP (NP (DT the) (JJ ankle) (NN joint.) (NNP Doc_12231232_512_551_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12231232_553_557_Chemical)) (: ;) (NP (QP (CD 0.5-15) (CD microg/0.5)) (NN microl)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (CC and) (JJ selective) (NN mGluR1) (NN antagonist)))))))))) (, ,)) (CC or) (NP (NP (NNP Doc_12231232_631_675_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12231232_677_687_Chemical)) (: ;) (NP (QP (CD 7.5-15) (CD microg/0.5)) (NN microl)) (-RRB- -RRB-)))))) (, ,) (NP (DT a) (JJ selective) (NN group) (NNP II) (NN agonist)) (, ,)) (VP (AUX was) (VP (VBN injected) (ADVP (RB bilaterally)) (PP (IN into) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (JJ Doc_12231232_792_803_Chemical-treated) (NNS animals))))))) (. .)))
12231232	3	(S1 (S (NP (NP (NN Doc_12231232_821_825_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 7.5-15) (CD microg/0.5)) (NN microl)))))) (VP (VBD diminished) (NP (DT the) (JJ Doc_12231232_878_889_Chemical-induced) (NNP Doc_12231232_898_913_Disease))) (. .)))
12231232	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_12231232_928_938_Chemical) (NNS injections)) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
12231232	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (MD may) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NP (JJ striatal) (NNS mGluR1)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN group) (NNP II) (NNS mGluRs)))) (, ,)))) (VP (MD may) (VP (VB ameliorate) (NP (NNP Doc_12231232_1097_1109_Disease) (NNP Doc_12231232_1110_1125_Disease)))))))) (. .)))
12448656	0	(S1 (NP (NP (DT A) (NN phase) (NNP II) (NN study)) (PP (IN of) (NP (NNP Doc_12448656_20_31_Chemical))) (PP (IN in) (NP (JJ advanced) (JJ metastatic) (NN Doc_12448656_55_75_Disease))) (. .)))
12448656	1	(S1 (FRAG (S (VP (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN Doc_12448656_105_113_Disease) (CC and) (NN activity)) (PP (IN of) (NP (NNP Doc_12448656_130_141_Chemical))) (PP (IN in) (NP (NNS patients)))) (PP (IN with) (NP (JJ advanced) (JJ metastatic) (NN Doc_12448656_179_196_Disease))))) (CC and) (VP (TO to) (VP (VB measure) (NP (NP (NNS changes)) (PP (IN of) (NP (CD one) (JJ angiogenic) (NN factor)))))))) (, ,) (NP (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP VEGF)) (-RRB- -RRB-))) (NP (CD 165))) (, ,) (PP (IN with) (NP (NN therapy))) (. .)))
12448656	2	(S1 (S (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (CD 29) (NNS patients))) (VP (AUX were) (VP (VBD enrolled) (PP (IN on) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NNP Doc_12448656_368_379_Chemical))))) (S (VP (VBG using) (NP (DT an) (JJ intra-patient) (NN dose) (NN escalation) (NN schedule)))))) (. .)))
12448656	3	(S1 (S (NP (NNS Patients)) (VP (VP (VBD began) (NP (NNP Doc_12448656_444_455_Chemical)) (PP (IN at) (NP (CD 400) (NN mg/d)))) (CC and) (VP (VBD escalated) (SBAR (IN as) (S (VP (VBN tolerated) (PP (TO to) (NP (CD 1200) (NN mg/d))) (PP (IN by) (NP (NN day) (CD 54)))))))) (. .)))
12448656	4	(S1 (S (S (NP (NP (NN Fifty-nine)) (PP (IN per) (NP (NP (NN cent)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX had) (VP (AUX had) (NP (NP (JJ previous) (NN therapy)) (PP (IN with) (NP (NN IL-2))))))) (CC and) (S (NP (CD 52) (NN %)) (VP (AUX were) (NP (NN performance) (NN status) (CD 2) (CC or) (CD 3)))) (. .)))
12448656	5	(S1 (S (NP (JJ Systemic) (NN plasma) (NN VEGF165) (NNS levels)) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (JJ dual) (JJ monoclonal) (NNP ELISA)) (PP (IN in) (NP (CD 8) (NNS patients))))))) (. .)))
12448656	6	(S1 (S (NP (CD 24) (NNS patients)) (VP (AUX were) (ADJP (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (PP (IN with) (NP (NP (CD one) (JJ partial) (NN response)) (PP (IN of) (NP (NP (CD 11) (NNS months) (NN duration)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NP (ADJP (JJ hepatic) (CC and) (JJ pulmonary)) (NNP Doc_12448656_848_858_Disease)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (, ,) (NP (CD one) (JJ minor) (NN response)) (, ,)))))))))))) (CC and) (ADJP (NP (CD 2) (NNS patients)) (JJ stable))) (PP (IN for) (NP (IN over) (CD 6) (NNS months)))) (. .)))
12448656	7	(S1 (S (S (NP (NP (NNP Doc_12448656_926_936_Disease)) (CC and) (NP (NNP Doc_12448656_941_953_Disease))) (VP (AUX were) (NP (JJ prominent) (NNP Doc_12448656_969_979_Disease)))) (CC and) (S (NP (JJS most) (NNS patients)) (VP (MD could) (RB not) (VP (VB tolerate) (NP (DT the) (CD 1200) (NN mg/day) (NN dose) (NN level))))) (. .)))
12448656	8	(S1 (S (NP (JJ Systemic) (NN plasma) (NN VEGF165) (NNS levels)) (VP (AUX did) (RB not) (VP (VB change) (PP (IN with) (NP (NN therapy))))) (. .)))
12448656	9	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ low) (NN level)) (PP (IN of) (NP (NP (NN activity)) (PP (IN of) (NP (NNP Doc_12448656_1178_1189_Chemical))) (PP (IN in) (NP (NNP Doc_12448656_1193_1213_Disease))))))))) (. .)))
12448656	10	(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNS doses))) (PP (IN over) (NP (CD 800) (NN mg/day)))) (VP (AUX was) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB achieve) (PP (IN in) (NP (DT this) (JJ patient) (NN population)))))))))) (, ,) (ADVP (RB however)) (S (NP (JJR lower) (NNS doses)) (VP (AUX were) (ADJP (JJ practical)))) (. .)))
12448656	11	(S1 (S (NP (NP (NP (DT The) (JJ dose-response) (NN relationship)) (PRN (, ,) (PP (IN if) (NP (DT any))) (, ,))) (PP (IN of) (NP (NNP Doc_12448656_1387_1398_Chemical))) (PP (IN for) (NP (NNP Doc_12448656_1403_1423_Disease)))) (VP (AUX is) (ADJP (JJ unclear))) (. .)))
12452237	0	(S1 (SQ (MD Can) (NP (NNP Doc_12452237_4_13_Chemical)) (VP (VB reduce) (NP (JJ Doc_12452237_21_36_Chemical) (VBN induced) (NN Doc_12452237_45_66_Disease))) (. ?)))
12452237	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_12452237_121_130_Chemical) (NN pretreatment))) (PP (IN on) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_12452237_160_175_Chemical-induced) (NNP Doc_12452237_184_191_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ general) (NN anesthesia)) (PP (IN for) (NP (JJ gynecological) (NN surgery))))))))))))))) (. .)))
12452237	2	(S1 (S (NP (NP (QP (CD One) (CD hundred))) (CC and) (NP (JJ thirty-five) (NNS patients))) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD three) (NNS groups)) (PP (IN in) (NP (DT a) (JJ prospective) (, ,) (JJ double) (JJ blind) (, ,) (JJ randomized) (NN manner))))))))) (. .)))
12452237	3	(S1 (S (NP (NP (NNP Group) (NNP PS)) (, ,) (NP (DT the) (NN control) (NN group)) (, ,)) (VP (VBD received) (NP (NP (JJ normal) (NN saline)) (CC and) (NP (NNP Doc_12452237_442_457_Chemical) (CD 1.5) (NN mg))) (NP (NP (NP (NNP x) (CD kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP Group) (NNP LS)) (, ,) (NP (NP (NNP Doc_12452237_485_494_Chemical) (CD 1.5) (NN mg)) (X (SYM x) (NP (NP (NP (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12452237_515_530_Chemical) (CD 1.5) (NNS mg))) (X (SYM x)) (NP (NP (NN kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))))) (: ;) (NP (NP (NNP Group) (NNP PR)) (, ,) (NP (JJ normal) (NN saline))) (CC and) (NP (NNP Doc_12452237_576_586_Chemical) (CD 0.6))) (S (VP (VBG mg) (NP (NP (NNP x) (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (. .)))
12452237	4	(S1 (S (NP (JJ Doc_12452237_604_612_Chemical) (CD 0.1) (NN mg)) (ADVP (LS x)) (VP (VBZ kg) (SBAR (S (S (NP (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-) (NNP iv)) (VP (AUX was) (VP (VBN given) (PP (IN for) (NP (NN premedication)))))) (CC and) (S (NP (DT all) (NNS patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN with) (NP (NP (DT a) (JJ noninvasive) (NN blood) (NN pressure) (NN monitor)) (, ,) (NP (NN ECG)) (CC and) (NP (NN pulse) (NN oximetry)))))))))) (. .)))
12452237	5	(S1 (S (NP (NNP Anesthesia)) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (NP (CD 5) (JJ mg.kg) (-LRB- -LRB-) (NN -1) (-RRB- -RRB-) (JJ Doc_12452237_799_809_Chemical) (NN iv.)) (VP (VBN followed) (PP (IN by) (NP (NP (NP (NNP Doc_12452237_826_841_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP PS)) (, ,) (NP (NNP LS)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12452237_860_870_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP PR)) (-RRB- -RRB-)))))))) (PP (IN for) (NP (JJ tracheal) (NN intubation))))) (. .)))
12452237	6	(S1 (S (PP (VBG Following) (NP (NP (NN administration)) (PP (IN of) (NP (DT these) (NNS agents))))) (, ,) (NP (NP (DT the) (NN presence)) (, ,) (CC and) (NP (NP (NN degree)) (PP (IN of) (NP (NNP Doc_12452237_977_990_Disease))))) (VP (AUX were) (VP (VBN assessed) (ADVP (RB visually)) (PP (IN on) (NP (DT a) (CD four) (NN point) (NN scale))) (PP (IN by) (NP (NP (CD one) (NN investigator)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN blinded) (PP (TO to) (NP (NP (DT the) (NN drug)) (VP (VBN administered)))))))))))) (. .)))
12452237	7	(S1 (S (NP (NP (DT The) (NN blood) (NN pressure) (CC and) (NN heart) (NN rate)) (PP (IN of) (NP (DT each) (NN patient)))) (VP (AUX were) (VP (VBN monitored) (PP (IN on) (NP (CD nine) (NNS occasions))))) (. .)))
12452237	8	(S1 (S (ADVP (NP (JJ Twenty-four) (NNS hours)) (RB later)) (, ,) (NP (NP (DT any) (NN Doc_12452237_1211_1218_Disease)) (VP (VBN experienced))) (VP (AUX was) (VP (VP (VBN assessed) (PP (VBG according) (PP (TO to) (NP (DT a) (JJ structured) (NN questionaire))))) (CC and) (VP (VBN graded) (PP (IN by) (NP (NP (DT a) (ADJP (CD four) (NN point)) (NN scale)) (PP (IN by) (NP (NP (CD one) (NN investigator)) (VP (VBN blinded) (PP (TO to) (NP (DT the) (JJ intraoperative) (NN management))))))))))) (. .)))
12452237	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_12452237_1404_1424_Disease)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN in) (NP (NNP Group) (NNP PR))) (SBAR (IN while) (S (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (NNP Group) (NNP LS)))) (VP (AUX had) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1507_1527_Disease))) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (NNP Group) (NNP PS)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (CD <) (CD 0.001))) (-RRB- -RRB-))))))))))))))) (. .)))
12452237	10	(S1 (S (PP (IN At) (NP (CD 24))) (NP (NNP h)) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1590_1597_Disease)))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NNP Group) (NNP PS)))) (PP (IN than) (PP (IN in) (NP (NP (NNP Group) (NNP LS)) (CC and) (NP (NP (NNP PR)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
12452237	11	(S1 (S (NP (DT A) (NN correlation)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN between) (NP (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1710_1717_Disease)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_12452237_1740_1760_Disease)))))))) (. .)))
12452237	12	(S1 (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (NP (JJ systolic) (CC and) (JJ diastolic) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))) (VP (AUX were) (RB not) (ADJP (JJ significant)) (PP (IN among) (NP (DT the) (CD three) (NNS groups)))) (. .)))
12452237	13	(S1 (S (PP (IN In) (NP (NP (NN conclusion)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_12452237_1896_1911_Chemical)) (VP (AUX is) (VP (VBN used))))))) (, ,) (NP (NNP Doc_12452237_1921_1930_Chemical)) (VP (AUX is) (VP (VBN proven) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ useful) (NN pretreatment) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN Doc_12452237_1998_2019_Disease))))))))))) (. .)))
12481039	0	(S1 (S (NP (JJ Reduced) (JJ Doc_12481039_8_14_Chemical) (NN channel) (NN density)) (, ,) (VP (VP (VBD altered) (NP (NP (NN voltage) (NN dependence)) (PP (IN of) (NP (NN inactivation))))) (, ,) (CC and) (VP (VBD increased) (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_12481039_108_116_Disease))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG lacking) (NP (JJ Doc_12481039_133_139_Chemical) (NN channel) (NN beta) (NNS 2-subunits))))))) (. .)))
12481039	1	(S1 (S (NP (JJ Doc_12481039_165_171_Chemical) (NN channel) (NNS beta-subunits)) (VP (VBP modulate) (NP (NP (NP (NN channel) (NN gating)) (, ,) (NP (NN assembly)) (, ,) (CC and) (NP (NN cell) (NN surface) (NN expression))) (PP (IN in) (NP (JJ heterologous) (NN cell) (NNS systems))))) (. .)))
12481039	2	(S1 (S (NP (PRP We)) (VP (VBD generated) (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN beta2))) (PP (IN in) (NP (NP (NN control)) (PP (IN of) (NP (NP (JJ Doc_12481039_363_369_Chemical) (NN channel) (NN density)) (, ,) (NP (NN localization)) (, ,) (CC and) (NP (NP (NN function)) (PP (IN in) (NP (NP (NNS neurons)) (PP (IN in) (NP (NN vivo))))))))))))))) (. .)))
12481039	3	(S1 (S (NP (NP (NNS Measurements)) (PP (IN of) (NP (NP (NP (JJ -LSB-) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNP H) (NN -RSB-) (NNP Doc_12481039_456_465_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12481039_467_470_Chemical)) (-RRB- -RRB-))) (VBG binding)))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN plasma) (NN membrane) (JJ Doc_12481039_543_549_Chemical) (NNS channels))) (PP (IN in) (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS neurons))))))) (. .)))
12481039	4	(S1 (S (NP (NP (DT The) (NN loss)) (PP (IN of) (NP (NNS beta2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (JJ negative) (NNS shifts)) (PP (IN in) (NP (NP (DT the) (JJ voltage) (NN dependence)) (PP (IN of) (NP (NN inactivation)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ significant) (NNS decreases)) (PP (IN in) (NP (NP (JJ Doc_12481039_706_712_Chemical) (JJ current) (NN density)) (PP (IN in) (NP (ADJP (RB acutely) (VBN dissociated)) (JJ hippocampal) (NNS neurons))))))))) (. .)))
12481039	5	(S1 (S (S (NP (NP (DT The) (JJ integral)) (PP (IN of) (NP (NP (DT the) (JJ compound) (NN action) (NN potential)) (PP (IN in) (NP (JJ optic) (NN nerve)))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced)))) (, ,) (CC and) (S (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NN action) (JJ potential) (NN generation)))) (VP (AUX was) (VP (VBN increased) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ functional) (NN plasma) (NN membrane) (JJ Doc_12481039_992_998_Chemical) (NNS channels))))))))))) (. .)))
12481039	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (NP (DT the) (NN conduction) (NN velocity)) (, ,) (NP (NP (DT the) (NN number) (CC and) (NN size)) (PP (IN of) (NP (NP (NNS axons)) (PP (IN in) (NP (DT the) (JJ optic) (NN nerve)))))) (, ,) (CC and) (NP (NP (DT the) (JJ specific) (NN localization)) (PP (IN of) (NP (NP (NNP Doc_12481039_1129_1131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP v)) (-RRB- -RRB-)))))) (NP (CD 1.6) (NNS channels))) (PP (IN in) (NP (DT the) (NNS nodes))) (PP (IN of) (NP (NNP Ranvier)))) (VP (AUX were) (VP (VBN unchanged.) (S (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VP (VBN displayed) (NP (NP (VBN increased) (NN susceptibility)) (PP (TO to) (NP (NNP Doc_12481039_1241_1249_Disease))))) (, ,) (VP (ADVP (RB as)) (VBN indicated) (PP (IN by) (NP (NP (VBN reduced) (NN latency) (CC and) (NN threshold)) (PP (IN for) (NP (JJ Doc_12481039_1301_1312_Chemical-induced) (NNP Doc_12481039_1321_1329_Disease)))))) (, ,) (CC but) (VP (VBD seemed) (ADJP (JJ normal)) (PP (IN in) (NP (JJ other) (JJ neurological) (NNS tests)))))))) (. .)))
12481039	7	(S1 (S (NP (PRP$ Our) (NNS observations)) (VP (VBP show) (SBAR (IN that) (S (NP (NNS beta2-subunits)) (VP (VP (VBP play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NP (JJ Doc_12481039_1464_1470_Chemical) (NN channel) (NN density)) (CC and) (NP (NN function))) (PP (IN in) (NP (NP (NNS neurons)) (PP (IN in) (NP (NN vivo))))))))))) (CC and) (VP (AUX are) (VP (VBN required) (PP (IN for) (NP (NP (JJ normal) (NN action) (JJ potential) (NN generation)) (CC and) (NP (NP (NN control)) (PP (IN of) (NP (NN excitability)))))))))))) (. .)))
12549952	0	(S1 (S (VP (VB Doc_12549952_0_19_Disease) (PP (IN with) (NP (NP (JJ concurrent) (NN Doc_12549952_36_45_Chemical)) (CC and) (NP (JJ Doc_12549952_50_61_Chemical) (NN therapy))))) (. .)))
12549952	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ fatal) (NN Doc_12549952_108_121_Disease)))) (ADVP (RB possibly))))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NNP Doc_12549952_165_174_Chemical)) (CC and) (NP (NNP Doc_12549952_179_190_Chemical))))))) (. .)))
12549952	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 41-year-old) (JJ Chinese) (NN man)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_12549952_250_265_Disease))) (SBAR (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12549952_288_299_Chemical)) (CC and) (NP (NNP Doc_12549952_304_315_Chemical)))) (PP (IN for) (NP (DT the) (JJ past) (CD 5) (NNS years))))))))))) (. .)))
12549952	3	(S1 (S (NP (PRP He)) (VP (VBD received) (NP (NP (DT a) (JJ 10-day) (NN course)) (PP (IN of) (NP (NNP Doc_12549952_369_378_Chemical)))) (PP (IN as) (NP (NP (DT an) (NN aid)) (PP (IN for) (S (VP (VBG smoking) (NP (NN cessation)) (ADVP (NP (CD 10) (NNS weeks)) (RB prior)) (PP (TO to) (NP (NN presentation))))))))) (. .)))
12549952	4	(S1 (S (NP (PRP He)) (VP (VBD developed) (NP (NN Doc_12549952_456_475_Disease)) (PP (IN with) (NP (NP (JJ rapid) (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))) (. .)))
12549952	5	(S1 (S (NP (NN Liver) (NNS biopsy)) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ nonspecific) (NNP Doc_12549952_564_595_Disease))))) (. .)))
12549952	6	(S1 (S (NP (PRP$ His) (NN condition)) (VP (AUX was) (VP (RBR further) (VBN complicated) (PP (IN by) (NP (NP (NNP Doc_12549952_638_644_Disease)) (CC and) (NP (NNP Doc_12549952_649_661_Disease)))))) (. .)))
12549952	7	(S1 (S (NP (NN Death)) (VP (VBD resulted) (PP (NP (CD 19) (NNS days)) (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
12549952	8	(S1 (S (NP (NP (DT The) (NN likelihood)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_12549952_735_744_Chemical)) (VP (VBN induced) (NP (NNP Doc_12549952_753_767_Disease)) (PP (IN in) (NP (PRP$ our) (NN patient))))))) (VP (AUX was) (ADJP (JJ possible)) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale))))) (. .)))
12549952	9	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX is) (NP (NP (JJ increasing) (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_12549952_890_904_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12549952_916_925_Chemical)))))))))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NN fatality))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX have) (VP (VBN resulted) (PP (IN from) (NP (NNP Doc_12549952_992_1011_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (JJ Doc_12549952_1035_1044_Chemical) (NN while)) (PP (IN on) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_12549952_1081_1092_Chemical))))))))))))))) (. .)))
12549952	10	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NNP Doc_12549952_1156_1174_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_12549952_1186_1195_Chemical) (VBN given) (NN concurrently)) (PP (IN with) (NP (JJ other) (JJ Doc_12549952_1226_1237_Disease) (NNS drugs))))))))))) (. .)))
1255900	0	(S1 (NP (NP (NP (JJ Pyeloureteral) (VBG filling) (NNS defects)) (VP (VBN associated) (PP (IN with) (NP (JJ systemic) (NN anticoagulation))))) (: :) (NP (NP (DT a) (NN case)) (SBAR (S (VP (VBP report))))) (. .)))
1255900	1	(S1 (S (NP (NP (DT The) (NN etiology)) (PP (IN of) (NP (NNP Doc_1255900_103_126_Disease)))) (VP (AUX has) (ADVP (RB long)) (VP (AUX been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN chronic) (NN Doc_1255900_163_172_Disease)) (CC and) (NP (NN Doc_1255900_177_189_Disease))))))) (. .)))
1255900	2	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN presented) (SBAR (IN that) (S (VP (AUX is) (ADJP (JJ unique)) (SBAR (IN in) (IN that) (S (NP (NP (NP (DT the) (JJ acute) (NN onset)) (CC and) (NP (DT the) (JJ rapid) (NN resolution))) (PP (IN of) (NP (JJ pyeloureteral) (VBG filling) (NNS defects))) (PP (IN in) (NP (DT this) (NN patient)))) (VP (AUX were) (VP (VBN documented) (PP (IN by) (NP (NN radiography)))))))))))) (. .)))
1255900	3	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN antecedent)) (CC or) (NP (JJ concurrent) (NN Doc_1255900_405_414_Disease))))) (PP (IN in) (NP (DT this) (NN patient)))) (. .)))
1255900	4	(S1 (S (NP (DT The) (NN disease)) (VP (VP (VBD occurred) (ADVP (JJ subsequent) (PP (TO to) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ Doc_1255900_485_492_Chemical) (NN therapy)))))) (PP (IN for) (NP (VBN suspected) (JJ pelvic) (NN Doc_1255900_522_538_Disease)))) (CC and) (VP (VBD cleared) (ADVP (RB rapidly) (JJ subsequent)) (PP (TO to) (NP (PRP$ its) (NN discontinuation))))) (. .)))
1255900	5	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NP (NN resolution)) (PP (IN of) (NP (DT the) (JJ radiographic) (NNS findings)))))) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful) (PP (IN in) (NP (NP (NN distinguishing)) (PP (IN between) (NP (NP (JJ true) (NNP Doc_1255900_692_715_Disease)) (CC and) (NP (NNP Doc_1255900_720_741_Disease))))))))) (. .)))
12571256	0	(S1 (NP (NP (JJ Doc_12571256_0_11_Disease) (NNS effects)) (PP (IN in) (NP (NP (JJ high-risk) (NNS patients)) (VP (VBG undergoing) (NP (NN angiography))))) (. .)))
12571256	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ iodinated) (NN contrast) (NN medium)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NNP Doc_12571256_129_140_Disease))))) (. .)))
12571256	2	(S1 (S (SBAR (IN Whether) (S (NP (JJ iso-osmolar) (NN contrast) (NN medium)) (VP (AUX is) (ADJP (ADJP (RBR less) (JJ Doc_12571256_186_197_Disease)) (PP (IN than) (NP (NP (JJ low-osmolar) (NN contrast) (NN medium)) (PP (IN in) (NP (JJ high-risk) (NNS patients))))))))) (VP (AUX is) (ADJP (JJ uncertain))) (. .)))
12571256	3	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ prospective) (, ,) (JJ multicenter) (NN study)) (VP (VBG comparing) (NP (NP (DT the) (NNP Doc_12571256_362_373_Disease) (NNS effects)) (PP (IN of) (NP (NP (DT an) (JJ iso-osmolar) (, ,) (JJ dimeric) (, ,) (JJ nonionic) (NN contrast) (NN medium)) (, ,) (NP (NNP Doc_12571256_436_445_Chemical)) (, ,))) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (JJ low-osmolar) (, ,) (JJ nonionic) (, ,) (JJ monomeric) (NN contrast) (NN medium)) (, ,) (NP (NNP Doc_12571256_513_520_Chemical)))))))))) (. .)))
12571256	4	(S1 (S (NP (DT The) (NN study)) (VP (VBD involved) (NP (CD 129) (NNS patients)) (PP (IN with) (NP (NNP Doc_12571256_559_567_Disease))) (PP (IN with) (NP (NP (JJ serum) (JJ Doc_12571256_579_589_Chemical) (NNS concentrations)) (PP (IN of) (NP (QP (CD 1.5) (TO to) (CD 3.5)) (NNS mg))) (PP (IN per) (NP (NP (NN deciliter)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (ADJP (JJ coronary) (CC or) (JJ aortofemoral)) (NN angiography)))))))))) (. .)))
12571256	5	(S1 (S (NP (DT The) (JJ primary) (NN end) (NN point)) (VP (AUX was) (NP (NP (DT the) (JJ peak) (NN increase)) (PP (IN from) (NP (NN base) (NN line))) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_754_764_Chemical) (NN concentration)) (PP (IN during) (NP (DT the) (CD three) (NNS days))) (PP (IN after) (NP (NN angiography))))))) (. .)))
12571256	6	(S1 (S (NP (JJ Other) (NN end) (NNS points)) (VP (AUX were) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_861_871_Chemical) (NN concentration)) (PP (IN of) (NP (CD 0.5) (NN mg))) (PP (IN per) (NP (JJR deciliter) (CC or) (JJR more)))))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 1.0) (NNS mg)) (PP (IN per) (NP (JJR deciliter) (CC or) (JJR more)))))) (, ,) (CC and) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_984_994_Chemical) (NN concentration)) (PP (IN from) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 7)))))))) (. .)))
12571256	7	(S1 (S (NP (DT The) (NNP Doc_12571256_1043_1053_Chemical) (NN concentration)) (VP (VBD increased) (ADVP (RB significantly) (RBR less)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN Doc_12571256_1122_1131_Chemical)))))))) (. .)))
12571256	8	(S1 (S (PP (PP (IN From) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 3)))) (, ,) (NP (NP (DT the) (JJ mean) (JJ peak) (NN increase)) (PP (IN in) (NP (NNP Doc_12571256_1180_1190_Chemical)))) (VP (AUX was) (NP (NP (CD 0.13) (NN mg)) (PP (IN per) (NP (NP (NP (NN deciliter)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1224_1233_Chemical) (NN group)))) (CC and) (NP (NP (CD 0.55) (NNS mg)) (PP (IN per) (NP (NP (NN deciliter)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1273_1280_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP P=0.001)) (: ;) (NP (NP (NP (DT the) (NN increase)) (PP (IN with) (NP (NNP Doc_12571256_1315_1324_Chemical)))) (CC minus) (NP (NP (DT the) (NN increase)) (PP (IN with) (NP (NNP Doc_12571256_1349_1356_Chemical)))))) (, ,) (NP (NP (CD -0.42) (NNS mg)) (PP (IN per) (NP (NN deciliter) (CD -LSB-95) (NN percent) (NN confidence) (NN interval)))) (, ,) (NP (QP (CD -0.73) (TO to) (CD -0.22)) (NNS -RSB-)) (-RRB- -RRB-))))))))))) (. .)))
12571256	9	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (DT the) (CD 64) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1462_1471_Chemical) (NN group)))))) (PRN (-LRB- -LRB-) (NP (CD 3) (NN percent)) (-RRB- -RRB-)) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1513_1523_Chemical) (NN concentration)) (PP (IN of) (NP (CD 0.5) (NNS mg)) (PP (IN per) (NP (NP (ADJP (JJR deciliter) (CC or) (JJR more)) (PRN (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (CD 17)) (PP (IN of) (NP (NP (DT the) (CD 65) (NNS patients)) (PP (IN in) (NP (NP (NP (DT the) (NNP Doc_12571256_1617_1624_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN percent)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P=0.002)) (: ;) (NP (NP (NNS odds) (NN ratio)) (PP (IN for) (NP (NP (PDT such) (DT an) (NN increase)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1693_1702_Chemical) (NN group))))))))))))))) (, ,)) (ADJP (QP (CD 0.09) (CD -LSB-95)) (NN percent)) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 0.02) (TO to) (CD 0.41)) (NNS -RSB-)) (-RRB- -RRB-)))))))) (. .)))
12571256	10	(S1 (S (S (NP (NP (DT No) (NN patient)) (VP (VBG receiving) (NP (NNP Doc_12571256_1785_1794_Chemical)))) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 1.0) (NNS mg)) (PP (IN per) (NP (NP (NN deciliter)) (CC or) (NP (JJR more))))))))) (, ,) (CC but) (S (NP (NP (CD 10) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1867_1874_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN percent)) (-RRB- -RRB-))) (VP (AUX did))) (. .)))
12571256	11	(S1 (S (NP (NP (DT The) (JJ mean) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1922_1932_Chemical) (NN concentration)) (PP (IN from) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 7)))))) (VP (AUX was) (NP (NP (QP (CD 0.07) (CD mg))) (PP (IN per) (NP (NP (NP (NN deciliter)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2000_2009_Chemical) (NN group)))) (CC and) (NP (NP (CD 0.24) (NN mg)) (PP (IN per) (NP (NP (NN deciliter)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_2049_2056_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP P=0.003)) (: ;) (NP (NP (NP (NN value)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2086_2095_Chemical) (NN group)))) (CC minus) (NP (NP (DT the) (NN value)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2125_2132_Chemical) (NN group)))))) (, ,) (NP (NP (CD -0.17) (NNS mg)) (PP (IN per) (NP (NN deciliter) (CD -LSB-95) (NN percent) (NN confidence) (NN interval)))) (, ,) (NP (QP (CD -0.34) (TO to) (CD -0.07)) (NNS -RSB-)) (-RRB- -RRB-))))))))))) (. .)))
12571256	12	(S1 (S (NP (NP (NN Doc_12571256_2227_2238_Disease)) (VP (VBN induced) (PP (IN by) (NP (NN contrast) (NN medium))))) (VP (MD may) (VP (AUX be) (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (VB develop) (PP (IN in) (NP (JJ high-risk) (NNS patients))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12571256_2323_2332_Chemical)) (VP (AUX is) (VP (VBN used) (PP (RB rather) (IN than) (NP (DT a) (JJ low-osmolar) (, ,) (JJ nonionic) (NN contrast) (NN medium))))))))) (. .)))
12600698	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_12600698_21_30_Chemical))) (PP (IN against) (NP (NP (NNP Doc_12600698_39_51_Chemical-induced) (NNP Doc_12600698_60_77_Disease)) (PP (IN in) (NP (DT the) (NN guinea) (NN pig))))) (. .)))
12600698	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (NN alleviation)) (PP (IN of) (NP (NNP Doc_12600698_136_148_Chemical-induced) (NNP Doc_12600698_157_174_Disease))) (PP (IN by) (NP (NNP Doc_12600698_178_187_Chemical))) (PP (IN in) (NP (NN guinea) (NNS pigs))))) (. .)))
12600698	2	(S1 (S (NP (NP (NNP Doc_12600698_204_213_Chemical)) (, ,) (NP (DT a) (JJ free) (JJ radical) (NN scavenger)) (, ,)) (VP (VP (AUX has) (NP (JJ potent) (JJ free) (JJ radical) (NN quenching) (NN action))) (CC and) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (NN practice))) (S (VP (TO to) (VP (VB treat) (NP (NN Doc_12600698_324_343_Disease)))))))) (. .)))
12600698	3	(S1 (S (S (NP (NNP Doc_12600698_345_357_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT the) (JJ inner) (NN ear))) (PP (IN by) (NP (NP (JJ osmotic) (NN pump)) (PP (IN for) (NP (NP (CD 24) (NNP h)) (, ,) (CC and) (NP (NP (NNP Doc_12600698_422_431_Chemical)) (PRN (-LRB- -LRB-) (NP (NN n=8)) (-RRB- -RRB-)))))))))) (CC or) (S (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB intraperitoneally)) (VP (VBN injected) (ADVP (RB once) (NP (DT a) (NN day)) (PP (IN for) (NP (CD 7) (NNS days))))))) (. .)))
12600698	4	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ horizontal) (NN vestibulo-ocular)) (ADJP (JJ reflex) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ postoperative) (NN vestibular) (NN function)))))))) (. .)))
12600698	5	(S1 (S (NP (NP (NNS Animals)) (VP (VBN injected) (PP (IN with) (NP (NN saline))))) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJR smaller)) (NNS gains)) (PP (IN than) (NP (NP (DT those)) (VP (VBN injected) (PP (IN with) (NP (NNP Doc_12600698_694_703_Chemical)))))))) (. .)))
12600698	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_12600698_732_741_Chemical)) (VP (VBZ suppresses) (NP (JJ Doc_12600698_753_765_Chemical-induced) (NN Doc_12600698_774_791_Disease)))))) (. .)))
12691807	0	(S1 (NP (NP (JJ Doc_12691807_0_8_Chemical-induced) (JJ oromandibular) (NN Doc_12691807_31_39_Disease)) (PP (IN in) (NP (NNP Doc_12691807_43_73_Disease))) (. .)))
12691807	1	(S1 (S (NP (JJ Doc_12691807_75_83_Chemical-induced) (NNP Doc_12691807_92_103_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNP Doc_12691807_126_145_Disease)) (CC and) (NP (NNP Doc_12691807_150_173_Disease))))))) (. .)))
12691807	2	(S1 (S (NP (NNP Cranial) (NNP Doc_12691807_183_192_Disease)) (VP (AUX are) (ADJP (JJ rare)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12691807_219_249_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12691807_251_254_Disease)) (-RRB- -RRB-))))))) (. .)))
12691807	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NP (JJ reversible) (JJ Doc_12691807_314_322_Chemical-induced) (NNP Doc_12691807_331_353_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12691807_355_358_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT a) (JJ Doc_12691807_365_368_Disease) (NN patient)) (SBAR (S (VP (TO to) (VP (VP (VB highlight) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG recognizing) (NP (DT this) (NN drug) (JJ related) (NN complication)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_12691807_472_475_Disease)))))))))) (, ,) (CC and) (VP (VB discuss) (NP (DT the) (JJ possible) (JJ underlying) (NN pathophysiology)))))))))) (. .)))
12734532	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (NP (NP (NNP Doc_12734532_13_21_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_23_42_Chemical)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NNP Doc_12734532_58_79_Disease)))))) (. .)))
12734532	1	(S1 (S (NP (NP (NNP Doc_12734532_81_100_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_102_105_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ sympathetic) (NN Doc_12734532_124_129_Chemical)) (VP (VBN used) (PP (IN in) (NP (NP (JJ over-the-counter) (JJ cold) (NNS remedies)) (CC and) (NP (JJ weight-control) (NNS preparations) (NX (NNP worldwide)))))))) (. .)))
12734532	2	(S1 (S (NP (PRP$ Its) (NN use)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_12734532_245_257_Disease) (NNS episodes)) (CC and) (NP (NP (NNP Doc_12734532_271_290_Disease)) (PP (IN in) (NP (JJR younger) (NNS women))))))))) (. .)))
12734532	3	(S1 (S (NP (JJ Several) (NNS reports)) (VP (AUX have) (VP (VBN linked) (NP (NP (DT the) (NN abuse)) (PP (IN of) (NP (NNP Doc_12734532_350_353_Chemical))) (PP (IN with) (NP (NNP Doc_12734532_359_376_Disease)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (NP (NNP Doc_12734532_394_402_Disease)) (VP (AUX is) (VP (VBN involved))))))) (. .)))
12734532	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (ADVP (RB here)) (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_12734532_449_457_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_459_462_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12734532_472_489_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG using) (NP (PRP it)) (PP (IN at) (NP (NP (JJ recommended) (NNS doses)) (PP (IN for) (NP (NN weight) (NN control)))))))))))) (. .)))
12734532	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP review) (NP (NP (DT the) (CD 7) (JJ other) (NNS cases)) (PP (IN of) (NP (JJ Doc_12734532_609_612_Chemical) (JJ related) (NN Doc_12734532_621_638_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB so) (RB far))))))))) (. .)))
12734532	6	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (NNS patients))) (VP (MD should) (VP (AUX be) (ADJP (JJ alert) (PP (TO to) (NP (NP (DT the) (JJ potential) (JJ cardiac) (NN risk)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12734532_768_771_Chemical))))))))) (, ,) (PP (ADVP (RB even)) (IN at) (NP (NP (NNS doses)) (VP (ADVP (RB generally)) (VBN considered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ safe)))))))))) (. .)))
12739036	0	(S1 (NP (NP (NN Differential) (NN diagnosis)) (PP (IN of) (NP (NP (JJ high) (JJ serum) (JJ Doc_12739036_37_45_Chemical) (NN kinase) (NNS levels)) (PP (IN in) (NP (NNP Doc_12739036_63_91_Disease))))) (. .)))
12739036	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ clinical) (CC and) (JJ bioptic) (NNS findings)) (PP (IN for) (NP (NP (DT a) (JJ 57-year-old) (NN woman)) (PP (IN with) (NP (JJ severe) (JJ Doc_12739036_173_184_Chemical-induced) (NN Doc_12739036_193_201_Disease))))))) (. .)))
12739036	2	(S1 (S (PP (IN Since) (NP (CD 1989))) (, ,) (NP (PRP she)) (VP (AUX had) (VP (AUX been) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_12739036_243_271_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12739036_273_276_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_12739036_283_300_Disease) (CC and) (VBN undergone) (NNS periods)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12739036_341_353_Chemical)) (CC and) (NP (NNP Doc_12739036_358_374_Chemical))))))))) (. .)))
12739036	3	(S1 (S (NP (NP (JJ Additional) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_12739036_400_411_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12739036_413_415_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN started) (PP (IN because) (IN of) (NP (NN Doc_12739036_440_450_Disease))))) (. .)))
12739036	4	(S1 (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (ADJP (RB slightly) (VBN increased)) (JJ Doc_12739036_489_497_Chemical) (NN kinase) (PRN (-LRB- -LRB-) (NP (NNP CK)) (-RRB- -RRB-)) (NNS levels)) (VP (AUX were) (VP (VBN noted))) (. .)))
12739036	5	(S1 (S (S (NP (NN Doc_12739036_529_537_Disease)) (VP (AUX was) (VP (VBN suspected)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12739036_586_594_Chemical)))))) (. .)))
12739036	6	(S1 (S (S (NP (DT The) (NN CK) (NN increase)) (VP (VBD persisted) (, ,) (ADVP (RB however)))) (, ,) (CC and) (S (NP (PRP she)) (VP (VBD developed) (NP (NP (JJ progressive) (NN Doc_12739036_662_679_Disease)) (CC and) (NP (NNP Doc_12739036_684_700_Disease))))) (. .)))
12739036	7	(S1 (S (NP (JJ Routine) (NNS controls)) (VP (VBD revealed) (NP (NP (ADJP (RB markedly) (JJ elevated)) (NN CK) (NNS levels)) (PP (IN of) (NP (CD 1,700) (NN U/l))))) (. .)))
12739036	8	(S1 (S (NP (DT The) (JJ neurological) (CC and) (JJ electrophysiological) (NNS findings)) (VP (AUX were) (RB not) (ADJP (JJ typical) (PP (IN of) (NP (NNP Doc_12739036_841_849_Disease))))) (. .)))
12739036	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN muscle) (NN biopsy)) (PP (IN of) (NP (DT the) (JJ deltoid) (NN muscle)))) (VP (AUX was) (VP (VBN performed) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB exclude) (NP (NP (NN Doc_12739036_927_939_Disease)) (CC or) (NP (JJ toxic) (NN Doc_12739036_949_957_Disease))))))))) (. .)))
12739036	10	(S1 (S (SBAR (IN As) (S (NP (PRP it)) (VP (VBD revealed) (NP (JJ Doc_12739036_974_985_Chemical-induced) (NN Doc_12739036_994_1002_Disease))))) (, ,) (NP (NN medication)) (VP (AUX was) (VP (VBN stopped))) (. .)))
12739036	11	(S1 (S (S (VP (VBG Discriminating) (PP (IN between) (NP (NP (JJ primary) (JJ Doc_12739036_1059_1062_Disease-induced) (NN Doc_12739036_1071_1110_Disease)) (CC and) (NP (JJ drug-induced) (NN side) (NNS effects)))))) (VP (AUX is) (ADJP (JJ important) (PP (IN for) (NP (NP (JJ appropriate) (NN treatment)) (PP (IN of) (NP (JJ Doc_12739036_1183_1186_Disease) (NNS patients))))))) (. .)))
12745515	0	(S1 (S (NP (NN Doc_12745515_0_7_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_12745515_24_41_Disease)) (CC and) (NP (JJ sustained-release) (NNP Doc_12745515_64_73_Chemical))))) (. .)))
12745515	1	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (JJ generalized) (NN Doc_12745515_116_123_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ sustained-release) (JJ Doc_12745515_158_167_Chemical) (NN use)) (CC and) (NP (NN Doc_12745515_176_193_Disease))))))) (. .)))
12745515	2	(S1 (S (NP (NP (DT The) (NN subject)) (, ,) (NP (DT a) (JJ 31-year-old) (NN female) (NN smoker)) (, ,)) (VP (AUX was) (VP (VBG participating) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN trial)) (VP (VBG evaluating) (NP (NP (DT an) (JJ investigational) (NN medication)) (PP (IN for) (S (VP (VBG smoking) (NP (NP (NN cessation)) (SBAR (WHNP (WDT that)) (S (VP (VBD used) (NP (JJ sustained-release) (NNP Doc_12745515_366_375_Chemical)) (PP (IN as) (NP (DT an) (JJ active) (NN control)))))))))))))))) (. .)))
12745515	3	(S1 (S (PP (IN After) (NP (NP (CD 5) (NNS weeks)) (PP (IN of) (NP (JJ Doc_12745515_415_424_Chemical) (NN use))))) (, ,) (NP (DT the) (NN subject)) (VP (VBD experienced) (NP (DT a) (JJ generalized) (NN tonic) (NN clonic) (NN Doc_12745515_481_488_Disease)) (PP (IN after) (S (VP (VP (VBG staying) (PRT (RP up)) (NP (QP (RB nearly) (PDT all)) (NN night) (NN packing))) (CC and) (VP (VBG moving) (PP (TO to) (NP (DT a) (JJ new) (NN residence)))))))) (. .)))
12745515	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_12745515_604_612_Disease)))) (. .)))
12745515	5	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_12745515_630_647_Disease)) (VP (MD may) (VP (VB add) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ Doc_12745515_671_680_Chemical-associated) (NN Doc_12745515_692_700_Disease)))))))))) (. .)))
12760988	0	(S1 (NP (NP (NP (NN Doc_12760988_0_21_Disease)) (PP (IN after) (NP (NNP Doc_12760988_28_43_Chemical)))) (: :) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (DT an) (JJ inflammatory) (NN origin)))) (. .)))
12760988	1	(S1 (S (NP (NP (DT A) (JJ common) (NN side) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12760988_122_137_Chemical))))) (VP (AUX is) (ADJP (JJ Doc_12760988_141_162_Disease))) (. .)))
12760988	2	(S1 (S (S (NP (NP (DT The) (NN pathogenesis)) (PP (IN of) (NP (DT this) (NN Doc_12760988_189_196_Disease)))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear)))) (: ;) (S (NP (NNP Doc_12760988_215_227_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN suggested)))) (CC but) (VP (PP (IN without) (NP (JJ convincing) (NN evidence)))))) (. .)))
12760988	3	(S1 (S (NP (PRP We)) (VP (VBD designed) (NP (NP (DT the) (JJ present) (NN study)) (SBAR (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (DT an) (JJ inflammatory) (NN reaction)) (VP (VBZ contributes) (PP (TO to) (NP (DT this) (NN Doc_12760988_378_385_Disease)))))))))))) (. .)))
12760988	4	(S1 (S (NP (NP (DT The) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ Doc_12760988_417_432_Chemical-associated) (NNP Doc_12760988_444_451_Disease)))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (CD 64) (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NNP Doc_12760988_508_521_Chemical)))) (PP (IN before) (NP (NP (NNP Doc_12760988_529_544_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 32)) (PP (IN for) (NP (DT each)))) (-RRB- -RRB-))))))))) (. .)))
12760988	5	(S1 (S (S (NP (NP (NN Incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_12760988_590_597_Disease)))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))))) (: :) (S (NP (NP (CD 15) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12760988_670_683_Chemical) (NN group)))) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_12760988_704_711_Disease))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 18) (NNS patients)) (PP (IN in) (NP (DT the) (NN saline) (NN group)))))))) (, ,) (CC and) (S (NP (JJ severe) (NNP Doc_12760988_770_777_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN by) (NP (NP (CD five) (NNS patients)) (CC and) (NP (NP (CD three) (NNS patients)) (PRN (, ,) (ADVP (RB respectively)) (-LRB- -LRB-) (ADJP (RB not) (JJ significant)) (-RRB- -RRB-)))))))) (. .)))
12760988	6	(S1 (S (PP (IN At) (NP (CD 48))) (NP (NNP h)) (PP (IN after) (NP (NN surgery))) (, ,) (NP (NP (CD 12) (NNS patients)) (PP (IN in) (NP (DT both) (NNS groups)))) (ADVP (RB still)) (VP (VBN suffered) (PP (IN from) (NP (NNP Doc_12760988_930_937_Disease))) (PRN (-LRB- -LRB-) (RB not) (ADJP (JJ significant)) (-RRB- -RRB-))) (. .)))
12760988	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN interleukin-6)) (PRN (-LRB- -LRB-) (NP (NN IL-6)) (-RRB- -RRB-)) (PP (IN as) (NP (NP (DT an) (JJ early) (NN marker)) (PP (IN of) (NP (NNP Doc_12760988_1013_1025_Disease)))))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NP (CD 10) (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NN saline)))))))))) (. .)))
12760988	8	(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN IL-6))) (PP (IN for) (NP (QP (RB only) (CD three)) (NNS patients)))))) (, ,) (CC but) (S (NP (QP (RB only) (CD one)) (NN patient)) (VP (VBD reported) (NP (NNP Doc_12760988_1176_1183_Disease)))) (: ;) (S (NP (NP (NP (DT no) (NN relationship)) (PP (IN between) (NP (NNP Doc_12760988_1209_1216_Disease)))) (CC and) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN IL-6))))) (VP (AUX was) (VP (VBN found)))) (. .)))
12760988	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (DT an) (JJ inflammatory) (NN origin)) (PP (IN of) (NP (NNP Doc_12760988_1319_1334_Chemical-associated) (NNP Doc_12760988_1346_1353_Disease))))))) (. .)))
12760988	10	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_12760988_1387_1400_Chemical))) (PP (IN before) (NP (NNP Doc_12760988_1408_1423_Chemical)))) (VP (AUX was) (RB not) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG decreasing) (NP (NP (NP (DT the) (NN incidence)) (CC or) (NP (DT the) (NN severity))) (PP (IN of) (NP (NNP Doc_12760988_1489_1504_Chemical-induced) (NNP Doc_12760988_1513_1534_Disease))))))))) (. .)))
12760988	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (NNP Doc_12760988_1595_1616_Disease)) (CC and) (NP (NN time) (NN course))) (PP (IN of) (NP (JJ interleukin-6) (NNS concentrations)))) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_12760988_1678_1690_Disease)))))))) (. .)))
12760988	12	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_12760988_1710_1723_Chemical)))) (VP (AUX is) (RB not) (VP (VBN justified) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_12760988_1752_1773_Disease)) (PP (IN after) (NP (NN Doc_12760988_1780_1795_Chemical)))))))) (. .)))
12842176	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_12842176_10_17_Chemical))) (PP (IN on) (NP (NP (JJ hepatic) (CC and) (NN brain) (NN cytochrome) (NNS P450s)) (CC and) (NP (NP (NN influence)) (PP (IN of) (NP (NP (CD P450) (NN modulation)) (PP (IN in) (NP (NP (NNP Doc_12842176_92_99_Chemical)) (VP (VBN induced) (NP (NNP Doc_12842176_108_121_Disease)))))))))) (. .)))
12842176	1	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_12842176_146_153_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 2.5) (, ,) (CD 5) (, ,) (CD 10) (CC and) (CD 15) (NN mg/kg)) (, ,) (NP (NN body) (NN weight)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 5) (NNS days)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NP (CD P450) (JJ dependent) (NN 7-ethoxyresorufin-O-deethylase)) (PRN (-LRB- -LRB-) (NP (NNP EROD)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ 7-pentoxyresorufin-O-dealkylase) (PRN (-LRB- -LRB-) (VB PROD) (-RRB- -RRB-)) (CC and) (NNP Doc_12842176_367_389_Chemical) (NN demethylase)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12842176_403_407_Chemical-d)) (-RRB- -RRB-))))) (PP (IN in) (NP (NN rat) (NN brain) (CC and) (NN liver))))))))))) (. .)))
12842176	2	(S1 (S (NP (NP (DT A) (JJ significant) (NN increase)) (PP (IN in) (NP (DT the) (JJ hepatic) (CC and) (NN brain) (NN P450) (NNS monooxygenases)))) (VP (AUX was) (VP (ADVP (RB also)) (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN exposure)) (PP (IN of) (NP (JJ low) (NN dose))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg))) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_12842176_578_585_Chemical)))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (CD 5) (NNS days))) (PP (TO to) (NP (QP (CD 15) (CC or) (CD 21)) (NNS days))))))))) (. .)))
12842176	3	(S1 (S (SBAR (IN As) (S (VP (VBN observed) (PP (IN with) (NP (JJ different) (NNS doses)))))) (, ,) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NN induction))) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ P450) (NNS monooxygenases)))))) (VP (AUX was) (ADJP (JJ several) (VB fold) (JJR higher)) (PP (IN in) (NP (NN liver) (NNS microsomes))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (NN brain))))))) (. .)))
12842176	4	(S1 (S (NP (JJ Western) (VBG blotting) (NNS studies)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (DT the) (CD P450) (NNS enzymes)))) (VP (MD could) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ P450) (NNS 1A1/1A2)) (, ,) (NP (NNS 2B1/2B2)) (CC and) (NP (JJ 2E1) (NNS isoenzymes))))))))))))))) (. .)))
12842176	5	(S1 (FRAG (SBAR (IN In) (S (NP (NP (NN vitro) (NNS studies)) (VP (VBG using) (NP (NP (JJ organic) (NNS inhibitors)) (PP (JJ specific) (IN for) (NP (NP (JJ individual) (JJ P450) (NNS isoenzymes)) (CC and) (NP (NN antibody) (NN inhibition) (NNS experiments))))))) (VP (AUX have) (ADVP (RB further)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (S (VP (VB PROD))) (, ,) (NNP EROD) (CC and) (NNP Doc_12842176_1170_1174_Chemical-d)))))) (VP (AUX are) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (CD P450) (CD 2B1/2B2) (, ,) (CD 1A1/1A2) (CC and) (CD 2E1) (NNS isoenzymes)))))))) (, ,) (ADVP (RB respectively))))))))) (. .)))
12842176	6	(S1 (S (NP (NN Induction) (NNS studies)) (VP (AUX have) (ADVP (RB further)) (VP (VBN shown) (SBAR (IN that) (S (SBAR (IN while) (S (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (NP (NNP Doc_12842176_1338_1358_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12842176_1360_1362_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NNP P4501A1/1A2)))) (, ,)))) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ significant) (NN effect)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_12842176_1451_1458_Chemical)) (VP (VBN induced) (NP (NNP Doc_12842176_1467_1478_Disease))))))))))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_12842176_1498_1511_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP PB)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (CD P450) (NNS 2B1/2B2)))) (CC or) (NP (NP (NNP Doc_12842176_1548_1555_Chemical)) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (QP (CD P450) (CD 2E1)) (JJ catalysed) (NNS reactions)))) (, ,))))) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12842176_1642_1649_Chemical))) (VP (VBN induced) (NP (NNP Doc_12842176_1658_1669_Disease))))))))) (. .)))
12842176	7	(S1 (S (ADVP (RB Similarly)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJ P450-mediated) (NN metabolism)) (PP (IN of) (NP (NNP Doc_12842176_1719_1726_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_12842176_1742_1757_Chemical))))))) (NP (NP (NN incidence)) (PP (IN of) (NP (NNP Doc_12842176_1771_1782_Disease)))) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12842176_1821_1828_Chemical))) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (JJ Doc_12842176_1845_1852_Chemical) (FW per) (FW se)) (CC or) (NP (NP (PRP$ its) (NNS metabolites)) (VP (VBN formed) (PP (IN by) (NP (NNP PB) (CC or) (NNP Doc_12842176_1895_1902_Chemical)))))) (VP (VBP inducible) (SBAR (S (NP (JJ P450) (NNS isoenzymes)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (PRP$ its) (JJ neurobehavioral) (NN Doc_12842176_1965_1973_Disease))))))))))))))))) (. .)))
12851669	0	(S1 (NP (NP (ADJP (JJ Absolute) (CC and) (JJ attributable)) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_34_56_Disease))) (PP (IN in) (NP (NNS women))) (PP (IN on) (NP (JJ combined) (NNP Doc_12851669_78_97_Chemical) (CC and) (NNP Doc_12851669_102_118_Chemical))) (. .)))
12851669	1	(S1 (FRAG (S (VP (TO To) (VP (VB achieve) (NP (NP (JJ absolute) (NN risk) (NNS estimates)) (PP (IN of) (NP (NP (NNP Doc_12851669_169_191_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_193_196_Disease)) (-RRB- -RRB-)))) (PP (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NP (NNP Doc_12851669_213_232_Chemical) (CC plus) (NNP Doc_12851669_238_254_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_256_259_Chemical/Doc_12851669_260_262_Chemical)) (-RRB- -RRB-)))))) (, ,) (CC and) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NP (NNP Doc_12851669_284_312_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_314_318_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
12851669	2	(S1 (S (PP (IN From) (NP (NP (NP (NP (DT the) (JJ Danish) (NNP National) (NNP Register)) (PP (IN of) (NP (NNS Patients)))) (PRN (-LRB- -LRB-) (NP (NNP NRP)) (-RRB- -RRB-))) (, ,) (NP (CD 1996) (TO to) (CD 1998)))) (, ,) (NP (NP (DT the) (NNS records)) (PP (IN of) (NP (NP (QP (CD 1.1) (CD million)) (JJ Danish) (NNS women)) (, ,) (NP (NP (NNS ages)) (NP (QP (CD 15) (TO to) (CD 44)) (NNS years))) (, ,)))) (VP (AUX were) (VP (VBD searched) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_12851669_489_492_Disease))))))) (. .)))
12851669	3	(S1 (S (NP (JJ Doc_12851669_494_497_Chemical) (NN use)) (VP (AUX was) (VP (VBN ascertained) (PP (IN through) (NP (VBN mailed) (NNS questionnaires))))) (. .)))
12851669	4	(S1 (S (NP (NP (JJ Sales) (NNS statistics)) (PP (IN of) (NP (NP (NNP Doc_12851669_569_573_Chemical)) (CC and) (NP (NNP Doc_12851669_578_581_Chemical/Doc_12851669_582_584_Chemical))))) (VP (AUX were) (VP (VBN provided) (PP (IN through) (NP (JJ Danish) (NN Drug) (NNS Statistics))))) (. .)))
12851669	5	(S1 (S (PP (IN During) (NP (NP (DT the) (NN time) (NN frame)) (PP (IN of) (NP (DT the) (NN study))))) (, ,) (NP (CD 330) (NNS women)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (VP (AUX had) (ADJP (JJ Doc_12851669_709_712_Disease)) (SBAR (IN while) (S (PP (IN on) (NP (NN Doc_12851669_722_726_Chemical))))))))))) (. .)))
12851669	6	(S1 (S (PP (IN Of) (NP (DT these) (NNS women))) (, ,) (NP (CD 67)) (VP (AUX were) (PP (IN on) (NP (NNP Doc_12851669_755_769_Chemical-containing) (NNP Doc_12851669_781_785_Chemical)))) (. .)))
12851669	7	(S1 (S (NP (CD Eleven)) (VP (AUX were) (PP (IN on) (NP (NNP Doc_12851669_802_805_Chemical/Doc_12851669_806_808_Chemical)))) (. .)))
12851669	8	(S1 (S (NP (NP (DT The) (JJ corresponding) (JJ absolute) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_845_848_Disease)))) (VP (AUX was) (NP (NP (NP (CD 3.4)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.1-3.8)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (DT the) (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_916_920_Chemical)))))))) (, ,) (NP (NP (CD 4.2)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.2-5.2)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_981_995_Chemical-containing) (NNP Doc_12851669_1007_1011_Chemical)))))))) (, ,) (CC and) (NP (NP (CD 3.1)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 1.3-4.9)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (DT the) (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_1080_1083_Chemical/Doc_12851669_1084_1086_Chemical)))))))))) (. .)))
12851669	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (S (NP (NP (DT the) (JJ absolute) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_1141_1144_Disease))) (PP (IN among) (NP (JJ Danish) (NNS women))) (PP (IN on) (NP (NNP Doc_12851669_1167_1171_Chemical)))) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN among) (NP (NP (NNS women)) (VP (VBG taking) (NP (NNP Doc_12851669_1210_1213_Chemical/Doc_12851669_1214_1216_Chemical)))))))))))) (. .)))
12852481	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ developmental) (NN toxicology)) (PP (IN of) (NP (NP (NNP Doc_12852481_42_49_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_51_71_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG using) (NP (JJ selected) (NN dosing)))))) (VP (VBZ paradigms)) (. .)))
12852481	1	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (DT the) (NN literature))) (PP (IN for) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT a) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_12852481_236_259_Disease)))) (VP (VBZ occurs) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN given) (PP (ADVP (RB NSAIDs)) (IN on) (NP (JJ specific) (NNS days))) (PP (IN during) (NP (NN organogenesis)))))))))) (. .)))
12852481	2	(S1 (S (NP (NP (NP (NNP Doc_12852481_327_334_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_12852481_336_356_Chemical) (JJ -LSB-Doc_12852481_358_361_Chemical) (NN -RSB-)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ irreversible) (ADJP (VB cyclooxygenase) (CD 1) (CC and) (CD 2)) (NN inhibitor)) (, ,)) (VP (VBZ induces) (NP (NP (NP (NP (NNP Doc_12852481_423_446_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NNP Wistar) (NNS rats))) (PP (IN on) (NP (JJ gestational) (NN day))))))) (PRN (-LRB- -LRB-) (NP (NNP GD)) (-RRB- -RRB-)) (NP (CD 9) (, ,) (CD 10) (, ,) (CC or) (CD 11))) (-LRB- -LRB-) (NP (NNP Kimmel) (MD CA)) (, ,) (NP (NNP Wilson) (NNP JG)) (, ,) (NP (NNP Schumacher) (NNP HJ)))) (. .)))
12852481	3	(S1 (NP (NP (NNP Teratology) (CD 4:15-24)) (, ,) (NP (CD 1971)) (-RRB- -RRB-) (. .)))
12852481	4	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (VBN published) (NNP Doc_12852481_605_608_Chemical) (NNS studies)) (VP (VBG using) (NP (NP (DT the) (JJ multiple) (NN dosing) (NN paradigm)) (PP (IN of) (NP (QP (RB GDs) (CD 6) (TO to) (CD 17)))))))) (. .)))
12852481	5	(S1 (S (NP (NP (NNS Objectives)) (PP (IN of) (NP (DT the) (JJ current) (NN study)))) (VP (AUX were) (S (S (VP (TO to) (VP (VB compare) (NP (NNS results)) (PP (IN between) (NP (NP (NP (NNP Sprague-Dawley)) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-))) (CC and) (NP (NNP Wistar) (NNS strains)))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12852481_776_779_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (IN on) (NP (NNP GD) (CD 9) (, ,) (CD 10) (, ,) (CC or) (CD 11)))))))))) (: ;) (S (VP (TO to) (VP (VB compare) (NP (DT the) (NN malformation) (NNS patterns)) (PP (VBG following) (NP (NP (ADJP (JJ single) (CC and) (JJ multiple)) (NNS dosings)) (PP (IN during) (NP (NP (NNS organogenesis)) (PP (IN in) (NP (JJ SD) (NNS rats)))))))))) (: ;) (CC and) (S (VP (TO to) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ maternal) (NNP Doc_12852481_965_990_Disease)) (VP (VBZ confounds) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ low) (NN incidence) (NN Doc_12852481_1032_1045_Disease)))) (PP (IN with) (NP (NNP Doc_12852481_1051_1054_Chemical))) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ multiple) (NN dosing) (NN paradigm)) (VP (AUX is) (VP (VBN used)))))))))))))) (. .)))
12852481	6	(S1 (S (NP (NNP Doc_12852481_1105_1108_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (PP (IN as) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN on) (NP (NP (NP (NNP GD) (CD 9)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 250)) (, ,) (NP (CD 500)) (, ,) (CC or) (NP (CD 625) (NNS mg/kg))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 500)) (, ,) (NP (CD 625)) (, ,) (CC or) (NP (CD 750) (NNS mg/kg))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (CD 11)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 500)) (, ,) (NP (CD 750)) (, ,) (CC or) (NP (CD 1000) (NN mg/kg))) (-RRB- -RRB-)))))))) (CC and) (PP (IN from) (NP (NNP GD) (CD 6)))) (S (VP (TO to) (VP (VB GD) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 50)) (, ,) (NP (CD 125)) (, ,) (CC or) (NP (NP (CD 250) (NNS mg/kg)) (NP (DT a) (NN day)))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ multiple) (NN dose) (NN study))) (PP (TO to) (NP (CD SD) (NNS rats)))))))) (. .)))
12852481	7	(S1 (S (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN killed) (PP (IN on) (NP (NNP GD) (CD 21)))))) (, ,) (CC and) (S (NP (NNS fetuses)) (VP (AUX were) (VP (VBN examined) (ADVP (RB viscerally))))) (. .)))
12852481	8	(S1 (S (S (NP (DT The) (NN literature) (NN evaluation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNS NSAIDs)) (VP (VB induce) (NP (NP (NP (NP (NP (NP (NP (NP (NNP Doc_12852481_1474_1500_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1502_1506_Disease)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12852481_1512_1527_Disease))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1529_1532_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NNS rats)))) (CC and) (NP (NNP Doc_12852481_1546_1566_Disease))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1568_1570_Disease)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_12852481_1573_1576_Disease)) (, ,) (CC and) (NP (NNP Doc_12852481_1582_1586_Disease))) (PP (IN in) (NP (NP (NNS rabbits)) (PRN (-LRB- -LRB-) (NP (NNP Cook) (NNP JC) (CC et) (NNP al.)) (, ,) (NP (CD 2003)) (-RRB- -RRB-))))))))) (: ;) (S (ADVP (RB hence)) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VBD focused) (PP (IN on) (NP (DT these) (NNP Doc_12852481_1664_1677_Disease))) (, ,) (SBAR (RB even) (IN though) (S (NP (NNP Doc_12852481_1691_1694_Chemical)) (VP (VBZ induces) (NP (JJ several) (JJ other) (NN low-incidence) (NNP Doc_12852481_1731_1744_Disease))))))) (. .)))
12852481	9	(S1 (S (PP (IN In) (NP (JJ single) (NN dose) (NNS studies))) (, ,) (NP (NP (NNP Doc_12852481_1770_1772_Disease)) (, ,) (NP (NNP Doc_12852481_1774_1776_Disease)) (, ,) (CC and) (NP (NNP Doc_12852481_1782_1785_Disease))) (VP (AUX were) (VP (VBN induced) (PP (IN on) (NP (NNP GDs) (CD 9) (CC and) (CD 10))))) (. .)))
12852481	10	(S1 (S (NP (NN Doc_12852481_1816_1819_Disease)) (ADVP (RB also)) (VP (AUX was) (VP (VBN noted) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN on) (NP (NNP GD) (CD 11))))))) (. .)))
12852481	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (S (NP (NP (NNP Doc_12852481_1878_1880_Disease)) (CC and) (NP (NNP Doc_12852481_1885_1887_Disease))) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (JJ multiple) (NN dose) (NN study) (NN design)) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ high-dose) (NN group)))))))) (, ,) (CC and) (S (NP (NNP Doc_12852481_1966_1969_Disease)) (VP (AUX was) (VP (VBN noted) (PP (IN across) (NP (DT all) (NN dose) (NNS groups)))))) (. .)))
12852481	12	(S1 (S (NP (NP (JJ High) (NN concordance)) (PP (IN in) (NP (NP (JJ major) (NN Doc_12852481_2043_2066_Disease)) (PP (IN between) (NP (NNP Wistar) (CC and) (NNP SD) (NNS rats)))))) (VP (AUX were) (VP (VBN noted) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NP (NNP Doc_12852481_2127_2130_Disease)) (PP (IN in) (NP (DT the) (CD SD) (NNS rats)))) (CC and) (NP (NP (NNP Doc_12852481_2150_2163_Disease)) (PP (IN in) (NP (DT the) (JJ Wistar) (NNS rats)))))))))) (. .)))
12852481	13	(S1 (S (NP (NNS Variations) (CC and) (NNP Doc_12852481_2199_2212_Disease)) (VP (AUX were) (UCP (JJ similar) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12852481_2231_2234_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (DT a) (JJ single) (NN dose))))))) (CC or) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NP (NNS organogenesis)) (PRN (-LRB- -LRB-) (NP (QP (RB GDs) (CD 6) (TO to) (CD 17))) (-RRB- -RRB-)))))))) (. .)))
12852481	14	(S1 (S (NP (PRP It)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ evident)) (SBAR (IN that) (S (, ,) (PP (IN by) (S (VP (VBG titrating) (NP (DT the) (NN dose) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT a) (JJ maximum) (JJ tolerated) (NN dose)) (, ,) (NP (NP (NNP Doc_12852481_2407_2420_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBP occur) (PP (IN at) (NP (JJ low) (NN incidence))))))) (, ,)) (SBAR (IN as) (S (VP (VBN reported) (PP (IN from) (NP (JJ previous) (JJ single) (NN dose) (NNS studies))))))))))))) (, ,) (VP (MD could) (ADVP (RB also)) (VP (AUX be) (VP (VBN induced) (PP (IN with) (NP (NP (NNP Doc_12852481_2533_2536_Chemical)) (VP (VBN given) (PP (IN at) (NP (JJ multiple) (NNS doses)))))))))))) (. .)))
1286498	0	(S1 (NP (NP (NP (NN Reversal)) (PP (IN of) (NP (JJ central) (JJ Doc_1286498_20_34_Chemical) (NNS effects))) (PP (IN by) (NP (NNP Doc_1286498_46_56_Chemical))) (PP (IN after) (NP (NP (JJ intravenous) (JJ conscious) (NN sedation)) (PP (IN with) (NP (NP (NNP Doc_1286498_99_107_Chemical)) (CC and) (NP (NNS opioids))))))) (: :) (NP (NP (NN report)) (PP (IN of) (NP (DT a) (JJ double-blind) (NN multicenter) (NN study)))) (. .)))
1286498	1	(S1 (NP (NP (DT The) (NNP Doc_1286498_169_179_Chemical)) (PP (IN in) (NP (NP (JJ Intravenous) (JJ Conscious) (NN Sedation)) (PP (IN with) (NP (NNP Doc_1286498_219_227_Chemical) (NNP Multicenter) (NNP Study) (NNP Group) (NNP II))))) (. .)))
1286498	2	(S1 (S (NP (NP (DT The) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_1286498_289_303_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_1286498_316_326_Chemical)) (, ,)))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (DT a) (JJ double-blind) (NN multicenter) (NN study))))) (. .)))
1286498	3	(S1 (S (NP (NP (NP (NNP Doc_1286498_379_389_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (, ,) (NP (CD 0.76) (NN mg))) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (, ,) (NP (CD 8.9) (NN ml))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PP (TO to) (NP (NP (QP (CD 130) (CC and) (CD 67)) (NNS patients)) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN given) (NP (NNP Doc_1286498_530_538_Chemical)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (DT an) (JJ opioid)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1286498_570_578_Chemical) (, ,) (NNP Doc_1286498_580_590_Chemical) (, ,) (CC or) (NNP Doc_1286498_595_603_Chemical)) (-RRB- -RRB-)))))) (PP (IN for) (NP (NP (DT the) (NN induction) (CC and) (NN maintenance)) (PP (IN of) (NP (NP (JJ intravenous) (JJ conscious) (NN sedation)) (PP (IN for) (NP (ADJP (JJ diagnostic) (CC or) (JJ therapeutic)) (JJ surgical) (NNS procedures)))))))))))))))) (. .)))
1286498	4	(S1 (S (NP (NP (DT The) (NN group) (NN assessable)) (PP (IN for) (NP (NN efficacy)))) (VP (VBN comprised) (NP (NP (NP (CD 122) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1286498_794_804_Chemical))))) (CC and) (NP (NP (CD 64) (NNS patients)) (VP (VBN given) (NP (NN placebo)))))) (. .)))
1286498	5	(S1 (S (PP (IN After) (NP (CD 5) (NNS minutes))) (, ,) (NP (NP (NP (CD 80/115)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-)) (JJ Doc_1286498_866_876_Chemical-treated) (NNS patients)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 21/63)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-)) (JJ placebo-treated) (NNS patients)))) (, ,)) (VP (AUX were) (ADJP (RB completely) (JJ awake) (CC and) (JJ alert)) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (DT a) (NN score))) (PP (IN of) (NP (NP (CD 5)) (PP (IN on) (NP (NP (NP (DT the) (NNP Observer) (POS 's)) (NN Assessment)) (PP (IN of) (NP (NNP Alertness/Sedation) (NN Scale))))))))))) (. .)))
1286498	6	(S1 (S (NP (NP (JJ Ninety-five) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (DT each) (NN group)) (SBAR (WHNP (WP who)) (S (VP (VBN attained) (NP (NP (DT a) (NN score)) (PP (IN of) (NP (CD 5)))) (PP (IN at) (NP (DT the) (JJ 5-minute) (NN assessment))))))))))) (VP (VBD showed) (NP (NP (DT no) (NN loss)) (PP (IN of) (NP (NN alertness)))) (PP (IN throughout) (NP (DT the) (JJ 180-minute) (NN assessment) (NN period)))) (. .)))
1286498	7	(S1 (S (NP (JJ Doc_1286498_1239_1249_Chemical-treated) (NNS patients)) (ADVP (RB also)) (VP (VBD performed) (ADVP (RB significantly)) (ADVP (RB better)) (PP (IN on) (NP (NP (DT the) (JJ Finger-to-Nose) (NN Test)) (CC and) (NP (NP (DT the) (NN recall)) (PP (IN of) (NP (NP (NNS pictures)) (VP (VBN shown) (PP (IN at) (NP (DT the) (JJ 5-minute) (NN assessment)))))))))) (. .)))
1286498	8	(S1 (S (NP (NN Doc_1286498_1391_1401_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (, ,) (PP (IN with) (NP (NP (DT no) (JJ serious) (JJ adverse) (NNS effects)) (VP (VBN reported)))))) (. .)))
1286498	9	(S1 (S (NP (NP (NN Thirty-nine)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ Doc_1286498_1485_1495_Chemical-treated) (NNS patients))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ placebo-treated) (NNS patients))))))) (VP (AUX had) (NP (QP (CD one) (CC or) (JJR more)) (JJ drug-related) (JJ adverse) (NNS experiences))) (. .)))
1286498	10	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS effects)) (VP (AUX were) (NP (NP (NP (NP (NNP Doc_1286498_1652_1658_Disease)) (CC and) (NP (NNP Doc_1286498_1663_1671_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_1286498_1679_1689_Chemical) (NN group)))) (CC and) (NP (NP (NP (NNP Doc_1286498_1700_1706_Disease)) (CC and) (NP (JJ injection-site) (NNP Doc_1286498_1726_1730_Disease))) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))) (. .)))
1286498	11	(S1 (S (NP (NN Doc_1286498_1753_1763_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (ADVP (RB promptly)) (VP (VB reverse) (NP (NP (NN sedation)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1286498_1814_1822_Chemical))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS opioids)))))))))))) (. .)))
12907924	0	(S1 (NP (NP (JJ Doc_12907924_0_15_Chemical-induced) (NNP Doc_12907924_24_53_Disease)) (PP (IN in) (NP (DT an) (JJ elderly) (NN man))) (. .)))
12907924	1	(S1 (S (NP (NP (DT An) (JJ 82-year-old) (NN man)) (PP (IN with) (NP (NP (NNP Doc_12907924_97_127_Disease)) (CC and) (NP (JJ early) (NNP Doc_12907924_138_157_Disease))))) (VP (AUX was) (VP (VBN started) (PP (IN on) (NP (NNP Doc_12907924_173_188_Chemical))))) (. .)))
12907924	2	(S1 (S (NP (JJ Significant) (NN Doc_12907924_202_231_Disease)) (VP (VP (VBD ensued)) (CC but) (VP (VBN diminished) (PP (IN over) (NP (JJ several) (NNS weeks))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12907924_278_293_Chemical)) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NN Doc_12907924_310_321_Chemical))))))))) (. .)))
12907924	3	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ prior) (JJ Doc_12907924_348_359_Disease) (NN history)))) (, ,) (CC but) (S (NP (PRP he)) (VP (AUX had) (NP (NP (DT a) (NN sister)) (PP (IN with) (NP (NNP Doc_12907924_394_423_Disease)))))) (. .)))
12907924	4	(S1 (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NNP Doc_12907924_441_456_Chemical)) (VP (VBD precipitated) (NP (NP (DT the) (NN patient) (POS 's)) (JJ pathological) (NN behavior)))))) (. .)))
12911170	0	(S1 (NP (JJ Doc_12911170_0_13_Chemical-induced) (JJ acute) (NNP Doc_12911170_28_50_Disease) (CC and) (NNP Doc_12911170_55_82_Disease) (. .)))
12911170	1	(S1 (S (NP (NN Doc_12911170_84_97_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NNP Doc_12911170_154_176_Disease)) (CC and) (NP (NNP Doc_12911170_181_197_Disease))))))))) (. .)))
12911170	2	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (DT both) (NN side) (NNS effects)))) (VP (AUX is) (ADJP (RB extremely) (JJ rare))) (. .)))
12911170	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_12911170_293_306_Chemical-induced) (NNP Doc_12911170_315_337_Disease) (CC and) (NNP Doc_12911170_342_369_Disease))))) (. .)))
12911170	4	(S1 (S (NP (NN Doc_12911170_371_387_Disease)) (VP (VBD improved) (PP (IN after) (S (VP (VBG stopping) (NP (NP (DT the) (NN drug) (CC and) (NN initiation)) (PP (IN of) (NP (JJ Doc_12911170_439_446_Chemical) (NN therapy)))))))) (. .)))
12911170	5	(S1 (S (ADVP (RB Unfortunately)) (, ,) (S (NP (JJ acute) (NN Doc_12911170_477_499_Disease)) (VP (AUX was) (ADJP (JJ irreversible)))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NN Doc_12911170_543_566_Disease)))) (. .)))
1300436	0	(S1 (NP (NP (JJ Potential) (JJ deleterious) (NN effect)) (PP (IN of) (NP (NNP Doc_1300436_32_42_Chemical))) (PP (IN in) (NP (NN radiocontrast) (NN Doc_1300436_60_71_Disease))) (. .)))
1300436	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_1300436_131_141_Chemical)))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ intravenous) (NNS fluids)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (JJ radiocontrast) (NNP Doc_1300436_211_222_Disease.) (CD 18) (NNS patients))))))))) (, ,) (PP (VBN referred) (PP (TO to) (NP (NP (DT a) (JJ radiocontrast) (NN study)) (, ,) (VP (VBN considered) (PP (IN at) (NP (NN risk))) (SBAR (IN because) (S (PP (IN of) (NP (JJ preexisting) (NNP Doc_1300436_314_333_Disease))) (, ,) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ controlled) (NN trial)) (, ,) (VP (VBN performed) (PP (IN at) (NP (NP (DT the) (JJ secondary) (NN care) (NN center)) (PP (IN of) (NP (DT a) (JJ 1,100-bed) (JJ private) (NN university) (NN hospital)))))))))))))))))))) (. .)))
1300436	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NNS fluids))))) (, ,) (NP (DT the) (NN treatment) (NN group)) (VP (VBD received) (NP (NP (NNP Doc_1300436_532_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (NP (CD 110) (NNS mg))) (-RRB- -RRB-))) (ADVP (RB intravenously)) (NP (CD 30) (NN min)) (ADVP (RB prior) (PP (TO to) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NN contrast) (NN material))))))) (. .)))
1300436	3	(S1 (S (NP (DT The) (NN control) (NN group)) (VP (VBD received) (NP (NP (NNS fluids)) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 3) (NNS liters)) (-RRB- -RRB-)))) (. .)))
1300436	4	(S1 (S (NP (JJ Radiological) (NNS studies)) (VP (AUX were) (ADVP (RB mostly)) (NP (NP (NNS angiographies)) (VP (VBN performed) (PP (IN with) (NP (DT both) (ADJP (JJ ionic) (CC and) (JJ non-ionic)) (NN contrast) (NN material))))) (, ,) (PP (IN at) (NP (NP (DT an) (JJ average) (NN dose)) (PP (IN of) (NP (QP (CD 245) (CD ml))))))) (. .)))
1300436	5	(S1 (S (NP (NP (NN Doc_1300436_815_856_Disease)) (PP (IN in) (NP (DT the) (NN group)))) (VP (VBD pretreated) (PP (IN with) (NP (NP (NNP Doc_1300436_886_896_Chemical)) (PRN (-LRB- -LRB-) (VP (VBN p) (NP (NNP <) (CD 0.005)) (PP (IN by) (NP (NNP ANOVA)))) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (JJ serum) (NNP Doc_1300436_940_950_Chemical))) (PP (IN from) (NP (NP (NP (CD 145) (NN +/-)) (NP (QP (CD 13) (TO to) (CD 182)) (JJ +/-) (CD 16) (NNS mumol/l))) (PP (IN at) (NP (CD 24))) (NP (NNP h)))))) (, ,) (SBAR (IN while) (S (NP (DT no) (NN change)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (CD 141) (NN +/-)) (NP (QP (CD 6) (TO to) (CD 142)) (JJ +/-) (CD 7) (NNS mumol/l)))) (-RRB- -RRB-)))))))) (. .)))
1300436	6	(S1 (S (NP (NN Doc_1300436_1083_1096_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_1300436_1117_1128_Disease)) (PP (IN in) (NP (DT the) (JJ Doc_1300436_1136_1146_Chemical-treated) (NN group))))))) (. .)))
1300436	7	(S1 (S (NP (NN Doc_1300436_1162_1172_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ deleterious)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NN radiocontrast) (NN Doc_1300436_1227_1238_Disease))))))) (. .)))
133615	0	(S1 (NP (JJ Progestational) (NNS agents) (CC and) (NNP Doc_133615_26_43_Disease) (. .)))
133615	1	(S1 (NP (NNP VII) (. .)))
133615	2	(S1 (NP (NP (NP (NP (NN Doc_133615_50_64_Disease)) (CC and) (NP (JJ other) (NNS complications))) (PP (IN of) (NP (JJ Doc_133615_92_110_Chemical) (NN therapy))) (PP (IN in) (NP (NN relationship))) (PP (TO to) (NP (NP (JJ pretreatment) (NNS levels)) (PP (IN of) (NP (JJ Doc_133615_161_178_Disease) (NNS factors)))))) (: :) (NP (NP (NN summary) (NN report)) (PP (IN of) (NP (DT a) (JJ ten-year) (NN study)))) (. .)))
133615	3	(S1 (S (PP (IN During) (NP (DT a) (JJ ten-year) (NN period))) (, ,) (NP (CD 348) (NNS women)) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 5,877) (JJ patient) (NNS months))) (PP (IN in) (NP (NP (CD four) (JJ separate) (NNS studies)) (VP (VBG relating) (NP (NNP Doc_133615_343_362_Chemical)) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ hematologic) (NNS parameters)))))))))))) (. .)))
133615	4	(S1 (S (NP (NP (JJ Significant) (NNS increases)) (PP (IN in) (NP (NP (NP (JJ certain) (NNS factors)) (PP (IN of) (NP (DT the) (NNP Doc_133615_449_466_Disease)))) (CC and) (NP (NN fibrinolysin) (NNS systems)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS factors)) (NP (PRP I))) (, ,) (NP (NP (NNP II)) (, ,) (NP (NNP VII)) (, ,) (NP (NNP VIII)) (, ,) (NP (CD IX)) (, ,) (CC and) (NP (NP (SYM X)) (CC and) (NP (NNS plasminogen))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT the) (VBN treated) (NNS groups))))) (. .)))
133615	5	(S1 (S (NP (JJ Severe) (NNS complications)) (VP (VBD developed) (PP (IN in) (NP (CD four) (NNS patients)))) (. .)))
133615	6	(S1 (S (NP (DT All) (CD four)) (VP (AUX had) (NP (DT an) (JJ abnormal) (NN Doc_133615_653_670_Disease) (NN profile)) (, ,) (S (VP (VBG suggesting) (`` ``) (NP (NNP Doc_133615_692_710_Disease)) ('' '') (PP (IN before) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy)))))))) (. .)))
133615	7	(S1 (S (S (NP (NP (DT Some)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (VBD represented) (NP (NP (DT the) (ADJP (RBS most) (JJ extreme)) (NNS abnormalities)) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (JJ entire) (NN group)) (PP (IN of) (NP (NNS patients))))))))) (: ;) (S (NP (DT some)) (VP (VBD increased) (ADVP (RB further)) (PP (IN during) (NP (NN therapy))))) (. .)))
133615	8	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (VBD developed) (NP (DT a) (NN Doc_133615_919_940_Disease)) (PP (IN before) (S (VP (VBG receiving) (NP (DT any) (NN medication))))) (, ,) (SBAR (ADVP (RB shortly)) (IN after) (S (NP (DT the) (JJ base-line) (NNS values)) (VP (AUX were) (VP (VBN obtained)))))) (. .)))
133615	9	(S1 (S (NP (CD One) (NN patient)) (VP (VBD developed) (SBAR (NP (NNP Doc_133615_1046_1057_Disease) (CD 19) (NNS months)) (IN after) (S (S (NP (PRP she)) (VP (VBD began) (NP (NN therapy)))) (, ,) (CC and) (S (NP (DT another)) (VP (VBD developed) (NP (NNP Doc_133615_1115_1131_Disease)) (PP (IN after) (NP (NP (CD 27) (NNS months)) (PP (IN of) (NP (NN therapy)))))))))) (. .)))
133615	10	(S1 (S (NP (DT The) (JJ fourth) (NN patient)) (VP (VBD developed) (NP (NNP Doc_133615_1189_1205_Disease) (CD 14) (NNS days)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ contraceptive) (NN therapy)))))) (. .)))
133615	11	(S1 (S (NP (DT All) (CD four) (NNS patients)) (VP (AUX were) (PP (IN of) (NP (DT the) (NNP A) (CC or) (NNP AB) (NN blood) (NN group)))) (. .)))
133615	12	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBD suggested) (NP (NP (DT the) (NN possiblility)) (PP (IN of) (NP (VBN increased) (NN propensity))) (PP (IN for) (NP (NNP Doc_133615_1380_1403_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG possessing) (NP (DT the) (NNP A) (NN antigen))))))) (. .)))
133615	13	(S1 (S (NP (PRP It)) (VP (VBZ appears) (PP (IN from) (NP (DT these) (NNS data))) (SBAR (IN that) (S (NP (JJ hematologic) (NNS work-ups)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful)) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (IN about) (S (VP (TO to) (VP (VB start) (NP (JJ long-term) (JJ Doc_133615_1551_1569_Chemical) (NN therapy)))))))))))))))) (. .)))
1355091	0	(S1 (S (NP (NN Doc_1355091_0_23_Disease)) (VP (VBZ occurs) (PP (VBG following) (NP (NP (NN alpha) (NN 2-adrenoceptor) (NN blockade)) (PP (IN in) (NP (JJ chronic) (JJ Doc_1355091_82_90_Chemical-pretreated) (JJ conscious) (ADJP (RB spontaneously) (JJ Doc_1355091_126_138_Disease)) (NN rats.) (CD 1)))))) (. .)))
1355091	1	(S1 (S (NP (NNS Studies)) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (JJ chronic) (JJ Doc_1355091_199_207_Chemical) (NN treatment)) (VP (VBZ alters) (NP (NP (DT the) (NN alpha) (NN 2-adrenoceptor) (NN function)) (PP (IN for) (NP (NP (JJ orthostatic) (NN control)) (PP (IN of) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (PP (IN in) (NP (NP (JJ conscious) (ADJP (RB spontaneously) (JJ Doc_1355091_337_349_Disease)) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-)) (. .) (CD 2)))))))))))))))) (. .)))
1355091	2	(S1 (S (NP (NP (JJ Conscious) (NNP SHR)) (PRN (-LRB- -LRB-) (NP (JJ male) (JJ 300-350) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (CD 90) (NNS degrees)) (SBAR (S (NP (NN head-up)) (VP (VBZ tilts) (PP (IN for) (NP (NP (CD 60) (NNP s) (JJ following) (JJ acute) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_1355091_482_490_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (JJ mg) (JJ kg-1) (NN i.p.)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_1355091_513_524_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-)))))))))))))) (. .)))
1355091	3	(S1 (S (NP (NN Doc_1355091_543_566_Disease)) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (JJ average) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NN %)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ mean) (JJ arterial) (NN pressure))) (PRN (-LRB- -LRB-) (NP (NN MAP) (NN femoral)) (-RRB- -RRB-)) (PP (IN over) (NP (DT the) (NN 60-s) (NN tilt) (NN period))))) (. .)))
1355091	4	(S1 (S (NP (NP (DT The) (JJ basal) (NN MAP)) (PP (IN of) (NP (JJ conscious) (NNP SHR)))) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (DT a) (JJ similar) (NN extent))) (PP (IN by) (NP (NP (NNP Doc_1355091_743_751_Chemical) (PRN (-LRB- -LRB-) (NP (CD -23) (NN %)) (-LRB- -LRB-) (NP (LST (: -) (-RRB- -RRB-)) (NP (CD -26) (NN %)) (NN MAP)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_1355091_774_785_Chemical) (PRN (-LRB- -LRB-) (NP (CD -16) (NN %)) (-LRB- -LRB-) (NP (LST (: -) (-RRB- -RRB-)) (NP (CD -33) (NN %)) (NN MAP)) (-RRB- -RRB-))))))) (. .)))
1355091	5	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (JJ head-up) (NN tilt)) (VP (VBN induced) (NP (NNP Doc_1355091_839_862_Disease)) (PP (IN in) (NP (NP (DT the) (NNP SHR)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1355091_887_895_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD -16) (NN %)) (NN MAP)) (, ,) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))))))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (NP (DT the) (NNP SHR)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1355091_947_958_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (JJR less) (IN than) (CD +2)) (NN %)) (NN MAP)) (, ,) (NP (NNP n) (SYM =) (CD 6))) (-RRB- -RRB-)) (. .) (CD 3)))))))) (. .)))
1355091	6	(S1 (S (NP (JJ Conscious) (NNS SHR)) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (NP (CD 4) (NNS days)) (PP (IN with) (NP (NNP Doc_1355091_1033_1041_Chemical))))) (PP (IN at) (NP (NP (CD 2) (JJ mg) (JJ kg-1) (JJ day-1) (NN i.p.)) (PP (IN for) (NP (JJ chronic) (NN alpha) (NN 1-adrenoceptor) (NN blockade))))))) (. .)))
1355091	7	(S1 (S (NP (NP (NN MAP)) (PP (IN in) (NP (JJ conscious) (NNS SHR))) (PP (IN after) (NP (JJ chronic) (JJ Doc_1355091_1144_1152_Chemical) (NN treatment)))) (VP (AUX was) (ADJP (ADJP (NP (CD 14) (NN %)) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ untreated) (NNP SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))))))) (. .)))
1355091	8	(S1 (S (NP (NP (NN Head-up) (VBZ tilts)) (PP (IN in) (NP (DT these) (NNS rats)))) (VP (AUX did) (RB not) (VP (VB produce) (NP (NNP Doc_1355091_1256_1279_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBD performed) (ADVP (RB either)) (PP (ADVP (RB prior)) (TO to) (CC or) (IN after) (NP (NP (JJ acute) (NN dosing)) (PP (IN of) (NP (NNP Doc_1355091_1336_1344_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 0.1) (JJ mg) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))))))))) (. .)))
1355091	9	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_1355091_1395_1406_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ chronic) (NNP Doc_1355091_1435_1443_Chemical)))) (VP (VBD treated) (SBAR (S (S (NP (NNP SHR)) (VP (VBD decreased) (NP (NP (DT the) (JJ basal) (NN MAP)) (PP (IN by) (NP (CD 12-31) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (JJ subsequent)) (VP (VBZ tilts) (S (VP (VBN induced) (NP (NP (JJ further) (NNS drops)) (PP (IN of) (NP (NN MAP)))) (PP (IN by) (NP (CD 19-23) (NN %))) (PP (IN in) (NP (DT these) (JJ rats.) (CD 4)))))))))) (. .)))
1355091	10	(S1 (S (NP (NP (DT The) (NN pressor) (NNS responses)) (CC and) (NP (NP (NP (NP (NNP Doc_1355091_1603_1614_Disease)) (PP (TO to) (NP (NP (NP (DT the) (NN alpha) (NN 1-agonist) (NNP Doc_1355091_1638_1648_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.6) (CC and) (CD 2) (NNS micrograms)) (NP (JJ kg-1) (NN i.v.))) (-RRB- -RRB-))) (, ,) (NP (DT the) (NN alpha) (NN 2-agonist))))) (NP (NP (NNP Doc_1355091_1703_1715_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC and) (CD 3) (NNS micrograms)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_1355091_1752_1765_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (CC and) (CD 1.0) (NNS micrograms)) (NP (JJ kg-1) (NN i.v.))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NP (JJ conscious) (NNP SHR)) (PP (IN with) (CC and) (PP (IN without) (NP (JJ chronic) (JJ Doc_1355091_1859_1867_Chemical) (NN pretreatment)))))))) (. .)))
1355091	11	(S1 (S (NP (NP (PDT Both) (DT the) (JJ pressor) (CC and) (JJ Doc_1355091_1903_1914_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_1355091_1926_1936_Chemical)))) (VP (AUX were) (VP (VBN abolished) (PP (IN in) (NP (NP (JJ chronic) (JJ Doc_1355091_1963_1971_Chemical) (VBN treated) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ untreated) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))))))) (. .)))
1355091	12	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (S (NP (NP (DT the) (JJ pressor) (NNS effects)) (PP (IN of) (NP (NNP Doc_1355091_2076_2088_Chemical)))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNP SHR))))))) (, ,) (CC but) (S (NP (DT the) (JJ accompanying) (NN Doc_1355091_2146_2157_Disease)) (VP (AUX was) (ADJP (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (NNP SHR))) (PP (IN with) (NP (JJ chronic) (JJ Doc_1355091_2190_2198_Chemical) (NN treatment)))) (PP (IN than) (PP (IN without) (NP (JJ such) (NN treatment))))))) (. .)))
1355091	13	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NNP Doc_1355091_2255_2266_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD accompanied) (SBAR (S (NP (NP (DT the) (JJ Doc_1355091_2288_2301_Chemical-induced) (JJ pressor) (NN effect)) (PP (IN in) (NP (NNP SHR)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN with) (CC and) (IN without) (NP (JJ chronic) (JJ Doc_1355091_2369_2377_Chemical) (NN treatment))) (PP (IN despite) (NP (NP (DT a) (ADJP (CD 47-71) (NN %)) (NN reduction)) (PP (IN of) (NP (DT the) (NN pressor) (NN effect))) (PP (IN in) (NP (JJ chronic) (NN alpha) (NN 1-receptor)))))))))))) (VP (VBD blocked) (NP (NP (NNP SHR.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 400) (NNS WORDS))))) (-RRB- -RRB-))))))
1415380	0	(S1 (S (NP (NN Doc_1415380_0_25_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NN ingestion)) (PP (IN of) (NP (NNP Doc_1415380_55_62_Chemical)))))) (. .)))
1415380	1	(S1 (S (NP (JJ Doc_1415380_64_89_Disease) (JJ following) (JJ Doc_1415380_100_107_Chemical) (NN ingestion)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB newly) (VBN described)) (NN phenomenon)) (, ,) (PP (IN with) (NP (NP (QP (RB just) (CD two)) (JJ previous) (NNS descriptions)) (PP (IN of) (NP (NP (CD 4) (NNS cases)) (PP (IN in) (NP (DT the) (NN literature))))))))) (. .)))
1415380	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (DT a) (JJ 5th) (NN case))) (. .)))
1415380	3	(S1 (S (NP (DT The) (NN reaction)) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS antibodies))))) (ADVP (RB reactive)) (PP (IN against) (NP (NNS platelets))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_1415380_346_353_Chemical)))))))) (. .)))
1415380	4	(S1 (S (NP (NN Treatment)) (VP (AUX has) (VP (VBN included) (NP (NP (NN use)) (PP (IN of) (NP (NN plasma) (NN exchange)))) (, ,) (NP (NP (NNP Doc_1415380_402_412_Chemical)) (, ,) (NP (NNP Doc_1415380_414_421_Chemical)) (, ,) (CC and) (NP (NNP Doc_1415380_427_439_Chemical))))) (. .)))
1415380	5	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX have) (DT all) (VP (VBN regained) (NP (NP (DT some) (NN degree)) (PP (IN of) (NP (JJ renal) (NN function)))))) (. .)))
1415380	6	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (NP (JJ pharmacological) (NN treatment)) (CC or) (NP (JJ spontaneous) (NN resolution))) (VP (AUX is) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (NN improvement)))))))) (. .)))
1415380	7	(S1 (S (NP (JJ Doc_1415380_622_629_Chemical-associated) (NN Doc_1415380_641_666_Disease)) (ADVP (RB probably)) (VP (VBZ occurs) (ADVP (ADVP (RBR more) (RB often)) (SBAR (IN than) (S (VP (AUX is) (VP (VBN recognized))))))) (. .)))
1415380	8	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important)) (S (VP (VP (TO to) (VP (VB recognize) (NP (DT this) (NN reaction)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ occurs)))))) (CC and) (VP (TO to) (VP (VB avoid) (NP (JJ further) (JJ Doc_1415380_793_800_Chemical) (NN exposure)))))) (, ,) (SBAR (IN since) (S (NP (DT the) (NN reaction)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ recurrent))))))))) (. .)))
1423339	0	(S1 (NP (NP (NP (NN Doc_1423339_0_17_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_1423339_34_45_Chemical) (NNP Doc_1423339_46_54_Disease))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
1423339	1	(S1 (S (NP (DT An) (JJ elderly) (NN woman)) (VP (VBD developed) (NP (DT an) (JJ Doc_1423339_101_110_Disease-like) (NN subacute) (NN Doc_1423339_125_133_Disease)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_1423339_149_160_Chemical) (NNP Doc_1423339_161_169_Disease)))))) (. .)))
1423339	2	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (DT the) (NNS manifestations)))) (VP (VBD showed) (SBAR (S (NP (NP (DT that) (JJ severe) (NN impairment)) (PP (IN of) (NP (NN memory)))) (VP (VBD accounted) (PP (IN for) (NP (NP (RB virtually) (DT all)) (PP (IN of) (NP (DT the) (NNS abnormalities))))))))) (. .)))
1423339	3	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (JJ cerebral) (NNS reactions)) (PP (TO to) (NP (NN drug) (NN Doc_1423339_342_350_Disease)))) (VP (MD can) (VP (VB exhibit) (NP (NP (NNS patterns)) (SBAR (WHNP (WDT that)) (S (VP (VBP suggest) (NP (NP (ADJP (RB highly) (JJ selective)) (NN involvement)) (PP (IN of) (NP (NP (JJ functional) (NNS subdivisions)) (PP (IN of) (NP (DT the) (NN brain)))))))))))))))) (. .)))
1445986	0	(S1 (FRAG (NP (JJ Doc_1445986_0_9_Chemical-induced) (JJ immune) (NN Doc_1445986_25_41_Disease)) (. .)))
1445986	1	(S1 (S (NP (NNP Immune) (NNP Doc_1445986_50_66_Disease)) (PP (JJ due) (TO to) (NP (DT a) (JJ drug-adsorption) (NN mechanism))) (VP (AUX has) (VP (AUX been) (VP (VBN described) (ADVP (RB primarily)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_1445986_153_164_Chemical)) (CC and) (NP (JJ first-generation) (NNP Doc_1445986_186_200_Chemical))))))))) (. .)))
1445986	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_1445986_238_244_Disease)) (PP (IN while) (S (VP (VBG receiving) (NP (JJ intravenous) (NN Doc_1445986_273_282_Chemical)))))))))) (. .)))
1445986	3	(S1 (S (NP (JJ Doc_1445986_284_293_Chemical-dependent) (NNS antibodies)) (VP (AUX were) (VP (VBN detected) (PP (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN serum))) (CC and) (PP (IN in) (NP (NP (DT an) (NN eluate)) (VP (VBN prepared) (PP (IN from) (NP (PRP$ his) (JJ red) (NN blood) (NNS cells))))))))) (. .)))
1445986	4	(S1 (S (NP (DT The) (NN eluate)) (ADVP (RB also)) (VP (VBD reacted) (ADVP (RB weakly)) (PP (IN with) (NP (NP (JJ red) (NN blood) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_1445986_474_483_Chemical))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ concomitant) (NN formation)) (PP (IN of) (NP (JJ warm-reactive) (NNS autoantibodies))))))) (. .)))
1445986	5	(S1 (S (NP (DT These) (NNS observations)) (, ,) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ clinical) (CC and) (NN laboratory) (NN evidence)) (PP (IN of) (NP (JJ extravascular) (NNP Doc_1445986_645_654_Disease))))))) (, ,) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ drug-induced) (NN Doc_1445986_689_705_Disease)) (, ,) (VP (ADVP (RB possibly)) (VBG involving) (NP (DT both) (NN drug-adsorption) (CC and) (JJ autoantibody) (NN formation) (NNS mechanisms))))))) (. .)))
1445986	6	(S1 (S (NP (DT This) (NN case)) (VP (VBZ emphasizes) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (VBN increased) (NN awareness)) (PP (IN of) (NP (NP (JJ hemolytic) (NNS reactions)) (PP (TO to) (NP (DT all) (NNP Doc_1445986_870_884_Chemical))))))))) (. .)))
14633084	0	(S1 (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_14633084_7_20_Chemical))) (PP (IN with) (NP (NNP Doc_14633084_26_31_Chemical))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_14633084_54_64_Chemical-induced) (NNP Doc_14633084_73_93_Disease))))) (. .)))
14633084	1	(S1 (S (NP (NP (NN Doc_14633084_100_120_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14633084_122_124_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (VBG limiting) (NN side-effect)) (PP (IN of) (NP (NN chemotherapy))) (PP (IN with) (NP (NP (NNP Doc_14633084_173_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14633084_185_188_Chemical)) (-RRB- -RRB-)))))) (. .)))
14633084	2	(S1 (S (PP (IN In) (NP (NP (DT the) (NN study)) (VP (VBN presented) (ADVP (RB here))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_14633084_247_260_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_14633084_281_286_Chemical))))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_14633084_309_312_Chemical-induced) (NNP Doc_14633084_321_323_Disease))))))) (. .)))
14633084	3	(S1 (S (NP (NP (JJ Male) (JJ Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 150-200) (NNP g)) (: ;) (NP (NP (CD 6) (NNS rats)) (PP (IN per) (NP (NN group))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_14633084_409_414_Chemical) (CD 5) (NN min)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-))))) (PP (IN before) (NP (NP (CC and) (CD 2) (CC and) (CD 6)) (NP (NNP h)))) (PP (IN after) (NP (NP (-LRB- -LRB-) (JJ v.o.) (-RRB- -RRB-) (NN administration)) (PP (IN of) (NP (NNP Doc_14633084_480_483_Chemical))))))) (. .)))
14633084	4	(S1 (S (NP (NP (CD One)) (, ,) (NP (NP (QP (CD two) (CC or) (CD three)) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_512_517_Chemical))))) (VP (AUX were) (VP (VBN replaced) (PP (PP (IN with) (NP (NP (NNP Doc_14633084_537_550_Chemical)) (ADVP (RB alone)))) (CC or) (PP (IN with) (NP (NP (NNP Doc_14633084_565_578_Chemical)) (CC plus) (NP (NNP Doc_14633084_584_589_Chemical))))))) (. .)))
14633084	5	(S1 (S (NP (NN Doc_14633084_591_599_Disease)) (VP (AUX was) (VP (VBN evaluated) (NP (CD 24) (NNP h)) (PP (IN after) (NP (PRP$ its) (NN induction))) (PP (PP (IN by) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN bladder) (JJ wet) (NN weight))))) (CC and) (PP (IN by) (NP (NP (NN macroscopic)) (CC and) (NP (JJ microscopic) (NN analysis))))))) (. .)))
14633084	6	(S1 (S (NP (NP (NP (DT The) (NN replacement)) (PP (IN of) (NP (DT the) (JJ last) (NN dose)))) (CC or) (NP (NP (DT the) (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_14633084_788_793_Chemical)) (PP (IN with) (NP (NNP Doc_14633084_799_812_Chemical))))))) (VP (VBD reduced) (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN bladder) (JJ wet) (NN weight)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14633084_867_870_Chemical))) (PP (IN by) (NP (NP (CD 84.79) (NN %)) (CC and) (NP (CD 89.13) (NN %)) (, ,) (ADVP (RB respectively)))))))) (. .)))
14633084	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP it)) (ADVP (RB almost)) (VP (VBD abolished) (NP (NP (DT the) (JJ macroscopic) (CC and) (JJ microscopic) (NNS alterations)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14633084_995_998_Chemical)))))) (. .)))
14633084	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_14633084_1026_1039_Chemical))) (PP (TO to) (NP (NP (DT the) (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1065_1070_Chemical)))))) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ efficient)) (PP (IN than) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1110_1115_Chemical)))))) (ADVP (RB alone)) (SBAR (WHADVP (WRB when)) (S (VP (VBN evaluated) (ADVP (RB microscopically)))))) (. .)))
14633084	9	(S1 (S (NP (NP (NN Doc_14633084_1166_1179_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_14633084_1200_1205_Chemical)))) (VP (AUX was) (ADJP (JJ efficient)) (PP (IN in) (S (VP (VBG blocking) (NP (JJ Doc_14633084_1232_1235_Chemical-induced) (NNP Doc_14633084_1244_1246_Disease)))))) (. .)))
14633084	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN replacement)) (PP (IN of) (NP (NP (NP (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1294_1299_Chemical))) (PP (IN with) (NP (NN saline)))) (CC or) (NP (NP (DT all)) (PP (IN of) (NP (NP (DT the) (JJ Doc_14633084_1326_1331_Chemical) (NNS doses)) (PP (IN with) (NP (NNP Doc_14633084_1343_1356_Chemical))))))))) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NNP Doc_14633084_1373_1375_Disease)))) (. .)))
14648024	0	(S1 (NP (NP (JJ Doc_14648024_0_24_Chemical-induced) (NN Doc_14648024_33_49_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_14648024_67_95_Disease))))) (. .)))
14648024	1	(S1 (S (NP (NP (NN Doc_14648024_97_113_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_14648024_130_154_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14648024_156_160_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NNP Doc_14648024_166_194_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14648024_196_199_Disease)) (-RRB- -RRB-)))))) (VP (AUX is) (ADJP (RB very) (JJ rare))) (. .)))
14648024	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD four) (NNS patients)) (PP (IN with) (NP (NP (JJ classic) (NNP Doc_14648024_254_257_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_14648024_272_288_Disease)) (PP (IN during) (NP (JJ Doc_14648024_296_300_Chemical) (NN therapy)))))))))) (. .)))
14648024	3	(S1 (S (NP (NP (NNP Doc_14648024_310_315_Disease)) (CC and) (NP (NP (JJ subsequent) (NN multiple) (NNP Doc_14648024_340_347_Disease) (NNP Doc_14648024_348_368_Disease)) (PP (IN over) (NP (NNS extremities))))) (VP (VBD developed) (PP (IN on) (NP (NP (NNP D11)) (, ,) (NP (NNP D16)) (, ,) (NP (NNP D17)) (, ,) (CC and) (NP (NNP D19)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN after) (NP (JJ Doc_14648024_443_447_Chemical) (NN therapy)))) (. .)))
14648024	4	(S1 (S (NP (NP (DT The) (NN skin) (NN biopsy)) (VP (VBN taken) (PP (IN from) (NP (DT each) (NN patient))))) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_14648024_517_533_Disease))))) (. .)))
14648024	5	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD received) (NP (NP (JJ short) (NN course)) (PP (IN of) (NP (NNP Doc_14648024_573_581_Chemical))))) (. .)))
14648024	6	(S1 (S (S (NP (NN Doc_14648024_583_588_Disease)) (VP (VBD subsided) (ADVP (RB rapidly)))) (CC and) (S (NP (DT the) (NN skin) (NNS lesions)) (VP (VBD regressed) (ADVP (RB completely)))) (. .)))
14648024	7	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD achieved) (NP (JJ complete) (NN remission)) (PP (IN without) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_14648024_712_716_Chemical)))))) (. .)))
14648024	8	(S1 (S (NP (NN Doc_14648024_718_722_Chemical)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (ADJP (RBS most) (JJ possible)) (NN etiology)) (PP (IN of) (NP (NNP Doc_14648024_766_782_Disease))) (PP (IN in) (NP (PRP$ our) (NNS patients)))))))) (. .)))
14648024	9	(S1 (S (NP (NP (JJ Short-term) (NN use)) (PP (IN of) (NP (NNP Doc_14648024_818_825_Chemical)))) (VP (AUX is) (ADJP (RB very) (JJ effective) (PP (IN in) (NP (NNP Doc_14648024_847_851_Chemical-induced) (NNP Doc_14648024_860_876_Disease))))) (. .)))
14704468	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (DT some) (NNS convulsants))) (PP (IN on) (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NNP Doc_14704468_57_68_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS combinations)) (PP (IN with) (NP (NP (NP (NNP Doc_14704468_95_104_Chemical)) (CC or) (NP (NNP Doc_14704468_108_118_Chemical))) (PP (IN in) (NP (JJ amygdala-kindled) (NNS rats)))))))) (. .)))
14704468	1	(S1 (S (NP (NP (NN Doc_14704468_145_156_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBN exerted) (NP (DT a) (JJ significant) (JJ protective) (NN action)) (PP (IN in) (NP (JJ amygdala-kindled) (NNS rats))) (, ,) (S (VP (VBG reducing) (NP (DT both) (JJ Doc_14704468_247_254_Disease) (CC and) (JJ afterdischarge) (NNS durations))))) (. .)))
14704468	2	(S1 (S (NP (NP (DT The) (NNS combinations)) (PP (IN of) (NP (NP (NNP Doc_14704468_305_316_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_14704468_334_343_Chemical)) (, ,) (NP (NNP Doc_14704468_345_355_Chemical)) (, ,) (CC or) (NP (NP (NNP Doc_14704468_360_373_Chemical)) (PRN (-LRB- -LRB-) (VP (VBN applied) (PP (IN at) (NP (PRP$ their) (JJ subprotective) (NNS doses)))) (-RRB- -RRB-)))))) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ antiseizure) (NN effect)) (PP (IN in) (NP (DT this) (NN test)))) (. .)))
14704468	3	(S1 (S (ADVP (RB However)) (, ,) (NP (QP (RB only) (CD two)) (JJ first) (NNS combinations)) (VP (VBD occurred) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (JJ pharmacodynamic) (NN nature))))))) (. .)))
14704468	4	(S1 (S (PP (IN Among) (NP (JJ several) (NNS chemoconvulsants))) (, ,) (NP (NP (NNP Doc_14704468_572_583_Chemical) (, ,) (NNP Doc_14704468_585_609_Chemical) (CC and) (NNP Doc_14704468_614_624_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN opener)) (PP (IN of) (NP (JJ L-type) (NNP Doc_14704468_647_654_Chemical) (NNS channels)))) (-RRB- -RRB-))) (VP (VBD reversed) (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_14704468_701_712_Chemical)) (ADVP (RB alone))))) (CC and) (NP (NP (PRP$ its) (NN combination)) (PP (IN with) (NP (NNP Doc_14704468_744_753_Chemical)))))) (. .)))
14704468	5	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Doc_14704468_774_785_Chemical) (, ,) (NNP Doc_14704468_787_800_Chemical) (CC and) (NNP Doc_14704468_805_815_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (JJ anticonvulsive) (NN action)) (PP (IN of) (NP (NP (NNP Doc_14704468_855_866_Chemical)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_14704468_881_891_Chemical)))))))) (. .)))
14704468	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NNP Doc_14704468_960_971_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS combinations)) (PP (IN with) (NP (JJ other) (NNS antiepileptics))))) (VP (MD may) (VP (VB involve) (NP (NP (NN potentiation)) (PP (IN of) (NP (NP (JJ GABAergic) (NN neurotransmission) (CC and) (NN blockade)) (PP (IN of) (NP (NP (NNP L-type)) (PP (IN of) (NP (NNP Doc_14704468_1101_1108_Chemical) (NNS channels)))))))))))))) (. .)))
14736955	0	(S1 (S (NP (NP (JJ Mitochondrial) (NN DNA)) (CC and) (NP (PRP$ its) (JJ respiratory) (NN chain) (NNS products))) (VP (AUX are) (ADJP (JJ defective)) (PP (IN in) (NP (NNP Doc_14736955_70_81_Chemical) (NNP Doc_14736955_82_91_Disease)))) (. .)))
14736955	1	(S1 (S (NP (NN Doc_14736955_105_116_Chemical)) (VP (VBZ induces) (NP (NP (DT a) (JJ self-perpetuating) (NN Doc_14736955_145_156_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ early) (NNP Doc_14736955_180_221_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
14736955	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NNP Doc_14736955_269_289_Disease))) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT these) (NNS lesions))))))) (. .)))
14736955	3	(S1 (S (NP (NNS Rats)) (VP (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ intravenous) (NNP Doc_14736955_365_376_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN mg) (NN kg) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN week)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 7) (NNS weeks))))) (CC and) (VP (AUX were) (VP (VBN sacrificed) (ADVP (RB either) (NP (NP (NP (NP (CD 1) (NN week)) (PRN (-LRB- -LRB-) ('' ') (NP (NN short-term) (POS ')) (-RRB- -RRB-))) (CC or) (NP (NP (CD 30) (NNS weeks)) (PRN (-LRB- -LRB-) (: ') (ADJP (JJ long-term)) ('' ') (-RRB- -RRB-)))) (VP (VBG following) (NP (DT the) (JJ last) (NN dose)))))))) (. .)))
14736955	4	(S1 (S (NP (JJ Additional) (NNS rats)) (VP (VBD received) (NP (NP (NP (DT a) (JJ single) (NN dose)) (NP (QP (RB either) (CD 6)) (NNS days))) (CC or) (NP (NP (CD 2) (NNP h)) (ADVP (RB prior) (PP (TO to) (NP (NN euthanasia))))))) (. .)))
14736955	5	(S1 (S (NP (DT All) (NNS rats)) (VP (AUX were) (VP (VBN killed) (PP (IN at) (NP (NP (CD 48) (NNS weeks)) (PP (IN of) (NP (NN age))))))) (. .)))
14736955	6	(S1 (S (NP (NN Doc_14736955_634_663_Disease)) (VP (VP (AUX was) (VP (VBN monitored))) (CC and) (VP (VBD correlated) (PP (TO to) (NP (NP (DT the) (NN activity) (CC or) (NN expression)) (PP (IN of) (NP (JJ respiratory) (NN chain) (NNS components))))))) (. .)))
14736955	7	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBN quantified) (NP (NP (NP (DT both) (JJ nuclear) (CC and) (JJ mitochondrial) (NN DNA)) (PRN (-LRB- -LRB-) (NP (NN mtDNA)) (-RRB- -RRB-))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_14736955_833_843_Chemical) (NN production)) (CC and) (NP (NP (DT the) (CD 4834) (NN base) (NN pair) (POS ')) (JJ common) ('' ') (NN mtDNA) (NN deletion))))) (. .)))
14736955	8	(S1 (S (NP (DT The) (ADJP ('' ') (JJ long-term)) ('' ') (NN group)) (VP (AUX had) (NP (NP (JJ significant) (NN Doc_14736955_950_980_Disease)) (, ,) (NP (NP (JJ depressed) (NNS activities)) (PP (IN of) (NP (NP (JJ mtDNA-encoded) (JJ NADH) (NN dehydrogenase)) (CC and) (NP (NP (JJ cytochrome-c) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)))))) (CC and) (NP (VBN increased) (JJ Doc_14736955_1084_1091_Chemical) (NN synthase) (NN activity)))) (. .)))
14736955	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ mtDNA-encoded) (NNP COX)))) (VP (VBD subunit) (SBAR (S (S (NP (PRP I)) (VP (AUX was) (VP (VBN reduced)))) (CC and) (S (NP (NN mtDNA) (NNS levels)) (VP (AUX were) (VP (VBN decreased))))))) (. .)))
14736955	10	(S1 (S (PP (IN In) (NP (: ') (JJ short-term) ('' ') (NNS rats))) (, ,) (NP (EX there)) (VP (AUX were) (UCP (ADJP (RBR fewer) (JJ Doc_14736955_1254_1269_Disease)) (, ,) (CC but) (NP (NP (JJ similar) (NNS numbers)) (PP (IN of) (NP (JJ Doc_14736955_1294_1312_Disease) (NN activity)))))) (. .)))
14736955	11	(S1 (S (PP (IN Among) (NP (DT all) (NNS animals))) (, ,) (NP (NNP Doc_14736955_1342_1371_Disease)) (VP (AUX were) (ADVP (RB inversely)) (VP (VBN correlated) (PP (IN with) (NP (NP (NN mtDNA) (NNS levels)) (, ,) (NP (JJ mtDNA-encoded) (JJ respiratory) (NN chain) (NNS activities)) (CC and) (PP (IN with) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (JJ mtDNA-encoded) (NN respiratory) (NN chain))))) (NP (JJ subunit) (NNS COX-I)))))) (. .)))
14736955	12	(S1 (S (NP (NN Injury)) (VP (AUX was) (ADVP (RB positively)) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ Doc_14736955_1576_1586_Chemical) (NN production)) (CC and) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (JJ nucleus-encoded) (NN mitochondrial)) (CC or) (NP (JJ cytoplasmic) (NNS enzymes))))))))) (. .)))
14736955	13	(S1 (S (S (NP (NP (NNS Kidneys)) (PP (IN from) (NP (DT the) ('' ') (JJ long-term) ('' ') (NN group)))) (VP (VBD showed) (NP (JJR more) (NN mtDNA) (NNS deletions)) (PP (IN than) (PP (IN in))))) (: ') (S (NP (NP (JJ short-term) ('' ') (NNS animals)) (CC and) (NP (DT these))) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ other) (NNS groups)))))) (. .)))
14736955	14	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN for) (NP (JJ quantitative) (CC and) (JJ qualitative) (NN mtDNA) (NNS alterations)))) (PP (IN through) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (JJ mtDNA-encoded) (JJ respiratory) (NN chain) (NN function)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_14736955_2002_2012_Chemical))) (PP (IN in) (NP (NNP Doc_14736955_2016_2027_Chemical-induced) (NNP Doc_14736955_2036_2049_Disease))))))))) (. .)))
14742097	0	(S1 (NP (NP (DT A) (JJ randomized) (, ,) (JJ placebo-controlled) (, ,) (JJ crossover) (NN study)) (PP (IN of) (NP (NNP Doc_14742097_53_62_Chemical))) (PP (IN for) (NP (JJ SSRI-induced) (NN female) (NN Doc_14742097_87_105_Disease))) (. .)))
14742097	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_14742097_160_169_Chemical)) (, ,) (NP (NP (DT an) (ADJP (JJ alpha-) (CC and) (JJ beta-adrenergic)) (NN agonist)) (VP (ADVP (RB previously)) (VBN shown) (S (VP (TO to) (VP (VB enhance) (NP (NP (JJ genital) (NN blood) (NN flow)) (PP (IN in) (NP (NNS women))))))))) (, ,)) (VP (AUX has) (NP (JJ beneficial) (NNS effects)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ antidepressant-induced) (NN Doc_14742097_325_343_Disease)))))))))))) (. .)))
14742097	2	(S1 (S (NP (NNP Nineteen) (NNP Doc_14742097_354_376_Disease) (NNS women)) (VP (VBG receiving) (NP (DT either) (NNP Doc_14742097_400_410_Chemical) (, ,) (NNP Doc_14742097_412_422_Chemical))) (, ,) (CC or) (S (NP (NNP Doc_14742097_427_437_Chemical)) (VP (VBD participated) (PP (IN in) (NP (NP (DT an) (JJ eight-week) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ cross-over) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_14742097_538_547_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ self-report) (NNS measures)) (PP (IN of) (NP (NP (JJ sexual) (NN desire)) (, ,) (NP (NN arousal)) (, ,) (NP (NN orgasm)) (, ,) (CC and) (NP (JJ sexual) (NN satisfaction)))))))))))) (. .)))
14742097	3	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX were) (NP (NP (JJ significant) (NNS improvements)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NN baseline)) (PP (IN in) (NP (NP (JJ sexual) (NN desire)) (CC and) (NP (NN orgasm) (NN intensity/pleasure)))))))) (PP (IN on) (NP (NP (QP (CD 50) (CD mg)) (JJ Doc_14742097_762_771_Chemical) (NNS 1-hr)) (PP (ADVP (RB prior)) (TO to) (NP (JJ sexual) (NN activity)))))))) (, ,) (NP (NP (JJ significant) (NNS improvements)) (PP (PP (IN in) (NP (DT these) (NNS measures))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (JJ sexual) (NN arousal)) (CC and) (NP (JJ orgasmic) (NN ability)))))) (ADVP (RB also)) (VP (AUX were) (VP (VBN noted) (PP (IN with) (NP (NN placebo))))) (. .)))
14742097	4	(S1 (S (NP (DT These) (NNS findings)) (VP (VB highlight) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG conducting) (NP (JJ placebo-controlled) (NNS trials)) (PP (IN for) (NP (DT this) (NN condition)))))))) (. .)))
14745746	0	(S1 (SQ (AUX Does) (NP (NP (NN hormone) (NN therapy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14745746_42_55_Disease)))))) (VP (AUX have) (NP (DT a) (NN Doc_14745746_63_105_Disease))) (. ?)))
14745746	1	(S1 (FRAG (NP (DT A) (NN pilot) (NN study)) (. .)))
14745746	2	(S1 (S (NP (DT This) (NN pilot) (NN study)) (VP (VBZ examines) (SBAR (IN whether) (S (NP (NP (NN hormone) (NN therapy)) (PP (IN for) (NP (NNP Doc_14745746_176_189_Disease)))) (VP (VBZ affects) (NP (NN cognition)))))) (. .)))
14745746	3	(S1 (S (NP (NP (NNS Patients)) (VP (VBG participating) (PP (IN in) (NP (NP (NP (DT a) (JJ randomised) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_14745746_257_268_Chemical)) (, ,) (NP (NP (NNP Doc_14745746_270_279_Chemical)) (ADVP (RB alone))) (CC or) (NP (NP (JJ combined) (-LRB- -LRB-) (NNP ATAC) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD n=94)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NNS women)))))) (PP (IN without) (NP (NP (NNP Doc_14745746_341_354_Disease)) (PRN (-LRB- -LRB-) (NP (CD n=35)) (-RRB- -RRB-)))))) (VP (VBD completed) (NP (NP (DT a) (NN battery)) (PP (IN of) (NP (JJ neuropsychological) (NNS measures))))) (. .)))
14745746	4	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (NN control) (NN group)))) (, ,) (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN impaired) (PP (PP (IN on) (NP (NP (DT a) (NN processing) (NN speed) (NN task)) (PRN (-LRB- -LRB-) (NP (CD p=0.032)) (-RRB- -RRB-)))) (CC and) (PP (IN on) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (NP (JJ immediate) (JJ verbal) (NN memory)) (PRN (-LRB- -LRB-) (NP (CD p=0.026)) (-RRB- -RRB-))))))) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN hormone) (NN replacement) (NN therapy))) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
14745746	5	(S1 (S (NP (JJ Patient) (NN group) (NN performance)) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ related) (PP (TO to) (NP (NP (NP (NN length)) (PP (IN of) (NP (NN treatment)))) (CC or) (NP (NP (NNS measures)) (PP (IN of) (NP (JJ psychological) (NN morbidity)))))))) (. .)))
14745746	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (JJ specific) (NNS impairments)) (PP (IN in) (S (VP (VBG processing) (NP (NP (NP (NN speed)) (CC and) (NP (JJ verbal) (NN memory))) (PP (IN in) (NP (NP (NNS women)) (VP (VBG receiving) (NP (JJ hormonal) (NN therapy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14745746_896_909_Disease))))))))))))) (. .)))
14745746	7	(S1 (S (NP (JJ Verbal) (NN memory)) (VP (MD may) (VP (AUX be) (ADJP (RB especially) (JJ sensitive) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_14745746_967_976_Chemical) (NNS levels)) (, ,) (NP (NP (DT a) (NN finding)) (VP (ADVP (RB commonly)) (VBN reported) (PP (IN in) (NP (NP (NNS studies)) (PP (IN of) (NP (NN hormone) (NN replacement) (NN therapy))) (PP (IN in) (NP (JJ healthy) (NNS women)))))))))))))) (. .)))
14745746	8	(S1 (S (PP (IN In) (NP (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN use)) (PP (IN of) (NP (NN hormone) (NNS therapies))) (PP (IN in) (NP (DT an) (NN adjuvant)))))) (CC and) (NP (JJ preventative) (NN setting)))) (NP (NP (PRP$ their) (NN impact)) (PP (IN on) (NP (JJ cognitive) (NN functioning)))) (VP (MD should) (VP (AUX be) (VP (VBN investigated) (ADVP (RBR more) (RB thoroughly))))) (. .)))
14975762	0	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (CD p300)))) (VP (VBZ protects) (NP (NP (JJ cardiac) (NNS myocytes)) (PP (IN from) (NP (NP (NNS apoptosis)) (PP (IN in) (NP (NN vivo))))))) (. .)))
14975762	1	(S1 (S (NP (NN Doc_14975762_69_80_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ anti-Doc_14975762_92_97_Disease) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ represses) (NP (JJ cardiac-specific) (NN gene) (NN expression))) (CC and) (VP (VBZ induces) (NP (JJ myocardial) (NN cell) (NN apoptosis)))))))) (. .)))
14975762	2	(S1 (S (NP (NN Doc_14975762_191_202_Chemical)) (VP (VBZ depletes) (NP (NP (JJ cardiac) (NN p300)) (, ,) (NP (NP (DT a) (JJ transcriptional) (NN coactivator)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (DT the) (JJ differentiated) (NN phenotype)) (PP (IN of) (NP (JJ cardiac) (NNS myocytes)))))))))))))) (. .)))
14975762	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (CD p300))) (PP (IN in) (NP (NP (NN protection)) (PP (IN against) (NP (JJ Doc_14975762_394_405_Chemical-induced) (NNS apoptosis)))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
14975762	4	(S1 (S (NP (NP (NNP Transgenic) (NNS mice)) (VP (VBG overexpressing) (NP (CD p300)) (PP (IN in) (NP (DT the) (NN heart) (CC and) (NN wild-type) (NNS mice))))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (JJ Doc_14975762_522_533_Chemical) (NN treatment))))) (. .)))
14975762	5	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ wild-type) (NNS mice)))) (, ,) (NP (NNP transgenic) (NNS mice)) (VP (VBD exhibited) (NP (NP (JJR higher) (NN survival) (NN rate)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (JJR more) (VBN preserved) (JJ left) (NN ventricular) (NN function)) (CC and) (NP (JJ cardiac) (NN expression))) (PP (IN of) (NP (JJ alpha-sarcomeric) (NN actin)))))) (. .)))
14975762	6	(S1 (FRAG (NP (NP (JJ Doc_14975762_724_735_Chemical) (VBN induced) (JJ myocardial) (NN cell) (NN apoptosis)) (PP (IN in) (NP (JJ wild-type) (NNS mice)))) (CC but) (RB not) (PP (IN in) (NP (NNP transgenic) (NNS mice))) (. .)))
14975762	7	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (CD p300)))) (VP (VBD increased) (NP (NP (NP (DT the) (JJ cardiac) (NN level)) (PP (IN of) (NP (NP (NN bcl-2)) (CC and) (NP (NN mdm-2))))) (, ,) (CC but) (RB not) (NP (NP (DT that)) (PP (IN of) (NP (NN p53)))) (CC or) (NP (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (JJ bcl-2) (NN family)))))) (. .)))
14975762	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN overexpression)) (PP (IN of) (NP (CD p300)))) (VP (VP (VBZ protects) (NP (NP (JJ cardiac) (NNS myocytes)) (PP (IN from) (NP (JJ Doc_14975762_1027_1038_Chemical-induced) (NNS apoptosis))))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_14975762_1089_1102_Disease)) (PP (IN in) (NP (NP (NN adult) (NNS mice)) (PP (IN in) (NP (NN vivo))))))))))))) (. .)))
14982270	0	(S1 (NP (JJ Doc_14982270_0_11_Chemical-induced) (NN Doc_14982270_20_40_Disease) (. .)))
14982270	1	(S1 (S (NP (NN Doc_14982270_42_53_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (ADJP (RB widely) (JJ used)) (CC and) (ADJP (RB generally) (JJ well-tolerated))) (NN antithyroid) (NN agent))) (. .)))
14982270	2	(S1 (S (NP (DT A) (JJ 43-year-old) (NN woman)) (VP (AUX had) (NP (NP (JJ severe) (NN Doc_14982270_150_158_Disease)) (CC and) (NP (NNP Doc_14982270_163_170_Disease) (CD 1) (NN month))) (PP (IN after) (S (VP (VBG receiving) (NP (NP (NP (NNP Doc_14982270_195_206_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg)) (NN tid)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_14982270_223_234_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg)) (NN tid)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_14982270_264_279_Disease))))))))) (. .)))
14982270	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD continued) (NP (NN treatment)) (PP (IN for) (NP (DT another) (CD 4) (NNS days))) (PP (IN after) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_14982270_356_364_Disease))))) (SBAR (IN until) (S (NP (PRP she)) (VP (VBD finished) (NP (DT both) (NNS medications)))))) (. .)))
14982270	4	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN seen) (PP (IN at) (NP (DT the) (NN emergency) (NN department))) (ADVP (NP (CD 2) (NNS weeks)) (RB later))))) (, ,) (NP (PRP she)) (ADVP (RB still)) (VP (AUX had) (NP (JJ severe) (NN Doc_14982270_476_483_Disease)))) (, ,) (NP (NP (NNP Doc_14982270_485_493_Disease)) (, ,) (CC and) (NP (NNP Doc_14982270_499_517_Disease)) (, ,)) (VP (VBD formed) (NP (NP (RB mainly)) (PP (IN of) (NP (DT the) (JJ conjugated) (NN fraction))))) (. .)))
14982270	5	(S1 (S (S (NP (JJ Doc_14982270_561_572_Chemical-induced) (NN Doc_14982270_581_592_Disease)) (VP (AUX was) (VP (VBN diagnosed)))) (, ,) (CC and) (S (NP (JJ Doc_14982270_612_623_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN resumed)))) (. .)))
14982270	6	(S1 (S (PP (IN Over) (NP (DT the) (JJ following) (CD 9) (NNS days))) (, ,) (S (NP (DT the) (NNS symptoms)) (VP (VBN improved))) (CC and) (S (NP (NN plasma) (NN Doc_14982270_705_714_Chemical) (NNS levels)) (VP (AUX were) (ADVP (RB normal)) (PP (IN after) (NP (CD 12) (NNS weeks))) (PP (IN without) (NP (NNP Doc_14982270_757_768_Chemical))))) (. .)))
14982270	7	(S1 (S (PP (IN In) (NP (NP (JJ rare) (NNS cases)) (PP (IN within) (NP (NP (DT the) (JJ first) (JJ few) (NNS weeks)) (PP (IN of) (NP (NN therapy))))))) (, ,) (NP (DT this) (NN drug)) (VP (MD can) (VP (VB cause) (NP (ADJP (JJ severe) (CC and) (JJ reversible)) (NN Doc_14982270_865_885_Disease)))) (. .)))
14982270	8	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (NNS patients))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ adverse) (NN effect)))) (SBAR (IN so) (IN that) (S (, ,) (PP (IN upon) (NP (NN occurrence))) (, ,) (NP (PRP they)) (VP (MD can) (VP (VP (VB discontinue) (NP (JJ Doc_14982270_997_1008_Chemical) (NN therapy))) (CC and) (VP (VB avoid) (NP (JJ unnecessary) (NN invasive) (NNS procedures))))))))) (. .)))
15042318	0	(S1 (S (NP (NP (JJ Doc_15042318_0_19_Disease) (JJ following) (NN chemotherapy)) (PP (IN for) (NP (NN stage)))) (VP (VBP IIIE) (NP (JJ diffuse) (JJ large) (NNP B-cell) (NNP Doc_15042318_79_95_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_15042318_114_132_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15042318_134_152_Disease)) (-RRB- -RRB-))))))) (. .)))
15042318	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP describe) (NP (NP (DT the) (JJ unusual) (NN association)) (PP (IN between) (NP (NP (NP (NNP diffuse) (NNP B-cell) (NNP Doc_15042318_223_239_Disease) (CC and) (NNP Doc_15042318_244_262_Disease)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN form)) (PP (IN of) (NP (JJ adult) (NNP Doc_15042318_294_312_Disease)))) (, ,)) (CC and) (NP (JJ sudden) (NNP Doc_15042318_325_344_Disease))))) (PP (VBG following) (NP (NP (CD one) (NN cycle)) (PP (IN of) (NP (JJ Doc_15042318_368_379_Chemical-based) (NN chemotherapy))) (PP (IN in) (NP (DT the) (JJ same) (NN patient)))))) (. .)))
15042318	2	(S1 (S (NP (NP (NN Doc_15042318_420_439_Disease)) (CC or) (NP (JJ other) (NN Doc_15042318_449_468_Disease))) (VP (AUX are) (NP (NP (JJ unusual) (NNS complications)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN chemotherapy)))))))) (. .)))
15042318	3	(S1 (S (NP (NP (DT The) (NN Doc_15042318_538_554_Disease)) (VP (ADVP (RB intrinsically)) (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ aggressive) (NN chemotherapy)) (VP (VBN employed)))))) (VP (MD could) (VP (VB function) (PP (IN as) (NP (NP (DT a) (VBG triggering) (NN factor)) (PP (IN for) (NP (NP (DT the) (NNP Doc_15042318_668_678_Disease)) (PP (IN in) (NP (NP (DT the) (JJ predisposed) (NN myocardium)) (PP (IN of) (NP (DT this) (NN patient))))))))))) (. .)))
1504402	0	(S1 (S (VP (VBP Doc_1504402_0_16_Disease) (NP (JJ immune) (NN reaction)) (PP (IN as) (NP (NP (DT a) (NN mechanism)) (PP (IN for) (NP (NNP Doc_1504402_52_61_Chemical-associated) (NNP Doc_1504402_73_82_Disease)))))) (. .)))
1504402	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (JJ lymphocyte) (NN reactivity)) (PP (PP (TO to) (NP (NNP Doc_1504402_130_139_Chemical))) (CC and) (PP (TO to) (NP (NP (NN serum)) (VP (VBG containing) (NP (NP (JJ putative) (ADJP (FW ex) (FW vivo)) (JJ Doc_1504402_181_190_Chemical) (NNS antigens)) (CC or) (NP (NP (NNS metabolites)) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_1504402_228_237_Chemical-induced) (NNP Doc_1504402_246_258_Disease)))))))))))))) (. .)))
1504402	2	(S1 (NP (NP (DT A) (JJ 58-year-old) (NN woman)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_1504402_318_327_Chemical-induced) (NNP Doc_1504402_336_348_Disease))))) (. .)))
1504402	3	(S1 (S (NP (NP (JJ Peripheral) (NN blood) (NN mononuclear) (NNS cells)) (VP (VBN collected) (PP (IN from) (NP (DT the) (NN patient))))) (VP (AUX were) (VP (VBN cultured) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (NN solution)) (PP (IN of) (NP (NNP Doc_1504402_468_477_Chemical))))))) (PP (CONJP (CC and) (RB also)) (PP (IN with) (NP (NP (NNS sera)) (VP (VBN collected) (PP (IN from) (NP (NP (DT a) (NN volunteer)) (ADVP (IN before))))))) (CC and) (PP (IN after) (NP (JJ Doc_1504402_541_550_Chemical) (NN intake)))))) (. .)))
1504402	4	(S1 (S (NP (DT A) (JJ similar) (NN protocol)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (DT a) (JJ healthy) (NN subject))))))) (. .)))
1504402	5	(S1 (S (NP (DT No) (JJ lymphocyte) (NN proliferation)) (VP (AUX was) (VP (VBN observed) (PP (CC either) (PP (IN in) (NP (DT the) (NN patient))) (CC or) (PP (IN in) (NP (NP (DT the) (JJ healthy) (NN volunteer)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ Doc_1504402_752_761_Chemical) (NNS solutions)))))))))) (. .)))
1504402	6	(S1 (S (NP (NP (DT A) (JJ significant) (JJ proliferative) (NN response)) (PP (TO to) (NP (NN serum))) (VP (VBN collected) (PP (IN after) (NP (JJ Doc_1504402_835_844_Chemical) (NN intake))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (DT the) (NN patient))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ proliferative) (NN response)) (PP (TO to) (NP (NP (DT the) (NN serum)) (VP (VBN collected) (PP (IN before) (NP (DT the) (NN drug) (NN intake))))))))))) (. .)))
1504402	7	(S1 (S (NP (DT No) (NN reactivity)) (VP (AUX was) (VP (VBN found) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (DT the) (JJ healthy) (NN subject)))) (VP (AUX were) (VP (VBN tested) (PP (IN under) (NP (JJ similar) (NNS conditions))))))))) (. .)))
1504402	8	(S1 (S (NP (NP (DT The) (NN methodology)) (VP (VBN used))) (VP (VBD allowed) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ lymphocyte) (NN sensitization)))) (PP (TO to) (NP (NP (NNS sera)) (VP (VBG containing) (ADVP (FW ex)) (NP (JJ vivo-prepared) (JJ Doc_1504402_1204_1213_Chemical) (NNS antigens))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (DT an) (JJ immunologic) (NN mechanism)) (PP (IN in) (NP (JJ Doc_1504402_1282_1291_Chemical-induced) (NNP Doc_1504402_1300_1312_Disease))))))))) (. .)))
15075188	0	(S1 (S (NP (NP (JJ Increased) (NN expression)) (CC and) (NP (NN apical))) (VP (VBG targeting) (PP (IN of) (NP (NP (JJ renal) (JJ ENaC) (NNS subunits)) (PP (IN in) (NP (NP (NNP Doc_15075188_68_93_Chemical-induced) (NNP Doc_15075188_102_120_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
15075188	1	(S1 (S (NP (NN Doc_15075188_130_148_Disease)) (VP (AUX is) (ADVP (RB often)) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ Doc_15075188_173_179_Chemical) (NN retention)) (CC and) (NP (JJ generalized) (NN Doc_15075188_206_211_Disease)))))) (. .)))
15075188	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (DT the) (VBN decreased) (JJ renal) (JJ Doc_15075188_266_272_Chemical) (NN excretion)))) (VP (VBZ remains) (ADJP (JJ undefined))) (. .)))
15075188	3	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (JJ epithelial) (JJ Doc_15075188_334_336_Chemical) (NN channel)) (PRN (-LRB- -LRB-) (NP (NNP ENaC)) (-RRB- -RRB-))) (VP (VBP subunit) (SBAR (S (NP (NN dysregulation)) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (VBN increased) (NNP Doc_15075188_411_417_Chemical) (NN retention)))))))))))) (. .)))
15075188	4	(S1 (S (NP (NP (DT An) (JJ experimental) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15075188_476_501_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15075188_503_506_Chemical)) (: ;) (NP (CD 180) (NN mg/kg) (NNP iv))) (-RRB- -RRB-)))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN control) (NN group)) (VP (VBD received) (NP (JJ only) (NN vehicle))))))) (. .)))
15075188	5	(S1 (S (PP (IN After) (NP (CD 7) (NNS days))) (, ,) (NP (NP (NP (JJ Doc_15075188_586_589_Chemical) (NN treatment)) (VP (VBN induced) (NP (JJ significant) (NNP Doc_15075188_620_631_Disease)))) (, ,) (NP (NNP Doc_15075188_633_648_Disease)) (, ,)) (VP (VBD decreased) (NP (NP (JJ urinary) (JJ Doc_15075188_668_674_Chemical) (NN excretion)) (, ,) (CC and) (NP (JJ extensive) (NN Doc_15075188_700_707_Disease)))) (. .)))
15075188	6	(S1 (S (NP (NP (DT The) (NN protein) (NN abundance)) (PP (IN of) (NP (NN alpha-ENaC) (CC and) (NN beta-ENaC)))) (VP (VP (AUX was) (VP (VBN increased) (PP (PP (IN in) (NP (NP (DT the) (JJ inner) (NN stripe)) (PP (IN of) (NP (NP (DT the) (JJ outer) (NN medulla)) (PRN (-LRB- -LRB-) (NP (NNP ISOM)) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ inner) (NN medulla)) (PRN (-LRB- -LRB-) (NP (NNP IM)) (-RRB- -RRB-))))))) (CC but) (VP (AUX was) (RB not) (VP (VBN altered) (SBAR (IN in) (S (NP (DT the) (JJ cortex.) (JJ gamma-ENaC) (NN abundance)) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN cortex)) (, ,) (NP (NN ISOM)) (, ,) (CC and) (NP (NN IM))))))))))) (. .)))
15075188	7	(S1 (S (NP (NP (JJ Immunoperoxidase) (NN brightfield-)) (CC and) (NP (JJ laser-scanning) (JJ confocal) (NN fluorescence) (NN microscopy))) (VP (VBD demonstrated) (NP (NP (NP (VBN increased) (VBG targeting)) (PP (IN of) (NP (NN alpha-ENaC)))) (, ,) (NP (NN beta-ENaC)) (, ,) (CC and) (NP (JJ gamma-ENaC) (NNS subunits))) (PP (TO to) (NP (DT the) (JJ apical) (NN plasma) (NN membrane))) (PP (IN in) (NP (NP (DT the) (JJ distal) (JJ convoluted) (NN tubule)) (PRN (-LRB- -LRB-) (NP (NNP DCT2)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG connecting) (NP (NP (NN tubule)) (, ,) (CC and) (NP (JJ cortical) (CC and) (JJ medullary) (NN collecting) (NN duct) (NNS segments)))))) (. .)))
15075188	8	(S1 (S (NP (JJ Immunoelectron) (NN microscopy)) (ADVP (RB further)) (VP (VBD revealed) (NP (NP (DT an) (JJ increased) (VBG labeling)) (PP (IN of) (NP (NP (ADJP (JJ alpha-ENaC) (PP (IN in) (NP (NP (DT the) (JJ apical) (NN plasma) (NN membrane)) (PP (IN of) (NP (JJ cortical) (NN collecting)))))) (JJ duct) (NN principal) (NNS cells)) (PP (IN of) (NP (JJ Doc_15075188_1413_1416_Chemical-treated) (NNS rats)))))) (, ,) (S (VP (VBG indicating) (NP (NP (VBN enhanced) (NN apical) (VBG targeting)) (PP (IN of) (NP (JJ alpha-ENaC) (NNS subunits))))))) (. .)))
15075188	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN protein) (NNS abundances)) (PP (IN of) (NP (NP (NP (NP (NP (NNP Doc_15075188_1531_1533_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NP (JJ /Doc_15075188_1537_1538_Chemical) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NN exchanger) (NN type))) (NP (CD 3))) (PRN (-LRB- -LRB-) (NP (NNP NHE3)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_15075188_1567_1569_Chemical) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -Doc_15075188_1573_1574_Chemical) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -2Doc_15075188_1579_1581_Chemical) (-LRB- -LRB-) (LST (: -) (-RRB- -RRB-)) (NP (NN cotransporter)) (PRN (-LRB- -LRB-) (JJ BSC-1) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ Doc_15075188_1612_1620_Chemical-sensitive) (NNP Doc_15075188_1631_1633_Chemical) (PRN (-LRB- -LRB-) (NNP +) (-RRB- -RRB-)) (JJ -Doc_15075188_1637_1639_Chemical) (PRN (-LRB- -LRB-) (NP (: -) (-RRB- -RRB-) (NN cotransporter)) (-LRB- -LRB-) (NP (NNP TSC)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN decreased))) (. .)))
15075188	10	(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN abundance)) (PP (IN of) (NP (NP (DT the) (NN alpha) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (NN -subunit)) (PP (IN of) (NP (DT the) (NNP Doc_15075188_1734_1736_Chemical-Doc_15075188_1737_1738_Chemical-ATPase)))))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (DT the) (NN cortex) (CC and) (NN ISOM)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT the) (NN IM))))) (. .)))
15075188	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (ADJP (VBN increased) (CC or) (VBN sustained)) (NN expression)) (PP (IN of) (NP (NP (JJ ENaC) (NNS subunits)) (VP (VBN combined) (PP (IN with) (S (NP (VBN increased) (NN apical)) (VP (VP (VBG targeting) (PP (IN in) (NP (DT the) (NN DCT2)))) (, ,) (VP (VBG connecting) (NP (NN tubule))) (, ,) (CC and) (VP (VBG collecting) (NP (NN duct)))))))))) (VP (AUX are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15075188_2017_2023_Chemical) (NN retention)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_15075188_2050_2053_Chemical-induced) (NNP Doc_15075188_2062_2080_Disease))))))))))) (. .)))
15075188	12	(S1 (S (NP (NP (DT The) (VBN decreased) (NN abundance)) (PP (IN of) (NP (NP (NNP NHE3)) (, ,) (NP (NNP BSC-1)) (, ,) (NP (NNP TSC)) (, ,) (CC and) (NP (NNP Doc_15075188_2131_2133_Chemical-Doc_15075188_2134_2135_Chemical-ATPase))))) (VP (MD may) (VP (VB play) (NP (NP (DT a) (JJ compensatory) (NN role)) (SBAR (S (VP (TO to) (VP (VB promote) (NP (JJ Doc_15075188_2183_2189_Chemical) (NN excretion))))))))) (. .)))
15096016	0	(S1 (NP (NP (JJ Pallidal) (NN stimulation)) (: :) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (NN pallidotomy)))) (. ?)))
15096016	1	(S1 (S (NP (NP (DT A) (NN resurgence)) (PP (IN of) (NP (NP (NN interest)) (PP (IN in) (NP (NP (DT the) (JJ surgical) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_15096016_107_126_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15096016_128_130_Disease)) (-RRB- -RRB-))))))))) (VP (VBD came) (PP (IN with) (NP (NP (DT the) (NN rediscovery)) (PP (IN of) (NP (JJ posteroventral) (NN pallidotomy))) (PP (IN by) (NP (NP (NNP Laitinen)) (PP (IN in) (NP (CD 1985)))))))) (. .)))
15096016	2	(S1 (S (NP (NP (NNP Laitinen) (POS 's)) (NN procedure)) (VP (VBD improved) (NP (JJS most) (NNS symptoms)) (PP (IN in) (NP (NP (JJ drug-resistant) (NNP Doc_15096016_271_273_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD engendered) (NP (NP (JJ wide) (NN interest)) (PP (IN in) (NP (DT the) (JJ neurosurgical) (NN community)))))))))) (. .)))
15096016	3	(S1 (S (NP (NP (DT Another) (JJ lesioning) (NN procedure)) (, ,) (NP (JJ ventrolateral) (NN thalamotomy)) (, ,)) (VP (AUX has) (VP (VBN become) (NP (NP (DT a) (JJ powerful) (NN alternative)) (SBAR (S (VP (TO to) (VP (VB stimulate) (NP (DT the) (NN nucleus) (NN ventralis) (NN intermedius))))))) (, ,) (S (VP (VBG producing) (NP (NP (JJ high) (JJ long-term) (NN success) (NNS rates)) (CC and) (NP (JJ low) (NN morbidity) (NNS rates))))))) (. .)))
15096016	4	(S1 (S (NP (JJ Pallidal) (NN stimulation)) (VP (AUX has) (RB not) (VP (VBN met) (PP (IN with) (NP (DT the) (JJ same) (NN success))))) (. .)))
15096016	5	(S1 (S (PP (VBG According) (PP (TO to) (NP (DT the) (NN literature)))) (NP (NN pallidotomy)) (VP (VBZ improves) (NP (NP (DT the) (`` ``) (ADJP (RB on)) ('' '') (NNS symptoms)) (PP (IN of) (NP (NNP Doc_15096016_666_668_Disease))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_15096016_678_689_Disease)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (`` ``) (ADJP (RB off)) ('' '') (NNS symptoms)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_15096016_730_738_Disease)) (, ,) (NP (NNP Doc_15096016_740_752_Disease)) (, ,) (CC and) (NP (JJ on-off) (NNS fluctuations))))))))) (. .)))
15096016	6	(S1 (S (S (NP (JJ Pallidal) (NN stimulation)) (VP (VBZ improves) (NP (NP (NNP Doc_15096016_809_821_Disease)) (CC and) (NP (NNP Doc_15096016_826_834_Disease))) (PP (TO to) (NP (DT a) (JJ minor) (NN extent))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP$ its) (NN strength)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (PP (IN in) (S (VP (VBG improving) (NP (JJ Doc_15096016_901_909_Chemical-induced) (NN Doc_15096016_918_929_Disease)))))))))) (. .)))
15096016	7	(S1 (S (NP (NN Stimulation)) (ADVP (RB often)) (VP (VP (VBZ produces) (NP (NP (DT an) (NN improvement)) (PP (IN in) (NP (DT the) (JJ Doc_15096016_980_1000_Disease) (JJ upper) (NNS limbs))))) (, ,) (CC but) (VP (VBZ increases) (NP (NP (DT the) (`` ``) (NN freezing) ('' '') (NN phenomenon)) (PP (IN in) (NP (DT the) (JJR lower) (NNS limbs))) (PP (IN at) (NP (DT the) (JJ same) (NN time)))))) (. .)))
15096016	8	(S1 (S (S (VP (VBG Considering) (NP (NP (NP (DT the) (JJ small) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN independence)))) (, ,) (NP (NP (DT the) (JJ high) (NNS costs)) (PP (IN of) (NP (JJ bilateral) (NNS implants)))) (, ,) (CC and) (NP (NP (NP (DT the) (NN difficulty)) (JJS most) (NNS patients) (NN experience)) (PP (IN in) (S (VP (VBG handling) (NP (DT the) (NNS devices))))))))) (, ,) (NP (DT the) (NN question)) (VP (VBZ arises) (PP (IN as) (PP (TO to) (SBAR (IN whether) (S (NP (JJ bilateral) (JJ pallidal) (NN stimulation)) (VP (AUX is) (NP (NP (DT a) (JJ real) (NN alternative)) (PP (TO to) (NP (NN pallidotomy)))))))))) (. .)))
15266215	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (JJ cyclooxygenase-2) (JJ specific) (NN inhibitor) (JJ Doc_15266215_51_61_Chemical) (CC versus) (JJ nonsteroidal) (NN antiinflammatory) (NNS agents)))) (CC and) (NP (NN placebo))) (PP (IN on) (NP (NP (JJ cardiovascular) (JJ Doc_15266215_136_146_Disease) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15266215_171_180_Disease))))))) (. .)))
15266215	1	(S1 (S (NP (EX There)) (VP (AUX have) (VP (AUX been) (NP (NNS concerns) (SBAR (IN that) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ cardiovascular) (JJ Doc_15266215_239_249_Disease) (NNS events)))) (VP (MD may) (VP (AUX be) (ADJP (ADJP (JJR higher) (PP (IN with) (NP (JJ cyclooxygenase) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)) (JJ -2-specific) (NNS inhibitors)))) (PP (IN than) (NP (NP (JJ nonselective) (JJ nonsteroidal) (NN antiinflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-)))))))))))) (. .)))
15266215	2	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (JJ cardiovascular) (NN event) (NNS data)) (PP (IN for) (NP (NP (NNP Doc_15266215_426_436_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (JJ COX-2-specific) (NN inhibitor)) (PP (IN in) (NP (QP (RB approximately) (CD 8000)) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_15266215_505_519_Disease) (CC and) (NNP Doc_15266215_524_544_Disease)) (VP (VBN treated) (PP (IN with) (NP (NP (DT this) (NN agent)) (PP (IN in) (NP (JJ randomized) (JJ clinical) (NNS trials))))))))))))) (. .)))
15266215	3	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ cardiovascular) (JJ Doc_15266215_632_642_Disease) (NNS events)) (PRN (-LRB- -LRB-) (NP (NP (JJ cardiac)) (, ,) (NP (NP (NN cerebrovascular)) (CC and) (NP (JJ peripheral) (NN vascular))) (, ,) (CC or) (NP (JJ arterial) (NNP Doc_15266215_713_723_Disease))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (S (VP (VBG analyzing) (NP (NP (NP (VBN pooled) (NNP Doc_15266215_760_770_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-80) (CD mg)) (NN daily)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ nonselective) (NN NSAID)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15266215_809_819_Chemical) (CD 75) (NN mg) (NN bid)) (, ,) (NP (NP (NNP Doc_15266215_831_840_Chemical) (CD 800) (NN mg) (NN tid)) (, ,) (CC or) (NP (NNP Doc_15266215_856_864_Chemical) (CD 500) (NN mg) (NN bid))) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo) (NNS data)) (PP (IN from) (NP (CD 10) (JJ randomized) (NNP Doc_15266215_913_927_Disease) (CC and) (NNP Doc_15266215_932_952_Disease) (NNS trials))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (NP (JJ 6-52) (NNS weeks)) (PP (IN in) (NP (NN duration))))))))))))) (. .)))
15266215	4	(S1 (S (NP (NP (DT The) (NN incidence) (NNS rates)) (PP (IN of) (NP (NNS events)))) (VP (AUX were) (VP (VBN determined) (PP (PP (IN in) (NP (NP (DT all) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7934)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (NP (NNS users)) (PP (IN of) (NP (NP (JJ low-dose) (PRN (-LRB- -LRB-) (NP (QP (CD <) (CC or) (CD =325) (CD mg)) (NN daily)) (-RRB- -RRB-)) (NNP Doc_15266215_1113_1120_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1051)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS nonusers)) (PP (IN of) (NP (NP (NNP Doc_15266215_1148_1155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6883)) (-RRB- -RRB-)))))))))) (. .)))
15266215	5	(S1 (S (NP (NP (JJ Crude) (CC and) (JJ exposure-adjusted) (NNS incidences)) (PP (IN of) (NP (JJ Doc_15266215_1210_1220_Disease) (NNS events)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (NNP Doc_15266215_1245_1255_Chemical)) (, ,) (NP (NNP NSAIDs)) (, ,) (CC and) (NP (NN placebo)))))) (. .)))
15266215	6	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (JJ serious) (JJ Doc_15266215_1298_1308_Disease) (NNS events)))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ similar)) (PP (IN for) (NP (DT each) (JJ Doc_15266215_1342_1352_Chemical) (NN dose)))) (. .)))
15266215	7	(S1 (S (NP (NN Doc_15266215_1359_1369_Disease) (NN risk)) (VP (AUX was) (ADJP (ADJP (RB consistently) (JJR higher) (PP (IN for) (NP (NP (NNS users)) (PP (IN of) (NP (JJ Doc_15266215_1412_1419_Chemical) (NNS users)))))) (PP (IN than) (NP (NP (NNS nonusers)) (PP (IN of) (NP (NP (NNP Doc_15266215_1443_1450_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (, ,) (NP (NP (NP (NP (QP (CD 1.4) (NN %) (CC vs.) (CD 0) (NN %))) (: ;) (NP (NP (NNP Doc_15266215_1474_1484_Chemical)) (, ,) (NP (NP (CD 1.7) (NN %)) (CC vs.) (NP (CD 0.2) (NN %)))) (: ;)) (ADVP (RB NSAIDs))) (, ,) (NP (CD 1.9) (NN %)) (CC vs.) (NP (CD 0.5) (NN %)))) (-RRB- -RRB-)))))))) (. .)))
15266215	8	(S1 (S (NP (NP (DT The) (NNS rates)) (PP (IN of) (NP (NNS events))) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_15266215_1557_1564_Chemical)))))) (VP (AUX were) (ADJP (JJ similar) (PP (PP (IN for) (NP (DT all) (CD 3) (NN treatment) (NNS groups))) (CC and) (PP (IN across) (NP (JJ Doc_15266215_1616_1626_Chemical) (NNS doses)))))) (. .)))
15266215	9	(S1 (S (NP (NP (NN Short-)) (CC and) (NP (NP (JJ intermediate-term) (NN treatment)) (PP (IN with) (NP (NP (NP (JJ therapeutic)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 20)) (NN mg) (NN daily)) (-RRB- -RRB-))) (CC and) (NP (JJ supratherapeutic) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (CC or) (CD 80)) (NN mg) (NN daily)) (-RRB- -RRB-)) (JJ Doc_15266215_1751_1761_Chemical) (NNS doses)))))) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_15266215_1818_1828_Disease) (NNS events)) (ADJP (JJ relative) (PP (TO to) (NP (NP (JJ nonselective) (NNS NSAIDs)) (CC or) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (NNP Doc_15266215_1882_1896_Disease) (CC and) (NNP Doc_15266215_1901_1921_Disease) (NNS patients)) (PP (IN in) (NP (JJ controlled) (JJ clinical) (NNS trials))))))))))))))) (. .)))
15266362	0	(S1 (S (NP (NNP Doc_15266362_0_16_Disease) (NNP Doc_15266362_17_28_Disease)) (VP (VBD complicating) (NP (JJ Doc_15266362_42_69_Disease) (NN heart))) (. .)))
15266362	1	(S1 (S (NP (DT The) (JJ present) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_15266362_116_140_Disease) (NN complicating) (NN Doc_15266362_154_181_Disease))))) (. .)))
15266362	2	(S1 (S (NP (NP (DT The) (JJ 47-year-old) (NN female) (NN patient)) (, ,) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_15266362_229_256_Disease)))))) (, ,)) (VP (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NNP Doc_15266362_276_297_Disease))))) (CC and) (VP (VBD managed) (ADVP (RB aggressively)) (PP (IN with) (NP (NP (JJ Doc_15266362_328_338_Chemical) (NN infusion)) (CC and) (NP (JJ other) (NNS drugs)))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN assessed) (PP (IN for) (NP (NN heart) (NN transplantation))))))))) (. .)))
15266362	3	(S1 (S (PP (IN On) (NP (JJ transthoracic) (NN echocardiogram))) (, ,) (NP (PRP she)) (VP (AUX had) (NP (JJ moderate) (NN Doc_15266362_462_490_Disease)) (PP (IN with) (NP (NP (JJ regional) (NN variability)) (CC and) (NP (JJ moderate) (NN Doc_15266362_530_550_Disease))))) (. .)))
15266362	4	(S1 (S (NP (NP (DT The) (NN recipient) (POS 's)) (NN heart)) (VP (VBD showed) (NP (NP (DT the) (NNS features)) (PP (IN of) (NP (JJ apical) (NNP Doc_15266362_604_631_Disease) (CC and) (NNP Doc_15266362_636_647_Disease))) (PP (IN with) (NP (JJ abundant) (NNS eosinophils))))) (. .)))
15266362	5	(S1 (S (S (NP (NN Doc_15266362_675_686_Disease)) (VP (AUX is) (ADJP (JJ rare)))) (CC and) (S (NP (NNP Doc_15266362_699_723_Disease)) (VP (AUX is) (NP (NN rarer)))) (. .)))
15266362	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (DT the) (NNP Doc_15266362_756_772_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_15266362_774_786_Disease)) (-RRB- -RRB-)) (NNP Doc_15266362_788_799_Disease)) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (JJ Doc_15266362_815_825_Chemical) (NN infusion) (NN therapy)))))))) (. .)))
15266362	7	(S1 (S (NP (NNP Doc_15266362_844_868_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (CD 2.4) (NN %))) (PP (TO to) (NP (CD 7.2) (NN %))))) (PP (IN in) (NP (VBN explanted) (NNS hearts)))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (JJ multidrug) (NN therapy))))))) (. .)))
15276120	0	(S1 (NP (NP (NN Time) (NNS trends)) (PP (IN in) (NP (NNP Doc_15276120_15_23_Chemical-associated) (NNP Doc_15276120_35_45_Disease))) (. .)))
15276120	1	(S1 (S (NP (NP (DT The) (JJ annual) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_15276120_71_79_Chemical-related) (NNP Doc_15276120_88_96_Disease)) (PP (IN at) (NP (NP (NNP Brigham) (CC and) (NNP Women) (POS 's)) (NNP Hospital)))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.97/1,000) (JJ patient) (NNS admissions))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN time) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (NNP January) (CD 1995)) (PP (TO to) (NP (NNP October) (CD 1998)))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 1.19/1,000) (JJ patient) (NNS admissions)) (PP (IN in) (NP (NP (DT the) (JJ second) (NN time) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (NNP November) (CD 1998)) (PP (TO to) (NP (NNP August) (CD 2002)))) (-RRB- -RRB-)) (PP (IN of) (NP (DT this) (NN study)))))))) (. .)))
15276120	2	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ major) (CC and) (NNP Doc_15276120_377_398_Disease)))))) (VP (VBD increased) (PP (IN from) (NP (NP (CD 20.2) (NN %)) (CC and) (NP (CD 1.9) (NN %)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (DT the) (JJ first) (NN time) (NN period))) (, ,) (PP (TO to) (NP (NP (NP (CD 33.3) (NN %)) (CC and) (NP (CD 7.8) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN in) (NP (DT the) (JJ second)))))) (. .)))
1535072	0	(S1 (NP (NP (JJ Doc_1535072_0_9_Chemical) (NN treatment)) (PP (IN of) (NP (NNP Doc_1535072_23_42_Disease))) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1535072_54_63_Chemical) (JJ reuptake) (NNS blockers)))) (. .)))
1535072	1	(S1 (S (NP (JJ Preclinical) (CC and) (JJ clinical) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1535072_141_150_Chemical)) (VP (VP (VBZ facilitates) (NP (JJ sexual) (NN behavior))) (CC and) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_1535072_218_232_Disease))))))))))) (. .)))
1535072	2	(S1 (S (NP (DT A) (JJ single) (NN case) (NN report)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_1535072_269_278_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (DT the) (NN Doc_1535072_304_323_Disease)) (PP (IN of) (NP (NN Doc_1535072_327_339_Chemical))))))))))))) (. .)))
1535072	3	(S1 (S (NP (DT This) (NN study)) (VP (VBN evaluated) (NP (NNP Doc_1535072_362_371_Chemical)) (PP (IN as) (NP (NP (DT a) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NNP Doc_1535072_395_414_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ Doc_1535072_425_434_Chemical) (JJ reuptake) (NNS blockers))))))))) (. .)))
1535072	4	(S1 (S (NP (NP (CD Six) (NNS patients)) (PP (IN with) (NP (NP (DT either) (NNP Doc_1535072_487_516_Disease)) (, ,) (NP (NNP Doc_1535072_518_534_Disease)) (, ,) (NP (NNP Doc_1535072_536_543_Disease)) (, ,) (CC or) (NP (NNP Doc_1535072_548_567_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (NNP Doc_1535072_581_600_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (JJ Doc_1535072_622_631_Chemical) (NN reuptake) (NNS blockers))))))) (VP (AUX were) (VP (VBN given) (NP (NNP Doc_1535072_661_670_Chemical)) (PP (IN on) (NP (NP (DT a) (JJ p.r.n.) (NN basis)) (PP (IN in) (NP (DT an) (JJ open) (JJ clinical) (NN trial))))))) (. .)))
1535072	5	(S1 (S (NP (NP (JJ Various) (NNS doses)) (PP (IN of) (NP (NNP Doc_1535072_733_742_Chemical)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ ideal) (NN dose)) (PP (IN for) (NP (DT each) (NN patient))))))))) (. .)))
1535072	6	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (DT the) (CD six) (NNS patients)))) (VP (VBD experienced) (NP (VBN improved) (JJ sexual) (NN functioning)) (PP (IN after) (S (VP (VBG taking) (NP (NN Doc_1535072_886_895_Chemical)))))) (. .)))
1535072	7	(S1 (S (NP (NP (CD One) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD failed) (S (VP (TO to) (VP (VB comply) (PP (IN with) (NP (JJ Doc_1535072_935_944_Chemical) (NN treatment)))))))))) (VP (AUX had) (NP (DT no) (JJ therapeutic) (NNS effects))) (. .)))
1535072	8	(S1 (S (NP (NP (JJ Side) (NNS effects)) (PP (IN of) (NP (NNP Doc_1535072_999_1008_Chemical)))) (VP (VBD included) (NP (NP (JJ excessive) (NN sweating)) (, ,) (NP (JJ increased) (NN Doc_1535072_1048_1055_Disease)) (, ,) (CC and) (NP (NP (DT a) (JJ wound-up) (NN feeling)) (PP (IN in) (NP (DT some) (NNS patients)))))) (. .)))
1535072	9	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_1535072_1150_1159_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NNP Doc_1535072_1198_1217_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ Doc_1535072_1228_1237_Chemical) (JJ reuptake) (NNS blockers)))))))))))) (. .)))
1535072	10	(S1 (S (NP (JJ Future) (JJ controlled) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (ADVP (RB further)) (VB investigate) (NP (NP (NP (DT the) (NN effectiveness)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NNP Doc_1535072_1349_1358_Chemical))) (PP (IN for) (NP (DT this) (NN indication))))))))) (. .)))
1545575	0	(S1 (S (VP (VB Doc_1545575_0_20_Disease) (S (VP (VBG complicating) (NP (NN bone) (NN marrow) (NN transplantation))))) (. .)))
1545575	1	(S1 (S (NP (NN Doc_1545575_63_83_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ serious)) (NN complication)) (PP (IN of) (NP (NP (JJ high-dose) (JJ Doc_1545575_135_151_Chemical) (NN therapy)) (VP (VBN administered) (PP (IN before) (NP (NN bone) (NN marrow) (NN transplantation)))))))) (. .)))
1545575	2	(S1 (S (PP (IN As) (NP (NP (JJ standard) (NN practice)) (PP (IN at) (NP (PRP$ our) (NN institution))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN scheduled) (S (VP (TO to) (VP (VB receive) (NP (DT a) (NN bone) (NN marrow) (NN transplant)))))))))) (VP (AUX are) (VP (VBN treated) (ADVP (RB prophylactically)) (PP (IN with) (NP (NP (JJ forced) (NN hydration)) (CC and) (NP (NN bladder) (NN irrigation)))))) (. .)))
1545575	3	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB obviate) (NP (NP (DT the) (NN inconvenience)) (PP (IN of) (NP (NN bladder) (NN irrigation))))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (NN feasibility) (NN trial)) (PP (IN of) (NP (NN uroprophylaxis))) (PP (IN with) (NP (NP (NNP Doc_1545575_510_515_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ neutralizes) (NP (NP (DT the) (JJ hepatic) (NN metabolite)) (PP (IN of) (NP (NNP Doc_1545575_561_577_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBZ causes) (NP (NN Doc_1545575_590_610_Disease))))))))))))) (. .)))
1545575	4	(S1 (S (PP (IN Of) (NP (NP (CD 97) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ standard) (NN prophylaxis))))))) (, ,) (NP (CD 4)) (VP (AUX had) (NP (JJ symptomatic) (NN Doc_1545575_680_700_Disease))) (. .)))
1545575	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (CD two)) (PP (IN of) (NP (CD four) (JJ consecutive) (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ Doc_1545575_761_766_Chemical) (NN uroprophylaxis)) (PP (IN before) (NP (JJ allogeneic) (NN bone) (NN marrow) (NN transplantation))))))) (VP (AUX had) (NP (NP (JJ severe) (NN Doc_1545575_839_859_Disease)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 2)) (NNS weeks))))) (. .)))
1545575	6	(S1 (S (PP (IN Because) (IN of) (NP (DT this) (JJ suboptimal) (NN result))) (, ,) (NP (PRP we)) (VP (VP (VBD resumed) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN bladder) (NN irrigation))))) (CC and) (VP (VBD forced) (NP (NN hydration)) (S (VP (TO to) (VP (VB minimize) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_1545575_1003_1023_Disease))))))))) (. .)))
15517007	0	(S1 (S (NP (NP (NN Consensus) (NN statement)) (VP (VBG concerning) (NP (NNP Doc_15517007_31_45_Disease)))) (VP (VBG occurring) (PP (IN during) (NP (NP (JJ haematopoietic) (NN stem) (NN cell) (NN transplantation)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_15517007_124_143_Disease))))))) (, ,) (PP (IN with) (NP (NP (JJ special) (NN reference)) (PP (TO to) (NP (NP (NNP Doc_15517007_171_189_Disease)) (CC and) (NP (NNP Doc_15517007_194_212_Disease))))))) (. .)))
15517007	1	(S1 (S (NP (JJ Autologous) (JJ haematopoietic) (NN stem) (NN cell) (NN transplantation)) (VP (AUX is) (ADVP (RB now)) (NP (NP (DT a) (ADJP (JJ feasible) (CC and) (JJ effective)) (NN treatment)) (PP (IN for) (NP (NP (JJ selected) (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_15517007_342_361_Disease))))))) (. .)))
15517007	2	(S1 (S (ADVP (NNP Worldwide)) (, ,) (NP (QP (IN over) (CD 650)) (NNS patients)) (VP (AUX have) (VP (AUX been) (VP (VBN transplanted) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (NN phase) (NN I)) (CC and) (NP (NNP II) (JJ clinical) (NNS trials))))))))) (. .)))
15517007	3	(S1 (S (NP (DT The) (NNS results)) (VP (AUX are) (ADJP (JJ encouraging) (RB enough) (S (VP (TO to) (VP (VB begin) (NP (JJ randomised) (NN phase) (NNP III) (NNS trials))))))) (. .)))
15517007	4	(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN as) (S (VP (VBN predicted)))) (, ,) (NP (NP (JJ significant) (JJ transplant-related) (NN morbidity)) (CC and) (NP (NN mortality))) (VP (AUX have) (VP (AUX been) (VP (VBN observed)))) (. .)))
15517007	5	(S1 (S (NP (DT This)) (VP (AUX is) (ADVP (RB primarily)) (ADJP (JJ due) (PP (PP (TO to) (NP (NP (NNS complications)) (VP (VBN related) (PP (TO to) (NP (NP (RB either) (DT the) (NN stage)) (PP (IN of) (NP (DT the) (NN disease))))) (PP (IN at) (NP (NN transplant)))))) (CC or) (RB due) (PP (TO to) (NP (NNP Doc_15517007_742_752_Disease)))))) (. .)))
15517007	6	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NNS deaths)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_15517007_786_802_Disease))))))) (VP (AUX is) (ADJP (JJ low))) (. .)))
15517007	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NN caution)) (VP (AUX is) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_15517007_845_861_Chemical) (CC or) (NNP Doc_15517007_865_879_Chemical)) (PP (JJ such) (IN as) (NP (NNP Doc_15517007_888_900_Chemical)))) (VP (AUX are) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (DT a) (JJ possible) (JJ underlying) (NN Doc_15517007_949_961_Disease))))) (, ,) (PP (IN for) (NP (NN example))) (, ,) (NP (NNP Doc_15517007_976_994_Disease) (NNS patients)))))))) (. .)))
15517007	8	(S1 (S (PP (IN In) (NP (NNP November) (CD 2002))) (, ,) (NP (DT a) (NN meeting)) (VP (AUX was) (VP (VBN held) (PP (IN in) (NP (NNP Florence))) (, ,) (S (VP (VBG bringing) (ADVP (RB together)) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS experts)) (PP (IN in) (NP (JJ various) (NNS fields))))) (, ,) (PP (VBG including) (NP (NN rheumatology) (, ,) (NN cardiology) (, ,) (NN neurology) (, ,) (NN pharmacology) (CC and) (NN transplantation) (NN medicine)))))))) (. .)))
15517007	9	(S1 (S (NP (NP (DT The) (NN object)) (PP (IN of) (NP (DT the) (NN meeting)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB analyse) (NP (NP (JJ existing) (NNS data)) (, ,) (ADJP (DT both) (JJ published) (CC or) (JJ available)) (, ,) (PP (IN in) (NP (DT the) (NNP European) (NNP Group))) (PP (IN for) (NP (NP (NNP Blood)) (CC and) (NP (NNP Marrow) (NNP Transplantation) (NNP Doc_15517007_1346_1364_Disease) (NN database))))))) (, ,) (CC and) (VP (TO to) (VP (VB propose) (NP (NP (DT a) (JJ safe) (NN approach)) (PP (TO to) (NP (JJ such) (NNS patients))))))))) (. .)))
15517007	10	(S1 (S (NP (NP (DT A) (JJ full) (JJ cardiological) (NN assessment)) (PP (IN before) (CC and) (IN during) (NP (DT the) (NN transplant)))) (VP (VBD emerged) (PP (IN as) (NP (DT the) (JJ major) (NN recommendation)))) (. .)))
15531665	0	(S1 (SQ (AUX Does) (NP (JJ supplemental) (JJ Doc_15531665_18_27_Chemical) (NN increase)) (VP (VBP Doc_15531665_37_59_Disease) (NP (NN risk)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_15531665_79_87_Disease)))))) (. ?)))
15531665	1	(S1 (S (S (NP (NN Doc_15531665_101_110_Chemical)) (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ potent) (NN antioxidant))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (MD can) (ADVP (RB also)) (VP (AUX be) (NP (NP (DT a) (NN prooxidant)) (CC and) (NP (JJ glycate) (NN protein))) (PP (IN under) (NP (JJ certain) (NNS circumstances))) (PP (IN in) (NP (NN vitro)))))) (. .)))
15531665	2	(S1 (S (NP (DT These) (NNS observations)) (VP (VBD led) (NP (PRP us)) (S (VP (TO to) (VP (VB hypothesize) (SBAR (IN that) (S (NP (NP (DT a) (JJ high) (NN intake)) (PP (IN of) (NP (NNP Doc_15531665_299_308_Chemical))) (PP (IN in) (NP (JJ Doc_15531665_312_320_Disease) (NNS persons)))) (VP (MD might) (VP (VB promote) (NP (NNP Doc_15531665_343_358_Disease)))))))))) (. .)))
15531665	3	(S1 (S (NP (DT The) (NN objective)) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_15531665_421_430_Chemical) (NN intake)) (CC and) (NP (NP (NN mortality)) (PP (IN from) (NP (NNP Doc_15531665_457_479_Disease))))))))))) (. .)))
15531665	4	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_15531665_521_530_Chemical) (NN intake)) (CC and) (NP (NN mortality))))) (PP (IN from) (NP (NP (NP (JJ total) (NNP Doc_15531665_563_585_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 281)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_15531665_597_620_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 175)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_15531665_636_642_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 57)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (CD 1923) (JJ postmenopausal) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (S (VP (AUXG being) (ADJP (JJ Doc_15531665_700_708_Disease)) (PP (IN at) (NP (NN baseline))))))))))) (. .)))
15531665	5	(S1 (S (S (S (NP (NNP Diet)) (VP (AUX was) (VP (VBN assessed) (PP (IN with) (NP (NP (DT a) (JJ food-frequency) (NN questionnaire)) (PP (IN at) (NP (NN baseline)))))))) (, ,) (CC and) (S (NP (NP (NNS subjects)) (ADJP (RB initially) (JJ free) (PP (IN of) (NP (NNP Doc_15531665_820_843_Disease))))) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN followed) (PP (IN for) (NP (CD 15) (NNP y.) (NNS RESULTS))))))) (: :) (S (PP (IN After) (NP (NP (NN adjustment)) (PP (IN for) (NP (NNP Doc_15531665_912_934_Disease) (NN risk) (NNS factors))))) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (NNP Doc_15531665_957_965_Disease) (NN medication)))) (VP (VP (VBD used)) (, ,) (NP (NP (NP (NN duration)) (PP (IN of) (NP (NNP Doc_15531665_995_1003_Disease)))) (, ,) (CC and) (NP (NP (NNS intakes)) (PP (IN of) (NP (NNP Doc_15531665_1020_1026_Chemical) (, ,) (NNP Doc_15531665_1028_1037_Chemical) (, ,) (CC and) (NNP Doc_15531665_1043_1056_Chemical)))) (, ,) (SBAR (S (NP (NP (DT the) (VBN adjusted) (JJ relative) (NNS risks)) (PP (IN of) (NP (JJ total) (NNP Doc_15531665_1095_1117_Disease) (NN mortality)))) (VP (AUX were) (NP (CD 1.0) (, ,) (CD 0.97) (, ,) (CD 1.11) (, ,) (CD 1.47) (, ,) (CC and) (CD 1.84)) (PRN (-LRB- -LRB-) (NP (NP (NNP P)) (PP (IN for) (NP (NN trend)))) (NP (NNP <) (CD 0.01)) (-RRB- -RRB-)) (PP (IN across) (NP (NP (NNS quintiles)) (PP (IN of) (NP (NP (JJ total) (JJ Doc_15531665_1212_1221_Chemical) (NN intake)) (PP (IN from) (NP (NN food) (CC and) (NNS supplements))))))))))))) (. .)))
15531665	6	(S1 (S (S (NP (NP (VBN Adjusted) (JJ relative) (NNS risks)) (PP (IN of) (NP (NNP Doc_15531665_1283_1306_Disease)))) (VP (AUX were) (NP (CD 1.0)))) (, ,) (NP (NP (CD 0.81) (, ,) (CD 0.99) (, ,) (CD 1.26) (, ,) (CC and) (CD 1.91) (-LRB- -LRB-) (NN P)) (PP (IN for) (NP (NN trend)))) (VP (SYM =) (NP (CD 0.01)) (-RRB- -RRB-) (PP (CC and) (PP (IN of) (NP (NNP Doc_15531665_1372_1378_Disease) (AUX were) (CD 1.0) (, ,) (CD 0.52) (, ,) (CD 1.23) (, ,) (CD 2.22) (, ,) (CC and) (CD 2.57))) (PRN (-LRB- -LRB-) (VP (VBN P) (PP (IN for) (NP (NN trend) (NN <) (CD 0.01)))) (-RRB- -RRB-)))) (. .)))
15531665	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN dietary)) (CC and) (NP (JJ supplemental) (NNP Doc_15531665_1468_1477_Chemical))) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB separately)))))) (, ,) (NP (RB only) (JJ supplemental) (NNP Doc_15531665_1522_1531_Chemical)) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN association)) (PP (IN with) (NP (NN mortality) (NNS endpoints))))) (. .)))
15531665	8	(S1 (S (NP (JJ Doc_15531665_1588_1597_Chemical) (NN intake)) (VP (AUX was) (ADJP (JJ unrelated) (PP (TO to) (NP (NP (NN mortality)) (PP (IN from) (NP (NNP Doc_15531665_1637_1659_Disease)))))) (PP (IN in) (NP (DT the) (JJ nondiabetic) (NNS subjects))) (PP (IN at) (NP (NN baseline)))) (. .)))
15531665	9	(S1 (S (NP (NP (DT A) (JJ high) (JJ Doc_15531665_1720_1729_Chemical) (NN intake)) (PP (IN from) (NP (NNS supplements)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN Doc_15531665_1794_1816_Disease) (NN mortality))) (PP (IN in) (NP (NP (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NNP Doc_15531665_1856_1864_Disease))))))))) (. .)))
15565293	0	(S1 (S (NP (JJ Optical) (NN coherence) (NN tomography)) (VP (MD can) (VP (VB measure) (NP (NP (JJ axonal) (NN loss)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_70_80_Chemical-induced) (NNP Doc_15565293_89_105_Disease)))))))) (. .)))
15565293	1	(S1 (S (TO To) (VP (VBP map) (CC and) (VBP identify) (NP (NP (DT the) (NN pattern)) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (PP (IN of) (NP (NP (NNP Doc_15565293_161_180_Disease)) (PP (IN in) (NP (NNP Doc_15565293_184_194_Chemical-induced) (NNP Doc_15565293_203_219_Disease)))))) (S (VP (VBG using) (NP (NP (JJ optical) (NN coherence) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NNP OCT)) (-RRB- -RRB-)))))) (. .)))
15565293	2	(S1 (S (NP (NN Doc_15565293_262_272_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ antimycobacterial) (NN agent)) (VP (ADVP (RB often)) (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN Doc_15565293_323_335_Disease)))))))) (. .)))
15565293	3	(S1 (S (NP (NP (DT A) (JJ serious) (NN complication)) (PP (IN of) (NP (NNP Doc_15565293_363_373_Chemical)))) (VP (AUX is) (NP (NP (DT an) (NN Doc_15565293_380_396_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ impairs) (NP (NP (JJ visual) (NN acuity)) (, ,) (NP (NN contrast) (NN sensitivity)) (, ,) (CC and) (NP (NN color) (NN vision)))))))) (. .)))
15565293	4	(S1 (S (ADVP (RB However)) (, ,) (ADVP (RB early) (RB on)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ toxic) (NN Doc_15565293_499_515_Disease)) (VP (AUX is) (ADJP (ADJP (JJ mild)) (CC and) (ADJP (RB partly) (JJ reversible)))))) (, ,) (NP (DT the) (JJ funduscopic) (NNS findings)) (VP (AUX are) (ADVP (RB often)) (ADJP (JJ subtle) (CC and) (JJ easy) (S (VP (TO to) (VP (VB miss)))))) (. .)))
15565293	5	(S1 (S (NP (NP (CD Three) (NNS subjects)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NNP Doc_15565293_649_659_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15565293_661_664_Chemical)) (-RRB- -RRB-))))))) (VP (VBD -induced) (SBAR (S (NP (NP (NNP Doc_15565293_674_690_Disease)) (PP (IN of) (NP (ADJP (JJ short-) (, ,) (JJ intermediate-) (, ,) (CC and) (JJ long-term)) (NNP Doc_15565293_731_746_Disease)))) (VP (AUX were) (VP (VBN administered) (NP (NP (DT a) (JJ full) (JJ neuro-ophthalmologic) (NN examination)) (PP (VBG including) (NP (NP (JJ visual) (NN acuity)) (, ,) (NP (NN color) (NN vision)) (, ,) (NP (NN contrast) (NN sensitivity)) (, ,) (CC and) (NP (JJ fundus) (NN examination)))))))))) (. .)))
15565293	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNP OCT)) (PRN (-LRB- -LRB-) (NP (NNP OCT) (CD 3000)) (, ,) (NP (NP (NNP Humphrey-Zeiss)) (, ,) (NP (NNP Dublin)) (, ,) (NP (MD CA))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (DT both) (NNS eyes)) (PP (IN of) (NP (DT each) (NN subject))) (VP (VBG using) (NP (DT the) (JJ retinal) (NN nerve) (NN fiber) (NN layer) (-LRB- -LRB-) (NN RNFL) (-RRB- -RRB-) (NN analysis) (NN protocol))))))) (. .)))
15565293	7	(S1 (S (NP (NNP OCT)) (VP (VBZ interpolates) (NP (NP (NNS data)) (PP (IN from) (NP (CD 100) (NNS points)))) (PP (IN around) (NP (NP (DT the) (JJ optic) (NN nerve)) (SBAR (S (VP (TO to) (ADVP (RB effectively)) (VP (NN map) (PRT (RP out)) (NP (DT the) (NNS RNFL))))))))) (. .)))
15565293	8	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ calculated) (NN average) (NN RNFL)) (PP (IN of) (NP (NP (JJ normal) (NNS eyes)) (VP (VBN accumulated) (PP (IN from) (NP (NP (CD four) (JJ prior) (NNS studies)) (VP (VBG using) (NP (NP (NNP OCT)) (, ,) (NP (CD n=661))))))))))))) (. .)))
15565293	9	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS subjects)) (PP (IN with) (NP (NP (NN history)) (PP (IN of) (NP (JJ Doc_15565293_1312_1315_Chemical-induced) (NNP Doc_15565293_1324_1340_Disease))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ mean) (NN loss)) (PP (IN of) (NP (NP (NP (CD 72) (NN %)) (NN nerve) (NN fiber) (NN layer) (NN thickness)) (PP (IN in) (NP (NP (DT the) (JJ temporal) (NNP quadrant)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN patient) (DT A)) (, ,) (PP (IN with) (NP (NP (JJ eventual) (NN recovery)) (PP (IN of) (NP (NP (JJ visual) (NN acuity)) (CC and) (NP (NP (NP (NP (NNS fields)) (, ,) (NP (NP (ADJP (CD 58) (NN %)) (NN loss)) (: ;) (NP (NN patient) (NNP B))) (, ,)) (PP (IN with) (NP (JJ intermediate) (NNP Doc_15565293_1527_1542_Disease)))) (, ,) (NP (NP (ADJP (CD 68) (NN %)) (NN loss)) (: ;) (NP (NN patient)) (X (SYM C)))))))) (, ,) (PP (IN with) (NP (JJ chronic) (NNP Doc_15565293_1578_1593_Disease)))) (, ,) (NP (ADJP (CD 90) (NN %)) (NN loss))) (-RRB- -RRB-))))))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ average) (JJ mean) (JJ optic) (NN nerve) (NN thickness)) (PP (IN of) (NP (CD 26+/-16) (NN microm)))))) (. .)))
15565293	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ combined) (JJ mean) (NN loss)) (PP (IN of) (NP (NP (CD 46) (NN %)) (PP (IN of) (NP (NP (NNS fibers)) (PP (IN from) (NP (NP (DT the) (JJ superior) (, ,) (JJ inferior) (, ,) (CC and) (JJ nasal) (NNS quadrants)) (PP (IN in) (NP (NP (DT the) (-LRB- -LRB-) (CD six) (-RRB- -RRB-) (NNS eyes)) (PP (IN of) (NP (NP (DT all) (CD three) (NNS subjects)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NP (JJ average) (NN thickness)) (PP (IN of) (NP (CD 55+/-29) (NN microm)))))) (-RRB- -RRB-)))))))))))))) (. .)))
15565293	11	(S1 (S (PP (IN In) (NP (NP (DT both) (NNS sets)) (PRN (-LRB- -LRB-) (NP (CD four)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNS eyes)) (PP (IN of) (NP (NP (DT the) (NNS subjects)) (PP (IN with) (NP (NP (JJ persistent) (NNP Doc_15565293_1909_1924_Disease)) (PRN (-LRB- -LRB-) (NP (NNS patients) (NNP B) (CC and) (NNP C)) (-RRB- -RRB-)))))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT an) (JJ average) (NN loss)) (PP (IN of) (NP (NP (CD 79) (NN %)) (PP (IN of) (NP (NN nerve) (NN fiber) (NN thickness))))) (PP (IN in) (NP (DT the) (JJ temporal) (NNP quadrant))))) (. .)))
15565293	12	(S1 (S (NP (NP (DT The) (NNP OCT) (NNS results)) (PP (IN in) (NP (NP (DT these) (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_2081_2084_Chemical-induced) (NNP Doc_15565293_2093_2109_Disease)))))) (VP (VBP show) (NP (NP (JJ considerable) (NN loss)) (ADVP (RB especially)) (PP (IN of) (NP (DT the) (JJ temporal) (NNS fibers))))) (. .)))
15565293	13	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ prior) (JJ histopathological) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBP show) (NP (NP (JJ predominant) (NN loss)) (PP (IN of) (NP (NP (JJ parvo-cellular) (NNS axons)) (-LRB- -LRB-) (CC or) (NP (JJ small-caliber) (NNS axons)) (-RRB- -RRB-)))) (PP (IN within) (NP (NP (DT the) (JJ papillo-macular) (NN bundle)) (PP (IN in) (NP (ADJP (JJ toxic) (CC or) (JJ hereditary)) (NNP Doc_15565293_2357_2375_Disease)))))))))))) (. .)))
15565293	14	(S1 (S (NP (NNP OCT)) (VP (MD can) (VP (AUX be) (NP (NP (DT a) (JJ valuable) (NN tool)) (PP (IN in) (NP (NP (DT the) (JJ quantitative) (NN analysis)) (PP (IN of) (NP (NN Doc_15565293_2436_2454_Disease)))))))) (. .)))
15565293	15	(S1 (S (ADVP (RB Additionally)) (, ,) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN management)) (PP (IN of) (NP (NNP Doc_15565293_2496_2499_Chemical-induced) (NNP Doc_15565293_2508_2524_Disease))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ important) (S (VP (VP (TO to) (ADVP (RB properly)) (VP (VB manage) (NP (NP (JJ Doc_15565293_2561_2571_Chemical) (NN dosing)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_2596_2612_Disease)))))))) (CC and) (VP (TO to) (VP (VB achieve) (NP (NP (JJ proper) (NN transition)) (PP (TO to) (NP (DT a) (NN maintenance) (NN dose)))) (SBAR (IN once) (S (NP (DT an) (JJ appropriate) (NN loading) (NN dose)) (VP (AUX has) (VP (AUX been) (VP (VBN reached)))))))))))) (. .)))
15579441	0	(S1 (NP (NP (NN Doc_15579441_0_7_Disease)) (PP (IN in) (NP (NNP Doc_15579441_11_24_Disease))) (PP (IN with) (NP (NNP Doc_15579441_30_41_Disease) (NN and/or) (NN glomerular) (NNP Doc_15579441_60_72_Disease))) (. .)))
15579441	1	(S1 (S (PP (IN Despite) (NP (NP (DT the) (VBG increasing) (NN need)) (SBAR (S (VP (TO to) (VP (VB identify) (CC and) (VB quantify) (NP (NN tissue) (NN oxygenation)) (PP (IN at) (NP (DT the) (JJ cellular) (NN level))))))))) (, ,) (NP (ADJP (RB relatively) (JJ few)) (NNS methods)) (VP (AUX have) (VP (AUX been) (ADJP (JJ available)))) (. .)))
15579441	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD developed) (NP (NP (DT a) (JJ new) (JJ Doc_15579441_247_254_Disease-responsive) (NN reporter) (NN vector)) (VP (VBG using) (NP (NP (DT a) (JJ Doc_15579441_290_297_Disease-responsive) (NN element)) (PP (IN of) (NP (NP (DT the) (CD 5) (POS ')) (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (JJ untranslated) (NN region))))))) (CC and) (VP (VBD generated) (NP (DT a) (JJ novel) (NNP Doc_15579441_404_411_Disease-sensing) (NNP transgenic) (NN rat)))) (. .)))
15579441	3	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD applied) (NP (DT this) (NN animal) (NN model)) (PP (TO to) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ tubulointerstitial) (NN Doc_15579441_509_516_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_15579441_524_539_Disease)))))) (. .)))
15579441	4	(S1 (S (PP (IN With) (NP (DT this) (NN model))) (, ,) (NP (PRP we)) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB identify) (NP (JJ diffuse) (JJ cortical) (NN Doc_15579441_600_607_Disease)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15579441_615_640_Chemical-induced) (UCP (NNP Doc_15579441_649_667_Disease) (CC and) (JJ focal) (CC and) (JJ segmental)) (NN Doc_15579441_692_699_Disease)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model)))))))))) (. .)))
15579441	5	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (DT the) (JJ Doc_15579441_747_754_Disease-responsive) (NN transgene)))) (VP (VBD increased) (PP (IN throughout) (NP (DT the) (JJ observation) (NN period))) (, ,) (S (VP (VBG reaching) (NP (NN 2.2-fold)) (PP (IN at) (NP (NP (CD 2) (NNS weeks)) (PP (IN in) (NP (DT the) (JJ Doc_15579441_857_882_Chemical) (NN model) (CC and) (NN 2.6-fold))))) (PP (IN at) (NP (NP (CD 4) (NNS weeks)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT that)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)))) (VP (VBD showed) (NP (DT a) (JJ mild) (NN decrease)) (, ,) (S (VP (VBG reflecting) (NP (NP (JJ distinct) (NNS behaviors)) (PP (IN of) (NP (DT the) (CD two) (NNS genes)))))))))) (. .)))
15579441	6	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (NNP Doc_15579441_1079_1086_Disease)))) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN with) (NP (NP (JJ microscopic) (NNP Doc_15579441_1134_1159_Disease)) (PP (IN in) (NP (DT both) (NNS models))))))) (. .)))
15579441	7	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (DT the) (NN localization)) (PP (IN of) (NP (VBG proliferating) (NN cell) (JJ nuclear) (ADJP (JJ antigen-positive) (, ,) (JJ ED-1-positive) (, ,) (CC and) (JJ terminal)) (JJ dUTP) (JJ nick-end) (JJ labeled-positive) (NNS cells))) (PP (IN in) (NP (NP (DT the) (JJ Doc_15579441_1336_1343_Disease) (JJ cortical) (NN area)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model))))))) (. .)))
15579441	8	(S1 (S (NP (PRP We)) (VP (VB propose) (ADVP (RB here)) (NP (NP (DT a) (JJ possible) (JJ pathological) (NN tie)) (PP (IN between) (NP (NP (JJ chronic) (JJ tubulointerstitial) (NN Doc_15579441_1466_1473_Disease)) (CC and) (NP (JJ progressive) (NN Doc_15579441_1490_1509_Disease)))))) (. .)))
15580403	0	(S1 (S (NP (NP (JJ Adequate) (NN timing)) (PP (IN of) (NP (NNP Doc_15580403_19_28_Chemical)))) (VP (NN reduction) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15580403_56_65_Disease))))) (PP (IN during) (NP (NP (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_15580403_96_106_Chemical)) (CC and) (NP (NNP Doc_15580403_111_120_Chemical)))) (PP (IN for) (NP (NNP Doc_15580403_125_144_Disease)))))) (. .)))
15580403	1	(S1 (S (NP (NN Doc_15580403_158_174_Disease)) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (JJ adverse) (NNS events)) (PP (IN of) (NP (NP (DT the) (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_15580403_240_250_Chemical)) (CC and) (NP (NNP Doc_15580403_255_264_Chemical)))))))))) (. .)))
15580403	2	(S1 (S (PP (IN Because) (IN of) (NP (JJ Doc_15580403_277_286_Chemical-related) (NN Doc_15580403_295_311_Disease))) (, ,) (NP (NN dose) (NN reduction)) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN event)) (PP (IN in) (NP (DT this) (NN therapy))))) (. .)))
15580403	3	(S1 (S (PP (IN In) (NP (DT this) (JJ clinical) (NN retrospective) (NN cohort) (NN study))) (NP (PRP we)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (JJ suitable) (NN timing)) (PP (IN of) (NP (NP (JJ Doc_15580403_447_456_Chemical) (NN reduction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_15580403_484_493_Disease)) (PP (IN during) (NP (NN combination) (NN therapy)))))))))))) (. .)))
15580403	4	(S1 (S (NP (NP (NNS Thirty-seven)) (PP (IN of) (NP (NP (CD 160) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (JJ HCV-genotype) (NNS 1b))) (, ,) (VP (AUX had) (NP (JJ high) (NN virus) (NN load))) (, ,) (CC and) (VP (VBN received) (NP (JJ 24-week) (NN combination) (NN therapy))))))))) (VP (VBD developed) (NP (NNP Doc_15580403_657_663_Disease)) (PP (IN with) (NP (NP (NP (NN hemoglobin) (NN level)) (NP (CD <10) (NNS g/dl))) (CC or) (NP (JJ Doc_15580403_698_704_Disease-related) (NNS signs)))) (PP (IN during) (NP (NN therapy)))) (. .)))
15580403	5	(S1 (S (PP (IN After) (NP (DT that))) (, ,) (NP (DT these) (CD 37) (NNS patients)) (VP (AUX were) (VP (VBN reduced) (NP (NP (CD one) (NN tablet)) (PP (IN of) (NP (NP (NNP Doc_15580403_792_801_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg)) (-RRB- -RRB-))))) (PP (IN per) (NP (NN day))))) (. .)))
15580403	6	(S1 (S (PP (IN After) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_15580403_839_848_Chemical))))) (, ,) (NP (NP (CD 27)) (PP (IN of) (NP (CD 37) (NNS patients)))) (VP (MD could) (VP (VB continue) (NP (NP (NN combination) (NN therapy)) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 24) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN group) (NN A)) (-RRB- -RRB-))))))))) (. .)))
15580403	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (QP (CD 10) (IN of) (CD 37)) (NNS patients)) (PP (IN with) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_15580403_983_992_Chemical)))))) (VP (MD could) (RB not) (VP (VB continue) (NP (NN combination) (NN therapy)) (SBAR (IN because) (S (NP (NP (NP (PRP$ their) (CD <8.5) (JJ g/dl) (NN hemoglobin) (NNS values)) (VP (VBN decreased) (PP (TO to)))) (CC or) (NP (JJ Doc_15580403_1090_1096_Disease-related) (JJ severe) (NN side) (NNS effects))) (VP (VBD occurred) (PRN (-LRB- -LRB-) (NP (NN group) (NN B)) (-RRB- -RRB-))))))) (. .)))
15580403	8	(S1 (S (S (NP (PRP We)) (VP (VBD assessed) (NP (DT the) (JJ final) (NN efficacy) (CC and) (NN safety)) (PP (IN after) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_15580403_1206_1215_Chemical)) (PP (IN in) (NP (NP (NP (NNS groups)) (NP (DT A))) (CC and) (NP (NNP B.) (NNS RESULTS)))))))))) (: :) (S (NP (NP (DT A) (JJ sustained) (JJ virological) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP SVR)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 29.6) (NN %)) (PRN (-LRB- -LRB-) (CD 8/27) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN group) (DT A)) (CC and) (NP (NP (NP (CD 10) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 1/10)) (-RRB- -RRB-))) (PP (IN in) (NP (NN group) (NN B))))))) (, ,) (ADVP (RB respectively)))) (. .)))
15580403	9	(S1 (S (NP (NP (DT A) (ADJP (CD 34.4) (NN %) (PRN (-LRB- -LRB-) (NP (CD 12/27)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ SVR) (NNS +)))) (JJ biological) (NN response)) (PP (IN in) (NP (NN group) (DT A)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (CD 10) (NN %)))) (PRN (-LRB- -LRB-) (NP (CD 1/10)) (-RRB- -RRB-)) (PP (IN in) (NP (NN group) (NN B))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.051)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (JJ slight) (NN significance)))) (. .)))
15580403	10	(S1 (S (PP (IN With) (NP (NP (NN respect)) (PP (TO to) (NP (NN hemoglobin) (NN level))))) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NNP Doc_15580403_1534_1543_Chemical))))) (NP (NN reduction)) (, ,) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (NN continuation)) (PP (IN of) (NP (NN therapy))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (QP (CD >) (CC or) (CD =10) (CD g/dl)) (NN hemoglobin)))))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (CD <10) (NNS g/dl)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.036)) (-RRB- -RRB-)))))))))) (. .)))
15580403	11	(S1 (S (NP (NP (NP (NN Reduction)) (PP (IN of) (NP (NNP Doc_15580403_1718_1727_Chemical))) (PP (IN at) (NP (NN hemoglobin) (NN level) (CD >)))) (CC or) (NP (CD =10) (NN g/dl))) (VP (AUX is) (ADJP (JJ suitable)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN efficacy) (CC and) (NN side) (NNS effects)))))) (. .)))
15638391	0	(S1 (S (NP (NP (VBG Aging) (NN process)) (PP (IN of) (NP (NP (JJ epithelial) (NNS cells)) (PP (IN of) (NP (DT the) (NN rat) (NN prostate) (NN lateral)))))) (VP (VBP lobe) (PP (IN in) (NP (NP (JJ experimental) (NN Doc_15638391_83_101_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15638391_113_124_Chemical))))))) (. .)))
15638391	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB examine) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NNP Doc_15638391_179_197_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15638391_210_221_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15638391_223_226_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN age) (JJ related) (NN morphology)))))))) (CC and) (VP (VB function) (NP (NP (NNS changes)) (PP (IN of) (NP (JJ epithelial) (NNS cells))) (PP (IN in) (NP (NN rat) (NN prostate) (NN lateral) (NN lobe))))))))) (. .)))
15638391	2	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (ADJP (RB sexually) (JJ mature)) (NN male) (NNS rats))))) (. .)))
15638391	3	(S1 (S (NP (NP (JJ Serum) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP prolactin)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15638391_414_417_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15638391_423_435_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15638391_437_438_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN measured))) (. .)))
15638391	4	(S1 (S (NP (NN Tissue) (NNS sections)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN light)) (CC and) (NP (NNP electron) (NN microscopy)))))) (. .)))
15638391	5	(S1 (S (NP (NP (JJ Immunohistochemical) (NNS reactions)) (PP (IN for) (NP (NP (JJ Anti-Proliferating) (NN Cell) (JJ Nuclear) (NN Antigen)) (PRN (-LRB- -LRB-) (NP (NNP PCNA)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN performed))) (. .)))
15638391	6	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (PP (IN of) (NP (DT the) (JJ experimental) (NN group))))) (, ,) (NP (NP (DT the) (JJ mean) (NN concentration)) (PP (IN of) (: :) (NP (NNP Doc_15638391_681_684_Chemical)))) (VP (AUX was) (ADVP (RBR more) (IN than)) (ADJP (RB twice) (JJR higher)) (, ,) (SBAR (IN whereas) (S (NP (JJ Doc_15638391_721_722_Chemical) (NN concentration)) (VP (AUX was) (ADJP (ADJP (RB almost) (RB twice) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))))))) (. .)))
15638391	7	(S1 (S (NP (JJ Light) (NN microscopy)) (VP (VBD visualized) (NP (NP (DT the) (NN following)) (: :) (NP (NP (NN Doc_15638391_835_846_Disease) (CC and) (NN epithelium) (NN Doc_15638391_862_873_Disease)) (PP (IN of) (NP (NP (DT the) (JJ glandular) (NNS ducts)) (, ,) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NNP PCNA) (NN expression))))))))) (. .)))
15638391	8	(S1 (S (NP (NNP Electron) (NN microscopy)) (VP (VBD revealed) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ columnar) (NN epithelial) (NNS cells))) (, ,) (VP (VBG concerning) (NP (NNS organelles))) (, ,) (VP (VBN engaged) (PP (IN in) (NP (NP (NN protein) (NN synthesis)) (CC and) (NP (NN secretion))))))) (. .)))
1564236	0	(S1 (NP (NP (NP (NN Relation)) (PP (IN of) (NP (NN perfusion) (NNS defects))) (VP (VBN observed) (PP (IN with) (NP (NP (JJ myocardial) (NN contrast)) (ADJP (JJ echocardiography) (PP (TO to) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_1564236_100_117_Disease)))))))))) (: :) (NP (NP (NN correlation)) (PP (IN with) (NP (JJ Doc_1564236_136_144_Chemical-201) (NN single-photon) (NN emission) (NN tomography)))) (. .)))
1564236	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (ADVP (RB previously)) (VBN shown) (SBAR (IN that) (S (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (AUX is) (NP (NP (DT a) (JJ valuable) (NN technique)) (PP (IN for) (NP (NP (JJ delineating) (NNS regions)) (PP (IN of) (NP (JJ myocardial) (NN underperfusion) (JJ secondary))) (PP (PP (TO to) (NP (NNP Doc_1564236_345_363_Disease))) (CC and) (PP (TO to) (NP (NP (JJ critical) (NNP Doc_1564236_380_397_Disease)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ Doc_1564236_417_426_Disease) (NN stimulation))))))))))))))))) (. .)))
1564236	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (VBN performed) (PP (IN with) (NP (NP (DT a) (JJ stable) (NN solution)) (PP (IN of) (NP (JJ sonicated) (NN albumin))))))) (VP (MD could) (VP (VB detect) (NP (NP (NNS regions)) (PP (IN of) (NP (NP (JJ myocardial) (NNS underperfusion)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ various) (NNS degrees)) (PP (IN of) (NP (NNP Doc_1564236_662_679_Disease))))))))))))))))) (. .)))
1564236	3	(S1 (S (NP (NP (DT The) (NN perfusion) (NN defect)) (VP (VBN produced) (PP (IN in) (NP (CD 16) (JJ open) (NN chest) (NNS dogs))))) (VP (AUX was) (PP (VBN compared) (PP (PP (IN with) (NP (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (VP (VBN measured) (PP (IN by) (NP (DT the) (NN postmortem) (NN dual-perfusion) (NN technique)))))) (CC and) (PP (IN with) (NP (NP (JJ Doc_1564236_838_846_Chemical-201) (JJ single-photon) (NN emission) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NN SPECT)) (-RRB- -RRB-))))))) (. .)))
1564236	4	(S1 (S (PP (IN During) (NP (DT a) (JJ transient) (-LRB- -LRB-) (NN 20-s) (-RRB- -RRB-) (NN Doc_1564236_920_938_Disease))) (, ,) (NP (DT a) (NN perfusion) (NN defect)) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NN contrast) (NN echocardiography))) (PP (IN in) (NP (NP (CD 14)) (PP (IN of) (NP (DT the) (CD 15) (NNS dogs))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN occlusion)) (VP (AUX was) (VP (VBN produced))))))))) (. .)))
1564236	5	(S1 (S (NP (DT The) (NN perfusion) (NN defect)) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area))) (PP (IN at) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.74)) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.002))) (-RRB- -RRB-))))) (. .)))
1564236	6	(S1 (S (PP (IN During) (NP (NNP Doc_1564236_1176_1188_Chemical-induced) (NNP Doc_1564236_1197_1206_Disease))) (, ,) (NP (NP (CD 12)) (PP (IN of) (NP (NP (DT the) (CD 16) (NNS dogs)) (PP (IN with) (NP (DT a) (JJ partial) (NN Doc_1564236_1241_1258_Disease)))))) (VP (AUX had) (NP (NP (DT a) (JJ visible) (NN area)) (PP (IN of) (NP (NN hypoperfusion)))) (PP (IN by) (NP (NN contrast) (JJ echocardiography)))) (. .)))
1564236	7	(S1 (S (NP (NP (DT The) (CD four) (NNS dogs)) (PP (IN without) (NP (DT a) (JJ perfusion) (NN defect)))) (VP (AUX had) (NP (NP (DT a) (NN stenosis)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ mild) (ADJP (-LRB- -LRB-) (NP (CD 0) (NN %) (TO to) (CD 50) (NN %)) (-RRB- -RRB-)) (NN reduction)) (PP (IN in) (NP (NNP Doc_1564236_1430_1442_Chemical-induced) (NNP Doc_1564236_1451_1460_Disease)))))))))) (. .)))
1564236	8	(S1 (S (NP (NP (DT The) (NN size)) (PP (IN of) (NP (NP (DT the) (JJ perfusion) (NN defect)) (PP (IN during) (NP (NNS stenosis)))))) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area))) (PP (IN at) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.61)) (: ;) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.02)))) (-RRB- -RRB-))))) (. .)))
1564236	9	(S1 (S (S (NP (CD Doc_1564236_1589_1597_Chemical-201) (NN SPECT)) (VP (VBD demonstrated) (NP (DT a) (JJ perfusion) (NN defect)) (PP (IN in) (NP (NP (DT all) (CD 14) (NNS dogs)) (VP (VBN analyzed) (PP (IN during) (NP (JJ Doc_1564236_1671_1683_Chemical-induced) (NNP Doc_1564236_1692_1701_Disease)))))))) (: ;) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (NN perfusion) (NN defect)))) (VP (VBD correlated) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.58)) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.03))) (-RRB- -RRB-)) (CC and) (PP (IN with) (NP (DT the) (NN perfusion) (NN defect)))) (PP (IN by) (NP (NP (NN contrast) (JJ echocardiography)) (PRN (-LRB- -LRB-) (NP (NP (SYM r)) (NP (SYM =) (CD 0.58))) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.03))) (-RRB- -RRB-)))))) (. .)))
1564236	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB visualize) (CC and) (VB quantitate) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ jeopardized) (NN myocardium)))) (PP (IN during) (NP (NP (ADJP (JJ moderate) (TO to) (JJ severe)) (NNS degrees)) (PP (IN of) (NP (NNP Doc_1564236_2053_2070_Disease))))))))))) (. .)))
1564236	11	(S1 (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (VBP show) (NP (NP (DT a) (NN correlation)) (PP (IN with) (NP (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN obtained) (PP (IN with) (NP (JJ Doc_1564236_2173_2181_Chemical-201) (NN SPECT))))))))))) (. .)))
15673851	0	(S1 (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (JJ spinal) (JJ Doc_15673851_25_45_Chemical) (NNS receptors)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NN degeneration)) (PP (IN of) (NP (NP (JJ spinal) (NN motor) (NNS neurons)) (VP (VBN induced) (PP (IN by) (NP (JJ neuraxial) (NN Doc_15673851_132_140_Chemical))) (PP (IN after) (NP (NP (DT a) (JJ noninjurious) (NN interval)) (PP (IN of) (NP (NNP Doc_15673851_174_194_Disease)))))))))))) (. .)))
15673851	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN degeneration)) (PP (IN of) (NP (JJ spinal) (NN motor) (NNS neurons)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NNP Doc_15673851_296_316_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15673851_318_322_Chemical)) (-RRB- -RRB-)) (NNS receptors))))))) (PP (IN after) (NP (JJ neuraxial) (NNP Doc_15673851_350_358_Chemical))) (PP (VBG following) (NP (NP (DT a) (JJ noninjurious) (NN interval)) (PP (IN of) (NP (NP (NNP Doc_15673851_396_412_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
15673851	2	(S1 (S (NP (NN Doc_15673851_422_442_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15673851_458_474_Disease))) (PP (IN for) (NP (NP (CD 6) (NN min)) (PP (IN with) (NP (DT a) (NN balloon) (NN catheter))))))) (. .)))
15673851	3	(S1 (S (PP (IN In) (NP (DT a) (NN microdialysis) (NN study))) (, ,) (S (NP (NP (CD 10) (NN muL)) (PP (IN of) (NP (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NP (NN group)) (X (SYM C)) (: ;) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 30) (NN mug)) (PP (IN of) (NP (NNP Doc_15673851_583_591_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP group) (NNP M)) (: ;) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN injected) (ADVP (RB intrathecally)) (PRN (-LRB- -LRB-) (PRP IT) (-RRB- -RRB-)) (NP (CD 0.5) (NNP h)) (PP (IN after) (NP (NN reflow)))))) (, ,) (CC and) (S (NP (NP (NP (CD 30) (NN mug)) (PP (IN of) (NP (NNP Doc_15673851_675_683_Chemical))) (PRN (-LRB- -LRB-) (NP (NN group) (CD SM)) (: ;) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))) (CC or) (NP (NP (CD 10) (NN muL)) (PP (IN of) (NP (NN saline))) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN SC)) (: ;) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN injected) (S (NP (PRP IT)) (NP (NP (CD 0.5) (NNP h)) (PP (IN after) (NP (JJ sham) (NN operation)))))))) (. .)))
15673851	4	(S1 (S (NP (NN Microdialysis) (NNS samples)) (VP (AUX were) (VP (VBN collected) (NP (NN preischemia)) (, ,) (PP (PP (IN before) (NP (PRP IT) (NN injection))) (, ,) (CC and) (PP (IN at) (NP (CD 2) (, ,) (CD 4) (, ,) (CD 8) (, ,) (CD 24) (, ,) (CC and) (NP (NP (NP (CD 48) (NNP h)) (PP (IN of) (NP (NN reperfusion)))) (PRN (-LRB- -LRB-) (PP (IN after) (NP (PRP IT) (NN injection))) (-RRB- -RRB-)))))))) (. .)))
15673851	5	(S1 (S (ADVP (JJ Second)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (PRP IT)) (NNP Doc_15673851_962_968_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mug)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (JJ histopathologic) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ spinal) (NN cord)) (PP (IN after) (NP (JJ Doc_15673851_1034_1042_Chemical-induced) (NN Doc_15673851_1051_1070_Disease))))))))) (. .)))
15673851	6	(S1 (S (PP (IN After) (NP (PRP IT))) (NP (NNP Doc_15673851_1081_1089_Chemical)) (, ,) (NP (DT the) (JJ cerebrospinal) (NN fluid) (PRN (-LRB- -LRB-) (NP (NNP CSF)) (-RRB- -RRB-)) (NNP Doc_15673851_1121_1130_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NN group))) (ADVP (NNP M) (JJ relative) (PP (TO to) (NP (NP (DT both) (NN baseline) (CC and) (NN group) (NN C)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
15673851	7	(S1 (S (NP (DT This) (NN increase)) (VP (VBD persisted) (PP (IN for) (NP (CD 8) (NNS hrs)))) (. .)))
15673851	8	(S1 (S (NP (PRP IT)) (NP (NNP Doc_15673851_1258_1264_Chemical)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ dark-stained) (NNS alpha-motoneurons)))) (PP (IN after) (NP (NNP Doc_15673851_1338_1346_Chemical-induced) (NNP Doc_15673851_1355_1374_Disease))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN saline) (NN group))))) (. .)))
15673851	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (PRP IT)) (ADVP (NNP Doc_15673851_1435_1443_Chemical)) (VP (VBZ induces) (NP (NNP Doc_15673851_1452_1471_Disease)) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN increase)) (PP (IN in) (NP (NNP CSF) (NNP Doc_15673851_1507_1516_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_15673851_1539_1543_Chemical) (NN receptor) (NN activation))))))))))))) (. .)))
15673851	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS opioids)) (VP (MD may) (VP (AUX be) (ADJP (JJ Doc_15673851_1596_1606_Disease)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NNP Doc_15673851_1625_1645_Disease))))) (PP (IN via) (NP (JJ Doc_15673851_1650_1654_Chemical) (NN receptor) (NN activation)))))))) (. .)))
15686794	0	(S1 (NP (NP (NP (JJ Acute) (NN Doc_15686794_6_19_Disease)) (PP (IN during) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_15686794_57_67_Chemical)))))) (: :) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
15686794	1	(S1 (S (NP (NN Doc_15686794_92_102_Chemical)) (VP (VBZ represents) (NP (NP (DT an) (JJ effective) (JJ antiarrhythmic) (NN drug)) (PP (IN for) (NP (NP (NP (NN cardioversion)) (PP (IN of) (NP (NP (JJ recent-onset) (NNP Doc_15686794_181_200_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15686794_202_204_Disease)) (-RRB- -RRB-))))) (CC and) (NP (NP (NN maintenance)) (PP (IN of) (NP (JJ sinus) (NN rhythm)))))))) (. .)))
15686794	2	(S1 (S (NP (PRP We)) (ADVP (RB briefly)) (VP (VBP describe) (NP (NP (CD two) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ recent-onset) (NNP Doc_15686794_300_319_Disease)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT an) (JJ acute) (JJ devastating) (NN Doc_15686794_358_371_Disease)) (PP (NP (DT a) (JJ few) (NNS minutes)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ intravenous) (JJ Doc_15686794_418_428_Chemical) (NN loading)))))))))) (. .)))
15686794	3	(S1 (S (ADVP (RB Notably)) (, ,) (NP (DT this) (NN side) (NN effect)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB ever)) (VP (VBN reported) (PP (IN in) (NP (DT the) (JJ medical) (NN literature)))))) (. .)))
15686794	4	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN reaction)))) (SBAR (IN since) (S (NP (NP (JJ prompt) (NN termination)) (PP (IN of) (NP (JJ parenteral) (NN administration)))) (VP (VBZ leads) (S (VP (TO to) (VP (VB complete) (NP (NN resolution)))))))))) (. .)))
15764424	0	(S1 (NP (NP (NP (JJ Quantitative) (NN drug) (NNS levels)) (PP (IN in) (NP (NN stimulant) (NN Doc_15764424_38_47_Disease)))) (: :) (NP (NP (NN relationship)) (PP (TO to) (NP (NP (NN symptom) (NN severity)) (, ,) (NP (NP (NNP Doc_15764424_83_97_Chemical)) (CC and) (NP (NNP Doc_15764424_102_114_Disease)))))) (. .)))
15764424	1	(S1 (S (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ quantitative) (NN stimulant) (NN drug) (NNS levels)) (, ,) (NP (NP (NNP Doc_15764424_188_202_Chemical)) (, ,) (CC and) (NP (NNP Doc_15764424_208_226_Disease))))))))) (, ,) (NP (NP (JJ nineteen) (NNS patients)) (PP (IN in) (NP (NP (DT a) (JJ Doc_15764424_251_262_Disease) (NN emergency) (NN service)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15764424_301_312_Chemical-) (CC or) (NNP Doc_15764424_317_324_Chemical-induced) (NNP Doc_15764424_333_342_Disease)))))))) (VP (AUX were) (VP (VBN interviewed)))) (, ,) (CC and) (S (NP (NP (NN plasma)) (CC and) (NP (NN urine))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (JJ quantitative) (NNS assays)) (PP (IN of) (NP (NN stimulant) (NN drug) (CC and) (JJ Doc_15764424_443_456_Chemical) (NN metabolite) (NNS levels)))))))) (. .)))
15764424	2	(S1 (S (NP (JJ Doc_15764424_476_491_Chemical) (CC or) (JJ Doc_15764424_495_506_Chemical) (NNS levels)) (VP (AUX were) (VP (VBN related) (PP (TO to) (NP (NP (JJ several) (NN psychopathology) (NNS scores)) (CC and) (NP (DT the) (JJ global) (NN Doc_15764424_576_588_Disease) (NN rating)))))) (. .)))
15764424	3	(S1 (S (NP (NN HVA) (NNS levels)) (VP (AUX were) (VP (VBN related) (PP (PP (TO to) (NP (JJ global) (NN Doc_15764424_631_643_Disease))) (CC but) (RB not) (PP (TO to) (NP (NN psychopathology) (NNS ratings)))))) (. .)))
15764424	4	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ many) (JJ other) (NNS factors)) (PP (JJ such) (IN as) (NP (NN sensitization)))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)))))) (, ,) (NP (NP (NN intensity)) (PP (IN of) (NP (JJ stimulant-induced) (NNP Doc_15764424_778_796_Disease) (CC and) (NNP Doc_15764424_801_813_Disease)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADVP (IN at) (JJS least)) (PP (IN in) (NP (NN part) (JJ dose-related))))))) (. .)))
15811908	0	(S1 (S (NP (NN Doc_15811908_0_16_Disease)) (VP (VBN unmasked) (PP (IN by) (NP (NP (NNP Doc_15811908_29_40_Chemical)) (CC and) (NP (NNP Doc_15811908_45_53_Chemical))))) (. .)))
15811908	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT the) (NN unmasking)) (PP (IN of) (NP (NNP Doc_15811908_95_111_Disease)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15811908_138_149_Chemical)) (CC and) (NP (NNP Doc_15811908_154_162_Chemical)))))))))) (. .)))
15811908	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 42-year-old) (JJ white) (NN man)) (VP (VBN developed) (NP (JJ acute) (NNP Doc_15811908_218_230_Disease)) (PP (IN with) (NP (NP (JJ severe) (NN Doc_15811908_243_251_Disease)) (CC and) (NP (NP (NNP Doc_15811908_256_264_Disease) (CD 2) (NNS hours)) (PP (IN after) (NP (NP (DT the) (JJ first) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_15811908_298_309_Chemical) (CD 100) (NNS mg)) (CC and) (NP (NNP Doc_15811908_321_329_Chemical) (CD 100) (NNS mg))))))))))) (. .)))
15811908	3	(S1 (S (S (NP (DT Both) (NNS drugs)) (VP (AUX were) (ADVP (RB immediately)) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD recovered) (PP (IN after) (NP (NP (JJ subsequent) (NN Doc_15811908_423_434_Chemical)) (CC and) (NP (JJ Doc_15811908_439_448_Chemical) (NN treatment)))))) (. .)))
15811908	4	(S1 (S (S (NP (JJ Abdominal) (NN ultrasound)) (VP (VBD showed) (NP (DT an) (JJ adrenal) (NN mass)))) (, ,) (CC and) (S (NP (JJ postoperative) (JJ histologic) (NN examination)) (VP (VBD confirmed) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15811908_573_589_Disease)))))) (. .)))
15811908	5	(S1 (S (S (NP (NP (JJ Drug-induced) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_15811908_628_644_Disease)))) (VP (AUX are) (ADVP (RB often)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (VBN substituted) (JJ Doc_15811908_694_703_Chemical) (NNS drugs)))))))) (, ,) (CC but) (S (NP (DT the) (JJ underlying) (NN mechanism)) (VP (AUX is) (ADJP (JJ unknown)))) (. .)))
15811908	6	(S1 (S (PP (IN In) (NP (PRP$ our) (NN case))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale)))) (VP (VBD indicated) (NP (NP (DT a) (JJ possible) (NN relationship)) (PP (IN between) (NP (NP (DT the) (JJ Doc_15811908_848_860_Disease) (NN crisis)) (CC and) (NP (NNP Doc_15811908_872_883_Chemical) (CC and) (NNP Doc_15811908_888_896_Chemical) (NN therapy)))))) (. .)))
15811908	7	(S1 (S (PP (IN As) (PP (IN of) (NP (NNP March) (CD 24) (, ,) (CD 2005)))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NNP Doc_15811908_976_987_Chemical-) (CC and) (NNP Doc_15811908_993_1001_Chemical-induced) (NNP Doc_15811908_1010_1022_Disease) (NN crisis))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_15811908_1048_1064_Disease))))))) (. .)))
15811908	8	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (JJ other) (NN healthcare) (NNS professionals))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT this) (JJ potential) (JJ adverse) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_15811908_1164_1172_Chemical)) (CC and) (NP (NNP Doc_15811908_1177_1188_Chemical))))))))) (. .)))
15814210	0	(S1 (NP (NP (NP (JJ Minor) (NN Doc_15814210_6_30_Disease)) (, ,) (NP (JJ cognitive) (NN development)) (, ,) (CC and) (NP (JJ somatic) (NN development))) (PP (IN at) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (QP (CD 3) (TO to) (CD 7)) (NNS years))))) (PP (IN after) (NP (NP (JJ Doc_15814210_112_125_Chemical) (NN treatment)) (PP (IN in) (NP (JJ very-low) (JJ birth-weight) (NNS infants))))) (. .)))
15814210	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (JJ minor) (NN Doc_15814210_218_242_Disease)) (, ,) (NP (JJ cognitive) (NN development)) (, ,) (CC and) (NP (JJ somatic) (NN development))) (PP (IN after) (NP (NP (JJ Doc_15814210_297_310_Chemical) (NN therapy)) (PP (IN in) (NP (JJ very-low-birthweight) (NNS infants))))))))) (. .)))
15814210	2	(S1 (S (NP (NP (JJ Thirty-three) (NNS children)) (PP (IN after) (NP (JJ Doc_15814210_380_393_Chemical) (NN treatment)))) (VP (AUX were) (VP (VBN matched) (PP (TO to) (NP (CD 33) (NNS children))) (PP (IN without) (NP (JJ Doc_15814210_440_453_Chemical) (NN treatment))))) (. .)))
15814210	3	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (JJ 3-7) (NNS years))))))) (. .)))
15814210	4	(S1 (S (NP (NN Doc_15814210_509_522_Chemical)) (VP (AUX was) (VP (VBN started) (PP (IN between) (NP (NP (DT the) (NN 7th)) (CC and) (NP (NP (DT the) (JJ 28th) (NN day)) (PP (IN of) (NP (NN life))) (PP (IN over) (NP (NP (CD 7) (NNS days)) (PP (IN with) (NP (NP (DT a) (JJ total) (NN dose)) (PP (IN of) (NP (CD 2.35) (NN mg/kg/day)))))))))))) (. .)))
15814210	5	(S1 (S (NP (NN Exclusion) (NNS criteria)) (VP (AUX were) (NP (NP (NNP Doc_15814210_649_657_Disease)) (, ,) (NP (NNP Doc_15814210_659_672_Disease)) (, ,) (NP (JJ major) (JJ surgical) (NNS interventions)) (, ,) (ADJP (JJ small) (PP (IN for) (NP (JJ gestational) (NN age)))) (, ,) (NP (JJ intraventricular) (NN Doc_15814210_748_759_Disease) (NNS grades) (NNP III) (CC and) (NNP IV)) (, ,) (NP (NNP Doc_15814210_779_807_Disease)) (, ,) (CC and) (NP (JJ severe) (NNP Doc_15814210_820_843_Disease)))) (. .)))
15814210	6	(S1 (S (NP (DT Each) (NN child)) (VP (AUX was) (VP (VP (VBN examined) (PP (IN by) (NP (NP (DT a) (NN neuropediatrician)) (PP (IN for) (NP (JJ minor) (NNP Doc_15814210_902_927_Disease)))))) (CC and) (VP (VBN tested) (PP (IN by) (NP (NP (DT a) (NN psychologist)) (PP (IN for) (NP (NP (JJ cognitive) (NN development)) (PP (IN with) (NP (NP (DT a) (NNP Kaufman) (NNP Assessment) (NNP Battery)) (PP (IN for) (NP (NP (NNS Children)) (CC and) (NP (DT a) (JJ Draw-a-Man) (NN Test))))))))))))) (. .)))
15814210	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ demographic) (NNS data)) (, ,) (NP (NN growth)) (, ,) (CC and) (NP (JJ socio-economic) (NN status)))) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
15814210	8	(S1 (S (NP (NP (JJ Fine) (NN motor) (NNS skills)) (CC and) (NP (JJ gross) (NN motor) (NN function))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR better) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD p<0.01)) (-RRB- -RRB-)))) (. .)))
15814210	9	(S1 (S (PP (IN In) (NP (DT the) (JJ Draw-a-Man) (NN Test))) (, ,) (NP (DT the) (NN control) (NN group)) (VP (VBD showed) (NP (NP (JJR better) (NNS results)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-)))) (. .)))
15814210	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NP (NN development)) (PP (IN of) (NP (NN speech)))) (, ,) (NP (JJ social) (NN development)) (, ,) (CC and) (NP (NP (DT the) (NNP Kaufman) (NNP Assessment) (NNP Battery)) (PP (IN for) (NP (NNS Children)))))))) (. .)))
15814210	11	(S1 (S (PP (IN After) (NP (JJ Doc_15814210_1460_1473_Chemical) (NN treatment))) (, ,) (NP (NNS children)) (VP (VBD showed) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (JJ minor) (NN Doc_15814210_1524_1549_Disease))))) (. .)))
15814210	12	(S1 (S (NP (JJ Neurological) (NN development)) (VP (AUX was) (VP (VBN affected) (PP (ADVP (RB even)) (IN without) (NP (JJ neurological) (NN diagnosis))))) (. .)))
15814210	13	(S1 (S (NP (JJ Further) (JJ long-term) (NN follow-up) (NNS studies)) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (ADVP (RB fully)) (VP (VB evaluate) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NNP Doc_15814210_1712_1725_Chemical))) (PP (IN on) (NP (NP (NN neurological)) (CC and) (NP (JJ cognitive) (NN development))))))))))) (. .)))
15858223	0	(S1 (NP (NP (JJ Doc_15858223_0_13_Chemical) (NN I)) (: :) (NP (NP (NN time) (NN course)) (PP (IN of) (NP (NP (NN lipid) (NN peroxidation) (NNS biomarkers)) (, ,) (NP (NN Doc_15858223_63_77_Disease)) (, ,) (CC and) (NP (JJ Doc_15858223_83_96_Chemical) (JJ metabolite) (NNS levels)))) (PP (IN in) (NP (NNS rats)))) (. .)))
15858223	1	(S1 (S (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_15858223_141_154_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_156_159_Chemical)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ antiepileptic) (NN drug))))) (, ,)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ oxidative) (NN stress)) (PP (IN in) (NP (NNS rats))))) (, ,) (SBAR (IN as) (S (ADVP (RB recently)) (VP (VBN demonstrated) (PP (IN by) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_297_317_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_319_332_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
15858223	2	(S1 (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (JJ Doc_15858223_398_401_Chemical-associated) (JJ oxidative) (NN stress)) (CC and) (NP (NNP Doc_15858223_434_448_Disease))) (PRN (, ,) (S (NP (JJ adult) (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (VBG ip) (PP (IN with) (NP (NP (NP (NNP Doc_15858223_502_505_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (CD 0.9) (NN %) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN vehicle)) (-RRB- -RRB-))) (CONJP (RB once) (RB daily) (IN for)) (CD 2) (, ,) (CD 4) (, ,) (CD 7) (, ,) (CD 10))))))) (, ,))) (CC or) (NP (CD 14) (NNS days)))))))))) (. .)))
15858223	3	(S1 (S (NP (JJ Oxidative) (NN stress)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG determining) (NP (NP (NN plasma) (CC and) (NN liver) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_655_668_Chemical)) (, ,) (NP (NP (NNP Doc_15858223_670_690_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_692_695_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_15858223_702_741_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_743_748_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
15858223	4	(S1 (S (NP (NN Plasma) (CC and) (NN liver) (NN Doc_15858223_768_781_Chemical)) (VP (VP (AUX were) (ADJP (JJ elevated))) (CC and) (VP (VBD reached) (NP (DT a) (NN plateau)) (PP (IN after) (NP (NP (NN day) (CD 2)) (PP (IN of) (NP (JJ Doc_15858223_833_836_Chemical) (NN treatment))) (PP (VBN compared) (PP (TO to) (NP (NN control)))))))) (. .)))
15858223	5	(S1 (S (NP (NN Liver) (NN Doc_15858223_874_877_Chemical) (NNS levels)) (VP (AUX were) (ADJP (RB not) (JJ elevated)) (PP (IN until) (NP (NP (NN day) (CD 7)) (PP (IN of) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (NP (NN 1.8-fold) (CC versus) (NN control)) (, ,) (NP (NNP p) (NNP <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
15858223	6	(S1 (S (NP (NN Liver) (CC and) (NN plasma) (NN Doc_15858223_982_987_Chemical)) (VP (AUX were) (RB not) (VP (VBN increased) (PP (IN until) (NP (NP (CD 14) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN 2-fold) (CC vs.) (NN control)) (, ,) (NP (NNP p) (NNP <) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
15858223	7	(S1 (S (NP (NN Doc_15858223_1053_1067_Disease)) (VP (AUX was) (VP (VBN evaluated) (PP (VBN based) (PP (IN on) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NP (JJ alpha-Doc_15858223_1113_1124_Chemical) (NN S-transferase)) (PRN (-LRB- -LRB-) (NP (NN alpha-GST)) (-RRB- -RRB-)))))) (CC and) (PP (IN by) (NP (NN histology)))))) (. .)))
15858223	8	(S1 (S (NP (NN Serum) (NN alpha-GST) (NNS levels)) (VP (AUX were) (ADJP (RB significantly) (JJ elevated) (PP (IN by) (NP (NN day) (CD 4)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD corresponded) (PP (TO to) (NP (NNP Doc_15858223_1252_1266_Disease))) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_15858223_1307_1319_Disease)) (PP (IN of) (NP (DT the) (NN liver) (NN capsule)))) (, ,) (NP (NNP Doc_15858223_1342_1350_Disease)) (, ,) (CC and) (NP (NNP Doc_15858223_1356_1365_Disease)))) (PP (IN throughout) (NP (DT the) (NN study)))))))))))) (. .)))
15858223	9	(S1 (S (NP (NP (DT The) (NN liver) (NNS levels)) (PP (IN of) (NP (NP (JJ beta-oxidation) (NNS metabolites)) (PP (IN of) (NP (NNP Doc_15858223_1438_1441_Chemical)))))) (VP (AUX were) (VP (VBN decreased) (PP (IN by) (NP (NN day) (CD 14))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_1488_1497_Chemical)) (CC and) (NP (LST (-LRB- -LRB-) (LS E) (-RRB- -RRB-)) (NN -Doc_15858223_1506_1519_Chemical))))) (VP (AUX were) (RB not) (ADJP (JJ elevated)) (PP (IN throughout) (NP (DT the) (NN study)))))))) (. .)))
15858223	10	(S1 (S (ADVP (RB Overall)) (, ,) (NP (DT these) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ Doc_15858223_1598_1601_Chemical) (NN treatment)) (VP (VBZ results) (PP (IN in) (NP (JJ oxidative) (NN stress))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_1666_1679_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ precedes) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_15858223_1709_1717_Disease)) (, ,) (NP (NNP Doc_15858223_1719_1728_Disease)) (, ,) (CC and) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (JJ serum) (NN alpha-GST))))))))))))))))))))) (. .)))
15867025	0	(S1 (NP (NP (NP (NN Assessment)) (PP (IN of) (NP (JJ perinatal) (NNP Doc_15867025_24_35_Disease) (CC and) (NNP Doc_15867025_40_47_Disease) (NN prevention))) (PP (IN in) (NP (NNP New) (NNP Hampshire)))) (NP (NN delivery) (NNS hospitals)) (. .)))
15867025	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (JJ current) (NN performance)) (PP (IN on) (NP (NP (JJ recommended) (NN perinatal) (NNP Doc_15867025_164_175_Disease) (CC and) (NNP Doc_15867025_180_187_Disease) (NN prevention) (NNS practices)) (PP (IN in) (NP (NNP New) (NNP Hampshire)))))))) (. .)))
15867025	2	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN extracted) (PP (IN from) (NP (NP (JJ 2021) (VBN paired) (NN mother-infant) (NNS records)) (PP (IN for) (NP (DT the) (NN year) (CD 2000) (NN birth) (NN cohort))) (PP (IN in) (NP (NP (NNP New) (NNP Hampshire) (POS 's)) (CD 25) (NN delivery) (NNS hospitals))))))) (. .)))
15867025	3	(S1 (S (NP (NN Assessment)) (VP (AUX was) (VP (AUX done) (PP (IN on) (NP (NP (DT the) (JJ following)) (: :) (NP (NP (NP (JJ prenatal) (NN screening)) (PP (IN for) (NP (NNP Doc_15867025_429_440_Disease) (CC and) (NNP Doc_15867025_445_452_Disease)))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNP Doc_15867025_476_487_Disease) (NN vaccine) (NN birth) (NN dose))) (PP (TO to) (NP (DT all) (NNS infants)))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_15867025_541_552_Disease) (JJ immune) (NN globulin))) (PP (TO to) (NP (NP (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (TO to) (NP (JJ Doc_15867025_597_624_Chemical-positive) (NNS mothers)))))))))) (, ,) (NP (NNP Doc_15867025_643_650_Disease) (NN immunity)) (, ,) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ in-hospital) (NN postpartum) (NNP Doc_15867025_706_713_Disease) (NN vaccine)) (PP (TO to) (NP (JJ Doc_15867025_725_732_Disease) (NN nonimmune) (NNS women))))))))))) (. .)))
15867025	4	(S1 (S (NP (NP (JJ Prenatal) (NN screening) (NNS rates)) (PP (IN for) (NP (NP (NP (NNP Doc_15867025_788_799_Disease)) (PRN (-LRB- -LRB-) (NP (CD 98.8) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15867025_812_819_Disease)) (PRN (-LRB- -LRB-) (NP (CD 99.4) (NN %)) (-RRB- -RRB-)))))) (VP (AUX were) (ADJP (JJ high))) (. .)))
15867025	5	(S1 (S (NP (JJ Doc_15867025_839_850_Disease) (NN vaccine) (NN birth) (NN dose)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (CD 76.2) (NN %)) (PP (IN of) (NP (DT all) (NNS infants))))))) (. .)))
15867025	6	(S1 (S (NP (NP (DT All) (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (TO to) (NP (JJ Doc_15867025_941_968_Chemical-positive) (NNS mothers)))))))) (ADVP (RB also)) (VP (VBD received) (NP (NNP Doc_15867025_1000_1011_Disease) (JJ immune) (NN globulin))) (. .)))
15867025	7	(S1 (S (NP (JJ Multivariate) (JJ logistic) (NN regression)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN month)) (PP (IN of) (NP (NP (NN delivery)) (CC and) (NP (NN infant) (NN birth) (NN weight))))) (VP (AUX were) (NP (NP (JJ independent) (NNS predictors)) (PP (IN of) (NP (JJ Doc_15867025_1151_1162_Disease) (NN vaccination)))))))) (. .)))
15867025	8	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (NP (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN vaccinated) (PP (IN in) (NP (NP (NNP January)) (CC and) (NP (NP (NNP February) (CD 2000)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 48.5) (NN %)) (CC and) (NP (CD 67.5) (NN %))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))))))) (VP (AUX was) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (DT any) (JJ other) (NNS months)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN proportion)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN vaccinated) (PP (IN in) (NP (NNP December) (CD 2000))))))) (PRN (-LRB- -LRB-) (NP (CD 88.2) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (NP (DT the) (JJS highest)))))) (. .)))
15867025	9	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (IN between) (NP (NP (CD 1971)) (CC and) (NP (CD 1975))))))))) (VP (AUX had) (NP (NP (DT the) (JJS highest) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_15867025_1466_1473_Disease) (NN nonimmunity)) (PRN (-LRB- -LRB-) (NP (CD 9.5) (NN %)) (-RRB- -RRB-)))))) (. .)))
15867025	10	(S1 (S (NP (JJ In-hospital) (NN postpartum) (NN Doc_15867025_1517_1524_Disease) (NN vaccine) (NN administration)) (VP (AUX was) (VP (VBN documented) (PP (IN for) (NP (NP (CD 75.6) (NN %)) (PP (IN of) (NP (JJ nonimmune) (NNS women))))))) (. .)))
15867025	11	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ documents) (NP (NP (JJ good) (NN compliance)) (PP (IN in) (NP (NP (NNP New) (NNP Hampshire) (POS 's)) (VBG birthing) (NNS hospitals))) (PP (IN with) (NP (NP (JJ national) (NNS guidelines)) (PP (IN for) (NP (JJ perinatal) (NNP Doc_15867025_1719_1730_Disease) (CC and) (NNP Doc_15867025_1735_1742_Disease) (NN prevention))))))) (CC and) (VP (VBZ highlights) (NP (NP (JJ potential) (NNS areas)) (PP (IN for) (NP (NN improvement)))))) (. .)))
15893386	0	(S1 (NP (NP (JJ Doc_15893386_0_15_Chemical-induced) (NN Doc_15893386_24_48_Disease)) (PP (IN during) (NP (NP (JJ bronchoscopic) (NN removal)) (PP (IN of) (NP (DT a) (JJ tracheal) (JJ foreign) (NN body))))) (. .)))
15893386	1	(S1 (S (NP (NP (NN Doc_15893386_106_130_Disease)) (PP (IN during) (NP (JJ general) (NNS anesthesia)))) (VP (AUX is) (VP (VBN considered) (S (NP (NP (DT an) (JJ early) (NN warning) (NN sign)) (PP (IN of) (NP (NP (DT a) (JJ possible) (NN episode)) (PP (IN of) (NP (NN Doc_15893386_218_240_Disease))))))))) (. .)))
15893386	2	(S1 (S (NP (DT The) (NN decision) (SBAR (IN whether) (S (VP (VP (TO to) (VP (VB continue))) (CC or) (VP (VB discontinue) (NP (DT the) (NN procedure))))))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN urgency)) (PP (IN of) (NP (NP (DT the) (NN surgery) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_15893386_358_382_Disease)))))))) (. .)))
15893386	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NNP Doc_15893386_419_443_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15893386_445_457_Disease)) (-RRB- -RRB-))))) (PP (IN after) (NP (NNP Doc_15893386_465_480_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15893386_482_485_Chemical)) (-RRB- -RRB-)) (NN administration))) (PP (IN during) (NP (NP (JJ general) (JJ anesthetic) (NN management)) (PP (IN for) (NP (NP (JJ rigid) (JJ bronchoscopic) (NN removal)) (PP (IN of) (NP (DT a) (JJ tracheal) (JJ foreign) (NN body)))))))) (. .)))
15893386	4	(S1 (S (NP (NN Anesthesia)) (VP (AUX was) (VP (VBN continued) (ADVP (RB uneventfully)) (PP (IN with) (NP (JJ Doc_15893386_642_650_Chemical) (NN infusion))) (SBAR (IN while) (S (NP (DT all) (NNS facilities)) (VP (AUX were) (ADJP (JJ available) (S (VP (TO to) (VP (VB detect) (CC and) (VB treat) (NP (NN Doc_15893386_716_738_Disease))))))))))) (. .)))
15897593	0	(S1 (S (NP (NNP Doc_15897593_0_11_Chemical)) (VP (VBZ protects) (PP (IN against) (NP (NNP Doc_15897593_29_45_Disease))) (PP (IN from) (NP (NP (DT the) (NN DNA) (NN cleavage-enhancing) (NNS drugs)) (ADJP (ADJP (JJ Doc_15897593_84_93_Chemical) (CC and) (JJ Doc_15897593_98_110_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_15897593_119_130_Chemical)))))) (. .)))
15897593	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_15897593_145_159_Chemical) (NNP Doc_15897593_160_172_Chemical) (CC and) (NNP Doc_15897593_177_188_Chemical)) (CC and) (NP (DT the) (NNP Doc_15897593_197_215_Chemical) (NNP Doc_15897593_216_225_Chemical))) (VP (AUX are) (NP (NP (JJ potent) (NN DNA) (NN cleavage-enhancing) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (JJ clinical) (NN oncology)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NNP Doc_15897593_318_334_Disease)) (CC and) (NP (NNP Doc_15897593_339_355_Disease))) (VP (VBP limit) (NP (PRP$ their) (NN use)))) (. .)))
15897593	2	(S1 (S (NP (NP (NNP Doc_15897593_373_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15897593_386_394_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN recommended) (PP (IN for) (NP (NP (NN protection)) (PP (IN against) (NP (NNP Doc_15897593_434_447_Chemical-induced) (NNP Doc_15897593_456_470_Disease))))))) (. .)))
15897593	3	(S1 (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (S (PP (IN Because) (IN of) (NP (PRP$ their) (JJ widespread) (NN use))) (, ,) (NP (NP (NP (DT the) (JJ Doc_15897593_530_550_Disease) (JJ following) (NN coadministration)) (PP (IN of) (NP (NNP Doc_15897593_581_592_Chemical)))) (CC and) (NP (DT these) (CD three) (ADJP (RB structurally) (JJ different)) (NN DNA) (NN cleavage) (NNS enhancers))) (VP (AUX was) (VP (VBN investigated)))) (: :) (S (NP (NP (NN Sensitivity)) (PP (IN of) (NP (JJ human) (CC and) (JJ murine) (NN blood) (NN progenitor) (NNS cells))) (PP (TO to) (NP (NP (NNP Doc_15897593_731_740_Chemical)) (, ,) (NP (NNP Doc_15897593_742_754_Chemical)) (, ,) (CC and) (NP (NNP Doc_15897593_760_771_Chemical) (NN +/-) (NNP Doc_15897593_776_787_Chemical))))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (JJ granulocyte-macrophage) (NN colony)) (VP (VBG forming) (NP (NNS assays))))))))) (. .)))
15897593	4	(S1 (S (S (ADVP (RB Likewise)) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (NP (NNP B6D2F1) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15897593_901_910_Chemical)) (, ,) (NP (NNP Doc_15897593_912_924_Chemical)) (, ,) (CC and) (NP (NNP Doc_15897593_930_941_Chemical)))) (, ,) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_15897593_959_970_Chemical))) (PP (IN over) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NNS doses)))))))) (: :) (S (NP (NP (NN posttreatment)) (, ,) (NP (DT a) (JJ full) (JJ hematologic) (NN evaluation))) (VP (AUX was) (VP (AUX done)))) (. .)))
15897593	5	(S1 (S (S (NP (NP (JJ Nontoxic) (NNS doses)) (PP (IN of) (NP (NNP Doc_15897593_1081_1092_Chemical)))) (VP (VP (VBD reduced) (NP (NNP Doc_15897593_1101_1117_Disease) (CC and) (NNP Doc_15897593_1122_1133_Disease)) (PP (IN from) (NP (NP (NNP Doc_15897593_1139_1151_Chemical)) (CC and) (NP (NNP Doc_15897593_1156_1165_Chemical)))) (PP (IN in) (NP (NNS mice)))) (CC and) (VP (VBD antagonized) (NP (PRP$ their) (JJ antiproliferative) (NNS effects)) (PP (IN in) (NP (DT the) (NN colony) (NN assay)))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_15897593_1252_1263_Chemical)) (ADVP (RB neither)) (VP (VBD reduced) (NP (NP (NNP Doc_15897593_1280_1296_Disease)) (, ,) (NP (NNP Doc_15897593_1298_1309_Disease)) (, ,) (CC nor) (NP (NP (DT the)) (PP (IN in) (NP (NNP vitro) (NNP Doc_15897593_1328_1340_Disease))))) (PP (IN from) (NP (NNP Doc_15897593_1346_1357_Chemical))))) (. .)))
15897593	6	(S1 (S (S (SBAR (IN Although) (S (NP (PRP$ our) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NN observation)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_15897593_1422_1433_Chemical)) (VP (VBZ reduces) (NP (NP (DT neither) (JJ hematologic) (NN activity) (CC nor) (NN antitumor) (NN activity)) (PP (IN from) (NP (NNP Doc_15897593_1499_1510_Chemical)))) (ADVP (RB clinically))))))))) (, ,) (NP (NP (DT the) (JJ potent) (NN antagonism)) (PP (IN of) (NP (JJ Doc_15897593_1548_1560_Chemical) (NN activity)))) (VP (VBZ raises) (NP (NN concern)))) (: ;) (S (NP (NP (DT a) (JJ possible) (NN interference)) (PP (IN with) (NP (NN anticancer) (NN efficacy)))) (ADVP (RB certainly)) (VP (MD would) (VP (VB call) (PP (IN for) (NP (VBN renewed) (NN attention)))))) (. .)))
15897593	7	(S1 (S (NP (PRP$ Our) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ significant) (JJ Doc_15897593_1718_1727_Chemical) (NN dose) (NN escalation)) (VP (AUX is) (ADVP (RB perhaps)) (ADJP (JJ possible)) (PP (IN by) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_15897593_1778_1789_Chemical))))))))) (. .)))
15897593	8	(S1 (S (NP (NP (JJ Clinical) (NNS trials)) (PP (IN in) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN brain) (NN Doc_15897593_1830_1840_Disease)) (VP (VBG combining) (NP (NNP Doc_15897593_1851_1862_Chemical)))))) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_15897593_1881_1890_Chemical))))))) (VP (AUX is) (ADJP (JJ ongoing) (PP (IN with) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG improving) (NP (NN efficacy)) (PP (IN without) (S (VP (VBG aggravating) (NP (NNP Doc_15897593_1957_1977_Disease)))))))))))) (. .)))
15897593	9	(S1 (S (SBAR (IN If) (ADJP (JJ successful))) (, ,) (NP (DT this)) (VP (VBZ represents) (NP (NP (DT an) (JJ exciting) (NN mechanism)) (PP (IN for) (NP (NP (JJ pharmacologic) (NN regulation)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (IN from) (NP (JJ cytotoxic) (NNS chemotherapy))))))))) (. .)))
15930398	0	(S1 (NP (NP (NP (NP (NN Assessment)) (PP (IN of) (NP (DT the) (NN onset)))) (CC and) (NP (NP (NN persistence)) (PP (IN of) (NP (NNP Doc_15930398_43_50_Disease))))) (PP (IN during) (NP (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_83_91_Chemical))))) (. .)))
15930398	1	(S1 (S (VP (TO To) (VP (VP (VB assess) (NP (NP (NNS patients) (POS ')) (NN ability) (S (VP (TO to) (VP (VB repeat) (CC and) (VB recall) (NP (NP (NNS words)) (VP (VBN presented) (PP (TO to) (NP (PRP them))))) (SBAR (IN while) (S (VP (VBG undergoing) (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_220_228_Chemical))))))))))) (, ,) (CC and) (VP (VB correlate) (NP (PRP$ their) (NN recall)) (PP (IN with) (NP (NP (PRP$ their) (NN level)) (PP (IN of) (NP (NN awareness))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (JJ bispectral) (NN index) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (-RRB- -RRB-)) (NN monitoring))))))))) (. .)))
15930398	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ prospective) (, ,) (JJ single-intervention) (NN study)) (PP (IN of) (S (VP (VBG consenting) (NP (NP (NN adult) (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_461_469_Chemical))) (PP (IN between) (NP (NP (NNP December) (CD 28) (, ,) (CD 2002)) (, ,) (CC and) (NP (NNP October) (CD 31) (, ,) (CD 2003)))))))))))) (. .)))
15930398	3	(S1 (S (NP (NN BIS) (NN monitoring)) (VP (AUX was) (VP (VBN initiated) (S (VP (VP (VBG starting) (NP (NP (CD 3) (NNS minutes)) (PP (IN before) (NP (DT the) (NN procedure))))) (CC and) (VP (VBG continuing) (SBAR (IN until) (S (NP (DT the) (NN patient)) (VP (AUX had) (VP (VBN regained) (NP (JJ baseline) (JJ mental) (NN status))))))))))) (. .)))
15930398	4	(S1 (S (PP (IN At) (NP (JJ 1-minute) (NNS intervals))) (PP (IN during) (NP (DT the) (JJ procedural) (NN sedation))) (, ,) (SBAR (IN until) (S (NP (DT the) (NN patient)) (VP (VBD regained) (NP (JJ baseline) (JJ mental) (NN status)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN procedure)))))))) (, ,) (S (NP (NP (DT a) (NN word)) (PP (IN from) (NP (DT a) (JJ standardized) (NN list)))) (VP (AUX was) (VP (VBN read) (ADVP (RB aloud))))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN asked) (S (VP (TO to) (ADVP (RB immediately)) (VP (VB repeat) (NP (DT the) (NN word)) (PP (TO to) (NP (DT the) (NN investigator))))))))) (. .)))
15930398	5	(S1 (S (NP (DT The) (NNS BIS)) (VP (VBP score) (PP (IN at) (NP (DT the) (NN time))) (SBAR (S (S (NP (DT the) (NN word)) (VP (AUX was) (VP (VBN read)))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN ability) (S (VP (TO to) (VP (VB repeat) (NP (DT the) (NN word)))))) (VP (AUX were) (VP (VBN recorded))))))) (. .)))
15930398	6	(S1 (S (PP (IN After) (NP (DT the) (NN procedure))) (, ,) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN asked) (S (VP (TO to) (VP (VB state) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS words)))) (PP (IN from) (NP (DT the) (NN list))) (SBAR (IN that) (S (NP (PRP he) (CC or) (PRP she)) (VP (MD could) (VP (VP (VB recall)) (, ,) (CC and) (VP (TO to) (VP (VB identify) (NP (NP (DT the) (JJ last) (NN word)) (VP (VBN recalled) (PP (PP (IN from) (ADVP (RB prior))) (PP (TO to) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT the) (NN procedure)))))))))))))))))))) (CC and) (S (NP (NP (DT the) (JJ first) (NN word)) (VP (VBN recalled) (PP (IN from) (PP (IN after) (NP (DT the) (NN procedure)))))) (VP (AUX was) (VP (VBN completed)))) (. .)))
15930398	7	(S1 (S (S (NP (JJ Seventy-five) (VBG consenting) (NNS patients)) (VP (AUX were) (VP (VBD enrolled)))) (: ;) (S (NP (CD one) (NN patient)) (VP (AUX was) (VP (VBN excluded) (PP (IN from) (NP (NN data) (NN analysis))) (PP (IN for) (NP (DT a) (NN protocol) (NN violation)))))) (. .)))
15930398	8	(S1 (S (NP (DT No) (JJ serious) (JJ adverse) (NNS events)) (VP (AUX were) (VP (VBN noted) (PP (IN during) (NP (DT the) (JJ procedural) (NNS sedations))))) (. .)))
15930398	9	(S1 (S (NP (NP (DT The) (JJ mean) (-LRB- -LRB-) (JJ +/-standard) (NN deviation) (-RRB- -RRB-) (NN time)) (PP (IN of) (NP (NN data) (NN collection)))) (VP (AUX was) (NP (NP (CD 16.4) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (CD +/-7.1)) (: ;) (S (VP (VB range) (NP (QP (CD 5) (TO to) (CD 34)) (NNS minutes)))) (-RRB- -RRB-)))) (. .)))
15930398	10	(S1 (S (NP (DT The) (JJ mean) (JJ initial) (-LRB- -LRB-) (NN preprocedure) (-RRB- -RRB-) (NN BIS) (NN score)) (VP (AUX was) (NP (NP (CD 97.1)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-2.3)) (: ;) (NP (NN range) (QP (CD 92) (TO to) (CD 99)))) (-RRB- -RRB-)))) (. .)))
15930398	11	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (VP (VBG occurring) (PP (IN during) (NP (DT these) (JJ procedural) (NNS sedations))))) (VP (AUX was) (NP (NP (CD 66.9)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-14.4)) (: ;) (NP (NN range) (CD 33) (TO to) (CD 91))) (-RRB- -RRB-)))) (. .)))
15930398	12	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN patient))) (S (VP (TO to) (ADVP (RB immediately)) (VP (VB repeat) (NP (NP (NNS words)) (VP (VBN read) (PP (IN from) (NP (DT the) (NN list)))))))))))) (VP (AUX was) (NP (NP (CD 77.1)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 74.3) (TO to) (CD 80.0))) (-RRB- -RRB-)))) (. .)))
15930398	13	(S1 (S (NP (NP (DT The) (JJ mean) (JJS highest) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (NNP Doc_15930398_1967_1992_Disease))))) (VP (AUX was) (NP (NP (CD 81.5)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 78.1) (TO to) (CD 84.8))) (-RRB- -RRB-)))) (. .)))
15930398	14	(S1 (S (NP (NP (DT The) (JJ mean) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (NP (DT the) (JJ last) (NN word)) (VP (VBD recalled) (PP (IN from) (ADVP (RB prior))) (PP (TO to) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (DT the) (NN sedation)))))))))) (VP (AUX was) (NP (NP (CD 96.7)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-2.4)) (: ;) (NP (NN range) (CD 84) (TO to) (CD 98))) (-RRB- -RRB-)))) (. .)))
15930398	15	(S1 (S (NP (NP (DT The) (JJ mean) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (JJ first) (NN word))))) (VP (VBD recalled) (SBAR (IN after) (S (S (NP (DT the) (NN procedure)) (VP (AUX was) (VP (VBN completed)))) (VP (AUX was) (NP (NP (CD 91.2)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 88.1) (TO to) (CD 94.3))) (-RRB- -RRB-))))))) (. .)))
15930398	16	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recalled) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN word)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (VP (VBN read) (PP (TO to) (NP (PRP them))) (PP (IN during) (NP (DT the) (NN protocol)))))))))) (. .)))
15930398	17	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (PP (IN for) (NP (DT any)))) (VP (VBD recalled) (SBAR (S (S (NP (NN word)) (VP (AUX was) (NP (NP (CD 91.5)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-11.1)) (: ;) (NP (NN range) (QP (CD 79) (TO to) (CD 98)))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT no) (NNS words)) (VP (AUX were) (VP (VBN recalled) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ corresponding) (NN BIS) (NN score)) (VP (AUX was) (NP (QP (JJR less) (IN than) (CD 90)))))))))))) (. .)))
15930398	18	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NN BIS) (NNS scores))) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (JJ sedated) (NNS patients)) (VP (VP (AUX are) (ADJP (JJ able) (S (VP (TO to) (VP (VB repeat) (NP (NP (NNS words)) (VP (VBN read) (PP (TO to) (NP (PRP them)))))))))) (CC but) (VP (AUX are) (RB not) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB subsequently)) (VP (VB recall) (NP (DT these) (NNS words)))))))))))) (. .)))
15930398	19	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNS patients)) (VP (AUX had) (NP (NP (DT no) (NN recall)) (PP (IN of) (NP (NNS words)))) (VP (VBD repeated) (ADVP (RB prior) (PP (TO to) (NP (JJ procedural) (NN sedation)))) (PP (IN in) (NP (NP (NN BIS) (NNS ranges)) (VP (VBN associated) (PP (IN with) (NP (NP (NN recall)) (PP (IN after) (NP (NP (JJ procedural) (NN sedation)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NNP Doc_15930398_2870_2888_Disease))))))))))))) (. .)))
1595783	0	(S1 (NP (NNP Doc_1595783_0_10_Chemical) (NNP Doc_1595783_11_29_Disease) (. .)))
1595783	1	(S1 (S (NP (NN Doc_1595783_31_41_Chemical)) (VP (AUX is) (NP (NP (NP (DT an) (JJ effective) (NN antiarrhythmic) (NN agent)) (SBAR (WHNP (WP$ whose) (NN utility)) (S (VP (AUX is) (VP (VBN limited) (PP (IN by) (NP (JJ many) (NNS side-effects)))))))) (, ,) (NP (DT the) (ADJP (RBS most) (JJ problematic)) (NN being) (NNP Doc_1595783_153_164_Disease)))) (. .)))
1595783	2	(S1 (S (NP (NP (DT The) (NNP Doc_1595783_170_188_Disease)) (PP (IN of) (NP (NNP Doc_1595783_192_202_Chemical)))) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (NP (JJ direct) (NN injury)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ intracellular) (NN accumulation)) (PP (IN of) (NP (NP (NN phospholipid)) (CC and) (NP (JJ T) (JJ cell-mediated) (NN Doc_1595783_321_349_Disease)))))))))))))) (. .)))
1595783	3	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ radiographic))) (NNS features)) (PP (IN of) (NP (NNP Doc_1595783_393_403_Chemical-induced) (NNP Doc_1595783_412_430_Disease)))) (VP (AUX are) (ADJP (ADJP (JJ characteristic)) (CC but) (ADJP (JJ nonspecific)))) (. .)))
1595783	4	(S1 (S (NP (DT The) (NN diagnosis)) (VP (VBZ depends) (PP (IN on) (NP (NP (NN exclusion)) (PP (IN of) (NP (NP (JJ other) (NNS entities)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_1595783_529_542_Disease)) (, ,) (NP (NNP Doc_1595783_544_553_Disease)) (, ,) (CC and) (NP (NNP Doc_1595783_559_569_Disease))))))))) (. .)))
1595783	5	(S1 (S (SBAR (IN While) (S (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_1595783_591_601_Chemical)))) (VP (VBZ leads) (PP (TO to) (NP (JJ clinical) (NN improvement))) (PP (IN in) (NP (NP (NN majority)) (PP (IN of) (NP (NNS cases)))))))) (, ,) (NP (DT this)) (VP (AUX is) (RB not) (ADVP (RB always)) (ADJP (ADJP (JJ possible)) (CC or) (ADJP (JJ advisable)))) (. .)))
1595783	6	(S1 (S (NP (NP (NN Dose) (NN reduction)) (CC or) (NP (JJ concomitant) (JJ Doc_1595783_726_733_Chemical) (NN therapy))) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (JJ selected) (NNS patients)))))) (. .)))
15974569	0	(S1 (S (NP (NP (CD Two) (NNS prodrugs)) (PP (IN of) (NP (ADJP (ADJP (JJ potent)) (CC and) (ADJP (JJ selective))) (NNP GluR5) (NNP Doc_15974569_43_50_Chemical) (NN receptor) (NNS antagonists)))) (VP (NNS actives) (PP (IN in) (NP (NP (CD three) (JJ animal) (NNS models)) (PP (IN of) (NP (NNP Doc_15974569_106_110_Disease)))))) (. .)))
15974569	1	(S1 (S (NP (NP (NP (JJ Amino) (NNS acids)) (ADVP (CD 5) (CC and) (CD 7))) (, ,) (NP (CD two) (ADJP (JJ potent) (CC and) (JJ selective)) (JJ competitive) (NNP GluR5) (NNP Doc_15974569_176_178_Chemical) (NN receptor) (NNS antagonists)) (, ,)) (VP (VBD exhibited) (NP (NP (JJ high) (JJ GluR5) (NN receptor) (NN affinity)) (PP (IN over) (NP (JJ other) (JJ Doc_15974569_251_260_Chemical) (NNS receptors))))) (. .)))
15974569	2	(S1 (S (NP (PRP$ Their) (NN ester) (NNS prodrugs)) (NP (NP (CD 6)) (CC and) (NP (CD 8))) (VP (AUX were) (ADJP (RB orally) (JJ active) (PP (IN in) (NP (NP (CD three) (NNS models)) (PP (IN of) (NP (NP (NP (NNP Doc_15974569_339_343_Disease)) (: :) (NP (NP (NN reversal)) (PP (IN of) (NP (JJ Doc_15974569_357_365_Chemical-induced) (NN paw) (VBG licking))))) (, ,) (NP (NNP Doc_15974569_387_398_Chemical-induced) (NNP Doc_15974569_407_427_Disease)) (, ,) (CC and) (NP (NNP Doc_15974569_433_442_Chemical-induced) (NNP Doc_15974569_451_474_Disease)))))))) (. .)))
15985056	0	(S1 (FRAG (NP (JJ Possible) (JJ Doc_15985056_9_21_Chemical-associated) (NN Doc_15985056_33_40_Disease)) (. .)))
15985056	1	(S1 (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ persistent) (NN Doc_15985056_84_91_Disease)) (VP (VBN associated) (PP (IN by) (NP (JJ Doc_15985056_106_118_Chemical) (NN therapy))))))))) (. .)))
15985056	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 76-year-old) (NN man)) (VP (VBN presented) (PP (IN with) (NP (JJ persistent) (NN Doc_15985056_186_193_Disease))) (PP (IN after) (S (VP (VBG beginning) (NP (NNP Doc_15985056_210_222_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_15985056_244_255_Disease)))))))))) (. .)))
15985056	3	(S1 (S (NP (NN Doc_15985056_257_264_Disease)) (VP (AUX were) (ADJP (ADJP (JJ persistent)) (CC and) (ADJP (JJ exhausting)))) (. .)))
15985056	4	(S1 (S (NP (NP (NP (NN Discontinuation)) (PP (IN of) (NP (NNP Doc_15985056_316_328_Chemical)))) (CC and) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_15985056_346_354_Chemical))))) (ADVP (RB finally)) (VP (VBD resolved) (NP (NNP Doc_15985056_372_379_Disease))) (. .)))
15985056	5	(S1 (S (NP (NP (DT No) (JJ organic) (NN cause)) (PP (IN of) (NP (NNP Doc_15985056_401_408_Disease)))) (VP (AUX was) (VP (VBN identified) (PP (IN despite) (NP (JJ extensive) (NN investigation))))) (. .)))
15985056	6	(S1 (S (NP (JJ Pharmacotherapeutic) (NNS agents)) (VP (AUX have) (VP (AUX been) (ADVP (RB uncommonly)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_15985056_533_540_Disease)))))) (. .)))
15985056	7	(S1 (S (NP (NP (NP (NNP Corticosteroids)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15985056_559_572_Chemical) (CC and) (NNP Doc_15985056_577_595_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_15985056_598_613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15985056_615_624_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ general) (NNS anaesthesia))) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (JJ specific) (NNS agents)) (VP (VBN mentioned) (ADVP (RBS most) (RB frequently)) (PP (IN in) (NP (DT the) (NN literature))) (PP (IN as) (S (VP (AUXG being) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15985056_768_775_Disease))))))))))))) (. .)))
15985056	8	(S1 (S (NP (NP (JJ Few) (NNS cases)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_15985056_803_810_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (VBN related) (PP (TO to) (NP (JJ Doc_15985056_841_850_Chemical) (NNS antimicrobials))))))) (. .)))
15985056	9	(S1 (S (S (VP (VBG Using) (NP (DT the) (NNP Naranjo) (JJ adverse) (NN effect) (NN reaction) (NN probability) (NN scale)) (NP (DT this) (NN event)))) (VP (MD could) (VP (AUX be) (VP (VBN classified) (PP (IN as) (NP (NP (JJ possible)) (PRN (-LRB- -LRB-) (NP (NN score) (CD 5) (NNS points)) (-RRB- -RRB-)))) (, ,) (PP (ADVP (RB mostly)) (IN because) (IN of) (NP (NP (DT the) (JJ close) (JJ temporal) (NN sequence)) (, ,) (NP (NP (JJ previous) (NNS reports)) (PP (IN on) (NP (NP (DT this) (NN reaction)) (PP (IN with) (NP (JJ other) (NNP Doc_15985056_1080_1090_Chemical)))))) (CC and) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT any) (JJ alternative) (NN explanation)) (PP (IN for) (NP (NNP Doc_15985056_1142_1149_Disease))))))))))) (. .)))
15985056	10	(S1 (S (NP (PRP$ Our) (NN hypothesis)) (VP (AUX is) (SBAR (IN that) (S (NP (NP (DT a) (JJ vagal) (NN mechanism)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_15985056_1204_1216_Chemical))))) (VP (MD could) (VP (AUX be) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_15985056_1246_1253_Disease))) (PP (IN in) (NP (PRP$ our) (NN patient))))))))) (. .)))
15985056	11	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_15985056_1309_1316_Disease)))) (VP (VP (AUX is) (ADJP (JJ difficult))) (CC and) (ADVP (RB often)) (VP (VBN achieved) (ADVP (RB only)) (PP (IN by) (NP (NP (DT a) (NN process)) (PP (IN of) (NP (NN elimination))))))) (. .)))
15985056	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_15985056_1392_1401_Chemical) (NNS antimicrobials)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (SBAR (IN with) (S (NP (NP (NNP Doc_15985056_1458_1465_Disease)) (CC and) (NP (JJ vagal) (NN mechanism))) (VP (MD could) (VP (VB explain) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT this) (NN side-effect))))))))))))))) (. .)))
16006300	0	(S1 (NP (NP (NNP Doc_16006300_0_17_Chemical) (NNP Doc_16006300_18_26_Disease)) (: :) (NP (DT the) (VBN updated) (NNP Doc_16006300_40_60_Disease)) (: ;) (NP (NP (NN report)) (PP (IN of) (NP (NP (CD 3) (NNS cases)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))) (. .)))
16006300	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB describe) (NP (NP (CD 3) (NNS patients)) (PP (IN with) (NP (NNP Doc_16006300_149_166_Chemical-induced) (NNP Doc_16006300_175_188_Disease))))) (CC and) (VP (VB gain) (NP (NP (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN cause) (CC and) (NN management)) (PP (IN of) (NP (DT the) (NNP Doc_16006300_244_264_Disease)))))))))) (. .)))
16006300	2	(S1 (S (NP (PRP We)) (VP (VP (VBP report) (NP (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NNS data)) (PP (IN in) (NP (NP (CD 3) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (NP (JJ severe) (NNP Doc_16006300_358_371_Disease)))))) (PRN (-LRB- -LRB-) (VP (VBN corrected) (NP (NP (NN serum) (JJ Doc_16006300_389_396_Chemical) (NN >)) (CC or) (NP (QP (SYM =) (CD 14) (CD mg/dL))))) (-RRB- -RRB-)))))) (CC and) (VP (VBP review) (NP (NP (DT the) (JJ pertinent) (NN literature)) (PP (IN on) (NP (NNP Doc_16006300_453_473_Disease)))))) (. .)))
16006300	3	(S1 (S (NP (DT The) (CD 3) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_16006300_503_528_Disease)) (, ,) (NP (JJ relative) (NN Doc_16006300_539_558_Disease)) (, ,) (CC and) (NP (NP (JJ low) (NN parathyroid) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP PTH)) (-RRB- -RRB-))) (, ,) (NP (JJ PTH-related) (NN peptide)) (, ,) (CC and) (NP (JJ Doc_16006300_620_643_Chemical) (NNS concentrations)))) (. .)))
16006300	4	(S1 (S (NP (DT No) (JJ malignant) (NN lesion)) (VP (AUX was) (VP (VBN found))) (. .)))
16006300	5	(S1 (S (NP (NN Treatment)) (VP (VBD included) (NP (NP (JJ aggressive) (NN hydration)) (CC and) (NP (NP (JJ varied) (NNS amounts)) (PP (IN of) (NP (NNP Doc_16006300_753_763_Chemical)))))) (. .)))
16006300	6	(S1 (S (NP (NP (DT The) (CD 2) (NNS patients)) (PP (IN with) (NP (DT the) (JJR higher) (NN serum) (JJ Doc_16006300_802_809_Chemical) (NNS concentrations)))) (VP (VBD received) (NP (NP (JJ Doc_16006300_834_845_Chemical) (NN intravenously)) (PRN (-LRB- -LRB-) (NP (NP (CD 60) (CC and) (CD 30) (NNS mg)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD caused) (NP (JJ severe) (NN Doc_16006300_910_922_Disease))))))) (. .)))
16006300	7	(S1 (S (PP (IN Of) (NP (DT the) (CD 3) (NNS patients))) (, ,) (NP (CD 2)) (VP (AUX were) (VP (VBG ingesting) (NP (NP (JJ acceptable) (NNS doses)) (PP (IN of) (NP (NP (JJ elemental) (NNP Doc_16006300_990_997_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NNP g)) (CC and) (NP (NP (CD 2) (NNP g) (NNP daily)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NNP Doc_16006300_1047_1064_Chemical))))))) (. .)))
16006300	8	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (PRP$ our) (VBN highlighted) (NNS cases))))) (, ,) (NP (PRP we)) (VP (VP (VBP review) (NP (NP (DT the) (NN history) (, ,) (NN classification) (, ,) (JJ pathophysiologic) (NNS features)) (, ,) (CC and) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_16006300_1187_1207_Disease)))))) (CC and) (VP (VB summarize) (NP (NP (DT the) (NNS cases)) (VP (VBN reported) (PP (IN from) (NP (JJ early) (CD 1995))) (PP (TO to) (NP (NNP November) (CD 2003))))))) (. .)))
16006300	9	(S1 (S (NP (NN Doc_16006300_1287_1307_Disease)) (VP (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ common) (NN cause)) (PP (IN of) (NP (JJ unexplained) (NN Doc_16006300_1345_1358_Disease)))))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBD precipitated) (PP (IN by) (NP (NP (JJ small) (NNS amounts)) (PP (IN of) (NP (NP (ADJP (RB orally) (VBN ingested)) (NNP Doc_16006300_1419_1436_Chemical)) (PP (IN in) (NP (JJ susceptible) (NNS persons))))))))))) (. .)))
16006300	10	(S1 (S (NP (NP (NP (NN Treatment)) (PP (IN with) (NP (NN hydration)))) (, ,) (NP (NP (NNP Doc_16006300_1487_1497_Chemical) (, ,) (CC and) (NN discontinuation)) (PP (IN of) (NP (DT the) (NNP Doc_16006300_1526_1533_Chemical)))) (CC and) (NP (JJ Doc_16006300_1538_1547_Chemical) (NN source))) (VP (AUX is) (ADJP (JJ adequate))) (. .)))
16006300	11	(S1 (S (NP (JJ Doc_16006300_1568_1579_Chemical) (NN treatment)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ considerable) (NN risk)) (PP (IN for) (NP (NNP Doc_16006300_1631_1643_Disease))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (ADJP (RB initially) (JJ severe)) (NNP Doc_16006300_1679_1692_Disease))))))) (. .)))
16047871	0	(S1 (NP (JJ Doc_16047871_0_8_Chemical-induced) (NN Doc_16047871_17_44_Disease) (. .)))
16047871	1	(S1 (S (NP (NP (NN Skin) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (JJ oral) (JJ Doc_16047871_82_90_Chemical-derived) (NNS anticoagulants))))) (VP (AUX are) (NP (DT an) (JJ uncommon) (NN occurrence))) (. .)))
16047871	2	(S1 (S (NP (NP (NN Doc_16047871_142_169_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16047871_171_173_Disease)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB primarily)) (NP (DT a) (NN Doc_16047871_190_223_Disease)) (, ,) (SBAR (IN though) (S (NP (JJ systemic) (NN involvement)) (VP (MD may) (VP (AUX be) (VP (VBN encountered))))))) (. .)))
16047871	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 4) (NNS patients)) (PP (IN with) (NP (JJ late-onset) (NN Doc_16047871_310_312_Disease)))) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NNP Doc_16047871_329_337_Chemical))))) (. .)))
16047871	4	(S1 (S (NP (DT All) (CD 4) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (NP (NN Doc_16047871_369_383_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (PP (IN after) (S (VP (VBG receiving) (NP (NN Doc_16047871_415_423_Chemical)) (PP (IN for) (NP (JJ several) (NNS years)))))))))))) (. .)))
16047871	5	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (JJ Doc_16047871_458_469_Disease) (NNS biopsies)))) (VP (AUX were) (ADJP (JJ available)) (PP (IN in) (NP (CD 3) (NNS patients))) (, ,) (S (VP (VBG confirming) (NP (NP (NNP Doc_16047871_520_540_Disease)) (VP (VBN resolved) (PP (IN in) (NP (DT all) (NNS patients))) (SBAR (IN after) (S (NP (NNP Doc_16047871_572_580_Chemical)) (VP (AUX was) (VP (VBN discontinued)))))))))) (. .)))
16047871	6	(S1 (S (PP (IN In) (NP (NP (CD 2)) (PP (IN of) (NP (DT the) (CD 4) (NNS patients))))) (, ,) (NP (NP (NN rechallenge)) (PP (IN with) (NP (NNP Doc_16047871_640_648_Chemical)))) (VP (VBD led) (PP (TO to) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT the) (NNS lesions)))))) (. .)))
16047871	7	(S1 (S (NP (NN Doc_16047871_683_685_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ late-onset) (JJ adverse) (NN reaction)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_16047871_739_747_Chemical) (NN therapy))))))) (. .)))
1610717	0	(S1 (S (NP (JJ Doc_1610717_0_7_Chemical-induced)) (VP (VBP brainstem) (NP (NP (NN Doc_1610717_26_34_Disease)) (CC and) (NP (NN behavior)))) (. .)))
1610717	1	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (JJ abnormal) (NN sensory/motor) (NNS behaviors)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ electrical) (NNS discharges)) (VP (VBN recorded) (PP (IN from) (NP (DT the) (JJ bilateral) (NN brainstem)))))))))) (VP (AUX were) (VP (VBN induced) (PP (IN in) (NP (JJ adult) (JJ WKY) (NNS rats))) (PP (PP (IN by) (NP (NP (JJ mechanical) (-LRB- -LRB-) (JJ electrode) (NNS implants) (-RRB- -RRB-)) (CC and) (NP (JJ DC) (JJ electrical) (JJ current) (NNS stimulations)))) (CC and) (PP (IN by) (NP (NP (ADJP (JJ acute) (CC and) (JJ chronic)) (NN administration)) (PP (IN of) (NP (NNP Doc_1610717_319_326_Chemical)))))))) (. .)))
1610717	2	(S1 (S (S (NP (DT The) (NN electrode) (NN implant)) (VP (VBN implicated) (NP (NP (NP (CD one) (NN side)) (CC or) (NP (DT the) (JJ other))) (PP (IN of) (NP (NP (DT the) (JJ reticular) (NN system)) (PP (IN of) (NP (DT the) (NN brainstem)))))))) (CC but) (S (NP (NNS subjects)) (VP (AUX were) (RB not) (VP (VBN incapacitated) (PP (IN by) (NP (DT the) (NNS stimulations)))))) (. .)))
1610717	3	(S1 (S (NP (NP (NN Doc_1610717_481_488_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB subcutaneously)) (PP (IN for) (NP (NP (DT an) (JJ acute) (NN experiment)) (CC and) (NP (JJ subsequent) (ADJP (CD 20) (NN mg/kg)) (NNS doses)))) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 3) (NNS days))) (PP (IN in) (NP (DT a) (JJ chronic) (NN study))))) (. .)))
1610717	4	(S1 (S (NP (NN Doc_1610717_625_632_Chemical)) (VP (VBD generated) (NP (ADJP (RBR more) (JJ abnormal)) (NNS behaviors)) (PP (IN in) (NP (DT the) (NN brainstem) (NN perturbation) (NN group))) (, ,) (NP (RB especially) (DT the) (ADJP (RB electrically) (JJ perturbated)) (NNS subjects))) (. .)))
1610717	5	(S1 (S (NP (DT The) (JJ abnormal) (NNS behaviors)) (VP (AUX were) (VP (VBG yawning) (, ,) (S (NP (NP (NN retrocollis)) (, ,) (NP (NP (NNP Doc_1610717_804_817_Disease)) (, ,) (NP (NNP Doc_1610717_819_835_Disease))) (, ,)) (VP (`` ``) (NN beating) (VB drum) ('' '') (NP (NP (NN behavior)) (, ,) (NP (NN squealing)) (, ,) (NP (NN head) (NN bobbing)) (, ,) (NP (NN circling)) (, ,) (NP (VBG sniffing)) (, ,) (NP (JJ abnormal) (NN posturing)) (, ,) (CC and) (NP (JJ facial) (NN twitching))))))) (. .)))
1610717	6	(S1 (S (NP (NP (NNS Shifts)) (PP (IN in) (NP (NP (DT the) (NN power) (NN frequency) (NNP spectra)) (PP (IN of) (NP (DT the) (NN discharge) (NNS patterns)))))) (VP (AUX were) (VP (VBN noted) (PP (IN between) (NP (UCP (JJ quiet) (CC and) (NN pacing)) (JJ behavioral) (NNS states))))) (. .)))
1610717	7	(S1 (S (S (NP (NP (NN Doc_1610717_1068_1084_Disease)) (PP (TO to) (NP (NP (JJ various) (NN auditory)) (, ,) (NP (NN tactile)) (, ,) (CC and) (NP (JJ visual) (NN stimulation))))) (VP (AUX was) (ADJP (JJ present)))) (CC and) (S (NP (NP (NNS shifts)) (PP (IN in) (NP (DT the) (NN brainstem) (NN ambient) (NN power) (NN spectral) (NN frequency)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ tactile) (NN stimulation))))))) (. .)))
1610717	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN brainstem)) (VP (VBZ generates) (CC and) (VBZ propagates) (NP (NP (JJ pathological) (NNS discharges)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN elicited) (PP (IN by) (NP (JJ mechanical) (CC and) (JJ DC) (JJ electrical) (NN perturbation))))))))))))) (. .)))
1610717	9	(S1 (S (NP (NN Doc_1610717_1414_1421_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VBP activate) (NP (DT the) (NN discharge) (NN system))) (CC and) (ADVP (RB thus)) (VP (VB induce) (NP (NP (JJ abnormal) (NNS behaviors)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBN generated) (PP (PP (IN at) (NP (DT the) (NN discharge) (NN site))) (CC and) (PP (IN at) (NP (NP (JJ distant) (NNS sites)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (DT the) (NN discharge)) (VP (VBZ propagates))))))))))))))))) (. .)))
1610717	10	(S1 (S (S (NP (JJ Cognitive) (NNS functions)) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (VP (VBN involved) (PP (IN since) (NP (NN dopaminergic))))))) (CC and) (S (NP (NP (JJ serotonergic) (JJ cellular) (NNS elements)) (PP (IN at) (NP (DT the) (NN brainstem) (NN level)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN implicated)))) (. .)))
16116131	0	(S1 (S (NP (NP (NNS rTMS)) (PP (IN of) (NP (NN supplementary) (NN motor) (NN area) (NNS modulates)))) (VP (VBD therapy-induced) (NP (NNP Doc_16116131_59_70_Disease)) (PP (IN in) (NP (NNP Doc_16116131_74_91_Disease)))) (. .)))
16116131	1	(S1 (S (NP (NP (NP (DT The) (JJ neural) (NNS mechanisms)) (CC and) (NP (NN circuitry))) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_16116131_141_149_Chemical-induced) (NNP Doc_16116131_158_168_Disease))))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
16116131	2	(S1 (S (S (VP (VBG Using) (NP (NP (JJ repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNS rTMS)) (-RRB- -RRB-))) (PP (IN over) (NP (NP (DT the) (JJ supplementary) (NN motor) (NN area)) (PRN (-LRB- -LRB-) (NP (NNP SMA)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_16116131_317_334_Disease))))))))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN modulation)) (PP (IN of) (NP (NN SMA) (NN excitability)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN modification)) (PP (IN of) (NP (NP (DT a) (JJ Doc_16116131_434_444_Disease) (NN state)) (VP (VBN induced) (PP (IN by) (NP (JJ continuous) (JJ Doc_16116131_473_484_Chemical) (NN infusion))))))))))))) (. .)))
16116131	3	(S1 (S (NP (NP (NNS rTMS)) (PP (IN at) (NP (CD 1) (NN Hz)))) (VP (AUX was) (VP (VBN observed) (S (VP (TO to) (VP (ADVP (RB markedly)) (VB reduce) (NP (NNP Doc_16116131_540_564_Disease))))) (, ,) (SBAR (IN whereas) (S (NP (NN 5-Hz) (NNS rTMS)) (VP (VBN induced) (UCP (DT a) (ADJP (JJ slight)) (CC but) (RB not) (NP (JJ significant) (NN increase)))))))) (. .)))
16132524	0	(S1 (NP (NP (NP (NP (JJ Intracavitary) (JJ chemotherapy)) (PRN (-LRB- -LRB-) (NP (JJ Doc_16132524_28_38_Chemical/Doc_16132524_39_50_Chemical) (JJ liquid) (JJ crystalline) (JJ cubic) (NNS phases)) (-RRB- -RRB-))) (PP (IN for) (NP (JJ recurrent) (NNP Doc_16132524_98_110_Disease)))) (: --) (NP (JJ clinical) (NNS observations)) (. .)))
16132524	1	(S1 (S (NP (JJ Human) (JJ malignant) (NN Doc_16132524_153_165_Disease)) (VP (AUX have) (NP (DT a) (JJ poor) (NN prognosis)) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (NN surgery)) (CC and) (NP (NN radiation) (NN therapy))))))) (. .)))
16132524	2	(S1 (S (NP (JJ Cubic) (NNS phases)) (VP (VBP consist) (PP (IN of) (NP (JJ curved) (JJ biocontinuous) (NN lipid) (NNS bilayers))) (, ,) (S (VP (VBG separating) (NP (NP (CD two) (JJ congruent) (NNS networks)) (PP (IN of) (NP (NN water) (NNS channels))))))) (. .)))
16132524	3	(S1 (S (S (VP (VBN Used) (PP (IN as) (NP (NP (DT a) (NN host)) (PP (IN for) (NP (JJ cytotoxic) (NNS drugs))))))) (, ,) (NP (DT the) (JJ gel-like) (NNP matrix)) (VP (MD can) (ADVP (RB easily)) (VP (AUX be) (VP (VBN applied) (PP (TO to) (NP (NP (DT the) (NNS walls)) (PP (IN of) (NP (DT a) (JJ surgical) (NN resection) (NN cavity)))))))) (. .)))
16132524	4	(S1 (S (PP (IN For) (NP (JJ human) (JJ Doc_16132524_478_490_Disease) (NNS recurrences))) (, ,) (NP (NP (DT the) (NN feasibility) (, ,) (NN safety) (, ,) (CC and) (JJ short-term) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ surgical) (NN intracavitary) (NN application)) (PP (IN of) (NP (NP (NNP Doc_16132524_595_605_Chemical)) (CC and) (NP (NNP Doc_16132524_610_621_Chemical)))) (VP (VBN encapsulated) (PP (IN by) (NP (JJ liquid) (JJ crystalline) (JJ cubic) (NNS phases))))))) (VP (AUX are) (VP (VBN examined) (PP (IN in) (NP (DT a) (NN pilot) (NN study))))) (. .)))
16132524	5	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN recurrence)) (PP (IN of) (NP (DT a) (NNP Doc_16132524_747_759_Disease) (NN multiforme)))))))) (VP (VP (VBD underwent) (NP (NN re-resection))) (CC and) (VP (VBD received) (NP (NP (DT an) (JJ intracavitary) (NN application)) (PP (IN of) (NP (NP (NNP Doc_16132524_839_849_Chemical)) (CC and) (NP (JJ Doc_16132524_854_865_Chemical) (JJ cubic) (NNS phases)))) (PP (IN in) (NP (JJ different) (NNS dosages)))))) (. .)))
16132524	6	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (VBD received) (NP (QP (JJR more) (IN than) (CD 15)) (NNS mg)) (NP (NNP Doc_16132524_946_956_Chemical))) (CC and) (VP (VBD suffered) (PP (IN from) (ADJP (JJ moderate) (TO to) (JJ severe))) (NP (NNP Doc_16132524_994_1005_Disease)) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ remaining) (NNS patients)) (VP (VBD received) (NP (NP (RB only) (DT a) (NN total)) (PP (IN of) (NP (CD 15) (NN mg) (NNP Doc_16132524_1067_1077_Chemical))))))))) (. .)))
16132524	7	(S1 (S (PP (IN In) (NP (DT the) (JJ latter) (NN group))) (, ,) (NP (NNP Doc_16132524_1100_1111_Disease)) (VP (VP (AUX was) (ADVP (RB markedly)) (VP (VBN reduced))) (CC and) (VP (VBD dealt) (ADVP (RB medically)))) (. .)))
16132524	8	(S1 (S (S (NP (NP (JJ Intracavitary) (NN chemotherapy)) (PP (IN in) (NP (JJ recurrent) (NNP Doc_16132524_1194_1206_Disease))) (VP (VBG using) (NP (JJ cubic) (NNS phases)))) (VP (AUX is) (ADJP (ADJP (JJ feasible)) (CC and) (ADJP (JJ safe))))) (, ,) (CC yet) (S (NP (DT the) (JJ clinical) (NN benefit)) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN in) (NP (DT a) (JJ clinical) (NN phase) (NNP II) (NN study))))))))) (. .)))
16157917	0	(S1 (S (NP (NN Doc_16157917_0_11_Chemical)) (VP (VBN associated) (PP (PP (IN with) (NP (NN exacerbation))) (CC or) (PP (IN de) (NP (NP (NNP novo) (NNP Doc_16157917_52_61_Disease)) (PP (IN in) (NP (NNP Doc_16157917_65_98_Disease))))))) (. .)))
16157917	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16157917_119_152_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_154_157_Disease)) (-RRB- -RRB-)))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16157917_172_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_185_188_Chemical)) (-RRB- -RRB-)))))) (VP (VBD experienced) (NP (NP (NN exacerbation)) (CC or) (NP (NP (FW de) (FW novo) (NN appearance)) (PP (IN of) (NP (NP (NNP Doc_16157917_240_255_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_257_259_Disease)) (-RRB- -RRB-))))))) (. .)))
16157917	2	(S1 (S (PP (IN In) (NP (CD three) (NNS patients))) (, ,) (NP (NNP Doc_16157917_281_284_Chemical)) (VP (VBD exacerbated) (NP (NNP Doc_16157917_297_299_Disease)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (PP (IN with) (NP (JJ early) (NN aggravation))) (PP (IN during) (NP (NN titration)))) (. .)))
16157917	3	(S1 (S (NP (NN Doc_16157917_368_370_Disease)) (VP (VBD disappeared) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_16157917_388_391_Chemical) (NN dose)) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (QP (CD 25) (TO to) (CD 50)) (NN %)))))))) (. .)))
16157917	4	(S1 (S (PP (IN In) (NP (CD two) (NNS patients))) (, ,) (NP (NNP Doc_16157917_442_445_Chemical)) (VP (VBD exacerbated) (NP (NNP Doc_16157917_458_460_Disease)) (PP (IN in) (NP (DT a) (ADJP (ADJP (VBN delayed)) (CC but) (ADJP (RBR more) (JJ severe))) (NN manner))) (, ,) (PP (IN with) (NP (NP (NN Doc_16157917_503_519_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB only)) (VP (VBD ceased) (PP (IN after) (NP (JJ Doc_16157917_543_546_Chemical) (NN withdrawal))))))))) (. .)))
16174948	0	(S1 (NP (NP (NN Absence)) (PP (IN of) (NP (JJ acute) (JJ cerebral) (NN vasoconstriction))) (PP (IN after) (NP (NNP Doc_16174948_49_56_Chemical-associated) (NNP Doc_16174948_68_91_Disease))) (. .)))
16174948	1	(S1 (S (NP (JJ Doc_16174948_107_114_Chemical) (NN use)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16174948_144_171_Disease))) (, ,) (PP (VBG including) (NP (NP (JJ arterial) (NN vasoconstriction)) (CC and) (NP (NN Doc_16174948_213_223_Disease))))))) (. .)))
16174948	2	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (JJ few) (NNS studies)) (PP (IN of) (NP (NP (JJ angiographic) (NNS effects)) (PP (IN of) (NP (NNP Doc_16174948_283_290_Chemical))))) (PP (IN on) (NP (JJ human) (JJ cerebral) (NNS arteries))))) (. .)))
16174948	3	(S1 (S (NP (NP (NN Information)) (PP (IN on) (NP (DT these) (NNS effects)))) (VP (MD could) (VP (AUX be) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS angiograms)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16174948_399_406_Chemical-associated) (NNP Doc_16174948_418_441_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16174948_443_446_Disease)) (-RRB- -RRB-)))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN angiography)) (PP (ADVP (RB shortly)) (IN after) (NP (JJ Doc_16174948_488_495_Chemical) (NN use))))))))))))) (. .)))
16174948	4	(S1 (S (NP (PRP We)) (VP (VP (VBD screened) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16174948_536_539_Disease) (NN retrospectively))))) (CC and) (VP (VBD identified) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ positive) (NN urine) (NN toxicology)) (PP (IN for) (NP (NP (NNP Doc_16174948_612_619_Chemical)) (CC or) (NP (PRP$ its) (NNS metabolites))))))))) (. .)))
16174948	5	(S1 (S (NP (NP (JJ Quantitative) (JJ arterial) (NN diameter) (NNS measurements)) (PP (IN from) (NP (NP (NNS angiograms)) (PP (IN of) (NP (DT these) (NNS patients)))))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (NNS measurements)) (PP (IN from) (NP (NN control) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_16174948_775_778_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN matched) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN known) (S (VP (TO to) (VP (VB influence) (NP (JJ arterial) (NN diameter)))))))))))))))))) (. .)))
16174948	6	(S1 (S (NP (NP (JJ Qualitative) (NNS comparisons)) (PP (IN of) (NP (JJ small) (NN artery) (NNS changes)))) (ADVP (RB also)) (VP (AUX were) (VP (VBN made))) (. .)))
16174948	7	(S1 (S (NP (NP (JJ Thirteen) (NNS patients)) (PP (IN with) (NP (JJ positive) (JJ Doc_16174948_951_958_Chemical) (NN toxicology)))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (CD 26) (NNS controls))))) (. .)))
16174948	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN in) (NP (NP (NP (DT the) (JJ mean) (NNS diameters)) (PP (IN of) (NP (DT the) (JJ intradural) (JJ internal) (NN carotid)))) (, ,) (NP (NP (JJ sphenoidal) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ middle) (JJ cerebral) (, ,) (JJ precommunicating) (NN segment)) (PP (IN of) (NP (DT the) (NNP anterior) (NN cerebral)))))) (, ,) (CC or) (NP (NP (NN basilar) (NNS arteries)) (PRN (-LRB- -LRB-) (NP (NP (NNS p)) (NP (NP (QP (JJR greater) (IN than) (CD 0.05))) (PP (IN for) (NP (DT all) (NNS comparisons)))) (, ,) (NP (JJ unpaired) (NNS t-tests))) (-RRB- -RRB-))))))))) (. .)))
16174948	9	(S1 (S (NP (EX There)) (ADVP (RB also)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (SBAR (WHADVP (WRB when)) (S (VP (VBG expressing) (NP (NNS diameters)) (PP (IN as) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NP (DT the) (JJ precommunicating) (NN segment)) (PP (IN of) (NP (NP (DT the) (NNP anterior) (JJ cerebral) (NN +) (NN sphenoidal) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ middle) (JJ cerebral) (NN +) (NN supraclinoid)) (NP (NP (JJ internal) (JJ carotid) (NN artery) (NN +) (NN basilar) (NN artery)) (VP (VBN divided) (PP (IN by) (NP (NP (DT the) (NN diameter)) (PP (IN of) (NP (NP (DT the) (JJ petrous) (JJ internal) (NN carotid) (NN artery)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR greater) (IN than) (CD 0.05))) (, ,) (NP (JJ unpaired) (NNS t-tests)) (-RRB- -RRB-))))))))))))))))))))))) (. .)))
16174948	10	(S1 (S (NP (JJ Qualitative) (NNS assessments)) (VP (VBD showed) (NP (NP (CD two) (JJ arterial) (NNS irregularities)) (PP (IN in) (NP (NP (DT the) (JJ distal) (NN vasculature)) (PP (IN in) (NP (DT each) (NN group))))))) (. .)))
16174948	11	(S1 (S (NP (NP (DT No) (JJ quantitative) (NN evidence)) (PP (IN for) (NP (NP (NN narrowing)) (PP (IN of) (NP (NP (JJ large) (JJ cerebral) (NNS arteries)) (CC or) (NP (JJ qualitative) (JJ angiographic) (NN evidence)))) (PP (IN for) (NP (NP (JJ distal) (NN narrowing)) (CC or) (NP (NNP Doc_16174948_1881_1891_Disease))))))) (VP (MD could) (VP (AUX be) (VP (VBN found) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN angiography)) (PP (IN after) (NP (NP (NNP Doc_16174948_1951_1961_Disease) (NNP Doc_16174948_1962_1965_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_16174948_1982_1989_Chemical) (NN use)))))))))))))) (. .)))
16192988	0	(S1 (S (NP (NP (JJ Doc_16192988_0_15_Chemical) (NNS causes) (NNS alterations)) (PP (IN in) (NP (DT the) (NN MAP)))) (VP (VBD kinase-related) (ADVP (RB pathways)) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NNS mice))))) (SBAR (IN that) (S (NP (NN display)) (VP (VBD increased) (NP (NNP Doc_16192988_115_129_Disease)))))) (. .)))
16192988	1	(S1 (S (NP (NNP Doc_16192988_131_151_Disease)) (VP (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP suffer) (PP (IN from) (NP (DT some) (NN Doc_16192988_204_225_Disease))))))))))) (, ,) (CC and) (VP (AUX are) (ADJP (JJ common) (PP (IN in) (NP (NNP Doc_16192988_245_260_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16192988_262_266_Chemical)) (-RRB- -RRB-)) (NNS abusers)))))) (. .)))
16192988	2	(S1 (S (NP (NN Herein)) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP (NP (JJ multiple) (PRN (-LRB- -LRB-) (CC but) (ADJP (RB not) (JJ single)) (-RRB- -RRB-)) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_340_344_Chemical)))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NNP Doc_16192988_369_383_Disease)) (PP (IN in) (NP (JJ male) (JJ CD-1) (NNS mice))))))) (. .)))
16192988	3	(S1 (S (NP (NP (DT This) (NN increase)) (PP (IN in) (NP (NNP Doc_16192988_420_434_Disease)))) (VP (AUX was) (RB not) (ADJP (JJ secondary) (PP (TO to) (NP (NNP Doc_16192988_456_460_Chemical-induced) (NNP Doc_16192988_469_482_Disease))))) (. .)))
16192988	4	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NN protein) (NN expression)) (VP (VBG using) (NP (NP (NN antibody) (NNS microarrays)) (CC and) (NP (JJ Western) (VBG blotting))))))) (VP (VBD revealed) (NP (NN differential) (NNS changes)) (PP (IN in) (NP (NN MAP) (JJ kinase-related) (NNS pathways))) (PP (IN after) (NP (NP (NN multiple)) (CC and) (NP (JJ single) (JJ Doc_16192988_650_654_Chemical) (NNS injections))))) (. .)))
16192988	5	(S1 (S (S (NP (EX There)) (VP (AUX were) (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (CD p<0.05)) (-RRB- -RRB-)))) (VP (VP (VBZ decreases) (PP (IN in) (NP (NP (NNP MEK1)) (, ,) (NP (NAC (NNP Erk2p) (, ,) (NNP GSK3alpha) (, ,)) (NN 14-3-3e)) (, ,)))) (CC and) (VP (VBZ MEK7) (PP (IN in) (NP (NP (DT the) (NN striata)) (PP (IN of) (NP (NNS mice))))) (PP (IN after) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_820_824_Chemical))))))) (. .)))
16192988	6	(S1 (S (NP (NN MEK1)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN decreased) (ADVP (RB also)) (PP (PP (IN after) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NNP Doc_16192988_892_896_Chemical))))) (, ,) (CC but) (PP (TO to) (NP (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN degree)) (PP (IN than) (PP (IN after) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_960_964_Chemical))))))))))) (. .)))
16192988	7	(S1 (S (PP (IN In) (NP (DT the) (JJ frontal) (NN cortex))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PP (IN in) (NP (NN GSK3alpha))) (PP (IN after) (NP (NP (JJ multiple) (PRN (-LRB- -LRB-) (CONJP (CC but) (RB not)) (ADJP (JJ single)) (-RRB- -RRB-)) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_1095_1099_Chemical))))))) (. .)))
16192988	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN MAP) (JJ kinase-related) (NNS pathways)) (PP (IN in) (NP (DT the) (JJ prefronto-striatal) (NNS circuitries)))))) (VP (MD might) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NNP Doc_16192988_1252_1272_Disease))) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
16225977	0	(S1 (S (NP (NN Doc_16225977_0_11_Chemical)) (VP (VBD related) (NP (NNP Doc_16225977_20_37_Disease)) (PP (IN in) (NP (DT an) (JJ adolescent) (NN Doc_16225977_55_68_Disease)))) (. .)))
16225977	1	(S1 (S (NP (NN Doc_16225977_70_83_Disease)) (VP (MD can) (VP (AUX be) (ADVP (RB effectively)) (VP (VBN treated) (PP (IN by) (NP (NP (JJ atypical) (NNS antipsychotics)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_16225977_146_157_Chemical)) (, ,) (NP (NNP Doc_16225977_159_169_Chemical)) (CC and) (NP (NNP Doc_16225977_174_185_Chemical))))))))) (. .)))
16225977	2	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (CD two) (NN case) (NNS reports)) (SBAR (WHNP (WDT that)) (S (VP (VBP show) (NP (NN Doc_16225977_233_250_Disease))))) (, ,) (PP (VBG including) (NP (UCP (NN motor) (CC and) (JJ phonic)) (NNS variants))) (, ,) (VP (VBG occurring) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_16225977_321_331_Chemical) (CC or) (NNP Doc_16225977_335_344_Chemical)))))) (. .)))
16225977	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 15-year-old) (NN girl) (NN Doc_16225977_376_389_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ frequent) (NN Doc_16225977_413_447_Disease)) (PP (IN after) (NP (NP (CD 5) (NNS months)) (PP (IN of) (NP (NP (JJ Doc_16225977_466_477_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))))))))) (. .)))
16225977	4	(S1 (S (NP (DT The) (NNP Doc_16225977_511_528_Disease)) (VP (VBD resolved) (ADVP (RB completely)) (SBAR (IN after) (S (NP (PRP we)) (VP (VBD reduced) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_16225977_578_589_Chemical)))) (ADVP (RB down)) (PP (TO to) (NP (NP (CD 800) (NNS mg)) (PP (IN per) (NP (NN day))))))))) (. .)))
16225977	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP her) (NNP Doc_16225977_627_636_Disease)) (VP (VBD recurred) (PP (IN after) (NP (DT the) (NN dose) (NN reduction)))) (. .)))
16225977	6	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD placed) (NP (PRP her)) (PP (IN on) (NP (NP (DT an) (JJ additional) (CD 100) (NNS mg)) (PP (IN per) (NP (NP (NN day)) (PP (IN of) (NP (NNP Doc_16225977_726_736_Chemical)))))))) (. .)))
16225977	7	(S1 (S (NP (PRP She)) (VP (VP (AUX has) (VP (AUX been) (PP (IN in) (NP (JJ complete) (NN remission))) (PP (IN under) (NP (NP (DT the) (VBN combined) (NNS medications)) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year))))))) (CC and) (VP (VBZ maintains) (NP (DT a) (JJ fair) (NN role) (NN function)))) (. .)))
16225977	8	(S1 (S (NP (DT No) (JJR more) (UCP (NNP Doc_16225977_871_888_Disease) (CC or) (JJ other)) (NN side) (NNS effects)) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
16225977	9	(S1 (S (ADVP (RB Together) (PP (IN with) (NP (ADJP (RB previously) (VBN reported)) (NNS cases)))) (, ,) (NP (PRP$ our) (NN patient)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_16225977_998_1015_Disease)) (VP (MD might) (VP (VB occur) (PP (IN in) (NP (JJ certain) (JJ vulnerable) (NNS individuals))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ atypical) (NNS antipsychotics)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_16225977_1116_1126_Chemical)) (, ,) (NP (NNP Doc_16225977_1128_1137_Chemical)) (, ,) (CC or) (NP (NNP Doc_16225977_1142_1153_Chemical))))))))))))) (. .)))
1628552	0	(S1 (NP (NP (NP (JJ Doc_1628552_0_11_Chemical) (JJ related) (JJ complete) (NN Doc_1628552_29_40_Disease)) (PP (IN with) (NP (NNP Doc_1628552_46_55_Disease)))) (: :) (NP (NN case) (NN report)) (. .)))
1628552	1	(S1 (S (NP (NP (DT A) (JJ 27-year) (JJ old) (JJ African) (NN woman)) (PP (IN with) (NP (NP (NN history)) (PP (IN of) (NP (JJ regular) (JJ Doc_1628552_122_133_Chemical) (NN ingestion)))))) (VP (VBD presented) (PP (IN with) (NP (JJ progressive) (NAC (NNP Doc_1628552_171_194_Disease) (, ,) (JJ easy) (NNP Doc_1628552_201_214_Disease) (, ,) (NNP Doc_1628552_216_224_Disease) (, ,)) (NNP Doc_1628552_226_235_Disease))) (PP (VBG progressing) (PP (TO to) (NP (NNP Doc_1628552_251_267_Disease))))) (. .)))
1628552	2	(S1 (S (NP (JJ Ophthalmological) (NN assessment)) (VP (VBD revealed) (NP (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_1628552_318_329_Chemical) (NNP Doc_1628552_330_341_Disease)))) (, ,) (NP (NP (JJ cardiac) (NN assessment) (VBN revealed) (NNS features)) (PP (IN of) (NP (NNP Doc_1628552_383_396_Disease)))) (CC and) (NP (NP (DT a) (JJ complete) (NN Doc_1628552_412_423_Disease)) (PP (IN with) (NP (NNP Doc_1628552_429_454_Disease) (NN pattern)))))) (. .)))
1628552	3	(S1 (S (S (NP (DT The) (NNP Doc_1628552_468_479_Disease)) (VP (AUX was) (VP (VBN treated) (PP (IN by) (NP (NN pacemaker) (NN insertion)))))) (CC and) (S (NP (DT the) (NNP Doc_1628552_523_536_Disease)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (VBG following) (NP (JJ Doc_1628552_570_581_Chemical) (NN discontinuation))))) (. .)))
1628552	4	(S1 (S (NP (PRP She)) (ADVP (RB however)) (VP (VBZ remains) (NP (NN Doc_1628552_619_624_Disease))) (. .)))
1636026	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_1636026_11_19_Chemical))) (PP (IN on) (NP (DT the) (VBN isolated) (JJ perfused) (NN rat) (NN kidney))) (. .)))
1636026	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_1636026_66_74_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_1636026_119_138_Disease))) (PP (IN in) (NP (QP (JJR greater) (IN than) (CD 100)) (NNS subjects)))))))))) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN damage)))) (VP (VBZ remains) (ADJP (JJ unclear))) (. .)))
1636026	2	(S1 (S (NP (NP (DT The) (JJ direct) (JJ Doc_1636026_221_232_Disease) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 15) (NN mg)) (PP (IN of) (NP (NNP Doc_1636026_270_278_Chemical)))))))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (DT the) (JJ recirculating) (JJ isolated) (NN rat) (NN kidney))) (PP (VBN perfused) (PP (IN with) (NP (JJ cell-free) (NN buffer)))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (CD 5) (NN mg/dL)) (PP (IN of) (NP (NNP Doc_1636026_408_417_Chemical)))))))))) (. .)))
1636026	3	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NP (JJ renal) (JJ Doc_1636026_466_472_Chemical) (NN excretion)) (, ,) (NP (JJ Doc_1636026_484_490_Chemical) (NN consumption)) (, ,) (CC or) (NP (JJ urinary) (NN flow) (NNS rates))) (PP (IN in) (NP (NP (NNS kidneys)) (VP (VBN perfused) (PP (IN with) (NP (NNP Doc_1636026_551_559_Chemical))))))))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ drug-free) (NN control) (NNS groups))))) (. .)))
1636026	4	(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT a) (JJ significant) (NN decline)) (PP (IN in) (NP (JJ glomerular) (NN filtration) (NN rate)))) (VP (AUX was) (VP (VBN found) (PP (IN after) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_1636026_705_713_Chemical))) (PP (TO to) (NP (NP (DT the) (NN kidney)) (VP (VBN perfused) (PP (IN with) (NP (NNP Doc_1636026_742_751_Chemical))))))))))) (: ;) (S (NP (DT no) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN with) (NP (NNP Doc_1636026_780_788_Chemical))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_1636026_807_816_Chemical)))))))) (. .)))
1636026	5	(S1 (S (NP (NP (DT A) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ baseline) (NN excretion) (NN rate)) (PP (IN of) (NP (NNP Doc_1636026_875_884_Chemical)))))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN given) (NP (NNP Doc_1636026_909_917_Chemical))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ drug-free) (NNS controls)))))) (. .)))
1636026	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ fractional) (NN excretion)) (PP (IN of) (NP (NNP Doc_1636026_990_999_Chemical)))) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN over) (NP (DT the) (JJ experimental) (NN period)))))) (. .)))
1636026	7	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NNP Doc_1636026_1075_1083_Chemical)) (VP (VBZ causes) (NP (NP (NNP Doc_1636026_1091_1123_Disease)) (, ,) (ADJP (RBS most) (JJ likely))) (PP (IN by) (S (VP (ADVP (RB directly)) (VBG altering) (NP (NP (DT the) (JJ intrarenal) (NN distribution)) (PP (IN of) (NP (NN Doc_1636026_1189_1198_Chemical)))))))) (. .)))
16364460	0	(S1 (S (NP (NP (NN Microinjection)) (PP (IN of) (NP (NNP Doc_16364460_18_28_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (NNS hippocampus)))))) (VP (VBZ improves) (NP (NP (JJ Doc_16364460_73_84_Chemical-induced) (NN Doc_16364460_93_100_Disease)) (PP (IN in) (NP (NN adult) (NN male) (NNS rats))))) (. .)))
16364460	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_16364460_135_145_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 5-HT2) (NN antagonist)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ Doc_16364460_168_179_Chemical) (PRN (-LRB- -LRB-) (NP (JJ muscarinic) (JJ cholinergic) (NN antagonist)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_16364460_224_231_Disease)) (PP (IN in) (NP (NNP Morris) (NN water) (NN maze))) (PRN (-LRB- -LRB-) (NP (NNP MWM)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
16364460	2	(S1 (S (NP (NNS Rats)) (VP (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (CD eight) (NNS groups))))) (CC and) (VP (ADVP (RB bilaterally)) (VBN cannulated) (PP (IN into) (NP (NP (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NN hippocampus))))))) (. .)))
16364460	3	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (NP (PRP they)) (VP (VBD received) (ADVP (RB repeatedly)) (NP (NP (NP (NNS vehicles)) (PRN (-LRB- -LRB-) (NP (NN saline)) (, ,) (NP (NNP Doc_16364460_435_439_Chemical)) (, ,) (NP (NN saline+Doc_16364460_448_452_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_16364460_455_466_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD microg/0.5)) (NN microl) (NN saline/side)) (: ;) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NN training)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16364460_526_536_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2)) (, ,) (NP (NP (QP (CD 4) (CC and) (CD 8) (CD microg/0.5)) (JJ microl) (NNP Doc_16364460_567_571_Chemical/side)) (: ;) (NP (NP (CD 20) (NN min)) (PP (IN before) (NP (NN training))))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_16364460_606_617_Chemical) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2) (CD microg/0.5)) (NN microl)) (: ;) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (JJ Doc_16364460_654_664_Chemical) (NN injection))))) (-RRB- -RRB-)) (NN +Doc_16364460_676_686_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4) (CD microg/0.5)) (NN microl)) (NP (NNP Doc_16364460_708_712_Chemical))) (-RRB- -RRB-)) (PP (IN through) (NP (NP (NNS cannulae)) (NP (DT each) (NN day))))) (. .)))
16364460	4	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NP (CD four) (JJ consecutive) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN trial/day)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD MWM)) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NP (DT the) (NN position)) (PP (IN of) (NP (JJ hidden) (NN platform)))) (VP (AUX was) (ADJP (JJ unchanged))))))))) (. .)))
16364460	5	(S1 (S (PP (IN In) (NP (DT the) (JJ fifth) (NN day))) (, ,) (NP (DT the) (NN platform)) (VP (AUX was) (VP (VBD elevated) (PP (IN above) (NP (NP (DT the) (NN water) (NN surface)) (PP (IN in) (NP (NP (DT another) (NN position)) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (UCP (NN motor) (, ,) (JJ motivational) (CC and) (JJ visual)) (NNS systems)))))))))))))) (. .)))
16364460	6	(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN escape) (NNS latencies))))) (CC and) (VP (VBD traveled) (NP (NP (NNS distances)) (SBAR (S (VP (TO to) (VP (VB find) (NP (NN platform)) (PP (IN in) (NP (JJ Doc_16364460_1129_1140_Chemical-treated) (NN group))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ saline) (NN group))))))))))))) (. .)))
16364460	7	(S1 (S (NP (NP (JJ Doc_16364460_1184_1194_Chemical-treated) (NNS rats)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD microg/0.5)) (NN microl/side)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (DT the) (VBN mentioned) (NNS parameters)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ Doc_16364460_1308_1312_Chemical-treated) (NN group))))))) (. .)))
16364460	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_16364460_1337_1348_Chemical) (CC and) (NNP Doc_16364460_1353_1363_Chemical) (NN co-administration)) (VP (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN escape) (NNS latencies)))))) (CC and) (VP (VBD traveled) (NP (NNS distances)) (ADVP (RB as)) (PP (VBN compared) (PP (TO to) (NP (DT the) (JJ Doc_16364460_1479_1490_Chemical-treated) (NNS rats)))))) (. .)))
16364460	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_16364460_1546_1556_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NNS hippocampus)))))) (VP (VBZ improves) (NP (DT the) (JJ Doc_16364460_1609_1620_Chemical-induced) (NN Doc_16364460_1629_1636_Disease)))))) (. .)))
16418614	0	(S1 (NP (NP (JJ Doc_16418614_0_3_Chemical-associated) (NN Doc_16418614_15_25_Disease)) (PP (IN in) (NP (NP (DT a) (NN girl)) (PP (IN with) (NP (NP (NNP Doc_16418614_41_56_Disease)) (CC and) (NP (NNP Doc_16418614_61_76_Disease)))))) (. .)))
16418614	1	(S1 (S (NP (NNP Palpable) (NNP Doc_16418614_87_94_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (VBG concerning) (JJ clinical) (NN finding)) (PP (IN in) (NP (JJ pediatric) (NNS patients))))) (CC and) (VP (MD can) (VP (AUX have) (NP (NP (JJ many) (NNS causes)) (, ,) (PP (VBG including) (NP (JJ infectious) (CC and) (JJ autoimmune) (NNS processes))))))) (. .)))
16418614	2	(S1 (S (NP (NP (DT A) (JJ rare) (NN cause)) (, ,) (NP (JJ drug-induced) (NNP Doc_16418614_250_260_Disease)) (, ,)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ antineutrophil) (JJ cytoplasmic) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (NNP ANCAs)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT a) (NN medication))))))) (. .)))
16418614	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN girl)) (PP (IN with) (NP (NP (NNP Doc_16418614_393_408_Disease)) (CC and) (NP (NNP Doc_16418614_413_428_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (NP (JJ palpable) (NN Doc_16418614_457_473_Disease)))))))) (. .)))
16418614	4	(S1 (S (NP (NP (DT The) (NN diagnosis)) (PP (IN of) (NP (NP (NNP Doc_16418614_492_508_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16418614_510_513_Chemical)) (-RRB- -RRB-))))) (VP (VBD -associated) (SBAR (S (NP (NNP Doc_16418614_526_536_Disease)) (VP (AUX was) (VP (VBN made) (PP (IN by) (NP (NP (NP (NN observation)) (PP (IN of) (NP (JJ consistent) (JJ clinical) (NNS features)))) (, ,) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (NP (JJ elevated) (NNP ANA)) (CC and) (NP (NNP ANCA)))) (PP (IN in) (NP (DT the) (NN blood)))) (, ,) (CC and) (NP (NP (DT the) (JJ observed) (JJ clinical) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (VBG following) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_16418614_720_723_Chemical))))))))))))) (. .)))
16418614	5	(S1 (S (NP (NP (JJ Subsequent) (NN treatment)) (PP (IN of) (NP (JJ persistent) (NNP Doc_16418614_760_775_Disease))) (PP (IN with) (NP (NN radioablation)))) (VP (AUX did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN exacerbation)) (PP (IN of) (NP (DT the) (NNP Doc_16418614_836_846_Disease)))) (, ,) (NP (NP (DT a) (NN complication)) (VP (VBN described) (PP (IN in) (NP (JJ prior) (NN case) (NNS reports))))))))) (. .)))
16428827	0	(S1 (S (NP (NN Doc_16428827_0_8_Chemical)) (VP (VP (VBZ activates) (NP (NP (JJ Doc_16428827_19_26_Chemical) (NN acetyltransferase)) (PP (IN from) (NP (JJ MC-IXC) (NNS cells))))) (CC and) (VP (VBZ improves) (NP (JJ drug-induced) (NN Doc_16428827_89_96_Disease)))) (. .)))
16428827	1	(S1 (S (NP (NP (DT The) (JJ Doc_16428827_102_109_Chemical) (NN acetyltransferase) (-LRB- -LRB-) (VB ChAT) (-RRB- -RRB-) (NN activator)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ enhances) (NP (JJ cholinergic) (NN transmission)) (PP (IN via) (NP (NP (DT an) (NN augmentation)) (PP (IN of) (NP (NP (DT the) (JJ enzymatic) (NN production)) (PP (IN of) (NP (NP (NNP Doc_16428827_237_250_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_252_255_Chemical)) (-RRB- -RRB-))))))))))) (, ,)) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN factor)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_16428827_301_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_322_324_Disease)) (-RRB- -RRB-)))))))) (. .)))
16428827	2	(S1 (S (NP (NP (JJ Methanolic) (NNS extracts)) (PP (IN from) (NP (NNP Pueraria) (NNS thunbergiana)))) (VP (VBD exhibited) (NP (NP (DT an) (JJ activation) (NN effect)) (PRN (-LRB- -LRB-) (NP (CD 46) (NN %)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (VB ChAT)) (PP (IN in) (NP (NN vitro)))))) (. .)))
16428827	3	(S1 (S (PP (IN Via) (NP (NP (DT the) (JJ sequential) (NN isolation)) (PP (IN of) (NP (NNP Pueraria) (NNS thunbergiana))))) (, ,) (NP (DT the) (JJ active) (NN component)) (VP (AUX was) (ADVP (RB ultimately)) (VP (VBN identified) (PP (IN as) (NP (NP (NNP Doc_16428827_534_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_544_569_Chemical)) (-RRB- -RRB-)))))) (. .)))
16428827	4	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_16428827_611_619_Chemical))) (PP (IN from) (NP (NNP Pueraria) (NNS thunbergiana))) (PP (IN on) (NP (NNP Doc_16428827_650_661_Chemical-induced) (NNP Doc_16428827_670_704_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (NN series)) (PP (IN of) (PP (IN in) (NP (NN vivo) (NNS tests)))))) (. .)))
16428827	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NNP Doc_16428827_764_772_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4.5) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS mice)))) (VP (AUX was) (VP (VBN shown) (ADVP (RB significantly)) (S (VP (TO to) (VP (VB reverse) (NP (JJ Doc_16428827_840_851_Chemical-induced) (NNP Doc_16428827_860_867_Disease))))) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT a) (JJ Y-maze) (NN test)))))))) (. .)))
16428827	6	(S1 (S (NP (NP (NNS Injections)) (PP (IN of) (NP (NNP Doc_16428827_926_937_Chemical))) (PP (IN into) (NP (NNS mice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN impaired) (NN performance)) (PP (IN on) (NP (NP (JJ Y-maze) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (CD 37) (NN %) (NNS decreases)) (PP (IN in) (NP (JJ alternation) (NN behavior)))) (-RRB- -RRB-))))))) (. .)))
16428827	7	(S1 (S (PP (IN By) (NP (NP (NN way)) (PP (IN of) (NP (NN contrast))))) (, ,) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16428827_1078_1086_Chemical))))) (ADVP (RB prior) (PP (TO to) (NP (DT the) (JJ Doc_16428827_1100_1111_Chemical) (NNS injections)))) (VP (AUX were) (ADVP (RB noticeably)) (VP (VBN protected) (PP (IN from) (NP (NP (DT this) (NN performance) (NN impairment)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (ADJP (QP (RB approximately) (CD 12)) (NN %)) (ADJP (CD -21) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ alternation) (NN behavior)))) (-RRB- -RRB-)))))) (. .)))
16428827	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NNP Doc_16428827_1271_1279_Chemical)) (VP (MD might) (VP (VB play) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NP (JJ Doc_16428827_1301_1314_Chemical) (NNS biosynthesis)) (PP (IN as) (NP (DT a) (VB ChAT) (NN activator)))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (ADVP (RB also)) (VP (VBZ ameliorates) (NP (JJ Doc_16428827_1378_1389_Chemical-induced) (NN Doc_16428827_1398_1405_Disease))))))) (. .)))
16471092	0	(S1 (NP (NP (NP (JJ Urinary) (NNS symptoms)) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life) (NNS changes))))) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NNP Doc_16471092_64_82_Disease))))) (PP (IN after) (NP (JJ Doc_16471092_89_100_Chemical) (NN treatment))) (. .)))
16471092	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN urinary) (NNS symptoms) (CC and) (NN quality)) (PP (IN of) (NP (NP (NN life) (NNS changes)) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NP (NNP Doc_16471092_201_219_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16471092_221_224_Disease)) (-RRB- -RRB-))))))))) (PP (IN after) (NP (JJ Doc_16471092_232_243_Chemical) (NN treatment)))))) (. .)))
16471092	2	(S1 (NP (NP (NP (NN MATERIAL)) (CC AND) (NP (NN METHOD))) (: :) (S (NP (NP (CD Thirty) (NNS women) (PRN (-LRB- -LRB-) (VP (VBN aged) (NP (CD 30-77) (NNS years))) (-RRB- -RRB-))) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (NP (NP (NN Doc_16471092_328_331_Disease)) (PP (IN at) (NP (DT the) (NNP Gynecology) (NNP Clinic)))) (, ,) (NP (NNP King) (NNP Chulalongkorn) (NNP Memorial) (NNP Hospital))) (PP (IN from) (NP (NNP January))) (PP (TO to) (NP (NNP April) (CD 2004)))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (JJ present) (NN study)))))) (. .)))
16471092	3	(S1 (S (NP (NP (NN Doc_16471092_458_469_Chemical) (CD 2) (NN mg)) (, ,) (RB twice) (RB daily)) (VP (AUX was) (VP (VBN given))) (. .)))
16471092	4	(S1 (S (PP (IN After) (NP (CD 8) (NNS weeks) (NN treatment))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN micturition) (NN diary) (NNS variables)) (CC and) (NP (NN tolerability))))) (VP (AUX were) (VP (VBN determined))) (. .)))
16471092	5	(S1 (S (NP (NP (JJ Short) (NN form) (CD 36) (-LRB- -LRB-) (CD SF36) (-RRB- -RRB-) (NNS questionaires)) (PRN (-LRB- -LRB-) (NP (NNP Thai) (NN version)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN given) (PP (IN before) (CC and) (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))) (. .)))
16471092	6	(S1 (S (PP (IN At) (NP (CD 8) (NNS weeks))) (, ,) (NP (NP (DT all) (NN micturition)) (PP (IN per) (NP (NN day)))) (VP (VBD decreased) (PP (IN from) (S (VP (VBG 16.) (NP (NP (CD 7) (NN +/-)) (VP (VBG 5.) (NP (NP (NP (QP (CD 3) (TO to) (CD 6.) (CD 7) (NN +/-))) (NP (CD 2.4) (NNS times))) (PP (IN per) (NP (NN day)))))))))) (. .)))
16471092	7	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ Doc_16471092_817_825_Disease) (NNS episodes)))) (VP (VBD decreased) (PP (IN from) (NP (NP (QP (CD 5.4) (JJ +/-) (CD 4.2) (TO to) (CD 1.1)) (JJ +/-) (CD 1.0) (NNS times)) (PP (IN per) (NP (NN night)))))) (. .)))
16471092	8	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN side) (NN effect)) (VP (AUX was) (ADJP (JJ Doc_16471092_926_935_Disease)) (PP (IN in) (NP (NP (CD 5) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 16.7) (NN %)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (CD 2) (NNS cases)) (VP (VBG reporting) (NP (NP (DT a) (JJ moderate) (NN degree)) (CC and) (NP (NP (CD 1) (NN case)) (PP (IN with) (NP (JJ severe) (NN degree))))))))) (. .)))
16471092	9	(S1 (S (NP (NP (QP (RB Only) (CD one)) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))) (VP (VBD withdrew) (PP (IN from) (NP (DT the) (JJ present) (NN study))) (ADVP (RB due)) (PP (TO to) (NP (DT a) (JJ severe) (NN Doc_16471092_1096_1105_Disease)))) (. .)))
16471092	10	(S1 (S (NP (DT The) (CD SF-36) (NNS scores)) (VP (VBD changed) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT the) (NNS domains)) (PP (IN of) (NP (NP (JJ physical) (NN functioning)) (, ,) (NP (NN role) (NN function) (JJ emotional)) (, ,) (NP (JJ social) (NN function)) (CC and) (NP (JJ mental) (NN heath))))))) (. .)))
16471092	11	(S1 (S (S (NP (NN Doc_16471092_1257_1268_Chemical)) (VP (AUX was) (VP (ADVP (RB well)) (VBN tolerated)))) (CC and) (S (NP (PRP$ its) (NNS effects)) (VP (VBD improved) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN life)))) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NNP Doc_16471092_1352_1355_Disease))))))) (. .)))
16563323	0	(S1 (S (NP (JJ Doc_16563323_0_12_Chemical) (NN pretreatment)) (VP (VBZ reduces) (NP (NN Doc_16563323_34_43_Disease)) (PP (IN after) (NP (NNP Doc_16563323_50_59_Chemical)))) (. .)))
16563323	1	(S1 (S (S (VP (VB STUDY) (NP (NN OBJECTIVE)))) (: :) (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (ADJP (JJ pretreatment) (PP (IN with) (NP (NNP Doc_16563323_146_158_Chemical) (CD 1)))) (NNS microg/kg)))) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN gender))) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_216_225_Disease))))))) (PP (IN after) (NP (NP (NN anesthesia) (NN induction)) (PP (IN with) (NP (NNP Doc_16563323_258_267_Chemical)))))))))) (. .)))
16563323	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN study))) (. .)))
16563323	3	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN at) (NP (DT a) (NN university) (NN hospital))))) (. .)))
16563323	4	(S1 (S (NP (CD Sixty) (NNS patients)) (VP (AUX were) (VP (VBN pretreated) (PP (IN in) (NP (NP (DT a) (JJ randomized) (JJ double-blinded) (NN fashion)) (PP (IN with) (NP (NP (NNP Doc_16563323_464_476_Chemical) (CD 1) (NN microg/kg)) (CC or) (NP (NN placebo)))))))) (. .)))
16563323	5	(S1 (S (PP (NP (CD Two) (NNS minutes)) (IN after) (NP (NP (NN Doc_16563323_519_531_Chemical)) (CC or) (NP (NN placebo) (NN injection)))) (, ,) (NP (NNP Doc_16563323_554_563_Chemical) (CD 0.3) (NN mg/kg)) (VP (AUX was) (VP (VBN given))) (. .)))
16563323	6	(S1 (S (NP (NN Doc_16563323_599_608_Disease)) (VP (AUX was) (VP (VBN recorded) (PP (IN with) (NP (NP (DT a) (NN scale)) (PP (IN of) (NP (NP (CD 0)) (PP (TO to) (NP (CD 3))))))))) (. .)))
16563323	7	(S1 (S (NP (NP (DT The) (NN grade)) (PP (IN of) (NP (NP (NP (NNP sedation)) (PRN (-LRB- -LRB-) (NP (NP (NN none)) (, ,) (ADJP (JJ mild) (, ,) (JJ moderate) (, ,) (JJ severe))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16563323_700_706_Disease)) (, ,) (NP (NNP Doc_16563323_708_716_Disease)) (, ,) (CC and) (NP (NNP Doc_16563323_722_727_Disease))))) (VP (AUX were) (VP (VBN recorded) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (DT both) (NNS drugs))))))) (. .)))
16563323	8	(S1 (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_804_813_Disease)))) (VP (AUX was) (ADJP (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN in) (NP (DT the) (NNP Doc_16563323_845_857_Chemical) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD 6.7) (NN %)) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (NP (NP (DT the) (NN placebo) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-))))))) (. .)))
16563323	9	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD experienced) (NP (NP (NNP sedation)) (, ,) (NP (NNP Doc_16563323_959_964_Disease)) (, ,) (NP (NNP Doc_16563323_966_972_Disease)) (, ,) (CC or) (NP (NNP Doc_16563323_977_985_Disease))) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (. .)))
16563323	10	(S1 (S (PP (IN In) (NP (DT the) (NN placebo) (NN group))) (, ,) (NP (JJ male) (NNS patients)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB significantly) (JJ increased)) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_1111_1120_Disease))) (PP (IN after) (NP (NNP Doc_16563323_1127_1136_Chemical) (NN administration))))))) (. .)))
16563323	11	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_16563323_1183_1195_Chemical) (CD 1)))) (ADVP (RB microg/kg)) (VP (VBD reduced) (NP (NNP Doc_16563323_1216_1225_Disease)) (PP (IN after) (NP (NP (JJ Doc_16563323_1232_1241_Chemical) (NN induction)) (PP (IN without) (NP (NP (JJ side) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN sedation)) (, ,) (NP (NNP Doc_16563323_1291_1296_Disease) (, ,) (NNP Doc_16563323_1298_1304_Disease) (, ,) (CC or) (NNP Doc_16563323_1309_1317_Disease))))))))) (. .)))
16563323	12	(S1 (S (NP (NNS Men)) (VP (VBP experience) (NP (NP (JJ increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_1357_1366_Disease))) (PP (IN than) (NP (NP (NNS women)) (PP (IN after) (NP (NNP Doc_16563323_1384_1393_Chemical) (NN administration))))))) (. .)))
16574713	0	(S1 (S (NP (NP (NN Memory) (NN function)) (CC and) (NP (JJ Doc_16574713_20_29_Chemical) (NN transporter) (NN promoter) (NN gene))) (VP (VBD polymorphism) (PP (IN in) (NP (NNP Doc_16574713_72_79_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_81_85_Chemical)) (-RRB- -RRB-)) (NNS users)))) (. .)))
16574713	1	(S1 (S (SBAR (IN Although) (S (NP (NP (NNP Doc_16574713_103_136_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_138_142_Chemical) (CC or) (NNP Doc_16574713_146_153_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB damage) (NP (NN brain) (NNP Doc_16574713_186_195_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_197_201_Chemical)) (-RRB- -RRB-)) (NNS neurons)) (PP (IN in) (NP (NP (NNS animals)) (CC and) (ADVP (RB possibly)) (NP (NNS humans)))))))))))) (, ,) (NP (JJ little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (JJ long-term) (NNS consequences)) (PP (IN of) (NP (NP (NNP Doc_16574713_295_299_Chemical-induced) (NNP Doc_16574713_308_312_Chemical) (NNP Doc_16574713_313_331_Disease)) (PP (IN on) (NP (NP (NNS functions)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNP Doc_16574713_354_358_Chemical)) (VP (AUX is) (VP (VBN involved))))) (, ,) (PP (JJ such) (IN as) (NP (JJ cognitive) (NN function))))))))))) (. .)))
16574713	2	(S1 (S (SBAR (IN Because) (S (NP (JJ Doc_16574713_408_412_Chemical) (NNS transporters)) (VP (VBP play) (NP (NP (DT a) (JJ key) (NN element)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ synaptic) (JJ Doc_16574713_475_479_Chemical) (NN transmission))))))))) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ important) (S (VP (TO to) (VP (VB control) (PP (IN for) (NP (NP (DT the) (JJ potential) (JJ covariance) (NN effect)) (PP (IN of) (NP (NP (DT a) (NN polymorphism)) (PP (IN in) (NP (NP (DT the) (JJ Doc_16574713_585_589_Chemical) (NN transporter) (NN promoter) (NN gene) (NN region)) (PRN (-LRB- -LRB-) (JJ 5-HTTLPR) (-RRB- -RRB-)))))))) (ADVP (WRB when)) (S (VP (VBG studying) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_16574713_663_667_Chemical)))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ cognitive) (NN functioning))))))))))) (. .)))
16574713	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ moderate) (CC and) (JJ heavy) (JJ Doc_16574713_776_780_Chemical) (NN use))) (PP (IN on) (NP (NP (JJ cognitive) (NN function)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ long-term) (NN abstention)) (PP (IN from) (NP (NNP Doc_16574713_860_864_Chemical))))))))) (, ,) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN genotyped) (PP (IN for) (NP (NN 5-HTTLPR)))))))))) (. .)))
16574713	4	(S1 (S (NP (NP (DT A) (JJ second) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT these) (NNS effects)) (VP (VBP differ) (PP (IN for) (NP (NP (NNS females)) (CC and) (NP (NNS males))))))))))) (. .)))
16574713	5	(S1 (S (NP (NP (NP (JJ Fifteen) (JJ moderate) (NNP Doc_16574713_1014_1018_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (CD <55) (NN lifetime) (NNS tablets)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 22) (JJ heavy) (NNP Doc_16574713_1058_1062_Chemical+) (NNS users)) (PRN (-LRB- -LRB-) (NP (CD >55) (NN lifetime) (NNS tablets)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 16) (JJ ex-Doc_16574713_1100_1104_Chemical+) (NNS users)) (PRN (-LRB- -LRB-) (S (NP (JJ last) (NN tablet)) (VP (VBD >) (NP (CD 1) (NN year)) (ADVP (RB ago)))) (-RRB- -RRB-))) (CC and) (NP (CD 13) (NNS controls))) (VP (AUX were) (VP (VBN compared) (PP (IN on) (NP (NP (DT a) (NN battery)) (PP (IN of) (NP (JJ neuropsychological) (NNS tests))))))) (. .)))
16574713	6	(S1 (S (NP (NP (NN DNA)) (PP (IN from) (NP (JJ peripheral) (JJ nuclear) (NN blood) (NNS cells)))) (VP (AUX was) (VP (VBN genotyped) (PP (IN for) (NP (NP (NNS 5-HTTLPR)) (VP (VBG using) (NP (NP (JJ standard) (NN polymerase) (NN chain) (NN reaction)) (SBAR (S (NP (CD methods.A) (JJ significant) (NN group) (NN effect)) (VP (AUX was) (VP (VBN observed) (PP (RB only) (PP (IN on) (NP (NP (NN memory) (NN function) (NNS tasks)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.04)) (-RRB- -RRB-)))) (CC but) (RB not) (PP (IN on) (NP (NP (NP (NN reaction) (NNS times)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.61)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ attention/executive) (NN functioning)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.59)) (-RRB- -RRB-)))))))))))))))) (. .)))
16574713	7	(S1 (S (NP (JJ Heavy) (CC and) (JJ ex-Doc_16574713_1505_1509_Chemical+) (NNS users)) (VP (VBD performed) (ADVP (RB significantly) (JJR poorer)) (PP (IN on) (NP (NP (NN memory) (NNS tasks)) (PP (IN than) (NP (NNS controls)))))) (. .)))
16574713	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_16574713_1607_1624_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (JJ moderate) (JJ Doc_16574713_1650_1654_Chemical) (NNS users))))) (. .)))
16574713	9	(S1 (S (NP (NP (DT No) (JJ significant) (NN effect)) (PP (IN of) (NP (NP (NN 5-HTTLPR)) (CC or) (NP (NN gender))))) (VP (AUX was) (VP (VBN observed))) (. .)))
16574713	10	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_16574713_1737_1741_Chemical))) (PP (IN in) (NP (NP (NNS quantities)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (VP (VBN considered) (S (`` ``) (ADJP (JJ moderate)) ('' '')))))))))) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16574713_1813_1840_Disease))))))) (, ,) (NP (NP (JJ heavy) (NN use)) (PP (IN of) (NP (JJ Doc_16574713_1855_1859_Chemical) (NN use)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ long) (JJ lasting) (NN Doc_16574713_1889_1907_Disease))))) (. .)))
16574713	11	(S1 (S (NP (NP (DT No) (NN effect)) (PP (IN of) (NP (NN 5-HTTLPR) (CC or) (NN gender))) (PP (IN on) (NP (NP (NN memory) (NN function)) (CC or) (NP (NN Doc_16574713_1963_1967_Chemical) (NN use))))) (VP (AUX was) (VP (VBN observed))) (. .)))
16584858	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (NNP Doc_16584858_8_18_Chemical))) (PP (IN on) (NP (NP (JJ biochemical) (NNS alterations)) (CC and) (NP (JJ antioxidant) (NN status)))) (PP (IN in) (NP (NP (NNP Doc_16584858_72_85_Chemical-induced) (NNP Doc_16584858_94_115_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
16584858	1	(S1 (S (NP (NP (DT The) (JJ current) (NN study)) (VP (VBN dealt) (PP (IN with) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NP (NNP Doc_16584858_177_187_Chemical)) (, ,) (NP (NP (DT a) (JJ Doc_16584858_191_201_Chemical)) (PP (IN from) (NP (NP (NNP Mangifera) (NNP indica) (NNP Linn) (. .)) (PRN (-LRB- -LRB-) (NP (NNP Anacardiaceae)) (-RRB- -RRB-))))) (, ,))))) (PP (IN on) (NP (NP (NNP Doc_16584858_250_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_265_269_Chemical)) (-RRB- -RRB-)))))) (VP (VBD -induced) (NP (NP (NNP Doc_16584858_279_300_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_302_304_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NNS rats))) (PP (IN through) (NP (PRP$ its) (JJ antioxidative) (NN mechanism)))) (. .)))
16584858	2	(S1 (S (NP (NP (JJ Subcutaneous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_16584858_377_381_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 200) (CD mg/kg)) (NN body) (NN weight)) (PP (IN in) (NP (QP (CD 1) (CD ml)) (NN saline)))) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats))) (PP (IN for) (NP (CD 2) (JJ consecutive) (NNS days)))) (VP (VBD caused) (SBAR (S (NP (NP (NNP Doc_16584858_459_476_Disease)) (PP (IN in) (NP (NN rat) (NN heart))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (JJ increased) (NN activity)) (PP (IN of) (NP (NP (NP (JJ serum) (JJ Doc_16584858_547_554_Chemical) (NN dehydrogenase)) (PRN (-LRB- -LRB-) (NP (NNP LDH)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_16584858_579_587_Chemical) (NN phosphokinase) (NNS isoenzymes)) (PRN (-LRB- -LRB-) (NP (NNP CK-MB)) (-RRB- -RRB-))))))))))) (, ,)) (VP (VP (VBD increased) (NP (NNP Doc_16584858_632_641_Chemical) (NN level))) (CC and) (VP (VBD reduced) (NP (NN plasma)) (NP (JJ Doc_16584858_667_671_Chemical) (VBG binding) (NN capacity))))))) (. .)))
16584858	3	(S1 (S (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Doc_16584858_713_723_Chemical)))) (VP (AUX was) (VP (VBN analyzed) (PP (IN by) (NP (NP (NNP Doc_16584858_740_770_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_772_775_Chemical)) (-RRB- -RRB-)) (NN test)) (VP (VBN used) (PP (IN for) (NP (NP (JJ macroscopic) (JJ enzyme) (NN mapping) (NN assay)) (PP (IN of) (NP (DT the) (NNP Doc_16584858_831_850_Disease)))))))))) (. .)))
16584858	4	(S1 (S (NP (NP (DT The) (NN heart) (NN tissue) (NN antioxidant) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (JJ Doc_16584858_897_907_Chemical) (NN dismutase)) (, ,) (NP (NN catalase)) (, ,) (NP (JJ Doc_16584858_929_940_Chemical) (NN peroxidase)) (, ,) (NP (JJ Doc_16584858_953_964_Chemical) (NN transferase)) (CC and) (NP (NP (JJ Doc_16584858_981_992_Chemical) (NN reductase) (NNS activities)) (, ,) (NP (NP (JJ non-enzymic) (NNS antioxidants)) (PP (JJ such) (IN as) (NP (NN cerruloplasmin)))) (, ,) (NP (NNP Doc_16584858_1064_1073_Chemical) (, ,) (NNP Doc_16584858_1075_1084_Chemical) (CC and) (NNP Doc_16584858_1089_1100_Chemical) (NNS levels)))))) (VP (AUX were) (VP (VBN altered) (PP (IN in) (NP (JJ Doc_16584858_1124_1126_Disease) (NNS rats))))) (. .)))
16584858	5	(S1 (S (S (PP (IN Upon) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_16584858_1156_1166_Chemical))))) (-LRB- -LRB-) (NP (NP (QP (CD 100) (CD mg/kg)) (NN body) (NN weight)) (VP (VBN suspended) (PP (IN in) (NP (NP (CD 2) (NN ml)) (PP (IN of) (NP (NNP Doc_16584858_1211_1230_Chemical))))))) (-RRB- -RRB-) (VP (VBN given) (ADVP (RB intraperitoneally)) (PP (IN for) (NP (CD 28) (NNS days))) (PP (TO to) (NP (NNP Doc_16584858_1271_1273_Disease) (NNS rats))))) (VP (VBD protected) (NP (NP (DT the) (JJ above-mentioned) (NNS parameters)) (SBAR (S (VP (TO to) (VP (VB fall) (PP (IN from) (NP (DT the) (JJ normal) (NNS levels))))))))) (. .)))
16584858	6	(S1 (S (NP (NP (NNS Activities)) (PP (IN of) (NP (NP (NN heart) (NN tissue) (NN enzymic) (NNS antioxidants)) (CC and) (NP (JJ serum) (JJ non-enzymic) (NNS antioxidants) (NNS levels))))) (VP (VBD rose) (ADVP (RB significantly)) (PP (IN upon) (NP (NNP Doc_16584858_1466_1476_Chemical) (NN administration))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ Doc_16584858_1507_1511_Chemical-induced) (JJ Doc_16584858_1520_1522_Disease) (NNS rats))))))) (. .)))
16584858	7	(S1 (S (PP (IN From) (NP (DT the) (JJ present) (NN study))) (NP (PRP it)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_16584858_1573_1583_Chemical)) (VP (VBZ exerts) (NP (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN against) (NP (NNP Doc_16584858_1619_1623_Chemical-induced) (NNP Doc_16584858_1632_1634_Disease)))) (ADVP (RB due) (PP (TO to) (NP (NP (PRP$ its) (JJ antioxidant) (NN potential)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBN regulated) (NP (DT the) (NNS tissues) (NN defense) (NN system)) (PP (IN against) (NP (NNP Doc_16584858_1720_1734_Disease)))))))))))))) (. .)))
16586083	0	(S1 (NP (NP (NP (JJ Cardiovascular) (NN risk)) (PP (IN with) (NP (NNP Doc_16586083_25_50_Chemical)))) (: :) (NP (NP (JJ general) (NN problem)) (PP (IN with) (NP (NN substance) (NN specific) (NNS differences)))) (. ?)))
16586083	1	(S1 (S (NP (NP (JJ Randomised) (JJ clinical) (NNS trials)) (CC and) (NP (JJ observational) (NNS studies))) (VP (AUX have) (VP (VBN shown) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_16586083_190_211_Disease) (, ,) (NNP Doc_16586083_213_219_Disease) (, ,) (NNP Doc_16586083_221_233_Disease) (CC and) (NNP Doc_16586083_238_251_Disease)))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16586083_274_299_Chemical))))))) (. .)))
16586083	2	(S1 (S (NP (JJ Adverse) (JJ cardiovascular) (NNS effects)) (VP (VBD occurred) (ADVP (RB mainly)) (, ,) (FRAG (CC but) (RB not) (ADVP (RB exclusively)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ concomitant) (NN risk) (NNS factors))))))) (. .)))
16586083	3	(S1 (S (NP (NN Doc_16586083_413_438_Chemical)) (VP (VBP cause) (NP (NP (JJ complex) (NNS changes)) (PP (IN in) (NP (ADJP (JJ renal) (, ,) (JJ vascular) (CC and) (JJ cardiac)) (NN prostanoid) (NNS profiles)))) (S (VP (ADVP (RB thereby)) (VBG increasing) (NP (NP (JJ vascular) (NN resistance)) (CC and) (NP (JJ fluid) (NN retention)))))) (. .)))
16586083	4	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ cardiovascular) (JJ adverse) (NNS events)))) (VP (VBZ tends) (S (VP (TO to) (VP (VB increase) (PP (IN with) (NP (NP (DT the) (JJ daily) (NN dose)) (CC and) (NP (JJ total) (NN exposure) (NN time)))))))) (. .)))
16586083	5	(S1 (S (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (JJ individual) (JJ selective) (CC and) (NN unselective) (NN Doc_16586083_735_760_Chemical)))) (VP (VBZ suggests) (NP (NP (JJ substance-specific) (NNS differences)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (MD may) (VP (VB depend) (PP (IN on) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ pharmacokinetic) (NNS parameters)) (CC or) (NP (JJ inhibitory) (NN potency)))))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN contributed) (PP (IN by) (NP (JJ Doc_16586083_912_925_Chemical-independent) (NNS effects))))))))))) (. .)))
16586083	6	(S1 (S (NP (NP (JJ Diagnostic) (NNS markers)) (PP (JJ such) (IN as) (NP (NP (NP (NNP Doc_16586083_974_1014_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16586083_1016_1025_Chemical)) (-RRB- -RRB-))) (CC or) (NP (JJ high-sensitive) (JJ C-reactive) (NN protein))))) (VP (MD might) (VP (VB help) (PP (IN in) (NP (NP (DT the) (JJ early) (NN identification)) (PP (IN of) (NP (NNS patients))) (PP (IN at) (NP (NN risk))))) (, ,) (S (ADVP (RB thus)) (VP (VBG avoiding) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ serious) (NNP Doc_16586083_1164_1187_Disease)))))))) (. .)))
16596970	0	(S1 (S (NP (NNP Doc_16596970_0_11_Chemical) (NNP Doc_16596970_12_20_Disease)) (VP (VB cause) (NP (JJ age-dependent) (NN Doc_16596970_41_87_Disease))) (. .)))
16596970	1	(S1 (S (NP (NP (NNS Children)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (NN Doc_16596970_107_125_Disease)))))) (VP (AUX have) (UCP (ADJP (JJ continuous)) (CC or) (VP (ADVP (RB rapidly)) (VBG repeating) (NP (NP (NN Doc_16596970_163_171_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (MD may) (VP (AUX be) (ADJP (JJ life-threatening)))) (CC and) (VP (MD may) (VP (VB cause) (NP (NP (JJ life-long) (NNS changes)) (PP (IN in) (NP (NN brain) (CC and) (NN behavior))))))))))))) (. .)))
16596970	2	(S1 (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NNP Doc_16596970_276_294_Disease)) (VP (VBZ causes) (NP (NN Doc_16596970_302_337_Disease)))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
16596970	3	(S1 (S (NP (DT A) (JJ naturalistic) (NN auditory) (NN location) (NN discrimination) (NN method)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (DT this) (NN question)) (S (VP (VBG using) (NP (NP (DT an) (NN animal) (NN model)) (PP (IN of) (NP (NNP Doc_16596970_465_483_Disease))))))))))) (. .)))
16596970	4	(S1 (S (NP (JJ Male) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (NP (NN saline)) (PP (IN on) (NP (JJ postnatal) (NN day))) (PRN (-LRB- -LRB-) (NP (NNP P)) (-RRB- -RRB-)) (CD 20)) (, ,) (CC or) (NP (NP (DT a) (JJ convulsant) (NN dose)) (PP (IN of) (NP (NNP Doc_16596970_585_596_Chemical))) (PP (IN on) (NP (NNP P20) (CC or) (NNP P45)))))))) (. .)))
16596970	5	(S1 (S (S (NP (NP (NN Doc_16596970_612_623_Chemical)) (PP (IN on) (NP (DT either) (NN day)))) (VP (VBN induced) (NP (NNP Doc_16596970_646_664_Disease)))) (: ;) (S (NP (NP (NNP Doc_16596970_666_684_Disease)) (PP (IN at) (NP (NNP P45)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ CA3) (NN cell) (NN loss)) (CC and) (NP (JJ spontaneous) (NN Doc_16596970_734_742_Disease)))) (, ,) (SBAR (IN whereas) (S (NP (NNP P20) (NNS rats)) (VP (AUX had) (NP (NP (DT no) (NN cell) (NN loss)) (CC or) (NP (JJ spontaneous) (NN Doc_16596970_793_801_Disease)))))))) (. .)))
16596970	6	(S1 (S (NP (JJ Mature) (NNS rats)) (VP (AUX were) (VP (VBN trained) (PP (IN with) (NP (NP (JJ sound-source) (NN location)) (CC and) (NP (JJ sound-silence) (NNS discriminations)))))) (. .)))
16596970	7	(S1 (S (NP (NNP Control) (PRN (-LRB- -LRB-) (NP (NN saline) (CD P20)) (-RRB- -RRB-)) (NNS rats)) (VP (VBD acquired) (NP (DT both) (NNS discriminations)) (ADVP (RB immediately))) (. .)))
16596970	8	(S1 (S (PP (IN In) (NP (NNP Doc_16596970_962_980_Disease) (PRN (-LRB- -LRB-) (NP (NNP P20)) (-RRB- -RRB-)) (NNS rats))) (, ,) (NP (NP (NN acquisition)) (PP (IN of) (NP (DT the) (JJ sound-source) (NN location) (NN discrimination)))) (VP (AUX was) (ADJP (RB moderately) (JJ impaired))) (. .)))
16596970	9	(S1 (S (NP (JJ Doc_16596970_1074_1092_Disease) (PRN (-LRB- -LRB-) (NP (NNP P45)) (-RRB- -RRB-)) (NNS rats)) (VP (VBD failed) (S (VP (TO to) (VP (VB acquire) (NP (DT either) (NN sound-source) (NN location) (CC or) (NN sound-silence) (NNS discriminations)))))) (. .)))
16596970	10	(S1 (S (NP (NP (NN Doc_16596970_1185_1203_Disease)) (PP (IN in) (NP (NN rat)))) (VP (VBZ causes) (NP (DT an) (JJ age-dependent) (, ,) (JJ long-term) (NN Doc_16596970_1246_1283_Disease))) (. .)))
16596970	11	(S1 (S (NP (DT This) (NN impairment)) (VP (MD may) (VP (VB explain) (NP (NP (CD one) (NN cause)) (PP (IN of) (NP (NP (NNP Doc_16596970_1326_1367_Disease)) (PP (IN in) (NP (NNS humans)))))))) (. .)))
16600756	0	(S1 (NP (NP (NP (NN Nerve) (NN growth) (NN factor)) (CC and) (NP (NN Doc_16600756_24_38_Chemical))) (PP (IN in) (NP (NP (DT the) (NN urine)) (PP (IN of) (NP (NP (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_76_94_Disease))))))) (. .)))
16600756	1	(S1 (S (S (NP (NP (NP (NN NGF)) (CC and) (NP (NNP Doc_16600756_113_116_Chemical))) (PP (IN in) (NP (DT the) (NN bladder)))) (VP (MD can) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NP (JJ pathological) (NNS changes)) (PP (IN in) (NP (DT the) (NN bladder))))))))) (CC and) (S (NP (DT these) (NNS changes)) (VP (MD can) (VP (AUX be) (VP (VBN detected) (PP (IN in) (NP (NN urine))))))) (. .)))
16600756	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ urinary) (NN NGF)) (CC and) (NP (NP (NNP Doc_16600756_274_277_Chemical)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_16600756_292_295_Disease)))))))))) (. .)))
16600756	3	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (DT The) (NN study) (NNS groups)) (VP (VBD included) (NP (NP (NP (NP (CD 65) (NNS women)) (PP (IN with) (NP (NNP Doc_16600756_360_363_Disease)))) (CC and) (NP (NP (CD 20)) (PP (IN without) (NP (NN bladder) (NNS symptoms))))) (SBAR (WHNP (WP who)) (S (VP (VBD served) (PP (IN as) (NP (NNS controls))))))))) (. .)))
16600756	4	(S1 (S (NP (NN Evaluation)) (VP (VBD included) (NP (NP (JJ patient) (NN history)) (, ,) (NP (NN urinalysis)) (, ,) (NP (DT a) (JJ voiding) (NN diary)) (CC and) (NP (JJ urodynamic) (NNS studies)))) (. .)))
16600756	5	(S1 (S (NP (NN Urine) (NNS samples)) (VP (AUX were) (VP (VBN collected))) (. .)))
16600756	6	(S1 (S (NP (NNP NGF) (, ,) (NNP Doc_16600756_544_548_Chemical) (, ,) (NNP Doc_16600756_550_559_Chemical) (CC and) (NNP Doc_16600756_564_568_Chemical)) (VP (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (JJ enzyme-linked) (NN immunosorbent) (NN assay)))))) (CC and) (VP (VBN compared) (PP (IN between) (NP (DT the) (NNS groups))))) (. .)))
16600756	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNS correlations)) (PP (IN between) (NP (NP (JJ urinary) (NNP NGF)) (CC and) (NP (NNP Doc_16600756_706_708_Chemical))))) (, ,) (CC and) (NP (NP (JJ urodynamic) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_753_756_Disease))))))) (VP (AUX were) (VP (VBN examined))) (. .)))
16600756	8	(S1 (S (NP (NP (NNP Urinary) (NNP NGF)) (, ,) (NP (NNP Doc_16600756_794_798_Chemical)) (CC and) (NP (NNP Doc_16600756_803_812_Chemical))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_859_862_Disease))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.05)) (-RRB- -RRB-))))))) (. .)))
16600756	9	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ urinary) (NNP Doc_16600756_914_918_Chemical)) (VP (AUX was) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (NP (NNS controls)) (CC and) (NP (NNS patients)))) (PP (IN with) (NP (NNP Doc_16600756_972_975_Disease)))) (. .)))
16600756	10	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_994_997_Disease))))) (NP (JJ urinary) (NNP Doc_16600756_1006_1010_Chemical)) (VP (ADVP (RB positively)) (VBD correlated) (PP (IN with) (NP (NN volume))) (PP (IN at) (NP (NP (JJ first) (NN desire)) (PP (TO to) (NP (NP (NP (VB void)) (CC and) (NP (NN maximum) (JJ cystometric) (NN capacity))) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.05)) (-RRB- -RRB-))))))) (. .)))
16600756	11	(S1 (S (NP (NP (NNP Urinary) (NNP NGF)) (, ,) (NP (NNP Doc_16600756_1126_1135_Chemical)) (CC and) (NP (NNP Doc_16600756_1140_1144_Chemical))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (JJ urodynamic) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_1207_1210_Disease))))))))) (. .)))
16600756	12	(S1 (S (NP (NP (NNP NGF)) (CC and) (NP (NNP Doc_16600756_1233_1236_Chemical))) (VP (AUX have) (NP (JJ important) (NNS roles)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_16600756_1280_1283_Disease) (NNS symptoms))) (PP (IN in) (NP (JJ female) (NNS patients)))))) (. .)))
16600756	13	(S1 (S (NP (NP (JJ Urinary) (NNS levels)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (MD may) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NNS markers))) (S (VP (TO to) (VP (VB evaluate) (NP (JJ Doc_16600756_1380_1383_Disease) (NNS symptoms)))))))) (. .)))
16629641	0	(S1 (NP (NP (NP (NP (NN Definition)) (CC and) (NP (NN management))) (PP (IN of) (NP (NNP Doc_16629641_29_35_Disease))) (PP (IN in) (NP (NNS patients)))) (NP (NNP Doc_16629641_48_79_Disease)) (. .)))
16629641	1	(S1 (S (NP (NP (NN Doc_16629641_81_121_Disease)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (VP (MD can) (VP (VB progress) (PP (TO to) (NP (NP (NNP Doc_16629641_144_153_Disease)) (, ,) (NP (NNP Doc_16629641_155_179_Disease)) (, ,) (CC and) (NP (NNP Doc_16629641_185_208_Disease)))))) (. .)))
16629641	2	(S1 (S (NP (NP (DT The) (JJ current) (JJS best) (NN treatment)) (PP (IN for) (NP (NNP Doc_16629641_241_254_Disease)))) (VP (AUX is) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (JJ pegylated) (NNP Doc_16629641_293_303_Chemical)) (CC and) (NP (NNP Doc_16629641_308_317_Chemical)))))) (. .)))
16629641	3	(S1 (S (SBAR (IN Although) (S (NP (DT this) (NN regimen)) (VP (VBZ produces) (NP (NP (JJ sustained) (JJ virologic) (NNS responses)) (PRN (-LRB- -LRB-) (NP (NNP SVRs)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (DT a) (ADJP (RB potentially) (JJ dose-limiting)) (NN Doc_16629641_475_491_Disease)))))) (. .)))
16629641	4	(S1 (S (S (NP (NN Hemoglobin) (NNS concentrations)) (VP (VB decrease) (ADVP (RB mainly)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (JJ Doc_16629641_550_559_Chemical-induced) (NNP Doc_16629641_568_577_Disease))))))) (, ,) (CC and) (S (NP (DT this) (NN Doc_16629641_588_594_Disease)) (VP (MD can) (VP (AUX be) (ADJP (JJ problematic)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16629641_631_644_Disease) (, ,) (RB especially) (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN comorbid) (NP (NNP Doc_16629641_681_714_Disease))))))))))))) (. .)))
16629641	5	(S1 (S (PP (IN In) (ADJP (JJ general))) (, ,) (NP (NNP Doc_16629641_728_734_Disease)) (VP (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))))))) (, ,) (CC and) (VP (MD may) (VP (AUX have) (NP (NP (JJ negative) (NNS effects)) (PP (IN on) (NP (NP (JJ cerebral) (NN function)) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))))))))) (. .)))
16629641	6	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_16629641_866_875_Chemical-associated) (NNP Doc_16629641_887_893_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN reversed) (PP (IN by) (NP (NP (NN dose) (NN reduction)) (CC or) (NP (NN discontinuation))))))))) (, ,) (NP (DT this) (NN approach)) (VP (VBZ compromises) (NP (NNS outcomes)) (PP (IN by) (S (VP (ADVP (RB significantly)) (VBG decreasing) (NP (NN SVR) (NNS rates)))))) (. .)))
16629641	7	(S1 (S (NP (JJ Recombinant) (JJ human) (NN erythropoietin)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB manage) (NP (JJ Doc_16629641_1079_1088_Chemical-associated) (NN Doc_16629641_1100_1106_Disease)))))))) (CC but) (VP (AUX has) (NP (JJ other) (JJ potential) (NNS disadvantages)))) (. .)))
16629641	8	(S1 (S (NP (NP (NNP Doc_16629641_1146_1156_Chemical)) (, ,) (NP (NP (DT a) (JJ liver-targeting) (NN prodrug)) (PP (IN of) (NP (NNP Doc_16629641_1187_1196_Chemical)))) (, ,)) (VP (AUX has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT the) (JJ virologic) (NN efficacy)) (PP (IN of) (NP (NNP Doc_16629641_1254_1263_Chemical)))) (SBAR (IN while) (S (VP (VBG decreasing) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_16629641_1293_1309_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Doc_16629641_1327_1346_Disease))))))))))))) (. .)))
16634859	0	(S1 (NP (NP (NN Impact)) (PP (IN of) (NP (NNP Doc_16634859_10_17_Chemical) (NN exposure))) (PP (IN after) (NP (NN pregnancy) (NN recognition))) (PP (IN on) (NP (JJ ultrasonographic) (JJ fetal) (NN growth) (NNS measures))) (. .)))
16634859	1	(S1 (S (SBAR (NP (QP (JJR More) (IN than) (CD 3)) (NNS decades)) (IN after) (S (NP (NP (NNP Jones) (CC and) (NNP Smith)) (PRN (-LRB- -LRB-) (NP (CD 1973)) (-RRB- -RRB-))) (VP (VBD reported) (PP (IN on) (NP (NP (DT the) (NN devastation)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_16634859_197_204_Chemical) (NN exposure))) (PP (IN on) (NP (JJ fetal) (NN development))))))))) (, ,) (NP (NP (DT the) (NNS rates)) (PP (IN of) (NP (NP (JJ heavy) (NN drinking)) (PP (IN during) (NP (NN pregnancy)))))) (VP (VBP remain) (ADJP (RB relatively) (JJ unchanged))) (. .)))
16634859	2	(S1 (S (NP (NP (JJ Early) (NN identification)) (PP (IN of) (NP (NP (JJ fetal) (JJ Doc_16634859_340_347_Chemical) (NN exposure)) (CC and) (NP (JJ maternal) (NN abstinence))))) (VP (VBD led) (PP (TO to) (NP (JJR better) (NN infant) (NNS outcomes)))) (. .)))
16634859	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NN biometry))) (PP (IN for) (S (VP (VBG detecting) (NP (JJ Doc_16634859_470_477_Chemical-related) (JJ fetal) (NN Doc_16634859_492_509_Disease))))))) (. .)))
16634859	4	(S1 (S (NP (PRP We)) (VP (VBD obtained) (NP (JJ fetal) (NN ultrasound) (NNS measures)) (PP (IN from) (NP (JJ routine) (NN ultrasound) (NNS examinations))) (PP (IN for) (NP (NP (CD 167) (JJ pregnant) (JJ hazardous) (NNS drinkers)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT a) (JJ brief) (JJ Doc_16634859_660_667_Chemical) (NN intervention) (NN study)))))))))) (. .)))
16634859	5	(S1 (S (NP (NP (DT The) (JJ fetal) (NNS measures)) (PP (IN for) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP quit) (PP (IN after) (NP (NP (NN learning)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies))))))))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (NNS measures)) (PP (IN for) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD continued) (NP (DT some) (NN drinking)) (PP (IN throughout) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))))))))))) (. .)))
16634859	6	(S1 (S (SBAR (IN Because) (S (NP (NP (NN intensity)) (PP (IN of) (NP (JJ Doc_16634859_893_900_Chemical) (NN consumption)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJR poorer) (JJ fetal) (NNS outcomes))))))) (, ,) (NP (JJ separate) (NNS analyses)) (VP (AUX were) (VP (VBN conducted) (PP (IN for) (NP (DT the) (JJ heavy) (PRN (-LRB- -LRB-) (NP (NP (JJ average)) (PP (IN of) (NP (JJ >or=5) (NNS drinks))) (PP (IN per) (NP (NN drinking) (NN day)))) (-RRB- -RRB-)) (JJ Doc_16634859_1045_1052_Chemical) (NNS consumers))))) (. .)))
16634859	7	(S1 (S (NP (NP (JJ Fetal) (NNS measures)) (PP (IN from) (NP (DT the) (JJ heavy-exposed) (NNS fetuses)))) (VP (AUX were) (ADVP (RB also)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS measures)) (PP (IN from) (NP (NP (DT a) (JJ nondrinking) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (NP (NP (NN representative)) (PP (IN of) (NP (NP (JJ normal) (, ,) (JJ uncomplicated) (NNS pregnancies)) (PP (IN from) (NP (PRP$ our) (NNS clinics))))))))))))))) (. .)))
16634859	8	(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NN covariance)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX were) (NP (NP (NNS differences)) (PP (IN between) (NP (NNS groups)))) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (NNS influences)) (PP (IN of) (NP (NP (JJ gestational) (NN age)) (CC and) (NP (NN Doc_16634859_1395_1405_Disease))))))))))))))))) (. .)))
16634859	9	(S1 (S (NP (NP (RB Nearly) (NN half)) (PP (IN of) (NP (DT the) (JJ pregnant) (NNS drinkers)))) (VP (VBD abstained) (PP (IN after) (NP (NP (NN learning)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))) (. .)))
16634859	10	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNS women)) (ADVP (RB reportedly)) (VP (VB quit) (NP (NN drinking)) (ADVP (RB early)) (PP (IN in) (NP (PRP$ their) (NNS pregnancies)))))) (, ,) (NP (JJ fetal) (NN growth) (NNS measures)) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT a) (JJ non-Doc_16634859_1630_1637_Chemical-exposed) (NN group)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (JJ prior) (NN drinking) (NNS patterns))))) (. .)))
16634859	11	(S1 (S (NP (NP (DT Any) (JJ Doc_16634859_1696_1703_Chemical) (NN consumption) (NN postpregnancy) (NN recognition)) (PP (IN among) (NP (DT the) (JJ heavy) (NNS drinkers)))) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_16634859_1779_1804_Disease) (CONJP (RB as) (RB well) (IN as)) (NNP Doc_16634859_1816_1848_Disease))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NNS women)) (SBAR (SBAR (WHNP (WP who)) (S (ADVP (RB either)) (VP (VBP quit) (NP (NN drinking))))) (CC or) (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NNS nondrinkers))))))))))) (. .)))
16634859	12	(S1 (S (NP (JJ Doc_16634859_1924_1935_Chemical) (NN abuse)) (VP (AUX was) (ADJP (JJ predictive) (PP (IN of) (NP (JJR larger) (NN cranial))) (PP (TO to) (NP (NN body) (NN growth) (NNS ratios))))) (. .)))
16634859	13	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (JJ fetal) (JJ biometric) (NNS measurements)))) (VP (AUX were) (VP (VBN observed) (PP (IN among) (NP (NP (DT the) (JJ heavy) (NNS drinkers)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (PRP they)) (VP (VBD continued) (NP (NN drinking)) (PP (IN after) (S (VP (VBG becoming) (ADJP (JJ aware) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))))))))))) (. .)))
16634859	14	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN reliance)) (PP (IN on) (NP (JJ self-reported) (NN drinking)))) (VP (AUX is) (NP (NP (DT a) (NN limitation)) (PP (IN in) (NP (DT this) (NN study))))))) (, ,) (NP (DT these) (NNS findings)) (VP (VBP support) (NP (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (JJ early) (NN abstinence)))) (CC and) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN ultrasound) (NNS examinations))))) (PP (IN in) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ fetal) (JJ Doc_16634859_2378_2385_Chemical) (NNS effects)))))) (. .)))
16710500	0	(S1 (NP (JJ Doc_16710500_0_10_Chemical-associated) (NN Doc_16710500_22_38_Disease) (. .)))
16710500	1	(S1 (S (NP (NN Doc_16710500_54_64_Chemical)) (VP (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_16710500_93_105_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB still)) (ADJP (JJ prevalent)) (PP (IN in) (NP (NNP Southeast) (NNP Asia)))))))))))) (, ,) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ permanent) (NN Doc_16710500_188_199_Disease))))))) (. .)))
16710500	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 3) (NNS cases)) (SBAR (WHNP (WDT which)) (S (VP (VBD presented) (PP (IN with) (NP (NN Doc_16710500_240_261_Disease)))))))) (. .)))
16710500	3	(S1 (NP (JJ CLINICAL) (NN PICTURE) (: :) (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (JJ Doc_16710500_301_311_Chemical-associated) (JJ toxic) (NN Doc_16710500_329_345_Disease)))) (VP (AUX are) (VP (VBN described)))) (. .)))
16710500	4	(S1 (S (NP (DT All) (CD 3) (NNS patients)) (VP (AUX had) (NP (NN Doc_16710500_380_452_Disease))) (. .)))
16710500	5	(S1 (S (NP (DT The) (NNP Doc_16710500_458_475_Disease)) (VP (AUX had) (NP (DT a) (JJ bitemporal) (NN flavour)) (, ,) (S (VP (VBG suggesting) (NP (NP (NN involvement)) (PP (IN of) (NP (DT the) (JJ optic) (NN chiasm))))))) (. .)))
16710500	6	(S1 (S (PP (IN Despite) (S (VP (VBG stopping) (NP (NNP Doc_16710500_574_584_Chemical)) (PP (IN on) (NP (NN diagnosis)))))) (, ,) (NP (JJ visual) (NN function)) (VP (VBD continued) (S (VP (TO to) (VP (VB deteriorate) (PP (IN for) (NP (DT a) (JJ few) (NNS months))))))) (. .)))
16710500	7	(S1 (S (NP (JJ Subsequent) (NN improvement)) (VP (AUX was) (ADJP (JJ mild)) (PP (IN in) (NP (CD 2) (NNS cases)))) (. .)))
16710500	8	(S1 (S (PP (IN In) (NP (DT the) (JJ third) (NN case))) (, ,) (S (NP (NP (JJ visual) (NN acuity)) (CC and) (NP (JJ colour) (NN vision))) (VP (VBD normalised))) (CC but) (S (NP (DT the) (JJ optic) (NNS discs)) (VP (AUX were) (ADJP (JJ pale)))) (. .)))
16710500	9	(S1 (S (NP (DT All) (CD 3) (NNS patients)) (VP (AUX had) (NP (DT some) (JJ permanent) (NN Doc_16710500_838_861_Disease))) (. .)))
16710500	10	(S1 (S (NP (JJ Doc_16710500_876_886_Chemical) (NN usage)) (VP (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ permanent) (NNP Doc_16710500_922_933_Disease))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (SBAR (IN if) (FRAG (ADJP (ADJP (ADJP (JJ possible)) (CC or) (ADJP (JJ used))) (PP (IN with) (NP (NP (NN caution)) (CC and) (NP (JJ proper) (JJ ophthalmological) (NN follow-up))))))))))) (. .)))
16710500	11	(S1 (S (NP (DT The) (NN author)) (VP (VBZ postulates) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ Doc_16710500_1067_1077_Chemical) (JJ associated) (NN chiasmopathy))))) (, ,) (NP (NNP Doc_16710500_1103_1113_Chemical)) (VP (MD may) (ADVP (RB initially)) (VP (VP (VB affect) (NP (DT the) (JJ optic) (NNS nerves))) (CC and) (VP (ADVP (RB subsequently)) (VB progress) (S (VP (TO to) (VP (VB involve) (NP (DT the) (JJ optic) (NN chiasm))))))))))) (. .)))
16720068	0	(S1 (S (NP (JJ Possible) (NN Doc_16720068_9_39_Disease)) (VP (VBD related) (PP (TO to) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_16720068_78_88_Chemical)) (CC and) (NP (NNP Doc_16720068_93_103_Chemical))))))) (. .)))
16720068	1	(S1 (S (NP (NP (DT A) (JJ 74-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_16720068_128_147_Disease)))) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NP (DT a) (NNP Doc_16720068_166_177_Disease) (NN hospital)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_16720068_194_202_Disease)) (, ,) (NP (NNP Doc_16720068_204_220_Disease)) (, ,) (NP (NN exhaustion)) (, ,) (CC and) (NP (NNP Doc_16720068_238_247_Disease))))))))) (. .)))
16720068	2	(S1 (S (NP (JJ Medical) (NN treatment)) (VP (AUX was) (VP (VBN initiated) (PP (IN at) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (QP (CD 20) (CD mg) (NN Doc_16720068_306_316_Chemical) (CC and) (CD 1.2) (CD mg)) (NNP Doc_16720068_328_338_Chemical))))))) (. .)))
16720068	3	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ 10th) (NN day)) (PP (IN of) (NP (NNP Doc_16720068_359_369_Chemical) (CC and) (NNP Doc_16720068_374_384_Chemical) (NN treatment))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD exhibited) (SBAR (S (VP (VBD marked) (NP (NP (NN Doc_16720068_425_448_Disease)) (, ,) (NP (NN disorientation)) (, ,) (CC and) (NP (NP (JJ severe) (NN Doc_16720068_477_492_Disease)) (PP (IN with) (NP (NNP Doc_16720068_498_505_Disease))))))))) (. .)))
16720068	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT a) (NN Doc_16720068_525_530_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 38.2) (NNS degrees)) (NP (SYM C))) (-RRB- -RRB-))) (, ,) (S (VP (VBG fluctuating) (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN between) (CD 165/90) (CC and) (CD 130/70) (CD mg)) (NNS mm)) (NP (NNP Hg))) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ severe) (NN Doc_16720068_625_648_Disease)))))) (. .)))
16720068	5	(S1 (S (NP (NN Laboratory) (NNS tests)) (VP (VBD showed) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (JJ Doc_16720068_690_698_Chemical) (NN phosphokinase)))) (PRN (-LRB- -LRB-) (NP (CD 2218) (NN IU/L)) (-RRB- -RRB-)) (, ,) (NP (JJ Doc_16720068_726_735_Chemical) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (CD 134) (NN IU/L)) (-RRB- -RRB-)) (, ,) (NP (JJ Doc_16720068_765_772_Chemical) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (CD 78) (NN IU/L)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ BUN) (PRN (-LRB- -LRB-) (NP (CD 27.9) (NNS mg/ml)) (-RRB- -RRB-)) (NNS levels)))) (. .)))
16720068	6	(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NP (NNP Doc_16720068_851_864_Chemical)) (CC and) (NP (NNP Doc_16720068_869_877_Chemical))) (S (VP (TO to) (VP (VB treat) (NP (PRP$ his) (NN symptoms.)) (ADVP (NP (CD 7) (NNS days)) (RB later))))))) (, ,) (S (NP (DT the) (NNP Doc_16720068_919_924_Disease)) (VP (VBD disappeared))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN serum) (NN CPK) (NNS levels)) (VP (AUX were) (VP (VBN normalized) (PRN (-LRB- -LRB-) (NP (CD 175) (NN IU/L)) (-RRB- -RRB-))))) (. .)))
16720068	7	(S1 (S (NP (DT This) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_16720068_1040_1070_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16720068_1072_1075_Disease)) (-RRB- -RRB-)))))) (, ,) (S (ADVP (RB thus)) (VP (VBG demonstrating) (SBAR (IN that) (S (NP (JJ Doc_16720068_1102_1105_Disease-like) (NNS symptoms)) (VP (MD can) (VP (VB occur) (PP (IN after) (NP (NP (JJ combined) (NN Doc_16720068_1145_1155_Chemical)) (CC and) (NP (JJ Doc_16720068_1160_1170_Chemical) (NN treatment))))))))))) (. .)))
16720068	8	(S1 (S (NP (NP (DT The) (JJ adverse) (NN drug) (NN reaction) (NN score)) (VP (VBN obtained) (PP (IN by) (NP (DT the) (NNP Naranjo) (NN algorithm))))) (VP (AUX was) (NP (CD 6)) (PP (IN in) (NP (PRP$ our) (NN case))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ probable) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN patient) (POS 's)) (JJ Doc_16720068_1324_1327_Disease-like) (JJ adverse) (NNS symptoms)) (CC and) (NP (NP (DT the) (VBN combined) (NN treatment)) (VP (VBN used) (PP (IN in) (NP (DT this) (NN case))))))))))) (. .)))
16720068	9	(S1 (S (NP (NP (DT The) (NN involvement)) (PP (IN of) (NP (NP (ADJP (JJ physiologic) (CC and) (JJ environmental)) (NNS aspects)) (ADJP (JJ specific) (PP (TO to) (NP (DT this) (NN patient))))))) (VP (AUX was) (VP (VBN suspected))) (. .)))
16720068	10	(S1 (S (NP (NP (JJ Several) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_16720068_1518_1521_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN noted) (PP (IN in) (NP (NP (JJ elderly) (JJ Doc_16720068_1549_1559_Disease) (NNS patients)) (SBAR (WHNP (WP$ whose) (NNS symptoms)) (S (ADVP (RB often)) (VP (VBP include) (NP (NP (NNP Doc_16720068_1598_1609_Disease)) (, ,) (NP (NNP Doc_16720068_1611_1620_Disease)) (, ,) (NP (NNP Doc_16720068_1622_1634_Disease)) (, ,) (CC and) (NP (NN exhaustion))))))))))) (. .)))
16720068	11	(S1 (S (NP (JJ Careful) (JJ therapeutic) (NN intervention)) (VP (AUX is) (ADJP (JJ necessary)) (PP (IN in) (NP (NP (NNS cases)) (VP (VBG involving) (NP (NP (JJ elderly) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP suffer) (PP (IN from) (NP (NN Doc_16720068_1750_1760_Disease))))))))))) (. .)))
16725121	0	(S1 (S (NP (NP (NN Down-regulation)) (PP (IN of) (NP (JJ Doc_16725121_19_33_Chemical) (NN transporter) (NN function)))) (VP (VBN induced) (PP (IN by) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_92_103_Chemical))) (VP (VBG linking) (PP (TO to) (NP (NP (NP (DT the) (NN alteration)) (PP (IN of) (NP (NP (NN sensitivity)) (PP (IN of) (NP (JJ local-anesthetics-induced) (NNP Doc_16725121_174_185_Disease)))))) (CC and) (NP (NP (DT the) (NN counteraction)) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN with) (NP (JJ local) (NNS anesthetics)))))))))))) (. .)))
16725121	1	(S1 (S (S (NP (NP (NNS Alterations)) (PP (IN of) (NP (JJ Doc_16725121_268_282_Chemical) (NN transporter))) (PRN (-LRB- -LRB-) (JJ NET) (-RRB- -RRB-))) (VP (VBP function) (PP (IN by) (NP (NP (JJ chronic) (NN inhibition)) (PP (IN of) (NP (NP (NN NET)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NN sensitization))) (PP (TO to) (NP (NNP Doc_16725121_371_379_Disease))))))))) (S (VP (VB induce) (PP (IN by) (NP (NNP Doc_16725121_390_397_Chemical))))))) (CC and) (S (NP (JJ local) (NNS anesthetics)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NNS mice)))))) (. .)))
16725121	2	(S1 (S (NP (NP (JJ Daily) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_16725121_466_477_Chemical)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN NET)))) (, ,))) (PP (IN for) (NP (CD 5) (NNS days)))) (VP (VBD decreased) (NP (JJ -LSB-) (PRN (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (NNP H) (NNS -RSB-)) (NP (JJ Doc_16725121_531_545_Chemical) (NN uptake)) (PP (IN in) (NP (NP (DT the) (NNP P2) (NNS fractions)) (PP (IN of) (NP (NP (NNS hippocampus)) (CONJP (CC but) (RB not)) (NP (NN cortex) (, ,) (NN striatum) (CC or) (NNS amygdalae))))))) (. .)))
16725121	3	(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NNP Doc_16725121_648_657_Chemical)) (, ,) (NP (NNP Doc_16725121_659_670_Chemical)) (CC or) (NP (NNP Doc_16725121_674_682_Chemical)))) (PP (IN with) (NP (NNP Doc_16725121_688_699_Chemical)))) (VP (VBD reversed) (NP (DT this) (NN effect))) (. .)))
16725121	4	(S1 (S (NP (NP (JJ Daily) (NN treatment)) (PP (IN of) (NP (NP (NP (JJ Doc_16725121_741_748_Chemical) (JJ increased) (NNS -LSB-)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (NP (NNP H) (NN -RSB-) (NNP Doc_16725121_765_779_Chemical))))) (VP (VBD uptake) (PP (IN into) (NP (DT the) (NN hippocampus)))) (. .)))
16725121	5	(S1 (S (NP (NP (JJ Daily) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_833_844_Chemical)))) (VP (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NN appearance)) (PP (IN of) (NP (JJ Doc_16725121_886_895_Chemical-induced) (NNP Doc_16725121_904_915_Disease))))))) (CC and) (VP (VBD decreased) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_16725121_938_945_Chemical-induced) (NNP Doc_16725121_954_965_Disease)))))) (. .)))
16725121	6	(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NNP Doc_16725121_988_997_Chemical))) (PP (IN with) (NP (NNP Doc_16725121_1003_1014_Chemical)))) (VP (VBD reversed) (NP (NP (DT the) (NNS changes)) (PP (IN of) (NP (NP (JJ Doc_16725121_1039_1049_Disease) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_16725121_1062_1071_Chemical)) (CC and) (NP (NNP Doc_16725121_1076_1083_Chemical)))) (VP (VBN induced) (PP (IN by) (NP (NP (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1122_1133_Chemical)))))))))) (. .)))
16725121	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (JJ hippocampal) (NN NET)) (VP (VBN induced) (PP (IN by) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1234_1245_Chemical))))))))) (VP (MD may) (VP (AUX be) (ADJP (JJ relevant) (PP (TO to) (NP (NP (JJ Doc_16725121_1265_1276_Chemical-induced) (NN sensitization)) (PP (IN of) (NP (NNP Doc_16725121_1302_1311_Chemical) (NNP Doc_16725121_1312_1323_Disease))))))))))) (. .)))
16725121	8	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_16725121_1339_1341_Chemical) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NNS channels))) (PP (IN by) (NP (JJ local) (NNS anesthetics)))) (VP (MD may) (VP (VB regulate) (NP (NP (JJ Doc_16725121_1388_1399_Chemical-induced) (NN down-regulation)) (PP (IN of) (NP (JJ NET) (NN function)))))) (. .)))
16725121	9	(S1 (S (NP (NP (VBN Repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1468_1475_Chemical)))) (VP (VBZ induces) (NP (NP (NN up-regulation)) (PP (IN of) (NP (JJ hippocampal) (JJ NET) (NN function))))) (. .)))
16725121	10	(S1 (S (NP (NP (JJ Doc_16725121_1527_1538_Chemical-induced) (NN sensitization)) (PP (IN of) (NP (NNP Doc_16725121_1564_1573_Chemical) (NNP Doc_16725121_1574_1582_Disease)))) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN mechanism)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (NN kindling)) (VP (VBG resulting) (PP (IN from) (NP (NP (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1669_1676_Chemical)))))))))))) (. .)))
16820346	0	(S1 (S (NP (NN Doc_16820346_0_12_Chemical)) (VP (VP (VBD prevented)) (CC and) (VP (VBD reversed) (NP (JJ Doc_16820346_36_49_Chemical-induced) (NN Doc_16820346_58_70_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
16820346	1	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (JJ antioxidant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_16820346_120_132_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16820346_134_140_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ Doc_16820346_145_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16820346_160_163_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_16820346_173_185_Disease))))))) (, ,) (NP (CD 60) (JJ male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16820346_233_239_Chemical) (CD 30) (NN mg/kg/day)))) (CC or) (VP (VB tap) (NP (NN water)) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
16820346	2	(S1 (S (NP (NNP Doc_16820346_279_282_Chemical)) (VP (VBD increased) (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB SBP)) (-RRB- -RRB-)) (PP (IN from) (NP (NP (NP (CD 109) (NN +/-)) (NP (QP (CD 1.8) (TO to) (CD 135)) (JJ +/-) (CD 0.6) (NNS mmHg))) (CC and) (NP (NN plasma) (NN Doc_16820346_371_381_Chemical)))) (PRN (-LRB- -LRB-) (S (NP (NP (CD 5711) (NN +/-) (CD 284.9) (NN saline)) (, ,) (NP (CD 7931) (CD +/-) (CD 392.8) (NNP U/ml) (NNP Doc_16820346_426_429_Chemical)) (, ,)) (VP (VBD P) (NP (QP (CD <) (CD 0.001))))) (-RRB- -RRB-))) (. .)))
16820346	3	(S1 (S (PP (IN In) (NP (DT this) (NN prevention) (NN study))) (, ,) (S (NP (NP (NN SBP)) (PP (IN in) (NP (DT the) (NNP Doc_16820346_480_486_Chemical) (NNP +) (NNP Doc_16820346_489_492_Chemical) (NN group)))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (CD 115) (NN +/-)) (NP (QP (CD 0.4) (TO to) (CD 124)) (JJ +/-) (CD 1.5) (NNS mmHg))))))) (, ,) (CC but) (S (NP (DT this)) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (PP (IN in) (NP (DT the) (JJ Doc_16820346_596_599_Chemical-only) (NN group))))) (PRN (-LRB- -LRB-) (S (NP (NNP P) (POS ')) (VP (VBG <) (NP (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
16820346	4	(S1 (S (NP (NNP Doc_16820346_624_630_Chemical)) (VP (VBD reversed) (NP (NP (NP (NNP Doc_16820346_640_643_Chemical-induced) (NNP Doc_16820346_652_664_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 129) (NN +/-)) (NP (CD 0.6) (NNS mmHg))) (, ,) (CC vs.) (NP (NP (CD 135) (NN +/-)) (NP (NP (CD 0.6) (JJ mmHg) (NNS P) (POS ')) (NNP <) (CD 0.05)))) (-RRB- -RRB-))) (CC and) (NP (NP (VBN decreased) (NN plasma) (NNP Doc_16820346_737_747_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 7931) (NN +/-) (CD 392.8) (NNP Doc_16820346_764_767_Chemical)) (, ,) (NP (CD 1187) (CD +/-) (CD 441.2) (NNP Doc_16820346_784_790_Chemical) (NNP +) (NNP Doc_16820346_793_796_Chemical))) (, ,) (NP (NNP P) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-))))) (. .)))
16820346	5	(S1 (S (NP (NP (NN Plasma) (NNP Doc_16820346_818_825_Chemical/Doc_16820346_826_833_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NOx)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (JJ Doc_16820346_857_860_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 11.2) (NN +/-) (CD 1.08) (NN microm)) (, ,) (NP (NP (CD 15.3) (NN +/-)) (NP (CD 1.17) (NN microm)) (, ,) (ADVP (RB respectively)))) (, ,) (NP (NP (CD P) (NNS <)) (NP (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
16820346	6	(S1 (S (NP (NN Doc_16820346_976_982_Chemical)) (VP (VBD affected) (NP (DT neither) (NN plasma) (NN NOx) (CC nor) (NN thymus) (NN weight))) (. .)))
16820346	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_16820346_1036_1048_Chemical)) (VP (VP (VBD prevented)) (CC and) (VP (VBD reversed) (NP (JJ Doc_16820346_1072_1085_Chemical-induced) (NN Doc_16820346_1094_1106_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
16826348	0	(S1 (S (NP (NN Doc_16826348_0_21_Disease)) (VP (VBD caused) (PP (IN by) (NP (JJ high-dose) (JJ Doc_16826348_42_62_Chemical) (NN treatment))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_16826348_91_113_Disease)))))) (. .)))
16826348	1	(S1 (S (S (NP (NP (DT The) (ADJP (JJ central) (JJ nervous)) (NN system) (NN Doc_16826348_142_150_Disease)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_16826348_164_184_Chemical)))) (VP (AUX is) (VP (ADVP (RB well)) (VBN recognized)))) (, ,) (CC but) (S (NP (NP (DT the) (NNP Doc_16826348_213_221_Disease)) (PP (IN of) (NP (NNP Doc_16826348_225_245_Chemical))) (PP (IN in) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))) (VP (AUX has) (VP (AUX been) (ADVP (RB infrequently)) (VP (VBN reported))))) (. .)))
16826348	2	(S1 (S (NP (DT A) (JJ 49-year-old) (JJ Japanese) (NN man)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_16826348_357_379_Disease))))) (. .)))
16826348	3	(S1 (S (SBAR (IN After) (S (NP (PRP he)) (VP (VBD achieved) (NP (JJ complete) (NN remission))))) (, ,) (NP (PRP he)) (VP (VBD received) (NP (NP (JJ high-dose) (JJ Doc_16826348_441_461_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 2) (NN g/m2)) (NP (RB twice) (DT a) (NN day))) (PP (IN for) (NP (CD 5) (NNS days)))) (: ;) (NP (NN total)) (, ,) (NP (CD 20) (NN g/m2))) (-RRB- -RRB-))) (PP (IN as) (NP (NN consolidation) (NN therapy)))) (. .)))
16826348	4	(S1 (S (S (NP (NP (DT The) (JJ first) (NN course)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_16826348_576_596_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (DT no) (JJ unusual) (NNS symptoms))))) (, ,) (CC but) (S (PP (IN on) (NP (NP (NN day) (CD 21)) (PP (IN of) (NP (NP (DT the) (JJ second) (NN course)) (PP (IN of) (NP (NN treatment))))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_16826348_705_713_Disease))) (PP (IN in) (NP (PRP$ his) (JJ right) (NN foot))))) (. .)))
16826348	5	(S1 (S (NP (NP (NN Electromyogram)) (CC and) (NP (NN nerve-conduction) (NNS studies))) (VP (VBD showed) (NP (NNP Doc_16826348_784_805_Disease)) (PP (IN in) (NP (DT both) (JJ peroneal) (NNS nerves)))) (. .)))
16826348	6	(S1 (S (S (NP (DT This) (NN Doc_16826348_836_846_Disease)) (VP (AUX was) (ADVP (RB gradually)) (VP (VBG resolving)))) (: ;) (S (ADVP (RB however)) (, ,) (SBAR (IN after) (S (NP (DT the) (NN patient)) (VP (VBD received) (NP (JJ allogeneic) (NN bone) (NN marrow) (NN transplantation))))) (, ,) (NP (DT the) (NNS symptoms)) (VP (VBD worsened) (, ,) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_16826348_995_1020_Disease))))) (, ,) (SBAR (S (CC and) (NP (DT the) (NNS symptoms)) (ADVP (RB subsequently)) (VP (VBD responded) (PP (TO to) (NP (NNP Doc_16826348_1065_1083_Chemical)))))))) (. .)))
16826348	7	(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_16826348_1112_1133_Disease)))) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ unclear))))) (, ,) (NP (JJ high-dose) (NNP Doc_16826348_1163_1183_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN therapy)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (RB potentially) (JJ toxic) (PP (TO to) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))) (, ,) (CC and) (S (NP (NN auto/alloimmunity)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT these) (NNS mechanisms)))))) (. .)))
16844102	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NNP Doc_16844102_10_26_Chemical)) (CC and) (NP (NNP Doc_16844102_31_43_Chemical)))) (PP (IN on) (NP (NNP Doc_16844102_47_62_Chemical-induced) (NNP Doc_16844102_71_84_Disease))) (. .)))
16844102	1	(S1 (S (NP (NP (NNP Doc_16844102_86_101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_103_105_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (NP (JJ dopaminergic) (NN Doc_16844102_128_141_Disease)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (VBN increased) (NN formation)) (PP (IN of) (NP (JJ free) (NNS radicals)))))))))))))) (. .)))
16844102	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_16844102_252_268_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_270_278_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN scavenger)) (PP (IN of) (NP (JJ reactive) (JJ Doc_16844102_305_311_Chemical) (NNS species)))) (, ,)) (CC and) (NP (NP (NP (NNP Doc_16844102_325_337_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_339_342_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT an) (NNP Doc_16844102_348_352_Chemical) (NN chelator)) (, ,)))) (PP (IN on) (NP (DT the) (JJ Doc_16844102_370_372_Chemical-induced) (NNP Doc_16844102_381_394_Disease))))) (. .)))
16844102	3	(S1 (S (NP (JJ Male) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16844102_424_426_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg)) (, ,) (NP (NP (DT every) (CD 2) (NNP h)) (PP (IN for) (NP (CD four) (NNS injections))))) (-RRB- -RRB-)))))) (. .)))
16844102	4	(S1 (S (NP (DT The) (NN rat)) (VP (VBD received) (NP (NP (DT either) (NNP Doc_16844102_494_502_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg)) (-RRB- -RRB-))) (PP (RB intraperitoneally) (PP (IN for) (NP (CD 3) (NNS days))) (CC and) (ADVP (NP (CD 30) (NN min)) (RB prior)) (PP (TO to) (NP (NP (JJ Doc_16844102_563_565_Chemical) (NN administration)) (CC or) (NP (NP (NNP Doc_16844102_584_587_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-)))))) (ADVP (RB subcutaneously)) (NP (CD 30) (NN min)) (PP (IN before) (NP (NNP Doc_16844102_628_630_Chemical) (NN administration)))) (. .)))
16844102	5	(S1 (S (NP (NP (DT The) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_16844102_669_677_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_679_681_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16844102_684_693_Chemical)) (CC and) (NP (PRP$ their) (NNS metabolites))))) (VP (VBD decreased) (ADVP (RB significantly)) (SBAR (IN after) (S (NP (NP (JJ Doc_16844102_746_748_Chemical) (NN administration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (NP (DT the) (NNP Doc_16844102_792_800_Chemical) (CC and) (NNP Doc_16844102_805_808_Chemical) (NN pretreatment.) (NNP Doc_16844102_823_831_Chemical) (CC and) (NNP Doc_16844102_836_839_Chemical)))))))) (VP (VBD attenuated) (NP (NP (DT the) (JJ Doc_16844102_855_857_Chemical-induced) (NN Doc_16844102_866_878_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNS alterations)) (PP (IN in) (NP (DT the) (NN locomotor) (NN activity))))))))) (. .)))
16844102	6	(S1 (S (S (NP (NP (DT The) (NN level)) (PP (IN of) (NP (NN lipid) (NN peroxidation)))) (VP (AUX was) (ADJP (JJR higher)))) (CC and) (S (NP (DT the) (VBN reduced) (JJ Doc_16844102_992_1003_Chemical) (NN concentration)) (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (JJ Doc_16844102_1035_1037_Chemical-treated) (NNS rats))))) (. .)))
16844102	7	(S1 (S (NP (DT These) (NNS changes)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN by) (NP (NP (NNP Doc_16844102_1099_1107_Chemical)) (CC and) (NP (NNP Doc_16844102_1112_1115_Chemical)))))) (. .)))
16844102	8	(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNP Doc_16844102_1136_1144_Chemical)) (CC and) (NP (NNP Doc_16844102_1149_1152_Chemical))) (VP (VBP ameliorate) (NP (DT the) (JJ Doc_16844102_1168_1170_Chemical-induced) (NN Doc_16844102_1179_1194_Disease)) (PP (IN by) (S (VP (VBG decreasing) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ oxidative) (NN stress))))))))))) (. .)))
1687392	0	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (DT both) (JJ D-1) (CC and) (JJ D-2) (JJ Doc_1687392_29_37_Chemical) (NNS receptors)))) (VP (MD may) (VP (VB induce) (NP (NN Doc_1687392_59_68_Disease)) (PP (IN in) (NP (NNP mice.) (CD 1))))) (. .)))
1687392	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_1687392_85_94_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1687392_106_114_Chemical) (NNS antagonists))))) (VP (AUX has) (VP (AUX been) (VP (VBN tested))))) (CC and) (S (NP (NP (DT the) (JJ possible) (JJ Doc_1687392_160_168_Chemical) (NNS subtypes)) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_1687392_190_199_Disease))))) (VP (AUX was) (VP (VBN determined.) (NP (CD 2))))) (. .)))
1687392	2	(S1 (S (NP (NP (JJ Doc_1687392_219_227_Chemical) (NN antagonist) (NNP Doc_1687392_239_251_Chemical)) (, ,) (NP (JJ D-1) (NN antagonist) (NNP Doc_1687392_268_277_Chemical)) (CC or) (NP (JJ D-2) (NN antagonist) (NNP Doc_1687392_296_305_Chemical))) (VP (VBN induced) (NP (NNP Doc_1687392_314_323_Disease))) (. .)))
1687392	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_1687392_339_351_Chemical)) (CC and) (NP (NNP Doc_1687392_356_365_Chemical))))) (VP (AUX was) (ADJP (JJ dose-dependent))) (. .)))
1687392	4	(S1 (S (NP (NP (NN Combination)) (PP (IN of) (NP (NNP Doc_1687392_401_410_Chemical))) (PP (IN with) (NP (NNP Doc_1687392_416_425_Chemical)))) (VP (AUX did) (RB not) (VP (VB induce) (NP (NN Doc_1687392_441_450_Disease) (NN potentiation.) (CD 3)))) (. .)))
1687392	5	(S1 (S (NP (JJ D-1) (JJ agonist) (ADJP (JJ Doc_1687392_480_489_Chemical) (CC or) (JJ D-2)) (NN agonist) (NN Doc_1687392_505_515_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN Doc_1687392_530_539_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_1687392_551_563_Chemical)) (, ,) (NP (NNP Doc_1687392_565_574_Chemical)) (CC or) (NP (NNP Doc_1687392_578_587_Chemical.) (CD 4))))))) (. .)))
1687392	6	(S1 (S (NP (NP (NN Combination)) (PP (IN of) (NP (NNP Doc_1687392_607_616_Chemical))) (PP (IN with) (NP (NNP Doc_1687392_622_632_Chemical)))) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (JJ potentiated) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_1687392_680_689_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1687392_701_709_Chemical) (NN antagonists.) (CD 5))))))))) (. .)))
1687392	7	(S1 (S (NP (DT The) (NNS data)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (SBAR (IN although) (S (NP (JJ D-2) (NN receptor) (NN blockade)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_1687392_799_808_Disease))))))) (, ,) (NP (DT the) (JJ D-1) (NN receptor)) (VP (MD may) (VP (VB plan) (NP (DT a) (NN role)))))))) (. .)))
16960342	0	(S1 (S (NP (NP (JJ Sustained) (JJ clinical) (NN improvement)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ decompensated) (NNP Doc_16960342_63_74_Disease)))))) (VP (VBD virus-related) (NP (NNP Doc_16960342_89_98_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16960342_120_130_Chemical) (CD monotherapy)))))) (. .)))
16960342	1	(S1 (S (NP (NP (NN Doc_16960342_144_177_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ causes) (NP (NP (NNP Doc_16960342_192_207_Disease)) (CC and) (NP (NNP Doc_16960342_212_236_Disease)))))) (, ,)) (VP (VBZ remains) (NP (NP (DT a) (JJ major) (NN health) (NN problem)) (PP (IN in) (NP (JJ Asian) (NNS countries))))) (. .)))
16960342	2	(S1 (S (NP (NP (JJ Recent) (NN development)) (PP (IN of) (NP (NN vaccine))) (PP (IN for) (NP (NN prevention)))) (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (ADJP (JJ successful) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (RB chronically) (JJ infected) (NNS carriers))))))))))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ standard) (JJ medical) (NNS therapies)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN established) (PRT (RP up)) (PP (TO to) (NP (RB now)))))))))) (. .)))
16960342	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBD encountered) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ decompensated) (JJ HBV-related) (NN Doc_16960342_567_576_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD exhibited) (NP (DT the) (JJ dramatic) (NNS improvements)) (PP (IN after) (NP (JJ antiviral) (NN therapy)))))))))) (. .)))
16960342	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (NP (DT a) (JJ 50-year-old) (NN woman))) (. .)))
16960342	5	(S1 (S (S (NP (JJ Previous) (JJ conventional) (JJ medical) (NNS treatments)) (VP (AUX were) (RB not) (ADJP (JJ effective)) (PP (IN for) (NP (DT this) (NN patient))))) (, ,) (S (ADVP (RB thus)) (NP (DT this) (NN patient)) (VP (AUX had) (VP (AUX been) (VP (VBN referred) (PP (TO to) (NP (PRP$ our) (NN hospital))))))) (. .)))
16960342	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_16960342_841_851_Chemical)) (, ,) (NP (DT a) (JJ reverse) (NN transcriptase) (NN inhibitor)) (, ,))) (PP (IN for) (NP (CD 23) (NNS months)))) (ADVP (RB dramatically)) (VP (VBD improved) (NP (PRP$ her) (NN liver) (NN severity))) (. .)))
16960342	7	(S1 (S (PP (IN During) (NP (DT this) (NN period))) (, ,) (S (NP (DT no) (NN drug) (NN resistant) (JJ mutant) (NN HBV)) (VP (VBD emerged))) (, ,) (CC and) (S (NP (DT the) (JJ serum) (NN HBV-DNA) (NN level)) (VP (AUX was) (ADVP (RB continuously)) (VP (VBN suppressed)))) (. .)))
16960342	8	(S1 (S (NP (DT These) (JJ virological) (NNS responses)) (VP (AUX were) (ADVP (RB also)) (VP (VBN maintained) (SBAR (RB even) (IN after) (S (NP (DT the) (JJ antiviral) (NN therapy)) (VP (AUX was) (VP (VBN discontinued))))))) (. .)))
16960342	9	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT both) (NNP Doc_16960342_1174_1215_Chemical)) (VP (AUX were) (VP (VBN observed) (S (VP (TO to) (VP (AUX have) (VP (VBN disappeared) (PP (IN in) (NP (DT this) (NN patient))))))))) (. .)))
16960342	10	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_16960342_1289_1299_Chemical))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ HBV-related) (NNP Doc_16960342_1329_1338_Disease)))))) (, ,) (PP (IN like) (NP (PRP$ our) (JJ present) (NN case))) (, ,) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (DT an) (JJ initial) (JJ medical) (JJ therapeutic) (NN option))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS countries)) (SBAR (WHADVP (WRB where)) (S (NP (NN liver) (NN transplantation)) (VP (AUX is) (RB not) (ADVP (RB reliably)) (ADJP (JJ available)))))))))) (. .)))
1700207	0	(S1 (S (NP (NP (JJ Antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NP (JJ optical) (NNS isomers)) (PP (IN of) (NP (NNP Doc_1700207_45_56_Chemical))))) (PP (IN on) (NP (NN canine)))) (VP (VBP Doc_1700207_67_90_Disease)) (. .)))
1700207	1	(S1 (S (NP (NP (NP (JJ Antiarrhythmic) (NNS effects)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NN -Doc_1700207_122_133_Chemical)))) (CC and) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NN -Doc_1700207_142_153_Chemical))) (VP (AUX were) (VP (VBN examined) (S (VP (VBG using) (NP (CD two) (JJ canine) (NNP Doc_1700207_185_207_Disease) (NNS models)))))) (. .)))
1700207	2	(S1 (S (NP (NP (NNP Doc_1700207_216_225_Chemical) (NNP Doc_1700207_226_236_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_1700207_261_263_Chemical) (NN channel) (NNS blockers))))))) (, ,)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intermittent) (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NN i.v.)) (-RRB- -RRB-)) (NN injection)) (PP (IN of) (NP (NNP Doc_1700207_342_349_Chemical))) (PP (IN in) (NP (JJ Doc_1700207_353_366_Chemical-anesthetized) (NNS dogs))))))) (. .)))
1700207	3	(S1 (S (NP (NP (NN Doc_1700207_386_407_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_1700207_432_434_Chemical) (NN channel) (NNS blockers))))))) (, ,)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1700207_468_478_Chemical) (NN infusion))) (PP (IN in) (NP (JJ Doc_1700207_491_500_Chemical-anesthetized) (NNS dogs))))) (. .)))
1700207	4	(S1 (S (NP (CD Ten) (CC and) (CD 5) (NN mg/kg) (NN i.v.) (-LRB- -LRB-) (NN +) (-RRB- -RRB-) (NN -Doc_1700207_545_556_Chemical)) (VP (VBD suppressed) (NP (NP (NNP Doc_1700207_568_577_Chemical-)) (CC and) (NP (NP (NNP Doc_1700207_583_593_Chemical-induced) (NNP Doc_1700207_602_613_Disease)) (, ,) (ADVP (RB respectively))))) (. .)))
1700207	5	(S1 (S (NP (NP (DT The) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -Doc_1700207_680_691_Chemical))) (PP (IN for) (NP (NP (NNP Doc_1700207_696_705_Chemical-)) (CC and) (NP (NNP Doc_1700207_711_721_Chemical-induced) (NNP Doc_1700207_730_741_Disease))))) (VP (AUX were) (NP (CD 1.4) (ADJP (JJ +/-) (NP (CD 0.4) (CC and) (CD 2.0))) (JJ +/-) (CD 0.6) (NN micrograms/ml)) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (, ,) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (. .)))
1700207	6	(S1 (S (NP (NP (DT A) (JJR lower) (NN dose)) (PP (IN of) (NP (NP (QP (CD 1) (CD mg/kg)) (NNS i.v.)) (PP (IN of) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NN -Doc_1700207_861_872_Chemical))))))) (VP (VBD suppressed) (NP (DT the) (JJ Doc_1700207_888_897_Chemical-induced) (NN Doc_1700207_906_916_Disease)) (, ,) (SBAR (IN whereas) (S (NP (CD 5) (JJ mg/kg) (NN i.v.)) (VP (AUX was) (VP (VBN needed) (S (VP (TO to) (VP (VB suppress) (NP (JJ Doc_1700207_962_972_Chemical-induced) (NN Doc_1700207_981_992_Disease)))))))))) (. .)))
1700207	7	(S1 (S (NP (NP (DT The) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (JJ -Doc_1700207_1045_1056_Chemical)) (PP (IN for) (NP (NNP Doc_1700207_1061_1070_Chemical-) (CC and) (NNP Doc_1700207_1076_1086_Chemical-induced) (NNP Doc_1700207_1095_1105_Disease)))))) (VP (AUX were) (NP (NP (CD 0.06) (JJ +/-) (NNS 0.04)) (CC and) (NP (NP (NP (CD 0.7) (NNS +/-)) (NP (CD 0.1) (NN micrograms/ml)) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (JJ +/-) (NNS SD)) (, ,) (NP (NNP n) (SYM =) (CD 6))) (-RRB- -RRB-))))) (. .)))
1700207	8	(S1 (S (NP (NP (DT The) (JJR stronger) (JJ antiarrhythmic) (NN effect)) (PP (IN of) (NP (NP (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (ADJP (JJ -Doc_1700207_1233_1244_Chemical) (SBAR (S (VP (VBZ indicates) (SBAR (IN that) (S (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NN -isomer)) (VP (MD may) (VP (AUX have) (NP (DT an) (NN effect))))))))) (QP (RB nearly) (CD 5-20) (NNS times))) (JJR stronger)) (PP (IN in) (NP (JJ suppressing) (NNP Doc_1700207_1332_1334_Chemical) (NNS channels)))) (, ,) (CC but) (NP (NNS effects))) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (PP (IN on) (NP (NNP Doc_1700207_1374_1376_Chemical) (NNS channels)))))))) (VP (MD may) (VP (AUX be) (ADJP (RB almost) (JJ equipotent)))) (. .)))
17019386	0	(S1 (NP (NP (NP (NN Passage)) (PP (IN of) (NP (NNP Doc_17019386_11_19_Chemical))) (PP (IN into) (NP (DT the) (NN brain))) (PP (IN around) (NP (NNP Doc_17019386_42_49_Disease)))) (: :) (NP (NP (DT a) (JJ potential) (NN cause)) (PP (IN of) (NP (NN rebound) (NN phenomenon)))) (. .)))
17019386	1	(S1 (NP (NP (DT A) (NN study)) (PP (IN on) (NP (CD 21) (NNS patients))) (. .)))
17019386	2	(S1 (S (NP (NP (JJ Widespread) (NN use)) (PP (IN of) (NP (NNP Doc_17019386_139_147_Chemical))) (S (VP (TO to) (VP (VP (VB reduce) (NP (NNP Doc_17019386_158_169_Disease))) (CC and) (VP (VB lower) (NP (NP (NN Doc_17019386_180_192_Disease)) (PP (IN in) (NP (NNP Doc_17019386_196_207_Disease) (NNS patients))))))))) (VP (VBZ continues) (S (VP (TO to) (VP (AUX be) (VP (VBN afflicted) (PP (IN by) (NP (DT the) (JJ so-called) (NN rebound) (NN phenomenon)))))))) (. .)))
17019386	3	(S1 (S (NP (NP (NN Leakage)) (PP (IN of) (NP (NNP Doc_17019386_291_299_Chemical))) (PP (IN into) (NP (DT the) (NN brain) (NN parenchyma))) (PP (IN through) (NP (NP (DT an) (JJ altered) (NNP BBB) (CC and) (JJ secondary) (NN reversal)) (PP (IN of) (NP (JJ osmotic) (NN gradient)))))) (VP (AUX is) (VP (VBN considered) (S (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NN rebound))))))) (. .)))
17019386	4	(S1 (S (NP (DT This)) (VP (AUX has) (ADVP (RB only)) (VP (AUX been) (VP (VBN demonstrated) (ADVP (RB experimentally)) (PP (IN in) (NP (NNS animals)))))) (. .)))
17019386	5	(S1 (S (PP (IN As) (NP (NP (DT a) (NN contribution)) (PP (TO to) (NP (DT this) (NN issue))))) (NP (PRP we)) (VP (VBD decided) (S (VP (TO to) (VP (VB research) (NP (NP (DT the) (JJ possible) (NN passage)) (PP (IN of) (NP (NNP Doc_17019386_573_581_Chemical)))) (PP (IN into) (NP (DT the) (NN brain))) (PP (IN after) (NP (NN administration))) (PP (TO to) (NP (CD 21) (NNP Doc_17019386_624_635_Disease) (NNS patients))))))) (. .)))
17019386	6	(S1 (S (NP (NP (NNP Doc_17019386_655_663_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 18) (NN %)) (NN solution)) (: ;) (NP (CD 1) (NN g/kg))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (NN bolus)) (PP (TO to) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD ten)) (VP (AUX had) (ADJP (JJ Doc_17019386_736_752_Disease)))) (, ,) (NP (NP (CD seven) (NN brain)) (NP (NNP Doc_17019386_766_776_Disease))) (CC and) (NP (NP (CD four)) (NP (NNP Doc_17019386_786_796_Disease)))) (-RRB- -RRB-)))))) (PP (IN about) (NP (NP (CD 30) (NNS minutes)) (PP (IN before) (NP (NN craniotomy))))))) (. .)))
17019386	7	(S1 (S (PP (IN During) (NP (NN resection))) (, ,) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (DT the) (VBG surrounding) (NNP Doc_17019386_880_889_Disease) (JJ white) (NN matter)))) (VP (AUX was) (VP (VBN taken) (PP (IN at) (NP (DT the) (JJ same) (NN time))) (PP (IN as) (NP (DT a) (CD 10) (NN ml) (NN venous) (NN blood) (NN sample))))) (. .)))
17019386	8	(S1 (S (NP (JJ Doc_17019386_962_970_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (NN plasma)) (CC and) (NP (JJ white) (NN matter)))) (PP (IN by) (NP (NP (DT a) (VBN modified) (NN version)) (PP (IN of) (NP (NP (DT the) (JJ enzyme) (NN assay)) (PP (IN of) (NP (NP (NNP Blonquist)) (CC et) (NP (NNP al)))))))))) (. .)))
17019386	9	(S1 (S (PP (IN In) (NP (JJS most) (NNP Doc_17019386_1106_1112_Disease) (NNS patients))) (, ,) (NP (NP (JJ Doc_17019386_1123_1131_Chemical) (NNS concentrations)) (PP (IN in) (NP (JJ white) (NN matter)))) (VP (AUX were) (ADJP (ADJP (QP (CD 2) (TO to) (CD 6) (NNS times)) (JJR higher)) (PP (IN than) (PP (IN in) (NP (NN plasma))))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 3.5) (NNS times)))) (-RRB- -RRB-))) (. .)))
17019386	10	(S1 (S (PP (IN In) (NP (NNP Doc_17019386_1224_1234_Disease) (CC and) (NNP Doc_17019386_1239_1249_Disease))) (NP (NP (NNS patients) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_17019386_1284_1292_Chemical)))) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ white) (NN matter) (NNS concentrations)))) (PP (IN except) (PP (IN in) (NP (NP (CD three) (NNS cases)) (PP (IN with) (NP (NP (NN infiltration)) (PP (IN by) (NP (JJ neoplastic) (NNS cells))))))))) (. .)))
17019386	11	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP show) (SBAR (IN that) (S (PP (ADVP (RB even)) (IN after) (NP (DT a) (JJ single) (NN bolus))) (, ,) (NP (NNP Doc_17019386_1474_1482_Chemical)) (VP (MD may) (VP (VB leak) (PP (IN through) (NP (NP (DT the) (VBN altered) (NNP BBB)) (PP (IN near) (NP (NNP Doc_17019386_1521_1528_Disease))))) (, ,) (S (VP (VP (VBG reversing) (NP (DT the) (JJ initial) (NN plasma-to-blood) (NN osmotic) (NN gradient))) (, ,) (VP (VBG aggravating) (NP (JJ peritumoral) (NNP Doc_17019386_1610_1615_Disease))) (CC and) (VP (VBG promoting) (NP (NP (NN rebound)) (PP (IN of) (NP (NNP ICP)))))))))))) (. .)))
17042884	0	(S1 (NP (NP (JJ Placebo-level) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_17042884_27_50_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042884_52_55_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_17042884_62_72_Chemical)) (PP (IN in) (NP (NP (JJ controlled) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17042884_112_125_Disease))))))))) (. .)))
17042884	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (NN Doc_17042884_151_174_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042884_176_179_Disease)) (-RRB- -RRB-)) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_192_201_Disease))) (, ,) (PP (IN with) (NP (NP (NNP Doc_17042884_208_218_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17042884_236_249_Disease))))))))))) (. .)))
17042884	2	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN from) (NP (CD four) (ADJP (RB similarly) (VBN designed)) (, ,) (ADJP (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ 3-) (TO to) (JJ 12-week)) (NNS studies))))) (. .)))
17042884	3	(S1 (S (NP (CD Two) (NNS studies)) (VP (VBN evaluated) (NP (NP (NP (NP (JJ Doc_17042884_380_390_Chemical) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 800)) (NN mg/day)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 209)) (-RRB- -RRB-)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 198)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (NNP Doc_17042884_463_470_Chemical) (CC or) (NNP Doc_17042884_474_485_Chemical) (NN monotherapy)) (PP (IN as) (NP (JJ respective) (JJ active) (NNS controls)))))) (. .)))
17042884	4	(S1 (S (NP (CD Two) (NNS studies)) (VP (VBN evaluated) (NP (NP (NNP Doc_17042884_551_561_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 800)) (NN mg/day)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (NN mood) (NN stabilizer) (-LRB- -LRB-) (NNP Doc_17042884_620_627_Chemical) (CC or) (NNP Doc_17042884_631_641_Chemical)) (, ,) (NP (NNP Doc_17042884_643_646_Chemical) (NNP +) (NNP Doc_17042884_649_651_Chemical/Doc_17042884_652_655_Chemical)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 196)) (-RRB- -RRB-))))) (PP (VBN compared) (PP (TO to) (NP (NP (NP (NN placebo) (CC and) (NN mood) (NN stabilizer)) (-LRB- -LRB-) (NP (NNP PBO) (NNP +) (NNP Doc_17042884_714_716_Chemical/Doc_17042884_717_720_Chemical)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 203)) (-RRB- -RRB-))))) (. .)))
17042884	5	(S1 (S (NP (NN Doc_17042884_733_756_Disease)) (VP (AUX were) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ Simpson-Angus) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NNP SAS)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNP Barnes) (NNP Akathisia) (NNP Rating) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNS BARS)) (-RRB- -RRB-))) (, ,) (NP (JJ adverse) (NN event) (NNS reports)) (CC and) (NP (JJ anticholinergic) (NN drug) (NN usage))))))) (. .)))
17042884	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ Doc_17042884_931_934_Disease-related) (JJ adverse) (NNS events)) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_969_978_Disease))) (, ,)))) (VP (AUX was) (ADJP (RB no) (JJ different) (PP (IN with) (NP (NP (JJ Doc_17042884_1002_1012_Chemical) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (CD 12.9) (NN %)) (-RRB- -RRB-)))) (PP (IN than) (PP (IN with) (NP (NN placebo))))) (PRN (-LRB- -LRB-) (NP (CD 13.1) (NN %)) (-RRB- -RRB-))) (. .)))
17042884	7	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ Doc_17042884_1071_1074_Disease-related) (JJ adverse) (NNS events)) (PP (IN with) (NP (NP (NNP Doc_17042884_1103_1106_Chemical) (NNP +) (NNP Doc_17042884_1109_1111_Chemical/Doc_17042884_1112_1115_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 21.4) (NN %)) (-RRB- -RRB-))))) (VP (AUX were) (ADJP (RB no) (JJ different) (PP (IN than) (PP (IN with) (NP (NP (NNP PBO) (NNP +) (NNP Doc_17042884_1158_1160_Chemical/Doc_17042884_1161_1164_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 19.2) (NN %)) (-RRB- -RRB-))))))) (. .)))
17042884	8	(S1 (S (NP (NP (JJ Adverse) (NNS events)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_17042884_1200_1203_Disease))))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 59.6) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17042884_1247_1258_Chemical) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 99)) (-RRB- -RRB-)) (NN monotherapy)))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 26.5) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VP (VBD treated) (PP (IN with) (NP (NNP Doc_17042884_1320_1327_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 98)) (-RRB- -RRB-)) (VP (VB monotherapy) (NP (NP (JJ experienced) (JJ adverse) (NNS events)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_17042884_1387_1390_Disease)))))))))) (. .)))
17042884	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_17042884_1409_1418_Disease)))) (VP (AUX was) (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ similar))) (PP (PP (IN with) (NP (NP (NNP Doc_17042884_1444_1454_Chemical) (JJ monotherapy) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 6.1) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (PP (IN with) (NP (NP (NP (NNP Doc_17042884_1503_1506_Chemical) (NNP +) (NNP Doc_17042884_1509_1511_Chemical/Doc_17042884_1512_1515_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.6) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP PBO) (NNP +) (NNP Doc_17042884_1533_1535_Chemical/Doc_17042884_1536_1539_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4.9) (NN %)) (-RRB- -RRB-))))))) (. .)))
17042884	10	(S1 (S (NP (NNP Doc_17042884_1548_1555_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN incidence)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_17042884_1623_1629_Disease))))) (PRN (-LRB- -LRB-) (NP (CD 18.4) (NN %)) (-RRB- -RRB-)) (SBAR (IN than) (S (NP (NP (NNP Doc_17042884_1643_1653_Chemical) (PRN (-LRB- -LRB-) (NP (CD 5.6) (NN %)) (-RRB- -RRB-)) (: ;) (NP (JJ cerebellar) (NNP Doc_17042884_1673_1679_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT a) (JJ known) (JJ adverse) (NN effect)) (PP (IN of) (NP (NNP Doc_17042884_1716_1723_Chemical))))))) (, ,)) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NP (DT the) (JJ elevated) (NN rate)) (PP (IN of) (NP (NNP Doc_17042884_1770_1776_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_17042884_1799_1806_Chemical) (NN therapy)))))))))))))) (. .)))
17042884	11	(S1 (S (NP (NNP Doc_17042884_1816_1827_Chemical)) (VP (VBN induced) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN incidence)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NNP Doc_17042884_1884_1893_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD 33.3) (NN %) (CC versus) (CD 5.9) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_17042884_1915_1921_Disease) (PRN (-LRB- -LRB-) (NP (NP (CD 30.3) (NN %)) (CC versus) (NP (CD 7.8) (NN %))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_17042884_1947_1970_Disease) (PRN (-LRB- -LRB-) (NP (NP (CD 35.4) (NN %)) (CC versus) (NP (CD 5.9) (NN %))) (-RRB- -RRB-))))) (PP (IN than) (NP (NNP Doc_17042884_1996_2006_Chemical))))) (. .)))
17042884	12	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (NNP Doc_17042884_2057_2067_Chemical)) (CC and) (NP (NN placebo)))) (PP (IN on) (NP (NP (NNP SAS)) (CC and) (NP (NNS BARS) (NNS scores)))))) (. .)))
17042884	13	(S1 (S (NP (JJ Anticholinergic) (NN use)) (VP (AUX was) (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ similar))) (PP (IN with) (NP (NP (NN Doc_17042884_2149_2159_Chemical)) (CC or) (NP (NN placebo))))) (. .)))
17042884	14	(S1 (S (PP (IN In) (NP (NNP Doc_17042884_2188_2201_Disease))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_17042884_2220_2223_Disease))) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_2235_2244_Disease))) (, ,) (PP (IN with) (NP (JJ Doc_17042884_2251_2261_Chemical) (NN therapy)))) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN with) (NP (NN placebo))))))) (. .)))
17049862	0	(S1 (SQ (AUX Is) (NP (NNP Doc_17049862_3_12_Chemical) (NN administration)) (ADJP (JJ safe) (PP (IN in) (NP (DT a) (JJ Doc_17049862_38_49_Disease) (NN child)))) (. ?)))
17049862	1	(S1 (S (NP (NP (DT A) (JJ male) (NN neonate)) (PP (IN with) (NP (NP (DT a) (NN Doc_17049862_79_98_Disease)) (CC and) (NP (DT a) (VBG leaking) (NN myelomeningocoele))))) (VP (VBD underwent) (NP (NP (JJ ventriculoperitoneal) (NN shunt) (NN insertion)) (VP (VBN followed) (PP (IN by) (NP (NP (NN repair)) (PP (IN of) (NP (NN myelomeningocoele)))))))) (. .)))
17049862	2	(S1 (S (PP (IN During) (NP (NP (NN anaesthesia)) (CC and) (NP (NN surgery)))) (, ,) (NP (PRP he)) (ADVP (RB inadvertently)) (VP (VBD became) (ADJP (RB moderately) (JJ Doc_17049862_286_297_Disease))) (. .)))
17049862	3	(S1 (S (NP (JJ Intravenous) (NNP Doc_17049862_311_320_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN during) (NP (NP (DT the) (JJ later) (NN part)) (PP (IN of) (NP (NP (DT the) (NN surgery)) (PP (IN for) (NP (JJ Doc_17049862_379_386_Disease) (NNS prophylaxis))))))))) (. .)))
17049862	4	(S1 (S (PP (VBG Following) (NP (NNP Doc_17049862_410_419_Chemical) (NN administration))) (, ,) (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NP (JJ acute) (JJ severe) (NN Doc_17049862_471_482_Disease)) (, ,) (ADJP (JJ refractory) (PP (TO to) (NP (NP (NNP Doc_17049862_498_506_Chemical)) (CC and) (NP (NNP Doc_17049862_511_521_Chemical))))))) (. .)))
17049862	5	(S1 (S (NP (NP (DT The) (JJ cardiac) (NN depressant) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_17049862_557_566_Chemical)) (CC and) (NP (NNP Doc_17049862_571_582_Disease))))) (VP (MD can) (VP (AUX be) (ADJP (JJ additive)))) (. .)))
17049862	6	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_17049862_618_627_Chemical))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_17049862_647_658_Disease)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (JJ adverse) (JJ cardiac) (NN event)) (PP (IN in) (NP (NNS children))))))) (. .)))
17049862	7	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_17049862_712_721_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN drug))))) (, ,) (NP (NNS clinicians)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN interaction)))))))) (. .)))
17074608	0	(S1 (NP (NP (NP (JJ Doc_17074608_0_9_Chemical-induced) (NN Doc_17074608_18_24_Disease)) (CC and) (NP (NNP Doc_17074608_29_43_Disease))) (PP (IN in) (NP (JJ atypical) (NNP Doc_17074608_56_82_Disease))) (. .)))
17074608	1	(S1 (S (NP (NN Doc_17074608_84_110_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17074608_116_149_Disease)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (NN defect)) (PP (IN in) (NP (DT the) (JJ Doc_17074608_175_182_Chemical) (NN cleavage) (NN system)))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT an) (NN accumulation)) (PP (IN of) (NP (NNP Doc_17074608_227_234_Chemical))) (PP (IN in) (NP (DT the) (NN brain) (CC and) (JJ other) (NN body) (NNS compartments)))))))))) (. .)))
17074608	2	(S1 (S (PP (IN In) (NP (DT the) (JJ classical) (NN form))) (NP (PRP it)) (VP (VBZ presents) (PP (IN as) (NP (NP (JJ neonatal) (NN Doc_17074608_323_328_Disease)) (, ,) (NP (JJ intractable) (NN Doc_17074608_342_350_Disease)) (, ,) (CC and) (NP (NP (NNP Doc_17074608_356_365_Disease)) (, ,) (VP (VBN followed) (PP (IN by) (NP (JJ significant) (NNP Doc_17074608_391_414_Disease)))))))) (. .)))
17074608	3	(S1 (S (NP (NP (DT An) (JJ important) (NN subset)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_17074608_453_479_Disease)))))) (VP (AUX are) (NP (NP (JJ atypical) (NNS variants)) (SBAR (WHNP (WP who)) (S (VP (VBP present) (PP (IN in) (NP (DT a) (JJ heterogeneous) (NN manner)))))))) (. .)))
17074608	4	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ mild) (NNP Doc_17074608_583_597_Disease) (CC and) (NNP Doc_17074608_602_620_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (VP (NNP Doc_17074608_644_670_Disease) (PP (VBG following) (NP (NP (PRP$ her) (NN presentation)) (PP (IN with) (NP (NP (JJ acute) (NNP Doc_17074608_709_723_Disease)) (CC and) (NP (NNP Doc_17074608_728_734_Disease)))))) (PP (ADVP (RB shortly)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_17074608_763_772_Chemical) (NN therapy))))))))))))))))) (. .)))
1711760	0	(S1 (NP (NP (NP (JJ Delayed) (NN institution)) (PP (IN of) (NP (NNP Doc_1711760_23_35_Disease))) (PP (IN during) (NP (JJ focal) (NN Doc_1711760_49_66_Disease)))) (: :) (NP (NP (NN effect)) (PP (IN on) (NP (NNP Doc_1711760_78_89_Disease)))) (. .)))
1711760	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (VBN induced) (NNP Doc_1711760_113_125_Disease)) (VP (VBN instituted) (PP (IN after) (NP (NP (DT a) (JJ 2-h) (NN delay)) (PP (VBG following) (NP (NP (NNP Doc_1711760_165_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1711760_199_203_Disease)) (-RRB- -RRB-))))))))) (PP (IN on) (NP (NP (JJ Doc_1711760_208_219_Disease) (NN formation)) (CC and) (NP (JJ histochemical) (NN injury))))) (VP (AUX was) (VP (VBN studied))) (. .)))
1711760	2	(S1 (S (PP (IN Under) (NP (JJ Doc_1711760_274_284_Chemical) (NN anesthesia))) (, ,) (NP (NP (DT the) (NNP MCA)) (PP (IN of) (NP (CD 14) (ADJP (RB spontaneously) (JJ Doc_1711760_325_337_Disease)) (NNS rats)))) (VP (AUX was) (VP (VBN occluded))) (. .)))
1711760	3	(S1 (S (PP (IN In) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT the) (JJ mean) (NN arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (VP (AUX was) (RB not) (VP (VBN manipulated))) (. .)))
1711760	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NNP Doc_1711760_448_460_Disease) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))) (, ,) (NP (DT the) (NN MAP)) (VP (AUX was) (ADJP (JJ elevated) (PP (IN by) (NP (NP (CD 25-30) (JJ mm) (NNP Hg) (NN beginning)) (, 2) (NP (NNP h) (IN after) (NNP Doc_1711760_532_536_Disease)))))) (. .)))
1711760	5	(S1 (S (PP (NP (CD Four) (NNS hours)) (IN after) (NP (NNP Doc_1711760_555_559_Disease))) (, ,) (S (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN killed)))) (CC and) (S (NP (DT the) (NNS brains)) (VP (VBN harvested))) (. .)))
1711760	6	(S1 (S (NP (DT The) (NNS brains)) (VP (AUX were) (VP (VBN sectioned) (PP (IN along) (NP (NP (JJ coronal) (NNS planes)) (VP (VBG spanning) (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NP (NNP Doc_1711760_684_692_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_1711760_705_709_Disease)))))))))))) (. .)))
1711760	7	(S1 (S (NP (NP (JJ Specific) (NN gravity)) (PRN (-LRB- -LRB-) (NP (NN SG)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN determined) (PP (PP (IN in) (NP (DT the) (NN subcortex))) (CC and) (PP (IN in) (NP (NP (CD two) (NNS sites)) (PP (IN in) (NP (DT the) (NN cortex))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN core)) (CC and) (NP (NN periphery))) (PP (IN of) (NP (DT the) (NNP Doc_1711760_823_831_Disease) (NN territory)))) (-RRB- -RRB-))))))) (. .)))
1711760	8	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NNP Doc_1711760_858_873_Disease)))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ Doc_1711760_892_918_Chemical) (NN staining))))) (. .)))
1711760	9	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_1711760_936_944_Disease) (NN core))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NNS SG)))) (PP (IN in) (NP (NP (DT the) (NN subcortex) (CC and) (NN cortex)) (PP (IN in) (NP (DT the) (CD two) (NNS groups)))))) (. .)))
1711760	10	(S1 (S (PP (IN In) (NP (NP (DT the) (NN periphery)) (PP (IN of) (NP (DT the) (NNP Doc_1711760_1052_1060_Disease) (NN territory))))) (, ,) (NP (NP (NN SG)) (PP (IN in) (NP (DT the) (NN cortex)))) (VP (AUX was) (ADJP (JJR greater)) (PRN (-LRB- -LRB-) (NP (JJR less) (NNP Doc_1711760_1107_1112_Disease) (NN accumulation)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NNP Doc_1711760_1134_1146_Disease) (NN group))) (PRN (-LRB- -LRB-) (NP (NP (CD 1.041) (JJ +/-) (CD 0.001) (NNP vs) (CD 1.039) (NN +/-)) (NP (CD 0.001))) (, ,) (NP (NNP P)) (NP (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (. .)))
1711760	11	(S1 (S (NP (NP (DT The) (NN area)) (PP (IN of) (NP (JJ histochemical) (NN injury)))) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN percent)) (PP (IN of) (NP (NP (DT the) (JJ cross-sectional) (NN area)) (PP (IN of) (NP (DT the) (NN hemisphere))))))) (-RRB- -RRB-)) (VP (AUX was) (ADJP (JJR less)) (PP (IN in) (NP (NP (DT the) (NNP Doc_1711760_1319_1331_Disease) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 33) (JJ +/-) (NP (CD 3) (NN %)) (NNP vs) (CD 21) (NN +/-) (CD 2) (NN %)) (, ,) (VP (VBD P) (NP (QP (JJR less) (IN than) (CD 0.05))))) (-RRB- -RRB-))))) (. .)))
1711760	12	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_1711760_1405_1418_Chemical-induced) (NNP Doc_1711760_1427_1439_Disease)) (VP (VBD instituted) (NP (CD 2)) (NP (NNP h)) (SBAR (SBAR (IN after) (S (NP (NNP Doc_1711760_1461_1465_Disease)) (VP (AUX does) (RB not) (VP (VB aggravate) (NP (NNP Doc_1711760_1485_1490_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_1711760_1498_1506_Disease) (NN core))))))) (, ,) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ improves) (NP (NNP Doc_1711760_1530_1535_Disease)) (PP (IN in) (NP (NP (DT the) (NN periphery)) (PP (IN of) (NP (DT the) (NNP Doc_1711760_1560_1568_Disease) (NN territory)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ reduces) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (JJ histochemical) (NNP Doc_1711760_1626_1646_Disease)))))))))))) (. .)))
17194457	0	(S1 (S (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NN pubertal)))) (VP (VBP anabolic) (NP (NP (JJ androgenic) (JJ Doc_17194457_51_58_Chemical) (NN exposure)) (PP (IN in) (NP (NP (JJ male) (NNS rats)) (PP (IN with) (NP (JJ low) (NNP Doc_17194457_90_99_Chemical))))))) (. .)))
17194457	1	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ interactive) (NNS effects)) (PP (IN of) (NP (NP (JJ chronic) (JJ anabolic) (NN androgenic) (NNP Doc_17194457_193_200_Chemical) (PRN (-LRB- -LRB-) (NP (NNP AAS)) (-RRB- -RRB-)) (NN exposure)) (CC and) (NP (NN brain) (NNP Doc_17194457_226_235_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_237_256_Chemical)) (, ,) (NP (NNP Doc_17194457_258_262_Chemical)) (-RRB- -RRB-)) (NN depletion)))) (PP (IN on) (NP (NP (NN behavior)) (PP (IN of) (NP (JJ pubertal) (JJ male) (NNS rats)))))))))) (. .)))
17194457	2	(S1 (S (S (NP (NN Doc_17194457_309_318_Chemical)) (VP (AUX was) (VP (VBN depleted) (S (VP (VBG beginning) (PP (IN on) (NP (NN postnatal) (NN day) (CD 26))) (PP (IN with) (NP (NNP Doc_17194457_367_390_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_392_396_Chemical) (QP (CD 100) (CD mg/kg))) (, ,) (NP (DT every) (JJ other) (NN day)) (-RRB- -RRB-))))))) (: ;) (S (NP (NNS controls)) (VP (VBD received) (NP (NN saline)))) (. .)))
17194457	3	(S1 (S (PP (IN At) (NP (NP (NN puberty)) (PRN (-LRB- -LRB-) (NP (NNP P40)) (-RRB- -RRB-)))) (, ,) (NP (NP (PDT half) (DT the) (JJ Doc_17194457_479_483_Chemical-treated) (NNS rats)) (CC and) (NP (PDT half) (DT the) (JJ saline-treated) (NNS rats))) (VP (VBD began) (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_17194457_551_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_565_566_Chemical)) (, ,) (NP (CD 5) (NN mg/kg)) (, ,) (NP (CD 5) (NN days/week)) (-RRB- -RRB-))))) (. .)))
17194457	4	(S1 (S (NP (JJ Behavioral) (NNS measures)) (VP (VBD included) (NP (NP (NN locomotion)) (, ,) (NP (NN Doc_17194457_632_644_Disease)) (, ,) (NP (NN copulation)) (, ,) (NP (NN partner) (NN preference)) (, ,) (CC and) (NP (NNP Doc_17194457_682_692_Disease)))) (. .)))
17194457	5	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NNP Doc_17194457_718_728_Disease))) (PP (IN in) (NP (PRP$ their) (NN home) (NN cage))) (, ,) (PP (DT both) (PP (IN with)) (CC and) (PP (IN without) (NP (NP (JJ physical) (NN provocation)) (PRN (-LRB- -LRB-) (NP (JJ mild) (NN tail) (NN pinch)) (-RRB- -RRB-))))))) (. .)))
17194457	6	(S1 (S (NP (NP (NN Brain) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_17194457_827_831_Chemical)) (CC and) (NP (NP (PRP$ its) (NN metabolite)) (, ,) (NP (NP (NNP Doc_17194457_852_878_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_880_886_Chemical)) (-RRB- -RRB-))) (, ,))))) (VP (AUX were) (VP (VBN determined) (S (VP (VBG using) (NP (NN HPLC)))))) (. .)))
17194457	7	(S1 (S (NP (NN Doc_17194457_917_921_Chemical)) (ADVP (RB significantly) (CC and) (RB substantially)) (VP (VBD depleted) (NP (NP (NNP Doc_17194457_963_967_Chemical)) (CC and) (NP (NNP Doc_17194457_972_978_Chemical))) (PP (IN in) (NP (NP (DT all) (NN brain) (NNS regions)) (VP (VBN examined))))) (. .)))
17194457	8	(S1 (S (NP (JJ Chronic) (JJ Doc_17194457_1018_1019_Chemical) (NN treatment)) (VP (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (NNP Doc_17194457_1054_1058_Chemical)) (CC and) (NP (NNP Doc_17194457_1063_1069_Chemical))) (PP (IN in) (NP (JJ certain) (NN brain) (NNS areas)))) (, ,) (CC but) (PP (TO to) (NP (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN extent)) (PP (IN than) (NP (NNP Doc_17194457_1127_1131_Chemical)))))) (. .)))
17194457	9	(S1 (S (NP (NP (JJ Chronic) (NN exposure)) (PP (TO to) (NP (NNP Doc_17194457_1153_1157_Chemical)))) (ADVP (RB alone)) (ADVP (RB significantly)) (VP (VBD decreased) (SBAR (S (NP (NN locomotor) (NN activity)) (VP (CC and) (VP (VBD increased) (NP (NNP Doc_17194457_1221_1233_Disease))) (CC but) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ sexual) (NN behavior)) (, ,) (NP (NN partner) (NN preference)) (, ,) (CC or) (NP (NNP Doc_17194457_1295_1305_Disease)))))))))) (. .)))
17194457	10	(S1 (S (NP (NP (NNP Doc_17194457_1307_1308_Chemical)) (ADVP (RB alone))) (VP (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN locomotion)) (, ,) (NP (NNP Doc_17194457_1344_1356_Disease)) (, ,) (CC or) (NP (JJ sexual) (NN behavior)))))) (CC but) (VP (VBD increased) (NP (NP (NN partner) (NN preference)) (CC and) (NP (NN Doc_17194457_1414_1424_Disease))))) (. .)))
17194457	11	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ striking)) (NN effect)) (PP (IN of) (NP (VBG combining) (NNP Doc_17194457_1464_1465_Chemical+Doc_17194457_1466_1470_Chemical)))) (VP (AUX was) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN attack) (NN frequency)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN latency)) (PP (TO to) (NP (NN attack))) (, ,) (PP (ADVP (RB particularly)) (VBG following) (NP (JJ physical) (NN provocation)))))))) (. .)))
17194457	12	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN speculated) (SBAR (IN that) (S (NP (NP (JJ pubertal) (NN AAS) (NNS users)) (PP (IN with) (NP (JJ low) (JJ central) (NN Doc_17194457_1706_1710_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (RB especially) (JJ prone) (PP (TO to) (NP (NN exhibit) (NN Doc_17194457_1746_1765_Disease))))))))))) (. .)))
17241657	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_17241657_11_16_Chemical)))) (CC and) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (JJ -Doc_17241657_27_32_Chemical) (, ,) (JJ putative) (JJ sigma2-preferring) (NNS antagonists)) (, ,)) (PP (IN on) (NP (NP (JJ behavioral) (NN toxic) (CC and) (NN stimulant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_17241657_119_126_Chemical)) (PP (IN in) (NP (NNS mice))))))) (. .)))
17241657	1	(S1 (S (NP (JJR Earlier) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN antagonism)) (PP (IN of) (NP (NN sigma1) (NNS receptors)))) (VP (VBZ attenuates) (NP (NP (DT the) (JJ Doc_17241657_221_231_Disease) (, ,) (JJ lethal) (, ,) (NN locomotor) (NN stimulatory) (CC and) (JJ rewarding) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_17241657_288_295_Chemical)) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
17241657	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (JJ sigma2) (NNS receptors)))) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN because) (S (NP (NP (JJ experimental) (NNS tools)) (SBAR (S (VP (TO to) (ADVP (RB selectively)) (VP (VB target) (NP (DT this) (NN subtype))))))) (VP (AUX are) (ADJP (JJ unavailable)))))) (. .)))
17241657	3	(S1 (S (S (VP (TO To) (VP (VB begin) (S (VP (VBG addressing) (NP (DT this) (NN need))))))) (, ,) (NP (PRP we)) (VP (VBD characterized) (NP (NP (NP (NNP Doc_17241657_493_498_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17241657_500_540_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_17241657_552_557_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17241657_559_601_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN receptor) (VBG binding)) (CC and) (NP (JJ behavioral) (NNS studies))))) (. .)))
17241657	4	(S1 (S (NP (NN Receptor) (JJ binding) (NNS studies)) (VP (VBD confirmed) (NP (DT that) (ADJP (JJ Doc_17241657_687_692_Chemical) (CC and) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_17241657_703_708_Chemical)) (NN display) (JJ preferential) (NN affinity)) (PP (IN for) (S (VP (VBG sigma2) (PP (IN over) (NP (JJ sigma1) (NNS receptors))))))) (. .)))
17241657	5	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS studies))) (, ,) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (NP (NNP Swiss) (NNP Webster) (NNS mice)) (PP (IN with) (NP (NNP Doc_17241657_836_841_Chemical)))) (CC or) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (NN -Doc_17241657_851_856_Chemical))))) (VP (VP (ADVP (RB significantly)) (VBD attenuated) (NP (JJ Doc_17241657_882_889_Chemical-induced) (NN Doc_17241657_898_909_Disease) (CC and) (NN locomotor) (NN activity))) (, ,) (CC but) (RB not) (VP (NN lethality))) (. .)))
17241657	6	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB alone))))) (, ,) (NP (-LRB- -LRB-) (NN +/-) (-RRB- -RRB-) (NN -Doc_17241657_984_989_Chemical)) (VP (VBD produced) (NP (NP (DT no) (JJ significant) (NNS effects)) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (NP (NP (NNS injections)) (PP (IN of) (NP (NN saline))))))))))) (, ,) (CC but) (S (NP (NNP Doc_17241657_1068_1073_Chemical)) (VP (AUX had) (NP (NN locomotor) (NN depressant) (NNS actions)))) (. .)))
17241657	7	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT the) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (JJ sigma2) (NN receptor) (NNS antagonists)) (VP (AUX have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_17241657_1234_1241_Chemical)))))))))))) (, ,) (CC and) (S (NP (NP (JJ further) (NN development)) (PP (IN of) (NP (ADJP (RBR more) (JJ selective)) (, ,) (JJ high) (NN affinity) (NNS ligands)))) (VP (AUX are) (VP (VBN warranted))))))) (. .)))
17263743	0	(S1 (S (VP (VB Doc_17263743_0_14_Disease) (PP (IN in) (NP (NP (DT a) (NN child)) (PP (IN with) (NP (NNP Doc_17263743_31_45_Disease))) (VP (VBG undergoing) (NP (NP (JJ Doc_17263743_57_68_Chemical) (NN induction)) (PP (IN of) (NP (NN anesthesia)))) (PP (IN after) (NP (JJ preoperative) (NN Doc_17263743_112_121_Chemical))))))) (. .)))
17263743	1	(S1 (S (NP (NN Doc_17263743_123_132_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB frequently) (VBN administered)) (NN alpha2-adrenergic) (NN agonist)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB decrease) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN blood) (NN pressure))))))))) (. .)))
17263743	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 5-year-old) (NN child)) (PP (IN with) (NP (NP (NNP Doc_17263743_283_297_Disease)) (CC and) (NP (NNP Doc_17263743_302_318_Disease)))))) (, ,) (VP (VBG receiving) (NP (NNP Doc_17263743_330_339_Chemical)) (PP (IN for) (NP (NP (NNP Doc_17263743_344_356_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN for) (NP (NP (NN placement)) (PP (IN of) (NP (DT a) (JJ Doc_17263743_391_399_Chemical) (NN pump))))))))))))) (. .)))
17263743	3	(S1 (S (PP (IN Without) (NP (NP (DT the) (NN knowledge)) (PP (IN of) (NP (DT the) (JJ medical) (NNS personnel))))) (, ,) (NP (NP (DT the) (NN patient) (POS 's)) (NN mother)) (VP (VBN administered) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NNP Doc_17263743_503_512_Chemical)))) (PP (IN during) (NP (DT the) (NN evening))) (PP (IN before) (NP (NP (CC and) (NN morning)) (PP (IN of) (NP (NN surgery))))) (S (VP (TO to) (VP (VB reduce) (NP (NN Doc_17263743_572_579_Disease)))))) (. .)))
17263743	4	(S1 (S (PP (IN During) (NP (NP (NN induction)) (PP (IN of) (NP (NN anesthesia))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NP (NNP Doc_17263743_635_646_Disease)) (CC and) (NP (NNP Doc_17263743_651_662_Disease))) (S (VP (VBG requiring) (NP (JJ cardiac) (NN resuscitation))))) (. .)))
17263743	5	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (JJ previous) (NNS reports)) (PP (IN of) (NP (NNP Doc_17263743_729_738_Chemical-associated) (NNP Doc_17263743_750_764_Disease)))) (PP (IN in) (NP (NP (DT a) (NN child) (VBG undergoing) (NN induction)) (PP (IN of) (NP (NN anesthesia)))))) (. .)))
17285209	0	(S1 (NP (NP (NP (JJ Angiotensin-converting) (JJ enzyme) (-LRB- -LRB-) (NN ACE) (-RRB- -RRB-) (JJ inhibitor-associated) (NN Doc_17285209_57_67_Disease)) (PP (IN of) (NP (DT the) (NN stomach) (CC and) (JJ small) (NN intestine)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
17285209	1	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN on) (NP (NP (DT a) (JJ 45-year) (JJ old) (JJ African-American) (NN female)) (PP (IN with) (NP (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_17285209_203_215_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN started) (PP (IN on) (NP (NP (DT a) (NN combination) (NN pill)) (PP (IN of) (NP (JJ Doc_17285209_258_268_Chemical/Doc_17285209_269_279_Chemical) (JJ 10/5) (NN mg))))))))))))))) (. .)))
17285209	2	(S1 (S (NP (DT The) (JJ very) (JJ next) (NN day)) (, ,) (NP (PRP she)) (VP (VBD presented) (PP (IN at) (NP (NP (DT the) (NN emergency) (NN room)) (PRN (-LRB- -LRB-) (NP (NNP ER)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_17285209_354_368_Disease)) (, ,) (NP (NNP Doc_17285209_370_376_Disease)) (CC and) (NP (NNP Doc_17285209_381_389_Disease))))) (. .)))
17285209	3	(S1 (S (NP (NP (JJ Physical) (NN exam)) (, ,) (NP (JJ complete) (JJ metabolic) (NN panel)) (, ,) (CC and) (NP (NN hemogram))) (VP (AUX were) (PP (IN in) (NP (DT the) (JJ normal) (NN range)))) (. .)))
17285209	4	(S1 (S (NP (PRP She)) (VP (AUX was) (VP (VBN discharged) (PP (IN from) (NP (DT the) (NN ER))) (PP (IN after) (NP (NP (DT a) (JJ few) (NNS hours)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NN fluid) (CC and) (NNS analgesics))))))) (. .)))
17285209	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP she)) (VP (VBD returned) (PP (TO to) (NP (DT the) (NN ER))) (NP (DT the) (JJ next) (NN day)) (PP (IN with) (NP (DT the) (JJ same) (NNS complaints)))) (. .)))
17285209	6	(S1 (S (NP (DT This) (NN time)) (NP (DT the) (JJ physical) (NN exam)) (VP (AUX was) (ADJP (JJ significant) (PP (IN for) (NP (NP (DT a) (JJ distended) (NN abdomen)) (PP (IN with) (NP (NN dullness))) (PP (TO to) (NP (NNP percussion))))))) (. .)))
17285209	7	(S1 (S (NP (NNS CT) (S (VP (VB scan) (PP (IN of) (NP (DT the) (NNS abdomen)))))) (VP (VBD revealed) (NP (NP (ADJP (RB markedly) (VBN thickened)) (NN antrum)) (PP (IN of) (NP (DT the) (NN stomach) (, ,) (NN duodenum) (CC and) (NN jejunum))) (, ,) (ADVP (IN along) (PP (IN with) (NP (NN fluid))))) (PP (IN in) (NP (DT the) (JJ abdominal) (CC and) (JJ pelvic) (NN cavity)))) (. .)))
17285209	8	(S1 (S (NP (NP (JJ Angiotensin-converting) (NN enzyme) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP ACEI)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (S (NP (NNP Doc_17285209_932_942_Disease)) (VP (AUX was) (VP (VBN suspected)))) (, ,) (CC and) (S (NP (JJ anti-Doc_17285209_967_979_Disease) (NNS medications)) (VP (AUX were) (VP (VBN discontinued))))))) (. .)))
17285209	9	(S1 (S (S (NP (PRP$ Her) (NNS symptoms)) (VP (VBD improved) (PP (IN within) (NP (DT the) (JJ next) (CD 24) (NNS hours))))) (, ,) (CC and) (S (NP (NP (NN repeat) (NN CT)) (PP (IN after) (NP (CD 72) (NNS hours)))) (VP (VBD revealed) (NP (NP (JJ marked) (NN improvement)) (PP (IN in) (NP (NP (NN stomach) (CC and) (JJ small) (NN bowel) (NN thickening)) (CC and) (NP (NP (NN resolution)) (PP (IN of) (NP (NNP Doc_17285209_1172_1179_Disease))))))))) (. .)))
17285209	10	(S1 (S (NP (NP (DT The) (NN recognition)) (PP (IN of) (NP (NP (NP (JJ Doc_17285209_1200_1211_Chemical-converting) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NN ACE)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_17285209_1240_1251_Chemical) (NN receptor) (NN blocker) (-LRB- -LRB-) (NN ARB) (-RRB- -RRB-) (NNP Doc_17285209_1275_1296_Disease))))) (VP (VBZ constitutes) (NP (NP (DT a) (NN challenge)) (PP (TO to) (NP (NP (JJ primary) (NN care) (NNS physicians)) (, ,) (NP (NNS internists)) (, ,) (NP (NN emergency) (NN room) (NN personal)) (CC and) (NP (NNS surgeons)))))) (. .)))
1728915	0	(S1 (NP (JJ Doc_1728915_0_13_Chemical-induced) (NN Doc_1728915_22_41_Disease) (. .)))
1728915	1	(S1 (NP (NP (NN Characterization)) (PP (IN of) (NP (CD two) (JJ distinct) (JJ clinical) (NNS syndromes))) (. .)))
1728915	2	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NP (JJ sinus) (NNP Doc_1728915_117_128_Disease)) (CC and) (NP (NP (NNP Doc_1728915_133_155_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1728915_168_181_Chemical)))) (, ,))))) (VP (VBD prompted) (NP (NP (DT an) (JJ extensive) (NN literature) (NN review)) (PP (IN of) (NP (DT all) (ADJP (RB previously) (VBN reported)) (NNS cases))))) (. .)))
1728915	3	(S1 (S (PP (IN From) (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (DT these) (NNS cases))))) (, ,) (NP (NP (CD two) (JJ distinct) (NNS forms)) (PP (IN of) (NP (NNP Doc_1728915_313_326_Chemical-associated) (NNP Doc_1728915_338_357_Disease)))) (VP (VBD emerged)) (. .)))
1728915	4	(S1 (S (NP (CD One) (JJ patient) (NN group)) (VP (VBD developed) (NP (NN Doc_1728915_395_413_Disease)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (DT a) (JJ massive) (JJ Doc_1728915_442_455_Chemical) (NN Doc_1728915_456_464_Disease)))))) (. .)))
1728915	5	(S1 (S (NP (DT The) (JJ second) (NN group)) (VP (VBD consisted) (ADVP (RB almost) (RB exclusively)) (PP (IN of) (NP (NP (JJ elderly) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (ADJP (RB potentially) (JJ life-threatening)) (NNP Doc_1728915_572_588_Disease) (CC or) (NNP Doc_1728915_592_625_Disease))))))) (, ,) (S (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (RB either) (JJ therapeutic)) (CC or) (ADJP (RB modestly) (JJ elevated))) (JJ Doc_1728915_683_696_Chemical) (NN serum) (NNS levels)))))) (. .)))
1728915	6	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_1728915_719_732_Chemical)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ many) (UCP (JJ neurologic) (CC and) (JJ Doc_1728915_788_799_Disease)) (NNS conditions))))))))) (, ,) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (DT the) (JJ latter) (NN syndrome)))) (VP (AUX has) (NP (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (NP (JJ elderly) (NNS patients))))))) (. .)))
1732442	0	(S1 (NP (NP (NN Detection)) (PP (IN of) (NP (NP (JJ abnormal) (JJ cardiac) (NN adrenergic) (NN neuron) (NN activity)) (PP (IN in) (NP (NP (JJ Doc_1732442_60_70_Chemical-induced) (NN Doc_1732442_79_93_Disease)) (PP (IN with) (NP (NNP Doc_1732442_99_133_Chemical))))))) (. .)))
1732442	1	(S1 (S (NP (NP (NP (NNP Doc_1732442_135_171_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1732442_173_177_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN analog)) (PP (IN of) (NP (NP (NNP Doc_1732442_193_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1732442_209_211_Chemical)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ serves) (PP (IN as) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (NP (JJ adrenergic) (NN neuron) (NN integrity)) (CC and) (NP (NN function))))))) (. .)))
1732442	2	(S1 (S (S (VP (VBG Using) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (JJ Doc_1732442_299_309_Chemical-induced) (NNP Doc_1732442_318_332_Disease)))))) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ abnormal) (JJ cardiac) (JJ adrenergic) (NN neuron) (NN activity)) (VP (MD may) (VP (VP (VB appear)) (CC and) (AUX be) (VP (VBN exacerbated) (ADVP (RB dose-dependently)) (PP (IN in) (NP (NNP Doc_1732442_458_468_Chemical) (NNP Doc_1732442_469_483_Disease)))))))))) (. .)))
1732442	3	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (NNP Doc_1732442_499_540_Disease)))) (VP (AUX was) (VP (VBN analyzed) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ Doc_1732442_585_595_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN mg/kg)) (, ,) (ADVP (RB once)) (NP (DT a) (NN week))) (-RRB- -RRB-)))))))))) (. .)))
1732442	4	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS abnormalities)) (CC or) (NP (JJ only) (JJ isolated) (NN degeneration))) (PP (IN in) (NP (NP (DT the) (ADJP (JJ 1-) (CC or) (JJ 2-wk)) (NN treatment) (NNS groups)) (, ,) (VP (VBN isolated) (CC or) (VBN scattered) (NP (NN degeneration)) (PP (IN in) (NP (NP (NP (NN half)) (PP (IN of) (NP (DT the) (NN 3-wk) (NN group)))) (, ,) (NP (NP (JJ frequent) (JJ scattered) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 4-wk) (NN group)))) (, ,) (NP (NP (JJ scattered) (CC or) (JJ focal) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 5-wk) (NN group)))) (, ,) (CC and) (NP (NP (JJ extensive) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 8-wk) (NN group)))))))))) (. .)))
1732442	5	(S1 (S (NP (NP (JJ Myocardial) (NN accumulation)) (PP (IN of) (NP (JJ -LSB-125I) (NN -RSB-) (NNP Doc_1732442_967_971_Chemical) (CD 4)))) (VP (VBD hr) (SBAR (IN after) (S (NP (JJ intravenous) (NN injection)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (DT the) (NNS controls)))))) (CC and) (S (NP (DT the) (NNS groups)) (VP (VBD treated) (NP (QP (CD 3) (CD wk) (CC or) (JJR less))))))) (. .)))
1732442	6	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN 4-wk) (NN group)) (VP (AUX had) (ADJP (ADJP (NP (NP (NP (DT a) (ADJP (RB slightly) (JJR lower)) (NN accumulation)) (PP (IN in) (NP (NP (NP (DT the) (JJ right) (NN ventricular) (NN wall)) (PRN (-LRB- -LRB-) (NP (NP (CD 82) (NN %)) (PP (IN of) (NP (DT the) (NN control)))) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (RB significantly) (JJR lower)) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ left) (NN ventricular) (NN wall))))))) (-LRB- -LRB-) (NP (NP (QP (RB about) (CD 66)) (NN %)) (PP (IN of) (NP (DT the) (NN control)))) (: :) (NP (NN p))) (JJR less) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (. .)))
1732442	7	(S1 (S (PP (IN In) (NP (DT the) (JJ 5-wk) (NN group))) (, ,) (NP (NP (JJ Doc_1732442_1318_1322_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NN ventricular) (NN wall)))) (VP (AUX was) (NP (NP (NP (CD 35) (NN %)) (CC and) (NP (NP (CD 27) (NN %)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls)))))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
1732442	8	(S1 (S (PP (IN In) (NP (DT the) (JJ 8-wk) (NN group))) (, ,) (NP (NP (JJ Doc_1732442_1465_1469_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NN ventricular) (NN wall)))) (VP (AUX was) (NP (NP (NP (CD 18) (NN %)) (CC and) (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls)))))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
1732442	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ Doc_1732442_1599_1603_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (NN myocardium)))) (VP (VBD decreased) (PP (IN in) (NP (DT an) (JJ Doc_1732442_1651_1661_Chemical) (JJ dose-dependent) (NN manner)))) (. .)))
1732442	10	(S1 (S (NP (NP (DT The) (NN appearance)) (PP (IN of) (NP (NP (VBN impaired) (JJ cardiac) (NN adrenergic) (NN neuron) (NN activity)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ slight) (NNP Doc_1732442_1773_1794_Disease)) (PRN (-LRB- -LRB-) (ADVP (JJ scattered) (CC or) (JJ focal)) (NP (NNP Doc_1732442_1815_1836_Disease)) (-RRB- -RRB-))))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ Doc_1732442_1853_1857_Chemical) (NN scintigraphy)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN method)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ Doc_1732442_1911_1921_Chemical-induced) (NNP Doc_1732442_1930_1944_Disease))))))))))) (. .)))
17344330	0	(S1 (NP (NP (NNP Doc_17344330_0_7_Disease) (CC and) (NNP Doc_17344330_12_27_Disease)) (PP (IN among) (NP (NNS patients))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_56_65_Chemical))) (PP (IN for) (NP (NP (JJ Doc_17344330_70_76_Chemical) (NN dependence)) (PP (IN in) (NP (NP (DT the) (NN city)) (PP (IN of) (NP (NNP Copenhagen)))))))) (. .)))
17344330	1	(S1 (S (NP (NN Doc_17344330_127_136_Chemical)) (VP (AUX is) (VP (VBN prescribed) (S (VP (TO to) (VP (NNP Doc_17344330_154_160_Chemical) (S (NP (NNS addicts)) (VP (TO to) (VP (VB decrease) (NP (JJ illicit) (JJ opioid) (NN use)))))))))) (. .)))
17344330	2	(S1 (S (NP (NP (NN Prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN in) (NP (NP (DT the) (NNS ECG)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17344330_261_279_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17344330_281_284_Disease)) (-RRB- -RRB-))))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (JJ Doc_17344330_307_316_Chemical) (NNS users)))))) (. .)))
17344330	3	(S1 (S (PP (IN As) (NP (NP (JJ Doc_17344330_327_333_Chemical) (NNS addicts)) (ADJP (RB sometimes) (JJ faint) (PP (IN while) (S (VP (VBG using) (NP (JJ illicit) (NNS drugs)))))))) (, ,) (S (NP (NNS doctors)) (VP (MD might) (VP (VP (VB attribute) (NP (NP (ADJP (RB too) (JJ many)) (NNS episodes)) (PP (IN of) (NP (NNP Doc_17344330_430_437_Disease)))) (PP (TO to) (NP (JJ illicit) (NN drug) (NN use)))) (CC and) (VP (ADVP (RB thereby)) (VB underestimate) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_17344330_501_504_Disease))) (PP (IN in) (NP (DT this) (JJ special) (NN population)))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ high) (NN mortality)) (PP (IN in) (NP (DT this) (NN population)))) (VP (MD may) (, ,) (PP (IN in) (NP (NN part))) (, ,) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ proarrhythmic) (NN effect)) (PP (IN of) (NP (NNP Doc_17344330_630_639_Chemical))))))))) (. .)))
17344330	4	(S1 (S (PP (IN In) (NP (DT this) (JJ cross-sectional) (NN study) (NN interview))) (, ,) (NP (NNS ECGs) (CC and) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NP (JJ adult) (JJ Doc_17344330_754_760_Chemical) (NNS addicts)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17344330_782_791_Chemical)) (CC or) (NP (NNP Doc_17344330_795_808_Chemical)))) (PP (IN on) (NP (DT a) (JJ daily) (NN basis)))))))))) (. .)))
17344330	5	(S1 (S (PP (IN Of) (NP (NP (DT the) (NNS patients)) (PP (IN at) (NP (DT the) (NNP Drug) (NN Addiction) (NN Service))) (PP (IN in) (NP (NP (DT the) (JJ municipal)) (PP (IN of) (NP (NNP Copenhagen))))))) (, ,) (NP (NP (CD 450)) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 52)) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN included))) (. .)))
17344330	6	(S1 (S (NP (DT The) (JJ QT) (NN interval)) (VP (AUX was) (VP (VBN estimated) (PP (IN from) (NP (CD 12) (JJ lead) (NNS ECGs))))) (. .)))
17344330	7	(S1 (S (NP (DT All) (NNS participants)) (VP (AUX were) (VP (VBN interviewed) (PP (IN about) (NP (NP (DT any) (NN experience)) (PP (IN of) (NP (NNP Doc_17344330_1051_1058_Disease))))))) (. .)))
17344330	8	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (NP (JJ opioid) (NN dose)) (CC and) (NP (NN QT))) (, ,) (CC and) (NP (JJ Doc_17344330_1108_1117_Chemical) (NN dose)) (CC and) (NP (NP (NN reporting)) (PP (IN of) (NP (NNP Doc_17344330_1140_1147_Disease))))))) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (JJ multivariate) (JJ linear) (NN regression)) (CC and) (NP (NP (JJ logistic) (NN regression)) (, ,) (ADVP (RB respectively)))))))) (. .)))
17344330	9	(S1 (S (NP (JJ Doc_17344330_1246_1255_Chemical) (NN dose)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB longer) (JJ QT)) (NN interval)) (PP (IN of) (NP (NP (CD 0.140) (NNS ms/mg)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
17344330	10	(S1 (S (NP (NP (DT No) (NN association)) (PP (IN between) (NP (NP (NNP Doc_17344330_1351_1364_Chemical)) (CC and) (NP (NNP QTc))))) (VP (AUX was) (VP (VBN found))) (. .)))
17344330	11	(S1 (S (PP (IN Among) (NP (NP (DT the) (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_1416_1425_Chemical)))))) (, ,) (NP (NP (ADJP (CD 28) (NN %)) (NNS men)) (CC and) (NP (ADJP (CD 32) (NN %)) (NNS women))) (VP (AUX had) (NP (NN Doc_17344330_1453_1475_Disease))) (. .)))
17344330	12	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_1511_1524_Chemical))))))) (VP (AUX had) (VP (VBN QTc) (NP (JJ interval) (NX (NX (CD >0.440) (NNP s)) (PRN (-LRB- -LRB-) (-LRB- -LRB-) (NNP 1/2) (-RRB- -RRB-) (-RRB- -RRB-)))))) (. .)))
17344330	13	(S1 (S (NP (DT A) (ADJP (NP (CD 50) (NN mg)) (JJR higher)) (JJ Doc_17344330_1574_1583_Chemical) (NN dose)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (CD 1.2) (ADJP (ADJP (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.1) (TO to) (CD 1.4))) (-RRB- -RRB-)) (CC times) (ADJP (JJR higher))) (NNS odds)) (PP (IN for) (NP (NNP Doc_17344330_1657_1664_Disease))))))) (. .)))
17344330	14	(S1 (S (NP (NN Doc_17344330_1679_1688_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNP Doc_17344330_1708_1723_Disease)) (CC and) (NP (NP (JJR higher) (NN reporting)) (PP (IN of) (NP (NNP Doc_17344330_1748_1755_Disease))))) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (JJ Doc_17344330_1775_1781_Chemical) (NNS addicts))))))))) (. .)))
17366349	0	(S1 (S (NP (NN Doc_17366349_0_30_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_17366349_42_53_Chemical))) (PP (IN on) (NP (NP (DT the) (JJ second) (NN day)) (PP (IN of) (NP (NN treatment)))))) (. .)))
17366349	1	(S1 (S (NP (NP (NN Doc_17366349_86_116_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17366349_118_121_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT the) (ADJP (ADJP (JJS rarest)) (CC and) (ADJP (RBS most) (JJ serious)))) (PP (IN of) (NP (DT the) (JJ neuroleptic-induced) (NN Doc_17366349_181_199_Disease))))) (. .)))
17366349	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_17366349_223_253_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17366349_255_258_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17366349_287_298_Chemical)))))))) (. .)))
17366349	3	(S1 (S (SBAR (IN Although) (S (NP (JJ conventional) (NNS neuroleptics)) (VP (AUX are) (ADVP (RBR more) (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17366349_371_374_Disease))))))) (, ,) (NP (NP (JJ atypical) (JJ antipsychotic) (NNS drugs)) (PP (IN like) (NP (NNP Doc_17366349_410_421_Chemical)))) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (NP (DT a) (NN cause)))) (. .)))
17366349	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX is) (NP (NP (DT a) (JJ 24-year-old) (NN male)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_17366349_495_508_Disease))))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NNP Doc_17366349_545_548_Disease)))) (PP (IN after) (NP (NP (CD 2) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (IN with) (NP (NP (DT an) (JJ 80-mg/day) (NN dose)) (PP (IN of) (NP (ADJP (RB orally) (VBN administrated)) (NNP Doc_17366349_622_633_Chemical)))))))))) (. .)))
17366349	5	(S1 (S (NP (DT This) (NN case)) (VP (AUX is) (NP (NP (DT the) (JJS earliest) (PRN (-LRB- -LRB-) (NP (NP (JJ second) (NN day)) (PP (IN of) (NP (NN treatment)))) (-RRB- -RRB-)) (ADJP (NNP Doc_17366349_687_690_Disease) (JJ due) (PP (TO to) (NP (NNP Doc_17366349_698_709_Chemical))))) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
17490790	0	(S1 (S (NP (JJ Peripheral) (NNP Doc_17490790_11_23_Chemical)) (VP (VBN induced) (NP (NNP Doc_17490790_32_68_Disease)) (PP (IN in) (NP (NN rat) (NN substantia) (NNS nigra)))) (. .)))
17490790	1	(S1 (S (NP (JJ Doc_17490790_94_98_Chemical) (NN accumulation)) (VP (AUX is) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NN Doc_17490790_164_183_Disease))))))))))) (. .)))
17490790	2	(S1 (S (S (VP (TO To) (VP (VB demonstrate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ peripheral) (JJ Doc_17490790_236_240_Chemical) (NN overload)) (CC and) (NP (JJ dopaminergic) (NN neuron) (NN loss))))) (PP (IN in) (NP (NP (NN rat) (NN substantia) (NN nigra)) (PRN (-LRB- -LRB-) (NP (NNP SN)) (-RRB- -RRB-))))))) (, ,) (PP (IN in) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD used) (NP (NP (JJ fast) (JJ cyclic) (NN voltammetry)) (, ,) (NP (NNP Doc_17490790_363_371_Chemical) (FW hydroxylase) (PRN (-LRB- -LRB-) (NP (NNP TH)) (-RRB- -RRB-)) (NN immunohistochemistry)) (, ,) (NP (NP (NNP Perls) (POS ')) (JJ Doc_17490790_418_422_Chemical) (NN staining)) (, ,) (CC and) (NP (JJ high) (NN performance) (NN liquid) (JJ chromatography-electrochemical) (NN detection))) (S (VP (TO to) (VP (VP (VB study) (NP (DT the) (NNP Doc_17490790_515_551_Disease))) (CC and) (VP (VBD increased) (NP (JJ Doc_17490790_566_570_Chemical) (NN content)) (PP (IN in) (NP (NP (DT the) (NN SN)) (PP (IN of) (NP (JJ Doc_17490790_592_604_Chemical) (JJ overloaded) (NNS animals)))))))))) (. .)))
17490790	3	(S1 (S (NP (DT The) (NNS findings)) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ peripheral) (JJ Doc_17490790_661_673_Chemical) (NN overload)) (VP (VP (VBD increased) (NP (DT the) (JJ Doc_17490790_697_701_Chemical) (JJ staining) (JJ positive) (NNS cells))) (CC and) (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ TH-immunoreactive) (NNS neurons)) (PP (IN in) (NP (DT the) (NN SN))))))))))) (. .)))
17490790	4	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (NP (JJ Doc_17490790_802_810_Chemical) (NN release)) (CC and) (NP (NP (NN content)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (PRP$ its) (NNS metabolites) (NNS contents)))) (VP (AUX were) (VP (VBN decreased) (PP (IN in) (NP (JJ caudate) (NNS putamen))))) (. .)))
17490790	5	(S1 (S (NP (ADJP (RB Even) (RBR more) (JJ dramatic)) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ chronic) (NN overload) (NN group))))) (. .)))
17490790	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ peripheral) (NNP Doc_17490790_1006_1018_Chemical)) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (JJ Doc_17490790_1036_1040_Chemical) (NN level)) (PP (IN in) (NP (NP (DT the) (NNP SN)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (JJ excessive) (NN Doc_17490790_1074_1078_Chemical)) (VP (VBZ causes) (NP (DT the) (NNP Doc_17490790_1090_1126_Disease))))))))))))) (. .)))
17490790	7	(S1 (S (NP (DT The) (JJ chronic) (JJ Doc_17490790_1140_1144_Chemical) (NN overload)) (VP (MD may) (VP (AUX be) (ADJP (RBR more) (JJ destructive) (PP (TO to) (NP (JJ dopaminergic) (NNS neurons))) (PP (IN than) (NP (DT the) (JJ acute) (JJ Doc_17490790_1217_1221_Chemical) (NN overload)))))) (. .)))
17490864	0	(S1 (NP (NP (JJ Attenuated) (NN disruption)) (PP (IN of) (NP (NN prepulse) (NN inhibition))) (PP (IN by) (NP (JJ dopaminergic) (NN stimulation))) (PP (IN after) (NP (NP (NP (JJ maternal) (NN deprivation)) (CC and) (NP (JJ adolescent) (JJ Doc_17490864_115_129_Chemical) (NN treatment))) (PP (IN in) (NP (NNS rats))))) (. .)))
17490864	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_17490864_168_181_Disease)))) (VP (MD may) (VP (VB include) (NP (NP (DT an) (JJ early) (JJ neurodevelopmental) (NN stress) (NN component)) (SBAR (WHNP (WDT which)) (S (VP (VBZ increases) (NP (NN vulnerability)) (PP (TO to) (NP (RBR later) (JJ stressful) (NN life) (NNS events))))))) (, ,) (PP (IN in) (NP (NP (NN combination)) (VP (VBG leading) (PP (TO to) (NP (NN overt) (NN disease)))))))) (. .)))
17490864	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT an) (JJ early) (NN stress)) (, ,) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (JJ maternal) (NN deprivation))))) (, ,) (VP (VBN combined) (PP (IN with) (NP (DT a) (JJ later) (NN stress)))) (, ,) (ADJP (JJ simulated) (PP (IN by) (NP (JJ chronic) (JJ periadolescent) (JJ Doc_17490864_492_506_Chemical) (NN treatment)))) (, ,))) (PP (IN on) (NP (NP (NN behaviour)) (PP (IN in) (NP (NNS rats))))))) (. .)))
17490864	3	(S1 (S (NP (NP (JJ Acute) (NN treatment)) (PP (IN with) (NP (NNP Doc_17490864_561_572_Chemical)))) (VP (VBD caused) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (JJ prepulse) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NNP PPI)) (-RRB- -RRB-)))) (PP (PP (IN in) (NP (NNS controls))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX had) (VP (VBN undergone) (NP (NP (DT either) (JJ maternal) (NN deprivation)) (CC or) (NP (JJ Doc_17490864_694_708_Chemical) (NN treatment))))) (, ,) (CC but) (VP (AUX was) (ADJP (RB surprisingly) (JJ absent)) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN undergone) (NP (DT the) (JJ combined) (JJ early) (CC and) (JJ late) (NN stress))))))))))))))))) (. .)))
17490864	4	(S1 (S (NP (JJ Doc_17490864_811_822_Chemical) (NN treatment)) (ADVP (RB significantly)) (VP (VP (VBD disrupted) (NP (NNP PPI)) (PP (IN in) (NP (DT both) (JJ non-deprived) (NNS groups)))) (, ,) (CC but) (VP (AUX was) (ADJP (JJ absent)) (PP (IN in) (NP (DT both) (JJ maternally) (VBN deprived) (NNS groups))))) (. .)))
17490864	5	(S1 (S (NP (NP (DT The) (JJ Doc_17490864_945_954_Chemical-1A) (NN receptor) (NN agonist)) (, ,) (NP (NNP Doc_17490864_976_985_Chemical)) (, ,)) (VP (VBN induced) (NP (NP (DT a) (JJ significant) (NN disruption)) (PP (IN of) (NP (NNP PPI)))) (PP (IN in) (NP (DT all) (NNS groups)))) (. .)))
17490864	6	(S1 (S (NP (JJ Doc_17490864_1042_1053_Chemical-induced) (NN Doc_17490864_1062_1085_Disease)) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT all) (NNS groups)))) (. .)))
17490864	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (NP (NP (DT an) (JJ inhibitory) (NN interaction)) (PP (IN of) (NP (JJ early) (NN stress))) (, ,) (VP (VBN caused) (PP (IN by) (NP (JJ maternal) (NN deprivation)))) (, ,) (VP (VBN combined) (PP (IN with) (NP ('' ') (JJ adolescent) ('' ') (NN stress)))) (, ,) (ADJP (JJ simulated) (PP (IN by) (NP (JJ Doc_17490864_1255_1269_Chemical) (NN treatment)))) (, ,)) (PP (IN on) (NP (NP (JJ dopaminergic) (NN regulation)) (PP (IN of) (NP (NNP PPI)))))) (. .)))
17490864	8	(S1 (S (NP (NP (DT The) (JJ altered) (NNS effects)) (PP (IN of) (NP (NNP Doc_17490864_1339_1350_Chemical) (CC and) (NNP Doc_17490864_1355_1366_Chemical)))) (VP (MD could) (VP (VB indicate) (NP (NP (NN differential) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_17490864_1406_1414_Chemical) (NN receptor) (NN signalling)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ functional) (NN desensitisation)) (, ,) (CC or) (NP (NP (JJ altered) (NN modulation)) (PP (IN of) (NP (NP (JJ sensory) (NN gating)) (PP (IN in) (NP (NP (DT the) (NN nucleus) (NNS accumbens)) (PP (IN by) (NP (JJ limbic) (NNS structures))) (PP (JJ such) (IN as) (NP (DT the) (NN hippocampus)))))))))))))))) (. .)))
17511042	0	(S1 (NP (NP (DT An) (ADJP (RB extremely) (JJ rare)) (NN case)) (PP (IN of) (NP (NNP Doc_17511042_26_48_Disease))) (PP (IN in) (NP (NP (DT a) (JJ Doc_17511042_54_73_Disease) (NN patient)) (PP (IN during) (NP (NNP Doc_17511042_89_118_Chemical) (CC and) (NNP Doc_17511042_123_132_Chemical) (NN treatment))))) (. .)))
17511042	1	(S1 (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ Doc_17511042_164_183_Disease) (NNS patients)) (PP (IN with) (NP (NP (NNP interferon)) (CC and) (NP (NNP Doc_17511042_213_222_Chemical)))))))) (, ,) (NP (NP (DT a) (NN lot)) (PP (IN of) (NP (NN side) (NNS effects)))) (VP (AUX are) (VP (VBN described))) (. .)))
17511042	2	(S1 (S (NP (NP (JJ Twenty-three) (NN percent) (TO to) (CD 44) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBP develop) (NP (NN Doc_17511042_309_319_Disease))) (. .)))
17511042	3	(S1 (S (NP (NP (DT A) (NN minority)) (PP (IN of) (NP (NNS patients)))) (VP (VB evolve) (S (VP (TO to) (VP (VB Doc_17511042_354_363_Disease))))) (. .)))
17511042	4	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (NP (DT no) (NNS cases)) (PP (IN of) (NP (NNP Doc_17511042_407_430_Disease))) (VP (VBG occurring) (PP (IN during) (NP (NNP interferon) (NN therapy))))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
17511042	5	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 49-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT a) (NN Doc_17511042_553_575_Disease)) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_17511042_598_627_Chemical) (NNP weekly) (CC and) (NNP Doc_17511042_639_648_Chemical)))))))) (. .)))
17511042	6	(S1 (S (NP (PRP She)) (VP (VBD complained) (PP (IN of) (S (VP (VBG seeing) (NP (NP (NNS parasites)) (CC and) (NP (NP (DT the) (NNS larvae)) (PP (IN of) (NP (NNS fleas))))) (PP (IN in) (NP (PRP$ her) (NNS stools))))))) (. .)))
17511042	7	(S1 (S (NP (DT This)) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN confirmed) (PP (IN by) (NP (DT any) (JJ technical) (NN examination)))))) (. .)))
17511042	8	(S1 (S (NP (PDT All) (DT the) (NNS complaints)) (VP (VP (VBD disappeared) (PP (IN after) (S (VP (VBG stopping) (NP (NNP Doc_17511042_828_857_Chemical)))))) (CC and) (VP (VBD reappeared) (PP (IN after) (S (VP (VBG restarting) (NP (PRP it))))))) (. .)))
17511042	9	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (DT a) (JJ complete) (JJ sustained) (JJ viral) (NN response))) (. .)))
17574447	0	(S1 (S (NP (NP (NNP Doc_17574447_0_14_Disease)) (CC and) (NP (NNP Doc_17574447_19_30_Disease))) (VP (VBD related) (PP (TO to) (NP (JJ long-term) (JJ Doc_17574447_52_65_Chemical) (NN therapy))) (: :) (NP (NP (DT an) (JJ autopsy) (NN report)) (PP (IN of) (NP (CD two) (NNS patients))))) (. .)))
17574447	1	(S1 (S (S (NP (NP (NNP Doc_17574447_110_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17574447_125_127_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (NP (NP (DT a) (NN reputation)) (PP (IN for) (NP (NN safety)))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX is) (VP (ADVP (RB commonly)) (VBN believed) (SBAR (IN that) (S (NP (NP (JJ Doc_17574447_191_193_Chemical-related) (NNS increases)) (PP (IN in) (NP (JJ serum) (NN aminotransferase) (NNS levels)))) (VP (AUX do) (RB not) (VP (VP (VB indicate)) (CC or) (VP (VB predict) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ significant) (JJ chronic) (NN Doc_17574447_311_324_Disease)))))))))))) (. .)))
17574447	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (PP (IN of) (NP (NP (NP (CD two) (NN adult) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ long) (NN history)) (PP (IN of) (NP (NNP Doc_17574447_386_394_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17574447_408_410_Chemical)))))) (SBAR (WHNP (WP who)) (S (VP (VBD died) (ADVP (RB suddenly)))))) (: :) (NP (CD one)))) (PP (IN as) (NP (NP (NN consequence)) (PP (IN of) (NP (NP (NNP Doc_17574447_452_466_Disease)) (, ,) (NP (NP (DT the) (JJ other)) (PP (IN of) (NP (JJ acute) (NNP Doc_17574447_487_503_Disease))))))))) (. .)))
17574447	3	(S1 (S (PP (IN At) (NP (NN autopsy))) (, ,) (NP (NP (NN analysis)) (PP (IN of) (NP (NN liver) (NN parenchyma)))) (VP (VBD revealed) (NP (NP (JJ rich) (NN portal) (JJ inflammatory) (VB infiltrate)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD consisted) (PP (IN of) (NP (JJ mixed) (NN eosinophil) (CC and) (NN monocyte) (NNS cells)))))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS foci)) (PP (IN of) (NP (NNP Doc_17574447_680_688_Disease))) (VP (VBN surrounded) (PP (IN by) (NP (NP (DT a) (JJ hard) (NN ring)) (PP (IN of) (NP (JJ non-specific) (JJ granulomatous) (NN tissue))))))))))) (. .)))
17574447	4	(S1 (S (NP (NP (JJ Inflammatory) (NNS reactions)) (PP (IN of) (NP (ADJP (JJ internal) (CC and) (JJ external)) (JJ hepatic) (NN biliary) (NNS ducts)))) (VP (AUX were) (ADVP (RB also)) (VP (VBN seen))) (. .)))
17574447	5	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP illustrate) (SBAR (IN that) (S (NP (NNP Doc_17574447_868_870_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_17574447_902_914_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (ADJP (ADJP (RBR more) (JJ serious)) (CC and) (ADJP (JJ deleterious))) (NNS consequences))))))))))))))) (. .)))
17574447	6	(S1 (S (PP (IN For) (NP (DT this) (NN reason))) (, ,) (NP (DT each) (NN clinician)) (VP (MD should) (VP (VB recognize) (NP (DT this) (NN entity)) (PP (IN in) (NP (NP (DT the) (NN differential) (NN diagnosis)) (PP (IN of) (NP (JJ Doc_17574447_1071_1073_Chemical-related) (JJ asymptomatic) (NN Doc_17574447_1095_1129_Disease))))))) (. .)))
17682013	0	(S1 (S (VP (VBN Delayed) (NP (NN Doc_17682013_8_27_Disease)) (PP (IN with) (NP (NP (JJ Doc_17682013_33_39_Disease-like) (NN presentation)) (PP (IN in) (NP (JJ chemotherapy) (NNS recipients)))))) (. .)))
17682013	1	(S1 (S (NP (DT A) (JJ transient) (NNP Doc_17682013_110_129_Disease) (NN mimicking) (NN Doc_17682013_140_164_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN chemotherapy))))) (, ,) (ADVP (RBS most) (RB commonly)) (PP (IN in) (NP (NP (NNS recipients)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_17682013_262_274_Chemical))) (PP (IN for) (NP (NN childhood) (NN Doc_17682013_289_298_Disease)))))))) (. .)))
17682013	2	(S1 (S (NP (ADJP (RB Recently) (VBN published)) (NN neuroimaging) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJ common) (NN pathophysiology)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ chemotherapy) (NNS agents)))) (CC and) (NP (NP (NNS modes)) (PP (IN of) (NP (NN administration))))))))) (. .)))
17682013	3	(S1 (S (NP (PRP We)) (VP (VBN reviewed) (NP (NP (DT the) (JJ medical) (NN literature)) (PP (IN for) (NP (NP (JJ single) (NNS reports) (CC and) (NN case) (NNS series)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG presenting) (PP (IN with) (NP (JJ Doc_17682013_555_561_Disease-like) (NNS episodes))) (SBAR (IN while) (S (VP (VBG receiving) (NP (JJ systemic) (CC or) (JJ intrathecal) (NN chemotherapy)))))))))))) (. .)))
17682013	4	(S1 (S (NP (PRP We)) (ADVP (RB only)) (VP (VBD included) (NP (NP (NNS studies)) (VP (VBG providing) (NP (JJ detailed) (JJ neuroimaging) (NNS data))))) (. .)))
17682013	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_17682013_707_732_Disease)))) (VP (AUX were) (VP (VBN excluded))) (. .)))
17682013	6	(S1 (S (NP (PRP We)) (VP (VBD identified) (NP (NP (CD 27) (NNS reports)) (PP (IN of) (NP (JJ toxic) (NNP Doc_17682013_791_810_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_17682013_836_848_Chemical)) (PRN (-LRB- -LRB-) (ADJP (JJ intrathecal) (, ,) (JJ systemic)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17682013_874_888_Chemical)) (CC and) (NP (PRP$ its) (JJ derivative) (NNP Doc_17682013_908_916_Chemical))) (, ,) (CC and) (NP (NNP Doc_17682013_922_934_Chemical)))))))) (. .)))
17682013	7	(S1 (S (NP (NP (NN Diffusion) (JJ weighted) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP DWI)) (-RRB- -RRB-)) (PP (IN of) (NP (DT all) (NNS patients)))) (VP (VBD revealed) (NP (NP (ADJP (RB well) (VBN demarcated)) (NN hyperintense) (NN Doc_17682013_1023_1066_Disease)) (PP (IN of) (NP (NP (DT the) (JJ cerebral) (NNS hemispheres)) (CC and) (NP (DT the) (JJ corpus) (NN callosum))))) (, ,) (PP (VBG corresponding) (PP (TO to) (NP (NP (NNS areas)) (PP (IN of) (NP (NP (VBN decreased) (NN proton) (NN diffusion)) (PP (IN on) (NP (NP (JJ apparent) (NN diffusion) (NN coefficient) (PRN (-LRB- -LRB-) (NP (NNP ADC)) (-RRB- -RRB-)) (NNS maps)) (PRN (-LRB- -LRB-) (ADJP (JJ available) (PP (IN in) (NP (CD 21/27) (NNS patients)))) (-RRB- -RRB-)))))))))) (. .)))
17682013	8	(S1 (S (NP (NNS Lesions)) (VP (VBD exceeded) (NP (NP (DT the) (NNS confines)) (PP (IN of) (NP (JJ adjacent) (JJ vascular) (NNS territories))))) (. .)))
17682013	9	(S1 (S (NP (NP (JJ Complete) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (IN within) (NP (JJ 1-4) (NNS days)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (NN normalisation)) (PP (IN of) (NP (JJ ADC) (NNS abnormalities))))))) (. .)))
17682013	10	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ fluid) (JJ attenuated) (NN inversion) (NN recovery) (PRN (-LRB- -LRB-) (NP (NN FLAIR)) (-RRB- -RRB-)) (NNS sequences)) (ADVP (RB frequently)) (VP (VBD revealed) (NP (JJ persistent) (NNP Doc_17682013_1510_1536_Disease))) (. .)))
17682013	11	(S1 (S (NP (NP (JJ Several) (JJ pathophysiological) (NNS models)) (PP (IN of) (NP (JJ delayed) (NNP Doc_17682013_1596_1615_Disease))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NN intrathecal)) (CC or) (NP (JJ systemic) (NN chemotherapy))))))) (VP (AUX have) (VP (AUX been) (VP (VBN proposed)))) (. .)))
17682013	12	(S1 (S (NP (NP (NN DWI) (NNS findings)) (PP (IN in) (NP (DT this) (NN cohort)))) (VP (VP (AUX are) (ADJP (JJ indicative) (PP (IN of) (NP (NNP Doc_17682013_1737_1782_Disease))))) (CC and) (VP (VB lend) (NP (NN support)) (PP (TO to) (NP (NP (DT an) (ADJP (ADVP (IN at) (JJS least)) (RB partially) (JJ reversible)) (JJ metabolic) (NN derangement)) (PP (IN as) (NP (NP (DT the) (NN basis)) (PP (IN for) (NP (DT this) (NN syndrome))))))))) (. .)))
17702969	0	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (NNP Doc_17702969_21_31_Chemical)))) (VP (VBZ induces) (NP (NN Doc_17702969_40_68_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
17702969	1	(S1 (S (NP (NN Doc_17702969_92_102_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ Doc_17702969_118_127_Chemical) (NN reuptake) (NN inhibitor) (NN antidepressant)) (VP (ADVP (RB widely)) (VBN used) (PP (IN by) (NP (JJ pregnant) (NNS women)))))) (. .)))
17702969	2	(S1 (S (NP (JJ Epidemiological) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_17702969_227_237_Chemical) (NN exposure)) (ADVP (RB prenatally)) (VP (VBZ increases) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (JJ persistent) (NN Doc_17702969_297_328_Disease)) (PP (IN of) (NP (DT the) (JJ newborn)))))))))) (. .)))
17702969	3	(S1 (S (NP (NP (DT The) (NN mechanism)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN effect))))) (VP (AUX is) (ADJP (ADJP (JJ unclear)) (CC and) (ADJP (JJ paradoxical))) (, ,) (S (VP (VBG considering) (NP (NP (DT the) (JJ current) (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ Doc_17702969_453_475_Disease) (JJ protective) (JJ Doc_17702969_487_497_Chemical) (NN effect)) (PP (IN in) (NP (JJ adult) (NNS rodents))))))))) (. .)))
17702969	4	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ Doc_17702969_551_561_Chemical) (NN effect)) (PP (IN on) (NP (JJ fetal) (NN rat))))))) (VP (VBP pulmonary) (NP (NP (JJ vascular) (JJ smooth) (NN muscle) (JJ mechanical) (NNS properties)) (CC and) (NP (NN cell) (NN proliferation) (NN rate)))) (. .)))
17702969	5	(S1 (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17702969_707_717_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN from) (NP (NNP Day) (CD 11))) (PP (IN through) (NP (NP (NNP Day) (CD 21)) (PP (IN of) (NP (NN gestation))))))) (. .)))
17702969	6	(S1 (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (NP (NNS Fetuses)) (VP (AUX were) (VP (VBN delivered) (PP (IN by) (NP (JJ cesarean) (NN section)))))) (. .)))
17702969	7	(S1 (S (SBAR (IN As) (S (VP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (, ,) (NP (JJ Doc_17702969_872_882_Chemical) (NN exposure)) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_17702969_904_932_Disease))) (SBAR (IN as) (S (VP (VBN evidenced) (PP (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN weight) (NN ratio)) (PP (IN of) (NP (DT the) (JJ right) (NN ventricle))) (PP (TO to) (NP (DT the) (JJ left) (NN ventricle) (CC plus) (NN septum))))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.02)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ pulmonary) (JJ arterial) (JJ medial) (NN thickness))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.01)) (-RRB- -RRB-))))))))) (. .)))
17702969	8	(S1 (S (S (NP (JJ Postnatal) (NN mortality)) (VP (AUX was) (VP (VBN increased) (PP (IN among) (NP (JJ experimental) (NNS animals)))))) (, ,) (CC and) (S (NP (JJ arterial) (JJ Doc_17702969_1194_1200_Chemical) (NN saturation)) (VP (VP (AUX was) (NP (NP (CD 96) (NN +/-)) (ADJP (CD 1) (NN %))) (PP (IN in) (NP (JJ 1-day-old) (NN control) (NNS animals)))) (CC and) (VP (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (ADJP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ Doc_17702969_1293_1303_Chemical-exposed) (NNS pups)) (PRN (-LRB- -LRB-) (NP (CD 79) (NN +/-) (CD 2) (NN %)) (-RRB- -RRB-))))))) (. .)))
17702969	9	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (NNP Doc_17702969_1340_1350_Chemical)) (VP (VBN induced) (NP (JJ pulmonary) (JJ arterial) (NN muscle) (NN contraction)) (PP (IN in) (NP (NP (JJ fetal) (, ,) (CONJP (CC but) (RB not)) (NP (NN adult))) (, ,) (NP (NP (NNS animals)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (JJ reduced) (JJ Doc_17702969_1453_1462_Chemical-induced) (NN contraction)))) (PP (IN at) (NP (NP (DT both) (NNS ages)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
17702969	10	(S1 (S (PP (IN After) (PP (IN in) (NP (NP (NN utero) (NN exposure)) (PP (TO to) (NP (DT a) (JJ low) (JJ Doc_17702969_1541_1551_Chemical) (NN concentration)))))) (NP (DT the) (JJ pulmonary) (JJ arterial) (JJ smooth) (NN muscle) (NN cell) (NN proliferation) (NN rate)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (ADJP (JJ fetal) (, ,) (CC but) (ADJP (RB not) (JJ adult)) (, ,)) (NNS cells)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
17702969	11	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (DT the) (NN adult))))) (, ,) (NP (NP (JJ Doc_17702969_1737_1747_Chemical) (NN exposure)) (PP (IN in) (NP (NN utero)))) (VP (VBZ induces) (NP (NN Doc_17702969_1774_1796_Disease)) (PP (IN in) (NP (DT the) (JJ fetal) (NN rat))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT a) (ADJP (RB developmentally) (VBN regulated)) (NN increase)) (PP (IN in) (NP (JJ pulmonary) (JJ vascular) (JJ smooth) (NN muscle) (NN proliferation)))))))) (. .)))
17786501	0	(S1 (NP (NP (JJ Doc_17786501_0_10_Chemical-induced) (JJ transient) (NN Doc_17786501_29_60_Disease)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
17786501	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_17786501_102_133_Disease)))) (PP (IN after) (NP (NP (JJ chronic) (NN use)) (PP (IN of) (NP (NNP Doc_17786501_155_165_Chemical))) (PP (IN for) (NP (NNP Doc_17786501_170_188_Disease) (NN management)))))))) (. .)))
17786501	2	(S1 (NP (NP (NP (NNS MATERIALS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (DT A) (NN case) (NN report)) (. .)))
17786501	3	(S1 (S (NP (DT A) (JJ 57-year-old) (NN male)) (VP (VBD presented) (PP (IN with) (NP (JJ gradual) (NNP Doc_17786501_290_304_Disease))) (PP (IN in) (NP (DT both) (NNS eyes))) (PP (IN with) (NP (NP (JJ intermittent) (NN Doc_17786501_336_345_Disease)) (PP (IN for) (NP (CD 2) (NNS months)))))) (. .)))
17786501	4	(S1 (S (NP (PRP He)) (ADVP (RB also)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_17786501_382_394_Disease))) (PP (IN with) (NP (NNP Doc_17786501_400_408_Disease))) (PP (IN in) (NP (DT both) (NNS feet)))) (. .)))
17786501	5	(S1 (S (NP (PRP$ His) (NN vision)) (VP (AUX was) (NP (NP (CD 6/15)) (CC and) (NP (CD 2/60))) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NNS eyes))) (, ,) (ADVP (RB respectively))) (. .)))
17786501	6	(S1 (S (NP (NN Fundoscopy)) (VP (VBD revealed) (NP (JJ bilaterally) (JJ swollen) (JJ optic) (NN nerve) (NNS heads))) (. .)))
17786501	7	(S1 (S (NP (JJ Visual) (NN field) (NN testing)) (VP (VBD confirmed) (NP (JJ bilateral) (JJ central-caecal) (NN Doc_17786501_609_618_Disease))) (. .)))
17786501	8	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NP (NN Doc_17786501_639_649_Chemical)) (PP (IN for) (NP (NNP Doc_17786501_654_672_Disease))) (PP (IN for) (NP (DT the) (JJ preceding) (CD 3) (NNS years))))))) (. .)))
17786501	9	(S1 (S (NP (JJ Doc_17786501_700_710_Chemical) (NN discontinuation)) (VP (VBP lead) (PP (TO to) (NP (DT an) (JJ immediate) (NN symptomatic) (NN improvement)))) (. .)))
17786501	10	(S1 (S (NP (NP (NNS Physicians)) (VP (VBG initiating) (NP (JJ long-term) (NN Doc_17786501_817_827_Chemical) (NN therapy)))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT these) (JJ adverse) (NNS effects)))))) (. .)))
17786501	11	(S1 (S (NP (PRP They)) (VP (MD should) (VP (VB recommend) (NP (JJ annual) (JJ ophthalmic) (NNS reviews)) (PP (IN with) (NP (JJ visual) (NN field) (NN testing))))) (. .)))
17786501	12	(S1 (S (NP (NNS Patients)) (VP (MD should) (VP (AUX be) (VP (VBN reassured) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN reversibility)) (PP (IN of) (NP (DT these) (JJ adverse) (NNS effects)))))))))) (. .)))
17923537	0	(S1 (S (NP (NP (JJ Intraocular) (NN pressure)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17923537_38_45_Disease)))))) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_17923537_59_81_Chemical) (NNS implants)))) (. .)))
17923537	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT the) (NN incidence) (CC and) (NN management)) (PP (IN of) (NP (NP (NNP Doc_17923537_145_174_Disease)) (PRN (-LRB- -LRB-) (NP (NNP IOP)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17923537_198_205_Disease))))))))) (VP (VBN treated) (PP (IN with) (NP (DT the) (JJ Doc_17923537_223_245_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17923537_247_249_Chemical)) (-RRB- -RRB-)) (JJ intravitreal) (NN implant)))) (. .)))
17923537	2	(S1 (S (NP (NP (VBN Pooled) (NNS data)) (PP (IN from) (NP (NP (NP (CD 3) (NN multicenter)) (, ,) (ADJP (JJ double-masked) (, ,) (JJ randomized)) (, ,) (VP (VBN controlled))) (, ,) (NP (NP (NP (NN phase)) (NP (CD 2b/3) (JJ clinical) (NNS trials))) (VP (VBG evaluating) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (DT the) (ADJP (JJ 0.59-mg) (CC or) (JJ 2.1-mg)) (NNP Doc_17923537_439_441_Chemical) (JJ intravitreal) (NN implant)))))) (CC or) (NP (JJ standard) (NN therapy))))) (VP (AUX were) (VP (VBN analyzed))) (. .)))
17923537	3	(S1 (S (PP (IN During) (NP (DT the) (JJ 3-year) (NN follow-up))) (, ,) (NP (NP (CD 71.0) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))) (VP (AUX had) (NP (NP (NP (DT an) (JJ IOP) (NN increase)) (PP (IN of) (NP (QP (CD 10) (CD mm)) (NP (NP (NNP Hg) (CC or) (NP (NP (NP (QP (JJR more) (IN than) (NN baseline) (CC and) (CD 55.1) (NN %))) (, ,) (NP (CD 24.7) (NN %)) (, ,)) (CC and) (NP (NP (CD 6.2) (NN %)) (PP (IN of) (NP (NNS eyes)))))) (VP (VBD reached) (NP (NP (DT an) (NN IOP)) (PP (IN of) (NP (CD 30) (NN mm) (NNP Hg)))))) (CC or) (NP (JJR more))))) (, ,) (NP (CD 40) (JJ mm) (NNP Hg) (CC or) (JJR more)) (, ,) (CC and) (NP (CD 50) (JJ mm) (NNP Hg) (CC or) (JJR more))) (, ,) (ADVP (RB respectively))) (. .)))
17923537	4	(S1 (S (S (NP (JJ Topical) (NN IOP-lowering) (NN medication)) (VP (AUX was) (VP (VBN administered) (PP (IN in) (NP (NP (CD 74.8) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))))))) (, ,) (CC and) (S (NP (NP (JJ IOP-lowering) (NNS surgeries)) (, ,) (SBAR (WHNP (JJS most) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX were) (NP (NP (NNS trabeculectomies)) (PRN (-LRB- -LRB-) (NP (CD 76.2) (NN %)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (NP (CD 36.6) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))))))) (. .)))
17923537	5	(S1 (S (NP (JJ Intraocular) (JJ pressure-lowering) (NNS surgeries)) (VP (AUX were) (VP (VBN considered) (S (NP (NP (DT a) (NN success)) (PRN (-LRB- -LRB-) (NP (NP (JJ postoperative) (NN IOP)) (PP (IN of) (NP (JJ 6-21) (NN mm) (NNP Hg))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ additional) (JJ IOP-lowering) (NN medication))))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD 85.1) (NN %)) (PP (IN of) (NP (NP (NNS eyes)) (PP (IN at) (NP (CD 1) (NN year)))))))))) (. .)))
17923537	6	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NNP Doc_17923537_1123_1131_Disease)))) (-LRB- -LRB-) (VP (VB IOP) (NP (NP (QP (CD </=) (CD 5)) (NNS mm)) (SBAR (S (NP (NNP Hg)) (-RRB- -RRB-) (VP (VBG following) (SBAR (S (NP (NP (NN IOP-lowering) (NN surgery)) (PRN (-LRB- -LRB-) (NP (CD 42.5) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (RB not) (JJ different) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (VBN implanted) (NNS eyes))))))))))))) (RB not) (VP (VBN subjected) (PP (TO to) (NP (NP (NP (NN surgery)) (PRN (-LRB- -LRB-) (NP (CD 35.4) (NN %)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .09)) (-RRB- -RRB-))))) (. .)))
17923537	7	(S1 (S (NP (JJ Elevated) (NN IOP)) (VP (VP (AUX is) (NP (NP (DT a) (JJ significant) (NN complication)) (PP (IN with) (NP (DT the) (JJ FA) (JJ intravitreal) (NN implant))))) (CC but) (VP (MD may) (VP (AUX be) (VP (VBN controlled) (PP (IN with) (NP (NP (NN medication)) (CC and) (NP (NN surgery)))))))) (. .)))
17943461	0	(S1 (S (NP (JJ Myocardial) (NNP Fas) (JJ ligand) (NN expression)) (VP (VBZ increases) (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17943461_61_64_Chemical-induced) (NNP Doc_17943461_73_87_Disease)))) (. .)))
17943461	1	(S1 (S (NP (NP (NP (NNP Doc_17943461_101_123_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_125_128_Disease)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17943461_134_145_Disease))) (VP (VBP occur) (PP (IN in) (NP (JJ many) (NNP Doc_17943461_160_172_Disease) (NNS individuals))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ symptomatic) (NNP Doc_17943461_211_224_Disease))) (PP (IN in) (NP (NP (QP (RB up) (TO to) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
17943461	2	(S1 (S (NP (NP (ADJP (RB Highly) (JJ active)) (NN antiretroviral) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HAART)) (-RRB- -RRB-))) (VP (VP (AUX has) (VP (ADVP (RB significantly)) (VBN reduced) (NP (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN of) (NP (NP (NNP Doc_17943461_348_382_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_384_388_Disease)) (-RRB- -RRB-))))))) (, ,) (CC but) (VP (AUX has) (VP (VBN resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_17943461_426_457_Disease)))))))) (. .)))
17943461	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VP (VB investigate) (PP (IN whether) (NP (DT the) (NN HAART) (NN component))) (SBAR (S (NP (NP (NNP Doc_17943461_532_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_544_573_Chemical)) (: ;) (NP (NNP Doc_17943461_575_578_Chemical)) (-RRB- -RRB-))) (VP (VBZ triggers) (NP (DT the) (JJ Fas-dependent) (JJ cell-death) (NN pathway)))))) (CC and) (VP (VB cause) (NP (NP (JJ cytoskeletal) (NN disruption)) (PP (IN in) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_17943461_681_684_Disease))))))))))) (, ,) (NP (NP (NP (JJ 8-week-old) (NNP transgenic)) (PRN (-LRB- -LRB-) (VP (VBG expressing) (NP (NP (NP (NNP Fas) (NN ligand)) (PP (IN in) (NP (DT the) (NN myocardium)))) (: :) (NP (NNP FasL) (NNP Tg)))) (-RRB- -RRB-))) (CC and) (NP (JJ non-transgenic) (PRN (-LRB- -LRB-) (NP (NNP NTg)) (-RRB- -RRB-)) (NNS mice))) (VP (VBD received) (NP (NP (NN water) (NN ad) (NN libitum)) (VP (VBG containing) (NP (NP (JJ different) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_17943461_854_857_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 0.07)) (, ,) (NP (CD 0.2)) (, ,) (CC and) (NP (CD 0.7) (NN mg/ml))) (-RRB- -RRB-))))))))) (. .)))
17943461	4	(S1 (S (PP (IN After) (NP (CD 6) (NNS weeks))) (, ,) (S (NP (JJ cardiac) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NN echocardiography)))))) (CC and) (S (NP (NN morphology)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (NN histopathologic)) (CC and) (NP (JJ immunohistochemical) (NNS methods))))))) (. .)))
17943461	5	(S1 (S (NP (ADJP (JJ NTg) (CC and) (JJ untreated)) (NNP FasL) (NNP Tg) (NNS mice)) (VP (VBD showed) (NP (NP (ADJP (JJ little) (CC or) (DT no)) (NN change)) (PP (IN in) (NP (NP (JJ cardiac) (NN structure)) (CC or) (NP (NN function)))))) (. .)))
17943461	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_17943461_1139_1142_Chemical-treated) (NNP FasL) (NNP Tg) (NNS mice)) (VP (VBD developed) (NP (NP (NN Doc_17943461_1174_1190_Disease)) (CC and) (NP (JJ depressed) (JJ cardiac) (NN function))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (PP (IN with) (NP (NP (JJ concomitant) (JJ inflammatory) (NN infiltration)) (PP (IN of) (NP (DT both) (NNS ventricles)))))) (. .)))
17943461	7	(S1 (S (NP (DT These) (NNS changes)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (VBN increased) (JJ sarcolemmal) (NN expression)) (PP (IN of) (NP (NNP Fas) (CC and) (NNP FasL)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN increased) (NN activation)) (PP (IN of) (NP (NN caspase) (CD 3)))) (, ,) (NP (NP (NN translocation)) (PP (IN of) (NP (NN calpain) (CD 1))) (PP (TO to) (NP (DT the) (NN sarcolemma) (CC and) (NN sarcomere)))) (, ,) (CC and) (NP (NP (VBN increased) (NNS numbers)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBG undergoing) (NP (NN apoptosis)))))))))) (. .)))
17943461	8	(S1 (S (NP (DT These)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN dystrophin)) (CC and) (NP (JJ cardiac) (NN troponin) (NN I) (NN localization))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN loss)) (PP (IN of) (NP (JJ sarcolemmal) (NN integrity)))))))) (. .)))
17943461	9	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NNP Fas) (CD ligand))) (PP (IN in) (NP (DT the) (NN myocardium)))) (PRN (, ,) (SBAR (IN as) (S (VP (VBN identified) (PP (IN in) (NP (JJ HIV-positive) (NNS patients)))))) (, ,)) (VP (MD might) (VP (VB increase) (NP (DT the) (NN susceptibility)) (PP (TO to) (NP (JJ HAART-induced) (NNP Doc_17943461_1840_1854_Disease))) (PP (JJ due) (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ apoptotic) (NNS pathways)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_17943461_1909_1941_Disease)))))))))) (. .)))
17965424	0	(S1 (NP (NP (NP (JJ Gastrointestinal) (NN tolerability)) (PP (IN of) (NP (NNP Doc_17965424_33_43_Chemical))) (PP (IN in) (NP (NNP Doc_17965424_47_67_Disease) (NNS patients)))) (: :) (NP (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NNP Doc_17965424_93_103_Chemical) (NNP vs) (NNP Doc_17965424_107_124_Chemical) (JJ gastrointestinal) (NN tolerability)))) (CC and) (NP (NP (NN effectiveness) (NN trial)) (PRN (-LRB- -LRB-) (NP (NNP EDGE-II)) (-RRB- -RRB-)))) (. .)))
17965424	1	(S1 (S (NP (DT A) (JJ randomised) (, ,) (JJ double-blind) (NN study)) (VP (TO to) (VP (VB compare) (NP (NP (NP (DT the) (JJ gastrointestinal) (PRN (-LRB- -LRB-) (NP (NNP GI)) (-RRB- -RRB-)) (NN tolerability)) (, ,) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NNP Doc_17965424_308_318_Chemical) (CC and) (NNP Doc_17965424_323_333_Chemical))) (PP (IN in) (NP (NNS patients)))) (PP (IN with) (NP (NP (NNP Doc_17965424_351_371_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17965424_373_375_Disease)) (-RRB- -RRB-)))))) (. .)))
17965424	2	(S1 (NP (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (NP (CD 4086) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age)) (NP (CD 60.8) (NNS years))) (-RRB- -RRB-)) (VP (VP (VBN diagnosed) (SBAR (IN with) (S (NP (NNP Doc_17965424_462_464_Disease) (AUX were)) (VP (VBD enrolled))))) (CC and) (VP (VBD received) (NP (NNP Doc_17965424_492_502_Chemical)) (ADVP (NP (CD 90) (NNS mg)) (RB daily)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2032)) (-RRB- -RRB-))))) (CC or) (NP (NP (NNP Doc_17965424_529_539_Chemical) (CD 75) (NNS mg)) (ADJP (ADJP (RB twice) (JJ daily)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2054)) (-RRB- -RRB-))))))) (. .)))
17965424	3	(S1 (S (NP (NP (NP (NN Use)) (PP (IN of) (NP (JJ gastroprotective) (NNS agents)))) (CC and) (NP (JJ low-dose) (NN Doc_17965424_614_621_Chemical))) (VP (AUX was) (VP (VBN allowed))) (. .)))
17965424	4	(S1 (S (NP (DT The) (JJ prespecified) (JJ primary) (NN end) (NN point)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT the) (JJ cumulative) (NN rate)) (PP (IN of) (NP (NP (JJ patient) (NNS discontinuations)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ clinical) (CC and) (NN laboratory) (NN GI) (JJ adverse) (NNS experiences)) (PRN (-LRB- -LRB-) (NP (NNP AEs)) (-RRB- -RRB-)))))))))) (. .)))
17965424	5	(S1 (S (NP (JJ General) (NN safety)) (VP (AUX was) (ADVP (RB also)) (VP (VBN assessed) (, ,) (PP (VBG including) (NP (JJ adjudicated) (NNP Doc_17965424_848_873_Disease) (NN event) (NNS data))))) (. .)))
17965424	6	(S1 (S (NP (NN Efficacy)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT the) (JJ Patient) (JJ Global) (NN Assessment)) (PP (IN of) (NP (NN Disease) (NN Status))) (PRN (-LRB- -LRB-) (NP (NP (NNP PGADS)) (: ;) (NP (JJ 0-4) (NN point) (NN scale))) (-RRB- -RRB-))))))) (. .)))
17965424	7	(S1 (S (NP (NP (JJ Mean) (PRN (-LRB- -LRB-) (NP (NNP SD)) (: ;) (NP (NN maximum)) (-RRB- -RRB-)) (NN duration)) (PP (IN of) (NP (NN treatment)))) (VP (AUX was) (NP (NP (NP (CD 19.3)) (PRN (-LRB- -LRB-) (NP (NP (CD 10.3)) (: ;) (NP (CD 32.9))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 19.1)) (PRN (-LRB- -LRB-) (NP (NP (CD 10.4)) (: ;) (NP (CD 33.1))) (-RRB- -RRB-)))) (NP (NP (NNS months)) (PP (IN in) (NP (DT the) (NNP Doc_17965424_1097_1107_Chemical) (CC and) (NNP Doc_17965424_1112_1122_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively))) (. .)))
17965424	8	(S1 (S (NP (NP (DT The) (JJ cumulative) (NN discontinuation) (NN rate)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_17965424_1188_1194_Disease))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN with) (NP (NNP Doc_17965424_1224_1234_Chemical)))) (PP (IN than) (NP (NNP Doc_17965424_1240_1250_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 5.2) (NNP vs) (CD 8.5) (NNS events)) (PP (IN per) (NP (NP (CD 100) (NNS patient-years)) (, ,) (ADVP (RB respectively)) (NP (NP (: ;) (NN hazard) (NN ratio) (NN 0.62)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (ADVP (RB CI))) (: :) (NP (NP (CD 0.47)) (, ,) (NP (CD 0.81))) (: ;) (NP (CD p<or=0.001))) (-RRB- -RRB-)))))) (-RRB- -RRB-))) (. .)))
17965424	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NNS discontinuations)) (PP (IN for) (NP (JJ Doc_17965424_1398_1410_Disease-related) (CC and) (JJ Doc_17965424_1423_1429_Disease-related) (NNS AEs)))))) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN with) (NP (NNP Doc_17965424_1473_1483_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 2.5) (NN %)) (CC and) (NP (CD 1.1) (NN %) (RB respectively))) (-RRB- -RRB-)) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_17965424_1527_1537_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1.5) (NN %)) (CC and) (NP (NP (CD 0.4) (NN %)) (ADVP (RB respectively)))) (: ;) (NP (NP (NP (CD p<0.001)) (PP (IN for) (NP (NNP Doc_17965424_1579_1591_Disease)))) (CC and) (NP (NP (CD p<0.01)) (PP (IN for) (NP (NNP Doc_17965424_1607_1613_Disease)))))) (-RRB- -RRB-))) (. .)))
17965424	10	(S1 (S (NP (NP (NN Doc_17965424_1616_1626_Chemical)) (CC and) (NP (JJ Doc_17965424_1631_1641_Chemical) (NN treatment))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ similar) (NN efficacy)) (PRN (-LRB- -LRB-) (S (NP (NNS PGADS)) (VP (VBP mean) (NP (NP (NNS changes)) (PP (IN from) (NP (NN baseline) (NN -0.62)))) (NP (NNP vs) (CD -0.58)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (. .)))
17965424	11	(S1 (S (NP (JJ Doc_17965424_1759_1769_Chemical) (CD 90) (NN mg)) (VP (VBD demonstrated) (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN risk)) (PP (IN for) (S (VP (VBG discontinuing) (NP (NN treatment)) (PP (JJ due) (TO to) (NP (NNP Doc_17965424_1851_1857_Disease))) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_17965424_1872_1882_Chemical) (CD 150) (NNS mg))))))))) (. .)))
17965424	12	(S1 (S (NP (NP (NNS Discontinuations)) (PP (IN from) (NP (NP (JJ renovascular) (NNS AEs)) (, ,) (SBAR (IN although) (S (ADJP (RBR less) (JJ common) (PP (IN than) (NP (NP (NNS discontinuations)) (PP (IN from) (NP (NNP Doc_17965424_1979_1985_Disease)))))))) (, ,)))) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN with) (NP (NNP Doc_17965424_2018_2028_Chemical)))) (. .)))
17975693	0	(S1 (NP (NP (JJ Anxiogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_17975693_24_37_Chemical)) (CC and) (NP (NNP Doc_17975693_42_53_Chemical)))) (PP (IN in) (NP (NNS rats))) (. .)))
17975693	1	(S1 (S (S (NP (NP (NP (DT The) (JJ possible) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_17975693_112_128_Chemical)))) (, ,) (ADVP (RB namely)) (NP (NP (NNP Doc_17975693_137_150_Chemical)) (CC and) (NP (NNP Doc_17975693_155_166_Chemical))) (, ,)) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (NP (JJ adult) (NNP Charles) (NNP Foster) (NN albino) (NNS rats)) (PP (IN of) (NP (DT either) (NN sex))))) (, ,) (S (VP (VBG weighing) (NP (CD 150-200) (NNP g.) (NNS METHODS))))))) (: :) (S (S (NP (DT The) (NNS drugs)) (VP (AUX were) (VP (VBN given) (ADVP (RB orally)) (, ,) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 50) (NNS mg/kg)) (PP (IN for) (NP (CD five) (JJ consecutive) (NNS days)))))))))) (CC and) (S (NP (DT the) (NNS experiments)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (DT the) (JJ fifth) (NN day))))))) (. .)))
17975693	2	(S1 (S (NP (DT The) (NNS tests)) (VP (VBD included) (NP (NP (JJ open-field) (JJ exploratory) (NN behaviour)) (, ,) (NP (JJ elevated) (JJ plus) (NN maze)) (CC and) (NP (NP (JJ elevated) (NN zero) (NN maze)) (, ,) (NP (JJ social) (NN interaction)) (CC and) (NP (JJ novelty-suppressed) (NN feeding) (NN latency) (NN behaviour))))) (. .)))
17975693	3	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_17975693_595_608_Chemical-)) (CC and) (NP (JJ Doc_17975693_614_625_Chemical-treated) (NNS rats))) (VP (VBD showed) (NP (NNP Doc_17975693_646_663_Disease)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NN control) (NNS rats))))) (PP (IN in) (NP (NP (PDT all) (DT the) (NNS parameters)) (VP (VBN studied)))))))) (. .)))
17975693	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNP Doc_17975693_734_747_Chemical-)) (CC and) (NP (JJ Doc_17975693_753_764_Chemical-treated) (NNS rats))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (NP (DT each) (JJ other))) (PP (IN in) (NP (JJ various) (JJ behavioural) (NNS parameters))))) (. .)))
17975693	5	(S1 (S (NP (DT The) (JJ present) (JJ experimental) (NNS findings)) (VP (VB substantiate) (NP (NP (DT the) (ADJP (RB clinically) (JJ observed)) (NN anxiogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_17975693_965_978_Chemical)) (CC and) (NP (NNP Doc_17975693_983_994_Chemical)))))) (. .)))
18006530	0	(S1 (NP (NP (NN Reduction)) (PP (IN of) (NP (NNP Doc_18006530_13_17_Disease))) (PP (IN during) (NP (NP (NN induction)) (PP (IN with) (NP (NP (JJ target-controlled) (NNP Doc_18006530_58_66_Chemical)) (CC and) (NP (NNP Doc_18006530_71_83_Chemical)))))) (. .)))
18006530	1	(S1 (S (NP (NP (NN Doc_18006530_97_101_Disease)) (PP (IN on) (NP (NN injection))) (PP (IN of) (NP (NNP Doc_18006530_118_126_Chemical)))) (VP (AUX is) (ADJP (JJ unpleasant))) (. .)))
18006530	2	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NNP Doc_18006530_163_171_Chemical) (NN infusion) (NNP Doc_18006530_181_185_Disease)) (VP (MD might) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (S (VP (VBG infusing) (NP (NNP Doc_18006530_217_229_Chemical)) (PP (IN before) (S (VP (VBG starting) (NP (DT the) (JJ Doc_18006530_250_258_Chemical) (NN infusion)) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN setting)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NP (JJ target-controlled) (NNS infusions)) (PRN (-LRB- -LRB-) (NP (NNP TCI)) (-RRB- -RRB-))) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (AUX were) (VP (VBN used))))))))))))))))))) (. .)))
18006530	3	(S1 (S (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ effect-site) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NNP Ce)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_18006530_486_498_Chemical))) (S (VP (TO to) (VP (VB prevent) (NP (DT the) (NNP Doc_18006530_514_518_Disease)) (PP (IN without) (NP (VBG producing) (NNS complications)))))))))))) (. .)))
18006530	4	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 128) (NNS patients)))) (VP (VBG undergoing) (NP (JJ general) (NN surgery)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ normal) (NN saline) (PRN (-LRB- -LRB-) (NN control) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_18006530_674_686_Chemical))) (PP (TO to) (NP (NP (NP (NP (NP (NP (NP (DT a) (NN target) (NNP Ce)) (PP (IN of) (NP (QP (CD 2) (CD ng)) (NNS ml)))) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R2)) (-RRB- -RRB-)) (, ,) (CD 4)) (NN ng) (NNS ml)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R4)) (-RRB- -RRB-)) (, ,) (CC or) (NP (QP (CD 6) (CD ng)) (NNS ml))) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R6)) (-RRB- -RRB-))) (VP (VBN administered) (PP (IN via) (NP (NNP TCI))))))))))) (. .)))
18006530	5	(S1 (S (SBAR (IN After) (S (NP (DT the) (NN target) (NN Ce)) (VP (AUX was) (VP (VBN achieved))))) (, ,) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_18006530_833_841_Chemical)))) (VP (AUX was) (VP (VBN started))) (. .)))
18006530	6	(S1 (S (S (NP (JJ Doc_18006530_855_867_Chemical-related) (NNS complications)) (VP (AUX were) (VP (VBN assessed) (PP (IN during) (NP (DT the) (JJ Doc_18006530_915_927_Chemical) (NN infusion)))))) (, ,) (CC and) (S (NP (NP (NN Doc_18006530_942_946_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18006530_957_965_Chemical))))) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT a) (JJ four-point) (NN scale)) (PP (IN during) (NP (DT the) (JJ Doc_18006530_1016_1024_Chemical) (NN infusion))))))))) (. .)))
18006530	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_18006530_1061_1065_Disease)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (NP (JJ R2) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12/32) (CC and) (CD 6/31)) (NNP vs) (CD 26/31) (CC and) (CD 25/32)) (, ,) (ADVP (RB respectively))) (, ,) (NP (NNP P<0.001)) (-RRB- -RRB-)))))))) (. .)))
18006530	8	(S1 (S (NP (NN Doc_18006530_1204_1208_Disease)) (VP (AUX was) (ADJP (RBR less) (JJ severe)) (PP (IN in) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (NP (JJ R2) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (-RRB- -RRB-))))))) (. .)))
18006530	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT both) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_18006530_1330_1334_Disease)))) (VP (AUX were) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6)))) (. .)))
18006530	10	(S1 (S (NP (DT No) (JJ significant) (NNS complications)) (VP (AUX were) (VP (VBN observed) (PP (IN during) (NP (DT the) (NN study))))) (. .)))
18006530	11	(S1 (S (PP (IN During) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP TCI))) (PP (IN of) (NP (NNP Doc_18006530_1498_1506_Chemical) (CC and) (NNP Doc_18006530_1511_1523_Chemical))))) (, ,) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NNP Doc_18006530_1552_1560_Chemical) (NN infusion) (NNP Doc_18006530_1570_1574_Disease)))) (VP (AUX was) (VP (VBN achieved) (PP (IN without) (NP (JJ significant) (NNS complications))) (PP (IN by) (NP (NP (JJ prior) (NN administration)) (PP (IN of) (NP (NNP Doc_18006530_1649_1661_Chemical))) (PP (IN at) (NP (NP (DT a) (NN target) (NN Ce)) (PP (IN of) (NP (NP (QP (CD 4) (CD ng)) (NNS ml)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))))))) (. .)))
18086064	0	(S1 (NP (NP (NP (NN Doc_18086064_0_15_Chemical) (CC and) (JJ cardiac) (NN protection)) (PP (IN for) (NP (JJ non-cardiac) (NN surgery)))) (: :) (NP (NP (DT a) (NN meta-analysis)) (PP (IN of) (NP (JJ randomised) (JJ controlled) (NNS trials)))) (. .)))
18086064	1	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_18086064_164_179_Chemical))) (PP (IN on) (NP (NP (JJ cardiac) (NNS outcomes)) (PP (VBG following) (NP (NN non-cardiac) (NN surgery))))))))) (. .)))
18086064	2	(S1 (S (NP (PRP We)) (VP (VBD included) (NP (NP (JJ prospective) (, ,) (JJ randomised) (JJ peri-operative) (NNS studies)) (PP (IN of) (NP (NNP Doc_18086064_293_308_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBD reported) (NP (NP (NN mortality)) (, ,) (NP (JJ cardiac) (NN morbidity)) (CC or) (NP (JJ adverse) (NN drug) (NNS events)))))))) (. .)))
18086064	3	(S1 (S (NP (DT A) (NNP PubMed) (NNP Central) (CC and) (NNP EMBASE) (NN search)) (VP (AUX was) (VP (VBN conducted) (PP (IN up) (PP (TO to) (NP (NNP July) (CD 2007)))))) (. .)))
18086064	4	(S1 (S (NP (NP (DT The) (NN reference) (NNS lists)) (PP (IN of) (NP (VBN identified) (NNS papers)))) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (JJ further) (NNS trials))))) (. .)))
18086064	5	(S1 (S (PP (IN Of) (NP (NP (CD 425) (NNS studies)) (VP (VBN identified)))) (, ,) (NP (CD 20)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (NNS meta-analysis)) (PRN (-LRB- -LRB-) (NP (CD 840) (NNS patients)) (-RRB- -RRB-)))))) (. .)))
18086064	6	(S1 (S (NP (NNP Doc_18086064_598_613_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN trend)) (PP (IN towards) (NP (JJ improved) (JJ cardiac) (NNS outcomes)))) (: ;) (NP (NP (JJ all-cause) (NN mortality)) (PRN (-LRB- -LRB-) (CC OR) (S (NP (NP (CD 0.27)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.01-7.13))) (, ,) (NP (CD p))) (VP (SYM =) (NP (CD 0.44)))) (-RRB- -RRB-)) (, ,) (NP (JJ non-fatal) (NNP Doc_18086064_746_767_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (CD 0.26))) (, ,) (NP (NP (CD 95) (NN %) (QP (CD CI) (CD 0.04-1.60))) (, ,) (NP (NNP p) (SYM =) (CD 0.14)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_18086064_811_831_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (CD 0.65))) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.26-1.63))) (, ,) (NP (NP (NNP p) (SYM =)) (NP (CD 0.36)))) (-RRB- -RRB-))))))) (. .)))
18086064	7	(S1 (S (NP (NP (NP (JJ Peri-operative) (NNP Doc_18086064_886_897_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 26) (NN %)) (, ,) (CC OR) (NP (CD 3.80)) (, ,) (NP (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.91-7.54) (, ,) (CD p))) (X (SYM =)) (CD 0.0001))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18086064_947_958_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 17) (NN %)) (, ,) (CC OR) (NP (CD 5.45)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 2.98-9.95)))) (, ,) (NP (NNP p) (QP (CD <) (CD 0.00001))) (-RRB- -RRB-)))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN increased))) (. .)))
18086064	8	(S1 (S (NP (DT An) (NN anticholinergic)) (VP (AUX did) (RB not) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18086064_1086_1097_Disease)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.43)))) (-RRB- -RRB-)))) (. .)))
18086064	9	(S1 (S (NP (NP (DT A) (JJ randomised) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NNP Doc_18086064_1151_1166_Chemical)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
18161408	0	(S1 (NP (NP (NP (NN Doc_18161408_0_21_Disease)) (PP (IN in) (NP (NN pregnancy))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18161408_51_69_Chemical))) (PP (IN for) (NP (NN ovulation) (NN induction))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
18161408	1	(S1 (S (NP (NP (NNP Doc_18161408_122_140_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18161408_142_144_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN prescribed) (PP (IN for) (NP (NN ovulation) (NN induction))))) (. .)))
18161408	2	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN considered) (S (ADJP (JJ safe))) (, ,) (PP (IN with) (NP (JJ minimal) (NN side) (NNS effects))))) (. .)))
18161408	3	(S1 (S (NP (NN Doc_18161408_244_259_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ life-threatening)) (NN complication)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (NN ovulation) (NN induction)) (PP (IN with) (NP (NNP Doc_18161408_358_360_Chemical)))))))))))) (. .)))
18161408	4	(S1 (S (NP (NP (JJ Spontaneous) (NNP Doc_18161408_374_393_Disease) (CC or) (NNP Doc_18161408_397_412_Disease)) (PP (IN with) (NP (JJ subsequent) (NN clot) (NNS lysis)))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS causes)) (PP (IN of) (NP (NP (NNP Doc_18161408_495_516_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18161408_518_520_Disease)) (-RRB- -RRB-)))))))) (PP (IN during) (NP (NN pregnancy))) (, ,) (PP (IN with) (NP (DT a) (ADJP (RB subsequently) (JJ normal)) (JJ coronary) (NN angiogram)))))) (. .)))
18161408	5	(S1 (S (NP (NP (DT A) (JJ 33-year-old) (NN woman)) (PP (IN with) (NP (DT a) (JJ 5-week) (NN gestation)))) (VP (VP (AUX had) (ADVP (RB recently)) (VP (VBN received) (NP (NNP Doc_18161408_659_661_Chemical)) (PP (IN for) (NP (NN ovulation) (NN induction))))) (CC and) (VP (VBD presented) (PP (IN with) (NP (NNP Doc_18161408_705_715_Disease))))) (. .)))
18161408	6	(S1 (S (NP (DT An) (NN electrocardiogram)) (VP (VBD showed) (NP (NP (DT a) (NN lateral)) (CC and) (NP (NNP anterior) (NNP wall) (NNP Doc_18161408_773_794_Disease)))) (. .)))
18161408	7	(S1 (S (NP (JJ Cardiac) (NNS enzymes)) (VP (VBD showed) (NP (NP (DT a) (JJ peak) (NN rise)) (PP (IN in) (S (VP (VBG troponin) (NP (PRP I)) (PP (TO to) (NP (QP (CD 9.10) (CD ng/mL))))))))) (. .)))
18161408	8	(S1 (S (NP (DT An) (JJ initial) (NN exercise) (NN stress) (NN test)) (VP (AUX was) (ADJP (JJ normal))) (. .)))
18161408	9	(S1 (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN admission))))) (, ,) (S (NP (DT the) (NN patient)) (VP (AUX was) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN of) (NP (NNP Doc_18161408_962_978_Disease))) (PP (TO to) (NP (DT the) (NN fetus))))))) (, ,) (CC so) (S (NP (DT a) (JJ coronary) (NN angiogram)) (VP (AUX was) (VP (VBN postponed) (PP (IN until) (NP (DT the) (JJ second) (NN trimester)))))) (. .)))
18161408	10	(S1 (S (NP (PRP It)) (VP (VBD showed) (NP (JJ normal) (JJ coronary) (NNS vessels))) (. .)))
18161408	11	(S1 (S (NP (DT This)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (VP (VBG documenting) (NP (NP (DT a) (JJ possible) (NN association)) (PP (IN between) (NP (NP (NNP Doc_18161408_1192_1194_Chemical)) (CC and) (NP (NNP Doc_18161408_1199_1220_Disease))))))))))) (. .)))
18161408	12	(S1 (S (NP (NN Doc_18161408_1222_1232_Disease)) (VP (MD might) (VP (AUX be) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ hazardous)) (NN complication)) (PP (IN of) (NP (NNP Doc_18161408_1279_1281_Chemical)))))) (. .)))
18161408	13	(S1 (S (PP (VBN Given) (NP (DT this) (JJ life-threatening) (NN complication))) (, ,) (NP (JJ appropriate) (JJ prophylactic) (NNS measures)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (JJ high-risk) (NN woman) (VBG undergoing) (NN ovarian) (NN stimulation)))))) (. .)))
18177388	0	(S1 (S (VP (VP (VB Reverse)) (CC or) (VP (VBN inverted) (NP (NP (NNP Doc_18177388_20_63_Disease)) (PRN (-LRB- -LRB-) (NP (JJ reverse) (NN Doc_18177388_73_97_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ Doc_18177388_134_145_Chemical) (NN use))))))))) (. .)))
18177388	1	(S1 (S (NP (JJ Transient) (NN Doc_18177388_161_204_Disease)) (VP (AUX was) (ADVP (RB first)) (VP (VBN described) (PP (IN in) (NP (NNP Japan))) (PP (IN as) (`` ``) (NP (NNP Doc_18177388_238_262_Disease))))) (. .) ('' '')))
18177388	2	(S1 (S (NP (DT This) (NN syndrome)) (VP (AUX has) (VP (AUX been) (VP (VBN identified) (PP (IN in) (NP (JJ many) (JJ other) (NNS countries)))))) (. .)))
18177388	3	(S1 (S (NP (NP (JJ Many) (NNS variations)) (PP (IN of) (NP (DT this) (NN syndrome)))) (VP (AUX have) (VP (AUX been) (VP (ADVP (RB recently)) (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
18177388	4	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NN rarest)))) (VP (AUX is) (NP (NP (DT the) (JJ reverse) (NN type)) (PP (IN of) (NP (DT this) (NN syndrome)))) (, ,) (PP (IN with) (NP (NP (NP (JJ hyperdynamic) (NN apex)) (CC and) (NP (JJ complete) (NN Doc_18177388_497_505_Disease))) (PP (IN of) (NP (NP (DT the) (NN base)) (PRN (-LRB- -LRB-) (SBAR (IN as) (S (VP (VBN opposed) (PP (TO to) (NP (DT the) (JJ classic) (NN Doc_18177388_545_562_Disease)))))) (-RRB- -RRB-))))))) (. .)))
18177388	5	(S1 (S (PP (IN In) (NP (DT this) (NN article))) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT an) (JJ interesting) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (S (NP (NP (DT this) (JJ rare) (NN type)) (PP (IN of) (NP (JJ reverse) (NNP Doc_18177388_674_700_Disease)))) (VP (VBG occurring) (PP (IN after) (NP (JJ Doc_18177388_717_728_Chemical) (NN use))))))))))))) (. .)))
18177388	6	(S1 (S (NP (DT This) (NN report)) (VP (AUX is) (VP (VBN followed) (PP (IN by) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))) (. .)))
18201582	0	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (NP (DT a) (JJ comparative) (, ,) (ADJP (NN phase) (NNP III) (, ,) (JJ 12-week) (, ,) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ randomized)) (, ,) (JJ double-blind) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (DT a) (JJ fixed-dose) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_18201582_172_183_Chemical)) (CC and) (NP (NNP Doc_18201582_188_198_Chemical) (CC versus) (NNP Doc_18201582_206_216_Chemical))))))))))) (VP (VB monotherapy) (PP (IN in) (NP (NP (JJ Indian) (NNS adults)) (PP (IN with) (NP (NN stage) (NNP II) (NNP Doc_18201582_260_272_Disease)))))) (. .)))
18201582	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (NP (DT a) (JJ new) (JJ fixed-dose) (NN combination)) (PRN (-LRB- -LRB-) (NP (NNP FDC)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_18201582_394_405_Chemical) (CD 40)))) (JJ mg) (CD +) (NNP Doc_18201582_414_424_Chemical) (NP (NP (CD 5) (NN mg)) (PRN (-LRB- -LRB-) (NP (NNP T+A)) (-RRB- -RRB-)) (VP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_18201582_450_460_Chemical) (JJ 5-mg) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ adult) (NNP Indian) (NNS patients))) (PP (IN with) (NP (NN stage))))) (NNP II) (NNP Doc_18201582_521_533_Disease)))))))) (. .)))
18201582	2	(S1 (S (NP (DT This) (JJ comparative) (, ,) (ADJP (NN Phase) (NNP III) (, ,) (JJ 12-week) (, ,) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind)) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ Indian) (NNS patients)) (VP (VBN aged) (NP (QP (CD 18) (TO to) (CD 65)) (NNS years)) (PP (IN with) (NP (JJ established) (NN stage) (NNP II) (NNP Doc_18201582_718_730_Disease)))))))) (. .)))
18201582	3	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ oral) (NN FDC)) (PP (IN of) (NP (NNP T+A)))) (CC or) (NP (NP (DT A) (NN QD)) (PP (IN before) (NP (NN breakfast)))))) (PP (IN for) (NP (CD 12) (NNS weeks)))))) (: ;) (S (NP (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (CC and) (NP (NN heart) (NN rate))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT the) (VBG sitting) (NN position)))))) (. .)))
18201582	4	(S1 (S (NP (JJ Primary) (NN efficacy) (NN end) (NNS points)) (VP (AUX were) (S (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ clinical) (JJ systolic) (NNP BP) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-)) (NNP /) (NN diastolic) (NNP BP)) (PRN (-LRB- -LRB-) (NP (NNP DBP)) (-RRB- -RRB-)))) (PP (IN from) (NP (NN baseline)))) (VP (TO to) (VP (VB study) (NP (NP (NN end) (CC and) (NN number)) (PP (IN of) (NP (NP (NNS responders)) (PRN (-LRB- -LRB-) (NP (NN ie)) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD achieved) (SBAR (S (NP (NN target) (NNS SBP/)) (VP (VBD DBP) (NP (CD <130/<80) (NN mm)) (NP (NNP Hg))))))))) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (NN end)) (PP (IN of) (NP (NN study))))))))) (. .)))
18201582	5	(S1 (S (NP (NN Tolerability)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ treatment-emergent) (JJ adverse) (NNS events)) (, ,) (VP (VBN identified) (S (VP (VBG using) (NP (NP (NN physical) (NN examination)) (, ,) (NP (NN laboratory) (NN analysis)) (, ,) (CC and) (NP (NN electrocardiography)))))))))) (. .)))
18201582	6	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 210) (NNS patients)))) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (NN study)))))) (: ;) (S (NP (NP (CD 203) (NNS patients) (PRN (-LRB- -LRB-) (NP (CD 143) (NNS men)) (, ,) (NP (CD 60) (NNS women)) (-RRB- -RRB-))) (VP (VBN completed) (NP (DT the) (NN study)) (PP (IN while) (NP (CD 7))))) (VP (AUX were) (VP (VP (VBN lost) (PP (TO to) (NP (NN follow-up))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4) (NNS patients)) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (CD 3)) (PP (IN in) (NP (DT the) (DT A) (NN group))))) (-RRB- -RRB-))) (CC and) (VP (VBN considered) (S (ADJP (JJ with-drawn))))))) (. .)))
18201582	7	(S1 (S (PP (IN At) (NP (NN study) (NN end))) (, ,) (NP (NP (ADJP (RB statistically) (JJ significant)) (NN percentage) (NNS reductions)) (PP (PP (IN from) (NP (NP (NN baseline)) (PP (IN within) (NP (NNS groups))))) (CC and) (PP (IN between) (NP (NNS groups))))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NP (NNP SBP)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A) (CD -LSB--27.4) (NN %) (NN -RSB-)) (: ;) (NP (DT A) (ADJP (CD -LSB--16.6) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNP DBP)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A) (ADJP (CD -LSB--20.1) (NN %)) (NN -RSB-)) (: ;) (NP (DT A) (ADJP (CD -LSB--13.3) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (DT all)) (, ,) (NP (NP (NN P)) (QP (CD <) (CD 0.05)))) (-RRB- -RRB-))))))) (. .)))
18201582	8	(S1 (S (NP (NN Response) (NNS rates)) (VP (AUX were) (NP (NP (NP (NP (CD 87.3) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 89/102)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (NP (CD 69.3) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 70/101)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NNP A) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
18201582	9	(S1 (S (NP (NP (DT The) (NNS prevalences)) (PP (IN of) (NP (JJ adverse) (NNS events)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (NP (DT the) (CD 2) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A)) (, ,) (NP (NP (CD 16.0) (NN %)) (NP (CD -LSB-17/106) (NN -RSB-)))) (: ;) (NP (NP (DT A)) (, ,) (NP (NP (CD 15.4) (NN %)) (NP (CD -LSB-16/104) (NNS -RSB-)))) (-RRB- -RRB-)))))) (. .)))
18201582	10	(S1 (S (S (S (NP (JJ Peripheral) (NNP Doc_18201582_1939_1944_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (CD 8.5) (NN %) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 9/106)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP T+A) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 13.5) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 14/104)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (DT A) (NN group)))))) (, ,) (CC and) (S (NP (NNP Doc_18201582_2049_2054_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (NP (CD 3.8) (NN %) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4/106)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (ADJP (CD 1.0) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 1/104)) (-RRB- -RRB-)) (NNS patients)) (PP (IN in) (NP (DT the) (DT A) (NN group)))))))))) (: ;) (S (NP (DT these) (NNS differences)) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance))))) (. .)))
18201582	11	(S1 (S (NP (NP (DT The) (NNS incidences)) (PP (IN of) (NP (NP (NNP Doc_18201582_2228_2236_Disease)) (, ,) (NP (NNP Doc_18201582_2238_2247_Disease)) (, ,) (CC and) (NP (NNP Doc_18201582_2253_2261_Disease))))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (CD 2) (NNS groups)))) (. .)))
18201582	12	(S1 (S (PP (IN Among) (NP (NP (DT these) (JJ Indian) (NNS patients)) (PP (IN with) (NP (NN stage) (NNP II) (NNP Doc_18201582_2352_2364_Disease))))) (, ,) (S (NP (NP (DT the) (NNP FDC)) (PP (IN of) (NP (NNP T+A)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB significantly) (RBR more) (JJ effective))))) (, ,) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NNP BP) (NNS reductions))))) (, ,) (ADVP (IN than) (DT A))))) (, ,) (CC and) (S (NP (DT both) (NNS treatments)) (VP (AUX were) (VP (ADVP (RB well)) (VBN tolerated)))) (. .)))
18239197	0	(S1 (S (NP (NP (VBN Increased) (NN Doc_18239197_10_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NNP APOE) (NN epsilon4))))) (VP (VBD allele) (PP (IN after) (NP (JJ Doc_18239197_72_87_Chemical) (JJ oral) (NN anticholinergic) (NN challenge))) (PP (IN in) (NP (JJ healthy) (JJ elderly)))) (. .)))
18239197	1	(S1 (S (NP (NP (DT The) (NNS objectives)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX were) (S (VP (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN APOE) (NNS epsilon4)) (CC and) (NP (NP (JJ subjective) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_18239197_261_276_Chemical)) (PP (IN on) (NP (NP (NNS measures)) (VP (VBG reflecting) (NP (NN sedation)))))) (CC and) (NP (NNP Doc_18239197_313_322_Disease)))))))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ Doc_18239197_367_382_Chemical-induced) (JJ subjective) (NNS effects)) (CC and) (NP (JJ objective) (NN memory) (NN performance)))))))))) (. .)))
18239197	2	(S1 (S (NP (DT This) (NN study)) (VP (VBN comprised) (NP (NP (CD 24) (ADJP (RB cognitively) (JJ intact)) (, ,) (ADJP (NN health) (JJ elderly)) (NNS adults)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNP APOE) (NN epsilon4) (NNS carriers)) (-RRB- -RRB-))) (PP (IN at) (NP (DT an) (NN outpatient) (NN geriatric) (NN psychiatry) (NN research) (NN clinic)))) (. .)))
18239197	3	(S1 (S (NP (DT This)) (VP (AUX was) (NP (DT a) (JJ randomized) (, ,) (JJ double) (JJ blind) (, ,) (JJ placebo-controlled) (, ,) (JJ three-way) (, ,) (JJ crossover) (JJ experimental) (NN design))) (. .)))
18239197	4	(S1 (S (NP (DT All) (NNS participants)) (VP (VBD received) (NP (NP (QP (CD 1.0) (CD mg) (CC or) (CD 2.0) (CD mg)) (NN Doc_18239197_744_759_Chemical)) (CC or) (NP (NP (NN placebo)) (VP (VBN administered) (PP (IN in) (NP (JJ counterbalanced) (NNS sequences))) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD three) (JJ consecutive) (NNS weeks))))))))) (. .)))
18239197	5	(S1 (S (NP (NP (NP (NNP Bond) (CC and) (NNP Lader) (POS 's)) (JJ visual) (JJ analog) (NNS scales)) (CC and) (NP (NP (JJ alternate) (NNS versions)) (PP (IN of) (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test))))) (VP (AUX were) (VP (VBN administered) (PP (IN in) (NP (DT a) (VBN repeated) (NNS measures) (NN design))) (PP (IN at) (NP (NN baseline) (, ,) (CD 1) (, ,) (CD 2.5) (, ,) (CC and) (CD 5) (NNS hours) (NN postdrug) (NN administration))))) (. .)))
18239197	6	(S1 (S (NP (NP (DT A) (JJ 2.0-mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NNP Doc_18239197_1093_1108_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ increased) (JJ subjective) (NNS ratings)) (PP (IN of) (NP (NNP Doc_18239197_1153_1168_Disease))))) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (DT the) (NNP APOE) (NN epsilon4) (NN allele))))) (ADVP (RB only))) (. .)))
18239197	7	(S1 (S (NP (NN Drug) (NNS effects)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (NN difference) (NNS scores)) (PP (IN between) (NP (QP (CD 2.0) (CD mg))))))))) (NP (NP (NNP Doc_18239197_1278_1293_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN on) (NP (NP (NNS ratings)) (PP (IN of) (NP (NNP Doc_18239197_1320_1335_Disease))))))) (VP (VP (ADVP (RB significantly)) (VBD correlated) (PP (IN with) (NP (NN total)))) (CC and) (VP (VBD delayed) (NP (NN recall)) (PP (IN on) (NP (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test)) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (DT the) (NNP APOE) (NN epsilon4) (NN allele))))))) (ADVP (RB only)))) (. .)))
18239197	8	(S1 (S (ADVP (RB However)) (, ,) (NP (DT no) (JJ significant) (NNS effects)) (VP (AUX were) (VP (VBN found) (PP (IN with) (NP (NP (JJ other) (JJ visual) (NN analog) (NNS scales)) (VP (VBG reflecting) (NP (NP (JJ subjective) (NN sedation)) (CC and) (NP (NN clear-headedness)))))))) (. .)))
18239197	9	(S1 (S (NP (NP (DT The) (JJ epsilon4) (NN allele)) (PP (IN in) (NP (JJ healthy) (JJ elderly)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (JJ subjective) (NN Doc_18239197_1697_1711_Disease)) (PP (IN after) (NP (JJ Doc_18239197_1718_1733_Chemical) (JJ anticholinergic) (NN challenge))))))) (. .)))
18356633	0	(S1 (NP (NP (DT An) (NN evaluation)) (PP (IN of) (NP (NNP Doc_18356633_17_25_Chemical) (NNP Doc_18356633_26_40_Disease))) (PP (IN in) (NP (DT the) (JJ hematology/oncology) (NN population))) (. .)))
18356633	1	(S1 (S (NP (NN Doc_18356633_80_88_Chemical)) (VP (AUX is) (NP (NP (DT an) (NN Doc_18356633_95_109_Chemical)) (VP (ADVP (RB commonly)) (VBN used) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ empirical) (JJ double) (JJ gram-negative) (NN treatment)) (PP (IN for) (NP (NP (NNP Doc_18356633_180_199_Disease)) (CC and) (NP (JJ other) (JJ suspected) (NNP Doc_18356633_220_230_Disease))))))))))) (. .)))
18356633	2	(S1 (S (S (NP (NP (NNS Strategies)) (PP (IN of) (NP (NP (NN extended-interval)) (CC and) (NP (JJ conventional) (NN dosing))))) (VP (AUX have) (VP (AUX been) (VP (VBN utilized) (ADVP (RB extensively)) (PP (IN in) (NP (DT the) (JJ general) (JJ medical) (NN population))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNS data)) (VP (AUX are) (VP (VBG lacking) (S (VP (TO to) (VP (VB support) (NP (NP (DT a) (VBG dosing) (NN strategy)) (PP (IN in) (NP (DT the) (JJ hematology/oncology) (NN population)))))))))) (. .)))
18356633	3	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (JJ Doc_18356633_460_468_Chemical-associated) (NN Doc_18356633_480_494_Disease)) (PP (IN in) (NP (DT an) (JJ adult) (NN hematology/oncology) (NN population)))))) (, ,) (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN trial)) (VP (AUX was) (VP (VBN conducted) (PP (IN at) (NP (DT a) (JJ university-affiliated) (JJ medical) (NN center))))) (. .)))
18356633	4	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN Doc_18356633_690_720_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (NN treatment)) (PP (IN with) (NP (DT an) (NNP Doc_18356633_753_767_Chemical)))))))))))) (VP (AUX were) (VP (VBN randomized) (PP (TO to) (NP (DT either) (JJ conventional) (CC or) (JJ extended-interval) (NN Doc_18356633_828_836_Chemical))))) (. .)))
18356633	5	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18356633_856_870_Disease))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN Doc_18356633_904_914_Chemical) (CC and) (NN evaluation)) (PP (IN of) (NP (NN efficacy))))))) (PP (IN via) (NP (NP (JJ Doc_18356633_946_954_Chemical) (NN serum) (NNS concentrations)) (PP (IN with) (NP (JJ respective) (NNS pathogens)))))))) (VP (AUX were) (VP (VBN assessed))) (. .)))
18356633	6	(S1 (S (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18356633_1035_1049_Disease)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (JJ conventional) (CC and) (JJ extended-interval) (NNS groups))) (, ,) (PP (IN at) (NP (NP (CD 10) (NN %)) (CC and) (NP (CD 5) (NN %)))) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 1.00)) (-RRB- -RRB-)) (. .)))
18356633	7	(S1 (S (NP (NP (CD Six) (NNS patients)) (PP (IN in) (NP (DT the) (JJ conventional) (NN group)))) (VP (AUX had) (NP (DT a) (JJ positive) (NN culture)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NN none)) (PP (IN in) (NP (NP (DT the) (JJ extended-interval) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
18356633	8	(S1 (S (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18356633_1301_1315_Disease)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (CD two) (JJ dosing) (NNS regimens))))) (, ,) (CC but) (S (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NN risk) (NNS factors)))) (VP (AUX was) (ADJP (JJ variable)) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
18356633	9	(S1 (S (NP (NN Efficacy)) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN assessed)))) (. .)))
18363626	0	(S1 (NP (NP (JJ High) (NN dose)) (ADJP (JJ Doc_18363626_10_25_Chemical) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ pediatric) (NNP MRI)))))) (. .)))
18363626	1	(S1 (S (NP (DT This) (JJ large-scale) (NN retrospective) (NN review)) (VP (VBZ evaluates) (NP (NP (DT the) (NN sedation) (NN profile)) (PP (IN of) (NP (NNP Doc_18363626_149_164_Chemical))))) (. .)))
18363626	2	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (DT the) (JJ hemodynamic) (NNS responses))))) (, ,) (NP (NP (NN efficacy)) (CC and) (NP (JJ adverse) (NNS events))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ high) (NN dose))) (PP (JJ Doc_18363626_276_291_Chemical) (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ magnetic) (NN resonance) (NN imaging) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-)) (NNS studies)))))))) (. .)))
18363626	3	(S1 (S (NP (NN Doc_18363626_371_386_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN at) (NP (PRP$ our) (NN institution))) (PP (IN since) (NP (CD 2005))) (S (VP (TO to) (VP (VB provide) (NP (NN sedation)) (PP (IN for) (NP (JJ pediatric) (JJ radiological) (NN imaging) (NNS studies))))))))) (. .)))
18363626	4	(S1 (S (PP (IN Over) (NP (NN time))) (, ,) (NP (NP (DT an) (JJ effective) (NN protocol)) (VP (VBG utilizing) (NP (JJ high) (NN dose) (NN Doc_18363626_548_563_Chemical)) (PP (IN as) (NP (DT the) (JJ sole) (NN sedative) (NN agent))))) (VP (AUX has) (VP (VBN evolved))) (. .)))
18363626	5	(S1 (NP (NP (NNS METHODS/MATERIALS)) (: :) (S (PP (IN As) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ ongoing) (NNP Quality) (NNP Assurance) (NN process))))) (, ,) (S (NP (NP (NNS data)) (PP (IN on) (NP (DT all) (NNS sedations)))) (VP (AUX are) (VP (VBN reviewed) (ADVP (RB monthly))))) (CC and) (S (NP (NNS protocols)) (VP (VBN modified) (SBAR (IN as) (S (VP (VBN needed))))))) (. .)))
18363626	6	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN from) (NP (NP (DT all) (CD 747) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_18363626_816_831_Chemical)) (PP (IN for) (NP (NNP MRI) (NN sedation))) (PP (PP (IN from) (NP (NNP April) (CD 2005))) (PP (TO to) (NP (NNP April) (CD 2007))))))))))) (. .)))
18363626	7	(S1 (S (PP (IN Since) (NP (CD 2005))) (, ,) (S (NP (NP (DT the) (JJ 10-min) (NN loading) (NN dose)) (PP (IN of) (NP (PRP$ our) (JJ Doc_18363626_932_947_Chemical) (NN protocol)))) (VP (VBD increased) (PP (IN from) (NP (NP (QP (CD 2) (TO to) (CD 3)) (NNS microg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (, ,) (CC and) (S (NP (DT the) (NN infusion) (NN rate)) (VP (VBD increased) (PP (IN from) (NP (QP (CD 1) (TO to) (CD 1.5)))) (PP (TO to) (NP (QP (CD 2) (CD microg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NNS .h))) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))) (. .)))
18363626	8	(S1 (S (NP (DT The) (JJ current) (NN sedation) (NN protocol)) (VP (VP (ADVP (RB progressively)) (VBD increased) (NP (NP (DT the) (NN rate)) (PP (IN of) (S (NP (NP (JJ successful) (NN sedation)) (PRN (-LRB- -LRB-) (S (NP (JJ able)) (VP (TO to) (VP (VB complete) (NP (DT the) (NN imaging) (NN study))))) (-RRB- -RRB-))) (ADVP (WRB when)) (VP (VBG using) (NP (NNP Doc_18363626_1200_1215_Chemical)) (ADVP (RB alone) (PP (IN from) (NP (CD 91.8) (NN %)))) (PP (TO to) (NP (CD 97.6) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.009)) (-RRB- -RRB-)))))) (, ,) (S (VP (VBG reducing) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (JJ adjuvant) (NNP Doc_18363626_1293_1306_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NN sedation) (NN failure))) (PP (IN with) (NP (NNP Doc_18363626_1345_1360_Chemical))) (ADVP (RB alone))))))) (CC and) (VP (VBD decreased) (NP (DT the) (JJ mean) (NN recovery) (NN time)) (PP (IN by) (NP (NP (CD 10) (NN min)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-)))))) (. .)))
18363626	9	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_18363626_1436_1451_Chemical) (NN sedation)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (CD 16) (NN %)) (NN incidence)) (PP (IN of) (NP (NNP Doc_18363626_1500_1511_Disease))))))))) (, ,) (S (NP (DT all) (JJ concomitant) (JJ mean) (JJ arterial) (NN blood) (NNS pressures)) (VP (AUX were) (PP (IN within) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (JJ age-adjusted) (JJ normal) (NN range))))))) (CC and) (S (NP (NNP Doc_18363626_1608_1614_Chemical) (NNS saturations)) (VP (AUX were) (ADJP (CD 95) (NN %) (CC or) (JJR higher)))) (. .)))
18363626	10	(S1 (S (NP (NP (NN Doc_18363626_1659_1674_Chemical)) (PP (IN in) (NP (JJ high) (NNS doses)))) (VP (VBZ provides) (NP (NP (JJ adequate) (NN sedation)) (PP (IN for) (NP (JJ pediatric) (NNP MRI) (NNS studies))))) (. .)))
18363626	11	(S1 (S (SBAR (IN While) (S (NP (NP (NN use)) (PP (IN of) (NP (JJ high) (NN dose) (NN Doc_18363626_1766_1781_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN blood) (NN pressure)))) (PP (IN outside) (NP (NP (DT the) (VBN established) (POS ')) (JJ awake) ('' ') (NNS norms))))))))) (, ,) (NP (DT this) (NN deviation)) (VP (VP (AUX is) (ADVP (RB generally)) (PP (IN within) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NNS norms)))))) (, ,) (CC and) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ adverse) (NNS sequelae)))))) (. .)))
18363626	12	(S1 (S (NP (NN Doc_18363626_1977_1992_Chemical)) (VP (AUX is) (ADJP (JJ useful) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ pediatric) (NNP MRI))))))) (. .)))
18405372	0	(S1 (NP (NP (NP (NN Doc_18405372_0_14_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18405372_31_44_Chemical))) (PP (IN in) (NP (JJ inflammatory) (NN Doc_18405372_61_70_Disease))))) (: :) (NP (NP (DT A) (NN case) (NN series)) (PP (IN from) (NP (NP (DT a) (JJ local) (NN surveillance)) (PP (IN of) (NP (JJ serious) (JJ adverse) (NNS events)))))) (. .)))
18405372	1	(S1 (S (NP (NP (JJ Spontaneous) (NN reporting) (NNS systems)) (PP (IN for) (NP (JJ adverse) (NN drug) (NNS reactions))) (PRN (-LRB- -LRB-) (NP (NNPS ADRs)) (-RRB- -RRB-))) (VP (AUX are) (VP (VBN handicapped) (PP (IN by) (NP (NP (NN under-reporting)) (CC and) (NP (JJ limited) (NN detail)))) (PP (IN on) (NP (JJ individual) (NNS cases))))) (. .)))
18405372	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (NN investigation)) (PP (IN from) (NP (NP (DT a) (JJ local) (NN surveillance)) (PP (IN for) (NP (NP (JJ serious) (JJ adverse) (NN drug) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (NP (NN disease)) (VP (VBG modifying) (NP (NP (JJ anti-rheumatic) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN triggered) (PP (IN by) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18405372_473_486_Disease))) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (PRP$ our) (NNS patients)))))))))))))))))))))) (. .)))
18405372	3	(S1 (S (NP (JJ Serious) (NN ADR) (NNS reports)) (VP (AUX have) (VP (AUX been) (VP (VBN solicited) (PP (IN from) (NP (JJ local) (NNS clinicians))) (PP (IN by) (NP (JJ regular) (NNS postcards))) (PP (IN over) (NP (DT the) (JJ past) (CD seven) (NNS years)))))) (. .)))
18405372	4	(S1 (S (NP (NP (NNS Patients) (POS ')) (, ,) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (NN Doc_18405372_649_663_Disease)) (PP (IN on) (NP (NNP Doc_18405372_667_680_Chemical)))) (CC and) (VP (VBD met) (NP (NP (DT a) (NN definition)) (PP (IN of) (NP (DT a) (JJ serious) (NN ADR)))))))) (, ,)) (VP (AUX were) (VP (VBN identified))) (. .)))
18405372	5	(S1 (S (NP (NP (CD Two) (NNS clinicians)) (VP (VBN reviewed))) (VP (VP (VBD structured) (NP (NN case) (NNS reports))) (CC and) (VP (VBN assessed) (NP (NN causality)) (PP (PP (IN by) (NP (NN consensus))) (CC and) (PP (IN by) (S (VP (VBG using) (NP (DT a) (JJ causality) (NN assessment) (NN instrument)))))))) (. .)))
18405372	6	(S1 (S (NP (NP (DT The) (JJ likely) (NN frequency)) (PP (IN of) (NP (NNP Doc_18405372_893_907_Disease))) (PP (IN with) (NP (NNP Doc_18405372_913_926_Chemical)))) (VP (AUX was) (VP (VBN estimated) (PP (IN by) (S (VP (VBG making) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ conservative) (NNS assumptions))))))))) (. .)))
18405372	7	(S1 (S (S (NP (CD Ten) (NNS cases)) (VP (AUX were) (VP (VBN identified)))) (: :) (S (NP (CD eight)) (VP (VBD occurred) (PP (IN during) (NP (NN surveillance))))) (. .)))
18405372	8	(S1 (S (S (NP (CD Eight) (NNS patients)) (VP (AUX were) (VP (VBN hospitalised) (, ,) (NP (NP (CD two)) (PP (IN in) (NP (NNP Doc_18405372_1102_1117_Disease))))))) (: -) (S (NP (CD one)) (VP (VBD died) (PP (IN after) (NP (DT a) (NN liver) (NN transplant))))) (. .)))
18405372	9	(S1 (S (NP (NP (DT All)) (PP (IN but) (NP (CD one) (NN event)))) (VP (VBD occurred) (PP (IN within) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (. .)))
18405372	10	(S1 (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (NN Doc_18405372_1232_1241_Disease)) (, ,) (NP (NP (CD three) (NN Doc_18405372_1249_1261_Disease)) (CC and) (NP (CD one) (NN Doc_18405372_1270_1292_Disease))))) (. .)))
18405372	11	(S1 (S (NP (CD Five) (NNS patients)) (VP (AUX were) (PP (IN of) (NP (NP (NNP Black) (NNPS British)) (PP (IN of) (NP (NNP African) (CC or) (NNP Caribbean) (NN descent)))))) (. .)))
18405372	12	(S1 (S (NP (NN Liver) (NNS enzymes)) (VP (VBD showed) (NP (NP (NP (DT a) (JJ hepatocellular) (NN pattern)) (PP (IN in) (NP (CD four) (NNS cases)))) (CC and) (NP (NP (DT a) (JJ mixed) (NN pattern)) (PP (IN in) (NP (CD six)))))) (. .)))
18405372	13	(S1 (S (NP (JJ Drug-related) (NN Doc_18405372_1464_1478_Disease)) (VP (AUX was) (VP (VBN judged) (UCP (ADJP (JJ probable)) (CC or) (ADJP (RB highly) (JJ probable) (PP (IN in) (NP (CD 8) (NNS patients))))))) (. .)))
18405372	14	(S1 (S (NP (NP (DT The) (JJ likely) (NN frequency)) (PP (IN of) (NP (JJ serious) (NN Doc_18405372_1565_1579_Disease))) (PP (IN with) (NP (NNP Doc_18405372_1585_1598_Chemical)))) (VP (AUX was) (VP (VBN estimated) (PP (IN at) (NP (NP (CD 0.4) (NN %)) (PP (IN of) (NP (VBN treated) (NNS patients))))))) (. .)))
18405372	15	(S1 (S (S (NP (NP (JJ Serious) (NN Doc_18405372_1662_1676_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18405372_1693_1706_Chemical))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN under-appreciated))))))) (CC and) (S (NP (NP (JJ intensive) (NN monitoring) (CC and) (NN vigilance)) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (VP (AUX is) (ADJP (RB especially) (JJ important)))) (. .)))
18441470	0	(S1 (S (NP (JJ Complete) (NN Doc_18441470_9_31_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_18441470_45_52_Chemical) (NN therapy)))) (. .)))
18441470	1	(S1 (S (NP (NN Doc_18441470_62_84_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (ADVP (RBS most) (RB frequently)) (PP (IN among) (NP (NP (DT the) (JJ adverse) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NNP Doc_18441470_163_170_Chemical)))))))) (. .)))
18441470	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN case))) (, ,) (NP (NP (JJ complete) (NN Doc_18441470_202_229_Disease)) (PP (IN with) (NP (NNP Doc_18441470_235_251_Disease)))) (VP (VBD developed) (ADVP (JJ secondary)) (PP (TO to) (NP (JJ Doc_18441470_275_282_Chemical) (NN therapy))) (, ,) (S (VP (VBG necessitating) (NP (JJ permanent) (NN pacemaker) (NN implantation))))) (. .)))
18441470	3	(S1 (S (NP (NNP Serum) (NNP Doc_18441470_346_353_Chemical) (NNS levels)) (VP (VBD remained) (PP (IN under) (CC or) (PP (IN within) (NP (DT the) (JJ therapeutic) (NN range)))) (PP (IN during) (NP (DT the) (NNP Doc_18441470_419_435_Disease)))) (. .)))
18441470	4	(S1 (S (NP (NN Doc_18441470_437_444_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (JJ extreme) (NN caution))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ mild) (NN disturbance)) (PP (IN of) (NP (CD AV) (NN conduction)))))))))) (. .)))
18483878	0	(S1 (S (NP (NP (JJ Exaggerated) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))) (PP (IN in) (NP (NP (JJ vasoactive) (JJ intestinal) (NN polypeptide) (NN knockout) (PRN (-LRB- -LRB-) (JJ VIP-/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NP (NNP Doc_18483878_114_130_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18483878_132_135_Chemical)) (-RRB- -RRB-))))))) (VP (VBD -induced) (NP (NNP Doc_18483878_145_153_Disease))) (. .)))
18483878	1	(S1 (S (NP (NP (JJ Vasoactive) (JJ intestinal) (NN polypeptide)) (PRN (-LRB- -LRB-) (NP (NN VIP)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ immunomodulatory) (NN neuropeptide)) (VP (VBN distributed) (PP (IN in) (NP (JJ micturition) (NNS pathways)))))) (. .)))
18483878	2	(S1 (S (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VB exhibit) (NP (NP (JJ altered) (NN bladder) (NN function)) (CC and) (NP (JJ neurochemical) (NNS properties))) (PP (IN in) (NP (NN micturition) (NNS pathways))) (SBAR (IN after) (S (NP (NP (NNP Doc_18483878_374_390_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18483878_392_395_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_18483878_405_413_Disease)))))) (. .)))
18483878	3	(S1 (S (PP (VBN Given) (NP (NP (NP (NN VIP) (POS 's)) (NN role)) (PP (IN as) (NP (DT an) (JJ anti-inflammatory) (NN mediator))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (MD would) (VP (VB exhibit) (NP (JJ enhanced) (JJ inflammatory) (NN mediator) (NN expression)) (PP (IN after) (NP (NNP Doc_18483878_563_571_Disease)))))))) (. .)))
18483878	4	(S1 (S (NP (NP (DT A) (NN mouse) (JJ inflammatory) (NN cytokine)) (CC and) (NP (NN receptor) (NN RT2) (NN profiler) (NN array))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (JJ regulated) (NNS transcripts)) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder)) (PP (IN of) (NP (NP (JJ wild) (NN type)) (PRN (-LRB- -LRB-) (NP (NNP WT)) (-RRB- -RRB-)))))))) (CC and) (VP (VB VIP) (NP (NP (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (CC or) (IN without) (NP (NP (JJ Doc_18483878_754_757_Chemical-induced) (NNP Doc_18483878_766_774_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 150) (CD mg/kg))) (: ;) (NP (CD i.p.)) (: ;) (NP (CD 48) (NNP h))) (-RRB- -RRB-))))))))))) (. .)))
18483878	5	(S1 (S (NP (CD Four) (JJ binary) (NNS comparisons)) (VP (AUX were) (VP (VBN made) (: :) (NP (NP (CD WT) (NN control)) (PP (IN versus) (NP (JJ Doc_18483878_853_856_Chemical) (NN treatment))) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NN control)) (CC versus) (NP (NP (NP (NNP Doc_18483878_899_902_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-)) (, ,) (NP (NNP WT) (NN control) (CC versus) (NN VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NN control)) (, ,) (CC and) (CD WT)) (PP (IN with) (NP (NP (NP (JJ Doc_18483878_969_972_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-))) (CC versus) (NP (NP (NN VIP)) (PRN (-LRB- -LRB-) (NP (NN -/-)) (-RRB- -RRB-))))) (PP (IN with) (NP (NNP Doc_18483878_1011_1014_Chemical) (NN treatment))))) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-))))) (. .)))
18483878	6	(S1 (S (NP (NP (DT The) (NNS genes)) (VP (VBN presented))) (VP (VBP represent) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NP (NP (JJR greater)) (SBAR (IN than) (S (NP (NP (NP (JJ 1.5-fold) (NN change)) (PP (IN in) (NP (DT either) (NN direction)))) (CC and) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (DT the) (JJ p) (NN value))) (VP (AUX is) (NP (QP (JJR less) (IN than) (CD 0.05))))))) (PP (IN for) (NP (NP (DT the) (NN comparison)) (VP (AUXG being) (VP (VBN made)))))) (. .)))
18483878	7	(S1 (S (NP (JJ Several) (JJ regulated) (NNS genes)) (VP (AUX were) (VP (VBN validated) (S (VP (VBG using) (NP (NP (JJ enzyme-linked) (NNS immunoassays)) (PP (VBG including) (NP (NP (NN IL-1beta)) (CC and) (NP (NN CXCL1))))))))) (. .)))
18483878	8	(S1 (S (NP (NP (JJ Doc_18483878_1287_1290_Chemical) (NN treatment)) (SBAR (S (ADVP (RB significantly)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-) (VP (VBD increased) (NP (NP (NP (NN expression)) (PP (IN of) (NP (NNP CXCL1) (CC and) (NNP IL-1beta))) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder)) (PP (IN of) (NP (NNP WT) (CC and) (NNP VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)))))) (, ,) (CC but) (NP (NN expression))) (PP (IN in) (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice))) (PP (IN with) (NP (JJ Doc_18483878_1460_1463_Chemical) (NN treatment))))))) (VP (AUX was) (S (ADVP (RB significantly)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-) (NP (NP (JJR greater) (PRN (-LRB- -LRB-) (ADJP (JJ 4.2-) (PP (TO to) (NP (JJ 13-fold) (NN increase)))) (-RRB- -RRB-))) (PP (IN than) (SBAR (WHNP (WDT that)) (S (VP (VBD observed) (PP (IN in) (NP (NP (JJ WT) (NN urinary) (NN bladder)) (PRN (-LRB- -LRB-) (ADJP (JJ 3.6-) (PP (TO to) (NP (JJ 5-fold) (NN increase)))) (-RRB- -RRB-))))))))))) (. .)))
18483878	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NNP Doc_18483878_1656_1676_Disease))))) (, ,) (NP (JJ inflammatory) (NNS mediators)) (VP (AUX are) (VP (VBN increased) (PP (IN above) (NP (NP (DT that) (JJ observed)) (PP (IN in) (NP (NP (NNS WT)) (PP (IN with) (NP (NNP Doc_18483878_1746_1749_Chemical)))))))))))) (. .)))
18483878	10	(S1 (S (NP (NP (DT This) (NN shift)) (PP (IN in) (NP (NN balance)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NP (VBN increased) (NN Doc_18483878_1801_1820_Disease)) (PP (IN in) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NNP Doc_18483878_1843_1863_Disease)))))) (CC and) (NP (NP (VBN altered) (JJ neurochemical) (NN expression)) (PP (IN in) (NP (NN micturition) (NNS pathways)))))))) (. .)))
1848636	0	(S1 (NP (NP (NP (JJ Doc_1848636_0_12_Chemical) (NN phenotype)) (CC and) (NP (DT the) (NNS pharmacokinetics)) (CC and) (NP (JJ beta-2) (NN receptor) (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NNP Doc_1848636_88_98_Chemical)) (CC and) (NP (PRP$ its) (NNS enantiomers)))) (. .)))
1848636	1	(S1 (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (DT the) (JJ cardioselective) (NN beta-blocker) (NN Doc_1848636_171_181_Chemical)))) (VP (AUX is) (PP (IN under) (NP (NP (JJ genetic) (NN control)) (PP (IN of) (NP (DT the) (JJ Doc_1848636_214_226_Chemical/Doc_1848636_227_236_Chemical) (NN type)))))) (. .)))
1848636	2	(S1 (S (NP (NP (DT The) (CD two) (JJ metabolic) (NNS phenotypes)) (, ,) (NP (NP (NP (JJ extensive)) (PRN (-LRB- -LRB-) (NP (NNP EM)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ poor) (NNS metabolizers)) (PRN (-LRB- -LRB-) (NP (NNP PM)) (-RRB- -RRB-)))) (, ,)) (VP (VBP show) (NP (NP (JJ different) (JJ stereoselective) (NN metabolism)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (ADJP (RB apparently) (JJR higher)) (JJ beta-1) (JJ adrenoceptor) (JJ antagonistic) (NN potency)) (PP (IN of) (NP (NP (JJ racemic) (NNP Doc_1848636_442_452_Chemical)) (PP (IN in) (NP (NNP EMs)))))))))) (. .)))
1848636	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN if) (S (NP (DT the) (NN latter)) (ADVP (RB also)) (VP (VBZ applies) (PP (TO to) (NP (DT the) (JJ beta-2) (NN adrenoceptor) (NN antagonism))) (PP (IN by) (NP (NNP Doc_1848636_545_555_Chemical))))))) (. .)))
1848636	4	(S1 (S (NP (NP (DT The) (NN drug) (NN effect)) (VP (VBN studied))) (VP (AUX was) (NP (NP (DT the) (NN antagonism)) (PP (IN by) (NP (NP (NNP Doc_1848636_603_613_Chemical)) (PP (IN of) (NP (NNP Doc_1848636_617_628_Chemical-induced) (NNP Doc_1848636_637_648_Disease))))))) (. .)))
1848636	5	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (JJ pharmacokinetic) (JJ pharmacodynamic) (NN modeling))))) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (JJ racemic) (NNP Doc_1848636_732_742_Chemical)) (CC and) (NP (DT the) (JJ active) (NNP S-isomer)) (, ,)))) (VP (AUX were) (VP (VBN quantitated) (PP (IN in) (NP (NP (NNP EMs)) (CC and) (NP (NNP PMs)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (CD IC50) (NNS values))))) (, ,) (S (VP (VBG representing) (NP (NP (JJ Doc_1848636_838_848_Chemical) (NN plasma) (NNS concentrations)) (VP (VBG resulting) (PP (IN in) (NP (JJ half-maximum) (NN receptor) (NN occupancy))))))))) (. .)))
1848636	6	(S1 (S (S (NP (CD Six) (NNP EMs)) (VP (VBD received) (NP (NP (CD 0.5) (NN mg)) (PP (IN of) (NP (NNP Doc_1848636_944_955_Chemical) (NNP s.c.)))) (PP (IN on) (NP (CD two) (JJ different) (NNS occasions))))) (: :) (S (LST (LS 1)) (-RRB- -RRB-) (NP (NP (NP (QP (CD 1) (CD hr))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT a) (NN placebo)))))) (CC and) (NP (CD 2))) (-RRB- -RRB-) (NP (CD 1) (NN hr) (SBAR (IN after) (S (NP (NP (CD 150) (NNS mg)) (PP (IN of) (NP (NNP Doc_1848636_1059_1069_Chemical)))) (VP (VBD p.o.) (SBAR (S (NP (CD Five) (NNS PMs)) (VP (AUX were) (VP (VBN studied) (PP (VBG according) (PP (TO to) (NP (DT the) (JJ same) (NN protocol)))) (, ,) (PP (IN except) (PP (IN for) (NP (NP (DT a) (JJR higher) (NNP Doc_1848636_1149_1160_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 0.75) (NN mg)) (-RRB- -RRB-)) (PP (IN on) (NP (NN day) (CD 2))))))))))))))) (. .)))
1848636	7	(S1 (S (NP (NP (NN Blood) (NNS samples)) (PP (IN for) (NP (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (NP (NN plasma) (NNP Doc_1848636_1227_1236_Chemical)) (, ,) (NP (NP (NNP Doc_1848636_1238_1249_Chemical)) (, ,) (NP (NP (NNP Doc_1848636_1251_1261_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ racemic)) (, ,) (NP (NNP R-) (CC and) (NNP S-isomer)) (-RRB- -RRB-)))) (, ,)))) (CC and) (NP (JJ Doc_1848636_1294_1317_Chemical) (NNS concentrations))))) (VP (AUX were) (VP (VBN taken) (PP (IN at) (NP (JJ regular) (NN time) (NNS intervals))) (, ,) (PP (IN during) (NP (NP (CD 8) (NN hr)) (PP (IN after) (NP (NNP Doc_1848636_1389_1399_Chemical))))))) (. .)))
1848636	8	(S1 (S (PP (IN In) (NP (NNP PMs))) (, ,) (NP (NNP Doc_1848636_1409_1419_Chemical)) (VP (VBD increased) (NP (DT the) (JJ Doc_1848636_1434_1445_Chemical) (NN area)) (PP (IN under) (NP (NP (DT the) (NN plasma) (NN concentration)) (CC vs.) (NP (NP (NN time) (NN curve)) (PRN (-LRB- -LRB-) (NP (CD +67) (NN %)) (-RRB- -RRB-)))))) (. .)))
1848636	9	(S1 (S (NP (NP (JJR Higher) (NNP Doc_1848636_1512_1522_Chemical/Doc_1848636_1523_1546_Chemical) (NNS ratios)) (PP (IN in) (NP (NNS PMs)))) (VP (AUX were) (ADJP (JJ predictive)) (PP (IN for) (NP (NP (JJR higher) (NN R-/S-isomer) (NNS ratios)) (PP (IN of) (NP (JJ unchanged) (NN drug)))))) (. .)))
1848636	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN difference)) (PP (IN in) (NP (JJ Doc_1848636_1652_1662_Chemical) (NN potency))) (PP (IN with) (NP (JJR higher) (JJ racemic) (NNP Doc_1848636_1691_1701_Chemical) (CD IC50) (NNS values))) (PP (IN in) (NP (NP (NNS PMs)) (PRN (-LRB- -LRB-) (NP (NP (CD 72) (NNS +/-)) (NP (CD 7) (NN ng.ml-1))) (-RRB- -RRB-)))) (PP (IN than) (NP (NP (NNP EMs)) (PRN (-LRB- -LRB-) (NP (NP (CD 42) (NNS +/-)) (NP (CD 8) (NN ng.ml-1))) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-)))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
18513945	0	(S1 (NP (NP (NP (DT The) (NNS hemodynamics)) (PP (IN of) (NP (NP (NNP Doc_18513945_20_28_Chemical)) (CC and) (NP (JJ other) (JJ vasoactive) (NNS agents)))) (PP (IN during) (NP (NP (JJ neuraxial) (NNS anesthesia)) (PP (IN for) (NP (JJ cesarean) (NN delivery)))))) (: :) (NP (NP (NNS findings)) (PP (IN in) (NP (CD six) (NNS cases)))) (. .)))
18513945	1	(S1 (S (NP (NN Doc_18513945_131_139_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN uterotonic)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (ADJP (ADJP (JJ significant)) (CC and) (ADJP (RB even) (JJ fatal))) (NN Doc_18513945_212_223_Disease)) (, ,) (SBAR (ADVP (RB particularly)) (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (DT a) (NN bolus)))))))))))) (. .)))
18513945	2	(S1 (S (NP (DT The) (JJ resulting) (NN Doc_18513945_275_286_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN produced) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (CC or) (NP (JJ cardiac) (NN output)))))) (PP (IN through) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ venous) (NN return)))))))) (. .)))
18513945	3	(S1 (S (NP (NP (NNS Parturients)) (PP (IN with) (NP (NP (JJ normal) (NN volume) (NN status)) (, ,) (NP (NN heart) (NNS valves)) (CC and) (NP (JJ pulmonary) (NN vasculature))))) (ADVP (RBS most) (RB often)) (VP (VB respond) (PP (TO to) (NP (DT this) (NN Doc_18513945_509_520_Disease))) (PP (IN with) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN Doc_18513945_568_574_Disease) (NN volume))))))) (. .)))
18513945	4	(S1 (S (NP (NP (JJ Doc_18513945_583_591_Chemical-induced) (NN Doc_18513945_600_611_Disease)) (PP (IN at) (NP (JJ cesarean) (NN delivery)))) (VP (MD may) (VP (AUX be) (VP (ADVP (RB incorrectly)) (VBN attributed) (PP (TO to) (NP (NNP Doc_18513945_666_676_Disease)))))) (. .)))
18513945	5	(S1 (S (NP (NP (NN Pulse) (NN power) (NN analysis)) (PRN (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN called) (S (`` ``) (NP (NN pulse) (NN contour) (NN analysis)) ('' ''))) (-RRB- -RRB-)) (PP (IN of) (NP (DT an) (JJ arterial) (NN pressure) (NN wave) (NN form)))) (VP (VBZ allows) (NP (NP (JJ continuous) (NN evaluation)) (PP (IN of) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (CC and) (NP (JJ cardiac) (NN output))))) (PP (IN in) (NP (JJ real) (NN time))) (, ,) (S (ADVP (RB thereby)) (VP (VBG elucidating) (NP (NP (DT the) (JJ causative) (NNS factors)) (PP (IN behind) (NP (NP (NNS changes)) (PP (IN in) (NP (NN blood) (NN pressure))))))))) (. .)))
18513945	6	(S1 (S (NP (NN Pulse) (NN power) (NN analysis)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (JJ cesarean) (NN delivery))) (VP (VBN performed) (PP (IN under) (NP (JJ neuraxial) (NN anesthesia)))))))) (. .)))
18513945	7	(S1 (S (NP (NP (NN Doc_18513945_1049_1060_Disease)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_18513945_1076_1084_Chemical)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ systemic) (NN vascular) (NN resistance)))) (CC and) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (NN Doc_18513945_1179_1185_Disease) (NN volume)) (, ,) (NP (NN heart) (NN rate)) (CC and) (NP (JJ cardiac) (NN output))))))))) (. .)))
18513945	8	(S1 (S (NP (NN Pulse) (NN power) (NN analysis)) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful) (PP (IN in) (S (VP (VP (VBG determining) (NP (DT the) (NN etiology)) (PP (IN of))) (CC and) (VP (VBG treating) (NP (NNP Doc_18513945_1305_1316_Disease)) (PP (IN during) (NP (NP (JJ cesarean) (NN delivery)) (PP (IN under) (NP (JJ neuraxial) (NNS anesthesia)))))))))))) (. .)))
18541230	0	(S1 (NP (NP (JJ Protective) (NNS effects)) (PP (IN of) (NP (NN antithrombin))) (PP (IN on) (NP (NP (NNP Doc_18541230_38_63_Chemical) (NNP Doc_18541230_64_73_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
18541230	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (FW antithrombin)) (, ,) (NP (NP (DT a) (NN plasma) (NN inhibitor)) (PP (IN of) (NP (NN coagulation) (NNS factors)))) (, ,))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_18541230_184_209_Chemical-induced) (NNP Doc_18541230_218_227_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ human) (NNP Doc_18541230_269_287_Disease))))))))))))) (. .)))
18541230	2	(S1 (S (NP (NP (NN Antithrombin)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 500)) (NNS IU/kg/i.v.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NNS rats))) (ADVP (RB once) (NP (DT a) (NN day))) (PP (IN for) (NP (CD 10) (NNS days))) (PP (ADVP (RB immediately)) (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_18541230_408_433_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg/i.v.)) (-RRB- -RRB-)))))))) (. .)))
18541230	3	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN antithrombin)))) (VP (VBD attenuated) (NP (DT the) (JJ Doc_18541230_494_519_Chemical-induced) (NNP Doc_18541230_528_555_Disease))) (. .)))
18541230	4	(S1 (S (NP (NP (JJ Doc_18541230_557_582_Chemical-induced) (NNP Doc_18541230_591_608_Disease)) (CC and) (NP (NNP Doc_18541230_613_627_Disease))) (VP (AUX were) (ADVP (RB also)) (VP (VBN suppressed))) (. .)))
18541230	5	(S1 (S (NP (JJ Histopathological) (NN examination)) (VP (VBD revealed) (NP (NP (JJ severe) (NN Doc_18541230_696_708_Disease)) (PP (JJ such) (IN as) (NP (NP (NP (NN proteinaceous) (VBZ casts)) (PP (IN in) (NP (NNS tubuli)))) (CC and) (NP (NP (JJ tubular) (NN expansion)) (PP (IN in) (NP (NP (DT the) (NN kidney)) (PP (IN of) (NP (NN control) (NNS rats))))))))) (, ,) (SBAR (IN while) (S (NP (NP (DT an) (NN improvement)) (PP (IN of) (NP (DT the) (NN damage)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (JJ antithrombin-treated) (NNS rats)))))))) (. .)))
18541230	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ antithrombin) (NN treatment)) (ADVP (RB markedly)) (VP (VBD suppressed) (NP (NP (JJ Doc_18541230_930_955_Chemical-induced) (NN apoptosis)) (PP (IN of) (NP (JJ renal) (JJ tubular) (NN epithelial) (NNS cells))))) (. .)))
18541230	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ Doc_18541230_1022_1047_Chemical-induced) (NNS increases)) (PP (IN in) (NP (JJ renal) (NN cytokine) (NN content)))) (VP (AUX were) (ADVP (RB also)) (VP (VBN decreased))) (. .)))
18541230	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN thrombin)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ Doc_18541230_1197_1222_Chemical-induced) (NN Doc_18541230_1231_1249_Disease))))))))) (. .)))
18541230	9	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN antithrombin)))) (VP (MD may) (VP (AUX be) (ADJP (RB clinically) (JJ effective)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18541230_1324_1342_Disease))))))) (. .)))
18589141	0	(S1 (NP (NP (JJ Doc_18589141_0_7_Chemical-induced) (NN Doc_18589141_16_32_Disease)) (PP (IN after) (NP (NN liver) (NN transplantation))) (. .)))
18589141	1	(S1 (S (NP (NP (NP (NNP Doc_18589141_74_103_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18589141_105_108_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_18589141_113_141_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP LMWH)) (-RRB- -RRB-)))) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (JJ anticoagulant) (NNS protocols))) (PP (IN at) (NP (JJ several) (NNS institutions))) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_18589141_219_229_Disease)) (PP (IN after) (NP (NN liver) (NN transplantation)))))))) (. .)))
18589141	2	(S1 (S (NP (NP (JJ Doc_18589141_259_266_Chemical-induced) (NNP Doc_18589141_275_291_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18589141_293_296_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ adverse) (JJ immune-mediated) (NN reaction)) (PP (TO to) (NP (NNP Doc_18589141_340_347_Chemical))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ platelet) (NN count) (NNS decreases)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 50)) (NN %)))))))) (. .)))
18589141	3	(S1 (S (NP (NP (DT The) (NNS frequencies)) (PP (IN of) (NP (NNP Doc_18589141_424_427_Disease))) (PP (IN after) (NP (NP (NP (NP (NN liver) (NN transplantation)) (CC and) (NP (NN platelet) (NN factor))) (JJ 4/Doc_18589141_478_485_Chemical-reactive) (NN antibody) (PRN (-LRB- -LRB-) (NNP Doc_18589141_505_508_Disease) (NN antibody) (-RRB- -RRB-)) (NN positivity)) (PP (IN in) (NP (NN liver) (NN transplantation) (NNS patients)))))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX are) (ADJP (JJ unknown))) (. .)))
18589141	4	(S1 (NP (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (S (NP (NP (DT The) (CD 32) (NNS men)) (CC and) (NP (CD 20) (NNS women))) (VP (VBD underwent) (S (VP (VBG living) (NP (NN donor) (NN liver) (NN transplantation)))))) (. .)))
18589141	5	(S1 (S (NP (PRP We)) (VP (VBD started) (NP (NP (NNP LMWH)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN IU/kg/h)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (JJ postoperative) (NN day)) (PRN (-LRB- -LRB-) (NP (NN POD)) (-RRB- -RRB-)))) (NP (CD 1)) (, ,) (S (VP (VBG switching) (PP (TO to) (NP (NP (NNP Doc_18589141_751_754_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5000) (NN U/d)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN POD) (QP (CD 2) (CC or) (CD 3))))))) (. .)))
18589141	6	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_18589141_793_796_Chemical)))) (VP (AUX was) (VP (VBN changed) (PP (VBG according) (PP (TO to) (NP (DT the) (VBN activated) (NN clotting) (NN time) (NN level)))))) (. .)))
18589141	7	(S1 (S (NP (NN Doc_18589141_857_860_Disease) (NN antibody) (NNS levels)) (VP (AUX were) (VP (VBN measured) (NP (NP (DT the) (NN day)) (PP (PP (IN before) (NP (NN surgery))) (CC and) (PP (IN on) (NP (NN POD) (CD 7) (CC and) (CD 14))))))) (. .)))
18589141	8	(S1 (S (NP (JJ Platelet) (NN count)) (VP (AUX was) (VP (VBN measured) (ADVP (RB daily)) (PP (IN for) (NP (CD 3) (NNS weeks))))) (. .)))
18589141	9	(S1 (S (S (NP (DT The) (JJ average) (NN platelet)) (VP (VBZ counts) (ADVP (RB preoperatively)))) (, ,) (CC and) (S (PP (IN on) (NP (NN POD) (CD 7))) (, ,) (NP (NP (CD 14)) (, ,) (CC and) (NP (CD 21))) (VP (AUX were) (NP (NP (NP (CD 65)) (, ,) (NP (CD 88)) (, ,) (NP (CD 149)) (, ,) (CC and) (NP (CD 169))) (NNP x) (CD 10) (-LRB- -LRB-) (CD 9) (-RRB- -RRB-) (NNS /L)) (, ,) (ADVP (RB respectively)))) (. .)))
18589141	10	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ hepatic) (NN artery) (NN Doc_18589141_1149_1159_Disease)) (PP (IN on) (NP (NN POD) (CD 11) (CC and) (CD 19))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN although) (S (S (NP (PRP they)) (VP (AUX were) (ADJP (NNP Doc_18589141_1211_1214_Disease) (JJ antibody-negative)))) (CC and) (S (NP (PRP$ their) (JJ platelet) (NNS counts)) (VP (AUX were) (ADJP (JJ stable))))))) (. .)))
18589141	11	(S1 (S (S (PP (IN In) (NP (CD 2) (JJ other) (NNS patients))) (, ,) (NP (DT the) (NN platelet) (NN count)) (VP (VBD decreased) (ADVP (RB suddenly)) (PP (IN from) (NP (CD 107))))) (NP (NP (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBD /L) (PP (IN on) (NP (NN POD))) (SBAR (S (NP (NP (QP (CD 4) (TO to) (CD 65)) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ /L) (PP (PP (IN on) (NP (NN POD) (CD 6))) (CC and) (PP (IN from) (NP (NP (CD 76) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-)) (VP (VBN /L) (PP (IN on) (NP (NP (NN POD)) (SBAR (S (NP (NP (QP (CD 7) (TO to) (CD 33)) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBD /L) (PP (IN on) (NP (NN POD) (CD 9))) (, ,) (ADVP (RB respectively))))))))))))))) (. .)))
18589141	12	(S1 (S (NP (DT The) (JJ Doc_18589141_1459_1466_Chemical-induced) (NN Doc_18589141_1475_1495_Disease) (NN test)) (VP (AUX was) (ADJP (JJ negative)) (PP (IN in) (NP (DT these) (NNS patients)))) (. .)))
18589141	13	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ Doc_18589141_1551_1554_Disease) (JJ antibody-positive) (NNS patients)))) (VP (AUX was) (NP (NP (NP (CD 0.5) (NN %)) (ADVP (RB preoperatively))) (, ,) (NP (NP (CD 5.6) (NN %)) (PP (IN on) (NP (NN POD) (CD 7)))) (, ,) (CC and) (NP (NP (CD 5.6) (NN %)) (PP (IN on) (NP (NN POD) (CD 14)))))) (. .)))
18589141	14	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS subjects/patients)))) (VP (VBD developed) (NP (JJ Doc_18589141_1682_1685_Chemical-related) (NN Doc_18589141_1694_1697_Disease))) (. .)))
18589141	15	(S1 (S (PP (IN In) (NP (PRP$ our) (NN series))) (, ,) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18589141_1745_1748_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation)))) (VP (AUX was) (ADJP (JJ uncommon))) (. .)))
18627295	0	(S1 (S (NP (NP (JJ Doc_18627295_0_11_Chemical) (JJ Doc_18627295_12_26_Disease-induced) (NN Doc_18627295_35_47_Disease)) (CC and) (NP (NN apoptosis))) (VP (AUX are) (VP (VBN attenuated) (PP (IN by) (NP (NP (NN gene) (NN deletion)) (PP (IN of) (NP (DT the) (JJ kinin) (JJ B1) (NN receptor))))))) (. .)))
18627295	1	(S1 (S (NP (NP (JJ Clinical) (NN use)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18627295_140_153_Chemical) (NNP Doc_18627295_154_165_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18627295_167_170_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (VP (VBN limited) (PP (IN by) (NP (NP (PRP$ its) (JJ Doc_18627295_190_201_Disease) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNS apoptosis))))))))))))) (. .)))
18627295	2	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ possible) (NN role)) (PP (IN of) (NP (NP (DT the) (JJ kinin) (JJ B1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP B1R)) (-RRB- -RRB-))))) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18627295_351_354_Chemical) (NNP Doc_18627295_355_369_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (NNP B1R) (NN knockout) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (NNP B1R)) (PRN (-LRB- -LRB-) (NP (NN -/-)) (-RRB- -RRB-))) (-RRB- -RRB-))) (PP (IN by) (S (VP (VBG investigating) (NP (JJ cardiac) (NN Doc_18627295_436_448_Disease) (CC and) (NN apoptosis)) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (JJ Doc_18627295_482_485_Chemical-induced) (NNP Doc_18627295_494_508_Disease))))))))) (. .)))
18627295	3	(S1 (S (NP (JJ Doc_18627295_510_513_Chemical) (NN control) (NNS mice)) (VP (VBD showed) (NP (NP (NN Doc_18627295_534_553_Disease)) (VP (VBN measured) (PP (IN by) (NP (NP (JJ pressure-volume) (NNS loops)) (PP (IN in) (NP (NN vivo)))))))) (. .)))
18627295	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (VBN reduced) (NN activation) (NN state)) (PP (IN of) (NP (NP (NNP AKT)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT an) (VBN increased) (NN bax/bcl2) (NN ratio)) (PP (IN in) (NP (JJ Western) (NNS blots)))))))) (, ,) (S (VP (VBG indicating) (NP (NNP Doc_18627295_725_742_Disease)))))) (. .)))
18627295	5	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN mRNA) (NNS levels)) (PP (IN of) (NP (DT the) (NN proinflammatory) (NN cytokine) (NN interleukin) (CD 6)))) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ cardiac) (NN tissue))))) (. .)))
18627295	6	(S1 (S (PP (IN In) (NP (NNP Doc_18627295_856_859_Chemical) (NNP B1R) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice))) (, ,) (NP (NNP Doc_18627295_875_894_Disease)) (VP (AUX was) (VP (VBN improved) (PP (VBN compared) (PP (TO to) (NP (NP (JJ Doc_18627295_920_923_Chemical) (NN control) (NNS mice)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (NN normalization)) (PP (IN of) (NP (DT the) (JJ bax/bcl-2) (NN ratio)))) (CC and) (NP (NN interleukin) (CD 6))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ AKT) (NN activation) (NN state))))))))))))) (. .)))
18627295	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP B1R)) (VP (AUX is) (ADJP (JJ detrimental)) (PP (IN in) (NP (NP (NNP Doc_18627295_1103_1106_Chemical) (NNP Doc_18627295_1107_1121_Disease)) (SBAR (WHPP (IN in) (WHNP (WDT that))) (S (NP (PRP it)) (VP (VBZ mediates) (NP (DT the) (JJ inflammatory) (NN response) (CC and) (NN apoptosis))))))))))) (. .)))
18627295	8	(S1 (S (NP (DT These) (NNS insights)) (VP (MD might) (VP (AUX have) (NP (NP (JJ useful) (NNS implications)) (PP (IN for) (NP (NP (JJ future) (NNS studies)) (VP (VBG utilizing) (NP (NNP B1R) (NNS antagonists)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ human) (NNP Doc_18627295_1297_1300_Chemical) (NNP Doc_18627295_1301_1315_Disease))))))))))) (. .)))
18657397	0	(S1 (NP (NP (JJ Detailed) (JJ spectral) (NN profile) (NN analysis)) (PP (IN of) (NP (NP (NNP Doc_18657397_38_48_Chemical-induced) (NNP Doc_18657397_57_78_Disease)) (PP (IN in) (NP (JJ anesthetized) (NNS rats))))) (. .)))
18657397	1	(S1 (S (NP (JJ Doc_18657397_101_111_Chemical) (NN model)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ experimental) (NN model)) (PP (IN for) (NP (JJ Doc_18657397_158_166_Disease) (NN research))))) (. .)))
18657397	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB portray) (NP (NP (DT a) (JJ detailed) (JJ spectral) (NN analysis)) (PP (IN of) (NP (NNP Doc_18657397_250_260_Chemical-induced) (NNP Doc_18657397_269_290_Disease)))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (JJ basal) (NN brain) (NN activity)) (PP (IN in) (NP (JJ anesthetized) (JJ Wistar) (NNS rats))))))))))) (. .)))
18657397	3	(S1 (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (ADJP (ADJP (JJ anesthetized) (PP (IN with) (NP (NNP i.p.) (NNP Doc_18657397_405_413_Chemical)))) (CC and) (ADJP (JJ connected) (PP (TO to) (NP (DT an) (JJ electrocorticogram) (NN setup)))))) (. .)))
18657397	4	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ short) (NN period)) (PP (IN of) (NP (JJ basal) (NN activity) (VBG recording))))) (, ,) (NP (NNP Doc_18657397_510_519_Disease) (NN focus)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (S (VP (VBG injecting) (NP (JJ 400IU/2) (NN microl) (NN Doc_18657397_566_588_Chemical)) (PP (IN into) (NP (DT the) (JJ left) (JJ lateral) (NN ventricle))) (SBAR (IN while) (S (NP (DT the) (JJ cortical) (NN activity)) (VP (AUX was) (ADVP (RB continuously)) (VP (VBN recorded)))))))))) (. .)))
18657397	5	(S1 (S (NP (NP (JJ Basal) (NN activity)) (, ,) (NP (NN latent) (NN period)) (CC and) (NP (DT the) (JJ Doc_18657397_714_724_Chemical-induced) (NN Doc_18657397_733_754_Disease) (NNS periods))) (VP (AUX were) (ADVP (RB then)) (VP (VBN analyzed) (S (VP (VBG using) (NP (NP (DT both) (JJ conventional) (NNS methods)) (CC and) (NP (JJ spectral) (NN analysis))))))) (. .)))
18657397	6	(S1 (S (NP (JJ Spectral) (NNS analyses)) (VP (AUX were) (VP (VBN conducted) (PP (IN by) (S (VP (VBG dividing) (NP (DT the) (JJ whole) (NN spectrum)) (PP (IN into) (NP (NP (JJ different) (NN frequency) (NNS bands)) (VP (VBG including) (NP (NP (NP (NN delta)) (, ,) (NP (NN theta)) (PRN (-LRB- -LRB-) (ADJP (JJ slow) (CC and) (JJ fast)) (-RRB- -RRB-)) (, ,) (NP (NN alpha-sigma)) (, ,) (NP (NP (NN beta)) (PRN (-LRB- -LRB-) (NP (CD 1) (CC and) (CD 2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN gamma)) (PRN (-LRB- -LRB-) (NP (CD 1) (CC and) (CD 2)) (-RRB- -RRB-)))) (NNS bands)))))))))) (. .)))
18657397	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (S (NP (DT the) (JJS most) (JJ affected) (NN frequency) (NNS bands)) (VP (AUX were) (NP (NN delta) (, ,) (NN theta) (, ,) (NN beta-2) (CC and) (NN gamma-2) (NNS bands)) (PP (IN during) (NP (DT the) (NNP Doc_18657397_1138_1159_Disease))))) (CC and) (S (NP (EX there)) (VP (AUX were) (NP (NP (JJ marked) (NNS differences)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ spectral) (NNS densities)) (PP (IN between) (NP (NP (CD three) (VBN investigated) (NNS episodes)) (PRN (-LRB- -LRB-) (NP (NP (JJ basal) (NN activity)) (, ,) (NP (NN latent) (NN period)) (CC and) (NP (NNP Doc_18657397_1296_1317_Disease))) (-RRB- -RRB-)))))))))))))) (. .)))
18657397	8	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (MD may) (VP (VB help) (S (VP (TO to) (VP (VB analyze) (NP (NP (JJ novel) (NNS data)) (VP (VBN obtained) (S (VP (VBG using) (SBAR (S (NP (NP (NP (JJ similar) (JJ experimental) (NNS models)) (CC and) (NP (DT the) (JJ simple) (NN analysis) (NN method))) (VP (VBD described) (ADVP (RB here)))) (VP (MD can) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (JJ similar) (NNS studies))) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ basic) (JJ neuronal) (NN mechanism)) (PP (IN of) (NP (NP (DT this)) (CC or) (NP (NP (JJ other) (NNS types)) (PP (IN of) (NP (JJ experimental) (NN Doc_18657397_1566_1576_Disease)))))))))))))))))))))))) (. .)))
18674790	0	(S1 (S (NP (JJ High) (JJ Doc_18674790_5_8_Chemical) (JJ diet-fed) (NN Doc_18674790_18_23_Disease) (NNS rats)) (VP (AUX are) (ADJP (RB highly) (JJ sensitive) (PP (TO to) (NP (NNP Doc_18674790_53_64_Chemical-induced) (NNP Doc_18674790_73_87_Disease))))) (. .)))
18674790	1	(S1 (S (ADVP (RB Often)) (, ,) (NP (NP (NN chemotherapy)) (PP (IN by) (NP (NP (NNP Doc_18674790_112_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18674790_125_135_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (VP (VBN limited) (PP (JJ due) (TO to) (NP (NP (NN life)) (VP (VBG threatening) (NP (NNP Doc_18674790_172_186_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN during) (CC and) (NP (NN posttherapy)))))))))) (. .)))
18674790	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ moderate) (NN diet) (NN restriction)) (ADVP (RB remarkably)) (VP (VBZ protects) (PP (IN against) (NP (NNP Doc_18674790_306_317_Chemical-induced) (NNP Doc_18674790_326_340_Disease)))))))) (. .)))
18674790	3	(S1 (S (NP (DT This) (NN cardioprotection)) (VP (AUX is) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (VBN decreased) (JJ cardiac) (NN oxidative) (NN stress)) (CC and) (NP (ADJP (JJ Doc_18674790_421_434_Chemical) (CC and) (JJ increased)) (JJ cardiac) (JJ fatty-acid) (NN oxidation))) (, ,) (NP (JJ Doc_18674790_479_482_Chemical) (NN synthesis)) (, ,) (CC and) (NP (JJ upregulated) (JJ JAK/STAT3) (NN pathway)))))) (. .)))
18674790	4	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (DT a) (JJ physiological) (NN intervention)) (PP (IN by) (S (VP (VBG feeding) (NP (NP (ADJP (CD 40) (NN %)) (JJ high) (JJ Doc_18674790_624_627_Chemical) (NN diet)) (PRN (-LRB- -LRB-) (NP (NNP HFD)) (-RRB- -RRB-)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ induces) (NP (NNP Doc_18674790_654_661_Disease)) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 250-275) (NNP g)) (-RRB- -RRB-))))))) (, ,)) (VP (VBZ sensitizes) (PP (TO to) (NP (NNP Doc_18674790_717_728_Chemical-induced) (NNP Doc_18674790_737_751_Disease))))))) (. .)))
18674790	5	(S1 (S (NP (NP (DT A) (JJ LD) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-)) (NN dose)) (PRN (-LRB- -LRB-) (NP (QP (CD 8) (CD mg)) (NN Doc_18674790_773_784_Chemical/kg)) (, ,) (NP (NN ip)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN on) (NP (NP (NN day) (CD 43)) (PP (IN of) (NP (DT the) (NNP HFD) (NN feeding) (NN regimen))))))) (VP (VBD led) (PP (TO to) (NP (NP (JJR higher) (NN Doc_18674790_857_871_Disease)) (, ,) (NP (NNP Doc_18674790_873_892_Disease)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (CC and) (NP (NP (ADJP (CD 80) (NN %)) (NN mortality)) (PP (IN in) (NP (NP (DT the) (NNP Doc_18674790_939_944_Disease) (PRN (-LRB- -LRB-) (NNP Doc_18674790_946_948_Disease) (-RRB- -RRB-)) (NNS rats)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT any) (JJ significant) (NN Doc_18674790_989_1014_Disease))))))))))) (. .)))
18674790	6	(S1 (S (NP (JJ Doc_18674790_1016_1027_Chemical) (NN toxicokinetics) (NNS studies)) (VP (VBD revealed) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN accumulation)) (PP (IN of) (NP (NP (NNP Doc_18674790_1089_1100_Chemical)) (CC and) (NP (NP (NNP Doc_18674790_1105_1118_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ toxic) (NN metabolite)) (-RRB- -RRB-))))))) (PP (IN in) (NP (DT the) (JJ normal) (JJ diet-fed) (PRN (-LRB- -LRB-) (CD ND) (-RRB- -RRB-)) (CC and) (NNP Doc_18674790_1170_1172_Disease) (NNS hearts))))) (. .)))
18674790	7	(S1 (S (NP (JJ Mechanistic) (NNS studies)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Doc_18674790_1215_1217_Disease) (NNS rats)) (VP (AUX are) (VP (VBN sensitized) (S (ADJP (JJ due) (PP (TO to) (NP (NP (: :) (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (JJR higher) (JJ oxyradical) (NN stress)) (VP (VBG leading) (PP (TO to) (NP (NN upregulation)) (PP (IN of) (NP (NP (VBG uncoupling) (NNS proteins)) (SBAR (S (NP (NP (CD 2) (CC and) (CD 3) (, ,) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN downregulation)) (PP (IN of) (NP (JJ cardiac) (NN peroxisome) (NNS proliferators))) (VP (VBN activated) (NP (NN receptor-alpha)) (PRN (, ,) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))) (VP (VBD decreased) (SBAR (S (NP (NP (NN plasma) (NN adiponectin) (NNS levels)) (PRN (, ,) (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (JJ cardiac) (JJ fatty-acid) (NN oxidation))))))))))))) (-LRB- -LRB-) (NP (NP (QP (CD 666.9+/-14.0) (CD nmol/min/g)) (NN heart)) (PP (IN in) (NP (NNP ND)))) (CC versus) (NP (NP (QP (CD 400.2+/-11.8) (CD nmol/min/g)) (NN heart)) (PP (IN in) (NP (NNP Doc_18674790_1573_1575_Disease)))) (-RRB- -RRB-))))) (, ,) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (VP (VBN decreased) (NP (NP (JJ mitochondrial) (JJ Doc_18674790_1606_1609_Chemical-alpha2) (NN protein) (NN kinase)) (, ,) (CC and) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NP (CD 86) (NN %) (NN drop))) (PP (IN in) (NP (NP (JJ cardiac) (JJ Doc_18674790_1661_1664_Chemical) (NNS levels)) (VP (VBN accompanied) (PP (IN by) (NP (NP (VBN decreased) (JJ Doc_18674790_1697_1700_Chemical/Doc_18674790_1701_1704_Chemical) (NN ratio)) (PP (IN after) (NP (NNP Doc_18674790_1717_1728_Chemical) (NN administration)))))))))))))) (. .)))
18674790	8	(S1 (S (NP (NP (VBN Decreased) (JJ cardiac) (NN erythropoietin)) (CC and) (NP (VBN increased) (NNS SOCS3))) (ADVP (RB further)) (VP (VBD downregulated) (NP (DT the) (JJ cardioprotective) (NN JAK/STAT3) (NN pathway))) (. .)))
18674790	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ HFD-induced) (NNP Doc_18674790_1887_1892_Disease) (NNS rats)) (VP (AUX are) (ADVP (RB highly)) (VP (VBN sensitized) (PP (TO to) (NP (NNP Doc_18674790_1923_1934_Chemical-induced) (NNP Doc_18674790_1943_1957_Disease))) (PP (IN by) (S (VP (VP (ADVP (RB substantially)) (VBG downregulating) (NP (JJ cardiac) (JJ mitochondrial) (JJ Doc_18674790_2012_2015_Chemical) (NN generation))) (, ,) (VP (VBG increasing) (NP (JJ oxidative) (NN stress))) (CC and) (VP (VBG downregulating) (NP (DT the) (JJ JAK/STAT3) (NN pathway)))))))) (. .)))
18808529	0	(S1 (S (NP (NN Doc_18808529_0_13_Chemical)) (VP (VBZ induces) (NP (NP (NP (JJ primary) (NN loss)) (PP (IN of) (NP (NN dystrophin))) (PP (IN in) (NP (NN rat) (NNS hearts)))) (: :) (NP (NP (NN correlation)) (PP (IN with) (NP (NNP Doc_18808529_81_98_Disease)))))) (. .)))
18808529	1	(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_18808529_117_130_Chemical-induced) (NNP Doc_18808529_139_156_Disease)))) (VP (AUX is) (ADJP (JJ unknown)))) (, ,) (CC but) (S (NP (NP (DT a) (NN mismatch)) (PP (IN of) (NP (NP (JJ Doc_18808529_187_193_Chemical) (NN supply)) (CC vs.) (NP (NP (NN demand)) (PP (VBG following) (NP (NP (JJ coronary) (NNP Doc_18808529_231_242_Disease)) (CC and) (NP (NNP Doc_18808529_247_271_Disease)))))))) (VP (AUX is) (NP (NP (DT the) (JJS best) (NN explanation)) (PP (IN for) (NP (NP (DT the) (JJ complex) (JJ morphological) (NNS alterations)) (VP (VBN observed))))))) (. .)))
18808529	2	(S1 (S (NP (NP (JJ Severe) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NN integrity)) (PP (IN of) (NP (NP (DT the) (NN sarcolemma)) (PP (IN of) (NP (NNS cardiomyocytes)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NN Doc_18808529_470_483_Chemical)))))))))) (. .)))
18808529	3	(S1 (S (S (VP (VBG Taking) (PP (IN into) (NP (NN account))) (SBAR (IN that) (S (NP (DT the) (JJ sarcolemmal) (NN integrity)) (VP (AUX is) (VP (VBN stabilized) (PP (PP (IN by) (NP (NP (DT the) (JJ dystrophin-glycoprotein) (NN complex)) (PRN (-LRB- -LRB-) (NP (NNP DGC)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBZ connects) (NP (NN actin) (CC and) (NN laminin)) (PP (IN in) (NP (NP (JJ contractile) (NN machinery)) (CC and) (NP (JJ extracellular) (NNP matrix))))))))) (CC and) (PP (IN by) (NP (NNS integrins)))))))))) (, ,) (NP (DT this) (NN study)) (VP (VBZ tests) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_18808529_732_745_Chemical)) (VP (VBZ affects) (NP (JJ sarcolemmal) (NN stability)) (PP (IN through) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NNS DGC) (CC and) (NNS integrins)))))))))) (. .)))
18808529	4	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (JJ different) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN DGC) (CC and) (NN integrin)))) (PP (TO to) (NP (JJ Doc_18808529_876_889_Chemical) (NN subcutaneous) (NN administration)))) (. .)))
18808529	5	(S1 (S (NP (JJ Immunofluorescent) (NN staining)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN dystrophin)) (VP (AUX is) (NP (NP (DT the) (RBS most) (JJ sensitive)) (PP (IN among) (NP (NP (DT the) (NNS structures)) (VP (VBG connecting) (NP (DT the) (NN actin)) (PP (IN in) (NP (NP (DT the) (JJ cardiomyocyte) (NN cytoskeleton)) (CC and) (NP (DT the) (JJ extracellular) (NNP matrix)))))))))))) (. .)))
18808529	6	(S1 (S (NP (DT The) (JJ sarcomeric) (NN actin) (NN dissolution)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT the) (NN reduction) (CC or) (NN loss)) (PP (IN of) (NP (NN dystrophin)))))) (. .)))
18808529	7	(S1 (S (ADVP (RB Subsequently)) (, ,) (PP (IN after) (NP (NP (NN lysis)) (PP (IN of) (NP (NNS myofilaments))))) (, ,) (NP (NP (JJ gamma-sarcoglycan)) (, ,) (NP (JJ beta-dystroglycan)) (, ,) (NP (JJ beta1-integrin)) (, ,) (CC and) (NP (JJ laminin) (JJ alpha-2) (NNS expressions))) (VP (AUX were) (VP (VBN reduced) (PP (VBN followed) (PP (IN by) (NP (PRP$ their) (NN breakdown)))) (, ,) (PP (IN as) (NP (NP (NN epiphenomena)) (PP (IN of) (NP (DT the) (JJ myocytolytic) (NN process))))))) (. .)))
18808529	8	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_18808529_1433_1446_Chemical))) (PP (TO to) (NP (NNS rats)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ primary) (NN loss)) (PP (IN of) (NP (NN dystrophin))))) (, ,) (S (NP (NP (DT the) (RBS most) (JJ sensitive)) (PP (IN among) (NP (NP (DT the) (JJ structural) (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (DT the) (NN DGC)) (SBAR (WHNP (WDT that)) (S (VP (VBZ connects) (NP (NP (DT the) (JJ extracellular) (NNP matrix)) (CC and) (NP (NP (DT the) (NN cytoskeleton)) (PP (IN in) (NP (NN cardiomyocyte))))))))))))))))) (. .)))
18808529	9	(S1 (S (NP (NP (DT These) (NNS changes)) (, ,) (VP (VBN related) (PP (TO to) (NP (NNP Doc_18808529_1665_1681_Disease)))) (, ,)) (VP (VBP explain) (NP (NP (NP (DT the) (JJ severe) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NN integrity)) (PP (IN of) (NP (NP (DT the) (NN sarcolemma)) (PP (IN of) (NP (NNS cardiomyocytes)))))))) (CC and) (NP (NP (RB hence) (JJ severe) (CC and) (JJ irreversible) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18808529_1830_1843_Chemical))))))) (. .)))
188339	0	(S1 (S (NP (NP (JJ Etiologic) (NNS factors)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_188339_41_53_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_188339_70_89_Chemical)))) (. .)))
188339	1	(S1 (S (PP (IN Within) (NP (DT the) (JJ last) (JJ several) (NNS years))) (, ,) (NP (ADJP (RB previously) (JJ rare)) (NNP Doc_188339_138_150_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (NP (JJ young) (NNS women)) (VP (VBG using) (NP (NNP Doc_188339_187_205_Chemical) (NNP Doc_188339_206_214_Chemical)))))))) (. .)))
188339	2	(S1 (S (NP (NP (DT The) (NNP Registry)) (PP (IN for) (NP (NP (NP (NNP Doc_188339_233_245_Disease) (NNP Associated)) (PP (IN with) (NP (NNP Doc_188339_262_281_Chemical))) (PP (IN at) (NP (NP (DT the) (NNP University)) (PP (IN of) (NP (NNP California)))))) (, ,) (NP (NNP Irvine)) (, ,)))) (VP (AUX has) (ADVP (RB clearly)) (VP (VBN identified) (NP (CD 27) (NNS cases)))) (. .)))
188339	3	(S1 (S (NP (DT The) (JJ recent) (NN literature)) (VP (VBZ contains) (NP (CD 44) (NN case) (NNS reports))) (. .)))
188339	4	(S1 (S (NP (NP (NN Common)) (PP (TO to) (NP (DT these) (CD 71) (NNS cases)))) (VP (AUX has) (VP (AUX been) (NP (NP (DT a) (JJ histopathologic) (NN diagnosis)) (PP (IN of) (NP (NP (NNP Doc_188339_469_494_Disease)) (, ,) (NP (NNP Doc_188339_496_503_Disease)) (, ,) (NP (NNP Doc_188339_505_514_Disease)) (, ,) (CC and) (NP (NNP Doc_188339_520_528_Disease))))))) (. .)))
188339	5	(S1 (S (NP (JJ Significant) (JJ statistical) (JJ etiologic) (NNS factors)) (VP (VBP include) (NP (NP (JJ prolonged) (JJ uninterrupted) (NN usage)) (PP (IN of) (NP (NNP Doc_188339_613_631_Chemical) (NNP Doc_188339_632_640_Chemical))))) (. .)))
188339	6	(S1 (S (NP (NP (NP (CD Eight) (NNS deaths)) (CC and) (NP (NN liver) (NN Doc_188339_665_672_Disease))) (PP (IN in) (NP (CD 18) (NNS patients)))) (VP (VB attest) (PP (TO to) (NP (NP (DT the) (NN seriousness)) (PP (IN of) (NP (DT this) (JJ new) (ADJP (RB potentially) (JJ lethal)) (JJ adverse) (NN phenomenon)))))) (. .)))
1899352	0	(S1 (NP (NP (JJ Doc_1899352_0_10_Chemical) (JJ continuous) (NN infusion)) (PP (IN without) (NP (NNP Doc_1899352_39_44_Chemical))) (. .)))
1899352	1	(S1 (NP (NP (DT A) (NN phase) (NN I) (NN trial)) (PP (IN of) (NP (DT a) (JJ 14-day) (NN cycle))) (. .)))
1899352	2	(S1 (S (NP (CD Twenty) (NNS patients)) (VP (VBD received) (NP (NP (CD 27) (NNS courses)) (PP (IN of) (NP (NNP Doc_1899352_120_130_Chemical))) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ 24-hour) (JJ continuous) (NN infusion)) (PP (IN for) (NP (NP (CD 14) (NNS days)) (PP (IN without) (NP (NNP Doc_1899352_197_202_Chemical)))))))))) (. .)))
1899352	3	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB deliver) (NP (NP (DT a) (NN dose) (NN rate)) (CC and) (NP (NP (JJ total) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_1899352_282_292_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (AUX be) (ADJP (JJ comparable) (PP (TO to) (NP (NP (NP (JJ standard) (NNS bolus)) (CC or) (NP (JJ short-term) (NNS infusions))) (VP (VBN administered) (PP (IN with) (NP (NNP Doc_1899352_378_383_Chemical))))))))))))))))) (. .)))
1899352	4	(S1 (S (NP (NN Dose) (NNS escalations)) (VP (VBD proceeded) (PP (IN from) (NP (NP (QP (CD 200) (TO to) (CD 300))) (, ,) (NP (CD 400)) (, ,) (NP (CD 450)) (, ,) (NP (CD 500)) (, ,) (CC and) (NP (QP (CD 550) (CD mg/m2/d)))))) (. .)))
1899352	5	(S1 (S (NP (CD Four) (NNS patients)) (VP (VBD developed) (NP (JJ transient) (JJ microscopic) (NN Doc_1899352_507_516_Disease)) (PP (IN at) (NP (NP (CD 400)) (, ,) (NP (CD 450)) (, ,) (CC and) (NP (CD 500) (NN mg/m2/d))))) (. .)))
1899352	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS instances)) (PP (IN of) (NP (JJ macroscopic) (NNP Doc_1899352_586_595_Disease))))) (. .)))
1899352	7	(S1 (S (PP (IN At) (NP (CD 550) (CD mg/m2/d))) (, ,) (NP (CD three) (NNS patients)) (VP (VBD experienced) (NP (NP (JJ nonurologic) (NNP Doc_1899352_652_660_Disease)) (: ;) (NP (NP (NNP Doc_1899352_662_671_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1899352_677_683_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Grade) (CD 2) (NNP Doc_1899352_701_711_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
1899352	8	(S1 (S (NP (NP (DT The) (JJ recommended) (NN dose)) (PP (IN of) (NP (CD 500) (NNS mg/m2/d)))) (VP (VBZ delivers) (NP (NP (DT a) (JJ total) (NN dose)) (PP (IN of) (NP (CD 7) (NN g/m2))) (PP (IN per) (NP (NP (NN cycle)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (VP (VBN delivered) (PP (IN in) (NP (NP (JJ clinical) (NN practice)) (PP (IN for) (NP (NP (NN bolus)) (CC or) (NP (JJ short-term) (NN infusion))))))))))))))))) (. .)))
1899352	9	(S1 (S (PP (IN Because) (NP (NP (JJ few) (NNS patients)) (VP (VBN received) (NP (JJ multiple) (NNS courses)) (PP (IN over) (NP (NN time)))))) (, ,) (NP (DT the) (JJ cumulative) (NNS effects)) (VP (AUX are) (ADJP (JJ indeterminate)) (PP (IN in) (NP (DT the) (JJ present) (NN trial)))) (. .)))
1899352	10	(S1 (S (S (NP (NP (DT The) (NN frequency) (CC and) (NN predictability)) (PP (IN of) (NP (NNP Doc_1899352_1046_1055_Disease)))) (VP (AUX are) (RB not) (ADJP (JJ precise)))) (, ,) (CC and) (S (NP (NP (ADVP (IN at) (JJS least)) (JJ daily) (NN monitoring)) (PP (IN by) (NP (NN urine) (NN Hematest)))) (VP (AUX is) (ADJP (JJ essential)) (, ,) (S (VP (VBG adding) (NP (NN Doc_1899352_1142_1147_Chemical)) (PP (TO to) (NP (NP (DT the) (NN infusate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ persistent) (NNP Doc_1899352_1192_1201_Disease))))))))))) (. .)))
1899352	11	(S1 (S (NP (NP (DT The) (JJ protracted) (NN infusion) (NN schedule)) (PP (IN for) (NP (NNP Doc_1899352_1240_1250_Chemical)))) (VP (VP (VBZ permits) (NP (JJ convenient) (NN outpatient) (NN administration)) (PP (IN without) (NP (NNP Doc_1899352_1304_1309_Chemical)))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN drug) (NN cost)) (PP (IN of) (NP (NP (JJ clinical) (NN usage)) (PP (IN of) (NP (DT this) (NN agent)))))) (PP (IN by) (NP (NP (QP (IN up) (TO to) (CD 890))) (PP (IN per) (NP (NN cycle))))))) (. .)))
1899352	12	(S1 (S (S (NP (JJ Clinical) (NN activity)) (VP (AUX was) (VP (VBN demonstrated) (PP (IN in) (NP (DT a) (JJ single) (NN patient)))))) (, ,) (CC but) (S (NP (NP (DT a) (JJ comparative) (NN trial)) (PP (IN of) (NP (JJ standard) (JJ bolus) (NNS schedules))) (PP (IN with) (NP (DT the) (JJ protracted) (NN infusion) (NN schedule)))) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ clinical) (NN effectiveness)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX is) (VP (VBN maintained)))))))))))) (. .)))
18997632	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_18997632_10_33_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_18997632_45_53_Chemical) (NN pretreatment)))) (. .)))
18997632	1	(S1 (S (NP (JJ Suboptimal) (NN Doc_18997632_79_86_Disease) (NN duration)) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN encountered) (PP (IN in) (NP (JJ electroconvulsive) (NN therapy) (NN practice))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (JJR older) (NNS patients)) (PP (IN with) (NP (JJR higher) (NNP Doc_18997632_200_207_Disease) (NNS thresholds))))))) (. .)))
18997632	2	(S1 (S (NP (JJ Intravenous) (NNP Doc_18997632_232_240_Chemical)) (VP (VP (AUX is) (ADVP (RB commonly)) (VP (VBN used) (S (VP (TO to) (VP (VB improve) (NP (NP (NNP Doc_18997632_269_276_Disease) (NN duration) (CC and) (NN quality)) (PP (IN in) (NP (JJ such) (NNS patients))))))))) (CC and) (VP (AUX is) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated) (PRT (RP aside)) (PP (IN from) (NP (NP (JJ occasional) (NNS reports)) (PP (IN of) (NP (ADJP (RB relatively) (JJ benign)) (NNP Doc_18997632_398_416_Disease)))))))) (. .)))
18997632	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (DT no) (JJ previous) (NN history)) (PP (IN of) (NP (NP (NNP Doc_18997632_468_483_Disease) (CC or) (NNP Doc_18997632_487_497_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (JJ sustained) (NN bigeminy)) (CC and) (NP (CD 2) (JJ brief) (NNS runs))) (PP (IN of) (NP (NNP Doc_18997632_551_574_Disease)))) (PP (IN after) (NP (NNP Doc_18997632_581_589_Chemical) (NN administration)))))))))))) (. .)))
18997632	4	(S1 (S (SBAR (IN Although) (S (NP (JJ intravenous) (NNP Doc_18997632_627_635_Chemical)) (VP (AUX is) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated))))) (, ,) (NP (DT the) (NN clinician)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (ADJP (JJ unpredictable) (CC and) (JJ serious)) (NNP Doc_18997632_742_765_Disease)))))))) (. .)))
19058474	0	(S1 (NP (NP (JJ Fatal) (NNP Doc_19058474_6_22_Disease) (CC and) (NNP Doc_19058474_27_55_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ possible) (NN interaction)) (PP (IN of) (NP (NN cranberry) (NN juice))) (PP (IN with) (NP (NNP Doc_19058474_108_116_Chemical)))))) (. .)))
19058474	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ fatal) (JJ internal) (NN Doc_19058474_153_164_Disease)))) (PP (IN in) (NP (NP (DT an) (JJ elderly) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD consumed) (NP (ADJP (RB only) (JJ cranberry)) (NN juice)) (PP (IN for) (NP (CD two) (NNS weeks))) (SBAR (IN while) (S (VP (VBG maintaining) (NP (NP (PRP$ his) (JJ usual) (NN dosage)) (PP (IN of) (NP (NNP Doc_19058474_269_277_Chemical))))))))))))) (. .)))
19058474	2	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (IN that) (S (NP (NP (ADJP (RB naturally) (VBG occurring)) (NNS compounds)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19058474_333_343_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADJP (JJ present)) (PP (IN in) (NP (NN fruit) (NNS juices)))))) (, ,)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NNP Doc_19058474_408_416_Chemical)))) (PP (IN by) (S (VP (VBG competing) (PP (IN for) (NP (NP (DT the) (NNS enzymes)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBP inactivate) (NP (NNP Doc_19058474_471_479_Chemical))))))))))))))) (. .)))
19058474	3	(S1 (S (SBAR (IN While) (S (ADVP (RB traditionally)) (VP (VBN regarded) (PP (IN as) (NP (NNS foodstuffs)))))) (, ,) (NP (NP (NN consumption)) (PP (IN of) (NP (NN fruit) (NNS juices)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NNS patients)) (VP (VBP develop) (NP (JJ adverse) (NN drug) (NNS reactions)))))))) (. .)))
19105845	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (VBG increasing) (JJ intraperitoneal) (NN infusion) (NNS rates))) (PP (IN on) (NP (NP (NNP Doc_19105845_55_78_Chemical-induced) (NNP Doc_19105845_87_95_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
19105845	1	(S1 (S (NP (PRP It)) (VP (AUX is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (NN input) (NN rate) (CC and) (NN incidence)) (PP (IN of) (NP (JJ Doc_19105845_196_205_Chemical-induced) (NN Doc_19105845_214_222_Disease))))))))))) (. .)))
19105845	2	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ important)) (, ,) (SBAR (IN since) (S (NP (NP (JJ different) (JJ controlled) (NN release) (NNS formulations)) (PP (IN of) (NP (NNP Doc_19105845_294_303_Chemical)))) (VP (VBP release) (NP (DT the) (JJ active) (NN drug)) (PP (IN at) (NP (JJ different) (NNS rates))))))) (. .)))
19105845	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (S (VP (VBG varying) (NP (NP (DT the) (JJ intraperitoneal) (NN infusion) (NNS rates)) (PP (IN of) (NP (NP (NNP Doc_19105845_433_446_Chemical) (QP (CD 120) (CD mg/kg))) (, ,) (NP (NP (DT a) (JJ known) (NNP Doc_19105845_466_476_Disease) (NN dose) (CD 50)) (PRN (-LRB- -LRB-) (NP (CD CD50)) (-RRB- -RRB-))) (, ,)))) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_19105845_526_535_Chemical-induced) (NNP Doc_19105845_544_555_Disease)) (PP (IN in) (NP (DT the) (NNP Swiss) (NN albino) (NNS mice)))))))))))) (. .)))
19105845	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 69) (NNS mice)) (, ,) (NP (NP (QP (RB approximately) (CD 7)) (NNS weeks)) (PP (IN of) (NP (NN age))))))) (, ,) (CC and) (S (PP (VBG weighing) (NP (QP (CD 21.0) (TO to) (CD 29.1)))) (NP (NNP g)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB Doc_19105845_686_699_Chemical) (NP (QP (CD 120) (CD mg/kg)) (NN treatment)) (PP (IN by) (NP (NP (JJ intraperitoneal) (PRN (-LRB- -LRB-) (NP (NNP IP)) (-RRB- -RRB-)) (NN administration)) (PP (IN in) (NP (NP (CD 7) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 9) (TO to) (CD 10)) (NNS animals)) (PP (IN per) (NP (NN group)))) (-RRB- -RRB-)))))))))))) (. .)))
19105845	5	(S1 (S (NP (NNP Doc_19105845_800_813_Chemical)) (VP (AUX was) (VP (VBN infused) (PP (IN through) (NP (NP (DT a) (ADJP (RB surgically) (VBN implanted)) (NN IP)) (VP (VBG dosing) (NP (NN catheter)) (PP (IN with) (NP (NP (NNS infusions)) (PP (IN in) (NP (NP (DT each) (NN group)) (PP (IN of) (NP (NP (CD 0) (NN min)) (, ,) (NP (CD 15) (NN min)) (, ,) (NP (CD 30) (NN min)) (, ,) (NP (CD 60) (NN min)) (, ,) (NP (CD 90) (NN min)) (, ,) (NP (CD 120) (NN min)) (, ,) (CC and) (NP (CD 240) (NN min))))))))))))) (. .)))
19105845	6	(S1 (S (NP (NP (DT The) (NN number)) (, ,) (NP (NP (NN time)) (PP (IN of) (NP (NP (NN onset)) (, ,) (NP (NN duration)) (CC and) (NP (NP (DT the) (NN intensity)) (PP (IN of) (NP (DT the) (NN Doc_19105845_1030_1041_Disease))))))) (CC or) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_19105845_1056_1067_Disease))))) (VP (AUX were) (VP (VBN recorded))) (. .)))
19105845	7	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN IP) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_19105845_1137_1150_Chemical) (CD 120) (NNS mg/kg)) (PP (IN by) (NP (JJ bolus) (NN injection)))))) (VP (VBN induced) (NP (NNP Doc_19105845_1188_1199_Disease)) (PP (IN in) (NP (CD 6))) (PP (IN out) (PP (IN of) (NP (CD 10) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (JJ convulsing) (NNS mice)))) (-RRB- -RRB-)) (PP (IN in) (NP (NN group) (CD 1))))))) (. .)))
19105845	8	(S1 (S (NP (JJ Logistic) (JJ regression) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN infusion) (NN time)) (VP (AUX was) (ADJP (JJ significant)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (SYM =) (CD 0.0004)) (: ;) (NP (NNS odds) (NN ratio)) (X (SYM =)) (CD 0.974)) (-RRB- -RRB-)) (CC and) (VP (VBG increasing) (NP (NP (DT the) (ADJP (CD IP) (NN infusion)) (NN time)) (PP (IN of) (NP (NNP Doc_19105845_1402_1415_Chemical))) (SBAR (S (NP (CD 120) (NN mg/kg)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (CD 91) (NN %)) (VBN reduced) (NNS odds)) (PP (IN of) (NP (NNP Doc_19105845_1468_1479_Disease))))) (PP (IN at) (NP (NP (NN infusion) (NNS times)) (PP (IN of) (NP (NP (QP (CD 15) (TO to) (CD 90)) (NN min)) (PP (VBN compared) (PP (TO to) (NP (JJ bolus) (NN injection)))))))))))))))))) (. .)))
19105845	9	(S1 (S (NP (NP (JJ Further) (NN increase)) (PP (IN in) (NP (NN infusion) (NN time)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ further) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NNS odds)) (PP (IN of) (NP (NNP Doc_19105845_1622_1633_Disease))))) (PP (TO to) (NP (ADJP (CD 99.8) (NN %)) (NN reduction))) (PP (IN at) (NP (CD 240) (NN min)))))) (. .)))
19105845	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (DT the) (NN demonstration)) (PP (IN of) (NP (NP (DT an) (NN inverse) (NN relationship)) (PP (IN between) (NP (NP (NN infusion) (NN time)) (PP (IN of) (NP (NP (DT a) (ADJP (JJ fixed) (CC and) (JJ Doc_19105845_1774_1784_Disease)) (NN dose)) (PP (IN of) (NP (NNP Doc_19105845_1793_1802_Chemical)))))))))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19105845_1819_1830_Disease))) (PP (IN in) (NP (DT a) (JJ prospective) (NN study))))) (VP (AUX is) (ADJP (JJ novel))) (. .)))
19135948	0	(S1 (NP (NP (NP (JJ Doc_19135948_0_25_Disease) (NNS prophylaxis)) (PP (IN with) (NP (NNP Doc_19135948_43_53_Chemical) (CC and) (NNP Doc_19135948_58_68_Chemical))) (SBAR (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_19135948_108_139_Disease) (CC and) (NNP Doc_19135948_144_159_Disease)))))))))) (: :) (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NNP EVTAC) (NN trial)))) (. .)))
19135948	1	(S1 (S (NP (NP (DT A) (JJ calcineurin) (NN inhibitor)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_19135948_227_239_Chemical))))) (VP (AUX is) (NP (NP (DT the) (JJ standard) (NN prophylaxis)) (PP (IN for) (NP (NP (NNP Doc_19135948_272_297_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_299_303_Disease)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (JJ allogeneic) (JJ hematopoietic) (NN stem) (NN cell) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NN HSCT)) (-RRB- -RRB-)))))) (. .)))
19135948	2	(S1 (S (NP (NP (NNP Doc_19135948_370_380_Chemical)) (, ,) (NP (NP (DT a) (NN derivative)) (PP (IN of) (NP (NNP Doc_19135948_398_407_Chemical)))) (, ,)) (VP (VBZ seems) (S (VP (TO to) (VP (VB mediate) (NP (NN antileukemia) (NNS effects)))))) (. .)))
19135948	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_19135948_478_488_Chemical) (CC and) (NNP Doc_19135948_493_503_Chemical)) (PP (IN in) (NP (NP (CD 24) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN age)) (, ,) (NP (CD 62) (NNS years))) (-RRB- -RRB-)))) (PP (IN with) (NP (DT either) (NNP Doc_19135948_554_578_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_580_583_Disease)) (: ;) (NP (NNP n) (SYM =) (CD 17)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_19135948_596_618_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_620_623_Disease)) (: ;) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-))))) (VP (VBG undergoing) (NP (NP (JJ intensive) (NN conditioning)) (VP (VBN followed) (PP (IN by) (NP (NP (NN HSCT)) (PP (IN from) (NP (ADJP (VBN related) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)) (CC or) (ADJP (JJ unrelated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (NNS donors))))))))))) (. .)))
19135948	4	(S1 (S (S (NP (DT All) (NNS patients)) (VP (VBD engrafted))) (, ,) (CC and) (S (NP (QP (RB only) (CD 1)) (NN patient)) (VP (VBD experienced) (NP (NN grade)) (NP (NNP IV) (NNP Doc_19135948_798_807_Disease)))) (. .)))
19135948	5	(S1 (S (NP (NP (NP (CD Nine) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 37) (NN %)) (-RRB- -RRB-)) (VP (VBN developed) (NP (JJ acute) (NN grade) (NNP II-IV) (NNP Doc_19135948_857_861_Disease)))) (, ,) (CC and) (NP (NP (QP (CD 11) (IN of) (CD 17)) (JJ evaluable) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-)))) (VP (VBD developed) (NP (JJ chronic) (JJ extensive) (NN Doc_19135948_929_933_Disease))) (. .)))
19135948	6	(S1 (S (NP (NP (NN Doc_19135948_935_977_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_979_982_Disease)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 7) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_19135948_1030_1049_Disease)))))) (. .)))
19135948	7	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN terminated) (ADVP (RB prematurely)) (SBAR (IN because) (S (NP (NP (DT an) (JJ additional) (CD 6) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (NP (NNP Doc_19135948_1137_1168_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_1170_1173_Disease)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (CD 2) (NNS cases)))))))))))) (. .)))
19135948	8	(S1 (S (PP (IN With) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 26) (NNS months))))) (, ,) (NP (DT the) (JJ 2-year) (JJ overall) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 47) (NN %))) (. .)))
19135948	9	(S1 (S (SBAR (IN Although) (S (NP (DT this) (JJ new) (NN combination)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective) (PP (IN as) (NP (NP (DT a) (JJ prophylactic) (NN regimen)) (PP (IN for) (NP (JJ acute) (NNP Doc_19135948_1374_1378_Disease)))))))))))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_19135948_1397_1400_Disease)) (CC and) (NP (NNP Doc_19135948_1405_1408_Disease))))) (VP (AUX is) (ADJP (ADJP (RB considerably) (JJR higher)) (SBAR (IN than) (S (VP (VBN seen) (PP (IN with) (NP (JJ other) (NNS regimens)))))))) (. .)))
19139001	0	(S1 (S (NP (NP (JJ Longitudinal) (NN assessment)) (PP (IN of) (NP (NN air) (NN conduction)))) (VP (VBZ audiograms) (PP (IN in) (NP (NP (DT a) (NN phase) (NNP III) (JJ clinical) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_19139001_86_109_Chemical)) (CC and) (NP (NNP Doc_19139001_114_122_Chemical)))) (PP (IN for) (NP (NP (NN prevention)) (PP (IN of) (NP (JJ sporadic) (NNP Doc_19139001_150_169_Disease)))))))) (. .)))
19139001	1	(S1 (S (NP (DT A) (NN phase) (NNP III) (JJ clinical) (NN trial)) (VP (VBD assessed) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_19139001_225_243_Disease)))) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (NP (CD 36) (NNS months)) (PP (IN with) (NP (NP (NP (NP (NNP Doc_19139001_279_302_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19139001_304_308_Chemical)) (-RRB- -RRB-))) (CC plus) (NP (NNP Doc_19139001_315_323_Chemical))) (CC or) (NP (VBN matched) (NNS placebos))))))) (. .)))
19139001	2	(S1 (S (NP (JJ Temporary) (NN Doc_19139001_355_367_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ known) (NN Doc_19139001_379_387_Disease)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_19139001_406_410_Chemical)) (, ,) (SBAR (RB thus) (S (NP (DT a) (JJ comprehensive) (NN approach)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB analyze) (NP (JJ serial) (NN air) (NN conduction) (NNS audiograms))))))))))))) (. .)))
19139001	3	(S1 (S (NP (DT The) (JJ generalized) (NN estimating) (NN equation) (NN method)) (VP (VBD estimated) (NP (NP (DT the) (JJ mean) (NN difference)) (PP (IN between) (NP (NN treatment) (NNS arms))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NN change)) (PP (IN in) (NP (NP (NN air) (NN conduction)) (SBAR (S (NP (JJ pure) (NN tone)) (VP (VBZ thresholds) (SBAR (IN while) (S (VP (VBG accounting) (PP (IN for) (NP (NP (JJ within-subject) (NN correlation)) (ADJP (JJ due) (PP (TO to) (NP (NP (VBN repeated) (NNS measurements)) (PP (IN at) (NP (NNS frequencies)))))))))))))))))))))) (. .)))
19139001	4	(S1 (S (PP (VBN Based) (PP (IN on) (NP (CD 290) (NNS subjects)))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT an) (JJ average) (NN difference)) (PP (IN of) (NP (CD 0.50) (NN dB))) (PP (IN between) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_19139001_847_851_Chemical) (CC plus) (NNP Doc_19139001_857_865_Chemical))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (NP (QP (CD -0.64) (TO to) (CD 1.63)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.39)))) (-RRB- -RRB-)) (, ,) (VP (VBN adjusted) (PP (IN for) (NP (NP (NN baseline) (NNS values)) (, ,) (NP (NN age)) (, ,) (CC and) (NP (NNS frequencies)))))))))))) (. .)))
19139001	5	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ normal) (NN speech) (NN range)) (PP (IN of) (NP (QP (CD 500) (TO to) (CD 3,000)) (NNPS Hz))))) (, ,) (NP (NP (DT an) (VBN estimated) (NN difference)) (PP (IN of) (NP (NP (CD 0.99) (NNS dB)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -0.17) (TO to) (CD 2.14)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.09))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN detected))) (. .)))
19139001	6	(S1 (S (NP (NN Dose) (NN intensity)) (VP (AUX did) (RB not) (VP (VB add) (NP (NN information)) (PP (TO to) (NP (NNS models))))) (. .)))
19139001	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (NP (NP (CD 14)) (PP (IN of) (NP (NP (CD 151)) (PRN (-LRB- -LRB-) (NP (CD 9.3) (NN %)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP Doc_19139001_1224_1228_Chemical) (CC plus) (NNP Doc_19139001_1234_1242_Chemical) (NN group)))) (CC and) (NP (NP (CD 4)) (PP (IN of) (NP (NP (CD 139)) (PRN (-LRB- -LRB-) (NP (CD 2.9) (NN %)) (-RRB- -RRB-)))))) (PP (IN in) (NP (DT the) (NN placebo) (NN group))) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (QP (IN at) (JJS least) (CD 15) (CD dB)) (NN hearing) (NN reduction)) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (QP (CD 2) (CC or) (JJR more)) (JJ consecutive) (NNS frequencies))) (PP (IN across) (NP (NP (DT the) (JJ entire) (NN range)) (VP (VBN tested) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.02)) (-RRB- -RRB-)))))))))) (. .)))
19139001	8	(S1 (S (NP (JJ Follow-up) (NN air) (NN conduction)) (VP (AUX done) (SBAR (NP (QP (IN at) (JJS least) (CD 6)) (NNS months)) (IN after) (S (NP (NP (NN end)) (PP (IN of) (NP (NN treatment)))) (VP (VBD showed) (NP (NP (DT an) (VBN adjusted) (JJ mean) (NN difference)) (PP (IN in) (NP (NP (NN hearing) (NNS thresholds)) (PP (IN of) (NP (NP (CD 1.08) (NNS dB)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -0.81) (TO to) (CD 2.96)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.26))) (-RRB- -RRB-)))))) (PP (IN between) (NP (NN treatment) (NNS arms)))))))) (. .)))
19139001	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS subjects)) (PP (IN in) (NP (DT the) (NNP Doc_19139001_1698_1702_Chemical) (CC plus) (NNP Doc_19139001_1708_1716_Chemical) (NN group))) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_19139001_1762_1774_Disease)) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group)))))))))))) (. .)))
19139001	10	(S1 (S (NP (NP (DT The) (VBN estimated) (JJ attributable) (NN risk)) (PP (IN of) (NP (NNP Doc_19139001_1843_1854_Disease))) (PP (IN from) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NN drug)))))) (VP (AUX is) (NP (NP (CD 8.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (NP (QP (CD -2.0) (NN %) (TO to) (CD 18.8) (NN %))) (: ;) (NP (NNP P) (SYM =) (CD 0.12)))) (-RRB- -RRB-)))) (. .)))
19139001	11	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (JJ <2) (JJ dB) (NN difference)) (PP (IN in) (NP (NP (JJ mean) (NN threshold)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19139001_2014_2018_Chemical)) (CC plus) (NP (NNP Doc_19139001_2024_2032_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NN placebo)))))))))))))) (. .)))
19203554	0	(S1 (S (VP (VB Proteinase) (NP (NP (JJ 3-antineutrophil) (JJ cytoplasmic) (NN antibody-)) (PRN (-LRB- -LRB-) (NP (NNP PR3-ANCA)) (-RRB- -RRB-))) (NP (JJ positive) (JJ necrotizing) (NN Doc_19203554_81_99_Disease)) (PP (IN after) (S (VP (VBG restarting) (NP (JJ Doc_19203554_117_131_Chemical) (NN treatment)))))) (. .)))
19203554	1	(S1 (S (NP (NP (DT A) (JJ 59-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_19203554_168_186_Disease)))) (VP (VBD developed) (NP (NNP Doc_19203554_197_205_Disease) (, ,) (NNP Doc_19203554_207_223_Disease) (, ,) (NNP Doc_19203554_225_237_Disease) (CC and) (NNP Doc_19203554_242_263_Disease)) (PP (IN after) (NP (NP (NN restarting)) (PP (IN of) (NP (JJ Doc_19203554_284_298_Chemical) (NN treatment)))))) (. .)))
19203554	2	(S1 (S (NP (NP (JJ Light) (NN microscopy)) (PP (IN of) (NP (DT a) (NN kidney) (NN biopsy)))) (VP (VBD revealed) (NP (NNP Doc_19203554_355_395_Disease)) (PP (IN without) (NP (NP (NN deposition)) (PP (IN of) (NP (NP (NN immunoglobulin)) (CC or) (NP (VB complement))))))) (. .)))
19203554	3	(S1 (S (S (NP (JJ Proteinase) (JJ 3-antineutrophil) (JJ cytoplasmic) (NN antibody) (PRN (-LRB- -LRB-) (NNP PR3-ANCA) (-RRB- -RRB-)) (NN titer)) (VP (AUX was) (ADJP (JJ elevated)) (PP (IN at) (NP (CD 183) (NNP ELISA) (NNS units))) (PRN (-LRB- -LRB-) (NP (NNP EU)) (-RRB- -RRB-)) (PP (IN in) (NP (NN sera))) (PRN (-LRB- -LRB-) (NP (JJ normal) (NN range)) (NP (QP (JJR less) (IN than) (CD 10)) (NN EU)) (-RRB- -RRB-)))) (, ,) (S (NP (NN myeloperoxidase-ANCA)) (VP (AUX was) (ADJP (JJ negative)))) (. .)))
19203554	4	(S1 (S (NP (NN PR3-ANCA) (NN titer)) (VP (AUX was) (NP (NP (QP (CD 250) (CC and) (CD 1,070)) (NN EU)) (PP (IN in) (NP (NNP Doc_19203554_665_682_Disease))) (PP (IN on) (NP (JJ right) (CC and) (JJ left) (NN side)))) (, ,) (ADVP (RB respectively))) (. .)))
19203554	5	(S1 (S (SBAR (IN Although) (S (NP (NP (NN cessation)) (PP (IN of) (NP (JJ Doc_19203554_743_757_Chemical) (NN treatment)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS improvements)) (PP (IN in) (NP (NP (NNP Doc_19203554_796_801_Disease) (, ,) (NNP Doc_19203554_803_811_Disease) (, ,) (NNP Doc_19203554_813_823_Disease)) (, ,) (NP (NP (NP (NN titer)) (PP (IN of) (NP (JJ C-reactive) (NN protein)))) (CC and) (NP (NP (NN volume)) (PP (IN of) (NP (DT the) (NNP Doc_19203554_871_888_Disease)))))))))))) (, ,) (NP (PRP we)) (VP (VBD initiated) (NP (JJ Doc_19203554_903_910_Chemical) (NN therapy)) (, ,) (SBAR (IN because) (S (S (NP (NNP PR3-ANCA) (NN titer)) (VP (VBD rose) (PP (TO to) (NP (QP (CD 320) (CD EU)))))) (, ,) (S (NP (NN eosinophil) (NN count)) (VP (VBD increased) (PP (TO to) (NP (CD 1,100) (NN cells/microl))))) (, ,) (CC and) (S (NP (DT the) (NNP Doc_19203554_1017_1033_Disease)) (VP (VBD remained)))))) (. .)))
19203554	6	(S1 (S (S (NP (NP (CD One) (NN month)) (PP (IN after) (NP (JJ Doc_19203554_1060_1067_Chemical) (NN therapy))) (, ,) (NP (DT the) (NNP Doc_19203554_1081_1097_Disease))) (VP (VBD disappeared))) (, ,) (CC and) (S (NP (JJ PR3-ANCA) (NN titer)) (VP (VBD normalized) (ADVP (NP (CD 3) (NNS months)) (RB later)))) (. .)))
19203554	7	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_19203554_1181_1195_Chemical)) (VP (MD can) (VP (VB induce) (NP (JJ PR3-ANCA-positive) (JJ necrotizing) (NN Doc_19203554_1237_1255_Disease))))))) (. .)))
19234905	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ unilateral) (NN pallidotomy) (CC and) (NN subthalamotomy) (NNS findings)) (PP (IN in) (NP (JJ advanced) (NNP Doc_19234905_77_107_Disease))))) (. .)))
19234905	1	(S1 (S (NP (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (NN pilot) (NN study)) (SBAR (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ stereotactic) (JJ unilateral) (NN pallidotomy)) (CC and) (NP (NN subthalamotomy)))) (PP (IN in) (NP (JJ advanced) (NNP Doc_19234905_254_284_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_19234905_286_288_Disease)) (-RRB- -RRB-)) (JJ refractory)))) (PP (TO to) (NP (JJ medical) (NN treatment)))))))) (VP (AUX was) (VP (VBN designed))) (. .)))
19234905	2	(S1 (S (NP (NP (NP (CD Ten) (JJ consecutive) (NNS patients)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age)) (, ,) (NP (NP (CD 58.4) (JJ +/-) (CD 6.8) (NNS years)) (PRN (: ;) (NP (CD 7) (NNS men)) (, ,) (NP (CD 3) (NNS women)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (JJ similar) (NNS characteristics)) (PP (IN at) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN disease)))))))) (-LRB- -LRB-) (NP (NP (JJ mean) (NN disease) (NN time)) (, ,) (NP (NP (CD 8.4) (NN +/-)) (NP (CD 3.5) (NNS years)))) (-RRB- -RRB-))) (, ,) (NP (NP (VBG disabling) (NN motor) (NNS fluctuations)) (PRN (-LRB- -LRB-) (NP (NP (NNP Hoehn) (NNP _) (NNP Yahr) (NN stage) (NN 3-5)) (PP (IN in) (NP (JJ off-drug) (NNS phases)))) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_19234905_581_589_Chemical-induced) (NN Doc_19234905_598_609_Disease))) (VP (AUX were) (VP (VBN selected))) (. .)))
19234905	3	(S1 (S (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (JJ bilateral) (NNS symptoms)))) (CC and) (S (NP (PRP$ their) (JJ Doc_19234905_671_679_Chemical) (JJ equivalent) (NN dosing)) (VP (AUX were) (VP (VBN analysed)))) (. .)))
19234905	4	(S1 (S (NP (CD Six) (NNS patients)) (VP (AUX were) (VP (VBN operated) (PRT (RP on)) (PP (IN in) (NP (NP (NP (DT the) (JJ globus) (JJ pallidus) (NNS interna)) (PRN (-LRB- -LRB-) (NP (NNP GPi)) (-RRB- -RRB-))) (CC and) (NP (NP (CD four)) (PP (IN in) (NP (DT the) (JJ subthalamic) (NN nucleus))) (PRN (-LRB- -LRB-) (NP (NNP STN)) (-RRB- -RRB-))))))) (. .)))
19234905	5	(S1 (S (NP (JJ Clinical) (NN evaluation)) (VP (VP (VBD included) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT the) (JJ Unified) (NNP Doc_19234905_875_894_Disease) (NNP Rating) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNP UPDRS)) (-RRB- -RRB-))))) (, ,) (NP (NNP Hoehn_Yahr) (NN score)) (CC and) (NP (NP (NNP Schwab) (NNP England) (NNS activities)) (PP (IN of) (NP (JJ daily) (VBG living) (-LRB- -LRB-) (NNP ADL) (-RRB- -RRB-) (NN score))))) (PP (IN in) ('' ') (NP (NN on'-)))) (CC and) (VP ('' ') (NP (NP (NP (JJ off'-drug) (NNS conditions)) (PP (IN before) (NP (NN surgery)))) (CC and) (NP (CD 6) (NNS months))) (PP (IN after) (NP (NN surgery))))) (. .)))
19234905	6	(S1 (S (NP (EX There)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (NP (NN improvement)) (PP (IN in) (NP (NP (DT all) (JJ contralateral) (JJ major) (JJ Doc_19234905_1145_1157_Disease) (NN motor) (NNS signs)) (PP (IN in) (NP (NP (DT all) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (CD 6) (NNS months))))))))) (. .)))
19234905	7	(S1 (S (NP (JJ Doc_19234905_1209_1217_Chemical) (JJ equivalent) (JJ daily) (NN intake)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (DT the) (JJ STN) (NN group))))) (. .)))
19234905	8	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NNP UPDRS)) (, ,) (NP (NNP Hoehn) (NNP _) (NNP Yahr)) (CC and) (NP (NNP Schwab) (NNP England) (NNP ADL) (NNS scores))))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
19234905	9	(S1 (S (NP (JJ Cognitive) (NNS functions)) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
19234905	10	(S1 (S (S (NP (NNS Complications)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (CD two) (NNS patients)))))) (: :) (S (NP (PRP one)) (VP (AUX had) (NP (DT a) (JJ left) (NN Doc_19234905_1487_1509_Disease)) (SBAR (IN after) (S (NP (NP (NN pallidotomy)) (CC and) (NP (NP (DT another) (NN one)) (VP (VBN developed)))) (VP (VBD left) (NP (JJ hemiballistic) (NNS movements)) (PP (NP (CD 3) (NNS days)) (IN after) (NP (NP (NN subthalamotomy)) (SBAR (WHNP (WDT which)) (S (ADVP (RB partly)) (VP (VBD improved) (PP (IN within) (NP (NP (CD 1) (NN month)) (PP (IN with) (NP (NNP Doc_19234905_1653_1662_Chemical))) (NP (CD 1000) (NN mg/day)))))))))))))) (. .)))
19234905	11	(S1 (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ unilateral) (NNP STN) (CC and) (NNP GPi)))) (VP (AUX are) (NP (NP (ADJP (RB equally) (JJ effective)) (NN treatment)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NN Doc_19234905_1813_1815_Disease))) (ADJP (JJ refractory) (PP (TO to) (NP (JJ medical) (NN treatment))))))))))) (. .)))
19274460	0	(S1 (NP (NP (CD DSMM) (CD XI) (NN study)) (: :) (NP (NP (NN dose) (NN definition)) (PP (IN for) (NP (NP (JJ intravenous) (NNP Doc_19274460_47_63_Chemical)) (PP (IN in) (NP (NN combination))))) (PP (IN with) (NP (NNP Doc_19274460_84_94_Chemical/Doc_19274460_95_108_Chemical))) (PP (IN for) (NP (NP (NN remission) (NN induction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_166_173_Disease)))))))) (. .)))
19274460	1	(S1 (S (NP (DT A) (JJ clinical) (NN trial)) (VP (AUX was) (VP (VBN initiated) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ recommended) (NN dose)) (PP (IN of) (NP (NNP Doc_19274460_242_258_Chemical))) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_19274460_279_289_Chemical) (CC and) (NNP Doc_19274460_294_307_Chemical)))) (PP (IN as) (NP (NP (JJ induction) (NN treatment)) (PP (IN before) (NP (NP (NN stem) (NN cell) (NN transplantation)) (PP (IN for) (NP (NP (JJR younger) (NNS patients)) (PP (IN with) (NP (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_406_422_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19274460_424_426_Disease)) (-RRB- -RRB-))))))))))))))) (. .)))
19274460	2	(S1 (S (NP (CD Thirty) (NNS patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (CD three) (JJ 21-day) (NNS cycles)) (PP (IN of) (NP (NP (NNP Doc_19274460_486_496_Chemical) (CD 1.3) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))) (PP (IN on) (NP (NNS days) (CD 1) (, ,) (CD 4) (, ,) (CD 8) (, ,) (CC and) (NP (CD 11)) (CC plus) (NP (NP (NNP Doc_19274460_538_551_Chemical) (CD 40) (NNS mg)) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of) (NP (NP (JJ Doc_19274460_572_582_Chemical) (NN injection)) (CC and) (NP (NP (DT the) (NN day)) (PP (IN after) (NP (JJ plus) (NNP Doc_19274460_616_632_Chemical))) (PP (IN at) (NP (NP (CD 900)) (, ,) (NP (CD 1,200)) (, ,) (CC or) (NP (CD 1,500) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN on) (NP (NN day) (CD 1))))))))))))))))) (. .)))
19274460	3	(S1 (S (NP (NP (DT The) (JJ maximum) (JJ tolerated) (NN dose)) (PP (IN of) (NP (NNP Doc_19274460_705_721_Chemical)))) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (CD 900) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))))) (. .)))
19274460	4	(S1 (S (PP (IN At) (NP (DT this) (NN dose) (NN level))) (, ,) (NP (NP (CD 92) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD achieved) (NP (ADVP (IN at) (JJS least)) (DT a) (JJ partial) (NN response))) (. .)))
19274460	5	(S1 (S (NP (NP (NP (NP (DT The) (JJ overall) (NN response) (NN rate)) (NP (JJ -LSB-complete) (NN response))) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-))) (CC plus) (NP (NP (JJ partial) (NN response) (PRN (-LRB- -LRB-) (NNP PR) (-RRB- -RRB-)) (NN -RSB-)) (PP (IN across) (NP (DT all) (NN dose) (NNS levels))))) (VP (AUX was) (NP (CD 77) (NN %)) (, ,) (PP (IN with) (NP (DT a) (ADJP (CD 10) (NN %)) (JJ CR) (NN rate)))) (. .)))
19274460	6	(S1 (S (NP (DT No) (NN patient)) (VP (VBD experienced) (NP (JJ progressive) (NN disease))) (. .)))
19274460	7	(S1 (S (NP (DT The) (JJS most) (JJ frequent) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (JJ Doc_19274460_1036_1081_Disease) (CONJP (RB as) (RB well) (IN as)) (JJ Doc_19274460_1093_1103_Disease))) (. .)))
19274460	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_19274460_1130_1140_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_19274460_1161_1177_Chemical))) (PP (IN at) (NP (NP (QP (CD 900) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (CC and) (NP (NNP Doc_19274460_1197_1210_Chemical))) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN induction) (NN treatment)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_1281_1283_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ warrants) (NP (JJ further) (NN investigation)))))))))) (. .)))
1928887	0	(S1 (NP (NP (JJ Doc_1928887_0_8_Chemical) (NN reversal)) (PP (IN of) (NP (NNP Doc_1928887_21_32_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_1928887_40_49_Chemical) (NNP Doc_1928887_50_58_Disease))) (. .)))
1928887	1	(S1 (S (NP (NP (DT The) (JJ hemodynamic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1928887_87_96_Chemical)) (CC and) (NP (JJ other) (NNP Doc_1928887_107_147_Chemical))))) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (DT the) (JJ endogenous) (NN opioid) (NN system)))))) (. .)))
1928887	2	(S1 (S (NP (DT The) (NN opioid) (NN antagonist) (NN Doc_1928887_219_227_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB block) (CC or) (VB reverse) (NP (NP (DT the) (JJ Doc_1928887_267_278_Disease) (NNS actions)) (PP (IN of) (NP (NNP Doc_1928887_290_299_Chemical)))))))))) (. .)))
1928887	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ intentional) (JJ Doc_1928887_336_345_Chemical) (NN Doc_1928887_346_354_Disease)) (, ,) (VP (VBN manifested) (PP (IN by) (NP (JJ marked) (NNP Doc_1928887_377_388_Disease)))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (ADVP (RB promptly)) (PP (IN with) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_1928887_440_448_Chemical)))))))))))) (. .)))
1928887	4	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (NNP Doc_1928887_503_512_Chemical-induced) (NNP Doc_1928887_521_532_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1928887_546_554_Chemical)))))))) (. .)))
1928887	5	(S1 (S (NP (PRP$ Our) (NN experience)) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ possible) (NN role)) (PP (IN of) (NP (NNP Doc_1928887_603_611_Chemical))) (PP (IN in) (NP (NP (DT the) (NN reversal)) (PP (IN of) (NP (NP (NNP Doc_1928887_631_642_Disease)) (VP (VBG resulting) (PP (IN from) (NP (NNP Doc_1928887_658_667_Chemical)))))))))) (. .)))
19289093	0	(S1 (NP (NP (NN Identification)) (PP (IN of) (NP (NP (DT a) (ADJP (JJ simple) (CC and) (JJ sensitive)) (NN microplate) (NN method)) (PP (IN for) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ oversulfated) (NNP Doc_19289093_93_112_Chemical))) (PP (IN in) (NP (JJ Doc_19289093_116_123_Chemical) (NNS products))))))) (. .)))
19289093	1	(S1 (S (NP (NN Doc_19289093_134_141_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN implemented)) (NN anticoagulant)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (ADJP (RB critically) (JJ ill)) (NNS patients)))))))) (. .)))
19289093	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (JJ commercial) (NNS lots)) (PP (IN of) (NP (NNP Doc_19289093_262_269_Chemical) (NNS products)))))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN contaminated) (PP (IN with) (NP (NP (DT an) (JJ oversulfated) (NNP Doc_19289093_330_349_Chemical) (PRN (-LRB- -LRB-) (NP (NNP OSCS)) (-RRB- -RRB-)) (NN derivative)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB elicit) (NP (DT a) (JJ Doc_19289093_388_399_Disease) (NN response)) (PP (IN in) (S (NP (NNS pigs)) (VP (VBG following) (NP (DT a) (JJ single) (JJ high-dose) (NN infusion))))))))))))))))) (. .)))
19289093	3	(S1 (S (S (VP (VBG Using) (NP (NP (DT both) (VBN contaminated) (JJ Doc_19289093_480_487_Chemical) (NNS products)) (CC and) (NP (DT the) (ADJP (RB synthetically) (VBN produced)) (NN derivative))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN OSCS)) (VP (VBZ produces) (NP (NP (JJ dose-dependent) (NN Doc_19289093_588_599_Disease)) (PP (IN in) (NP (NNS pigs)))))))) (. .)))
19289093	4	(S1 (S (NP (NP (DT The) (ADJP (RB no) (JJ observed)) (NN effect) (NN level)) (PRN (-LRB- -LRB-) (NP (NNP NOEL)) (-RRB- -RRB-)) (PP (IN for) (NP (DT this) (NN contaminant)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RB approximately) (JJ 1mg/kg)) (, ,) (S (VP (VBG corresponding) (PP (TO to) (NP (NP (DT a) (NN contamination) (NN level)) (PP (IN of) (NP (QP (RB approximately) (CD 3)) (NN %))))))))))) (. .)))
19289093	5	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNS OSCS)) (VP (MD can) (VP (AUX be) (VP (VBN identified) (PP (IN in) (NP (NP (JJ Doc_19289093_814_821_Chemical) (NNS products)) (VP (VBG using) (NP (NP (DT a) (JJ simple) (, ,) (JJ inexpensive) (, ,) (ADJP (RB commercially) (JJ available)) (JJ Doc_19289093_883_890_Chemical) (JJ enzyme) (NN immunoassay) (PRN (-LRB- -LRB-) (NP (NNP EIA)) (-RRB- -RRB-)) (NN kit)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (NP (DT a) (NN limit)) (PP (IN of) (NP (NP (NN detection)) (PP (IN of) (NP (QP (RB approximately) (CD 0.1)) (NN %)))))) (, ,) (PP (ADVP (RB well)) (IN below) (NP (DT the) (NNP NOEL)))))))))))))))) (. .)))
19289093	6	(S1 (S (NP (DT This) (NN kit)) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ useful) (NN method)) (SBAR (S (VP (TO to) (VP (VB test) (NP (NP (JJ Doc_19289093_1039_1046_Chemical) (NNS products)) (PP (IN for) (NP (NP (NN contamination)) (PP (IN with) (NP (JJ oversulfated) (NN GAG) (NNS derivatives))))))))))))) (. .)))
19300240	0	(S1 (NP (NP (JJ Doc_19300240_0_14_Chemical-induced) (NN Doc_19300240_23_49_Disease)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
19300240	1	(S1 (S (NP (NP (DT The) (NNP Doc_19300240_70_96_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19300240_98_101_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB recently) (VBN described)) (JJ stress-mediated) (NN Doc_19300240_143_165_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ transient) (NN wall-motion) (NNS abnormalities)) (VP (VBG involving) (NP (NP (DT the) (NN apex) (CC and) (NN midventricle)) (PP (IN with) (NP (NP (NNP Doc_19300240_260_272_Disease)) (PP (IN of) (NP (NP (DT the) (JJ basal) (NN left) (NN ventricular) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-)) (NNS segments)) (PP (IN without) (NP (JJ obstructive) (NNP Doc_19300240_337_364_Disease)))))))))))))) (. .)))
19300240	2	(S1 (S (NP (NN Doc_19300240_366_380_Disease)) (VP (AUX is) (RB not) (NP (NP (DT an) (JJ uncommon) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ chemotherapeutic) (NNS agents))))) (. .)))
19300240	3	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (ADJP (NNP Doc_19300240_476_479_Disease) (JJ secondary) (TO to) (JJ chemotherapeutic)) (NNS agents))))) (. .)))
19300240	4	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT the) (NN syndrome)) (PP (IN after) (S (VP (VBG chemotherapy) (PP (IN for) (NP (JJ metastatic) (NN Doc_19300240_611_617_Disease))))))))))))) (. .)))
19300240	5	(S1 (S (NP (NP (DT A) (JJ 79-year-old) (NN woman)) (VP (VBN presented) (PP (IN with) (NP (JJ typical) (NNP Doc_19300240_662_670_Disease) (NNP Doc_19300240_671_681_Disease))))) (, ,) (VP (VBD elevated) (NP (NP (JJ cardiac) (NNS enzymes)) (PP (IN with) (NP (NP (JJ significant) (JJ ST-segment) (NNS abnormalities)) (PP (IN on) (NP (PRP$ her) (NN electrocardiogram))))))) (. .)))
19300240	6	(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NP (JJ recent) (NN chemotherapy)) (PP (IN with) (NP (NNP Doc_19300240_815_827_Chemical))) (PP (IN for) (NP (JJ metastatic) (NN Doc_19300240_843_860_Disease))))) (. .)))
19300240	7	(S1 (S (NP (NN Echocardiography)) (VP (VBD revealed) (NP (NP (DT a) (JJ wall-motion) (NN abnormality)) (VP (VBG involving) (NP (NP (DT the) (ADJP (JJ apical) (CC and) (JJ periapical)) (NNS segments)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (NP (NNP Doc_19300240_974_982_Disease))))))))) (. .)))
19300240	8	(S1 (S (NP (JJ Coronary) (NN angiography)) (VP (VBD revealed) (NP (DT no) (JJ obstructive) (JJ coronary) (NNS lesions))) (. .)))
19300240	9	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN stabilized) (PP (IN with) (NP (JJ medical) (NN therapy))))) (. .)))
19300240	10	(S1 (S (ADVP (NP (CD Four) (NNS weeks)) (RB later)) (NP (PRP she)) (VP (VBD remained) (ADJP (RB completely) (JJ asymptomatic))) (. .)))
19300240	11	(S1 (S (NP (NN Echocardiogram)) (VP (VBD revealed) (NP (NP (DT a) (JJ normal) (NN ejection) (NN fraction)) (CC and) (NP (NP (DT a) (NN resolution)) (PP (IN of) (NP (DT the) (JJ apical) (NN Doc_19300240_1233_1241_Disease)))))) (. .)))
19300240	12	(S1 (S (NP (NP (JJ Pathogenetic) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_19300240_1270_1291_Disease))) (PP (IN in) (NP (NP (JJ Doc_19300240_1295_1301_Disease) (NNS patients)) (VP (VBG undergoing) (NP (NN chemotherapy)))))) (VP (VBP include) (NP (NP (NNP Doc_19300240_1343_1361_Disease)) (, ,) (NP (NN endothelial) (NN damage)) (CC and) (NP (JJ consequent) (NN Doc_19300240_1397_1405_Disease) (NN formation)))) (. .)))
19300240	13	(S1 (S (PP (IN In) (NP (PRP$ our) (NN patient))) (, ,) (NP (NP (DT both) (JJ supraphysiologic) (NNS levels)) (PP (IN of) (NP (NP (NN plasma) (UCP (JJ Doc_19300240_1472_1486_Chemical) (CC and) (NN stress)) (JJ related) (NNS neuropeptides)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ Doc_19300240_1530_1536_Disease) (NN diagnosis)) (CONJP (RB as) (RB well) (IN as)) (NP (NN chemotherapy)))))))) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19300240_1611_1614_Disease))))))) (. .)))
19319147	0	(S1 (S (NP (NP (JJ Rapid) (NN reversal)) (PP (IN of) (NP (NN anticoagulation)))) (VP (VBZ reduces) (NP (NN Doc_19319147_42_52_Disease) (NN volume)) (PP (IN in) (NP (NP (DT a) (NN mouse) (NN model)) (PP (IN of) (NP (NNP Doc_19319147_80_88_Chemical-associated) (NNP Doc_19319147_100_124_Disease)))))) (. .)))
19319147	1	(S1 (S (NP (NP (JJ Doc_19319147_126_134_Chemical-associated) (NNP Doc_19319147_146_170_Disease)) (PRN (-LRB- -LRB-) (NP (NNP W-Doc_19319147_174_177_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ severe) (NN type)) (PP (IN of) (NP (NN Doc_19319147_199_205_Disease))))) (. .)))
19319147	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN consensus)) (PP (IN on) (NP (NP (DT the) (JJ optimal) (NN treatment)) (PP (IN for) (NP (NN W-Doc_19319147_260_263_Disease))))))) (. .)))
19319147	3	(S1 (S (S (VP (VBG Using) (NP (DT a) (NN mouse) (NN model)))) (, ,) (NP (PRP we)) (VP (VBD tested) (SBAR (IN whether) (S (NP (NP (DT the) (JJ rapid) (NN reversal)) (PP (IN of) (NP (NP (NN anticoagulation)) (VP (VBG using) (NP (NP (JJ human) (NNP Doc_19319147_354_385_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19319147_387_390_Chemical)) (-RRB- -RRB-))))))) (VP (MD can) (VP (VB reduce) (NP (JJ hemorrhagic) (NN blood) (NN volume))))))) (. .)))
19319147	4	(S1 (S (NP (JJ Male) (JJ CD-1) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19319147_462_470_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg) (IN over) (CD 24)) (NNP h)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ mean) (PRN (-LRB- -LRB-) (JJ +/-s.d.) (-RRB- -RRB-)) (JJ International) (JJ Normalized) (NN Ratio)) (PP (IN of) (NP (CD 3.5+/-0.9))))))))) (. .)))
19319147	5	(S1 (S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT an) (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ human) (NN Doc_19319147_628_631_Chemical)))) (ADVP (RB rapidly)) (VP (VBD reversed) (NP (NN anticoagulation)) (PP (IN in) (NP (NNS mice))))))) (. .)))
19319147	6	(S1 (S (ADVP (JJ Second)) (, ,) (NP (NP (DT a) (JJ stereotactic) (NN injection)) (PP (IN of) (NP (NN collagenase)))) (VP (AUX was) (VP (VBN administered) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_19319147_749_759_Disease)) (PP (IN in) (NP (DT the) (JJ right) (NN striatum)))))))) (. .)))
19319147	7	(S1 (S (ADVP (NP (JJ Forty-five) (NNS minutes)) (RB later)) (, ,) (NP (DT the) (NNS animals)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_19319147_848_851_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN U/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ saline) (NNS i.v.)) (PRN (-LRB- -LRB-) (NP (NP (CD n=12)) (PP (IN per) (NP (NN group)))) (-RRB- -RRB-))))))) (. .)))
19319147	8	(S1 (S (PP (NP (JJ Twenty-four) (NNS hours)) (IN after) (NP (NNP Doc_19319147_920_930_Disease) (NN induction))) (, ,) (NP (JJ hemorrhagic) (NN blood) (NN volume)) (VP (AUX was) (VP (VBN quantified) (S (VP (VBG using) (NP (DT a) (JJ photometric) (NN hemoglobin) (NN assay)))))) (. .)))
19319147	9	(S1 (S (NP (DT The) (JJ mean) (JJ hemorrhagic) (NN blood) (NN volume)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (JJ Doc_19319147_1069_1072_Chemical-treated) (NNS animals)) (PRN (-LRB- -LRB-) (NP (CD 6.5+/-3.1) (NN microL)) (-RRB- -RRB-)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ saline) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 15.3+/-11.2) (NN microL)) (, ,) (NP (NNP P=0.015))) (-RRB- -RRB-))))))) (. .)))
19319147	10	(S1 (S (PP (IN In) (NP (DT the) (JJ saline) (NN group))) (, ,) (NP (NP (CD 45) (NN %)) (PP (IN of) (NP (DT the) (NNS mice)))) (VP (VBD developed) (NP (NP (JJ large) (NN Doc_19319147_1222_1231_Disease)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (ADJP (CD >15) (NN microL)) (-RRB- -RRB-)))) (. .)))
19319147	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ such) (JJ extensive) (NNS lesions)) (VP (AUX were) (ADVP (RB never)) (VP (VBN found) (PP (IN in) (NP (DT the) (NNP Doc_19319147_1312_1315_Chemical) (NN group))))) (. .)))
19319147	12	(S1 (S (NP (PRP We)) (VP (VBP provide) (NP (NP (JJ experimental) (NNS data)) (VP (VBG suggesting) (NP (NNP Doc_19319147_1363_1366_Chemical)) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (JJ acute) (NN treatment)) (PP (IN for) (NP (NN W-Doc_19319147_1408_1411_Disease)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (S (VP (VBG reducing) (NP (JJ hemorrhagic) (NN blood) (NN volume))))))))))))) (. .)))
19319147	13	(S1 (S (NP (JJ Future) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ therapeutic) (NN potential)) (VP (VBG emerging) (PP (IN from) (NP (PRP$ our) (NN finding))) (PP (IN for) (NP (JJ human) (NN W-Doc_19319147_1559_1562_Disease)))))))))) (. .)))
19370593	0	(S1 (NP (NP (JJ Long) (NN term) (NN hormone) (NN therapy)) (PP (IN for) (NP (JJ perimenopausal) (CC and) (JJ postmenopausal) (NNS women))) (. .)))
19370593	1	(S1 (S (NP (NP (NN Hormone) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HT)) (-RRB- -RRB-))) (VP (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN for) (S (VP (VBG controlling) (NP (JJ menopausal) (NNS symptoms))))))) (CC and) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN management) (CC and) (NN prevention)) (PP (IN of) (NP (NNP Doc_19370593_215_237_Disease) (, ,) (NNP Doc_19370593_239_251_Disease) (CC and) (NNP Doc_19370593_256_264_Disease))) (PP (IN in) (NP (JJR older) (NNS women))))))))) (. .)))
19370593	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT an) (VBN updated) (NN version)) (PP (IN of) (NP (NP (DT the) (JJ original) (JJ Cochrane) (NN review)) (VP (ADVP (RB first)) (VBN published) (PP (IN in) (NP (CD 2005)))))))) (. .)))
19370593	3	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ long-term) (NNS HT))) (PP (IN on) (NP (NP (NN mortality)) (, ,) (NP (JJ cardiovascular) (NNS outcomes)) (, ,) (NP (NP (NNP Doc_19370593_453_459_Disease) (, ,) (NNP Doc_19370593_461_480_Disease) (, ,) (NN cognition) (, ,) (NN Doc_19370593_493_502_Disease) (CC and) (NN quality)) (PP (IN of) (NP (NN life)))))))))) (. .)))
19370593	4	(S1 (NP (NP (NN SEARCH) (NN STRATEGY)) (: :) (S (NP (PRP We)) (VP (VBD searched) (NP (NP (NP (DT the) (JJ following) (NNS databases)) (PP (TO to) (NP (NNP November) (CD 2007)))) (: :) (NP (NP (NP (NNS Trials) (NNP Register)) (PP (IN of) (NP (DT the) (NNP Cochrane) (NNP Doc_19370593_627_646_Disease) (CC and) (NNP Subfertility) (NNP Group)))) (, ,) (NP (NP (NNP Cochrane) (NNP Central) (NNP Register)) (PP (IN of) (NP (JJ Controlled) (NNS Trials)))) (, ,) (NP (NNP MEDLINE)) (, ,) (NP (NNP EMBASE)) (, ,) (NP (JJ Biological) (NNS Abstracts)))))) (. .)))
19370593	5	(S1 (FRAG (ADVP (RB Also)) (NP (NP (JJ relevant) (JJ non-indexed) (NNS journals)) (CC and) (NP (NN conference) (NNS abstracts))) (. .)))
19370593	6	(S1 (NP (NP (NN SELECTION) (NNS CRITERIA)) (: :) (NP (NP (JJ Randomised) (JJ double-blind) (NNS trials)) (PP (IN of) (NP (NN HT))) (PP (IN versus) (NP (NN placebo))) (, ,) (VP (VBN taken) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN year))) (PP (IN by) (NP (JJ perimenopausal) (CC or) (JJ postmenopausal) (NNS women))))) (. .)))
19370593	7	(S1 (S (NP (NNS HT)) (VP (VBD included) (NP (NNP Doc_19370593_975_985_Chemical)) (, ,) (PP (IN with) (CC or) (PP (IN without) (NP (NNP Doc_19370593_1003_1015_Chemical)))) (, ,) (PP (IN via) (NP (ADJP (JJ oral) (, ,) (JJ transdermal) (, ,) (JJ subcutaneous) (CC or) (JJ transnasal)) (NNS routes)))) (. .)))
19370593	8	(S1 (NP (NP (NP (NNS DATA) (NN COLLECTION)) (CC AND) (NP (NN ANALYSIS))) (: :) (NP (NP (CD Two) (NNS authors)) (VP (VP (ADVP (RB independently)) (VBN assessed) (NP (NN trial) (NN quality))) (CC and) (VP (VBN extracted) (NP (NN data))))) (. .)))
19370593	9	(S1 (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (S (NP (NP (JJ Nineteen) (NNS trials)) (VP (VBG involving) (NP (CD 41,904) (NNS women)))) (VP (AUX were) (VP (VBN included)))) (. .)))
19370593	10	(S1 (S (PP (IN In) (NP (ADJP (RB relatively) (JJ healthy)) (NNS women))) (, ,) (NP (VBN combined) (JJ continuous) (NNS HT)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_19370593_1330_1353_Disease)) (CC or) (NP (JJ coronary) (NN event))) (PRN (-LRB- -LRB-) (PP (IN after) (NP (NP (CD one) (NN year) (POS 's)) (NN use))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19370593_1396_1402_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (CD three) (NNS years))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_19370593_1424_1437_Disease)) (CC and) (NP (NNP Doc_19370593_1442_1461_Disease)))))) (. .)))
19370593	11	(S1 (S (NP (JJ Long-term) (JJ Doc_19370593_1473_1482_Chemical-only) (NNS HT)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_19370593_1527_1550_Disease)) (, ,) (NP (NP (NNP Doc_19370593_1552_1558_Disease) (CC and) (NNP Doc_19370593_1563_1582_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (NP (NP (QP (CD one) (TO to) (CD two)) (NNS years)) (, ,) (NP (CD three) (NNS years))) (CC and) (NP (NP (CD seven) (NNS years) (POS ')) (NN use))) (ADVP (RB respectively))) (-RRB- -RRB-))) (, ,))))) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB significantly)) (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19370593_1703_1716_Disease))))))) (. .)))
19370593	12	(S1 (S (NP (NP (DT The) (ADJP (RB only) (RB statistically) (JJ significant)) (NNS benefits)) (PP (IN of) (NP (NN HT)))) (VP (AUX were) (NP (NP (DT a) (VBN decreased) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_19370593_1798_1807_Disease)) (CC and) (PRN (-LRB- -LRB-) (PP (IN for) (NP (JJ combined) (NNS HT))) (-RRB- -RRB-)) (NP (NNP Doc_19370593_1830_1842_Disease))))) (, ,) (PP (IN with) (NP (JJ long-term) (NN use)))) (. .)))
19370593	13	(S1 (S (PP (IN Among) (NP (NP (NNS women)) (VP (VBN aged) (PP (IN over) (NP (CD 65)))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (RB relatively) (JJ healthy)) (PRN (-LRB- -LRB-) (FW i.e.) (ADVP (RB generally)) (NP (NN fit)) (, ,) (PP (IN without) (NP (NN overt) (NN disease))) (-RRB- -RRB-)) (CC and) (VP (VBG taking) (NP (JJ continuous) (JJ combined) (NNS HT)))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_19370593_2063_2071_Disease))))))) (. .)))
19370593	14	(S1 (S (PP (IN Among) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_19370593_2090_2112_Disease))))) (, ,) (NP (NP (JJ long-term) (NN use)) (PP (IN of) (NP (JJ combined) (JJ continuous) (NNS HT)))) (VP (ADVP (RB significantly)) (VBN increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19370593_2190_2213_Disease))))) (. .)))
19370593	15	(S1 (S (NP (CD One) (NN trial)) (VP (VBD analysed) (NP (NP (NNS subgroups)) (PP (IN of) (NP (NP (CD 2839) (ADJP (RB relatively) (JJ healthy) (QP (CD 50) (TO to) (CD 59)) (NN year)) (JJ old) (NNS women)) (VP (VBG taking) (NP (NP (JJ combined) (JJ continuous) (NN HT)) (CC and) (NP (NP (CD 1637)) (VP (VBG taking) (NP (NP (JJ Doc_19370593_2340_2349_Chemical-only) (NNS HT)) (, ,) (CC versus) (NP (JJ similar-sized) (NN placebo) (NNS groups))))))))))) (. .)))
19370593	16	(S1 (S (S (NP (NP (DT The) (JJ only) (ADJP (RB significantly) (JJ increased)) (NN risk)) (VP (VBD reported))) (VP (AUX was) (PP (IN for) (NP (NNP Doc_19370593_2451_2474_Disease))) (PP (IN in) (NP (NP (NNS women)) (VP (VBG taking) (NP (JJ combined) (JJ continuous) (NNS HT))))))) (: :) (S (NP (PRP$ their) (JJ absolute) (NN risk)) (VP (VBD remained) (ADJP (JJ low)) (, ,) (PP (IN at) (NP (QP (JJR less) (IN than) (CD 1/500)))))) (. .)))
19370593	17	(S1 (S (ADVP (RB However)) (, ,) (NP (DT this) (NN study)) (VP (AUX was) (RB not) (VP (VBN powered) (S (VP (TO to) (VP (VB detect) (NP (NP (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN of) (NP (JJR younger) (NNS women))))))))))) (. .)))
19370593	18	(S1 (NP (NP (NP (NNS AUTHORS) (POS ')) (NNS CONCLUSIONS)) (: :) (S (NP (NN HT)) (VP (AUX is) (RB not) (VP (VBN indicated) (PP (IN for) (NP (NP (DT the) (JJ routine) (NN management)) (PP (IN of) (NP (NN chronic) (NN disease)))))))) (. .)))
19370593	19	(S1 (S (NP (PRP We)) (VP (AUX need) (NP (NP (JJR more) (NN evidence)) (PP (IN on) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (NNS HT)) (PP (IN for) (NP (JJ menopausal) (NN symptom) (NN control)))))))) (, ,) (SBAR (IN though) (S (NP (JJ short-term) (NN use)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RB relatively) (JJ safe)) (PP (IN for) (NP (JJ healthy) (JJR younger) (NNS women)))))))))) (. .)))
19642243	0	(S1 (S (VP (VB Doc_19642243_0_19_Disease) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_19642243_37_41_Disease))))) (PP (IN on) (NP (NNP Doc_19642243_45_54_Chemical))) (PP (IN while) (S (VP (VBG receiving) (NP (JJ prolonged) (JJ Doc_19642243_81_91_Chemical) (NN course)) (PP (IN for) (NP (NNP Doc_19642243_103_116_Disease))))))) (. .)))
19642243	1	(S1 (S (NP (NN Doc_19642243_118_131_Disease)) (VP (VBD developed) (PP (IN after) (NP (NP (DT a) (JJ prolonged) (NN course)) (PP (IN of) (NP (JJ Doc_19642243_170_180_Chemical) (NN therapy))))) (PP (IN in) (NP (NP (CD 2) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (S (VP (VBG receiving) (NP (NNP Doc_19642243_222_251_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT an) (JJ antiretroviral) (NN regimen))))))))))))) (. .)))
19642243	2	(S1 (S (NP (NN Doc_19642243_290_299_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_19642243_342_358_Disease)) (CC and) (NP (NNP Doc_19642243_363_382_Disease)))))) (PP (IN because) (IN of) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (DT the) (JJ proximal) (JJ renal) (NN tubule)))))))) (. .)))
19642243	3	(S1 (S (NP (NNP Doc_19642243_436_446_Chemical) (NNP Doc_19642243_447_461_Disease)) (VP (VP (AUX is) (ADJP (JJ infrequent))) (CC but) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NN coadministration))) (PP (IN with) (NP (DT a) (JJ Doc_19642243_520_531_Disease) (NN agent)))))) (. .)))
19642243	4	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (NNP Doc_19642243_571_580_Chemical)) (VP (MD may) (VP (VB raise) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19642243_603_616_Disease)))) (PP (IN during) (NP (NP (VBN prolonged) (NN administration)) (PP (IN of) (NP (NN Doc_19642243_652_662_Chemical)))))))))))) (. .)))
19674115	0	(S1 (S (NP (NNP Recurrent) (NNP Doc_19674115_10_18_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19674115_30_42_Chemical)))) (. .)))
19674115	1	(S1 (S (NP (NN Doc_19674115_44_56_Chemical)) (VP (MD can) (VP (AUX have) (NP (NP (JJ adverse) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19674115_90_106_Disease)) (, ,) (NP (NNP Doc_19674115_108_121_Disease)) (CC or) (NP (JJ digestive) (NNS disorders))))))) (. .)))
19674115	2	(S1 (S (PP (IN In) (NP (JJ rare) (NNS cases))) (, ,) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN taste)) (CC and) (NP (NN smell) (NN function))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN for) (NP (NNP Doc_19674115_224_236_Chemical))) (SBAR (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (JJ other) (NNS drugs))))))))) (. .)))
19674115	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ reversible) (NNP Doc_19674115_300_318_Disease))) (VP (VBN related) (PP (TO to) (NP (NNP Doc_19674115_330_342_Chemical))))) (PP (IN in) (NP (DT a) (NN woman))) (, ,) (PP (IN with) (NP (DT a) (JJ positive) (NN rechallenge)))) (. .)))
19674115	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD presented) (NP (DT every) (NN day)) (NP (NP (DT a) (NN sensation)) (PP (IN of) (S (VP (VBG smelling) (NP (NP (NN something)) (VP (VBG burning) (NP (CD 15) (NN min)) (PP (IN after) (NP (NN drug) (NN intake)))))))))) (. .)))
19674115	5	(S1 (S (NP (NN Doc_19674115_484_492_Disease)) (VP (VP (VBD disappeared) (ADVP (RB completely)) (PP (IN after) (NP (JJ Doc_19674115_522_534_Chemical) (NN withdrawal)))) (CC and) (VP (VBD recurred) (PP (IN after) (NP (PRP$ its) (NN rechallenge))))) (. .)))
19674115	6	(S1 (S (NP (DT The) (NN case)) (VP (AUX was) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (NNP Tunisian) (NNP Centre)) (PP (IN of) (NP (NN Pharmacovigilance))))))) (. .)))
19692487	0	(S1 (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN mPGES-1)))) (VP (AUX are) (ADJP (JJ resistant) (PP (TO to) (NP (NNP Doc_19692487_38_45_Chemical-induced) (NNP Doc_19692487_54_62_Disease))))) (. .)))
19692487	1	(S1 (S (NP (NN Cyclooxygenase-2) (NN activity)) (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19692487_125_132_Chemical-induced) (NNP Doc_19692487_141_149_Disease))))))) (. .)))
19692487	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT a) (JJ specific) (, ,) (JJ terminal) (NNP Doc_19692487_200_213_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19692487_215_217_Chemical)) (-RRB- -RRB-)) (NN isomerase)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN evaluated)))) (. .)))
19692487	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB assess) (NP (NP (JJ Doc_19692487_296_303_Chemical-induced) (NN Doc_19692487_312_320_Disease)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN deficient) (PP (IN in) (NP (NP (JJ microsomal) (JJ Doc_19692487_353_368_Chemical) (NN synthase-1)) (PRN (-LRB- -LRB-) (NP (JJ mPGES-1)) (-RRB- -RRB-))))))))))))) (. .)))
19692487	4	(S1 (S (NP (NP (DT A) (NN 2-wk) (NN administration)) (PP (IN of) (NP (NNP Doc_19692487_416_420_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD mmol.kg)) (ADJP (ADJP (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (JJ .day)) (PRN (-LRB- -LRB-) (ADJP (JJ -1)) (-RRB- -RRB-))) (NNS ip)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ mPGES-1) (NN +/+) (NNS mice)))) (VP (VBD led) (PP (TO to) (NP (DT a) (VBN marked) (NNP Doc_19692487_484_492_Disease))) (PP (IN with) (NP (JJ hyposmotic) (NN urine)))) (. .)))
19692487	5	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ elevated) (JJ renal) (JJ mPGES-1) (NN protein) (NN expression)) (CC and) (NP (VBN increased) (NN urine) (NN Doc_19692487_603_609_Chemical) (NN excretion)))))) (. .)))
19692487	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ mPGES-1) (JJ -/-) (NNS mice)) (VP (AUX were) (ADJP (RB largely) (JJ resistant) (PP (TO to) (NP (NP (JJ Doc_19692487_677_684_Chemical-induced) (NN Doc_19692487_693_701_Disease)) (CC and) (NP (NP (DT a) (NN urine)) (VP (VBG concentrating) (NP (NN defect))))))) (, ,) (S (VP (VBN accompanied) (PP (IN by) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN blockade)) (PP (IN of) (NP (JJ high) (NN urine) (UCP (JJ Doc_19692487_790_796_Chemical) (CC and) (NN cAMP)) (NN output)))))))) (. .)))
19692487	7	(S1 (S (NP (ADJP (JJ Immunoblotting) (, ,) (JJ immunohistochemistry) (, ,) (CC and) (JJ quantitative)) (PRN (-LRB- -LRB-) (NP (NNP q)) (-RRB- -RRB-)) (NNP RT-PCR)) (ADVP (RB consistently)) (VP (VBD detected) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (JJ aquaporin-2) (PRN (-LRB- -LRB-) (NP (NNP AQP2)) (-RRB- -RRB-)) (NN protein) (NN expression)) (PP (IN in) (NP (PDT both) (DT the) (JJ renal) (NN cortex)))))) (CC and) (NP (NP (NN medulla)) (PP (IN of) (NP (JJ Doc_19692487_1006_1013_Chemical-treated) (NN +/+) (NNS mice)))))) (. .)))
19692487	8	(S1 (S (NP (DT This) (NN decrease)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN in) (NP (DT the) (JJ -/-) (NNS mice))))) (. .)))
19692487	9	(S1 (S (NP (NNP qRT-PCR)) (VP (VBD detected) (NP (NP (JJ similar) (NNS patterns)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ AQP2) (NNS mRNA)))))) (PP (PP (IN in) (NP (DT the) (NN medulla))) (CC but) (PP (RB not) (IN in) (NP (DT the) (NN cortex))))) (. .)))
19692487	10	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (DT the) (JJ total) (NN protein) (NN abundance)) (PP (IN of) (NP (DT the) (JJ Doc_19692487_1234_1236_Chemical-Doc_19692487_1237_1238_Chemical-2Doc_19692487_1240_1242_Chemical) (NN cotransporter))) (PRN (-LRB- -LRB-) (NP (NNP NKCC2)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (DT the) (NN medulla) (CC but) (RB not)) (PP (IN in) (NP (NP (DT the) (NN cortex)) (PP (IN of) (NP (DT the) (JJ +/+) (NNS mice)))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (JJ Doc_19692487_1347_1354_Chemical) (NN treatment))))) (. .)))
19692487	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN dowregulation)) (PP (IN of) (NP (JJ renal) (JJ medullary) (NN NKCC2) (NN expression)))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN in) (NP (DT the) (JJ -/-) (NNS mice))))) (. .)))
19692487	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ mPGES-1-derived) (NNP Doc_19692487_1512_1518_Chemical)) (VP (VBZ mediates) (NP (JJ Doc_19692487_1528_1535_Chemical-induced) (NNP Doc_19692487_1544_1552_Disease)) (ADVP (RB likely)) (PP (IN via) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN AQP2)) (CC and) (NP (JJ NKCC2) (NN expression)))))))))) (. .)))
1969772	0	(S1 (S (NP (NP (NN Preservation)) (PP (IN of) (NP (JJ renal) (NN blood)))) (VP (VBP flow) (PP (IN during) (NP (NP (NN Doc_1969772_40_51_Disease)) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_1969772_65_75_Chemical))) (PP (IN in) (NP (NNS dogs))))))) (. .)))
1969772	1	(S1 (S (NP (NP (DT The) (NN introduction)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB induce) (NP (NN Doc_1969772_129_140_Disease)) (PP (IN with) (NP (JJ different) (JJ pharmacological) (NNS actions)))))))))) (VP (MD would) (VP (AUX be) (ADJP (JJ advantageous)) (SBAR (IN because) (S (NP (NP (JJ side) (NNS effects)) (ADJP (JJ unique) (PP (TO to) (NP (DT a) (JJ specific) (NN drug))))) (VP (MD could) (VP (AUX be) (VP (VBN minimized) (PP (IN by) (S (VP (VBG selecting) (NP (JJ appropriate) (NN therapy)))))))))))) (. .)))
1969772	2	(S1 (S (NP (NP (NP (JJ Specific) (NNP Doc_1969772_311_319_Chemical-1)) (, ,) (PRN (-LRB- -LRB-) (NP (NNP Doc_1969772_324_326_Chemical1)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_1969772_333_341_Chemical-2) (PRN (-LRB- -LRB-) (NP (NNP Doc_1969772_345_347_Chemical2)) (-RRB- -RRB-)) (NN receptor) (NNS agonists))) (VP (AUX are) (ADVP (RB now)) (PP (IN under) (NP (JJ clinical) (NN investigation)))) (. .)))
1969772	3	(S1 (S (NP (NN Doc_1969772_406_425_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ specific) (NN DA1) (NN receptor) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VBZ lowers) (NP (NN blood) (NN pressure)) (PP (IN by) (NP (NN vasodilatation)))))))) (. .)))
1969772	4	(S1 (S (NP (NP (DT The) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_1969772_527_537_Chemical)) (VP (MD could) (VP (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_1969772_562_573_Disease))))))) (CC and) (VP (VB preserve) (NP (NN blood) (NN flow)) (PP (TO to) (NP (DT the) (NN kidney))))))))) (VP (AUX was) (VP (VBN tested))) (. .)))
1969772	5	(S1 (S (NP (NP (JJ Systemic) (JJ aortic) (NN blood) (NN pressure)) (CC and) (NP (JJ renal) (NN blood) (NN flow))) (VP (AUX were) (VP (VBN measured) (ADVP (RB continuously)) (PP (IN with) (NP (NP (DT a) (JJ carotid) (JJ arterial) (NN catheter)) (CC and) (NP (NP (DT an) (JJ electromagnetic) (NN flow) (NN probe)) (ADVP (RB respectively))))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (ADJP (JJ cardiovascular) (CC and) (JJ renal)) (JJ vascular) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1969772_853_863_Chemical)) (CC and) (NP (NNP Doc_1969772_868_874_Chemical) (NNP Doc_1969772_875_888_Chemical)))) (PP (IN in) (NP (CD ten) (NNS dogs)))) (PP (IN under) (NP (JJ Doc_1969772_907_916_Chemical) (JJ general) (NN anaesthesia))))))))) (. .)))
1969772	6	(S1 (S (NP (JJ Mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (VBN decreased) (NP (CD 30) (NN +/-)) (NP (NP (CD 8)) (PP (IN per) (NP (NN cent)))) (PP (IN from) (NP (NP (NN control)) (PP (IN with) (NP (NP (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_1969772_1023_1033_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.4) (NN +/-) (QP (CD 2.0) (CD micrograms.kg-1.min-1))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 34) (NNS +/-)) (NP (NP (CD 4)) (PP (IN per) (NP (NP (NN cent)) (PP (IN with) (NP (NP (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_1969772_1109_1115_Chemical) (NNP Doc_1969772_1116_1129_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5.9) (NN micrograms.kg-1.min-1)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP NS)) (-RRB- -RRB-)))))))))))))))))) (. .)))
1969772	7	(S1 (S (NP (NP (JJ Renal) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN RBF)) (-RRB- -RRB-))) (VP (VP (VBD increased) (PP (IN during) (NP (NP (JJ Doc_1969772_1204_1214_Chemical-induced) (NNP Doc_1969772_1223_1234_Disease) (CD 11) (NN +/-) (CD 7)) (PP (IN per) (NP (NN cent)))))) (CC and) (VP (VBD decreased) (NP (CD 21) (NN +/-)) (NP (NP (CD 8)) (PP (IN per) (NP (NN cent)))) (PP (IN during) (NP (NP (NNP Doc_1969772_1292_1298_Chemical) (NNP Doc_1969772_1299_1312_Chemical-induced) (NNP Doc_1969772_1321_1332_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
1969772	8	(S1 (S (NP (NN Sodium) (NNP Doc_1969772_1360_1373_Chemical)) (VP (AUX is) (NP (NP (NP (DT a) (JJ non-selective) (NN arteriolar)) (CC and) (NP (JJ venous) (NN vasodilator))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB produce) (NP (NP (NN redistribution)) (PP (IN of) (NP (NN blood) (NN flow)))) (ADVP (RB away) (PP (IN from) (NP (DT the) (NN kidney) (SBAR (IN during) (S (VP (VBN induced) (NP (NNP Doc_1969772_1509_1520_Disease)))))))))))))) (. .)))
1969772	9	(S1 (S (NP (NNP Fenoldopam)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ Doc_1969772_1548_1556_Chemical-1) (PRN (-LRB- -LRB-) (NP (NNP DA1)) (-RRB- -RRB-)) (NN receptor) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ causes) (NP (NN vasodilatation)) (PP (TO to) (NP (NP (DT the) (NN kidney) (CC and) (JJ other) (NNS organs)) (PP (IN with) (NP (JJ DA1) (NNS receptors)))))) (CC and) (VP (VBZ preserves) (NP (NN blood) (NN flow)) (PP (TO to) (NP (DT the) (NN kidney) (SBAR (IN during) (S (VP (VBN induced) (S (NP (NNP Doc_1969772_1713_1724_Disease)))))))))))))) (. .)))
19707748	0	(S1 (NP (NP (NP (NN Doc_19707748_0_8_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_19707748_25_37_Chemical))))) (: :) (NP (NP (NN case) (NN presentation)) (CC and) (NP (NN literature) (NN review))) (. .)))
19707748	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_19707748_134_142_Disease)) (PP (ADVP (RB shortly)) (IN after) (S (VP (VP (VBG initiating) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_19707748_183_195_Chemical)))) (CC and) (VP (TO to) (VP (VB discuss) (NP (NP (DT the) (JJ potential) (NN drug-drug) (NNS interactions)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (JJ cytochrome) (NNP P450) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-)) (NNS 1A2)) (PP (PP (IN in) (NP (DT this) (NN case))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (JJ other) (NNS cases)))))) (, ,) (PP (IN of) (NP (JJ Doc_19707748_347_359_Chemical-induced) (NNP Doc_19707748_368_376_Disease))))))))))))))))))) (. .)))
19707748	2	(S1 (S (NP (JJ Several) (JJ biomedical) (NNS databases)) (VP (AUX were) (VP (VBD searched) (PP (VBG including) (NP (NP (NNP MEDLINE)) (, ,) (NP (NNP Cochrane)) (CC and) (NP (NNP Ovid)))))) (. .)))
19707748	3	(S1 (S (NP (NP (DT The) (JJ main) (NN search) (NNS terms)) (VP (VBN utilized))) (VP (AUX were) (NP (NP (NN case) (NN report)) (CC and) (NP (NN Doc_19707748_520_532_Chemical)))) (. .)))
19707748	4	(S1 (S (NP (DT The) (NN search)) (VP (AUX was) (ADJP (JJ limited) (PP (TO to) (NP (NP (NNS studies)) (VP (VBN published) (PP (IN in) (NP (NNP English)))))))) (. .)))
19707748	5	(S1 (S (NP (NP (CD Six) (NNS cases)) (PP (IN of) (NP (NNP Doc_19707748_612_624_Chemical-induced) (NNP Doc_19707748_633_641_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
19707748	6	(S1 (S (NP (NP (JJ Drug-drug) (NNS interactions)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN CYP1A2))) (PP (IN by) (NP (NNP Doc_19707748_742_754_Chemical))))))) (VP (AUX are) (ADVP (RB likely)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NN outcome)) (PP (IN of) (NP (DT these) (NNS cases))))))) (. .)))
19707748	7	(S1 (S (NP (NNS Clinicians)) (VP (AUX are) (VP (VBN exhorted) (S (VP (TO to) (VP (VB pay) (NP (JJ close) (NN attention)) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (JJ Doc_19707748_891_903_Chemical) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NNS medications)) (PP (IN with) (NP (JJ epileptogenic) (NNS properties))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBG CYP1A2) (NP (NNS substrates)))))))))))))))))) (. .)))
19719056	0	(S1 (NP (NP (JJ Doc_19719056_0_7_Chemical-Doc_19719056_8_16_Chemical) (NNS conjugates)) (: :) (NP (NP (NN synthesis)) (, ,) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo) (NN evaluation))))) (. .)))
19719056	1	(S1 (S (NP (NP (NNP Doc_19719056_73_81_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19719056_83_84_Chemical)) (-RRB- -RRB-))) (, ,) (VP (AUX is) (NP (DT a) (JJ non-narcotic) (UCP (JJ analgesic) (CC and) (NN antiinflammatory)) (NN drug))) (. .)))
19719056	2	(S1 (S (NP (DT A) (JJ biodegradable) (NN polymer) (NN Doc_19719056_166_173_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN utilized) (PP (IN as) (NP (NP (DT a) (NN carrier)) (PP (IN for) (NP (NP (NN synthesis)) (PP (IN of) (NP (NP (JJ Doc_19719056_222_230_Chemical-Doc_19719056_231_238_Chemical) (NNS conjugates)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)))))))) (S (VP (TO to) (VP (VP (VB improve) (NP (PRP$ its) (JJ aqueous) (NN solubility))) (CC and) (VP (VB reduce) (NP (JJ gastrointestinal) (NN side) (NNS effects))))))))) (. .)))
19719056	3	(S1 (S (NP (NP (DT An) (VBN activated) (NN moiety)) (, ,) (PP (FW i.e.) (NP (NP (JJ Doc_19719056_357_372_Chemical) (NN derivative)) (PP (IN of) (NP (NP (NNP Doc_19719056_387_395_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19719056_397_400_Chemical)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX was) (ADJP (JJ condensed) (PP (IN with) (NP (NP (NP (DT the) (JJ polysaccharide) (NN polymer)) (NP (NNP Doc_19719056_449_456_Chemical))) (PP (IN of) (NP (JJ different) (JJ molecular) (NNS weights)))))) (PRN (-LRB- -LRB-) (NP (CD 40000) (, ,) (CD 60000) (, ,) (CD 110000) (CC and) (CD 200000)) (-RRB- -RRB-))) (. .)))
19719056	4	(S1 (S (NP (JJ IR) (NN spectral) (NNS data)) (VP (VBD confirmed) (NP (NP (NN formation)) (PP (IN of) (NP (NN ester) (NN bonding)))) (PP (IN in) (NP (DT the) (NNS conjugates)))) (. .)))
19719056	5	(S1 (S (NP (JJ Doc_19719056_596_604_Chemical) (NNS contents)) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (JJ UV-spectrophotometric) (NN analysis))))) (. .)))
19719056	6	(S1 (S (NP (DT The) (JJ molecular) (NNS weights)) (VP (AUX were) (VP (VBN determined) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN viscosity)) (VP (VBG using) (NP (DT the) (NNP Mark-Howink-Sakurada) (NN equation))))))))) (. .)))
19719056	7	(S1 (SINV (PP (IN In) (NP (NP (NN vitro) (NNS hydrolysis)) (PP (IN of) (NP (NNP ED))))) (VP (AUX was) (VP (AUX done) (PP (PP (IN in) (NP (NP (JJ aqueous) (NNS buffers)) (PRN (-LRB- -LRB-) (NP (CD pH) (CD 1.2) (, ,) (CD 7.4) (, ,) (CD 9)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (CD 80) (NN %)) (PRN (-LRB- -LRB-) (NP (NN v/v)) (-RRB- -RRB-))))))) (NP (NP (JJ human) (NN plasma)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.4)) (-RRB- -RRB-))) (. .)))
19719056	8	(S1 (S (PP (IN At) (NP (NN pH) (CD 9))) (, ,) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_19719056_903_911_Chemical) (NN release)) (PP (IN from) (NP (NNP ED)))))) (VP (AUX was) (VP (VBN observed) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (NP (JJ aqueous) (NN buffer)) (PP (IN of) (NP (NN pH) (CD 7.4)))) (CC and) (NP (NP (NP (CD 80) (NN %)) (NP (JJ human) (NN plasma))) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.4)) (-RRB- -RRB-))))))) (, ,) (PP (VBG following) (NP (JJ first-order) (NNS kinetics))))) (. .)))
19719056	9	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NNS investigations)) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (NNS animals))))) (. .)))
19719056	10	(S1 (S (NP (JJ Acute) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (VP (AUX were) (VP (VBN ascertained) (S (VP (VBG using) (NP (NP (JJ Doc_19719056_1165_1176_Chemical) (VBN induced) (NN Doc_19719056_1185_1193_Disease) (NN model)) (PRN (-LRB- -LRB-) (NP (NNS mice)) (-RRB- -RRB-)) (CC and) (NP (JJ Doc_19719056_1211_1222_Chemical-induced) (NN rat) (NN paw) (NNP Doc_19719056_1239_1244_Disease) (NN model)) (, ,) (ADVP (RB respectively))))))) (. .)))
19719056	11	(S1 (S (PP (IN In) (NP (NP (NN comparison)) (PP (TO to) (NP (NN control))))) (, ,) (NP (NP (NNP Doc_19719056_1292_1293_Chemical)) (CC and) (NP (NNP ED1-ED4))) (VP (VBD showed) (NP (NP (ADJP (RB highly) (JJ significant)) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.001)) (-RRB- -RRB-)))) (. .)))
19719056	12	(S1 (S (NP (JJ Biological) (NN evaluation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NNS conjugates)) (PRN (-LRB- -LRB-) (NP (NN ED1-ED4)) (-RRB- -RRB-))) (VP (VBD retained) (NP (JJ comparable) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (PP (IN with) (NP (ADJP (RB remarkably) (VBN reduced)) (NN ulcerogenicity))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN parent) (NN drug--Doc_19719056_1579_1587_Chemical)))))))))) (. .)))
19721134	0	(S1 (NP (NP (NP (DT The) (JJ antiarrhythmic) (NN effect)) (CC and) (NP (JJ possible) (JJ ionic) (NNS mechanisms))) (PP (IN of) (NP (NNP Doc_19721134_59_70_Chemical))) (PP (IN on) (NP (NN animal) (NNS models))) (. .)))
19721134	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_19721134_140_151_Chemical))))) (CC and) (VP (VB explore) (NP (DT the) (JJ underlying) (JJ ionic) (NN mechanism)))))) (, ,) (S (VP (VBG using) (NP (DT both) (JJ Doc_19721134_207_216_Chemical-induced) (NN rat) (CC and) (JJ Doc_19721134_233_240_Chemical-induced) (NN guinea) (NN pig)) (NP (NNP Doc_19721134_260_270_Disease) (NNS models)))))) (. .)))
19721134	2	(S1 (S (NP (JJ Confocal) (NN microscopy)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NP (JJ intracellular) (JJ free-Doc_19721134_338_345_Chemical) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (JJ -LSB-Doc_19721134_363_365_Chemical) (PRN (-LRB- -LRB-) (JJ 2+) (-RRB- -RRB-)) (JJ -RSB-)) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-))) (-RRB- -RRB-))) (PP (IN in) (NP (JJ isolated) (NNS myocytes)))))))) (. .)))
19721134	3	(S1 (S (NP (DT The) (JJ current) (NNS data)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_19721134_426_437_Chemical)) (ADVP (RB significantly)) (VP (VP (VBD delayed) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_19721134_469_480_Disease))))) (, ,) (VP (VBD decreased) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NNP Doc_19721134_511_551_Disease))))) (, ,) (VP (VBD reduced) (NP (NNP Doc_19721134_561_571_Disease) (NN score))) (, ,) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN survival) (NN time)) (PP (IN of) (NP (NNP Doc_19721134_614_624_Disease) (NNS rats) (CC and) (NN guinea) (NN pigs.))) (SBAR (S (NP (NP (JJ -LSB-Doc_19721134_648_650_Chemical) (PRN (-LRB- -LRB-) (VBG 2+) (-RRB- -RRB-)) (JJ -RSB-) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (NN overload)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19721134_679_688_Chemical) (CC or) (NNP Doc_19721134_692_699_Chemical))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (JJ isolated) (NNS myocytes)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_19721134_749_760_Chemical)))))))))))))))) (. .)))
19721134	4	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NP (NNP M)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (NP (JJ -muscarinic) (JJ Doc_19721134_788_801_Chemical) (NN receptor) (PRN (-LRB- -LRB-) (NP (NN mAChR)) (-RRB- -RRB-)) (NN antagonist)) (NNP Doc_19721134_830_836_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19721134_838_885_Chemical)) (-RRB- -RRB-))) (ADVP (RB partially)) (VP (VBD abolished) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19721134_933_944_Chemical))))) (. .)))
19721134	5	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_19721134_970_981_Chemical)) (VP (VBD produced) (NP (NP (JJ antiarrhythmic) (NNS actions)) (PP (IN on) (NP (NP (NNP Doc_19721134_1017_1027_Disease) (NN rat) (CC and) (NN guinea) (NN pig) (NNS models)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_19721134_1065_1074_Chemical)) (CC or) (NP (NNP Doc_19721134_1078_1085_Chemical)))) (PP (IN via) (S (VP (VBG stimulating) (NP (DT the) (JJ cardiac) (NNP M) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -mAChR))))))))))))) (. .)))
19721134	6	(S1 (S (NP (DT The) (NN mechanism)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN improvement)) (PP (IN of) (NP (NNP Doc_19721134_1177_1179_Chemical) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-)) (NN handling)))))))) (. .)))
19761039	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_19761039_10_32_Chemical))) (PP (IN on) (NP (NP (NP (JJ Doc_19761039_36_45_Chemical-induced) (NN neurobehavioral)) (CC and) (NP (JJ biochemical) (NNS alterations))) (PP (IN in) (NP (NNS rats))))) (. .)))
19761039	1	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NP (JJ methanolic) (VB extract)) (PP (IN of) (NP (NNP Doc_19761039_139_161_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 100-300) (NN mg/kg)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN studied) (PP (IN on) (NP (NP (JJ Doc_19761039_193_202_Chemical-induced) (JJ orofacial) (NN Doc_19761039_221_231_Disease)) (CC and) (NP (JJ neurochemical) (NNS alterations)))))) (. .)))
19761039	2	(S1 (S (NP (DT The) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ intraperitoneal) (NNP Doc_19761039_306_315_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN mg/kg)) (, ,) (NP (NN ip))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (CD 3) (NNS days)) (NP (DT every) (JJ other) (NN day)))))) (. .)))
19761039	3	(S1 (S (PP (IN On) (NP (NN day) (CD 5))) (, ,) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NNS protrusions))) (VP (AUX were) (VP (VBN counted) (PP (IN for) (NP (CD 5) (NN min))))) (. .)))
19761039	4	(S1 (S (NP (JJ Doc_19761039_441_450_Chemical) (VBN treated) (NNS rats)) (ADVP (RB significantly)) (VP (VBD developed) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NNS protrusions))) (ADVP (RB however)) (, ,) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (JJ Doc_19761039_566_588_Chemical) (NNS roots)))) (VP (VB extract) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (, ,) (CD 200) (CC and) (CD 300) (NNS mg/kg)) (, ,) (PP (IN per) (NP (RB orally)))) (-RRB- -RRB-)) (VP (VBN attenuated) (NP (DT the) (NNS effects)))))) (. .)))
19761039	5	(S1 (S (NP (NP (JJ Biochemical) (NN analysis)) (PP (IN of) (NP (NN brain)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (JJ Doc_19761039_712_721_Chemical) (NN treatment)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NN lipid) (NN peroxidation))) (CC and) (VP (VBD decreased) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NP (JJ Doc_19761039_799_809_Chemical) (NN dismutase)) (PRN (-LRB- -LRB-) (NP (NNP SOD)) (-RRB- -RRB-))) (, ,) (NP (NP (NN catalase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_19761039_846_857_Chemical) (NN reductase)) (PRN (-LRB- -LRB-) (NP (NN GSH)) (-RRB- -RRB-)) (, ,) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (JJ oxidative) (NN stress) (NN process))))))))))))) (. .)))
19761039	6	(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (VB extract)))) (VP (VP (ADVP (RB significantly)) (VBD reduced) (NP (DT the) (NN lipid) (NN peroxidation))) (CC and) (VP (VBD reversed) (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN brain) (NN SOD)) (, ,) (NP (NN CAT)) (CC and) (NP (JJ GSH) (NNS levels)))))) (. .)))
19761039	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_19761039_1094_1116_Chemical)) (VP (AUX had) (NP (DT a) (JJ protective) (NN role)) (PP (IN against) (NP (NP (JJ Doc_19761039_1147_1156_Chemical-induced) (JJ orofacial) (NN Doc_19761039_1175_1185_Disease)) (CC and) (NP (JJ oxidative) (NN stress)))))))) (. .)))
19893084	0	(S1 (NP (NP (JJ Dynamic) (NN response)) (PP (IN of) (NP (NP (NN blood) (NN vessel)) (PP (IN in) (NP (NNP Doc_19893084_36_55_Disease))))) (. .)))
19893084	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD postulated) (SBAR (SBAR (IN that) (S (PP (IN during) (NP (NP (NNP Doc_19893084_97_116_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19893084_128_138_Chemical)))))) (NP (NP (DT the) (ADJP (ADJP (JJ transient)) (CC or) (ADJP (JJ dynamic))) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels)))) (VP (MD could) (VP (AUX be) (VP (VBN affected)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNS antioxidants)) (VP (MD can) (VP (VB prevent) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJ dynamic) (NNS responses)) (PP (IN of) (NP (NN blood) (NNS vessels)))))))))))) (. .)))
19893084	2	(S1 (S (NP (NP (DT The) (JJ new) (NN approach)) (PP (TO to) (NP (FW ex) (FW vivo) (NN blood) (NN vessel) (NNS experiments))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (ADVP (RB not) (RB only)) (NP (NP (DT the) (NN end) (NNS points)) (PP (IN of) (NP (NP (NP (NNS vessels)) (SBAR (S (NP (NP (NN response)) (PP (IN within) (NP (DT the) (NN time) (NN interval)))) (VP (AUX is) (VP (VBN considered)))))) (, ,) (CONJP (CC but) (RB also)) (NP (NP (NNS dynamics)) (PP (IN of) (NP (DT this) (NN response))))))))) (, ,)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (DT this) (NN paper))))) (. .)))
19893084	3	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP confirm) (NP (DT the) (NN alteration)) (PP (IN in) (NP (NP (JJ dynamic) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN during) (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN pressure))) (PP (IN in) (NP (JJ Doc_19893084_605_615_Chemical-treated) (NNS animals)))))) (. .)))
19893084	4	(S1 (S (NP (NP (DT The) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19893084_659_668_Chemical) (NN administration))) (PP (TO to) (NP (JJ Doc_19893084_687_697_Chemical-treated) (NNS animals)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN confirmed) (PP (IN through) (NP (: :) (NP (NP (NP (JJR lower) (NN level)) (PP (IN of) (NP (NN blood) (NNP Doc_19893084_763_767_Chemical) (CC and) (NNP Doc_19893084_772_782_Chemical)))) (CC and) (NP (NP (JJR higher) (NN level)) (PP (IN of) (NP (NNP Doc_19893084_803_812_Chemical))))))))) (. .)))
19893084	5	(S1 (S (NP (NP (DT The) (NN pressure) (JJ dynamic) (NNS responses)) (PP (IN of) (NP (JJ isolated) (NN blood) (NNS vessels)))) (VP (VBP show) (NP (NP (DT a) (JJR faster) (NN pressure) (NN change)) (PP (IN in) (NP (JJ Doc_19893084_904_914_Chemical-treated) (NNS animals)))) (PRN (-LRB- -LRB-) (NP (CD 8.07) (NN +/-) (CD 1.7) (NNP s) (CC vs.) (CD 5.64) (NN +/-) (CD 0.18)) (PRP s) (-RRB- -RRB-))) (. .)))
19893084	6	(S1 (S (NP (NP (JJ Doc_19893084_969_978_Chemical) (NN administration) (VBN induced) (NN slowdown)) (PP (IN of) (NP (NN pressure)))) (VP (VBP change) (ADVP (RB back)) (PP (TO to) (NP (DT the) (NN control) (NNS values)))) (. .)))
19893084	7	(S1 (S (NP (NP (DT The) (NN pressure) (JJ dynamic) (NNS properties)) (, ,) (VP (ADVP (RB quantitatively)) (VBN defined) (PP (IN by) (NP (NP (JJ comparative) (NN pressure) (NN dynamic)) (CC and) (NP (JJ total) (NN pressure) (NN dynamic))))) (, ,)) (VP (VBP confirm) (NP (DT the) (NN alteration)) (PP (IN in) (NP (NP (JJ dynamic) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN during) (NP (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN pressure))) (PP (IN in) (NP (JJ Doc_19893084_1267_1277_Chemical-treated) (NNS animals)))) (CC and) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19893084_1320_1329_Chemical) (NN administration))))))) (. .)))
19917396	0	(S1 (NP (NP (NP (JJ Reversible) (NN Doc_19917396_11_33_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19917396_45_55_Chemical))) (PP (IN in) (NP (DT a) (JJ pediatric) (NN heart) (NN transplant) (NN recipient))))) (: :) (NP (NN case) (NN report)) (. .)))
19917396	1	(S1 (S (NP (NN Doc_19917396_112_122_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ potent) (NN immunosuppressant)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NN organ) (NN transplantation))))))))) (. .)))
19917396	2	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ adverse) (NNS effects)) (VP (VBP include) (NP (NN Doc_19917396_236_252_Disease))) (. .)))
19917396	3	(S1 (S (ADVP (RB Herein)) (NP (PRP we)) (VP (VBP describe) (NP (NP (JJ transient) (NNP Doc_19917396_283_305_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19917396_317_327_Chemical))) (PP (IN after) (NP (NN heart) (NN transplantation)))))) (. .)))
19917396	4	(S1 (S (NP (DT The) (NNP Doc_19917396_361_372_Disease)) (VP (VP (VBD caused) (NP (DT no) (JJ clinical) (NNS symptoms))) (CC but) (VP (AUX was) (VP (VP (VBN noted) (PP (IN because) (IN of) (NP (NP (NN elevation)) (PP (IN of) (NP (NN plasma) (NN brain) (NN natriuretic) (NN peptide) (NN concentration)))))) (CC and) (VP (VBN confirmed) (PP (IN at) (NP (NN echocardiography))))))) (. .)))
19917396	5	(S1 (S (S (ADVP (RB Initially)) (, ,) (NP (NN allograft) (NN rejection)) (VP (AUX was) (VP (VBN feared)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ myocardial) (NN biopsy) (NNS samples)) (VP (VBD revealed) (NP (NP (JJ only) (JJ interstitial) (NN Doc_19917396_626_631_Disease)) (CC and) (NP (JJ mild) (NN Doc_19917396_641_663_Disease))))) (: ;) (S (NP (DT neither) (JJ cellular) (CC nor) (JJ humoral) (NN rejection)) (VP (AUX was) (VP (VBN detected)))) (. .)))
19917396	6	(S1 (S (S (NP (DT The) (NN blood) (JJ Doc_19917396_728_738_Chemical) (NN concentration)) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ usual)))) (PP (IN at) (NP (DT that) (NN time))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (JJ Doc_19917396_795_805_Chemical) (NN dosage)) (VP (AUX was) (VP (VBN reduced)))) (. .)))
19917396	7	(S1 (S (NP (NN Doc_19917396_826_848_Disease)) (VP (ADVP (RB completely)) (VBN resolved) (PP (IN upon) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN target) (NN concentration)) (PP (IN of) (NP (NNP Doc_19917396_911_921_Chemical))))) (CC and) (VP (AUX did) (RB not) (VP (VB recur)))))) (, ,) (SBAR (IN as) (S (VP (VBN confirmed) (PP (IN at) (NP (NP (NN echocardiography)) (CC and) (NP (JJ myocardial) (NN biopsy)))))))) (. .)))
19917396	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_19917396_1020_1030_Chemical)) (VP (VBZ induces) (NP (JJ reversible) (NN Doc_19917396_1050_1072_Disease)))))) (. .)))
19917396	9	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_19917396_1096_1106_Chemical) (NN therapy))))) (, ,) (NP (NN blood) (NN concentration)) (VP (MD should) (VP (AUX be) (VP (VP (ADVP (RB carefully)) (VBN controlled)) (CC and) (VP (NP (JJ extreme) (NN attention)) (VBD paid) (PP (TO to) (NP (JJ cardiac) (NN involvement))))))) (. .)))
19923525	0	(S1 (S (NP (NN Doc_19923525_0_10_Chemical)) (VP (VBZ prevents) (NP (NP (NN Doc_19923525_20_37_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_19923525_48_61_Chemical-induced) (NNP Doc_19923525_70_81_Disease)) (PP (IN in) (NP (NN adult) (NNS mice)))))))) (. .)))
19923525	1	(S1 (S (NP (NP (NN Doc_19923525_109_120_Disease)) (CC and) (NP (NP (DT a) (JJ resultant) (NN decrease)) (PP (IN in) (NP (JJ cerebral) (NN blood) (NN flow))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19923525_212_233_Disease)))))))) (. .)))
19923525	2	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (DT the) (NN hypothesis)) (SBAR (IN that) (S (NP (NP (NNP Doc_19923525_265_275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19923525_277_281_Chemical)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_19923525_312_325_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19923525_327_330_Chemical)) (-RRB- -RRB-)))))))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_19923525_340_351_Disease)) (VP (MD would) (VP (VB preserve) (NP (JJ long-term) (JJ associative) (NN memory)))))))))) (. .)))
19923525	3	(S1 (S (NP (DT The) (NN passive) (NN avoidance) (PRN (-LRB- -LRB-) (NP (NNP PA)) (-RRB- -RRB-)) (NN paradigm)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NN memory) (NN retention))))))) (. .)))
19923525	4	(S1 (S (PP (IN For) (NP (NNP PA) (NN training))) (, ,) (NP (NP (NNS latencies)) (PRN (-LRB- -LRB-) (NP (NNS seconds)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (NN entry))) (PP (IN from) (NP (DT a) (VBN suspended) (NN platform))) (PP (IN into) (NP (NP (DT a) (NNP Plexiglas) (NN tube)) (SBAR (WHADVP (WRB where)) (S (NP (DT a) (NN shock)) (VP (AUX was) (ADVP (RB automatically)) (VP (VBN delivered))))))))) (. .)))
19923525	5	(S1 (S (NP (NNS Latencies)) (VP (AUX were) (VP (VBN recorded) (NP (CD 48) (NNP h)) (ADVP (RB later)) (PP (IN for) (NP (DT a) (NN testing) (NN trial))))) (. .)))
19923525	6	(S1 (S (NP (NNP Ninety-six) (NNP Swiss-Webster) (PRN (S (NP (NP (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD 30-35) (NNP g)) (, ,) (NP (JJ 6-8) (NNS wk)) (-RRB- -RRB-)) (, ,)) (VP (AUX were) (VP (VBN randomized) (PP (IN into) (NP (CD 6) (NNS groups))) (NP (NP (CD 1) (-RRB- -RRB-) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-)))))) (, ,) (NP (CD 2)) (-RRB- -RRB-)) (NNP Doc_19923525_790_793_Chemical)) (ADVP (RB immediately) (IN after)) (VP (VBG learning) (PRN (, ,) (NP (CD 3)) (-RRB- -RRB-)) (NP (NNP Doc_19923525_825_828_Chemical) (CD 3) (NNP h)) (PP (IN after) (S (VP (VBG learning) (PRN (, ,) (NP (NP (CD 4) (-RRB- -RRB-) (NNP Doc_19923525_852_855_Chemical)) (CC and) (NP (NNP Doc_19923525_860_864_Chemical))) (, ,) (NP (CD 5)) (-RRB- -RRB-)) (NP (NP (NN vehicle)) (, ,) (CC and) (NP (NP (CD 6) (-RRB- -RRB-) (NNP Doc_19923525_885_889_Chemical)) (ADVP (RB alone)))))))) (. .)))
19923525	7	(S1 (S (NP (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NNP Doc_19923525_911_922_Disease)))) (CC and) (NP (NP (NNS changes)) (PP (PP (IN in) (NP (NP (NN brain) (NN tissue) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP PbtO)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (JJ cerebral) (NN blood) (NN flow)))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NNS animals))))))) (. .)))
19923525	8	(S1 (S (NP (DT All) (NNS groups)) (VP (VBD exhibited) (NP (NP (JJ similar) (NN training) (NNS latencies)) (PRN (-LRB- -LRB-) (NP (CD 17.0) (NN +/-) (CD 4.6)) (PRP s) (-RRB- -RRB-)))) (. .)))
19923525	9	(S1 (S (NP (NP (NNS Mice)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_19923525_1138_1149_Disease) (NNS episodes))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NN latency) (NN time)) (PRN (-LRB- -LRB-) (NP (QP (CD 178) (CD +/-)) (CD 156)) (PRP s) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VP (VBN injected) (PP (IN with) (NP (NP (NN saline)) (, ,) (NP (NNP Doc_19923525_1263_1266_Chemical) (NNP +) (NNP Doc_19923525_1269_1273_Chemical)) (, ,)))) (CC or) (VP (VBN delayed) (NP (NNP Doc_19923525_1286_1289_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 580) (JJ +/-) (NX (NX (CD 81) (NNP s)) (, ,) (NX (CD 557) (JJ +/-) (CD 67) (NNP s)) (, ,) (CC and) (NX (CD 493) (JJ +/-) (CD 146)))) (NP (NP (PRP s)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
19923525	10	(S1 (S (NP (NP (DT A) (JJ Kruskal-Wallis) (JJ 1-way) (NN analysis)) (PP (IN of) (NP (NN variance)))) (VP (VBD indicated) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN among) (NP (NP (DT the) (CD 4) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP H) (SYM =) (CD 15.34)) (: ;) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
19923525	11	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NNS mice))) (VP (RB not) (VBN subjected) (PP (TO to) (NP (JJ behavioral) (NNS studies)))))) (, ,) (NP (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_19923525_1567_1570_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_19923525_1583_1586_Chemical) (NNP +) (NNP Doc_19923525_1589_1593_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-)))))) (VP (VBD caused) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (S (VP (TO to) (VP (VB decrease) (PP (PP (IN from) (NP (NP (CD 85.9) (JJ +/-) (ADJP (CD 3.8) (NN mm)) (NNP Hg) (NN sem)) (PP (TO to) (NP (NP (CD 31.6) (NN +/-)) (NP (CD 0.8) (JJ mm) (NNP Hg) (NN sem)))))) (CC and) (PP (IN from) (NP (NP (CD 86.2) (NN +/-)) (NP (CD 3.7) (JJ mm) (NNP Hg) (NN sem))))) (PP (TO to) (NP (NP (CD 32.6) (NNS +/-)) (NP (CD 0.2) (JJ mm) (NNP Hg) (NN sem)) (, ,) (ADVP (RB respectively)))))))) (. .)))
19923525	12	(S1 (S (NP (NP (JJ Mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_19923525_1827_1831_Chemical))))))) (ADVP (RB alone)) (VP (VBD decreased) (PP (IN from) (NP (QP (CD 88.1) (CD +/-)) (QP (CD 3.8) (CD mm)))) (NP (NNP Hg)) (PP (TO to) (NP (NP (CD 80.0) (NNS +/-)) (NP (CD 2.9) (NN mm) (NNP Hg))))) (. .)))
19923525	13	(S1 (S (S (NP (DT The) (NNP intergroup) (NN difference)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)))) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-)) (. .)))
19923525	14	(S1 (S (NP (NP (NNP PbtO)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBD decreased) (PP (PP (IN from) (NP (NP (CD 51.7) (NN +/-)) (NP (CD 4.5) (JJ mm) (NNP Hg) (NN sem)))) (PP (TO to) (NP (NP (NP (CD 33.8) (NN +/-)) (NP (CD 5.2) (JJ mm) (NNP Hg) (NN sem))) (PP (IN in) (NP (DT the) (NNP Doc_19923525_2042_2045_Chemical) (NN group))))) (CC and) (PP (IN from) (NP (NP (CD 38.6) (JJ +/-) (ADJP (CD 6.1) (NN mm)) (NNP Hg) (NN sem)) (PP (TO to) (NP (NP (CD 25.4) (NN +/-) (ADJP (CD 2.0) (NN mm)) (NNP Hg) (NN sem)) (PP (IN in) (NP (DT the) (NNP Doc_19923525_2117_2120_Chemical) (NNP +) (NNP Doc_19923525_2123_2127_Chemical) (NNS groups)))))))) (, ,) (ADVP (RB respectively))) (. .)))
19923525	15	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ significant) (NNS differences)) (PP (IN among) (NP (NNS groups)))) (. .)))
19923525	16	(S1 (S (PP (IN In) (NP (DT a) (NNP PA) (NN retention) (NN paradigm))) (, ,) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_19923525_2259_2262_Chemical))) (PP (ADVP (RB immediately)) (IN after) (NP (NN learning)))) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN impairment)) (PP (IN of) (NP (JJ long-term) (JJ associative) (NN memory)))) (PP (IN in) (NP (NNS mice))) (, ,) (SBAR (IN whereas) (S (NP (JJ delayed) (VBN induced) (NN Doc_19923525_2389_2400_Disease)) (VP (AUX had) (NP (DT no) (NN effect)))))) (. .)))
19923525	17	(S1 (S (NP (NN Doc_19923525_2416_2420_Chemical)) (VP (VP (VBD attenuated) (NP (DT the) (NN disruption)) (PP (IN in) (NP (NP (NN consolidation)) (PP (IN of) (NP (JJ long-term) (NN memory))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_19923525_2494_2497_Chemical))))))) (CC but) (VP (AUX did) (RB not) (VP (VB improve) (NP (NN latency)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_19923525_2544_2555_Disease)))))))) (. .)))
19923525	18	(S1 (S (NP (NP (DT The) (JJ observed) (NN effect)) (PP (IN of) (NP (NNP Doc_19923525_2580_2584_Chemical)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (ADJP (JJ attributable) (PP (TO to) (NP (NP (DT the) (NN preservation)) (PP (IN of) (NP (JJ Doc_19923525_2635_2642_Chemical) (NNS homeostasis))) (PP (IN during) (NP (NNP Doc_19923525_2662_2673_Disease)))))) (, ,) (SBAR (IN because) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NNP PbtO) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNS indices)) (PP (IN among) (NP (NNS groups)))))))))))) (. .)))
19940105	0	(S1 (S (NP (JJ Metabotropic) (NNP Doc_19940105_13_22_Chemical) (CD 7) (NN receptor) (NN subtype)) (VP (VBZ modulates) (NP (NN motor) (NNS symptoms)) (PP (IN in) (NP (NP (JJ rodent) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_87_106_Disease)))))) (. .)))
19940105	1	(S1 (S (NP (NNP Metabotropic) (NNP Doc_19940105_121_130_Chemical) (PRN (-LRB- -LRB-) (NP (NN mGlu)) (-RRB- -RRB-)) (NNS receptors)) (VP (VP (VBP modulate) (NP (NP (JJ synaptic) (NN transmission)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system))))) (CC and) (VP (VBP represent) (NP (NP (JJ promising) (JJ therapeutic) (NNS targets)) (PP (IN for) (NP (NP (JJ symptomatic) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_19940105_282_301_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_303_305_Disease)) (-RRB- -RRB-))))))))) (. .)))
19940105	2	(S1 (S (PP (IN Among) (NP (DT the) (CD eight) (NN mGlu) (NN receptor) (NNS subtypes))) (, ,) (S (NP (NN mGlu7) (NN receptor)) (VP (AUX is) (ADVP (RB prominently)) (VP (VBN expressed) (PP (IN in) (NP (DT the) (JJ basal) (NN ganglia)))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN role)) (PP (IN in) (S (VP (VBG restoring) (NP (NN motor) (NN function)) (PP (IN in) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_471_473_Disease))))))))) (VP (AUX is) (RB not) (VP (VBN known)))) (. .)))
19940105	3	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_19940105_503_554_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_556_562_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ first) (JJ selective) (NN allosteric) (NN activator)) (PP (IN of) (NP (JJ mGlu7) (NNS receptors)))) (, ,)))) (VP (AUX were) (ADVP (RB thus)) (VP (VBN tested) (PP (IN in) (NP (NP (JJ different) (JJ rodent) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_673_675_Disease))))))) (. .)))
19940105	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NP (NP (JJ oral)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ intrastriatal) (NN administration)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (CC and) (CD 0.5) (NN nmol)) (-RRB- -RRB-)))) (PP (IN of) (NP (NNP Doc_19940105_765_771_Chemical)))) (VP (VBZ reverses) (NP (NP (JJ Doc_19940105_781_792_Chemical-induced) (NN Doc_19940105_801_810_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
19940105	5	(S1 (S (NP (NP (NN Doc_19940105_820_826_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CC and) (CD 5)) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (JJ Doc_19940105_853_864_Chemical-induced) (NNS rotations)) (PP (IN in) (NP (JJ unilateral) (NNP Doc_19940105_897_914_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_916_922_Chemical)) (-RRB- -RRB-)) (JJ -lesioned) (NNS rats))))) (. .)))
19940105	6	(S1 (S (PP (IN In) (NP (NP (DT a) (ADJP (RBR more) (JJ complex)) (NN task)) (VP (ADVP (RB commonly)) (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (JJ major) (JJ Doc_19940105_994_1002_Disease) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_19940105_1015_1017_Disease) (NNS patients)))))))))) (, ,) (NP (CD 5) (JJ mg/kg) (NN Doc_19940105_1036_1042_Chemical)) (VP (VBZ reverses) (NP (NP (DT the) (VBN increased) (NN reaction) (NN time)) (SBAR (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (DT a) (NN cue)) (PP (IN of) (NP (JJ bilateral) (JJ Doc_19940105_1113_1119_Chemical-lesioned) (NNS rats))))))))))) (. .)))
19940105	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_19940105_1148_1154_Chemical)) (VP (VP (VBZ reduces) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_19940105_1179_1190_Chemical-induced) (NNP Doc_19940105_1199_1208_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ mGlu7) (JJ receptor-dependent) (NN manner)) (PP (IN in) (NP (NN wild-type)))))) (CC but) (RB not) (VP (VBZ mGlu7) (NP (NN receptor) (NN knockout) (NNS mice)))) (. .)))
19940105	8	(S1 (S (NP (NP (JJR Higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_19940105_1313_1319_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC and) (CD 20)) (JJ mg/kg) (NNS p.o.)) (-RRB- -RRB-))) (VP (AUX have) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ same) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_1380_1382_Disease))))))) (. .)))
19940105	9	(S1 (S (ADVP (JJ Overall)) (NP (DT these) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ mGlu7) (NN receptor) (NN activation)) (VP (MD can) (VP (VB reverse) (NP (NP (NN motor) (NN dysfunction)) (VP (VBN associated) (PP (IN with) (NP (JJ reduced) (JJ Doc_19940105_1500_1508_Chemical) (NN activity)))))))))) (. .)))
19940105	10	(S1 (S (NP (NP (JJ Selective) (NNS ligands)) (PP (IN of) (NP (NN mGlu7) (NN receptor) (NNS subtypes)))) (VP (MD may) (ADVP (RB thus)) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (JJ promising) (NNS compounds)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ antiparkinsonian) (JJ therapeutic) (NNS strategies)))))))))) (. .)))
19944333	0	(S1 (NP (NP (JJ Doc_19944333_0_9_Chemical-induced) (JJ acute) (NN Doc_19944333_24_45_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_19944333_53_74_Disease)))) (. .)))
19944333	1	(S1 (S (NP (NP (DT A) (JJ 65-year-old) (NN man)) (PP (IN with) (NP (JJ advanced) (NNP Doc_19944333_108_128_Disease)))) (VP (AUX was) (VP (VBN admitted) (PP (JJ due) (TO to) (S (VP (VBG continuing) (NP (NN Doc_19944333_160_170_Disease)) (PP (IN at) (NP (NN rest)))))))) (. .)))
19944333	2	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN before) (NP (PRP$ his) (NN admission))) (, ,) (NP (NNP Doc_19944333_212_221_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN started)))) (. .)))
19944333	3	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (JJ non-ST-elevation) (NN Doc_19944333_279_300_Disease))) (PP (IN by) (NP (NP (NN laboratory) (NNS data)) (CC and) (NP (NN electrocardiogram)))))) (. .)))
19944333	4	(S1 (S (NP (JJ Enhanced) (NN heart) (JJ magnetic) (NN resonance) (NN imaging)) (ADVP (RB also)) (VP (VBD showed) (NP (NN Doc_19944333_397_422_Disease))) (. .)))
19944333	5	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN stenosis)) (PP (IN in) (NP (NP (JJ coronary) (NNS arteries)) (PP (IN on) (NP (NN angiography))))))) (. .)))
19944333	6	(S1 (S (NP (NN Doc_19944333_492_513_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (DT a) (JJ provocative) (NN test))))) (. .)))
19944333	7	(S1 (S (S (NP (NP (NP (NN Cessation)) (PP (IN of) (NP (NNP Doc_19944333_562_571_Chemical)))) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ Doc_19944333_594_596_Chemical-channel) (NN blocker)) (CC and) (NP (NNP Doc_19944333_617_625_Chemical)))))) (VP (VBD ameliorated) (NP (PRP$ his) (NNS symptoms)))) (, ,) (CC but) (S (NP (NN relapse)) (VP (VBD occurred) (PP (IN after) (NP (NP (NN resumption)) (PP (IN of) (NP (NNP Doc_19944333_693_702_Chemical))))))) (. .)))
19944333	8	(S1 (S (NP (NP (NN Addition)) (PP (IN of) (NP (JJ oral) (NNP Doc_19944333_721_731_Chemical)))) (VP (VP (VBD reduced) (NP (PRP$ his) (NNS symptoms))) (CC and) (VP (VBD maintained) (NP (JJ Doc_19944333_768_781_Disease) (NN status)))) (. .)))
19944333	9	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_19944333_818_827_Chemical-induced) (NN Doc_19944333_836_857_Disease))))) (. .)))
19944333	10	(S1 (S (NP (NN Doc_19944333_859_868_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ multikinase) (NN inhibitor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ targets) (NP (NP (VBG signaling) (NNS pathways)) (ADJP (JJ necessary) (PP (IN for) (NP (NP (JJ cellular) (NN proliferation)) (CC and) (NP (NN survival))))))))))) (. .)))
19944333	11	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (DT the) (NNP Rho/ROCK) (NN pathway)) (VP (AUX has) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_19944333_1064_1085_Disease))))))) (. .)))
19944333	12	(S1 (S (NP (PRP$ Our) (NN report)) (VP (MD may) (VP (VB show) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ Rho/ROCK) (NN pathway)) (PP (IN by) (NP (JJ Doc_19944333_1152_1161_Chemical) (NN use)))))))) (. .)))
19944736	0	(S1 (S (NP (DT A) (JJ novel) (NN animal) (NN model)) (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system))) (S (VP (TO to) (VP (VB promote) (NP (DT the) (NN passage)) (PP (IN through) (NP (DT the) (NNP BBB))))))))) (. .)))
19944736	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN potentiality)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN animal) (NN model)) (SBAR (S (VP (TO to) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (DT the)) (PP (IN in) (NP (NP (NN vivo) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system))) (S (VP (TO to) (VP (VB promote) (NP (DT the) (NN passage)) (PP (IN through) (NP (NP (DT the) (JJ blood-brain) (NN barrier) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)) (NN and/or)) (SBAR (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN brain) (NN localization)) (PP (IN of) (NP (DT a) (JJ bioactive) (NN compound))))))))))))))))))))))))))))))) (. .)))
19944736	2	(S1 (S (NP (DT A) (JJ Tween) (JJ 80-coated) (JJ Doc_19944736_425_443_Chemical) (NN nanoparticles)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ colloidal) (NN drug) (NN delivery) (NN system))))) (, ,) (ADJP (JJ able) (PP (TO to) (NP (NN trespass)) (NP (DT the) (NNP BBB)))))) (. .)))
19944736	3	(S1 (S (NP (NP (NN Doc_19944736_539_546_Chemical)) (, ,) (VP (VBN administered) (PP (IN in) (NP (JJ Doc_19944736_564_568_Chemical) (JJ pre-treated) (NNS rats)))) (, ,)) (VP (VBZ induces) (NP (NP (JJ electrocorticographic) (NN Doc_19944736_617_625_Disease)) (CC and) (NP (JJ delayed) (NN Doc_19944736_638_656_Disease)))) (. .)))
19944736	4	(S1 (S (NP (NP (NP (DT The) (JJ toxic) (NNS effects)) (PP (IN of) (NP (JJ Doc_19944736_679_686_Chemical-loaded) (JJ Doc_19944736_694_712_Chemical) (NNS nanoparticles)))) (PRN (-LRB- -LRB-) (NP (CD 5mg/kg)) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (JJ saline) (NN solution)) (PP (IN of) (NP (NP (NNP Doc_19944736_758_765_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 5mg/kg)) (-RRB- -RRB-))))) (CC and) (NP (DT an) (JJ empty) (JJ colloidal) (JJ nanoparticle) (NN suspension))) (VP (AUX were) (VP (VBN compared) (PP (VBG following) (NP (NP (NN i.p.) (NN administration)) (PP (IN in) (NP (JJ Doc_19944736_869_873_Chemical-pre-treated) (NNP Wistar) (NNS rats))))))) (. .)))
19944736	5	(S1 (S (NP (NP (PDT All) (DT the) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_19944736_928_935_Chemical-loaded) (NNS nanoparticles))))) (VP (VBD showed) (NP (NP (DT an) (JJR earlier) (NN outcome)) (PP (IN of) (NP (NP (NNP CNS) (JJ adverse) (NNS symptoms)) (, ,) (NP (FW i.e.) (FW Doc_19944736_1013_1022_Disease) (NN onset)) (, ,)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT those) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJ free) (NN compound)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN min)) (PP (IN vs.) (ADVP (NP (CD 22) (NN min)) (RB respectively)))) (-RRB- -RRB-)))))))))) (. .)))
19944736	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ Doc_19944736_1138_1145_Chemical-loaded) (NNS nanoparticles) (NN administration)) (VP (VBN induced) (NP (NNP Doc_19944736_1190_1214_Disease)) (PP (IN in) (NP (NP (CD CA1) (NN field)) (PP (IN of) (NP (NP (DT the) (NNS hippocampus)) (PP (IN in) (NP (DT all) (VBN treated) (NNS animals))))))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (JJ saline) (NN solution)) (PP (IN of) (NP (NP (NNP Doc_19944736_1300_1307_Chemical)) (PP (ADVP (RB only)) (IN in) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NNS animals))))))))))) (. .)))
19944736	7	(S1 (S (NP (JJ Empty) (NNS nanoparticles)) (VP (VBD provided) (NP (JJ similar) (NNS results)) (S (VP (TO to) (VP (VB control) (NP (NP (-LRB- -LRB-) (JJ saline-treated) (-RRB- -RRB-) (NN group)) (PP (IN of) (NP (NNS animals)))))))) (. .)))
19944736	8	(S1 (S (PP (IN In) (NP (NP (NN conclusion)) (, ,) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (NN time-to-onset)) (PP (IN of) (NP (NNS symptoms)))))) (CC and) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (JJ neurodegenerative) (NNS processes)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ Doc_19944736_1545_1552_Chemical-Doc_19944736_1553_1560_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_19944736_1570_1578_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))))))) (, ,) (VP (MD could) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (RB preliminarily) (DT the) (NN capability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system)))) (PP (TO to) (NP (NN trespass))) (PRN (-LRB- -LRB-) (CC or) (RB not) (-RRB- -RRB-)) (S (NP (DT the) (NNP BBB)) (PP (IN in) (NP (NN vivo)))))))))) (. .)))
19996135	0	(S1 (S (NP (NNP High-dose) (NNP Doc_19996135_10_25_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ nonischemic) (JJ clinical) (NN Doc_19996135_66_74_Disease)) (PP (IN in) (NP (JJ cardiac) (JJ surgical) (NNS patients))))))) (. .)))
19996135	1	(S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS centers))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT a) (JJ notable) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (NNP Doc_19996135_205_215_Disease) (NNP Doc_19996135_216_224_Disease))))) (PP (IN from) (NP (CD 1.3) (NN %)))) (PP (TO to) (NP (CD 3.8) (NN %))) (PP (IN in) (NP (NP (NNS patients)) (VP (AUXG having) (VP (VBN undergone) (NP (JJ major) (JJ cardiac) (JJ surgical) (NNS procedures))))))) (. .)))
19996135	2	(S1 (S (NP (DT These) (NNS events)) (VP (AUX were) (ADJP (RB temporally) (JJ coincident) (PP (IN with) (NP (NP (DT the) (JJ initial) (NN use)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_19996135_381_396_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19996135_398_401_Chemical)) (-RRB- -RRB-)) (NN therapy))) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NN aprotinin))) (PP (IN from) (NP (JJ general) (JJ clinical) (NN usage))))))))) (. .)))
19996135	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN review)))) (VP (AUX was) (S (VP (TO to) (VP (VB perform) (NP (NP (DT a) (JJ retrospective) (NN analysis)) (SBAR (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_19996135_585_588_Chemical) (NN usage)) (CC and) (NP (NN Doc_19996135_599_607_Disease))))) (PP (IN after) (NP (JJ cardiac) (NN surgery))))))))))))))) (. .)))
19996135	4	(S1 (S (NP (DT An) (JJ in-depth) (NN chart) (NN review)) (VP (AUX was) (VP (VBN undertaken) (PP (IN in) (NP (NP (DT all) (CD 24) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ perioperative) (NN Doc_19996135_727_735_Disease))))))))) (. .)))
19996135	5	(S1 (S (S (NP (JJ Electroencephalographic) (NN activity)) (VP (AUX was) (VP (VBN recorded) (PP (IN in) (NP (NP (CD 11)) (PP (IN of) (NP (DT these) (NNS patients)))))))) (, ,) (CC and) (S (NP (DT all) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ formal) (NN neurological) (NN evaluation)) (CC and) (NP (NN brain) (NN imaging) (NNS studies))))) (. .)))
19996135	6	(S1 (S (S (NP (NP (CD Twenty-one)) (PP (IN of) (NP (DT the) (CD 24) (NNS patients)))) (VP (AUX did) (RB not) (VP (AUX have) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ new) (NNP Doc_19996135_957_981_Disease))))))) (, ,) (CC but) (S (NP (NNP Doc_19996135_987_995_Disease)) (VP (AUX were) (ADJP (RB likely) (JJ due) (PP (TO to) (NP (NNP Doc_19996135_1015_1036_Disease)))) (PP (IN in) (NP (CD 3) (NNS patients))))) (. .)))
19996135	7	(S1 (S (NP (NP (DT All) (NNS patients)) (PP (IN with) (NP (NNP Doc_19996135_1070_1078_Disease)))) (VP (AUX did) (RB not) (VP (AUX have) (NP (JJ permanent) (NN Doc_19996135_1102_1128_Disease)))) (. .)))
19996135	8	(S1 (S (NP (NP (DT All) (CD 24) (NNS patients)) (PP (IN with) (NP (NNP Doc_19996135_1151_1159_Disease)))) (VP (VBD received) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_19996135_1183_1186_Chemical)))) (ADVP (RB intraoperatively)) (SBAR (S (S (S (VP (VBG ranging) (PP (IN from) (NP (QP (CD 61) (TO to) (CD 259)) (NNS mg/kg))))) (, ,) (VP (AUX had) (NP (NP (DT a) (JJ mean) (NN age)) (PP (IN of) (NP (CD 69.9) (NNS years)))))) (, ,) (CC and) (S (NP (NP (CD 21)) (PP (IN of) (NP (CD 24)))) (VP (AUX had) (VP (VBN undergone) (NP (NP (JJ open) (NN chamber)) (CONJP (RB rather) (IN than)) (NP (JJ coronary) (NN bypass) (NNS procedures))))))))) (. .)))
19996135	9	(S1 (S (NP (NP (DT All)) (PP (IN but) (NP (CD one) (NN patient)))) (VP (AUX were) (VP (VBN managed) (S (VP (VBG using) (NP (NN cardiopulmonary) (NN bypass)))))) (. .)))
19996135	10	(S1 (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (NP (NN Doc_19996135_1422_1436_Disease)) (, ,) (NP (NN metabolic)) (, ,) (CC or) (NP (NP (JJ Doc_19996135_1452_1464_Disease-induced) (NNS causes)) (PP (IN for) (NP (PRP$ their) (NN Doc_19996135_1490_1498_Disease))))))) (VP (AUX was) (ADJP (JJ apparent))) (. .)))
19996135	11	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN use)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_19996135_1567_1570_Chemical))) (PP (IN in) (NP (NP (JJR older) (NNS patients)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ cardiopulmonary) (NN bypass)) (CC and) (NP (JJ open-chamber) (JJ cardiac) (NN surgery))))))))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NN Doc_19996135_1693_1701_Disease)) (PP (IN in) (NP (JJ susceptible) (NNS patients)))))))))) (. .)))
2004	0	(S1 (S (NP (NP (NP (JJ Electrocardiographic) (NNS changes)) (CC and) (NP (NN Doc_2004_33_52_Disease))) (PP (IN in) (NP (NNS patients)))) (VP (VBG receiving) (NP (JJ psychotropic) (NNS drugs))) (. .)))
2004	1	(S1 (S (NP (CD Eight) (NNS patients)) (VP (AUX had) (NP (NP (NP (JJ cardiac) (NNS manifestations)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ life-threatening)) (PP (IN in) (NP (CD five))) (SBAR (IN while) (S (VP (VBG taking) (NP (JJ psychotropic) (NNS drugs))))))))) (, ,) (CC either) (NP (ADJP (JJ Doc_2004_212_226_Chemical) (CC or) (JJ tricyclic)) (NNS antidepressants)))) (. .)))
2004	2	(S1 (S (SBAR (IN Although) (S (NP (JJS most) (NNS patients)) (VP (AUX were) (VP (VBG receiving) (NP (JJ several) (NNS drugs)))))) (, ,) (NP (NP (NNP Doc_2004_310_318_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_320_332_Chemical)) (-RRB- -RRB-))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (NNP Doc_2004_379_402_Disease))) (, ,) (SBAR (WHNP (CD one) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (DT a) (CD 35) (NN year) (JJ old) (NN woman))))))))))))) (. .)))
2004	3	(S1 (S (NP (NN Doc_2004_451_479_Disease)) (VP (VBD developed) (PP (IN in) (NP (NP (CD one) (NN patient)) (VP (VBG receiving) (NP (NP (NNP Doc_2004_515_524_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_526_540_Chemical)) (-RRB- -RRB-))))))) (. .)))
2004	4	(S1 (S (NP (NP (NP (NNP Doc_2004_543_550_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_552_565_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2004_571_577_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_579_592_Chemical)) (-RRB- -RRB-)))) (DT each) (VP (VBD produced) (NP (NNP Doc_2004_608_632_Disease)) (PP (IN in) (NP (DT a) (CD 73) (NN year) (JJ old) (NN woman)))) (. .)))
2004	5	(S1 (S (NP (NP (JJ Electrocardiographic) (NNS T)) (CC and) (NP (NNP U) (NN wave) (NNS abnormalities))) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (JJS most) (NNS patients)))) (. .)))
2004	6	(S1 (S (S (NP (DT The) (NNP Doc_2004_740_763_Disease)) (VP (VBD responded) (PP (PP (TO to) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_2004_807_816_Chemical))))) (CC and) (PP (TO to) (NP (JJ direct) (JJ current) (JJ electric) (NN shock)))))) (: ;) (S (NP (JJ ventricular) (NN pacing)) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (NP (NP (DT some) (NNS instances)) (CC and) (NP (JJ intravenous) (NN administration))) (PP (IN of) (NP (NNP Doc_2004_939_950_Chemical))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ ventricular) (NN pacing)) (PP (IN in) (NP (CD one))))))))))) (. .)))
2004	7	(S1 (S (NP (NP (DT The) (NN Doc_2004_996_1012_Disease)) (VP (ADVP (RB generally)) (VBN subsided) (PP (IN within) (NP (CD 48) (NNS hours))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNS drugs))))))) (VP (AUX was) (VP (VBN stopped))) (. .)))
2004	8	(S1 (S (S (NP (NP (CD Five)) (PP (IN of) (NP (DT the) (CD eight) (NNS patients)))) (VP (AUX were) (NP (NP (NP (CD 50) (NNS years)) (PP (IN of) (NP (NN age)))) (CC or) (NP (JJR younger))))) (: ;) (S (NP (QP (RB only) (CD one))) (ADVP (RB clearly)) (VP (AUX had) (NP (JJ antecedent) (NN Doc_2004_1187_1200_Disease)))) (. .)))
2004	9	(S1 (S (NP (NNP Major) (NNP Doc_2004_1208_1227_Disease)) (VP (AUX are) (NP (NP (DT a) (JJ potential) (NN hazard)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN without) (NP (NNP Doc_2004_1271_1284_Disease))))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG receiving) (NP (NP (JJ customary) (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (JJ psychotropic) (NNS drugs)))))))))) (. .)))
2004	10	(S1 (S (NP (DT A) (JJ prospective) (JJ clinical) (NN trial)) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_2004_1420_1441_Disease))) (PP (TO to) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2004_1464_1478_Chemical)))) (CC or) (NP (JJ tricyclic) (JJ antidepressant) (NNS drugs)))))))))) (. .)))
2004015	0	(S1 (NP (NP (NN Sensitivity)) (PP (IN of) (NP (JJ erythroid) (NN progenitor) (NNS colonies))) (PP (TO to) (NP (NP (NN erythropoietin)) (PP (IN in) (NP (JJ Doc_2004015_66_80_Chemical) (VBN treated) (NN Doc_2004015_89_104_Disease) (NNS mice))))) (. .)))
2004015	1	(S1 (S (NP (NP (NP (DT The) (NNP Doc_2004015_115_122_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2004015_134_161_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004015_163_166_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
2004015	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN used) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NP (NNP Doc_2004015_221_225_Disease)) (, ,) (NP (NP (NNP Doc_2004015_227_236_Disease)) (PP (IN of) (NP (NP (JJ female) (NNP C57BL/6) (NNS mice)) (PP (IN with) (NP (JJ LP-BM5) (NN murine) (NNP Doc_2004015_279_288_Disease) (PRN (-LRB- -LRB-) (NP (NNP MuLV)) (-RRB- -RRB-)) (NN virus)))))) (, ,)))) (S (VP (TO to) (VP (VB determine) (SBAR (S (IN if) (NP (NNP Doc_2004015_319_322_Chemical-induced) (NNP Doc_2004015_331_338_Disease)) (VP (AUX is) (ADJP (JJ due)) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (TO to) (NP (NP (VBN decreased) (NN responsiveness)) (PP (IN of) (NP (NP (JJ erythropoietic) (NNS precursors)) (PRN (-LRB- -LRB-) (NP (NNP BFU-e)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NNP EPO)) (-RRB- -RRB-)))))))))))))) (. .)))
2004015	3	(S1 (S (NP (NP (NNS Mice)) (PP (IN in) (NP (NP (DT the) (JJ early) (NN stage)) (PP (IN of) (NP (JJ LP-BM5) (JJ MuLV) (NN disease)))))) (VP (AUX were) (VP (VBN given) (NP (NNP Doc_2004015_504_507_Chemical)) (PP (IN in) (NP (PRP$ their) (NN drinking) (NN water))) (PP (IN at) (NP (QP (CD 1.0) (CC and) (CD 2.5) (CD mg/ml)))))) (. .)))
2004015	4	(S1 (S (NP (NN Doc_2004015_554_557_Chemical)) (VP (VBD produced) (NP (NNP Doc_2004015_567_574_Disease)) (PP (IN in) (NP (DT both) (NNS groups))) (, ,) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion)))) (. .)))
2004015	5	(S1 (S (PP (IN Despite) (NP (DT the) (NNP Doc_2004015_632_639_Disease))) (, ,) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN splenic) (CC and) (NN bone) (NN marrow) (NN BFU-e)) (PP (IN in) (NP (JJ Doc_2004015_688_691_Chemical) (VBN treated) (NNS mice)))))) (VP (VBD increased) (PRT (RP up)) (S (VP (TO to) (VP (VB five-fold) (PP (IN over) (NP (NP (NNS levels)) (VP (VBN observed) (PP (IN in) (NP (JJ infected) (JJ untreated) (NNS animals))) (PP (IN after) (NP (NP (CD 15) (NNP d)) (PP (IN of) (NP (NN treatment)))))))))))) (. .)))
2004015	6	(S1 (S (NP (NP (NN Colony) (NN formation)) (PP (IN by) (NP (NP (NN splenic)) (CC and) (NP (NN bone) (NN marrow) (NN BFUe))))) (VP (AUX was) (VP (VBN stimulated) (PP (IN at) (NP (NP (JJR lower) (NNS concentrations)) (PP (IN of) (NP (NNP EPO))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG receiving) (NP (NNP Doc_2004015_920_923_Chemical)) (PP (IN for) (NP (NP (CD 15) (NNP d)) (PP (IN than) (PP (IN for) (NP (JJ infected) (, ,) (JJ untreated) (NNS mice))))))))))))) (. .)))
2004015	7	(S1 (S (PP (IN By) (NP (NN day) (CD 30))) (, ,) (NP (NP (NN sensitivity)) (PP (IN of) (NP (NP (DT both) (NN splenic) (CC and) (NN bone) (NN marrow) (NNS BFU-e)) (PP (IN of) (NP (VBN treated) (NNS animals)))))) (VP (VBD returned) (PP (TO to) (NP (DT that))) (PP (VBN observed) (PP (IN from) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ infected) (JJ untreated) (NNS animals))))))) (. .)))
2004015	8	(S1 (S (NP (NP (DT The) (JJ mean) (NN plasma) (NNS levels)) (PP (IN of) (NP (NNP EPO)))) (VP (VBD observed) (SBAR (IN in) (S (NP (NNP Doc_2004015_1158_1161_Chemical)) (VP (VBD treated) (SBAR (S (NP (NNS mice)) (VP (AUX were) (ADJP (JJ appropriate) (PP (IN for) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_2004015_1210_1217_Disease))) (VP (VBD observed) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NP (NNP Doc_2004015_1246_1261_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004015_1263_1266_Chemical)) (-RRB- -RRB-))) (VBN treated) (NNS mice))))))))))))))))) (. .)))
2004015	9	(S1 (S (NP (NP (NP (DT The) (NNS numbers)) (PP (IN of) (NP (NNP BFU-e)))) (CC and) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NN bone) (NN marrow) (NNS erythroblasts))))) (VP (VBD observed) (SBAR (S (VP (AUX were) (ADJP (JJ comparable) (PP (IN in) (NP (NP (NNP Doc_2004015_1379_1382_Chemical) (CC and) (NNP Doc_2004015_1387_1390_Chemical) (VBN treated) (NNS mice)) (PP (IN with) (NP (NP (JJ similar) (NNS degrees)) (PP (IN of) (NP (NNP Doc_2004015_1428_1435_Disease)))))))))))) (. .)))
2004015	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_2004015_1446_1461_Disease)) (VP (AUX was) (ADJP (JJ inappropriate) (PP (IN for) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_2004015_1498_1505_Disease))) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_2004015_1518_1521_Chemical) (VBN treated) (JJ infected) (NNS mice)))))))) (. .)))
2004015	11	(S1 (S (NP (NP (NP (JJ Doc_2004015_1545_1548_Chemical-induced) (JJ peripheral) (NN Doc_2004015_1568_1575_Disease)) (PP (IN in) (NP (NP (DT the) (NN face)) (PP (IN of) (NP (NP (VBN increased) (NNS numbers)) (PP (IN of) (NP (NNP BFU-e)))))))) (CC and) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NN plasma) (NNP EPO))))) (VP (VBP suggest) (NP (NP (DT a) (NN lesion)) (PP (IN in) (NP (JJ terminal) (NN differentiation))))) (. .)))
20042557	0	(S1 (S (NP (NN Sedation)) (VP (NN depth) (PP (IN during) (NP (NP (JJ spinal) (NN anesthesia)) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20042557_63_85_Disease)))))) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_20042557_117_129_Disease) (NN repair)))))) (. .)))
20042557	1	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (VP (VBG limiting) (NP (JJ intraoperative) (NN sedation) (NN depth)) (PP (IN during) (NP (NP (JJ spinal) (NNS anesthesia)) (PP (IN for) (NP (NP (NN Doc_20042557_238_250_Disease) (NN repair)) (PP (IN in) (NP (JJ elderly) (NNS patients))))))))))))) (VP (MD can) (VP (VB decrease) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_309_331_Disease)))))) (. .)))
20042557	2	(S1 (FRAG (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD performed) (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (JJ controlled) (NN trial)) (PP (IN at) (NP (NP (DT an) (JJ academic) (JJ medical) (NN center)) (PP (IN of) (NP (NP (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD >or=65) (NNS years)) (-RRB- -RRB-)))))) (PP (IN without) (NP (NP (JJ preoperative) (NN Doc_20042557_498_506_Disease)) (CC or) (NP (NP (JJ severe) (NN Doc_20042557_517_525_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NNP Doc_20042557_540_552_Disease) (NN repair)) (PP (IN under) (NP (NP (JJ spinal) (NNS anesthesia)) (PP (IN with) (NP (JJ Doc_20042557_589_597_Chemical) (NN sedation))))))))))))) (. .)))
20042557	3	(S1 (S (S (NP (JJ Sedation) (NN depth)) (VP (AUX was) (VP (VBN titrated) (S (VP (VBG using) (NP (NP (VBN processed) (NN electroencephalography)) (PP (IN with) (NP (DT the) (JJ bispectral) (NN index))) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (DT either) (ADJP (ADJP (JJ deep)) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (, ,) (NP (QP (RB approximately) (CD 50))) (-RRB- -RRB-)) (CC or) (ADJP (JJ light)) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (, ,) (NP (CD >or=80)) (-RRB- -RRB-))) (NN sedation)))))))) (. .)))
20042557	4	(S1 (S (NP (NN Doc_20042557_817_839_Disease)) (VP (AUX was) (VP (VBN assessed) (SBAR (IN as) (S (VP (VBN defined) (PP (IN by) (NP (NP (NNP Diagnostic) (CC and) (NNP Statistical) (NNP Manual)) (PP (IN of) (NP (NP (NNP Doc_20042557_904_920_Disease) (PRN (-LRB- -LRB-) (NP (JJ Third) (NN Edition) (JJ Revised)) (-RRB- -RRB-)) (NNS criteria)) (VP (VBG using) (NP (NP (DT the) (NN Confusion) (NN Assessment) (NN Method)) (VP (VBG beginning) (PP (IN at) (NP (DT any) (NN time))) (PP (IN from) (NP (NP (DT the) (JJ second) (NN day)) (PP (IN after) (NP (NN surgery))))))))))))))))) (. .)))
20042557	5	(S1 (S (PP (IN From) (NP (NNP April) (CD 2) (, ,) (CD 2005))) (, ,) (PP (IN through) (NP (NNP October) (CD 30) (, ,) (CD 2008))) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 114) (NNS patients)))) (VP (AUX were) (VP (VBN randomized))) (. .)))
20042557	6	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_1163_1185_Disease)))) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (DT the) (JJ light) (NN sedation) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 11/57) (CD -LSB-19)) (NN %)) (JJ -RSB-) (NNP vs) (CD 23/57) (ADJP (CD -LSB-40) (NN %)) (NN -RSB-)) (PP (IN in) (NP (DT the) (JJ deep) (NN sedation) (NN group)))) (: ;) (NP (NNP P=.02))) (-RRB- -RRB-)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (CD 1) (NN incident)) (PP (IN of) (NP (NNP Doc_20042557_1332_1340_Disease)))) (VP (MD will) (VP (AUX be) (VP (VBN prevented) (PP (IN for) (NP (NP (DT every) (CD 4.7) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ light) (NN sedation)))))))))))))) (. .)))
20042557	7	(S1 (S (NP (NP (DT The) (JJ mean) (JJ +/-) (NN SD) (NN number)) (PP (IN of) (NP (NP (NNS days)) (PP (IN of) (NP (NNP Doc_20042557_1445_1453_Disease))))) (PP (IN during) (NP (NN hospitalization)))) (VP (AUX was) (ADJP (ADJP (JJR lower) (PP (IN in) (NP (DT the) (JJ light) (NN sedation) (NN group)))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ deep) (NN sedation) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5+/-1.5) (NNS days)) (NP (NNP vs) (CD 1.4+/-4.0) (NNS days)) (: ;) (NP (NNP P=.01))) (-RRB- -RRB-))))))) (. .)))
20042557	8	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ light) (JJ Doc_20042557_1619_1627_Chemical) (NN sedation)))) (VP (VBD decreased) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_1665_1687_Disease))) (PP (IN by) (NP (CD 50) (NN %)))) (PP (VBN compared) (PP (IN with) (NP (JJ deep) (NN sedation))))) (. .)))
20042557	9	(S1 (S (S (VP (VBG Limiting) (NP (NP (NN depth)) (PP (IN of) (NP (NN sedation)))) (PP (IN during) (NP (JJ spinal) (NNS anesthesia))))) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ simple) (, ,) (JJ safe) (, ,) (CC and) (JJ cost-effective)) (NN intervention)) (PP (IN for) (S (VP (VBG preventing) (NP (NNP Doc_20042557_1842_1864_Disease)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (ADVP (RB widely) (CC and) (RB readily)) (VBN adopted))))))))))))) (. .)))
20103708	0	(S1 (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN in) (NP (NNP Doc_20103708_31_45_Chemical-induced) (NNP Doc_20103708_54_74_Disease))) (. .)))
20103708	1	(S1 (S (NP (NN Doc_20103708_87_107_Disease)) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (NNS causes)) (PP (IN of) (NP (NP (NNP Doc_20103708_138_151_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_20103708_204_210_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNS ROS)) (-RRB- -RRB-)))))))))))))))) (. .)))
20103708	2	(S1 (S (NP (NN Nrf2)) (VP (AUX is) (NP (NP (DT the) (JJ primary) (NN transcription) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ controls) (S (NP (DT the) (JJ antioxidant) (NN response)) (ADJP (JJ essential) (PP (IN for) (S (VP (VBG maintaining) (NP (JJ cellular) (NN redox) (NNS homeostasis)))))))))))) (. .)))
20103708	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (PRP$ our) (NNS findings)) (VP (VBG demonstrating) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN against) (NP (NNP Doc_20103708_437_457_Disease))))))) (. .)))
20103708	4	(S1 (NP (NP (NN RESEARCH) (NN DESIGN) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VB explore) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN against) (NP (NNP Doc_20103708_535_555_Disease)))) (S (VP (VBG using) (NP (JJ human) (NN kidney) (NN biopsy) (NNS tissues)) (PP (IN from) (NP (NP (JJ Doc_20103708_595_615_Disease) (NNS patients)) (, ,) (NP (NP (DT a) (JJ Doc_20103708_628_642_Chemical-induced) (NNP Doc_20103708_651_671_Disease) (NN model)) (PP (IN in) (NP (JJ Nrf2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)))) (, ,) (CC and) (NP (JJ cultured) (JJ human) (JJ mesangial) (NNS cells)))))))) (. .)))
20103708	5	(S1 (S (NP (NP (DT The) (NNS glomeruli)) (PP (IN of) (NP (JJ human) (NNP Doc_20103708_765_785_Disease) (NNS patients)))) (VP (VP (AUX were) (PP (IN under) (NP (JJ oxidative) (NN stress)))) (CC and) (VP (AUX had) (NP (JJ elevated) (JJ Nrf2) (NNS levels)))) (. .)))
20103708	6	(S1 (S (PP (IN In) (NP (DT the) (NN animal) (NN study))) (, ,) (NP (NNP Nrf2)) (VP (AUX was) (VP (VBN demonstrated) (S (VP (TO to) (VP (AUX be) (ADJP (JJ crucial)) (PP (IN in) (S (VP (VBG ameliorating) (NP (JJ Doc_20103708_926_940_Chemical-induced) (NN Doc_20103708_949_961_Disease)))))))))) (. .)))
20103708	7	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ evident) (PP (IN by) (NP (NP (NNP Nrf2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VP (AUXG having) (NP (JJR higher) (NN ROS) (NN production))) (CC and) (VP (VBG suffering) (PP (IN from) (NP (NP (JJR greater) (JJ oxidative) (NN DNA) (NN damage)) (CC and) (NP (NNP Doc_20103708_1078_1090_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NNP Nrf2) (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-) (NNS mice)))))))))) (. .)))
20103708	8	(S1 (S (NP (NP (JJ Mechanistic) (NNS studies)) (PP (PP (IN in) (NP (NP (DT both)) (PP (IN in) (NP (NN vivo))))) (CC and) (PP (IN in) (NP (NN vitro) (NNS systems))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (JJ Nrf2-mediated) (NN protection)) (PP (IN against) (NP (NNP Doc_20103708_1227_1247_Disease)))) (VP (AUX is) (, ,) (ADVP (IN at) (JJS least)) (, ,) (PP (ADVP (RB partially)) (IN through) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (VBG transforming) (NN growth) (NNS factor-beta1)) (PRN (-LRB- -LRB-) (JJ TGF-beta1) (-RRB- -RRB-))))) (CC and) (NP (NP (NN reduction)) (PP (IN of) (NP (JJ extracellular) (NNP matrix) (NN production)))))))))) (. .)))
20103708	9	(S1 (S (PP (IN In) (NP (JJ human) (JJ renal) (NN mesangial) (NNS cells))) (, ,) (NP (JJ high) (NNP Doc_20103708_1426_1433_Chemical)) (VP (VP (VBN induced) (NP (NNP ROS) (NN production))) (CC and) (VP (VBN activated) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NNP Nrf2)) (CC and) (NP (PRP$ its) (JJ downstream) (NNS genes))))))) (. .)))
20103708	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN activation) (CC or) (NN overexpression)) (PP (IN of) (NP (NNP Nrf2)))) (VP (VBD inhibited) (NP (NP (DT the) (NN promoter) (NN activity)) (PP (IN of) (NP (NN TGF-beta1)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (SBAR (IN whereas) (S (VP (VBN knockdown) (PP (IN of) (NP (NNP Nrf2))) (PP (IN by) (S (VP (VBG siRNA) (NP (NP (JJ enhanced) (JJ TGF-beta1) (NN transcription)) (CC and) (NP (JJ fibronectin) (NN production)))))))))) (. .)))
20103708	11	(S1 (S (NP (DT This) (NN work)) (ADVP (RB clearly)) (VP (VBZ indicates) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN in) (NP (NNP Doc_20103708_1805_1825_Disease)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NP (NN dietary)) (CC or) (NP (JJ therapeutic) (NN activation))) (PP (IN of) (NP (NNP Nrf2)))) (VP (MD could) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN strategy)) (SBAR (S (VP (TO to) (VP (VP (VB prevent)) (CC or) (VP (VB slow) (PRT (RP down)) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_20103708_1956_1976_Disease))))))))))))))))))) (. .)))
20164825	0	(S1 (S (NP (NN Doc_20164825_0_9_Chemical)) (VP (VBZ prevents) (NP (JJ experimental) (JJ Doc_20164825_32_42_Chemical-induced) (NN Doc_20164825_51_62_Disease)) (PP (IN by) (NP (DT a) (JJ mitochondria-dependent) (NN pathway)))) (. .)))
20164825	1	(S1 (S (NP (DT The) (JJ antidiabetic) (NN drug) (NN Doc_20164825_122_131_Chemical)) (VP (MD can) (VP (VP (VB diminish) (NP (NP (NNS apoptosis)) (VP (VBN induced) (PP (IN by) (NP (JJ oxidative) (NN stress))) (PP (IN in) (NP (JJ endothelial) (NNS cells)))))) (CC and) (VP (VB prevent) (NP (NNP Doc_20164825_216_236_Disease)) (PP (ADVP (RB even)) (IN in) (NP (JJ nondiabetic) (NNS patients)))))) (. .)))
20164825	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD tested) (SBAR (IN whether) (S (NP (PRP it)) (VP (AUX has) (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_20164825_335_345_Chemical) (NNP Doc_20164825_346_354_Disease))))))))) (. .)))
20164825	3	(S1 (S (NP (NP (JJ Mitochondrial) (NN analysis)) (, ,) (NP (NN respiration) (NN intensity)) (, ,) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ reactive) (JJ Doc_20164825_422_428_Chemical) (NNS species)))) (, ,) (NP (NN permeability) (NN transition)) (, ,) (CC and) (NP (JJ cytochrome) (NN c) (NN release))) (VP (AUX were) (VP (VBN assessed) (PP (NP (QP (CD 3) (CC and) (CD 6)) (NNS days)) (IN after) (NP (NNP Doc_20164825_521_531_Chemical) (NN administration))))) (. .)))
20164825	4	(S1 (S (NP (JJ Doc_20164825_548_557_Chemical) (NN treatment)) (ADVP (RB fully)) (VP (VBD blocked) (NP (JJ Doc_20164825_582_592_Chemical-mediated) (NNP Doc_20164825_602_621_Disease))) (. .)))
20164825	5	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJR lower) (NN activity)) (PP (IN of) (NP (NNP N-acetyl-beta-D-glucosaminidase))))) (, ,) (ADVP (RB together) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NN lipid) (NN peroxidation)))) (CC and) (NP (NP (NN increase)) (PP (IN of) (NP (NN antioxidant) (NNS systems))))))))) (. .)))
20164825	6	(S1 (S (NP (NN Doc_20164825_784_793_Chemical)) (ADVP (RB also)) (VP (VBD protected) (NP (DT the) (NN kidney)) (PP (IN from) (NP (JJ histological) (NN damage))) (PP (NP (CD 6) (NNS days)) (IN after) (NP (NNP Doc_20164825_858_868_Chemical) (NN administration)))) (. .)))
20164825	7	(S1 (S (NP (NP (NP (DT These)) (PP (IN in) (NP (NP (NN vivo) (NNS markers)) (PP (IN of) (NP (NNP Doc_20164825_910_928_Disease)))))) (CC and) (NP (NP (PRP$ their) (NN correction)) (PP (IN by) (NP (NNP Doc_20164825_953_962_Chemical))))) (VP (AUX were) (VP (VBN complemented) (PP (IN by) (NP (NP (ADJP (IN in) (NN vitro)) (NNS studies)) (PP (IN of) (NP (JJ mitochondrial) (NN function))))))) (. .)))
20164825	8	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (JJ Doc_20164825_1042_1052_Chemical) (NN treatment)) (VP (VBD depleted) (NP (NP (JJ respiratory) (NNS components)) (PRN (-LRB- -LRB-) (NP (NP (NN cytochrome) (NN c)) (, ,) (NP (NNP NADH))) (-RRB- -RRB-))) (, ,) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NP (DT the) (NN opening)) (PP (IN of) (NP (JJ mitochondrial) (NN transition) (VBZ pores)))))))))) (. .)))
20164825	9	(S1 (S (NP (NP (DT These) (NNS injuries)) (, ,) (VP (ADVP (RB partly)) (VBN mediated) (PP (IN by) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (JJ reactive) (JJ Doc_20164825_1234_1240_Chemical) (NNS species)) (PP (IN from) (NP (DT the) (NNP electron) (NN transfer) (NN chain)))))))) (, ,)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN by) (NP (NNP Doc_20164825_1315_1324_Chemical))))) (. .)))
20164825	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ pleiotropic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20164825_1379_1388_Chemical)))) (VP (MD can) (VP (VP (VB lessen) (NP (NNP Doc_20164825_1400_1410_Chemical) (NNP Doc_20164825_1411_1425_Disease))) (CC and) (VP (VB improve) (NP (JJ mitochondrial) (NN homeostasis)))))))) (. .)))
20195852	0	(S1 (NP (NP (NP (NN Risk)) (PP (IN of) (NP (NNP Doc_20195852_8_19_Disease))) (PP (IN after) (NP (NP (NN consumption)) (PP (IN of) (NP (JJ nonionic) (NNP Doc_20195852_50_64_Chemical))) (PP (IN by) (NP (NP (NNS children)) (VP (VBG undergoing) (NP (JJ cardiac) (NN angiography)))))))) (: :) (NP (DT a) (JJ prospective) (NN study)) (. .)))
20195852	1	(S1 (S (PP (IN Despite) (S (VP (VBG increasing) (NP (NP (NNS reports)) (PP (IN on) (NP (NP (JJ nonionic) (JJ Doc_20195852_169_183_Chemical-induced) (NNP Doc_20195852_192_203_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_205_208_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (VBN hospitalized) (NN adult) (NNS patients))) (PP (IN during) (NP (JJ cardiac) (NNS procedures)))))) (, ,) (NP (NP (DT the) (NNS studies)) (PP (IN in) (NP (NNS pediatrics)))) (VP (AUX are) (ADJP (JJ limited)) (, ,) (SBAR (IN with) (S (NP (NP (ADJP (RB even) (JJR less)) (NN focus)) (PP (IN on) (NP (NP (JJ possible) (JJ predisposing) (NNS factors)) (CC and) (NP (NP (JJ preventive) (NNS measures)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ cardiac) (NN angiography)))))))))))) (. .)))
20195852	2	(S1 (S (NP (DT This) (JJ prospective) (NN study)) (VP (VP (VBD determined) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20195852_481_484_Disease))) (PP (IN for) (NP (CD two) (JJ nonionic) (NNP Doc_20195852_502_516_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_518_520_Chemical)) (-RRB- -RRB-)) (, ,) (NNP Doc_20195852_523_532_Chemical) (CC and) (NNP Doc_20195852_537_544_Chemical))) (, ,) (PP (IN among) (NP (CD 80) (NNS patients)))) (NP (QP (JJR younger) (IN than) (CD 18)) (NNS years))) (CC and) (VP (VBD compared) (NP (NP (DT the) (NNS rates)) (PP (IN for) (NP (DT this) (NN complication)))) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (NP (DT the) (NN type) (CC and) (NN dosage)) (PP (IN of) (NP (NNP Doc_20195852_669_671_Chemical)))) (CC and) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_20195852_692_700_Disease)))))))))) (. .)))
20195852	3	(S1 (S (NP (NP (DT The) (CD 80) (NNS patients)) (PP (IN in) (NP (DT the) (NN study)))) (ADVP (RB consecutively)) (VP (VBD received) (NP (NP (NP (DT either) (NNP Doc_20195852_761_770_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN A)) (, ,) (NP (NNP n) (SYM =) (CD 40))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_20195852_792_799_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NNP B)) (, ,) (NP (NNP n) (SYM =) (CD 40))) (-RRB- -RRB-))))) (. .)))
20195852	4	(S1 (S (NP (NP (NNP Serum) (NNP Doc_20195852_825_831_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_833_835_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20195852_838_847_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_849_850_Chemical)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NNP Doc_20195852_857_867_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_869_871_Chemical)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VP (VBN measured) (NP (CD 24) (NNP h)) (PP (IN before) (NP (NN angiography))) (PP (IN as) (NP (NN baseline) (NNS values)))) (, ,) (VP (ADVP (RB then)) (VBN measured) (ADVP (RB again)) (PP (IN at) (NP (ADJP (JJ 12-) (, ,) (JJ 24-) (, ,) (CC and) (JJ 48-h)) (NNS intervals))) (PP (IN after) (NP (JJ Doc_20195852_989_991_Chemical) (NN use)))))) (. .)))
20195852	5	(S1 (S (NP (NP (NN Urine) (NNS samples)) (PP (IN for) (NP (NP (NNP Doc_20195852_1015_1017_Chemical)) (CC and) (NP (NNP Doc_20195852_1022_1024_Chemical))))) (ADVP (RB also)) (VP (AUX were) (VP (VBN checked) (PP (IN at) (NP (DT the) (JJ same) (NNS intervals))))) (. .)))
20195852	6	(S1 (S (NP (NP (NN Risk)) (PP (IN of) (NP (NP (NP (NNP Doc_20195852_1074_1087_Disease)) (, ,) (NP (NNP Doc_20195852_1089_1109_Disease) (, ,) (NNP Doc_20195852_1111_1137_Disease) (, ,) (NNP Doc_20195852_1139_1162_Disease)) (, ,)) (CC and) (NP (NP (NNP End-stage) (NNP Doc_20195852_1178_1190_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RIFLE) (NNS criteria)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB define) (NP (NP (NNP Doc_20195852_1228_1231_Disease)) (CC and) (NP (PRP$ its) (NN incidence))) (PP (IN in) (NP (DT the) (NN study) (NN population)))))))) (. .)))
20195852	7	(S1 (S (ADVP (RB Accordingly)) (, ,) (PP (IN among) (NP (NP (DT the) (CD 15) (JJ Doc_20195852_1301_1304_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 18.75) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 7.5) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (NN group) (DT A)))))) (VP (AUX had) (VP (VBN increased) (NP (NP (NN risk)) (CC and) (NP (NP (CD 3.75) (NN %)) (SBAR (S (VP (AUX had) (NP (NNP Doc_20195852_1389_1401_Disease))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (NN group) (NN B)))) (VP (AUX had) (VP (VBN increased) (NP (NP (NN risk)) (CC and) (NP (NP (CD 2.5) (NN %)) (SBAR (S (VP (AUX had) (NP (NNP Doc_20195852_1457_1469_Disease))))))))))))) (. .)))
20195852	8	(S1 (S (SBAR (IN Whereas) (S (NP (NP (CD 33.3) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_20195852_1506_1509_Disease)))))) (VP (AUX were) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT the) (JJ proper) (NN dosage)) (PP (IN of) (NP (NNP Doc_20195852_1561_1563_Chemical)))))))))))) (, ,) (NP (DT the) (NN percentage)) (VP (VBN increased) (PP (TO to) (NP (CD 66.6) (NN %))) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJR larger) (NNS doses))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20195852_1688_1691_Disease))))) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ different) (NNS dosages)) (PP (IN of) (NP (NP (NNP Doc_20195852_1728_1730_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.014)) (-RRB- -RRB-)))))))))) (. .)))
20195852	9	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 15) (NNS patients)) (PP (IN with) (NP (NNP Doc_20195852_1771_1774_Disease))))) (, ,) (S (NP (CD 6)) (VP (AUX had) (NP (JJ cyanotic) (NN Doc_20195852_1791_1816_Disease)))) (, ,) (CC but) (S (NP (DT the) (NN incidence)) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (NP (NP (DT that)) (PP (IN for) (NP (DT the) (JJ noncyanotic) (NNS patients))))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.243)) (-RRB- -RRB-))))) (. .)))
20195852	10	(S1 (S (SBAR (IN Although) (S (ADJP (RB clinically) (JJ silent)))) (, ,) (NP (NNP Doc_20195852_1945_1948_Disease)) (VP (AUX is) (RB not) (ADJP (JJ rare)) (PP (IN in) (NP (NN pediatrics)))) (. .)))
20195852	11	(S1 (S (S (NP (DT The) (NN incidence)) (VP (VBZ depends) (PP (PP (IN on) (NP (NN dosage))) (CC but) (RB not) (PP (IN on) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (VBN consumed) (JJ nonionic) (NNP Doc_20195852_2049_2051_Chemical))))) (, ,) (CC nor) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_20195852_2076_2084_Disease)))))))) (, ,) (CC and) (S (SBAR (IN although) (S (NP (NNP Doc_20195852_2099_2102_Disease)) (ADVP (RB usually)) (VP (AUX is) (ADJP (JJ reversible))))) (, ,) (NP (JJR more) (NN concern)) (VP (AUX is) (VP (VBN needed) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (PDT such) (DT a) (NN complication))) (PP (IN in) (NP (NNS children)))))))) (. .)))
2021202	0	(S1 (NP (NP (NP (JJ Renal) (NN function)) (CC and) (NP (NNS hemodynamics))) (PP (IN during) (NP (NP (VBN prolonged) (JJ Doc_2021202_49_59_Chemical-induced) (NN Doc_2021202_68_79_Disease)) (PP (IN in) (NP (NNS humans))))) (. .)))
2021202	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_2021202_105_115_Chemical-induced) (NNP Doc_2021202_124_135_Disease))) (PP (IN on) (NP (NP (JJ glomerular) (NN function)) (CC and) (NP (JJ renal) (NN blood) (NN flow))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (CD 20) (JJ human) (NNS subjects))))) (. .)))
2021202	2	(S1 (S (NP (NP (NP (JJ Glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (SYM GFR)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (PRN (-LRB- -LRB-) (NP (NNP ERPF)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (NN inulin)) (CC and) (NP (NNP Doc_2021202_319_338_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_2021202_340_343_Chemical) (-RRB- -RRB-)) (NN clearance)))) (, ,) (ADVP (RB respectively)))) (. .)))
2021202	3	(S1 (S (NP (NN Anesthesia)) (VP (AUX was) (VP (VBN maintained) (PP (IN with) (NP (NP (NNP Doc_2021202_401_409_Chemical)) (, ,) (NP (NNP Doc_2021202_411_424_Chemical)) (, ,) (NP (NNP Doc_2021202_426_432_Chemical)) (, ,) (CC and) (NP (NNP Doc_2021202_438_448_Chemical)))))) (. .)))
2021202	4	(S1 (S (NP (NNP Doc_2021202_450_461_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN for) (NP (CD 236.9) (NN +/-))) (NP (CD 15.1) (NN min)) (PP (IN by) (S (VP (VBG increasing) (NP (DT the) (ADJP (NNP Doc_2021202_515_525_Chemical) (JJ inspired)) (NN concentration) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT a) (JJ mean) (JJ arterial) (NN pressure)) (PP (IN of) (NP (CD 59.8) (JJ +/-) (CD 0.4) (NNS mmHg))))))))))))) (. .)))
2021202	5	(S1 (S (NP (NP (NNP GFR)) (CC and) (NP (NNP ERPF))) (VP (VBD decreased) (UCP (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN anesthesia))))) (CC but) (RB not) (ADJP (RB significantly) (JJR more))) (PP (IN during) (NP (NNP Doc_2021202_698_709_Disease)))) (. .)))
2021202	6	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (NNP ERPF)) (VP (VBD returned) (S (VP (TO to) (VP (VB preoperative) (NP (NNS values))))) (, ,) (SBAR (IN whereas) (S (NP (SYM GFR)) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ preoperative) (NNS values)))))))) (. .)))
2021202	7	(S1 (S (NP (JJ Renal) (JJ vascular) (NN resistance)) (VP (VP (VBD increased) (PP (IN during) (NP (NN anesthesia)))) (CC but) (VP (VBD decreased) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_2021202_888_899_Disease)) (VP (AUX was) (VP (VBN induced)))))) (, ,) (S (VP (VBG allowing) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (JJ renal) (NN blood) (NN flow))))))) (. .)))
2021202	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (JJ renal) (JJ compensatory) (NNS mechanisms)) (VP (AUX are) (VP (VBN preserved) (PP (IN during) (NP (JJ Doc_2021202_1027_1037_Chemical-induced) (NN Doc_2021202_1046_1057_Disease))))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ renal) (NN function)) (CC and) (NP (NNS hemodynamics))) (ADVP (RB quickly)) (VP (VBP return) (PP (TO to) (ADJP (JJ normal))) (SBAR (WHADVP (WRB when)) (S (NP (NN normotension)) (VP (AUX is) (VP (VBN resumed)))))))))) (. .)))
20304337	0	(S1 (S (NP (NP (NN Doc_20304337_0_20_Disease)) (PP (IN in) (NP (DT an) (NN infant)))) (ADVP (RB prenatally)) (VP (VBD exposed) (PP (TO to) (NP (NNP Doc_20304337_56_63_Chemical)))) (. .)))
20304337	1	(S1 (S (NP (JJ Many) (NNS authors)) (VP (VBD described) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN fetus)) (PP (IN of) (NP (JJ maternal) (NNP Doc_20304337_125_138_Disease))) (PP (IN during) (NP (NN pregnancy))))))) (. .)))
20304337	2	(S1 (S (NP (NN Vasoconstriction)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ common) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NN Doc_20304337_246_261_Disease))))))))))))) (. .)))
20304337	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT an) (NN infant)) (PP (IN with) (NP (NNP Doc_20304337_291_325_Disease))) (ADJP (JJ attributable) (PP (TO to) (NP (NNP Doc_20304337_342_362_Disease)))) (, ,) (VP (VBN born) (PP (TO to) (NP (DT a) (JJ Doc_20304337_374_390_Disease) (NN mother))))))) (. .)))
20331935	0	(S1 (NP (NP (DT A) (JJ cross-sectional) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_20331935_46_57_Chemical)) (CC and) (NP (JJ selective) (JJ Doc_20331935_72_81_Chemical) (JJ reuptake) (NNS inhibitors)))) (PP (IN on) (NP (NP (NN bone) (NN mineral) (NN density)) (PP (IN in) (NP (NNS boys))))))) (. .)))
20331935	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_20331935_208_219_Chemical-induced) (NNP Doc_20331935_228_246_Disease))) (PP (IN on) (NP (NP (JJ trabecular) (NN bone) (NN mineral) (NN density)) (PRN (-LRB- -LRB-) (NP (NNP BMD)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents))))))))))) (. .)))
20331935	2	(S1 (S (NP (NP (ADJP (RB Medically) (JJ healthy)) (NNS 7-)) (PP (TO to) (NP (NP (JJ 17-year-old) (NNS males)) (ADJP (RB chronically) (VBN treated)) (, ,) (PP (IN in) (NP (DT a) (JJ naturalistic) (NN setting))) (, ,) (PP (IN with) (NP (NNP Doc_20331935_420_431_Chemical)))))) (VP (AUX were) (VP (VBN recruited) (PP (IN for) (NP (DT this) (JJ cross-sectional) (NN study))) (PP (IN through) (NP (NP (NN child) (NN psychiatry) (NN outpatient) (NNS clinics)) (PP (IN between) (NP (NNP November) (CD 2005) (CC and) (NP (NNP June) (CD 2007)))))))) (. .)))
20331935	3	(S1 (S (NP (NP (JJ Anthropometric) (NNS measurements)) (CC and) (NP (NN laboratory) (NN testing))) (VP (AUX were) (VP (VBN conducted))) (. .)))
20331935	4	(S1 (S (S (NP (DT The) (JJ clinical) (NNS diagnoses)) (VP (AUX were) (VP (VBN based) (PP (IN on) (NP (NN chart) (NN review)))))) (, ,) (CC and) (S (NP (NP (NN developmental)) (CC and) (NP (NN treatment) (NN history))) (VP (AUX was) (VP (VBN obtained) (PP (IN from) (NP (DT the) (JJ medical) (NN record)))))) (. .)))
20331935	5	(S1 (S (S (NP (NP (JJ Volumetric) (NN BMD)) (PP (IN of) (NP (DT the) (JJ ultradistal) (NNS radius)))) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (JJ peripheral) (JJ quantitative) (JJ computed) (NN tomography))))))) (, ,) (CC and) (S (NP (NP (JJ areal) (NN BMD)) (PP (IN of) (NP (DT the) (JJ lumbar) (NN spine)))) (VP (AUX was) (VP (VBN estimated) (S (VP (VBG using) (NP (JJ dual-energy) (NN x-ray) (NN absorptiometry))))))) (. .)))
20331935	6	(S1 (S (NP (NN Doc_20331935_957_975_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (CD 49) (NN %)) (PP (IN of) (NP (NP (NP (CD 83) (NNS boys)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 41)) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_20331935_1028_1039_Chemical))) (PP (IN for) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 2.9) (NNS years)))))))))))) (. .)))
20331935	7	(S1 (S (NP (JJ Serum) (JJ Doc_20331935_1071_1083_Chemical) (NN concentration)) (VP (VP (VBD increased) (PP (IN with) (NP (JJ pubertal) (NN status)))) (CC but) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_20331935_1153_1171_Disease)))))) (. .)))
20331935	8	(S1 (S (SBAR (IN As) (S (VP (VBN expected)))) (, ,) (NP (NP (NN bone) (NN mineral) (NN content)) (CC and) (NP (NNS BMD))) (VP (VBN increased) (PP (IN with) (NP (JJ sexual) (NN maturity)))) (. .)))
20331935	9	(S1 (S (PP (IN After) (S (VP (VBG adjusting) (PP (IN for) (NP (NP (NP (DT the) (NN stage)) (PP (IN of) (NP (NP (JJ sexual) (NN development)) (CC and) (NP (NN height))))) (CC and) (NP (NNP BMI) (NN z) (NNS scores))))))) (, ,) (NP (NN serum) (NN prolactin)) (VP (AUX was) (ADVP (RB negatively)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ trabecular) (JJ volumetric) (NNS BMD)) (PP (IN at) (NP (NP (DT the) (JJ ultradistal) (NNS radius)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .03))) (-RRB- -RRB-)))))))) (. .)))
20331935	10	(S1 (S (PP (VBG Controlling) (PP (IN for) (NP (JJ relevant) (NNS covariates)))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD found) (NP (NN treatment)) (PP (IN with) (NP (NP (JJ selective) (NNP Doc_20331935_1514_1523_Chemical) (NN reuptake) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP SSRIs)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJR lower) (NN trabecular)) (VP (VBN BMD) (PP (IN at) (NP (DT the) (JJ radius) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .03)) (-RRB- -RRB-)) (CC and) (NNP BMD) (NNP z) (NN score))) (PP (IN at) (NP (NP (DT the) (JJ lumbar) (NN spine)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .05)) (-RRB- -RRB-)))))))))))) (. .)))
20331935	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBD became) (ADJP (RBR more) (JJ marked)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN analysis)) (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (JJ non-Hispanic) (JJ white) (NNS patients)))))))) (. .)))
20331935	12	(S1 (S (PP (IN Of) (NP (CD 13) (VBN documented) (NNP Doc_20331935_1782_1791_Disease))) (, ,) (NP (CD 3)) (VP (VBD occurred) (SBAR (IN after) (S (S (NP (NP (NNP Doc_20331935_1810_1821_Chemical)) (CC and) (NP (NNP SSRIs))) (VP (AUX were) (VP (VBN started)))) (, ,) (CC and) (S (NP (NN none)) (VP (VBD occurred) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20331935_1881_1899_Disease)))))))))) (. .)))
20331935	13	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN study)) (SBAR (S (VP (TO to) (VP (VB link) (NP (NNP Doc_20331935_1946_1957_Chemical-induced) (NNP Doc_20331935_1966_1984_Disease) (CC and) (NNP SSRI) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NNS BMD)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents)))))))))))) (. .)))
20331935	14	(S1 (S (NP (JJ Future) (NN research)) (VP (MD should) (VP (VP (VB evaluate) (NP (NP (DT the) (JJ longitudinal) (NN course)) (PP (IN of) (NP (DT this) (JJ adverse) (NN event)))) (S (VP (TO to) (VP (VB determine) (NP (PRP$ its) (JJ temporal) (NN stability)))))) (CC and) (VP (PP (IN whether) (NP (DT a) (JJR higher) (JJ fracture) (NN rate) (NNS ensues)))))) (. .)))
20394767	0	(S1 (S (NP (NP (JJ Fear-potentiated) (NN Doc_20394767_17_24_Disease)) (, ,) (CC but) (NP (RB not) (JJ light-enhanced) (NN Doc_20394767_49_56_Disease)) (, ,)) (VP (AUX is) (VP (VBN enhanced) (PP (IN by) (NP (JJ anxiogenic) (NNS drugs))))) (. .)))
20394767	1	(S1 (NP (NP (NP (NN RATIONALE)) (CC AND) (NP (NNS OBJECTIVES))) (: :) (S (NP (NP (DT The) (JJ light-enhanced) (NNP Doc_20394767_136_143_Disease) (CD paradigm)) (PRN (-LRB- -LRB-) (NP (NNP LES)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB model) (NP (NNP Doc_20394767_181_188_Disease))))) (, ,) (PP (IN because) (IN of) (NP (NP (DT the) (JJ non-specific) (NN cue)) (CC and) (NP (DT the) (JJ long-term) (NN effect))))))) (. .)))
20394767	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJ fear-potentiated) (NNP Doc_20394767_282_289_Disease)) (PRN (-LRB- -LRB-) (NP (NNP FPS)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB model) (NP (VBN conditioned) (NN fear))))))) (. .)))
20394767	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ pharmacological) (NNS profiles)) (PP (IN of) (NP (DT these) (CD two) (NNS paradigms)))) (VP (AUX are) (ADJP (RB very) (JJ similar))) (. .)))
20394767	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ putative) (JJ anxiogenic) (NNS drugs))) (PP (IN on) (NP (NNP LES) (CC and) (NNP FPS))))) (CC and) (VP (VBD aimed) (PP (IN at) (S (VP (VP (VBG determining) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (NNP LES)))) (PP (IN for) (NP (JJ anxiogenic) (NNS drugs)))) (CC and) (VP (TO to) (ADVP (RB potentially)) (VP (VBG showing) (NP (NP (DT a) (JJ pharmacological) (NN differentiation)) (PP (IN between) (NP (DT these) (CD two) (NNS paradigms))))))))))) (. .)))
20394767	5	(S1 (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (VP (VBD received) (NP (NP (DT each) (NN dose)) (PP (IN of) (NP (NP (NP (NP (DT the) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN -adrenoceptor) (NN antagonist) (NP (NP (NP (NP (NNP Doc_20394767_746_755_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 0.25-1.0mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ Doc_20394767_777_781_Chemical) (PRN (-LRB- -LRB-) (NP (CD 2C)) (-RRB- -RRB-)) (NN receptor) (NN agonist) (NNP Doc_20394767_803_827_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20394767_829_833_Chemical)) (, ,) (NP (NN 0.5-2.0mg/kg)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NNP Doc_20394767_856_860_Chemical))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))) (NN inverse) (NN receptor) (NN agonist) (NNP Doc_20394767_889_907_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20394767_909_912_Chemical)) (, ,) (NP (NN 3-30mg/kg)) (-RRB- -RRB-)))))) (CC and) (VP (AUX were) (ADVP (RB subsequently)) (VP (VBN tested) (PP (IN in) (NP (DT either) (NNP LES) (CC or) (NNP FPS)))))) (. .)))
20394767	6	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS drugs)))) (VP (VBD enhanced) (NP (NNP LES)) (, ,) (PP (IN whereas) (NP (NP (JJ Doc_20394767_1025_1029_Chemical) (VBN increased) (NN percentage) (NNS FPS)) (CC and) (NP (JJ Doc_20394767_1059_1068_Chemical) (JJ increased) (JJ absolute) (NNS FPS) (NNS values))))) (. .)))
20394767	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_20394767_1113_1122_Chemical)) (VP (VBD increased) (NP (JJ baseline) (JJ Doc_20394767_1142_1149_Disease) (NN amplitude)) (PP (IN in) (NP (DT the) (NNP LES))) (, ,) (SBAR (IN while) (S (S (NP (NNP Doc_20394767_1178_1182_Chemical)) (VP (VBD suppressed) (NP (JJ baseline) (NN Doc_20394767_1203_1210_Disease)) (PP (IN in) (NP (DT both) (DT the) (NNP LES) (CC and) (NNP FPS))))) (CC and) (S (NP (NNP Doc_20394767_1239_1242_Chemical)) (VP (VBD suppressed) (NP (JJ baseline) (NNP Doc_20394767_1263_1270_Disease)) (PP (IN in) (NP (DT the) (NNS FPS)))))))) (. .)))
20394767	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (NNS findings)) (PP (IN in) (NP (DT the) (JJ FPS) (NNS paradigm))))))) (, ,) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS drugs)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB exacerbate) (NP (DT the) (NNP LES) (NN response))))))) (. .)))
20394767	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (DT a) (JJ clear) (NN pharmacological) (NN differentiation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (NNP LES)) (CC and) (NP (NNP FPS)))))) (. .)))
20466178	0	(S1 (S (NP (NNP Rosaceiform) (NNP Doc_20466178_12_22_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ topical) (JJ Doc_20466178_47_57_Chemical) (NN treatment)))) (. .)))
20466178	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (QP (RB herein) (CD 3)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_20466178_113_120_Disease-like) (NNP Doc_20466178_126_136_Disease) (NNP Doc_20466178_137_146_Disease)))))) (PP (IN while) (S (VP (VBG using) (NP (NP (NP (NP (CD 0.03) (NN %)) (CC or) (NP (CD 0.1) (NN %))) (NNP Doc_20466178_173_183_Chemical) (NN ointment)) (PP (IN for) (NP (NNP Doc_20466178_197_214_Disease)))))))) (. .)))
20466178	2	(S1 (S (NP (NN Skin) (NN biopsy) (NNS specimens)) (VP (VBD showed) (NP (NP (NN Doc_20466178_245_259_Disease)) (CC and) (NP (JJ noncaseating) (JJ epithelioid) (JJ granulomatous) (NN tissue) (NN formation))) (PP (IN in) (NP (NP (DT the) (NN papillary)) (PP (TO to) (NP (NNP mid) (NNS dermis)))))) (. .)))
20466178	3	(S1 (S (NP (NP (JJ Continuous) (JJ topical) (NN use)) (PP (IN of) (NP (NP (NNS immunomodulators)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20466178_403_413_Chemical)) (CC or) (NP (NNP Doc_20466178_417_429_Chemical))))))) (VP (MD should) (VP (AUX be) (VP (VBN regarded) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN cause)) (PP (IN of) (NP (JJ rosaceiform) (NNP Doc_20466178_485_495_Disease))))) (, ,) (SBAR (IN although) (S (NP (JJ many) (NNS cases)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported))))))))) (. .)))
20510337	0	(S1 (S (NP (JJ Doc_20510337_0_12_Chemical) (NN treatment)) (VP (VBZ ameliorates) (NP (NP (JJ acute) (JJ Doc_20510337_41_50_Chemical) (NN Doc_20510337_51_65_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
20510337	1	(S1 (S (NP (NP (DT The) (JJ nephroprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_20510337_106_118_Chemical)))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_20510337_149_167_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_20510337_206_215_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))))))))))) (. .)))
20510337	2	(S1 (S (NP (NP (JJ Doc_20510337_227_239_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg/day)) (, ,) (NP (NN i.p.))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN applied) (PP (IN for) (NP (CD 6) (JJ consecutive) (NNS days))) (, ,) (S (VP (VBG starting) (NP (NP (CD 1) (NN day)) (PP (IN before) (NP (NNP Doc_20510337_329_338_Chemical) (NN administration)))))))) (. .)))
20510337	3	(S1 (S (NP (NN Doc_20510337_355_367_Chemical)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (ADJP (JJ Doc_20510337_390_409_Chemical) (CC and) (JJ serum)) (JJ Doc_20510337_420_430_Chemical) (NNS levels)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN increased) (PP (IN by) (NP (NNP Doc_20510337_462_471_Chemical))))))))) (. .)))
20510337	4	(S1 (S (NP (NP (JJ Doc_20510337_473_485_Chemical) (ADJP (RB significantly) (VBN compensated)) (NNS deficits)) (PP (IN in) (NP (NP (DT the) (JJ antioxidant) (NN defense) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (JJ Doc_20510337_560_579_Chemical) (NN level)) (CC and) (NP (JJ Doc_20510337_590_600_Chemical) (JJ dismutase) (NN activity))) (-RRB- -RRB-)))) (, ,) (VP (VBN suppressed) (NP (NN lipid) (NN peroxidation))) (, ,)) (VP (VP (VBD decreased) (NP (NP (DT the) (NNS elevations)) (PP (IN of) (NP (NP (NNP Doc_20510337_681_686_Disease) (NNP Doc_20510337_687_695_Disease) (NN factor-alpha)) (, ,) (NP (NNP Doc_20510337_710_722_Chemical) (CC and) (NNP Doc_20510337_727_735_Chemical) (NN ion) (NN concentration)) (, ,))))) (CC and) (VP (VBD attenuated) (NP (NP (DT the) (NNS reductions)) (PP (IN of) (NP (NNP Doc_20510337_788_796_Chemical) (CC and) (NNP Doc_20510337_801_805_Chemical) (NNS ions)))) (PP (IN in) (NP (NP (JJ renal) (NN tissue)) (VP (VBN resulted) (PP (IN from) (NP (NNP Doc_20510337_841_850_Chemical) (NN administration)))))))) (. .)))
20510337	5	(S1 (S (ADVP (RB Also)) (, ,) (NP (NP (JJ histopathological) (NN Doc_20510337_891_910_Disease)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_20510337_923_932_Chemical))))) (VP (AUX was) (VP (VBN ameliorated) (PP (IN by) (NP (JJ Doc_20510337_952_964_Chemical) (NN treatment))))) (. .)))
20510337	6	(S1 (S (NP (JJ Immunohistochemical) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Doc_20510337_1019_1031_Chemical)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (JJ Doc_20510337_1060_1069_Chemical-induced) (NN overexpression)) (PP (IN of) (NP (NP (JJ inducible) (JJ Doc_20510337_1106_1118_Chemical) (NN synthase)) (, ,) (NP (JJ nuclear) (NN factor-kappaB)) (, ,) (NP (NN caspase-3)) (CC and) (NP (NN p53)))) (PP (IN in) (NP (JJ renal) (NN tissue)))))))) (. .)))
20510337	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_20510337_1209_1221_Chemical)) (VP (VBZ represents) (NP (NP (DT a) (JJ potential) (JJ therapeutic) (NN option)) (SBAR (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (JJ acute) (JJ Doc_20510337_1289_1298_Chemical) (NN Doc_20510337_1299_1313_Disease)) (VP (ADVP (RB commonly)) (VBN encountered) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))))))))) (. .)))
2051906	0	(S1 (NP (NP (JJ Reversible) (NNP Doc_2051906_11_22_Disease)) (PP (IN with) (NP (NP (NNP Doc_2051906_28_44_Disease)) (VP (VBG following) (NP (JJ Doc_2051906_55_67_Chemical) (NN therapy))))) (. .)))
2051906	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
2051906	2	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN patient)) (, ,) (PP (PP (IN with) (NP (JJ primary) (NNP Doc_2051906_128_140_Disease))) (CC and) (PP (IN without) (NP (NP (JJ previous) (NN evidence)) (PP (IN of) (NP (NNP Doc_2051906_174_187_Disease)))))) (, ,)) (VP (VBD developed) (NP (NP (JJ clinical) (CC and) (JJ biochemical) (NNS features)) (PP (IN of) (NP (JJ severe) (NNP Doc_2051906_243_254_Disease) (CD 3) (NNS months)))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_2051906_284_296_Chemical) (NN therapy)))))) (. .)))
2051906	3	(S1 (S (NP (NN Liver) (NN biopsy)) (VP (VBD showed) (NP (NN Doc_2051906_326_337_Disease)) (PP (IN with) (NP (NP (DT both) (JJ cytological) (CC and) (JJ architectural) (NNS alterations)) (PP (IN of) (NP (JJ interlobular) (JJ bile) (NNS ducts)))))) (. .)))
2051906	4	(S1 (S (NP (JJ Doc_2051906_418_430_Chemical) (NN withdrawal)) (VP (VBD resulted) (PP (IN after) (NP (CD 7) (NNS weeks))) (PP (IN in) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ biochemical))) (NNS abnormalities)))))) (. .)))
2051906	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN believed) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (JJ reversible) (JJ Doc_2051906_592_604_Chemical-induced) (NN Doc_2051906_613_624_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ histological) (NN evidence)) (PP (IN of) (NP (NN Doc_2051906_666_682_Disease)))))))))))))) (. .)))
20533999	0	(S1 (S (NP (NN Doc_20533999_0_8_Chemical)) (VP (AUX is) (RB not) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20533999_49_64_Chemical-induced) (NNP Doc_20533999_73_86_Disease)))))) (. .)))
20533999	1	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (ADVP (RB widely)) (VBN believed) (SBAR (IN that) (S (NP (NP (NNP Doc_20533999_115_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20533999_125_127_Chemical)) (-RRB- -RRB-))) (VP (VBZ mediates) (SBAR (S (NP (NP (NNP Doc_20533999_138_153_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20533999_155_159_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_20533999_169_177_Disease)) (PP (TO to) (NP (NN brain) (NN dopaminergic) (NNS neurons))) (, ,) (PP (IN because) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NNP Doc_20533999_243_245_Chemical) (NN neurotransmission) (NN decrease) (NNP Doc_20533999_273_281_Disease)))))))) (, ,) (PP (IN whereas) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (S (NP (JJ Doc_20533999_311_313_Chemical) (NN neurotransmission)) (VP (VB enhance) (NP (NNP Doc_20533999_340_348_Disease))))))))))))))))) (. .)))
20533999	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN temperature) (NNS effects)) (PP (IN of) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB manipulate) (NP (NN brain) (JJ Doc_20533999_428_430_Chemical) (NN neurotransmission))))))))))) (VP (VBP confound) (NP (NP (NN interpretation)) (PP (IN of) (NP (DT the) (NNS data))))) (. .)))
20533999	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (RB recently) (VBN reported)) (NN ability)) (PP (IN of) (NP (NNP Doc_20533999_537_561_Chemical))) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_20533999_598_624_Chemical))) (PP (IN on) (NP (NNP Doc_20533999_628_632_Chemical-induced) (NNP Doc_20533999_641_643_Chemical) (NNP Doc_20533999_644_657_Disease)))))))) (VP (AUX is) (ADVP (RB also)) (VP (VBN confounded) (PP (IN by) (NP (NP (NN drug) (NNS effects)) (PP (IN on) (NP (NN body) (NN temperature)))))))))) (. .)))
20533999	4	(S1 (S (ADVP (RB Further)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNS mice)) (VP (ADVP (RB genetically)) (VBN engineered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ deficient)) (PP (IN in) (NP (NN brain) (NNP Doc_20533999_789_791_Chemical)))))))) (VP (VBP develop) (NP (NNP Doc_20533999_800_804_Chemical) (NNP Doc_20533999_805_818_Disease)) (, ,) (ADVP (ADVP (RB as) (RB long)) (SBAR (IN as) (S (NP (NP (DT the) (JJ thermic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20533999_854_858_Chemical)))) (VP (AUX are) (VP (VBN preserved)))))))))) (. .)))
20533999	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NNS mice)) (ADJP (RB genetically) (VBN engineered))) (VP (TO to) (VP (AUX have) (S (NP (JJ unilateral) (NN brain) (NN Doc_20533999_960_962_Chemical) (NNS deficits)) (VP (VB develop) (NP (NP (JJ Doc_20533999_980_984_Chemical-induced) (NN Doc_20533999_993_1014_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (PP (IN of) (NP (JJ comparable) (NN magnitude))) (PP (IN on) (NP (NP (DT both) (NNS sides)) (PP (IN of) (NP (DT the) (NN brain)))))))))))))))) (. .)))
20533999	6	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS findings)) (VP (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_20533999_1124_1126_Chemical)) (VP (AUX is) (RB not) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_20533999_1167_1171_Chemical-induced) (JJ dopaminergic) (NN Doc_20533999_1193_1206_Disease))))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS mechanisms)) (ADJP (JJ independent) (PP (IN of) (NP (NNP Doc_20533999_1250_1252_Chemical))))) (VP (VBP warrant) (NP (ADJP (RBR more) (JJ intense)) (NN investigation))))))) (. .)))
20552622	0	(S1 (FRAG (NP (NP (JJ Swallowing-induced) (NN Doc_20552622_19_41_Disease)) (VP (VBN triggered) (PP (IN by) (NP (NNP Doc_20552622_55_65_Chemical))))) (: :) (NP (NP (NN case) (NN report) (CC and) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (. .)))
20552622	1	(S1 (S (NP (DT A) (JJ 49-year-old) (NN patient)) (VP (VBD experienced) (NP (NN chest) (NN discomfort)) (SBAR (IN while) (S (VP (VBG swallowing))))) (. .)))
20552622	2	(S1 (S (PP (IN On) (NP (NN electrocardiogram))) (, ,) (NP (NP (NNS episodes)) (PP (IN of) (NP (NNP Doc_20552622_218_240_Disease)))) (VP (AUX were) (VP (VBN recorded) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG swallowing) (NP (NP (: ;) (JJ 24-hour) (NN Holter)) (VP (VBG monitoring) (NP (JJ recorded) (JJ several) (NNS events))))))))) (. .)))
20552622	3	(S1 (S (NP (DT The) (NNP Doc_20552622_340_350_Disease)) (VP (VP (VBD resolved) (PP (IN after) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_20552622_379_387_Chemical)))))) (, ,) (CC but) (VP (VBD recurred) (NP (DT a) (NN year)) (ADVP (RB later)))) (. .)))
20552622	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD noticed) (SBAR (IN that) (S (PP (IN before) (NP (DT these) (NNS episodes))) (NP (PRP he)) (VP (AUX had) (VP (AUX been) (S (VP (VBG using) (NP (NP (DT an) (NN inhalator)) (PP (IN of) (NP (NN Doc_20552622_497_507_Chemical))))))))))) (. .)))
20552622	5	(S1 (S (PP (PP (IN After) (S (VP (VBG stopping) (NP (DT the) (NN beta-agonist))))) (, ,) (CC and) (PP (IN after) (NP (NP (DT a) (NN week)) (PP (IN with) (NP (DT the) (NNP Doc_20552622_568_576_Chemical)))))) (, ,) (NP (DT the) (NNP Doc_20552622_582_592_Disease)) (VP (VBD disappeared)) (. .)))
20552622	6	(S1 (S (NP (NP (JJ Swallowing-induced) (NNP Doc_20552622_637_659_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20552622_661_665_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (DT a) (JJ rare) (NN phenomenon))) (. .)))
20552622	7	(S1 (S (NP (NP (QP (JJR Fewer) (IN than) (CD 50)) (NNS cases)) (PP (IN of) (NP (NNP Doc_20552622_712_716_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
20552622	8	(S1 (S (NP (DT This) (NN article)) (VP (VBZ summarizes) (NP (NP (PDT all) (DT the) (NNS cases)) (VP (VBN published))) (, ,) (S (VP (VBG creating) (NP (NP (NP (DT a) (JJ comprehensive) (NN review)) (PP (IN of) (NP (DT the) (JJ current) (NN knowledge)))) (CC and) (NP (NP (NN approach)) (PP (TO to) (NP (NNP Doc_20552622_878_882_Disease)))))))) (. .)))
20552622	9	(S1 (S (NP (PRP It)) (VP (VBZ discusses) (NP (NP (NNS demographics)) (, ,) (NP (NP (JJ clinical) (NNS characteristics) (CC and) (NNS types)) (PP (IN of) (NP (NNP Doc_20552622_949_959_Disease)))) (, ,) (NP (NP (JJ postulated) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_20552622_986_990_Disease)))) (, ,) (CC and) (NP (NP (JJ different) (NN treatment) (NNS possibilities)) (PP (JJ such) (IN as) (NP (NP (NNS medications)) (, ,) (NP (NN surgery)) (, ,) (CC and) (NP (NP (NN radiofrequency) (NN catheter) (NN ablation)) (PRN (-LRB- -LRB-) (NP (NNP RFCA)) (-RRB- -RRB-)))))))) (. .)))
20552622	10	(S1 (S (NP (NN Doc_20552622_1117_1127_Chemical)) (VP (AUX is) (VP (VBN presented) (ADVP (RB here)) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN trigger)) (PP (IN for) (NP (NNP Doc_20552622_1172_1176_Disease))))))) (. .)))
20552622	11	(S1 (S (SBAR (IN Although) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB define) (NP (NN causality)) (PP (IN in) (NP (DT a) (NN case) (NN report))))))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ logical) (S (VP (TO to) (VP (VB think) (SBAR (SBAR (IN that) (S (NP (NP (DT a) (NN beta-agonist)) (PP (IN like) (NP (NNP Doc_20552622_1289_1299_Chemical))) (PRN (-LRB- -LRB-) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_20552622_1317_1328_Disease)))))) (-RRB- -RRB-))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN trigger)) (PP (IN of) (NP (NP (JJ adrenergic) (NNS reflexes)) (VP (VBG originating) (PP (IN in) (NP (DT the) (NN esophagus))))))) (SBAR (IN while) (S (VP (VBG swallowing)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (NN beta-blocker)) (PP (JJ such) (IN as) (NP (NNP Doc_20552622_1450_1458_Chemical))) (PRN (-LRB- -LRB-) (PP (IN that) (NP (NNS blocks)) (NP (DT the) (JJ adrenergic) (NN activity))) (-RRB- -RRB-))) (VP (MD may) (VP (VB relieve) (NP (PRP it)))))))))))) (. .)))
2055425	0	(S1 (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NN insulin) (NN treatment))) (S (VP (TO to) (VP (VP (VB reverse)) (CC or) (VP (VB prevent) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (JJ urinary) (NN bladder) (NN function))))))))) (VP (VBD caused) (PP (IN by) (NP (JJ Doc_2055425_105_119_Chemical-induced) (NNP Doc_2055425_128_145_Disease.) (CD 1)))) (. .)))
2055425	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN insulin) (NN treatment))) (PP (IN on) (PP (IN in) (NP (NN vivo))) (CC and) (PP (IN in) (NP (NP (NN vitro) (NN urinary) (NN bladder) (NN function)) (PP (IN in) (NP (JJ Doc_2055425_235_249_Chemical-Doc_2055425_250_258_Disease) (NNS rats))))))) (VP (AUX were) (VP (VBN investigated.) (NP (CD 2)))) (. .)))
2055425	2	(S1 (S (NP (NP (NN Doc_2055425_286_294_Disease)) (PP (IN of) (NP (QP (CD 2) (NNS months)) (NN duration)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN body) (NN weight)))) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN fluid) (NN consumption)) (, ,) (NP (NN urine) (NN volume)) (, ,) (NP (NP (NN frequency)) (PP (IN of) (NP (NN micturition)))) (, ,) (CC and) (NP (NP (JJ average) (NN volume)) (PP (IN per) (NP (NP (NN micturition)) (: ;) (NP (NP (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN prevented) (PP (IN by) (NP (NN insulin) (NN treatment.) (CD 3))))))))))))))))) (. .)))
2055425	3	(S1 (S (NP (NN Insulin) (NN treatment)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (JJ contractile) (NNS responses)) (PP (IN of) (NP (NN bladder) (NN body) (NNS strips)))))) (PP (PP (IN from) (NP (JJ Doc_2055425_619_627_Disease) (NNS rats))) (PP (TO to) (NP (NN nerve) (NN stimulation)))) (, ,) (NP (NP (NNP Doc_2055425_655_658_Chemical)) (, ,) (CC and) (NP (NNP Doc_2055425_664_675_Chemical.) (CD 4)))) (. .)))
2055425	4	(S1 (S (NP (NP (NN Doc_2055425_680_688_Disease)) (PP (IN of) (NP (QP (CD 4) (NNS months)) (NN duration)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN body) (NN weight)))) (, ,) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN fluid) (NN consumption)) (, ,) (NP (NN urine) (NN volume)) (, ,) (NP (NP (NN frequency)) (PP (IN of) (NP (NN micturition)))) (, ,) (CC and) (NP (NP (JJ average) (NN volume)) (PP (IN per) (NP (NN micturition)))) (, ,) (NP (NP (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NP (NN insulin) (NN treatment)) (PP (IN for) (NP (NP (DT the) (JJ final) (CD 2) (NNS months)) (PP (IN of) (NP (DT the) (NN study.) (CD 5)))))))))))))))))) (. .)))
2055425	5	(S1 (S (NP (NN Insulin) (NN treatment)) (VP (VBD reversed) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (NP (JJ contractile) (NNS responses)) (PP (IN of) (NP (NP (NN bladder) (NN body) (NNS strips)) (PP (IN from) (NP (NNP Doc_2055425_1048_1056_Disease) (NNS rats))))) (PP (TO to) (NP (NN nerve) (NN stimulation)))) (, ,) (NP (NP (NNP Doc_2055425_1084_1087_Chemical)) (, ,) (CC and) (NP (NNP Doc_2055425_1093_1104_Chemical.) (CD 6))))))) (. .)))
2055425	6	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2055425_1147_1161_Chemical-induced) (NNP Doc_2055425_1170_1178_Disease))) (PP (IN on) (NP (JJ urinary) (NN bladder) (NN function)))) (VP (AUX are) (DT both) (VP (VP (VBN prevented)) (CC and) (VP (VBN reversed) (PP (IN by) (NP (NN insulin) (NN treatment))))))))) (. .)))
20558148	0	(S1 (S (NP (NP (JJ Glutamatergic) (NN neurotransmission)) (VP (VBN mediated) (PP (IN by) (NP (JJ Doc_20558148_44_48_Chemical) (NNS receptors))) (PP (IN in) (NP (DT the) (JJ inferior) (NNS colliculus))))) (VP (MD can) (VP (VBP modulate) (NP (JJ Doc_20558148_99_110_Chemical-induced) (NN Doc_20558148_119_128_Disease)))) (. .)))
20558148	1	(S1 (S (S (NP (NP (DT The) (JJ inferior) (NN colliculus)) (PRN (-LRB- -LRB-) (NP (NN IC)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB primarily)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN processing)) (PP (IN of) (NP (JJ auditory) (NN information)))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (VP (VBN distinguished) (PP (IN from) (NP (NP (JJ other) (JJ auditory) (NNS nuclei)) (PP (IN in) (NP (DT the) (NN brainstem))))) (PP (IN by) (NP (NP (PRP$ its) (NNS connections)) (PP (IN with) (NP (NP (NNS structures)) (PP (IN of) (NP (DT the) (NN motor) (NN system)))))))))) (. .)))
20558148	2	(S1 (S (NP (NP (JJ Functional) (NN evidence)) (VP (VBG relating) (NP (DT the) (NNS IC)) (PP (TO to) (NP (NN motor) (NN behavior))))) (VP (VBZ derives) (PP (IN from) (NP (NP (NNS experiments)) (VP (VBG showing) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NNS IC))) (PP (IN by) (NP (NP (JJ electrical) (NN stimulation)) (CC or) (NP (JJ excitatory) (JJ Doc_20558148_501_511_Chemical) (NN microinjection))))) (VP (VBZ causes) (NP (NP (NN freezing)) (, ,) (NP (JJ escape-like) (NN behavior)) (, ,) (CC and) (NP (NN immobility)))))))))) (. .)))
20558148	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (DT this) (NN immobility)))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
20558148	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ excitatory) (JJ Doc_20558148_694_704_Chemical-mediated) (NNS mechanisms)) (PP (IN in) (NP (DT the) (NN IC))))) (PP (IN on) (NP (NP (DT the) (NNP Doc_20558148_742_751_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNP Doc_20558148_767_775_Chemical) (NN receptor) (NN blocker) (NNP Doc_20558148_793_804_Chemical)) (VP (VBN administered) (ADVP (RB systemically)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC or) (CD 0.5)) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
20558148	5	(S1 (S (NP (JJ Doc_20558148_857_868_Chemical-induced) (NNP Doc_20558148_877_886_Disease)) (VP (AUX was) (VP (VBN challenged) (PP (PP (IN with) (NP (NP (NP (JJ prior) (JJ intracollicular) (NNS microinjections)) (PP (IN of) (NP (NNP Doc_20558148_948_957_Chemical) (NNP Doc_20558148_958_962_Chemical) (NN receptor) (NNS antagonists)))) (, ,) (NP (NP (NP (NNP Doc_20558148_985_991_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC or) (CD 30) (CD mmol/0.5)) (NN microl)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20558148_1023_1026_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 20) (CD nmol/0.5)) (NN microl)) (-RRB- -RRB-)))))) (, ,) (CC or) (PP (IN of) (NP (NP (DT the) (JJ Doc_20558148_1065_1069_Chemical) (NN receptor) (NN agonist) (NNP Doc_20558148_1087_1107_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20558148_1109_1113_Chemical)) (, ,) (NP (QP (CD 20) (CC or) (CD 30) (CD nmol/0.5)) (NN microl)) (-RRB- -RRB-))))))) (. .)))
20558148	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (NP (DT that) (JJ intracollicular) (NN microinjection)) (PP (IN of) (NP (NNP Doc_20558148_1200_1206_Chemical) (CC and) (NNP Doc_20558148_1211_1214_Chemical) (JJ previous)))) (PP (TO to) (NP (NP (JJ systemic) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_20558148_1250_1261_Chemical)) (VP (ADVP (RB significantly)) (VBN attenuated) (NP (DT the) (NNP Doc_20558148_1291_1300_Disease))))))) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (DT a) (JJ reduced) (NN latency)) (SBAR (S (VP (TO to) (VP (VB step) (PRT (RP down)) (PP (IN from) (NP (DT a) (JJ horizontal) (NN bar))))))))))))) (. .)))
20558148	7	(S1 (S (ADVP (RB Accordingly)) (, ,) (NP (NP (NN intracollicular) (NN microinjection)) (PP (IN of) (NP (NNP Doc_20558148_1419_1423_Chemical)))) (VP (VBD increased) (NP (DT the) (NN latency)) (PP (TO to) (NP (NN step))) (PP (IN down) (NP (DT the) (NN bar)))) (. .)))
20558148	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_20558148_1496_1505_Chemical-mediated) (NNS mechanisms)) (PP (IN in) (NP (DT the) (JJ neural) (NNS circuits))) (PP (IN at) (NP (DT the) (JJ IC) (NN level)))) (VP (VP (VBP influence) (NP (JJ Doc_20558148_1575_1586_Chemical-induced) (NNP Doc_20558148_1595_1604_Disease))) (CC and) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN motor) (NN activity)))))))))) (. .)))
20635749	0	(S1 (NP (NP (NP (JJ Severe) (JJ Doc_20635749_7_31_Disease) (NN patient)) (PP (IN on) (NP (NNP Doc_20635749_43_53_Chemical) (VBG presenting))) (PP (IN with) (NP (NNP Doc_20635749_70_84_Disease)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
20635749	1	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN of) (NP (NNP Doc_20635749_126_139_Disease) (JJ secondary))) (PP (TO to) (NP (NP (NNP Doc_20635749_153_163_Chemical-induced) (NNP Doc_20635749_172_186_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_20635749_212_236_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20635749_238_241_Disease)) (-RRB- -RRB-)))))))))) (. .)))
20635749	2	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (CC and) (PP (IN after) (S (VP (VBG reviewing) (NP (DT the) (NN literature))))) (NP (EX there)) (VP (AUX is) (NP (NP (CD one) (NN case) (VB report)) (PP (IN of) (NP (NNP Doc_20635749_324_337_Disease))) (PP (IN during) (NP (JJ long) (NN term) (JJ Doc_20635749_355_365_Chemical) (NN therapy))))) (. .)))
20635749	3	(S1 (S (NP (NN Doc_20635749_375_388_Disease)) (VP (AUX is) (NP (NP (DT a) (NN life) (VBG threatening) (NN condition)) (SBAR (WHNP (WDT that)) (S (VP (VBZ carries) (NP (NP (DT a) (NN mortality)) (VP (VBG reaching) (NP (QP (RB as) (JJ high) (IN as) (CD 20)) (NN %)) (PP (IN with) (NP (NN treatment)))))))))) (. .)))
20635749	4	(S1 (S (NP (DT The) (NN condition)) (VP (AUX is) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ intravenous) (NNP Doc_20635749_528_537_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20635749_539_541_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ intravenous) (NNP Doc_20635749_558_576_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20635749_578_580_Chemical)) (-RRB- -RRB-))))))) (. .)))
20635749	5	(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_20635749_597_600_Disease))) (PP (IN on) (NP (NNP Doc_20635749_604_614_Chemical)))) (VP (MD may) (VP (VB suffer) (NP (NP (JJ serious) (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN from) (NP (NNP Doc_20635749_663_677_Disease)))))) (, ,) (CC and) (S (ADVP (RB thus)) (VP (MD may) (VP (VB deserve) (ADVP (RBR closer)) (VP (VB follow) (PRT (RP up)) (PP (IN for) (NP (JJ thyroid) (JJ stimulating) (NN hormone) (PRN (-LRB- -LRB-) (NP (NNP TSH)) (-RRB- -RRB-)) (NNS levels))))))) (. .)))
20635749	6	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ carries) (NP (NP (DT an) (JJ important) (JJ clinical) (NN application)) (VP (VBN given) (NP (NP (DT the) (JJ frequent) (NN usage)) (PP (IN of) (NP (NNP Doc_20635749_850_860_Chemical))) (PP (IN among) (NP (NNP Doc_20635749_867_870_Disease) (NNS patients))))))) (. .)))
20635749	7	(S1 (S (NP (NP (DT The) (JJ myriad) (JJ clinical) (NN presentation)) (PP (IN of) (NP (NP (NNP Doc_20635749_917_930_Disease)) (CC and) (NP (NP (PRP$ its) (JJ serious) (NN morbidity)) (CC and) (NP (NN mortality)))))) (VP (VBZ stresses) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB suspect) (NP (DT this) (JJ clinical) (NN syndrome)) (PP (IN among) (NP (NP (JJ Doc_20635749_1029_1032_Disease) (NNS patients)) (VP (VBG presenting) (PP (IN with) (NP (NP (NNP Doc_20635749_1058_1069_Disease)) (, ,) (NP (NNP Doc_20635749_1071_1079_Disease)) (CC or) (NP (JJ other) (JJ unexplained) (NNS symptoms)))))))))))) (. .)))
20683499	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (JJ active) (NNS constituents)) (PP (IN of) (NP (NNP Crocus) (NNS sativus) (NNP L.) (, ,) (NNP Doc_20683499_53_59_Chemical))))) (PP (IN on) (NP (NP (JJ Doc_20683499_63_75_Chemical-induced) (NN model)) (PP (IN of) (NP (JJ sporadic) (NNP Doc_20683499_102_121_Disease))) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
20683499	1	(S1 (S (NP (NP (DT The) (NN involvement)) (PP (IN of) (NP (NP (JJ water-soluble) (NAC (NNP Doc_20683499_181_192_Chemical) (, ,) (NNP Doc_20683499_194_201_Chemical) (, ,))) (PP (IN as) (NP (NP (DT the) (JJ main) (CC and) (JJ active) (NNS components)) (PP (IN of) (NP (NNP Crocus) (FW sativus) (NNP L.))))) (VP (VB extract) (PP (IN in) (NP (NP (NN learning)) (CC and) (NP (NN memory) (NNS processes)))))))) (VP (AUX has) (VP (AUX been) (VP (VBN proposed)))) (. .)))
20683499	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_20683499_354_361_Chemical))) (PP (IN on) (NP (NP (JJ sporadic) (NN Doc_20683499_374_393_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intracerebroventricular) (PRN (-LRB- -LRB-) (NP (NN icv)) (-RRB- -RRB-)) (NNP Doc_20683499_435_447_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20683499_449_452_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ male) (NNS rats))))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
20683499	3	(S1 (S (NP (NP (JJ Male) (NN adult) (NN Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (QP (SYM =) (CD 90) (CC and) (CD 260-290))) (NP (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (NP (CD 1)) (, ,) (NP (NP (NN control)) (: ;) (NP (NP (CD 2) (CC and) (CD 3)) (, ,) (NP (NP (NNP Doc_20683499_579_586_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC and) (CD 30)) (NN mg/kg)) (-RRB- -RRB-)))) (: ;) (NP (NP (CD 4)) (, ,) (NP (NNP Doc_20683499_609_612_Chemical))) (: ;) (NP (CD 5) (CC and) (CD 6))) (, ,)) (NNP Doc_20683499_623_626_Chemical) (NNP +) (NNP Doc_20683499_629_636_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC and) (CD 30)) (NNS mg/kg)) (-RRB- -RRB-)) (NNS groups))))) (. .)))
20683499	4	(S1 (S (PP (IN In) (NP (JJ Doc_20683499_666_685_Disease) (NNS groups))) (, ,) (S (NP (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (JJ Doc_20683499_718_721_Chemical-icv) (NN bilaterally)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ first) (NN day)))))) (CC and) (S (ADVP (NP (CD 3) (NNS days)) (RB later)) (, ,) (NP (DT a) (JJ similar) (JJ Doc_20683499_789_792_Chemical-icv) (NN application)) (VP (AUX was) (VP (VBN repeated)))) (. .)))
20683499	5	(S1 (S (PP (IN In) (NP (NNP Doc_20683499_826_829_Chemical) (NNP +) (NNP Doc_20683499_832_838_Chemical) (NN animal) (NNS groups))) (, ,) (NP (NNP Doc_20683499_854_860_Chemical)) (VP (AUX was) (VP (VBN applied) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 15) (CC and) (CD 30)) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (, ,) (UCP (ADJP (NP (CD one) (NN day)) (JJ pre-surgery)) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD three) (NNS weeks))))))))))) (. .)))
20683499	6	(S1 (S (NP (NP (NN Prescription)) (PP (IN of) (NP (NNP Doc_20683499_975_981_Chemical))) (PP (IN in) (NP (DT each) (NN dose)))) (VP (AUX was) (VP (VBN repeated) (ADVP (RB once)) (PP (IN for) (NP (CD two) (NNS days))))) (. .)))
20683499	7	(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT the) (NN learning) (CC and) (NN memory) (NN performance)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (JJ passive) (NN avoidance) (NNS paradigm))))))) (, ,) (CC and) (S (PP (IN for) (NP (JJ spatial) (NN cognition) (NN evaluation))) (, ,) (NP (JJ Y-maze) (NN task)) (VP (AUX was) (VP (VBN used)))) (. .)))
20683499	8	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (PRT (RP out)) (SBAR (IN that) (S (NP (NP (NNP Doc_20683499_1210_1216_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD -treated) (SBAR (S (NP (JJ Doc_20683499_1236_1239_Chemical-injected) (NNS rats)) (VP (VBP show) (NP (NP (NP (JJR higher) (JJ correct) (NNS choices)) (CC and) (NP (NP (JJR lower) (NNS errors)) (PP (IN in) (NP (NN Y-maze))))) (PP (IN than) (NP (JJ vehicle-treated) (JJ Doc_20683499_1330_1333_Chemical-injected) (NNS rats)))))))))))) (. .)))
20683499	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNP Doc_20683499_1362_1368_Chemical)) (PP (IN in) (NP (DT the) (VBN mentioned) (NN dose)))) (VP (MD could) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NNP Doc_20683499_1422_1452_Disease)) (PP (IN in) (NP (NP (VBN treated) (JJ Doc_20683499_1464_1467_Chemical-injected) (NN group)) (PP (IN in) (NP (JJ passive) (NN avoidance) (NN test))))))) (. .)))
20683499	10	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (DT these) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (NNP Doc_20683499_1580_1586_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))))) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (NN Doc_20683499_1618_1636_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_20683499_1647_1650_Chemical-icv))))) (PP (IN in) (NP (NP (NNS rats)) (CC and) (NP (NP (PRP$ its) (NN potential)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_20683499_1701_1727_Disease)) (PP (JJ such) (IN as) (NP (NNP Doc_20683499_1736_1755_Disease)))))))))))))) (. .)))
20705401	0	(S1 (S (NP (NN Doc_20705401_0_9_Chemical) (CD 6) (NN receptor) (NN gene)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_20705401_45_60_Chemical-induced) (NNP Doc_20705401_69_78_Disease)) (PP (IN in) (NP (DT a) (JJ Japanese) (NN population))))))) (. .)))
20705401	1	(S1 (S (NP (JJ Altered) (JJ serotonergic) (NN neural) (NN transmission)) (VP (AUX is) (VP (VBN hypothesized) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ susceptibility) (NN factor)) (PP (IN for) (NP (NP (NNP Doc_20705401_208_227_Disease)) (PP (JJ such) (IN as) (NP (NN Doc_20705401_236_249_Disease))))))))))) (. .)))
20705401	2	(S1 (S (S (NP (DT The) (NP (NP (NNP Doc_20705401_255_264_Chemical) (CD 6)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20705401_268_272_Chemical6)) (-RRB- -RRB-))) (NN receptor)) (VP (AUX is) (ADVP (RB therapeutically)) (VP (VBN targeted) (PP (IN by) (NP (NP (JJ several) (JJ second) (NN generation) (NNS antipsychotics)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20705401_365_374_Chemical)) (CC and) (NP (NNP Doc_20705401_379_389_Chemical))))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_20705401_395_408_Chemical-induced) (NNP Doc_20705401_417_430_Disease)) (PP (IN in) (NP (NNS rats)))) (VP (AUX is) (VP (VBN corrected) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT a) (JJ selective) (NNP Doc_20705401_480_484_Chemical6) (NN receptor) (NN antagonist)))))))) (. .)))
20705401	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (VBN disrupted) (NN prepulse) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20705401_565_578_Chemical) (CC or) (NNP Doc_20705401_582_595_Chemical))))) (VP (AUX was) (VP (VBN restored) (PP (IN by) (NP (NNP Doc_20705401_612_616_Chemical6) (NN receptor) (NN antagonist))) (PP (IN in) (NP (NP (DT an) (NN animal) (NN study)) (VP (VBG using) (NP (NNS rats))))))) (. .)))
20705401	4	(S1 (S (S (NP (DT These) (NN animal) (NNS models)) (VP (AUX were) (VP (VBN considered) (S (VP (TO to) (VP (VB reflect) (NP (NP (DT the) (JJ positive) (NNS symptoms)) (PP (IN of) (NP (NN Doc_20705401_741_754_Disease)))))))))) (, ,) (CC and) (S (NP (DT the) (JJ above) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ altered) (NNP Doc_20705401_801_805_Chemical6) (NNS receptors)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20705401_856_875_Disease))))))))))) (. .)))
20705401	5	(S1 (S (NP (NP (DT The) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_20705401_893_908_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20705401_910_914_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_20705401_924_933_Disease)))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_20705401_958_985_Disease))))))) (. .)))
20705401	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (DT the) (JJ Doc_20705401_1049_1053_Chemical6) (NN gene))))) (PRN (-LRB- -LRB-) (NP (NNP HTR6)) (-RRB- -RRB-)) (PP (IN with) (NP (JJ Doc_20705401_1072_1076_Chemical-induced) (NNP Doc_20705401_1085_1094_Disease))))) (. .)))
20705401	7	(S1 (S (S (VP (VBG Using) (NP (NP (CD five) (NN tagging) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (, ,) (CD rs1805054) (, ,) (CD rs4912138) (, ,) (CD rs3790757) (CC and) (CD rs9659997)) (-RRB- -RRB-))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (JJ genetic) (NN association) (NN analysis)) (PP (IN of) (NP (NP (JJ case-control) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NP (CD 197) (JJ Doc_20705401_1261_1265_Chemical-induced) (NNP Doc_20705401_1274_1283_Disease) (NNS patients)) (CC and) (NP (CD 337) (NNS controls))) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ Japanese) (NN population))))) (. .)))
20705401	8	(S1 (S (NP (NP (DT The) (NN age) (CC and) (NN sex)) (PP (IN of) (NP (DT the) (NN control) (NNS subjects)))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ Doc_20705401_1412_1427_Chemical) (NN dependence) (NNS patients))))))) (. .)))
20705401	9	(S1 (S (NP (CD rs6693503)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_20705401_1488_1492_Chemical-induced) (JJ Doc_20705401_1501_1510_Disease) (NNS patients)) (PP (IN in) (NP (DT the) (JJ allele/genotype-wise) (NN analysis))))))) (. .)))
20705401	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT this) (NN association)) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN after) (NP (NNP Bonferroni) (NN correction)))) (. .)))
20705401	11	(S1 (S (PP (IN In) (NP (DT the) (JJ haplotype-wise) (NN analysis))) (, ,) (NP (PRP we)) (VP (VBD detected) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (CD two) (NNS markers)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (CC and) (CD rs1805054)) (-RRB- -RRB-))) (CC and) (NP (NP (CD three) (NNS markers)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (, ,) (CD rs1805054) (CC and) (CD rs4912138)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNS HTR6)) (CC and) (NP (JJ Doc_20705401_1807_1811_Chemical-induced) (NN Doc_20705401_1820_1829_Disease) (NNS patients)))) (, ,) (ADVP (RB respectively))) (. .)))
20705401	12	(S1 (S (NP (NN HTR6)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (NNP Doc_20705401_1924_1928_Chemical-induced) (NNP Doc_20705401_1937_1946_Disease)) (PP (IN in) (NP (DT the) (JJ Japanese) (NN population))))))))) (. .)))
20727411	0	(S1 (S (NP (NP (JJ Neural) (NNS correlates)) (PP (IN of) (NP (NNP Doc_20727411_21_31_Chemical)))) (VP (VBN induced) (NP (NNP Doc_20727411_40_49_Disease)) (PP (IN during) (NP (JJ overt) (JJ continuous) (JJ verbal) (NN fluency)))) (. .)))
20727411	1	(S1 (S (NP (DT The) (JJ glutamatergic) (NNP Doc_20727411_108_128_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20727411_130_134_Chemical)) (-RRB- -RRB-)) (NN receptor)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20727411_191_204_Disease)))))))) (. .)))
20727411	2	(S1 (S (PP (VBN Administered) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (, ,) (NP (NP (DT a) (JJ subanesthetic) (NN dose)) (PP (IN of) (NP (DT the) (JJ non-competitive) (JJ Doc_20727411_286_290_Chemical) (NN receptor)))) (VP (VBP antagonist) (NP (NP (JJ Doc_20727411_311_319_Chemical) (NNS leads)) (PP (TO to) (NP (NP (JJ psychopathological) (NNS symptoms)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_20727411_386_399_Disease))))))))))) (. .)))
20727411	3	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20727411_418_431_Disease))))) (, ,) (NP (NNP Doc_20727411_433_441_Chemical)) (VP (VBZ exacerbates) (NP (NP (DT the) (JJ core) (NNS symptoms)) (PP (IN of) (NP (NN illness)))) (, ,) (S (VP (VBG supporting) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (DT a) (NN Doc_20727411_515_540_Disease))))))) (. .)))
20727411	4	(S1 (S (PP (IN In) (NP (DT a) (JJ counterbalanced) (, ,) (JJ placebo-controlled) (, ,) (JJ double-blind) (NN study) (NN design))) (, ,) (NP (JJ healthy) (NNS subjects)) (VP (AUX were) (VP (VBN administered) (NP (DT a) (JJ continuous) (JJ subanesthetic) (JJ Doc_20727411_673_683_Chemical) (NN infusion)) (SBAR (IN while) (S (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ BOLD) (NNS responses)) (VP (VBN measured) (PP (IN with) (NP (NN fMRI))))))) (VP (AUX were) (VP (VBN detected))))))) (. .)))
20727411	5	(S1 (S (PP (IN During) (NP (DT the) (VBG scanning) (NN period))) (, ,) (NP (NNS subjects)) (VP (VBD performed) (NP (NP (JJ continuous) (JJ overt) (JJ verbal) (NN fluency) (NNS tasks)) (PRN (-LRB- -LRB-) (ADJP (JJ phonological) (, ,) (JJ lexical) (CC and) (JJ semantic)) (-RRB- -RRB-)))) (. .)))
20727411	6	(S1 (S (NP (JJ Doc_20727411_886_894_Chemical-induced) (NN psychopathological) (NNS symptoms)) (VP (AUX were) (VP (VBN assessed) (PP (IN with) (NP (NP (DT the) (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NN PANSS)) (-RRB- -RRB-)))))) (. .)))
20727411	7	(S1 (S (NP (NN Doc_20727411_1000_1008_Chemical)) (VP (VBD elicited) (NP (NNP Doc_20727411_1018_1027_Disease)) (PP (IN like) (NP (NN psychopathology)))) (. .)))
20727411	8	(S1 (S (NP (JJ Post-hoc) (NNS t-tests)) (VP (VBD revealed) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NN placebo)) (CC and) (NP (NNP Doc_20727411_1120_1128_Chemical))))) (PP (IN for) (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NP (NNS words)) (VP (VBN generated) (PP (IN during) (NP (NP (NN lexical)) (CC and) (NP (JJ semantic) (JJ verbal) (NN fluency))))))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ phonological) (NN domain)) (VP (VBD remained) (ADJP (JJ unaffected)))))) (. .)))
20727411	9	(S1 (S (NP (NN Doc_20727411_1259_1267_Chemical)) (VP (VBD led) (PP (TO to) (NP (NP (JJ enhanced) (JJ cortical) (NNS activations)) (PP (IN in) (NP (NP (JJ supramarginal) (CC and) (JJ frontal) (NN brain) (NNS regions)) (PP (PP (IN for) (NP (NP (NN phonological)) (CC and) (NP (JJ lexical) (JJ verbal) (NN fluency)))) (, ,) (CC but) (RB not) (PP (IN for) (NP (JJ semantic) (JJ verbal) (NN fluency))))))))) (. .)))
20727411	10	(S1 (S (NP (NN Doc_20727411_1430_1438_Chemical)) (VP (VBZ induces) (NP (NP (NN activation) (NNS changes)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20727411_1529_1542_Disease))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJ frontal) (CC and) (JJ temporal) (NN brain) (NNS regions))))))))))) (. .)))
20727411	11	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP provide) (NP (NP (JJ further) (NN support)) (PP (IN for) (NP (NP (DT the) (NNS hypothesis)) (PP (IN of) (NP (NP (DT an) (JJ Doc_20727411_1657_1661_Chemical) (NN receptor) (NN dysfunction)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20727411_1709_1722_Disease))))))))))) (. .)))
20735774	0	(S1 (NP (NP (JJ Long-term) (NN prognosis)) (PP (IN for) (NP (NP (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_53_64_Chemical-induced) (NNP Doc_20735774_73_92_Disease))))) (. .)))
20735774	1	(S1 (S (NP (NP (DT The) (NN prognosis)) (PP (IN for) (NP (NP (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_153_164_Chemical-induced) (NNP Doc_20735774_173_192_Disease)))))) (VP (VBZ remains) (NP (NN unknown))) (. .)))
20735774	2	(S1 (S (S (VP (TO To) (VP (VB examine) (SBAR (IN whether) (S (NP (NNP Doc_20735774_234_245_Chemical-induced) (NNP Doc_20735774_254_273_Disease)) (VP (VBZ increases) (NP (JJ long-term) (NN mortality)))))))) (. .)))
20735774	3	(S1 (S (NP (PRP We)) (VP (VBD followed) (PRT (RP up)) (NP (NP (DT all) (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_362_373_Chemical-induced) (NNP Doc_20735774_382_400_Disease))) (, ,) (VP (VBN hospitalized) (PP (IN in) (NP (DT a) (JJ Danish) (JJ national) (NN referral))) (NP (NNP centre)) (PP (IN during) (NP (CD 1984-2004)))))) (. .)))
20735774	4	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (JJ age-specific) (NN mortality) (NNS rates)) (PP (IN from) (NP (CD 1) (NN year) (NN post-discharge)))) (PP (IN through) (NP (CD 2008))) (PP (IN between) (NP (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT the) (NNP Doc_20735774_577_589_Disease)) (VP (VBD led) (PP (TO to) (NP (DT an) (NN Doc_20735774_600_619_Disease))))))) (CC and) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (PRP it)) (VP (AUX did) (RB not)))))))) (. .)))
20735774	5	(S1 (S (NP (PRP We)) (VP (VBD included) (NP (CD 641) (NNS patients))) (. .)))
20735774	6	(S1 (S (PP (IN On) (NP (NN average))) (, ,) (S (NP (JJ age-specific) (NN mortality) (NNS rates)) (VP (AUX were) (ADJP (RB slightly) (JJR higher)) (PP (IN for) (NP (NP (DT the) (CD 101) (NNS patients)) (SBAR (WHNP (WP$ whose) (JJ Doc_20735774_774_785_Chemical-induced) (NN Doc_20735774_794_806_Disease)) (S (VP (AUX had) (VP (VBN caused) (NP (NP (DT an) (NN Doc_20735774_821_840_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ adjusted) (NN mortality) (NN rate) (NN ratio) (SYM =) (CD 1.70)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.02-2.85)))) (-RRB- -RRB-))))))))))) (, ,) (CC but) (S (NP (DT the) (NN association)) (VP (AUX was) (ADJP (JJ age-dependent)))) (, ,) (CC and) (S (NP (NP (DT no) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_958_977_Disease)))) (VP (VBD died) (PP (IN of) (NP (NNP Doc_20735774_986_999_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NNS suicides)) (VP (AUX were) (ADJP (JJ frequent)) (PP (IN in) (NP (DT both) (NNS groups)))))))) (. .)))
20735774	7	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP speak) (PP (IN against) (NP (NP (JJ long-term) (NNS effects)) (PP (IN of) (NP (NNP Doc_20735774_1102_1121_Disease)))))) (. .)))
20735774	8	(S1 (S (ADVP (RBR More) (JJ likely)) (, ,) (NP (DT the) (JJ elevated) (NN mortality) (NN rate) (NN ratio)) (VP (VBD resulted) (PP (IN from) (NP (NP (JJ incomplete) (NN adjustment)) (PP (IN for) (NP (NP (DT the) (JJR greater) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20735774_1236_1251_Disease))) (PP (IN among) (NP (NP (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_1271_1290_Disease)))))))))) (. .)))
20735774	9	(S1 (S (NP (JJ Doc_20735774_1305_1316_Chemical-induced) (NNP Doc_20735774_1325_1344_Disease)) (VP (AUX did) (RB not) (VP (VB affect) (NP (JJ long-term) (NN mortality)))) (. .)))
20735774	10	(S1 (S (NP (JJ Clinical) (NN follow-up)) (VP (MD may) (VP (AUX be) (VP (VBN justified) (PP (PP (IN by) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_20735774_1437_1450_Disease))))) (, ,) (CC but) (RB not) (PP (IN by) (NP (DT the) (NN Doc_20735774_1467_1480_Disease) (PRP itself))))))) (. .)))
20973483	0	(S1 (FRAG (PP (IN In) (NP (NP (NN vivo) (NN characterization)) (PP (IN of) (NP (NP (DT a) (JJ dual) (NN Doc_20973483_35_71_Chemical)) (PP (IN in) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_92_111_Disease))))))))) (. .)))
20973483	1	(S1 (S (NP (NP (DT The) (ADJP (IN in) (NN vivo)) (NN characterization)) (PP (IN of) (NP (DT a) (JJ dual) (NN Doc_20973483_152_192_Chemical))) (PP (IN in) (NP (NP (JJ several) (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_221_240_Disease)))))) (VP (AUX is) (VP (VBN described))) (. .)))
20973483	2	(S1 (S (NP (NP (NN Discovery) (CC and) (NN scale-up) (NNS syntheses)) (PP (IN of) (NP (NN compound) (CD 1)))) (VP (AUX are) (VP (VBN described) (PP (IN in) (NP (NN detail))) (, ,) (S (VP (VBG highlighting) (NP (NP (NN optimization) (NNS steps)) (SBAR (WHNP (WDT that)) (S (VP (VBD increased) (NP (NP (DT the) (JJ overall) (NN yield)) (PP (IN of) (NP (QP (CD 1) (IN from) (CD 10.0)) (NN %)))) (PP (TO to) (NP (CD 30.5) (NN %))))))))))) (. .)))
20973483	3	(S1 (S (NP (NN Compound) (CD 1)) (VP (AUX is) (NP (NP (DT a) (JJ potent) (DT A) (PRN (-LRB- -LRB-) (NP (CD 2A)) (-RRB- -RRB-)) (NN /A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (PP (IN in) (NP (NP (NN vitro)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT A) (-LRB- -LRB-) (CD 2A) (-RRB- -RRB-) (NNP K) (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (NP (QP (SYM =) (CD 4.1) (CD nM))))) (: ;) (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NNP K))) (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (NP (SYM =)) (CD 17.0) (CD nM)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (JJ excellent) (NN activity)) (, ,) (PP (IN after) (NP (NP (JJ oral) (NN administration) (PRN (, ,) (PP (IN across) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_616_635_Disease))))) (VP (VBG including) (NP (NP (NN mouse) (CC and) (NN rat) (NNS models)) (PP (IN of) (NP (JJ Doc_20973483_670_681_Chemical-induced) (NNP Doc_20973483_690_699_Disease))))))) (, ,)) (NN mouse) (NN model)) (PP (IN of) (NP (JJ Doc_20973483_716_725_Chemical-induced) (NNP Doc_20973483_734_742_Disease))))) (, ,) (VP (VB rat) (NP (NP (NNP Doc_20973483_748_765_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_20973483_767_773_Chemical) (-RRB- -RRB-)) (NN lesion) (NN model)) (PP (IN of) (NP (NP (JJ drug-induced) (NN rotation)) (, ,) (CC and) (NP (JJ Doc_20973483_818_822_Chemical-treated) (JJ non-human) (NN primate) (NN model))))))))))) (. .)))
21294084	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (JJ hippocampal) (JJ deep) (NN brain) (NN stimulation))) (PP (IN on) (NP (NP (JJ cortical) (JJ Doc_21294084_62_71_Disease) (NNS discharges)) (PP (IN in) (NP (NNP Doc_21294084_86_96_Chemical)))))) (: -) (NP (NP (VBN induced) (JJ Doc_21294084_107_115_Disease) (NN model)) (PP (IN in) (NP (NNS rats)))) (. .)))
21294084	1	(S1 (S (S (NP (JJ Experimental) (CC and) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN revealed) (SBAR (IN that) (S (NP (JJ hippocampal) (NNS DBS)) (VP (MD can) (VP (VB control) (NP (JJ Doc_21294084_217_226_Disease) (NN activity))))))))) (, ,) (CC but) (S (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (AUX is) (ADJP (JJ obscure)))) (CC and) (S (NP (JJ optimal) (NN stimulation) (NNS parameters)) (VP (AUX are) (RB not) (ADVP (RB clearly)) (VP (VBN defined))))) (. .)))
21294084	2	(S1 (S (NP (DT The) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ high) (NN frequency) (NN hippocampal) (NN stimulation))) (PP (IN on) (NP (NP (JJ cortical) (JJ Doc_21294084_426_435_Disease) (NN activity)) (PP (IN in) (NP (JJ Doc_21294084_448_458_Chemical-induced) (JJ Doc_21294084_467_475_Disease) (NN model)))))))))) (. .)))
21294084	3	(S1 (S (NP (NP (NN MATERIAL) (CC AND) (NNS METHODS)) (: :) (NP (CD Twenty-five) (JJ Sprague-Dawley) (NNS rats))) (VP (AUX were) (VP (VBN implanted) (NP (NNS DBS) (NNS electrodes)))) (. .)))
21294084	4	(S1 (S (SBAR (IN In) (S (NP (JJ group-1) (PRN (-LRB- -LRB-) (CD n=10) (-RRB- -RRB-)) (JJ hippocampal) (NNS DBS)) (VP (AUX was) (UCP (ADVP (RB off)) (CC and) (PP (IN in) (NP (DT the) (JJ group-2) (PRN (-LRB- -LRB-) (CD n=10) (-RRB- -RRB-)) (JJ hippocampal) (NNS DBS))))))) (VP (AUX was) (PP (IN on) (S (-LRB- -LRB-) (NP (NP (CD 185) (NNP Hz) (, ,) (NN 0.5V) (, ,) (NN 1V) (, ,) (NN 2V) (, ,) (CC and) (NN 5V)) (PP (IN for) (NP (CD 60) (NNP sec)))) (-RRB- -RRB-) (VP (VBG following) (NP (JJ Doc_21294084_711_723_Chemical) (NN injection)) (ADVP (RB intracortically)))))) (. .)))
21294084	5	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group) (NN hippocampal))) (NP (NNP DBS)) (VP (AUX was) (PP (IN on) (S (VP (VBG following) (NP (CD 8) (NN l) (NN saline) (NN injection)) (ADVP (RB intracortically)))))) (. .)))
21294084	6	(S1 (S (NP (NNP EEG) (NNS recordings)) (VP (AUX were) (VP (VBN obtained) (PP (PP (IN before) (CC and) (NP (NP (CD 15) (NNS minutes)) (VP (VBG following) (NP (NNP Doc_21294084_905_917_Chemical) (NN injection))))) (, ,) (CC and) (PP (IN at) (NP (NP (JJ 10th) (NNS minutes)) (VP (VBG following) (NP (NP (DT each) (NN stimulus)) (PP (IN for) (NP (NN analysis)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN frequency)) (, ,) (NP (NN amplitude)) (, ,) (CC and) (NP (NN power) (NN spectrum)))))))))))) (. .)))
21294084	7	(S1 (S (NP (JJ High) (NN frequency) (NN hippocampal) (NNS DBS)) (VP (VBD suppressed) (NP (NP (DT the) (JJ acute) (JJ Doc_21294084_1101_1111_Chemical-induced) (NN cortical) (NN Doc_21294084_1129_1138_Disease) (NN activity)) (ADJP (JJ independent) (PP (IN from) (NP (NN stimulus) (NN intensity)))))) (. .)))
21294084	8	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (, ,) (NP (JJ hippocampal) (NN stimulation)) (ADVP (RB alone)) (VP (VBP lead) (S (ADVP (RB only)) (VP (TO to) (VP (VB diffuse) (NP (NP (NN slowing)) (PP (IN of) (NP (JJ cerebral) (NN bioelectrical) (NN activity)))) (PP (IN at) (NP (CD 5V) (NN stimulation))))))) (. .)))
21294084	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ continuous) (JJ high) (NN frequency) (NN stimulation)) (PP (IN of) (NP (DT the) (NN hippocampus)))) (VP (VBD suppressed) (NP (JJ acute) (JJ cortical) (NN Doc_21294084_1441_1450_Disease) (NN activity)) (ADVP (RB effectively)) (PP (IN without) (S (VP (VBG causing) (NP (JJ secondary) (JJ Doc_21294084_1498_1507_Disease) (NNS discharges))))))))) (. .)))
21294084	10	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (S (VP (VBG defining) (NP (NP (DT the) (JJ optimal) (NNS parameters)) (PP (IN of) (NP (JJ hippocampal) (NNS DBS))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_21294084_1628_1636_Disease)))))))))))) (. .)))
21418164	0	(S1 (NP (NP (NP (NNP Doc_21418164_0_4_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_21418164_6_15_Chemical)) (-RRB- -RRB-)) (NNP Doc_21418164_17_25_Disease)) (PP (IN in) (NP (NNS dogs)))) (: :) (NP (NP (DT a) (JJ retrospective) (NN study)) (PRN (-LRB- -LRB-) (NP (CD 2002-07)) (-RRB- -RRB-))) (. .)))
21418164	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_21418164_108_170_Disease))) (PP (IN in) (NP (NP (JJ tumour-bearing) (NNS dogs)) (VP (VBG receiving) (NP (NP (NNP Doc_21418164_204_248_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_21418164_250_254_Chemical)) (-RRB- -RRB-)))))))))) (. .)))
21418164	2	(S1 (S (NP (NP (DT The) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 206) (NNS dogs)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_21418164_320_324_Chemical))) (PP (IN at) (NP (DT the) (NNP Melbourne) (JJ Veterinary) (NN Specialist) (NNP Centre))))))))) (PP (IN between) (NP (NP (NNP February) (CD 2002)) (CC and) (NP (NNP December) (CD 2007))))) (VP (AUX were) (VP (ADVP (RB retrospectively)) (VBN evaluated))) (. .)))
21418164	3	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 206) (NNS dogs)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_21418164_481_485_Chemical)))))) (, ,) (NP (CD 185)) (VP (VBD met) (NP (NP (DT the) (NN inclusion) (NNS criteria)) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN class)) (PP (IN of) (NP (NNP Doc_21418164_544_552_Disease))))))) (. .)))
21418164	4	(S1 (S (NP (NN Doc_21418164_554_558_Chemical)) (VP (AUX was) (VP (VBN used) (ADVP (RBS most) (RB commonly)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_21418164_602_610_Disease) (, ,) (NNP Doc_21418164_612_628_Disease) (, ,) (NNP Doc_21418164_630_642_Disease) (, ,) (NNP Doc_21418164_644_663_Disease) (CC and) (NNP Doc_21418164_668_692_Disease))))))) (. .)))
21418164	5	(S1 (S (PP (IN Throughout) (NP (NN treatment))) (, ,) (NP (NP (CD 56.9) (NN %)) (PP (IN of) (NP (NNS dogs)))) (VP (VBD experienced) (NP (NP (NNP Doc_21418164_742_753_Disease)) (, ,) (NP (NP (NP (CD 34.2) (NN %)) (VP (VBN experienced) (NP (NNP Doc_21418164_773_780_Disease)))) (CC and) (NP (NP (CD 14.2) (NN %)) (VP (VBN experienced) (NP (NNP Doc_21418164_803_819_Disease))))))) (. .)))
21418164	6	(S1 (S (S (NP (NN Doc_21418164_821_847_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (CD 37.8) (NN %)) (PP (IN of) (NP (NNS dogs)))))))) (, ,) (S (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN sign)) (PP (IN of) (NP (WDT which)))) (VP (AUX was) (NP (NP (NNP Doc_21418164_913_921_Disease)) (PRN (-LRB- -LRB-) (NP (CD 24.3) (NN %)) (-RRB- -RRB-))))) (. .)))
21418164	7	(S1 (S (NP (NP (JJ Potential) (JJ renal) (NN Doc_21418164_947_955_Disease)) (CC and) (NP (JJ elevated) (JJ Doc_21418164_969_976_Chemical) (NN transaminase) (PRN (-LRB- -LRB-) (NNP ALT) (-RRB- -RRB-)) (NN concentration))) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (CD 12.2) (NN %)) (CC and) (NP (NP (CD 48.8) (NN %)) (PP (IN of) (NP (NNS dogs)))) (, ,) (ADVP (RB respectively)))))) (. .)))
21418164	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_21418164_1083_1098_Disease)))) (VP (AUX was) (NP (CD 1.2) (NN %))) (. .)))
21418164	9	(S1 (S (NP (NP (JJ Doc_21418164_1122_1126_Chemical-associated) (NN Doc_21418164_1138_1146_Disease)) (PP (IN in) (NP (NNS dogs)))) (VP (VP (AUX is) (ADJP (JJ common))) (, ,) (CC but) (VP (AUX is) (ADJP (RB usually) (RB not) (NN life) (JJ threatening)))) (. .)))
2220369	0	(S1 (NP (NP (NP (NNP Central) (NNP Doc_2220369_8_23_Disease)) (CC and) (NP (JJ topical) (NNP Doc_2220369_36_57_Chemical))) (. .)))
2220369	1	(S1 (S (NP (DT A) (NN report)) (VP (AUX is) (VP (VBN given) (PP (IN on) (NP (NP (DT an) (JJ 83-year-old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (VBD acquired) (NP (JJ central) (NNP Doc_2220369_123_138_Disease)) (PP (IN in) (NP (PRP$ her) (VBG seeing) (NN eye) (CD one) (NN day))) (PP (IN after) (S (VP (AUXG having) (VP (VBN started) (NP (JJ topical) (NN medication)) (PP (IN with) (NP (NNP Doc_2220369_210_231_Chemical))) (PP (IN for) (NP (NP (VBN advanced) (NN Doc_2220369_245_253_Disease)) (VP (VBN discovered) (PP (IN in) (NP (DT the) (JJ other) (NN eye))))))))))))))))) (. .)))
2220369	2	(S1 (S (PP (IN From) (NP (NP (JJ present) (NN knowledge)) (PP (IN about) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ adrenergic) (NN eye) (NNS drops))) (PP (IN on) (NP (JJ ocular) (NN blood) (NN circulation))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB suggest) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (DT the) (CD two) (NNS events))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (ADJP (JJ coincidental)) (ADVP (RB only))))))) (. .)))
2257294	0	(S1 (S (NP (NN Doc_2257294_0_19_Chemical)) (VP (VBZ reverses) (NP (JJ Doc_2257294_29_43_Chemical-induced) (NN Doc_2257294_52_70_Disease)) (PP (IN without) (NP (NP (NN impairment)) (PP (IN of) (NP (JJ anti-human) (JJ Doc_2257294_104_120_Disease) (NN virus) (NN activity)))))) (. .)))
2257294	1	(S1 (S (NP (NP (JJ Increased) (JJ extracellular) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_2257294_179_186_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_188_191_Chemical)) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce)))) (, ,) (PP (IN in) (NP (NP (NN vitro)) (, ,) (NP (NP (NNP Doc_2257294_233_247_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_249_252_Chemical)) (-RRB- -RRB-)) (NP (NP (JJ -induced) (NN inhibition)) (PP (IN of) (NP (JJ human) (JJ granulocyte-macrophage) (NN progenitor) (NNS cells))) (PP (IN without) (NP (NP (NN impairment)) (PP (IN of) (NP (PRP$ its) (JJ antihuman) (JJ Doc_2257294_358_374_Disease) (NN virus) (PRN (-LRB- -LRB-) (NNP HIV) (-RRB- -RRB-)) (NN activity)))))))))))) (. .)))
2257294	2	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (JJ clinical) (NN Doc_2257294_421_431_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (JJ Doc_2257294_456_459_Chemical) (NN administration)))))) (, ,) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NNP Doc_2257294_491_510_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_512_515_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NN effect)))) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (NP (NNP Doc_2257294_537_540_Chemical-induced) (NNP Doc_2257294_549_555_Disease) (CC and) (NNP Doc_2257294_560_570_Disease)) (VP (AUX was) (VP (VBN assessed))) (. .)))
2257294	3	(S1 (S (NP (DT This) (NN agent)) (VP (VP (VBZ inhibits) (NP (JJ Doc_2257294_605_608_Chemical) (NN catabolism))) (CC and) (PRN (, ,) (PP (IN in) (NP (NN vivo))) (, ,)) (VP (VBZ increases) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_2257294_672_675_Chemical)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (PP (IN without) (NP (JJ Doc_2257294_712_715_Chemical-related) (NN Doc_2257294_724_732_Disease))))) (. .)))
2257294	4	(S1 (S (PP (IN In) (NP (NP (NNS mice)) (VP (VBN rendered) (NP (NNP Doc_2257294_751_757_Disease) (CC and) (NNP Doc_2257294_762_772_Disease)) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_2257294_798_801_Chemical)) (PP (IN for) (NP (NP (CD 28) (NNS days)) (PP (IN in) (NP (NN drinking) (NN water))) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NNS mg/mL)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (JJ continued) (NN administration)) (PP (IN of) (NP (NNP Doc_2257294_877_880_Chemical)))) (CC plus) (NP (NP (JJ daily) (NNP Doc_2257294_892_895_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 300) (NNS mg/kg)) (, ,) (ADVP (RB orally)) (-RRB- -RRB-))))) (VP (ADVP (RB partially)) (VBN reversed) (NP (NNP Doc_2257294_935_938_Chemical-induced) (NNP Doc_2257294_947_953_Disease) (CC and) (NNP Doc_2257294_958_968_Disease))))) (PRN (-LRB- -LRB-) (ADVP (RB P) (JJR less)) (PP (IN than) (NP (CD .05))) (-RRB- -RRB-))))) (, ,) (NP (NP (VBN increased) (JJ peripheral) (NNS reticulocytes)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 4.9) (NN %))) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD .01))) (-RRB- -RRB-)) (, ,)) (VP (VP (VBD increased) (NP (NN cellularity)) (PP (IN in) (NP (DT the) (NN marrow)))) (, ,) (CC and) (VP (VBN improved) (NP (NNP Doc_2257294_1101_1116_Disease)))) (. .)))
2257294	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN coadministered) (PP (IN with) (NP (NNP Doc_2257294_1143_1146_Chemical))) (PP (IN from) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN drug) (NN administration)))))))) (, ,) (NP (NNP Doc_2257294_1186_1189_Chemical)) (VP (VBD reduced) (NP (JJ Doc_2257294_1198_1201_Chemical-induced) (NN Doc_2257294_1210_1225_Disease))) (. .)))
2257294	6	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (CD 100) (CD mumol/L))))) (, ,) (NP (NNP Doc_2257294_1272_1275_Chemical)) (VP (VP (VBZ possesses) (NP (JJ minimal) (JJ anti-HIV) (NN activity))) (CC and) (VP (AUX has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_2257294_1348_1351_Chemical))) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ HIV-induced) (JJ cytopathic) (NN effect)) (PP (IN in) (NP (JJ MT4) (NNS cells)))))))))))) (. .)))
2257294	7	(S1 (S (NP (NP (DT The) (JJ clinical) (CC and) (JJ biochemical) (NNS implications)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
2320800	0	(S1 (S (NP (NNP Lethal) (NNP Doc_2320800_7_13_Disease)) (VP (VBD complicating) (NP (JJ high) (NN dose) (JJ Doc_2320800_37_47_Chemical) (NN chemotherapy)) (PP (IN in) (NP (NP (DT a) (JJ Doc_2320800_66_79_Disease) (NN patient)) (PP (IN with) (NP (DT an) (NNP Doc_2320800_96_119_Disease)))))) (. .)))
2320800	1	(S1 (S (NP (NP (DT A) (JJ sixty-year-old) (NN woman)) (PP (IN with) (NP (JJ advanced) (NNP Doc_2320800_158_171_Disease))) (, ,) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NNP Doc_2320800_197_206_Chemical)))) (, ,)) (VP (VBD developed) (NP (NP (DT an) (JJ irreversible) (JJ lethal) (NN Doc_2320800_241_254_Disease)) (PP (IN with) (NP (NP (NNP Doc_2320800_260_266_Disease)) (, ,) (NP (NP (DT the) (NN day)) (PP (IN after) (NP (CD 5) (JJ g/m2) (JJ bolus) (NN Doc_2320800_295_305_Chemical)))))))) (. .)))
2320800	2	(S1 (S (NP (NN Doc_2320800_307_324_Disease)) (VP (AUX was) (VP (VBN excluded) (PP (IN by) (NP (NN echography))))) (. .)))
2320800	3	(S1 (S (NP (DT A) (JJ prerenal) (NN component)) (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NNP Doc_2320800_400_413_Disease))) (PP (IN because) (IN of) (NP (DT a) (JJ transient) (NN Doc_2320800_437_448_Disease))) (, ,) (PP (JJ due) (PP (TO to) (NP (NP (DT an) (VBG increasing) (NN ascitis)) (, ,) (VP (VBG occurring) (ADVP (RB just)) (PP (IN before) (NP (NNP Doc_2320800_502_508_Disease)))))))))) (. .)))
2320800	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN correction)) (PP (IN of) (NP (DT the) (JJ hemodynamic) (NNS parameters)))) (VP (AUX did) (RB not) (VP (VB improve) (NP (JJ renal) (NN function)))) (. .)))
2320800	5	(S1 (S (NP (NN Doc_2320800_592_602_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ known) (JJ Doc_2320800_614_625_Disease) (NN drug)) (PP (IN with) (NP (VBN demonstrated) (NN Doc_2320800_649_662_Disease))))) (. .)))
2320800	6	(S1 (S (NP (PRP We)) (ADVP (RB strongly)) (VP (VBP suspect) (SBAR (IN that) (S (NP (DT this) (JJ lethal) (NN Doc_2320800_701_707_Disease)) (VP (AUX was) (ADJP (RB mainly) (JJ due) (PP (TO to) (NP (NNP Doc_2320800_726_736_Chemical)))) (, ,) (S (VP (VBG occurring) (PP (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (AUXG having) (VP (VBN received) (NP (JJ previous) (JJ Doc_2320800_786_795_Chemical) (NN chemotherapy)))))) (CC and) (PP (IN with) (NP (NP (JJ poor) (NN kidney) (NNS perfusion)) (ADJP (JJ due) (PP (TO to) (NP (JJ transient) (NNP Doc_2320800_857_868_Disease))))))))))))) (. .)))
2320800	7	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (NP (JJ careful) (NN use)) (PP (IN of) (NP (NNP Doc_2320800_898_908_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NP (JJ Doc_2320800_937_948_Disease) (NN chemotherapy)) (CC and) (NP (JJ inadequate) (JJ renal) (NN perfusion))))))))) (. .)))
2322844	0	(S1 (S (NP (JJ Nociceptive) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intrathecal) (NN administration)) (PP (IN of) (NP (NNP Doc_2322844_61_94_Chemical))) (PP (TO to) (NP (JJ conscious) (NNS mice)))))) (. .)))
2322844	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN intrathecal) (NN administration)) (PP (IN of) (NP (NNP Doc_2322844_159_173_Chemical))))) (PP (IN on) (NP (JJ Doc_2322844_177_181_Disease) (NNS responses))) (PP (IN in) (NP (JJ conscious) (NNS mice)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG using) (NP (NP (JJ hot) (NN plate)) (CC and) (NP (JJ Doc_2322844_248_259_Chemical) (VBG writhing) (NNS tests)))))))) (. .)))
2322844	2	(S1 (S (NP (NP (NNP Doc_2322844_276_292_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.5-3) (NN ng/mouse)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT a) (NNP Doc_2322844_316_328_Disease) (NN action)) (PP (IN on) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ hot) (NN plate)) (PP (IN during) (NP (NP (DT a) (JJ 3-60) (NN min) (NN period)) (PP (IN after) (NP (NN injection))))))))))) (. .)))
2322844	3	(S1 (S (S (NP (NN Doc_2322844_409_425_Chemical)) (VP (VBD showed) (NP (DT a) (NNP Doc_2322844_435_447_Disease) (NN effect)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 1) (NN Doc_2322844_469_471_Chemical) (TO to) (CD 10)) (NN ng/mouse))))))) (, ,) (CC but) (S (NP (DT the) (NN effect)) (VP (VBD lasted) (NP (NP (JJR shorter) (PRN (-LRB- -LRB-) (NP (CD 3-30) (NN min)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_2322844_542_558_Chemical)))))))) (. .)))
2322844	4	(S1 (S (NP (JJ Similar) (NNS results)) (VP (AUX were) (VP (VBN obtained) (PP (IN by) (NP (JJ Doc_2322844_593_604_Chemical) (VBG writhing) (NNS tests))))) (. .)))
2322844	5	(S1 (S (NP (NP (DT The) (JJ Doc_2322844_625_637_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2322844_648_664_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (NP (JJ simultaneous) (NN injection)) (PP (IN of) (NP (NP (DT a) (NN substance)) (ADJP (ADJP (RB P) (JJ antagonist)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 100) (CD ng)))) (-RRB- -RRB-))))))) (CC but) (PP (RB not) (IN by) (NP (NP (NNP Doc_2322844_776_782_Chemical)) (, ,) (NP (DT a) (JJ prostanoid) (NN EP1-receptor) (NN antagonist))))))) (. .)))
2322844	6	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_2322844_834_850_Chemical-induced) (NNP Doc_2322844_859_871_Disease)) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (NNP Doc_2322844_887_893_Chemical))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (QP (CD 500) (CD ng)))))) (-RRB- -RRB-)) (CC but) (RB not) (PP (IN by) (NP (DT the) (NN substance) (NN P) (NN antagonist)))))) (. .)))
2322844	7	(S1 (S (NP (NN Doc_2322844_967_989_Chemical)) (VP (AUX had) (NP (NP (JJ little) (NN effect)) (PP (IN on) (NP (JJ Doc_2322844_1011_1015_Disease) (NNS responses))))) (. .)))
2322844	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT both) (NNP Doc_2322844_1063_1079_Chemical) (CC and) (NNP Doc_2322844_1084_1100_Chemical)) (VP (VBP exert) (NP (NNP Doc_2322844_1107_1119_Disease)) (PP (PP (IN in) (NP (DT the) (JJ spinal) (NN cord))) (, ,) (CC but) (PP (IN in) (NP (JJ different) (NNS ways)))))))) (. .)))
2334179	0	(S1 (NP (NP (NN Doc_2334179_0_15_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_2334179_36_57_Disease))))) (. .)))
2334179	1	(S1 (S (NP (NN Doc_2334179_59_80_Disease)) (VP (VP (AUX has) (NP (DT no) (VBN recognized) (JJ internal) (NN organ) (NN involvement))) (CC but) (VP (MD may) (VP (AUX be) (VP (VP (VBG disfiguring)) (CC and) (VP (VBG disabling) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ cutaneous) (NNS lesions)) (VP (VP (AUX are) (ADJP (JJ extensive))) (CC or) (VP (VBP affect) (NP (NNS children))))))))))) (. .)))
2334179	2	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB no)) (VP (VP (VBN accepted)) (CC or) (VP (VBN proven) (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_2334179_269_290_Disease)))))) (. .)))
2334179	3	(S1 (S (NP (NP (NN Case) (NNS reports)) (PP (IN of) (NP (CD 11) (NNS patients))) (PP (IN with) (NP (NP (JJ severe) (, ,) (JJ extensive) (NNP Doc_2334179_343_364_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_2334179_387_402_Chemical)))))))))) (VP (AUX are) (VP (VBD summarized) (PP (IN in) (NP (DT this) (NN article))))) (. .)))
2334179	4	(S1 (S (NP (DT This) (NN drug)) (VP (AUX was) (VP (VBN judged) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ favorable) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN disease) (NN course)) (PP (IN in) (NP (CD 7))))) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 11) (NNS patients))))))))) (. .)))
2334179	5	(S1 (S (NP (NN Improvement)) (VP (VP (VBD began) (PP (IN within) (NP (QP (CD 3) (TO to) (CD 6)) (NNS months)))) (CC and) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (NN cessation)) (PP (IN of) (NP (JJ active) (JJ cutaneous) (NNS lesions))) (PP (IN in) (NP (DT all) (CD 7) (NNS patients)))) (, ,) (NP (NP (NN skin)) (VP (VBG softening) (PP (IN in) (NP (CD 5))))) (, ,) (CC and) (NP (NP (ADJP (RBR more) (JJ normal)) (NN growth)) (PP (IN of) (NP (DT the) (VBN affected) (NN limb))) (PP (IN in) (NP (QP (CD 2) (IN of) (CD 3)) (NNS children)))))))) (. .)))
2334179	6	(S1 (S (NP (NP (JJ Joint) (NN stiffness)) (CC and) (NP (NN Doc_2334179_750_762_Disease))) (ADVP (RB also)) (VP (VBD improved)) (. .)))
2334179	7	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_2334179_790_805_Chemical))) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ favorable) (NN response))))) (VP (AUX was) (ADJP (RB as) (JJ low) (PP (IN as) (NP (QP (CD 2) (TO to) (CD 5)) (NN mg/kg)))) (PP (IN per) (NP (NP (NN day)) (VP (VBN given) (PP (IN over) (NP (NP (DT a) (NN period)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 15) (TO to) (CD 53)) (NNS months)))))))))) (. .)))
2334179	8	(S1 (S (S (NP (NNP Doc_2334179_928_943_Chemical)) (VP (VBD caused) (NP (NNP Doc_2334179_951_969_Disease)) (PP (IN in) (NP (NP (NP (CD 1) (NN patient)) (CC and) (NP (JJR milder) (JJ reversible) (NN Doc_2334179_1005_1016_Disease))) (PP (IN in) (NP (CD 3) (JJ other) (NNS patients))))))) (: ;) (S (NP (NN none)) (VP (VBD developed) (NP (NNP Doc_2334179_1053_1072_Disease)))) (. .)))
2334179	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_2334179_1098_1113_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)) (PP (IN in) (NP (NP (JJ severe) (NNS cases)) (PP (IN of) (NP (NNP Doc_2334179_1150_1171_Disease)))))))))) (. .)))
2339463	0	(S1 (NP (NP (NN Doc_2339463_0_25_Disease)) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN hazard)) (PP (IN of) (NP (NP (JJ antifibrinolytic) (NN treatment)) (PP (IN in) (NP (NNP Doc_2339463_81_92_Disease))))))) (. .)))
2339463	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 42-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ superior) (NN Doc_2339463_149_194_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prolonged) (JJ Doc_2339463_221_246_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_2339463_259_270_Disease)))))))))))) (. .)))
2339463	2	(S1 (S (NP (DT This) (JJ antifibrinolytic) (NN agent)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_2339463_328_339_Disease))))) (S (VP (TO to) (VP (VP (VB promote) (NP (NN clotting))) (CC and) (VP (VB reduce) (NP (NN Doc_2339463_371_381_Disease))))))))) (. .)))
2339463	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ increased) (NN risk)) (PP (IN of) (NP (NNP Doc_2339463_410_432_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2339463_473_498_Chemical)))))))))) (, ,) (NP (NNP Doc_2339463_500_525_Disease)) (VP (AUX has) (RB not) (VP (AUX been) (VP (ADVP (RB previously)) (VBN described)))) (. .)))
2339463	4	(S1 (S (NP (NP (JJ Careful) (NN use)) (PP (IN of) (NP (JJ Doc_2339463_576_601_Chemical) (NN therapy)))) (VP (AUX is) (VP (VBN recommended))) (. .)))
2343592	0	(S1 (NP (NP (NP (NN Doc_2343592_0_7_Disease) (NN activity)) (PP (IN with) (NP (JJ Doc_2343592_22_30_Chemical) (NN therapy)))) (: :) (NP (NP (NN incidence)) (CC and) (NP (NN risk) (NNS factors))) (. .)))
2343592	1	(S1 (S (NP (NP (CD Two) (JJ elderly) (NNS patients)) (PP (IN with) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (CC either) (NP (NP (NNP Doc_2343592_114_140_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2343592_142_145_Disease)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_2343592_150_161_Disease))))) (CC and) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_2343592_181_194_Disease))))))) (VP (VBD developed) (NP (NNP Doc_2343592_205_213_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NP (JJ maximum) (NNS doses)) (PP (IN of) (NP (NNP Doc_2343592_247_266_Chemical)))))))) (. .)))
2343592	2	(S1 (S (NP (DT Neither) (NN patient)) (VP (VP (AUX had) (VP (VBN reported) (NP (NP (JJ previous) (NN Doc_2343592_306_314_Disease)) (CC or) (NP (JJ Doc_2343592_318_325_Disease-like) (NN activity))))) (CC nor) (VP (AUX was) (VP (VBG receiving) (NP (JJ anticonvulsant) (NNS agents))))) (. .)))
2343592	3	(S1 (S (NP (DT All) (NNP Doc_2343592_385_393_Disease)) (VP (AUX were) (VP (VBN controlled) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NNP Doc_2343592_436_445_Chemical))))))) (. .)))
2343592	4	(S1 (S (NP (DT Both) (NNS patients)) (VP (AUX had) (VP (VBN received) (NP (NP (JJ maximum) (NNS doses)) (PP (IN of) (NP (JJ other) (JJ Doc_2343592_497_508_Chemical) (NNS antibiotics)))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ Doc_2343592_541_548_Disease) (NN activity))))))) (. .)))
2422478	0	(S1 (S (NP (NP (NNP Midline) (NNP B3) (NNP Doc_2422478_11_20_Chemical) (NNS nerves)) (PP (IN in) (NP (NN rat) (NN medulla)))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ Doc_2422478_59_70_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2422478_81_91_Chemical))))))) (. .)))
2422478	1	(S1 (S (NP (NP (JJ Previous) (NNS experiments)) (PP (IN in) (NP (DT this) (NN laboratory)))) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NNP Doc_2422478_167_177_Chemical)) (PP (IN onto) (NP (NP (DT the) (JJ ventrolateral) (NNS cells)) (PP (IN of) (NP (NP (DT the) (NNP B3) (NNP Doc_2422478_217_226_Chemical) (NNS neurons)) (PP (IN in) (NP (DT the) (NN medulla)))))))))) (VP (VBZ elicits) (NP (NP (DT a) (JJ Doc_2422478_260_271_Disease) (NN response)) (VP (VBN mediated) (PP (IN by) (NP (NP (DT a) (NN projection)) (VP (VBG descending) (PP (IN into) (NP (DT the) (JJ spinal) (NN cord))))))))))))) (. .)))
2422478	2	(S1 (S (NP (DT The) (JJ present) (NNS experiments)) (VP (AUX were) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (DT the) (JJ midline) (NNS cells)) (PP (IN of) (NP (DT the) (NNP B3) (NNP Doc_2422478_432_441_Chemical) (NNS neurons)))))) (PP (IN in) (NP (DT the) (NN medulla))) (, ,) (S (VP (VBG coinciding) (PP (IN with) (NP (DT the) (NNP raphe) (NNP magnus)))))))))) (. .)))
2422478	3	(S1 (S (PP (IN In) (NP (ADJP (RB spontaneously) (JJ Doc_2422478_517_529_Disease)) (, ,) (JJ Doc_2422478_531_537_Disease-prone) (NNS rats))) (, ,) (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_2422478_568_578_Chemical))) (PP (IN into) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (DT the) (JJ midline) (NNP B3) (NNP Doc_2422478_611_620_Chemical) (NN cell) (NN group))) (PP (IN in) (NP (DT the) (JJ ventral) (NN medulla)))))) (VP (VBD caused) (NP (NP (DT a) (JJ potent) (NN Doc_2422478_671_682_Disease)) (PP (IN of) (NP (NP (JJ 30-40) (NN mm) (NNP Hg)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (ADJP (JJ maximal) (NP (CD 2-3) (NNP h))) (PP (IN after) (NP (NN administration)))) (CC and) (VP (AUX was) (VP (VBN abolished) (PP (IN by) (NP (NP (DT the) (JJ Doc_2422478_769_778_Chemical) (NN neurotoxin)) (SBAR (S (NP (NP (NNP Doc_2422478_790_813_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2422478_815_822_Chemical)) (-RRB- -RRB-))) (VP (VBD injected) (ADVP (RB intracerebroventricularly)))))))))))))))) (. .)))
2422478	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ intraspinal) (NN injection)) (PP (IN of) (NP (NNP Doc_2422478_894_901_Chemical))) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (ADJP (RBR more) (JJ selective)) (NN lesion)) (PP (IN of) (NP (JJ only) (VBG descending) (NNP Doc_2422478_956_965_Chemical) (NNS projections)))) (PP (IN in) (NP (DT the) (JJ spinal) (NN cord)))))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (DT this) (NN Doc_2422478_1017_1028_Disease)))) (. .)))
2422478	5	(S1 (S (NP (NP (JJ Further) (, ,) (JJ Doc_2422478_1039_1046_Chemical) (NN lesion)) (PP (IN of) (NP (NP (JJ Doc_2422478_1057_1066_Chemical) (NNS nerves)) (VP (VBG travelling) (PP (IN in) (NP (NP (DT the) (JJ median) (NN forebrain) (NN bundle)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ main) (VBG ascending) (NNS pathways)) (PP (IN from) (NP (DT the) (NNP B3) (NNP Doc_2422478_1164_1173_Chemical) (NNS cells)))))) (, ,))))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ midline) (NNP B3) (NNP Doc_2422478_1252_1261_Chemical) (NNP Doc_2422478_1262_1272_Chemical) (NN injection))))))))) (. .)))
2422478	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (ADVP (RB therefore)) (SBAR (IN that) (S (, ,) (PP (IN unlike) (NP (NP (DT the) (JJ ventrolateral) (NNP B3) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VB mediate) (NP (NP (DT a) (JJ Doc_2422478_1366_1376_Chemical-induced) (NNP Doc_2422478_1385_1396_Disease)) (PP (IN via) (NP (VBG descending) (NNS projections))))))))) (, ,) (NP (NP (DT the) (JJ midline) (NNP Doc_2422478_1437_1446_Chemical) (NNP B3) (NNS cells)) (PP (IN in) (NP (DT the) (NN medulla)))) (VP (VBP contribute) (PP (PP (TO to) (NP (NP (DT the) (NNP Doc_2422478_1489_1500_Disease) (NN action)) (PP (IN of) (NP (NNP Doc_2422478_1511_1521_Chemical))))) (, ,) (CC either) (PP (IN by) (NP (NP (NN way)) (PP (IN of) (NP (NP (DT an) (VBG ascending) (NN projection)) (SBAR (WHNP (WDT which)) (S (VP (AUX does) (RB not) (VP (VB pass) (PP (IN through) (NP (DT the) (JJ median) (NN forebrain) (NN bundle))))))))))) (, ,) (CC or) (PP (IN through) (NP (NP (DT a) (NN projection)) (VP (VBN restricted) (PP (TO to) (NP (DT the) (JJ caudal) (NN brainstem)))))))))))) (. .)))
2435991	0	(S1 (S (NP (NP (JJ Antiarrhythmic) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_2435991_40_51_Chemical))) (PP (IN on) (NP (NN canine)))) (VP (VBP Doc_2435991_62_85_Disease)) (. .)))
2435991	1	(S1 (S (S (S (VP (VBG Using) (NP (NP (JJ two-stage) (JJ coronary) (NN ligation-)) (, ,) (NP (NN Doc_2435991_123_132_Chemical-)) (, ,) (CC and) (NP (JJ Doc_2435991_139_149_Chemical-induced) (NN canine) (NN Doc_2435991_165_188_Disease))))) (, ,) (NP (NP (JJ antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NNP Doc_2435991_216_227_Chemical)))) (VP (AUX were) (VP (VBN examined)))) (CC and) (S (NP (NP (DT the) (JJ minimum) (JJ effective) (NN plasma) (NN concentration)) (PP (IN for) (NP (DT each) (NNP Doc_2435991_298_308_Disease) (NN model)))) (VP (AUX was) (VP (VBN determined)))) (. .)))
2435991	2	(S1 (S (S (NP (NNP Doc_2435991_331_342_Chemical)) (VP (VBD suppressed) (NP (PDT all) (DT the) (NN Doc_2435991_362_373_Disease)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN for) (NP (NNP Doc_2435991_427_438_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ 24-h) (JJ coronary) (NN ligation)) (, ,) (NP (JJ 48-h) (JJ coronary) (NN ligation)) (, ,) (NP (NNP Doc_2435991_498_507_Chemical)) (, ,) (CC and) (NP (NNP Doc_2435991_513_523_Chemical)))))) (VP (AUX were) (NP (NP (NP (QP (CD 1.9) (CD +/-)) (CD 0.9)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 8) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 1.6) (NN +/-)) (NP (NP (CD 0.5)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 8) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 0.6) (NN +/-)) (NP (NP (CD 0.2)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 2) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-)))) (, ,) (CC and) (NP (NP (NP (CD 3.5) (NN +/-)) (NP (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 5) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-))) (NP (NN micrograms/ml)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SDM)) (, ,) (NP (NNP n) (SYM =) (JJ 6-7)) (-RRB- -RRB-)))))) (. .)))
2435991	3	(S1 (S (NP (NP (DT The) (NN concentration)) (PP (IN for) (NP (NNP Doc_2435991_731_741_Chemical-induced) (NNP Doc_2435991_750_760_Disease)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN for) (NP (NP (DT the) (JJ other) (NNS types)) (PP (IN of) (NP (NNP Doc_2435991_820_831_Disease))))))))) (. .)))
2435991	4	(S1 (S (S (NP (DT This) (JJ pharmacological) (NN profile)) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_2435991_885_895_Chemical)) (CC and) (NP (NNP Doc_2435991_900_909_Chemical))))))))) (, ,) (CC and) (S (NP (DT all) (CD three) (NNS drugs)) (VP (AUX have) (NP (ADJP (JJ central) (JJ nervous)) (NN system) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (NN stimulant) (NN action)))) (. .)))
2435991	5	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_2435991_991_1002_Chemical)) (VP (VP (AUX had) (NP (NP (JJ only) (JJ weak) (NN Doc_2435991_1017_1028_Disease)) (CC and) (NP (JJ sinus) (JJ node) (NNP Doc_2435991_1044_1054_Disease) (NNS effects)))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB orally) (JJ active)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (TO to) (NP (JJ coronary) (JJ ligation) (NNP Doc_2435991_1129_1139_Disease) (NNS dogs)))))))))))))) (, ,) (NP (PRP$ its) (JJ clinical) (NN usefulness)) (VP (AUX is) (VP (VBN expected))) (. .)))
2466960	0	(S1 (NP (NP (NP (JJ Continuous) (JJ ambulatory) (NNS ECG)) (VP (VBG monitoring) (PP (IN during) (NP (JJ Doc_2466960_44_56_Chemical) (NN therapy))))) (: :) (NP (DT a) (JJ prospective) (NN study)) (. .)))
2466960	1	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (JJ anecdotal) (NNS reports)) (PP (IN of) (NP (NNP Doc_2466960_133_149_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_2466960_166_178_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2466960_180_184_Chemical)) (-RRB- -RRB-)) (NN therapy))))))))) (, ,) (NP (DT this) (NN phenomenon)) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN studied) (PP (IN in) (NP (DT a) (JJ systematic) (NN fashion)))))) (. .)))
2466960	2	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBD performed) (NP (JJ continuous) (JJ ambulatory) (NN ECG) (NN monitoring)) (PP (IN on) (NP (NP (CD 25) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_2466960_347_351_Chemical) (NN infusion)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ solid) (NNP Doc_2466960_384_390_Disease)))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_2466960_427_435_Disease) (NNP ST) (NNS changes))))))))) (. .)))
2466960	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN for) (NP (NP (NP (CD 23) (JJ +/-) (CD 4) (NNS hours)) (PP (IN before) (NP (JJ Doc_2466960_498_502_Chemical) (NN infusion)))) (, ,) (CC and) (NP (NP (CD 98) (JJ +/-) (CD 9) (NNS hours)) (PP (IN during) (NP (JJ Doc_2466960_539_543_Chemical) (NN infusion)))))))) (. .)))
2466960	4	(S1 (S (S (NP (NN Doc_2466960_554_561_Disease) (NNS episodes)) (VP (AUX were) (ADJP (JJ rare)))) (: :) (S (NP (QP (RB only) (CD one)) (NN patient)) (VP (AUX had) (NP (NP (NN Doc_2466960_603_609_Disease)) (PRN (-LRB- -LRB-) (PP (IN during) (NP (JJ Doc_2466960_618_622_Chemical) (NN infusion))) (-RRB- -RRB-))))) (. .)))
2466960	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ asymptomatic) (NNP ST) (NNS changes)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 1) (JJ mm) (NNP ST) (NN deviation)))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ common)) (PRN (: :) (NP (NP (NP (CD six)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-)))) (VP (AUX had) (NP (NNP ST) (NNS changes)) (SBAR (IN before) (S (NP (JJ Doc_2466960_772_776_Chemical) (NN infusion)) (VP (VBD v) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 68) (NN %)) (-RRB- -RRB-))) (PP (IN during) (NP (JJ Doc_2466960_804_808_Chemical) (NN infusion)))))))) (-LRB- -LRB-) (NP (CD P) (JJR less)) (PP (IN than) (NP (CD .002)))) (-RRB- -RRB-))) (. .)))
2466960	6	(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_2466960_855_863_Disease) (NNS episodes)) (PP (IN per) (NP (NN patient))) (PP (IN per) (NP (NN hour)))))) (VP (AUX was) (NP (NP (NP (CD 0.05) (NN +/-)) (NP (CD 0.02))) (VP (ADVP (RB prior) (PP (TO to) (NP (JJ Doc_2466960_921_925_Chemical) (NN infusion)))) (VBG v) (NP (NP (NP (CD 0.13) (NN +/-)) (NP (NP (CD 0.03)) (PP (IN during) (NP (JJ Doc_2466960_958_962_Chemical) (NN infusion))))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-))))))) (: ;) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ ECG) (NNS changes)))) (VP (AUX was) (NP (NP (NP (CD 0.6) (NN +/-)) (NP (CD 0.3) (NNS minutes))) (PP (IN per) (NP (NN patient)))) (PP (IN per) (NP (NN hour))) (SBAR (IN before) (S (NP (NNP Doc_2466960_1072_1076_Chemical)) (VP (VBD v) (NP (NP (CD 1.9) (JJ +/-) (CD 0.5) (NNS minutes)) (PP (IN per) (NP (NN patient))) (PP (IN per) (NP (NN hour)))) (PP (IN during) (NP (NP (NNP Doc_2466960_1127_1131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .01))) (-RRB- -RRB-))))))))) (. .)))
2466960	7	(S1 (S (NP (JJ ECG) (NNS changes)) (VP (AUX were) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ known) (NNP Doc_2466960_1206_1229_Disease)))))) (. .)))
2466960	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_2466960_1255_1267_Disease))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD occurred) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ chemotherapy) (NN course)))))))))) (. .)))
2466960	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ Doc_2466960_1348_1352_Chemical) (NN infusion)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ silent) (NNP ST) (NN segment) (NN deviation) (NN suggestive)) (PP (IN of) (NP (NNP Doc_2466960_1449_1457_Disease))))) (, ,) (PP (ADVP (RB particularly)) (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2466960_1492_1515_Disease)))))))))))) (. .)))
2466960	10	(S1 (S (NP (NP (NP (DT The) (NN mechanism)) (CC and) (NP (JJ clinical) (NN significance))) (PP (IN of) (NP (DT these) (JJ ECG) (NNS changes)))) (VP (VBP remain) (S (VP (TO to) (VP (AUX be) (VP (VBN determined)))))) (. .)))
2528969	0	(S1 (NP (NP (NP (NP (NN Nature)) (, ,) (NP (NN time) (NN course)) (CC and) (NP (NN dose) (NN dependence))) (PP (IN of) (NP (JJ Doc_2528969_43_53_Chemical-related) (NN side) (NNS effects)))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (DT the) (NNP Multicenter) (NNP Canadian) (NNP Doc_2528969_114_128_Chemical) (NN Trial)))) (. .)))
2528969	1	(S1 (S (S (VP (TO To) (VP (VB characterize) (NP (NP (NP (DT the) (NN nature)) (, ,) (NP (NN time) (NN course)) (CC and) (NP (NN dose) (NN dependency))) (PP (IN of) (NP (JJ Doc_2528969_199_209_Chemical-related) (NN side) (NNS effects))))))) (, ,) (NP (PRP we)) (VP (VBD undertook) (NP (DT a) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ dose-range) (NN finding) (NN study))) (. .)))
2528969	2	(S1 (S (NP (PRP$ Our) (NN study) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 74) (JJ HIV-positive) (JJ homosexual) (NNS men)) (VP (VBG belonging) (PP (TO to) (NP (NP (NNS groups)) (NP (NP (NNP II) (NNP B)) (, ,) (NP (NNP III)) (CC and) (NP (NNP IV) (NNP C2))) (PP (IN from) (NP (NP (DT the) (NNPS Centers)) (PP (IN for) (NP (NP (NP (NP (NNP Disease) (NNP Control)) (PRN (-LRB- -LRB-) (NP (NNP CDC)) (-RRB- -RRB-))) (NN classification)) (PP (IN of) (NP (NNP Doc_2528969_460_471_Disease))))))))))))) (. .)))
2528969	3	(S1 (S (PP (VBG Following) (NP (DT a) (JJ 3-week) (NN observation) (NN period))) (, ,) (NP (NNS volunteers)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_2528969_541_551_Chemical) (CD 600) (NN mg/day))) (PP (IN for) (NP (NP (CD 18) (NNS weeks)) (, ,) (NP (NP (NP (CD 900) (NN mg/day)) (PP (IN for) (NP (CD 9) (NNS weeks)))) (CC and) (NP (NP (CD 1200) (NN mg/day)) (PP (IN for) (NP (CD 9) (NNS weeks))))) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ washout) (NN period)) (PP (IN of) (NP (CD 6) (NNS weeks))) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (PRP they)) (VP (AUX were) (VP (VBN re-started) (PP (IN on) (NP (NP (CD 1200) (NN mg/day)) (CC or) (NP (NP (DT the) (JJS highest) (JJ tolerated) (NN dose)) (PP (IN at) (NP (JJ 8-hourly) (NNS intervals))))))))))))))))) (. .)))
2528969	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (ADJP (JJ 4-hourly) (CC or) (JJ 8-hourly)) (NNS regimens))) (PP (IN within) (NP (NNP CDC) (NNS groups))) (SBAR (IN while) (S (VP (VBG taking) (NP (QP (CD 600) (CC and) (CD 1200)) (NN mg/day))))))) (. .)))
2528969	5	(S1 (S (NP (JJ Clinical) (CC and) (NN laboratory) (NNS evaluations)) (VP (AUX were) (VP (VBN performed) (PP (IN at) (NP (JJ 3-week) (NNS intervals))))) (. .)))
2528969	6	(S1 (S (NP (JJ Symptomatic) (JJ adverse) (NNS effects)) (VP (AUX were) (ADJP (JJ present) (PP (IN in) (NP (NP (CD 96) (NN %)) (PP (IN of) (NP (NP (NNS subjects)) (, ,) (ADVP (RBS most) (RB commonly)) (NP (NP (NP (NNP Doc_2528969_1034_1040_Disease)) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2528969_1048_1055_Disease)) (PRN (-LRB- -LRB-) (NP (CD 55) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2528969_1066_1074_Disease)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
2528969	7	(S1 (S (NP (DT These)) (VP (AUX were) (ADVP (RB generally)) (ADJP (JJ self-limited)) (, ,) (S (VP (VBG reappearing) (ADVP (RB briefly)) (PP (IN at) (NP (DT each) (NN dose) (NN increment)))))) (. .)))
2528969	8	(S1 (S (NP (NP (DT A) (NN decrease)) (PP (IN in) (NP (NN hemoglobin)))) (VP (VBD occurred) (ADVP (RB shortly)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy)))))) (. .)))
2528969	9	(S1 (S (NP (DT This)) (VP (VP (AUX was) (RB not) (ADJP (NN dose) (JJ dependent))) (CC and) (VP (VBD reversed) (ADVP (RB rapidly)) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN treatment))))))) (. .)))
2528969	10	(S1 (S (NP (NP (DT A) (JJ red) (NN blood) (NN cell) (NN count) (NN decrease)) (, ,) (NP (DT a) (JJ mean) (NN cell) (NN volume) (NN increase)) (CC and) (NP (DT a) (JJ granulocyte) (NN count) (NN decrease))) (VP (VBD developed) (ADVP (RB early)) (PP (IN in) (NP (DT a) (JJ dose-independent) (NN fashion))) (, ,) (S (VP (VBG reverting) (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (PP (IN during) (NP (DT the) (JJ washout) (NN phase)))))) (. .)))
2528969	11	(S1 (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (JJ reticulocyte) (NN count)))) (VP (AUX was) (ADJP (NN dose) (VBN related)) (NP (QP (IN between) (CD 600) (CC and) (CD 900)) (NN mg/day)) (PP (IN with) (NP (NP (DT no) (JJ further) (NN change)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN escalated) (PP (TO to) (NP (CD 1200) (NN mg/day)))))))))) (. .)))
2528969	12	(S1 (S (NP (NN Bone) (NN marrow) (NNS changes)) (VP (VBD occurred) (ADVP (RB rapidly)) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NNP Doc_2528969_1714_1729_Disease))) (PP (IN in) (NP (NP (CD 95) (NN %)) (PP (IN of) (NP (CD 65) (NNS specimens))))) (PP (IN at) (NP (NP (NN week) (NNS 18.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2533791	0	(S1 (NP (NP (JJ National) (NN project)) (PP (IN on) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (JJ mother-to-infant) (NNP Doc_2533791_55_85_Disease)) (PP (IN in) (NP (NNP Japan))))))) (. .)))
2533791	1	(S1 (S (PP (IN In) (NP (NNP Japan))) (, ,) (NP (NP (DT a) (JJ nationwide) (NN prevention) (NN program)) (PP (IN against) (NP (NP (JJ mother-to-infant) (NNP Doc_2533791_163_193_Disease)) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-))))) (VP (VBD started) (PP (IN in) (NP (CD 1985)))) (. .)))
2533791	2	(S1 (S (NP (DT This) (NN program)) (VP (VBZ consists) (PP (IN of) (NP (NP (JJ double) (NNS screenings)) (PP (IN of) (NP (NP (JJ pregnant) (NNS women)) (CC and) (NP (JJ prophylactic) (NN treatment)))) (PP (TO to) (NP (NP (DT the) (NNS infants)) (VP (VBN born) (PP (TO to) (NP (NP (NP (NP (DT both) (NNP Doc_2533791_333_360_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2533791_362_367_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2533791_373_394_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2533791_396_401_Chemical)) (-RRB- -RRB-)))) (JJ positive) (NNS mothers))))))))) (. .)))
2533791	3	(S1 (S (NP (DT These) (NNS infants)) (VP (AUX are) (VP (VBN treated) (PP (IN with) (NP (NP (NP (CD two) (NNS injections)) (PP (IN of) (NP (NP (JJ Doc_2533791_470_481_Disease) (JJ immune) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP HBIG)) (-RRB- -RRB-))))) (CC and) (NP (NP (QP (IN at) (JJS least) (CD three)) (NNS injections)) (PP (IN of) (NP (NP (NN plasma)) (VP (VBN derived) (NP (NNP Doc_2533791_553_572_Chemical)))))))))) (. .)))
2533791	4	(S1 (S (S (NP (PRP We)) (VP (VBD sent) (NP (NP (NNS questionnaires)) (PP (IN about) (NP (NP (DT the) (NNS numbers)) (PP (IN of) (NP (DT each) (NN procedure) (CC or) (NN examination)))))) (PP (IN during) (NP (NP (CD nine) (NNS months)) (PP (IN of) (NP (NP (NN investigation) (NN period)) (PP (TO to) (NP (DT each) (JJ local) (NN government))))))) (PP (IN in) (NP (CD 1986))))) (CC and) (S (NP (ADJP (QP (CD 1987.) (CD 93.4)) (NN %)) (JJ pregnant) (NNS women)) (VP (AUX had) (NP (DT the) (NN chance) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN for) (NP (NNP Doc_2533791_789_794_Chemical)))))))))) (, ,) (CC and) (S (NP (DT the) (JJ positive) (NN rate)) (VP (AUX was) (NP (QP (CD 1.4) (TO to) (CD 1.5)) (NN %)))) (. .)))
2533791	5	(S1 (S (NP (NP (DT The) (JJ Doc_2533791_839_844_Chemical) (JJ positive) (NN rate)) (PP (IN in) (NP (JJ Doc_2533791_862_867_Chemical) (NN positive)))) (VP (AUX was) (NP (QP (CD 23) (TO to) (CD 26)) (NN %))) (. .)))
2533791	6	(S1 (S (NP (NP (DT The) (JJ Doc_2533791_896_901_Chemical) (JJ positive) (NN rate)) (PP (PP (IN in) (NP (NNS neonates))) (CC and) (PP (IN in) (NP (NNS infants)))) (PP (IN before) (NP (CD two) (NNS months)))) (VP (AUX were) (ADVP (NP (NP (CD 3) (NN %)) (CC and) (NP (CD 2) (NN %))) (RB respectively))) (. .)))
2533791	7	(S1 (S (NP (DT Some) (NNS problems)) (VP (MD may) (VP (VB arise) (, ,) (SBAR (IN because) (S (NP (NP (QP (CD 27) (TO to) (CD 30)) (NN %)) (PP (IN of) (NP (NNS infants)))) (VP (AUX need) (NP (NP (DT the) (JJ fourth) (NN vaccination)) (PP (IN in) (NP (DT some) (VBN restricted) (NNS areas))))))))) (. .)))
2557556	0	(S1 (NP (NP (NN Involvement)) (PP (IN of) (NP (DT the) (JJ mu-opiate) (NN receptor))) (PP (IN in) (NP (JJ peripheral) (NNP Doc_2557556_52_61_Disease))) (. .)))
2557556	1	(S1 (S (NP (NP (DT The) (JJ intradermal) (NN injection)) (PP (IN of) (NP (NP (NP (NN mu)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2557556_96_104_Chemical) (, ,) (NNP Doc_2557556_106_134_Chemical) (CC and) (NNP Doc_2557556_139_151_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NN kappa)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2557556_161_236_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ delta) (PRN (-LRB- -LRB-) (NP (NNP Doc_2557556_249_270_Chemical) (CC and) (NNP Doc_2557556_275_303_Chemical)) (-RRB- -RRB-)) (JJ selective) (NNS opioid-agonists))))) (, ,) (PP (IN by) (NP (PRP themselves))) (, ,) (VP (AUX did) (ADVP (RB not) (RB significantly)) (VP (VB affect) (NP (NP (DT the) (JJ mechanical) (NN nociceptive) (NN threshold)) (PP (IN in) (NP (NP (DT the) (NN hindpaw)) (PP (IN of) (NP (DT the) (NN rat)))))))) (. .)))
2557556	2	(S1 (S (NP (NP (JJ Intradermal) (NN injection)) (PP (IN of) (NP (NP (NNS mu)) (, ,) (CONJP (CC but) (RB not)) (NP (NN delta) (CC or) (NN kappa) (NNS opioid-agonists))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD produced) (NP (NP (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NNP Doc_2557556_556_572_Chemical-induced) (NNP Doc_2557556_581_593_Disease))))) (. .)))
2557556	3	(S1 (S (NP (NP (DT The) (JJ analgesic) (NN effect)) (PP (IN of) (NP (DT the) (JJ mu-agonist) (NNP Doc_2557556_634_642_Chemical)))) (VP (AUX was) (ADVP (RB dose-dependently)) (VP (VP (VBN antagonized) (PP (IN by) (NP (NNP Doc_2557556_679_687_Chemical)))) (CC and) (VP (VBN prevented) (PP (IN by) (NP (NP (NN co-injection)) (PP (IN of) (NP (NN pertussis) (NN toxin)))))))) (. .)))
2557556	4	(S1 (S (NP (NNP Doc_2557556_738_746_Chemical)) (VP (AUX did) (RB not) (, ,) (ADVP (RB however)) (, ,) (VP (VB alter) (NP (NP (DT the) (NN Doc_2557556_775_787_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2557556_799_837_Chemical))))))) (. .)))
2557556	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ analgesic) (NN action)) (PP (IN of) (NP (NNS opioids))) (PP (IN on) (NP (NP (DT the) (JJ peripheral) (NNS terminals)) (PP (IN of) (NP (JJ primary) (NNS afferents)))))) (VP (AUX is) (PP (IN via) (NP (NP (DT a) (JJ binding) (NN site)) (PP (IN with) (NP (NP (NNS characteristics)) (PP (IN of) (NP (DT the) (JJ mu-opioid) (NN receptor)))))))))) (CC and) (SBAR (IN that) (S (NP (DT this) (NN action)) (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT the) (JJ Doc_2557556_1060_1090_Chemical) (JJ second) (NN messenger) (NN system))))))))))) (. .)))
2564649	0	(S1 (NP (NP (NN Involvement)) (PP (IN of) (NP (NP (JJ locus) (NN coeruleus)) (CC and) (NP (JJ noradrenergic) (NN neurotransmission)))) (PP (IN in) (NP (NP (NNP Doc_2564649_70_78_Chemical-induced) (NNP Doc_2564649_87_104_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
2564649	1	(S1 (S (SBAR (IN Whereas) (S (NP (NNP Doc_2564649_125_142_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN side) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ high-dose) (JJ Doc_2564649_205_213_Chemical) (NNS anesthesia))))))))))) (, ,) (NP (NP (DT a) (NN paucity)) (PP (IN of) (NP (NN information)))) (VP (VBZ exists) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (PRP$ its) (JJ underlying) (NN mechanism)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-))))))) (. .)))
2564649	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (PP (IN in) (NP (DT this) (NN study))) (NP (NP (DT the) (JJ possible) (NN engagement)) (PP (IN of) (NP (NP (JJ locus) (NNS coeruleus)) (PP (IN of) (NP (NP (DT the) (NNP pons)) (PP (IN in) (NP (DT this) (NN phenomenon)))))))) (, ,) (S (VP (VBG using) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (ADJP (JJ anesthetized) (PP (IN with) (NP (NNP Doc_2564649_456_464_Chemical)))))))) (. .)))
2564649	3	(S1 (S (PP (IN Under) (NP (NP (JJ proper) (NN control)) (PP (IN of) (NP (NP (NN respiration)) (, ,) (NP (NN body) (NN temperature)) (CC and) (NP (JJ end-tidal) (NNP Doc_2564649_534_537_Chemical)))))) (, ,) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_2564649_569_577_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 100)) (NNS micrograms/kg)) (-RRB- -RRB-))) (VP (ADVP (RB consistently)) (VBD promoted) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ electromyographic) (NN activity))) (PP (VBN recorded) (PP (IN from) (NP (DT the) (JJ gastrocnemius) (CC and) (JJ abdominal) (JJ rectus) (NNS muscles)))))) (. .)))
2564649	4	(S1 (S (NP (NP (PDT Such) (DT an) (VBN induced) (NN Doc_2564649_746_763_Disease)) (PP (IN by) (NP (DT the) (JJ narcotic) (NN agent)))) (VP (AUX was) (VP (VP (ADVP (RB significantly)) (VBN antagonized)) (CC or) (VP (ADVP (RB even)) (VBN reduced) (PP (IN by) (NP (NP (JJ prior) (JJ electrolytic) (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus) (CC or) (NN pretreatment))) (PP (IN with) (NP (NP (DT the) (NN alpha-adrenoceptor) (NN blocker)) (, ,) (NP (NNP Doc_2564649_938_946_Chemical))))))))) (. .)))
2564649	5	(S1 (S (NP (NP (NN Microinjection)) (PP (IN of) (NP (NP (NP (NNP Doc_2564649_966_974_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD micrograms/50)) (NNP nl)) (-RRB- -RRB-))) (ADVP (RB directly) (PP (IN into) (NP (DT this) (JJ pontine) (NN nucleus))))))) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBD elicited) (NP (JJ discernible) (JJ electromyographic) (NN excitation))) (. .)))
2564649	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN speculated) (SBAR (IN that) (S (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_2564649_1143_1160_Disease))) (PP (IN by) (NP (NNP Doc_2564649_1164_1172_Chemical)))) (VP (MD may) (VP (VB involve) (NP (NP (DT the) (JJ coerulospinal) (NN noradrenergic) (NNS fibers)) (PP (TO to) (NP (DT the) (JJ spinal) (NNS motoneurons)))))))))) (. .)))
2569282	0	(S1 (S (NP (NP (NN Doc_2569282_0_15_Chemical)) (, ,) (VP (VBG acting) (PP (IN through) (NP (JJ central) (JJ alpha-2) (NNS adrenoceptors)))) (, ,)) (VP (VBZ prevents) (NP (JJ opiate-induced) (NN Doc_2569282_87_102_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
2569282	1	(S1 (S (NP (NP (DT The) (JJ highly-selective) (JJ alpha-2) (JJ adrenergic) (NN agonist) (NNP Doc_2569282_163_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2569282_180_185_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inducing) (NP (NP (NP (NN Doc_2569282_210_227_Disease)) (CC and) (NP (NN anesthesia))) (PP (IN in) (NP (NNS rats) (CC and) (NNS dogs))))))))) (. .)))
2569282	2	(S1 (S (NP (JJ Intense) (JJ generalized) (NN Doc_2569282_281_296_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ undesirable) (NN side) (NN effect)) (PP (IN of) (NP (JJ potent) (NN opiate) (NNS agonists))))) (. .)))
2569282	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN neurochemistry)) (PP (IN of) (NP (JJ opiate-induced) (NNP Doc_2569282_400_408_Disease)))) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB fully)) (VBN elucidated)))))))) (, ,) (NP (JJ recent) (NN work)) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT a) (JJ central) (NN adrenergic) (NN mechanism))))) (. .)))
2569282	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD determined) (SBAR (IN if) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2569282_568_573_Chemical)))) (VP (VBZ prevents) (NP (NP (DT the) (NN Doc_2569282_587_602_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ high-dose) (JJ Doc_2569282_623_633_Chemical) (NNS anesthesia)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
2569282	5	(S1 (S (S (NP (NP (NNS Animals)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 42)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ following) (CD six) (NNS regimens)))) (: :) (NP (NP (LST (LS 1) (-RRB- -RRB-)) (NP (NNP L-MED)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ inactive) (NNP L-isomer)) (PP (IN of) (NP (NNP Doc_2569282_780_792_Chemical)))) (-RRB- -RRB-)) (, ,) (NP (CD 30) (NN micrograms/kg))) (: ;) (NP (LST (LS 2) (-RRB- -RRB-)) (NP (NNP Doc_2569282_816_821_Chemical)) (, ,) (NP (CD 10) (NN micrograms/kg))) (: ;) (NP (LST (LS 3) (-RRB- -RRB-)) (NP (NNP Doc_2569282_844_849_Chemical)) (, ,) (NP (CD 30) (NN micrograms/kg))) (: ;) (NP (LST (LS 4) (-RRB- -RRB-)) (NP (JJ Doc_2569282_872_877_Chemical) (JJ -LSB-30) (NN micrograms/kg) (NN -RSB-)) (CC and) (NP (NP (DT the) (JJ central-acting) (JJ alpha-2) (NN antagonist)) (, ,) (NP (JJ Doc_2569282_940_948_Chemical) (JJ -LSB-10) (JJ mg/kg) (NNS -RSB-)))))))))) (: ;) (S (NP (CD 5) (-RRB- -RRB-) (NNP Doc_2569282_964_969_Chemical) (CD -LSB-30)) (VP (VBD micrograms/kg) (NP (NP (NP (NN -RSB-)) (CC and) (NP (DT the) (JJ peripheral-acting) (JJ alpha-2) (NN antagonist) (NNP Doc_2569282_1034_1041_Chemical) (JJ -LSB-10) (NN mg/kg) (NN -RSB-))) (, ,) (CC or) (PRN (: ;) (CD 6) (-RRB- -RRB-)) (NP (NN saline))))) (. .)))
2569282	6	(S1 (S (NP (JJ Baseline) (NN electromyographic) (NN activity)) (VP (AUX was) (VP (VBN recorded) (PP (IN from) (NP (DT the) (JJ gastrocnemius) (NN muscle))) (PP (IN before) (CC and) (IN after) (NP (NN drug) (NN treatment))))) (. .)))
2569282	7	(S1 (S (NP (DT Each) (NN rat)) (VP (AUX was) (ADVP (RB then)) (VP (VBN injected) (PP (IN with) (NP (NP (NNP Doc_2569282_1213_1223_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_2569282_1225_1228_Chemical)) (, ,) (NP (CD 0.5) (NN mg/kg) (NN sc))) (-RRB- -RRB-)))))) (. .)))
2569282	8	(S1 (S (NP (JJ Doc_2569282_1245_1248_Chemical) (NN injection)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (JJ hindlimb) (NN EMG) (NN activity)) (PP (IN in) (NP (NP (DT the) (JJ L-MED) (NN treatment) (NN group)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT that)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NN saline)))))))))))))))))))) (. .)))
2569282	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_2569282_1431_1436_Chemical)) (VP (VBD prevented) (NP (JJ Doc_2569282_1447_1457_Chemical-induced) (NNP Doc_2569282_1466_1481_Disease)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion)))) (. .)))
2569282	10	(S1 (S (NP (NP (DT The) (JJ small) (NN EMG) (NNS values)) (VP (VBN obtained) (PP (IN in) (NP (DT the) (JJ high-dose) (JJ Doc_2569282_1558_1563_Chemical) (NN group))))) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT those)) (VP (VBN recorded) (PP (IN in) (NP (NP (JJR earlier) (NNS studies)) (PP (IN from) (NP (NP (NN control) (NNS animals)) (SBAR (S (RB not) (VP (VBN given) (NP (DT any) (NN opiate)))))))))))))) (. .)))
2569282	11	(S1 (S (NP (DT The) (JJ high-dose) (JJ Doc_2569282_1682_1687_Chemical) (NNS animals)) (VP (AUX were) (UCP (ADJP (JJ flaccid)) (, ,) (ADJP (JJ Doc_2569282_1710_1718_Disease)) (, ,) (CC and) (VP (VBD lacked) (NP (DT a) (JJ Doc_2569282_1733_1740_Disease) (NN response)) (PP (IN during) (NP (NP (DT the) (JJ entire) (JJ experimental) (NN period.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))
2576810	0	(S1 (NP (NP (DT Some) (JJ central) (NNS effects)) (PP (IN of) (NP (VBN repeated) (NN treatment))) (PP (IN with) (NP (NNP Doc_2576810_48_59_Chemical))) (. .)))
2576810	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ repeated) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_2576810_115_126_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_2576810_140_149_Chemical) (NN uptake) (NN inhibitor)) (, ,))))) (PP (PP (IN on) (NP (NP (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNS dopaminomimetics) (CC and) (NNP Doc_2576810_214_225_Chemical))))) (CC and) (PP (IN on) (NP (NP (DT the) (NN animal) (NN behavior)) (PP (IN in) (NP (DT the) (`` ``) (JJ behavioral) (NN despair) ('' '') (NN test)))))))) (. .)))
2576810	2	(S1 (S (NP (NP (DT A) (VBN repeated) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_2576810_313_324_Chemical)) (PRN (-LRB- -LRB-) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 14) (NNS days)))) (-RRB- -RRB-))))) (VP (VBD potentiated) (PP (PP (IN in) (NP (NNS mice))) (CC and) (PP (IN in) (NP (NNS rats))) (PRN (-LRB- -LRB-) (JJR weaker) (-RRB- -RRB-))) (NP (DT the) (JJ Doc_2576810_396_407_Chemical-induced) (NNP Doc_2576810_416_429_Disease))) (. .)))
2576810	3	(S1 (S (NP (NP (DT The) (NNP Doc_2576810_435_448_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2576810_460_471_Chemical))) (PP (IN in) (NP (NNS mice))))) (VP (VBD remained) (ADJP (JJ unaffected)) (PP (IN by) (NP (NNP Doc_2576810_503_514_Chemical)))) (. .)))
2576810	4	(S1 (S (NP (NP (DT The) (NN stimulation)) (PP (IN of) (NP (NN locomotor) (NN activity))) (PP (IN by) (NP (ADJP (RB intracerebroventricularly) (VBN administered)) (NNP Doc_2576810_596_607_Chemical)))) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ repeated) (NN treatment)) (PP (IN with) (NP (NNP Doc_2576810_652_663_Chemical))))))) (. .)))
2576810	5	(S1 (S (S (VP (VBN Given) (NP (CD three) (NNS times)))) (NP (NNP Doc_2576810_683_694_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ immobilization) (NN time)) (PP (IN in) (NP (NP (DT the) (`` ``) (JJ behavioral) (NN despair) ('' '') (NN test)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
2576810	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_2576810_804_815_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (VP (VBZ acts) (ADVP (RB differently)) (PP (IN than) (NP (NP (NNP Doc_2576810_855_865_Chemical)) (, ,) (NP (DT another) (JJ selective) (NNP Doc_2576810_885_894_Chemical) (NN uptake) (NN inhibitor)) (, ,)))) (CC and) (VP (VBZ differs) (ADVP (RB also)) (PP (IN from) (NP (JJ other) (NN antidepressant) (NNS drugs)))))))) (. .)))
2594614	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ specific) (JJ platelet-activating) (NN factor) (NN antagonist)) (, ,) (NP (NNP Doc_2594614_71_79_Chemical)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_2594614_84_95_Chemical-induced) (NNP Doc_2594614_104_130_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
2594614	1	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT the) (JJ local) (JJ anaesthetic) (NNP Doc_2594614_180_191_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CC or) (CD 2) (CD mg/kg))) (, ,) (NP (NNP i.v.)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats)))) (VP (VBD elicited) (NP (NP (DT a) (JJ marked) (NN Doc_2594614_241_307_Disease)) (VP (VBG leading) (PP (TO to) (NP (NN death)))) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (CD 67) (NN %)) (CC or) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (NNS animals))))) (ADVP (RB respectively))) (-RRB- -RRB-)))) (. .)))
2594614	2	(S1 (S (NP (NP (JJ Intravenous) (NN injection)) (PP (IN of) (NP (NP (NP (DT the) (JJ specific) (JJ platelet-activating) (NN factor) (PRN (-LRB- -LRB-) (NP (NNP PAF)) (-RRB- -RRB-)) (NN antagonist) (NNP Doc_2594614_448_456_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NNP Doc_2594614_483_494_Chemical) (NN administration)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (PDT both) (DT the) (NNP Doc_2594614_545_567_Disease))) (. .)))
2594614	3	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 1) (NN mg/kg) (NNP Doc_2594614_599_607_Chemical)))) (VP (VBN given) (NP (CD 30) (NN min)) (SBAR (IN before) (S (NP (NP (QP (CC or) (CD 10)) (NNS mg/kg)) (VP (VBN administered) (NP (CD 5) (NN min)) (PP (IN before) (NP (NP (CD i.v.) (NN injection)) (PP (IN of) (NP (NNP Doc_2594614_684_695_Chemical))))))) (VP (AUX were) (ADJP (JJ ineffective)))))) (. .)))
2594614	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NNP Doc_2594614_719_727_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB immediately)) (PP (IN after) (NP (NP (NNP Doc_2594614_775_786_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT a) (JJ partial) (NN reversion)) (PP (IN of) (NP (DT the) (NNP Doc_2594614_825_847_Disease)))) (VP (AUX was) (ADJP (JJ observed)) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 10) (NNS mg/kg)))) (VP (AUX was) (ADJP (JJ ineffective)))))) (. .)))
2594614	5	(S1 (S (NP (NP (DT A) (JJ partial) (NN recovery)) (PP (IN of) (NP (JJ Doc_2594614_930_941_Chemical-induced) (NN ECG) (NNS alterations)))) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (DT the) (NNS rats)) (PP (IN with) (NP (NNP Doc_2594614_1015_1023_Chemical))))))))) (. .)))
2594614	6	(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2594614_1053_1061_Chemical)))) (, ,) (PP (IN at) (NP (NP (DT all) (NNS doses)) (VP (VBN studied)))) (, ,) (VP (AUX did) (RB not) (VP (VB alter) (NP (NNS MBP) (CC and) (NNS HR)) (PP (IN at) (NP (NP (DT the) (NNS doses)) (VP (VBN used)))))))) (, ,) (NP (NP (DT the) (NN bulk)) (PP (IN of) (NP (DT these) (NNS results)))) (ADVP (RB clearly)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ protective) (NN action)) (PP (IN of) (NP (NP (NNP Doc_2594614_1198_1206_Chemical)) (, ,) (NP (NP (DT a) (JJ specific) (NN antagonist)) (PP (IN of) (NP (NN PAF)))) (, ,))) (PP (IN against) (NP (NNP Doc_2594614_1246_1257_Chemical-induced) (NNP Doc_2594614_1266_1289_Disease))))) (. .)))
2594614	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (ADJP (JJ consistent) (PP (IN with) (NP (NP (PRP$ its) (JJ direct) (NN effect)) (PP (IN on) (NP (NN heart)))))) (, ,) (NN PAF)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (JJ Doc_2594614_1373_1384_Chemical-induced) (NN Doc_2594614_1393_1419_Disease)))))))) (. .)))
2598570	0	(S1 (NP (NP (DT The) (NN epidemiology)) (PP (IN of) (NP (DT the) (JJ acute) (JJ Doc_2598570_30_40_Disease) (NN syndrome))) (PP (IN from) (NP (NNP Doc_2598570_55_63_Chemical))) (. .)))
2598570	1	(S1 (S (NP (NP (NNP Doc_2598570_65_73_Chemical)) (, ,) (NP (DT a) (JJ new) (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug)) (, ,)) (VP (AUX was) (VP (VBN marketed) (PP (IN in) (NP (JJ early) (CD 1986))) (PP (IN as) (NP (DT an) (JJ analgesic) (NN agent))))) (. .)))
2598570	2	(S1 (S (SBAR (IN Until) (S (NP (NNS physicians)) (VP (VBD began) (S (VP (VBG reporting) (NP (NP (DT an) (JJ unusual) (JJ acute) (NN Doc_2598570_218_228_Disease) (NN syndrome)) (PP (TO to) (NP (DT the) (JJ spontaneous) (NN reporting) (NN system))))))))) (, ,) (NP (CD 700,000) (NNS persons)) (VP (VBD used) (NP (DT the) (NN drug)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (. .)))
2598570	3	(S1 (S (PP (IN Through) (NP (NNP August) (CD 1986))) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 163) (NNS cases)) (PP (IN of) (NP (DT this) (NN syndrome)))))) (VP (AUX were) (VP (VBN reported))) (. .)))
2598570	4	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NN epidemiology)) (PP (IN of) (NP (DT the) (NN syndrome))))))) (, ,) (NP (DT a) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN performed) (, ,) (S (VP (VBG comparing) (NP (NP (CD 62)) (PP (IN of) (NP (NP (DT the) (NN case) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (JJ spontaneous) (NN reporting) (NN system)) (PP (TO to) (NP (NP (CD 185) (JJ Doc_2598570_583_591_Chemical-exposed) (NN control) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (DT the) (NN syndrome)))))))))))))))))))))) (. .)))
2598570	5	(S1 (S (NP (NN Case) (NNS patients)) (VP (AUX were) (ADJP (RBR more) (JJ likely) (S (VP (VP (TO to) (VP (AUX be) (NP (NP (NNS men)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (CD 3.8))) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (CD 1.2-12.1))) (-RRB- -RRB-))))) (, ,) (VP (VB suffer) (PP (IN from) (NP (NP (NNP Doc_2598570_755_764_Disease) (CC and) (NNP Doc_2598570_769_775_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (CD 3.4))) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (CD 1.0-11.9))) (-RRB- -RRB-))))) (: ;) (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (JJ regular) (NN exercise)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (NP (CD 5.9)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))) (, ,) (NP (CD 1.1-30.7)) (-RRB- -RRB-)))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Nautilus) (NN equipment)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.02)) (-RRB- -RRB-)))))))) (: ;) (CC and) (VP (TO to) (VP (VB use) (NP (NNP Doc_2598570_986_993_Chemical))))))) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (NP (CD 4.4)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))) (, ,) (NP (CD 1.1-17.5)) (-RRB- -RRB-))) (. .)))
2598570	6	(S1 (S (NP (JJ Possible) (NN risk) (NNS factors)) (VP (VBD included) (NP (NP (JJ young) (NN age)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NP (JJ other) (JJ analgesic) (NNS agents)) (PRN (-LRB- -LRB-) (ADVP (RB especially)) (NP (NNP Doc_2598570_1143_1152_Chemical)) (-RRB- -RRB-))) (, ,) (NP (JJ preexisting) (NNP Doc_2598570_1167_1180_Disease))))) (, ,) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_2598570_1195_1208_Disease)))) (, ,) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_2598570_1223_1227_Disease)))) (, ,) (NP (NP (DT a) (JJ recent) (NN increase)) (PP (IN in) (NP (NN activity)))) (, ,) (NP (NP (DT a) (JJ recent) (NN increase)) (PP (IN in) (NP (NN sun) (NN exposure)))) (, ,) (CC and) (NP (NP (NN residence)) (PP (IN in) (NP (DT the) (NNP Sunbelt)))))) (. .)))
2598570	7	(S1 (S (NP (DT These)) (VP (AUX were) (NP (NP (NNS findings)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX were) (ADJP (JJ suggestive))) (CC but) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ conventional) (JJ statistical) (NN significance))))))))) (. .)))
2598570	8	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (JJ postulated) (NN mechanism)) (PP (IN for) (NP (NP (DT this) (JJ unusual) (NN syndrome)) (: :) (NP (NP (JJ acute) (NN diffuse) (NN crystallization)) (PP (IN of) (NP (NNP Doc_2598570_1543_1552_Chemical))) (PP (IN in) (NP (JJ renal) (NNS tubules)))))))))) (. .)))
2709684	0	(S1 (S (NP (JJ Doc_2709684_0_9_Chemical-induced) (NNP Doc_2709684_18_28_Disease)) (VP (AUX does) (RB not) (VP (VB prevent) (NP (NP (NNP Doc_2709684_46_56_Chemical) (NNP Doc_2709684_57_71_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
2709684	1	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_2709684_99_113_Chemical-induced) (NNP Doc_2709684_122_139_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_141_143_Disease)) (-RRB- -RRB-))))) (VP (AUX have) (NP (NP (DT a) (JJ high) (NN solute) (NN diuresis)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_2709684_174_184_Disease)) (PP (IN of) (NP (QP (CD 10) (TO to) (CD 12)) (NN g/day)))) (-RRB- -RRB-)))))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT this)) (VP (MD may) (PP (IN in) (NP (NN part))) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (PRP$ their) (NN resistance)) (PP (TO to) (NP (NP (JJ Doc_2709684_284_294_Chemical-induced) (NNP Doc_2709684_303_322_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_324_327_Disease)) (-RRB- -RRB-))))))))))))) (. .)))
2709684	2	(S1 (S (NP (NP (DT The) (NN protection)) (PP (IN from) (NP (NNP Doc_2709684_350_360_Chemical) (NNP Doc_2709684_361_375_Disease)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (JJ non-Doc_2709684_395_403_Disease) (NNS rats)) (PP (IN with) (NP (NP (JJ chronic) (JJ solute) (NNS diuresis)) (VP (VBN induced) (PP (IN by) (NP (NP (NN blockage)) (PP (IN of) (NP (NP (JJ tubular) (JJ Doc_2709684_469_476_Chemical) (NN reabsorption)) (PP (IN with) (NP (NP (NNP Doc_2709684_495_504_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_506_507_Chemical)) (-RRB- -RRB-))))))))))))))) (. .)))
2709684	3	(S1 (S (NP (NP (JJ Doc_2709684_510_512_Disease) (NNS rats)) (PP (IN with) (NP (NP (JJ mild) (NNP Doc_2709684_528_538_Disease)) (PRN (-LRB- -LRB-) (ADJP (JJ similar) (PP (IN in) (NP (NN degree))) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ Doc_2709684_573_574_Chemical) (VBN treated) (NNS animals)))))) (-RRB- -RRB-))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN studied))) (. .)))
2709684	4	(S1 (S (NP (JJ Unanesthetized) (NN adult) (NN female) (, ,) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VP (VBN divided) (PP (IN in) (NP (CD four) (NNS groups)))) (CC and) (VP (VBN studied) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
2709684	5	(S1 (S (NP (NP (NNP Group) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_722_723_Chemical) (RB alone)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NP (NNP Doc_2709684_740_741_Chemical)) (, ,) (NP (CD 360) (NN mg/day)) (, ,) (PP (IN for) (NP (CD 15) (NNS days)))) (: ;) (NP (NP (NNP Group) (NNP II)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_778_779_Chemical) (NNP +) (NNP Doc_2709684_782_792_Chemical)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP Group) (NNP III)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_806_816_Chemical) (RB alone)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Group) (NNP IV)) (PRN (-LRB- -LRB-) (NP (JJ mild) (NNP Doc_2709684_843_845_Disease) (NNP +) (NNP Doc_2709684_848_858_Chemical)) (-RRB- -RRB-))))) (. .)))
2709684	6	(S1 (S (NP (NP (NP (JJ Doc_2709684_861_872_Disease) (NNS doses)) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (CD mg/kg)) (NN body) (NN wt/day)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_2709684_905_915_Chemical)))) (VP (AUX were) (VP (VBN injected) (PP (IN during) (NP (NP (DT the) (JJ last) (CD nine) (NNS days)) (PP (IN of) (NP (NN study))))) (PP (TO to) (NP (NP (DT the) (NNS animals)) (PP (IN of) (NP (NP (NNS groups)) (VP (NNP II) (PP (TO to) (NP (NNP IV)))))))))) (. .)))
2709684	7	(S1 (S (PP (IN In) (NP (NNP Group) (NNP I))) (, ,) (NP (NNP Doc_2709684_1012_1013_Chemical)) (VP (VP (VBN induced) (NP (NP (DT a) (ADJP (JJ moderate) (CC and) (JJ stable)) (NN Doc_2709684_1044_1054_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.9) (NN +/-)) (NP (CD 0.1) (NN g/day))) (, ,) (FW SE) (-RRB- -RRB-)))) (, ,) (NP (CC and) (NP (NP (DT no) (ADJP (JJ functional) (CC or) (JJ morphologic)) (NN evidence)) (PP (IN of) (NP (NNP Doc_2709684_1125_1142_Disease))) (PRN (-LRB- -LRB-) (NP (JJ baseline) (NNP CCr) (CD 2.1) (NN +/-) (CD 0.1) (NN ml/min)) (, ,) (NP (JJ undetectable) (NN lysozymuria)) (-RRB- -RRB-))) (CC or) (NP (NP (NN damage)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_1214_1230_Disease) (NN score) (NN -LSB-maximum) (CD 4) (NN -RSB-)) (, ,) (NP (CD zero)) (-RRB- -RRB-))))) (. .)))
2709684	8	(S1 (S (PP (IN In) (NP (NNP Group) (NNP II))) (, ,) (NP (NNP Doc_2709684_1270_1271_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (NNP Doc_2709684_1288_1298_Chemical-Doc_2709684_1299_1302_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ maximal) (NN decrease)) (PP (IN in) (NP (NNP CCr))) (PP (IN at) (NP (NN day))) (NP (NP (NP (NP (CD 9.89) (NN %)) (, ,) (NP (NNP Doc_2709684_1342_1343_Chemical))) (QP (JJR less) (IN than) (CD 0.001))) (: ;) (NP (NP (JJ peak) (NN lysozymuria)) (, ,) (NP (NP (CD 1863) (NN +/-)) (NP (CD 321) (NN micrograms/day)))) (: ;) (CC and) (NP (JJ Doc_2709684_1412_1428_Disease) (NN score)))) (, ,) (NP (CD 3.9) (JJ +/-) (CD 0.1)) (-RRB- -RRB-))))) (. .)))
2709684	9	(S1 (S (NP (DT These) (NNS values)) (VP (AUX were) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NP (NP (DT those)) (PP (IN of) (NP (NNP Group) (NNP III)))) (: :) (NP (NP (NP (JJ maximal) (NN decrease)) (PP (IN in) (NP (NNP CCr))) (NP (CD 73) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_1536_1537_Chemical) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (: ;) (NP (NP (NN lysozymuria)) (, ,) (NP (NP (CD 2147) (NN +/-)) (NP (CD 701) (NN micrograms/day)))) (: ;) (NP (NP (JJ Doc_2709684_1598_1614_Disease) (NN score)) (, ,) (NP (QP (CD 3.8) (CD +/-)) (NNS 0.1.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2716967	0	(S1 (NP (NP (NP (NN Doc_2716967_0_9_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNS combinations)) (PP (IN of) (NP (NNP Doc_2716967_37_45_Chemical) (CC and) (NNP Doc_2716967_50_58_Chemical))))))) (: :) (NP (NP (NP (NN potentiation)) (, ,) (NP (NN antagonism)) (, ,) (NP (NN tolerance)) (CC and) (NP (NN cross-tolerance))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
2716967	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT both) (NNP Doc_2716967_168_176_Chemical) (CC and) (NNP Doc_2716967_181_189_Chemical)) (VP (VBN induced) (NP (NP (NNP Doc_2716967_198_207_Disease)) (CC and) (NP (NNP Doc_2716967_212_221_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
2716967	2	(S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN with) (NP (NNP Doc_2716967_253_261_Chemical)))) (VP (VBD produced) (NP (NN cross-tolerance)) (PP (TO to) (NP (NNP Doc_2716967_290_298_Chemical))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_2716967_326_334_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB induce) (NP (NN cross-tolerance)) (PP (TO to) (NP (NNP Doc_2716967_369_377_Chemical))))) (CC but) (VP (ADVP (RB rather)) (VBD augmented) (NP (DT the) (JJ Doc_2716967_403_413_Disease) (NN response)))))))) (: ;) (S (NP (DT this) (NN augmentation)) (VP (AUX was) (VP (VBN attributed) (PP (TO to) (NP (NP (JJ residual) (NNP Doc_2716967_469_477_Chemical)) (PP (IN in) (NP (DT the) (NN brain)))))))) (. .)))
2716967	3	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBD explored) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (DT the) (NN loss)) (PP (IN of) (S (VP (VBG righting) (NP (NP (JJ reflex)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2716967_599_607_Chemical)) (CC and) (NP (NNP Doc_2716967_612_620_Chemical))))))))))) (, ,) (VP (VBN administered) (ADVP (RB simultaneously))))))) (. .)))
2716967	4	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ mutual) (NN potentiation)) (PP (IN between) (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2716967_712_720_Chemical)) (CC and) (NP (NNP Doc_2716967_725_733_Chemical))))))))) (, ,) (CC but) (S (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NNP Doc_2716967_762_770_Chemical)))) (VP (ADVP (RB partly)) (VBN antagonized) (NP (NP (JJ fully-effective) (NNS doses)) (PP (IN of) (NP (NNP Doc_2716967_815_823_Chemical)))))) (. .)))
2716967	5	(S1 (S (NP (NP (NN Latency)) (PP (TO to) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ righting) (JJ reflex) (, ,) (NN Doc_2716967_865_873_Disease) (CC and) (NN behavior))) (PP (IN on) (NP (NN recovery))))) (, ,)) (VP (VBD reflected) (NP (NP (DT the) (JJ relative) (NN predominance)) (PP (IN of) (NP (NP (NNP Doc_2716967_939_947_Chemical)) (CC or) (NP (NNP Doc_2716967_951_959_Chemical)))) (PP (IN in) (NP (DT each) (NN combination))))) (. .)))
2716967	6	(S1 (S (NP (NN Doc_2716967_981_989_Chemical)) (VP (VBD inhibited) (NP (DT the) (VBN induced) (NNP Doc_2716967_1012_1022_Disease) (NNS effects))) (. .)))
2716967	7	(S1 (S (NP (NP (DT The) (NN degree) (CC and) (NN time) (NN course)) (PP (IN of) (NP (NP (NN development)) (PP (IN of) (NP (NN tolerance))))) (PP (TO to) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NP (JJ sub-effective) (NN dose) (NNS combinations)) (PP (IN of) (NP (NNP Doc_2716967_1149_1157_Chemical) (CC and) (NNP Doc_2716967_1162_1170_Chemical)))))))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
2716967	8	(S1 (S (NP (NP (NNS Rats)) (, ,) (ADJP (JJ tolerant) (PP (TO to) (NP (JJ Doc_2716967_1203_1211_Chemical-dominant) (NNS combinations)))) (, ,)) (VP (AUX were) (ADJP (JJ cross-tolerant) (PP (TO to) (NP (DT both) (NNS drugs)))) (, ,) (SBAR (IN while) (S (NP (NP (DT those) (JJ tolerant)) (PP (TO to) (NP (JJ Doc_2716967_1294_1302_Chemical-dominant) (NNS combinations)))) (VP (VP (AUX were) (ADJP (JJ cross-tolerant) (PP (TO to) (NP (NNP Doc_2716967_1348_1356_Chemical))))) (CC but) (VP (VBD showed) (NP (CC either) (NP (DT no) (NN cross-tolerance)) (CC or) (NP (NP (DT an) (JJ augmented) (NN response)) (PP (TO to) (NP (NNP Doc_2716967_1422_1430_Chemical)))))))))) (. .)))
2716967	9	(S1 (S (SBAR (IN While) (S (NP (DT the) (JJ mutual) (NN potentiation) (, ,) (NN antagonism) (CC and) (NN tolerance)) (VP (VBP suggest) (NP (JJ common) (NNS mechanisms)) (PP (IN for) (NP (DT the) (VBN induced) (NNP Doc_2716967_1530_1539_Disease)))))) (, ,) (NP (NP (NP (NNS differences)) (PP (IN in) (NP (NN latency) (, ,) (NN Doc_2716967_1565_1573_Disease) (CC and) (NN behavior)))) (, ,) (NP (NP (NN asymmetry)) (PP (IN of) (NP (NN cross-tolerance)))) (CC and) (NP (NP (DT a) (JJ widely-different) (NN ID50)) (PP (IN for) (NP (NNP Doc_2716967_1649_1657_Chemical))))) (VP (MD would) (VP (VB argue) (PP (IN against) (NP (NP (DT an) (NN action)) (PP (IN at) (NP (DT a) (JJ single) (NN opioid) (NN site))))))) (. .)))
2722224	0	(S1 (NP (NP (NP (JJ Doc_2722224_0_14_Chemical-induced) (NN Doc_2722224_23_35_Disease)) (PP (IN in) (NP (NNS humans)))) (: :) (NP (NP (JJ pressor) (NN responsiveness)) (CC and) (NP (JJ sympathetic) (NN function))) (. .)))
2722224	1	(S1 (S (NP (JJ Oral) (NN Doc_2722224_101_115_Chemical)) (VP (VP (VBZ increases) (NP (NN blood) (NN pressure))) (CC and) (VP (VBZ enhances) (NP (NP (NN pressor) (NN responsiveness)) (PP (IN in) (NP (JJ normal) (JJ human) (NNS subjects)))))) (. .)))
2722224	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NP (JJ oral) (NNP Doc_2722224_244_258_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg/day)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (NP (JJ total) (JJ peripheral) (NN resistance)) (, ,) (NP (JJ forearm) (JJ vascular) (NN resistance)) (, ,) (CC and) (NP (JJ Doc_2722224_369_383_Chemical) (NN spillover))))) (PP (TO to) (NP (NN plasma))) (PP (IN in) (NP (CD eight) (JJ healthy) (NN male) (NNS volunteers)))) (. .)))
2722224	3	(S1 (S (SBAR (IN Although) (S (NP (JJ diastolic) (NN blood) (NN pressure)) (VP (VBD remained) (ADJP (JJ unchanged))))) (, ,) (NP (JJ systolic) (NN blood) (NN pressure)) (VP (VBN increased) (PP (IN from) (NP (CD 119))) (PP (TO to) (NP (NP (CD 135) (NNS mm)) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (JJ SED) (NN +/-) (CD 3.4)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NNP Doc_2722224_600_624_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.85-7.73) (NN l/min)) (, ,) (NP (JJ SED) (JJ +/-) (NN 0.46))) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))))) (. .)))
2722224	4	(S1 (S (NP (JJ Total) (JJ peripheral) (NN vascular) (NN resistance)) (VP (VBD fell) (PP (IN from) (NP (NP (QP (CD 15.1) (TO to) (CD 12.2) (CD mm)) (NNP Hg/l/min)) (PRN (-LRB- -LRB-) (NP (NNP SED) (CD +/-) (CD 1.03)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
2722224	5	(S1 (S (S (NP (JJ Resting) (NN forearm) (NN vascular) (NN resistance)) (VP (VBD remained) (ADJP (JJ unchanged)))) (, ,) (CC but) (S (NP (NP (DT the) (JJ reflex) (NN response)) (PP (TO to) (NP (DT the) (JJ cold) (NN pressor) (NN test)))) (VP (AUX was) (VP (VBN accentuated) (, ,) (NP (NP (DT the) (NN rise)) (PP (IN in) (NP (NP (NN resistance) (VBG increasing)) (PP (IN from) (NP (NP (CD 10.5) (JJ mm) (NNP Hg/ml/100) (NN ml/min)) (PRN (-LRB- -LRB-) (NP (NN R) (NNS units)) (-RRB- -RRB-)))))) (PP (IN before) (NP (NN treatment))) (PP (TO to) (NP (CD 32.6) (NN R) (NNS units))) (PP (IN after) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (JJ SED) (NN +/-) (CD 6.4)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.025))) (-RRB- -RRB-)))))) (. .)))
2722224	6	(S1 (S (NP (NP (DT The) (NN rise)) (PP (IN in) (NP (NP (JJ forearm) (JJ vascular) (NN resistance) (VBG accompanying) (JJ intra-arterial) (NNP Doc_2722224_1129_1143_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 25)) (, ,) (NP (CD 50)) (, ,) (CC and) (NP (CD 100) (NN ng/min))) (-RRB- -RRB-))))) (VP (AUX was) (ADVP (RB also)) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN after) (NP (NNP Doc_2722224_1206_1220_Chemical)))) (, ,) (S (VP (VBG increasing) (PP (PP (IN from) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (QP (CD 14.9) (CD +/-)) (ADJP (CD 2.4) (NN R)) (NNS units)) (PP (IN before) (NP (NN treatment))))))) (PP (TO to) (NP (NP (QP (CD 35.1) (CD +/-)) (ADJP (CD 5.5) (NN R)) (NNS units)) (PP (IN after) (NP (NP (NNP Doc_2722224_1320_1334_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ SED) (JJ +/-) (NN 6.0)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))))))) (. .)))
2722224	7	(S1 (S (NP (NP (NP (DT A) (NN shift)) (PP (TO to) (NP (DT the) (NN left))) (PP (IN in) (NP (DT the) (JJ dose-response) (NN relation)))) (CC and) (NP (NP (NN fall)) (PP (IN in) (NP (NN threshold))))) (VP (VBD suggested) (NP (JJ increased) (NN sensitivity)) (PP (TO to) (NP (NNP Doc_2722224_1475_1489_Chemical))) (PP (IN after) (NP (NN treatment)))) (. .)))
2722224	8	(S1 (S (NP (NP (NN Measurement)) (PP (IN of) (S (VP (VBG resting) (NP (JJ Doc_2722224_1530_1544_Chemical) (NN spillover) (NN rate)) (PP (TO to) (NP (NP (NN plasma)) (CC and) (NP (JJ Doc_2722224_1574_1588_Chemical) (NN uptake)))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (JJ overall) (JJ resting) (ADJP (JJ sympathetic) (JJ nervous)) (NN system) (NN activity)) (VP (AUX was) (RB not) (VP (VBN increased)))))) (. .)))
2722224	9	(S1 (S (NP (NP (DT The) (NNP Doc_2722224_1686_1716_Disease)) (PP (IN with) (NP (NNP Doc_2722224_1722_1736_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (NNP Doc_2722224_1759_1783_Disease)) (PRN (-LRB- -LRB-) (ADJP (RB presumably) (JJ due) (PP (TO to) (NP (JJ increased) (NN blood) (NN volume)))) (-RRB- -RRB-)) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))
2750819	0	(S1 (NP (NP (NN Doc_2750819_0_22_Disease)) (PP (IN with) (NP (NP (NNP Doc_2750819_28_45_Chemical)) (CC and) (NP (NNP Doc_2750819_50_60_Chemical)))) (. .)))
2750819	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN tocolysis)) (PP (IN with) (NP (NNP Doc_2750819_100_110_Chemical))))))) (VP (VBD developed) (NP (NNP Doc_2750819_121_143_Disease)) (SBAR (IN after) (S (NP (NP (CD 500) (NN mg)) (PP (IN of) (NP (NNP Doc_2750819_160_177_Chemical)))) (VP (AUX was) (VP (VBN administered)))))) (. .)))
2750819	2	(S1 (S (NP (DT This) (NN reaction)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NNP Doc_2750819_228_238_Chemical)) (VP (MD can) (ADVP (RB seriously)) (VP (VB potentiate) (NP (NP (DT the) (NN Doc_2750819_268_276_Disease)) (PP (IN of) (NP (NN Doc_2750819_280_289_Chemical))))))))) (. .)))
2750819	3	(S1 (S (NP (NN Caution)) (VP (MD should) (VP (AUX be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD two) (NNS tocolytics)) (VP (AUX are) (VP (VBN combined)))))))) (. .)))
2790457	0	(S1 (S (NP (JJ Chronic) (NNP Doc_2790457_8_21_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ local) (JJ anesthetic) (NN Doc_2790457_67_75_Disease)) (VP (VBN kindled) (PP (IN by) (NP (NP (NNP Doc_2790457_87_94_Chemical)) (CC and) (NP (NNP Doc_2790457_99_108_Chemical))))))))) (. .)))
2790457	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_2790457_125_138_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2790457_140_143_Chemical)) (-RRB- -RRB-)) (NN treatment))) (PP (IN on) (NP (NP (JJ local) (JJ anesthetic-kindled) (NN Doc_2790457_183_191_Disease)) (CC and) (NP (NN lethality))))) (VP (AUX were) (VP (VBN evaluated) (PP (PP (IN in) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (DT the) (JJ kindling) (NN process))))) (CC and) (PP (IN under) (NP (NP (JJ different) (NNS methods)) (PP (IN of) (NP (NNP Doc_2790457_296_299_Chemical) (NN administration)))))))) (. .)))
2790457	2	(S1 (S (NP (JJ Chronic) (JJ oral) (NN Doc_2790457_329_332_Chemical)) (VP (VP (VBD inhibited) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT both) (NNP Doc_2790457_367_376_Chemical-) (CC and) (NNP Doc_2790457_382_389_Chemical-induced) (NNP Doc_2790457_398_406_Disease))))) (, ,) (CC but) (VP (AUX had) (NP (NP (JJ little) (NN effect)) (PP (IN on) (NP (DT the) (ADJP (RB fully) (VBN developed)) (JJ local) (JJ anesthetic) (NN Doc_2790457_470_478_Disease)))))) (. .)))
2790457	3	(S1 (S (NP (JJ Chronic) (NN Doc_2790457_488_491_Chemical)) (ADVP (RB also)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ Doc_2790457_524_531_Disease-related) (NN mortality))) (PP (IN in) (NP (DT the) (JJ Doc_2790457_557_564_Chemical-injected) (NNS rats))))) (. .)))
2790457	4	(S1 (S (NP (NP (JJ Acute) (NN Doc_2790457_586_589_Chemical)) (PP (IN over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 15-50) (NNS mg/kg)) (-RRB- -RRB-))))))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (VBN completed) (ADJP (JJ Doc_2790457_653_662_Chemical-kindled) (CC or) (JJ acute)) (JJ Doc_2790457_680_687_Chemical-induced) (NN Doc_2790457_696_704_Disease))))) (. .)))
2790457	5	(S1 (S (NP (NP (VBN Repeated) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2790457_733_736_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (AUX was) (PP (IN without) (NP (NN effect))) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2790457_794_803_Chemical-) (CC or) (NNP Doc_2790457_808_815_Chemical-kindled) (NNP Doc_2790457_824_832_Disease)))))) (. .)))
2790457	6	(S1 (S (NP (NP (DT The) (NN differential) (NNS effects)) (PP (IN of) (NP (NNP Doc_2790457_862_865_Chemical))) (PP (VBG depending) (PP (IN upon) (NP (NN stage)))) (PP (IN of) (NP (JJ Doc_2790457_890_897_Disease) (NN development)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ distinct) (NNS mechanisms)) (VP (VB underlie) (NP (NP (DT the) (NN development) (CC versus) (NN maintenance)) (PP (IN of) (NP (JJ local) (JJ anesthetic-kindled) (NN Doc_2790457_1015_1023_Disease)))))))) (. .)))
2790457	7	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ chronic)) (CC but) (ADJP (RB not) (JJ repeated))) (, ,) (JJ intermittent) (NNS injections)) (PP (IN of) (NP (NNP Doc_2790457_1099_1102_Chemical)))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ different) (JJ biochemical) (NNS consequences)) (VP (VBP result) (PP (IN from) (NP (DT the) (JJ different) (NN treatment) (NNS regimens))))))) (. .)))
2790457	8	(S1 (S (NP (NP (DT The) (JJ possible) (NN utility)) (PP (IN of) (NP (JJ chronic) (NNP Doc_2790457_1230_1233_Chemical))) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ toxic) (NN side) (NNS effects))) (PP (IN in) (NP (JJ human) (JJ Doc_2790457_1295_1302_Chemical) (NNS users)))))))) (VP (VP (AUX is) (VP (VBN suggested) (PP (IN by) (NP (DT these) (NNS data))))) (, ,) (CC but) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB directly)) (VBN evaluated))))))) (. .)))
2819587	0	(S1 (S (NP (NP (JJ Magnetic) (NN resonance) (NN imaging)) (PP (IN of) (NP (JJ cerebral) (NNP Doc_2819587_39_56_Disease)))) (ADJP (JJ secondary) (PP (TO to) (NP (`` ``) (JJ low-dose) ('' '') (NN birth) (NN control) (NNS pills)))) (. .)))
2819587	1	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ radiographic))) (NNS features)) (PP (IN of) (NP (JJ cerebral) (NNP Doc_2819587_153_175_Disease))) (PP (IN in) (NP (DT a) (JJ 21-year-old) (JJ white) (NN woman)))) (VP (AUX are) (VP (VBN presented))) (. .)))
2819587	2	(S1 (S (NP (DT This) (JJ nulliparous) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (NP (ADJP (RB relatively) (JJ mild)) (JJ clinical) (NNS symptoms)) (CC and) (NP (VBG progressing) (JJ mental) (NN status) (NNS changes))))) (. .)))
2819587	3	(S1 (S (NP (DT The) (JJ only) (JJ known) (NN risk) (NN factor)) (VP (AUX was) (NP (`` ``) (JJ low-dose) ('' '') (JJ Doc_2819587_375_393_Chemical) (NNS pills))) (. .)))
2819587	4	(S1 (S (NP (NP (DT The) (JJ magnetic) (NN resonance) (NN image)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (NP (VBN increased) (NN signal) (NN intensity)) (PP (IN from) (NP (DT the) (JJ internal) (JJ cerebral) (NNS veins)))) (, ,) (NP (NP (NN vein)) (PP (IN of) (NP (NNP Galen)))) (, ,) (CC and) (NP (JJ straight) (NN sinus)))) (. .)))
2819587	5	(S1 (S (NP (DT The) (NN diagnosis)) (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (JJ arterial) (NN angiography))))) (. .)))
2826064	0	(S1 (NP (NP (NP (JJ Beta-2-adrenoceptor-mediated) (NN Doc_2826064_29_40_Disease)) (CC and) (NP (NP (PRP$ its) (NN abolishment)) (PP (IN by) (NP (NNP Doc_2826064_64_74_Chemical))))) (. .)))
2826064	1	(S1 (S (NP (NP (NP (DT The) (NN time) (NN course)) (CC and) (NP (JJ concentration-effect) (NN relationship))) (PP (IN of) (NP (NNP Doc_2826064_133_144_Chemical-induced) (NNP Doc_2826064_153_164_Disease)))) (VP (AUX was) (VP (VBN studied) (, ,) (S (VP (VBG using) (NP (JJ computer-aided) (JJ pharmacokinetic-dynamic) (NN modeling)))))) (. .)))
2826064	2	(S1 (S (ADVP (RB Subsequently)) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_2826064_278_288_Chemical)))) (PP (IN in) (S (VP (VBG antagonizing) (NP (JJ such) (NN Doc_2826064_310_321_Disease))))) (, ,) (ADVP (RB together)) (PP (IN with) (NP (NP (DT the) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (DT both) (NNS drugs)))))) (. .)))
2826064	3	(S1 (S (NP (CD Six) (JJ healthy) (NNS subjects)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (ADJP (CD 0.5) (NN mg)) (JJ subcutaneous) (NN dose)) (PP (IN of) (NP (NNP Doc_2826064_451_462_Chemical))) (PP (IN on) (NP (NP (CD two) (NNS occasions)) (: :) (NP (NP (NP (CD 1) (NN hour)) (PP (IN after) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (DT a) (NN placebo)))))) (CC and) (NP (NP (CD 1) (NN hour)) (PP (IN after) (NP (CD 80) (JJ mg) (NNP Doc_2826064_550_560_Chemical) (NN orally)))))))))) (. .)))
2826064	4	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ 7-hour) (NN period)) (PP (IN after) (NP (NNP Doc_2826064_596_607_Chemical) (NN administration))))) (, ,) (NP (NN plasma) (NNS samples)) (VP (AUX were) (VP (VBN taken) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_2826064_678_687_Chemical) (NNS levels)) (CC and) (NP (NN drug) (NNS concentrations)))))))) (. .)))
2826064	5	(S1 (S (NP (DT The) (JJ sigmoid) (JJ Emax) (NN model)) (VP (VBD offered) (NP (NP (DT a) (JJ good) (NN description)) (PP (IN of) (NP (DT the) (NN relation))) (PP (IN between) (NP (NP (JJ Doc_2826064_794_805_Chemical) (NNS concentrations)) (CC and) (NP (JJ Doc_2826064_825_834_Chemical) (NNS effects)))))) (. .)))
2826064	6	(S1 (S (NP (NN Doc_2826064_844_854_Chemical)) (VP (VBD caused) (NP (NP (NP (NNS decreases)) (PP (IN of) (NP (NP (CD 65) (NN %)) (CC and) (NP (NP (CD 56) (NN %)) (PP (IN of) (NP (NP (JJ Doc_2826064_890_901_Chemical) (NN volume)) (PP (IN of) (NP (NN distribution) (CC and) (NN clearance)))))) (, ,) (ADVP (RB respectively)) (, ,)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 130) (NN %)) (PP (IN of) (NP (PRP$ its) (NNS AUC)))))))) (. .)))
2826064	7	(S1 (S (PP (IN In) (NP (NP (NN spite)) (PP (IN of) (NP (JJR higher) (NNP Doc_2826064_1009_1020_Chemical) (NNS concentrations))) (PP (IN after) (NP (JJ Doc_2826064_1042_1052_Chemical) (NN pretreatment))))) (, ,) (NP (DT the) (NNP Doc_2826064_1071_1082_Disease)) (VP (AUX was) (ADVP (RB almost) (RB completely)) (VP (VBN antagonized) (PP (IN by) (NP (DT the) (JJ beta) (JJ 2-blocking) (NN action))))) (. .)))
2840807	0	(S1 (NP (NP (DT A) (JJ Doc_2840807_2_10_Disease-like) (NN syndrome)) (PP (IN after) (NP (NP (JJ neuropeptide) (PRN (-LRB- -LRB-) (NP (NNP Doc_2840807_45_48_Chemical/Doc_2840807_49_53_Chemical)) (-RRB- -RRB-)) (NN stimulation)) (PP (IN of) (NP (DT the) (NN rat) (NN locus) (NN ceruleus))))) (. .)))
2840807	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_2840807_98_115_Disease)) (VP (VBN investigated) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (AUX has) (NP (DT some) (NNS features)) (PP (IN in) (NP (NP (NN common)) (PP (IN with) (NP (JJ human) (JJ idiopathic) (NN Doc_2840807_196_204_Disease))))))) (, ,) (CC and) (S (NP (NP (NN information)) (VP (VBN obtained) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (JJ potential) (JJ clinical) (NN benefit)))))) (. .)))
2840807	2	(S1 (S (NP (DT The) (JJ present) (JJ experimental) (NNS results)) (VP (VBD indicated) (SBAR (S (NP (NP (DT that) (JJ peptidergic) (NN stimulation)) (PP (IN of) (NP (DT the) (NNS LC)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ NE-mediated) (NN inhibition)) (PP (IN of) (NP (NP (JJ cerebellar) (NNP Purkinje) (NNS cells)) (VP (VBN located) (PP (IN at) (NP (NP (NNS terminals)) (PP (IN of) (NP (DT the) (JJ ceruleo-cerebellar) (NN pathway)))))))))))))) (. .)))
2840807	3	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ certain) (SBAR (IN as) (FRAG (PP (TO to) (NP (DT the) (NN following))) (: :) (PRN (-LRB- -LRB-) (NP (DT a)) (-RRB- -RRB-)) (WHNP (WP what)) (S (NP (NNS receptors)) (VP (AUX were) (VP (VBN stimulated) (PP (IN by) (NP (NP (DT the) (JJ Doc_2840807_580_584_Chemical) (JJ N-terminal) (NNS fragments)) (PP (IN at) (NP (NP (DT the) (NN LC)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT this) (NN disorder)) (PRN (: ;) (-LRB- -LRB-) (NP (NNP b)) (-RRB- -RRB-)) (PP (IN whether) (NP (NNP NE))) (, ,) (VP (VBN released) (PP (IN onto) (NP (NP (NNP Purkinje) (NN cell) (NNS synapses)) (VP (VBN located) (PP (IN at) (NP (NP (NNS terminals)) (PP (IN of) (NP (NP (DT the) (JJ ceruleo-cerebellar) (NN pathway)) (, ,) (SBAR (S (VP (AUX did) (RB indeed) (VP (VB cause) (NP (DT the) (JJ long-term) (NNP Doc_2840807_788_798_Disease)) (PP (IN at) (NP (NP (NP (NP (NP (NP (NNP Purkinje) (NN cell) (NNS synapses)) (PRN (-LRB- -LRB-) (VP (ADVP (RB previously)) (VBN described) (PP (IN by) (NP (NNS others)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (JJ long) (NN duration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2840807_900_917_Disease)) (PRN (: ;) (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (PP (IN whether) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (JJ inhibitory) (NNP Purkinje) (NNS cells))))))))))))) (VP (VBD resulted) (PP (IN in) (NP (NN disinhibition))))) (CC or) (NP (VBN increased) (NN excitability))) (PP (IN of) (NP (DT the) (JJ unilateral) (NN cerebellar) (NN fastigial)))) (CC or) (JJ interpositus) (FW nuclei) (, ,) (NP (NP (DT the) (NN output) (NNS targets)) (PP (IN of) (NP (NP (DT the) (NNP Purkinje) (NN cell) (NNS axons)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT an) (JJ important) (JJ contributing) (NN factor)) (PP (TO to) (NP (DT this) (NN disorder)))))))))))))))))))))))))))))))))))))))))) (. .)))
2840807	4	(S1 (S (NP (DT These) (NNS questions)) (VP (AUX are) (ADVP (RB currently)) (VP (AUXG being) (VP (VBN investigated)))) (. .)))
2886572	0	(S1 (S (NP (NP (JJ Enhanced) (JJ stimulus-induced) (NN neurotransmitter) (NN overflow)) (PP (IN in) (NP (JJ Doc_2886572_55_66_Chemical-induced) (JJ Doc_2886572_75_87_Disease) (NNS rats)))) (VP (AUX is) (RB not) (VP (VBN mediated) (PP (IN by) (NP (JJ prejunctional) (NN beta-adrenoceptor) (NN activation))))) (. .)))
2886572	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ examines) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ 6-day) (JJ Doc_2886572_203_214_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NNS micrograms/kg)) (PP (IN per) (NP (NP (NNP h)) (, ,) (NP (NNP s.c.))))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ stimulus-induced) (PRN (-LRB- -LRB-) (NP (CD 1) (NNPS Hz)) (-RRB- -RRB-)) (JJ endogenous) (NN neurotransmitter) (NN overflow)) (PP (IN from) (NP (NP (DT the) (VBN isolated) (JJ perfused) (NN kidney)) (PP (IN of) (NP (ADJP (JJ vehicle-) (CC and) (JJ Doc_2886572_371_382_Chemical-treated)) (NNS rats))))))))) (. .)))
2886572	2	(S1 (S (NP (NP (NP (JJ Renal) (JJ Doc_2886572_403_416_Chemical) (NNS stores)) (CC and) (NP (JJ stimulus-induced) (NN overflow))) (PP (IN in) (NP (DT the) (JJ vehicle-treated) (NN group)))) (VP (VBD consisted) (PP (IN of) (NP (NNP Doc_2886572_496_510_Chemical) (RB only)))) (. .)))
2886572	3	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_2886572_526_537_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN incorporation)) (PP (IN of) (NP (NNP Doc_2886572_581_592_Chemical))))) (PP (IN into) (NP (NP (JJ renal) (JJ Doc_2886572_604_617_Chemical) (NNS stores)) (ADJP (JJ such) (SBAR (IN that) (S (NP (NP (QP (RB approximately) (CD 40)) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_2886572_660_673_Chemical) (NN present)))) (VP (AUX was) (ADJP (JJ Doc_2886572_686_697_Chemical)) (SBAR (IN while) (S (NP (DT the) (JJ Doc_2886572_708_722_Chemical) (NN content)) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (DT a) (JJ similar) (NN degree)))))))))))))) (. .)))
2886572	4	(S1 (S (NP (NP (JJ Total) (NN tissue) (NN Doc_2886572_777_790_Chemical) (NN content)) (PP (IN of) (NP (DT the) (NN kidney))) (PP (IN on) (NP (DT a) (JJ molar) (NN basis)))) (VP (AUX was) (ADJP (JJ unchanged))) (. .)))
2886572	5	(S1 (S (NP (NP (JJ Stimulus-induced) (JJ fractional) (NN overflow)) (PP (IN of) (NP (NN neurotransmitter))) (PP (IN from) (NP (DT the) (JJ Doc_2886572_911_922_Chemical-treated) (NNS kidneys)))) (VP (VP (AUX was) (ADJP (RB approximately) (RB twice) (JJ normal))) (CC and) (VP (VBD consisted) (PP (IN of) (NP (DT both) (NNP Doc_2886572_992_1006_Chemical) (CC and) (NNP Doc_2886572_1011_1022_Chemical))) (PP (IN in) (NP (NP (NNS proportions)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (DT the) (NN kidney))))))))))) (. .)))
2886572	6	(S1 (S (NP (NP (DT This) (NN difference)) (PP (IN in) (NP (JJ fractional) (NN overflow))) (PP (IN between) (NP (NNS groups)))) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN neuronal)) (CC and) (NP (JJ extraneuronal) (JJ uptake) (NN blockade)))))) (. .)))
2886572	7	(S1 (S (NP (NN Doc_2886572_1194_1205_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ stimulus-induced) (NN overflow)) (PP (IN in) (NP (DT either) (NN group)))))) (. .)))
2886572	8	(S1 (S (NP (NN Doc_2886572_1266_1278_Chemical)) (VP (VBD increased) (NP (JJ stimulus-induced) (NN overflow)) (PP (IN in) (NP (DT both) (NNS groups))) (SBAR (IN although) (S (NP (NP (DT the) (NN increment)) (PP (IN in) (NP (NN overflow)))) (VP (AUX was) (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (JJ Doc_2886572_1384_1395_Chemical-treated) (NN group))))))) (. .)))
2886572	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ chronic) (JJ Doc_2886572_1434_1445_Chemical) (NN treatment)) (VP (VBZ results) (PP (IN in) (NP (JJ enhanced) (JJ fractional) (NN neurotransmitter) (NN overflow)))) (. .)))
2886572	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT neither) (NNS alterations)) (PP (IN in) (NP (NP (JJ prejunctional) (JJ beta-adrenoceptor) (NNS influences)) (CC nor) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN neuronal)) (CC and) (NP (JJ extraneuronal) (JJ uptake) (NNS mechanisms)))))))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN alteration)))))))) (. .)))
2886572	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NNS data)) (VP (VBN obtained) (PP (IN with) (NP (NNP Doc_2886572_1731_1743_Chemical))))) (ADVP (RB alone)) (VP (AUX do) (RB not) (VP (VB suggest) (NP (NN alpha-adrenoceptor) (NN desensitization)) (PP (IN as) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (JJ enhanced) (NN neurotransmitter) (NN overflow)) (PP (IN after) (NP (JJ Doc_2886572_1861_1872_Chemical) (NN treatment))))))))) (. .)))
2893236	0	(S1 (S (NP (NP (JJ Doc_2893236_0_4_Chemical) (NN involvement)) (PP (IN in) (NP (NP (JJ Doc_2893236_20_28_Chemical) (VBN induced) (NN reversal)) (PP (IN of) (NP (NNP Doc_2893236_49_70_Disease)))))) (VP (VBD produced) (PP (IN by) (NP (NNP Doc_2893236_83_93_Chemical)))) (. .)))
2893236	1	(S1 (S (NP (DT No) (NN agent)) (VP (AUX is) (ADVP (RB yet)) (ADJP (JJ available)) (S (VP (TO to) (VP (VB reverse) (NP (NP (NN Doc_2893236_132_153_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (JJ CNS) (NNS depressants)) (, ,) (PP (JJ such) (IN as) (NP (JJ general) (NNS anesthetics))))))))))) (. .)))
2893236	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NNP Doc_2893236_226_234_Chemical)) (VP (VP (VBD reversed) (S (NP (NNP Doc_2893236_244_265_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2893236_277_287_Chemical))) (PP (IN in) (NP (NN rats.) (CD 25) (NN mg/kg))) (, ,) (S (VP (VBG i.v.) (NP (JJ Doc_2893236_312_322_Chemical) (VBN produced) (NN anesthesia)) (PP (IN without) (S (VP (VBG altering) (NP (NN respiratory) (NN rate)))))))))) (, ,) (VP (VBD increased) (NP (NNP Doc_2893236_388_392_Chemical))) (, ,) (VP (VBD decreased) (NP (NNP Doc_2893236_404_413_Chemical))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NNP Doc_2893236_436_445_Chemical) (CC or) (NNP Doc_2893236_449_456_Chemical) (NNS levels)))) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))) (PP (IN in) (NP (NP (NN rat) (NN cortex)) (CC and) (NP (NN brain) (NN stem)))))) (. .)))
2893236	3	(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_2893236_541_558_Chemical))))) (PP (IN for) (NP (CD 30) (NNS minutes)))) (VP (VBD abolished) (NP (NP (DT the) (JJ anesthetic) (NN action)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (JJ respiratory) (NN depressant) (NN action)) (PP (IN of) (NP (NNP Doc_2893236_654_664_Chemical.))))) (NP (CD 50) (NN mg/kg)))) (, ,) (CC i.v.) (S (NP (NNP Doc_2893236_681_691_Chemical)) (VP (VBD produced) (NP (NNP Doc_2893236_701_719_Disease)) (PP (IN with) (NP (NP (NP (JJR further) (NN increase)) (PP (IN in) (NP (NNP Doc_2893236_745_749_Chemical)))) (CC and) (NP (NP (NN decrease)) (PP (IN in) (NP (NNP Doc_2893236_766_775_Chemical)))))) (PP (ADVP (RB again)) (IN in) (NP (NP (NN cortex)) (CC and) (NP (NN brain) (NN stem)))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2893236_836_847_Chemical)) (VP (VBN studied) (PP (IN in) (NP (NP (CD four) (NNS regions)) (PP (IN of) (NP (NN rat) (NN brain)))))))))))))) (. .)))
2893236	4	(S1 (S (NP (NP (NNP Doc_2893236_886_894_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg))) (, ,) (NP (NNP i.v.)) (-RRB- -RRB-))) (VP (VBD reversed) (NP (NNP Doc_2893236_922_943_Disease) (, ,) (NNP Doc_2893236_945_954_Chemical) (CC and) (NNP Doc_2893236_959_963_Chemical) (NNS levels)) (PP (TO to) (NP (NN control) (NNS values))) (PP (IN in) (NP (NP (NN brain) (NN stem) (CC and) (NN cortex)) (PP (IN with) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NN caudate) (CC or) (NN cerebellum)))))))) (. .)))
2893236	5	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NNP Doc_2893236_1075_1083_Chemical)) (VP (VP (VBZ reverses) (NP (NP (NNP Doc_2893236_1093_1114_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_2893236_1127_1137_Chemical)))))) (CC and) (VP (VBZ involves) (NP (NP (NN Doc_2893236_1151_1155_Chemical)) (PP (IN in) (NP (PRP$ its) (NN action))))))))) (. .)))
2894433	0	(S1 (S (NP (NN Doc_2894433_0_8_Chemical)) (VP (VBZ facilitates) (NP (NP (JJ reflex) (NN Doc_2894433_28_39_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
2894433	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_2894433_74_82_Chemical))) (PP (IN on) (NP (JJ cardiovascular) (NN function)))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
2894433	2	(S1 (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2894433_173_181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1-30) (CD mg)) (NN kg-1)) (-RRB- -RRB-))))) (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN decrease)) (PP (IN in) (NP (NP (PDT both) (DT the) (JJ mean) (JJ arterial) (NN pressure)) (CC and) (NP (DT the) (NN heart) (NN rate)))))) (. .)))
2894433	3	(S1 (S (ADVP (RB Also)) (, ,) (NP (JJ reflex) (NN Doc_2894433_300_311_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_2894433_360_370_Chemical)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 1.25-2.5) (NNS micrograms)) (JJ kg-1)) (-RRB- -RRB-)))))))) (. .)))
2894433	4	(S1 (S (NP (NP (JJ Intravenous) (NN pretreatment)) (PP (IN of) (NP (DT the) (NNS rats))) (PP (IN with) (NP (NNP Doc_2894433_441_449_Chemical)))) (, ,) (SBAR (IN although) (S (VP (VBG causing) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (DT the) (JJ Doc_2894433_485_495_Chemical-induced) (NN pressor) (NN effect))))))) (, ,) (VP (AUX did) (VP (VB enhance) (NP (DT the) (JJ Doc_2894433_536_546_Chemical-induced) (JJ reflex) (NN Doc_2894433_562_573_Disease)))) (. .)))
2894433	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ Doc_2894433_588_596_Chemical) (NN enhancement)) (PP (IN of) (NP (JJ Doc_2894433_612_622_Chemical-induced) (JJ reflex) (NN Doc_2894433_638_649_Disease)))) (VP (AUX was) (VP (VBN antagonized) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NP (DT an) (JJ intravenous) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2894433_718_728_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agent)) (VP (NNS blocks) (NP (JJ Doc_2894433_746_754_Chemical) (NNS channels)) (PP (IN by) (S (VP (VBG binding) (PP (TO to) (NP (NP (NNS sites)) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ Doc_2894433_804_818_Chemical-Doc_2894433_819_823_Chemical-Doc_2894433_824_832_Chemical) (NN channel) (NN macromolecular) (NN complex))))))))))) (-RRB- -RRB-)))))))))) (. .)))
2894433	6	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_2894433_889_897_Chemical)) (VP (VBZ acts) (PP (IN through) (NP (NP (DT the) (JJ Doc_2894433_915_929_Chemical-Doc_2894433_930_934_Chemical-Doc_2894433_935_943_Chemical) (NN channel) (NN macromolecular) (NN complex)) (PP (IN within) (NP (NP (DT the) (ADJP (JJ central) (JJ nervous)) (NN system)) (SBAR (S (VP (TO to) (VP (VB facilitate) (NP (NP (JJ reflex) (NN Doc_2894433_1030_1041_Disease)) (VP (VBN mediated) (PP (IN through) (NP (NN baroreceptor) (NNS reflexes))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT an) (JJ acute) (NN increase)) (PP (IN in) (NP (JJ arterial) (NN pressure))))))))))))))))))))) (. .)))
28952	0	(S1 (NP (NP (NP (NP (JJ Initial) (JJ Doc_28952_8_17_Chemical) (NN loss)) (CC and) (NP (NP (NN Doc_28952_27_39_Disease)) (PP (IN during) (NP (NNP Doc_28952_47_61_Chemical) (NN administration))))) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (JJ essential) (NNP Doc_28952_104_116_Disease)))) (: :) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ dietary) (JJ Doc_28952_143_149_Chemical) (NN restriction)))) (. .)))
28952	1	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (JJ initial) (JJ Doc_28952_190_199_Chemical) (NN loss) (CC and) (NN development)) (PP (IN of) (NP (NNP Doc_28952_224_236_Disease)))) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT an) (JJ oral) (NN diuretic)))))))) (, ,) (NP (JJ metabolic) (NN balance) (NNS studies)) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (CD ten) (NNS patients))) (PP (IN with) (NP (NP (JJ essential) (NNP Doc_28952_356_368_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN shown) (NP (NNP Doc_28952_383_395_Disease)) (PP (IN under) (NP (JJ prior) (JJ oral) (JJ diuretic) (NN treatment))))))))))) (. .)))
28952	2	(S1 (S (NP (NP (NN Doc_28952_433_447_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg)) (NN daily)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (PP (IN for) (NP (CD 14) (NNS days))))) (. .)))
28952	3	(S1 (S (NP (CD Six) (NNS patients)) (VP (VBD received) (NP (NP (DT a) (JJ normal-Doc_28952_516_522_Chemical) (NN diet)) (CC and) (NP (NP (CD four)) (NP (DT a) (JJ low-Doc_28952_543_549_Chemical) (PRN (-LRB- -LRB-) (NP (CD 17) (NN mmol/day)) (-RRB- -RRB-)) (NN diet))))) (. .)))
28952	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ normal) (JJ initial) (JJ total) (NN body) (NN Doc_28952_615_624_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 40K)) (-RRB- -RRB-)))) (. .)))
28952	5	(S1 (S (NP (NP (DT The) (JJ electrolyte) (NNS balances)) (, ,) (NP (NN weight)) (, ,) (NP (JJ bromide) (NN space)) (, ,) (NP (NN plasma) (NN renin) (NN activity)) (, ,) (CC and) (NP (JJ Doc_28952_708_719_Chemical) (NN secretion) (NN rate))) (VP (AUX were) (VP (VBN measured))) (. .)))
28952	6	(S1 (S (PP (IN In) (NP (DT both) (NNS groups))) (NP (DT a) (JJ Doc_28952_767_776_Chemical) (NN deficit)) (VP (VBD developed) (, ,) (PP (IN with) (NP (NP (ADJP (RB proportionally) (JJR larger)) (NNS losses)) (PP (IN from) (NP (DT the) (NN extracellular))))) (PP (IN than) (PP (IN from) (NP (DT the) (JJ intracellular) (NN compartment))))) (. .)))
28952	7	(S1 (S (S (PP (IN In) (NP (DT the) (JJ normal-Doc_28952_908_914_Chemical) (NN group))) (NP (DT the) (JJS highest) (JJ mean) (JJ Doc_28952_938_947_Chemical) (NN deficit)) (VP (AUX was) (NP (NP (CD 176) (NN mmol)) (PP (IN on) (NP (NN day) (CD 9))) (, ,) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (DT some) (NNP Doc_28952_996_1005_Chemical)) (VP (AUX was) (VP (VBN regained)))))))) (: ;) (S (PP (IN in) (NP (DT the) (JJ low-Doc_28952_1031_1037_Chemical) (NN group))) (NP (DT the) (JJS highest) (NN deficit)) (VP (AUX was) (NP (CD 276) (NN mmol)) (PP (IN on) (NP (NN day) (CD 13))))) (. .)))
28952	8	(S1 (S (S (NP (DT The) (JJ normal-Doc_28952_1099_1105_Chemical) (NN group)) (VP (VBD showed) (NP (NP (DT an) (ADJP (ADJP (JJ immediate)) (CC but) (ADJP (JJ temporary))) (NN rise)) (PP (IN of) (NP (DT the) (JJ renin) (CC and) (JJ Doc_28952_1168_1179_Chemical) (NNS levels)))))) (: ;) (S (PP (IN in) (NP (NP (DT the) (JJ low-Doc_28952_1199_1205_Chemical) (NN group) (NN renin)) (CC and) (NP (NNP Doc_28952_1222_1233_Chemical)))) (VP (VP (VBD increased) (ADVP (RBR more) (RB slowly))) (CC but) (VP (VBD remained) (ADJP (JJ elevated))))) (. .)))
28952	9	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ dietary) (JJ Doc_28952_1308_1314_Chemical) (NN restriction)) (VP (VBZ increases) (NP (JJ diuretic-induced) (JJ Doc_28952_1354_1363_Chemical) (NN loss)) (, ,) (PP (ADVP (RB presumably)) (IN by) (NP (NP (DT an) (JJ increased) (NN activity)) (PP (IN of) (NP (DT the) (JJ renin-Doc_28952_1419_1430_Chemical-Doc_28952_1431_1442_Chemical) (NN system))))) (, ,) (SBAR (IN while) (S (NP (NP (JJ Doc_28952_1457_1463_Chemical) (NN delivery)) (PP (TO to) (NP (DT the) (JJ distal) (JJ renal) (NNS tubules)))) (VP (VBZ remains) (ADJP (RB sufficiently) (JJ high) (SBAR (S (VP (TO to) (VP (VB allow) (NP (VBN increased) (JJ Doc_28952_1546_1555_Chemical) (NN secretion))))))))))))))) (. .)))
2907585	0	(S1 (NP (NP (NN Reversal)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_2907585_32_41_Disease))) (PP (IN by) (NP (JJ novel) (JJ Doc_2907585_51_66_Chemical) (JJ anxiolytic) (NNS drugs))) (. .)))
2907585	1	(S1 (S (NP (NP (DT The) (JJ novel) (JJ anxiolytic) (NN drug)) (, ,) (NP (NNP Doc_2907585_112_121_Chemical)) (, ,)) (VP (VBZ reverses) (NP (NP (NNP Doc_2907585_132_141_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2907585_153_164_Chemical)))))) (. .)))
2907585	2	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NP (JJ Doc_2907585_178_193_Chemical) (NNS analogues)) (PP (IN of) (NP (NP (NNP Doc_2907585_207_216_Chemical)) (CC and) (NP (JJ other) (NNP Doc_2907585_227_259_Chemical))))))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB reverse) (NP (JJ Doc_2907585_301_312_Chemical) (VBN induced) (NN Doc_2907585_321_330_Disease))))))))) (. .)))
2907585	3	(S1 (S (NP (NP (DT Those) (NNS drugs)) (PP (IN with) (NP (JJ strong) (NN affinity))) (PP (IN for) (NP (JJ Doc_2907585_369_388_Chemical1a) (NNS receptors)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB reverse) (NP (NN Doc_2907585_422_431_Disease))))))) (. .)))
2907585	4	(S1 (S (NP (NP (NNS Drugs)) (PP (IN with) (NP (NN affinity))) (PP (IN for) (NP (NP (JJ other) (JJ Doc_2907585_463_467_Chemical) (NNS receptors)) (CC or) (NP (JJ weak) (NN affinity))))) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
2907585	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ postsynaptic) (JJ Doc_2907585_549_553_Chemical) (NNS receptors)))) (VP (CC neither) (VP (VBD inhibited) (CC nor) (VBD potentiated) (NP (NP (NN reversal)) (PP (IN of) (NP (NNP Doc_2907585_610_619_Disease))))) (CC and) (VP (VBZ leaves) (NP (JJ open) (DT the) (NN question)) (PP (IN as) (PP (TO to) (NP (NP (DT the) (NN site) (CC or) (NN mechanism)) (PP (IN for) (NP (DT this) (NN effect)))))))) (. .)))
2917114	0	(S1 (NP (NP (JJ Doc_2917114_0_14_Chemical) (NNS requirements)) (PP (IN for) (NP (NP (NN antagonism)) (PP (IN of) (NP (NP (DT the) (JJ muscarinic) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_2917114_77_88_Chemical))))))) (. .)))
2917114	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN compared) (, ,) (PP (IN in) (NP (CD 60) (NN adult) (NNS patients))) (, ,) (NP (NP (DT the) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2917114_160_174_Chemical) (CD 5) (NNS micrograms)) (ADJP (ADJP (JJ kg-1)) (CC and) (ADJP (NP (CD 10) (NNS micrograms)) (JJ kg-1))) (VP (VBN given) (UCP (DT either) (ADVP (RB simultaneously)) (CC or) (NP (NP (CD 1) (NN min)) (PP (IN before) (NP (NNP Doc_2917114_260_271_Chemical) (CD 1))) (NP (CD mg) (NN kg-1)))))))))) (. .)))
2917114	2	(S1 (S (NP (NP (JJ Significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD four) (NNS groups)))) (VP (AUX were) (VP (VBN detected) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
2917114	3	(S1 (S (NP (NP (DT Both) (NNS groups)) (VP (VBG receiving) (NP (CD 10) (NNS micrograms) (JJ kg-1)))) (VP (VBD showed) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (PP (IN of) (NP (NP (QP (IN up) (TO to) (CD 30) (NN beat)) (NN min-1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NP (NN confidence) (NNS limits))) (ADJP (CD 28-32) (NN beat) (JJ min-1))) (-RRB- -RRB-)))))))) (. .)))
2917114	4	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_2917114_510_524_Chemical) (CD 5) (NN micrograms) (NN kg-1)))) (VP (VP (VBD provided) (NP (JJR greater) (JJ cardiovascular) (NN stability))) (CC and) (VP (, ,) (PP (VBN given) (NP (NP (CD 1) (NN min)) (PP (IN before) (NP (DT the) (NNP Doc_2917114_613_624_Chemical))))) (, ,) (AUX was) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB minimize) (NP (JJ early) (, ,) (JJ Doc_2917114_660_671_Chemical-induced) (NNP Doc_2917114_680_692_Disease)))))))) (. .)))
2917114	5	(S1 (S (NP (NP (DT This) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_2917114_711_725_Chemical)))) (VP (VBD provided) (NP (NP (JJ good) (NN control)) (PP (IN of) (NP (JJ oropharyngeal) (NNS secretions))))) (. .)))
2980315	0	(S1 (NP (NP (JJ Selective) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2980315_23_31_Chemical)) (, ,) (NP (NNP Doc_2980315_33_40_Chemical)) (CC and) (NP (NNP Doc_2980315_45_55_Chemical)))) (PP (IN into) (NP (NP (DT the) (JJ left) (JJ coronary) (NN artery)) (PP (IN of) (NP (DT the) (NN dog))))) (. .)))
2980315	1	(S1 (NP (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NNP Doc_2980315_111_135_Disease)))) (CC and) (NP (NP (NN decrease)) (PP (IN of) (NP (JJ aortic) (NN pressure))))) (. .)))
2980315	2	(S1 (S (PP (IN In) (NP (CD twenty) (JJ beagle) (NNS dogs))) (NP (JJ selective) (NNS injections)) (VP (AUX were) (VP (VBN made) (PP (IN into) (NP (NP (DT the) (JJ left) (JJ coronary) (NN artery)) (PP (IN with) (NP (NP (NNP Doc_2980315_257_265_Chemical) (, ,) (NNP Doc_2980315_267_274_Chemical) (CC and) (NNP Doc_2980315_279_289_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 4) (CD ml))) (, ,) (NP (QP (CD 8) (CD ml))) (CC and) (NP (QP (CD 16) (CD ml))))))))))))) (. .)))
2980315	3	(S1 (S (NP (NP (JJ Thirty-six) (JJ Doc_2980315_335_343_Chemical) (NNS injections)) (, ,) (NP (CD 35) (JJ Doc_2980315_359_366_Chemical) (NNS injections)) (CC and) (NP (CD 37) (JJ Doc_2980315_385_395_Chemical) (NNS injections))) (VP (AUX were) (VP (VBN made))) (. .)))
2980315	4	(S1 (S (NP (NP (NNS Frequencies)) (PP (IN of) (NP (NNP Doc_2980315_433_457_Disease)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD p) (JJR less))) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (PP (IN after) (NP (NP (NP (NNP Doc_2980315_508_516_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2980315_526_533_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN after) (NP (NP (NNP Doc_2980315_550_560_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-)))))) (. .)))
2980315	5	(S1 (S (NP (NP (NNP Doc_2980315_568_576_Chemical)) (CC and) (NP (NNP Doc_2980315_581_588_Chemical))) (ADVP (RB also)) (VP (VBD produced) (NP (NP (ADJP (RB significantly) (JJR less)) (NN decrease)) (PP (IN in) (NP (JJ aortic) (NN blood) (NN pressure))) (PP (IN than) (NP (NNP Doc_2980315_661_671_Chemical)))) (PP (IN at) (NP (DT the) (JJ different) (NNS doses)))) (. .)))
3001299	0	(S1 (NP (NP (NP (JJ Thyroid) (NN function)) (CC and) (NP (JJ urine-concentrating) (NN ability))) (PP (IN during) (NP (JJ Doc_3001299_56_63_Chemical) (NN treatment))) (. .)))
3001299	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (SBAR (IN that) (S (NP (JJ adenylate) (NN cyclase) (NN inhibition)) (VP (MD may) (VP (AUX be) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT both) (NNP Doc_3001299_175_205_Disease) (CC and) (NNP Doc_3001299_210_224_Disease))))) (PP (IN during) (NP (JJ Doc_3001299_232_239_Chemical) (NN treatment)))))))))) (. .)))
3001299	2	(S1 (S (NP (PRP We)) (VP (VBD measured) (NP (NP (JJ serum) (NN Doc_3001299_269_278_Chemical)) (CC and) (NP (NP (JJ urine-concentrating) (NN ability)) (PRN (-LRB- -LRB-) (NP (NNP Umax)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN desmopressin)) (PRN (-LRB- -LRB-) (NP (NN DDAVP)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (CD 85) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3001299_379_386_Chemical)))))) (. .)))
3001299	3	(S1 (S (NP (NN Doc_3001299_388_402_Disease)) (VP (VBD developed) (PP (IN in) (NP (CD eight) (NNS patients))) (SBAR (IN while) (S (NP (PRP they)) (VP (AUX were) (VP (VBG taking) (NP (NN Doc_3001299_454_461_Chemical))))))) (. .)))
3001299	4	(S1 (S (NP (VBN Impaired) (NN Umax)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT both) (NN euthyroid) (CC and) (NN Doc_3001299_509_520_Disease) (NNS patients))) (SBAR (IN while) (S (NP (DT some) (NNP Doc_3001299_541_552_Disease) (NNS patients)) (VP (VBD concentrated) (NP (PRP$ their) (NN urine)) (ADVP (RB well))))))) (. .)))
3001299	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (DT the) (JJ dominant) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_3001299_647_654_Chemical)) (VP (VBZ exerts) (NP (DT these) (CD two) (NNS effects)))))) (VP (AUX are) (ADJP (JJ different))))))) (. .)))
3015327	0	(S1 (NP (NP (NN Remodelling)) (PP (IN of) (NP (NN nerve) (NN structure))) (PP (IN in) (NP (NP (JJ experimental) (NNP Doc_3015327_47_56_Chemical) (NNP Doc_3015327_57_67_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
3015327	1	(S1 (S (NP (NP (DT The) (NN Doc_3015327_84_94_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_3015327_122_131_Chemical))) (PP (IN in) (NP (NNS rats))))))) (VP (AUX was) (VP (VBN studied) (PP (IN with) (NP (DT a) (JJ computer-assisted) (NN morphometric) (NN method))))) (. .)))
3015327	2	(S1 (S (NP (NP (NN Scatter) (NNS diagrams)) (PP (IN of) (NP (NP (DT the) (NNP g) (NN ratio)) (PRN (-LRB- -LRB-) (NP (JJ quotient) (NN fibre) (NN diameter/axon) (NN diameter)) (-RRB- -RRB-))))) (VP (VB define) (NP (NP (JJ regenerating) (NNS fibres)) (PP (IN as) (NP (NP (DT a) (JJ distinct) (NN population)) (, ,) (ADJP (JJ distinguishable) (PP (IN from) (NP (NP (DT the) (VBG surviving) (NNS fibres)) (PP (IN by) (NP (NP (VBN reduced) (NN sheath) (NN thickness)) (CC and) (NP (VBN reduced) (NN axon) (NN calibre))))))))))) (. .)))
3015327	3	(S1 (S (NP (EX There)) (VP (AUX was) (ADVP (RB also)) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ subtle) (JJ direct) (JJ toxic) (NN effect)) (PP (IN on) (NP (DT the) (JJ entire) (NN fibre) (NN population)))))) (, ,) (S (VP (VBG causing) (NP (NP (NN axon) (NN shrinkage)) (VP (VBN masked) (PP (IN by) (NP (NP (NN readjustment)) (PP (IN of) (NP (DT the) (JJ myelin) (NN sheath)))))))))) (. .)))
3057041	0	(S1 (S (NP (NP (NNP Multicenter)) (, ,) (ADJP (JJ double-blind) (, ,) (JJ multiple-dose)) (, ,)) (VP (VBZ parallel-groups) (NP (NP (NP (NP (NN efficacy)) (CC and) (NP (NN safety) (NN trial))) (PP (IN of) (NP (NP (NNP Doc_3057041_87_97_Chemical)) (, ,) (NP (NNP Doc_3057041_99_115_Chemical)) (, ,)))) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3057041_149_173_Disease)))))))) (. .)))
3057041	1	(S1 (S (NP (NP (NNP Doc_3057041_175_185_Chemical)) (, ,) (NP (DT a) (JJ novel) (JJ antiallergic) (NN medication)) (, ,)) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_3057041_238_262_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN for) (NP (NP (NP (NN efficacy)) (CC and) (NP (NN safety))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_3057041_319_343_Disease)) (PP (IN in) (NP (DT a) (JJ multicenter) (, ,) (JJ double-blind) (, ,) (JJ multiple-dose) (, ,) (JJ parallel-groups) (NN study)))))))))))))) (. .)))
3057041	2	(S1 (S (NP (QP (CD One) (CD hundred)) (JJ fifty-five) (NNS subjects)) (VP (VBD participated)) (. .)))
3057041	3	(S1 (S (NP (NNS Subjects)) (VP (VP (VBD ranged) (PP (IN in) (NP (NN age))) (PP (IN from) (NP (NP (QP (CD 18) (TO to) (CD 60)) (NNS years)) (PP (IN of) (NP (NN age)))))) (CC and) (VP (AUX had) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (JJ 2-year) (NN history)) (PP (IN of) (NP (NNP Doc_3057041_547_571_Disease))) (, ,) (VP (VBN confirmed) (PP (IN by) (NP (NP (JJ positive) (NN skin) (NN test)) (PP (TO to) (NP (NN spring) (NNS aeroallergens))))))))) (. .)))
3057041	4	(S1 (S (S (NP (NNS Medications)) (VP (AUX were) (VP (VBN given) (NP (CD four) (NNS times)) (ADVP (RB daily))))) (: ;) (S (NP (DT the) (JJ Doc_3057041_675_685_Chemical) (NNS groups)) (VP (VBD received) (NP (NP (CD 0.5)) (, ,) (NP (CD 1.0)) (, ,) (CC or) (NP (NP (QP (CD 2.0) (CD mg))) (PP (IN in) (NP (DT the) (NN morning) (CC and) (NN evening))))) (PP (IN with) (NP (NN placebo))) (PP (IN in) (NP (DT the) (JJ early) (CC and) (JJ late) (NN afternoon))))) (: ;) (S (NP (DT the) (NNP Doc_3057041_799_815_Chemical) (NN group)) (VP (VBD received) (NP (CD 4.0) (NN mg)) (ADVP (NP (CD four) (NNS times)) (RB daily)))) (. .)))
3057041	5	(S1 (S (NP (JJ Daily) (NN subject) (NN symptom) (NNS cards)) (VP (AUX were) (VP (VBN completed) (PP (IN during) (NP (NP (DT a) (NN screening) (NN period)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (JJ pretreatment) (NNS symptoms)) (PP (CC and) (PP (IN during) (NP (NP (DT a) (JJ 4-week) (NN treatment) (NN period)) (SBAR (WHNP (IN while)) (S (NP (NNS subjects)) (VP (VBD received) (NP (NN study) (NNS medications)))))))))))))))) (. .)))
3057041	6	(S1 (S (NP (NP (JJ Individual) (NNS symptoms)) (, ,) (NP (JJ total) (NNS symptoms)) (, ,) (CC and) (NP (JJ major) (NNS symptoms))) (VP (AUX were) (VP (VBN compared) (S (VP (TO to) (VP (VB determine) (NP (NP (NN efficacy)) (PP (IN of) (NP (NN medication))))))))) (. .)))
3057041	7	(S1 (S (VP (VP (VBD Elicited)) (, ,) (VP (VBD volunteered)) (, ,) (CC and) (VP (VBD observed) (SBAR (S (NP (JJ adverse) (NNS experiences)) (VP (AUX were) (VP (VP (VBN recorded) (PP (IN for) (NP (DT each) (NN subject)))) (CC and) (VP (VBN compared) (PP (IN among) (NP (NNS groups)))))))))) (. .)))
3057041	8	(S1 (S (NP (NP (JJ Vital) (NNS signs)) (, ,) (NP (NN body) (NNS weights)) (, ,) (NP (NN serum) (NN chemistry) (NNS values)) (, ,) (NP (JJ complete) (NN blood) (NN cell) (NNS counts)) (, ,) (NP (NN urine) (NNS studies)) (, ,) (CC and) (NP (NNS electrocardiograms))) (VP (AUX were) (VP (VP (VBN obtained) (PP (IN for) (NP (DT each) (NN subject)))) (CC and) (VP (VBN compared) (PP (IN among) (NP (NNS groups)))))) (. .)))
3057041	9	(S1 (S (NP (NP (NNS Symptoms) (NN relief)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBG receiving) (NP (NP (DT the) (JJS highest) (NN concentration)) (PP (IN of) (NP (NNP Doc_3057041_1501_1511_Chemical))))))) (PRN (-LRB- -LRB-) (ADJP (QP (CD 2.0) (CD mg)) (RB twice) (JJ daily)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (RB statistically) (JJR greater)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))) (PP (IN during) (NP (NP (DT all) (NNS weeks)) (PP (IN of) (NP (DT the) (NN study)))))) (. .)))
3057041	10	(S1 (S (NP (NP (JJR Lower) (NNS doses)) (PP (IN of) (NP (NNP Doc_3057041_1631_1641_Chemical)))) (VP (AUX were) (ADJP (RB statistically) (RBR more) (JJ effective)) (PP (IN than) (NP (NN placebo))) (PP (ADVP (RB only)) (IN during) (NP (NP (NNS portions)) (PP (IN of) (NP (NP (DT the) (JJ first) (CD 3) (NNS weeks)) (PP (IN of) (NP (DT the) (NN study)))))))) (. .)))
3057041	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ Doc_3057041_1771_1787_Chemical) (NN group)) (VP (AUX did) (VP (AUX have) (NP (JJR fewer) (NNS symptoms)) (PP (IN than) (NP (DT the) (NN placebo) (NN group))) (PP (IN during) (NP (DT the) (NN study))))))) (, ,) (NP (DT the) (NN difference)) (ADVP (RB never)) (VP (VBD reached) (NP (JJ statistical) (NN significance)) (PP (IN during) (NP (NP (DT any) (NN week)) (PP (IN of) (NP (DT the) (NN study)))))) (. .)))
3057041	12	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ serious) (NN side) (NNS effects)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN treatment) (NNS groups)))))) (. .)))
3057041	13	(S1 (S (NP (NP (NNP Doc_3057041_2010_2020_Disease)) (CC and) (NP (NNP Doc_3057041_2025_2049_Disease))) (VP (AUX were) (VP (VBN increased) (ADVP (RB significantly)) (PP (IN over) (NP (NN placebo))) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ high-dose) (JJ Doc_3057041_2114_2124_Chemical) (NN group))))) (. .)))
3057041	14	(S1 (S (NP (NN Doc_3057041_2132_2142_Chemical)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ safe) (, ,) (JJ efficacious) (NN medication)) (PP (IN for) (NP (NN Doc_3057041_2192_2218_Disease)))))))) (. .)))
3084782	0	(S1 (S (VP (VBP Doc_3084782_0_8_Disease) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ remission) (VBG inducing) (NNS drugs)) (PP (IN in) (NP (NNP Doc_3084782_44_64_Disease))))))) (. .)))
3084782	1	(S1 (S (NP (NP (NN Association)) (PP (IN with) (NP (NP (NNP HLA-B35)) (CC and) (NP (NNP Cw4))))) (VP (VBZ antigens)) (. .)))
3084782	2	(S1 (S (NP (NP (NP (CD Twenty-five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_3084782_135_155_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3084782_157_159_Disease)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3084782_175_183_Disease)) (SBAR (IN while) (S (VP (VBG taking) (NP (JJ remission) (VBG inducing) (NNS drugs))))))))))) (CC and) (NP (NP (CD 30)) (PP (IN without) (NP (NNP Doc_3084782_237_245_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (JJ possible) (NNS associations))) (PP (IN with) (NP (NP (NN class) (NN I)) (CC and) (NP (NNP II) (NNP HLA) (NNS antigens)))))) (. .)))
3084782	3	(S1 (S (NP (DT A) (JJ strong) (NN association)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (PP (IN between) (NP (NP (NP (NNP Doc_3084782_363_372_Disease) (CC and) (NNP Doc_3084782_377_387_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (NNP Doc_3084782_395_404_Chemical)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ Doc_3084782_408_423_Chemical) (JJ like) (NN compound)) (-RRB- -RRB-))) (CC and) (NP (NN class) (NN I))))) (NNS antigens)) (ADJP (JJ B35-Cw4)))) (, ,) (CC and) (PP (IN between) (NP (NNP Doc_3084782_481_491_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_3084782_499_503_Chemical) (NNP Doc_3084782_504_516_Chemical) (CC and) (NNP B35))))))) (. .)))
3084782	4	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ healthy) (NNS controls)))) (NP (DT a) (JJR lower) (NN DR5) (NN frequency)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3084782_607_609_Disease))))) (PP (IN except) (PP (IN for) (NP (DT the) (JJ Doc_3084782_625_634_Chemical) (JJ related) (NN Doc_3084782_643_652_Disease) (NN group)))))) (. .)))
3088349	0	(S1 (S (NP (NP (JJ Transient) (NN Doc_3088349_10_32_Disease)) (VP (VBG following) (NP (JJ unilateral) (NNP Doc_3088349_54_77_Disease)))) (VP (VBZ reflects) (NP (NP (NN susceptibility)) (PP (IN of) (NP (DT the) (JJ nigrostriatal) (NN system))) (PP (TO to) (NP (NN exhaustion))) (PP (IN by) (NP (NNP Doc_3088349_147_158_Chemical))))) (. .)))
3088349	1	(S1 (S (PP (VBG Following) (NP (JJ unilateral) (JJ Doc_3088349_181_187_Chemical) (VBN induced) (NN Doc_3088349_196_205_Disease))) (, ,) (NP (NP (DT a) (JJ transient) (NN period)) (PP (IN of) (NP (NNP Doc_3088349_229_251_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB precede) (NP (DT the) (JJ predominant) (NN Doc_3088349_297_317_Disease)))))))) (. .)))
3088349	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (DT this) (JJ initial) (NN Doc_3088349_366_388_Disease)))))))) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN recovery) (NN period)))))) (PP (IN after) (NP (DT the) (NN lesion))) (, ,) (PP (IN on) (NP (NNP Doc_3088349_468_479_Chemical-induced) (NNP Doc_3088349_488_507_Disease)))) (. .)))
3088349	3	(S1 (S (NP (NP (CD Three) (NNS days)) (PP (IN post) (NP (NN lesion) (, ,) (JJS most) (NNS rats)))) (VP (VBD circled) (ADVP (RB predominantly)) (ADVP (RB contralaterally)) (PP (TO to) (NP (DT the) (NN lesion)))) (. .)))
3088349	4	(S1 (S (NP (JJ Such) (NN Doc_3088349_601_623_Disease)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (NP (DT either) (JJ degeneration-induced) (NN breakdown)) (PP (IN of) (NP (DT the) (NN DA) (NN pool)))) (, ,) (CC or) (NP (NP (JJ lesion-induced) (NN increase)) (PP (IN of) (NP (NN DA) (NN turnover)))))) (PP (IN in) (NP (DT the) (VBN spared) (NNS neurons))))) (. .)))
3088349	5	(S1 (S (NP (NP (DT A) (JJ substantial) (NN degree)) (PP (IN of) (NP (JJ contralateral) (NN preference)))) (VP (AUX was) (ADVP (RB still)) (ADJP (JJ evident)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3088349_831_842_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN for) (NP (NP (NP (DT the) (JJ first) (NN time)) (NP (CD 24) (NNS days))) (PP (IN after) (NP (NN lesioning))))) (, ,) (S (VP (VBG indicating) (NP (NP (NN involvement)) (PP (IN of) (NP (NP (VBN spared) (NNS cells)) (PP (IN in) (NP (DT the) (NNP Doc_3088349_950_972_Disease))))))))))))) (. .)))
3088349	6	(S1 (S (ADVP (RB However)) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN recovery)) (PRN (-LRB- -LRB-) (CC and) (NP (NP (NP (RB irrespective)) (PP (IN of) (NP (DT either) (NN lesion) (NN volume)))) (, ,) (NP (JJ Doc_3088349_1065_1076_Chemical) (NN dose)) (, ,) (CC or) (NP (NN post-lesion) (NN motor) (NN exercise))) (-RRB- -RRB-))))))) (, ,) (NP (NNP Doc_3088349_1115_1126_Chemical-induced) (NNP Doc_3088349_1135_1143_Disease)) (VP (VBD tended) (S (VP (TO to) (VP (VB become) (ADJP (ADVP (RB gradually) (RBR more)) (JJ ipsilateral)) (SBAR (IN as) (S (S (NP (DT the) (NN observation) (NN session)) (VP (VBD progressed))) (, ,) (CC and) (S (NP (DT all) (NNS rats)) (VP (VBD circled) (ADVP (RB ipsilaterally)) (PP (TO to) (NP (DT the) (NN lesion))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ further) (JJ Doc_3088349_1299_1310_Chemical) (NNS injections))))))))))))) (. .)))
3088349	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3088349_1351_1362_Chemical)) (VP (AUX has) (NP (NP (DT an) (JJ irreversible) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ post-lesion) (NN DA) (NN pool)) (VP (VBG contributing) (PP (TO to) (NP (NN Doc_3088349_1433_1455_Disease))))))))))) (. .)))
3108839	0	(S1 (S (NP (NN Doc_3108839_0_11_Chemical)) (VP (VBN associated) (NP (NNP Doc_3108839_23_48_Disease))) (. .)))
3108839	1	(S1 (S (NP (NP (JJ Doc_3108839_50_61_Chemical) (JJ associated) (NNP Doc_3108839_73_98_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3108839_100_103_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ fatal) (CC but) (JJ uncommon)) (NN condition)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (RB not) (ADVP (RB yet)) (VP (ADVP (RB widely)) (VBN recognised))))))) (. .)))
3108839	2	(S1 (S (NP (PRP It)) (VP (VP (VBZ consists) (PP (IN of) (NP (NP (JJ microangiopathic) (NN Doc_3108839_218_234_Disease)) (, ,) (NP (NNP Doc_3108839_236_252_Disease)) (CC and) (NP (NP (JJ progressive) (NN Doc_3108839_269_282_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3108839_299_310_Chemical) (NN treatment)))))))) (CC and) (VP (VBZ affects) (NP (NP (QP (RB about) (CD 10)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT this) (NN agent))))))))) (. .)))
3108839	3	(S1 (S (S (NP (DT The) (NNP Doc_3108839_384_397_Disease)) (ADVP (RB usually)) (VP (VBZ develops) (PP (IN about) (NP (CD 8-10) (NN mth))) (PP (IN after) (NP (NP (NN start)) (PP (IN of) (NP (JJ Doc_3108839_445_456_Chemical) (NN treatment))))))) (CC and) (S (NP (DT the) (NN mortality)) (VP (AUX is) (NP (NP (QP (RB approximately) (CD 60)) (NN %)) (PP (IN from) (NP (NP (NNP Doc_3108839_511_524_Disease)) (CC or) (NP (NNP Doc_3108839_528_543_Disease))))))) (. .)))
3108839	4	(S1 (S (NP (NN Doc_3108839_545_558_Disease)) (VP (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (JJ idiopathic) (NNP Doc_3108839_599_602_Disease)))))))) (CC and) (VP (VBP include) (NP (NP (JJ arteriolar) (NN fibrin) (NN Doc_3108839_633_640_Disease)) (, ,) (NP (NP (VBN expanded) (NN subendothelial) (NNS zones)) (PP (IN in) (NP (JJ glomerular) (NN capillary) (NNS walls)))) (, ,) (NP (NP (NNP Doc_3108839_703_711_Disease) (NN wrinkling)) (PP (IN of) (NP (JJ glomerular) (NN basement) (NNS membranes)))) (CC and) (NP (NN mesangiolysis))))) (. .)))
3108839	5	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (AUX is) (VP (VBN postulated) (PP (IN as) (NP (JJ Doc_3108839_815_826_Chemical-induced) (JJ endothelial) (NN cell) (NN damage))))) (. .)))
3108839	6	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (JJ clinical) (NN course)) (CC and) (NP (JJ pathological) (NNS findings))) (PP (IN in) (NP (NP (DT a) (CD 65) (JJ yr-old) (NN man)) (PP (IN with) (NP (NP (NNP Doc_3108839_942_964_Disease)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed) (NP (NNP Doc_3108839_979_992_Disease) (CC and) (NNP Doc_3108839_997_1013_Disease) (NN while)) (PP (IN on) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_3108839_1038_1049_Chemical)))) (CC and) (VP (VBD died) (PP (IN in) (NP (NNP Doc_3108839_1062_1077_Disease)))))))))))) (. .)))
3115150	0	(S1 (S (NP (JJ Doc_3115150_0_10_Chemical) (NN pretreatment)) (VP (VBZ reverses) (NP (JJ Doc_3115150_33_43_Chemical-induced) (NN Doc_3115150_52_67_Disease))) (. .)))
3115150	1	(S1 (S (NP (NP (JJ Systemic) (NN pretreatment)) (PP (IN with) (NP (NP (NNP Doc_3115150_96_106_Chemical)) (, ,) (NP (DT a) (ADJP (RB relatively) (JJ specific)) (JJ type-2) (JJ Doc_3115150_137_146_Chemical) (NN receptor) (NN antagonist)) (, ,)))) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NP (DT the) (NNP Doc_3115150_197_212_Disease)) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (DT the) (JJ potent) (JJ short-acting) (NN opiate) (NN agonist) (NNP Doc_3115150_272_282_Chemical)))))) (. .)))
3115150	2	(S1 (S (PP (VBG Following) (NP (NP (NN placement)) (PP (IN of) (NP (JJ subcutaneous) (NNS electrodes))) (PP (IN in) (NP (NP (DT each) (NN animal) (POS 's)) (JJ left) (JJ gastrocnemius) (NN muscle))))) (, ,) (NP (NNP Doc_3115150_375_383_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG analyzing) (NP (JJ root-mean-square) (JJ electromyographic) (NN activity))))))) (. .)))
3115150	3	(S1 (S (NP (NP (JJ Intraperitoneal) (JJ Doc_3115150_471_481_Chemical) (NN administration)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 0.63) (CC and) (CD 2.5) (NN mg/kg)))))) (VP (VBD prevented) (NP (NP (DT the) (JJ Doc_3115150_542_552_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ electromyographic) (NN activity)))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NN saline)))))))) (. .)))
3115150	4	(S1 (S (NP (NP (NN Doc_3115150_646_662_Chemical)) (PP (IN at) (NP (QP (NNS doses) (IN up) (TO to) (CD 10)) (NNS mg/kg)))) (VP (VBD failed) (S (VP (TO to) (VP (ADVP (RB significantly)) (VB influence) (NP (NP (DT the) (NN Doc_3115150_725_733_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3115150_746_756_Chemical))))))))) (. .)))
3115150	5	(S1 (S (PP (IN Despite) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_3115150_781_789_Disease))))) (, ,) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_813_823_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (JJR greater) (IN than) (CD 0.31) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_3115150_867_877_Chemical))))))))) (VP (AUX were) (ADJP (ADJP (JJ motionless)) (, ,) (ADJP (JJ flaccid)) (, ,) (CC and) (ADJP (RBR less) (JJ responsive) (PP (TO to) (NP (JJ external) (NNS stimuli)))) (SBAR (IN than) (S (VP (AUX were) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NNP Doc_3115150_972_982_Chemical)) (ADVP (RB alone))))))))) (. .)))
3115150	6	(S1 (S (NP (NP (NNS Rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_1009_1019_Chemical)) (CC and) (NP (NNP Doc_3115150_1024_1034_Chemical))))))) (VP (VBD exhibited) (NP (JJR less) (NN rearing) (CC and) (JJ exploratory) (NN behavior)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (JJ 60-min) (NN recording) (NN period)) (SBAR (IN than) (S (VP (AUX did) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_1156_1166_Chemical)) (ADVP (RB alone))))))))))))))) (. .)))
3115150	7	(S1 (S (NP (DT These) (NNS results)) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ previous) (NN work))))) (, ,) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_3115150_1237_1252_Disease)) (, ,) (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN side-effect)) (PP (IN of) (NP (JJ parenteral) (JJ narcotic) (NN administration)))) (, ,)) (VP (MD may) (VP (AUX be) (ADVP (RB partly)) (VP (VBN mediated) (PP (IN via) (NP (JJ serotonergic) (NNS pathways))))))))) (. .)))
3115150	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (JJ type-2) (JJ Doc_3115150_1402_1411_Chemical) (NNS antagonists)))) (VP (MD may) (VP (AUX be) (ADJP (RB clinically) (JJ useful) (PP (IN in) (S (VP (VBG attenuating) (NP (JJ opiate-induced) (NNP Doc_3115150_1479_1487_Disease)))))) (, ,) (SBAR (IN although) (S (NP (JJ further) (NNS studies)) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (RB possibly) (JJ enhanced) (NNS CNS)) (, ,) (NP (NNP Doc_3115150_1584_1626_Disease))))))))))))))) (. .)))
3120485	0	(S1 (NP (NP (NN Antagonism)) (PP (IN of) (NP (JJ Doc_3120485_14_22_Chemical-induced) (JJ sedative) (NNS effects))) (PP (IN by) (NP (NNP Doc_3120485_51_60_Chemical))) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (NN surgery))) (PP (IN under) (NP (JJ lumbar) (JJ epidural) (NN block))) (. .)))
3120485	1	(S1 (NP (NP (DT A) (JJ double-blind) (JJ placebo-controlled) (NN investigation)) (PP (IN of) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))) (. .)))
3120485	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (S (VP (TO to) (VP (VB assess) (NP (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_3120485_240_249_Chemical)))) (CC and) (NP (NP (DT a) (NN placebo)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ Doc_3120485_277_285_Chemical-induced) (NNS effects)) (PP (IN after) (NP (NN surgery))) (PP (IN under) (NP (JJ epidural) (NN block))))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ local) (UCP (NN tolerance) (CC and) (JJ general)) (NN safety)) (PP (IN of) (NP (NNP Doc_3120485_396_405_Chemical))))))))) (. .)))
3120485	3	(S1 (S (NP (JJ Fifty-seven) (NNS patients)) (VP (AUX were) (VP (VBN sedated) (PP (IN with) (NP (NNP Doc_3120485_446_454_Chemical))) (PP (IN for) (NP (NN surgery))) (PP (IN under) (NP (JJ epidural) (NNS anaesthesia))))) (. .)))
3120485	4	(S1 (S (NP (NP (NN Antagonism)) (PP (IN of) (NP (JJ Doc_3120485_509_517_Chemical-induced) (NNS effects))) (PP (IN by) (NP (NNP Doc_3120485_537_546_Chemical)))) (VP (AUX was) (VP (VBN investigated) (ADVP (RB postoperatively)) (PP (IN in) (NP (DT a) (JJ double-blind) (JJ placebo-controlled) (NN trial))))) (. .)))
3120485	5	(S1 (S (NP (NP (NP (NP (DT The) (NN patient) (POS 's)) (JJ subjective) (NN assessment)) (PP (IN of) (NP (NP (NN mood) (NN rating)) (, ,) (NP (NP (DT an) (JJ objective) (NN test)) (PP (IN of) (NP (NN performance)))) (, ,) (NP (NP (DT a) (NN test)) (PP (IN for) (NP (NNP Doc_3120485_721_728_Disease)))) (, ,)))) (CC and) (NP (JJ vital) (NNS signs))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (QP (IN up) (TO to) (CD 300)) (NN min))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN trial) (NN drug))))))) (. .)))
3120485	6	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (NP (NN mood) (NN rating)) (, ,) (NP (NN Doc_3120485_899_906_Disease)) (, ,) (CC or) (NP (JJ vital) (NNS signs)))))) (. .)))
3120485	7	(S1 (S (NP (DT The) (NNP Doc_3120485_928_937_Chemical) (NN group)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN improvement)) (PP (IN in) (NP (DT the) (NN performance) (NN test)))) (ADVP (RB up)) (PP (TO to) (NP (CD 120) (NN min))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
3120485	8	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN reaction)))) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (. .)))
3123611	0	(S1 (S (NP (NN Doc_3123611_0_6_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3123611_23_41_Chemical)))) (. .)))
3123611	1	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD developed) (NP (NN Doc_3123611_68_74_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NN Doc_3123611_91_110_Chemical)))))) (. .)))
3123611	2	(S1 (S (NP (CD Two)) (VP (AUX were) (NP (NP (JJ young) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN Doc_3123611_142_148_Disease)) (S (VP (VP (VBD developed) (SBAR (ADVP (RB long)) (IN after) (S (NP (NN treatment)) (VP (AUX had) (VP (AUX been) (VP (VBN started))))))) (CC and) (VP (VBD disappeared) (SBAR (ADVP (RB soon)) (IN after) (S (NP (PRP it)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued)))))))))))) (. .)))
3123611	3	(S1 (S (NP (DT The) (JJ third) (NN patient)) (VP (AUX had) (NP (JJ acute) (JJ Doc_3123611_278_289_Chemical-induced) (NN Doc_3123611_298_304_Disease)) (PP (IN after) (NP (JJ prolonged) (NN Doc_3123611_321_339_Chemical)))) (. .)))
3123611	4	(S1 (S (NP (NP (VBN Prolonged) (NN administration)) (PP (IN of) (NP (JJ female) (NN sex) (NNS hormones)))) (VP (AUX is) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_3123611_412_418_Disease))) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (RB not) (ADVP (RB previously)) (VP (AUX had) (NP (NP (NNP Doc_3123611_456_462_Disease)) (CC or) (NP (NNP Doc_3123611_466_481_Disease))))))))))) (. .)))
3131282	0	(S1 (NP (NP (JJ Co-Doc_3131282_3_15_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_3131282_26_41_Chemical))) (PP (IN on) (NP (NP (NNP Doc_3131282_45_71_Disease)) (PP (IN of) (NP (NP (JJ male) (JJ F344) (NNS rats)) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_3131282_103_127_Chemical)))))))) (. .)))
3131282	1	(S1 (S (NP (NP (DT The) (JJ potential) (NN modifying) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3131282_163_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_180_182_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNP Doc_3131282_187_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_213_216_Chemical)) (-RRB- -RRB-)))) (NP (JJ -induced) (NN rat) (NN Doc_3131282_230_255_Disease))) (VP (AUX was) (VP (VBN examined))) (. .)))
3131282	2	(S1 (S (NP (NP (JJ Male) (NNP F344) (NNS rats)) (, ,) (NP (NP (CD 5) (NNS weeks)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NP (NN diet)) (VP (VBG containing) (NP (ADJP (QP (CD 1) (NN %) (CC or) (CD 2) (NN %))) (NNP Doc_3131282_346_349_Chemical))))) (PP (IN by) (NP (NN weight))))) (CC and) (VP (ADVP (RB simultaneously) (PP (IN on) (NP (NN drinking) (NN water)))) (VBD supplemented) (PP (IN with) (NP (NNP Doc_3131282_415_417_Chemical))) (PP (IN at) (NP (JJ various) (NNS concentrations))) (PRN (-LRB- -LRB-) (JJ w/v) (-RRB- -RRB-)) (PP (IN for) (NP (CD 52) (NNS weeks))))) (. .)))
3131282	3	(S1 (S (PP (IN In) (NP (NP (NNS groups)) (VP (VBN given) (NP (ADJP (CD 2) (NN %)) (NNP Doc_3131282_483_486_Chemical))))) (, ,) (SBAR (IN although) (S (NP (NP (JJ marked) (JJ hyperplastic) (NNS changes)) (PP (IN of) (NP (DT the) (JJ forestomach) (NN epithelium)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT all) (NNS animals))))))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_3131282_612_614_Chemical))) (ADJP (ADVP (RB significantly)) (-LRB- -LRB-) (NP (CD P)) (JJR less) (SBAR (IN than) (S (NP (CD 0.05)) (-RRB- -RRB-) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_3131282_675_693_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_695_718_Disease) (CC and) (NNP Doc_3131282_723_732_Disease)) (-RRB- -RRB-))))) (PP (TO to) (NP (CD 60) (NN %))) (PRN (-LRB- -LRB-) (NP (CD 9/15)) (, ,) (NP (NP (CD 2) (NNS rats)) (PP (IN with) (NP (NNP Doc_3131282_760_769_Disease)))) (-RRB- -RRB-)) (PP (IN from) (NP (CD 15) (NN %))) (PRN (-LRB- -LRB-) (NP (CD 3/20)) (, ,) (NP (NP (CD one) (NN rat)) (PP (IN with) (NP (NNP Doc_3131282_800_809_Disease)))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NN group)))))))) (VP (VBN given) (NP (JJ Doc_3131282_830_832_Chemical-free) (NN water))) (. .)))
3131282	4	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (VP (VBN given) (NP (ADJP (CD 1) (NN %)) (NNP Doc_3131282_862_865_Chemical))))) (, ,) (NP (NNP Doc_3131282_867_869_Chemical) (JJ co-administered) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.05) (, ,) (CD 0.1) (, ,) (CD 0.2) (CC or) (CD 0.25) (NN %)))))) (VP (VBD showed) (NP (NP (DT a) (JJ dose-dependent) (VBG enhancing) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ Doc_3131282_990_993_Chemical-induced) (NNP Doc_3131282_1002_1024_Disease))))))) (. .)))
3131282	5	(S1 (S (NP (NP (NN Doc_3131282_1026_1032_Disease)) (, ,) (NP (DT all) (NNP Doc_3131282_1038_1048_Disease)) (, ,)) (VP (AUX were) (VP (VBN induced) (PP (PP (IN in) (NP (NP (CD 3) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)) (PP (IN with) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_3131282_1090_1092_Chemical))))) (CC and) (PP (IN in) (NP (NP (CD one) (NN rat)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (PP (IN with) (NP (ADJP (CD 0.05) (NN %)) (JJ Doc_3131282_1125_1127_Chemical) (NN co-administration))))) (. .)))
3131282	6	(S1 (S (NP (NP (NN Doc_3131282_1147_1149_Chemical)) (ADVP (RB alone))) (VP (AUX did) (RB not) (VP (VB induce) (NP (NP (JJ hyperplastic) (NNS changes)) (PP (IN in) (NP (DT the) (NN forestomach)))))) (. .)))
3131282	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_3131282_1241_1243_Chemical)) (VP (VBD acted) (PP (IN as) (NP (NP (DT a) (NN co-carcinogen)) (PP (IN in) (NP (NP (DT the) (NNP Doc_3131282_1276_1279_Chemical) (NNP Doc_3131282_1280_1306_Disease)) (PP (IN of) (NP (DT the) (NN rat))))))))))) (. .)))
3137399	0	(S1 (NP (NP (DT A) (JJ prospective) (NN study)) (PP (IN on) (NP (NP (DT the) (NN dose) (NN dependency)) (PP (IN of) (NP (NNP Doc_3137399_46_60_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3137399_72_83_Chemical)))))) (. .)))
3137399	1	(S1 (S (PP (IN Since) (NP (CD 1975))) (NP (NP (NNP Doc_3137399_96_107_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3137399_109_112_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_3137399_139_150_Disease))))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (CC or) (PP (VBN given) (NP (JJ following) (NNP Doc_3137399_201_212_Chemical)))))))))) (. .)))
3137399	2	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NN dose) (NN dependency) (CC or) (NN incidence)) (VP (VBG concerning) (NP (DT this) (NN side) (NN effect)))))) (VP (AUX were) (RB not) (VP (VBN known))) (. .)))
3137399	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN initiated) (NP (NP (DT a) (JJ prospective) (NN study)) (SBAR (S (VP (TO to) (VP (VB obtain) (NP (NP (DT some) (JJR more) (NNS data)) (PP (IN on) (NP (DT these) (NNS subjects))))))))))) (. .)))
3137399	4	(S1 (S (S (NP (JJ Forty-four) (JJ Doc_3137399_388_391_Chemical-treated) (NNS patients)) (VP (AUX were) (VP (VBN studied)))) (, ,) (S (NP (NP (CD 37)) (PP (IN of) (NP (PRP them)))) (VP (MD could) (VP (AUX be) (VP (VBN evaluated))))) (. .)))
3137399	5	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (VP (VBN studied) (PP (IN by) (NP (NP (VBN repeated) (JJ physical) (NNS examinations)) (, ,) (NP (NN chest) (NNS X-rays)) (, ,) (NP (ADJP (JJ electro-) (CC and) (JJ echocardiography) (CC and) (JJ radionuclide)) (JJ left) (NN ventricular) (NN ejection) (NN fraction) (-LRB- -LRB-) (NN EF) (-RRB- -RRB-) (NNS determinations)))))) (. .)))
3137399	6	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (VP (VBN evaluated) (PP (IN per) (NP (JJ cumulative) (NN dose) (NN level))))) (. .)))
3137399	7	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_3137399_716_731_Disease)) (PP (IN after) (NP (NP (ADJP (NP (CD 30) (NNS mg)) (JJ m-2)) (NNP Doc_3137399_748_751_Chemical)) (CC and) (NP (ADJP (NP (QP (RB only) (CD 150)) (NNS mg)) (JJ m-2)) (NNP Doc_3137399_772_783_Chemical))))) (. .)))
3137399	8	(S1 (S (NP (DT The) (NNP Doc_3137399_789_804_Disease)) (VP (AUX was) (VP (VBN predicted) (PP (IN by) (NP (NP (DT a) (NN drop)) (PP (IN in) (NP (NP (NNS EF)) (VP (VBN determined) (PP (IN during) (NP (DT a) (JJ cold) (NN pressor) (NN test)))))))))) (. .)))
3137399	9	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (JJ other) (NNS patients)))) (VP (VBD developed) (NP (JJ clinical) (NN Doc_3137399_920_934_Disease)))) (, ,) (CC nor) (SINV (AUX did) (NP (DT the) (VBN studied) (NNS parameters)) (VP (VB change))) (. .)))
3137399	10	(S1 (S (NP (NP (DT The) (NN literature)) (PP (IN on) (NP (DT this) (NN subject)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN reviewed))) (. .)))
3137399	11	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (VBN combined) (NNS data)) (PP (IN from) (NP (NP (DT the) (JJ present) (NN study)) (CC and) (NP (DT the) (NN literature))))))) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3137399_1111_1114_Chemical-related) (NNP Doc_3137399_1123_1137_Disease)) (VP (AUX is) (ADJP (NN dose) (JJ dependent)) (, ,) (S (VP (VBG occurring) (PP (IN at) (NP (NP (JJ cumulative) (NN dose) (NNS levels)) (PP (IN of) (NP (CD 30) (NNS mg))) (ADJP (JJ m-2) (CC or) (JJR more)) (, ,) (PP (ADVP (RB mainly)) (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB also) (PRN (-LRB- -LRB-) (ADVP (ADVP (RB previously)) (CC or) (ADVP (RB simultaneously))) (-RRB- -RRB-))) (VBN treated) (PP (IN with) (NP (NNP Doc_3137399_1283_1294_Chemical)))))))))))))) (. .)))
3137399	12	(S1 (S (NP (DT The) (NN incidence)) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (NP (QP (JJR less) (IN than) (CD 10)) (NN %)))))) (ADVP (RB even)) (PP (IN for) (NP (DT this) (NN risk) (NN group)))) (. .)))
3183120	0	(S1 (NP (NP (NP (JJ Reversible) (NN Doc_3183120_11_27_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3183120_44_54_Chemical) (NN usage))))) (: :) (NP (NNP MR) (NN demonstration)) (. .)))
3183120	1	(S1 (S (NP (NN Doc_3183120_80_90_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ experimental) (NN chemotherapeutic) (NN agent)) (VP (ADVP (RB currently)) (VBG undergoing) (NP (JJ clinical) (NN evaluation))))) (. .)))
3183120	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (PRP$ our) (NNS results)) (PP (IN with) (NP (NP (JJ magnetic) (NN resonance)) (PRN (-LRB- -LRB-) (NP (NNP MR)) (-RRB- -RRB-))))) (PP (IN in) (S (VP (VBG demonstrating) (NP (NP (JJ reversible) (NN Doc_3183120_254_276_Disease)) (ADJP (JJ concurrent) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))))))) (. .)))
3183120	3	(S1 (S (NP (NP (DT The) (NNS abnormalities)) (PP (IN on) (NP (NNP MR)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NNS findings))) (PP (PP (IN on) (NP (NN CT))) (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (JJ cerebral) (NN angiography)))))) (. .)))
3183120	4	(S1 (S (NP (NP (DT The) (NN utility)) (PP (IN of) (NP (NNP MR))) (PP (IN in) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT this) (JJ new) (NN agent)))))))) (VP (AUX is) (VP (VBN illustrated))) (. .)))
3220106	0	(S1 (NP (NP (NN Receptor) (NNS mechanisms)) (PP (IN of) (NP (NP (NNP Doc_3220106_23_31_Chemical-induced) (NNP Doc_3220106_40_63_Disease)) (PP (IN in) (NP (JJ chronic) (JJ Doc_3220106_75_83_Chemical-treated) (NNS rats))))) (. .)))
3220106	1	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_3220106_134_142_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1.5) (NN mg/kg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))) (PP (IN by) (S (ADVP (RB subcutaneously)) (VP (VBG implanting) (NP (DT each) (JJ animal)) (PP (IN with) (NP (NP (DT an) (NNP Alzet) (JJ osmotic) (NN mini-pump)) (SBAR (WHNP (WDT which)) (S (ADVP (RB continuously)) (VP (VBD released) (NP (NP (NN saline)) (CC or) (NP (NNP Doc_3220106_274_282_Chemical))) (PP (IN for) (NP (CD 1) (, ,) (CD 5) (CC and) (CD 14) (NNS days))))))))))))) (. .)))
3220106	2	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT each) (JJ pretreatment) (NN period))))) (, ,) (NP (NNS animals)) (VP (AUX were) (VP (VBN used) (PP (IN for) (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (VP (VBG determining) (NP (PRP$ their) (NN locomotor) (NN response)) (PP (TO to) (VP (ADVP (RB acutely)) (VBN injected) (NP (NP (NP (NNP Doc_3220106_428_436_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NNS mg/kg)) (, ,) (NP (NNP s.c.)) (-RRB- -RRB-))) (CC and) (NP (-LRB- -LRB-) (NNP ii) (-RRB- -RRB-))) (S (VP (VBG measuring) (NP (NP (DT the) (NN density)) (PP (IN of) (NP (NP (JJ L--LSB-3H) (JJ -RSB-) (ADJP (JJ Doc_3220106_495_503_Chemical) (CC and) (JJ -LSB-3H)) (JJ -RSB-) (JJ Doc_3220106_512_521_Chemical) (JJ binding) (NNS sites)) (PP (IN in) (NP (DT the) (NN striatum))))))))))))))) (. .)))
3220106	3	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_3220106_579_587_Chemical-induced) (NN locomotor) (NN response)) (, ,) (NP (JJ striatal) (JJ L--LSB-3H) (JJ -RSB-) (NN Doc_3220106_631_639_Chemical)) (CC and) (NP (JJ -LSB-3H) (JJ -RSB-) (NN Doc_3220106_648_657_Chemical) (VBG binding)))) (PP (IN in) (NP (DT the) (NNS animals)))) (PP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_697_705_Chemical)))) (PP (IN for) (NP (CD 1) (NN day)))) (. .)))
3220106	4	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_752_760_Chemical))) (PP (IN for) (NP (CD 5) (NNS days))))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_3220106_813_821_Chemical-stimulated) (NN locomotor) (NN response)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ L--LSB-3H) (JJ -RSB-) (NNP Doc_3220106_913_921_Chemical) (VBG binding) (NNS sites))))))) (CC and) (PP (ADVP (RB also)) (IN with) (NP (NP (DT an) (JJ elevated) (NNP Doc_3220106_962_970_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3220106_972_974_Chemical)) (-RRB- -RRB-)) (NN level)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))) (. .)))
3220106	5	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ striatal) (JJ -LSB-3H) (NN -RSB-) (NN Doc_3220106_1026_1035_Chemical) (VBG binding) (NNS sites)))) (VP (AUX was) (RB not) (VP (VBN affected))) (. .)))
3220106	6	(S1 (S (PP (IN In) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_1095_1103_Chemical))) (PP (IN for) (NP (CD 14) (NNS days)))))) (, ,) (NP (DT the) (JJ Doc_3220106_1121_1129_Chemical-induced) (JJ locomotor) (NN response)) (VP (VBD remained) (S (VP (TO to) (VP (AUX be) (VP (VBN potentiated)))))) (. .)))
3220106	7	(S1 (S (ADVP (RB However)) (, ,) (NP (DT this) (NN response)) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (DT an) (JJ elevated) (NN number)) (PP (IN of) (NP (JJ striatal) (JJ -LSB-3H) (JJ -RSB-) (NNP Doc_3220106_1263_1272_Chemical) (VBG binding) (NNS sites))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ striatal) (JJ L--LSB-3H) (JJ -RSB-) (JJ Doc_3220106_1325_1333_Chemical) (JJ binding) (NNS sites)) (CC and) (NP (DT the) (JJ striatal) (JJ Doc_3220106_1365_1367_Chemical) (NN level))))) (VP (AUX were) (ADJP (JJ normal))))))) (. .)))
3220106	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ chronic) (JJ Doc_3220106_1422_1430_Chemical-treated) (NNS rats)) (VP (VBP develop) (NP (NNP Doc_3220106_1452_1475_Disease)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_3220106_1491_1499_Chemical))) (PP (ADVP (RB initially)) (JJ due) (PP (TO to) (NP (NP (NNS increases)) (PP (IN of) (NP (NP (PDT both) (DT the) (NN density)) (PP (IN of) (NP (NP (JJ nicotinic) (NNS receptors)) (CC and) (NP (JJ Doc_3220106_1574_1576_Chemical) (NN concentration)))) (, ,) (VP (VBN followed) (PP (IN by) (S (VP (VBG inducing) (NP (JJ Doc_3220106_1613_1615_Chemical) (NN receptor) (NN supersensitivity)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))))))) (. .)))
326460	0	(S1 (NP (NP (NN Amelioration)) (PP (IN of) (NP (NNP Doc_326460_16_30_Chemical-induced) (NNP Doc_326460_39_50_Disease))) (PP (IN by) (NP (NNP Doc_326460_54_61_Chemical))) (. .)))
326460	1	(S1 (S (S (NP (NP (DT The) (JJ beta) (JJ adrenergic) (VBG blocking) (NN drug)) (, ,) (NP (NNP Doc_326460_98_105_Chemical)) (, ,)) (VP (VBD tended) (S (VP (TO to) (VP (VB correct) (NP (NP (DT the) (NN Doc_326460_129_140_Disease)) (PP (IN of) (NP (NP (JJ short-term) (JJ Doc_326460_155_169_Chemical) (NN treatment)) (PP (IN in) (NP (ADJP (CD 6) (JJ healthy) (NN male)) (NNS subjects))))))))))) (CC and) (S (SBAR (IN although) (S (NP (DT the) (NN effect)) (VP (AUX was) (ADJP (JJ small))))) (NP (PRP it)) (VP (AUX was) (ADJP (JJ significant)))) (. .)))
326460	2	(S1 (S (NP (NNP Doc_326460_261_268_Chemical)) (ADVP (RB also)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN rise)) (PP (IN in) (NP (NP (NN plasma) (NN Doc_326460_301_312_Chemical)) (CC and) (NP (NN urine) (JJ Doc_326460_323_332_Chemical) (NN excretion)))) (PP (VBG following) (NP (NNP Doc_326460_353_367_Chemical))))) (CC and) (VP (VBD increased) (NP (DT the) (NN urine) (NN Doc_326460_392_398_Chemical/Doc_326460_399_408_Chemical) (NN ratio)))) (. .)))
326460	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (DT a) (NN shift)) (PP (IN of) (NP (NNP Doc_326460_452_461_Chemical))) (PP (IN from) (NP (DT the) (NN intracellular))) (PP (TO to) (NP (DT the) (NN extracellular) (NN space))))))) (. .)))
3300918	0	(S1 (NP (NP (NP (NN Doc_3300918_0_18_Disease)) (, ,) (ADVP (ADVP (RB then)) (CC and) (ADVP (RB now)))) (: :) (NP (NP (DT a) (NN case) (NN report)) (CC and) (NP (JJ historical) (NN review))) (. .)))
3300918	1	(S1 (S (NP (NP (DT A) (JJ rare) (NN case)) (PP (IN of) (NP (JJ morbid) (NNP Doc_3300918_93_102_Disease)))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (JJ striking) (JJ angiographic) (NNS findings))) (, ,) (VP (AUX is) (VP (VBN described) (PP (JJ secondary) (TO to) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NNP Doc_3300918_193_205_Chemical))))) (PP (IN by) (NP (DT a) (JJ 48-year-old) (NN woman))))) (. .)))
3300918	2	(S1 (S (NP (NP (DT A) (JJ brief) (NN review)) (PP (IN of) (NP (NP (DT the) (NN literature)) (PP (IN on) (NP (JJ similar) (NNS cases)))))) (VP (AUX is) (VP (VBN presented))) (. .)))
3300918	3	(S1 (S (NP (NP (DT A) (NN discussion)) (PP (IN of) (NP (NP (DT the) (NN history)) (PP (IN of) (NP (NNP Doc_3300918_325_330_Chemical)))))) (VP (VBZ includes) (NP (NP (PRP$ its) (JJ original) (NN discovery)) (, ,) (NP (NP (DT the) (NNS epidemics)) (PP (IN of) (NP (NNP Doc_3300918_381_389_Disease))) (SBAR (WHNP (WDT that)) (S (NP (PRP it)) (VP (AUX has) (VP (VBN caused) (PP (IN through) (NP (NP (DT the) (NNS ages)) (CC and) (NP (NP (PRP$ its) (ADJP (JJ past) (CC and) (JJ present)) (NN role)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_3300918_477_494_Disease))))))))))))))) (. .)))
3300918	4	(S1 (S (PP (IN Despite) (NP (NP (DT the) (NN advent)) (PP (IN of) (NP (NP (JJ Doc_3300918_518_525_Chemical) (NN channel) (NNS blockers)) (CC and) (NP (JJ beta-adrenergic) (NNS antagonists)))))) (, ,) (NP (NNP Doc_3300918_576_581_Chemical) (NNS preparations)) (VP (VBP continue) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (JJ Doc_3300918_628_636_Disease) (NN therapy)))))) (, ,) (SBAR (IN so) (IN that) (S (NP (NP (DT the) (NN danger)) (PP (IN of) (NP (NNP Doc_3300918_668_686_Disease)))) (VP (VBZ persists))))) (. .)))
3311455	0	(S1 (NP (NP (JJ Cardiac) (NN transplantation)) (: :) (NP (NP (VBN improved) (NN quality)) (PP (IN of) (NP (NN survival))) (PP (IN with) (NP (DT a) (VBN modified) (NN immunosuppressive) (NN protocol)))) (. .)))
3311455	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN on) (NP (JJ renal) (NN function))) (PP (IN on) (NP (CD two) (JJ different) (NN immunosuppressive) (NNS protocols)))) (VP (AUX were) (VP (VBN evaluated) (ADVP (RB retrospectively)) (PP (IN in) (NP (NP (CD two) (JJ subsequent) (NNS groups)) (PP (IN of) (NP (NN heart) (NN transplant) (NNS recipients))))))) (. .)))
3311455	2	(S1 (S (PP (IN In) (NP (NN group))) (NP (PRP I)) (, ,) (NP (NNP Doc_3311455_273_285_Chemical)) (VP (VP (AUX was) (VP (VBN given) (PP (IN before) (NP (DT the) (NN procedure))) (PP (IN at) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 17.5) (NN mg/kg))))))) (CC and) (VP (ADVP (RB then)) (VBD continued) (PP (IN after) (NP (DT the) (NN procedure))) (S (VP (TO to) (VP (VB keep) (NP (DT a) (JJ whole) (NN blood) (NN level)) (PP (IN about) (NP (CD 1000) (NN ng/ml)))))))) (. .)))
3311455	3	(S1 (S (PP (IN In) (NP (NN group) (NNP II))) (, ,) (NP (NNP Doc_3311455_447_459_Chemical)) (VP (VP (AUX was) (VP (VBN started) (ADVP (RB only)) (PP (IN after) (NP (DT the) (NN procedure))) (PP (IN at) (NP (DT a) (JJR lower) (NN dosage))))) (CC and) (VP (AUX was) (VP (VBN complemented) (PP (IN by) (NP (NP (NNP Doc_3311455_539_551_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN used) (PP (IN for) (NP (DT the) (JJ first) (JJ postoperative) (NN week)))))))))))) (. .)))
3311455	4	(S1 (S (NP (NNP Group) (NNP II)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RBR better) (JJ perioperative)) (JJ renal) (NN function)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN serum) (NN blood) (NNP Doc_3311455_685_698_Chemical) (CC and) (NNP serum) (NNP Doc_3311455_709_719_Chemical) (NNS levels)))))))) (. .)))
3311455	5	(S1 (S (NP (NNP Group) (NNP II)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN of) (NP (JJ chronic) (JJ Doc_3311455_783_797_Disease) (JJ secondary))) (PP (TO to) (NP (NP (JJ long-term) (NN therapy)) (PP (IN with) (NP (NNP Doc_3311455_834_846_Chemical))))))) (. .)))
3311455	6	(S1 (S (PP (IN Despite) (NP (NP (DT this) (NN improvement)) (PP (IN in) (NP (JJ late) (JJ renal) (NN function))))) (, ,) (NP (NNP group) (NNP II)) (ADVP (RB still)) (VP (VBZ shows) (NP (NP (DT a) (JJ slow) (NN rise)) (PP (IN in) (NP (JJ serum) (NNP Doc_3311455_939_949_Chemical))))) (. .)))
3311455	7	(S1 (S (NP (PRP We)) (VP (VBP think) (SBAR (SBAR (IN that) (S (NP (NP (RB even) (DT these) (JJR lower) (NNS dosages)) (PP (IN of) (NP (NNP Doc_3311455_993_1005_Chemical)))) (VP (MD can) (VP (VB cause) (NP (JJ chronic) (NN Doc_3311455_1024_1038_Disease)))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ further) (NN modification)) (PP (IN of) (NP (DT the) (JJ immunosuppressive) (NN regimen)))) (VP (AUX is) (VP (VBN required) (S (VP (TO to) (VP (ADVP (RB completely)) (VB abolish) (NP (DT this) (JJ toxic) (NN side) (NN effect))))))))))) (. .)))
33969	0	(S1 (NP (NP (NP (NNP Doc_33969_0_13_Chemical)) (CC and) (NP (NNP Doc_33969_18_29_Chemical))) (PP (IN in) (NP (JJ neuroleptic-induced) (NNP Doc_33969_53_65_Disease))) (. .)))
33969	1	(S1 (S (PP (IN In) (NP (DT a) (JJ 12-week) (JJ controlled) (NN study))) (NP (NNP Doc_33969_97_110_Chemical)) (VP (AUX was) (PP (VBN compared) (PP (TO to) (NP (NP (NNP Doc_33969_127_138_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_33969_159_171_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_33969_183_205_Chemical))) (PP (IN in) (NP (CD 60) (JJ Doc_33969_212_225_Disease) (NNS outpatients)))))))))) (. .)))
33969	2	(S1 (S (NP (NP (NNP Doc_33969_239_252_Chemical)) (CC and) (NP (NNP Doc_33969_257_268_Chemical))) (VP (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG controlling) (NP (NNP Doc_33969_319_340_Disease))))))))))) (CC and) (VP (AUX were) (ADJP (RB as) (JJ efficacious) (PP (IN as) (NP (NP (NNP Doc_33969_368_380_Chemical)) (, ,) (NP (PRP$ their) (JJ previous) (JJ antiparkinsonian) (NN drug))))))) (. .)))
33969	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_33969_429_440_Chemical)) (VP (VP (VBD treated) (SBAR (S (NP (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NNP Doc_33969_488_506_Disease))) (PP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN condition))))) (PP (IN during) (NP (JJ Doc_33969_542_555_Chemical) (NN treatment))))))) (, ,) (CC and) (VP (ADVP (RB significantly) (RBR more)) (NP (NP (NNP Doc_33969_590_597_Disease)) (CC and) (NP (NNP Doc_33969_602_612_Disease))) (PP (IN than) (NP (JJ Doc_33969_618_631_Chemical) (VBN treated) (NNS patients))))) (. .)))
33969	4	(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_33969_669_680_Chemical)) (VP (AUX is) (RB not) (NP (NP (DT the) (JJ anticholinergic) (NN drug)) (PP (IN of) (NP (NN choice))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_33969_763_784_Disease)))))) (, ,) (PP (IN because) (IN of) (NP (PRP$ its) (ADJP (RBR more) (JJ toxic)) (ADJP (JJ central) (CC and) (JJ peripheral)) (JJ atropinic) (NN effect))))))) (. .)))
3411101	0	(S1 (FRAG (NP (JJ Doc_3411101_0_32_Chemical-induced) (NN fulminant) (NN Doc_3411101_51_60_Disease)) (PP (IN in) (NP (DT a) (JJ pregnant) (NN woman))) (. .)))
3411101	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
3411101	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 19-year-old) (JJ Laotian) (NN patient)) (VP (VBN affected) (PP (IN by) (NP (JJ fulminant) (NNP Doc_3411101_171_180_Disease))) (PP (IN during) (NP (NP (DT the) (JJ third) (NN trimester)) (PP (IN of) (NP (PRP$ her) (NN pregnancy))) (PP (IN after) (NP (NP (DT a) (JJ 1-month) (NN administration)) (PP (IN of) (NP (NNP Doc_3411101_259_291_Chemical)))))))))))) (. .)))
3411101	3	(S1 (S (PP (IN After) (NP (NN delivery))) (, ,) (NP (DT the) (NN patient)) (VP (VBD underwent) (NP (JJ orthotopic) (NN liver) (NN transplantation))) (. .)))
3411101	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (PP (IN in) (NP (JJ good) (NN condition))) (PP (NP (CD 16) (NNS months)) (IN after) (NP (NN liver) (NN transplantation)))) (. .)))
3411101	5	(S1 (S (NP (NP (NP (NN Doc_3411101_438_447_Chemical)) (NP (PRP itself))) (CC or) (NP (NNP Doc_3411101_458_480_Chemical))) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ fulminant) (NN Doc_3411101_514_523_Disease)) (PP (IN in) (NP (DT this) (NN patient)))))))) (. .)))
3413271	0	(S1 (NP (NP (NP (NNPS Mechanisms)) (PP (IN of) (NP (NNP Doc_3413271_14_33_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3413271_45_56_Chemical))))) (: :) (NP (NP (NN comparison)) (PP (IN with) (NP (JJ exercise-induced) (NNP Doc_3413271_91_99_Disease)))) (. .)))
3413271	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_3413271_113_124_Chemical))) (PP (IN in) (S (VP (VBG eliciting) (NP (NNP Doc_3413271_138_157_Disease)))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3413271_188_211_Disease))))))) (. .)))
3413271	2	(S1 (S (NP (NP (NP (JJ Objective) (NNS signs)) (PP (IN of) (NP (NNP Doc_3413271_232_240_Disease)))) (CC and) (NP (NP (NNS factors)) (VP (VBG increasing) (NP (JJ myocardial) (JJ Doc_3413271_275_281_Chemical) (NN consumption))))) (VP (AUX were) (VP (VBN compared) (PP (IN during) (NP (NP (JJ Doc_3413271_315_326_Chemical) (NN infusion)) (CC and) (NP (JJ supine) (NN bicycle) (NN exercise)))))) (. .)))
3413271	3	(S1 (S (CC Both) (NP (NP (NNP Doc_3413271_370_381_Chemical)) (CC and) (NP (NN exercise))) (VP (VBD produced) (NP (NNP Doc_3413271_404_423_Disease)) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NNP ST) (NN segment) (NNP Doc_3413271_451_461_Disease) (CC and) (NNP Doc_3413271_466_472_Disease))))))) (. .)))
3413271	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_3413271_501_520_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3413271_532_543_Chemical))))) (VP (AUX were) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (NN exercise))))))) (. .)))
3413271	5	(S1 (S (NP (JJ Exercise-induced) (NNP Doc_3413271_614_633_Disease)) (VP (AUX was) (VP (VBN marked) (ADVP (RB predominantly)) (PP (IN by) (NP (NP (VBN increased) (NN heart) (NN rate)) (CC and) (NP (JJ rate-pressure) (NN product)))) (PP (IN with) (NP (NP (DT a) (JJ minor) (NN contribution)) (PP (IN of) (NP (JJ end-diastolic) (NN volume))))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_3413271_766_777_Chemical-induced) (NNP Doc_3413271_786_794_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NN contractility)))) (CC and) (NP (NP (DT a) (ADJP (RBR less) (JJ pronounced)) (NN increase)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN rate-pressure) (NN product))))))))))))) (. .)))
3413271	6	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_3413271_952_960_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3413271_973_984_Chemical))))) (, ,) (SBAR (IN as) (S (VP (MD may) (VP (VB occur) (PP (IN during) (NP (NP (NNS states)) (PP (IN of) (NP (JJ emotional) (NN distress))))))))) (, ,) (VP (AUX has) (NP (NP (DT a) (NN mechanism)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (ADJP (JJ due) (PP (TO to) (NP (JJ physical) (NN exertion)))))))))))) (. .)))
3431591	0	(S1 (S (NP (NP (JJ Recent) (JJ preclinical) (CC and) (JJ clinical) (NNS studies)) (PP (IN with) (NP (DT the) (JJ thymidylate) (NN synthase)))) (VP (VBP inhibitor) (NP (NP (NNP Doc_3431591_80_115_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3431591_117_124_Chemical)) (-RRB- -RRB-)))) (. .)))
3431591	1	(S1 (S (NP (NP (NN Doc_3431591_127_134_Chemical)) (, ,) (NP (NNP Doc_3431591_136_171_Chemical)) (, ,)) (VP (AUX is) (NP (NP (DT a) (JJ tight-binding) (NN inhibitor)) (PP (IN of) (NP (NP (JJ thymidylate) (NN synthase)) (-LRB- -LRB-) (NP (NNP TS)) (-RRB- -RRB-) (SBAR (WHNP (WP$ whose) (NN Doc_3431591_237_249_Disease)) (S (VP (AUX is) (VP (VBN mediated) (ADVP (RB solely)) (PP (IN through) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (DT this) (NN enzyme))))))))))))) (. .)))
3431591	2	(S1 (S (NP (JJ Recent) (NN preclinical) (NNS studies)) (VP (AUX have) (VP (VBN focused) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN formation)) (PP (IN of) (NP (JJ Doc_3431591_382_389_Chemical) (NNS polyglutamates))))))) (. .)))
3431591	3	(S1 (S (PP (VBG Following) (NP (NP (DT a) (JJ 12-hour) (NN exposure)) (PP (IN of) (NP (JJ L1210) (NNS cells))) (PP (TO to) (NP (ADJP (CD 50) (NN microM)) (JJ -LSB-3H) (JJ -RSB-) (NN Doc_3431591_467_474_Chemical))))) (, ,) (NP (NP (CD 30) (NN %)) (PP (IN of) (NP (DT the) (JJ extractable) (NN radioactivity)))) (VP (MD could) (VP (AUX be) (VP (VBN accounted) (PP (IN for) (NP (ADJP (RB as) (JJ Doc_3431591_539_546_Chemical)) (NN tetra-) (CC and) (NN pentaglutamate))) (, ,) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (JJ high-pressure) (NN liquid) (NN chromatography) (PRN (-LRB- -LRB-) (NP (NNP HPLC)) (-RRB- -RRB-)) (NNS analyses))))))))) (. .)))
3431591	4	(S1 (S (PP (IN As) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (VBN isolated) (NNP L1210) (NNS TS))))) (, ,) (NP (NP (NP (NNP CB) (CD 3717) (JJ di-) (, ,) (JJ tri-) (, ,) (JJ tetra-) (CC and) (JJ pentaglutamate) (AUX are) (ADJP (JJ 26-) (, ,) (JJ 87-) (, ,) (JJ 119-) (CC and) (JJ 114-fold))) (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NNP Doc_3431591_774_781_Chemical)))) (, ,) (ADVP (RB respectively)) (, ,) (CC and) (NP (PRP$ their) (NN formation))) (VP (MD may) (, ,) (ADVP (RB therefore)) (, ,) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NNP Doc_3431591_864_871_Chemical) (NNP Doc_3431591_872_884_Disease)))))) (. .)))
3431591	5	(S1 (S (PP (IN In) (NP (NP (JJ early) (JJ clinical) (NNS studies)) (PP (IN with) (NP (NNP Doc_3431591_917_924_Chemical))))) (, ,) (NP (NN activity)) (VP (AUX has) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (NP (NNP Doc_3431591_952_965_Disease)) (, ,) (NP (NNP Doc_3431591_967_981_Disease)) (, ,) (NP (NNP Doc_3431591_983_991_Disease)) (, ,) (CC and) (NP (NNP Doc_3431591_997_1009_Disease))))))) (. .)))
3431591	6	(S1 (S (NP (NN Doc_3431591_1011_1021_Disease)) (VP (VBD included) (NP (NP (NNP Doc_3431591_1031_1045_Disease)) (, ,) (NP (NNP Doc_3431591_1047_1054_Disease)) (, ,) (CC and) (NP (JJ dose-limiting) (NNP Doc_3431591_1074_1088_Disease)))) (. .)))
3431591	7	(S1 (S (NP (DT This) (JJ latter) (NN effect)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NN drug) (NN precipitation)))) (PP (IN within) (NP (NP (DT the) (JJ renal) (NN tubule)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (JJ poor) (NN solubility)) (PP (IN of) (NP (NNP Doc_3431591_1214_1221_Chemical))) (PP (IN under) (NP (JJ acidic) (NNS conditions)))))))))))))) (. .)))
3431591	8	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB overcome) (NP (DT this) (NN problem))))))) (, ,) (NP (NP (DT a) (JJ clinical) (NN trial)) (PP (IN of) (NP (NNP Doc_3431591_1307_1314_Chemical))) (VP (VBN administered) (PP (IN with) (NP (JJ alkaline) (NNS diuresis))))) (VP (AUX is) (PP (IN under) (NP (NN way)))) (. .)))
3431591	9	(S1 (S (NP (NP (JJ Preliminary) (NNS results)) (PP (IN at) (NP (QP (CD 400) (CC and) (CD 500)) (NNS mg/m2)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NNP Doc_3431591_1434_1448_Disease)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN achieved) (PP (IN with) (NP (NP (QP (RB only) (CD 1)) (NN instance)) (PP (IN of) (NP (NNP Doc_3431591_1496_1510_Disease))) (PP (IN in) (NP (CD 10) (NNS patients)))))))))))) (. .)))
3431591	10	(S1 (S (NP (NP (NNP Doc_3431591_1527_1541_Disease)) (CC and) (NP (NNP Doc_3431591_1546_1553_Disease))) (VP (AUX are) (ADVP (RB again)) (NP (DT the) (RBS most) (JJ frequent) (NN side) (NNS effects))) (. .)))
3431591	11	(S1 (S (NP (NP (NN Evidence)) (PP (IN of) (NP (NN antitumor) (NN activity)))) (VP (AUX has) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (CD 3) (NNS patients)))))) (. .)))
3431591	12	(S1 (S (NP (JJ Pharmacokinetic) (NNS investigations)) (VP (AUX have) (VP (VBN shown) (SBAR (SBAR (IN that) (S (NP (NN alkaline) (NN diuresis)) (VP (AUX does) (RB not) (VP (VB alter) (NP (NP (JJ Doc_3431591_1736_1743_Chemical) (NN plasma) (NNS levels)) (CC or) (NP (JJ urinary) (NN excretion))))))) (CC and) (SBAR (IN that) (S (NP (JJ satisfactory) (NN urinary) (NN alkalinization)) (VP (MD can) (VP (AUX be) (ADVP (RB readily)) (VP (VBN achieved))))))))) (. .)))
343678	0	(S1 (NP (NP (NP (NN Doc_343678_0_16_Disease)) (PP (IN after) (NP (NN needle-stick) (NN exposure)))) (: :) (NP (NP (NN prevention)) (PP (IN with) (NP (JJ Doc_343678_62_73_Disease) (JJ immune) (NN globulin)))) (. .)))
343678	1	(S1 (NP (NP (NP (JJ Final) (NN report)) (PP (IN of) (NP (DT the) (NNP Veterans) (NNP Administration)))) (NP (NNP Cooperative) (NNP Study)) (. .)))
343678	2	(S1 (S (NP (NP (NP (JJ Doc_343678_154_165_Disease) (JJ immune) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP HBIG)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ immune) (NN serum) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP ISG)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN trial)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (PRP$ their) (JJ relative) (NNS efficacies)) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_343678_321_337_Disease)) (PP (IN after) (NP (NP (JJ needle-stick) (NN exposure)) (PP (TO to) (NP (NNP Doc_343678_369_396_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_343678_398_403_Chemical)) (-RRB- -RRB-)) (JJ -positive) (NNS donors)))))))))))))))) (. .)))
343678	3	(S1 (S (S (NP (JJ Clinical) (NNP Doc_343678_431_440_Disease)) (VP (VBD developed) (PP (PP (IN in) (NP (NP (CD 1.4) (NN %)) (PP (IN of) (NP (NNP HBIG))))) (CC and) (PP (IN in) (NP (NP (CD 5.9) (NN %)) (PP (IN of) (NP (NP (JJ ISG) (NNS recipients)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.016)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (NP (NN seroconversion)) (PRN (-LRB- -LRB-) (NP (NNS anti-HBs)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 5.6) (NN %)) (CC and) (NP (NP (NP (CD 20.7) (NN %)) (PP (IN of) (NP (PRP them))) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NP (RB P) (JJR less)) (PP (IN than) (NP (CD 0.001)))) (-RRB- -RRB-))))))) (. .)))
343678	4	(S1 (S (NP (JJ Mild) (CC and) (JJ transient) (NNS side-effects)) (VP (AUX were) (VP (VBN noted) (PP (PP (IN in) (NP (NP (CD 3.0) (NN %)) (PP (IN of) (NP (NNP ISG))))) (CC and) (PP (IN in) (NP (NP (CD 3.2) (NN %)) (PP (IN of) (NP (NN HBIG) (NNS recipients)))))))) (. .)))
343678	5	(S1 (S (NP (JJ Available) (NN donor) (NNS sera)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NP (NP (NN DNA) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN DNAP)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN e) (NN antigen)) (CC and) (NP (NN antibody))) (PRN (-LRB- -LRB-) (NP (NNP Doc_343678_788_793_Chemical)) (: ;) (NP (NN anti-HBE)) (-RRB- -RRB-))))))) (. .)))
343678	6	(S1 (S (CC Both) (NP (NP (NNP DNAP)) (CC and) (NP (NNP Doc_343678_820_825_Chemical))) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB highly) (RB statistically) (JJ significant)) (NN correlation)) (PP (IN with) (NP (NP (DT the) (NN infectivity)) (PP (IN of) (NP (JJ Doc_343678_904_909_Chemical-positive) (NNS donors))))))) (. .)))
343678	7	(S1 (S (NP (JJ Doc_343678_927_938_Disease) (JJ immune) (NN globulin)) (VP (VBD remained) (ADJP (RB significantly) (JJ superior) (PP (TO to) (NP (NNP ISG)))) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_343678_1008_1024_Disease)) (ADVP (RB even))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN analysis)) (VP (AUX was) (VP (VBN confined) (PP (TO to) (NP (DT these) (CD two) (JJ high-risk) (NNS subgroups)))))))) (. .)))
343678	8	(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NNP ISG))) (PP (IN in) (S (VP (VBG preventing) (NP (JJ Doc_343678_1129_1145_Disease) (NN cannot)))))) (VP (AUX be) (VP (VBN ascertained) (SBAR (IN because) (S (NP (DT a) (JJ true) (NN placebo) (NN group)) (VP (AUX was) (RB not) (VP (VBN included))))))) (. .)))
3461217	0	(S1 (NP (NP (NN Production)) (PP (IN of) (NP (NP (JJ autochthonous) (NN Doc_3461217_28_43_Disease)) (PP (IN in) (NP (JJ Lobund-Wistar) (NNS rats))))) (PP (IN by) (NP (NP (NNS treatments)) (PP (IN with) (NP (NP (NNP Doc_3461217_85_107_Chemical)) (CC and) (NP (NNP Doc_3461217_112_124_Chemical)))))) (. .)))
3461217	1	(S1 (S (S (NP (NP (QP (JJR More) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (NNP Lobund-Wistar) (PRN (-LRB- -LRB-) (NP (NNP L-W)) (-RRB- -RRB-)) (NN strain) (NNS rats)))) (VP (VBD developed) (NP (JJ large) (, ,) (JJ palpable) (NNP Doc_3461217_201_225_Disease) (PRN (-LRB- -LRB-) (NNP Doc_3461217_227_230_Disease) (-RRB- -RRB-)) (JJ following) (NNS treatments)) (PP (IN with) (NP (NP (NP (NNP Doc_3461217_258_280_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CAS)) (: :) (NP (CD 684-93-5)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_3461217_301_324_Chemical) (JJ -LSB-) (PRN (-LRB- -LRB-) (NP (NNP Doc_3461217_327_329_Chemical)) (-RRB- -RRB-)) (NNP CAS)))) (: :) (NP (JJ 57-85-2) (NN -RSB-)))) (, ,) (CC and) (S (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (JJ Doc_3461217_362_367_Disease-bearing) (NNS rats)))) (VP (VBD manifested) (NP (JJ metastatic) (NNS lesions)))) (. .)))
3461217	2	(S1 (S (NP (DT The) (JJ incubation) (NNS periods)) (VP (VBD averaged) (NP (CD 10.6) (NNS months))) (. .)))
3461217	3	(S1 (S (PP (IN Within) (NP (DT the) (JJ same) (NN timeframe))) (, ,) (NP (DT no) (JJ L-W) (NN rat)) (VP (VBD developed) (NP (DT a) (JJ similar) (NN palpable) (NN Doc_3461217_524_526_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (ADVP (RB only)) (PP (IN with) (NP (NNP Doc_3461217_550_552_Chemical))))))) (. .)))
3461217	4	(S1 (S (PP (IN In) (NP (JJ L-W) (NNS rats))) (, ,) (NP (NNP Doc_3461217_567_569_Chemical)) (VP (VBD acted) (PP (IN as) (NP (DT a) (JJ Doc_3461217_581_586_Disease) (NN enhancement) (NN agent))) (, ,) (PP (IN with) (NP (NP (JJ primary) (NN emphasis)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3461217_650_665_Disease)))))))) (. .)))
3535719	0	(S1 (NP (NP (NP (JJ Relative) (NN efficacy)) (CC and) (NP (NN Doc_3535719_22_30_Disease))) (PP (IN of) (NP (NP (NNP Doc_3535719_34_44_Chemical)) (CC and) (NP (NNP Doc_3535719_49_59_Chemical)))) (PP (IN in) (NP (NN oncology) (NNS patients))) (. .)))
3535719	1	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBD compared) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_3535719_135_153_Chemical) (CC or) (NNP Doc_3535719_157_175_Chemical)))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_3535719_196_215_Chemical))) (PP (IN in) (NP (CD 118) (JJ immunocompromised) (NNS patients))) (PP (IN with) (NP (JJ presumed) (JJ severe) (NN Doc_3535719_271_281_Disease)))))) (. .)))
3535719	2	(S1 (S (NP (DT The) (CD two) (NN treatment) (NNS regimens)) (VP (AUX were) (ADJP (RB equally) (JJ efficacious))) (. .)))
3535719	3	(S1 (S (NP (NN Doc_3535719_336_350_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ similar) (NN proportion)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3535719_409_419_Chemical)) (CC and) (NP (NP (NNP Doc_3535719_424_434_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 17) (NN %)) (NNP vs) (CD 11) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
3535719	4	(S1 (S (NP (NN Doc_3535719_449_460_Disease)) (VP (VBD occurred) (PP (PP (IN in) (NP (NP (NP (CD four)) (PRN (-LRB- -LRB-) (NP (CD 9.5) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 42) (NNP Doc_3535719_491_501_Chemical) (CC and) (NNP Doc_3535719_506_518_Chemical))))) (CC and) (PP (IN in) (NP (NP (NP (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 54) (ADJP (JJ Doc_3535719_541_551_Chemical) (CC and) (JJ Doc_3535719_556_568_Chemical-treated)) (NNS patients))))))) (. .)))
3535719	5	(S1 (S (PP (IN Of) (NP (NP (DT those)) (VP (VBN evaluated) (PP (IN with) (NP (JJ posttherapy) (NNS audiograms)))))) (, ,) (NP (NP (CD three)) (PP (IN of) (NP (CD four) (UCP (NNP Doc_3535719_649_659_Chemical) (CC and) (JJ Doc_3535719_664_676_Chemical-treated)) (NNS patients)))) (VP (AUX had) (S (NP (NN auditory) (NNS thresholds)) (VP (VB return) (PP (TO to) (NP (NN baseline))) (PP (VBN compared) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (CD nine) (UCP (NNP Doc_3535719_763_773_Chemical) (CC and) (JJ Doc_3535719_778_790_Chemical-treated)) (NNS patients))))))))) (. .)))
3535719	6	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (JJ 15-dB) (NNS increases)) (PP (IN in) (NP (JJ auditory) (NN threshold))) (PP (IN as) (NP (NP (DT a) (NN proportion)) (PP (IN of) (NP (NP (JJ total)) (ADJP (JJR greater) (IN than) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (NP (JJ 15-dB) (NNS changes)) (PRN (-LRB- -LRB-) (NP (NP (NNS increases)) (CC and) (NP (NNS decreases))) (-RRB- -RRB-))))))))))))))) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NNP Doc_3535719_1003_1013_Chemical) (CC and) (NNP Doc_3535719_1018_1030_Chemical-) (NNP vs) (NNP Doc_3535719_1035_1045_Chemical)) (CC and) (NP (NP (JJ Doc_3535719_1050_1062_Chemical-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 18) (IN of) (CD 78)) (NNP vs) (CD 67)) (PP (IN of) (NP (CD 115)))) (-RRB- -RRB-)))))) (. .)))
3535719	7	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_3535719_1122_1136_Chemical-associated) (NNP Doc_3535719_1148_1159_Disease)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ severe)) (CC and) (ADJP (RBR more) (RB often) (JJ reversible) (PP (IN with) (NP (NNP Doc_3535719_1207_1217_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_3535719_1228_1238_Chemical))))))))) (. .)))
3653576	0	(S1 (NP (NP (NP (NN Urinary) (NNS enzymes)) (CC and) (NP (NN protein) (NNS patterns))) (PP (IN as) (NP (NP (NNS indicators)) (PP (IN of) (NP (NNP Doc_3653576_54_95_Disease))))) (. .)))
3653576	1	(S1 (S (NP (NP (NN Doc_3653576_97_138_Disease)) (PP (TO to) (NP (NP (DT the) (JJ proximal) (JJ tubular) (, ,) (NN glomerular) (, ,) (CC and) (NN papillary) (NNS regions)) (PP (IN of) (NP (DT the) (NN rat)))))) (VP (AUX were) (VP (VBN produced) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_3653576_244_268_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_270_274_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3653576_277_302_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_304_307_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3653576_314_331_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_333_336_Chemical)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))))))) (. .)))
3653576	2	(S1 (S (NP (NP (NP (JJ Several) (JJ routine) (NNS indicators)) (PP (IN of) (NP (NP (NNP Doc_3653576_383_397_Disease)) (, ,) (NP (NP (DT the) (JJ enzymes) (NN alkaline) (NN phosphatase)) (CC and) (NP (NN N-acetyl-beta-glucosaminidase))) (, ,)))) (CC and) (NP (NP (DT the) (JJ molecular) (NN weight)) (PP (IN of) (NP (NNP Doc_3653576_495_512_Disease))))) (VP (AUX were) (VP (VBN determined) (PP (IN on) (NP (NN urine) (NNS samples))))) (. .)))
3653576	3	(S1 (S (NP (NP (JJ Tubular) (NN damage)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3653576_574_578_Chemical)) (CC or) (NP (NNP Doc_3653576_582_585_Chemical)))))) (VP (AUX was) (VP (VBN discriminated) (ADVP (DT both) (RB quantitatively) (CC and) (RB qualitatively)) (PP (IN from) (NP (NP (NNP Doc_3653576_647_664_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3653576_677_680_Chemical)))))))) (. .)))
3653576	4	(S1 (S (NP (DT The) (NN latter)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ pronounced) (NN increase)) (PP (IN in) (NP (NP (NNP Doc_3653576_739_756_Disease)) (, ,) (NP (NP (RB especially) (NNS proteins)) (PP (IN with) (NP (JJ molecular) (NN weight))) (ADJP (QP (JJR greater) (IN than) (CD 40,000)) (NN Da))))))))) (. .)))
3653576	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN Doc_3653576_837_854_Disease)) (PP (IN in) (NP (JJ tubular) (NN damage)))) (VP (AUX was) (VP (VP (VBN raised) (ADVP (RB only) (RB slightly))) (CC and) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_3653576_919_940_Disease)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (JJ molecular) (NNS weights)))))))))) (. .)))
3653576	6	(S1 (S (S (NP (JJ Proximal) (JJ tubular) (NN damage)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3653576_1013_1017_Chemical))))) (CC and) (S (NP (NP (JJ papillary) (NN damage)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3653576_1049_1052_Chemical))))) (VP (AUX were) (VP (VBN distinguished) (PP (DT both) (PP (IN by) (NP (NP (JJ conventional) (NNS urinalysis)) (PRN (-LRB- -LRB-) (NP (NP (NN volume)) (CC and) (NP (JJ specific) (NN gravity))) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (NN measurement)) (PP (IN of) (NP (DT the) (CD two) (JJ urinary) (NNS enzymes))))))))) (. .)))
3653576	7	(S1 (S (S (NP (NP (JJ Alkaline) (NN phosphatase)) (CC and) (NP (NNP Doc_3653576_1206_1213_Chemical))) (VP (AUX were) (ADVP (RB markedly) (CC and) (RB transiently)) (ADJP (JJ elevated)) (PP (IN in) (NP (JJ proximal) (JJ tubular) (NN damage))))) (CC and) (S (NP (NNP N-acetyl-beta-glucosaminidase)) (VP (VBD showed) (NP (DT a) (JJ sustained) (NN elevation)) (PP (IN in) (NP (JJ papillary) (NN damage))))) (. .)))
3653576	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (DT both) (JJ selective) (NN urinary)) (VP (VBZ enzymes))) (CC and) (S (NP (NP (DT the) (JJ molecular) (NN weight) (NN pattern)) (PP (IN of) (NP (JJ urinary) (NNS proteins)))) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ diagnostic) (NN information)) (PP (IN about) (NP (NP (DT the) (JJ possible) (NN site)) (PP (IN of) (NP (NNP Doc_3653576_1542_1554_Disease))))))))))))))))) (. .)))
3670965	0	(S1 (FRAG (NP (DT A) (NN catch)) (PP (IN in) (NP (DT the) (NNP Doc_3670965_15_19_Disease))) (. .)))
3670965	1	(S1 (S (NP (NP (JJ Twenty-six) (NNS cases)) (PP (IN of) (NP (NP (NP (NNP Doc_3670965_41_54_Disease)) (PP (IN from) (NP (NP (DT The) (NNS Children) (POS 's)) (NNP Hospital)))) (, ,) (NP (NNP Camperdown)) (, ,) (NP (NNP Australia)) (, ,))) (VP (VBG occurring) (PP (IN between) (NP (CD 1973) (CC and) (CD 1982))))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
3670965	2	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (NP (CD 20) (NNS cases)) (VP (VBD met) (NP (DT the) (NNP US) (NNP Public) (NNP Health) (NNP Service) (NNPS Centers)) (PP (IN for) (NP (NNP Disease) (NNP Control))) (NP (NP (NNS criteria)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3670965_265_278_Disease))))))) (. .)))
3670965	3	(S1 (S (S (NP (NNP Doc_3670965_280_287_Chemical) (CC or) (NNP Doc_3670965_291_301_Chemical) (NN ingestion)) (VP (AUX had) (VP (VBN occurred) (PP (IN in) (NP (NP (RB only) (CD one)) (PP (IN of) (NP (NP (DT the) (CD 20) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_3670965_363_374_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3670965_376_389_Chemical)) (-RRB- -RRB-))) (VP (AUX had) (VP (AUX been) (VP (VBN administered) (PP (IN in) (NP (NP (RB only) (CD six)) (PP (IN of) (NP (DT the) (NNS cases))))) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)))))) (. .)))
3670965	4	(S1 (S (NP (NP (JJ Pathologic) (NN confirmation)) (PP (IN of) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3670965_489_502_Disease)))))) (VP (AUX was) (VP (VBN accomplished) (PP (IN in) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (DT the) (NNS cases))))))) (. .)))
3670965	5	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_3670965_558_571_Disease))) (PP (IN in) (NP (NP (NNP New) (NNP South) (NNP Wales)) (, ,) (NP (NNP Australia)) (, ,)))) (VP (AUX is) (VP (VBN estimated) (PP (IN from) (NP (DT this) (NN study) (S (VP (TO to) (VP (AUX be) (NP (NP (QP (RB approximately) (CD nine)) (NNS cases)) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (PP (VBN compared) (PP (IN with) (NP (JJ recent) (NNP US) (NNS data)))))) (PP (IN of) (NP (QP (CD ten) (TO to) (CD 20)) (NNS cases))) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (CC and) (NP (NP (QP (CD three) (TO to) (CD seven)) (NNS cases)) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (PP (IN in) (NP (NNP Great) (NNP Britain)))))))))))))))) (. .)))
3670965	6	(S1 (S (NP (NP (DT The) (NN mortality)) (PP (IN for) (NP (DT these) (NNP Doc_3670965_847_860_Disease) (NNS cases))) (PP (IN in) (NP (NNP Australia)))) (VP (AUX was) (NP (CD 45) (NN %)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT a) (ADJP (CD 32) (NN %)) (JJ case-fatality) (NN rate)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))))))) (. .)))
3670965	7	(S1 (S (PP (IN In) (NP (NNP Australia))) (, ,) (NP (NP (DT the) (JJ pediatric) (NN usage)) (PP (IN of) (NP (NNP Doc_3670965_989_996_Chemical)))) (VP (AUX has) (VP (AUX been) (ADJP (RB extremely) (JJ low)) (PP (IN for) (NP (NP (DT the) (JJ past) (CD 25) (NNS years)) (PRN (-LRB- -LRB-) (NP (NP (QP (JJR less) (IN than) (CD 1)) (NN %)) (PP (IN of) (NP (JJ total) (NN dosage) (NNS units))) (VP (VBN sold))) (-RRB- -RRB-)))) (, ,) (SBAR (IN with) (S (NP (NP (NNP Doc_3670965_1090_1101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3670965_1103_1116_Chemical)) (-RRB- -RRB-))) (VP (VBG dominating) (NP (DT the) (JJ pediatric) (JJ analgesic) (CC and) (JJ antipyretic) (NN market))))))) (. .)))
3670965	8	(S1 (S (NP (NN Doc_3670965_1177_1190_Disease)) (VP (MD may) (VP (AUX be) (VP (VBG disappearing) (PP (IN from) (NP (NNP Australia))) (PP (IN despite) (NP (NP (DT a) (JJ total) (NN lack)) (PP (IN of) (NP (NN association))) (PP (IN with) (NP (NNP Doc_3670965_1267_1278_Chemical) (CC or) (NNP Doc_3670965_1282_1289_Chemical) (NN ingestion))))) (, ,) (SBAR (IN since) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS cases)) (VP (VBN found) (PP (IN at) (NP (NP (NP (DT The) (NNP Children) (POS 's)) (NNP Hospital)) (PP (IN in) (NP (NP (CD 1983)) (, ,) (NP (CD 1984)) (, ,) (CC or) (NP (CD 1985)))))))))))))) (. .)))
3686155	0	(S1 (S (NP (NNP Postpartum) (NNP Doc_3686155_11_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3686155_32_45_Chemical)))) (. .)))
3686155	1	(S1 (S (NP (NP (CD Two) (NN multigravida) (NNS patients)) (PP (IN with) (NP (DT no) (JJ prior) (JJ Doc_3686155_87_98_Disease) (NN history)))) (VP (AUX were) (VP (VBN seen) (PP (IN with) (NP (NN postpartum) (NN Doc_3686155_133_142_Disease))) (, ,) (S (VP (AUXG having) (VP (VBN received) (NP (NNP Doc_3686155_160_173_Chemical)) (PP (IN for) (NP (NNP Doc_3686155_178_201_Disease)))))))) (. .)))
3686155	2	(S1 (S (NP (NP (NN Doc_3686155_203_216_Chemical)) (VP (VBN given) (PP (IN in) (NP (JJ high) (NNS doses))))) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_3686155_262_271_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT the) (NN drug)) (PP (IN for) (NP (NN Doc_3686155_307_326_Disease))))))))))) (. .)))
3686155	3	(S1 (S (NP (DT These) (NNS cases)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_3686155_357_370_Chemical)) (VP (MD may) (VP (VB cause) (NP (NN Doc_3686155_381_390_Disease)) (SBAR (ADVP (RB even)) (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (JJ low) (NNS doses))))))))))) (. .)))
3703509	0	(S1 (NP (NP (NP (NN Doc_3703509_0_27_Disease)) (CC and) (NP (NN death))) (PP (IN in) (NP (NNP Doc_3703509_41_62_Disease))) (. .)))
3703509	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ presents) (NP (NP (DT the) (ADJP (JJ clinical) (CC and) (JJ metabolic)) (NNS findings)) (PP (IN in) (NP (NP (CD two) (JJ young) (NNS boys)) (PP (IN with) (NP (JJ long-standing) (NN Doc_3703509_157_178_Disease))))))) (. .)))
3703509	2	(S1 (S (PP (VBG Following) (NP (NP (JJ short) (NN exposure)) (PP (TO to) (NP (JJ oral) (NNP Doc_3703509_213_223_Chemical))))) (, ,) (NP (DT both) (NNS boys)) (VP (VBD developed) (NP (NN Doc_3703509_245_253_Disease)) (, ,) (S (VP (VBG increasing) (NP (NP (NNP Doc_3703509_266_276_Disease)) (, ,) (NP (NNP Doc_3703509_278_288_Disease)) (, ,) (NP (NNP Doc_3703509_290_300_Disease)) (, ,) (CC and) (NP (NNP Doc_3703509_306_314_Disease)))))) (. .)))
3703509	3	(S1 (S (NP (DT Both)) (VP (VBD presented) (PP (IN in) (NP (DT the) (NN emergency) (NN room))) (PP (IN with) (NP (NP (JJ profound) (NNP Doc_3703509_367_371_Disease)) (, ,) (NP (NNP Doc_3703509_373_384_Disease)) (, ,) (NP (JJ severe) (NNP Doc_3703509_393_406_Disease)) (, ,) (CC and) (NP (NNP Doc_3703509_412_420_Disease))))) (. .)))
3703509	4	(S1 (S (S (NP (NNP Nonketotic) (NNP Doc_3703509_433_448_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (CD one)))))) (CC and) (S (NP (NP (NNP Doc_3703509_472_479_Disease)) (PP (IN without) (NP (DT a) (JJ known) (NN serum) (JJ Doc_3703509_502_509_Chemical) (NN level)))) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (DT the) (JJ other)))))) (. .)))
3703509	5	(S1 (S (S (NP (NN Doc_3703509_542_561_Disease)) (ADVP (RB rapidly)) (VP (VBD ensued))) (CC and) (S (NP (DT both) (NNS patients)) (VP (VBD expired) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (NNS efforts)) (PP (IN at) (NP (NN resuscitation))))))))) (. .)))
3703509	6	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (S (NP (DT these) (CD two) (NNS cases)) (VP (VBP represent) (NP (NP (DT a) (ADJP (ADJP (RB newly) (VBN described)) (CC and) (ADJP (JJ catastrophic))) (NN Doc_3703509_713_740_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_3703509_748_769_Disease)))))))) (. .)))
3708922	0	(S1 (NP (NP (JJ Experimental) (JJ Doc_3708922_13_25_Chemical) (NN Doc_3708922_26_40_Disease)) (: :) (NP (NP (NN risk)) (PP (IN of) (NP (JJ concomitant) (NNS chemotherapy)))) (. .)))
3708922	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NNP Doc_3708922_88_100_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3708922_102_105_Chemical)) (-RRB- -RRB-)))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ various) (NNS chemotherapeutics)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3708922_184_198_Disease))))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNS rats))))) (. .)))
3708922	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (CD 20) (NN mg/kg/day) (NNP Doc_3708922_253_256_Chemical))) (PP (IN for) (NP (CD 4) (NNS weeks)))) (VP (VBD caused) (NP (NP (JJ renal) (JJ functional) (CC and) (JJ structural) (NNS changes)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN reported) (PP (IN in) (NP (NN man))))))))) (. .)))
3708922	3	(S1 (S (NP (NP (DT The) (VBN combined) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3708922_381_384_Chemical) (CC and) (JJ various) (JJ chemotherapeutic) (NNS drugs)) (PP (IN with) (NP (DT a) (NNP Doc_3708922_427_438_Disease) (NN potential))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NNP Doc_3708922_458_468_Chemical)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (JJ therapeutic) (NNS doses))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_3708922_493_508_Chemical)) (CC and) (NP (NNP Doc_3708922_513_525_Chemical)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (JJ immunosuppressed) (NNS patients))))))) (, ,)) (VP (AUX did) (RB not) (VP (VB aggravate) (S (NP (DT the) (NNP Doc_3708922_605_608_Chemical)) (VP (VBN induced) (NP (NNP Doc_3708922_617_625_Disease)) (PP (IN in) (NP (DT the) (NN rat) (NN model))))))) (. .)))
3708922	4	(S1 (S (NP (NP (NN Doc_3708922_644_654_Chemical)) (PP (IN at) (NP (JJ toxic) (NNS doses)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD increased) (NP (NNP Doc_3708922_690_693_Chemical) (NNP Doc_3708922_694_708_Disease))) (. .)))
3708922	5	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NNP Doc_3708922_720_734_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3708922_746_749_Chemical))))) (VP (AUX has) (NP (DT a) (JJ different) (JJ pathogenetic) (NN mechanism))) (. .)))
3732088	0	(S1 (NP (NP (NP (NNP Diuretics)) (, ,) (NP (NNP Doc_3732088_11_20_Chemical)) (CC and) (NP (NNP Doc_3732088_25_36_Disease))) (PP (IN in) (NP (NNP Doc_3732088_40_52_Disease) (NNP Doc_3732088_53_69_Disease))) (. .)))
3732088	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (JJ modest) (NNS changes)) (PP (IN in) (NP (NN plasma) (NN Doc_3732088_122_131_Chemical)))) (VP (MD can) (VP (VB alter) (NP (DT the) (NN tendency)) (PP (IN towards) (NP (NN Doc_3732088_163_182_Disease)))))))))) (. .)))
3732088	2	(S1 (S (SBAR (IN If) (S (NP (DT this)) (VP (AUX were) (ADVP (RB so))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3732088_215_238_Disease)))) (VP (MD might) (VP (AUX be) (ADJP (RB especially) (JJ susceptible)))) (. .)))
3732088	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ myocardial) (JJ electrical) (NN excitability)) (VP (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mild) (JJ essential) (NN Doc_3732088_358_370_Disease))))))) (CC and) (VP (VBN known) (NP (NNP Doc_3732088_381_404_Disease)) (PP (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (DT a) (JJ Doc_3732088_439_448_Chemical-conserving) (NN diuretic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_470_479_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ similar) (NN period)) (PP (IN on) (NP (NP (DT a) (JJ Doc_3732088_507_516_Chemical-losing) (NN diuretic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_534_548_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT a) (JJ randomised) (NN study)))))))))))) (. .)))
3732088	4	(S1 (S (NP (NN Plasma) (NN Doc_3732088_580_589_Chemical) (NNS concentrations)) (VP (AUX were) (PP (IN on) (NP (NN average))) (ADVP (NP (CD 1) (CD mmol/L)) (JJR lower)) (PP (IN during) (NP (DT the) (JJ Doc_3732088_647_661_Chemical) (NN phase))) (PP (VBN compared) (PP (TO to) (NP (JJ Doc_3732088_680_689_Chemical) (NN therapy))))) (. .)))
3732088	5	(S1 (S (NP (NP (NN Blood) (NN pressure)) (CC and) (NP (NN volume) (NNS states))) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (NN bodyweight)) (, ,) (NP (NN plasma) (NN renin)) (CC and) (NP (NP (NNP Doc_3732088_776_789_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_791_805_Chemical)) (-RRB- -RRB-)))))))) (NP (NNS concentrations)) (VP (AUX were) (ADJP (JJ similar) (PP (IN on) (NP (DT the) (CD 2) (NNS regimens))))) (. .)))
3732088	6	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ Doc_3732088_866_875_Chemical) (NN treatment)))) (, ,) (NP (DT the) (JJ Doc_3732088_891_905_Chemical) (NN phase)) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN frequency)) (PP (IN of) (NP (NP (NP (NNP Doc_3732088_958_983_Disease)) (PRN (-LRB- -LRB-) (NP (JJ 24-hour) (NNP Holter) (NN monitoring)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJR higher) (NNP Lown) (NN grading)) (, ,) (NP (NP (VBN increased) (NN upslope) (CC and) (NN duration)) (PP (IN of) (NP (DT the) (JJ monophasic) (NN action) (NN potential)))) (, ,) (NP (JJ prolonged) (JJ ventricular) (JJ effective) (JJ refractory) (NN period)) (, ,)))))))) (CC and) (VP (VBD increased) (NP (JJ electrical) (NN instability)) (PP (IN during) (NP (JJ programmed) (NN ventricular) (NN stimulation))))) (. .)))
3732088	7	(S1 (S (NP (DT The) (JJ above) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (IN because) (S (NP (JJ Doc_3732088_1277_1286_Chemical-losing) (JJ diuretic) (NN therapy)) (VP (MD can) (VP (VB increase) (NP (JJ myocardial) (JJ electrical) (NN excitability)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3732088_1376_1399_Disease))))))))) (, ,) (NP (NP (ADJP (RB even) (JJ minor)) (VBZ falls)) (PP (IN in) (NP (NN plasma) (NNP Doc_3732088_1428_1437_Chemical) (NNS concentrations)))) (VP (AUX are) (ADVP (RB probably)) (VP (ADVP (RBS best)) (VBN avoided) (PP (IN in) (NP (JJ such) (NNS patients)))))))) (. .)))
3762968	0	(S1 (NP (NP (NN Transketolase) (NN abnormality)) (PP (IN in) (NP (NNP Doc_3762968_29_39_Chemical-induced) (NNP Doc_3762968_48_73_Disease))) (. .)))
3762968	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (JJ Doc_3762968_88_96_Chemical-dependent) (NN enzyme)) (, ,) (NP (NN transketolase)) (, ,)) (PP (IN from) (NP (NP (NNS fibroblasts)) (PP (IN of) (NP (NP (DT a) (NNP Doc_3762968_152_160_Disease) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3762968_183_208_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3762968_227_237_Chemical))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB delineate) (SBAR (IN if) (S (NP (DT this) (NN patient)) (ADVP (RB also)) (VP (AUX had) (NP (JJ transketolase) (JJ abnormality) (JJ -LSB-high) (NNS Km)) (PP (IN for) (NP (NNP Doc_3762968_325_347_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3762968_349_352_Chemical)) (-RRB- -RRB-)) (NN -RSB-))) (, ,) (SBAR (IN as) (S (ADVP (RB previously)) (VP (VBN reported) (PP (IN in) (NP (JJ postalcoholic) (NNP Doc_3762968_396_423_Disease)))))))))))))))))))))))) (. .)))
3762968	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (DT this) (NN patient))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD studied) (NP (DT this) (NN enzyme)) (PP (IN from) (NP (CD three) (JJ Doc_3762968_493_501_Disease) (NNS kindreds))) (PP (PP (IN without) (NP (NP (DT any) (NN history)) (PP (IN of) (NP (NNP Doc_3762968_534_559_Disease))))) (CC and) (PP (IN from) (NP (CD four) (JJ normal) (NNS controls))))) (. .)))
3762968	3	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NP (DT the) (JJ above-mentioned) (NN patient)) (CC and) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ Doc_3762968_648_656_Disease) (NNS kindreds))))) (PP (IN with) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_3762968_685_710_Disease)))))) (VP (AUX had) (NP (JJ abnormal) (NN transketolase)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (PRP$ its) (NN Km)) (PP (IN for) (NP (NNP Doc_3762968_766_769_Chemical)))))))))))) (. .)))
3762968	4	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (NN similarity)) (PP (IN between) (NP (NP (JJ postalcoholic) (NN Doc_3762968_825_852_Disease)) (CC and) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (JJ Doc_3762968_874_884_Chemical-induced) (NNP Doc_3762968_893_918_Disease))) (PP (IN from) (NP (NP (DT the) (NN standpoint)) (PP (IN of) (NP (NN transketolase) (NN abnormality)))))))))) (. .)))
3769769	0	(S1 (NP (NP (NN Doc_3769769_0_11_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_3769769_19_48_Chemical)))) (. .)))
3769769	1	(S1 (S (NP (DT A) (JJ chronic) (NN Doc_3769769_60_73_Disease) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT an) (JJ anticholinergic) (NN drug)) (, ,) (NP (NNP Doc_3769769_124_153_Chemical)))))) (. .)))
3769769	2	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (, ,) (ADVP (RB paradoxically)) (, ,) (NP (JJ sinus) (NN Doc_3769769_199_210_Disease))) (. .)))
3769769	3	(S1 (S (NP (DT The) (NN reaction)) (VP (AUX was) (UCP (ADJP (JJ specific) (PP (TO to) (NP (NNP Doc_3769769_241_256_Chemical)))) (CC and) (RB not) (PP (TO to) (NP (JJ other) (JJ anticholinergic) (NNS drugs))))) (. .)))
3769769	4	(S1 (S (S (NP (DT This) (JJ antidyskinetic) (NN drug)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (JJ Doc_3769769_349_360_Disease) (NN practice)))))) (CC and) (S (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN side) (NN effect))))))) (. .)))
3780697	0	(S1 (NP (NP (JJ Post-operative) (NN Doc_3780697_15_23_Disease)) (PP (IN after) (NP (NNP Doc_3780697_30_38_Chemical) (NN administration))) (. .)))
3780697	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ thoraco-abdominal) (NNP Doc_3780697_83_91_Disease))) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_3780697_103_122_Disease))))) (VP (AUX is) (VP (VBN described) (PP (IN in) (NP (DT the) (JJ post-operative) (NN period))) (PP (IN in) (NP (NP (DT an) (JJ elderly) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT a) (JJ moderate) (NN dose)) (PP (IN of) (NP (NN Doc_3780697_219_227_Chemical))))))))))) (. .)))
3780697	2	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_3780697_263_271_Chemical))))) (. .)))
3780697	3	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (VP (ADVP (RB possibly)) (VBN implicated) (PP (IN in) (NP (DT this) (NN accident))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
3780814	0	(S1 (S (NP (NP (JJ Anti-Doc_3780814_5_17_Disease) (NN action)) (PP (IN of) (NP (NNP Doc_3780814_28_41_Chemical)))) (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_68_86_Chemical))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
3780814	1	(S1 (S (NP (DT The) (JJ present) (NN work)) (VP (AUX has) (VP (AUX been) (VP (VBN planned) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3780814_169_182_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3780814_184_186_Chemical)) (: :) (NP (NP (CD 15) (NNS mg)) (PP (IN per) (NP (NP (NN rat)) (PP (IN of) (NP (JJ ingested) (NN dose))))))) (-RRB- -RRB-)))) (PP (IN on) (NP (NNP Doc_3780814_223_237_Disease)))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (AUX is) (VP (VBN administered) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NNP Doc_3780814_282_300_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3780814_302_305_Chemical)) (: :) (NP (CD 10) (NN mg/kg/day))) (-RRB- -RRB-)))))))))))))) (. .)))
3780814	2	(S1 (S (NP (NP (JJ Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 180) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (PP (IN by) (NP (NP (NNP Doc_3780814_358_361_Chemical)) (ADVP (RB alone)))) (CC or) (PP (IN by) (NP (NNP Doc_3780814_374_377_Chemical) (NNP +) (NNP Doc_3780814_380_382_Chemical)))) (PP (IN during) (NP (CD 2) (, ,) (CD 4) (CC and) (CD 6) (NNS weeks))) (PP (VBG according) (PP (TO to) (NP (NP (PRP$ our) (NN schedule)) (PP (IN for) (NP (NNP Doc_3780814_437_457_Disease)))))))) (. .)))
3780814	3	(S1 (S (PP (IN After) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN treatment))))) (, ,) (NP (NP (DT the) (NN number)) (CC and) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (VBN induced) (NNP PAS) (JJ positive) (NN Doc_3780814_539_557_Disease))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3780814_589_591_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_622_625_Chemical))) (PP (IN for) (NP (QP (CD 4) (CC and) (CD 6)) (NNS weeks))))))))) (. .)))
3780814	4	(S1 (S (NP (NP (DT The) (JJ mitotic) (NN inhibition)) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (FW micronuclei))))) (ADVP (RB normally)) (VP (VBD observed) (SBAR (IN after) (S (NP (NP (JJ partial) (NN hepatectomy)) (PP (IN in) (NP (JJ Doc_3780814_749_752_Chemical) (VBN treated) (NNS rats)))) (VP (AUX were) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBN decreased) (PP (IN in) (NP (JJ Doc_3780814_803_806_Chemical) (JJ +) (JJ Doc_3780814_809_811_Chemical) (VBN treated) (NNS rats)))))))) (. .)))
3780814	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN treatment)) (VP (VB last) (NP (QP (RB only) (CD 2)) (NNS weeks))))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_3780814_880_882_Chemical)))) (VP (AUX did) (RB not) (VP (NN change) (ADVP (RB significantly)) (NP (DT the) (JJ last) (NNS parameters)))) (. .)))
3780814	6	(S1 (S (PP (IN In) (NP (JJ Doc_3780814_936_939_Chemical) (JJ +) (JJ Doc_3780814_942_944_Chemical) (VBN treated) (NNS rats))) (, ,) (S (NP (DT the) (NN survival)) (VP (AUX was) (VP (VBN prolonged)))) (CC and) (S (NP (DT the) (NNP Doc_3780814_994_999_Disease) (NN incidence)) (VP (VBD decreased) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS results)) (VP (VBN obtained) (PP (IN by) (NP (NP (NNP Doc_3780814_1061_1064_Chemical)) (ADVP (RB alone)))))))))))) (. .)))
3780814	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NNP Doc_3780814_1093_1095_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ promotes) (NP (NN Doc_3780814_1112_1126_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN after) (NP (DT the) (JJ Doc_3780814_1155_1158_Chemical) (NN treatment))))))))) (, ,)) (VP (VBZ reduces) (NP (DT the) (NN carcinogen) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_1231_1234_Chemical))))))))))) (. .)))
3780814	8	(S1 (S (S (NP (DT This)) (VP (POS ') (ADJP (JJ anti-carcinogen)))) (: ') (S (NP (NN effect)) (VP (VBZ acts) (PP (PP (IN on) (NP (DT the) (NN initiation))) (CONJP (RB as) (RB well) (IN as)) (PP (IN on) (NP (NP (DT the) (NN promotion)) (PP (IN of) (NP (DT the) (NNP Doc_3780814_1324_1344_Disease)))))))) (. .)))
3780814	9	(S1 (S (NP (JJ Biochemical) (NNS investigations)) (VP (AUX are) (PP (IN in) (NP (NN progress))) (S (VP (TO to) (VP (VB obtain) (NP (NP (JJR more) (NN information)) (PP (IN about) (NP (NP (DT this) ('' ') (NN paradoxical) (POS ')) (NNP Doc_3780814_1441_1443_Chemical) (NN effect)))))))) (. .)))
384871	0	(S1 (S (VP (VB Doc_384871_0_26_Disease) (ADVP (RB due)) (PP (TO to) (NP (JJ combined) (NNP Doc_384871_43_53_Chemical) (CC and) (NNP Doc_384871_58_67_Chemical) (NN treatment)))) (. .)))
384871	1	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 40-year-old) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD underwent) (NP (DT an) (JJ unsuccessful) (NN cadaver) (NN kidney) (NN transplantation))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_384871_195_205_Chemical)) (CC and) (NP (NNP Doc_384871_210_219_Chemical)))))))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
384871	2	(S1 (S (NP (NP (DT A) (NN Doc_384871_235_267_Disease)) (PP (IN with) (NP (DT an) (JJ unusual) (JJ central) (NN bitemporal) (NN hemianopic) (NN Doc_384871_314_321_Disease)))) (VP (AUX was) (VP (VBN found))) (. .)))
384871	3	(S1 (S (S (NP (NN Doc_384871_333_343_Chemical)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (NP (JJ only) (JJ small) (NN improvement)) (PP (IN of) (NP (DT the) (JJ visual) (NN acuity)))) (VP (VBD followed))) (. .)))
384871	4	(S1 (S (NP (NN Doc_384871_414_423_Chemical)) (VP (AUX was) (VP (VBN discontinued) (ADVP (RB later)) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ dramatic) (NN improvement)) (PP (IN in) (NP (DT the) (JJ visual) (NN acuity))))))))) (. .)))
384871	5	(S1 (S (NP (NP (DT The) (NNS hazards)) (PP (IN of) (NP (JJ optic) (NN nerve) (NN Doc_384871_532_540_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_384871_548_558_Chemical)))) (VP (AUX are) (VP (VBN known))) (. .)))
384871	6	(S1 (S (NP (PRP We)) (VP (VB emphasize) (NP (DT the) (JJ potential) (NN danger)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_384871_618_628_Chemical)) (CC and) (NP (NNP Doc_384871_633_642_Chemical))))))) (. .)))
3934126	0	(S1 (NP (NP (DT A) (JJ prospective) (NN study)) (PP (IN of) (NP (JJ adverse) (NNS reactions))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3934126_57_67_Chemical) (NN therapy)))) (. .)))
3934126	1	(S1 (S (NP (NP (NP (DT A) (JJ prospective) (NN evaluation)) (PP (IN of) (NP (DT the) (NN efficacy)))) (CC and) (NP (NP (NN safety)) (PP (IN of) (NP (NNP Doc_3934126_132_142_Chemical))))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (CD 54) (JJ consecutive) (NNS patients))) (PP (IN over) (NP (DT a) (JJ 16-month) (NN period))))) (. .)))
3934126	2	(S1 (S (NP (NN Doc_3934126_208_218_Chemical)) (VP (AUX was) (ADJP (JJ curative)) (PP (IN in) (NP (NP (CD 95) (NN %)) (PP (IN of) (NP (NP (CD 43) (NNS patients)) (PP (IN with) (NP (JJ proven) (NNP Doc_3934126_266_275_Disease)))))))) (. .)))
3934126	3	(S1 (S (S (NP (NNS Drugs)) (VP (AUX were) (VP (VBN ceased) (PP (IN in) (NP (CD six) (NNS patients))) (PP (IN because) (IN of) (NP (JJ adverse) (NNS reactions)))))) (: ;) (S (NP (NP (IN in) (CD three)) (PP (IN of) (NP (DT these) (NNP Doc_3934126_359_369_Chemical)))) (VP (AUX was) (VP (VBN considered) (S (NP (DT the) (JJ likely) (NN cause)))))) (. .)))
3934126	4	(S1 (S (NP (NNS Reactions)) (VP (VBD included) (NP (NP (NP (NNP Doc_3934126_422_438_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 20)) (PP (IN of) (NP (CD 54) (NNS patients)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3934126_460_464_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 54)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3934126_476_490_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 50)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3934126_502_513_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (CD 50)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3934126_528_539_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (NP (CD 11) (NNS patients)) (VP (VBN tested) (PP (IN by) (NP (NN audiometry))))))) (-RRB- -RRB-))))) (. .)))
3934126	5	(S1 (S (S (NP (NN Doc_3934126_581_597_Disease)) (VP (VBD occurred) (ADVP (RB only)) (PP (IN with) (NP (NN infusion))) (PP (IN through) (NP (JJ peripheral) (NNS cannulae))))) (: ;) (S (NP (NP (NNP Doc_3934126_655_669_Disease)) (CC and) (NP (NNP Doc_3934126_674_685_Disease))) (VP (AUX were) (VP (VBN confined) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT an) (NNP Doc_3934126_725_739_Chemical) (CC plus) (NNP Doc_3934126_745_755_Chemical)))))))) (. .)))
3934126	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NNP Doc_3934126_774_784_Chemical)) (, ,) (VP (VBN administered) (ADVP (RB appropriately))) (, ,)) (VP (VBZ constitutes) (NP (NP (JJ safe) (, ,) (JJ effective) (NN therapy)) (PP (IN for) (NP (NP (NNP Doc_3934126_854_864_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ susceptible) (NNS bacteria))))))))))) (. .)))
3950060	0	(S1 (S (NP (NNS Factors)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN Doc_3950060_24_38_Disease)) (CC and) (NP (JJ clinical) (NN outcome))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3950060_82_90_Chemical)))))))) (. .)))
3950060	1	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (CD 60) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3950060_127_135_Chemical))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3950060_178_192_Disease)))))))) (. .)))
3950060	2	(S1 (S (PP (IN In) (NP (NP (CD 42)) (PP (IN of) (NP (DT these) (NNS patients))))) (, ,) (NP (NNS data)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (JJ clinical) (NN outcome)))))))) (. .)))
3950060	3	(S1 (S (NP (NP (NNS Variables)) (VP (VBN evaluated))) (VP (VBD included) (SBAR (S (NP (NP (JJ patient) (NN weight) (, ,) (NN age) (, ,) (NN sex) (, ,) (JJ serum) (NNP Doc_3950060_345_355_Chemical) (NN level)) (, ,) (NP (NNP Doc_3950060_363_373_Chemical) (NN clearance)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN therapy)))) (, ,) (NP (JJ total) (NN dose)) (, ,)) (VP (VBP mean) (S (NP (NP (JJ daily) (NN dose)) (, ,) (NP (NN organism) (NN minimum) (NN inhibitory) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NNP MIC)) (-RRB- -RRB-)) (, ,)) (VP (VP (VB mean) (NP (NN peak) (NNS levels))) (, ,) (VP (VB mean) (NP (NN trough) (NNS levels))) (, ,) (VP (VB mean) (NP (NN area)) (PP (IN under) (NP (NP (NP (DT the) (NN serum)) (JJ concentration-time) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)) (, ,) (NP (JJ total) (NNP AUC))))) (, ,) (VP (VB mean) (S (NP (NNP AUC)) (ADJP (JJR greater) (PP (IN than) (NP (NP (JJ MIC) (, ,) (JJ total) (NNS AUC)) (ADJP (ADJP (JJR greater) (PP (IN than) (NP (JJ MIC) (PRN (, ,) (S (VP (VB mean) (NP (NP (NP (NNP Schumacher) (POS 's)) (NN intensity) (NN factor)) (PRN (-LRB- -LRB-) (IN IF) (-RRB- -RRB-))))) (, ,)) (NN total)))) (SBAR (IN IF) (, ,) (PP (IN In) (PRN (-LRB- -LRB-) (VP (VB mean) (NP (NN maximum) (NN concentration)) (NP (JJ -LSB-Cmax) (JJ -RSB-) (NN /MIC))) (-RRB- -RRB-)))))))))))))))) (. .)))
3950060	4	(S1 (S (NP (JJ Model-dependent) (JJ pharmacokinetic) (NNS parameters)) (VP (AUX were) (VP (VBN calculated) (PP (IN by) (NP (NN computer))) (PP (VBN based) (PP (IN on) (NP (DT a) (JJ one-compartment) (NN model)))))) (. .)))
3950060	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNS parameters)) (VP (AUX were) (VP (VBN examined) (ADVP (RB individually)))))) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN therapy) (CC and) (NN total) (NN AUC)))) (VP (VBD correlated) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .05))) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_3950060_976_990_Disease)))) (. .)))
3950060	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT a) (JJ stepwise) (NN discriminant) (NN function) (NN analysis)) (VP (VBD identified) (NP (NP (JJ only) (NN duration)) (PP (IN of) (NP (NN therapy))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-))) (PP (IN as) (NP (DT an) (JJ important) (NN factor)))) (. .)))
3950060	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT this) (NN model))) (CC and) (PP (IN on) (NP (NP (NNP Bayes) (POS ')) (NN theorem)))) (, ,) (NP (NP (DT the) (JJ predictive) (NN accuracy)) (PP (IN of) (S (VP (VBG identifying) (NP (`` ``) (JJ Doc_3950060_1209_1220_Disease) ('' '') (NNS patients)))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.17))) (PP (TO to) (NP (CD 0.39)))) (. .)))
3950060	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN examined) (ADVP (RB individually))))) (, ,) (VP (VB mean) (SBAR (IN IF) (, ,) (S (NP (NP (JJ MIC) (, ,) (JJ total) (NN dose)) (, ,) (NP (JJ mean) (JJ daily) (NN dose)) (, ,) (CC and) (NP (NP (NNS ln)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NNP Cmax/MIC)) (-RRB- -RRB-)))) (VP (VBD correlated) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .05))) (-RRB- -RRB-)) (PP (IN with) (NP (NN cure))))))) (. .)))
3950060	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT a) (JJ simultaneous) (JJ multivariable) (NN analysis)) (VP (VBN identified) (SBAR (IN IF) (, ,) (S (NP (NP (NN MIC)) (, ,) (CC and) (NP (JJ total) (NN dose)) (PP (VBG according) (PP (TO to) (NP (NP (CD one) (NN model)) (CC and) (NP (NP (NNS ln)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NNP Cmax/MIC)) (-RRB- -RRB-))))))) (PP (VBG according) (PP (TO to) (NP (NP (DT a) (JJ second) (JJ statistical) (NN model)) (PP (IN of) (NP (NP (NNS parameters)) (VP (VBN selected) (S (VP (TO to) (VP (AUX have) (NP (DT the) (JJS greatest) (JJ prospective) (NN value)))))))))))))) (. .)))
3950060	10	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (NP (NNP Bayes) (POS ')) (NN theorem)) (CC and) (NP (DT the) (JJ first) (NN model))))) (, ,) (NP (NP (DT the) (JJ predictive) (NN accuracy)) (PP (IN of) (NP (NP (VBG identifying) (NNS patients)) (VP (RB not) (VBN cured))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.19))) (PP (TO to) (NP (CD 0.83)))) (. .)))
3950060	11	(S1 (S (PP (IN For) (NP (DT the) (JJ second) (NN model))) (, ,) (NP (DT the) (JJ predictive) (NN accuracy)) (VP (VBD increased) (PP (IN from) (NP (CD 0.19))) (PP (TO to) (NP (CD 0.50.))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
3952818	0	(S1 (NP (NP (NN Doc_3952818_0_16_Disease)) (PP (IN of) (NP (NNP Doc_3952818_20_34_Chemical))) (. .)))
3952818	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ spontaneous) (NNP Doc_3952818_68_74_Disease))))) (. .)))
3952818	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_3952818_111_126_Disease)) (CC and) (NP (NN liver) (NN Doc_3952818_137_147_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (NP (NNP Doc_3952818_162_172_Disease)) (PP (IN after) (NP (NNP Doc_3952818_179_193_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3952818_195_199_Chemical)) (-RRB- -RRB-)) (NN administration)))))))))) (. .)))
3952818	3	(S1 (S (S (NP (JJ Clinical) (JJ electrocardiographic) (NN evolution)) (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_3952818_289_308_Disease))))))))) (, ,) (CC and) (S (NP (NNP Doc_3952818_314_324_Disease)) (VP (ADVP (RB promptly)) (VBN resolved) (PP (IN with) (NP (NNP Doc_3952818_348_358_Chemical))))) (. .)))
3952818	4	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_3952818_384_398_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NNP Doc_3952818_419_433_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_3952818_441_445_Chemical)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNP Doc_3952818_456_463_Chemical) (NNS antagonists)) (VP (MD may) (ADVP (RB probably)) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN prevention) (CC or) (NN treatment)) (PP (IN of) (NP (NNP Doc_3952818_531_535_Chemical) (NNP Doc_3952818_536_550_Disease)))))))))))) (. .)))
3961813	0	(S1 (NP (NP (JJ Dose-related) (JJ beneficial) (CC and) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ dietary) (NNP Doc_3961813_55_69_Chemical))) (PP (IN on) (NP (NP (JJ Doc_3961813_73_89_Chemical-induced) (JJ delayed) (NN Doc_3961813_106_116_Disease)) (PP (IN in) (NP (NNS chickens))))) (. .)))
3961813	1	(S1 (S (S (NP (NP (NNP Doc_3961813_130_155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3961813_157_161_Chemical)) (-RRB- -RRB-)) (, ,) (NP (CD 360) (NN mg/kg)) (, ,)) (VP (VBD po))) (, ,) (CC and) (S (NP (NP (NP (NNP Doc_3961813_183_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3961813_221_224_Chemical)) (-RRB- -RRB-))) (, ,) (NP (QP (CD 1) (CD mg/kg)) (NN sc)) (, ,)) (VP (AUX were) (VP (VBN administered) (PP (TO to) (NP (JJ adult) (NNP White) (NNP Leghorn) (NNS chickens))) (SBAR (NP (CD 24) (NNS hr)) (IN after) (S (NP (PRP they)) (VP (AUX were) (VP (VBN placed) (PP (IN on) (NP (NP (NNS diets)) (VP (VBG containing) (NP (QP (CD 0) (TO to) (CD 300) (CD ppm)) (NNP Doc_3961813_351_365_Chemical)))))))))))) (. .)))
3961813	2	(S1 (S (NP (JJ Supplemented) (NNS diets)) (VP (AUX were) (VP (VBN continued) (SBAR (IN until) (S (NP (NP (JJ clinical) (NNS signs)) (CC and) (NP (NP (NNS lesions)) (PP (IN of) (NP (JJ delayed) (NNP Doc_3961813_445_455_Disease))))) (VP (VBD appeared)))))) (. .)))
3961813	3	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (JJ low) (NNS concentrations)) (PRN (-LRB- -LRB-) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 50) (NN ppm)))) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_3961813_528_542_Chemical)))) (VP (AUX had) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN on) (NP (NNP Doc_3961813_569_573_Chemical-induced) (NNP Doc_3961813_582_592_Disease))))))) (, ,) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (QP (CD 200) (CD ppm))))) (VP (VBD exacerbated) (NP (NP (JJ clinical) (NNS signs)) (PP (IN in) (NP (NP (NNS chickens)) (VP (VBN given) (NP (DT either) (NNP Doc_3961813_679_683_Chemical) (CC or) (NNP Doc_3961813_687_690_Chemical))))))) (. .)))
3961813	4	(S1 (S (NP (JJ Doc_3961813_692_702_Disease) (NN esterase) (NNS activities)) (PP (NP (CD 24) (NNS hr)) (IN after) (NP (NP (NNP Doc_3961813_735_739_Chemical)) (CC or) (NP (NNP Doc_3961813_743_746_Chemical)))) (VP (AUX were) (NP (NP (QP (JJR less) (IN than) (CD 20)) (NN %)) (PP (IN of) (NP (NP (NNS values)) (VP (VBN measured) (PP (IN in) (NP (NP (NNS chickens)) (SBAR (S (RB not) (VP (VBN given) (NP (JJ Doc_3961813_807_824_Chemical) (NNS compounds)))))))))))) (. .)))
3961813	5	(S1 (S (NP (NP (NNS Chickens)) (VP (VBN given) (NP (QP (CD 200) (CD ppm)) (NNP Doc_3961813_859_873_Chemical)) (PP (IN without) (NP (NNP Doc_3961813_882_886_Chemical) (CC or) (NNP Doc_3961813_890_893_Chemical))))) (VP (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJ elevated)) (NN activity)) (PP (IN of) (NP (NN plasma) (NN cholinesterase))))) (CC and) (VP (ADVP (RB significantly)) (VBD inhibited) (NP (NP (NN activity)) (PP (IN of) (NP (NN liver) (NN carboxylesterase)))))) (. .)))
3961813	6	(S1 (S (NP (NN Doc_3961813_1019_1049_Disease)) (VP (AUX were) (ADVP (RB also)) (ADJP (JJ evident)) (PP (IN in) (NP (NP (JJ distal) (NNS levels)) (PP (IN of) (NP (NP (DT the) (JJ peripheral) (NNS nerves)) (PP (IN of) (NP (NP (NNS chickens)) (VP (VBN given) (NP (NNP Doc_3961813_1128_1132_Chemical) (CC or) (NNP Doc_3961813_1136_1139_Chemical)))))))))) (. .)))
3962737	0	(S1 (NP (NP (NN Doc_3962737_0_14_Disease)) (PP (IN of) (NP (NNP Doc_3962737_18_28_Chemical))) (. .)))
3962737	1	(S1 (S (NP (NN Doc_3962737_30_40_Chemical)) (VP (AUX has) (VP (VBN proved) (ADJP (RB very) (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (RB otherwise) (JJ resistant)) (JJ cardiac) (NN Doc_3962737_115_131_Disease))))))) (. .)))
3962737	2	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_3962737_144_154_Chemical)))) (VP (AUX has) (, ,) (ADVP (RB however)) (, ,) (VP (AUX been) (VP (VBN limited) (PP (JJ due) (TO to) (NP (PRP$ its) (JJ serious) (NNS side-effects)))))) (. .)))
3962737	3	(S1 (S (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NNP Doc_3962737_230_251_Disease))) (PP (JJ due) (TO to) (NP (JJ Doc_3962737_259_269_Chemical) (NN treatment)))) (VP (AUX is) (VP (VBN presented) (ADVP (RB below))))) (CC and) (S (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (DT the) (NNP Doc_3962737_319_333_Disease)) (PP (IN of) (NP (NNP Doc_3962737_337_347_Chemical)))))) (VP (AUX is) (VP (VBN given)))) (. .)))
3962737	4	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (JJ solid) (NN evidence) (VBZ exists)) (PP (IN of) (NP (NNP Doc_3962737_404_418_Disease))) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_3962737_426_436_Chemical) (NN treatment)))) (, ,) (VP (VBG including) (NP (NNP Doc_3962737_458_467_Disease))) (, ,)) (VP (VBZ alterations) (S (VP (VBG resembling) (NP (NP (NNP Doc_3962737_492_511_Disease)) (, ,) (NP (NNP Doc_3962737_513_534_Disease)) (CC and) (NP (JJ micronodular) (NNP Doc_3962737_552_574_Disease)))))))))) (. .)))
3962737	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NNP Doc_3962737_595_605_Chemical)))) (VP (MD should) (VP (AUX be) (ADVP (RB regularly)) (VP (VBN screened) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (JJ hepatic) (JJ enzyme) (NNS levels)))))))) (. .)))
3962737	6	(S1 (S (NP (NN Therapy)) (VP (MD should) (VP (AUX be) (VP (VBN discontinued) (PP (IN on) (NP (NP (DT the) (NN suspicion)) (PP (IN of) (NP (NP (NNP Doc_3962737_725_743_Disease)) (CC or) (NP (NNP Doc_3962737_747_759_Disease))))))))) (. .)))
3969369	0	(S1 (S (NP (NP (NP (JJ Promotional) (NNS effects)) (PP (IN of) (NP (NNP Doc_3969369_23_35_Chemical)))) (CC and) (NP (NP (NN dietary) (NN fat)) (PP (IN on) (NP (NN prostate))))) (VP (VBP Doc_3969369_64_78_Disease) (PP (IN in) (NP (ADJP (RB genetically) (JJ susceptible)) (NNS rats)))) (. .)))
3969369	1	(S1 (S (NP (NP (NNP Germfree) (PRN (-LRB- -LRB-) (NP (NNP GF)) (-RRB- -RRB-)) (NNP Lobund) (NN strain) (NNP Wistar) (PRN (-LRB- -LRB-) (NP (NNP LW)) (-RRB- -RRB-)) (NNS rats)) (, ,) (VP (VBN fed) (NP (NN vegetable) (NN diet) (CD L-485))) (, ,)) (VP (AUX have) (VP (VBN developed) (NP (NNP Doc_3969369_199_223_Disease)) (ADVP (RB spontaneously)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %) (NN incidence)) (-RRB- -RRB-)) (PP (IN at) (NP (NP (JJ average) (NN age)) (NP (CD 34) (NNS months)))))) (. .)))
3969369	2	(S1 (S (S (NP (NP (JJ Conventional) (NN LW) (NNS rats)) (, ,) (VP (VBN implanted) (PP (IN with) (NP (NNP Doc_3969369_317_329_Chemical))) (PP (IN at) (NP (NP (NN age)) (NP (CD 4) (NNS months))))) (, ,)) (VP (VBD developed) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NNP Doc_3969369_379_394_Disease)))) (PP (IN after) (NP (NP (DT an) (JJ average) (NN interval)) (PP (IN of) (NP (CD 14) (NNS months))))))) (: :) (S (NP (CD 24) (NN %)) (VP (AUX had) (VP (VBN developed) (NP (NP (JJ gross) (NN Doc_3969369_459_465_Disease)) (, ,) (CC and) (NP (CD 40) (NN %))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD included) (NP (JJ microscopic) (NN Doc_3969369_504_510_Disease)))))))) (. .)))
3969369	3	(S1 (S (NP (JJ Preliminary) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NP (JJ Doc_3969369_546_558_Chemical-treated) (NN LW) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN fed) (NP (DT the) (JJ same) (NN diet))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN supplemented) (PP (IN with) (NP (NN corn) (NN oil))) (ADVP (RB up) (PP (TO to) (NP (ADJP (CD 20) (NN %)) (NN fat)))))))) (, ,)) (VP (VBD developed) (NP (NNP Doc_3969369_666_681_Disease)) (PP (IN after) (NP (NP (NNS intervals)) (PP (IN of) (NP (CD 6-12) (NNS months))))))))) (. .)))
3969369	4	(S1 (S (NP (VBN Aged) (NNP GF) (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats)) (VP (AUX have) (RB not) (VP (VBN developed) (NP (NN Doc_3969369_766_781_Disease)) (ADVP (RB spontaneously)))) (. .)))
3969369	5	(S1 (S (NP (NP (JJ Conventional) (NN SD) (NNS rats)) (VP (VP (VBN fed) (NP (NN diet) (CD L-485))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3969369_850_862_Chemical)))))) (VP (VBD developed) (NP (RB only) (NNP Doc_3969369_878_889_Disease))) (. .)))
3969369	6	(S1 (S (NP (JJ Experimental) (NNS designs)) (VP (MD should) (VP (VB consider) (NP (JJ genetic) (NN susceptibility)) (PP (IN as) (NP (NP (DT a) (JJ basic) (NN prerequisite)) (PP (IN for) (NP (NP (NNS studies)) (PP (IN on) (NP (JJ experimental) (NN Doc_3969369_1003_1018_Disease))))))))) (. .)))
3973521	0	(S1 (S (NP (NP (NN Time) (NN course) (NNS alterations)) (PP (IN of) (NP (NNP QTC)))) (VP (VB interval) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_3973521_47_57_Chemical))))) (. .)))
3973521	1	(S1 (S (NP (NP (JJ Sequential) (NN measurement)) (PP (IN of) (NP (CD QT) (NN interval))) (PP (IN during) (NP (JJ left) (NN ventricular) (NN angiography)))) (VP (AUX was) (VP (VBN made) (NP (NP (CD 30) (NNS seconds)) (CC and) (NP (NP (CD one) (, ,) (CD three) (, ,) (CD five) (CC and) (CD ten) (NNS minutes)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_3973521_209_219_Chemical))))))))) (. .)))
3973521	2	(S1 (S (NP (DT The) (NNS subjects)) (VP (AUX were) (NP (NP (CD ten) (NNS patients)) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (JJ normal) (NN left) (NNS ventricles)) (CC and) (NP (JJ coronary) (NNS arteries))))))))) (. .)))
3973521	3	(S1 (S (NP (JJ Significant) (NN Doc_3973521_324_340_Disease)) (VP (VBD occurred) (PP (IN in) (NP (CD 30) (NNS seconds))) (PP (TO to) (NP (CD one) (NN minute))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (JJ marked) (NN Doc_3973521_405_416_Disease)) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ cardiac) (NN output))))))))) (. .)))
4038130	0	(S1 (NP (NN Rat) (NN extraocular) (NN muscle) (NN regeneration) (. .)))
4038130	1	(S1 (NP (NP (NN Repair)) (PP (IN of) (NP (JJ local) (JJ anesthetic-induced) (NN damage))) (. .)))
4038130	2	(S1 (S (NP (NP (JJ Local) (NNS anesthetics)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADVP (RB commonly)) (VP (VBN used) (PP (IN in) (NP (NP (JJ ophthalmic) (NN surgery)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.75) (NN %)) (NP (NNP Doc_4038130_150_175_Chemical))) (, ,) (NP (NP (CD 2.0) (NN %)) (NP (NNP Doc_4038130_182_207_Chemical))) (, ,) (CC and) (NP (NP (NP (CD 2.0) (NN %)) (NP (NNP Doc_4038130_218_241_Chemical))) (PP (CC plus) (NP (CD 1:100,000) (NN Doc_4038130_257_268_Chemical))))) (-RRB- -RRB-))))))))) (VP (AUX were) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (JJ retrobulbar) (NN area)) (PP (IN of) (NP (NN rat) (NNS eyes))))))) (. .)))
4038130	3	(S1 (S (NP (NNS Controls)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (JJ physiological) (NN saline))))) (. .)))
4038130	4	(S1 (S (NP (DT All) (CD three) (NNS anesthetics)) (VP (VBD produced) (NP (NP (JJ massive) (NN degeneration)) (PP (IN of) (NP (DT the) (JJ extraocular) (NNS muscles))))) (. .)))
4038130	5	(S1 (S (NP (NN Doc_4038130_453_472_Disease)) (VP (AUX is) (VP (VBN followed) (PP (IN by) (NP (NP (NN regeneration)) (PP (IN of) (NP (DT the) (VBN damaged) (NN muscle) (NNS fibers))))))) (. .)))
4038130	6	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_4038130_546_559_Disease))))) (, ,) (NP (JJ severe) (NN damage)) (VP (AUX was) (ADVP (RB also)) (VP (VBN seen) (PP (IN in) (NP (JJ harderian) (NNS glands))) (, ,) (PP (ADVP (RB especially)) (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_4038130_639_650_Chemical)) (CC and) (NP (NP (NNP Doc_4038130_655_664_Chemical)) (CC plus) (NP (NNP Doc_4038130_670_681_Chemical))))))))) (. .)))
4038130	7	(S1 (S (PP (IN With) (NP (NP (DT these) (NNS findings)) (PP (IN in) (NP (NNS rats))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (DT the) (JJ temporary) (NN Doc_4038130_750_758_Disease)) (VP (ADVP (RB sometimes)) (VBN seen) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (JJ ophthalmic) (NN surgery))))) (VP (MD might) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ anesthetic-induced) (NN damage)) (PP (TO to) (NP (DT the) (JJ extraocular) (NNS muscles)))))))))))) (. .)))
4069770	0	(S1 (NP (NP (NNP Doc_4069770_0_10_Chemical) (NNP Doc_4069770_11_22_Disease)) (PP (IN in) (NP (DT a) (NN neonate))) (. .)))
4069770	1	(S1 (S (NP (NP (DT The) (JJ clinical) (CC and) (JJ autopsy) (NNS findings)) (PP (IN in) (NP (DT a) (JJ premature) (NN baby))) (SBAR (WHNP (WP who)) (S (VP (VBD died) (PP (IN of) (NP (NNP Doc_4069770_103_122_Disease))) (PP (IN after) (NP (NN therapy))) (PP (IN with) (NP (NP (NP (NNP Doc_4069770_142_152_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg/day)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_4069770_171_181_Chemical)))))))) (VP (AUX are) (VP (VBN presented))) (. .)))
4069770	2	(S1 (S (NP (DT The) (NN serum) (NN Doc_4069770_207_217_Chemical) (NN concentration)) (VP (AUX had) (VP (VBN reached) (NP (JJ toxic) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_4069770_262_268_Disease)) (VP (VBD developed)))))) (. .)))
4069770	3	(S1 (S (NP (NP (JJ Numerous) (NNP Doc_4069770_289_302_Chemical) (NNP Schiff) (PRN (-LRB- -LRB-) (NP (NNP PAS)) (-RRB- -RRB-)) (JJ positive) (, ,) (JJ diastase) (JJ resistant) (JJ cytoplasmic) (NN inclusion) (NNS bodies)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (PP (IN as) (NP (NN myelin) (NNS figures))) (PP (IN in) (NP (NP (NNS cytosegresomes)) (PP (IN under) (NP (DT the) (NNP electron) (NN microscope))))))))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ proximal) (JJ convoluted) (NNS tubules))))) (. .)))
4069770	4	(S1 (S (NP (NP (DT The) (JJ pathological) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_4069770_543_553_Chemical))) (PP (IN in) (NP (DT the) (JJ human) (JJ neonatal) (NNS kidneys))))) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN reported)))) (. .)))
4090988	0	(S1 (NP (NP (NN Induction)) (PP (IN by) (NP (NP (NNP Doc_4090988_13_24_Chemical)) (PP (IN of) (NP (NNP Doc_4090988_28_53_Disease))))) (PP (IN in) (NP (DT the) (NN rat))) (. .)))
4090988	1	(S1 (NP (NP (NNS Effects)) (PP (IN on) (NP (JJ hepatocyte) (NN fine) (NN structure))) (. .)))
4090988	2	(S1 (S (NP (NP (NNS Groups)) (PP (IN of) (NP (ADJP (JJ male) (CC and) (JJ female)) (JJ inbred) (NNS Leeds)))) (VP (VBP strain) (SBAR (S (NP (NNS rats)) (VP (AUX were) (VP (VBN fed) (NP (NP (NNS diets)) (VP (VBG containing) (NP (DT either) (ADJP (ADJP (CD 0.5) (NN %)) (CC or) (ADJP (CD 1.0) (NN %))) (NNP Doc_4090988_201_212_Chemical)))) (PP (IN by) (NP (NN weight))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 18)) (NNS months)))))))) (. .)))
4090988	3	(S1 (S (PP (IN At) (NP (DT the) (ADJP (CD 1.0) (NN %)) (NN dosage) (NN level))) (, ,) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN of) (NP (DT both) (NNS sexes)))))) (VP (VBD developed) (NP (NP (NP (JJ neoplastic) (NNS nodules)) (PP (IN of) (NP (DT the) (NN liver)))) (, ,) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN incidence)))) (. .)))
4090988	4	(S1 (S (NP (DT These) (NNS rats)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (NP (JJ gross) (NN enlargement)) (PP (IN of) (NP (PRP$ their) (NNS livers)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNS foci)) (PP (IN of) (NP (JJ cellular) (NN alteration))))))) (, ,) (S (NP (DT the) (NN latter)) (ADVP (RB also)) (VP (AUXG being) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ low) (NN dosage) (NN male) (NNS rats))))))) (. .)))
4090988	5	(S1 (S (S (NP (NP (NN Doc_4090988_543_553_Disease)) (PP (IN of) (NP (NP (DT the) (JJ transitional) (NN epithelium)) (PP (IN of) (NP (DT the) (NN bladder)))))) (VP (VBD developed) (PP (IN in) (NP (DT all) (JJ Doc_4090988_617_628_Chemical-treated) (NNS groups))))) (, ,) (CC and) (S (NP (CD three) (NNS rats)) (VP (VBD bore) (NP (NN Doc_4090988_665_683_Disease)))) (. .)))
4090988	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ significant) (NNS yields)) (PP (IN of) (NP (NNP Doc_4090988_716_731_Disease)))) (VP (AUX were) (ADVP (RB only)) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ low) (NN dosage) (NNS females)) (CC and) (NP (JJ high) (NN dosage) (NNS males)))))) (. .)))
4090988	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (QP (CD 20) (TO to) (CD 25)) (NN %)) (PP (IN of) (NP (JJ Doc_4090988_825_836_Chemical-treated) (NNS rats)))) (VP (VBD developed) (NP (NP (NNP Doc_4090988_860_871_Disease)) (PP (IN of) (NP (DT the) (NN bladder) (NN epithelium))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (RB not) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_4090988_945_960_Disease))))))))))) (. .)))
4090988	8	(S1 (S (NP (NP (DT A) (JJ low) (NN yield)) (PP (IN of) (NP (NNP Doc_4090988_977_984_Disease))) (PP (IN at) (NP (JJ various) (JJ other) (NNS sites)))) (ADVP (RB also)) (VP (VBD arose) (PP (VBG following) (NP (JJ Doc_4090988_1029_1040_Chemical) (NN feeding)))) (. .)))
4090988	9	(S1 (S (NP (NP (DT An) (NNP electron) (NN microscope) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS livers)) (PP (IN of) (NP (JJ Doc_4090988_1096_1107_Chemical-treated) (NNS rats)))))) (VP (VBD revealed) (NP (NP (JJ ultrastructural) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS hepatocytes)) (SBAR (WHNP (WDT that)) (S (VP (VBP resemble) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (PP (IN from) (NP (NN exposure))) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ known) (NN Doc_4090988_1241_1258_Disease))))))))))))))))) (. .)))
430165	0	(S1 (NP (NP (JJ Transient) (NN Doc_430165_10_21_Disease)) (: :) (NP (NP (DT a) (JJ rare) (NN manifestation)) (PP (IN of) (NP (NNP Doc_430165_47_64_Chemical) (NNP Doc_430165_65_73_Disease)))) (. .)))
430165	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (CD two) (NNS cases))) (. .)))
430165	2	(S1 (S (PP (IN Among) (NP (NP (DT the) (JJ common) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_430165_129_146_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_430165_148_151_Chemical)) (-RRB- -RRB-)) (NNP Doc_430165_153_161_Disease))))) (, ,) (NP (DT the) (ADJP (ADVP (RBS most) (RB frequently)) (VBN encountered)) (JJ neurological) (NNS signs)) (VP (AUX are) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_430165_227_249_Disease))))) (. .)))
430165	3	(S1 (S (ADVP (RB Very) (RB rarely)) (, ,) (NP (NP (DT the) (JJ toxic) (JJ neurological) (NNS manifestations)) (PP (IN of) (NP (DT this) (NN drug)))) (VP (AUX are) (PP (IN of) (NP (JJ cerebral) (NN origin)))) (. .)))
430165	4	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX are) (VP (VBN presented) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (JJ progressive) (NNP Doc_430165_391_402_Disease)) (PP (JJ due) (PP (TO to) (NP (NNP Doc_430165_410_413_Chemical) (NNP Doc_430165_414_422_Disease))))))))) (. .)))
430165	5	(S1 (S (NP (DT Both)) (VP (AUX had) (NP (NN brain) (NN surgery)) (PP (IN before) (NP (JJ Doc_430165_454_457_Chemical) (NN treatment)))) (. .)))
430165	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN assumed) (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN with) (NP (DT some) (NN Doc_430165_507_522_Disease)))) (VP (AUX are) (ADJP (JJ liable) (PP (TO to) (NP (JJ manifest) (NNP Doc_430165_546_549_Chemical) (NNP Doc_430165_550_558_Disease)))) (PP (IN as) (NP (JJ focal) (JJ neurological) (NNS signs)))))))) (. .)))
458486	0	(S1 (NP (NP (NN Doc_458486_0_8_Chemical)) (PP (IN in) (NP (NNP Doc_458486_12_20_Chemical-induced) (NNP Doc_458486_29_50_Disease))) (. .)))
458486	1	(S1 (S (NP (NP (NNP Doc_458486_52_60_Chemical)) (, ,) (NP (NP (DT a) (VBN substituted) (JJ Doc_458486_76_85_Chemical) (NN derivative)) (ADJP (RB closely) (JJ related) (PP (TO to) (NP (NNP Doc_458486_116_130_Chemical))))) (, ,)) (VP (VBD reduced) (NP (NP (JJ Doc_458486_140_148_Chemical-induced) (JJ peak) (NN dose) (NN Doc_458486_167_188_Disease)) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (NNP Doc_458486_209_239_Disease))))))) (. .)))
458486	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT an) (JJ unacceptable) (NN increase)) (PP (IN in) (NP (NN disability))) (PP (IN from) (NP (NNP Doc_458486_294_306_Disease))) (PP (IN with) (NP (NP (NN aggravation)) (PP (IN of) (NP (JJ end-of-dose) (NN Doc_458486_339_347_Disease)))))) (VP (VBD led) (PP (TO to) (NP (NP (PRP$ its) (NN cessation)) (PP (IN in) (NP (CD 14) (NNS patients)))))) (. .)))
458486	3	(S1 (S (NP (NN Doc_458486_385_393_Chemical)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ Doc_458486_411_419_Chemical-induced) (JJ early) (NN morning)) (PP (IN of) (NP (`` ``) (JJ off-period) ('' '') (NN segmental) (NN Doc_458486_468_476_Disease))))))) (. .)))
458486	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP fail) (S (VP (TO to) (VP (VB support) (NP (DT the) (NN notion) (SBAR (IN that) (S (NP (NNP Doc_458486_524_532_Chemical-induced) (NNP Doc_458486_541_552_Disease)) (VP (AUX are) (VP (VBN caused) (PP (IN by) (NP (NP (NN overstimulation)) (PP (IN of) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (JJ Doc_458486_606_614_Chemical) (NNS receptors)))))))))))))))) (. .)))
48362	0	(S1 (NP (NNP Doc_48362_0_9_Chemical) (NNP Doc_48362_10_19_Disease) (. .)))
48362	1	(S1 (S (NP (NP (JJ Long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_48362_49_58_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ persistent) (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN SGOT)) (, ,) (NP (JJ Doc_48362_133_144_Chemical) (NN dehydrogenase)) (, ,) (CC and) (NP (JJ alkaline) (NN phosphatase)))))))))) (. .)))
48362	2	(S1 (S (NP (NN Liver) (NNS biopsy)) (VP (VBD showed) (NP (JJ active) (NN Doc_48362_213_222_Disease))) (. .)))
48362	3	(S1 (S (NP (NP (NN Discontinuance)) (PP (IN of) (NP (JJ Doc_48362_242_251_Chemical) (NN therapy)))) (VP (VBD led) (PP (TO to) (NP (NP (NN normalization)) (PP (IN of) (NP (NN liver) (NN function) (NNS tests)))))) (. .)))
48362	4	(S1 (S (NP (NP (DT A) (NN challenge) (NN dose)) (PP (IN of) (NP (NNP Doc_48362_326_335_Chemical)))) (VP (VBD caused) (NP (NP (NP (JJ clinical) (NNS symptoms)) (CC and) (NP (JJ abrupt) (NN elevation))) (PP (IN of) (NP (NP (NN SGOT)) (, ,) (NP (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (JJ Doc_48362_417_428_Chemical) (NN dehydrogenase) (NNS values)))))) (. .)))
48362	5	(S1 (S (NP (PRP We)) (VP (VBD concluded) (SBAR (IN that) (S (NP (DT this) (NN patient)) (VP (VP (AUX had) (NP (NNP Doc_48362_486_495_Chemical) (NNP Doc_48362_496_510_Disease))) (CC and) (VP (VB believe) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (VP (VBN reported) (PP (IN with) (NP (NN liver) (JJ biopsy) (NN documentation))))))))))))) (. .)))
48362	6	(S1 (S (NP (DT This) (NN report)) (ADVP (RB also)) (VP (VBZ suggests) (SBAR (IN that) (S (, ,) (PP (ADVP (RB even)) (IN after) (NP (JJ long-term) (NN administration))) (, ,) (NP (DT the) (NNP Doc_48362_666_682_Disease)) (VP (AUX is) (ADJP (JJ reversible)))))) (. .)))
591536	0	(S1 (NP (NP (NP (JJ Arterial) (NN Doc_591536_9_24_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ systemic) (NN Doc_591536_56_63_Chemical) (NN therapy)))))) (: :) (NP (NP (DT a) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_591536_104_111_Chemical-induced) (NNP Doc_591536_120_136_Disease))))) (. .)))
591536	1	(S1 (S (NP (NNP Arterial) (NNP Doc_591536_147_162_Disease)) (VP (AUX is) (NP (NP (DT a) (VBN recognized) (NN complication)) (PP (IN of) (NP (JJ systemic) (JJ Doc_591536_204_211_Chemical) (NN therapy))))) (. .)))
591536	2	(S1 (S (NP (NP (NN Characteristic)) (PP (IN of) (NP (DT the) (NN entity)))) (VP (AUX is) (VP (JJ Doc_591536_253_271_Disease) (PP (IN by) (S (NP (NP (JJ platelet-fibrin) (NN Doc_591536_291_298_Disease)) (PP (IN with) (NP (JJ distal) (NNP Doc_591536_311_319_Disease)))) (VP (VBG occurring) (NP (QP (CD four) (TO to) (CD twenty)) (NNS days)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ Doc_591536_374_381_Chemical) (NN therapy))) (, ,) (VP (VBN preceded) (PP (IN by) (NP (JJ profound) (NNP Doc_591536_412_428_Disease))) (PP (IN with) (NP (NP (JJ platelet) (NNS counts)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (QP (CD 30,000) (TO to) (CD 40,000))) (PP (IN per) (NP (JJ cubic) (NN millimeter))))))))))))))))) (. .)))
591536	3	(S1 (S (NP (DT The) (ADJP (RB clinically) (JJ apparent)) (NN occlusion)) (VP (VP (MD may) (VP (AUX be) (VP (VBN preceded) (PP (IN by) (NP (NNP Doc_591536_558_603_Disease))) (SBAR (IN that) (S (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_591536_622_630_Disease)) (PP (IN in) (NP (NN origin)))))))))))) (, ,) (CC and) (VP (MD might) (VP (VB serve) (S (VP (TO to) (VP (VB warn) (NP (NP (DT the) (NN clinician)) (PP (IN of) (NP (DT these) (NNS complications)))))))))) (. .)))
591536	4	(S1 (S (NP (NP (NP (JJ Previous) (NNS reports)) (PP (IN of) (NP (DT these) (NNS phenomena)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ recent) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_591536_783_790_Chemical))))))) (VP (AUX are) (VP (VBN reviewed))) (. .)))
591536	5	(S1 (S (NP (NP (DT The) (JJ common) (NN factor)) (VP (VBG relating) (NP (NP (NNP Doc_591536_832_847_Disease)) (CC and) (NP (NNP Doc_591536_852_868_Disease))))) (VP (AUX is) (NP (JJ Doc_591536_872_879_Chemical-induced) (NN Doc_591536_888_908_Disease))) (. .)))
591536	6	(S1 (S (NP (JJ Appropriate) (NN treatment)) (VP (VBZ consists) (PP (IN of) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_591536_963_970_Chemical)))) (, ,) (CC and) (NP (NP (NN anticoagulation)) (PP (IN with) (NP (NNP Doc_591536_997_1012_Chemical)))))) (SBAR (IN if) (FRAG (ADJP (JJ necessary))))) (. .)))
591536	7	(S1 (S (NP (JJ Vascular) (NNS procedures)) (VP (AUX are) (VP (VBN performed) (SBAR (IN as) (S (VP (VBN indicated)))))) (. .)))
6111982	0	(S1 (NP (NP (NP (NNP Pharmacology)) (PP (IN of) (NP (NNP Doc_6111982_16_27_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_6111982_29_42_Chemical)) (, ,) (NP (NNP Doc_6111982_44_51_Chemical)) (-RRB- -RRB-))) (NP (DT a) (JJ new) (JJ potent) (JJ beta-adrenergic) (NN antagonist)) (. .)))
6111982	1	(S1 (S (NP (DT The) (NN compound) (NN Doc_6111982_107_118_Chemical)) (, ,) (PP (IN as) (NP (DT a) (JJ beta-adrenergic) (NN antagonist))) (, ,) (VP (AUX is) (NP (NP (JJ 3-8) (NNS times)) (ADJP (RBR more) (JJ potent) (PP (PP (IN than) (NP (NNP Doc_6111982_183_194_Chemical))) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))) (. .)))
6111982	2	(S1 (S (NP (PRP$ Its) (JJ antiarrhythmic) (NN effectiveness)) (VP (VBZ surpasses) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNP Doc_6111982_268_279_Chemical)) (CC and) (NP (NNP Doc_6111982_284_292_Chemical))))) (S (VP (VBG inhibiting) (NP (DT the) (NNP Doc_6111982_308_315_Chemical) (NNP Doc_6111982_316_326_Disease)) (PP (IN in) (NP (NNS dogs) (CC and) (NNS cats)))))) (. .)))
6111982	3	(S1 (S (S (NP (NN Doc_6111982_345_356_Chemical)) (VP (AUX has) (NP (DT a) (JJ negligible) (NN cardiodepressant) (NN activity)))) (: ;) (S (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ cardioselective)))) (. .)))
6111982	4	(S1 (S (NP (DT The) (NN compound)) (VP (VBZ shows) (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ long))) (JJ lasting) (NN effect))) (. .)))
6111982	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ prolonged) (NN elimination)) (PP (IN of) (NP (DT the) (NN radioactivity)))) (PP (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_6111982_558_568_Chemical))) (PP (TO to) (NP (NNS rats) (CC and) (NNS dogs)))))) (. .)))
6111982	6	(S1 (S (NP (NP (DT The) (JJ half) (NN life)) (PP (IN of) (NP (DT the) (VBN unlabeled) (NN substance))) (PP (IN in) (NP (NNS humans)))) (VP (AUX was) (NP (QP (JJR more) (IN than) (CD 10)) (NNS hours))) (. .)))
6115999	0	(S1 (NP (NP (JJ Adverse) (NNS reactions)) (PP (TO to) (NP (NP (NNP Doc_6115999_21_35_Chemical)) (CC and) (NP (NNP Doc_6115999_40_51_Chemical)))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ mild) (NNP Doc_6115999_78_90_Disease))))) (. .)))
6115999	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NNP Medical) (NNP Research) (NNP Council) (NNP Working) (NNP Party))) (PP (IN on) (NP (ADJP (JJ Mild) (TO to) (JJ Moderate)) (NNP Doc_6115999_161_173_Disease))) (. .)))
6115999	2	(S1 (S (NP (NP (NNS Participants)) (PP (IN in) (NP (NP (DT the) (NNP Medical) (NNP Research) (NNP Council) (NN treatment) (NN trial)) (PP (IN for) (NP (JJ mild) (NN Doc_6115999_245_257_Disease)))))) (VP (AUX are) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (NP (NP (CD one)) (PP (IN of) (NP (CD four) (NN treatment) (NNS groups)))) (: :) (NP (NP (NP (NNP Doc_6115999_314_328_Chemical)) (, ,) (NP (NNP Doc_6115999_330_341_Chemical)) (, ,)) (CC or) (NP (NP (DT a) (NN placebo)) (PP (IN for) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .)))
6115999	3	(S1 (S (NP (DT The) (NN trial)) (VP (AUX is) (VP (VBN single-blind.) (SBAR (S (NP (NP (QP (CD 23) (CD 582)) (NNS patient-years)) (PP (IN of) (NP (NN observation)))) (VP (AUX have) (VP (AUX been) (VP (VBN completed) (ADVP (RB so) (RB far)) (, ,) (NP (NP (NP (QP (CD 10) (CD 684))) (PP (IN on) (NP (JJ active) (NNS drugs)))) (CC and) (NP (NP (QP (CD 12) (CD 898))) (PP (IN on) (NP (NNS placebos)))))))))))) (. .)))
6115999	4	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (S (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NNP Doc_6115999_561_575_Chemical) (NNP treatment) (CC and) (NNP Doc_6115999_590_599_Disease)) (, ,) (CC and) (NP (NNP Doc_6115999_605_614_Disease))))) (ADVP (RB also)) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNP Doc_6115999_664_675_Chemical)) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (VP (VBG taking) (NP (NNS placebos))))))))))))) (. .)))
6115999	5	(S1 (S (NP (NP (JJ Other) (JJ adverse) (NNS reactions)) (VP (ADVP (RB significantly)) (VBN linked) (PP (IN with) (NP (JJ active) (NNS drugs))))) (VP (VBP include) (NP (NP (NP (NP (NP (NNP Doc_6115999_778_804_Disease)) (PP (IN in) (NP (NNS men) (CC and) (NNS women)))) (CC and) (NP (NP (NNP Doc_6115999_826_830_Disease)) (PP (IN in) (NP (NNS men))))) (, ,) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_6115999_855_869_Chemical) (NN treatment)))) (, ,)) (CC and) (NP (NP (NP (NNP Doc_6115999_885_905_Disease)) (CC and) (NP (NNP Doc_6115999_910_918_Disease))) (PP (IN in) (NP (NP (NNS men) (CC and) (NNS women)) (VP (VBG taking) (NP (NNP Doc_6115999_943_954_Chemical)))))))) (. .)))
6115999	6	(S1 (S (NP (DT No) (NN Doc_6115999_959_974_Disease)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (VP (VBN occurred) (PP (IN in) (NP (DT the) (JJ Doc_6115999_1008_1019_Chemical) (NN group))))))))) (. .)))
6115999	7	(S1 (S (S (NP (JJ Mean) (NN serum) (JJ Doc_6115999_1038_1047_Chemical) (NN level)) (VP (VBD fell))) (, ,) (CC and) (S (NP (NNP Doc_6115999_1064_1068_Chemical) (CC and) (NNP Doc_6115999_1073_1082_Chemical) (NNS levels)) (VP (VBD rose) (, ,) (PP (IN in) (NP (NP (NNS men) (CC and) (NNS women)) (VP (VBG taking) (NP (NNP Doc_6115999_1120_1134_Chemical))))))) (. .)))
6115999	8	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_6115999_1143_1154_Chemical) (NN group))) (, ,) (S (NP (NP (NN serum) (NN Doc_6115999_1168_1177_Chemical)) (CC and) (NP (JJ Doc_6115999_1182_1191_Chemical) (NNS levels))) (VP (VBD rose) (PP (IN in) (NP (DT both) (NNS sexes))))) (, ,) (CC but) (S (NP (DT the) (NNP Doc_6115999_1227_1231_Chemical) (NN level)) (VP (VBD rose) (ADVP (RB significantly)) (PP (IN in) (NP (NNS women)) (ADVP (RB only))))) (. .)))
6118280	0	(S1 (S (NP (NP (JJ Serotonergic) (NNS drugs)) (, ,) (NP (NP (NNP Doc_6118280_20_35_Chemical)) (CC and) (NP (NNP Doc_6118280_40_48_Chemical)))) (VP (VBP block) (NP (JJ Doc_6118280_55_63_Chemical-induced) (NN Doc_6118280_72_87_Disease)) (PP (IN in) (NP (NP (DT a) (NN strain)) (PP (IN of) (NP (NNS mice)))))) (. .)))
6118280	1	(S1 (S (PP (IN In) (NP (JJ male) (JJ Swiss) (NNS mice))) (, ,) (NP (NNP Doc_6118280_129_137_Chemical)) (VP (VBD produced) (NP (NN Doc_6118280_147_162_Disease))) (. .)))
6118280	2	(S1 (S (S (NP (NP (DT A) (ADJP (ADJP (CD 3) (NN mg/kg)) (PRN (-LRB- -LRB-) (JJ i.p.) (-RRB- -RRB-))) (NN dose)) (VP (VBN induced) (NP (DT this) (NN response)) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS mice))))))) (VP (VBD tested))) (CC and) (S (NP (NP (DT the) (JJ peak) (NN response)) (PP (IN of) (NP (NP (CD 73) (NNS jerks)) (PP (IN per) (NP (NN min)))))) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (CD 27) (CC and) (CD 45) (NN min)))))) (. .)))
6118280	3	(S1 (S (S (VP (VBG Increasing) (NP (DT the) (NN brain) (NN Doc_6118280_333_342_Chemical) (NNS levels)) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6118280_375_394_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-160) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT a) (JJ peripheral) (NN decarboxylase) (NN inhibitor))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (DT the) (JJ Doc_6118280_500_508_Chemical) (NN effect)))))) (. .)))
6118280	4	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT a) (JJ similar) (NN experiment))) (NP (NP (NNP Doc_6118280_550_556_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-160) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (PP (IN without) (NP (NN effect)))) (. .)))
6118280	5	(S1 (S (PP (IN In) (NP (NP (NNS doses)) (PP (IN of) (NP (JJ 3-10) (NNS mg/kg))))) (, ,) (NP (DT the) (JJ Doc_6118280_620_629_Chemical) (NN receptor) (NN agonist) (NN Doc_6118280_647_653_Chemical)) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN blockade)) (PP (IN of) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NNP Doc_6118280_706_714_Chemical))))))) (. .)))
6118280	6	(S1 (S (PP (IN Of) (NP (DT the) (NNP Doc_6118280_723_738_Chemical))) (, ,) (NP (NP (NNP Doc_6118280_740_750_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1-0.3) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (JJ several) (S (VP (VB fold) (ADJP (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NP (NNP Doc_6118280_813_821_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.3-3) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG blocking) (NP (DT the) (NNP Doc_6118280_852_867_Disease))))))))))))) (. .)))
6118280	7	(S1 (S (SBAR (IN While) (S (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NP (JJ -Doc_6118280_879_887_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 1-3) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD proved) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN antagonist)) (PP (IN of) (NP (NP (NNP Doc_6118280_940_948_Chemical) (, ,) (PRP$ its) (-LRB- -LRB-) (NNP +) (-RRB- -RRB-) (NN -isomer)) (PRN (-LRB- -LRB-) (NP (CD 5-20) (NNS mg/kg)) (-RRB- -RRB-))))))))))) (VP (VBD lacked) (NP (DT this) (NN property))) (. .)))
6118280	8	(S1 (S (S (VP (VBG Considering) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NNP Doc_6118280_1026_1031_Chemical)) (CC and) (NP (DT the) (NNP Doc_6118280_1040_1055_Chemical))) (VP (AUX have) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ clinical) (NNP Doc_6118280_1119_1128_Disease)))))))))))))))) (, ,) (NP (DT the) (JJ Doc_6118280_1134_1142_Chemical-induced) (NN Doc_6118280_1151_1160_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ satisfactory) (NN animal) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB prove) (ADJP (JJ useful) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ new) (NN drug) (NNS treatments)) (PP (IN for) (NP (DT this) (NN condition))))))))))))))))) (. .)))
6118280	9	(S1 (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBD indicated) (NP (NP (DT the) (JJ possible) (NN value)) (PP (IN of) (NP (NP (NNP Doc_6118280_1336_1342_Chemical)) (CC and) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NN -Doc_6118280_1351_1359_Chemical)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ clinical) (NNP Doc_6118280_1390_1399_Disease)))))))))) (. .)))
6127992	0	(S1 (NP (NP (JJ Adverse) (NN interaction)) (PP (IN between) (NP (NP (NP (NNP Doc_6127992_28_58_Chemical)) (CC and) (NP (NNP Doc_6127992_63_72_Chemical--report))) (PP (IN of) (NP (CD three) (NNS cases))))) (. .)))
6127992	1	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (NNP Doc_6127992_117_140_Disease)))) (VP (VBD developed) (NP (NP (JJ profound) (NNP Doc_6127992_160_175_Disease)) (, ,) (NP (NNP Doc_6127992_177_188_Disease)) (CC and) (NP (NNP Doc_6127992_193_204_Disease))) (PP (IN during) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_6127992_234_243_Chemical)) (CC and) (NP (NNP Doc_6127992_248_278_Chemical))))))) (. .)))
6127992	2	(S1 (S (NP (DT This) (JJ clinical) (NN picture)) (VP (VBD resolved) (ADVP (RB completely)) (PP (IN with) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (VBN combined) (NN therapy)))))) (. .)))
6127992	3	(S1 (S (NP (NN Baseline)) (VP (VP (VBD left) (NP (NN ventricular) (NN function))) (, ,) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ cardiac) (NN catheterisation)) (CC or) (NP (JJ nuclear) (NN angiography))))) (, ,) (VP (AUX was) (ADVP (RB normal)) (PP (IN in) (NP (CD two) (NNS patients)))) (CC and) (VP (ADVP (RB only) (RB mildly)) (VBN reduced) (PP (IN in) (NP (DT the) (JJ other))))) (. .)))
6127992	4	(S1 (S (ADVP (RB Simultaneously)) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6127992_556_586_Chemical)) (CC and) (NP (NNP Doc_6127992_591_600_Chemical))))) (VP (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ profound) (JJ adverse) (NNS interactions))))) (CC and) (VP (MD should) (ADVP (RB only)) (VP (AUX be) (VP (VBN administered) (PP (IN with) (NP (JJ great) (NN caution))))))) (. .)))
6150641	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NNP Doc_6150641_35_45_Chemical) (CC and) (NNP Doc_6150641_50_60_Chemical))))) (PP (IN in) (S (VP (VBG inhibiting) (NP (NN acid) (NN secretion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ gastric) (JJ hypersecretory) (NNS states)))))))) (. .)))
6150641	1	(S1 (S (NP (NP (DT The) (JJ H2-Doc_6150641_145_154_Chemical) (NN receptor) (NNS antagonists)) (ADJP (JJ Doc_6150641_176_186_Chemical) (CC and) (JJ Doc_6150641_191_201_Chemical))) (VP (AUX were) (VP (VBN compared) (SBAR (IN for) (S (NP (PRP$ their) (NNS abilities)) (VP (TO to) (VP (VB control) (NP (JJ gastric) (NN acid) (NN hypersecretion)) (PP (IN on) (NP (NP (DT a) (ADJP (JJ short-) (CC and) (JJ long-term)) (NN basis)) (PP (IN in) (NP (NP (CD 22) (NNS patients)) (PP (IN with) (NP (JJ gastric) (NN acid) (NN hypersecretory) (NNS states))))))))))))) (. .)))
6150641	2	(S1 (S (S (NP (JJ Nineteen) (NNS patients)) (VP (AUX had) (NP (NN Doc_6150641_385_411_Disease)))) (, ,) (S (NP (CD one) (NN patient)) (VP (AUX had) (NP (NN Doc_6150641_429_450_Disease)))) (, ,) (CC and) (S (NP (CD two) (NNS patients)) (VP (AUX had) (NP (JJ idiopathic) (NN hypersecretion)))) (. .)))
6150641	3	(S1 (S (NP (NP (DT The) (NNS rates)) (PP (IN of) (NP (NP (NN onset)) (PP (IN of) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NNP Doc_6150641_536_546_Chemical)) (CC and) (NP (NNP Doc_6150641_551_561_Chemical))))))))) (VP (AUX were) (NP (DT the) (JJ same))) (. .)))
6150641	4	(S1 (S (S (NP (NP (DT The) (NNS actions)) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (AUX were) (VP (VBN increased) (PP (IN by) (NP (JJ anticholinergic) (NNS agents)))))) (, ,) (CC and) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ close) (NN correlation)) (PP (IN between) (NP (NP (DT the) (JJ daily) (NN maintenance) (NN dose)) (PP (IN of) (NP (DT each) (NN drug))) (VP (VBN needed) (S (VP (TO to) (VP (VB control) (NP (NN acid) (NN secretion))))))))))) (. .)))
6150641	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_6150641_770_780_Chemical)) (VP (AUX was) (ADJP (ADVP (RB threefold) (RBR more)) (JJ potent) (PP (IN than) (NP (NNP Doc_6150641_812_822_Chemical)))) (PP (DT both) (PP (IN in) (NP (JJ acute) (NN inhibition) (NNS studies))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ median) (NN maintenance) (NN dose)) (VP (VBN needed) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1.2)) (NP (NNP g)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (NNP Doc_6150641_917_927_Chemical)))) (CC and) (NP (NP (CD 3.6) (NNP g)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (NNP Doc_6150641_950_960_Chemical))))) (-RRB- -RRB-))))))) (. .)))
6150641	6	(S1 (S (NP (NP (CD Sixty) (NN percent)) (PP (IN of) (NP (DT the) (NNS males)))) (VP (VP (VBD developed) (NP (NP (NN breast) (NNS changes)) (CC or) (NP (NN Doc_6150641_1018_1027_Disease))) (SBAR (IN while) (S (VP (VBG taking) (NP (NNP Doc_6150641_1041_1051_Chemical)))))) (CC and) (VP (PP (IN in) (NP (DT all) (NNS cases))) (NP (DT these) (NNS changes)) (VBD disappeared) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_6150641_1100_1110_Chemical)) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NNP Doc_6150641_1127_1137_Chemical))))))))) (. .)))
6150641	7	(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_6150641_1168_1178_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD one) (TO to) (CD 60)) (NNS months)) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 11) (NNS months))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_6150641_1220_1230_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD two) (TO to) (CD 31)) (NNS months)) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 14) (NNS months))) (-RRB- -RRB-)))))))) (VP (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6150641_1293_1324_Disease))))) (CC or) (VP (VBZ alterations) (PP (IN of) (NP (NN serum) (NN gastrin) (NNS concentrations)))))) (, ,) (CC but) (S (NP (JJ Doc_6150641_1377_1387_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN serum) (JJ Doc_6150641_1444_1454_Chemical) (NN level)) (SBAR (IN than) (S (VP (VBN seen) (PP (IN with) (NP (JJ Doc_6150641_1476_1486_Chemical) (NN therapy))))))))))) (. .)))
6150641	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (DT both) (NNS drugs)) (VP (MD can) (ADVP (RB adequately)) (VP (VB inhibit) (NP (NN acid) (NN secretion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ gastric) (JJ hypersecretory) (NNS states)))))))))) (. .)))
6150641	9	(S1 (S (S (NP (DT Both)) (VP (AUX are) (ADJP (JJ safe)) (PP (IN at) (NP (JJ high) (NNS doses))))) (, ,) (CC but) (S (NP (NNP Doc_6150641_1648_1658_Chemical)) (VP (VP (AUX is) (ADVP (RB threefold)) (ADJP (RBR more) (JJ potent))) (CC and) (VP (AUX does) (RB not) (VP (VB cause) (NP (NP (DT the) (JJ antiandrogen) (NN side) (NNS effects)) (VP (ADVP (RB frequently)) (VBN seen) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_6150641_1768_1778_Chemical))))))))))) (. .)))
6153967	0	(S1 (NP (NP (NP (NP (JJ Epileptogenic) (NNS properties)) (PP (IN of) (NP (NNP Doc_6153967_28_37_Chemical)))) (CC and) (NP (PRP$ their) (JJ clinical) (NN interpretation))) (. .)))
6153967	1	(S1 (S (NP (NP (CD Three) (NNS cases)) (PP (IN of) (NP (NNP EEG) (NNS changes))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ single) (NN exposure)) (PP (TO to) (NP (JJ Doc_6153967_130_139_Chemical) (NNS anesthesia))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
6153967	2	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP (NNP Doc_6153967_181_190_Chemical)) (VP (VBN administered) (PP (IN during) (NP (NP (DT a) (NN donor) (NN nephrectomy)) (VP (VBN resulted) (PP (IN in) (NP (JJ unexpected) (JJ partial) (NN motor) (NN Doc_6153967_268_276_Disease))))))) (. .)))
6153967	3	(S1 (S (SBAR (IN Until) (S (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_6153967_301_309_Disease)))) (VP (AUX was) (ADVP (RB correctly)) (VP (VBN identified))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (ADVP (RB inappropriately)) (VP (VBN treated) (PP (IN with) (NP (NNS anticonvulsants))))) (. .)))
6153967	4	(S1 (S (NP (CD Two) (JJ other) (NNS patients)) (VP (VBD suffered) (PP (IN from) (NP (JJ partial) (, ,) (ADJP (JJ complex) (CC and) (JJ generalized)) (JJ Doc_6153967_464_472_Disease) (JJ uncontrolled))) (PP (IN by) (NP (NN medication)))) (. .)))
6153967	5	(S1 (S (S (NP (NP (JJ Doc_6153967_501_510_Disease) (NNS foci)) (VP (VP (VBN delineated)) (CC and) (VP (VBN activated) (PP (IN by) (NP (NNP Doc_6153967_544_553_Chemical)))))) (VP (AUX were) (ADVP (RB surgically)) (VP (VBN ablated)))) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX are) (ADVP (RB now)) (ADJP (JJ Doc_6153967_603_610_Disease-free)))) (. .)))
6153967	6	(S1 (S (NP (NP (JJ Previous) (NNS exposures)) (PP (TO to) (NP (NNP Doc_6153967_639_648_Chemical)))) (VP (AUX have) (S (VP (TO to) (VP (AUX be) (VP (VBN disclosed) (S (VP (TO to) (VP (VB avoid) (NP (NNS mistakes)) (PP (IN in) (NP (NP (JJ clinical) (NN interpretation)) (PP (IN of) (NP (DT the) (NNP EEG))))))))))))) (. .)))
6153967	7	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Doc_6153967_746_755_Chemical)) (VP (MD may) (VP (VB prove) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ safe) (JJ fast) (JJ acting) (NN activator)) (PP (IN of) (NP (NNP Doc_6153967_804_813_Disease) (CD foci)))) (PP (IN during) (NP (NP (NN corticography)) (CC or) (NP (NN depth) (NN electrode) (NN intraoperative) (NNS recordings))))))))) (. .)))
6203632	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_6203632_15_28_Chemical-induced) (NNP Doc_6203632_37_56_Disease))) (. .)))
6203632	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_6203632_77_96_Disease)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (JJ adult) (JJ female) (JJ Wistar) (NNS rats)) (VP (VBG following) (NP (NP (JJ daily) (JJ subcutaneous) (NNS injections)) (PP (IN of) (NP (NP (NP (NNP Doc_6203632_180_193_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6203632_195_198_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 0.3) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-)))))))))) (. .)))
6203632	2	(S1 (S (NP (DT A) (NN time) (NN course)) (VP (AUX was) (VP (VBN established) (PP (IN for) (NP (NP (NP (DT the) (NN change)) (PP (IN in) (NP (NP (NN tissue) (NN mass)) (, ,) (NP (NNP RNA)) (CC and) (NP (NN DNA) (NN content))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ Doc_6203632_318_332_Chemical) (NN content)))))) (. .)))
6203632	3	(S1 (S (NP (NN Heart) (NN weight)) (VP (VBD increased) (NP (CD 44) (NN %)) (PP (IN after) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (IN with) (NP (NP (DT a) (JJ half) (NN time)) (PP (IN of) (NP (CD 3.4) (NN days)))))) (. .)))
6203632	4	(S1 (S (NP (JJ Ventricular) (NNP RNA) (NN content)) (VP (AUX was) (VP (VBD elevated) (NP (CD 26) (NN %)) (PP (IN after) (NP (NP (CD 24) (NNP h)) (PP (IN of) (NP (DT a) (JJ single) (NN injection)))))) (CC and) (VP (VBD reached) (NP (DT a) (JJ maximal) (NN level)) (PP (VBG following) (NP (NP (CD 8) (NN days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
6203632	5	(S1 (S (NP (NP (DT The) (JJ half) (NN time)) (PP (IN for) (NP (NNP RNA) (NN accumulation)))) (VP (AUX was) (NP (CD 2.0) (NNS days))) (. .)))
6203632	6	(S1 (S (NP (NP (DT The) (JJ total) (NN content)) (PP (IN of) (NP (NNP Doc_6203632_626_640_Chemical)))) (VP (VP (VBD remained) (ADJP (JJ stable)) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS days)) (PP (IN of) (NP (NN treatment)))))) (CC but) (VP (VBD increased) (NP (CD 46) (NN %)) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
6203632	7	(S1 (S (NP (JJ Ventricular) (NN DNA) (NN content)) (VP (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN during) (NP (NP (NP (DT the) (JJ early) (NN stage)) (PRN (-LRB- -LRB-) (NP (JJ 1-4) (NNS days)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_6203632_812_824_Disease) (NN growth)))))) (CC but) (VP (VBD increased) (PP (TO to) (NP (DT a) (JJ new) (JJ steady-state) (NN level))) (NP (CD 19) (NN %)) (PP (IN above) (NP (DT the) (NNS controls))) (PP (IN after) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))))) (. .)))
6203632	8	(S1 (S (NP (NP (JJ Intraventricular) (NNS pressures)) (CC and) (NP (JJ coronary) (NN flow) (NNS measures))) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (NN control)) (CC and) (NP (JJ experimental) (NNS animals))))) (PP (VBG following) (NP (NP (CD 4) (NN days)) (PP (IN of) (NP (JJ developed) (NNP Doc_6203632_1058_1069_Disease)))))) (. .)))
6203632	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN dP/dt)) (PP (IN in) (NP (DT the) (JJ Doc_6203632_1093_1096_Chemical-treated) (NNS hearts)))) (VP (AUX was) (ADJP (ADVP (RB slightly) (CC but) (RB significantly)) (PRN (-LRB- -LRB-) (NP (QP (RB P) (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (JJ elevated))) (. .)))
6203632	10	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ adaptive) (NN response)) (PP (TO to) (NP (NNP Doc_6203632_1222_1225_Chemical)))) (VP (VBZ shows) (NP (NP (DT an) (JJ early) (NN Doc_6203632_1241_1253_Disease) (NN phase)) (PRN (-LRB- -LRB-) (NP (JJ 1-4) (NNS days)) (-RRB- -RRB-)) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (JJ substantial) (NN increase)) (PP (IN in) (NP (NNP RNA) (NN content)))) (CC and) (NP (NP (JJ cardiac) (NN mass)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NNP DNA)))))))))))))))) (. .)))
6203632	11	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ prolonged) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (CD 8-12) (NNS days)) (-RRB- -RRB-))) (VP (VBZ appears) (S (VP (TO to) (VP (VB represent) (NP (NP (DT a) (JJ complex) (NN integration)) (PP (IN of) (NP (NP (DT both) (JJ cellular) (NNP Doc_6203632_1480_1491_Disease) (CC and) (NNP Doc_6203632_1496_1507_Disease)) (PP (IN within) (NP (DT the) (NN heart)))))))))) (. .)))
6216862	0	(S1 (NP (NP (JJ Multiple) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ Doc_6216862_25_38_Chemical) (NN therapy))) (PP (IN in) (NP (NP (CD one) (NN patient)) (PP (IN with) (NP (NNP Doc_6216862_67_87_Disease))))) (. .)))
6216862	1	(S1 (S (NP (NNP Doc_6216862_89_100_Disease) (, ,) (NNP Doc_6216862_102_113_Disease) (, ,) (NNP Doc_6216862_115_143_Disease) (, ,) (NNP Doc_6216862_145_157_Disease) (CC and) (NNP Doc_6216862_162_179_Disease)) (VP (AUX have) (DT all) (VP (AUX been) (VP (VBN recorded) (PP (IN as) (NP (NP (NNS complications)) (PP (IN of) (NP (NP (JJ Doc_6216862_223_236_Chemical) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6216862_262_282_Disease)))))))))))) (. .)))
6216862	2	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN developed) (NP (QP (DT all) (CD 5)))))))) (VP (AUX is) (ADVP (RB now)) (VP (VBN described))) (. .)))
6216862	3	(S1 (S (NP (DT The) (NNP Doc_6216862_340_351_Disease)) (VP (VBD resembled) (NP (NP (NNP Doc_6216862_362_393_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (JJ rare) (NN side) (NN effect)) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6216862_458_474_Disease))))) (CC but) (PP (RB not) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6216862_500_520_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6216862_534_547_Chemical)))))))))))))))))) (. .)))
625456	0	(S1 (NP (NP (ADJP (JJ Obsolete) (CC but) (JJ dangerous)) (NN antacid) (NNS preparations)) (. .)))
625456	1	(S1 (S (NP (NP (NP (CD One) (NN case)) (PP (IN of) (NP (JJ acute) (NN Doc_625456_63_77_Disease)))) (CC and) (NP (NP (CD two)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_625456_99_114_Disease))))) (VP (AUX are) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB regularly)) (VP (VBN consumed) (NP (NP (JJ large) (NNS amounts)) (PP (IN of) (NP (JJ Doc_625456_184_202_Chemical-Doc_625456_203_221_Chemical) (NNS powders)))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 20)) (NNS years))))))))))) (. .)))
625456	2	(S1 (S (NP (DT The) (NNS powders)) (VP (AUX had) (VP (AUX been) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS pharmacists)) (ADJP (JJ unknown) (PP (TO to) (NP (NP (DT the) (NNS patients) (POS ')) (JJ medical) (NNS practitioners))))))))) (. .)))
625456	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (SBAR (IN that) (S (NP (DT these) (NNS preparations)) (VP (AUX were) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN patient) (POS 's)) (NNS problems))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (JJ such) (NNS powders)) (VP (MD should) (ADVP (RB no) (RB longer)) (VP (AUX be) (ADJP (RB freely) (JJ obtainable))))))))) (. .)))
6292680	0	(S1 (NP (NP (NNP Doc_6292680_0_11_Chemical) (NNP Doc_6292680_12_26_Disease)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (JJ left-sided) (NNP Doc_6292680_55_66_Disease))))) (. .)))
6292680	1	(S1 (S (NP (NP (CD Two) (NNS children)) (PP (IN with) (NP (NP (NNP Doc_6292680_86_97_Disease)) (PP (IN of) (NP (DT the) (VBN left) (NN kidney)))))) (VP (VBD experienced) (NP (JJ severe) (NNP Doc_6292680_136_149_Chemical) (NNP Doc_6292680_150_164_Disease)) (PP (IN after) (NP (NP (NP (NN irradiation)) (PP (TO to) (NP (DT the) (NNP Doc_6292680_190_195_Disease) (NN bed)))) (CC and) (NP (NP (JJ conventional) (NN dosage)) (PP (IN of) (NP (NNP Doc_6292680_227_238_Chemical))))))) (. .)))
6292680	2	(S1 (S (NP (DT The) (NNP Doc_6292680_244_258_Disease)) (VP (AUX is) (VP (VBN attributed) (NP (CD 1)) (-RRB- -RRB-) (PP (TO to) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NN radiation) (NNS fields)) (PP (IN for) (NP (JJ left) (NNP Doc_6292680_319_330_Disease)))) (VP (VB include) (NP (NP (DT the) (JJR lower) (NN portion)) (PP (IN of) (NP (DT the) (NN heart) (CC and) (CD 2)))) (-RRB- -RRB-) (PP (TO to) (NP (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NNP Doc_6292680_399_410_Chemical)))) (CC and) (NP (NP (NN irradiation)) (PP (IN on) (NP (JJ cardiac) (NN muscle))))))))))))) (. .)))
6292680	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ Doc_6292680_469_480_Chemical) (NN dosage)) (VP (AUX be) (VP (ADVP (RB sharply)) (VBN restricted) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NNP Doc_6292680_527_538_Disease)) (PP (IN of) (NP (NP (DT the) (JJ left) (NN kidney)) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (JJ postoperative) (NN irradiation))))))))))))))))) (. .)))
6293644	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NN calcitonin))) (PP (IN on) (NP (NN rat) (JJ extrapyramidal) (NN motor) (NN system)))) (: :) (NP (JJ behavioral) (CC and) (JJ biochemical) (NNS data)) (. .)))
6293644	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ i.v.c.) (NN injection)) (PP (IN of) (NP (NN human) (CC and) (NN salmon) (NN calcitonin))))) (PP (IN on) (NP (NP (JJ biochemical) (CC and) (JJ behavioral) (NNS parameters)) (VP (VBN related) (PP (TO to) (NP (DT the) (JJ extrapyramidal) (NN motor) (NN system))) (, ,))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
6293644	2	(S1 (S (NP (JJ Calcitonin) (NN injection)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN potentiation)) (PP (IN of) (NP (JJ Doc_6293644_322_333_Chemical-induced) (NN Doc_6293644_342_351_Disease)))) (CC and) (NP (NP (DT a) (JJ partial) (NN prevention)) (PP (IN of) (NP (NNP Doc_6293644_380_391_Chemical-induced) (NNP Doc_6293644_400_413_Disease))))))) (. .)))
6293644	3	(S1 (S (ADVP (RB Moreover)) (NP (NN calcitonin)) (VP (VBN induced) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ nigral) (NN GAD) (NN activity)))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (JJ striatal) (NNP Doc_6293644_515_517_Chemical) (CC and) (NNP Doc_6293644_522_527_Chemical) (NN concentration) (CC or) (NN GAD) (NN activity)))))) (. .)))
6293644	4	(S1 (S (NP (DT The) (NNS results)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT a) (JJ primary) (NN action)) (PP (IN of) (NP (NN calcitonin))) (PP (IN on) (NP (NP (DT the) (JJ striatonigral) (JJ GABAergic) (NN pathway)) (VP (VBG mediating) (NP (NP (DT the) (JJ Doc_6293644_680_682_Chemical-related) (JJ behavioral) (NNS messages)) (PP (IN of) (NP (JJ striatal) (NN origin))))))))))))) (. .)))
6308526	0	(S1 (S (NP (JJ Doc_6308526_0_10_Chemical) (NN pretreatment)) (VP (VBZ modifies) (NP (NP (NN cardiorespiratory)) (, ,) (NP (NN temperature)) (, ,) (CC and) (NP (NP (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_6308526_91_99_Chemical)))))) (. .)))
6308526	1	(S1 (S (NP (NP (JJ Behavioral) (CC and) (JJ cardiorespiratory) (NNS responses)) (PP (TO to) (NP (NP (DT a) (JJ lethal) (NN dose)) (PP (IN of) (NP (NNP Doc_6308526_164_172_Chemical)))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_6308526_222_232_Chemical)) (, ,) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (QP (JJ high-affinity) (CD mu) (CD 1)) (JJ opioid) (NNS receptors)))))))))))) (. .)))
6308526	2	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_6308526_306_316_Chemical)))) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NNP Doc_6308526_339_347_Chemical) (NNP Doc_6308526_348_357_Disease)) (, ,) (NP (NNP Doc_6308526_359_368_Disease)) (CC and) (NP (NNP Doc_6308526_373_384_Disease))) (PP (IN at) (NP (NP (DT a) (NN dose)) (SBAR (WHNP (WDT which)) (S (ADVP (RB completely)) (VP (VBD eliminated) (NP (NP (NN high-affinity)) (VP (VBG binding) (PP (IN in) (NP (NN brain) (NNS membranes))))))))))) (. .)))
6308526	3	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_6308526_475_485_Chemical)) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (DT the) (NNP Doc_6308526_515_523_Chemical-induced) (NNP Doc_6308526_532_543_Disease) (CC and) (NNP Doc_6308526_548_570_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_6308526_580_588_Chemical-induced) (NNP Doc_6308526_597_608_Disease)) (VP (AUX was) (ADJP (RBR less) (JJ affected)))))) (. .)))
6308526	4	(S1 (S (NP (NNS Results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNS subpopulations)) (PP (IN of) (NP (NN mu) (NNS receptors)))) (VP (MD may) (VP (VB mediate) (NP (NP (JJ selective) (JJ behavioral) (CC and) (JJ cardiorespiratory) (NNS responses)) (PP (TO to) (NP (NNP Doc_6308526_749_757_Chemical))))))))) (. .)))
6323692	0	(S1 (NP (NP (NN Modification)) (PP (IN of) (NP (NN drug) (NN action))) (PP (IN by) (NP (NNP Doc_6323692_31_45_Disease))) (. .)))
6323692	1	(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_6323692_65_81_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_6323692_83_88_Chemical) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (CD 6) (NN mmol/kg)) (NP (NNP s.c.))) (-RRB- -RRB-))))) (VP (ADVP (RB approximately)) (VBD doubled) (NP (NP (DT the) (NN time)) (SBAR (S (NP (JJ Doc_6323692_138_146_Chemical-treated) (NNS mice)) (VP (VP (VBD remained) (PP (IN on) (NP (DT a) (JJ hot) (NN surface)))) (CC and) (VP (ADVP (RB similarly)) (VBD increased) (NP (JJ muscular) (NNP Doc_6323692_219_233_Disease)) (PP (IN by) (NP (NNP Doc_6323692_237_245_Chemical)))))))))) (, ,) (CC but) (S (NP (NP (JJ Doc_6323692_251_256_Chemical) (NN treatment)) (ADVP (RB alone))) (VP (AUX had) (NP (DT no) (NN effect)))) (. .)))
6323692	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_6323692_294_308_Disease)) (VP (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG altering) (NP (NN drug) (NN action))))))) (CC and) (VP (MD must) (VP (AUX be) (VP (VBN considered) (PRT (RP along)) (PP (IN with) (NP (NP (VBN impaired) (NN drug) (NN metabolism)) (PP (IN in) (NP (NP (JJ enhanced) (NN drug) (NNS responses)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6323692_446_459_Disease)))))))))))) (. .)))
6323692	3	(S1 (S (NP (NP (NNS Experiments)) (PP (IN in) (NP (NN vitro)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ Doc_6323692_494_507_Chemical-induced) (JJ Doc_6323692_516_529_Chemical) (NN release)) (PP (IN from) (NP (JJ bovine) (JJ adrenal) (NN medulla)))) (VP (AUX is) (VP (VBN depressed) (NP (QP (RB as) (JJ much) (IN as) (CD 50)) (NN %)) (PP (IN by) (NP (NP (CD 0.3) (NN mM)) (SBAR (S (NP (NP (NNP Doc_6323692_604_609_Chemical)) (CC and) (NP (NP (JJ Doc_6323692_614_617_Chemical-induced) (NNS contractions)) (PP (IN of) (NP (NN guinea-pig) (NN ileum))))) (VP (AUX were) (VP (VBD inhibited) (NP (CD 20) (NN %)) (PP (IN by) (NP (CD 5) (NN mM) (NNP Doc_6323692_686_691_Chemical)))))))))))))) (. .)))
6323692	4	(S1 (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (JJ excess) (NNP Doc_6323692_712_719_Chemical)))) (VP (VBD reversed) (NP (DT the) (NN Doc_6323692_733_743_Disease)) (PP (IN in) (NP (DT both) (NNS tissues))))) (, ,) (CC but) (S (NP (NP (JJ Doc_6323692_765_772_Chemical-independent) (JJ Doc_6323692_785_798_Chemical) (NN release)) (PP (IN by) (NP (NNP Doc_6323692_810_822_Chemical)))) (VP (AUX was) (RB not) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_6323692_842_847_Chemical)))))) (. .)))
6323692	5	(S1 (S (NP (DT These) (NNS results)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_6323692_878_885_Chemical)) (VP (NNS blocks) (NP (JJ Doc_6323692_893_900_Chemical) (NNS channels)))))) (. .)))
6323692	6	(S1 (S (NP (NP (NP (NNS Parallels)) (PP (IN in) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_6323692_939_944_Chemical)))))) (CC and) (NP (NP (DT the) (JJ Doc_6323692_953_960_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_6323692_977_986_Chemical)))) (VP (VBP support) (NP (DT this) (NN concept))) (. .)))
6323692	7	(S1 (S (S (NP (NP (NP (DT Both) (NNP Doc_6323692_1014_1023_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_6323692_1044_1049_Chemical) (NN pretreatment))) (VP (VP (VBD enhanced) (NP (NP (NNP Doc_6323692_1072_1080_Chemical) (NNP Doc_6323692_1081_1090_Disease-)) (CC and) (NP (JJ Doc_6323692_1096_1104_Chemical-induced) (JJ muscular) (NN Doc_6323692_1122_1136_Disease)))) (CC and) (VP (VBD antagonized) (NP (JJ Doc_6323692_1153_1164_Chemical-induced) (NN motor) (NN activity))))) (, ,) (CC and) (S (NP (DT neither) (NNP Doc_6323692_1201_1210_Chemical) (CC nor) (NNP Doc_6323692_1215_1220_Chemical)) (VP (VBD affected) (NP (NP (DT the) (JJ convulsant) (NN action)) (PP (IN of) (NP (NNP Doc_6323692_1255_1263_Chemical)))))) (. .)))
6323692	8	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6323692_1287_1301_Disease)) (VP (VBZ exerts) (NP (NP (DT a) (JJ Doc_6323692_1311_1318_Chemical) (NN channel)) (VP (VBG blocking) (NP (NN action))) (SBAR (WHNP (WDT which)) (S (VP (VBZ enhances) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ central) (JJ nervous) (NN system) (NNS depressants)) (CC and) (NP (JJ certain) (NN opioid) (NNS analgesics))))))))))))) (. .)))
6381653	0	(S1 (NP (NP (NP (JJ Doc_6381653_0_8_Chemical-induced) (NN Doc_6381653_17_27_Disease)) (CC and) (NP (NN thalamotomy))) (. .)))
6381653	1	(S1 (S (NP (NP (JJ Doc_6381653_45_53_Chemical-induced) (NNP Doc_6381653_62_72_Disease)) (PP (IN of) (NP (NP (DT the) (NNS limbs)) (PP (IN in) (NP (NP (JJ thirteen) (NNS cases)) (PP (IN of) (NP (NNP Doc_6381653_107_119_Disease))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ choreic) (, ,) (JJ ballistic) (CC or) (JJ Doc_6381653_153_161_Disease)) (PP (IN in) (NP (NN type)))))) (, ,)) (VP (VP (AUX was) (VP (VBN alleviated) (ADVP (RB almost) (RB completely)) (PP (IN by) (NP (JJ stereotaxic) (NN surgery))) (S (VP (VBG using) (NP (NP (DT a) (JJ microelectrode) (NN technique)) (PP (IN for) (NP (NP (DT the) (FW ventralis) (FW oralis) (NNP anterior)) (CC and) (NP (NP (JJ posterior) (NNS nuclei)) (PP (IN of) (NP (DT the) (NN thalamus))))))))))) (, ,) (CC but) (VP (ADJP (RB much) (JJR less)) (PP (IN by) (NP (DT the) (NN ventralis) (JJ intermedius) (NN nucleus))))) (. .)))
6381653	2	(S1 (S (NP (NP (NN Control)) (PP (IN of) (NP (NNP Doc_6381653_395_403_Chemical-induced) (NNP Doc_6381653_412_423_Disease))) (PP (IN by) (NP (NNP Doc_6381653_427_443_Disease))) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (JJ routine) (NN treatment)) (PP (IN of) (NP (NNP Doc_6381653_482_494_Disease)))))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
6402369	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_6402369_13_23_Chemical-induced) (NNP Doc_6402369_32_51_Disease))) (PP (IN by) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6402369_78_112_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_114_119_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NNP Doc_6402369_149_160_Disease))))))) (. .)))
6402369	1	(S1 (S (NP (NP (DT The) (JJ protective) (NN effect)) (PP (IN of) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_6402369_214_219_Chemical) (NN compound) (NNP Doc_6402369_229_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_265_270_Chemical)) (-RRB- -RRB-)))) (PP (IN against) (NP (NP (NNP Doc_6402369_280_299_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_6402369_311_321_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_323_325_Chemical)) (-RRB- -RRB-)))))))))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 45) (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NNP Doc_6402369_380_391_Disease))))))) (PP (IN under) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_6402369_413_415_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 2250) (NN mg/m2)) (PP (IN on) (NP (NNS days)))) (NP (CD 2-5)) (-RRB- -RRB-)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ polychemotherapy) (NN regimen)) (VP (VBN repeated) (PP (IN in) (NP (DT a) (JJ 4-week) (NN cycle)))))))))) (. .)))
6402369	2	(S1 (S (NP (NNP Doc_6402369_507_512_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB orally)) (PP (IN on) (NP (NP (DT the) (NNS days)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_6402369_560_562_Chemical)) (PP (IN in) (NP (NP (CD 3) (NNS doses)) (PP (IN of) (NP (NP (CD 840) (NNS mg/m2)) (, ,) (NP (NP (DT each) (VBN administered) (QP (IN at) (CD 0)) (NNS hr)) (PRN (-LRB- -LRB-) (NP (NP (NP (SYM =)) (NP (NN injection))) (PP (IN of) (NP (NNP Doc_6402369_630_632_Chemical)))) (-RRB- -RRB-))) (, ,) (NP (CD 4) (NN hr)) (CC and) (NP (NP (QP (CD 8) (CD hr)) (NNS p.i.)) (PP (IN Out) (PP (IN of) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 88) (NNS courses)) (PP (IN of) (NP (NP (DT this) (NN treatment)) (SBAR (S (NP (PRP we)) (VP (VBD observed) (NP (NP (CD 10) (NNS episodes)) (PP (IN of) (NP (NP (JJ asymptomatic) (JJ microscopic) (NN Doc_6402369_753_763_Disease)) (CC and) (NP (NP (DT no) (NNS episodes)) (PP (IN of) (NP (JJ gross) (NNP Doc_6402369_789_799_Disease)))))))))))))))))))))))))))) (. .)))
6402369	3	(S1 (S (PP (IN In) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NP (CD 45) (NNS patients)) (PP (IN under) (NP (NP (NN protection)) (PP (IN with) (NP (NNP Doc_6402369_852_857_Chemical))))))))) (NP (EX there)) (VP (AUX were) (NP (NP (NP (CD 5) (JJ complete) (NNS remissions)) (CC and) (NP (CD 9) (JJ partial) (NNS remissions))) (PRN (-LRB- -LRB-) (NP (QP (JJ total) (CD 31)) (NN %)) (-RRB- -RRB-)))) (. .)))
6402369	4	(S1 (S (NP (NP (DT A) (JJ further) (NN group)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (PP (IN under) (NP (NN polychemotherapy))) (PP (IN with) (NP (NNP Doc_6402369_988_990_Chemical)))))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (JJ conventional) (JJ prophylactic) (NNS measures)) (PRN (-LRB- -LRB-) (NP (NP (VBN raised) (NN fluid) (NN intake)) (CC and) (NP (JJ forced) (NNS diuresis))) (-RRB- -RRB-)))))) (. .)))
6402369	5	(S1 (S (S (PP (IN In) (NP (DT this) (NN group))) (NP (EX there)) (VP (AUX were) (NP (NP (CD 1) (JJ complete) (CC and) (CD 5) (JJ partial) (NNS remissions)) (PRN (-LRB- -LRB-) (NP (JJ total) (CD 24) (NN %)) (-RRB- -RRB-))))) (, ,) (CC but) (S (NP (QP (RB nearly) (PDT all)) (NNS patients)) (VP (VBD developed) (NP (NP (DT either) (JJ gross) (JJ Doc_6402369_1206_1216_Disease) (NN and/or) (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_6402369_1236_1254_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_1256_1264_Disease) (CC and) (NNP Doc_6402369_1269_1281_Disease)) (-RRB- -RRB-))))))) (. .)))
6402369	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ appreciable) (NNS differences)) (PP (IN between) (NP (NP (DT the) (JJ Doc_6402369_1334_1339_Chemical) (NN series)) (CC and) (NP (DT the) (JJ conventional) (NN prophylaxis) (NNS series)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT either) (ADJP (JJ haematological) (CC or) (JJ systemic)) (NN Doc_6402369_1437_1445_Disease)) (PP (IN of) (NP (DT the) (JJ cytostatic) (NN treatment))))))))) (. .)))
6402369	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP support) (NP (DT the) (NN view) (SBAR (IN that) (S (NP (NP (NNP Doc_6402369_1509_1514_Chemical)) (, ,) (VP (VBN given) (ADVP (RB orally)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ combined) (JJ cytostatic) (NNS regimens)) (SBAR (WHNP (WDT which)) (S (VP (VBP include) (NP (NNP Doc_6402369_1592_1594_Chemical)))))))))) (, ,)) (VP (VP (VBZ simplifies) (NP (DT the) (NN treatment))) (CC and) (VP (VBZ provides) (NP (NP (JJ optimum) (NN protection)) (PP (IN for) (NP (DT the) (JJ urinary) (NN epithelium)))))))))) (. .)))
6402369	8	(S1 (S (NP (NP (NN Protection)) (PP (IN with) (NP (JJ oral) (NNP Doc_6402369_1702_1707_Chemical)))) (VP (AUX is) (ADJP (RB particularly) (JJ suitable) (PP (IN for) (NP (NNS outpatients))))) (. .)))
6415512	0	(S1 (S (VP (VBP Doc_6415512_0_39_Disease) (NP (NP (JJ following) (NN institution)) (PP (IN of) (NP (JJ Doc_6415512_65_78_Chemical) (NN therapy))) (PP (IN in) (NP (NNS children))))) (. .)))
6415512	1	(S1 (S (NP (NP (CD Five) (NNS children)) (, ,) (VP (VBN aged) (NP (QP (CD 3) (TO to) (CD 11)) (NNS years))) (, ,) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6415512_148_161_Chemical))) (PP (IN for) (NP (NNP Doc_6415512_166_174_Disease)))) (, ,)) (VP (AUX had) (NP (NP (DT an) (JJ acute) (NN aberrant) (NN reaction)) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_6415512_237_301_Disease))))) (PP (IN within) (NP (DT a) (JJ few) (NNS days)))))) (. .)))
6415512	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6415512_330_343_Chemical)) (VP (AUX was) (VP (VBN discontinued))))) (, ,) (NP (NP (CD two)) (PP (IN of) (NP (DT the) (NNS children)))) (VP (VBD returned) (PP (TO to) (NP (PRP$ their) (JJ former) (NN state))) (ADVP (RB very) (RB quickly)) (, ,) (SBAR (S (S (NP (CD two)) (VP (AUX had) (NP (NP (DT the) (JJ minor) (NN motor) (NN Doc_6415512_451_459_Disease) (NN resolve)) (PP (IN in) (NP (QP (CD 3) (CC and) (CD 6)) (NNS months)))))) (, ,) (CC and) (S (NP (NN one)) (VP (AUX had) (S (NP (DT the) (NNP Doc_6415512_503_511_Disease)) (VP (VB persist)))))))) (. .)))
6415512	3	(S1 (S (NP (NP (DT The) (NN child)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT the) (NNP Doc_6415512_543_551_Disease)) (VP (VBD persisted))))) (VP (AUX was) (ADVP (RB later)) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_6415512_586_607_Disease))))))) (. .)))
6415512	4	(S1 (S (NP (DT The) (JJ other) (NNS children)) (VP (AUX are) (VP (VBG doing) (ADVP (RB well)) (PP (IN on) (NP (JJ other) (NNS anticonvulsants))))) (. .)))
6433367	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_6433367_10_23_Chemical) (JJ synthetase) (NNS inhibitors))) (PP (IN on) (NP (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_6433367_72_83_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
6433367	1	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (NN relationship)) (PP (IN of) (NP (NP (NNP Doc_6433367_128_142_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6433367_144_147_Chemical)) (-RRB- -RRB-))))) (PP (TO to) (NP (NNP Doc_6433367_152_159_Disease) (NN induction)))))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (CD six) (JJ PG) (NN synthetase) (NNS inhibitors))) (PP (IN on) (NP (NP (NP (NP (NNP Doc_6433367_218_229_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6433367_241_250_Chemical) (, ,) (NNP Doc_6433367_252_262_Chemical) (, ,) (NNP Doc_6433367_264_275_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_6433367_277_280_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NN electroshock)) (CC or) (NP (NNP Doc_6433367_299_310_Chemical))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
6433367	2	(S1 (S (S (NP (NP (NNP Doc_6433367_327_336_Chemical) (, ,) (NNP Doc_6433367_338_346_Chemical) (, ,) (NNP Doc_6433367_348_362_Chemical) (, ,) (CC and) (JJ low) (NN dose)) (NP (NNP Doc_6433367_377_394_Chemical))) (VP (VBD increased) (NP (NP (DT the) (NN latency-to-onset)) (PP (IN in) (NP (DT the) (JJ Doc_6433367_433_442_Chemical) (JJ and/or) (NNP Doc_6433367_450_453_Chemical) (NNS models)))))) (: ;) (S (NP (DT the) (NN electroshock) (, ,) (NNP Doc_6433367_480_490_Chemical) (CC and) (NNP Doc_6433367_495_506_Chemical) (NNS models)) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN affected) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ pretreatment) (NNS agents)))))))) (. .)))
6433367	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6433367_608_611_Chemical)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (DT the) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (S (VP (VBG underlying) (UCP (JJ Doc_6433367_656_665_Chemical-) (CC and) (NNP Doc_6433367_671_674_Chemical-induced) (NNP Doc_6433367_683_694_Disease) (, ,) (CC but) (RB not) (ADJP (JJ Doc_6433367_704_714_Chemical-)) (, ,) (ADJP (JJ electroshock-)) (, ,) (CC or) (NP (JJ Doc_6433367_735_746_Chemical-induced) (NN Doc_6433367_755_766_Disease)))))))))))) (. .)))
6436733	0	(S1 (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN Doc_6436733_23_30_Chemical)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_6436733_73_86_Chemical)))))) (. .)))
6436733	1	(S1 (S (NP (NP (NNP Doc_6436733_88_101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6436733_103_106_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ Doc_6436733_124_133_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADVP (RB already)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs)))))))))))) (. .)))
6436733	2	(S1 (S (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP Doc_6436733_237_240_Chemical)))) (VP (AUX was) (VP (VBN administered)))) (, ,) (CC and) (S (NP (JJ venous) (NN blood)) (VP (AUX was) (VP (VBN sampled) (PP (IN at) (NP (CD 0) (, ,) (CD 1) (, ,) (CD 2) (, ,) (CD 3) (, ,) (CC and) (CD 4) (NNS hours)))))) (. .)))
6436733	3	(S1 (S (NP (NP (NNP Doc_6436733_316_323_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6436733_325_328_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NNP Doc_6436733_399_409_Disease)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))))))))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ symptom-free)) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-))))))))) (, ,) (SBAR (IN although) (S (NP (JJ Doc_6436733_483_486_Chemical) (NN plasma) (NNS levels)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups))))))) (. .)))
6436733	4	(S1 (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ Doc_6436733_543_546_Chemical-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (JJ Doc_6436733_572_575_Chemical) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_6436733_660_663_Chemical)) (VP (AUX is) (VP (VBN given) (ADVP (RB chronically)))))))) (. .)))
6454943	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6454943_10_19_Chemical))) (PP (IN on) (NP (NP (JJ pre-existing) (CC and) (JJ Doc_6454943_40_55_Chemical-induced) (NN Doc_6454943_64_75_Disease)) (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_6454943_93_105_Disease)) (NNS rats))))) (. .)))
6454943	1	(S1 (S (NP (NN Doc_6454943_112_123_Disease)) (VP (AUX is) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (NP (JJ Doc_6454943_144_153_Chemical) (NN treatment)) (PP (IN in) (NP (JJ Doc_6454943_167_179_Disease) (NNS patients))))))) (. .)))
6454943	2	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (S (VP (VBG reproducing) (NP (NP (DT the) (JJ same) (NN Doc_6454943_230_247_Disease)) (PP (IN with) (NP (NNP Doc_6454943_253_262_Chemical)))))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NNP SHR))))) (. .)))
6454943	3	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_6454943_307_316_Chemical))) (PP (IN at) (NP (CD 100) (CD mg/kg))) (PP (IN for) (NP (CD 14) (NNS days)))) (VP (VBD failed) (S (VP (TO to) (VP (VB aggravate) (NP (NP (JJ Doc_6454943_362_373_Disease) (NN pre-existing)) (PP (IN in) (NP (NNP SHR)))))))) (. .)))
6454943	4	(S1 (S (ADVP (RB Also)) (, ,) (NP (JJ Doc_6454943_401_410_Chemical) (NN treatment)) (VP (VBD failed) (S (VP (TO to) (VP (VB potentiate) (CC or) (VB facilitate) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ massive) (NN Doc_6454943_479_490_Disease)) (VP (VBN invoked) (PP (IN by) (NP (NNP Doc_6454943_502_527_Chemical))) (PP (IN in) (NP (NNP SHR))))))))))) (. .)))
6454943	5	(S1 (S (NP (NNP Doc_6454943_536_545_Chemical)) (VP (AUX had) (NP (NP (ADJP (JJ little) (CC or) (DT no)) (JJ demonstrable) (NNS effects)) (PP (IN on) (NP (NP (NN serum) (NN electrolyte) (NNS concentrations)) (, ,) (NP (NP (NP (NN excretion)) (PP (IN of) (NP (NN urine)))) (, ,) (NP (NNP Doc_6454943_641_647_Chemical) (CC and) (NNP Doc_6454943_652_661_Chemical)) (, ,) (NP (JJ endogenous) (JJ Doc_6454943_674_684_Chemical) (NN clearance)) (, ,) (NP (NN body) (NN weight)) (, ,) (CC and) (NP (NN food) (CC and) (NN water) (NN consumption))))))) (. .)))
6454943	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_6454943_750_756_Chemical) (NNS bodies)) (VP (AUX were) (ADJP (RB consistently) (JJ present) (PP (IN in) (NP (NP (NN urine)) (CC and) (NP (NP (JJ several) (NNS lethalities)) (VP (VBN occurred) (PP (IN during) (NP (NP (JJ multiple) (NN dosing)) (PP (IN of) (NP (NP (NNP Doc_6454943_858_867_Chemical)) (PP (IN in) (NP (NNP SHR))))))))))))) (. .)))
6496797	0	(S1 (S (VP (VB Complete) (NP (NNP Doc_6496797_9_20_Disease)) (PP (VBG following) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_6496797_48_57_Chemical)))))) (. .)))
6496797	1	(S1 (S (PP (NP (CD Forty) (NNS minutes)) (IN after) (S (VP (VBG receiving) (NP (NP (DT a) (JJ single) (NN starting) (NN dose)) (PP (IN of) (NP (NNP Doc_6496797_115_124_Chemical))))))) (, ,) (NP (DT a) (NN patient)) (VP (VBD developed) (NP (JJ complete) (NN Doc_6496797_155_166_Disease))) (. .)))
6496797	2	(S1 (S (NP (DT The) (NN case)) (VP (VBZ illustrates) (SBAR (IN that) (S (, ,) (PP (IN despite) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJR earlier) (NNS studies))))) (, ,) (NP (NP (NP (NNP Doc_6496797_235_244_Chemical) (POS 's)) (NN effect)) (PP (IN on) (NP (JJ cardiac) (NN conduction)))) (VP (MD may) (VP (AUX be) (ADJP (JJ severe)) (PP (IN in) (NP (NNS individuals))) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NN conduction) (NN delay)))))))))) (. .)))
6504332	0	(S1 (NP (NP (JJ Doc_6504332_0_13_Chemical-induced) (NNP Doc_6504332_22_32_Disease)) (PP (IN in) (NP (DT a) (JJ Doc_6504332_38_61_Disease) (NN child))) (. .)))
6504332	1	(S1 (S (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (NN Doc_6504332_99_120_Disease)))) (VP (VBD developed) (NP (DT a) (NN Doc_6504332_133_143_Disease)) (PP (ADVP (RB soon)) (IN after) (S (VP (VBG starting) (NP (NP (JJ Doc_6504332_164_177_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_6504332_190_198_Disease)))))))) (. .)))
6504332	2	(S1 (S (NP (NP (JJ Known) (NNS causes)) (PP (IN of) (NP (NNP Doc_6504332_216_234_Disease)))) (VP (AUX were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation))))) (. .)))
6504332	3	(S1 (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NNP Doc_6504332_294_307_Chemical))))) (, ,) (NP (DT the) (NNP Doc_6504332_313_323_Disease)) (VP (VBD recurred)) (. .)))
6504332	4	(S1 (S (NP (NN Doc_6504332_334_347_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (JJ anticonvulsant) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN Doc_6504332_415_433_Disease))))))))))))) (. .)))
6540303	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_6540303_11_16_Chemical)))) (VP (VBP pretreatment) (PP (IN on) (NP (NP (NNP Doc_6540303_33_41_Chemical) (NNP Doc_6540303_42_51_Disease)) (PP (IN in) (NP (UCP (JJ pinealectomized) (CC or) (JJ hypophysectomized)) (NNS animals)))))) (. .)))
6540303	1	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (AUX were) (VP (VBN designed) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (UCP (NNP Doc_6540303_158_172_Chemical) (CC and) (JJ pineal)) (NNS idolamines))) (PP (IN on) (NP (NP (NNP Doc_6540303_198_206_Chemical-induced) (NNP Doc_6540303_215_224_Disease)) (PP (IN in) (NP (DT the) (ADJP (JJ intact) (, ,) (JJ pinealectomized) (CC or) (JJ hypophysectomized)) (NN chick) (CC and) (NN rat))))))))))) (. .)))
6540303	2	(S1 (S (PP (IN In) (NP (DT the) (VBN pinealectomized) (NN chick))) (, ,) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6540303_340_348_Chemical)))) (VP (VBD increased) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_6540303_375_384_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DOC)) (-RRB- -RRB-))))) (PP (IN after) (NP (NNP Doc_6540303_397_405_Chemical))))) (, ,) (CC but) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6540303_429_443_Chemical)))) (VP (AUX did) (RB not))) (. .)))
6540303	3	(S1 (S (NP (DT The) (JJ pineal) (NNS indolamines)) (VP (VBD exhibited) (NP (JJ mixed) (NNS actions))) (. .)))
6540303	4	(S1 (S (NP (NP (NP (NNP Doc_6540303_501_510_Chemical)) (CC and) (NP (NNP Doc_6540303_515_533_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (VBD augmented) (NP (NNP Doc_6540303_550_558_Chemical) (NNP DOC))))) (, ,)) (VP (AUX did) (RB not) (VP (AUX do) (ADVP (RB so)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (JJ pineal) (NN gland))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_6540303_622_631_Chemical)) (VP (VBD potentiated) (NP (DT the) (NNP Doc_6540303_648_656_Chemical) (NNP DOC)) (PP (IN in) (NP (PDT both) (DT the) (ADJP (JJ intact) (CC and) (JJ pinealectomized)) (NN chick)))))))) (. .)))
6540303	5	(S1 (S (S (S (NP (NN Doc_6540303_707_715_Chemical)) (VP (AUX was) (ADJP (RBR more) (JJ potent)) (PP (IN in) (NP (DT the) (VBN hypophysectomized) (NN chick))))) (CC and) (S (NP (NP (DT the) (JJ circadian) (NN rhythm)) (VP (VBN noted) (PP (IN in) (NP (DT the) (JJ intact) (NN chick))))) (VP (AUX was) (ADJP (JJ absent))))) (: ;) (S (ADVP (RB furthermore)) (, ,) (NP (NNP Doc_6540303_839_848_Chemical)) (VP (AUX did) (RB not) (VP (VB augment) (NP (DT the) (NNP Doc_6540303_869_877_Chemical) (NNP DOC)) (SBAR (IN whereas) (S (NP (NNP Doc_6540303_890_898_Chemical)) (VP (VBD continued) (S (VP (TO to) (VP (AUX do) (ADVP (RB so))))))))))) (. .)))
6540303	6	(S1 (S (NP (DT This) (NN study)) (VP (AUX did) (RB not) (VP (VB demonstrate) (NP (NP (DT a) (NNS species) (NN difference)) (VP (VBG regarding) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (NNP Doc_6540303_997_1003_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (NN pineal)) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (DT the) (JJ immature) (JJ blood-brain) (NN barrier)) (PP (IN in) (NP (DT the) (JJ young) (NN chick)))))))) (CC and) (NP (NP (DT the) (JJ intact) (NN barrier)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
6540303	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT these) (NNS data)) (VP (VBP indicate) (NP (NP (DT a) (JJ direct) (NN role)) (PP (IN of) (NP (DT the) (NN pituitary))) (PP (IN in) (NP (NP (DT the) (NN augmentation)) (PP (IN of) (NP (NNP Doc_6540303_1204_1212_Chemical) (NNP DOC))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6540303_1228_1237_Chemical)))))))) (. .)))
6540303	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_6540303_1252_1260_Chemical)) (VP (VBD appeared) (S (VP (TO to) (VP (VP (VB act) (PP (IN on) (NP (NP (NNS systems)) (VP (ADVP (RBR more) (RB closely)) (VBN involved) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_6540303_1332_1340_Chemical) (NNP Doc_6540303_1341_1350_Disease))))))))) (CONJP (RB rather) (IN than)) (ADVP (RB directly)) (PP (IN on) (NP (DT the) (NN pituitary))))))) (. .)))
6615052	0	(S1 (NP (NP (JJ Doc_6615052_0_7_Chemical-induced) (NNP Doc_6615052_16_32_Disease)) (, ,) (NP (NNP Doc_6615052_34_44_Disease)) (, ,) (CC and) (NP (NNP Doc_6615052_50_60_Disease)) (. .)))
6615052	1	(S1 (S (NP (NP (JJ Sixty-two) (NNS patients)) (PP (IN with) (NP (DT a) (JJ Doc_6615052_88_95_Chemical-induced) (NN Doc_6615052_104_120_Disease)))) (VP (AUX are) (VP (VBN reported))) (. .)))
6615052	2	(S1 (S (NP (NP (JJ Clinical) (NNS manifestations)) (PP (IN of) (NP (DT this) (NN disorder)))) (VP (VBP include) (NP (NP (NNP Doc_6615052_184_194_Disease)) (CC or) (, ,) (ADVP (RBR more) (RB frequently)) (, ,) (NP (NP (JJ Doc_6615052_216_230_Disease) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN Doc_6615052_260_267_Chemical)))))))) (. .)))
6615052	3	(S1 (S (NP (NN Laboratory) (NN testing)) (VP (AUX has) (VP (VBN revealed) (NP (NP (NN Doc_6615052_301_325_Disease)) (, ,) (NP (NP (VBN increased) (NN resistance)) (PP (TO to) (NP (NNP Doc_6615052_351_358_Chemical)))) (, ,) (CC and) (NP (NP (NN aggregation)) (PP (IN of) (NP (NNS platelets))))) (PP (IN by) (NP (NP (DT the) (NN patient) (POS 's)) (NN plasma))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_6615052_418_425_Chemical)) (VP (AUX is) (VP (VBN added))))))) (. .)))
6615052	4	(S1 (S (NP (JJ Immunologic) (NN testing)) (VP (AUX has) (VP (VBN demonstrated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ Doc_6615052_491_498_Chemical-dependent) (NN platelet) (NN membrane) (NN antibody)))))) (. .)))
6615052	5	(S1 (S (NP (NP (NP (DT The) (CD 20) (NNS deaths)) (, ,) (NP (CD 52) (NN Doc_6615052_555_599_Disease))) (, ,) (CC and) (NP (NP (CD 21) (JJ surgical) (NNS procedures)) (VP (TO to) (VP (VB manage) (NP (DT the) (NNS complications)))))) (VP (VBP confirm) (NP (NP (DT the) (NN seriousness)) (PP (IN of) (NP (DT the) (NN disorder))))) (. .)))
6615052	6	(S1 (S (S (NP (JJ Specific) (NN risk) (NNS factors)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN identified))))) (: ;) (S (ADVP (RB therefore)) (, ,) (NP (NP (DT all) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_6615052_779_786_Chemical)))) (VP (MD should) (VP (AUX be) (VP (VBN monitored))))) (. .)))
6615052	7	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN platelet) (NN count)) (VP (VBZ falls) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 100,000/mm3)))) (, ,) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (AUX is) (VP (VBG receiving) (NP (JJ Doc_6615052_893_900_Chemical) (, ,) (JJ Doc_6615052_902_922_Disease) (NN testing))))))))) (, ,) (S (VP (VBG using) (NP (NP (DT the) (NN patient) (POS 's)) (NN plasma)))) (, ,) (VP (AUX is) (VP (VBN indicated))) (. .)))
6615052	8	(S1 (S (NP (NN Management)) (VP (VBZ consists) (PP (IN of) (NP (NP (NN cessation)) (PP (IN of) (NP (NP (NNP Doc_6615052_1010_1017_Chemical)) (, ,) (NP (JJ platelet) (JJ anti-aggregating) (NNS agents)) (, ,) (CC and) (NP (NP (JJ alternate) (NNS forms)) (PP (IN of) (NP (NN anticoagulation)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN indicated))))) (. .)))
663266	0	(S1 (NP (NP (NN Doc_663266_0_24_Disease)) (PP (IN from) (NP (NNP Doc_663266_30_41_Chemical))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (JJ chelating) (NNS agents)))) (. .)))
663266	1	(S1 (S (NP (NP (DT The) (NNP Doc_663266_81_89_Disease)) (PP (IN of) (NP (NNP Doc_663266_93_107_Chemical)))) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_663266_134_145_Chemical))))) (PP (IN by) (NP (NP (JJ selective) (NN injection)) (PP (IN of) (NP (DT each))) (PP (IN into) (NP (NP (DT the) (JJ right) (JJ coronary) (NN artery)) (PP (IN of) (NP (NNS dogs))))))))) (. .)))
663266	2	(S1 (S (NP (NN Doc_663266_217_227_Chemical)) (VP (VBZ contains) (NP (NP (DT the) (NN chelating) (NNS agents)) (ADJP (JJ Doc_663266_258_272_Chemical) (CC and) (JJ Doc_663266_277_293_Chemical))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_663266_301_308_Chemical)) (VP (VBZ contains) (NP (NP (NNP Doc_663266_318_342_Chemical)) (CC and) (NP (DT no) (NNP Doc_663266_350_364_Chemical))))))) (. .)))
663266	3	(S1 (S (NP (NN Doc_663266_366_390_Disease)) (VP (VBD occurred) (ADVP (RB significantly) (ADVP (RBR more) (RB often))) (PP (IN with) (NP (NNP Doc_663266_430_440_Chemical))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN chelating) (NNS agents)) (VP (VBP contribute) (S (VP (TO to) (VP (VB Doc_663266_489_497_Disease) (PP (IN in) (NP (JJ coronary) (NN angiography)))))))))))) (. .)))
6637851	0	(S1 (NP (NP (NP (JJ Long-term) (NN efficacy)) (CC and) (NP (NN Doc_6637851_23_31_Disease))) (PP (IN of) (NP (JJ high-dose) (JJ Doc_6637851_45_55_Chemical) (NN therapy))) (PP (IN for) (NP (NP (NNP Doc_6637851_68_91_Disease)) (CC or) (NP (NNP Doc_6637851_95_119_Disease)))) (. .)))
6637851	1	(S1 (S (NP (NN Doc_6637851_121_131_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (CD 154) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN sustained) (, ,) (NP (NP (NP (NP (JJ symptomatic) (NNP Doc_6637851_196_219_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6637851_221_223_Disease)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 118)) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (NNP Doc_6637851_240_254_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 36)) (-RRB- -RRB-)))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ refractory) (PP (TO to) (NP (JJ conventional) (JJ antiarrhythmic) (NNS drugs)))))))))))) (. .)))
6637851	2	(S1 (S (S (NP (DT The) (NN loading) (NN dose)) (VP (AUX was) (NP (NP (CD 800) (NN mg/day)) (PP (IN for) (NP (CD 6) (NNS weeks)))))) (CC and) (S (NP (DT the) (NN maintenance) (NN dose)) (VP (AUX was) (NP (CD 600) (NN mg/day)))) (. .)))
6637851	3	(S1 (S (NP (NP (JJ Sixty-nine) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (VP (VBD continued) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_6637851_467_477_Chemical)))) (CC and) (VP (AUX had) (NP (NP (DT no) (NN recurrence)) (PP (IN of) (NP (NP (JJ symptomatic) (NNP Doc_6637851_515_517_Disease)) (CC or) (NP (NP (NNP Doc_6637851_521_545_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6637851_547_549_Disease)) (-RRB- -RRB-)))))) (PP (IN over) (NP (NP (DT a) (NN follow-up)) (PP (IN of) (NP (QP (CD 6) (TO to) (CD 52)) (NNS months))))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD +/-) (JJ standard) (NN deviation)) (NP (CD 14.2) (NN +/-) (CD 8.2)))) (-RRB- -RRB-)))) (. .)))
6637851	4	(S1 (S (NP (NP (CD Six) (NN percent)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (AUX had) (NP (NP (DT a) (JJ nonfatal) (NN recurrence)) (PP (IN of) (NP (NNP Doc_6637851_687_689_Disease))))) (CC and) (VP (AUX were) (ADVP (RB successfully)) (VP (VBN managed) (PP (IN by) (S (VP (VBG continuing) (NP (NNP Doc_6637851_734_744_Chemical)) (PP (PP (IN at) (NP (DT a) (JJR higher) (NN dose))) (CC or) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (DT a) (JJ conventional) (JJ antiarrhythmic) (NN drug)))))))))))) (. .)))
6637851	5	(S1 (S (NP (QP (CD One) (CC or) (JJR more)) (JJ adverse) (NN drug) (NNS reactions)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 51) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
6637851	6	(S1 (S (NP (JJ Adverse) (NNS effects)) (VP (VBD forced) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_6637851_934_944_Chemical))))) (PP (IN in) (NP (CD 41) (NN %)))) (CC and) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_6637851_975_985_Chemical))) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
6637851	7	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ symptomatic) (JJ adverse) (NNS reactions)) (VP (AUX were) (NP (NP (NP (NNP Doc_6637851_1057_1063_Disease) (CC or) (NNP Doc_6637851_1067_1073_Disease)) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_6637851_1081_1087_Disease) (CC and) (NNP Doc_6637851_1092_1100_Disease) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-) (, ,)) (NNP Doc_6637851_1107_1131_Disease)) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_6637851_1138_1168_Disease) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_6637851_1178_1212_Disease) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))))) (. .)))
6637851	8	(S1 (S (SBAR (IN Although) (S (NP (JJ large-dose) (NNP Doc_6637851_1239_1249_Chemical)) (VP (AUX is) (ADJP (RB highly) (JJ effective) (PP (IN in) (NP (NP (DT the) (JJ long-term) (NN treatment)) (PP (IN of) (NP (NNP Doc_6637851_1300_1302_Disease) (CC or) (NNP Doc_6637851_1306_1308_Disease))) (ADJP (JJ refractory) (PP (TO to) (NP (JJ conventional) (JJ antiarrhythmic) (NNS drugs)))))))))) (, ,) (NP (PRP it)) (VP (VBZ causes) (NP (JJ significant) (NN Doc_6637851_1380_1388_Disease)) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
6637851	9	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN dose)) (VP (AUX is) (VP (VBN adjusted) (PP (VBN based) (PP (IN on) (NP (NP (JJ clinical) (NN response)) (CC or) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ adverse) (NNS effects))))))))))) (, ,) (NP (NP (CD 75) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6637851_1545_1547_Disease)) (CC or) (NP (NNP Doc_6637851_1551_1553_Disease))))))) (VP (MD can) (VP (AUX be) (ADVP (RB successfully)) (VP (VBN managed) (PP (IN with) (NP (NNP Doc_6637851_1587_1597_Chemical)))))) (. .)))
6674249	0	(S1 (SBARQ (WHADVP (WRB Why)) (SQ (MD may) (NP (NP (NNP Doc_6674249_8_33_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_35_39_Chemical)) (-RRB- -RRB-))) (VP (VB induce) (NP (NNP Doc_6674249_48_56_Disease)) (PP (IN in) (NP (NN man))))) (. ?)))
6674249	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NP (DT a) (NN case)) (CC and) (NP (NN literature) (NN review)))) (. .)))
6674249	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6674249_115_135_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ short) (NNP Doc_6674249_151_176_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_178_182_Chemical)) (-RRB- -RRB-)) (NN treatment)) (PP (IN in) (NP (NP (DT a) (CD 72) (JJ year-old) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_6674249_224_248_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_250_253_Disease)) (-RRB- -RRB-)))))))))) (VP (AUX is) (VP (VBN described))) (. .)))
6674249	3	(S1 (S (NP (JJ Pathogenetic) (NNS hypotheses)) (VP (AUX are) (VP (VBN discussed))) (. .)))
6695415	0	(S1 (S (NP (NN Doc_6695415_0_19_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6695415_36_55_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_6695415_76_84_Chemical)))))) (. .)))
6695415	1	(S1 (S (NP (NP (NNP Doc_6695415_86_105_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6695415_107_110_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ serious) (JJ side) (NNS effects)) (PP (VBG including) (NP (NN Doc_6695415_183_189_Disease)))))))))))) (. .)))
6695415	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB often)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_6695415_217_225_Chemical))) (PP (IN in) (NP (NP (NN diet) (NNS preparations)) (CC and) (NP (`` ``) (JJ look-alike) ('' '') (NNS pills)))))) (. .)))
6695415	3	(S1 (S (SBAR (IN In) (S (NP (NN order)) (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NNP Doc_6695415_296_299_Chemical/Doc_6695415_300_308_Chemical)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_6695415_321_327_Disease)) (PP (IN in) (NP (JJ normotensive) (JJ and/or) (NNP Doc_6695415_351_363_Disease) (NNS rats))))))))))))) (, ,) (NP (PRP we)) (VP (VBN administered) (NP (NP (DT the) (NN combination)) (PP (IN in) (NP (NP (NP (CD six) (NNS times)) (NP (DT the) (JJ allowed) (JJ human) (NN dose))) (VP (VBN calculated) (PP (IN on) (NP (NP (DT a) (FW per) (NN weight) (NN basis)) (PP (IN for) (NP (DT the) (NNS rats))))))))) (NP (CD two) (NNS times)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD five) (NNS days)))) (. .)))
6695415	4	(S1 (S (NP (NN Doc_6695415_517_553_Disease)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 18) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_6695415_578_590_Disease) (NNS rats))))))) (. .)))
6695415	5	(S1 (S (NP (NP (DT A) (JJ single) (NNP Doc_6695415_606_609_Chemical/Doc_6695415_610_618_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (JJ same) (NN dose)) (-RRB- -RRB-))) (VP (VBP lead) (PP (TO to) (NP (NP (JJ acute) (NN Doc_6695415_660_672_Disease)) (PP (IN in) (NP (DT both) (DT the) (JJ normotensive) (CC and) (JJ Doc_6695415_702_714_Disease) (NNS animals)))))) (. .)))
6695415	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6695415_751_754_Chemical/Doc_6695415_755_763_Chemical)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_6695415_776_795_Disease)) (PP (IN in) (NP (ADJP (RB previously) (JJ Doc_6695415_810_822_Disease)) (NNS animals))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (JJR greater)) (PP (IN than) (NP (DT the) (JJ allowed) (NN dosage))))))))))))) (. .)))
6695415	7	(S1 (S (NP (NP (DT An) (JJ acute) (NN elevation)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (MD may) (VP (AUX be) (NP (DT a) (JJ contributing) (NN factor)))) (. .)))
6699841	0	(S1 (NP (NP (NN Doc_6699841_0_24_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_6699841_32_40_Chemical)))) (. .)))
6699841	1	(S1 (S (NP (NP (DT A) (JJ 31-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_6699841_65_85_Disease))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB previously)) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_6699841_124_132_Chemical)) (, ,) (NP (NNP Doc_6699841_134_152_Chemical)) (, ,) (NP (JJ high) (NN dose) (NNP Doc_6699841_164_175_Chemical)) (CC and) (NP (JJ Doc_6699841_180_184_Chemical) (NNS salts))))))))) (, ,)) (VP (VBD developed) (NP (NP (NNP Doc_6699841_202_226_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6699841_228_231_Disease)) (-RRB- -RRB-)) (NP (CD 4) (NNS months))) (PP (IN after) (NP (NP (NN institution)) (PP (IN of) (NP (JJ Doc_6699841_263_271_Chemical) (NN therapy)))))) (. .)))
6699841	2	(S1 (S (NP (NP (DT No) (JJ other) (NN factor)) (VP (VBG predisposing) (PP (TO to) (NP (NNP Doc_6699841_313_316_Disease))))) (VP (MD could) (VP (AUX be) (VP (VBN discovered)))) (. .)))
6699841	3	(S1 (S (S (NP (NN Doc_6699841_338_346_Chemical)) (VP (AUX was) (VP (VBN substituted) (PP (IN for) (NP (NNP Doc_6699841_367_375_Chemical)))))) (CC and) (S (NP (DT no) (JJ further) (JJ adverse) (JJ renal) (NNS effects)) (VP (VBD occurred) (PP (IN over) (NP (DT the) (JJ next) (CD 12) (NNS months))))) (. .)))
6699841	4	(S1 (S (NP (PRP We)) (VP (VP (VBP review) (NP (NP (JJ previous) (NNS reports)) (VP (VBG linking) (NP (NNP Doc_6699841_482_485_Disease)) (PP (TO to) (NP (JJ antiinflammatory) (NN drug) (NN use)))))) (CC and) (VP (VB discuss) (NP (NP (JJ possible) (NNS advantages)) (PP (IN of) (NP (NNP Doc_6699841_550_558_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN experienced) (NP (NNP Doc_6699841_592_606_Disease)) (PP (IN from) (NP (JJ other) (NN antiinflammatory) (NNS agents))))))))))) (. .)))
6728084	0	(S1 (S (VP (VB Doc_6728084_0_11_Disease) (NP (NP (NNS effects)) (PP (IN of) (NP (JJ Doc_6728084_23_37_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ renal) (NN protein) (NN reabsorption)) (CC and) (NP (NN accumulation)))))) (. .)))
6728084	1	(S1 (S (S (VP (TO To) (VP (VB quantify) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_6728084_123_133_Chemical) (, ,) (NNP Doc_6728084_135_144_Chemical) (CC and) (NNP Doc_6728084_149_159_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN protein) (NN reabsorption)) (CC and) (NP (NN accumulation)))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (AUX were) (VP (VBN administered) (PP (TO to) (NP (NNS rats))) (ADVP (RB intraperitoneally)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg/day)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 7) (, ,) (CD 14) (CC or) (CD 21) (NNS days))))) (. .)))
6728084	2	(S1 (S (PP (VBG Scanning) (NP (NP (NNP electron) (NN microscopy)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN endothelia))))) (, ,) (NP (NP (JJ urinary) (NNS measurements)) (PP (IN of) (NP (NP (NNP Doc_6728084_384_390_Chemical)) (, ,) (NP (NNP Doc_6728084_392_401_Chemical)) (, ,) (NP (JJ endogenous) (NN lysozyme)) (, ,) (NP (NNP N-acetyl-beta-D-glucosaminidase) (PRN (-LRB- -LRB-) (NNP NAG) (-RRB- -RRB-)) (PP (IN as) (PP (ADVP (RB well)) (IN as) (NP (NP (NN clearance) (CC and) (NN accumulation) (NNS experiments)) (PP (IN after) (NP (NP (NN i.v.) (NN administration)) (PP (IN of) (NP (NP (JJ egg-white) (NN lysozyme) (CC and) (NNS measurements)) (PP (IN of) (NP (NP (NN inulin) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP GFR)) (-RRB- -RRB-))))))))))))))) (VP (AUX were) (VP (AUX done) (PP (IN in) (NP (DT each) (NN treatment) (NN group))))) (. .)))
6728084	3	(S1 (S (NP (JJ Doc_6728084_638_648_Chemical) (NN administration)) (VP (VBD decreased) (NP (NP (NP (NN diameter)) (, ,) (NP (NN density)) (CC and) (NP (NN shape))) (PP (IN of) (NP (JJ endothelial) (NNS fenestrae))))) (. .)))
6728084	4	(S1 (S (NP (NP (NNP Doc_6728084_728_737_Chemical)) (CC and) (NP (NNP Doc_6728084_742_752_Chemical))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (DT no) (NN effect)) (PP (IN at) (NP (NP (DT the) (NN dose)) (VP (VBN used)))))))) (. .)))
6728084	5	(S1 (S (NP (DT All) (CD three) (NNP Doc_6728084_808_823_Chemical)) (VP (VP (VBD decreased) (NP (NN GFR))) (CC and) (VP (VBD increased) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NNP Doc_6728084_873_879_Chemical) (CC and) (NNP Doc_6728084_884_893_Chemical)))))) (. .)))
6728084	6	(S1 (S (SBAR (IN While) (S (NP (NP (NNP Doc_6728084_901_911_Chemical)) (CC and) (NP (NNP Doc_6728084_916_925_Chemical))) (VP (VBD decreased) (NP (NP (DT the) (NN percentage) (NN reabsorption) (CC and) (NN accumulation)) (PP (IN of) (NP (NN lysozyme)))) (PP (IN after) (NP (NP (NN i.v.) (NN administration)) (PP (IN of) (NP (JJ egg-white) (NN lysozyme)))))))) (NP (NNP Doc_6728084_1041_1051_Chemical)) (VP (AUX had) (NP (DT no) (NN effect))) (. .)))
6728084	7	(S1 (S (NP (NP (JJ Daily) (NN excretion)) (PP (IN of) (NP (NP (JJ total) (NN protein)) (, ,) (NP (JJ endogenous) (NN lysozyme)) (CC and) (NP (NN NAG))))) (VP (VBD increased) (ADVP (RB only)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_6728084_1165_1174_Chemical)) (CC and) (NP (NNP Doc_6728084_1179_1189_Chemical))))) (. .)))
6728084	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_6728084_1197_1212_Chemical)) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NNS nephrotoxicants))) (PP (IN at) (NP (NP (JJ glomerular) (NN and/or) (JJ tubular) (NN level)) (VP (VBG inducing) (NP (NP (NN Doc_6728084_1284_1316_Disease) (CC and) (NN accumulation)) (PP (IN of) (NP (NNS proteins))))))))) (. .)))
6732043	0	(S1 (NP (NP (NN Induction)) (PP (IN of) (NP (NP (DT the) (NNP Doc_6732043_17_49_Disease)) (PP (IN in) (NP (DT a) (NN woman))))) (PP (IN by) (NP (JJ exogenous) (JJ Doc_6732043_74_82_Chemical) (NN administration))) (. .)))
6732043	1	(S1 (S (NP (PRP We)) (VP (VBN documented) (NP (JJ airway) (NN occlusion)) (PP (IN during) (NP (NP (NN sleep)) (CC and) (NP (DT an) (ADJP (RB abnormally) (JJ high)) (NN supraglottic) (NN resistance)))) (SBAR (IN while) (S (ADJP (JJ awake) (PP (IN in) (NP (NP (DT a) (JJ 54-yr-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN developed) (NP (NP (JJ physical) (NNS changes)) (CC and) (NP (DT the) (NN Doc_6732043_266_301_Disease))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN administered) (NP (JJ exogenous) (NNP Doc_6732043_337_346_Chemical)))))))))))))))) (. .)))
6732043	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6732043_357_366_Chemical)) (VP (AUX were) (VP (VBN withdrawn))))) (, ,) (NP (NP (NP (DT the) (NN patient) (POS 's)) (JJ physical) (NNS changes)) (, ,) (NP (NNS symptoms)) (, ,) (NP (NN sleep) (NN study)) (, ,) (CC and) (NP (JJ supraglottic) (NN resistance))) (ADVP (RB all)) (VP (VBN returned) (PP (TO to) (NP (JJ normal)))) (. .)))
6732043	3	(S1 (S (NP (NP (DT A) (NN rechallenge)) (PP (IN with) (NP (NNP Doc_6732043_509_517_Chemical)))) (VP (VBD produced) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_6732043_539_562_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD abated) (PP (IN upon) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN hormone)))))))))) (. .)))
6732043	4	(S1 (S (NP (JJ Previous) (NNS reports)) (VP (AUX have) (VP (VBN favored) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NNP Doc_6732043_647_656_Chemical))) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_6732043_680_691_Disease)))))))) (. .)))
6732043	5	(S1 (S (NP (PRP$ Our) (NN report)) (VP (VBZ provides) (NP (JJ direct) (NN evidence)) (PP (IN for) (NP (DT this) (NN role)))) (. .)))
6732043	6	(S1 (S (NP (ADJP (JJ Structural) (CC and) (JJ functional)) (NNS measurements)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_6732043_797_806_Chemical)) (VP (VBP exert) (NP (NP (DT a) (ADJP (JJ permissive) (CC or) (JJ necessary)) (NN action)) (PP (IN on) (NP (NP (DT the) (JJ structural) (NN configuration)) (PP (IN of) (NP (NP (DT the) (NN oropharynx)) (SBAR (WHNP (WDT that)) (S (VP (VBZ predisposes) (PP (TO to) (NP (NN obstruction))) (PP (IN during) (NP (NN sleep))))))))))))))) (. .)))
6732043	7	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (DT the) (NNP Doc_6732043_961_993_Disease)))) (VP (MD must) (VP (AUX be) (VP (VBN considered) (S (NP (NP (DT a) (JJ possible) (NN side) (NN effect)) (PP (IN of) (NP (JJ Doc_6732043_1039_1047_Chemical) (NN therapy)))))))) (. .)))
6769133	0	(S1 (S (NP (NNP Doc_6769133_0_11_Disease)) (S (CC and) (NP (NP (JJ possible) (JJ leukemogenic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_6769133_49_59_Chemical)) (PP (IN in) (NP (NP (JJ nonhuman) (NN primates.)) (SBAR (S (NP (NP (CD 10) (NNS monkeys)) (PRN (-LRB- -LRB-) (NP (NNS macaques)) (-RRB- -RRB-))) (VP (VBD received) (NP (NNP Doc_6769133_113_123_Chemical)) (PP (IN by) (NP (NP (JJ monthly) (JJ intravenous) (NNS injections)) (PP (IN at) (NP (NP (CD 12) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NP (CD 1) (NNS mg/kg)) (-RRB- -RRB-))))))))))) (. .) (CD 8))) (PP (IN of) (NP (DT the) (CD 10) (NNS monkeys)))) (VP (VBD developed) (NP (NNP Doc_6769133_211_235_Disease)) (PP (IN at) (NP (NP (NP (DT an) (JJ average) (JJ cumulative) (JJ Doc_6769133_261_271_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 310) (NNS mg/m2)) (-RRB- -RRB-))) (RB well) (RB below) (IN that) (VP (VBN considered) (S (NP (NP (DT the) (JJ safe) (JJ upper) (NN limit)) (PRN (-LRB- -LRB-) (NP (CD 550) (NNS mg/m2)) (-RRB- -RRB-))) (PP (IN in) (NP (NN man))))))))) (. .)))
6769133	1	(S1 (S (S (ADVP (RB Histologically)) (, ,) (NP (DT the) (NNP Doc_6769133_377_395_Disease)) (VP (VBD resembled) (SBAR (S (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (NP (JJ human) (JJ Doc_6769133_427_440_Chemical-induced) (NNP Doc_6769133_449_463_Disease.) (CD 1)) (PP (IN of) (NP (DT the) (CD 10) (NNS monkeys))))))) (VP (VBD developed) (NP (NN Doc_6769133_495_522_Disease)) (PP (IN after) (S (VP (VBG receiving) (NP (NP (CD 324) (NN mg/m2)) (PP (IN of) (NP (NNP Doc_6769133_552_562_Chemical)))))))))))) (: ;) (S (NP (DT the) (JJ 10th) (NN monkey)) (VP (AUX is) (ADJP (JJ alive) (CC and) (RB well)) (PP (NP (CD 26) (NNS months)) (IN after) (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN drug))))))) (. .)))
6769133	2	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_6769133_662_672_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN cardiotoxin)) (PP (IN in) (NP (NNS monkeys)))) (PP (IN than) (PP (IN in) (NP (NN man))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNP Doc_6769133_735_743_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (VBN prolonged) (NN treatment))) (PP (IN with) (NP (DT this) (NN drug)))))))))) (. .)))
6794356	0	(S1 (NP (NP (NP (NN Doc_6794356_0_29_Disease)) (CC and) (NP (NNP Doc_6794356_34_51_Chemical) (NNP Doc_6794356_52_60_Disease))) (PP (IN in) (NP (DT a) (JJ newborn) (NN infant))) (. .)))
6794356	1	(S1 (S (NP (NP (DT A) (JJ newborn)) (PP (IN with) (NP (NP (JJ massive) (NNP Doc_6794356_105_128_Disease)) (, ,) (NP (NNP Doc_6794356_130_144_Disease)) (, ,) (NP (NNP Doc_6794356_146_170_Disease)) (, ,) (CC and) (NP (DT a) (JJ high) (JJ serum) (NNP Doc_6794356_189_196_Chemical) (NN level))))) (VP (AUX is) (VP (VBN described))) (. .)))
6794356	2	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (RB initially) (JJ manifest) (NNP Doc_6794356_265_288_Disease) (CC and) (NNP Doc_6794356_293_307_Disease)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ 11th) (VBN described) (NN patient)) (PP (IN with) (NP (NNP Doc_6794356_345_360_Disease))) (PP (IN among) (NP (NNS infants)))) (VP (VBD exposed) (PP (TO to) (NP (JJ Doc_6794356_386_393_Chemical) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy))))))) (. .)))
6794356	3	(S1 (S (NP (NP (JJ Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (AUX had) (VP (VBN tricuspid) (NP (NN valve) (NN involvement)))) (. .)))
6794356	4	(S1 (S (NP (NN Doc_6794356_511_528_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (NNP Doc_6794356_576_600_Disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy)))))))) (. .)))
6794356	5	(S1 (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (NNP Doc_6794356_651_672_Disease)) (, ,) (NP (NNP Doc_6794356_674_682_Disease)) (, ,) (CC and) (NP (NNP Doc_6794356_688_706_Disease))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (ADVP (RB prior) (PP (TO to) (NP (NN delivery)))))))) (. .)))
6817363	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (NN novel)))) (VP (VB compound) (NP (NP (NNP Doc_6817363_30_40_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6817363_42_52_Chemical)) (-RRB- -RRB-))) (PP (IN upon) (NP (NP (NNP Doc_6817363_59_87_Disease)) (PP (IN in) (NP (NNS rodents)))))) (. .)))
6817363	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_6817363_114_124_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6817363_126_136_Chemical)) (, ,) (NP (NNP Doc_6817363_138_163_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VP (VBN studied) (PP (IN on) (NP (NP (JJ various) (NNS forms)) (PP (IN of) (NP (NP (RB experimentally) (NNP Doc_6817363_212_240_Disease)) (PRN (-LRB- -LRB-) (NP (NN learning) (CC and) (NN memory)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NNS rodents)))) (CC and) (VP (VBN produced) (NP (NP (DT the) (VBG following) (NNS effects)) (: :) (NP (NP (ADJP (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (RB almost) (JJ complete)) (NN prevention)) (PP (IN of) (NP (DT the) (NN incapacity) (S (VP (TO to) (VP (VB learn) (NP (DT a) (JJ discrete) (NN escape) (NN response)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN exposed) (PP (TO to) (NP (JJ sublethal) (NNP Doc_6817363_424_435_Disease))) (S (NP (NP (ADVP (RB immediately) (PP (IN before) (NP (NP (DT the) (NN acquisition) (NN session)) (PRN (: ;) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (JJ partial) (-LRB- -LRB-) (NNS rats) (-RRB- -RRB-)) (CC or) (NP (JJ complete) (PRN (-LRB- -LRB-) (NP (NNS mice)) (-RRB- -RRB-)) (NN prevention)))) (IN of)) (DT the) (JJ Doc_6817363_536_547_Chemical-induced) (JJ short-term) (NNP Doc_6817363_567_574_Disease)) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task) (PRN (: ;) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ complete) (NN protection)) (PP (IN against) (NP (NNP Doc_6817363_637_644_Disease))) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (PP (IN in) (NP (NNS rats))) (VP (VBN submitted) (S (VP (TO to) (VP (VB electroconvulsive) (PP (NN shock) (PP (ADVP (RB immediately)) (IN after) (NP (NP (NN avoidance) (NN acquisition) (PRN (: ;) (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NN prevention)) (PP (IN of) (NP (NP (DT the) (JJ long-term) (ADJP (JJ retention-) (CC or) (JJ retrieval-deficit) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (VP (VBN induced) (PP (IN in) (NP (NNS rats) (CC and) (NNS mice))) (PP (IN by) (NP (NNP Doc_6817363_881_896_Chemical) (CC or) (NNP Doc_6817363_900_913_Chemical)))) (VP (VBN administered) (PP (ADVP (RB immediately)) (IN after) (NP (NN acquisition))))))) (PRN (: ;) (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (NN reversal)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN as) (ADJP (JJ late) (PP (IN as) (NP (NP (CD 1) (NNP h)) (PP (IN before) (NP (DT the) (NN retention) (NN test))) (, ,) (PP (IN of) (NP (NP (DT the) (NN deficit)) (PP (IN in) (NP (NP (NN retention) (CC or) (NN retrieval)) (PP (IN of) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6817363_1112_1125_Chemical))) (SBAR (S (VP (VBD injected) (NP (CD 2) (NNS days)) (ADVP (RB previously)) (: ;) (S (S (NP (NP (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN prevention)) (PP (IN of) (NP (DT the) (NN deficit))) (PP (IN in) (NP (NP (DT the) (NN retrieval)) (PP (IN of) (NP (DT an) (JJ active) (NN avoidance) (NN task)))))) (VP (VBN induced) (PP (IN in) (NP (NNS mice))) (PP (IN by) (NP (JJ subconvulsant) (NN electroshock))))) (CC or) (S (NP (NNP Doc_6817363_1278_1289_Disease)) (VP (VBD applied) (ADVP (RB immediately)) (PP (IN before) (NP (NP (NN retrieval) (NN testing)) (PRN (-LRB- -LRB-) (NP (NP (CD 24) (NNP h)) (PP (IN after) (NP (NN acquisition)))) (-RRB- -RRB-)))))))))))))))))))))))))))))))))))))))))))))))))))) (. .)))
6817363	2	(S1 (S (NP (NP (DT These) (NNS improvements) (CC or) (NNS normalizations)) (PP (IN of) (NP (NNP Doc_6817363_1401_1429_Disease)))) (VP (AUX were) (VP (VBN seen) (PP (IN at) (NP (NP (JJ oral) (JJ Doc_6817363_1448_1458_Chemical) (NNS doses)) (PP (IN of) (NP (CD 10-100) (NN mg/kg))))))) (. .)))
6817363	3	(S1 (S (ADVP (RB Generally)) (, ,) (NP (DT the) (JJ dose-response) (NNS curves)) (VP (AUX were) (ADJP (JJ bell-shaped))) (. .)))
6817363	4	(S1 (S (NP (NP (NP (DT The) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Doc_6817363_1578_1588_Chemical)))))) (CC and) (NP (PRP$ its) (POS ') (JJ therapeutic) (NN window) ('' '))) (VP (AUX are) (ADJP (JJ unknown))) (. .)))
6817363	5	(S1 (S (ADVP (JJ Doc_6817363_1631_1640_Chemical)) (, ,) (NP (DT another) (JJ Doc_6817363_1650_1663_Chemical) (NN derivative)) (VP (AUX was) (VP (VBN used) (PP (IN for) (NP (NN comparison))))) (. .)))
6817363	6	(S1 (S (NP (PRP It)) (VP (VP (AUX was) (ADJP (JJ active)) (PP (RB only) (IN in) (NP (QP (CD six) (IN of) (CD nine)) (NNS tests)))) (CC and) (VP (AUX had) (PP (IN about) (NP (NN one-tenth))) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NNP Doc_6817363_1779_1789_Chemical)))))) (. .)))
6817363	7	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_6817363_1817_1827_Chemical)) (VP (VBZ improves) (NP (NP (JJ cognitive) (NNS functions)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (VP (VBN impaired) (PP (PP (IN by) (NP (JJ different) (NN procedure))) (CC and) (PP (IN in) (NP (NP (JJ different) (NNS phases)) (PP (IN of) (NP (DT the) (NN learning) (CC and) (NN memory) (NN process))))))))))))))) (. .)))
6892185	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6892185_10_26_Chemical))) (PP (IN on) (NP (JJ gross) (JJ behavioural) (NNS changes))) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_68_77_Chemical)) (CC and) (NP (NNP Doc_6892185_82_89_Chemical)))) (PP (IN in) (NP (NNS cats)))) (. .)))
6892185	1	(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_6892185_113_129_Chemical)))) (VP (VBD injected) (PP (IN into) (NP (NP (DT the) (JJ cerebral) (NNS ventricles)) (PP (IN of) (NP (JJ group-housed) (JJ unanaesthetized) (NNS cats))))) (PP (IN upon) (NP (NP (NN vocalization)) (PRN (-LRB- -LRB-) (NP (NN rage)) (, ,) (NP (VBG hissing) (CC and) (VBG snarling)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG fighting) (PRN (-LRB- -LRB-) (NP (NP (NP (NN attack)) (PP (IN with) (NP (NNS paws) (CC and) (NNS claws)))) (, ,) (NP (NP (NN defense)) (PP (IN with) (NP (NNS paws) (CC and) (NNS claws)))) (CC and) (NP (VBG biting))) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNP Doc_6892185_332_341_Disease) (, ,) (NNP Doc_6892185_343_349_Disease) (CC and) (NNP Doc_6892185_354_378_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_391_400_Chemical)) (CC and) (NP (NNP Doc_6892185_405_412_Chemical)))))) (VP (VBD injected) (SBAR (S (RB similarly) (VP (AUX was) (VP (VBN investigated)))))) (. .)))
6892185	2	(S1 (S (NP (NNP Doc_6892185_450_466_Chemical)) (VP (VP (VBD depressed)) (CC or) (VP (ADVP (RB almost) (RB completely)) (VBD abolished) (NP (NP (DT the) (NN vocalization) (CC and) (NN fighting)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_6892185_545_554_Chemical)) (CC and) (NP (NNP Doc_6892185_559_566_Chemical)))))))) (. .)))
6892185	3	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NNP Doc_6892185_587_596_Disease) (, ,) (NNP Doc_6892185_598_604_Disease) (CC and) (NNP Doc_6892185_609_633_Disease)) (VP (VBN evoked) (PP (IN by) (NP (NP (NNP Doc_6892185_644_653_Chemical)) (CC and) (NP (NNP Doc_6892185_658_665_Chemical)))))) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN changed) (PP (IN by) (NP (NNP Doc_6892185_700_716_Chemical))))) (. .)))
6892185	4	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ apparent)) (SBAR (IN that) (S (NP (NNP Doc_6892185_738_754_Chemical)) (VP (MD can) (VP (`` ``) (VB dissociate) ('' '') (NP (NN vocalization) (CC and) (NN fighting)) (PP (IN from) (NP (NP (NN autonomic) (CC and) (NN motor) (NNS phenomena)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_6892185_841_850_Disease) (, ,) (NNP Doc_6892185_852_858_Disease) (CC and) (NNP Doc_6892185_863_887_Disease)) (VP (VBD caused) (PP (IN by) (NP (NP (NNP Doc_6892185_898_907_Chemical)) (CC and) (NP (NNP Doc_6892185_912_919_Chemical)))))))))))))) (. .)))
6892185	5	(S1 (S (NP (NNP Doc_6892185_921_937_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (NN vocalization) (CC and) (NN fighting)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_990_999_Chemical)) (CC and) (NP (NNP Doc_6892185_1004_1011_Chemical)))) (PP (ADVP (RBS most) (RB probably)) (IN by) (NP (NP (DT a) (JJ nonspecific) (VBG stabilizing) (NN action)) (PP (IN on) (NP (JJ central) (JJ muscarinic) (NN cholinoceptive) (NNS sites)))))))) (. .)))
6892185	6	(S1 (S (NP (DT These) (NNS results)) (ADVP (RB further)) (VP (VBP support) (NP (DT the) (NN view) (SBAR (IN that) (S (NP (NP (JJ Doc_6892185_1150_1157_Chemical) (NNS ions)) (PP (IN in) (NP (NN excess)))) (VP (AUX have) (NP (DT an) (JJ Doc_6892185_1181_1189_Chemical-like) (NN action)) (ADVP (RB also)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))) (. .)))
6942642	0	(S1 (NP (NP (JJ Doc_6942642_0_8_Chemical) (NNS diuretics)) (, ,) (NP (NP (NNP Doc_6942642_20_31_Disease)) (CC and) (NP (NNP Doc_6942642_36_55_Disease))) (. .)))
6942642	1	(S1 (S (NP (JJ Doc_6942642_57_65_Chemical) (NNS diuretics)) (VP (AUX are) (ADVP (RB widely)) (VP (VBN accepted) (PP (IN as) (NP (NP (DT the) (NN cornerstone)) (PP (IN of) (NP (JJ antihypertensive) (NN treatment) (NNS programs))))))) (. .)))
6942642	2	(S1 (S (NP (NN Doc_6942642_155_166_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN encountered)) (NN metabolic) (NN consequence)) (PP (IN of) (NP (JJ chronic) (JJ Doc_6942642_226_234_Chemical) (NN therapy))))) (. .)))
6942642	3	(S1 (S (NP (PRP We)) (VP (VBN treated) (NP (NP (CD 38) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (JJ low) (NN renin)) (, ,) (NP (CD 16) (JJ normal) (NN renin)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ moderate) (NN Doc_6942642_313_335_Disease)) (PP (IN with) (NP (NP (NNP Doc_6942642_341_360_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6942642_362_366_Chemical)) (-RRB- -RRB-)))) (VP (VBN administered) (PP (IN on) (NP (DT a) (RB twice) (JJ daily) (NN schedule))))))) (. .)))
6942642	4	(S1 (S (S (NP (JJ Initial) (NN dose)) (VP (AUX was) (NP (CD 50) (NN mg)))) (CC and) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN increased) (PP (IN at) (NP (JJ monthly) (NNS intervals))) (PP (TO to) (NP (CD 100) (CD mg))) (, ,) (ADVP (NP (QP (CD 150) (CD mg) (CC and) (CD 200)) (NNS mg)) (RB daily)) (SBAR (IN until) (S (NP (NN blood) (NN pressure)) (VP (VBD normalized))))))) (. .)))
6942642	5	(S1 (S (NP (NP (DT The) (NN serum) (NN Doc_6942642_557_558_Chemical)) (PP (IN during) (NP (DT the) (NN control) (NN period)))) (VP (AUX was) (NP (NP (CD 4.5) (NN +/-)) (NP (CD 0.2) (NN mEq/l))) (NP (NP (DT an) (ADJP (ADVP (IN on)) (NP (CD 50) (, ,) (CD 100) (, ,) (CD 150) (CC and) (CD 200) (NNS mg)) (JJ Doc_6942642_637_641_Chemical)) (JJ daily) (CD 3.9) (NN +/-) (CD 0.3) (, ,) (CD 3.4) (QP (JJ +/-) (CD 0.2))) (, ,) (NP (NP (CD 2.9) (NN +/-)) (NP (CD 0.2))) (, ,) (CC and) (NP (NP (CD 2.4) (NN +/-)) (NP (CD 0.3) (NNS mEq/l)))) (, ,) (ADVP (RB respectively))) (. .)))
6942642	6	(S1 (S (NP (NP (JJ Corresponding) (NNS figures)) (PP (IN for) (NP (JJ whole) (NN body) (NNP Doc_6942642_761_762_Chemical)))) (VP (AUX were) (NP (NP (NP (CD 4107)) (ADJP (JJ +/-) (NP (CD 208)))) (, ,) (NP (CD 3722) (JJ +/-) (CD 319)) (, ,) (NP (CD 3628) (JJ +/-) (CD 257)) (, ,) (NP (CD 3551) (JJ +/-) (CD 336)) (, ,) (CC and) (NP (NP (CD 3269) (NN +/-)) (NP (CD 380) (NNS mEq))) (, ,) (ADVP (RB respectively)))) (. .)))
6942642	7	(S1 (S (PP (IN In) (NP (CD 13) (NNS patients))) (NP (PRP we)) (VP (VP (VBD observed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_6942642_902_906_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CD mg)) (NN daily)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))))) (PP (IN during) (NP (NN rest)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (JJ static)) (CC and) (NP (JJ dynamic) (NN exercise))))) (. .)))
6942642	8	(S1 (S (PP (IN During) (NP (NN rest))) (NP (PRP we)) (VP (VBD observed) (NP (CD 0.6) (NN +/-)) (UCP (NP (CD 0.08) (NNP PVC) (JJ beats/min) (JJ +/-) (NN SEM)) (CC and) (PP (IN during) (NP (NP (JJ static) (CC and) (JJ dynamic) (NN exercise) (CD 0.6) (NN +/-)) (NP (CD 0.06) (CC and) (CD 0.8) (NN +/-) (CD 0.15)) (, ,) (ADVP (RB respectively)))))) (. .)))
6942642	9	(S1 (S (NP (NP (JJ Corresponding) (NNS figures)) (PP (IN during) (NP (JJ Doc_6942642_1188_1192_Chemical) (NN therapy)))) (ADVP (NP (CD 100) (NNS mg)) (RB daily)) (VP (AUX were) (NP (CD 1.4) (NX (NX (JJ +/-) (CD 0.1)) (, ,) (NX (CD 3.6) (JJ +/-) (CD 0.7)) (CC and) (NX (CD 5.7) (JJ 4/-) (CD 0.8)))) (, ,) (ADVP (RB respectively))) (. .)))
6942642	10	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NN serum) (NNP Doc_6942642_1347_1348_Chemical+) (JJ observed) (NN r)) (X (SYM =)) (NP (CD 0.72))))) (, ,) (S (VP (VBG p) (NP (QP (JJR less) (IN than) (CD 0.001)))))) (. .)))
6942642	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (JJ Doc_6942642_1416_1424_Chemical) (NNS diuretics)) (VP (VBP cause) (NP (NP (NP (NN Doc_6942642_1441_1452_Disease)) (CC and) (NP (NN depletion))) (PP (IN of) (NP (NN body) (NN Doc_6942642_1475_1484_Chemical)))))))) (. .)))
6942642	12	(S1 (X (NP (DT The) (ADJP (RBR more) (JJ profound)) (NN Doc_6942642_1504_1515_Disease)) (, ,) (X (DT the) (JJR greater)) (NP (NP (DT the) (NN propensity)) (PP (IN for) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))))) (. .)))
7007443	0	(S1 (FRAG (S (VP (VBG Circulating) (NP (NP (JJ lysosomal) (NNS enzymes)) (CC and) (NP (NNP Doc_7007443_34_56_Disease))))) (. .)))
7007443	1	(S1 (S (NP (NP (DT The) (NNS activities)) (PP (IN of) (NP (NP (DT the) (JJ lysosomal) (NNS enzymes) (NN acid)) (CC and) (NP (NP (JJ neutral) (NN protease)) (, ,) (NP (NN N-acetylglucosaminidase)) (, ,) (CC and) (NP (NN acid) (NN phosphatase)))))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7007443_215_240_Disease))))))))) (. .)))
7007443	2	(S1 (S (NP (NN Acid) (NN protease) (PRN (-LRB- -LRB-) (NNP cathepsin) (NNP D) (-RRB- -RRB-)) (NN activity)) (VP (AUX was) (VP (VP (VBN increased) (ADVP (IN about) (RB tenfold)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD died))))))) (CC and) (VP (ADVP (RB nearly)) (VBN fourfold) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD survived) (NP (NNP Doc_7007443_370_395_Disease)) (PP (IN after) (NP (NNP Doc_7007443_402_413_Chemical) (NNP Doc_7007443_414_422_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NNS activities)) (VP (AUX were) (VP (VBN increased) (ADVP (RB equally)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7007443_483_508_Disease))))) (PP (JJ due) (TO to) (NP (NNP Doc_7007443_516_531_Disease))) (SBAR (IN whether) (CC or) (RB not) (S (NP (PRP they)) (VP (VBD survived)))))))))))))))) (. .)))
7007443	3	(S1 (S (S (NP (DT A) (NN correlation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (NN serum) (NN acid) (NN protease) (NN activity)) (CC and) (NP (NN prothrombin) (NN time))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (JJ cathepsin) (NNP D) (NN activity)))) (VP (AUX was) (VP (VBN sustained) (PP (IN over) (NP (JJ several) (NNS days))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_7007443_732_741_Chemical) (NN aminotransferase)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (NP (NP (DT a) (JJ sharp) (JJ early) (NN peak)) (CC and) (ADVP (RB then)) (NP (DT a) (NN fall)))))))))))) (. .)))
7007443	4	(S1 (S (S (NP (VBG Circulating) (JJ lysosomal) (NNS proteases)) (VP (MD can) (VP (VB damage) (NP (JJ other) (NNS organs))))) (, ,) (CC and) (S (NP (NP (NN measurement)) (PP (IN of) (NP (PRP$ their) (NN activity)))) (VP (MD may) (ADVP (RB therefore)) (VP (AUX be) (PP (IN of) (NP (JJ added) (NN value))) (PP (IN in) (S (VP (VBG assessing) (NP (NN prognosis)) (PP (IN in) (NP (DT this) (NN condition))))))))) (. .)))
7053705	0	(S1 (S (NP (NN Doc_7053705_0_30_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7053705_41_54_Chemical)))) (. .)))
7053705	1	(S1 (S (NP (ADJP (RB Clinically) (JJ reversible)) (NNP Doc_7053705_78_113_Disease)) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ 23-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_7053705_150_176_Disease))))) (PP (IN after) (NP (NP (CD 10) (NNS months)) (PP (IN of) (NP (NP (NN maintenance) (NN therapy)) (PP (IN with) (NP (NNP Doc_7053705_221_234_Chemical)))))))) (. .)))
7053705	2	(S1 (S (NP (JJ Serial) (NN liver) (NNS biopsies)) (VP (VBD showed) (NP (NP (DT the) (NN development) (CC and) (NN resolution)) (PP (IN of) (NP (JJ intense) (JJ sinusoidal) (NN engorgement))))) (. .)))
7053705	3	(S1 (S (SBAR (IN Although) (S (NP (DT this) (NN disease)) (VP (AUX was) (RB clinically) (ADJP (JJ reversible))))) (, ,) (NP (NP (DT some) (JJ subintimal) (NN Doc_7053705_396_404_Disease)) (PP (IN about) (NP (DT the) (JJ terminal) (JJ hepatic) (NNS veins)))) (VP (VBD persisted)) (. .)))
7053705	4	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBD presented) (NP (DT a) (JJ unique) (NN opportunity) (S (VP (TO to) (VP (VB observe) (NP (NP (DT the) (JJ histologic) (NNS features)) (PP (IN of) (NP (ADJP (RB clinically) (JJ reversible)) (NN Doc_7053705_550_580_Disease)))) (PP (IN over) (NP (NN time)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NP (NN veno-occlusive)) (VP (VBN related) (PP (ADVP (RB solely)) (TO to) (NP (NNP Doc_7053705_654_667_Chemical)))))))))) (. .)))
7059267	0	(S1 (NP (JJ Doc_7059267_0_14_Chemical-induced) (NN Doc_7059267_23_39_Disease) (. .)))
7059267	1	(S1 (S (NP (NP (DT A) (JJ 65-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_7059267_66_86_Disease))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7059267_100_114_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7059267_116_125_Chemical)) (-RRB- -RRB-)))))) (VP (AUX had) (NP (NP (DT a) (NN Doc_7059267_133_155_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (PP (IN with) (NP (NP (NN discontinuation)) (PP (IN of) (NP (JJ Doc_7059267_194_208_Chemical) (NN therapy)))))))))) (. .)))
7059267	2	(S1 (S (S (NP (NN Doc_7059267_218_229_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (NNP Doc_7059267_240_249_Disease))) (PP (IN for) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS reasons))))))) (, ,) (CC and) (S (NP (JJ accurate) (NN diagnosis)) (VP (AUX is) (ADJP (JJ necessary)) (S (VP (TO to) (VP (VB institute) (NP (JJ appropriate) (NN therapy))))))) (. .)))
7059267	3	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (DT a) (JJ drug-induced) (NN Doc_7059267_380_396_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN differential) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_7059267_451_462_Disease))) (PP (IN in) (NP (NNP Doc_7059267_466_475_Disease)))))))) (. .)))
7066357	0	(S1 (NP (NP (NP (NN Plasma) (CC and) (NN urinary) (NNS lipids)) (CC and) (NP (NP (NNS lipoproteins)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_7066357_69_87_Disease))))))) (VP (VBN induced) (PP (IN in) (NP (DT the) (NN rat))) (PP (IN by) (NP (NNP Doc_7066357_110_135_Chemical)))) (. .)))
7066357	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB ascertain) (SBAR (IN whether) (S (NP (NP (DT the) (NNS alterations)) (PP (IN of) (NP (NP (NN plasma) (NNS lipoproteins)) (VP (VBN found) (PP (IN in) (NP (NNP Doc_7066357_232_250_Disease)))))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7066357_262_287_Chemical))))) (VP (AUX were) (ADJP (JJ due) (PP (PP (TO to) (NP (NNP Doc_7066357_300_318_Disease) (FW per) (FW se))) (, ,) (CC or) (PP (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (TO to) (NP (DT the) (NNP Doc_7066357_356_371_Chemical))))))))))))) (. .)))
7066357	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NN plasma) (CC and) (NN urinary) (NNS lipoproteins)) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_7066357_501_526_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg/kg)) (PP (IN for) (NP (CD 7) (NNS days)))) (-RRB- -RRB-))))))))) (CC and) (NP (NP (DT the) (JJ subsequent) (NN development)) (PP (IN of) (NP (NNP Doc_7066357_583_601_Disease))))))))) (. .)))
7066357	3	(S1 (S (SBAR (IN Since) (S (NP (JJ massive) (NN Doc_7066357_617_628_Disease)) (VP (VBD occurred) (PP (IN after) (NP (NP (CD 6) (NNS days)) (PP (IN of) (NP (NN treatment)))))))) (, ,) (NP (DT the) (JJ time-course) (NN study)) (VP (AUX was) (VP (VBN divided) (PP (IN into) (NP (NP (CD two) (NNS stages)) (: :) (NP (NP (NP (JJ pre-Doc_7066357_720_729_Disease) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 1-5)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7066357_750_759_Disease) (NN stage)) (PRN (-LRB- -LRB-) (NN day) (NN 6-11) (-RRB- -RRB-)))))))) (. .)))
7066357	4	(S1 (S (PP (IN In) (NP (JJ pre-Doc_7066357_785_794_Disease) (NN stage))) (NP (NP (DT the) (NN plasma) (NN level)) (PP (IN of) (NP (NP (NNP Doc_7066357_821_832_Chemical)) (, ,) (NP (NNP Doc_7066357_834_849_Chemical)) (CC and) (NP (NNP VLDL))))) (VP (VBD decreased) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (NN phospholipid) (, ,) (NNP Doc_7066357_897_915_Chemical) (CC and) (NNP HDL)))) (VP (VBD remained) (ADJP (JJ constant)))))) (. .)))
7066357	5	(S1 (S (NP (NN Plasma) (NN apolipoprotein) (NNS A-I)) (VP (VBD tended) (S (VP (TO to) (VP (VB increase) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 40) (NN %)) (NN increase)) (PP (IN at) (NP (NN day) (CD 5)))) (-RRB- -RRB-)))))) (. .)))
7066357	6	(S1 (S (PP (IN At) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NNP Doc_7066357_1033_1042_Disease) (NN stage))))) (PRN (-LRB- -LRB-) (NP (NN day) (CD 6)) (-RRB- -RRB-)) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN plasma) (NN albumin)))) (VP (VBD dropped) (PP (TO to) (NP (DT a) (ADJP (RB very) (JJ low)) (NN level))) (, ,) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (JJ apolipoprotein) (NNP A-I)))) (VP (VP (VBD increased) (ADVP (RB abruptly)) (PRN (-LRB- -LRB-) (NP (JJ 4-fold) (NN increase)) (-RRB- -RRB-))) (CC and) (VP (VBD continued) (S (VP (TO to) (VP (VB rise) (PRN (, ,) (PP (IN although) (NP (NP (JJR less)) (ADVP (RB steeply)))) (, ,)) (PP (IN in) (NP (DT the) (VBG following) (NNS days))))))))))) (. .)))
7066357	7	(S1 (S (NP (NP (DT The) (NN plasma) (NN concentration)) (PP (IN of) (NP (NNS HDL)))) (VP (VBD followed) (NP (DT the) (JJ same) (NN pattern))) (. .)))
7066357	8	(S1 (S (NP (NP (NN Plasma) (NNS VLDL)) (CC and) (NP (NNS LDL))) (VP (VBN increased) (PP (IN at) (NP (NP (DT a) (JJ later) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 9)) (-RRB- -RRB-))))) (. .)))
7066357	9	(S1 (S (NP (NN Plasma) (NN apolipoprotein) (NNP A-I)) (VP (AUX was) (VP (VBN found) (PP (RB not) (PP (ADVP (RB only)) (IN in) (NP (NP (NNP HDL)) (PRN (-LRB- -LRB-) (NP (JJ 1.063-1.210) (NN g/ml)) (-RRB- -RRB-)))) (CC but) (PP (ADVP (RB also)) (IN in) (NP (NP (DT the) (NNP LDL) (NN density) (NN class)) (PRN (-LRB- -LRB-) (NP (CD 1.025-1.050) (NN g/ml)) (-RRB- -RRB-))))))) (. .)))
7066357	10	(S1 (S (PP (IN In) (NP (DT the) (JJ pre-Doc_7066357_1512_1521_Disease) (NN stage))) (NP (NN lipoproteinuria)) (VP (AUX was) (ADJP (JJ negligible)) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (JJ early) (NN Doc_7066357_1579_1588_Disease) (NN stage))) (NP (NP (DT the) (JJ urinary) (NN loss)) (PP (IN of) (NP (NN plasma) (NNS lipoproteins)))) (VP (VBD consisted) (PP (ADVP (RB mainly)) (IN of) (NP (NN HDL))))))) (. .)))
7066357	11	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_7066357_1693_1718_Chemical)) (VP (VBZ alters) (NP (NN plasma) (NNS lipoproteins)) (PP (IN by) (S (VP (VP (VBG lowering) (NP (NN VLDL))) (CC and) (VP (VBG increasing) (NP (NN HDL)))))))))) (. .)))
7066357	12	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (JJ early) (CC and) (JJ striking)) (NN increase)) (PP (IN of) (NP (NP (NN plasma) (NNS HDL)) (VP (VBN found) (PP (IN in) (NP (JJ Doc_7066357_1856_1865_Disease) (NNS rats))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN on) (NP (CD HDL) (NN metabolism)))))))))) (. .)))
7072798	0	(S1 (S (NP (JJ Fatal) (NNP Doc_7072798_6_21_Disease)) (VP (VBG following) (NP (NP (JJ topical) (NN administration)) (PP (IN of) (NP (JJ ophthalmic) (NNP Doc_7072798_69_84_Chemical))))) (. .)))
7072798	1	(S1 (S (NP (DT A) (JJ 73-year-old) (NN woman)) (VP (VBD died) (PP (IN of) (NP (NNP Doc_7072798_114_129_Disease))) (PP (NP (QP (JJR less) (IN than) (CD two)) (NNS months)) (IN after) (S (VP (VP (VBG undergoing) (NP (JJ Doc_7072798_168_176_Disease) (NN extraction))) (CC and) (VP (VBG beginning) (NP (NP (JJ topical) (NN therapy)) (PP (IN with) (NP (NNP Doc_7072798_223_238_Chemical))))))))) (. .)))
7072798	2	(S1 (S (NP (NP (DT The) (JJ first) (NNS signs)) (PP (IN of) (NP (NNP Doc_7072798_259_271_Disease)))) (VP (VBD began) (PP (IN within) (NP (NP (CD one) (NN month)) (PP (IN of) (NP (DT the) (NN surgery)))))) (. .)))
7072798	3	(S1 (S (NP (NP (DT The) (NN pattern)) (PP (IN of) (NP (DT the) (NNP Doc_7072798_330_345_Disease)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ idiosyncratic) (NN response)) (PP (TO to) (NP (NNP Doc_7072798_395_410_Chemical))))))) (. .)))
7072798	4	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT the) (JJ second) (NN report)) (PP (IN of) (NP (JJ fatal) (NN Doc_7072798_448_463_Disease)))) (PP (IN after) (NP (NP (JJ topical) (NN treatment)) (PP (IN with) (NP (NNP Doc_7072798_493_508_Chemical))) (PP (IN for) (NP (JJ ocular) (NNS conditions))))) (, ,) (SBAR (IN although) (S (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ reversible) (NNP Doc_7072798_565_587_Disease)))) (VP (AUX have) (ADVP (RB also)) (VP (AUX been) (VP (VBN reported))))))) (. .)))
7072798	5	(S1 (S (NP (NP (DT Any) (JJ other) (VBN suspected) (NNS cases)) (PP (IN of) (NP (NNP Doc_7072798_642_657_Disease))) (VP (VBN associated) (PP (IN with) (NP (ADJP (RB topically) (VBN applied)) (NNP Doc_7072798_692_707_Chemical))))) (VP (MD should) (VP (AUX be) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (NNP National) (NNP Registry)) (PP (IN of) (NP (NP (JJ Drug-Induced) (JJ Ocular) (NN Side) (NNS Effects)) (, ,) (NP (NP (NP (NNP Oregon) (NNP Health) (NNPS Sciences) (NNP University)) (, ,) (NP (NNP Portland)) (, ,)) (CC OR) (NP (CD 97201)))))))))) (. .)))
7102237	0	(S1 (S (NP (NN Doc_7102237_0_9_Chemical)) (VP (VBN compared) (PP (IN with) (NP (NNP Doc_7102237_24_35_Chemical))) (PP (IN as) (NP (DT an) (NN induction) (NN agent)))) (. .)))
7102237	1	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBN premedicated) (PP (IN with) (NP (NP (NNP Doc_7102237_89_100_Chemical) (NNP +) (NNP Doc_7102237_103_111_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD +5) (NN mg) (NNP Doc_7102237_119_129_Chemical)) (NP (DT the) (NN evening))) (PP (IN before) (NP (NN surgery)))) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (JJ sleep-inducing) (NN effect)) (PP (IN of) (NP (NNP Doc_7102237_188_197_Chemical) (CD 0.15) (NN mg/kg) (NNS i.v.)))) (VP (AUX was) (ADJP (ADJP (RB clearly) (JJR slower) (PP (IN in) (NP (NN onset)))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_7102237_255_266_Chemical))) (SBAR (S (S (NP (CD 4.67) (NN mg/kg)) (VP (VBD i.v.) (SBAR (S (NP (ADJP (RB Somewhat) (JJR fewer)) (JJ cardiovascular) (CC and) (JJ local) (NNS sequelae)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (NNP Doc_7102237_350_359_Chemical) (NN group))))))))) (, ,) (CC but) (, ,) (S (SBAR (IN although) (S (NP (NNP Doc_7102237_381_387_Disease)) (VP (VBD occurred) (ADVP (RBR less) (RB often)) (PP (IN in) (NP (DT the) (NNP Doc_7102237_415_424_Chemical) (NN group)))))) (NP (PRP it)) (VP (VBD lasted) (ADVP (RBR longer)))))))))) (. .)))
7102237	2	(S1 (S (PP (IN On) (NP (DT the) (NN whole))) (, ,) (NP (NP (DT the) (NNS differences)) (PP (IN between) (NP (NP (NNP Doc_7102237_487_496_Chemical)) (CC and) (NP (NNP Doc_7102237_501_512_Chemical))))) (VP (AUX had) (NP (DT no) (JJ apparent) (JJ clinical) (NNS consequences))) (. .)))
7102237	3	(S1 (S (NP (NN Doc_7102237_552_561_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ new) (NN alternative) (NN agent)) (PP (IN for) (NP (NP (NN induction)) (PP (IN in) (NP (NN combination) (NNS anaesthesia))))))) (. .)))
7161250	0	(S1 (NP (NP (NP (JJ Extrapyramidal) (NN side) (NNS effects)) (CC and) (NP (JJ oral) (NN Doc_7161250_37_48_Chemical))) (: :) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (JJ explanatory) (NN patient) (CC and) (NN treatment) (NNS characteristics)))) (. .)))
7161250	1	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ extrapyramidal) (NN side) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NNS EPS)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD 98) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7161250_209_220_Chemical)))))))) (. .)))
7161250	2	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_7161250_239_251_Disease)))) (VP (AUX was) (ADJP (JJR higher)) (PP (PP (IN at) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_7161250_282_293_Chemical))))) (CC and) (PP (IN in) (NP (JJR younger) (NNS patients))))) (. .)))
7161250	3	(S1 (S (NP (JJ Prophylactic) (NN antiparkinsonian) (NN medication)) (VP (AUX was) (UCP (ADJP (JJ effective) (PP (IN in) (NP (JJR younger)))) (CC but) (PP (RB not) (IN in) (NP (JJR older) (NNS patients))))) (. .)))
7161250	4	(S1 (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS medications)) (VP (AUX were) (ADJP (RBR more) (JJ effective)) (PP (IN in) (NP (DT both) (JJ young) (CC and) (JJ old) (NNS patients))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (SBAR (IN after) (S (NP (NNP Doc_7161250_507_519_Disease)) (VP (VBD developed)))))))) (. .)))
7161250	5	(S1 (S (NP (NN Doc_7161250_531_540_Disease)) (VP (AUX was) (VP (VBN controlled) (PP (IN by) (NP (NP (DT the) (NNP Doc_7161250_563_577_Chemical) (NNP Doc_7161250_578_587_Chemical)) (PP (IN in) (NP (NP (CD 14) (NN out)) (PP (IN of) (NP (CD 16) (NNS patients))))))) (, ,) (SBAR (IN while) (S (NP (JJ prophylactic) (NNS antiparkinsonians)) (VP (AUX were) (ADJP (JJ ineffective))))))) (. .)))
7161250	6	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ points) (PP (TO to) (NP (NP (JJ patient) (NNS characteristics)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN significance))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNS EPS)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7161250_782_793_Chemical))))))))))))))) (. .)))
7189975	0	(S1 (NP (NP (NNS Deaths)) (PP (IN from) (NP (NP (JJ local) (JJ anesthetic-induced) (NN Doc_7189975_37_48_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
7189975	1	(S1 (S (NP (NP (NP (NP (JJ Median) (NN convulsant)) (PRN (-LRB- -LRB-) (NP (CD CD50)) (-RRB- -RRB-))) (CC and) (NP (JJ median) (JJ lethal) (PRN (-LRB- -LRB-) (CD LD50) (-RRB- -RRB-)) (NNS doses))) (PP (IN of) (NP (CD three) (JJ representative) (JJ local) (NNS anesthetics)))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NN adult) (NNS mice))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN threat)) (PP (TO to) (NP (NP (NN life)) (PP (IN of) (NP (JJ local) (JJ anesthetic-induced) (NN Doc_7189975_245_256_Disease))))))))))) (. .)))
7189975	2	(S1 (S (NP (DT The) (CD CD50) (CC and) (CD LD50)) (, ,) (ADVP (RB respectively)) (, ,) (VP (AUX were) (NP (NP (NP (QP (CD 57.7) (CC and) (CD 58.7)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_320_331_Chemical)))) (, ,) (NP (NP (QP (CD 111.0) (CC and) (CD 133.1)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_359_368_Chemical)))) (, ,) (CC and) (NP (NP (QP (CD 243.4) (CC and) (CD 266.5)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_400_414_Chemical)))))) (. .)))
7189975	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB intraperitoneally))))) (, ,) (NP (NNP Doc_7189975_446_457_Chemical)) (ADVP (RB thus)) (VP (AUX was) (ADVP (RB only)) (PP (IN about) (NP (NP (NP (QP (RB twice) (IN as) (JJ toxic))) (PP (IN as) (NP (NNP Doc_7189975_496_505_Chemical)))) (CC and) (NP (NP (QP (CD four) (NNS times) (IN as) (JJ toxic))) (PP (IN as) (NP (NNP Doc_7189975_533_547_Chemical))))))) (. .)))
7189975	4	(S1 (S (NP (NN Doc_7189975_549_560_Disease)) (ADVP (RB always)) (VP (VBN preceded) (NP (NN death)) (, ,) (PP (IN except) (PP (IN after) (NP (NP (JJ precipitous) (NN Doc_7189975_609_631_Disease)) (PP (IN from) (NP (JJ extreme) (NNS doses))))))) (. .)))
7189975	5	(S1 (S (NP (NP (DT A) (CD CD50) (NN dose)) (PP (IN of) (NP (JJ local) (NN anesthetic))) (PRN (-LRB- -LRB-) (VP (VBG causing) (NP (NNP Doc_7189975_693_704_Disease)) (PP (IN in) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NNS mice)))))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (NNP Doc_7189975_741_752_Chemical-induced) (NNP Doc_7189975_761_769_Disease))))) (, ,) (PP (IN in) (NP (NP (NP (CD 57) (NN %)) (PP (IN of) (NP (DT the) (NNP Doc_7189975_785_799_Chemical) (NN group)))) (, ,) (CC and) (NP (NP (QP (IN in) (CD 6)) (NN %)) (PP (IN of) (NP (DT the) (NNP Doc_7189975_824_833_Chemical) (NN group))))))) (. .)))
7189975	6	(S1 (S (NP (NP (DT The) (JJ narrow) (NN gap)) (PP (IN between) (NP (NP (JJ convulsant) (CC and) (JJ lethal) (NNS doses)) (PP (IN of) (NP (JJ local) (NNS anesthetics)))))) (VP (VBZ indicates) (NP (NP (DT that) (JJ untreated) (NNP Doc_7189975_938_949_Disease) (NN present)) (ADJP (ADJP (RB much) (JJR more) (PP (IN of) (NP (NP (DT a) (NN threat)) (PP (TO to) (NP (NN life)))))) (PP (IN than) (ADJP (RB heretofore) (VBN appreciated)))))) (. .)))
7197363	0	(S1 (S (NP (NN Doc_7197363_0_21_Disease)) (VP (VBZ changes) (NP (NP (JJ behavioral) (NN response)) (PP (TO to) (NP (NP (NN catecholaminergic)) (CC and) (NP (NP (JJ serotonergic) (NN receptor) (NN activation)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
7197363	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7197363_132_153_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7197363_155_159_Disease)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NP (NNP Doc_7197363_164_175_Chemical-induced) (NNP Doc_7197363_184_198_Disease)) (CC and) (NP (NNP Doc_7197363_203_212_Chemical-induced) (NNP Doc_7197363_221_234_Disease))) (PP (IN in) (NP (NNS rats)))))) (VP (AUX were) (VP (VBN determined))) (. .)))
7197363	2	(S1 (S (NP (NP (JJ Forty-eight) (NNS hr)) (PP (IN of) (NP (NNP Doc_7197363_278_282_Disease)))) (VP (VP (VBN increased) (NP (JJ Doc_7197363_293_304_Chemical-induced) (NNP Doc_7197363_313_327_Disease))) (, ,) (CC and) (VP (VBN reduced)) (PRN (-LRB- -LRB-) (PP (ADVP (RB immediately)) (IN after) (NP (NP (VBG completing)) (PP (IN of) (NP (NNP Doc_7197363_374_378_Disease))))) (-RRB- -RRB-)) (CC or) (VP (VBD increased) (S (-LRB- -LRB-) (NP (NP (CD 96) (NN hr)) (PP (IN after) (NP (NP (VBG completing)) (PP (IN of) (NP (NNP Doc_7197363_420_424_Disease)))))) (-RRB- -RRB-) (NP (NNP Doc_7197363_426_435_Chemical-induced) (NNP Doc_7197363_444_457_Disease))))) (. .)))
7197363	3	(S1 (S (NP (NNS Results)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN similarity))))) (PP (TO to) (NP (NP (JJ pharmacological) (NNS effects)) (PP (IN of) (NP (JJ other) (JJ antidepressive) (NNS treatments))))))) (. .)))
7263204	0	(S1 (S (NP (JJ Fatal) (NNP Doc_7263204_6_21_Disease)) (VP (NNS due) (PP (TO to) (NP (JJ Doc_7263204_29_41_Chemical--lymphocyte) (NN transformation) (NNS tests))) (PP (IN in) (NP (NN vitro)))) (. .)))
7263204	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_7263204_94_106_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_7263204_150_165_Disease))))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (DT a) (JJ few) (JJ clinical) (NNS observations)))))))))) (, ,) (NP (PRP$ its) (NN role)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB definitely)) (VP (VBN established)))) (. .)))
7263204	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ fatal) (NNP Doc_7263204_273_288_Disease)))) (VP (AUX is) (VP (VBN described) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT no) (NNS drugs)) (ADVP (JJ other) (PP (IN than) (NP (NP (NNP Doc_7263204_331_342_Chemical)) (CC and) (NP (NNP Doc_7263204_347_359_Chemical))))) (VP (AUX were) (VP (VBN given))))))) (. .)))
7263204	3	(S1 (S (NP (NN Doc_7263204_372_384_Chemical)) (VP (AUX was) (ADVP (RB first)) (VP (VBN given) (ADVP (NP (CD four) (NNS weeks)) (RB prior)) (PP (TO to) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNS symptoms))))))) (. .)))
7263204	4	(S1 (S (NP (NP (DT A) (JJ positive) (JJ lymphocyte) (NN transformation) (NN test)) (PP (IN with) (NP (NP (NNP Doc_7263204_491_503_Chemical)) (PP (IN in) (NP (NN vitro)))))) (ADVP (RB further)) (VP (VBZ substantiates) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_7263204_578_593_Disease)) (PP (IN in) (NP (DT a) (JJ susceptible) (NN patient)))))))) (. .)))
7263204	5	(S1 (S (ADVP (RB Fortunately)) (, ,) (NP (DT this)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (DT a) (ADJP (RB very) (JJ rare)) (NN complication)))))) (. .)))
7282516	0	(S1 (NP (NP (NP (NN Dose-effect)) (CC and) (NP (JJ structure-function) (NNS relationships))) (PP (IN in) (NP (NNP Doc_7282516_52_63_Chemical) (NNP Doc_7282516_64_78_Disease))) (. .)))
7282516	1	(S1 (S (NP (NP (DT The) (NNP Doc_7282516_84_98_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_100_102_Disease)) (-RRB- -RRB-)) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (NN anticancer) (NN drug)) (NP (NP (NP (NNP Doc_7282516_136_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_149_152_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_155_165_Chemical)) (-RRB- -RRB-))))))) (VP (VBZ provides) (NP (DT a) (JJ unique) (NN opportunity) (S (VP (TO to) (VP (VB analyze) (NP (UCP (JJ dose-effect) (CC and) (NN structure-function)) (NNS relationships)) (PP (IN during) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_7282516_279_297_Disease)))))))))) (. .)))
7282516	2	(S1 (S (NP (PRP We)) (VP (VBN measured) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ morphologic) (NN damage)))) (PP (IN by) (NP (NP (NP (JJ ultrastructural) (NN examination)) (PP (IN of) (NP (JJ endomyocardial) (NN biopsy)))) (CC and) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN performance)))))) (PP (ADVP (RB abnormally)) (IN by) (NP (NP (JJ right) (NN heart) (NN catheterization)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_7282516_494_497_Chemical)))))))) (. .)))
7282516	3	(S1 (S (NP (JJ Morphologic) (NN damage)) (VP (VP (AUX was) (ADJP (JJ variable))) (CC but) (VP (AUX was) (ADJP (JJ proportional) (PP (TO to) (NP (NP (DT the) (JJ total) (JJ cumulative) (JJ Doc_7282516_576_579_Chemical) (NN dose)) (PP (IN between) (NP (QP (CD 100) (CC and) (CD 600) (CD mg/m2))))))))) (. .)))
7282516	4	(S1 (S (NP (NN Performance) (NNS abnormalities)) (VP (VP (VBD correlated) (ADVP (RB weakly)) (PP (IN with) (NP (NN dose)))) (, ,) (VP (VBD exhibited) (NP (DT a) (JJ curvilinear) (NN relationship))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT a) (`` ``) (NN threshold) ('' '')) (PP (IN for) (NP (NN expression)))))) (. .)))
7282516	5	(S1 (S (S (NP (NN Catheterization) (NNS abnormalities)) (VP (VBD correlated) (ADVP (RB well)) (PP (IN with) (NP (NP (JJ morphologic) (NN damage)) (PRN (-LRB- -LRB-) (NP (QP (SYM r) (SYM =) (CD 0.57) (TO to) (CD 0.78))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NN exercise) (NNS hemodynamics)) (VP (AUX were) (VP (VBN measured))))))))))) (, ,) (CC and) (S (NP (DT this) (NN relationship)) (ADVP (RB also)) (VP (VBD exhibited) (NP (NP (DT a) (NN curvilinear)) (, ,) (NP (NN threshold) (NN configuration))))) (. .)))
7282516	6	(S1 (S (PP (IN In) (NP (NNP Doc_7282516_983_986_Chemical-Doc_7282516_987_989_Disease) (NNP Doc_7282516_990_1007_Disease))) (VP (AUX is) (ADJP (JJ proportional) (PP (TO to) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ cytotoxic) (NN insult)))))) (PRN (-LRB- -LRB-) (NP (JJ Doc_7282516_1059_1062_Chemical) (NN dose)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (JJ myocardial) (NN function)) (VP (AUX is) (VP (VBN preserved) (SBAR (IN until) (S (NP (NP (DT a) (JJ critical) (NN dose)) (CC or) (NP (NP (NN degree)) (PP (IN of) (NP (NN damage))))) (VP (AUX is) (VP (VBN reached) (, ,) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (JJ myocardial) (NN performance)) (VP (VBZ deteriorates) (ADVP (RB rapidly)))))))))))))) (. .)))
7337133	0	(S1 (NP (NP (NP (JJ Massive) (NN Doc_7337133_8_22_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ fulminant) (NN Doc_7337133_49_64_Disease)) (PP (IN in) (NP (NNP Doc_7337133_68_81_Chemical) (NNP Doc_7337133_82_90_Disease))))))) (: :) (NP (NP (JJ possible) (NN role)) (PP (IN of) (NP (JJ cranial) (NN decompression)))) (. .)))
7337133	1	(S1 (S (NP (NN Doc_7337133_132_146_Disease)) (VP (MD may) (VP (VB complicate) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_7337133_176_201_Disease)))))) (. .)))
7337133	2	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (JJ conventional) (NN therapy)))) (VP (AUX has) (VP (AUX been) (ADJP (JJ disappointing)))) (. .)))
7337133	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ fatal) (JJ Doc_7337133_292_305_Chemical-induced) (NN Doc_7337133_314_339_Disease))) (, ,) (PP (IN with) (NP (NP (NNS signs)) (CC and) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_7337133_368_382_Disease)))))) (, ,) (ADJP (JJ unresponsive) (PP (TO to) (NP (JJ conventional) (JJ medical) (NN therapy)))))) (. .)))
7337133	4	(S1 (S (NP (JJ Cranial) (NN decompression)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
7337133	5	(S1 (S (NP (NP (DT A) (NN justification)) (PP (IN of) (NP (DT the) (NN need))) (PP (IN for) (NP (NP (JJ further) (NN evaluation)) (PP (IN of) (NP (JJ cranial) (NN decompression))))) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (AUX is) (VP (VBN presented))) (. .)))
7416947	0	(S1 (NP (NP (JJ Subjective) (NN assessment)) (PP (IN of) (NP (NP (NNP Doc_7416947_25_43_Disease)) (PP (IN of) (NP (NNS patients))))) (PP (IN on) (NP (NP (JJ long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_7416947_87_94_Chemical))))) (. .)))
7416947	1	(S1 (S (NP (JJ Various) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ male) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN received) (NP (NNP Doc_7416947_154_161_Chemical)) (PP (IN on) (NP (DT a) (JJ longterm) (NN basis)))))))) (VP (AUX have) (VP (VP (VBN increased) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_7416947_213_221_Chemical))))) (CC and) (VP (VBN decreased) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_7416947_253_265_Chemical)) (CC and) (NP (NP (JJ luteinizing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP LH)) (-RRB- -RRB-)))))))))))) (. .)))
7416947	2	(S1 (S (NP (DT This) (NN study)) (VP (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS links)) (PP (IN between) (NP (NP (DT the) (JJ long-term) (NN administration)) (PP (IN of) (NP (JJ Doc_7416947_387_394_Chemical) (NN therapy) (CC and) (JJ sexual) (NN behavior))))))))))) (, ,) (CC and) (VP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_7416947_442_449_Chemical)))) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_7416947_470_479_Chemical)) (, ,) (NP (NNP Doc_7416947_481_493_Chemical)) (, ,) (CC and) (NP (NNP LH)))))))) (. .)))
7416947	3	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN of) (NP (DT the) (NN study) (CC and) (NN control) (NN group))) (PRN (-LRB- -LRB-) (PP (IN without) (NP (NNP Doc_7416947_556_563_Chemical))) (-RRB- -RRB-))) (VP (VP (AUX were) (PP (IN of) (NP (NP (JJ similar) (JJ cardiac) (JJ functional) (NN capacity)) (CC and) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (JJ 25-40) (NNS years)) (-RRB- -RRB-)))))) (CC and) (VP (AUX were) (ADJP (RB randomly) (VBN selected)) (PP (IN from) (NP (DT the) (JJ Doc_7416947_667_690_Disease) (NNS patients))))) (. .)))
7416947	4	(S1 (S (NP (NP (NP (DT A) (JJ subjective) (NN assessment)) (PP (IN of) (NP (JJ sexual) (NN behavior))) (PP (IN in) (NP (DT the) (NN study)))) (CC and) (NP (NN control) (NNS groups))) (VP (AUX was) (VP (VBN carried) (ADVP (RB out)) (, ,) (S (VP (VBG using) (NP (NP (NNS parameters)) (PP (JJ such) (IN as) (NP (NP (JJ sexual) (NN desire)) (, ,) (NP (JJ sexual) (NN excitement)) (, ,) (CC and) (NP (NP (NN frequency)) (PP (IN of) (NP (JJ sexual) (NNS relations))))))))))) (. .)))
7416947	5	(S1 (S (NP (NP (JJ Personal) (NNS interviews)) (CC and) (NP (DT a) (NN questionnaire))) (VP (AUX were) (ADVP (RB also)) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (JJ sexual) (NN behavior))))))) (. .)))
7416947	6	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NNS reports)) (VP (VBG concerning) (NP (NP (JJ Doc_7416947_1025_1032_Chemical) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNP Doc_7416947_1050_1059_Chemical)) (, ,) (NP (NNP Doc_7416947_1061_1073_Chemical)) (, ,) (CC and) (NP (NNP LH)))))))) (. .)))
7416947	7	(S1 (S (NP (NP (DT The) (NNS differences)) (PP (IN in) (NP (DT the) (NNS means)))) (VP (AUX were) (ADJP (JJ significant))) (. .)))
7416947	8	(S1 (S (NP (NP (NNS Tests)) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (JJ sexual) (NN behavior))))))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN Doc_7416947_1205_1230_Disease)) (, ,) (NP (NP (JJ sexual) (NN excitement) (NN phase)) (PRN (-LRB- -LRB-) (NP (NN erection)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN frequency)) (PP (IN of) (NP (JJ sexual) (NNS relations))) (PP (IN in) (NP (DT the) (NN study) (NN group)))))) (. .)))
7421734	0	(S1 (NP (NP (NN Doc_7421734_0_21_Disease)) (PP (IN after) (NP (NP (NNP Doc_7421734_28_43_Disease)) (PP (IN in) (NP (NN childhood))))) (. .)))
7421734	1	(S1 (S (NP (DT A) (JJ 34-year-old) (NN patient)) (VP (VBD developed) (NP (JJ metastic) (NN Doc_7421734_99_120_Disease)) (PP (IN after) (NP (NNP Doc_7421734_127_142_Disease))) (PP (IN in) (NP (NN childhood)))) (. .)))
7421734	2	(S1 (S (NP (PRP She)) (VP (VP (AUX had) (ADJP (JJ Doc_7421734_165_180_Disease)) (PP (IN after) (NP (NP (JJ abdominal) (NN irradiation)) (CC and) (NP (NP (NN chemotherapy)) (PP (IN for) (NP (NNP Doc_7421734_230_245_Disease))))))) (, ,) (CC and) (VP (VBD received) (NP (NN exogenous)) (NP (NP (NNP Doc_7421734_270_279_Chemical)) (, ,) (NP (NP (DT a) (NN treatment)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_7421734_326_344_Disease))) (PP (IN in) (NP (JJ menopausal) (NNS women)))))))))) (. .)))
7421734	3	(S1 (S (NP (NP (JJ Young) (NNS women)) (PP (IN on) (NP (NP (NN replacement) (NN Doc_7421734_393_402_Chemical)) (PP (IN for) (NP (NNP Doc_7421734_407_422_Disease))) (PP (IN after) (NP (JJ Doc_7421734_429_435_Disease) (NN therapy)))))) (VP (VP (MD may) (ADVP (RB also)) (VP (AUX have) (VP (VBN increased) (NP (NP (NN risk)) (PP (IN of) (NP (NNP Doc_7421734_476_497_Disease))))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN examined) (ADVP (RB periodically)))))) (. .)))
7437994	0	(S1 (NP (NP (NP (JJ Long-term) (JJ Doc_7437994_10_17_Chemical) (NN treatment)) (CC and) (NP (DT the) (NN kidney))) (. .)))
7437994	1	(S1 (NP (NP (JJ Interim) (NN report)) (PP (IN on) (NP (NN fifty) (NNS patients))) (. .)))
7437994	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN report)) (PP (IN on) (NP (NP (DT the) (JJ first) (NN part)) (PP (IN of) (NP (NP (PRP$ our) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ long-term) (JJ Doc_7437994_154_161_Chemical) (NN treatment))) (PP (IN on) (NP (DT the) (NN kidney))))))))))) (. .)))
7437994	3	(S1 (S (NP (NP (JJ Doc_7437994_187_197_Chemical) (NN clearance)) (, ,) (NP (NN maximum) (NN urinary) (NN osmolality)) (CC and) (NP (ADJP (CD 24) (NN hour)) (NN urine) (NN volume))) (VP (AUX have) (VP (AUX been) (VP (VBN tested) (PP (IN in) (NP (NP (CD 50) (JJ affectively) (JJ ill) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (AUX been) (PP (IN on) (NP (JJ long-term) (NNP Doc_7437994_336_343_Chemical))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year)))))))))))) (. .)))
7437994	4	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX have) (VP (AUX been) (VP (VBN compared) (PP (PP (IN with) (NP (NNS norms))) (CC and) (PP (IN with) (NP (NP (NNS values)) (PP (IN of) (NP (NP (DT the) (JJ same) (NNS tests)) (PP (IN from) (S (VP (VBG screening) (ADVP (RB prior)) (PP (TO to) (NP (NNP Doc_7437994_471_478_Chemical)))))) (, ,) (ADJP (JJ available) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (PRP$ our) (NNS patients)))))))))))))) (. .)))
7437994	5	(S1 (S (NP (DT No) (NN evidence)) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NP (DT any) (NN reduction)) (PP (IN of) (NP (JJ glomerular) (NN filtration))) (PP (IN during) (NP (JJ Doc_7437994_588_595_Chemical) (NN treatment))))))) (. .)))
7437994	6	(S1 (S (NP (NP (JJ Low) (NN clearance) (NNS values)) (VP (VBN found) (PP (IN in) (NP (JJ several) (NNS patients))))) (VP (MD could) (VP (AUX be) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (PRP$ their) (NN age)) (CC and) (NP (PRP$ their) (JJ pre-Doc_7437994_704_711_Chemical) (NNS values))))))) (. .)))
7437994	7	(S1 (S (S (NP (JJ Urinary) (NN concentration) (NN defect)) (VP (VBD appeared) (ADJP (JJ frequent)))) (CC but) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (NN impairment)))) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB assess) (PP (IN because) (IN of) (NP (NP (DT the) (NN uncertainty)) (PP (IN about) (NP (NP (DT the) (NNS norms)) (ADJP (JJ applicable) (PP (TO to) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))))))))))))))))) (. .)))
7437994	8	(S1 (S (NP (DT The) (NN concentration) (NN defect)) (VP (VBD appeared) (ADJP (JJ reversible)) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part)))) (. .)))
7437994	9	(S1 (S (NP (NP (NN Doc_7437994_968_976_Disease)) (PP (IN above) (NP (QP (CD 3) (CD litres/24)) (NNS hours)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
7437994	10	(S1 (S (NP (DT An) (NN attempt)) (VP (AUX is) (VP (VBN made) (S (VP (TO to) (VP (VB draw) (NP (JJ practical) (NNS conclusions)) (PP (IN from) (NP (DT the) (JJ preliminary) (NNS findings)))))))) (. .)))
7542793	0	(S1 (NP (NP (NP (NN Doc_7542793_0_14_Disease)) (PP (IN of) (NP (NP (NNP Doc_7542793_18_31_Chemical)) (CC and) (NP (NNP Doc_7542793_36_41_Chemical))))) (: :) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN calcineurin) (NN phosphatase)))) (. .)))
7542793	1	(S1 (S (NP (NP (NP (NP (NP (NNP Doc_7542793_82_95_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_7542793_97_100_Chemical)) (: ;) (NP (CD 50) (NNS mg/kg))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7542793_116_126_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_7542793_128_133_Chemical)) (: ;) (NP (CD 5) (NN mg/kg))) (-RRB- -RRB-))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (JJ related) (JJ Doc_7542793_165_174_Chemical) (NN immunosuppressant) (NNP Doc_7542793_193_202_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (, ,)) (VP (VBD caused) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (, ,) (NP (NP (JJ degenerative) (NNS changes)) (PP (IN of) (NP (JJ proximal) (JJ tubular) (NN epithelium)))) (, ,) (CC and) (NP (NP (NNP Doc_7542793_321_332_Disease)) (PP (IN of) (NP (NP (DT the) (JJ juxtaglomerular) (NN apparatus)) (PP (IN in) (NP (JJ male) (NNP Wistar) (NNS rats))))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN for) (NP (CD 10) (NNS days))))))) (. .)))
7542793	2	(S1 (S (NP (NP (DT The) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_7542793_438_441_Chemical) (CC and) (NNP Doc_7542793_446_451_Chemical) (NNP Doc_7542793_452_460_Disease)))) (VP (AUX were) (VP (VBN investigated))) (. .)))
7542793	3	(S1 (S (NP (NP (NNP Cyclophilin) (NNP A)) (CC and) (NP (NP (JJ Doc_7542793_498_503_Chemical-binding) (NN protein)) (, ,) (NP (NP (DT the) (JJ main) (JJ intracytoplasmic) (NNS receptors)) (PP (IN for) (NP (NP (NNP Doc_7542793_561_564_Chemical)) (CC and) (NP (NNP Doc_7542793_569_574_Chemical)) (, ,) (ADVP (RB respectively))))) (, ,))) (VP (AUX were) (DT each) (VP (VBN detected) (PP (IN in) (NP (JJ renal) (NN tissue) (VB extract))))) (. .)))
7542793	4	(S1 (S (PP (IN In) (NP (DT the) (NN kidney))) (, ,) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NN immunoreactive)) (CC and) (NP (JJ enzymatically) (JJ active) (NN calcineurin))))) (VP (AUX were) (VP (VBN found) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBD inhibited) (PP (PP (IN by) (NP (DT the) (NNS immunosuppressants) (NNP Doc_7542793_774_777_Chemical) (CC and) (NNP Doc_7542793_782_787_Chemical))) (, ,) (CC but) (RB not) (PP (IN by) (NP (NNP Doc_7542793_800_809_Chemical)))))))))) (. .)))
7542793	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (JJ specific) (NN immunophilin-drug-calcineurin) (NNS complexes)) (VP (VBN formed) (PP (RB only) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_7542793_900_903_Chemical)) (CC and) (NP (NNP Doc_7542793_908_913_Chemical)))))) (, ,) (CC but) (RB not) (ADJP (JJ Doc_7542793_923_932_Chemical)))) (. .)))
7542793	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ Doc_7542793_965_976_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_7542793_988_991_Chemical) (CC and) (NNP Doc_7542793_996_1001_Chemical)))) (VP (AUX is) (ADVP (RB likely)) (VP (VBN mediated) (PP (IN through) (S (VP (VBG binding) (PP (TO to) (NP (NP (JJ renal) (NN immunophilin)) (CC and) (NP (NN inhibiting) (NN calcineurin) (NN phosphatase)))))))))))) (. .)))
7565311	0	(S1 (NP (NP (NN Doc_7565311_0_19_Disease)) (PP (IN in) (NP (NP (JJ high) (NN dose)) (ADJP (NNP Doc_7565311_33_44_Chemical) (JJ chemotherapy)))) (. .)))
7565311	1	(S1 (S (NP (NN Doc_7565311_59_70_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_7565311_98_117_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (JJ high) (NNS doses)) (PP (TO to) (NP (NN adult) (NNS patients)))))))))))))) (. .)))
7565311	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (ADJP (CD 4) (NN 1/2-year-old)) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NN Doc_7565311_232_243_Chemical))) (PP (IN for) (NP (JJ metastatic) (JJ parameningeal) (NN Doc_7565311_273_299_Disease))))))))) (. .)))
7565311	3	(S1 (S (NP (NN Doc_7565311_301_320_Disease)) (VP (VBD developed) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ slow) (JJ partial) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function))))))) (. .)))
7565311	4	(S1 (S (NP (JJ Possible) (JJ contributing) (NNS factors)) (VP (AUX are) (VP (VBN discussed))) (. .)))
7596955	0	(S1 (NP (NP (JJ Clinical) (NN evaluation)) (PP (IN on) (NP (NP (VBN combined) (NN administration)) (PP (IN of) (NP (NP (JJ oral) (JJ Doc_7596955_55_67_Chemical) (NN analogue) (NNP Doc_7596955_77_86_Chemical)) (CC and) (NP (NN phosphodiesterase) (NN inhibitor) (NNP Doc_7596955_119_129_Chemical)))))) (. .)))
7596955	1	(S1 (S (PP (IN Among) (NP (JJ various) (JJ oral) (NNS antiplatelets))) (, ,) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NP (DT a) (JJ novel) (JJ Doc_7596955_190_202_Chemical) (NN analogue) (NNP Doc_7596955_212_221_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_223_226_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ potent) (NN phosphodiesterase) (NN inhibitor) (NNP Doc_7596955_269_279_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_281_284_Chemical)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ untoward) (JJ clinical) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ possible) (JJ synergistic) (NN elevation)) (PP (IN of) (NP (NP (JJ intracellular) (NNP Doc_7596955_381_385_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_387_423_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
7596955	2	(S1 (S (ADVP (RB Thereby)) (, ,) (NP (NP (DT a) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (DT the) (VBN combined) (NN administration)) (PP (IN of) (NP (DT the) (CD two) (NNS agents)))))) (VP (AUX was) (VP (VBN attempted))) (. .)))
7596955	3	(S1 (S (S (NP (CD Twelve) (JJ healthy) (NNS volunteers)) (VP (AUX were) (VP (VBN assigned) (S (VP (TO to) (VP (VB take) (NP (NP (NP (NNP Doc_7596955_564_567_Chemical/Doc_7596955_568_571_Chemical)) (PP (IN in) (NP (DT the) (JJ following) (NN schedule)))) (: ;) (NP (NP (NNP Doc_7596955_599_602_Chemical)) (: :) (NP (NP (NP (CD 40) (NNS micrograms)) (PP (IN at) (NP (NN day) (CD 1)))) (CC and) (NP (NP (CD 120) (NNS micrograms)) (VP (VBN t.i.d.) (PP (IN from) (NP (NN day) (CD 7))) (PP (TO to) (NP (CD 14))))))) (, ,) (NP (NNP Doc_7596955_671_674_Chemical))))))))) (: :) (S (NP (CD 200) (NNS mg)) (VP (VBN t.i.d.) (PP (PP (IN from) (NP (NN day) (CD 3))) (PP (TO to) (NP (CD 14)))))) (. .)))
7596955	4	(S1 (S (PP (IN At) (NP (JJ various) (NN time) (NNS intervals))) (, ,) (NP (NP (NP (JJ physical) (NN examination)) (CC and) (NP (NN blood) (NN collection))) (PP (IN for) (NP (NP (FW ex) (NN vivo) (NN Doc_7596955_789_809_Disease)) (CC and) (NP (NP (NN determination)) (PP (IN of) (NP (JJ intraplatelet) (NNP Doc_7596955_845_849_Chemical))))))) (VP (AUX were) (VP (VBN performed))) (. .)))
7596955	5	(S1 (S (PP (IN Throughout) (NP (DT the) (JJ observation) (NN period))) (, ,) (NP (NP (DT no) (JJ significant) (NN alteration)) (PP (IN in) (NP (JJ vital) (NNS signs)))) (VP (AUX was) (VP (VBN observed))) (. .)))
7596955	6	(S1 (S (NP (NP (CD Seven)) (PP (IN out) (PP (IN of) (NP (CD 12) (NNS subjects))))) (VP (VBD experienced) (NP (NP (NP (NNP Doc_7596955_993_1001_Disease)) (PP (IN of) (NP (NP (DT a) (JJ short) (NN duration)) (VP (VBG accompanying) (NP (NNP Doc_7596955_1035_1047_Disease)) (PP (IN in) (NP (CD one))))))) (CC and) (NP (NP (NNP Doc_7596955_1059_1065_Disease)) (PP (IN in) (NP (CD one))))) (, ,) (PP (ADVP (RB especially)) (IN after) (NP (NP (NN ingestion)) (PP (IN of) (NP (NNP Doc_7596955_1104_1107_Chemical)))))) (. .)))
7596955	7	(S1 (S (S (NP (NP (DT All)) (PP (IN of) (NP (DT these) (NNS symptoms))) (, ,) (VP (ADVP (RB probably)) (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ vasodilating) (NN effect)) (PP (IN of) (NP (DT the) (CD two) (NNS agents)))))) (, ,)) (VP (AUX were) (PP (IN of) (NP (JJ mild) (NN degree))))) (CC and) (S (NP (DT no) (JJ special) (NN treatment)) (VP (AUX was) (VP (VBN required)))) (. .)))
7596955	8	(S1 (S (NP (JJ Intraplatelet) (JJ Doc_7596955_1267_1271_Chemical) (NN content)) (VP (VP (AUX was) (ADVP (RB gradually))) (CC but) (VP (ADVP (RB significantly)) (VBD increased) (PP (TO to) (NP (CD 9.84) (NN +/-))) (SBAR (S (NP (NP (CD 4.59) (NN pmol)) (PP (IN per) (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))))) (VP (VBZ platelets) (PP (IN at) (NP (NN day) (CD 14))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (JJ initial) (NN value)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.87) (NN +/-)) (NP (CD 2.25) (NN pmol))) (-RRB- -RRB-))))))))))) (. .)))
7596955	9	(S1 (S (S (NP (DT The) (NN platelet) (NN aggregability)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN suppressed) (PP (IN at) (NP (JJ various) (NN time) (NNS intervals)))))) (CC but) (S (NP (NP (DT no) (ADJP (JJ additive) (CC or) (JJ synergistic)) (JJ inhibitory) (NN effect)) (PP (IN by) (NP (DT the) (VBN combined) (NN administration)))) (VP (AUX was) (VP (VBN noted)))) (. .)))
7596955	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (VBN combined) (NN administration)) (PP (IN of) (NP (NNP Doc_7596955_1652_1655_Chemical/Doc_7596955_1656_1659_Chemical)))) (VP (AUX is) (ADJP (JJ safe)) (PP (IN at) (NP (NP (NNS doses)) (VP (VBN used) (PP (IN in) (NP (DT the) (NN study)))))) (, ,) (SBAR (IN though) (S (NP (NP (DT the) (JJ beneficial) (JJ clinical) (NN effect)) (PP (IN of) (NP (DT the) (VBN combined) (NN administration)))) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN elucidated))))))))) (. .)))
7604176	0	(S1 (NP (JJ Doc_7604176_0_11_Chemical-associated) (NN Doc_7604176_23_31_Disease) (. .)))
7604176	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (DT a) (NN case))) (. .)))
7604176	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_7604176_67_88_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_7604176_116_127_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (JJ hydrophilic) (JJ 3-hydroxy-3) (NN methylglutaril) (NN coenzyme)) (NP (DT A) (JJ reductase) (NN inhibitor))) (, ,))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
7604176	3	(S1 (S (NP (DT The) (NN patient)) (, ,) (NP (DT a) (JJ 69-year-old) (NN man)) (VP (AUX was) (VP (VBN affected) (PP (IN by) (NP (NP (NNP Doc_7604176_266_305_Disease)) (CC and) (NP (NNP Doc_7604176_310_322_Disease)))))) (. .)))
7604176	4	(S1 (S (NP (PRP He)) (VP (VBD assumed) (NP (NP (NNP Doc_7604176_335_346_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/day)) (-RRB- -RRB-))) (PP (IN because) (IN of) (NP (NN Doc_7604176_370_390_Disease)))) (. .)))
7604176	5	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NP (JJ acute) (NN Doc_7604176_419_427_Disease)) (PP (IN of) (NP (NP (DT the) (JJR lower) (NNS limbs)) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN in) (NP (DT a) (JJ few) (NNS days))) (PP (IN after) (NP (JJ Doc_7604176_482_493_Chemical) (NN discontinuation)))))))))))) (. .)))
7604176	6	(S1 (S (NP (NP (DT A) (ADJP (RB previously) (JJ unknown)) (NN Doc_7604176_532_546_Disease)) (, ,) (ADJP (RB probably) (JJ due) (PP (TO to) (NP (NN chronic) (NN Doc_7604176_572_594_Disease)))) (, ,)) (VP (AUX was) (VP (VBN evidenced))) (. .)))
7604176	7	(S1 (S (NP (NP (NN Muscle) (NN biopsy)) (PRN (-LRB- -LRB-) (NP (JJ left) (NN gastrocnemius)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (DT a) (ADJP (JJ perimysial) (CC and) (JJ endomysial)) (JJ inflammatory) (VB infiltrate)) (PP (IN with) (NP (NP (DT a) (NN prevalence)) (PP (IN of) (NP (JJ CD4+) (NNS lymphocytes))))))) (. .)))
7604176	8	(S1 (S (SBAR (IN While) (S (NP (NP (NNP Doc_7604176_752_762_Chemical)) (CC and) (NP (NNP Doc_7604176_767_778_Chemical))) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (JJ toxic) (NN Doc_7604176_811_819_Disease)))))))) (, ,) (NP (NNP Doc_7604176_821_832_Chemical-associated) (NNP Doc_7604176_844_852_Disease)) (VP (MD could) (VP (VB represent) (NP (DT a) (JJ distinct) (, ,) (JJ inflammatory) (NN entity)))) (. .)))
761833	0	(S1 (NP (NP (NP (NN Reversal)) (PP (IN of) (NP (NNP Doc_761833_12_19_Chemical) (NNP Doc_761833_20_24_Disease))) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNP Doc_761833_36_42_Chemical)))) (: :) (NP (DT a) (JJ peripheral) (NN effect)) (. .)))
761833	1	(S1 (S (NP (NNP Doc_761833_65_72_Chemical) (NNP Doc_761833_73_77_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN within) (NP (NP (QP (CD 10) (TO to) (CD 15)) (NNS minutes)) (PP (IN of) (NP (NP (DT an) (NN intraperitonealinjection)) (PP (IN of) (NP (CD 1.7) (JJ mmol) (NN Doc_761833_166_171_Chemical))))))))) (. .)))
761833	2	(S1 (S (NP (DT This) (NN Doc_761833_178_182_Disease)) (VP (AUX was) (VP (VBN prevented) (PP (IN with) (NP (NP (CD 1.68) (JJ mmol) (NN Doc_761833_212_218_Chemical)) (VP (VBN given) (PP (IN by) (NP (JJ gastric) (NN intubation))) (PP (NP (CD 15) (NNS minutes)) (IN before) (NP (DT the) (NNP Doc_761833_269_282_Chemical) (NN injection)))))))) (. .)))
761833	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_308_314_Chemical)))) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN blood)) (CC and) (NP (NN brain) (NN Doc_761833_365_372_Chemical))))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN brain) (NN Doc_761833_395_403_Chemical)))) (, ,) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ renal) (NN excretion)) (PP (IN of) (NP (NNP Doc_761833_443_450_Chemical) (CC and) (NNP Doc_761833_455_459_Chemical)))))))))) (. .)))
761833	4	(S1 (S (NP (NP (JJ Intraventricular) (NN infusion)) (PP (IN of) (NP (NNP Doc_761833_490_498_Chemical))) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB raise) (NP (DT the) (NN brain) (NN Doc_761833_529_537_Chemical)) (PP (TO to) (NP (DT the) (JJ same) (NN extent)))))))) (VP (AUX did) (RB not) (VP (VP (VB prevent) (NP (DT the) (NNP Doc_761833_577_584_Chemical) (NNP Doc_761833_585_589_Disease))) (CC nor) (VP (VB affect) (NP (DT the) (NN blood) (CC and) (NN brain) (NN Doc_761833_621_628_Chemical) (NNS concentrations))))) (. .)))
761833	5	(S1 (S (S (NP (JJ Bilateral) (NN nephrectomy)) (VP (VBD eliminated) (NP (NP (DT the) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_703_709_Chemical))) (PP (IN on) (NP (NN blood) (CC and) (NN brain) (NN Doc_761833_729_736_Chemical)))))) (CC and) (S (NP (DT the) (NNP Doc_761833_745_752_Chemical) (NNP Doc_761833_753_757_Disease)) (VP (AUX was) (RB not) (VP (VBN prevented)))) (. .)))
761833	6	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NN blood) (CC and) (NN brain) (NN Doc_761833_816_823_Chemical)))) (CC and) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_761833_846_853_Chemical) (NNP Doc_761833_854_858_Disease))) (PP (IN after) (NP (NNP Doc_761833_865_871_Chemical)))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (DT the) (JJ peripheral) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_922_930_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (CONJP (RB rather) (IN than)) (NP (PRP$ its) (JJ central) (NN action))))))))) (. .)))
761833	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (DT a) (JJ reasonable) (NN explanation)) (PP (IN for) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (VP (VBN observed) (PP (IN in) (NP (NP (DT some) (JJ Doc_761833_1072_1087_Disease) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_761833_1107_1113_Chemical)))))))))) (. .)))
7619765	0	(S1 (NP (JJ Doc_7619765_0_9_Chemical-related) (NN Doc_7619765_18_39_Disease) (. .)))
7619765	1	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (DT a) (NN Doc_7619765_61_82_Disease)))) (VP (AUX is) (VP (VBN reported) (PP (IN after) (NP (NP (NNS chemotherapy)) (VP (VBG containing) (NP (NNP Doc_7619765_125_134_Chemical))))) (, ,) (PP (IN in) (NP (NP (DT a) (NN man)) (PP (IN with) (NP (NP (DT no) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_7619765_170_192_Disease))))))))) (. .)))
7619765	2	(S1 (S (NP (JJ Possible) (NN causal) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed))) (. .)))
7647582	0	(S1 (S (NP (VBD Halogenated) (NNS anesthetics)) (VP (VBP form) (NP (NP (NP (NN liver) (NNS adducts)) (CC and) (NP (NNS antigens))) (SBAR (WHNP (WDT that)) (S (VP (VBP cross-react) (PP (IN with) (NP (JJ Doc_7647582_78_87_Chemical-induced) (NNS antibodies)))))))) (. .)))
7647582	1	(S1 (S (NP (NP (CD Two) (VBD halogenated) (NNS anesthetics)) (, ,) (NP (NP (NNP Doc_7647582_137_146_Chemical)) (CC and) (NP (NNP Doc_7647582_151_161_Chemical))) (, ,)) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ allergic-type) (UCP (NNP Doc_7647582_206_220_Disease) (CC both) (JJ alone) (CC and) (VBG following)) (JJ previous) (NN exposure)) (PP (TO to) (NP (NNP Doc_7647582_267_276_Chemical)))))))) (. .)))
7647582	2	(S1 (S (NP (NNP Doc_7647582_278_287_Chemical) (NNP Doc_7647582_288_297_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (VB involve) (NP (DT an) (JJ aberrant) (JJ immune) (NN response)))))) (. .)))
7647582	3	(S1 (S (NP (NP (DT An) (NN antibody) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ protein-bound) (NN biotransformation) (NN product)) (PRN (-LRB- -LRB-) (NP (JJ Doc_7647582_413_428_Chemical) (NN adduct)) (-RRB- -RRB-))))) (VP (AUX has) (VP (AUX been) (VP (VBN detected) (PP (IN on) (NP (NNP Doc_7647582_458_467_Chemical) (NNP Doc_7647582_468_477_Disease) (NNS patients)))))) (. .)))
7647582	4	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB determine) (NP (NP (NN cross-reactivity)) (PP (IN between) (NP (NP (NNP Doc_7647582_551_560_Chemical)) (CC and) (NP (NNP Doc_7647582_565_575_Chemical)))) (PP (IN with) (NP (NP (DT the) (NNP Doc_7647582_585_601_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7647582_613_622_Chemical)))))))))))) (. .)))
7647582	5	(S1 (S (S (NP (NP (DT The) (ADJP (JJ subcellular) (CC and) (JJ lobular)) (NN production)) (PP (IN of) (NP (JJ hepatic) (NNS neoantigens)))) (VP (VBD recognized) (PP (IN by) (NP (JJ Doc_7647582_700_709_Chemical-induced) (NNS antibodies))) (PP (VBG following) (NP (NP (NNP Doc_7647582_739_748_Chemical)) (CC and) (NP (NNP Doc_7647582_753_763_Chemical)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ biochemical) (NN nature)) (PP (IN of) (NP (DT these) (NNS neoantigens)))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (CD two) (NN animal) (NNS models)))))) (. .)))
7647582	6	(S1 (S (NP (JJ Doc_7647582_852_861_Chemical) (NN administration)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS neoantigens)) (VP (VBN detected) (PP (PP (IN in) (NP (NP (PDT both) (DT the) (JJ microsomal) (CC and) (JJ cytosolic) (NN fraction)) (PP (IN of) (NP (NN liver) (NNS homogenates))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ centrilobular) (NN region)) (PP (IN of) (NP (DT the) (NN liver)))))))))) (. .)))
7647582	7	(S1 (S (PP (IN In) (NP (DT the) (JJ same) (NN liver))) (, ,) (NP (JJ biochemical) (NN analysis)) (VP (VBD detected) (NP (NP (JJ fluorinated) (NN liver) (NNS adducts)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADVP (RB up) (PP (TO to) (NP (NN 20-fold)))) (ADJP (JJR greater) (PP (IN in) (NP (NN guinea) (NNS pigs))) (PP (IN than) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
7647582	8	(S1 (S (NP (DT This)) (VP (VP (VBZ supports)) (CC and) (VP (VBZ extends) (NP (NP (JJ previous) (NN evidence)) (PP (IN for) (NP (NP (DT a) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_7647582_1228_1237_Chemical) (FW and/or) (NNP Doc_7647582_1245_1255_Chemical)) (VP (MD could) (VP (VB produce) (NP (NP (DT a) (JJ Doc_7647582_1272_1288_Disease) (NN condition)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_7647582_1318_1327_Chemical) (NNP Doc_7647582_1328_1337_Disease)))))))))))))) (ADVP (RB either)) (UCP (ADVP (RB alone)) (CC or) (ADJP (JJ subsequent) (PP (TO to) (NP (NNP Doc_7647582_1368_1377_Chemical) (NN administration))))))) (. .)))
7647582	9	(S1 (S (NP (DT The) (NN guinea) (NN pig)) (VP (MD would) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (NP (NP (JJ further) (NNS investigations)) (PP (IN of) (NP (NP (DT the) (JJ immunological) (NN response)) (PP (TO to) (NP (DT these) (NNS antigens))))))))))))) (. .)))
7650771	0	(S1 (S (NP (NNP Cholinergic) (NNP Doc_7650771_12_20_Disease)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ ocular) (NN instillation)) (PP (IN of) (NP (JJ Doc_7650771_59_79_Chemical) (NN eye) (NNS drops)))))) (. .)))
7650771	1	(S1 (S (NP (DT A) (NN patient)) (VP (VP (VBD developed) (NP (DT a) (JJ severe) (JJ cholinergic) (NN syndrome)) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Doc_7650771_157_177_Chemical) (JJ ophthalmic) (NNS drops)) (, ,) (VP (VBN presented) (PP (IN with) (NP (JJ profound) (NN Doc_7650771_220_235_Disease))))))))) (CC and) (VP (AUX was) (ADVP (RB initially)) (VP (VBN given) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_7650771_277_294_Disease))))))) (. .)))
7650771	2	(S1 (S (S (NP (JJ Red) (NN blood) (NN cell) (CC and) (NN serum) (NN cholinesterase) (NNS levels)) (VP (AUX were) (ADVP (RB severely)) (VP (VBN depressed)))) (CC and) (S (NP (NNS symptoms)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (VBG following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN eye) (NNS drops))))))) (. .)))
7651879	0	(S1 (NP (NP (NN Doc_7651879_0_7_Disease)) (PP (IN after) (NP (NNP Doc_7651879_14_24_Chemical) (NN administration))) (PP (IN in) (NP (DT a) (JJ pediatric) (NN patient))) (. .)))
7651879	1	(S1 (S (S (NP (NN Doc_7651879_64_74_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ Doc_7651879_80_94_Chemical) (NN receptor) (NN antagonist)) (VP (VBN used) (S (VP (TO to) (VP (VB reverse) (NP (NN sedation))))))))) (CC and) (S (NP (NNP Doc_7651879_144_166_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7651879_178_193_Chemical))))) (. .)))
7651879	2	(S1 (S (NP (NP (NNP Doc_7651879_195_203_Disease)) (CC and) (NP (NNP Doc_7651879_208_227_Disease))) (VP (AUX have) (VP (VBN complicated) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (NN adult) (NNS patients)))))) (. .)))
7651879	3	(S1 (S (NP (NP (JJ Doc_7651879_272_280_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN coingested) (NP (JJ tricyclic) (NNS antidepressants))))))) (VP (AUX have) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (DT these) (NNS complications))))) (. .)))
7651879	4	(S1 (S (NP (JJ Little) (NN information)) (VP (VBZ exists) (S (VP (VBG concerning) (NP (NP (JJ adverse) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7651879_435_445_Chemical)) (PP (IN in) (NP (NNS children))))))))) (. .)))
7651879	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT a) (JJ generalized) (NN Doc_7651879_501_521_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ pediatric) (NN patient)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_7651879_577_587_Chemical)))))))) (. .)))
7707116	0	(S1 (S (VP (VB Phase) (S (NP (PRP I)) (NP (NP (NN trial)) (PP (IN of) (NP (NNP Doc_7707116_17_37_Chemical))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_7707116_55_68_Disease) (JJ following) (NN bone) (NN marrow) (NN transplantation)))))))) (. .)))
7707116	1	(S1 (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NP (JJ Doc_7707116_130_143_Disease) (NN cell) (NNS lines)) (PP (IN with) (NP (NP (NNP Doc_7707116_160_180_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7707116_182_188_Chemical)) (-RRB- -RRB-))))))) (VP (MD can) (VP (VB cause) (NP (NP (JJ sustained) (NN inhibition)) (PP (IN of) (NP (NN proliferation)))))) (. .)))
7707116	2	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_7707116_245_251_Chemical)) (VP (AUX has) (VP (VBN demonstrated) (NP (JJ clinical) (NNS responses)) (PP (IN in) (NP (NNP Doc_7707116_291_304_Disease) (NNS patients))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG preventing) (NP (NN relapse)) (PP (IN after) (NP (JJ cytotoxic) (NN therapy))))))))) (. .)))
7707116	3	(S1 (S (S (NP (DT This) (NN phase) (NN I) (NN trial)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (NP (NP (NP (DT the) (JJ maximal-tolerated) (NN dosage)) (PRN (-LRB- -LRB-) (NP (NNP MTD)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_7707116_463_473_Disease))))))))) (, ,) (CC and) (S (NP (NP (NNS pharmacokinetics)) (PP (IN of) (NP (NNP Doc_7707116_499_505_Chemical)))) (VP (VBN administered) (PP (IN on) (NP (DT an) (JJ intermittent) (NN schedule))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_7707116_564_577_Disease))))) (PP (VBG following) (NP (NP (NN bone) (NN marrow) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP BMT)) (-RRB- -RRB-)))))) (. .)))
7707116	4	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (JJ Fifty-one) (JJ assessable) (NNS patients)) (, ,) (NP (NP (QP (CD 2) (TO to) (CD 12)) (NNS years)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ oral) (NN Doc_7707116_721_727_Chemical)) (VP (VBN administered) (PP (IN in) (NP (NP (CD two) (ADJP (RB equally) (VBN divided)) (NNS doses)) (ADJP (JJ daily) (PP (IN for) (NP (CD 2) (NNS weeks)))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 2-week) (NN rest) (NN period)))) (, ,)))))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 12)) (NNS courses))))) (. .)))
7707116	5	(S1 (S (NP (DT The) (NN dose)) (VP (AUX was) (VP (VBN escalated) (PP (IN from) (NP (QP (CD 100) (TO to) (CD 200)) (NNS mg/m2/d))) (SBAR (IN until) (S (NP (NP (JJ dose-limiting) (NNP Doc_7707116_912_920_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DLT)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed))))))) (. .)))
7707116	6	(S1 (S (NP (DT A) (JJ single) (NN intrapatient) (NN dose) (NN escalation)) (VP (AUX was) (VP (VBN permitted))) (. .)))
7707116	7	(S1 (S (NP (NP (DT The) (NN MTD)) (PP (IN of) (NP (NNP Doc_7707116_1014_1020_Chemical)))) (VP (AUX was) (NP (CD 160) (NN mg/m2/d))) (. .)))
7707116	8	(S1 (S (NP (NP (JJ Dose-limiting) (NN Doc_7707116_1052_1062_Disease)) (PP (IN in) (NP (NP (QP (CD six) (IN of) (CD nine)) (NNS patients)) (PP (IN at) (NP (CD 200) (NNS mg/m2/d)))))) (VP (VBD included) (NP (NP (NP (NNP Doc_7707116_1111_1124_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_7707116_1134_1138_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_7707116_1152_1158_Disease/Doc_7707116_1159_1175_Disease/Doc_7707116_1176_1182_Disease/Doc_7707116_1183_1187_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1)) (-RRB- -RRB-))))) (. .)))
7707116	9	(S1 (S (NP (NP (DT All) (NN Doc_7707116_1201_1211_Disease)) (VP (VBN resolved) (PP (IN after) (NP (NNP Doc_7707116_1227_1233_Chemical))))) (VP (AUX was) (VP (VBN discontinued))) (. .)))
7707116	10	(S1 (S (NP (CD Three) (JJ complete) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NN marrow) (NN Doc_7707116_1301_1311_Disease))))) (. .)))
7707116	11	(S1 (S (NP (NP (NN Serum) (NNS levels)) (PP (IN of) (NP (NP (NP (NP (CD 7.4) (NN +/-)) (NP (CD 3.0) (NNS mumol/L))) (PRN (-LRB- -LRB-) (NP (NN peak)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 4.0) (NN +/-) (QP (CD 2.8) (CD mumol/L))) (PRN (-LRB- -LRB-) (NP (NN trough)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (NN MTD)))) (VP (AUX were) (VP (VBN maintained) (PP (IN during) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
7707116	12	(S1 (S (NP (NP (DT The) (NN DLT)) (VP (VBN correlated) (PP (IN with) (NP (JJ serum) (NNS levels))))) (VP (VBD >) (NP (QP (CC or) (SYM =) (CD 10) (CD mumol/L)))) (. .)))
7707116	13	(S1 (S (NP (NP (DT The) (NN MTD)) (PP (IN of) (NP (NNP Doc_7707116_1522_1528_Chemical))) (VP (VBN given) (PP (IN on) (NP (DT this) (JJ intermittent) (NN schedule))))) (VP (AUX was) (NP (CD 160) (NN mg/m2/d))) (. .)))
7707116	14	(S1 (S (NP (NP (NN Serum) (NNS levels)) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective))))) (PP (IN against) (NP (NNP Doc_7707116_1625_1638_Disease))) (PP (IN in) (NP (NN vitro))))) (VP (AUX were) (VP (VBN achieved) (PP (IN at) (NP (DT this) (NN dose))))) (. .)))
7707116	15	(S1 (S (NP (DT The) (NN DLT)) (VP (VP (VBD included) (NP (NNP Doc_7707116_1693_1706_Disease))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN predicted) (PP (IN by) (NP (JJ serum) (JJ Doc_7707116_1738_1744_Chemical) (NNS levels))))))) (. .)))
7707116	16	(S1 (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (JJ serum) (UCP (NNP Doc_7707116_1773_1780_Chemical) (CC and) (NNP Doc_7707116_1785_1791_Chemical)) (NNS levels)))) (VP (AUX is) (VP (VBN indicated) (PP (IN in) (NP (JJ future) (NNS trials))))) (. .)))
7710775	0	(S1 (NP (NP (NN Time) (NN dependence)) (PP (IN of) (NP (NP (NN plasma) (NNP Doc_7710775_26_41_Chemical)) (, ,) (NP (NNP Doc_7710775_43_53_Chemical)) (, ,) (CC and) (NP (NNP Doc_7710775_59_70_Chemical)))) (PP (IN during) (NP (NP (JJ incomplete) (NN Doc_7710775_89_106_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
7710775	1	(S1 (S (NP (NP (JJ Incomplete) (NN Doc_7710775_130_147_Disease)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN min)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (DT the) (NN rat))) (PP (IN by) (S (ADVP (RB bilaterally)) (VP (VBG clamping) (NP (DT the) (JJ common) (JJ carotid) (NNS arteries))))))) (. .)))
7710775	2	(S1 (S (NP (JJ Peripheral) (JJ venous) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (JJ femoral) (NN vein))) (NP (CD four) (NNS times)) (PRN (-LRB- -LRB-) (PP (IN once) (NP (DT every) (CD 5) (NN min))) (-RRB- -RRB-)) (PP (IN before) (NP (NP (NP (NNP Doc_7710775_339_347_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN time)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 5)) (, ,) (NP (CD 15)) (, ,) (CC and) (NP (NP (CD 30) (NN min)) (PP (IN after) (NP (NNP Doc_7710775_385_393_Disease))))))))) (. .)))
7710775	3	(S1 (S (NP (NN Plasma) (NNS extracts)) (VP (AUX were) (VP (VBN analyzed) (PP (IN by) (NP (NP (DT a) (ADJP (RB highly) (JJ sensitive)) (NN high-performance) (NN liquid) (NN chromatographic) (NN method)) (PP (IN for) (NP (NP (DT the) (JJ direct) (NN determination)) (PP (IN of) (NP (NP (NNP Doc_7710775_526_541_Chemical)) (, ,) (NP (NNP Doc_7710775_543_553_Chemical)) (, ,) (CC and) (NP (NNP Doc_7710775_559_570_Chemical)))))))))) (. .)))
7710775	4	(S1 (S (PP (IN During) (NP (NNP Doc_7710775_579_587_Disease))) (, ,) (NP (NP (DT a) (JJ time-dependent) (NN increase)) (PP (IN of) (NP (NN plasma)))) (NP (NP (NNP Doc_7710775_625_635_Chemical)) (CC and) (NP (NNP Doc_7710775_640_651_Chemical))) (VP (AUX was) (VP (VBN observed))) (. .)))
7710775	5	(S1 (S (NP (NP (NN Plasma) (NN Doc_7710775_673_688_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ present)) (PP (IN in) (NP (JJ minimal) (NN amount))) (PP (IN at) (NP (NP (CD zero) (NN time)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.058) (NN mumol/liter) (NN plasma)) (: ;) (NP (NNP SD) (CD 0.015))) (-RRB- -RRB-))))))) (, ,)) (VP (VBN increased) (PP (IN after) (NP (NP (CD 5) (NN min)) (PP (IN of) (NP (NNP Doc_7710775_802_810_Disease))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (ADJP (RB fivefold)) (NN increase)) (PP (IN after) (NP (NP (CD 30) (NN min)) (PP (IN of) (NP (NP (JJ carotid) (NN occlusion)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.298) (NN mumol/liter) (NN plasma)) (: ;) (NP (NNP SD) (CD 0.078))) (-RRB- -RRB-))))))))))) (. .)))
7710775	6	(S1 (S (NP (VBN Increased) (NN plasma) (NN Doc_7710775_934_949_Chemical)) (VP (AUX was) (ADVP (RB also)) (VP (VBN recorded) (PP (IN in) (NP (NP (CD two) (JJ other) (NNS groups)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN subjected) (PP (TO to) (NP (NP (DT the) (JJ same) (JJ experimental) (NN model)) (, ,) (NP (NP (CD one)) (VP (VBG receiving) (NP (NP (QP (CD 20) (CD mg/kg)) (NNS b.w.)) (PP (IN of) (NP (DT the) (NN cyclooxygenase) (NN inhibitor) (NNP Doc_7710775_1101_1117_Chemical)))) (ADVP (RB intravenously) (RB immediately)) (PP (IN before) (NP (NNP Doc_7710775_1151_1159_Disease))))) (, ,))) (NP (DT the) (JJ other) (S (VP (VBG receiving) (NP (NP (QP (CD 650) (CD micrograms/kg)) (NNS b.w.)) (PP (IN of) (NP (NP (DT the) (NNP Doc_7710775_1211_1222_Disease) (NN drug) (NNP Doc_7710775_1228_1241_Chemical)) (PP (IN at) (NP (NP (DT a) (NN flow) (NN rate)) (PP (IN of) (NP (CD 103) (NN microliters/min)))))))) (ADVP (RB intravenously)) (PP (IN during) (NP (NNP Doc_7710775_1301_1309_Disease))))))))))) (, ,) (SBAR (IN although) (S (PP (IN in) (NP (DT this) (JJ latter) (NN group))) (NP (NNP Doc_7710775_1341_1356_Chemical)) (VP (AUX was) (ADJP (RB significantly) (JJR higher))))))) (. .)))
7710775	7	(S1 (S (NP (DT The) (JJ present) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NP (NNP Doc_7710775_1435_1450_Chemical)) (, ,) (NP (NNP Doc_7710775_1452_1462_Chemical)) (, ,) (CC and) (NP (NP (NNP Doc_7710775_1468_1479_Chemical)) (PP (IN in) (NP (JJ peripheral) (NN blood)))) (, ,)))) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (JJ metabolic) (NNS alterations)) (PP (IN of) (NP (NP (NNS tissues)) (VP (VBG occurring) (PP (IN during) (NP (NP (JJ Doc_7710775_1578_1586_Disease) (NNS phenomena.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))))))))))))
7724492	0	(S1 (S (NP (NP (JJ Acute) (NN Doc_7724492_6_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_7724492_24_35_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7724492_37_47_Chemical)) (-RRB- -RRB-))))) (VP (VBD -loaded) (NP (JJ Doc_7724492_56_69_Chemical) (NNS nanoparticles))) (. .)))
7724492	1	(S1 (S (NP (JJ Acute) (JJ Doc_7724492_91_102_Chemical-loaded) (FW nanoparticle) (PRN (-LRB- -LRB-) (NP (NNP DXNP)) (-RRB- -RRB-)) (NNP Doc_7724492_130_144_Disease)) (VP (AUX was) (VP (VBN explored) (PP (IN in) (NP (DT both) (JJ normal) (NNS rats) (CC and) (NNS rats))) (PP (IN with) (NP (JJ experimental) (NN Doc_7724492_205_223_Disease))))) (. .)))
7724492	2	(S1 (S (PP (IN In) (NP (JJ normal) (NNS rats))) (, ,) (S (NP (NN 2/6) (NNS rats)) (VP (VBN given) (NP (NP (NP (JJ free) (NNP Doc_7724492_261_272_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7724492_274_276_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-)) (VP (VBN died) (PP (IN within) (NP (CD one) (NN week)))) (, ,)) (PP (IN whereas) (NP (DT all) (NN control) (NNS animals))))) (CC and) (S (NP (DT all) (NNS rats)) (VP (AUXG having) (VP (VBN received) (NP (JJ free) (NN NP))))) (CC or) (S (NP (NNS DXNP)) (VP (VBN survived))) (. .)))
7724492	3	(S1 (S (NP (NP (DT A) (ADJP (QP (CD 3) (NNS times)) (JJR higher)) (NN Doc_7724492_410_421_Disease)) (VP (VBN appeared) (PP (IN in) (NP (NNS animals))))) (VP (VBN treated) (PP (IN with) (NP (NN DXNP))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7724492_487_489_Chemical)))))))) (. .)))
7724492	4	(S1 (S (NP (JJ Free) (NNS NP)) (VP (AUX did) (RB not) (VP (VB provoke) (NP (DT any) (NN Doc_7724492_519_530_Disease)))) (. .)))
7724492	5	(S1 (S (NP (NP (QP (CD Two) (CD hr)) (NN post-injection)) (, ,) (NP (NNP DXNP))) (VP (AUX was) (ADJP (ADJP (QP (CD 2.7) (NNS times)) (RBR more) (JJ concentrated)) (PP (IN in) (NP (NNS kidneys))) (PP (IN than) (NP (NP (JJ free) (JJ Doc_7724492_613_615_Chemical)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.025))) (-RRB- -RRB-)))))) (. .)))
7724492	6	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ immune) (JJ experimental) (NN Doc_7724492_662_680_Disease))))) (, ,) (NP (NP (JJ 5/6) (NNS rats)) (VP (VBN given) (NP (NNP Doc_7724492_697_699_Chemical)))) (VP (VBD died) (PP (IN within) (NP (CD 7) (NNS days))) (, ,) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN by) (NP (NP (NN DXNP)) (, ,) (ADJP (JJ NP) (, ,) (CC or) (JJ untreated)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB all)) (VP (VBD survived)))))))))))) (. .)))
7724492	7	(S1 (S (S (NP (NN Doc_7724492_798_809_Disease)) (VP (VBD appeared) (PP (IN in) (NP (DT all) (NN series))))) (, ,) (CC but) (S (VP (AUX was) (ADJP (ADJP (QP (CD 2-5) (NNS times)) (RBR more) (JJ intense)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD >)) (CD 0.001)) (-RRB- -RRB-)) (CC and) (VBN prolonged)) (PP (IN after) (NP (NP (JJ Doc_7724492_897_908_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 400-700) (NN mg/day)) (-RRB- -RRB-)))) (, ,) (PP (IN without) (NP (NP (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NNP DXNP)) (CC and) (NP (NNP Doc_7724492_985_987_Chemical)))))))) (. .)))
7724492	8	(S1 (S (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN by) (NP (JJ unloaded) (NNS NP))))) (VP (VBD behaved) (PP (IN as) (NP (NNS controls)))) (. .)))
7724492	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (DT these) (JJ experimental) (NNS conditions))) (, ,) (ADVP (RB DXNP)) (VP (VBD killed) (NP (JJR less) (NNS animals)) (PP (IN than) (NP (JJ free) (NNP Doc_7724492_1139_1141_Chemical))) (, ,) (PP (IN despite) (IN of) (NP (NP (DT an) (JJ enhanced) (NN Doc_7724492_1166_1180_Disease)) (PP (IN of) (NP (DT the) (JJ former))))))))) (. .)))
7724492	10	(S1 (S (NP (NP (DT Both) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NP (JJR better) (NN survival)) (CC and) (NP (NNP Doc_7724492_1230_1239_Disease))) (-RRB- -RRB-))) (VP (AUX are) (ADJP (ADVP (RBS most) (RB probably)) (VBN related) (PP (TO to) (NP (NP (DT an) (JJ enhanced) (NN capture)) (PP (IN of) (NP (NN DXNP))) (PP (IN by) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ mononuclear) (NN phagocyte) (NN system))) (, ,) (PP (VBG including) (NP (JJ mesangial) (NNS cells))))))))) (. .)))
7752389	0	(S1 (NP (NP (NP (JJ Doc_7752389_0_16_Chemical-induced) (NN Doc_7752389_25_46_Disease)) (PP (IN in) (NP (JJ normal) (, ,) (JJ conscious) (NNS rats)))) (: :) (NP (NP (NN involvement)) (PP (IN of) (NP (NNP Doc_7752389_89_100_Chemical)))) (. ?)))
7752389	1	(S1 (S (PP (IN In) (NP (NP (JJ normal) (JJ conscious) (NNS rats)) (VP (VBN investigated) (PP (IN by) (NP (JJ continuous) (NN cystometry)))))) (, ,) (NP (ADJP (RB intravesically) (VBN instilled)) (NNP Doc_7752389_191_212_Chemical)) (VP (VP (VBD facilitated) (NP (NN micturition))) (CC and) (VP (VBD increased) (NP (JJ basal) (JJ intravesical) (NN pressure)))) (. .)))
7752389	2	(S1 (S (NP (DT The) (NN effect)) (VP (AUX was) (VP (VBN attenuated) (PP (IN by) (NP (PDT both) (NP (DT the) (ADJP (CD NK1) (NN receptor)) (JJ selective) (NN antagonist) (NN Doc_7752389_352_361_Chemical)) (CC and) (NP (DT the) (ADJP (CD NK2) (NN receptor)) (JJ selective) (NN antagonist) (NN Doc_7752389_404_413_Chemical)))) (, ,) (S (VP (VBN given) (ADVP (RB intra-arterially)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX was) (VP (VBN mediated) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT both) (NNP NK1) (CC and) (NNP NK2) (NNS receptors))))))))))))))) (. .)))
7752389	3	(S1 (S (NP (ADJP (RB Intra-arterially) (VBN given)) (NNP Doc_7752389_540_544_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ distinct) (NN increase)) (PP (IN in) (NP (NN bladder) (NN pressure)))) (PP (IN before) (S (VP (VBG initiating) (NP (DT a) (NN micturition) (JJ reflex))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (NNP Doc_7752389_654_656_Chemical)) (VP (AUX had) (NP (NP (DT a) (JJ direct) (JJ contractant) (NN effect)) (PP (IN on) (NP (DT the) (JJ detrusor) (JJ smooth) (NN muscle)))))))))) (. .)))
7752389	4	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ intra-arterial) (NNP Doc_7752389_749_753_Chemical)))) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN blocked) (PP (IN by) (NP (NP (JJ intra-arterial) (NNP Doc_7752389_793_802_Chemical) (CC or) (NNP Doc_7752389_806_815_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ opens) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (JJ micturition) (JJ reflex) (NN elicited)) (PP (IN by) (NP (JJ intra-arterial) (NNP Doc_7752389_900_904_Chemical)))) (VP (AUX was) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS pathways)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT the) (JJ reflex)) (VP (VBN initiated) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_7752389_971_973_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB intravesically))))))))))))))))))))))))) (. .)))
7752389	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (ADVP (RB thus)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ intra-arterial) (NNP Doc_7752389_1053_1057_Chemical)) (, ,) (VP (VBN given) (PP (IN near) (NP (DT the) (NN bladder)))) (, ,)) (VP (MD may) (VP (VB initiate) (NP (NP (NN micturition)) (PP (IN in) (NP (DT the) (JJ normal) (NN rat)))) (ADVP (RB chiefly)) (PP (IN by) (S (VP (ADVP (RB directly)) (VBG contracting) (NP (NP (DT the) (JJ smooth) (NN muscle)) (PP (IN of) (NP (DT the) (NN detrusor)))))))))))) (. .)))
7752389	6	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB intravesically))))) (, ,) (NP (NNP Doc_7752389_1229_1233_Chemical)) (VP (MD may) (VP (VB stimulate) (NP (NN micturition)) (PP (IN by) (S (VP (VBG releasing) (NP (NNP Doc_7752389_1273_1284_Chemical)) (PP (IN from) (NP (NNS nerves))) (PP (IN in) (NP (NN and/or))) (PP (ADVP (RB immediately)) (IN below) (NP (DT the) (NN urothelium)))))))) (. .)))
7752389	7	(S1 (S (NP (DT These) (NNP Doc_7752389_1347_1358_Chemical)) (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (VB initiate) (NP (NP (DT a) (NN micturition)) (ADJP (JJ reflex) (PP (IN by) (NP (NP (JJ stimulating) (NNS NK1)) (CC and) (NP (JJ NK2) (NNS receptors))))))) (. .)))
7752389	8	(S1 (S (S (NP (NN Doc_7752389_1437_1448_Chemical)) (VP (MD may) (, ,) (PP (IN via) (NP (NP (NN release)) (PP (IN of) (NP (NNP Doc_7752389_1469_1480_Chemical))))) (, ,) (VP (VB contribute) (PP (TO to) (NP (DT both) (NN urge)))))) (CC and) (S (NP (NNP Doc_7752389_1510_1531_Disease)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ inflammatory) (NNS conditions)) (PP (IN of) (NP (DT the) (JJR lower) (NN urinary) (NN tract))))))) (. .)))
7785794	0	(S1 (NP (NP (NP (JJ Refractory) (NN Doc_7785794_11_28_Disease)) (CC and) (NP (JJ complete) (NN Doc_7785794_42_53_Disease))) (PP (IN after) (NP (NNP Doc_7785794_60_69_Chemical) (NNP SR) (CC and) (NNP Doc_7785794_77_87_Chemical) (NN treatment))) (. .)))
7785794	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
7785794	2	(S1 (S (NP (DT A) (JJ seventy-eight-year-old) (NN woman)) (VP (VBD presented) (PP (IN with) (NP (NP (JJ complete) (NNP Doc_7785794_169_180_Disease)) (CC and) (NP (JJ refractory) (NNP Doc_7785794_196_207_Disease)))) (PP (NP (CD two) (NNS days)) (IN after) (NP (NP (DT a) (JJ therapeutic) (NN dose)) (PP (IN of) (NP (JJ sustained-release) (NNP Doc_7785794_263_272_Chemical))) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NNP Doc_7785794_297_307_Chemical)))))))) (. .)))
7785794	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD continued) (S (VP (TO to) (VP (VB remain) (NP (NNP Doc_7785794_341_352_Disease)) (PP (PP (IN with) (NP (JJ complete) (NNP Doc_7785794_367_378_Disease))) (, ,) (RB even) (PP (IN with) (NP (NP (NP (JJ multiple) (NNS uses)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_7785794_419_427_Chemical)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN pressor) (NNS agents))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_7785794_476_484_Chemical)) (CC and) (NP (NNP Doc_7785794_489_499_Chemical)))))))))))) (. .)))
7785794	4	(S1 (S (ADVP (RB However)) (, ,) (PP (ADVP (RB shortly)) (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_7785794_547_563_Chemical))))) (, ,) (NP (NP (DT the) (JJ refractory) (NN Doc_7785794_580_591_Disease)) (CC and) (NP (JJ complete) (NN Doc_7785794_605_616_Disease))) (VP (VBD resolved)) (. .)))
7791169	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_7791169_21_32_Chemical))) (PP (IN on) (NP (NNP Doc_7791169_36_48_Chemical))) (VP (VBN induced) (NP (NNP Doc_7791169_57_74_Disease)) (PP (IN in) (NP (JJ elderly) (NNS patients)))) (. .)))
7791169	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ possible) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_7791169_154_165_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (VBN hospitalized) (JJ elderly) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7791169_230_242_Chemical)))))))))))) (. .)))
7791169	2	(S1 (S (NP (NP (NP (JJ Forty-five) (VBN hospitalized) (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD >) (CD 65)) (NNS years)) (ADJP (JJ old))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAID)) (-RRB- -RRB-))))))))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (NP (NP (NP (NNP Doc_7791169_422_434_Chemical)) (, ,) (NP (CD 150) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP A)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_7791169_461_473_Chemical) (CD 150))) (NN mg/day)) (PP (IN plus) (NP (NNP Doc_7791169_490_501_Chemical)))) (PP (IN at) (NP (NP (CD 0.6) (NN mg/day)) (-LRB- -LRB-) (NP (NNP Group) (NNP B)) (-RRB- -RRB-)))))))) (. .)))
7791169	3	(S1 (S (NP (NP (NN Laboratory) (NNS variables)) (PP (IN of) (NP (NP (JJ renal) (NN function) (NN -LSB-serum) (NNP Doc_7791169_573_583_Chemical)) (, ,) (NP (NP (NNP Doc_7791169_585_604_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7791169_606_609_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNS electrolytes) (NNS -RSB-))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN before) (NP (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy)))) (CC and) (NP (DT every) (CD 2) (NNS days)))) (, ,) (PP (IN until) (NP (NP (NN termination)) (PP (IN of) (NP (NP (DT the) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 6)) (NNS days)))) (-RRB- -RRB-)))))))) (. .)))
7791169	4	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (NN treatment)))) (VP (AUX was) (VP (VBN estimated) (PP (IN by) (NP (NP (DT the) (JJ visual) (NN analog) (NN scale)) (PP (IN for) (NP (NP (NN severity)) (PP (IN of) (NP (NNP Doc_7791169_832_836_Disease))))))))) (. .)))
7791169	5	(S1 (S (NP (NP (NP (JJ Forty-two) (NNS patients)) (VP (VBN completed) (NP (DT the) (NN study)))) (, ,) (NP (NP (CD 22)) (PP (IN in) (NP (NNP Group) (NNP A)))) (CC and) (NP (NP (CD 20)) (PP (IN in) (NP (NP (NNP Group) (NNP B.) (NNP Doc_7791169_920_923_Chemical)) (CC and) (NP (NNP Doc_7791169_928_938_Chemical)))))) (VP (VBD increased) (PP (IN by) (NP (NP (NP (NP (NP (QP (CD >) (CD 50)) (NN %)) (PP (IN of) (NP (NP (NN baseline) (NNS levels)) (PP (IN in) (NP (CD 54)))))) (CC and) (NP (NP (CD 45) (NN %)) (PP (IN of) (NP (NNP Group))))) (NP (DT A) (NNS patients))) (, ,) (ADVP (RB respectively)))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (QP (RB only) (CD 20) (CC and) (CD 10) (NN %))) (PP (IN of) (NP (NP (NNP Group) (NNP B) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
7791169	6	(S1 (S (NP (NP (JJ Doc_7791169_1086_1095_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7791169_1097_1098_Chemical)) (-RRB- -RRB-)) (NN increment)) (PP (IN of) (NP (QP (CD 0.6) (CD mEq/l) (CC or) (JJR more))))) (VP (AUX was) (VP (VBN observed) (PP (PP (IN in) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NNP Group) (NNP A))))) (, ,) (CC but) (PP (IN in) (NP (NP (QP (RB only) (CD 15)) (NN %)) (PP (IN of) (NP (NP (NNP Group) (NNP B) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
7791169	7	(S1 (S (NP (NP (DT The) (JJ mean) (NNS increments)) (PP (IN in) (NP (NP (NNP Doc_7791169_1234_1237_Chemical)) (, ,) (NP (NNP Doc_7791169_1239_1249_Chemical)) (, ,) (CC and) (NP (NNP Doc_7791169_1255_1256_Chemical))))) (VP (AUX were) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 63)) (, ,) (NP (CD 80)) (, ,) (CC and) (NP (CD 42) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (SBAR (IN in) (S (NP (NNP Group) (NNP B) (NNS patients)) (PP (VBN compared) (PP (TO to) (NP (NP (NNP Group) (NNP A.) (NNP Response)) (PP (TO to) (NP (NN treatment)))))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD 2) (NNS groups))))))))) (. .)))
7791169	8	(S1 (S (NP (VBN Hospitalized) (JJ elderly) (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NN risk))) (PP (IN for) (S (VP (VBG developing) (NP (JJ Doc_7791169_1487_1499_Chemical) (JJ related) (NN Doc_7791169_1508_1525_Disease)))))) (. .)))
7791169	9	(S1 (S (NP (NP (NN Addition)) (PP (IN of) (NP (NNP Doc_7791169_1539_1550_Chemical)))) (VP (MD can) (VP (VB minimize) (NP (DT this) (NN Doc_7791169_1569_1585_Disease)) (PP (IN without) (S (VP (VBG affecting) (NP (JJ Doc_7791169_1604_1608_Disease) (NN control))))))) (. .)))
7803371	0	(S1 (NP (NP (NP (NN Doc_7803371_0_23_Disease)) (PP (IN from) (NP (NP (JJ long-term) (NN abuse)) (PP (IN of) (NP (NNP Doc_7803371_48_64_Chemical)))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
7803371	1	(S1 (S (NP (NP (NP (NNP Doc_7803371_81_97_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7803371_99_101_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ dextrorotatory) (NN isomer)) (PP (IN of) (NP (NNP Doc_7803371_133_160_Chemical)))) (, ,)) (VP (AUX is) (NP (NP (DT the) (JJ main) (NN ingredient)) (PP (IN in) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (ADJP (RB widely) (JJ available)) (, ,) (JJ over-the-counter) (NNS antitussives))))))) (. .)))
7803371	2	(S1 (S (NP (NP (JJ Initial) (NNS studies)) (PRN (-LRB- -LRB-) (NP (NNP Bornstein) (CD 1968)) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP it)) (VP (VBN possessed) (NP (NP (DT no) (JJ respiratory) (NN suppressant) (NNS effects)) (CC and) (NP (DT no) (NN addiction) (NN liability))))))) (. .)))
7803371	3	(S1 (S (ADVP (RB Subsequently)) (, ,) (ADVP (RB however)) (, ,) (NP (NP (JJ several) (NNS articles)) (VP (VBG reporting) (NP (NP (NN abuse)) (PP (IN of) (NP (DT this) (NN drug)))))) (VP (AUX have) (VP (VBN appeared) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
7803371	4	(S1 (S (NP (DT The) (NN drug)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ acute) (JJ toxic) (NNS effects)) (, ,) (VP (VBG ranging) (PP (IN from) (NP (NP (NNP Doc_7803371_546_552_Disease) (, ,) (NNP Doc_7803371_554_566_Disease) (, ,) (NNP Doc_7803371_568_576_Disease) (, ,) (NNP Doc_7803371_578_584_Disease) (, ,)) (VBN slurred) (NN speech) (CC and) (NP (NNP Doc_7803371_605_614_Disease) (PRN (PP (TO to) (NP (NP (NN mood) (NNS changes)) (, ,) (NP (JJ perceptual) (NNS alterations)) (, ,) (NP (NN inattention)) (, ,) (NP (NN disorientation)) (CC and) (NP (NNP Doc_7803371_688_707_Disease)))) (-LRB- -LRB-) (NP (NNP Rammer) (FW et) (NNP al) (CD 1988)) (: ;) (NP (NP (NP (NP (NNP Katona)) (CC and) (NP (NNP Watson) (CD 1986))) (: ;) (NP (NP (NNP Isbell)) (CC and) (NP (NNP Fraser) (CD 1953))) (: ;) (NP (NNP Devlin) (FW et) (NNP al) (CD 1985)) (: ;) (NP (NNP McCarthy) (CD 1971)) (: ;) (NP (NNP Dodds)) (CC and) (NP (NNP Revai) (CD 1967))) (: ;) (NP (NNP Degkwitz) (CD 1964)) (: ;) (NP (NNP Hildebrand) (FW et) (NNP al) (CD 1989))) (-RRB- -RRB-)))))))))))))) (. .)))
7803371	5	(S1 (S (NP (EX There)) (VP (AUX have) (ADVP (RB also)) (VP (AUX been) (NP (NP (CD two) (JJ reported) (NNS fatalities)) (PP (IN from) (NP (JJ Doc_7803371_921_923_Chemical) (NNS overdoses)))) (PRN (-LRB- -LRB-) (NP (NNP Fleming) (CD 1986)) (-RRB- -RRB-)))) (. .)))
7803371	6	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (DT no) (NNS reports)) (VP (VBG describing) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN chronic) (NN abuse))))))) (. .)))
7803371	7	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_7803371_1053_1076_Disease))) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ prolonged) (NN use)) (PP (IN of) (NP (NNP Doc_7803371_1109_1111_Chemical)))))))) (. .)))
783197	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_783197_11_18_Chemical))) (PP (IN on) (NP (NP (JJ myocardial) (JJ Doc_783197_33_39_Chemical) (NN supply)) (CC and) (NP (NP (NN demand)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_783197_83_106_Disease)))))))) (. .)))
783197	1	(S1 (NP (NP (DT A) (ADJP (ADJP (JJ hemodynamic)) (, ,) (ADJP (JJ volumetric)) (, ,) (CC and) (ADJP (JJ metabolic))) (NN study)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN without) (NP (NNP Doc_783197_175_188_Disease))))) (. .)))
783197	2	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_783197_205_225_Chemical))) (PP (IN on) (NP (NP (JJ myocardial) (JJ Doc_783197_240_246_Chemical) (NN supply)) (CC and) (NP (NN demand))))) (VP (VP (AUX are) (PP (IN of) (NP (NP (JJ particular) (NN interest)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ obstructive) (NNP Doc_783197_323_346_Disease)))))))) (, ,) (CC but) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN measured) (ADVP (RB previously)) (PP (IN in) (NP (NN man))))))) (. .)))
783197	3	(S1 (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_783197_421_428_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.015) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (ADJP (JJ hemodynamic) (, ,) (JJ volumetric) (, ,) (CC and) (JJ metabolic)) (NNS parameters)) (PP (IN in) (NP (NP (CD 11) (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NN chronic) (NN Doc_783197_543_566_Disease)) (PP (IN without) (NP (JJ clinical) (NNP Doc_783197_584_608_Disease))))))))))) (. .)))
783197	4	(S1 (S (SBAR (IN Because) (S (NP (DT the) (NN protocol)) (VP (VP (AUX was) (ADVP (RB long))) (CC and) (VP (VBN involved) (NP (NP (NNS interventions)) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB affect) (NP (DT the) (NNS determinations))))))))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD studied) (PP (IN in) (NP (CD nine) (NNS patients))) (S (VP (VBG using) (NP (NP (DT an) (JJ identical) (NN protocol)) (SBAR (WHNP (IN except)) (S (NP (DT that) (NNP Doc_783197_779_786_Chemical) (NN administration)) (VP (AUX was) (VP (VBN omitted))))))))) (. .)))
783197	5	(S1 (S (NP (NP (JJ Left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (CC and) (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN volume))) (VP (VBD fell) (PP (IN in) (NP (NP (DT each) (NN patient)) (VP (VBN given) (NP (NNP Doc_783197_924_931_Chemical))))) (, ,) (SBAR (RB even) (IN though) (S (NP (PRP they)) (VP (AUX were) (ADVP (RB initially)) (ADJP (JJ elevated)) (PP (IN in) (NP (QP (RB only) (CD two)) (NNS patients))))))) (. .)))
783197	6	(S1 (S (NP (JJ Left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (VP (VP (VBD fell) (PP (IN from) (NP (NP (CD 11.5+/-1.4)) (PRN (-LRB- -LRB-) (JJ mean+/-SE) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 5.6+/-0.9) (JJ mm) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))) (CC and) (VP (VBD left) (SBAR (S (NP (JJ ventricular) (JJ end-diastolic) (NN volume)) (VP (VBD fell) (PP (IN from) (NP (NP (QP (CD 100+/-17) (TO to) (CD 82+/-12)) (NNS ml/m2)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)) (NP (CD 1) (NNP h)))) (SBAR (IN after) (S (NP (JJ Doc_783197_1215_1222_Chemical) (NN infusion)) (VP (AUX was) (VP (VBN completed)))))))))) (. .)))
783197	7	(S1 (S (NP (NP (DT The) (JJ maximum) (NN velocity)) (PP (IN of) (NP (JJ contractile) (NN element) (NN shortening)))) (VP (VP (VBD increased) (PP (IN from) (NP (CD 1.68+/-0.11) (NN ml/s))) (PP (TO to) (NP (NP (JJ 2.18+/-0.21) (NNS muscle-lengths/s)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (CC and) (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN contractility)))))))) (. .)))
783197	8	(S1 (S (NP (NP (DT No) (JJ significant) (NN change)) (PP (IN in) (NP (DT these) (NNS parameters)))) (VP (VBD occurred) (PP (IN in) (NP (DT the) (JJ control) (NNS patients)))) (. .)))
783197	9	(S1 (S (S (NP (NP (DT No) (JJ significant) (NN change)) (PP (IN in) (NP (JJ myocardial) (JJ Doc_783197_1550_1556_Chemical) (NN consumption)))) (VP (VBD occurred) (PP (IN after) (NP (NNP Doc_783197_1584_1591_Chemical) (NN administration))))) (CC but) (S (NP (DT this)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT a) (JJR greater) (NN decrease)) (PP (IN in) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN in) (NP (DT the) (JJ Doc_783197_1686_1693_Chemical) (NNS patients)))))))) (PP (IN than) (PP (IN in) (NP (DT the) (NN control) (NNS patients))))))) (. .)))
783197	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_783197_1775_1798_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (RB not) (PP (IN in) (NP (JJ clinical) (NNP Doc_783197_1823_1847_Disease) (NNP Doc_783197_1848_1891_Disease))) (PP (IN after) (NP (NNP Doc_783197_1898_1905_Chemical) (NN administration))) (SBAR (RB even) (WHADVP (WRB when)) (S (NP (PRP it)) (VP (AUX is) (ADVP (RB initially)) (ADJP (JJ normal))))))))))) (. .)))
783197	11	(S1 (S (SBAR (IN Though) (S (NP (DT this) (NN fall)) (VP (VP (MD would) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN wall) (NN tension)))))))) (, ,) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (PP (IN of) (NP (JJ myocardial) (JJ Doc_783197_2055_2061_Chemical) (NN consumption)))))) (, ,) (NP (PRP it)) (VP (MD may) (RB not) (VP (AUX be) (PP (IN of) (NP (JJ sufficient) (NN magnitude))) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT a) (JJ net) (NN increase)) (PP (IN in) (NP (JJ myocardial) (JJ Doc_783197_2153_2159_Chemical) (NN consumption))))))))) (. .)))
783197	12	(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (JJ compensatory) (NNS mechanisms)) (VP (VBP prevent) (NP (NP (DT a) (NN deterioration)) (PP (IN of) (NP (JJ resting) (JJ myocardial) (NN metabolism))))) (. .)))
7843916	0	(S1 (NP (NP (JJ Doc_7843916_0_13_Chemical-induced) (NN Doc_7843916_22_41_Disease)) (PP (IN in) (NP (JJ perfusion-cultured) (JJ human) (NNS eyes))) (. .)))
7843916	1	(S1 (S (NP (JJ Glucocorticoid) (NN administration)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_7843916_146_165_Disease)) (CC and) (NP (NNP Doc_7843916_170_193_Disease)))) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (DT the) (NN population)) (PP (IN through) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (JJ aqueous) (NN humor) (NN outflow) (NN facility))))))))))))) (. .)))
7843916	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (JJ glucocorticoid) (NN treatment)) (VP (MD can) (ADVP (RB directly)) (VP (VB affect) (NP (NP (DT the) (NN outflow) (NN facility)) (PP (IN of) (NP (JJ isolated) (, ,) (JJ perfusion-cultured) (JJ human) (NNS eyes)))))))))))) (. .)))
7843916	3	(S1 (S (NP (NP (DT The) (NNP anterior) (NNS segments)) (PP (IN of) (NP (NP (JJ human) (NN donor) (NNS eyes)) (PP (IN from) (NP (JJ regional) (NN eye) (NNS banks)))))) (VP (AUX were) (VP (VBN placed) (PP (IN in) (NP (DT a) (JJ constant) (NN flow) (, ,) (JJ variable) (NN pressure) (NN perfusion) (NN culture) (NN system))))) (. .)))
7843916	4	(S1 (S (NP (VBN Paired) (NNS eyes)) (VP (AUX were) (VP (VBN perfused) (PP (IN in) (NP (NP (JJ serum-free) (NNS media)) (PP (IN with) (NP (QP (CC or) (IN without) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN -7)) (-RRB- -RRB-)) (NNP M) (NNP Doc_7843916_665_678_Chemical))))) (PP (IN for) (NP (CD 12) (NNS days))))) (. .)))
7843916	5	(S1 (S (NP (JJ Intraocular) (NN pressure)) (VP (AUX was) (VP (VBN monitored) (ADVP (RB daily)))) (. .)))
7843916	6	(S1 (S (PP (IN After) (NP (NN incubation))) (, ,) (NP (DT the) (NNS eyes)) (VP (AUX were) (RB morphologically) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ light) (NN microscopy)) (, ,) (NP (NN transmission) (CC and) (VBG scanning) (NNP electron) (NN microscopy)) (, ,) (CC and) (NP (VBG scanning) (NN laser) (JJ confocal) (NN microscopy)))))) (. .)))
7843916	7	(S1 (S (NP (NP (DT A) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ intraocular) (NN pressure)) (VP (VBN developed) (PP (IN in) (NP (NP (CD 13)) (PP (IN of) (NP (NP (DT the) (CD 44) (NNS pairs)) (PP (IN of) (NP (NNS eyes))))))))))) (VP (VBD perfused) (PP (IN with) (NP (NNP Doc_7843916_1014_1027_Chemical))) (PP (IN with) (NP (NP (DT an) (JJ average) (NN pressure) (NN rise)) (PP (IN of) (NP (CD 17.5) (NN +/-))) (NP (CD 3.8) (NN mm)))) (NP (NNP Hg)) (PP (IN after) (NP (NP (CD 12) (NNS days)) (PP (IN of) (NP (NNP Doc_7843916_1097_1110_Chemical) (NN exposure)))))) (. .)))
7843916	8	(S1 (S (NP (NP (DT The) (JJ contralateral) (NN control) (NNS eyes)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX did) (RB not) (VP (VB receive) (NP (NN Doc_7843916_1175_1188_Chemical)))))) (, ,)) (VP (VBD maintained) (NP (DT a) (JJ stable) (NN intraocular) (NN pressure)) (PP (IN during) (NP (DT the) (JJ same) (NN period)))) (. .)))
7843916	9	(S1 (S (NP (NP (DT The) (NN outflow) (NN pathway)) (PP (IN of) (NP (DT the) (JJ untreated) (NNS eyes)))) (VP (VBD appeared) (ADJP (RB morphologically) (JJ normal))) (. .)))
7843916	10	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT the) (JJ Doc_7843916_1347_1360_Chemical-treated) (NNP Doc_7843916_1369_1386_Disease)) (VP (AUX had) (NP (NP (JJ thickened) (NN trabecular) (VBZ beams)) (, ,) (VP (VP (VBN decreased) (NP (NN intertrabecular) (NNS spaces))) (, ,) (VP (VBN thickened) (NP (JJ juxtacanalicular) (NN tissue))) (, ,) (VP (VBN activated) (NP (JJ trabecular) (NN meshwork) (NNS cells))) (, ,) (CC and) (VP (VBN increased) (NP (NP (NNS amounts)) (PP (IN of) (NP (JJ amorphogranular) (JJ extracellular) (NN material)))))) (, ,) (PP (RB especially) (PP (IN in) (NP (DT the) (JJ juxtacanalicular) (NN tissue))) (CC and) (PP (IN beneath) (NP (NP (DT the) (JJ endothelial) (NN lining)) (PP (IN of) (NP (NP (DT the) (NN canal)) (PP (IN of) (NP (NNP Schlemm)))))))))) (. .)))
7843916	11	(S1 (S (NP (DT The) (JJ Doc_7843916_1696_1709_Chemical-treated) (NN nonresponder) (NNS eyes)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (RB morphologically) (JJ similar) (PP (TO to) (NP (DT the) (JJ untreated) (NNS eyes))))))) (, ,) (SBAR (IN although) (S (NP (JJ several) (JJ subtle) (JJ Doc_7843916_1822_1835_Chemical-induced) (NN morphologic) (NNS changes)) (VP (AUX were) (ADJP (JJ evident)))))) (. .)))
7843916	12	(S1 (S (NP (NP (JJ Doc_7843916_1890_1903_Chemical) (NN treatment)) (PP (IN of) (NP (JJ isolated) (, ,) (JJ perfusion-cultured) (JJ human) (NNS eyes)))) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NNP Doc_7843916_1982_2001_Disease))))) (PP (IN in) (NP (NP (QP (RB approximately) (CD 30)) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_7843916_2030_2043_Chemical-treated) (NNS eyes)))))) (. .)))
7843916	13	(S1 (S (NP (JJ Doc_7843916_2058_2065_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ morphologic) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ trabecular) (NN meshwork)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN reported) (PP (IN for) (NP (NP (NNP Doc_7843916_2165_2188_Disease)) (CC and) (NP (NNP Doc_7843916_2193_2212_Disease))))))))))))) (. .)))
7843916	14	(S1 (S (NP (DT This) (NN system)) (VP (MD may) (VP (VB provide) (NP (NP (DT an) (JJ acute) (NN model)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ pathogenic) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_7843916_2309_2325_Disease)) (CC and) (NP (NNP Doc_7843916_2330_2357_Disease))))))))))))) (. .)))
7880714	0	(S1 (S (NP (JJ Auditory) (NN disturbance)) (VP (VBN associated) (PP (IN with) (NP (JJ interscalene) (JJ brachial) (NN plexus) (NN block)))) (. .)))
7880714	1	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT an) (JJ audiometric) (NN study)) (PP (IN in) (NP (NP (CD 20) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (NN surgery)) (PP (IN of) (NP (DT the) (NN shoulder) (NN region)))) (PP (IN under) (NP (NP (DT an) (JJ interscalene) (JJ brachial) (NN plexus) (NN block)) (PRN (-LRB- -LRB-) (NP (NNP IBPB)) (-RRB- -RRB-))))))))))) (. .)))
7880714	2	(S1 (S (NP (NP (NN Doc_7880714_219_230_Chemical) (CD 0.75) (NN %)) (PP (IN with) (NP (NNP Doc_7880714_242_252_Chemical)))) (VP (AUX was) (VP (VBN given) (PP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ 24-hr) (JJ continuous) (NN infusion)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_7880714_312_323_Chemical)))))))) (. .)))
7880714	3	(S1 (S (NP (NP (CD Three) (JJ audiometric) (NN threshold) (NNS measurements)) (PRN (-LRB- -LRB-) (NP (CD 0.25-18) (NN kHz)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN made) (: :) (NP (NP (NP (DT the) (JJ first)) (PP (IN before) (NP (NP (NNP IBPB)) (, ,) (NP (NP (NP (DT the) (JJ second) (NN 2-6)) (NP (NNP h))) (PP (IN after) (NP (NN surgery))))))) (CC and) (NP (NP (DT the) (JJ third)) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN after) (NP (NN operation))))))))) (. .)))
7880714	4	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (NP (NP (NNP Doc_7880714_510_528_Disease)) (PP (IN on) (NP (NP (DT the) (NN side)) (PP (IN of) (NP (DT the) (NN block)))))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN after) (NP (NN operation))) (, ,) (PP (PP (IN in) (NP (CD three) (NNS measurements))) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of) (NP (NN surgery))))) (CC and) (PP (IN in) (NP (NP (CD one)) (PP (IN on) (NP (DT the) (JJ following) (NN day)))))))) (. .)))
7880714	5	(S1 (S (NP (NP (DT The) (NNS frequencies)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (DT the) (NN impairment)) (VP (VBD occurred) (VP (VBN varied) (PP (IN between) (NP (NNS patients)))))))) (: ;) (PP (IN in) (NP (CD one))) (NP (NP (RB only) (JJ low) (NNS frequencies)) (PRN (-LRB- -LRB-) (NP (CD 0.25-0.5) (NNS kHz)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN involved))) (. .)))
7880714	6	(S1 (S (NP (NP (DT The) (NN maximum) (NN change)) (PP (IN in) (NP (NN threshold)))) (VP (AUX was) (NP (CD 35) (NN dB)) (PP (IN at) (NP (NP (CD 6) (NN kHz)) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_7880714_898_909_Chemical))))))))))) (. .)))
7880714	7	(S1 (S (NP (DT This) (NN patient)) (VP (AUX had) (NP (NP (NN hearing) (NN threshold) (NNS changes)) (PRN (-LRB- -LRB-) (NP (CD 15-20) (NNS dB)) (-RRB- -RRB-))) (PP (IN at) (NP (NP (JJ 6-10) (NNS kHz)) (PP (IN on) (NP (DT the) (JJ opposite) (NN side))))) (ADVP (RB also))) (. .)))
7880714	8	(S1 (S (NP (NNS IBPB)) (VP (MD may) (VP (VB cause) (NP (JJ transient) (NN Doc_7880714_1029_1049_Disease)) (PP (IN in) (NP (DT the) (JJ ipsilateral) (NN ear))) (, ,) (PP (ADVP (RB possibly)) (IN via) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (JJ sympathetic) (NN innervation))))))) (. .)))
7905523	0	(S1 (S (NP (NP (DT The) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (NP (NN combination) (NNP Doc_7905523_39_63_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7905523_65_73_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7905523_79_89_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_7905523_107_122_Disease)) (CC and) (NP (CD 200-500) (NNS CD4))))))) (VP (VBZ cells/mm3)) (. .)))
7905523	1	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (NN phase) (NNP II) (NN study)) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN safety) (CC and) (NN activity)) (PP (IN of) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_7905523_269_293_Chemical) (-LRB- -LRB-) (NNP Doc_7905523_295_303_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (DT an) (JJ alpha-glucosidase) (NN I) (NN inhibitor)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7905523_344_354_Chemical) (CC versus) (NNP Doc_7905523_362_372_Chemical)) (ADVP (RB alone)))))))))))))) (. .)))
7905523	2	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NP (QP (CD 200) (TO to) (CD 500)) (JJ CD4) (NNS cells/mm3)) (SBAR (WHNP (WP who)) (S (VP (VBD tolerated) (NP (CD <)))))) (CC or) (NP (NP (NP (SYM =)) (NP (CD 12) (NNS weeks))) (PP (IN of) (NP (JJ prior) (JJ Doc_7905523_458_468_Chemical) (NN therapy))))))) (VP (VBD received) (NP (NP (NP (NP (NP (NNP Doc_7905523_486_494_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNP h))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7905523_519_529_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CD mg)) (DT every) (CD 8) (NNP h)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_7905523_552_562_Chemical)) (CC and) (NP (NN placebo))))) (. .)))
7905523	3	(S1 (S (NP (CD Sixty) (NNS patients)) (VP (VBD received) (NP (NP (NN combination) (NN therapy)) (CC and) (NP (NP (CD 58)) (, ,) (NP (NP (NN Doc_7905523_628_638_Chemical)) (CC and) (NP (NN placebo)))))) (. .)))
7905523	4	(S1 (S (NP (NP (NP (JJ Twenty-three) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_717_727_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBN discontinued) (NP (NP (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.15)) (-RRB- -RRB-)))) (. .)))
7905523	5	(S1 (S (NP (NP (DT The) (JJ mean) (JJ Doc_7905523_792_800_Chemical) (JJ steady-state) (NN trough) (NN level)) (PRN (-LRB- -LRB-) (NP (NP (CD 4.04) (NN +/-)) (NP (CD 0.99) (NNS micrograms/ml))) (-RRB- -RRB-))) (VP (AUX was) (PP (IN below) (NP (NP (DT the) (ADJP (IN in) (NN vitro)) (NN inhibitory) (NN concentration)) (PP (IN for) (NP (NP (JJ human) (JJ Doc_7905523_915_931_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HIV)) (-RRB- -RRB-))))))) (. .)))
7905523	6	(S1 (S (NP (NP (DT The) (JJ mean) (NN increase)) (PP (IN in) (NP (NP (JJ CD4) (NNS cells)) (PP (IN at) (NP (NN week) (CD 4)))))) (VP (AUX was) (NP (NP (QP (CD 73.8) (NN cells/mm3) (CC and) (CD 52.4) (CD cells/mm3))) (PP (IN for) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_1048_1058_Chemical) (NNS groups))))) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD >)) (CD 0.36)) (-RRB- -RRB-))) (. .)))
7905523	7	(S1 (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ prior) (JJ Doc_7905523_1116_1126_Chemical) (NN therapy))))) (, ,) (NP (NP (DT the) (JJ mean) (NN change)) (PP (IN in) (NP (JJ CD4) (NNS cells))) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_1188_1198_Chemical) (NNS groups))))) (VP (AUX was) (NP (NP (CD 63.7) (NN cells/mm3)) (CC and) (NP (NP (CD 4.9) (NN cells/mm3)) (PP (IN at) (NP (NN week))) (NP (QP (CD 8) (CC and) (CD 6.8) (NN cells/mm3) (CC and) (CD -45.1) (NN cells/mm3))))) (PP (IN at) (NP (NN week) (CD 16))) (, ,) (ADVP (RB respectively))) (. .)))
7905523	8	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNS patients)))) (VP (PP (IN with) (NP (NN suppression))) (SBAR (IN of) (S (NP (NNP HIV) (CD p24) (NN antigenemia)) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (NNP Doc_7905523_1403_1413_Chemical) (NNS groups)))) (VP (AUX was) (NP (NP (NP (NP (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN %)) (-RRB- -RRB-)))) (PP (IN at) (NP (NN week) (CD 4)))) (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.10)) (-RRB- -RRB-)) (CC and) (NP (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (NN week) (CD 24)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.08)) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively)))))) (. .)))
7905523	9	(S1 (S (NP (NP (NNP Doc_7905523_1536_1544_Disease)) (, ,) (NP (NNP Doc_7905523_1546_1556_Disease)) (, ,) (NP (NNP Doc_7905523_1558_1572_Disease)) (, ,) (CC and) (NP (NNP Doc_7905523_1578_1589_Disease))) (VP (AUX were) (ADJP (JJ common) (PP (IN for) (NP (NN combination) (NN recipients.)))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
7910951	0	(S1 (S (VP (VBN Prolonged) (NP (NNP Doc_7910951_10_19_Disease)) (PP (JJ due) (TO to) (NP (NP (NNP Doc_7910951_27_72_Chemical)) (CC and) (NP (NNP Doc_7910951_77_92_Chemical))))) (. .)))
7910951	1	(S1 (S (S (NP (NP (DT The) (JJ long-term) (NN use)) (PP (IN of) (NP (NP (NNP Doc_7910951_115_160_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7910951_162_169_Chemical)) (-RRB- -RRB-))))) (VP (AUX has) (ADVP (RB recently)) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (JJ prolonged) (NNP Doc_7910951_224_239_Disease))))) (, ,) (PP (IN although) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (DT the) (NN lesion))))))))) (CC and) (S (NP (DT the) (JJ predisposing) (NNS factors)) (VP (AUX have) (VP (AUX been) (ADJP (JJ unclear))))) (. .)))
7910951	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN age)) (NP (CD 37-52) (NNS years))) (-RRB- -RRB-))) (PP (IN with) (NP (JJ acute) (NNP Doc_7910951_371_396_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ prolonged) (NN Doc_7910951_421_429_Disease)) (PP (VBG following) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (NNP Doc_7910951_463_471_Chemical)))))))))) (. .)))
7910951	3	(S1 (S (NP (CD Two) (NNS patients)) (ADVP (RB also)) (VP (VBD received) (NP (JJ intravenous) (NNP Doc_7910951_512_527_Chemical))) (. .)))
7910951	4	(S1 (S (S (NP (JJ Renal) (NN function)) (VP (AUX was) (ADJP (JJ normal)))) (CC but) (S (NP (JJ hepatic) (NN function)) (VP (AUX was) (VP (VBN impaired) (PP (IN in) (NP (DT all) (NNS patients)))))) (, ,) (CC and) (S (NP (DT all)) (VP (AUX had) (NP (NN Doc_7910951_618_626_Disease)))) (. .)))
7910951	5	(S1 (S (NP (JJ Electrophysiologic) (NNS studies)) (VP (VBD revealed) (NP (NP (JJ low) (JJ amplitude) (NN compound) (NN motor) (NN action) (NNS potentials)) (, ,) (NP (JJ normal) (JJ sensory) (NNS studies)) (, ,) (CC and) (NP (NNS fibrillations)))) (. .)))
7910951	6	(S1 (S (NP (NP (JJ Repetitive) (NN stimulation)) (PP (IN at) (NP (CD 2) (NN Hz)))) (VP (VBD showed) (NP (DT a) (JJ decremental) (NN response)) (PP (IN in) (NP (CD 2) (NNS patients)))) (. .)))
7910951	7	(S1 (S (NP (NP (DT The) (NN serum) (JJ Doc_7910951_841_851_Chemical) (NN level)) (VP (VBN measured) (PP (IN in) (NP (CD 1) (NN patient))) (SBAR (NP (CD 14) (NNS days)) (IN after) (S (NP (DT the) (NN drug)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued)))))))) (VP (AUX was) (NP (CD 172) (NN ng/mL))) (. .)))
7910951	8	(S1 (S (NP (NP (DT A) (NN muscle) (NN biopsy)) (PP (IN in) (NP (DT this) (NN patient)))) (VP (VBD showed) (NP (NN Doc_7910951_979_1010_Disease))) (. .)))
7910951	9	(S1 (S (NP (NP (DT The) (NN Doc_7910951_1016_1024_Disease)) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX is) (ADJP (ADJP (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1053_1097_Disease)))) (PRN (-LRB- -LRB-) (ADVP (RBS most) (RB likely)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1118_1125_Chemical)))) (-RRB- -RRB-)) (CC and) (NN muscle)) (PRN (-LRB- -LRB-) (ADVP (RBS most) (RB likely)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1158_1173_Chemical)))) (-RRB- -RRB-)))) (. .)))
7910951	10	(S1 (S (NP (NP (NN Doc_7910951_1176_1195_Disease)) (CC and) (NP (NN Doc_7910951_1200_1208_Disease))) (VP (AUX are) (NP (JJ contributing) (NN risk) (NNS factors))) (. .)))
8012887	0	(S1 (NP (NP (NN Failure)) (PP (IN of) (NP (NN ancrod))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_8012887_38_45_Chemical-induced) (JJ arterial) (NN Doc_8012887_63_73_Disease))))) (. .)))
8012887	1	(S1 (S (NP (NP (DT The) (NN morbidity) (CC and) (NN mortality)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8012887_119_126_Chemical-induced) (NNP Doc_8012887_135_145_Disease))))) (VP (VBP remain) (ADJP (JJ high)) (PP (IN despite) (NP (JJ numerous) (JJ empirical) (NNS therapies)))) (. .)))
8012887	2	(S1 (S (S (NP (NNP Ancrod)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (ADVP (RB successfully)) (PP (IN for) (NP (NN prophylaxis))) (PP (IN against) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_8012887_269_279_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8012887_297_304_Chemical) (VBN induced) (NN Doc_8012887_313_333_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (JJ brief) (NN reexposure)) (PP (TO to) (NP (NNP Doc_8012887_366_373_Chemical)))))))))))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN success)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN developed) (NP (DT the) (NNP Doc_8012887_426_436_Disease) (NN syndrome))))))))) (VP (AUX is) (RB not) (VP (ADVP (RB well)) (VBN defined)))) (. .)))
8012887	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NN failure)) (PP (IN of) (NP (NN ancrod) (NN treatment)))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8012887_543_550_Chemical-induced) (NNP Doc_8012887_559_569_Disease)))))) (. .)))
803783	0	(S1 (S (NP (NN Doc_803783_0_18_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_803783_35_43_Chemical) (NN administration))) (PP (IN during) (NP (JJ saline-induced) (NN Doc_803783_81_89_Disease)))) (. .)))
803783	1	(S1 (S (NP (NP (CD Four) (NNS cases)) (PP (IN of) (NP (NNP Doc_803783_105_123_Disease))) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NNP Doc_803783_143_151_Chemical) (NN administration))))) (PP (IN during) (NP (JJ saline-induced) (NN Doc_803783_189_198_Disease)))) (VP (AUX are) (VP (VBN described))) (. .)))
803783	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_803783_231_249_Disease)))) (VP (AUX is) (VP (VBN discussed) (PP (IN in) (NP (NP (NN regard)) (PP (TO to) (NP (DT these) (NNS cases))))))) (. .)))
803783	3	(S1 (S (NP (NP (JJ Doc_803783_289_297_Chemical) (NN administration)) (PP (IN during) (NP (JJ midtrimester-induced) (NNP Doc_803783_341_350_Disease)))) (VP (AUX is) (VP (VBN advocated) (SBAR (RB only) (IN if) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VP (VBN carried) (PRT (RP out)) (PP (IN under) (NP (NP (JJ careful) (NNS observations)) (PP (IN of) (NP (DT an) (JJ alert) (NN nursing) (NN staff))))) (, ,) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_803783_473_491_Disease))))))) (CC and) (VP (VBN instructed) (S (VP (TO to) (VP (VP (VB watch) (NP (DT the) (NN diuresis))) (CC and) (VP (VB report) (NP (NP (JJ such) (JJ early) (NNS signs)) (PP (IN of) (NP (DT the) (NN syndrome)))))))) (PP (IN as) (NP (NP (NNP Doc_803783_576_584_Disease)) (, ,) (NP (JJ muscular) (NNP Doc_803783_595_607_Disease)) (, ,) (CC or) (NP (NNP Doc_803783_612_621_Disease)))))))))))) (. .)))
803783	4	(S1 (S (NP (DT The) (NNP Doc_803783_627_635_Chemical)) (VP (MD should) (VP (VP (AUX be) (VP (VBN given) (ADVP (RB only)) (PP (IN in) (NP (NNP Ringers) (NNP Doc_803783_668_675_Chemical))))) (CC or) (, ,) (ADVP (RB alternately)) (, ,) (PP (IN in) (NP (NP (NNP Ringers) (NNP Doc_803783_704_711_Chemical)) (CC and) (NP (NP (DT a) (CD 5)) (PP (IN per) (NP (NP (NN cent) (NN Doc_803783_729_737_Chemical)) (CC and) (NP (NN water) (NNS solutions))))))))) (. .)))
803783	5	(S1 (S (S (NP (DT The) (JJ urinary) (NN output)) (VP (MD should) (VP (AUX be) (VP (VBN monitored))))) (CC and) (S (NP (NP (DT the) (NNP Doc_803783_806_814_Chemical) (NN administration) (VBN discontinued)) (CC and) (NP (DT the) (JJ serum) (NNS electrolytes))) (VP (VBD checked) (SBAR (IN if) (S (NP (DT the) (JJ urinary) (NN output)) (VP (VBZ decreases)))))) (. .)))
803783	6	(S1 (S (NP (DT The) (NNP Doc_803783_915_923_Chemical)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN administered) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (CD 36) (NNS hours)))))))) (. .)))
803783	7	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN patient)) (VP (AUX has) (RB not) (VP (VBN aborted) (PP (IN by) (NP (RB then))))))) (NP (DT the) (NNP Doc_803783_1017_1025_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN discontinued) (PP (IN for) (NP (QP (CD 10) (TO to) (CD 12)) (NNS hours))) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VP (VB perform) (NP (NN electrolyte) (NNS determinations))) (CC and) (VP (VB correct) (NP (DT any) (JJ electrolyte) (NN imbalance))))))))) (. .)))
804391	0	(S1 (S (NP (NP (NP (JJ Light) (NN chain) (NN Doc_804391_12_23_Disease)) (CC and) (NP (JJ cellular) (JJ mediated) (NN immunity))) (PP (IN in) (NP (NNP Doc_804391_58_66_Chemical)))) (VP (VBD treated) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_804391_89_101_Disease))))) (. .)))
804391	1	(S1 (S (NP (JJ Light) (NN chain) (NN Doc_804391_115_126_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (QP (CD 9) (IN of) (CD 17)) (JJ Doc_804391_148_160_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_804391_183_191_Chemical)))))))) (. .)))
804391	2	(S1 (S (NP (NP (NP (JJ Concomitant) (NN assay)) (PP (IN of) (NP (NP (JJ cellular) (JJ mediated) (NN immunity)) (PP (IN in) (NP (NP (DT these) (NNS patients)) (VP (VBG using) (NP (NN skin) (NN test) (NN antigen)))))))) (CC and) (NP (NP (DT a) (NN lymphokine)) (PP (IN in) (NP (NN vitro) (NN test))))) (VP (VBD provided) (NP (NP (NNS results)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ different))))))) (. .)))
804391	3	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (NNP Varidase) (NN skin) (NN test) (NN antigen)))) (VP (AUX was) (ADJP (JJ negative) (SBAR (IN for) (S (S (NP (DT all) (CD eight) (NNP Doc_804391_418_430_Disease) (NNS patients)) (VP (VBN tested))) (, ,) (CC but) (S (NP (EX there)) (VP (VBN occurred) (NP (NP (DT a) (NN hyper-responsiveness)) (PP (IN of) (NP (NP (DT the) (NNS lymphocytes)) (PP (IN of) (NP (DT these) (CD eight) (NNS patients)))))) (S (VP (TO to) (VP (VB phytomitogen) (PRN (-LRB- -LRB-) (NP (NN PHA-P)) (-RRB- -RRB-))))))) (. .))) (RB as) (PP (ADVP (RB well)) (IN as) (IN of) (NP (NP (DT those)) (PP (IN of) (NP (CD seven) (JJ other) (NNP Doc_804391_593_604_Disease) (NNS patients))))))) (. .)))
804391	4	(S1 (S (NP (DT This) (JJ last) (NN finding)) (VP (MD may) (VP (AUX be) (ADJP (VBN related) (PP (TO to) (NP (NP (NN time)) (PP (IN of) (S (VP (VBG testing) (NP (NP (NN and/or) (JJ endogenous) (NN serum) (VBG binding)) (PP (IN of) (NP (NNP Doc_804391_702_710_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (VP (VBD inhibited) (NP (CD mitogen) (NN activity)) (PP (IN for) (NP (DT the) (NN lymphocyte))))))))))))))))) (. .)))
8045270	0	(S1 (NP (NP (NN Doc_8045270_0_7_Chemical)) (: :) (NP (NP (DT a) (JJ novel) (JJ selective) (NNP Doc_8045270_27_36_Chemical) (NNP A2A) (NN receptor) (NN antagonist)) (PP (IN with) (NP (JJ anticataleptic) (NN activity)))) (. .)))
8045270	1	(S1 (S (NP (NN Doc_8045270_91_98_Chemical)) (VP (AUX is) (NP (DT a) (JJ novel) (JJ selective) (NNP Doc_8045270_120_129_Chemical) (NNP A2A) (NN receptor) (NN antagonist))) (. .)))
8045270	2	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_8045270_178_185_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (, ,) (CD 10.0) (CC and) (CD 30.0) (NN mg/kg)) (-RRB- -RRB-))))) (ADVP (RB significantly)) (VP (VBD ameliorated) (NP (NP (DT the) (JJ Doc_8045270_243_253_Disease) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN intracerebroventricular) (NN administration)) (PP (IN of) (NP (NP (DT an) (NNP Doc_8045270_320_329_Chemical) (NNP A2A) (NN receptor) (NN agonist)) (, ,) (NP (NP (NNP Doc_8045270_352_361_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS micrograms)) (-RRB- -RRB-))) (, ,))))))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
8045270	3	(S1 (S (NP (NN Doc_8045270_407_414_Chemical)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (DT the) (NN Doc_8045270_432_441_Disease)) (VP (VBN induced) (PP (PP (IN by) (NP (NP (NNP Doc_8045270_453_464_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (NNP Doc_8045270_487_496_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))))))) (. .)))
8045270	4	(S1 (S (NP (DT These) (JJ anticataleptic) (NNS effects)) (VP (AUX were) (VP (VBN exhibited) (S (VP (NN dose) (ADVP (RB dependently)) (PP (IN at) (NP (NNS doses))) (PP (IN from) (NP (QP (CD 0.625) (CC and) (CD 2.5) (CD mg/kg)) (NNS p.o.))) (, ,) (ADVP (RB respectively)))))) (. .)))
8045270	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NNP Doc_8045270_638_645_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.625) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-))) (VP (VBD potentiated) (NP (NP (DT the) (JJ anticataleptic) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ subthreshold) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_8045270_730_758_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8045270_760_766_Chemical)) (: ;) (NP (CD 25) (JJ mg/kg) (NNS i.p.))) (-RRB- -RRB-))) (CC plus) (NP (NP (NNP Doc_8045270_788_799_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 6.25) (JJ mg/kg) (NNS i.p.)) (-RRB- -RRB-))))))))) (. .)))
8045270	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBD suggested) (SBAR (SBAR (IN that) (S (NP (NNP Doc_8045270_848_855_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (RB centrally) (JJ active)) (NNP Doc_8045270_878_887_Chemical) (NNP A2A) (NN receptor) (NN antagonist))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJ dopaminergic) (NN function)) (PP (IN of) (NP (DT the) (JJ nigrostriatal) (NN pathway)))) (VP (AUX is) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_8045270_994_1003_Chemical) (NNP A2A) (NN receptor) (NNS antagonists))))))))) (. .)))
8045270	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_8045270_1043_1050_Chemical)) (VP (MD may) (VP (AUX be) (NP (DT a) (JJ useful) (NN drug)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8045270_1092_1104_Disease))))))) (. .)))
8106150	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ nondopaminergic) (NNS drugs))) (PP (IN on) (NP (NP (NNP Doc_8106150_35_41_Chemical-induced) (NNP Doc_8106150_50_61_Disease)) (PP (IN in) (NP (JJ Doc_8106150_65_69_Chemical-treated) (NNS monkeys))))) (. .)))
8106150	1	(S1 (S (NP (NP (DT A) (NN group)) (PP (IN of) (NP (CD four) (NNS monkeys)))) (VP (AUX was) (VP (VBN rendered) (NP (NNP Doc_8106150_124_136_Disease)) (PP (IN with) (NP (DT the) (NN toxin) (NN Doc_8106150_152_156_Chemical))))) (. .)))
8106150	2	(S1 (S (NP (PRP They)) (VP (AUX were) (ADVP (RB then)) (VP (VBN treated) (ADVP (RB chronically)) (PP (IN with) (NP (NNP Doc_8106150_198_216_Chemical) (CD 50/12.5))) (SBAR (IN mg/kg) (S (VP (VBN given) (ADVP (RB orally) (RB daily)) (PP (IN for) (NP (CD 2) (NNS months)))))))) (. .)))
8106150	3	(S1 (S (S (NP (DT This) (NN dose)) (VP (VBD produced) (NP (DT a) (JJ striking) (NN antiparkinsonian) (NN effect)))) (, ,) (CC but) (S (NP (DT all) (NNS animals)) (VP (VBD manifested) (NP (NN Doc_8106150_346_356_Disease)))) (. .)))
8106150	4	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NP (NNS agents)) (VP (VBG acting) (ADVP (RB primarily)) (PP (IN on) (NP (NP (NNS neurotransmitters)) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_8106150_426_434_Chemical)))))))))) (VP (AUX were) (ADVP (RB then)) (VP (VBN tested) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_8106150_472_478_Chemical))) (S (VP (TO to) (VP (VB see) (SBAR (IN if) (S (NP (DT the) (NNP Doc_8106150_493_503_Disease) (NNS movements)) (VP (MD would) (VP (AUX be) (VP (VBN modified))))))))))) (. .)))
8106150	5	(S1 (S (NP (NP (JJ Several) (NNS drugs)) (, ,) (PP (VBG including) (NP (NNP Doc_8106150_558_567_Chemical) (, ,) (NNP Doc_8106150_569_582_Chemical) (, ,) (NNP Doc_8106150_584_596_Chemical) (, ,) (NNP Doc_8106150_598_604_Chemical) (, ,) (NNP Doc_8106150_606_617_Chemical) (, ,) (CC and) (NNP Doc_8106150_623_629_Chemical))) (, ,)) (VP (VP (ADVP (RB markedly)) (VBD reduced) (NP (DT the) (JJ Doc_8106150_652_662_Disease) (NNS movements))) (CC but) (VP (PP (IN at) (NP (NP (DT the) (NN cost)) (PP (IN of) (NP (NP (DT a) (NN return)) (PP (IN of) (NP (JJ Doc_8106150_704_716_Disease) (NN symptomatology))))))))) (. .)))
8106150	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNP Doc_8106150_742_751_Chemical)) (CC and) (NP (NNP Doc_8106150_756_766_Chemical))) (VP (VBD reduced) (ADVP (RB predominantly)) (NP (DT the) (JJ Doc_8106150_793_803_Disease) (NNS movements))) (. .)))
8106150	7	(S1 (S (NP (NN Doc_8106150_815_823_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ useful)) (PP (IN in) (NP (NP (CD one) (NN monkey)) (PP (IN against) (NP (NP (DT a) (ADJP (RBR more) (JJ Doc_8106150_869_877_Disease)) (NN form)) (PP (IN of) (NP (NNP Doc_8106150_886_896_Disease)))))))) (. .)))
8106150	8	(S1 (S (NP (NN Doc_8106150_898_906_Chemical)) (VP (VBD converted) (NP (DT the) (JJ Doc_8106150_921_929_Disease) (NNS movements)) (PP (IN into) (NP (NN Doc_8106150_945_951_Disease)))) (. .)))
8111719	0	(S1 (NP (NNP Doc_8111719_0_14_Disease) (CC and) (NNP Doc_8111719_19_29_Chemical-induced) (NNP Doc_8111719_38_51_Disease) (. .)))
8111719	1	(S1 (S (NP (NP (NN Doc_8111719_65_79_Disease)) (PP (IN as) (NP (NP (DT a) (NN symptom)) (PP (IN of) (NP (JJ central) (NNP Doc_8111719_104_117_Disease)))))) (VP (AUX are) (NP (NP (DT a) (ADJP (ADJP (VBN known)) (CC but) (ADJP (RB poorly) (VBN described))) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_8111719_166_176_Chemical))))) (. .)))
8111719	2	(S1 (S (NP (NP (JJS Most) (NNS cases)) (PP (IN of) (NP (NNP Doc_8111719_192_202_Chemical-induced) (NNP Doc_8111719_211_225_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (JJ other) (JJ mental) (NN status) (NNS changes)))))) (. .)))
8111719	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VBD interviewed) (NP (CD six) (NNS persons)) (PP (IN with) (NP (NNP Doc_8111719_329_339_Chemical-induced) (NNP Doc_8111719_348_362_Disease))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ clear) (NN sensorium)))))) (. .)))
8111719	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (S (VP (VBG receiving) (NP (JJ high-dose) (NN Doc_8111719_439_449_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (PRP$ their) (NN bone) (NN marrow) (NN transplant) (NN procedure)))))))) (. .)))
8111719	5	(S1 (S (NP (NN Doc_8111719_510_524_Disease)) (VP (VBD occurred) (ADVP (RB only)) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN patient) (POS 's)) (NNS eyes)) (VP (VP (AUX were) (ADJP (JJ closed))) (CC and) (PRN (, ,) (PP (IN in) (NP (NP (DT all)) (PP (CC but) (NP (CD one) (NN case))))) (, ,)) (VP (AUX were) (VP (VBN reported) (PP (IN as) (ADJP (ADJP (JJ disturbing)) (CC or) (ADJP (JJ frightening)))))))))) (. .)))
8111719	6	(S1 (S (NP (NP (NN Underreporting)) (PP (IN of) (NP (DT these) (NNP Doc_8111719_669_683_Disease))) (PP (IN by) (NP (NNS patients)))) (VP (AUX is) (ADJP (JJ likely))) (. .)))
8111719	7	(S1 (S (NP (NN Doc_8111719_720_734_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ sole) (CC or) (JJ first) (NN manifestation)) (PP (IN of) (NP (NN Doc_8111719_777_790_Disease)))))) (. .)))
8111719	8	(S1 (S (NP (DT The) (NN incidence)) (VP (MD may) (VP (AUX be) (ADJP (NP (NP (NN dose)) (CC and) (NP (NN infusion-time))) (VBN related)))) (. .)))
8111719	9	(S1 (S (NP (DT The) (NN clinician)) (VP (MD should) (VP (AUX be) (VP (VBD alerted) (PP (IN for) (NP (NP (JJ possible) (JJ Doc_8111719_890_900_Chemical-induced) (NN Doc_8111719_909_923_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB occur) (SBAR (IN without) (S (NP (NP (JJ other) (NNS signs)) (PP (IN of) (NP (NNP Doc_8111719_964_977_Disease.) (`` ``) (NNP Eyes-closed) ('' '') (NNP Doc_8111719_993_1006_Disease) (NNS experiences)))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ unusual) (NN feature)) (PP (IN of) (NP (DT this) (NN presentation))))))))))))))))))) (. .)))
8111719	10	(S1 (S (NP (NP (NNS Patients)) (ADJP (JJ anxious) (PP (IN about) (NP (DT this) (NN experience))))) (VP (VB respond) (ADVP (RB well)) (PP (TO to) (NP (NP (NN support)) (CC and) (NP (NN education)))) (PP (IN about) (NP (DT this) (NN occurrence)))) (. .)))
8111719	11	(S1 (S (NP (NP (JJ Optimal) (JJ pharmacologic) (NN management)) (PP (IN of) (NP (JJ disturbed) (NNS patients)))) (VP (AUX is) (ADJP (JJ unclear))) (. .)))
8111719	12	(S1 (S (SBAR (IN If) (S (NP (NNP Doc_8111719_1243_1252_Disease)) (VP (VBZ becomes) (ADJP (JJ marked))))) (, ,) (NP (NP (JJ high-potency) (NNS neuroleptics)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_8111719_1302_1313_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)))) (. .)))
8251368	0	(S1 (FRAG (NP (JJ Photodistributed) (JJ Doc_8251368_17_27_Chemical-induced) (JJ facial) (NN Doc_8251368_43_57_Disease)) (. .)))
8251368	1	(S1 (S (PP (NP (CD Five) (NNS months)) (IN after) (S (VP (VBG starting) (NP (NP (NNP Doc_8251368_86_96_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8251368_98_104_Chemical)) (-RRB- -RRB-)))))) (, ,) (NP (CD two) (NNS patients)) (VP (VBD developed) (NP (NP (JJ photodistributed) (JJ facial) (NN Doc_8251368_154_168_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD became) (ADJP (RBR more) (JJ noticeable)) (PP (IN with) (NP (NN time)))))))) (. .)))
8251368	2	(S1 (S (NP (DT Neither) (NN patient)) (VP (VBD complained) (PP (IN of) (NP (NP (NN photosensitivity)) (CC or) (NP (NN Doc_8251368_260_268_Disease))))) (. .)))
8251368	3	(S1 (S (NP (DT Both) (NNS patients)) (VP (VBD reported) (NP (DT a) (JJ significant) (NN cosmetic) (NN improvement)) (PP (IN after) (S (VP (VBG discontinuing) (NP (DT the) (NN drug)))))) (. .)))
8251368	4	(S1 (S (NP (NN One)) (VP (VBD commenced) (NP (DT the) (ADJP (RB closely) (JJ related)) (NN drug) (NN Doc_8251368_397_407_Chemical)) (ADVP (NP (CD 3) (NNS years)) (RB later)) (, ,) (PP (IN with) (NP (NP (NN recurrence)) (PP (IN of) (NP (NNP Doc_8251368_442_456_Disease)))))) (. .)))
8251368	5	(S1 (S (NP (NP (DT The) (NN photodistribution)) (PP (IN of) (NP (DT the) (NNP Doc_8251368_487_501_Disease)))) (VP (VBZ suggests) (NP (DT a) (JJ significant) (NN drug/light) (NN interaction))) (. .)))
8267029	0	(S1 (S (VP (VBN Doc_8267029_0_13_Chemical-induced) (ADVP (RB rapidly)) (NP (JJ progressive) (NN Doc_8267029_42_60_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8267029_79_99_Disease)))))) (. .)))
8267029	1	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_8267029_126_146_Disease)))) (VP (VBD presented) (ADVP (RB rapidly)) (NP (NP (JJ progressive) (NNP Doc_8267029_177_195_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8267029_197_201_Disease)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (CD 5) (NNS months)) (PP (IN of) (NP (NNP Doc_8267029_221_236_Chemical) (PRN (-LRB- -LRB-) (NP (CD 250) (NN mg/day)) (-RRB- -RRB-)) (NN treatment)))))) (. .)))
8267029	2	(S1 (S (NP (JJ Light) (JJ microscopy) (NN study)) (VP (VBD showed) (NP (JJ severe) (NN Doc_8267029_298_316_Disease)) (PP (IN with) (NP (NN crescent) (NN formation))) (PP (IN in) (NP (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (DT the) (NNS glomeruli)))) (CC and) (NP (NP (NN infiltration)) (PP (IN of) (NP (JJ inflammatory) (NNS cells)))))) (PP (IN in) (NP (NP (DT the) (NN wall)) (PP (IN of) (NP (DT an) (NN arteriole)))))) (. .)))
8267029	3	(S1 (S (NP (NN Immunofluorescence)) (VP (VBD revealed) (NP (CD scanty) (JJ granular) (NNP IgG) (, ,) (NNP IgA) (CC and) (NNP C3) (NNS deposits)) (PP (IN along) (NP (NP (DT the) (JJ capillary) (NNS walls)) (CC and) (NP (NN mesangium))))) (. .)))
8267029	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (JJ Doc_8267029_572_579_Chemical) (NN pulse)) (, ,) (NP (NN plasmapheresis)) (, ,) (NP (NNP Doc_8267029_603_619_Chemical)) (CC and) (NP (NNP Doc_8267029_624_643_Chemical)))))) (. .)))
8267029	5	(S1 (S (NP (NP (DT A) (JJ complete) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (DT a) (JJ few) (NNS weeks))))) (. .)))
8267029	6	(S1 (S (NP (NP (DT This) (JJ new) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8267029_729_733_Disease)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ Doc_8267029_751_766_Chemical) (NN treatment)))))))) (VP (VBZ emphasizes) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NP (JJ renal) (NN function) (CC and) (NN evaluation)) (PP (IN of) (NP (JJ urinary) (NN sediment)))))) (CC and) (NP (NP (NNP Doc_8267029_878_889_Disease)) (PP (IN in) (NP (DT these) (NNS patients)))))))) (. .)))
8267029	7	(S1 (S (NP (NP (DT The) (JJ prompt) (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_8267029_939_954_Chemical)) (CC and) (NP (JJ vigorous) (NN treatment) (NNS measures))))) (VP (MD could) (VP (VB allow) (PP (IN for) (NP (NP (DT a) (JJ good) (NN prognosis)) (PP (IN as) (PP (IN in) (NP (DT this) (NN case)))))))) (. .)))
8268147	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_8268147_10_22_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8268147_41_66_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_8268147_80_95_Chemical)))))) (. .)))
8268147	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_8268147_106_121_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN for) (NP (JJ many) (NN Doc_8268147_145_167_Disease)))))))) (, ,) (NP (NNP Doc_8268147_169_177_Disease)) (VP (VBZ limits) (NP (NP (PRP$ its) (NN usefulness)) (PP (IN in) (NP (JJ many) (NNS patients))))) (. .)))
8268147	2	(S1 (S (S (NP (NN Doc_8268147_218_230_Disease/Doc_8268147_231_246_Disease)) (VP (MD can) (VP (VB develop) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ autoimmune) (NNS complications)) (PP (IN of) (NP (JJ Doc_8268147_301_316_Chemical) (NN treatment)))))))))) (, ,) (CC but) (S (NP (PRP$ its) (JJ exact) (NN pathogenesis)) (VP (VBZ remains) (ADJP (JJ unclear)))) (. .)))
8268147	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8268147_397_422_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_8268147_438_450_Disease)) (PP (IN while) (S (VP (VBG receiving) (NP (JJ Doc_8268147_467_482_Chemical) (NN therapy)))))))))))) (. .)))
8268147	4	(S1 (S (NP (PRP We)) (VP (VBD described) (NP (NP (DT the) (JJ special) (JJ clinical) (NN course)) (PP (IN of) (NP (DT the) (NN patient))))) (. .)))
8268147	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ Doc_8268147_568_583_Chemical) (NN therapy)))) (VP (MD should) (VP (AUX be) (VP (VBN followed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ autoimmune) (NNS complications)) (PP (IN like) (NP (NNP Doc_8268147_674_686_Disease/Doc_8268147_687_702_Disease)))))))))) (. .)))
8278214	0	(S1 (S (NP (NP (NP (NNP Doc_8278214_0_12_Disease)) (CC and) (NP (NNP Doc_8278214_17_26_Disease))) (PP (IN in) (NP (JJ terminal) (NNP Doc_8278214_39_45_Disease) (NNS patients)))) (VP (VBN treated) (PP (IN with) (NP (JJ continuous) (JJ intravenous) (NNP Doc_8278214_91_99_Chemical)))) (. .)))
8278214	1	(S1 (S (NP (NP (CD Eight) (JJ Doc_8278214_107_113_Disease) (NNS patients)) (PP (IN in) (NP (NP (DT the) (JJ terminal) (NNS stages)) (PP (IN of) (NP (DT the) (NN disease)))))) (VP (VBN treated) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (JJ intravenous) (JJ Doc_8278214_200_208_Chemical) (VBN developed) (NN Doc_8278214_219_231_Disease)))))) (. .)))
8278214	2	(S1 (S (NP (DT All) (NNS cases)) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN sampled) (PP (IN from) (NP (CD three) (JJ different) (NNS hospitals))) (PP (IN in) (NP (NNP Copenhagen))))) (. .)))
8278214	3	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD developed) (NP (NP (NP (JJ universal) (NN Doc_8278214_352_364_Disease)) (CC and) (NP (NN Doc_8278214_369_382_Disease))) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (CD 2) (NNS cases))) (VP (AUX were) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_8278214_420_429_Disease))))))))) (. .)))
8278214	4	(S1 (S (PP (PP (IN In) (NP (NP (CD 3) (NNS patients)) (SBAR (S (NP (DT a) (JJ pre-existing) (NN Doc_8278214_460_469_Disease)) (VP (VBD increased) (PP (TO to) (NP (JJ excruciating) (NN intensity)))))))) (CC and) (PP (IN in) (NP (NP (CD 2)) (PP (IN of) (NP (DT these) (NNS cases)))))) (NP (NNP Doc_8278214_530_539_Disease)) (VP (VBD occurred) (ADVP (RB simultaneously))) (. .)))
8278214	5	(S1 (S (SBAR (IN Although) (S (NP (NP (QP (RB only) (JJ few)) (JJ clinical) (NNS descriptions)) (PP (IN of) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_8278214_633_645_Disease/Doc_8278214_646_655_Disease)) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_8278214_674_682_Chemical))))))))) (VP (AUX are) (ADJP (JJ available))))) (, ,) (NP (NP (JJ experimental) (NN support)) (PP (IN from) (NP (NN animal) (NNS studies)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (NNP Doc_8278214_754_762_Chemical)) (, ,) (CC or) (NP (PRP$ its) (NNS metabolites)) (, ,)) (VP (VBZ plays) (NP (NP (DT a) (JJ causative) (NN role)) (PP (IN for) (NP (DT the) (JJ observed) (JJ behavioural) (NN syndrome)))))))) (. .)))
8278214	6	(S1 (S (S (NP (DT The) (JJ possible) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed)))) (CC and) (S (NP (NN treatment) (NNS proposals)) (VP (VBN given) (S (VP (VBG suggesting) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (ADJP (RBR more) (JJ efficacious)) (NNS opioids)))) (PP (IN with) (NP (NP (ADJP (RBR less) (JJ excitatory)) (NN potency)) (PP (IN in) (NP (DT these) (NNS situations))))))))) (. .)))
8305357	0	(S1 (NP (NP (NP (NNP Liposomal) (NNP Doc_8305357_10_22_Chemical)) (PP (IN in) (NP (JJ advanced) (NN Doc_8305357_35_51_Disease)))) (: :) (NP (DT a) (NN phase) (NNP II) (NN study)) (. .)))
8305357	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ non-randomized) (NN Phase)) (SBAR (S (NP (NNP II) (JJ clinical) (NN trial)) (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (JJ liposomal) (NNP Doc_8305357_169_181_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DaunoXome)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_8305357_214_218_Disease) (JJ related) (NN Doc_8305357_227_243_Disease))))))))))) (. .)))
8305357	2	(S1 (S (NP (NP (CD Eleven) (JJ homosexual) (NNS men)) (PP (IN with) (NP (JJ advanced) (NN Doc_8305357_281_297_Disease)))) (VP (AUX were) (VP (VBN entered) (PP (IN in) (NP (DT the) (NN trial))))) (. .)))
8305357	3	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NP (NN size)) (, ,) (NP (NN colour)) (CC and) (NP (JJ associated) (NN Doc_8305357_364_370_Disease))) (PP (IN of) (NP (NP (VBN selected) ('' ') (NN target) (POS ')) (NNS lesions)))))) (VP (AUX were) (VP (VBN measured))) (. .)))
8305357	4	(S1 (S (NP (JJ Clinical) (, ,) (ADJP (ADJP (JJ biochemical)) (CC and) (ADJP (JJ haematological))) (NNP Doc_8305357_456_466_Disease)) (VP (AUX were) (VP (VBN assessed))) (. .)))
8305357	5	(S1 (S (NP (CD Ten) (NNS subjects)) (VP (AUX were) (VP (VBN evaluated))) (. .)))
8305357	6	(S1 (S (NP (DT A) (JJ partial) (NN response)) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NP (CD four)) (, ,) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (CD two)) (ADVP (RB subsequently)) (VP (VBD relapsed)))))))) (. .)))
8305357	7	(S1 (S (NP (NP (NN Stabilization)) (PP (IN of) (NP (NNP Doc_8305357_604_620_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (DT the) (JJ remaining) (CD six))) (, ,) (S (VP (VBN maintained) (PP (IN until) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (NN trial) (NN period)) (PP (IN in) (NP (CD four)))))))))) (. .)))
8305357	8	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated) (, ,) (PP (IN with) (NP (NP (JJ few) (JJ mild) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8305357_771_779_Disease))))))) (. .)))
8305357	9	(S1 (S (NP (NP (DT The) (JJ main) (NN problem)) (VP (VBN encountered))) (VP (AUX was) (NP (JJ haematological) (NNP Doc_8305357_829_837_Disease)) (, ,) (PP (IN with) (NP (NP (CD three) (NNS subjects)) (VP (VBG experiencing) (NP (NP (JJ severe) (NN Doc_8305357_879_890_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN neutrophil) (NN count)) (SBAR (S (NP (NP (QP (CD <) (CD 0.5)) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ /l))))) (-RRB- -RRB-))))))) (. .)))
8305357	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_8305357_952_966_Disease))))) (. .)))
8305357	11	(S1 (S (PP (IN In) (NP (DT this) (JJ small) (NN patient) (NN sample))) (, ,) (NP (JJ liposomal) (NNP Doc_8305357_1008_1020_Chemical)) (VP (AUX was) (NP (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (RB well) (JJ tolerated))) (NN agent)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8305357_1083_1099_Disease))))))) (. .)))
8384253	0	(S1 (NP (NP (JJ Long-term) (NNS effects)) (PP (IN of) (NP (NNP Doc_8384253_21_32_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system))) (. .)))
8384253	1	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NNP Doc_8384253_87_109_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_8384253_123_134_Chemical))) (PP (IN between) (NP (NP (CD 1984)) (CC and) (NP (CD 1990))))) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ cumulative) (NN dose)) (NP (CD 12) (NNS mg))) (PP (IN in) (NP (CD 18-24) (NNS weeks)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN investigated) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ long) (NN term) (NNS effects)) (PP (IN of) (NP (NNP Doc_8384253_260_271_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))) (. .)))
8384253	2	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX were) (VP (VBN interviewed) (PP (IN with) (NP (NN emphasis))) (PP (IN on) (NP (NN Doc_8384253_353_373_Disease))))) (. .)))
8384253	3	(S1 (S (NP (NP (JJ Physical) (CC and) (JJ quantitative) (JJ sensory) (NN examination)) (PP (IN with) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ vibratory) (NN perception)) (CC and) (NP (JJ thermal) (NN discrimination) (NNS thresholds))))))) (VP (AUX were) (VP (VBN performed) (, ,) (PP (NP (NP (QP (CD four) (TO to) (CD 77)) (NNS months)) (PRN (-LRB- -LRB-) (NP (JJ median) (CD 34) (NNS months)) (-RRB- -RRB-))) (IN after) (NP (JJ Doc_8384253_561_572_Chemical) (NN treatment))))) (. .)))
8384253	4	(S1 (S (NP (JJ Twenty-seven) (NNS patients)) (VP (VBD reported) (NP (NN Doc_8384253_615_635_Disease))) (. .)))
8384253	5	(S1 (S (PP (IN In) (NP (NP (CD 13)) (PP (IN of) (NP (DT these) (CD 27) (NNS patients))))) (NP (NNS symptoms)) (VP (AUX were) (ADVP (RB still)) (ADJP (JJ present)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN examination)))))) (. .)))
8384253	6	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (NP (JJ sensory) (NNS signs) (CC and) (NNS symptoms)) (VP (VBD predominated)) (. .)))
8384253	7	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (CD 14) (NNS patients))) (NP (NNS symptoms)) (VP (AUX had) (VP (AUX been) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN past)))))) (. .)))
8384253	8	(S1 (S (NP (NNS Symptoms)) (VP (VBD persisted) (NP (QP (RB maximally) (CD 40)) (NNS months)) (PP (IN since) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy)))))) (. .)))
8384253	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN age) (NN difference)) (PP (IN between) (NP (NP (NNS patients)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NNS complaints)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN examination)))))))))))) (. .)))
8384253	10	(S1 (S (NP (JJ Normal) (NNS reflexes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (CD two) (NN third)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8384253	11	(S1 (S (NP (JJ Neuropathic) (NNS complaints)) (VP (AUX were) (RB not) (ADJP (RB very) (JJ troublesome) (PP (IN on) (NP (DT the) (JJ long) (NN term))))) (. .)))
8384253	12	(S1 (S (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (PP (IN with) (NP (DT the) (ADJP (RB above) (VBN mentioned)) (JJ Doc_8384253_1177_1188_Chemical) (NN dose) (NN schedule))) (NP (NP (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8384253_1225_1236_Chemical) (NNP Doc_8384253_1237_1247_Disease)))) (VP (AUX are) (ADJP (JJ reversible) (PP (IN for) (NP (DT a) (JJ great) (NN deal)))))))))) (CC and) (S (NP (NN prognosis)) (VP (AUX is) (ADJP (RB fairly) (JJ good)))) (. .)))
839274	0	(S1 (NP (NP (NP (NNP Hepatic) (NNP Doc_839274_8_16_Disease) (CC and) (NNP Doc_839274_21_46_Disease)) (PP (IN of) (NP (DT the) (NN liver))) (PP (IN in) (NP (JJ young) (NNS women))) (PP (IN on) (NP (NNP Doc_839274_78_97_Chemical)))) (: :) (NP (NN case) (NNS reports)) (. .)))
839274	1	(S1 (S (NP (NP (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (JJ hepatic) (NNP Doc_839274_134_141_Disease)))) (CC and) (NP (NP (CD one)) (PP (IN of) (NP (NNP Doc_839274_153_178_Disease))))) (VP (ADVP (RB presumably)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_839274_217_236_Chemical))))) (, ,))) (VP (AUX are) (VP (VBN reported))) (. .)))
839274	2	(S1 (S (NP (JJ Special) (NN reference)) (VP (AUX is) (VP (VBN made) (PP (TO to) (NP (NP (PRP$ their) (JJ clinical) (NN presentation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (ADJP (RB totally) (NN asymptomatic)))))))))) (. .)))
839274	3	(S1 (S (S (NP (NN Liver-function) (NNS tests)) (VP (AUX are) (PP (IN of) (NP (JJ little) (JJ diagnostic) (NN value))))) (, ,) (CC but) (S (NP (JJ valuable) (NN information)) (VP (MD may) (VP (AUX be) (VP (VBN obtained) (PP (IN from) (NP (DT both) (NN liver) (VBG scanning) (CC and) (NN hepatic) (NN angiography))))))) (. .)))
839274	4	(S1 (S (NP (NP (NP (JJ Histologic) (NNS differences)) (CC and) (NP (JJ clinical) (NNS similarities))) (PP (IN between) (NP (NP (NNP hepatic) (NNP Doc_839274_554_561_Disease) (CC and) (NNP Doc_839274_566_591_Disease)) (PP (IN of) (NP (DT the) (NN liver)))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
8410199	0	(S1 (S (NP (NP (NN Loss)) (PP (IN of) (NP (NNP Doc_8410199_8_17_Chemical)))) (VP (VBP decarboxylase) (NP (NP (JJ mRNA-containing) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NN rat) (NN dentate) (NNS gyrus)) (VP (VBG following) (NP (JJ Doc_8410199_91_102_Chemical-induced) (NNP Doc_8410199_111_119_Disease))))))) (. .)))
8410199	1	(S1 (FRAG (SBAR (IN In) (S (NP (JJ situ) (NN hybridization) (NNS methods)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (NNP Doc_8410199_177_190_Chemical) (FW decarboxylase) (PRN (-LRB- -LRB-) (NP (NNP GAD)) (-RRB- -RRB-)) (NN mRNA-containing) (NNS neurons)) (PP (IN within) (NP (NP (DT the) (NN hilus)) (PP (IN of) (NP (DT the) (JJ dentate) (NN gyrus)))))) (VP (AUX are) (ADJP (JJ vulnerable) (PP (TO to) (NP (NP (JJ Doc_8410199_291_298_Disease-induced) (NN damage)) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ chronic) (NNP Doc_8410199_336_344_Disease)))))))))))))))))) (. .)))
8410199	2	(S1 (S (S (NP (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN injected) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NNP Doc_8410199_403_414_Chemical)))))) (, ,) (CC and) (S (NP (DT the) (JJ hippocampal) (NN formation)) (VP (AUX was) (VP (VBN studied) (ADVP (RB histologically)) (PP (IN at) (NP (CD 1) (, ,) (CD 2) (, ,) (CD 4) (, ,) (CC and) (CD 8) (NN week) (NNS intervals))) (PP (IN after) (NP (NNP Doc_8410199_512_523_Chemical-induced) (NNP Doc_8410199_532_540_Disease)))))) (. .)))
8410199	3	(S1 (S (PP (IN In) (NP (JJ situ) (NN hybridization) (NN histochemistry))) (, ,) (S (VP (VBG using) (NP (DT a) (JJ Doc_8410199_588_599_Chemical-labeled) (NNP GAD) (NN cRNA) (NN probe)))) (, ,) (VP (VBD demonstrated) (NP (NP (DT a) (JJ substantial) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons))))) (PP (IN in) (NP (NP (DT the) (NN hilus)) (PP (IN of) (NP (NP (DT the) (JJ dentate) (NNS gyrus)) (PP (IN in) (NP (DT the) (JJ Doc_8410199_746_757_Chemical-treated) (NNS rats)))))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NNS controls))) (PP (IN at) (NP (DT all) (NN time) (NNS intervals))))))) (. .)))
8410199	4	(S1 (S (NP (NP (JJ Additional) (JJ neuronanatomical) (NNS studies)) (, ,) (PP (VBG including) (NP (NP (JJ Doc_8410199_865_878_Chemical) (NN staining)) (, ,) (NP (JJ Doc_8410199_889_910_Disease) (NNS methods)) (, ,) (CC and) (NP (NP (JJ histochemical) (NN localization)) (PP (IN of) (NP (JJ glial) (JJ fibrillary) (JJ acidic) (NN protein)))))) (, ,)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)))))) (VP (AUX was) (VP (VP (VBN related) (PP (TO to) (NP (NNP Doc_8410199_1075_1088_Disease)))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ GAD) (NN mRNA) (NNS levels)))))))))) (. .)))
8410199	5	(S1 (S (NP (NP (DT The) (NN loss)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons))) (PP (IN in) (NP (DT the) (NN hilus)))) (VP (VBN contrasted) (PP (IN with) (NP (NP (DT the) (JJ relative) (NN preservation)) (PP (IN of) (NP (VBN labeled) (JJ putative) (NN basket) (NNS cells))) (PP (IN along) (NP (NP (DT the) (JJ inner) (NN margin)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer)))))))) (. .)))
8410199	6	(S1 (S (NP (NP (JJ Quantitative) (NNS analyses)) (PP (IN of) (NP (NP (VBN labeled) (NNS neurons)) (PP (IN in) (NP (NP (CD three) (NNS regions)) (PP (IN of) (NP (NP (DT the) (JJ dentate) (NN gyrus)) (PP (IN in) (NP (DT the) (ADJP (CD 1) (CC and) (CD 2)) (NN week) (NNS groups)))))))))) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN number)) (PP (IN of) (NP (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NNS hilus)) (PP (IN of) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (JJ experimental) (NNS animals))))))))))))) (. .)))
8410199	7	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (NP (DT the) (JJ molecular) (NN layer)) (CC or) (NP (DT the) (JJ granule) (NN cell) (NN layer))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (VBN labeled) (NNS neurons)) (PP (IN along) (NP (NP (DT the) (JJR lower) (NN margin)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer)))))))))))) (. .)))
8410199	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (DT this) (NN model))) (, ,) (NP (NP (DT a) (NN subpopulation)) (PP (IN of) (NP (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)) (PP (IN within) (NP (DT the) (JJ dentate) (NNS gyrus)))))) (VP (AUX is) (ADJP (RB selectively) (JJ vulnerable) (PP (TO to) (NP (JJ Doc_8410199_1877_1884_Disease-induced) (NN damage)))))))) (. .)))
8410199	9	(S1 (S (NP (JJ Such) (NN differential) (NN vulnerability)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT another) (NN indication)) (PP (IN of) (NP (NP (DT the) (NN heterogeneity)) (PP (IN of) (NP (JJ Doc_8410199_1990_1994_Chemical) (NNS neurons)))))))))) (. .)))
8424298	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ deliberate) (NNP Doc_8424298_22_33_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_45_54_Chemical))) (PP (IN with) (NP (NNP Doc_8424298_60_70_Chemical))) (PP (IN on) (NP (JJ neuropsychological) (NN function)))) (. .)))
8424298	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ deliberate) (NN Doc_8424298_128_139_Disease))) (PP (IN on) (NP (NP (NN brain) (NN function)) (VP (VBN measured) (PP (IN by) (NP (JJ neuropsychological) (NNS tests))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 41) (NN adult) (NNS patients))))) (. .)))
8424298	2	(S1 (S (NP (JJ Twenty-four) (NNS patients)) (VP (AUX were) (VP (VBN anaesthetized) (PP (IN for) (NP (NP (JJ middle-ear) (NN surgery)) (PP (IN with) (NP (NP (JJ deliberate) (NNP Doc_8424298_308_319_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_331_340_Chemical))) (PP (IN with) (NP (NP (NNP Doc_8424298_346_356_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8424298_358_369_Disease) (NN group)) (-RRB- -RRB-))))))))))) (. .)))
8424298	3	(S1 (S (NP (NP (CD Seventeen) (NNS patients)) (PP (IN without) (NP (NNP Doc_8424298_405_416_Disease)))) (VP (VBD served) (PP (IN as) (NP (DT a) (NN control) (NN group)))) (. .)))
8424298	4	(S1 (S (NP (DT The) (JJ mean) (JJ arterial) (NN pressure)) (VP (AUX was) (NP (NP (NP (NP (CD 77) (NN +/-) (QP (CD 2) (CD mmHg))) (PRN (-LRB- -LRB-) (NP (NP (CD 10.3) (NN +/-)) (NP (CD 0.3) (NN kPa))) (-RRB- -RRB-))) (PP (IN before) (NP (NP (NNP Doc_8424298_515_526_Disease)) (CC and) (NP (NP (CD 50) (JJ +/-) (CD 0) (NNS mmHg)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.7) (NN +/-)) (NP (CD 0.0) (NN kPa))) (-RRB- -RRB-))))) (PP (IN during) (NP (NNP Doc_8424298_570_581_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_8424298_589_600_Disease) (NN group)))) (, ,) (CC and) (NP (NP (CD 86) (NN +/-) (QP (CD 2) (CD mmHg))) (PRN (-LRB- -LRB-) (NP (NP (CD 11.5) (NN +/-)) (NP (CD 0.3) (NN kPa))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (NN anaesthesia)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (. .)))
8424298	5	(S1 (S (S (NP (DT The) (JJ following) (JJ psychological) (NNS tests)) (VP (AUX were) (VP (VBN performed)))) (: :) (S (NP (NP (CD four) (NNS subtests)) (PP (IN of) (NP (NP (DT the) (NNP Wechsler) (NN Adult) (NNP Intelligence) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNS similarities) (, ,) (NN digit) (NN span) (, ,) (NN vocabulary) (CC and) (NN digit) (NN symbol)) (-RRB- -RRB-))))) (, ,) (NP (JJ Trail-Making) (NNS tests)) (VP (NP (NP (NP (DT A)) (CC and) (NP (NN B))) (, ,) (NP (NP (JJ Zung) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (JJ self-rating) (JJ Doc_8424298_900_907_Disease) (NN scale)) (CC and) (NP (JJ self-rating) (JJ Doc_8424298_930_940_Disease) (NN scale))) (-RRB- -RRB-))) (CC and) (NP (JJ two-part) (NN memory) (NN test) (NN battery))) (PP (IN with) (NP (JJ immediate) (CC and) (JJ delayed) (NN recall))))) (. .)))
8424298	6	(S1 (S (NP (DT The) (NNS tests)) (VP (VP (AUX were) (VP (VBN performed) (ADVP (RB preoperatively)))) (CC and) (VP (NP (CD 2) (NNS days)) (ADVP (RB postoperatively)))) (. .)))
8424298	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS tests)) (PP (IN in) (NP (NP (DT the) (NNS changes)) (PP (IN from) (NP (JJ preoperative) (NN value))) (PP (TO to) (NP (NN postoperative) (NN value))))))))))))) (. .)))
8424298	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_8424298_1264_1275_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_1287_1296_Chemical))) (PP (IN with) (NP (NNP Doc_8424298_1302_1312_Chemical))))) (VP (AUX has) (NP (NP (DT no) (JJ significant) (JJ harmful) (NNS effects)) (PP (IN on) (NP (NP (JJ mental) (NNS functions)) (VP (VBN compared) (S (VP (TO to) (VP (VB normotensive) (NP (NN anaesthesia))))))))))))) (. .)))
8441146	0	(S1 (NP (NP (JJ Apparent) (NN cure)) (PP (IN of) (NP (NNP Doc_8441146_17_37_Disease))) (PP (IN by) (NP (NN bone) (NN marrow) (NN transplantation))) (. .)))
8441146	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ sustained) (NNS remissions)))) (CC and) (NP (NP (JJ possible) (NN cure)) (PP (IN of) (NP (NP (JJ severe) (JJ erosive) (NNP Doc_8441146_156_176_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8441146_178_180_Disease)) (-RRB- -RRB-)))))) (PP (IN by) (NP (NP (NN bone) (NN marrow) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP BMT)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD 2) (NNS patients)))) (. .)))
8441146	2	(S1 (S (NP (NN BMT)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ severe) (NN Doc_8441146_263_278_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN caused) (PP (IN by) (NP (NP (NP (NNP Doc_8441146_299_303_Chemical)) (PP (IN in) (NP (CD one) (NN case)))) (CC and) (NP (NP (NNP Doc_8441146_320_335_Chemical)) (PP (IN in) (NP (DT the) (JJ other)))))))))))))))) (. .)))
8441146	3	(S1 (S (PP (IN In) (NP (NP (DT the) (QP (CD 8) (CC and) (CD 6)) (NNS years)) (PP (IN since) (NP (NP (DT the) (NNS transplants)) (PRN (-LRB- -LRB-) (VP (VBG representing) (NP (QP (CD 8) (CC and) (CD 4)) (NNS years)) (PP (IN since) (NP (NP (NN cessation)) (PP (IN of) (NP (DT all) (JJ immunosuppressive) (NN therapy))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (NNP Doc_8441146_490_492_Disease)) (PP (IN in) (NP (DT each) (NN case)))) (VP (AUX has) (VP (AUX been) (ADJP (RB completely) (JJ quiescent)))) (. .)))
8441146	4	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ short) (NN term) (NN remission)) (PP (IN of) (NP (JJ severe) (JJ Doc_8441146_577_579_Disease) (JJ following) (NNS BMT)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported)))))) (, ,) (NP (DT these)) (VP (AUX are) (NP (NP (DT the) (JJ first) (NNS cases)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (JJ prolonged) (NN followup)) (VP (AUX has) (VP (AUX been) (ADJP (JJ available)))))))) (. .)))
8441146	5	(S1 (S (NP (DT This) (NN experience)) (VP (VBZ raises) (NP (NP (DT the) (NN question)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (S (VP (VBG BMT) (NP (PRP itself)) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN option)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ uncontrolled) (JJ destructive) (NN Doc_8441146_817_826_Disease)))))))))))))) (. .)))
8473723	0	(S1 (S (NP (NN Doc_8473723_0_8_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ combined) (JJ Doc_8473723_29_44_Chemical-Doc_8473723_45_56_Chemical) (NN treatment)))) (. .)))
8473723	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ combined) (JJ Doc_8473723_97_112_Chemical-Doc_8473723_113_124_Chemical) (JJ treatment-induced) (NN Doc_8473723_143_151_Disease))))) (. .)))
8473723	2	(S1 (S (NP (PRP It)) (VP (VBZ seems) (SBAR (IN that) (S (NP (NP (JJ combined) (NN treatment)) (PP (IN of) (NP (NNP Doc_8473723_189_200_Chemical))) (PP (IN with) (NP (NNP Doc_8473723_206_220_Chemical)))) (VP (MD may) (VP (VB possess) (NP (JJ proconvulsive) (NN activity))))))) (. .)))
8475949	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (ADJP (JJ Doc_8475949_13_24_Chemical) (CC and) (JJ polymorphic)) (NNP Doc_8475949_41_64_Disease) (NNP revisited)) (. .)))
8475949	1	(S1 (S (NP (NN Doc_8475949_76_99_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8475949_125_153_Disease))) (, ,) (PP (VBG including) (NP (NN Doc_8475949_165_183_Disease)))))) (. .)))
8475949	2	(S1 (S (NP (DT This) (NN article)) (VP (VP (VBZ reports) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (DT this) (NN complication))))) (CC and) (VP (VBZ reviews) (NP (NP (DT all) (VBN reported) (NNS cases)) (PP (TO to) (NP (NN date)))))) (. .)))
8475949	3	(S1 (S (S (NP (JJ Doc_8475949_277_288_Chemical-induced) (NNP Doc_8475949_297_315_Disease)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (JJ serum) (JJ Doc_8475949_340_349_Chemical) (NNS levels))))))) (CC and) (S (NP (NNP Doc_8475949_361_375_Disease)) (VP (MD may) (ADVP (RB synergistically)) (VP (VB induce) (NP (NN torsade))))) (. .)))
8475949	4	(S1 (S (NP (NN Doc_8475949_412_430_Disease)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_8475949_486_497_Chemical)))))))) (. .)))
8475949	5	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT no) (JJ other) (JJ acute) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_8475949_549_560_Chemical)))) (VP (AUX were) (VP (VBN observed))) (. .)))
8475949	6	(S1 (S (NP (NN Doc_8475949_576_594_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN treated) (SBAR (WHADVP (WRB when)) (S (VP (VBD recognized) (ADVP (RB early))))) (, ,) (PP (ADVP (RB possibly)) (IN without) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_8475949_669_680_Chemical)))))))) (. .)))
8475949	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_8475949_687_712_Disease)) (VP (AUX is) (ADJP (JJ observed))))) (, ,) (NP (JJ early) (JJ Doc_8475949_732_741_Chemical) (NN supplementation)) (VP (AUX is) (VP (VBN advocated))) (. .)))
8480959	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN tolerability))) (PP (IN of) (NP (NNP Doc_8480959_29_39_Chemical))) (PP (IN in) (NP (NP (CD 3390) (NNS women)) (PP (IN with) (NP (JJ moderate) (NNP Doc_8480959_68_88_Disease))))) (. .)))
8480959	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_8480959_140_150_Chemical))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (JJ moderate) (NNP Doc_8480959_174_194_Disease))))))))) (. .)))
8480959	2	(S1 (NP (NP (NP (DT The) (JJ Expanded) (JJ Clinical) (NN Evaluation)) (PP (IN of) (NP (NNP Doc_8480959_240_250_Chemical) (PRN (-LRB- -LRB-) (NP (NNP EXCEL)) (-RRB- -RRB-)) (NNP Study)))) (, ,) (NP (NP (DT a) (ADJP (JJ multicenter) (, ,) (JJ double-blind) (, ,) (JJ diet-) (CC and) (JJ placebo-controlled)) (NN trial)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNS participants)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (NN placebo)) (CC or) (NP (NP (NNP Doc_8480959_398_408_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NP (QP (CD 20) (CC or) (CD 40)) (NNS mg)) (ADJP (RB once) (JJ daily))) (, ,) (CC or) (NP (NP (QP (CD 20) (CC or) (CD 40)) (NNS mg)) (ADJP (RB twice) (JJ daily))))))))) (PP (IN for) (NP (CD 48) (NNS weeks))))))))))) (. .)))
8480959	3	(S1 (S (NP (JJ Ambulatory) (NNS patients)) (VP (VBD recruited) (PP (IN by) (NP (CD 362) (VBG participating) (NNS centers))) (PP (IN throughout) (NP (DT the) (NNP United) (NNPS States)))) (. .)))
8480959	4	(S1 (NP (NP (NP (NNS Women)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3390)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT the) (JJ total) (NN cohort)) (PP (IN of) (NP (CD 8245) (NNS volunteers))))) (. .)))
8480959	5	(S1 (S (NP (NP (NN Plasma) (NN total)) (, ,) (NP (NN low-density) (NN lipoprotein)) (PRN (-LRB- -LRB-) (NP (NNP LDL)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ high-density) (FW lipoprotein) (PRN (-LRB- -LRB-) (NP (NNP HDL)) (-RRB- -RRB-)) (NNP Doc_8480959_747_758_Chemical)) (, ,) (CC and) (NP (NNP Doc_8480959_764_777_Chemical)) (: ;) (CC and) (NP (NP (NN laboratory)) (CC and) (NP (NP (JJ clinical) (NN evidence)) (PP (IN of) (NP (JJ adverse) (NNS events)))))) (VP (VBD monitored) (ADVP (RB periodically)) (PP (IN throughout) (NP (DT the) (NN study)))) (. .)))
8480959	6	(S1 (S (PP (IN Among) (NP (NNS women))) (, ,) (NP (NP (NNP Doc_8480959_901_911_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (TO to) (CD 80)) (NN mg/d)) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (JJ sustained) (PRN (-LRB- -LRB-) (ADJP (JJ 12-) (TO to) (JJ 48-week)) (-RRB- -RRB-) (, ,)) (JJ dose-related) (NNS changes)) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-)) (: :) (NP (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NP (NNP LDL) (NNP Doc_8480959_1016_1027_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 24) (NN %) (TO to) (CD 40)) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_8480959_1045_1058_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 9) (NN %)) (PP (TO to) (NP (CD 18) (NN %)))) (-RRB- -RRB-)))))) (, ,) (CC and) (NP (NNS increases))) (PP (IN in) (NP (NP (NNP HDL) (NNP Doc_8480959_1093_1104_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.7) (NN %)) (PP (TO to) (NP (CD 8.6) (NN %)))) (-RRB- -RRB-))))))) (. .)))
8480959	7	(S1 (S (PP (VBG Depending) (PP (IN on) (NP (DT the) (NN dose)))) (, ,) (S (NP (NP (QP (IN from) (CD 82) (NN %) (TO to) (CD 95) (NN %))) (PP (IN of) (NP (JJ Doc_8480959_1163_1173_Chemical-treated) (NNS women)))) (VP (VBD achieved) (NP (NP (NP (NP (DT the) (NNP National) (NNP Doc_8480959_1210_1221_Chemical) (NNP Education) (NN Program) (NN goal)) (PP (IN of) (NP (NNP LDL) (NNP Doc_8480959_1252_1263_Chemical) (NNS levels)))) (NP (QP (JJR less) (IN than) (CD 4.14)) (NNS mmol/L))) (PRN (-LRB- -LRB-) (NP (CD 160) (NNS mg/dL)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (CD 40) (NN %)) (PP (TO to) (NP (CD 87) (NN %)))) (VP (VBD achieved) (NP (NP (DT the) (NN goal)) (PP (IN of) (NP (NP (CD 3.36) (NNS mmol/L)) (PRN (-LRB- -LRB-) (NP (CD 130) (NNS mg/dL)) (-RRB- -RRB-))))))) (. .)))
8480959	8	(S1 (S (NP (JJ Successive) (NN transaminase) (NNS elevations)) (NP (NP (QP (JJR greater) (IN than) (CD three) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal)))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (CD 0.1) (NN %)) (PP (IN of) (NP (NNS women)))))) (CC and) (VP (AUX were) (ADJP (NN dose) (JJ dependent)) (PP (IN above) (NP (DT the) (JJ 20-mg) (NN dose))))) (. .)))
8480959	9	(S1 (S (NP (NP (NN Doc_8480959_1525_1533_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (NN muscle) (NNS symptoms)) (PP (IN with) (NP (JJ Doc_8480959_1567_1575_Chemical) (NN kinase) (NNS elevations))))) (NP (NP (QP (JJR greater) (IN than) (CD 10) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal))))) (, ,)) (VP (VP (AUX was) (ADJP (JJ rare))) (CC and) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJS highest) (JJ recommended) (JJ daily) (NN dose)) (PP (IN of) (NP (NNP Doc_8480959_1710_1720_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 80) (NN mg)) (-RRB- -RRB-)))) (. .)))
8480959	10	(S1 (S (NP (NN Estrogen-replacement) (NN therapy)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NN efficacy) (CC or) (NN safety) (NN profile)) (PP (IN of) (NP (NN Doc_8480959_1830_1840_Chemical)))))))))) (. .)))
8480959	11	(S1 (S (NP (NN Doc_8480959_1854_1864_Chemical)) (VP (AUX is) (ADJP (ADJP (RB highly) (JJ effective)) (CC and) (ADJP (RB generally) (RB well) (JJ tolerated) (PP (IN as) (NP (NN therapy)))) (PP (IN for) (NP (NP (JJ primary) (NN Doc_8480959_1937_1957_Disease)) (PP (IN in) (NP (NNS women))))))) (. .)))
8492347	0	(S1 (S (NP (NP (NNP Doc_8492347_0_6_Disease)) (CC and) (NP (NNP Doc_8492347_11_25_Disease))) (VP (JJ due) (PP (TO to) (NP (NP (JJ surreptitious) (NN Doc_8492347_47_57_Chemical--importance)) (PP (IN of) (NP (JJ Doc_8492347_73_82_Chemical) (NN supplementation)))))) (. .)))
8492347	1	(S1 (S (NP (NNS Diuretics)) (VP (MD may) (VP (VB induce) (NP (NP (NNP Doc_8492347_121_132_Disease)) (, ,) (NP (NNP Doc_8492347_134_146_Disease)) (CC and) (NP (NNP Doc_8492347_151_165_Disease))))) (. .)))
8492347	2	(S1 (S (SBAR (IN While) (S (NP (JJ severe) (NNP Doc_8492347_180_191_Disease)) (VP (MD may) (VP (VB cause) (NP (NNP Doc_8492347_202_217_Disease)))))) (, ,) (NP (JJ severe) (NNP Doc_8492347_226_240_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_8492347_260_273_Disease) (CC and) (NNP Doc_8492347_278_284_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBP cannot) (VP (AUX be) (VP (VBN corrected) (PP (IN by) (NP (NP (NNP Doc_8492347_314_323_Chemical) (CC and) (NNP Doc_8492347_328_335_Chemical) (NN supplementation)) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (NN 1,2)) (-RRB- -RRB-))))))))))))) (. .)))
8492347	3	(S1 (S (NP (JJ Surreptitious) (JJ diuretic) (NN ingestion)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (, ,) (PP (ADVP (RB mainly)) (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (JJ concerned) (SBAR (IN that) (S (NP (PRP they)) (VP (AUX are) (NP (NP (NNP Doc_8492347_466_471_Disease)) (CC or) (NP (NNP Doc_8492347_475_484_Disease))))))))))))))) (. .)))
8492347	4	(S1 (S (S (NP (NNP Symptomatic) (NNP Doc_8492347_498_509_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ such) (NNS patients)) (PRN (-LRB- -LRB-) (JJ 3-7) (-RRB- -RRB-)))))))) (CC and) (S (PP (IN in) (NP (CD one) (NN case))) (S (NP (NNP Doc_8492347_567_579_Disease)) (VP (AUX was) (VP (VBN observed) (PRN (-LRB- -LRB-) (NP (CD 8)) (-RRB- -RRB-))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_8492347_617_626_Chemical) (NN depletion)))) (VP (AUX were) (RB not) (VP (VBN noted) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .)))
8494478	0	(S1 (NP (NP (JJ Doc_8494478_0_13_Chemical-induced) (NN Doc_8494478_22_36_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8494478_54_60_Disease))))) (. .)))
8494478	1	(S1 (S (NP (NP (NN Doc_8494478_62_76_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8494478_93_106_Chemical))))) (VP (AUX is) (ADJP (JJ uncommon))) (. .)))
8494478	2	(S1 (S (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_8494478_139_145_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_8494478_160_179_Disease))))))) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_8494478_209_222_Chemical))))))) (VP (AUX are) (VP (VBN described)))) (CC and) (S (NP (NP (DT an) (JJ additional) (CD 15) (NNS cases)) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))))) (VP (AUX are) (VP (VBN reviewed)))) (. .)))
8494478	3	(S1 (S (NP (ADJP (JJ Other) (PP (IN than) (NP (NP (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (JJ Doc_8494478_335_345_Chemical) (NNS levels)) (, ,) (NP (JJ characteristic) (JJ clinical) (NNS manifestations)) (CC and) (NP (JJ abnormal) (NN laboratory))))))) (NNS findings)) (VP (AUX are) (RB not) (ADVP (RB frequently)) (ADJP (JJ present))) (. .)))
8494478	4	(S1 (S (NP (JJ Allergic) (NN Doc_8494478_463_485_Disease)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (DT the) (JJ underlying) (NN pathological-process))))))) (. .)))
8494478	5	(S1 (S (NP (JJ Definitive) (NN diagnosis)) (VP (VBZ requires) (NP (NP (NN performance)) (PP (IN of) (NP (JJ renal) (NN biopsy)))) (, ,) (SBAR (IN although) (S (NP (DT this)) (VP (AUX is) (RB not) (ADVP (RB always)) (ADJP (JJ feasible)))))) (. .)))
8494478	6	(S1 (NP (NP (DT An) (NN improvement)) (PP (IN in) (NP (NP (JJ renal) (NN function)) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (DT the) (VBG offending) (JJ antibiotic) (NNS supports)))) (NP (NP (DT the) (JJ presumptive) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_8494478_771_784_Chemical-induced) (NNP Doc_8494478_793_812_Disease))))))))) (. .)))
8514073	0	(S1 (NP (NP (NN Doc_8514073_0_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_8514073_24_33_Chemical)) (CC versus) (NP (NNP Doc_8514073_41_49_Chemical)))) (. .)))
8514073	1	(S1 (S (SBAR (IN Although) (S (NP (DT some) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (NP (NP (JJR fewer) (NNP Doc_8514073_94_114_Disease) (AUX are)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8514073_135_144_Chemical))))) (ADVP (IN than) (PP (IN with) (NP (NNP Doc_8514073_155_163_Chemical)))) (PP (IN for) (NP (JJ endoscopic) (NNS procedures))))))) (, ,) (NP (DT this) (NN variable)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
8514073	2	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8514073_279_299_Disease)))) (PP (IN after) (NP (NP (JJ intravenous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_8514073_331_339_Chemical)) (CC or) (NP (NNP Doc_8514073_343_352_Chemical)))))) (PP (IN in) (NP (NP (CD 122) (JJ consecutive) (NNS patients)) (VP (VBG undergoing) (ADJP (JJ colonoscopy) (CC and) (JJ esophagogastroduodenoscopy)))))) (. .)))
8514073	3	(S1 (S (ADVP (JJ Overall)) (, ,) (NP (NNP Doc_8514073_445_465_Disease)) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ frequent)) (PP (IN with) (NP (NNP Doc_8514073_490_498_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 22)) (PP (IN of) (NP (CD 62) (NNS patients)))) (-RRB- -RRB-)) (PP (IN than) (PP (IN with) (NP (NP (NP (NNP Doc_8514073_529_538_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))))) (. .)))
8514073	4	(S1 (S (NP (DT A) (JJ palpable) (JJ venous) (NN cord)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (NP (CD 23) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 14)) (PP (IN of) (NP (CD 62)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_8514073_643_651_Chemical) (NN group)))))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 2) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ Doc_8514073_702_711_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
8514073	5	(S1 (S (NP (NP (NN Doc_8514073_731_735_Disease)) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 35) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 22)) (PP (IN of) (NP (CD 62)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_8514073_804_812_Chemical) (NN group))))))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (JJ Doc_8514073_862_871_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))))) (. .)))
8514073	6	(S1 (S (NP (NP (NP (NN Doc_8514073_891_899_Disease)) (CC and) (NP (NN warmth))) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
8514073	7	(S1 (S (NP (NP (NP (NP (NN Smoking)) (, ,) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug) (NN use)) (, ,) (NP (JJ intravenous) (NN catheter) (NN site)) (, ,) (NP (NN dwell) (NN time))) (PP (IN of) (NP (DT the) (NN needle)))) (, ,) (NP (JJ Doc_8514073_1093_1100_Chemical) (NN use)) (, ,) (CC and) (NP (NNP Doc_8514073_1110_1114_Disease))) (PP (IN during) (NP (DT the) (NN injection))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8514073_1170_1190_Disease))))))) (. .)))
8546130	0	(S1 (NP (NP (JJ Doc_8546130_0_14_Chemical-associated) (NN Doc_8546130_26_47_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8546130_66_87_Disease))))) (PP (IN on) (NP (JJ continuous) (JJ ambulatory) (JJ peritoneal) (NN dialysis))) (. .)))
8546130	1	(S1 (S (NP (NN Doc_8546130_134_155_Disease)) (VP (VP (AUX are) (NP (NP (DT a) (JJ rare) (NN event)) (PP (IN in) (NP (NNP Doc_8546130_176_197_Disease))))) (CC and) (RB not) (VP (VBN related) (S (VP (TO to) (VP (VB Doc_8546130_217_223_Disease) (ADVP (FW per) (FW se))))))) (. .)))
8546130	2	(S1 (SINV (ADJP (JJ Unreported) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX is)) (NP (NP (NNP Doc_8546130_264_285_Disease)) (VP (VBG occurring) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (DT the) (JJ new) (JJ Doc_8546130_324_333_Chemical) (JJ antibiotic)) (, ,) (NP (NNP Doc_8546130_346_360_Chemical)))))))) (. .)))
8546130	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (PDT such) (DT a) (NN case)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8546130_404_427_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8546130_429_433_Disease)) (-RRB- -RRB-)))) (VP (VBN maintained) (PP (IN on) (NP (NP (JJ continuous) (JJ ambulatory) (JJ peritoneal) (NN dialysis)) (PRN (-LRB- -LRB-) (NP (NNP CAPD)) (-RRB- -RRB-)))))))) (. .)))
8546130	4	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN dose)) (PP (IN of) (NP (NNP Doc_8546130_544_558_Chemical))) (PP (IN in) (NP (NP (NN face)) (PP (IN of) (NP (NP (NNP Doc_8546130_570_591_Disease)) (PP (IN in) (NP (DT a) (ADJP (RB functionally) (JJ anephric)) (NN patient)))))))))) (, ,) (PP (IN with) (NP (JJ underlying) (JJ Doc_8546130_644_652_Chemical) (NN intoxication))) (, ,) (VP (MD may) (VP (AUX have) (VP (VBN facilitated) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT this) (NNP Doc_8546130_711_721_Disease) (NN side) (NN effect))))))) (. .)))
8546130	5	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important) (S (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NNS medications)))) (PP (IN in) (NP (NP (NN face)) (PP (IN of) (NP (NP (NNP Doc_8546130_812_833_Disease)) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN drug) (NNS interactions)))) (, ,))))))))) (SBAR (CC and) (WHADVP (WRB how)) (S (NP (DT these) (NNS factors)) (VP (MD should) (VP (VB help) (VP (VB guide) (NP (NN medication) (NN therapy)) (PP (IN in) (NP (DT the) (NNP Doc_8546130_939_943_Disease) (NN patient))))))))) (. .)))
85485	0	(S1 (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NNS peroxisomes)) (PP (IN in) (NP (NP (JJ preneoplastic) (NN liver) (CC and) (NN Doc_85485_50_58_Disease)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_85485_78_104_Chemical)))))))))) (. .)))
85485	1	(S1 (S (NP (NP (NNS Peroxisomes)) (PP (IN in) (NP (NP (NNP Doc_85485_121_130_Disease)) (CC and) (NP (JJ hyperplastic) (JJ preneoplastic) (NNP Doc_85485_162_175_Disease)))) (VP (VBN induced) (PP (IN in) (NP (NNS mice))) (PP (IN by) (NP (CD 500) (NN ppm) (NNP Doc_85485_203_229_Chemical))))) (VP (AUX were) (VP (VP (VBN examined) (ADVP (RB histochemically))) (CC and) (VP (NP (NNP electron)) (ADVP (RB microscopically))))) (. .)))
85485	2	(S1 (S (SBAR (IN Although) (S (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNP Doc_85485_311_320_Disease)))) (VP (AUX were) (VP (VP (VBN well-differentiated) (NP (NNP Doc_85485_346_352_Disease))) (CC and) (VP (VBN contained) (NP (NP (DT a) (JJ considerable) (NN number)) (PP (IN of) (NP (NNS peroxisomes))))))))) (, ,) (NP (DT the) (JJ Doc_85485_409_414_Disease) (NNS cells)) (VP (AUX did) (RB not) (VP (VB respond) (PP (TO to) (NP (NNP Doc_85485_440_478_Chemical))) (PP (IN with) (NP (NP (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes))))))) (. .)))
85485	3	(S1 (S (PP (IN At) (NP (NP (DT the) (JJ 16th) (NN week)) (PP (IN of) (NP (NN carcinogen) (NN feeding))))) (, ,) (NP (JJ hyperplastic) (NNS nodules)) (VP (VP (VBD appeared)) (CC and) (VP (VBD advanced) (PP (TO to) (NP (JJ further) (NNS stages))))) (. .)))
85485	4	(S1 (S (NP (NP (DT A) (NN majority)) (PP (IN of) (NP (DT the) (NNS nodules)))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ considerable) (NN number)) (PP (IN of) (NP (NNS peroxisomes)))) (CC and) (NP (NP (DT the) (JJ inductive) (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes)))))) (. .)))
85485	5	(S1 (S (PP (IN Within) (NP (DT the) (NNS nodules))) (, ,) (NP (NP (NNS foci)) (PP (IN of) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (DT the) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (DT no) (NN inducibility)) (PP (IN of) (NP (NP (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes)))))))))))))) (VP (VBD appeared)) (. .)))
85485	6	(S1 (S (S (NP (DT These) (NNS cells)) (VP (VBN proliferated) (ADVP (RB further)) (, ,) (S (VP (VBG replacing) (NP (NP (DT the) (JJS most) (NN part)) (PP (IN of) (NP (DT the) (NNS nodules)))))))) (, ,) (CC and) (S (PP (IN with) (NP (DT this) (NN process))) (NP (NNP Doc_85485_955_964_Disease)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (VP (AUX been) (VP (VBN formed)))))))) (. .)))
85485	7	(S1 (S (NP (NP (DT No) (JJ abnormal) (JJ matrical) (NNS inclusions)) (PP (IN of) (NP (NNS peroxisomes)))) (VP (AUX were) (VP (VBN formed) (PP (IN in) (NP (NP (DT the) (NNS cells)) (PP (IN of) (NP (JJ hyperplastic) (NNS nodules))))) (PP (IN by) (NP (NP (NNP Doc_85485_1094_1132_Chemical)) (ADJP (IN unlike) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NNS rats)))))))))) (. .)))
8586822	0	(S1 (S (NP (NP (NN Contribution)) (PP (IN of) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system))) (PP (TO to) (NP (NN salt-sensitivity))) (PP (IN in) (NP (NN lifetime)))) (VP (VBD Doc_8586822_79_88_Chemical-treated) (ADVP (RB spontaneously)) (NP (NNP Doc_8586822_111_123_Disease) (NNS rats))) (. .)))
8586822	1	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (, ,) (PP (IN in) (NP (NP (NN lifetime) (JJ Doc_8586822_182_191_Chemical-treated) (RB spontaneously) (JJ Doc_8586822_214_226_Disease) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-))))))))) (, ,) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system)) (VP (VBZ contributes) (ADVP (RB importantly)) (PP (TO to) (NP (NP (DT the) (JJ Doc_8586822_301_313_Disease) (NN effect)) (PP (IN of) (NP (JJ Doc_8586822_324_347_Chemical) (NN supplementation)))))) (. .)))
8586822	2	(S1 (S (NP (NP (JJ Male) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (VBN aged) (CD 6) (NNS weeks)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN from) (NP (NN conception))))))))) (ADVP (RB onward) (PP (IN with) (NP (DT either) (NN Doc_8586822_455_464_Chemical) (CC or) (NN vehicle)))) (VP (VP (VBD remained) (PP (IN on) (NP (DT a) (JJ basal) (JJ Doc_8586822_496_511_Chemical) (NN diet)))) (CC or) (VP (AUX were) (VP (VBN fed) (NP (DT a) (JJ high) (JJ Doc_8586822_536_551_Chemical) (NN diet))))) (. .)))
8586822	3	(S1 (S (PP (IN After) (NP (CD 2) (NNS weeks))) (, ,) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (JJ ganglionic) (NN blockade)) (CC and) (ADVP (NP (CD 2) (NNS days)) (RB later)) (, ,) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NNP Doc_8586822_653_662_Chemical)))))))) (. .)))
8586822	4	(S1 (S (NP (NN Lifetime) (JJ Doc_8586822_682_691_Chemical) (NN treatment)) (ADVP (RB significantly)) (VP (VBD lowered) (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
8586822	5	(S1 (S (NP (NP (JJ Intravenous) (NN infusion)) (PP (IN of) (NP (DT the) (JJ ganglionic) (NN blocker) (NN Doc_8586822_810_823_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ rapid) (NN decline)) (PP (IN in) (NP (NN MAP))) (SBAR (WHNP (WDT that)) (S (VP (VBD eliminated) (NP (NP (DT the) (JJ Doc_8586822_879_902_Chemical-induced) (NN Doc_8586822_911_926_Disease)) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
8586822	6	(S1 (S (NP (NP (NN Infusion)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system) (NNP Doc_8586822_982_1016_Chemical) (NNP Doc_8586822_1017_1026_Chemical)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJR greater) (NN reduction)) (PP (IN in) (NP (NN MAP))) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNP SHR))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN fed) (NP (DT the) (JJ high) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (IN with) (NP (DT the) (NN basal)))) (-RRB- -RRB-)) (JJ Doc_8586822_1142_1157_Chemical) (NN diet))))))))))) (. .)))
8586822	7	(S1 (S (PP (IN In) (NP (DT both) (NN lifetime) (UCP (JJ Doc_8586822_1194_1203_Chemical-treated) (CC and) (NN control)) (NN SHR))) (, ,) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ pressor) (NNS effects)) (PP (IN of) (NP (DT a) (JJ high) (JJ Doc_8586822_1305_1320_Chemical) (NN diet)))))) (. .)))
8599504	0	(S1 (S (NP (NN Doc_8599504_0_10_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8599504_27_37_Chemical) (NN administration)))) (. .)))
8599504	1	(S1 (S (NP (NP (NN Doc_8599504_54_64_Disease)) (, ,) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NP (NNP Doc_8599504_80_99_Disease)) (CC or) (NP (NNP Doc_8599504_103_120_Disease))))) (, ,)) (VP (AUX is) (NP (NP (DT a) (JJ well-demarcated) (, ,) (JJ localized) (NN Doc_8599504_154_159_Disease)) (VP (VBG involving) (NP (NP (DT the) (JJ subcutaneous) (NNS tissues)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB cause) (NP (NN Doc_8599504_210_234_Disease)))))))))) (. .)))
8599504	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (ADJP (RB previously) (JJ healthy)) (JJ 19-year-old) (NN man)) (PP (IN with) (NP (NP (DT no) (JJ known) (NN Doc_8599504_309_323_Disease)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NNP Doc_8599504_332_342_Disease)) (PP (IN with) (NP (NP (JJ significant) (NN Doc_8599504_360_375_Disease)) (CC and) (NP (NN protrusion))))) (VP (VBD developed) (PP (IN within) (NP (NP (CD 10) (NNS minutes)) (PP (IN of) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NNP IV) (NN dose)) (PP (IN of) (NP (NNP Doc_8599504_464_474_Chemical)))))))))))))))))) (. .)))
8600333	0	(S1 (NP (NP (JJ Late) (NN Doc_8600333_5_19_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (DT a) (JJ malignant) (NN Doc_8600333_52_62_Disease))) (. .)))
8600333	1	(S1 (S (NP (JJ Cardiac) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ long-term) (NNS survivors)) (PP (IN of) (NP (JJ malignant) (NNP Doc_8600333_130_141_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (VBG according) (PP (TO to) (NP (NP (NNP Doc_8600333_172_198_Chemical)) (, ,) (NP (NP (DT both)) (PP (VBG including) (NP (NNP Doc_8600333_215_226_Chemical))))))))))))))) (. .)))
8600333	2	(S1 (S (NP (NP (JJ Thirty-one) (NNS patients)) (, ,) (NP (NN age) (JJ 10-45) (NNS years)) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN age)) (NP (CD 17.8) (NNS years))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN evaluated) (NP (NP (CD 2.3-14.1) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ median) (CD 8.9) (NNS years)) (-RRB- -RRB-)) (VP (VBG following) (NP (NP (NN completion)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
8600333	3	(S1 (S (NP (NP (JJ Cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_8600333_393_404_Chemical)))) (VP (AUX were) (NP (NP (JJ 225-550) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NP (NN median) (NN dose) (CD 360)) (-RRB- -RRB-)))) (. .)))
8600333	4	(S1 (S (S (NP (DT The) (NN evaluation)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT a) (NN history)) (, ,) (NP (JJ physical) (NN examination)) (, ,) (NP (NP (NN electrocardiogram)) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))))))) (, ,) (NP (NN signal)) (VP (VBD averaged) (NP (NP (NN ECG)) (, ,) (NP (JJ 24-hour) (JJ ambulatory) (NN ECG)) (, ,) (NP (NN echocardiography)) (CC and) (NP (NN radionuclide) (NN angiography)))) (. .)))
8600333	5	(S1 (S (S (NP (NP (CD Eighteen)) (PP (IN of) (NP (CD 31) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD showed) (NP (NP (NNP Doc_8600333_658_674_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (S (VP (AUXG having) (NP (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT the) (JJ following) (NNS abnormalities))))))))))) (: :) (S (NP (NP (JJ late) (NNS potentials)) (, ,) (NP (JJ complex) (NNP Doc_8600333_763_786_Disease)) (, ,)) (VP (VP (VBD left) (NP (NNP Doc_8600333_793_813_Disease))) (, ,) (VP (VBD decreased) (NP (NN shortening) (NN fraction))) (, ,) (CC or) (VP (VBD decreased) (NP (JJ ejection) (NN fraction))))) (. .)))
8600333	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_8600333_895_916_Disease)))) (VP (VBN increased) (PP (IN with) (NP (NP (NN length)) (PP (IN of) (NP (NN follow-up))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CC or) (SYM =) (CD .05)) (-RRB- -RRB-))) (. .)))
8600333	7	(S1 (S (NP (DT No) (NN correlation)) (VP (MD could) (VP (AUX be) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NP (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_8600333_1031_1042_Chemical)))) (CC and) (NP (JJ cardiac) (NN status)))) (, ,) (PP (IN except) (PP (IN for) (NP (NN heart) (NN rate) (NN variability))))))) (. .)))
8600333	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN adjusted) (PP (TO to) (NP (NP (NN body) (NN surface) (NN area)) (, ,) (NP (NP (DT the) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN thickness)) (PRN (-LRB- -LRB-) (NP (CD LVPW) (NN index)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (DT all) (NNS patients))))) (. .)))
8600333	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_8600333_1241_1252_Chemical-induced) (NNP Doc_8600333_1261_1275_Disease)))) (VP (VP (AUX is) (ADJP (JJ high))) (CC and) (VP (VBZ increases) (PP (IN with) (NP (NN follow-up))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (JJ cumulative) (NN dose)))))) (. .)))
8600333	10	(S1 (S (NP (NP (JJ Life-long) (JJ cardiac) (NN follow-up)) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
8600333	11	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN heart) (NN rate) (NN variability)) (CC and) (NP (JJ LVPW) (NN index))) (VP (MD could) (VP (AUX be) (NP (NP (JJ sensitive) (NNS indicators)) (PP (IN for) (NP (NN Doc_8600333_1517_1531_Disease))))))))) (. .)))
8607407	0	(S1 (S (NP (JJ Acute) (NN blood) (NN pressure)) (VP (NNS elevations) (PP (IN with) (NP (NNP Doc_8607407_37_45_Chemical))) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (JJ borderline) (JJ systemic) (NN Doc_8607407_78_90_Disease)))))) (. .)))
8607407	1	(S1 (S (SBAR (IN Whether) (S (NP (NP (DT the) (JJ vasoconstrictive) (NNS actions)) (PP (IN of) (NP (NNP Doc_8607407_132_140_Chemical)))) (VP (AUX are) (VP (VBN enhanced) (PP (IN in) (NP (JJ Doc_8607407_157_169_Disease) (NNS persons))))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN demonstrated)))) (. .)))
8607407	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (NNP Doc_8607407_211_219_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN mg/kg)) (-RRB- -RRB-))) (CC versus) (NP (NN placebo))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NP (NP (CD 48) (JJ healthy) (NNS men)) (PRN (-LRB- -LRB-) (VP (VBN aged) (NP (QP (CD 20) (TO to) (CD 35)) (NNS years))) (-RRB- -RRB-))) (VP (VBN selected) (PP (IN after) (S (VP (VBG screening) (PP (IN on) (NP (CD 2) (JJ separate) (NNS occasions))))))))))) (. .)))
8607407	3	(S1 (S (NP (NNP Borderline) (NNP Doc_8607407_359_371_Disease) (NNS men)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 24)) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN selected) (PP (IN with) (S (VP (VBG screening) (NP (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-)) (PP (IN of) (NP (QP (CD 140) (TO to) (CD 160)) (NNS mm)))) (S (NP (NNP Hg) (NN and/or)) (ADJP (JJ diastolic) (NP (NNP BP) (CD 90)) (PP (TO to) (NP (CD 99) (NN mm) (NNP Hg)))))))))) (. .)))
8607407	4	(S1 (S (NP (NP (JJ Low-risk) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 24)) (-RRB- -RRB-))) (VP (VP (VBD reported) (NP (NP (DT no) (JJ parental) (NN history)) (PP (IN of) (NP (NNP Doc_8607407_558_570_Disease))))) (CC and) (VP (AUX had) (S (NP (NN screening) (NNP BP) (NNP <) (CD 130/85)) (VP (VBG mm) (NP (NNP Hg)))))) (. .)))
8607407	5	(S1 (S (S (NP (NNS Participants)) (VP (AUX were) (ADVP (RB then)) (VP (VBN tested) (PP (IN on) (NP (CD 2) (NNS occasions))) (PP (IN after) (NP (NP (JJ 12-hour) (NN abstinence)) (PP (IN from) (NP (NNP Doc_8607407_683_691_Chemical))))) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (CD 2) (NNS protocols)))))))) (: ;) (S (NP (DT this)) (VP (VBD required) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 4) (NN laboratory) (NNS visits)))))) (. .)))
8607407	6	(S1 (S (NP (NP (JJ Doc_8607407_762_770_Chemical-induced) (NNS changes)) (PP (IN in) (NP (JJ diastolic) (NNP BP)))) (VP (VP (AUX were) (ADJP (ADJP (QP (CD 2) (TO to) (CD 3) (NNS times)) (JJR larger) (PP (IN in) (NP (JJ borderline) (NNS subjects)))) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD +8.4) (NNP vs) (CD +3.8)) (VP (VBG mm) (NP (NNP Hg)))) (, ,) (NP (NNP p) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (AUX were) (ADJP (JJ attributable) (PP (TO to) (NP (NP (JJR larger) (NNS changes)) (PP (IN in) (NP (NP (JJ impedance-derived) (NNS measures)) (PP (IN of) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NP (CD +135) (NNP vs) (CD +45) (NN dynes.s.cm-5)) (, ,) (NP (NNP p) (NNP <) (CD 0.004))) (-RRB- -RRB-))))))))))) (. .)))
8607407	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VP (AUX were) (ADJP (JJ consistent))) (CC and) (VP (VBD reached) (NP (NN significance)) (PP (IN in) (NP (DT both) (NNS protocols))))) (. .)))
8607407	8	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ borderline) (NNS subjects))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ diastolic) (NNP BP) (NNS changes)) (VP (VBD exceeded) (NP (DT the) (JJ median) (NN control) (NN response)))))) (VP (AUX was) (NP (CD 96) (NN %))) (. .)))
8607407	9	(S1 (S (ADVP (RB Consequently)) (, ,) (SBAR (IN whereas) (S (NP (DT all) (NNS participants)) (VP (VBD exhibited) (NP (NN normotensive) (NNS levels)) (PP (IN during) (NP (DT the) (JJ resting) (NN predrug) (NN baseline)))))) (, ,) (NP (NP (CD 33) (NN %)) (PP (IN of) (NP (JJ borderline) (NNS subjects)))) (VP (VBD achieved) (NP (NNP Doc_8607407_1373_1385_Disease) (NNP BP) (NNS levels)) (PP (IN after) (NP (JJ Doc_8607407_1402_1410_Chemical) (NN ingestion)))) (. .)))
8607407	10	(S1 (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (JJ borderline) (JJ Doc_8607407_1442_1454_Disease) (NNS men))) (, ,) (NP (NP (JJ exaggerated) (NNS responses)) (PP (TO to) (NP (NNP Doc_8607407_1485_1493_Chemical)))) (VP (AUX were) (UCP (: :) (ADJP (ADJP (JJ selective) (PP (IN for) (NP (JJ diastolic) (NNP BP)))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJR greater) (NN vasoconstriction)) (, ,) (VP (VBN replicated) (PP (IN in) (NP (CD 2) (NNS protocols)))) (, ,)))) (CC and) (ADJP (JJ representative) (PP (IN of) (NP (NP (RB nearly) (DT all)) (VP (VBN borderline) (NP (NNP Doc_8607407_1641_1654_Disease))))))))) (. .)))
8607407	11	(S1 (S (NP (PRP We)) (VP (VBP suspect) (SBAR (IN that) (S (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NNP Doc_8607407_1690_1698_Chemical))) (S (VP (TO to) (VP (VB stabilize) (NP (NP (JJ high) (NN resistance) (NNS states)) (PP (IN in) (NP (JJ susceptible) (NNS persons)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP$ its) (NN use)) (VP (MD may) (VP (VP (VB facilitate) (NP (PRP$ their) (NN disease) (NN progression))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VB hinder) (NP (JJ accurate) (NN diagnosis) (CC and) (NN treatment))))))))))) (. .)))
8617710	0	(S1 (NP (NP (NN Absence)) (PP (IN of) (NP (NN effect))) (PP (IN of) (NP (NNP Doc_8617710_21_31_Chemical))) (PP (IN on) (NP (NP (JJ time-based) (NN sensitization)) (PP (IN of) (NP (NNP Doc_8617710_63_83_Disease))) (PP (IN with) (NP (NNP Doc_8617710_89_100_Chemical))))) (. .)))
8617710	1	(S1 (S (NP (DT This) (JJ double-blind) (, ,) (JJ randomized) (, ,) (JJ placebo-controlled) (NN study)) (VP (VBN evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_8617710_183_194_Chemical)) (ADVP (RB alone))) (CC and) (NP (NNP Doc_8617710_205_216_Chemical) (CC plus) (NNP Doc_8617710_222_232_Chemical))))) (PP (IN on) (NP (NP (NN cognitive)) (CC and) (NP (NN psychomotor) (NN function)))) (PP (IN in) (NP (CD 24) (JJ healthy) (NN male) (NNS subjects)))) (. .)))
8617710	2	(S1 (S (NP (DT All) (NNS subjects)) (VP (VBD received) (NP (NN placebo)) (PP (IN on) (NP (NP (NNP Day) (CD 1)) (CC and) (NP (NNP Doc_8617710_351_362_Chemical) (CD 2)))) (S (VP (VBG mg) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 25)))))) (. .)))
8617710	3	(S1 (S (S (PP (IN From) (NP (NNS Days) (CD 9) (TO to) (CD 25))) (, ,) (NP (NNS subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (DT either) (NP (NP (NNP Doc_8617710_447_457_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS subjects)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS subjects)) (-RRB- -RRB-)))))))) (: ;) (S (NP (DT the) (JJ Doc_8617710_502_512_Chemical) (NN dose)) (VP (VP (AUX was) (VP (VBN titrated) (PP (IN from) (NP (NP (QP (CD 50) (TO to) (CD 200)) (NN mg/day)) (PP (IN from) (NP (NNS Days) (CD 9) (TO to) (CD 16))))))) (, ,) (CC and) (VP (VBD remained) (PP (IN at) (NP (CD 200) (NN mg/day))) (PP (IN for) (NP (NP (DT the) (JJ final) (CD 10) (NNS days)) (PP (IN of) (NP (DT the) (NN drug) (NN administration) (NN period)))))))) (. .)))
8617710	4	(S1 (S (NP (JJ Cognitive) (NN function) (NN testing)) (VP (AUX was) (VP (VBN performed) (PP (PP (IN before) (NP (NN dosing))) (CC and) (PP (IN over) (NP (DT a) (JJ 24-hour) (NN period)))) (PP (IN after) (S (VP (VBG dosing) (PP (IN on) (NP (NNS Days))) (NP (CD 1) (, ,) (CD 2) (, ,) (CC and) (CD 25))))))) (. .)))
8617710	5	(S1 (S (NP (NN Doc_8617710_781_813_Disease)) (VP (AUX was) (VP (VBD observed) (NP (QP (CD 6) (TO to) (CD 8)) (NNS hours)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8617710_864_875_Chemical))))) (PP (IN on) (NP (NNP Day) (CD 2)))) (CC but) (VP (AUX was) (RB not) (ADJP (JJ evident)) (PP (NP (CD 23) (NNS hours)) (IN after) (NP (NN dosing))))) (. .)))
8617710	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ single-dose) (NNP Doc_8617710_945_956_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB again)) (ADVP (NP (CD 25) (NNS days)) (RB later)))))) (, ,) (NP (NP (JJR greater) (NN impairment)) (PP (IN with) (NP (JJR earlier) (NN onset)))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (JJ several) (NNS tests)) (PP (IN in) (NP (DT both) (NN treatment) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (NN enhancement)) (PP (IN of) (NP (DT this) (NN effect)))))))) (. .)))
8617710	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (NN indication) (SBAR (IN that) (S (NP (NNP Doc_8617710_1147_1157_Chemical)) (VP (VBD exacerbated) (SBAR (S (NP (NP (DT the) (NN impairment)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_8617710_1197_1208_Chemical))) (PP (IN since) (NP (DT an) (JJ equivalent) (NN effect))))) (ADVP (RB also)) (VP (VBD occurred) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))))))))) (. .)))
8617710	8	(S1 (S (NP (NP (CD Three) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 2)) (PP (IN on) (NP (NNP Doc_8617710_1293_1303_Chemical)))) (CC and) (NP (NP (CD 1)) (PP (IN on) (NP (NN placebo))))) (-RRB- -RRB-))) (VP (VBD withdrew) (PP (IN from) (NP (DT the) (NN study))) (PP (IN because) (IN of) (NP (NN side) (NNS effects)))) (. .)))
8617710	9	(S1 (S (NP (NP (CD Ten) (NNS subjects)) (PP (IN in) (NP (DT each) (NN group)))) (VP (VBD reported) (NP (NP (JJ side) (NNS effects)) (VP (VBN related) (PP (TO to) (NP (NN treatment)))))) (. .)))
8617710	10	(S1 (S (NP (NP (DT The) (JJ side) (NN effect) (NNS profiles)) (PP (PP (IN of) (NP (NNP Doc_8617710_1470_1480_Chemical))) (CC and) (PP (IN of) (NP (NN placebo))))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
8617710	11	(S1 (S (NP (NN Doc_8617710_1522_1533_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ clear) (NN profile)) (PP (IN of) (NP (NNP Doc_8617710_1562_1582_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (RB not) (VP (VBN worsened) (PP (IN by) (NP (JJ concomitant) (JJ Doc_8617710_1620_1630_Chemical) (NN administration))))))))) (. .)))
8638876	0	(S1 (NP (NP (NN Coexistence)) (PP (IN of) (NP (NNP Doc_8638876_15_75_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ exogenous) (NN sex) (NNS hormones)))) (. .)))
8638876	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
8638876	2	(S1 (S (NP (DT A) (JJ forty-six) (JJ year-old) (JJ premenopausal) (NN woman)) (VP (VBD developed) (SBAR (S (NP (NP (NNP Doc_8638876_182_190_Disease)) (, ,) (NP (NNP Doc_8638876_192_198_Disease) (CC and) (NNP Doc_8638876_203_211_Disease)) (, ,)) (VP (VBD left) (NP (NNP Doc_8638876_218_229_Disease) (CC and) (NNP Doc_8638876_234_241_Disease) (CD two) (NNS days)) (PP (IN after) (NP (NP (JJ parenteral) (NN use)) (PP (IN of) (NP (NP (NNP Doc_8638876_275_287_Chemical)) (CC and) (NP (NNP Doc_8638876_292_301_Chemical)))))))))) (. .)))
8638876	3	(S1 (S (NP (NP (NN Doc_8638876_303_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8638876_322_324_Disease)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN found) (PP (IN during) (NP (NN admission))))) (. .)))
8638876	4	(S1 (S (NP (JJ Computed) (NN tomography)) (VP (VP (VBD showed) (NP (DT a) (NN Doc_8638876_383_402_Disease)) (PP (IN in) (NP (DT the) (JJ right) (JJ frontal) (NN lobe)))) (CC and) (VP (VBD increased) (NP (NN density)) (PP (IN in) (NP (NP (DT the) (JJ superior) (NN sagittal) (NN sinus)) (PRN (-LRB- -LRB-) (NP (NN SSS)) (-RRB- -RRB-)))))) (. .)))
8638876	5	(S1 (S (NP (JJ Left) (JJ carotid) (NN angiography)) (VP (VBD found) (NP (NP (NNP Doc_8638876_520_565_Disease)) (PRN (-LRB- -LRB-) (NP (NNP ICA)) (-RRB- -RRB-)))) (. .)))
8638876	6	(S1 (S (NP (JJ Right) (NN carotid) (NNS angiograms)) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (NP (NP (DT the) (ADJP (JJ SSS) (CC and) (JJ inferior)) (NN sagittal) (NN sinus)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NNP Doc_8638876_664_687_Disease))))))))) (. .)))
8638876	7	(S1 (S (NP (NP (NN Coexistence)) (PP (IN of) (NP (DT the) (NNP Doc_8638876_708_754_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN described) (ADVP (RB infrequently))))) (. .)))
8638876	8	(S1 (S (PP (IN In) (NP (DT this) (NN case))) (, ,) (NP (DT the) (NNS authors)) (VP (VBP postulate) (SBAR (IN that) (S (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_8638876_840_849_Chemical)) (CC and) (NP (NNP Doc_8638876_854_866_Chemical))))) (CC and) (NP (DT the) (VBG underlying) (NNP Doc_8638876_886_888_Disease))) (VP (VBD increased) (NP (NP (JJ vascular) (NN thrombogenicity)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD provided) (NP (NP (DT a) (JJ common) (NN denominator)) (PP (IN for) (NP (NNP Doc_8638876_965_1012_Disease)))))))))))) (. .)))
8643966	0	(S1 (NP (NP (NP (NN Chemotherapy)) (PP (IN of) (NP (JJ advanced) (JJ inoperable) (NN Doc_8643966_36_62_Disease))) (PP (IN with) (NP (NNP Doc_8643966_68_78_Chemical)))) (: :) (NP (DT a) (NN phase) (NNP II) (NN trial)) (. .)))
8643966	1	(S1 (S (NP (NP (NNP Doc_8643966_98_108_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643966_110_115_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-))) (VP (AUX has) (VP (VBN demonstrated) (NP (JJ significant) (JJ antineoplastic) (NN activity)) (PP (IN against) (NP (NP (JJ different) (JJ Doc_8643966_233_238_Disease) (NNS types)) (, ,) (ADVP (RB notably)) (NP (NNP Doc_8643966_254_282_Disease)))))) (. .)))
8643966	2	(S1 (S (NP (NP (NP (CD Two) (NN phase)) (NP (NNP II) (NNS trials))) (PP (IN of) (NP (NP (JJ 24-hour) (JJ Doc_8643966_315_325_Chemical) (NNS infusions)) (PP (IN in) (NP (NP (JJ chemotherapy-naive) (NNS patients)) (PP (IN with) (NP (NP (NN stage) (NN IIIB)) (CC or) (NP (NP (NNP IV) (NNP Doc_8643966_389_415_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8643966_417_422_Disease)) (-RRB- -RRB-)))))))))) (VP (VBD reported) (NP (NP (NN response) (NNS rates)) (PP (IN of) (NP (NP (CD 21) (NN %)) (CC and) (NP (CD 24) (NN %)))))) (. .)))
8643966	3	(S1 (S (S (NP (NN Doc_8643966_464_474_Disease)) (VP (AUX was) (ADJP (NN dose) (VBG limiting)))) (: :) (S (NP (NP (QP (RB as) (JJ many) (IN as) (CD 62.5)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD experienced) (NP (NN grade) (CD 4) (NN Doc_8643966_543_553_Disease)))) (. .)))
8643966	4	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_8643966_588_596_Disease)) (PP (IN of) (NP (DT a) (JJ 3-hour) (JJ Doc_8643966_609_619_Chemical) (NN infusion))) (PP (IN in) (NP (NP (DT a) (NN phase) (NNP II) (NN trial)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NN stage) (NNP IIIB) (CC or) (NNP IV) (NNP Doc_8643966_694_699_Disease))))))))) (. .)))
8643966	5	(S1 (S (NP (DT The) (CD 58) (NNS patients)) (VP (VBD treated) (SBAR (S (-LRB- -LRB-) (NP (NP (CD 41) (NNS men)) (CC and) (NP (CD 17) (NNS women))) (-RRB- -RRB-) (VP (AUX had) (NP (NP (NP (DT a) (JJ median) (NN age)) (PP (IN of) (NP (NP (CD 59) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN age) (NN range)) (, ,) (NP (QP (CD 25) (TO to) (CD 75))) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (NN performance) (NN status)) (PP (IN of) (NP (NP (CD 0)) (PP (IN through) (NP (CD 2))))))))))) (. .)))
8643966	6	(S1 (S (NP (NP (JJS Most) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 72.4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (VP (VB stage) (NP (NNP IV) (NNP Doc_8643966_874_879_Disease)))) (. .)))
8643966	7	(S1 (S (NP (NN Doc_8643966_881_891_Chemical) (CD 225) (NN mg/m2)) (VP (AUX was) (VP (VBN infused) (PP (IN over) (NP (NP (CD 3) (NNS hours)) (NP (NP (DT every) (CD 3) (NNS weeks)) (PP (IN with) (NP (JJ standard) (JJ prophylactic) (NN premedication)))))))) (. .)))
8643966	8	(S1 (S (PP (IN Of) (NP (NP (CD 50) (NNS patients)) (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (, ,) (SBAR (S (NP (NP (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (JJ partial) (NN remission)))))))))) (, ,) (S (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT no) (NN change)))) (, ,) (CC and) (S (NP (CD 12)) (VP (AUX had) (NP (NP (NN disease) (NN progression)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))))) (. .)))
8643966	9	(S1 (S (S (NP (NNP Hematologic) (NNP Doc_8643966_1128_1138_Disease)) (VP (AUX were) (ADJP (JJ mild)))) (: :) (S (NP (NP (QP (RB only) (CD one)) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NN grade)) (NP (QP (CD 3) (CC or) (CD 4)) (NN Doc_8643966_1195_1206_Disease)) (, ,) (SBAR (IN while) (S (NP (CD 29) (NN %)) (VP (AUX had) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2))))))) (. .)))
8643966	10	(S1 (S (NP (NP (NN Grade) (CD 1)) (CC or) (NP (CD 2) (NN Doc_8643966_1249_1263_Disease))) (VP (VBD affected) (NP (NP (CD 56) (NN %)) (PP (IN of) (NP (NNS patients)))) (SBAR (IN while) (S (NP (NP (RB only) (CD one)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD experienced) (NP (JJ severe) (NN Doc_8643966_1328_1342_Disease)))))) (. .)))
8643966	11	(S1 (S (ADVP (RB Similarly)) (, ,) (S (NP (ADJP (NN grade) (CD 1) (CC or) (CD 2)) (NNP Doc_8643966_1368_1375_Disease/Doc_8643966_1376_1386_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 63.2) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (, ,) (CC but) (S (NP (QP (RB only) (CD 14.3)) (NN %)) (VP (VBD experienced) (NP (NN grade) (CD 3) (CC or) (CD 4)))) (. .)))
8643966	12	(S1 (S (NP (NP (NNP Doc_8643966_1463_1469_Disease)) (CC and) (NP (NNP Doc_8643966_1474_1482_Disease))) (VP (AUX were) (ADJP (JJ infrequent)) (, ,) (PP (IN with) (NP (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2)))))) (CC and) (NP (NP (QP (RB only) (CD 2)) (NN %)) (VP (VBG experiencing) (NP (NN grade) (CD 3) (CC or) (CD 4))))))) (. .)))
8643966	13	(S1 (S (NP (NNP Doc_8643966_1586_1596_Chemical)) (VP (AUX is) (ADVP (RB thus)) (NP (NP (DT an) (JJ active) (JJ single) (NN agent)) (PP (IN in) (NP (DT this) (JJ patient) (NN population))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ 3-hour) (NN infusion) (NN proving)) (ADJP (ADJP (RB comparably) (JJ effective) (PP (TO to) (NP (DT a) (JJ 24-hour) (NN infusion)))) (CC and) (ADJP (JJ superior) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (ADJP (JJ hematologic) (CC and) (JJ nonhematologic)) (NNP Doc_8643966_1803_1811_Disease))))))))))))) (. .)))
8643966	14	(S1 (S (S (NP (NP (JJ Further) (NN phase) (NNP II) (NNS studies)) (PP (IN with) (NP (NNP Doc_8643966_1843_1853_Chemical))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (JJ active) (IN against) (NP (NNP Doc_8643966_1895_1900_Disease))))))) (VP (AUX are) (VP (VBN indicated)))) (, ,) (CC and) (S (NP (NP (NN phase) (NNP III) (NNS studies)) (VP (VBG comparing) (NP (NNP Doc_8643966_1948_1958_Chemical)) (PP (IN with) (NP (JJ standard) (NN chemotherapy))))) (VP (VBP remain) (S (VP (TO to) (VP (AUX be) (VP (VBN completed))))))) (. .)))
8643973	0	(S1 (S (NP (NN Doc_8643973_0_10_Chemical)) (VP (VBD combined) (PP (IN with) (NP (NNP Doc_8643973_25_36_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ first-line) (NN treatment)) (PP (IN of) (NP (JJ advanced) (NN Doc_8643973_77_91_Disease)))))) (. .)))
8643973	1	(S1 (S (PP (IN In) (NP (NP (DT a) (NN phase)) (SBAR (S (NP (PRP I)) (VP (VBP study) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ maximum) (JJ tolerated) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_8643973_155_165_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643973_167_172_Chemical)) (: ;) (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company))) (, ,) (NP (NNP Princeton)) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)))) (VP (VBN given) (PP (IN as) (NP (DT a) (JJ 3-hour) (NN infusion))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_8643973_266_277_Chemical))) (VP (VBN administered) (NP (DT every) (CD 21) (NNS days)) (PP (TO to) (NP (NP (NNS women)) (PP (IN with) (NP (JJ advanced) (NNP Doc_8643973_328_342_Disease)))))))))))))))))) (, ,) (NP (NNP Doc_8643973_344_354_Chemical) (NNS doses)) (VP (AUX were) (VP (VBN escalated) (SBAR (IN as) (S (VP (VBZ follows) (: :) (NP (NP (NN level) (CD 1)) (, ,) (NP (NP (CD 135) (NN mg/m2)) (: ;) (NP (NP (NN level) (CD 2)) (, ,) (NP (CD 160) (NNS mg/m2))) (: ;) (NP (NP (NN level) (CD 3)) (, ,) (NP (CD 185) (NN mg/m2))) (: ;) (CC and) (NP (NP (NN level)) (NP (CD 4,210) (NNS mg/m2)))))))))) (. .)))
8643973	2	(S1 (S (NP (NP (DT The) (JJ fixed) (NN dose)) (PP (IN of) (NP (NNP Doc_8643973_489_500_Chemical))) (PP (IN at) (NP (NNS levels) (CD 1) (IN through) (CD 4)))) (VP (AUX was) (VP (VBN given) (S (VP (TO to) (VP (VB achieve) (NP (DT an) (NN area)) (PP (IN under) (NP (NP (DT the) (JJ concentration-time) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 5))))) (S (VP (VBG using) (NP (DT the) (NNP Calvert) (NN formula))))))))) (. .)))
8643973	3	(S1 (S (PP (IN In) (NP (NNS levels) (CD 5) (CC and) (CD 6))) (NP (DT the) (NNP Doc_8643973_647_658_Chemical) (NN dose)) (VP (AUX was) (VP (VBN targeted) (PP (IN at) (NP (NP (NNS AUCs)) (PP (IN of) (NP (NP (CD 6)) (CC and) (NP (CD 7.5)))))) (, ,) (ADVP (RB respectively)) (, ,) (PP (VBN combined) (PP (IN with) (NP (NP (DT a) (VBN fixed) (JJ Doc_8643973_735_745_Chemical) (NN dose)) (PP (IN of) (NP (QP (CD 185) (CD mg/m2))))))))) (. .)))
8643973	4	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (NP (NP (CD 30) (ADJP (RB previously) (JJ untreated)) (NNS patients)) (, ,) (NP (NP (DT all)) (PP (IN with) (NP (NP (DT a) (JJ good) (NN performance) (NN status)) (PRN (-LRB- -LRB-) (NP (NP (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group)) (QP (CD 0) (TO to) (CD 2))) (-RRB- -RRB-)))))) (VP (AUX have) (VP (AUX been) (VP (VBN entered) (PP (IN into) (NP (DT this) (JJ ongoing) (NN study)))))) (. .)))
8643973	5	(S1 (S (NP (NP (DT The) (JJ dose-limiting) (NN Doc_8643973_948_956_Disease)) (PP (IN of) (NP (DT the) (NN combination)))) (VP (AUX was) (NP (NP (NNP Doc_8643973_980_996_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643973_998_1008_Disease)) (, ,) (NP (NNP Doc_8643973_1010_1026_Disease)) (, ,) (CC and) (NP (NNP Doc_8643973_1032_1048_Disease))) (-RRB- -RRB-)))) (. .)))
8643973	6	(S1 (S (NP (NN Doc_8643973_1051_1064_Disease)) (VP (AUX was) (ADJP (RB largely) (JJ moderate))) (. .)))
8643973	7	(S1 (S (S (ADVP (RB So) (RB far)) (, ,) (NP (CD 14) (NNS patients)) (VP (AUX are) (ADJP (JJ evaluable)) (PP (IN for) (NP (NN response))))) (: ;) (S (PP (IN of) (NP (DT these))) (, ,) (NP (NP (CD eight)) (PRN (-LRB- -LRB-) (NP (CD 57) (NN %)) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (S (NP (NP (JJ objective) (PRN (-LRB- -LRB-) (ADJP (JJ complete) (CC or) (JJ partial)) (-RRB- -RRB-)) (NN response)) (CC and) (NP (NN disease))) (VP (VBD stabilized) (PP (IN in) (NP (CD six) (NNS patients)))))))) (. .)))
8643973	8	(S1 (S (NP (DT No) (NN patient)) (VP (AUX had) (NP (NN disease) (NN progression))) (. .)))
8643973	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_8643973_1317_1327_Chemical) (CD 185) (NNS mg/m2)) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ 3-hour) (NN infusion)) (VP (VBN followed) (ADVP (RB immediately)) (PP (IN by) (NP (NP (DT a) (JJ 1-hour) (NN infusion)) (PP (IN of) (NP (NNP Doc_8643973_1417_1428_Chemical))))) (PP (IN at) (NP (NP (DT an) (NN AUC)) (PP (IN of) (NP (CD 6)))))))))))) (VP (MD can) (VP (AUX be) (VP (VBN administered) (ADVP (RB safely)) (PP (IN in) (NP (DT a) (JJ 21-day) (NN schedule))) (PP (IN in) (NP (DT the) (NN outpatient) (NN setting))))))))) (. .)))
8643973	10	(S1 (S (NP (NP (DT The) (VBN recommended) (NN dose)) (PP (IN for) (NP (NN phase) (NNP III) (NNS studies)))) (VP (AUX is) (NP (NP (NNP Doc_8643973_1565_1575_Chemical) (CD 185) (NN mg/m2)) (CC and) (NP (NNP Doc_8643973_1590_1601_Chemical) (NNP AUC) (CD 6)))) (. .)))
8665051	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ acute) (JJ Doc_8665051_17_24_Chemical) (NN administration))) (PP (IN on) (NP (NP (JJ ventilatory) (CC and) (JJ peripheral) (NNS muscles)) (PP (IN in) (NP (NNS rats))))) (. .)))
8665051	1	(S1 (S (NP (JJ Occasional) (NN case) (NNS reports)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ acute) (NN Doc_8665051_133_141_Disease)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ massive) (NNS doses)) (PP (IN of) (NP (NNP Doc_8665051_194_209_Chemical)))))))))))))) (. .)))
8665051	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (NN Doc_8665051_233_241_Disease)))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
8665051	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (CD 60) (JJ male) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ daily) (NN injection)) (PP (IN of) (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP C)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP Doc_8665051_353_371_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8665051_373_374_Chemical)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NNP Doc_8665051_380_393_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8665051_395_396_Chemical)) (-RRB- -RRB-)))))))))) (SBAR (S (NP (NP (CD 80) (NN mg/kg/d)) (PP (IN for) (NP (CD 5) (NNP d.) (NNP Nutritional) (NN intake))) (, ,) (VP (VBN measured) (ADVP (RB daily)) (PP (IN in) (NP (CD 15) (NNS animals)))) (, ,)) (VP (VBD showed) (NP (DT a) (JJ significant) (NN Doc_8665051_489_513_Disease)) (PP (IN in) (NP (NP (DT the) (JJ Doc_8665051_521_528_Chemical-treated) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -50) (CC and) (CD -79)) (NN %)) (PP (IN in) (NP (NNP Doc_8665051_561_562_Chemical) (CC and) (NNP Doc_8665051_567_568_Chemical)))) (, ,) (RB respectively) (-RRB- -RRB-))))))))) (. .)))
8665051	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ similar) (NN Doc_8665051_620_639_Disease))))) (. .)))
8665051	5	(S1 (S (PP (IN In) (NP (DT the) (CD 45) (JJ remaining) (NNS animals))) (, ,) (NP (NP (NP (JJ diaphragm) (NN contractility)) (CC and) (NP (JJ histopathologic) (NNS features))) (PP (IN of) (NP (JJ several) (NNS muscles)))) (VP (AUX were) (VP (VBN studied))) (. .)))
8665051	6	(S1 (S (NP (NP (NNS Weights)) (PP (IN of) (NP (NP (NN respiratory)) (CC and) (NP (JJ peripheral) (NNS muscles))))) (VP (AUX were) (ADVP (RB similarly)) (VP (VBN decreased) (PP (IN after) (NP (JJ Doc_8665051_833_840_Chemical) (NN treatment))))) (. .)))
8665051	7	(S1 (S (NP (NP (JJ Maximal) (NNS twitches)) (PP (IN of) (NP (DT the) (NNS diaphragm)))) (VP (AUX were) (ADJP (JJR lower)) (PP (IN in) (NP (NP (NP (DT the) (NNP C) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 653) (JJ +/-) (CD 174) (NNS g/cm)) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (DT the) (NNP Doc_8665051_946_947_Chemical) (NN group))))) (-LRB- -LRB-) (NP (NP (CD 837) (JJ +/-) (CD 171) (NNS g/cm)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (: ;) (RB p) (QP (CD <) (CD 0.05))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NNP Doc_8665051_994_995_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 765) (JJ +/-) (CD 145) (NNS g/cm)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NNP NS))) (-RRB- -RRB-)))))) (. .)))
8665051	8	(S1 (S (S (NP (JJ Half-relaxation) (NN time)) (VP (AUX was) (VP (VBN prolonged) (PP (IN in) (NP (DT both) (JJ Doc_8665051_1072_1079_Chemical) (NNS groups)))))) (, ,) (CC and) (S (NP (NP (NN time)) (PP (TO to) (NP (JJ peak) (NN tension)))) (VP (AUX was) (ADVP (RB longer)) (PP (IN with) (NP (NNP Doc_8665051_1129_1130_Chemical))) (, ,) (SBAR (IN whereas) (S (NP (JJ Doc_8665051_1140_1147_Disease) (NNS tensions)) (VP (AUX were) (ADJP (JJ similar))))))) (. .)))
8665051	9	(S1 (S (NP (JJ Doc_8665051_1171_1178_Chemical) (NN treatment)) (ADVP (RB also)) (VP (VBN induced) (NP (NP (DT a) (JJ leftward) (NN shift)) (PP (IN of) (NP (DT the) (NN force-frequency) (NN curve)))) (PP (IN at) (NP (CD 25) (CC and) (CD 50) (NN Hz))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ saline) (NN treatment)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
8665051	10	(S1 (S (NP (NP (JJ ATPase) (NN staining)) (PP (IN of) (NP (NP (DT the) (JJ diaphragm) (, ,) (JJ scalenus) (NNS medius)) (, ,) (CC and) (NP (NNS gastrocnemius))))) (VP (VBD showed) (NP (NP (NP (NN type) (NNP IIb) (NN fiber) (NNP Doc_8665051_1403_1410_Disease)) (PP (IN in) (NP (DT the) (JJ Doc_8665051_1418_1425_Chemical) (NNS groups)))) (CC and) (ADVP (RB also)) (NP (JJ diaphragmatic) (NN type) (NNP IIa) (NNP Doc_8665051_1465_1472_Disease))) (PP (IN with) (NP (NNP Doc_8665051_1478_1479_Chemical))) (, ,) (SBAR (IN whereas) (S (NP (JJ histologic) (NNS examinations)) (VP (VBD revealed) (NP (NP (DT a) (JJ normal) (JJ muscular) (NN pattern)) (PP (IN with) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_8665051_1564_1572_Disease)))))))))) (. .)))
8665051	11	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT a) (JJ pair-fed) (PRN (-LRB- -LRB-) (NP (NNP PF)) (-RRB- -RRB-)) (NN study)) (, ,) (VP (VBN performed) (PP (IN in) (NP (NP (CD 18) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP C)) (, ,) (NP (NP (NNP Doc_8665051_1631_1632_Chemical)) (, ,) (CC and) (NP (NNP PF))) (-RRB- -RRB-))))) (, ,)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_8665051_1655_1669_Disease)) (VP (AUX was) (ADJP (ADJP (ADVP (RB considerably) (RBR less)) (JJ pronounced)) (PP (IN in) (NP (JJ PF) (NNS animals))) (PP (IN than) (PP (IN in) (NP (JJ Doc_8665051_1725_1726_Chemical-treated) (NNS animals))))))))) (. .)))
8665051	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (S (NP (IN that) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ short-term) (NN treatment)) (PP (IN with) (NP (NP (JJ massive) (NNS doses)) (PP (IN of) (NP (NNP Doc_8665051_1808_1816_Chemical))) (VP (VBN induced) (NP (NP (JJ severe) (NN respiratory) (CC and) (NN limb) (NN muscle) (NN wasting)) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT both) (NNS types)) (PP (IN of) (NP (NNP Doc_8665051_1887_1895_Chemical))) (VP (VBN induced) (ADVP (RB predominantly)) (NP (NN type) (NNP IIb) (NNP Doc_8665051_1927_1934_Disease)))))))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (VBN expected) (NNS alterations)) (PP (IN in) (NP (NP (JJ diaphragm) (JJ contractile) (NNS properties)) (PRN (: ;) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))))))) (CC neither) (NP (NNP Doc_8665051_2023_2030_Chemical))) (VP (VBD caused) (NP (NN muscle) (NNP Doc_8665051_2045_2053_Disease))))) (: ;) (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NN type) (S (NP (NNP IIb) (NNP Doc_8665051_2068_2075_Disease)) (VP (AUX was) (RB not) (VP (VBN caused) (PP (IN by) (NP (JJ acute) (JJ nutritional) (NN deprivation)) (ADVP (RB alone)))))))) (. .)))
8677458	0	(S1 (S (NP (NP (JJ Continuous) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_8677458_42_47_Chemical)))) (VP (TO to) (VP (VB prevent) (NP (JJ Doc_8677458_59_69_Chemical-induced) (NNP Doc_8677458_78_98_Disease)))) (. .)))
8677458	1	(S1 (S (NP (NN Doc_8677458_100_120_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ potential) (NN Doc_8677458_142_150_Disease)) (PP (IN of) (NP (NNP Doc_8677458_154_164_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (S (VP (VBG administering) (NP (NNP Doc_8677458_204_209_Chemical)) (ADVP (RB along)) (PP (IN with) (NP (DT the) (JJ cytotoxic) (NN agent))))))))))))) (. .)))
8677458	2	(S1 (S (NP (NN Doc_8677458_242_247_Chemical)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN administered) (PP (IN by) (NP (DT the) (JJ intravenous) (NN route))) (, ,) (SBAR (IN although) (S (NP (NP (NN experience)) (PP (IN with) (NP (NP (JJ oral) (NN delivery)) (PP (IN of) (NP (DT the) (NN drug)))))) (VP (AUX has) (VP (VBN increased))))))) (. .)))
8677458	3	(S1 (S (NP (NP (DT The) (JJ continuous) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_8677458_412_417_Chemical)))) (VP (AUX has) (NP (NP (DT the) (NN advantage)) (PP (IN of) (S (VP (RB not) (VBG requiring) (NP (JJ intravenous) (NN access))))))) (. .)))
8677458	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ subcutaneous) (NN delivery)) (PP (IN of) (NP (DT the) (VBG neutralizing) (NN agent)))) (VP (MD will) (RB not) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ inadequate) (JJ urinary) (JJ Doc_8677458_593_598_Chemical) (NNS concentrations)) (, ,) (PP (JJ such) (IN as) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (JJ oral) (NNP Doc_8677458_648_653_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VP (VBZ experiences) (NP (JJ severe) (JJ Doc_8677458_677_687_Chemical-induced) (NN Doc_8677458_696_702_Disease))) (CC and) (VP (AUX is) (ADJP (JJ unable) (S (VP (TO to) (VP (VB absorb) (NP (DT the) (NN drug)))))))))))))))))))))) (. .)))
8677458	5	(S1 (S (NP (NP (VBN Limited) (JJ clinical) (NN experience)) (PP (IN with) (NP (JJ continuous) (JJ subcutaneous) (NNP Doc_8677458_794_799_Chemical) (NN administration)))) (VP (VBZ suggests) (SBAR (S (NP (PRP it)) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ safe)) (, ,) (ADJP (JJ practical)) (, ,) (CC and) (ADJP (JJ economic))) (NN method)) (PP (IN of) (NP (NN drug) (NN delivery))) (SBAR (WHNP (WDT that)) (S (VP (VBZ permits) (S (NP (NNP Doc_8677458_899_909_Chemical)) (VP (TO to) (VP (AUX be) (VP (VBN administered) (ADVP (RB successfully)) (PP (IN in) (NP (DT the) (NN outpatient) (NN setting))))))))))))))) (. .)))
8686832	0	(S1 (NP (NP (NN Doc_8686832_0_17_Disease)) (PP (IN after) (NP (NP (JJ spinal) (NNS anaesthesia)) (VP (VBG involving) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_8686832_67_77_Chemical))))) (. .)))
8686832	1	(S1 (S (NP (NP (JJ Fifty-four) (NNS patients)) (, ,) (VP (VBN aged) (NP (CD 27-90) (NNS years))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN given) (NP (NNP Doc_8686832_133_143_Chemical)) (NP (CD 5) (NN %)) (PP (IN in) (NP (NP (ADJP (CD 6.8) (NN %)) (JJ Doc_8686832_155_162_Chemical) (NN solution)) (PP (IN for) (NP (JJ spinal) (NNS anaesthesia)))))))))) (VP (AUX were) (VP (VBN studied))) (. .)))
8686832	2	(S1 (S (NP (NP (NNS Thirteen)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (VBD experienced) (NP (NNP Doc_8686832_248_276_Disease)) (PP (IN after) (NP (NP (NN recovery)) (PP (IN from) (NP (NN anaesthesia)))))) (. .)))
8686832	3	(S1 (S (S (NP (NP (DT The) (NNS patients)) (VP (VBN affected))) (VP (AUX were) (ADJP (JJR younger)))) (PRN (-LRB- -LRB-) (VP (VBN p) (NP (NNP <) (CD 0.05))) (-RRB- -RRB-)) (CC and) (S (NP (NP (DT the) (NN site)) (PP (IN of) (NP (DT the) (JJ dural) (NN puncture)))) (VP (AUX was) (ADJP (ADJP (ADJP (JJR higher)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.01)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those) (NNS individuals)) (PP (IN without) (NP (NNP Doc_8686832_444_448_Disease)))))))) (. .)))
8686832	4	(S1 (S (NP (NP (NP (CD Five)) (PP (IN of) (NP (NP (DT the) (CD 13) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_8686832_485_489_Disease)))) (CC and) (NP (NP (CD seven)) (PP (IN of) (NP (NP (DT the) (CD 41) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)))) (PP (IN without) (NP (NNP Doc_8686832_533_537_Disease))))) (VP (VBD admitted) (PP (TO to) (NP (NP (DT a) (JJ high) (JJ Doc_8686832_557_564_Chemical) (NN intake)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (AUX be) (NP (DT a) (JJ contributing) (NN factor))))))))) (. .)))
8686832	5	(S1 (S (NP (NN Doc_8686832_611_631_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ intrathecal) (NN use)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_8686832_688_698_Chemical))))))) (. .)))
871943	0	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN serum)))) (VP (VBP cholinesterase) (PP (IN in) (NP (NNP Doc_871943_35_50_Chemical) (NNP Doc_871943_51_57_Disease)))) (. .)))
871943	1	(S1 (S (NP (NP (JJ Fifteen) (NNS patients)) (VP (VBG demonstrating) (NP (NP (JJ unexpected) (JJ prolonged) (NN Doc_871943_111_117_Disease)) (VP (VBG lasting) (NP (JJ several) (NNS hours)) (PP (IN after) (NP (NNP Doc_871943_146_161_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN by) (NP (NP (DT a) (JJ new) (NN preparation)) (PP (IN of) (NP (JJ human) (NN serum) (NN cholinesterase)))))))) (. .)))
871943	2	(S1 (S (NP (JJ Adequate) (JJ spontaneous) (NN respiration)) (VP (AUX was) (VP (VBN re-established) (PP (IN in) (NP (NP (DT an) (JJ average) (NN period)) (PP (IN of) (NP (CD ten) (NNS minutes))) (PP (IN after) (NP (DT the) (NN injection))))))) (. .)))
871943	3	(S1 (S (PP (IN In) (NP (CD 12) (NNS patients))) (NP (JJ biochemical) (JJ genetic) (NNS examinations)) (VP (VBD confirmed) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT an) (JJ atypical) (NN serum) (NN cholinesterase))))) (. .)))
871943	4	(S1 (S (PP (IN In) (NP (CD three) (NNS patients))) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (JJ usual) (NNS variants)))) (VP (AUX were) (VP (VBN found))) (. .)))
871943	5	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (VP (VBN supposed) (SBAR (IN that) (S (NP (NP (JJ other) (JJ unknown) (NNS variants)) (PP (IN of) (NP (NN serum) (NN cholinesterase)))) (VP (VBP exist) (SBAR (WHNP (WDT which)) (S (ADVP (RB cannot)) (VP (VBP hydrolyze) (NP (NNP Doc_871943_612_627_Chemical)))))))))) (. .)))
871943	6	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN serum) (NN cholinesterase))) (PP (IN in) (NP (NNP Doc_871943_664_679_Chemical) (NNP Doc_871943_680_686_Disease)))) (VP (VBD provided) (NP (JJ considerable) (NN relief)) (PP (TO to) (NP (PDT both) (NP (NN patient)) (CC and) (NP (NN anaesthetist))))) (. .)))
873132	0	(S1 (S (VP (VP (VBN Increased) (NP (NN sulfation))) (CC and) (VP (VBD decreased) (NP (NP (NN 7alpha-hydroxylation)) (PP (IN of) (NP (NNP Doc_873132_58_74_Chemical)))) (PP (IN in) (NP (NP (NNP Doc_873132_78_95_Chemical-induced) (NNP Doc_873132_104_115_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
873132	1	(S1 (S (NP (NP (NN Doc_873132_125_141_Chemical) (NN conjugation)) (, ,) (NP (NN transport) (NN capacity)) (, ,) (CC and) (NP (NN metabolism))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NN control)) (CC and) (NP (JJ Doc_873132_219_236_Chemical-treated) (NNS rats)))))) (. .)))
873132	2	(S1 (S (S (NP (NN Control) (NNS rats)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN capacity)) (SBAR (S (VP (TO to) (VP (VB transport) (NP (NNP Doc_873132_313_329_Chemical)) (PP (IN than) (NP (NNP Doc_873132_335_356_Chemical)))))))))))))) (, ,) (CC and) (S (NP (DT both)) (VP (AUX were) (VP (VBN decreased) (PP (IN by) (NP (JJ Doc_873132_385_402_Chemical) (NN treatment)))))) (. .)))
873132	3	(S1 (S (PP (IN During) (NP (JJ -LSB-24-14C) (JJ -RSB-) (JJ Doc_873132_429_448_Chemical) (NN infusion))) (, ,) (S (NP (JJ -LSB-14C) (JJ -RSB-) (NN biliary) (NN Doc_873132_472_481_Chemical) (NN secretion)) (VP (VBD increased))) (, ,) (CC but) (S (NP (JJ bile) (NN flow)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly)) (PP (IN in) (NP (UCP (DT either) (NN control) (CC or) (JJ Doc_873132_567_584_Chemical-treated)) (NNS rats)))))) (. .)))
873132	4	(S1 (S (NP (JJ Doc_873132_599_616_Chemical-treated) (NNS animals)) (VP (VBD excreted) (NP (ADJP (RB significantly) (JJR less)) (NN 14C)) (PP (IN as) (NP (NNP Doc_873132_668_684_Chemical))) (SBAR (IN than) (S (VP (AUX did) (VP (VB control) (NP (NP (NNS animals)) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (NN impairment)) (PP (IN of) (NP (NP (NN 7alpha-hydroxylation)) (PP (IN of) (NP (NNP Doc_873132_768_789_Chemical)))))))))))))) (. .)))
873132	5	(S1 (S (NP (JJ Doc_873132_791_808_Chemical) (NN treatment)) (VP (VP (AUX did) (RB not) (VP (VB impair) (NP (NP (NN conjugation)) (PP (IN of) (NP (NNP Doc_873132_849_865_Chemical)))))) (, ,) (CC but) (VP (AUX did) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN sulfation)) (PP (IN of) (NP (NNP Doc_873132_913_934_Chemical))))) (PP (PP (IN from) (NP (NP (CD 1.5) (NN %)) (PP (IN in) (NP (NNS controls))))) (PP (TO to) (NP (QP (RB nearly) (CD 4.0)) (NN %)))))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
873132	6	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (DT the) (NN rat)) (VP (AUX has) (NP (NP (DT a) (JJR poorer) (NN tolerance)) (PP (IN for) (NP (NNP Doc_873132_1081_1097_Chemical))) (SBAR (IN than) (SINV (AUX do) (NP (JJ certain) (JJ other) (NNS species)))))))))))) (. .)))
873132	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (NN rat)) (VP (VBZ converts) (NP (NP (NNP Doc_873132_1159_1175_Chemical)) (, ,) (NP (DT a) (JJ poor) (NN choleretic)) (, ,)) (PP (TO to) (NP (NP (NNP Doc_873132_1199_1215_Chemical)) (, ,) (NP (DT a) (JJ good) (NN choleretic))))) (. .)))
873132	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (NN conversion)) (VP (AUX is) (VP (VBN impaired) (PP (IN with) (NP (JJ Doc_873132_1274_1291_Chemical) (NN treatment))))))) (, ,) (NP (NN sulfation)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ important) (JJ alternate) (NN pathway)) (PP (IN for) (NP (NP (NN excretion)) (PP (IN of) (NP (DT this) (ADJP (RB potentially) (JJ harmful)) (NN Doc_873132_1393_1402_Chemical)))))))) (. .)))
8742498	0	(S1 (NP (NP (NN Influence)) (PP (IN of) (NP (NP (NN diet) (JJ free)) (PP (IN of) (NP (NNP Doc_8742498_26_29_Chemical-precursors))))) (PP (IN on) (NP (NP (NNP Doc_8742498_44_57_Chemical) (NNP Doc_8742498_58_72_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
8742498	1	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (NP (NP (DT the) (JJ hepatoprotective) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_8742498_140_160_Chemical)) (, ,) (NP (NP (DT a) (JJ selective) (NN inhibitor)) (PP (IN of) (NP (JJ Doc_8742498_187_203_Chemical) (NN polymerase))))) (PRN (-LRB- -LRB-) (NP (NP (NNP PARP)) (: ;) (NP (NNP EC) (CD 2.4.2.30))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNS mice)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_8742498_258_271_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8742498_273_276_Chemical)) (-RRB- -RRB-)) (NN -Doc_8742498_278_287_Disease))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (JJ Doc_8742498_309_312_Chemical-induced) (NN Doc_8742498_321_333_Disease)) (VP (VBZ involves) (NP (NP (DT a) (NN step)) (SBAR (WHNP (WDT which)) (S (VP (VBZ depends) (PP (IN on) (NP (NN adenoribosylation))))))))))))) (. .)))
8742498	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBZ investigates) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT a) (NN diet)) (ADJP (JJ free) (PP (IN of) (NP (NP (NNS precursors)) (PP (IN of) (NP (NP (NNP Doc_8742498_461_464_Chemical)) (, ,) (NP (NP (DT the) (NN substrate)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (NNP PARP)) (VP (VBZ acts))))) (, ,))) (PP (IN in) (NP (NP (JJ female) (NNP NMRI) (NNS mice)) (PP (IN with) (NP (NNP Doc_8742498_525_528_Chemical) (NNP Doc_8742498_529_538_Disease)))))))))))) (CC and) (VP (VBZ evaluates) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ simultaneous) (JJ Doc_8742498_583_590_Chemical) (NN consumption))) (PP (IN in) (NP (DT these) (NNS animals)))))) (. .)))
8742498	3	(S1 (S (NP (NN Doc_8742498_621_635_Disease)) (VP (AUX were) (VP (VBN quantified) (PP (IN as) (NP (NP (JJ serum) (NNS activities)) (PP (IN of) (NP (NP (NP (JJ Doc_8742498_675_684_Chemical-Doc_8742498_685_697_Chemical) (NN transaminase)) (PRN (-LRB- -LRB-) (VP (VBD GOT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_8742498_721_730_Chemical-Doc_8742498_731_739_Chemical) (NN transaminase)) (PRN (-LRB- -LRB-) (NP (NN GPT)) (-RRB- -RRB-))))))))) (. .)))
8742498	4	(S1 (S (SBAR (IN While) (S (NP (NNP Doc_8742498_766_769_Chemical)) (VP (VBD caused) (NP (NP (DT a) (JJ 117-fold) (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (NN transaminase) (NNS activities)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN kept) (PP (IN on) (NP (NP (DT a) (JJ standard) (NN laboratory) (NN diet)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (VP (ADVP (RB significantly)) (VBN exacerbated) (PP (IN by) (NP (NNP Doc_8742498_914_921_Chemical))))) (CC and) (VP (VBD inhibited) (PP (IN by) (NP (NP (NNP Doc_8742498_939_959_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8742498_961_964_Chemical)) (-RRB- -RRB-))))))))))))))))))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN fed) (NP (NP (DT a) (NN diet)) (ADJP (JJ free) (PP (IN of) (NP (NP (NNS precursors)) (PP (IN of) (NP (NNP Doc_8742498_1038_1041_Chemical)))))))))))) (. .)))
8742498	5	(S1 (S (S (PP (IN In) (NP (DT these) (NNS animals))) (, ,) (NP (NP (ADJP (RB only) (JJ minor)) (NNS increases)) (PP (IN of) (NP (NN serum) (NN transaminase) (NNS activities)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_8742498_1148_1151_Chemical)))))))) (, ,) (CC and) (S (PP (IN unlike) (NP (NP (DT the) (NN exacerbation)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_8742498_1191_1198_Chemical))) (PP (IN in) (NP (NP (NNS mice)) (PP (IN on) (NP (DT a) (JJ standard) (NN diet)))))))) (, ,) (NP (DT the) (NNP Doc_8742498_1231_1243_Disease)) (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (NP (CD 50) (NN %))) (PP (IN by) (NP (NNP Doc_8742498_1268_1275_Chemical)))))) (. .)))
8742498	6	(S1 (S (NP (NP (DT A) (JJ further) (ADJP (CD 64) (NN %)) (NN reduction)) (PP (IN of) (NP (NNP Doc_8742498_1304_1313_Disease)))) (VP (AUX was) (ADJP (JJ observed)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_8742498_1333_1336_Chemical)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NN Doc_8742498_1350_1357_Chemical/Doc_8742498_1358_1361_Chemical-mice)))))))) (. .)))
8742498	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (JJ Doc_8742498_1406_1409_Chemical-induced) (NN Doc_8742498_1418_1427_Disease)) (CC and) (NP (NP (PRP$ its) (NN exacerbation)) (PP (IN by) (NP (NNP Doc_8742498_1452_1459_Chemical))))) (VP (MD can) (ADVP (RB either)) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (NP (NP (JJ end-product) (NN inhibition)) (PP (IN of) (NP (NNP PARP))))) (PP (PP (IN by) (NP (NNP Doc_8742498_1519_1522_Chemical))) (CC or) (PP (IN by) (NP (NP (JJ dietary) (NN depletion)) (PP (IN of) (NP (NP (DT the) (NN enzyme) (POS 's)) (JJ substrate) (NN Doc_8742498_1573_1576_Chemical))))))))))))) (. .)))
8742498	8	(S1 (S (NP (PRP We)) (VP (VBP see) (NP (NP (DT the) (JJ main) (NN application)) (PP (IN of) (NP (NNP Doc_8742498_1609_1612_Chemical)))) (PP (IN as) (PP (IN for) (NP (NP (DT the) (JJ combinational) (NN use)) (PP (IN in) (NP (NP (JJ pharmaceutical) (NNS preparations)) (PP (IN of) (NP (NNP Doc_8742498_1676_1689_Chemical))) (PP (IN in) (NP (NN order))))) (S (VP (TO to) (VP (VB avoid) (NP (NNP Doc_8742498_1708_1722_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT this) (ADJP (RB widely) (VBN used)) (JJ analgesic))))))))))))) (. .)))
8766220	0	(S1 (S (NP (NP (NNS Nightmares)) (CC and) (NP (NN Doc_8766220_15_29_Disease))) (PP (IN after) (NP (NP (JJ long-term) (NN intake)) (PP (IN of) (NP (NNP Doc_8766220_56_64_Chemical))))) (VP (VBN combined) (PP (IN with) (NP (NNS antidepressants)))) (. .)))
8766220	1	(S1 (S (NP (NNP Doc_8766220_96_104_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ weak) (NN opioid)) (PP (IN with) (NP (NP (NNS effects)) (PP (IN on) (NP (NP (JJ adrenergic) (CC and) (JJ serotonergic) (NN neurotransmission)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNP Doc_8766220_206_212_Disease) (NNP Doc_8766220_213_217_Disease)) (CC and) (NP (JJ chronic) (JJ non) (JJ malignant) (NNP Doc_8766220_244_248_Disease)))))))))))))))) (. .)))
8766220	2	(S1 (S (NP (DT This) (NN drug)) (VP (AUX was) (VP (VBN initiated) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (NNP Doc_8766220_294_304_Chemical)) (CC and) (NP (NNP Doc_8766220_309_333_Chemical)))) (PP (IN in) (NP (NP (DT a) (JJ Doc_8766220_339_351_Disease) (NN patient)) (PP (IN with) (NP (NNP Doc_8766220_365_377_Disease))))))) (. .)))
8766220	3	(S1 (S (NP (JJ Fifty-six) (NNS days)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (DT the) (NN treatment))))) (NP (DT the) (NN patient)) (VP (VBD presented) (NP (NP (NN Doc_8766220_450_464_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB only)) (VP (VBD stopped) (PP (IN after) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NP (JJ psycho-active) (NNS drugs)) (CC and) (NP (NNP Doc_8766220_531_539_Chemical))))))))))) (. .)))
8766220	4	(S1 (S (NP (DT The) (NN case) (NN report)) (VP (VBZ questions) (NP (NP (DT the) (JJ long) (NN term) (NN use)) (PP (IN of) (NP (NP (JJ Doc_8766220_588_592_Disease) (NNS killers)) (VP (VBN combined) (PP (IN with) (NP (JJ psycho-active) (NNS drugs))) (PP (IN in) (NP (JJ chronic) (NN non))) (NP (JJ malignant) (NNP Doc_8766220_660_664_Disease)) (, ,) (SBAR (ADVP (RB especially)) (IN if) (S (NP (NNP Doc_8766220_680_684_Disease)) (VP (AUX is) (PP (IN under) (NP (NN control))))))))))) (. .)))
8800187	0	(S1 (NP (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8800187_10_26_Chemical)))) (CC and) (NP (JJ Doc_8800187_31_46_Chemical) (NN therapy))) (PP (IN on) (NP (NP (NNP Doc_8800187_58_69_Chemical) (NNP Doc_8800187_70_78_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
8800187	1	(S1 (S (NP (NN Doc_8800187_100_111_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN contributor)) (PP (TO to) (NP (NN mortality))) (PP (IN in) (NP (JJ tricyclic) (JJ antidepressant) (NN Doc_8800187_176_184_Disease))))) (. .)))
8800187	2	(S1 (S (NP (JJ Recent) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ tricyclic) (NNS antidepressants)) (VP (VBP inhibit) (NP (JJ Doc_8800187_245_252_Chemical) (NN influx)) (PP (IN in) (NP (DT some) (NNS tissues))))))) (. .)))
8800187	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD addressed) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (JJ Doc_8800187_320_327_Chemical) (NN channel) (NN blockade))) (PP (IN in) (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_381_392_Disease))))) (. .)))
8800187	4	(S1 (S (NP (CD Two) (NNS interventions)) (VP (AUX were) (VP (VBN studied) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN shown) (ADVP (RB previously)) (S (VP (TO to) (VP (VB improve) (NP (NN blood) (NN pressure)) (PP (IN with) (NP (NP (JJ Doc_8800187_497_504_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_8800187_521_529_Disease)))))))))))))) (. .)))
8800187	5	(S1 (NP (NNP Doc_8800187_531_536_Chemical) (CC and) (NNP Doc_8800187_541_556_Chemical) (. .)))
8800187	6	(S1 (S (NP (JJ Anesthetized) (NNS rats)) (VP (VBD received) (NP (DT the) (JJ tricyclic) (JJ antidepressant) (JJ Doc_8800187_614_625_Chemical) (NN IP)) (S (VP (TO to) (VP (VB produce) (NP (NP (NNP Doc_8800187_640_651_Disease)) (, ,) (NP (NNS QRS) (NN prolongation)) (, ,) (CC and) (NP (NNP Doc_8800187_675_686_Disease))))))) (. .)))
8800187	7	(S1 (S (ADVP (NP (CD Fifteen) (NN min)) (RB later)) (, ,) (NP (NNS animals)) (VP (VBD received) (NP (NP (NNP Doc_8800187_724_729_Chemical)) (, ,) (NP (NNP Doc_8800187_731_737_Chemical)) (, ,) (CC or) (NP (NN saline)))) (. .)))
8800187	8	(S1 (S (PP (IN In) (NP (DT a) (JJ second) (NN experiment))) (, ,) (NP (NNS rats)) (VP (VBD received) (NP (NP (JJ tricyclic) (JJ antidepressant) (JJ Doc_8800187_813_824_Chemical) (NNS IP)) (VP (VBN followed) (PP (IN in) (NP (CD 15) (NN min))) (PP (IN by) (NP (NP (NNP Doc_8800187_850_865_Chemical)) (CC or) (NP (NN saline))))))) (. .)))
8800187	9	(S1 (S (NP (NP (JJ Doc_8800187_886_892_Chemical) (NN briefly)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN min)) (-RRB- -RRB-))) (VP (VP (VBD reversed) (NP (NN Doc_8800187_918_929_Disease))) (CC and) (VP (VBZ QRS) (NP (NN prolongation)))) (. .)))
8800187	10	(S1 (S (NP (NP (NNP Doc_8800187_952_957_Chemical)) (CC and) (NP (NNP Doc_8800187_962_977_Chemical))) (VP (VBD failed) (S (VP (TO to) (VP (VB improve) (NP (NN blood) (NN pressure)))))) (. .)))
8800187	11	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_8800187_1029_1052_Disease)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.004)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_8800187_1069_1077_Disease)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.03)))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NNP Doc_8800187_1096_1101_Chemical) (NN group)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT the) (JJ other) (NNS groups))))) (. .)))
8800187	12	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_8800187_1176_1181_Chemical)) (CC or) (NP (NNP Doc_8800187_1185_1200_Chemical))))) (VP (AUX did) (RB not) (VP (VB reverse) (NP (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_1250_1261_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
8800187	13	(S1 (S (NP (JJ Doc_8800187_1271_1276_Chemical) (NN therapy)) (VP (MD may) (ADVP (RB possibly)) (VP (VB worsen) (NP (DT both) (NNP Doc_8800187_1310_1360_Disease)))) (. .)))
8800187	14	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX do) (RB not) (VP (VB support) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (JJ Doc_8800187_1403_1410_Chemical) (NN channel) (NN inhibition)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_1486_1497_Disease)))))))))) (. .)))
8841157	0	(S1 (NP (NP (NP (NN Doc_8841157_0_9_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (JJ Doc_8841157_17_31_Chemical) (NN antagonist)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ essential) (NNP Doc_8841157_74_86_Disease))))))) (: :) (NP (NP (DT a) (JJ comparative) (NN study)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN against) (NP (NNP Doc_8841157_143_153_Chemical)))))) (. .)))
8841157	1	(S1 (FRAG (S (VP (TO To) (VP (VB compare) (NP (NP (DT the) (JJ antihypertensive) (NN efficacy)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_8841157_216_230_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_8841157_243_252_Chemical)) (, ,)))) (PP (IN with) (NP (NP (DT a) (NN reference) (NN therapy)) (, ,) (NP (NNP Doc_8841157_280_290_Chemical))))))) (. .)))
8841157	2	(S1 (S (NP (NP (QP (CD One) (CD hundred)) (JJ sixty-eight) (NN adult) (NNS outpatients)) (PP (IN with) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NNP Doc_8841157_365_377_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (IN in) (NP (NP (JJ double-blind) (NN fashion)) (CC and) (NP (JJ equal) (NN number)))) (S (VP (TO to) (VP (VB receive) (NP (QP (CD 80) (CD mg) (NN Doc_8841157_460_469_Chemical) (CC or) (CD 5) (CD mg)) (NN Doc_8841157_478_488_Chemical)) (PP (IN for) (NP (CD 12) (NNS weeks)))))))) (. .)))
8841157	3	(S1 (S (PP (IN After) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN therapy))))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (NN blood) (NN pressure)) (S (VP (VBD remained) (ADJP (JJ uncontrolled))))))) (, ,) (NP (CD 5) (JJ mg) (NN Doc_8841157_590_600_Chemical)) (VP (AUX was) (VP (VBN added) (PP (TO to) (NP (DT the) (JJ initial) (NN therapy))))) (. .)))
8841157	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NP (CD 4)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 12) (NNS weeks)))))) (. .)))
8841157	5	(S1 (S (NP (DT The) (JJ primary) (NN efficacy) (NN variable)) (VP (AUX was) (NP (NP (NN change)) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (NP (NN mean)) (VP (VBG sitting) (NP (JJ diastolic) (NN blood) (NN pressure)) (PP (IN at) (NP (CD 8) (NNS weeks)))))))) (. .)))
8841157	6	(S1 (S (NP (JJ Secondary) (NNS variables)) (VP (VBD included) (NP (NN change)) (PP (IN in) (S (VP (VBG sitting) (NP (NP (JJ systolic) (NN blood) (NN pressure)) (CC and) (NP (NN responder) (NNS rates))))))) (. .)))
8841157	7	(S1 (S (NP (PDT Both) (NP (NNP Doc_8841157_895_904_Chemical)) (CC and) (NP (NNP Doc_8841157_909_919_Chemical))) (VP (AUX were) (ADJP (JJ effective) (PP (IN at) (S (VP (VBG lowering) (NP (NN blood) (NN pressure)) (PP (IN at) (NP (NP (CD 4)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 12) (NNS weeks))))))))) (. .)))
8841157	8	(S1 (S (NP (JJ Similar) (NNS decreases)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT both) (NNS groups))) (, ,) (PP (IN with) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN for) (NP (NP (DT any) (NN variable)) (VP (VBD analyzed)))))))))) (. .)))
8841157	9	(S1 (S (PP (IN For) (NP (DT the) (JJ primary) (NN variable))) (NP (DT the) (NN difference)) (VP (VP (AUX was) (NP (CD 0.5) (NN mm)) (NP (NNP Hg)) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NNP Doc_8841157_1191_1200_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (SYM =) (CD 0.68)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval))) (, ,) (NP (QP (CD -2.7) (TO to) (CD 1.7))) (-RRB- -RRB-))) (. .)))
8841157	10	(S1 (S (NP (NP (NN Responder) (NNS rates)) (PP (IN at) (NP (CD 8) (NNS weeks)))) (VP (AUX were) (NP (NP (NP (CD 66.7) (NN %)) (PP (IN for) (NP (NNP Doc_8841157_1293_1302_Chemical)))) (CC and) (NP (NP (CD 60.2) (NN %)) (PP (IN for) (NP (NP (NNP Doc_8841157_1317_1327_Chemical)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.39)))) (-RRB- -RRB-))))))) (. .)))
8841157	11	(S1 (S (NP (DT Both) (NNS treatments)) (VP (AUX were) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
8841157	12	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (ADJP (JJ drug-related) (JJ dependent)) (NNP Doc_8841157_1417_1422_Disease)))) (VP (AUX was) (ADJP (RB somewhat) (JJR higher)) (PP (IN in) (NP (DT the) (NNP Doc_8841157_1450_1460_Chemical) (NN group))) (, ,) (PP (ADVP (RB particularly)) (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (NP (CD 10) (NNS mg)) (PP (IN per) (NP (NN day)))) (-LRB- -LRB-) (NP (NP (NP (CD 2.4) (NN %)) (PP (IN for) (NP (NP (CD 80) (NNS mg)) (NP (NNP Doc_8841157_1524_1533_Chemical))))) (: ;) (NP (NP (CD 3.6) (NN %)) (PP (IN for) (NP (CD 5) (NN mg) (NNP Doc_8841157_1549_1559_Chemical)))) (: ;) (NP (NP (CD 0) (NN %)) (PP (IN for) (NP (NP (NNP Doc_8841157_1568_1577_Chemical)) (CC plus) (NP (CD 5) (JJ mg) (NNP Doc_8841157_1588_1598_Chemical))))) (: ;) (NP (NP (CD 14.3) (NN %)) (PP (IN for) (NP (CD 10) (NN mg) (NNP Doc_8841157_1616_1626_Chemical))))) (-RRB- -RRB-)))))) (. .)))
8841157	13	(S1 (S (NP (DT The) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_8841157_1661_1670_Chemical)) (VP (AUX is) (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ effective)) (PP (IN as) (NP (NNP Doc_8841157_1699_1709_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NNP Doc_8841157_1747_1759_Disease))))))))) (. .)))
8841157	14	(S1 (S (NP (DT The) (NNS results)) (ADVP (RB also)) (VP (VP (VBP show) (S (NP (NNP Doc_8841157_1783_1792_Chemical)) (VP (TO to) (VP (AUX be) (ADVP (RB well)) (VP (VBN tolerated)))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJ side) (NNS effects)) (ADJP (JJ characteristic) (PP (IN of) (NP (DT this) (JJ comparator) (NN class))))) (, ,) (NP (NNP Doc_8841157_1911_1926_Chemical) (NNP Doc_8841157_1927_1934_Chemical) (NNS antagonists)))))))))) (. .)))
8854309	0	(S1 (NP (NP (DT A) (NN measure)) (PP (IN of) (NP (NNP Doc_8854309_13_34_Disease))) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_8854309_50_57_Chemical-induced) (NNP Doc_8854309_66_74_Disease))))) (. .)))
8854309	1	(S1 (S (NP (NP (JJ Doc_8854309_76_83_Chemical-induced) (NNP Doc_8854309_92_100_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8854309_102_105_Disease)) (-RRB- -RRB-))) (VP (VBZ remains) (NP (NP (DT an) (JJ important) (JJ drug-induced) (NN model)) (PP (IN of) (NP (JJ idiopathic) (NNP Doc_8854309_161_169_Disease))) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (DT no) (JJ psychophysiologic) (NN marker)) (VP (AUX has) (ADVP (RB yet)) (VP (VBN emerged))))))) (. .)))
8854309	2	(S1 (S (NP (NP (NNS Measures)) (PP (IN of) (NP (NNP Doc_8854309_237_258_Disease)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB distinguish) (S (NP (NP (DT a) (NN group)) (PP (IN of) (NP (JJ abstinent) (JJ Doc_8854309_319_332_Chemical) (NNS abusers)))) (VP (VBG endorsing) (NP (JJ past) (NNP Doc_8854309_356_359_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 32)) (-RRB- -RRB-)) (PP (IN from) (NP (NP (DT another) (NN group)) (PP (IN of) (NP (NP (JJ Doc_8854309_391_396_Chemical) (NNS addicts)) (SBAR (WHNP (WP who)) (S (VP (VBD denied) (NP (JJ past) (NNP Doc_8854309_421_424_Disease))))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 29)) (-RRB- -RRB-))))))) (. .)))
8888541	0	(S1 (NP (NP (NN Doc_8888541_0_18_Disease)) (PP (IN from) (NP (JJ Doc_8888541_24_35_Chemical-Doc_8888541_36_51_Chemical) (NN interaction))) (. .)))
8888541	1	(S1 (S (NP (NP (JJ Excessive) (NN stimulation)) (PP (IN of) (NP (JJ Doc_8888541_90_99_Chemical) (NN 5HT1A) (NNS receptors)))) (VP (VBZ causes) (NP (NP (DT a) (NN syndrome)) (PP (IN of) (NP (JJ Doc_8888541_137_146_Chemical) (NN excess))) (SBAR (WHNP (WDT that)) (S (VP (VBZ consists) (PP (IN of) (NP (VBG shivering) (, ,) (NNP Doc_8888541_182_197_Disease) (, ,) (NNP Doc_8888541_199_209_Disease) (, ,) (NNP Doc_8888541_211_220_Disease) (, ,) (NNP Doc_8888541_222_231_Disease) (CC and) (NNP Doc_8888541_236_248_Disease)))))))) (. .)))
8888541	2	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (DT this) (NN syndrome)))) (VP (AUX is) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NP (DT a) (JJ monoamine) (NN oxidase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP MAOI)) (-RRB- -RRB-))) (CC and) (NP (DT a) (JJ specific) (JJ Doc_8888541_367_376_Chemical) (NN reuptake) (NN inhibitor)))))) (. .)))
8888541	3	(S1 (S (NP (NN Doc_8888541_397_408_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ new) (NN antidepressant) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN reuptake)) (PP (IN of) (NP (NP (NNP Doc_8888541_469_478_Chemical)) (CC and) (NP (NNP Doc_8888541_483_497_Chemical)))))))))) (. .)))
8888541	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NNP Doc_8888541_511_522_Chemical-MAOI) (NN interaction)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (DT the) (NNP Doc_8888541_561_579_Disease))) (PP (IN in) (NP (NP (DT a) (JJ 23-y-old) (NN male)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_8888541_614_629_Chemical)) (PP (IN for) (NP (NN Doc_8888541_634_644_Disease)))))))))))))) (. .)))
8888541	5	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (ADVP (RB well)) (PP (IN until) (NP (NP (DT the) (NN morning)) (PP (IN of) (NP (NN presentation))))) (SBAR (WHADVP (WRB when)) (S (NP (PRP he)) (VP (VBD took) (NP (NP (CD 1/2) (NN tab)) (PP (IN of) (NP (NNP Doc_8888541_721_732_Chemical))))))))) (. .)))
8888541	6	(S1 (S (PP (IN Within) (NP (CD 2) (NNP h))) (NP (PRP he)) (VP (VBD became) (VP (VBN confused) (PP (IN with) (S (VP (VBG jerking) (NP (NP (NNS movements)) (PP (IN of) (NP (NP (PRP$ his) (NNS extremities)) (, ,) (NP (NP (NNP Doc_8888541_807_814_Disease)) (CC and) (NP (NNP Doc_8888541_819_827_Disease))))))))))) (. .)))
8888541	7	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN brought) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT a) (NN hospital)) (SBAR (WHADVP (WRB where)) (S (NP (PRP he)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN agitated) (CC and) (VBN confused) (PP (IN with) (NP (VBG shivering) (, ,) (NNP Doc_8888541_930_945_Disease) (, ,) (NNP Doc_8888541_947_955_Disease) (, ,) (NNP Doc_8888541_957_967_Disease) (CC and) (NNP diaphoresis))))))))))))))) (. .)))
8888541	8	(S1 (S (NP (PRP$ His) (NNS pupils)) (VP (VP (AUX were) (NP (CD 7) (NN mm))) (CC and) (VP (ADVP (RB sluggishly)) (VBP reactive) (S (VP (TO to) (VP (VB light)))))) (. .)))
8888541	9	(S1 (S (S (NP (JJ Vital) (NNS signs)) (VP (AUX were))) (: :) (S (NP (NN blood) (NN pressure) (CD 120/67)) (VP (VBD mm) (NP (NP (NNP Hg)) (, ,) (NP (NP (NN heart) (NN rate) (NN 127/min)) (, ,) (NP (NN respiratory) (NN rate) (NN 28/min)) (, ,) (CC and) (NP (NN temperature) (CD 97) (NN F)))))) (. .)))
8888541	10	(S1 (S (PP (IN After) (NP (NP (CD 180) (NN mg)) (PP (IN of) (NP (JJ Doc_8888541_1170_1178_Chemical) (NNS i.v.))))) (NP (PRP he)) (VP (VBD remained) (ADJP (JJ tremulous) (PP (IN with) (NP (UCP (NNP Doc_8888541_1211_1226_Disease) (CC and) (JJ clenched)) (NNS jaws))))) (. .)))
8888541	11	(S1 (S (NP (PRP He)) (VP (VP (AUX was) (VP (VBN intubated) (PP (IN for) (NP (NP (JJ airway) (NN protection)) (CC and) (NP (NP (IN because)) (PP (IN of) (NP (NNP Doc_8888541_1300_1315_Disease)))))))) (, ,) (CC and) (VP (AUX was) (ADJP (JJ Doc_8888541_1325_1334_Disease) (S (VP (TO to) (VP (VB control) (NP (NNP Doc_8888541_1346_1361_Disease)))))))) (. .)))
8888541	12	(S1 (S (NP (PRP$ His) (JJ subsequent) (NN course)) (VP (AUX was) (ADJP (JJ remarkable) (PP (IN for) (NP (NP (JJ non-immune) (NN Doc_8888541_1415_1431_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved)))))))) (. .)))
8888541	13	(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ maximal) (NN temperature)) (VP (AUX was) (NP (CD 101.2) (NN F)))) (CC and) (S (NP (PRP$ his) (NN CPK)) (VP (VBD remained) (S (VP (VBG <) (NP (CD 500) (NN units/L)) (PP (IN with) (NP (NP (DT no) (JJ other) (NN evidence)) (PP (IN of) (NP (NNP Doc_8888541_1555_1569_Disease))))))))) (. .)))
8888541	14	(S1 (S (S (NP (PRP$ His) (JJ mental) (NN status)) (VP (VBD normalized))) (CC and) (S (NP (PRP he)) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT a) (NN psychiatry) (NN ward)))))) (. .)))
8888541	15	(S1 (S (NP (DT This) (NN patient)) (VP (VBD survived) (PP (IN without) (NP (NP (NNS sequelae)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ aggressive) (NN sedation)) (CC and) (NP (NN neuromuscular) (NN Doc_8888541_1733_1742_Disease)))))))) (. .)))
8911359	0	(S1 (NP (NP (JJ Doc_8911359_0_16_Chemical) (JJ associated) (JJ Doc_8911359_28_42_Disease--a) (ADJP (RB highly) (JJ aggressive)) (NN disease)) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (CD 12) (NNS cases)))) (. .)))
8911359	1	(S1 (S (NP (PRP We)) (VP (VBD gained) (NP (NP (NN knowledge)) (PP (IN of) (NP (NP (DT the) (NN etiology) (, ,) (NN treatment) (CC and) (NN prevention)) (PP (IN of) (NP (NNP Doc_8911359_169_185_Chemical) (NNP associated) (NNP Doc_8911359_197_214_Disease))))))) (. .)))
8911359	2	(S1 (S (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (DT The) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (NP (CD 6) (NNS men)) (CC and) (NP (CD 6) (NNS women))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age)) (NP (CD 55) (NNS years))) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_8911359_305_321_Chemical) (NNP associated) (NNP Doc_8911359_333_347_Disease)))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
8911359	3	(S1 (S (NP (DT All) (NNP Doc_8911359_376_382_Disease)) (VP (AUX were) (NP (NP (NN grade) (CD 3)) (CC or) (NP (CD 4) (JJ transitional) (NN cell) (NN Doc_8911359_419_428_Disease)))) (. .)))
8911359	4	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 5) (NNS patients)) (VP (ADVP (RB initially)) (VBN treated) (PP (IN with) (NP (JJ endoscopic) (NN resection)))))) (NP (RB alone) (QP (RB only) (CD 1))) (VP (AUX is) (ADJP (JJ alive)) (PP (IN without) (NP (NN disease)))) (. .)))
8911359	5	(S1 (S (NP (NP (IN Of) (DT the) (CD 6) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ early) (JJ cystectomy) (CD 4)))))) (VP (AUX were) (ADJP (JJ alive)) (PP (IN at) (NP (QP (CD 24) (TO to) (CD 111)) (NNS months)))) (. .)))
8911359	6	(S1 (S (NP (NP (DT The) (VBG remaining) (NN patient)) (PP (IN with) (NP (JJ extensive) (NN Doc_8911359_651_657_Disease)))) (VP (VP (VBD underwent) (NP (JJ partial) (NN cystectomy)) (PP (IN for) (NP (NN palliation)))) (CC and) (VP (VBD died) (ADVP (NP (CD 3) (NNS months)) (RB later)))) (. .)))
8911359	7	(S1 (S (NP (JJ Doc_8911359_740_756_Chemical) (JJ associated) (NN Doc_8911359_768_781_Disease)) (VP (AUX is) (NP (DT an) (JJ aggressive) (NN disease))) (. .)))
8911359	8	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ long-term) (NN survival)) (VP (AUX is) (ADJP (JJ possible)) (SBAR (WHADVP (WRB when)) (S (NP (JJ radical) (NN cystectomy)) (VP (AUX is) (VP (VBN performed) (PP (IN for) (NP (NNP Doc_8911359_889_903_Disease))) (PP (PP (IN with) (NP (NP (DT any) (NN sign)) (PP (IN of) (NP (NN invasion))))) (CC and) (PP (IN for) (NP (JJ recurrent) (JJ high) (NN grade) (NN disease)))) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBP noninvasive))))))))) (. .)))
8958188	0	(S1 (S (NP (NP (DT A) (NN phase) (NN I) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (DT the) (NNP Doc_8958188_32_42_Chemical) (NN antifolate) (NNP Doc_8958188_54_64_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8958188_66_72_Chemical)) (-RRB- -RRB-))))) (VP (VBN given) (PP (IN with) (NP (JJ oral) (NNP Doc_8958188_90_100_Chemical)))) (. .)))
8958188	1	(S1 (S (NP (NN Doc_8958188_102_112_Chemical)) (VP (AUX is) (NP (NP (DT an) (NN antifolate)) (SBAR (WHNP (WDT which)) (S (VP (VBZ inhibits) (NP (NP (JJ Doc_8958188_145_171_Chemical) (NN formyltransferase)) (PRN (-LRB- -LRB-) (NP (NN GARFT)) (-RRB- -RRB-))) (, ,) (S (NP (DT an) (NN enzyme)) (ADJP (JJ essential) (PP (IN for) (NP (FW de) (FW novo) (JJ Doc_8958188_231_237_Chemical) (NN synthesis)))))))))) (. .)))
8958188	2	(S1 (S (NP (JJ Extensive) (JJ experimental) (CC and) (JJ limited) (JJ clinical) (NNS data)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_8958188_314_324_Chemical)) (VP (AUX has) (NP (NP (NN activity)) (PP (IN against) (NP (NP (NP (NNP Doc_8958188_346_353_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADJP (JJ refractory) (PP (TO to) (NP (JJ other) (NNS drugs)))))))) (, ,) (ADVP (RB notably)) (NP (NNP Doc_8958188_399_411_Chemical)))))))))) (. .)))
8958188	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ initial) (JJ clinical) (NN development)) (PP (IN of) (NP (NNP Doc_8958188_458_468_Chemical)))) (VP (AUX was) (VP (VBN curtailed) (PP (IN because) (IN of) (NP (JJ severe) (CC and) (JJ cumulative) (NN antiproliferative) (NN Doc_8958188_534_544_Disease))))) (. .)))
8958188	4	(S1 (S (NP (JJ Preclinical) (NN murine) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_8958188_595_603_Disease)) (PP (IN of) (NP (NNP Doc_8958188_607_617_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (NP (NP (JJ low) (NN dose) (NNP Doc_8958188_647_657_Chemical) (NN administration)) (, ,) (NP (NP (FW i.e.)) (PP (IN for) (NP (NP (CD 7) (NNS days)) (ADVP (RB prior) (PP (TO to)))))) (CC and) (NP (NP (CD 7) (NNS days)) (PP (VBG following) (NP (DT a) (JJ single) (JJ bolus) (NN dose)))))))))))) (. .)))
8958188	5	(S1 (S (NP (DT This) (NN observation)) (VP (VBD prompted) (NP (NP (DT a) (NN Phase) (NN I) (JJ clinical) (NN study)) (PP (IN of) (NP (NNP Doc_8958188_795_805_Chemical))) (VP (VBN given) (PP (IN with) (NP (NP (JJ Doc_8958188_817_827_Chemical) (NN supplementation)) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (VBN confirmed) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_8958188_873_881_Disease)) (PP (IN of) (NP (NNP Doc_8958188_885_895_Chemical)))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB markedly)) (VBN reduced) (PP (IN by) (NP (JJ Doc_8958188_923_933_Chemical) (NN supplementation))))))))))))))))) (. .)))
8958188	6	(S1 (S (NP (NP (NN Doc_8958188_951_967_Disease)) (CC and) (NP (NN Doc_8958188_972_981_Disease))) (VP (AUX were) (NP (DT the) (JJ major) (NN Doc_8958188_997_1007_Disease))) (. .)))
8958188	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ clear) (NN relationship)) (PP (IN between) (NP (NP (JJ clinical) (NN Doc_8958188_1058_1066_Disease)) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN plasma) (JJ Doc_8958188_1092_1098_Chemical) (NN elevation)))))))) (. .)))
8958188	8	(S1 (S (NP (JJ Associated) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (JJ Doc_8958188_1147_1157_Chemical) (NN plasma) (NNS pharmacokinetics)) (VP (AUX were) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (JJ Doc_8958188_1202_1212_Chemical) (NN administration)) (VP (VBG indicating) (SBAR (IN that) (S (NP (NN supplementation)) (VP (AUX is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB reduce) (NP (NNP Doc_8958188_1282_1290_Disease)) (PP (IN by) (S (VP (VBG enhancing) (NP (JJ Doc_8958188_1304_1314_Chemical) (NN plasma) (NN clearance)))))))))))))))))))) (. .)))
8958188	9	(S1 (S (NP (NP (DT The) (NN work)) (VP (VBN described) (PP (IN in) (NP (DT this) (NN report))))) (VP (AUX has) (VP (VBN identified) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (NP (NP (DT a) (ADJP (RB clinically) (JJ acceptable)) (NN schedule)) (PP (IN for) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (JJ GARFT) (NN inhibitor)))))))) (. .)))
8958188	10	(S1 (S (NP (DT This) (NN information)) (VP (MD will) (VP (VB facilitate) (NP (NP (DT the) (JJ future) (NN evaluation)) (PP (IN of) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NP (NNS compounds)) (PP (IN in) (NP (JJ Doc_8958188_1564_1570_Disease) (NN therapy)))))))))) (. .)))
8988571	0	(S1 (S (S (NP (JJ Fatal)) (VP (VBN excited) (NP (NNP Doc_8988571_14_22_Disease)) (PP (VBG following) (NP (JJ Doc_8988571_33_40_Chemical) (NN use))))) (: :) (S (NP (JJ epidemiologic) (NNS findings)) (VP (VBP provide) (NP (NP (JJ new) (NN evidence)) (PP (IN for) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_8988571_108_115_Chemical) (NNP Doc_8988571_116_124_Disease)))))))) (. .)))
8988571	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT an) (NN outbreak)) (PP (IN of) (NP (NP (NNS deaths)) (PP (IN from) (NP (NP (JJ Doc_8988571_165_172_Chemical-induced) (JJ excited) (NNP Doc_8988571_189_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8988571_199_203_Disease)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNP Dade) (NNP County)) (, ,) (NP (NNP Florida)))) (PP (IN between) (NP (CD 1979) (CC and) (CD 1990))))) (. .)))
8988571	2	(S1 (S (PP (IN From) (NP (NP (DT a) (NN registry)) (PP (IN of) (NP (NP (DT all) (JJ Doc_8988571_275_282_Chemical-related) (NNS deaths)) (PP (IN in) (NP (NP (NNP Dade) (NNP County)) (, ,) (NP (NNP Florida)) (, ,))) (PP (IN from) (NP (CD 1969-1990))))))) (, ,) (NP (CD 58) (NN Doc_8988571_342_346_Disease)) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (CD 125) (NNS victims)) (PP (IN of) (NP (NP (JJ accidental) (NNP Doc_8988571_392_399_Chemical) (NNP Doc_8988571_400_408_Disease)) (PP (IN without) (NP (VBN excited) (NN Doc_8988571_425_433_Disease))))))))) (. .)))
8988571	3	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NNS controls)))) (, ,) (NP (NNP Doc_8988571_459_463_Disease)) (VP (AUX were) (ADVP (RBR more) (RB frequently)) (ADJP (JJ black) (, ,) (JJ male) (, ,) (CC and) (JJR younger))) (. .)))
8988571	4	(S1 (S (NP (PRP They)) (VP (AUX were) (ADJP (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (DT a) (JJ low) (NN body) (NN mass) (NN index)))))) (, ,) (CC and) (ADJP (RBR more) (JJ likely) (S (VP (VP (TO to) (VP (AUX have) (VP (VBN died) (PP (IN in) (NP (NN police) (NN custody)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN received) (NP (JJ medical) (NN treatment)) (ADVP (RB immediately)) (PP (IN before) (NP (NN death)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN survived) (PP (IN for) (NP (DT a) (JJR longer) (NN period)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN developed) (NP (NNP Doc_8988571_729_741_Disease))))) (, ,) (CC and) (VP (TO to) (VP (AUX have) (VP (VBN died) (PP (IN in) (NP (NN summer) (NNS months))))))))))) (. .)))
8988571	5	(S1 (S (NP (NNP Doc_8988571_778_782_Disease)) (VP (AUX had) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_8988571_805_812_Chemical)) (CC and) (NP (NNP Doc_8988571_817_832_Chemical))) (PP (IN in) (NP (JJ autopsy) (NN blood))))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN for) (NP (NNS controls))))))))))) (. .)))
8988571	6	(S1 (S (NP (DT The) (JJ epidemiologic) (NNS findings)) (VP (AUX are) (ADJP (RBS most) (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (JJ chronic) (JJ Doc_8988571_971_978_Chemical) (NN use) (NNS disrupts)) (ADVP (RB dopaminergic)) (VP (VBP function) (SBAR (S (CC and) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN coupled) (PP (IN with) (NP (JJ recent) (JJ Doc_8988571_1044_1051_Chemical) (NN use)))))) (, ,) (VP (MD may) (VP (VB precipitate) (NP (NP (NNP Doc_8988571_1073_1082_Disease)) (, ,) (NP (NNP Doc_8988571_1084_1092_Disease)) (, ,) (NP (NN aberrant) (NN thermoregulation)) (, ,) (NP (NNP Doc_8988571_1121_1135_Disease)) (, ,) (CC and) (NP (NNP Doc_8988571_1141_1153_Disease)))))))))))))) (. .)))
9022662	0	(S1 (NP (NP (JJ Doc_9022662_0_8_Chemical) (VBN induced) (JJ acute) (NN Doc_9022662_23_38_Disease)) (: :) (NP (NP (NN case) (NN report) (CC and) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (. .)))
9022662	1	(S1 (S (NP (NN Doc_9022662_94_102_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ Doc_9022662_109_120_Chemical) (NN derivative)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX is) (ADJP (RB structurally) (JJ different) (PP (IN from) (NP (NNP Doc_9022662_168_180_Chemical))))) (CC and) (VP (VBD used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9022662_210_236_Disease))))))))))) (. .)))
9022662	2	(S1 (S (NP (NN Doc_9022662_238_246_Chemical)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB commonly)) (VP (VBN associated) (PP (IN in) (NP (DT the) (NN literature))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (JJ acute) (NNP Doc_9022662_318_336_Disease)))))))) (. .)))
9022662	3	(S1 (S (NP (DT The) (JJ following) (NN case)) (VP (VBZ describes) (NP (NP (CD two) (NNS children)) (VP (ADVP (RB acutely)) (VBN poisoned) (PP (IN with) (NP (NP (NNP Doc_9022662_402_410_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (JJ profound) (NN Doc_9022662_436_451_Disease)))))))))) (. .)))
9022662	4	(S1 (NP (NP (NN CASE) (NN REPORT)) (: :) (NP (NP (CD Two) (, ,) (JJ 3-year-old) (JJ male) (, ,) (JJ identical) (JJ twin) (NNS siblings)) (VP (VBN presented) (PP (TO to) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN after) (NP (NP (VBN found) (VBG playing)) (PP (IN with) (NP (NP (DT a) (DT an) (JJ empty) (NN bottle)) (PP (IN of) (NP (NNP Doc_9022662_596_604_Chemical))) (VP (ADVP (RB originally)) (VBG containing) (NP (CD 59) (NNS tablets))))))))))) (. .)))
9022662	5	(S1 (S (NP (DT The) (NNS children)) (VP (AUX had) (NP (NP (DT a) (JJ medical) (NN history)) (ADJP (JJ significant) (PP (IN for) (NP (NNP Doc_9022662_690_716_Disease))))) (ADVP (RB previously)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9022662_741_756_Chemical))) (PP (IN without) (NP (NN success))))) (. .)))
9022662	6	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (PRP$ their) (JJ first) (NN day)) (PP (IN of) (NP (JJ Doc_9022662_802_810_Chemical) (NN therapy))))) (. .)))
9022662	7	(S1 (S (NP (DT The) (NNP Doc_9022662_824_838_Disease) (NNS movements)) (VP (VBD began) (NP (QP (CD 45) (NN min) (TO to) (CD 1))) (NP (NNP h)) (PP (IN after) (NP (NN ingestion)))) (. .)))
9022662	8	(S1 (S (NP (DT The) (NNS children)) (VP (VP (VBD gave) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (JJ prior) (NN Doc_9022662_924_942_Disease))))) (CC and) (VP (ADVP (RB there)) (AUX was) (NP (NP (DT no) (NN family) (NN history)) (PP (IN of) (NP (NNP Doc_9022662_978_996_Disease)))))) (. .)))
9022662	9	(S1 (S (NP (DT The) (NNS children)) (VP (VBD received) (NP (NP (JJ gastrointestinal) (NN decontamination)) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_9022662_1083_1098_Chemical))))) (PP (IN in) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB control) (NP (DT the) (JJ Doc_9022662_1128_1142_Disease) (NNS movements)))))))) (. .)))
9022662	10	(S1 (S (PP (IN Despite) (NP (NN treatment))) (, ,) (NP (DT the) (NNS children)) (VP (VBD continued) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_9022662_1204_1219_Disease)) (PP (IN for) (NP (QP (RB approximately) (CD 24)) (NNS hours))))))) (. .)))
9022662	11	(S1 (S (PP (NP (JJ Forty-eight) (NNS hours)) (IN after) (NP (NN admission))) (, ,) (NP (DT the) (NNS children)) (VP (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (PP (IN at) (NP (PRP$ their) (NN baseline))))))) (CC and) (VP (AUX were) (VP (VBN discharged) (NP (NN home))))) (. .)))
9022662	12	(S1 (S (NP (JJ Doc_9022662_1367_1375_Chemical) (JJ associated) (NN Doc_9022662_1387_1404_Disease)) (VP (AUX has) (VP (AUX been) (ADVP (RB rarely)) (VP (VBN reported) (PP (IN in) (NP (DT the) (JJ acute) (NN toxicology) (NN literature)))))) (. .)))
9022662	13	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ Doc_9022662_1485_1499_Disease) (NNS movements)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG presenting) (PP (IN after) (NP (NNP Doc_9022662_1560_1568_Chemical) (NNP Doc_9022662_1569_1577_Disease))))))))) (. .)))
9041081	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ myopic) (NN excimer) (NN laser) (NN photorefractive) (NN keratectomy))) (PP (IN on) (NP (NP (DT the) (JJ electrophysiologic) (NN function)) (PP (IN of) (NP (DT the) (ADJP (JJ retina) (CC and) (JJ optic)) (NN nerve))))) (. .)))
9041081	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (PP (IN by) (NP (JJ electrophysiologic) (NN testing))) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ photorefractive) (NN keratectomy)) (PRN (-LRB- -LRB-) (NP (NNP PRK)) (-RRB- -RRB-)))) (PP (IN on) (NP (DT the) (NN retina) (CC and) (JJ optic) (NN nerve))))))) (. .)))
9041081	2	(S1 (NP (NP (NP (NNP Eye) (NNP Clinic)) (, ,) (NP (NNP S.) (NNP Salvatore) (NNP Hospital)) (, ,)) (NP (NP (NNP L') (NNP Aquila) (NNP University)) (, ,) (NP (NNP Italy))) (. .)))
9041081	3	(S1 (S (NP (NP (NP (JJ Standard) (NN pattern) (NNS electroretinograms)) (PRN (-LRB- -LRB-) (NP (NNP P-ERGs)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ standard) (NN pattern) (JJ visual) (JJ evoked) (NNS potentials)) (PRN (-LRB- -LRB-) (NP (NNP P-VEPs)) (-RRB- -RRB-)))) (VP (AUX were) (VP (AUX done) (PP (IN in) (NP (NP (CD 25) (NNS eyes)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (JJ myopic) (NN PRK)) (PP (IN for) (NP (NP (DT an) (VBN attempted) (NN correction)) (PP (IN between) (NP (NP (CD 5.00) (CC and) (CD 15.00) (NNS diopters)) (-LRB- -LRB-) (NP (NNP D)) (-RRB- -RRB-) (-LRB- -LRB-) (VP (VB mean) (NP (CD 8.00) (NNP D))) (-RRB- -RRB-))))))))))))))) (. .)))
9041081	4	(S1 (S (NP (NN Testing)) (VP (VP (AUX was) (VP (AUX done) (ADVP (RB preoperatively)))) (CC and) (VP (NP (NP (CD 3)) (, ,) (NP (CD 6)) (, ,) (NP (CD 12)) (, ,) (CC and) (NP (CD 18) (NNS months))) (ADVP (RB postoperatively)))) (. .)))
9041081	5	(S1 (S (NP (DT The) (JJ contralateral) (NNS eyes)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
9041081	6	(S1 (S (PP (IN During) (NP (DT the) (NN follow-up))) (, ,) (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (JJ Doc_9041081_737_744_Chemical-induced) (NN Doc_9041081_753_782_Disease)) (PRN (-LRB- -LRB-) (NP (NN IOP)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (SBAR (IN after) (S (NP (JJ Doc_9041081_809_823_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN discontinued)))))))))) (. .)))
9041081	7	(S1 (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (VP (AUX were) (VP (VBN seen) (PP (PP (IN between) (NP (NP (VBN treated)) (CC and) (NP (NN control) (NNS eyes)))) (CC nor) (PP (IN between) (NP (NP (VBN treated) (NNS eyes)) (ADVP (RB preoperatively) (CC and) (RB postoperatively))))))) (. .)))
9041081	8	(S1 (S (NP (JJ Myopic) (NN excimer) (NN laser) (NN PRK)) (VP (AUX did) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB affect) (NP (DT the) (NN posterior) (NN segment))))))) (. .)))
9041081	9	(S1 (S (NP (DT The) (JJ transient) (JJ Doc_9041081_1101_1108_Chemical-induced) (NN Doc_9041081_1117_1125_Disease)) (VP (AUX did) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB cause) (NP (JJ functional) (NN impairment))))))) (. .)))
9061311	0	(S1 (NP (NP (NNP Neutrophil) (NNP Doc_9061311_11_21_Chemical) (CC and) (NNP Doc_9061311_26_43_Chemical) (NN production)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9061311_72_91_Disease))))) (. .)))
9061311	1	(S1 (S (NP (NP (NNS Defects)) (PP (IN in) (NP (NNP Doc_9061311_104_114_Chemical) (CC and) (NNP Doc_9061311_119_136_Chemical) (NN production)))) (VP (MD may) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_9061311_191_211_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9061311_229_248_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9061311_250_253_Disease)) (-RRB- -RRB-))))))))))) (. .)))
9061311	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (JJ Doc_9061311_278_284_Chemical) (JJ radical) (NN production)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9061311_321_324_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_9061311_332_343_Chemical) (NNP Doc_9061311_344_352_Disease))))))) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ healthy) (NNS volunteers))))))) (. .)))
9061311	3	(S1 (S (NP (NP (NNS Neutrophils)) (PP (IN from) (NP (CD 14) (NNP Doc_9061311_419_422_Disease) (NNS patients)))) (VP (AUX were) (VP (VBN stimulated) (PP (IN via) (NP (NP (DT the) (VB complement) (NNS receptors)) (VP (VBG using) (NP (NP (NN zymosan)) (VP (VBN opsonized) (PP (IN with) (NP (NP (NN Doc_9061311_506_509_Disease)) (CC or) (NP (NN control) (NN serum))))))))))) (. .)))
9061311	4	(S1 (S (NP (NP (ADJP (JJ Doc_9061311_528_538_Chemical) (CC and) (JJ Doc_9061311_543_560_Chemical)) (NN production)) (PP (IN by) (NP (NP (JJ Doc_9061311_575_578_Disease) (NNS neutrophils)) (VP (VBN stimulated) (PP (IN with) (NP (NN zymosan))) (PP (VBN opsonized) (PP (IN with) (NP (JJ Doc_9061311_630_633_Disease) (NN serum)))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))))))) (. .)))
9061311	5	(S1 (S (NP (DT This) (NN defect)) (VP (VBD persisted) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN zymosan)) (VP (VBN opsonized) (PP (IN by) (NP (NN control) (NN serum))))) (VP (AUX was) (VP (VBN used) (PRN (-LRB- -LRB-) (S (NP (NNS P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-))))))) (. .)))
9061311	6	(S1 (S (NP (NP (ADJP (JJ Doc_9061311_796_806_Chemical) (CC and) (JJ Doc_9061311_811_828_Chemical)) (NN production)) (PP (IN in) (NP (NP (NNS neutrophils)) (VP (VBN stimulated) (PP (IN with) (NP (NP (NNP Doc_9061311_871_908_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9061311_910_914_Chemical)) (-RRB- -RRB-)))) (PP (IN from) (NP (DT a) (JJ further) (CD 18) (JJ Doc_9061311_934_937_Disease) (NNS patients))))))) (VP (AUX was) (ADJP (JJ unaffected)) (PP (VBN compared) (PP (IN with) (NP (NN control) (NNS neutrophils))))) (. .)))
9061311	7	(S1 (S (NP (NNP Serum) (NNP C3)) (VP (VB complement) (SBAR (S (NP (NNS levels)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (JJ Doc_9061311_1054_1057_Disease) (NNS patients))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.0005))) (-RRB- -RRB-)))))))))) (. .)))
9061311	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ neutrophil) (NN defect)) (PP (IN in) (NP (NNP Doc_9061311_1161_1164_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_9061311_1172_1183_Chemical) (NNP Doc_9061311_1184_1192_Disease))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (S (VP (VB complement) (ADJP (JJ dependent) (CC but) (JJ independent) (PP (IN of) (NP (NP (NN serum)) (VP (VB complement) (, ,) (ADVP (RB possibly)) (VBN connected) (PP (TO to) (NP (DT the) (VB complement) (NN receptor)))))))))))))) (. .)))
9067481	0	(S1 (S (NP (JJ Doc_9067481_0_25_Chemical) (NN treatment)) (VP (VBZ protects) (NP (NNS rodents)) (PP (IN from) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9067481_79_92_Chemical) (, ,) (NNP Doc_9067481_94_104_Chemical) (, ,) (NNP Doc_9067481_106_126_Chemical) (, ,) (NNP Doc_9067481_128_138_Chemical) (CC and) (NNP Doc_9067481_143_156_Chemical)))))) (. .)))
9067481	1	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (PRP$ its) (NN use)) (PP (IN as) (NP (NP (DT a) (NN stabilizer/rigidifier)) (PP (IN of) (NP (NNS membranes))))))))) (, ,) (NP (NNP Doc_9067481_222_247_Chemical) (, ,) (NNP Doc_9067481_249_258_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9067481_260_262_Chemical)) (-RRB- -RRB-)) (NN administration)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB protect) (NP (NNS rats)) (PP (IN from) (NP (NP (DT the) (JJ Doc_9067481_324_335_Disease) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_9067481_347_367_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9067481_369_373_Chemical)) (-RRB- -RRB-)))))))))))) (. .)))
9067481	2	(S1 (S (S (VP (TO To) (VP (VB further) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (JJ Doc_9067481_425_427_Chemical) (NN cytoprotection))))))))) (, ,) (NP (PRP we)) (VP (VBD examined) (PP (IN in) (NP (NNS rats) (CC and) (NNS mice))) (NP (NP (DT the) (JJ protective) (NNS abilities)) (PP (IN of) (NP (NP (NNP Doc_9067481_501_503_Chemical)) (CC and) (NP (NP (DT the) (JJ non-hydrolyzable) (NN ether) (NN form)) (PP (IN of) (NP (NP (NNP Doc_9067481_543_545_Chemical)) (, ,) (NP (NNP Doc_9067481_547_579_Chemical)) (, ,) (NP (NP (NNP Doc_9067481_581_590_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9067481_592_595_Chemical)) (-RRB- -RRB-))))) (PP (IN against) (NP (NNP Doc_9067481_605_618_Chemical-) (, ,) (NNP Doc_9067481_621_631_Chemical-) (, ,) (NNP Doc_9067481_634_654_Chemical-) (, ,) (NNP Doc_9067481_657_667_Chemical-) (CC and) (NNP Doc_9067481_673_686_Chemical-induced) (NNP Doc_9067481_695_703_Disease)))))))) (. .)))
9067481	3	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (JJ Doc_9067481_752_754_Chemical-mediated) (NN protection)) (VP (AUX is) (RB not) (ADJP (JJ selective)) (PP (IN for) (NP (NP (DT a) (JJ particular) (NNS species)) (, ,) (NP (NN organ) (NN system)) (CC or) (NP (NN toxic) (NN chemical)))))))) (. .)))
9067481	4	(S1 (S (NP (NP (DT A) (JJ 24-h) (NN pretreatment)) (PP (IN of) (NP (NP (DT both) (NNS rats) (CC and) (NNS mice)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_9067481_914_916_Chemical))) (PRN (-LRB- -LRB-) (NP (NN 100mg/kg)) (, ,) (NP (CD i.p.)) (-RRB- -RRB-)) (, ,)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NN protection)) (PP (PP (IN against) (NP (NP (DT the) (NNP Doc_9067481_982_993_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_9067481_1005_1009_Chemical) (, ,) (NNP Doc_9067481_1011_1016_Chemical) (, ,) (NNP Doc_9067481_1018_1031_Chemical) (CC and) (NNP Doc_9067481_1036_1049_Chemical))))) (CC and) (PP (IN against) (NP (NP (DT the) (JJ lethal) (PRN (-LRB- -LRB-) (CC and) (ADVP (RB presumably)) (NP (NNP Doc_9067481_1089_1100_Disease)) (-RRB- -RRB-)) (NN effect)) (PP (IN of) (NP (NNP Doc_9067481_1112_1122_Chemical) (NN administration))))))))) (. .)))
9067481	5	(S1 (S (NP (JJ Maximal) (JJ Doc_9067481_1147_1149_Chemical-mediated) (NN protection)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (JJ experimental) (NNS animals)) (VP (VBN pretreated) (NP (CD 24) (NNP h)) (PP (ADVP (RB prior)) (TO to) (NP (DT the) (JJ toxic) (NN insult)))))))) (. .)))
9067481	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9067481_1274_1276_Chemical)) (VP (VBZ intervenes) (PP (IN in) (NP (NP (DT a) (JJ critical) (JJ cellular) (NN event)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (NP (NP (DT an) (JJ important) (JJ common) (NN pathway)) (PP (TO to) (NP (JJ toxic) (NN cell) (NN death))))))))))))) (. .)))
9067481	7	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (JJ Doc_9067481_1391_1393_Chemical) (NN protection)))) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN chemical) (NN bioactivation))) (PP (TO to) (NP (NP (DT a) (JJ toxic) (NN reactive)) (ADJP (ADJP (JJ intermediate)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (NN light)) (PP (IN of) (NP (NP (DT the) (NN protection)) (VP (VBN observed) (PP (IN against) (NP (NNP Doc_9067481_1559_1572_Chemical) (NNP Doc_9067481_1573_1587_Disease)))))))) (-RRB- -RRB-))))))))))))) (. .)))
9067481	8	(S1 (S (ADVP (RB However)) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NNS data)) (VP (VBN presented))))) (, ,) (NP (PRP we)) (VP (MD can) (RB not) (VP (VB exclude) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (JJ Doc_9067481_1668_1670_Chemical) (NN administration)) (VP (VBZ inhibits) (NP (NN chemical) (NN bioactivation)))))))) (. .)))
9067481	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (AUX do) (VP (VB suggest) (SBAR (IN that) (S (NP (JJ Doc_9067481_1748_1750_Chemical-mediated) (NN protection)) (VP (AUX is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (DT the) (JJ intact) (JJ anionic) (JJ Doc_9067481_1820_1822_Chemical) (NN molecule)) (PRN (-LRB- -LRB-) (S (NP (JJ non-hydrolyzable) (NN Doc_9067481_1850_1853_Chemical)) (VP (AUX was) (ADJP (RB as) (JJ protective) (PP (IN as) (NP (NNP Doc_9067481_1875_1877_Chemical)))))) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WP$ whose) (NN mechanism)) (S (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN defined)))))))))))))))) (. .)))
9098464	0	(S1 (NP (NP (NP (DT A) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_9098464_18_29_Disease)))) (: :) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9098464_46_64_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9098464_76_100_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_9098464_114_123_Chemical) (NN reuptake) (NN inhibitor)) (, ,))) (PP (IN on) (NP (NP (JJ Doc_9098464_147_158_Disease) (NN induction)) (PP (IN in) (NP (NNP Wistar) (NN albino) (NNS rats))))))) (. .)))
9098464	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NNP Doc_9098464_252_262_Chemical)) (VP (VBN given) (PP (TO to) (NP (NP (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS rats)) (VP (VBN caused) (NP (NNP Doc_9098464_311_329_Disease)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NNP Doc_9098464_362_373_Disease))))))))))))))) (. .)))
9098464	2	(S1 (S (NP (NP (NNP Doc_9098464_383_393_Chemical)) (, ,) (NP (DT a) (JJ Doc_9098464_397_406_Chemical) (NN reuptake) (NN inhibitor)) (, ,)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NNP Wistar) (NNP Albino) (NNS rats))) (PP (IN for) (NP (NP (CD 98) (NNS days)) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NN Doc_9098464_482_500_Disease)))))))))) (. .)))
9098464	3	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN given) (PP (PP (TO to) (NP (NP (CD two) (NNS groups)) (VP (VBG consisting) (PP (IN of) (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS rats)))))) (CC and) (PP (VBN compared) (PP (TO to) (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS controls))))))))) (. .)))
9098464	4	(S1 (S (S (NP (NN Prolactin) (NNS levels)) (VP (AUX were) (VP (VBN measured)))) (CC and) (S (NP (NP (DT the) (NN uteri)) (PP (IN of) (NP (DT the) (NNS rats)))) (VP (AUX were) (VP (VBN removed) (PP (IN for) (NP (JJ histopathological) (NN analysis))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (CD 98) (NN days)))))))) (. .)))
9098464	5	(S1 (NP (NP (NP (NNP Marmara) (NNP University) (NNP School)) (PP (IN of) (NP (NNP Medicine)))) (, ,) (NP (NP (NP (NNP Department)) (PP (IN of) (NP (NP (NNP Histology)) (CC and) (NP (NNP Embryology))))) (, ,) (NP (NNP Zeynep) (NNP Kamil) (NNP Women)) (CC and) (NP (NP (NNP Children) (POS 's)) (NNP Hospital))) (. .)))
9098464	6	(S1 (NP (NP (JJ MAIN) (NN OUTCOME) (NNS MEASURES)) (: :) (NP (NP (NNP Serum) (JJ prolactin) (NNS levels)) (, ,) (NP (NN uterine) (NN histopathology))) (. .)))
9098464	7	(S1 (S (NP (NP (DT The) (JJ prolactin) (NNS levels)) (PP (IN of) (NP (NP (ADJP (VBN castrated) (CC and) (VBN noncastrated)) (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9098464_1055_1065_Chemical))))))) (VP (AUX were) (ADJP (RB statistically) (RB significantly) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (PRP$ their) (JJ respective) (NN control) (NNS groups))))))) (. .)))
9098464	8	(S1 (S (NP (JJ Histological) (NNS studies)) (VP (VBD revealed) (NP (NP (NP (CD 11) (NNS cases)) (PP (IN of) (NP (NNP Doc_9098464_1198_1209_Disease)))) (, ,) (NP (NP (DT all)) (PP (IN within) (NP (DT the) (JJ noncastrated) (NN group) (NN receiving) (NNP Doc_9098464_1255_1265_Chemical)))))) (. .)))
9098464	9	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN suggested) (SBAR (IN that) (S (NP (JJ high) (NN serum) (NN prolactin) (NNS levels)) (VP (VBP cause) (NP (NP (NN degeneration)) (PP (IN of) (NP (JJ myometrial) (NNS cells)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ ovarian) (NNP Doc_9098464_1395_1403_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ myometrial) (NN invasion)) (PP (IN by) (NP (JJ endometrial) (NN stroma))))))))))))))) (. .)))
9098464	10	(S1 (S (NP (DT This) (NN invasion)) (ADVP (RB eventually)) (VP (VBZ progresses) (S (VP (TO to) (VP (VB Doc_9098464_1504_1515_Disease))))) (. .)))
9105126	0	(S1 (S (NP (NNP Postinfarction) (NNP Doc_9105126_15_40_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ long-term) (JJ Doc_9105126_67_74_Chemical) (NN therapy)))) (. .)))
9105126	1	(S1 (S (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NP (NN postinfarction) (NN Doc_9105126_112_138_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ long-term) (JJ Doc_9105126_164_171_Chemical) (NN therapy)))))))) (VP (AUX are) (VP (VBN presented)))) (CC and) (S (NP (NP (DT the) (JJ favourable) (NN outcome)) (PP (IN in) (NP (DT both) (NNS cases)))) (VP (VBD described))) (. .)))
9105126	2	(S1 (S (NP (NP (DT A) (JJ possible) (NN association)) (PP (IN between) (NP (NP (JJ Doc_9105126_277_284_Chemical) (NN therapy)) (CC and) (NP (JJ subsequent) (NN postinfarction) (NN Doc_9105126_323_337_Disease))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
9121607	0	(S1 (S (NP (NNP Neuroactive) (NNP Doc_9121607_12_20_Chemical)) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_9121607_37_48_Chemical-)) (CC and) (NP (JJ Doc_9121607_54_65_Chemical-induced) (JJ limbic) (NNP Doc_9121607_81_89_Disease) (CC and) (NNP Doc_9121607_94_112_Disease)))) (PP (IN in) (NP (NNS mice)))) (. .)))
9121607	1	(S1 (S (NP (NP (NP (JJ Several) (ADJP (RB structurally) (VBN related)) (NNS metabolites)) (PP (IN of) (NP (NP (NP (NNP Doc_9121607_166_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_180_212_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9121607_218_237_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_239_279_Chemical)) (-RRB- -RRB-)))))) (CC and) (NP (PRP$ their) (CD 3) (NNS beta-epimers))) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NP (JJ protective) (NN activity)) (PP (IN against) (NP (NP (NNP Doc_9121607_353_364_Chemical-) (, ,) (NNP Doc_9121607_367_378_Chemical-) (CC and) (NNP Doc_9121607_384_404_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_406_410_Chemical)) (-RRB- -RRB-)))) (VP (VBN -induced) (NP (NNP Doc_9121607_420_428_Disease)) (PP (IN in) (NP (NNS mice)))))))) (. .)))
9121607	2	(S1 (S (NP (NP (NN Doc_9121607_438_446_Chemical)) (PP (IN with) (NP (NP (DT the) (JJ 3-hydroxy) (NN group)) (PP (IN in) (NP (NP (DT the) (NN alpha-position) (CC and) (NN 5-H)) (PP (IN in) (NP (DT the) (NNS alpha-) (CC or) (NNS beta-configurations)))))))) (VP (AUX were) (ADJP (RB highly) (JJ effective) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NP (NP (NNP Doc_9121607_583_594_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 416) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))) (NP (NP (JJ -induced) (JJ limbic) (NN motor) (NNP Doc_9121607_634_642_Disease) (CC and) (NNP Doc_9121607_647_665_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD ED50) (NNS values)) (, ,) (NP (CD 7.0-18.7) (NNS mg/kg))) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)))))))))) (. .)))
9121607	3	(S1 (S (NP (NP (DT The) (JJ corresponding) (NNS epimers)) (PP (IN with) (NP (DT the) (JJ 3-hydroxy) (NN group))) (PP (IN in) (NP (DT the) (NN beta-position)))) (VP (AUX were) (ADJP (ADJP (ADVP (RB also)) (JJ effective)) (CC but) (ADJP (RBR less) (JJ potent))) (PRN (-LRB- -LRB-) (NP (NP (CD ED50) (NNS values)) (, ,) (NP (CD 33.8-63.5))) (, ,) (NP (CD i.p.)) (-RRB- -RRB-))) (. .)))
9121607	4	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ neuroactive) (NNP Doc_9121607_868_876_Chemical)) (VP (AUX were) (ADJP (ADVP (RB considerably) (RBR less)) (JJ potent) (PP (IN than) (NP (DT the) (NNP Doc_9121607_916_930_Chemical) (NNP Doc_9121607_931_941_Chemical)))) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NNP Doc_9121607_964_975_Chemical) (NNP Doc_9121607_976_984_Disease))))))))) (, ,) (NP (NP (NNP Doc_9121607_986_994_Chemical)) (PP (IN with) (NP (DT the) (CD 5) (NN alpha,3) (NN alpha-configuration)))) (VP (AUX had) (NP (NP (ADJP (JJ comparable) (CC or) (JJR higher)) (JJ protective) (NN index) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (CD TD50)) (PP (IN for) (NP (NN motor) (NN impairment))) (VP (VBN divided) (PP (IN by) (NP (NP (CD ED50)) (PP (IN for) (NP (NN Doc_9121607_1130_1137_Disease) (NN protection))))))) (-RRB- -RRB-)) (PP (IN than) (NP (NNP Doc_9121607_1155_1165_Chemical))) (, ,) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT some) (JJ neuroactive) (NNP Doc_9121607_1200_1208_Chemical)) (VP (MD may) (VP (AUX have) (NP (JJR lower) (JJ relative) (NN Doc_9121607_1233_1241_Disease))))))))) (. .)))
9121607	5	(S1 (S (NP (NP (NN Doc_9121607_1243_1251_Chemical)) (PP (IN with) (NP (DT the) (QP (CD 5) (CD alpha,3) (NN alpha-) (CC or) (CD 5) (NN beta,3)) (NNS alpha-configurations)))) (ADVP (RB also)) (VP (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN delay)) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ limbic) (NNP Doc_9121607_1371_1379_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9121607_1391_1402_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 32) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))))))))))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB completely)) (VB protect) (PP (IN against) (NP (DT the) (NNP Doc_9121607_1464_1472_Disease)))))) (. .)))
9121607	6	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ second) (NN dose)) (PP (IN of) (NP (DT the) (NNP Doc_9121607_1509_1516_Chemical)))) (VP (AUX was) (VP (VBN administered) (NP (CD 1) (NN hr)) (PP (IN after) (NP (DT the) (JJ first) (NN dose))))))) (, ,) (NP (NP (JJ complete) (NN protection)) (PP (IN from) (NP (NP (DT the) (JJ Doc_9121607_1590_1601_Chemical-induced) (JJ limbic) (NNP Doc_9121607_1617_1625_Disease)) (CC and) (NP (NNP Doc_9121607_1630_1648_Disease))))) (VP (AUX was) (VP (VBN obtained))) (. .)))
9121607	7	(S1 (S (NP (DT The) (NNP Doc_9121607_1667_1675_Chemical)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (DT a) (JJ dose-dependent) (NN delay)) (PP (IN in) (NP (JJ Doc_9121607_1714_1718_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 257) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)) (JJ -induced) (NN lethality)))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB completely)) (VB protect) (PP (IN against) (NP (NP (NNP Doc_9121607_1795_1799_Chemical) (NNP Doc_9121607_1800_1808_Disease)) (CC or) (NP (NN lethality))))))) (. .)))
9121607	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ neuroactive) (NNP Doc_9121607_1852_1860_Chemical)) (VP (VP (AUX are) (ADJP (RB highly) (JJ effective) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NP (NNP Doc_9121607_1904_1915_Chemical-)) (CC and) (NP (NNP Doc_9121607_1921_1932_Chemical-induced) (NNP Doc_9121607_1941_1949_Disease) (CC and) (NNP Doc_9121607_1954_1972_Disease)))) (PP (IN in) (NP (NNS mice)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN utility))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT some) (NNS forms)) (PP (IN of) (NP (NP (NNP Doc_9121607_2038_2056_Disease)) (PP (IN in) (NP (NNS humans))))))))))))))) (. .)))
9154656	0	(S1 (NP (NP (NP (NN Hepatic)) (CC and) (NP (JJ extrahepatic) (JJ angiotensinogen) (NN gene) (NN expression))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ acute) (NNP Doc_9154656_76_94_Disease))))) (. .)))
9154656	1	(S1 (S (NP (NP (NP (NN Plasma) (NN concentration)) (CC and) (NP (NN urine) (NN excretion))) (PP (IN of) (NP (DT the) (JJ renin-Doc_9154656_150_161_Chemical) (NN system) (NNS proteins)))) (VP (AUX are) (VP (VBN altered) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_9154656_203_221_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9154656_223_225_Disease)) (-RRB- -RRB-)))))))) (. .)))
9154656	2	(S1 (S (PP (IN In) (NP (DT this) (NN work))) (NP (NP (DT the) (NN messenger) (NN ribonucleic) (NN acid) (-LRB- -LRB-) (NN mRNA) (-RRB- -RRB-) (NNS levels)) (PP (IN of) (NP (NP (NNS angiotensinogen)) (PRN (-LRB- -LRB-) (NP (NNP Ao)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN with) (NP (NP (DT the) (JJ slot-blot) (NN hybridization) (NN technique)) (PP (IN in) (NP (NP (UCP (NN liver) (CC and) (JJ other)) (JJ extrahepatic) (NNS tissues)) (: :) (NP (NP (NN kidney)) (, ,) (NP (NN heart)) (, ,) (NP (NN brain)) (, ,) (CC and) (NP (NP (JJ adrenal) (NN gland)) (PP (IN from) (NP (NP (NN control)) (, ,) (NP (NNP Doc_9154656_462_471_Disease)) (, ,) (CC and) (NP (JJ pair-fed) (PRN (-LRB- -LRB-) (NP (NNP PF)) (-RRB- -RRB-)) (NNS rats)))))))))))) (. .)))
9154656	3	(S1 (S (NP (NN Doc_9154656_497_499_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_9154656_537_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9154656_565_568_Chemical)) (-RRB- -RRB-)))))))) (. .)))
9154656	4	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (DT a) (JJ great) (NN urinary) (NN excretion)) (CC and) (NP (JJ half-normal) (NN plasma) (NNS levels))) (PP (IN of) (NP (NNP Ao)))) (VP (AUX were) (VP (VBN observed) (PP (IN on) (NP (NN day) (CD 6))) (PP (IN after) (NP (JJ Doc_9154656_671_674_Chemical) (NN injection))))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_9154656_691_693_Disease)) (VP (AUX was) (ADVP (RB clearly)) (VP (VBN established))))) (, ,) (NP (JJ hepatic) (NNP Ao) (NN mRNA) (NNS levels)) (VP (AUX did) (RB not) (VP (VB change))) (. .)))
9154656	5	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (JJ Ao) (NN mRNA) (NNS levels)) (VP (VP (AUX did) (RB not) (VP (VB change) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ extrahepatic) (NNS tissues)) (VP (VBN studied) (PP (IN on) (NP (NN day) (CD 6)))))))))) (, ,) (CC nor) (VP (AUX did) (NP (PRP$ its) (JJ hepatic) (NNS levels)) (PP (IN at) (NP (NP (NNS days)) (VP (NP (CD 1) (, ,) (CD 3) (, ,) (CD 5) (, ,) (CC or) (CD 7)) (PP (IN after) (NP (JJ Doc_9154656_913_916_Chemical) (NN injection)))))))) (. .)))
9154656	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (ADJP (JJ hepatic) (CC and) (JJ extrahepatic)) (NN Ao) (NN mRNA) (NNS levels)) (VP (AUX are) (ADJP (JJ unaltered)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT the) (JJ acute) (NN Doc_9154656_1046_1048_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9154656_1060_1063_Chemical)))))))))))) (. .)))
9165568	0	(S1 (S (VP (VB Doc_9165568_0_30_Disease) (PP (IN with) (NP (NNP Doc_9165568_36_47_Chemical)))) (. .)))
9165568	1	(S1 (S (NP (NN Doc_9165568_49_79_Disease)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_9165568_109_117_Chemical) (NNP D2) (NN receptor) (NN blockade)))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (DT the) (JJ basal) (NNS ganglia)))))))))) (. .)))
9165568	2	(S1 (S (NP (NP (NNP Doc_9165568_177_188_Chemical)) (, ,) (NP (DT a) (NNP Doc_9165568_192_205_Chemical) (NN derivative) (NN antipsychotic)) (, ,)) (VP (AUX has) (NP (NP (JJ high) (JJ Doc_9165568_241_250_Chemical) (JJ 5-HT2) (NN receptor) (NN blockade)) (CC and) (NP (JJ dose-related) (JJ D2) (NN receptor) (NN blockade)))) (. .)))
9165568	3	(S1 (S (NP (DT The) (JJ high) (NN ratio)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (VB impart) (NP (NP (DT the) (JJ low) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_372_395_Disease))) (PP (IN with) (NP (NNP Doc_9165568_401_412_Chemical))) (PP (IN at) (NP (JJ low) (NNS dosages))))))))) (. .)))
9165568	4	(S1 (S (PP (IN With) (NP (NP (DT this) (JJ low) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_456_479_Disease))))) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN thought) (SBAR (S (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_513_543_Disease)))) (VP (MD might) (ADVP (RB also)) (VP (AUX be) (VP (VBN lowered)))))))) (. .)))
9165568	5	(S1 (S (NP (DT A) (JJ 73-year-old) (NN woman)) (VP (VBD developed) (NP (NN Doc_9165568_597_627_Disease)) (PP (IN after) (S (VP (VBG monotherapy) (PP (IN with) (NP (NNP Doc_9165568_651_662_Chemical))))))) (. .)))
9165568	6	(S1 (S (NP (DT The) (NN syndrome)) (VP (VBD reversed) (PP (IN after) (S (VP (VP (VBG discontinuing) (NP (NNP Doc_9165568_706_717_Chemical))) (CC and) (VP (VBG starting) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_9165568_746_756_Chemical)) (CC and) (NP (NNP Doc_9165568_761_774_Chemical)))))))))) (. .)))
9165568	7	(S1 (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NP (DT the) (NN protection)) (PP (IN from) (NP (JJ extrapyramidal) (NN side) (NNS effects))) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_9165568_854_865_Chemical))))) (VP (AUX does) (RB not) (VP (VB ensure) (NP (NP (NN protection)) (PP (IN from) (NP (NN Doc_9165568_898_928_Disease))))))))) (. .)))
9201797	0	(S1 (NP (NP (DT The) (JJ attenuating) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_9201797_26_49_Chemical)) (, ,) (NP (DT a) (JJ beta-adrenoceptor) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (JJ neuroleptic-induced) (NN Doc_9201797_106_115_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
9201797	1	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN known) (SBAR (IN that) (S (NP (NN beta-adrenoceptor) (NNS antagonists)) (VP (AUX are) (ADJP (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9201797_206_215_Disease)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ extrapyramidal) (NN side) (NNS effects))) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN during) (NP (JJ neuroleptic) (NN treatment)))))))))))))))) (. .)))
9201797	2	(S1 (S (NP (NP (JJ Neuroleptic-induced) (NNP Doc_9201797_317_326_Disease)) (, ,) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ neuroleptic-induced) (JJ extrapyramidal) (NN side) (NNS effects)))) (, ,)) (VP (AUX was) (VP (VBN considered) (S (ADJP (JJ suitable) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN for) (S (VP (VBG predicting) (NP (NP (JJ neuroleptic-induced) (NN Doc_9201797_458_467_Disease)) (PP (IN in) (NP (NNS humans))))))))))) (, ,) (SBAR (IN although) (S (NP (JJ neuroleptic-induced) (NNP Doc_9201797_508_517_Disease)) (VP (AUX was) (RB not) (VP (VBN considered) (S (NP (NP (DT a) (JJ specific) (NN test)) (PP (IN for) (NP (JJ neuroleptic-induced) (NN Doc_9201797_577_586_Disease))))))))))) (. .)))
9201797	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_9201797_614_623_Chemical)) (, ,) (NP (DT a) (JJ beta-adrenoceptor) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_9201797_660_671_Chemical-induced) (NNP Doc_9201797_680_689_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (VP (AUX were) (ADVP (RB behaviorally)) (VP (VBN studied))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_9201797_751_762_Chemical)) (CC and) (NP (NP (NNP Doc_9201797_767_776_Chemical)) (, ,) (NP (DT a) (JJ muscarinic) (NN receptor) (NN antagonist))))))))) (. .)))
9201797	4	(S1 (S (NP (NP (NNP Doc_9201797_812_821_Chemical)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_9201797_834_845_Chemical)) (CC and) (NP (NNP Doc_9201797_850_859_Chemical))) (, ,)) (VP (VBD inhibited) (NP (DT the) (JJ Doc_9201797_875_886_Chemical-induced) (NN Doc_9201797_895_904_Disease))) (. .)))
9201797	5	(S1 (S (NP (NP (DT The) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NNP Doc_9201797_931_940_Chemical)))) (VP (VP (AUX was) (ADJP (RB almost) (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9201797_974_985_Chemical))))))) (, ,) (CC but) (VP (AUX was) (ADJP (JJR weaker) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9201797_1015_1024_Chemical)))))))) (. .)))
9201797	6	(S1 (S (NP (NNP Doc_9201797_1026_1035_Chemical)) (VP (AUX did) (RB not) (VP (VB evoke) (NP (NP (JJ postsynaptic) (JJ Doc_9201797_1063_1071_Chemical) (JJ receptor-stimulating) (JJ behavioral) (NNS signs)) (PP (JJ such) (IN as) (NP (NP (NN stereotypy)) (CC and) (NP (NP (NN Doc_9201797_1133_1148_Disease)) (PP (IN in) (NP (NNS rats))))))))) (. .)))
9201797	7	(S1 (S (NP (NNP Doc_9201797_1158_1167_Chemical)) (VP (AUX did) (RB not) (VP (VP (VB antagonize) (NP (NP (DT the) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NNP Doc_9201797_1213_1224_Chemical))) (PP (IN on) (NP (JJ Doc_9201797_1228_1239_Chemical-induced) (NN stereotypy))))) (CC and) (VP (VB locomotor) (NP (NP (NN activity)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9201797	8	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_9201797_1304_1313_Chemical)) (VP (VP (AUX did) (RB not) (VP (VP (VB evoke) (NP (NP (JJ 5-HT1A) (JJ receptor-stimulating) (JJ behavioral) (NNS signs)) (PP (JJ such) (IN as) (NP (JJ flat) (NN body) (NN posture))))) (CC and) (VP (VB forepaw) (NP (NN treading))))) (CC and) (VP (AUX did) (RB not) (VP (VB inhibit) (S (NP (JJ Doc_9201797_1440_1459_Chemical-induced) (NN head)) (VP (VB twitch) (PP (IN in) (NP (NNS rats)))))))) (. .)))
9201797	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NNP Doc_9201797_1498_1507_Chemical)) (VP (AUX did) (RB not) (VP (VB inhibit) (NP (NP (JJ Doc_9201797_1524_1537_Chemical-induced) (NN lethality)) (PP (IN in) (NP (NNS rats)))))) (. .)))
9201797	10	(S1 (S (NP (DT These) (NNS results)) (VP (ADVP (RB strongly)) (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9201797_1601_1610_Chemical)) (VP (VP (VBZ improves) (NP (NP (JJ Doc_9201797_1620_1631_Chemical-induced) (NN Doc_9201797_1640_1649_Disease)) (PP (IN via) (NP (PRP$ its) (JJ beta-adrenoceptor) (JJ antagonistic) (NN activity))))) (CC and) (VP (AUX is) (VP (VBN expected) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9201797_1750_1759_Disease)))))) (PP (IN without) (S (VP (VBG attenuating) (NP (NP (JJ neuroleptic-induced) (JJ antipsychotic) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ postsynaptic) (NNP Doc_9201797_1846_1854_Chemical) (NN receptor) (JJ antagonistic) (NN activity))))))))))))))))) (. .)))
9205462	0	(S1 (S (NP (NN Doc_9205462_0_33_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ antecedent) (JJ Doc_9205462_61_70_Chemical) (NN use)))) (. .)))
9205462	1	(S1 (S (NP (VBN Increased) (NN attention)) (VP (AUX has) (VP (AUX been) (VP (VBN focused) (ADVP (RB recently)) (PP (IN on) (NP (NP (DT the) (JJ estrogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9205462_163_172_Chemical)))))))) (. .)))
9205462	2	(S1 (S (NP (NP (NN Review)) (PP (IN of) (NP (DT the) (NN literature)))) (VP (VBZ reveals) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (JJ Doc_9205462_230_239_Chemical) (NN use)) (CC and) (NP (JJ gynecologic) (NN Doc_9205462_260_266_Disease)))))) (. .)))
9205462	3	(S1 (S (NP (DT A) (JJ 52-year-old) (NN postmenopausal) (NN woman)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9205462_326_335_Chemical))) (PP (IN for) (NP (NN stage) (NNP II) (JJ Doc_9205462_349_357_Chemical) (JJ receptor-positive) (NN Doc_9205462_376_392_Disease))))) (. .)))
9205462	4	(S1 (S (NP (PRP$ Her) (JJ Doc_9205462_398_407_Chemical) (ADJP (JJ transaminase) (CC and) (JJ Doc_9205462_425_432_Chemical)) (NN transaminase) (NNS levels)) (VP (VBP increase) (ADVP (RB markedly)) (PP (IN after) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (JJ Doc_9205462_489_498_Chemical) (NN use)))))) (. .)))
9205462	5	(S1 (S (PP (IN After) (NP (NP (DT an) (JJ additional) (CD 17) (NNS months)) (PP (IN of) (NP (JJ elevated) (NN serum) (NNS transaminases))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (DT a) (NN stage) (NNP Ic) (NN Doc_9205462_608_641_Disease))))))) (. .)))
9205462	6	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_9205462_669_678_Chemical-induced) (NNP Doc_9205462_687_704_Disease)))) (VP (MD may) (VP (AUX be) (PP (IN at) (NP (NP (JJ increased) (NN risk)) (PP (IN for) (NP (NNP Doc_9205462_734_755_Disease))))) (PP (IN because) (IN of) (NP (NP (NNS alterations)) (PP (IN in) (NP (JJ Doc_9205462_782_791_Chemical) (NN metabolism))))))) (. .)))
9209318	0	(S1 (S (NP (NP (NN Lifetime) (NN treatment)) (PP (IN of) (NP (NNS mice))) (PP (IN with) (NP (NP (NNP Doc_9209318_32_46_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9209318_48_51_Chemical)) (-RRB- -RRB-))))) (VP (VBZ produces) (NP (NN Doc_9209318_62_76_Disease))) (. .)))
9209318	1	(S1 (S (NP (NNP Doc_9209318_78_81_Chemical)) (VP (AUX has) (VP (VBN induced) (NP (NP (DT a) (NN Doc_9209318_96_113_Disease)) (PP (IN in) (NP (NP (JJ Doc_9209318_117_121_Disease) (NNS patients)) (PP (IN on) (NP (JJ long) (NN term) (JJ Doc_9209318_144_147_Chemical) (NN therapy)))))))) (. .)))
9209318	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN assumed) (SBAR (IN that) (S (NP (NN DNA) (NN elongation)) (VP (AUX is) (VP (VBN stopped) (PP (IN by) (S (NP (NP (DT the) (NN insertion)) (PP (IN of) (NP (NNP Doc_9209318_232_235_Chemical))) (PP (IN into) (NP (DT the) (NN chain))) (PP (IN in) (NP (NN place))) (PP (IN of) (NP (NNP Doc_9209318_263_272_Chemical)))) (ADVP (RB thus)) (VP (VP (VBG preventing) (NP (DT the) (JJ Doc_9209318_293_302_Chemical) (NN hydroxyl) (NNS linkages))) (CC and) (VP (ADVP (RB therefore)) (VBZ suppresses) (NP (JJ hemopoietic) (NN progenitor) (NN cell) (NN proliferation)) (PP (IN in) (NP (NP (DT an) (JJ early) (NN stage)) (PP (IN of) (NP (NN differentiation))))))))))))))) (. .)))
9209318	3	(S1 (S (NP (NNP CBA/Ca) (NN male) (NNS mice)) (VP (VP (VBD started) (PP (IN on) (NP (NNP Doc_9209318_454_457_Chemical) (CD 0.75) (NN mg/ml))) (NP (NNP H2O)) (PP (IN at) (NP (NP (CD 84) (NNS days)) (PP (IN of) (NP (NN age)))))) (CC and) (VP (VBD kept) (PP (IN on) (NP (PRP it))) (PP (IN for) (NP (NP (CD 687) (NNS days)) (SBAR (WHADVP (WRB when)) (S (NP (NN dosage)) (VP (VBD reduced) (PP (TO to) (NP (QP (CD 0.5) (CD mg/ml)))) (SBAR (S (NP (NP (NNP H2O)) (PP (IN for) (NP (NP (DT a) (NN group)) (, ,) (NP (NP (DT another) (NN group)) (VP (VBN removed) (PP (IN from) (NP (NNP Doc_9209318_596_599_Chemical))) (S (VP (TO to) (VP (VB see) (NP (NN recovery))))))) (, ,) (CC and) (NP (JJ third) (NN group))))) (VP (VBD remained) (PP (IN on) (NP (CD 0.75) (NN mg))))))))))))) (. .)))
9209318	4	(S1 (S (PP (IN At) (NP (CD 687) (NNS days))) (NP (NP (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (PP (IN on) (NP (CD 0.75) (NN mg)))))))) (VP (AUX had) (NP (NP (JJ average) (NN platelet) (NNS counts)) (PP (IN of) (NP (NP (QP (CD 2.5) (SYM x) (CD 10))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)))))) (. .)))
9209318	5	(S1 (S (NP (NP (JJ Histological) (NN examination)) (PP (IN on) (NP (NP (QP (CD 9) (IN of) (CD 10)) (NNS mice)) (PP (IN with) (NP (JJ such) (NN Doc_9209318_791_807_Disease)))))) (VP (VBD showed) (NP (NP (NNS changes)) (ADJP (JJ compatible) (PP (IN with) (NP (NP (NNP Doc_9209318_839_863_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9209318_865_868_Disease)) (-RRB- -RRB-))))))) (. .)))
9209318	6	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (JJ histological) (NNS patterns)))) (VP (AUX was) (VP (VBN observed))) (. .)))
9209318	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ hypocellular) (NNP Doc_9209318_957_971_Disease)))) (, ,) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ hypersegmented) (NNP Doc_9209318_1001_1016_Disease) (NNS granulocytosis)))) (, ,) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NP (JJ hypercellular) (NN marrow)) (PP (IN with) (NP (NP (JJ abnormal) (NNS megakaryocytes)) (PP (IN with) (NP (JJ bizarre) (NNS nuclei)))))))) (, ,) (NP (NP (CD one) (NN case)) (PP (IN of) (NP (NP (JJ megakaryocytic) (NNS myelosis)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NNP Doc_9209318_1171_1190_Disease) (, ,) (NNP Doc_9209318_1192_1207_Disease) (CC and) (DT a) (NNP Doc_9209318_1214_1233_Disease) (CC and) (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_9209318_1251_1265_Disease))))) (PP (IN with) (NP (NP (NNP Doc_9209318_1271_1288_Disease)) (, ,) (NP (NNP Doc_9209318_1290_1303_Disease)) (CC and) (NP (DT a) (NNP Doc_9209318_1310_1329_Disease)))))))))) (. .)))
9209318	8	(S1 (S (IN Above) (NP (VBN mentioned) (JJ Doc_9209318_1347_1350_Chemical) (NN incorporation)) (VP (MD may) (VP (AUX have) (VP (VBN induced) (NP (DT an) (JJ ineffective) (NN hemopoiesis)) (PP (IN in) (NP (NP (DT the) (JJ primitive) (JJ hemopoietic) (NN progenitor) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (VP (VBN seen) (ADVP (RB commonly)) (PP (IN in) (NP (DT the) (NNP Doc_9209318_1498_1522_Disease)))))))))))))))) (. .)))
921394	0	(S1 (NP (NP (JJ Biphasic) (NN response)) (PP (IN of) (NP (NP (DT the) (NNP SA) (NN node)) (PP (IN of) (NP (DT the) (NN dog) (NN heart))) (PP (IN in) (NP (NN vivo))))) (PP (TO to) (NP (NP (JJ selective) (NN administration)) (PP (IN of) (NP (NNP Doc_921394_89_97_Chemical))))) (. .)))
921394	1	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_921394_109_117_Chemical))) (PP (IN on) (NP (NP (DT the) (NNP SA) (NN node)) (PP (IN of) (NP (DT the) (NN dog) (NN heart)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (NNS vivo)) (VP (VBG using) (NP (NP (DT a) (JJ selective) (NN perfusion) (NN technique)) (PP (IN of) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))) (. .)))
921394	2	(S1 (S (NP (NP (NNS Injections)) (PP (IN of) (NP (NNP Doc_921394_245_253_Chemical))) (PP (IN in) (NP (NP (NNS doses)) (PP (IN from) (NP (NP (QP (CD 100) (NN microgram) (TO to) (CD 3) (NN mg))) (PP (IN into) (NP (DT the) (NN artery)))))))) (VP (VBD produced) (NP (NP (DT a) (NN Doc_921394_317_327_Disease)) (PP (IN of) (NP (DT the) (NNP SA) (NN nodal) (NN activity))) (PP (IN by) (NP (DT a) (JJ direct) (NN action))))) (. .)))
921394	3	(S1 (S (NP (DT This) (NN Doc_921394_378_388_Disease)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT the) (JJ sudden) (NN appearance)) (PP (IN of) (NP (DT a) (JJ stimulatory) (NN phase))))))) (. .)))
921394	4	(S1 (S (NP (NP (JJ Bilateral) (NN vagotomy)) (CC and) (NP (NP (NP (NN sympathectomy)) (CC or) (NP (JJ prior) (NN administration))) (PP (IN of) (NP (DT a) (NN ganglion) (NN blocker))))) (VP (VBD failed) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT the) (JJ Doc_921394_574_582_Chemical-induced) (NN Doc_921394_591_602_Disease))))))) (, ,) (SBAR (IN while) (S (NP (PRP it)) (VP (AUX was) (VP (ADVP (RB completely)) (VBN abolished) (PP (PP (IN in) (NP (DT the) (JJ reserpinized) (NNS dogs))) (CC or) (PP (IN by) (NP (NP (DT a) (JJ prior) (NN injection)) (PP (IN of) (NP (NP (DT a) (JJ beta-blocking) (NN agent)) (PP (IN into) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))))))) (. .)))
921394	5	(S1 (S (NP (DT This)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (DT the) (JJ peripheral) (NN adrenergic) (NN mechanism)))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT the) (JJ excitatory) (NN effect)) (PP (IN of) (NP (NNP Doc_921394_882_890_Chemical))) (VP (VBN injected) (PP (IN in) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))))))) (. .)))
9214597	0	(S1 (S (PP (IN Over) (NP (NP (NP (NN expression)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)))) (CC and) (NP (NP (PRP$ its) (NN receptor)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_9214597_97_105_Chemical-induced) (NN rat)))))))) (NP (NNP Doc_9214597_118_134_Disease)) (VP (MD may) (VP (VB mediate) (NP (JJ Doc_9214597_147_155_Chemical-initiated) (JJ Doc_9214597_166_171_Disease) (NNS angiogenesis)))) (. .)))
9214597	1	(S1 (S (NP (NP (NN Doc_9214597_186_195_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS types)) (PP (IN of) (NP (ADJP (JJ human) (CC and) (JJ animal)) (NNP Doc_9214597_263_270_Disease)))))))))) (, ,)) (VP (MD can) (VP (VB induce) (NP (NNP Doc_9214597_283_288_Disease) (NNS angiogenesis)) (PP (IN in) (NP (NP (DT the) (NN pituitary)) (PP (IN of) (NP (NNP Fischer) (CD 344) (NNS rats))))))) (. .)))
9214597	2	(S1 (S (NP (NP (DT The) (JJ mechanistic) (NNS details)) (PP (IN of) (NP (NNP Doc_9214597_367_372_Disease) (NN angiogenesis) (NN induction)))) (, ,) (PP (IN during) (NP (NNP Doc_9214597_404_412_Chemical) (NNP Doc_9214597_413_427_Disease))) (, ,) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ unknown))) (. .)))
9214597	3	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_9214597_473_481_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NNP Doc_9214597_503_508_Disease) (NNS angiogenesis)) (PP (IN in) (NP (NP (DT the) (NN pituitary)) (PP (IN of) (NP (JJ female) (NNS rats)))))))))))) (, ,) (NP (NP (DT the) (NN density)) (PP (IN of) (NP (NN blood) (NNS vessels)))) (VP (AUX was) (VP (VBN analysed) (S (VP (VBG using) (NP (NP (NN factor)) (SBAR (S (NP (NP (NP (NP (NNP VIII) (JJ related) (NN antigen) (PRN (-LRB- -LRB-) (NNP FVIIIRAg) (-RRB- -RRB-)) (NN immunohistochemistry)) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth))))) (JJ factor/vascular) (NN permeability) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP VEGF/VPF)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN examined) (PP (IN by) (NP (NP (NNP Western) (NNP blot)) (CC and) (NP (JJ immunohistochemical) (NN analysis))))))))))))) (. .)))
9214597	4	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (JJ VEGF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP VEGFR-2/Flk-1/KDR)) (-RRB- -RRB-))))) (VP (AUX was) (ADVP (RB also)) (VP (VBN examined) (PP (IN by) (NP (NN immunohistochemistry))))) (. .)))
9214597	5	(S1 (S (NP (DT The) (NNS results)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NNP Doc_9214597_948_964_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9214597_966_968_Chemical)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (NP (NN neovascularization)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN growth) (CC and) (NN enlargement)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NN exposure))))))))) (. .)))
9214597	6	(S1 (S (NP (DT The) (JJ high) (JJ Doc_9214597_1088_1093_Disease) (JJ angiogenic) (NN potential)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ elevated) (JJ VEGF/VPF) (NN protein) (NN expression)) (PP (IN in) (NP (NP (DT the) (JJ Doc_9214597_1182_1184_Chemical) (VBN exposed) (NN pituitary)) (PP (IN of) (NP (JJ ovariectomized) (PRN (-LRB- -LRB-) (NP (NNP OVEX)) (-RRB- -RRB-)) (NNS rats))))))))) (. .)))
9214597	7	(S1 (S (NP (NNP VEGF/VPF) (CC and) (NNP FVIIIRAg) (JJ immunohistochemistry) (CC and) (JJ endothelial) (JJ specific) (NN lectin) (PRN (-LRB- -LRB-) (NP (NNP UEA1)) (-RRB- -RRB-)) (JJ binding) (NNS studies)) (, ,) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (JJ VEGF) (NN protein) (NN expression)))) (ADVP (RB initially)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT both) (NN blood) (NNS vessels)) (CC and) (NP (JJ non-endothelial) (NNS cells)))))))) (. .)))
9214597	8	(S1 (S (PP (IN After) (NP (NP (CD 15) (NNS days)) (PP (IN of) (NP (NNP Doc_9214597_1473_1475_Chemical) (NN exposure))))) (, ,) (NP (NNP VEGF/VPF) (NN protein) (NN expression)) (, ,) (PP (IN in) (NP (DT the) (JJ non-endothelial) (NN cell) (NN population))) (, ,) (VP (VP (ADVP (RB sharply)) (VBN declined)) (CC and) (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (DT the) (NN blood) (NNS vessels)))))) (. .)))
9214597	9	(S1 (S (NP (NP (DT The) (NN function)) (PP (IN of) (NP (JJ non-endothelial-derived) (NNS VEGF)))) (VP (AUX is) (RB not) (ADJP (JJ clear))) (. .)))
9214597	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NN immunohistochemical) (NNS studies)) (VP (VBD demonstrated) (SBAR (S (NP (DT that) (JJ VEGFR-2) (PRN (-LRB- -LRB-) (JJ flk-1/KDR) (-RRB- -RRB-) (, ,)) (NN expression)) (VP (AUX was) (VP (VBD elevated) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT the) (JJ endothelial) (NNS cells)) (PP (IN of) (NP (NN microblood) (NNS vessels))))) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NNP Doc_9214597_1853_1855_Chemical) (NN exposure)))))))))) (. .)))
9214597	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (IN over) (NN expression)) (PP (IN of) (NP (NP (NNS VEGF)) (CC and) (NP (NP (PRP$ its) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN VEGFR-2)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN step)) (PP (IN of) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ Doc_9214597_2013_2021_Chemical) (VBN induced) (JJ Doc_9214597_2030_2035_Disease) (NNS angiogenesis)) (PP (IN in) (NP (DT the) (NN rat) (NN pituitary)))))))))))))) (. .)))
9226773	0	(S1 (S (NP (JJ Persistent) (NNP Doc_9226773_11_41_Disease)) (VP (VBG following) (NP (JJ Doc_9226773_52_59_Chemical) (NN therapy))) (. .)))
9226773	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ severe) (JJ hypernatraemic) (NN Doc_9226773_137_148_Disease)) (PP (VBG following) (NP (DT a) (NN Doc_9226773_161_172_Disease)))))))))) (. .)))
9226773	2	(S1 (S (S (ADVP (NP (CD Ten) (NNS years)) (RB previously)) (NP (PRP he)) (VP (AUX had) (VP (AUX been) (VP (VBN diagnosed) (S (VP (TO to) (VP (AUX have) (NP (JJ Doc_9226773_225_232_Chemical-induced) (NN Doc_9226773_241_271_Disease))))))))) (, ,) (CC and) (S (NP (JJ Doc_9226773_277_284_Chemical) (NN therapy)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued))))) (. .)))
9226773	3	(S1 (S (S (NP (PRP He)) (VP (VBD remained) (ADJP (JJ thirsty) (CC and) (JJ Doc_9226773_340_348_Disease)) (PP (IN despite) (NP (NP (NN cessation)) (PP (IN of) (NP (NNP Doc_9226773_370_377_Chemical))))))) (CC and) (S (NP (NP (NNS investigations)) (PP (IN on) (NP (NN admission)))) (VP (VBD showed) (NP (PRP him)) (S (VP (TO to) (VP (AUX have) (NP (NP (JJ normal) (JJ osmoregulated) (NN thirst)) (CC and) (NP (JJ Doc_9226773_461_472_Chemical) (NN secretion)))))) (, ,) (PP (IN with) (NP (NP (JJ clear) (NN evidence)) (PP (IN of) (NP (NNP Doc_9226773_507_537_Disease))))))) (. .)))
9226773	4	(S1 (S (S (NP (NP (NN Doc_9226773_539_546_Chemical)) (VP (VBN induced) (NP (NNP Doc_9226773_555_585_Disease)))) (VP (AUX is) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ reversible)) (PP (IN on) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))))))))))) (CC but) (S (NP (NNP Doc_9226773_645_653_Disease)) (VP (VBD persisted) (PP (IN in) (NP (DT this) (NN patient))) (PP (IN for) (NP (CD ten) (NNS years))) (SBAR (IN after) (S (NP (NNP Doc_9226773_700_707_Chemical)) (VP (AUX was) (VP (VBN stopped))))))) (. .)))
9226773	5	(S1 (S (NP (PRP We)) (VP (VB discuss) (NP (NP (DT the) (JJ possible) (JJ renal) (NNS mechanisms)) (CC and) (NP (NP (DT the) (NNS implications)) (PP (IN for) (NP (NP (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9226773_815_822_Chemical-induced) (NNP Doc_9226773_831_861_Disease)))))))))) (. .)))
9228650	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_9228650_11_18_Chemical))) (PP (IN on) (NP (NP (NN cholinesterase)) (CC and) (NP (JJ Doc_9228650_41_52_Chemical-induced) (NN Doc_9228650_61_68_Disease)))) (. .)))
9228650	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_9228650_85_92_Chemical))) (PP (IN on) (NP (NP (NN cholinesterase)) (, ,) (NP (JJ Doc_9228650_112_123_Chemical-induced) (NN Doc_9228650_132_139_Disease)) (CC and) (NP (JJ spontaneous) (NN movement))))) (VP (VP (AUX were) (VP (VBN examined))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ well-known) (NN cholinesterase) (NNS inhibitors)) (ADJP (JJ Doc_9228650_247_254_Chemical) (CC and) (JJ Doc_9228650_259_265_Chemical)))))))) (. .)))
9228650	2	(S1 (S (NP (NNP Doc_9228650_267_274_Chemical) (, ,) (NNP Doc_9228650_276_283_Chemical) (CC and) (NNP Doc_9228650_288_294_Chemical)) (ADVP (RB all) (RB strongly)) (VP (VBD inhibited) (NP (NP (NN acetylcholinesterase)) (PRN (-LRB- -LRB-) (NP (NNP AChE)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ human) (JJ red) (NN blood) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD IC50s) (SYM =) (CD 1.0) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (JJ -6) (-RRB- -RRB-) (, ,)) (CD 2.9) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (JJ -7) (-RRB- -RRB-)) (CC and) (CD 3.7)) (NNP x) (CD 10) (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-) (NNP M)) (, ,) (NP (RB respectively))) (-RRB- -RRB-))))) (. .)))
9228650	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNP Doc_9228650_455_462_Chemical)) (CC and) (NP (NNP Doc_9228650_467_474_Chemical))) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_9228650_484_490_Chemical)) (, ,)) (ADVP (RB strongly)) (VP (VBD inhibited) (NP (NP (NN butyrylcholinestrase)) (PRN (-LRB- -LRB-) (NP (NNP BuChE)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ human) (NN serum)))) (. .)))
9228650	4	(S1 (S (NP (DT All) (CD three) (NNS drugs)) (VP (VBD produced) (NP (NP (VBN mixed) (NN inhibition)) (PP (IN of) (NP (NN AChE) (NN activity))))) (. .)))
9228650	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NNP Doc_9228650_651_658_Chemical))) (PP (IN on) (NP (NN AChE)))) (VP (AUX was) (ADJP (JJ reversible))) (. .)))
9228650	6	(S1 (S (NP (NP (DT All) (NNS compounds)) (PP (IN at) (NP (JJ 0.1-1) (NN mg/kg) (NNS p.o.)))) (VP (ADVP (RB significantly)) (VBN improved) (NP (NP (DT the) (NNP Doc_9228650_744_751_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9228650_763_774_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (NN mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG performing) (NP (DT a) (JJ passive) (NN avoidance) (NN task)))))))) (. .)))
9228650	7	(S1 (S (NP (NP (DT The) (CD three) (NNS compounds)) (PP (IN at) (NP (QP (CD 1) (CC and) (CD 3) (CD mg/kg)) (NNS p.o.)))) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB decrease) (NP (NP (JJ spontaneous) (NN movement)) (PP (IN by) (NP (NNS rats)))))) (. .)))
9228650	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_9228650_968_975_Chemical)) (PP (IN at) (NP (NP (DT a) (JJ low) (NN dose)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-1) (NN mg/kg) (NN p.o.)) (-RRB- -RRB-))))) (VP (VP (VBZ improves) (NP (JJ Doc_9228650_1018_1029_Chemical-induced) (NN Doc_9228650_1038_1045_Disease))) (CC but) (VP (AUX does) (RB not) (VP (VB affect) (NP (JJ spontaneous) (NN movement)))))))) (. .)))
9228650	9	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9228650_1114_1121_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_9228650_1164_1183_Disease))))))))))) (. .)))
9270571	0	(S1 (NP (NP (NP (NP (JJ Potential) (JJ therapeutic) (NN use)) (PP (IN of) (NP (DT the) (JJ selective) (NNP Doc_9270571_43_51_Chemical) (NNP D1) (NN receptor) (NN agonist)))) (, ,) (NP (NNP Doc_9270571_73_80_Chemical))) (: :) (NP (NP (DT an) (JJ acute) (NN study)) (PP (IN in) (NP (JJ Doc_9270571_100_112_Disease) (JJ Doc_9270571_113_121_Chemical-primed) (NNS monkeys)))) (. .)))
9270571	1	(S1 (S (NP (NP (DT The) (JJ clinical) (NN utility)) (PP (IN of) (NP (NNP Doc_9270571_162_170_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_172_174_Chemical)) (-RRB- -RRB-)) (NNP D1) (NN receptor) (NNS agonists))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9270571_217_236_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_238_240_Disease)) (-RRB- -RRB-))))))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
9270571	2	(S1 (S (NP (NP (DT The) (JJ therapeutic) (NN use)) (PP (IN of) (NP (NP (JJ selective) (NNP Doc_9270571_293_295_Chemical) (NNP D1) (NN receptor) (NNS agonists)) (PP (JJ such) (IN as) (NP (NP (NP (NNP Doc_9270571_325_334_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_336_425_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9270571_431_438_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_440_535_Chemical)) (-RRB- -RRB-)))))))) (VP (VBZ seems) (VP (VBN limited) (PP (IN because) (IN of) (NP (NP (PRP$ their) (NN duration)) (PP (IN of) (NP (NN action))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (ADJP (RB too) (JJ short) (PP (IN for) (NP (NNP Doc_9270571_611_620_Chemical)))) (PRN (-LRB- -LRB-) (NP (QP (CD <) (CD 1)) (NNS hr)) (-RRB- -RRB-)) (CC and) (ADJP (ADJP (RB too) (JJ long)) (PP (IN for) (NP (NNP Doc_9270571_647_654_Chemical)))) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CD 20)) (NN hr)) (, ,) (ADJP (JJ leading) (PP (TO to) (NP (JJ behavioral) (NN tolerance)))) (-RRB- -RRB-)))))))))) (. .)))
9270571	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD conducted) (NP (DT the) (JJ present) (JJ acute) (NN dose-response) (NN study)) (PP (IN in) (NP (NP (CD four) (JJ Doc_9270571_768_812_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_814_818_Chemical)) (-RRB- -RRB-)) (JJ -exposed) (NN cynomolgus) (NNS monkeys)) (VP (VBN primed) (S (VP (TO to) (VP (VB exhibit) (NP (JJ Doc_9270571_865_873_Chemical-induced) (NNP Doc_9270571_882_893_Disease)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN locomotor)) (CC and) (NP (NP (NP (NNP Doc_9270571_924_934_Disease) (NNS effects)) (PP (IN on) (NP (NN challenge))) (PP (IN with) (NP (CD four) (NNS doses))) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 0.03) (TO to) (CD 1.0)) (NNS mg/kg))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NNP Doc_9270571_1000_1007_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_1009_1114_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ full)) (NNP Doc_9270571_1138_1140_Chemical) (NNP D1-like) (NN receptor) (NN agonist)) (PP (IN with) (NP (NP (DT an) (JJ intermediate) (NN duration)) (PP (IN of) (NP (NN action)))))))))))))))))))) (. .)))
9270571	4	(S1 (S (NP (NP (NN Doc_9270571_1207_1215_Chemical)) (CC and) (NP (NP (DT the) (JJ Doc_9270571_1224_1226_Chemical) (JJ D2-like) (NN receptor) (NN agonist)) (, ,) (NP (NP (NNP Doc_9270571_1253_1262_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_1264_1354_Chemical)) (-RRB- -RRB-))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN used) (PP (IN for) (NP (NN comparison))))) (. .)))
9270571	5	(S1 (S (NP (NP (JJ Acute) (NN administration)) (PP (IN of) (NP (NNP Doc_9270571_1411_1418_Chemical)))) (VP (VP (AUX was) (ADJP (RB as) (JJ efficacious) (PP (IN in) (S (VP (VBG alleviating) (NP (JJ Doc_9270571_1453_1457_Chemical-induced) (NN Doc_9270571_1466_1478_Disease)) (PP (IN as) (NP (NNP Doc_9270571_1482_1490_Chemical) (CC and) (NNP Doc_9270571_1495_1504_Chemical)))))))) (, ,) (CC but) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (VB reproduce) (NP (DT the) (JJ Doc_9270571_1543_1551_Chemical-induced) (NN Doc_9270571_1560_1571_Disease)) (PP (IN in) (NP (DT these) (NNS animals))))))) (PP (IN than) (PP (IN with) (NP (NP (DT either) (JJ Doc_9270571_1606_1615_Chemical) (CC or) (JJ subsequent) (NN challenge)) (PP (IN of) (NP (NNP Doc_9270571_1643_1651_Chemical))))))))) (. .)))
9270571	6	(S1 (S (NP (NP (JJ Selective) (NN stimulation)) (PP (IN of) (NP (DT the) (NNP Doc_9270571_1682_1684_Chemical) (NNP D1) (NN receptor)))) (VP (MD may) (VP (VB provide) (NP (NP (JJR better) (NN integration)) (PP (IN of) (NP (NP (JJ neural) (NNS inputs)) (VP (VBN transmitted) (PP (TO to) (NP (NP (DT the) (JJ internal) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ globus) (NNS pallidus)) (PRN (-LRB- -LRB-) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT the) (JJ basal) (NN ganglia) (NN output)))) (-RRB- -RRB-)))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_9270571_1860_1868_Chemical)) (CC and) (NP (JJ selective) (NNP Doc_9270571_1883_1885_Chemical) (NNP D2) (NN receptor) (NN agonist))))))) (. .)))
9270571	7	(S1 (S (NP (NP (JJ Potent) (JJ Doc_9270571_1914_1916_Chemical) (NNP D1) (NN receptor) (NNS agents)) (PP (IN with) (NP (NP (DT an) (JJ intermediate) (NN duration)) (PP (IN of) (NP (NN efficacy))))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_9270571_1986_1993_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 4)) (NN hr)) (PP (IN at) (NP (NP (JJR higher) (NNS doses)) (VP (VBN tested))))) (-RRB- -RRB-))))) (VP (VP (AUX are) (NP (NP (JJ potential) (JJ therapeutic) (NNS tools)) (PP (IN in) (NP (NNP Doc_9270571_2073_2075_Disease))))) (CC and) (VP (VBP merit) (NP (JJ further) (NN attention)))) (. .)))
9305828	0	(S1 (NP (NP (JJ Neuropeptide-Y) (NN immunoreactivity)) (PP (IN in) (NP (NP (DT the) (JJ Doc_9305828_39_50_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_60_82_Disease))))) (. .)))
9305828	1	(S1 (S (NP (NP (NNP Neuropeptide-Y)) (PRN (-LRB- -LRB-) (NP (NNP NPY)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN expressed) (PP (IN by) (NP (NP (JJ granule) (NNS cells)) (CC and) (NP (NP (JJ mossy) (NNS fibres)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN dentate) (NN gyrus))) (PP (IN during) (NP (NP (JJ experimental) (NNP Doc_9305828_205_227_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9305828_229_232_Disease)) (-RRB- -RRB-))))))))) (. .)))
9305828	2	(S1 (S (NP (DT This) (NN expression)) (VP (MD may) (VP (VB represent) (NP (NP (DT an) (JJ endogenous) (VBG damping) (NN mechanism)) (SBAR (IN since) (S (NP (NNP NPY)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB block) (NP (JJ Doc_9305828_331_338_Disease-like) (NNS events)) (PP (VBG following) (NP (NP (NN high-frequency) (NN stimulation)) (PP (IN in) (NP (JJ hippocampal) (NNS slices)))))))))))))))) (. .)))
9305828	3	(S1 (S (NP (NP (DT The) (NNP Doc_9305828_415_426_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9305828_428_432_Chemical)) (-RRB- -RRB-)) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_443_451_Disease)))) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (DT an) (JJ acute) (NN period)) (PP (IN of) (NP (NNP Doc_9305828_491_509_Disease))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ spontaneous) (JJ recurrent) (NN Doc_9305828_544_552_Disease)) (CC and) (NP (JJ related) (NN Doc_9305828_565_577_Disease))))))))) (. .)))
9305828	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ peroxidase-antiperoxidase) (NN immunostaining)) (PP (IN for) (NP (NN NPY)))) (PP (IN in) (NP (NP (JJ several) (NN brain) (NNS regions)) (PP (IN in) (NP (DT this) (NN model)))))) (. .)))
9305828	5	(S1 (S (NP (JJ Doc_9305828_678_682_Chemical-injected) (NNS animals)) (VP (VBD exhibited) (NP (JJ NPY) (NN immunoreactivity)) (PP (IN in) (NP (NP (DT the) (NN region)) (PP (IN of) (NP (DT the) (JJ mossy) (JJ fibre) (NNS terminals))))) (, ,) (PP (PP (IN in) (NP (DT the) (JJ dentate) (JJ gyrus) (JJ inner) (JJ molecular) (NN layer))) (CC and) (, ,) (PP (IN in) (NP (DT a) (JJ few) (NNS cases)))) (, ,) (PP (IN within) (NP (JJ presumed) (NN granule) (NNS cells)))) (. .)))
9305828	6	(S1 (S (NP (JJ NPY) (NN immunoreactivity)) (VP (AUX was) (ADVP (RB also)) (VP (ADVP (RB dramatically)) (VBN changed) (PP (IN in) (NP (NP (DT the) (JJ entorhinal) (NN cortex)) (, ,) (NP (NN amygdala)) (CC and) (NP (NN sensorimotor) (NNS areas)))))) (. .)))
9305828	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_9305828_993_997_Chemical)) (VP (VBD injected) (SBAR (S (NP (NNS animals)) (VP (VBD exhibited) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ NPY-immunoreactive) (NNS interneurons)))))) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))))))) (. .)))
9305828	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NNS changes)) (PP (IN in) (NP (JJ NPY) (NN expression))) (, ,) (PP (VBG including) (NP (NP (NP (NN expression)) (PP (IN in) (NP (NP (DT the) (JJ granule) (NNS cells)) (CC and) (NP (JJ mossy) (NNS fibres))))) (CC and) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ vulnerable) (JJ NPY) (NNS neurons)))))) (, ,)) (VP (AUX are) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (JJ Doc_9305828_1284_1288_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_1298_1301_Disease)))))))))) (. .)))
9305828	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (NP (DT this) (JJ changed) (NN synthesis)) (PP (IN of) (NP (NN NPY)))))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN determined)))))) (. .)))
9321531	0	(S1 (NP (NP (JJ Posteroventral) (JJ medial) (NN pallidotomy)) (PP (IN in) (NP (JJ advanced) (NNP Doc_9321531_46_65_Disease))) (. .)))
9321531	1	(S1 (S (S (NP (JJ Posteroventral) (NN medial) (NN pallidotomy)) (ADVP (RB sometimes)) (VP (VBZ produces) (NP (NP (JJ striking) (NN improvement)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_9321531_179_198_Disease)))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS studies)) (PP (TO to) (NP (NN date)))) (VP (AUX have) (VP (VBN involved) (NP (NP (JJ small) (NNS numbers)) (PP (IN of) (NP (NP (NNS patients)) (CC and) (NP (JJ short-term) (NN follow-up)))))))) (. .)))
9321531	2	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NNP Doc_9321531_319_338_Disease)))) (VP (VBD underwent) (NP (JJ serial) (, ,) (JJ detailed) (NNS assessments)) (PP (DT both) (PP (IN after) (NP (NP (NN drug) (NN withdrawal)) (PRN (-LRB- -LRB-) (NP (`` ``) (JJ off) ('' '') (NN period)) (-RRB- -RRB-)))) (CC and) (PP (IN while) (S (VP (VBG taking) (NP (NP (PRP$ their) (JJ optimal) (JJ medical) (NNS regimens)) (PRN (-LRB- -LRB-) (`` ``) (PP (IN on) ('' '') (NP (NN period))) (-RRB- -RRB-)))))))) (. .)))
9321531	3	(S1 (S (S (S (NP (DT All) (NNS patients)) (VP (AUX were) (VP (VBN examined) (ADVP (RB preoperatively))))) (CC and) (S (NP (CD 39)) (VP (AUX were) (VP (VBN examined) (PP (IN at) (NP (CD six) (NNS months))))))) (: ;) (S (NP (NP (CD 27)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (AUX were) (ADVP (RB also)) (VP (VBN examined) (PP (IN at) (NP (CD one) (NN year))))) (, ,) (CC and) (VP (NP (CD 11)) (PP (IN at) (NP (CD two) (NNS years)))))) (. .)))
9321531	4	(S1 (S (NP (NP (DT The) (NN percent) (NNS improvements)) (PP (IN at) (NP (CD six) (NNS months)))) (VP (AUX were) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (JJ off-period) (NN score)) (PP (IN for) (NP (JJ overall) (NN motor) (NN function)))) (, ,) (NP (NP (ADJP (ADJP (CD 28) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 19) (TO to) (CD 38)) (NN percent)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (NP (JJS most)) (PP (IN of) (NP (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (DT the) (JJ contralateral) (NNS limbs)))) (: ;) (NP (NP (JJ off-period) (NN score)) (PP (IN for) (NP (NP (NNS activities)) (PP (IN of) (NP (NP (JJ daily) (NN living)) (, ,) (NP (NP (CD 29) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 19) (TO to) (CD 39)) (NN percent)) (-RRB- -RRB-)))))))) (: ;))))) (NN on-period)) (NN score)) (PP (IN for) (NP (JJ contralateral) (NNP Doc_9321531_1009_1020_Disease)))) (, ,) (NP (NP (NP (NP (CD 82) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 72) (TO to) (CD 91)) (NN percent)) (-RRB- -RRB-)) (: ;)) (CC and) (NP (JJ on-period) (NN score))) (PP (IN for) (NP (JJ ipsilateral) (NNP Doc_9321531_1121_1132_Disease)))) (, ,) (NP (NP (CD 44) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 29) (TO to) (CD 59)) (NN percent)) (-RRB- -RRB-)))))) (. .)))
9321531	5	(S1 (S (NP (NP (NP (DT The) (NNS improvements)) (PP (IN in) (NP (NNP Doc_9321531_1217_1228_Disease)))) (CC and) (NP (NP (DT the) (JJ total) (NNS scores)) (PP (IN for) (NP (NP (JJ off-period) (NNP Doc_9321531_1265_1277_Disease)) (, ,) (NP (JJ contralateral) (NNP Doc_9321531_1293_1305_Disease)) (, ,) (CC and) (NP (NNP Doc_9321531_1311_1319_Disease)))))) (VP (AUX were) (VP (VBN sustained) (PP (IN in) (NP (NP (DT the) (CD 11) (NNS patients)) (VP (VBN examined) (PP (IN at) (NP (CD two) (NNS years)))))))) (. .)))
9321531	6	(S1 (S (S (NP (NP (DT The) (NN improvement)) (PP (IN in) (NP (JJ ipsilateral) (NNP Doc_9321531_1408_1419_Disease)))) (VP (AUX was) (VP (VBN lost) (PP (IN after) (NP (CD one) (NN year)))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS improvements)) (PP (IN in) (NP (NP (JJ postural) (NN stability)) (CC and) (NP (NN gait))))) (VP (VBD lasted) (NP (QP (RB only) (CD three) (TO to) (CD six)) (NNS months)))) (. .)))
9321531	7	(S1 (S (NP (NP (QP (RB Approximately) (PDT half)) (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (ADJP (JJ dependent) (PP (IN on) (NP (NN assistance)))) (PP (IN in) (NP (NP (NNS activities)) (PP (IN of) (NP (NP (JJ daily) (NN living)) (PP (IN in) (NP (NP (DT the) (JJ off) (NN period)) (PP (IN before) (NP (NN surgery)))))))))))))) (VP (VBD became) (ADJP (JJ independent)) (PP (IN after) (NP (NN surgery)))) (. .)))
9321531	8	(S1 (S (S (NP (NP (DT The) (NNS complications)) (PP (IN of) (NP (NN surgery)))) (VP (AUX were) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated)))) (, ,) (CC and) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN medication)))))))) (. .)))
9321531	9	(S1 (S (PP (IN In) (NP (JJ late-stage) (NNP Doc_9321531_1847_1866_Disease))) (, ,) (NP (NN pallidotomy)) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (JJ Doc_9321531_1902_1910_Chemical-induced) (NN Doc_9321531_1919_1930_Disease)) (CC and) (NP (JJ off-period) (NN disability)))) (. .)))
9321531	10	(S1 (S (NP (NP (RB Much)) (PP (IN of) (NP (DT the) (NN benefit)))) (VP (AUX is) (VP (VBN sustained) (PP (IN at) (NP (CD two) (NNS years))) (, ,) (SBAR (IN although) (S (NP (NP (DT some) (NNS improvements)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (PP (IN on) (NP (DT the) (JJ ipsilateral) (NN side))) (CC and) (PP (IN in) (NP (JJ axial) (NNS symptoms)))))) (, ,)) (VP (VBP wane) (PP (IN within) (NP (DT the) (JJ first) (NN year)))))))) (. .)))
9321531	11	(S1 (S (NP (NP (DT The) (JJ on-period) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ resistant) (PP (TO to) (NP (JJ dopaminergic) (NN therapy)))))))) (VP (AUX do) (RB not) (VP (VB respond) (PP (TO to) (NP (NN pallidotomy))))) (. .)))
9326871	0	(S1 (NP (JJ Doc_9326871_0_14_Chemical-induced) (NN Doc_9326871_23_46_Disease) (. .)))
9326871	1	(S1 (S (NP (NN Doc_9326871_48_62_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB relatively) (JJ new)) (JJ Doc_9326871_83_92_Chemical) (JJ antibiotic)) (SBAR (WHNP (WDT that)) (S (VP (VBZ offers) (NP (JJ twice-daily) (NN dosing))))))) (. .)))
9326871	2	(S1 (S (NP (PRP It)) (VP (VBZ differs) (PP (IN from) (NP (NNP Doc_9326871_152_164_Chemical))) (PP (RB only) (IN in) (NP (NP (DT the) (NN methylation)) (PP (IN of) (NP (DT the) (NN hydroxyl) (NN group))) (PP (IN at) (NP (NN position) (CD 6)))))) (. .)))
9326871	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ side-effect) (NN profile)) (PP (IN of) (NP (NNP Doc_9326871_262_274_Chemical)))) (VP (AUX is) (VP (VBN established))))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_9326871_301_316_Disease)) (CC and) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (ADJP (JJ subject) (PP (TO to) (NP (JJ hepatic) (NN mixed-function) (NN oxidase) (NN metabolism))))))))) (, ,) (NP (NP (NN experience)) (PP (IN with) (NP (DT the) (JJR newer) (NN Doc_9326871_431_441_Chemical)))) (VP (AUX is) (ADVP (RB still)) (VP (AUXG being) (VP (VBN recorded)))) (. .)))
9326871	4	(S1 (S (NP (NN Doc_9326871_467_481_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (PP (IN after) (NP (NP (DT both) (JJ intravenous) (CC and) (JJ oral) (NN administration)) (PP (IN of) (NP (NNP Doc_9326871_554_566_Chemical)))))))) (CC but) (VP (AUX has) (ADVP (RB never)) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (DT the) (JJR newer) (NN Doc_9326871_610_620_Chemical))))))) (. .)))
9326871	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9326871_642_666_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (NP (CD six) (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NN Doc_9326871_712_726_Chemical)))))))))) (. .)))
9326871	6	(S1 (S (NP (DT The) (NNP Doc_9326871_732_744_Disease)) (VP (VBD resolved) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
9431903	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_9431903_10_29_Chemical))) (PP (IN on) (NP (DT the) (NNP Doc_9431903_37_60_Disease)))) (VP (VBN evoked) (PP (IN by) (NP (JJ Doc_9431903_71_82_Chemical-Doc_9431903_83_91_Chemical) (NN administration)))) (. .)))
9431903	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_147_166_Chemical))) (PP (IN on) (NP (DT the) (JJ Doc_9431903_174_185_Chemical-Doc_9431903_186_194_Chemical-induced) (NN Doc_9431903_203_226_Disease)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD nine) (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_9431903_270_298_Disease))))))) (. .)))
9431903	2	(S1 (S (NP (NN Doc_9431903_308_331_Disease)) (VP (AUX was) (VP (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_9431903_347_358_Chemical-Doc_9431903_359_367_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (JJ mg) (NNP Doc_9431903_391_402_Chemical) (NN intramuscularly)) (CC and) (NP (CD 10) (JJ mg) (NNP Doc_9431903_429_437_Chemical) (NN subcutaneously))) (-RRB- -RRB-))))) (CC and) (VP (VBN visualized) (PP (IN by) (NP (JJ quantitative) (NN hepatobiliary) (NN scintigraphy)))))) (. .)))
9431903	3	(S1 (S (NP (DT The) (JJ entire) (NN procedure)) (VP (AUX was) (VP (VBN repeated) (PP (IN during) (NP (NP (JJ Doc_9431903_554_573_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9431903_584_596_Chemical) (CD 1)) (VP (VBN microg/kg/min) (PP (IN for) (NP (CD 120) (NN min))))) (-RRB- -RRB-)))))) (. .)))
9431903	4	(S1 (S (NP (JJ Doc_9431903_636_647_Chemical-Doc_9431903_648_656_Chemical) (NN provocation)) (VP (VBD caused) (NP (NP (NP (NP (JJ significant) (NNS increases)) (PP (PP (IN in) (NP (NP (NP (DT the) (NN time)) (S (VP (TO to) (VP (VB peak) (NP (NP (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP Tmax)) (-RRB- -RRB-))) (PP (IN over) (NP (DT the) (JJ hepatic) (NN hilum)))))) (PRN (-LRB- -LRB-) (NP (NNP HH)) (: :) (NP (NP (CD 34.33) (NNS +/-)) (NP (CD 5.05) (CC vs.) (CD 22.77) (NN +/-) (CD 3.26))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ common) (JJ bile) (NN duct)) (PRN (-LRB- -LRB-) (NP (NNP CBD)) (: :) (NP (NP (CD 60.44) (NNS +/-)) (NP (CD 5.99) (CC vs.) (CD 40.0) (NN +/-) (CD 2.88))) (-RRB- -RRB-))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN half-time)) (PP (IN of) (NP (NN excretion))))))) (PRN (-LRB- -LRB-) (NP (NNP T1/2)) (-RRB- -RRB-))) (PP (IN over) (NP (DT the) (NN liver) (NN parenchyma))) (PRN (-LRB- -LRB-) (NP (NNP LP)) (: :) (NP (NP (CD 120.04) (NN +/-)) (NP (CD 16.01) (CC vs.) (CD 27.37) (NN +/-) (CD 2.19))) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP HH)) (PRN (-LRB- -LRB-) (NP (NP (CD 117.61) (NN +/-)) (NP (CD 14.71) (CC vs.) (CD 31.85) (NN +/-) (CD 3.99))) (-RRB- -RRB-))) (CC and) (NP (NNP CBD))) (PRN (-LRB- -LRB-) (NP (QP (CD 158.11) (CD +/-) (NN 9.18) (CC vs.) (CD 40.1) (NN +/-)) (CD 6.24)) (-RRB- -RRB-))) (, ,) (S (VP (VBG indicating) (NP (DT a) (JJ complete) (NN Doc_9431903_1080_1085_Disease)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (DT the) (NN sphincter)) (PP (IN of) (NP (NNP Oddi)))))))))) (. .)))
9431903	5	(S1 (S (NP (JJ Doc_9431903_1125_1144_Chemical) (NN infusion)) (ADVP (RB completely)) (VP (VBD normalized) (NP (DT the) (JJ Doc_9431903_1180_1191_Chemical-Doc_9431903_1192_1200_Chemical-induced) (NNS alterations)) (PP (IN in) (NP (NP (DT these) (JJ quantitative) (NNS parameters)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ TmaX)) (PP (IN over) (NP (DT the) (NN LP)))) (: :) (NP (NP (CD 11.33) (NN +/-)) (NP (CD 1.13)) (: ;) (PP (PP (IN over) (NP (NP (DT the) (NN HH)) (: :) (NP (NP (CD 18.88) (NN +/-)) (NP (CD 1.48))) (: ;))) (CC and) (PP (IN over) (NP (NP (NP (NP (DT the) (VBG CBD)) (: :) (NP (NP (CD 36.22) (NNS +/-)) (NP (CD 1.92))) (: ;) (CC and) (NP (NNP T1/2))) (PP (IN over) (NP (DT the) (NN LP)))) (: :) (NP (NP (CD 28.21) (NNS +/-)) (NP (CD 1.83))) (: ;) (PP (IN over) (NP (DT the) (NN HH))) (: :) (NP (NP (CD 33.42) (NNS +/-)) (NP (CD 3.10))) (: ;))) (CC and) (PP (IN over) (NP (DT the) (NNP CBD))))) (: :) (NP (NP (CD 41.66) (NNS +/-)) (NP (CD 6.33)))) (-RRB- -RRB-)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (JJ effective) (JJ sphincter-relaxing) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_1507_1526_Chemical))))))) (. .)))
9431903	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (DT the) (JJ first) (NN evidence)) (PP (IN of) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NNP Doc_9431903_1605_1624_Chemical))))) (PP (IN on) (NP (NP (DT the) (JJ Doc_9431903_1632_1640_Chemical-induced) (NN Doc_9431903_1649_1672_Disease)) (PP (IN in) (NP (NNS humans))))))) (. .)))
9431903	7	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_9431903_1690_1709_Chemical)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB overcome) (ADVP (RB even)) (NP (NP (DT the) (JJ drastic) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_1757_1765_Chemical))))))))))) (, ,) (NP (PRP it)) (VP (MD might) (VP (AUX be) (PP (IN of) (NP (NN relevance))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9431903_1812_1840_Disease))))))) (. .)))
950631	0	(S1 (NP (NP (NN Immunopathology)) (PP (IN of) (NP (NNP Doc_950631_19_32_Chemical-induced) (NNP Doc_950631_41_59_Disease))) (. .)))
950631	1	(S1 (S (NP (NP (CD Four) (NNS patients)) (PP (IN with) (NP (NNP Doc_950631_80_100_Disease)))) (VP (VBD developed) (NP (JJ heavy) (NN Doc_950631_117_128_Disease)) (PP (IN after) (NP (NP (QP (CD five) (TO to) (CD 12)) (NNS months)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_950631_171_186_Chemical)))))))) (. .)))
950631	2	(S1 (S (NP (NP (JJ Light) (NN microscopy)) (PP (IN of) (NP (JJ renal) (NN biopsy) (NNS samples)))) (VP (VBD showed) (NP (NP (NP (JJ minimal) (JJ glomerular) (JJ capillary) (NN wall) (VBG thickening)) (CC and) (NP (JJ mesangial) (NNP matrix) (NN increase))) (, ,) (CC or) (NP (NP (DT no) (NN departure)) (PP (IN from) (NP (JJ normal)))))) (. .)))
950631	3	(S1 (S (NP (NNP Electron) (NN microscopy)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD revealed) (NP (NP (JJ subepithelial) (JJ electron-dense) (NNS deposits)) (, ,) (NP (NP (NP (NN fusion)) (PP (IN of) (NP (JJ epithelial) (NN cell) (NN foot) (NNS processes)))) (, ,) (CC and) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ mesangial) (NN cell) (NN hyperactivity))))))) (. .)))
950631	4	(S1 (S (NP (JJ Immunofluorescence) (NN microscopy)) (VP (VBD demonstrated) (NP (NP (JJ granular) (NN capillary) (NN wall) (NNS deposits)) (PP (IN of) (NP (NP (NNP IgG)) (CC and) (NP (NNP C3)))))) (. .)))
950631	5	(S1 (S (NP (DT The) (NNS findings)) (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (JJ early) (NNP Doc_950631_642_671_Disease)))))) (, ,) (S (NP (NNS differences)) (VP (AUXG being) (VP (VBN observed) (ADVP (RB however)) (PP (IN in) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN staining))) (PP (IN for) (NP (DT the) (NN early-acting) (VB complement) (NNS components) (NNP C1q) (CC and) (NNP C4))))))))) (. .)))
950631	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB tentatively)) (VP (VBN concluded) (SBAR (IN that) (S (VP (VB complement) (SBAR (S (VP (AUX was) (VP (VBN activated) (PP (IN by) (NP (DT the) (JJ classical) (NN pathway)))))))))))) (. .)))
9514561	0	(S1 (NP (NP (NP (JJ Experimental) (JJ cranial) (NN Doc_9514561_21_25_Disease)) (VP (VBN elicited) (PP (IN by) (NP (NNP Doc_9514561_38_47_Chemical))))) (: :) (NP (DT a) (JJ PET) (NN study)) (. .)))
9514561	1	(S1 (S (S (VP (VBG Using) (NP (DT a) (NN positron) (NN emission) (NN tomography) (-LRB- -LRB-) (NN PET) (-RRB- -RRB-) (NN study)))) (NP (PRP it)) (VP (AUX was) (VP (VBN shown) (ADVP (RB recently)) (SBAR (IN that) (S (PP (IN in) (NP (NNP Doc_9514561_141_149_Disease))) (PP (IN without) (NP (NN aura))) (NP (NP (JJ certain) (NNS areas)) (PP (IN in) (NP (DT the) (NN brain) (NN stem)))) (VP (AUX were) (UCP (VP (VBN activated) (PP (IN during) (NP (DT the) (NNP Doc_9514561_221_229_Disease) (NN state)))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ Doc_9514561_252_260_Disease) (JJ free) (NN interval))))))))) (. .)))
9514561	2	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT this) (NN brain) (NN stem) (NN activation)) (VP (VP (AUX is) (ADJP (JJ inherent) (PP (TO to) (NP (NP (DT the) (NNP Doc_9514561_344_352_Disease) (NN attack)) (NP (PRP itself)))))) (CC and) (VP (VBZ represents) (NP (DT the) (ADJP (RB so) (VBN called)) ('' ') (JJ Doc_9514561_397_405_Disease) (NN generator) (POS ')))))))) (. .)))
9514561	3	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT this) (NN hypothesis))))) (NP (PRP we)) (VP (VBD performed) (NP (DT an) (JJ experimental) (NN Doc_9514561_471_475_Disease) (NN study)) (PP (IN in) (NP (CD seven) (JJ healthy) (NNS volunteers))) (, ,) (S (VP (VBG using) (NP (NP (DT the) (JJ same) (NN positioning)) (PP (IN in) (NP (DT the) (JJ PET) (NN scanner)))) (PP (IN as) (PP (IN in) (NP (DT the) (JJ Doc_9514561_567_575_Disease) (NNS patients))))))) (. .)))
9514561	4	(S1 (S (NP (NP (DT A) (JJ small) (NN amount)) (PP (IN of) (NP (NNP Doc_9514561_604_613_Chemical)))) (VP (AUX was) (VP (VBN administered) (ADVP (RB subcutaneously)) (PP (IN in) (NP (DT the) (JJ right) (NN forehead))) (S (VP (TO to) (VP (VB evoke) (NP (DT a) (NN burning) (NN Doc_9514561_687_694_Disease) (NN sensation)) (PP (IN in) (NP (NP (DT the) (JJ first) (NN division)) (PP (IN of) (NP (DT the) (JJ trigeminal) (NN nerve)))))))))) (. .)))
9514561	5	(S1 (S (NP (NP (NNS Increases)) (PP (IN of) (NP (NP (JJ regional) (JJ cerebral) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN rCBF)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN found) (ADVP (RB bilaterally)) (PP (IN in) (NP (DT the) (NN insula))) (, ,) (PP (IN in) (NP (NP (DT the) (NNP anterior) (NN cingulate) (NN cortex)) (, ,) (NP (DT the) (JJ cavernous) (NN sinus)) (CC and) (NP (DT the) (NN cerebellum)))))) (. .)))
9514561	6	(S1 (S (S (VP (VBG Using) (NP (NP (DT the) (JJ same) (JJ stereotactic) (NN space) (NNS limits)) (PP (IN as) (PP (IN in) (NP (DT the) (ADJP (RB above) (VBN mentioned)) (NN Doc_9514561_980_988_Disease) (NN study))))) (NP (DT no) (NN brain) (NN stem) (NN activation)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ acute) (NNP Doc_9514561_1043_1047_Disease) (NN state))) (PP (VBN compared) (PP (TO to) (NP (DT the) (JJ Doc_9514561_1070_1074_Disease) (JJ free) (NN state)))))) (. .)))
9514561	7	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN activation))) (PP (IN in) (NP (NP (DT the) (NN region)) (PP (IN of) (NP (DT the) (JJ cavernous) (NN sinus)))))) (ADVP (RB however)) (, ,) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT this) (NN structure)) (VP (AUX is) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (JJ trigeminal) (JJ transmitted) (NNP Doc_9514561_1245_1249_Disease))) (PP (PP (IN as) (NP (JJ such))) (, ,) (CONJP (RB rather) (IN than)) (PP (IN in) (NP (NP (DT a) (JJ specific) (NN type)) (PP (IN of) (NP (NNP Doc_9514561_1293_1301_Disease)))))) (SBAR (IN as) (S (VP (AUX was) (VP (VBN suggested) (PP (IN for) (NP (NNP Doc_9514561_1323_1339_Disease)))))))))))))))) (. .)))
9523850	0	(S1 (NP (NP (NP (NN Value)) (PP (IN of) (NP (NNP Doc_9523850_9_27_Chemical))) (PP (IN in) (NP (NP (NN prevention)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9523850_49_59_Disease-Doc_9523850_60_67_Disease) (NN syndrome)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ total) (NN dose) (NN infusion)) (PP (IN of) (NP (NNP Doc_9523850_120_132_Chemical))))))))))) (: :) (NP (DT a) (JJ double) (JJ blind) (JJ randomized) (NN trial)) (. .)))
9523850	1	(S1 (S (NP (NP (DT The) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (JJ total) (NN dose) (NN infusion))) (PRN (-LRB- -LRB-) (NP (NNP TDI)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9523850_223_235_Chemical)))) (VP (AUX has) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
9523850	2	(S1 (S (PP (IN In) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (VBN treated) (NNS patients))))) (, ,) (NP (DT an) (JJ Doc_9523850_293_303_Disease-Doc_9523850_304_311_Disease) (NN syndrome)) (VP (VBZ develops)) (. .)))
9523850	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ prospective) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (S (NP (NP (IN whether) (JJ intravenous) (-LRB- -LRB-) (NN i.v.) (-RRB- -RRB-) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9523850_459_477_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9523850_479_481_Chemical)) (-RRB- -RRB-))))) (VP (VBZ prevents) (NP (DT this) (NN complication))))))))) (. .)))
9523850	4	(S1 (S (NP (NP (NP (JJ Sixty-five) (NNS patients)) (, ,) (NP (CD 34) (NNS women)) (CC and) (NP (CD 31) (NNS men))) (, ,) (NP (NP (NNS ages)) (NP (QP (CD 36) (TO to) (CD 80)) (NNS years))) (, ,)) (VP (VBD received) (NP (DT either) (JJ normal) (NN saline)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PRN (-LRB- -LRB-) (NP (NN group) (CD 1)) (-RRB- -RRB-)))) (, ,) (NP (CD 125) (NN mg)) (NP (JJ i.v.) (NNP Doc_9523850_648_650_Chemical)) (SBAR (IN before) (S (NP (CC and) (NP (NP (NN saline)) (PP (IN after) (NP (NNP TDI))) (PRN (-LRB- -LRB-) (NP (NN group) (CD 2)) (-RRB- -RRB-)) (, ,)) (CC or) (NP (CD 125) (NN mg))) (VP (VBD i.v.) (NP (NNP Doc_9523850_705_707_Chemical)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PRN (-LRB- -LRB-) (NP (NN group) (CD 3)) (-RRB- -RRB-)))))))) (. .)))
9523850	5	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (CD 72) (NNS hours)))))) (CC and) (S (NP (NNS reactions)) (VP (AUX were) (VP (VBN recorded) (CC and) (VBN graded) (PP (VBG according) (PP (TO to) (NP (NN severity))))))) (. .)))
9523850	6	(S1 (S (NP (NP (NP (JJ Fifty-eight) (NN percent)) (PP (IN of) (NP (NN group) (CD 1) (NNS patients)))) (, ,) (NP (NP (CD 33) (NN %)) (PP (IN of) (NP (NN group) (CD 2)))) (, ,) (CC and) (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (NN group) (CD 3))))) (VP (AUX had) (NP (NP (NNS reactions)) (PP (TO to) (NP (NNP TDI))))) (. .)))
9523850	7	(S1 (S (NP (NP (DT The) (NN severity)) (PP (IN of) (NP (NP (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ minimal) (, ,) (JJ mild) (, ,) (CC and) (JJ moderate) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))) (VP (AUX was) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (NN group) (NN 1--6)) (, ,) (NP (NP (CD 6)) (, ,) (CC and) (NP (CD 2)))) (: ;) (NP (NP (NN group) (NN 2--1)) (, ,) (NP (NP (CD 5)) (, ,) (CC and) (NP (CD 0)))) (: ;) (NP (NN group) (NN 3--5)) (, ,) (NP (CD 1)) (, ,) (CC and) (NP (CD 0))))) (. .)))
9523850	8	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN by) (NP (NP (NP (DT the) (JJ two-sided) (NNP Fisher) (POS 's)) (JJ exact) (NN test)) (VP (VBG using) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NNS intervals)) (PP (IN with) (NP (NP (DT the) (NN approximation)) (PP (IN of) (NP (NNP Woolf)))))))))) (. .)))
9523850	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_9523850_1254_1256_Chemical))) (PP (IN before) (CC and) (IN after) (NP (NNP TDI)))) (VP (VBZ reduces) (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (DT the) (JJ Doc_9523850_1320_1330_Disease-Doc_9523850_1331_1338_Disease) (NN syndrome)))))))) (. .)))
9523850	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (CD 125) (JJ mg) (NN i.v.) (NN Doc_9523850_1378_1380_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN given) (ADVP (RB routinely)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PP (IN of) (NP (NNP Doc_9523850_1431_1443_Chemical))))))))))) (. .)))
9545159	0	(S1 (S (NP (NN Doc_9545159_0_31_Disease)) (VP (VBD related) (PP (TO to) (NP (JJ Doc_9545159_43_52_Chemical-Doc_9545159_53_62_Chemical) (NN interaction)))) (. .)))
9545159	1	(S1 (S (NP (NP (NNP Doc_9545159_76_85_Chemical)) (, ,) (NP (DT a) (JJ cytochrome) (JJ P450) (NN 3A4) (PRN (-LRB- -LRB-) (NNP CYP3A4) (-RRB- -RRB-)) (NN substrate)) (, ,)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN prescribed) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9545159_171_206_Disease))))))) (. .)))
9545159	2	(S1 (S (NP (NNP Doc_9545159_208_235_Disease) (, ,) (NNP Doc_9545159_237_256_Disease) (, ,) (CC and) (NNP Doc_9545159_262_282_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (JJ concomitant) (NN administration)) (PP (PP (IN with) (NP (NNP Doc_9545159_340_352_Chemical) (CC or) (NNP Doc_9545159_356_361_Chemical) (NN antifungal) (NNS agents))) (, ,) (CC but) (RB not) (PP (IN with) (NP (JJ other) (JJ CYP3A4) (NNS inhibitors))))))))) (. .)))
9545159	3	(S1 (S (NP (DT A) (JJ possible) (NN drug) (NN interaction)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ 45-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_9545159_494_503_Chemical)) (PP (IN for) (NP (NP (NNP Doc_9545159_508_540_Disease)) (CC and) (NP (NP (NNP Doc_9545159_545_554_Chemical)) (, ,) (NP (NP (DT an) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (NP (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NNS CYP3A4)))))))) (, ,) (PP (IN for) (NP (NNP Doc_9545159_607_619_Disease))))))))))))) (. .)))
9545159	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (ADVP (RB in)) (PP (IN near) (NP (NNP Doc_9545159_645_652_Disease)))) (CC and) (VP (AUX had) (NP (NN Doc_9545159_661_685_Disease)))) (. .)))
9545159	5	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (NNP Doc_9545159_707_716_Chemical))))) (, ,) (S (NP (DT the) (JJ QT) (NN interval)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))))) (CC and) (S (NP (NNS symptoms)) (VP (AUX did) (RB not) (VP (VB recur)))) (. .)))
9545159	6	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN caution)) (VP (AUX be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_9545159_819_828_Chemical)) (VP (AUX is) (VP (VBN prescribed) (PP (IN with) (NP (NP (DT any) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4))) (, ,) (PP (VBG including) (NP (NNP Doc_9545159_890_899_Chemical)))))))))))))) (. .)))
9549528	0	(S1 (NP (NP (JJ Cortical) (NN motor) (NN overactivation)) (PP (IN in) (NP (NP (JJ Doc_9549528_33_45_Disease) (NNS patients)) (PP (IN with) (NP (JJ Doc_9549528_60_66_Chemical-induced) (JJ peak-dose) (NN Doc_9549528_85_95_Disease))))) (. .)))
9549528	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN studied) (SBAR (S (NP (NP (DT the) (JJ regional) (JJ cerebral) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN rCBF)) (-RRB- -RRB-))) (VP (VBZ changes) (S (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NN execution)) (PP (IN of) (NP (DT a) (JJ finger-to-thumb) (NN opposition) (NN motor) (NN task))) (PP (PP (IN in) (NP (NP (NP (DT the) (JJ supplementary) (CC and) (JJ primary) (NN motor) (NN cortex)) (PP (IN of) (NP (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (NP (JJ Doc_9549528_292_304_Disease) (NNS patients)) (PP (IN on) (NP (JJ Doc_9549528_317_323_Chemical) (NN medication)))))) (, ,) (NP (NP (DT the) (JJ first) (CD one)) (PP (IN without) (NP (NNP Doc_9549528_358_364_Chemical))) (VP (VBN induced) (NP (NNP Doc_9549528_373_383_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 23)) (-RRB- -RRB-))))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN with) (NP (NP (JJ moderate) (JJ peak-dose) (NNP Doc_9549528_431_441_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 15)) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (IN of) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (CD 14) (JJ normal) (NNS subjects))))))))))))))) (. .)))
9549528	2	(S1 (S (NP (NP (JJ Single) (NN photon) (NN emission) (NN tomography)) (PP (IN with) (NP (JJ i.v.) (NNS 133Xe)))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (DT the) (JJ rCBF) (NNS changes))))))) (. .)))
9549528	3	(S1 (S (NP (DT The) (NNP Doc_9549528_582_592_Disease) (NNP Doc_9549528_593_605_Disease) (NNS patients)) (VP (VBD exhibited) (NP (NP (DT a) (NN pattern)) (PP (IN of) (NP (NP (NN response)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (RB markedly) (JJ different) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ normal) (NNS subjects)) (CC and) (NP (JJ non-Doc_9549528_718_728_Disease) (NN Doc_9549528_729_741_Disease) (NNS patients))))))))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN overactivation)) (PP (IN in) (NP (NP (DT the) (JJ supplementary) (NN motor) (NN area)) (CC and) (NP (DT the) (ADJP (JJ ipsi-) (CC and) (JJ contralateral)) (JJ primary) (NN motor) (NNS areas))))))) (. .)))
9549528	4	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ compatible) (PP (IN with) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT an) (NNP Doc_9549528_928_940_Disease) (NNP Doc_9549528_941_970_Disease)) (, ,) (PP (IN like) (NP (JJ Doc_9549528_977_983_Chemical-induced) (NN peak) (NN dose) (NNP Doc_9549528_1002_1012_Disease))) (, ,)) (VP (AUX is) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN disinhibition)) (PP (IN of) (NP (NP (DT the) (JJ primary) (CC and) (JJ associated) (NN motor) (NN cortex)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT an) (JJ excessive) (NN outflow)) (PP (IN of) (NP (DT the) (JJ pallidothalamocortical) (NN motor) (NN loop)))))))))))))))))) (. .)))
9564988	0	(S1 (NP (NP (JJ Open-label) (NN assessment)) (PP (IN of) (NP (NNP Doc_9564988_25_37_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_75_84_Disease)) (PP (IN in) (NP (NNS adults))))))) (. .)))
9564988	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_9564988_144_156_Chemical)))) (PRN (-LRB- -LRB-) (S (NP (CD 500)) (VP (VBG mg) (ADVP (RB orally) (RB once) (RB daily)) (PP (IN for) (NP (QP (CD 10) (TO to) (CD 14)) (NNS days))))) (-RRB- -RRB-)) (PP (IN in) (S (VP (VBG treating) (NP (NN adult) (NNS outpatients)) (PP (IN with) (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_253_262_Disease))))))))) (. .)))
9564988	2	(S1 (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 329) (NNS patients))) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (NN study))) (PP (IN at) (NP (CD 24) (NNS centers))))) (. .)))
9564988	3	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ pre-therapy) (NN Gram)) (SBAR (S (VP (AUX 's) (NP (NP (NP (VB stain)) (CC and) (NP (NN culture))) (PP (IN of) (NP (NP (JJ sinus) (NN exudate)) (VP (VBN obtained) (PP (IN by) (NP (NP (JJ antral) (NN puncture)) (CC or) (NP (JJ nasal) (NN endoscopy))))))))))))) (. .)))
9564988	4	(S1 (S (NP (JJ Clinical) (NN response)) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NNS signs) (CC and) (NNS symptoms)) (CC and) (NP (NP (JJ sinus) (NN radiograph)) (CC or) (NP (JJ computed) (NN tomography) (NNS results))))))))) (. .)))
9564988	5	(S1 (S (NP (JJ Microbiologic) (NN cure) (NNS rates)) (VP (AUX were) (VP (VBN determined) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (VBN presumed) (CC plus) (VBN documented) (NN eradication)) (PP (IN of) (NP (NP (DT the) (JJ pre-therapy) (NNS pathogen)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)))))))))) (. .)))
9564988	6	(S1 (S (NP (DT The) (JJS most) (JJ common) (NNS pathogens)) (VP (AUX were) (NP (NP (JJ Haemophilus) (NNS influenzae)) (, ,) (NP (JJ Streptococcus) (NNS pneumoniae)) (, ,) (NP (NN Staphylococcus) (NN aureus)) (, ,) (CC and) (NP (NN Moraxella) (NN catarrhalis)))) (. .)))
9564988	7	(S1 (S (PP (IN Of) (NP (CD 300) (ADJP (RB clinically) (JJ evaluable)) (NNS patients))) (, ,) (S (NP (NP (CD 175)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN cured)))) (CC and) (S (NP (NP (CD 90)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN improved) (PP (IN at) (NP (NP (DT the) (JJ post-therapy) (NN evaluation)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN success) (NN rate)) (PP (IN of) (NP (CD 88) (NN %))))))))))) (. .)))
9564988	8	(S1 (S (NP (NP (JJ Thirty-five) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (ADVP (RB clinically)) (VP (VBD failed) (NP (NN treatment))) (. .)))
9564988	9	(S1 (S (NP (NP (DT The) (JJ microbiologic) (NN eradication) (NN rate)) (PRN (-LRB- -LRB-) (ADJP (VBN presumed) (CC plus) (VBN documented)) (-RRB- -RRB-)) (PP (IN among) (NP (CD 138) (JJ microbiologically) (NN evaluable) (NNS patients)))) (VP (AUX was) (NP (CD 92) (NN %))) (. .)))
9564988	10	(S1 (S (NP (NP (NP (JJ Microbiologic) (NN eradication) (NNS rates)) (PRN (-LRB- -LRB-) (VP (VBN presumed) (CC plus) (VBN documented)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (RBS most) (JJ common) (NNS pathogens)))) (VP (VBD ranged) (PP (PP (IN from) (NP (NP (CD 93) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP M.) (NN catarrhalis)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 100) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP S.) (NNP pneumoniae)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (JJ post-therapy) (NN visit)))) (. .)))
9564988	11	(S1 (S (S (NP (NP (DT All)) (CC but) (NP (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (CD 265) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN cured) (CC or) (VBN improved) (PP (IN at) (NP (NP (JJ post-therapy)) (VP (VBN returned) (PP (IN for) (NP (DT a) (JJ long-term) (JJ follow-up) (NN visit))))))))))))) (: ;) (NP (CD 243)) (PRN (-LRB- -LRB-) (NP (CD 92) (NN %)) (-RRB- -RRB-)))) (VP (VBD remained) (ADVP (RB well) (NP (QP (CD 4) (TO to) (CD 6)) (NNS weeks))) (PP (IN after) (NP (NN therapy))))) (: ;) (CC and) (S (NP (NP (CD 21)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT a) (NN relapse)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
9564988	12	(S1 (S (NP (NP (JJ Adverse) (NNS events)) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9564988_1613_1625_Chemical) (NN administration))))))))) (VP (AUX were) (VP (VBN reported) (PP (IN by) (NP (NP (CD 29) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-)))))) (. .)))
9564988	13	(S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ drug-related) (JJ adverse) (NNS events)) (VP (AUX were) (NP (NP (NNP Doc_9564988_1725_1733_Disease)) (, ,) (NP (NNP Doc_9564988_1735_1745_Disease)) (, ,) (CC and) (NP (NNP Doc_9564988_1751_1757_Disease))))) (: ;) (S (NP (JJS most) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (PP (IN in) (NP (NN severity))))))))) (. .)))
9564988	14	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9564988_1866_1878_Chemical) (CD 500)) (VP (VBD mg) (SBAR (IN once) (S (NP (NN daily)) (VP (AUX is) (NP (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (JJ safe))) (NN treatment)) (PP (IN for) (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_1952_1961_Disease))))))))))) (. .)))
9579567	0	(S1 (S (NP (NP (JJ Iatrogenic) (NNS risks)) (PP (IN of) (NP (NNP Doc_9579567_20_41_Disease))) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (NNP Doc_9579567_62_75_Disease))) (PP (IN in) (NP (DT a) (JJ large) (JJ French) (NN case-control)))) (VP (VBP study)) (. .)))
9579567	1	(S1 (NP (NP (NNP F) (NNP d) (FW ration) (NNP Nationale) (FW des) (NNP Centres) (FW de) (NNP Lutte) (NNP Contre) (FW le) (NNP Cancer)) (PRN (-LRB- -LRB-) (NP (NNP FNCLCC)) (-RRB- -RRB-)) (. .)))
9579567	2	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_9579567_191_200_Chemical)) (VP (VP (AUX is) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (JJ Doc_9579567_219_232_Disease) (NN treatment))))) (CC and) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_9579567_287_300_Disease))))))))))) (, ,) (NP (PRP$ its) (JJ endometrial) (JJ iatrogenic) (NNS effects)) (VP (MD must) (VP (AUX be) (VP (ADVP (RB carefully)) (VBN examined)))) (. .)))
9579567	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN investigated) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (NNP Doc_9579567_410_428_Disease)) (CC and) (NP (NNP Doc_9579567_433_442_Chemical)) (NX (NX (NN use)) (CC or) (NX (JJ other) (NNS treatments)))) (PP (IN in) (NP (NP (NNS women)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_9579567_488_501_Disease))) (PP (IN in) (NP (DT a) (JJ case-control) (NN study))))))))))) (. .)))
9579567	4	(S1 (S (S (NP (NP (NNS Cases)) (PP (IN of) (NP (NNP Doc_9579567_536_554_Disease)))) (VP (VBD diagnosed) (PP (IN after) (NP (NNP Doc_9579567_571_584_Disease))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 135)) (-RRB- -RRB-)) (CC and) (S (NP (NP (CD 467) (NNS controls)) (VP (VBN matched) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NP (NN year)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_9579567_650_663_Disease)))))) (CC and) (NP (NP (NP (NN hospital)) (CC and) (NP (NN survival) (NN time))) (PP (IN with) (NP (DT an) (JJ intact) (NN uterus)))))))) (VP (AUX were) (VP (VBN included)))) (. .)))
9579567	5	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NNP Doc_9579567_755_764_Chemical))))))) (VP (AUX were) (ADJP (ADVP (RB significantly) (RBR more)) (JJ likely) (S (VP (TO to) (VP (AUX have) (S (NP (NNP Doc_9579567_804_822_Disease)) (VP (VBN diagnosed) (PP (IN than) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not)))))))))))) (PRN (-LRB- -LRB-) (FRAG (NP (NP (JJ crude) (JJ relative) (NN risk)) (NP (SYM =) (CD 4.9) (, ,) (CD p))) (X (SYM =)) (NP (CD 0.0001))) (-RRB- -RRB-))) (. .)))
9579567	6	(S1 (S (NP (NP (NNP Univariate)) (CC and) (NP (VBN adjusted) (NNS analyses))) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN risk)) (VP (VBD increased) (PP (IN with) (NP (NP (NP (DT the) (NN length)) (PP (IN of) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_9579567_1029_1038_Chemical))) (VP (VBN received) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.0001)))) (-RRB- -RRB-)))))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (DT the) (JJ daily) (NN dose)))))))) (. .)))
9579567	7	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN undergone) (NP (JJ pelvic) (NN radiotherapy))))))) (ADVP (RB also)) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN risk)) (PRN (-LRB- -LRB-) (NP (JJ crude) (JJ relative) (NN risk) (SYM =) (CD 7.8)) (, ,) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-)))) (. .)))
9579567	8	(S1 (S (PP (IN After) (S (VP (VBG adjusting) (PP (IN for) (NP (JJ confounding) (NNS factors)))))) (, ,) (NP (DT the) (NN risk)) (VP (AUX was) (ADJP (JJR higher)) (PP (IN for) (NP (NP (JJ Doc_9579567_1267_1276_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0012)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN treatment)) (PP (IN for) (NP (NP (NP (QP (JJR more) (IN than) (CD 3)) (NNS years)) (PRN (-LRB- -LRB-) (NP (DT all) (JJ p) (CD <) (CD 0.03)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ pelvic) (NNS radiotherapy)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.012)))) (-RRB- -RRB-))))))) (. .)))
9579567	9	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (NN Doc_9579567_1395_1413_Disease))) (CC and) (VP (AUX had) (VP (VBN received) (NP (NNP Doc_9579567_1431_1440_Chemical)))))))) (VP (AUX had) (ADJP (ADJP (RBR more) (JJ Doc_9579567_1450_1466_Disease)) (CC and) (ADJP (JJR poorer) (NN prognosis) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_9579567_1504_1522_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not) (VP (VBN received) (NP (DT this) (NN treatment))))))))))) (. .)))
9579567	10	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ causal) (NN role)) (PP (IN of) (NP (NNP Doc_9579567_1597_1606_Chemical))) (PP (IN in) (NP (NP (NNP Doc_9579567_1610_1628_Disease)) (, ,) (SBAR (ADVP (RB particularly)) (WHADVP (WRB when)) (S (VP (VBN used) (SBAR (IN as) (S (ADVP (RB currently)) (VP (VBN proposed) (PP (IN for) (NP (NN Doc_9579567_1679_1692_Disease) (NN prevention))))))))))))) (. .)))
9579567	11	(S1 (S (NP (JJ Pelvic) (NN radiotherapy)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ additional) (NN iatrogenic) (NN factor)) (PP (IN for) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_9579567_1779_1792_Disease)))))))) (. .)))
9579567	12	(S1 (S (NP (NP (NN Doc_9579567_1794_1813_Disease)) (VP (VBN diagnosed) (PP (IN in) (NP (NP (NNS women)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9579567_1846_1855_Chemical)))))))) (VP (AUX have) (NP (JJR poorer) (NN prognosis))) (. .)))
9579567	13	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (NNP Doc_9579567_1897_1906_Chemical)) (PP (IN for) (NP (NNP Doc_9579567_1911_1924_Disease))))))) (VP (MD should) (VP (AUX be) (VP (VBN offered) (NP (NN gynaecological) (NN surveillance)) (PP (IN during) (CC and) (IN after) (NP (NN treatment)))))) (. .)))
9579567	14	(S1 (S (NP (NP (DT A) (JJ long-term) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (JJ risk-benefit) (NN ratio)) (PP (IN of) (NP (NNP Doc_9579567_2051_2060_Chemical))) (PP (IN as) (NP (NP (DT a) (JJ preventive) (NN treatment)) (PP (IN for) (NP (NNP Doc_9579567_2091_2104_Disease)))))))) (VP (AUX is) (ADVP (RB clearly)) (VP (VBN warranted))) (. .)))
9630698	0	(S1 (NP (NP (NN Contribution)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_20_27_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_36_40_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (JJ rostral) (CC and) (JJ intermediate-caudal) (NNS parts)) (PP (IN of) (NP (DT the) (NN striatum))))))) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN muscle) (NN tone)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9630698	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_217_224_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_233_237_Chemical) (NNS receptors))))) (PP (IN in) (NP (DT the) (NN striatum))) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN muscle) (NN tone)))))))))) (. .)))
9630698	2	(S1 (S (NP (NN Muscle) (NN tone)) (VP (AUX was) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NP (DT a) (JJ combined) (NN mechanoand) (NN electromyographic) (NN method)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD measured) (ADVP (RB simultaneously)) (NP (NP (DT the) (NN muscle) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NNP MMG)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NN rat) (POS 's)) (JJ hind) (NN foot)))) (PP (TO to) (NP (NP (JJ passive) (NN extension)) (CC and) (NP (NP (NN flexion)) (PP (IN in) (NP (NP (NP (DT the) (JJ ankle) (NN joint)) (CC and) (NP (NP (DT the) (JJ electromyographic) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP EMG)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (DT the) (JJ antagonistic) (NNS muscles)) (PP (IN of) (NP (DT that) (NN joint)))))))))))))) (: :) (NP (NP (NN gastrocnemius) (CC and) (NN tibialis)) (NP (NNP anterior)))))))) (. .)))
9630698	3	(S1 (S (S (NP (NN Doc_9630698_631_646_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NP (NNP Doc_9630698_662_673_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)) (. .)) (NNP Doc_9630698_692_718_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9630698_720_728_Chemical)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (JJ selective) (JJ Doc_9630698_743_750_Chemical) (NN site) (NN antagonist)) (, ,) (VP (VBN injected) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 2.5) (CC and) (CD 4.5) (CD microg/0.5)) (NN microl))))) (ADVP (RB bilaterally)) (, ,) (PP (IN into) (NP (NP (DT the) (JJ rostral) (NN region)) (PP (IN of) (NP (DT the) (NN striatum)))))) (, ,)) (VP (VBD decreased) (SBAR (S (NP (DT both) (NP (NP (NP (DT the) (JJ Doc_9630698_892_903_Chemical-induced) (NNP Doc_9630698_912_927_Disease)) (PRN (-LRB- -LRB-) (NP (NNP MMG)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ enhanced) (JJ electromyographic) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP EMG)) (-RRB- -RRB-)) (. .))) (NNP Doc_9630698_985_993_Chemical)) (VP (VP (VBD injected) (ADVP (RB bilaterally)) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (QP (CD 4.5) (CD microg/0.5)) (NN microl))))) (PP (IN into) (NP (NP (DT the) (JJ intermediate-caudal) (NN region)) (PP (IN of) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (NNS rats)))))))) (RB not) (VP (VBN pretreated) (SBAR (IN with) (S (NP (NNP Doc_9630698_1130_1141_Chemical)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (DT the) (NN muscle) (NN tone)))))))))))) (. .)))
9630698	4	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN blockade)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_1225_1232_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_1241_1245_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (JJ rostral) (NN part)) (PP (IN of) (NP (DT the) (NN striatum)))))))) (VP (MD may) (VP (AUX be) (ADJP (RB mainly) (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ antiparkinsonian) (NN action)) (PP (IN of) (NP (DT this) (NN drug))))))))))) (. .)))
9636837	0	(S1 (NP (NP (JJ Doc_9636837_0_11_Chemical) (JJ toxic) (NNS effects)) (PP (IN on) (NP (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)) (PP (IN of) (NP (DT the) (NN rat))))) (. .)))
9636837	1	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ striking))) (PP (IN of) (NP (NP (NP (NP (NNP Doc_9636837_104_115_Chemical) (POS 's)) (NNS advantages)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9636837_130_135_Chemical)) (-RRB- -RRB-))) (PP (IN over) (NP (NP (NNP Doc_9636837_142_151_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9636837_153_157_Chemical)) (-RRB- -RRB-))))))) (VP (AUX is) (NP (NP (PRP$ its) (ADJP (RB markedly) (VBN reduced)) (NN rate)) (PP (IN of) (NP (JJ Doc_9636837_191_201_Disease) (NNS effects))))) (. .)))
9636837	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_9636837_231_236_Chemical) (NN higher-intensity) (NNS schedules)))) (CC and) (NP (NP (DT the) (NN association)) (PP (IN with) (NP (NP (JJ other) (JJ Doc_9636837_295_305_Disease) (NNS drugs)) (PP (IN in) (NP (NN polychemotherapy))))))) (VP (MD may) (VP (VB cause) (NP (NP (DT some) (NN concern)) (PP (IN about) (NP (PRP$ its) (NN safety)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NNP Doc_9636837_388_420_Disease))))))) (. .)))
9636837	3	(S1 (S (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (CD Two) (JJ different) (NNS schedules)) (PP (IN of) (NP (NNP Doc_9636837_472_477_Chemical) (NN administration))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 10) (CD mg/kg) (CC and) (CD 15)) (JJ mg/kg) (NNS i.p.)) (NP (RB twice) (DT a) (NN week))) (PP (IN for) (NP (CD nine) (NNS times)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (JJ Wistar) (NNS rats))))) (. .)))
9636837	4	(S1 (S (NP (NN Doc_9636837_581_594_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN for) (NP (NP (JJ behavioral) (-LRB- -LRB-) (JJ tail-flick) (NN test) (-RRB- -RRB-)) (, ,) (NP (NP (NN neurophysiological)) (PRN (-LRB- -LRB-) (NP (NP (NN nerve) (NN conduction) (NN velocity)) (PP (IN in) (NP (DT the) (NN tail) (NN nerve)))) (-RRB- -RRB-))) (, ,) (NP (NN morphological)) (, ,) (NP (NN morphometrical)) (CC and) (NP (JJ analytical) (NNS effects)))))) (. .)))
9636837	5	(S1 (S (NP (JJ Doc_9636837_771_776_Chemical) (NN administration)) (VP (VBN induced) (NP (JJ dose-dependent) (NNP Doc_9636837_815_839_Disease))) (. .)))
9636837	6	(S1 (S (NP (NP (NP (JJ Doc_9636837_841_845_Disease) (NN perception)) (CC and) (NP (NN nerve) (NN conduction) (NN velocity))) (PP (IN in) (NP (DT the) (NN tail)))) (VP (AUX were) (ADJP (RB significantly) (JJ impaired)) (, ,) (PP (ADVP (RB particularly)) (IN after) (NP (DT the) (JJ high-dose) (NN treatment)))) (. .)))
9636837	7	(S1 (S (NP (NP (DT The) (JJ dorsal) (NN root) (NN ganglia) (JJ sensory) (NNS neurons)) (CC and) (PRN (, ,) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,)) (NP (NN satellite) (NNS cells))) (VP (VBD showed) (NP (NP (DT the) (JJ same) (NNS changes)) (PP (IN as) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9636837_1097_1101_Chemical))))))) (, ,) (S (ADVP (RB mainly)) (VP (VBG affecting) (NP (NP (DT the) (NN nucleus) (CC and) (NN nucleolus)) (PP (IN of) (NP (JJ ganglionic) (JJ sensory) (NNS neurons))))))) (. .)))
9636837	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ significant) (NNS amounts)) (PP (IN of) (NP (NNP Doc_9636837_1210_1218_Chemical)))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (JJ dorsal) (NN root) (NN ganglia)) (CC and) (NP (NN kidney)))) (PP (IN after) (NP (JJ Doc_9636837_1277_1282_Chemical) (NN treatment))))) (. .)))
9636837	9	(S1 (S (S (NP (NN Doc_9636837_1307_1312_Chemical)) (VP (AUX is) (ADJP (JJ Doc_9636837_1316_1326_Disease)) (PP (IN in) (NP (PRP$ our) (NN model))))) (, ,) (CC and) (S (NP (NP (DT the) (NN type)) (PP (IN of) (NP (JJ pathological) (NNS changes)))) (NP (PRP it)) (VP (VBZ induces) (SBAR (S (VP (AUX are) (ADJP (ADJP (RB so) (RB closely) (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9636837_1431_1435_Chemical))))))) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ probable)) (SBAR (IN that) (S (NP (NNP Doc_9636837_1461_1474_Disease)) (VP (AUX is) (VP (VBN induced) (PP (IN in) (NP (DT the) (CD two) (NNS drugs))) (PP (IN by) (NP (DT the) (JJ same) (NN mechanism)))))))))))))))) (. .)))
9636837	10	(S1 (S (NP (DT This) (NN model)) (VP (MD can) (VP (AUX be) (VP (VBN used) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_9636837_1615_1620_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))))))))) (. .)))
9669632	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_9669632_11_20_Chemical))) (PP (IN on) (NP (NNS symptoms)))) (CC and) (NP (JJ postcibal) (JJ small-bowel) (NN motor) (NN function))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9669632_91_115_Disease))))) (. .)))
9669632	1	(S1 (S (NP (NN Doc_9669632_129_153_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (JJ common) (NN cause)) (PP (IN of) (NP (NP (NN Doc_9669632_175_189_Disease)) (CC and) (NP (NN discomfort)))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9669632_227_263_Disease))))))) (. .)))
9669632	2	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ prokinetic) (NN agent)) (, ,) (NP (NNP Doc_9669632_347_356_Chemical)) (, ,))))) (PP (IN on) (NP (NP (JJ postprandial) (JJ jejunal) (NN motility)) (CC and) (NP (NP (NNS symptoms)) (PP (IN in) (NP (NP (DT the) (NNP Doc_9669632_411_435_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9669632_437_440_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
9669632	3	(S1 (S (NP (NP (JJ Thirty-eight) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9669632_479_482_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9669632_484_496_Disease-predominant)) (, ,) (NP (NNP n) (SYM =) (CD 17))) (: ;) (NP (NP (NNP Doc_9669632_518_527_Disease-predominant)) (, ,) (NP (NNP n) (SYM =) (CD 21))) (-RRB- -RRB-))))) (VP (VBD underwent) (NP (JJ 24-h) (JJ ambulatory) (JJ jejunal) (NN manometry)) (PP (IN before) (CC and) (IN after) (NP (NP (CD 12) (NN week) (POS 's)) (NN treatment) (NN -LSB-Doc_9669632_631_640_Chemical))) (, ,) (S (NP (NP (NP (NP (CD 5) (NN mg)) (NP (QP (CD three) (NNS times)) (NN daily))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 19)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 19)) (-RRB- -RRB-)))) (ADJP (JJ -RSB-)))) (. .)))
9669632	4	(S1 (S (PP (IN In) (NP (JJ Doc_9669632_708_717_Disease-predominant) (NNS patients))) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NN contraction) (NNS characteristics)))) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (DT the) (NN Doc_9669632_820_829_Chemical) (CC and) (NN placebo) (NNS groups))))) (. .)))
9669632	5	(S1 (S (IN In) (JJ Doc_9669632_853_862_Chemical-treated) (JJ Doc_9669632_871_880_Disease-predominant) (NNS patients) (DT the) (VB mean) (NN contraction) (NN amplitude) (AUX was) (JJR higher) (-LRB- -LRB-) (CD 29.3) (JJ +/-) (CD 3.2) (CC versus) (CD 24.9) (JJ +/-) (CD 2.6) (CD mm) (NNP Hg) (, ,) (NNP Doc_9669632_985_994_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 25.7) (JJ +/-) (CD 6.0) (CD mm) (NNP Hg) (-RRB- -RRB-) (, ,) (DT the) (VB mean) (NN contraction) (NN duration) (RB longer) (-LRB- -LRB-) (CD 3.4) (JJ +/-) (CD 0.2) (CC versus) (CD 3.0) (JJ +/-) (CD 0.2) (NNP sec) (, ,) (NNP Doc_9669632_1132_1141_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 3.1) (JJ +/-) (CD 0.5) (NNP sec) (-RRB- -RRB-) (, ,) (CC and) (DT the) (VB mean) (NN contraction) (NN frequency) (JJR lower) (-LRB- -LRB-) (CD 2.0) (JJ +/-) (CD 0.2) (CC versus) (CD 2.5) (JJ +/-) (CD 0.4) (NN cont./min) (, ,) (NNP Doc_9669632_1286_1295_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 2.5) (JJ +/-) (CD 1.1) (NN cont./min) (JJ -RSB-) (IN than) (NNS patients) (VBN treated) (IN with) (NN placebo) (. .)))
9669632	6	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN in) (NP (JJ jejunal) (NN motility)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ Doc_9669632_1462_1474_Disease-predominant) (NN Doc_9669632_1487_1490_Disease) (NN group))))) (. .)))
9669632	7	(S1 (S (NP (NNS Symptoms)) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (S (VP (VBG using) (NP (DT a) (JJ visual) (NN analogue) (NN scale)) (PP (IN before) (CC and) (IN after) (NP (NN treatment)))))))) (. .)))
9669632	8	(S1 (S (NP (NP (NN Symptom) (NNS scores)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_9669632_1625_1637_Disease))))))) (VP (AUX were) (ADJP (JJR lower)) (PP (IN in) (NP (NP (JJ Doc_9669632_1652_1661_Chemical-treated) (JJ Doc_9669632_1670_1682_Disease-predominant) (NNP Doc_9669632_1695_1698_Disease) (NNS patients) (NN -LSB-score)) (, ,) (NP (NP (CD 54) (NN +/-)) (NP (QP (CD 5) (CC versus) (CD 67)) (JJ +/-) (CD 14) (NNS mm))) (, ,) (NP (NNP Doc_9669632_1746_1755_Chemical)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)) (: ;) (NP (NN pretreatment)) (, ,) (NP (NP (CD 62) (NNS +/-)) (NP (CD 19) (CD mm) (NN -RSB-))))))) (. .)))
9669632	9	(S1 (S (NP (JJ Doc_9669632_1812_1821_Disease-predominant) (NNP Doc_9669632_1834_1837_Disease) (NNS patients)) (VP (AUX had) (NP (DT a) (JJR higher) (NN Doc_9669632_1860_1864_Disease) (NN score)) (PP (IN after) (NP (NP (JJ Doc_9669632_1877_1886_Chemical) (NN therapy) (NN -LSB-score)) (, ,) (NP (NP (CD 55) (NN +/-)) (NP (QP (CD 15) (CC versus) (CD 34)) (JJ +/-) (CD 12) (NNS mm))) (, ,) (NP (NNP Doc_9669632_1934_1943_Chemical)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)) (: ;) (NP (NN pretreatment)) (, ,) (NP (NP (CD 67) (NNS +/-)) (NP (QP (CD 19) (CD mm)) (NN -RSB-))))))) (. .)))
9669632	10	(S1 (S (NP (NN Doc_9669632_2012_2021_Chemical)) (VP (VBZ affects) (NP (NP (JJ jejunal) (NN contraction) (NNS characteristics)) (CC and) (NP (NP (DT some) (NNS symptoms)) (PP (IN in) (NP (NNP Doc_9669632_2087_2090_Disease)))))) (. .)))
9672273	0	(S1 (NP (NP (NP (NN Prevention)) (PP (IN of) (NP (NNP Doc_9672273_14_27_Disease))) (PP (IN with) (NP (NNP Doc_9672273_33_42_Chemical)))) (: :) (NP (NP (JJ preliminary) (NNS findings)) (PP (IN from) (NP (NP (DT the) (JJ Italian) (JJ randomised) (NN trial)) (PP (IN among) (NP (JJ hysterectomised) (NNS women)))))) (. .)))
9672273	1	(S1 (NP (NNP Italian) (NNP Doc_9672273_136_145_Chemical) (NNP Prevention) (NNP Study) (. .)))
9672273	2	(S1 (S (NP (NN Doc_9672273_176_185_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN candidate) (JJ chemopreventive) (NN agent)) (PP (IN in) (NP (NNP Doc_9672273_226_239_Disease)))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN drug)) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN Doc_9672273_301_319_Disease))))))))))) (. .)))
9672273	3	(S1 (S (ADVP (RB Therefore)) (NP (PRP we)) (VP (AUX did) (NP (DT a) (NN trial)) (PP (IN in) (NP (NP (JJ hysterectomised) (NNS women)) (PP (IN of) (NP (NNP Doc_9672273_374_383_Chemical))))) (PP (IN as) (NP (DT a) (NN chemopreventive)))) (. .)))
9672273	4	(S1 (S (PP (IN In) (NP (NP (NNP October)) (, ,) (NP (CD 1992)))) (, ,) (NP (PRP we)) (VP (VBD started) (NP (NP (DT a) (JJ double-blind) (JJ placebo-controlled) (, ,) (JJ randomised) (NN trial)) (PP (IN of) (NP (NNP Doc_9672273_499_508_Chemical))) (PP (IN in) (NP (NP (NP (NNS women)) (PRN (-LRB- -LRB-) (PP (ADVP (RB mainly)) (IN in) (NP (NNP Italy))) (-RRB- -RRB-))) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_9672273_553_566_Disease)))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (NP (DT a) (NN hysterectomy))))))))))) (. .)))
9672273	5	(S1 (S (NP (NNS Women)) (VP (AUX were) (VP (VBN randomised) (S (VP (TO to) (VP (VB receive) (NP (NP (NNP Doc_9672273_632_641_Chemical) (CD 20) (NNS mg)) (PP (IN per) (NP (NP (NN day)) (CC or) (NP (NN placebo)))))))) (, ,) (FRAG (CC both) (RB orally) (PP (IN for) (NP (CD 5) (NNS years)))))) (. .)))
9672273	6	(S1 (S (NP (DT The) (JJ original) (NN plan)) (VP (AUX was) (S (VP (TO to) (VP (VB follow) (NP (DT the) (NN intervention) (NN phase)) (PP (IN by) (NP (NP (CD 5) (NNS years) (POS ')) (NN follow-up))))))) (. .)))
9672273	7	(S1 (S (PP (IN In) (NP (NP (NNP June)) (, ,) (NP (CD 1997)))) (, ,) (NP (NP (DT the) (NNS trialists)) (CC and) (NP (DT the) (JJ data-monitoring) (NN committee))) (VP (VBD decided) (S (VP (TO to) (VP (VB end) (NP (NN recruitment)) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS women)))))))) (S (VP (VBG dropping) (PP (IN out) (PP (IN of) (NP (DT the) (NN study))))))) (. .)))
9672273	8	(S1 (S (S (NP (NN Recruitment)) (VP (VBD ended) (PP (IN on) (NP (NNP July) (CD 11) (, ,) (CD 1997))))) (, ,) (CC and) (S (NP (DT the) (NN study)) (VP (MD will) (VP (VB continue) (SBAR (IN as) (S (VP (VBN planned))))))) (. .)))
9672273	9	(S1 (S (NP (DT The) (JJ primary) (NNS endpoints)) (VP (AUX are) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (CC and) (NP (NP (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_1065_1078_Disease))))))) (. .)))
9672273	10	(S1 (S (NP (DT This) (JJ preliminary) (JJ interim) (NN analysis)) (VP (AUX is) (VP (VBN based) (PP (IN on) (NP (NN intention-to-treat))))) (. .)))
9672273	11	(S1 (S (S (NP (CD 5408) (NNS women)) (VP (AUX were) (VP (VBN randomised)))) (: ;) (S (NP (VBG participating) (NNS women)) (VP (AUX have) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 46) (NNS months))) (PP (IN for) (NP (NP (JJ major) (CD endpoints.) (CD 41) (NNS cases)) (PP (IN of) (NP (NNP Doc_9672273_1274_1287_Disease)))))) (VP (VBN occurred) (ADVP (RB so) (RB far))))) (: ;) (S (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (DT no) (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_1336_1349_Disease))))))) (. .)))
9672273	12	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (JJ Doc_9672273_1377_1390_Disease) (NN frequency))) (PP (IN between) (NP (NP (NP (DT the) (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 22) (NNS cases)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_9672273_1436_1445_Chemical) (-LRB- -LRB-) (CD 19) (-RRB- -RRB-) (NNS arms)))))) (. .)))
9672273	13	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_9672273_1507_1520_Disease)) (PP (IN among) (NP (NP (NNS women)) (VP (VBG receiving) (NP (NP (NNP Doc_9672273_1543_1552_Chemical)) (SBAR (WHNP (WP who)) (S (ADVP (RB also)) (VP (VBD used) (NP (JJ hormone-replacement) (NN therapy)) (PP (IN during) (NP (DT the) (NN trial)))))) (: :) (PP (IN among) (NP (CD 390) (NNS women)))) (PP (IN on) (NP (JJ such) (NN therapy))))))))))) (CC and) (S (S (VP (VBN allocated) (PP (TO to) (NP (NN placebo))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (CD eight) (NNS cases)) (PP (IN of) (NP (NNP Doc_9672273_1695_1708_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NP (CD one) (NN case)) (PP (IN among) (NP (NP (CD 362) (NNS women)) (VP (VBN allocated) (PP (TO to) (NP (NNP Doc_9672273_1761_1770_Chemical))))))))))) (. .)))
9672273	14	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group)))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB significantly) (JJ increased)) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_9672273_1849_1864_Disease)) (CC and) (NP (NNP Doc_9672273_1869_1890_Disease)))) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NNP Doc_9672273_1906_1915_Chemical))))))) (. .)))
9672273	15	(S1 (S (SBAR (IN Although) (S (NP (DT this) (JJ preliminary) (NN analysis)) (VP (AUX has) (NP (JJ low) (NN power))))) (, ,) (PP (IN in) (NP (NP (DT this) (NN cohort)) (PP (IN of) (NP (NNS women))) (PP (IN at) (NP (NP (JJ low-to-normal) (NN risk)) (PP (IN of) (NP (NNP Doc_9672273_2032_2045_Disease))))))) (, ,) (NP (NP (DT the) (VBN postulated) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_9672273_2084_2093_Chemical)))) (VP (AUX are) (RB not) (ADVP (RB yet)) (ADJP (JJ apparent))) (. .)))
9672273	16	(S1 (S (NP (NP (NNS Women)) (VP (VBG using) (NP (JJ hormone-replacement) (NN therapy)))) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (VP (VBN benefited) (PP (IN from) (NP (NP (NN use)) (PP (IN of) (NP (NN Doc_9672273_2193_2202_Chemical)))))))))) (. .)))
9672273	17	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_2230_2243_Disease))) (VP (VBN recorded) (PP (IN in) (NP (NP (NNS women)) (PP (IN in) (NP (DT the) (NN study)))))))) (. .)))
9672273	18	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ essential) (S (VP (TO to) (VP (VB continue) (S (NP (NN follow-up)) (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (JJ long-term) (NNS risks)) (CC and) (NP (NP (NNS benefits)) (PP (IN of) (NP (JJ Doc_9672273_2362_2371_Chemical) (NN therapy))))))))))))) (. .)))
9758264	0	(S1 (S (NP (NP (JJ Epileptogenic) (NN activity)) (PP (IN of) (NP (NNP Doc_9758264_26_36_Chemical))) (PP (IN after) (NP (NN drug)))) (VP (VBZ induces) (NP (NP (NNP Doc_9758264_56_59_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9758264_61_71_Chemical)) (CC and) (NP (NNP Doc_9758264_76_84_Disease))) (-RRB- -RRB-))))))
9758264	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ Doc_9758264_120_130_Chemical-containing) (NN multivitamin) (NN supplementation)) (PP (IN in) (NP (JJ Doc_9758264_174_183_Disease) (NNS women)))))) (PP (IN before) (CC and) (IN during) (NP (NN pregnancy))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ structural) (NN Doc_9758264_263_276_Disease)) (CC and) (NP (JJ Doc_9758264_281_289_Disease-related) (NN side) (NNS effects)))))))))))) (. .)))
9758264	2	(S1 (NP (NP (NN STUDY) (NN DESIGN)) (: :) (NP (NP (RB First) (DT a) (JJ randomised) (NN trial)) (, ,) (NP (NP (JJ later) (NN periconception) (NN care)) (VP (VBG including) (PP (IN in) (NP (JJ total) (CD 12225) (NNS females)))))) (. .)))
9758264	3	(S1 (S (PP (IN Of) (NP (NP (CD 60) (JJ Doc_9758264_427_436_Disease) (NNS women)) (PP (IN with) (NP (JJ periconceptional) (NNP Doc_9758264_465_475_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.8) (NN mg)) (-RRB- -RRB-)) (NN -containing) (NN multivitamin) (NN supplementation))))) (, ,) (NP (DT no) (CD one)) (VP (VBD developed) (NP (JJ Doc_9758264_543_551_Disease-related) (NN side) (NNS effects)) (PP (IN during) (NP (DT the) (JJ periconception) (NN period)))) (. .)))
9758264	4	(S1 (S (NP (CD One) (NNP Doc_9758264_611_620_Disease) (NN woman)) (VP (VBD delivered) (NP (NP (DT a) (JJ newborn)) (PP (IN with) (NP (NNP Doc_9758264_652_672_Disease))))) (. .)))
9758264	5	(S1 (S (NP (DT Another) (NN patient)) (VP (VBD exhibited) (PP (IN with) (NP (NP (DT a) (NN cluster)) (PP (IN of) (NP (NNP Doc_9758264_718_726_Disease))))) (PP (IN after) (NP (NP (DT the) (JJ periconception) (NN period)) (VP (VBG using) (NP (DT another) (NN multivitamin)))))) (. .)))
9758264	6	(S1 (S (NP (DT This) (JJ 22-year-old) (NNP Doc_9758264_804_813_Disease) (NN woman)) (VP (AUX was) (VP (VP (VBN treated) (ADVP (RB continuously)) (PP (IN by) (NP (NNP Doc_9758264_848_861_Chemical)))) (CC and) (VP (NP (DT a) (JJ Doc_9758264_868_878_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg))) (-RRB- -RRB-)) (JJ -containing) (NN multivitamin)) (PP (IN from) (NP (NP (DT the) (JJ 20th) (NN week)) (PP (IN of) (NP (NN gestation)))))))) (. .)))
9758264	7	(S1 (S (NP (PRP She)) (VP (VBD developed) (NP (NP (NP (NN Doc_9758264_957_975_Disease)) (CC and) (NP (JJ later) (NNS symptoms))) (PP (IN of) (NP (NNP Doc_9758264_998_1026_Disease))))) (. .)))
9758264	8	(S1 (S (NP (PRP$ Her) (NN pregnancy)) (VP (VBN ended) (PP (IN with) (NP (NNP Doc_9758264_1053_1063_Disease)))) (. .)))
9758264	9	(S1 (S (S (NP (NP (NP (DT The) (JJ Doc_9758264_1082_1091_Disease) (JJ pregnant) (NN patient) (POS 's)) (NNP Doc_9758264_1111_1129_Disease)) (PRN (-LRB- -LRB-) (NP (RB probably) (JJ drug-induced) (NNP Doc_9758264_1153_1158_Disease)) (-RRB- -RRB-))) (VP (MD could) (VP (VB damage) (NP (DT the) (JJ blood-brain) (NN barrier))))) (, ,) (RB therefore) (S (NP (NP (DT the) (JJ therapeutic) (NN dose)) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CC or) (CD =1)) (NN mg)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9758264_1245_1255_Chemical)))) (VP (VBD triggered) (NP (NP (DT a) (NN cluster)) (PP (IN of) (NP (NNP Doc_9758264_1279_1287_Disease)))))) (. .)))
9758264	10	(S1 (S (NP (NP (NP (JJ Physiological) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD <1) (NN mg)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_9758264_1319_1329_Chemical) (CD both))) (PP (IN in) (NP (JJ healthy))) (CC and) (NP (NP (CD 60) (JJ Doc_9758264_1353_1362_Disease) (NNS women)) (, ,) (NP (NP (DT all)) (PP (IN without) (NP (DT any) (NN Doc_9758264_1386_1404_Disease)))) (, ,))) (VP (AUX did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNP Doc_9758264_1436_1454_Disease)))))) (. .)))
9799166	0	(S1 (S (NP (NP (NNP Doc_9799166_0_6_Disease)) (CC and) (NP (NNP Doc_9799166_11_18_Chemical)) (CC or) (NP (NNP Doc_9799166_22_33_Chemical))) (VP (VBP use)) (. .)))
9799166	1	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NNP Doc_9799166_58_65_Chemical) (CC and) (NNP Doc_9799166_70_81_Chemical) (NN use))) (PP (IN with) (NP (NP (NN hemorrhagic)) (CC and) (NP (NNP Doc_9799166_107_115_Disease) (NNP Doc_9799166_116_122_Disease))))) (VP (AUX is) (VP (VBN based) (PP (ADVP (RB almost) (RB solely)) (IN on) (NP (NP (NNS data)) (PP (IN from) (NP (NN case) (NNS series))))))) (. .)))
9799166	2	(S1 (S (NP (NP (DT The) (JJ limited) (NN number)) (PP (IN of) (NP (NP (NP (JJ epidemiologic) (NNS studies)) (PP (IN of) (NP (NNP Doc_9799166_219_225_Disease)))) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_9799166_237_244_Chemical) (FW and/or) (NNP Doc_9799166_252_263_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (AUX done) (PP (IN in) (NP (NP (NNS settings)) (SBAR (WHNP (WDT that)) (S (VP (VBP serve) (ADVP (RB mostly)) (NP (DT the) (JJ poor) (NN and/or) (NNS minorities)))))))))) (. .)))
9799166	3	(S1 (S (NP (DT This) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (DT the) (VBN defined) (NN population)) (VP (VBG comprising) (NP (NP (NNS members)) (PP (IN of) (NP (NP (NNP Kaiser) (NNP Permanente)) (PP (IN of) (NP (NNP Northern) (CC and) (NNP Southern) (NNP California))))))))))) (. .)))
9799166	4	(S1 (S (NP (PRP We)) (VP (VBD attempted) (S (VP (TO to) (VP (VB identify) (NP (DT all) (NN incident) (NN Doc_9799166_516_523_Disease)) (PP (IN in) (NP (NNS women) (NNS ages)))))) (NP (CD 15-44) (NNS years)) (PP (IN during) (NP (NP (DT a) (JJ 3-year) (NN period)) (VP (VBG using) (NP (NP (NN hospital) (NN admission) (CC and) (NN discharge) (NNS records)) (, ,) (NP (NN emergency) (NN department) (VBZ logs)) (, ,) (CC and) (NP (NP (NN payment) (NNS requests)) (PP (IN for) (NP (JJ out-of-plan) (NNS hospitalizations))))))))) (. .)))
9799166	5	(S1 (S (NP (PRP We)) (VP (VBD selected) (NP (NP (NNS controls)) (, ,) (VP (VBN matched) (PP (IN on) (NP (NP (NP (NN age)) (CC and) (NP (NN facility))) (PP (IN of) (NP (JJ usual) (NN care)))))) (, ,)) (PP (IN at) (NP (JJ random))) (PP (IN from) (NP (NP (JJ healthy) (NNS members)) (PP (IN of) (NP (DT the) (NN health) (NN plan)))))) (. .)))
9799166	6	(S1 (S (NP (PRP We)) (VP (VBD obtained) (NP (NN information)) (PP (IN in) (NP (JJ face-to-face) (NNS interviews)))) (. .)))
9799166	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD 347) (VBN confirmed) (NN Doc_9799166_896_902_Disease) (NNS cases)) (CC and) (NP (JJ 1,021) (NNS controls)))) (. .)))
9799166	8	(S1 (S (NP (NP (DT The) (JJ univariate) (VBN matched) (NNS odds) (NN ratio)) (PP (IN for) (NP (NNP Doc_9799166_967_973_Disease))) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD admitted) (PP (TO to) (S (VP (VBG using) (NP (NNP Doc_9799166_1005_1012_Chemical) (FW and/or) (NNP Doc_9799166_1020_1031_Chemical))))))))))) (VP (AUX was) (NP (NP (CD 8.5)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (SYM =) (CD 3.6-20.0)) (-RRB- -RRB-)))) (. .)))
9799166	9	(S1 (S (PP (IN After) (NP (NP (JJ further) (NN adjustment)) (PP (IN for) (NP (JJ potential) (NNS confounders))))) (, ,) (NP (NP (DT the) (NNS odds) (NN ratio)) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (S (VP (VBG using) (NP (NNP Doc_9799166_1173_1180_Chemical) (FW and/or) (NNP Doc_9799166_1188_1199_Chemical)))))))))) (VP (AUX was) (NP (NP (CD 7.0)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (SYM =) (CD 2.8-17.9)) (-RRB- -RRB-)))) (. .)))
9799166	10	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_9799166_1257_1264_Chemical) (FW and/or) (NNP Doc_9799166_1272_1283_Chemical)))) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN risk) (NN factor)) (PP (IN for) (NP (NNP Doc_9799166_1312_1318_Disease))) (PP (IN in) (NP (DT this) (ADJP (RB socioeconomically) (JJ heterogeneous) (, ,) (JJ insured)) (JJ urban) (NN population))))) (. .)))
982002	0	(S1 (S (NP (NN Doc_982002_0_19_Disease)) (ADJP (JJ subsequent) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_982002_56_66_Chemical)))))) (. .)))
982002	1	(S1 (S (NP (NP (DT A) (JJ follow-up) (NN study)) (PP (IN of) (NP (NNS cases)))) (VP (VBD reported) (ADVP (RB earlier))) (. .)))
982002	2	(S1 (S (NP (DT A) (JJ clinical) (NN presentation)) (VP (AUX is) (VP (VBN made) (PP (IN of) (NP (NP (DT a) (CD 2-3) (NN year) (NN follow-up)) (PP (IN of) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (NNP Doc_982002_185_204_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB earlier))))))))))) (. .)))
982002	3	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX had) (VP (VBN developed) (NP (JJ transient) (NN Doc_982002_275_288_Disease)) (PP (IN after) (NP (NP (DT the) (JJ intermittent) (NN administration)) (PP (IN of) (NP (NNP Doc_982002_330_340_Chemical))))))) (. .)))
982002	4	(S1 (S (S (NP (NP (DT The) (NN stage)) (PP (IN of) (NP (NN olig-Doc_982002_360_366_Disease)))) (VP (VBD lasted) (PP (IN for) (NP (JJ 1-3) (NNS weeks))))) (, ,) (CC and) (S (NP (NP (CD five)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NN hemodialysis)))))) (. .)))
982002	5	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD died) (PP (JJ due) (TO to) (NP (JJ unrelated) (NNS causes))) (PP (IN during) (NP (DT the) (JJ follow-up) (NN period)))) (. .)))
982002	6	(S1 (S (NP (NP (DT The) (CD four) (NNS patients)) (VP (VBN re-examined))) (VP (AUX were) (ADVP (RB clinically)) (VP (VBN cured))) (. .)))
982002	7	(S1 (S (NP (NP (JJ Pathologic) (NNS findings)) (PP (IN by) (NP (NP (JJ light) (NN microscopy)) (CC and) (NP (NN immunofluorescence)))) (PP (IN at) (NP (NN biopsy)))) (VP (AUX were) (ADJP (JJ scarce))) (. .)))
982002	8	(S1 (S (NP (NN Nothing) (JJ abnormal)) (VP (AUX was) (VP (VBN seen) (PP (IN by) (NP (NNP electron) (CD microscopy))) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (VP (VBN studied)))))))) (. .)))
982002	9	(S1 (S (NP (JJ Renal) (NN function)) (VP (AUX was) (ADJP (JJ normal))) (. .)))
982002	10	(S1 (S (PP (IN In) (NP (CD three) (NNS cases))) (NP (NP (DT the) (NN excretion)) (PP (IN at) (NP (JJ 131I-hippuran) (NN renography)))) (VP (AUX was) (ADVP (RB slightly)) (VP (VBN slowed))) (. .)))
982002	11	(S1 (S (SBAR (IN Although) (S (PP (IN in) (NP (DT the) (JJ acute) (NN stage))) (NP (DT the) (NNP Doc_982002_876_889_Disease) (NN histologically)) (VP (VBD appeared) (ADJP (JJ toxic))))) (, ,) (NP (NP (NN evidence) (NN suggestive)) (PP (IN of) (NP (DT an) (JJ immunological) (NN mechanism)))) (ADVP (RB cannot)) (VP (AUX be) (VP (VBN excluded))) (. .)))
9848575	0	(S1 (NP (NP (JJ Chronic) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ novel) (JJ synthetic) (JJ Doc_9848575_37_50_Chemical) (NN derivative)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9848575_63_70_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ normal) (NN heart)) (CC and) (NP (NP (JJ Doc_9848575_92_103_Chemical-induced) (NN Doc_9848575_112_126_Disease)) (PP (IN in) (NP (JJ beagle) (NNS dogs)))))) (. .)))
9848575	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (DT the) (JJ chronic) (JJ Doc_9848575_194_205_Disease) (NN potential)) (PP (IN of) (NP (NNP Doc_9848575_219_226_Chemical)))) (CC and) (NP (NP (DT a) (JJ possible) (JJ deteriorating) (NN effect)) (PP (IN of) (NP (NNP Doc_9848575_266_273_Chemical))))) (PP (IN on) (NP (NP (JJ low-grade) (NN Doc_9848575_287_301_Disease)) (VP (VBN pre-induced) (PP (IN by) (NP (NNP Doc_9848575_317_328_Chemical))) (PP (IN in) (NP (JJ beagle) (NNS dogs))))))))))) (. .)))
9848575	2	(S1 (S (PP (IN In) (NP (DT the) (JJ chronic) (NN treatment))) (, ,) (NP (NP (JJ beagle) (NNS dogs)) (PP (IN of) (NP (DT each) (NN sex)))) (VP (AUX were) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN once) (NP (DT every) (CD 3) (NNS weeks))) (, ,) (CC either) (NP (NP (DT a) (JJ sublethal) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_9848575_467_478_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9848575_494_501_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
9848575	3	(S1 (S (NP (DT The) (NN experiment)) (VP (AUX was) (VP (VBN terminated) (NP (CD 3) (NNS weeks)) (PP (IN after) (NP (DT the) (JJ ninth) (NN dosing))))) (. .)))
9848575	4	(S1 (S (NP (NP (NNS Animals)) (SBAR (WHNP (WDT which)) (S (VP (VBD received) (PP (IN over) (NP (NP (CD six) (NNS courses)) (PP (IN of) (NP (NNP Doc_9848575_620_631_Chemical))))))))) (VP (VBD demonstrated) (NP (NP (DT the) (NN electrocardiogram) (-LRB- -LRB-) (NN ECG) (-RRB- -RRB-) (NNS changes)) (, ,) (NP (NP (NN decrease)) (PP (IN of) (NP (NN blood) (NN pressure)))) (CC and) (NP (JJ high-grade) (JJ histopathological) (NN Doc_9848575_742_756_Disease))) (, ,) (SBAR (IN while) (S (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADVP (RB terminally)) (VP (VBN sacrificed) (PP (IN after) (NP (DT the) (NNP Doc_9848575_815_822_Chemical) (NN administration)))))))) (VP (AUX did) (RB not) (VP (VB show) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (NN ECG)) (, ,) (NP (NN blood) (NN pressure)) (CC and) (NP (JJ histopathological) (NNS examinations)))))))))) (. .)))
9848575	5	(S1 (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT a) (ADJP (RB possibly) (VBG deteriorating)) (NN Doc_9848575_958_969_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_9848575_980_987_Chemical))))))) (, ,) (NP (JJ low-grade) (NNP Doc_9848575_999_1013_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (NNS dogs))) (PP (IN by) (NP (NP (CD four) (NNS courses)) (PP (IN of) (NP (NP (NNP Doc_9848575_1053_1064_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
9848575	6	(S1 (S (S (NP (CD Nine) (NNS weeks)) (PP (IN after) (NP (NN pre-treatment)))) (, ,) (NP (NNS dogs)) (VP (AUX were) (VP (VBN given) (NP (NP (CD four) (NNS courses)) (PP (IN of) (NP (NP (NP (DT either) (NNP Doc_9848575_1149_1160_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9848575_1176_1183_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN once) (NP (DT every) (CD 3) (NNS weeks))))) (. .)))
9848575	7	(S1 (S (NP (DT The) (JJ low-grade) (NN Doc_9848575_1230_1241_Disease) (NNS changes)) (VP (AUX were) (VP (VBN enhanced) (PP (IN by) (NP (DT the) (JJ additional) (JJ Doc_9848575_1282_1293_Chemical) (NN treatment))))) (. .)))
9848575	8	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (DT the) (JJ Doc_9848575_1326_1333_Chemical) (NN treatment)) (VP (AUX did) (RB not) (VP (VB progress) (NP (NP (DT the) (NN grade)) (PP (IN of) (NP (NNP Doc_9848575_1374_1388_Disease)))))) (. .)))
9848575	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNP Doc_9848575_1405_1412_Chemical)) (VP (AUX does) (RB not) (VP (AUX have) (NP (NP (NP (DT any) (NN potential)) (PP (IN of) (NP (JJ chronic) (NNP Doc_9848575_1452_1466_Disease)))) (CC and) (NP (NP (VBG deteriorating) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_9848575_1495_1506_Chemical-induced) (NNP Doc_9848575_1515_1529_Disease)) (PP (IN in) (NP (NNS dogs))))))))) (. .)))
9867728	0	(S1 (NP (NP (NN Risk)) (PP (IN for) (NP (NNP Doc_9867728_9_31_Disease))) (PP (IN among) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_9867728_47_59_Chemical)) (CC and) (NP (NNP Doc_9867728_64_79_Chemical)))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN echocardiography)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (NN medication)))))))))) (. .)))
9867728	1	(S1 (S (SBAR (IN Because) (S (NP (JJ uncontrolled) (JJ echocardiographic) (NNS surveys)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (QP (IN up) (TO to) (CD 30) (NN %) (TO to) (CD 38) (NN %))) (PP (IN of) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_9867728_240_252_Chemical)) (CC and) (NP (NNP Doc_9867728_257_272_Chemical))))))) (VP (AUX had) (NP (NN Doc_9867728_277_293_Disease)))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (AUX were) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (NN market))))) (. .)))
9867728	2	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NP (ADJP (JJ new) (CC or) (VBG worsening)) (NN Doc_9867728_393_415_Disease)) (PP (IN among) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_9867728_431_443_Chemical) (CC or) (NNP Doc_9867728_447_462_Chemical))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN echocardiography)) (SBAR (IN before) (S (NP (PRP they)) (VP (VBD began) (S (VP (TO to) (VP (VB take) (NP (DT these) (NNS medications))))))))))))))))))) (. .)))
9867728	3	(S1 (S (NP (NNS Cohort)) (VP (VBP study)) (. .)))
9867728	4	(S1 (FRAG (NP (JJ Academic) (JJ primary) (NN care) (NNS practices)) (. .)))
9867728	5	(S1 (S (NP (NP (CD 46) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD used) (NP (NP (NNP Doc_9867728_634_646_Chemical)) (CC or) (NP (NNP Doc_9867728_650_665_Chemical))) (PP (IN for) (NP (CD 14) (NNS days) (QP (CC or) (JJR more))))) (CC and) (VP (AUX had) (NP (NNS echocardiograms))))))) (VP (VBN obtained) (PP (IN before) (NP (NN therapy)))) (. .)))
9867728	6	(S1 (NP (JJ Follow-up) (NN echocardiography) (. .)))
9867728	7	(S1 (S (NP (DT The) (JJ primary) (NN outcome)) (VP (AUX was) (NP (NP (ADJP (JJ new) (CC or) (VBG worsening)) (NNP Doc_9867728_818_830_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (NN progression)) (PP (IN of) (NP (DT either) (NNP Doc_9867728_865_895_Disease))))) (PP (IN by) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN degree)) (PP (IN of) (NP (NP (NN severity)) (CC and) (NP (NN disease)))) (SBAR (WHNP (WDT that)) (S (VP (VBD met) (NP (NNP U.S.) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (NP (NP (NNS criteria)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (ADJP (JJS least) (JJ mild)) (ADJP (JJ Doc_9867728_1010_1030_Disease) (CC or) (JJ moderate)) (NNP Doc_9867728_1043_1063_Disease))) (-RRB- -RRB-))))))))))) (. .)))
9867728	8	(S1 (S (NP (NP (CD Two) (NNS patients) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4.3) (NN %)) (ADJP (CD -LSB-95) (NN %)) (NN CI)) (, ,) (NP (QP (CD 0.6) (NN %) (TO to) (CD 14.8) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NNP Doc_9867728_1129_1141_Chemical-Doc_9867728_1142_1153_Chemical)))) (VP (VBD developed) (NP (NNP Doc_9867728_1164_1186_Disease))) (. .)))
9867728	9	(S1 (S (NP (NN One)) (VP (AUX had) (NP (NP (NP (JJ baseline) (NN Doc_9867728_1205_1226_Disease)) (CC and) (NP (JJ mild) (NN Doc_9867728_1236_1256_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD progressed) (PP (TO to) (NP (JJ moderate) (NN regurgitation)))))))) (. .)))
9867728	10	(S1 (S (NP (DT The) (JJ second) (NN patient)) (VP (VBD developed) (NP (JJ new) (JJ moderate) (NN Doc_9867728_1342_1362_Disease))) (. .)))
9867728	11	(S1 (S (NP (NP (NNS Users)) (PP (IN of) (NP (NN diet) (NNS medications)))) (VP (AUX are) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NNP Doc_9867728_1418_1440_Disease)))))) (. .)))
9867728	12	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN incidence)) (VP (MD may) (VP (AUX be) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (VP (VBN reported) (ADVP (RB previously)))))))) (. .)))
9875685	0	(S1 (NP (NP (NP (JJ Therapeutic) (NN drug) (NN monitoring)) (PP (IN of) (NP (NNP Doc_9875685_31_41_Chemical)))) (: :) (NP (NP (NN once-daily)) (PP (IN versus) (NP (JJ twice-daily) (NN dosage) (NNS schedules)))) (. .)))
9875685	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN dosage) (NN regimen))) (PRN (-LRB- -LRB-) (ADJP (JJ once-daily) (CC vs.) (JJ twice-daily)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9875685_175_185_Chemical)))) (PP (IN on) (NP (NP (JJ steady-state) (NN serum) (NNS concentrations)) (CC and) (NP (NNP Doc_9875685_227_235_Disease))))))) (. .)))
9875685	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (NP (NNPS Patients)) (VP (VBG undergoing) (NP (NN treatment)) (PP (IN with) (S (VP (VBG i.v.) (NP (NP (NNP Doc_9875685_300_310_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg/day)) (-RRB- -RRB-)))))))) (VP (AUX were) (VP (VBN randomised) (PP (TO to) (NP (CD two) (NNS groups)))))) (. .)))
9875685	3	(S1 (S (NP (NP (NNP Group) (NNP OD)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 22)) (-RRB- -RRB-))) (VP (VBD received) (SBAR (S (NP (NP (NP (DT a) (JJ once-daily) (NN dose)) (PP (IN of) (NP (NNP Doc_9875685_404_414_Chemical)))) (CC and) (NP (NP (NN group) (NN TD)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 21)) (-RRB- -RRB-)))) (VP (VBD received) (NP (NP (DT the) (JJ same) (NN dose)) (VP (VBN divided) (PP (IN into) (NP (CD two) (NNS doses))))) (ADVP (RB daily)))))) (. .)))
9875685	4	(S1 (S (NP (NP (JJ Doc_9875685_490_500_Chemical) (NN serum) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (NN peak)) (CC and) (NP (NN trough))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (ADJP (RB enzyme) (VBN multiplied)) (NN immunoassay))))) (. .)))
9875685	5	(S1 (S (NP (NP (DT The) (JJ renal) (CC and) (JJ auditory) (NNS functions)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (VP (VBN monitored) (ADVP (IN before)) (, ,) (PP (PP (IN during)) (CC and) (PP (ADVP (RB immediately)) (IN after) (NP (NN treatment)))))) (. .)))
9875685	6	(S1 (S (NP (DT The) (CD two) (NNS groups)) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (NP (NN body) (NN weight)) (CC and) (NP (JJ renal) (NN function)))))))) (. .)))
9875685	7	(S1 (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (JJ mean) (JJ daily) (NN dose)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN treatment)))) (, ,) (CC or) (NP (JJ cumulative) (NN dose)))))) (. .)))
9875685	8	(S1 (S (NP (NN Trough) (NNS concentrations)) (VP (AUX were) (VP (VBN <) (NP (CD 2) (NN g/ml)) (PP (IN in) (NP (DT the) (CD two) (NNS groups))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN %)) (-RRB- -RRB-)))) (. .)))
9875685	9	(S1 (S (NP (NN Peak) (NNS concentrations)) (VP (AUX were) (VP (VBG >) (NP (NP (CD 6) (NN microg/ml)) (PP (IN in) (NP (NP (NP (CD 100) (NN %)) (PP (IN of) (NP (DT the) (JJ OD) (NN group)))) (CC and) (NP (NP (QP (IN in) (CD 67)) (NN %)) (PP (IN of) (NP (DT the) (JJ TD) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.01)) (-RRB- -RRB-))))) (. .)))
9875685	10	(S1 (S (S (NP (JJ Mean) (NN peak) (NNS concentrations)) (VP (AUX were) (ADJP (RB markedly) (JJ different)))) (: :) (S (NP (NP (CD 11.00+/-2.89) (NN microg/ml)) (PP (IN in) (NP (CD OD) (CC vs.) (CD 6.53+/-1.45)))) (VP (VBD microg/ml) (PP (IN in) (NP (NP (NNP TD)) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.01)) (-RRB- -RRB-)))))) (. .)))
9875685	11	(S1 (S (NP (DT The) (JJ pharmacokinetics) (NNS parameters)) (VP (AUX were) (: :) (NP (NP (NNP Ke)) (, ,) (PRN (-LRB- -LRB-) (NP (NP (JJ 0.15+/-0.03/h)) (PP (IN in) (NP (CD OD) (CC vs.) (CD 0.24+/-0.06/h))) (PP (IN in) (NP (NNP TD)))) (-RRB- -RRB-)) (, ,) (NP (CD t1/2)) (PRN (, ,) (-LRB- -LRB-) (NP (NP (CD 4.95+/-1.41) (NAC (NNP h) (PP (IN in) (NP (CD OD) (CC vs.) (CD 3.07+/-0.71)))) (NNP h)) (PP (IN in) (NP (NNP TD)))) (-RRB- -RRB-)) (, ,) (NP (NNP Vd)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.35+/-0.11) (NN l/kg)) (PP (IN in) (NP (NNP OD)))) (CC vs.) (NP (NP (CD 0.33+/-0.09) (NN l/kg)) (PP (IN in) (NP (NNP TD))))) (-RRB- -RRB-)) (, ,) (NP (NNP Cl)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.86+/-0.29) (NN ml/min/kg)) (PP (IN in) (NP (NNP OD)))) (CC vs.) (NP (NP (CD 1.28+/-0.33) (NN ml/min/kg)) (PP (IN in) (NP (NNP TD))))) (-RRB- -RRB-)))) (. .)))
9875685	12	(S1 (S (NP (VBN Increased) (NN serum) (NN Doc_9875685_1478_1488_Chemical)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD 73) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNP OD)))))) (CC versus) (NP (NP (CD 57) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNP TD)))))))) (, ,) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_9875685_1577_1591_Disease))))))) (. .)))
9875685	13	(S1 (S (PP (IN In) (NP (CD TD) (NN group))) (, ,) (NP (CD three) (NNS patients)) (VP (VBD developed) (NP (NP (NNP Doc_9875685_1631_1658_Disease)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (PRP one)) (VP (VBD presented) (PP (IN with) (NP (NP (DT an) (NN Doc_9875685_1691_1704_Disease)) (PP (IN of) (NP (JJ -30) (NNS dB))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (DT the) (NN OD) (NN group))) (NP (QP (RB only) (CD one)) (NN patient)) (VP (VBD presented) (NP (NNP Doc_9875685_1767_1794_Disease)))))))))) (. .)))
9875685	14	(S1 (S (NP (DT This) (JJ small) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT a) (JJ once-daily) (NN dosing) (NN regimen)) (PP (IN of) (NP (NNP Doc_9875685_1870_1880_Chemical)))) (VP (VP (AUX is) (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ effective) (RB as))) (CC and) (VP (AUX is) (ADJP (ADJP (ADJP (RB no) (JJR more)) (CC and) (ADJP (ADVP (RB possibly)) (RBR less) (JJ toxic))) (PP (IN than) (NP (DT the) (JJ twice-daily) (NN regimen))))))))) (. .)))
9875685	15	(S1 (S (S (S (VP (VBG Using) (NP (DT a) (JJ single-dose) (NN therapy)))) (, ,) (NP (JJ peak) (NN concentration) (NN determination)) (VP (AUX is) (RB not) (ADJP (JJ necessary)))) (, ,) (S (NP (JJ only) (NN trough) (NNS samples)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (S (VP (TO to) (VP (VB ensure) (NP (NP (NNS levels)) (PP (IN below) (NP (CD 2) (NN microg/ml))))))))))) (. .)))
9915601	0	(S1 (S (NP (JJ Enhanced) (NN Doc_9915601_9_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ beta-adrenoceptor) (NNS antagonists)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_9915601_86_95_Chemical))))))))) (. .)))
9915601	1	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NNP Doc_9915601_111_120_Chemical)))) (VP (VP (VB increase) (NP (NP (NN Doc_9915601_130_141_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNS vasodilators)))))) (CC and) (VP (VB change) (NP (NP (DT the) (JJ accompanying) (JJ reflex) (NN Doc_9915601_201_212_Disease)) (PP (TO to) (NP (NP (NNP Doc_9915601_216_227_Disease)) (, ,) (NP (NP (DT an) (NN interaction)) (VP (VBN attributed) (PP (TO to) (NP (NP (VBN decreased) (NN synthesis)) (PP (IN of) (NP (NP (NN brain) (NNP Doc_9915601_287_310_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9915601_312_316_Chemical)) (-RRB- -RRB-))))))))))))) (. .)))
9915601	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (JJ possible) (NN enhancement)) (PP (IN by) (NP (NP (NNP Doc_9915601_369_378_Chemical)) (PP (IN of) (NP (NNP Doc_9915601_382_393_Disease))))) (VP (VBN induced) (PP (IN by) (NP (JJ beta-adrenoceptor) (NNS antagonists))))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN anaesthetised) (PP (IN with) (NP (NNP Doc_9915601_477_487_Chemical-Doc_9915601_488_496_Chemical)))))))) (. .)))
9915601	3	(S1 (S (NP (NN Doc_9915601_498_507_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NNP Doc_9915601_532_543_Disease)) (PP (PP (IN after) (NP (NNP Doc_9915601_550_561_Chemical) (, ,) (NNP Doc_9915601_563_571_Chemical) (, ,) (NNP Doc_9915601_573_582_Chemical) (CC and) (NNP Doc_9915601_587_595_Chemical))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN after) (NP (NNP Doc_9915601_614_623_Chemical))) (, ,) (CONJP (CC but) (RB not)) (PP (IN after) (NP (NP (NNP Doc_9915601_639_652_Chemical)) (CC or) (NP (NNP Doc_9915601_656_665_Chemical)))))) (. .)))
9915601	4	(S1 (S (NP (NN Enhancement)) (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (NNS rats)) (VP (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_9915601_720_734_Chemical)))) (CC or) (VP (ADVP (RB previously)) (VBN vagotomised))))))) (. .)))
9915601	5	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ compatible) (PP (IN with) (NP (NP (NN interference)) (PP (IN by) (NP (NNP Doc_9915601_812_821_Chemical))) (PP (IN with) (NP (NP (JJ GABAergic) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ parasympathetic) (NN tone))))))))) (. .)))
9915601	6	(S1 (S (NP (JJ Such) (NN interference)) (VP (MD could) (VP (AUX be) (VP (VBN exerted) (ADVP (RB centrally)) (, ,) (PP (ADVP (RB possibly)) (PP (IN at) (NP (DT the) (NN nucleus) (NN ambiguus))) (, ,) (CC or) (ADVP (RB peripherally)) (PP (IN at) (NP (DT the) (JJ sinus) (NN node))))))) (. .)))
9952311	0	(S1 (NP (NP (NP (NN Doc_9952311_0_52_Disease)) (PP (IN in) (NP (NP (NNP Doc_9952311_56_66_Chemical-induced) (NNP Doc_9952311_75_89_Disease)) (PP (IN in) (NP (NNS mice)))))) (: :) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ cytochrome) (NNP c) (FW oxidase) (NNP II) (NN gene) (NN expression)))) (. .)))
9952311	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NNP Doc_9952311_166_176_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9952311_178_181_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_9952311_186_192_Disease) (CD chemotherapy)))) (VP (AUX has) (VP (AUX been) (VP (VBN limited) (PP (JJ due) (TO to) (NP (PRP$ its) (JJ cumulative) (NN Doc_9952311_245_268_Disease)))))) (. .)))
9952311	2	(S1 (S (NP (NP (JJR Earlier) (NNS observations)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_9952311_296_299_Chemical)) (VP (VP (VBZ interacts) (PP (IN with) (NP (NP (JJ mitochondrial) (JJ cytochrome) (NN c) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-))))) (CC and) (VP (VBZ suppresses) (NP (PRP$ its) (JJ enzyme) (NN activity))))))) (VP (VBD led) (S (NP (PRP us)) (VP (TO to) (VP (VB investigate) (NP (NP (NP (NNP Doc_9952311_413_416_Chemical) (POS 's)) (NN action)) (PP (IN on) (NP (NP (DT the) (JJ cardiovascular) (NNS functions)) (CC and) (NP (NP (NN heart) (JJ mitochondrial) (NN morphology)) (PP (IN in) (NP (NP (JJ Balb-c) (NNS mice)) (VP (ADVP (RB i.p.)) (VBN treated) (PP (IN with) (NP (NNP Doc_9952311_526_529_Chemical))) (PP (IN for) (NP (JJ several) (NNS weeks)))))))))))))) (. .)))
9952311	3	(S1 (S (PP (IN At) (NP (NP (JJ various) (NNS times)) (PP (IN during) (NP (NN treatment))))) (, ,) (NP (DT the) (NNS animals)) (VP (AUX were) (VP (VBN assessed) (PP (PP (IN for) (NP (NP (JJ cardiovascular) (NNS functions)) (PP (IN by) (NP (NN electrocardiography))))) (CC and) (PP (IN for) (NP (NP (NN heart) (NN tissue) (NN damage)) (PP (IN by) (NP (NNP electron) (CD microscopy)))))))) (. .)))
9952311	4	(S1 (S (PP (IN In) (NP (NN parallel))) (, ,) (NP (JJ total) (NNP RNA)) (VP (VP (AUX was) (VP (VBN extracted) (PP (IN from) (NP (NP (NNS samples)) (PP (IN of) (NP (VBN dissected) (NN heart))))))) (CC and) (VP (VBD analyzed) (PP (IN by) (NP (NNP Northern) (NNP blot) (NN hybridization))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ steady-state) (NN level)) (PP (IN of) (NP (NP (CD three) (NNP RNA) (NNS transcripts)) (VP (VBN encoded) (PP (IN by) (NP (DT the) (NNP COXII) (, ,) (NNP COXIII) (, ,) (CC and) (NNP COXIV) (NNS genes)))))))))))) (. .)))
9952311	5	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (NNS samples)) (VP (VBN obtained) (PP (IN from) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (DT the) (JJ same) (NNS animals))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (JJ comparative) (NNS studies))))) (. .)))
9952311	6	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (CD 1)) (-RRB- -RRB-) (S (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_9952311_1090_1093_Chemical)))))) (VP (VBD caused) (SBAR (S (NP (NNP Doc_9952311_1101_1127_Disease)) (VP (VBD characterized) (PP (IN by) (NP (NP (NNP Doc_9952311_1145_1156_Disease)) (, ,) (NP (NP (NN extension)) (PP (IN of) (NP (NP (JJ ventricular) (NN depolarization) (NN time)) (PRN (-LRB- -LRB-) (NP (NNS tQRS)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN failure)))) (PP (IN of) (NP (NNS QRS)))))) (PP (IN at) (NP (JJ high) (NNS concentrations))) (PRN (-LRB- -LRB-) (NP (QP (CD 10-14) (CD mg/kg)) (NN body) (NN weight)) (NP (JJ cumulative) (NN dose)) (-RRB- -RRB-))))))) (: ;) (S (LST (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN heart) (NN mitochondria)) (VP (VBD underwent) (NP (NP (NNP Doc_9952311_1332_1340_Disease) (, ,) (NN fusion) (, ,) (NN dissolution) (, ,) (JJ and/or) (NN disruption)) (PP (IN of) (NP (JJ mitochondrial) (NNS cristae)))) (PP (IN after) (NP (NP (JJ several) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))))))) (. .)))
9952311	7	(S1 (S (NP (JJ Such) (NNS abnormalities)) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN mitochondria)) (PP (IN of) (NP (NN liver) (NN tissue))))) (PRN (: ;) (CC and) (NP (CD 3)) (-RRB- -RRB-)) (SBAR (IN among) (S (NP (NP (DT the) (CD three) (NNS genes)) (PP (IN of) (NP (NNP COX) (NN enzyme)))) (VP (VBD examined) (, ,) (SBAR (S (NP (QP (RB only) (CD COXII)) (NN gene) (NN expression)) (VP (AUX was) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_9952311_1612_1615_Chemical) (NN treatment))))))) (, ,) (PP (ADVP (RB mainly)) (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN in) (NP (DT both) (NN heart) (CC and) (NN liver)))))))))) (. .)))
9952311	8	(S1 (S (S (VP (VBG Knowing) (SBAR (IN that) (S (NP (NN heart) (NNS mitochondria)) (VP (VBP represent) (NP (NP (QP (RB almost) (CD 40)) (NN %)) (PP (IN of) (NP (NN heart) (NN muscle)))) (PP (IN by) (NP (NN weight)))))))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (JJ deteriorating) (NNS effects)) (PP (IN of) (NP (NNP Doc_9952311_1799_1802_Chemical))) (PP (IN on) (NP (JJ cardiovascular) (NN function)))) (VP (VBP involve) (NP (NN Doc_9952311_1838_1888_Disease)))))) (. .)))
